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MONDAY – ORAL ABSTRACTS
PAIRED RENAL EXCHANGECONCURRENT ORAL SESSION 1: 
 1 A NATIONAL LIVING DONOR KIDNEY EXCHANGE 
PROGRAM AS THE LOGISTIC SOLUTION FOR 
INCOMPATIBLE COUPLES
M. Klerk De1,2, M. Witvliet3, B. Haase2, F. Claas3, W. Weimar1,2
1Erasmus Mc University Medical Center Rotterdam, Dept. of Internal 
Medicine, 2Dutch Transplant Foundation, Leiden, The Netherlands, 
3National Reference Laboratory for Histocompatibility, Department of 
Immunohematology and Blood Transfusion, Leiden University Medical 
Center, Leiden, The Netherlands
Background: Over the last decade, strategies to expand the living donor pool 
have increased. In the Netherlands we embarked on a national living donor 
kidney exchange program in 2004. We here report the results achieved with 
242 incompatible couples enrolled over four years. 
Methods: In the Netherlands, with a population of 16 million, all seven kidney 
transplant centers agreed on a joint protocol, in which donor/acceptor criteria 
and the logistics of the donation/transplantation procedures are described. 
Donor kidney exchange takes place on an anonymous basis, while the allocation 
is the responsibility of an independent organization, the Dutch Transplantation 
Foundation. Allocation criteria include bloodtype (fi rst identical, then 
compatible), HLA match probability within each actual kidney exchange donor 
pool and the wait time on dialysis. All the cross matches between the recipients 
and their newly matched donors are centrally performed in the National 
Reference Laboratory for histocompatibility in Leiden. A computerized match 
procedure runs every three months. Donors travel to the recipient centers to 
ensure short ischemia times.
Results: From January 2004 until December 2007 we registered 125 pairs with 
blood type incompatibility and 117 pairs with a positive cross match. Median 
PRA in the ABO blood type incompatible group was 2% (0-100) and 46% 
(2-100) in the positive cross match group. Sixteen match procedures were 
performed. The median input of new donor-recipient pairs was 14 (range 7 – 
22 pairs) and the median number of couples participating in a match procedure 
was 47 (range 16 -66 pairs). On the basis of allocation criteria the computer 
constructed 132 ABO compatible cross match negative new donor-recipient 
pairs. These 132 pairs were derived from 82 positive cross match pairs and 50 
ABO blood type incompatible pairs. The median PRA of the matched recipients 
in the positive cross match group was 42% (2-100) and in the ABO blood type 
incompatible group 0% (0-38). There was no statistically signifi cant difference 
in success rate between the positive cross match group (70%) and the couples 
with non-O recipients in the ABO blood type incompatible group (76%). We 
were least successful for ABO blood type incompatible pairs with blood type O 
recipients, but for 21/87, 24% there were possibilities. 
Conclusion: The Dutch living donor kidney exchange program resulted in a 
55% (132/242) successful match rate. The success of a living donor kidney 
exchange program depends on collaboration between the transplant centers, 
supervision by an independent allocation organization and centrally performed 
cross matches.
REPORT FROM A 60 TRANSPLANT CENTER 2 
MULTIREGIONAL KIDNEY PAIRED DONATION PROGRAM
M. Rees1, R. Pelletier2, S. Mulgaonkar3, D. Laskow4, B. Nibhanupudy5, 
J. Kopke6, A. Roth7, U. Unver8, T. Sandholm9, J. Rogers10
1University of Toledo Medical Center, 2Ohio State University, 3St Barnabas 
Health Care, 4Robert Wood Johnson Univ Hosp, 5Florida Hospital Transplant 
Center, 6University of Cincinnati, 7Harvard University, 8University of 
Pittsburgh, 9Carnegie Mellon University, 10Wake Forrest University
Introduction: Sixty US transplant programs in 21 states have partnered to 
increase the access of their patients to a large pool of incompatible pairs for 
kidney paired donation.
Methods: Donor/recipient characteristics were entered into a web-based 
matching program; characteristics include ABO, gender, ethnicity, HLA 
specifi cities, unacceptable antigens, height, weight, PRA, reason for ESRD, and 
relationship of the donor (if any). Since February 2007, computer match runs 
have been performed every 4-6 weeks generating a solution that simultaneously 
optimizes for quality and quantity of transplants in 2-, 3- and 4-way matches as 
well as altruistic donor initiated chains.
Results: The number of unique recipients included in each match run ranged 
from 56-101 while the total number of pairs in the pool ranged from 74-121. 
In the February 2008 match run there were 4 altruistic donors available. In the 
fi rst year of operation, six match runs completed the entire process of match run 
to transplant resulting in 17 transplants (4 additional transplants are scheduled 
and 17 possible transplants are undergoing further evaluation). The number of 
crossmatches required per match run has varied from 7-48. Of the 21 transplants 
performed or scheduled, 4 have resulted from simple 2-way paired donations 
and the remaining 17 transplants were made possible through altruistic donor 
initiated chains. Of the 60 participating transplant programs 18 have entered 
pairs. Seven centers have enrolled more than 10 pairs and two centers have 
enrolled more than 50 pairs each.
Conclusion: Large pools of incompatible pairs from a multiregional alliance 
of transplant programs has increased the likelihood of identifying matches for 
these diffi cult to match patients.
THE DEVELOPMENT OF A SUCCESSFUL MULIT-3 
REGIONAL KIDNEY PAIRED DONATION PROGRAM
R. Hanto1, W. Reitsma2, F. Delmonico1
1New England Organ Bank, 2New Jersey Sharing Network
Using an optimization matching algorithm the New England Program for 
Kidney Exchange (NEPKE) effi ciently matches incompatible donor/recipient 
pairs. In 2006, the Mid-Atlantic Paired Exchange Program (MAPEP) and other 
individual transplant programs began sharing data with NEPKE. This is a 
report of the success of two regional programs working together to increase the 
probability of participants in both programs fi nding a compatible match.
Methods: Incompatible pairs and non-directed donors (NDD) are referred to 
NEPKE through transplant centers. Donor and recipient ABO, HLA and recipient 
HLA antibody screening are entered into the computer database. Utilizing the 
optimization program, searches for compatible matches are conducted every 
30 to 45 days. The program identifi es potential 2 and 3-way matches, NDD 
chains, and list exchange chains. Following the determination of compatibility 
NEPKE notifi es transplant centers involved of the potential match and centers 
accept or decline the offer. Transplant centers notify their pairs and preliminary 
crossmatches are performed. A conference call is scheduled to coordinate 
simultaneous donor nephrectomies and recipient transplants. Surgeons speak 
prior to incision to ensure simultaneous donation.
Results: From July 2005 to January 2008, 193 pairs and 11 NDDs have 
entered NEPKE. During this time frame over one thousand possible matches 
were identifi ed, with the majority of these matches involving the same pairs 
in multiple matches. After “optimizing” and eliminating multiple matches 
13 two-way exchanges; 15 three-way exchanges; 8 three-way list chain 
exchanges; and 26 NDD chain matches were offered to transplant centers as 
possible matches. Most common reason offers were declined include: positive 
crossmatch (16%); donor factors (16%). and recipient inactive or transplanted 
(24%). Four potential offers occurred in MAPEP alone pairs, 31 in NEPKE 
alone, and 27 offers were cross-regional. Of the 8 matches that moved forward 
to donation and transplantation, seven involved NDD chains and one involved 
a 2-way exchange. Of the 19 transplants resulting from these matches, 17 
involved NDD chains.
Conclusion: Using a computerized optimization algorithm to match 2 and 3 
way exchanges, NDD and list exchange chains has lead to a substantial increase 
in the number of KPD matches and transplants performed. Cross-regional 
coordination is feasible and expands the number of transplants performed 
beyond the ability of individual exchange programs.
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EXCHANGE LIVING-DONOR KIDNEY 4 
TRANSPLANTATION; ITS MERIT AND LIMITATION
K.H. Huh1,2, M.S. Kim1,2, M.K. Ju1,2, H.J. Ahn3, D.J. Joo1, S.J. Kim1, 
S.I. Kim1,2, Y.S. Kim1,2, K. Park3
1Yonsei University College of Medicine Department of Surgery, 2Yonsei 
University College of Medicine The Research Institute for Transplantation, 
3Department of Surgery, Kwandong University College of Medicine
The shortage of donor organs is one of the major barriers to transplantation 
worldwide, and especially in countries where cadaveric organ donations 
are limited. An exchange donor (swap) program between two families was 
launched in Korea in 1991. After the success of direct donor exchanges, we 
have developed the swap-around program by enrolling many kinds of unrelated 
donors. We report here on our results of exchange living-donor kidney 
transplants.
From September 1995 to September 2006, we performed 1,163 kidney 
transplants. The living-unrelated donors (LURDs) were composed of 129 
exchange donors and 269 non-exchange donors. We compared the results of 
exchange donor transplants with non-exchange donor kidney transplants.
Compared with the non-exchange group, exchange group spent a lot of time on 
pretransplant dialysis until transplantation. And the proportion of preemptive 
kidney transplant was extremely lower in the exchange group (3.9%) than 
in the non-exchange group (14.1%) (p=0.005). In exchange group, blood O 
type kidneys were restrictively allocated to blood O type recipients (78.9%) 
compared to non-exchange donor group (54.4%) (p=0.007). Therefore the 
proportion of ABO identical matching transplantation of the exchange donor 
group was signifi cantly higher than that of the non-exchange donor group 
(87.6% versus 75.1%) (p=0.004). The overall 10-year graft survival rate 
(86.3%) for exchange donor kidney transplants was comparable to that for 
non-exchange donor (82.3%) and one-haplomatch (81.2%) kidney transplants 
(p=0.2994) (Fig.). The incidence of acute rejection was similar between the 
exchange (32.0%) and non-exchange (29.3%) donor groups. In multivariate 
survival analysis, the donor type (exchange versus non-exchange) did not 
impact on the graft survival rate. We can expect excellent clinical results by the 
exchange living-donor kidney transplant program as an option to reduce the 
donor organ shortage. But the exchange program has a considerable limitation 
in blood O type recipients.
OUTCOME OF LIVING DONOR KIDNEY EXCHANGE 5 
POOL MATCHING CAN BE MAXIMIZED BY NOT LIMITING 
CHAIN LENGTH
E. de Buijzer1, B. Haase1, W. van der Deijl2, A. Bomans2, 
M. de Klerk1, W. Weimar3
1Dutch Transplant Foundation, 2Eurotransplant International Foundation, 
3Dept. of Nephrology, Erasmus Medical Center
Introduction: Since January 2004 the Netherlands has a successful Living 
Donor Kidney Exchange (LDKE) program. Over these 4 years, the matching 
algorithm was adapted to match a pool of donor-recipient pairs for doublets in 
2004, for triplets in 2005 and for maximum possible chain length in 2007.
Methods: In the Dutch national LDKE program, donor and recipients pairs 
can be included if they are unable to donate directly to each other, either due 
to blood type incompatibility or due to immunological reasons. The pool of 
donor-recipient pairs is matched 4 times a year. The LDKE algorithms used 
donor HLA and recipient unacceptable HLA antigens to determine all possible 
combinations in a pool. We compared the three algorithms to study whether the 
chain length would affect the number of recipients that could be helped.
Results: Until 2007 the maximum number of pairs in a chain was limited to 
3. As of 2007 there is no limit anymore on the donors and recipients in a chain 
of pairs that can donate to each other. This resulted in an exponential growth 
of possible combinations. Based on theoretical grounds, using this algorithm 
would result in helping more recipients with a living donor kidney transplant.
In the pool of January 2007 57 pairs were included. Matching for doublets 
resulted in helping 8 pairs. Matching for triplets resulted in helping 12 pairs. 
However, using the new algorithm without the limitation of the chain length 
resulted in successful matching of 17 pairs. In order to help these 17 pairs the 
maximum chain length required was 6 pairs.
Conclusion: The results of LDKE matching can be increased substantially by 
matching a pool of donors without limiting the chain length.
IMPACT OF ALTRUISTIC UNBALANCED PAIRED 6 
KIDNEY EXCHANGE & DONOR/RECIPIENT ATTITUDES 
TOWARDS PARTICIPATION
L.E. Ratner, A. Rana, E.R. Ratner, J. Kelly, D.J. Cohen, V. Ernst, D. Kornfeld, 
I. Wiener
Columbia University
Background: Altruistic Unbalanced Paired Kidney Exchange (AUPKE) utilizes 
compatible live donor/recipient pairs (D/R) to exchange with incompatible live 
D/R pairs to allow all recipients to receive a compatible donor kidney.
Purpose: 1) To determine the impact of AUPKE if practiced in its simplest 
form using ABO compatible, but non-identical donors (ABONI) at individual 
centers. 2) To determine patient s attitudes towards AUPKE to be able to 
effectively encourage participation.
Methods: At initial evaluation, potential donors recipients were administered a 
survey regarding attitudes toward AUPKE. A 5-point Likert Scale was utilized.
Results: 1396 (22.8%) ABONI live donor txs were performed in the US in 2005 
of which 91% of the donors were blood group O. Recipient survey respondants 
were more likely than donors (p=0.002) to favor participation in AUPKE in the 
absence of any advantage to themselves. However, a number of circumstances 
increased the propensity to view AUPKE favorably for both recipients donors 
(p<0.05) (see fi gures 1 2 respectively).
Conclusions: 1) AUPKE can have a profound impact on the number of live 
donor renal txs. 2) In its simplest form, utilizing ABONI donors AUPKE can 
be performed at individual centers without requiring large sharing networks or 
complex computer algorithms. 3) Blood group O recipients with incompatible 
donors are likely to be the primary benefi ciary of AUPKE. 4) D/R attitudes 
are not static, and can be infl uenced in favor of participating in AUPKE, 
particularly if there is a perceived benefi t to the recipient. 5) Both donors 
recipients are more willing to participate in AUPKE if their intended recipient 
or donor (respectively) are enthusiatic about participating. 6) Finally, AUPKE 
refl ects a major paradigm shift for live donation, converting a private resource 
(the donor) to a shared or public one.
SELECTING THE BEST COMBINATIONS IN AFTER 7 
MATCHING A POOL OF LIVING DONOR KIDNEY EXCHANGE 
PAIRS
E. De Buijzer1, B. Haase-Kromwijk1, W. van der Deijl2, A. Bomans2, 
M. de Klerk1, W. Weimar3
1Dutch Transplant Foundation, 2Eurotransplant International Foundation, 
3Dept. of Nephrology, Erasmus Medical Center
Introduction: Computerized matching of a pool donor-recipient pairs in the 
Dutch Living Donor Kidney Exchange (LDKE) program resulted in a huge 
number of possible combinations of donor-recipient pairs that could donate to 
each other.
Matching a pool of donor-recipient pairs implies that some pairs can be 
matched with many others, whereas for other pairs only one or no combination 
can be found. For allocation a computerized selection was required according 
to preset conditions.
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Methods: In order to select the best possible combination in a match, sorting is 
performed based on preset conditions. These conditions are:
1. Helping as many as possible recipients
2.  Blood type identical matches before blood type compatible to avoid 
accumulation of blood type 0 recipients in the pool while draining the blood 
type 0 donors
3. Most diffi cult to match patients fi rst based on a match probability
4. Short chains preferred
5. Patients preferably dispersed over multiple centers
6. Longest number of days on dialysis
7. Number of negative X-matches
By changing the sort order, the outcome of best possible combination can be 
infl uenced.
Results: In the LDKE pool of January 2007 57 donor-recipient pairs 
participated. Depending on donor and recipient factors, like blood group, HLA 
and PRA, some pairs can be matched with multiple other pairs. Matching this 
pool without limiting the chain length of pairs that can donate to each other 
resulted in 3.427.603 possible combinations. Using this sort order resulted 
in the selection of a single combination that was considered to be the best 
according to the pre-defi ned conditions.
Conclusions: By sorting according to preset conditions, a single combination 
of matched pairs can be selected from a huge set of results after LDKE matching 
of a pool of recipients.
EXPERIENCE WITH 100 GOOD SAMARITAN KIDNEY 8 
DONOR CANDIDATES
W. Zuidema1, L. Kranenburg2, R. Erdman2, M. Hilhorst3, M. de Klerk1, 
J. IJzermans4, W. Weimar1
1Internal Medicine, Erasmus MC, 2Medical Psychology and Psychotherapy, 
Erasmus MC, 3Medical Ethics, Erasmus MC, 4General Surgery, Erasmus MC
Background: Living donation provides for an increasing proportion of 
kidney transplants. However, not all patients have a suitable living donor. 
For patients without willing donors the only option is to wait for a deceased 
donor kidney. Patients with willing but incompatible donors have the choice to 
participate in a living donor kidney exchange program. Unfortunately, in case 
of ABO incompatibility the success rate for O recipients in these programs is 
disappointingly low (24%). Good Samaritan kidney donation may be a solution 
for patients without willing donors, for recipients of ABO incompatible 
couples or for both categories at the same time in domino-paired procedures. 
We describe the results of such a program in which one Good Samaritan can 
make 2 transplants possible.
Methods: We prospectively collected data from all individuals that made 
inquiries about altruistic kidney donation to non-genetically and non-
emotionally related patients.
Results: 100 donor candidates approached us since the year 2000. All were 
sent written information on living kidney donation in general and on our Good 
Samaritan protocol, which includes a psychological evaluation procedure. 
(SCL-90 and an in-depth interview). On the basis of written information 28 
persons decided not to donate, 5 have not decided yet and 5 were referred to 
another center. We enrolled 62 potential donors in our screening procedures, 
and found medical and/or psychological contra-indication in 14 instances, 
while 11 procedures are still pending. We accepted 37 individuals for donor 
nephrectomy. One person withdrew consent. The remaining 36 Good Samaritans 
made a total of 55 kidney transplants possible: directed donation in 6 cases, and 
11 undirected anonymous donations to patients on the wait list. In 19 cases we 
arranged domino-paired procedures in which Good Samaritans were coupled 
to recipients of unsuccessful ABO incompatible crossover couples. The donors 
of these couples agreed to donate to wait list patients according to routine 
allocation criteria.
Conclusion: Integration of programs for Good Samaritan donation and living 
donor kidney exchange results in true synergy.
NEW YORK STATE GUIDELINES FOR LIVE-KIDNEY 9 
DONATION
M. Gallichio1, J. Bromberg2, D. Distant3, T. Powell4, D.Cohen5, D. Conti1
1Albany Medical College, 2Mt. Sinai Medical Center, 3SUNY Downstate, New 
York, 4New York State Department of Health, 5Presbyterian Hospital, New York
The kidney transplant wait list continues to rapidly increase. In response, living 
kidney donation rates have tripled in the past decade. This area continues to 
evolve: individuals with higher medical risk and non-traditional relationships 
with recipients are now frequently considered for live donation. To address 
concerns about these practices and to protect potential live kidney donors (and 
recipients). New York State Department of Health (NYS-DOH) convened 
a committee (COMM) to develop guidelines for centers performing live-
donor kidney transplants. The COMM. consisted of representatives of all 
NYS Transplant Programs, expert outside consultants, transplant physicians, 
surgeons, mental health professionals, live- kidney donors, coordinators, 
and DOH staff. The COMM. addressed 3 areas: 1) Medical Evaluation; 2) 
Non-Medical Evaluation (donor advocacy, informed consent, psychosocial 
evaluation, long-term follow-up); and 3) Unrelated Donors (“Solicited” donors, 
paired donation, non-directed donation). The Medical Evaluation Sub-COMM. 
emphasized minimizing the risk to the donor and adopted the recommended 
minimal screening guidelines as articulated by the Amsterdam Forum, and 
addressed areas of particular concern in expanding the range of acceptable 
medical criteria for donation: renal function, hypertension, obesity, glycemia, 
malignancy, cardiovascular risk. The Non-Medical Evaluation Sub-COMM 
focused on the importance of the psychosocial assessment of the potential 
donor, who must understand the risks and benefi ts, not be subject to coercion, 
and maintain autonomy in deciding whether to proceed with donation. The 
Unrelated Donor Sub-COMM emphasized the specifi c elements needed in the 
evaluation process for this “new” type of donors who have neither a biologic nor 
a long-standing emotional relationship with the potential recipients. This group 
stressed the importance of understanding donor motivation in each type of non-
traditional donation, additional elements in the informed consent process, and 
protection of donor and recipient privacy. These guidelines have been approved 
by the NYS Transplant Council and are intended to be consistent with and 
complementary to the UNOS Living Kidney Donor Evaluation Guidelines
LIVER OUTCOMES 1CONCURRENT ORAL SESSION 2: 
PATIENT OUTCOMES IN TWO STEROID-FREE 10 
REGIMENS USING TACROLIMUS MONOTHERAPY AFTER 
DACLIZUMAB INDUCTION AND TACROLIMUS AND MMF IN 
LIVER TRANSPLANTATION
T. Becker1, G. Otto2, I. Bilbao3, D. D’Amico4, M. Colledan5, A. Bernardos6, 
C. Broelsch7, H. Isoniemi8, J. Pirenne9, J. Jaray10
1Medizinische Hochschule Hannover, Germany, 2Universitätsklinikum Mainz, 
Germany, 3Hospital Vall d’Hebron, Barcelona, Spain, 4Azienda Ospedaliera 
di Padova, Italy, 5Azienda Ospedaliera Spedali Riuniti, Bergamo, Italy, 
6Hospital Virgen del Rocio, Sevilla, Spain, 7Universitätsklinikum Essen, 
Germany, 8Helsinki University Central Hospital, Finland, 9UZ Gasthuisberg, 
Leuven, Belgium, 10Semmelweis University of Medicine, Budapest, Hungary
Introduction: Evidence has shown that long-term steroid administration 
after liver transplantation is a predisposing factor to infectious and metabolic 
complications. Similar complications are associated with multi-agent 
immunosuppressant use. Providing optimal immunoprophylaxis while using 
a minimum of immunosuppressant agents could be key to improving clinical 
outcome in liver transplantation.
Methods: 627 patients were randomised. Patients in the full analysis set (TAC/
DAC, N=305; TAC/MMF, N=297) received an initial daily TAC dose of 0.15 
mg/kg. DAC induction was administered twice: 2.0mg/kg intraoperatively 
and 1.0mg/kg given once during Week 1. MMF was administered at 2 g/day 
to Day 14 and thereafter at 1 g/day. Both groups received a single steroid 
bolus (≤ 500mg) on Day 0. Target TAC trough levels were 10-15 ng/ml up 
to Day 42 and then <10 ng/ml. The primary endpoint was incidence and time 
of fi rst biopsy proven acute rejection (BPAR) requiring treatment. Secondary 
endpoints included patient/graft survival, creatinine clearance (Cockcroft and 
Gault) and adverse events.
Results: Patient study completion rates were similar (TAC/DAC, 72% and 
TAC/MMF, 68.7%); study discontinuation due to any adverse event was 15% 
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in both groups. TAC trough levels were comparable and refl ected protocol 
guidelines. Of completers, 6% in the TAC/DAC group and 4% in the TAC/
MMF group took steroids and 66% of TAC/MMF patients took MMF at Month 
3. The incidence of treated BPAR was 18.5% (TAC/DAC) and 17.8% (TAC/
MMF) (ns). Three-month patient survival (Kaplan-Meier method) was 91.8% 
(TAC/DAC) and 91.6% (TAC/MMF); graft survival was 88.2% and 87.8%, 
respectively.
Generally, adverse events were reported less frequently in the TAC/DAC group 
(Table 1).
Table 1: Most Frequently Reported* Adverse Events –% of Patients
TAC/DAC
N=305
TAC/MMF
N=297
Infection
Renal & Urinary
Metabolism Disorder
Gastrointestinal Tract
Hepatobiliary
Blood & Lymphatic System
Respiratory
Vascular
Nervous System
Immune System
General
Musculoskeletal
52.1
43.6
36.4
32.8
31.8
25.2
25.9
23.6
19.3
20.3
13.8
6.9
55.9
39.4
42.4
39.1
34.7
37.0
27.3
20.2
23.2
20.2
17.8
8.4
FAS; *>5% in either treatment group
Rates of bacterial infection were 18.4% with TAC/DAC and 23.2% with 
TAC/MMF, hepatobiliary infection was 8.2% and 8.1%, CMV was 6.2% and 
8.8%, HCV was 7.2% and 5.1%, respectively. Indicies for renal function were 
similar between the two treatment groups. Calculated creatinine clearance 
for completers at Month 3 was 69.7 mL/min (TAC/DAC) and 66.6 mL/min 
(TAC/MMF) and mean serum creatinine was 104.3μmol/L and 98.1μmol/L, 
respectively. Low incidences of de novo diabetes mellitus (>30 days antidiabetic 
treatment) were reported during Months 2-3 in both groups: 5.4%/221 patients 
in the TAC/DAC group and 6.2%/227 patients in the TAC/MMF group.
Conclusion: The two tacrolimus-based regimens optimised immunoprophylaxis 
while eliminating risks associated with steroids. Although effi cacy outcomes 
were comparable between TAC/DAC and TAC/MMF, safety outcomes, 
especially blood and lymphatic disorders, metabolism disorders, gastrointestinal 
disorders, and infection tended to be less frequently reported with maintenance 
therapy consisting of tacrolimus monotherapy than with tacrolimus/MMF dual 
maintenance therapy.
RENAL FUNCTION IN LIVER TRANSPLANT 11 
RECIPIENTS ACCORDING TO THE IMMUNOSUPPRESSIVE 
PROTOCOL: THE TRY STUDY
F. Saliba3, N. Janus1, S. Karie2, J. Dumortier3, N. Launay-Vacher1, 
Y. Calmus4, C. Duvoux5, R Lorho6, G. Deray1, G.P Pageaux7.
1Pitie-Salpetriere, Paris; 2Edouard Herriot, Lyon; 3Paul Brousse, Villejuif; 
4Cochin, Paris; 5Henri Mondor, Créteil; 6Pontchaillou, Rennes; 7Saint-Eloi, 
Montpellier, France.
The TRY study was designed to evaluate 1) the prevalence of kidney disease 
after liver transplantation (LTx). and 2) the potential differences in the clinical 
course of patients’ renal function (RF) depending on the immunosuppressive 
drugs they receive. We describe here the RF of liver transplant recipients 
according to the immunosuppressive protocol, before transplantation (BT). at 1 
month (1M). 1 year (1Y) and 5 years (5Y) after LTx.
Methods: TRY (liver Transplantation and Renal insuffi ciencY) is a French 
retrospective, multicenter observational study. The data collection was 
performed at 4 time points: BT, at 1M, 1Y, and 5Y after LTx. RF was assessed 
with the aMDRD formula.
Results: 1508 patients were included from 15 centers. Changes in GFR were 
compared according to the immunosuppressive protocol:
-group “CNI+MMF” where patients received a CNI associated with 
mycophenolate mofetil (MMF) at 1M, at 1Y, at 5Y.
-group “CNI” where patients received a CNI without MMF at 1M, at 1Y, at 5Y. 
In this group, most patients received only CNI and some CNI + Azathioprine. 
There was no difference between those 2 sub-groups on RF. All those patients 
were thus pooled in the same group and compared to “CNI+MMF”.
In both groups, the GFR decreased as compared to BT: -18.9% in CNI+MMF” 
vs -26.5% in “CNI” at 1M (NS). -18.1% vs -30.6% at 1Y (p=0.035). and 
-14.6% vs -33.3% at 5Y (p=0.013). The decrease in GFR was signifi cantly 
lower in group “CNI+MMF” as compared to “CNI” although mean GFR BT 
was signifi cantly lower in the group “CNI+MMF” (88 vs 96 mL/min/1.73m2, 
p=0.0009).
In addition, comparing the 117 patients who were on CNI+MMF at 1M and at 
1Y, and at 5Y with the 677 patients who were on CNI alone at each time, the 
decrease in GFR was also signifi cantly lower in the “CNI + MMF” group at 
1Y and 5Y (cf. Table 1).
Conclusion: The reduction in GFR was less pronounced in the group 
“CNI+MMF” even if these patients were signifi cantly more at a renal risk since 
their GFR BT was signifi cantly lower. At 1Y and at 5Y, there was no difference 
in CNI blood levels between the 2 groups, suggesting that the sustained lower 
decrease in GFR observed in group “CNI+MMF may not be only explained by 
a reduction in CNI exposition.
Table 1: Relative decrease in GFR in patients with or without MMF and 
comparison of CNI blood levels.
GFR,% Blood levels, ng/ml
1M 1Y 5Y 1M 1Y 5Y
CsA FK CsA FK CsA FK
CNI+MMF, 
n=117 -16.62 -15.50 -14.61 274.55 9.53 154.47 8.43 158.77 5.92
CNI, n=677 -26.09 -29.38 -32.85 342.66 11.83 199.98 8.51 135.17 6.31
p NS 0.05 0.02 NS <0.0001 NS NS NS NS
SINGLE-CENTER EXPERIENCE OF FIRST 1000 12 
CASES OF ADULT-TO-ADULT LIVING DONOR LIVER 
TRANSPLANTATION
D.H. Jung, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B Moon, T.Y. Ha, 
J.H. Ryu, E.J. Lee, E.S. Yang
Department of Surgery, Division of Hepatobiliary Surgery And Liver 
Transplantati
The outcomes of fi rst 1000 adult recipients undergoing living donor liver 
transplantation (LDLT) in a single center from February 1997 to January 2006 
were retrospectively analyzed. Recipient mean age was 47.9+/-8.6 years. Major 
primary diagnoses included hepatitis B virus-associated cirrhosis (n=845). 
acute liver failure (n=56). hepatitis C virus-associated cirrhosis (n=33) and 
alcoholic liver disease (n=30). Primary liver malignancy was detected in 300 
patients. Graft types were right liver grafts (n=651). left liver grafts (n=176) 
and dual liver grafts (n=173). Most right lobe grafts had middle hepatic vein 
outfl ow pathway through reconstructed or native vessel trunk. Median graft-to-
recipient weight ratio was 0.97. Retransplantation was performed in 9. Overall 
1-year, 3-year and 5-year patient survival rates were 89.3%, 84.7% and 82.9%, 
respectively. Five-year patient survival rate was 73.8% and 87.1% in patients 
with and without hepatocellular carcinoma, respectively. The most common 
causes of patient mortality and morbidity were hepatocellular carcinoma 
recurrence and biliary complication, respectively. Five-year hepatitis B 
virus reinfection rate was 7.3% after high-dose hepatitis B immunoglobulin 
monotherapy combined with rescue antiviral therapy. Overall perioperative 
recipient mortality rate within fi rst 3 months was 5.8%, whereas perioperative 
mortality rates in the 1st, 2nd, 3rd, 4th and 5th 200 cases were 12%, 6%, 5.5%, 
3% and 2.5%, respectively. A total number of 1175 living donors recovered 
without sequelae except 1 case of renal failure requiring kidney transplantation. 
The most important point of donor selection criteria for right liver harvest was 
preservation of at least 30% of the whole liver mass with full preservation 
of hepatic venous drainage. In conclusion, the perioperative mortality rate 
decreased much according to the accumulation of surgical experience. Prudent 
selection of patients with hepatocellular carcinoma appears to be critical to 
achieve favorable long-term survival. Biliary complication was not overcome 
by technical refi nement and remains as the most serious drawback of adult 
LDLT leading to deterioration of quality of life.
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DOES LIVING DONATION OFFER AN ADVANTAGE IN 13 
SURVIVAL AFTER PEDIATRIC LIVER TRANSPLANTATION IN 
THE MELD/PELD ERA?: ANALYSIS OF OPTN/UNOS DATA
Y. Cho1,2, T. Steljes1, J. Cicciarelli1,2, I. Hutchinson1,2, M. Stapfer2, R. Mateo2, 
L. Sher2, R. Selby2, Y. Genyk2
1National Institute of Transplantation, 2USC School of Medicine
Background: Recent studies demonstrated better outcomes of graft and patient 
survival in living donor liver transplantation (LDLT) compared with those of 
whole liver (WLT) and split liver transplantation (SLT). However their results 
often utilize recipients from both pre and post model-for-end-stage- liver-
disease (MELD/PELD) implementation.
Aims: This study retrospectively compares LDLT, SLT, and WLT in pediatrics 
in the MELD/PELD era by examining the OPTN/UNOS database with the 
intent to identify recipient factors that may impact outcomes.
Materials and Methods: From January 1, 2002 to December 31, 2006, 1,976 
liver transplant (LT) in recipients age<12 years old were reported to the OPTN/
UNOS. Of these, 298 LDLTs, 384 SLTs, and 1,294 WLTs were identifi ed. 
Multiple organ transplants were excluded from the study. The log-rank test was 
used for comparison of the two survival curves.
Results: Unadjusted graft survival rates of LDLT (85% at 1-yr and 82% 3-yr) 
were not signifi cantly different to those of SLT (81% at 1-yr and 75% 3-yr, 
P=0.11) and WLT (81% at 1-yr and 75% 3-yr, P=0.08) (Figure). Patient survival 
rates of LDLT (91% at 1-yr and 90% 3-yr) were also not signifi cantly different 
to those of SLT (90% at 1-yr and 86% 3-yr, P=0.54) and WLT (88% at 1-yr 
and 84% 3-yr, P=0.12) (fi gure). Incidence of primary graft failure was 3.4% 
for LDLT compared with 3.9% for SLT (P=0.70) and 3.5% WLT (P=0.91). 
Incidence of graft loss due to vascular thrombosis in LDLT group (6.0%) also 
was not signifi cantly different than those of SLT (6.0%, P=0.98) and WLT group 
(5.1%, P=0.91). Incidence of biliary tract complications was the highest in SLT 
(2.1%) among 3 group, but the differences were not statististically signifi cant 
(0.7% in LDLT, P=0.13 and 0.7% WLT, P=0.96). In multivariate analyses, both 
adjusted graft and patient survival rates of LDLT were not signifi cantly different 
than those of SLT (Relative Risk (RR) =0.79 (95% CI: 0.59-1.07). P=0.13 for 
graft and RR=0.77 (0.52-1.14). P=0.19 patient) and WLT group (RR=0.92 
(0.71-1.18). P=0.50 for graft and RR=0.75 (0.53-1.06). P=0.10 patient) after 
adjusting for confounding factors such as PELD and regraft.
Conclusion: In the MELD era, both SLT and WLT in pediatrics yielded 
comparable graft and patient survival to LDLT.
THE DOMINO LIVER WORLD TRANSPLANT 14 
REGISTER (DLTR) PERSPECTIVE ON DOMINO LIVER 
TRANSPLANTATION.
H. Wilczek, M. Larsson, B-G. Ericzon
Department of Transplantation Surgery, Karolinska University Hospital 
Huddinge, Karolinska Institute
Background: The DLTR was founded in 1999. It registers data on liver 
transplant recipients who received explanted livers from other patients who 
themselves underwent liver transplantation. As of Dec 2007, 48 hospitals in 
17 countries have been reporting domino liver transplantations (DLT) to the 
register. Currently 60–65 DLT: s are done annually worldwide.
Results: By December 31, 2007 a total of 625 DLT: s in 615 patients were 
recorded. The male/female ratio is 75% and 25%, respectively, with a mean 
recipient age at the time of transplantation of 54.4±9.6 years (range 17.0 – 73.9 
years, median 55.6 years). Overall, the frequency of retransplantations amounted 
to approximately 5%. The vast majority of the livers used for DLT came from 
FAP/amyloidotically affl icted donors (99%). but DLT using livers from donors 
with metabolic diseases other than amyloidosis have also been reported to the 
Registry. In 8 cases the DLT liver was used as a split and transplanted into 16 
recipients. The survival in FAP patients who became liver donors themselves 
did not differ from those FAP patients who did not donate a liver. The overall 
1-year, 5-year and 8-year graft survival in DLT recipients was 80%, 66% and 
63%, respectively. The most common domino liver donor mutation was the 
Val30Met. Overall, patients with malignancy diagnoses amounted to 43% in 
the Val30Met group and to 53% in the non-Val30Met group. Domino recipients 
transplanted because of malignancy had signifi cantly inferior survival rates 
compared to non-malignant recipients. In total, 185 out of 615 DLT recipients 
have died. Tumour recurrence and septicaemia accounted for the majority the 
deaths (40%). A signifi cantly better graft survival was observed in recipients 
of non-Val30Met mutated livers compared to Val30Met mutated livers (5-year 
survival 85% and 74%, respectively p<0.05).
Discussion: Patients accepted for Ltx can themselves, in carefully selected cases 
serve as hepatic organ donors. In experienced hands the procedure is safe both 
for the domino donor and the recipient. The immediate and short-term outcome 
in the domino recipients is excellent. The more long-term survival must also be 
deemed good, in view of the poor pretransplant condition and dismal prognosis 
domino recipients have without transplantation. As expected, the survival 
among domino recipients transplanted because of malignancy is inferior to that 
in recipients without malignancy Recipients of Val30met mutated livers show 
inferior survival rates to recipients of other TTR mutated livers. The reason for 
this difference is not clear. Domino livers make a valuable resource, but there 
is a need for caution and vigilant long-term monitoring because of the hitherto 
relatively unknown TTR kinetics following DLT and a risk of transferring the 
donor disease to the domino recipient.
THE POSITIVE EFFECT OF PROSTAGLANDIN E1 ON 15 
HEPATIC MICROCIRCULATION FOLLOWING CLINICAL 
LIVER TRANSPLANTATION IS ENHANCED IN STRONG 
ISCHEMIA/REPERFUSION INJURY
M. Angelescu1, E. Klar1, T. Kraus2
1Dept. of Surgery, Rostock University, Germany, 2Dept. of Surgery, 
Krankenhaus Nordwest, Frankfurt, Germany
Background: Literature data suggest that Prostaglandins have a benefi cial 
impact on graft quality following liver transplantation by their vasodilating 
and cytoprotective effect. However, prophylactic as well as therapeutical 
administration in graft non-function is still a controversial issue. The aim 
of this study was to analyze the dose-dependent effect of Prostaglandin E1 
(PGE1) on hepatic microcirculation in clinical transplantation by continuous 
thermodiffusion monitoring, and to defi ne which patients will benefi t most 
from PGE1-therapy.
Methods: In 30 liver transplant recipients a thermodiffusion probe was inserted 
into liver segment IVb for intra- and postoperative quantifi cation of hepatic 
microcirculation. On the second postoperative day PGE1 (Alprostadil) was 
intravenously administered at a gradually increasing dose (0.1–0.6 μg/kg/h). 
Dosage was titrated by 0.1 μg/kg/h in one-hour intervals. Microcirculation was 
quantifi ed prior to PGE1-administration, at the end of each dosage interval, as 
well as 3 and 12 hours after therapy was completed. Perfusion increment during 
PGE1-application was correlated to intraoperative microperfusion (PERFop). 
postoperative peak transaminases (ASTmax, ALTmax) and cold ischemia time 
as parameters refl ecting graft quality.
Results: Hepatic microperfusion signifi cantly increased from 69+2ml/100g/
min to 80+3ml/100g/min at a dosage of 0.2μg/kg/h (p<0.005). Maximum 
perfusion (89+5ml/100g/min) was achieved at a dose of 0.4μg/kg/h (p<0.001). 
High perfusion increment during PGE1-administration correlated with 
low intraoperative microperfusion (PERFop<60ml/100g/min – perfusion 
increment 55% vs PERFop>80ml/100g/min – perfusion increment 29%). high 
postoperative peak transaminases (ASTmax>1500U/l – perfusion increment 
76% vs ASTmax<500U/l – perfusion increment 30%). and a cold ischemia time 
greater than 9 hours (CIT>9h perfusion increment 47% vs CIT<9h perfusion 
increment 29%).
Conclusion: Low-dose Prostaglandin E1 signifi cantly improves hepatic 
microcirculation following liver transplantation with no further benefi cial effect 
above 0.4μg/kg/h. The highest perfusion increment is seen in patients with 
compromised microperfusion at the end of transplantation, high postoperative 
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serum transaminases as indicator of hepatocellular injury, and cold ischemia 
time above 9hours. We conclude that particularly patients with strong ischemia 
– reperfusion injury will benefi t most from PGE1-therapy.
DONOR TREATMENT WITH STEROIDS REDUCES 16 
INFLAMMATION AND IMPROVES GRAFT FUNCTION 
AND OUTCOME FOLLOWING DECEASED LIVER 
TRANSPLANTATION
A. Pascher1, F. Ulrich1, K. Kotsch2, A. Reutzel-Selke1, O. Kuecuek3, A. Lun4, 
S. Tullius5, P. Neuhaus1, J. Pratschke1
1Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow, Berlin, 
Germany, 2Inst. of Medical Immunology, Charité, Campus Mitte, Berlin, 
Germany, 3Deutsche Stiftung Organtransplantation, Berlin, Germany, 4Inst. 
of Lab. Medicine, Charite, Campus Virchow, Berlin, Germany, 5Division 
of Transplant Surgery, Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA, United States.
Body: In brain death (BD). induction of infl ammatory cytokines leads to an 
intensifi ed YR injury and an increased rate of primary non-function or acute 
rejection after liver transplantation (LT).
Methods: In a prospective randomized treatment-versus-control study in 100 
BD donors we investigated whether corticosteroid treatment of the deceased 
donor is able to attenuate BD-associated damage in clinical LT. Donor treatment 
(n=50) consisted of 250 mg methylprednisolone at time of BD diagnosis and a 
subsequent infusion of 100 mg/h until recovery of organs. A liver biopsy was 
taken immediately after laparotomy and blood samples were obtained after BD 
diagnosis and before organ recovery.
Results: Following steroid treatment, cortisol plasma levels were signifi cantly 
higher (pcO.O5) and a signifi cant decrease of soluble interleukins, MCP-1 
and IP-10 was observed. Corticosteroid treatment resulted in a signifi cant 
downregulation of ICAM-1, TNFa, MHC class II, FasL, IP-10 and CD68 
intragraft mRNA expression. Signifi cantly lower AST and bilirubin levels in 
the posttransplant course were accompanied by a decreased incidence of acute 
rejection and ischemic type biliary lesion.
Conclusions: Our present study verifi es the protective effect of steroid 
treatment in deceased donor LT, suggesting it as a potential therapeutical 
approach especially for marginal donor livers.
DONOR MANNOSE-BINDING LECTIN DEFICIENCY 17 
TRIPLES THE RISK OF POST-LIVER TRANSPLANTATION 
INFECTION.
D. Worthley1, D. Johnson2, D. Eisen3, S. Heatley4, M. Dean5,J-P. Tung5, 
H. Harley6, R. Padbury7, J. Scott8, C. Mullighan9, P. Angus10, P. Bardy11,12
1Royal Brisbane And Women’s Hospital And Queensland Institute of Medical 
Research, 2Department of Infectious Disease, Austin Health, 3Department 
of Infectious Disease, Royal Melbourne Hospital, 4Australian Red Cross 
Blood Service, 5Australian Red Cross Blood Service, 6Department of 
Gastroenterology and Hepatology, The Royal Adelaide Hospital, 7South 
Australian Liver Transplant Unit, Flinders Medical Centre, 8Statistics Unit, 
Royal Brisbane and Women’s Hospital and Queensland Institute of Medical 
Research, 9Pathology, St. Jude Children’s Research Hospital, 10Victorian Liver 
Transplant Unit, Austin Health 11Division of Haematology, Royal Adelaide 
Hospital and Institute of Medical and Veterinary Science, SA, Australia 
12Department of Haematology, The Queen Elizabeth Hospital, SA, Australia.
Background: Mannose-binding lectin (MBL) is an important mediator of 
innate immunity, primarily synthesized by the liver. MBL defi ciency occurs 
in approximately 40% of the population, is primarily due to polymorphisms 
in the gene encoding MBL (MBL2), and is associated with an increased risk 
of infection. Clinically signifi cant infection (CSI) is the chief complication 
following liver transplantation (OLT). We have examined associations between 
donor and recipient MBL status and transplant outcome in a large retrospective 
study of OLT. 
Methods: One hundred and two consecutive adult donor-recipient liver 
transplant pairs were identifi ed through the Victorian Liver Transplant Unit, 
Australia. Donors and recipients were genotyped for promoter (-550H/L, 
-221X/Y) and coding (codon 52Cys, 54Asp, and 57Glu) MBL2 polymorphisms 
by PCR-SSP. MBL defi ciency was defi ned as any defi cient MBL2 coding allele. 
Pre-OLT and post-OLT sera was analysed for functional MBL activity using 
the ELISA-based mannan-binding and C4-deposition assays. The primary 
clinical endpoint was CSI, defi ned as symptomatic, invasive, microbiologically 
confi rmed infection. Episodes of pneumonia where confi rmatory testing failed 
or was impossible, but with typical clinical and radiologic features were also 
considered CSIs. Secondary endpoints were graft rejection, hospital stay and 
transplant failure. Multivariate analysis of the factors associated with CSI was 
performed using logistic regression. 
Results: The median duration of post-OLT follow up was 4.5 years (range 
2.1-8.1). Thirty-eight percent of patients developed post-OLT CSI. Thirty-nine 
percent of donors and 35% of recipients had MBL2 coding mutations. Twenty-
seven percent of patients receiving an MBL suffi cient liver compared to 55% 
of patients receiving a liver with an MBL2 coding mutation developed CSI 
(p=0.005). In multivariate analysis CSI was signifi cantly associated with donor 
derived MBL defi ciency (OR 3.34, 95% CI 1.35-8.3, p=0.009), increasing 
recipient age (OR=1.001, 95% CI 1.00-1.001, p=0.044) and CMV prophylaxis 
was protective (OR 0.22, 95% CI 0.078-0.616, p=0.004). Recipient MBL status 
did not infl uence OLT outcomes. 
Conclusions: Transplant recipients of MBL defi cient livers have a signifi cantly 
increased risk of developing post-OLT CSI. Post transplant immunoprophylaxis 
with recombinant MBL is likely to be benefi cial in this setting.
TERLIPRESSIN AS THERAPY FOR RENAL FAILURE 18 
AND HYPONATRAEMIA IN PATIENTS WITH LIVER FAILURE 
AWAITING TRANSPLANTATION
E. Prakoso, D. Koorey, S. Strasser, G. McCaughan, N. Shackel
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred 
Hospital, Sydney
Background: Renal failure and hyponatraemia are associated with increased 
morbidity and mortality in patients with liver failure. We performed an analysis 
of terlipressin therapy for renal failure and isolated hyponatraemia (hypoNa) 
in patients with liver failure at the Australian National Liver Transplantation 
Unit (ANLTU).
Methods: A retrospective analysis was performed on patients at the ANLTU, who 
received terlipressin for a minimum of 24 hours for the indications of renal failure, 
either hepatorenal syndrome (HRS) or nonHRS, and isolated hyponatraemia 
(serum Na <130 mmol/L without renal failure). Response was defi ned as: (a) the 
return of serum creatinine to ≤133 μmol/L in HRS, (b) normalisation of serum 
creatinine (≤110 μmol/L) in nonHRS renal failure, and (c) an increase in serum 
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Na level by ≥5 mmol/L from baseline in isolated hypoNa.
Results: Between August 2003 – February 2007, 85 patients (61M, 24F) with 
median age of 52 years (range 27-78) were treated with terlipressin. Seventy-
six patients received 1 course of terlipressin, 6 received 2 courses, and another 
3 received 3 courses (total courses = 97). Indications for terlipressin were type 
1 HRS (13). type 2 HRS (41). nonHRS renal failue (18). and isolated hypoNa 
(25). Median duration of treatment was 6 days (range 1-60). Baseline MELD 
score was >25 in 79%. Aetiology of liver failure was mostly viral hepatitis 
(42%) and alcohol (41%). For all indications, terlipressin resulted in an 
overall improvement in serum creatinine from a median of 164 to 116 μmol/L 
(p=0.001) and an increase in serum Na from a median of 128 to 134 mmol/L 
(p<0.001). Response rates for type 1 HRS, type 2 HRS, nonHRS renal failure 
and isolated hypoNa were 15%, 51%, 39% and 76% respectively. There were 
26 (27%) adverse events (19 pulmonary oedema, 2 cyanosis, 3 chest pain, 1 
livedo reticularis and 1 bleeding ischaemic gastric ulcers). After the initial 
terlipressin therapy, the follow-up duration was 27 days (range 1-1248). The 
overall mortality was 66%. In the survival analysis, those who responded to 
their initial terlipressin therapy had a signifi cantly better survival (p=0.004). 
The median survival of patients who responded was 65 days compared to 16 
days in those who did not respond. Thirteen (15%) patients underwent liver 
transplant after terlipressin therapy and these individuals had a signifi cantly 
greater survival (p<0.001). The 30-day survival rate was 85% in patients who 
were transplanted and only 31% for those who did not have a liver transplant.
Conclusions: Terlipressin therapy resulted in improved renal function and 
increased serum Na in patients with advanced liver failure. However, overall 
prognosis is poor without liver transplant. Those who responded to terlipressin 
survived longer, allowing these patients to be listed for liver transplant. 
Therefore, terlipressin may be used as a bridging therapy in patients with renal 
failure and isolated hypoNa who are awaiting liver transplant.
CONCURRENT ORAL SESSION 3: 
IMMUNOSUPPRESSION AND T REGULATORY CELLS
DOMINANT T CELL REGULATION ACHIEVED EX-VIVO 19 
VIA IFN-GAMMA/STAT-1 SIGNALING AND NITRIC OXIDE 
INDUCTION
G. Feng1, R. Francis1, W. Gao2, T. Strom2, M.Oukka3, K. Wood1, A. Bushell1
1Transplantation Research Immunology Group, Nuffi eld Department of 
Surgery, University of Oxford, 2Transplant Research Centre, Beth Israel 
Deaconess Medical Centre, Harvard Medical School, 3Center for Neurologic 
Diseases, Brigham and Women’s Hospital, Harvard Medical School
Background and Aims: IFN-gamma is usually considered to be a pro-
infl ammatory effector cytokine, but increasing evidence indicates that it also 
plays an important role in regulating the development of T cell responses in 
vivo. We have exploited this potential and have previously shown that naïve 
CD4+ T cells stimulated with allogeneic bone-marrow derived DC ex-vivo in 
the presence of IFN-gamma results in a population of regulatory T cells with 
the capacity to prevent skin graft allograft rejection. The aim of this study was 
to identify the origin and key mechanistic steps involved in development of this 
population with a view to possible translation to the human setting.
Methods and Results: Stimulation of CBA (H2k) CD4+ T cells with B10 
(H2b) GMCSF/TGF-beta conditioned bone marrow derived DC (BM-DC) in 
the presence of 5ng/ml IFN-gamma results in (i) preferential apoptosis within 
responding Foxp3-ve cells (49.0±3% apoptosis versus 9.5±7.0% in Foxp3-ve 
and Foxp3+ve cells respectively, P<0.05); (ii) STAT-1 dependent inhibition 
of Th17 responses; (iii) direct conversion of Foxp3-ve into Foxp3+ve cells 
(input population <0.5% Foxp3+ve; resultant population 17% Foxp3+ve 
demonstrated using Foxp3-GFP-reporter mice). Furthermore, using a system 
in which naturally occurring Treg and non-Treg can be distinguished on the 
basis of stable cell surface markers, we demonstrate that IFN-gamma driven 
conversion of Foxp3-ve precursors is partially dependent on the presence of 
pre-existing regulatory cells.
To explore in more detail the mechanisms responsible, inhibition of NOS using 
L-NMMA resulted in a striking dose-dependent decrease in Foxp3+ve cells 
from 40.0±6.3% without inhibitor to 33.4±15.4% with 0.1mM, 18.2±14.4% 
with 0.5mM and 4.5±2.6% with 1.0 mM inhibitor (P<0.05). In addition, 
provision of a NO donor (SNAP) in the absence of IFN-gamma replicates the 
IFN-gamma effect in that the proportion of Foxp3+ve cells increased from a 
baseline of <10% to 22.1±16.9%, 33.0±24%, 49.5±14.9% and 67.9±15.4% at 
0.1, 0.2, 0.3 and 0.4 mM SNAP respectively. These data indicate an important 
role for NO in the emergence of allo-reactive, Foxp3+ve adaptive regulatory 
T cells.
Conclusion and Signifi cance: When total CD4+ cells are driven by allogeneic 
APC in the presence of IFN-gamma, a combination of apoptosis of non-Treg, 
expansion of existing Treg and conversion of non-Treg precursors results in 
a 5-8 fold increase in the proportion of Foxp3+ve regulatory cells and the 
emergence of a dominant regulatory T cell population that can control allograft 
rejection. The data presented in this study provide mechanistic insights into this 
process and indicate adjunctive and alternative strategies which may enable 
translation to the human setting to provide robust populations of regulatory T 
cells for use in both transplantation and autoimmune disease.
ADOPTIVE TRANSFER OF CD4+CD25+ REGULATORY 20 
CELLS COMBINED WITH LOW-DOSE SIROLIMUS 
PRESERVES SUPPRESSIVE FUNCTION OF REGULATORY 
T CELLS AND DELAYED ACUTE REJECTION OF RENAL 
ALLOGRAFTS IN CYNOMOLGUS MONKEYS
H. Chen, A. Ma, S. Qi, L. Song, G. Yu, Y. Hu, H. Dun, Z. Xiong, 
D. Xu, P. Daloze
Research Center, CHUM, Notre-Dame Hospital, University of Montreal.
Exploring new immunosuppressive strategies to induce donor-alloantigen-
specifi c hyporesponsiveness is an important challenge in transplantation. 
CD4+CD25+ regulatory T cells have been known to play an important role in 
transplantation and autoimmune diseases. However, therapeutic applications 
are limited by poor capacity of CD4+CD25+ regulatory T cells. In this study, 
isolated CD4+CD25+ regulatory T cells from cynomolgus monkeys were 
expanded effi ciently in vitro by a co-culture system. These cells expanded 
50-60-fold in 4 weeks, and expressed high levels of CD25+ and FoxP3+ 
regulatory molecules. Expanded cynomolgus CD4+CD25+ regulatory T cells 
were anergic and suppressed the proliferation of autologous PBMC in donor 
alloantigen-dependent and cell dose-dependent fashion, and the suppression 
was partially reversed by anti-TGF-?1 and anti-IL-10 neutralizing antibodies. 
Adoptive transfer of expanded CD4+CD25+ regulatory T cells without any 
immunosuppressant could prolong survival time of totally MHC-mismatched 
renal allografts in cynomolgus monkeys compared to naive control group 
(MST, 38.0 ± 19.7 vs. 6.7 ± 2.5 days, p = 0.0261). 
Our previous study proved that sirolimus is a potent immunosuppressant with 
10- to 100-fold greater potency than cyclosporine in prevention of allograft 
rejection (H. Chen, et al, J Immunol. 1994; 15: 3107?18). To reach feasibility to 
clinical transplantation, our study addressed the hypothesis of whether a short-
term sirolimus therapy will profi t the generation of the CD4+CD25+ regulatory 
T cells in vitro, and whether exposure of CD4+CD25+ T cells to sirolimus 
can preserve suppressive function of regulatory T cells and can prolong the 
allograft survival. 
Our results showed that low-dose sirolimus (< 50 nM) could permit the 
expansion of cynomolgus CD4+CD25+FoxP3+ regulartory T cells in vitro. 
Our preclinical study is the fi rst report a tolerance-inducing strategy, adoptive 
transfer of CD4+CD25+ regulatory T cells combined with sirolimus of 14-day 
short-term and low-dose (0.5 mg/kg/day) therapy preserved suppressive 
function of regulatory T cells and delayed the onset of renal allograft rejection 
in cynomolgus monkeys, compared to the group of sirolimus treatment 
alone and controls (MST, 39.3 ± 19.6 vs. 29.0 ± 4.0 days and 6.7 ± 2.5 days, 
respectively, p = 0.2602, 0.0229). Even though the cell numbers of CD4+ T 
cell subsets were found to decrease in peripheral blood, sirolimus selectively 
enhanced the ratios of CD4+CD25+ regulatory T cells to CD4+ T cells. In 
addition, the frequency of CD4+CD25+IL-10+ (type 1 regulatory cells) cells 
was elevated in combined treated monkeys. This study provides a platform for 
forthcoming preclinical study of regulatory T cells in nonhuman primates as 
cellular immunomodulators.
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DIRECT FUNCTIONAL ACTIVATION OF 21 
CD4+CD25+FOXP3+ T CELLS BY INTRAVENOUS 
IMMUNOGLOBULINS PROMOTES SKIN ALLOGRAFT 
ACCEPTANCE
A.R. Bushell2, T. Tha-In1,2, J. Kwekkeboom1, H.J. Metselaar1, K.J. Wood2
1Erasmus Medical Center, Rotterdam, The Netherlands, 2Nuffi eld Department 
of Surgery, Oxford, United Kingdom
Intravenous Immunoglobulins (IVIg) is an effective treatment for T cell mediated 
graft rejection and autoimmune diseases. IVIg treatment is associated with rapid 
clinical improvements without the side effects of global immunosuppression. 
This prompted us to ask whether IVIg might enhance directly the suppressive 
function CD4+CD25+Foxp3+ regulatory T cells in vitro and in vivo.
In vitro, mouse CBA/Ca (H2k) total CD4+ or CD4+CD25- responder cells 
were stimulated with C57BL/10 (H2b) splenocytes, and human CD4+ or 
CD4+CD25- cells were stimulated with allogeneic antigen presenting cells. 
In vivo, 1*105 total CD4+ or CD4+CD25- T cells of CBA/Ca mice were 
adoptively transferred into CBA/RAG1-/- mice, and one day later transplanted 
with a tail skin graft of C57BL/10 mice. IVIg was administered i.v. on day 
1,3,7,10 and 14. Human Serum Albumin (HSA) was used as a control. Binding 
of IVIg and activation status of Foxp3+ CD4+ T cells were determined.
In vivo, only when total CD4+ T cells, but not CD25- T cells, were adoptively 
transferred, IVIg protected against T-cell mediated rejection of the fully 
mismatched skingraft (MST: IVIg >100 vs HSA 16 days, p<0.01). IVIg binds 
to 16±2% of Foxp3+ T cells, while binding to Foxp3- T cells was minimal. 
Furthermore, IVIg treatment resulted in activation of CD25+ T cells as 
detected by increased expression of phosphorylated ZAP70/Syk, which could 
be abrogated by specifi c tyrosine kinase inhibition. In vitro, IVIg inhibited 
the alloproliferative response of murine CD4+ T cells by 75±25%, but after 
depletion of CD25+ T cells, this inhibition decreased to 17±12% (N=6, p<0.01). 
Similar results were found in human MLR, where depletion of CD25+ T cells 
resulted in twofold reduction in IVIg mediated suppression. Signifi cantly, 
incubation of human CD4+CD25+ with IVIg enhanced their ability to suppress 
allogeneic T-cell proliferation (IVIg 63±8% vs HSA 37±10% of inhibition, 
N=5, p<0.05) .
Our results identify a novel pathway through which IVIg treatment induces 
direct functional activation of both mouse and human regulatory T cells. 
Immediate binding and activation of regulatory T cells is one of the mechanisms 
in the immunomodulatory repertoire of IVIg, which allows rapid inhibition 
of allogeneic responses, and therefore can be a valuable tool after organ 
transplantation.
MAINTENANCE OF TREG POPULATION AND 22 
PROLONGATION OF ALLOGRAFT SURVIVAL BY 
HEPATOCYTE GROWTH FACTOR IN MHC-INBRED CLAWN 
MINIATURE SWINE
M. Oku1, M. Okumi1, H. Sahara1, H. Tsubouchi2, A. Shimizu1, M. Sada1, 
K. Yamada1
1Frontier Science Research Center, Kagoshima University, 2Department of 
Digestive and Life-style Related Disease, Kagoshima University
Aims: We have previously reported that 12 days of FK506 facilitates the 
induction of tolerance to fully allogeneic kidneys in MGH miniature swine. 
The aims of this study are (1) to determine whether the same regimen facilitates 
the induction of tolerance to fully allogeneic kidneys in DNA-typed MHC-
inbred CLAWN miniature swine; and, if not, (2) whether hepatocyte growth 
factor (HGF) has benefi cial effects on graft functions.
Methods: 7 CLAWN miniature swine recipients received fully MHC 
mismatched kidneys with 12 days (days 0-11) of FK506 in an identical manner 
to that used for MGH miniature swine. Average blood levels were maintained 
between 35 and 45ng/ml, which uniformly facilitates the induction of tolerance 
to renal allografts across fully MHC mismatched barriers in MGH miniature 
swine. Four recipients received FK506 alone (Group 1) and three received 12 
days of FK506 with either 7 days (0.03mg/kg/day) or 14 days (0.015mg/kg/
day) of HGF starting at day 11 (Group 2) infused through a catheter placed in 
the renal artery. Statistics were calculated using Students t-test.
Results: In contrast to our previous report in MGH miniature swine, no animal 
treated with FK506 alone (Group 1) became tolerant despite using an identical 
protocol. These recipients developed either a severe acute rejection crisis (Cre 
>9mg/dl) or complete rejection within 3 weeks post KTx. In contrast, all three 
recipients that received HGF (Group 2) maintained stable renal function in 
the fi rst 2 months, although grafts were eventually rejected beyond day 80. 
Although creatinine levels were similar between the groups immediately after 
discontinuing FK506 (1.9 mg/dl Group 1 vs. 1.9 mg/dl Group 2 at day 13). 
there was a signifi cant difference in the creatinine levels 7 days after cessation 
of FK506 (9.5 mg/dl Group 1 vs. 1.9 Group 2 at day 18, p=0.002). Notably, 
a marked decrease in the percentage of CD4+CD25+Foxp3+ cells in the 
peripheral blood during the induction period was seen in Group 1, while HGF 
treated recipients maintained this population (p<0.02).
Conclusions: This study demonstrates: (1) a 12 day course of FK506 failed to 
induce tolerance across full MHC mismatched barriers in CLAWN miniature 
swine; (2) a short course of HGF inhibited acute rejection and was associated 
with higher levels of CD4+CD25+Foxp3+ Tregs. These data suggest that 
CLAWN miniature swine may be a more stringent large animal model to 
test pre-clinical tolerance protocols and that a short course of HGF prolongs 
renal allograft function and may either augment or maintain Treg cells. To 
our knowledge, this is the fi rst demonstration of the immunoprotective effect 
of HGF in a large animal model and suggests that HGF may be useful as an 
adjunct to induce tolerance by regulatory mechanisms.
ALLOGRAFT TOLERANCE AFTER IN VIVO EXPANSION 23 
OF TREGS WITH IL-2/IL-2 MAB COMPLEXES
K. Webster1, S. Walters1, T. Mrkvan1, O. Boyman2, S. Grey1, J. Sprent1
1Garvan Institute of Medical Research, 2Ludwig Institute for Cancer Research
Regulatory T cells (Tregs) are a small subset of lymphocytes crucial to tolerance; 
they actively mediate unresponsiveness to self-antigens and negatively regulate 
responses to foreign antigens. This capacity for such comprehensive regulation 
holds therapeutic promise for many fi elds of medical biology, including that 
of transplantation. Indeed the ability of these cells to diminish the allogeneic 
response to a graft has been well documented in animal models. However, graft 
acceptance can only be achieved when large numbers of Tregs are present, as 
at 5-10% of CD4+ T cells they are too few to elicit this outcome. While in vitro 
methods for the expansion of Tregs are the subject of much research, the in 
vivo expansion of these cells is also desirable.
In vivo, interleukin 2 (IL-2) is required for maintenance of peripheral Tregs, and 
stimulates these cells by binding to a trimeric high-affi nity receptor, composed 
of an α; chain (CD25). β; chain (CD122) and γ;c chain. By contrast, a dimeric 
intermediate-affi nity β;γ; receptor is expressed by “resting” T cells, such as 
memory CD8+ T cells, and NK cells. Hence, depending on the cell stimulated, 
IL-2 can effectively suppress or boost the immune response. Recently, a novel 
approach to enhancing IL-2 mediated T cell proliferation was observed in our 
laboratory (Boyman et al. 2006). The combination of IL-2 and an IL-2 antibody 
(clone S4B6). was found to stimulate the proliferation of T cells bearing the 
β;γ; receptor, to a far greater extent than cytokine alone. In contrast, the 
combination of IL-2 with IL-2 antibody clone JES6-1, selectively enhanced the 
Treg (α;β;γ; receptor) population. Thus the potential exists to utilise IL-2/IL-2 
mAb complexes to stimulate different subsets of IL-2 responsive cells, and thus 
direct the immune response towards immunity or tolerance.
We found that administration of IL-2 and IL-2 mAb clone JES6-1 to mice, 
rapidly and selectively boosts the Treg population to 50-60% of CD4+ T cells. 
Intriguingly, these Tregs upregulated cell surface molecules important for 
activation, adhesion, migration and suppression, showed enhanced function in 
in vitro suppression assays, and demonstrated signifi cant proliferation to IL-2 
in the absence of TCR stimulus. To test the effi cacy of these expanded Tregs in 
restraining an allogeneic immune response, we utilised an islet allograft model. 
C57BL/6 mice were treated with IL-2/IL-2 mAb (JES6-1) complexes prior to 
transplantation to achieve optimal Treg expansion and function. As expected, 
control C57BL/6 H-2b mice rejected their H-2d islet allografts with a MST of 
~19 days (n=10). In marked contrast, 80% of IL-2/IL-2 mAb treated C57BL/6 
mice did not reject their H-2d islet allografts (MST >100 days, n=22). We are 
currently examining the response to secondary BALB/c allografts to determine 
the nature of tolerance. The survival of grafts long term after only a short 
treatment protocol, and in the absence of constitutively high numbers of Tregs 
or immunosuppressive drugs, holds potential for therapeutic application.
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IMMUNOMODULATION INDUCED BY A CD28 24 
ANTAGONIST IN KIDNEY ALLOGRAFT BABOON RECIPIENT.
N. Poirier1, C. Mary1, E. Allain-Launay1, T. Haudebourg1, K. Renaudin2, 
X. Tillou1, S. Le Bas-Bernardet1, K. Georges1, B. Vanhove1, G. Blancho1
1INSERM Unit 643, 2Anapathology unit, CHU Hotel Dieu
Aims: Blocking selectively the CD28/B7 activation pathway and not the 
CTLA-4/B7 inhibitory pathway during initial antigen exposure, is one 
promising candidate strategy to promote tolerance. Here, we studied such a 
blockade in a baboon kidney allograft model using sc28AT, a non activating 
monovalent CD28 antagonist, alone and in combination with Tacrolimus.
Methods: Papio anubis received life-supporting kidney allografts (full MHC 
class II mismatch, stimulation index >10). The animals were divided into four 
groups: A) control group (untreated, n=3); B) sc28AT induction monotherapy 
(daily i.v. 4mg/kg during the fi rst 25 days, n=4); C) Tacrolimus monotherapy 
(through level: 10-20 ng/ml upon 90 days, n=4) and D) combination of group 
B and C (n=4).
Results: Although sc28AT monotherapy modestly prolonged graft survivals 
at this dosage (mean survival 10,5±1.8 d. vs 6.6±0.3 d. for control group) it 
induced a down-modulation of CD28 expression in circulating T cells without 
modifi cation of T cell counts and no cytokine storm. At rejection, we observed 
an inhibition of B cell infi ltration, an increase of CTLA4-positive T cells in the 
cellular infi ltrates and an enhancement of IDO and HO-1 expression within 
the graft. Tacrolimus monotherapy was suboptimal in prolonging graft survival 
(50% of acute rejection at one week and 50% at the treatment discontinuation). 
whereas selective blockade of CD28 potentiated Tacrolimus in preventing 
acute graft rejection (no early rejection episode in the fi rst month). Moreover, 
circulating CD4 CD25+ Foxp3+ CD127low regulatory T cells were quickly 
increased in bitherapy recipient (from day 1 or 2). These recipients exhibited 
at one month a nearly 4-fold increase in Tregs as compared with Tacrolimus 
monotherapy recipients (4,7±0,8% of CD4 T cells vs 1,2±0,3% respectively). 
Finally, CD25+ T cells extracted from these bitherapy recipients were found to 
be suppressive even in a ratio of 1 CD25+ to 128 CD25- cells.
Conclusion: Blocking CD28/B7 and not CTLA4/B7 interactions in baboon 
with an antagonist monovalent Ab against CD28 revealed no immunological 
toxicity, synergized with Tacrolimus in preventing acute rejection, promoted 
upregulation of immunomodulatory mechanisms and enhanced the proportion 
of circulating Tregs.
INFUSION OF ALLOGENEIC MESENCHYMAL 25 
STROMAL CELLS CAN DELAY BUT NOT PREVENT GVHD 
AFTER MURINE TRANSPLANTATION
M. Kambouris, B. Turner, L. Sinfi eld, H. Cullup, D. Hart, K. Atkinson, 
A. Rice
Mater Medical Research Institute
Multipotent, mesenchymal stromal cells (MSC) are emerging as means 
of immunosuppression for patients with steroid refractory graft-versus-
host disease (GVHD). Despite clinical use, pre-clinical data is lacking. We 
established an in vivo model using MSC to control GVHD and determine 
their mode of immunosuppression. In vitro our MSC highly suppress T cell 
proliferation, even at low ratios of 1 MSC per 100 T cells. We then examined 
the effects of donor-derived intraperitoneally (IP) or intravenously (IV) injected 
MSC on GVHD in a myeloablative conditioned, full mismatched model of 
haematopoietic stem cell transplantation (HSCT) [UBI-GFP/Bl6 (H-2b) to 
BALB/c (H-2d) ]. 4x10*5 donor-derived MSC/mouse were injected 4hrs pre or 
24hrs post HSCT then mice were monitored daily for GVHD. Only mice given 
MSC IP 24hrs post HSCT showed a signfi cant delay in death from GVHD, 
where median survival was increased by 10 days (d) (d7 vs d17, p<0.001. 
We then investigated if MSC delivered IP pre or post HSCT altered cytokine-
driven traffi cking of cellular effectors known to play a role in GVHD via timed 
sacrifi ce. Control mice (HSCT and no MSC or MSC and no HSCT) were also 
sacrifi ced daily for 6 days following HSCT. We found that MSC given post-
HSCT enter an environment of signifi cantly increased activated dendritic cells 
(DC) in the spleen and at d3 and d6 post HSCT, mice given MSC pre HSCT had 
increased levels of activated splenic DC compared to mice treated with MSC 
24hrs later. At d3, we also saw more IFN-gamma in spleen washings in mice 
treated pre HSCT compared to controls. We then determined the role of MSC in 
GVHD control in a minor mismatch model [UBI-GFP/Bl6 (H-2b) to BALB.B 
(H-2b) ]. MSC were given various MSC infusions, either: d1, 7, or 14; d1 and 
d7; or to mice with established GVHD (>25% weight loss with other surrogate 
GVHD markers more than 14d post HSCT). Mice given MSC therapy after 
GVHD onset showed no increase in survival compared to controls. However, 
MSC administered prophylactically at d1 (4x10*5/mouse) or d7 (1x10*6/
mouse) showed signifi cantly increased survival compared to controls but not 
in the multiple injection (d1 and d7) or the d14 alone cohorts, suggesting that 
the timing of MSC administration is important for their impact on GVHD. In 
summary, IP injection of MSC infl uences GVHD and survival and may have 
in vivo infl uence on activated DC. Elucidation of the mechanism by which 
MSC control GVHD may ultimately lead to wider application of their use to 
assist HSCT.
MECHANISMS OF ANTIGEN-SPECIFIC SUPPRESSION 26 
MEDIATED BY DOUBLE NEGATIVE REGULATORY T CELLS
Z. Li1, M. Ford1, K. Young1, J. Gao1, B. Joe1
1University Health Network, 2University of Toronto, 3Toronto General 
Research Institute
Regulatory T (Treg) cells, found in both mice and humans, have been 
demonstrated to play an important role in controlling the development of 
various immune pathologies including transplant rejection and autoimmune 
disease development. Recent data have demonstrated that treatment with 
ƒÑƒÒ-TCR+CD3+CD4-CD8-NK1.1- (double negative, DN) Treg cells 
can inhibit autoimmune diabetes development and enhance allo- and xeno-
transplant survival in an antigen-specifi c fashion. However, the mechanisms 
of DN Treg cell-mediated antigen-specifi c suppression of immune responses 
remain largely unknown. Here, we demonstrate that DN Treg cells can acquire 
donor alloantigens and present these antigens on their cell surface following 
alloantigen exposure in vivo. Furthermore, only DN Treg cells that had 
acquired high levels of alloantigen in vivo were able to induce cytotoxicity of 
primary activated syngeneic CD8+ T cells. DN Treg cell acquisition requires 
specifi c interaction between the high affi nity peptide/MHC and the specifi c 
T cell receptor. Interestingly, activated B cells are more effi cient than mature 
dendritic cells at donating alloantigens to DN Treg cells. Furthermore, DN Treg 
cells are able to kill dendritic cells but not B cells. These data provide new 
insights into how Treg cells can mediate antigen-specifi c T cell suppression and 
may enhance our ability to use DN Treg cells as a therapy to prevent transplant 
rejection and autoimmune diseases.
PRO-TOLEROGENIC PROPERTIES OF RAPAMYCIN 27 
THAT FAVOR INDEFINITE HEART ALLOGRAFT SURVIVAL 
MEDIATED BY REGULATORY T CELLS.
G. Raimondi1, B. Matta1, P. Santos1, Z. Wang1, A. Thomson1,2
1TE Starzl Transplantation Institute – Dep of Surgery, University of 
Pittsburgh, 2Dep of Immunology, Univrsity of Pittsburgh
A short course of Rapamycin (Rapa; 1mg/Kg/day i.p. d0-9) combined with 
post-transplant infusion of allo-Ag specifi c Treg (AAsTreg; d7) promotes 
tolerance induction in a mouse vascularized heart transplant model (BALB/c 
to C57BL/10 [B10]; unmanipulated). We investigated the cellular effects 
associated with Rapa administration that permit (and are probably necessary 
for) the success of the protocol.
Method: B10 naïve animals and B10 recipients of BALB/c hearts received 
Rapa (1mg/Kg/day i.p.; 7 days) or were untreated. The T cell profi le in 
different lymphoid compartments was evaluated. Additionally, ex vivo T cell 
reactivity against donor-derived DC and susceptibility to Treg suppression 
were investigated.
Results: Administration of Rapa to naïve animals signifi cantly reduced lymph 
node T cell absolute numbers (abs#) (approx 2-fold). but the incidence of CD4+, 
CD8+, and Foxp3+ cells was preserved. Splenic T cell abs# were not altered, 
but the incidence of CD4+ and CD8+ cells was increased. Strikingly, the abs# 
and incidence of splenic Foxp3+ cells was markedly reduced. Rapa exerted a 
striking effect on the thymus: total cellularity was reduced 8-fold. The frequency 
of double-negative (DN) cells was markedly increased, while that of double-
positive (DP) cells was reduced. The proportion of single-positive (SP) cells rose 
signifi cantly and, strikingly, among the CD4+ SP cells, the frequency of Foxp3+ 
cells increased 3-fold. Administration of Rapa to heart allograft recipients 
exerted distinct effects. Splenic and lymph node T cell abs# dropped (greater 
effect on CD4+ than CD8+ cells). but the proportion of Foxp3+ T cells increased 
signifi cantly. CD4 T cells purifi ed from spleens of transplant recipients treated 
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with Rapa showed stronger ex-vivo reactivity to donor DC than cells from naïve 
animals, confi rming that Rapa permits T cell priming but promotes anergy 
induction and/or conversion to Foxp3 expression. Additionally, CD4 T cells 
isolated from untreated recipients showed a signifi cant degree of “resistance” 
to in vitro suppression of proliferation by titrated numbers of Treg. Such 
“resistance” was not evident in T cells from Rapa-treated recipients. Moreover, 
Rapa treatment prevented allograft T cell infi ltration, and elevation of serum IL-6 
(responsible for the observed T cell “resistance” to Treg suppression). Finally, 
preliminary results indicate the capacity of Rapa to signifi cantly reduce the 
proliferative capacity of in vitro-generated memory T cells, whose contribution 
to transplant rejection has been well demonstrated.
Conclusion: Rapa contributes to tolerance induction at multiple levels. It 
lowers circulating T cells by reducing thymocyte development and favors Treg 
ontogeny. In transplant recipients, Rapa causes additional T cell decreases that 
correlate with its ability to favor activation-induced cell death (AICD). The 
increased proportion of splenic Foxp3+ cells correlates with both the Treg-
sparing properties of Rapa and its reported induction of Foxp3 in T cells. 
Finally, Rapa exerts signifi cant anti-infl ammatory activity that favors Treg 
suppressive function, even at the level of memory T cell regulation.
CONCURRENT ORAL SESSION 4: 
CORNEA AND BIOARTIFICIAL ORGANS
PROLONGATION OF CORNEAL GRAFT 28 
SURVIVAL FOLLOWING ADMINISTRATION OF 
3-HYDROXYKYNURENINE.
A. Khan, A. George1, S. Zaher1, C. Germain1, H. Fu1, and F. Larkin2
1Department of Immunology, Division of Medicine, Imperial College London, 
Hammersmith campus, London, UK and 2Moorfi eld’s Eye Hospital, London. UK.
Indoleamine 2,3-dioxygenase (IDO) has been shown to prolong corneal graft 
survival. IDO modulates the immune response by depletion of the essential amino 
acid tryptophan and by the production of kynurenines which act directly on T cells. 
We have therefore investigated the role of the kynurenines in corneal graft rejection.
In order to assess the effect of kynurenines on T cell responses, the molecules 
were added into both mixed lymphocyte reactions and anti-CD3/CD28 bead 
stimulation of T cells. In both human and mouse 3-Hydroxykynurenine (3-HK) 
and 3-Hydroxyanthranilic acid (3-HAA). but not L-Kynurenine or Quinolinic 
acid, inhibited T cell proliferation. This was accompanied by signifi cant cell T 
cell death. There is no evidence of induction of regulatory T cells as shown in 
the mouse by failure to induce FoxP3 expression. Neither 3-HK nor 3-HAA 
has a major effect on dendritic cell function, nor do they affect apoptosis or the 
activation status of corneal endothelial cells.
In order to determine if these agents can prolong graft survival we carried 
out corneal allografts in a murine model. Administration of 3-HK on a daily 
basis to BALB/c mice receiving a C3H corneal graft resulted in considerable 
prolongation of graft survival (MST of controls = 12 days, of treated = 19 
days). This was seen when the 3-HK was given between day 1-7, 7-14 or 1-14. 
Chronic administration of 3-HK resulted in no signifi cant alteration in CD4, 
CD8 or FoxP3 positive splenic T cells.
These data therefore indicate that one mechanism by which IDO prolongs 
corneal graft survival is by the production of kynurenines, in particular 3-HK 
and 3-HAA. In addition it highlights the potential of these molecules as agents 
for preventing allograft rejection.
EFFICACY OF A STEROID-INDUCIBLE PROMOTER FOR 29 
LENTIVIRUS-MEDIATED TRANSDUCTION OF THE CORNEA
S. Klebe, D. Parker, A. Clarke, H.M. Brereton, D.J. Coster, K.A. Williams
Flinders University
Corneal transplantation can restore vision to patients with corneal opacities. 
The evidence for effi cacy of systemic immunosuppression in such patients is 
extremely limited. Topical corticosteroids are currently prescribed long-term 
in all patients for prophylaxis and treatment of graft rejection, but are tapered 
in eyes with stable grafts. Kaplan-Meier corneal graft survival within Australia 
is 51% at 15 years, and the most common cause of failure is immunological 
rejection. Ex vivo gene therapy directed at the donor cornea shows promise 
for modulating corneal transplant rejection in animal models and may 
eventually provide adjunctive treatment for humans. Use of an appropriate 
viral vector coupled with a glucocorticoid-sensitive promoter might permit 
inducible expression of a therapeutic transgene after administration of a 
topical ophthalmic steroid. Ophthalmic steroids penetrate the eye effectively, 
and topical administration would provide a convenient method for controlling 
transgene expression. 
Aim: Our aim was to investigate a steroid-inducible promoter for use in gene 
therapy of the cornea. 
Methods: A 320 base pair sequence encoding fi ve glucocorticoid response 
elements (GRE) from the rat tyrosine aminotransferase gene, upstream of the 
adenovirus 2 major late promoter TATA box/initiation site was cloned into a 
non-replicative, self-inactivating, VSVG-pseudotyped lentiviral vector (LV) 
carrying the ovine interleukin 10 (IL10) gene. A similar vector carrying the 
simian virus 40 (SV40) promoter was used for comparative purposes. A549 
cells and ovine and human corneas were cultured in vitro in the presence or 
absence of dexamethasone. Transgene expression was assessed by an ovine 
IL10-specifi c ELISA. 
Results: A549 cells were transduced with LV-GRE-IL10 and cultured for 48 
hours in medium containing 0, 2.5 nM, 50 nM or 1000 nM dexamethasone. 
Expression of secreted IL10 was 45-fold higher in samples from cells cultured 
in the presence of 50 nM and 1000 nM dexamethasone than in the absence of 
dexamethasone. Dexamethasone withdrawal resulted in the return of secreted 
IL10 to control levels. Ovine corneas were transduced with LV-GRE-IL10 
and organ-cultured in the presence or absence of 50 nm dexamethasone. 
Basal expression of IL10 was low in the absence of dexamethasone. After 9 
days of organ culture, supernatants from corneas transduced with LV-GRE-
IL10 and cultured with glucocorticoid contained 9 times the concentration 
of IL10 detected in supernatants from control corneas, and 3 times more 
than supernatants from corneas transduced with LV-SV40-IL10 at the same 
multiplicity of infection. Human corneas were then transduced with LV-
GRE-IL10 or LV-SV40-IL10 and organ-cultured for 9 days in the presence or 
absence of 50 nM dexamethasone. Levels of IL10 in supernatants from corneas 
transduced with LV-GRE-IL10 or LV-SV40-IL10 were approximately 14 times 
and 12 times higher, respectively, than in supernatants from transduced corneas 
cultured without dexamethasone. 
Conclusions: Transduction with a lentiviral vector containing a steroid-
inducible promoter resulted in a 35-fold upregulation of IL10 expression in 
A549 cells and a 9-fold upregulation in transduced ovine and human corneas. 
The expression levels were equivalent to (human). or superior to (ovine) levels 
achieved by a vector containing the SV40 promoter. The promoter showed low 
leakiness in the absence of dexamethasone.
LENTIVIRUS-MEDIATED GENE TRANSFER TO THE 30 
OVINE AND HUMAN CORNEA
D. Parker, S. Klebe, H.M. Brereton, D.J. Coster, D.S. Anson, K.A. Williams
Flinders University
Patients disabled by blinding corneal disease can be treated surgically by 
corneal transplantation, but many grafts fail from allograft rejection. Gene 
therapy of the donor cornea can modulate corneal transplant rejection in 
experimental animals but the most appropriate vector for gene transfer has yet 
to be determined. 
Aims: Our aims were to explore the use of a recombinant, non-replicative, self-
inactivating, VSVG-pseudotyped lentivirus in the ovine and human cornea. 
Methods: Lentivectors (LV) that carried the enhanced yellow fl uorescent 
protein (eYFP) gene under the control of the simian virus 40 early (SV40) 
promoter, the phosphoglycerate kinase (PGK) promoter, and the elongation 
factor-1α; (EF) promoter, or that carried the ovine interleukin 10 (IL10) gene 
under the control of the SV40 or the cytomegalovirus (CMV) promoter, were 
constructed. Ovine and human corneas were transduced in vitro and organ-
cultured for up to 15 days. LV-mediated expression in transduced ovine and 
human corneal endothelium was assessed by fl uorescence microscopy, real-
time quantitative RT-PCR or ELISA. Gene expression was compared with 
expression driven by analogous adenoviral vectors following alterations of 
transduction period duration and vector dose, as well as in the presence or 
absence of polybrene. The stability of eYFP expression in ovine corneas and the 
infl uence of IL10 expression on graft survival following ex vivo transduction 
of the donor cornea was assessed following orthotopic corneal transplantation 
in outbred sheep. 
Results: LV-SV40-eYFP transduced 80-90% of ovine corneal endothelial cells 
after in vitro organ-culture, and eYFP expression was maintained for at least 
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28 days in vivo in recipient sheep after orthotopic corneal allotransplantation 
of a transduced donor cornea. However, the kinetics of LV-mediated gene 
expression were slower than those achieved by comparable adenoviral vectors. 
Further, 24 hour transduction of ovine corneal endothelium with LV-IL10 
resulted in mRNA levels that were logarithmically lower than those achieved 
by an adenoviral vector. Shortening the transduction period to 2 hours led to a 
further reduction in gene expression. The addition of 40 μ;g/ml polybrene to the 
transduction mixture restored expression to levels comparable to those attained 
after a 24 hour transduction period, but at the cost of associated toxicity for 
corneal epithelium. Allografts transduced for 2–3 hours with LV-SV40-IL10 in 
the absence of polybrene were rejected at a median of 25 days (n=7) compared 
with 18 days in the combined sham-treated and LV-SV40-eYFP control group 
(n=14) (p=0.026). Vectors containing the PGK or EF promoter were not more 
effective than LV-SV40-eYFP in driving transgene expression in ovine corneas, 
but LV-CMV-eYFP generated signifi cantly better, faster expression at low 
multiplicity of infection. Interestingly, LV-mediated eYFP and IL10 expression 
was signifi cantly higher and more rapid in organ-cultured human corneas (the 
eventual target species of interest) than in ovine corneas. 
Conclusions: Ovine and human corneal endothelial cells were effi ciently 
transduced by the lentiviral vector. LV-SV40-IL10 prolonged ovine corneal 
allograft survival to a modest, albeit signifi cant extent. Species differences 
were apparent in LV-mediated transduction effi ciency, but promoter exchange 
signifi cantly improved transgene expression levels.
RISK FACTORS FOR FULL-THICKNESS HUMAN 31 
CORNEAL GRAFT FAILURE WITHIN THE AUSTRALIAN 
CORNEAL GRAFT REGISTRY
K. Williams, T-L. Kelly, M. Lowe, C. Bartlett, D. Coster
Flinders University
Aims: Our aims were to examine graft survival and visual outcome after 
corneal transplantation and to identify risk factors for graft failure within a 
large, prospective national register. 
Methods: Records of 17,090 full-thickness (penetrating) corneal grafts were 
examined within a prospectively-maintained, national database, with annual 
archival follow-up extending from one to 22 years. Information was available 
on the recipient, donor, eye bank practice, surgical procedure, and on post-
operative outcomes. Kaplan-Meier survival analysis was used to indicate 
variables of interest for Cox proportional hazards regression analysis. A model 
clustered by individual patient to control for inter-eye or inter-graft dependence 
was constructed to identify variables best predicting penetrating corneal graft 
failure. Visual acuity in the grafted eye was measured by best-corrected Snellen 
acuity (without pinhole). 
Results: The major indications for corneal transplantation were keratoconus 
(32%). bullous keratopathy (26%). failed previous graft (19%). corneal 
dystrophy (7%). and herpetic eye disease (4%). Probability of corneal graft 
survival was 0.87 at one year, 0.73 at 5 years, 0.62 at 10 years and 0.51 at 
15 years. Variables predicting graft failure in multivariate analysis included 
transplant centre, location and volume of surgeon’s case-load, graft era, 
indication for graft, number of previous ipsilateral grafts, lens status, corneal 
neovascularisation at the time of graft, history of ocular infl ammation or 
raised intraocular pressure in the eye to be grafted, graft diameter, early suture 
removal, and post-operative events including graft neovascularisation, rejection 
episodes, need for refractive surgery to the grafted eye, and arrangements 
for recipient follow-up. No factors relating to the donor (including donor 
age) or to eye bank practices (including corneal preservation time) could be 
demonstrated to infl uence graft survival in multivariate analysis. The major 
reasons for corneal graft failure were irreversible rejection (31%). corneal 
endothelial cell failure (21%). infection including recurrent herpetic keratitis 
(13%) and glaucoma (8%). The desired outcome of corneal transplantation was 
improvement in vision (70%). pain relief (4%). structural repair of a damaged 
globe (6%). improved cosmesis (<1%) or a mixture of two or more of these 
reasons (19%). A best-corrected Snellen acuity of 6/12 or better was achieved 
by 45%, and of less than 6/60 by 26%, of grafted eyes at last follow-up.
Conclusions: The short-term survival of penetrating corneal transplants is 
excellent, but long-term outcomes are no better than for vascularized organ 
transplantation. The attrition rate of corneal grafts is slow but inexorable.
COMPARISON OF IMMUNOSUPPRESSION RELATED 32 
TOXICITIES AND COMPLICATIONS IN OCULAR 
SURFACE TRANSPLANT AND RENAL TRANSPLANT 
RECIPIENTS: IMPLICATIONS FOR COMPOSITE TISSUE 
TRANSPLANTATION
G. Mogilishetty1, D. Hair2, R.R. Alloway1, M.J. Everly2, L. Cole1, M. Meyer1, 
A. Govil1, P. Roy-Chaudhury1, E.J. Holland2 and E.S. Woodle1.
1Transplantation and 2Cincinnati Eye Institute, University of Cincinnati, 
Cincinnati, OH.
Body: Ocular surface transplant (OST) differs from routine cornea transplant 
by exposure to surrounding vascularized recipient tissue, enhancing rejection 
risk. Improved OST results are achieved with systemic immunosuppression 
(IS). We evaluated OST and renal transplant (RT) patients (pts) managed at the 
same center to determine differences.
Methods: Pts receiving OST or RT were retrospectively analyzed at 
0,3,6,12,24mos post transplant for demographics, IS exposure, effi cacy and 
toxicity variables. The RT matched control was based upon IS regimen and 
followup. Anemia defi ned as Hct<35%. Leukopenia defi ned as WBC<4000.
Results: 66pts received 74 OST and were compared to 32 RT. Demographic 
characteristics of gender, age, and primary transplant were similar between 
the groups. IS maintenance of tacrolimus, Cellcept (MMF). and steroids was 
similar between groups, with RT receiving Simulect induction. IS exposure is 
summarized below.
Immunosuppression Exposure
IS Agent @ 0, 3, 6, 12, 24, 36mo OST (n=66) RT (n=32) 
Prednisone mean dose (mg/d) -, 11, 9, 10, 5, - 164, 9, 6, 5, 4, 5
MMF mean dose (G/d) 1.5, 1.5, 1.3, 1.1, 1.2 2.1, 2.1, 2.1, 1.9, 1.6, 1.5
Mean tacrolimus level (ng/mL) 7.2, 7.9, 7.8, 6.7, 6.8, - 1.6, 9.0, 8.6, 8.2, 7.6, 6.7
Outcome and toxicity variables are summarized below. 95% of OST pts visual 
acuity scores improved, with 53% >20/200. No reports of PTLD.
Outcome and IS Toxicity Variables
Variable OST (n=66) RT (n=32) p-value
Mean Followup (yrs) 2.0 + 1.6 2.8 + 0.8 NS
Rejection (%) 19% 25% NS
Graft Survival (%) 77% 97% 0.006
Patient Survival (%) 100% 94% 0.02
SrCr (mg/dL) at 0, 3, 6, 12, 
24mo
0.9, 1.0, 1.0, 1.0, 
0.9, 1.1
7.2, 1.3, 1.3, 1.4, 
2.2, 1.5 <0.0001
New onset HPT@1yr (%pts) 5% 9% NS
New Onset DM (%pts) 2% 9% NS
Cardiovascular Event (%pts) 2% 13% 0.05
Anemia@1yr (%pts) 13% 9% NS
Leukopenia@1yr (%pts) 0% 13% 0.001
Infection (%pts) 5% 16% 0.03
Conclusion: OST pts demonstrated remarkably reduced IS related toxicity. 
These observations indicate underlying systemic disease signifi cantly 
infl uences IS related toxicity profi les. This experience suggests composite 
tissue transplant recipients experience substantially fewer adverse effects with 
systemic IS.
PERMANENT REVERSAL OF AUTOIMMUNE DIABETES 33 
IN NON OBESE DIABETIC MICE AFTER LENTIVIRAL 
HEPATIC INSULIN GENE THERAPY
B. Ren1, B. O’Brien1, M. Byrne1, E. Ch’ng1, M. Swan2, R. Gijsbers3, 
Z. Debyser3, A. Simpson1
1University of Technology Sydney, 2University of Sydney, 3IRC KULAK and 
KU Leuven
Type I diabetes (TID) mellitus results from the T-cell mediated autoimmune 
destruction of the insulin-producing pancreatic beta cells. Exogenous insulin 
therapy cannot mimic the precise physiologic control of blood glucose 
concentrations achieved by beta cells and debilitating complications develop 
due to fl uctuations in blood glucose levels. Gene therapy is one strategy being 
actively explored to cure TID by affording non-beta cells the ability to secrete 
insulin in response to physiological stimuli. In a recent study, we used a novel 
surgical technique to express furin-cleavable human insulin (INS-FUR) in the 
livers of streptozotocin diabetic-Wistar rats using the HMD lentiviral vector 
(1). Normoglycaemia was observed for 500 days (experimental endpoint). a 
signifi cantly longer period than previously reported and this was the fi rst to 
report, permanent reversal of diabetes using a lentiviral vector. The aim of the 
present study was to determine if our methodology could reverse diabetes in 
the most widely used autoimmune model of diabetes, the non obese diabetic 
(NOD) mouse. Lentiviral vectors were produced using 293T cells and then 
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purifi ed and concentrated by tangential fl ow fi ltration and ultracentrifugation 
(40,000g/4h). Following delivery of INS-FUR or empty vector (3.5 x 108 
transduction units) to spontaneously diabetic NOD mice (blood glucose 
>14mM). mice were monitored for body weight and blood glucose levels. 
An intravenous glucose tolerance test (IVGTT) was performed after a 14 
h fast in untreated (n=6). empty vector-transduced (n=10) and INS-FUR-
transduced NOD mice (n=10). together with non-obese resistant (NOR) 
mice (n=10) as an additional control. At various times after the infusion of 
glucose (1 g/kg body weight). blood samples were collected and assayed for 
glucose, c-peptide and insulin. Liver, pancreas, kidney, spleen and lung were 
harvested at the experimental endpoint (5 months). Expression of insulin was 
determined by RT-PCR, immunohistochemistry, and transmission electron 
microscopy. Triple immunofl uorescent staining for the pancreatic hormones, 
insulin, glucagon and somatostatin was performed on pancreas and liver tissue 
sections. Immunofl uorescent staining was used to identify CD4+/CD25+ T cell 
populations within the spleen.
We have achieved 37„b1.9% (n=5) transduction effi ciency of hepatocytes in 
vivo. Mice treated with INS-FUR, exhibited reversal of hyperglycaemia within 
48h and normoglycaemia was maintained for 5 months, without the induction 
of hypoglycemia. IVGTTs revealed that insulin-transduced mice showed 
similar responses to elevated blood glucose concentrations as nondiabetic NOR 
mice. The transduction procedure resulted in expression of several beta cell 
transcription factors (PDX-1, Ngn3, Nkx2.2, Pax4, Pax6). pancreatic hormones 
glucagon and somatostatin and signifi cant hepatic insulin storage in granules 
characteristic of beta cells. No beta cell transcription factors or pancreatic 
hormones were expressed in the livers of animals treated with the empty 
vector alone. Liver function tests remained normal and there was no evidence 
of lymphocytic infi ltration in the livers of HMD/INS-FUR-treated animals. 
Numbers of CD4+/CD25+ T cells by immunofl urescent staining, signifi cantly 
increased (P<0.01) in HMD/INS-FUR treated NOD diabetic mice. Importantly, 
pancreatic exocrine transdifferentiation did not occur. Our data suggest that this 
regimen may ultimately be employed clinically to cure TID.
IMPROVED OUTCOME OF PORCINE HEPATOCYTE 34 
TRANSPLANTS IN ACUTE LIVER FAILURE RATS BY 
CULTURE WITH NANOPARTICLES AND COLLAGEN
Z. Chen1, W. Zhu1, W. Guan1, H. Cai1, F.Tang1, L. Lu2, S. Qian2
1Hepatobiliary Surgery, Nantong University Affi liated Hospital, 2Department 
of Immunology and General Surgery, Cleveland Clinic
Acute liver failure (ALF) is a life-threatening condition with high mortality. 
Due to the potent regeneration capacity of the liver, temporary liver function 
support, by hepatocyte transplantation may provide critical time for ALF 
patients to recover through liver regeneration. Use of xenogeneic hepatocytes is 
considered an approach to relief of limited hepatocyte sources, but the outcome 
has been poor due to profound immune responses including both cellular and 
humoral. In this study, we used a novel approach; porcine hepatocytes were 
cultured with polylactic acid-O-carboxymethylated chitosan (PLA-O-CMC) 
nanoparticles, embedded in rat collagen gel. The gel blocks were transplanted 
into the peritoneal cavity of SD rats whose ALF was induced by i.p. injection 
with D-galactosamine (gal). 48 hr after D-gal injection, 5 x l07 porcine 
hepatocytes alone (Group A). porcine hepatocytes embedded in collagen gel 
(Group B). and porcine hepatocytes cultured with PLA-O-CMC nanoparticles 
plus embedded in collagen gel (Group C) were transplanted (n=55 in each 
group). Without hepatocyte transplant, only 18.5% animals survived by POD 
14. Porcine hepatocyte transplant signifi cantly improved animal survival (Group 
A, 56.3%, Group B, 62.5%, Group C, 75%, all p<0.05 compared to controls). 
Plasma levels ofHGF and VEGF, which have been widely used for indication 
of liver regeneration in ALF, were monitored following transplantation. Plasma 
HGF was elevated posttransplantation with a peak at 12 hr, and declined 
thereafter. Plasma VEGF levels were peak at 72 hr post-transplant. Group C 
showed signifi cantly higher plasma HGF and VEGF levels, compared with 
other groups. Liver pathologic examination showed more hepatocytes with 
double nuclei, richer mitochondria and rough endoplasmic reticulum in Group 
C rats, suggesting active regeneration. In conclusion, transplant of porcine 
hepatocytes provides a critical time window for hepatocyte regeneration in 
this animal model. Nanoparticle plus collagen gel may function as temporary 
barriers to attenuate immunological attacks.
TISSUE ENGINEERING USING PARTIAL INTESTINAL 35 
GRAFT AS A POSSIBLE SCAFFOLD FOR LIVER 
REGENERATION IN PIGS
T. Hata1,2, S.Uemoto1, E. Kobayashi2
1Department of Surgery, Kyoto University, 2Division of Organ Replacement 
Research, Jichi Medical University
Portal hypertension is serious condition with multiple symptoms such as 
ascites, variceal bleeding, encephalopathy and eventually liver failure. 
Various therapies including radio-interventional and surgical portosystemic 
shunt have been applied, in order to improve it, with the increasing risk of 
encephalopathy and possible reduction of effective hepatic blood fl ow. Once 
liver failure occurred, cadaveric and living donor liver transplantation is only 
option, whereas limited number of donor results in serious shortness of graft 
and causes ethical and social problems all over the world.
To make a breakthrough in this situation, we have developed a new method of 
partial intestinal graft as a portocaval shunt, with the strategy to innovate the 
effective shunt system with hepatic function, and demonstrated the possibility 
for the scaffold of liver regeneration.
First, we established rodent model using luciferase transgenic Lewis (Luc-LEW) 
rat as a donor of partial intestine and syngenic Lewis (LEW) rat as a recipient 
with anastomosing the host portal vein (PV) trunk with graft artery and host 
inferior vena cava (IVC) with graft PV. In vivo bioluminescent imaging showed 
graft survival by portal blood fl ow for 1 month and histologically the graft wall 
structures were preserved except mucosa. In another model, we evaluated the 
intensity of luminescence from hepatocyts of Luc-LEW rat transplanted into 
intestinal lumen of syngenic LEW rat. We confi rmed the increase of intensity 
by the host hepatectomy, suggesting the possibility of scaffold.
Then, to apply this system to preclinical porcine model, we measured the shunt 
volume through porcine partial intestinal graft ex vivo and the satisfactory 
results were obtained. According to all results, we established an auto-
transplantation model in pigs. In this model, we donated terminal ileum, and 
engrafted it to the same pig with anastomosis similar to rodent model: the host 
PV trunk with graft artery and host IVC with graft PV in side-to-end fashion. 
We performed 4 operations using miniature pigs without portal hypertension 
and confi rmed that suffi cient blood supply to the grafts was well observed and 
the graft walls were preserved histologically.
We showed that partial intestinal graft can be applied to portocaval shunt in 
pig. This new technique might lead to the new concept of intestinal scaffold 
with the possible application for various kinds of tissue regeneration from stem 
cells.
CONCURRENT ORAL SESSION 5: 
GENOMIC AND MOLECULAR DIAGNOSTICS
A FOXP3 POLYMORPHISM THAT INFLUENCES GRAFT 36 
SURVIVAL AFTER KIDNEY TRANSPLANTATION
C. Baan1, A. Peeters1, J. van de Wetering1, J. IJzermans2, W. Weimar1
1Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The 
Netherlands, 2Surgery, Erasmus MC, University Medical Center Rotterdam
CD4+CD25+FOXP3+ regulatory T-cells are crucial for the balance of 
immunological reactivity to self and non-self. A short (GT) n allele has been 
associated with increased FOXP3 promoter activity. We studied the infl uence 
of recipient FOXP3 genotype on clinical outcome of kidney transplantation.
DNA from 684 recipients who survived at least 1 year and with a follow up of 
6 y (median; range 1-12 y) was genotyped. Maintenance immunosuppressive 
therapy consisted of calcineurin inhibitors in combination with MMF or AZA. 
Acute rejection occurred in 23% of the patients.
For (GT) n genotype, recipients were divided into two classes: short alleles (£ 
15 repeats; class S) and long alleles (>;16 repeats; class L). As a result of its 
location on the X-chromosome and allele location, 78% the female patients 
and 50% male patients are carriers of the FOXP3 S-allele. Graft survival 
was associated with the studied gene polymorphism (log rank p=0.02). This 
benefi cial effect of the FOXP3 polymorphism was observed in grafts exposed 
to prolonged cold ischemia time and acute rejection. Graft survival of deceased 
donor kidneys (exposed to >14 h cold ischemia) transplanted in carriers of 
the S-allele (N=205) was signifi cantly better than those of L-homozygotes 
(N=142). 89% vs 82%, respectively, p=0.02. These graft survival rates were 
comparable to grafts from living donors with short ischemia times. Also in 
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patients (N=160) who experienced a graft rejection episode an effect of the 
FOXP3 polymorphism was found. The 5-year graft survival of rejectors who 
were carriers of the S-allele was 14% higher than that of non-carriers of the 
S-allele, 91% vs 77%, p=0.0003. In the multivariate analysis the FOXP3 
S-allele proved to be an independent variable associated with reduced risk for 
graft failure (odds ratio 0.59, 95%CI 0.39-0.91, p=0.015).
These data show that the recipient FOXP3 genotype is associated with 
outcome after kidney transplantation. Carriers of the FOXP3 S-allele and thus 
with increased regulatory T-cell capacities showed superior control of tissues 
damage due to non-immunological and immunological events leading to in 
better graft survival.
INTEGRATIVE GENOMICS TO IDENTIFY NON-HLA 37 
ALLOGENIC KIDNEY-SPECIFIC TARGETS AFTER KIDNEY 
TRANSPLANTATION
M. Sarwal, L. Li, P. Wadia, R. Chen, M. Naesens, D. Miklos, A. Butte
Stanford University
Aims: To identify if serological responses to allogenic non-HLA renal 
compartment-specifi c antigens can be detected after renal transplantation (txp).
Methods: 36 paired pre- and post-transplant (mean time 25 months) serum 
samples from 18 pediatric kidney allograft recipients were used for identifi cation 
of de novo non-HLA antibody formation assessed using Invitrogen ProtoArray 
(v3). measuring signal post-pre. Probes from the Protoarray and cDNA 
microarray platforms were re-annotated to current NCBI Entrez gene identifi ers 
using AILUN. 34 cDNA arrays (GSE: 3931) from 7 normal kidney regions 
(inner and outer cortex, inner and outer medulla, papillary tips, renal pelvis and 
glomeruli; see Table) were analyzed for compartment-specifi c genes by SAM, 
and the highest-ranked genes in each compartment (KS two-sample test p < 
0.001) and were ranked against each individual patients numerical antibody 
response across the 5057 proteins on the Protoarray.
Results: In 83% of patients (15/18). kidney-specifi c serological responses 
against the renal pelvis were the fi rst to be detected, followed by responses 
against renal cortex. Control gene expression data sets from other solid organs 
(GSE: 1133; lung, heart, pancreas) did not demonstrate immune-response 
enrichment. The presence of these antibodies was not associated with donor 
specifi c HLA class I or II antibody levels.
Conclusion: We demonstrated de novo formation of circulating non-HLA non-
ABO antibodies after txp, irrespective of HLA antibodies, are detected against 
kidney-specifi c protein targets. As these antibodies are not seen against other 
solid organs, the response is likely allogeneic. The renal pelvis and renal cortex 
have the highest immunogenic potential. Two selected pelvis and cortex targets 
and localizations were confi rmed by IHC. This study provides a roadmap of 
renal compartment-specifi c non-HLA antigens generating post-transplant 
alloimmune responses, opening the door for clinical correlations with post-
transplant dysfunction.
Table A: Allo-antigenic targets by anatomic regions mapped between cDNA 
microarray and ProtoArray Human Protein Microarrays
Anatomic 
region of 
kidney
# of genes up in 
region
Measured on 
ProtoArray
Overlapped 
Percentage
 (cDNA and 
ProtoArray) 
Glomeruli 842 161 19%
Inner Cortex 900 201 22%
Outer Cortex 1405 336 24%
Inner Medulla 37 9 24%
Outer Medulla 150 29 19%
Pelvis 2299 466 20%
Papillary Tip 675 167 25%
PROBABILISTIC (BAYESIAN) MODELING OF GENE 38 
EXPRESSION IN TRANSPLANT GLOMERULOPATHY
T. Brown1, J. Hawksworth1,2, O. Cheng3, D. Leeser2, A. Stojadinovic2, 
D. Tadaki1, E. Elster1,4, R. Mannon3
1Regenerative Medicine, Naval Medical Research Center, Silver Spring, MD, 
2Surgery, Walter Reed Army Medical Center, Silver Spring, MD, 3National 
Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of 
Health, Bethesda, MD, 4Surgery, National Naval Medical Center, Bethesda, MD
Introduction: Transplant glomerulopathy (TG) is a distinctive lesion identifi ed 
on allograft biopsy associated with rapid decline in glomerular fi ltration rate 
and poor outcome. Recent evidence increasingly supports an immunologic 
pathogenesis of TG, however the molecular pathways involved have not been 
elucidated. Furthermore, use of gene expression data to reliably predict TG has 
not been previously published.
Methods: Retrospective review of 963 renal transplant core biopsies from 166 
patients identifi ed TG in 20 biopsies from 18 (10.8%) patients. A cohort of 
patients (n=32) with stable function (SF) allografts were studied for comparison. 
TG was graded by the current Banff classifi cation and 43/52 samples were 
stained for C4d. The biopsies were analyzed for transcript expression of 87 
genes with quantitative real-time PCR. Data was analyzed using Bayesian 
modeling software, and dependence relationships between transcript expression 
and TG were established. A probabilistic Bayesian model was generated and 
validated to predict histopathology based on gene expression signatures.
Results: The mean grade (±SD) of TG was 2.65 ±0.49. Of the stained biopsies, 
peritubular capillary C4d deposition was identifi ed in 15/18 (83.3%) with TG and 
8/25 (32.0%) with SF (p<0.001). Interestingly, the resulting probabilistic model 
illustrated a critical relationship between CD86 and TG. TG was also predicted 
by upregulation of CCL2, CCL3, CCL5, CXCL9, IL-8, IL-10, and ICAM gene 
expression. Ten percent of the samples were excluded randomly from the initial 
model, and subsequently used for validation. In the validation analysis, the model 
effectively predicted TG (area under the curve (AUC) of 0.92; 90% positive 
predictive value (PPV) ) and SF (AUC of 0.866; 83% PPV).
Conclusions: This study provides a compelling and clinically relevant example 
of the combination of quantitative gene expression with probabilistic Bayesian 
modeling to predict renal allograft pathology. Potentially important molecular 
pathways associated with transplant glomerulopathy were also identifi ed. The 
application of this integrated approach has broad implications in the fi eld of 
transplant diagnostics and interpretation of large data sets.
URINARY CELL 39 mRNA PROFILES ACCURATELY 
PREDICT RENAL ALLOGRAFT INTERSTITIAL FIBROSIS AND 
TUBULAR ATROPHY
T. Muthukumar, R. Wanchoo, D. Dadhania, R. Ding, C. Snopkowski, 
C. Chang, B. Li, V. Sharma, S. Seshan, M. Suthanthiran.
Nephrology and Transplantation Medicine, Cornell University Medical 
College, New York, NY, USA
Renal allograft interstitial fi brosis (IF) and tubular atrophy (TA) are predictive 
of graft outcome and their presence can only be ascertained by allograft biopsy. 
Renal tubular epithelial cell-mesenchymal transition (EMT) is a critical event 
in the development of IF. We reasoned that mRNA phenotyping of urinary cells 
that includes measurement of mRNA for tubule specifi c proteins, and mRNA 
encoding proteins implicated in EMT would be informative of renal allograft 
status with respect to presence or absence of interstitial fi brosis and tubular 
atrophy.
We tested our hypothesis by urinary cell mRNA profi ling of 75 renal allograft 
recipients. We obtained urine samples at the time of diagnostic or protocol 
allograft biopsies; 25 urine specimens from 25 renal allograft recipients 
with biopsy confi rmed episode of chronic allograft nephropathy (CAN) and 
50 samples from 50 recipients with normal graft biopsy and stable graft 
function (Normal Biopsy). We isolated total RNA from urine cell pellets and 
reverse transcribed to cDNA. We developed a pre-amplifi cation assisted real 
time quantitative PCR assay in our laboratory and ascertained EMT/IF by 
measurement of mRNA levels of TGFβ1, α-smooth muscle actin (αSMA) and 
E-cadherin (ECad) and TA by measurement of mRNA of Uterine Sensitization 
Associated Gene-1 (USAG-1) & NaK2Cl transporter (NKCC2) both expressed 
in tubular cells. mRNA copies were normalized to 18S rRNA copies and 
correlated with the allograft status.
Urine specimens from the CAN group expressed higher transcript levels of 
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EMT/IF genes compared to Normal Biopsy group. Tubular atrophy in CAN 
was evident by the reduced levels of expression of USAG-1 and NKCC2 
compared to Normal Biopsy group (table).
mRNA* Chronic Allograft 
Nephropathy (N=25) 
Normal
Biopsy (N=50) 
P (Mann-Whitney 
test) 
median copies (normalized to 18s rRNA) 
USAG-1 Tubular 
Atrophy
2.7 127.5 <0.0001
NKCC2 40.9 278.5 <0.0001
TGFβ1/ECad Interstitial 
Fibrosis
16.8 5.99 0.01
αSMA/ECad 0.43 0.12 0.01
•  mRNA copies were measured by pre-amplifi cation assisted real time quantitative 
PCR assay and expressed as copy numbers per one microgram of total RNA
By the use of receiver operating characteristic curve analysis, USAG mRNA 
predicted CAN with specifi city of 88% and sensitivity of 80%. The calculated 
area under the curve was 0.85 for USAG-1, 0.80 for NKCC2 (both P<0.0001). 
0.67 for TGFβ1/E Cad and 0.67 for αSMA/E Cad (both P=0.01).
We conclude that urinary cell mRNA profi les that include levels of mRNA 
encoding tubular proteins and mRNA encoding proteins implicated in EMT 
offers a noninvasive means of ascertaining renal allograft status with respect 
to presence or absence of interstitial fi brosis and tubular atrophy. These 
biomarkers besides obviating the need for allograft biopsies may help improve 
the outcome of renal transplantation.
WHOLE BLOOD GENOMIC BIOMARKERS OF ACUTE 40 
ALLOGRAFT REJECTION
P. Keown, Z. Hollander, G. Cohen Freue, D. Lin, R. Balshaw, R. Ng, A. Mui, 
R. McMaster, B. McManus, 
University of British Columbia
Transplant patients are currently monitored regularly by blood tests, organ 
function tests, and the tissue biopsy, an expensive and invasive procedure. The 
Biomarkers in Transplantation (BiT) team is seeking effective and minimally 
invasive biomarkers of heart, kidney and liver acute and chronic allograft 
rejection.
The BiT team has enrolled more than 500 heart, kidney and liver transplant 
patients and collected more than 20,000 blood, urine, and tissue samples over 3 
years. Genomic, proteomic and metabolomic approaches are used. The current 
analysis focuses on microarray analysis of PAXgene whole blood samples 
from heart, liver and kidney transplant patients. Samples were collected before 
transplant and at weeks 1, 2, 3, 4, and 12 and analyzed with Affymetrix HG 
U133 plus 2.0 microarrays. Samples were defi ned as acute rejection (AR) or no 
rejection (NR) based on organ-specifi c biopsy criteria. Single time point analysis 
was performed for each organ separately using the robust version of eBayes 
available in the Linear Models for Microarray Data (limma) BioConductor 
package. A false discovery rate (FDR) cut off of 1% was used. Classifi er genes 
were identifi ed for each organ by applying Stepwise Discriminant Analysis 
(SDA) with forward selection on the statistically signifi cant probe sets. Leave 
one out cross-validation was done using Linear Discriminant Analysis (LDA).
Nine probe sets were identifi ed that best differentiated AR from NR heart 
samples. Seven differentially expressed genes made up the classifi er set that 
differentiated liver AR and NR. Nine genes were essential in the kidney 
classifi er. Thus, BiT identifi ed an initial set of genes from each heart, liver and 
kidney transplant samples that can differentiate rejection from non-rejection. 
INDOLEAMIN 2,3 DIOXYGENASE (IDO) AS 41 
DISCRIMINATION FACTOR FOR LONG-TERM FUNCTION 
AFTER RENAL TRANSPLANTATION
D. Abendroth1, M. Marzinzig1, J. Kaden2
1Center of Surgery, University of Ulm, 2Vivantes Hospital Friedrichshain, 
Berlin
IDO suppresses T-cell reactivity via degradation of tryptophane and is 
upregulated by the proinfl ammatory cytokines IFN-γ; and TNF-α;. There 
is evidence, that IDO is promoting tolerance. We investigated the impact 
as a decrimination factor concerning the long-term function after kidney 
transplantation.
Patients and Methods: In a consecutive group of patients transplanted between 
10/1989 and 10/1991 (n=168) treated either with quadruple drug induction 
(QDT, n= 136; ATG-F, CsA, AZA, MP) or triple drug (TDT, n=32; CsA, AZA, 
MP) as immunosuppressive therapy, we investigated the role of IDO as a marker 
for rejection as well as a predictive tool for long-term function. Concentration 
of l-kynurenine was analyzed by the method published by Fuchs et al. 2002 
(using only uv-detection). L-kynurenine (IDO-activity) was detectable at very 
low levels (n=150; 2,51 + 0,66 μmol/L) in serum of healthy volunteers and 
were signifi cant increased (p<.001) in non-rejecting renal allograft recipients 
(n=150; 5,4 + 2,5 μmol/L). We differentiated two groups of patients, all with 
no surgical failures, no delayed graft function, no rejection episode and no 
infections including CMV-reactivation within the fi rst 2 months: Gr.I (n=28) 
involved patients showing IDO levels < 4,0 μmol/L, Gr.II (n=25) > 5,5 μmol/L 
at day 21 and thereafter at least for 3 times. There was no statistic difference in 
demographic data between both groups.
Results: Gr. I showed 1/5/10 year graft survival of 100/89/71% vs. Gr.II with 
87/54/29% (p<0,001 at year 5 and 10, all data death censored). The median 
survival in Gr.I was 120 months vs. 63 months in II. Gr.I included 25% patients 
with TDT vs. 14% in II. Patients with 120 and more months of survival (n=25, 
47%) showed in 80% QDT, given as “bolus”- therapy in 85%.
Conclusion: Monitoring of IDO is a novel non-invasive tool of immune 
monitoring. Acute rejection is associated with an early simultaneously 
increased serum concentration prior creatinine. There was a clear signifi cant 
differentiation between both groups showing IDO as a discriminating marker 
concerning long-term renal function. The role of induction therapy might be 
kind of a ”silencing” factor representing the balance between infl ammation and 
immunosuppressive therapy.
DEVELOPMENT OF A NONINVASIVE MOLECULAR 42 
DIAGNOSTIC ASSAY FOR ALLOGRAFT MONITORING: 
AUTHENTICATION WITH AN EXPERIMENTAL MODEL OF 
CARDIAC TRANSPLANTATION
M. Mehra, A. Khanna, J. Xu, C. Baquet
University of Maryland, Baltimore
Background: More recently, analysis of a peripheral blood transcriptomic 
signature to identify acute cellular rejection has been proposed using Allomap 
test. This test is based on microarray analysis of gene expression using RNA 
isolated from blood and the biopsies of cardiac transplant recipients. This 
score dependent test is based on the analysis of expression of number of genes 
that results in a complicated score system that may refl ect the post-transplant 
ischemic injury therefore, a number of times a high score may be recorded in 
the absence of rejection. Therefore, analysis of expression of a small number 
of genes in blood from cardiac transplant recipients using a effi cient test that is 
easy to perform and analyze, could provide a practicality and clinical utility for 
cardiac transplant recipients. Using splenocytes and cardiac allograft tissues 
from histocompatibility mismatched rat cardiac transplant recipients, we 
analyzed the transcriptomic patterns expression of IL1R2, PDCD-1, which are 
part of Allomap scoring system and stromal cell-derived factor-1 (SDF-1). the 
only known biological natural ligand for chemokine CXC receptor-4 (CXCR4). 
whose expression increases in rejecting allografts and during cardiac damage.
Methods: Heterotopic heart transplantations were performed (n= 12 
immunosuppresed allografts; n=9, untreated rejecting n=3) and isografts 
n=3) using histocompatibility mismatched rat strains, Wistar Furth (WF) and 
Lewis (LEW). as donors and recipients. Immunosuppression regimens used in 
3 recipients each was CsA (2.5 mg/kg/day). TAC (0.25 mg/kg/day) and SRL 
(0.25 mg/kg/day) for 30 days. Recipients were monitored for rejection using a 
validated heart palpation scale. Samples for mRNA analysis were isolated from 
spleen, native and allogeneic cardiac tissues. Using Real Time PCR, the results 
are expressed as relative fold expression with respect to ƒÒ-actin.
Results: Intragraft mRNA expression of IL1-R2 (p<0.01). PDCD-1 (p<0.05) 
and SDF-1 (p<0.01) was signifi cantly increased in rejecting allografts 
compared to the isografts. In the periphery, similar fi ndings were observed in 
cells derived from splenocytes of allogeneic animals compared with isografts 
for IL1R2 (p<0.001). PDCD-1 (p<0.01) and SDF-1 (p<0.01). A comparison 
of mRNA expression of these biomarkers demonstrated similar expression in 
splenocytes and allograft tissues for IL-1R2 (59.15 ¡Ó 2.96 vs 54.36 ¡Ó 5.1). 
PDCD-1 (42.44 ¡Ó 3.68 vs 45.47 vs 3.58); SDF-1 (40.67 ¡Ó 6.5 vs 37.82 ¡Ó 
5.78). Immunosuppressed animals were noted to exhibit marked suppression of 
IL1-R2, PDCD-1 and SDF-1 mRNA and no differences in expression of these 
genes as a function of type of immunosuppressant used.
Discussion: These in-vivo fi ndings provide direct evidence for the validity of 
the peripheral circulating transcriptomic markers IL1-R2, PDCD-1 and SDF-1 
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for the determination of quiescence or rejection in cardiac transplantation. Thus, 
peripheral transcriptomic signals in the domains of IL1R2, PDCD1 and SDF-1 
are refl ective of ongoing intragraft events, thereby providing support for their 
diagnostic utility in cardiac transplantation. The validation of these markers 
in clinical samples will have potential of a noninvasive multiplex molecular 
diagnostic assay for monitoring of rejection in cardiac transplant recipients
EXPRESSION PROFILING OF HUMAN KIDNEY 43 
BIOPSIES FROM LIVING AND DECEASED DONORS REVEALS 
CANDIDATE SIGNALING PATHWAYS
M. Naesens1, L. Li1, L.H Ying1, P. Sansanwal1, T. Sigdel1, N. Kambham1, 
E. Lerut2, O. Salvatierra1, A. Butte1, M. Sarwal1
1Stanford University, CA, USA, 2University Hospitals Leuven, Belgium
Introduction: A better knowledge of the molecular mechanisms associated 
with the use of deceased donor (DD) kidneys for renal transplantation could 
pave the way for targeted therapy to bridge the survival gap between DD and 
living donor (LD) kidneys.
Methods: A total of 53 human renal allograft protocol biopsies were included 
in this study, 18 training set (9 DD, 9 LD) and 10 test set biopsies (5 DD, 5 
LD) obtained at implantation prior to revascularization, 18 post-transplantation 
protocol biopsies (9 DD, 9 LD) and 7 additional paired post-transplantation 
samples. No graft had delayed graft function. Whole genome expression 
profi les were assessed using Affymetrix HG U133 Plus 2.0 microarrays and 
validated using qRT-PCR.
Results: The biopsy samples obtained at implantation segregated in 2 distinct 
groups according to donor origin, with a cluster of 319 unique identifi ed 
genes higher expressed in DD compared to LD kidneys, and 329 genes lower 
expressed. PAM perfectly classifi ed the blinded test set samples. Using pathway 
analysis software we identifi ed a signifi cant local renal overrepresentation of 
complement genes of both the classical (C1Q, C1R, C1S, C2, C3, C4). the 
alternative pathway (C3, CFB) and the common pathway (C6, C7 in DD 
implantation biopsies. Complement gene expression in deceased donor kidneys 
related to donor death, but also correlated with the length of cold ischemia time. 
The gene expression differences between living and deceased donor kidneys 
in implantation biopsies were no longer present in the biopsies obtained after 
transplantation. However, there was a signifi cant overexpression of C1Q, C1R, 
C1S, C3 and CFB genes in biopsies obtained after transplantation, regardless 
of donor source.
Conclusion: Our study provides an in-depth analysis of the gene expression 
differences between pristine kidneys from living and deceased donors, with 
a major overexpression of complement genes in deceased donor kidneys and 
continuous upregulation of complement genes after transplantation. Targeted 
therapy interfering with complement activation, prior to organ recovery, during 
organ storage or in the post-transplant period, is an attractive therapeutic target 
that deserves further investigation.
ISCHEMIC REPERFUSION INJURY AND ITS 44 
INFLUENCE ON THE EPIGENETIC MODIFICATION OF THE 
DONOR KIDNEY GENOME.
M.D. Parker1, P. Chambers2, J.P.A. Lodge3 and J.R. Pratt1
1Leeds Institute of Molecular Medicine, Leeds, United Kingdom, 2CR-UK 
Mutation Detection Facility, Leeds, United Kingdom and 3Department for 
Organ Transplantation, Leeds, United Kingdom
In clinical transplantation, there is a link between organ ischemia and damage 
that occurs upon reperfusion. This is caused by O2 and OH free radicals that 
are formed by the degradation of ATP to Hypoxanthine during ischaemia, 
and by the further conversion to Xanthine upon organ reperfusion. Oxidative 
damage of 5-methyl-Cytosines (5mC) in genomic DNA is known to be capable 
of converting such 5mC to unmethylated Cytosines for which no known DNA 
repair mechanism exists. We hypothesise that such oxidative damage leads to 
aberrant demethylation of CpG sites in regulatory sites within gene promoters 
of donor tissue. Normally, such methylated CpG sites control the accessibility of 
DNA binding proteins to regulate transcription factor binding, and therefore gene 
expression. Conversion of methylated cytosines to non-methylated cytosines by 
oxidative damage in post-ischaemic organs may modulate gene expression in 
donor organs and affect transplant outcomes in the short and long term.
Kidneys were exposed to 4 hours cold ischaemia and 2 hours of reperfusion. 
Ischemia/reperfusion injury (I/RI) was assessed by histopathology and DNA 
methylation by bisulphite modifi ed PCR. Primers were designed to assess 
methylation in the promoter of the Complement C3 gene – known to be 
important in the donor infl ammatory response to I/RI. Our data produced an 
epigenetic map of the rat renal C3 promoter and identifi ed methylated CpG sites 
coincident to cytokine response elements and NF-kB binding sites. A similar 
map has been produced for the rat renal TGFβ promoter. Analysis of the samples 
showed a signifi cant (p<0.05) decrease in methylation in the C3 promoter in 
response to ischemia, and a further decrease in response to reperfusion. In 
order to assess site specifi c demethylation at the IL-1/IL-6 response element 
(RE). and the NF-κB binding site, we have undertaken pyrosequencing of 
the genomic DNA taken from our tissue samples. Preliminary results from 
pyrosequencing show that compared to normal rat kidney the CpG sites within 
the IL-2/IL-6 RE and the NF-κB binding site are less methylated following I/
RI. Since such epigenetic modifi cation is believed to be stable and heritable to 
daughter cells upon mitosis, we speculate that aberrant demethylation in genes 
linked to chronic allograft nephropathy (CAN) such as TGFβ may play a role 
in chronic fi brotic changes after transplantation. To assess this we are repeating 
this study in a model of CAN.
In conclusion, the fi ndings of aberrant demethylation of DNA resulting from 
ischemia and reperfusion injury describe an unrecognised phenomenon in 
transplantation. Aberrant demethylation has been linked to the development of 
tumours and our data suggest a similar mechanism of gene dysregulation may 
be initiated by the ischaemic insult inherent in organ transplantation. These 
data may contribute to a further understanding of the how the short lived and 
transient ischemic insult infl uences chronic pathological changes that occur 
even in syngeneic models of transplantation in the long term.
SIGNALINGCONCURRENT ORAL SESSION 6: 
TLR4-MYD88 SIGNALING IS REQUIRED FOR 45 
THE DEVELOPMENT OF MOUSE CHRONIC CARDIAC 
ALLOGRAFT DAMAGE IN A MODEL OF CHRONIC CARDIAC 
ALLOGRAFT REJECTION
G. Chen, H. Wu, K. Wyburn, J. Yin, J. Eris, S. Chadban
Collaborative Transplantation Research Group, University of Sydney/Royal 
Prince Alfred Hospital
Toll like receptors (TLRs) play an important role in innate immunity but 
also provide a link between innate and adaptive immunity. MyD88 is a key 
TLR signal adaptor. A recent clinical study reported that activation of innate 
immunity in heart-transplantation recipients through TLR4 contributes to the 
development of chronic rejection after cardiac transplantation. In this study, 
we aimed to determine whether TLR4-MyD88 signaling is required for the 
development of chronic allograft damage using TLR4-/- and MyD88-/- mice in 
a model of chronic cardiac allograft rejection.
Methods: Cardiac transplants were performed: B6.C-H-2bm12 (B6.H-2bm12) 
hearts to WT, MyD88-/- and TLR4-/- mice (all C57BL/6-H-2b – single MHC 
class II mismatch) as allografts (n = 6-8/group) and C57BL/6 to C57BL/6 
isografts (n = 5). Blood and tissue were harvested at day 49 after transplantation. 
Cell infi ltration, fi brosis and vasculopathy were assessed histologically (grade 
0 – 5). CD4+ cells were extracted from spleen and examined by FACS to 
determine subpopulations including CD4+Foxp3+ cells.
Results: All hearts remained pulsatile until sacrifi ce. Histology of TLR4-/- 
and MyD88-/- recipients showed protection from leukocyte infi ltration 
(1.2±1.1&1.0±1.1vs 3.2±1.4, p < 0.01). fi brosis (0.75±1.0& 0.6±1.2 vs 2.6±2.0, 
p < 0.05) and vasculopathy (0.28±0.6 & 0.04±0.1 vs 1.9±2.2) compared to 
WT recipients. By FACS, the ratio of CD4+FoxP3+ regulatory T (Treg) cells 
to total CD4+ cells at day 49 post transplantation in spleen was signifi cantly 
increased in TLR4-/- and MyD88-/- recipients versus WT allograft and isograft 
mice (18.1±0.2 & 19±0.9% vs 12.9 ±1.1 & 11.8±0.2%, P <0.01).
Conclusion: Absence of TLR4 and MyD88 signaling reduces chronic allograft 
damage in a murine model of chronic cardiac rejection. One mechanism of 
protection may be enhancement of regulatory T cell function. Regulation 
of Treg generation via the TLR4/MyD88 pathway may be one important 
consequence of cross-talk between innate and adaptive immunity.
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HSP-27 INHIBITS HUMAN CARDIAC ENDOTHELIAL 46 
CELL AND SMOOTH MUSCLE CELL PROLIFERATION 
AFFORDING PROTECTION AGAINST GRAFT 
VASCULOPATHY.
M. Rose1, D. Trott1, C. McManus2, A. Robinson2, M. Dunn2
1Imperial College, 2Conway Institute, University College, Dublin
Recent evidence suggest that maintenance of high levels of hsp27 in the 
vessel wall protects against transplant and non-transplant atherosclerosis. Thus 
proteomic studies have demonstrated that cardiac biopsies from long term 
cardiac transplant recipients, without cardiac graft vasculopathy, demonstrated 
signifi cantly more hsp27, phosphorylated at ser82 and 78, than patients who 
developed graft vasculopathy. In order to understand the mechanisms, we have 
investigated the effect of over expression of wild type and mutant hsp27 on 
vascular endothelial and smooth muscle cells proliferation. Primary and immortal 
human cardiac endothelial (HMEC-1) and smooth muscle cells (hTERTSMC) 
were infected with adenoviruse 5 carrying wild type and mutant hsp27 cDNA. 
Numbers of cells were counted over a 7 day period. Proliferation of both types 
of primary and immortal cells was inhibited by over-expression of wild type 
hsp27 and mutant versions of hsp27 that mimic the phosphorylated protein. In 
contrast, the hypophopsphorylated mutant promoted cell division compared to 
the empty vector control. In HMEC-1 cells proliferation was 41.4 +/- 9.3% (wild 
type hsp27). 115.8 +/- 6.4% (hypo-phosphorylated hsp27). 34.0 +/- 5.8% (hyper-
phosphorylated hsp27) and 24.6 +/- 5.9% (anti-sense hsp27) relative to the empty 
vector control (mean +/- SD, n= 5 experiments). Taken together these results 
suggest that a critical level of endogenous hsp27 is required for normal cell cycle 
control and that it is the phosphorylated form of the protein that functions to inhibit 
cell division. Proteomics was used to identify the proteins and pathways involved. 
Infected cells were lysed and proteins were separated by 2-D gel electrophoresis, 
detected by silver staining and analyzed using Progenesis software.
Four proteins associated with the actin cytoskeleton were found to be 
signifi cantly upregulated in cells over-expressing wild type hsp27 compared to 
the mutant hyper- and hypo-phosphorylated forms. They were human moesin 
(involved in connecting cytoskeletal structures to the plasma membrane) and 
the actin/tubulin-binding proteins stathmin, tubulin-specifi c chaperone A (a 
tubulin- folding protein) and coactosin-like protein (binds to F-actin). Actin 
fi laments are a major component of the contractile ring and essential for 
cytokinesis and hsp27 is known to be a modulator of F-actin polymerization. 
Thus we hypothesize that over-expression of hsp27 inhibits the growth of cardiac 
endothelial and smooth muscle cells through control of actin polymerization 
and this function is modulated by phosphorylation of hsp27 protein. These 
results suggest that hsp27 is a natural regulator of endothelial and smooth 
muscle proliferation; future studies will investigate endogenous inducers of 
hsp27 and gene therapy as methods of inhibiting graft vasculopathy.
TGFE946; AND LONG TERM ACCEPTANCE OF 47 
INTESTINAL ALLOGRAFTS BY ALY/ALY MICE
J. Wang, Y. Dong, J. Sun, I. Williams, K. Newell
Emory University
Long term treatment-free survival of intestinal allografts has proven elusive. 
Intestinal allografts survive indefi nitely in aly/aly mice with defective NFκ;B 
signaling. Our data suggest that this may be due to effects of TGFβ;.
Methods: C3H intestines transplanted into C57BL/6 wild type (WT) or aly/
aly mice were assessed for rejection by histology. T cell migration to graft 
lymph nodes (LN) and the intraepithelial compartment (IEL) was examined 
by fl ow cytometry. T cells (107) from aly/aly mice with long term surviving 
intestinal allografts were transferred into WT mice undergoing intestinal 
transplantation to assess transferable tolerance. Some aly/aly recipients also 
received unmanipulated T cells (107) from WT or TGF receptor II dominant 
negative (TGFRII DN) mice or magnetic bead purifi ed (>90%) naive (CD44lo) 
T cells.
Results: Non-splenectomized aly/aly mice reject heart allografts with normal 
kinetics indicating that they are not globally immunosuppressed. Transfer of 
aly/aly T cells into skin-grafted RAG-/- mice resulted in rejection suggesting 
that T cell function is not directly impaired. Consistent with this, reconstitution 
of aly/aly mice with WT T or B cells failed to promote rejection. There were 
no differences between WT and aly/aly recipients in the tempo of T cell 
migration to the allograft LN or IEL compartments. Another possibility is that 
regulatory mechanisms contribute to prolonged allograft survival. However, 
CD4+CD25hi and FoxP3+ cells were reduced 2-3 fold in aly/aly vs. WT 
recipients and transfer of cells from aly/aly long term allograft acceptors 
into WT recipients of intestinal allografts failed to transfer tolerance. This 
suggested that an alternative regulatory mechanism may contribute to allograft 
acceptance. To examine the role of the regulatory cytokine TGFβ;, T cells 
from TGFRII DN mice were transferred into aly/aly recipients at the time of 
intestinal transplantation. In contrast to WT T cells transfer of bulk, or purifi ed 
naïve, T cells from TGFRII DN mice caused prompt rejection.
Conclusions: Indefi nite survival of intestinal allografts in aly/aly mice appears 
not to be due to intrinsic defects in T or B cells, impaired migration of T cells to 
allografts, or regulation mediated by FoxP3+ cells. Rather, rejection mediated 
by TGFRII DN T cells that can not be regulated via TGFβ; suggests that TGFβ; 
contributes to long term intestinal allograft survival. Ongoing experiments to 
quantify TGFβ; production and determine the responsiveness of aly/aly T cells to 
TGFβ; may help to confi rm this hypothesis.
JAK/STAT SIGNALING PATHWAYS IN THE 48 
INFLAMMATION RESPONSE DURING LIVER ISCHEMIA/
REPERFUSION INJURY
J. Kupiec-Weglinski, C. Freitas, Y. Zhai, R. Busuttil
Dumont-UCLA Transplant Ctr
The JAK/STAT signaling is one of the major pathways for cytokine signal 
transduction. The signal transducer and activator of transcription 1 (STAT1) 
is mainly activated by IFN-gamma. The activation of STAT1 by IFN-gamma 
has been implicated in hepatic infl ammation. We have shown that activation 
of Toll-like receptor (TLR) 4 complex initiates pro-infl ammatory response 
leading to liver ischemia/reperfusion injury (IRI). Indeed, TLR4 signaling 
in vitro activates STAT1, which in turn triggers production of type-1 IFN-
dependent CXCL10 (IP-10). This study was designed to analyze the cross-
talk between STAT1 and the MAP kinase (ERK) downstream of JAK/STAT 
signaling pathways.
We used a mouse liver model of partial warm ischemia (90 min). followed by 
reperfusion (6 h). First, we employed STAT1 KO (n=17) and control WT (n=16) 
mice. The hepatocellular damage, as measured by sALT levels (IU/L). was 
signifi cantly decreased in 10/17 STAT1 KO mice (p<0.005); the remaining 7/17 
of STAT1 KO showed sALT levels comparable with WT. Hence, we distinguished 
two groups of STAT1 “protected” vs. “nonprotected” STAT1-defi cient recipients. 
Histology revealed minimal sinusoidal congestion without edema/vacuolization 
or necrosis in STAT1 KO protected group. The induction of mRNA coding for 
TNF-alpha/IL-6 was higher in STAT1 KO nonprotected livers. The expression 
of CXCL10, the product of STAT1 activation downstream of TLR4 in Type I 
IFN pathway, was profoundly and selectively depressed in livers from STAT1 
KO protected mice, as compared to IRI susceptible livers. Similarly, Western 
blot-assisted phospho-ERK expression was up regulated selectively in the 
STAT1 KO protected group. In the second series, C57BL/6 mice were treated 
1 h prior to liver ischemic insult with JAK-2 inhibitor (Tyrphostin AG490; 40 
mg/kg, i.p.; n=5). or vehicle (n=5). The hepatocellular damage, as measured by 
sALT levels (IU/L). and histology was signifi cantly decreased in AG490 group, 
as compared with controls (mean = 12770 vs. 28770; p<0.05).
In conclusion, the disruption of JAK/STAT signaling by inhibiting JAK2 
uniformly ameliorates the infl ammatory immune response in liver IRI. However, 
the blockage of STAT1 alone is insuffi cient to reproducibly exert cytoprotection. 
As JAK2 is upstream of STAT1 as well as upstream of MAP kinase (ERK). this 
study highlights the role of both signaling pathways in hepatic IRI.
DAMAGE TO ETHANOL-INDUCED MURINE FATTY 49 
LIVER GRAFTS MEDIATED BY LPS RECEPTOR CD14
T. Theruvath1, Z. Zhong1, J. Lemasters1,2
1Medical Univesity of South Carolina, Center for Cell Death, Injury and 
Regeneration, Department of Pharmaceutical and Biomedical Sciences, 
2Department of Biochemistry and Molecular Biology
Background: Ethanol causes hepatic steatosis. Transplantation of ethanol-
induced fatty livers from otherwise healthy donors results in higher rates of 
graft dysfunction and failure. The LPS receptor CD14 has been implicated to 
play a detrimental role after lean liver transplantation, but its impact after fatty 
liver transplantation remains unclear.
Aim: Accordingly, our aim was to compare ethanol-induced fatty liver grafts 
from wildtype and CD14 defi cient mice to test the hypothesis that CD14 
increases TNFα; release and reactive oxygen species (ROS) formation in fatty 
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liver graft injury.
Methods: C57BL6/J wildtype (WT) and CD14 knockout (B6.129S-
Cd14tm1Frm/J) mice on a BL6 background (KO) were used in all experiments. 
Mice were gavaged with ethanol (6 g/kg) or water. Serum ALT, hepatic 
triglycerides, and serum TNFα; were assessed 12 h later. In other experiments 
livers were explanted and transplanted into WT mouse recipients after 18 h 
of cold storage in UW solution. Serum ALT and TNFα;, graft necrosis by 
histology, and apoptosis and lipid peroxidation in non-necrotic areas by 
TUNEL and 4-hydroxynonenal (4-HNE) immunostaining, respectively, were 
measured 8 h postoperatively.
Results: After ethanol treatment, histology showed comparable lipid 
accumulation in parenchymal cells of WT and KO livers, corresponding to a 
measured 10-fold increase of triglycerides. ALT and TNFα;, however, did not 
increase after ethanol treatment of WT and KO mice. After sham operation, 
ethanol-treated WT and KO mice did not differ in ALT, necrosis and apoptosis. 
After transplantation ALT increased from 150 ± 42 U/L after sham operation to 
29,833 ± 2,276 U/L in WT liver grafts compared to 11,259 ± 1,685 U/L in KO 
grafts (p<0.01). Similarly, necrosis increased from 0% after sham operation 
to 35% in WT grafts vs. 11% in KO grafts (p<0.05). Apoptosis assessed by 
TUNEL also increased from 2 ± 0.2 cells per high power fi eld (HPF) after 
sham operation to 24.9 ± 4.9 cells/HPF after transplantation of WT livers. By 
contrast, TUNEL was 11.3 ± 3.2 cells/HPF after transplantation of KO livers 
(p<0.05). After sham operation, serum TNFα; serum was 4 ± 2 and 6 ± 2 pg/ml 
in ethanol-treated WT and KO mice, respectively (n.s.). After transplantation, 
TNFα; increased to 80 ± 33 pg/ml in WT graft recipients but only to 26 ± 7 pg/
ml in KO graft recipients (p<0.05). Furthermore, lipid peroxidation assessed 
by 4-HNE staining also increased in WT grafts, which was markedly less in 
KO grafts.
Conclusions: The LPS receptor CD14 enhances storage/reperfusion injury 
to ethanol-induced fatty mouse livers grafts and leads to increased TNFα; 
and ROS generation. Targeting the LPS receptor CD14 in fatty liver grafts 
might therefore decrease graft injury after clinical transplantation and permit 
increased use of marginal fatty livers to increase the donor pool.
INHIBITION OF NF-KAPPA B AND/OR NFAT 50 
ACTIVATION AUGMENTS OR ABROGATES 
IMMUNOMODULATORY EFFECTS OF DONOR SPECIFIC 
TRANSFUSION.
R. Goto1, K. Yamashita1, S. Ueki1, M. Taniguchi1, T. Suzuki1, T. Shimamura1, 
H. Furukawa1, K. Umezawa2, M. Ozaki1, S. Todo1
11st Dept of Surgery, Hokkaido University, 2Dept of Applied Chemistry, Keio 
University
Background: Both NF-κB and NFAT signaling pathways play crucial roles 
upon activation of T cells and subsequent alloimmune responses. Inhibition 
of these transcription factors suppresses T cell activation and proliferation; 
however, it has been shown that use of carcineurin inhibitors block AICD 
and abrogate tolerance induction in certain protocols. Also, recent works have 
shown that NFAT activation is involved in functions of regulatory T cells. 
Tolerance can be successfully achieved by costimulation blockades together 
with donor-specifi c transfusion (DST). while the effects of NF-κB and/or 
NFAT blockade in combination with DST are unknown.
Aim: To clarify the role of transcription factors, NF-κB and NFAT, on DST 
mediated immunomodulation, the effects of a novel NF-κB inhibitor, DHMEQ 
and tacrolimus (TAC) together with DST were examined in mouse heart 
transplantation.
Methods: A fully MHC incompatible C57BL/6J (H-2b) cardiac graft was 
transplanted into BALB/c (H-2d) mouse. DST (20x106 donor splenocytes) was 
given at 7 days before grafting. DHMEQ (30 mg/kg/day) was administered 
i.p. for 14 days following DST. Tacrolimus (1.5 mg/kg/day) was given i.p. 
for 14 days starting from either day -7 (D-7) or day 0 (D0). IFN-γ (ELISpot). 
apoptosis (annexin V). intracellular CD154 and Foxp3 expressions in CD4+ T 
cells were assessed. CFSE-labeling technique was applied to track alloreactive 
cells in vivo.
Results: Control mice rejected allografts within 8 days (n=7). In a sharp 
contrast, DHMEQ plus DST allowed long-term graft acceptance for over 100 
days in 5 (62.5%) of 8 animals (Figure). whereas DHMEQ monotherapy and 
DST alone modestly prolonged graft median survival time (GMST) to 16 (n=7) 
and 34 days (n=12). respectively. DHMEQ signifi cantly induced apoptosis 
upon activated CD4+ T cells (n=3, p<0.01 vs. control). Furthermore, frequency 
of IFN-γ producing cells and donor-specifi c alloreactive CD154+CD4+ T 
cells were signifi cantly reduced (n=3, p<0.05 vs. DST alone) in the spleen 
of DST+DHMEQ treated cardiac recipients. Conversely, CD4+CD25+Foxp3+ 
T cells were increased in these animals when examined on days 0 and 7. 
Interestingly, the benefi cial immunomodulatory effect of DHMEQ plus DST 
was abrogated (n=7, GMST: 50 days, Figure). when NFAT was inhibited 
together with NF-κB (DST+DHMEQ+TAC (D-7) ). This phenomenon was 
associated with signifi cantly lower in vivo development of CD4+CD25+Foxp3+ 
T cells (n=4, p<0.05) and inhibition of pro-apoptotic effect of DHMEQ on 
allo-reactive CD4+ T cells (n=3, p<0.05). In contrast, 8 (88.9%) of 9 animals 
accepted heart allografts for over 100 days when tacrolimus was administered 
starting from day 0 under the DHMEQ plus DST protocol.
Conclusion: Inhibition of NF-κB activation enhances the immunomodulatory 
effect of DST by promoting deletion of alloreactive but generation of regulatory 
T cells in vivo. Such immunosuppressive effect can be either augmented or 
abrogated by NFAT blockade, depending on the timing of inhibition.
KIDNEY ISCHEMIA REPERFUSION INJURY 51 
UPREGULATES EXPRESSION OF NKG2D LIGANDS (RAE-1 
AND MULT-1) BY INTRINSIC KIDNEY CELLS THROUGH 
TLR4-MYD88 SIGNALING
G. Chen1, S. Chadban1, K. Wyburn1, S. Alexander2, A. Sharland1, H. Wu1
1Collaborative Transplantation Research Group, University of Sydney/Royal 
Prince Alfred Hospital, 2Central for Kidney Research, The Children Hospital 
at Westmead
NKG2D is an activating receptor expressed on NK cells and CD8+ T cells. 
Ligands for NKG2D including RAE-1, MULT-1 and H60 in mouse, may be 
upregulated by tissues in response to stress. A study in mouse macrophages 
described upregulation of RAE-1 in response to stimulation through TLR4 
by LPS. We have shown that TLR4 mediates kidney ischemia reperfusion 
injury (IRI) and also observed RAE-1 upregulation in IRI kidneys. We now 
determined whether: 1) kidney IRI could induce the expression of NKG2D 
ligands: 2) expression of NKG2D ligands is TLR4 dependent; 3). bone marrow 
(BM) derived cells or parenchymal kidney cells express NKG2D ligands.
Methods: Kidney-ischemia was induced for 22 min in WT (C57BL/6).TLR4-/-, 
& MyD88-/- and Balb/c mice for 45 min. Blood and tissue were harvested at 
days 1, 3 & 5 for C57BL/6 TLR4-/- & MyD88-/-and days 1, 3, 5, 7, 14 a & 
28 for BALB/c mice. Primary cultures of mouse tubular cells (TECs) were 
also subjected to ischaemia (mineral oil overlay for 1 hr) or TLR4 activation 
(LPS stimulation). BM chimeric mice were generated by transplanting BM into 
irradiated recipient mice before IRI was induced.
Results: In C57BL/6 mice, RAE-1 mRNA level in IRI kidney was increased 
from day 1 to day 5, peaking at day 3 compared to sham operated kidney 
(14-48 fold increase, P < 0.001) measured by real time PCR. RAE-1 protein 
was detected in renal tubular cells from ischemic kidney but not from sham-
operated control by fl ow cytometry. MULT-1 mRNA expression was also 
increased from day 1 to day 5 (15- 51 fold increase, P <0.005). H60 mRNA 
expression was not detected in IR kidney from C57BL/6 WT mice however 
was increased in IRI kidney of BALB/c mice from day 1 to day 28, peaking 
at day 7 and 14 (9 – 64 fold increases, p< 0.01 to 0.001) compared to sham 
operated kidney. Both RAE-1 and MULT-1 mRNA levels were reduced in 
TLR4-/- and MyD88-/- IRI kidneys (2-8 fold reduction) versus WT controls 
(P < 0.01). TLR4-/- and MyD88-/- primary cultured TECs submitted to IRI in 
vitro also showed less RAE1 and MULT-1 mRNA expression than WT controls 
(p < 0.01). LPS stimulated RAE-1 and MULT-1 expression in WT but not in 
TLR4-/- TECs. TLR4-/- mice bearing WT hemopoietic cells had signifi cantly 
lower kidney RAE-1 and MULT-1 mRNA expression after IRI versus WT mice 
with TLR4-/- BM (p < 0.05).
Conclusions: Kidney IRI causes expression of NKG2D ligands including RAE-1 
MULT-1 and H60 and kidney parenchymal cells are the dominant source. TECs 
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can be stimulated to express RAE-1 and MULT-1 by ischemia or LPS via the 
TLR4 pathway in vitro and defi ciencies in this pathway provide protection against 
IRI and RAE-1 and MULT-1 expression in vitro and in vivo. Thus, kidney IRI 
causes upregulation of NKG2D ligands by parenchymal kidney cells via TLR4.
GENERATING ISLET ALLOGRAFT TOLERANCE 52 
BY BLOCKING NF-KB ACTIVATION AND PREVENTING 
APOPTOSIS.
D. Liuwantara1, J. Gunton1, A. Yam1, S. Walters1, E. Marino1, 
A. McShea2, S. Grey1
1Garvan Institute of Medical Research, 2Combimatrix Corp.
Transplantation of islets of Langerhans is a potential therapy for the treatment 
of type I diabetes (T1D). However, the clinical applicability and widespread 
use of this therapy is severely hampered by the requirement for a large number 
of islets per subject, and by the need for heavy immunosuppression to ensure 
successful islet graft survival. The reasons underlying the requirement for 
large numbers of islets and heavy immunosuppression are multifactorial, but 
in general relate to massive loss of beta-cell mass and function after grafting 
mediated by both immune and non-immune factors. Activation of NF-kB and 
beta-cell death by apoptosis are major factors in mediating islet graft failure.
Previously we have reported that A20 was the highest expressed anti-apoptotic 
gene up-regulated in beta-cells. A20 has a dual function in beta cells; A20 
inhibits NF-kB activation and prevents cytokine-induced apoptosis. These data 
support the concept that A20 is a major islet protective gene.
We examined whether genetic engineering of islet graft with A20 could delay 
or prevent islet allograft rejection. To do this we utilised an islet allograft 
transplantation model, i.e. islets were isolated from BALB/c (H2d) mice and 
transplanted into streptozotocin (STZ) -induced diabetic C57BL/6 (H2b) 
recipients. A20-gene transduction was achieved using recombinant-adenovirus 
mediated gene transfer, and A20 expression was confi rmed by western blot and 
immuno-histochemistry. We found that control allografts were rejected by ~20 
days (MST ~14.3 ± 3.4 days, n = 25). In marked contrast, we found that A20-
expressing islets exhibited prolonged allograft survival. Indeed in the absence 
of additional immunosuppression, ~21% (5/23) of A20-expressing islet grafts 
survived long term (i.e. >100 days).
A20 has both anti-apoptotic and an anti-infl ammatory function. We questioned, 
which of these two functions was involved in the mechanism of prolonged 
allograft survival. To test whether A20-mediated protection was due to NF-
kB-inhibitory function, we transplanted adenovirus-induced Iκ;Bα;-expressing 
islet grafts from BALB/c mice, into STZ-induced C57BL/6 diabetic recipients. 
Blockade of NF-kB activity was confi rmed by inhibition of NF-κ;B dependent 
genes Cxl2, Ccl2, Cxcl1, Cxcl10, TNF, IL-6 and A20, in vitro after IL-1β; 
treatment. As expected, C57BL/6 mice vigorously rejected BALB/c grafts with 
a MST of ~15 days (n = 12). NF-kB-blocked islet-grafts were also rejected with 
a similar tempo (MST ~15 days, n = 26). Similar results were achieved when 
islets were pre-treated with the NF-kB-inhibitor “pyrrolidine dithiocarbamate”, 
(n = 12). Therefore, we found that blockade of NF-kB alone did not replicate 
the protective effect of A20-over-expression.
Our fi ndings demonstrate that genetic engineering of islets to express A20 resulted 
in prolonged allograft survival, consistent with the induction of a state of allograft 
tolerance. In future we will investigate whether A20 could further improve 
allograft survival if used as an adjunct with sub-optimal immunosuppression.
SIGNALING THROUGH MUCOSAL MYD88 DEPENDENT 53 
TLRS INFLUENCES SMALL BOWEL ALLOGRAFT 
REJECTION
Z. Zhang, Y. Lu, K. Chen and J. Fryer
Northwestern University Feinberg School of Medicine, Chicago, Illinois, 
United States.
We have previously shown that TNFR independent activation of graft-derived 
NFκB increases gut permeability and augments small bowel (SB) allograft 
rejection in mice. We hypothesized that interactions between Toll-like 
receptors (TLR) with products from the luminal fl ora as well as endogenous 
ligands released due to ischemia/reperfusion injury are required in mediating 
mucosal NFκB activation and accelerating small bowel allograft rejection. 
To identify the involvement of determine whether TLRs are involved in 
SB allograft rejection, epithelial cells were isolated from SB (B6) isografts, 
allografts (B6→BALB/c). and non-transplanted B6 SB controls and subjected 
to western blot analysis. We found that in normal SBs, TLR5 and TLR9 
were strongly expressed, while there was minimal expression of TLR2 and 
TLR4. The expression patterns of TLRs in SB isografts were similar to those 
of normal SBs. In SB allografts TLR5 and TLR9 expression was unchanged 
compared to controls on POD3 and POD5, while TLR2 and TLR4 expressions 
were remarkably upregulated by POD5. These fi ndings suggest that epithelial 
TLR2 and TLR4, but not TLR5 and TLR9, signaling pathways are involved in 
SB allograft rejection. To determine the role of MyD88, a downstream adaptor 
protein that mediates intracellular signaling for most TLRs, in SB allograft 
rejection, SBs from MyD88-/- and MyD88+/+ (wt) mice were transplanted into 
BALB/c recipients and were evaluated for epithelial NFkB (p65) activation 
and gut permeability to Alexa Fluor labeled-Dextran probes on POD5. Our 
results revealed that NFkB activation in the epithelium of MyD88-/- allograft 
was markedly reduced compared to the wt allografts. Furthermore, we showed 
that while gut permeability was increased signifi cantly in wt SB allografts 
compared to isografts, this was signifi cantly reduced with the MyD88-/- SB 
allografts. Accordingly, mucosal infl ammation including villus sloughing and 
lymphocyte infi ltration were noticeably minimized in MyD88-/- SB allografts. 
These data indicate that TLR2 and TLR4 interactions, via MyD88 signaling, 
may contribute to escalating mucosal infl ammation during SB allograft 
rejection and may possibly contribute to the unique volatility associated with 
SB allograft rejection episodes.
RENAL PATHOLOGYCONCURRENT ORAL SESSION 7: 
A PROTOCOL BIOPSY ANALYSIS FROM AN NIH 54 
MULTICENTER PEDIATRIC RENAL TRANSPLANT TRIAL 
REVEALS NO ADVERSE EFFECT OF STEROID AVOIDANCE 
ON THE HISTOLOGICAL EVOLUTION OF CHRONIC GRAFT 
INJURY
M. Naesens, N. Kambham, T. Sigdel, J. Waskerwitz, O. Salvatierra, 
M. Sarwal
Department of Pediatrics, Pathology and Surgery
Aim: To assess the subclinical histological evolution in the fi rst year of an 
open-label NIH-CCTPT multicenter trial of 130 pediatric renal transplant 
recipients, randomized to steroid-free (SF; n=60) or steroid-based (SB; n=70) 
immunosuppression.
Methods: 268 protocol biopsies performed at 0, 6 and 12 mo, were blindly 
analyzed by a single pathologist using the Banff, CADI and CNIT classifi cations. 
All indication biopsies with clinical acute rejection (AR; 23.3% for SF and 
21.4% for SB) were excluded from this analysis. The histological and clinical 
parameters were assessed using multivariate generalized-estimating-equations 
statistical analysis.
Results: Subclinical AR was present in 12.2% SF vs. 8.5% SB bx at 6 mo and 
0% SF vs 5% SB bx at 12 mo (p=NS); borderline AR was seen in 2.4% SF vs. 
8.5% SB bx at 6 mo and 10% SF vs. 5% SB bx at 12 mo (p=NS). Despite the 
pristine condition of the kidneys at implantation, regardless of steroid exposure, 
there was a signifi cant trend increase (p<0.0001) in chronic tubulo-interstitial 
damage; 35% of 6 mo bx and 53% of 12 mo bx demonstrated IFTA; with 
moderate/severe changes (IFTA grade 2-3) in 6.8% and 10% of 6 and 12 mo 
bx respectively. The prevalence of biopsies with ischemic glomerular changes 
(p<0.0001). tubular microcalcifi cations (p=0.009). vascular intimal thickening 
(p=0.0008) and the number of sclerosed glomeruli (p<0.0001) increased over 
the fi rst year after transplantation, without any difference between the SB 
and SF group. A critical risk factor for IFTA injury by multivariate analysis, 
independent of time after transplantation, was smaller recipient size.
Conclusion: In this fi rst ever serial histological analysis, embedded in a 
randomized multicenter pediatric study of steroid avoidance, we found signifi cant 
progression of chronic graft injury in the fi rst year post-transplantation in both 
study arms. Small recipient size is the primary risk factor for tubulo-interstitial 
damage, likely related to vascular size discrepancies between recipient and the 
graft, resulting in chronic graft ischemia.
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ARE PROTOCOL BIOPSIES INDICATED IN A LIVE 55 
RELATED RENAL TRANSPLANT PROGRAM?
S. Guleria1, S. Jain1, A. Dinda1, S. Mahajan1, S. Gupta1, D.Bhowmik1, 
S. Aggarwall1, S. Tiwari1, A. Panigrahi1, N. Mehra1
1All India Institute of Medical Sciences, 2All India Institute of Medical 
Sciences, 3All India Institute of Medical Sciences, 4All India Institute of 
Medical Sciences, 5All India Institute of Medical Sciences, 6All India Institute 
of Medical Sciences, 7All India Institute of Medical Sciences, 8All India 
Institute of Medical Sciences, 9All India Institute of Medical Sciences, 10All 
India Institute of Medical Sciences
Aim: The aim of the present study was to assess the impact of protocol 
biopsies in tacrolimus based immunosuppression era in a live related renal 
transplant program.
Material and Methods: Sixty six live related renal transplant recipients were 
randomly allotted to a protocol biopsy group (Group I) or a non protocol biopsy 
group (Group II) Both groups were put on immunosuppression which consisted 
of tacrolimus, Mycophenolate Mofetil/Azathioprine or steroids. Protocol 
biopsies were carried out in Group I on day thirty, Ninety and one year post 
transplant with an intention to treat.
Both groups were analyzed at the end of one year with regard to graft survival, 
patient survival and the serum creatinine.
Results: Group I consisted of 30 males and four females with a mean age 
of 36.55 years. Group II consisted of 30 males and two females with a mean 
age of 31.58. The number of HLA mismatches in Group I was 2.7 and in 
Group II was 2.4.Group I had 29 patients on Mycophenolate Mofetil and 5 on 
Azathioprine while Group II had 24 patients on Mycophenolate Mofetil and 
8 on Azathioprine. Tacrolimus was given at a dose of 0.15 mg/kg adjusted to 
blood levels of 8-12 ng/ml during the fi rst three months and 6-8 during the 
next three months and 4-6 ng/ml thereafter. There was no difference in both 
the groups with regards to the warm ischemia time or the cold ischemia time. 
There was no signifi cant difference between the mean tacrolimus level between 
the two groups at one month, six month and one year. Group I had 18.75% of 
sub-clinical rejection at one month, 9.09% at six months and none at twelve 
months. However the incidence of CNI toxicity was 12% at one month, 36% 
at six months and none at one year. Group II had 5.88% acute rejection in the 
fi rst month, 2.9% by the end of six months and none at the end of one year. 
There was no difference in graft survival, patient survival or the mean serum 
creatinine between the two groups.
Conclusion: Protocol biopsies have a limited role in a live well-matched renal 
transplant program with tacrolimus based immunosuppression in the short 
term. However the long term impact needs further evaluation
PATTERNS OF ACUTE REJECTION IN KIDNEY 56 
TRANSPLANT RECIPIENTS TREATED WITH ALEMTUZUMAB 
INDUCTION AND STEROID-FREE MAINTAINANCE THERAPY
F. Wright, A. Bingaman, J. Palma-Vargas, P. Foster
Texas Transplant Institute
Background: Alemtuzumab (Campath 1H) has been used as induction therapy 
for kidney transplant recipients with acute rejection rates reported by us and 
others of 7 to 20% at one year. The histologic type of rejection and the time 
frame for occurrance after treatment with alemtuzumab have not been well 
established. This study is a retrospective single center review of acute rejection 
episodes of kidney transplant recipients treated with alemtuzumab induction 
with respect to the kinetics and histologic patterns of acute allograft rejection.
Methods: From 11/01/03 to 10/31/06, 416 kidney transplants were done. 
All patients had negative T and B cell fl ow cytometric crossmatchs and 
received induction therapy with alemtuzumab 30mg IV intra-operatively, 
methylprednisolone 500-750 mg during the fi rst 24 hours, and were then 
maintained on tacrolimus (target level 5-7) and mycophenolate mofetil 
(MMF) without steroids. All episodes of biopsy-proven acute rejection 
(AR) were reviewed. Patients in pre-transplant desensitization protocols or 
with documented non-adherence with medications were excluded from the 
analysis.
Results: A total of 44 of 416 patients (10.6%) experienced AR during the study 
period, with a mean follow up of 28 months (range 14- 48 months). Of the AR 
episodes, 19 (43%) occurred within the fi rst 3 months post-transplant, 13 (30%) 
occurred between 3-6 months, 5 (11%) occurred between 6-9 months, 1 (2%) 
occurred between 9-12 months, and 6 (14%) occurred more than one year post 
transplant. Of the rejection episodes within the fi rst 3 months post-transplant, 
9/19 occurred within the fi rst 30. Histologic analysis showed that 9/19 (47%) 
of rejection episodes within the fi rst 3 months included an antibody mediated 
component (6/9 within the fi rst 30 days.) In contrast, 3/25 rejection episodes 
(12%) which occurred greater than 3 months post-transplant were antibody 
mediated. Of the 12 patients with antibody mediated rejection, 3 patients had 
panel reactive antibody (PRA) levels > 30% at the time of transplant.
Conclusion: This large experience with alemtuzumab induction therapy 
with a steroid-free maintainance protocol, demonstrates that the majority of 
rejection episodes occur within the fi rst 6 months post-transplant, with the 
largest fraction in the fi rst 3 months. A signifi cant number of early rejection 
episodes are antibody mediated and occur in unsensitized recipients. Allograft 
dysfunction early after transplantation with alemtuzumab induction warrants 
aggressive investigation, including biopsy with appropriate studies to identify 
antibody mediated rejection.
HISTOPATHOLOGIC PARAMETERS ASSOCIATED WITH 57 
ACUTE ANTIBODY MEDIATED REJECTION CORRELATE 
BETTER WITH THE DEVELOPMENT OF CHRONIC 
ALLOGRAFT INJURY COMPARED TO PARAMETERS 
ASSOCIATED TO ACUTE CELLULAR REJECTION
J. Pisrch1, J. Torrealba1, J. Pascual2, F. Lopez3, A. Djamali1, S. Knechtle1, H. 
Sollinger1, M. Samaniego1
1University of Wisconsin, Madison, Wisconsin, 2Hospital Ramon y Cajal, 
Madrid, Spain, 3San Rafael Hospital, New Haven, Connecticut
Chronic allograft injury/rejection (CAI) is a major cause of allograft failure 
in clinical transplantation; however its precise pathogenesis/etiology is poorly 
understood. In order to investigate histopathologic parameters of acute rejection 
associated to the progression to CAI we evaluated 167 kidney transplant patients 
from 2002 to 2005 that had undergone at least 3 consecutive kidney biopsies 
during that period (632 biopsies). We analyzed biopsies for acute cellular 
(ACR) and antibody-mediated rejection (AMR) and subsequent development 
of severe CAI, including severe chronic transplant glomerulopathy (TG). 
interstitial fi brosis, tubular atrophy and/or chronic allograft vasculopathy.
30 patients (18%) developed severe CAI. The development of CAI was strongly 
associated with a biopsy diffusely positive (>50% peritubular capillaries, PTC) 
for C4d (p<0.014, RR 4.41). capillary leukocyte margination (p<0.008, RR 
3.57). intimal fi brinoid necrotic arteritis (p<0.02, RR 7.8). severe interstitial 
mononuclear infl ammation (p<0.018, RR 9.3). Parameters not associated with 
the development of severe CAI were focally positive C4d (<50% positive PTC). 
acute tubular necrosis, interstitial hemorrhages, any degree of tubulitis, acute 
glomerulitis, intimal cellular arteritis, recurrence of primary glomerulopathy 
and arteriolar hyalinosis.
62 patients (37.12%) developed mild to severe TG. Only the diffuse pattern of 
C4d staining and not the focal pattern was associated with the development of 
TG (p<0.0006, RR 10.2).
In conclusion, the majority of histologic parameters associated with the 
development of severe CAI were related to fi ndings traditionally related to 
acute AMR more than ACR. In addition, persistent severe chronic mononuclear 
interstitial infl ammatory infi ltrate of the allograft, regardless of any degree of 
tubulitis seemed to also correlate with ulterior development of CAI.
RENAL BIOPSY APPEARANCES AFTER ANTIBODY 58 
INCOMPATIBLE TRANSPLANTATION: EARLY GLOMERULAR 
MARGINATION AND SUBSEQUENT CAPILLARITIS IN 
RELATION TO CLINICAL STATUS AND DONOR SPECIFIC 
ANTIBBDY LEVELS
R. Higgins1, K. Chen1, R. Hamer1, N. Krishnan1, S. Fletcher1, D. Briggs2, 
J. McKinnell1, D. Zehnder3
1University Hospital, 2Histocompatiblity Laboratory, UK Blood and 
Transplant, 3Warwick Medical School
Background: The current understanding of the histological appearances of 
antibody-mediated rejection is described in the Banff 07 classifi cation of renal 
allograft pathology. The aim of this study was to compare the classifi cation 
with the fi ndings in our programme of antibody incompatible transplantation.
Methods: Renal biopsies from patients with donor specifi c antibodies (DSA) 
to HLA were scored by Banff 07, and were stained for CD45, and a subset also 
for CD20, CD68 and CD3. Numbers of positively stained glomerular cells, and 
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total cortical cells per high power fi eld (hpf) were counted.
Results: 36 patients had 72 renal biopsies; 29 patients had pre-transplant 
plasmapheresis to remove DSA. 29 biopsies were performed 30 minutes after 
graft reperfusion. The mean number of CD45+ cells per glomerulus was higher 
than in control antibody compatible grafts (p<0.04). The number of glomerular 
cells was associated with the DSA level (p<0.01). and 8/8 patients with 
greater than 5 CD45+ cells per glomerulus had rejection or oliguria, compared 
to 11/21 with up to 5. In the fi rst 10 days post-transplant, 25 biopsies were 
performed in 20 patients, 13 of whom proceeded to ATG or OKT3. Although 
PTC 3 margination and C4d deposition were specifi c for rejection, their 
sensitivities were low. PTC3 leucocyte margination developed by day 2 after 
transplantation, but the extent of cellular infi ltration rose to peak levels by day 
6. PTC C4d staining was not seen in the fi rst 5 days after transplant, even in 
the presence of rejection, but was present in the majority of later biopsies with 
rejection. In biopsies with leucocyte subset staining, the glomerular cells were 
1% CD20+, 66.6% CD68+, and 32.4% CD3+; the interstitial cells were 1.8% 
CD20+, 50.2% CD68+, and 48% CD3+.
Conclusions: Glomerular margination of lympho-histiocytic (CD45 +) cells 
occurred early after transplantation and was associated with DSA level and 
early graft dysfunction. The Banff 07 PTC margination scoring system was 
easy to apply, PTC3 was always associated with rejection, but PTC1-2 were 
not specifi c for serious rejection. A signifi cant proportion of the leucocytes in 
glomeruli and renal interstitium were CD3+. C4d was not seen in PTC for the 
fi rst few days after transplantation, even in the presence of cellular margination, 
and this requires further investigation.
DECREASED INTERSTITIAL FIBROSIS AFTER RENAL 59 
TRANSPLANTATION OBSERVED WITH INHIBITION OF 
THE RENIN-ANGIOTENSIN SYSTEM (RAS): RESULTS OF A 
MULTICENTRE PROTOCOL BIOPSY (PBX) STUDY. D. RUSH 
FOR THE CANADIAN FKC008 STUDY GROUP.
P. Nickerson, D. Rush1, A. Boucher2, S. Cockfi eld3, C. Girardin4, G. Knoll5, 
J-G. Lachance6, D. Landsberg7, J. Shapiro8, A. Shoker9, S. Yilmaz10
1Health Sciences Centre, 2Hopital Maisonneuve-Rosemont, 3University of 
Alberta, 4CHUM Hopital Notre Dame, 5The Ottawa Hospital, 6Hotel-Dieu 
de Quebec, 7St. Paul’s Hospital, 8Diamond Health Care Centre, 9St. Paul’s 
Hospital, 10Foothills Medical Centre
We reported a multicentre randomized study in which patients were randomized 
to PBx at 1, 2, 3, 6 and 24 months (PBx arm; n=121) or to biopsies at 6 and 
24 months only (Control arm; n=119). Patients in both arms were biopsied at 
implantation and treated with TAC/MMF/prednisone. The aim of the study was 
to determine the effect of detection and treatment of early subclinical rejection 
on chronic histology (ci+ct ≥2) at 6 months. We found no benefi t of early PBx, 
possibly because the prevalence of subclinical rejection was <10% between 
months 1-3. In the ITT biopsied population (n=192). the prevalence of ci+ct ≥2 
was 2 vs. 3%, 20.5 vs. 35%, and 39 vs. 48% in the Control and PBx arms, at 
implantation, 6 months and 24 months, respectively. The preliminary logistic 
regression analysis, adjusted for 14 baseline prognostic variables, showed that 
the only independent correlate of ci+ct ≥2 at 24 months was having received a 
kidney from a deceased donor (ATC 2007).
In this post-hoc analysis, we determined the effect of RAS inhibition with ACE 
inhibitors (ACEi) ± AII receptor blockers (ARB) on interstitial fi brosis. Of the 
192 biopsied patients, 100 (52.1%) never received ACEi/ARB and 92 (47.9%) 
received ACEi/ARB at some point during the study. By logistic regression, use 
of ACEi/ARB was associated with a decrease in ∆ fi brosis ≥0.5 between 6-24 
months (p=0.0072).
We next evaluated a cohort of 101 patients that had both a 6 and a 24 month 
biopsy. Of these, 70 were designated the No ACEi/ARB group, of which 12 
(17.1%). had a mean ACEi/ARB exposure of only 109 ± 64 days (range 3-198 
days). The 31 remaining patients, the ACEi/ARB group, had a mean exposure 
of 479 ± 96 days (range 314-840 days). The number of patients that had ci+ct 
≤ 2 at 6 months and ci+ct ≥2 at 24 months was 22/70 (31.4%) in the No ACEi/
ARB group; and 5/31 (16.1%) in the ACEi/ARB group (p=0.001). The fi nal 
logistic regression analysis showed that neither the original randomization 
variables (treatment arm, donor age->50 vs. ≤ 50- and donor status –living vs. 
deceased). nor any other variables except for ACEi/ARB use had a signifi cant 
effect on the progression of ci+ct ≤ 2 at 6 months to ci+ct ≥2 at 24 months (χ2 
4.277; odds ratio 0.234; CI of odds ratio 0.059-0.927; p=0.0386). There was 
no effect of ACEi/ARB use vs. no use in terms of the ClCr (77.62 ± 21.52 vs. 
76.20 ± 22.32 ml/min) or Hgb (139.6 ± 14.6 vs. 138.6 ± 13.5 g/L) respectively, 
at 24 months.
These fi ndings suggest that progression of interstitial fi brosis in renal transplant 
patients under TAC/MMF/prednisone and ACEi/ARB may be decreased in 
comparison to those under TAC/MMF/prednisone and no ACEi/ARB, and call 
for randomized trials that include both clinical and histological endpoints in 
such patients.
DONOR AGE AND THE SUSCEPTIBILITY TO CHRONIC 60 
CALCINEURIN INHIBITOR NEPHROTOXICITY LESIONS IN 
PROTOCOL BIOPSIES AFTER RENAL TRANSPLANTATION
M. Naesens, E. Lerut, H. De Jonge, Y. Vanrenterghem, B. Van Damme, 
D. Kuypers
Departments of Nephrology and Pathology, University Hospitals Leuven, 
Belgium
Background: Although histological lesions typically attributed to chronic 
calcineurin inhibitor nephrotoxicity (interstitial fi brosis/tubular atrophy 
[IFTA], arteriolar hyalinosis [ah], glomerular capsular fi brosis [gcf] and 
glomerulosclerosis [gs]) are major determinants of long-term graft outcome, 
little is know about the risk factors for development of these lesions.
Methods: 252 adult renal allograft recipients, all treated with the combination 
of tacrolimus, mycophenolate mofetil and corticosteroids, underwent protocol 
biopsies at implantation and at 3, 12, and 24 months after transplantation. 
In total, 722 good-quality renal allograft biopsies (179 for indication and 
543 per protocol) were reviewed and scored according to the updated Banff 
classifi cation. Risk factors for the histological evolution were assessed using 
uni- and multivariate ordered logistic regression and generalized estimating 
equation statistics.
Results: Already in the fi rst 2 years after transplantation, and mainly in the fi rst 
months after transplantation, there was a progressive and signifi cant increase 
in IFTA, gcf and gs scores (all p<0.0001). These chronic lesions were closely 
interrelated. Higher donor age (> 50 years compared to < 30 years and 30-50 
years) was associated with higher IFTA scores at implantation (respectively 
p=0.0002 and p<0.0001). with higher IFTA at all time points after transplantation 
(p<0.0001). with a signifi cantly and gradually higher increase in IFTA by time 
after transplantation (p=0.009) and with earlier onset of IFTA progression 
(p<0.05). Kidney allografts from older donors also had signifi cantly more 
arteriolar hyalinosis lesions at all time points after transplantation (p=0.007). 
Other risk factors for higher IFTA included prior biopsy-proven acute rejection, 
which in itself was associated with higher donor age (p=0.04) and the number 
of HLA-DR mismatches (p<0.0001). Exposure to tacrolimus, as measured 
using all tacrolimus pre-dose trough levels performed in the fi rst 2 years 
after transplantation (N=13,667). was neither associated with the histological 
appearance of the renal grafts, nor with progression of histological damage. 
At all protocol biopsy time points, there was a highly signifi cant correlation 
between donor age, chronic tubulo-interstitial damage and MDRD creatinine 
clearance (p<0.0001).
Conclusion: High donor age impacts on renal allograft histological evolution 
beyond the immediate peritransplant period. Donor age forms a major 
determinant of the histological appearance of the graft and, more importantly, 
of the increase in chronic histological lesions typically attributed to calcineurin 
inhibitor nephrotoxicity. Progression of histological damage suggestive of 
calcineurin inhibitor nephrotoxicity is not directly related to tacrolimus blood 
levels, and should be interpreted carefully.
PREDICTING GRAFT OUTCOME WITH EVALUATION 61 
OF PRE-TRANSPLANT KIDNEY BIOPSY USING A 
CUMULATIVE PATHOLOGY SCORE
R.B. Munivenkatappa1, J.C. Papadimitriou2, C.B. Drachenberg2, A. Haririan3, 
F. Rasetto4, M.M. Cooper1, E. Schweitzer1, L. Campos1, R. Barth1, 
S.T. Bartlett1, B. Philosophe*1 
1Department of Surgery, Division of Transplantation, 2Pathology, 3Division 
of Nephrology. 4School of Pharmacy, University of Maryland School of 
Medicine, Baltimore, MD 21201
Predicting graft outcome after renal transplantation using marginal donors based 
on donor histological features has remained elusive and is subject to institutional 
variability. We propose a pre-transplant donor pathology scoring system that 
reliably predicts graft outcome regardless of recipient characteristics.
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We retrospective analyzed 286 imported deceased donors which were initially 
rejected by other centers due to donor parameters between 1/00-6/05. All 
kidneys were re-biopsied at our center prior to implantation. Morphometric 
analysis performed consisted of measuring and calculating wall to lumen ratio 
(WLR) of glomerular-size arterioles, interlobular, and arcuate/interlobar arteries; 
calculating% glomerulosclerosis (GS); depicting the presence of arteriolar 
hyalinosis (AH). scar (SCAR). and periglomerular fi brosis (PGF). The patients 
were followed for a mean of 33±25 months. Multivariate Cox analysis was done 
to evaluate the predictive value of these variables to graft outcome.
Recipient demographics are summarized in table 1. AH, GS>15%, WLR>0.5 
of interlobular arteries, PGF, and SCAR were found to independently predict 
graft outcome; The relative risk for each variable was rounded to an index score 
and the sum created the Maryland Aggregate Pathology Index (MAPI) which 
ranged from 0 to 13 (table2). MAPI reliably predicted outcome, independent of 
donor and recipient parameters (table3). Kaplan Meier curves for transplants 
with low (0-<7). intermediate (7-11). and high (>11) MAPI scores were 
signifi cantly different; six year graft survival was 84%, 67% and 41% for low, 
intermediate and high MAPI, p =0.002 (fi gure1). The relative risk of graft loss 
increased 15% for every MAPI point increase. Patients with PRA <40% had a 
six year graft survival of 87%, 71% and 57% (p=0.035) for low, intermediate 
and high groups in comparison to patient’s with PRA >40% who had 60%, 27% 
and 0% (p=0.15 not signifi cant). respectively.
MAPI is a reliable predictor of graft outcome after renal transplantation in marginal 
donors, independent of other donor and recipient parameters. The relative risk of 
graft loss increased by 15% for every point increase in MAPI score. Previously 
sensitized patients with PRA >40% have a very poor outcome when transplanted 
with higher MAPI kidneys and this combination should be avoided.
Recipient’s characteristics  Donor’s characteristics  
AGE 58 ± 13 Age 49±15
MALE 64% Gender (Male) 61.50%
AFRICAN AMERICAN 53.8% Race (AA) 18.90%
DM 44% Terminal Creatinine 1.23 ± 0.5mg
HTN 86%  HTN 40.20%
HLA MISMATCHES 99.70%  DM 7%
PEAK PRA 11.4 ± 25.2% CVA’s 59.10%
DGF 52.10%   
ANTI-CD25 84.30%   
CNI’s 92%   
STEROID WITHDRAWAL 11%   
MMF 91%   
Cold ischemia (Hrs) 33±10   
Table: 1 Demographics of recipient’s and donors.
Maryland Aggregate Pathology Index (MAPI) 
 Index Score
Pathology Variable’s Univariate (RR) (95% CI) P Present Absent
Arteriolar Hyalinosis 2.8 (1.3 – 6) 0.007 3 0
Glomerulosclerosis >15% 2.3 (1.3 – 4.3) 0.007 2 0
Interlobular artery wall to lumen ratio >0.5 2 (1.1 – 3.6) 0.03 2 0
Periglomerular fi brosis 3.7 (1.2 – 12) 0.03 4 0
Scar 2.2 (1 – 5.3) 0.06 2 0
Table: 2; Univariate analysis for histopathological variables in pre-implantation wedge biopsies; Based 
on the hazard ratio an index score value was attributed to each parameter and were added resulting in 
the Maryland Aggregate pathology Index (MAPI). Score ranges from 0-13
Prognostic Indicators Multivariate (RR) (95% CI) P
MAPI 1.15 (1-1.3) 0.01
 
Donor Characteristics   
Donor Age >60 years 0.5 (0.2-0.9) 0.02
Donor cause of death (CVA) 1.4 (0.6-2.6) 0.49
Donor history of HTN 0.9 (0.4-1.9) 0.81
Donor Terminal SCr > 1.5 1 (0.4-2.3) 0.98
 
Cold ischemia >36 hrs 0.8 (0.4-1.7) 0.57
 
Recipient Characteristics   
PRA >40% 0.4 (0.2-0.9) 0.02
Recipient HLA Mismatch 0.8 (0.6-1.1) 0.12
Recipient BMI 1 (0.9-1) 0.12
Recipient history of DM 1.6 (0.8-3.3) 0.16
Recipient history of HTN 0.5 (0.2-1.4) 0.20
Induction 0.5 (0.2-1.4) 0.20
Delayed Graft function (DGF) 0.7 (0.3-1.3) 0.21
Recipient sex (Female) 0.8 (0.3-1.6) 0.47
Steroid Withdrawal 1.6 (0.5-5.3) 0.48
Recipient Age (Years) 1 (0.9-1) 0.67
Table 3: Multivariate analysis with donor characteristics, cold ischemia >36 hrs and recipient 
characteristics, induction agent, steroid withdrawal and DGF
Figure 1: Graft survival Kaplan Meier curves of the Low risk (CP <7). 
Intermediate risk (CP 7-11) and High risk (CP >11) groups and six year graft 
survival were 84%, 67% and 41%, p =0.002.
A SYSTEMATIC STUDY OF LINEAR C4D DEPOSITION IN 62 
GLOMERULAR CAPILLARY LOOPS IN RENAL TRANSPLANT 
BIOPSIES
E. Vilayur, P. Trevillian, R. Nanra, A. Gillies, B. Jones, S. Carney, M. Heer
John Hunter Hospital
Background: Circumferential C4d staining of peri-tubular capillaries is one of 
the major criteria for diagnosis of antibody mediated rejection under the Banff 
schema. However, C4d staining by immunoperoxidase using a polyclonal 
antibody allows interpretation of glomerular staining patterns. We present the 
fi rst systematic analysis of the histological and clinical signifi cance of linear 
C4d deposits in glomerular capillary loops.
Methods: Since 2002 we have performed routine C4d staining of all transplant 
biopsies using both immunoperoxidase and immunofl uorescent techniques. 
These include implantation biopsies, 3 month protocol biopsies and service 
biopsies done for clinical reasons. Linear diffuse or linear focal C4d staining 
was readily differentiated from focal granular mesangial deposits. Biopsies 
were scored using light, I.F. +/- E.M. and graded using Banff criteria. Clinical 
data (e.g. serum anti-HLA antibodies, proteinuria, GFR) were used to support 
the histological diagnosis where appropriate.
Results: 536 biopsies from 181 patients were examined. Linear diffuse (LD) 
or linear focal (LF) C4d staining was observed in at least one biopsy from 
55 patients (LD=27, LF = 28). The following diagnoses were made in these 
patients:
1. Transplant glomerulopathy (TG): 15 patients (LD=14, LF=1) 
2.  Delayed acute antibody mediated rejection (DAAbMR): 6 patients (LD=3, 
LF=3) 
3. DAAbMR and TG: 4 patients (LD=4) 
4. Recurrent glomerulonephritis (GN): 4 patients (LD=3, LF=1) 
5. Acute tubular necrosis: 2 patients (LD=1, LF=1) 
5. Acute antibody mediated rejection: 3 patients (LD=2, LF=1) 
6. Chronic allograft nephropathy: 1 patient (LF=1) 
7.  Normal/minor transplant changes: 20 patients (LF=20) 
14  of 55 patients (26%) with glomerular capillary C4d have lost their grafts.
11 of these patients had TG (LD=10, LF=1). 2 had TG + DAAMR (DF=2) 
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and one had recurrent GN (LF=1) Overall 19 of 181 (11%) patients had TG 
(LD=18,LF=1). The 5 TG patients with surviving grafts had TG diagnosed 
on protocol biopsies and 4 were known to be highly sensitised with donor 
specifi c antibodies. In these patients the LD glomerular C4d has persisted in all 
subsequent biopsies even though 4 grafts still function well.
Only 2 of 98 implantation biopsies showed LF C4d. Of these, 13 patients had 
LF C4d in their 3 month protocol biopsies with normal histology. In 11 the 
C4d was transient, not appearing in subsequent biopsies. In 2 the LF C4d has 
persisted (both highly sensitised recipients) 
Conclusions: Linear diffuse C4d staining in glomeruli is invariably a marker of 
signifi cant disease in kidney transplant biopsies. It is always found in patients 
with TG with or without DAAbMR. It is found in 3 month protocol biopsies 
in highly sensitised individuals with donor specifi c antibodies, the majority of 
whom have already developed early TG. Linear diffuse staining in glomeruli 
also predicts graft loss. It is likely that LD C4d staining in glomeruli is an early 
marker of chronic or subacute antibody mediated rejection and therefore may 
be used to direct us toward treatment strategies.
ORGAN PROCUREMENTCONCURRENT ORAL SESSION 8: 
THE INFLUENCE OF DONOR AND RECIPIENT 63 
ETHNICITY ON OUTCOMES FOLLOWING DONATION AFTER 
CARDIAC DEATH KIDNEY TRANSPLANTATION
J. Locke, D. Warren, F. Dominici, A. Cameron, M. Leffell, A. Zachary, 
J. Melancon, D. Segev, A. Singer, R. Montgomery
Johns Hopkins University
Background: Although the majority of deceased donor kidneys are donated 
after brain death (DBD). increased recovery of kidneys donated after cardiac 
death (DCD) could reduce the organ shortage and is now a national priority. 
Racial outcome disparities in DBD renal transplantation have been well 
described and we sought to determine if such outcomes also occur with DCD 
kidneys.
Methods: Adult recipients of deceased donor kidney transplants between 1993 
and 2006 were evaluated based on UNOS data. Black and white recipients 
of deceased donor kidneys were stratifi ed by donor ethnicity (white or black) 
and type (DCD, standard criteria DBD, and expanded criteria DBD). Death-
censored graft survival was analyzed by Kaplan-Meier (unadjusted) and 
Cox proportional hazards analyses (adjusted multivariate clinical judgment 
model). Multiple sensitivity analyses were performed, including multivariate 
models based on forward and backward selection as well as stratifi cation by 
transplant year to account for changes in immunosuppression and matched 
control analyses. Results were robust to all sensitivity analyses and model 
diagnostics.
Results: We found strong evidence that DCD kidneys from black donors 
perform best in black recipients. In fact, for black recipients, DCD kidneys 
from black donors confer a 57% reduction in the risk of graft loss compared 
to standard criteria DBD kidneys from white donors [AHR 0.43, 95% CI 0.23 
to 0.84, p=0.002]. Further, black recipients of DCD kidneys from black donors 
have a 5-year death censored graft survival that is not statistically different from 
white recipients of standard criteria DBD kidneys from white donors [83.8% 
vs. 83.5%, p=0.5], the best deceased donor option for white recipients.
Conclusion: Our fi ndings indicate that DCD kidney transplantation is 
not associated with the same racial outcome disparities as DBD kidney 
transplantation, and further, that DCD kidneys from black donors provide black 
recipients with the best long-term graft survival.
ORGAN PROCUREMENT AND TRANSPLANT IN 64 
“CALCULATED RISK” DONORS IN ITALY. GRAFT AND 
RECIPIENT SURVIVAL
C. De Cillia1, S. Venettoni1, L. Rizzato1, A. Ricci1, D.A. Mattucci1, 
P. Grossi2, A. Nanni Costa1
1Italian National Transplant Centre, Istituto Superiore di Sanità, Roma, Italy 
2University of Insubria, Varese, Italy
Introduction: The imbalance between organ donation and demand continues 
to represent one of the main issues in transplant activity, thus “non standard” 
organ transplantations have been performed over the years. The “calculated 
risk” protocol has been in use nationwide.
Aim of the study: Aim of this study is to review organ procurement in Italy 
and related transplantations from 2003 to 2007, then to assess graft outcome 
and recipients survival among transplants carried out from 2003 to 2005.
Material and Methods: “Calculated risk” donors have been divided in 
7 categories: 1) HBsAg+ 2) HCV+ 3) HBsAg+ and HCV+ 4) HCV+ and 
HBcAb+ 5) HBcAb+ 6) Meningitis 7) Bacteremia
All “calculated risk” effective donors and all organs with related transplants 
from the 1st of January 2003 to the 31st of December 2007 have been reviewed. 
Afterwards organ and recipient survival data concerning transplantations 
which were carried out from the 1st of January 2003 to the 31st of December 
2005 have been analyzed and compared with those concerning the sample of 
all transplanted in the same period of time.
Results: 980 “calculated risk” effective organ donors with 2571 donated organs 
in all (240 hearts, 818 livers, 1432 kidneys, 20 pancreas and 61 lungs) were 
reported between the 1st of January 2003 and the 31st of December 2007. In this 
period 2458 patients were transplanted with the 2571 organs (57 double kidney, 
15 liver/kidney, 16 kidney/pancreas, 2 heart/liver, 2 heart/lung, 42 double 
lung). Table 1 shows heart, liver and kidney transplants divided according to 
the risk category.
Heart 2003 2004 2005 2006 2007 Total
HBsAg+ 1 6 2 1 3 13
HCV+ 3 1 1 2 4 11
HBsAg+HCV+ 0 0 0 0 0 0
HCV+HBcAb+ 0 3 1 0 0 4
HBcAb+ 40 47 38 22 36 183
Meningitis 0 0 4 4 4 12
Bacteremia 2 3 1 5 6 17
Total 46 60 47 34 53 240
Liver 2003 2004 2005 2006 2007 Total
HBsAg+ 1 10 7 7 9 34
HCV+ 6 12 11 10 11 50
HBsAg+HCV+ 0 0 1 1 0 2
HCV+HBcAb+ 2 3 5 6 3 19
HBcAb+ 113 149 139 80 126 607
Meningitis 0 4 9 10 9 32
Bacteremia 8 11 3 19 33 74
Total 130 189 176 133 191 818
Kidney 2003 2004 2005 2006 2007 Total
HBsAg+ 2 24 6 9 8 49
HCV+ 14 28 16 10 16 84
HBsAg+HCV+ 0 0 0 0 0 0
HCV+HBcAb+ 2 10 6 4 6 28
HBcAb+ 207 259 251 132 205 1052
Meningitis 0 5 12 15 18 50
Bacteremia 9 15 5 33 50 112
Total 234 239 296 203 303 1375
Table 1.
Graft and recipient survival appears to be comparable to that concerning the 
sample of all transplanted in the same period of time, except for hearts provided 
by HBsAg+ organ donors and livers provided by meningitis and bacteremia 
organ donors categories. Table 2 shows recipient survival in heart, liver and 
kidney transplants.
Recipient survival 1 year 2 years 3 years 4 years
Heart % % % %
All transplanted sample 84,7 82,1 81 78,9
HBsAg+ 60 60 60 60
HCV+ 90 90 78,7 78,7
HCV+HBcAb+ 100 100 100 100
HBcAb+ 88,7 85,2 83,8 82,2
Meningitis 100 100 100 100
Bacteremia 87,5 87,5 87,5 87,5
Liver % % % %
All transplanted sample 86,5 82,5 79,4 77,9
HBsAg+ 84,2 84,2 84,2 84,2
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HCV+ 91,9 89,6 86,5 86,5
HBsAg+HCV+ 100 100 100 100
HCV+HBcAb+ 100 100 100 100
HBcAb+ 87,8 82,6 77,1 76,5
Meningitis 84,6 76,2 66,6 66,6
Bacteremia 88,8 76,6 72,1 72,1
Kidney % % % %
All transplanted sample 96,9 96,1 95 93,7
HBsAg+ 100 100 96,2 96,2
HCV+ 98,5 98,5 98,5 98,5
HCV+HBcAb+ 100 100 100 100
HBcAb+ 96,7 95,8 95,6 94,8
Meningitis 100 100 100 100
Bacteremia 94,5 94,5 94,5 94,5
Table 2.
Conclusion: Graft and recipient survival appears to be satisfying in every risk 
category; whilst data regarding HBcAb+ category are several, those regarding 
the other categories are quite few. The positive issues of this study, along with 
the improvements in trating these infections, should encourage to enlarge the 
range of organ choice in order to increase organ procurement.
IDENTIFICATION OF ORGAN CHARACTERISTICS 65 
UNSUITABLE FOR IMPLANTATION IN THE UNITED STATES
T. Mone1, M. Nowicki2, M. Stadtler1, V. Simmons1, C. Chinchilla2, 
R. Mendez2, R. Mendez2, T. Shah2, Y. Cho2, S. Takemoto2
1OneLegacy, 2National Institute of Transplantation
As a possible consequence of public disclosure of center survival rates in the 
United States, organs from consenting donors may not be utilized because of 
a low expected benefi t to the recipient. This study examines the reasons for 
non-utilization with the aim of identifying characteristics of organs not suitable 
for transplantation in the United States, which could possibly be implanted 
elsewhere.
Reasons for non-procurement and discard were examined in a retrospective 
record review of 2,136 potential deceased donors for whom consent was 
obtained from 2001-2006. Cases with consent for organ donation but blood 
tests indicating positive serology may not be procured or reported to the national 
registry so we augmented data from the local organ procurement agency with 
results from the serologic laboratory. Statistical signifi cance was tested using 
two-tailed chi-square.
During the period of study, procurement records indicate consent was obtained 
for 4,223 kidneys, 76% (n=3,231) were transplanted, 6% were not recovered 
(n=237) and 18% (n=751) were discarded after procurement. The most common 
reason given for non-transplantation was histological fi ndings in the biopsy 
accounting for 475 (51%) of the non-transplanted kidneys. Organ quality (n=96, 
10%). virology (n=111, 12%). donor history (n=48, 5%). ischemia (n=32, 4%). 
anatomic (n=25, 3%). no recipient available (n=4, 0.5%) were other reasons 
given for non-transplantation.
CMV virology results were reported for 1,514 of the 2,136 donors in the 
procurement database. Results were positive for 69% (n=1,046). The discard 
rate was 26% when positive compared to 23% for CMV negative donors 
(P=0.11). Hepatitis serology (HCV and/or HBV) was positive in 10% (n=145) 
of reports with a 37% discard rate when positive versus to 24% (P=0.001) 
when negative. There were no reported positive HIV results and 4 positive for 
HTLV-I/II with organs from 2 of these donors discarded.
Review of serology data obtained testing donors (‘shut down cases’) identifi ed 
372 additional donors with positive serology for hepatitis viruses (HCV and/
or HBV). 7 for HIV and 32 for HTLV-I/II. These results indicate an additional 
393 donors have not been procured because of positive serology indicating 
infection with one or more viruses.
Retrospective examination of records in a single procurement region in the 
United States suggests that over 6 years, as many as 1,732 additional kidneys 
were not transplanted (54%). The majority of kidneys were discarded because 
of biopsy or, to lesser degree, virology serology fi ndings. Other studies have 
indicated histologic evaluation may not accurately distinguish poor and good 
kidney function after transplantation. Furthermore, certain viruses, HTLV-II in 
particular, may not have an immediate impact on the recipient health. Some of 
the donors maybe considered even if some serologies are positive (i.e. HTLV-
II) or a compatible recipient (HBV+ or HBV vaccinated) is available. These 
results indicate dramatic increases in deceased donor organ transplantation 
may be achieved by utilizing kidneys that are currently discarded.
FACTORS PREDICTIVE OF THE DISCARD OF ECD 66 
KIDNEYS DO NOT PREDICT OUTCOME
F.L. Delmonico1, K. O’Connor1, R. Pietroski2, K. Meyer4, G. Lipkowitz3, 
J. Stoff1, D. Schaubel4, R. Merion4, F. Port4, A.B. Leichtman4
1New England Organ Bank, 2Gift of Life Michigan, 3LifeChoice Donor 
Services, 4Arbor Research Collaborative for Health
Extending the opportunity of transplantation of kidneys from expanded criteria 
donors (ECD) has been limited by the high rate of ECD discard. We investigated 
the relationship between donor characteristics that are highly predictive of 
kidney discard and post-transplant outcomes.
Methods: As part of a U.S. Health and Human Services sponsored research 
grant (1 H39 OT 00123-01). factors predictive of ECD discard were determined 
using Logistic Regression models adjusted for multiple donor and recipient 
factors. The predictive value of those factors were then tested against several 
post-transplant outcomes, including delayed graft function (DGF). graft loss, 
length-of-stay (LOS). and a combined outcome (of delayed graft function, graft 
loss or death during the fi rst post-operative year).
Results: Five factors were statistically predictive of discard: percent 
glomerulosclerosis (GS) 10-19% compared to GS equal to 0% (OR=2.07, 
p=0.013); GS > 20% compared to GS equal to 0% (OR=4.61, p<0.0001); a fi nal 
pulsatile perfusion pump resistance > 0.4 compared 0-0.2 (OR=2.95, p=0.005); 
age > 70 years compared to 50-59 (OR=3.27, p=0.0020); and the presence 
of kidney cysts (OR=1.89, p=0.005). Of these factors, none was predictive of 
DGF, LOS, or the combined outcome. Only age > 70 was predictive of graft 
failure counting death as an event (HR=1.91, p=0.034, and only age > 70 (HR 
= 2.38, p=0.025) and GS > 20% (HR=3.22, p=0.022) were predictive of death 
censored graft failure. However, 55 of 256 (22%) kidneys recovered from ECD 
under the age of 70 years, and with a resistance less than 0.4 and GS less than 
20% were discarded.
Conclusions: Refl ecting widely held beliefs within the kidney transplant 
professional community, GS, resistance and age are highly predictive of 
ECD kidney discard. However, this study disputes the misperception of a 
relationship between those factors predictive of discard and several post-
transplant outcomes. Transplant centers should reexamine the criteria by which 
decisions to discard ECD kidneys are being made.
EARLY RESULTS OF A CONTROLLED NON-67 
HEARTBEATING PROGRAMME
J.A. Akoh, S.B. Bradshaw, M.B. Walker, J.B. Barwell, M.D. Denton, T. Rana
Plymouth Hospitals NHS Trust
Introduction: The continued mismatch between supply and demand for organs 
has led to the development of controlled non-heart beating donation (CNHBD) 
programmes. Between April 2006 and March 2007, 159 CNHBD yielded 307 
kidneys in the UK. Key considerations in establishing a CNHBD programme 
include the diffi culty in prediction of asystole, logistical issues relating to 
the process and outcomes of CNHBD organs. We present our experience of 
CNHBD in a University Hospital with a mixed critical care unit a transplant 
centre serving a population of 2.2 million. 
Methods: Prior to implementation of CNHBD, a steering group determined 
that the programme was feasible and an implementation committee produced 
protocols covering all aspects of the programme. All referrals for CNHBD 
between January 2005 and January 2008 are included in this analysis. The 
cause of death, withdrawal-to-asystole, machine perfusion, organ usage, warm 
and cold ischaemia times, delayed graft function, early and late graft function 
were analysed. 
Results: During the period, 79 patients were referred resulting in 35 proceeding 
to retrieval and 61 kidneys being successfully transplanted. Forty-four patients 
did not proceed because of delayed asystole (15). declined/no assent (10). 
medical unsuitability (14). early asystole (4) with one becoming brain stem 
dead prior to withdrawal of treatment. Of the 35 donors, 18 had intracranial 
haemorrhage, 10 hypoxic brain damage and 7 traumatic brain injury. The 
median time from withdrawal of futile life-sustaining therapy to asystole was 
15 min (IQR 10.0-23.0). The median primary warm ischaemic time (systolic 
blood pressure <50 mmHg to perfusion) was 20 min (IQR 16.0-27.0) and the 
median cold ischaemic time was 18 hours (IQR 11.7-20.00). Forty one percent 
(16/39) kidneys preserved by machine perfusion showed delayed graft function 
compared to forty-fi ve percent (10/22) of kidneys preserved in cold storage. 
The median time to halving of serum creatinine was 7 days. 
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Conclusion: Structured implementation resulted in a successful CNHBD 
programme providing 61 successful renal transplants from 35 CNHBDs’ in 3 
years – contributing about 35% to the total number of transplants during the 
period .We consider early involvement of all stakeholders contributed to the 
success of the programme. Donors generally reached asystole quickly despite 
low levels of ventilatory support and relatively little circulatory support.
DECEASED DONOR KIDNEY TRANSPLANTATION 68 
USING EXTENDED CRITERIA DONOR KIDNEYS 
FOLLOWING PULSATILE MACHINE PERFUSION--SHORT 
TERM OUTCOMES
A. Basu1, I. Dvorchik1, C. Morgan1, H. Tan1, J. Donaldson1, B. Yelochan1, 
S. Stuart2, P. Randhawa1, A. Marcos1, R. Shapiro1
1Thomas E Starzl Transplantation Institute, 2Center for Organ Recovery and 
Education
Aim: We studied early outcomes of deceased donor kidney transplantation using 
machine perfused (MP) extended criteria donor (ECD) kidneys and compared 
these to results of transplantation using ECD kidneys that were cold-stored.
Methods: Forty-four sequential kidney transplants were done after MP using 
ECD [per United Network of Organ Sharing (UNOS) criteria] between May 
2006 and December 2007. MP was done using the Waters RM3 (Waters 
Instruments, Rochester, MN) or the Lifeport Kidney Transporter (Organ 
Recovery Systems, Des Plaines, IL) machines. MP was continued until pump 
parameters were optimal for transplantation, which was then performed. The 
control group consisted of 88 transplants that were done using cold-stored 
ECD kidneys that were transplanted into age-matched recipients between 
October 2002 and November 2007.All patients received pre-conditioning 
with Alemtuzumab (Campath 1H) followed by Tacrolimus monotherapy, with 
spaced weaning where applicable. Statistical analysis was done using SPSS 
15.0 (Chicago, IL, USA). Incidence of delayed graft function (DGF). donor 
hypertension and donor cause of death were compared using the likelihood 
ratio Chi-square test. Donor and recipient age, donor terminal creatinine, length 
of hospital stay (LOS) after transplantation, readmissions within 3 months, 
number of dialysis within 30 days post transplant, number of rejection episodes 
and cold ischemia times (CIT) were compared using t-test with Levene’s test 
for verifi cation of equality of variances assumption.
Results: The CIT was signifi cantly longer in the MP group (32.1+/-9.6 vs 
24.4+/-7.6 hours, p<0.0001).In spite of the longer CIT, no difference was 
noted in the incidence of DGF between the MP and control groups (p>0.38).
No difference was noted in the incidence of hypertension in the donor (p>0.7) 
or, in the causes of donor death (p=0.32). No signifi cant difference was noted 
in the donor age (61+/-7.7 vs 61+/-6 yrs, p=0.85). donor creatinine (1.6+/-0.9 
vs 1.5+/-3 mg/dl, p=0.84). recipient age (61+/-9.7 vs 61.5+/-9.1 yrs, p=0.68). 
LOS (9+/-14 vs 6.4+/-3.8 days, p=0.22). readmissions within 3 months 
(0.9+/-1.4 vs 1+/-1.3, p=0.68). number of dialysis treatments 30 days post-
transplant (0.45+/-1.3 vs 0.82+/-1.8, p=0.23). or rejection episodes (0.61+/-1.1 
vs 0.7+/-1, p=0.7). The LOS tended to be longer, and the number of dialyses 
tended to be fewer in the MP group.
Conclusions: Early outcomes are similar using MP ECD kidneys with longer 
CIT compared with non-MP ECD kidney transplants. This fi nding may have 
important implications for the transportation and sharing of kidneys across the 
various UNOS regions.
KIDNEY TRANSPLANTATION FROM EXPANDED 69 
CRITERIA DONORS: EXPERIENCE IN A SERIES OF 197 CASES
T. Karatzas1, A. Gompou2, G. Zavos3, J. Bokos3, B. Papanikolaou4, 
G. Miserlis4, S. Drakopoulos5, M. Koukoulaki5, K. Xiromeritis6, A. 
Papachristodoulou1
1Second Propaedeutic Department of Surgery, University of Athens, 2Hellenic 
National Organization of Transplantation, 3Transplantation Unit, Laiko 
General Hospital, Athens, Greece, 4Transplantation Unit, Laiko General 
Hospital, Athens, Greece, 5Surgical Department of Transplantation, 
University of Thessaloniki, Medical School, Thessaloniki, Greece, 6Surgical 
Department of Transplantation, University of Thessaloniki, Medical School, 
Thessaloniki, Greece, 7Transplantation Unit, Evangelismos General Hospital, 
Athens, Greece, 8Transplantation Unit, Evangelismos General Hospital, 
Athens, Greece, 9First Department of Surgery, University of Athens, Medical 
School, Athens, Greece, 10Second Propaedeutic Department of Surgery, 
University of Athens
The persistent shortage of organs for transplantation universally has resulted 
in the implementation of strategies for utilizing organs from extended criteria 
donors (ECDs). Most transplant centers encourage the use of kidneys from 
ECDs, having one or two risk variables.
Objective: We retrospectively reviewed our cadaveric kidney transplantations 
(KTx) from ECDs and examined their impact on patient outcome and graft 
function, rejection episodes and survival.
Patients and Methods: ECDs data reported from Registry of the National 
Organization of Transplantation of Greece and KTx medical fi les, were 
reviewed. Totally 742 cadaveric KTxs were performed during a 5-year period 
(2001-2006). of which 197 (26.6%) kidneys were provided from ECDs and the 
rest 545 (73.4%) from conventional donors. ECDs in our series included:
- Expanded age limits (≥ 65 yrs, ≤ 5 yrs) 
- Age > 55 yrs with 1 or 2 of the following criteria: donors with history of 
diabetes (DM). hypertension (HT) > 10 yrs, cause of death a cerebrovascular 
accident (CVA) and serum creatinine (Cr) > 1.5 mg/dl.
Kidneys were not accepted for transplantation if a donor met three or more 
criteria. No specifi c donor upper age limit was excluded from consideration. 
The patient parameters examined included: age, sex, length of hospitalization, 
patient and graft survival, rejection episodes, graft function (urea, Cr, GFR). 
DGF and cause of graft loss.
Results: Kidneys provided from ECDs were: 71 from donors ≥ 65 years or 
older, 11 from pediatric donors (≤ 5 years). 51 from HT, 7 from DM and 57 
from CVA and Cr > 1.5 mg/dl. Several donors had two risk factors. Of the 161 
KTxs eligible for inclusion analysis, 131 (81.87%) had functioning graft at 
5-year follow-up, with Cr ranging from 1.5 mg/dl (Pediatric donors) to 2.66 
mg/dl (DM donors). Actuarial graft survival of KTxs at 1 through 5 years was 
85.3%, 77.8%, 68.2%, 60.0% and 65.0% respectively, mean urea was 76.4, 
89.2, 95.2, 94.4 and 94.4 mg/dl and mean Cr was 1.95, 2.30, 2.40, 2.60 and 
2.60 mg/dl respectively. Among the 161 KTxs, 73 (45.3%) presented EGF, 
as post-transplant dialysis was not required. Of these 63 (86.3%) remain with 
functioning graft 5 years post-transplant. The rest 88 (54.7%) KTxs developed 
DGF and required one or more dialysis sessions post-transplant. Sixty-eight 
(77.3%) of these had functioning graft 5 years post-transplant and 20 were lost, 
with rejection being the most common cause of graft loss. KTxs from older 
donors presented moderately increased rejection rate, urea (74 mg/dl) and Cr 
(2.15 mg/dl). compared to pediatric donors. KTxs from HT, DM, CVA and Cr 
>1.5 mg/dl donors presented increased rejection rate, urea (range: 78-98 mg/dl) 
and Cr (range: 2.25-2.66 mg/dl). 5 years post-transplant.
Conclusions: The utilization of ECDs signifi cantly increased our donor pool 
of KTx in the last 5 years. Extreme donor age alone is not a prohibiting factor 
in KTx. Donor HT, DM, CVA, or Cr 1.5 mg/dl and DGF, all had an adverse 
effect on renal function and survival at 1 to 5 years, but none reached statistical 
signifi cance.
CORRELATIONS BETWEEN RESPONSES TO CDC 70 
GUIDED SCREENING QUESTIONS FOR HIGH RISK 
BEHAVIOR AND RESULTS OF EIA ANTIBODY SCREENING 
ASSAYS IN POTENTIAL DECEASED ORGAN DONORS
M. Mozes, M. Harmon, A. Jaramillo, B. Labuda
Gift of Hope Organ and Tissue Donor Network, Elmhurst, Il, USA
Introduction: In 1994 the CDC published guidelines for classifying donors 
of organs, tissues and cellular products as “High Risk” based on responses 
to questions designed to identify behaviors which increase risk of HIV 
transmission. Laboratory screening tests for transmissible viral diseases 
including HIV, HCV and HBV are routinely performed on potential deceased 
organ donors.
We examined whether there is correlation between affi rmative responses to 
screening questions and the incidence of positive antibody screening results 
for HIV. Additionally, we examined the correlation with HCV and HBV EIA 
testing.
Methods: Retrospective analysis of records from 4877 consented deceased 
donor cases age >10 from 1995 to 2007 was performed. Donors were divided 
into two groups: “CDC High Risk” (CDC-HR) where an affi rmative answer (s) 
to at least one CDC recommended screening questions was given (N=561) and 
“Non-CDC High Risk” where no affi rmative answers were given (N=4316). 
Serological screening results for HIV-1/2, HCV, HBcAb and HBsAg were 
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available in all cases.
Results:
Group N (%) HIV HCV ** HBsAg HBcAb**
CDC High Risk* 561 (11.5%) 5 (0.9%) 77 (13.7%) 5 (0.9%) 66 (12%) 
Non-CDC High Risk 4316 (88.5%) 16 (0.3%) 171 (3.5%) 17 (0.4%) 243 (5.6%) 
TOTAL 4877 21 (0.4%) 248 (5.0%) 22 (0.5%) 309 (6.3%) 
*CDC High Risk was determined by screening questions only, other CDC recommended screening 
including physical assessment fi ndings, hemodilution etc. were not included in this analysis.
** p< .0001
21/4877 (0.4%) potential donors tested HIV-1/2 antibody positive. The 
incidence in the CDC-HR group was 5/561 (0.9%) vs.16/4316 (0.3%) in the 
Non-CDC HR group (p= 0.15).
The incidence of HCV+ tests in the CDC-HR group was 77/561 (13.7%) as 
compared to 171/4316 (3.5%) in the Non-CDC-HR group (p<.0001). The 
incidence of HBsAg + tests in the CDC-HR was 0.9% vs. 0.4% in the Non-
CDC HR group (p=.18). The incidence of HBѕAb+ tests in the CDC HR group 
was 66/561 (12%) vs. 243/4316 (5.6%) in the Non-CDC HR group (P<.0001).
Summary and Conclusions: There was a trend for higher incidence of positive 
serology for all tests in the CDC HR group but this was signifi cant only for 
HCV and HBcAb. The majority of positive cases for each of the tests were in 
the non High Risk group. These data need further confi rmation and should be 
considered when contemplating routine prospective NAT testing for potential 
organ donors. Considerations of logistics, cost and potential inadvertent loss of 
donors and organs associated with prospective NAT testing need to be weighed 
against the current low incidence of disease transmission.
METHYLPREDNISOLONE INFUSION EFFECTIVELY 71 
DECREASES PLASMA INTERLEUKIN-6 (IL-6) AT 
EXPLANTATION IN ORGAN DONORS AFTER BRAIN DEATH
M. Mathur1, M. Stadtler3, S. Collazo3, T. Mone3, R. Hawthorne3, 
C. Chinchilla4, V. Pravica4,5, F. Petersen2, K. Bahjri2 and I. Hutchinson4,5.
Loma Linda University Children’s Hospital1and Health Research 
Consulting Group2, Loma Linda, CA; OneLegacy3, National Institute of 
Transplantation4and University of Southern California5, Los Angeles, CA, 
USA.
Background: IL-6 is a key pro-infl ammatory cytokine upregulated after 
Brain Death (BD) in humans. It leads to adhesion molecule activation and 
leukocyte invasion in all organs. Pre-explantation organ dysfunction is a 
direct consequence of infl ammation, and renders many organs unsuitable for 
transplantation. Functionally, IL-6 elevation correlates with deteriorating donor 
cardiac function in humans and its upregulation in kidney and liver donors 
worsens ischemia-reperfusion injury in recipients. Corticosteroids modulate 
gene expression of pro-infl ammatory cytokines (including IL-6) thereby 
ameliorating the infl ammatory cascade after BD. Reduced infl ammation may 
help to improve the number of transplantable organs procured from each donor. 
(The current average is 3.6 organs out of a possible 8 in the United States). 
Though a bolus dose of Methylprednisolone (Solumedrol) is a component of 
hormonal resuscitation in hemodynamically unstable BD donors, its plasma 
half-life is <3 hours and independent of the dose given.
Aim: To determine whether Solumedrol given as a continuous infusion 
suppresses infl ammation after BD better than usual care, using IL-6 level as a 
marker for the degree of infl ammation.
Methods: Clinical data and serial blood samples were prospectively collected 
from 11 BD subjects (ages 15-65 years) after obtaining research consent. All 
patients received a 30mg/kg Solumedrol bolus as a part of usual hormonal 
resuscitation. Five randomly selected patients also received Solumedrol infusion 
(100mg/hr) until explantation (experimental SoluDRIP group). while the other 
6 served as controls. APACHE II scores (range 12-26) were similar between 
groups. Plasma IL-6 at baseline; 8, 16 and 24 hours after the Solumedrol bolus 
and at explantation was quantifi ed using IL-6 ELISA (Biogen®) with a lower 
limit of detection at 4 pg/ml. IL-6 levels were compared between groups at 
each time point using student t-test with alpha at .05.
Plasma IL-6 (pg/ml) and OTPD SoluDRIP Control
Time-points Mean SD Mean SD
Baseline 709 755 849 587
8 Hours 444 697 607 672
24 Hours 232 378 510 709
Explantation* (p=.02) 129 120 668 422
Actual OTPD 4.0 2.1 3.00 2.1
Results: All patients had elevated IL-6 at baseline. (Mean ± SD shown in 
the table, only means are graphed for clarity). Despite the small sample 
size, reduction in IL-6 in the Solumedrol infusion group at explantation was 
signifi cant (p=.02). Though IL-6 level at other time-points was statistically 
similar, the SD stabilized in SoluDRIP subjects but not controls. OTPD trend 
appeared favorable, although unconfi rmed in this sample.
Conclusions: Continuous Methylprednisolone infusion reduces plasma IL-6 at 
explantation signifi cantly compared to current donor management. Suppression 
of infl ammation by Methylprednisolone infusion should be further investigated 
to determine whether clinical outcomes such as organs transplanted per donor 
and recipient graft survival can also be favorably impacted.
CONCURRENT ORAL SESSION 9: 
XENOTRANSPLANTATION – COAGULATION/ISLETS
THE INNATE IMMUNE RESPONSE AND ACTIVATION OF 72 
COAGULATION IN α1,3-GALACTOSYLTRANSFERASE GENE-
KNOCKOUT XENOGRAFT RECIPIENTS
M. Ezzelarab1, C.C. Lin1,2,3, H. Hara1, D. Ayares4, A. Dorling2, D.K.C. Cooper1
1Thomas E. Starzl Transplantation Institute, University of Pittsburgh, PA 
2Department of Immunology, Imperial College London, Hammersmith 
Hospital, London, UK 3Department of Surgery, Chang Gung Memorial 
Hospital, Kaoksiung, Taiwan 4Revivicor Inc., Blackburg, VA
Background: Acute humoral xenograft rejection (AHXR). frequently 
associated with disseminated intravascular coagulation (DIC). remains a major 
challenge in pig-to-primate xenotransplantation (Tx). The precise factors 
initiating graft intravascular thrombosis, particularly when the predominant 
pathology is thrombotic microangiopathy (TM). remain to be elucidated. 
Upregulation of donor tissue factor (TF) in the xenograft has been implicated 
in these processes but the importance of recipient TF has not been addressed.
Methods: Organs and aortic patches from α1,3-galactosyltransferase gene-
knockout (GTKO) pigs were transplanted into baboons (n=18). with or without 
immunosuppression. Immunohistochemistry was used to identify IgM, IgG, 
complement deposition, cellular infi ltration, and primate TF expression in 
the graft. Baboon TF mRNA in the graft was measured by qPCR. Baboon 
monocytes and platelets were isolated from peripheral blood before and after 
Tx, and analyzed for TF activity and by fl ow cytometry. Functional TF activity 
was determined by clotting assays after mixing monocytes and platelets with 
recalcifi ed Factor VII (FVII) -defi cient plasma with or without FVII.
Results: In all grafts (with or without immunosuppression). IgM, IgG, and 
complement deposition was present, with neutrophil and macrophage infi ltrates 
(some cells expressed TF). and intravascular fi brin deposition and platelet 
aggregation characteristic of TM. Clinical and/or laboratory features of DIC 
occurred in >50% of organ xenograft recipients. Before Tx, monocytes and 
platelets did not express TF or display TF-dependent procoagulant activity. 
After pig aortic patch Tx, circulating recipient platelets (but not monocytes) 
expressed TF and promoted TF-dependent clotting in recalcifi ed plasma. 
After pig organ Tx, recipient platelets expressed TF as early as day 3, while 
monocytes began to express TF later. Furthermore, the organs expressed high 
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levels of baboon TF mRNA.
Conclusions: Irrespective of the presence or absence of the adaptive immune 
response, the development of AHXR is associated with the expression of TF 
on recipient monocytes and platelets. TF expression by innate immune cells 
of the recipient may be a major procoagulant factor that contributes to the 
development of TM. Pigs transgenic for tissue factor pathway inhibitor (TFPI) 
should have advantages in preventing AHXR.
HUMAN COMPLEMENT REGULATORY PROTEIN 73 
EXPRESSION ATTENUATES THROMBIN GENERATION BY 
GALTKO LUNGS
R.N. Pierson1, T. Stoddard1, S. Kelishadi1, T. Zhang1, C. Avon1, E. Welty1, 
A. Laaris1, X-F. Cheng1, D. Ayares2, A.M. Azimzadeh1
1University of Maryland Medical Center, 2Revivicor, Blacksburg, VA
Purpose: Hyperacute lung rejection (HALR, defi ned as signifi cant graft 
injury within 4 hours) is usually observed when GalTKO lungs are perfused 
with human blood. We evaluated whether the additional expression of human 
complement regulatory protein protects GalTKO lungs from injury.
Methods: Heparinized fresh human blood expanded with fresh frozen plasma 
was used to perfuse GalTKO lungs expressing CD46 (hMCP) (n=4) or 
CD55 (hDAF) (n=1). Pulmonary function was assessed by measuring fl ow, 
pulmonary vascular resistance (PVR). airway pressure, and gas exchange. 
The results obtained from these studies were compared with the fi ndings from 
previous perfusions of GalTKO lungs (n=14). Surviving lungs were censored 
at four hours.
Results: Median survival for the GalTKO (114 min, range 15-360) and 
GalTKO/hMCP (135 min, range 90-240) groups were not signifi cantly 
different. The average PVR at 10 minutes was 88±68 mm-Hg/L and 
215±236 mm-Hg/L for GalTKO and GalTKO/hMCP, respectively (p= 
0.46). Preliminary data suggest that, as expected, complement activation 
is well controlled in GalTKO lungs expressing complement regulators. 
Surprisingly, addition of hCD46 or hDAF attenuated thrombin generation 
at 15’ (mean Δ; F1+2 = 0 nM) versus the GalTKO group (mean Δ; F1+2 = 
4.6±8 nM) (p=0.0028). Platelet activation as measured by BTG levels did not 
signifi cantly differ between GalTKO (mean Δ;BTG = 251±134 IU/ml) and 
GalTKO/MCP (mean Δ;BTG = 300±68 IU/ml). and neutrophil and platelet 
sequestration were not prevented.
Conclusion: Though GalTKO lungs are not fully protected against HALR 
by expression of human complement regulatory proteins, our observations 
demonstrate that coagulation cascade activation is partially attenuated. 
Additional strategies to better control platelet activation and prevent neutrophil 
sequestration may prove pivotal to protect GalTKO lungs from injury by 
human blood.
COAGULATION CONTROL USING GENE TRANSFER OF 74 
HUMAN DAF AND THROMBOMODULIN IN PIG TO PRIMATE 
XENOTRANSPLANTATION
Y. Miwa1,6, K. Yamamoto2, A. Katayama1,7, T. Nagasaka3, A. Onishi4, 
M. Iwamoto5,4, K. Kadomatsu6, K. Uchida3, A. Nakao7, T. Kobayashi1,7
1Department of Applied Immunology, Nagoya University School of 
Medicine, Nagoya JAPAN, 2Department of Transfusion Medicine, 
Nagoya University School of Medicine, Nagoya, JAPAN, 3Department of 
Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, JAPAN, 
4Department of Development Biology, National Institute of Agrobiological 
Sciences, Tsukuba, JAPAN, 5Prime Tech LTD, Tsuchiura, JAPAN, 
6Department of Biochemistry, Nagoya University School of Medicine, 
Nagoya, JAPAN, 7Department of Surgery II, Nagoya University School of 
Medicine, Nagoya, JAPAN
Introduction: Coagulation disorder such as thrombotic microangiopathy is 
one of the remaining problems after hyperacute rejection was successfully 
suppressed in xenotransplantation from GT-KO cloned pigs (lacking Gal 
expression) or human (h) DAF transgenic pigs (expressing complement 
regulatory proteins). One possible cause is assumed to be the molecular 
incompatibility in coagulation system between pigs and primates, which 
suggests that porcine thrombomodulin (TM) in endothelial cells binds human 
thrombin, but cannot effectively convert human protein C into activated protein 
C (APC). We previously reported that complement activation certainly causes 
endothelial activation, resulting in subsequent procoagulation. The purpose of 
this study was to clarify the protective effect of hDAF and hTM expression in 
pig endothelial cells on coagulation disorder.
Methods: hDAF-expressed porcine aortic endothelial cells (hDAF-PAEC) 
were collected from hDAF cloned pig. hTM-expressed PAEC (hTM-
PAEC) were obtained from hTM gene transfection by electroporation. After 
incubation with human sera, endothelial cell activation was evaluated by semi-
quantifi cation of porcine infl ammatory gene expression. TM co-factor activity, 
namely APC production capacity in human aortic endothelial cells (HAEC). 
PAEC and hTM-PAEC was determined using APC specifi c chromogenic 
substrate S-2366. Clotting assay was performed by mixing the cells (1_105) 
with human plasma including clotting buffer. Inhibition assay was conducted 
by anti hTM (EGF 5 epitope) monoclonal antibody which specifi cally blocks 
the binding site.
Results: hDAF-PAEC almost completely suppressed the upregulation of 
pig tissue factor and plasminogen activator inhibitor-1 mRNA induced by 
preincubation with human sera, and consequently improved the shortened 
clotting time. Although APC production capacity in PAEC showed as low 
as one-tenth of that in HAEC, some clones of hTM-PAEC expressing the 
same level of TM as HAEC exhibited compatible level of APC production 
capacity. Inhibition assay demonstrated that anticoagulant effect of hTM 
expression was observed not in stable condition, but in activated condition 
of PAEC.
Conclusions: hDAF expression in PAEC alleviated the infl ammatory response 
such as upregulation of TF and PAI-1 mRNA, resulting in prevention of 
the subsequent procoagulation. hTM expression in PAEC regulated the 
procoagulant state particularly in activated condition (e.g., induced by antibody 
binding, complement activation or infection). The production of cloned pigs 
expressing both hDAF and hTM genes which are useful for coagulation control 
is in progress.
DELETION OF GAL INHIBITS THE INSTANT BLOOD-75 
MEDIATED INFLAMMATORY REACTION (IBMIR) 
FOLLOWING EXPOSURE OF PORCINE NEONATAL ISLET-
CELL CLUSTERS (NICC) TO HUMAN BLOOD.
W.J. Hawthorne1, D.M. Simond1, A.T. Patel1, J. OHara1, K. Waite1, K. Moyle1, 
E. Salvaris2, N. Fisicaro2, S.L. Londrigan3, A. Lew3, E. Favaloro1, S.C. 
Robson4, M. Nottle5, A. d’Apice2, P.J. Cowan2, P.J. O’Connell1.
1The Centre for Transplant & Renal Research, Westmead Millennium 
Institute, Westmead, 2St Vincent’s Health, Melbourne. 3The Walter and Eliza 
Hall Institute of Medical Research, Melbourne, 4Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, 5University of Adelaide, 
Adelaide.
Aims: To determine the effect of deletion of the Gal antigen, with or without 
expression of CD39 and treatment with activated protein C (APC). on IBMIR.
Methods: Purpose bred piglets lacking α1,3-galactosyltransferase (Gal-/-) or 
wild type (WT) controls were used as NICC donors. Select Gal-/- and WT 
NICC were also transduced using an adenoviral vector expressing human 
CD39 (CD39) & treated with 1.25 or 2.5ug APC. 5,000 NICC were exposed 
to 7ml of human blood in a heparin bound loop system on a rocking incubator 
for 60 mins.
Results: Gal-/- NICC showed less clotting & reduced platelet (Plt) & neutrophil 
consumption compared to WT control NICC. Gal-/- NICC expressing human 
CD39 and treated with 2.5ug APC demonstrated the greatest reduction in clot 
size, reduced Plt, neutrophil, fi brinogen & D-Dimers consumption compared 
to all other NICC. Histology also demonstrated that Gal-/- NICC transduced 
CD39 treated with 2.5ug APC were the most intact having less infi ltration of 
neutrophils than the WT clots.
Conclusions: These studies clearly demonstrate that more than one strategy 
or agent will be required to prevent the full extent of IBMIR. Removal of 
αGal must be part of the strategy to prevent the early innate response to NICC 
xenografts.
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TRANSGENIC OVEREXPRESSION OF HUMAN EPCR 76 
CONFERS PROTECTION AGAINST INFLAMMATION AND 
COAGULATION
E. Lee, J.C. Roussel, B. Lu, L. Murray-Segal, O. Ischenko, A. d’Apice, 
P. Cowan, H. Gock
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Australia.
Background: Despite success in overcoming hyperacute rejection in pig-to-
primate xenotransplantation, organ xenografts are still susceptible to a number 
of insults leading to graft failure, including ischaemia-reperfusion injury 
(IRI) and acute vascular rejection (AVR). The contribution of IRI is currently 
unknown but both conditions involve infl ammation and coagulation. The latter 
is a particular problem in AVR, one feature of which is widespread thrombosis 
within small blood vessels. Our strategy to counter these effects is to overexpress 
and increase the distribution of human coagulation and infl ammation regulators 
in donor tissue. The endothelial protein C receptor (EPCR) not only enhances 
protein C activation to regulate coagulation, but generates anti-infl ammatory 
and cytoprotective signals to endothelial cells via the PAR-1 receptor. However, 
expression of EPCR is limited to large blood vessels. We recently generated 
C57BL/6 transgenic mice expressing human EPCR (hEPCR) from the H-2Kb 
promoter, which we have previously demonstrated drives transgene expression 
in both large and small blood vessels.
Aims: To examine the phenotype of the hEPCR transgenic mice with regard to 
coagulation and infl ammation.
Methods: (1) Tissue expression and distribution of hEPCR were determined 
by immunohistochemistry. (2) Anti-coagulant phenotype was assessed in two 
ways. (i) Tail bleeding time: the tails of anaesthetised hEPCR (n=4) and wild-
type (WT) (n=4) mice were transacted near the tip and immersed in warm 
saline, and time to cessation of bleeding was recorded. (ii) Resistance to 
intravascular thrombosis: anaesthetised hEPCR (n=8) and WT (n=9) mice were 
injected with 0.6μ;g collagen/g body weight via the jugular vein. Survival and 
lung histology for thromboembolism were assessed. (3) Anti-infl ammatory and 
cytoprotective phenotype was examined using an in vivo kidney IRI model. 
After removal of the right kidney, the left renal pedicle of hEPCR (n=9) and 
WT (n=20) mice was clamped for 18 minutes followed by 24 hrs of reperfusion. 
Body temperature was maintained at 37ºC during surgery. Renal function 
was determined by serum creatinine and urea levels, and tissue damage was 
assessed by histopathology.
Results: (1) hEPCR was widely expressed in small and large vessels in all solid 
organs in the transgenic mice. (2) (i) hEPCR mice had a prolonged bleeding 
time compared to WT mice (mean = 2.6 ± 1.1 min versus 10.8 ± 1.9 min, 
p<0.02). (ii) hEPCR mice were more resistant to collagen-induced intravascular 
thrombosis than WT mice (survival rate 75% versus 22%, p<0.05). and showed 
fewer pulmonary thromboemboli. (3) hEPCR mice were more resistant to 
renal IRI than WT mice, with superior renal function at 24 hrs (mean serum 
creatinine 39 ± 2.3 μmol/L versus 82.6 ± 10.0 μmol/L, p<0.01; mean urea 16 
± 1.1 mmol/L versus 31.5 ± 2.8 mmol/L, p<0.01). Histopathological analysis 
confi rmed less renal injury in the hEPCR mice compared to WT mice.
Conclusion: Overexpression and wide distribution of hEPCR protects against 
IRI and collagen-induced thrombosis, consistent with increased regulation of 
coagulation and infl ammation, and results in only a mild bleeding phenotype. 
Transgenic expression of hEPCR may therefore be a useful donor genetic 
modifi cation in xenotransplantation.
OVER-EXPRESSION OF CD39 IN TRANSGENIC MICE 77 
AFFECTS NKT CELL DEVELOPMENT AND FUNCTION – 
IMPLICATIONS FOR LIVER XENOTRANSPLANTATION
S. Pommey1, S. Robson2, A. d’Apice1, P. Cowan1, K. Dwyer1
1Immunology Research Centre, St Vincent’s Hospital, 2Beth Israel Deaconess 
Medical Center, Harvard Medical School
Introduction and Aim: The critical shortfall in human donor organs has led 
to renewed interest in xenotransplantation. Genetic modifi cation of the donor 
animal by deletion of Gal or expression of complement regulatory proteins 
has overcome hyperacute rejection. In an attempt to overcome acute vascular 
rejection, the next immunological hurdle, we have generated transgenic mice 
and pigs that express human CD39 (hCD39). CD39 is a major vascular and 
immune ectonucleotidase that, in concert with CD73, hydrolyses extracellular 
ATP (a ¡¥danger¡¦ signal) and ADP (a platelet agonist) to the anti-infl ammatory 
molecule adenosine. In mouse models, we have shown that the expression 
of hCD39 protects against renal ischaemia-reperfusion injury and affords 
a survival advantage in a cardiac transplant model. However, enhanced 
adenosine generation in the hCD39 transgenic (hCD39tg) animals may have a 
wider impact because of adenosine¡¦s well documented infl uence on thymocyte 
development and T cell proliferation. Transgene expression is under the 
control of the murine H-2Kb (MHC class I) promoter and TCR£\ enhancer, 
which together would be expected to drive high expression in the thymus and 
therefore potentially accentuate any effects on thymic maturation. We therefore 
investigated the effect of hCD39 over-expression on the development and 
function of leukocytes in hCD39tg mice. We paid particular attention to NKT 
cells, which (at least in rodents) form a large resident population within the liver 
and may be responsible for the spontaneous acceptance of liver allografts.
Methods: The development and maturation stages of thymocytes and 
peripheral lymphocytes in hCD39tg and wild type (WT) mice were analysed 
by fl ow cytometry. Lymphocyte function was assessed in vitro and in vivo 
using anti-CD3/anti-CD28 antibody stimulation and intra-peritoneal injection 
of £\-galactosylceramide respectively.
Results: Flow cytometric analysis revealed two-fold higher expression of 
hCD39 in the thymus of hCD39tg mice compared to the spleen and liver, 
and this was associated with a marked reduction in total thymocyte number 
compared to WT mice. Thymic maturation was arrested at the CD4+CD8+ 
double-positive stage resulting in a defi ciency of both CD4+ and CD8+ single-
positive thymocytes, and hCD39tg mice exhibited a peripheral CD4+ T cell 
lymphopenia. Residual lymphocytes displayed decreased proliferation in 
response to anti-CD3/anti-CD28 stimulation evident at day 4 of activation. 
Notably, hCD39 transgenic mice had a profound defi ciency in NKT cells, 
which was particularly marked in the liver (more than 30% reduction versus 
WT). Surviving NKT cells displayed impaired IFN-ƒ× and IL-4 production 
following in vivo injection of £\-galactosylceramide as demonstrated by 
intracellular cytokine staining and ELISA, respectively.
Conclusion: Our data strongly suggest that over-expression of hCD39 
affects T lymphocyte and, in particular, NKT cell development and function. 
Given the importance of resident NKT cells in rodent models of hepatic 
transplantation, we will explore the relevance of this defi ciency using a murine 
liver transplant model. This may have signifi cant implications for the future of 
liver xenotransplantation.
INHIBITION OF THE INSTANT BLOOD-MEDIATED 78 
INFLAMMATORY RESPONSE (IBMIR) BY EXPRESSION 
OF HUMAN CD39 ON PORCINE NEONATAL ISLET-CELL 
CLUSTERS (NICC).
D.M. Simond1, A.T. Patel1, S.L. Londrigan2, J. O’Hara1, K. Waite1, K. Moyle1, 
S. Ginn3, E. Favaloro1, M. Nottle4, A. Lew2, E. Salvaris5, N. Fisicaro5, 
S.C. Robson6, A. d’Apice5, P.J. Cowan5, P.J. O’Connell1 and W.J. Hawthorne1
1The Centre for Transplant & Renal Research, Westmead Millennium 
Institute, Westmead, 2The Walter and Eliza Hall Institute of Medical Research, 
Melbourne, 3Gene Therapy Research Unit, The Children’s Hospital, 
Westmead, 4University of Adelaide, Adelaide. 5St Vincent’s Health, Melbourne. 
6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.
Aims: IBMIR is elicited upon exposure of porcine neonatal islet-cell clusters 
(NICC) to human blood. The aim of this study was to investigate whether over 
expression of the anti-thrombotic ecto-nucleotidase CD39 can inhibit IBMIR.
Methods: NICC were transduced using an adenoviral vector expressing 
human CD39. Transduced or wild type NICC were placed in 7ml human 
blood in a heparinised loop system for 60 min. 1.25 or 2.5μg activated 
protein C (APC) was added to select loops to down-regulate coagulation and 
infl ammation. Clot weight, haematological parameters, coagulation factors & 
immunohistochemistry were assessed.
Results: Clot formation, platelet sequestration into clots and neutrophil 
consumption were signifi cantly reduced with the combination of CD39 
expression & 2.5μg APC when compared with CD39 or APC alone. Reduction 
in consumption of monocytes and eosinophils and an increase in basophils 
were seen in those loops containing CD39 NICCs with 2.5μg APC. CD39-
expressing cells were mainly localised around the periphery of the NICC. 
There was less neutrophil adhesion and infi ltration in NICC with CD39 plus 
APC when compared with wild type NICC with CD39 or APC alone.
Conclusions: Transduction of NICC with CD39 inhibited the thrombotic 
effects of xenogenic IBMIR and worked synergistically with a clinically 
relevant dose of APC.
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CYTOKINE-MEDIATED UPREGULATION OF 79 
TRANSGENE EXPRESSION IN TRANSGENIC PIG 
ENDOTHELIAL CELLS
E. Salvaris1, M. Nottle2, A. d’Apice1, P. Cowan1
1Immunology Research Centre, 2University of Adelaide
Background: We have previously generated transgenic (Tg) pigs expressing 
human CD55 and CD59 from the murine H-2Kb (MHC Class I) promoter and 
demonstrated signifi cant expression on solid organs and islets. This expression 
is suffi cient to prevent hyperacute rejection (HAR) of pig-to-baboon renal 
xenografts. Because MHC class I expression is upregulated by proinfl ammatory 
cytokines, we investigated here whether transgene expression in porcine aortic 
endothelial cells (PAEC) isolated from the Tg pigs could be upregulated by 
treatment with various human and pig cytokines.
Aim: To determine the effect of treatment of CD55-CD59 Tg PAEC with 
different cytokines (human TNFalpha, IFNgamma and IL-1beta; porcine 
IFNgamma) on transgene expression.
Methods: PAEC were isolated from CD55-CD59 Tg and wild type (WT) pigs 
and purifi ed to >95% purity using MACS beads and an anti-CD31 monoclonal 
antibody. Low passage primary cultures were treated separately with human 
TNFalpha (10ng/ml). human IFNgamma (5ng/ml). human IL-1 beta (5ng/
ml) or porcine IFNgamma (5n/ml) for 24 or 48 hours. Cells were analysed for 
CD55 expression by FACS.
Results: Untreated Tg and WT PAEC stained for human CD55 had a mean 
channel fl uorescence (MCF) of 120 ± 10 and 21 ± 2, respectively. Treatment 
of Tg cells with human TNFalpha or pig IFNgamma for 24 hrs increased 
CD55 expression 3.4-fold and 4.1-fold, respectively, with no further increase 
observed between 24 and 48 hrs. In contrast, treatment with human IFNgamma 
or IL-1 beta had minimal effect (<0.3-fold increase). Cytokine treatment of WT 
PAEC had no effect on MCF.
Conclusions: Our results suggest that the use of the cytokine-inducible H-2Kb 
promoter to express protective transgenes may offer considerable advantages in 
the infl ammatory environment of the xenograft. Indeed, effective suppression 
of HAR using our CD55-CD59 pigs as donors may be due in part to transgene 
upregulation by primate TNFalpha. Furthermore, it opens the possibility for 
cytokine treatment of cultured Tg pig islets to boost transgene expression prior 
to transplantation, although counterbalancing of these positive effects with 
induction of potentially detrimental molecules such as SLA must be taken into 
consideration. The lack of effect of human IFNgamma is intriguing, but not 
unexpected in the light of earlier reports of species-specifi city in the effi cacy 
of this cytokine.
REDUCED INSULIN REQUIREMENTS IN TRANSIENTLY 80 
IMMUNOSUPPRESSED NON-HUMAN PRIMATES 
TRANSPLANTED WITH MICROISLET P™ (ALGINATE 
ENCAPSULATED PORCINE ISLETS): A NON CLINICAL 
SAFETY STUDY
I. Stuiver, L. Ricks, W. Soo Hoo, M. Patel, N. LaFontaine, A. Basu,
MicroIslet, Inc.
Due to our consistent success in rodents, a non-clinical/non GLP study in non- 
human primates was initiated. Initial studies indicated that a transient course of 
immunosuppression was necessary to promote an increased duration of graft 
survival. Juvenile pig islets were encapsulated in a biodegradable alginate 
microcapsule and transplanted (Tx) at a dose of 30,000 ± 3000 IEQ/kg into 19 
transiently immunosuppressed Rhesus Macaques. The safety study consistst of 
4 arms: Two animals with a single Tx for 6 months; Six animals with two Tx 
for 6 months; Five animals with a single Tx for 12 months; Six animals with 3 
transplants for 12 months. Body weight, blood glucose, fasting blood glucose, 
glycosuria, insulin, porcine c-peptide, HbA1C, fructosamine and duration of 
graft function were monitored. IVGTTs monitoring the diabetic state were also 
performed.
Diabetes was induced with a single dose of streptozotocin into heathly Rhesus 
Macaques and confi rmed by a signifi cant rise in daily blood glucose levels, 
diabetogenic fructosamine and IVGTT glucose levels. The diabetic animals 
were maintained on 2-3 daily doses of insulin (Humulin® and/or Lantus®) 
for at least 1 month prior to transplantation, to confi rm stable diabetes. Three 
days prior to Tx, the animals were administered therapeutic levels of two 
immunosuppressive agents, Tacrolimus (FK506) and Sirolimus (rapamycin). 
The trough levels were monitored throughout the course of administration, for 
a duration of 6 weeks, after which each agent was gradually tapered off starting 
with Tacrolimus. Encapsulated islets were transplanted at a dose of 30,000 ± 
3000 IEQ/kg 2 days after initiation of immunosuppression and blood glucose 
and animal health monitored closely. No product related adverse reactions 
were observed throughout the study. Normoglycemia (80-150 mg/dl) was 
achieved for several days after Tx, after which 0.5-1.5 units of insulin was 
necessary to maintain blood glucose levels below 250 mg/dl for a duration of 
2-4 weeks. Though there was a progressive increase in insulin requirements, 
several animals maintained reduced insulin requirements for up to 6 months. 
In two arms of the study, the effect of retransplantation on acute rejection 
was monitored. The majority of animals responded similarly to the second 
and third Tx as to the fi rst Tx. At necrospy, gross pathological examination 
revealed no peritonitis and the peritoneal membrane was clear and glistening. 
No organs were affected by the transplants. However in some animals, small 
pin-point adhesions were observed on or near the bladder. Minimal evidence 
of residual beads remained in singly or multiply Tx’d primates at the time of 
their termination, which illustrates the biodegradable nature of the product. 
The dissolution of the encapsulated islet reduced the duration of effi cacy but 
did not effect the safety of the animal. The data derived from this study will 
be submitted to the FDA as part of an IND package for the initiated of Phase I 
safety studies in man.
CONCURRENT ORAL SESSION 10: 
PANCREAS TRANSPLANTATION
ABSENCE OF THROMBOSIS FOLLOWING PANCREAS 81 
TRANSPLANTATION: IT CAN BE POSSIBLE.
F. Vistoli1,2, G. Karam1, U. Boggi2, M. Giral1, C. Croce2, M. Del Chiaro2, 
C. Moretto2, F. Mosca2, J-P. Soulillou1 and D. Cantarovich1
1Institut de Transplantation et de Recherche en Transplantation – Centre 
Hospitalier Universitaire de Nantes, Nantes, France 2Regional Referral 
Center for Treatment of Pancreatic Diseases, Tuscany Region and University 
of Pisa, Pisa, Italy
Background: Although signifi cant improvements in surgical and medical 
procedures, vascular thrombosis (T) accounts for more than 70% of all technical 
failures after pancreas transplantation (PTx).
Methods: Between May 1996 and November 2007, 472 PTx (94.5% primary) 
were performed in 2 European Institutions, including 320 simultaneous 
pancreas-kidney transplants (SPK). 27 simultaneous cadaver pancreas living 
kidney transplants (SPLK). 88 PTx alone (PTA) and 36 pancreas after kidney 
transplants (PAK). Recipient’s age ranged from 20 to 61 yr (mean, 40). 
The majority of grafts (n= 453) were enteric diverted and more than half 
(n= 259) with portal insulin drainage. Prophylaxis with heparine, low-dose 
aspirin and/or sodium warfarin was systematically given. Graft function and 
vascular monitoring (daily plasma C peptide and color echo-doppler) were 
routinely performed. Multivariate Cox proportional hazard model was used 
to investigate the impact of 56 different variables related to donor, recipient, 
transplantation and immediate postoperative period as putative risk factors 
of thrombosis.
Results: One and 5-year overall pancreas survival was 85.5% and 75%, 
respectively. Patient survival was 95% at 1 year and 91% at 5 years. 
Graft failure due to complete thrombosis occurred in 5.7% of recipients 
(SPK+SPLK= 5.8%; PTA= 4.5%; PAK= 11%) after a mean of 5.8 days 
following PTx (SPK+SPLK= 6 d; PTA= 5.3 d; PAK= 5.5 d). According to 
univariate analysis [pValue (Hazard ratio) ], cold ischemia time (irrespective 
to perfusion solution used) was the major factor infl uencing pancreas 
thrombosis (0.0001 [2.6]). followed by steroid avoidance (0.02 [HR 2.5]) 
and more recent transplant period activity (0.04 [HR 2.4]). Donor body mass 
index (0.09). thymoglobulin induction (0.09). non-local harvesting (0.12) 
and waiting time (0.16) failed to reach a statistically signifi cance but were 
included in the multivariate analysis. No pancreas thrombosis occurred in the 
95 recipients (20.1%) with cold ischemia <10 hours. Cox regression analysis 
[pValue (Hazard ratio) ] confi rmed cold ischemia time as the powerfull 
variable risk factor for thrombosis [0.0001 (2.7) ], as well as steroid 
avoidance [0.02 (2.6) ] and the more recent period of centre activity [0.008 
(3.2) ]. Cox analysis also demonstrated that pancreas cold ischemia time 
reached statistical signifi cance after 11 hr, with a consistent and progressive 
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augmentation in the hazard ratio (from 2.5 to 6.2) following every single hr 
up to 19 hr.
Conclusion: Pancreas allograft thrombosis could be avoided if transplantation 
is performed below 10 hr of cold ischemia. After this time-point, the risk 
of thrombosis and graft failure increases progressively within time. In 
addition, the non use of steroids signifi cantly favour the risk of thrombosis. 
These 2 variables suggest that infl ammatory processes related to brain 
death and ischemia reperfusion syndrome can be main reasons of graft 
thrombosis. Logistic strategies to reduce cold ischemia and systematic use 
of antiinfl ammatory drugs in the donor and during the postoperative period 
could improve the outcome of pancreas transplantation.
PANCREAS TRANSPLANT ALONE (PTA) AS AN 82 
INDEPENDENT RISK FACTOR FOR THE DEVELOPMENT OF 
RENAL FAILURE
J. Scalea 1, J. Nogueira2, L. Campos1, A. Haririan2, R. Barth1, B. Philosophe1, 
S. Bartlett1 and M. Cooper1
1Dept of Surgery and 2Medicine, University of Maryland, Baltimore, MD, 
United States.
Background: Pancreas transplant alone (PTA) is a controversial procedure. 
Without clearly demonstrating improved patient survival, many recipients 
report improved quality of life. Nephrotoxic side-effects of maintenance 
immunosuppression may signifi cantly exacerbate diabetic renal injury post-
transplantation.
Methods: A retrospective review of patients receiving PTA over a 14 year 
period (1993-2007) at a single institution was completed. Patient demographics, 
surgical outcomes including infections and episodes of rejection, and patient/
graft survival were analyzed. Patients were classifi ed according to stage of 
chronic kidney disease (CKD) based upon calculated CrCl. A subset of patients 
in this cohort developed ESRD requiring kidney transplantation (KT). Student’s 
T-test was used to determine signifi cance.
Results: 132 patients with an average age of 40.1 were identifi ed. 7 patients 
were retransplated, 1 received a third pancreas. Mean graft survival was 3.26 
yrs (0-11.3y) with 23 pts (17%) lost to follow-up. One and fi ve year patient 
survival was 96.6% and 91.5% (mean – 7.15y). 9 patients presented with a 
CrCl < 60mL/min preoperatively; whereas 57 patients did so post-PTA. Mean 
pre-txp CrCl was 110.4 mL/min vs 72.3 post-txp (p<0.0001) with average 
follow-up of 3.68yrs. All but 13 (9.5%) patients showed a decrease in CrCl. 
Mean decrement was 33 mL/min. 13 patients developed ESRD and required 
KT. Average time following PTA for KT was 4.36 yrs. 21/53 patients early in 
this series received ATGAM or OKT3 induction and developed post-txp CKD. 
All 13 patients requiring KT were among this group (p<0.0001). 28/70 patients 
receiving Thymoglobulin as induction had post-txp CKD. All patients received 
a calcineurin inhibitor (CNI) for maintenance immunosuppression (IS). 83 
total pts had an episode of rejection (10 developed ESRD/KT). In pts with 
post-txp CKD (CrCl<60). graft survival was 3.2 yrs v. 2.4 yrs for those without 
(p=0.13). Patients requiring KT, however, pancreatic graft survival was 7.9 
yrs vs 2.9 yrs (p<0.0001). Mean CrCl was 96 mL/min for patients with early 
pancreatic graft loss at an average follow-up of 6.29yr. CIT for those with and 
without RF requiring KT were 20hrs and 19hrs respectively (p=NS). Deceased 
donor ages for those requiring KT was 19.4 vs. 24.3 yrs old (p=0.02). Pre-txp 
CrCl for those requiring KT was 88 mL/min compared with 112 (p=0.05).
Conclusions: Pancreas transplant confers an increased quality of life not 
easily quantifi able. Patients that undergo PTA are at increased risk for CKD/
KT. Comparing age, gender, race, donor age, and IS, PTA is an independent 
risk factor for the development of kidney disease. Recipients of pancreatic 
allografts with increased survival demonstrated lower CrCl. Patients developing 
renal failure occurred early in this series refl ecting improved patient and organ 
selection. Preoperative CrCl should best guide appropriate intervention for 
those with Type I DM.
PREDICTORS OF NEW ONSET DIABETES AFTER 83 
PANCREAS TRANSPLANT
N. Neidlinger, N. Singh, J. Odorico, H. Sollinger and J. Pirsch
University of Wisconsin Department of Surgery, Division of Transplantation
Introduction: The incidence, cause, and risk factors for new onset diabetes 
(NODM) after successful pancreas transplant (PTX) are undefi ned. Small 
series and case reports have suggested that immunosuppression and donor 
factors may play a role, and that serum markers and glucose tolerance assays 
may predict NODM. We sought to analyze risk factors for NODM after PTX.
Methods: We retrospectively reviewed 686 consecutive pancreas transplants 
performed over a 12 year period at our institution. We analyzed patients 
with combined kidney-pancreas and solitary pancreas transplants that had at 
least 6 months of pancreas graft function. All patients underwent systemic 
venous drainage and were maintained on steroid-based immunosuppression. 
We reviewed the association of early potential risk factors with the onset of 
NODM after PTX including donor weight, race, body mass index (BMI). 
and cytomegalovirus (CMV) status as well as recipient age, weight, sex, 
race, CMV status and BMI at time of PTX. Furthermore, we evaluated post-
operative weight gain, median fasting glucose levels at 1week and 1 month 
post-transplant, presence of rejection, primary vs. non-primary transplant, 
immunosuppressive agent, graft leak and need for re-operation as potential 
risk factors. We defi ned NODM as two consecutive hemoglobinA1C (HbA1C) 
values greater than 6.5 mg/dl.
Results: Of the 686 transplants, 58 (8.4%) developed NODM. For short 
term analysis, patients were stratifi ed by their HbA1C level at 6 months after 
transplant. The only risk factors that were associated with the risk of NODM 
at 6 months after PTX were high pre-PTX weight, hyperglycemia within 1 
week and 1 month after PTX, and donor CMV status (see table). With regard 
to CMV, donor +/recipient – patients were at highest risk among all groups. 
At long term follow up (8-12 years). signifi cant risk factors for NODM using 
Kaplan-Meier analysis were hyperglycemia at 1 week (p=0.007) and 1 month 
(p=0.003) after PTX, recipient CMV negative status (p=0.04). non-Caucasian 
recipient race (p=0.03) and rejection episode within the fi rst 6 months (p= 
0.00006). Induction immunosuppression and choice of calcineurin inhibitor 
did not affect NODM, nor did weight gain of more than 5 kilograms or 10% of 
total body weight within in the fi rst 6 months after PTX.
HgBA1C at 
6m post TX.
 RISK FACTORS
Mean Wt. at 
TX (kg) 
Median Fasting 
Glucose 1 week 
(mg/dl) 
Median Fasting 
Glucose 1month 
(mg/dl) 
Donor CMV 
positive
Donor CMV 
negative
< 6.0 72.0± 14.2 (n= 
474 ) 
 104.5 (n=285)  98.5 (n=365) 87% (n= 240) 94% (n= 231) 
 6.0-6.5  74.2± 9.2 (n= 
41) 
 118.2 (n=22)  107.0 (n =27)  4% (n= 25) 5% (n= 13) 
> 6.5 81.3± 19.9 
(n= 13) 
 144.2 (n=2)  131.0 (n=5) 9% (n= 11)  1% (n= 2) 
P-VALUE  0.02  0.003  0.0002  0.01
Conclusion: Obesity, early hyperglycemia, donor positive and recipient 
negative CMV status and non- Caucasian race are important risk factors for 
the NODM after PTX.
NEGATIVE IMPACT OF 84 DE NOVO ANTI-HLA 
ANTIBODIES AFTER SIMULTANEOUS PANCREAS-KIDNEY 
TRANSPLANTATION
D. Cantarovich1, F. Vistoli1, G. Karam1, M. Giral1, J. Dantal1, G. Blancho1, 
J.P. Soulillou1 and J.D. Bignon2
1Institut de Transplantation et de Recherche en Transplantation (ITERT). 
2Laboratoire d’Histocompatibilité, Etablissement Français de Sang (EFS). 
Centre Hospitalier et Universitaire de Nantes, France.
Background: A pancreatic graft, which includes exocrine and endocrine 
tissues, a large segment of duodenum and multiple lymphe nodes, is highly 
antigenic and immunogenic. In fact, the incidence of rejection is higher and 
graft survival is lower when compared to a kidney transplantation. Whether 
de novo post-transplant anti-HLA sensitization could be in part responsible of 
these observations is not known.
Aim: To prospectively test the development of de novo anti-HLA antibodies in 
recipients of SPK according to different immunosuppressive regimens and to 
evaluate the impact on rejection and graft survival.
Patients and Methods: From december 1999 to december 2007, 106 non-
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anti-HLA-immunized (i.e. PRA <5%) recipients (60% men; mean age 40±7 
yrs; range, 23-61) of primary SPK were evaluated. All patients received 
Thymoglobulin induction, calcineurin inhibitor or sirolimus and MMF. Anti-
HLA antibodies were routinely tested by Elisa and/or Luminex screening tests 
and confi rmed for class I and class II by Luminex.
Results: 39 (37%) patients were screened positive and 22 of them (21%) were 
confi rmed having de novo anti-HLA antibodies (64% donor specifi c). 40 (38%) 
patients were included in a CNI-based/steroid-free regimen, 56 (53%) received 
the same regimen plus steroids for 3 months and 10 (9.4%) received sirolimus, 
MMF and steroids without CNI. The incidence of de novo anti-HLA antibodies 
was, 17.5%, 15.4% and 60%, respectively (CNI vs sirolimus, p=0.001). The 
rejection rate in patients with anti-HLA antibodies was signifi cantly higher than 
in those without anti-HLA antibodies: 45% vs 8% (p<0.0001). Graft survival 
(censored for death and technical failures) was also negatively and signifi cantly 
impact by anti-HLA sensitization: for the pancreas 96% vs 68% (p=0.0003) 
and for the kidney 99% vs 80% (p=0.05) at 5 years.
Conclusion: de novo anti-HLA antibodies (mostly against the donor) were 
found in a relatively high proportion of patients (21%) following SPK. These 
patients experienced signifi cantly more rejections and had signifi cantly lower 
grafts survivals than non-sensitized patients. Recipients under sirolimus seem 
to develop more sensitization than recipients under calcineurin inhibitors and 
the absence of steroids did not infl uence sensitization.
PANCREAS ALLOGRAFT REJECTION BANFF 85 
WORKING GRADING SCHEMA
C, Drachenberg1
1Department of Pathology, University of Maryland, 2Banff Pancreas 
Consensus discussion Group
The schema consists of 6 main diagnostic categories, some of which may 
occur concurrently. The severity of the pathological process is graded based 
on the global assessment of the biopsy. In addition, the extent of fi brosis 
and parenchymal atrophy are also assessed to determine the “stage” of graft 
sclerosis.
1. NORMAL
2. INDETERMINATE Septal infl ammation that appears active but the overall features do not fulfi ll 
the criteria for mild cell mediated acute rejection.
3. CELL-MEDIATED REJECTION
Acute cell mediated rejection
– Grade I/Mild acute cell mediated rejection
Active septal infl ammation (activated, blastic lymphocytes, ± eosinophils) involving septal structures: 
venulitis (subendothelial accumulation of infl ammatory cells and endothelial damage in septal veins, 
ductitis (epithelial infl ammation and damage of ducts). Neural/perineural infl ammation.
and/or
Focal acinar infl ammation. No more than 2 infl ammatory foci^ per lobule with absent or minimal 
acinar cell injury.
– Grade II/Moderate acute cell mediated rejection
Multifocal (but not confl uent or diffuse) acinar infl ammation (≥ 3 foci^ per lobule) with spotty 
(individual) acinar cell injury and drop–out.
and/or
Minimal intimal arteritis
– Grade III/Severe acute cell mediated rejection
Diffuse, (widespread, extensive) acinar infl ammation with focal or diffuse multicellular/confl uent 
acinar cell necrosis.
and/or
Moderate or severe intimal arteritis
and/or
Transmural infl ammation – Necrotizing arteritis
Chronic active cell–mediated rejection. Chronic allograft arteriopathy (arterial intimal fi brosis with 
mononuclear cell infi ltration in fi brosis, formation of neo-intima) 
4. ANTIBODY MEDIATED REJECTION =C4d positivity** + confi rmed donor specifi c antibodies 
+ graft dysfunction
Hyperacute rejection Inmediate graft necrosis (≤ 1 hour) due to preformed anibodies in recipient’s 
blood
Accelerated antibody mediated rejection Severe, fulminant form of antibody mediated rejection 
with morphological similarities to hyperacute rejection but occurring later (within hours or days of 
transplantation).
Acute antibody mediated rejection Specify percentage of biopsy surface (focal or diffuse). 
Associated histological fi ndings: ranging from none to neutrophilic or mononuclear cell margination 
(capillaritis). thrombosis, vasculitis, parenchymal necrosis.
Chronic active antibody–mediated rejection. Features of categories 4 and 5.
5. CHRONIC ALLOGRAFT REJECTION/GRAFT SCLEROSIS
– Stage I (mild graft sclerosis) <30% of the core surface
– Stage II (moderate graft sclerosis) 30–60% of the core surface.
– Stage III (severe graft sclerosis) >60% of the core surface
6. OTHER HISTOLOGICAL DIAGNOSIS. Pathological changes not considered to be due acute 
and/or chronic rejection. e.g. CMV pancreatitis, PTLD, etc.
Footnotes: # Categories 2 to 6 may be diagnosed concurrently and should be listed in the diagnosis in 
the order of their clinicopathological signifi cance.
* See table 2 for morphological defi nition of lesions.
**If there are no donor specifi c antibodies or this data is unknown, identifi cation of histological features 
of antibody mediated rejection may be diagnosed as “suspicious for acute antibody mediated rejection”, 
particularly if there is graft dysfunction.
C4D POSITIVE INTERACINAR CAPILLARIES 86 
CORRELATES WITH DONOR-SEPCIFIC ANTIBODY 
MEDIATED REJECTION IN PANCREAS ALLOGRAFTS CORRE
J. Odorico1, J. Torrealba1, M. Samaniego1, J. Pascual2, Y. Becker1, J. Pirsch1, 
H. Sollinger1, 
1University of Wisconsin, Madison, Wisconsin, 2Hospital Ramon y Cajal, 
Madrid, Spain
The deposition of the complement split fragment C4d in peritubular capillaries 
of renal allografts is considered a reliable histologic marker of antibody-
mediated rejection. Its role, however, in pancreas transplant (PTx) is less 
characterized, with only rare case reports published in the literature. To further 
characterized the value of C4d in PTx we included in the present study 27 PTx 
biopsies from 18 patients (Pts) transplanted between 2004 and 2007.
Biopsies were immunolabeled with anti-C4d Abs and scored for allograft 
rejection according to the Maryland criteria. The presence of C4d was graded 
in interacinar capillaries (IAC). islets, interstitium and small and medium-size 
vessels. Sera obtained at the time or within 5 days of the biopsy were analyzed 
for the presence of anti-donor specifi c antibodies (DSA) by the fl ow-based 
fl uorescent-conjugated beads technique (LuminexR). 14 biopsies (51.8%) 
showed at least 5% C4d+ IAC (range 5-90%). Of those, 5 biopsies (18.5%) 
revealed diffuse labeling (>50% C4d+ IAC) and 9 (33.3%) showed focal 
staining (5-50% C4d+ IAC). C4d+ IAC (>5%) was signifi cantly associated 
with the presence of strong DSA (>500 MFI) for either Class I or Class II 
(p<0.004). Considered separately, both the diffuse and focal patterns of C4d 
staining of IAC were also signifi cantly associated with Class I and Class II DSA 
(p< 0.04 and 0.046, respectively). C4d staining of the media or endothelium of 
small and medium-size vessels was a common fi nding in all biopsies without 
any association with DSA. Similarly, staining of islets and parenchymal 
interstitium was not statistically associated with DSA. 9 Pts with C4d+ biopsies 
and clinical rejection were treated. Of those, 7 Pts received corticosteroids, 
with the addition of IVIg (3 Pts). Thymoglubulin (3 Pts). plasmapheresis and 
rituximab (1 Pt) and increased maintenance immunosuppression (4 Pts). By the 
time of this report, 3 Pts had failed allografts (back on insulin therapy and no 
detectable C-peptide). 1 Pt had marginal function (on insulin therapy but with 
detectable C-peptide) and 5 Pts had excellent allograft function and glucose 
control.
Our fi ndings support the role of C4d labeling of PTx biopsies in the diagnosis 
of antibody-mediated rejection and emphasize the staining of IAC as the most 
valuable histologic parameter for the diagnosis.
C4D+ ANTIBODY MEDIATED REJECTION AND 87 
CAMPATH INDUCTION ARE RISK FACTORS FOR GRAFT 
LOSS FOLLOWING PANCREAS TRANSPLANTATION
R. Munivenkatappa1, E. Schweitzer1, C. Drachenberg2, E. Mccann3, A. Dock4, 
D. Kukuruga2, L. Campos1, J. Papadimitriou2, S. Bartlett1, B. Philosophe1
1Surgery, Division of Transplantation, University of MD School of Medicine, 
2Pathology, University of MD School of Medicine, 3Pharmacy, University of 
MD School of Medicine, 4The Living Legacy Foundation of Maryland
C4d + antibody mediated rejection (AMR) has been demonstrated in kidney, 
cardiac and lung transplantation even in the presence of signifi cant T cell 
depletion. C4d + AMR following pancreatic transplantation has not been well 
characterized and is therefore analyzed
We retrospectively analyzed 257 recipients from Jan 2000 to the present with at 
least 3 months of follow up. The mean follow up was 34±29 months. We excluded 
grafts with early thrombosis due to technical failure. The impact of demographic 
variables, HLA, PRA, re-transplantation, and induction, immunosuppresion, 
was analyzed using a multivariate Cox proportional hazard test.
The mean age of the recipients was 47±9 yrs with 44% female and 91% 
Caucasian. The cohort was divided into three groups based on the induction 
agent received. There was no signifi cant difference between the groups for 
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the recipient parameters except for recipient race (table 1). By multivariate 
analysis, the relative risk (RR) for graft loss in patients who were induced 
with anti CD52 was 3.8 compared to those who received anti lymphocyte 
induction or anti CD25 (p=0.05). Patients with C4D+ AMR and acute cellular 
rejection (ACR) had a RR for graft loss of 5.9 and 2.2 respectively, (p=0.008 
and 0.02 respectively). The RR for graft loss in patients with 5 or more HLA 
antigen mismatches was 2.2 (p=0.03) and 2.1 for patients with a peak PRA 
>40% (p=0.04, table 2). There was no difference in 8 year graft survival 
between patients induced with Simulect or Anti-lymphocytes (65% and 58% 
respectively). Patients induced with Campath had a signifi cantly lower 1 
year graft survival compared to the others (62%, p=0.05, fi gure 1). Patients 
with ACR had a similar 8 year graft survival compared to patients without 
any biopsy proven rejection (52% and 62% respectively). Patients with C4D+ 
AMR had a signifi cantly lower 1 year graft survival compared to the others 
(27%, p=0.004; fi gure 2).
Recipients of pancreas transplants who experience no rejection have an 
excellent long-term graft survival. C4D+ AMR was present in nearly half the 
patients induced with Campath and both of these factors were associated with 
the highest risk of graft loss.
Recipient Characteristics Anti Lymphocyte Anti CD25 Anti CD52 p
N 192 27 20
Age (mean yrs) 47±8 49±10 39±8 0.6
Male/Female (%) 106 (55%) /86 (45%) 18 (67%) /9 (33%) 10 (50%) /10 (50%) 0.5
Caucasian/AA (%) 179 (93%) /13 (7%) 24 (89%) /3 (11%) 14 (70%) /6 (30%) 0.003
% PRA (mean) 16±29 22±34 5.4±10 0.8
HLA mismatch 4±1 4±1 4±0.9 0.7
Re-Txp/denovo (%) 19 (10%) /164 (90%) 5 (18)%/22 (82%) 1 (5%) /19 (95%) 0.3
Biopsy C4d+/C4d- 3 (13%) /20 (87%) 1 (14%) /6 (86%) 3 (43%) /4 (57%) 0.2
Steroids @ DC/No 
steroids 174 (97%) /6 (3%) 25 (100%) /0 (0%) 18 (95%) / (1 (5%) 0.6
Table 1. Recipient Variables and Induction Immunosuppression
Multivariate COX ANALYSIS   
RR (95% CI) p
C4d+ Antibody Mediated Rejection (AMR) 5.9 (1.6-21.6) 0.008
Acute Cellular Rejection (ACR) 2.1 (1.1-4) 0.02
5 or 6 HLA Mismatches 2.2 (1.1-4.4) 0.03
PRA >40% 2.1 (1-4.4) 0.04
Campath Induction 3.8 (1-14) 0.05
Table 2: Recipient variables and their risks of graft loss.
Figure 1: Pancreas graft survival as a function of induction.
 
Figure 2: Pancreas graft survival as a function of rejection.
ANTIBODY-MEDIATED REJECTION OF THE 88 
KIDNEY AFTER SIMULTANEOUS PANCREAS-KIDNEY 
TRANSPLANTATION (SPKT): ALEMTUZUMAB IS NOT 
SUPERIOR TO BASILIXIMAB AS INDUCTION TREATMENT
J. Pascual1, J.D. Pirsch1, J.R. Torrealba2, J.S. Odorico1, A. Djamali3, 
Y.T. Becker1, G. Leverson1, S.J. Knechtle1, H.W. Sollinger1, M.D. Samaniego3
1Department of Surgery, Division of Transplantation, 2Department of 
Pathology and Laboratory Medicine, 3Department of Medicine, University of 
Wisconsin School of Medicine and Public Health, Madison, WI, USA
The information on the best regimen to prevent antibody-mediated rejection 
(AMR) after simultaneous pancreas-kidney transplantation (SPKT) is 
particularly limited. A retrospective comparative cohort study was performed 
including 136 SPKT patients transplanted in 2002-2005 receiving maintenance 
immunosuppression with tacrolimus, MMF and prednisone. Two groups were 
compared: those who received induction with alemtuzumab (n=97) and those 
who were induced with basiliximab (n=39).
Donor and recipient characteristics were similar. Biopsy-proven kidney acute 
cellular rejection (ACR) was more frequent with basiliximab (2-yr 12.8% 
vs 3.1%, p=0.04). but the incidence of biopsy-proven kidney AMR was 
similar (2-yr 18% with basiliximab vs 13.8% with alemtuzumab, p=NS). No 
differences in prevalence were detected considering early AMR (<91st day) or 
late AMR (>90th day) separately. Multivariate analyses showed that the only 
detected signifi cant risk factor for AMR was female gender (adjusted Hazard 
Ratio [HR] 2.97, p=0.016). The biopsy-proven kidney rejection was associated 
with clinical pancreas rejection in 13 out of the 21 AMR cases (62%). without 
differences between both groups. Post-rejection kidney graft survival was 
similar in both groups (2-year basiliximab/alemtuzumab 94.7/91.2%). but 
death-censored kidney survival was lower with alemtuzumab (100/91.2%, 
p=0.05). The predominant cause of kidney loss was death-with-function with 
basiliximab (n=3) and acute or chronic active AMR with alemtuzumab (n=5). 
Pancreas survival was similar between both groups. More pancreas losses due 
to acute rejection occurred in alemtuzumab treated group than in basiliximab 
treated group (4 vs 1). Nearly all early episodes resolved with treatment and 
were not associated with worse graft survival. Conversely, late AMR episodes 
carried a worse prognosis, with decreased two-year kidney (61.5% vs 96.2%, 
p<0.0001) and pancreas graft survival (47.7 vs 92.3%, p<0.0001). Late AMR 
was associated with graft loss in multivariate Cox models (kidney loss HR 
3.34, p=0.05 and pancreas HR=3.22, p=0.049).
AMR was common in SPKT recipients. ACR is better prevented with 
alemtuzumab than with basiliximab, but no relevant difference is found 
between alemtuzumab and basiliximab in AMR. Late (as opposed to early) 
AMR episodes were associated with signifi cantly decreased kidney and 
pancreas survival rates despite treatment. Preventive and/or different treatment 
strategies are required to address late AMR in SPKT.
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IMPROVEMENT IN DIABETIC NEUROPATHY AFTER 89 
SUCCESSFUL PANCREAS TRANSPLANTATION DETECTED 
BY CORNEAL CONFOCAL MICROSCOPY- TWO YEAR DATA
S. Mehra1, M. Tavakoli2, A. Tavakoli1, N. Parrott1, R. Malik2, T. Augustine1
1Manchester Royal Infi rmary, 2Division of Cardiovascular and Endocrine 
Sciences, University of Manchester
Introduction: Successful pancreas transplantation (PTx) in Type 1 diabetes 
has been shown to prevent progression of retinopathy and nephropathy but to a 
lesser extent neuropathy. Data suggests that small nerve fi bres are the earliest to 
repair, however, their assessment has been limited due to the invasive nature of 
skin/nerve biopsy. Corneal confocal microscopy (CCM) is a rapid, non invasive 
in vivo clinical examination technique which quantifi es corneal small nerve 
fi bre damage and repair and which acts as surrogate marker for peripheral and 
autonomic neuropathy.
Method: 42 Type 1 diabetic patients undergoing combined pancreas and 
renal transplantation (PTx). 7 non diabetic patients with end stage renal 
failure (ESRF) (eGFR<10) undergoing renal transplantation (KTx) and 14 
non diabetic control subjects (C) underwent corneal confocal microscopy to 
quantify corneal nerve fi bre density (NFD). nerve fi bre length (NFL) and nerve 
branch density (NBD) within 1 month of transplantation and at 6 month and 
yearly interval over 2 years.
Results: Corneal NFD (no.mm2) (11.8 1.9 v 42.7, P =0.0001). NBD (no.mm2) 
(4.3 1.3 v 29.0 2.9, P=0.0001) and NFL (ìm) (2.2 0.8 v 8.8 0.6, P=0.001) were 
signifi cantly reduced in diabetic patients at transplantation compared to control 
subjects, respectively. 25 patients underwent repeat assessment 6 months after 
successful PTx. HbA1c (5.6±0.1 v 8.3±0.3, P<0.0001). NFD (18.2 1.3 v 10.8 
1.9, P= 0.001) and NFL (3.50 0.3 v 1.9 0.4, P=0.002) improved signifi cantly. 
In patients with ESRF NFD (27.5±4.6, P=0.05). NBD (19.8±2.8, P=0.05) and 
NFL (5.2±0.9, P=0.003) were also signifi cantly reduced but to a lesser extent 
than patients with diabetes. However, whilst KTx resulted in an improvement 
in eGFR (48.8 ±4.7, P<0.0001) there was no improvement in NFD (30.7±5.4, 
P=0.66). NBD (20.8±3.1, P=0.62) or NFL (5.2±0.9, P=0.97).
Conclusion: Despite severe neuropathy in Type 1 diabetic patients undergoing 
PTx, small fi bre repair can be detected within 6 months of PTx using CCM. 
ESRF alone can result in nerve damage but successful renal transplantation 
has no benefi t. Corneal confocal microscopy is a novel, non-invasive, in vivo 
clinical examination technique which may be used to diagnose neuropathy 
secondary to diabetes and chronic kidney disease and may also be employed to 
assess the benefi ts of therapeutic intervention.
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NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN 90 
(NGAL) AS A BIOMARKER TO PREDICT ACUTE TUBULAR 
NECROSIS (ATN) IN RENAL TRANSPLANT ALLOGRAFTS.
A. Panigrahi1, J. Shidhiki1, A. Margoob1, D. Bhowmik2, S. Tiwari2, 
S. Guleria3, N. Mehra1
1Dept of Transplant Immunology,All India Instutute of Medical Sciences, 
2Dept of Nephrology, ,All India Instutute of Medical Sciences, 3Dept of 
Surgery, ,All India Instutute of Medical Sciences
Neutrophil gelatinase-associated lipocalin (NGAL) is being reported one of 
the most dramatically up-regulated genes in the kidney after ischemia, and was 
found to be a highly predictive biomarker of acute kidney injury in patients 
undergoing cardiac surgery. We therefore tested the hypothesis that serum 
NGAL represents a novel early biomarker to distinguish between rejections or 
acute tubular necrosis in patients undergone life related renal transplantation. 
Post transplant serum samples collected from 175 recipients of living donor 
kidneys with in the 1st week of renal transplantation and 30 health controls 
were tested retrospectively for the detection of NGAL. The detection of 
NGAL has been done by ELSA Kit using manufactures instruction.12% of 
patients who had experienced with acute tubular necrosis in the fi rst week of 
post transplant showed a signifi cant rise in NGAL (501.25±192) as compared 
to the health controls (88.75±53) and also patients having well functioning 
grafts (190±91.65 ).However we did not fi nd any signifi cant change in the 
level of NGAL among those patients having early acute (90±8.6) or chronic 
rejections (154.5±46.6). when compared to the well functioning grafts. Other 
way patients at their pre transplant levels showed a remarkable change in 
their NGAL levels (1180±503.6). when it was been compared to their post 
transplant serums (195±85.9). Additionally we also found a signifi cant 
positive correlation of serum creatinine with the rise of NGAL among the post 
transplant patients. Therefore measurement of NGAL in post transplant period 
could be a predictive biomarker for the assessment of graft function, especially 
to distinguish between rejection and ATN.
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ASSOCIATION OF PRETRANSPLANT SOLUBLE 91 
GLYCOPROTEIN 130 (SGP130) PLASMA LEVELS WITH EARLY 
POSTTRANSPLANT ACUTE TUBULAR NECROSIS (ATN) IN 
RENAL TRANSPLANT RECIPIENTS.
M. Sadeghi1, D. Volker1, I. Lahou1, C. Naujokat1, R. Weimer2, R. Fabrice2, 
J. Schmidt3, A. Mehrabi3, M. Zeier4, G. Opelz1
1Institute of Immunology, Department of Transplantation Immunology, 
University of Heidelberg, Germany, 2Department of Internal Medicine, 
University of Giessen, Germany, 3Department of Visceral Surgery, University 
of Heidelberg, Germany, 4Department of Nephrology, University of 
Heidelberg, Germany
Objective: Kidney biopsy is the gold standard for diagnosing acute rejection 
(AR) and acute tubular necrosis (ATN) in the kidney transplant recipients. 
It is of great interest to fi nd non-invasive diagnostic tools for identifi cation 
of patients at risk of ATN or rejection. Previously, we reported that high 
pretransplant sIL-6R plasma levels are associated with posttransplant ATN. In 
this study we examined associations of pretransplant plasma levels of another 
member of the IL-6 subfamily with posttransplant renal outcome.
Patients and Methods: Between March 2000 and November 2007, pretransplant 
sIL-1RA, IL-2, sIL-2R, IL-4, IL-6, sIL-6R, sgp130, IL-10, TNF-α, and IFN-γ 
plasma levels were studied in 138 renal transplant recipients. Seventy-fi ve 
patients had immediate graft function (IGF) posttransplant. Biopsy-proven 
AR occurred in 24 patients during 12.9±9.7 posttransplant days. ATN was 
diagnosed in 39 patients within 13.1±10.6 posttransplant days by biopsy.
Results: Pretransplant, serum Cr. (p=0.009) and proinfl ammtory sIL-6R 
plasma levels were higher (p=0.006) in patients with posttransplant ATN 
than in patients with AR. Conversely, pretransplant anti-infl ammatory sgp130 
plasma levels were lower in patients with ATN than in patients with AR and/or 
IGF (p=0.003 and 0.002 respectively).
Conclusion: Patients at risk of ATN showed a preactivated immune system 
immediately pretransplant, with high proinfl ammtory sIL-6R and low anti-
infl ammatory sgp130, suggesting a strong contribution of the IL-6 cytokine 
family to the development of ATN. It might be useful to measure sIL-6R and 
sgp130 plasma levels pretransplant to identify patients that have an increased 
risk of developing ATN posttransplant.
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THE INVOLVEMENT OF ACTIVATED T CELLS AND 92 
CYTOKINES PRODUCTIONS CORRELATES WITH CLINICAL 
OUTCOMES IN CHRONIC RENAL ALLOGRAFT REJECTION
I. Humar1, Z. Puretic1, N. Goreta1, Z. Mihaljevic2, M. Puc1, J. Sertic1
1University Hospital Zagreb, Croatia, 2Vet Inst Zagreb, Croatia
The induction and maintenance of immune tolerance to transplanted tissues 
constitute an active process involving multiple mechanisms that work 
cooperatively to prevent graft rejection. We hypothesize that vascularized 
transplants have the potential to activate naive T cells in the absence of 
secondary lymphoid organs, when no other alloactivation pathways are present. 
The priming and effector pathway could be operative for the lifetime of the 
allograft and thus contribute to the development of chronic rejection (CR). 
Antibodies are produced by cells, and in this sense all rejections are cellular. 
The difference is: (a) are grafts destroyed by the action of antibodies or (b) by 
direct cellular cytotoxicity, as occurs with cytotoxic T cells (CT).
Aim: In order to provide further insight into the immunologic basis of CR, 
a cross-sectional analysis of cellular and humoral immunity in human renal 
allograft recipients with or without deteriorating renal function was performed. 
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The prospective study of possible risk factors for CR is based on 6,7+- 3,7 
years (form 1-19 years).
Method: To assess whether peripheral T cells control immune responses in 
immunosuppressed renal transplant patients, we analyzed the suppressive 
capacities of these cells using limited dilution and serum level of cytokines 
(sCD30,TNF-á, IL-2 and IL-2R). pre and post- transplant in 116 renal 
transplant recipients. MHC-reactive alloantibodies were detected by standard 
CDC. Cox regression model was used to assess the signifi cance of PRA, Thp, 
cytotoxic T lymphocytes, serum concentration of sCD30, IL-2, IL-2R, TNF-á 
and glomerular fi ltration rate, (GFR) on graft survival. All P values are two-
sided and considered statistically signifi cant if less than 0.05. All calculations 
were performed by STATA 7.0
Results: Allogeneic stimulation of patient’s peripheral blood mononuclear cells 
was associated with T-cell proliferation. CTL frequencies of donor-reactive 
lymphocytes and the number of individuals who responded to donor antigens 
per group were statistically higher in CR patients versus non CR control (P< 
0.032). In CR group signifi cant difference is present between measurements 
r=1.163.66; P< 0.05, opposite to non CR recipients. Serum level of sCD30, 
IL-2, sIL-2R have no difference while mean level of TNF-á is signifi cantly 
correlated with chronic rejection (P=0,025) and GFR. Development of de novo 
antibodies in patients with functioning grafts presage subsequent failure with 
OR=3.92. Thus, there were signifi cantly more failures in those who developed 
antibodies (P=0,01).
Conclusions: T cells with alloreactivity against anti-donor-responsive T cells 
are readily detectable in renal allograft recipients during treatment with full 
dosage immunosuppression and long term function. Signifi cant difference 
of TNF-á and renal function are interrelated. Both immune reactivity and 
tolerance are the net result of immune responses with opposing, i.e. enhancing 
or suppressing properties. Immunological quiescence, like immune reactivity 
is thus not per se an inert situation, but an active state, in which checks and 
balances have resulted in responsiveness in recipients with chronic rejection. 
Patients with persistently detectable anti-donor immune reactivity, with 
deteriorating kidney function, may benefi t from alterations in therapy directed 
at controlling activated T cells or B cells, depending on the type of alloreactivity 
detected.
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ACUTE ANTIBODY-MEDIATED REJECTION (AMR) OF 93 
THE KIDNEY ALLOGRAFT: IS THERE ANY DIFFERENCE IN 
OUTCOMES IN FOCAL VS DIFFUSE C4D STAINING CASES?
J. Pascual1, J.R. Torrealba2, A. Djamali3, G. Leverson1, Y.T. Becker1, 
S.J. Knechtle1, H.W. Sollinger1, J.D. Pirsch1, M.D. Samaniego3
1Department of Surgery, Division of Transplantation, 2Department of 
Pathology and Laboratory Medicine, 3Department of Medicine, University of 
Wisconsin School of Medicine and Public Health, Madison, WI, USA
The signifi cance of focal deposition of C4d in peritubular capillaries (PTC) is 
not well known. Given that some reports have suggested absence of impact 
on survival, the usual approach to these cases is not aggressive treatment, 
as it is when the staining is diffuse. From 2002 to 2005, 829 isolated kidney 
transplantations in adults were performed at our institution. Alemtuzumab 
induction was used in 613 of them, 602 without primary non-function. In 
addition to MMF and steroids, immunosuppression was based on CsA (n=294). 
tacrolimus (n=187) or CNI-free (n=121). Our main interest was to analyze 
the signifi cance of mildly stained C4d positive forms of AMR, so we defi ned 
“Focal” staining as less than 25% of PTC stained, and diffuse more than 
25%. During 2.5 years of mean follow-up, biopsy proven C4d-positive AMR 
was diagnosed in 128 patients (21.2%). 58 early (before day 90th, E-AMR) 
and 70 late (after day 90th, L-AMR) cases. Among the 58 E-AMR cases, 49 
were diffuse and 9 were focal, whereas among the 70 L-AMR cases, 54 were 
diffuse and 16 were focal. C4d diffusely positive E-AMR cases were treated 
with plasmapheresis, IVIg and rituximab, and C4d diffusely positive L-AMR 
cases with IVIg and rituximab. Usually, focal (<25% PTCs) cases remained 
untreated.
Two-year post-AMR graft survival was: E-AMR Focal 33% vs E-AMR 
Diffuse 50%; L-AMR Focal 55% vs L-AMR Diffuse 60%; the number of focal 
cases was low, and the numerically evident differences were not statistically 
signifi cant (log-rank p=NS).
However, post-AMR graft survival censored for death with function was 
signifi cantly lower in E-AMR Focal vs Diffuse (41% vs 67%, p=0.04).
Focally positive C4d AMR if remain untreated carry a worse prognosis than 
previously thought, and graft survival is signifi cantly affected. Probably, any 
C4d deposition in the allograft, in the context of graft function deterioration, 
should be aggressively treated as a conventional AMR episode.
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EFFECTIVE REDUCTION OF IMMUNODOMINANT DE 94 
NOVO DONOR SPECIFIC ANTI-HLA ANTIBODY LEVELS 
DECREASES RENAL ALLOGRAFT LOSS.
M. Everly1, J. Everly1, P. Brailey1, B. Susskind1, L. Arend1, A. Govil1, 
S. Young1, R.R. Alloway1, A. Tevar1, E.S. Woodle1
1University of Cincinnati, Cincinnati, Ohio, USA
Background: Traditionally, acute rejection (AR) reversal has been defi ned 
by histology and function (serum creatinine). Despite successful AR reversal 
(by serum creatinine and histology). many patients have sustained unaffected 
humoral alloresponses due to persistently elevated DSA levels. The purpose 
of this study was to determine whether reduction in DSA levels during AR 
treatment infl uences graft survival.
Methods: Renal allograft pts with AR between 1/1/2003 and 10/1/2007 and 
DSA measurements [Luminex platform with Labscreen single antigen beads] at 
AR and 14 days post were analyzed. DSA levels were quantifi ed by converting 
fl uorescence intensity to molecules of equivalent soluble fl uorescence (MESF). 
In all pts, DSA were absent pre-transplant. Immunodominant DSA (iDSA) was 
defi ned as DSA with highest MESF. AR was defi ned by biopsy (bx) /Banff 
criteria. Rejection reversal was defi ned as histologic resolution or a serum 
creatinine (SCr) decrease to within 115% of baseline. Survival analysis was 
performed using STATA/SE v9.2.
Results: Of 90 pt with AR, 16 had serial DSA evaluations and were analyzed 
(Table1). Ten patients had a <50% reduction and 6 patients had a >50% 
reduction in de novo iDSA titer at 14 days post-AR diagnosis. Median follow-
up was 21.417.1 mos. Pts with <50% reduction in iDSA had reduced graft 
survival by Kaplan Meier (p=0.039, Log-rank) (Figure 1).
Table 1: Patient Demographics Stratifi ed by iDSA Reduction
 iDSA 
Reduction>50%
iDSA 
Reduction<50%
p-value
AMR, pts (%) 2 (33) 7 (70) NS
Peritubular capillary C4d, pts (%) 4 (67) 9 (90) NS
Class I DSA, pts (%) 4 (67) 3 (30) NS
Class II DSA, pts (%) 2 (33) 7 (70) NS
Mean iDSA level at biopsy 620,195 437,472 324, 857 232,990 NS
Rejection Reversal, pts (%) 5 (83) 9 (90) NS
Recurrent Rejection, pts (%) 1 (17) 1 (10) NS
2 year Graft Survival (Kaplan-Meier) 100% 63% 0.039
Figure 1. Death Censored Allograft Survival Stratifi ed by iDSA Reduction at 14 Days After Biopsy
Conclusions: This data indicates effective treatment to an iDSA reduction of 
greater than 50% within 14 days of initial biopsy has a positive impact on long 
term renal allograft survival.
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INTRARENAL CD20+ CELLS DO NOT PREDICT 95 
CLINICAL OUTCOME IN ACUTE RENAL ALLOGRAFT 
REJECTION.
I. ten Berge1, C.G. Scheepstra2, F.J. Bemelman1, A.T. Rowshani1, K. Van
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt 
Pathology, Academic Medical Centre, Amsterdam
Introduction and Aim: The role of intrarenal CD20+ B cell infi ltrates in 
renal allograft rejection has yet to be elucidated. Recent reports suggest a 
correlation between CD20+ B cell aggregates and poorer clinical outcome. 
This fi nding would enable the identifi cation of a group of patients that 
would benefi t from the administration of anti-CD20 antibodies (rituximab). 
However, these studies did not differentiate between scattered infi ltrates of 
B cells and clusters of B cells. Therefore, we retrospectively differentiated 
between CD20+ cells in aggregates and CD20+ cells distributed throughout 
the interstitium. The same was done for CD3+ cells. We related CD20 
counts, CD3 counts, Banff classifi cation parameters and positive staining 
of peritubular capillaries for C4d, a marker of humoral rejection, to clinical 
outcome.
Materials and Methods: From 50 patients with clinically suspect and 
histologically proven fi rst acute renal allograft rejection 54 biopsies were 
taken and immunostained (CD20, CD3, C4d). Immunosuppressive drug 
treatment consisted of cyclosporin or tacrolimus, mycophenolate mofetil 
and low dose prednisone. Rejection treatment consisted of pulse doses 
methylprednisolone. In each biopsy the total scores for CD20+ cells, CD3+ 
cells and the aggregates of CD20+ cells and CD3+ cells were expressed 
per High Power Field of vision (1 HPF = 0.024 mmƒU). The interstitial 
immunopositive cells were scored according to a system shown in table 1. 
Immunostaining for C4d in the peritubular capillaries was scored as follows: 
No positive staining = 0; 0-25% positivity = 1; 25-75% positivity = 2; >75% 
positivity = 3.
Response to therapy was defi ned as decrease in serum creatinine level to 
maximally 125% of the lowest value prior to the clinically diagnosed episode 
of allograft rejection. Statistical analysis was performed with SPSS-software, 
using the Mann-Whitney rank-sum test for differences between unpaired 
groups of variables and Spearman rank correlation test for correlations.
Results: A signifi cant correlation was observed between interstitial 
infi ltrates of CD20+ cells and CD3+ cells (Spearman¡¦s correlation 
coeffi cient r = 0.720, p < 0.001). suggesting that B- and T cell infi ltrates 
occur in a concurrent fashion in rejection. Surprisingly, no correlation was 
found between intrarenal B cell infi ltrates and C4d-positivity, a hallmark 
of humoral rejection. In contrast to previous reports, no correlation was 
found between the number of CD20+ cells, either in aggregates or in the 
interstitium, and response to conventional therapy. Of the Banff parameters 
only the presence of endothelialitis was an indicator of poor response to 
therapy (Mann-Whitney rank-sum test, p-value 0.043). C4d-positivity in 
peritubular capillaries was an indicator of poor clinical outcome as well 
(Mann-Whitney test, p-value 0.010) 
Conclusion: In contrast to other studies, we did not fi nd a relationship between 
a high number of CD20+ cells in renal allografts upon rejection, either in 
aggregates or in the interstium, and poorer clinical outcome. Therefore, our 
results do not warrant anti-CD20-antibody therapy for allograft rejection in 
patients with high CD20+ cell counts in the biopsy.
Table 1. Histological scoring of interstitial CD20+ cells and CD3+ cells
score nr. cells
0 0-2
1 3-10
2 11-20
3 21-40
4 41-80
5 > 80
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SIX YEARS POSTTRANSPALNT FOLLOW UP OF RENAL 96 
RECIPIENTS WITH RESPECT TO HLA ANTOBODIES AS 
PREDICTING FACTOR OF CHRONIC REJECTION
I. Humar, Z. Puretic, L. Bubic, V. Kerhin-Brkljacic
University Hospital Zagreb
Aims: Chronic graft rejection that remains the main cause of graft loss after 
renal transplantation in subset is associated with anti-HLA antibodies. Evidence 
has accumulated in recent years that HLA antibodies may be responsible for the 
chronic failure of transplants. With the recent availability of improved antibody 
detection methods, we wish to demonstrate conclusively, in a larger series of 
patients, that the presence of HLA antibodies does indeed predict chronic 
graft failure. Since only about 5% of functioning patients can be expected to 
fail in one year, it is diffi cult in short time to obtain a clear answer to this 
question. If it is shown that patients with HLA antibodies fail at a higher rate, 
clinicians will be convinced to monitor their patients and to intervene with 
other immunosuppression to eliminate the antibodies. Also, among those who 
have no antibodies, immunosuppression might be reduced.
Methods: Prettransplant sera of 273 recipients were obtained and between 
1-37.2 years posttransplant. The presences of anti-HLA antibodies were 
determined with standard complement dependent cytotoxicity and ELISA. 
Statistical analysis Survival curves were estimated using the Kaplan-Meier 
method. Cox regression model was used to assess the signifi cance of PRA, 
serum concentration of creatinine and graft survival. All P values are two-sided 
and considered statistically signifi cant if less than 0.05. All calculations were 
performed by STATA 7.0 (Stata Statistical Software: Release 7.0. College 
Station, TX: StataCorp LP.) 
Results: 33.3.7% of recipients had HLA reactive alloantibodies after 
transplantation. The incidence of antibodies post transplantation was 17% 
among those who had antibodies prior to transplantation, and 73% among those 
who did not have pre-transplant antibodies. In subset of 180 renal patients, 
who did not have pre-transplant antibodies, 1.5% of patients had lost graft in 
this study period. In 93 recipients with incidence of anti–MHC alloantibodies 
17.5% failed, compared to 2.2% failure among 180 patients who did not develop 
antibodies statistically signifi cant. PRA, had statistically signifi cant effect after 
transplantation for graft lost due to alloantibodies (P =0, 01) and 3.92 relative 
risk higher in this selected group. With respect to type of immunosuppression 
used in our transplant center, we found a wide range of percentage antibodies 
formed. Four combination of immunosuppressive therapy (1.CsA+S+I; 
2.CsA+S+CC; 3.CsA+S; 4. S+I) had statistically signifi cant effect after 
adjustment. First and third combination of drugs, as compared with second, 
did increase the risk of graft failure (relative risk with fi rst and third is, 1.79; 
P<0.0158). 
Conclusion: These results suggest that eliminating some combination as 
a priority would have a less negative effect on graft survival and risk for 
chronic rejection. Post transplant detectable alloantibodies are risk factor for 
chronic allograft rejection, suggesting that humoral mechanisms are rather the 
cause than consequences of chronic rejection. On average, kidneys that have 
experienced an anti-MHC alloantibodies production manifest loss of function 
and reduced probability of long-term survival. Although this current data is 
based on single center study, those patients who developed de novo antibodies 
have a signifi cantly greater chance of failure.
POSTER BOARD NUMBER P1 – 294
FUNCTIONAL GRAFT AND PATIENT SURVIVAL 97 
OF RENAL TRANSPLANT RECIPIENTS WITH BIOPSY 
CONFIRMED ACUTE REJECTION (BCAR) AND USE OF ATG 
OR OKT3
A. Kainz1,2, R. Kramar3, B. Mayer4, R. Oberbauer1,2
1KH Elisabethinen, Linz, Austria, 2Medical University of Vienna, Austria, 3KH 
Wels, Austria, 4emergentec biodevelopment, Vienna, Austria
OKT3 and ATG are frequently used in renal transplant recipients for the 
treatment of BCAR. It has never been elucidated however whether the use of 
these agents is associated with graft and patient survival.
Therefore we studied the association of the drug use and transplant failure or 
death in patients with BCAR. We made use of 2310 transplants from 1990 to 
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2005 entered in the Austrian Dialysis and Transplant Registry. Of these subjects 
724 experienced a BCAR. Multivariable time to event analysis was used to 
identify the effect of polyclonal antibody use on graft and patient survival in 
this population.
OKT3 use was associated with a numerical higher hazard ratio (HR) for 
functional graft loss compared to ATG use when adjusted for PRA, HLA 
mismatch sum, number and year of transplantation (HR = 1.73, 95% CI 0.91 – 
3.30). Twenty fi ve percent of OKT3 users exhibited graft loss after 0.72 years 
whereas only 7.5% of ATG treated subjects experienced functional graft loss 
(Log rank p = 0.059, Wilcoxon p = 0.015).
The use of OKT3 was not associated with reduced patient survival when 
compared to ATG users adjusted for similar covariables as functional survival 
(HR = 1.29; 95% CI 0.657 – 2.545). The median patients survival was 9.07 
years in the OKT3 group and 10.38 years in the ATG group (Log rank p = 
0.306).
These data suggest that ATG use in renal transplant recipients with BCAR 
is associated with prolonged functional graft survival. Causal inference can 
however not be drawn from this associational study.
POSTER BOARD NUMBER P1 – 295
PROLONGED COLD PRESERVATION AND INTERTITIAL 98 
FIBROSIS/TUBULAR ATROPHY IN NON HUMAN PRIMATE 
KIDNEY GRAFTS
E. Preussing1, M. Bigaud1, A. Maxime2, N. Volker3, W. Grazyna1
1Novartis Institute for Biomedical Research – Basel, 2Hopital de Hautepierre 
– Chirurgie Générale & Transplantation, 3University of North Carolina, 
Laboratory of Nephrology
Prolonged cold preservation prior to transplantation (Tx) is recognized as a 
major risk factor for the development of interstitial fi brosis/tubular atrophy 
(IF/TA). the main causes of late kidney allograft dysfunction and loss. Hence, 
prolonged cold ischemia is included in the protocol of most of “chronic 
rejection” (CR) models described, without clearly understanding the impact 
of cold ischemia on IF/TA in the absence of allostimulus. In the context of 
our attempts to study CR in NHP kidney allografts (Wieczorek et al., 2006). 
we attempted to clarify this point by monitoring the appearance of IF/TA in 
kidney autologous grafts submitted to prolonged cold preservation prior to re-
implantation.
Methods: Five cynomolgus monkeys underwent autologous kidney Tx. The 
grafts were preserved in cold University of Wisconsin solution for 24 (n=3) 
or 40 hrs (n=2) prior to implantation back into the donors. Contralateral 
nephrectomies were performed, so the autologous grafts were life supporting. 
Post-Tx care lasted six months and included monitoring of kidney function 
using urine production and serum creatinine (Screa). Histological changes in 
the kidneys were also evaluated using protocol biopsies (at week 1, 2, 4, 8, 12, 
16, 20 and 24) as well as at necropsy (week 26).
Results: Prior to surgery, all animals had normal renal function, with mean 
urine production of 100-300 ml/day and Screa levels of 80-110 μmol/l.
Upon re-implantation, the kidneys subjected to 24 hrs cold ischemia had a fast 
functional recovery as shown by urine outputs that, after an initial reduction of 
25-50%, went back to normal within 2 days. Meanwhile, Screa levels increased 
by 2-5 folds and returned gradually to normal within 2-4 weeks. Signs of focal 
or diffuse acute tubular necrosis (ATN) associated with minimal interstitial 
edema and mixed infl ammatory infi ltrates were observed in kidney biopsies 
up to week 4 and disappeared thereafter. Overall, normal kidney function and 
normal kidney histology were observed from week 8 until termination.
More severe tissue injury and delayed graft function were observed for the 
kidneys subjected to 40 hrs cold ischemia. Urine output dropped by 90-95% 
during the fi rst 2 days and returned to normal within a week post-Tx. Screa 
increased constantly from day 1 to 5 post-Tx (up to ~1500 μmol/l) before 
starting to slowly decline. About 2 months were required for Screa to lessen 
to ≤200 μmol/l and 6 months to return to 100-150 μmol/l. Mild diffuse ATN 
with interstitial edema, focal infl ammatory infi ltrates and IF were observed in 
biopsies during the fi rst 4 weeks. Signs of minimal IF persisted up to week 12. 
At necropsy, minimal to mild IF/TA was observed and scored as ci1 and ct1 
according to the Banff classifi cation.
Conclusions: In the absence of allostimulus, cold preservation limited to 24 hrs 
has only minimal impact on the functional recovery of NHP kidney grafts and 
does not trigger the development of IF/TA for up to 6 months. Nevertheless, 
delayed graft function and IF/TA development become signifi cant with cold 
preservation prolonged beyond 24 hrs. This should be taken into consideration 
when studying CR in kidney allografts.
POSTER BOARD NUMBER P1 – 296
IS DE NOVO MEMBRANOUS GLOMERULONEPHRITIS 99 
(MGN) A FORM OF CHRONIC HUMORAL REJECTION (CHR) 
? CORRELATION WITH C4D DEPOSITION AND DONOR 
SPECIFIC ANTIBODIES (DSA) 
A.B. Collins1,2, W. Wong1,2, S. Saidman1,2, N. Tolkoff-Rubin1,2, N. Goes1,2, 
D. Ko1,2, A.B.Cosimi1,2, R. Colvin1,2
1Massachuetts General Hospital, 2Harvard Medical School
De novo MGN is one of the more common de novo glomerular diseases arising 
in renal allografts, yet its pathogenesis is unknown. Studies in rats argue that 
non-MHC antigens in the glomerulus can serve as a target of alloantibodies 
that induce de novo MGN (Thoenes, Lab Invest 41: 321, 1979) and a recent 
publication associates the onset and loss of HLA-DSA with proteinuria due 
to de novo MGN (El Kossi, Clin Transpl 22: 124, 2008). We therefore sought 
evidence of features of CHR in the form of C4d in peritubular capillaries 
(PTC) in grafts with de novo and recurrent MGN and other types of de novo 
glomerular disease among cases over the last 10 years with suffi cient tissue 
in the MGH renal tissue bank and database. During this time CHR was 
diagnosed on 8.4% of 738 transplant biopsies. C4d was detected by triple layer 
immunofl uorescence in frozen tissue; HLA-DSA was detected by cellular and 
solid phase techniques.
The results show a strong association of PTC C4d in recipients with de novo 
MGN among 17 patients (20 biopsies).
N pts  N C4d+ PTC %C4d+
De novo MGN 17 7 41% (p=0.017 vs 
all de
De novo FSGS 14 0  0% novo 
combined) 
De novo IgA  3 0  0%
De novo HCV   4 2 50%
De novo misc GN   3 0  0%
Recurrent MGN  5 1 20%
Only de novo hepatitis C virus (HCV) GN had a similar level of association 
with C4d, an association previously noted. Recurrent MGN and HCV were not 
statistically different from de novo. Three de novo MGN patients were tested 
for HLA-DSA and were positive (3 class I, 1 also class II). One patient had 
three biopsies over 4 years all with de novo MGN, but C4d was present only in 
the last biopsy. CHR was diagnosed in 71% of those with C4d+. We conclude 
that C4d+ in PTC, the hallmark of CHR, is strongly associated with de novo 
MGN, but not other de novo GN except for that of HCV. The lack of a tight 
association argues that different antigens are the target of de novo MGN and 
CHR. The association may be due to a propensity to form alloantibodies of any 
type or promotion of an immune response to glomerular antigens secondary 
to injury mediated by HLA antibodies. In any case, this study supports a 
previously unrecognized relationship between chronic antibody mediated 
rejection and de novo MGN.
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EARLY MARKERS OF CHRONIC ALLOGRAFT 100 
NEPHROPATHY: POTENTIAL ROLE FOR ALPHA-SMA 
STAINING ?
F. Kleemann1, B.W. Beaumont2, M.J. Merrilees2, H.L. Pilmore1
1Department of Nephrology, Auckland City Hospital and 2Department of 
Anatomy with Radiology, University of Auckland, New Zealand
Aim:
Chronic Allograft Nephropathy (CAN) is the commonest cause of kidney graft 
failure.
Biomarkers to detect early changes of tubulointerstitial fi brosis are urgently 
needed. This study examined the potential role of the most commonly used 
epithelial mesenchymal transition (EMT) and fi broblast activation markers.
Methods:
A total of 81 serial renal transplant biopsies from 25 patients, including time 
0 (implantation biopsy). 3 months and 12 months post transplantation as well 
as diagnostic biopsies, were stained with monoclonal antibody to α-smooth 
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muscle actin (α-SMA). A subgroup of 10 patients (30 biopsies) was also stained 
for E-cadherin, β-catenin and vimentin.
Cortical tubulointerstitial staining was quantifi ed by point counting of 10 high 
power fi elds per biopsy. Data were analyzed using the two-sided t-test with 
signifi cance level p<0.05.
Results: All biopsies had been assessed by a histopathologist. 13 patients had a 
histological diagnosis of CAN at an average of 105.8 +/-42.1 days and 12 were 
classed as normal at an average of 230.5 +/-143.2 days post transplantation.
The CAN and non-CAN groups did not differ with respect to mean age 
(48.1+/-17.4 years vs 44.7+/-11.9 years, p=0.6). gender distribution, 
immunosuppressants used (cyclosporine or tacrolimus + mycophenolate or 
azathioprine + prednisone). and percentage of deceased donors (77% vs 50%, 
p=0.17). The 10 patient subgroup profi le was similar to the whole group.
Interstitial fi broblasts stained for α-SMA; tubular epithelial cells (TEC) did not 
stain. α-SMA staining was signifi cantly higher in the CAN group at 3 months 
and revealed peak levels signifi cantly earlier than in the non-CAN group.
Table 1: Allograft pathology and function and α-SMA staining results
CAN non-CAN t-test
Banff ci score at implantation 0.1 +/-0.3 0.0 +/-0.0 p=0.35
α-SMA staining at implantation 6.8 +/-3.0% 2.8 +/-2.8% p=0.004
α-SMA staining peak time 98.4 +/-66.7 days 199.1 +/-144.0 days p=0.041
α-SMA staining at peak time 26.6 +/-9.5% 8.1 +/-5.8% p<0.001
α-SMA staining doubling time 40.0 +/-48.4 days 136.1 +/-101.5 days p=0.009
α-SMA staining at 3 months 21.2 +/-5.7% 5.4 +/-2.2% p<0.001
Creatinine at 3 months 180.5 +/-37.8 mcmol/L 129.3 +/-36.2 mcmol/L p=0.003
Length of follow up 846.2 +/-647.6 days 747.3 +/-623.6 days p=0.7
Creatinine at end of follow up 212.2 +/-140.5 mcmol/L 128.2 +/-31.2 mcmol/L p=0.06
TEC of both groups stained for E-cadherin (30-40% of tubules) and vimentin 
(0-35%). but with no change in staining over time in either group. β-catenin staining 
at time 0 was variable and there were no differences at the other time points.
Conclusion: α-SMA staining increased signifi cantly earlier than the 
histopathological diagnosis of CAN (40.0 +/-48.4 days vs 105.8 +/-42.1 days, 
p=0.001). Interestingly, despite no difference in the chronic Banff score at 
implantation, expression of α-SMA was signifi cantly greater at time 0. There 
may be a role for routine α-SMA staining in the early prediction of interstitial 
fi brosis, despite the unclear role of EMT in the development of CAN.
IMMUNOSUPPRESSION 1: MINI-ORAL SESSION 2: 
MYCOPHENOLATES AND NOVEL AGENTS
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DOES MYCOPHENOLATE MOFETIL CONFER 101 
CLINICAL BENEFIT OVER AZATHIOPRINE IN RENAL 
TRANSPLANTATION? A SYSTEMATIC REVIEW AND META-
ANALYSIS.
S. Knight1,2, N. Russell1.3, L. Barcena1, P. Morris1
1Centre For Evidence In Transplantation, Royal College of Surgeons of 
England, 2Oxford Transplant Unit, Oxford, UK, 3Cambridge University 
Department of Surgery, Cambridge, UK.
Introduction: Mycophenolate Mofetil (MMF) has increasingly become the 
anti-metabolite of choice in immunosuppressive protocols since its introduction 
in the early 90’s, replacing azathioprine (AZA). Initial large multi-centre 
RCTs showed a clinical benefi t in reducing the incidence of acute rejections, 
but without signifi cantly improving graft survival at 1 year. More recently 
it has been questioned whether this benefi t is signifi cant when using newer 
formulations of Cyclosporine (Neoral) and Tacrolimus.
Methods: A detailed literature search was performed using the Transplant 
Library from 1995- June 2007. The library, produced by the Centre for 
Evidence in Transplantation, included all randomised controlled trials (RCTs) 
in organ transplantation from 1995 to the present day at the time the search 
was conducted (it now goes back to 1970). For trials before 1995 we searched 
Medline and Embase combining all search terms for MMF and AZA. All 
RCTs which directly compared the use of MMF to AZA from time of renal 
transplantation were included. All trials were assessed for quality using the 
Jadad scoring system. Outcome data were extracted independently by 2 
reviewers, and the results were analysed using the meta-analysis software 
Review Manager. All groups were analysed with a fi xed effects model and 
confi dence intervals (CI) were set at 95%.
Results: 20 studies were identifi ed which met the inclusion criteria; these 
included a total of 3218 transplant recipients. Study quality is poor, with 
a mean Jadad score of 1.4 and only 2 studies scoring ≥; 3. MMF is found 
to signifi cantly reduce the risk of acute rejection and importantly its action 
is independent of type or formula of Calcineurin Inhibitor (CNI) used (18 
studies, 3043 patients, RR 0.63, 0.56-0.71, p<0.00001). The risk of graft loss 
is also signifi cantly reduced in patients treated with MMF (14 studies, 2800 
patients, RR 0.76, 0.60-0.97, p< 0.03). There is no signifi cant difference in 
patient survival between the two groups, nor in renal transplant function as 
determined by serum creatinine. There is no signifi cant difference in rate of 
CMV infection, anaemia, leukopenia or rates of malignancy. There is however 
a signifi cant increase in GI side effects with MMF. Use of MMF results in a 
greater risk of vomiting (4 studies, 1487 patients, RR 1.27, 1.01-1.61, p<0.04) 
and a greater risk of diarrhoea (6 studies, 1903 patients, RR 1.56, 1.32-1.84, 
p<0.00001).
Conclusion: We have shown that MMF used with a CNI does indeed confer 
a clinical benefi t over AZA by reducing the risk of acute rejection and also 
in reducing graft loss. We have also shown that this benefi cial effect is 
independent of whether MMF is used in combination with Sandimmune, 
Neoral or Tacrolimus.
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A 12-MONTH, PROSPECTIVE, RANDOMIZED, SINGLE 102 
CENTER, OPEN LABEL PILOT STUDY TO EVALUATE THE 
SAFETY AND EFFICACY OF MYFORTIC® IN COMBINATION 
WITH TACROLIMUS AND THYMOGLOBULIN® IN EARLY 
CORTICOSTEROID WITHDRAWAL
N. Weimert1, R. Alloway1, A. Vinks1, A. Rike1, S. Young1, M. Cardi2, 
G. Mogilishetty1, E.S. Woodle1
1University of Cincinnati, 2The Christ Hospital
Background: Mycophenolic acid has been proven effective in the prevention 
of acute rejection in kidney transplant patients however, its narrow therapeutic 
window has limited the utility of universal dosing. The safety and effectiveness 
of enteric coated mycophenolic acid (EC-MPS, Myfortic®) has not been 
evaluated in kidney transplant recipients undergoing early corticosteroid 
withdrawal. The aim of this study was to evaluate the safety and effi cacy of 
Myfortic® in combination with tacrolimus and anti-thymocyte globulin in an 
early corticosteroid withdrawal (ECSWD) protocol. Secondary objective is to 
determine the pharmacokinetic-pharmacodynamic and genetic variables that 
would impact exposure to EC-MPS in a corticosteroid withdrawal protocol.
Methods: This prospective, randomized, single center open label pilot study 
was designed to investigate the safety and effi cacy of mycophenolic acid 
sodium given as a loading or standard dose in combination with tacrolimus 
under ESWD in patients undergoing kidney transplantation. In addition, a 
subset of patients was also enrolled in a concurrent pharmacokinetic study 
to evaluate the pharmacokinetic (MPA and MPAG trough and 12 hour 
AUC) and pharmacodynamic (IMPDH activity baseline and AUC) profi le of 
mycophenolic acid sodium.
Results: 45 patients were enrolled. Baseline patient and transplant 
demographics were comparable between patients with load or standard EC-
MPS dose. Patient and allograft outcomes were similar between groups 
as illustrated in table below. More patients in the no load group had acute 
rejection, however multivariate analyses revealed no risk factor associated with 
an increased of acute rejection. UGT enzyme profi les designed to determine 
the presence of differences in EC-MPS metabolism also revealed that in 
patients where data was available most were negative for UGT1A9-275/2152 
polymorphisms, with 90% (33/37) of patients possessing the wild-type SNP. 
Indicating no alteration in metabolism would be present. However, 20% 
(7/35) of patients did possess UGT2B7 variant which may change the amount 
of the acyl-glucoronide metabolite increasing their risk for gastrointestinal 
and bone marrow toxicity. The average MPA AUC at 40 days post-transplant 
was 46±12 mg*hr/dL in the no load group (n=11) and 54±15 mg*hr/dL in the 
load group (n=12). which was not signifi cant (p=0.18). One patient in each 
group had an MPA AUC < 30, the threshold value associated with effi cacy in 
the fi rst month post-transplant. At 3 months, 40% (4/10) patients had an MPA 
AUC < 30 mg*hr/dL versus 8% (1/12) in the load group, however this was 
not statistically signifi cant, p=0.14. No pharmacokinetic or pharmacodynamic 
marker was able to predict acute rejection or toxicity which maybe the result 
of inadequate power.
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Conclusion: Based on the overall rate of acute rejection and 12 month 
allograft function, EC-MPS appears to be effective in a tacrolimus based early 
corticosteroid withdrawal protocol. Genetic and pharmacodynamic markers 
associated with MPA exposure and clinical outcomes may need further analysis 
with a larger sample size to validate results found in this study.
No Load (n=23) Load (n=22) P-value
Graft Survival 100% (0) 91% (1) 0.46
Patient Survival 100% (0) 100% (0) 0.13
Acute Rejection ≥1A 17% (4) 5% (1) 0.35
BKN (viremia & viuria) 17% (4) 9% (2) 0.665
CMV 13% (3) 5% (1) 0.608
GI SAE 17% (4) 9% (2) 0.665
PTLD 4% (1) 0% (0) 1.000
Average Scr (mg/dL) 6 mo 1.4±0.4 1.3±0.2 0.32
Average Scr (mg/dL) 12 mo 1.4±0.3 1.3±0.3 0.27
**included BKN, viremia and viuria
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ACUTE REJECTION EARLY AFTER RENAL 103 
TRANSPLANTATION IS ASSOCIATED WITH ELEVATED PRE-
TRANSPLANT IMPDH2 EXPRESSION IN CD4+ CELLS
S. Bremer1,2, R. Mandla1,2, N.T. Vethe1,2, I. Rasmussen1,2, H. Rootwelt1, 
P-D. Line3, K. Midtvedt4, S. Bergan1,5
1Department of Medical Biochemistry, Rikshospitalet University Hospital, 
Oslo, 2Institute of Clinical Biochemistry, University of Oslo, 3Surgical 
Department, Section of Transplant Surgery, Rikshospitalet University 
Hospital, Oslo, 4Medical Department, Section of Nephrology, Rikshospitalet 
University Hospital, Oslo, 5School of Pharmacy, University of Oslo
Background and Objectives: Mycophenolic acid (MPA) mediates 
immunosuppressive effects by inhibiting inosine monophosphate 
dehydrogenase (IMPDH). Measurement of IMPDH activity has been suggested 
as a pharmacodynamic approach for individualization and improvement of 
MPA treatment. However, IMPDH enzyme activity, as well as gene expression, 
is infl uenced by factors like the current immune status and immunosuppressive 
therapy, displaying wide inter- and intra-individual variability.
The objective of this study was to examine the expressions of the two 
IMPDH isoforms, type 1 and 2, in blood cells from renal allograft recipients 
pre- and post-transplantation and following initiation of immunosuppressive 
therapy, including MPA. Possible associations between the IMPDH 1 and 2 
expression, acute rejection episodes, dialysis pre-transplant and the current 
immunosuppressive treatment were investigated.
Materials and Methods: Whole blood, CD4+ cell and reticulocyte samples 
were collected from 30 renal transplant patients pre- and post-transplantation. 
The expressions of IMPDH 1 and 2 were analyzed by real time RT-PCR and 
quantifi ed using a housekeeping gene index.
Results: During the follow-up (12–19 days post-transplant). 11 patients (37%) 
experienced acute rejection (median day 12, range 3–19 days). The patients 
with rejection demonstrated higher IMPDH2 expression in CD4+ cells pre-
transplant than non-rejecting patients (median expression 1.26 vs. 0.87 
respectively, P=0.017). There was a trend towards higher rejection rates in the 
population receiving dialysis pre-transplant (n=16) having 8 (50%) rejection 
episodes, while 3 (21%) of the patients without dialysis (n=14) experienced 
rejection.
Conclusions: Elevated IMPDH2 expression in CD4+ cells pre-transplant 
may be an indicator of increased immune activation, caused by e.g. pre-
sensitized lymphocytes, and thus explain the association to higher risk of 
acute rejection. Exposure to dialysis is associated with non-specifi c cellular 
activation, alloreactivity and increased risk of rejection early post-transplant. 
This supports the observed trend towards more frequent rejections among the 
patients receiving dialysis pre-transplant compared to non-dialysis patients.
Characterization of IMPDH 1 and 2 expression in transplant patients is 
important considering the action of MPA on IMPDH and the potential for 
pharmacodynamic monitoring of MPA by measuring IMPDH activity. Further 
studies are, however, needed to evaluate the clinical implications of different 
IMPDH expression levels.
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IMPDH ACTIVITY IS CORRELATED WITH THE 3757T>C 104 
POLYMORPHISM IN THE IMPDH TYPE 2 GENE IN MMF 
TREATED KIDNEY TRANSPLANT PATIENTS
T. van Gelder1, F. Sombogaard1, R. van Schaik1, R. Mathot1, K. Budde2, 
W. Weimar1, P. Glander2
1Erasmus Medical Center, 2Charité University, Berlin, Germany
Introduction: Mycophenolic acid (MPA). the active metabolite of MMF, 
reversibly inhibits inosine monophosphate dehydrogenase (IMPDH) to 
prevent graft rejection. It is thought that pre-transplantation, total IMPDH 
activity mostly consists of constitutively expressed IMPDH type 1, whereas 
post-transplantation IMPDH type 2 from activated lymphocytes has the major 
contribution. The considerable post-transplantation inter-individual variability 
in IMPDH activity may be caused by functional polymorphisms in the IMPDH2 
gene. The aim of this paper is to compare IMPDH activity with functional 
polymorphisms in the IMPDH2 gene.
Methods: A cohort of 100 patients was prospectively monitored for 
pharmacokinetics (MPA plasma levels) and pharmacodynamics (IMPDH 
activity) of MMF treatment. Patients received MMF, tacrolimus and steroids 
for immunosuppressive therapy. Blood samples were taken pre- and post-
transplantation (pre-morning dose, 0.5, 1, 2, 6 and 12h after MMF intake). The 
enzyme activity of IMPDH in PBMCs was measured using a validated HPLC 
method. IMPDH activity and MPA exposure was calculated as the area under 
the activity or concentration–time curve (AUECact and AUCMPA) using a 
linear trapezoidal rule. Genomic DNA from all patients was analysed for the 
IMPDH2 3757T>C polymorphism by a newly developed TaqMan 5’-nuclease 
assay.
Results: From 80 patients (age 19-76 years). a full AUCMPA and AUECact 
could be calculated on day 6 (range 3-11) post transplantation. In 12 patients 
the IMPDH2 3757C allele was found (10 heterozygous and 2 homozygous 
individuals). giving an allele frequency of 6.9%.
The presence of an IMPDH2 3757C allele correlated with a signifi cantly higher 
total IMPDH activity in post transplantation patients under MMF exposure 
(AUECact 420±320 vs. 265±160 h*ìmol/s/mol AMP; p=0.035). whereas 
the polymorphism was not correlated with pre-transplant IMPDH activity 
(54.4±44.2 vs. 53.3±37.2 h*ìmol/s/mol AMP; p=0.82). AUCMPA was not 
signifi cantly different between the two IMPDH genotype groups (42.0±18.0 
and 35.5±19.1 h*mg/L; p=0.18).
Conclusion: The 3757T>C polymorphism in the IMPDH2 gene is 
signifi cantly correlated with IMPDH activity, measured as AUECact after renal 
transplantation. Whether this genotype is also associated with increased risk of 
acute rejection will be subject of future studies.
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POPULATION PHARMACOKINETICS OF 105 
MYCOPHENOLIC ACID IN COMBINATION WITH FREE OR 
REDUCED DOSES OF CALCINEURIN INHIBITORS DURING 
THE FIRST WEEK IN RENAL TRANSPLANT: THE SYMPHONY 
STUDY
H. Colom1, I. Fernández De Trocóniz2, A. Caldés3, F. Oppenheimer4, 
J. Sánchez Plumed5, M.A. Gentil6, D. Kuypers7, M. Brunet8, H. Ekberg9, 
J.M. Grinyó3
1Pharmacokinetics And Biopharmacy Dept. Pharmacy Faculty. Universidad 
De Barcelona., 2Pharmacy And Pharmaceutical Technology Dept. School of 
Pharmacy, University of Navarra., 3Nephrolgy Dept. Hospital of Bellvitge., 
4Nephrology Dept. Hospital Clinic Barcelona, 5Nephrology Dept. Hospital 
Universitario La Fe., 6Nephrology Dept. Virgen Del Rocío University 
Hospital, 7Nephrology And Renal Transplantation Dept. University Hospitals 
Leuven, University of Leuven, 8Pharmacology Department (Cdb). Hospital 
Clinic Barcelona., 9Nephrology And Transplantation Dept. Lund University, 
University Hospital.
Background: The objective of Symphony clinical trial was to test the safety 
and effi cacy of immunosuppressive regimens based on low doses of xenobiotic 
drugs in combination with Daclizumab, mycophenolate mofetil (MMF) and 
corticosteroids. A pharmacokinetic substudy was carried out to investigate 
the effect of those immunosuppressive regimens on the pharmacokinetics of 
mycophenolate acid (MPA).
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Objective: To develop a population pharmacokinetic (PK) model for MPA 
that accurately describes the time profi le of plasma MPA concentrations after 
daily oral administration of mycophenolate mofetil (MMF) on day seven after 
kidney transplantation in the studied population.
Patients and Methods: 58 patients from 9 sites in Spain and Belgium received 
either standard-dose of Cyclosporine (CsA). MMF and corticosteroids (n=13). 
or daclizumab induction, MMF and corticosteroids plus low-dose CsA (n=14). 
low-dose Tacrolimus (Tac) (n=12) or low-dose Sirolimus (SRL) (n=19). 
Sampling was performed on day seven after transplantation, before and 
at 20, 40, 75 min, 2, 3, 6, 8,10 and 12 hours post-dose. Population analysis 
was performed using NONMEM VI. Covariates screened were gender, age, 
body weight, renal function (serum creatinin, creatinin clearance, BUN) 
and hepatic enzimes and bilirrubin, haemoglobin, haematocrit, albumin and 
inmunosupressive co-therapy (CsA, Trl or Srl).
Results: The PK of MPA was best described by a two compartment open 
model with fi rst order absorption and lag time. Although some of the individual 
concentration-time profi les showed the evidence of enterohepatic recirculation 
(given by a secondary peak between 6 and 12 hours) it could not be succesfully 
modeled in the present study. It suggested that this phenomenon did not 
infl uence the PK of MPA to a large extent in the studied population on day 
seven after renal transplantation. Inter-individual variability (IIV) was included 
in total plasma clearance [CL, (41%) ], and central distribution volume [VC, 
(161% ) ]. The inclusion of the exposure to CsA (C0hCsA,μg/ml) as a covariate 
in the model for the total plasma clearance, reduced the IIV of this parameter 
from 47% to 41%: CLMPA=20.5 x (1+2.17 x C0hCsA) L/h. According to 
this relationship, CLMPA would be smaller in patients receiving Tac or Srl 
than in those receiving CsA. CLMPA would increase with increasing CsA 
exposure (2.17 L/h increase in CLMPA with each 1 &#61549;g/mL increase 
in C0hCsA). The fi nal population estimates for the other PK parameters were: 
VC=23.3 L;VP, volume of distribution of peripheral compartment=684 L; 
CLD, intercompartmental clearance =33.8 L/h; KA, 1st order rate constant of 
absorption =0.80 h-1and Lag time=0.28 h.
Conclusion: The developed population PK model adequately describes 
the time profi les of MPA on day seven after kidney transplantation in the 
studied population. It incorporates the exposure to CsA to predict the total 
drug clearance. CLMPA increases with increasing CsA exposure, that may 
be explained by the inhibition of multidrug resistance-associated protein 2 
(MRP-2) by CsA. The CLMPA prediction by the model developed could help 
to optimize the MMF dosing in the de novo renal transplant patients to achieve 
the required exposure to avoid acute rejection episodes.
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FIXED AND WEIGHT BASED MYCOPHENOLATE 106 
DOSING IS NOT IDEAL FOR INDIAN TRANSPLANT 
RECIPIENTS
G.T. John1, V.M. Annapandian1, S.B. Mathew2, G. Basu1, G.H. Fleming2, 
S. Varughese1,
1Dept. of Nephrology, Christian Medical College, Vellore, 2Dept. of Clinical 
Pharmacology, Christian Medical College, Vellore
Background: Weight based dose of mycophenolate has been recommended for 
renal transplantation.
Aim: To determine the relationship between the weight adjusted mycophenolate 
(MPA) dose and drug exposure (AUC) among Indian renal transplant recipients 
at Christian Medical College, Vellore, India.
Patients and Methods: We studied steady state pharmacokinetics of MPA 
in 120 consecutive renal allograft recipients who underwent transplantation 
at our centre between Jan 2004 and Nov 2007, receiving MPA (mofetil-
MMF/sodium-MNa) along with cyclosporine/tacrolimus and corticosteroids 
as primary immunosuppression. After renal transplantation, the total drug 
exposure (MPA-AUC 0-12). was quantifi ed using HPLC, within one month, at 
3 months, 6 months and thereafter as required. Equivalent dose of MPA was 
calculated considering 22 mg of MNa ≡ 30 mg of MMF.
Results: Among recipients, 76.8% were males. Average recipient age was 
34.9±12.0 years. Deceased donors accounted for 6.7% of the allografts. 
Among live related donors 81.4% had ≥2 HLA class1 antigen matches with 
their recipients. 50% of patients received basiliximab and 3 (2.5%) received 
ATG as induction. Along with mycophenolate (MMF-46.7%, MNa-53.3%). 
70% of patients received Tacrolimus and the rest, Cyclosporine. Average MPA-
AUC’s of 45.4±17.7mg.h/L and 55.5±19.2mg.h/L were achieved with average 
doses of 35.6±9.1mg/kg/day and 29.0±8.6mg/kg/day of MPA within and after 
3 months respectively. Only 65% and 56% of patients achieved the target AUC 
of 30-60mg.h/L within and after 3 months respectively. The average doses 
of MPA among patients who had AUC <30, 30-60 and >60mg.h/L were not 
signifi cantly different (31.4±8.3, 32.3±8.7 and 32.9±6.3mg/kg/day respectively, 
p=0.921). The median (min-max) dose in above groups were also similar [1750 
(1500-2250). 1750 (1000-3500) and 2000 (1250-2500) mg/day respectively]. 
Among those who achieved the target AUC of 30-60mg.h/L, 20% required 
<25mg/kg/day, 43% required 25-35mg/kg/day, 26% required 35-45mg/kg/day 
and the rest 11% required >45mg/kg/day of MPA. If a fi xed dose of 2grams/
day were to be used, 16% of patients would achieve an AUC of <30mg.h/L, 
and 23% would overshoot to >60mg.h/L within 3 months of transplantation. 
With the same dose, after 3 months, 53% of patients would cross the upper 
limit AUC of >60mg.h/L. With a weight based dose of 30mg/kg/day, only 55% 
and 42.5% of patients would achieve the target AUC of 30-60mg.h/L, within 
and after 3 months respectively (10.8%, 39.2% would cross the therapeutic 
limit of 60mg.h/L).
With level (AUC) controlled mycophenolate dosing we observed biopsy 
proven acute rejection rate of 15.8% (10.8% early rejection within 1 month). 
graft loss-2.5%, and CAN at 1 year-1.7%, patient loss-1.7%, UTI-24.2%, CMV 
disease-9.2%, TB-1.7%, leucopenia-12.5% and diarrhea-4.2%. The average 
eGFR (abb. MDRD) was 72±22.5, 72.5±18.3 and 63.8±20.1ml/min/1.73sq.m. 
at 1,6 and 12 months respectively.
Conclusion: A fi xed or weight based dosing of mycophenolate is not ideal and 
fails to achieve target AUC in a signifi cant percentage of Indian renal allograft 
recipients. Level controlled mycophenolate dosing is recommended for renal 
transplantation in India.
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COST-EFFECTIVENESS ANALYSIS OF ADVERSE 107 
EVENTS IN LOW TOXICITY IMMUNOSUPPRESSIVE 
REGIMENS. PRELIMINARY RESULTS OF THE QUALITY OF 
LIFE SUBSTUDY WITHIN THE SYMPHONY STUDY.
F. Oppenheimer1, P. Rebollo2, J.M. Grinyo3, F. Ortega2, J. Sanchez-Plumed4, 
M. Gonzalez-Molina5, D. Hernandez6, F. Anaya7, H. Ekberg8
1Spanish HRQoL Symphony-substudy Group, Hospital Clinic i Provincial, 
Barcelona, Spain, 2Oviedo, 3Barcelona, 4Valencia, 5Málaga, 6Santa Cruz de 
Tenerife, 7Madrid, 8Malmoe, Sweeden
Introduction: The Symphony study compares 4 immunosuppressant regimens 
in renal transplant patients in terms of clinical outcomes, resource consumption 
and gained health related quality of life (HRQoL). Here we focus on highlighting 
the importance of avoiding adverse events (AE) in order to gain quality of life 
and to minimize the treatment costs in kidney transplant patients during the 
fi rst year of follow up.
Objective: To compare the cost and the HRQoL of patients with mild or severe 
AE during the fi rst year after kidney transplantation.
Subjects and Methods: In total, 156 renal transplant recipients at 14 Spanish 
centres were included in the Symphony study. Patients were randomized to 4 
immunosuppressive regimens, all in addition to MMF and steroids. Only six 
patients had not suffered an AE during the follow up. Cost per patient & year 
(CP) in patients with mild or sever AE was obtained by adding up the average 
costs of its most consumed resources (biochemical test –BT, hemogram -HM, 
nephrologist’s consultation -NpC, nurse´s consultation -NsC and hospital 
admittances to transplant unit -HATU). Health related quality of life was 
measured by the SF-36 Health Survey and translated into standardized utilities 
by the SF-6D. Independent samples test was used to evaluate the differences 
between groups in HRQoL during the fi rst year after transplantation. 
Furthermore, mean cost-effectiveness scores were calculated in both groups by 
dividing the respective total costs and gained utilities.
Results: an analysis was performed with 148 patients. No statistical signifi cant 
differences between the 4 immunosuppressant regimens in age, gender, 
opportunistic infections or AR were found. Mean utility score in patients with 
mild AE was higher than in patients with severe AE (0.812 & 0.763 respectively; 
p= 0.060). 1st year mean cost in patients with mild AE was 20,082 € instead of 
34,738.29 € (in patients with severe AE).
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1st YEAR COSTS/patient MILD AEMean (SD) - €
SEVERE AE
Mean (SD) - €
BT 173.15 (49.91) 216.90 (91.99) 
HM 161.13 (43.19) 185.50 (78.45) 
NpC 3,107.76 (1183.65) 4,401.11 (3383.12) 
NsC 219.67 (22.08) 324.28 (457.95) 
HATU 16,572.51 (12976.93) 29,281.48 (19637.18) 
TOTAL COST/patient 20,082. 51 (13,586.43) 34,738.29 (21,251.43) 
In addition, the respective mean cost-effectiveness ratios were 24,739.61 € 
(mild AE) and 45,526.51 € (severe AE).
Conclusions: cost effectiveness analysis highlighted the economic and 
HRQoL impact of severe AE during the fi rst year after kidney transplantation. 
This burden should be considered when comparing the effi ciency of different 
immunosuppressive regimens. Finally, sensibility analyses should be applied to 
resource consumption and costs to manage the uncertainty of these outcomes.
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RANDOMIZED TRIAL OF SODIUM MYCOPHENOLATE 108 
AND BASILIXIMAB IN COMBINATION WITH REDUCED 
OR STANDARD CYCLOSPORINE EXPOSURE IN OLD 
RECIPIENTS OF KIDNEY TRANSPLANTS FROM DECEASED 
DONORS
M. Salvadori, M.P Scolari, S. Stefoni, E. Bertoni, S. Sandrini, P. Rigotti, 
V. Cambi, G. Civati, L. Boschiero, G. Piredda
Renal Unit Careggi University Hospital
Introduction: Old recipients of kidney transplants (KTx) are at increased risk 
of cardiovascular diseases, infections and cancer. The current strategy of organ 
allocation favors the use of aged donor organs in old recipients (old for old). but 
this increases the risk of delayed graft function. In addition, old donor kidneys 
are highly immunogenic, increasing the risk of acute rejection (AR). Attempts 
to overcome these hurdles combining anti-CD25 antibodies, MMF and steroids 
in a calcineurin inhibitor (CNI) free regimen, failed because of high AR rate 
(>50%). with about 60% of patients reintroducing CNI.
Patients and Methods: In this controlled, randomized, multicenter, parallel 
group, open-label trial we investigated whether cyclosporin for microemulsion 
(CsA) at reduced initial exposure plus enteric-coated mycophenolate sodium 
(EC-MPS) (Group 1) might improve the 12-month renal function in old KTx 
recipients, in comparison with standard-CsA exposure plus EC-MPS (Group 
2). CsA exposure was measured according to CsA whole blood levels 2 hours 
after the morning dose (C2).
Transplant recipients aged >55 years were randomized to Group 1 (Month 1-2: 
900 ng/mL, then 800 ng/mL) or Group 2 (Month 1: 1500 ng/mL, tapered to 
1000 ng/mL by Month 6 and 800 ng/mL thereafter). Both groups received EC-
MPS (2160 mg/day for 5 days, then 1440 mg/day). basiliximab (20 mg on Day 
0 and 4) and short-term steroids (stopped by Day 8). After the enrolment of 
about 50 patients, an increased incidence of early biopsy proven AR (BPAR) 
was evident. Therefore the protocol was amended allowing for continued low-
dose steroids up to M12. To avoid overimmunosuppression, starting EC-MPS 
dose was reduced to 1440 mg/day.
Results: Overall, 117 patients (Group 1: N=49, Group 2: N=68). mean age 
59.2±5.2 and 60.4±5.1 years respectively, were enrolled. Mean donor ages 
were 62.0±6.8 and 63.6±7.4 years. The 12-month probability of BPAR was 
10.8% in Group 1 and 18.1% in Group 2 (p=NS). Mean creatinine clearance 
(Cockcroft and Gault). was better in Group 1 (50.6±13.7 Vs. 47.4±16.8 mL/
min). but not signifi cantly. The 12-month graft survival (uncensored for death) 
was 91.7% in Group 1 and 95.5% in Group 2 (p=NS). In Group 1, there were 4 
failures: 2 patients died (cardiac arrest; pulmonary embolia) and two others lost 
the graft (primary non function; renal infarction). In Group 2, 3 patients died 
(sepsis; myocardial infarction; stroke). Within the 53 patients in both groups 
who underwent early steroid withdrawal, 12 (22.6%) had a BPAR within 3 
months, all of them of grade I and easily reversible with steroid boluses. Only 
4 out of the 64 patients on low dose continuous steroids had a BPAR (6.2%). 
Anemia, hypertension, leucopenia, urinary tract infections and cytomegalovirus 
infections were the most frequent adverse events, with no signifi cant differences 
between the two groups.
Conclusions: The combination of EC-MPS, basiliximab and low dose steroids, 
either with low or standard dose CsA, is highly effective in preventing BPAR 
and well tolerated in old recipients of kidney grafts from old deceased donors. 
Early steroid withdrawal might increase the risk of mild, reversible BPAR.
POSTER BOARD NUMBER P1 – 306
MYCOPHENOLIC ACID PLASMA CONCENTRATIONS 109 
AND ACUTE REJECTION RATE IN HIGH RISK VERSUS 
LOW RISK RENAL TRANSPLANT PATIENTS RECEIVING 
MYCOPHENOLATE MOFETIL.
T. Van Gelder1, N. Gafner2, On behalf of all FDCC investigators
1Erasmus Medical Center, 2Roche Basel
Introduction: Mycophenolic acid (MPA) plasma concentrations have been 
found to be predictive of the risk of developing acute rejection after renal 
and cardiac transplantation. Guidelines for the implementation of therapeutic 
drug monitoring (TDM) for mycophenolate mofetil (MMF) have been 
published. In these guidelines it is recommended to perform TDM in selected 
patient populations. In order to better defi ne such subpopulations, a post-
hoc, exploratory analysis on the FDCC database was performed to study the 
relationship between MPA plasma concentrations and the incidence of acute 
rejection in high risk versus low risk renal transplant (rtx) patients.
Methods: In a randomized controlled trial (FDCC-study) rtx patients were 
treated with MMF, corticosteroids and either cyclosporine (CsA -n = 488) or 
tacrolimus (TRL -n = 413). Abbreviated MPA-AUCs (3 samples within the 
fi rst 2 hours after administration) were measured on day 3, day 10, week 4 and 
months 3, 6 and 12, to calculate MPA-AUC0-12h. Patients were followed for 
12 months. Patients were defi ned post hoc as “high risk” if they had one or 
more of the following characteristics: delayed graft function, second or third 
transplantation, panel reactive antibodies > 15%, 4 or more HLA-mismatches. 
All other patients were considered “low risk”.
Results: In the full study population of 901 patients, a MPA-AUC0-12 
below 30 mg*h/L on day 3 after transplantation was associated with a risk 
of developing acute rejection in the fi rst month of 35/308 (11.4%). compared 
to 33/517 (6.4%) in patients with MPA-AUC0-12 above 30 mg*h/L (p = 
0.018). A total of 491 patients (54%) were classifi ed as high risk, of whom 254 
were on CsA treatment and 237 on TRL. In high risk patients the difference 
in rejection incidence (14.6% vs 7.9%) was comparable to the whole study 
population, while in low risk patients there were similar rejection rates above 
and below30 mg*h/L (5.5% vs 4.4%). In the subgroup of high risk tacrolimus 
treated patients the difference in the incidence of acute rejection in the fi rst 
month between patients with MPA-AUC0-12 below or above 30 mg*h/L was 
most pronounced: 16/66 (24.2%) vs 18/171 (10.5%); p = 0.012.
Conclusion: In an analysis of all patients there was a signifi cant relationship 
between MPA AUC and the risk of developing acute rejection after renal 
transplantation. In a post hoc subset analysis of high risk and low risk, the risk 
of acute rejection is higherhigh risk patients had a higher risk of rejection and 
there was a signifi cant difference in the incidence of acute rejection between 
high risk patients with MPA-AUC0-12 above or below 30 mg*h/L. In contrast, 
a difference in risk of acute rejection in low risk patients with MPA-AUC0-12 
below or above 30 mg*h/L was not observed. This supports the recommendation 
to perform TDM for MMF in selected patient populations.
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THE EFFECT OF A NOVEL NUCLEAR FACTOR K 110 
(KAPPA) B ACTIVATION INHIBITOR ON THE RENAL 
INFLAMMATORY RESPONSES IN RENAL ISCHEMIA 
REPERFUSION IN RAT
H. Kono1, K. Nakagawa1, S. Morita1, T. Koshida1, K. Shinoda1, T. Shinojima1, 
A. Miyajima1, K. Umezawa2, M. Oya1
1Keio university, the department of urology, 2Keio university, the department 
of applied chemistry
Purpose: The purpose of the study was to investigate the effect of a novel nuclear 
factor ƒÈB (NFƒÈB) activation inhibitor dehydroxymethylepoxyquinomicin 
(DHMEQ). which is derived from epoxyquinomicin C, on the renal 
infl ammatory responses in renal ischemia reperfusion.
Materials and Methods: DHMEQ was intraperitoneally administered at 
8mg/kg to Lewis rats on a daily basis after the onset of ischemia reperfusion 
(DHMEQ post-treatment group). The second group of rats was injected once 
intraperitoneally with DHMEQ just before renal artery clamping (DHMEQ 
pre-treatment group). The third group of rats was not administered DHMEQ 
(control group). For the DHMEQ pre-treatment group and the control group, 
only saline was administered daily. Urine samples were collected daily from rats 
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placed in metabolic cages for 24 hours. The kidneys were harvested on either 
day 1 or 7 after renal artery clamping from each group of rats. Thereafter, renal 
sections were made and stained with either hematoxylin and eosin, Masson 
trichrome, PAS stain, or some immunohistochemichal agents. Then they were 
examined using light microscopy. The clamping time was thirty minutes.
Results: In the DHMEQ pre-treatment group, the urine volume for 24 hours 
from days 1 to 3 after ischemia reperfusion was signifi cantly larger than in 
the control group (p<0.05). In comparison with the control group, the serum 
creatinine level of the DHMEQ pre-treatment group decreased by 60% and 
BUN level decreased by 50% at day1. The kidneys of the DHMEQ pre-treatment 
group at day1 demonstrated less severe lesions in the tubulointerstitium, with 
a loss of the brush border, the detachment of epithelial cells from the basement 
membrane, and interstitial edema. P65 which is a subunit of NFƒÈB was 
mostly detected in renal tubular cytoplasm of the kidneys of the DHMEQ pre-
treatment group at day1. And signifi cantly higher levels of granulocytes were 
present in the kidneys of the control group at day1. TUNEL stain revealed 
higher levels of tubular cell apoptosis were detected in the kidneys of the 
control group at day 1.
The kidneys from the DHMEQ pre-treatment group and post-treatment 
group at day 7 demonstrated less interstitial fi brosis in comparison with the 
control group.
Conclusion: Treatment with DHMEQ before renal artery clamping may 
therefore be useful for ischemia reperfusion injury in the kidneys.
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MONITORING CELLULAR IMMUNITY AFTER KIDNEY 111 
TRANSPLANTATION: THE IMMUKNOW® ASSAY DOES NOT 
PROPERLY REFLECT CHANGES IN T CELL REACTIVITY
R. Olsson1, A.K. Lidehäll2, M. Engstrand1,2, J. Henriksson1, G. Tydén1, 
O. Korsgren2 and L. Wennberg1
Departments of 1Transplantation Surgery, Karolinska University Hospital, 
Huddinge, Stockholm and 2Clinical Immunology, Uppsala University, 
Uppsala, both in Sweden.
Background: To optimize kidney graft survival, and to minimize the risk 
for complications (such as acute rejection, infection and malignancy). 
there is an obvious need for methods to properly monitor the degree of 
immunosuppression. Recently, the ImmuKnow¦  assay was marketed as such 
a method. The ImmuKnow® assay measures PHA-induced ATP production 
of the recipient’s CD4+ T cells, and correlations between the ATP production 
and the relative risk of both acute rejection (high ATP production, ≥525 ng/
ml) and infections (low ATP production, ≤225 ng/ml) have been reported. 
Presently, we are including patients in a study comparing the results of the 
Immuknow¦  assay with changes in cellular immunity against cytomegalovirus 
(CMV). Approximately 80% of all adults are seropositive to CMV and it causes 
signifi cant morbidity in immunosuppressed organ transplant recipients.
Materials and Methods: Nine CMV seropositive kidney transplant recipients 
(4 deceased and 5 living donors) have so far been evaluated in this study. All 
patients received 500 mg of methylprednislone immediately prior to surgery and 
maintenance immunosuppression was composed of tacrolimus in combination 
with prednisolone and mycophenolate mofetil (n=4) or azathioprin (n=5). 
Recipient T cell reactivity was analyzed immediately before transplantation and 
at 1 week, 2 weeks and 1 month postoperatively using both the ImmuKnow® 
assay (Cylex Inc., Columbia, MD, USA) and a novel method developed at the 
Department of Clinical Immunology, Uppsala University Hospital, Sweden. 
In brief, recipient blood was stimulated with CMV-specifi c proteins (a lysate 
produced from CMV-infected fi broblasts and overlapping peptides spanning 
the entire pp65 and IE1 proteins, respectively) in vitro and the number of CD4+ 
or CD8+ T cells producing IFN γ was separately determined by fl uorescence-
activated cell sorting (FACS). For statistical analysis, paired comparisons were 
made using the Wilcoxon Matched-Pairs Signed-Ranks test.
Results: During the fi rst month after kidney transplantation, there were no 
signifi cant changes of the ImmuKnow® results. Moreover, both total peripheral 
CD4+ and CD8+ lymphocyte numbers were unchanged. However, one week 
post-transplantation the CMV-reactive CD4+ lymphocytes were signifi cantly 
reduced compared to pre-transplantation data [median 700 CD4+ cells/
ml (range 0-41 600 CD4+ cells/ml) vs. median 6 950 CD4+ cells/ml (range 
250-92 250 CD4+ cells/ml) ], whereas the number of CMV-reactive CD8+ 
cells remained unchanged.
Conclusions: During the fi rst month after kidney transplantation the 
ImmuKnow® results did not change. Considering the heavy immunosuppression 
given during this postoperative time period, the ImmuKnow® assay does not 
seem to properly refl ect early changes in immunosuppression. In contrast, 
T cell reactivity against CMV is markedly decreased suggesting that this 
analysis may be a better alternative for immunological monitoring after organ 
transplantation. In addition, assays for T cell reactivity against other dormant 
viruses (BK, Epstein-Barr) may further improve the sensitivity and specifi city 
of this method.
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DIFFERENT IMPACT OF MAINTENANCE 112 
IMMUNOSUPPRESSIVE REGIMENS ON THE IMMUNE 
RESPONSE OF RENAL TRANSPLANT RECIPIENTS
R. Weimer1, S. Deisz1, F. Renner1, H. Dietrich1, V. Daniel2, S. Kamali-Ernst3, 
W. Ernst4, 
W. Padberg5, G. Opelz2,
1Department of Internal Medicine, University of Giessen, 2Institute of 
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar, 
4Dialysis Center, Langenselbold, 5Department of Surgery, University of 
Giessen
The Symphony study showed superior 1-year kidney graft outcome on a Tacr/
MMF maintenance regimen. To analyze effects of different maintenance 
regimens on clinically relevant immune parameters of Th1/Th2, B cell and 
monocyte responses, we assessed CD4 helper activity, immunoglobulin-
secreting cell (ISC) formation, neopterin and intracellular cytokine production 
in a prospective randomized study of 84 renal transplant recipients (CsA/Aza, 
CsA/MMF, Tacr/Aza) at 2 years posttransplant.
Two-year patient and graft survival were 100% and 93%, respectively. 
Tacr-based immunosuppression was associated with lower neopterin 
levels (corrected for graft function; p=0.01). increased IL-2 (p<0.0001, 
CD4 cells; p=0.007, CD8 cells) and CD4 cell IL-4 responses (p=0.008) 
compared to CsA. The impact on cytokine responses was confi rmed by 
multivariate logistic regression (p<0.0001, CD4 cell IL-2; p=0.01, CD8 
cell IL-2; p=0.046, CD4 cell IL-4). Patients on MMF versus Aza therapy 
showed suppressed CD4 helper activity (p=0.009). CD4 cell IL-4 (p=0.01) 
and IL-10 responses (p=0.001) together with lower ISC responses (p=0.04, 
SAC I; p=0.006, PWM) and a profound decline in IL-6R expression on B 
cells (p<0.0001). Logistic regression confi rmed suppressed CD4 cell IL-10 
responses (p=0.008) and B cell responses on MMF treatment (p=0.02, ISC 
formation; p<0.0001, B cell IL-6R). The highest T-cell responses of the 
B-cell factor IL-10 were observed on Tacr/Aza therapy (p=0.005, CD4 cells; 
p=0.02, CD8 cells) which coincided with early graft loss due to acute vascular 
rejection in this treatment group only (n=3). Potent immunosuppressive 
effects were found on Tacr/MMF, the only regimen being associated with 
downregulation of CD4 cell CD28 and CD8 cell IL-2R (CD25) expression 
(p=0.03 and p=0.02, respectively). Tacr treatment provided an independent 
factor predicting better 2-year graft function (creatinine clearance; p=0.01, 
logistic regression).
Our data suggest that a Tacr/MMF regimen was most effective in its impact 
on immunological parameters being associated with better graft outcome. 
Previously shown graft protective effects of Th2 responses (enhanced CD4 
cell IL-4, decreased CD4 helper activity and IL-10 responses) may be 
achieved by Tacr (IL-4) and MMF therapy (CD4 help and IL-10). Monocyte 
and B cell functions playing a role in chronic allograft nephropathy were 
suppressed by Tacrolimus (neopterin) and MMF (B cell IL-6R expression; 
ISC responses).
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Oral Abstracts Monday 11 August 2008
4 1
M
O
N
D
AY
MINI-ORAL SESSION 3: 
RENAL 2: DETERMINANTS OF LONG-TERM OUTCOMES
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NGAL (NEUTROPHIL GELATINASE-ASSOCIATED 113 
LIPOCALIN) IS A NEW AND SENSITIVE MARKER OF KIDNEY 
FUNCTION IN CHRONIC KIDNEY DISEASE PATIENTS AND 
RENAL ALLOGRAFT RECIPIENTS
J. Malyszko1, J. Malyszko1, H. Bachorzewska-Gajewska2, S. Dobrzycki2, 
E. Koc-Zorawska1, M. Mysliwiec1
1Medical University, Department of Nephrology and Transplantation, 
2Medical University, Department of Invasive Cardiology
Background/Aims: Very few biomarkers exist for monitoring chronic kidney 
disease. NGAL (neutrophil gelatinase-associated lipocalin). a member of 
lipocalin family, has been recently prove useful in the quantitation of CKD. 
Because of its small molecular size (25kDa) and resistance to degradation, 
NGAL is readily excreted and detected in urine The aim of the study was to 
assess whether NGAL could represent a novel, sensitive marker of kidney 
function in adult patients with CKD and kidney transplant recipients. We also 
studied possible relations between serum NGAL, creatinine and estimated 
GFR in 92 non-diabetic patients with CKD stages 2-4, 80 non-diabetic 
kidney transplant recipients on triple therapy: calcineurin inhibitor/MMF or 
azathioprine, prednisone) and healthy volunteers (n=30, mean age 50 years).
Methods: NGAL was evaluated using commercially available ELISA from 
ANTIBODYSHOP (Gentofte, Denmark). We assessed kidney function 
according to the simplifi ed MDRD formula.
Results: Serum NGAL, creatinine was signifi cantly higher and eGFR was 
signifi cantly lower in kidney allograft recipients and patients with CKD over 
controls. NGAL were similar in the same stages of CKD in patients with CKD 
and kidney allograft recipients. NGAL rose gradually reaching the higher value 
in the stage 4 CKD. Serum NGAL was related, in univariate analysis, to serum 
creatinine, hemoglobin, hematocrit, leukocyte count, eGFR. Predictors of 
serum NGAL were creatinine, and eGFR in patients with CKD. In the healthy 
volunteers, serum NGAL correlated with age, serum creatinine, eGFR, and 
leukocyte count. Serum NGAL was related, in univariate analysis, to serum 
creatinine, urea, hemoglobin, hematocrit, white blood cell count, duration of 
hypertension, age, eGFR albumin. In multiple regression analysis, predictors 
of NGAL were eGFR, white blood cell count and albumin explaining 85% of 
NGAL concentration. When eGFR was substituted by creatinine the results 
were the same.
Conclusion: NGAL should be investigated as a potential early and sensitive 
marker of kidney impairment/injury, which might provide an additional 
accurate measure of kidney impairment in CKD and kidney transplant 
recipients, particularly at advanced stages.
POSTER BOARD NUMBER P1 – 311
DIALYSIS TIME IS A RISK FACTOR FOR LONG-TERM 114 
DECEASED-DONOR TRANSPLANT SURVIVAL
M. Gallichio, S. Yarlagadda, A. Rainow, O. Elbahoul, D. Conti
Albany Medical College
The duration of dialysis prior to transplantation has been shown to be a risk 
factor for renal transplant survival. However, these analyses, in deceased-donor 
renal transplantation, failed to control adequately for donor and procurement 
risk factors which may have a signifi cant impact on allograft function and 
survival. For example, three-year survival of expanded criteria donor kidneys 
is signifi cantly less than standard criteria donor kidneys. To adequately 
control for these donor-related variables, we analyzed long-term graft survival 
rates in deceased-donor recipients of paired kidneys derived from the same 
procurement procedure, preserved in the same manner, implanted by the same 
surgical team, subjected to similar cold ischemia times (CIT) and treated with 
the same immunosuppressive protocol. Recipient pairs consisted of 1 recipient 
whose dialysis duration was less than 1-year (mean 6 months, Group A) and 1 
recipient who was treated with dialysis for more than 1-year (mean 31 months, 
Group B).
Between 11/1990 and 11/2002, 71 deceased-donor procurement procedures 
provided kidneys for 1 Group A and 1 Group B recipient at our center. In 
all cases paired kidneys derived from the same procurement procedure were 
preserved in the same manner and recipients of paired kidneys were treated 
with the same immunosuppressive protocol. Demographics between the 
groups were similar with respect to age, gender, ethnicity, CIT, diabetes, and 
retransplant status.
Actual 1-year graft survival was 96% in Group A and 92% in Group B (p=NS). 
Actual 5-year patient and graft survival (n=71 in both groups) was 97% and 
82% in Group A and 89% and 66% in Group B (P<0.05 for graft survival).
This analysis of paired deceased-donor kidneys corroborates earlier analyses 
and demonstrates that a one-year duration of dialysis pre-transplant is a 
signifi cant risk factor for long-term renal transplant outcome.
POSTER BOARD NUMBER P1 – 312
POST-TRANSPLANTATION ANEMIA AND THE IMPACT 115 
OF IMMUNOSUPPRESSIVE THERAPY: DATA FROM THE 
TRANCEPT OBSERVATIONAL STUDY
H.T. Da Silva1, U. Heemann2, P. Merville3, C. Bernasconi4, 
H-U. Meier-Kriesche5
1University of Sao Paulo, Sao Paulo, Brazil, 2Technical University, Munich, 
Germany, 3Hopital Pellegrin, Bordeaux, France, 4F. Hoffmann-La Roche, 
Basel, Switzerland, 5University of Florida, Gainsville, USA
Renal transplantation is often the treatment of choice for patients with chronic 
kidney disease (CKD). many of whom have renal anemia. Immunosuppression 
is one of several factors known to infl uence Hb levels following transplantation. 
One commonly used immunosuppressant drug following transplantation 
is mycophenolate mofetil (MMF). which can be introduced in the late post-
transplant phase to allow reduced dosage of the more nephrotoxic CNIs 
(cyclosporine A [CsA], tacrolimus [Tac]) or steroids.
Using data from the TranCept study, we report an exploratory analysis on 
the relationship between Hb levels at enrollment and factors that may impact 
upon anemia, looking in particular at immunosuppressants. TranCept is a 
multicenter, observational, global study in 4399 patients of all ages who were 
introduced to MMF due to declining renal function or intolerance of previous 
immunosuppressive drugs, or who were receiving MMF since transplantation. 
Patients were transplanted 6 months to 20 yrs before enrollment in the study. 
Our exploratory analysis has evaluated data from 3692 adult patients (>18 yrs) 
using descriptive statistics, non-parametric univariate tests and multivariate 
linear models, with a signifi cance level of 5%. Anemia was defi ned as <12 g/
dL for females, and <13 g/dL for males.
Mean Hb (SD) at enrollment was 12.7 (+/-2.2) g/dL and 713 (19%) had Hb <11 
g/dL. As previously reported, post-transplantation Hb values fell with declining 
renal function. Hb levels were not dependent upon time after transplantation. 
There was a negative dose-effect relationship for Tac (p=0.04) and particularly 
for CsA (p<0.0001); multivariate models including age, gender, GFR and 
duration of MMF treatment confi rmed this result. Patients who had a CNI 
reduction up to months 6 (n=608; CsA dosage decrease >40 mg/day or Tac 
> 1 mg/day) had improved Hb levels after 1 yr compared with patients with 
no CNI reduction (n=3084; p=0.0014). Hb improvement was independent of 
GFR at 1 yr and of the change in GFR from enrollment. Lower Hb levels were 
observed in patients receiving sirolimus vs CsA and Tac (12.0, 12.7 and 12.7 g/
dL, respectively; p=0.0008). Hb levels were almost identical in patients treated 
with MMF and azathioprine, with no dependence of Hb levels on MMF dose 
or time from MMF introduction, indicating that MMF does not increase the 
prevalence of post-transplantation anemia. Those patients with anemia had a 
higher incidence of a composite endpoint of graft loss, acute heart failure, MI, 
coronary artery disease or stroke vs patients without anemia (13.4% vs 9% 
respectively, p<0.001); anemia (but not Hb) was an independent risk factor in 
models including also GFR and age (p=0.03).
We conclude that patients with reduced graft function should be evaluated for 
anemia. Patients who are at risk of anemia complications may require a re-
evaluation of their immunosuppressive treatment.
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KIDNEY TRANSPLANTATION ONLY PARTIALLY 116 
RESTORES ESRD PATIENT SURVIVAL
A. Leichtman1, K. McCullough2, R. Wolfe2
1Dept of Medicine, Div. of Nephrology, U. of Michigan, 2Arbor Research 
Collaborative for Health
Introduction: Kidney transplantation is now accepted as providing a 
survival advantage compared to remaining on dialysis. The extent to which 
deceased donor kidney transplantation restores normal longevity has not been 
quantifi ed.
Methods: We compared median lifetimes for the general US population, 
wait listed patients (WL). most of whom were on dialysis, and deceased 
donor kidney-alone or kidney-pancreas transplant recipients (KT). Estimated 
lifetimes were based on the 1996 Interpolated Abridged Life Table from the 
US Public Health Service for the US Pop; prevalent samples of active WL 
patients taken on Jan. 1 of 1988, 1990, 1994, 1998, and 2002; and 1987–2004 
transplant recipients. Both WL and PT data were from the Scientifi c Registry of 
Transplant Recipients with extra death ascertainment from the Social Security 
Death Master File. WL and PT lifespan medians were based on the average 
estimated median lifespan for candidates who were active on the waitlist on 
January 1, 2004.
Results: At each age, the median lifetime was shorter for dialysis patients than 
for KT, and KT lifetimes were less than half that of the comparable age group 
of the general US population.
Conclusion: Compared to the general age-matched population, dialysis and 
transplantation incompletely restore lifespan. Some of the differences in 
survival might refl ect differences in patient selection with the least healthy 
patients excluded from certain therapies, but these adjusted analyses account 
for many patient variables. Thus, differences between WL and KT survival 
probably refl ect true differences in the effi cacy of therapeutic modalities.
POSTER BOARD NUMBER P1 – 314
THE RELATION BETWEEN TRANSPLANT 117 
CENTER VOLUME AND THE OUTCOMES OF KIDNEY 
TRANSPLANTATION: A SYSTEMATIC REVIEW
J. Kim1,2,3, T. Louis2, B. Astor2,3, E. Boulware2,3, D. Al-Riyami1, N. Powe2,3
1Toronto General Hospital, University Health Network, University of 
Toronto, 2Johns Hopkins Bloomberg School of Public Health, Johns Hopkins 
University, 3Welch Center for Prevention, Epidemiology and Clinical 
Research, Johns Hopkins University
Background: Hospitals performing a higher volume of procedures have been 
associated with more favorable patient outcomes across numerous surgical and 
medical disciplines. The relation between transplant center volume and kidney 
transplant outcomes remains uncertain.
Objective: To systematically review studies relating kidney transplant 
procedural volume in U.S. and non-U.S. kidney transplant centers to the 
survival of patients and their allografts.
Data Sources: English-language articles in MEDLINE (1 Jan 1965 to 1 Oct 
2007). EMBASE (1 Jan 1980 to 1 Oct 2007). the Cochrane database, and 
reference searches from retrieved articles.
Study Selection: All studies examining transplant center volume (i.e., the 
number or rate of kidney transplant surgeries performed over a specifi ed period 
of time) as a predictor of kidney transplant outcomes (i.e., patient and/or 
allograft survival) in adult recipients.
Data Extraction: One investigator used a standardized form to collect key 
study characteristics and results while another independently reviewed the data 
for accuracy and completeness.
Data Synthesis: Eight of 18 studies (44%) showed a positive and statistically 
signifi cant relation between center volume and graft survival (i.e., higher center 
volume is associated with higher graft survival). Center volume in 2 of 6 studies 
showed a positive relation with patient survival. The methodologic rigor of 
the studies varied widely and was generally suboptimal. When the studies 
were grouped into those from the U.S. (10 studies). those including patients 
transplanted since 1985 (11 studies). and those of the highest methodologic 
quality (6 studies). a total of 4, 6, and 3 reports, respectively, continued to 
display a volume-outcome relationship.
Conclusions: A center volume effect may exist in kidney transplantation 
but fi rm conclusions cannot be drawn due to methodologic shortcomings of 
existing studies. Volume-based policies in kidney transplantation can neither 
be endorsed nor rejected at this time.
POSTER BOARD NUMBER P1 – 315
GERIATRIC RECIPIENTS OF DECEASED DONOR 118 
RENAL TRANSPLANTS DEMONSTRATE EQUAL GRAFT 
SURVIVAL TO NON-GERIATRIC POPULATIONS
A. Sener, E. Schweitzer, M. Cooper, L. Campos, S. Bartlett, B. Philosophe, 
R. Barth
University of Maryland School of Medicine
Renal transplantation has become increasingly prevalent in the geriatric 
population accounting for 13.2% renal transplants performed nationally. We 
reviewed 3297 renal transplant recipients from our transplant database over the 
last 15 years to evaluate outcomes in the geriatric population. We used Kaplan-
Meier survival estimates and logrank estimates of statistical signifi cance. Our 
center has performed 468 living (LDRTx) and deceased donor renal transplants 
(DDRTx) in patients over the age of 65 years old since 1991. We have 
performed 14.2% of all renal transplants in patients over the age of 65 years 
old, 5.7% of transplants in patients over 70 years old, and 1.8% (60 transplants) 
in patients over 75 years old. Geriatric recipients (over 65 years old) of DDRTx 
demonstrated 83.0%, 74.1%, and 64.1% graft survivals at 1, 3, and 5 years. 
Geriatric DDRTx recipients had overall equal graft survivals to adult DDRTx 
(p=0.49). Geriatric recipients of LDRTx demonstrated 1 year graft survival of 
94.3%, 3 year graft survival of 88.8%, and 5 year graft survival of 72.3%. These 
results were better than geriatric DDRTx recipients (p=0.04). but not as good as 
graft survival in adult (18-64 years old) LDRTx recipients (p=0.006). This was 
predominantly driven by poorer graft survival in LDRTx recipients older than 
75 years (p=0.004). Graft survival in geriatric LDRTx recipients 65-69 years 
old (p=0.04) and 70-74 years old (p=0.4) had more equivalent outcomes to 
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adult LDRTx recipients. These data support the good outcomes of both LDRTx 
and DDRTx in the geriatric population. DDRTx geriatric recipients had similar 
graft survivals to adult DDRTx recipients. LDRTx geriatric recipients had 
better outcomes than geriatric DDRTx recipients; although, not equal to the 
excellent results of younger LDRTx recipients.
POSTER BOARD NUMBER P1 – 316
METABOLIC SYNDROME AND RISK OF RENAL GRAFT 119 
LOSS IN THE ALERT TRIAL.
I. Soveri1, H. Holdaas2, A. Jardine3, N. Eriksson4, B. Fellström1
1Department of Medical Sciences, 2Rikshospitalet, 3University of Glasgow, 
4Uppsala Clinical Research Center
Background: Metabolic Syndrome (MS) is a risk factor for cardiovascular 
disease (CVD) and diabetes mellitus in the general population. Renal transplant 
recipients (RTR) have unfavorable metabolic conditions, partly due to 
immunosuppression. Some, but not all studies in RTR have shown that MS has 
adverse effect on graft survival.
Aim: To study MS as risk factor for renal end points in RTR. To investigate the 
effect of fl uvastatin treatment on renal risk in RTR with MS.
Methods: In total, 1708 stable RTR without diabetes mellitus in the ALERT 
trial were randomized to treatment with fl uvastatin or placebo. Follow-up was 
7-8 years (ALERT-extension trial). MS was defi ned at baseline using ATPIII 
defi nition. The registered renal endpoints included graft loss and graft loss or 
doubling of serum creatinine.
Results: In the ALERT study, 29% of the non-diabetic RTR had MS. Graft loss 
risk was increased in RTR with MS [RR (95% CI) ] 1.40 (1.10-1.78). RTR with 
MS also had increased RR for losing renal graft or doubling in serum creatinine 
1.27 (1.02-1.59). No favorable effects of statin treatment were observed.
Conclusion: RTR with MS are at higher risk for losing renal graft. Treatment 
with fl uvastatin does not reduce the risk.
POSTER BOARD NUMBER P1 – 317
NEGATIVE IMPACT OF PRETRANSPLANT 120 
COMORBIDITY IN GRAFT AND PATIENT SURVIVAL IN 
KIDNEY TRANSPLANTATION.
A. Sanchez-Fructuoso2, I. Perez-Flores1, N. Calvo3, N. Ridao4, M. Giorgi5, 
M. Marques6, A. Rodriguez7, A. Barrientos8
1Hospital Clinico San Carlos, 2Hospital Clinico San Carlos, 3Hospital Clinico 
San Carlos, 4Hospital Clinico San Carlos, 5Hospital Clinico San Carlos, 
6Hospital Clinico San Carlos, 7Hospital Clinico San Carlos, 8Hospital Clinico 
San Carlos
Aims: To report pre- and peritransplant comorbidity. To study whether it could 
predict patient and graft outcome after kidney transplantation. To validate and 
compare several comorbidity indices in this population.
Methods: We retrospectively collected the next comorbid condition: heart failure, 
left ventricular hypertrophy (LVH). myocardial infarction, cerebrovascular 
disease, peripheral vascular disease, chronic pulmonary disease, peptic ulcer, 
mild liver disease, vascular calcifi cation, urinary tract pathology, diabetes pre 
and postransplantation, acute tubular necrosis postransplantation, renal function 
at discharge and at one year postransplantation. We analyzed the impact of 
each one of them in the survival of 500 kidney transplantation performed in 
our unit between 1999 and 2004. We studied the ability of two comorbidity 
indices to predict patient and graft outcome by using a Cox regression model. 
The Charlson Comorbidity Index (CCI) and a novel prognostic index proposed 
to Hernandez were the indices used. Based on the ROC curve for CCI, the 
patients were divided into different groups: low and high comorbidity (≤2 and 
>2, respectively).
Results: There were a high number of patients with some comorbidity at 
baseline (67%). The most common comorbid factors in our patients were: LVH 
(55%). diabetes pre- and postransplantation (23% and 10.3%) and liver disease 
(8.5%). The overall 5-years-patient and graft survival were 92% and 83.5%, 
respectively. Of comorbidity indices examinated, the model containing the CCI 
showed the best profi le and the urinary tract pathology did not improve this 
model. After adjustment for covariates, patients with high comorbidity had an 
increased mortality after kidney transplantation (HR 7.74, 95% CI 1.49-40.01, 
p = 0.015). The main causes of death depending on score of comorbidity were: 
cardiovascular disease and malignancies in patients with high comorbidity, and 
infection in low score group (p = 0.031). Comorbidity also was related to graft 
outcome in the adjusted model. Rejection and high comorbidity score were the 
main risk factors for graft failure during the fi rst month postransplantation (HR 
2.17, 95% CI 1.07-4.40, p = 0.031; HR 2.29, 95% CI 1.04-5.06, p = 0.039, 
respectively). However, the CCI is the strongest predictor of graft survival after 
fi rst month, even when we censored for death with functioning graft (HR 2.24, 
95% CI 1.12-4.48, p = 0.02).
Conclusions: Our results suggest that: 1) High pre-transplant comorbidity is 
one of the main risk factor for renal graft failure and patients mortality. 2) The 
CCI is a great tool for the prediction of outcome in kidney transplantation. 3) A 
best control of comorbid condition might be one of the most important aims to 
improve the results in kidney transplantation.
POSTER BOARD NUMBER P1 – 318
GLOMERULONEPHRITIS FOLLOWING RENAL 121 
TRANSPLANTATION
P. Keown, W. Chailimpamontree, S. Dmitrienko, G. Li, R. Balshaw, A. Magil, 
D. Landsberg, R.J. Shapiro, J. Gill, and the Genome Canada Biomarkers in 
Transplantation Group.
University of British Columbia, Vancouver, Canada.
Introduction: The study correlated patient risk factors and treatment with 
the case incidence, cumulative probability, kinetics, and consequences of 
glomerulonephritis (GN) following renal transplantation in 2026 patients 
received a primary renal transplant in a single Canadian centre. 
Results: The frequency of PTGN varied according to the category of original 
disease. Post-transplant GN was most common (94/734; 12.8%) in subjects who 
had biopsy-proven GN in their native kidney, was intermediate (9/159; 5.8%) 
in those with presumed GN not confi rmed by biopsy, and was least frequent 
(4/1133; 3.6%) among those who had chronic kidney disease due to other 
causes. Independent predictors of PTGN were male gender, non-Caucasian, 
younger age, presence of prior GN (p<0.05 in Cox regression model). The most 
common histological forms of PTGN were IgA nephropathy which occurred in 
61 subjects (3.0%) and FSGS which developed in 53 subjects (2.6%). while all 
other forms occurred in < 1% of subjects The cumulative probability of PTGN 
increased over time reaching 15.7% (Kaplan-Meier Estimate) by 15 years 
post-transplant, and was almost three-fold higher in patients with prior GN 
than in patients whose original disease was due to other causes (KM estimates: 
24.3% vs 10.5%, p=0.001). The incidence of PTGN was signifi cantly greater 
in patients transplanted during the period1996-2005 compared with those 
transplanted prior to this date (p=0.02). The probability of graft survival at 
15 years was signifi cantly reduced in patients with PTGN (10.2% vs. 69.7%; 
0.00001).
Conclusion: The cumulative frequency of PTGH has not declined with new 
immunosuppressive agents. PTGN occurs in 15.7% of patients by 15 years 
post-transplant and IgA and FSGS are the most frequent forms. PTGN is most 
common in patients with GN in their native kidney, and is an important cause 
of accelerated graft failure.
POSTER BOARD NUMBER P1 – 319
SERUEM FROM RENAL TRANSPLANT RECIPIENTS 122 
IMPROVES MARKERS OF IN VITRO ENDOTHELIAL CELL 
ACTIVATION COMPARED TO DIALYSIS RECIPIENTS, BUT 
NOT TO BASELINE LEVELS.
S. Sen1,2, W.Y. Sun3, T. Coates1,2, S. McDonald1,2, C. Bonder3
1Transplant Immunology Laboratory, Department of Nephrology And 
Transplantation Services, The Queen Elizabeth Hospital (TQEH). Woodville 
South, Australia, 2Department of Medicine, University of Adelaide, Adelaide, 
Australia, 3Institute for Medical and Veterinary Science (IMVS). Adelaide, 
Australia
Introduction: Cardiovascular disease (CVD) is over-represented as a cause 
of death in patients on renal replacement therapy (RRT). with transplantation 
reducing but not reversing this risk. The endothelium plays a crucial role in CVD 
in chronic kidney disease (CKD). with both atherosclerosis and arteriosclerosis 
occurring at increased rates. Risk factors, including tumour necrosis factor 
(TNF) alpha, CRP, and uraemic agents such as p-cresol are predictive of CVD 
risk in CKD patients. Other markers of endothelial activation and infl ammation 
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have also been found to be increased in dialysis patients, including ICAM-1, 
VCAM-1 and MCP-1. VCAM-1 expression can also be increased on cultured 
human umbilical vein endothelial cells (HUVECs) after exposure to serum 
from haemodialysis patients, but increased apoptosis has not been described. 
We hypothesised that renal transplantation reverses the effect of uremic toxins 
on vascular endothelium, and investigated this potential effect using an in vitro 
culture system.
Methods: Cultured HUVECs were exposed to serum from stable transplant 
patients on calcineurin inhibitor treatment (n=10). haemodialysis recipients 
(n=10) and healthy control subjects (n=9). Patient demographics were collected, 
as well as baseline biochemistry and haematology. A cytokine immunofl ow bead 
kit (Bender MedSystems) was used to measure circulating levels of TNF alpha, 
V-CAM, I-CAM and other markers of endothelial activation and infl ammation 
in serum samples. Serum from subjects was added to normal HUVEC culture 
conditions at 20% concentration for a minimum of 4 and a half hours, with 
0.5ng/ml TNF alpha added after 30 minutes to maximise stimulation. Cells 
were then prepared for either fl ow cytometry for VCAM-1 expression, or lysate 
preparation for Western Blotting. The latter were later analysed for markers of 
cellular senescence, including Akt phosphorylation and ERK.
Results: Renal transplant recipients’ serum induced signifi cantly lower 
V-CAM-1 expression on HUVECs compared to haemodialysis patients’ 
serum (MFI 77.6 versus MFI 88.8, p<0.05). Western blot analysis for Akt 
phosphorylation and ERK showed reduced intracellular protein in HUVECS 
exposed to renal transplant patient serum compared to haemodialysis patient 
serum. These differences could not be explained by baseline serum levels of 
circulating infl ammatory mediators including TNF between renal transplant 
serum and haemodialysis patients serum, and importantly did not return to 
levels achieved by normal control serum.
Conclusions: Renal transplantation partially reverses the effect of uraemic 
serum on endothelial markers of vascular damage. The causal factors remain 
to be elucidated. This in vitro assay may be used as a tool to investigate the 
nature of proinfl ammatory markers of endothelial damage as well as evaluate 
the effect of alternative treatment regimes/interventions on markers of vascular 
damage.
POSTER BOARD NUMBER P1 – 320
DOES CHANGE IN URINARY NEUTROPHIL 123 
GELATINASE-ASSOCIATED LIPOCALIN (NGAL) PREDICT 
ALLOGRAFT FUNCTION?
P. Roy-Chaudhury, I.A. Meyer, R.R. Alloway, M. Meyer, E.S. Woodle, A. 
Jane, M. Bennett, 
P. Devarajan, C.V. Thakar, 
University of Cincinnati.
Introduction: Ischemia reperfusion injury (IRI) infl uences short-term and 
long-term allograft function; creatinine is not tissue specifi c and does not 
represent the magnitude of cellular injury. Parikh et al reported that absolute 
levels of urinary NGAL at 24 hours were predictive of delayed graft function 
(DGF). We examined whether NGAL, followed over time during the fi rst seven 
days post-transplant can predict on-going ischemic injury.
Methods: Prospective collection of serum and urine specimens was performed 
post-transplant at 4hrs, 6hrs, 24hrs and daily from day 2 to day 7. Patients 
were divided into 2 groups based on renal function, delayed graft function 
(DGF) or immediate graft function (IGF). DGF was defi ned as the need for 
dialysis at 7 days. All other patients were considered to have IGF. Urinary 
NGAL levels were analyzed by ELISA, standardized for urine creatinine 
levels, and expressed as ng/mg of creatinine. NGAL levels at POD1 and POD2 
minus POD1 were expressed as mean and median, and compared by t-tests for 
univariate comparison.
Results: Twenty consecutive kidney transplant recipients (85% male, 70% 
Caucasian, 35% deceased donors) were evaluated. ESRD origin included 
hypertension (n=8). diabetes mellitus (n=3). PCKD (n=3). IgA Nephropathy 
(n=3). FSGS (n=1). and glomerulonephritis (n=1). with 1 unknown. Three 
(15%) experienced DFG. All patients with IGF had NGAL values of < 1,000 
ng/mg at POD1. The mean value of urine NGAL measured on POD1 in the 
DGF group was 64,224ng/mg as compared to 668.3 ng/mg in the IGF group. 
(median IGF =343ng/mg versus 13,059ng/mg for median DGF). The mean 
difference between POD2 and POD1 NGAL levels for IGF patients was – 
366ng/mg versus 319,744ng/mg in DGF patients. Log NGAL levels at POD1 
and POD2 minus POD1 were signifi cantly different between the two groups 
(P <0.05). All patients in DGF group had an increase in NGAL between POD1 
and POD2; 14/17 (82%) IGF patients showed a decline in NGAL levels at 
POD2.
Conclusions: This study confi rms that patients without DGF usually have urine 
NGAL levels of ≤1000ng/mg. Additionally, an increase in NGAL, an indicator 
of ongoing IRI, is observed in all patients with DGF. In contrast, the majority 
of patients who show a decline in NGAL go on to improve their renal function 
over time. Temporal changes in NGAL (a tissue specifi c marker of IRI) may 
be a useful addition to the predictive accuracy of a panel of biomarkers for the 
early diagnosis of delayed graft function.
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ADMINISTRATION OF DONOR ALLOANTIGEN VIA THE 124 
RESPIRATORY TRACT GENERATES CD11C+ REGULATORY 
CELLS AND INDUCES HYPORESPONSIVENESS TO FULLY 
ALLOGENEIC CARDIAC GRAFTS
N. Shirasugi1, Q. Zhang1, D. Iwami1, O. Aramaki2 and M. Niimi1
Surgery, 1Teikyo University and 2Nihon University, Tokyo, Japan.
Backgrounds: Soluble proteins delivered through mucosal surfaces 
(the respiratory tract and the gastrointestinal tract) can induce peripheral 
unresponsiveness, which has been termed mucosal tolerance. We have 
previously reported that administration of donor alloantigen via the recipients’ 
respiratory tract induced hyporesponsiveness to fully mismatched cardiac 
allografts in mice and generated regulatory cells. Here we show in this model 
that the regulatory cells, which were induced by administration of donor 
alloantigen via the recipients’ respiratory tract, contain CD11c+ population 
secreting higher amount of IL-10. 
Methods: CBA mice (H-2k) were given 1x107 C57BL/10 (B10, H-2b) 
splenocytes via the trachea (pretreatment). Seven days later, the CBA mice 
underwent transplantation of B10 hearts. In adoptive transfer studies, CBA 
mice (primary mice) received the pretreatment and 7 days later, CD4+ cells or 
CD11c+ cells were purifi ed from the spleen of the primary mice and the CD4+ 
cells (2x107) or the CD11c+ cells (1x106) were adoptively transferred into the 
naive CBA mice (secondary recipients). which were given transplantation of 
B10 hearts immediately afterwards. Cytokine profi le of the CD11c+ cells was 
also examined. 
Results: Untreated CBA recipients rejected B10 allografts acutely (median 
survival time (MST). 8 days). The pretreatment induced prolongation of B10 
allograft survival in CBA recipients (MST, 85 days). Secondary CBA recipients 
given not only whole but also CD4+ splenocytes from the primary mice had 
signifi cantly prolonged survival of B10 allografts (MST, 89 and 68 days, 
respectively, compared to those in control recipients with adoptive transfer 
of naive whole or CD4+ splenocytes, MST, 9.5 and 12 days, respectively). 
Surprisingly, adoptive transfer of CD11c+ cells, which were purifi ed from the 
pretreated primary CBA mice, also induced prolonged B10 allograft survival 
in naive secondary recipients, (MST, 75 days, compared to those in control 
recipients with adoptive transfer of naive CD11c+ cells, MST, 9 days). When 
restimulated in vitro with LPS, the CD11c+ cells purifi ed from the pretreated 
primary CBA mice demonstrated up-regulation of interleukin (IL) -10 and 
down-regulation of IL-12, whereas naïve CD11c+ cells produced higher 
amount of IL-12 and only small amount of IL-10. Fourteen days after the 
adoptive transfer of the CD11c+ cells purifi ed from the pretreated primary 
CBA mice into naïve secondary recipients with B10 cardiac allografting, CD4+ 
splenocytes were purifi ed from the secondary recipients and were adoptively 
transferred into naive CBA recipients (third recipients). The third recipients 
underwent B10 cardiac grafting immediately afterwards. The third CBA 
recipients enjoyed remarkable prolongation of cardiac allografts (MST, >90 
days, compared to that in CBA recipients with adoptive transfer of naive CD4+ 
cells, 12 days). 
Conclusion: These data suggest that; 1) administration of donor alloantigen via 
the recipients’ respiratory tract induced CD11c+ regulatory cells (presumably 
regulatory dendritic cells (DC) ). as well as CD4+ regulatory cells, 2) regulatory 
DC produced higher amount of IL-10, and 3) regulatory DC induced CD4+ 
regulatory cells in vivo.
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Oral Abstracts Monday 11 August 2008
4 5
M
O
N
D
AY
POSTER BOARD NUMBER P1 – 322
EFFECT OF B-CELL DEPLETIONAL THERAPIES ON 125 
ALLOIMMUNE HUMORAL RESPONSES IN A MURINE MODEL
B. Book Indiana University
There is growing interest in B-cell-directed therapy in transplantation, yet 
there are limited data on its immunologic impact. We report the effect of two 
distinct B-cell depletion regimens on allo-antibody (Ab) responses using 
a murine model. B-cell depletion was accomplished with a BR3-Fc fusion 
protein (soluble BAFF antagonist), and anti-BR3 (dual function BAFF agonist 
and cell depleter). C57BL/6 mice received BR3-Fc or anti-BR3. Initial fl ow 
cytometric (FCM) analysis documented B-cell depletion and recovery. Cohorts 
received one dose intraperitoneal (IP) anti-BR3 (200?g/mouse). BR3-Fc (200 
?g) was given IP twice weekly for 6 weeks (wk). To examine the impact of 
B-cell depletion, immunization was performed at 7 days (D) after the dose 
of anti-BR3 and 14 D after the fi rst dose of BR3-Fc. Cohorts of mice (n=3) 
were immunized IP with BALB/c splenocytes (2x107 cells) and boosted 1 
month later. Controls included no anti-B-cell therapy (positive control, PC) and 
autologous sera for negative control. Serum samples were obtained weekly for 
6 weeks. Two-fold dilutions of sera were incubated with cells and secondary 
anti-IgG- or –IgM-FITC. Binding was detected by FCM. The sum of the 
mean fl uorescence channel was calculated after subtracting autologous serum 
control. Statistical analyses used Kruskal-Wallis one-way analysis of variance 
and Dunn’s Method of pairwise comparison. B220 expression in peripheral B 
cells was determined at baseline, 1,2,4,6,8,10 and 12 wks post therapy by FCM. 
Statistical analyses utilized Student s t-test (p<0.05 was signifi cant). Anti-BR3 
led to rapid B-cell depletion from 42% to 6% at one week with recovery to 
35% at 12 weeks(wks). BR3-Fc required 4 wks for B-cell depletion from 43% 
to 8% and continued to be low at wk 12 (7%). Both agents suppressed the allo 
Ab response. IgG, but not IgM Allo-Ab was suppressed signifi cantly with anti-
BR3 and despite recovery of peripheral B cells a booster response was delayed 
and the level reduced. There was a slight effect on antibody with BR3-Fc. This 
difference could be due to small sample size, the level of B-cell depletion at 
time of immunization, or a qualitative difference in residual B cells. From a 
clinical perspective, the more rapid and complete inhibition with anti-BR3 
makes it a more favorable agent to move into clinical trials.
POSTER BOARD NUMBER P1 – 323
IDENTIFYING CANDIDATES FOR ABO-INCOMPATIBLE 126 
TRANSPLANTATION: A NOVEL METHOD TO DETECT B 
CELLS SPECIFIC FOR ABO BLOOD GROUP ANTIGENS
L. West3, S. Gelowitz1, L. Guembes Hidalgo2,
1University of Alberta – Medical Microbiology and Immunology, 2University 
of Alberta – Department of Medicine, Alberta Transplant Applied Genomics 
Centre, 3University of Alberta – Departments of Pediatrics, Surgery, and 
Immunology
Intro: Infant candidates for ABO-incompatible transplants are currently 
identifi ed by the absence of circulating anti-A and anti-B antibodies. While 
antibody titre is generally a good predictor of whether a patient can safely 
receive an ABO incompatible transplant, it cannot distinguish between 
endogenous anti-A/-B antibodies and those passively acquired through 
administration of blood products. Recipients of ABO-incompatible grafts 
during infancy maintain a persistent donor-specifi c defi ciency in anti-A and/
or anti-B-antibodies. However, it is unclear whether these children may be 
retransplanted with additional ABO-incompatible grafts since donor A/B-
specifi c B cells, if present, may lead to hyperacute rejection if another ABO-
incompatible graft is given during immune maturity. 
Methods: A fl ow cytometry-based conjugate assay was designed to detect and 
quantify A/B antigen-specifi c B cells in human splenocyte/PBMC populations. 
BSA conjugated to A or B antigen was immobilized onto fl uorescent beads to 
screen the blood group-specifi city of CD19+ B cells. B cell enrichment and 
panning onto BSA-coated plates was used to decrease Background: 
Results: Initial results show that cognate interaction between B cells and A/B 
antigen-coated beads resulted in antigen-specifi c labeling of CD19+ cells using 
PBMCs from A, B, or O donors (Figure). Although only a small percent of 
peripheral B cells recognize A/B antigen-coated beads, this is consistently much 
higher than background levels and is expected due to a diverse B cell repertoire. 
Conclusions: This assay may be used together with clinical isoagglutinins and 
a functional assay currently under development in our laboratory to detect B 
cell specifi city as well as B cell activation in response to A and B antigens. 
Together, these tools will help to identify candidates for ABO incompatible 
transplantation by providing information for a more complete and accurate risk 
assessment.
Figure: Percent of CD19+ B cells specifi c for blood group A and B antigens, 
as detected by fl ow cytometry using PBMCs and A/B antigen-coated 
fl uorescent beads
POSTER BOARD NUMBER P1 – 324
SINGLE-TUBE CROSSMATCH ASSAY FOR 127 
SIMULTANEOUS DETECTION OF ANTIBODIES REACTIVE 
WITH DONOR ENDOTHELIAL CELLS AND LYMPHOCYTES.
J. Holgersson1, S.M. Johansson2, D. Hauzenberger2, P. Grufman3, 
M. Alheim2
1Karolinska Institutet, 2Karolinska University Hospital, Huddinge, 3AbSorber AB
Conventional fl ow cytometric crossmatch testing using donor T and/or B 
lymphocytes, is adequate to detect HLA class I- and II-specifi c antibodies. 
Despite negative lymphocyte crossmatches (LXM). approximately 15% 
of kidney transplants undergo early rejections some of which are due to the 
presence of non-HLA specifi c antibodies reactive against donor endothelial 
cells (EC). A fl ow cytometric endothelial cell crossmatch (ECXM) test (XM-
ONE®; AbSorber AB, Stockholm) for detection of antibodies reactive against 
donor EC was recently developed. This assay is based on the isolation of 
EC from donor peripheral blood using magnetic beads carrying antibodies 
specifi c for the angiopoietin receptor, Tie-2. Apart from EC, a large number 
of lymphocytes are also present within the isolated Tie-2+ fraction. This latter 
fi nding encouraged us to evaluate whether XM-ONE® could be used as a 
single-tube crossmatch assay for simultaneous detection of antibodies reactive 
with donor endothelial cells and lymphocytes. Comparison of the T-/B-ECXM 
and the conventional T/B-LXM were performed using sera from hitherto 28 
patients undergoing evaluation for living-donor kidney transplantation. We 
demonstrate a highly signifi cant correlation between the two assays with regard 
to the T-cells, which was lower with regard to the B-cells. Importantly, a second 
follow-up study using sera from patients with known levels of panel reactive 
antibodies (PRA) and donor cells confi rmed the initial results. In conclusion, 
both donor lymphocyte- and EC-reactive antibodies can be detected using this 
novel single-tube crossmatch assay.
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CHANGES IN DONOR SPECIFIC AND THIRD PARTY 128 
HLA ANTIBODY LEVELS AFTER ANTIBODY INCOMPATIBLE 
TRANSPLANTATION; PRODUCTION, ABSORPTION AND 
DONOR-SPECIFIC MODULATION.
R. Higgins1, D. Briggs2, D. Lowe2, M. Hathaway2, R. Hamer1, N. Krishnan1, 
D. Zehnder3
1University Hospital, 2Histocompatibility Laboratory, UK Blood and 
Transplant, 3Warwick Medical School
Background: After HLA antibody incompatible transplantation, it is recognised 
that donor specifi c and third party HLA antibodies may be found in the blood, 
and that there is a donor-specifi c fall in these levels during the fi rst 40 days. 
However, the changes in antibody levels have not previously been described 
in detail.
Methods: HLA antibody level, both donor-specifi c (DSA) and third party, 
were measured using the microbead method in 44 presensitised patients who 
had renal transplantation.
Results: Compared to 3rd party HLA antibodies, DSA fell in the fi rst 4 
days after transplantation, in a pattern compatible with absorption of 
antibody onto the graft. Falls in DSA were detectable for Class I and DR 
during the operation (p<0.01). and over days 2-4, Class 1 had 57.8% fall 
compared with 20.2% for 3rd party (p<0.001); HLA DR fell 63.0% vs 
24.3% (p<0.001) and DP/DQ/DRB fell 34% vs 17.5% (p=0.014). Peak 
DSA levels occurred at a mean of 13 days post-transplant, and this peak 
was higher than pre-treatment levels in 25 (57%) patients, and lower in 
19 (43%). in some patients with sustained and profound falls developing 
soon after the transplant. The incidence of rejection was higher in those 
who had the greatest change in DSA posttransplant, both rises and falls 
(p<0.01). DSA levels subsequently fell in all patients in a donor specifi c 
manner (p<0.0001). and the magnitude of the fall was greater in those who 
had an early rejection episode (67.1% fall in DSA after rejection vs 33.5% 
fall after no rejection, p<0.03).
Conclusion: These data show the patterns of rise and fall of DSA post-
transplant in antibody incompatible transplantation and provide a framework 
for rational investigation of the pathogenicity of DSA, and also the production 
and elimination of DSA.
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DONOR SPECIFIC LYSATE LUMINEX® 129 
CROSSMATCHING: COMPARISON WITH LUMINEX® 
CHARACTERISED HLA ANTIBODIES.
E. Tsiopelas1, S. Deayton1, A. Fleet1, G. Bennett1, P. Bardy1, P. Coughlan1, 
G. Russ1,2,3, P. Coates1,2,3
1National Transplantation Services, Australian Red Cross Blood Service, 
2Department of Nephrology and Transplantation Services, The Queen 
Elizabeth Hospital, 3Department of Medicine, University of Adelaide
Introduction: The optimal means of detection of Donor Specifi c Antibodies 
(DSA) for renal transplant has not been determined. Lysate crossmatching is a 
novel technique wherein donor Class I and Class II glycoproteins are captured 
on fl uorescent microspheres. We compared this new method with standard 
Complement Dependent Cytotoxicity (CDC) and Luminex® HLA antibody 
(Ab) identifi cation.
Methods: Donor lymphocytes isolated from peripheral blood or spleen are 
used as the source material for HLA glycoproteins. The kit used will not 
identify incompatibilities due to anti DQ or DP allo antibodies. Whole blood or 
spleen cell suspensions are layered on a lymphocyte density separation media 
washed and counted. The packed cells are completely lysed using kit lysis 
buffer. After centrifugation to sediment the cell membranes, the supernatant 
(lymphocyte lysate) is transferred into a clean tube. Lysates were tested using 
Tepnel LifeCodes DSA kit to detect IgG antibodies to donor–specifi c Class I 
and Class II HLA. The DSA Luminex® Beads ($1950 AUD/96 test) are mixed 
with the donor lysate and capture the solubilised HLA, making a donor-specifi c 
HLA target for Ab’s in the serum sample. After capture of donor HLA, coated 
beads are incubated with patient serum and subsequently anti-human IgG 
phycoerythrin (PE) is added to the beads and analysed on Luminex machine. 
Selected patient sera were also tested for the presence of HLA antibodies by 
Tepnel Lifecodes Class I and Class II Identifi cation (ID) kits. These kits are 
composed of different Luminex® Beads to which affi nity purifi ed Class I and 
Class II glycoproteins are conjugated. Where DSA could not be determined 
by Id kits, due to high Panel Reactive Antibodies (PRA%). Tepnel LifeCodes 
Single Antigen Bead (SAB) assay ($2500AUD/24 Tests) was used to determine 
the presence of DSA.
Results: Four patient groups were studied comprising patients 1) undergoing 
desensitisation protocol (n=8). 2) with grafts from live donors (n=18). 3) 
with grafts from deceased organ donors and early rejection episodes (n=8) 
and 4) with grafts from deceased organ donors and no rejection episodes 
(n=13). Sera of all groups were tested by Luminex®bead assay for the 
detection of HLA antibodies. There was complete concordance between 
antibodies detected with Luminex® SAB and with Donor Lysate cross 
match in all groups studied. Both Luminex®SAB and Donor Lysate assay 
consistently detected DSA in CDC crossmatch negative patients. Sample 
lysate preparation time was comparable to CDC preparation time. Frozen 
donor lysates were stable and allowed crossmatching to be performed 
retrospectively in living donors without the inconvenience of requiring 
fresh samples.
Conclusion: Tepnel LifeCodes DSA assay: i) is more sensitive than the 
current CDC crossmatch ii) is a cost effective method in detecting DSA 
compared to performing Single Antigen bead. iii) has a strong correlation 
between positive DSA crossmatch and the presence of low titre DSA. iv) 
is useful in monitoring patients undergoing desensitisation protocols by 
evaluating decreases in DSA crossmatch values over time v) allows the 
crossmatch to be performed at any time since multiple vials of donor lysate 
can be stored frozen for up to two years.
POSTER BOARD NUMBER P1 – 327
SUCCESSFUL INDUCTION OF MIXED CHIMERISM AND 130 
TOLERANCE WITH NON-MYELOABLATIVE CONDITIONING 
IN MICE PRE-SENSITIZED WITH FULLY MHC MISMATCHED 
SKIN GRAFTS
V. Levesque, P. Bardwell, F. Haspot, M. Sykes
Transplantation Biology Research Center
A growing number of patients do not qualify for organ transplantation 
because they have been pre-sensitized to donor MHC via previous transplants, 
pregnancy, and blood transfusions. These patients have extended wait list times 
and inferior graft outcomes. The ability to induce donor-specifi c tolerance in 
pre-sensitized recipients would represent a major clinical advance, broadening 
the pool of eligible transplant recipients. While lethal irradiation has been 
shown to allow engraftment of high doses of allogeneic bone marrow in pre-
sensitized mice, such regimens would be neither appropriate nor effective 
in the clinical setting. We used pre-sensitized B-cell defi cient μMT B6 mice 
lacking antibody to assess the ability of non-myeloablative bone marrow 
transplantation (BMT) regimens to tolerize pre-sensitized T cells. 12 weeks 
after skin grafting μMT B6 (H-2b) mice with fully MHC-disparate B10.A 
(H-2a) tail skin, we administered anti OX40L, anti-CD40L, anti-CD4, anti-
CD8, and anti-NK1.1 monoclonal antibodies along with sublethal 3Gy total 
body irradiation (TBI) and high dose BMT. Mixed chimerism and donor-
specifi c skin graft tolerance were achieved in these mice. Pre-sensitized WT 
B6 mice receiving the same regimen 40wks after skin grafting also achieved 
mixed chimerism and accepted donor skin grafts. We further refi ned this 
regimen to include only Day -5 CD4 and CD8 T-cell depleting monoclonal 
antibodies and Day 0 anti-CD40L along with 3Gy TBI and high dose BMT. 
Using this non-myeloablative “minimal regimen” we were able to establish 
multilineage mixed chimerism in 8 of 8 pre-sensitized μMT B6 mice, and 
donor-specifi c skin graft tolerance in 5 of 7 chimeras, while third party skin 
grafts were rejected at a median of 12 days. Our results indicate that T-cell 
tolerance can be established in pre-sensitized hosts without the use of lethal 
irradiation. In future experiments we will use the minimal regimen to establish 
mixed chimerism and tolerance in pre-sensitized WT B6 mice after allowing 
alloantibody to clear.
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HEPATIC ARTERY THROMBOSIS AFTER ADULT LIVING 131 
DONOR LIVER TRANSPLANTATION: RISK FACTORS AND 
MANAGEMENT FOR SUCCESSFUL OUTCOMES
D. Mulligan, A. Moss, S. Reddy, K. Mekeel, T. Byrne, E. Carey, M.E. 
Harrison, H. Vargas, D. Douglas, J. Rakela
Mayo Clinic Arizona
The risk of hepatic artery thrombosis (HAT) in adult live donor liver transplants 
(LDLT) is estimated between 3.8 and 5.6% in most series, but as high as 30.8% 
in others, and remains a major source of graft loss after LDLT. This is a single 
center analysis of the risk factors that contribute to the development of HAT, 
as well as the management that may contribute to graft salvage. Since 2001, 
78 LDLTs have been completed at our institution. 14 patients (19%) developed 
HAT after transplant, however only 6 patients (8%) had eventual graft loss 
and the remaining grafts were successfully salvaged. In 13 patients the HAT 
developed between 0 and 6 days after transplant (mean 4.5) and in one patient 
it developed late on POD#41. A logistic regression of risk factors found that 
cold ischemic time and graft to recipient body weight ratio were signifi cant 
risk factors contributing to the development of HAT (Table 1). Aggressive 
intervention in 7 of the 14 patients (50%) resulted in graft salvage, which 
included thrombectomy, revision and systemic anti-coagulation, including 
intra-arterial TPA in three patients. The single patient with late thrombosis has 
good graft function and is being treated with coumadin. 6 patients (8%) had graft 
failure, and 5 were re-transplanted. One patient died prior to retransplantation, 
and one patient died after retransplantation. In summary, a low GBWR appears 
to be a risk factor for the development of HAT, but if it does occur aggressive 
post operative management with thromectomy and thrombolytic therapy when 
indicated can decrease the risk of graft loss and need for retransplantation.
POSTER BOARD NUMBER P1 – 329
GRAFT LOSS AFTER ORTHOTOPIC LIVER 132 
TRANSPLANTATION DUE TO THROMBOSIS AFTER 
EMERGENCY USE OF RECOMBINANT FACTOR VIIA
F.A. Helfritz1, S. Ciesek2, M. Neipp1, C.P. Strassburg2, R. Lueck1, 
J. Klempnauer1, T. Becker1
1General-, Visceral- and Transplantation Surgery, Hannover Medical School, 
2Gastroenterology, Hepatology and Endocrinology, Hannover Medical School
Background: The genetically engineered recombinant activated factor 
VII (FVIIa) was primarily developed for treatment of bleeding episodes in 
hemophilia patients with inhibitors. Several studies have shown effi cacy and 
safety. Furthermore the use in patients with liver disease and consequently 
with complex coagulopathies was examined in different studies for both 
prophylaxis and therapy of bleeding complications as well as in orthotopic 
liver transplantation (OLT).
Case reports: Between 2002 and 2004 amongst others 5 patients with bleeding 
complications after OLT were treated with FVIIa as a rescue therapy. All of 
them suffered from graft loss due to thrombotic complications and needed 
mandatory retransplantation (Re-OLT).
Pat. I was treated with 240 kIU on the fi rst postop. day. Just some hours later a 
thrombosis of the arteria hepatica was diagnosed through ultrasound.
Pat. II was treated several times with a total of 3360 kIU between the 2. and the 5. 
postop. day due to persistent diffuse bleeding. Multiple thromboses in the inferior 
cava vein as well as in several intrahepatic vessels were diagnosed afterwards. 
The patient died due to multi organ failure a few days after Re-OLT.
Pat. III was treated with 480 kIU on postop. day 1. On day 3 thrombosis of the 
portal vein as well as hepatic artery was diagnosed leading to mandatory Re-OLT.
Pat. IV was treated with a total of 720 kIU on the fi rst postop. day. Due to a 
thrombosis of the hepatic artery also this patient needed Re-OLT.
Pat. V was treated with a total of 1440 kIU on the day of transplantation. 
Bleeding was stopped, but due to a thrombosis of the hepatic artery a Re-OLT 
was necessary. The patient died after Re-OLT with multi organ failure.
Discussion: Treatment with FVIIa is established in patients with hemophilia 
and inhibitors. The action of FVIIa, in contrast to other procoagulatory agents, 
limited to the site of vessel-lesions due to its dependency to initial existence 
of tissue factor (TF). As an adverse side effect a strong exprimation of TF 
can lead to thrombembolic incidents. So far only rare cases of thrombembolic 
related diseases are described. But above mentioned cases implicate a potential 
increase of the risk of thromboses after OLT through application of FVIIa. Thus 
the treatment with FVIIa in this collective of patients – in our opinion – should 
be critically discussed and only conducted as an ultima ratio.
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ANATOMICAL VARIATIONS OF THE ORIGIN OF 133 
SEGMENT 4 HEPATIC ARTERY AND THEIR CLINICAL 
IMPLICATIONS
B.H. Cho, H.C. Yu, G.Y. Jin, J.H Lee
Chonbuk National University Medical School
Ischemic complications in remaining part of left liver following massive 
resection such as living donor right hepatectomy or right hepatectomy with 
caudate lobectomy for the type 3a hilar cholangiocarcinoma has been haunting 
surgeons for many years. Postmortem dissection of 62 livers was performed 
to investigate anatomical variation of the principal artery for segment 4 (A4). 
The origin of A4 was examined separately in the liver with (n=46) or without 
(n=16) aberrant left hepatic artery (abLHA). In the liver, A4 was found to be 
extra- or intra- hepatic branches of the right, left or proper hepatic arteries, 
categorized into four different types according to their origin. The right hepatic 
artery (RHA) type, originated from the right or right anterior hepatic artery 
(RAHA). was the most common pattern in our series. The A4 roots still had 
a strong tendency of stemming from the RHA (n=12) even in the livers with 
abLHA (n=16). Among the RHA type, the A4 arising from RAHA (n=2) is 
supposed to be the most dangerous form of a variant, which can possibly cause 
ischemic change in the remaining part of the liver. In the era of living donor liver 
transplantation (LDLT) using right lobe of the liver, paying particular attention 
to the point of origin of A4 is prerequisite especially when the lateral section 
is relatively small. Arterial injuries to A4 during split liver transplantation 
may also cause an increased risk of hepatic artery thrombosis and ischemic 
cholangiopathy.
POSTER BOARD NUMBER P1 – 331
AN ARTIFICIAL BILE DUCT MADE OF 134 
BIOABSORBABLE POLYMER CAN SERVE AS A SUBSTITUTE 
FOR NARROWED PORTIONS OF THE EXTRAHEPATIC BILE 
DUCT
M. Miyazawa, M. Aikawa, Y. Toshimitsu, K. Okada, K. Okamoto, I. Koyama
Saitama Medical University International Medical Center
Extrahepatic bile duct stenosis due to infl ammation or cancer is now treated 
by removal of the affected area. As of this writing, however, no grafts for 
replacement of the excised tissue are available. Our group investigated whether 
an artifi cial bile duct made of bioabsorbable polymer could serve as a substitute 
for narrowed portions of the bile duct. 
Materials and Methods): The experiments were performed using hybrid 
pigs (n=11). After laparotomy under general anesthesia, the extrahepatic bile 
duct was identifi ed and ligated around the confl uence with the cystic duct. A 
week later, the animals were re-laparotomized by the same method and the 
bile duct on the hepatic side of the ligature was resected. The cut end was 
connected to the duodenum using a bioabsorbable artifi cial bile duct fabricated 
from a copolymer of polycaprolactone and polylactic acid reinforced with 
polyglycolic acid fi bers. The materials selected for the graft normally degrade 
inside the body within 6 to 8 weeks of implantation. There was no prior cell 
seeding on the artifi cial duct. The grafts were recovered for gross, histological, 
and blood chemical studies at 4 months after the surgery. 
Results: All recipient pigs survived until sacrifi ce for collection of the implants. 
A week of ligation of the extrahepatic bile duct dilated the duct to about 1 cm 
in diameter and increased T-bil to 1.9 }0.7 mg/dL. T-bil had returned to the 
pre-implantation level in all but 4 animals at post-implantation. Examinations 
of the grafts revealed complete freedom of stricture and the regeneration of a 
neo-bile duct of about 1 cm in diameter from the graft site in 10 of 11 animals. 
Gross observation of the graft from the 1 remaining animal revealed stricture at 
the anastomosis site and poor bile duct epithelization. 
Conclusion: We have concluded that this bioabsorbable polymer bile can serve 
as a replacement for narrowed portions of the bile duct.
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Monday 11 August 2008 Oral Abstracts
48
M
O
N
D
AY
POSTER BOARD NUMBER P1 – 332
INTRAOPERATIVE PORTAL VEIN STENTING FOR 135 
PORTAL VEIN STENOSIS IN LIVING DONOR LIVER 
TRANSPLANATION
C-S. Ahn, S-G. Lee, S. Hwang, K. Kim, D-B. Moon, H-Y. Ha, G-W. Song, 
D-H. Jung, J-H. Ryu
Asan Medical Center
In cirrhotic liver, portal thrombosis or stricture, which preclude portal fl ow 
and make collateral veins, are not uncommon due to the portal hypertension. 
But maintaining the adequate portal fl ow is essential for initial graft function 
and its regeneration after living donor liver transplantation (LDLT). Usually 
thrombectomy or venoplasty is applied to improve portal fl ow and easy 
anastomosis, but it may be insuffi cient if the luminal narrowing is located at 
more proximal portion. In that case, we placed portal vein stents intraoperatively 
to keep the portal vein wide.
After the explantation of diseased liver, we examined the portal stump, if the 
lumen was narrowed we have performed thrombectomy or venoplasty. Direct 
portogram was taken through inferior mesenteric vein just after the anstomosis 
and reperfusion of the graft and intraportal stents was inserted. We applied 
balloon dilatation when the lumen was not fully expanded after stenting. Some 
of collaterals of portal vein were also embolized during portogram, to prevent 
portal fl ow steal.
From Jan.2004 to Nov.2006, 615 adult to adult living donor liver 
transplantations were performed in Asan Medical Center. In 114 cases 
(18.5%). portal vein thrombosis or stricture were detected. We did direct 
portograms in 20 cases (3.2%). The patients were 14 men and 6 women. 
The underlined disease were hepatitis B associated cirrhosis in 14, alcoholic 
cirrhosis in 3, others in 3, and 8 of them had hepatomas. In three cases, we 
did only portogram without stenting, and we inserted 20 stents (metallic 
stent diameter 1cm, length 4-8cm) in 17 cases. Balloon venoplasty was 
applied in 6 cases, which showed severe narrowing after stent insertion. Coil 
embolization of coronary vein was performed in one case. The median follow 
up period was 20 months (1-34 months). and all patients has good portal fl ow 
until now except one case who expired at postoperative10 month due to the 
intracranial hemorrhage.
In conclusion, in the case of severe portal vein stenosis, intraoperative stent 
insertion can be a simple but good solution to get suffi cient portal fl ow to the 
transplanted graft and long term good results.
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THE CLINICAL OUTCOME OF THE CORONARY 136 
ARTERY BYPASS GRAFT SURGERY INTERVENED BY 
ISCHEMIC PRECONDITIONING: A SYSTEMATIC REVIEW
Y.P. Li, Z.P. Zhen, Y.C. Huang, N. Zhao, L. Feng, Y.S. Li, L.L. Pang, L.L. Li, 
C.T. Zhang, S.F. Li, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Coronary artery disease (CAD) is the major cardiovascular disease and 
predominant cause of death for the middle-older aged. WHO forecast ischemic 
heart diseases will become the fi rst cause of death in 2030 according to the 
current trend in 2007. The coronary artery bypass graft (CABG) surgery is 
an effective treatment for CAD, but with adverse effects of ischemia and 
reperfusion injury (I/RI) on myocardium. Both clinical trials and animal 
experiments have confi rmed that ischemic preconditioning (IP) can reduce I/
RI to myocardium and increase myocardial tolerance to subsequent long-term 
ischemic insult. However, so far, the IP is still not be popularized into clinical 
practice. The present systematic review fi rst summarized the effects of IP 
intervention protocols on clinical outcome of CABG surgery.
Materials and Methods: An electronic search of Medline, Embase and 
Cochrane Library from 1966 to 2007 was performed. Two reviewers excluded, 
included and assessed RCTs independently. The evaluation criteria for 
methodology were followed the cochrane systematic review handbook (version 
4.2.5). We used the postoperation mortality as the primary outcome and serous 
indicators as well as postoperative care parameters as the secondary outcomes 
to assess clinical outcomes of IP intervention.
Results: Fourteen RCTs including 14 comparisons (501 patients aged 
from 40 to 70) with 6 B and 8 C quality met inclusion criteria, which had 
3 double-blind studies and fi ve sorts of IP protocols. No death happened 
during the follow-up period of those trials. The ATP intervened groups by 2* 
(3minI+2minR) protocol in the end of 10 minutes cross-clamping (p=0.005). 
the mechanical ventilation (p=0.002). free of inotropic agents (p=0.0007) 
and duration of using inotropic agents (p=0.04) were statistically signifi cant 
different from control group. No marked difference of ICU time (p=0.88). 
using another 2* (2minI+3minR) protocol (275 patients) was confi rmed. 
Serous CTnT/I and CKMB only show descending trends, and cannot be 
quantifi ed by meta-analysis.
Conclusion: The systematic review confi rmed IP could protect myocardium, 
restore ATP in myocardium, reduce mechanical ventilation, and administrate 
no or less inotropic agents for CABG patients, but not decrease the time 
in ICU.
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PRESERVATION OF RECIPIENT’S MIDDLE HEPATIC 137 
VEIN (MHV) IS USEFUL FOR RECONSTRUCTING 
MHV TRIBUTARIES IN LIVING DONOR RIGHT LIVER 
TRANSPLANTATION
H. Tashiro, H. Ohdan, T. Itamoto, H. Amano, A. Oshita, K. Ide, T. Asahara
Department of Surgery
Background: A right liver graft lacking the middle hepatic vein can cause 
congestion of the anterior segment in living donor liver transplantation. Various 
solutions designed to overcome this problem have been reported, including a 
right liver graft with the reconstruction of the middle hepatic vein tributaries 
using various interposition vein grafts. We did not use the extended right hemi-
liver graft including the MHV trunk because of the negative impact on donor 
safety. 
Method: Since Jan 2005, we have usually performed the reconstruction of 
MHV tributaries of the liver grafts using the recipient’s own MHV trunks 
when there are signifi cant MHV tributaries (> 5mm in diameter) during 
the donor hepatectomy The recipient hepatectomy was completed with 
preservation of middle hepatic vein tributaries. In the right-liver living 
donor transplantation, the middle hepatic vein tributaries draining segments 
V (V5) and VIII (V8) of a right lobe graft were reconstructed with the 
recipient’s own middle hepatic vein. When the recipient’s middle hepatic 
vein is too short for reconstruction of the V5, the recipient’s right or left 
hepatic vein which was harvested ex vivo from recipient liver was used as 
an interposition graft between the V5 of the liver graft and the recipient’s 
middle hepatic vein. The preservation of the MHV trunk was excluded 
when hepatocellur carcinomas (HCC) was located on the ventral side of 
the MHV or was not at least 1 cm away from the MHV trunk in patients 
with HCC. 
Results: These techniques were used in 16 branches of V8 and 15 branches 
of V5 among 21 patients. The 3-month patency rate of the V8 and V5 
reconstructed were 92% and 76%, respectively. All liver transplant patients 
that underwent these operations are alive. On the other hand, in 15 patients 
that did not undergo preservation of MHV trunk because of HCC, the 1- and 
3- year survival rates were 75% and 75%, respectively. The patients without 
reconstructed MHV tributaries had a signifi cant increase in ALT on day 14 
(344 } 243 versus 152 } 114 IU/L, p=0.029). The patients in whom the MHV 
tributaries in the right liver graft were reconstructed using the recipient fs 
native MHV trunk showed excellent results of low portal vein pressure (PVP) 
(13 }4 mmHg) after reperfusion, compared with the PVP (18 }6 mmHg) of 
those without reconstructing the MHV tributaries in right liver grafts. Except 
the ruptured HCC case, there was no recurrence of HCC among 14 patients 
with HCC that was reconstructed MHV tributaries, with mean follow-up of 
17 } 7 months. 
Conclusions: The use of the recipient fs own middle hepatic vein is a suitable 
option for reconstructing middle hepatic vein tributaries (V8 and V5) in right-
liver living donor transplantation.
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TWO-STAGE TREATMENT OF LIVER 138 
METASTASIZED NEUROENDOCRINE TUMORS OF THE 
PANCREAS, INCLUDING CLUSTER LIVER-PANCREAS 
TRANSPLANTATION
D. Ysebaert, G. Roeyen, P. Abrams, K. De Greef, S. Francque, P. Michielsen, 
P. Jorens, T. Chapelle
Antwerp University Hospital
Patients with neuroendocrine tumors (NET) of the pancreas often present with 
liver metastases, so diffuse that they are no longer suitable for hepatic resection, 
even not in a staged way. Extensive liver/pancreatic resection combined with 
simultaneous liver transplantation has been considered a treatment option, however 
results are very poor (5-year patient survival = 47%, 5-year disease free survival = 
24%). due to incomplete tumor resection (Lehnert, Transplantation 1998).
Therefore, we adopted a two-stage treatment modality for NET’s with diffuse 
unresectable liver metastases, consisting of 1) aggressive radical resection 
of primary tumor site (outside liver). 2) a waiting period of > 6 months for 
ruling out extrahepatic disease and observation of natural behaviour of the 
tumour, 3) thereafter orthotopic liver- (pancreas) -transplantation to resect all 
liver metastases, and to treat pancreatic insuffi ciencies. Risks of surgery and 
immunosuppressive therapy after transplantation must of course be balanced 
against natural course of the disease.
Since 2002 n=7 patients were enrolled in this protocol, meanwhile we hade to 
exclude n=3 patients with evidence of tumor recurrence during waiting time, 
n=1 is in his waiting time. Three patients (mean age 41,3 y) were transplanted: 
2 MEN-1 patients after 95% pancreatectomy for malignant insulinoma 
and glucagonoma and cluster liver-pancreastransplantation, 1 patient with 
malignant somatostatinoma after extensive distal splenopancreatectomy and 
solitary liver transplantation.
Although long-term follow-up is necessary for defi nite conclusions, mid-term 
follow-up (mean: 55,3 (36-70) months) is excellent: no recurrence so far in 
those patients with survival > 5 years.
Although excellent but only mid-term results are achieved, these promising 
approach should be reserved for young patients (< 50y) who have a chance to 
be cured by this agressive approach and who can endure extensive surgery.
POSTER BOARD NUMBER P1 – 336
LIVER TRANSPLANTATION FOR ACUTE LIVER 139 
FAILURE
S. Sevmis1, H. Karakayali1, F. Ozcay2, A. Torgay2, U. Yilmaz3, N. Savas3, 
B. Demirhan4, B. Bilezikci4, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Anesthesiology, 
3Baskent University Faculty of Medicine, Department of Gastroenterology, 
4Baskent University Faculty of Medicine, Department of Pathology
The only proven therapy for patients who are unlikely to recover from 
acute liver failure (ALF) is liver transplantation. Therefore, recognition and 
urgent referral to a transplant center is extremely important. In this study, we 
evaluated 23 ALF patients who had undergone liver transplantation (LT) at a 
single center during a 5-year period. The reasons for transplantation for the 
23 ALF patients were 5 hepatitis A; 6 non-A, non-E hepatitis; 2 autoimmune 
hepatitis; 6 fulminant Wilson’s disease; and 1 Amanita phalloides (mushrooms) 
poisoning, 1 cytomegalovirus virus infection, 1 hepatitis B, and 1 due to both 
hepatitis B and toxic hepatitis (with lefl unomide). Ten were female and 13 male 
and the mean age was 12 &#61617; 8 years (range, 16 months to 30 years). Six 
received right liver lobe grafts, 2 received whole liver grafts, and the remainder 
left or left lateral lobe grafts. All of the patients recovered from hepatic coma 
the day after transplantation except fi ve. Overall 5 patients died at the 2nd, 
8th, 12th, 45th, and 81st postoperative days due to three brain death, adult 
respiratory distress syndrome, and sepsis with multiorgan failure, respectively. 
Eighteen patients (78.3%) are healthy at a range of 2 to 69months’ follow-up. 
Worldwide experience with living-donor LT for ALF is limited but when it is 
required, living-donor LT is the only option for ALF in the countries with low 
organ donation rates. In such conditions, preparation of the donor in a limited 
time is a major problem. At our center, we have been able to decrease this time 
interval to approximately 3 hours including the liver biopsy of the donor.
POSTER BOARD NUMBER P1 – 337
GLYCINE PROTECTS LIVERS FROM REPERFUSION 140 
INJURY DUE TO PNEUMOPERITONEUM FOR 
LAPAROSCOPIC LIVING DONOR HEPATECTOMY: AN IN 
VIVO MICROSCOPY STUDY
A. Nickkholgh1, M. Al-Saeedi1, C. Flechtenmacher2, H. Bruns1, M. Zorn3, 
R. Liang1, M.W. Büchler1, C.N. Gutt1, P. Schemmer1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Dept. of 
Pathology, Ruprecht-Karls University of Heidelberg, 3Central Laboratory, 
Ruprecht-Karls University of Heidelberg
Background: Laparoscopic organ retrieval has been successfully performed 
for human living donor liver transplantation (LDLT). Experimental 
pneumoperitoneum induces ischemia/reperfusion injury (IRI) in liver most 
likely via activation of Kupffer cells. Glycine has been shown to ameliorate 
reperfusion injury in various animal models. Thus, this study was performed to 
assess its effects on liver after pneumoperitoneum.
Materials and Methods: Sprague-Dawley rats (200-230 g) underwent CO2 
pneumoperitoneum (12 mmHg) for 90 minutes. Some rats received i.v. glycine 
(1.5 ml, 300 mM) 10 min before pneumoperitoneum. Controls were given 
the same volume of Ringer’s solution. Subsequently, transaminases, hepatic 
microcirculation, and latex beads phagocytosis to index both liver injury and 
Kupffer cell activation were investigated. Analysis of variance (ANOVA) 
followed by t test or ÷2 (or Fisher’s exact) test were performed as appropriate. 
Results are presented as mean ± SEM.
Results: Glycine signifi cantly decreased AST, ALT, and LDH after 
pneumoperitoneum from 145 ± 19 U/L, 53 ± 5 U/L, and 500 ± 58 U/L in 
controls to 94 ± 4 U/L, 40 ± 2 U/L, and 334 ± 27 U/L, respectively (p<0.05). In 
parallel, glycine signifi cantly blunted the permanent adherence of leukocytes 
to the endothelium by up to 35% of controls (p<0.05) while the rate of 
phagocytosis decreased by more than 50% (p<0.05).
Conclusion: Glycine decreased IRI after CO2 pneumoperitoneum most likely 
via inactivation of Kupffer cells and an improved hepatic microperfusion.
PANCREASMINI-ORAL SESSION 6: 
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MYOCARDIAL PERFUSION SCINTIGRAPHY-A 141 
SENSITIVE TOOL FOR CARDIAC EVALUATION 
IN ASYMPTOMATIC DIABETICS FOR PANCREAS 
TRANSPLANTATION
S. Mehra1, A. Tavakoli1, N. Parrott1, P. Arumugam2, T. Augustine1
1Department of Pancreas and Renal Transplantation, Manchester Royal 
Infi rmary, 2Department of Nuclear medicine, Manchester Royal Infi rmary
Aim: The aim of this study is to evaluate our method of evaluation for 
signifi cant silent coronary disease prior to listing for pancreas transplantation, 
its sensitivity and implications.
Methods: All patients referred for pancreas transplantation to our institution 
undergo a stress myocardial perfusion (myoview) scan, which if positive, 
triggers referral to cardiology for further evaluation, prior to transplant listing. 
Patients are counselled that coronary evaluation could uncover signifi cant silent 
disease requiring invasive coronary management before transplant listing. 
Summary: Between January 2001 and October 2007, 238 patients were 
referred for pancreas transplantation. Complete evaluation data were available 
in 201 asymptomatic patients who underwent detailed coronary evaluation .9 
patients underwent pre-referral coronary angiography (normal). 15 patients 
didn’t undergo myoview scan (2 adolescents, 3 short onset of diabetes, 4 
dobutamine stress echo,6 others). 177 patients underwent myoview scans of 
which 116 (65.5%) were normal and were activated. 61 (31.4%) patients had 
positive myoview scans which were graded as mild to moderate reversible 
ischemia (31) or signifi cant reversible ischemia 30 (17%) and referred to 
cardiology for further evaluation. 12 of the mild to moderate group were 
considered insignifi cant and activated without angiograms. 16 of this group 
underwent angiogrm and 4 required intervention for signifi cant lesions upon 
full cardiology evaluation, awaited (3). In the signifi cant group 30 patients 
have undergone angiography with PTCA/Stent (8). CABG (3). Normal (6).
Moderate not requiring intervention (6). Diffuse cardiac disease with no 
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possible intervention (2) Awaited (5). 108 transplants have been done in this 
period with 2 perioperative coronary deaths with a normal angiogram.
Conclusions: Signifi cant silent coronary disease is present in about 20% of 
pancreas transplant referrals. Stress myocardial perfusion scanning is a sensitive 
non-invasive method of identifying patients requiring intervention without the 
need for coronary angiography in all patients. The mild to moderate positive 
group requires a more critical cardiology evaluation prior to listing. With this 
approach there is very low incidence of perioprtative coronary events.
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SUCCESSFUL SIMULTANEOUS PANCREAS AND KIDNEY 142 
TRANSPLANTATION FROM ABO-INCOMPATIBLE LIVING 
DONORS.
T. Kenmochi1, T. Asano2, K. Saigo1, M. Maruyama1, N. Akutsu1, C. Iwashita1, 
K. Otsuki1, T. Ito1
1Department of Surgery, Chiba-East National Hospital, 2Department of 
Surgery, Teikyo University Hospital
Objectives: As an option for the treatment of type 1 diabetic patients with end-
stage renal disease (ESRD) because of a limited use of brain dead donors in our 
country, we have introduced simultaneous pancreas and kidney transplantation 
from ABO-incompatible living donors. 
Patients and Methods: Recipients were 31-year-old female (Case 1). 30-year-
old female (Case 2). and 30-year-old male (Case 3). All patients were type 1 
diabetes with ESRD. Their serum C-peptide levels (CPR) were ƒ0.03ng/ml 
and hypoglycemic shocks were frequently occurred. Serum creatinine level 
was 7.55 mg/dl in Case 1 and Cases 2 and 3 had 2 year and 3 year history 
of hemodialysis. Donors were mothers (58,55,60-year-old). Although ABO 
blood types were incompatible (A ¨O in Cases 1 and 3, AB ¨B in Case 2). 
they fulfi lled our donor criteria for living pancreas and kidney transplantation. 
Pretransplant treatment for the recipients to decrease an anti-A antibody 
titer was achieved by splenectomy, double fi ltrated plasmapheresis, and 
plasma exchange according to our protocol for ABO-incompatible kidney 
transplantation. Segmental pancreatic graft was transplanted into the right iliac 
fossa using bladder drainage technique and the kidney graft into the left iliac 
fossa. Quadruple therapy by tacrolimus, MMF, predonisone, and basiliximab 
was used for immunosuppression. 
Results: All donors showed no complication including pancreatic fi stula, 
diabetes, and renal dysfunction. In all recipients, the pancreas and kidney 
grafts functioned immediately after transplantation, resulting in a rapid 
decrease of serum creatinine levels and insulin independency. All recipients 
showed positive serum CPR (2-5ng/ml). and decreased HbA1C (8.5 to 4.5% 
in Case 1, 7.5 to 5.5% in Case 2, and 9.0 to 5.9% in Case 3 at two months). 
No hypoglycemic episode was experienced after transplantation. IgM and IgG 
titers of anti-A antibody did not elevate more than 8 folds during two months. 
An antibody-mediated humoral rejection as well as an acute cellular rejection 
was not observed in both cases. Normal blood glucose curve as well as normal 
insulin secretion was obtained from 75g-oral glucose tolerance test performed 
at 4 months in all cases. Although surgical complications were not observed, 
cytomegalovirus antigenemia was positive in case 2 and 3. 
Conclusions: Our clinical data clearly demonstrated that ABO-incompatible 
pancreatic transplantation is possible using the protocol for ABO-incompatible 
kidney transplantation. Simultaneous pancreas and kidney transplantation 
from ABO-incompatible living donor may become an effective tool for type 1 
diabetic patients with ESRD especially in our country.
POSTER BOARD NUMBER P1 – 340
40 CASES OF DUODENO- DUODENOSTOMY IN 143 
PANCREAS- TRANSPLANTATION: SINGLE CENTER PROOF 
OF A SAFE AND SIMPLE TECHNIQUE
R. Viebahn1, P. Schenker1, P. Petersen2, N. Ertas1, A. Wunsch1, M. Schaeffer1, 
H. Klein3
1Knappschaftskrankenhaus/Ruhr- University, 2University of Tuebingen, 
3Klinikum Bergmannsheil/Ruhr University
Kombined pancreas- kidney transplantation (NPTX) is a life- saving procedure 
in patients with type I diabetes who suffer from end stage kidney disease and 
improves quality of life signifi cantly in a small subgroup of diabetics who require 
pancreas transplantation alone (PTA). Different technical procedures have been 
develloped successfully to perform pancreas transplantation with special respect 
to exocrine drainage: Bladder drainage by duodenocystostomy (DC). enteral 
drainage by side- to side duodenojejunostomy (DJ) or duodenojejunostomy 
via Roux en Y technique (DJR). Recently fi rst experiences were reported about 
direct anastomosis between the duodenal segment of the pancreas transplant 
and the duodenum of the recipient (DD).
Since all enteral drainage procedures are associated with the so called „tail 
down“ position of the pancreas transplant the donor duodenum frequently 
touches the recipients duodenum so that a DD seems to be a promising 
technique.
Material and Methods: Between 4/1998 and 3/2008 145 NPTX were performed 
under the responsibility of the presenting author in two different institutions. Due 
to the fact that no standards were given for the mode of exocrine drainage, DD was 
performed eventually between 1998 and 2005 when topography of the transplant 
allowed it. After 10/2005 all NPTX were performed in the Boggi- technique 
were the transplant portal vein is anastomosed to the mesenteric vein so that both 
duodena touch each other. In all these cases DD was performed so that a total 
of 40 cases was operated using DD. In the other cases 103 DJ and 2 DC were 
performed. From the DJ cases a control group was generated wich mathed by age, 
CIT, donor age, duration of diabetes and the prevalence of coagulation disorders.
Results: Patient survival was 100% in the DD group and 97% in the DJ 
group, pancreas graft survival was 95% (DD) vs 90% (DJ) after 1 year. No 
DD insuffi ciency was reported in the DD group, 2 patients in the DJ group had 
to be switched to DJR due to insuffi ciency. Both recipients were the pancreas 
had to be removed after early graft thrombosis in the DD group experienced 
uncomplicated closure of the duodenal opening wereas one of 4 patients in the DJ 
group required relaparotomy due to insuffi ciency of the jejunal closure. The need 
of oral sodiumbicarbonate substitution was slightly lower in the DJ group.
Conclusion: Duodenoduodenostomy is a safe an easy form of exocrine drainage 
in pancreas transplantation. It is equivalent to other well established techniques 
and extends the possibility of anastomotic sites especially in recipients who 
have a second transplant or had prior surgery wich does not allow other enteral 
anastomoses.
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SIMULTANEOUS KIDNEY PANCREAS 144 
TRANSPLANTATION USING RAPID STEROID TAPER WITH 
PROTOCOL BIOPSIES: COMPARISON OF R-ATG VERSUS 
ALEMTUZUMAB
R. Heilman, K.S. Reddy, A. Moss, M. Mazur, K. Mekeel, H. Chakkera, 
D. Post, D. Mulligan
Mayo Clinic Arizona
Body: In Jan 2005, we expanded the use of rapid steroid taper protocol with 
rabbit antithymocyte globulin (r-ATG) induction to patients (pts) receiving 
simultaneous kidney pancreas transplantation (SKPT). In Jan 2007, we started 
using induction with Alemtuzumab (Alem) and report our experience in this 
group of pts compared to a retrospective cohort of pts receiving r-ATG.
Of the 64 SKPTs performed at our center between Jan 2005 to Nov 2007, 
53 pts received immunosuppression with rapid steroid taper (11 pts received 
positive crossmatch Txs with long-term steroid use). 33 pts received induction 
with r-ATG (1.5 mg/kg x 4 for a total dose of 6mg/kg) while 20 pts received 
induction with Alem (30 mg single dose). Maintainance immunosuppression 
consisted Tacrolimus and MMF. Steroids were discontinued after post op day 
4. Protocol biopsies were performed at 1 month, 4 months 12 months and every 
year thereafter.
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The mean age of the pts is similar between the groups (r-ATG 45 13 yrs, Alem 
44 16 yrs). All were primary Txs except one pt in the Alem group who received 
a previous kidney Tx. Four pts became insulin dependent (r-ATG group: 2 
vascular thrombosis, 1 noncompliance; Alem group: 1 glucose intolerance) and 
2 pts lost the kidney graft (both in the r-ATG group: 1 CAN 1 noncompliance). 
Other Tx characteristics, acute rejection, CMV infection, BK nephropathy, 
graft and patient survival in the 2 groups are shown in the
 Alemtuzumab (n=20) r-ATG (n=33) p value
PRA 0% 90% 97% NS
Preemptive Tx 30% 36% NS
Biopsy confi rmed clinical acute rejection 10% 12% NS
Subclinical rejection (protocol biopsy) 5% 6% NS
CMV infection 5% 21% NS (0.23) 
BK nephropathy 0% 6% NS
Patient survival 100% 100% NS
Kidney graft survival 100% 94% NS
Pancreas graft survival 95% 91% NS
Median followup (in months) 7 22 0.0001
Conclusion: In non sensitized pts, SKPT using rapid steroid taper and 
induction with either r-ATG or Alem is safe and effective. Both induction 
agents are associated with excellent short term outcomes and the incidence of 
acute rejection, CMV and BK nephropathy are similar between the two groups. 
Alem is easier to administer and is less expensive. Further long-term follow-up 
is needed to confi rm these excellent results.
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COMBINED PANCREAS AND EN-BLOC KIDNEY 145 
TRANSPLANTATION FROM VERY SMALL PEDIATRIC 
DONORS
J. Sageshima, G. Ciancio, L. Chen, H. Illanes, R. Garcia, G.W. Burke
University of Miami, Surgery, Kidney/Pancreas Transplant
Objective: Very small pediatric donors are underutilized in pancreas 
transplantation (Tx) for fear of inadequate islet cell mass and increased risk of 
technical complications. The aim of this study is to determine the lower age and 
size limit for pancreas donors.
Methods: We retrospectively reviewed 11 type 1 diabetic uremic patients who 
received a pediatric pancreas and en-bloc kidney Tx with Thymoglobulin plus 
daclizumab induction and triple maintenance immunosuppression (tacrolimus, 
steroids, and mycophenolate or sirolimus).
Results: All donors were 7 years old or younger and weighed 30 kg or less; of 
those, 8 donors were 4 years or younger and weighed 16 kg or less. The youngest 
donor was 17 months and the smallest donor weighed 11 kg. All recipients were 
adults weighing more than 60 kg (Table). Postoperative anticoagulation was 
used to prevent thrombotic complications. No patient required either dialysis or 
long-term insulin therapy after Tx. With median follow-up of 27 months (range: 
8 mo – 7 years). patient, pancreas and kidney graft survival were 100%. Current 
mean serum creatinine is 1.3 mg/dL and HbA1c is 5.4%. No acute rejection 
episode was observed; polyoma virus-associated nephropathy was seen in one 
patient 32 months after Tx (current creatinine: 3.6 mg/dL). One patient who 
received organs from a 13 kg donor lost the left kidney 10 days after Tx due to 
renal artery thrombosis while retaining the function of the right kidney (current 
creatinine: 1.6 mg/dL). Another patient ruptured the right kidney due to renal 
vein stenosis, which required mesh repair. Four recipients developed splenic 
vein thrombosis, which was successfully treated with intravenous heparin 
infusion. Mixed-meal challenge tests performed > 12 months after Tx (n=2) 
demonstrated normal glucose tolerance and C-peptide response.
Table
Donor Age: 3.0 (1.4 – 7) years
Donor Body Weight: 15 (11 – 30) kg
Kidney Weight (Lt + Rt): 90 (47 – 157) g
Recipient Age 45: (39 – 56) years
Recipient Body Weight: 70 (60 – 85) kg
Donor/Recipient Weight Ratio: 0.22 (0.15 – 0.40) 
Cold Ischemia Time (Pancreas/Kidney): 23 (16 – 28) /24 (14 – 30) hours
Warm Ischemia Time (Pancreas/Kidney): 50 (37 – 69) /66 (50 – 106) minutes
Conclusion: Our observation suggests that combined pancreas and en-bloc 
kidney Tx from very small pediatric donors demonstrates excellent outcome. 
Although technical complication rates might be slightly higher than with adult 
donor pancreas Tx, organs from very small donors seem to have the capacity 
to meet the metabolic demand of adult recipients. Donors aged as young as 2 
years and weighing as little as 15 kg should be considered for pancreas Tx.
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EFFICACY AND SAFETY OF OCTREOTIDE 146 
PROPHYLAXIS FOR PREVENTING TECHNICAL 
COMPLICATIONS AFTER PANCREAS TRANSPLANTATION£ºA 
META-ANALYSIS OF RCTS
Y.P. Li, L.L. Li, Y.S. Li, D. Long, L.L. Pang, N. Zhao, L. Feng, S.F. Li, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Technical complications related to the exocrine are major causes leading 
to graft loss after pancreas transplantation. Octreotide has been widely 
used in the management of minimizing these complications. However, 
the role of prophylactic octreotide remains controversial. The objective of 
this review was to determine evidence for the effectiveness and security of 
prophylactic octreotide for preventing technical complications after pancreas 
transplantation.
Methods: We searched the Cochrane library (2008, Issue 1). PUBMED 
(1970 to Feb 2008) and EMBASE (1974 to Feb 2008) and selected six studies 
concerning prophylactic octreotide for preventing technical complications after 
pancreas transplantation. Of these, three RCTs (enrolling a total of 82 patients) 
were identifi ed. Meta-analysis analyzed the data. Types of outcome measures 
included pancreatitis, fi stula, thrombosis, rejection, hemorrhage, infection, 
pancreas and pancreas survival.
Results: Octreotide group had lower levels of serum amylase and amylase in 
the applied period, though the difference reached statistical signifi cance only 
for serum amylase in the fi rst postoperative day. The incidences of technical 
complications had no signifi cant difference between octreotide group and 
control group. The value of OR for pancreatitis was 0.41 (95% CI 0.06 to 2.94). 
1.13 (95% CI 0.06 to22.10) for fi stula, (OR 2.06, 95% CI 0.32 to 13.13 ) for 
thrombosis, 0.96 (95% CI 0.35 to 2.61) for rejection, 0.67 (95% CI 0.12 to 
3.67) for hemorrhage, 0.71 (95% CI 0.06 to 8.19) for infection and 0.65 (95% 
CI 0.15 to2.86) for pancreas survival. The differences between the two groups 
in patient survival at 6 and 12 months were not statistically signifi cant.And 
there was not any signifi cant effect of octreotide on CsA or FK506 absorption.
Conclusions: Currently available evidences from RCTs do not support 
prophylactic octreotide for preventing pancreatitis, fi stula, thrombosis, 
rejection after pancreas transplantation. And there is unavailability on pancreas 
and pancreas survival. Until more research is completed, the effectiveness 
of prophylactic octreotide following pancreas transplantation cannot be 
determined because studies published to date are fl awed by biases. Large, 
appropriately designed RCTs are needed.
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OUTCOMES OF SOLITARY PANCREAS TRANSPLANTS 147 
RELATED TO INDUCTION THERAPY AND TRANSPLANT 
TYPE
J. Odorico, S. Hanish, Y. Becker, H. Sollinger
University of Wisconsin Hospital And Clinic
We sought to review our experience of solitary pancreas transplants over the 
last decade and evaluate outcomes with different induction strategies.
A single institution, retrospective review of 133 consecutive solitary pancreas 
transplants from 1997 to December, 2006, was performed. The analysis 
included 48 pancreas after kidneys (PAK). 24 pancreas after simultaneous 
kidney pancreas transplant (PASPK). and 61 pancreas transplants alone (PTA). 
Patients received either daclizumab or basiliximab (anti-Il2R) or alemtuzumab 
(ALEM). End points evaluated were time to initial biopsy proven rejection, 
patient and graft survival, death censored graft survival, and opportunistic 
infections. Outcomes were compared among different induction groups for the 
entire cohort and then for each transplant type. Analysis was performed using a 
Kaplan-Meier Cox proportional hazards model.
For the entire cohort, patient survival was signifi cantly worse at two years 
in the ALEM group vs. anti-IL2R (88% vs. 100%, p=0.02). The Alem group 
also trended toward more opportunistic infections whereas the anti-IL2R 
group trended toward less graft loss. Time to initial rejection rates were not 
signifi cantly different among the groups. ALEM trended toward less rejection 
at 2 years. Death censored graft loss was signifi cantly better in anti-IL2R 
vs. ALEM (18% vs. 33% at 2 years, p=0.01). Subgroup analysis revealed 
that in PAK, ALEM had a 100% incidence of opportunistic infections within 
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the fi rst year whereas the incidence in anti-il2R was only 15%, (p<0.02). 
Further, PAKs in the ALEM group experienced signifi cantly higher two year 
recipient mortality vs. anti-IL2R (20% vs. 4%, p=0.006). whereas there was 
no advantage to ALEM with regard to rejection rates in PAK patients. In 
contrast, there was a trend toward improved rejection rates in ALEM treated 
PTA patients compared to other induction agents, whereas patient mortality 
and graft survival rates were similar between the induction groups. In general, 
lower opportunistic infection rates were seen in PTA patients compared to 
PAK patients.
Analysis of solitary pancreas transplants treated with different induction 
strategies reveal that anti-IL2R monoclonal antibodies or alemtuzumab 
are associated with acceptable graft and patient survival. The higher risk of 
opportunistic infections and poor patient outcomes in PAK recipients receiving 
alemtuzumab calls into question its use in this setting.
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FORTY SEVEN CONSECUTIVE PANCREAS 148 
TRANSPLANTS WITHOUT STEROIDS; A SUCCESSFUL 
ALTERNATIVE
A. Asderakis, A. Ilham, C. Puliati, R. Chavez
Transplant Unit, University Hospital of Wales, UK
Background: The widely known adverse effects of long-term therapy with 
steroids have motivated interest in steroid-free immunosuppression. It is 
especially attractive in pancreas recipients because it avoids the increased 
insulin resistance, lipid problems, and eye complications caused by steroids. 
This should be counterbalanced with the increased risk and detrimental effect 
of a rejection occuring in Pancreas Transplantation.
Methods: We evaluated the outcome of a steroid-free immunosuppressive 
protocol in pancreas transplant recipients. Between December 2004 and 
March 2008, a total of 47 pancreas transplant recipients received steroid-free 
immunosuppression, consisting of induction with thymoglobulin (1.25 mg/kg 
for fi ve days). and maintenance on tacrolimus adjusted to a target trough level 
between 5-10 ng/l for the fi rst month (and 4-8 subsequently) and Mycophenolate 
Mofetil up to 2g daily (median dose 1g).
Results: 32 patients received simultaneous pancreas and kidney transplant 
(SPK) and 15 pancreas after kidney transplant (PAK). Median recipient age 
was 38 years, median donor age was 40 and mean HLA mismatch was 4.2. 
Patient and pancreas survival rates were 95.7% and 84%, respectively. Pancreas 
censored for death survival was 87%.
Among the SPK there were 3 grade IA and IB biopsy proven rejections as 
well as 2 biopsy proven borderline rejections, which were treated giving an 
overall rejection rate of 15.6% (including borderline). Two of those patients 
presented with severe rejection 3 months post-transplant. The fi rst one due to 
severe gastroparesis and malabsorption lost both the kidney and the pancreas 
despite aggressive treatment. The second one had steroid resistant rejection and 
was successfully rescued with ATG, repeated steroid pulses and Rituximab. 
Only this patient requires long term maintenance steroids following her 
treatment. There were also two presumed pancreas only rejection in the PAK 
group, diagnosed on the basis of elevated amylase, CRP and absence of clinical 
symptoms of pancreatitis, that were treated successfully. None of them required 
long-term steroids.
Reasons for patient loss included one death from aspiration pneumonia, and 
one early cardiovascular death.
All other patients who have been treated for rejection have been off steroids 
for the duration of follow-up. Patients with functioning pancreata have a mean 
HB1Ac of 5% and normal insulin and peptide C levels.
Conclusion: Excellent graft survival with a low incidence of acute rejection 
can be achieved using a fully steroid-free immunosuppressive regimen using 
appropriate induction treatment.
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ASYMMETRIC DIMETHYLARGININE (ADMA) 149 
CONCENTRATIONS ARE ELEVATED IN RENAL TRANSPLANT 
RECIPIENTS
M. Klinger, R. Krawczyk, W. Weyde, M. Krajewska, K. Madziarska
Department of Nephrology And Transplantation Medicine, Medical University
Cardiovascular morbidity and mortality remain high after renal transplantation. 
ADMA is a strong endogenous inhibitor of nitric oxide synthase, and by 
reducing nitric oxide availability it may trigger pro-atherogenic effects. The 
aim of the study was to evaluate ADMA levels in two groups of renal transplant 
recipients (RT pts): 1) 18 RT pts between 6 and 24 months post-transplantation 
(median GFR, aMDRD formula: 66.4 ml/min) and 2) 24 RT pts over 60 
months post-transplantation (median GFR: 68.6 ml/min). All RT pts received 
an immunosuppressive regimen with calcineurin inhibitors. The control group 
encompassed 37 healthy volunteers. The tested groups were matched with 
respect to age and gender. ADMA concentrations were measured by the HPLC 
method. The plasma ADMA levels (mean ± SD in μmol/l) in the study groups 
were 0.84 ± 0.36 in the healthy controls, 1.09 ± 0.52 in the RT pts 6-24 months 
post-transplantation (p=0.06 versus controls). and 1.23 ± 0.71 in RT pts >60 
months post-transplantation (p<0.05 versus controls).
Conclusions: Plasma ADMA concentrations rise during the post-transplantation 
period, reaching signifi cantly higher values than in healthy controls fi ve years 
after transplantation.
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LONG TERM RESULTS AFTER SIMULTANEOUS 150 
PANCREAS-KIDNEY TRANSPLANTATION USING DONORS 
AGED 45 YEARS OR OLDER
P. Schenker, O. Vonend, A. Wunsch, M. Schaeffer, R. Viebahn
Ruhr-University-Bochum
Background: With the shortage of organ donors there is a critical need to use 
all available pancreas grafts for transplantation.
Methods: From 06/1994 – 12/2006 we performed 340 pancreas transplantations 
(317 SPK, 5 PTA, 18 PAK) including 69 (20%) transplantations from donors 
aged 45 years (y) or older. Pancreas grafts from older donors (OD) > 45y 
were analyzed for graft and patient survival as well as surgical complications, 
compared to results from younger donors (YD) < 45y.
Results: Overall patient, kidney- and pancreas graft survival were 89%, 78% 
and 70%, with a mean follow up of 79 month. Recipient characteristics were 
comparable in both groups. In the OD group mean donor age was 47.8y (±2,1) 
vs. 27.9 y (±10.3) in YD group. Cumulative patient survival was (OD vs. YD) 
96% vs. 98% after 1y, 82% vs. 91% after 5y and 82% vs. 88% after 10y. 1-,5- 
and 10-year kidney survival were 82%, 72%, 57% in OD and 93%, 83%, 73% 
in YD. Pancreas transplant survival were after 1-,5- and 10-y 69%, 60%, 45% 
in OD and 88%, 76% and 72% in YD. There were 14 (20%) cases of venous 
thrombosis in the OD group and 25 (9%) in the YD group (p= 0.012).
Conclusions: The results demonstrate that utilization of pancreas grafts from 
donors > 45 years results in acceptable outcomes after SPKT and could expand 
the organ donor pool. In the OD group patient survival is slightly lower than 
in the YD group, whereas pancreas graft function is signifi cantly inferior 
(p<0,01). Since venous thrombosis is the main reason for pancreas graft loss in 
OD group, anticoagulation is essential.
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MINI-ORAL SESSION 7: 
ORGAN PROCUREMENT AND PRESERVATION
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HTK: WHY DOES IT APPEAR TO CAUSE DELAYED 151 
GRAFT FUNCTION FOLLOWING PROLONGED COLD 
ISCHAEMIA?
C. Corps1, M. Shires2, D. Crellin2, D. Potts3, J. Pratt2, R. Smolenski4, 
J.P.A. Lodge1
1St. James’s University Teaching Hospital, 2LIMM, Leeds University, 
3Department of Biological Science, Leeds, University, 4Harefi eld Hospital, 
Imperial College London,
Introduction: Several papers recently comparing HTK to other preservation 
solutions in both liver and kidney transplants, suggest that HTK is as good, as 
or better than UW for short cold ischaemic times, such as in live donation, but 
not as effi cient for longer periods of cold ischaemia, causing a higher number 
of cases of delayed graft function. Work carried out in our institute looking at 
energy levels, metabolites and histology show some reasons why this occurs.
Methods: Livers were perfused with HTK, UW or a LS (a new phosphate based 
preservation solution, under development at our institution) and at various time 
points, tissue samples were taken to be analysed for ATP and metabolites by 
HPLC, or for histological analysis.
Results: Fig.1: Change in Energy Charge  Fig.2: Change in Uridine Levels over
24 hours.  24 hours.
 
Energy Charge is refl ective of what is happening in ATP, ADP and AMP levels 
and is calculated from the equation:
Energy Charge = (ATP + 0.5*ADP) / (ATP + ADP + AMP) 
The high energy charge seen with HTK plateau after 5 minutes, by 60 minutes 
it begins to drop, following the same trend as other samples. The plateau is due 
to the excess glucose being available, but after 1 hour this is beginning to be 
used up.
The low level of Uridine, needed for glycogen production, found in HTK, 
means that at reperfusion there will be none available for glycogen synthesis; 
whilst the higher concentrations found in LS and UW may be advantageous to 
these livers following reperfusion.
Glycogen is found to have disappeared from hepatocytes which were preserved 
in HTK after only 5 minutes, whilst it was still visible in hepatocytes perfused 
in UW after 2 hours and in those perfused in LS glycogen was still present 
after 24 hours.
Conclusion: HTK contains α – Ketaglutarate, which allows the TCA cycle 
to continue, even in anaerobic conditions, so using up the lactate produced 
by glycolysis. This means that more glucose is required for glycolysis to 
occur; therefore glycogen is broken down in the liver into glucose. This can 
be seen by the initial high energy charge, due to glycolysis occurring and 
the rapid breakdown and depletion of glycogen from hepatocytes. Once the 
glycogen has been broken down and all the glucose used up, glycolysis can 
no longer occur, so the TCA cycle also has to halt and hence the decline in 
energy charges.
Overall HTK does well for the fi rst 2 hours but then any advantage seen 
initially starts to disappear. A liver perfused in HTK and transplanted after 120 
minutes would react like one from a person starved for a period, as it has no 
energy charge, glycogen store or ability to synthesis glycogen due to lack of 
Uracil. Whereas LS and UW show higher levels of uracil and do not lose their 
glycogen content to the same extent.
These results go someway towards answering the question of why HTK causes 
delayed graft function after longer periods of cold ischaemia.
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N-ACETYLCYSTEINE BEFORE CEREBRAL 152 
ANGIOGRAPHY INLUENCES GRAFT FUNCTION AFTER 
KIDNEY TRANSPLANTATION FROM DECEASED DONORS
B. Grandtnerova1, J. Miklusica2, L. Laca2, M. Fani2, M. Adamik2, E. Kurca3, 
K. Machalekova4, H. Polacek5
1Transplant Centre, Faculty Hospital Martin, 2Clinic of Vascular and 
Transplant Surgery, Faculty Hospital Martin, 3Clinic of Neurology, Faculty 
Hospital Martin, 4Institut of Pathological Anatomy, Faculty Hospital Martin, 
5Clinic of Radiodiagnostics, Faculty Hospital Martin
N-acetylcysteine (NAC) is a potent antioxidant that scavenges a wide variety 
of oxygen-derived free radicals. It may prevent contrast agent-induced 
nephrotoxicity as well as decrease reperfusion damage in experimental 
transplantation.
Objective: to evaluate infl uence of NAC administration before cerebral 
angiography (AG) in brain death donors on subsequent kidney graft function.
Patients and Methods: Organ donors were sorted into 3 groups: group A (n=19) 
– cerebral AG without NAC, group B (n=37) – 600 mg of NAC administrated 
IV immediately before AG, group C (n=24) – clinical determination of brain 
death only. Mean age was 44 ± 2.9 vs 40.7 ± 2.5 vs 41.8 ± 3 years (p = ns). 
best GFR (Cocroft – Gault formula) 2.0 ± 0.18 vs 2.27 ± 0.11 vs 1.67 ± 0.11 
ml/s (B vs C p < 0,01). S-Na before harvesting 147 ± 3 vs 143 ± 1 vs 144 ± 
2 mmol/l (p = ns). Kidney recipients were sorted into 3 groups corresponding 
with their donors. Mean age was 44.5 ± 2.8 vs 49 ± 1.6 vs 47.8 ± 2.3 years (p= 
ns). cold ischemia time 883 ± 56 vs 768 ± 63 vs 703 ± 69 min (p = ns). median 
compatibility index 9.5 vs 13 vs 12 (p = ns). In zero biopsies, the extent of 
glomerular sclerosis, tubular atrophy and interstitial fi brosis was comparable 
between all groups; the extent of mild arteriolar hyalinosis was slightly higher 
in group B. Neither the numbers of delayed graft function nor rejection episodes 
were signifi cantly different.
Results: After transplantation, we found signifi cant differences in 24-hour 
creatinine clearance corrected for body surface area between 3 groups of 
recipients. At day 7: CrCl was 0.49 ± 0.08 vs 0.87 ± 0.08 vs 0.94 ± 0.1 ml/s 
(p < 0,01); at the 1st month: 0.72 ± 0.05 vs 0.93 ± 0.07 vs 1.14 ± 0.1 ml/s (p 
< 0,01); at the 3rd month: 0.75 ± 0.07 vs 0.97 ± 0.05 vs 1.19 ± 0.07 ml/s (p < 
0,001) and at one year (group A and B available only): 0.84 ± 0.09 vs 1.26 ± 
0.13 (p < 0.05).
Conclusions: Our results suggest that kidney graft function up to one year 
after Tx was signifi cantly better if brain death donors were pre-treated with 
NAC before cerebral angiography. However, kidney graft function from donors 
pre-treated with NAC was still slightly worse that from donors with clinical 
determination of brain death only.
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RECOVERY OF WARM ISCHEMICALLY DAMAGED 153 
KIDNEYS USING THE AIRDRIVE PERFUSION SYSTEM
M.C. Schreinemachers1, B.M. Doorschodt1, M.M. Idu1, R.H. Tolba2, 
T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands, 
2University Clinic of Aachen, Aachen, Germany
Introduction: The gold standard for preservation of warm ischemically damaged 
kidneys is cold storage (CS) using HTK solution. However, hypothermic 
machine perfusion (MP) has proven to be benefi cial in the preservation of warm 
ischemically damaged kidney grafts. Recently, a disposable perfusion system 
for oxygenated hypothermic preservation of kidney and liver grafts has been 
developed, the Airdrive (AD). For use with the AD, also a new low-viscosity 
perfusion solution was developed, named Polysol (PS).
The aim of the study was to assess the effi cacy of the AD MP system in 
combination with PS, for the preservation of warm ischemically damaged 
kidney grafts in a porcine autotransplantation model in comparison to CS using 
HTK or PS and uninephrectomy controls.
Methods: Pigs (25-36 kg) underwent left nephrectomy after clamping the 
renal vessels for 30 minutes. Kidney grafts were fl ushed with PS (n=6) or HTK 
(n=6) and stored for 20 hr at 4 C (CS) or fl ushed with PS and perfused in the 
AD (n=6) for 20 hr using PS. Pulsatile perfusion was performed with a mean 
arterial pressure of 20 mmHg at a temperature of 2-6 C. After the preservation 
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period, the preserved kidney was heterotopically implanted and the contralateral 
kidney removed. As controls, pigs underwent uninephrectomy (Uni, n=4). 
Renal function was assessed daily for seven days. Seven days posttransplant, 
animals were sacrifi ced and the kidney grafts removed. 
Results: All animals survived for 7 days. All PS-AD and PS-CS preserved 
grafts showed immediate function, as demonstrated by urine production within 
the fi rst 24 hr after reperfusion as compared to 3 out of 6 in the HTK CS group. 
Renal function of warm ischemically damaged grafts preserved using PS-AD 
did not differ from renal function of non-transplanted, non-ischemic kidneys in 
the uninephrectomy control group. Peak serum creatinine and peak blood urea 
values did not differ between both groups (PS-AD 286.7 ± 37.0, Uni 170.8 ± 
27.1 umol/l, p=0.053 and PS-AD 10.0 ± 1.4, Uni 6.5 ± 1.0 umol/l, p=0.105, 
resp.). Both the Airdrive MP and Polysol CS groups showed improved renal 
function compared to HTK stored grafts (creatinine area under the curve (AUC) 
p<0.0001 and p<0.001, resp.) with more favourable results for PS-AD when 
compared to PS-CS (creatinine AUC, p<0.001). PS-AD creatinine clearance 
rates did not differ from the Uni group and were higher than the HTK and PS-
CS groups (creatinine clearance rate AUC, PS AD vs HTK CS p<0.0001, PS 
AD vs PS CS p<0.01). 
Conclusion: Perfusion preservation of warm ischemically damaged porcine 
kidney grafts using the novel Airdrive MP system in combination with the new 
Polysol solution results in improved preservation quality compared to CS using 
HTK or Polysol. A complete functional recovery was seen in the Airdrive MP 
group, comparable to non-transplanted controls. This study demonstrates for 
the fi rst time that full functional recovery of pre-damaged kidney grafts can 
be achieved with oxygenated pulsatile perfusion using the Airdrive MP system 
with Polysol.
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UTILIZATION OF PULSATILE PERFUSION WITH 154 
TISSUE PLASMINOGEN ACTIVATOR CONTAINING 
PERFUSATE IN DECEASED DONOR KIDNEYS WITH 
EXTENSIVE INTRAGLOMERULAR THROMBOSIS
D. Nghiem, K. Sureshkumar
Allegheny General Hospital
Introduction: Pulsatile perfusion (PP) is known to improve delayed graft 
function and tissue plasminogen activator (tPA) can lyse thrombi. We studied 
the role of PP with tPA containing pefusate in deceased donor kidneys (DDK) 
with 50% thrombosed glomeruli and hence rejected by other transplant 
centers.
Material and Methods: Fourteen DDK with extensive intra-glomerular 
thrombi on primary biopsies were preserved on a RM3 apparatus using HTK 
solution containing 200 mg of tpA. Wedge biopsies were performed prior to 
and after PP with tpA containing perfusate.
Results: Causes of donor death were: closed head trauma for 8 kidneys, anoxia 
for 2 kidneys and stroke for 4 kidneys. Average donor age was 33.3 years (range 
17-55) who had fi nal 24 hour urine volume of 1933 ml (1300-2500). terminal 
serum creatinine of 1.8 mg/dl (0.3-3.3) and BUN of 20 mg/dl (11-29).Donor 
had an average WBC count of 10,000/μL (4,000-20,300) and a platelet count 
of 128,000/μL (53,000-474,000). The kidneys were preserved by PP with tpA 
containing perfusate and had initial fl ow of 47 ml (19-105) which improved to 
111 ml/min (55-196) after 16.17 hours (7-24). Resistive Indices (RI) decreased 
from 0.69 (0.4-1.57) to 0.26 (0.12-0.45) at 4.2 degrees C (3.2-5.1).Biopsies after 
PP showed a reduction in the extend of microvascular and glomerular thrombi 
from 50% to 23%. Recipients averaged 54.9 years of age (range 37-67). received 
antibody induction,4 days of steroids and maintenance immunosuppression 
with calcineurin inhibitor and MMF. Average cold ischemia time was 35.5 hours 
(22.4-51.1). One patient had primary allograft non-function, 3 required transient 
hemodialysis and 10 had prompt allograft function. Average recipient follow-up 
was 10 months (1-18).with serum creatinine of 4.3 mg/dl (1.9-9.7) at 1 week, 
2.0 mg/dl (1.4-3.2) at 1 month and 1.8 mg/dl (1.2-2.9) at last follow-up.
Conclusion: 1) Reanl allografts with extensive microvascular thrombosis 
showed improve biopsy appearance following PP with tpA containing perfusate. 
2) Improvements in PP parameters such as decrease in RI and increase in fl ows 
permitted successful transplantion of such kidneys which otherwise would have 
been discarded. 3) PP with tpA containing perfusate appears to be benefi cial for 
kidneys with extensive microvascular thrombosis.
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GENES ASSOCIATED WITH HEART FAILURE DETECT 155 
KINDEYS AT RISK FOR DELAYED GRAFT FUNCTION
T. Mueller, L. Cairo, P. Halloran
University of Alberta
A recent review described biological processes associated with heart failure 
[N Engl J Med 2007; 356: 1140-1151]. In particular, alterations in myocardial 
energy metabolism seem to refl ect chronic heart failure. Our hypothesis was 
that transcript changes of genes associated with heart failure can also score 
kidney injury at time of transplantation.
Based on the described biological processes, the corresponding metabolic 
pathways were identifi ed (KEGG library) and one representative gene chosen 
arbitrarily: ACAT1 – fatty acid utilization; G6PC glucose utilization; PPARA 
– fatty acid metabolism; SDHC respiratory chain; ATP6V1A ATP synthase; 
NDUFS1 oxygen consumption; PPARGC1A – oxidative phosphorylation; 
SLC6A8 creatine transporter; CKMT1 mitochondrial energy homeostasis; 
ABCA1 ATP transfer. The expression of these heart failure genes were measured 
in post-reperfusion implant biopsies of a total of 117 kidneys (53 DD, 64 LD 
kidneys) using Affymetrix microarrays. The transcriptome was analyzed by 
unsupervised hierarchical clustering and principal component analysis (PCA) 
methods and related to clinical phenotypes.
The transcript levels of the heart failure genes differentiated the kidneys into 
two major groups, group A comprising 51 (47 LD and 4 DD) and group B 66 
samples, resp (17 LD and 49 DD). These groups were signifi cantly different for 
the occurrence of DGF (group A 2%, group B 15%, p < 0.05). The heart failure 
transcriptome further revealed two subclusters within the group B kdineys that 
differed in regard to long-term transplant function (s-crea month 1 to 12, p < 
0.05).
The PCA analysis shows the continuity in the distribution of the kidney 
samples, from LD kidneys on the right to the DD kidneys on the left. The 
kidneys that developed delayed graft function (DGF) are scattered to the far 
left. DGF cases due to post-transplant factors (i.e. hypotension n=2 and sepsis 
n=1) are indicated by circles, they distribute randomly.
Thus the heart failure transcriptome scores the quality of donor kidneys at 
time of transplantation. This indicates stereotyped injury and repair responses 
among different organs, and demonstrates that altered metabolism is a common 
theme in organ injury
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ORGAN DONATION PROCESS IN THE NETHERLANDS 156 
BETWEEN 2005 AND 2007 QUANTIFIED; MAJORITY OF 
DONOR POTENTIAL LOSS EXPLAINED BY RELATIVES’ 
REFUSAL
H. van Leiden, N. Jansen, A. Hoitsma, B. Haase-Kromwijk
Dutch Transplant Foundation
Purpose: The Netherlands are still confronted with an absolute shortage of 
organ donors just like many other countries. The last 10 years the number of 
deceased heart beating (HB) and non-heart beating (mainly NHB category 3) 
donors fl uctuated around 200 donors, except for the year 2007 (257 donors). 
With the Dutch Medical Record Review, implemented in two thirds of all 
hospitals in the Netherlands from the years 2005 to 2007, we had insight in the 
number of potential organ donors. We quantifi ed the major issues in the process 
of organ donation and could explain changes in the number of donors yearly 
referred for organ donation, that paralleled changes in donors referred for organ 
donation in the whole country in the years 2005, 2006 and 2007.
Material and Methods: Medical records of patients died in intensive care 
units (ICU) from 64 hospitals during the years 2005 to 2007 were reviewed by 
transplant coordinators and donation offi cers. Data regarding organ donation 
were collected in a centrally registered database.
Results: The medical potential of ventilated HB donors, and NHB donors 
aged 65 years or younger fl uctuated around 480 donors. Doctors detected these 
donors in 96% (2005) to 99% (2007) and consulted the national Donor Register 
(DR) more often as well (from 87% to 92% in 2007). In the DR Dutch citizens 
can record their will on donation. The registered consent rate for donation in 
the DR, when consulted, increased from 17% in 2005 to 21% in 2007, while the 
registered refusal rate remained stable (17-18%).
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When the DR was not decisive or not consulted, relatives had to decide for 
donation. Relatives were not requested in 10% of these cases. Most reported 
reasons for not requesting were absence of the relatives or strong emotions 
among relatives. The relatives’ refusal rate was 66% in 2005 and increased 
to 71% in 2006, but decreased signifi cantly to 59% in 2007. Of the medical 
potential 68-69% was fi nally not referred for organ donation in the years 2005 
and 2006, but in 2007 this total loss was 59%. Thereby, refusal by relatives 
accounted for about 60% of this lost group of potential donors during these 
years.
Conclusion: The potential of organ donors is 2-3 times higher than the number 
of donors reported for donation. Most issues in the donation process from 
donor identifi cation till donor referral, including consent in the DR improved in 
recent years. The increase in donation in 2007 can be explained by a decrease in 
refusal by relatives. Thus far relatives still turned out to be the most restrictive 
factor in the organ donation process. Therefore the request process among 
relatives still need special attention to increase the number of organ donors in 
the Netherlands.
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KIDNEY TRANSPLANTATION FROM UNCONTROLLED 157 
CARDIAC DEATH AND BRAIN-DEATH DONORS.
COMPARISON OF EARLY RESULTS.
O. Reznik1, S. Bagnenko1, I. Loginov1, A. Ananyev1, A. Skvorzov1, 
I. Ulyankina1, Y. Moysyuk2
1Transplantology Department of Saint-Petersburg’s State Research Institute 
For Ememrgency, 2National Research Institute of Transplantology and 
Artifi cial Organs
Introduction: Due to the lack of donor’s organs the interest to such resource of 
organs as uncontrolled donors after cardiac death (uDCD) is appeared. The number 
of brain dead donors is unsatisfactory in Russia, and only uncontrolled NHBD 
(Maastricht category II and IV) can use as a recourse for kidney transplantation 
according to legislation. The use of kidneys from uDCD remains disputable. The 
main problem is ischemically-reperfusion injuries which caused by signifi cant 
warm ischemic time (WIT). This problem leads to the need to have the reliable 
tool for estimating quality of kidneys before transplantation, and good instrument 
for preventing inevitable ischemic-reperfusion injury after this one.
Materials and Methods: From December 2005 till July 20 were studied 3 groups 
of recipients. The results of transplantation of 21 pump perfused kidneys (study 
group, PP DCD) were compared with 17 cold stored kidneys (control group, CS 
DCD) from the same 22 uDCDs. All DCDs were II category (Maastricht class., 
1995). The WIT was defi ned as the time between cardiac arrest and the start of 
initial perfusion of kidneys “in situ”. In this defi nition didn’t include the agonal 
period with unstable hemodynamic. The 30-minute advanced cardiopulmonary 
resuscitation was obligatory in each case. Average WIT was 42.7±1.6 min (min 
34.0; 65.0 max). The recipients of kidneys from brain-death donors compounded 
the comparison group (n-31). The kidneys from BDDs underwent cold storage 
method of preservation. The characteristics of uDCDs and BDD are shown in Table 
1. The comparison of early postoperative results is presented in Table 2 and Fig.1.
Table 1. Characteristics of donors groups.
Parameters BDDs, n-28
uDCDs,
n-22
p
Age 40,0±2,0 49,3±1,5 <0,001
Dopamine, mkg/kg/min 4,7±0,5 10,0±0,8 <0,001
Serum creatinine, mmol/l 89,3±5,4 125,9±17,3 <0, 05
Diuresis/last hour 0,8±0,1 0,3±0,1 <0,001
Table 2. Comparison of early postoperative parameters
Parameters Control DCD group (cold-stored). n-17
Study DCD (pump 
perfused) group, n-21
Comparison BDD 
group, n-31
Immediately function 3 (18%) ** 10 (48%) * 23 (47%) *
Delayed function 14 (82%) ** 11 (52%) * 14 (53%) *
Heamodialysis/30 4.9±0.9** 2.3±0.6* 2.7±0.3*
Creatinine D21 376.9±27.4** 213.0±30.0* 206.7±23.5*
Creatinine D 90 177.0±7.4** 139.7±7.0* 124.0±4.8*
Discarded kidneys 5 1 0
Rejection episodes/30 4 1 2
PNFT 3 0 0
Surg.complications 
CCcocomplications 3 1 1
*p >0,05; **p<0,05.
Fig.1 Serum creatinine in different groups of recipients (DCD PP – recipients 
pump perfused kidneys from DCD, DCD CS – recipients of the cold stored 
kidneys from the same DCDs, and BDD – recipients of the cold stored kidneys 
from BDD) 
Results: The use of the recovering effects of pulsatile perfusion has allowed 
the use for transplantation the kidneys from uDCD with good clinical results. 
At the same time, 5 pair kidneys from control group were discarded and results 
were worse: the rate of immediate function in study group was 30% higher than 
in the control group. The creatinine level in control group was two times as high 
on day 21 and in 3 months after transplantation, compared to the study group. 
The results of transplantation pump perfused kidneys from uDCDs don’t differ 
from results of transplantations of the cold stored kidneys from BDDs on 21st 
and 90th day after operation.
Conclusion: The use of machine perfusion is the effective instrument for 
improving uDCD kidneys function as well as for enlarging kidney’s donor’s 
pool.
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IMPROVED PRESERVATION OF THE RAT HEART 158 
USING CELSIOR SOLUTION SUPPLEMENTED WITH A 
RECOMBINANT HUMAN NEUREGULIN-1 PEPTIDE
A. Jabbour1,2, L. Gao1, J. Kwan1, A. Watson1,2, X. Liu3, M. Zhou3, 
R.M. Graham1,2, M. Hicks1,2, P.S. Macdonald1,2
1Victor Chang Cardiac Research Institute, 2St Vincent’s Hospital, Sydney, 
Australia, 3Zensun (Shanghai) Sci & Tech Co., Ltd., Shanghai, China
Background: The neuregulin-1/ErbB receptor complex plays a critical role 
in normal heart function and in the adaptation of the heart to injury. In adult 
cardiomyocytes NRG-1 protects against myofi brillar disarray and promotes 
cell survival, via pro-survival pathways involving ERK1/2 and PI3-K/Akt via 
activation of ErbB2/4 receptors. We have shown previously that rhNRG-1, 
a 61-amino acid receptor-active recombinant human neuregulin-1 (beta2a 
isoform) peptide improves cardiac function and survival in various animal 
models of ischaemic, dilated and viral cardiomyopathy.
Hypothesis: That the addition of rhNRG-1 to a commercial preservation 
solution (Celsior; C) improves cardiac preservation after prolonged hypothermic 
storage.
Methods: Pre-arrest indices of cardiac function were measured in 46 isolated 
working rat hearts. Hearts were arrested and stored for 6 hours at 2-3°C in C 
± rhNRG-1 (14nM). A second group of hearts were pre-treated with rhNRG-1 
(14nM) for 15 minutes prior to arresting the heart, a third group at the time of 
reperfusion, and a fourth group at both time points in addition to storage in C 
+ rhNRG-1. A fi nal group of isolated hearts were pre-treated with the PI3K 
inhibitor, Wortmannin, before storage in C plus rhNRG-1. After storage, hearts 
were remounted and functional measurements repeated. Total and phosho-Akt 
were assessed by Western Blotting.
Results: Recovery of cardiac function was signifi cantly better in hearts stored 
in C plus rhNRG-1 vs. C alone. Post-storage recovery of each parameter is 
expressed as a percentage of its pre-storage baseline (mean ± SEM). Cardiac 
output recovery increased from 1.4±0.62 to 21.2±7.9 (p=0.03). Coronary fl ow 
recovery increased from1.7±1.1 to 39±11.5 (p<0.01). Heart rate recovery 
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increased from 32.2±8.6 to 75.7±11.7 (p=0.01). Treatment with rhNRG-1 prior 
to cardiac arrest and at the time of reperfusion, in conjunction with storage 
in C plus rhNRG-1 did not provide any incremental benefi t over storage in C 
plus rhNRG-1 alone. Pre-treatment with rhNRG-1 prior to cardiac arrest alone, 
resulted in improved preservation of the stored rat heart compared with control. 
Western blotting revealed increased expression of phospho-Akt in rhNRG-1 
stored hearts (p<0.05). confi rming up-regulation of the PI3K/Akt pathway; an 
effect abrogated by Wortmannin (p<0.05).
Conclusions: rhNRG-1 improves transplanted heart function after hypothermic 
storage by activation of the pro-survival Akt pathway. rhNRG-1 shows promise 
for enhancing donor heart preservation.
POSTER BOARD NUMBER P1 – 356
THE CLINICAL SIGNIFICANCE OF THE HYPOXIA 159 
INDUCIBLE FACTOR-1Α AND C4D IN IMPLANTATION RENAL 
BIOPSIES AND POST-TRANSPLANT BIOPSIES.
S. Lee1, S.J. Kim1, D.J. Kim1, S.G. Park1, S.J. Hyun1, J.E. Oh2, E.S. Nam3
Department of 1Surgery, 2Internal Medicine and 3Pathology Hallym 
University College of Medicine, Seoul, Korea
Purpose: Hypoxia inducible factor-1α (HIF-1α) is induced in response to 
ischemic states and in turn activates transcription of several growth factors 
implicated in cell survival. These growth factors have been recognized as 
role players in the development of chronic allograft nephropathy (CAN). C4d 
depositions in the peritubular capillaries of renal allografts have been reported 
to be sensitive markers of acute humoral rejection. The purpose of this study 
was to determine the effects of HIF-1α expression and C4d deposition in 
implantation biopsies of renal allografts. 
Materials and Methods: Implantation biopsies and 22 rejection proven 
biopsies of 54 renal transplantation recipients (Male: Female=31: 23) in 
Kangdong Sacred Heart Hospital from December 1996 to July 1999 were 
done. Immunohistochemical studies were performed using mouse monoclonal 
antibody (1: 1000, Novus Biological Inc., Littleton, CO, USA) as the primary 
antibody and CSA (Catalyzed Signal Amplifi cation System, Dako, Denmark) 
as the secondary antibody for HIF-1α. Rabbit polyclonal antibody (1: 200 
Biogenesis, UK) and DAB kit (Dako) were used for C4d detection. Expression 
of HIF-1α was defi ned as positive nuclei staining under 10 HPF (high power 
fi eld) and C4d deposition was defi ned as 1+ when the pericapillary deposition 
was under 50% and 2+ when over 50% and 0 when there were no traces of 
deposition. 
Results: HIF-1α was demonstrated in 19 cases (35%) of the 54 implantation 
biopsy cases. The expression of HIF-1α was statistically higher in the deceased 
donor group compared to the living donor group. The HIF-1α positive group had 
a longer mean cold ischemic time than the HIF-1α negative group but was not 
statistically signifi cant. The age of the donor and HIF-1α expression showed no 
correlation. Expression of HIF-1α of the implantation biopsies also showed no 
difference in the rejection group (n=22) compared to the non-rejection group 
(n=32). There was no signifi cant difference of HIF-1α expression in the graft 
loss group (n=7) and the graft functioning group (n=47). C4d deposition was 
detected in one implantation allograft biopsy (1.9%). The C4d positive patient 
developed acute accelerated rejection on the fourth postoperative day. HIF-1α 
and C4d were demonstrated in 22 (100%) and 11 (50%) of the 22 rejection 
biopsies, respectively. In patients who showed rejection, HIF-1α expression 
was signifi cantly higher in the rejection biopsies compared to the implantation 
biopsy group. HIF-1α expression of the patients who showed rejection within 
one month and those with rejection later than three months after engraftment 
showed no signifi cant difference. 
Conclusion: Expression of HIF-1α in implantation biopsies showed signifi cant 
correlation with deceased kidney donors. The relation with cold ischemic time 
was not statistically proven but the HIF-1α positive group showed a tendency 
of longer cold ischemic time. Biopsies from the renal allografts with rejection 
showed signifi cantly higher expression of HIF-1α compared to the implantation 
biopsies. The deposition rate of C4d was extremely low in implantation biopsies 
that we could not prove any relevance with acute rejection.
POSTER BOARD NUMBER P1 – 357
A NEW CLASS OF OXYGEN CARRIERS IMPROVES 160 
LONG-TERM STORAGE OF PORCINE AND HUMAN 
PANCREATA FOR SUBSEQUENT ISLET ISOLATION
H. Brandhorst,1 B. Theisinger,2 M. Iken,3 M. Ott,3 O. Korsgren,1 
D. Brandhorst,1
1Department of Clinical Immunology, University Hospital, Uppsala, Sweden; 
2Novaliq GmbH, Heidelberg, Germany; 3Department of Gastroenterology, 
Hepatology and Endocrinology, Hanover Medical School, Hanover, Germany
Objective: Shipment of explanted organs is frequently associated with 
prolonged ischemia deteriorating viability of transplanted tissue. Previous 
studies in human islet transplantation demonstrated that storage on oxygen-
charged perfl uorodecalin (PFD) does not prevent ischemically induced 
pancreas damage compared to storage in UW-solution. In contrast, experiments 
in rats indicated that perfl uorohexyloctan (F6H8). a semifl uorinated alkane 
characterized by lipophilic qualities and a relatively low density (1.33 g/cm3). 
improves yield, viability and posttransplant function of islets isolated from 
long-term stored pancreata compared to PFD (1.93 g/cm3). The present study 
investigated therefore the effi ciency of this potential oxygen carrier to facilitate 
islet isolation from long-term stored porcine and human pancreata.
Materials and Methods: Freshly resected and UW-perfused pig pancreata 
(n=6) were dissected into the splenic or connective lobe and stored for 12 ± 
2 hours in oxygen-charged F6H8 or PFD. Human research grade pancreata 
were subjected to oxygenation in F6H8 (n=5) or PFD (n=5) for additional 24 
hours subsequent to UW-storage of 11 ± 1 hours (F6H8) or 10 ± 2 hours (PFD). 
Subsequently, the intrapancreatic partial oxygen pressure (pO2) was measured 
utilizing a fi ber optic technique. Human and porcine islets were isolated and 
purifi ed as previously described. Islet quality control assessed yield, glucose-
stimulated insulin release determined as stimulation index, viability and 
recovery after 3 days of culture.
Results: Compared to F6H8 the pO2 measured in the core of pig pancreata 
was decreased utilizing PFD (10.1 ± 5.2 vs 3.5 ± 3.0 mm Hg, NS). Although 
yield of islet equivalents (IE) did not differ between pig pancreata stored in 
F6H8 or PFD (2600 ± 340 vs 3640 ± 1050 IE/g, NS) recovery after culture 
was signifi cantly improved after storage in F6H8 (51 ± 7 vs 29 ± 3%, p<0.05). 
Moreover, glucose stimulation index was enhanced in islets isolated after F6H8 
storage (1.9 ± 0.2 vs 1.3 ± 0.3, p<0.05).
The intrapancreatic pO2 in human pancreata was signifi cantly higher after 
storage in preoxygenated F6H8 (8.9 ± 4.6 vs 1.2 ± 0.5 mm Hg, p<0.05). This 
correlated with signifi cantly increased yield (4220 ± 430 vs 2680 ± 360 IE/g, 
p<0.05) and viability (80 ± 3 vs 51 ± 6%, p<0.05) of islets isolated from F6H8-
stored pancreata. In addition, recovery after culture was enhanced after F6H8 
storage compared to PFD (84 ± 5 vs 49 ± 5%, p<0.01). No signifi cant difference 
was found regarding human islet in vitro function.
Conclusions: The dense and fi rm structure of the human pancreas seems to 
require the utilization of lipohilic oxygen carriers that can penetrate into deeper 
tissue layers of cold-stored pancreata. In contrast, the specifi c histomorphological 
structure of the pig pancreas seems to facilitate the release of oxygen into the 
pancreatic core. The present data suggest that F6H8 is superior to PFD in terms 
of supplying oxygen to large mammalian pancreata if successful islet isolation 
is intended. The posttransplant function of islets isolated after pancreas storage 
in different oxygen carriers is under current investigation.
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ISOLATION, CHARACTERISATION AND 161 
DIFFERENTIATION OF A NOVEL BIPOTENTIAL 
PROGENITOR CELL FROM THE ADULT PANCREAS
P. Shiels, K. Stevenson, A. Mac Intyre
University of Glasgow
We have isolated a novel progenitor cell population from adult rat pancreatic 
ducts, termed pancreas derived progenitor cells (PDPCs). Here, we report 
the in vitro culture, selection and characterisation of Thy1.1 positive and 
Thy1.1 negative PDPC sub-poplualtions. These cells exhibit bipotentiality for 
differentiation into both pancreatic/hepatic cell types.
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We have observed a time course of both morphologic and gene expression 
changes indicative of hepatic lineage differentiation by use of a serum free 
FGF-4 containing differentiation protocol. These cells express albumin, 
CYP2B1 and store glycogen, typical features of mature hepatocytes. Previous 
studies have demonstrated hepatic differentiation of a number of different 
cell types, including bone marrow derived MSCs, MAPCs, endometrial and 
pancreatic derived MSCs. The Thy1.1 positive subpopulation of PDPCs share 
the morphological phenotype and express a number of cell surface markers 
with these populations, including CD44 +, CD24-, CD45-, CD31- and CD34. 
In contrast to this, however, Thy1.1 positive PDPCs appear to be a distinct cell 
type, expressing GATA4, HNF3beta and alpha feto protein, which have not 
been described as expressed for any of these other cell types.
The Thy1.1 sub-population also displays the capacity to form islets in vitro, 
when cultured with nicatinomide. No morphological evidence of islet like 
clusters was observed using the Thy1.1 negative population. Neither insulin 
nor glucagon was expressed within this population. In contrast, Thy1.1 positive 
PDPCs could readily be induced to a pancreatic lineage with characteristic 
morphological changes resulting in three dimensional islet like structures and 
the transcriptional expression of PDX-1, insulin and glucagon.
POSTER BOARD NUMBER P1 – 359
HEPATOCYTE TRANSPLANTATION: A POTENTIAL 162 
NEW THERAPY FOR HEMOPHILIA B
K. Ohashi1, K. Tatsumi2, M. Shima2, Y. Nakajima3, A. Yoshioka2, T. Okano1
1Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s 
Medical University, 2Department of Pediatrics, Nara Medical University, 
3Department of Surgery, Nara Medical University
Background: Hemophilia B is a recessive X-chromosome linked congenital 
bleeding disorder, and the bleeding diathesis in these individuals is due to a 
failure in the production of biologically active coagulation factor IX (FIX). 
Achieving >1% coagulation activity results in signifi cant improvement in the 
quality of life of the hemophilia B patients. Since hepatocytes are the primary 
and sole responsible cell type for the production of FIX, establishment of cell-
based therapy using hepatocytes should be highlighted. Extensive experimental 
and clinical studies suggest that hepatocyte transplantation offers an promising 
therapeutic option for acute and metabolic liver diseases. The present study 
was designed to establish cell transplantation therapies using mouse model of 
hemophilia B.
Method: Donor hepatocytes were isolated from C57Bl/6 using two-step 
collagenase perfusion method. Hepatocytes were separated from non-
parenchymal cells using low-speed centrifugation (hepatocyte purity >99%). 
Isolated hepatocytes (1.5 x 106 cells/recipient) were transplanted into the liver 
of factor IX-knockout mice (FIX-KO) mice (C57Bl/6 genetic background). In 
some of the recipient mice, additional hepatocyte transplantation procedure 
was performed 15 days after the initial transplantation. Engraftments of the 
transplanted hepatocytes were determined by fl uorescence in situ hybridization 
(FISH) and quantitative real-time PCR for FIX expressions. Therapeutic 
effi cacy of hepatocyte transplantation was determined by measuring plasma 
FIX activity of the recipient mice using 1-stage clotting assay based on the 
activated partial thromboplastin time.
Results: In the FIX-KO mice that received hepatocyte transplantation, the 
plasma FIX activities increased at 1-2%. An additional increase was achieved 
by repeated procedure of hepatocyte transplantation. Close correlation between 
FIX mRNA expression levels of the liver and plasma FIX activity levels was 
observed. FISH analyses demonstrated that transplanted hepatocytes had been 
engrafted within the liver parenchyma. We have confi rmed the persistency of 
the therapeutic effects up to 12 weeks (the length of the experiment). None 
of the recipient mice developed a humoral response against the de novo 
synthesized FIX protein.
Conclusions: The present study confi rmed that engrafted hepatocytes within the 
liver of hemophilia B possess full functionality for clotting FIX productions. In 
all, these data provide the proof-concept feasibility of hepatocyte transplantation 
as a new mode to provide therapeutic benefi ts in the treatment of hemophilia B.
POSTER BOARD NUMBER P1 – 360
INHIBITORY EFFECT OF RAT MESENCHYMAL STEM 163 
CELLS ON LYMPHOCYTE PROLIFERATION
Y. Lu, K. Gao, C. Cong, Y. Yuan, L. Wei, S. Li, Y. Chen, C. Qiao, Y. Li, 
J. Cheng, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
The objective of the research is to investigate the mechanism of inhibitory 
effects induced by rat MSCs on nonspecifi c mitogen stimulated lymphocytes 
(LCs) and lymphoblasts (LBs). In this study, 2nd to 8th passage MSCs 
prepared from Sprague-Dawley (SD) rat were used. LCs were separated from 
spleens of SD rats. Mixed lymphocyte reactions of mitomycin C treated MSCs 
with ConA-stimulate LCs or LBs were performed, and the growth inhibition 
effect was tested through MTS assay. Cytotoxicity of MSCs against naive and 
ConA-stimulated LBs were detected after coculturing for 24 hours by lactate 
dehydrogenase release assay. Apoptotic rate of ConA-stimulated LBs was 
measured on fl ow cytometry after incubating with MSCs for 9 hour in ratio 
of 10: 1. After treatment with blocking antibodies of FasL, TGF-¦Â and IL-10 
respectively, MSCs were cocultured with ConA-stimulated LBs to observe 
apoptosis and growth inhibitory effects. The main outcome measures included 
adhesive bone marrow derived CD29+, CD44+, CD45-, CD54+, CD95+ and 
SH-2+ MSCs. FasL, TGF-¦Â and IL-10 production of MSCs were visualized 
by immunocytochemistry. MSCs exhibited a dose-dependent growth inhibitory 
effect on ConA-stimulated LCs and LBs. When treated with anti-FasL and 
IL-10 blocking antibodies, inhibitory effects of MSCs on LB (MSCs: LBs=1: 
10) proliferation decreased from 100% to 54.2 ¡À 7.4% and 68.7 ¡À 8.8% 
respectively, and apoptosis induction effect on LBs decreased by 27.0 ¡À 
4.3% and 73.3 ¡À 10.2% respectively. Treatment with anti-TGF-¦Â blocking 
antibody had no signifi cant infl uence on those effects of MSCs. These in vitro 
phenomena demonstrate that MSCs could suppress lymphocyte proliferation 
induced by ConA, and the inhibitory effects of MSCs against activated LBs 
were signifi cantly stronger than naive LCs. FasL and IL-10, rather than 
TGF-¦Â play an important role in MSC-mediated suppression of lymphocyte 
proliferation.
POSTER BOARD NUMBER P1 – 361
MECHANISM OF ANTIGEN SPECIFIC MESENCHYMAL 164 
STEM CELLS-MEDIATED IMMUNOREGULATION: NEW 
INSIGHTS FROM AN IN VIVO STUDY
E. Morelon7, H. Perrin1, A. Hennino3, M. Vocanson2, J-F. Nicolas5, 
J-L. Tourraine4, O. Thaunat6
1INSERM U851; Edouard Herriot Hospital, Lyon, France, 2INSERM U851, 
IFR128, Lyon, France, 3INSERM U851, IFR128, Lyon, France, 4INSERM 
U851, IFR128, Lyon, France, 5INSERM U851, IFR128, Lyon, France, 
6Edouard Herriot Hospital, Lyon, France, 7INSERM U851; IFR128; Edouard 
Herriot Hospital, Lyon, France
Background: Mesenchymal stem cells (MSCs) are nonhematopoietic bone 
marrow stromal cells that support haematopoiesis. MSCs immunoregulatory 
properties suggest that these cells might be potent candidates for the treatment 
of allograft rejection. However, the immunoregulatory features of MSCs have 
been mostly demonstrated in vitro, and little is known so far regarding the in 
vivo mechanisms supporting MSCs-mediated immunoregulation.
The aim of the study was to analyze the effects of MSCs in vivo, on an antigen-
specifi c immune response.
Methods and Results: We have established and characterized by fl ow 
cytometry murine primary MSCs. C3H10T1/2 and S17 murine MSC cells lines 
were also used. All these cells were able to inhibit lymphocyte proliferation in 
vitro, in a dose dependant and CMH independent fashion.
The allergic contact dermatitis (ACD) is a well defi ned mouse model in which 
the intensity of the CD8 T cell-mediated antigen-specifi c immune response is 
reliably quantifi ed by the measure of oedema 5 days after DFNB rechallenge 
on the ear.
The subcutaneous injection of 1.106 primary MSCs or S17 cells at the time 
of sensitization resulted in a 50% reduction of ear oedema, demonstrating the 
inhibition of ACD in vivo. This inhibitory effect was not observed when MSCs 
were injected during the rechallenge (secondary contact with DNFB) or after 
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non specifi c irritation. This suggests that the benefi cial effect of MSCs is rather 
the consequence of a MSCs-mediated inhibition of the DNFB-specifi c immune 
response than a non-specifi c anti-infl ammatory effect.
To further challenge this hypothesis, we have analysed the events taking place 
in the draining lymph nodes at the time of the initiation of the DNFB¡Vspecifi c 
response. We found that lymphocyte proliferation and IFNƒ× secretion were 
not altered in treated animals, suggesting that MSCs do not modify the antigen 
presentation and the priming of CD8+ T cells. In contrast, we demonstrated 
that effector cell infi ltration at the infl ammatory site (measured by CD4, 
CD8, IFNƒ× mRNA expression in mouse ear) was signifi cantly blunted by 
the presence of MSCs. Experiments are currently performed to determine the 
mechanisms of by which MSCs are able to modify the homing of effector cells 
(chemokines secretion, skin homing receptor expression).
Conclusion: We demonstrated for the fi rst time that MSCs have the 
immunoregulatory properties in vivo in the ACD model. Our data suggest 
that MSCs-mediated immunoregulation is antigen-specifi c and relies on their 
ability to reprogram the homing of effector cells.
POSTER BOARD NUMBER P1 – 362
DONOR-DERIVED MESENCHYMAL STEM CELLS 165 
SUPPRESS ALLOREACTIVITY OF KIDNEY TRANSPLANT 
RECIPIENTS
C. Baan1, M. Crop1, J. IJzermans2, I. Alwayn2, W. Weimar1, M. Hoogduijn1
1Department of Internal Medicine, 2Department of Surgery Erasmus Medical 
Center
Introduction: Human mesenchymal stem cells (MSC) have immunomodulatory 
capacities. They have shown to be effective in the treatment of graft-versus-
host-disease. However, their effect on alloreactivity in human solid organ 
transplantation is still unknown. In this study, we isolated MSC from donor 
tissue and examined their immunosuppressive effect on recipient anti-donor 
reactivity, before and after kidney transplantation.
Methods: Anti-donor reactivity was established in mixed lymphocyte reactions 
(MLR) of 14 living kidney donor-recipient pairs. Recipient PBMC were 
isolated before and 1 month after transplantation, and stimulated by g-irradiated 
donor PBMC and fully-mismatched third-party PBMC. Perirenal fat derived 
MSC from donors and third-party controls were added to the various MLR in 
a 1: 5 ratio and proliferation measured by 3H-thymidine incorporation. The 
proliferation of lymphocyte subsets was analyzed by fl owcytometry after PKH 
labelling of responder PBMC.
Results: Donor MSC signifi cantly inhibited the recipient anti-donor 
reactivity pre- and post-transplant MLR with comparable effi cacy. The 
immunosuppressive effect of MSC appeared to be independent of the donor 
source (autologous or allogeneic). Flowcytometric analysis showed that MSC 
inhibited the proliferation of CD4+ and CD8+ T lymphocyte subsets in pre- and 
post-transplant MLR. MSC not only reduced the percentage of proliferating 
responder cells, but also their number of cell divisions. MSC had no effect on 
B or NK cell proliferation.
Conclusion: Donor MSC signifi cantly inhibited the proliferation of allo-
activated T cells before and after transplantation. This capacity of MSC may be 
useful to control graft rejection in solid organ transplantation medicine.
POSTER BOARD NUMBER P1 – 363
MESENCHYMAL STEM CELLS PREVENT ACUTE 166 
REJECTION IN EXPERIMENTAL RENAL TRANSPLANTATION
M. Alessiani1, S. Zonta1, T. Rampino2, M. Gregorini2, F. Frassoni3, M. De 
Martino1, A. Ibatici3, G. Piotti2, G. Bedino2, C. Piacenza2, 
1University Of Pavia Department of Surgery, IRCCS policlinico San Matteo, 
Pavia, 2Neprology and dialisis Unit, 3Oncoemathology Unit and cell 
transplant centre San Martino Hospital, Genova
Mesenchymal stem cells (MSC) are multipotent cells that can differentiate into 
various mature cell types. MSC prefentially home to damaged tissues, where 
they may contribute to cell regeneration and repair. In addition, MSC have 
immunomodulatory effects. In vitro, MSC inhibit T cell proliferation induced 
by alloantigens and mitogens and prevent the development of cytotoxic T cells; 
in vivo, they prolong the survival of experimental skin and cardiac allografts. 
As yet, the effects of MSC in renal allograft have not been explored. We 
investigated whether infusion of MSC modifi es the course of renal allograft 
in the rat model.
Transgenic Sprague–Dawley (SD) rats expressing enhanced green 
fl uorescence protein (EGFP) were used as MSC donors. Syngraft (Lewis 
RT1 to Lewis RT1, Fisher F344 to Fisher F344) and allograft (Fisher F344 
to Lewis RT1) orthotopic kidney transplantations were performed following 
bilateral nephrectomy. Group A: rats were infused with saline solution in 
renal artery soon after grafting. Group B: rats were infused with intraarterial 
3X106 MSC. No immunosuppressive therapy was administrated. Animals 
were sacrifi ced on day 7 and kidney was removed for morphological 
study. Creatinine clearance was measured on days 0, 3 and 7. Tubulitis 
and vasculitis were scored according to Banff classifi cation on Movat 
pentachromic stained renal sections, analysing respectively 150 consecutive 
tubuli and 10 arteries/section. ED1 and CD8 positive cells were evaluated by 
immunohistochemistry.
The transplant procedure was comparable in both groups in terms of total 
ischemia time, timing of surgical procedure and post-reperfusion graft diuresis. 
MSC improved renal function in group B vs group A. Tubulitis resulted less 
heavy in MSC treated (B) than in not treated (A) rats (score% tubuli, T0: 
B=64.5%, A=36%, p<0.005; T3: B=2.6%, A=12.8%, p<0.0001). Vasculitis 
was signifi cantly less severe in group B than in group A (V0: B=50%, A=16%, 
p<0.0001; V3: B=33%, A=70% p<0.0001). MSC reduced infl ammatory 
infi ltrate; in group B ED1 positive cells number was lower in comparison with 
A (number of cells per microscopic fi eld B=42.8±8.6, A=78.1±2.1, p<0.005) 
and CD8 positive cells were signifi cantly reduced in group B than in A (B= 
14.8±8.4, A=29.4±0.5, p<0.05).
Our study demonstrates that MSC infusion signifi cantly attenuates acute 
cellular rejection in the absence of immunosuppresive therapy.
POSTER BOARD NUMBER P1 – 364
INTERLEUKIN-10 ENGINEERED MESENCHYMAL STEM 167 
CELL THERAPY TO PREVENT ISCHEMIA-REPERFUSION 
INJURY IN LUNG TRANSPLANTS
S. Salgar, E. Manning, S. Pham, S. Li, J. Mathew, P. Ruiz, 
Department of Surgery, University of Miami
Aim: Following lung transplantation, early graft dysfunction due to ischemia-
reperfusion (IR) injury is a serious problem occurring in about 30% of the 
patients. Viral interleukin-10 (vIL-10) is a potent anti-infl ammatory cytokine. 
Mesenchymal Stem Cells (MSC) have immunosuppressive properties and can 
serve as a vehicle to deliver vIL-10. In this study, autologous MSC and vIL-10 
engineered MSC were tested for their ability to prevent lung IR injury. 
Methods: Bone marrow derived MSC from Lewis rat were transduced with 
rvIL-10-retrovirus & selected on neomycin (1mg/ml for 7 days). Left lung 
ischemia was induced by clamping left pulmonary artery/vein/bronchus at 
end inspiration. Following 120 min of left lung ischemia, Group A, rats 
received vIL-10 transduced MSC (~15 x 106; i.v.); Group B, received empty 
vector engineered MSC; Group C, received MSC; and Group D, received 
saline. Group E received no ischemia or MSC. At 4h, 24h, 72h, & 7 days 
following ischemia, blood was collected from left and right pulmonary 
veins, separately. 
Results: Mean blood oxygenation (PaO2/FiO2 ratio, mmHg) was reduced 
(P<0.05) at 24h post-IR injury in Group B (138+ 86; n=9) and Group D 
(87+39; n=10). compared to MSC-vIL10 (353+105; Group A; n=10) treated 
animals. By days 3 & 7 following IR injury with MSC-vIL10 therapy 
oxygenation levels approached normal (475+55 & 435+33; n>9) but empty 
vector control was low (238+164 & 217+158; n>9). As early as 4h following 
IR injury lung function was improved signifi cantly (P<0.05) in MSC-vIL-10 
group (319+94 mmHg; n=7) compared to untreated controls (63+19 mm 
Hg; n=6). Long-term cultured MSC (passage >25) therapy increased PaO2/
FiO2 slightly (152+51 Vs 87+39 in controls, 24h post-IR; n > 8). However, 
earlier passage MSC (p1 to p6) therapy increased PaO2/FiO2 signifi cantly 
(454 + 59) at 24h post-IR. Extravasation of Evans blue dye (as a measure 
of capillary permeability/damage) was lower (P<0.5) in MSC-vIL10 treated 
animals. Bronchoalveolar lavage from IR injured lung at 24h post-MSC-
vIL10 therapy demonstrated reduced (P<0.05) infl ammatory cells (x106) 
compared to untreated controls (Granulocytes, 2.8 Vs 5.4; Macrophages, 3.3 
Vs 2.9; CD4 T cells, 0.6 Vs 2.2; CD8 T cells, 1.1 Vs 3.1). IR injured lungs 
(4h reperfusion) with no treatment had a higher (P<0.05) injury score (3.5 + 
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1.3; n=5) compared to MSC-vIL10 (1.21+ 0.6; n=7) & MSC (1.6+0.9; n=6) 
treated groups. Neutrophil infi ltration, microvascular permeability and wet: 
dry ratio of the lung were lower in MSC-vIL10 treated animals. Infl ammatory 
mediators IL-1á, MCP-1á, MIP-1á, & IL1-â protein levels were markedly 
increased in the injured lung compared to sham operated controls; their 
analysis in MSC, MSC-vIL10 treated & untreated groups are underway. MSC 
were highly positive for stem cell markers CD29, CD90, and CD44 (70-95%) 
and weakly positive for CD31, CD34, CD45, CD80, CD86, CD11b, MHC 
Class II (0-24%). 
Conclusion: MSC and IL-10 delivery via MSC to prevent IR injury in lung 
transplants seems promising.
POSTER BOARD NUMBER P1 – 365
SURVIVAL AND PROLIFERATION OF MESENCHYMAL 168 
STEM CELL TREATED BY BMP-2 AND TRANSDUCED WITH 
PFUG-TF LENTIVIRAL VECTOR AFTER CARDIAC DELIVERY 
IN VIVO VISUALIZATION
Z. Shen, S. Xue
The First Affi niatied Hospital of Soochow University
Objectives: To provide theoretical support at the cellular level for future 
clinical application in the treatment of myocardial diseases with MSCs.
Methods: Marrow mesenchymal stem cells (MSCs) were selected from the 
marrow of SD rats and were induced with BMP-2. MSCs stably transduced 
with a lentiviral vector carrying pFUG-TF reporter gene that consists of fi refl y 
luciferase, monomeric red fl uorescence protein, and truncated thymidine 
kinase (fl uc-mrfp-ttk).The acute myocardial infarction model of nude rat was 
established and the bone marrow MSCs were implanted into the acute infarct 
site via topical injection. The survival and proliferation of implanted cells were 
studied by the bioluminescence and positron emission tomography (PET) 
signals.
Results: The primary cells grew well and displayed a fi broblast -like 
morphology£®Fo11owing the time of passage increases£¬the positive 
rate of CD29 increased£»CD90 decreased£¬the negative rates of CD34 
and CD45 increased. Shape and arrangement of the cells changed after 
induction with BMP-2. In RT-PCR analysis, The expressions of BMPRIA and 
BMPRII£¬Nkx2.5 and GATA-4 were increased one week after induction. cTnT 
mRNA expressed one week after induction while it was not observed before 
induction. In immunocytochemical staining, cTnT and Cx-43 was expressed 
two week after induction£®Expression of cTnT was strong three to four weeks 
after induction£®The structure was dense and striation-like£®Cx-43 was 
located beneath the membrane two weeks after induction£®In three weeks after 
induction, the protein was observed at cell conjunctions£®It was granular and 
dense, and located at conjunctions between cells of myotube- like structure four 
weeks after induction. There is no difference between mesenchymal stem cells 
transduced with pFUG-TF lentiviral vector and cells non-transduced in Trypan 
blue cell viability. Cells transduced with pFUG-TF lentiviral vector express 
cardiac transcription factors (Nkx2.5) and myosin heavy chain (¦Â-MHC).
Cells transduced with pFUG-TF lentiviral vector also express reporter genes 
(fl uc). The bioluminescence and positron emission tomography signals in study 
animals increased progressively from week 1 to week 4.
Conclusion: (1) The surface antigen markers of MSC will change during the 
process of culture, and the changes of these markers may refl ect the changement 
of cell purity or other unknown mechanism. (2) BMP-2 induces diferentiation 
of MCSCs into cardiomyocytes via mediation of BMPRIA and BMPRII. (3) 
Transducing mesenchymal stem cells treated by BMP-2 with a lentiviral vector 
carrying pFUG-TF reporter gene has no adverse on cell viability, proliferation, 
and differentiation ability. (4) Mesenchymal Stem Cell Treated by BMP-2 
could survive and propagation in the acute myocardial infarction model
Keywords: Mesenchymal stem cells, Bone morpho-genetic protein-2, lentiviral 
vector, bioluminescence, PET
POSTER BOARD NUMBER P1 – 366
THE ROLE OF TOLL-LIKE RECEPTOR SIGNALING 169 
IN ATTENUATING NEUROGENESIS OF NEURAL STEM/
PROGENITOR CELLS ALLOGRAFTS IN THE ADULT 
HIPPOCAMPUS.
L. Phillips1, Z. Chen2, P. Carpentier2, T. Palmer2, S. Krams1, O. Martinez1
1Surgery/Division of Transplantation, Stanford University, Stanford, 
CA, United States, 2Neurosurgery, Stanford University, Stanford, CA, 
United States.
Neural Stem/Progenitor Cells (NPCs) are self-renewing multipotent 
progenitors that can differentiate into neurons, oligodendrocytes, and 
astrocytes. Endogenous NPCs reside in the hippocampal dentate gyrus, a 
region of the brain where the process of homeostatic neurogenesis continues 
throughout adult life. However, the regenerative capacity of this endogenous 
pool appears inadequate in a variety of central nervous system (CNS) 
diseases and is severely impacted following cranial irradiation treatment for 
CNS malignancies. Transplantation of NPC has the potential to repopulate, 
or repair, damaged areas of the CNS. Whereas BrdU-labeled syngeneic NPC 
grafts placed in the dentate gyrus differentiate and contribute to neurogenesis 
within 28 days post-transplant, BrdU-labeled NPC allografts are not rejected 
but instead, fail to differentiate. Interestingly, intraperitoneal injection of LPS 
signifi cantly reduces ongoing neurogenesis in the brain of normal adult mice. 
These results suggest that infl ammation may impair neurogenesis. Moreover, 
because LPS is a potent ligand for toll like receptor (TLR) 4, these fi ndings 
suggest that TLR may play an important role in regulating differentiation 
of NPC allografts. Thus, we investigated TLR2 and TLR4 expression in the 
hippocampus of normal mice and mice that received a single intraperitoneal 
injection of LPS (60 μ;g/kg). Using quantitative real time PCR we found that 
TLR4 mRNA is constitutively expressed in normal hippocampus of Balb/C 
(mean=0.026 relative units (RU) compared to GAPDH) and C57Bl/6 mice 
(mean=0.028 RU). TLR4 mRNA expression is increased in the hippocampus 
of C57Bl/6 mice by 4.7 fold (mean=0.13 RU) 72 hours after LPS injection. 
TLR4 protein is expressed at highest levels on glial cells in the dentate gyrus as 
determined by immunohistochemical staining. TLR2 mRNA was also detected 
in the hippocampus of normal Balb/C (mean=1.48 RU) and C57Bl/6 mice 
(mean=1.77 RU) but unlike TLR4, LPS injection did not affect TLR2 levels 
in C57Bl/6 mice (mean=2.75 RU). However, the levels of TLR2 and TLR4 in 
the normal mouse hippocampus are signifi cantly lower than the corresponding 
TLR levels in normal spleen (31.5 RU and 6.39 RU, respectively). These results 
indicate that infl ammation augments TLR4 expression in the brain and suggest 
that TLR and the innate immune response may participate in attenuating 
neurogenesis following transplantation of NPC allografts.
POSTER BOARD NUMBER P1 – 367
3-D CULTURING OF HUMAN MESCHYMAL STEM 170 
CELLS IN ROATING WALL VESSEL AS A FASTER METHOD 
FOR IN VIVO REPAIR
S. Sharp1, W. Cerwinka2,3, C. Yates1, H.E. Zung1, L. Chung1
1Department of Biology and Center for Cancer Research, Tuskegee 
University, Tuskegee, Alabama, USA, 2Georgia Pediatric Urology, Emory 
University School of Medicine, Atlanta, Geordia, USA, 3Department of 
Urology, Emory University School of Medicine, Atlanta, Geordia, USA
The transplant community has been forced to consider other therapeutic 
options for dealing with end-stage organ failure. Current challenges include 
insuffi cient number of donor organs, negative side affects from continuous 
immunosuppression, and immunological incompatibility dictate the need for 
additional solutions. Human mesenchymal stem cells (hMSC) offer a new 
therapeutic approach to circumvent these challenges. Within this study we 
cultured commercially available hMSC harvested from human bone marrow, 
onto a surgifoam a porous and absorbable gelatin, in microgravity conditions 
utilizing the NASA designed Rotating Wall Vessel (RWV). To determine the 
number of hMSCs attached to the surgifoam we quantifi ed the DNA content per 
spheroid. Surgifoam loading of 2, 3, and 4 million cells were evaluated in 10 
ml medium with 3 million cells yielding optimal surgifoam cell loading. Time 
to maximum spheroid size was also evaluated by harvesting spheroids at day 1, 
2, 3, 4, and 8. Spheroid DNA was quantifi ed and cell number extrapolated by 
establishing a standard curve. Maximum carrier loading was seen at day 3 with 
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a mean of 367,000 cells per spheroid. This is in direct contrast to other systems 
that use longer time windows to allow for cell adherence to the scaffolding. 
Upon, histological examination of the spheroids cultured in the RWV, we found 
in the H&E and TEM that these spheroids exhibited multicelluar structures, 
and close cell-cell contact. Upon further characterization of these spheroids we 
were able to observe that 3 day spheroids retain their undifferentiated stem cell 
characteristics (ability to differentiate into multiple lineages and expression of 
stem cell markers). This was evidenced by these spheroids being induced to 
chondrogenic (collagen II). osteogenic (von Kossa). and adipogenic (oil red 
staining) differentiation by day 7 after induction, in the presence of lineage 
specifi c differentiation media respectively. Although preliminary, these results 
describe a novel model for the utilization of patient derived hMSC as cellular 
therapy for organ repair. Mesenchymal stem cells are found in abundance in 
bone marrow and may be easily harvested from bone marrow thereby avoid 
rejection episodes and the waiting time for a cadaveric donor. These results 
offer a strong case for exploring the possibilities that hMSCs when harvested 
from the patients own bone marrow, introduced to the RWV system, and 
transplanted in to a differentiation inducing media could be a link for in vivo 
and or in vitro regeneration of organs for transplantation
MONDAY – ORAL ABSTRACTS (CONTINUED)
CAN AND FIBROSISCONCURRENT ORAL SESSION 11: 
THE ROLE OF EPITHELIAL-TO-MESENCHYMAL 171 
TRANSITION IN TRANSPLANT TUBULOINTERSTITIAL 
DAMAGE, THE FIRST 12 MONTHS
M. Vitalone1, P. O’Connell2, E. Jimenez-Vera1, A. Yuksel4, M. Wavamunno1, 
C. Fung3, J. Chapman2, B. Nankivell2
1Westmead Millennium Institute, 2Department of Renal Medicine, Wesmead 
Hospital, 3Departrment of Tissue Pathology, Westmead Hospital, 4Histology, 
Westmead Millennium Institute
Background: Tubular epithelial cell transition into myofi broblasts (EMT) 
following injury has been postulated to cause the tubulointerstitial fi brosis seen 
in renal transplants. The study aim was to prospectively assess EMT prevalence 
by histochemistry and transcriptome profi ling early after kidney transplantation; 
in order to evaluate its contribution to later fi brosis. Methods: Protocol kidney 
transplant biopsies at implantation, 1, 3 and 12months (n=85 biopsies, 24 
patients). were dual-stained for E-cadherin and α;SMA (immunoperoxidase) 
or S100A4 (immunofl uorescence) to identify EMT. Interstitial fi brosis was 
measured by image analysis using Gomori trichrome stains, and blinded 
slides were scored by the Banff criteria. From snap-frozen samples, RNA 
was extracted, processed into cDNA and hybridized onto 8K human cDNA 
microarrays. Analysis for differential expression of EMT-associated genes was 
validated by QRT-PCR of 12 EMT/MET markers. 
Results: Transplant tubulointerstitial damage (TID) on protocol biopsy 
increased from 34% at 1month, to 54% at 3months. EMT via α;SMA was found 
in 61% of biopsies located in tubules, tubular lumen and interstitial space, but 
was present at low levels across all times points and did not increase over 
time. Using the less specifi c but a more sensitive marker, S100A4 showed a 
much higher incidence of EMT, which also did not increase over time. Dual 
staining with either marker of EMT (aSMA or S100A4) did not correlate with 
TID (ci, ct, measured fi brosis) or serum creatinine on contemporaneous or 
sequential histology at any time point, instead being correlated with subclinical 
immune activity (r=0.6, P<0.05). In TID samples, microarrays showed 
differential expression of 127 genes at 1month (B value>1, P<0.01) and 67 
genes by 3months (B>1, P<0.015). predominantly associated with fi brosis, 
tissue remodelling and immune response. Of the 173 EMT-associated genes 
interrogated, 8.1% (COL1A2, MMP2, FAP, TWIST, etc) showed signifi cant 
differential expression at 1 or 3 months; however the remainder 91.9% were 
not differentially altered or discordant to an EMT pattern (CTGF, TGFBR3 
and TIMP2 all showing anti-EMT expression). QRT-PCR of 12 key EMT 
markers showed appropriate up-regulation of 2 genes (S100A4 and BCAT) in 
association with TID. 
Conclusion: EMT was observed in protocol histology soon after transplantation, 
but occurred in isolated tubular cells at varying levels on biopsy. It was 
unaccompanied by evidence of intracellular EMT gene activation or subsequent 
tubulointerstitial damage, suggesting a minor role in early transplant fi brosis.
PROGRESSION OF INTERSTITIAL FIBROSIS AND 172 
TUBULAR ATROPHY IN THE FIRST YEAR AFTER RENAL 
TRANSPLANTATION: EARLY PROGRESSION ESPECIALLY IN 
NON-HEART BEATING KIDNEYS
M.H.L. Christiaans1, M.A.C.J. Gelens1, F.M.E.G. Steegh2, J.P. van Hooff1, 
R.J. van Suylen2, E.L.W. van Heurn3, C.J. Peutz-Kootstra2, 
1University Hospital Maastricht,department of internal medicine, 2University 
Hospital Maastricht, department of pathology, 3University Hospital 
Maastricht, department of surgery
Introduction: Chronic allograft damage is a major cause of graft loss. This is 
already seen early after renal transplantation and is characterized by interstitial 
fi brosis and tubular atrophy (IF/TA).
In this study we investigated which clinical factors are associated with the 
increase in IF/TA from implantation to 12 months after transplantation in 
patients receiving a tacrolimus (TAC) -based immunosuppressive regimen in 
combination with mycophenolate mofetil (MMF) or sirolimus (SRL) and =< 
10 days steroids.
Methods: From April 2003 until January 2006, two TAC-based 
immunosuppressive regimens were in use: one with low dose (1 mg) SRL and 
the other with MMF 500 mg bid. Steroids (10 mg/d) were stopped within 10 
days. In patients who experienced biopsy proven acute rejection, steroids were 
maintained or reintroduced, and tapered to 5 mg daily maintenance in the next 
2 months.
Protocol biopsies were taken after revascularization (zero hour). at 3 and 12 
months. All contained at least 5 glomeruli and 1 artery. From 59 recipients 
both a zero and 3-month biopsy were collected. A 12-month biopsy was also 
available from 56 of these recipients. A blinded pathologist scored the biopsies 
according to the Banff 2005 criteria: IF/TA score 0: no interstitial fi brosis (ci) 
and tubular atrophy (ct). 1: mild ci and ct (<25% of cortical area). 2: moderate 
ci and ct (26-50% of cortical area). 3: severe ci and ct (>50% of cortical area).
Statistics: Data are given as median or percentage. SPSS was used for non-
parametric testing (Wilcoxon). and multiple linear regression (independent 
parameters: donor age, donor type, occurrence of acute rejection < month 3 
(yes vs. no). type of additional immunosuppression (SRL vs. MMF). use of 
steroids at month 3 (yes vs. no). anastomosis time, Cold Ischemia Time (CIT).
Results: Nineteen patients received a living kidney-donor (LK, 34%). 18 
patients a post-mortal heart-beating kidney (HB, 32%). and 19 patients received 
a post-mortal non-heart-beating kidney (NHB, 34%).
Recipient age at transplantation was 51 years, donor age was 48.5 years, 
recipient male gender 62.5%, steroids-use at three months 18%, anastomosis 
time 30 minutes, and CIT of the post-mortal donors was 18 hours.
In the zero hour biopsy, the IF/TA score was only signifi cantly correlated 
towards donor age (more in older donors). but not to the other parameters, 
including donor type.
IF/TA score rose signifi cantly both between month 0 and month 3 (from 0.64 
to 1.27; p<0.001 Wilcoxon). and between month 3 to month 12 (from 1.27 to 
1.50, p=0.04, Wilcoxon).
In a multiple linear regression analysis using progression of IF/TA score in 
the fi rst three months as the dependant factor and using the recipient, donor 
and transplant parameters as independent factors, only donor source was 
a signifi cant predictor of the increase in IF/TA (p=0.004). The increase was 
signifi cantly higher in biopsies of NHB donors.
In multiple regression analysis of progression of IF/TA scores between 3 and 
12 months none of these parameters were statistically signifi cant.
Conclusions: In the fi rst year after renal transplantation there is a signifi cant 
increase in interstitial fi brosis and tubular atrophy (IF/TA).
This increase is not related towards the use of SRL 1 mg vs. MMF 500mg bid, 
the occurrence of acute rejection or the use of corticosteroids.
A major increase occurs especially in NHB donors during the fi rst three months 
after transplantation.
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Oral Abstracts Monday 11 August 2008
6 1
M
O
N
D
AY
RAPAMYCIN REDUCES VASCULAR INJURY BUT 173 
EXACERBATES PROTEINURIA IN ASSOCIATION WITH 
INHIBITION OF VEGF AND VEGF-R IN CHRONIC KIDNEY 
ALLOGRAFT DYSFUNCTION
H-T. Ko1,2, J.L. Yin1, V. Levidiotis1, K.R. Wybunn1, J.M Eris1, A/Prof Steve J 
Chadban1
1Renal Medicine, Royal Prince Alfred Hospital, 2University of Sydney
Background: Recent immunosuppressive therapy outcomes suggest 
Rapamycin (Rapa) can halt chronic kidney allograft dysfunction (CAD). but 
treatment with Rapa is often associated with new onset proteinuria. Vascular 
endothelial growth factor (VEGF) has a signifi cant role in atherosclerosis, 
fi brosis and glomerulosclerosis. VEGF can induce migration and proliferation 
of endothelial cells and regulate vascular and glomerular permeability through 
VEGF receptor 1/2 (VEGR1) and (VEGFR2). The mammalian target of 
rapamycin (mTOR) is known to regulate VEGF production, but the role of 
the mTOR inhibitor, Rapa, in the VEGF/VEGFR meditated pathway, during 
the development of CAD is unknown. In this study, we investigate the roles of 
VEGF and VEGFR1/2 in a rat model of CAD,
Methods: F344 to Lewis rat kidney allografts were performed. Animals were 
either treated with Rapa (N=6) or CsA (N=6) for 180 days. Alongside this 
model, a model of CAD was developed. Animals were either treated with CsA 
or Rapa for 10 days post transplantation, thereafter no immunnosuppresion was 
used, until animals were sacrifi ced at 180 days. Glomeruli and arteries were 
separated by laser capture microdissection. Results of the treatment with CsA or 
Rapa were determined by renal function and histopathology. VEGF, VEGFR1 
and VEGFR2 expressions were determined by immunohistochemistry and real-
time PCR. In vitro the effects of Rapa or CsA on VEGF production was also 
determined on endothelial cell tubular cells, mesangial cells and podocytes.
Results: The CAD model was confi rmed at 180 days by the detection 
of proteinuria and histopathological fi ndings of intimal-arteritis and 
glomerulosclerosis. These CAD changes were ameliorated in the 180 day 
treated CsA (1.5 mg/kg) and Rapa (1.0 mg/kg). recipients, as demonstrated 
by improved proteinuria, macrophage infi ltration and glomerulosclerosis (all 
p<0.01). In the 180 day CsA-treated and Rapa-treated groups the expression of 
CXCR3, IL-10, IL-12, IL-18 and IFN-γ were reduced (all p<0.05). no change 
was noted for TGF-β. Uniquely in the 180 day CsA-treated recipients, intimal-
arteritis was signifi cantly increased compared to the Rapa-treated recipients 
(p<0.05). Proteinuria was greater in the 180 day Rapa-treated recipients 
compared with 180 day CsA-treated recipients (p<0.05). Moreover, the levels 
of VEGF, VEGFR1 and VEGFR2 in glomeruli were signifi cantly lower in 180 
day Rapa-treated recipients (all p<0.05). Arterial levels of VEGF and VEGFR1 
were reduced, in the 180 day Rapa-treated recipients however there were no 
tubular expression differences. In vitro, Rapa and CsA did not inhibit VEGF 
production in stimulated tubular and mesangial cells, Rapa however reduced 
VEGF podocyte and endothelial cell production (p<0.05).
Conclusion: These results support the hypothesis that long-term Rapa but 
not CsA treatment can reduce intimal-arteritis. Moreover Rapa can induce 
signifi cant proteinuria and one possible mechanism maybe by way of reduced 
podocyte-VEGF and VEGFR1/2 production. These fi ndings signifi cantly 
contribute to our understanding of the possible mechanisms and mediators of 
CAD
HOST ENDOTHELIAL AND MESENCHYMAL 174 
CHIMERISM IN EXPERIMENTAL CHRONIC ALLOGRAFT 
NEPHROPATHY
J.L. Hillebrands1, H. Rienstra1, M. Boersema2, A. Zandvoort1,5, A. Smit-van 
Oosten5, 
H. van Goor3, J. Rozing1, G.J. Navis4, 
1University Medical Center Groningen, Dept. Cell Biology – Immunology, 
2University Medical Center Groningen, Dept. Pathology and Laboratory 
Medicine, Div. Medical Biology, 3University Medical Center Groningen, Dept. 
Pathology and Laboratory Medicine, Div. Pathology, 4University Medical 
Center Groningen, Dept. Internal Medicine, Div. Nephrology, 5University 
Medical Center Groningen, Central Animal Facility
Background: Vascular and interstitial remodeling are hallmarks of chronic 
allograft nephropathy (CAN). Vascular remodeling (transplant arteriopathy) 
is characterized by occlusive neointima formation resulting from uncontrolled 
smooth muscle cell (SMC) proliferation. Interstitial remodeling is characterized 
by myofi broblast recruitment and proliferation culminating in interstitial 
fi brosis. Both transplant arteriopathy and interstitial fi brosis supposedly lead to 
deterioration of graft function. The origin (graft vs. host) of neointimal ECs and 
SMCs as well as interstitial myofi broblasts in CAN still is a matter of debate. 
We therefore determined the origin of ECs, SMCs and myofi broblasts in an 
experimental model of CAN in rats.
Methods: Dark Agouti (DA) allografts were transplanted to human 
Placental Alkaline Phosphatase (hPAP) transgenic F344 rats. hPAP F344 
rats constitutively express hPAP in nucleated cells which can be detected by 
hPAP-specifi c immunostaining. DA isografts served as controls. Recipient 
rats received ciclosporin (5 mg/kg) on the fi rst 10 days after transplantation. 
Contralateral nephrectomy was performed 10 days after transplantation. Renal 
function was determined before transplantation and 4, 8 and 12 weeks after 
transplantation. Recipients were sacrifi ced 12 weeks after transplantation or 
earlier in case of poor condition. Grafts were processed for histological analysis 
and severity of transplant arteriopathy, glomerulosclerosis and interstitial 
fi brosis was determined. Furthermore, host EC, SMC and myofi broblast 
chimerism was determined by specifi c immunofl uorescent staining using the 
following antibodies: RECA-1 (ECs). 1A4 (á-smooth muscle actin [SMCs/
myofi broblasts]). MN4-91-6 (DA MHC class I) and anti-hPAP (transgene).
Results: Compared with isografts, allografts presented with severe CAN 
characterized by glomerulosclerosis, tubular atrophy, transplant arteriopathy 
and interstitial fi brosis. These histological changes were associated with 
reduced renal function as indicated by proteinuria and reduced creatinine 
clearance. Graft survival was inversely correlated with the severity of 
transplant arteriopathy. Immunolabeling for hPAP, DA MHC class I and 
smooth muscle actin revealed graft origin (co-expression DA MHC class I and 
smooth muscle actin) of virtually all neointimal SMCs in allografts. Similar 
results were obtained for neointimal ECs. However, host EC-chimerism 
was detected in peritubular and glomerular capillaries; 62% of glomeruli in 
allografts contained host-derived ECs (RECA-1+hPAP+; ~2 host ECs/chimeric 
glomerulus/cross-section). Staining for smooth muscle actin revealed increased 
numbers of cortical interstitial myofi broblasts in allografts (vs. isografts). 
indicative of interstitial fi brosis. Immunolabeling for hPAP, DA MHC class I 
and smooth muscle actin revealed presence of both graft- and recipient-derived 
interstitial myofi broblasts. Quantitative analysis revealed 53% of interstitial 
myofi broblasts to be of host-origin.
Conclusions: Neointimal SMCs and ECs in CAN are graft-derived indicating 
that endothelial repair as well as neointima formation in graft arteries are 
mediated by cells residing within the graft. In contrast to vascular remodeling 
in the larger arteries, the development of interstitial fi brosis involves both 
graft- and host-derived myofi broblasts. These results suggest that interstitial 
myofi broblasts are derived from distinct cell lineages, which may separately 
or in concert contribute to interstitial fi brosis in CAN. We propose that host-
derived mesenchymal progenitor cells are a putative target for therapeutic 
intervention. Reduced mesenchymal progenitor cell recruitment is expected to 
attenuate interstitial fi brosis resulting in prolonged graft function.
CTGF SIRNA CAN PREVENT RATS RENAL ALLOGRAFT 175 
FIBROSIS
Y.P. Lu, G.H. Luo, J. Song, L. Yang, L. Luo, X. Ma, L.Y. Zhang, Y.P. Li
Transplantation Institute of west china hospital
Aim: CTGF is a highly profi brogenic molecule implicated in renal fi brogenesis. 
Small interfering RNA (siRNA) is an effective tool to silence gene expression. 
This study is to determine if siRNA targeting CTGF can inhibit CTGF 
expression of rat kidneys in vitro and vivo and whether it can protect the kidney 
from renal fi brosis in rats undergoing chronic allograft nephropathy (CAN).
Methods: Rat TEC-line (NRK-52E) anoxia model was built; siRNA-targeting 
CTGF was transfected into cells by liposome package. The rat renal CAN 
model, which was reinforced by cold ischemic injury, was built by using 
Fisher344 rat and Lewis rat as donor and recipient, respectively. At 6w after 
transplant, the recipients were divided into three groups: (1) Vehicle: vehicle 
orally; (2) Control siRNA; (3) siRNA. The group 2 and 3 were given Control 
siRNA and siRNA-targeting CTGF (0.1mg/kg). respectively Qd×14d by caudal 
vein injection. The morphological changes and cytoskeleton remodeling in 
NRK-52E cells were detected. SCr and the pathologic changes were measured 
and observed; the expression of CTGF, E-cadherin, collagen I, IV and α-SMA 
were assessed.
Results: After stimulated with anoxia, NRK-52E cells became round, enlarged 
and cytoskeleton remodeled. The expression of CTGF were up regulated since 
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6h, and reached its peak at 48h. The transfection effi ciency of siRNA was found 
over 85%. The silencing effect on CTGF mRNA/protein in siRNA group was 
found since 6h/12h, and reached its peak at 12h/24h in the TEC cells. After 
exposed with siRNA-targeting CTGF, the morphology and cytoskeleton of TEC 
cells tended into normal range in the cell anoxia model, and fi brosis-associated 
genes also down regulated. In rat renal CAN model, SCr (μmol/L) increased 
gradually at 4w (110±55.84) and 6w (228± 43.27). At 8w, SCr in Vehicle, 
control siRNA and siRNA group was 285±15.51, 278±10.21 and 190±24.02, 
respectively. At 8w, the Banff score in siRNA group was 2.330.58, which was 
signifi cantly lower than that in Vehicle (5.001.00) and in control siRNA group 
(5.671.52). p<0.05. At 8w, the expression of mRNA/protein (DQ ratio) of CTGF 
were signifi cantly down regulated in siRNA group (22.66±0.76/0.74±0.02) than 
those in Vehicle (25.00±0.50/1.04±0.11) and in control siRNA group (25.00±0.86/1.00± 
0.02). p<0.01. The expression of type I, IV collagen and a-SMA were also 
signifi cantly down regulated and E-cadherin lose was abated in siRNA group 
than those in Vehicle and control siRNA group at 8w.
Conclusions: This study at fi rst time shows that CTGF siRNA can signifi cantly 
inhibit the expression of CTGF and EMT-associated genes in rat kidneys 
and can effectively prevent the fi brosis in cell anoxia model and in rat renal 
allografts undergoing CAN. The results suggest that siRNA-targeting CTGF 
has the potential to be a novel therapeutical strategy for anti-CAN.
ADENOVIRUS-MEDIATED ANTISENSE ERK2 GENE 176 
THERAPY INHIBITS THE PROCESS OF EPITHELIAL-
MESENCHYMAL TRANSITION AND AMELIORATES 
CHRONIC ALLOGRAFT NEPHROPATHY IN A RAT MODEL
Z. Ding, X. Chen, Z. Chen, X. Chen, N. Gong
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College
Objective: To investigate the effect of Adenovirus-mediated antisense ERK2 
(Adanti-ERK2) gene therapy upon the process of epithelial-mesenchymal 
transition and the protection of graft against chronic allograft nephropathy in 
vivo. 
Methods: Male Lewis (LEW, RT11) rat received male Fisher (F344, RT11v1) 
renal allograft. The recipients were divided into three groups: (1) control group 
(no gene transfected); (2) vector control group (allograft transfected with Ad-
LacZ, 5x109); (3) gene therapy group (allograft transfected with Adanti-ERK2, 
5x109). All recipients were sacrifi ced for grafts and serum at 24 weeks after 
transplantation. Morphometric analysis was used to determine the fi brosis of 
grafts. Immunohistochemistry was used to detect the expression of E-Cadherin, 
Vimentin, ¦Á-SMA and the infi ltration of CD4+ T lymphocyte, CD8 + T 
lymphocyte and ED-1 + monocytes. ELISA was used to detect the change of 
TGF-¦Â1 in serum. 
Results: The grafts in control group and vector control group showed with 
graft interstitial fi brosis and infi ltration of CD4+ T lymphocyte, CD8 + T 
lymphocyte and ED-1 + monocytes in renal interstitium. In the control groups, 
the renal tubular epithelial cells expressed less E-Cadherin but the interstitium 
expressed more Vimentin and ¦Á-SMA in comparison with the gene therapy 
group, indicating the Adanti-ERK2 inhibited the process of EMT in the 
allografts. Meanwhile, the moderate fi brosis and less T lymphocytes and ED-1 
+ monocytes infi ltrating in the interstitium was observed in gene therapy group, 
showing chronic allograft nephropathy was ameliorated. Compared with the 
control groups, the serum expression of TGF-¦Â1 in gene therapy group was 
down-regulated. 
Conclusion: Adanti-ERK2 gene therapy inhibits epithelial-mesenchymal 
transition of the renal tubular. This effect would be close relatively with graft 
protection by attenuating graft fi brosis, decreasing infi ltration of CD4+ T 
lymphocyte, CD8 + T lymphocyte and ED-1 + monocytes in interstitium, and 
down-regulating TGF-¦Â1 level of serum. .
BIOLOGICAL AGEING IN PRE-TRANSPLANT RENAL 177 
ALLOGRAFT BIOPSIES PREDICTS ORGAN FUNCTION AT 6 
MONTHSPOST TRANSPLANT
L. McGLynn, K. Stevenson, K. LAmb, S. Zino, M. Brown, P. Shiels
University of Glasgow
As the number of available organs for transplantation is limiting the use of 
organs from older, or marginal donors increases, though this may result in 
poorer transplant outcome. Even though such organs may function adequately 
initially, the presence of substantial physiological senescence will make them 
more susceptible to the effects of transplant-related stress.
As a consequence, the biological age of the organ, rather than just its 
chronological age, may have substantive impact on post transplant organ 
function. This implies that the expression of genes involved in biological 
ageing, should provide suitable reporters for investigating such a hypothesis.
We have undertaken an investigation using a range of markers corresponding 
to a variety of biological ageing components, linking telomere biology, DNA 
damage and cell cycle regulation.
We have analysed the expression of these markers in pre transplant renal 
biopsies, taken immediately prior to organ engraftment, to determine how donor 
age and the biological age of the organ at the time of transplantation impact 
upon post transplant renal function, as determined by creatinine clearance (CC) 
six months after transplantation.
Methods: Cortical biopsies of renal transplants were obtained using an 18 
gauge needle from transplants of varying donor ages (9 years to 78 years old). 
These were derived from cadaveric or living donor organs prior to engraftment. 
Quantitative real time PCR (qRT-PCR) was used to estimate mRNA levels 
corresponding to the reporter genes p16ink4a, XRCC5, POT1 and SIRT2. Data 
analyses were performed using an SPSS statistical package. Power calculations 
for biopsies were undertaken using the Minitab Statistical package where 
?=0.52,?=0.05 and 1-? = 1.000.
Spearmans rank correlations were used to evaluate inter gene expression 
comparisons.
Results and Discussion: Creatinine clearance at six months post transplant 
showed signifi cant negative correlations with donor age (p<0.000 n=59 ). DNA 
damage (XRCC5 expression: p=0.043, n=43) and cell cycle (Sirt 2 expression: 
p=0.048,n=41). in keeping with the previous observations describing poorer 
post transplant function from older donor organs. No signifi cant correlations 
were observed with any of the other markers tested.
Older organs did display a signifi cant positive correlation with p16 ink4a 
expression (p=0.042, n=40). indicating elevated levels of biological age. 
The level of p16 ink4a displayed signifi cant positive correlations with Sirt 2 
(p=0.001, n=51) and the telomere associated marker POT 1 (p=0.012, n=42).
The expression of POT 1 also showed a strong positive correlation with XRCC5 
(<0.000, n=49) and SIRT 2 (<0.000). SIRT 2 correlated positively with XRCC5 
expression (<0.000 n=53).
These data suggest that biological age strongly infl uences graft function post 
transplant. The association between p16 and chronological age indicates that 
the poorer outcome observed with older allografts is due to elevated cellular 
senescence in such organs. Our data also indicate that DNA damage (XRCC5). 
cell cycle destabilisation (SIRT 2) and telomere destabilisation (POT1) 
contribute to post transplant graft function at 6 months.
These should provide useful prognostic markers for pre-transplant evaluation 
of subsequent graft function.
INFLUENCE OF NICOTINE ON CIGARETTE SMOKE 178 
INDUCED RENAL DAMAGE IN ORGAN TRANSPLANTATION: 
AN IN VITRO STUDY WITH RENAL CELLS
M. Mehra, A. Khanna, J. Xu, P. Uber, C. Baquet,
University of Maryland, Baltimore
Background: Cigarette smoking accelerates and promotes the progression of 
chronic kidney diseases and is also responsible for decreased quality of life 
of organ transplant recipients. Since nicotine is the main pharmacologically 
active constituent of cigarette smoke, we performed studies to understand the 
complex relationship between Nicotine and immunosuppressive drugs with 
respect to tissue repair molecules and oxidative stress the major players in the 
development of transplant nephrotoxicity.
Methods: We studied HK-2: an immortalized proximal tubule epithelial (PTE) 
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cell line from normal adult human kidney obtained from ATCC by growing them 
in OPTI-MEM (5% FBS). Using a 96 well plate, we cultured 10-5 cells in each 
well overnight. The cells were replaced with serum free medium and treated 
with SRL (100 nM). Nicotine (10-7 M, a concentration found in the plasma 
of active smokers) and MMF (10 microM) either alone or in combinations. 
After 24 h of treatment cells were treated with tetrazolium salt WST-1. Using 
Real time PCR mRNA for TGF-ƒÒ, CTGF, NADPH oxidase components and 
western blot for p22phox and NOX-1 protein expression was studied. The 
results are presented as Normalized fold expression (Mean ¡Ó SEM, n=3) using 
ƒÒ-actin as a reference gene and untreated PTE cells as a control.
Results: The results were calculated as the difference in percent inhibition with 
respect to the OD of treated and untreated cells (all in triplicate). SRL (-52.7 
¡Ó2.85%). Nicotine (-47.3 ¡Ó3.84%) and MMF (-53.3¡Ó2.4%) in isolation 
resulted in signifi cantly decreased viability of PTE cells. Combination of SRL 
with either Nicotine (-63 ¡Ó2.3%, p<0.04) or MMF (-64.3¡Ó1.45%, p<0.02) 
further worsens cell viability. More importantly, the combination of SRL and 
MMF in the presence of nicotine has the worst effect on cell viability (-78 2%, 
p<0.007) compared to SRL alone. Nicotine treatment of PTE cells resulted in 
increased mRNA expression of TGF-ƒÒ (13.7 ¡Ó 1.3- folds). CTGF (14.45 
¡Ó 2.2) OPN (10.3 ¡Ó 0.74). Renin (3.89 ¡Ó 0.52). p22phox (17.9 ¡Ó 1.06). 
NOX-1 (16.45 ¡Ó 1.35) and Rac-1 (12.42 ¡Ó 0.87). and decreased mRNA 
expression of antioxidants [Superoxide dismutase (SOD) 0.685 ¡Ó 0.15) and 
thioredoxin (TXN) 0.472 ¡Ó 0.098]. The pretreatment of cells with inhibitor of 
superoxide generator DPI reversed the effects of nicotine and Nicotine, SRL 
and MMF treatment increased protein expression in PTE cells. Nicotine treated 
also resulted in a signifi cant increase in the secretion of TGF-ƒÒ protein in the 
conditioned medium (p<0.01). The effects of SRL alone or in combination with 
MMF on these markers were amplifi ed in the presence of nicotine.
Discussion: The fi ndings suggest that Nicotine amplifi es the effects of SRL and 
MMF on the viability of PTE and subsequent modulation of tissue repair and 
oxidative stress markers. These results suggest that conventional renal sparing 
regimens (SRL and MMF) possess an inherent potential for renal tubular 
toxicity in transplant recipients with history of smoking. Ongoing studies in 
animal and human conditions will further validate these sentinel observations.
ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) AND 179 
PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) DONOR 
GENETIC POLYMORPHISMS ARE OF SIGNIFICANCE IN ONE-
YEAR KIDNEY ALLOGRAFT FUNCTION
M. Klinger, M. Krajewska, K. Koscielska-Kasprzak, D. Drulis-Fajdasz W. 
Weyde, K. Madziarska, O. Mazanowska
Department of Nephrology And Transplantation Medicine, Wroc³aw Medical 
University
The quality of the transplanted organ is a decisive factor for short- and long-
term allograft survival. The genetic characteristics of the donor are signifi cant 
for ischemic reperfusion injury and repair. Therefore the aim of this study 
was to evaluate the impact of functional polymorphisms of selected donor 
factors involved in vascular wall damage. The genetic polymorphisms tested 
were: fetuin A, homocysteine, plasminogen activator inhibitor-1 (PAI-1). 
metalloproteinase 9 (MMP-9). myeloperoxidase (MPO). endothelial nitric 
oxide synthase (eNOS). interleukin 1â (IL-1â). interleukin 6 (IL-6). and 
C-reactive protein (CRP). and their effects on kidney allograft function one 
year after transplantation were analyzed.
Material and Methods: The study group encompassed 89 donors (55 males, 
34 females, mean age: 46.8±11.6 years) from whom 125 kidney allografts 
were obtained. The source of donor DNA was cryopreserved lymphocytes 
or splenocytes remaining after histocompatiblity typing. AHSG 1/2, MMP9 
-1562 C/T, IL6 -174G/C, IL1â 3954C/T, MTHFR 677C/T, MTHFR 1298A/C, 
NOS3 -786C/T, and PAI1 4G/5G single-nucleotide polymorphisms (SNPs) 
were determined with the use of sequence-specifi c probe PCR (SSP-PCR) with 
allele-specifi c primers and an HGH or DRB1 internal control. Genotyping of 
MPO -463G/A and allele A of CRP -390C/T/A was performed as Acil or Spel 
restriction fragment length analysis. NOS3 IV a/b polymorphism, which is 
a VNTR (variable number of tandem repeat) polymorphism, was genotyped 
by gel electrophoresis of the respective PCR-generated DNA fragment. All 
genotyping procedures were verifi ed by DNA sequencing of the selected 
samples. The function of the transplanted kidney was evaluated on the basis 
of eGFR using the Cockcroft-Gault or Modifi cation of Diet in Renal Disease 
(MDRD) equation. Statistical analysis was conducted using the Statistica 7.1 
computer program.
Results: The presence of donor genotype aa of the eNOS gene polymorphism 
was connected with worse kidney allograft function after twelve months 
(p=0.003). Occurrence of the aa genotype was also linked with acute rejection. 
Affi rmation of the signifi cance of the connection by multivariable analysis 
proved the independence of this factor’s impact. Allograft function was also 
signifi cantly affected by donor PAI1 gene polymorphism. The lowest values 
of glomerular fi ltration rate after twelve months were achieved by recipients 
who received a graft with the homozygotic 5G polymorphism (p<0.004). 
The remaining tested polymorphisms did not signifi cantly infl uence one-year 
allograft function.
Conclusion: It is shown for the fi rst time that endothelial nitric oxide 
synthase (eNOS) and plasminogen activator inhibitor-1 (PAI-1) donor genetic 
polymorphisms are signifi cant independent factors in long-term kidney 
allograft function.
LIVER: VIRAL HEPATITISCONCURRENT ORAL SESSION 12: 
IN VIVO PROTECTION AGAINST HCV BY BROADLY 180 
NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
N. Kneteman, M. Law, T. Maruyama, J. Lewis, E. Giang, D. Burton
Dept of Surgery, University of Alberta, Edmonton; Depts of Immunology and 
Molecular Biology, Scripps Research Institute, La Jolla, Ca
Introduction: The extreme variability due to quasispecies evolution of HCV 
has challenged efforts at both vaccine design and passive immunotherapy. 
Two previous clinical trials attempting to prevent HCV re-infection after liver 
transplant with human anti-HCV immunoglobulin preparations failed, as did a 
recent trial with anti-HCV monoclonal antibodies (mAbs).
Methods and Results: Utilizing an Fab phage-display library, 115 clones with 
specifi c binding to HCV E2 were isolated and 3 groups recognizing specifi c 
antigenic regions were generated. After conversion to full length IgG1s, 
binding affi nities ranged from 0.4-6 nM, but only mAbs specifi c for antigenic 
region 3 (AR3) reacted with both genotype 1a and 2a E1-E2 complex and cross 
–neutralized JFH-1 virus and many HCV pseudotypes. To test the ability of 
these broadly neutralizing AR-3 specifi c mAbs to protect against heterologous 
HCV quasispecies as are encountered in clinical infection, 3 groups of 6 SCID/
uPA human liver chimeric mice with high level human hepatocyte repopulation 
received 200mg/kg of 2 AR3 mAbs (AR3A, AR3B) or isotype control Ab IP 
24 hours prior to IV inoculation with genotype 1a infected human serum (2 X 
105 copies).
All 4 surviving control mice demonstrated high titre HCV. HCV was detected 
in 5 of 9 mice in the treatment groups on day 1, but was cleared in all on day 
6 after virus challenge. 3 of 5 AR3A treated mice demonstrated breakthrough 
infection on days 14, 21, and 28 with 2 protected through 6 weeks. While 1 
AR3B treated mouse demonstrated breakthrough at week 3, 3 of 4 AR3B 
treated mice remained HCV negative through 6 weeks at which time Ab level 
would be predicted to have declined to <10% initial neutralizing serum level.
Conclusions: These results demonstrate the ability to protect against a 
heterologous HCV quasispecies swarm with mAbs against AR3 of HCV E2 and 
raise the potential for such mAbs to achieve protection from HCV reinfection 
after liver transplant.
DOES INTERFERON USE PRIOR TO LIVER 181 
TRANSPLANT INFLUENCE HEPATITIS C OUTCOMES 
FOLLOWING TRANSPLANTATION?
G. Smallwood, C. Fasola, A. Stieber, T. Heffron
Emory University School of Medicine
The most frequent reason for liver transplantation in this country is due to 
complications of hepatitis C (HCV) with recurrence of HCV being universal. 
Recent reports have shown that both patient and graft survival for the HCV 
patient following transplant have decreased over time. Whereas use of 
interferon products has become wide spread with the majority of HCV patients 
are currently being treated prior to transplant.
Aim: To review the outcomes of HCV patients that have received interferon 
products prior to liver transplant compared to HCV patients that never received 
interferon prior to transplant.
Method: Single-center, retrospective review of patients transplanted for HCV 
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since December 1998 (n = 131). Patients must have received a primary graft for 
a diagnosis of HCV and demonstrate survival greater than 3 months. Primary 
endpoint is the effect of IFN exposure prior to transplant on post transplant 
outcomes.
Results: Patients receiving interferon tx prior to transplant (preIFN group; n 
= 45) had a more aggressive recurrence of HCV when compared to patients 
not receiving interferon prior to liver transplant (noIFN group; n= 86). This 
aggressive HCV recurrence was demonstrated by the preIFN group’s early 
recurrence (181.1 ± 236 days vs. 303.4 ± 327 days; p = 0.031). frequency of 
HCV recurrence [41/45 (91.1%) vs. 62/86 (72.1%); p = 0.013], and 1 year 
HCV recurrence free survival [48.2% (± 0.05) vs. 20.0% (± 0.06); p = 0.005]. 
Most disturbing was the decreased patient survival in the preIFN group at 
1yr. and 3 yr. [79.7% (± 0.06) vs. 90.5% (± 0.03); 65.7 (±0.08) vs. 75.9% (± 
0.05); p = 0.05] when compared to the patients not receiving interferon prior 
to transplant.
Conclusions: Based on this study, interferon use prior to transplant for the 
HCV patient indicates poor outcomes following liver transplantation. Due to 
the increasing numbers of HCV patients coming to transplant, validation of 
these results should be of utmost importance.
EFFICACY OF INTERFERON Β; COMBINED 182 
CYCLOSPORINE A TREATMENT IN THE RETREATMENT OF 
CHRONIC HEPATITIS C -PROMISING ASPECT OF CONQUEST 
OF POSTTANSPLANTATION HEPATITIS C
K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Background/Aim: A signifi cant proportion of chronic hepatitis C patients 
fails to achieve sustained virological response (SVR) even after the treatment 
with pegylated interferon (IFN) combined ribavirin. The effective treatment 
for patients who previously failed combination standard IFN plus ribavirin 
or pegylated IFN plus ribavirin has not been established. Management of 
these patients is the most challenging task. We have originally developed IFN 
combined cyclosporine A (CsA) treatment and also reported its favorable anti-
HCV effect. CsA is an oral cyclophilin Inhibitor with anti-HCV activity
Methods: We included 59 patients (median age, 63) with 1) histologically 
proven chronic hepatitis C, 2) genotype 1b and 3) non-responders and relapsers 
to combination IFN plus ribavirin or combination pegylated IFN plus ribavirin. 
We conducted the present study to confi rm the effi cacy, safety and tolerability 
of our protocol. Serum HCV RNA level was 3900 KIU/ml. The treatments 
consisted of an induction therapy, an intensifi ed therapy and a maintenance 
therapy. The induction therapy comprised intravenous 1 MU IFNβ; every 4 
hours for the fi rst 3 days, 1.5 MU IFNβ; every 6 hours for the next 4 days 
and 2 MU IFNβ; every 8 hours for the following 3 weeks, totaling 168 MU 
of IFNβ;. The intensifi ed therapy was induction therapy shortened to 2weeks. 
The maintenance therapy comprised of pegylated IFNα;2b and ribavirin. CsA 
was given 4 times daily for a total dose of 200 mg during the induction and the 
intensifi ed therapies. Ribavirin was given twice daily for a total dose of 800 mg 
or 600 mg during the maintenance therapy.
Results: The ETR and SVR rate of the present study were 73% (43/59) 
and 59% (35/59). respectively. The relapse rate was 19% (8/43). SVR in 
previous combination therapy relapsers was 80% (32/40) and that in previous 
combination therapy non-responders was 16% (3/19).
Conclusion: We concluded that our protocol should be effective in relapsers 
to the previous combination therapies. Host factor targeting treatment will 
become a promising treatment option for posttransplantation HCV.
INTRA PORTAL DONOR SPECIFIC ANTIGEN 183 
TRANSFUSION MIGHT PREVENT RE-INFECTION OF 
HEPATITIS C VIRUS AFTER LIVING RELATED LIVER 
TRANSPLANTATION IN HEPATITIS C HEPATIC CIRRHOSIS
Y. Sato1, S. Yamagiwa2, S. Yamamoto1, H. Oya1, T. Kobayashi1, H. Hokai1, K. 
Hatakeyama1
1First Dept. of Surg., School of Medicine, Niigata University, 2Dept. of 
Hepatology., School of Medicine, Niigata University
Re-infection of hepatitis C virus (HCV) is very important for prognosis after 
liver transplantation of HCV cirrhosis. It has been reported that the 30 to 40% 
of patients, who got IFN-ribavirine therapy became sustained virological 
response (SVR) after liver transplantation. In the mechanism of re-infection 
of HCV, the peri-transplant immunity included the immunosuppression must 
be very important for getting the solution of prevention of its infection. We 
already reported that the intra-portal donor specifi c antigen transfusion (DST) 
induced macrochimerism of donor-type NKT cells and obtained rapid reduction 
of immunosuppression and steroid withdrawal. In this study, we investigated 
about the infl uences of intraportal DST for HCV-reinfection after living related 
liver transplantation (LRLT). (Patients and method) The 12 patients, who 
underwent LRLT for the endo-stage of HCV liver cirrhosis from 1999 to 2007 
in our hospital, were estimated about the infl uence of intraportal DST for re-
infection of HCV. Immunological analysis by fl owcytometry was performed 
for the patient who got a spontaneous disappearance of HCV and 11 patients of 
chronic hepatitis C who got SVR by IFN-ribavirine therapy.
Results: The 9 patients had gotten perioperative IFN therapy and intraportal 
DST after LRLT. All patients could be steroid withdrawal within 2 months. The 
HCV disappeared in the 6 patients of all (66.7%) after LRLT. The four of six 
patients were SVR. Two patients, who could not be virological response, were 
performed the IFN-ribavirine therapy after a progression to chronic hepatitis C 
and the last patient did not get IFN-ribavirin therapy.
The patient who got preoperative IFN-ƒÀ revealed the macrochimerism of donor 
type CD56+T cell in the graft liver one month after LRLT. The immunological 
analysis about the patient, who got spontaneous disappearance of HCV two 
months after LRLT, demonstrated that CD56+T cells strongly developed the 
both FasL and TRAIL expressions and the suppressive receptor of NK2GA 
expression. The ratio of NK cell and NKT cells among the leukocytes in the 
peripheral blood was similar to the SVR patients of CHC. 
Conclusion: The 66.7% of all patients, who got intraportal DST, disappeared 
HCV after LRLT. In this study, the clinical and immunological fi ndings 
suggested that intraportal DST might affect for the clearance of HCV by the 
both host immunity and IFN-ribavirin therapy.
INSULIN RESISTANCE, SERUM ADIPOKINES AND 184 
THE RISK OF FIBROSIS PROGRESSION IN PATIENTS 
TRANSPLANTED FOR HEPATITIS C: A PROSPECTIVE 
COHORT STUDY
M. Charlton1, B. Veldt1,3, K. Watt1, J. Poterucha1, R. Wiesner1, J. Hay1, 
C. Rosen2, J. Heimbach2, H. Janssen3
1Mayo Clinic Division of Gastroenterology and Hepatology, Rochester, 
Minnesota, USA, 2Mayo Clinic Division of Transplantation Surgery, 
Rochester, Minnesota, USA, 3Erasmus MC University Medical Center, 
Department of Gastroenterology and Hepatology, Rotterdam, the Netherlands
Diabetes mellitus is a risk factor for disease progression in patients with chronic 
hepatitis C virus (HCV) infection. However, patients transplanted for HCV 
might already be at risk of fi brosis progression even before diabetes mellitus 
is manifest, if decreased insulin sensitivity occurs during immunosuppressive 
treatment.
Aim: To investigate the whether the Homeostasis Model Assessment of Insulin 
Resistance (HOMA-IR) can be used as a more sensitive tool to identify insulin 
resistant patients at risk for rapid fi brosis progression.
Methods: Single center prospective cohort study. Serum insulin, glucose and 
adipokines were measured at 4 months after liver transplantation in patients 
transplanted for chronic hepatitis C between 1-1-1995 and 1-1-2005. Liver 
biopsies were routinely performed at 1, 3 and 5 years after transplantation. All 
patients gave informed consent.
Results: One hundred eighty-one patients were included; 27 patients (21%) 
were treated for diabetes mellitus, all except 1 received insulin. Another 38 
patients (15%) were pre-diabetic, defi ned as HOMA-IR >2.5.
During a median follow-up of 4.9 years, 51 patients developed advanced 
fi brosis or cirrhosis. The 5-year occurrence of advanced fi brosis was increased 
in patients treated for diabetes mellitus and in pre-diabetic patients (49.4%; 
confi dence interval (CI) 23.0-75.8 and 49.3%; CI 17.9-80.7, respectively) 
compared to patients with normal insulin sensitivity (20.5%; CI 0.9-31.7) 
(p=0.069 normal versus pre-diabetic and p=0.010 normal versus diabetes 
mellitus). Neither leptin, adiponectin, insulin-like growth factor-1, tumor 
necrosis factor-alpha or interleukin-6 were associated with development of 
advanced fi brosis in univariate Cox regression analysis.
Time-dependent multivariate Cox regression analysis showed that insulin 
resistance (Hazard Ratio (HR) 1.89; CI 1.05-3.41, p=0.033). donor age 
(HR 1.43; CI 1.17-1.75, p<0.001). aspartate aminotransferase (HR 1.03; CI 
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1.01-1.05, p=0.001) and bilirubin levels (HR 2.97; CI 1.14-7.72, p=0.026) were 
statistically signifi cantly associated with development of advanced fi brosis, 
whereas steatosis, interferon treatment and body mass index were not.
In conclusion, HOMA-IR is an important tool to identify insulin resistant 
patients at risk for rapid fi brosis progression after liver transplantation for 
hepatitis C. Treatment with insulin alone had no signifi cant benefi cial effect 
on the fi brosis progression rates, suggesting there might be a potential role for 
treatment with insulin sensitizing agents.
DONOR AGE PREDICTS RECURRENT DISEASE IN 185 
LIVER TRANSPLANTATION RECIPIENTS WITH HEPATITIS C
U.P. Neumann, M. Bahra, J. Pratschke, P. Neuhaus
Charité, Virchow Clinic
The impact of donor age on outcome in hepatitis C positive liver transplant 
recipients has been shown in a number of studies. However, analyzing large 
liver transplant databases this effect has been proven for all other indications as 
well. Despite this fact donor shortage is responsible for the increased acceptance 
of marginal grafts in all patients. Aim of our study was to analyze donor age 
related increase of fi brosis progression and mortality after liver transplantation 
(OLT) in hepatitis C virus (HCV) -infected patients based on protocol liver 
biopsies.
Overall 283 hepatitis C positive liver transplants in 259 recipients were 
analyzed. Protocol liver biopsies were performed after 1-, 3-, 5-, 7-, and 10 
years and staged according to the Scheuer score.
Overall post transplant patient survival fi gures were 86% at one year, 78% 
at 3 years, and 72% at 5 years. Hepatitis C related patient death occurred in 
41/259 (16%) of the patients. Donor age was signifi cantly associated to overall 
survival, hepatitis C related graft loss, and fi brosis progression.
The risk of hepatitis C related graft loss increased from 4.9% in patients 
receiving a graft from a donor below 30 years to 14.2% in transplants with a 
donor age between 30-50 years, to 27.1% in transplants with donor age between 
50-65 years and 30% in older donors.
Donor age was signifi cantly associated to all relevant outcome parameters in 
hepatitis positive patients after liver transplantation. The strongest increase in 
the frequency of hepatitis C related death was detected in transplants utilizing 
donors > 50 years.
USE OF LIVER GRAFTS FROM DONORS OLDER THAN 186 
70 YEARS IN RECIPIENTS WITH CHRONIC HCV
R. Charco1, A. Escartin1, J.L. Lazaro1, I. Bilbao1, H. Allende3, C. Dopazo1, M. 
Caralt1, L. Castells2
1Department of HBP Surgery and Trasnsplants, 2Department of Hepatology, 
3Department of Histology nt of Hepatology No
Abstract Document: The aim of the present study was to evaluate the outcome 
of HCV infected patients underwent liver trasplantation (LT) with liver grafts 
from donors older than 70 years.
Patients And Methods: Between 1998 and 2006, 438 underwent LT in our 
Hospital, 230 of them due to chronic HCV infection. 127 of 230 HCV patients 
received grafts from donors over 50 years. After exclusion for co-infection 
HBV or HIV and split livers, 97 patients entered in the study.
The study group were patients underwent LT with donors aged more than 70 
years (Group A, n=26). Control group was composed by patients underwent 
LT with donors between 50 and 70 years (Group B, n=71). Data have been 
prospectively recorded.
All patients survived for at least 1 year, with exception of patients who died due 
to HCV recurrence. Median follow-up was 28.5 months (1.6-102) in Group A 
and 37.7 months (3.5-112) in Group B.
Protocol liver biopsies were performed at 1, 3 and 5 years after LT or when 
liver dysfunction occurred during follow-up.
Biopsies showing evidence of chronic hepatitis were scored for 
necroinfl ammation and fi brosis according to Ishak index. Hepatitis without 
fi brosis (F0). fi brosis without bridges (F1-F2). fi brosis with bridges (F3-F4) 
and established cirrhosis (F5-F6).
Results: There were no differences in donor and recipient characteristics or 
surgical aspects, except in UCI stay. Donors form group A has a shorter stay 
in comparison with group B (1 day, r=1 to 8, vs 3 day, r=1 to 36, respectively). 
During the follow-up no differences were found regarding the one-year acute 
rejection rate, incidence of CMV infection or incidence of vascular or biliary 
complications.
A total of 189 liver biopsies were reviewed for the study. 19 patients developed 
cirrhosis or died due to an aggressive recurrence, 3 (12%) in group A and 16 
(22.5%) in group B (p=ns). Moreover, until 29 patients had developed at least 
F3 degree fi brosis, 6 (24%) in group A and 23 (32,5%) in group B (p=ns) 
Although there was a lower incidence of fi brosing cholestatic hepatitis in patients 
of group A, differences were not statistical signifi cant (11% vs 17%, p=ns). 
Regarding HCV histological progression, the cumulative actuarial fi brosis 
grade was similar between groups. Cumulative probability of developing graft 
fi brosis ≥; F3 (fi brosis with bridges) at 1, 3 and 5 years was 23%, 64%, 64% 
in group A vs 32%, 66%, 72% in group B, p=0.3. Cumulative probability of 
developing graft cirrhosis at 1,3 and 5 years was 12%, 30%, 44% in group A vs 
23%, 38%, 47% in group B, p=0.4.
There were no differences in the actuarial patient survival at 1, 3 and 5 years. 
(Group A: 96%-77%-77% and Group B: 89%-70%-59% ).
Conclusion: Despite the small number of patients, liver grafts from donors 
older than 70 years can be used in HCV recipients with similar results obtained 
with the utilization of donors between 50 and 70 years old.
PRELIMINARY TRIAL OF ENTECARVIR 187 
MONOTHERAPY AFTER CONVERSION FROM HEPATITIS 
B IMMUNOGLOBULIN AND LAMIVUDINE THERAPY IN 
LIVING DONOR LIVER TRANSPLANTATION FOR CHRONIC 
HEPATITIS B INFECTION
H. Furukawa1, T. Shimamura2, T. Suzuki1, M. Taniguchi3, K. Yamashita3, 
T. Kamiyama3, M. Matsushita3, S. Todo3
1Departmet of Organ Transplantation and Regenerative Medicine, Hokkaido 
University School of Medicine, 2Division of Organ Transplantation, 
Hokkaido University Hospital, 3Department of General Surgery, Hokkaido 
University School of Medicine
Objectives: This prospective study to determine the safety and effi cacy of 
entecavir monotherapy after converted from HB immunoglobulin (HBIg) 
and lamivudine (LAM) therapy for the patients with living donor liver 
transplantation (LDLT) for chronic hepatitis B (HBV) infection.
Materials and Methods: From Sep. 1997 to Dec. 2006 LDLT was performed 
in 118 adults in our center. Twenty four cases of patients with chronic HBV 
infection who survived until the end of 2006 were involved in the study. All 
patients had positive HBsAg before liver transplantation, of which 7 patients 
had positive HBV-DNA. All patients received HBIg and LAM therapy after 
liver transplantation. The patients had 5,000 IU of HBIG at anhepatic phase 
during transplantation and daily for 7 days. HBIg was administered to maintain 
HBsAb more than 500 mIU/ml fi rst 3 months after transplantation and more 
than 300 mIU/ml thereafter. The patients had 100 mg of LAM daily from the 
day of transplantation. Entecavir was given in a dose of 0.5 mg daily. Of twenty 
four patients in the study, 13 patients (group A) were converted to entecavir 
monotherapy. Those were compared with the other 11 patients (group B) 
with the continuous HBIg and LAM regimen. @Primary end point was the 
recurrence of hepatitis B infection with positive HBsAg and HBV DNA. At 
the entry of the study patients demographics were not signifi cantly different 
between two groups.
Results: No patients in both groups had HBV recurrence during the follow-
up of 47 weeks. No difference was found in liver function tests between two 
groups (group A vs B); total bilirubin (1.1 0.6 vs 1.1 0.5). AST (29 15 vs 25 
8). ALT (27 16 vs 30 24). GGTP (58 65 vs 126 185). All patients in group 
A continue on entecarvir without adverse effect. The patients in group B 
received 7-11 times of 3,000 IU of HBIg to maintain HBsAb to 296.0 149.2 
mIU/ml.
Conclusion: Entecavir monotherapy seems to be a promising agent to prevent 
HBV infection after converted from HBIG and LAM therapy without signifi cant 
adverse effect. Further follow-up is necessary to confi rm its effi cacy.
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ANTI-DONOR SPECIFIC HYPORESPONSIVENESS 188 
INDUCED BY MINIMIZING IMMUNOSUPPRESSION CAN 
LEAD TO SUCCESSFUL HEPATITIS B VACCINATION IN 
LIVER TRANSPLANT RECIPIENTS
H. Tahara1,3, H. Ohdan1,3, Y. Tanaka1,3, H. Tashiro1,3, T. Itamoto1,3, T. Asahara1,3, 
M. Imamura2,3, S. Takahashi2,3, K. Chayama2,3
1Department of Surgery, Division of Frontier Medical Science, Programs for 
Biomedical Research, Graduate School of Biomedical Science, Hiroshima 
University, 2Department of Medicine and Molecular Science, Division of 
Frontier Medical Science, Programs for Biomedical Research, Graduate 
School of Biomedical Science, Hiroshima University, 3Liver Research Project 
Center, Hiroshima University
Combined treatment with either a nucleoside or nucleotide analog and 
hepatitis B immunoglobulins (HBIg) has been the gold standard for 
prophylaxis of hepatitis B virus (HBV) reinfection after liver transplantation 
(LT) due to HBV-related disease. However, indefi nite prophylaxis with HBIg 
has substantial drawbacks, such as escalating costs and the risk of emergence 
of HBV envelope protein mutations. Therefore, active immunization with 
an HBV vaccine would be a preferable alternative. Several groups have 
attempted HBV vaccination of LT recipients against HBV; however, the 
response rates of vaccination in all of these studies except for one trial using an 
unconventional adjuvant in the vaccine have been very disappointing, ranging 
from 1.9 to 40%. The immunosuppressive environment in LT recipients is 
believed to elicit a poor response to vaccination. Minimizing the exposure of 
the HBV-infected LT recipients to immunosuppressants would be benefi cial 
in inducing adaptive immunity against HBV by vaccination. In the present 
study, in addition to efforts to minimize immunosuppression, prophylaxis 
with HBV vaccination combined with continuous HBIg administration was 
performed in 11 LT recipients who had undergone transplantation due to 
HBV-related diseases. All participants received a recombinant HBV vaccine 
subcutaneously every 4 weeks at a dose of 10ƒÊg in combination with HBIg 
and lamivudine with/without adefovir. The response to vaccination was 
defi ned as (1) a reconfi rmed increase in the anti-HBs titer to >100 IU/l that 
could not be explained by HBIg administration and (2) no decrease in the 
anti-HBs titer to <100 IU/l after discontinuation of combined administration 
of the vaccine and HBIg. If anti-HBs titers exceeded above-mentioned 
responsive increasing level, HBIg substitution and the vaccine were 
discontinued. The vaccine was continuously administered till given response. 
The overall response rate to HBV vaccination was 72.7%. In order to evaluate 
the immune status of the LT recipient vaccinees, we employed a mixed 
lymphocyte reaction assay using an intracellular carboxyfl uorescein diacetate 
succinimidyl ester (CFSE) -labeling technique in response to allostimulation. 
Irradiated stimulator peripheral blood mononuclear cells (PBMCs) were 
cultured with CFSE-labeled responder PBMCs. By FCM analysis, the 
number of division precursors was extrapolated from the number of daughter 
cells of each division and from the mitotic events, and precursor frequencies 
in CD4+ and CD8+ T cell subsets. This, then, allows to separately quantify 
the number of viable CD4+ and CD8+ responder T cells that proliferate in 
response to allostimulation. Patients showing a donor-specifi c hyporesponse 
with a well-maintained response to the third-party stimulus always achieved 
a sustained immune response to the vaccine. In contract, patients showing 
a hyporesponse to both the donor and the third-party stimulus were unable 
to do so, suggesting an excessively immunosuppressive state. On the 
other hand, the following factors did not exhibit statistically signifi cant 
differences between the good and poor responders: age, sex, indication for 
LT, HBV viremia, immunosuppressive regimen at the time of vaccination, 
duration between vaccination and transplantation, duration between steroid 
withdrawal and transplantation, and even tacrolimus trough levels. Thus, 
inducing an antidonor-specifi c immunosuppressive status by minimizing 
immunosuppression should enable posttransplant HBV vaccination to be a 
promising prophylactic strategy.
CONCURRENT ORAL SESSION 13: 
NEW IMMUNOSUPPRESSIVE AGENTS
QUALITY OF REPORTING OF RANDOMIZED 189 
CONTROLLED TRIALS IN SOLID ORGAN 
TRANSPLANTATION.
P.J. Morris, L.H.M. Pengel, L. Barcena
Centre For Evidence In Transplantation, Royal College of Surgeons of 
England And The London School of Hygiene And Tropical Medicine, 
University of London, London, United Kingdom
We examined all reports in English of randomized controlled trials (RCTs) in solid 
organ transplantation that were published between 2004 and 2006. Trials were 
rated for methodological quality using the 0-5 Jadad scale with trials scoring 3 or 
greater being considered as good quality trials. Two other quality features were 
also examined, namely allocation concealment and whether analysis was based on 
intention to treat. In addition, we examined the author instructions of the ten most 
cited specialty journals for mention of the CONSORT statement. The CONSORT 
statement was introduced in 1996 to improve the quality of reporting of RCTs. 
For each report we recorded if a fl ow diagram or a satisfactory description of 
participant fl ow at each stage of the study was included as is required by the 
CONSORT statement. Funding sources (commercial, nonprofi t or mixed) and 
whether a trial was a single centre or multicentre trial were also recorded.
There were 334 RCTs over this 3 year period. Approximately a third of trials 
(37%) was considered to be of good methodological quality, 34% used allocation 
concealment and 45% of trials analysed data according to intention to treat. The 
CONSORT statement was mentioned in the author instructions in 3 out of the 
10 most cited specialty journals. Only a small number of studies included a fl ow 
diagram (14%) but 65% of papers that did not include a fl ow diagram provided 
an adequate description of withdrawals and dropouts. Funding sources were 
declared in 63% of the reports. About a third of all trials (37%) was sponsored by 
commercial companies, 18% of all trials was sponsored by nonprofi t institutions 
and 8% of all trials received mixed funding. Trials funded by commercial 
companies or trials that received mixed funding were of better quality than trials 
funded by nonprofi t institutions. For example, 52% of trials funded by commercial 
companies and 59% of trials that received mixed funding were considered to be 
of good quality versus only 30% of nonprofi t sponsored trials.
Sponsorship number of studies Jadad >=3 Allocation 
concealment
ITT
Commercial 123 64 (52%) 51 (41%) 83 (67%) 
nonprofi t 61 18 (30%) 20 (33%) 16 (26%) 
Mixed 27 16 (59%) 12 (44%) 15 (56%) 
No funding 
received
1 1 1 1
Funding not listed 122 25 (20%) 30 (25%) 36 (30%) 
There were 217 single centre trials conducted in 31 different countries and 117 
multicentre trials most of which were conducted internationally, in the USA 
or across Europe. A higher percentage of the multicentre trials was of good 
quality compared to the single centre trials (53% versus 28%). used allocation 
concealment (50% versus 27%) or intention to treat analysis (71% versus 31%).
Even though guidelines have been published to improve the quality of 
reporting of RCTs, most journals and authors show insuffi cient compliance. 
Trials that were funded by commercial companies appear to be of better quality 
than nonprofi t sponsored trials. As RCTs represent level 1 evidence in medical 
practice these fi ndings are disappointing.
IMMUNOSUPPRESSION BY A HUMAN ANTI-CD40 190 
MAB, 4D11, IS NOT ABROGATED WHEN COMBINED WITH 
TACROLIMUS ON CYNOMORGUS MONKEY RENAL 
TRANSPLANTATION.
M. Uno1, K. Yamashita1, T. Suzuki1, T. Miura2, T. Itoh3, T. Aoyagi1, 
M. Taniguchi1, T. Shimamura1, H. Furukawa1, S. Todo1
11st Dept. of Surgery, Hokkaido Univ. School of Medicine, 2Kirin Pharma 
Company, Ltd, 3Dept. of Surgical Pathology, Hokkaido Univ. School of 
Medicine
Background: The blockade of CD40-CD154 costimulation pathway 
by anti-CD154 antibodies induces a potent immunosuppressive effect. 
Addition of calcineurin inhibitors, however, has been shown to abrogate the 
immunosuppressive effect of CD154 signal blockade in rodents and nonhuman 
primates. Previously, we have shown that blockade of CD40-CD154 signal 
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by anti-CD40 mAb, 4D11, markedly prolongs renal allograft survival in 
cynomolgus monkeys.
Aim: In this study, we examined the immunosuppressive effects of 4D11 when 
combined with tacrolimus.
Method: Kidney Txs was performed between MHC incompatible (stimulation 
index: >3 in MLRs) and blood-type identical cynomolgus monkey pairs. 
Transplant recipient was given either no-treatment, 4D11, tacrolimus or 4D11 
plus tacrolimus. The 4D11 was administered intravenously on days 0, 4, 7, 
11 and 14 at a dose of 5 mg/kg, and once weekly at 2.5 mg/kg thereafter. 
Tacrolimus (1 mg/kg/day) was given orally starting from day 0. Both agents 
were discontinued at 6 month post-Tx, and no further immunosuppression 
was given. Graft survival, serum anti-donor and anti-4D11 antibody levels, 
peripheral lymphocyte population, MLR and graft histopathology were 
assessed.
Results: Graft survivals, serum anti-donor antibodies under treatment, C4d on 
graftectomy were summarized below.
In the scheduled graft biopsies, a moderate-to-severe infi ltration was noted 
among the 4D11 administered animals at the early post-Tx period. These 
infi ltrating cells were mainly CD4+ and CD8+ cells and to a lesser extent 
CD20+ cells. In contrast, such graft infi ltrates, including all phenotypes, 
were suppressed by 4D11 and tacrolimus combination. During the treatment 
course of 4D11, all animals developed anti-donor antibodies and one of them 
had also anti-4D11 antibody in sera. However, neither antibody was detected 
in the 4D11 plus tacrolimus group unless the treatment was discontinued. 
Furthermore, graft C4d was negative in the combined 4D11 plus tacrolimus 
group. Peripheral CD20+ cells were transiently declined in the 4D11 treated 
animals regardless of tacrolimus combinaion at the early post-operation 
period, although the numbers recovered thereafter. MLRs against donor and 
3rd party antigens were suppressed in both 4D11 and 4D11 plus tacrolimus 
given groups. Drug interaction was not seen based on the concentrations of 
4D11 and tacrolimus blood trough levels. No apparent side-effect including 
thrombosis or thrombocytopenia was noted in the 4D11 administered animals 
with or without tacrolimus.
Conclusion: The 4D11 inhibits both cellular and humoral responses against 
donor antigens. Addition of tacrolimus strengthens these immunosuppressive 
effects of 4D11. The effects of CD40 blockade by 4D11 are not abrogated but 
enhanced when combined with tacrolimus in a non-human primate renal Tx.
A NOVEL HUMAN ANTI-CD40 MONOCLONAL 191 
ANTIBODY, 4D11, FOR LIVER TRANSPLANTATION IN NON-
HUMAN PRIMATE.
T. Oura1, K. Yamashita1, T. Suzuki1, D. Fukumori1, T. Miura2, K. Kubota3, M. 
Taniguchi1, T. Shimamura1, H. Furukawa1, S. Todo1
11st Department of Surgery, Hokkaido University School of Medicine, 2Kirin 
Pharma Company, Ltd, 3Department of Surgical Pathology, Hokkaido 
University School of Medicine
Background: We have previously shown that a novel human anti-CD40 
monoclonal antibody, 4D11 signifi cantly prolongs renal allograft survival in 
cynomolgus monkeys.
Aim: In this study, we evaluated the immunosuppressive effect of 4D11 in a 
non-human primate liver transplantation (LTx) model.
Methods: Orthotopic LTx was performed among cynomolgus monkey pair 
(blood type identical, MLR stimulation index >5 and MHC class II DR β 
mismatched). Liver grafting was carried out with or without clamping superior 
mesenteric artery (SMA) during anhepatic phase. Venous-venous bypass was 
not placed. In the control group, the SMA clamping technique was adopted, 
and received no treatment. In the treatment group, 4D11 was administered 
intravenously at a dose of 10 mg/kg on days 0, 4, 7, 11 and 14; 5 mg/kg 
was given weekly thereafter. Graft survival, serum liver function tests, graft 
histology (sequential biopsies) and MLRs were assessed.
Results: Graft survival and early serum ALT levels are show below.
Control animal died on P.O.D. 4 by fulminant graft rejection. Without SMA 
occlusion during an anhepatic phase, post-Tx serum ALT levels were markedly 
elevated, and 4 out of 5 animals were lost due to immediate or delayed hepatic 
dysfunction. Histopathologic examination revealed severe ischemia reperfusion 
injury in these liver grafts. In contrast, 4 of 5 recipients, underwent the SMA 
clamping, are surviving by 4D11 treatment. Biopsies taken on P.O.D. 60 had 
no acute cellular or humoral rejection. MLRs against donor antigens were 
suppressed in long-surviving animals.
Conclusion: 4D11 treatment prolonged liver allograft survival in non-human 
primate. Clamping the SMA during an anhepatic phase facilitated successful 
LTx.
A NEW PROTOCOL OF CLONAL DELETION AND 192 
ALLOGENEIC STEM CELL TRANSPLANTATION WITH NO 
POSTTRANSPLANT IMMUNOSUPPRESSION IN LIVING 
RELATED DONOR RENAL TRANSPLANTATION
H.L. Trivedi1, P.I. Terasaki, A. Firoz, A.V. Vanikar, V. Shankar, 
V.B. Trivedi, H. Kaneku, A. Idica, P.R. Modi, S.I. Khemchandani
1Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS) - Gulabben 
Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of Kidney Diseases & 
Research Centre (IKDRC). 2Paul Terasaki Foundation, L.A., U.S.A, 3Dr. H.L. 
Trivedi Institute of Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi 
And Kamlaben Mafatlal Mehta Institute of Kidney Diseases & Research 
Centre (IKDRC). 4Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS) 
- Gulabben Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of Kidney 
Diseases & Research Centre (IKDRC). 5Shri Krishna Hospital and Medical 
Research Centre, Karamsad, Anand, India, 6Dr. H.L. Trivedi Institute of 
Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi And Kamlaben 
Mafatlal Mehta Institute of Kidney Diseases & Research Centre (IKDRC). 
7Paul Terasaki Foundation, L.A., U.S.A., 8Paul Terasaki Foundation, 
L.A., U.S.A., 9Dr. H.L. Trivedi Institute of Transplantation Sciences (ITS) 
- Gulabben Rasiklal Doshi And Kamlaben Mafatlal Mehta Institute of 
Kidney Diseases & Research Centre (IKDRC). 10Dr. H.L. Trivedi Institute 
of Transplantation Sciences (ITS) - Gulabben Rasiklal Doshi And Kamlaben 
Mafatlal Mehta Institute of Kidney Diseases & Research Centre (IKDRC) 
Introduction and Methods: New modifi cation of tolerance induction 
protocol using clonal deletion, donor leucocyte, peripheral blood stem cell 
infusion followed by total lymphoid irradiation, anti-T-cell antibody and 
cyclophosphamide was introduced. Clonal deletion was monitored for 
completeness by luminex single antigen bead testing and followed by intra-
portal donor adipose tissue derived mesenchymal stem cell + cultured bone 
marrow infusion, and challenging with second donor leucocyte infusion. Re-
measurement was done by single antigen tests. Absence of antibody response at 
the end of challenge indicated complete clonal deletion. Twenty three patients 
have been enrolled into this protocol, 3 have thus far been transplanted. 
Patients 1 and 2 were transplanted with immunosuppression of Cyclosporin, 2 
mg/kg BW/day and Prednisolone, 0.2 mg/Kg BW/day for 2-3 weeks followed 
by gradual complete withdrawal. Patient 3 was transplanted without any 
immunosuppression.
Results: Serum creatinine of fi rst patient is 1.1 mg% at 36 days post-transplant 
(10 days of complete drug withdrawal (CDW) ). of 2nd patient, 1.2 mg% at 35 
days post-transplant (2 days post-CDW). third patient has 0.7mg% at 3 weeks 
post-transplant. He is believed to be the fi rst patient in history, transplanted 
with no postoperative immunosuppressives. By the time of the Congress, he 
will be 6 months post-transplant; 20 others are anticipated to be transplanted 
without any immunosuppression in next 1-2 months. Antibody response at 1 
month post-transplant in all 3 patients was absent.
Conclusions: Tolerance induction has been achieved using new clonal deletion 
protocol with allogeneic stem cell transplantation in living-related renal 
transplantation.
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THE PERSISTENT ELIMINATION OF B CELLS 193 
RESPONDING TO BLOOD GROUP CARBOHYDRATES 
BY TEMPORAL DEPLETION OF B CELLS AND B-1 CELL 
DIFFERENTIATION BLOCKADE: NOVEL CONCEPT IN ABO-
INCOMPATIBLE TRANSPLANTATION
H. Ohdan, T. Irei, T. Asahara
Department of Surgery, Division of Frontier Medical Science, Programs For 
Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima 
University
The use of ABO-incompatible liver grafts is a possible solution for the shortage 
of donor organs for liver transplantation. Specifi c and persistent inhibition of 
anti-A/B antibody (Ab) production might be necessary for successful ABO-
incompatible transplantation. We recently demonstrated that B cells with 
receptors for A-carbohydrates belonging to the CD5+CD11b+ B-1 subset mainly 
exist in the peritoneal cavity. We also demonstrated that calcineurin inhibitors 
(CNIs) block T cell-independent B-1 cell differentiation but have no effect on T 
cell-dependent Ab production in a mouse model. Similar to human blood group 
O or B individuals, mice have naturally occurring Abs against human blood 
group A-carbohydrates in their sera. B cells with receptors for A-carbohydrates 
in mice belonging to the CD5+CD11b+B-1a subset, have phenotypic properties 
similar to those of human B cells. These cells could be temporarily eliminated by 
injecting synthetic A-carbohydrates (GalNAcƒ¿1-3,Fucƒ¿1-2Gal) conjugated to 
bovin serum albumin (BSA) (A-BSA) and anti-BSA Abs. In mice that received 
the injection of A-BSA/anti-BSA Abs, the serum levels of anti-A IgM were 
reduced, but immunization with human A erythrocytes resulted in increased 
serum levels of anti-A Abs. When combined with calcineurin inhibitor (CNI) 
treatment, which blocks B-1a cell differentiation, and treatment with A-BSA/
anti-BSA Abs, the serum levels of anti-A Abs were persistently undetectable in 
the mice even after the immunization. B cells with receptors for A carbohydrates 
were markedly reduced in these mice. These results are consistent with the 
hypotheses that CNI treatment prevents the replenishment of B cells responding 
to A-determinants after temporary depletion of B cells. Based on these fi ndings, 
in order to permanently eliminate B cells responding to A/B carbohydrates, 
we established a novel immunosuppressive regimen. In this regimen, 
instead of treatment with A-BSA/anti-BSA Abs, anti-CD20 monoclonal Abs 
(Rituximab) are administered 2 weeks before transplantation for temporarily 
eliminating differentiated B-1 cells. Further, CNI and mycophenolate mofetil 
are simultaneously administered for blocking B-1 cell differentiation and 
inhibiting pre-existing plasma cells, respectively. We performed 5 cases of 
ABO-incompatible living donor-related adult liver transplantation using this 
regimen. In all cases, CD5+ B-1 cells disappeared at the time of the operation. 
Both anti-donor blood group IgM and IgG titers were remained less than 8 after 
plasma exchange. Intraoperative analysis revealed that CD5+ B-1 cells and IgM-
CD38+CD19+ plasma cells had also disappeared from their spleens. Therefore, 
we did not perform splenectomy, except in 2 cases. In 1 case, splenectomy for 
conducting subsequent interferon-therapy were required due to hepatitis C. In the 
other case, splenectomy had previously been performed for esophageal varices. 
Anti-donor blood group IgM and IgG titers remained at undetectable levels in 
all cases. Further, an uneventful course without antibody-mediated rejection and 
severe postoperative infections was seen in all patients, except in the previously 
splenectomized patient with local bacterial peritonitis. Notably, all patients 
showed rapid recovery of total IgM and IgG levels, probably because CNI per 
se has no effects on T cell-dependent Ab production. This successful experience 
indicates that this novel immunosuppressive regimen is suitable for safely 
regulating B cells that respond to blood group carbohydrate determinants.
INDUCTION OF PROLONGED SURVIVAL 194 
OF FULLY ALLOGENEIC CARDIAC GRAFTS AND 
GENERATION OF REGULATORY CELLS BY PURIFIED 
EICOSAPENTAENOIC ACID
D. Iwami1,2, Q. Zhang1, O. Aramaki3, K. Nonomura2, N. Shirasugi1, 
and M. Niimi1.
1Surgery, Teikyo University, Tokyo, Japan, 2Renal and Genitourinary Surgery, 
Hokkaido University, Sapporo, Japan and Surgery, 3Nihon University, Tokyo, Japan
Backgrounds: Many studies have shown immunosuppressive effects of dietary 
intake of fi sh oil rich in eicosapentaenoic acid (EPA) in various models such as 
autoimmune diseases and transplantation, as well as its anti-atherosclerotic and 
anti-hyperlipidaemic effects. However, its mechanisms remain uncertain. Here 
we tested the ability of purifi ed EPA to inhibit alloimmune response in mouse 
fully allogeneic cardiac transplantation model. 
Methods: CBA recipients (H-2k) were given single injection of purifi ed EPA 
intraperitoneally on the same day as transplantation of a heart from C57BL/10 
(B10) donors (H-2b). In the recipients with functioning B10 cardiac grafts 
unrejected over 100 days, skin grafts from B10 or third party, BALB/c (H-2d) 
donors were performed to determine whether the hyporesponsiveness was 
donor-specifi c or not. Mixed leukocyte reaction (MLR) assay and enzyme 
linked immunosorbent assay (ELISA) were also performed to evaluate the 
effect of purifi ed EPA on cellular alloproliferation and cytokine production. 
To determine the presence of regulatory cells, adoptive transfer study was 
conducted. 
Results: Untreated CBA recipients rejected B10 cardiac allografts with median 
survival time (MST). 8 days. In contrast, CBA recipients treated with purifi ed 
EPA (1.0g/kg) had signifi cant prolongation of allograft survival (MST, >100 
days, p<0.01). CBA recipients treated with 0.1g/kg purifi ed EPA eventually 
rejected allografts (MST, 13 days). In the recipients with functioning B10 
cardiac allografts 100 days after grafting, skin allografts from donor-specifi c 
B10 mice had signifi cantly prolonged survival (MST, 15 days, p<0.01). 
compared to that of third-party BALB/c skin grafts (MST, 7 days). In MLR 
assay, treatment with 1.0 g/kg purifi ed EPA suppressed alloproliferation of 
splenocytes in the recipients. The treatment also inhibited production of IL-2, 
IL-12 and IFNg by the splenocytes in the recipients. In contrast, production 
of IL-10 by the splenocytes in the recipients treated with 1.0 g/kg purifi ed 
EPA was signifi cantly increased (p<0.01). When splenocytes were harvested 
from the recipients treated with 1.0g/kg purifi ed EPA 30 days after cardiac 
allografting and were adoptively transferred into naive secondary recipients, 
the adoptive transfer induced signifi cant prolongation of cardiac allograft in 
naive secondary recipients (MST >30 days, compared to that in the recipients 
with adoptive transfer of nave splenocytes, MST, 10 days). 
Conclusions: Purifi ed EPA induced signifi cantly prolonged survival of fully 
mismatched cardiac allografts, and generated regulatory cells.
PROTEASOME INHIBITION EFFECTIVELY TREATS 195 
ACUTE CELLULAR REJECTION, ANTIBODY MEDIATED 
REJECTION, AND PROVIDES LONG-TERM REDUCTION OF 
DONOR SPECIFIC ANTIBODIES
M. Everly, J. Everly, P. Brailey, B. Susskind, L. Arend, R.R Alloway, A. 
Govil, P. Roy-Chaudhury, G. Mogilishetty, E.S. Woodle
University of Cincinnati
Background: Current antibody mediated rejection (AMR) therapies (IVIg, 
apheresis, rituximab, polyclonal antibodies) provide inconsistent and suboptimal 
results and do not target the major antibody producing B-lymphocyte (plasma 
cell). We report the fi rst clinical experience of a novel agent (bortezomib) that 
targets plasma cells. Bortezomib is FDA approved for treatment of plasma cell 
tumors (multiple myeloma).
Methods: Acute cellular rejection (ACR) and AMR episodes were diagnosed 
by Banff ‘97 criteria
 (update 2005) and treated with bortezomib (1.3 mg/m2/dose x 4). Patients 
(pts) were monitored by serial donor specifi c anti-HLA antibody (DSA) 
determinations [Luminex/Labscreen beads] and quantifi ed by converting 
fl uorescence intensity to Molecules of Equivalent Soluble Fluorescence 
(MESF). Immunodominant DSA (iDSA) was defi ned as DSA with highest 
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MESF value at the time of rejection diagnosis. Non-iDSA was defi ned as the 
DSA specifi cities with levels lower than the iDSA. In fi gures below, day 1 is 
the fi rst day of bortezomib treatment.
Results: Five patients (2 kidney/pancreas and 3 kidney transplant recipients) 
with renal allograft biopsies consistent with AMR were treated with bortezomib 
(median follow-up 6.9 months). Each patient also had coexisting ACR. In each 
case, bortezomib treatment led to prompt ACR and AMR rejection reversal. 
iDSA levels decreased signifi cantly in all patients (except one patient who 
has short follow-up). Most patients had several other non-iDSA specifi cities. 
Bortezomib treatment also resulted in marked reduction of the non-iDSA 
levels. For most DSA specifi cities, bortezomib therapy also provided long 
term suppression for up to 6 months post therapy. Toxicity from bortezomib 
included a transient grade III thrombocytopenia (1 patient) and mild-to-
moderate nausea, vomiting, and/or diarrhea (3/5 patients). No opportunistic 
infections were observed.
 
Conclusions: Bortezomib therapy provides: 1) effective treatment for AMR 
and ACR with minimal toxicity, 2) effective reduction in iDSA and non-iDSA 
levels, and 3) long term suppression of DSA levels. These results indicate that 
proteasome inhibition provides an effective means for treating both humoral 
and cellular rejection. Thus, bortezomib offers a novel and promising approach 
for treating humorally mediated rejection by targeting the antibody-producing 
plasma cell.
PRE-CLINICAL ASSESSMENT OF GENZ-29155, A NOVEL 196 
SMALL MOLECULE INHIBITOR OF APOPTOSIS WITH ANTI-
REJECTION EFFECTS IN NON-HUMAN PRIMATES. 
A. Kirk1, T. Weaver1, A. Charafeddine1, F. Leopardi1, A. Agarwal1, 
D.S. Batty2, J. Williams2, S. Nahill2
1Emory Transplant Center, Atlanta, GA, United States and 2Genzyme 
Corporation, Framingham, MA, United States.
Genz-29155 is a novel, oral immune-modulatory agent identifi ed in a high-
throughput screen designed to fi nd inhibitors of TNF-induced apoptosis. The 
molecular target of the compound remains under investigation but is likely 
downstream of the TNF cell surface receptor. In vitro studies have shown 
Genz-29155 to be an effective inhibitor of the TNF-triggered caspase cascade 
but not anti-CD3 or Fas-mediated apoptosis, and thus may act by inducing 
allograft resistance to immune attack rather than suppressing the alloimmune 
response per se. It has been shown to synergize with sirolimus in murine 
heterotopic cardiac allotransplant models. In order to test this promising new 
agent in a more clinically relevant model of solid organ transplantation, we 
studied Genz-29155 in a mismatched NHP (rhesus macaque) renal transplant 
model. Genz-29155 (n=3) was administered (3mg/kg, IV, Days 0-14) with 
sirolimus (1mg/kg, PO, Days 0-30). Five control animals received only 
sirolimus and vehicle (1mg/kg, PO, Days 0-30). All animals were followed 
serially by polychromatic fl ow cytometry to determine the relative and 
absolute numbers of CD4+ and CD8+ T cell subsets in peripheral blood. Time 
to allograft rejection, the primary end point, was determined by a signifi cant 
rise in serum creatinine and BUN, as identifi ed with biweekly monitoring. 
After diagnosis of rejection, allografts were removed for histological and 
transcriptional studies, along with splenocytes for immune function assays. 
In this pilot study, prolongation of rejection-free survival was signifi cantly 
improved with Genz-29155 and sirolimus combined vs. sirolimus alone (42.67 
days vs. 17.20 days, respectively, p = 0.05). No signifi cant depletional or 
enhancing changes were observed in peripheral blood CD4+ or CD8+ T cell 
subset populations; T (naïve). T (central memory). or T (effector memory). 
Given these initial results, we have initiated a larger study (n=12) to optimize 
the dose and duration of Genz-29155. Five animals, transplanted within the 
past month remain alive and well in this study. Further investigation of this 
agent will allow us to better understand the benefi t of inhibiting TNF-mediated 
apoptotic effects in both cellular alloimmune response and allograft injury in 
solid organ transplantation.
DEVELOPMENT OF CYCLIN KINASE INHIBITOR AS A 197 
POTENT IMMUNOSUPPRESSIVE DRUG
M. Mehra, A. Khanna
University of Maryland,, Baltimore
Background: Currently clinically used immunosuppressive agents 
cyclosporine (CsA), Tacrolimus (TAC) and Sirolimus (SRL) have though 
improved rejection rates but have failed to promote long-term graft survival. 
This is mainly because of side-effects associated with immunosuppressive 
agents such as nephrotoxicity, malignancy and viral infections. Our studies 
have shown that these drugs induce expression of cyclin kinase inhibitor p21, 
overexpression of p21 in vitro and in vivo render lymphocytes less responsive 
to allo-and mitogen-induced proliferation and prolong allograft survival in rat 
heart transplant recipients.
Methods: We prepared recombinant p21 protein to explore its 
immunosuppressive properties using in vitro and in vivo models. The purity of 
p21 was confi rmed by western blot and specifi c ELISA. The proliferation was 
quantifi ed by [3H] thymidine uptake assay. We also performed experiments to 
study the effect of p21 protein on the levels of TNF-ƒÑ, IL-2, and IFN-ƒ× in the 
conditioned medium of lymphocytes activated with and without either a p21 
protein (20 U/ml) or the control protein for 24 h. Cytokines were quantifi ed by 
specifi c ELISA kits 
Results: Recombinant p21 protein but not the control p21 protein signifi cantly 
(p < 0.01) inhibited proliferation of lymphocytes, which was similar to the 
inhibition observed with CsA (p < 0.01), TAC (p < 0.01), and SRL (p < 0.01). 
The treatment with p21 protein also resulted in the inhibition of IL-2 mRNA 
in activated lymphocytes. The results demonstrate that the inhibition of 
lymphocyte proliferation by p21 also results in signifi cantly decreased protein 
levels of IL-2 (p<0.02), IFN-ƒ×ƒnƒvƒàƒ¬ƒ~ƒ|ƒ~ƒ¤ƒw, and TNF-ƒÑ (p<0.03). 
We also performed studies to understand the mechanism of these effects of 
p21 on T lymphocytes, the fi ndings suggest that using an intrinsically present 
protein transduction domain p21 protein enters the nucleus of lymphocytes 
and modulate the activity of transcription factors NFkB, NFATc and NFATp 
resulting in the inhibition of lymphocyte proliferation. In vivo treatment of mice 
with p21 protein rendered spleen cells less responsive to the anti-CD3-induced 
proliferation, whereas no differences were observed between the effects of the 
control protein and untreated animals. Recombinant p21 protein increased graft 
survival in rats compared to control protein and untreated recipients, which 
was similar to CsA. Intragraft expression of pro-infl ammatory cytokines and 
cytolytic markers was signifi cantly decreased in p21 protein treated recipients. 
These results demonstrate that recombinant p21 protein can be administered in 
vivo to suppress lymphocyte function. Parenthetically, there were no apparent 
differences in the health of mice after a week of treatment with p21 relative to 
control mice. A renal histological analysis was performed on all of the animals 
that received the p21 protein and did not demonstrate any of the abnormalities 
observed with long-term CsA treatment.
Discussion: These results demonstrate that recombinant p21 protein inhibits 
lymphocyte proliferation, expression of pro-infl ammatory cytokines, and 
promotes cardiac graft survival. Based on the known effects of p21 as one 
of the potent inhibitors of the viral replication and tumor cell proliferation, 
it is likely that its long-term use will not result in either malignancy or viral 
infections in organ transplant recipients
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CONCURRENT ORAL SESSION 14: 
INTESTINAL TRANSPLANTATION
PEDIATRIC INTESTINAL TRANSPLANTATION AT THE 198 
UNIVERSITY OF MIAMI: 13 YEAR EXPERIENCE
G. Selvaggi, T. Kato, P. Ruiz, J. Moon, S. Nishida, D. Levi, E. Island, 
L. Smith, A. Tzakis
University of Miami
We here present the results in pediatric intestinal transplantation at our 
institution from June 1994 through December 2007. We performed 180 
intestinal transplants in 157 recipients. Primary grafts were 157 cases; re-
transplantation was performed in 23 cases and 21 recipients (two patients 
received three grafts). The youngest recipient was 96 days old, the smallest 
weighed 4.4 kg. Most common original diagnoses were gastroschisis, 
necrotizing enterocolitis and intestinal atresia. Type of graft in primary 
transplants was isolated intestine (I) n=29, liver-intestine (LI) n=27, 
multivisceral (MV) n=92, modifi ed multivisceral (MMV) n=9. In re-
transplant cases, grafts were I n=6; LI n=2; MV n=12; MMV n=3. Spleen 
was included in MV or MMV grafts in 53 primary cases and 2 re-transplants; 
large intestine was part of the graft in 65 primary cases and 6 re-transplants. 
Patient survival for primary grafts was 62.6% at one year, 51% at 3 years; 
graft survival was 59.4% and 47.5% at one and three years, respectively. 
Infection was leading cause of death (n=34). followed by rejection (n=23) 
and other causes (n=30). Rejection of any grade in primary grafts was 
experienced in 65.6% of patients, severe rejection occurred in 19.7% of 
cases. Only 8/31 patients who had severe rejection are still alive (25.8%); 
additionally, 10/31 patients with severe rejection required a second intestinal 
graft. GVHD was diagnosed in 18 patients (11.5%). PTLD in 18 patients as 
well. The presence of spleen in the graft did not signifi cantly increase the risk 
of developing GVHD, but a trend towards less development of rejection and 
PTLD was seen. Our experience in pediatric intestinal transplantation shows 
improved patient and graft survival over the years. Rejection and infectious 
complications still are the most diffi cult problems in the post-operative 
management of such patients.
PEDIATRIC INTESTINAL RETRANSPLANTATION: 199 
TECHNIQUE, MANAGEMENT AND OUTCOMES
G. Mazariegos1, Z. Machaidze1, K. Soltys1, G. Bond1, R. Jaffe1, D. Martin2, R. 
Squires1, K.A. Elmagd2, R. Sindhi1
1Hillman Center For Pediatric Transplantation. Children’s Hospital 
of Pittsburgh. Pittsburgh, PA. USA, 2Thomas E. Starzl Institute of 
Transplantation. Pittsburgh, PA. USA
Background: Intestinal retransplantation (Re-ITx) has historically been 
associated with high morbidity and mortality.
Methods/Aim: The records of all children receiving Re-ITx between 
1990-09/2007 at our center were reviewed for incidence, indications, techniques 
and outcomes of Re-ITx.
Results: 172 children received primary intestinal grafts. Fourteen children 
(8.1%) were retransplanted with 15 grafts. Causes of graft failure were: acute 
rejection (ACR, n=4). liver failure (n=2). chronic rejection (n=4). PTLD (n=1). 
graft dysmotility (n=2). ACR with severe infection (n=1). and arterial graft 
aneurysm (n=1). Initial transplants were: isolated bowel (IB) in 9, liver-bowel 
(LB) in 5, and 1 multivisceral (MV). The mean time of initial graft survival 
was 34.8 m (range 1-134). Re-ITx was with IB in 2, LB in 4 and MV in 9. 
Cross match at initial ITx was positive in 2 patients. At Re-ITx, 4 patients 
had positive cross match (1 B-cell+, 2 T-cell+, and 1 B and T cell+). Initial 
immunosuppression (IS) was with Tac-Pred in 9 and rATG-Tac in 6 cases. Re-
ITx was carried out under Tac-Pred in 7 and rATG-Tac in 7 and Campath in 
1 case.
10 (71.4%) patients are alive with functioning grafts at a median current follow-
up time of 44.1m (range 6-123.9). 4 patients died from PTLD, severe ACR and 
fungal sepsis, bleeding from pseudoaneurysm respectively, at a mean time of 
5.6 m post Re-ITx. After Re-ITx, 11 patients experienced rejection (5 mild, 
3 moderate and 3 severe) but only one treated under rATG-Tac experienced 
severe ACR. Current IS is with Tac monotherapy in 6, Tac/Pred in 3 patients 
and Sirolimus/Pred in 1. All surviving patients weaned off TPN at a median 
time of 23 days and are off of IV fl uids.
Summary: Long term survival and outcome have improved in pediatric 
Re-Itx. This success rate may be attributed to improvements in IS protocols, 
technical modifi cations, proper timing of Re-ITx and improved infectious 
disease monitoring. Re-ITx frequently required LB or MV transplant after 
initial isolated intestinal Tx. Careful patient selection and post transplant 
management are essential to successful long term outcome.
A SEVEN-YEAR ITALIAN EXPERIENCE IN CLINICAL 200 
INTESTINAL AND MULTIVISCERAL TRANSPLANTATION
C. Zanfi 1, L. Ansaloni1, M. Cescon1, A. Lauro1, A. Dazzi1, G. Ercolani1, 
A. Cucchetti1, M. Zanello1, L. Pironi2, A. Pinna1
1U.O Chirurgia Dei Trapianti Di Fegato E Muliorgano-Sant’Orsola 
-Malpighi-Università Di Bologna-Bologna-Italy, 2Chronic Intestinal Failure 
Center (Head: Prof. L. Pironi) -University of Bologna – S.Orsola-Malpighi 
Hospital, 3Chronic Intestinal Failure Center (Head: Prof. L. Pironi) 
-University of Bologna – S.Orsola-Malpighi Hospital
Introduction: Adult isolated intestinal transplant is by now accepted 
worldwide as the standard treatment for patients with intestinal failure and life-
threatening parenteral nutrition (TPN) -related complications. Here we report 
the experience in intestinal transplantation in an single European Center.
Patients and Methods: Between December 2000 and March 2008, 
we performed 39 intestinal transplants in 38 adult patients: 30 isolated 
intestinal and 9 multivisceral (5 with liver). In 3 cases abdominal wall 
transplant was added. All patients were adult, with a male: female ratio of 
22: 17, a median age of 34 years (17-55) and median weight at transplant 
of 57 kg (40-97). All these recipients were on TPN for a median time of 
12 months (0-264). Underliyng diseases were mainly represented by short 
bowel sindrome (16 patients). chronic intestinal pseudo-obstruction (9 
patients) and Gardner Syndrome (9 cases). Indications for transplantation 
were: loss of venous access (16 patients). recurrent sepsis (12 cases). 
electrolyte-fluid imbalance (8 patients); reversible liver dysfunction 
was present in 19 cases. Organ procurement was performed using an in 
vivo tecnique. Immunosuppressive regimens were based on Daclizumab, 
Tacrolimus and steroids (12 cases) up to 2002, and Alemtuzumab (25 
cases) or Thymoglobuline (2 cases) combined with Tacrolimus thereafter. 
Abdominal wall closure represented a serious problem in 12 patients 
due to previous laparotomies and consequent reduction of the abdominal 
cavity. We tried graft reduction, only skin closure, mesh closure, two-
step abdominal wall closure and adbominal wall transplant. Rejection 
monitoring was accomplished by performing graft ileoendoscopies and 
intestinal biopsies through the temporary ileostomy 2 times/week in the 
first month, 1 time every 15 days in the first 3 months and every month in 
the first 6 months and then 1 biopsy every 3 months.
Results: After a median follow-up of 937 days (1-2603). actuarial 5-year 
patient survival is 67% for isolated intestinal transplant and 33% for 
multivisceral transplant (p= 0.03). while 5-year graft survival is 64% for 
isolated intestinal graft and 33% for multivisceral (p=0.06). The main cause 
of death was sepsis (68.7%). the main cause of graftectomy was untractable 
rejection (50%). Among the 22 recipients alive, 77% has a normal bowel 
function with a regular diet without parenteral support, 2 patients are on 
parenteral nutrition (1 patient is waiting for retransplantation due to graft 
trombosis) and 1 patient needs enteral support. We experienced 2 death 
related to abdominal wall closure. No abdominal wall graft experienced 
istological proved rejection. Graft versus host disease was not seen in our 
series. Five patients experienced PTLDs.
Discussion and Conclusion: In our series, isolated intestinal transplant has 
acceptable results in terms of patient and graft survival. In cases of pre-transplant 
liver dysfunction associated to parenteral nutrition, timely isolated intestinal 
transplant can prevent the progression to liver failure. A careful evaluation of 
the remnant abdominal cavity is necessary in candidates to intesinal transplant. 
When diffi cult abdominal wall closure is expected, abdominal wall transplant 
seems to represent a reasonable strategy, especially if co-operation with plastic 
surgeons is possible.
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PATHOLOGICAL FEATURES AND REGULATORY 201 
CELL SUBPOPULATIONS ASSOCIATED WITH 
SUBCLINICAL ACUTE REJECTION IN SMALL INTESTINAL 
TRANSPLANTATION
H. Takahashi, T. Kato, G. Selvaggi, V. Delacruz, J. Gaynor, J. Moon, 
S. Nishida, D. Levi, A. Tzakis, P. Ruiz
University of Miami
Introduction: Subclinical acute rejection (SCR) is a recognized notion in 
various organ transplants and is defi ned as histopathologically proven acute 
cellular rejection (ACR) without concurrent clinical indications of ACR. We 
recently characterized SCR in small intestinal transplantation (Itx) and found 
it has a negative impact on graft survival. The purpose of this study was to 
investigate the histomorphological characteristics of SCR in Itx in comparison 
with clinically signifi cant acute cellular rejection (CSR).
Methods: SCR in Itx was defi ned as a biopsy showing histopathological ACR 
without any clinical signs of ACR, including endoscopical fi ndings, and not 
treated with adjuvant immunosuppression. Histopathologically proven ACR 
with clinical signs for ACR were defi ned as clinically signifi cant ACR (CSR). 
A total of 100 cases (50 cases for SCR and CSR) from 32 patients, which 
showed histopathologically grade 1 ACR, were blindly reviewed without 
information of rejection status and compared for the following histopathological 
factors: number of apoptotic bodies in 10 representative crypts, “macroscopic 
apoptosis”, infl ammatory infi ltrate in lamina propria, mucosal edema, blunting 
of villi, vascular congestion and red blood cell extravasation. We used a semi-
quantitative scoring system which assigned a numerical score of 0-3 for each 
histopathological factor. Using a 3-color immunofl uorescence technique, we 
also evaluated the population of CD4 (+) Foxp3 (+) regulatory T cells in the 
infl ammatory infi ltrate.
Results: Among a total of 32 patients, 12 were male and 20 were female. 
Median age was 1.3 year old, ranging from 0.26 to 52.5. The types of grafts 
used in Itx were as follows: isolated intestine (n=6). liver-intestine (n=1). 
multivisceral transplant (n=22) and multivisceral transplant without liver 
(modifi ed multivisceral transplant, n=3). The median number of biopsies from 
each patient was 3, ranging from 1 to 14. SCR cases showed “big apoptosis” 
more frequently than CSR cases (42% vs. 14%; p=0.004). CSR cases showed 
severe blunting of villi (p<0.001). There were not signifi cant differences 
between SCR and CSR in the number of apoptotic bodies in 10 representative 
crypts, infl ammatory infi ltrate in lamina propria, mucosal edema, vascular 
congestion and red blood cell extravasation in lamina propria and submucosa. 
Immunohistochemical staining for CD4 and Foxp3 revealed CD4 (+) Foxp3 
(+) regulatory T cell populations in both SCR and CSR cases.
Conclusion: There were only minor differences in morphology between SCR 
and CSR in Itx and regulatory cell subpopulations were seen in both situations. 
Therefore, histopathological evaluation of biopsies by routine methodology 
shows SCR cases having features compatible with a vigorous alloimmune 
response and without other novel changes.
FECAL CALPROTECTIN LEVEL IS A SENSITIVE 202 
MARKER DETECTING SMALL BOWEL ALLOGRAFT 
PATHOLOGIES
E. Akpinar1, J. Vargas1, T. Kato1, L. Smith2, E. Hernandez2, G. Selvaggi1, E. 
Island1, J. Moon1, P. Ruiz3, A. Tzakis1
1Miami Transplant Institute, Liver GI Transplantation, Miami-FL, USA, 2Dept 
of Pediatric Gastroenterology, Univ of Miami, Miami-FL, USA, 3Dept of 
Pathology, Univ of Miami, Miami-FL, USA
Introduction: Protocol endoscopy with biopsy is currently the gold standard of 
small bowel transplant (SBTx) monitoring, however it is invasive, costly, needs 
skilled operator, may require anesthesia and may cause complications. Fecal 
calprotectin level (FCL) is a candidate noninvasive marker for posttransplant 
monitoring in SBTx patients.
Material and Methods: A pilot study was performed to test the utility of FCL 
measurements in follow up of SBTx patients. Ileostomy effl uents were collected 
at various postoperative days during endoscopy/biopsy procedures. FCLs were 
measured by an ELISA based commercial kit using rabbit polyclonal antibody. 
The results were retrospectively evaluated in combination with clinical, 
endoscopic and histopathological fi ndings. FCL values are presented as median 
(min-max) ng/mg.
Results: FCLs were measured in 122 samples that were obtained from 29 pts at 
various periods after SBTx. Retrospective evaluation showed that 11 samples 
from 6 pts with a level of 217 (116-499) coincided with rejection episodes, 6 
samples from 3 pts with a level of 125 (105-509) coincided with viral enteritis, 
51 samples from 21 pts with a level of 207 (101-507) coincided with nonspecifi c 
infl ammation, 11 samples from 2 pts with a level of 998 (146-1062) coincided 
with chronic intestinal ulceration, and fi nally 50 samples from 19 pts with a 
level of 43 (5-475) coincided with normal histopathological fi ndings (Fig 1). 
FCLs in patients with normal intestinal morphology were signifi cantly lower 
compared to all other categories. No signifi cant FCL difference was found 
between rejection and infl ammation. FCL evolution in rejecting individuals 
showed that FCL can predict rejection days before histopathological diagnosis 
(Fig 2).
Conclusion: FCL is a very sensitive test detecting ongoing organic intestinal 
allograft pathologies. It is not useful differentiating rejection from other 
causes of infl ammation. It might be useful as prescreening marker to avoid 
unnecessary endoscopies.
EFFECT OF BLOCKING CHEMOKINE RECEPTORS BY A 203 
NOVEL COMPOUND, TAK-779, IN A RAT SMALL INTESTINAL 
TRANSPLANTATION MODEL
H. Xu, Y. Ihara, S. Firdawes, S. Uehara, M. Fukuzawa, S. Miyagawa
Osaka University Graduate School of Medicine
Background: Small intestinal transplantation is one of the most important 
treatments for patients with irreversible intestinal failure. Recently, the graft 
survival rate has improved signifi cantly due to the development of surgical 
techniques and new drugs. However, the immune response of intestinal 
transplantation is still diffi cult to control, compared to that of other organs, 
because of the gut-associated lymphoid tissue. In this study, we investigated 
the effect of blocking lymphocyte chemokine receptors, CCR5 and CXCR3, 
with a novel small molecule compound, TAK-779. Immunological changes in 
peripheral and graft-infi ltrating lymphocytes were monitored using a rat small 
intestinal transplantation model.
Methods: Dark Agouti (DA) rat (RT-1a) small intestines were heterotopically 
transplanted into Lewis (LEW) rats (RT-1l). The recipients were treated either 
with or without TAK-779 (10mg/kg/day, SC). for 10 days (day 0 to day 10) 
after the operation. [Group S: LEW to LEW, Group A: DA to LEW, and Group 
T: DA to LEW with TAK-779] Graft survival and histological changes, such 
as lymphocyte infi ltration, destruction of intestinal architecture, and villus 
height (VH) and submucosal thickness (ST) of the graft, were examined. Graft-
infi ltrating lymphocytes were studied using immunostaining, and followed by 
the fl uoro-luminance Analyser. Furthermore, expression of the chemokine 
receptors, CCR5, CXCR3 and CXCR1, on the graft-infi ltrating lymphocytes 
in the mesenteric lymph node (MLN) and Peyer fs patches (PP) were measured 
by FACS analysis.
Results: Average duration of survival was greater for Group T than Group A. 
[Group S: >50 days, Group A: 7.0 }0.3, Group T: 9.8 }0.5 days, p<0.05, Group 
T vs. Group A]. Histological fi ndings and graft scores were consistent with 
the prolonged survival in TAK-779-treated animals. [VH & ST (mm); Group 
S: 752 }35 & 45.1 }2.2, Group A: 467 }29 & 27.6 }1.8, Group T: 722 }40 & 
38.4 }2.4, respectively. p<0.05, Group T vs. Group A] Immunohistochemistry 
of the graft showed that the numbers of infi ltrating CD4+ and CD8+ T cells 
were signifi cantly lower in Group T compared with Group A. In the FACS 
analysis, while the percentage of each CD4+ and CD8+ cells was unchanged, 
the numbers of both CD4+ and CD8+ cells were signifi cantly suppressed in the 
blood, spleen, and MLN of the recipient, and in the PP of the graft. In addition, 
double-staining of graft-infi ltrating lymphocytes in MLN and PP showed a 
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signifi cant reduction in the numbers of CD4+/- T cells expressing CCR5 and 
CXCR3.
Conclusion: These results demonstrate that chemokines play an important role 
in small intestinal graft rejection. TAK779 diminished not only the number of 
the graft-infi ltrating cells, and their expression of CCR5 and CXCR3, but also 
the total number of recipient T cells that play a role in graft rejection.
HYDROGEN, A NOVEL MEDICAL GAS, PREVENTS 204 
INTESTINAL DYSFUNCTION AND COLD ISCHEMIA/
REPERFUSION INJURY FOLLOWING INTESTINAL 
TRANSPLANTATION IN RATS
B. Buchholz1, D. Kaczorowski2, R. Sugimoto2, R. Yang3, Y. Wang2, J.H. 
Zhan2, K. McCurry2, A. Bauer1, A. Nakao4
1Department of Medicine, DIvision of Gastroenterology, University of 
Pittsburgh, 2Department of Surgery, University of Pittsburgh, 3Department 
of Critical Care Medicine, University of Pittsburgh, 4Department of Surgery, 
Thomas E Starzl Transplantation Institute, University of Pittsburgh
Background: Cold ischemia/reperfusion (I/R) injury following small intestinal 
transplantation (SITx) may cause several potential complications including 
bowel dysmotility, infl ammation and multiple organ failure. Hydroxyl radicals, 
the most reactive products of ROS generated during IRI, play a critical role 
in lipid peroxidation and graft injury. Recent evidence has demonstrated 
that exogenously provided hydrogen (H2) eliminates toxic hydroxyl radicals 
and thereby prevents I/R injury. In this study, we tested the hypothesis 
that perioperative H2 inhalation can ameliorate cold I/R injury and bowel 
dysfunction following SITx.
Methods: Syngeneic, orthotopic SITx (LEW rats) was performed with 3 hrs 
of cold ischemia time in Lactate Ringer solution. In the hydrogen treated 
group, both donor and recipients were treated with 2% hydrogen inhalation 
1 hr before and 1 hr after reperfusion. Gastrointestinal transit was determined 
by measuring the intestinal distribution of orally fed fl uorescein-labeled 
dextran and calculation of geometric center. Bethanechol-stimulated jejunal 
circular muscle contractility was also investigated. Graft oxidative injury was 
determined by measuring the tissue malondialdehyde (MDA) concentration, a 
marker of lipid peroxidation, and reductive capacity.
Results: Inhalation of 2% hydrogen for 1 hr resulted in elevation of arterial 
dissolved hydrogen levels to 578 ± 63 ng/mL compared to 158.5 ng/mL in 
sham animals exposed to air. SITx with prolonged cold storage caused a 
delayed intestinal in-vivo transit and decreased in-vitro jejunal circular muscle 
contractile activity 24 hours after SITx. Hydrogen treatment attenuated graft 
injury and resulted in signifi cantly improved intestinal transit as well as 
smooth muscle contractility in response to bethanechol. In air-treated SITx, I/R 
injury initiated mRNA upregulation of infl ammatory mediators such as IL-6 
and MCP-1. Hydrogen inhalation treatment resulted in signifi cantly reduced 
upregulation of these infl ammatory mediators 3 hrs after reperfusion revealed 
by qPCR. Demonstrating an antioxidant effect, hydrogen inhalation resulted 
in signifi cant reduction of lipid peroxidation 3 hrs after transplant compared 
to elevated tissue MDA levels in air-treated control grafts. Similarly, intestinal 
reductive capacity revealed less oxidative injury in hydrogen treated grafts. 
Histopathlogical analysis of intestinal grafts 3 hrs after reperfusion showed 
pronounced mucosal erosion and massive epithelial lifting in air-control 
grafts, causing increased intestinal permeability resulting in mucosal barrier 
breakdown. These mucosal damages were signifi cantly attenuated by hydrogen 
treatment. Furthermore, intestinal I/R injury has deleterious effects on remote, 
nonischemic organs including the lung. Preventing systemic effects of SITx, 
hydrogen treatment signifi cantly reduced neutrophil recruitment as well as 
induction of mRNA levels for TNFα and IL-6 in lungs.
Conclusion: Hydrogen inhalation therapy signifi cantly ameliorates cold 
I/R injury and prevents remote organ infl ammation following SITx via its 
antioxidant effects. Administration of perioperative hydrogen gas may be a 
potent and clinically applicable therapeutic strategy for intestinal I/R injury.
Table. Effects of Hydrogen for intestinal cold I/R injury (*p<0.05 vs SITx/air) 
Geometric
Center 
(24h) 
Contractility
 (24h, 
100μM, gr/
mm2/s) 
IL-6 
mRNA 
(3h) 
reductive 
capacity 
(3h) 
MDA
 (3h, μM/
protein) 
permeability 
(3h, pL/min/
cm) 
PMN in 
lung (3h,/
x400HPF) 
Sham (air) 9.6 2.63 1.0 1.65 0.039 0.36 7.2
Sham (H2) 9.6 2.66 1.5 1.58 0.027 0.30 12.0
SITx (air) 5.8 1.23 3286.3 0.84 0.15 0.88 98.6
SITx (H2) 8.2* 2.56* 1484.4* 1.20* 0.086* 0.50* 64.6*
CLINICAL TOLERANCECONCURRENT ORAL SESSION 15: 
ANTI-THYMOCYTE GLOBULIN INDUCTION FAVORS 205 
THE GENERATION OF FUNCTIONAL CD4+FOXP3+CD127-/
LOW REGULATORY T CELLS IN PATIENTS AFTER KIDNEY 
TRANSPLANTATION
V. Sewgobind1,2, M. Kho1, L. van der Laan2, T. van Dam1, H. Tilanus2, 
J. IJzermans2, W. Weimar1, C. Baan1 
1Department of Internal Medicine, Erasmus Medical Center, 2Department of 
Surgery, Erasmus Medical Center
Background: It has been hypothesized that the clinical benefi ts of Anti-
Thymocyte Globulin (ATG) induction therapy do not completely result from 
immunodepletion, but may also result from induction of immunoregulatory 
T-cells (Treg). In this prospective, controlled study, we investigated the 
effect of ATG-induction therapy on the frequency and function of peripheral 
CD4+FoxP3+ CD127-/low T-cells in kidney transplant patients.
Methods: After transplantation, 16 patients received ATG-induction therapy 
(Thymoglobulin®) and triple therapy consisting of tacrolimus, MMF and 
steroids. The control group (n=18) received triple therapy only. In the peripheral 
blood of pre-transplant, 4 wks and 26 wks after transplantation T-cells markers 
associated with immune regulation: CD25, FoxP3 and CD127 were analyzed 
by fl ow cytometry. Within the FoxP3+ T-cell population, the CD45RO 
(memory) and CCR7 (homing receptor) markers were characterized. To study 
their suppressive capacities, pre- and post-transplant Treg were isolated and 
cocultured with CD25neg T cells (Teff) in mixed lymphocyte reactions at a 1: 10 
ratio, stimulated with donor- and third party antigens.
Results: Pre-transplant levels of CD4+FoxP3+CD127-/low T-cells were 6% 
(median, ranging from 3-17%) of CD4+ T-cells. One wk post ATG induction 
therapy, no measurable numbers of Treg were present. At 12 wks post ATG-
induction therapy a higher proportion of fi rst detectable T-cells expressed FoxP3 
compared to the control-group (ATG vs. control-group; 8% vs. 6%, median, 
respectively, p=0.02) and then returned to pre-transplant levels at 26 wks. This 
increased proportion of CD4+FoxP3+CD127-/low T-cells resulted in a signifi cantly 
higher FoxP3+/FoxP3neg ratio than the control-group at 12 wks; (ATG vs. 
control-group; 0.074 vs. 0.047, median, p=0.02). At 26 wks, the proportion 
of memory T-cells exceeded that in the control-group (ATG vs. control-group; 
75% vs. 67%, median, p=0.0053). which was mainly due to an increase in the 
proportion of effector memory FoxP3+ Treg (CD45RO+CCR7neg). Although the 
cell numbers of both Teff and Treg decreased after ATG immunodepletion, the 
regulatory capacity of the Treg remained unaltered after transplantation, while 
the proliferative response of the Teff diminished (p=0.0039 and p=0.0078; 
donor and third party respectively). Depletion of CD25bright T cells resulted in 
an increased proliferation against donor (p=0.0098) and third party antigens 
(p=0.0020) at 26 wks post-transplant. Moreover, the isolated CD25bright T cells 
were able to inhibit the anti-donor (65%) and third party response (77%) at a 
ratio of 1: 10.
Conclusion: After ATG-induced immune cell depletion, a shift towards 
CD4+FoxP3+CD127-/low peripheral regulatory T-cells with the memory 
phenotype was measured in kidney transplant patients. Although the cell 
number and the proliferative capacity of the Teff dramatically decreased, Treg 
remained able to suppress the Teff against donor and third party antigens after 
transplantation. These fi ndings suggest that ATG treatment mainly affects the 
function of the Teff and triggers the generation of de novo functional peripheral 
regulatory T-cells by homeostatic proliferation.
INDUCTION OF CD8+ EFFECT T CELL APOPTOSIS 206 
BY CO-TRANSPLANT WITH HEPATIC STELLATE CELLS, A 
NOVEL APPROACH TO PROTECT ISLET ALLOGRAFTS
H-R. Yang1, G. Jiang2, J. Fung1, S. Qian1,2, L. Lu1,2
1Department of General Surgery, Cleveland Clinic, 2Department of 
Immunology, Lerner Research Institute, Cleveland Clinic
Spontaneous acceptance of liver allograft in many species indicates that 
transplant tolerance is achievable, although the underlying mechanisms 
remain to be elucidated. Interestingly, albeit liver allografts are accepted, 
hepatocyte transplants in the same combination are promptly rejected, 
indicating a pivotal role of liver tissue cells in immune suppression. We 
have demonstrated a profound T cell inhibitory activity of hepatic stellate 
cells (HpSC). which are known to participating in repairing and fi brosis 
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during liver injury. Addition of activated (a) HpSC, but not quiescent HpSC, 
signifi cantly inhibited allo-DC induced-T cell proliferative responses 
(MLR) in a dose dependent manner, which was associated with enhanced 
T cell apoptosis (TUNEL). Neutralization of B7-H1 by anti-B7-H1 mAb 
signifi cantly reduced the HpSC-induced T cell apoptosis and reversed 
the inhibition of T cell proliferation, suggesting a key role of B7-H1. To 
evaluate this in vivo, BALB/c islets (300) were co-transplanted with 3 x 105 
activated HpSC (B6) into STZ-induced diabetic B6 recipients. Co-transplant 
with HpSC effectively protects islet allografts from rejection. This was 
associated with reduction of graft infi ltrating T cells and enhancement of 
apoptotic activity. Co-transplant with HpSC from B7-H1-/- livers markedly 
lost their islet graft protective capacity, associated with less apoptosis of 
infi ltrating cells. To determine the subsets of apoptotic T cells, T cells were 
isolated from spleen, draining lymph nodes, and grafts for phenotype and 
function analyses. On POD 8, a marked reduction of graft infi ltrating CD4+ 
(30.7%) and CD8+ T cells (31.3%) was seen in HpSC co-transplant group, 
as compared to islets alone, which was further progressed thereafter. CD8 T 
cells dropped ~7 folds on POD 140. CD4+/CD8+ ratio was increased from 
0.5 at the early POD to 2.0 in the long-term survival grafts. Adoptive transfer 
of CFSE-labeled DES transgenic T cells was used to track the response and 
fate of antigen-specifi c CD8+ T cells. The results showed active division 
of DES+ cells within the allograft in both the islet only and HpSC co-
transplantation groups. However, accumulation of these DES+ cells was 
signifi cantly lesser in the HpSC co-transplantation group as compared to 
that in the islet only group (1.9¡Á103 vs. 10¡Á103 cells per graft). These 
fi ndings suggest that HpSC may not inhibit activation of antigen-specifi c 
CD8+ T cells, but induce their robust apoptotic death, which is partially 
mediated by inducibly expressed B7-H1 on HpSC. This could be one of 
the important mechanisms by which tolerance in the peripheral organs is 
maintained.
A UNIQUE B CELL SIGNATURE ASSOCIATED WITH 207 
OPERATIONAL TOLERANCE
K. Newell1, A. Asare2, A. Kirk1, T. Gisler2, M. Suthanthiran3, W. Burlingham4, 
W. Marks5, L. Turka6, V. Seyfert-Margolis2
1Emory University, 2University of California, San Francisco, 3Cornell 
University Medical Center, 4University of Wisconsin, 5Swedish Medical 
Center, 6University of Pennsylvania School of Medicine
Introduction: Decisions about the minimization and ultimate withdrawal of 
immunosuppression (IS) would be facilitated by the identifi cation of biomarkers 
associated with operational tolerance (OT). 
Methods: As part of an ITN/NIH supported study tolerant kidney transplant 
recipients (off all IS for > 1yr with stable function, N=22) were compared 
to recipients with stable function on IS (SIS, N=34). recipients with chronic 
allograft nephropathy (CAN, N=20). and healthy volunteers (HV, N=18). 
PBMC, whole blood total RNA, and urine samples from each group were 
examined using fl ow cytometry, microarrays, and RT-PCR respectively. 
Results: Analysis of microarrays revealed signifi cantly higher expression of 
B cell differentiation genes in tolerant recipients compared to the SIS and 
CAN groups. Consistent with this fi nding, tolerant recipients also displayed 
higher numbers of naïve B cells in peripheral blood and increased expression 
of CD20 in urine relative to the SIS and CAN groups. No differences in Treg 
or genes associated with regulatory cells were observed in tolerant recipients 
relative to other groups. These analyses failed to demonstrate signifi cant 
differences between tolerant recipients and HVs although support vector 
machine learning methods suggested potential differences in a number 
of genes including NFAT and calcineurin. Finally, relative to tolerant 
patients, those with CAN showed decreased numbers of T and NK cells and 
expressed lower levels of genes associated with immune cell activation in 
peripheral blood. 
Conclusions: Differences in B cell numbers may be useful in identifying 
tolerant renal transplant recipients or those predisposed to developing tolerance 
and could potentially provide insights into the mechanisms of tolerance.
DONOR MARROW INFUSION IN KIDNEY 208 
TRANSPLANTATION: RESULTS OF PRELIMINARY STUDY
M. Marvin, K. Ravindra1, R. Herzig2, K. Paris3, J. Buell4, S. Ildstad5
1Department of Surgery, University of Louisville, 2Blood & Marrow 
Transplant Program, University of Louisville, 3Radiation Oncology 
Department, University of Louisville, 4Department of Surgery, University of 
Louisville, 5Institute for Cellular Therapeutics, University of Louisville
Introduction: Long-term function of renal allografts is compromised by 
chronic rejection and adverse effects of immunosuppression. Achieving donor 
specifi c tolerance has been the goal of the transplant community. Success has 
been reported with donor stem cell transfusion in animal studies and prevention 
of chronic rejection in cardiac allograft recipients in the clinic. This report 
details the results of the initial phase of a study in humans.
Methods: A prospective phase I/II FDA approved pilot protocol was initiated 
to evaluate the effects of donor graft facilitating cell (FC) /stem cell infusion in 
kidney transplant recipients. Conditioning was performed with 200 cGy of total 
body irradiation. Bone marrow processed to remove GVHD-producing cells 
but retain CD8+/TCR- FC and stem cells was infused 24 hours post-operatively. 
The dosage of stem cells was limited by the T cell dosage. The starting dose 
was 1 x 105 T cells. This was increased in steps of 2 x 105 per patient. As 
the study spans a 7-year period, the immunosuppression changed: 3 patients 
received cyclosporine (CyA). MMF and Prednisone; 3 were induced with 
Basiliximab and maintained on CyA (2) /FK (1). Cellcept and Prednisone; and 
3 received Alemtuzumab induction and maintenance with FK and MMF. All 
patients underwent tolerance testing and immunoprofi ling studies.
Results: Of the 9 patients, 6 received live donor kidney transplants. One graft 
was lost from arterial thrombosis on day 2. Delayed graft function was seen 
in 3 patients. Good long-term graft function was seen in the other 8 patients. 
Acute rejection was noted only in 1 and infectious complications (CMV-1, 
Histoplasma-1) in 2 patients. Two patients died with functioning grafts – one 
at 4 years from lung cancer and another from complications from diabetes 
at 6 years. Six patients are alive with functioning grafts at mean follow-up 
of 4.3 years with a mean creatinine at 1.3 mg/dl. No GVHD was detected in 
any of the patients. Leucopenia and thrombocytopenia (nadir phase) was seen 
in all patients at the end of 3 weeks and lasted 10-14 days. Macrochimerism 
was not detected in any of the patients at any point. Notably, in spite of the 
fact that durable engraftment was not yet achieved, none of the patients was 
sensitized as a result nor did they experience immunologic sequelae. MLR 
testing revealed delayed recovery of response to Candida and donor antigen in 
patients induced with Alemtuzumab.
Conclusions: In our patients there were no untoward sequelae related to either 
the conditioning regimen or marrow infusion. The incidence of acute rejection 
even on long-term follow up has been low. We currently propose to reduce the 
immunosuppression further in these patients.
THE ROLE OF B-CELL DEPLETION THERAPY FOR 209 
DONOR-SPECIFIC B-CELL TOLERANCE AFTER ABO-
INCOMPATIBLE ADULT LIVER TRANSPLANTATION
Purpose: ABO-incompatible liver transplantation is often performed because 
of organ shortage. Production of anti-donor blood type antibodies (Abs) is 
suppressed following ABO-incompatible liver transplantation in most cases, 
while non anti-donor blood type Abs still persist. This phenomenon suggests 
the development of donor blood type antigen-specifi c B-cell tolerance. Previous 
reports of B-cell tolerance following ABO-incompatible transplantation were 
limited to infants. We investigated the mechanism of development of such 
B-cell tolerance after ABO-incompatible liver transplantation using in-vivo 
humanized mouse models, including of adult recipients.
Method: We studied 14 patients who received ABO-incompatible liver grafts 
between 1996 and 2006. These patients were classifi ed into three groups. 
Group ‡T: 4 recipients (A to O in 2, B to O in 2 cases) aged around 1 year old 
when they received the grafts; Group ‡U: 8 recipients (A to O in 3, B to O in 
3, A to B in 2 cases) treated with rituximab as B-cell depletion therapy, ranging 
in age from 6 to 50 years old at the time of transplantation; Group ‡V: 2 adult 
recipients (one each of A to O and AB to A) who did not receive rituximab, 
aged 42 and 44 years old at the time of transplantation. In order to investigate 
the immune responses to the donor blood type antigens, we inoculated the 
peripheral blood mononuclear cells (PBMCs) of the recipients into NOD-
SCIDƒÁ-null mice (human PBMC-NOG mice) and immunized the mice with 
the donor blood type antigens. Flow cytometry was performed for phenotyping 
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to confi rm the human cell engraftment and ELISA for detection of the human 
anti-A Abs, anti-B Abs and total immunoglobulin produced in the mice.
Result: All mice were successfully engrafted with the human PBMCs as 
determined by FACS and ELISA. In the mice inoculated with the PBMCs from 
the Group‡T/‡Urecipients and immunized with the donor blood type antigens, 
no anti-donor blood type human Abs were detected despite the production 
of human immunoglobulins against other antigens. Strikingly, however, 
signifi cant production of anti-donor blood type human Abs was observed in the 
mice engrafted with the PBMCs of the group‡V recipients.
Conclusion: In this study, we provide evidence of B-cell tolerance to blood 
group antigens. Deletion is the primary mechanism of suppression of antibody 
production in not only infantile, but also adult recipients of transplants 
treated with rituximab, while anergy plays the key role in adult recipients not 
receiving rituximab. This is the fi rst report of adult B-cell tolerance after ABO-
incompatible transplantation.
PERIPHERAL CD4210 +CD25HIGHFOXP3+ T CELLS OF 
HEART TRANSPLANT PATIENTS WHO EXPERIENCE ACUTE 
REJECTION HAVE AN INADEQUATE IMMUNE REGULATORY 
FUNCTION
C. Baan1, E. Dijke1, S. Korevaar1, A. Balk2, K. Caliskan2, L. Maat3, 
W. Weimar1. 
1Internal Medicine, Erasmus MC, Rotterdam; 2Cardiology, Erasmus MC, 
Rotterdam; 3Thoracic Surgery, Erasmus MC, Rotterdam, the Netherlands.
Introduction: This study explores the immune regulatory function of 
peripheral CD4+CD25highFoxP3+ regulatory T cells during acute allogeneic 
immune reactivity after clinical heart transplantation.
Methods: Peripheral blood mononuclear cells (PBMC) of 12 rejectors collected 
before and during an acute cellular rejection (n=22) and PBMC (n=25) of 
patients who remained free from acute rejections (nonrejectors; n=9) were 
studied (time after transplantation: 7–138 days). The regulatory function of 
CD4+CD25high T cells was examined by measuring the anti-donor proliferative 
response before and after depletion, and their subsequent reconstitution 
(CD25high: CD25neg/dim=1: 10). Additionally, fl ow cytometry was used to analyze 
the expression of CD4, CD25, FoxP3 and CD127 (IL-7Rα chain).
Results: Between nonrejectors and rejectors, the% of CD25highFoxP3+ T 
cells within the CD4+ T cells was comparable (median: 3.0% vs. 2.6%). Yet, 
differences were found in the CD127 expression: CD4+CD25highFoxP3+ T 
cells of nonrejectors had a signifi cantly lower expression of CD127 compared 
with those of rejectors (median fl uorescence value: 18.0 vs. 26.8; p<0.0001). 
Functional analysis revealed that depletion of CD4+CD25high T cells increased 
the anti-donor proliferative response of both nonrejectors and rejectors 
(p<0.001 and p=0.03). The suppressive potency of the CD4+CD25high T 
cells, however, was signifi cantly different: in rejectors only a 2-fold increase 
(median) in response was measured, while the response in nonrejectors became 
14 times (median) higher (p=0.001). suggesting lower regulatory function of 
CD4+CD25high T cells of rejectors. Reconstitution of these cells confi rmed 
this observation: the response of CD25neg/dim effector cells of nonrejectors 
was abundantly suppressed (p<0.0001). while the response of the rejectors 
was scarcely inhibited (p=0.14). Within rejectors, the inhibitory effect of 
CD4+CD25high T cells was comparable between samples taken before and those 
sampled during rejection.
Conclusion: Peripheral CD4+CD25highFoxP3+ T cells of heart transplant 
patients who experience acute rejection, on which an upregulated expression 
of CD127 was found, showed inferior immune regulatory function in vitro 
compared with those of nonrejecting patients. These fi ndings suggest that 
CD4+CD25highFoxP3+ T cells may be involved in preventing acute cellular 
rejection after clinical heart transplantation.
RECRUITMENT OF FOXP3 EXPRESSING T CELLS INTO 211 
THE GRAFTS OF TOLERANT HUMAN LIVER TRANSPLANT 
RECIPIENTS
Y. Li1, X. Zhao1, D. Cheng2, H. Haga3, T. Tsuruyama4, K. Wood5, 
S. Sakaguchi6, K. Tanaka7, S. Uemoto2, T. Koshiba1
1Innovation Center For Immunoregulation Technologies And Drugs,Graduate 
School of Medicine, Kyoto University, 2Department of Surgery, Graduate 
School of Medicine, Kyoto University, 3Department of Diagnostic Pathology, 
Kyoto University Hospital, 4Department of Pathology and Biology of 
disease, Graduate School of Medicine, Kyoto University, 5Transplantation 
Research Immunology Group, 4Nuffi eld Department of Surgery, University of 
Oxford, John Radcliffe Hospital, Headington, 6Department of Experimental 
Pathology, Institute for Frontier Medical Science, Kyoto University, 
7Foundation for Biomedical Research and Innovation
Background: The recruitment of regulatory T cells (Tregs) into grafts has 
been shown to be important for the development of operational tolerance (Tol) 
in experimental models of transplantation. To determine if the recruitment of 
Tregs correlates with continued graft survival in operationally tolerant living 
donor liver transplant (LDLT) recipients, the expression of FOXP3 mRNA and 
the presence of FOXP3+ cells were quantifi ed in biopsies from tolerant, i.e. 
immunosuppression free, liver transplant recipients. 
Method: Liver tissue was obtained from 13 tolerant recipients using an 
automated biopsy gun under guidance of ultrasonography (Gr-Tol). Total 
RNA was extracted for cDNA synthesis. The expression level of the FOXP3 
mRNA was quantifi ed by real-time PCR. Immunohistochemistry and double 
immunofl uorescent stainings for CD4,CD8, and FOXP3 were performed 
using paraffi n embedded sections. The results were compared with 
biopsy samples from the liver allografts of (i) recipients on maintenance 
immunosuppression (Gr-IS) in whom biopsy samples were obtained in the 
same manner as Gr-Tol before starting weaning IS, (ii) grafts removed as a 
result of chronic rejection (Gr-CR) or (iii) from normal liver i.e. donor zero 
biopsy (Gr-NL). 
Results: The expression of FOXP3 mRNA in Gr-Tol was higher than that in Gr-
IS and Gr-NL, but equivalent to that in Gr-CR (log FOXP3/HPRT ~106 Gr-Tol, 
Gr-IS, Gr-CR and Gr-NL: 4.1 } 0.5, 3.6 } 0.7, 4.4 } 0.4 and 3.0 } 0.7; Gr-Tol vs. 
Gr-IS p=0.06, Gr-CR vs. Gr-IS p<0.05, Gr-Tol, Gr-CR vs. Gr-NL p <0.0005, 
Gr-Tol vs. Gr-CR NS). Immunohistochemistry and double immunofl uorescent 
stainings demonstrated that in Gr-Tol, FOXP3+ cells were readily detectable in 
the portal area, accumulated within clusters of CD4+ and CD8+ cells and were 
CD4+. Both the number of FOXP3+ cells and their frequency amongst CD4+ 
cells were signifi cantly increased in Gr-Tol, compared to that in Gr-IS, Gr-CR, 
and Gr-NL (The number of FOXP3+ cells; Gr-Tol, Gr-IS, Gr-CR and Gr-NL: 
10.8 }10.8, 3.4 }6.7, 0 }0 and 2 }1.9 cells/10 portal areas, Gr-Tol vs. Gr-IS p 
< 0.05, Gr-Tol vs. Gr-CR p<0.05, Gr-Tol vs. Gr-NL p < 0.05, Gr-CR vs. Gr-
NL NS) (FOXP3+/CD4+; Gr-Tol, Gr-IS, Gr-CR and Gr-NL: 0.34 }0.21, 0.097 
}0.12, 0 }0, and 0,14 }0.2, Gr-Tol vs. Gr-IS,-CR,-NL p<0.05). 
Conclusions: This is the fi rst report showing that CD4+FOXP3+ cells 
accumulate in tolerant grafts after human liver transplantation. Our fi ndings 
suggest that the analysis of intra-graft expression of FOXP3 protein detectable 
by immunohistochemistry, but not FOXP3mRNA, may aid the identifi cation of 
LDLT recipients who can successfully stop IS.
STUDY OF COMPLETE IMMUNOSUPPRESSIVE DRUG 212 
WITHDRAWAL FROM LIVER TRANSPLANT PATIENTS 
CONDITIONED WITH POSTTRANSPLANT TOTAL LYMPHOID 
IRRADIATION (TLI) AND ANTI-THYMOCYTE GLOBULIN 
(ATG) 
A. Bonham, C. Esquivel, W. Concepcion, S. Strober
Stanford University Medical School
Previous studies in rodents have shown that immune tolerance to MHC-
mismatched heart transplants in recipients conditioned with posttransplant TLI 
and ATG requires an infusion of donor bone marrow cells and development of 
chimerism. In contrast, almost all Lewis rat recipients of ACI liver trasnplants 
develop tolerance after TLI and ATG without a donor cell infusion (Millan, M. 
et al, 2007, Transplantation, ). Based on these results, we developed a clinical 
protocol in which liver transplant patients were conditioned with posttransplant 
TLI (10 doses of 80cGy each) starting on posttransplant days 3-5, and 5 doses 
of ATG starting on day 0. After conditioning, patients were maintained on 
daily conventional doses of tacrolimus for 3 months, and then tapered to 
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discontinuation at 6 months. Tapering was performed by gradual reduction of 
the number of days per week of tacrolimus therapy.The protocol considered 
patients with rejection episodes any time as experimental therapy failures to 
be returned to standard anti-rejection and maintenance immunosuppressive 
drug therapy. At present, 6 patients have been enrolled in the protocol, 
and none have had rejection episodes. Patient 1 is off immunosuppressive 
drugs at 7 months posttranplant, and patients 2 through 6 are receiving 
tacrolimus 2,3,4, 5, and 7 days per week respectively. No severe infections 
have been observed other than recurrence of hepatitis C in 1 patient that is 
under treatment with interferon alpha and ribovirin with a good response. In 
conclusion, we have applied the tolerance induction protocol of posttransplant 
TLI and ATG that was successful in preclinical studies to patients undergoing 
liver transplantation. The protocol has been well tolerated, and tapering of 
immunosuppressive drugs has not been associated with rejection episodes in 
the fi rst 6 patients studied.
DEVELOPMENT OF OPERATIONAL TOLERANCE 213 
AFTER PEDIATRIC LIVER TRANSPLANTATION IS 
ASSOCIATED WITH THE ABSENCE OF EARLY REJECTION 
AND THE PRESENCE OF HLA-B MISMATCH BETWEEN 
DONORS AND RECIPIENTS
H. Ohe1, M. Yoshitomi1, T. Koshiba2, S. Uemoto1
1Department of Surgery, Graduate School of Medicine,Kyoto University, 
2Innovation Center for Immunoregulation Technologies and Drugs, Graduate 
School of Medicine, Kyoto University
Background: In the setting of our pediatric living-donor liver transplantation 
(Ltx). 15% of all the patients (signifi cantly higher proportion, compared 
with those of other transplant centers) achieved complete withdrawal of 
immunosuppression (IS). which is reffered to as operational tolerance 
(Transplant Immunol,2007,17: 94). Nonetheless, some patients encountered 
rejection while they were undergoing weaning from IS. It is,therefore,essential 
to identify and characterize the differences that will enable patients in these two 
distinct populations to be distinguished reliably. 
Methods: The study groups consisted of group tolerance (Gr-Tol) in 
which 88 patients are successfully weaned off from IS, and group rejection 
(Gr-Rej) in which 22 patients experienced clinically evident rejection 
during or after weaning process. The correlation between the clinical 
outcome (success or failure of weaning IS) and following parameters was 
assessed; donor/recipient age, donor/recipient gender, ABO compatibility, 
HLA mismatch, graft size, early (<1month) rejection episode and initial 
immunosuppression. 
Results: There was no difference between Gr-Tol and Gr-Rej with respect to 
donor/recipient age (Gr-Tol and Gr-Rej; 32y and 32y NS/35m and 26m NS). 
or donor/recipient gender (Gr-Tol and Gr-Rej (female); 60% and 50% NS/60% 
and 73% NS). ABO compatibility did not differ between the two groups (Gr-
Tol and Gr-Rej; identical: compatible: incompatible ;63%: 27%: 10% and 55%: 
27%: 18% NS).The presence of HLA-B mismatch was more frequent in Gr-
Tol than that in Gr-Rej (Gr-Tol and Gr-Rej; 95% and 76% p<0.05 ). while 
the presence of HLA-A or DR mismatch did not affect success or failure of 
weaning IS (HLA-A Gr-Tol and Gr-Rej;73% and 76% NS, HLA-DR ;83% and 
82% NS). Graft size did not differ between the two groups (GBWR Gr-Tol and 
Gr-Rej; 2.9% and 3.2% NS). The patients in Gr-Rej experienced early rejection 
(< 1 month) more frequently than those in Gr-Tol (Gr-Tol and Gr-Rej; 17% 
and 50% p<0.05). Mean trough level of tacrolimus within 7 days after Ltx was 
comparable between the two groups (Gr-Tol and Gr-Rej ;11ng/ml and 11ng/
ml NS). 
Conclusions: Development of operational tolerance after pediatric Ltx was 
associated with the absence of early rejection and the presence of HLA-B 
mismatch between donors and recipients. Thus, those parameters may be 
promising candidate for identifying recipients who can stop IS successfully 
amongst the recipients who start weaning IS.
INFLAMMATIONCONCURRENT ORAL SESSION 16: 
GENE EXPRESSION PATTERNS OF MAJOR 214 
PROINFLAMMATORY MEDIATORS DIFFER BETWEEN 
ACUTE CELLULAR AND HUMORAL REJECTIONS AND 
ALLOW TO DISCRIMINATE RENAL ALLOGRAFTS AT RISK 
FOR FAILURE
O. Viklicky1,2, J. Slatinska1, I. Brabcova1, K. Bartosova1, P. Hribova2
1Dept. of Nephrology, Transplant Center, Institute For Clinical And 
Experimental Medicine, 2Transplant Laboratory, Institute For Clinical And 
Experimental Medicine
Background: Early acute humoral rejection (AHR) is a rare complication after 
kidney transplantation with poor prognosis and ill-defi ned pathogenesis.
Methods: Out of 730 patients who had undergone kidney transplantation in 
2002-2005 and had received CNI+MMF+steroid based immunosuppression, 
21 patients (2.9%) with early (POD 9) AHR were identifi ed. As a control group, 
a matched group of 43 patients with early acute cellular rejection (ACR) was 
used. Using real-time quantitative PCR, the intragraft expression profi les of 
proinfl ammatory and tissue injury markers (TGF-â1, FoxP3, TNF-á, MCP-1, 
RANTES, HMOX1, CD3, CD20, and IgJ mRNA) during AHR and ACR were 
analyzed.
Results: There was a higher intrarenal mRNA expression of RANTES (p<0.05) 
while lower of HOX1 (p<0.05) during AHR as compared to ACR. Grafts that 
failed as a consequence of AHR had revealed lower intrarenal TGF-â1 (p<0.05). 
RANTES (p<0.05). CD20 (p<0.01). IgJ (p<0.05) and FoxP3 (p<0.05) mRNA 
expression, while lower expression of CD3, CD20 and IgJ was found in grafts 
failed as a consequence of ACR. The enhanced intrarenal expressions of 
TGF-â1, CD20 and RANTES mRNA during early AHR were associated with 
longer graft survival (Kaplan-Meier). Using Cox regression, the both lower 
TGF-â1 and CD20 mRNA expressions during AHR were associated with the 
risk of graft failure in the fi rst year (OR 24.0; p<0.01 and OR 14.0; p<0.05 
respectively).
Conclusion: A lower mRNA expression levels of proinfl ammatory and 
tissue injury markers during early acute cellular and humoral rejections may 
identify grafts with poor prognosis and thus requiring additional therapeutical 
intervention.
SOLUTION TO A LONG-STANDING PARADOX? 215 
DISPROPORTIONATE PROLIFERATION OF THE INDIRECT 
PATHWAY DURING ACUTE REJECTION
H. Zaid, T. Brennan, T. Hayden, F. Liu, Q. Tang, S-M. Kang
UCSF Division of Transplantation
Although the existence of indirect alloreactive T lymphocytes is now fi rmly 
established, the relative contributions of the direct and indirect pathways in 
alloimmune responses have not been fully elucidated. The precursor frequency 
of alloreactive T cells responding via the indirect pathway is thought to be at 
least several orders of magnitude lower than for the direct pathway, which has 
been estimated to be 5-10% of the T cell pool. Thus, the direct pathway has 
been assumed to be the dominant mediator of acute rejection while the indirect 
pathway has been implicated in chronic rejection. This paradigm, however, has 
failed to explain the fi nding that the pace of acute rejection is largely unaltered 
by elimination of the direct pathway.
To explore the relative contributions of the direct and indirect pathways to 
the alloimmune response, we have developed a novel T cell receptor (TCR) 
transgenic system that can simultaneously track the CD4-direct (CD4-d). 
CD4-indirect (CD4-i). and CD8-direct (CD8-d) pathways after transplantation. 
Using this system, we have observed a profoundly greater proliferation 
of CD4-i T cells relative to CD4-d and CD8-d T cells after allogeneic skin, 
heart, or islet transplantation. Furthermore, the robust priming of the indirect 
pathway is associated with a much larger proportion of CD4-i T cells attaining 
an effector phenotype, as defi ned by the production of IFN-gamma. To rule 
out an artifact of our TCR transgenic system, we analyzed endogenous, wild-
type T cells from the spleen and lymph nodes using ELISPOT analysis. In 
naïve animals, T cells with indirect reactivity were undetectable by ELISPOT 
analysis, while T cells with direct reactivity were abundant. However, 10 days 
after skin or heterotopic heart transplantation in the BALB/c to C57BL/6 
strain combination, CD4-i T cells comprised approximately 10% of the CD4+ 
response. Strikingly, by 60 days post-transplant, CD4-i T cells comprised 20% 
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of the IFN-gamma producing alloreactive CD4+ T cells, suggesting that CD4-i 
T cells persist and are further enriched over time. Thus, the indirect T cells 
appears to preferentially expand and accumulate relative to the direct pathway, 
allowing comparatively rare CD4-i T cells to comprise a signifi cant proportion 
of alloreactive CD4+ T cells after transplantation.
Based on the increased relative priming of the indirect pathway, we hypothesized 
that the CD4-i T cells would be further enriched in the effector cells migrating 
to the allograft. Indeed, ELISPOT analysis of graft-infi ltrating CD4+ T cells 
7 days after heterotopic heart transplantation showed that CD4-i T cells 
accounted for approximately 33% of IFN-gamma producing cells among graft-
infi ltrating lymphocytes.
Our results demonstrate that priming of the CD4-i pathway is favored after 
transplantation and allows a rare population to rapidly become a major 
component of the CD4+ T cell response in acute allograft rejection. These 
fi ndings on the fundamental differences in the dynamics of the CD4-i and 
CD4-d pathways may have signifi cant implications for rational design of 
immunosuppressive and tolerance-induction regimens.
A NEW MECHANISM OF GRAFT REJECTION IN THE 216 
COMPLETE ABSENCE OF ADAPTIVE IMMUNE CELLS
A. Kroemer, X. Xiao, K. Edtinger, N. Degauque, G. Demirci, X.C. Li
Transplant Research Center, Departments of Medicine And Surgery, Beth 
Israel Deaconess Medical Center, Harvard Medical School
Background: While transplant rejection is primarily mediated by adaptive 
immune cells such as T and B cells, which are also responsible for the specifi city 
and memory of rejection response, dismantling allografts involves many other 
cell types including cells in the innate immune system. Because innate immune 
cells do not express germ-line encoded cell surface receptors that recognize 
foreign antigens, the assumption has been that these only participate in the 
destruction of allografts when recruited by T cells. The ongoing diffi culty in 
creating transplant tolerance under stringent conditions has stimulated renewed 
interests in the role of innate immune cells, especially NK cells, in the induction 
of transplant rejection.
Methods: We used Rag-/- and Rag-/-IL-2Rγ;-/- double knockout mice as 
transplant recipients to critically examine the alloreactivity of NK cells in a 
stringent skin transplant model. Both Rag-/- and Rag-/-IL-2Rγ;-/- mice are 
defi cient for T and B cells. In addition, the Rag-/-IL-2Rγ;-/- mice are defi cient 
for NK cells, while the Rag-/- mice possess a large population of functional NK 
cells. This allowed us to precisely study the role of NK cells in mediating skin 
allograft rejection in the absence of adaptive immune cells.
Results: To ascertain the cytolytic activity of NK cells in Rag-/- mice, we 
adoptively transferred CFSE labelled syngeneic B6 and allogeneic DBA/2 
spleen cells into Rag-/- and Rag-/-IL-2Rγ;-/- recipients. Both syngeneic B6 
and allogeneic DBA/2 spleen cells survived in the Rag-/-IL-2Rγ;-/- mice. 
However, the DBA/2 cells, but not the B6 cells, were readily killed in the 
Rag-/- mice, demonstrating that NK cells are potent effectors in allogeneic cell 
rejection. Nevertheless, DBA/2 skin allografts were accepted by both Rag-/- 
and Rag-/-IL-2Rγ;-/- mice without any sign of rejection (>100 days). Thus, NK 
cells by themselves, though cytolytic to DBA/2 cells, fail to reject the DBA/2 
skin allografts. To test the hypothesis that the activation status of NK cells 
dictates their alloreactive potential, we treated the Rag-/- mice with IL-15/IL-
15Rα; complex to maximally stimulate the NK cells. As suspected, the IL-15 
treated Rag-/-, but not the Rag-/-IL-2Rγ;-/- mice, readily rejected the DBA/2 
skin allografts (MST=18 days). IL-15, when complexed to its private IL-15Rα; 
chain, proved to be highly potent in stimulating NK cells in vivo, which in 
turn expressed an activated phenotype that rendered them surprisingly potent in 
mediating acute skin allograft rejection in the absence of any adaptive immune 
cells. Furthermore, NK cell-mediated graft rejection did not show features of 
memory responses.
Conclusions: Our data demonstrate that when fully activated and differentiated, 
NK cells are potent alloreactive cells in allograft rejection. We further found 
that IL-15 is critically important in this regard. Thus the fate of allografts 
may depend on the activation status of NK cells and the availability of NK 
stimulating cytokines. These fi ndings may have important clinical implications 
in models of transplantation tolerance and autoimmunity.
SUSCEPTIBILITY OF ISLETS TO INFLAMMATION IN 217 
A MOUSE MODEL OF DIABETES IS INFLUENCED BY THE 
LEVEL OF EXPRESSION OF CD39
J. Chia1, T. Craig1, S. Robson2, A. d’Apice1, P. Cowan1, K. Dwyer1
1Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Victoria, 
Australia, 2Beth Israel Deaconess Medical Centre, Harvard Medical School, 
Boston, MA, USA
Background: Type 1 diabetes mellitus results from the autoimmune destruction 
of pancreatic islets. Islet transplantation is a potential cure for this devastating 
illness, but initial enthusiasm has been tempered by loss of graft function 
such that only 15% of recipients are insulin-free at 5 years. This decline in 
insulin independence is complex and not fully understood. Detrimental factors 
include a destructive infl ammatory response to islets transplanted into the liver, 
metabolic exhaustion and recurrent β cell autoimmunity. We are investigating 
protection of islet grafts by overexpressing various proteins including CD39, 
which works in concert with CD73 to hydrolyse pro-infl ammatory extracellular 
nucleotides (ATP, ADP) to the anti-infl ammatory molecule adenosine. We have 
shown that expression of human CD39 (hCD39) on murine islets prevents 
thrombosis when they are mixed with human blood. Others have shown that 
inosine, a metabolite of adenosine, protects against development of diabetes 
and rejection of transplanted islets.
Aim: To examine whether the level of expression of CD39 infl uences the 
development of diabetes in the multiple low dose streptozotocin (MLDS) 
mouse model.
Methods: 8-week old male CD39 null, hCD39 transgenic (hCD39TG) and 
wild-type (WT) mice on a C57BL/6 background were treated with MLDS for 
5 days. Fasting blood glucose levels (BGL) were recorded on day 0. Thereafter 
non-fasting BGL were measured three times weekly. Mice with BGL of 15-20 
and >20mmol/L for at least 2 consecutive readings were deemed hyperglycemic 
and overtly diabetic, respectively. Histological analyses were performed to 
assess the integrity of islets after challenge with MLDS.
Results: WT mice were hyperglycemic (mean BGL 19.4±1.5mmol/L) by day 
30. In contrast, CD39 null mice were overtly diabetic (BGL 24.5±1.6 mmol/L, 
P<0.05 versus WT) by this time, whereas hCD39TG mice were normoglycemic 
(mean BGL 13.3±0.8 mmol/L, P<0.05 versus WT). Histologically, islets from 
CD39 null mice were hypercellular and showed a higher level of apoptosis 
than WT islets, and insulin production was severely hampered. Islets from 
hCD39TG mice were normocellular and exhibited less apoptosis, and insulin 
production was not affected by MLDS treatment.
Conclusion: The level of CD39 expression correlated with the severity of 
diabetes in this model, suggesting that elevated CD39 expression may prolong 
islet graft survival by preventing the recurrence of autoimmunity. Further 
transplantation studies will address this question and determine the impact of 
CD39 overexpression on the kinetics of mouse islet allograft rejection. Isolating 
hCD39 expression to either bone marrow-derived circulating cells or the islets 
via adoptive transfer experiments will be used to further defi ne the mechanism 
of protection in vivo. If expression on islets alone is found to be suffi cient to 
protect against immune-mediated injury, this may have clinical implications in 
islet transplantation as islets may be supplemented with CD39 by gene therapy 
prior to transplantation.
EFFECT OF ACUTE AND CHRONIC LITHIUM 218 
ADMINISTRATION ON RENAL ISCHEMIA/REPERFUSION 
INJURY IN RAT: THE ROLE OF NITRIC OXIDE
H. Emami1, S.S. Talab1, B.G. Nezami1, A. Elmi1, S. Assa1, S.M. Tavangar2, 
A.R. Dehpour1
1Department of Pharmacology, School of Medicine, Medical Sciences/
University of Tehran, Tehran, Iran, 2Department of Pathology, Shariati 
Hospital, Medical Sciences/University of Tehran, Tehran, Iran
Introduction: Renal ischemia/reperfusion injury (IRI) is a major problem 
in renal transplantation which occurs during the process of organ retrieval 
and storage; and is closely associated with acute rejection episodes and late 
allograft failure. However, recent studies have revealed a new phenomenon 
called “chemical preconditioning” which can induce tolerance against the 
ischemic stress via a variety of proposed pathways especially nitric oxide 
(NO) system. Lithium is suggested to modulate the intracellular NO signaling, 
although the exact mechanism underlying the drug’s therapeutic action is not 
yet understood. In this study we investigated the preconditioning properties 
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of acute and chronic lithium pretreatment in preventing renal IRI and the 
involvement of NO pathway.
Materials & Method: Forty-eight adult male Sprague-dawley rats were 
divided into six groups. All groups underwent right nephrectomy 14 days before 
intervention. Groups 1 and 2 received acute intraperitoneal (IP) LiCl (40 mg/
kg) and 30 minutes later IRI was induced by clamping the left renal pedicle for 
60 minutes. Group 1 (Acute Li+ L-NAME) received the nitric oxide synthase 
inhibitor, L-NAME (10 mg/kg) 15 minutes before LiCl administration and 
group 2 (Acute Li) received its vehicle. In groups 3 (Chronic Li+ L-NAME) 
and 4 (Chronic Li). oral Li (600 mg/lit in water) treatment was started 7 days 
before right nephrectomy to achieve the therapeutic plasma level of lithium. 
Fourteen days after nephrectomy, animals received either L-NAME (10 mg/
kg) or its vehicle and renal IRI was induced 45 minutes later. Groups 5 and 
6 (Control) received either L-NAME (10 mg/kg) or its vehicle 45 minutes 
before IRI. Rats were killed 24 h after IRI, the blood samples were collected 
and assessed for serum BUN and Cr level, and tissue samples were fi xed in 
formalin for histopathologic tubular damage scoring (H-score).
Results: The mean BUN, Cr and H-score were 154.6±29.46, 4.3±0.77 and 
82±5%, respectively in control group. Acute Li signifi cantly improved BUN 
(116±20.1). Cr (3.35±0.95) and H-score (32±28%) in IRI animals compared 
to those not treated with acute lithium (P<0.05); and L-NAME pretreatment 
signifi cantly reversed the protective effect of acute lithium (BUN= 175.5±8.37, 
Cr= 4.93±0.173 ,H-score= 66±13%). Similarly, Chronic Li signifi cantly (but 
more potently) improved BUN (59±17.1). Cr (1.08±0.1) and H-score (7.5±5%) 
in IRI animals compared to those not treated with chronic lithium (p<0.05) 
and L-NAME signifi cantly reversed the chronic lithium induced protection 
(BUN= 15.3±19.2, Cr= 3.8±0.4, H-score= 26.3±3%). There was no signifi cant 
difference between rats treated with L-name alone (group 5) and the control 
group.
Conclusion: Our study demonstrates that preconditioning of kidney with either 
acute or chronic lithium protects renal tissue against ischemia/reperfusion 
injury; and this phenomenon is mediated with Nitric oxide system. The results 
suggest a potential application for lithium in terms of protecting the kidney 
before transplantations and also reducing the risk of tissue rejection afterwards.
CYCLOXYGENASE-2 SELECTIVE INHIBITION 219 
DOWNREGULATES METALLOPROTEINASE-9 ACTIVATION 
AND IMPAIRS NEUTROPHIL MIGRATION IN HEPATIC 
ISCHEMIA/REPERFUSION INJURY
A.J Coito1, T. Hamada1, S. Tsuchihashi1, S. Duarte1, R.W Busuttil1
1The Dumont UCLA Transplant Center, Los Angeles, CA, United States.
Neutrophils are critical mediators in infl ammatory liver injury. This study tests 
the hypothesis that cyclooxygenase-2 (COX-2). a potent infl ammatory mediator 
regulates neutrophil recruitment in liver ischemia/reperfusion (I/R) injury. 
Methods and Results: COX-2 -/- mice (COX-2 KO) and matched COX-2 
+/+ controls (WT) were submitted to 90 minutes warm ischemia followed by 
6h and 24h of reperfusion. The synthesis of PGE2 (pg/20mg protein: 636±192 
vs. 1,167±157; p<0.008, n=4/gr). and TXB2 (pg/20mg protein: 169±117 vs. 
652±291; p<0.04, n=4/gr) was signifi cantly reduced in COX-2 defi cient livers 
at 6h of I/R injury, as compared to WT controls. Liver function, as evidenced 
by the sGOT (IU/L) (6h: 1,505±1,125 vs. 15,502±11,344; p<0.03; 24h: 
3483 vs. 974±193; p<0.01, n=5-6/gr). and sGPT (U/L) (6h: 2,639±1,930 vs. 
15,466±7,552; p<0.003; 24h: 206±45 vs. 1,244±600; p<0.01, n=4-5/gr) levels 
was signifi cantly improved in COX-2 KO mice as compared to WT controls 
after I/R. COX-2 KO livers showed overall improved histological preservation 
after the I/R insult, contrasting with extensive sinusoidal congestion and 
necrosis observed in controls. Moreover, the levels of anti-apoptotic BcL-2 
(0.83±0.14 vs. 0.08±0.09, p<0.01; n=4/gr) and Bcl-XL (1.38±0.11 vs. 0.58±0.19, 
p<0.01; n=4/gr) were signifi cantly higher in COX-2 KO livers after 6h of I/R 
injury. One of the most striking effects observed in COX-2 KO mice was the 
markedly reduced neutrophil recruitment in livers after I/R as indicated by the 
decreased levels of MPO activity (U/g) (6h: 2.0±1.0 vs. 13.7±4.3; p<0.01; 24h: 
1.2±0.4 vs. 3.4±1.5; p<0.01; n=5-6/gr). and by the reduced Ly-6G neutrophil 
infi ltration at both 6h (35%, p<0.01) and 24h (50%, p<0.01). CXCL-2 mRNA 
expression, a major neutrophil chemoattractant (6h: 9.1±0.7 vs. 11.1±0.7; 
p<0.05; 24h: 3.1±3.0 vs. 10.0±3.5; p<0.05) was decreased in COX-2 KO 
livers after I/R. Overall, leukocyte transmigration is dependent upon cell 
activating chemokines, adhesive interactions, as well as matrix degradation 
mechanisms. MMP-9 activity, which is induced and mediates liver I/R injury, 
was signifi cantly reduced in COX-2 KO livers at both 6h (2-fold) and 24h 
(4-fold) of reperfusion. Indeed, Ly-6G neutrophils co-expressing MMP-9 were 
highly detected in damaged WT livers and profoundly depressed in COX-2 
KO livers after I/R insult. Interestingly, the addition of NS-398, a selective 
COX-2 inhibitor, to fMLP-stimulated neutrophils, markedly depressed MMP-9 
activation (5 to10 fold) by these cells in a dose-dependent manner. Furthermore, 
the treatment of isolated neutrophils with MMP-9 inhibitor-I, a specifi c MMP-9 
inhibitor, signifi cantly disrupted their migration across fi bronectin in transwell 
fi lters (35% vs. 63%, p<0.004). 
Conclusion: Our novel fi ndings support the view of an important function for 
COX-2 in the pathogenesis of hepatic I/R injury. Moreover, they evidence a 
regulatory role for COX-2 on MMP-9 activation by neutrophils, which is likely 
a key factor in the recruitment of these cells in liver I/R injury.
ROLES OF ISLET-ASSOCIATED HEPARAN SULFATE 220 
(HS) AND HEPARANASE IN ISLET BETA CELL SURVIVAL AND 
ISLET ALLOGRAFT REJECTION
C. Simeonovic1, F.J. Choong2, S. Popp3, A. Ziolkowski4, C. Freeman5, 
C. Parish6
1The John Curtin School of Medical Research, The Australian National 
University, 2The John Curtin School of Medical Research, The Australian 
National University, 3The John Curtin School of Medical Research, The 
Australian National University, 4The John Curtin School of Medical 
Research, The Australian National University, 5The John Curtin School of 
Medical Research, The Australian National University, 6The John Curtin 
School of Medical Research, The Australian National University
Autoimmune destruction of pancreatic islets and the development of Type 
1 diabetes in NOD/Lt mice correlates with increased expression of the HS 
degradative enzyme heparanase, which targets HS proteoglycans in islet 
basement membranes (BM) and the intra-islet extracellular matrix (ECM). Our 
study investigated the role of HS in islet beta cell viability and the contribution of 
heparanase to the rejection of islet allografts. Islet-associated HS was identifi ed 
by histological staining with alcian blue and by immunohistochemistry using 
10E4 anti-HS mAb (Seikagaku) and the M.O.M immunodetection kit (Vector 
Labs). BALB/c islets were dissociated into single cells using Dispase (1mg/
ml) and beta cells were identifi ed by immunofl uorescence microscopy using 
guinea-pig anti-swine insulin serum and FITC-donkey anti-guinea pig IgG. 
Beta cell-associated HS was removed by in vitro treatment with bacterial 
heparitinase I, II and III (Sigma; 0.25U/ml) and cell viability was assessed after 
2 days of culture by fl uorescence microscopy using Sytox Green (Invitrogen) 
to distinguish dead cells. Heparanase and ubiquitin-conjugating enzyme (UBC; 
house-keeping gene) transcripts were analysed quantitatively in cDNA from 
BALB/c (H-2d) islet allografts and CBA/H (H-2k) islet isografts at 3 – 8 days 
post-transplant to CBA/H mice, using Taqman real-time PCR. Heparanase 
protein was identifi ed by immunohistochemistry in mouse pancreas and islet 
transplants using polyclonal rabbit anti-heparanase antibodies. Islets in situ 
were shown to be enriched in HS. Beta cells constituted 92.3 ± 3.2% (n=3) 
of dissociated BALB/c islet cells. Heparitinase treatment of isolated islet 
cells signifi cantly increased beta cell death from 21.1 ± 6.8% (in controls) to 
78.8 ± 7.3% (n=12; P<0.0001). Treated beta cells were rescued from dying 
by culturing them on an exogenous ECM (prepared from PK-15 cells (a pig 
kidney epithelial cell line); P<0.0001) or with 5-50 micrograms/ml heparin 
(a highly sulfated analogue of HS; P<0.0001). Intragraft heparanase mRNA 
increased 4-fold during rejection, compared to isografts and peaked at day 7. In 
situ and post-transplant, islets showed intense staining of inactive heparanase 
(proheparanase) protein. Alloimmune islet damage correlated with localisation 
of active heparanase in the host cellular infi ltrate and in the periphery of 
transplanted islets, adjacent to infi ltrating leukocytes. Active heparanase was 
not detected in engrafted isogeneic islets. Our fi ndings demonstrate that islet 
beta cells require HS for survival and are exquisitely sensitive to loss of cell-
associated HS. Since heparanase is the only mammalian endoglycosidase that 
can degrade HS, our fi ndings suggest that during rejection, host leukocyte-
derived heparanase functions in disrupting the BM of engrafted islets and this 
process represents an initial alloimmune assault. Thereafter, leukocyte-derived 
heparanase and possibly donor islet-derived heparanase activated via cytokines 
produced by infi ltrating host leukocytes, degrade the intra-islet HS necessary 
for beta cell survival. This mechanism of rejection could therefore potentially 
involve a novel process of islet cell-mediated “self-destruction”. Our fi ndings 
suggest that inhibitors of heparanase may represent a novel anti-graft rejection 
strategy for islet allografts.
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HUMAN CYTOMEGALOVIRUS INFECTION HAS A 221 
CRITICAL IMPACT ON LEUKOCYTE TELOMERE LENGTH
P.J.E.J. van de Berg1,2, S.L. Yong2, F. J. Bemelman1, I.J.M. ten Berge1 and 
R.A.W. van Lier2.
1Renal Transplant Unit, Dept. of Internal Medicine and 2Dept. of 
Experimental Immunology, AMC, Amsterdam.
Introduction: Reduction of mean leukocyte telomere length is associated 
with a high risk of cardiovascular disease but the basis for this association is 
unknown. Cytomegalovirus (CMV) infection causes an expansion of highly 
differentiated effector CD8+ T lymphocytes. Given the many cell divisions 
during development to effector cells, we studied telomere length in relation to 
CMV serostatus in healthy people.
Methods: Peripheral blood was obtained from 10 CMV seronegative and 10 
CMV seropositive age- and sex matched healthy volunteers, as well as from 
20 renal transplant recipients. The composition of the peripheral CD8+ T cell 
compartment was studied by FACS analysis using the subset markers CD45RA, 
CD27 and CD28. In addition, telomere length was measured by fl ow-fi sh, a 
FACS based assay using telomere specifi c FITC-labelled probe.
Results: We found that the inter-individual variation in the mean telomere 
length of blood cells is almost exclusively determined by the composition of 
the lymphocyte pool and not by granulocytes or monocytes. Renal transplant 
patients show a sudden and sustained drop in telomere length in the course of 
primary infection, also the lymphocyte pool changed permanently to a more 
differentiated state. CMV seropositive healthy individuals showed a strong 
increase in numbers of highly differentiated effector CD8+ T lymphocytes and 
the mean telomere length in CMV seropositive individuals was signifi cantly 
shorter than in CMV seronegative individuals (p<0,008). Importantly, the 
mean telomere length appeared to be directly dependent on the size of the 
CD45RA+CD27-CD8+ effector T cell pool (r=-0,74).
Conclusion: We show that the mean telomere length of full blood is 
directly related to the differentiation status of the lymphocyte pool. Given 
the established association of mean telomere length with cardiovascular 
disease our data suggest that the quantity and quality of the cellular immune 
response to CMV might be an etiological factor in the development of 
atherosclerosis.
BI-DIRECTIONAL TRANSFER OF MAJOR 222 
HISTOCOMPATIBILITY COMPLEX CLASS II MOLECULES 
BETWEEN DONOR AND RECIPIENT CELLS IN VIVO 
FOLLOWING SOLID ORGAN TRANSPLANTATION
W. Wong, K. Brown, S. Sacks, 
King’s College London
Cells have the ability to exchange surface molecules with their neighbours, 
including intact MHC molecules. The functional signifi cance is unknown, 
but it may be an important element of the immune response in areas such as 
autoimmunity and infection. Transplantation is the only example in which 
foreign MHC molecules are deliberately transferred between individuals. If 
donor MHC molecules are transferred whole to the surface of recipient antigen 
present cells (APC) such as dendritic cells, they will be recognised by recipient 
T cells that would normally recognise them via the direct antigen presentation 
pathway, despite being presented by recipient APC. These recipient APC will 
also express self MHC molecules that can present donor derived peptides, 
which are recognised by recipient T cells via the indirect pathway. Thus, 
transfer of MHC class II complexes can potentially link allospecifi c T cells of 
the direct and indirect pathways to enable bystander activation or regulation 
(linked suppression). However, the extent of this phenomenon in vivo after a 
solid organ graft is unknown.
Vascularised BALB/c or DBA/2 (both H-2d) mouse kidney or heart 
allografts were transplanted into BL/6 (H-2b) recipients. Recipient spleens 
were harvested at various time points post transplantation. Following 
transplantation of BALB/c, DBA/2 kidneys or DBA/2 hearts, the number 
of donor I-Ad positive cells within recipient spleen rose to a maximum of 
28.4+4.8 cells per high power fi eld (hpf). After co-staining for recipient 
I-Ab, followed by digital overlay, cells positive for both donor and recipient 
class II MHC molecules could be clearly seen, and were shown by confocal 
microscopy to be co-localised on the cell surface. These double positive cells 
rose to a peak of 32.92+13.95% and 26+1.8% of all donor I-Ad positive cells 
for BALB/c and DBA/2 kidney graft recipients respectively. The majority 
of double positive cells were CD11c+ dendritic cells (62.5+7.3% following 
BALB/c transplantation). however macrophages and B cells could also 
acquire MHC class II molecules. The majority of cells positive for both donor 
and recipient MHC class II molecules also expressed the co-stimulatory 
molecules CD40 and CD86, suggesting a capacity to elicit a T cell response. 
FISH analysis showed that donor cells were capable of acquiring recipient 
MHC class II molecules and vice versa, demonstrating that MHC transfer is 
bi-directional.
MHC transfer between donor and recipient cells is a common occurrence 
following transplantation with up to 30% of cells expressing both donor and 
recipient MHC molecules. This process represents a potentially novel and 
major route of T cell activation which may link allospecifi c T cells of the direct 
and indirect pathways, and the extent of the transfer suggests a signifi cant role 
for this antigen presentation pathway.
BK VIRUS NEPHROPATHYCONCURRENT ORAL SESSION 17: 
INTENSIVE SCREENING FOR POLYOMAVIRUS 223 
REACTIVATION AND A PRE-DETERMINED STEPWISE 
MODIFICATION IN MAINTENANCE IMMUNOSUPPRESSION 
THERAPY: A ROAD MAP TO IMPROVE THE OUTCOME.
R. Wali1, C. Drachenberg1, H. Hirsch2, E. Ramos1
1University of Maryland School of Medicine, 2University of Basel, 
Switzerland
Intensive screening for the detection of polyoma viral reactivation can result 
in early detection of this disease and will allow to change or modify the 
maintenance immunosuppression therapy to prevent the development of graft 
disease; polyoma virus nephritis (PVN).
We performed a prospective single center study. We randomly assigned de 
novo kidney transplant (cluster randomization) to Intensive Screening (IS: 
n=648) and Routine Care (RC: n=260) for the detection of decoy cells in 
random sample of urine. This was complemented with urine and blood nucleic 
acid testing for different types of polyomaviruses. All patients had biopsies 
performed for detection of polomya nephritis (PVN). Both groups were treated 
with pre-determined stepwise modifi cation of maintenance immunosuppression 
based on cell cytology and viremia (Step 1: decrease dose of cellcept by 50%, 
Step 2: decrease dose of tacrolimus by 50%, or switch to sirolimus therapy, 
Step 3: discontinue cellcept). Primary outcome included persistence of decoy 
cells/viremia following each step in modifi cation of immunosuppression every 
three months and secondary outcomes included acute rejection, graft function 
and graft loss.
Results: Polyomaviral reactivation developed in 11.7% in IS group and 40% 
had PVN without changes in serum creatinine. The estimated cumulative 
rate of primary outcome in the IS versus RC groups, 3-months (51% vs. 
79%) relative risk (RR). 0.47; 95%CI,0.20-1.08;p=0.051); 6-months (20% 
vs. 52%) (RR=0.67; 95% CI,0.38-1.20; p=0.009); and 12-months (2% 
vs. 33%) (RR=0.88; 95% CI, 0.41-1.43; p=0.003). Secondary outcomes: 
despite similar degrees of modification in maintenance therapy, rate of 
acute rejection was non-significant (p=0.25). but 25% of patients in RC 
group lost the graft compared to no graft loss in IS group. Patients who 
continue to remain on tacrolimus vs. those who were switched to sirolimus 
therapy demonstrated persistent viremia (OR=10.25; 95%CI, 1.2-92.0; 
p=0.003).
Conclusion: IS for poloymaviral reactivation allows early detection of PVN 
in the presence of stable graft function. Stepwise modifi cation in maintenance 
immunosuppression therapy resulted in early resolution of decoy cells as well 
as viremia in both groups, albeit slowly in RC group. This intervention did not 
prevent the graft loss in RC group. Thus we demonstrate that active surveillance 
for polyomaviral activation after solid organ transplant allows an opportunity 
to prevent the disease progression and prevented graft loss in the recipients of 
kidney transplant population. The results of this study will allow to develop 
a uniform protocol for immunosuppression therapy following reactivation of 
polyoma virus.
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BK VIRUS (BKV) LARGE T-ANTIGEN (LTA) ATPASE 224 
DOMAIN IS A PROMISING TARGET FOR DRUG DISCOVERY
P. Randhawa, G. Zheng, N. Farasati, C.J. Camacho and M.Bueno.
Departments of Pathology and Computational Biology, University of 
Pittsburgh, Pittsburgh, PA, USA.
Background: Polyomavirus LTA is a hexameric protein with a helicase activity 
that is powered by ATP binding and hydrolysis. The helicase function is critical 
for viral replication. This prompted an evaluation of the suitability of BKV 
ATPase domain as a target for drug discovery.
Methods: Protein modeling techniques were applied to BKV LTA using the 
known crystal structure of SV40 LTA. The QuikChange multi site-directed 
mutagenesis kit (Stratagene) was used to generate ATPase mutations in the 
BKV-pBR322 plasmid. Viral replication in culture was measured using real 
time PCR. Inhibition of LTA ATPase was measured by a colorimetric assay in 
which the dye malachite green binds inorganic phosphate released following 
LTA mediated hydrolysis of ATP.
Results: Alignment of 30 BK and 13 SV40 amino acid sequences in the 
Swiss-Prot database showed 70% identity and 90% similarity. On homology 
modeling, all ATP binding residues identifi ed as being critical for SV40 LTA 
ATPase activity were also present in BKV LTA. Transfection of viral DNA with 
Lys420Ala, Arg421Ala, Asp504Ala, and Arg542Ala mutations showed only 
2.46 fold increase in DNA copy number over 6 weeks, compared to a 2090 
fold increase for wild type BKV DNA. This established that BKV LTA ATPase 
activity facilitates viral replication.
CASTp method calculation of the LTA ATP binding pocket volume (338 Å3) 
indicated that it was suitable for discovery of small molecule inhibitors. Sixty 
two (62) kinase inhibitors obtained from the TimTek ActiTarg library were then 
screened in a real time PCR based BKV replication system, and 3 were found to 
show anti-BKV activity, as judged by a CC50/EC50 ration (selective index) >10. 
To accelerate our drug discovery effort we initiated in-silico high throughput 
screening for small molecules that bind the LTA ATPase domain. Virtual 
docking of 24 compounds, calculations of energy binding, and correlation with 
biochemical ATPase inhibition activity indicated that the docking and scoring 
method developed will be useful for large scale screening of additional anti-
BKV compounds. Following up on this prediction, we used known chemical 
structures of published Hsp90 and Rho-kinase inhibitors to search compound 
databases and obtain a subset of 8294 small molecules capable of docking LTA. 
Cross-referencing the top solutions obtained by energy ranking, we were able 
to identify 50 compounds that bind LTA in all 6 conformational states. A subset 
of 5 compounds simultaneously binds three different LTA domains, namely, the 
ATP binding site, hexamerization surface, and hinge region.
Conclusions: Large T-antigen ATP binding site is a promising target for 
discovery of anti-polyomavirus drugs. The lead compounds identifi ed so far are 
will need to be optimized for their anti-viral and pharmacokinetic parameters, 
prior to experimental and clinical testing.
CLINICAL CORRELATES OF BK VIRUS CAPSID 225 
ANTIBODY SUBCLASS MEASUREMENTS IN KIDNEY 
TRANSPLANT RECIPIENTS
P. Randhawa1, D. Bohl2, D. Brennan2, K. Ruppert1, G. Storch2, 
B. Ramaswami1, R. Shapiro1, J. March1, S. Muner1, R. Viscidi3
1University of Pittsburgh, 2Washington University at St. Louis, 3Johns Hopkins 
Hospital
Background: The humoral immune response to BK virus (BKV) infection 
is incompletely characterized. This study sought the clinical correlates of the 
circulating IgG, IgM, and IgA antibodies to BKV VP-1 virus like particles 
(VLP).
Methods: BKV-specifi c antibodies were measured in serum from 107 kidney 
transplant recipients with evidence of active BK infection 1, 4, 12 wk, 6m, and 
1 yr post-transplant using VLP-based ELISA assay. Viral DNA was quantitated 
in urine and plasma using real time PCR.
Results: IgG titer at week 1, as measured by optical density, showed a 
negative correlation with peak viral load in patients who went on to develop 
viruria (r=-0.25, p=0.05). IgA titer at week 1 was lower in patients who went 
on to develop viremia (0.15+/-0.19). compared to those developed viruria 
(0.22+/-0.21). persistent viruria (0.23+/-0.31) or no viruria (0.25+/-0.21). On 
analyzing immunoglobulin subclass distribution in individual patients, the 
prevalence of IgG+IgA+ phenotype at week 1 was also lower in patients who 
went on to develop viremia (viremia=14.3% versus viruria=42.2%, persistent 
viruria=40.8% and no viruria=44.2%).On evaluation of serial samples, patients 
who never developed BK viruria or viremia had IgA and IgM antibodies 
detectable in respectively 26/43 (60.5%) and 7/43 (16.3%) of baseline 
samples. Conversely, at the time of active viruria, ELISA assays performed on 
serum detected IgA and IgM antibodies in only 78.0% and 52.0% of samples 
respectively. Transient reversion to a seronegative state, defi ned as inability to 
detect IgG, IgA, or IgM antibodies at one or more time points was observed in 
18.4% of all patients This transient loss of antibody production to BKV capsids 
was (a) independent of the relative prevalence of immunoglobulin isotypes at 
week 1, and (b) not consistently related to the onset of viruria or viremia and (c) 
occurred without augmentation of maintenance immunosuppression.
Optical density (OD) cut off values of 1.8, 0.84, and 0.24 for IgG, IgA, and 
IgM, respectively, could distinguish PCR positive and PCR negative samples 
with 91.2-95.1% specifi city but only 28.6-41.7% sensitivity. A rise in OD 
(delta OD) above the baseline for IgA, IgM or IgG had a sensitivity of 70.3- 
78.1% and a specifi city of 67.2-72.0% for BKV viruria/viremia. Peak viremia 
correlated with delta OD for IgA and IgM (r=0.37, p=0.003, and r=0.52, 
p=0.001 respectively, while peak viruria correlated with delta OD for all three 
immunoglobulin isotypes (IgG r=0.36, IgA r=0.36, IgM r= 0.43, p<0.004).
Conclusions: BKV activation as assessed by viruria or viremia correlates 
imperfectly with detection of IgA and IgM antibodies to viral capsid proteins. 
However, baseline immunoglobulin isotype measurement provides prognostic 
information: low IgG and IgA titers are associated with a higher peak urinary 
viral load and greater risk of viremia.
PROGNOSTICATION OF BKV NEPHRITIS USING 226 
GENE EXPRESSION PATTERNS AND DEVELOPMENT OF A 
COMBINATION REGIMEN OF IVIG, LEFLUNOMIDE AND 
REDUCED TACROLIMUS (ILRT) TO OPTIMIZE OUTCOME
D. Dadhania1,2, C. Snopkowski1, R. Ding1, M. Aull1, J. Lee1,2, V. Sharma1,2, S. 
Kapur1, S. Seshan1, M. Suthanthiran1
1Weill Cornell Medical Center, 2Rogosin Institute
BKV nephritis is associated with >50% risk of renal allograft loss, and its 
outcome is diffi cult to predict using viral load or renal histopathology. In the 
current investigation, we tested the hypothesis that (1) heightened expression 
of urinary cell granzyme B and CD103 mRNA levels predicts renal allograft 
loss in patients with BKV nephritis, and
(2) renal allograft outcome following a diagnosis of BKV nephritis can be 
optimized with a combination regimen of IVIG, lefl unomide and Reduced 
Tacrolimus (ILRT).
We collected urine specimens from 13 patients with biopsy confi rmed BKV 
nephritis and measured urinary cell levels of mRNA for granzyme B, a 
cytotoxic attack molecule and CD103, a cell surface protein for intraepithelial 
localization of CD8+ CTLs. Our data demonstrating that histological changes 
at the time of BKV nephritis diagnosis were not informative whereas urinary 
cell levels of mRNA for granzyme B and CD103 are predictive of allograft 
outcome are shown in Table 1.
Table 1. Predictors of Renal Allograft Loss in Subjects with BKV Nephritis
Parameter Graft Loss (n=3) No Graft Loss (n=10)  P value
Biopsy Tubulitis
Score
0,1,2 0,0,0,1,1,1,1,2,2,3 n/a
Biopsy Cytopathic
Score
1,1,3 1,1,1,1,1,1,1,1,2,3 n/a
Granzyme B mRNA
 (median copy number ) 
113,000 2,265 0.01
CD103
 (median copy number) 
10,900 470 0.02
Our treatment regimen for BKV nephritis consisted of a reduction in tacrolimus 
dosage and removal of MMF therapy (N=14, historical control). and the 
regimen was changed to the combination regimen of IVIG (2g/kg single dose). 
lefl unomide (20mg bid) in place of MMF, and reduced tacrolimus dosage 
(trough of 3-5ng/ml) since January 2005 (N=13, ILRT regimen).
The overall graft loss rate in the historical control group was 50% whereas it 
was 7.7% in the ILRT group (Table 2). Logistic regression analysis revealed 
that ILRT therapy was associated with OR = 0.83 (0.008, 0.83; P=0.01).
Table2. Graf Loss Rate in Patients with BKV Nephritis
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Historical Ctrl (n=14) ILRT Rx (n=13) P value
Serum Creatinine
at time of diagnosis
 (mean ± SE) 
2.5 ± 0.23 2.3 ± 0.22 0.6
Graft Loss at 6 months 
post diagnosis (%) 
29% 7.7% 0.32
Graft Loss at last 
follow-up (%) 
50% 7.7% 0.03
BKV viremia clearance 
(%) 
n/a 82%
Our gene expression profi les suggest that renal allografts with enhanced 
infl ammation at the time of diagnosis of BKV nephritis diagnosis are at 
increased risk for renal allograft loss. Our data also suggest that management 
of BKV nephritis using a combination approach of IVIG, lefl unomide and 
reduced tacrolimus is associated with improved outcomes.
IMPACT OF RABBIT ANTI-THYMOCYTE GLOBULIN 227 
INDUCTION THERAPY ON REACTIVATION OF BK VIRUS IN 
RENAL TRANSPLANT RECIPIENTS
A. Agarwal, A. Metha, A. Turner, K. Kokko, N. Turgeon, P. Tso, K. Newell, 
C. Larsen, A. Kirk
Emory University
Reactivation of Polyoma BK virus has been recognized as an important 
cause of kidney allograft nephropathy and loss. BK nephropathy (BKN) 
has been associated with potent immunosuppression regimens. The impact 
of rabbit anti-thymocyte globulin (RATG) induction on BK viremia (BKV) 
and BK nephropathy has not been well defi ned. RATG has been associated 
with increased viral activation such as EBV. At our institution, all kidney 
recipients are maintained on triple immunosuppression including tacrolimus, 
mycophenolate and prednisone unless contraindicating complications require 
a change. Prior to January 2007, no induction therapy was used and thereafter 
RATG was used. Trough tacrolimus targets were not changed. Throughout 
our experience, we have prospectively monitored for BKV. We now report 
the results of a retrospective analysis of the impact of RATG on BKN and 
BKV (primary end-points). BKV was monitored via serum BKV PCR at post 
transplant months 1, 2, 3, 4, 5, 6, 9, and 12. In addition, CMV and EBV PCR 
were performed based on clinical indications. Those with positive viremia 
had reductions in immunosuppression. Evidence of renal dysfunction with 
positive BK viremia led to renal biopsy. BKN was diagnosed by histological 
and immunohistochemical changes. Univariate analysis included Student¡¦s 
t-test, Mann Whitney test, Fisher¡¦s exact test, and log-rank test (p value 
<0.05 was signifi cant). Stepwise (forward step likelihood ratio method) 
Cox regression model was performed to assess predictive factors for BK 
viremia. Between January 2006 and December 2007, 275 isolated kidney 
transplantations were analyzed (40 were excluded for clinical indications 
that warranted changes). In total, 110 kidney recipients received no induction 
(Group I) while 135 pts had RATG (Group II). There were no differences 
between donor and patient demographics except for follow-up (I: 571„b148 
days vs. II: 246„b102; p<0.01). Data was censored at one year follow up. 
Patient (I: 97% vs. II: 99%; p=0.78) and graft survival (I: 95% vs. II: 99%; 
p=0.63) were similar. Though one year actuarial incidence of BKV was 
similar (I: 19% vs. II: 29%; p=0.11). BKV developed earlier in RATG cohort 
(I: 163¡Ó22 vs. II: 108¡Ó 74 days; p=0.03). There was no difference in the 
BK log viral copies/mL (I: 3.8¡Ó0.8 vs. II: 4.0¡Ó0.8; p=0.11). Although BK 
nephropathy was more prevalent in Group I (I: 7.2% vs. II: 0.7%; p=0.01). 
no grafts were lost to BKN. There was no difference in CMV (I: 23% vs. II: 
12%; p=0.08) nor EBV infection (I: 3.6% vs. II: 6.2%; p=0.24). Multivariate 
analysis revealed that only age (HR: 1.05 95%CI: 1.02-1.07; p=0.001) 
and induction therapy (HR: 2.2; 95%CI: 1.2-4.1; p=0.01) were predictors 
of BKV. The preliminary data suggest RATG leads to increased BK virus 
reactivation; despite no evidence of changes in CMV or EBV infection. 
However aggressive BK PCR monitoring could curtail the progression of 
earlier BKV to BK nephropathy. Long-term follow-up is on going in order to 
determine aggregate BK viremia and nephropathy.
THE IMPACT OF CLINICAL POLYOMAVIRUS DISEASE 228 
ON GRAFT SRUVIVAL OF PEDIATRIC KIDNEY TRANSPLANT 
RECIPIENTS – AN ANALYSIS OF OPTN/UNOS DATABASE
Y. Cho2,3, B. Hardy1, K. Lemley1, J. Cicciarelli2,3, R. Mendez2,3, 
I. Hutchinson2,3, T. Shah2
1Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC 
School of Medicine
Background: Polyomavirus-associated nephropathy often precedes renal 
allograft dysfunction in adult renal transplant recipients. The OPTN/UNOS 
began collecting information regarding polyomavirus test results using follow-
up forms since June 30, 2004. The aim of this study is to evaluate the impact 
of clinical polyomavirus disease (PVD) on graft survival after pediatric kidney 
transplantation.
Methods: From Jan 2004 to Dec 2006, a total of 2,065 pediatric kidney alone 
transplants (age 2-20 yrs) with functioning graft at 6 months were identifi ed 
the OPTN/UNOS data as of Aug 20, 2007. Graft survival rates were compared 
for the following 3 groups: PVD group – Patients who had developed PVD 
(n=57); no PVD group – Patients who had PV test and hadn’t developed PVD 
(nPVD) (n=272); and Control group – Patients who had not performed PV 
test on followup record (nPVT) (n=1,736). Univariate and multivariate Cox 
regression analyses were performed to identify risk factors of graft loss.
Results: Overall graft survival rates of PVD group were not signifi cantly 
different from those of control group (nPVT group, log-rank P=0.25) and 
nPVD group (log-rank P=0.97). In multivariate analysis, both nPVD (RR=1.55 
vs nPVT, P=0.31) and PVD (RR=1.00 vs nPVT, P=0.99) were not signifi cant 
risk factors of graft loss after adjusting for age, race, and rejection treatment 
within 6 months (Table). Pediatric patients may have a lower rate of graft loss 
because they are able to mount a more vigorous immune defense against BK 
virus than adult kidney transplant recipients.
Conclusions: Clinical polyomavirus (BK virus) disease may not be as 
signifi cant a risk for pediatric kidney survival as it is for adult recipients. Larger 
prospective studies are needed to understand the impact of BK virus infection, 
replication, and disease on pediatric kidney transplant outcome.
Table. Results of univariate and multivariate Cox regression analyses
 Unadjusted
RR (95%CI) P value
Adjusted
RR (95% CI) P value
Recip Age 15-20 
vs 2-14
1.47 (1.00-2.16) 0.050 1.48 (1.01-2.19) 0.046
Recip Black vs 
others
2.15 (1.43-3.22) <0.001 2.10 (1.40-3.15) <0.001
Rejection in 6 mon 
vs none
3.28 (2.11-5.01) <0.001 3.17 (2.04-4.94) <0.001
CPVD nPVT 
(control) 
1.0  1.0  
 nPVD 1.89 (0.82-4.32) 0.13 1.55 (0.67-3.56) 0.31
 PVD 0.99 (0.54-1.82) 0.98 1.00 (0.54-1.83) 0.99
MYCOPHENOLATE HAS ANTIVIRAL PROPERTIES IN 229 
BK VIRUS INFECTED VERO CELLS
P. Acott, P. O’Regan, P. Wornell, J. Crocker
IWK Health Centre
We previously reported mycophenolic acid (MPA) reliably reduces BK virus 
(BKV) copy count in Vero cells (Green monkey kidney cell origin) with 
infection from various BKV strains. Subsequently we explored potential 
mechanisms including anti-metabolite effects and molecular markers of mRNA 
production.
Vero cells were infected with BKV (NCCR rearranged VJ strain) by a 2 hr 
incubation with 6.5 X 105 BKV copies, washed, then cultured for 1, 7, 14, 21, 
28, and 35 days. Culture media with MPA (0, 2 and 8 mg/l) was exchanged 
weekly. We quantifi ed cellular protein and determined BK viral copy numbers 
in both cell fractions and SN at all time points. RNA was extracted and reverse 
transcribed for subsequent quantititative mRNA analysis for Transforming 
Growth Factor Beta (TGFß). Collagen 1A1, Alpha Smooth Muscle actin 
(α;SMA). and Heat Shock Protein 47 (HSP) relative to Ribosomal Polymerase 
II (RPII) which we have shown remains stable in its expression in chronic Vero 
cell culture ± BKV infection. Quantifi cation of BKV replication and mRNA 
was by quantitative real time PCR using the Roche Lightcycler 2.0.
MPA (2 and 8 mg/l) reduced BKV copy count greater than 1 log fold in both 
SN and cells after day 14. There was reduction of protein amount by 50 – 75% 
in chronic MPA exposed Vero cells consistent with an anti-metabolite effect 
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without an increase in cytopathic effect. There was no difference at any time 
point of HSP, TGFß or α;SMA mRNA levels. MPA reduced Collagen 1A1 in 
chronic culture.
MPA appears to exert an anti-metabolite effect on viral replication and reduce 
production of Collagen 1A1 in chronically infected cells exposed to MPA. Our 
in vitro data suggests that Mycophenolate might have a protective effect in 
BKV infected renal tubular cells with both antiviral and anti-fi brotic response.
MONITORING OF BKV LOAD IN URINE ALLOWS 230 
IDENTIFICATION OF PATIENTS WITH THE HIGH RISK FOR 
BKV-ASSOCIATED NEPHROPATHY SEVERAL WEEKS PRIOR 
TO DEVELOPMENT OF VIREMIA: ANALYSIS OF 4128 URINE 
AND SERUM SAMPLES
N. Babel1, J. Fendt1, S. Karaivanov1, L. Stele1, H-D. Volk2, P. Reinke1
1Department of Nephrology, 2Institute of Medical Immunology
Background: BKV reactivation plays the causative role in the development of 
BKV associated nephropathy. The quantitative analysis of BKV load in serum 
and urine for monitoring of BKV infection is well established. However, the 
data on relation between BKV load in serum and urine is contradictory. Here 
we performed a large cross-sectional and prospective epidemiologic study on 
BKV load in urine and serum of renal transplant patients and analyzed the 
correlation between both tests and clinical course of infection.
Methods: Total of 4,128 urine and serum samples obtained from 433 renal 
transplant patients (female/male 175/258, mean age 50.5 years) were analyzed 
for BKV positivity by real-time PCR. The prospective analysis included 7 
measurements during the fi rst posttransplant year.
Results: total of 23 (5.3%) and 63 (14.5%) patients were positive for BKV 
in serum and urine, respectively. There was a good correlation between the 
level of viremia and viruria (p<0.01). Interestingly, the BKV load rise in serum 
was preceded by the elevation of BKV load in urine. The prospective analysis 
demonstrated that the peak of viral load and number of positive patients appeared 
during the 3rd and 5th posttransplant month for urine and serum, respectively. 
While 100% of patients with BK viremia were BKV positive in urine, only 
36.5% of patients with BK viruria showed simultaneous BKV positivity in 
serum. However, gradual comparison between viremia and viruria revealed an 
association between the level of BK viruria and percentage of BKV positivity 
in serum: 91% of patients with high level viruria (more than 107copies/ml) 
were BKV positive in serum. 22.2% of patient with persistent BK viremia and 
high level BK viruria developed histologically proven BKVAN within 5 and 11 
weeks after BKV reactivation in urine and serum, respectively. 60% of patients 
with elevated viral load value in serum showed resolution of BK viremia within 
a mean of 33 weeks.
The data obtained from this large prospective study demonstrate a good 
correlation between BKV load in urine and serum. Since the peak of viral load 
in urine appears 8 weeks earlier than the reactivation in serum and shows a 
clear correlation with viremia, the analysis of BKV load in urine will allow 
identifying patients with a high risk for BKVAN development at a very early 
stage.
LOW PREVALENCE AND INCIDENCE OF BK VIREMIA 231 
AND VIRURIA IN A SIMULTANEOUS PANCREAS/KIDNEY 
TRANSPLANT (SPK) RECIPIENT POPULATION FROM A 
SINGLE CENTRE
P. Boucek1, M. Mindlova1, T. Jedinakova1, F. Saudek1, K. Lipar1, 
M. Adamec1, H. Hirsch2
1Institute for Clinical and Experimental Medicine, Prague, 2Institute for 
Medical Microbiology, Basel
BK-virus nephropathy (BKVN) has become a major cause of renal graft loss 
following SPK in some transplant centers. The reported rate of BKVN of 
5-7% may support the systematic screening of BK virus replication in SPK 
recipients. We performed an analysis of the prevalence and incidence of BK 
viral loads in plasma and urine as adjunctive screening tests for BKVN in a 
single-centre SPK population.
Methods: Type 1 diabetic patients on immunosuppressive treatment (IS) with 
at least one functioning graft following SPK in the Institute for Clinical and 
Experimental Medicine in Prague in the period 9/1987-12/2006 were examined 
for the prevalence study (point prevalence at 2/2007). Incidence was assessed 
by another cross-sectional examination performed after one year. Viral 
DNA loads in plasma and urine were quantifi ed by real-time PCR. Samples 
containing >104 and >107 copies/ml were considered as high-level BKV DNA 
positive for plasma and urine, respectively; samples with plasma levels 103-104 
as low-level positive.
Results: Prevalence was assessed in 187 SPK patients (M/F ratio 102/85, mean 
age±SD 44±9 years, diabetes (DM) duration 27±8 years, insulin-independence 
in 156 (83%) ) at 1683 (median; range 42-6661) days from SPK or most recent 
kidney retransplant. High-level replication in plasma and urine was identifi ed 
in 2 (1.1%) and 5 (2.7%) patients, respectively, with 1 additional recipient 
having a low-level plasma replication. IS based on tacrolimus (Tac) was more 
frequent in the positive high-level + low-level replication group (Tac/CyA 7/0 
vs. 99/84; p=0.016). At 2/2008, one-year incidence data were available from 
192 SPK recipients who were initially BK negative (n=167) or underwent 
their fi rst SPK in the preceding one-year period (n=25). High-level plasma and 
urine replication was seen in 2 (1.0%, one recipient with new fi rst SPK in 
the preceding year; BKVN biopsy confi rmed as stage B in both cases) and 
3 (1.6%) patients, respectively, with low-level plasma replication occurring 
in 1 additional SPK recipient. In all BK positive cases IS consisted of the 
combination of Tac/MMF.
Conclusions: A rather low prevalence and incidence of BK viremia and 
viruria were demonstrated in SPK transplant recipients in our centre. While 
possibly infl uenced by its cross-sectional design, the study results may suggest 
that additional factors such as more intensive immunosuppression could be 
responsible for the increased occurrence of BKVN reported in other centers.
ORGAN PRESERVATIONCONCURRENT ORAL SESSION 18: 
MACHINE PRESERVATION OF KIDNEYS DONATED 232 
AFTER CARDIAC DEATH DOES NOT REDUCE DELAYED 
GRAFT FUNCTION: THE PPART STUDY
C. Watson1, A. Wells1, R. Roberts1, J. Akoh2, P. Friend3, M. Akyol4, 
F. Calder5, J. Allen6, D. Collett6
1University Department of Surgery, Addenbrookes Hospital, 2Renal 
Transplant Unit, Derriford Hospital, 3Oxford Transplant Centre, Churchill 
Hospital, 4The Transplant Unit, The Royal Infi rmary of Edinburgh, 5The Renal 
and Transplant Unit, Guys and St Thomas’s Hospital, 6Statistics & Audit 
Directorate, United Kingdom Transplant
Background: Cold machine preservation has been shown to improve outcome 
following transplantation of deceased heart-beating donor kidneys. To determine 
whether cold machine preservation also improves outcome of kidneys donated 
after cardiac death (DCD) we undertook a multicentre randomized controlled 
trial in the UK comparing machine perfusion with simple cold storage.
Methods: One kidney from each DCD donor was randomized to machine 
perfusion (Organ Recovery Systems LifePort device with KPS-1 solution). 
the other to perfusion with UW (ViaSpan) solution followed by simple cold 
storage. The primary outcome measure was the need for dialysis in the fi rst 
7 days (delayed graft function, DGF); secondary outcome measures included 
total duration of dialysis; GFR at 1 week & 3 months (MDRD technique); and 
3 month graft and patient survival.
A sequential design was used with the data inspected after 60 transplants and 
then every 20. All recipients received basiliximab, mycophenolate sodium, 
tacrolimus and prednisolone. The signifi cance of the initial results has been 
tested using paired T tests and McNemar’s exact tests.
Results: Recruitment was stopped after 46 donors when the unadjusted 
sequential analysis concluded that there was no difference in the incidence of 
DGF. 91 of the 92 kidneys were transplanted; one was not used for anatomical 
reasons. One kidney suffered primary non function; it had been machine 
preserved.
The results shown below represent intention to treat, but are not signifi cantly 
different when analysed according to actual treatment.
Machine perfusion 
(n=45) 
Simple cold storage 
(n = 45) 
Signifi cance
 (p-value) 
Recipient Age: Mean (StDev) 50 (14) 49 (14) 0.55
Total ischaemic time: Mean (StDev) 14h 55m
 (4h27m) 
15h 12m
 (4h45m) 
0.83
DGF incidence 26 (58%) 25 (56%) 0.99
Days to last dialysis: Mean (StDev) 6.5 (17.1) 4.7 (7.7) 0.53
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GFR on day 7: Mean (StDev) 17.0 (14.6) 14.9 (13.2) 0.24
GFR at 3 months: Mean (StDev) 46.0 (18.1) 48.9 (21.3) 0.42
3 month graft survival % (95%CI) 96 (90-100) 100 0.16
3 month patient survival % (95%CI) 98 (93-100) 100 0.32
Conclusion: Cold machine perfusion of kidneys from DCD donors does 
not reduce the incidence of delayed graft function in the context of the short 
ischaemic times seen in the study.
MACHINE PERFUSION VERSUS COLD STORAGE IN 233 
RENAL PRESERVATION: A COMPARATIVE IN VIVO STUDY 
OF KIDNEY TRANSPLANTATION
G. La Manna1, A. Faenza2, D. Conte1, M. Cappuccilli1, B. Nardo2, R. Bertelli2, 
L. Puviani2, N. Lanci1, M.P Scolari1, S. Stefoni1
1Nephrology, Dialysis and Renal Transplant Unit, University of Bologna, St. 
Orsola Hospital, 2Renal Transplant Surgery Section, University of Bologna, 
St. Orsola Hospital
Introduction: The development of effective methods of organ preservation 
represents a crucial achievement in reducing the magnitude of ischemia/
reperfusion (IR) injury. The two available modalities currently used for renal 
preservation are cold storage (CS) and machine perfusion (MP). Although the 
superior costs of personnel and technology of MP have limited its application, 
there is increasing proof that MP is an effective strategy to lessen IR injury, 
because it allows for the monitoring of fl ow rate, renal arterial pressure 
and internal vascular resistance and, if necessary, allows for the addition of 
electrolytes, nutrients and oxygen during storage.
Aims: This study was designed to compare the degree of tissue damage 
after hypothermic preservation by MP or CS in an animal model of kidney 
autotransplantation.
Methods: Twelve pigs underwent left nephrectomy after warm ischemic time; 
the organs were preserved in MP (n=6) or CS (n=6) and then autotransplanted 
with immediate contralateral nephrectomy. The animals were monitored for a 
4-day period before sacrifi ce.
At each experimental step, haematological (creatinine, urea, sodium, potassium) 
and urine (specifi c gravity, pH, proteinuria) parameters of renal function and 
blood/gas analysis values were measured. Histological features, ATP content 
from renal biopsy, perforin gene expression and organ weight changes were 
compared before and after preservation with both techniques.
Results: No signifi cant differences between CS and MP groups were observed in 
terms of renal functional indicators and arterial gas/electrolyte analysis values. 
However, during the 4-day follow-up period, the worsening of kidney function 
in the CS group showed a rapidly progressive course, while serum creatinine 
and urea tended to stabilize around the 3rd day post-transplant in the animals 
who received machine-perfused organs. Histology revealed a comparable 
extent of injury in both groups, even if one single animal transplanted with 
a cold-stored kidney displayed extensively more damaged cells in the biopsy 
taken before sacrifi ce.
The cellular ATP (μg per milligram of tissue from renal biopsy) was not 
signifi cantly decreased in machine-perfused kidneys (from 172.6±157.6 to 
146.4±41.8, p=n.s.). while a considerable drop was found in cold-preserved 
ones (216.6±151.6 to 58.2 ± 28.5, p=0.015).
The average fold increase of perforin mRNA expression above the level 
measured before storage was 1.48±1.23 in the MP group (p<0.05) and 
2.15±1.77 in the CS group (p<0.01). Thus, the study of apoptosis induction 
revealed enhanced perforin expression after storage in both groups, but to a 
signifi cantly higher extent in the kidneys which underwent CS (p<0.001).
Organ weight was signifi cantly reduced after CS (116.2±17.7 g vs 93.0±14.4 g; 
p=0.032). but it remained quite stable for machine-perfused kidneys (111.5±4.4 
g vs 111.2±5.6 g; p=n.s.).
Conclusion: The present model seems to suggest that machine-perfused 
kidneys display a more limited cellular impairment in comparison with cold-
stored ones. According to our data, MP may help to prevent IR injury and limit 
microstructural damage in organs for transplantation. Although the superior 
costs in terms of personnel and technology of MP might limit its routine 
application, this preservation technique possibly will be considered more 
appropriate for grafts from marginal donors or for preservation times longer 
than 24 hours.
MACHINE PERFUSION VERSUS COLD STORAGE 234 
PRESERVATION IN NON-HEART-BEATING KIDNEY 
DONATION AND TRANSPLANTATION: FIRST RESULTS OF A 
MULTICENTRE TRIAL IN EUROTRANSPLANT.
F. Van Gelder1, C. Moers², J.M. Smits², M.H.J. Maathuis², J. Treckmann², B.P. 
Napieralski², M. van Kasterop-Kutz², J.J. Homan van der Heide², 
E. van Heurn², G.R. Kirste², A. Rahmel², H.G.D. Leuvenink², A. Paul², J. 
Malaise², C. Randon², D. Ysebaert², J.P. Squiffl et², R.J. Ploeg², J. Pirenne²
1University Hospitals Leuven, Leuven, Belgium ² Eurotransplant MP Trial, 
Leiden, The Netherlands
Rationale; Delayed Graft Function (DGF) after Kidney Transplantation causes 
additional morbidity and cost, and may negatively affect graft function and 
survival. Kidney grafts procured in Non-Heart-Beating Donors (NHBD) are 
exposed to both warm and cold ischemia and thus particularly vulnerable 
to DGF. Compared to standard Cold Storage (CS). hypothermic Machine 
Perfusion (MP) has been reported to provide superior preservation. This fact 
could be of great importance particularly for NHBD kidneys, but evidence to 
support this view is limited in quality and numbers. 
Aim: To compare the effi cacy of MP vs CS for the preservation of NHBD 
kidneys. 
Methods: In an international prospectively randomized controlled trial we 
enrolled kidney pairs of 82 consecutive NHBD. All NHBDs were Maastricht 
category 3 (awaiting cardiac arrest/planned therapy withdrawal). One kidney 
was randomly assigned to MP and the contralateral kidney to conventional 
CS. Kidneys were allocated using the standard allocation algorithm. At time 
of offer, the type of preservation (MP vs CS) and perfusion parameters were 
not revealed. All 164 recipients were followed-up and 3 month data were 
analyzed. 
Results: Donor age (y) was 43 (17-67). Baseline demographics were comparable 
between MP vs CS arms: recipient age (y) 49 (24-73) vs 52 (24-77). p=0.81; 
preTx dialysis duration (days) 1542 (366-6402) vs 1448 (132-3904). p=0.48; 
fi rst/reTx 34/48 vs 34/48, p=0.56;% current PRA (0-5/6-84/85+) 71/11/0 vs 
71/10/1, p=0.73;% of 0 HLA A,B and DR mismatches was 2.4 vs 3.7, p=0.5. 
Cold Ischemia Time (CIT) (h) was 15 (4.3-28.9) for MP vs 15.9 (8.6-46.6) for 
CS (p=0.7). Incidence of DGF was 53.7% in MP vs 69.5% in CS recipients, 
p=0.027. Duration of DGF (days) was 9 (1-48) in MP vs 13 (2-43) in CS 
kidneys, p=0.04. DGF < 7days occurred in 12/32 (27%) in the MP vs 6/51 
(10.5%) in the CS arm, p= 0.028. Creatinine clearance (ml/min) at d7, d14, 
1mth, and 3mth in MP vs CS was 13 vs 9, p=0.009; 23 vs 13, p=0.001; 46 vs 38, 
p=0.078; and 57 vs 49, p=0.19, resp. PNF rate was identical after MP and CS 
(2.4%). Acute rejection rate was 7.3% in MP vs 12.2% in CS kidneys; p=0.22. 
Graft loss (<3mth) was identical after MP and CS (3.6%). Patient survival was 
98.7% in MP vs 100% in CS recipients. Logistic regression analysis showed 
that MP (p=0.035; Odds ratio 0.476) and CIT (p=0.009; Odds ratio 1.118) 
independently had an impact on DGF. 
Conclusion; This study demonstrates for the fi rst time in a large controlled trial 
that MP of NHBD kidneys reduces the incidence, the duration and the severity 
of DGF and ameliorates graft function after kidney transplantation.
PRESERVATION OF KIDNEYS IN MACHINE PERFUSION 235 
(MP) LIMITS ISCHEMIA/REPERFUSION INJURY.
M. Wszola1, M. Kosieradzki1, A. Kwiatkowski1, M. Bieniasz1, K. Ostrowski1, 
P. Domagala1, A. Kaminska2, M. Durlik2, W. Rowinski1, A. Chmura1
1Department of General And Transplantation Surgery, Warsaw Medical 
University, 2Transplantation Institute, Warsaw Medical University
Recent prospective and retrospective studies have shown benefi cial effects of 
Machine Perfusion (MP) on early and long-term graft survival. Histopathological 
analysis undertaken in our center revealed signifi cantly lower incidence of 
chronic rejection, interstitial fi brosis/tubular atrophy in kidneys preserved by 
MP. Ischemia/reperfusion injury (I/R-I) is thought to play a role in explaining 
these fi ndings.The aim of the present study was to assess activation of genes 
associated with I/R-I depending on the method of preservation of grafts prior 
to transplantation. 
Patients and method: Between 2005 and 2006, sixty-nine kidney biopsies from 
69 allografts were obtained. Kidneys prior to transplantation were preserved 
by MP (n=26) or cold storage (CS; n=36). 7 kidneys were donated by living 
related donors (LRD group).Deceased donors in the MP and CS groups didnot 
differ regarding age, gender, hemodynamic status. Cold ischemia time (CIT) 
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was similar: 23 6h in CS vs 28 7h in MP (p=NS). in both groups. There were 
no signifi cant differences between the recipients as to age, gender, duration 
of ESRD treatment, PRA titres, HLA incompatibility and immunosuppressive 
treatment. Biopsies were obtained 30 min after reperfusion and snap frozen 
at 750C. Expression of genes for IL-1b, VEGF, hemoxygenase 1 (HO-1) 
and hypoxia inducible factor 1 (HIF-1) was analyzed by real-time PCR.
Results: Mean Ct for m-RNA expression for HIF-1 in kidney biopsies 30 min 
after reperfusion were: 0,63 1,54; 1,70 1,08 and 2,11 1,84 for CS, MP and LRD 
group respectively (p=0.001 for CS vs MP; p=0.001 for CS vs LRD; p=NS for 
MP vs LRD). Mean m-RNA expression for IL-1b, VEGF and HO-1 did not 
differ signifi cantly between the groups. 
Conclusions: Mean m-RNA expression for hypoxia inducible factor 1 is 
signifi cantly higher in group of kidneys preserved by cold storage in comparison 
to machine perfusion and living related donors. There is no difference between 
MP and LRD group regarding expression of HIF-1. Ischemia/reperfusion 
injury, which can affect early and long-term graft survival is reduced by 
machine perfusion preservation of cadaveric kidneys. Ischemia/reperfusion 
injury of kidneys stored by MP is similar to those observed in LRD.
MACHINE PERFUSION VERSUS COLD STORAGE IN 236 
TRANSPLANTATION OF KIDNEYS FROM OLDER DECEASED 
DONORS: RESULTS OF A PROSPECTIVE RANDOMIZED 
MULTICENTER TRIAL
A. Paul1, C. Moers2, J. Smits3, H. Maathuis2, J. Homan van der Heide2, E. van 
Heurn4, J.P. Squiffl et5, J. Pirenne6, R. Ploeg2, J. Treckmann1
1University Hospital Essen, Germany, Clinic For General, Visceral And 
Transplantation Surg, 2University Hospital Groningen, Netherlands, 
3Eurotransplant Foundation, 4University Hopsital Maastricht, Netherlands, 
5University Hospital Brussels, Belgium, 6University Hospital Leuven, Belgium
Rationale; Delayed graft function after renal transplantation especially from 
older donors negatively correlates with long and short term graft function and 
graft survival. Retrospective studies suggest a benefi cial effect of hypothermic 
machine perfusion (MP) on post- transplant outcome when compared to 
standard cold storage (CS) preservation.
Aim: Comparison of post- transplant outcome after machine perfusion vs cold 
storage in recipients of kidneys derived from deceased donors ¡Ý 55 years
Methods: As part of an international prospective randomized controlled 
trial n= 118 consecutive donation after brain death donors aged 55 years and 
older were included between Novermber 2005 and November 2006. In each 
donor one kidney was randomly assigned to MP and the contralateral kidney 
to conventional CS. Eurotransplant standard allocation algorithms were not 
affected by the trial. The accepting recipient center was blinded regarding 
preservation mode and perfusion parameters. Primary endpoint of the study 
was delayed graft function defi ned as necessity of dialysis in the fi rst seven 
days after transplantation. Furthermore standard donor and recipient data were 
collected, as well as graft and patient survival, primary non function (PNF) and 
acute rejection episodes. All 236 recipients were prospectively followed up 
until six months after transplantation.
Results: Donor age was 63 yr (55-81). Baseline demographics were comparable 
between the MP vs the CS arm: recipient age (year) 63 (11-79) vs 61 (7-79). 
p=0.8; preTx dialysis duration (days) 1728 (417-5154) vs 1773 (149-3866). 
p=0.5;% current PRA (0-5/6-84/85+) 105/12/1 vs 109/8/1, p=0.3;% of 0 HLA 
A,B and DR mismatches was 8.5 vs 11, p=0.3. Cold ischemia time (CIT) (hr) 
was 14 (3.5-53.75) in MP vs 13 (2.5-25) in CS (p=0.6). Incidence of DGF was 
22.0% in MP vs 31.4% in CS recipients, p=0.07. DGF < 7days occurred in 10/26 
in the MP vs 5/37 in the CS arm, p= 0.02. PNF rate was 2.5% in MP vs 10.2% 
in CS kidney recipients (p=0.015) Creatinine clearance showed no differences 
at day 7 and 14. The rate of acute rejections was not different between the 
groups. When DGF occurred six month graft survival was signifi cantly better 
in kidneys preserved with MP than by CS: 84% vs. 60%, p=0.026. Logistic 
regression analysis showed that MP (p=0.015; Odds ratio 0.432 vs CS) and CIT 
(p< 0.0001; Odds ratio 1.145) independently impacted on DGF.
Conclusion: Hypothermic machine perfusion of kidney grafts from older 
deceased donors lowers the incidence and duration of delayed graft function, 
strongly reduces primary non- function and improves graft survival at six 
months post- transplant.
MACHINE PULSATILE PERFUSION AND ITS 237 
PREDICTIVE VALUE FOR DELAYED GRAFT FUNCTION IN 
CADAVERIC RENAL TRANSPLANTS (CRT) 
G. Roelant1, J. Miller2, A. Haririan3, J. Nogueira3, B. Philosophe1, S. Bartlett1, 
and M. Cooper1
1Dept of Surgery and 3Medicine, University of Maryland, Baltimore, MD, 
USA.2Living Legacy Foundation of Maryland, Baltimore, MD USA.
Background: As the number of patients seeking kidney transplantation 
continues to rise, greater use of marginal and expanded donors has followed. 
Increased volumes cannot supplant desirable outcomes. Clinicians have 
developed an increased interest in machine pulsatile perfusion to guide 
decision-making in organ utilization. We sought to determine variables 
potentially predictive of delayed graft function (DGF) and develop a model to 
assist in decision-making of utilization of CRTs.
Methods: A retrospective analysis of pulsatile parameters and the fi rst 90 days 
following transplant for all machine perfused renal allografts performed at a 
single institution over a 4 year period was performed. Demographics, perfusion 
parameters, organ criteria- standard (SCD). expanded (ECD). or donation after 
cardiac death (DCD). biopsy results, DGF, and lowest Cr achieved in the 90 
day study period was analyzed. Pump pressures were maintained constant, 
fl ows measured, and resistance calculated.
Results: 187 CRTs (46 SCD, 113 ECD, 28 DCD) comprised the cohort. DGF 
was recognized in 55% (21 SCD, 64 ECD, 17 DCD). Donor and recipient 
demographics were similar in both groups (DGF v. No DGF).
Pump Parameter DGF (n =102) Mean + SD No DGF (n =85) p value
Kidney Size 210.6 + 87.0 206.2 + 109.2 0.764
Pre-pump CIT (hr) 18.3 + 8.5 17.9 + 8.4 0.783
Total Pump Time 18.3 + 6.9 18.8 + 7.8 0.651
Initial Flow (ml/min) 103.9 + 28.8 103.2 + 35.2 0.881
8-hr Flow 147.8 + 35.4 153.8 + 37.1 0.284
Initial Resistance 0.33 + 0.1 0.36 + 0.2 0.116
8-hr Resistance 0.20 + 0.05 0.20 + 0.06 0.607
Change Resistance 0-8hr 0.13 + 0.10 0.17 + 0.14 0.031
Init Res./Kidnney Size 23.0 + 19.3 18.6 + 10.2 0.048
Neither sclerosis, interstitial fi brosis, nor vascular changes on biopsy had a 
statistically signifi cant impact on DGF. For transplants without DGF, linear 
regression demonstrates correlation in lowest achieved Cr with pumping 
resistances at zero, four and eight hrs, and kidney size (p<0.05 for all). 
Transplants that experienced DGF had one linear regression correlating with 
fi nal Cr -pumping resistance at eight hours (p=0.022). Linear and nonlinear 
multivariate and neural network models were developed to attempt to predict 
DGF by pre-transplant data.
Conclusion: The prediction of DGF based upon demographics and pre-
transplant data for pulsatile perfused renal allografts remains a diffi cult task 
and the complexity and number of variables makes a simple model unlikely. 
Numerous biases are inherent as only organs thought suitable for transplant 
based on history and biopsy were initiated on pump. Pumping parameters 
demonstrated the mean difference in starting to eight hour pumping resistance 
was lower in those experiencing DGF as was initial resistance/kidney size 
perhaps refl ecting degree of pre-pump injury. Further subanalysis is ongoing 
including duration of DGF.
ASSESSMENT OF AUTO-REGULATION AND 238 
ENDOTHELIAL FUNCTION IN KIDNEYS UNDERGOING 
HYPOTHERMIC PULSATILE PERFUSION.
I. Winburn2,1, Y. Yao1, J. Hill2, Z. Endre2, R. Walker2, I. Sammut1
1Department of Pharmacology and Toxicology,University of Otago, NZ, 
2Department of Medicine, University of Otago, NZ
Introduction: Donor kidneys that have undergone hypothermic pulsatile 
perfusion (HPP) have been reported to demonstrate improved outcomes 
following transplantation. The underlying mechanism by which protection 
is offered remains unclear. The preservation of endothelial function may be 
responsible for the improved outcomes observed following HPP, however 
this has not previously been studied. Endothelial function is a prerequisite of 
renal auto-regulation; namely the ability of the kidney to maintain a constant 
glomerular fi ltration rate in response to variations in perfusion pressure. This 
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study details for the fi rst time both vascular smooth muscle and endothelial 
function during HPP. In addition we detail whether donor kidneys undergoing 
HPP are capable of auto-regulation.
Methods: Kidneys were retrieved from Sprague-Dawley rats following renal 
artery cannulation and perfused ex vivo with a modifi ed Krebs Henseleit 
solution (or Belzer machine perfusion solution for auto-regulation experiments) 
under either normothermic (37ºC) or hypothermic (8ºC) conditions. Following 
equilibration, perfusion parameters were recorded in response to angiotensin II 
(AngII; 1x10-11-1x10-7 M) or methacholine (MCh; 1x10-9-1x10-4 M). Cumulative 
pressure, fl ow and vascular resistance dose response curves were generated. The 
vasodilatory effects of another endothelial dependent vasodilator, adenosine 
diphosphate (ADP) were assessed in the presence or absence of an intact renal 
vascular endothelium (denuded with 0.1% CHAPS). Auto-regulation during 
HPP was investigated ex-vivo by pressure ramping experiments using AngII 
(10nM). phenylepherine (5nM). ADP (1uM) and papaverine (100mM).
Results: Kidneys perfused at both 37ºC and 8ºC demonstrated dose-dependent 
vasoconstriction in response to AngII (EC50 37ºC= 0.32±0.028nM vs. EC50 8ºC 
= 9.0±1.39 nM; p<0.001). Only kidneys subjected to 37ºC perfusion vasodilated 
(EC50= 187±35nM) in response to MCh. ADP did however induce vasodilation 
(EC50=1330±295nM) in kidneys perfused at 8ºC. These vasodilatory effects 
were signifi cantly (p<0.001) reduced following endothelial disruption with 
CHAPS. Auto-regulation was only induced in HPP kidneys following infusion 
of AngII (10nM) as compared to controls (auto-regulatory index 0.78±0.10 vs. 
1.129±0.04 respectively; p=0.037). Interestingly phenylepherine, administered 
at an equivalent vasoconstrictor concentration, failed to induce auto-regulation 
in HPP kidneys.
Discussion: This is the fi rst time that auto-regulation and specifi cally 
endothelial function have been described during HPP and our data indicates 
that the endothelium remains active under these conditions. Although MCh 
responses were not observed at 8ºC, the presence of endothelial dependent 
vasodilation induced by ADP does imply altered MCh pharmacodynamics 
during hypothermia. The underlying mechanism of AngII induced auto-
regulation is unlikely to be a product of AngII’s pressor properties given the 
absence of auto-regulation with phenylepherine. The fi ndings of this study 
provide evidence to support the notion that pharmaco-modulation of HPP 
kidneys is an exciting therapeutic strategy that can improve post transplant 
function.
EX-VIVO REPAIR OF DAMAGED HUMAN DONOR 239 
LUNGS FOR TRANSPLANTATION
M. Cypel, M. Rubacha, S. Hirayama, J. Yeung, M. Anraku, M.Sato, M. Liu, 
T.K. Waddell, M. de Perrot, and S. Keshavjee. 
Thoracic Surgery, Toronto Lung Transplant Program, Latner Thoracic 
Surgery Laboratory, University of Toronto, Toronto, Ontario, Canada, M5G 
1L7.
Purpose: Lung infl ammation and blood-alveolar barrier disruption are common 
fi ndings in injured human donor lungs. We aimed to evaluate the potential for 
ex-vivo attenuation of lung infl ammation, recovery of epithelial tight junctions 
and improvement in lung function.
Methods and Materials: Human lungs from 10 different donors determined to 
be unsuitable for transplantation were subjected to 12h of normothermic ex-vivo 
lung perfusion (EVLP) with Steen solution. The perfused lungs were allocated 
into 2 groups: EVLP (control) or EVLP with 4x1010pfu of trans-bronchial 
AdhIL-10 (IL-10 group).Lung functional parameters were evaluated during 
the perfusion period. Infl ammatory cytokines and the tight junction integrity 
protein ZO-1 were assessed in the lung tissue before and after treatment.
Results: Baseline donor lung characteristics were similar between the 2 groups. 
Improvement from baseline in delta PO2/FiO2 was 129.838.7mmHg in IL-10 
group vs 29.3 17.9mmHg in control group (p<0.05).ZO-1 protein stain showed 
recovery of tight junction integrity (Fig.1) in 4/5 in the IL-10 group and 1/5 in 
the control group. Donor lung infl ammation was signifi cantly decreased after 
12h of perfusion in lungs treated with IL-10 gene therapy (Fig.2).
Conclusions: Repair of injured human donor lungs is achievable during 
prolonged EVLP. Improvements in lung oxygenation capacity, restoration of 
alveolar barrier integrity and attenuation of lung infl ammation are enhanced by 
ex-vivo IL-10 gene therapy.
Fig 1
Fig2
CONCURRENT ORAL SESSION 19: 
CLINICAL ISLET TRANSPLANTATION
2007 UPDATE ON ALLOGENEIC ISLET 240 
TRANSPLANTATION FROM THE COLLABORATIVE ISLET 
TRANSPLANT REGISTRY (CITR) 
R. Alejandro1, B. Hering2, F. Barton3, M. Appel4, F. Kandeel5, M. Garfi nkel6, 
S. Wease3
1University of Miami, 2University of Minnesota, 3The EMMES Corporation, 
4The National Institute of Diabetes, Digestive and KidneyDiseases, 5City of 
Hope Medical Center, 6University of Chicago
Primary aim: To summarize the fi ndings from the Collaborative Islet 
Transplant Registry (CITR) on human-to-human islet transplantation in North 
America and one European center from 1999 to 2007.
Methods: With local IRB approval, participating centers reported pre-transplant, 
six-month and annual follow-up information on islet infusions including islet 
and donor characteristics, induction and maintenance immunosuppression, 
insulin use, markers of diabetes control, hypoglycemia, metabolic measures, 
laboratory fi ndings and adverse events. Islet recipients give informed consent 
for reporting their data to the Registry.
Results: As of September 30, 2007, CITR comprised 315 allograft recipients 
(285 islet-alone and 30 islet-after-kidney) in suffi cient detail for analysis. 
They received 617 infusion procedures derived from a total of 672 donors. 
Non-steroidal immunosuppression was used in the vast majority of the cases. 
Ninety of the recipients (29%) received a single islet infusion, 153 (49%) 
received two, 67 (21%) received three infusions, generally within one year 
of the initial infusion, and fi ve received four infusions. Insulin independence 
(II) was achieved by 70% of the recipients, and was maintained for a median 
of 24 months (11-48 IQR). Of those who achieved II, 82%, 72%, 48% and 
37% were still II at 6, 12, 24 and 36 months later; 75-90% had islet function 
three years later. Overall, about 10% lost their graft function by one year after 
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their last infusion. Key changes from baseline to one year after last infusion 
were: HbA1c declined from 7.7+1.3% (mean+SD) to 6.2+0.9; C-peptide 
increased from 0.1+0.2 ng/mL to 1.3+1.1; and the proportion experiencing 
severe hypoglycemia events (80% pre-transplant) declined to 10%. About 
one-third of the recipients experienced one or more serious adverse events 
that were deemed related to either procedural or immunosuppression factors. 
In all but 14 patients, these events resolved without complications. One of 
the fi ve reported deaths was due to viral meningitis. Ten cases of neoplasm 
were reported.
Conclusions: Islet transplantation in 1999-2007 represents a promising 
procedure for vastly improving glycemic control and nearly eliminating severe 
hypoglycemia. Procedural complications have been virtually eliminated. 
Undesirable effects of immunosuppression need to be balanced against the 
benefi ts of the procedure. The registry is growing large enough to begin 
identifying factors that affect success and identify the patients best suited for 
islet transplantation.
RESULTS OF A MULTI-YEAR COMPARISON OF 241 
ISLET TRANSPLANTATION WITH INTENSIVE MEDICAL 
THERAPY ON THE PROGRESSION OF MICROVASCULAR 
COMPLICATIONS IN TYPE 1 DIABETES
G.L. Warnock1, M. Meloche1, J. Shapiro1, Z. Ao1, P. Keown1, J.D. Johnson1, 
B. Verchere1, N. Partovi2, D. Thompson1
1The University of British Columbia, 2Vancouver General Hospital
The British Columbia Islet Transplant Program is conducting a prospective, 
crossover, cohort study comparing intensive medical therapy and islet cell 
transplantation (ICT) on the progression of diabetic retinopathy, nephropathy 
and neuropathy. A cohort of 44 patients was enrolled between January 2002 – 
January 2005. All patients began intensive medical therapy upon enrollment 
and then crossed-over to transplantation when an appropriate donor became 
available. Patients received immunosuppression with ATG induction, followed 
by tacrolimus and mycophenylate together with > 12,000 islet equivalents 
(IE) /kg from 1 – 4 donors. 31 patients received 64 islet infusions. They were 
followed for an average duration of 39 months post-ICT and 37 months for 
medical treatment. Analysis was by intention to treat and endpoints were pre-
specifi ed before the study began. We present an interim analysis of outcomes. 
Comparison of median HbA1c (%) for all subjects showed 7.5±1.2 for medical 
versus 6.7±0.9 for ICT (p<0.01).
Retinopathy was assessed using 7-fi eld stereo fundus photography and graded 
using the international scale. Progression was defi ned as nonproliferative 
retinopathy advancing by 1 or more levels or proliferative retinopathy 
reaching a severity that qualifi ed for laser treatment. Progression occurred 
signifi cantly more often in subjects on medical therapy (10/82 eyes) than 
after ICT (0/51 eyes) (p < .01). Considering only ICT subjects, progression 
occurred in 6/51 eyes while on medical treatment than post ICT (0/51) (p 
< .02).
The primary endpoint for nephropathy was rate of change in GFR measured by 
blood clearance of 99mTc-DPTA measured every 6 months. GFR values were 
analysed by linear regression to calculate the rate of change for each subject. 
Individual patient results were combined to determine the mean intrapatient 
rate of change in GFR. Change in GFR did not differ for ICT (-3.8 ± 12.7 ml/
min/yr) compared with medical (-5.1 ± 8.4). Both values are greater than the 
general population (-1 ml/min/yr). Change in urinary albumin excretion also 
did not differ between the groups.
Neuropathy was measured by nerve conduction studies of 7 peripheral 
nerves performed annually. Values for each nerve were combined to produce 
a composite value for each study and then the rate of change over time was 
calculated. Baseline nerve conduction velocity (NCV) was 47.8 ± 6.2 m/sec for 
medical and 47 ± 4.8 for ICT patients (P = NS). below the normal value of 53.9 
± 5.4. Rate of decline was similar: – 1 m/sec/yr for medical and – 1.2 post-ICT. 
Subgroup analysis of individual nerves or stratifi ed by baseline NCV showed 
no differences between the groups. We conclude that over 3 years, ICT results 
in improved HbA1c and less progression of diabetic retinopathy compared 
with intensive medical therapy.
METABOLIC OUTCOMES AFTER ISLET 242 
TRANSPLANTATION
G.L. Warnock1, M. Meloche1, J. Shapiro1, Z. Ao1, P. Keown1, J.D. Johnson1, 
B. Verchere1, N. Partovi2, D. Thompson1
1The University of British Columbia, 2Vancouver General Hospital
The British Columbia Islet Transplant Program has been active since March 
2003 and is studying the effect of islet transplantation on the microvascular 
complications of diabetes. As of March 2008, we have performed 64 islet 
infusions in 31 recipients. All recipients had some degree of retinopathy and 
nephropathy to be eligible for the study. 67% also had a history of severe 
hypoglycemia. Patients entered intensive medical therapy until a suitable 
donor became available. At the time of initial islet infusion, the average age 
of recipients was 45.9 ± 8.5 yrs, diabetes duration 33.5 ± 8.7 years, weight 
70.3 ± 11.1 kg, daily insulin dose 42.7 ± 14.6 units and HbA1c 7.1±0.7%. 
The initial goal was to transplant > 12,000 islet equivalents/kg in 1 – 3 
infusions. Some patients were given supplemental infusions to improve graft 
function. Six subjects have stopped immunosuppression (skin cancer, CMV 
infection, primary graft failure (2). immunosuppression side effects (2) ) and 
four have not yet received > 12,000 IE/kg; the remaining 21 are the subject 
of this report. Islets suitable for transplantation were isolated from > 75% of 
donated pancreases and the mean IE per infusion was 494,000 ± 204,000. 
One islet infusion has been given to 3 patients, 2 infusions to 7, 3 infusions 
to 8 and 4 infusions to 3. The mean duration of follow-up from initial islet 
infusion is 39 months.Twelve of the 21 patients (57%) are not taking insulin at 
present. The average dose of the patients still taking insulin is 26% of their pre-
transplant dose. The median HbA1c post-transplant is 6.5% with no increase 
over time. HbA1c compared favourably with intensive medical therapy which 
was 7.5±1.2 (p<0.01). Severe hypoglycemia has been largely eliminated. The 
mean fasting C peptide level in patients off insulin is higher than those still 
taking some insulin (448 ± 184 pmol vs 241 ± 140 pmol, p< .01). All but 1 
patient has remained C peptide positive since their last islet infusion. There 
is no apparent decline in C peptide levels over time in patients remaining off 
insulin. There is no correlation between C peptide levels or need for insulin 
and number of IE/kg infused. We conclude that islet transplantation yields long 
term function in patients with microvascular complications of diabetes, with 
insulin independence at 3 years of 57%.
ISLET AUTO-TRANSPLANTATION AFTER TOTAL 243 
PANCREATECTOMY: A CONTRAST TO ISLET ALLOGRAFT 
OUTCOMES
D.E.R. Sutherland, A.M. Carlson, J. Blondet, G. Beilman, B.J. Hering, 
A.C. Gruessner
University of Minnesota Department of Surgery
Introduction: Islet allografts with a large beta cell mass (>10,000 islet 
equivalents (IE) /kg) are currently associated with a high rate of function 
(C-peptide positive) and early insulin-independence (II). but after one 
year II rates rapidly decline for reasons not clear (immunological or non-
immunological?). We have a large islet autotransplant (IAT) experience which 
shows not only durable function but extended II rates even though the beta 
cell mass, as estimated by #IE transplanted, is less than for islet allografts. IAT 
outcomes give a minimum theoretical standard for islet allograft outcomes.
Methods: From Feb, 1977 to Nov, 2007, 152 adult patients underwent total 
pancreatectomy (TP) and intraportal IAT to treat chronic pancreatitis. Islet 
function was considered full in patients while II, partial if euglycemic on once-
daily long acting insulin, and failed if on a standard insulin regimen. Full/
partial graft function rates, as well as II rates, were calculated actuarially (death 
censored) overall and by IE/kg. Comparison was made to published data from 
the Collaborative Islet Transplant Registry (CITR).
Results: IAT patient survival rates at 1, 2, 5 and 10 yrs were 95, 92, 85 and 
74%. IAT function rates (full/partial-combined) were 57, 54, 47 and 43% at 
1, 2, 5 and 10 yrs; corresponding II rates were 30%, 26%, 15% and 10% (7 
patients II>10 yrs). Of IATs that functioned at all, 95% still were 2 yrs later, 
slightly higher than the 86% for allografts reported by CITR; however, 87% 
of IAT recipients who achieved II were still II 2 years later, vs. only 30% for 
allografts. IAT function correlated (p<0.05) with yield and was present at 1 yr 
in 26, 79 and 82% of recipients of<2,500 (n=58). 2501-5000 (n=52) and>5000 
(n=42) IE/kg; the corresponding II rates were 5, 41 and 65% (p<0.05). [In 
contrast to CITR where II was virtually never reported with<5000 allogenic 
IE/kg]. IAT function rates signifi cantly (p<0.03) improved by era, at 1 yr 42% 
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(1977-95). 48% (1996-2001) and 69% (2001-07).
Conclusion: Islet autografts that function (>half, correlated with yield) are 
durable with three-fourths still functioning at 10 years, but the main contrast to 
allografts is the durability of II; of the IAT recipients that achieve II, half are 
still II at 5 and a third at 10 yrs, in contrast to the islet allograft recipients where 
less than a fi fth are still II at 5 yrs. Since islet allograft recipients maintain 
C-peptide in the face of insulin-dependence, rejection seems an unlikely 
explanation and most likely the viable islet mass engrafted in allograft recipients 
is less than in IAT recipients (allogenic islets usually not fresh; procured and 
preserved from brain-dead stressed donors; etc). The absence of diabetogenic 
immunosuppression in IAT recipients also allows a smaller beta cell mass to be 
adequate. The IAT results also belie the hypothesis that the portal vein/hepatic 
environment is inherently hostile to islets, given the many IAT recipients who 
have been II for more than a decade. Islet allograft protocols should try to 
incorporate as many of the IAT favorable circumstances as possible for clinical 
application.
USE OF ALEMTUZUMAB INDUCTION AND 244 
CALCINEURIN-FREE LONG TERM IMMUNOSUPPRESSION 
TO IMPROVE SHORT AND LONG TERM OUTCOMES IN 
ISLET TRANSPLANTATION.
T. Froud1,2,3, D.A Baidal1, P. Cure1, A. Curry1, G. Selvaggi1,2, N.S. Kenyon1, 
C. Ricordi1,2, R. Alejandro1,4.
University of Miami Miller School of Medicine, Miami, USA 1Diabetes 
Research Institute, 2Department of Surgery, 3Department of Radiology, 
4Department of Medicine,
An important limitation of islet transplantation is the loss of functional islet 
mass over time. To attempt to prevent these losses, a protocol was begun using 
alemtuzumab (Campath 1H®) for induction, a relatively new agent that causes 
profound, long lasting T-lymphocyte depletion, and reducing long term exposure 
to calcineurin inhibitors, which are toxic to ß-cells. Two doses of alemtuzumab 
were administered with the fi rst islet infusion, a single dose with the second if 
lymphocyte count was >5% and maintenance immunosuppression consisted 
sirolimus indefi nitely with tacrolimus for three months and mycophenolate 
mofetil thereafter.
To date, three subjects have been transplanted using this regimen (group 
A). All have been followed for more than 2 years after completion infusion. 
Comparison, at 3,6,12,18 and 24 months post transplant, is with sixteen islet 
recipients (group B) transplanted using daclizumab induction and sirolimus/
tacrolimus maintenance (Edmonton protocol).
Parameters examined include peak C-peptide during mixed meal tolerance test 
(MMTT). mixed meal stimulation index (MMSI). acute C-peptide release to 
glucose (ACPRg) and insulin requirements (ins/kg/day). Results are expressed 
as intent to treat using mean±SE and unpaired t-test to compare each parameter 
in both groups.
There were no signifi cant differences in demographics between groups A&B 
(mean age 41.3±1.76 vs 41.1±2.49 years; duration of diabetes 29.7±7.22 
vs 27.0±3.10 years; insulin requirements 0.51±0.08 vs 0.48±0.02 insulin/
kg/day; islet equivalents (IEQ) transplanted 817,786.7±262,996.3 vs 
917,708.2±65,778.5 IEQ/kg).
In group A, 2/3 subjects and in group B 14/16 subjects achieved insulin 
independence; in those that did not, a second islet infusion was contraindicated 
or declined. In group A, insulin independence and insulin requirements were 
unchanged over the 24 months of follow-up, while in group B only 6/14 (43%) 
remained insulin independent at 24 months. 8/14 (57%) had reintroduced 
exogenous insulin for graft dysfunction (insulin/kg/day at 3 and 24 months: 
group A 0.06±0.06 and 0.05±0.05; group B 0.02±0.02 and 0.15±0.06).
Comparing groups A&B, measures of graft function were better in group 
A at three months (peak C-peptide 4.7±0.88 vs 3.5±0.18; MMSI 1.1±0.19 
vs 0.7±0.06; ACPRg 1.34±0.42 vs 0.81±0.09) despite higher mean insulin 
requirements (insulin/kg/day 0.06±0.06 vs 0.02±0.02). By 24 months the 
discrepancy was greater, with group A remaining stable or improving slightly 
compared to overall deterioration in group B (peak C-peptide 5.0±0.50 vs 
3.1±0.29 p<0.05; MMSI 1.0±0.08 vs 0.57±0.1 p<0.01; ACPRg 1.31±0.61 vs 
0.60±0.20) [see fi gure below].
LONG TERM INSULIN INDEPENDENCE AND 245 
RESTORATION OF FIRST PHASE INSULIN RELEASE 
AFTER SUPPLEMENTAL ISLET INFUSION UNDER 
EXENATIDE TREATMENT IN SUBJECTS WITH ISLET GRAFT 
DYSFUNCTION
T. Froud, R.N. Faradji, T. Tharavanij, S. Messinger, A. Pileggi, D.A. Baidal, 
L. Dinkins, G. Selvaggi, C. Ricordi, R. Alejandro
Diabetes Research Institute, University of Miami, Miami, FL
Objective: To assess the effects of exenatide on supplemental islet infusions 
(SI).
Methods: Five subjects with islet graft dysfunction underwent SI under 
Edmonton-like protocol in 2003 without exenatide (SI-C group) and 4 with 
exenatide in 2006 (SI-EXN group). Clinical and metabolic profi les were 
assessed every 3 months for18 months.
Results: SI-EXN group was on this drug for median time of 171 days pre-
SI. Both groups were similar except for duration from post-completion to 
graft dysfunction (648±34 vs 221±58 in SI-EXN and SI-C group respectively, 
p<0.05) and duration of graft dysfunction before SI (664±83 vs 326±93, 
p=0.03). SI-C and SI-EXN groups received mean of 8713±2123 and 5613±485 
IEQ/kg, respectively (NS). Only 3/5 of SI-C patients achieved insulin 
independence for 303, 403 and >1670 days after SI. All subjects in SI-EXN 
group achieved insulin independence for more than 443, 621, 641, 654 days. At 
18 months insulin independence was 20% in SI-C and 100% in SI-EXN group. 
Comparing pre and post-SI, SI-EXN group had signifi cantly lower A1C at 3-18 
months and lower AUC glucagon at 6 and 15 months (p<0.05). AUC C-peptide 
in SI-EXN group was signifi cantly higher than SI-C at 3, 9 and 15 months. 
Acute exenatide administration during intravenous glucose tolerance test at 
15 month in SI-EXN revealed signifi cantly increased acute insulin response 
to glucose (difference 11±4.6 μIU/ml, p=0.02) which indicates improved fi rst 
phase insulin release [fi gure1].
Conclusion: Supplemental islet infusions under exenatide lead to insulin 
independence, restore fi rst phase insulin secretion and result in long term 
insulin independence.
Figure 1: Insulin levels in SI-EXN group after intravenous glucose tolerance 
test with (Exn+) and without exenatide (Exn-) administration before the test at 
15th month post-SI.
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ISLET TRANSPLANTATION IN TYPE 1 DIABETICS 246 
USING A CALCINEURIN INHIBITOR-FREE PROTOCOL 
BASED ON EFALIZUMAB AND SIROLIMUS.
A. Posselt1, G. Szot1, L. Fong1, L. Frasetto1, U. Masharani1, J. McElroy1, 
D. Ramos1, T. Rojas1, B. Hering2, P. Stock1
1University of California, San Francisco, 2University of Minnesota
Background: Although islet transplantation has become an option for treatment 
of type 1 diabetes mellitus, the immunosuppressive protocols currently used 
to promote graft survival rely on drugs with signifi cant nephro- and beta 
cell toxicities. Here we describe a novel immunosuppressive protocol using 
sirolimus and the anti-LFA 1 antibody efalizumab that permits prolonged islet 
allograft survival without the need for corticosteroids or calcineurin inhibitors 
(CI).
Materials and Methods: Between February and December 2007, 5 consecutive 
type 1 diabetic patients with hypoglycemic unawareness and normal renal 
function received allogeneic pancreatic islet transplants. Islets were infused 
intraportally after 48h in culture. Induction immunosuppression consisted of 
2 doses of thymoglobulin given on pre-transplant days -2 and -1, sirolimus 
(starting on d -1) and efalizumab (5mg/kg subcutaneously/week starting on d 
-1 ). Maintenance immunosuppression consisted of sirolimus and efalizumab.
Results: All patients achieved insulin independence after single islet infusions 
(mean IEQ=598,681; mean IEQ/kg=9,689). Four of 5 had appropriate 
reductions in HbA1c and 3/5 remain insulin independent 5 or more months 
after transplant. The other 2 patients resumed low dose insulin (approximately 
10% of their original doses) 3-6 weeks after transplant and are awaiting a 
second islet infusion. Blood glucose control is markedly improved in all 
patients and none have experienced any hypoglycemic episodes. All patients 
show persistent c-peptide secretion and have stable renal function. Side effects 
associated with efalizumab were limited to transient irritation at the injection 
site. Immunologic monitoring of these patients indicates that these clinical 
effects are associated with an increase in the percentage of circulating FoxP3+ 
CD4+ regulatory T cells (T reg) and reduced allospecifi c T cell proliferative 
responses.
Patient 1 2 3 4 5
# of Islet Infusions 1 1 1 1 1 (2donors) 
IEQ Infused 574,950 482,500 630,165 459,290 846,502
IEQ/kg 8,711 8,041 11,458 7,408 12,826
C Peptide at 4 mo Yes Yes Yes Yes Yes
Insulin Independence 
>30d Yes Yes Yes Yes No
Duration of insulin 
independence 1.5 months >8 months >8 months >5 months
3
weeks
Currently on
Insulin
Yes (3-5U/d) No No No Yes (4U/d) 
HbA1c
decrease >2.5%
No Yes Yes Yes Yes
Conclusions: Thymoglobulin induction followed by sirolimus and efalizumab 
maintenance immunosuppression is well tolerated and allows prolonged islet 
allograft survival. This novel immunosuppressive regimen is the fi rst CI/
steroid free islet regimen resulting in insulin independence with a single donor 
islet infusion. By eliminating CI, this protocol minimizes nephro- and islet 
toxicity and may thus improve long-term islet allograft survival and function. 
Preliminary in vitro studies indicate that the mechanism (s) responsible for 
graft survival in this setting may involve induction of T reg subsets.
HYPOGLYCEMIA AWARENESS AFTER ISLET 247 
TRANSPLANTATION
C.B. Leitao, P. Cure, A. Pileggi, .D.A. Baidal, T. Tharavanij, D. Mineo, 
K. Bernetti, T. Froud, C. Ricordi, R. Alejandro
Diabetes Researsh Institute, University of Miami
The aim of this study was to determine if optimal metabolic control achieved by 
islet transplantation (IT) has sustained effects on hypoglycemia unawareness. 
A retrospective cohort study was conducted in 29 IT recipients followed before 
and after the procedure as treatment for unstable type 1 diabetes mellitus. 
Hypoglycemia unawareness was accessed through a validated questionnaire 
(Clarke score; score = 0 if no reported hypoglycemia; score >4 = hypoglycemia 
unawareness) before and at end of follow-up. Subjects were grouped based on 
graft function: off-insulin (n = 8). graft dysfunction (on insulin and stimulated 
C-peptide >0.3 ng/ml, n = 13) and graft failure (stimulated C-peptide <0.3 ng/
ml, n = 8). The mean hypoglycemic score pre-transplant was 5.28 +/-1.56 and 
an inverse and statistically signifi cant correlation between it and pre-transplant 
glycemic control, measured by A1c, was found (r = -0.37, P = 0.049). As 
expected, a decline in the score was demonstrated posttransplantation (1.14 
+/- 1.66, P <0.001) as was the proportion of patients with hypoglycemia 
unawareness (10 vs. 86%, P <0.001). In addition, an increment in the threshold 
for hypoglycemic symptoms was observed (59.7 +/- 9.5 vs. 41.7 +/- 18.5 mg/dl, 
P = 0.001). These results were sustained even after patient’s stratifi cation based 
on islet function (off-insulin-pre: 5.63 +/- 2.00 vs. post: 0.00 +/- 0.00, P <0.001; 
graft dysfunction-pre: 5.31 +/- 1.49 vs. post: 1.15 +/- 1.63, P <0.001 and graft 
failure-pre: 4.88 +/- 1.25 vs. post: 2.25 +/- 1.91, P = 0.009). However, post-
transplant scores were higher in graft failure group when comparing with off-
insulin subjects (P = 0.016). Additionally, lower hypoglycemic score values were 
correlated with better beta cell function (r = -0.396, P = 0.033 and r = -0.450, P 
= 0.016 for fasting and stimulated C-peptide, respectively). In conclusion, stable 
metabolic control achieved with clinical IT restores hypoglycemia awareness 
and these effects have persisted even after islet graft failure.
RECURRENCE OF AUTOIMMUNITY IN ISLET 248 
ALLOTRANSPLANT RECIPIENTS EVALUATED BY GAD65 
AND IA2 AUTOANTIBODIES
D. Mineo1, K. Monroy2, P. Cure3, G. Allende4, C. Leitao5, T. Froud6, 
G.W. Burke7, C. Ricordi8, A. Pugliese9, R. Alejandro10
1University of Miami, 2University of Miami, 3University of Miami, 4University 
of Miami, 5University of Miami, 6University of Miami, 7University of Miami, 
8University of Miami, 9University of Miami, 10University of Miami
Islet allotransplantation can restore insulin secretion and glucose control in 
patients with brittle type 1 Diabetes (T1D). Allorejection, drug toxicity, hostile 
hepatic environment and recurrence of autoimmunity may account for the 
limited longevity of the islet graft.
In the present study, we aimed to determine in islet allotransplant recipients the 
possible infl uence of recurrent autoimmunity on graft function and survival by 
evaluating GAD65 and IA2 autoantibodies (AAbs) during the follow-up.
Forty-three patients with long-term T1D, who received an islet allotransplant 
at our institution within different protocols from 2000 to 2006, were classifi ed 
as negative, converter or persistent according to their AAbs levels during 
follow-up (positivity was defi ned by 2 or more values above the normal levels 
for either or both type of AAbs). Kaplan-Meier (K-M) curves for islet graft 
dysfunction and failure were analyzed.
Prior to transplant, 20 patients were AAbs positive (11 for GAD65, 4 for IA2 and 
5 for both AAbs) whereas 23 were AAbs negative. After islet transplantation, 17 
recipients persisted positive, 14 remained negative while 8 converted to positive 
(2 to GAD65, 2 to IA2 and 4 to both); no data was available for 4 recipients.
K-M curves for graft dysfunction (36 recipients with islet dysfunction, 3 insulin-
free) were not different among groups, while K-M curves for graft failure (23 
recipients with islet function, 16 C-peptide negative) showed longer estimated 
time to failure (mean±SE) in the AAbs negative (49±7months) and persistent 
(47±7months) groups in respect to the converter one (44±8months).
Comparison among K-M curves became signifi cant only after 3 years from the 
fi rst islet transplant, the AAbs converter group showing an earlier graft failure 
compared to the persistent and the negative ones (p=0.039).
In conclusion, AAbs can persist after islet allotransplantation or even recur, 
despite immunosuppressive therapy. While infl uence on graft dysfunction 
seemed not relevant, recurrence of autoimmunity may contribute to reduce the 
overall graft survival in the long-term.
Figure 
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CONCURRENT ORAL SESSION 20: 
LIVING DONOR RENAL SURGERY
A DECADE OF MINIMALLY INVASIVE DONATION: 249 
EXPERIENCE WITH 1175 LAPAROSCOPIC DONOR 
NEPHRECTOMIES AT A SINGLE INSTITUTION
J. Leventhal, J.C. Caciedo, A. Skaro, A. Koffron, T. Baker
Northwestern University
The past decade has seen laparoscopic donor nephrectomy (LDN) transform 
into a standard of care procedure for kidney transplantation. Furthermore, LDN 
has evolved with the introduction of new technologies aimed at increasing 
the effi ciency and safety of the procedure. There are few large, single center 
experiences detailing the results of LDN, its associated complications, and their 
management. We performed a retrospective review of 1175 LDN performed at 
our center for both pediatric and adult recipients from 10/97 thru 3/08. We 
evaluated preoperative donor characteristics, intraoperative parameters and 
complications, postoperative recovery and complications. A modifi cation of 
the Clavien classifi cation (Leventhal et al Surgery, Oct. 2004; 881-90) was 
used to grade complication severity.
Results: Mean BMI of donors was 26.9 (range 17-48) with 24.7% having 
a BMI > 30 and 5.9% with a BMI > 35. 26% of kidneys had multiple renal 
arteries. >99% were left LDN. The mean length of stay was 1.37 +/- 0.6 
days, which decreased to 1.1 +/- 0.5 days for the last 450 cases. The overall 
complication rate for our series was 4.2%. 19/1175 (1.6%) of pts experienced 
an intraoperative complication, including 8 renovascular injuries; 7/8 
renovascular injuries led to open conversion. 4 open conversions were elective; 
our overall conversion rate is 0.9%. 31/1175 (2.6%) had a postoperative 
complication. 15/1175 (1.2%) required readmission for complication 
mgmt. 3/1175 patients have been lap. Reoperated for prolonged ileus and 
internal hernia (2). respectively. When graded by severity, 19/50 (38%) of 
complications were Grade 1 (Non-Life Threatening). 29/50 (58%) Grade 2 
(No Residual Disability). and 2/50 (4%) were Grade 3 (Residual Disability). 
There have been no cases of donor renal failure or death. Since 2003 we have 
routinely used hand-assisted LDN (HALDN). 482 LDN were compared to 
693 HALDN. Donor demographics were comparable between both groups. 
Graft function was similar in LDN and HALDN kidneys. Intraoperative 
and postoperative complication rates were also similar. Conversion rates 
were 1.9% for LDN and 0.4% for HALDN. HALDN was associated with a 
reduction in the number of operating ports and in operating room time. There 
have been no cases of primary non-function. Urologic complications have 
occurred in 3/1175 LDN renal transplants. Conclusions: Our series supports 
the safety and effi cacy of LDN/HALDN.
NOVEL SOURCES OF RENAL ALLOGRAFTS: KINDEYS 250 
WITH INTRINSIC DISEASES, WORLD WIDE EXPERIENCE.
S. Fujita1, K. Nannba2, M. Nishi3, N. Mitsuhata4, Y. Tsutsumi5, R. Mannami6, 
M. Mannami6, D. Nicol7
1University of Florida, 2Rokumeisou Pathology Center, 3Kagawa Rosai 
Hospital, 4Kure Kyosai Hospital, 5Fujita Health University, 6Uwajima 
Tokushukai Hospital, 7University of Queensland
Introduction: We embarked on a novel procedure gRestored kidney 
transplantation (RKT) h in which 42 renal allografts were obtained from 
patients with intrinsic disease including small renal cell carcinoma, ureteral 
stenosis and renal artery aneurysm (Am J Transplant. 2008 Apr;8 (4): 811-8.). 
In this report, we review the world-wide experience of this novel approach to 
increase transplant numbers.
Materials and Methods: Cases of RKT were identifi ed from MEDLINE and 
through personal communication. Donor and recipient information including 
long term follow-up was obtained by direct contact with transplant units 
performing RKT as much as possible. Accumulated cases are summarized and 
reviewed. As Australian cases will be presented elsewhere in this symposium 
in more detail, they were exempted.
Results: A total of 210 cases of RKT were identifi ed, including 78 small 
renal cell carcinomas, 8 ureteral carcinomas, 21 benign neoplasm (including 
15 angiomyolipomas). 8 nephrotic syndromes, and 95 various non-neoplastic 
lesions. There was one local recurrence of ureteral carcinoma (15 months after 
transplantation) and one remote recurrence of small renal cell carcinoma (9 
years after transplantation).
Discussion: RKT is now being considered in a number of transplant centers 
in North America, Europe and Asia-Pacifi c. The reported experience shows 
comparable outcomes to conventional renal transplants. Transmission of the 
donor disease appears extremely rare. This novel approach has a great potential 
as an alternative source of renal allografts for patients who would otherwise not 
be able to receive a transplant.
OUTCOMES OF TRANSPLANTS FROM KIDNEYS 251 
REMOVED WITH SMALL RENAL TUMOURS COMPARED TO 
CONVENTIONAL LIVE UNRELATED AND DECEASEDDONOR 
TRANSPLANTS.
D. Nicol, N. Gibbons, A. Griffi n, D. Wall, S. Wood, N. Isbel, C. Hawley, 
S. Campbell, J. Preston, D. Johnson
Princess Alexandra Hospital
We have recently reported the successful utilization of kidneys from patients 
with incidentally detected small renal tumours (< 3cm) for transplantation 
(Nicol et al BJU Int 2008). Following ex-vivo excision of the lesion and repair 
of the parenchymal defect the kidney is transplanted into selected recipients. 
These restored kidney transplants (RKT) appear a novel means of increasing 
the possibility of transplantation for selected patients who may otherwise not 
receive a transplant. In this study we compare outcomes of RKT to other modes 
of renal replacement therapy. During the period May 1996 to December 2007 
49 RKT were performed at our centre. Recipients were considered suitable 
for transplantation but marginal based on age and co-morbidities. Graft and 
patient outcomes in this group were compared to conventional live unrelated 
transplant recipients (n=120). deceased donor transplants (n=768) and to 
survival of patientsl on the active transplant waiting list who did not receive a 
kidney during this period (n=153).
Patients receiving RKT were signifi cantly more likely to be older, have 
diabetes mellitus and coronary artery disease compared to the other groups 
(p<0.01). Kaplan-Meier survival analysis demonstrated that the recipients 
of RKT kidneys experienced an early increase in mortality compared with 
the other 2 transplant groups. By approximately 4 years post-transplant, 
survival of the RKT kidney recipients was signifi cantly superior to that of 
dialysis patients who were accepted onto the renal transplant list but inferior 
to that of deceased donor and live unrelated kidney transplant recipients 
(who were both signifi cantly younger and had fewer comorbidities). 
Respective 1-, 3- and 5-year survival rates were 92%, 88% and 88% for 
RKT recipients compared to 99%, 997% and 97% for live unrelated kidney 
transplant recipients, 96%, 92% and 90% and 98%, 92% and 74% for 
dialysis patients accepted onto the deceased donor kidney transplant list 
(log rank score 10.4, p=0.005). In a subsequent matched cohort analysis of 
the transplanted patients RKT, live unrelated and deceased donor recipients 
were matched for age (within 2 years). gender and HLA mismatch. With 
this there was no difference in overall survival between the 3 groups (log 
rank score 0.09, p=0.77). No differences in graft survival were noted at 
any time point in the 3 transplant groups. In the 49 RKT recipients graft 
loss occurred due to recurrent FSGS in one case and death due to unrelated 
causes in 4 cases. Only one recipient experienced tumour recurrence 9 years 
post transplantation. This patient declined intervention and is currently 
under active surveillance.
Conclusions: RKT using kidneys removed with small, localized renal tumours 
following ex-vivo resection results in similar outcomes to conventional 
deceased and live unrelated living donor transplants. It also appears to confer 
a signifi cant survival advantage for patients who would otherwise be unable 
to receive a transplant. Despite the apparent contradiction of an intuitive 
principal of transplantation and immunosuppression, these kidneys should be 
considered for transplantation into carefully selected patients who may not 
otherwise have access to renal transplantation increasing quality and length 
of life
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THERE ARE NO ANATOMICAL BARRIERS TO 252 
LAPAROSCOPIC DONOR NEPHRECTOMY
C. Crane1, V.W.T. Lam1,2, A. Alsakran3, L. Dealtry2, D.J. Verran3, A. Vasilaras3, 
B. Ryan2, H. Lau2, H.C.C. Pleass2, R.D.M. Allen1,2,3
1Department of Surgery, University of Sydney, Sydney, Australia; 2Department 
of Surgery, Westmead Hospital, Sydney, Australia; 3Department of 
Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia
Aims: To investigate the effect of living donor right kidney and multiple 
donor renal arteries on donor and recipient outcomes after laparoscopic donor 
nephrectomy.
Methods: Between September 1998 and December 2006, 200 laparoscopic 
living donor nephrectomies were performed. The impact of donor right kidney 
and multiple donor renal arteries on operative time, hospital stay, graft function 
and donor and recipient complications were analysed.
Results: No donors were refused the option of laparoscopic donor surgery on the 
basis of perceived anatomical diffi culties. 200 donors underwent laparoscopic 
surgery, 29 for donation of right sided kidneys. 34 donors had multiple renal 
arteries found at the time of the donor procedure. The open conversion rate 
was 7% with no signifi cant difference between laparoscopic donor right and 
left nephrectomy groups (2/28 vs. 12/172; p=0.975) and kidneys with multiple 
renal arteries and single renal artery (5/39 vs. 9/161; p=0.112).
Right kidneys had a similar fi rst warm ischaemic time (4 mins vs. 4 mins; 
p=1.0) and second warm ischaemic time (31 mins vs. 30 mins; p= 0.804) 
compared to those of left kidneys. Right kidneys had no signifi cant effect on 
complication rate while providing similar recipient graft function compared to 
left kidneys.
Thirty-one of the 34 kidneys with multiple renal arteries required vascular 
reconstruction of these vessels while 3 had small polar vessels and ligated. 
Kidneys with multiple renal arteries had a longer second warm ischaemic time 
(38 mins vs. 32 mins, p=0.002) but similar fi rst warm ischaemic time (4 mins 
vs. 4 mins, p=0.234) when compared to that of kidneys with single renal artery. 
Kidneys with multiple renal arteries had no signifi cant effect on complication 
rate while providing similar recipient graft function compared to kidneys with 
single artery.
Conclusion: With careful technique, both with the laparoscopic donor 
nephrectomy and the recipient procedure, right kidneys and kidneys with 
multiple renal arteries can be procured safely with no demonstrated adverse 
impact on graft function and complication rates in the donor or recipient.
COMPARISON OF RECIPIENT OUTCOMES 253 
FOLLOWING OPEN AND LAPAROSCOPIC DONOR 
NEPHRECTOMY: AN ANALYSIS FROM THE AUSTRALIAN 
AND NEW ZEALAND DIALYSIS AND TRANSPLANT 
REGISTRY (ANZDATA).
 D. Nicol1,3, N. Gibbons1, S. McDonald2, J. Preston1,
1Renal Transplant Unit, Princess Alexandra Hospital, 2ANZDATA Registry, 
Adelaide, Australia, 3University of Queensland
Introduction: Laparoscopic donor nephrectomy has been widely adopted 
despite no randomized controlled trials having been performed comparing 
recipient outcomes with open donor nephrectomy. Review of registry data now 
appears the most feasible mechanism to compare outcomes. The ANZDATA 
registry prospectively captures data on all renal transplants performed in 
Australia and New Zealand including long term follow-up of recipients.
Aim; To compare graft outcomes among recipient of kidneys from donors 
undergoing nephrectomy using open vs laparoscopic techniques, through 
analysis of the ANZDATA registry following the introduction of laparoscopic 
donor surgery in Australia and New Zealand in 1997.
Methods: Operative technique data for live donor transplants were collected 
from May 1997 to December 2003; outcomes of all live donor transplants were 
examined with follow up to December 2006. Donor and recipient demographic 
variables and graft outcomes were compared between the laparoscopic and open 
donor groups. Standard techniques for continuous and categorical variables 
were used; Cox analyses used Kaplan-Meier and Cox regression analyses.
Results: A total of 1,474 live donor transplants were performed in 27 
transplant centres in Australia and NZ. Of these 296 (20.08%) were performed 
laparoscopically in 10 centres and 1,159 (78.63%) open in these centres and 
the remaining 16 transplant units. Of the laparoscopic cases 237 (80%) were 
performed in 3 centres whilst open nephrectomy was performed exclusively 
in 16 centres (n=390, 33.6%). Nineteen laparoscopic cases (1.28%) were 
converted to open. There was no signifi cant difference in donor characteristics 
with respect to age, gender as well as relationship and matching with recipients. 
Recipient groups were also identical with respect to age, weight, gender, pre-
emptive transplantation and cause of renal failure.
The laparoscopic donor nephrectomy group had a signifi cantly longer total 
ischaemia time (3.16 hours) compared to the open donor group (1.61 hrs, 
p<0.0001). The laparoscopic recipient group experienced a lower incidence 
of rejection episodes 29.2% versus 38.6% (p = 0.002). In terms of technical 
and other post operative complications and delayed graft function, there was 
no signifi cant difference between donor groups, including those in whom the 
donor operation was converted from laparoscopic to open. There were a total 
of 242 graft failures, 175 graft losses and 67 deaths with a functioning graft. 
Among surviving grafts there was no difference in creatinine at any time point. 
At 1 year and 5 years, the mean creatinine for the laparoscopic group was 138 
umol/l and 138 umol/l and for the open group was 136 umol/l and 145 umol/l 
respectively. Graft and patient survivals were similar in both groups (at 1 and 5 
years – laparoscopic 95.6%, 87.5% and 99%, 95% versus open 95.5%, 85.7% 
and 98.5%, 94.5%).
Conclusions: Based on analysis of all live live donor transplants performed 
in Australia and New Zealand, there appears to be no difference in short or 
long term recipient outcomes between open and laparoscopic live donor 
nephrectomy.
PREDICTORS OF POOR EARLY GRAFT FUNCTION 254 
FOLLOWING LAPAROSCOPIC DONOR NEPHRECTOMY 
(LDN)
M. Cooper1, A. Haririan2, S. Jacobs3, M. Phelan3, B. Philosophe1, 
S. Bartlett1 and J. Nogueira2.
1Dept of Surgery, 2Medicine and 3Urology, University of Maryland, Baltimore, 
MD, USA.
Body: LDN has become the standard of care in many transplant centers. Poor 
early graft function remains an important complication. Medium and long-term 
recipient outcomes are directly correlated with early allograft function. We 
conducted a retrospective study to evaluate the risk factors for slow or delayed 
graft function following LDN
Methods: Donor and recipient records from the fi rst 1000 LDN were reviewed 
(1996-2005).
Results: Slow graft function (SGF) was defi ned as Cr>3.0mg/dl at POD5 and 
DGF as the need for dialysis within the fi rst week following transplantation. 
Donor variables examined included age, sex, race, BMI, eGFR, and number of 
renal arteries. Recipient variables included age, sex, race, BMI, prior tx, pre-tx 
DM, history of smoking and drug usage. Additional variables evaluated included 
degree of relationship (LURT). HLA mismatch, antilymphocyte induction, de 
novo CNI usage, R v. L nephrectomy, WIT, total OR time, and performance 
of simultaneous deceased donor pancreas tx (SPLK). Univariate analysis was 
performed with signifi cance defi ned as p<0.05. Signifi cant variables were then 
included in the multivariate analysis.
Parameter Univariate (OR, 95%CI) p-value
Multivariate (OR, 
95%CI) p-value
Male Recip 1.48 (0.92-1.18) 0.04 1.49 (0.95-2.32) 0.08
AA Recip 1.68 (1.17-2.42) 0.005 1.34 (0.49-3.62) 0.57
Donor Age/decade 1.19 (1.02-1.39) 0.02 1.32 (1.08-1.60) 0.005
AA Donor 1.63 (1.12-2.37) 0.01 1.18 (0.43-3.23) 0.75
Prior Tx 0.36 (0.13-1.00 0.05 0.74 (0.24-2.22) 0.59
LURT 1.47 (1.02-2.11) 0.04 0.97 (0.58-1.65) 0.92
SPLK 0.33 (0.13-0.83) 0.02 0.41 (0.14-1.19) 0.10
Recip BMI/5kg/m2 1.49 (1.30-1.72) 0.000 1.49 (1.26-1.78) 0.000
HLA MM 1.18 (1.05-1.32) 0.003 1.14 (0.97-1.34) 0.10
R Kidney 2.52 (1.12-5.69) 0.03 2.87 (1.17-7.06) 0.02
WIT 1.00 (1.02-1.28) 0.02 1.16 (1.02-1.33) 0.03
Recip Smoke 1.48 (1.04-2.12) 0.03 1.40 (0.92-2.15) 0.12
Conclusion: Both donor and recipient variables may account for early allograft 
function. Our results suggest that donor age, recipient BMI, male recipient, 
WIT and right lap nephrectomies are independent risk factors for SGF/DGF 
following LDN. Many are modifi able variables and worthy of intervention and 
further study in an effort to improve outcomes.
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200 CONSECUTIVE HAND ASSISTED LAPAROSCOPIC 255 
DONOR NEPHRECTOMIES – THE AMSTERDAM 
EXPERIENCE.
I.JM ten Berge1, R.C. Minnee2, W.A. Bemelman2, K.AMI van Donselaar1, J. 
Booij3, B.L.F. van Eck-Smit3, S. ter Meulen1, F.J. Bemelman1, M.M. Idu2
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of 
Surgery, Academic Medical Centre, Amsterdam, 3Dpt of Nuclear Medicine, 
Academic Medical Centre, Amsterdam
Introduction: The hand assisted laparoscopic donor nephrectomy was 
introduced as a modality to facilitate the laparoscopic donor nephrectomy. The 
advantages include: the ability to use tactile feedback, less kidney traction, 
rapid kidney removal and shorter warm ischemic periods. There is an ongoing 
discussion whether a laparoscopic donor nephrectomy should be performed by 
a total laparoscopic procedure or by a hand assisted laparoscopic method. The 
purpose of this study is to evaluate our results and investigate the frequency 
and occurrence of delayed graft function.
Patients and Methods: All 200 consecutive living donors who underwent a 
laparoscopic donor nephrectomy between January 2002 and July 2007 were 
prospectively included in the study. Delayed graft function was defi ned as the 
need for dialysis within the fi rst postoperative week.
Results: The mean donor operative time was 177 minutes and the hospital 
stay and a mean hospital stay for donors was 4.8 days. No conversions were 
necessary, intraoperative complications and postoperative complications 
occurred in ten donors (5%) and twenty-four donors (13.5%). In fourteen 
recipients (7.0%) there were ureteric complications, including obstruction 
in nine and leakage in four. Our one-year graft survival was 95%. Delayed 
graft function was diagnosed is 12 patients (6%). Two risk factors for delayed 
graft function were identifi ed: counts per second on Tmax during renal donor 
scintigraphy (odds ratio 15.33, 95% confi dence interval (CI): 2.96-79.02) and 
multiple renal veins (odds ratio 6.04, 95% CI: 1.24-29.45).
Conclusion: HALDN is a safe procedure regarding donor morbidity rates and 
graft survival. The correlation between counts per second on Tmax during 
renography and delayed graft function may represent hyperfi ltration injury 
of a relatively small donor kidney. When renal donor scintigraphy shows 
asymmetric function between both kidneys, the question arises if we should 
hesitate to transplant this functional inferior kidney or exclude the donor from 
donation.
150 CONSECUTIVE HAND-ASSISTED LAPAROSCOPIC 256 
DONOR NEPHRECTOMY: A SUCCESSFUL SINGLE CENTER 
EXPERIENCE
P.W. Baron1, R. Ben-Youssef1, E. Franco1, A. Elihu1, A. Kore1, 
D.D. Baldwin2, O. Ojogho1
1Loma Linda University Medical Center, Transplantation Institute, 2Loma 
Linda University Medical Center, Urology
Background: Hand-assisted laparoscopic donor nephrectomy (HALDN) 
is a well-established technique for living kidney donation. We describe our 
continuous success with HALDN.
Method: We reviewed the data of 150 consecutive HALDN performed from 
Jan 2003 to Aug 2007. The initial 41 cases (G1) were compared to the next 
59 cases (G2) and to the last 50 cases (G3). We analyzed the donor operative 
time, estimated blood loss (EBL), serum creatinine at discharge (D/C), length 
of hospital stay (LOS), recipient serum creatinine at D/C and delayed graft 
function rate (DGF). 
Results: All cases were completed laparoscopically. Operative time was 
293 57, 278 44, and 290 53 min in group G1, G2 and G3. EBL was lowest 
in G3 (p=0.001). Minor peri-operative complications occurred in donors 
and recipients: minor bleeding controlled laparoscopically without blood 
transfusion in 2 G1, 1 G2, and 1 G3 donors; mild rhabdomyolisis in 1 G1, 1 G2, 
and 3 G3 donors; abdominal ileus in 4 G3 donors; epididimytis in 1 G2 donor, 
and persistent left testicular pain in 1 G1, and 1 G2 donors. A recipient of a G3 
kidney underwent exploration for kinked vascular anastomosis. A recipient of 
a G1 kidney developed DGF due to hypotension after endomyocardial biopsy. 
A recipient of a G1 kidney developed moderate hydronephrosis one week 
posttransplant and underwent successful ureteral reimplantation. One recipient 
of a G2 kidney and 2 recipients of G3 kidneys developed acute rejections 4, 
2 and 8 days posttransplant, respectively. They were treated successfully. The 
recipient mean serum creatinine at discharge was 1.3 0.8 mg/dL in G1, 1.2 0.4 
mg/dL in G2, and 1.6 1.4 mg/dL in G3 (p< 0.0001). 
Table 1. Donor characteristics
 G1 (n=41) G2 (n=59) G3 (n=50) P-value
Age (y) 36.7 ±10.7 34.2±10.4 35.9±10.1 NS
BMI (kg/m2) 25.2 ±5.2 25.8±2.8 25.6±3.5 NS
Renal arteries, n (%) 
1 34 (82.9) 48 (81.4) 44 (88.0) NS
2 6 (14.6) 11 (18.6) 5 (10.0) NS
3 1 (2.4) 0 1 (2.0) NS
MeanSD=
Table 2. Donor outcome (mean SD) 
 G1 (n=41) G2 (n=59) G3 (n=50) P-value
EBL (mL) 110.4±76.8 80.7±49.5 43.0±19.9 0.001
LOS (d) 3.1±0.4 3±0.2 3.1±0.4 NS
Ser Creatinine @ D/C (mg/dL) 1.2±0.2 1.2±0.2 1.2±0.3 NS
Conclusion: These data showed persistently excellent outcome with HALDN. 
The procedure has minimal donor morbidity and supplies excellent quality 
kidney allografts.
RENAL VEIN EXTENSION USING GONADAL VEIN. A 257 
USEFUL STRATEGY FOR RIGHT KIDNEY LIVING DONOR 
HARVESTED BY LAPAROSCOPY
P. Troncoso, J. Domínguez, S. Guzman
P Universidad Católica De Chile
Introduction: Vascular management of right renal vein during laparoscopic 
living donor nephrectomy is still an unsolved problem. The shortness of this 
vessel has limited the use of right kidneys in opposition to left kidneys. However, 
in some instances the right kidney should be harvested, particularly when the 
left kidney presents complex vascular anatomy. Based on the experience in 
open donor nephrectomy, our unit has used donor gonadal vein to obtain longer 
right renal veins in this setting.
Methods: Four consecutive living related donors with multiple left renal 
arteries and indication of laparoscopic right nephrectomy were submitted to 
this procedure. Three donors were female and the average age was 48,5 years 
with a range of 30 to 61 years. The renal vein was controlled with a 30 mm 
universal stapler and during the harvesting 5 to 6 centimeters of the ipsilateral 
gonadal vein was included. The donor kidney was perfused and renal vessels 
were prepared in cold conditions in the usual fashion. The gonadal vein was then 
opened longitudinally and sutured to the donor right renal vein as a wide tube in 
3 cases and as a spiral tube in one with 6-0 monofi lament suture material.
Results: This procedure extended the bench work between 25 to 40 minutes and 
permitted an extension of 2,5 to 3,5 centimeters of the donor vein. Transplants 
were done in the usual mode and the vein enlargement facilitated enormously 
the implant surgery. All receptors presented immediate graft function and no 
complications were observed with this strategy.
Conclusions: Vein extension with gonadal vein is a simple and safe way to 
enlarge the renal vein of right living donor kidneys procured by laparoscopy.
TUESDAY – ORAL ABSTRACTS
LATE BREAKINGCONCURRENT ORAL SESSION 21: 
TRANSFECTION OF NF258 ƒÛB DECOY 
OLIGODEOXYNUCLEOTIDES USING "EFFICIENT 
ULTRASOUND – GENE TRANSFER" INTO DONOR KIDNEYS 
PROLONGED SURVIVAL OF RAT RENAL ALLOGRAFTS
H. Azuma 1, H. Nomi 1, N. Ibuki 1, N. Tomita 2, R. Morishita 2, S. Horie 3, 
S. Takahara 4, Y. Katsuoka 1
1 Department of Urology Osaka Medical College, 2 Division of Gene 
Therapy Science, Osaka University Graduate School of Medicine, 3 
Department of Urology, Teikyo University Medical School, 4 Department of 
Advanced Technology for Transplantation, Osaka University Graduate School 
of Medicine
Objectives: Nuclear factor κB (NFκB) plays a pivotal role in the coordinated 
transactivation of a series of genes of cytokines and adhesion molecules that 
are highly involved in the onset of acute rejection in organ transplantation. 
We previously developed decoy cis-elements oligo deoxyribonucleic acid 
against NFκB (NFκB-decoy) that effectively inhibited the activation of major 
infl ammatory mediators in vitro and in vivo. Accordingly, we hypothesized 
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that transfection of NFκB-decoy into the donor kidney would prevent acute 
rejection and prolong graft survival, and thus provide effective therapy for 
renal acute rejection.
Methods: To transfect NFκB-decoy, we employed a novel approach using 
ultrasound exposure with an echocardiographic contrast agent, Optison, and 
clearly demonstrated successful transfection of NFκB-decoy into renal tissue. 
The therapeutic effect of NFκB-decoy on renal allografts was then evaluated in 
a rat renal allograft model (Wistar-Lewis).
Results: Ultrasound-Optison-mediated gene transfection procedure successfully 
transfected the FITC-labeled NFkB-decoy transfer into renal allografts (Figure 
1). In the control group, graft function signifi cantly deteriorated with marked 
destruction of renal tissue (Figure 2), accompanied by increased production of 
major infl ammatory mediators (Figure 3), and all animals died of renal failure by 
9 days (Figure 4). In contrast, graft function (serum creatinine on day 2, NFκB-
treated: 0.97 ± 0.16 vs. control: 1.84 ± 0.23 mg/dL, p<0.01) and histological 
structure was well preserved (Figure 2) with signifi cantly decreased expression 
of NFκB-regulated cytokines and adhesion molecules, including IL-1, iNOS, 
MCP-1, TNF-α, and ICAM-1 (Figure 3), in allografts transfected with NFκB-
decoy. As a result, animal survival was signifi cantly prolonged in this group as 
compared to controls (Figure 4; 14.2 ± 5.2 vs. 7.1 ± 1.2 days, p<0.01).
Figure 1. FITC-labeled NFkB-decoy transfer
Figure 2. Graft function and histology
Figure 3. Expression of cytokines and adhesion molecules in allografts
Figure 4. Animal survival
Conclusions:ڤwe established a novel ultrasound-Optison-mediated gene 
transfection approach and demonstrated the signifi cant prolongation of graft 
survival by the successful transfection of NFκB-decoy into the donor kidney in 
a rat renal allograft model.
LONG TERM SURVIVAL AND FUNCTION OF 259 
ADULT PORCINE ISLETS CO-TRANSPLANTED WITH 
ADULT PORCINE SERTOLI CELLS INTO RATS WITHOUT 
IMMUNOSUPPRESSION.
D.J.G. White 1,2, C. Hasilo 2, G. Vilk 2, D.M. Mazzuca 2, A. Pepper 1, C. Gall 2, 
A. MacGillivary 2, J. Melling 2
1 Schulich School of Medicine University of Western Ontario London Ontario 
Canada, 2 London Health Sciences Centre University Hospital London 
Ontario Canada
In our abstract (#485) titled "Adult Porcine Sertoli Cells Suppress The Xenograft 
Responses to Porcine Islets In Rats More Effectively than Neonatal Sertoli 
Cells” to be presented at this conference we report that adult porcine Sertoli 
cells elicit no immune response as assessed by anti pig IgG when transplanted 
into non-diabetic Lewis rats. Further, the IgG response to porcine islets when 
co-transplanted with adult porcine Sertoli cells is also inhibited. Porcine islets 
alone or porcine islets co-transplanted with neonatal porcine Sertoli cells induce 
substantial anti-pig IgG responses when transplanted into Lewis rats.
We have now exploited this observation by co-transplanting adult porcine 
islets and adult Sertoli cells under the kidney capsule of streptozotocin induced 
diabetic Lewis rats. Recipients were transplanted at a ratio of 2000 adult 
porcine Sertoli cells per islets and received either 1000, 4000 or 8000 adult 
porcine islets mixed with the appropriate number of Sertoli cells to maintain 
the 2000:1 ratio. Transplants of islets alone (1000, 4000 or 8000) acted as a 
control. Recipients were tested for the presence of porcine insulin and porcine 
C-peptide and were sacrifi ced for histological examination at days 74 and 186 
(approximately six months). There were 8 animals per group. 
All animals receiving the co-transplants gained weight and remained healthy 
in contrast to controls. All animals sacrifi ced at day 74 showed the presence 
of porcine insulin positive cells by immunohistochemistry and all produced 
a porcine insulin response following intravenous glucose challenge. Basal 
(unstimulated) levels of urinary C-peptide were 0.35ng/ml. Porcine insulin levels 
ranged from 0.15ng/ml to 0.28ng/ml, islets alone were negative for porcine 
insulin <0.02ng/ml). At six months post transplant immunohistochemistry 
showed 3 of 5 grafts studied staining positive for insulin producing cells with 
porcine insulin production varying from 0.12 ng/ml (1000 islets) to 0.82ng/
ml (8000 islets). C-peptide levels are currently being determined. None of the 
recipients became normoglycemic. This is to be expected since porcine insulin 
is highly ineffi cient in rats.
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Co-transplantation of porcine islets with adult porcine Sertoli cells may be a 
solution to both the problem of supply and systemic immunosuppression in 
islet transplantation for type 1 diabetes.
VIRUS-SPECIFIC CD8+ T-CELL FUNCTION AND 260 
PROTECTION FROM HCMV REACTIVATION/DISEASE IN 
SOLID ORGAN TRANSPLANT PATIENTS
T. Crough1, C. Fazou1, J. Weiss1, S. Walker1, S. Bell2, K. McNeil2, A. 
Galbraith2, S. Jones3, R. Khanna1.
1Australian Centre for Vaccine Development, Queensland Institute of Medical 
Research, Brisbane, Queensland, Australia. 2The Prince Charles Hospital, 
Brisbane, Queensland, Australia. 3Cellestis Ltd, Melbourne, Australia.
We have longitudinally analysed human cytomegalovirus (HCMV)-specifi c 
CD8+ T-cell responses in a cohort of solid organ (heart, lung, renal) transplant 
patients. The detection of active virus replication correlated with reduced IFN-γ 
expression by HCMV-specifi c CD8+ T-cells and an up-regulation of CD38 
expression on the surface of virus-specifi c CD8+ T-cells, although there was 
no signifi cant change in the number of virus-specifi c cells. Most importantly, 
analysis of IFN-γ production by virus-specifi c CD8+ T-cells in patients with 
HCMV disease suggested that disease was associated with a reduction in CD8+ 
T-cell responsiveness to both structural and immediate-early antigens. Based 
on these results, we have developed a novel diagnostic technology to monitor 
the HCMV-specifi c CD8+ T-cell responses referred to as QuantiFERON®-
CMV. Evaluation of QuantiFERON®-CMV in healthy individuals and 
solid organ transplant patients revealed that this technology was at least as 
sensitive and with some HCMV epitopes more sensitive than the ELISPOT 
for detecting ex vivo IFN-γ. Results from QuantiFERON®-CMV assays 
showed 97% (36/37 individuals) agreement with the anti-HCMV serology test 
in healthy individuals. Taken together, this study indicates a pivotal role for 
IFN-γ producing virus-specifi c CD8+ T-cells in protecting transplant patients 
from HCMV disease, and this protection is dependent on a broadly focused T 
cell responses rather than a response directed towards any one single antigen. 
Furthermore, QuantiFERON®-CMV is a simple, reproducible and reliable test 
for the detection of IFN-γ in response to HCMV CD8+ T-cell epitopes, and 
may be a valuable diagnostic test for the detection of HCMV infection and a 
useful clinical tool for monitoring the immune response in immunosuppressed 
patients during therapy.
AN ANALYSIS OF THE LIST AND DEATHS AMONG 261 
CANDIDATES WAITING FOR A KIDNEY TRANSPLANT
F. Delmonico 1, M.A McBride 2
1 Transplantation Center, Massachusetts General Hospital, Boston, MA, 
2 United Network for Organ Sharing, Richmond, VA
Background: The status (active versus inactive), demographic characteristics 
and deaths of patients waiting for a kidney transplant were analyzed to make a 
current assessment of the kidney waitlist. This report focuses upon the kidney 
waitlist versus all other organ lists because most of the patients dying on 
the list are in need of a kidney transplant. The "inactive" Status 7 within the 
UNetSM system is a designation that transplant centers can defi ne for wait list 
candidates not currently suitable for kidney transplantation but theoretically 
still an appropriate patient for transplantation. During the period of kidney 
wait list inactivity the candidate accrues wait time but does not receive offers 
for a deceased donor kidney. Finally, kidney listing practices may have been 
infl uenced by a 2003 OPTN/UNOS rule change regarding the wait time 
afforded to patients who are inactive on the list. 
Methods: A snapshot of the waiting list on February 29, 2008 was reviewed 
by organ type, age at listing and by the active versus inactive status of the 
candidate on the list to determine total length of time in inactive status, time 
of inactive status during the most recent inactive period, and total time on the 
list. The pattern of inactivity among candidates waiting for kidneys was also 
examined for those waiting between 2003 (after the rule change) and 2007. 
Results: Since 2003, the kidney wait list has not increased in the total number 
of active candidates, but only by the number and percentage of inactive. 
Currently 33% of the list is inactive (>24,000 patients). Of the 24,226 patients 
inactive on Feb. 29, 2008, 6333 (25%) have been inactive > 2 years. Of 20,234 
patients inactive on Dec. 31, 2006, 9797 (48%) are currently inactive. Of the 
27,289 patients added to the list in 2004, 6,275 (23%) are still waiting, and 
2,430 of these are waiting in inactive status.
Among the 2,431 candidates that died with inactive status while waiting for a 
kidney during 2007, 53% were inactive for > one year over the entire course of 
their time on the list, and 47% were listed as inactive status consecutively for 
more than one year prior to their death.
Among the 4,642 candidates that died while waiting for a kidney in 2007, 73% 
of the deaths were among candidates over the age of 50, and 26% were age ? 
65. Nearly half of the candidates who died (47%) were White, 31% were Black, 
and 15% were Hispanic, similar to the distribution of ethnicity among all the 
candidates waiting during 2007
Conclusion: These data are indicative of a wait list that could conceivably be 
managed more transparently by alerting transplant centers of those patients 
remaining on the list inactive for more than one year, more effi ciently by 
transplant centers notifying HLA laboratories if patients are not going to be 
activated for at least one year, and with a patient advocacy by posting an inactive 
alert for patients inactive for more than 2 years. The causes of death on the list 
should be examined to determine if those patients dying on the list (inactive) 
within 2 years of listing were suitable candidates for transplantation.
PREGNANCY AFTER KIDNEY DONATION262 
H. Ibrahim, S. Akkina, E. leister, H. Guo, T. Rogers, A. Matas
University of Minnesota
The outcome of pregnancy in living kidney donors has generally been viewed 
to be favorable, but previous studies have been small. Therefore, we assessed 
fetal and maternal outcomes in a large cohort of female kidney donors at the 
University of Minnesota.
We sent female kidney donors self-administered questionnaires that addressed 
fetal (e.g., full-term deliveries, prematurity, fetal loss) and maternal (e.g., 
preeclampsia, gestational hypertension, gestational diabetes) outcomes. 
Results Since June 1963, a total of 2,025 women have donated kidneys at 
our institution. Of these, 965 reported ever becoming pregnant (822 donors 
reported 2,416 pregnancies before donation and 223 reported 459 pregnancies 
after donation). Pre-donation (vs. post-donation) pregnancies were associated 
with a higher likelihood of full-term deliveries (83.7% vs. 72.3%, p<0.0001) 
and a lower likelihood of fetal loss (11% vs. 19.8%, p=0.006). Pre-donation 
(vs. post-donation) pregnancies were also associated with a lower risk of 
gestational diabetes (0.7% vs. 2.4%, p=0.0004), gestational hypertension (0.4% 
vs. 4.4%, p<0.0001), and preeclampsia (0.7% vs. 5.2%, p<0.0001). Logistic 
regression analysis identifi ed post-donation pregnancies as risk factors for both 
adverse fetal (prematurity: odds ratio [OR], 2.3; 95% confi dence intervals [CI], 
1.27 to 4.17; fetal loss: OR, 2.2; 95% CI, 1.5 to 3.2) and maternal (combined 
gestational diabetes, hypertension, or preeclampsia: OR, 5.81; 95% CI, 3.5 to 
9.6) outcomes.
Conclusion: The risk of prematurity, fetal loss, gestational hypertension, 
gestational diabetes, and preeclampsia in female kidney donors is comparable 
to that seen in the general population, but higher than the risk in pre-donation 
pregnancies.
USING VOCLOSPORIN PHARMACOKINETICS 263 
(CONCENTRATION) AND PHARMACODYNAMICS 
(CALCINEURIN ACTIVITY) TO PREDICT OPTIMUM 
IMMUNOSUPPRESSION IN A PHASE 2B RENAL 
TRANSPLANTATION TRIAL
H-U. Meier-Kriesche 1, A. Jevnikar 2, R. Alloway 3, T. Batiuk 4, I. Bajjoka 5, 
P.R. Mayo 6, S. Ling 6, S. Mulgaonkar 7
1University of Florida, Gainesville, FL, 2London Health Sciences Center, 
London, ON, 3University of Cincinnati Medical Center, Cincinnati, OH, 
4Legacy Transplant Services, Portland, OR, 5Henry Ford Transplant Institute, 
Detroit, MI, 6Isotechnika Inc., Edmonton, AB, 7St. Barnabas Medical Center, 
Livingston, NJ.
Background: Voclosporin (VCS), a next generation calcineurin inhibitor, 
developed for solid organ transplantation. Traditionally, calcineurin inhibitor-
based immunosuppression is titrated to trough concentration ranges (C0). 
VCS has been developed using calcineurin activity (CNA) as a biomarker 
of immunosuppressant activity. Data just became available from a Phase 2b 
renal transplant trial to explore the PK and PD of VCS as a means of dose 
optimization. 
Methods: A subset of de novo renal allograft recipients (n = 99) divided 
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into three dose groups participated in a sparse sampling PK-PD protocol 
which measured VCS concentrations and CNA at time 0, 1, 2, and 4 hours. 
Drug concentrations were determined using LC/MS. CNA was determined 
with a P32-based assay. Both PK and PD were analyzed using standard non-
compartmental analysis, t-test, and receiver-operator characteristic analysis. 
Data up to and including 180 days were stratifi ed by clinical outcomes defi ned 
as optimum and as rejection. 
Results: 
Variable Outcome Mean ± sd p ROC P
C0
Optimum 43.3 ± 26.7
0.013 0.617 0.040Rejection 33.4 ± 16.8
AUC(0-4)
Optimum 638.4 ± 398.4
0.356 0.584 0.146Rejection 564.2 ± 364.6
CNA0
Optimum 1.03 ± 0.44
0.002 0.671 0.003Rejection 1.33 ± 0.56
CNAmin
Optimum 0.40 ± 0.30
0.007 0.601 0.08Rejection 0.59 ± 0.51
C0 = Concentration at Time 0, AUC(0-4) = Area-Under-the-Curve from 0 to 4 hours
CNA0 = Calcineurin Activity at Time 0. CNAmin = Minimum Measured Calcineurin Activity
CNA at time 0 was found to be superior to trough and AUC(0-4) as a predictor 
of clinical outcome. In addition, ROC analysis suggests that trough was also 
a useful predictor of clinical outcome. Maximum calcineurin inhibition in the 
optimum group compared to the rejection group was 61% and 55%, respectively 
when using time zero as baseline. 
A discriminant analysis correctly identifi ed 83.2% of patients as optimum 
without rejection based on a combination of trough concentration and CNA. 
Interestingly, the use of post-dose time points for concentration did not improve 
predictive performance. PK-PD correlation between drug concentration and 
CNA revealed a good relationship with an Emax of 1.5 ± 0.03 pmol/min/mg 
and an EC50 of 97.5 ± 5.4 ng/mL.
Conclusions: PD based dose optimization using the direct measurement of 
CNA may provide a more accurate means of dose titration than traditional 
PK methods. PK factors with known variability in de novo transplant 
patients such as polymorphisms in drug metabolism (CYP450) and transport 
(p-glycoprotein) are summarized by direct measurement of the drugs molecular 
target. This novel PD dosing paradigm for VCS will be explored more in detail 
in upcoming Phase 3 studies.
RENAL FUNCTION, EFFICACY AND SAFETY OF 264 
EVEROLIMUS (RAD) / ENTERIC-COATED MYCOPHENOLATE 
SODIUM (EC-MPS) THERAPY AFTER CALCINEURIN 
INHIBITOR (CNI) WITHDRAWAL IN DE NOVO RENAL 
TRANSPLANT PATIENTS: FINAL OUTCOMES OF THE ZEUS 
STUDY
K. Budde1, J. Klempnauer2, W. Arns3, C. Sommerer4, P. Reinke5, U. 
Eisenberger6, W. Fischer7, S. Kramer7, F. Pietruck8
1Nephrology, Charité, Berlin, Germany; 2Department of Visceral and 
Transplantation Surgery, Hannover Medical School, Hannover, Germany; 
3Cologne General Hospital, Merheim Medical Centre, Cologne, Germany; 
4Department of Nephrology, University Hospital, Heidelberg, Germany; 
5Department of Nephrology and Internal Intensive Care, Campus Virchow 
Clinic, Charité University Medicine, Berlin, Germany; 6Department of 
Nephrology and Hypertension, University Hospital of Bern, Switzerland; 
7Novartis, Nuernberg, Germany; 8Department of Nephrology, University 
Hospital, School of Medicine, Essen, Germany
Background: The ultimate aim of immunosuppressive therapy in 
transplantation is to provide an effi cacious regimen while minimizing non-
immune toxicities. By combining synergistic drugs, it may be possible to 
reduce the exposure to individual agents and therefore avoid adverse effects 
whilst maintaining favorable clinical outcomes. Until now, no therapy has been 
recognized as being effi cient in the prevention of long-term allograft loss due 
to chronic allograft dysfunction (CAD) refl ecting an unmet medical need in 
transplantation. Therefore, the use of antiproliferative drugs like Everolimus in 
combination with the withdrawal of CNI has become an interesting concept in 
treating calcineurin inhibitor toxicity leading to chronic slow deterioration of 
renal allograft function. 
Purpose: The purpose of the here presented ZEUS study was to assess whether 
an Everolimus /EC-MPS regimen after Calcineurin inhibitor (CNI) withdrawal 
is as safe and well-tolerated in de novo renal transplant patients as the CNI-
based standard regimen but results in a better renal function. 
Methods: This 1-year, prospective, open-label, randomized, controlled, 
multicenter study compared the effi cacy, safety and tolerability of an 
immunosuppressive regimen with Everolimus and EC-MPS to that of 
Cyclosporine (CsA) and EC-MPS in 300 renal allograft recipients. After 
induction therapy with Basiliximab all patients were treated with CsA, 
EC-MPS and corticosteroids for the fi rst 4.5 months post transplantation. 
Subsequently patients were randomized 1:1 to either a) (n=150) continue the 
current regimen of CsA and EC-MPS (720mg BID) or b) (n=150) to convert 
from CsA to Everolimus over a 4 week period and continue with Everolimus 
(adjusted according to trough levels of 6-10 ng/ml) and EC-MPS (720mg BID). 
Corticosteroids were prescribed according to center practice with a minimum 
dose of 5 mg/day. Renal function of the two treatment arms was assessed by 
the determination of Glomerular Filtration Rate (GFR), calculated according 
to Nankivell-method as the primary endpoint. Additional renal endpoints 
included GFR calculated according to Cockcroft-Gault and MDRD method, 
Serum creatinine and slope of creatinine. Effi cacy and safety endpoints implied 
rejection episodes (treated and biopsy proven), graft loss, death, lost to follow 
up, as well as treatment failure as a composite endpoint. 
Results: Renal function outcomes of the fi rst 147 subjects receiving 
Everolimus/EC-MPS and 140 receiving CsA/EC-MPS completing 12 months 
will be reported here. Final outcomes of all 300 subjects will be presented 
at the congress. Groups were similar at baseline (timepoint of randomization 
4.5 month post-transplant) for all reported renal function endpoints. Calculated 
GFRs (Nankivell formula) were 64.4 ± 17.7 and 64.2 ± 15.5 at baseline, 
respectively 72.3 ± 19.1 and 63.2 ± 17.5 mL/min/1.73m² at month 12 for the 
Everolimus/EC-MPS and CsA/EC-MPS treatment group. Regarding effi cay 
and safety outcomes: For the 12-month study period BPAR was reported in 
24/147 (16.3%) Everolimus/EC-MPS-treated patients and 18/140 (12.9%) 
receiving CsA/EC-MPS. No patients in both treatment groups died. Graft loss 
occurred neither in the Everolimus/EC-MPS nor in the CsA/EC-MPS group. 
The number and proportion of patients withdrawn for adverse events at 12 
months were 18/147 (12.2%) in the Everolimus/EC-MPS group and 8/140 
(5.7%) in CsA/EC-MPS group.
Conclusions: In summary, the ZEUS study results confi rm the expected 
improvement of renal function after CNI withdrawal and the introduction of the 
Everolimus/EC-MPS treatment in de novo renal transplant patients. Switching 
the immunosuppressive regimen early after transplantation to an Everolimus/
EC-MPS therapy results in a safe and well-tolerated regimen. Defi nitive 
conclusions about the effects of the ZEUS regimen will be provided at the 
congress.
COST-EFFECTIVENESS OF HYPOTHERMIC MACHINE 265 
PERFUSION VERSUS STATIC COLD STORAGE IN KIDNEY 
TRANSPLANTATION: FIRST RESULTS OF THE PROSPECTIVE 
EUROPEAN RCT
H. Groen1, C. Moers2, J.M. Smits3, J. Treckmann4, F. van Gelder5, A. Rahmel3, 
A. Paul4, J. Pirenne5, R.J. Ploeg2, E. Buskens1. 
1Epidemiology, University Medical Center Groningen, Netherlands; 2Surgery, 
University Medical Center Groningen, Netherlands; 3Eurotransplant 
International Foundation, Leiden, Netherlands; 4Abdominal and Transplant 
Surgery, University Hospital Essen, Germany; 5Abdominal Transplant 
Surgery, University Hospital Leuven, Belgium.
Introduction: Static cold storage (CS) is the most widely used organ 
preservation method for deceased donor kidney grafts. Retrospective analyses 
have indicated that preservation by hypothermic machine perfusion (MP) 
may lead to improved outcome after renal transplantation. We performed an 
economic evaluation of the use of MP versus CS with data from the recently 
conducted European multicenter prospective RCT. This analysis concerns the 
short term cost-effectiveness of MP versus CS, balancing cost of preservation 
versus cost of renal dysfunction and related complications after transplantation. 
This is the fi rst MP related cost-effectiveness study to be based on prospectively 
randomized clinical data.
Methods: The clinical study involved inclusion of 336 consecutive kidney 
pairs from the same donor, one being randomized to MP and the contralateral 
organ to CS. This short-term analysis’ scope comprised the clinical outcome 
and costs up to one year after transplantation. The primary clinical endpoint 
was delayed graft function (DGF). An economic evaluation was performed as 
a cost-effectiveness analysis with the percentage of patients with a functioning 
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graft after one year as the clinical outcome. Costs were calculated from a 
hospital perspective: direct medical costs associated with hospital stay, dialysis 
treatment and function related complications were included, and compared per 
preservation modality. Missing data regarding dialysis treatment following graft 
failure were imputed conservatively based on established clinical practice.
Results: MP signifi cantly reduced the risk of DGF (OR 0.62; p=0.02) and also 
reduced the risk of graft failure (HR 0.39; p=0.03). Costs of dialysis (€760 vs. 
€940), graft failure or DGF (€136 vs. €193) and hospital readmission (€2,157 
vs. €2,399) tended to be lower per patient with MP than with CS, but this 
fi nding was not statistically signifi cant. Costs of preservation with MP were 
higher than with CS for each case (€842 vs. €167). Imputation of dialysis 
costs contributed considerably to average dialysis expenses, which rose to 
€4,354 for CS and to €2,564 for MP. Average total costs per patient after 
imputation were €4,896 for MP and €5,309 for CS. Bootstrap analysis (5,000 
iterations) showed that the baseline probability of cost-effectiveness for MP 
was 71%. Further analyses including sensitivity analysis on the impact of 
variation of the major cost components are currently performed and prepared 
for presentation.
Conclusion: The clinical data show that MP has benefi cial effects on renal 
grafts compared to CS. The fi rst results from this cost-effectiveness analysis 
suggest that the additional costs of MP are more than compensated by savings 
due to reduced costs of graft function related complications, especially of 
reduced need for continued or renewed dialysis in case of DGF, primary non-
function, or graft failure.
COMPARISON OF AN INITIALLY INTENSIFIED DOSING 266 
REGIMEN VERSUS A STANDARD DOSING REGIMEN OF 
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) 
IN RENAL TRANSPLANT PATIENTS: EFFICACY AND SAFETY 
ANALYSIS OF 75 PATIENTS.
W. Arns 1, P. Glander 2, C. Sommerer 3, T. Ariatabar 1, K. Eichele 4, W. Fischer 
4, M. Zeier 3
1 Nephrology, Köln-Merheim, 2 Nephrology, Charité, Berlin, 3 Nephrology, 
Univ. Heidelberg, 4 Novartis, Nuremberg, Germany
Objective: The aim of this prospective randomized study was to investigate 
whether an intensifi ed dosing regimen of EC-MPS in comparison to a 
standard dosing regimen will lead to higher MPA exposure early after 
transplantation. Furthermore, we examined whether an initially intensifi ed 
dosing regimen will lead to better effi cacy without compromising safety. 
Methods: A total of 75 de-novo kidney transplant recipients were treated 
with basiliximab induction and cyclosporine (CsA) and randomized to a 
standard (SD) EC-MPS dose (1440mg/d; n=36) or to an intensifi ed (ID) 
EC-MPS dosing (day 0-14: 2880 mg/d; day 15-42: 2160 mg/d; followed 
by 1440 mg/d; n=39). Safety and tolerability as well as the incidence of 
biopsy-proven acute rejection (BPAR) and graft loss was assessed after 180 
days of treatment.
Results: Incidence of BPAR was low throughout the study with a trend to 
a lower rate in the ID group (1(2.6%) vs. 5 (13.5%). During the period of 
intensifi ed treatment, no rejections occurred (0 vs. 5 within 84 days, p=0.025). 
No graft loss was observed, but 1 death recorded in the ID group after 3 
months. Overall incidence of adverse events was comparable between both 
treatment regimens. An ID regimen was not associated with a higher rate 
of hematological disorders except a slight increase in thrombocytopenia 
(anaemia: 8 vs. 10; leucopenia: 8 vs. 8, thrombocytopenia: 3 vs. 0). With 
respect to gastrointestinal symptoms, more events were reported in the ID 
group (76 vs. 58). The difference can mainly be ascribed to a higher incidence 
of abdominal pain (8 vs. 4), diarrhea (16 vs. 13) and fl atulence (8 vs. 2). 
Infections were similar (62 vs. 65) with CMV in 1 vs.5 patients and rate of 
malignancies was low (0 vs. 2) (ID vs. SD).
Conclusion: Based on these data, an intensifi ed dosing regimen of EC-MPS 
in combination with CsA can safely be administered and leads to a lower 
risk of BPAR. This supports previous data showing that early adequate MPA 
exposure is crucial for the clinical outcome. Larger studies are ongoing to 
confi rm the safety and effi cacy of an initially intensifi ed MPA regimen.
CONCURRENT ORAL SESSION 22: 
LIVING DONOR LIVER TRANSPLANTS
COMBINED USE OF RITUXIMAB AND INTRA PORTAL 267 
INFUSION THERAPY FOR ADULT ABO-INCOMPATIBLE 
LIVING-DONOR LIVER TRANSPLANTATION
M. Tanabe1, S. Kawachi1, H. Obara1, M. Shinoda1, T. Hibi1, Y. Fuchimoto1, 
K. Hoshino1, M. Sakamoto2, Y. Morikawa1, Y. Kitagawa1
1Department of Surgery, School of Medicine, Keio University, 2Department of 
Pathology, School of Medicine, Keio University
Background and aims: ABO-incompatible living donor liver transplantation 
(ABO-I LDLT) in adult patients has been controversial due to the high risk of 
liver necrosis and intrahepatic bile duct injury mediated by preformed anti-
ABO antibodies. Since we fi rst introduced intra-portal infusion therapy (IP) 
into adult ABO-I LDLT in 1998, the concept of elocal immunomodulation f 
in the graft liver has become the most critical breakthrough to overcome the 
ABO-blood group barrier in Japan. In 2005, rituximab (anti-CD20 monoclonal 
antibody) prophylaxis and rescue was applied in combination with IP to 
selectively eliminate B cells thus permitting effective reduction of anti-ABO 
antibody titer. The aim of this study was to analyze short- and long-term 
outcomes to evaluate our current treatment strategy for adult ABO-I LDLT.
Methods: From 2005 to 2008, 12 consecutive adult patients underwent 
ABO-I LDLT by the new protocol in our institution. As a routine approach 
to incompatible cases, we performed preoperative plasma exchange and 
splenectomy during transplant to reduce recipient fs antibody level against the 
donor fs blood type. Baseline immunosuppressive therapy included tacrolimus/
cyclosporine, systemic steroid, and antimetabolites. IP regimen was composed 
of methylprednisolone, prostaglandin E1, and gabexate mesilate. Rituximab 
was used perioperatively with reference to the lymphocyte subset profi le of the 
peripheral blood.
Results: Anti-donor blood type antibody titers on admission ranged from x16 
to x4096, which was effectively reduced to ≤; x128 on the day of transplant 
by rituximab and plasma exchange. In 6 cases, the maximum anti-donor 
blood type antibody titers reached to x128 to x512 within two weeks after 
transplant, and persistently positive thereafter. Immunohistochemical study 
revealed that the donor blood type antigen remained positive in the graft liver 
at least for a year; however, none of them suffered from antibody-mediated 
rejection, liver necrosis, or intrahepatic bile duct injury. These fi ndings suggest 
that eaccommodation f may have occurred. It took 6-12 months for the 
peripheral CD20+ B lymphocytes to recover preoperative condition, although 
hypogammaglobulinemia or retractable infection did not occur during this 
interval. Subclinical cytomegalovirus infection did develop sporadically and 
antiviral therapy was performed on such occasions. Two of 12 patients died of 
sepsis and refractory cholangitis at 117 POD and 533 POD, respectively. The 
other 10 recipients are currently alive with a cumulative 3-year survival of 78% 
[range, 101 to 1102 days].
Conclusions: Intra-portal infusion therapy combined with rituximab for 
adult ABO-I LDLT can be safely performed and provides excellent control of 
antibody-mediated rejection with no major morbidities. Long-term prognosis 
has now become comparable with ABO-identical/compatible cases.
COMPLETE HILAR PLATE LOOPING IN THE 268 
LIVING LIVER DONOR PREVENTS RECIPIENT BILIARY 
COMPLICATIONS 
A. Soin, V. Kumaran, R. Kakodkar, N. Mohan, S. Saigal, N. Saraf, S. Nundy
Sir Ganga Ram Hospital
Background: Biliary complications remain a major cause of morbidity after 
living donor liver transplantation (LDLT). The effect of graft hepatic duct(HD) 
isolation by the complete hilar plate looping method on biliary complications 
was assessed in 60 consecutive LDLT recipients.
Methods: The 216 LDLTs performed at our centre until January 2008 were 
divided into 3 groups (A-C) of the fi rst 75, next 81 and the last 60 cases 
according to donor bile duct anatomic exclusion criteria and techniques 
of donor dissection and biliary reconstruction. Donors with >3 ducts were 
excluded in groups A and B but accepted in group C as long as >2 ducts were 
close together. In groups B and C, meticulous attention was paid to inclusion 
of all periductal tissue with the HD in the donor and recipient, avoiding close 
dissection of the ductal confl uence in the donor in pursuit of a single graft HD, 
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and reconstructing segment 5 venous outfl ow in the recipient to prevent peri-
HD venous congestion. In group C, additionally, the complete hilar plate and 
Glissonian sheath around the HD was looped after full parenchymal transection 
and inferior retraction of the portal vein. This thick cover of hilar plate around 
the graft HD(s) kept any multiple ducts together, preserved the peri-HD arterial 
plexus, and prevented their retraction. Single or multiple graft HD to recipient 
HD or jejunal Roux loop anastomoses with fi ne PDS were standard in all 
recipients. All roux anastomoses were stented, and duct-duct were not.
Results: The incidence of bile leak and stricture in groups A to C was 12% 
and 6%; 6% and 3%; and 3% and 2% respectively. None of the patients had 
associated arterial complications. The operative mortality in the three groups 
was 13%, 11% and 5%; while the proportion of biliary complications needing 
surgical correction were 35%, 40% and 0%. The rest were managed by 
endoscopic intervention and/or percutaneous drainage. One patient in group 
A died from biliary sepsis. In the donors, there were no biliary strictures while 
the incidence of bile leak in the 3 groups was 4%, 4% and 3% respectively. Of 
these, 2 patients – 1 each in groups A and B required temporary endobiliary 
stenting and recovered. The rest had cut surface leaks which settled with simple 
drainage.
Conclusion: This new technique of complete hilar plate looping during donor 
surgery signifi cantly reduces recipient biliary complications in LDLT. Most 
complications that do occur are minor, do not result in mortality and can be 
managed by non-surgical methods.
INHIBITION OF MITOCHONDRIAL BIOGENESIS 269 
IN SMALL-FOR-SIZE LIVER GRAFTS
Z. Zhong, H. Rehman, T. Theruvath, J. Lemasters
Medical University of South Carolina, Charleston, SC, USA
Background and aim. Mitochondrial biogenesis is required after partial 
liver transplantation to compensate for increased metabolic burden, replace 
damaged mitochondria, and support liver regeneration. Our previous study 
showed that ATP production decreased markedly in small-for-size liver grafts. 
Poor energetic production caused by failure of mitochondrial biogenesis could 
inhibit recovery of graft function, suppresses liver regeneration, and eventually 
lead to graft failure. This study investigated if mitochondrial biogenesis is 
suppressed in small-for-size grafts, leading to compromised energy supply.
Methods: After harvest, Lewis rat liver grafts were reduced in size to ~50% ex 
vivo, stored in UW solution at 0-1oC for 6 h and then implanted into recipients 
of similar or greater body weight, resulting in a relative graft weight of 50% 
(half-size) or 25% (quarter-size).
Results: Total bilirubin increased slightly after transplantation of full-size 
and half-size grafts but increased ~100-fold in quarter-size (small-for-size) 
grafts. Cell proliferation detected by 5-bromo-2’-deoxyuridine incorporation 
increased from <1% in full-size to 17% in half-size grafts but did not increase 
in quarter-size grafts, indicating poorer function and slower regeneration of 
small-for-size liver grafts. ATP synthase-β (AS-β), a nuclear DNA (nDNA)-
encoded oxidative phosphorylation (OXPHOS) enzyme, protein expression 
decreased after 18 h but recovered to the control levels after 38 h, suggesting 
mitochondrial biogenesis. By contrast, AS-β in quarter-size grafts decreased 
by 65% at 18 h but did not recover after 38 h. Cytochrome c oxidase (COX) 
IV, another nDNA-encoded OXPHOS enzyme, also decreased substantially 
in quarter-size liver grafts at 38 h. Mitochondrial DNA (mtDNA)-encoded 
OXPHOS proteins NADH dehydrogenase-3 and COX II also decreased by 
30% in quarter-size liver grafts (p<0.05). Furthermore, expression of PGC-
1α, a transcriptional coactivator that controls transcription of nDNA-encoded 
OXPHOS proteins, and mtTFA, a nDNA-encoded transcription factor 
that controls mtDNA replication and transcription, decreased markedly in 
small-for-size liver grafts. mtDNA that encodes mitochondrial OXPHOS 
proteins decreased by 30% in quarter-size grafts, indicating compromised 
mitochondrial biogenesis. Alkaline gel Southern blotting also showed 
that mitochondrial DNA underwent single-strand damage in quarter-size 
liver grafts.
In conclusion, mitochondrial biogenesis is inhibited in small-for-size liver 
grafts, most likely due to decreases of signaling molecules PGC-1α and mtTFA 
and damage to mtDNA. Inhibition of mitochondrial biogenesis may contribute, 
at least in part, to compromised energetic status and poorer regeneration and 
graft function after small-for-size liver transplantation (NIDDK).
VANISHING GRAFT SYNDROME IN DUAL LIVING 270 
DONOR LIVER TRANSPLANTATION
G-W. Song, S-G. Lee, S. Hwang, C-S. Ahn, K-H. Kim, D-B. Moon, T-Y. Ha, 
D-H. Jung
Asan Medical Center
Background: Dual living donor liver transplantation (DLDLT) makes up a 
unique situation which cannot be found in other types of LDLT. The atrophy 
of one graft among trnasplanted two grafts without the derangement of liver 
function is one of the unique phenomena which can occur only in DLDLT. 
We called this phenomenon the vanishing graft syndrome (VGS) which was 
defi ned that the graft volume decreased more than the half of original graft 
volume measured at CT volumetry of donor. In this study, we tried to explain 
this pecuilar phenomenon and elucidate the risk factors for graft atrophy.
Patients and methods: All clinicopathological data were collected 
retrospectively. We compared all clinicopathological factors for the analysis of 
host-related and graft-related risk factor for unilateral graft atrophy.
Results: From March 2002 to June 2007, 207 LDLT were performed by dual 
donors. The VGS were observed in 19 cases. The median interval from operation 
to occurrence of VGS was 7.85 months. For the analysis of host-related risk 
factor, we compared MELD, UNOS status, original disease, GRWR, GV/
SLV, intraoperative transfusion requirement, type of graft combination. But we 
could not fi nd out statistically signifi cant relating factor for graft atrophy. In 
7 cases of VGS, antecedent causes for graft atrophy were evident (secondary 
vanishing graft syndrome). Two episodes of biliary stricture, 2 hepatic vein 
outfl ow obstruction (HVOO), 2 portal vein stenosis (PVS), 1 case of unilateral 
acute cellular rejection (ACR) were observed. In 12 cases, there was no defi nite 
antecedent cause for atrophy (primary vanishing graft syndrome). The primary 
VGS was occurred more frequently in left-sided graft (p=0.034) but secondary 
VGS did not show site preference. The portal vein fl ow and regenerative rate 
during 1st postoperative month were signifi cantly low in vanishing graft in 
primary VGS. Graft steatosis, ABO, donor age, graft size or type did not 
infl uence the development of graft atrophy.
Conclusion: In DLDLT, biliary stricture, HVOO, PVS or unilateral ACR can 
cause secondary VGS. And the left-sided graft in DLDLT was more vulnerable 
to primary VGS. In primary VGS, portal vein fl ow to vanishing graft and 
regeneration rate were signifi cantly low.
RIGHT HEPATIC LOBE AND KIDNEY 271 
TRANSPLANTATION FROM THE SAME LIVING DONOR: 5 
CASES INCLUDING 1 ABO-INCOMPATIBLE
S. Gautier, M. Kaabak, O. Tsiroulnikova, E. Kim, A. Semenkov, A. Filin, 
H. Hizroev, A. Ammosov, E. Chekletsova
National Research Center of Surgery
Simultaneous liver/kidney transplantation (SLKT) is rather common procedure 
in cadaveric organ transplantation. In practice of living donor transplantation 
a few cases of left lateral sector and kidney harvesting from one donor were 
described. Since 1997 to 2007 in our center totally 151 living donor right 
hepatic lobe transplantations were performed. In 5 patients (4 male and 1 
female 6 - 18 years old) right hepatic lobe and kidney from the same donor were 
transplanted simultaneously. The indications for SLKT were Caroli disease 
associated with polycystic kidney disease in 3 cases and biliary hypoplasia 
associated with kidney dysplasia in 2 cases. All patients had advanced liver 
cirrhosis and terminal renal failure (hemodialysis in 2 patients and peritoneal 
dialysis in 3 patients). Donors were parents of patients (3 mothers and 
2 fathers 31 - 44 years old). Two donors were ABO-identical to recipients, 
other 2 donors were ABO-compatible and 1 donor was ABO-incompatible. 
The donor’s procedure included right hepatectomy without middle hepatic 
vein and nephrectomy (right in 4 cases and left in 1 case). The procedure in 
recipient included hepatectomy, bilateral nephrectomy, orthotopic implantation 
of right hepatic lobe and heterotopic implantation of kidney into right (3) or 
left (2) fossa iliaca. In all cases after liver graft revascularization the kidney 
graft was implanted and native ureter was used for urinary reconstruction. 
The last step was biliary reconstruction. In 1 case of ABO-incompatibility the 
recipient (6-years old boy with blood group O) received liver and kidney from 
his 34-years old mother with blood group A. During preoperative management 
the initial anti-A antibody level 1/16 was reduced to 1/4 by plasmapheresis. 
All recipients received 3-drug immunosuppressive protocol including anti-
CD25 monoclonal induction, tacrolimus and mycophenolates. All recipients 
are alive with good function of their fi rst grafts. The follow-up is 8 - 54 mo. No 
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signs of rejection were observed including ABO-incompatible case. Neither 
intraoperative complications nor postoperative morbidity were observed in 
donors. All donors returned to their former way of life including engagement in 
sports. Living related SLKT is safe and lifesaving procedure in selected cases.
OLDER AGE AND RIGHT HEPATECTOMY ARE 272 
ASSOCIATED WITH INCREASED RISK OF INTRAOPERATIVE 
COMPLICATIONS DURING DONOR HEPATECTOMY IN 
LIVING-DONOR LIVER TRANSPLANTATION
A. Pirat1, A. Torgay1, S. Balci1, P. Zeyneloglu1, H. Karakayali2, G. Arslan1, 
M. Haberal2
1Baskent University Faculty of Medicine, Department of Anesthesiology, 
2Baskent University Faculty of Medicine, Department of General Surgery
The shortage of available brain-dead organ donors continues to limit deceased-
donor liver transplants. For this reason, living-donor liver transplant (LDLT) is 
now accepted as an established treatment modality in patients with end-stage 
liver disease. However, the major ethical and medical concern during LDLT 
is safety of the healthy donor. Every effort should be made to optimize the 
safety of donor during this procedure. Although several studies have focused 
on the surgical complications in donors of LDLT, there are scant data regarding 
the intraoperative complications that may occur in these patients. The aim of 
this study was to evaluate the predictors of intraoperative complications during 
donor hepatectomy for LDLT.
We reviewed the data of 114 consecutive LDLT patients who underwent 
a lobectomy between May 2002 and February 2007. The data included 
demographic features, intraoperative and postoperative transfusions, amount 
of administered intraoperative crystalloid and colloids, intraoperative 
hemodynamics, preoperative and postoperative laboratory values (renal and 
liver functions), intraoperative and postoperative urine output, and length of 
hospital stay. Intraoperative complications such as hypotension, hypertension, 
arrhythmia, hypoxemia, hypothermia, and need for transfusions were collected 
using anesthesia and patient charts.
Eighty-fi ve (74.6%) of 114 donor lobectomies had at least 1 intraoperative 
complication. The most commonly noted intraoperative complication was 
hypothermia (n=70, 61.4%), followed by hypotension (n=38, 33.3%), need for 
transfusions (n=16, 14%), hypertension (n=4, 4.6%), extravasation of IV fl uids 
into the arm (n=1, 1.1%), and brachial plexus injury (n=1, 1.1%). Patients who 
had an intraoperative complication(s) were older (37.2 &#61617; 9.5 years vs 
30.3 &#61617; 6.6 years P < .001) and had a larger graft volume (679 &#61617; 
255 mL vs 482 &#61617; 203 mL, P < .001) than those who did not have these 
complications. The frequencies of intraoperative complications for right and 
left hepatectomies were 91% and 60% (P < .001). Multivariate logistic analyses 
revealed that only age (OR: 1.1, P = .004) and type of hepatectomy (OR: 5.8, 
P = .002) were independent risk factors for intraoperative complications. All 
patients recovered fully, and the occurrence of intraoperative complications 
had no impact on postoperative recovery and length of hospital stay.
In conclusion, older age and right hepatectomy were associated with an 
increased risk of intraoperative complications during donor hepatectomy in 
our LDLT series. Although these complications were mostly mild and did not 
have a negative impact on the outcomes in these patients, it is imperative to 
undertake all preventive measures to avoid physiological derangements in 
otherwise healthy donors.
LAPAROSCOPIC HEPATECTOMY FOR A MODIFIED 273 
RIGHT GRAFT IN ADULT-TO-ADULT LIVING DONOR LIVER 
TRANSPLANTATION
K-S. Suh, N-J. Yi, J. Kim, W.Y. Shin, H.W. Lee, E-M. Kim, K.U. Lee
Departement of Surgery, Seoul National University College of Medicinen
To our knowledge, this is the fi rst report of a modifi ed right hepatectomy 
preserving the middle hepatic vein (MHV) branches done completely by 
hand-assisted laparoscopic surgery (HALS) under pneumoperitoneum in 
adult-to-adult live donor liver transplantation (LDLT). Two young women 
(24- and 25-year-old) volunteered to be a live donor for their parents who had 
hepatocellular carcinoma. The donors expressed concern about a scar and a HALS 
was performed. Mobilization of the right liver and the hepatic parenchymal 
transection was performed under pneumoperitoneum. Parenchymal transection 
was performed using a laparoscopic ultrasonic aspirator without the Pringle 
maneuver. During parenchymal transection, 3 MHV branches were preserved 
using hem-o-lock clips. The graft was extracted through the site of the hand 
port device. On the back table, the 3 MHV branches were reconstructed using 
an artifi cial vascular graft. The graft was transplanted without any problem. 
The operation time for the donors was 765 and 898 minutes including more 
than 2 hours for wound closure. The donors did not require a transfusion or 
reopertaion; they were discharged on postoperative day (POD) 10 and 14 
with normal liver function. In conclusion, a HALS under pneumoperitoneum 
for a modifi ed right graft was technically feasible. This laparoscopic right 
hepatectomy may be a new therapeutic option and may improve the quality of 
life of donors participating in LDLT.
ADULT-TO-ADULT LIVING DONOR LIVER 274 
TRANSPLANTATION USING EXTENDED RIGHT LOBE LIVER 
GRAFTS
K.H. Kim, S.G. Lee, J.H. Ryu, C.S. Ahn, D.B. Moon, T.Y. Ha, D.H. Jung, 
K.W. Kim, N.K. Choi
Asan Medical Center
Background: Adult-to-adult living donor liver transplantation(AALDLT) 
using extended right lobe grafts has become as an treatment method to solve 
the problem of graft insuffi ciency since Hong Kong group fi rst successfully 
performed for a 90-kg man with fulminant Wilson’s disease in May 1996. 
The authors report their experience with adult-to-adult living donor liver 
transplantation using extended right lobe graft in a single center.
Methods: From March 1998 to December 2007, 1576 AALDLTs were 
performed at the Asan Medical Center. Among them, 23 AALDLTs using 
extended right lobe graft were included in this retrospective study. 3 types 
of techniques for hepatic vein reconstruction have been used to enable the 
suffi cient venous outfl ow drainage of extended right lobe grafts.
Results: There were 18 male and 5 female. The median age of recipients was 
47 years (range, 19-62 years) and median MELD score was 20(range, 9-36). 
Of 21 patients, 13 had HBV related LC, 7 had HBV related LC with HCC, and 
3 had acute liver failure. The median percentage of steatosis was 5%(range, 
0-15%), the median graft weight was 605 gm(range, 400-800 gm) and the 
median GRWR was 0.86%(range, 0.69-1.16%). There were 2 in-hospital 
mortalities caused by sepsis. The median age of donors was 28 yers(range, 
16-39 years). Over the entire hospitalization period of donors, the mean level 
of AST was 171.6¡¾84.8 IU/L, the mean level of ALT was 151.2¡¾61.3 
IU/L, the mean level of PT(INR) was 1.56¡¾0.28, and the mean level of TB 
was 2.85¡¾2.2 mg/dL. There was no donor mortality. As for hepatic vein 
reconstruction in this study, there were 3 types of techniques in the following 
order: 16 quilt venoplasties make ¡°common-large opening¡± using GSV and 
PV of recipient, 4 direct RHV anastomoses and separate reconstructions of 
MHV with interposition vein graft, and 3 separate RHV and MHV anastomoses 
without interposition vein graft. Modifi cation of graft procurement technique 
by preserving S4b hepatic vein was performed in 3 cases.
Conclusions: The extended right lobe graft may provide an alternative option 
to overcome the small-for-size graft in AALDLT if the meticulous donor 
hepatectomy and complete donor selection can be performed for donor safety.
CONCURRENT ORAL SESSION 23: 
LIVER IMMUNOSUPPRESSION
THE INFLUENCE OF INDUCTION THERAPY ON GRAFT 275 
AND PATIENT SURVIVAL IN LIVER TRANSPLANT PATIENTS 
WITH AND WITHOUT HEPATITIS C USING THE UNOS/SRTR 
DATABASE
D. Moonka, D. Kim, A. Kapke, A. Yoshida
Henry Ford Health Systems
Studies to date have reported confl icting results on the effect of induction 
therapy on recurrent hepatitis C (HCV) after orthotopic liver transplantation 
(OLT). We used the United Network for Organ Sharing (UNOS) Scientifi c 
Registry of Transplant Recipients (SRTR) to determine graft and patient 
survival in OLT recipients with HCV who received induction therapy and to 
compare them to HCV patients who did not receive induction and to HCV 
negative patients.
Methods: We identifi ed all patients who received an initial OLT in the SRTR/
UNOS database who had defi ned HCV antibody status. We excluded patients 
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with live donors, multi-organ transplants, HIV, alemtuzumab induction or 
incomplete follow-up. 40,796 patients were divided into 4 groups: HCV 
negative without induction (18.904), HCV negative with induction (3,563), HCV 
positive without induction (15,438) and HCV positive with induction (2,891). 
Induction therapy was defi ned as “induction” dosing with thymoglobulin, 
anti-lymphocyte globulin, OKT3, daclizumab or basiliximab. Groups were 
compared for patient and graft survival using Kaplan-Meier analysis with log 
rank tests. A Cox regression model was used to control for additional variables 
including MELD scores.
Results: Overall, patients who received induction did better than those who 
did not with 5 year survival of 76% vs 73% (p=0.001). HCV pos patients who 
received induction did better than those who did not (71% vs 69%: p=0.008). 
HCV neg patients who received induction also did better than those who did 
not with fi ve year survival of 79% vs 76% (p=0.001). Five year graft survival 
was better in all patients who received induction than those who did not (70% 
vs 67%: p<0.0001) and 5 year graft survival was better in HCV pos patients 
who received induction vs those who did not (65% vs 62%: p<0.0001). On 
multivariable Cox regression analysis, the following factors infl uenced patient 
survival in HCV pos patients: African-American race (Hazard Ratio (HR) =1.38: 
P<0.0001), recipient age by 10 year increments (HR=1.23: P<0.0001), donor 
age by 10 year increment (HR=1.15: P<0.0001), MELD score at transplant 
(HR=1.02: P<0.0001) and induction (HR=0.88: P=0.038). On multivariate 
analysis, induction was also associated with favorable graft survival in HCV 
pos patients (HR=0.86: p=0.004).
Patient Survival by HCV/Induction Status
1 year estimates 3 year estimates 5 year estimates
HCV/Induction Survival Probability 95% CI
Survival 
Probability 95% CI
Survival 
Probability 95% CI
HCV neg, No Ind 0.875 0.870, 0.879 0.816 0.809, 0.821 0.765 0.758, 0.772
HCV neg, Ind 0.896 0.885, 0.906 0.841 0.822, 0.851 0.787 0.769, 0.803
HCV pos, No Ind 0.868 0.862, 0.874 0.765 0.758, 0.773 0.690 0.681, 0.699
HCV pos, Ind 0.879 0.866, 0.891 0.790 0.768, 0.804 0.712 0.690, 0.734
*Log-rank test: p<.0001
Conclusion: Using the SRTR/UNOS database, induction dosing was associated 
with at least equivalent patient and graft survival in all patients and in those who 
were HCV positive. On multivariate analysis, induction dosing was associated 
with improved patient and graft outcomes in all liver transplant recipients and 
in HCV positive patients.
SPARE-THE-NEPHRON (STN) TRIAL IN LIVER 276 
TRANSPLANT RECIPIENTS: INTERIM EFFICACY AND 
SAFETY OF MYCOPHENOLATE MOFETIL (MMF)/SIROLIMUS 
(SRL) MAINTENANCE THERAPY AFTER CNI WITHDRAWAL
D. Moonka1, L. Teperman2, L. Sher3, P. Marotta4, A. Sebastian5, B. Koneru6, 
D. Patel7, G. Klintmalm8
1Henry Ford Transplant Institute, 2New York University, 3University of 
Southern California, 4London Health Sciences Hospital, 5Integris Baptist 
Medical Center, 6Univ. of Medicine and Denistry, NJ, 7Roche, 8Baylor Medical 
Center
Purpose: To compare the effi cacy and safety of maintenance immunosuppression 
with MMF and SRL to that of MMF and a CNI in liver allograft recipients. 
Methods: Prospective, randomized open-label, controlled multicenter study, 
294 patients who were maintained on MMF and a CNI were randomized 
30-90 days after transplantation to receive MMF (1-1.5 g BID) plus SRL (2-4 
mg/day; trough 5-10 ng/mL) and discontinue the CNI (MMF/SRL group) or 
continue their current regimen (MMF/CNI group). Antibody induction and/
or corticosteroids were administered according to individual center practice. 
Primary effi cacy variables included the percent of patients with biopsy-proven 
acute rejection (BPAR), graft loss, and death, and mean percent change in 
calculated glomerular fi ltration rate (GFR; MDRD-6 equation) at month 12. 
BPAR was assessed by Banff grade and Rejection Activity Index (RAI). Safety 
outcomes included incidence of adverse events, malignancies, and opportunistic 
infections at months 12 and 24.
Results: Interim 12-month data from 276 patients (MMF/SRL, n=139; MMF/
CNI, n=137) were analyzed; baseline characteristics were similar between 
groups. Mean time from transplant to randomization was 54 days in the MMF/
SRL and 52 days in the MMF/CNI groups.
Outcomes, n (%) MMF/SRL MMF/CNI
Mean GFR increase, baseline to month 12,%(n) 22.1% (52) 5.2% (59)
Patient survival to date 137 (99%) 132 (96%)
Graft survival to date 137 (99%) 132 (96%)
Withdrew from study 51 (35%) 27 (18%)
BPAR GradeII and RAI4 15 (11%)* 4 (3%)
BPAR Grade=I or RAI<4 13 (9%) 11 (8%)
* Includes 1 severe BPAR
Withdrawals in the MMF/SRL group vs the MMF/CNI group were primarily 
due to skin connective tissue disorders (rash, ulcers, etc) 19 (14%) vs 0%, 
leucopenia 7 (5%) vs 5 (3%), GI disorders 7 (5%) vs 5 (3%), and infections 
5(3%) vs 4 (3%).
Conclusions: MMF/SRL appears to improve renal function at 1 year compared 
to MMF/CNI-containing regimens but with more frequent rejections and more 
patient withdrawals. Final results will identify the target patients in whom 
stopping the CNI regimen may be feasible for improvement of renal function.
HEPATITIS C (HCV)- 3 STUDY: DOES 277 
IMMUNOSUPPRESSION (IS) AFFECT HCV RECURRENCE 
(HCVR) PROGRESSION AFTER LIVER TRANSPLANTATION 
(OLT)?
G. Klintmalm1, C. Fasola2, L. Jennings1, Hepatitis C Study Group3
1Baylor University Medical Center, 2Emory University, 3Multicenter (n = 18)
Aims: To assess the effi cacy and safety of a steroid (Pred)-free IS regimen of 
daclizumab (DAC), tacrolimus (TAC) and mycophenolate mofetil (MMF) to 
minimize acute rejection (ACR), HCVR and adverse events post OLT. 
Methods: Open-label, prospective, multicenter study (n=18) on 312 adult HCV 
(+) recipients randomized (1:1:2) to 3 IS arms. Liver tests and histology were 
done on clinical or protocol (days 90, 365, 730) basis. ACR graded according 
to Banff schema and HCVR staged according to Batts-Ludwig classifi cations. 
Main endpoints: ACR (Grade ≥2 + RAI ≥4) and/or HCVR (Stage ≥2 or Grade 
≥3). Signifi cant statistics: p ≤0.05.
Results: Arm 1 (n=80): TAC + Pred; Arm 2 (n=79): TAC + Pred + MMF; Arm 
3 (n=153): DAC (days 1, 3 and 8) + TAC + MMF. All data (intention to treat 
[ITT]; central pathologist) reported at 2 years in Arm 1, 2 and 3 respectively. 
Graft and patient survivals were: 79%, 78%, 84% (NS)- 83%, 81% and 87% 
(NS). ACR-free rates: 86%, 87% and 86% (NS). HCVR-free rates: 33%, 27% 
and 34% (NS). Arm analysis showed severe HCVR (stage ≥3) in 33%, 28% 
and 19% (p=0.08). Severe accelerated HCVR noted between years 1-2 in Arms 
1 and 2. On patients with no HCVR in year 1, freedom of stage ≥3 at year 2 
was: 75%, 85% and 93% (graph, p<0.01). Differences persist for Arms 1 + 2 
(steroids) vs. 3 (no-steroids): 75% vs. 93% (p<0.01) and for Arms 1 (no-MMF) 
vs. 2 + 3 (MMF): 80% vs. 93% (p<0.01). Although not signifi cant (p ≤ 0.2), 
similar results noted in other analyses (ITT/local path; per protocol/central or 
local path). Similar HCV-RNA levels in all arms.
Conclusions: During this 2-year follow up period, this report suggests no 
differences across arms in the incidence of HCVR. However once HCVR has 
occurred, the rate of fi brosis progression is signifi cantly lesser for recipients on 
MMF or on the steroid-free regimens. Longer-term follow-up is indispensable 
to confi rm these initial fi ndings.
Year 2 Freedom from Severe HCV Recurrence (Stage≥3) ITT/Central *
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A RANDOMIZED, OPEN-LABEL, COMPARATIVE 278 
EVALUATION OF CONVERSION FROM CALCINEURIN 
INHIBITORS TO SIROLIMUS VERSUS CONTINUED USE 
OF CALCINEURIN INHIBITORS IN LIVER ALLOGRAFT 
RECIPIENTS
M.F. Abdelmalek1, A. Humar2, F. Stickel3, C-M. Lo4, P. Andreone5, 
R. Firpi-Morell1, E.S. Maller6, for the Sirolimus Liver Conversion Trial Study 
Group
1University of Florida, Gainesville, FL, 2University of Minnesota, 
Minneapolis, MN, 3Hospital of the University of Bern, Bern, Switzerland, 
4Queen Mary Hospital, Hong Kong, 5University of Bologna, Bologna, Italy, 
6Wyeth Research, Collegeville, PA
Sirolimus (SRL) is a potent inhibitor of cell-cycle progression that represents 
a potential alternative to long-term calcineurin inhibitor (CNI)-based 
immunosuppression in liver allograft recipients. A prospective, open-label, 
comparative clinical trial was conducted to evaluate the safety and effi cacy 
of conversion of maintenance liver transplant patients from CNI- to SRL-
based immunosuppression. Patients were randomly assigned (2:1) to undergo 
abrupt conversion (<24 hours) from cyclosporine (CsA) or tacrolimus (TAC) 
to SRL, or to continue CNI for up to 6 years. The co-primary endpoints, both 
assessed at 52 weeks after randomization, are baseline-adjusted, calculated 
GFR (Cockcroft-Gault formula), and the cumulative rate of graft loss or 
death. Eligible patients had received living or deceased donor liver allografts 6 
to 144 months previously and had been treated with CsA or TAC since the early 
posttransplant period. Randomization was stratifi ed based on hepatitis C (HCV) 
infection status and use of antimetabolite (either azathioprine or mycophenolate 
mofetil) within 30 days before randomization. Baseline biopsies were required 
for eligibility within 6 months of randomization for all HCV-positive subjects, 
to rule out ongoing rejection, and for HCV-negative or HCV-positive subjects 
with any lab abnormality in liver function >2X upper limit of normal within 
3 months of randomization. A total of 607 patients were randomly assigned 
over 4 years: 393 to SRL conversion (SRLC) and 214 to CNI continuation 
(CNIC). Demographic characteristics are presented in the table; no signifi cant 
differences were observed between cohorts.
Demographic Characteristics of Patient Population
SRLC (n=393) CNIC (n=214)
HCV positive by PCR, n (%) 46 (12) 27 (13)
Antimetabolite therapy, n (%) 151 (38) 88 (41)
Mean time from transplant to randomization, years 4.0 4.0
*Mean age, years 55.4 54.7
*Sex, male, n (%) 269 (69) 146 (70)
*Ethnicity,% Black
 White
 Other 
 5
80
15
 3
80
17
*Calculations based on safety population: SRLC, n=389; CNIC, n=210.
This is the largest prospective, randomized clinical trial of conversion from 
CNI- to SRL-based immunosuppression yet conducted in liver allograft 
recipients. The last randomized patient reached the week 52 primary endpoint 
visit in November 2007. Aggregate safety and effi cacy data will be available in 
time for presentation in May 2008.
STEROID-FREE IMMUNOSUPPRESSION IN LIVER 279 
RECIPIENTS COMPARING TACROLIMUS MONOTHERAPY 
AFTER DACLIZUMAB INDUCTION VERSUS TACROLIMUS 
AND MMF – THE MARSILEA STUDY
G. Otto1, T. Becker2, I. Bilbao3, D. D’Amico4, M. Colledan5, A. Bernardos6, 
C.E. Broelsch7, H. Isoniemi8, J. Pirenne9, J. Jaray10
1Universitätsklinikum Mainz, 2Medizinische Hochschule, 3Hospital Vall 
d’Hebron, 4Azienda Ospedaliera di Padova, 5Azienda Ospedaliera Spedali 
Riuniti, 6Hospital Virgen del Rocio, 7Universitätsklinikum Essen, 8Helsinki 
University Central Hospital, 9UZ Gasthuisberg, 10Semmelweis University of 
Medicine
Introduction: Liver recipients treated with tacrolimus monotherapy after 
daclizumab induction (TAC+DAC) experience less diabetes and fewer steroid-
resistant acute rejections compared with standard TAC + steroid dual therapy 
(MASTER study; Liver Transpl 2005;11:61). The objectives of the present 
3-month study were to evaluate the safety and effi cacy of a novel TAC+MMF 
steroid-free dual therapy compared with TAC+DAC.
Methods: A total of 602 patients received TAC+DAC (N=305) or TAC+MMF 
(N=297) at an initial daily TAC dose of 0.15 mg/kg. Both groups received 
a single peri-operative 500 mg steroid dose. DAC was administered in two 
doses at 2 mg/kg IV on Day 0 and at 1 mg/kg IV Days 7-10 to TAC+DAC 
patients. MMF was given at 2 g/day to Day 14 and thereafter at 1 g/day in 
TAC+MMF patients. Target TAC trough levels were 10-15 ng/ml up to Day 
42 and then <10 ng/ml. The primary endpoint at 3 months was incidence 
and time of fi rst biopsy proven acute rejection (BPAR) requiring treatment 
(superiority shown if treatment difference p<0.05). Secondary endpoints 
included: patient/graft survival, creatinine clearance (Cockcroft and Gault) 
and adverse events.
Results: Demographics were similar with 220/305 (72.1%) TAC+DAC 
and 204/297 (68.7%) TAC+MMF patients completing the 3-month study. 
Withdrawals were mostly for adverse events (14.8% vs. 15.5% patients). TAC 
dosing and exposure were comparable across the groups and within the targeted 
window. For patients completing the study, <6% patients required steroids 
in each arm. The overall estimated rate of patients free from biopsy proven 
acute rejection was not signifi cantly different: 77.9% TAC+DAC vs. 81.3% 
TAC+MMF. The incidence of BPAR requiring treatment (primary endpoint) 
was 16.4% vs. 15.5% (ns), steroid-resistant BPAR was 3.9% vs. 2.0% (ns) 
and patient/graft Kaplan-Meier survival estimates were 91.8%/88.2% vs. 
91.6%/87.8%. Mean calculated creatinine clearance for study completers 
at Month 3 was 66.6 mL/min TAC+DAC vs. 69.7 mL/min TAC+MMF. 
In patients not diabetic prior to transplant, 18/221 (8.1%) TAC+DAC vs. 
21/227 (9.3%) TAC+MMF patients required antidiabetic medication for >30 
consecutive days.
Conclusions: Tacrolimus and MMF dual therapy allows for avoidance of 
concomitant steroids. The regimen was as effi cacious as tacrolimus following 
daclizumab induction. Both steroid-free regimens resulted in low rates of acute 
rejection and were well tolerated.
BENEFIT OF MYCOPHENOLATE MOFETIL, DELAYED 280 
AND REDUCED TACROLIMUS AND DACLIZUMAB IN DE 
NOVO LIVER TRANSPLANTATION – RESULTS FROM THE 
PER PROTOCOL POPULATION AT 12 MONTHS
A.D. Mayer, J. Neuberger
Queen Elizabeth Hospital
Introduction: In the prospective ReSpECT study, primary liver transplant 
patients were randomised to: A) standard-dose tacrolimus (target trough level 
>10 ng/ml) for the 1st month; B) 2 g mycophenolate mofetil (MMF) + reduced-
dose tacrolimus (target trough level ¡Ü8 ng/ml); or C) 2 g MMF + reduced-
dose tacrolimus introduced on day 5 + daclizumab on days 1 and 7. Steroids 
were given in all groups according to local protocol. Results from the intent-to-
treat (ITT) population at 1 year showed that 2 g MMF + delayed and reduced 
tacrolimus + daclizumab was associated with signifi cantly less impairment of 
renal function compared with standard-dose tacrolimus. Here we present the 
results of the per protocol (PP) population.
Methods: The PP population was defi ned prior to the sub-group analysis. It 
consisted of patients from the full analysis set (FAS) who had no inclusion/
exclusion criteria violation, had at least one calculated creatinine clearance 
(CrCl) value beyond 6 months, were treated according to the protocol, and did 
not receive any prohibited medication during the fi rst 14 days or for more than 
1 week at any time during the study. A composite endpoint comprising freedom 
from renal dysfunction (¡Ý20% decrease from baseline in calculated CrCl), 
acute rejection, graft loss or death was also investigated.
Results: The PP population included 69, 67 and 67 patients in Groups A, B 
and C, respectively, compared with 181, 168 and 168 patients in the FAS. The 
mean difference in calculated CrCl from baseline to 1 year was signifi cantly 
smaller in Group C compared with Group A (-10.7 ml/min vs -22.0 ml/min, 
p = 0.038), but was not signifi cantly different between Groups A and B 
(-20.50 ml/min). The number of patients receiving dialysis during the study 
was similar in the three groups (8.7, 6.0 and 7.5% in groups A, B and C, 
respectively). The incidence of biopsy-proven or presumed acute rejection at 
1 year was signifi cantly lower in Group C compared with Group A (9.0% vs 
36.2%, p <0.001), but was not signifi cantly different between Groups A and B 
(25.4%). Death (n = 2, 0, 1) and graft loss (n = 1, 0, 0) occurred infrequently 
in all three groups. The incidence of the composite endpoint at 1 year was 
also signifi cantly lower in Group C compared with Group A (70% vs 93%, p 
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< 0.0001) or group B (85%, p = 0.001).
Conclusions: The results from the PP population confi rm those from the ITT 
population that 2 g MMF + delayed and reduced tacrolimus + daclizumab is 
associated with less impairment of renal function compared with standard 
tacrolimus treatment. Graft and patient survival at 1 year were not affected. 
Furthermore, in the PP population, a signifi cant reduction in the rate of acute 
rejection was observed, further demonstrating the benefi ts of a 2 g MMF + 
delayed, low-dose tacrolimus regimen.
EVEROLIMUS IS EFFECTIVE AND SAFE IN A SIX-281 
MONTH, RANDOMIZED, MULTICENTER CONVERSION 
TRIAL IN MAINTENANCE LIVER TRANSPLANT RECIPIENTS
H.J. Metselaar1, F. Nevens2, M. Sterneck3, J. Dumortier4, L. Rostaing5, 
E. Giostra6, E. Varo7, P. De Simone8
1Erasmus Medical Center, Rotterdam, Netherlands, 2University Ziekenhuis 
Gasthuisberg, Leuven, Belgium, 3Uniklinikum Hamburg-Eppendorf, 
Hamburg, Germany, 4Hôpital Edouard Herriot, Lyon, France, 5CHU 
Rangueil, Toulouse, France, 6Hôpital Cantonal, Geneva, Switzerland, 
7Hospital Clinico Universitario Santiago de Compostela, Santiago de 
Compostela, Spain, 8Liver Transplant Unit, Pisa, Italy
Renal dysfunction is the most common complication in liver transplant 
recipients. Almost one in fi ve recipients develops chronic renal failure or end-
stage renal disease in the fi rst fi ve years post-transplant. Long-term treatment 
with calcineurin inhibitors (CNIs) can lead to nephrotoxicity and declining renal 
function in maintenance liver transplant patients. Everolimus, a proliferation 
signal inhibitor, facilitates CNI elimination or CNI reduction that may lead to 
improved renal function.
Methods: A multicenter, open-label, randomized, two-arm study was carried 
out in maintenance liver transplant patients. The trial was of 6 months’ 
duration, with a 6-month extension period. Patients were included if they had 
CNI-related renal impairment defi ned as creatinine clearance (CrCl) ≥20mL/
min and ≤60mL/min. Patients randomized to the control arm continued to 
receive standard-dose CNI (cyclosporine or tacrolimus) ± mycophenolic acid 
± corticosteroids. Patients randomized to everolimus either discontinued 
CNI therapy or switched to reduced-dose CNI + everolimus (target C0 range 
3-8ng/mL) ± corticosteroids. The primary endpoint was a between-group 
difference of 8mL/min in the change in CrCl (Cockcroft-Gault) from baseline 
to month 6. 
Results: In total, 145 patients (72 everolimus, 73 controls) were randomized. 
At month 6, 80% of patients receiving everolimus had discontinued CNI 
entirely. The mean change in CrCl from baseline to month 6 did not differ 
signifi cantly between groups (everolimus 1.0±10.2mL/min, controls 
2.3±7.8mL/min; p=0.463 [last observation carried forward method]). Among 
the 111 patients who remained on-treatment, the median change in CrCl 
from baseline to month 6 was numerically greater with everolimus (3.9mL/
min) compared to control patients (2.8mL/min). The small difference in 
CrCl at month 6 was infl uenced by (a) a higher-than-anticipated rate of 
CNI dose reductions in the control group (77% of patients received a dose 
reduction and 26% had a dose reduction of >25%, against protocol) and (b) 
the relatively long time post-transplant (mean >3 years). The rate of biopsy-
proven acute rejection was identical in both groups (1.4%) and there were 
no graft losses. The safety profi le of everolimus was consistent with that 
reported in previous studies.
Conclusion. In the majority of maintenance liver transplant patients included in 
this study, CNI discontinuation could be achieved after conversion to everolimus 
without compromising effi cacy. In patients who were treated with study drug for 
6 months (on-treatment patients), the improvement in renal function (CrCl) was 
greater with everolimus than in controls. CNI reductions were more frequent and 
larger than anticipated in control patients, and the mean time post-transplant was 
>3 years, factors that may have contributed to not meeting the primary endpoint. 
Earlier intervention with everolimus to avoid CNI-related deterioration of renal 
function is being investigated in follow-up studies.
STRATEGY FOR TAILORING MINIMAL 282 
IMMUNOSURPPRESSION AFTER LIVING DONOR LIVER 
TRANSPLANTATION: PREDICTIVE ALGORITHM BASED 
ON MULTIPARAMETER MIXED LYMPHOCYTE REACTION 
ASSAY USING CFSE-LABELING TECHNIQUE
Y. Tanaka, H. Tashiro, K. Ishiyama, T. Asahara, H. Ohdan
Hiroshima University
Background: Although liver allografts are considered immunologically 
privileged, no reliable immunological parameters exist for identifying patients in 
whom immunosuppressants can be safely withdrawn. For minimizing/weaning 
maintenance immunosuppressants, we established an algorithm determining 
anti-donor alloreactivity based on multiparameter mixed lymphocyte reaction 
(MLR) assay, wherein the number and phenotype of alloreactive precursors can 
be quantifi ed by combining CFSE-labeling and FCM analyses.
Methods: We enrolled 68 adults undergoing living donor liver transplantation 
(LT). The initial immunosuppressive regimen comprised tacrolimus/
cyclosporine and methylprednisolone, which were gradually tapered off by 
6 months after LT. Thereafter, therapeutic adjustments were determined by a 
policy of slow tapering off in the case of completely normal liver function. 
MLR assay was performed at 3–6 month intervals to monitor immune status. 
In this assay, CFSE-labeled PBMCs from recipients were used as responders. 
Irradiated autologous, donor, and third-party PBMCs were used as stimulators. 
After coculture, the responder cells were stained with CD4 or CD8 mAbs along 
with CD25 mAb, followed by FCM analyses. Divisions of reactive cells, which 
were identifi ed and determined by their CFSE intensities, were labeled from 
0 to n as dividing time. The number of division precursors was extrapolated 
from the number of daughter cells of each division and from proliferation 
events and precursor frequency in CD4+ and CD8+ T-cell subsets. With use 
of these values, proliferation events and proliferation index were calculated. 
Stimulation index was calculated by dividing proliferation index of allogeneic 
combinations by those of self-control.
Results: The simulation indexes in each CD4+ and CD8+ T-cell subsets and 
CD25 expression on proliferating CD8+ T cells in response to anti-donor 
and anti-third-party stimuli were analyzed using MLR; the immune status 
of LT patients was categorized as hypo-response, norm-response, or hyper-
response for CD4+ T cells and as hyper-response for CD8+ T cells. Of the 68 
patients, 33 had normal liver function at >6 months after LT. We examined the 
fl uctuation of immunosuppressants at 6 months after MLR in these patients. In 
patients whose immune status was categorized as hyper-response for CD4+ or 
CD8+ T cells (n = 4), immunosuppressants could not be reduced and instead 
had to be increased. In patients with norm-response immune status (n = 7), 
immunosuppressant tapering was abandoned. Immunosuppressant therapy was 
successfully tapered off in patients with hypo-response immune status (n = 
22). Of 10 patients with hypo-response immune status at >3 years after LT, 
immunosuppressants were completely discontinued in 3. Despite anti-donor 
hypo-response in CD4+ T cells in these “operational tolerance” patients, the 
precursor frequency of anti-donor CD4+ T cells (mean = 5.2 ± 1.9%) was not 
reduced compared to that in non-tolerance patients, suggesting that donor-
specifi c immune tolerance is maintained via inhibitory/suppressive mechanisms 
rather than via clonal deletion.
Conclusion: Algorithm based on multiparameter MLR assay can provide 
a clinically validated rule predicting the success of tailoring/weaning 
immunosuppression.
TACROLIMUS MONOTHERAPY IN LIVER 283 
TRANSPLANTATION: ONE-YEAR RESULTS OF 
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND PLACEBO-
CONTROLLED STUDY
J. Lerut
St-Luc University Hospital
Background: Minimal immunosuppression (IS) is desirable in organ 
transplantation in order to reduce side effects and to promote the process of 
tolerance induction.
Material and methods: Between February 2000 and September 2004, 
156 adults (> 15 yrs old) receiving a primary liver graft were enrolled in a 
prospective, randomized, double-blind, placebo-controlled, investigator-driven 
single-centre study comparing tacrolimus (TAC)-placebo(PL) and TAC – low-
dose, short-term (64 days) steroid(ST) IS. All patients had a 12 month follow-
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up (range 12–84).
Results: By day 7, 3 and 12 months, rejection treatment had been given in 
3.8%, 17.9% and 21.8% (16 patients) of TAC-PL patients, respectively, and 
1%, 10.5% and 17.9% (14 patients) of TAC-ST patients (ns). The total number 
of patients treated at 3 .(16pts-20.5% vs 10pts -12.5%)and 12 (18 pts-23% 
vs 15pts-19.2%) months was not signifi cantly different between the TAC-PL 
and TAC-ST groups. Corticosteroid-resistant rejection at 3 and 12 months was 
recorded in 12.8% (10pts) of TAC-PL patients and 3.8% (3pts) of TAC-ST 
patients (p 0.04). Vanishing bile duct syndrome was diagnosed in one (1.2%) 
TAC-PL patient and four (5.1%) of the TAC-ST patients (ns).
Three- and 12-month patient survival rates were 93.6% and 85.9%, respectively, 
in the TAC-PL group and 98.7% and 93.6% in TAC-ST group. Three and twelve 
month graft survival rates were 92.3% and 83.3% vs. 97.4% and 92.3% (ns).
By one year, 78.2% of TAC-PL patients and 82% of TAC-ST patients were 
on TAC monotherapy. When considering the 67 TAC-PL and 74 TAC-ST 
survivors, these rates of monotherapy were 91% (61 pts) and 86.5% (64pts), 
respectively (ns). At one year, 53.7% (36/67 pts) of TAC-PL survivors and 
56.8% (42/74 pts) of TAC-ST survivors were on low-dosage (< 6ng/ml) TAC 
monotherapy (ns).
Conclusion: Although more corticosteroid-resistant rejections were noted in 
the Tacrolimus-Placebo group, these events did not infl uence graft nor patient 
survival. Tacrolimus monotherapy can be achieved safely in primary adult 
liver transplantation. Such strategy should lay the basis for further large scale 
minimization studies in liver transplantation.
CONCURRENT ORAL SESSION 24: 
POST TRANSPLANT MALIGNANCY
IMMUNOSUPPRESSION FOR PRIMARY RENAL 284 
DISEASE AND THE RISK OF CANCER IN SUBSEQUENT 
RENAL TRANSPLANTATION
A.D. Hibberd1, P.R. Trevillian1, J.H. Wlodarczyk2, A.M. Stein1, 
A.H.B. Gillies3, M.K. Heer1, A.G.R. Sheil4
1Newcastle Transplant Unit, John Hunter Hospital and Faculty of Medicine, 
University of Newcastle, Newcastle, Australia, 2Biostatistics Consulting 
Service, New Lambton, Newcastle, Australia, 3Department of Nephrology, 
John Hunter Hospital and Faculty of Medicine, University of Newcastle 
Newcastle, Australia, 4National Liver Transplantation Unit, Royal Prince 
Alfred Hospital, Sydney, Australia
Background: The aim of this study was to determine whether immunosuppressive 
agents used to treat primary renal disease contributed to the risk of de novo 
cancer after renal transplantation. The use of immunosuppressive agents after 
transplantation and some viral infections are the two major risk factors for 
cancer after transplantation.
Methods: This population based study consisted of 7953 renal transplant 
recipients who received 9460 transplants between 1965 and 1990. The follow 
up was 40 years. All data were derived from the Australian and New Zealand 
Dialysis and Transplant Registry. The effects of these factors upon the risks 
of developing either non-Hodgkin’s lymphoma (NHL) or carcinoma of the 
cervix, vagina and vulva (CCVV)in subsequent renal transplantation were 
determined by multivariate analyses: immunosuppression for primary renal 
disease; primary glomerular disease; the use of anti-thymocyte globulin (ATG) 
or anti-T cell monoclonal antibodies (OKT3); year of transplant; recipient age 
at transplant; the use of cyclosporin A (CsA), azathioprine or prednisolone; 
dialysis and sex. Proportional hazards regression models including the family 
of study factors were used to estimate hazard ratios (95% CI’s) for each factor. 
A stepwise backwards elimination method was used to choose study factors 
to be included in the multivariate analyses. All analyses were done using 
Statistical Analysis Software.
Results: The incidence of NHL was 165/7953 (2.07%) and the incidence 
of CCVV was 94/3374 (2.79%). For immunosuppression for primary renal 
disease the risk of NHL was 1.88([95% CI 1.23 to 2.88]; p=0.003) and the risk 
of CCVV was 2.26([95% CI 1.30 to 3.92]; p=0.003). For primary glomerular 
disease the risk of NHL was 1.45([95% CI 1.06 to 1.96]; p=0.01) and the risk 
of CCVV was 1.725([95% CI 1.15 to 2.59]; p=0.009). With respect to recipient 
age at transplant the risk of NHL was reduced to 0.49([95% CI 0.23 to 1.06]; 
p=0.07) for recipient age between 30 and 40 years but the risk of CCVV was 
increased to 5.1 ([95% CI 2.17 to 11.97]; p=0.0002) for recipients aged up to 
30 years. In the presence of other immunosuppression after transplantation the 
use of azathioprine or prednisolone reduced the risks of either cancer (p<0.001 
for all four comparisons) and CsA reduced the risk of CCVV to 0.93([95% CI 
0.89 to 0.96]; p<0.0001) but not NHL which was 0.98([95% CI 0.96 to 1.00]; 
p=0.13). Neither dialysis nor ATG had a signifi cant effect on the risk of either 
cancer. Transplantation before 1984 reduced the risk of NHL to 0.49 ([95% CI 
0.35 to 0.68]; p<0.0001) but had no signifi cant effect upon the risk of CCVV 
which was 0.82 ([95% CI 0.54 to 1.26]; p=0.36).
Conclusions: The study provides evidence that the use of immunosuppressive 
agents to treat primary renal disease before renal transplantation 
independently increased the risks of NHL and CCVV during subsequent renal 
transplantation:this is the fi rst population based study to report this association. 
The presence of primary glomerular disease causing renal failure also seemed 
to increase the risks of both cancers. The risk of CCVV is also strongly related 
to the recipient age at transplant.
IMMUNOSUPPRESSION IS A RISK FACTOR FOR 285 
URINARY TRACT CANCERS IN RENAL TRANSPLANT 
RECIPIENTS
A.T.H. Goh, Y.M. Lu, A. Vathsala
Department of Renal Medicine, Singapore General Hospital
Urinary tract carcinoma (UTC) occurs at a higher incidence in renal transplant 
recipients (RTX). Increasing use of abdominal ultrasonography (US) permits 
early diagnosis and intervention for UTC. Although postulated risk factors 
for UTC include acquired cystic kidney disease and duration of dialysis, the 
role of immunosuppression on UTC development post-transplant has not been 
examined. This study examined duration of dialysis, development of native 
renal cysts (NRC), duration of follow-up and immunosuppression used post-
transplant, and correlated these to the occurrence of UTC. Type and amount of 
immunosuppression administered was quantifi ed using an Immunosuppression 
Scale (IS), which accorded points for each immunosuppressant per year of 
use: (Azathioprine-1, Cyclosporine-2, Tacrolimus-2.5, Mycophenolate-2, 
mTOR inhibitors-2), or per treatment course: (IL2 receptor antagonists-5, 
Antilymphocyte preparations-10).
1,118 RTX (55.3% Male, 83.7% Chinese, 69.4% deceased donor), on follow-
up at our centre for at least 6 months between January 1995 and July 2007, 
were reviewed. RTX underwent US of native and transplant kidneys within 
1-month, then 5 yearly post-transplant (2-yearly for those with renal cysts). 
26 (2.3%) with underlying polycystic kidney disease and 63 RTX (5.6%) who 
did not undergo US or had undergone native nephrectomy, were excluded from 
subsequent analysis. Suspicious lesions were further investigated, and treated 
appropriately. With screening, 14 UTC (13 asymptomatic, 10 native renal cell 
carcinoma (RCC), 4 transitional cell carcinoma (TCC)), were diagnosed at a 
median interval of 5.8 years post-transplant, representing a 144-fold incidence 
of UTC above the general population. 5-year patient survivals for RCC in RTX 
vs. the general population were comparable (100% vs. 94%).
RTX were stratifi ed into 3 groups: those with no cysts (No-NRC), pre-existing 
cysts (Pre-NRC) and new native renal cysts (New-NRC). In comparison to No-
NRC, RTX with Pre-NRC had a signifi cantly longer duration of dialysis and shorter 
duration of follow-up post-transplant, but nonetheless a 6.7-fold higher risk of 
RCC. Furthermore, exposure to more potent immunosuppression was signifi cantly 
higher for Pre-NRC. Of note was the signifi cantly higher duration of follow-up 
post-transplant and the higher incidence of RCC in New-NRC vs. No-NRC.
Incidence and Risk Factors for RCC in Study Population
No-NRC New-NRC Pre-NRC
Number of RTX 388 (34.7%) 184 (16.5%) 457 (40.9%)
Number with RCC 1 (0.26%) 1 (0.54%)d 8 (1.75%)a
Dialysis Duration, yearse 2.5+2.7 3.0+2.6 5.0+3.9b, a, c
Follow up post-transplant, yearse 10.1+5.6 12.1+5.2d 7.7+5.6b, a, c, d
IS per yeare 3.5+2.2 3.3+2.8c 3.9+2.3b, a, c
a Pre-NRC vs. No-NRC, p<0.05, b p<0.05 (ANOVA), c Pre-NRC vs. New-NRC, p<0.05,
d New-NRC vs. No-NRC, p=0.000, e Mean+standard deviation.
These results demonstrate a strong association between duration of dialysis 
with occurrence of renal cysts and the subsequent development of RCC upon 
exposure to more potent immunosuppression following renal transplantation. 
NRC development appears not to be arrested despite transplantation, as new 
cysts continue to appear post-transplant and may predispose to the later 
development of UTC. These results advocate for early and regular screening 
for NRC in RTX so as to allow early detection and treatment of UTC in this 
high-risk population.
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QUANTITATING THE EFFECT OF 286 
IMMUNOSUPPRESSION ON THE BIOLOGIC BEHAVIOR OF 
CANCER
Y. Miao, J.J. Everly, R.R. Alloway, T.G. Gross, M.R. First, A. Tevar, 
C. Muthiah, M.J Everly, A. Webster, E.S. Woodle
Department of Transplantation, University of Cincinnati, OH
Background: Epidemiologic studies have established that transplant (TX) 
recipients are at increased risk of malignancy. However, the infl uence 
of immunosuppression (IS) on the biologic behavior of post transplant 
malignancies has not been rigorously defi ned by substantive epidemiologic 
data. The purpose of this study was to examine the infl uence of IS on the 
biologic behavior of specifi c cancers by comparing stage-stratifi ed disease-
specifi c survival (DSS) for specifi c cancers in transplant recipients and the 
general population.
Methods: Data for de novo Renal Cell Cancer (RCC), Malignant Melanoma 
(MM), Non-Small Cell Lung Cancer (NSCLC), and Colon Cancer (CC) in 
transplant recipients [from the Israel Penn International Transplant Tumor 
Registry (IPITTR)] were compared to data from the general population 
[Surveillance, Epidemiology, and End Results (SEER) database from the 
National Cancer Institute]. All cancers were staged by AJCC criteria. Fisher 
exact, Chi-Square, Kaplan-Meier were performed using SPSS 15.0.
Results: Number of patients, age at cancer diagnosis, and stage-stratifi ed DSS 
are presented in the table below. Transplant recipients were diagnosed at an 
earlier age compared to SEER patients for each cancer (all p values <0.001). 
The proportion of patients with early stage (AJCC Stage I/II) RCC was greater 
in transplant recipients; proportion of patients with early stage (AJCC Stage I/
II) MM and CC was greater in the SEER population.
Renal Cell Cancer Malignant Melanoma
IPITTR SEER p IPITTR SEER p
# Pts 84 57,029 45 100,876
Mean Age at Diagnosis 50+/-11 63+/-13 <0.001 51+/-11 57+/-17 <0.001
% of pts with early stage 
(StageI/II) 73% 57% 0.002 62% 90% <0.001
DSS at 1,3,5 Y
Stage I 100,100,91 98,96,94 NS 92,92,92, 100,98,96 NS
Stage II 100,100, 100 97,89,84 NS 86,57,57 96,81,71 NS
Stage III 100,100, 100 89,75,67 NS 72,48,48 90,65,54 NS
Stage IV 23,--,-- 32,13,8 0.012 --,--,--, 37,18,14
Non-Small 
Cell Lung 
Cancer
Colon Cancer
IPITTR SEER p IPITTR SEER p
# Pts 179 200,556 72 137,466
Mean Age at Diagnosis 57+/-9 67+/-11 <0.001 59+/-10 70+/-13 <0.001
% of pts with early stage 
(StageI/II) 24% 27% NS 40% 54% 0.013
DSS at 1,3,5 Y
Stage I 84,60,18 86,65,54 NS 87,69,69 97,95,92 0.021
Stage II 60,--,-- 70,34,21 0.014 88,30,30 93,86,81 0.001
Stage III 22,7,-- 39,13,8 NS 67,35,26 86,68,60 <0.001
Stage IV 23,9,5 17,3,1 <0.001 9,--,-- 43,14,8 0.003
DSS was greater for the SEER population for each stage of CC. DSS was 
similar between populations for each stage of MM, for stage I, II and III for 
RCC, and for stage I and III for NSCLC. DSS was greater for RCC in the SEER 
population for Stage IV only. DSS was greater in the IPITTR population only 
in Stage IV NSCLC.
Conclusions: 1) De novo RCC, MM, NSCLC, and CC are diagnosed at an 
earlier age (by average of 10 years) in Transplant recipients; 2) Transplant 
recipients with de novo cancers post transplant do not have a universally 
lower DSS compared with the SEER population; 3) Rather, DSS varies 
signifi cantly by AJCC Stage and tumor type. In summary, these epidemiologic 
analyses indicate that systemic IS does not universally enhance the biologic 
aggressiveness of malignancies that arise following transplantation.
CURRENCY OF RECEIPT OF IMMUNOSUPPRESSIVE 287 
AGENTS AND OTHER RISK FACTORS FOR LIP CANCER 
FOLLOWING RENAL TRANSPLANTATION
M. van Leeuwen1, A. Grulich1, A. Webster2,3, S. McDonald2,4, M. McCredie5, 
J. Stewart5, J. Amin1, J. Kaldor1, J. Chapman2,6, C. Vajdic1
1National Centre in HIV Epidemiology and Clinical Research, University 
of New South Wales, 2Australia and New Zealand Dialysis and Transplant 
Registry, Queen Elizabeth Hospital, 3School of Public Health, University of 
Sydney, 4Disciplines of Medicine and Public Health, University of Adelaide, 
5Department of Preventive and Social Medicine, University of Otago, 
6Center for Transplant and Renal Research, Millennium Institute, Westmead 
Hospital, University of Sydney
Purpose: Lip cancer occurs at greatly increased rates following organ 
transplantation and in other immunodefi cient states. However, understanding 
of lip cancer aetiology, either in the context of immunodefi ciency or in the 
general population, remains incomplete. This study aimed to examine the 
role of immunosuppression and other risk factors for lip cancer in a large, 
population-based, Australian cohort of renal transplant recipients.
Methods: Diagnoses of lip cancer in a cohort of 8,162 renal transplant recipients 
during 1982 – 2002 were ascertained through probabilistic data linkage 
between the Australia and New Zealand Dialysis and Transplant (ANZDATA) 
Registry and the National Cancer Statistics Clearing House (NCSCH). All 
cancers within the lip rubric (ICD10 C00) were included; cancers of the skin 
adjacent to the mucosa of the lip (ICD10 C43, C44) were excluded. Person-
years of follow-up were accrued from the date of transplantation until the fi rst 
diagnosis of lip cancer, death, or last contact. Multivariate Poisson regression 
was used to compute incidence rate ratios (IRR) for lip cancer during periods 
of transplantation and dialysis, as well as risk factors for squamous cell 
carcinoma (SCC) of the lower vermillion (‘lip-stick zone’) of the lip during 
the period following fi rst transplantation only. To account for changes in 
immunosuppressive regimen over time, the regression models included time-
dependent covariates for exposure to the major immunosuppressive agents.
Results: 203 diagnoses of lip cancer were recorded after transplantation 
(335 cases per 100,000 person-years), most commonly in the vermillion of 
the lip. Incidence was signifi cantly reduced (IRR 0.04, 95% CI 0.01 – 0.32, 
p=0.002) after transplant failure and resumption of dialysis, returning to 
near pre-transplantation level. During the fi rst transplantation, SCC of the 
lower vermillion (n=122) was independently associated with increasing age 
(p<0.001), greater time since transplantation (p=0.001), increasing years of 
prior dialysis (p=0.024), current use of azathioprine (IRR 2.60, 95%CI 1.35 – 
5.01, p<0.001), and current use of cyclosporine (IRR 1.70, 95%CI 1.05 – 2.77, 
p=0.032). Risk was signifi cantly lower among females (IRR 0.29, 95%CI 0.18 
– 0.46, p<0.001), and those born outside of Australia/New Zealand (p=0.008), 
both surrogates for lower sun exposure. A non-linear association with latitude 
was observed (p=0.015).
Conclusion: Lip cancer risk following renal transplantation appears largely 
driven by the interaction between sun exposure and current receipt of 
immunosuppressive agents. Current receipt of azathioprine, thought to 
increase UVA photosensitivity, and cyclosporine, which inhibits DNA repair 
mechanisms, may potentiate UV-related cellular damage and malignancy. The 
fact that lip cancer risk was confi ned almost entirely to periods of transplantation 
demonstrates that it is currency of receipt of immunosuppressive agents 
that determines risk, and that the heightened risk is reversible on cessation 
of immunosuppression. As lip cancer shares certain risk factors with non-
melanoma skin cancer (NMSC), these fi ndings may inform the high risk for 
NMSC widely documented in this group.
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TWENTY YEAR CANCER OUTCOMES OF A 288 
RANDOMISED TRIAL OF IMMUNOSUPPRESSION 
IN KIDNEY TRANSPLANT RECIPIENTS: RESULTS 
OF THE AUSTRALIAN MULTICENTRE TRIAL OF 
CYCLOSPORINE WITHDRAWAL
M.P Gallagher1, A.C. Webster2, M.J. Jardine1, V. Perkovic1, A. Cass1, 
J.M. Eris3
1The George Institute For International Health, 2School of Public Health, 
University of Sydney, 3Royal Prince Alfred Hospital, Sydney, Australia
Background: Malignancy is a well recognised complication of renal 
transplantation, and cumulative incidence increases with time since 
transplantation. Potential differences in carcinogenicity among components 
of immune suppressive regimens are the subject of much interest and 
debate. Until now, analyses have largely relied on observational data. 
Randomised data is scarce due to the relatively long latency of most cancer 
events and the paucity of trials with correspondingly sufficient follow 
up periods. We present 20 year cancer outcomes from a large Australian 
randomised trial.
Methods: This randomised, open-label, multicentre study allocated fi rst 
cadaveric renal transplant recipients into one of three different immune 
suppression regimens: azathioprine and prednisolone (AP), long term 
cyclosporine alone (Cy) or 3 months of cyclosporine followed by a switch to 
azathioprine and prednisolone (CyAP). Following consent from the participating 
Units, data from the study database was matched with the Australian and New 
Zaland Dialysis and Transplantation Registry (ANZDATA) to provide 20 year 
outcomes and malignancy rates. All records of incident non-melanocytic skin 
(NMSC) and non-skin cancers were analysed, regardless of graft failure. The 
Kaplan Meier method was used to compare malignancy-free survival among 
the groups, using the log rank test.
Results: A total of 489 patients were randomised (AP = 158, Cy = 166, 
CyAP = 165) in 7 Australian centres, with 20 year follow up data available 
for 482 (99%) recipients with 7 (1%) lost to follow up. At a mean of 20 years 
post transplant 295 patients had died (respectively 104, 97, 94) and 395 
patients had died or lost their grafts (132,140,123). A total of 229 patients 
were diagnosed with cancer at any time post transplant (174 with NMSC 
and 95 with non-skin cancers). Overall median patient survival was similar 
across the three groups (14.3, 16.9, 15.1yrs, p = 0.13) and the median time 
to fi rst malignancy or death was similar (6.6, 8.8, 8.9 yrs, p = 0.18). The 
median time to death or fi rst NMSC was not different among the three 
groups (7.6, 8.6, 9.8 yrs, p = 0.23). Similarly, the median time to death or 
fi rst non-skin malignancy was not different among the groups (12.6, 14.8, 
12.8 yrs, p =0.18).
Conclusions: Overall rates of all malignancy, taking in both skin and non-skin 
cancers, is similar in these three different renal allograft immune suppression 
regimens out to 20 years post transplant.
THE EFFECT OF CONVERSION TO SIROLIMUS ON 289 
IMMUNE PHENOTYPE IN TRANSPLANT RECIPIENTS WITH 
CUTANEOUS SQUAMOUS CELL CARCINOMA
R. Carroll1,2, P.N. Harden2, K. Wood1
1Transplantation Research Immunology Group, Nuffi eld Department of 
Surgery, John Radcliffe Hospital, Oxford, UK, 2Oxford Kidney Unit, Churchill 
Hospital, Oxford, UK
Background: Renal transplant recipients (RTR) have a 3 fold increase risk of 
cancer and substantially worse prognosis for late stage disease compared to age 
matched controls. The risk of cutaneous squamous cell carcinoma (cSCC) is 
×200 greater than the general population in the UK, with substantial morbidity 
and mortality.
Conventional immunosuppressants are linked to this increased risk of cancer in 
RTR. A new immunosuppressant, Sirolimus, has anti cancer effects. RESCUE 
is an international randomized control trial investigating the effi cacy of 
Sirolimus in reducing in the rate of new cSCC in renal transplant patients with 
a previous history of cSCC
In the non RTR population high numbers of FOXP3+CD25highCD4+ T cells are 
associated with malignancy and predict poor prognosis and recurrent cancer. 
There are no data on whether FOXP3+CD25highCD4+ T associate with cancer in 
transplant recipients. This cell population could defi ne RTR at increased risk of 
cancer or cancer recurrence.
Patients and methods: 24 patients from RESCUE were enrolled in a sub 
study. These RTR have prolonged graft survival (20.4 ± SD 7.5 years) and 
advanced age (61.8 ± SD 9.9 years).
The immune phenotype of these patients was assessed by multi parameter fl ow 
cytometry. The laboratory investigators were blinded to the immunosuppressive 
regimens of the patients.
Flow cytometry was performed before study entry, to determine the baseline 
immune phenotype. Assessment, 3 and 6 months after randomisation, has 
been used determine the effects of conversion from conventional immune 
suppression to a Sirolimus based regimen. The study will be un-blinded in June 
2008.
In a concurrent study the immune phenotypes of RESCUE patients were 
compared with age, sex and duration of immunosuppression matched 
controls.
Results: Before entry into the RESCUE study the median (range) number 
of FOXP3+CD25highCD4+ was 21 (6-96) cell/μl blood in RTR with cSCC. In 
controls the median (range) was lower 16 (1-29) cell/μl blood (Mann Whitney 
test p=0.013).
High numbers of FOXP3+CD25highCD4+ were associated with a history multiple 
cSCC, recent tumour resection or occurrence of new cSCC during the study 
period.
Patients in RESCUE had lower number of NK cells compared to matched 
controls (Mann Whitney p=0.047). Over the study period the median (range) 
number of NK cells increased from 63 (3-221) cell/μl blood to 138 (19-518) 
cell/μl blood (Mann Whitney p=0.021).
Conclusions: In this population high numbers of FOXP3+CD25highCD4+ cells 
and low NK cell numbers correlates with recurrent or multiple cSCC. This 
immune phenotype may defi ne RTR at risk of recurrent cSCC.
IMPACT OF KIDNEY TRANSPLANTATION AND CANCER 290 
CO-MORBIDITY COMPARED WITH CANCER ALONE ON 
EXPECTED SURVIVAL: A REGISTRY ANALYSIS FROM 
AUSTRALIA AND NEW ZEALAND
A. Webster1,2, A. Hayen1, P.J. Kelly1, J.R. Chapman3, J.C. Craig1,2
1School of Public Health, University of Sydney,, 2Centre For Kidney 
Research, Children’s, 3Centre For Renal And Transplant Research, Westmead 
Hospital,
Background: Increased risk of cancer in transplant recipients has been 
comprehensively investigated, but data describing the impact of the co-
morbidity of transplantation on cancer survival has never been examined with 
respect to the broader cancer or general populations.
Aims: To examine the relative survival of cancer patients and transplant 
patients with cancer, compared to the general population.
Methods: Using inception cohort data from the Australia and New Zealand 
Dialysis and Transplant Registry, the New Zealand Health Information Service, 
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Statistics New Zealand and the Australian Bureau of Statistics, we compared 
5-year relative survival of transplant recipients with cancer and the general 
population with cancer. Non-melanocytic skin cancers were excluded as data 
are not available for the general population. Relative survival was calculated 
as the ratio of observed survival of cancer patients and transplant recipients 
with cancer, compared to the expected survival in the general population 
of Australia and NZ, with the same age and sex distribution, over the same 
time period. A relative survival ratio of 1 indicates that the survival rate is 
equivalent to the general population, and ratios <1 indicate the survival rate is 
lower (mortality rate is higher) compared to the general population (with 95% 
confi dence intervals)
Results: Data were available from all sources for the period 1988-2004. 
There were 9,556 kidney transplant recipients of whom 1309 (13.7%) were 
diagnosed with at least 1 cancer. There were 255,600 people with cancer 
diagnosed in NZ. Overall, 5-year relative survival was 0.43 (0.40-0.46) 
for transplant recipients with cancer, and 0.51(0.50-0.51) for the overall 
cancer population, compared to the general population. Relative survival 
of transplant recipients with cancer was lower for all age groups compared 
to the overall cancer population (see graph). Five-year relative survival for 
female transplant recipients with cancer was 0.45 (0.40-0.49) compared 
with 0.54 (0.53-0.54) in the overall cancer population; for male recipients 
with cancer the relative survival was 0.41 (0.37-0.45) compared with 0.47 
(0.47-0.48) for males with cancer. The difference in relative survival for 
males and females recipients with cancer was not constant and altered with 
age (see table).
5 year relative survival by age and sex 
Age < 35 years 35-44 45-54 >=55
Sex m f m f m f M f
Tx + 
cancer
0.71
(0.57-0.81)
0.69
(0.55-0.80)
0.64
(0.53-0.73)
0.59
(0.46-0.70)
0.48
(0.39-0.55)
0.51
(0.41-0.60)
0.27
(0.22-0.33)
0.33
(0.28-0.39)
cancer
0.74
(0.74-0.76
0.77
(0.76-0.78)
0.66
(0.64-0.67)
0.74
(0.73-0.75)
0.54
(0.53-0.55)
0.67
(0.66-0.68)
0.45
(0.44-0.45)
0.46
(0.46-0.47)
Conclusions: Transplant recipients not only have increased cancer incidence, 
but also increased mortality when diagnosed with cancer compared to the 
cancer and general populations. It is not clear whether cancer treatment is 
less effective in transplant recipients, or whether underlying morbidity from 
ESKD contributes. A fuller analysis of the pattern of relative survival for 
specifi c cancer sites will increase understanding, and inform surveillance and 
treatment programs.
IMPACT OF CANCER ON SURVIVAL AFTER KIDNEY 291 
TRANSPLANTATION
A.C. Webster12, A. Hayen1, P.J. Kelly1, J.R. Chapman3, J.C. Craig12
1School of Public Health, University of Sydney, 2Centre for Kidney Research, 
Children’s Hospital at Westmead, 3Centre for Renal and Transplant research, 
Westmead Hospital, Australia.
Background: Recently, the increased risk of cancer in transplant recipients 
has been quantifi ed comprehensively, but data describing the impact of cancer 
on survival after kidney transplantation are sparse.
Aims: To evaluate the relative and absolute survival of transplant recipients 
with and without cancer, compared with the general population with and 
without cancer.
Methods: Using inception cohort data from the Australia and New Zealand 
Dialysis and Transplant Registry (1963-2004), rates of death and standardised 
mortality ratios (SMR) were calculated by age, sex and year compared to 
the general population of Australia and New Zealand. Within the transplant 
population, risk factors for early death were identifi ed using Cox regression 
(hazard ratios: HR; 95%CI), and absolute risk of death with and without cancer 
(excluding non-melanocytic skin cancer) was estimated for different recipient 
groups.
Results: Of 15,183 recipients (mean follow-up 9.0 years, total 135,968 years 
of risk), 1642 (10.8%) developed cancer and 6,479 (42.7%) died. Overall, for 
female transplant recipients SMR was 10.0(9.5-10.4), rising to 26.6 (24.2-29.2) 
for those who also had cancer. For male recipients SMR was 6.5 (6.3-6.8), 
but 22.8 (20.9-24.7) with cancer. Relative mortality rates varied by age and 
sex (see graph), but for all age groups was greatly increased by cancer co-
morbidity. Female recipients aged 35-45 had SMR 23.6 (20.8-26.7) rising to 
SMR 81.5 (59.0-112.5) after cancer diagnosis, for males of the same age SMR 
were 12.4 (11.20-13.75) and 59.40 (45.2-78.2) respectively. For recipients over 
55 yrs sex differences were less pronounced: for females SMR 6.9 (6.4-7.3) 
and 20.6 (18.4-23.1) with concurrent cancer, for males SMR 4.6 (4.4-4.9) and 
17.9 (16.1-19.8) respectively. Within the transplant population, older age and 
male sex increased risk of death (transplanted >55yrs versus <35yrs HR 4.47: 
4.15-4.83, male versus female HR 1.09: 1.04-1.15), as did diabetic ESKD 
(versus glomerulonephritis, HR 1.78: 1.61-1.96) and graft failure (HR 3.81: 
3.62-4.01), but white racial background was protective (HR 0.79: 0.73-0.85). 
After allowing for these effects, cancer diagnosis increased risk of early 
death more than four fold (HR 4.12: 3.84-4.43). Absolute risk of death at 1 
year varies: for a young (<35yrs) white woman with glomerulonephritis and 
no cancer, risk is 1:42, but rises to 1:10 with cancer. A non-white man aged 
45-55yrs with diabetic ESKD and a functioning transplant, can expect a 1:17 
risk of death at 1 year, rising to 1:4 with cancer.
Conclusions: Transplant recipients have death rates similar to people 30 
years older in the general population, but cancer co-morbidity has devastating 
consequences. It is unclear whether cancer is not treated, treated differently, 
or if treatment is ineffective in this population. Further work on behaviour of 
specifi c cancers may inform understanding of treatment, screening strategies, 
and service provision.
SEQUENTIAL TREATMENT WITH RITUXIMAB AND 292 
CHOP CHEMOTHERAPY IN B-CELL PTLD – WILL RISK 
STRATIFIED SEQUENTIAL TREATMENT BECOME THE NEW 
STANDARD IN THERAPY?
R. Trappe1, S. Choquet2, S. Oertel1, V. Leblond2, T. Ekman3, M. Sender3, 
P. Mollee4, P. Reinke1, H. Lehmkuhl5, M. Hummel5, S. Jonas1, R. Neuhaus1, 
G. Salles6, F. Morschhauser7, A. Jaccard8, D. Dierickx9, T. Lamy10, 
B. Dörken1, I. Anagnostopoulos1, M. Raphael11, H. Riess1 for the German, 
French, Swedish, Australian and Belgian Study Group on PTLD
1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Hôpital Pitié-
Salpétrière, Paris, France, 3Sahlgrens Hospital, Gothenburg, Sweden
4Princess Alexandra Hospital, Brisbane, Australia, 5Deutsches Herzzentrum 
Berlin, Berlin, Germany, 6Hopital Lyon Sud, Lyon, France
7Hopital Claude Huriez, Lille, France, 8Hopital Dupuytren, Limoges, France 
9University Hospital Gasthuisberg,Leuven, Belgium, 10Hopital Ponchaillou, 
Rennes, France, 11Hoptital du Kremlin Bicetre, Le Kremlin Bicetre, France
Purpose: This trial aimed to investigate the effi cacy and safety of sequential 
treatment with rituximab and CHOP-21 in patients with PTLD unresponsive to 
reduction of immunosuppression.
Methods: An ongoing prospective multicenter phase II trial was initiated in 
January 2003. Patients were treated sequentially with rituximab at days 1, 8, 
15 and 22 (4xR) followed by four cycles of CHOP-21 combined with G-CSF 
support starting 4 weeks after the last dose of rituximab (sequential treatment, 
ST). To further improve the very promising results with ST reported at the 
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ITC meeting in 2007 a protocol amendment was introduced in October 2006. 
As treatment response to 4xR was shown to predict overall survival, risk 
stratifi cation according to response to rituximab was introduced. In the amended 
protocol patients with a CR after 4xR will go on with 4 additional applications 
of rituximab while all others will go on with four cycles of R-CHOP-21 instead 
of CHOP-21 (risk stratifi ed sequential treatment, RSST).
Results: In this analysis from March 2008 a total of 86 patients are reported. 
The median follow up are 24.6 months for ST (69 pts. included) and 6.4 months 
for RSST (17 pts. included). 64 ST and 17 RSST patients were diagnosed with 
monomorphic PTLD, 5/0 with polymorphic PTLD. 22/9 patients were kidney, 
16/4 liver, 14/4 heart, 4/0 lung, 2/0 heart+lung, 3/0 kidney+pancreas transplant 
recipients (8/0 others). Median age was 54/60 years. 59%/65% had advanced 
stage of disease. 51%/67% of tumors were EBV positive. 78%/82% of patients 
had late PTLD (i.e. later than 1 year after transplantation). LDH was elevated 
in 69%/56% of patients. The overall response rate of ST was 88% (CR 65%, PR 
23%). 73.7% and 62.0% of patients included were without disease progression 
at one and two years, respectively, and 79.1% and 74.9% of patients responding 
remained in disease remission at 1 and 2 years (Fig 1). Following ST, 33% 
of patients suffered from WHO °3/4 infections. There were ten early therapy-
associated deaths (17%), 6 due to infections, 2 due to haemorrhage, 2 due to 
primary refractory disease. With RSST the overall response rate was 92% and 
85% achieved a complete remission. 92.9% of patients included were without 
disease progression at one year and with a median follow up of 6.4 months not 
a single patient responding to treatment had disease progression so far (Fig 
1). 5/15 patients (33%) suffered from WHO °3/4 infections. With RSST there 
were two early therapy-associated deaths (16%), one due to infection, one due 
to primary refractory disease.
Conclusions: This is the largest prospective study in PTLD. Sequential 
treatment with rituximab and CHOP-21 + G-CSF is well tolerated and highly 
effective. As compared to rituximab monotherapy more patients achieve a 
CR with sequential treatment and time to progression (TTP) is very much 
prolonged. Our fi rst prospective data evaluating risk stratifi ed sequential 
treatment suggest even superior CR rates and further increased TTP with a 
similar toxicity level.
Figure 1
CONCURRENT ORAL SESSION 25: 
TOLERANCE INDUCTION MECHANISMS
MACROPHAGES DRIVEN TO A NOVEL STATE OF 293 
ACTIVATION PROMOTE T CELL REGULATION AND ORGAN 
TRANSPLANT TOLERANCE
E. Geissler1, H. Schlitt1, S. Inoue1, J. Hutchingson2, B. Brem-Exner1, 
G. Koehl1, F. Faendrich2, K. Kronenberg1
1University of Regensburg, Department of Surgery, 2University Hospital 
Schleswig Holstein, Kiel, Department of Surgery
Background: The use of immunomodulatory cells in organ transplantation 
is a promising approach for tolerance induction. Here we describe a novel 
tolerogenic macrophage population capable of enriching T regulatory (Treg) 
cells and promoting tolerance.
Methods: Balb/c bone marrow, spleen and blood cells were cultured with 
M-CSF for 5 days, and on the last day IFN-gamma (IFN-g) was pulsed into 
the cultures to produce what we refer to as IFN-g-induced monocyte derived 
cells (IFNg-MdCs). IFNg-MdCs were phenotypically characterized by FACS 
and immunomodulation was determined by cell counting assays and FACS 
analysis for Tregs. Mouse heterotopic heart transplantation was used to test 
in vivo effects.
Results: IFNg-MdCs express high levels of CD11c/b, MHCII, F4/80 and PD-L1. 
They are positive for CD40 and CD86, but negative for CD80. Compared to 
classically activated (M1) macrophages IFNg-MdCs express less CD40/
CD86, but higher levels of CD11c. IFNg-MdCs profoundly delete activated, 
but not resting, lymphocytes (>60%), and cell contact (transwell system) and 
caspases (caspase inhibitors) were found to be essential. Interestingly, IFNg-
MdC cultures are highly enriched for CD4+CD25highFoxp3+ Treg cells (41 
+/-2%; n=27); direct comparison to classically activated macrophages and 
dendritic cells showed only Treg enrichment with IFNg-MdCs. The same, or 
even higher, proportions of Tregs could be detected when IFNg-MdCs were 
generated from MACS-purifi ed CD11b+ and CD4+ cell populations (1:1) 
versus a standard mixed starting cell population. ELISA analysis of IFNg-MdC 
cultures revealed high levels of IL-10 in comparison to standard monocyte 
cultures (183 +/-42 ng/ml vs. <30 pg/ml, respectively), suggesting IL-10 as 
one potential mediator. IFNg receptor signaling and CD40 interactions are 
required for Treg enrichment, as shown using IFNg receptor and CD40 knock-
out mouse strains (C57BL6 mice). IFNg-MdCs derived from CD11b+ cells 
and CD4+ lymphocytes of OVA-transgenic OTII mice showed enrichment of 
Treg by 10-fold with high-affi nity OVA peptide (323-339) versus Treg levels 
using a low-affi nity OVA peptide (OVA 323-334), suggesting antigen-specifi c 
Treg cells could be enriched with IFNg-MdCs. Finally, a single post-heart Tx 
(d+1) i.v. injection of 5 million donor (C3H)-derived IFNg-MdCs prolonged 
allograft survival in Balb/c recipients from 8.5 +/-0.8d (n=5) to 21.4 +/-8.3d 
(n=11; P=0.001).
Conclusions: IFNg-MdCs are a novel macrophage population capable of 
deleting activated T cells and highly enriching remaining lymphocytes for 
Tregs. These properties make this cell an attractive new cell therapy option for 
promoting tolerance near the time of organ transplantation.
LIVER SINUSOIDAL ENDOTHELIAL CELLS 294 
SUPPRESS ALLOIMMUNE RESPONSES VIA MHC CLASS II 
RECOGNITION IN LIVER TRANSPLANTATION
M. Banshodani, M. Shishida, Y. Igarashi, Y. Tanaka, H. Tashiro, T. Asahara, 
H. Ohdan
Department of Surgery, Hiroshima University
The liver is widely regarded as a tolerogenic organ. Although livers transplanted 
across MHC barriers in mice are normally accepted without recipient immune 
suppression, the underlying mechanisms remain unclear. To identify the cell 
type contributing to the induction of such a tolerant state, we established a 
mixed hepatic constituent cell-lymphocyte reaction (MHLR) assay. Irradiated 
C57BL/6 (B6) or Balb/c mouse hepatic constituent cells (HCs) and CFSE-
labeled B6 splenocytes were cocultured. During the allogeneic MHLR 
assay, whole HCs did not promote T cell proliferation. When liver sinusoidal 
endothelial cells (LSECs) were depleted from among the HC stimulators by 
magnetic cell sorting using anti-CD105 mAbs (an LSEC marker), allogeneic 
MHLR induced marked proliferation of reactive CD4+ and CD8+ T cells, 
suggesting possible tolerogenicity in CD105+ LSECs. Physical separation of 
LSECs from responder-stimulator cells with a dual-chamber transwell culture 
system in the allogeneic MHLR assay signifi cantly reduced the suppressive 
effects of LSEC on alloreactive CD4+ and CD8+ cell proliferation, indicating 
that cell-cell contact was required for immunosuppression. Phenotypic analysis 
by fl ow cytometry (FCM) confi rmed that LSECs constitutively expressed all 
molecules for antigen presentation (MHC class I, class II, CD40, CD80, and 
CD86). To test the tolerance capacity of LSECs toward alloreactive T cells, 
B6 splenocytes that had transmigrated in vitro through a monolayer of B6, 
Balb/c, or SJL/j LSECs were restimulated with irradiated Balb/c splenocytes. 
Nonresponsiveness and marked proliferation of T cells that had transmigrated 
through allogeneic Balb/c LSECs and syngeneic B6 or third-party SJL/j 
LSECs, respectively, were observed after the restimulation. Transmigration 
across the FasL-defi cient Balb/c LSECs failed to render the CD4+ T cells 
tolerant. Thus, we demonstrated that FasL expressed on naive LSECs can 
impart tolerogenic potential upon alloantigen recognition via the direct 
pathway. The cells harvested after the allogeneic MHLR culture, using whole 
HC stimulators including LSECs, were stained with annexin V along with 
7-AAD. FCM revealed that the proliferation of 7-AAD-negative alloreactive 
CD4+ and CD8+ T cells were detectable. These proliferating T cells during 
the early stage of cell division were bound to annexin V. These fi ndings are 
consistent with a model wherein the FasL-induced apoptosis of alloreactive 
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T cells activated in responses to LSECs is a critical event in induction of liver 
allograft tolerance. We next established an in vivo model for evaluating the 
immunomodulatory effects of LSECs on alloreactive T cells. LSECs isolated 
from BALB/c mice were injected into recombinase-activating gene-2 (RAG-2)/
gamma-chain double knockout (WKO) B6 mice, lacking T, B, and NK cells, 
via the portal vein (4 ~ 106/mouse). When orthotopic LSEC implantation into 
the liver sinusoids was observed 7 d after the adoptive transfer, splenocytes 
from wild-type B6 mice were intravenously injected into WKO B6 mice 
via the tail vein (20 ~ 106/mouse). Seven days after splenocyte inoculation, 
the mixed lymphocyte reaction (MLR) assay with splenocytes from these 
recipients revealed specifi c inhibition of CD4+ T cell proliferation in response 
to stimulation with irradiated Balb/c mouse splenocytes (n = 5). Thus, we 
conclude that LSECs suppress alloimmune responses via MHC recognition 
during allogeneic liver transplantation.
LIVER DENDRITIC CELLS ARE POTENT INDUCERS 295 
OF REGULATORY T CELLS AND LIVER TRANSPLANT 
TOLERANCE
W. Li, R. Bakthavatsalam, K. Carper, J. Perkins, J. Reyes
University of Washington, Dept of Surgery, Div of Transplantation
Liver transplantation in mice results in spontaneous liver allograft acceptance and 
subsequent systemic tolerance to other transplanted organs from the same liver 
donor without requirement for immunosuppressive therapy. The mechanisms 
underlying this phenomenon remain largely undefi ned. Our previous studies 
have demonstrated that liver dendritic cells (DCs) and Foxp3+CD25+CD4+ 
regulatory T (Treg) cells contribute signifi cantly to tolerance induction. Treg 
appear to underpin the liver tolerance process. How Treg are induced and their 
functional mechanisms in the regulation of liver transplant tolerance remain 
undefi ned. In this study, we manipulated Treg induction in vitro by coculture of 
CD4+ T cells and allogeneic liver DCs in the presence of TGF-beta and IL-2, 
and examined the function of those Treg on inhibition of allogeneic immune 
responses in vivo by adoptive transfer to the heart allograft recipients. We 
further adopted Fms-like tyrosine kinase 3 ligand (Flt3L) mutation mice, which 
have severe reduction in all types of DCs, to critically examine the role of liver 
DCs in liver transplant tolerance in vivo by liver transplantation from Flt3L-/- 
donors to allogeneic C3H recipients. Our results showed that liver DCs were a 
more potent generator of Foxp3+CD25+CD4+ Treg. After 5-7 days culture at 
1:4 ratio of DC:CD4 T cells, around 50% of CD4 T cells become CD25+ and 
Foxp3+ compared to 25% in the spleen DC generated group. Adoptive transfer 
of those CD4+ Treg generated from liver DC signifi cantly prolonged heart 
allograft survival compared to the CD4 treated controls. Moreover, the liver 
grafts from Flt3L-/- mice were rejected acutely in the C3H recipients. MST was 
6.3+/-2.3 days, P<0.001 vs 55+/-33 in WT controls. Immunohistochemistry 
staining revealed that Foxp3+ cells were reduced, but IL-2, IL-10, and IFN-
gamma producing cells were increased signifi cantly in the liver grafts and 
recipient spleens from Flt3L-/- donors. Thus, liver DCs appear to have a critical 
role in the induction of Treg, which underpin spontaneous acceptance of MHC-
mismatched liver allografts in mice.
CD25296 +GITR+ REGULATORY T CELLS PLAY AN 
ESSENTIAL ROLE IN ALLOGRAFT PROTECTION 
IN NON-LYMPHOPENIC TOLERISED PRIMARY TRANSPLANT 
RECIPIENTS
A. Bushell, K. Wood
Nuffi eld Department of Surgery
Background and aims: Transient immunotherapy can lead to long-term 
operational tolerance in rodent transplant models and in many cases, graft 
survival correlates with the presence of induced CD25+CD4+ regulatory T 
cells (Treg). However, unequivocal demonstration of function usually requires 
adoptive transfer into lymphopenic hosts where homeostatic proliferation can 
confound a clear interpretation of the ability of these cells to provide active 
regulation of effector mechanisms. The aim of this study was to determine the 
role of regulation in tolerised primary transplant recipients by specifi c targeting 
of induced regulatory T cells.
Methods: CBA mice (H2k) mice were pre-treated with 200μg of the IgG2a anti-
CD4 antibody YTS 177.9 on days -28 and -27 plus a donor-specifi c transfusion 
(DST) of C57BL/10 (B.10, H2b) blood on day -27. This induction protocol 
leads to the indefi nite survival of B.10 hearts transplanted on day 0 but more 
importantly, generates CD4+ CD25+ Treg prior to transplant that prevent skin 
graft rejection in a sensitive adoptive transfer model. To test for a link between 
adaptive Treg and graft outcome in primary graft recipients, Treg were targeted 
using either anti-CD25 antibody (PC61) or anti-GITR antibody (DTA-1). Anti-
CD25 antibody was delivered after tolerance induction but before transplant 
(day -14), to manipulate induced regulatory cells in isolation from effector T 
cells and anti-GITR antibody given peri-transplant (day -1 to +9.).
Results: Tolerised mice given a single dose of anti-CD25 antibody at a time 
when adoptive transfer experiments had confi rmed induced Treg to be present, 
rejected their primary cardiac allografts acutely (a). A similar result was 
obtained using the anti-GITR antibody DTA-1 (b). Importantly, acute rejection 
in anti-GITR treated mice was not due to co-stimulation of effector cells since 
rejection mediated by CD4+CD25- or CD8+CD25- T cells was not enhanced by 
anti-GITR antibody and GITR cross-linking did not augment CD4+CD25- or 
CD8+CD25- T cell proliferation in vitro in response donor APC as judged by 
CFSE division history analysis (c).
Conclusion and signifi cance: These data show that irrespective of the limitations 
of adoptive transfer models for assessing Treg function, CD4+CD25+GITR+ 
T-regs play an essential role in early graft protection in primary transplant 
recipients following tolerance induction. The data provide further support 
for attempts to identify protocols that generate similar populations in clinical 
transplantation.
THE POWERFUL T-CELL TOLERIZING 297 
CONSEQUENCES OF BLOCKING EXPRESSION OF PRO-, NOT 
ANTI-INFLAMMATORY MECHANISM
M. Koulmanda, L. Hoffman, A. Qipo, D. Hanidziar, H. Shi, Z. Fan, J.F. Flier, 
T.B. Strom
Departments of Surgery and Medicine, Harvard Medical School, Transplant 
Research Center, Beth Israel Deaconess Medical Center, Boston, MA
In hosts with diabetogenic auto-immunity, the onset of overt disease, 
hyperglycemia, is known to coincide with loss of a critical portion of the islet 
cell mass. Thus, restoration of a portion of the lost islet cell mass should be 
suffi cient to create euglycemia if a defi cit in insulin producing tissue is the 
sole cause of disease. It is notable that many potent T-cell tolerizing therapies 
have failed to enable restoration of euglycemia in new onset T1D NOD mice 
with or without transplantation of islets. Hence, we have searched for other 
potentially complicating features, e.g. insulin resistance, that may serve as an 
additional barrier to restoration of euglycemia. We now report that new onset 
T1D is associated with infl ammation induced insulin resistance created by 
faulty phosphorylation of crucial elements of the insulin signaling pathway 
(insulin receptor and IRS-1). To test the hypotheses that infl ammation, insulin 
resistance and T1DM disease expression are linked we have tested the effects 
of select anti-infl ammatory agents in T1DM NOD mice. We now report that 
treatment for 15 days with alpha-1-antitrypsin (AAT) or 20 days with anti-
TNF-α (i) restores a euglycemic state in 14 of 16 or 22 of 24 treated new onset 
diabetic NOD mice (ii) ablated insulin resistance and (iii) produces specifi c 
tolerance to syngeneic, not acceptance of allogeneic, islets that is manifest 
long after cessation of treatment of new onset diabetic NODs while preserving 
other immune responses. In this experiment spontaneously diabetic (NOD-sp), 
or formerly diabetic euglycemic AAT or anti TNF-α treated NOD rendered 
diabetic with STZ (NOD-sp/stz) were transplanted with allogeneic or syngeneic 
islets (see Table).
Donor (Islets) Recipients Treatment Normoglycemic/Total # of mice used Survival (days)
None NOD-sp NONE 0/150 <60
None NOD-sp AAT 14/16 >300
None NOD-sp Anti-TNF-α 22/26 >300
NOD-scid NOD-sp NONE 5/5 14 –21 (n=5)
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NOD-scid NOD-sp/stz
250-300 days after 
ATT or anti-TNF-α 
treatment
11/11 >70 (n=11)
C57BL/6 NOD-sp/stz NONE 20/20  5 – 8 (n=20)
C57BL/6 NOD-sp/ stz
250-300 days after 
ATT or anti-TNF-α 
treatment
7/7
3 - 11 (n=7)
Despite cessation of therapy, remission of the diabetic state is durable 
throughout long follow periods. Remarkably, treatments with agents that 
primarily alter the fi ne texture of infl ammation (as proven in our genome wide 
DNA array studies), and may not directly target T cells restore self-tolerance 
to beta cells in NOD-sp mice. In short, the restoration of euglycemia, self-
tolerance, and of and the faulty insulin receptor and IRS-1 phosphorylation 
patterns can be corrected by treatment with alpha1 anti-trypsin (AAT), an 
acute phase reactant with potent anti-infl ammatory activity, and/or anti-
TNF-α.
CASPASE INHIBITOR THERAPY SYNERGIZES WITH 298 
COSTIMULATION BLOCKADE TO PROMOTE TOLERANCE 
INDUCTION AND PREVENT ALLOSENSITIZATION IN ISLET 
TRANSPLANTATION
J. Emamaullee1, J. Davis1, C. Toso1, S. Merani1, B. Tseng2, J. Shapiro1
1University of Alberta, 2Epicept Corporation
Background: Recent work has demonstrated that caspase inhibitor therapy 
using EP1013 prevents early engraftment islet loss and thus markedly reduces 
the human islet mass required to reverse diabetes in mice (Diabetes 2008). Data 
investigating the ‘danger’ hypothesis suggests that reduction in graft apoptosis 
should reduce the threshold for immunosuppression and potentially increase 
the possibility for tolerance induction. Thus, the impact of combination of 
EP1013 treatment with costimulation blockade therapies was investigated in 
the present study.
Results: Islet allografts were completed in fully MHC-mismatched mice 
(Balb to B6). Transplanted mice received either EP1013, anti-ICOS, CTLA4-
Ig, or combinations of these agents. When animals received vehicle, EP1013, 
anti-ICOS, or EP1013+anti-ICOS, there was no difference in graft survival 
(MST 16.8-27.5 days). CTLA4-Ig resulted in prolonged graft survival in 
50% of the animals (MST 123.0 days), while EP1013+CLTA4-Ig resulted 
in a signifi cant increase in graft survival (91% >180 days; P=0.04). The 
combination of CTLA4-Ig+anti-ICOS+EP1013 resulted in 100% graft 
survival >180 days (N=8). Recovery nephrectomies were performed and 
either same donor (Balb) or third party (C3H) islets were implanted to 
test for tolerance. Retransplantation with Balb islets led to prolonged graft 
survival in N=6/7 recipients, while use of C3H islets resulted in 100% 
rejection, confi rming donor-specifi c tolerance. Histological analysis of islet 
grafts harvested from tolerant animals revealed low numbers of CD8+ and 
CD4/Foxp3+ regulatory cells around the graft. Splenocytes harvested at 
day 10 post-transplant revealed that animals receiving EP1013+CTLA4-Ig 
have a reduced frequency of alloreactive IFNg-secreting T-cells (P<0.001 
vs untreated controls; ELISPOT). Interestingly, animals receiving caspase 
inhibitor alone had a signifi cantly reduced frequency of alloreactive IFNg-
secreting T-cells at day 10 post-transplant as well, even though this treatment 
protocol results in no prolongation of graft survival. Alloantibody assays have 
shown that our EP1013+CTLA4-Ig tolerizing protocol prevents both IgM and 
IgG allosensitization (p<0.001 for IgM and p<0.05 for IgG vs. vehicle treated 
animals). Further studies using in vivo tracking/proliferation assays and fl ow 
cytometry are underway and should reveal the mechanism of caspase inhibitor 
mediated tolerance induction in this model.
Conclusion: This study suggests that addition of caspase inhibitor therapy to 
known immunomodulatory agents will improve clinical islet transplantation 
by minimizing immune stimulation and thus reduce or negate the requirement 
for long term immunosuppressive therapy. The approach also prevents 
allosensitization, which may be an important component of chronic graft loss 
in clinical islet transplantation.
COMBINATION OF ANTI-LFA-1 AND ANTI-CD154 299 
MONOCLONAL ANTIBODIES INDUCES TISSUE-
SPECIFIC TOLERANCE TO NEONATAL PORCINE 
ISLET XENOGRAFTS
H. Arefanian1, E.B. Tredget1, R.V. Rajotte1, R.G. Gill2, G.S. Korbutt1, 
G.R. Rayat1
1Alberta Diabetes Institute, Department of Surgery, University of Alberta, 
2Alberta Diabetes Institute, Department of Medical Microbiology and 
Immunology, University of Alberta
Background: A variety of transient therapies directed against T lymphocyte 
activation and function result in long-term islet allograft survival. However, 
there are relatively few examples of durable islet xenograft survival using 
similar short-term approaches, especially regarding highly phylogenetically-
disparate xenograft donors. Our previous study demonstrate that combined 
anti-LFA-1 and anti-CD154 monoclonal antibody (mAb) therapy results in a 
robust form of islet xenograft protection not observed with either individual 
monotherapy. The aim therefore of this study was to determine whether 
tolerance to islet xenografts could be achieved by transient blockade of 
adhesion and co-stimulatory pathways using monoclonal antibodies.
Methods: Streptozotocin-induced diabetic B6 mice were transplanted with 
2000 neonatal porcine islets (NPI) under the left kidney capsule and were 
treated with short-term intraperitoneal injections of a combination of anti-
LFA-1 and anti-CD154 mAbs. Blood glucose levels (BGLs) were monitored 
for 100 days post-transplantation at which time, all of the mice achieved 
normoglycemia. The mice were randomly divided in two separate groups: 
Group 1- mice were re-transplanted with a second party NPI. BGLs were 
monitored for another 100 days and a survival nephrectomy of the fi rst graft-
bearing kidney was performed. BGLs were measured for an additional 100 
days to monitor the function of the second party NPI graft and a nephrectomy 
of the second graft-bearing kidney was performed to determine that euglycemia 
was graft-dependent. Group 2-mice were transplanted with full-thickness skin 
from allogeneic BALB/c mouse or xenogeneic neonatal pig donors. Skin grafts 
were inspected daily until the time of graft rejection, defi ned as necrosis of 
the graft. In a parallel experiment, skin transplantation was also performed on 
naïve immune-competent B6 mice and immune-defi cient B6 rag-/- mice as 
control groups. NPI xenografts and spleen cells from tolerant B6 mice were 
harvested for further characterization using immunohistochemistry, RT-PCR 
and fl ow cytometric analyses.
Results: Short-term administration of a combination of anti-LFA-1 and 
anti-CD154 mAbs resulted in prolonged (>100 days) NPI xenogaft survival 
in 40/40 B6 mouse recipients. The NPI xenografts contained well-preserved 
islets with few mononuclear cells surrounding the NPI. Flow cytometric 
analysis of spleen cells from tolerant mice demonstrated that CD4+ T cells 
have higher expression of CD25, foxp3, PD-1, and CTLA-4 compared to that 
found on naïve B6 mouse spleen cells. In addition, the expression of GITR on 
CD4+CD25+ T cells was higher compared to the expression found on naïve B6 
mouse spleen cells. RT-PCR and immunohistochemistry analyses of the grafts 
from tolerant B6 mice showed high expression of IL-10 and TGFβ; cytokines 
as well as foxp3, respectively. All of the mice (n=5) transplanted with a second 
party NPI xenograft maintained normoglycemia for over 100 days post-harvest 
of the fi rst graft-bearing kidney. In contrast, all of the mice transplanted with 
allogeneic BALB/c (n=5) or xenogeneic second party pig skin (n=5) rejected 
their grafts (10.8 ± 0.66 and 15.8 ± 1.65, respectively).
Conclusion: These results show that a short-term administration of a 
combination of anti-LFA-1 and anit-CD154 mAbs induces tissue-specifi c 
tolerance to NPI xenografts and strongly suggest that this strategy may be 
useful in clinical islet xenotransplantation.
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TARGETING OF COSTIMULATION BLOCKADE 300 
RESISTANT T - EFFECTOR MEMORY (TEM) CELLS IN NON-
HUMAN PRIMATE RENAL TRANSPLANTATION WITH LFA-3-
IG (ALEFACEPT) PROLONGS ALLOGRAFT SURVIVAL
A. Kirk1, T. Weaver1, A. Charafeddine1, A. Agarwal1, F. Leopardi1, R. 
Kampen1, M. Starost2
1Emory Transplant Center, Atlanta, GA, 2Veterinary Pathology, NIH, 
Bethesda, MD
Costimulation blockade (CoB) of the CD28/B7 pathway has long been 
suggested as a means of attaining indefi nite, well-tolerated, antigen-specifi c 
prophylaxis from allograft rejection. Although effective in rodent models, 
CD28/B7 blockade is not alone suffi cient to prevent rejection in more robust 
primate models, including humans. The relative presence of allo-crossreactive 
T effector memory (TEM) cells, is one mechanism of CoB resistant rejection. 
Leukocyte functioning antigens (LFAs) found on the extracellular surface 
of antigen presenting cells (APCs) and some activated parenchymal cells 
contribute to the development of an immune response, however their potential 
as therapeutic targets in transplantation remains to be elucidated. LFA3-Ig is an 
approved agent for the treatment of psoriasis, shown clinically to specifi cally 
deplete TEM cells in psoriatic lesions and peripheral blood. We hypothesize 
that LFA3-Ig specifi cally targets CoB resistance cells, including heterologous 
alloreactive T cell memory, while avoiding interference with peripheral 
mechanisms that foster CoB-mediated allograft acceptance. To study this, 
rhesus monkeys underwent MHC mismatched renal allotransplantation, 
following confi rmation of donor-recipient alloreactivity by MLR. CTLA4-Ig, 
abatacept, CD28/B7 costimulation blocker was given 20 mg/kg IV on days -1, 
0, 3, 7, 14, 21, 28 and 10 mg/kg IV on days 35, 42, 49, 56. LFA3-Ig, (0.3 mg/
kg IV) was given on day -1, 0, 3, 7 then weekly for a total of 8 wks. Sirolimus 
was given orally (1mg/kg) on days 0 - 90 and donor specifi c transfusion (7 ml/
kg IV) on day -1. Animals were followed by polychromatic fl ow-cytometry to 
quantify T cell subsets. Primary end point, allograft rejection, was determined 
by a signifi cant rise in serum creatinine and BUN. Renal allografts were 
removed for histological and transcriptional studies, along with splenocytes 
for immune function assays. LFA3-Ig synergized with CTLA4-Ig successfully 
preventing renal allograft rejection in this model and leading to indefi nite 
survival in 2/5 animals (Table). This enhanced survival was associated with a 
signifi cant reduction in TEM cells in animals treated with LFA3-Ig compared 
to animals without LFA3-Ig treatment (Figure). LFA3-Ig withdrawal led to 
TEM re-population and rejection. This regimen, consisting of all clinically 
available agents, promotes CoB-mediated graft acceptance without the use of 
calcineurin inhibitors, steroids, or gross T cell depletion.
Treatment Group Rejection Free Survival
p-value 
compared to 
Group 7
1. No Treatment 5, 6, 7, 7, 8 0.015
2. Sirolimus Alone 8, 10, 21, 23, 28 0.021
3. Sirolimus, DST 10, 6, 5 0.016
4. CTLA4-lg, Sirolimus, DST 13, 33, 44 0.028
5. LFA3-lg, Sirolimus, DST 18, 41, 49 0.033
6. CTLA4-lg, LFA3-lg, Sirolimus 80, 83, 131 0.336
7. CTLA4-lg, LFA3-lg, Sirolimus, DST 56, 105, 108,>168,>243 –
STEM CELLSCONCURRENT ORAL SESSION 26: 
EMBRYONIC STEM CELL-DERIVED CXCR4+ 301 
DEFINITIVE ENDODERMAL PROGENITOR CELLS CORRECT 
FACTOR VIII DEFICIENCY IN MICE
N. Zavazava2,4, K-M. Chan1,2, L. Xie3, M.E. Sarvida3, P.B. McCray Jr3, 
W-C. Lee1, 
1Department of General Surgery, Linkou Chang Gung Memorial Hospital, 
Chang Gung University College of Medicine, Taoyuan, Taiwan, 2Department 
of Internal Medicine, University of Iowa and Veteran Affair Medical Center, 
Iowa City, Iowa, USA, 3Department of Pediatrics, University of Iowa, Iowa 
City, Iowa, USA, 4Division of Allergy/Immunology, University of Iowa, Iowa 
City, Iowa, USA
Hemophilia A is a widespread common disorder caused by the abnormality of 
plasma coagulation factor VIII (FVIII). Protein and serum product replacement 
treatments as well as gene therapy for this condition unfortunately remain 
unsatisfactory. Here, we exploited the pluripotent properties of embryonic stem 
(ES) cells, to determine whether newly differentiated defi nitive endodermal 
(DE) cells cure FVIII defi ciency in a mouse model. Initially, enhanced Green 
Fluorescence Protein (eGFP) transduced ES cells were cultured in a serum-free 
medium containing Activin A and bFGF for 6- 8 days, then the differentiated 
cells developed into an epithelial monolayer yielding more than 70% of CXCR4 
expressing cells. The CXCR4+ cells were purifi ed using immunomagnetic 
bead separation to more than 99% purity. Molecularly, the CXCR4+ cells 
express typical defi nitive endodermal genes in particular, FoxA2, Sox-17, 
GSC, and HNF4£\. The CXCR4+ DE cells were then transplanted into carbon 
tetrachloride (CCL4)-treated FVIIInull mice. The recipient mice were bled 
and sacrifi ced at determined time point to determine the FVIII activity and 
engraftment of DE cells, respectively. We found that DE cells not only readily 
engrafted in the liver of recipient mice but also corrected FVIII activity of 
FVIIInull mice. Genetic analysis and immune-fl uorescence staining confi rmed 
that DE-derived cells were responsible for the production of FVIII. These results 
demonstrate that ES cell-derived DE cells could further differentiate into liver 
parenchymal cells as well as correct FVIII defi ciency in a Hemophilia A mouse 
model, suggesting an approach that could fi nd application in the treatment of 
hemophilias and possibly acute liver failure in humans.
HOXB4 REGULATES DIFFERENTIATION OF 302 
HEMATOPOIETIC PROGENITOR CELLS FROM EMBRYONIC 
STEM CELLS
N. Zavazava1, S. Bonde1, K.N. Chan2, W. Tabayoyong1
1University of Iowa and VAMC Iowa City, USA, 2Chang Gung University 
College of Medicine, Taiwan
Embryonic stem cells are pluripotent, providing a great opportunity for 
their manipulation into cells that could be used for the treatment of disease. 
In transplantation, generating hematopoietic cells is of interest as these cells 
may potentially be less immunogenic than bone marrow cells currently used to 
induce mixed chimerism. More importantly, the newly developed cells lack self-
renewal properties, dying due to apoptosis after a few weeks in culture or in vivo. 
Thus, a number of approaches have been pursued to improve on the generation 
of hematopoietic cells. Incubation of ES cells with BMP4, a TGF-â homologue, 
results in the upregulation of a number of genes including that of HOXB4, a 
hematopoietic transcription factor that has been shown to promote proliferation 
of hematopoietic stem cells. Transduction of ES cells with the HOXB4 gene 
resulted in 100-1000fold growth advantage of CD45+ hematopoietic progenitor 
cells. These cells hardly express MHC antigens. Transplanted in Rag2-/-ãc-/- 
mice, they fully reconstituted bone marrow. To determine the effi cacy of these 
newly derived cells to engraft across MHC barriers, we transplanted them in 
allogenic MRL or Balb/c mice. The cells engrafted long-term after sublethal 
irradiation of the recipient mice, without the use of immunosuppression. These 
chimeric mice were tolerant to donor-derived allografts, suggesting that the low 
immunogenicity of these cells gave them an advantage over bone marrow cells 
that are acutely rejected. Grafts were free of infi ltrating cells and any signs of 
chronic rejection. Studies on the T cell repertoire of these mice showed that 
tolerance was not due to clonal deletion but rather due to T cell anergy. Thus, our 
data show that high numbers of CD45+ hematopoietic progenitor cells can be 
derived from embryonic stem cells and that these cells are poorly immunogenic 
engrafting across MHC barriers. More importantly, they induce graft tolerance 
without severe pre-conditioning.
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USE OF MURINE MESENCHYMAL STEM CELLS TO 303 
EXPRESS DONOR-DERIVED MHC CLASS I MOLECULES FOR 
DONOR-SPECIFIC IMMUNOSUPPRESSION
C. Graeb1, K-W. Jauch1, C. Zuelke2, E. K. Geissler2, P. Camaj1
1Dept. of Surgery, 2Dept. of Surgery
Aims: Graft rejection and multiple side effects of current immunosuppressants 
are still of major concern in organ transplantation. Therefore, the introduction of 
a donor-specifi c immunosuppression without conventional immunosuppressive 
drugs is one of the main goals for the future. In previous experiments we 
were able to show that donor-derived soluble MHC class I molecules have 
the potential to downregulate in a donor specifi c manner the immune system 
of organ recipients. In the past, viral vectors, among others, have failed to 
express suffi cient amounts of these molecules to induce a tolerogeneic state. 
In our current experiments we describe the use of immortalized mesenchymal 
stem cells (MSC), which by themselves have immunoregulatory capacities to 
express donor derived soluble MHC molecules.
Methods: Gene construct: PCR cloning of the mouse MHC class I gene H2Dd 
specifi c for the strain DBA2 was applied. RNA from mouse spleen was isolated 
and amplifi ed by RT-PCR using the Superscript III one step RT-PCR system 
and cloned using Platinum High Fidelity Taq and TOPO into the pcDNA3.2 
GW/V5 vector.
Soluble H2Dd gene construct: fusion of the gene fragments H2Dd with 
the region of the soluble rat MHC molecule Q10a was performed by PCR 
(H2DdQ10a) after identifi cation by protein sequencing analysis. According to 
cloning of the soluble form, the membrane bound form of H2Dd was cloned, 
followed by transfection of mMSC with linear DNA.
Western blotting: membrane-bound MHC molecules were prepared from cell 
lysates in Complete M EDTA-free lysis buffer, the soluble form was isolated 
from culture supernatants by ultra-centrifugation through Vivaspin 500 
columns. Proteins were separated using 12% SDS-PAGE, transferred to PVDF 
membranes and detected by HRP anti-H2Dd antibodies (Ab).
FACS: FACS analysis of transfected cells was performed using anti-H2Dd-Ab, 
FITC-anti-mouse-Ab, and anti-idiotypic-Ab as negative controls.
ELISA: in order to quantitatively evaluate expression of soluble or membrane-
bound MHC molecules a H2Dd specifi c ELISA was developed using a 
biotinylated-anti-H2Dd-Ab.
Results: By using the described PCR cloning technique, soluble (H2DdQ10a) 
as well as the membrane-bound H2Dd were generated as confi rmed by 
sequencing analysis. Subsequent stable transfection of immortalized recipient 
derived MSC (C57 BL/6) was confi rmed by Western blotting and FACS 
analysis. Quantitative expression of both forms of MHC molecules by antigen-
specifi c ELISA revealed amounts (1000-1600ng/ml/1x106 cells) comparable 
to those detected in our previously used hepatocyte cultures. After i.v. cell 
injection of GFP transfected mMSC, cells were detectable in liver, lung, spleen, 
and peripheral lymph nodes.
Conclusion: Our results show that mMSC can be used to effi ciently express 
adequate amounts of donor-derived MHC molecules in both, soluble and 
membrane-bound forms. The use of immortalized MSC in general may 
potentially add to a immunosuppressive effect induced by the soluble form of 
donor MHC molecules.
REGENERATIVE CELLULAR THERAPY: POSITIVE 304 
REMODELING AFTER MYOCARDIAL INFARCTION USING IV 
INJECTED MESENCHYMAL STEM CELLS AND CYTOKINE 
ENHANCEMENT
S. Schrepfer, T. Deuse, W. Stein IV, R.C. Robbins, M.P. Pelletier
Department of Cardiothoracic Surgery, Stanford University School of 
Medicine, USA
Purpose: The injured myocardium is thought to release signals via the blood 
stream to mobilize stem cells from their major reservoir, the bone marrow, into 
the circulation. However, additional local cytokine enhancement (CE) might be 
necessary to attract stem cells to the site of myocardial injury and to stimulate 
the immigrated stem cells to support tissue remodeling.
Methods:
MSCs were stably transfected with fi refl y luciferase for bioluminescence 
imaging (BI), and labeled with CSFE for histology (H). High-throughput 
proteomics and a battery of in vitro assays were used to profi le 20 key cardiac-
specifi c cytokines upregulated following MI for their effects on the biologic 
performance of MSCs. The next steps were to enrich the infarcted areas with 
those cytokines that were found to be effective to fortify the injury signals and 
to increase the number of IV injected MSCs migrated to the heart to strengthen 
the stem cell-based repair potential. After LAD ligation, mice received IV MSC 
injections and were closely monitored by in vivo BI and H. To investigate a 
possible improvement of the contractile heart function by migrated MSCs, the 
ejection fraction (EF), LVEDV, and LVESV were measured by a specifi cally 
designed small animal micro-CT. Therefore, animals were scanned before, 24 
hours, two weeks and six months after LAD ligation/MSC injection.
Results: Due to their large size (19um), huge amounts of IV-injected MSCs 
were trapped within the pulmonary capillaries. Homing of IV-injected MSCs 
into ischemic myocardium after LAD ligation was very ineffi cient and only 
1±0.5 fl uorescent positive MSCs per HPF were detected. Additional CE with 
HGF 40ng/ml or VEGF 8ng/ml, however, signifi cantly increased the MSC 
homing to 11±4 cells/HPF and 7±4 cells/HPF, respectively (p=0.001 each). The 
fi gure shows CT images of longitudinal and transversal axis of left ventricles, 
captured in the systole. The CE-treated hearts showed no signifi cant short term 
benefi t (14d measurements) in ventricle geometry (LVEDV, LVEDV) and EF. 
However, after 6 months, a positive remodeling could be demonstrated for the 
CE-treated hearts (see fi gure).
Conclusions: Positive remodeling after myocardial infarction can be achieved 
by MSC injection combined with CE enhancement in the border zone to attract 
IV delivered MSCs and to create a benefi cial microenviroment.
PREVENT REMODELING AND REPAIR INFARCTED 305 
MYOCARDIUM BY AUTOLOGOUS INTRACORONARY 
MESENCHYMAL STEM CELLS MODIFIED WITH AKT IN 
SWINES
Z. Shen1, Y. Yu2, W. Ye3, P. Jiao4, H. huang5, M. He6
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University, 4The First Affi niatied Hospital of Soochow University, 5The First 
Affi niatied Hospital of Soochow University, 6The First Affi niatied Hospital of 
Soochow university
Objective: This study aimed to engineer swine bone marrow-derived MSCs 
to overexpress AKT1 and test the hypothesis that AKT1-engineered MSCs 
were more resistant to apoptosis and could enhance cardiac repair after 
transplantation into the ischemia swine heart.
Methods: MSCs were isolated from bone marrow and purifi ed by centrifuge. 
The proliferation and growth characteristics were observed in primary and 
passage culture. Cell cycle was analyzed by measuring DNA content with 
fl owcytometer. The CDS (regulation domin of AKT1)AKT1-cDNA fragment 
was amplifi ed, then pPACKH1- Lentivector Packaging Kit was used to 
transfect Mesenchymal stem cells. MI models were created by occluding 
the distal LAD in 24 MEISHAN pigs£¨21-25 ©K£© with gelatin sponge. 
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The cardiac function was evaluated by magnetic resonance image(MRI) 
measurements and echocardiography 4 weeks later. All the pigs were divided 
into four groups: the control group(Group A, n=6), the DMEM group(Group B, 
n=6), the MSCs group(Group C, n=6), and the AKT-transfected group(Group 
D, n=6). The MSCs were transfected with the AKT1 gene (Group D).Then 
autologous BrdU labeled stem cells(1¡Á107/5 mL) was injected into LAD of 
the infarct heart by transcatheter in the group C and D. In the group B, 5 mL 
DMEM was injected in the same distraction by same approach. In group A, 
without injecting anything after occluding the LAD. Then after 4 weeks later, 
the cardiac function and regional perfusion measurements were repeated by 
MRI and Echocardiography, and the histological characteristics of the hearts 
were also studied to assess MSCs engraftment. CX-43, BrdU and VWF were 
tested with ELISA. VEGF, TGF-¦Â1were analysised in the same time.
Results: Before the cells implantation, the LV end-diastolic dimension(EDLVd) 
increased and the stroke volume(SV) decreased in the MI hearts. After the cells 
implantation, the MRI scans showed that the cardiac function was signifi cantly 
improved(compared with pre-implantation, P<0.05), and the implanted MSCs 
prevented the infarct region from thinning and expanding, improved contraction 
and increased perfusion in all groups relative to the control hearts(P<0.05). 
The left ventricular chamber size were smaller (P<0.05) in the hearts with 
being transplanted cells than that in the control hearts (P<0.05). Also, the 
improvement was even markedly greater in Group D (compared with Group C 
and B). The level of VEGF reached a¡¡high level 1 week after implanting the 
MSCs£¬ but the level of TGF-¦Â1 decreased gradually.
Conclusion: MSCs could improve the cardiac function by attenuating 
contractile dysfunction and pathologic thinning in this model of left ventricular 
wall infarction. This improvement might result from myocardial regeneration 
and angiogenesis in injured hearts by engrafted cells. Some cytokines played an 
important role in repairing the ischemic myocardium. The overexpression AKT 
of MSCs could resist apoptosis that caused by the ischemia microenvironment, 
which was devoid of nutrients and oxygen, and the therapeutic benefi t was more 
powerful than that of MSCs. Combined gene transfer and cell transplantation 
strategies will be an effective approach for the treatment of MI.
MESENCHYMAL STROMAL CELLS IN 306 
RENAL TRANSPLANTATION: MIGRATION AND 
IMMUNOMODULATION
S. McTaggart1,2, B. Jones1, G. Brooke1, C. Tracey1, L. Francis3, 
K. Atkinson1,2
1Mater Medical Research Institute, 2University of Queensland, 3Pathology 
Queensland
Introduction: Mesenchymal stromal cells (MSC) migrate to sites of ischemic 
damage and are immunosuppressive in vitro, making them attractive potential 
candidates for immunotherapy in renal transplantation. In this study, we 
assessed the migratory and immunomodulatory potential of MSC in a rat renal 
transplant model.
Methods: MSC were isolated from rat bone marrow and characterised by both 
surface marker expression and differentiation into osteogenic, chondrogenic 
and adipogenic lineages. Orthotopic transplantation of the right kidney 
was performed using fully mismatched rats (DA to Lewis) with syngeneic 
transplants (Lewis to Lewis) as controls. PVG strain MSC (10-15x106) 
were injected into the femoral vein of recipient rats at the time of transplant. 
Immunohistochemistry was used to localise injected MSC and clinical course 
was assessed by measurement of serum creatinine and histology of transplanted 
kidneys. Rejection was assessed by a pathologist blinded to treatment group 
and graded according to Banff criteria.
Results: MSC had typical cell surface phenotype, differentiation capacity 
and were immunosuppressive in vitro. Third-party MSC injected into rats at 
the time of allogeneic renal transplant were shown to preferentially migrate 
to transplanted kidneys. However, MSC infusion failed to attenuate transplant 
rejection with no signifi cant difference in histology and serum creatinine 
between allogeneic transplants and syngeneic control animals. Additionally, 
the immune phenotype of splenocytes, as assayed by fl ow cytometry using a 
panel of antibodies, was not modifi ed by MSC treatment. In addition, in these 
experiments there was no signifi cant effect of MSC administration on serum 
IDO activity.
Conclusion: Although in vitro studies have suggested a potential role for 
MSC as a cellular immunosuppressive therapy, this data suggests this may not 
translate directly into the in vivo setting of renal transplantation.
HEPATIC STELLATE CELLS MORE EFFECTIVELY 307 
PROTECT ISLET ALLOGRAFTS THAN BONE MARROW-
DERIVED MESENCHYMAL STEM CELLS
H-R. Yang1, Z. Yin2, J. Fung1, L. Lu1,2, S. Qian1,2
1Department of General Surgery, Cleveland Clinic, 2Department of 
Immunology, Lerner Research Institute, Cleveland Clinic
The tolerogenic property of the liver has been demonstrated by spontaneous 
acceptance of liver allografts, as well as tolerance to antigens that are delivered 
through portal vein in many species. The involved mechanisms are not 
completely understood. Although liver allografts are accepted in mice, but 
hepatocytes transplants in same combination are acutely rejection, suggesting 
a crucial role of liver non-parenchymal components (NPC) in protecting 
parenchymal cells from immune attacks. We have demonstrated that hepatic 
stellate cells (HpSC), well known to participate in liver fi brogenesis, markedly 
inhibit T cell responses in vitro and protect co-transplanted islets allografts from 
rejection in a mouse islet transplant model. Mesenchymal stem cells (MSC) have 
also shown immune inhibitory activity. The aim of this study was to compare 
the immunosuppressive effect of HpSC and MSC. To test the inhibition of T 
lymphocyte proliferation in vitro, irradiated B6 (H-2b) HpSC or bone marrow-
derived MSC were added to a mixed leukocyte reaction where irradiated 
BALB/C (H-2d) dendritic cells and B6 spleen T cells were used as stimulators 
and responders respectively. To determine the immunosuppressive activity in 
vivo, B6 HpSC or MSC were mixed with islets isolated from BALB/C pancreata 
and transplanted under the capsule of the left kidney of Streptozocin-induced 
diabetic B6 mice. Transplant of islets alone was used as control.B7-H1 knockout 
mice were used to examine the role of B7-H1 in the immunomodulatory effect. 
Both HpSC and MSC markedly inhibited T cell proliferative responses in MLR 
in a dose dependent manner. At a T:DC:HpSC (or MSC) ratio of 10:1:1, T cell 
thymidine uptake was almost completed inhibited by HpSC or MSC. None of 
mice in the control group remained euglycemic by 15 days after transplant. 
Co-transplant with MSC prolonged islet graft survival [medium survival time 
(MST) 28days, compared to11days in islet grafts alone group]. Co-transplant 
with HpSC markedly prolonged islet graft survival (MST>60days). 55% of 
recipients that received islets plus HpSC remained euglycemic for more than 
60 days. Expression of B7-H1 was up-regulated both in activated HpSC and 
MSC, and was crucial in their immune regulatory activity. Cotransplantataion of 
HpSC or MSC from B7-H1 knockout mice largely lost their capacity to protect 
islet allografts from rejection (HSC, MST=26 vs >60, p<0.05; MSC, MST=14 
vs 28, p<0.05). Immunohistochemical studies demonstrated a multiple-layered 
capsule surrounding the islets formed by co-transplanted HpSC. However, this 
multiple-layered capsule was not observed in co-transplantation with MSC. In 
conclusion, both HpSC and MSC have strong capacity to inhibit an ongoing 
allogeneic response in vitro. Co-transplantation with HpSC or MSC can protect 
islet allografts from rejection. However, MSC are far less effective than HpSC 
in this protective activity.
HEPATOCYTE BASED INSULIN GENE THERAPY308 
H. Sollinger, T. Alam, D. Held, E. Forsberg
Surgery Department, University of Wisconsin, Madison, WI, U.S.A.
Gene-therapy based glucose-regulated hepatic insulin production is a promising 
strategy to treat Type I diabetes. We have previously shown that hepatocytes 
engineered with the insulin gene construct 3SAM2 (which has a liver-specifi c 
albumin promoter coupled with 3 glucose inducible regulatory elements 
(GIRE)s from the S-14 gene and a proinsulin gene modifi ed for furin cleavage) 
corrected fasting hyperglycemia, improved glucose tolerance, and stabilized 
body weights in streptozotocin (STZ)-induced diabetic rats. However, due to 
insulin insuffi ciency, postprandial hyperglycemia was not fully corrected and 
weight loss in experimental animals was not reversed.
To increase the insulin output we generated a new insulin gene construct 
(TA1). The new construct contains an additional translational enhancer 
derived from vascular endothelial growth factor and the 3’-UTR from 
albumin. TA1 retained glucose responsiveness and caused 20-30 fold higher 
insulin production in isolated hepatocytes when compared to the old 3SAM2 
construct. In this study, STZ-diabetic rats were treated with the TA1 insulin 
gene construct. Our construct corrected fasting hyperglycemia during the fi rst 
4 weeks (treated diabetic rats (n=4): 117±31 mg/dl; STZ-diabetic rats (n=7): 
457±83 mg/dl; normal rats (n=4): 94±15 mg/dl) and signifi cantly (P<0.0001) 
reduced postprandial hyperglycemia (treated diabetic rats (n=4): 374±51 mg/
dl; STZ-diabetic rats (n=7): 619±118 mg/dl; normal rats (n=4): 130±11 mg/
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dl). Although the blood glucose levels gradually increased over the 6 months 
of study, the reduction in blood glucose levels of TA1 treated animals remained 
signifi cant (d73-103 measurements, mean±SDev: 248±140 vs 439±162 mg/
dl; P<0.0001).
For the fi rst time we have observed signifi cant weight gain in diabetic rats. 
As shown in the fi gure, during the fi rst four weeks, the rate of weight gain in 
insulin gene treated rats was statistically indistinguishable from that of normal 
rats. Beyond the initial one month period, treated rats continued to gain weight 
but at a reduced rate. The overall benefi t of a single insulin gene treatment on 
body weight can last up to 6 months.
Our data demonstrates that the new and enhanced insulin gene construct was 
able to greatly improve glucose-dependent hepatic insulin secretion in vivo. Our 
construct established fasting euglycemia without any signs of hypoglycemia 
and restored lasting weight gain. This study supports the feasibility of a gene 
therapy-based future treatment for type I diabetes.
COMPLETE REVERSAL OF STZ INDUCED DIABETES 309 
USING ADULT PDPC CELLS
P. Shiels1, L. McGlynn1, D. Chen2, K. Stevenson1, A. Dorling2, A. MacIntyre1, 
R.W. Davies1
1University of Glasgow, 2Imperial College London
Introduction: Cellular therapies hold potential for the treatment of diabetes. 
Evidence that candidate cells which might fulfi ll this role, reside in the pancreatic 
ducts, has been provided by rodent models of pancreatic regeneration. We have 
sought to isolate such cells and demonstrate that they can mitigate the effects 
of diabetes in vivo.
Methods: Novel candidate cells were isolated from adult rat and human 
pancreatic ducts and characterized by ICC, FACs and RT-PCR. The ability 
of these cells to mitigate the effects of diabetes was assessed in a double-
blinded trials in a xenogeneic mouse model of streptozotocin-induced diabetes 
mellitus. Female C57Bl/6 mice (n=4 per treatment group) were made diabetic 
by injection of streptotozocin (STZ) at a dose of 250 mg/kg on day 0 of the 
experiment. PDPCs were injected into the tail vein on day 3 after STZ injection. 
Control animals were given no cells. Blood glucose was monitored every 3 
days. All procedures were conducted under authority of the UK Home Offi ce.
Results: Direct intravenous injection of either rat, or human, PDPCs into STZ 
diabetic mice, completely normalizes blood glucose levels for over 100 days 
(Figure 1). Body weight and pancreatic histology in treated animals also appears 
normal. Crucially, the insulin produced in these treated animals is principally 
mouse in origin and is of both type I (embryonic) and II (adult). Human and 
rat PDPCs do not appear to integrate into reconstituted islets in the respective 
treatment groups. Detection of human or rat chromosomes in these groups 
is at a frequency of less than 0.007% in These data indicate that the primary 
mechanism of PDPC action is by stimulation of host tissue to regenerate.
Discussion: These results described for the fi rst time the use of an adult human 
cell type to achieve complete correction of diabetes in a rodent model for an 
extended period of time. The results reproducibly demonstrate the feasibility of 
using adult cells to regenerate damaged tissue and enhance our understanding 
of the mechanisms relating to such repair. Furthermore, they suggest a means 
for novel therapeutic intervention in diabetes.
Figure 1
Time course of blood glucose levels in STZ diabetic mice (n=4) treated with 
PDPC cells. Group A: Control. Group B: Rat PDPC. Group C: Rat PDPC sub 
population A. Group D: Rat PDPC sub population B. Group E: Human PDPC.
CONCURRENT ORAL SESSION 27: 
ANITBODY AND COMPLEMENT
SPECIFIC INHIBITOR OF PLASMINOGEN ACTIVATOR 310 
INHIBITOR-1 ATTENUATES MYOCARDIAL CELL 
INFILTRATION AND GRAFT ARTERIAL DISEASES IN 
MURINE CARDIAC ALLOGRAFTS
J-I. Suzuki1, M. Ogawa1, S. Muto2, Y. Yamaguchi2, A. Itai2, M. Isobe1
1Tokyo Medical and Dental University, 2Institute of Medicinal Molecular 
Design
Background: Acute rejection and graft arterial disease (GAD) in cardiac 
transplantation limits the long-term survival of recipients; these processes are 
enhanced by infl ammation and thrombus formation. Plasminogen activator 
inhibitor-1 (PAI-1) is critical in infl ammation and thrombus formation.
Methods: To test the hypothesis that inhibition of PAI-1 can attenuate acute 
rejection and GAD, we performed administration of the specifi c PAI-1 inhibitor 
(IMD-1622) into murine recipients of cardiac allografts. Murine hearts were 
heterotopically transplanted using major mismatch combinations for evaluation 
of acute rejection and class II allomismatch combinations for GAD.
Results: Nontreated allografts of the major mismatch group were acutely 
rejected (7.3 +/- 0.2 days), while the PAI-1 inhibitor prolonged their survival 
(13. 7 +/- 2.4 days, p< 0.05). While severe cell infi ltration and intimal thickening 
with enhancement of infl ammatory factors were observed in untreated allografts 
(cell infi ltration; 40.77 +/- 3.32%, intimal thickening; 28.60 +/- 6.35%) in the 
class II mismatch group on day 60, the PAI-1 inhibitor attenuated these changes 
(cell infi ltration; 25.80 +/- 1.88%, intimal thickening; 8.07 +/- 3.46%, p< 0.05 
respectively). RPA revealed that the PAI-1 inhibition markedly increased the 
IL-10 (a Th2 cytokine)/ IFN-gamma (a Th1 cytokine) ratio compared with 
that of the non-treated group. In vitro study showed that the PAI-1 inhibitor 
suppressed antigen-induced T cell proliferation. ELISA analysis using 
supernatants of the cell proliferation assay revealed that production of IFN-
gamma by the PAI-1 inhibitor treatment was suppressed (125.84 +/- 5.26 ƒÊg/
ml) in comparison to the control group (228.47 +/- 12.66 ƒÊg/ml, p< 0.05).
Conclusion: The PAI-1 inhibitor is potent for the suppression of both allograft 
rejection and GAD because they are critically involved in the development of 
rejection through the suppression of infl ammation and thrombus formation.
PLASMA LIPIDS INFILTRATE ARTERIAL ALLOGRAFTS 311 
AND ACCELERATE THE DEVELOPMENT OF TRANSPLANT 
ARTERIOSCLEROSIS
A. Schiopu, S. Nadig, K.J. Wood
Transplantation Research Immunology Group, Nuffi eld Department of 
Surgery, John Radcliffe Hospital, Oxford University, United Kingdom
Introduction: Transplant arteriosclerosis (TA), defi ned as diffuse intimal 
hyperplasia in arteries of the transplanted organs, is the main pathological 
process leading to chronic allograft rejection. Although this process is 
mainly immune mediated, there are other important non-immune factors 
that contribute to the pathogenesis of transplant arteriosclerosis. Lipid levels 
are generally increased in transplant patients and lipids are known to be 
heavily involved in the pathogenesis of native atherosclerosis in the general 
population. Nevertheless, the relative importance of lipids for chronic 
rejection is still unknown.
Material and methods: We have studied the infl uence of the lipid environment 
on the development of transplant arteriosclerosis in a fully mismatched arterial 
interposition graft model. CBA (H2k) arterial grafts were transplanted into 
the abdominal aorta of C57Bl/6 (H2b) ApoE-/- mice kept on normal diet or 
on a high-fat diet. Normolipidaemic wild-type C57Bl/6 recipients served as 
controls. Due to impaired cholesterol transport and clearance, the ApoE-/- mice 
have very high cholesterol and triglyceride plasma levels which are further 
exacerbated when the mice are kept on a high-fat diet. The arterial grafts were 
harvested 7 or 21 days after transplantation and we assessed the extent of 
transplant arteriosclerosis, cellular and lipid infi ltration into the neointima and 
the expression of VCAM-1 on the endothelium, as well as plasma cholesterol 
levels. The extent of transplant arteriosclerosis was expressed as percentage 
of the area inside the internal elastic lamina which is occupied by the newly 
formed neointima.
Results: Twenty-one days after transplantation CBA vessels transplanted into 
the hyperlipidaemic ApoE-/- mice presented a 100% increase in transplant 
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arteriosclerosis compared to the wild-type C57Bl/6 recipients (34.4±13.4% 
versus 16.6±10.5%, P<0.05). In the ApoE-/- mouse group kept on a high fat 
diet plasma cholesterol levels were markedly increased compared to the 
normal diet group and this resulted in further exacerbation of the pathogenic 
process (40.2±19.6% intimal expansion). The Oil Red O lipid staining revealed 
an intense diffuse lipid infi ltration throughout the neointima in the ApoE-/- 
recipients, whereas the lesions developed in wild type C57Bl/6 mice presented 
only minimal lipid infi ltration. We recorded a marginal increase in neointimal 
macrophage content at 21 days in the ApoE-/- group compared to the control 
(8.6±4% vs 7.1±3.7%), but this difference did not reach statistical signifi cance. 
Interestingly, no differences were recorded between the groups in terms of 
CD4+ and CD8+ T cell infi ltration or endothelial VCAM-1 expression, either 
at 7 or 21 days after transplantation.
Conclusion: Our study further highlights the importance of post-transplant 
lipid management in all solid organ recipients. We show that lipids exacerbate 
the development of transplant arteriosclerosis in a dose-dependent manner 
and heavily infi ltrate the newly formed neointimal layer. The lack of 
quantitative differences between the cellular infi ltrate in vessels transplanted 
into a hyperlipidaemic versus a normolipidaemic environment indicate that 
lipids infl uence neointima formation by mechanisms other than increased 
recruitment of infl ammatory cells, possibly by alternative activation of 
macrophages present at the infl ammatory site. Future dissection of these 
mechanisms might offer additional therapeutic targets for improvement of 
long-term allograft survival.
EFFECT OF PROBUCOL ON REJECTION OF 312 
HEART ALLOGRAFTS AND TRANSPLANT RECIPIENT 
ENDOTHELIAL FUNCTION
J. Laurence1, B. Wu2, Y. Wang2, V. Lam1, C. Wang1, R. Allen1, A. Sharland1, 
R. Stocker2, A.G Bishop1
1Collaborative Transplantation Research Group, University of Sydney, NSW, 
Australia, 2Centre for Vascular Research, Bosch Institute, University of 
Sydney, NSW, Australia
Background: Endothelial dysfunction may contribute to graft failure and 
systemic vascular complications in allograft recipients. We examined the 
effects of the anti-atherosclerotic drug probucol on cardiac graft rejection and 
recipient vessel function.
Methods: Rat allograft survival was assessed in the LEW>F344 and 
PVG>DA heterotopic rat heart transplant models. In the LEW>F344 model, 
recipient endothelial function was examined by relaxation of pre-constricted 
thoracic and abdominal aortic rings in response to acetylcholine; intragraft 
gene expression by qRT-PCR; and infl ammation, rejection and fi brosis by 
histology and immunostaining at six hours, three and twenty days after 
transplantation. Sera of recipients were analyzed for interferon-γ (IFNγ) by 
ELISA.
Results: Probucol 1% (wt/wt), given two weeks prior to, and throughout the 
time following, transplantation prolonged allograft survival in the PVG>DA 
(MST 8 versus 11 days, p=0.04) and LEW>F344 models (MST 31 versus >100 
days, p=0.0002). No differences were observed between treatment and control 
groups in graft infi ltration by T- or B-lymphocytes or macrophages, or in the 
expression of interleukin-2, IFNγ, inducible nitric oxide synthase, indoleamine 
2,3-dioxygenase or heme oxygenase-1. No differences were detected in 
serum IFNγ. Endothelium-dependent relaxation in response to acetylcholine 
became increasingly impaired in both aortic segments adjacent to and distant 
from the cardiac allograft. The extent of endothelial dysfunction increased 
with increasing duration post-transplantation (p<0.05); probucol signifi cantly 
inhibited endothelial dysfunction (p<0.05). Endothelium-dependent relaxation 
was also impaired in recipients of isografts, but this was similar to the 
impairment associated with laparotomy and aortic cross-clamping without 
transplantation.
Conclusion: These studies demonstrate for the fi rst time that heterotopic 
cardiac allograft is associated with systemic endothelial dysfunction, and that 
probucol inhibits this process as well as rejection.
COMPLETE INHIBITION OF AORTIC TRANSPLANT 313 
ARTERIOSCLEROSIS WITHOUT IMMUNOSUPPRESSION BY 
MANIPULATING CD34+ VASCULAR PROGENITOR CELLS TO 
PROMOTE REGENERATIVE REPAIR
A. Dorling, S. Shrivastava, J. Abrahams, D. Chen
Imperial College London
Background: Transplant arteriosclerosis (TA), characterised by intimal 
hyperplasia (IH) and vascular remodelling, is a manifestation of chronic 
rejection (CR) which results in progressive ischaemia, fi brosis and organ 
dysfunction. Many of the ‘synthetic’ vascular smooth muscle cells (VSMC) 
that proliferate to form the expanding neointima are known to derive from 
recipient vascular progenitor cells (VP). As such, they are not the targets of 
ongoing alloimmune responses. Many pro-infl ammatory factors, including 
coagulation proteases such as tissue factor (TF) and thrombin, have been 
shown to promote the development of IH. This study examined the impact of 
expressing anticoagulant fusion proteins specifi cally on new VP infi ltrating the 
neointima during TA.
Methods: BALB/c aortae were transplanted orthotopically into C57BL/6 
(WT) or α;-TFPI-Tg mice (backcrossed onto BL/6 for >12 generations). These 
mice express membrane-bound human tissue factor pathway inhibitor (TFPI) 
anticoagulant fusion proteins on α;-smooth muscle actin (SMA)-expressing 
cells (VSMC and some VP). Aortae were harvested 6 weeks later and examined 
for IH and by immunohistology. Dendritic cells (DC), CD4+ and CD8+ T cells 
were purifi ed using conventional protocols from recipient and donor mice, 
phenotyped by fl ow cytometry and used to examine primary and secondary 
allogeneic proliferative and cytokine responses. CD34+ VP were purifi ed from 
the peripheral blood of Tg or control mice following mobilisation into the 
circulation by carotid artery injury.
Results: T cells and DC from α;-TFPI-Tg mice did not express the human TFPI 
fusion protein by fl ow cytometry (compared to high expression on purifi ed 
control VSMC and a subset of α;-SMA-expressing VP). CD4+ and CD8+ T 
cells mounted primary proliferative and cytokine responses to mature BALB/c 
DC that were indistinguishable from those of WT mice. DC from the Tg 
mice stimulated primary allogeneic responses from BALB/c T cells that were 
similar to those initiated by WT DC. Secondary responses from transplanted 
animals will be reported. Whereas aortae transplanted into WT mice showed 
signifi cant IH at 6 weeks, those transplanted into α;-TFPI-Tg mice showed 
no IH. Immunohistology of aortae in WT mice revealed that IH consisted of 
large numbers of cells expressing α;-SMA and E-selectin, in the absence of 
a distinct endothelium. In contrast, aortae from the Tg animals maintained a 
quiescent endothelium, beneath which were found α;-SMA+ cells expressing 
human TFPI. CD34+ VP isolated from Tg mice were recruited into areas of IH 
when injected into WT mice 1 week post-transplantation. These cells switched 
on expression of TFPI and inhibited the progressive IH seen in controls.
Conclusions: The biology of VP is known to be crucially infl uenced by TF 
and FIIa. In this study, we have shown that inhibiting the function of TF 
on the surface of circulating recipient VP is suffi cient to completely inhibit 
the progressive TA that develops in aortae transplanted across a full MHC 
mismatch (in the absence of immunosuppression). Despite mounting a normal 
allogeneic immune response against the transplanted aortae, manipulation of 
the VP in this way promoted regeneration of normal vascular architecture. 
These results suggest a novel therapeutic strategy to inhibit the progressive 
organ dysfunction of chronic rejection.
MODULATION OF ISCHEMIA REPERFUSION INJURY 314 
BY THE NANOPARTICLE DELIVERY OF C3 SPECIFIC SMALL 
INTERFERING RNA (SIRNA)
M.D. Parker1, P. Lu2, M. Woodle3, F. Xie3, P.A. Lodge4, J.R. Pratt1
1Leeds Institute of Molecular Medicine, Leeds, United Kingdom, 2Sirnaomics 
Inc, Gaithersburg, United States, Department for Organ Transplantation, 
Leeds, United Kingdom, 3Intradigm Corporation, Palo Alto, United States, 
4Department for Organ Transplantation, Leeds, United Kingdom
RNA interference blocks gene expression using small unique segments of 
gene sequence. This natural process can be exploited to reduce transcription 
of specifi c genes and offers a new strategy to block gene expression. In 
transplantation, it has been established that donor derived Complement C3 is 
rapidly upregulated at the time of transplantation, and that such C3 contributes 
to ischemia/reperfusion injury and infl ammation during immune rejection of the 
organ. This study sought to exploit a novel nanoparticle strategy to treat donor 
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organs with siRNA to knockdown C3 gene expression in the donor kidney.
10μg of siRNA was packaged into synthetic polycationic histidine:lysine 
nanoparticles to facilitate in vivo siRNA transfection. The nanoparticles were 
added to Hyper Osmolar Citrate perfusion fl uid and administered to donor rat 
kidneys at the time of organ harvest. After 4hours of cold ischemia, the kidneys 
were transplanted into syngeneic hosts, and 2 days later were harvested. C3, IFN 
gamma, IFN alpha and IL-1 beta gene expression were then determined by Real-
Time PCR to assess the degree of gene knockdown and the effect of C3 gene 
knockdown on other pro-infl ammatory genes that could be infl uence by ‘off-target’ 
effects of siRNA. Histopathology of the tissues was performed to assess the effect 
of C3 gene knockdown on post-ischaemic tissues, and immunohistochemistry for 
C3 assessed the affect of C3 siRNA on local C3 deposition.
Delivery of naked C3 siRNA did not produce signifi cant C3 gene knockdown, 
however, using the siRNA packaged in the nanoparticle co-polypeptide at 
ratios of 4.5:1, 3:1 and 1.5:1 w/w with C3 siRNA produced signifi cant C3 gene 
knockdown (50% / 61% / 46% respectively, compared to untreated control 
transplanted kidneys: P<0.05, n=3/group). The use of a scrambled control 
sequence of siRNA did not reduce C3 expression, suggesting the effect was target 
specifi c. Assessment of off-target effects so far indicates the siRNA sequence 
used did not itself induce an infl ammatory response and analysis to date does 
not indicate any toxicity associated with the in vivo use of the co-polypeptide 
packaged siRNA. By histology, the reduced local expression of C3 in the donor 
organ was associated with diminished acute tubular necrosis characteristic of 
severe ischemia / reperfusion injury, and immunohistochemistry revealed a 
marked reduction in the deposition of C3 in the transplanted tissues.
In conclusion, packaging siRNAs into the nanoparticles provides a novel strategy 
to effectively reduce pro-infl ammatory gene expression in the transplanted 
kidney. The strategy offers clear clinical potential to reduce the local expression 
of genes contributing to post-transplant infl ammation and in the future we will 
develop arrays of specifi c siRNA to diminish pro-infl ammatory gene expression 
in donor organs as adjunct therapies to conventional immunosupression or 
tolerance induction.
ELICITED ANTIBODY RESPONSES TO IGB3 315 
GLYCOLIPID IS DEPENDENT ON A NOVEL PATHWAY
H. Vaughan, N. Dodge, E. Mouhtouris, Y. Qin Li, J. Milland, D. Christiansen, 
M. Sandrin
University of Melbourne
Background: Naturally occurring anti-carbohydrate antibodies, such as 
those to the ABO blood group antigens, are mainly T cell independent and 
IgM’s. Mice and pigs with a disruption in the α;1,3galactosyltransferase gene 
GGTA1, which generates Galα;(1,3)Gal (α;Gal), have been produced in an 
effort to combat the hyperacute rejection (HAR) of xenografts, caused by 
naturally occurring antibodies to the major pig xenoepitope α;Gal. However 
we, and others have shown that α;1,3galactosyltransferase knock out mice 
and pigs (α;GT-/-) express residual α;Gal, which is synthesised exclusively on 
glycolipids by another glycosyltransferase, iGb3 synthase (iGb3S). Therefore 
the production of elicited anti-α;Gal antibodies to lipid α;Gal will be of 
relevance in the rejection of α;GT-/- pigs in xenotransplantation. It has been 
previously reported that anti-α;Gal antibodies elicited in α;GT-/- mice, after 
immunisation with pig tissues, are T cell dependent.
Methods: Mice were immunized with glycolipids prepared from transfected 
cell lines. ELISAs were used to measure anti-carbohydrate antibody titres. Mice 
were treated with Mabs to CD3, CD4, CD40L and NK1.1 blocking antibodies 
to examine if antibody production could be prevented in vivo.
Results: Our studies show that anti-α;Gal IgM and IgG3 antibodies produced 
in α;GT-/- mice after immunisation with α;Gal glycolipids are CD4 and CD40 
dependent but CD1 independent, suggesting other non-CD1 mechanism(s) are 
involved in providing B cell help for the anti-iGb3 responses. Furthermore there 
was no requirement for either Vα;14+NKT or NK cells for these responses. 
Preliminary data suggest this novel presentation method is also observed with 
the α;Gal related B blood group glycolipid.
Conclusions: These observations suggest an alternative pathway for lipid 
antigen presentation, independent of CD1d, and raise the question of which T 
cells are involved in the immune effector functions, which elicit strong specifi c 
anti-glycolipid antibody responses in α;GT-/- animals.
INDUCTION OF RENAL ALLOGRAFT 316 
ACCOMMODATION IN DONOR SKIN-PRESENSITIZED 
NONHUMAN PRIMATES BY SHORT-TERM INHIBITION OF 
CIRCULATING COMPLEMENT
G. Chen1, S. Chen1, J. Li1, Y. Xiang1, S. Zhong1, H. Guo1, W. Wang2, 
Y. Xiong2, S. Chen1
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science And Technology, Wuhan, China, 2Kunming 
Institute of Zoology, Chinese Academy of Sciences, Kunming, China
Background: The immunologically sensitized recipients with donor-specifi c 
antibody (DSA) are considered to be at greater risk for the development of 
acute humoral rejection following transplantation. Induction of self-protection 
against DSA-mediated humoral injury known as accommodation may allow an 
allograft survives continuously in presensitizated recipient. The present study 
was undertaken to determine whether renal allograft accommodation could 
be induced in donor skin-presensitized monkeys by short-term inhibition of 
circulating complement, and to investigate its possible mechanisms via analysis 
of intragraft protective gene expression.
Methods: ABO-compatible and MHC-mismatched rhesus monkeys were paired 
as donor and recipient. Donor skin allografts were transplanted to presensitize 
recipients 14 days prior to renal transplantation. The presensitized recipients 
were allocated into the following groups: (1)no treatment; (2)CsA+MMF+Pred; 
(3)CsA+MMF+Pred+Cobra venom factor (CVF, 0.05 mg/kg iv. on day -2 and 
-1, then 0.02 mg/kg iv. every other day from POD 0-13). Renal allografts 
transplanted into non-presensitized recipients served as controls. Serum DSA 
and its mediated CDC were detected by FACS using donor lymphocytes as 
targets. Intragraft Heme oxygenase-1(HO-1), Bcl-2 and Bcl-xl gene expression 
at different time-point were determined by Immunohistochemical stainning.
Results: Donor skin-presensitization induced the production of DSA (mainly 
IgG), which mediated elevated CDC against donor lymphocytes in different 
degree. Without any treatment, renal allografts only survived for 3-4 days 
(3,3,4 days) in presensitized recipients (P<0.05 vs. 10.7¡À2.5 days in non-
presensitized controls), which developed sereve actue humoral rejection 
with massive IgG, C3, C4d and C5b-9 deposition. Triple therapy with 
CsA+MMF+Pred did not prolonged graft survival (2,3,4 days), while adding 
a short-term CVF therapy in the early period signifi cantly prolonged graft 
survival to a median survival of 145 days (41,140,>250,>435 days; P<0.01 vs. 
other groups). Repetitive low doses of CVF treatment led to very dramatic fall 
in serum C3 level and CH50 for at least 2 weeks, and 50% of monkeys received 
this therapy survived continuously with normal renal function even after the 
serum C3 levels returned to normal. Bcl-2, Bcl-xl and HO-1 were signifi cantly 
increased in long-term survival grafts via analysis of immunohistochemistry at 
different time-points (especially on POD 50 and 100).
Conclusions: Donor skin-presensitization signifi cantly accelerated renal 
allograft rejection with predominantly humoral injury in monkeys, which 
could not be prevented by regular CsA triple therapy. Additionally using CVF 
in the early critical period allowed long-term renal allograft survival in most 
presensitized recipients and most likely induced successful accommodation. 
The establishment of accommodation in this model may be associated with 
up-regulation of certain protective genes in grafts. These encouraging results 
indicate that the complement inhibition-based strategy may be valuable in 
future clinical cross-match positive or ABO-incompatible transplantation.
ONE POSSIBLE MECHANISM OF ANTIBODY 317 
MEDIATED, COMPLEMENT INDEPENDENT TRANSPLANT 
ARTERIOPATHY IN MICE
T. Hirohashi1, S. Uehara3, C. Chase1, P. DellaPelle2, P.J. Madesn1, P. Russell1, 
R. Colvin2
1Department of Surgery, Massachusetts General Hospital, Boston, MA, 
2Department of Pathology, Massachusetts General Hospital, Boston, MA, 
3Department of Pediatric Surgery, Osaka University Graduate School of 
Medicine, Osaka, Japan
Purpose: Based on experimental and clinical studies, alloantibodies are 
believed to be one of the pathogenic mechanisms responsible for chronic 
transplant arteriopathy, a major cause of late graft loss. We previously 
reported one pathway without the participation of complement that led to 
the development of CAV in transplanted mouse hearts. We also found that 
even non-complement fi xing antibodies can cause late graft injury. There are 
several possible mechanisms by which chronic vasculopathy can develop in 
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the absence of complement. These include but are not limited to: direct effects 
of NK cells, activation of NK cells or macrophages through Fc receptors, and 
the effects of interferon-gamma on the proliferation of smooth muscle cells. In 
this study we have focused upon the possible direct effect of NK cells in the 
development of CAV using a monoclonal antibody treatment protocol.
Methods: This murine heart transplant system focuses on the use of double 
knockout recipients. Hearts from B10.BR (H-2k) donors were transplanted 
heterotopically to C57BL6 recipients (H-2b) contrived to lack both T and B 
cell activity (RAG1-/-) as well as the gene for C3, a double KO B6.RAG-
/-C3-/-. Recipients received mouse monoclonal anti-H-2Kk(IgG2a), or both 
the monoclonal anti-H-2Kk(IgG2a) and a monoclonal antibody directed 
against NK1.1 cells (PK136). These treatments consisted of the following: 
30μg of purifi ed anti H-2Kk(IgG2a) antibody given i.p. on day +1 and 2x/
week thereafter, and in a second set of experiments, the previous treatment was 
supplemented with 100ìg of anti NK1.1 antibody given i.p. on day-6, +1 and 
1x/week thereafter. A control group receiving neither antibody treatment was 
also included. On day 28, the transplanted hearts were removed and evaluated 
histologically for coronary allograft vasculopathy (CAV) using the elastic 
tissue stain (ETS), for C4d deposition by immunohistochemistry and for the 
severity of CAV by morphometric analysis (neointimal index).
Results: In the anti-H-2Kk(IgG2a) antibody treated group, 9 of 10 transplanted 
hearts developed coronary lesions. However, in sharp contrast only 2 of 7 
transplants in the group receiving both the anti-H-2Kk(IgG2a) and anti NK1.1 
antibodies developed vascular lesions (p<0.05). When the neointimal index 
for lesion severity was employed, the index of severity of the former group 
was 68.5±32.0% and of the latter group 12.8±25.4% (p<0.01). In the untreated 
control group, 1 of 4 of the transplanted hearts developed CAV.
Conclusions: These data demonstrate that anti NK1.1 antibody treatment 
strongly inhibits the development of complement independent CAV, 
suggesting that the development of complement independent CAV involves the 
participation of NK cells.
VALUE OF FOXP3 MRNA IN PERIPHERAL BLOOD AS 318 
REJECTION MARKER AFTER MINIATURE SWINE LUNG 
TRANSPLANTATION
N. Satoda1, T. Shoji1, Y. Wu2, T. Fujinaga3, F. Chen3, T. Bando3, H. Date1, 
E. Kobayashi4, S. Uemoto5, T. Koshiba2
1Department of Thoracic Surgery, Graduate School of Medicine, Kyoto 
University, 2Department of Innovation Center for Immunoregulation 
Technologies and Drugs, Graduate School of Medicine, Kyoto University, 
3Department of Organ Preservation Technology, Graduate School 
of Medicine, Kyoto University, 4Department of Organ Replacement, 
Jichi Medical College, 5Department of Surgery, Graduate School of 
Medicine,Kyoto University
Background: The outcome of lung-transplantation (Tx) remains inferior 
to those of other solid organ Txs, despite the development of potent 
immunosuppressants. This may result from the lack of non-or minimal-invasive 
method to detect early rejection, in addition to its profound immunogenecity. 
Recently, there is emerging evidence that the expression of FOXP3 mRNA (a 
specifi c marker for regulatory T cells (Tregs)) is paradoxically up-regulated 
within rejecting graft in clinics.
Methods: Orthotopic left lung-Tx was performed, using high-responder 
combinations of outbred miniature swines (MLR >5000cpm) without 
immunosuppression (IS) (Group-acute rejection: Gr-AR n=10). Ischemia/
reperfusion injury model was used as a control (i.e. solely by clamping the 
vessels of the lung without Tx) (Gr-IRI n=4). Chest radiography and open 
lung biopsies were performed to monitor rejection. The expressions of 
FOXP3, perforin, Fas-L ,and IP-10 in the peripheral blood lymphocytes 
(PBL) or the lung biopsy specimens were quantifi ed at transcriptional 
level by real-time PCR. Additionally, steroid pulse + 6 day-FK506 
were administered to Tx recipients from post-operative day (POD) 4 
or POD 6 as a rescue therapy (Gr-day 4 RT n= 6) (Gr-day 6 RT n=4).
Results: In Gr-AR, rejection was suspected with chest radiography after 
POD6 (vs. Gr-IRI), but not before POD5. The specimens of biopsy in Gr-AR 
displayed moderate AR on POD4 and end-stage AR on POD 7 or POD10 (graft 
survival; 9.1 days). The expression of FOXP3 in the PBL reached its highest 
value as early as POD 4, while FOXP3 in Gr-IRI remained low at the same 
time point (p<0.0001). The FOXP3 level in PBL correlated with the intragraft 
FOXP3 level during rejection (p<0.0001 R2=0.925). Unlike FOXP3, neither 
perforin, Fas-L nor IP-10 exhibited signifi cant increase at any time point in Gr-
AR. In Gr-day 4 RT, a rescue therapy from POD4, when the peak of FOXP3 
was seen, signifi cantly prolonged graft survival to 23.5 27.2days (p<0.001 vs. 
Gr-AR). However, in Gr-day 6 RT, a rescue therapy from POD6, when rejection 
was suspected by chest radiography, did not prolong graft survival (11.0 days 
NS vs. Gr-AR). Similar to Gr-AR, in Gr-day 4 RT, the FOXP3 level in the 
PBL increased at POD4 and thereafter, declined during IS administration, but 
subsequently increased before chest radiography suspected late rejection.
Conclusions: Clinically relevant miniature swine lung-Tx model demonstrated 
that FOXP3 mRNA in the peripheral blood lymphocytes may be more 
promising candidate for a minimal invasive method to detect rejection at an 
early stage, rather than chest radiography and conventional rejection markers. 
Since the FOXP3 level in the peripheral blood lymphocytes would be likely 
to be a useful indicator for rejection, regardless of whether IS is used or not, 
the combination of FOXP3 level and current IS may contribute to improved 
outcome of clinical lung-Tx.
ALLOCATION POLICIESCONCURRENT ORAL SESSION 28: 
IMPACT OF DONOR AGE, DONATION AFTER CARDIAC 319 
DEATH, AND RISK OF DISEASE TRANSMISSION ON RATE OF 
ORGANS TRANSPLANTED PER DECEASED DONOR
K.J. O’Connor, J.W. Bradley, L. Sussman, R. Luskin, F.L. Delmonico
New England Organ Bank, Newton, MA, United States
Purpose: In an effort to increase the rate of organs transplanted per deceased 
donor (OTPD), careful evaluation of the impact of donor age, donation after 
cardiac death, and risk of disease transmission on OTPD is warranted. In this 
review, the impact of these factors on a single OPO’s OTPD rate is examined.
Methods: All deceased organ donors from one OPO from 1/1/2004 to 
11/28/2007 (n=841) were classifi ed as DCD (donation after cardiac death) or 
DBD (donation after brain death) donors and grouped by age < 50 years or age 
> 50 years. Records were reviewed to determine the presence of any of the 
following: anti-HCV+, HBCoreAb (IGM)+, history of cancer, CNS tumor as 
cause of death, social/behavioral risk factors for HIV infection (e.g. IV drug 
abuse). Donors with one or more of these fi ndings were classifi ed as risk factor 
donors (RFD); all others were classifi ed as no risk factor donors (NRFD).
Results: RFDs were encountered in 11.7% of all donors in this DSA. Among 
the 4 subgroups the frequencies of RFDs were similar (range 8.9% to 11.8%, 
table 1). Overall, RFDs yielded 0.72 less OTPD than NRFDs (2.42 vs. 3.14 
OTPD; P<.001). OTPD rates differed signifi cantly in both DCD age groups and 
the younger DBD group; reduced OTPD differences in RFD were evident in 
older DBD’s, but did not reach statistical signifi cance (Table 2).
Table 1.
Age Donor Type RFD NRFD % RFD
0-49 DCD 10 102 8.93%
50-85 DCD 7 72 8.86%
0-49 DBD 52 354 12.81%
50-85 DBD 29 215 11.89%
Table 2.
Age Risk DCD-HBD OTPD Signifi cance Organs_Tx Donors
0-49 NRFD DCD 2.39 P<.001 244 102
0-49 RFD DCD 1.60 16 10
50-85 NRFD DCD 1.53 P<.05 110 72
50-85 RFD DCD 0.71 5 7
0-49 NRFD DBD 4.12 P<.02 1459 354
0-49 RFD DBD 3.06 159 52
50-85 NRFD DBD 2.43 P<.1 522 215
50-85 RFD DBD 1.97 57 29
P values determined by t-test for Equality of Means
Discussion: Risk factors are associated with decreased rates of OTPD in 
all cases. Since donor acceptance practices vary among DSAs, developing 
standardized methods that incorporate risk factors for evaluating OTPD rates 
will allow more accurate comparative analyses and targeted identifi cation of 
opportunities for improvement.
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TEN YEARS OF NON-HEART BEATING DONATION IN 320 
THE NETHERLANDS REVIEWED; ARE WE BETTER OFF?
H. van Leiden1, B. Haase-Kromwijk1, E. de Buijzer1, W. Weimar2
1Dutch Transplant Foundation, 2Erasmus Medical Center Rotterdam
Purpose: The Netherlands stimulated non-heart beating category 3 (NHB3) 
donation (donors awaiting cardiac arrest) at a national level to create an extra 
pool of organs of deceased donors. Experience in the Dutch approach to fi ght 
organ shortage illustrates the impact of introducing NHB3 donation on the 
donor program.
Methods: Data on deceased donors in the Netherlands over the period 
1998-2007 were analyzed.
Results: Although the number of NHB3 donors signifi cantly increased, the 
number of HB donors decreased at the same time. Therefore the total number 
of deceased donors stabilized around 200 (+30), while only a shift towards 
NHB3 donation was observed to 43% of all deceased donors until 2005. 
NHB category 2 donation is performed only in some regions and contributed 
for less than 6% of the deceased donors these years. Due to the increasing 
number of predominantly NHB kidney-only donors the proportion of multi 
organ donors among deceased donors decreased from 62% to 52%, affecting 
the number of heart donors. Furthermore the discard rate of kidneys reported 
for transplantation increased from 8% to 22%.
After focussing on this problem and stimulating HB donation again, the 
percentage of HB among deceased donors increased to 66% in 2007, leading 
to a stop in the decrease of MOD’s. Even more, the total number of deceased 
donors, increased to 257 in 2007. This increase in HB donors resulted in a 
considerable increase in the number of transplantations in the Netherlands 
compared to the year 2006 (kidney 21%, liver 55%, heart 37%, lung 22% and 
pancreas 30%).
Conclusion: The original aim of stimulating NHB3 donation to solve the 
organ shortage by creating a new pool of donors has not been accomplished 
and might even have harmed the heart transplant program. Results in recent 
years did not decrease our suspicion of a competition between HB and NHB3 
donation and stresses the importance of stimulating HB donation instead of 
NHB3 donation.
IMPACT OF LEGAL REGULATIONS IN ORGAN 321 
TRANSPLANTATION
D. Norba, G. Kirste
Deutsche Stiftung Organtransplantation
In the light of the upcoming European Directive based on Art. 152 of the Treaty 
establishing the European community (TEC) the European Commission is 
funding various projects related to organ donation and transplantation. In the 
Alliance-O project (European Group for Coordination of National Research 
Programmes on Organ Donation and Transplantation) DSO (Deutsche 
Stiftung Organtransplantation) was in charge of investigating the legal and 
ethical aspects of organ donation and transplantation across the participating 
countries Germany, France, Hungary, Italy, Spain, UK, Portugal. Furthermore 
a more general overview about the legal framework of organ donation and 
transplantation was elaborated in the general report of the DOPKI project 
(Improving the Knowledge and Practices in Organ Donation) in which 15 OPO’s 
participated. Based on the investigations of these projects an overview about 
the relevance and impact of regulations in organ donation and transplantation 
shall be given.
It is important to distinguish legal regulations related to post mortem organ 
donation that can be based either on Heart-Beating-Donation or Non-Heart-
Beating-Donation on the one hand and legal restrictions to living donation.
First of all it has to be stressed that in all the participating countries the main 
cornerstones of organ donation and transplantation are regulated through 
parliamentary act which has not been the case some 15 years ago.
The two major prerequisites for post mortem heart beating organ donation are 
the brain death of the patient and the consent of the patient respectively his/her 
relatives. This is true for all the participating countries. However the criteria 
for brain death and in particular the regulations for the obtaining of consent 
differ immensely. One of the aims of the Alliance-O project was to investigate 
in detail the concepts of presumed consent and informed consent. The most 
interesting fi nding of this examination was to fi nd out that in the end in day 
to day practice those two concepts do not differ signifi cantly since the wishes 
of the relatives of a deceased person are always respected no matter what the 
legal regulation says.
Differences can be found in particular regarding the acceptance of Non-Heart-
Beating Donation. Only in 4 out of the 16 countries that were examined only 
in Croatia, German, Hungary and Poland NHBD is legally not permitted. 
However only in UK the law allows Non-heart-beating Donation in all four 
Maastricht Categories.
In terms of living donation existing regulations always imply a restriction in 
order to protect the potential living donor or to prevent organ traffi cking. Hence 
it is only consequent that those restrictions are regulated by law since they effect 
the right of the living donor do decide himself about his physical integrity and 
it also deprives the living donor recipient from a possibly lifesaving treatment. 
In all participating countries organ traffi cking is penalized and living donation 
has to be altruistic. The majority of the participating countries however require 
a specially defi ned relationship between donor and recipient and 10 out of 
sixteen countries have installed ethical committees that need to approve of the 
planned donation or require an approval by court.
PRELIMINARY RESULTS OF A PROSPECTIVE 322 
ALLOCATION POLICY OF EXPANDED CRITERIA DONORS 
(ECD) KIDNEYS: COMPARISON OF CORRELATIONS 
BETWEEN A CLINICAL AND HISTOPATHOLOGICAL 
SCORING SYSTEMS WITH OUTCOMES
L. Santiago Re, D. Curcio, J. Goldberg, M. Rial, D. Casadei
Instituto De Nefrología De Buenos Aires
The best way to allocate ECD kidneys has not been fully elucidated yet. 
Some transplant programs base their decision on whether to accept or not an 
organ on the clinical characteristics of the donor (e.g. deceased donor score, 
DDS) while others give more importance to the biopsy results (e.g. Double 
Kidney Transplant Group, DKTG). In a previous retrospective study we 
reported that donors clinical characteristics as measured by the DDS are more 
relevant than the biopsy fi ndings in terms of graft outcomes. Thus, we decided 
to prospectively allocate ECD kidneys based on the clinical score. A kidney 
biopsy was performed on all of them at the time of procurement but these 
results were not considered for decision-making. A single kidney transplant was 
performed in every case. The patients were divided into two groups according 
to the DKTG score of the kidney they received in order to assess if there were 
any differences in terms of 2-year graft function and survival in such cases that, 
according to DKTG, should have received a single (3) or double (>3) transplant. 
48 kidney transplant recipients of ECD donors performed between October 
2003 and October 2005 were analysed. Donor age, HLA mismatch, CIT, 
immunosuppressive regimen, induction use and 1-year acute rejection rate 
were not different between both groups. No differences were found in the mean 
values of creatinine clearance (p= 0.65) nor in the curves of mean values of 
creatinine clearance over time (p=0.55) (MANOVA test, Figure 1).There were 
no signifi cant differences in 2-year graft survival either (table 1). ECD kidney 
donors as defi ned by DDS can be safely used as single transplants in a cohort of 
low immunological risk de novo kidney transplant recipients, and 2-year graft 
outcomes are similar between kidneys that, according to the histological score, 
should be used for single or double transplantation.
Figure 1
Group 0= DKTG 0-3. Group 1= DKTG 4-8
Table 1
  DKTG 0-3 DKTG 4-8 P value
2-yr graft survival 83% 92% 0.281
Cr Cl 12 (ml/min) 56.2 29.2 56.2 22.8 NS
Cr Cl 24 m (ml/min) 43.4 19.5 48.8 17.9 NS
TU
ESD
AY
 
Oral Abstracts Tuesday 12 August 2008
1 1 5Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
CONSEQUENCES OF ALLOCATING DECEASED 323 
DONOR ORGANS BASED ON RECIPIENT ANTIBODY 
SPCIFICITIES (CPRA)
R. Kerman1, C. Van Buren1, S. Katz1, B. Kahan1, J. Lappin1, C. Olivarez2, 
T. Shafer2
1The University of Texas Medical School-Houston, 2LifeGift OPO
The UNOS Board of Directors has approved the change from using Panel 
Reactive Antibodies (PRA) to calculated PRA (CPRA). The CPRA is a 
formulated PRA based upon the frequency of the specifi cities of HLA antigens 
found in the donor pool and is expected to standardize the degree of patient 
sensitization. Donor organs expressing unacceptable antigens will not be 
offered to a recipient with donor (HLA) antigen specifi c antibodies (DSA). 
Highly sensitive, single antigen bead and solid phase assays (Flow PRA and 
Luminex) are used to identify these HLA antibodies (Abs). Each transplant 
center can determine the criteria used for identifying an unacceptable antigen, 
for example, based upon DSA titer or the fl uorescence intensity (FI) coming 
from the donor-specifi c single antigen bead. It is unclear whether Abs identifi ed 
by these techniques are clinically relevant for organ allocation.
We retrospectively evaluated Flow-PRA, fl ow cytometry crossmatching 
(FCXM), HLA Ab specifi cities and titers of 300 pre-transplant (Tx) sera from 
transplant recipients of deceased renal allograft donors transplanted following 
a negative cytotoxic-anti-human globulin crossmatch.
The two year graft survival of 91% for the recipients (44/54, 81%) with 
low-titer (1:16) donor specifi c HLA Ab and a negative (-) FCXM was 
signifi cantly better when compared to the 60% two year graft survival of 
the 19% (10/54) of recipients presenting with (+) DSA but a (+) FCXM 
(p< 0.001). Recipients (55/110, 50%) with non-donor specifi c HLA Abs 
(high or low titer) and a (-) FCXM also experienced a better two year graft 
survival of 89% compared to the 74% for the other 50% of recipients with 
(+) FCXMs (p < 0.001).
These data suggest that in the presence of donor-specifi c or non-donor-
specifi c HLA Abs you can not predict the crossmatch outcome without 
actually performing the crossmatch which will then infl uence donor organ 
allocation and graft survival outcome. In the face of low-titer DSA and a 
(-) FCXM recipients experienced excellent graft outcome when compared 
to recipients with (+) FCXMs. Therefore, donor organ allocation based 
on CPRA (Ab specifi city and unacceptable Ags) utilizing highly sensitive 
single antigen bead and solid phase Luminex assays may disadvantage 
recipients (no donor crossmatch) who could otherwise be successfully 
transplanted.
INFORMING ORGAN ALLOCATION POLICY: DEFINING 324 
EQUITABLE AND UTILITY-BASED AGE CUT-OFFS FOR 
DONOR AND RECIPIENT AGE MATCHING
J.S. Gill1, P.W. Nickerson2, G.A. Knoll3, E.H. Cole4
Division of Nephrology, Universities of 1British Columbia, 2Manitoba, 
3Ottawa and 4Toronto, Canada.
In Canada between 1995- 2005, 28% kidney transplant recipients (KTRs) under 
the age of forty received kidneys from deceased donors (DD) > 50 years, while 
30% of KTRs older than 55 years received kidneys from DD < 30 years. In a 
recent national forum on organ allocation, the Canadian transplant community 
agreed that it was desirable to avoid allocation of “Old Donor kidneys” to 
“Young Recipients” but no age cut-offs were specifi ed.
Using data from n = 6,191 fi rst, kidney only, transplant recipients between 
1995-2005 provided by the Canadian Organ Replacement Register, we 
performed a variety of multivariate regression analyses to quantify the potential 
benefi t of age matching. The benefi t of age matching was calculated as the 
difference between expected patient survival after transplantation, and death 
censored graft survival. This benefi t was determined at a variety of donor and 
recipient age cut-offs. Pediatric recipients, recipients of pediatric DD kidneys, 
and expanded criteria donor kidneys (donors ≥ 60 years) were excluded from 
the analyses.
The life expectancy of recipients < 55 years was greater than their anticipated 
graft survival at all donor age cut-offs explored (i.e. donor age 30, 35, 40, 
45 and 50 years). Thus patients < 55 years would be expected to spend less 
time on dialysis after transplant failure if prioritized to receive DD kidneys 
from below each of donor age cut-offs we explored. Among recipients < 
55 years, relatively small incremental benefi ts in patient and graft survival 
were achieved as we explored progressively younger DD age cut-offs (i.e. 
45, 40, 35 and 30 years). Thus our primary consideration in deciding on a 
DD age cut-off was the anticipated number of DD kidneys above and below 
a given donor age cut-off: The DD age cut-off < 35 years provided the best 
balance of utility in younger recipients (52% of recipients 19-54 years would 
be anticipated to receive kidneys from DD < 35 years), while maintaining 
equity in access to kidney transplantation among older recipients (waiting 
time for transplantation projected to increase by 16% among recipients ≥ 
55 years).
In summary, we recommend that DD donor kidneys under 35 years be prioritized 
to wait-listed Canadian patients < 55 years. This recommendation was accepted 
for implementation in our deceased donor kidney allocation algorithms at a 
recent consensus meeting of Canadian transplant programs.
THE IMPACT OF A NEW KIDNEY ALLOCATION 325 
SCHEME IN THE UK
C. Rudge1, S. Fuggle1, L. Mumford1, R. Johnson1, J. Forsythe2
1UK Transplant, Bristol, UK, 2Royal Infi rmary of Edinburgh, Edinburgh, UK
In April 2006 a new UK national kidney allocation scheme was introduced in 
response to concerns about equity of access to transplant for patients throughout 
the UK.
The previous scheme, in place since 1998, was only partly national. 
Approximately 50% of kidneys from donors after brain death (DBD) were 
allocated nationally to well matched patients, while the remaining kidneys 
were allocated according to local transplant centre policy. These allocation 
arrangements contributed to inequity in access to transplant in terms of blood 
group, ethnicity, HLA phenotype frequency and geography. Average waiting 
times between centres ranged from one to over four years.
The principal aim of the 2006 scheme was to address the inequities by (a) 
allocating all kidneys from DBD on a national, patient-specifi c basis, (b) 
relaxing the priority afforded to HLA matching beyond 000 HLA-A, B, DR 
mismatches and (c) prioritising other factors such as waiting time.
While all 000 mismatched patients and well-matched paediatric patients 
continue to receive priority, 75% of kidneys are allocated to other patients on 
the basis of a new points scoring system. This is based primarily on points for 
waiting time and for HLA match linked to patient age, although points are 
also allocated for other factors including donor-recipient age match and HLA 
homozygosity.
The results of the fi rst 18 months of the scheme show that 30% of transplants 
have been in patients waiting at least 5 years for transplant, compared with 11% 
of transplants in 2005 (the last year of the previous scheme), p<0.0001. The 
effect on the UK waiting list is already apparent: by September 2007 only 10% 
of patients on the active list had been waiting over 5 years, compared with 17% 
of patients on the list at the end of 2005, p<0.0001.
Linking points for HLA match and age has resulted in young patients receiving 
well-matched grafts, while older patients, who are less likely to be suitable for 
retransplantation in the event of graft failure and thus have less need to avoid 
sensitisation, do not wait for well-matched grafts which confer only marginal 
benefi t in terms of transplant outcome.
There have also been more transplants for diffi cult to match patients (24% 
of transplants compared with 17% previously, p=0.0002) and HLA-DR 
homozygous patients (20% of transplants compared with 11% previously, 
p<0.0001).
Despite national allocation of all kidneys there has been no increase in average 
cold ischaemia time (median 17 hours) and one-year graft and patient survival 
have remained unchanged (93 and 97%, respectively).
The 2006 UK National Kidney Allocation Scheme demonstrates clear benefi ts 
over the previous scheme, although geographical inequities will take time to 
resolve.
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EFFECT OF DONOR ETHNICITY ON KIDNEY SURVIVAL 326 
IN DIFFERENT RECIPIENT ETHNICITY - AN ANALYSIS OF 
OPTN/UNOS DATABASE
C. Callender1, W. Cherikh2
1Howard University, 2United Network for Organ Sharing
Background: Previous multivariate analysis using kidney transplants during 
4/1/94-12/31/00 from the Organ Procurement Transplant Network/United 
Network for Organ Sharing (OPTN/UNOS) database has shown that Black 
kidney donors were associated with poorer graft survival, especially when they 
were transplanted into Black recipients. The present study was conducted to 
see if this result still holds on a more recent cohort of US kidney transplants. In 
this study, we have compared graft and patient survival of different donor-to-
recipient ethnic combinations.
Methods: 72,495 recipients of deceased and living donor kidney alone 
transplants during 2001-2005 from the OPTN/UNOS database were included 
in the analysis. To analyze the effect of donor-recipient ethnicity on graft and 
patient survival within 5 years of transplant, and to adjust for the effects of other 
donor, recipient and transplant characteristics, a multivariate Cox regression 
method was used. Results are presented as hazard ratio (HR) with the 95% 
confi dence limit (CL) and p-value.
Results: Table below shows adjusted HR of graft loss and death within 5 years 
of transplant for selected donor to recipient ethnicity combinations. HR>1 
indicates worse survival, and HR<1 indicates better survival as compared to 
the reference group (White to White).
Graft Loss Death
Donor to Recipient Ethnicity HR [95% CL] P-value HR [95% CL] P-value
White to White (N=37,241) 1.00 - 1.00 -
Black to White (N=1,637) 1.35 (1.22, 1.50] <0.001 1.22 [1.06, 1.40] 0.005
Black to Black (N=6,550) 1.49 [1.32, 1.49] <0.001 0.97 [0.88, 1.06] 0.47
Black to Hispanic (N=466) 0.87 [0.71, 1.07] 0.18 0.69 [0.51, 0.93] 0.01
Black to Asian (N=217) 0.69 [0.48, 0.99] 0.05 0.59 [0.35, 0.98] 0.04
Black to Other (N=106) 1.38 [0.93, 2.04] 0.11 0.90 [0.47, 1.74] 0.77
White to Black (N=8,555) 1.15 [1.08, 1.21] <0.001 0.86 [0.79, 0.93] <0.001
Hispanic to Black (N=1,311) 1.20 [1.07, 1.34] 0.002 0.92 [0.77, 1.09 0.32
Asian to Black (N=202) 1.26 [0.97, 1.64] 0.08 1.01 [0.69, 1.48] 0.97
Other to Black (N=178) 1.17 [0.85, 1.61] 0.34 1.15 [0.76, 1.75] 0.52
Summary: Results of this study show that kidneys from Black donors are 
associated with signifi cantly worse graft survival when transplanted to White 
and Black recipients. Black donors are also associated with worse patient 
survival when transplanted to White recipients. As a group, Black recipients 
exhibited poorer graft survival regardless of the donor ethnic group. The 
graft and patient survival rates for Asian, Hispanic and Other recipients were 
not signifi cantly affected by Black donor ethnicity. While transplantation 
is benefi cial for all ethnic groups, these results confi rm the need to further 
review and examine underlying causes of the reduced survival with Black 
donors or for Black recipients. The medical literature has for some time noted 
a higher prevalence of Blacks with underlying disease factors that lead to 
End Stage Renal Disease and dialysis dependency. This analysis underscores 
the need for increased diligence in identifying and treating these diseases in 
minority populations and the need to identify ways to improve their post-
transplant survival.
INFLUENCE OF DONOR TYPE ON ELDERLY KIDNEY 327 
TRANSPLANT SURVIVAL AND ALLOGRAFT FUNCTION
L. Shen, S. Kuppachi, A. Agarwal, N. Turgeon, P. Tso, K. Newell, T. Pearson, 
C.Larsen, A. Kirk
Emory University
Background: Patients aged 60 years and older account for more than 50% of 
the people with end stage renal disease in the US. Use of living donor (LD) and 
expanded criteria donor (ECD) kidneys has progressively increased to assist 
with the growing demand for kidney transplants. Value of transplanting ECD 
kidneys continues to be questioned due to concerns regarding decreased patient 
survival and outcomes.
Methods: We performed a retrospective review to evaluate and compare the 
patient and graft outcomes of kidney transplant recipients aged 60 years and 
older stratifi ed by donor type (LD, standard criteria donor (SCD) and ECD).
Results: Between January 2002 and November 2007, 195 living and deceased 
donor elderly kidney transplants were performed. Median follow-up was 2.0 
years. Most (89%) were on renal replacement therapy (RRT) at the time of 
transplant. Length of RRT prior to transplant was signifi cantly shorter (p<0.01) 
in the LD (1.5 years) when compared to SCD (3.6) and ECD (3.0). Length of 
hospital stay was shortest in the LD (6.3 ± 5.0 days), followed by SCD (7.1 ± 
4.0) and ECD (9.2 ± 8.5, p=0.001).
Donor type is a signifi cant factor in patient survival. The survival rate at 1 
month, 1 year, and 3 years for SCD was 98.4%, 90.5%, and 76.7%, for ECD 
85.2%, 64.0%, and 44.8%, and for LD 100%, 94.3%, and 80.0% respectively. 
Compared to the ECD, both SCD (p=0.012) and LD (p=0.05) recipients had 
signifi cantly higher survival rates. Delayed graft function was highest in the 
ECD group (20.7%) followed by the SCD (16.8%) and LD (7.3%, p=0.15). 
Acute rejection occurred in 6 (20.7%) ECD, 5 (12.2%) LD, and 9 (7.2%) SCD 
(p=0.15).
Mortality rate of ECD was 34.5%, SCD 20.8%, and LD 14.6%. The mortality 
of ECD was 1.7x rate of SCD as projected by UNOS. The mortality of LD was 
0.7x rate of SCD. Two-thirds expired with a functioning renal allograft.
Pre-operative creatinine (p=0.055) was not different between groups. But, 
pre-operative creatinine clearance (p=0.0013) was different (LD: 13.0 ml/min, 
SCD: 10.7, and ECD: 9.5). Post-transplant creatinine was higher (p=0.007) and 
creatinine clearance was lower (p=0.0002) in the ECD (1.7 ± 0.5 mg/dl, 44 ± 12 
ml/min) than in the SCD (1.4 ± 0.5, 58 ± 17) and LD (1.4 ± 0.4, 61 ± 15).
Conclusion: ECD kidneys are an effective means of RRT but are associated 
with signifi cantly lower survival and reduced graft function in elderly patients. 
Use of these grafts should be weighed against the risk of prolonged dialysis and 
the availabilty of LD kidneys.
CONCURRENT ORAL SESSION 29: 
PAEDIATRIC KIDNEY/HEART TRANSPLANTATION
THE RELATIONSHIP OF DONOR SOURCE AND AGE 328 
ON SHORT- AND LONG-TERM ALLOGRAFT SURVIVAL IN 
PEDIATRIC RENAL TRANSPLANTATION
A. Dale-Shall2, J. Smith1, M. McBride3, S. Hingorani1, W. Harmon4, 
R. McDonald1
1Seattle Children’s Hospital, 2Levine Children’s Hospital at Carolinas Medical 
Center, Charlotte, 3United Network for Organ Sharing, 4Boston Children’s 
Hospital
Limited pediatric data on allograft survival from advanced aged kidney 
donors exists. To determine the infl uence of donor source and age on 
allograft survival in pediatric renal transplant recipients, we analyzed 
the Organ Procurement and Transplantation Network database. Allograft 
survival for 7,291 pediatric renal transplants was evaluated. Up to 5 years 
post-transplantation, graft survival was higher for living donor (LD) versus 
deceased donor (DD) recipients. At 7 years, allograft survival was 71% in 
18-54 year-old LD recipients, 59.1% in ≥ 55 year-old LD, and 45.1% in ≥ 
50 year-old DD recipients. An approximate 35% improvement in allograft 
survival in 18-54 year-old LD recipients was observed. Multivariate results 
showed that recipients of LD 35-49 (aRR 0.66, 95% CI 0.55-0.80) and LD 
50-54 (aRR 0.65, 95% CI 0.45-0.94) have a graft survival advantage over the 
ideal DD. In LD ≥ 55 years, no improvement in graft survival was observed 
when compared to the 18-34 year-old DD. In summary, we observed in a 
pediatric population, < 55 year-old LD kidneys afford improved long-term 
allograft survival when compared to DD kidney recipients. Increasing 
awareness of the long-term graft survival advantage for children receiving a 
LD kidney, even from older donors, should be a priority.
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A MINIMAL, HIGHLY SPECIFIC AND SENSITIVE 329 
GENE-SET FOR PERIPHERAL BLOOD-BASED 
DIAGNOSIS AND PREDICTION OF ACUTE RENAL 
TRANSPLANT REJECTION
L. Ying, L. Li, J. Martin, S. Hsieh, M. Sarwal
Stanford University
Background: A critical 11 gene-set for acute renal rejection (AR) diagnosis 
in peripheral blood has been previously identifi ed in our group using cross-
platform hybridization of 71 unique peripheral blood samples with matched 
biopsy diagnosis, with AR (n=44) and without AR (STA; n=27), with cross-
hybridization across 3 human microarray platforms: 30k cDNA Lymphochip, 
44k Agilent and 54k Affymetrix HU133plus. In this study we proposed to 
verify and validate this gene-set for AR diagnosis and prediction by peripheral 
blood PCR-based analysis.
Method: Total of 147 peripheral blood samples were selected for 384-well 
format multiplex ABI-TaqMan qPCR validation of AR diagnosis across 11 gene-
set. 50/147 (33 AR, 17 STA) samples had already been tested on microarray, 
whereas the other 97 samples were new, time and immunosuppression matched, 
peripheral blood samples (57AR, 40STA) and used as a test-set for blinded 
prediction of AR diagnosis using qPCR across the most informative 11 genes.
57 sequential samples from 19 AR patients (at AR, 1-6 months prior to, and 
after AR) were also examined by qPCR for these 11 genes for blinded AR 
prediction, prior to biopsy proven AR. Prediction models were generated using 
logistic regression analysis and p<0.05 considered signifi cant.
Result: In the validation set of 50 samples, 9/11 genes were highly signifi cant 
for confi rming peripheral blood-AR diagnosis (p<0.05). In the test group of 97 
samples, AR was predicted with a very high level of sensitivity and specifi city 
(PPV and NPV> 90%). In the group of 19 AR patients with sequential samples 
pre- and post-AR, expression for 3 of 11 genes were signifi cantly elevated in 
the pre-AR samples (vs. STA, p<0.03) but were not different between pre-AR 
and AR values.
Conclusion: A highly specifi c and sensitive biomarker panel of 11 genes has 
been derived and tested by cross-platform microarray analysis. this gene-set has 
now been validated and further verifi ed by multiplex PCR, for AR diagnosis 
and prediction, even 3 months prior to the rejection event. Utility of this gene-
set should be further validated in real-time by serial longitudinal peripheral 
blood testing, for more sensitive and specifi c minimally invasive monitoring 
for graft rejection.
CALCINEURIN INHIBITORS ARE A FACTOR IN 330 
THE UNCHANGED RATE OF RENAL GRAFT LOSS 
SURVIVING MORE THAN 5 YEARS: EVIDENCE FROM THE 
ANZDATA REGISTRY
J. Fletcher1,2, S. Chang4, F. Mackie3, S. McDonald4, S. Alexander2
1Department of Paediatrics, Nepean Hospital, Penrith, Sydney., 2Centre for 
Kidney Research, The Children’s Hospital at Westmead, Westmead, Sydney, 
Australia, 3Department of Nephrology Sydney Children’s Hospital, 4Australia 
and New Zealand Dialysis and Transplant Registry (ANZDATA)
We reviewed the rate of graft loss and effect of Calcineurin inhibitors (CNI) on 
graft survival in children who received a renal transplant in Australia or New 
Zealand over the last 30 years.
Methods: Data was obtained on all ESRD patients less than 20 years of age 
and those with a functioning graft at fi ve years via the ANZDATA registry. Age 
at transplantation and immunosuppression at time of transplant and at 5 years 
was analysed. Cohorts were divided into 5-year intervals from 1963 for graft 
survival analysis and divided into 5- year cohorts from 1975 to 1995 for CNI 
analysis. Impact of CNI use at induction out to 5 years on graft survival was 
compared for 0-5 years and > 5 years using a multivariate logistic regression 
model adjusted for year of transplant, age, sex, race, donor age, primary 
disease, duration of RRT pre transplant, graft number, HLA mismatch, peak 
PRA, donor source and initial CNI usage.
Results: There are 1763 children (<20 years of age) with ESRD and 1312 
transplant recipients in the ANZDATA registry. 68% of children had received 
CNI as maintenance immunosuppression. There were 657 functioning renal 
grafts at 5 years. 68% of patients received CNI at time of transplant and 64% 
at 5 years. We assessed the rate of graft loss after censoring for death. Graft 
loss rate has remained relatively constant over the 30 years. In 1968-72 (4.56 
grafts per 100 patient years) compared with 1993-97 (4.92 grafts per 100 
patient years). CNI use was protective for graft survival in the fi rst 5 years post 
transplant (Hazard ratio 0.65 [95% CI 0.44-0.96]) with loss of protection and a 
trend to worse outcomes in those whose graft survived > 5years (Hazard ratio 
1.41 [95% CI 0.77-2.59]) after adjustment.
Conclusion: The initial protective benefi t of CNI use in the fi rst 5 years 
post transplant is lost after 5 years graft survival. CNI toxicity may explain 
unchanged rate of graft loss in kidneys surviving beyond 5 years.
PEDIATRIC LIVING DONOR KIDNEY 331 
TRANSPLANTATION USING ALEMTUZUMAB PRE-
CONDITIONING AND TACROLIMUS MONOTHERAPY
H. Tan, D. Ellis, M. Moritz, A. Basu, A. Vats, E. Erkan, J. Donaldson, 
D. Connors, C. McFeaters, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Introduction: We have previously reported that Alemtuzumab (Campath-
1H) pre-conditioning with tacrolimus monotherapy provides effective 
immunosuppression for solid organ transplantation. We extend our study to a 
4-year experience of recipient pre-transplant lymphoid depletion and minimal 
post-transplant steroid-free immunosuppression in pediatric living donor renal 
transplantation.
Methods: Alemtuzumab pre-conditioning was used in 35 consecutive 
unselected living donor renal transplant recipients between January 14th 
2004 and November 7th 2007. Donor kidneys were removed laparoscopically 
(LLDN). Post-operatively, patients were treated with steroid-free tacrolimus 
monotherapy, and immunosuppression was weaned when possible. The mean 
follow up was 21.5+14.5 mos.
Results: The mean donor and recipient ages were 34.5 + 7.7 and 8.3 + 6.0 
years, respectively. The mean HLA mismatch was 2.6 + 1.1. LLDN was 
associated with 0% delayed graft function (DGF). The mean creatinine (mg/
dL) at 1, 2, 3-yr was 0.89 + 0.44 (n=24), 0.87+0.37 (n=15), and 0.86+0.48 
(n=7), respectively. The mean GFR (mL/min/1.73m2) at 1, 2, 3-yr was 
69.2+38.1, 76.1+36.1, and 85.4+64.5, respectively. Patient survival at 1, 2, 
and 3-yrs was 100%, 95%, and 95%, respectively. Graft survival at 1, 2, and 
3-yrs was 100%, 89.7%, and 89.7%, respectively. The loss of 2 renal allografts 
was related to vascular torsion of an intraperitoneal allograft 645 days after 
transplantation and a patient death unrelated to the transplant. The cumulative 
incidence of acute cellular rejection (ACR) at 1, 2, and 3 yrs was 2.9% (day 22, 
preweaning), 2.9%, and 5.7% (day 834, postweaning), respectively. Weaning 
was attempted in 46% of recipients. At follow-up, 12 (35%) of children were 
tapered to spaced tacrolimus monotherapy, and 88.2% (n=30) were steroid free 
and on tacrolimus monotherapy. There was no tissue invasive cytomegalovirus 
(CMV) infection, no post-transplant lymphoproliferative disease, and no BK 
viral nephropathy. There was no donor mortality or morbidity.
Conclusion: This study represents the largest series to date of unselected 
live donor pediatric kidney transplant recipients receiving alemtuzumab 
preconditioning, and confi rms the mid-term safety and effi cacy of this 
approach. LLDN is not a risk factor for DGF or ACR in pediatric kidney 
transplant recipients.
KIDNEY TRANSPLANTATION IN CHILDREN AND 332 
ADOLESENTS - ANALYSIS OF OPTN/UNOS DATA
Y. Cho2,3, B. Hardy1, T. Shah2, J. Cicciarelli2,3, K. Lemley1, I. Hutchinson2,3
1Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC 
School of Medicine
Background: It is very important to investigate whether specifi c pediatric 
allocation schemes can not only lead to minimization of waiting time, but also 
to better clinical outcomes for children with end-stage renal disease (ESRD).
Materials and methods: We analyzed the OPTN/UNOS data for all patients 
aged 2-20 years who received kidney transplants from living or deceased 
donors aged 5-35 years between January 1, 1994 and December 31, 2006. 
Multiple organ transplants were excluded from this study. The outcome of 4,125 
deceased donor kidney transplants (DDKT) was compared with those of 6,456 
living donor kidney transplants (LDKT) using univariate and multivariate Cox 
regression analyses.
Results: Unadjusted graft survival rates of DDKT were signifi cantly lower 
than those of LDKT (HR=1.53, P<0.001). Chronic rejection was reported 
in 416 (10.1%) of 4,125 DDKT group compared with 537 (8.3%) of 6,456 
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LDKT group (P<0.001). Among black recipients, 65 (3.3%) grafts were lost 
due to non-compliance as a contributory cause of failure compared with 126 
(1.5%) among other races (P<0.001). A signifi cantly lower incidence of non-
compliance was observed in children (0.9%) compared with adolescent (2.2% 
in age 10-14, P<0.001) and high teens (2.0% age 15-20, P<0.001). Multivariate 
analysis showed that adjusted graft survival rates of LDKT were superior to 
DDKT (HR=1.22, P<0.001) after adjusting for recipient race, recipient age, 
regraft status, and HLA mismatch.
Conclusion: It is recommended that LDKT be offered fi rst to children instead 
of DDKT.
Table. Results of univariate and multivariate analyses.
Unadjusted
HR (95% CI)
P value
Adjusted
HR (95% CI)
P value
DDKT vs LDKT 1.53 (1.42-1.65) <0.001 1.22 (1.12-1.34) <0.001
Recip race Black vs others 2.01 (1.85-2.20) <0.001 1.81 (1.66-1.98) <0.001
Recip Age 10-14 vs 2-9 1.47 (1.30-1.66) <0.001 1.43 (1.27-1.62) <0.001
 15-20 vs 2-9 1.91 (1.72-2.12) <0.001 1.87 (1.68-2.08) <0.001
Regraft vs primary 1.51 91.35-1.68) <0.001 1.39 (1.24-1.56) <0.001
HLA mismatch (0-6) 1.14 (1.11-1.16) <0.001 1.07 (1.04-1.10) <0.001
OUTCOMES OF PAEDIATRIC KIDNEY TRANSPLANTS 333 
AFTER SWITCH TO SIROLIMUS
S.E. Kennedy1, F.E. Mackie1,2, G. Kainer1, E. Craig1, A.R. Rosenberg1,2
1Sydney Children’s Hospital, Randwick and 2University of N.S.W, Sydney. 
Australia
We report results of paediatric kidney transplant recipients converted from 
calcineurin inhibitors (CNI) to sirolimus (SRL).
Since 2003, 15 child/adolescent recipients have received SRL at our centre. All 
had initially received basiliximab induction with maintenance CNI, prednisone, 
and either azathioprine or mycophenolate. The median age at time of transplant 
was 11 years (range 23m-16y). SRL was introduced at a median time of 16 
months posttransplant (range 2–90 months). CNIs were discontinued in 14 
and reduced in 1. All were biopsied prior to conversion. Complete follow up 
was available for 353 patient-months of SRL treatment (mean 23±13 months/
recipient). SRL was discontinued in one because of upper limb oedema and 
one graft failed due to non-adherence. SRL was otherwise well tolerated. Mean 
cholesterol levels 12 months after SRL were similar to baseline (4.78 ± 1.25 vs 
4.86 ± 0.77 mmol/L, baseline vs 12 months post conversion respectively) but 
there was an increase in the use of statin therapy (mean atorvastatin dose 1.7 vs 
11.3 mg/day; baseline vs 12 months. P<0.01). No adverse effects of statin therapy 
occurred. The mean triglyceride level increased with SRL use (2.0 ± 1.7 vs 2.7 
± 1.4 mmol/L; baseline vs 12 months. p<0.05). Haemoglobin levels were stable 
over 12 months (115 ± 12 vs 117 ± 19; baseline vs 12 months). Four recipients 
have received darbepoetin therapy. The most recent ten recipients started SRL 
within 20 months of transplant; all had histological evidence suggestive of either 
acute or chronic CNI nephrotoxicity. Eight of this group have been followed for 
at least 12 months. The mean GFR was unchanged during the fi rst 12 months 
after conversion (64 ± 12 vs 62 ± 12 ml/min/1.73m2; baseline vs 12 months after 
conversion) but had fallen in those seven patients followed for 24 months (55 ± 
15 ml/min/1.73m2. p<0.05 vs baseline). Four recipients had episodes of steroid 
reversible acute rejection (AR) while taking SRL. We compared the number of 
AR episodes in the 9 recipients treated by SRL within 20 months post-transplant 
to an age-matched historical cohort who had been treated with a CNI based 
regimen (n=9). All in the control group had been treated for suspected AR 
between 2 and 5 years after transplant. Rates of rejection after SRL conversion 
were less than in controls during years 2 to 5 after transplant (0.01 vs 0.1 
rejection episodes per month in SRL vs control; p<0.01).
We conclude that SRL conversion is well tolerated by paediatric kidney 
transplant recipients and offers at least as good a degree of protection from 
acute rejection as CNI based regimens.
EXTENDED ENROLLMENT AND ANALYSIS OF A 334 
PROSPECTIVE STEROID-FREE IMMUNOSUPPRESSION 
TRIAL SUPPORTS STUDY SAFETY AND EFFICACY
M. Sarwal, L. Li, O. Salvatierra, W. Concepcion, C. Wong, S. Alexander, 
P. Grimm, J. Martin
Stanford University
Aim: To evaluate the long-term safety and effi cacy of a prospective, single-
center, pilot, steroid-free (SF) pediatric renal transplantation.
Methods: 112 consecutive pediatric renal transplant recipients of living 
(n=88) and deceased donors were enrolled since 1999 in a steroid avoidance 
protocol with extended Daclizumab induction (6mo), TAC and MMF. 105 
matched recipients on a steroid-based (SB) protocol of induction (Daclizumab/
Thymoglobulin) +steroids+TAC+MMF were controls (33% propsective). All 
SF and prospective SB patients had protocol biopsies at 3, 6, 12, and 24 mo 
and for graft dysfunction. Statistical analysis including T, survival analysis, 
chi-square, repeated measures were done by SAS.
Results: Mean follow-up for SF patients was 53.6 mo. SF patient survival 
and death-censored graft survival at 1 yr was 99% and 100% and at 4 yrs 
was 92% and 100%. SF patients had a low incidence of acute rejection (AR) 
(7% vs. 28%, p=0.0001), with mean time to 1st AR at 21 mo. Signifi cant 
benefi ts in SF were seen for linear growth with maximal benefi t in the <6 yr 
old and excellent graft function (see fi gure). SF patients had signifi cantly less 
hypertension and hyperlipidemia (p<0.01) upto 4 yrs by mixed model. At 1 
yr SF required more erythropoetin (25% vs 10%, p=0.004) and GCSF (18% 
vs 0%, p<0.0001) skewed towards early study enrollment, but there were no 
differences in hematocrit, EPO use, leucopenia or GCSF usage at 4 yrs. In 
the SF group, there was 1 nodal PTLD, 2 CMV disease and 2 BK nephritis. 
14% (n=16) broke SF protocol at mean 10 mo post-txp, with reccurrence of 
primary disease in 6 patients. 3% SF vs 13% SB patients had PTDM at 4 yrs 
(p=0.0035).
Conclusions: SF immunosuppression protocol offers excellent continued graft 
and patient outcomes for pediatric renal txp recipients with signifi cant benefi ts 
for growth, rejection, graft function, hypertension, hyperlipidemia, PTDM, and 
graft survival.
TWENTY YEAR OUTCOMES AFTER HEART 335 
TRANSPLANTATION DURING INFANCY
R.E. Chinnock, T. Shankel, D. Cutler, R. Larsen, M. Kuhn, A. Razzouk, 
J. Fitts, J. Johnston, L. Bailey
Loma Linda University Children’s Hospital, Loma Linda, CA USA
Purpose: The fi rst successful heart transplant procedure in an infant was 
performed in 1985. That patient is now 22 y/o, still with his fi rst allograft. Since 
then, much has been learned. Now we are better prepared to describe the long-
term outcome of infant heart transplantation. We will describe the single center 
clinical outcomes of a 22 year experience with infant heart transplantation.
Methods: The clinical data repository was retrospectively reviewed to 
gather information on our patient survival, rejection history, cardiac allograft 
vasculopathy (CAV), post-transplant lymphoproliferative disease (PTLD), 
renal function, and developmental outcome.
Results: 102 newborns (0-30d) and 199 infants (1-12 mo) have undergone 
heart transplantation. Actuarial survival at 20 years for newborns is 63%, 
for infants it is 50%. There are now 7 infants who have survived beyond 
20 years. The patient half-life for infant recipients is 17 years. The patient 
half-life for newborn recipients is still undefi ned. Actuarial risk for rejection 
beyond 10 years is 19%. Fifty patients have been diagnosed with CAV – 
an actuarial risk at 20 years of 31%. Thirty-six pts have experienced late 
(beyond 1 yr) rejection with hemodynamic compromise. This group had a 
TU
ESD
AY
 
Oral Abstracts Tuesday 12 August 2008
1 1 9Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
57% risk for developing CAV within 2 years of this event. There were 25 
re-transplants, and 3 have had a 3rd transplant. There have been 27 cases of 
PTLD, with a 20 year actuarial risk of 18%, and a 48% mortality. Isotopic 
glomerular fi ltration rates (obtained within the past 3 years) were available 
for 74 pts with a mean +/- SD = 76+/-29 mL/min/1.73m2 (normal 80-120). 
Six pts have undergone and 2 are awaiting renal transplantation. Fractional 
shortening data (within the prior 3 yrs) was available for 125 patients with 
mean±SD of 37±6 (normal 28-44%). Information for current educational 
status (assessed by parental questionnaire) is available for 170 survivors. Of 
these, 98 (57%) are normal, 68 (40%) require education assistance, and 4 
(3%) are severely impaired.
Conclusion: Twenty year survival after heart transplantation in the fi rst year 
of life has now been demonstrated. Re-transplantation in 25 pts has been 
required to achieve this result, and more could have benefi ted. Rejection 
is still a concern, even in these presumed immunologically privileged 
patients. Compliance during adolescence may contribute to late rejection 
and graft loss, and is a signifi cant concern. Rejection and CAV are the 
largest contributors to late graft loss. PTLD is also a signifi cant concern. 
Renal function is acceptable for most, but strategies to minimize calcineurin 
inhibitor use are needed. Educational performance is acceptable for most, 
and consistent with results from other patients who underwent cardiac 
surgery during infancy.
EVEROLIMUS IN PEDIATRIC HEART 336 
TRANSPLANTATION: FIRST REPORT ON ROUTINE CLINICAL 
USE IN INFANTS BELOW THE AGE OF 9 MONTHS
H. Lehmkuhl, S. Schubert, N. Hiemann, M. Dandel, C. Knosalla, M. Hübler, 
O. Grauhan, R. Hetzer
Deutsches Herzzentrum Berlin
Purpose: Everolimus is used in combination with cyclosporine A (CsA) in 
adult heart transplantation for prevention of acute rejection. There exists 
experience in 19 pediatric renal TX with everolimus in children aged above 1 
year. To date no experience exists in infant heart transplantation.
Methods/materials: To date, we performed 151 pediatric heart transplantations 
(HTx). Since 12/2004 twenty six children received everolimus in combination 
with CSA and steroids. We report on 5 HTx infants below the age of 1 year 
exposed to everolimus. Graft rejection was assessed non-invasively by tissue 
Doppler echocardiography (TDI) and intramyocardial electrocardiography 
(IMEG). Dose of everolimus was initiated at 0.8 mg / sqm BSA and guided by 
target trough levels of 3 to 8 ng/ml with concomitant CsA with C0 target levels 
of 200–300ng/mL (1 month), 175–250ng/mL (2–3 months) and 150–200ng/
mL (4–6 months).
Results: The infants were 8, 6, 5, 4 and 3 months of age. 3 infants were 
awaiting HTx on LVAD. Mean CsA levels were 214ng/mL and 296 ng/ml at 2 
respectively 4 weeks after HTX and reduced at 3 and 6 months to a mean level 
of 203 ng/ml respectively 188 ng/ml. Post-transplant everolimus trough levels 
were 3.9 ng/mL at 2 weeks, 8.8ng/mL at 4 weeks, 6ng/mL at 3 month and 
5.6ng/ml at 6 months. There were 2 rejection episodes in 2 infants which were 
treated with steroids. Everolimus was interrupted in 2 infants at week 3 (wound 
healing problem and renal dysfunction) and week 2 (poor enteral resorption). 
Creatinine levels were normal in 4/5 children. 1 child´s kidney function with 
crea max of 1.46 mg/dl at 2 weeks post HTx returned to normal by month 2 
following discontinuation of everolimus. All but 1 of the infants had normal 
serum lipids (max. Cholesterol 320 mg/dl at week 4 post HTx). There was no 
signifi cant thrombocytopenia. 1 Child experienced CMV infection. No severe 
infection occurred.
Conclusion: In a routine clinical setting, everolimus in infants shows similar 
effi cacy and safety demonstrated elsewhere in adult HTX. Further controlled 
studies in larger cohorts are warranted to defi ne the role of everolimus in 
pediatric heart transplantation.
CONCURRENT ORAL SESSION 30: 
KIDNEY TRANSPLANTATION – SURGICAL COMPLICATIONS
THE BENEFIT OF SINGLE AND DOUBLE KIDNEY 337 
TRANSPLANTATION FROM EXPANDED CRITERIA DONORS 
AND DONATION AFTER CARDIAC DEATH
J. Sageshima1, G. Ciancio1, L. Chen1, T. Cordovilla1, D. Roth2, W. Kupin2, G. 
Guerra2, L. Hanson1, G. Burke1
1University of Miami, Surgery, Kidney and Pancreas Transplant, 2Medicine, 
Nephrology and Hypertension
Purpose: The recent expansion of donor criteria to increase the number of 
patients transplanted may be associated with worse outcome. The aim of this 
study is to evaluate patient and graft survival, and renal allograft function 
of expanded criteria donors (ECD) and donation after cardiac death (DCD) 
recipients.
Methods: We retrospectively analyzed 411 consecutive adult patients 
(November 2004 - October 2007, median follow-up 16 mo) who received 
deceased donor kidney-alone transplantation (Tx) at a single center. The 
pediatric en-bloc kidney Tx (n = 17) were excluded from the study. To decrease 
discard and improve transplant rate, all kidneys were evaluated histologically 
and via fl ow/resistance parameters while preserved on pulsatile perfusion. 
The kidneys from ECD/DCD were Tx’d as single (n = 46) or double (n = 
46) grafts based on donor age, renal function, medical history, histological 
fi ndings and fl ow/resistance. All recipients were induced with antilymphocyte 
antibodies (Thymoglobulin, daclizumab and/or alemtuzumab) and maintained 
with mycophenolate and tacrolimus. To reduce nephrotoxicity, tacrolimus was 
withheld until serum creatinine levels fell down to 4.0 mg/dl and trough levels 
were targeted to 5 - 8 ng/ml thereafter; corticosteroids were withdrawn from 
majority of the recipients.
Results: The ECD/DCD kidneys were Tx fd into older patients than the standard 
criteria donor (SCD) kidneys (SCD: 50.3 } 13.7, single ECD/DCD: 55.6 } 14.5, 
double ECD/DCD: 59.7 } 8.6 year old, p < 0.001). This was associated with 
lower 1-year patient survival (SCD: 98.3%, single ECD/DCD: 94.6%, double 
ECD/DCD: 91.1%, p = 0.016). The ECD/DCD kidneys were associated with 
signifi cantly higher delayed graft function (DGF requiring dialysis within 1 
week posttransplant) rate than SCD kidneys (SCD: 3.6%, single ECD/DCD: 
13.0%, double ECD/DCD: 8.7%, p = 0.007), however only slightly lower 
1-year death censored graft survival (SCD: 95.1%, single ECD/DCD: 93.5%, 
double ECD/DCD: 90.2%, p = 0.044). The single ECD/DCD recipients had 
signifi cantly lower calculated GFR at 1 year than the SCD recipients (SCD: 
63.8 } 16.7, single ECD/DCD: 49.3 } 17.1, double ECD/DCD: 61.5 } 20.6 ml/
min/1.73m2, p < 0.001) although the double ECD/DCD were recovered from 
donors with lower GFR (SCD: 78.1 } 25.4, single ECD/DCD: 70.6 } 26.2, 
double ECD/DCD: 56.6 } 24.1 ml/min/1.73m2, p < 0.001).
Conclusion: Although the SCD Tx has better patient and graft survival 
than the ECD/DCD Tx, the utilization of ECD/DCD increases the number 
of Tx, particularly into older recipients, without compromising the outcome 
exceedingly. The double kidney grafting is an effective option to optimize renal 
graft function of Tx from donors with less than optimal renal function.
PREEMPTIVE REPEAT KIDNEY TRANSPLANTATION 338 
IS ASSOCIATED WITH AN INCREASED RISK OF SECOND 
GRAFT LOSS IN PATIENTS WITH A SHORT DURATION 
OF FIRST GRAFT SURVIVAL
O. Johnston, C.L. Rose, J.S. Gill
Division of Nephrology, St. Paul’s Hospital, University of British Columbia, 
Vancouver, British Columbia, Canada.
Among fi rst kidney transplant recipients, preemptive transplantation is 
associated with a decreased risk of graft loss. Previous studies have shown 
that second graft survival is lower in patients who had early fi rst graft failure. 
We performed this analysis to determine whether preemptive transplantation in 
second transplant recipients (rPTX) is also benefi cial, and whether the benefi t 
of rPTX is affected by the duration of fi rst graft survival.
We determined in the risk of graft loss in preemptive and non-preemptive adult 
(>18 years) kidney-only repeat transplant recipients (n = 6,140), captured in the 
United States Renal Data system between 1995-2003, using a Cox multivariate 
regression analysis, which included adjustment for multiple confounders.
Surprisingly rPTX was not uniformly benefi cial (fi gure): Among patients with 
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fi rst graft survival ≤ 3 years, rPTX was associated with an increased risk of all 
cause and death censored second graft failure. The risk of death censored graft 
loss was also higher among preemptive transplant recipients with fi rst graft 
survival of 3.1-5.0 years. rPTX was only associated with a decreased risk of 
graft loss in patients with fi rst graft survival > 10 years.
We conclude that rPTX is associated with an increased risk of second graft loss 
in patients with fi rst graft survival ≤ 3 years and that there is no survival benefi t 
to rPTX in patients with fi rst survival ≤ 10 years. The mechanisms underlying 
the increased risk of graft failure in rPTX patients with short fi rst transplant 
survival should be further studied.
* P<0.01
 All Cause Graft Loss  Death-Censored Graft Loss
Reference=1.00 (non pre-emptive repeat transplant)
Figure: Risk of pre-emptive repeat transplant graft loss by duration of primary 
graft survival
ANTICOAGULATION AFTER RENAL 339 
TRANSPLANTATION PREVENTS GRAFT THROMBOSIS IN 
PATIENTS WITH THROMBOPHILIA
C. Hwang1, C. Pagano2, E. Alfrey1
1Department of Surgery, Southern Illinois University, 2Department of 
Emergency Medicine, The University of California, San Diego
Introduction: Patients with thrombophilia and end-stage renal disease 
(ESRD) are at increased risk for kidney graft thrombosis. We examined 
if postoperative anticoagulation in renal transplant patients with known 
thrombophilia prevents thrombosis.
Methods: Due to retrospective discovery of patients with thrombophilia after 
catastrophic adverse events, we began studying patients at risk prospectively. 
We considered risk factors to include previous graft thrombosis, frequent 
fi stula thrombosis, history of deep venous thrombosis, peritoneal dialysis, 
or predialysis patients. Patients with thrombophilia pretransplant were 
anticoagulated posttransplant. Patients’ charts were reviewed in a retrospective 
manner. The data was entered into a relational database. Recipients received 
calcineurin based triple therapy. The recipient age in years, type of transplant 
(living donor vs. cadaveric), presence of thrombophilia, use of anticoagulation, 
postoperative bleeding complications, and graft loss secondary to thrombosis 
were examined. Categorical variables were compared using the unpaired 
Students T-test. Nominal variables were compared using Chi-square. 
Differences were signifi cant at P < 0.05.
Results: Of 197 patients studied, 97 had thrombophilia including Protein C 
defi ciency (n=7), Protein S defi ciency (n=4), Factor V Leiden mutation (n=4), 
anticardiolipin antibody (n=6), lupus anticoagulant (n=8), prothrombin gene 
mutation (n=1), antithrombin III defi ciency (n=3), elevated homocysteine 
(n=16), antinuclear antibody (n=1), mixed (any combination of the preceding, 
n=27), or unknown (n=7). There were 24 patients that were HIPA positive. 
There were no statistically signifi cant differences between the two groups in 
terms of age, HLA match, BMI, or incidence of acute rejection. Eight patients 
with graft thorombosis were subsequently diagnosed with thrombophilia. 
Four of these patients were successfully retransplanted using anticoagulation 
with either heparin or argatroban and then coumadin for one year. None 
of the patients who had a known thrombophilia and were anticoagulated 
had graft thrombosis. Of the patients who were anticoagulated, 32% had a 
bleeding complication, either need for transfusion or reoperation while 4% 
of patients who did not have a thrombophilia had a bleeding complication 
(p<0.001).
Summary: No patients with a thrombophilia treated with anticoagulation 
had graft thrombosis. Four patients with previous graft thrombosis and 
thrombophilia were successfully retransplanted using anticoagulation. One-
third of patients on anticoagulation developed a bleeding complication. Our 
study did not support more rejection in patients with thrombophilia reported 
by others.
Conclusion: Thrombophilia is an underreported cause of graft thrombosis in 
ESRD.
Anticoagulation prevents graft thrombosis in patients with thrombophilia.
A SYSTEMATIC APPROACH TO MINIMIZING WOUND 340 
PROBLEMS FOR DE NOVO SIROLIMUS TREATED KIDNEY 
RECIPIENTS
S.M. Flechner, H.Y. Tiong, A. Wee, L. Zhou, B. Lane, B. Mastroianni, 
K. Savas, D. Goldfarb, C. Modlin
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 
Cleveland, OH, USA
Purpose: Posttransplant lymphoceles and wound healing problems are 
reported with greater frequency in kidney recipients given de novo sirolimus. 
We report a program to reduce these problems based on the use of patient 
selection; closed suction drains, and altered wound closure techniques.
Methods: Consecutive series of adult kidney-only recipients given antibody 
induction followed by de novo sirolimus, mycophenolate mofetil, and steroids 
were compared. Group 1- 103 patients transplanted with a weight restriction 
<32 kg/m2; retroperitoneal closed suction drains placed at surgery (Jackson-
Pratt or Blake); multilayer non-absorbable sutures, and no loading dose of 
sirolimus. Sirolimus was introduced day 0-5 at 5mg. Group 2- A control group 
of 204 patients were transplanted, many with BMI >30 kg/m2, with no drains, 
and various suture techniques. All records and imaging studies were reviewed 
for delayed wound healing and fl uid collections greater than 3.0 cm after drain 
removal.
Results: There was no signifi cant difference in recipient demographics 
between Group 1 and 2 groups, including mean age (47.8 vs. 48.4), BMI 
(25.7 vs. 26.6), males (63.1% vs. 68.1%), whites (69.9% vs. 78.9%), 
deceased donors (50.5% vs. 50%), Retransplants (8.7% vs. 7.3%), and 
diabetics (27.9% vs. 28.4%). Median day drain removal was 18. There 
was a signifi cant (P <0.0001) reduction in lymphoceles identifi ed, treated, 
and treated by surgery in patients with closed suction drains (Table 1). In 
addition there was a signifi cant reduction in total (P=0.0054) and non-
operative (P=0.0095) wound healing problems. Multivariate analysis 
demonstrated a dramatic reduction in lymphoceles in drained patients (OR 
0.33; 95%CI .181-.596; p<.0001); while acute rejections (OR 3.14), DGF 
(OR 1.54), and age (OR 1.16) increased the risk. Similarly, there was a 
signifi cant reduction in all wound healing problems in drained patients (OR 
0.48; 95%CI .236-.997; p<.005).
Conclusions: A program of patient restriction by BMI, closed suction drains, 
altered surgical technique, and no loading dose of sirolimus dramatically reduces 
the incidence of lymphoceles and wound problems for patients starting de novo 
on sirolimus based immunosuppression. Using this program wound healing 
problems are similar or less than that reported with other immunosuppressive 
combinations.
Number (%)
Group 1 Drained
N=103 (%)
Group 2 
Undrained
N=204 (%)
Totals
N=307
P Value
Lymphocele identifi ed 23 (22.30) 95 (46.7) 118 (39.3) 0.0002
 Total treated 5 (4.8) 50 (24.5) 55 (18.3) <0.0001
 Operative drainage 2 (1.9) 29 (14.2) 31 (10.3) <0.0001
Wound Problems Total 8 (7.8) 40 (19.6) 48 (15.6) 0.0054
 Non Operative 3 (2.9) 29 (14.2) 32 (10.4) 0.0095
 Operative repair 5 (4.8) 11 (5.4) 16 (5.2) 0.76
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AN OBSERVATIONAL MULTICENTER SPANISH 341 
STUDY OF SURGICAL COMPLICATIONS AFTER 
KIDNEY TRANSPLANTATION IN THE NEW ERA OF 
IMMUNOSUPPRESSION
J. Pascual, F.J. Burgos, J. Zamora, A. Muriel, N. Plana on behalf of the 
Spanish Surgical Complications after Kidney Transplantation Study Group.
Servicios de Nefrología, Urología and Bioestadística. Hospital Ramón y 
Cajal, Madrid, Spain.
Surgical complications after kidney transplantation constitute an old problem 
that requires revisiting in view of the increasing donor and recipient age and co-
morbidity, and the use of anti-proliferative immunosuppressive drugs that alter 
tissue healing. We have assessed the prevalence of such complications and their 
impact on survival rates in an observational study performed in 26 adult KT Spanish 
units, including patients who received a KT during 2004 and were followed-up for 
1 year (n=1434). Multiple organ transplants (n=41) and patients with insuffi cient 
data (n=52) were excluded, so the fi nal studied population comprised 1341 KTs, 
including 16 double KTs. Mean donor age was 48.4±17.3 years, 97.2% were 
deceased donors and 2.8% living related donors, mean recipient age was 51.1±13.5 
years, 59% were males and 13.4% retransplantations. Initial immunosuppression 
included steroids (99%), MMF (92%), tacrolimus (66%), CsA (18%), or sirolimus 
(9%). Delayed graft function was observed in 37% and treated acute rejection 
in 20.5%. During the fi rst year of evolution, 8.6% of the grafts were lost and 
3% of the recipients died. Cumulative incidences of the complications were: 
wound (non-infectious) 6%, wound infection 4.8%, lymphocele 5.7%, perigraft 
hematoma 4.8%, perigraft abscess 1.3%, vascular thrombosis 2.9%, vascular 
hemorrhage 1.2%, urinary tract leaks 5.7% (ureteral 4.3%, bladder 1.3%), urinary 
tract stenoses 5.5% (ureteral 3.8%, pyeloureteral 1.7%). In the univariate analysis, 
the development of at least one complication was associated with 4-fold graft loss 
risk (17.1% vs 4.9%, OR 4.04, p=0.0001). In the multivariate logistic regression 
analysis, detected risk factors for graft loss were stroke as the cause of donor death 
(OR 2.75, p=0.001), more than 3 HLA mismatches (OR 2.38, p=0.008), a low 
serum albumin (OR 0.52, p=0.001), delayed graft function (OR 2.41, p=0.003), 
treated acute rejection (OR 3.56, p<0.0001), ureteral or ureterovesical leak (OR 
3.57, p=0.007), perigraft abscess (OR 26.8, p<0.0001) or vascular graft thrombosis 
(OR 95.9, p<0.0001). Patient mortality was only associated with recipient age 
(OR 1.09, p<0.0001) and graft loss (OR 3.92, p=0.001).
In addition to classical complications associated with graft loss such as DGF 
or acute rejection, and surgical complications obviously determining lower 
graft survival (vascular thrombosis and perigraft abscesses), ureteral leaks are 
associated with 3.5-fold risk of graft loss despite surgical intervention, and 
indirectly impair patient survival.
DIAGNOSIS AND SIGNIFICANCE OF TRANSPLANT 342 
RENAL ARTERY STENOSIS
M. Allen1, F. Meybodi1, K. Busch2, L. Garry1, J. Raleigh3, J. Harris2, 
K. Wyburn1, D.J. Verran1, J. Eris1, S. Chadban1
1Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia, 
2Camperdown Vascular Laboratory, Sydney Australia, 3Dept of Radiology, 
Royal Prince Alfred Hospital, Sydney, Australia
Transplant renal artery stenosis (TRAS) is a poorly understood entity with 
incidence dependent on defi nition and imaging modality. Its clinical relevance 
is complicated by the high frequency and multiple causes of hypertension 
after kidney transplantation (KT). Doppler ultrasound is a frequently utilised 
investigation modality after KT and should provide simple surveillance for 
TRAS. However, diagnostic parameters specifi c to KT have not been elaborated 
and the appropriate response to fi ndings remains unclear.
Aim: To evaluate the value of TRAS surveillance using two ultrasound techniques 
in the fi rst 3 months after KT and to correlate fi ndings with clinical management.
Methods: Consecutive KT patients underwent ultrasound assessment in a 
hospital-based general ultrasound service on a routine basis and to investigate 
transplant dysfunction. A diagnosis of TRAS was made after intrarenal 
ultrasound (IUS) assessment using downstream waveform fi ndings of ‘parvus 
tardus’ and of resistive index (RI) <0.5. Findings were compared with a routine 
outpatient assessment at 6-8 weeks after KT by a vascular surgery ultrasound 
service assessing extrarenal (EUS) artery. The EUS diagnosis used well 
established native renal artery criteria for a stenosis of >60% with maximum 
peak systolic velocity (PSV) (>260cm/sec), demonstration of turbulence and 
iliac to renal artery ratio (>3.0) as diagnostic parameters of a TRAS >60%. 
Results were retrospectively compared with clinical data and outcomes.
Results: From Jan 2004 to September 2007, 249 patients underwent KT with 
minimum follow up of 3 months. They had 1077 hospital-based IUS in fi rst 3 
months (4.3 +/- 2.3 per patient) reporting 7 TRAS (including one occlusion)
(2.8%). Two of these IUS diagnoses were demonstrated subsequently to be 
false positives.
In comparison, 191 patients additionally underwent routine EUS at 52+/-22 
days after KT with 44 patients meeting criteria for TRAS >60% (23%) 
(P<0.0001). For clinical indications or degree of stenosis, 19 of these patients 
underwent CT angiography with one false positive fi nding.
Using the combination of imaging techniques for 48 TRAS, the site and cause 
of stenosis was the result a kink adjacent to the anastomosis in 48%, mid artery 
kink 25%, anastomotic 14% and donor atheroma 13%. Kinks tended to have 
a more benign clinical course with only 2 of 31 patients requiring intervention 
(7%) compared 6 of 17 patients with donor atheroma or anastomotic issues 
(35%)(P<0.05). Donor origin and confi guration of anastomoses were not 
signifi cant risk factors.
Conclusions: The incidence of TRAS is defi nition dependant. In the fi rst 3 
months after transplantation, it is 23% if based on extrarenal US assessment. 
If based on need for intervention, it is 3%. The long term downstream effect 
of clinically insignifi cant stenoses of >60% on kidney transplant function is 
unknown but may be determined by longitudinal study provided that it is not 
based on intrarenal US assessment.
RENAL TRANSPLANTATION IN THE MORBIDLY OBESE343 
W.M. Bennett, K.R. Henell, K.M. McEvoy, T. Batiuk, S. Pidikiti, 
V. Douzdjian
Renal Transplant Program, Legacy Good Samaritan Hospital, Portland, OR, 
United States 
Renal transplantation is offered to many patients with severe co-morbidities 
such as diabetes mellitus and atherosclerotic vascular disease but is often 
denied to the morbidly obese, BMI > 35 kg/m2.(1) Since transplantation has a 
survival advantage compared to dialysis despite morbid obesity, there is no a 
priori ethical basis for denying transplantation in this population. We report a 
large experience with high-BMI renal transplant recipients compared to non-
obese controls. Of 626 consecutive kidney-only transplants performed between 
1999 and the end of 2007, 94 were in morbidly obese recipients, 39 of whom 
had BMI > 40. Demographics and outcomes are summarized in the table.
BMI<30
n=439
BMI 30-35
n=109
BMI>35.1-40
n=55
BMI>40
n=39
Graft Survival at 1 year (%) 92 92 88 84
Graft Survival at 3 years (%) 84 86 70 74
Deep Surgical Wound Infection (%) 1.7 2.8 7.3 10.3
Median Anastomosis Time (min) 31 33 34 34
Median Cold Ischemia (hours) 9 12 13 13
Median Length of Stay (days) 6 6 6 6
% Diabetic Cause of ESRD 28.6 40.4 47.3 41
% Living Donors 39.5 32.5 34.5 28.2
% Male 57 58 40 51
Median Age (years) 49 53 51 51
% Expanded Criteria DD Kidneys 20.3 28.4 19.4 21.4
% DCD DD Kidneys 3.9 6.8 5.6 3.6
Median BMI 24.7 32.2 36.9 43.1
There were no signifi cant differences between groups in patient survival, while 
the survival advantage of transplant over dialysis is clear. (Figure 1) Graft 
survival in the BMI > 40 group was slightly but signifi cantly worse than the 
BMI 35-40 group, leading us to change our protocol to require a BMI < 40 
prior to acceptance. As expected, wound infections were more common in the 
most obese.
Conclusion: Renal transplantation can be offered to the morbidly obese since 
transplantation carries a survival over dialysis and can be done relatively 
safely.
Figure 1. Actuarial Patient Survivals, Transplant vs. Dialysis
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WEIGHT GAIN IN THE FIRST YEAR AFTER KIDNEY 344 
TRANSPLANTATION IN THE U.S.
D. Steffi ck1, F. Luan2, S. Norman2, A. Ojo2
1Arbor Research, 2University of Michigan
Background: Obesity is associated with inferior outcomes after kidney 
transplantation, though much of the research on posttransplant weight gain 
comes from small studies. We evaluated the descriptive features and risk 
factors for weight gain during the fi rst year after kidney transplantation in the 
U.S. Weight gain following transplant appears to be common and multifactorial 
in origin.
Methods: 61,365 recipients of solitary kidney transplants in the United States, 
engrafted between 1/1/2000 and 12/31/2006, were studied. Multivariate 
logistic regression analysis was used to evaluate the relationship between 
weight gain and characteristics of the recipient, donor, transplant, and discharge 
immunosuppression regimen.
Results: Most recipients gained weight in the fi rst year following transplant 
(68.6%), although some lost weight (29.6%), and very few stayed the same 
(1.8%). Among those discharged with steroids as part of their maintenance 
immunosuppression, 70% gained weight compared to 63.5% for those 
without steroids (p<0.001). The median weight gain was 2.5kg (interquartile 
range=9.9kg) for those without steroids and 4.1kg (interquartile range=10.9kg) 
for those with steroids (Figure 1).
Figure 1: Percentage of Kidney Transplant Recipients by Change in Weight and 
Steroids at Discharge
The results from models of the odds of gaining 10kg+, 15kg+, or 20kg+ were 
similar to each other. Factors signifi cantly, positively associated with weight 
gain were: younger age, African American, Hispanic, BMI at transplant of 
25 or higher, primary diagnosis of diabetes, hypertension, or congenital/rare/
familial/metabolic disorders and zero HLA mismatch.
Factors signifi cantly associated with lower odds of gaining 10kg+, 15kg+, or 
20kg+ were: no steroids as maintenance immunosuppression, older age, male 
sex, BMI less than 20 or missing at transplant, diagnosis of polycystic kidney 
or tubular/interstitial disease, transplanted within 1 year starting ESRD or 6+ 
years after starting ESRD, and having a donor who was older, female, Asian, 
died from stroke, or weighed more than the recipient.
Aside from corticosteroids, other maintenance immunosuppression regimens 
had signifi cant effects on the likelihood of gaining 10kg or more. With the 
combination of tacrolimus and mycophenolate mofetil as the reference group 
(the regimen for 51% of the sample), tacrolimus alone (HR=1.26, p=0.006) and 
cyclosporine and mycophenolate mofetil (HR=1.36, p<0.001) were associated 
with greater odds of 10kg weight gain. Conversely, tacrolimus and sirolimus/
everolimus (HR=0.81, p<0.001), mycophenolate mofetil and sirolimus/
everolimus (HR=0.73, p<0.001), and tacrolimus, mycophenolate mofetil, and 
sirolimus/everolimus (HR=0.69, p<0.001) were associated with lower odds of 
a 10kg weight gain.
Conclusion: Weight gain is common after kidney transplantation in the U.S. 
Immunosuppressant drug regimen is signifi cantly associated with weight gain, 
in addition to the known risk factor of corticosteroids. However, several less 
easily modifi able factors, such as age, race, gender and cause of kidney failure 
are also associated with gaining weight in the fi rst year posttransplant.
MORTALITY-PREDICTABILITY OF BODY MASS INDEX 345 
(BMI) IN TRANSPLANT-WAIT-LISTED MAINTENANCE 
HEMODIALYSIS PATIENTS: A 5-YEAR NATIONAL COHORT 
STUDY
K. Kalantar-Zadeh1, E. Streja1, J. Jing1, C.J. McAllister3, G.M. Danovitch2, S. 
Bunnapradist2
1Harold Simmons Center for Kidney Disease Research and Epidemiology at 
Harbor-UCLA, 2UCLA Kidney Transplant Program; and (3) DaVita, Inc; Los 
Angeles and Torrance, CA
Background: Even though obesity appears associated with greater survival in 
maintenance hemodialysis (MHD) patients, a phenomenon known as “obesity 
paradox” or “reverse epidemiology”, obese MHD patients who are in the 
waiting list for a deceased renal transplant are usually asked to lose weight. 
We hypothesized that higher BMI in transplant-waitlisted MHD patients is 
incrementally associated with greater survival during the waiting period. 
Methods: By linking the 5-year (7/2001-6/2006) national database of a large 
dialysis organization (DaVita Inc) to the Scientifi c Registry of Transplant 
Recipients (SRTR), we identifi ed 10,830 DaVita MHD patients, who were 
transplant-waitlisted but did not receive any kidney transplantation over the 
5-year period. Time-dependent survival model examined the assocaition of the 
calendar-quarterly BMI (using 13-week averaged post-HD dry weight) with 
survival adjusted for case-mix and time-varying surrogates of malnutrition-
infl ammation complex syndrome (MICS).
Results: The 10,830 MHD patients were 59.1±15.4 years old and included 
48% women and 37% diabetics. The 13-week averaged BMI was 27.4±7.1 kg/
m2. Unadjusted and adjusted survival analyses showed incrementally greater 
survival with higher BMI>23 kg/m2 (see Figure):
Conclusions: Obese transplant-waitlisted MHD patients appear to have 
greater survival that is incrementally associated with higher height-adjusted-
weight, i.e., a reverse epidemiology with dose-response phenomenon. These 
fi ndings question the benefi t of recommending weight reduction during the pre-
transplant wait-listing in obese MHD patients.
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METABOLIC SYNDROME COMPONENTS BEFORE 346 
LIVING KIDNEY DONATION AND LONG-TERM RENAL 
FUNCTION OUTCOME FOR THE DONORS 
J. Alberu1, M. Arvizu-Hernandez1, R. Bermudez2, L.M. Miranda2, A. Arvizu1, 
M. Vilatoba1, L.E. Morales3, B. Gabilondo1, R. Correa-Rotter3, and F.J. 
Gomez-Perez2.
 1Transplantation, 2Endocrinology and 3Nephrology, Inst. Nal. Ciencias 
Medicas y Nutricion SZ, Mexico. 
Background: Metabolic syndrome (MS) may represent an additional burden 
for the remaining kidney of donors. 
Aim: To evaluate the impact of 3 criteria for MS on long-term renal function of 
individuals who donated a kidney. 
Methods: Data regarding MS criteria and renal function were gathered for 95 
kidney donors before nephrectomy (BN) and at last follow-up. For the analysis, 
donors were divided into 2 groups: those with ≥3 criteria for MS BN (group 1), 
and those with < 3 criteria for MS (group 2). 
Results: The Table summarizes demography of the study population, metabolic 
parameters and renal function obtained BN as well as at last visit. 
Conclusions: A signifi cantly greater decline in eGFR was observed for group 
1 despite of a shorter time elapsed since nephrectomy. This fi nding suggests 
that MS risk factors (RF) detected before donation can impact donor renal 
function outcome. Whether strict supervision and specifi c intervention for the 
correction of MS RF after nephrectomy could modify these results is a matter 
that deserves further evaluation. These interventions ought to be included in 
prospective studies. 
 BEFORE NEPHRECTOMY LAST FOLLOW-UP
 GROUP 1 GROUP 2 GROUP 1 GROUP 2 *P
Gender F/M 12/15 50/18 12/15 50/18
Age (yr) 45. 4 ± 12. 4 34. 2 ± 10. 5 49. 6 ± 11. 8 42. 4 ± 11. 2 0. 004
Time after donation (yr) 4. 8 ± 3. 6 7. 8 ± 5. 5 0. 009
BMI kg/m2 27. 2 ± 2. 1 24. 9 ± 3. 1 27. 2 ± 2. 9 25. 9 ± 3. 6 NS
Triglycerides mg/dl 207. 5 ± 84. 9 105. 9 ± 45. 5 219. 7 ± 92. 5 139. 2 ± 94. 3 0. 000
HDL-C mg/dl 35. 8 ± 6. 9 47. 1 ± 11. 3 39. 7 ± 23. 3 44. 9 ± 13. 5 NS
SBP mmHg 119 ± 11 112 ± 9. 5 119. 2 ± 10. 3 112. 5 ± 13. 4 0. 02
DBP mmHg 77. 8 ± 7 71. 7 ± 7. 8 78. 3 ± 8. 8 74. 7 ± 9. 4 NS
Fasting glucose mg/dl 94. 8 ± 9. 7 89. 1 ± 8. 7 93. 2 ± 11. 1 98. 4 ± 10. 4 NS
Microalb mg/24h 2. 6 ± 6. 2 5. 7 ± 11. 9 30. 3 ± 82. 3 12. 2 ± 13. 6 NS
eGFR ml/min/1. 73 m2 94. 6 ± 23. 2 90. 9 ± 20. 7 65. 1 ± 15. 1 72. 5 ± 15. 2 0. 04
eGFR -34. 3 ± 31. 6 -19. 4 ± 19. 4 0. 006
*P value corresponds to last follow-up comparisons 
NS = no signifi cant
POSTER BOARD NUMBER P2 – 376
PSYCHOSOCIAL SCREENING AND FOLLOW UP 347 
PRACTICES FOR LIVING KIDNEY DONORS (LKD) IN THE US
N. Schroder1, A. Haririan2, C. Welsh3 and M. Cooper4. 
1Department of Social Work; 2Medicine; 3Psychiatry and 4Surgery, University 
of Maryland Medical Center, Baltimore, MD, United States. 
Body: Psychosocial health of LKDs before and after donation is of great 
importance. Unfortunately, this issue has been neglected to a large extent. 
Although a psychosocial evaluation is considered a mandatory component 
of all LKD evaluations in the United States, a standardized protocol does not 
exist. Similarly, follow-up of donors after surgery appears to be an infrequent 
practice, given the limited data available about post-operative outcomes. 
Methods: We examined the variability in psychosocial screening and follow-
up practices across transplant (Tx) centers by conducting a 68-question 
online survey regarding practices and related donor issues. Several questions 
allowed for more than one response. The survey was mailed via listservs of 2 
professional Tx societies. 
Results: Characteristics of the 69 participating Tx centers are summarized in Table 1. 
Tx Center Characteristics
Number per year Tx (% of centers) LKD Evaluations (% of 
centers)
LKD Tx (% of centers)
≤ 50 21. 9 43. 9 63. 4
51-100 37. 5 22. 8 22. 2
101-200 23. 4 19. 3 11
200+ 17. 7 14 3. 2
Psychosocial Screening Practices: 88. 3% of centers require donors to 
complete a psychosocial evaluation, conducted by social workers (92. 5%), 
psychologists (16. 6%) and/or psychiatrists (12. 9%). Psychosocial evaluations 
are most often completed concurrently with the medical evaluation (84. 9%). 
30. 1% may initiate it prior to medical evaluation and 9. 4% wait until after 
their medical evaluation is complete. 87% inquire about mental health in the 
evaluation, though only 30. 6% of centers use a standardized questionnaire. 98. 
6% assess alcohol use and 95. 7% assess drug use. Utilization of standardized 
questionnaires for alcohol and drug use is uncommon (24. 5%, 17. 4%). 
Interestingly, 18% permit donation with alcohol abuse and 36. 7% with drug 
abuse. 58. 3% allow donors with a recent history of substance abuse (current 
abstinence of less than one year) to proceed with the evaluation process. More 
than 95% exclude cocaine or heroine users, while 95. 1% allow marijuana users 
to donate. Only 21. 7% require donors to stop smoking prior to surgery. 
17% of centers proceed with medical testing despite concerns with mental 
health, cognitive functioning or substance abuse. 
Follow-Up Practices: Only 38. 3% actively follow donors regarding 
psychosocial health after donation. The professionals most often involved are 
social workers (72%) and nurse coordinators (69%). The majority of follow-
up is conducted via phone (83. 3%); though appointments (69. 4%) and 
questionnaires (11. 1%) are also utilized. 65% initiate follow-up with donors 
1-4 weeks post-operatively, whereas only 27% of programs maintain contact 
at both 3-6 months and 12 months. 83. 3% offer post-operative psychosocial 
support; 62% only under certain circumstances. This support is provided 
by social workers (90%), psychologists (30%), and/or psychiatrists (28%). 
Support is available indefi nitely in 68% of programs. 
Conclusion: The results of this survey clearly demonstrate that practices 
utilized for the psychosocial evaluation and follow-up of LKDs at US Tx centers 
are widely variable. Without routine follow-up of donors, Tx centers are less 
likely to capture post-operative psychosocial issues that may result from organ 
donation. Standardized psychosocial evaluations and post-operative follow-up 
of LKDs should become a mandatory part of their care, which will require 
increased support from health care policy makers. 
POSTER BOARD NUMBER P2 – 377
CORRELATION OF RENAL FUNCTIONAL 348 
MEASUREMENTS AND IMPLANTATION BIOPSY WITH 
OUTCOMES IN LIVING DONOR RENAL TRANSPLANTATION
T.S.M. Tan1, A.S.T. Liew1, M. Teh2, M. Kaur1, C-L. Goh1, A. Vathsala1
1Division of Nephrology, Department of Medicine, National University 
Hospital 2Department of Pathology, National University Hospital
Background: Defi ning the level of renal function for suitability for renal donation 
in living donor renal transplant (LDRT) is crucial to ensuring donor safety and 
optimizing recipient outcomes. Creatinine clearances (CCT) as calculated by 
24-hour urine collections, while commonly used, may under- or over-estimate 
glomerular fi ltration rate (GFR) in patients with normal renal function as in 
renal donors. Creatinine-based formulae have been likewise suggested to be 
insuffi cient to determine suitability in renal donors; thus guidelines recommend 
the need for supplementation or replacement of creatinine-based estimations of 
GFR with radio-isotopic measurements. The aim of this study was to determine 
the correlation of creatinine-based renal functional measurements in an Asian 
population with implantation biopsies (IB), performed as part of a routine 
protocol biopsy program, as well as recipient outcomes post LDRT. 
Methods: 22 live renal donors and their recipients undergoing LDRT with an 
IB between June 2004 and August 2006 were included in the study. All live 
renal donors met standard criteria for suitability for renal donation with normal 
renal function and no proteinuria. IB were scored semi-quantitatively based 
on glomerular sclerosis, tubular atrophy, interstitial fi brosis, and arteriolar 
narrowing, using a novel scoring system with a minimum score of 0, and a 
maximum score of 12. Donor CCT was correlated with GFR calculated with 
the abbreviated Modifi cation of Diet in Renal Disease (MDRD) equation 
(eGFR) and the modifi ed MDRD equation for Chinese population (c-aGFR) 
and IB scores. IB scores were likewise correlated with the incidence of delayed 
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graft function (DGF), acute rejection (AREJ) and eGFR, in LDRT recipients at 
1 year post-transplantation. 
Results: 22 living donors (45. 5% male, 45. 5% Chinese, mean age 41. 4 years, 
mean baseline serum creatinine level 82. 5 (±23. 59) μmol/L) had a mean CCT 
of 90. 57 (± 27. 09) mL/min, a mean eGFR of 84. 95 (± 16. 55) mL/min and a 
mean c-aGFR of 69. 15 (± 44. 81) mL/min. There was no correlation between 
CCT and eGFR, or c-aGFR in the overall study population and in the Chinese 
subgroup. The majority of donors had an IB score of 0 (59. 1%, compared with 
22. 7% with score 1, 9. 1% with score 2, and 9. 1% with score 3), and there 
was no correlation between any of the renal functional measurements with IB 
scores. Furthermore, there was no correlation of IB scores with outcomes post 
LDRT in recipients (4. 6% had DGF, 22. 7% had AREJ at 1 year) nor with 
1-year eGFR (52 ± 17. 31 mL/min). 
Conclusion: As few LDRT donors had evidence of any signifi cant histological 
damage on IB, our study demonstrates that CCT remains a reliable and useful 
screening tool for renal functional measurement in live renal donors. Moreover, 
both abbreviated MDRD and c-aMDRD formulae have poor correlation to 
CCT and should not be used as a substitute in live renal donors. Excellent 
graft outcomes can thus be achieved in LDRT using standard measures of renal 
function alone. 
POSTER BOARD NUMBER P2 – 378
LONG-TERM RISK OF HYPERTENSION AND RENAL 349 
DYSFUNCITON IN LIVING KIDNEY DONORS
S.H. Kim 1, 3, H.E. Yoon 1, S.C. Park 2, B.S. Choi 1, Y.S. Kim 1, I.S. Moon 2, 
B.K. Bang 1, S.Y. Kim 1, Y.B. Koh 2, C.W. Yang 1
1 Department of Internal Medicine, The Catholic University Of Korea, 2 
Department of Surgery, The Catholic University of Korea, 3 Department of 
Internal Medicine, Chung-Ang University
Background: Donor nephrectomy may result in remnant single nephron 
hyperfi ltration with associated hypertension and progressive renal dysfunction. 
Our aim was to assess the long-term risks for kidney donors of developing 
hypertension, proteinuria and renal dysfunction. 
Methods: From 1969 to 2005, 1356 live kidney nephrectomies were performed 
at Kangnam St. Mary’s hospital in Korea. We retrospectively reviewed patient’s 
chart, blood pressure, serum creatinine, glomerular fi ltration rate and urine 
protein. MDRD formula was used to estimate glomerular fi ltration rate. 
Result: There were 152 (11%) donors who were followed 1 or more years 
after nephrectomy. The donors were 44 ± 14 (range 21-87) years old, 73 (48%) 
were males and median time since donation was 2. 5 (1-21) years. Mean serum 
creatinine was 1. 17±0. 75 (0. 57-10) mg/dL, creatinine clearance 69±13 ml/
min. Blood pressure had increased from 113 ± 10/75 ± 8 to 116 ± 12/77 ± 
8 (p < 0. 01), and 9 (6%) of the donors are taking antihypertensive drugs. 
Urinary protein excretion after donation was not increased. Three (2%) donors 
developed proteinuria (>300mg/day). Overall renal function is well preserved 
after donor nephrectomy, but 3/1356 (0. 019%) of the donors developed end 
stage renal disease requiring renal replacement therapy and 6 showed elevated 
serum creatinine more than 1. 5 mg/dL. 
Conclusion: Follow-up rate of living donor after donation is still low, but there 
is an increasing tendency of chronic kidney disease after donation. Follow 
up of all living kidney donors with blood pressure, creatinine clearance and 
proteinuria was strongly recommended. 
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ARE WE TAKING A PROPER CARE OF THE LIVING 350 
DONORS? A FOLLOW – UP STUDY OF LIVING KIDNEY 
DONORS IN POLAND AND FURTHER MANAGEMENT 
PROPOSAL
W. Rowinski 1, A. Chmura 2, M. Ostrowski 3, Z. Wlodarczyk 4, B. Rutkowski 5, 
M. Bieniasz 2, M. Durlik 2, K. Dziewanowski 6, J. Matych 7, R. Grenda 8
1 Polish Union Transplantation Medicine, 2 Medical University Warsaw, 3 
Pomeranian Medical School, 4 Collegium Medicum Bydgosiensis, 5 Medical 
School Gdansk, 6 Regional Hospital Szczecin, 7 Medical University £odŸ, 8 
Institute Child Health Center
The fi rst kidney transplantation was done in Poland in 1966. Since that time 
approximately 11 000 patients have undergone this procedure, but most of them 
received the kidney from deceased donors. Although the fi rst living donor kidney 
transplantation was done as early as in 1967 only 342 such procedures were 
done (2. 7%), most transplants were performed (197) between 1997 – 2007. 
Legal regulations in Poland require careful long-term follow-up of the donors. 
The aim of this study was to review the results of the living donors follow 
– up study in Poland. The questionnaire was send to eleven centers who 
performed during last 10 years 197 LD kidney transplantations. The answers 
came back only from 6 centers reporting data on 118 donors. In two centers 
no follow-up of the donors was available. Donors (nearly all genetically or 
emotionally related) were 23 to 61 years old (males, females). In no donor 
any abnormality was found regarding cardiovascular function or metabolic 
abnormalities. Eleven (out of 118 donors) has not reported to the control 
visit. The follow-up of remaining donors ranged from 2 to 8 years. 4 donors 
died (4-5 years after nephrectomy (due to cerebral hemorrhage, brain tumor, 
stomach cancer and car accident respectively). The mean serum creatinine 
rose from 0. 8 mg/dL to 1. 25 mg/dL, (but in two pts was over 2 mg/dL) 
Calculated creatinine clearance (aMDRD) decreased from 95ml/min to 65 
ml/min (p<0. 05). In 3 donors proteinuria (>0. 6g/24h) was observed 3-5 
years after donation. Three patients experienced mild hypertension (two 
requiring treatment), in the remaining donors the blood pressure remained 
normal. 
Conclusions: Since 2008 several changes have been introduced. Transplant 
centers are obliged to report all data on each LD procedure with the follow-
up data. The Living Donor Register is obligatory (no reporting, no fi nancial 
reimbursement from the Insurance). All donors are insured (by Alianz SA) 
for 3 months from transplantation. Stem-wise interventional reno- and 
cardioprotection program has been prepared to be used after nephrectomy for 
life donors. 
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LONGITUDINAL STUDY ON RENAL EFFECTS OF 351 
CHANGES IN BODY WEIGHT AFTER LIVING KIDNEY 
DONATION: WEIGHT GAIN BURDENS THE REMNANT 
KIDNEY
M. Rook1, H. Tent1, S. Hofker2, R. Ploeg2, J. Homan van de Heide1, 
W. van Son1 and G. Navis1. 
Departments of 1Nephrology and 2Surgery, University Medical Center 
Groningen, the Netherlands
Whereas presence of overweight is associated with hyperfi ltration and in 
particular with renal function loss after (donor) nephrectomy, renal effects 
of weight gain are currently unknown. Therefore, we analysed longitudinally 
whether a post-donation increase in body weight had impact on long-term renal 
fi ltration and renal adaptation. 
We invited 55 consecutive donors (mean age at donation 47±12 years; 
27% male) who completed the screening protocol with subsequent donor 
nephrectomy in our centre in 2000-2002 for follow-up of renal hemodynamic 
measurements. 37 donors consented (67%) and GFR (iothalamate), ERPF 
(hippuran) and fi ltration fraction (FF, GFR/ERPF*100) were measured six 
years after donation. Mean body weight increased from 77±12 kg to 81±13 kg 
(range -9 to +20; p≤0. 01). BMI hereby increased from 25. 9±4. 4 to 27±4. 7 
kg/m2 (p≤0. 01). After six years, single kidney GFR and ERPF had increased 
by 25±8 and 99±33, respectively (both p≤0. 001). The amount of weight gain 
correlated with the increase in GFR (R=0. 33, p≤0. 05), but not ERPF. Whereas 
mean FF was stable, FF signifi cantly increased in donors with weight gain and 
decreased in donors with weight loss (R=0. 57, p≤0. 001). 
In conclusion, post-donation changes in body weight or BMI affected renal 
adaptation after nephrectomy. Weight gain induced higher fi ltration fraction, 
indicating hyperfi ltration, which potentially threatens renal function. Post-
donation weight gain thus poses an extra burden on the remaining kidney which 
can and should be prevented. This must be emphasized in donor screening, 
evaluation and follow-up. 
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EVALUATING POTENTIAL LIVING KIDNEY 352 
DONORS BY RENAL FUNCTION EQUATIONS LEADS TO 
UNNECESSARY REDUCTION OF THE DONOR POOL
M. Rook1, H. Tent1, M. Lanen1, W.J. van Son1, H.S. Hofker2, R.J. Ploeg2, 
J.J. Homan van der Heide1, G.J. Navis1. 
Departments of 1Nephrology and 2Surgery, University Medical Centre 
Groningen, the Netherlands. 
Renal function equations are advocated for cheap and simple estimation of 
renal function. Many centres estimate glomerular fi ltration rate (GFR) by 
these equations to evaluate potential living kidney donors. However, these 
renal function equations were developed in populations with renal disease and 
generally perform poorly in subjects without renal function impairment. We 
therefore analysed MDRD and Cockcroft-Gault (CG) in comparison to true 
GFR, before as well as after donor nephrectomy in 250 consecutive donors 
who donated between 1996 and 2007. 
GFR was measured as the clearance of 125I-iothalamate 4 months before and 
2 months after kidney donation; MDRD and CG were calculated from data 
obtained on these same days. GFR and CG were normalized for body surface 
area to allow comparison with MDRD. Based on clinical practise, we applied 
a hypothetical lower limit of 80 ml/min/1. 73 m2 by either MDRD or CG and 
analyzed true GFR as well as post-donation outcome in donors considered not-
eligible to donate by renal function equations. 
Mean donor age was 50±11 years, 56% female. For the entire population, pre-
donation GFR was 103±15, CG 79±14 and MDRD 70±10 ml/min/1. 73 m2. 
After donation, mean GFR was 65±11, CG 61±11 and MDRD 52±7 ml/min/1. 
73 m2. When the limit of eGFR<80 was applied, 210 donors would have been 
declined for donation by MDRD and 141 donors by CG. Donors with eGFR 
below the threshold were signifi cantly older and more often female. 
Donors with MDRD<80 were 51±10 years old and had a GFR of 102±15 ml/
min/1. 73 m2. After donation, GFR was 65±10 ml/min/1. 73 m2 in this subgroup. 
Donors with CG<80 were 55±8 years old and had a GFR of 99±13 ml/min/1. 
73 m2. Post-donation GFR was 62±10 ml/min/1. 73 m2 in this subgroup. For 
comparison: donors with either MDRD≥80 or CG≥80 had a post-donation 
GFR of 70±10 ml/min/1. 73 m2 (both p<0. 05). 
Thus, renal function equations considerably underestimated true GFR. Donors 
who would not have been eligible to donate based on MDRD or CG below 80 
ml/min/1. 73 m2, displayed adequate and acceptable remnant renal function 
after donation. In conclusion, use of renal function equations for selection of 
kidney donors lead to an unnecessary reduction of the donor pool. MDRD in 
particular is not suitable for the use in donor screening. 
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COMPENSATORY INCREASE IN GFR UP TO 10 YEARS 353 
AFTER RENAL DONATION
U. Berg 
Division Of Pediatrics, Dept. Of Clinical Science, Intervention And 
Technology
124 (70 males) living kidney donors, 40±9 years of age with a BMI of 24. 
9±3. 2 kg/m2 at donation, were repeatedly investigated with renal function, 
blood pressure and urine albumin excretion rate 3 months after and then every 
other year up to 16 years after donation. 69 donors were also investigated 
before donation. Glomerular fi ltration rate (GFR) and effective renal plasma 
fl ow (ERPF) were determined by renal clearances of inulin and PAH during 
water diuresis and continuous infusion. Before donation absolute GFR and 
ERPF (ml/min) was signifi cantly higher in male donors compared with female 
donors but when calculated in relative values (ml/min per 1. 73m2) there was 
no difference between males and females. In those 69 donors investigated both 
before and 3 months after donation GFR decreased from 104±13 to 69±10 ml/
min per 1. 73m2, i. e. 66% of predonation value and ERPF from 536±97 to 
349±68 ml/min per 1. 73m2, i. e. 65% of predonation value. 
123 donors were studied 3 months after donation and GFR was 69±10 and 
ERPF 344±65 ml/min per 1. 73m2. GFR increased successively up to 10 years 
after donation (77±11 ml/min per 1. 73m2) whereafter GFR remained stable. 
ERPF, however, did not change during the follow-up. There was no difference 
in relative GFR or ERPF between sexes during follow-up. 
Four years after donation 33% of the males and 25% of the females showed 
hypertension (>140/90) but none had developed albuminuria not even 
microalbuminuria. 
In conclusion GFR increases up to 10 years after donation irrespective of donor 
age at donation. 
POSTER BOARD NUMBER P2 – 383
EFFECT OF PRE-DONATION BLOOD PRESSURE, GFR 354 
AND PROTEINURIA ON THEIR POST-DONATION LEVELS
A. Rizvi, F. Jawad, E. Ahmed, M.N. Zafar, A. Naqvi
Sindh Institute of Urology And Transplantation
Objective: To study the impact of pre-donation blood pressure, 24 hours urinary 
protein and GFR on the development of Hypertension (BP>140/90 mmHg) 
(HTN), persistent protein excretion (>150mg in 24 hours) and declining renal 
function GFR (¡Ü 60 ml/min) after live related donor nephrectomy. The role of 
duration of nephrectomy was also analysed. 
Methods: The records of 993 kidney donors were analysed. Pre and post 
donation blood pressure fi gures were noted along with 24 hours urine proteins 
and GFR results. The data was statistically analysed by using the t-test, chi 
square test and logistic regression and p-values were obtained for signifi cance. 
Results: A total of 993 donors were studied. The mean age was 36. 6¡À10. 8 
years, with the majority being < 30 years. The male to female ratio was 1. 1: 1. 
Hypertension was found in 159 (16%) donors, proteinuria (>300 mg/24 hours) 
in 42 (5%) and GFR ¡Ü 60 ml/min in 67 (7%) donors. 
The multivariate analysis showed that age>40 years (OR=1. 6), pre-donation 
systolic BP>130mm Hg (OR=1. 6), pre-donation GFR (¡Ü100 ml/min) (OR=1. 
7) and pre-donation protein excretion >150mg/24hours (OR=1. 8) were 
signifi cant for development of post-donation HTN. 
Post-donation low GFR (< 60 ml/min) was associated with age> 40 years 
(OR=2. 6) and pre-donation systolic blood pressure >130 mm Hg (OR=1. 9). 
Persistent proteinuria >150 mg/24 hours was related to high pre-donation 
protein excretion >150mg/24 hours (OR=2. 6) and smoking (OR=1. 9). 
Duration of nephrectomy was signifi cantly associated with the development of the 
studied factors. A period of ¡Ý10 years showed 27% donors to have hypertension, 
8. 2% had GFR ¡Ü 60 ml/min and 14% had proteinuria >300 mg/24 hours. 
Conclusion: Pre-donation factors play an important role in the evolution of 
hypertension, proteinuria and declining GFR. 
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IS LAPAROSCOPIC DONOR NEPHRECTOMY REALLY 355 
THE WAY AHEAD?
S. Guleria1, R. Kumar1, S. Reddy1, S. Jain1, S. Aggarwall1, S. Mahajan1, 
S. Gupta1, D. Bhowmik1, S. Aggarwall1, S. Tiwari1
1All India Institute of Medical Sciences, 2All India Institute of Medical 
Sciences, 3All India Institute of Medical Sciences, 4All India Institute of 
Medical Sciences, 5All India Institute of Medical Sciences, 6All India Institute 
of Medical Sciences, 7All India Institute of Medical Sciences, 8All India 
Institute of Medical Sciences, 9All India Institute of Medical Sciences, 10All 
India Institute of Medical Sciences
Aim: The present study was carried out to assess the impact of the laparoscopic 
donor nephrectomy on donor morbidity. 
Material and Methods: Sixty consecutive live related donors were randomized 
in to two groups. Group I underwent a laparoscopic donor nephrectomy 
through a trans-peritoneal approach while Group II underwent an open mini 
donor nephrectomy through a retroperitoneal approach. The laparoscopic 
donor nephrectomy was carried out through a standard four-port technique 
by a trans-peritoneal approach. The mini donor nephrectomy was carried out 
through a six cm fl ank retro- peritoneal incision. Both Groups were evaluate 
with regard to operative time, post –operative stay and the visual analogue pain 
score at the time of discharge 
Results: The mean age of the group that underwent open donor nephrectomy 
was 47. 3 with a mean of BMI 19. 9 while that of the laparoscopic donor 
nephrectomy group was 40. 6 with a mean BMI of 21. 9. There were 6 males 
and 24 females in the open group and 26 females and 4 males in the laparoscopic 
group. The mean operating time was 55. 23 minutes in the open group and 132. 
34 minutes in the laparoscopic group. 
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The post –operative stay was three days in the open group and four days in the 
laparoscopic group. There was no wound infection or chest infection in either 
group. However the laparoscopic group had a signifi cantly higher incidence of 
ileus as compared to the open group. The visual pain score was 4 in the open 
group and 6 in the laparoscopic group. At one-month post operatively there 
was no difference between the two groups with regards to pain score. The graft 
function was also similar in the two groups. 
Conclusion: The mini open donor nephrectomy is time tested and has lesser 
post operaqtive stay and pain than the laparoscopic donor nephrectomy group 
especially in our settings where most of our donors have a low BMI. It may be 
the procedure of choice in patients with a low BMI
MINI-ORAL SESSION 10: 
IMMUNOSUPPRESSION 2 – LIVER AND LUNG
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CAMPATH-1H (C1H) INDUCTION IN ADULT LIVER 356 
TRANSPLANTATION: SIX YEARS EXPERIENCE OF A SINGLE 
CENTER. 
P. Tryphonopoulos, D. Weppler, S. Nishida, D. Levi, J. Moon, A. Sornaraj, A. 
Berlanga, G. Selvaggi, T. Kato, E. Island, P. Ruiz, A. Tzakis
University of Miami
Introduction: We report our 6 years experience with the use of Campath-1H 
(C1H) induction in adult liver transplantation. 
Materials and methods: Since December 2001, C1H induction with low dose 
maintenance tacrolimus immunosuppression was administered to 166 adult 
recipients of a liver allograft. Most common primary diseases were Laennec (n=60), 
cryptogenic cirrhosis (n=31) and autoimmune: PSC (n=17), PBC (n=16) and AIH 
(n=14). The fi rst dose of C1H was administered immediately before (n=74) or after 
(n=92) the transplant procedure. Follow up was until December, 2007. 
Results: Five year patient and graft survival was 90% and 85% respectively. 
There were 14 deaths due to stroke (n=2), chronic rejection (n=2), failure to 
thrive/pneumonia (n=3), sepsis (n=2), hepatic artery thrombosis, HCC, prostate 
cancer, graft lymphoma and non-compliance (one each). Seven patients were 
retransplanted, for primary non function (n=2), portal vein thrombosis (n=1), 
hepatic artery thrombosis (n=1), hepatitis B (n=1) and chronic rejection (n=2). 
Thirty six patients had biopsy proven rejection episodes: mild (n=28), 
moderate (n=9) or severe (n=3). The average tacrolimus 12 hour trough 
levels were 6. 6, 5. 2 ng/ml and 2. 78 ng/ml for the 1rst, 3nd and 5th year 
post-transplantation, respectively. There was no signifi cant difference in the 
outcome of the transplant so far, between patients that received C1H before or 
after the transplant procedure. 
Immunosuppression-related complications included A). Opportunistic infections: 
most common were Herpes Zoster (n=19), CMV (n=3), and Herpes Simplex (n=3), 
B). Neoplasms: skin cancer (n=3), Kaposi sarcoma (n=1), lymphoma (n=2) and 
C). Nephrotoxicity: Five patients received a kidney graft for diabetic nephropathy 
(n=2), nephrotic syndrome (n=1) and calcineurin nephrotoxicity (n=2). 
Conclusion: The use of C1H induction with half the usual dose of tacrolimus 
is an effective regimen in adult liver transplantation. The timing of C1H 
administration does not seem to affect the clinical outcome so far. 
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CONVERSION TO ENTERIC-COATED MYCOPHENLATE 357 
SODIUM (EC-MPS) FROM MYCOPHENOLATE MOFETIL 
(MMF) IN STABLE LIVER TRANSPLANT RECIPIENTS 
– COMPARISON OF PHRAMACOKINETICS (PK) AND 
GASTROINTESTINAL DISTURBANCES
T. Kato1, T. Panagiotis1, W. Wolowich2, K. Hamamura1, M. Torres1, 
D. Weppler1, A. Tzakis1
1University of Miami, 2Nova Southeastern University
Purpose: To compare mycophenolate mofetil (MMF) and enteric-coated 
mycophenoate sodium (EC-MPS) in terms of the phramacokinetics (PK) 
profi le and GI disturbances in liver recipients. 
Patients and Methods: Twenty stable adult liver transplant recipients who 
were taking MMF as part of their maintenance immunosuppression for more 
than 1 month were enrolled. A 12 hour PK study was done before to convert 
to EC-MPS. Conversion to EC-MPS was done according to the standard 
conversion rate. Another PK study was obtained at 28 days from the conversion. 
GI disturbance were monitored using gastrointestinal symptom rating scale 
(GSRS) prior to conversion, 1, 2 and 3 months from the conversion. Follow up 
was until November 30, 2007. 
Results: All 20 patients completed the study. At conversion, patients were 
taking MMF 250-1000 mg twice daily. Average dose-adjusted (adjusted to 
MMF 1000mg and EC-MPS 720mg) peak mycophenolic acid (MPA) level 
(Cmax) and area under the curve (AUC) were 23. 1 mg/L and 24. 8 mg/L 
(Cmax), and 36. 2 mg/L*h and 35. 4 mg/L*h (AUC), respectively before and 
after the conversion. As expected, average Tmax was signifi cantly delayed 
after conversion (2. 88h vs 1. 06h, p=. 00001). Mean relative bioavailability 
(F relative) was 1. 02 (EC-MPS vs MMF). GSRS revealed that diarrhea and 
loose stools were signifi cantly reduced at 3 month visit after the conversion 
(p=. 0019 and. 0068, respectively). No other GI disturbance profi les including 
abdominal pain, nausea, rumbling and stool urgency showed statistical changes 
after conversion. No acute rejection was seen during the follow up period. 
Four patients switched back to MMF due to complaints of constipation (n=1), 
weight gain (n=1) and insurance coverage issues (n=2). All other patients opted 
to continue using EC-MPS over MMF at the end of the trial. 
Conclusions: Conversion to enteric coated mycophenolate sodium is safe 
in stable liver recipients. EC-MPS provided the same drug exposure to the 
patients in the standard conversion rate. Diarrhea was signifi cantly reduced 
after the conversion. 
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EARLY IMMUNOSUPPRESSION WEANING AFTER 358 
CADAVER LIVER TRANSPLANTATION USING ATG 
INDUCTION AND RAPAMYCIN
V. Donckier1, A. Buggenhout1, R. Troisi2, V. Lucidi2, X. Rogiers1, 
N. Nagy1, L. Craciun1, N. Bourgeois1, B. de Hemptinne2, M. Goldman1
1Abdominal Transplantation and Immunology, Hôpital Erasme, Université 
Libre De Bruxelles, Brussels, Belgium, 2Surgery and Hepatogastroenterology, 
Universitair Ziekenhuis Gent, Ghent, Belgium
Background: Immunosuppression (IS) minimisation or withdrawal 
(operational tolerance) is a major objective in clinical organ transplantation. 
In liver transplantation (LT), several observations suggest that T cell depletion 
in the peri-transplant period and avoidance of calcineurin inhibitors (CNI) may 
favour tolerance induction. 
Aim of the study: To allow early IS minimisation and possibly withdrawal 
after cadaver LT, using high doses anti-thymocyte globulin (ATG) followed by 
rapamycin-based IS. 
Patients and Methods: Hepatitis C, autoimmune diseases and re-
transplantations were excluded. Recipients of LT received 3. 75 mg/kg ATG 
from day 1 to 5, followed by rapamycin (started on day 7, target through level: 
8-12 ng/ml). Steroids were given for the 1st month. Weaning was started after 
month 3, according to clinical and biological data. Several immunomonitoring 
tests were performed at various time points pre- and post-transplantation, 
including mRNA microarray analyses on peripheral blood leucocytes (PBL) 
and liver biopsies (LB). 
Results: In 11 evaluable patients, IS has been withdrawn in 3, respectively 
at days 140, 206 and 124 after LT. At days 286, 280 and 165 post-LT, 
these 3 patients developed Grade 2 acute rejection (AR) which respond to 
steroids and reintroduction of IS. AR post IS withdrawal was remarkable 
for the predominance of polymorphonuclear cells and macrophages in LB. 
Furthermore, interleukin-17 (IL-17) mRNA accumulated at the graft level and 
IL-17 was synthesized by recipients’ PBL exposed in vitro to donor cells at the 
time of AR. Among the 8 remaining patients, 2 developed AR under rapamycin 
monotherapy, successfully treated with steroids. Of note, none of the 11 patients 
maintained in the protocol developed post-transplant renal insuffi ciency or de 
novo diabetes. 
Conclusions: Rapamycin monotherapy is feasible after LT and ATG induction. 
In contrast with CNI-based IS, this regimen is protective for renal function and 
does not induce de novo diabetes. However, such regimen does not allow early 
IS withdrawal. Preliminary results suggest that failure of operational tolerance 
induction in these conditions could be related to activation of a Th17-mediated 
pathway of transplant rejection. 
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PHARMACOKINETICS (PK) OF TACROLIMUS FOR 359 
A ONCE DAILY PROLONGED RELEASE FORMULATION 
(ADVAGRAF®) VERSUS TWICE-DAILY (PROGRAF®) IN DE 
NOVO LIVER TRANSPLANT RECIPIENTS IN A PHASE III 
MULTICENTRE STUDY
N. Undre9, B-G. Ericzon1, E. Varo2, P. Trunecka3, X. Rogiers4, 
M. Colledan5, B. Gridelli6, J.O. De Urbina7, J. O’Grady8, J. Dickinson9
1Karolinska University Hospital Huddinge, 2Hospital Clinico Universitario 
de Santiago, 3IKEM, 4Universitaets-Krankenhaus Eppendorf, 5Azienda 
Ospedaliera Spedali Riuniti, 6Ospedale Civico, 7Hospital de Cruces, 8Kings 
College Hospital, 9Astellas Pharma Europe
Introduction: Advagraf® (ADV) is a prolonged release formulation of 
tacrolimus to enable once daily administration. A previous Phase II study in 
liver transplant recipients has shown that the mean AUC of tacrolimus on Day 
1 following administration of ADV was approximately 50% lower than that 
for Prograf (PRG); however, the exposure was comparable by Day 14. The 
objective of this study was to further describe the PK of tacrolimus for ADV 
versus PRG during the fi rst 2 weeks post-transplant. 
Methods: Twenty fi ve patients (ADV n=13, PRG n=12), participating in a 
Phase III study, provided four evaluable PK profi les. The fi rst dose of PRG was 
0. 10 mg/kg/day and that of ADV 0. 2 mg/kg/day, with target whole blood trough 
levels of 10 to 20 ng/mL. PK profi les (17 samples over 24 hours) were obtained 
following the fi rst administration of tacrolimus (Day 1), Day 3, Day 7 and Day 
14. All samples were analysed using HPLC with tandem mass spectrometric 
detection. Laboratory and safety parameters were also evaluated. 
Results: The AUC0 24 mean values for ADV were 320 (Day 1), 452 (Day 
3), 359 (Day 7) and 353 (Day 14) ng•h/mL. Corresponding values for PRG 
were 217 (Day 1), 318 (Day 3), 249 (Day 7) and 283 (Day 14) ng•h/mL. 
Dose normalised systemic exposure to tacrolimus for ADV on Day 1 was 
approximately 77% compared to PRG. On Days 3, 7 and 14 AUC0-24 of 
tacrolimus for ADV compared to PRG was approximately 88%, 117% and 
84% respectively. 
There was good correlation between AUC0-24 and C24 for ADV and PRG 
(r=0. 96 and r=0. 86, respectively) with similar slopes. 
Conclusion: This study has confi rmed that systemic exposure to tacrolimus for 
ADV normalises to that of PRG within 3 to 7 days post-transplant and that the 
same trough level monitoring concept can be used for both formulations. 
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CALCINEURIN INHIBITOR (CNI) WITHDRAWAL IN 360 
ADULT LIVER TRANSPLANT RECIPIENTS: AN ANALYSIS OF 
LONG TERM EFFICACY
J. Thompson, D. Radosevich, A. Humar, J. Lake
University of Minnesota
Background: Several small studies have demonstrated that mycophenolate 
mofetil (MMF) or sirolimus (SRL) may substitute for CNIs and lead to 
improved renal function, but some have raised concern for rejection risk. We 
report the largest series of adult LT patients in whom CNIs were withdrawn. 
Methods: Patients transplanted 1995-2007, started on CNIs and taken off 
for any reason (renal=85, neurologic=7, other=8) were studied. Tacrolimus 
(TAC) was originally given to 71 patients and cyclosporine to 29. After CNI 
discontinuation, 58 patients received MMF and prednisone, 42 received SRL. 
Deaths, graft failures and biopsy proven acute rejections (BPAR) were extracted 
from the LT database. Creatinine at time of CNI discontinuation, yearly and 
at last follow up were recorded from medical records. Glomerular fi ltration 
rate (GFR) was calculated using the re-expressed modifi cation of diet in renal 
disease (MDRD) equation. 
Patients: Mean age was 54 years. Reason for transplantation: alcoholic 
cirrhosis, 20; HCV, 31; cholestatic disease, 17; cryptogenic cirrhosis, 13; HCC, 
4; other, 15. 
Results: Mean follow up time was 28. 4 mo after CNI discontinuation 
(MMF=30 mo, SRL=27 mo). Mean time to CNI discontinuation after LT was 
47. 8 mo (MMF=67 mo, SRL=20 mo). Patient survival (%) at 1, 3 and 5 years 
was 100, 96. 4 and 89. 9 in the MMF group and 95. 1, 78. 9 and 73. 3 in the SRL 
group. Graft survival (%) at 1, 3, and 5 years was 100, 96. 4, 94 in the MMF 
group and 97. 6, 85. 9 and 85. 9 in the SRL group. After CNI discontinuation, 
there was 1 episode of BPAR in the MMF group and 6 in the SRL group (4 
mild, 2 moderate). The MMF patient had severe irreversible acute rejection 
and died during retransplantation. Two patients were restarted on TAC due to 
MMF intolerance (weight loss), and SRL intolerance (mouth ulcers). Table 1 
shows renal function results. 
Conclusions: Based on our series, which is the largest and with the longest 
reported follow-up, we conclude CNI withdrawal is safe in LT recipients 
and provides for stable or improved renal function in greater than 80% of LT 
recipients. 
TABLE 1 Creatinine 
Improved 
(≥20% 
decrease)
Creatinine 
Stable
Creatinine 
Worsened 
(≥20% 
increase)
Creatinine at 
time of CNI 
d/c, most recent 
f/u (mean)
GFR at time 
of CNI d/c, 
most recent f/u 
(mean)
MMF 46% 41% 13% 2. 2, 1. 8 33. 3, 42. 1
SRL 32% 47% 21% 2. 0, 1. 9 40. 3, 45. 8
ALL 40% 44% 16% 2. 0, 1. 8 37. 6, 44. 3
Taken off for
Renal Insuff
55% 29% 16% 2. 3, 1. 9
Creat ≥ 2 at 
CNI d/c
62% 20% 18% 2. 6, 2. 2
Creatinine in mg/dL, GFR in ml/min. D/C=disciontinuation. F/U=follow-up
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MONITORING VIRUS SPECIFIC T CELLS MAY 361 
IMPROVE THE MANAGEMENT OF IMMUNOSUPPRESSION 
AFTER LIVER TRANSPLANTATION
R. Olsson1, A-K. Lidehäll2, M. Engstrand1,2, J. Henriksson1, H. Gjersen1, 
O. Korsgren2, L. Wennberg1
1Department of Transplantation Surgery, Karolinska University Hospital, 
2Department of Clinical Immunology, Uppsala University
Background: To improve the clinical outcome of liver transplantation, and 
to minimize the risk for complications such as acute rejection and recurrence 
of hepatitis C, methods to properly monitor the degree of immunosuppression 
are needed. For this purpose, the ImmuKnow® assay was recently marketed 
to monitor PHA-induced ATP production of recipient CD4+ T cells 
(overimmunosuppression, ≤225 ng/ml and underimmunosuppression, 
≥525 ng/ml). In the present study, we are including liver recipients pre-
transplantation to compare the ImmuKnow® results with changes in T cell 
reactivity against cytomegalovirus (CMV). Moreover, we monitor the degree 
of immunosuppression in liver recipients treated for recurrence of hepatitis 
C (HCV) using ImmuKnow® as well as T cell reactivity to HCV specifi c 
proteins. 
Materials and Methods: We report data from seven CMV seropositive 
liver recipients followed during the fi rst month post-transplantation and 
one patient treated for HCV recurrence. All recipients received 1000 mg of 
methylprednislone at transplantation and the maintenance immunosuppressive 
drugs were tacrolimus and prednisolone. T cell reactivity was measured pre-
transplantation, and at 1 week, 2 weeks and 1 month postoperatively or before 
and 3 months after starting treatment of HCV recurrence (interferon α and 
ribavirin) using both ImmuKnow® (Cylex Inc. , Columbia, MD, USA) and a 
novel method developed at the Department of Clinical Immunology, Uppsala 
University Hospital, Sweden. Briefl y, after in vitro stimulation with CMV 
or HCV specifi c proteins, the CD4+ or CD8+ T cells producing IFN γ were 
separately determined by FACS, and expressed per ml blood. For statistical 
analysis, paired comparisons were made using the Wilcoxon Matched-Pairs 
Signed-Ranks test. 
Results: During the fi rst month post-transplantation, the ImmuKnow® results 
remained unchanged. In contrast, one week post-transplantation both the CD4+ 
and CD8+ T cell numbers were decreased to 30-35% of pre-transplantation 
values (31±8% and 34±10%, n=7, p<0, 05), and the CMV specifi c CD4+ T cells 
were markedly decreased in all recipients [median 250 cells/ml (range 0-13 600 
cells/ml) vs. median 3 350 cells/ml (range 350-45 150 cells/ml); n=7, p<0. 05]. 
Furthermore, after three months of treatment for HCV recurrence one patient 
had unchanged ImmuKnow® result (75 ng/ml vs. 45 ng/ml ATP), suggesting 
a continued overimmunosuppression. However, the patient developed HCV 
reactive CD8+ cells (590 cells/ml) and the viral load decreased from >69x106 
IU/ml to 8x106 IU/ml, indicating that the cellular anti-HCV immune response 
was improved. 
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Conclusions: The ImmuKnow® assay was insensitive to the heavy 
immunosuppressive treatment given during the fi rst month after liver 
transplantation. This suggests that ImmuKnow® may not properly refl ect early 
changes in immunosuppression. Interestingly, our fi nding that CMV specifi c 
CD4+ T cells were markedly decreased one week post-transplantation supports 
this hypothesis. Furthermore, in the recipient treated for HCV recurrence, 
interferon α and ribavirin did not affect the ImmuKnow® assay, although the 
recipient developed HCV specifi c CD8+ T cells and reduced the viral load. 
In conclusion, these preliminary data suggest that monitoring T cell reactivity 
against viruses (CMV, HCV) may be a sensitive clinical tool to monitor 
immunosuppression in the future. 
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LONG TERM CALCINEURIN SPARING WITH 362 
DACLIZUMAB USED IN AN OUTPATIENT LIVER 
TRANSPLANT CLINIC
G. Smallwood, C. Fasola, A. Stieber, T. Heffron
Emory University School of Medicine
Background: The monoclonal antibodies to the CD-25 (daclizumab and 
basiliximab) cell are currently used for induction therapy following solid organ 
transplant. These agents have been used for short term use to spare the use of 
calcineurin inhibitors during initial hospitalization. 
Aim: The aim of this study was to evaluate stable liver transplant patients 
receiving daclizumab on an outpatient basis while sparing the use of tacrolimus 
for greater than two weeks. 
Methods: Patients unable to tolerate tacrolimus due to adverse events (renal 
or other reasons) were begun on daclizumab 1mg/kg given intravenously 
weekly in an outpatient liver transplant clinic. This is an IRB approved study 
with inclusion criteria requiring that the patients had to be off of tacrolimus 
for at least two weeks. Patients were evaluated for both renal and transplant 
outcomes. 
Results: 51 patients received daclizumab while sparing the use of tacrolimus. 
Patients receiving daclizumab was 50. 7 ± 12. 9 years of age, 331 ± 432 days 
from transplant at time of tacrolimus sparing, 37. 3% (19/51) female, and 19. 
6% (10/51) were African-American. Patients’ mean calcineurin free time was 
39. 8 ± 17. 8 days. The renal group (n = 34) had improved GFR [28. 3 ± 9. 7 
ml/min/1. 73m2 vs. 44. 4 ± 14. 4 ml/min/1. 73m2, p < 0. 0001], improved sr. cr. 
[2. 07 ± 0. 7 mg/dl vs. 1. 37 ± 0. 36 mg/dl; p <0. 0001], while maintaining liver 
function as described by ALT (p = 0. 326), AST (p= 0. 375), and T. bili (p = 0. 
781). Patients sparing tacrolimus for other reasons (n = 17), maintained GFR 
[51. 8 ± 28. 1 ml/min/1. 73m2 vs. 45. 5 ± 29. 8 ml/min/1. 73m2, p = 0. 260], 
while maintaining liver function test. Only one patient (1. 9%) had histological 
proven rejection while on daclizumab. Patients having rejection episodes prior 
to daclizumab use (n = 4) did not experience rejection when off of tacrolimus. 
Overall patient survival was 88. 3% and graft survival was 86. 3%. 
Conclusions: Liver transplant patients can safely be immunosuppressed with 
weekly daclizumab dosing on an outpatient basis while holding tacrolimus for 
up to 40 days. With the use of daclizumab, adverse events from calcineurin 
inhibitors have the opportunity to resolve. 
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A THREE YEAR FOLLOW-UP STUDY OF STABLE LIVER 363 
TRANSPLANT RECIPIENTS CONVERTED FROM TWICE 
DAILY PROGRAF® TO ONCE DAILY ADVAGRAF (EXTENDED 
RELEASE TACROLIMUS)
S. Florman
for The Tacrolimus Extended Release Liver Transplant Conversion Study 
Group, Tulane University School of Medicine, New Orleans, LA
Purpose: To assess safety and effi cacy three years following conversion from 
tacrolimus twice daily (Prograf BID) to extended release tacrolimus (Advagraf, 
previously Modifi ed Release tacrolimus or MR) once daily (QD a. m. ) in stable 
liver transplant recipients. 
Methods: Seventy patients were enrolled in the pharmacokinetic (PK) portion 
of the study (days 0-56). Sixty-nine patients were subsequently maintained on 
Advagraf QD a. m. Patients were evaluated for Advagraf dosing and trough levels, 
laboratory values, concomitant medications, graft survival, and adverse events. 
Results: The results of the PK portion of the study indicated that mg: mg 
conversion from Prograf BID to Advagraf QD a. m. dosing resulted in equivalent 
tacrolimus exposure in stable liver transplant recipients. 69 patients agreed to 
the extension portion of the study, and 54 patients completed the third year 
of the study. Attrition was due to lower extremity pain, headache, worsening 
gastrointestinal acidity, increase bilirubin, chronic cholestasis secondary to 
6MP, fatigue, elevated blood pressure, increased thirst, increased urine output, 
granulomas on biopsy, granulomatous hepatitis, elevated liver function tests, 
diarrhea, rejection, withdrawal of consent, patient’s discretion (year 1), lung 
squamous cell carcinoma (resulting in death, year 2), renal impairment, non-
compliance with protocol procedures, (year 3). Through the third year, renal 
function remained stable. 
Pre-Advagraf 
Baseline 
N=70
1 Year Post-
Conversion
N=57†
2 Year Post-
Conversion
N=56†
3 Year Post-
Conversion
N=54†
Mean Dose (mg/
day)
Range (mg/day)
5. 3
 (1-18)
5. 6 
 (2-16)
5. 5
 (2-14)
5. 0 
 (1-12)
Mean Trough 
Conc. (ng/mL)
Range (ng/mL)
7. 2 
 (2. 9-14. 7)
6. 4 
 (2-11. 7)
6. 2 
 (1. 5-12. 7)
5. 8
 (1. 5-13. 6)
Mean Serum 
Creatinine (mg/dL)
Range (mg/dL)
1. 3 
 (0. 6-2. 2)
1. 3 
 (0. 5-2. 0)
1. 3 
 (0. 6-2. 3)
1. 5 
 (0. 5-3. 3)
† N = completers at each year
Patient and graft survival were 99% at three years post conversion. Through 
three years, four biopsy confi rmed acute rejections occurred in four patients; 
two Grade I (days 153 & 233), one Grade II (day 400) and one Grade III (day 
53). Through three years, multiple rejection episodes were not reported in any 
patients. All episodes resolved with steroid treatment. 
Medication use for diabetes and hypertension remains similar to usage at 
conversion and at three years. There have been ten occurrences of glucose 
intolerance (based on fasting plasma glucose of ≥ 126 mg/dL); two of these 
required insulin therapy and three required oral hypoglycemic agents. There 
were no patients with hemoglobinA1c ≥ 6%. 
Conclusions: The three year data continues to support the safety and effi cacy 
of conversion from Prograf BID to Advagraf QD a. m. in liver transplant 
patients. 
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MTOR INHIBITORS (MTOR-I) AND LUNG 364 
TRANSPLANTATION: CAN ITS USE BE JUSTIFIED?
P. Ussetti, M. Carreño, R. Laporta, C. Garcia-Gallo, T. Lazaro, A. de Pablo, 
J. Ferreiro
Clínica Puerta De Hierro
Aim: To analyze the effi cacy and adverse effects of mTOR-I in lung transplant 
recipients. 
Patients: Lung transplant recipients treated with mTOR-I for progressive BOS 
or toxicity from other immunossupressive drugs (AZA or MMF). 
Methods: mTOR-I were always administered in combination with calcineurin 
inhibitors (CyA or TAC). The choice of sirolimus or everolimus depended on 
their availability and/or the physician attending the patient. mTOR-I levels 
were maintained between 5-10 ng/ml, CsA between 100-200 ng/ml and TAC 
between 5-10 ng/ml. 
We analyzed demographic data, mTOR-I type, evolution of FEV1 from 3 
months prior to initiating administration of the drug until its withdrawal for 
adverse events, or for a 12 month follow-up. The development of adverse 
clinical or analytical effects were closely monitored during treatment. 
Clinical response to mTOR-I in patients with BOS was considered favourable 
when during the 12 month follow-up FEV1 levels were maintained, with no 
more than 10% drop from their initial value. 
Statistical analyses were performed using Chi-square, t-test and ANOVA. 
Results: 36 patients received treatment with mTOR-I (16 sirolimus and 16 
everolimus). mTOR-I was introduced for BOS in 28 cases, and for toxicity 
associated to AZA or MMF in the other 8 cases. 
In 17 of the 28 patients treated for BOS (60%), pulmonary function became 
stabilized during the 12 month follow-up period (Table 1). 
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FEV1 (ml)
-3 month
FEV1 (ml)
-1 month
FEV1 (ml)
baseline
FEV1 (ml)
+3 month
FEV1 (ml)
+6 month
FEV1 (ml)
+12 month
responders
 (n=17)
18919 ±
738
1676±
643
1600±
574
1680±
590
1657±
590
1647±
548
Non-
responders
 (n=11)
2622±
666
2214±
547
2001±
539
1704±
664
1499±
732
1474±
779
Analytical anormalities during the follow-up period included a signifi cant 
deterioration in renal function, increased lipids and decreased VCM (Table 2).
Creatinin Creat. 
Clearance
Cholesterol HDL LDL VCM
Pre-mTOR-I 1. 5 ±. 48  60 ±29  192 ±39 66 ±20  97 ±33 89 ±9
Post-mTOR-I 1. 7 ±1 *  52 ±30*  239 ±45* 77 ±23* 120 ±37* 86 ±7*
 (*p<. 005)
Treatment was discontinued in 14 of the 36 recipients (39%) due to the 
development of adverse effects. The most noteworthy for their severity were 4 
patients with nephrotic syndrome, with permanent hemodialysis being required 
in 2 cases, and 4 episodes of diverticulitis which required laparotomy with a 
temporary colostomy. 
Conclusions: mTOR-I can stabilize pulmonary function in more than 50% 
of patients with BOS. However, a considerable percentage of patients have 
treatment withdrawn due to adverse effects which can be severe. 
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PRONOSTIC FACTOR FOR MTOR INHIBITORS 365 
(MTOR-I) PROTEINURIA AFTER LUNG TRANSPLANTATION
P. Ussetti1, J. Rovira2, M. Carreño1, R. Laporta1, B. Sanchez1, J. Ferreiro1, 
J. Campistol2
1Clínica Puerta De Hierro. Madrid. Spain, 2Hospital Clinic. Barcelona. Spain
Objective: To study the frequency and prognostic factors of proteinuria in lung 
transplant recipients treated with mTOR-I. 
Patients: Lung transplant recipients treated with mTOR-I for progressive BOS 
(n= 28) or adverse reactions due to others drugs (n= 8). 
Methods: mTOR-I were administered in combination with a calcineurin 
inhibitor (CNI) (CsA n= 5 or TAC n = 31). The choice of sirolimus or 
everolimus depended on their availability and/or the physician attending the 
patient. mTOR-I levels were maintained between 5-10 ng/ml, CsA between 
100-200 ng/ml and TAC between 5-10 ng/ml (MEIA, IFPA). 
We analyzed demographic data, diabetes, HTA and its treatment (diltiazem vs. 
ACE-inhibitors), and duration of previous CNI treatments. Proteinuria was 
evaluated before and during mTOR-I treatment. 
Statistical analyses were performed using Chi-square, t-test and multivariate 
logistic regression. 
Results: 36 patients were treated with mTOR-I (18 sirolimus, 18 everolimus). 
Five patients presented moderate proteinuria (0. 3 to 0. 5 g/L) before mTOR-I. 
13 patients (36%) developed persistent proteinuria >0. 3 g/L during mTOR-I 
treatment, and proteinuria was higher than 1 g/L in 8 cases. Mean time from 
commencing mTOR-I to the onset of proteinuria was 15„b9 months (range 
1-55). 4 of the 5 patients with moderate proteinuria prior to mTOR-I developed 
nephrotic syndrome (p<0. 01), with renal failure, which required permanent 
hemodialysis in two. 
Patients who developed proteinuria had longer previous exposure to CNI (82„b42 
vs 59„b35 months; p<0. 05). Other variables associated with proteinuria were 
diabetes (RR 2. 9; p<0. 16), and HTA treated with diltiazen (RR 10. 6; p<0. 
001). None of the patients treated with ACE-inhibitors presented proteinuria. 
In the multivariate analysis only previous CNI treatments exceeding 60 
months, and HTA treatment with diltiazen, maintained statistical signifi cation. 
Creatinine clearance tended to be lower (48„b19 vs. 60„b22; p=0. 09), and 
mTOR-I treatment time tended to be longer (63„b56 vs36„b31; p=0. 09), in 
patients with proteinuria >1 g/L with respect to those who did not develop the 
same. 
Conclusions: Proteinuria due to mTOR-I is not uncommon in lung transplant 
patients treated for BOS, especially in recipients with diabetes and HTA treated 
with diltiazen. Moderate proteinuria before mTOR should be considered a risk 
factor for nephrotic syndrome. 
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OUTCOME OF PATIENTS RECEIVING TACROLIMUS 366 
AFTER LUNG LUNG/HEART TRANSPLANTATION – ONE 
CENTER EXPERIENCE. 
C. Chaparro, C. Gutierrez, S. Keshavjee
Toronto Lung Transplant Program
Background: Our institution standard immunosuppressive protocol includes 
cyclosporine (CSA), azathioprine, and glucocorticoids. Since the introduction of 
tacrolimus we have used it for different indications that include bronchiolitis obliterans 
(BO), acute rejection, renal dysfunction, neuro- and gastrointestinal toxicity.
Objective: We reviewed the effi cacy and tolerance among patients converted 
to tacrolimus from CSA for different indications.
Methods: Retrospective review of those patients switched to tacrolimus from 
CSA between Aug 1983 and January 2006. We recorded indication for the 
switch, effectiveness of the switch and time to improvement.
Results: We identifi ed 238 patients that were switched to tacrolimus from 
CSA. Twenty-three patients were excluded for different reasons. Indications for 
conversion among the remaining patients were: Bronchiolitis Obliterans (BO) 
104 (48%), Acute Rejection 31(14%), neurotoxicity 25 (12%), renal dysfunction 
24(11%), gastrointestinal intolerance to CSA 23 (10.5%), hirsutism 4 (2%), 
diffi culty to get therapeutic levels 3 (2%) and gingival hypertrophy 1 (0.5%). 
Among the 104 patients switched due to BO, 45 showed stability in their lung 
function, 6 improved, no major changes were seen in 25, and in 28 more there 
was evidence of slow progression of functional decline. All patients switched 
due to neurotoxicity, gastrointestinal intolerance and/or renal dysfunction 
showed improvement over time (2 weeks to 6 months).   
Conclusions: Tacrolimus is a good alternative for patients who present acute 
rejection, chronic rejection, toxicity and/or intolerance to CSA. Despite being 
a calcineurin inhibitor too, tacrolimus is well tolerated and appears a safe 
alternative for those indications.
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DESCRIPTIVE ANALYSIS OF PULMONARY 367 
TRANSPLANT PATIENTS, AFTER MYCOPHENOLATE 
MOFETIL TO ENTERIC-COATED MYCOPHENOLATE 
SODIUM CONVERSION TREATMENT. 
A. Solé1, A. Pastor1, A. Saura1, E. Ansotegui1, R. Vicente1, J. Padilla1
1Hospital Universitario La Fe, 2Hospital Universitario La Fe, 3Hospital 
Universitario La Fe, 4Hospital Universitario La Fe, 5Hospital Universitario 
La Fe, 6Hospital Universitario La Fe
Purpose: Descriptive analysis of pulmonary transplant patients, following 
conversion treatment. 
Methods: Clinical data compilation of pulmonary transplant recipients 
following a conversion treatment from mycophenolate mofetil (MMF) to 
enteric-coated mycophenolate sodium (EC-MPS) with a 12 month follow-up 
period (visits at 5, and 12 days, 1, 3, 6, and 12 months). 
Results: A total of 8 pulmonary transplant recipients were evaluated (5 
women and mean age±SD 31. 3±13. 2 years). Seven patients had bilateral lung 
transplant, and one patient a cardiopulmonar transplant. The main transplant 
etiology was cystic fi brosis (50%). Following transplant, and previously to 
conversion treatment, all patients were treated with anticalcineurinic agents 
(100% tacrolimus), 37. 5% azathioprine, 62. 5% mycophenolate mofetil, and 
steroids (100%). Seven patients had a rejection previous to conversion. Mean 
time from transplant to conversion was 28. 6±38. 5 months. The main reasons 
for conversion were: gastrointestinal intolerance to MMF (50%), previous 
rejection (50%), post-transplant diabetes (37. 5%), and nephrotoxicity (25%). 
During the follow-up period, the EC-MPS doses decreased from 855. 0±343. 
6 mg/day at conversion visit (median 810. 0, range: 360. 0-1440. 0) to 642. 
9±309. 3 mg/day (median 720. 0, range: 180. 0-1080. 0) at 6 months (7 
patients), and 360±0. 0 mg/day at 12 months (2 patients). Anticalcineurinic 
agents (100% tacrolimus), and steroids (100%) treatments were maintained 
during the 12 month follow-up, except for one patient that changed tacrolimus 
to cyclosporine after 1 month. Only one patient had a post-conversion rejection 
(at one month). At conversion visit, the glucose, triglycerides, and creatinine 
levels were 159. 1±142. 7 mg/dl, 321. 1±295. 2 mg/dl, and 1. 6±1. 1 mg/dl, 
respectively, and after 6 months were 92. 0±46. 1 mg/dl, 155. 0±39. 6 mg/dl, 
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and 2. 7±2. 5 mg/dl, respectively (n. s). The pulmonary function parameters at 
conversion visit: forced vital capacity (FVC), forced expiratory volume in one 
second (FEV1), and FEV 25%-75% were 3300. 0±1162. 7 ml, 2994. 0±1103. 
5 ml, and 3768. 0±1904. 2 ml/s, respectively, and after 6 months were 3547. 
1±1020. 8 ml (p=0. 0224), 2894. 3±999. 8 ml (n. s), and 2797. 1±1574. 6 ml/s 
(n. s), respectively. At 12 months (2 patients), the levels of glucose were 74. 
0±4. 2 mg/dl, triglycerides 79. 5±3. 5 mg/dl, creatinine 5. 4±4. 7 mg/dl, FVC 
3340. 0±70. 7 ml, FEV1 2370. 0±254. 6 ml, and FEV 25%-75% 1575. 0±714. 
2 ml/s. 
Conclusions: The conversion to EC-MPS treatment in lung transplant patients 
was mainly due to gastrointestinal intolerance to MMF, and previous rejection. 
A decrease in rejection rate was observed after conversion to EC-MPS. The 
FVC improved during the follow-up conversion period. 
INFECTIOUS DISEASES 1: MINI-ORAL SESSION 11: 
BACTERIAL, FUNGAL AND OTHER INFECTIONS
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IMPACT OF EXTENDED-SPECTRUM BETA-368 
LACTAMASE-PRODUCING ENTEROBACTERIACEAE 
URINARY TRACT INFECTION IN KIDNEY TRANSPLANT 
PATIENTS
M-F. Lam, K-C. Tse, T. Yip, T-M. Chan, K-N. Lai
University Department of Medicine, Queen Mary Hospital
Introduction: Urinary tract infection (UTI) is commonly seen in kidney 
transplanted patients. Because of increased prevalence of Extended-spectrum 
beta-lactamase (ESBL)-producing Enterobacteriaceae in the community, 
transplant recipients with UTI caused by the ESBL strain are not uncommonly 
seen. Whether UTI affects the allograft function is still controversial, the delayed 
in using appropriate antibiotic, mainly carbapenems, treating UTI caused 
by ESBL producing strain, may result in allograft damage or bacteraemia. 
We studied the prevalence of UTI caused by ESBL strains and its impact on 
allograft function. 
Method: Kidney transplant recipients developed UTI from year 2003 
to 2008 were retrieved for analysis. Asymptomatic bacteruria were 
excluded. Patients received standard immunosuppressive regimes such as 
prednisolone, calcineurin inhibitors, mycopheolate mofetil or azathioprine. 
Patients infected with ESBL strains were treated with carbapenems while 
other organisms were treated with either quinolone or cephalosporins. The 
serum creatinine before the onset of UTI and 1 month after were used to be 
compared. Hospital acquired defi ned as UTI developed after 48 hours of 
hospitalization. 
Result: Over the fi ve year study period, there were total 87 episodes of UTI 
detected in 36 transplant patients (female: 32) with age 44. 4±11. 7 yrs. The 
average onset of UTI was 8. 8 ± 6. 6yrs after transplant. 24 patients had 
recurrent UTI and 12 (33. 3%) of them received prophylactic antibiotics. 
Patients with diabetic mellitus and vesicoureteric refl ux (VUR) were 12 
(33. 3%) and 15 (41. 7%), respectively. 30 episodes of UTI were caused 
by ESBL producing bacteria which responded to carbapenems. However, 
24 (80%) out of 30 ESBL producing UTI were community acquired. The 
serum creatinine did not statistically signifi cantly impaired after an episode 
of UTI caused by usual stain bacteria (before: 170±90 vs 1 month after: 
183±108 umol/L, p=0. 18) or ESBL stain bacteria (before: 160±107 vs 1 
month after: 176±152umol/L, p=0. 13). Though patients with VUR, recurrent 
UTI associated with frequency episode of ESBL-UTI, it was statistical not 
signifi cant (p>0. 3)
Conclusion: UTI seems have some adverse effect on the allograft function. 
The high incident rate of community acquired ESBL-UTI suggests the usual 
empirical antibiotics may not teat the infection at the earlier stage, which may 
predispose the patients to have bacteraemia and allograft damage. Whether 
patients with VUR, recurrent UTI and on prophylactic antibiotics predispose at 
risk to ESBL UTI need further study. 
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PNEUMONIA IN SOLID ORGAN RECIPIENTS: REVIEW 369 
OF 217 EPISODES
H. Bonatti, R. Sawyer, T. Pruett, T. Schmitt, K. Brayman
University of Virginia
Background: Lower respiratory tract infection (LRTI) remains a leading cause 
of morbidity and mortality after solid organ transplantation (SOT). 
Patients and methods: A retrospective analysis of 217 episodes of LRTI in 143 
SOT recipients from a single centre was performed. 
Results: There were 94 men and 49 women (85% Caucasian) with a median 
age of 51 (range 17-79) years including 50 renal, 86 liver, 6 pancreas and 
one lung recipient. Forty patients had multiple episodes of LRTI. Median 
APACHE 2 score was 17 (range 5-40), median temperature was 38 (range 
35. 3-40. 2) centigrade, and median WBC was 12000 (range 100-106000). 
Pneumonia developed at a median of 11 (range 2-191) days after the last 
surgical intervention. 163 of the 217 LRTIs were nosocomial infections (60 
ventilator associated). Overall crude mortality was 21% and was increased in 
patients with multiple episodes of LRTI (25%) and after liver transplantation 
(33%). In 40 cases no causative organism could be identifi ed. Overall, 202 
microorganisms were found (41 mixed infections): Staphylococcus aureus 
(n=32) of which 81% were MRSA; E. coli (n=9), Klebsiella spp. (n=7), 
Enterobacter spp. (n=11), Serratia spp. (n=12), Pseudomonas aeruginosa 
(n=15), Stenotrophomonas maltophila (n=15), Acinetobacter spp. (n=9), fungi 
(n=18) and viruses (n=17). 
Conclusion: LRTI remains one of the most common and dangerous infections 
in transplant recipients with higher mortality than in other populations. MRSA 
is a particular problem. As a signifi cant number of SOT recipients develop 
multiple episodes of LRTI, a thorough reevaluation of the current guidelines 
for the treatment of pneumonia is urgently needed. 
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RELATIONSHIP BETWEEN INFECTION-RELATED 370 
RENAL ALLOGRAFT FAILURE AND REJECTION RATE: UNOS 
DATA ANALYSIS FROM 1990-2006
R. Parasuraman1, A. Patel1 , D. Kim2, M. Abouljoud2, G. Jacobsen3, and 
K.K. Venkat1. 
1Division of Nephrology and Hypertension; 2Transplant Institute and 
3Department of Research and Bioststistics, Henry Ford Hospital, Detroit, MI, 
United States.
Body: Long-term renal allograft survival has not improved despite signifi cant 
decline in acute rejection rate. Infections such as BK virus as the primary cause 
and/or systemic infections requiring reduction or withdrawal of immuno-
suppression contributing to graft failure is observed clinically but not well 
documented. 
Aim: To study the role of infections as a primary cause or contributing factor 
(death censored) for renal allograft failure and its relation to rejection rate. 
Method and Results: The UNOS data from 1990-2006 was analyzed and 38, 
286 fi rst and only renal transplants that resulted in graft failure were identifi ed 
with 31, 420 having known contributory infection status. Results compared 
between two periods (period I [1990-1996] and period II [1997-2006]) 
showed a signifi cant increase in infection contributed graft loss from 6. 3% 
(1037/16419) to 9. 1% (1360/14907) p < 0. 001 and a signifi cant decrease in 
treated for rejection rate from 20. 3% (3316/16302) to 12. 2% (1635/13350) p 
< 0. 001 respectively. Other signifi cant fi ndings are shown in table1. 
First renal transplants that resulted in graft failure (1990-2006)
Transplant year Number of grafts failed
Infection 
contributing to 
graft failure (%)
Recipient death 
(%)
Any induction 
medication 
use (%)
Treated for 
rejection (%)
1990 1735 6. 4 20 27. 4 27. 7
1992 2176 5. 7 21. 1 25. 7 23. 5
1994 2847 6. 1 19. 1 83. 1 18. 5
1996 2542 7. 5 20. 4 87. 9 14. 2
1998 2215 8. 1 23. 5 84. 1 11. 3
2000 1871 9. 0 22. 3 83. 8 9. 8
2002 1509 9. 6 22. 2 86. 3 10. 4
2004 949 9. 6 20. 3 87. 2 10. 4
2006 407 10. 1 17 89. 3 7. 1
The relationship between rejection rate and Infection Related Graft loss is 
shown in fi qure 1
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Conclusion: Infections contributing to renal allograft loss has increased 
signifi cantly with corresponding signifi cant decrease in rejection rate from 
1990 to 2006. Increase use of potent induction and maintenance IS may explain 
this additional important cause for poor long-term graft outcome. 
POSTER BOARD NUMBER P2 – 400
CHANGING PATTERNS OF CANDIDAEMIA 371 
FOLLOWING SOLID ORGAN TRANSPLANTATION IN THE 
ERA OF ANTIFUNGAL PROPHYLAXIS: THE AUSTRALIAN 
EXPERIENCE. 
S.V. Hal1, D. Marriott1, Q. Nguyen2, S. Chen2, T. Sorrell2, D. Ellis4, 
M. Slavin3, and the Australian Candidaemia Study group
1. Department of Microbiology and Infectious Diseases, St Vincent’s Hospital, 
Sydney Australia, 2Centre for Infectious Diseases and Microbiology and 
the University of Sydney, Westmead Hospital, Sydney Australia, 3Victorian 
Infectious Diseases Service, Royal Melbourne Hospital, Melbourne Australia, 
4Mycology Unit, Women’s and Children’s Hospital, North Adelaide, Australia
Solid organ transplant (SOT) recipients have documented high rates of invasive 
fungal infections (IFI). Candida species are the most commonly isolated fungi 
accounting for 35% to 90% of all IFIs. These infections are associated with 
signifi cant morbidity and mortality rates between 5% and 77%. The aim of this 
study was to determine the difference between incidence rates, risk factors, 
clinical presentation and outcome between SOT and non-SOT patients, using 
national transplant registries and data from the Australian Candidaemia Study 
(ACS). 
Between 2001 and 2004, the ACS collected clinical, epidemiological and 
organism data on patients with one or more blood cultures growing Candida 
spp. Information collected included the transplant status of patient and the 
period between transplant and infection. SOT data was retrieved from the 
respective transplant registries. 
In the study period, 24 (2. 3%) of the 1068 patients with candidaemia had a SOT. 
Transplanted organs during the study period included: liver (n=455), kidney 
(n=1605), single lung, (n=57), bilateral lung (n=183), heart and lung (n=18), 
heart (n=157) and pancreas (n=62). The overall incidence of candidaemia in 
SOT patients was 9. 9 per 1000 transplant admissions compared to 0. 21 per 
1000 admissions for non-SOT patients (p<0. 01). 
In 54% of SOT patients, the development of candidaemia occurred 6 months or 
greater post transplantation. Renal transplant recipients were signifi cantly more 
likely than other SOT recipients to develop candidaemia, 6 months or greater 
post transplantation (OR 16. 5, p<0. 01). 
SOT recipients with candidaemia were more likely to receive corticosteroid 
therapy (OR 5. 9; p<0. 01) and antifungal prophylaxis (OR 3. 4; p< 0. 01) than 
non-SOT patients. The 30 day mortality rate was not signifi cantly different 
between these two groups but SOT patients were signifi cantly more likely to 
die within the fi rst 5 days of diagnosis compared with non-SOT patients (p<0. 
01). Non-albicans candidemia was signifi cantly more likely to occur in patients 
(SOT and non-SOT patients) on antifungal prophylaxis (OR 2. 22, 95% CI: 
1. 47 to 3. 35; p <0. 01). However, antifungal prophylaxis did not select for 
fl uconazole resistant Candida species (C. glabrata and C krusei). 
In conclusion, SOT patients continue to have a high incidence of candidaemia, 
the incidence and timing of which is infl uenced by the type of solid organ 
transplanted. Apart from corticosteroid therapy, risk factors are identical to non-
SOT patients with candidaemia. Antifungal prophylaxis did not select for more 
resistant Candida species and did not alter mortality in SOT patients. All-cause 
mortality was no different to non-SOT patients but remains high at 21%. 
POSTER BOARD NUMBER P2 – 401
PULMONARY ASPERGILLOSIS AFTER SOLID ORGAN 372 
TRANSPLANTATION: DIAGNOSIS AND TREATMENT BASED 
ON SINGLE CENTER EXPERIENCES FOR 28 YEARS
K.H. Huh, M.K. Ju1,3, D.J. Joo1, S.J. Kim1, W.I. Yang2, M.S. Kim1,3, S.I. 
Kim1,3, Y.S. Kim1,3
1Department of Surgery, 2Pathology and 3Transplantation institutes Yonsei 
University College of Medicine, Seoul, Korea
Pulmonary aspergillosis is a serious and lethal complication among organ 
transplant recipients. This research wishes to review clinical manifestations 
of pulmonary aspergillosis. Method) From January 1979 to December 2007, 
3,215 patients underwent organ transplantation (2,954 kidney and 261 liver 
transplants) were enrolled in this study. Results) Nine cases of invasive 
pulmonary aspergillosis and 13 cases of localized pulmonary aspergillus were 
occurred. Overall incidence of pulmonary aspergillosis was 0.684% (invasive 
0.280% and localized 0.404%). Incidence of pulmonary aspergillosis after liver 
transplantation (1.533%) was more common than after kidney transplantation 
(0.609%). In clinical comparison between invasive and localized infection 
recipients, there was no statistical difference in demographics, the number of 
transplantations, immunosuppressive induction agents, and onset timing of 
infection between the invasive and localized infection groups (p=0.201, 0.51, 
0.291, 0.483, and 0.272, respectively). However, recipients with use history 
of anti-thymocyte globulin/anti-lymphocyte globulin and liver transplant were 
liable to invasive infection. And majority (6 among 9) of invasive infection was 
occurred within 1 year after transplantation. Five invasive infection recipients 
(55.6%) were diagnosed by pathologic study through transbronchial lung biopsy 
and 4 (44.4%) recipients were revealed by sputum culture study or clinical/
radiologic study. Except two recipients with invasive infection, all infected 
recipients were primarily treated by either amphotericine B or voriconazole. 
The invasive infection recipients showed high mortality rate (55.6%, 5/9), but 
localized infection recipients didn’t show mortality by aspergillus infection. 
Conclusion) Clinical prognosis of invasive aspergillosis infection recipients is 
fetal. Early diagnosis and application of an anti-fungal agent is sole strategies 
for invasive pulmonary aspergillosis. Therefore, when an invasive fungal 
infection is suspected, we should not delay in the use of an anti-fungal agent or 
surgical intervention, if required.
Table. Clinical manifestations of pulmonary aspergillus recipients
Invasive (n=9) Localized (n=13) Total (n=22) p-value
Sex (M:F) 7:2 (77.8%:22.2%) 7:6 (53.8%:46.2%) 14:8 (63.6%:36.4%) 0.201
Age (years) 50.3 ± 8.4 52.6 ± 8.1 51.5 ± 8.1 0.510
Transplant organ
 (Kidney:Liver) 7:2 (77.8%::22.2%) 11:2 (84.6%:15.4%) 18:4 (81.8%:18.2%) 0.003
No of transplantation
(1st:2nd) 8:1* (88.9%:11.1%) 10:3 (76.9%:23.1%) 18:4 (81.8%:18.2%) 0.291
Induction 0.483
Steroid only 4 (44.4%) 6 (46.2%) 10 (45.4%)
ATG/ALG 4 (44.4%) 2 (15.4%) 6 (27.3%)
IL-2 receptor 
antibody 1 (11.2%) 5(38.5%) 6 (27.3%)
Time of infection 0.272
< 1year 6 (66.7%) 1 (7.7%) 7 (31.8%)
1~2 years 0 (0.0%) 2 (15.4%) 2 (9,1%)
2~5 years 1 (11.1%) 5 (38.5%) 6 (26.2%)
5~10 years 2 (22.2%) 1 (7.7%) 3 (13.6%)
>10 years 0 (0.0%) 4 (30.8%) 4 (18.2%)
* Previous underwent kidney transplantation
** M; male, F; female, YUHS; Yonsei University Health System, ATG; anti-
thymocyte globulin, ALG; anti-lymphocyte globulin, IL-2; interleukin-2
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PREEMPTIVE VALGANCICLOVIR THERAPY IS NOT 373 
ASSOCIATED WITH INCREASE IN CYTOMEGALOVIRUS 
(CMV) DNA IN RENAL ALLOGRAFT BIOPSY SPECIMENS 
COMPARED WITH VALACYCLOVIR PROPHYLAXIS
T. Reischig1, J. Nemcova2, T. Vanecek2, P. Jindra3, O. Hes2, M. Bouda1, 
V. Treska4
1Department of Internal Medicine I, Charles University Medical School And 
Teaching Hospital, 2Department of Pathology, Charles University Medical 
School And Teaching Hospital, 3Department of Hemato-oncology, Charles 
University Medical School And Teaching Hospital, 4Department of Surgery, 
Charles University Medical School And Teaching Hospital
Aim: In our recently published randomized study (Am J Transplant 2008; 8: 69) 
we observed similar incidence of CMV disease with preemptive valganciclovir 
therapy as compared with valacyclovir prophylaxis. However, the 12-month 
incidence of CMV DNAemia and biopsy-proven acute rejection during 12 
months were both signifi cantly higher in the preemptive group. The aim of the 
study was to evaluate the presence of CMV DNA in renal biopsy specimens. 
Methods: Renal transplant (RTx) recipients at risk for CMV (D+/R-, D+/
R+, D-/R+) were randomized to 3-month prophylaxis with valacyclovir (2g 
q. i. d. , n=34) or preemptive therapy with valganciclovir (900mg b. i. d. for a 
minimum of 14 days, n=36) for signifi cant CMV DNAemia (≥2000 copies/mL 
by quantitative PCR in whole blood). All renal biopsies (including 3-month 
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protocol biopsy) performed during 12 months post-RTx were assessed. 
Results: A total of 59 biopsies in 35 patients in preemptive group and 57 
biopsies in 32 patients with valacyclovir prophylaxis were available for tissue 
CMV DNA analysis. CMV DNA was detected in 4 (11%) and 2 (6%; P=0. 
467) patients in preemptive and prophylaxis groups, respectively. Overall, 4/59 
(7%) and 2/57 (3%; P=0. 675) biopsies were positive for tissue CMV DNA in 
preemptive and prophylaxis groups, respectively. 
Conclusion: Preemptive valganciclovir therapy is not associated with 
increase in tissue CMV DNA in renal allograft compared with valacyclovir 
prophylaxis. 
POSTER BOARD NUMBER P2 – 403
PTLD DERIVED TUMOR VARIANTS OF EBV LATENT 374 
MEMBRANE PROTEIN 1 INDUCE SUSTAINED ERK 
ACTIVATION AND CFOS INDUCTION 
O. Martinez1,2, M. Vaysberg1,2, B. Wong1, S. Lambert1,2, S. Krams1,2, 
C. Esquivel1, 
1Stanford University School of Medicine, Dept of Surgery, 2Program in 
Immunology
Background: Post-transplant lymphoproliferative disorder (PTLD) is a serious 
complication of organ transplantation and is associated with Epstein Barr Virus 
(EBV) infection. EBV+ PTLD lymphomas express several latent cycle viral 
genes including latent membrane protein 1 (LMP1), an oncogene required for 
human B cell transformation. LMP1 is expressed in the membrane of EBV-
infected cells and activates multiple signaling pathways including Erk, JNK, 
p38, NF-κ;B and PI3K. Variant forms of LMP1 have been characterized on the 
basis of sequence differences. The aim of this study is to determine whether 
LMP1 isolated from PTLD tumors differs in sequence and signaling ability 
from LMP1 derived from the B. 95 strain of EBV, originally isolated from a 
patient with infectious mononucleosis. 
Methods: LMP1 variants isolated from a panel of fi ve EBV+ PTLD-associated 
B cell lines were cloned, sequenced and classifi ed according to previously 
defi ned LMP1 groups. Inducible chimeric constructs containing the LMP1 
C-terminus and nerve growth factor receptor (NGFR) transmembrane 
domain were created for each tumor variant and expressed in the Burkitts B 
lymphoma cell line BL41. LMP1 signaling in BL41 clones was induced by 
crosslinking of NGFR. Activation of p38, Erk, Akt and JNK was assayed by 
Western Blotting (WB) with phospho-specifi c antibodies. NF-κ;B activation 
was assayed by WB for Iκ;B while cFos induction was analyzed by WB and 
c-Fos activity was determined in DNA binding assays. 
Results: Sequencing of LMP1 from PTLD-derived EBV+ B cell lines 
revealed that all of the tumors could be assigned to LMP1 group A, B, or C 
and were distinct from B95. 8 LMP1. All tumor variants of LMP1, as well 
as the B95. 8 LMP1 isoform, could induce p38 phosphorylation within 30 
minutes of NGFR crosslinking while Akt and JNK were activated within 10 
minutes. All variants showed similar ability to activate NF-κ;B, as assayed by 
Iκ;B degradation. However, Erk activation differed between tumor variants of 
LMP1 and B95. 8 derived LMP1. All tumor-derived LMP1 variants induced 
prolonged Erk activation (up to 3 hours) while the B95. 8 LMP1 variant 
induced transient Erk activation. cFos is induced by the Erk pathway but 
only during the sustained phase of Erk activation. Indeed, the tumor variants 
of LMP1, but not B. 95 LMP1, were able to induce cFos protein. Similarly, 
cFos binding to the AP1 consensus DNA binding site was only observed 
in nuclear lysates induced by tumor-derived LMP1. Two mutations in the 
C-terminus- aa212 (Ser vs Gly) and aa366 (Thr vs Ser) -are conserved in the 
tumor variants of LMP1 compared to B. 95 LMP1. Point mutation of either 
of these amino acids from the B95. 8 variant to the tumor variant version, in 
the context of LMP1 activation via NGFR-LMP1 crosslinking, allowed for 
sustained activation of Erk and subsequent cFos induction and binding to 
the AP1 site. Thus, tumor-derived LMP1 has enhanced ability to induce the 
cFos oncogene and this property can be localized to two amino acids in the 
C terminus. These fi ndings suggest that these specifi c amino acid residues 
of LMP1 are important in determining whether EBV infection is benign or 
results in PTLD. 
POSTER BOARD NUMBER P2 – 404
WU AND KI POLYOMAVIRUSES – NEW RESPIRATORY 375 
VIRUSES IN ADULT HSCT RECIPIENTS
P. Ferguson1,2, N. Gilroy1,2, K. Bradstock2,3, T. Sloots4, M. Nissen4, 
T. Sorrell1,2
1Centre for Infectious Diseases and Microbiology, Westmead Hospital, 
Sydney, Australia, 2Centre of Clinical Research Excellence, Infection and 
Bioethics in Haematological Malignancies, 3Bone Marrow Transplant Unit, 
Westmead Hospital, Sydney, Australia, 4Queensland Paediatric Infectious 
Diseases Laboratory
Two novel respiratory polyomaviruses, WU and KI, were described in 2007. 
Several prevalence studies have shown predominance of these viruses in 
children. Three cases have been reported in immunosuppressed adults. 
Aim: To describe the prevalence of WU and KI polyomaviruses in episodes of 
respiratory tract infection in adult haematopoietic stem cell transplant (HSCT) 
recipients. 
Methods: A prospective cohort study of all adult HSCT recipients at Westmead 
Hospital, Sydney, Australia was undertaken over 27 months. Symptomatic 
patients had nose/throat swabs (NTS) and/or bronchoalveolar lavage (BAL) 
specimens collected. Polymerase chain reaction testing of batched respiratory 
samples for WU and KI polyomaviruses and 13 other respiratory viruses was 
performed. Clinical data were collected prospectively following approval by 
the Western Sydney Area Health Service Human Ethics Committee. 
Results: Of 646 samples tested, 20/595 NTS and 0/49 BALs were positive for 
KI or WU (3. 1%), with an annual prevalence of 1. 6% and 1. 3% respectively. 
KI was detected in 10 episodes of respiratory tract infection involving 9 
patients and WU in 7 episodes involving 6 patients. One patient had separate 
episodes with each virus. Either virus was the sole potential pathogen in 10 
of the 17 episodes of infection. Respiratory virus co-infections were present 
in 6/10 KI infections, including three with rhinovirus, and 1/7 WU infections. 
Pneumonia was present in 3/10 episodes of KI associated respiratory infection 
and 4/7 episodes of WU; upper respiratory infection alone was present in seven 
and three episodes respectively. One case of KI and rhinovirus co-infection 48 
months post-HSCT was fatal. Two KI and three WU infections were managed 
as outpatients. Sixteen of the 17 episodes of KI and WU- associated respiratory 
tract infections occurred in allogeneic HSCT recipients: 4 were sibling donor 
transplant recipients and 9 unrelated donor transplant recipients, including 
three cord HSCT recipients. One autologous HSCT recipient had WU detected 
with upper respiratory symptoms pre-HSCT (Day -9) and with pneumonia 
before neutrophil engraftment occurred (Day +15). Graft versus host disease 
was present in 7/10 KI and 4/6 WU infections involving allogeneic HSCT 
recipients. Cases with KI and WU occurred a median duration post-HSCT of 9. 
5 months (range 0-48 months) and 7. 5 months (0-157 months) respectively. All 
patients were receiving immunosuppression. Lymphopenia (<0. 5x109/L) was 
present in 7/10 KI infections (median 0. 2x109/L, range 0. 0-2. 4 x109/L) and 
7/8 WU infections (median 0. 3 x109/L, range 0. 0-4. 6 x109/L). 
Conclusions: WU and KI polyomaviruses have been detected in adult HSCT 
recipients with respiratory tract infection. It remains to be determined whether 
these viruses cause acute primary respiratory infection, or reactivation of virus 
in tissue reservoirs following primary infection in childhood, in the setting of 
immunosuppression and other viral infections. 
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TUBERCULOSIS AND TRANSPLANTATION376 
M. Lindemann1, Y. Dioury1, S. Beckebaum2,3, V.R. Cicinnati2, G. Gerken2, 
C.E. Broelsch3, P. Wrighton-Smith4, H. Grosse-Wilde1
1Institut für Immunologie, 2Klinik für Gastroenterologie und Hepatologie, 
3Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, 
Universitätsklinikum, 4Oxford Immunotec
Background: Despite the availability of anti-tuberculosis drugs, tuberculosis 
(TB) remains a life-threatening condition in immunocompromized individuals 
such as patients awaiting liver transplantation. Here, the major problem arises 
from reactivation of latent TB. As immune responses to pathogens are commonly 
reduced in this patient cohort, a sensitive method for the detection of latent TB 
is necessary. Some years ago, an enzyme-linked immunospot (ELISpot) assay 
for its detection became available (T-SPOT. TB, Oxford Immunotec). 
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Aim: To examine the performance of this ELISpot assay in the liver 
transplant setting. 
Methods: We analyzed 48 consecutive patients from our liver transplant waiting 
list. They were tested with T-SPOT. TB, Mendel-Mantoux tuberculin skin test 
(TST), and lymphocyte transformation test (LTT) using tuberculin as stimulus. 
A patient questionnaire was used to gain information on TB exposure. 
Results: Overall, four patients (8%) were defi ned as positive by ELISpot, 
six (13%) by TST, and 28 (58%) by LTT. Interestingly, the patients 
displaying positive results to T-SPOT. TB were positive also in the TST and 
the LTT. The two patients who tested negative by T-SPOT. TB but positive 
by TST were both born in Turkey; neither reported contact to an infectious 
TB case and one had received the BCG vaccine. In addition, both patients 
were positive to the tuberculin LTT. Thus, an in vitro lymphocyte response 
was detectable to tuberculin, but not to TB-specifi c peptides; supporting the 
assumption that these T-SPOT. TB negative patients were truly negative. 
We considered the four patients with positive reaction to the T. SPOT. TB 
to have latent TB infection as they reported exposure to TB patients or were 
born in countries with a higher TB incidence relative to Germany. Active 
TB was excluded on the basis of negative multislice computed tomography, 
negative culture and absence of symptoms. These four patients were 
repeatedly positive to the T-SPOT. TB test. The follow-up of one patient 
with positive T-SPOT. TB reactions twice prior to transplantation indicated 
that 1 and 2 months post transplantation reactions disappeared, showing 
the effect of post-transplant immunosuppression. In another patient weakly 
positive reactions prior to and at month 8 post transplantation signifi cantly 
increased at month 12, indicating that responses to T. SPOT. TB increase 
with improved immune function. Furthermore, in two patients tested 
two times pre transplantation the strength of reactions remained in the 
same range. 
Conclusion: Our data are the fi rst evidence that T-SPOT. TB may be a valuable 
tool for the diagnosis of latent TB in patients awaiting liver transplantation. It 
could be necessary to test patients prior to transplantation as positive reactions 
may disappear initially post transplantation. 
MINI-ORAL SESSION 12: 
IMMUNOBIOLOGY 2: TOLERANCE AND REJECTION
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PIVOTAL ROLE OF THE NATURAL KILLER T CELL FOR 377 
THE INDUCTION OF MIXED CHIMERISM IN THE THYMUS
T. Onzuka, Y. Tomita, I. Shimizu, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu 
University
Purpose: Cyclophosphamide (CP)-induced tolerance is a mixed chimerism 
based tolerance conditioning, which donor skin allograft tolerance is achieved 
in recipients with MHC-matched minor antigen-mismatched donors. Invariant 
Natural Killer T (iNKT) cell recognize galactosphingolipid on CD1d, 
and produce several cytokines, such as IFN-γ, IL-4, and present several 
immunoresponses. The aim of this study is to investigate the function of NKT 
cells for the induction of mixed chiemrism in CP-induced tolerance. 
Methods: DBA/2 (DBA; H-2d, Ly1. 1) mice and BALB/c (BALB; H-2d, Ly1. 
2) wild type (WT), or iNKT knockout (KO) (Jα18-/-, BALB background) 
mice were used as donors and recipients. In the fi rst experiment, iNKT 
KO recipients were reconstituted with iNKT cells from WT or cytokine 
(IFN-γ, IL-4 or IL-10) KO mice with 3Gy whole body irradiation on day 
-28. In the second experiment, WT recipients were pretreated with 2 μg of 
α-galactcylceramide (GC) on day -7, -4 and -1 (group A), single doses of 
α-GC on day -1 (group B), or on day 0 (group C). All recipient mice were 
treated with tolerance conditioning, which consisted with 1x108 DBA/2 
splenocyte (SC) on day 0 and 200 mg/kg CP on day 2. Donor skin grafting 
was performed on day 28. The level of mixed chimerism (Ly1. 1+ cells 
in Ly1+ cells) and the kinetics of donor-reactive T cells (Mls-1a-reactive 
CD4+Vβ6+ T cells) were assessed by fl ow cytometry. The serum cytokine 
was examined by ELISA assay. 
Results: Donor skin graft was accepted in WT recipients treated with DBA 
SC and CP. However, donor skin grafts were chronically rejected in iNKT 
KO recipients treated with DBA SC and CP. Donor mixed chimerism was 
diminished in the iNKT KO recipients at 8 weeks. Flow cytometric analysis 
revealed the failure of donor mixed chimerism induction in the thymus, 
suggestive of inadequate maintenance of central tolerance in iNKT KO 
mice. Donor skin grafts were accepted in iNKT KO recipients, which were 
reconstituted with iNKT cells from either IFN-γ, IL-4, or IL-10 KO mice and 
treated with DBA SC and CP. 
The immediate and the abundant production of IL-2, IL-4, and IFN-γ was 
observed after the treatment with a single dose of GC. On the contrary, the 
production of IL-2, IL-4, and IFN-γ disappeared in the sera of mice treated 
with multiple doses of GC. All donor skin grafts were accepted in group B and 
C, which received single dose of GC (group B, C), and iNKT cells showed 
enhanced cytokine production. Whereas, chronic rejection of donor skin grafts 
were observed in group A, which received multiple dose of GC, and iNKT cells 
were failed to produce cytokines. 
Conclusions: These results indicated that iNKT cells were essential for the 
skin allograft tolerance. However, the major cytokines (such as IFN-γ, IL-4) 
produced by iNKT cells were dispensable in the NKT cell function for the 
induction of mixed chimerism. 
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REQUIREMENT OF THE THYMUS FOR BREAKING 378 
TOLERANCE TO RENAL ALLOGRAFTS VIA THE INDIRECT 
PATHWAY
K. Yamada, A. Griesemer, Y. Ishikawa, A. Hirakata, M. Okumi, J. Etter, P. 
Martins, 
A. Shimizu, D. Sachs
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: We have shown previously that long-term tolerance to class I 
disparate renal allografts in miniature swine can be induced by a short course 
of Cyclosporine A (CyA). This tolerance persists when the graft is removed 
and replaced immediately with a new, donor-matched kidney without 
immunosuppression. After transplant nephrectomy, tolerance is lost over 
approximately 3 months, but this loss can be hastened by injection of donor 
class I peptide during the absence of donor kidneys. In this study, we examined 
the role of thymus and the indirect pathway in the loss of tolerance. &#12288;
Methods: Four MGH miniature swine (SLAdd) received class I MHC 
mismatched renal transplants (SLAgg) with a 12-day course of CyA to 
induce tolerance. The primary donor kidneys were removed on POD 100 and 
recipient-matched SLAdd kidneys were transplanted to keep the recipient 
alive during the absence of the donor kidneys. Class I-donor type peptide 
was injected subcutaneously 6 weeks after donor graftectomy. Second donor-
matched kidneys (SLAgg) were transplanted 12 weeks after the primary donor 
graftectomy without immunosuppression. In 2 of 4 recipients, the thymus 
was removed 80 days following primary kidney transplant in so no naïve T 
cells would be generated during the absence of the donor antigen. MLR with 
depletion of antigen presenting cells in the stimulators was performed to assess 
sensitization of the indirect pathway. 
Results: Both non-thymectomized recipients developed anti-donor class-I 
IgG as well as anti-donor peptide antibodies (Ab) following class-I peptide 
injection. The second donor-matched kidneys were rejected in an accelerated 
acute fashion (< 5 days). In contrast, thymectomized recipients did not develop 
anti-donor class-I Ab despite developing anti-peptide Ab. These animals did not 
reject their second donor-matched kidneys in an accelerated manner. Indirect 
MLR responses, assessing CD4 T cell activation via the indirect pathway, 
increased after removal of the primary donor kidneys in non-thymectomized 
recipients. &#12288;
Conclusions: The persistence of the donor organ is required for the indefi nite 
maintenance of tolerance. During the 3-month period of the absence of donor 
antigen, the thymus appears to play an essential role in generating the CD4 
T cell-help responsible for the breaking of tolerance. That these CD4 T cells 
could be activated via the indirect pathway by donor peptide immunization 
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demonstrates the critical role of the indirect pathway in the loss of tolerance.
POSTER BOARD NUMBER P2 – 408
INCREASED PRODUCTION OF THE REGULATORY 379 
T-CELL TRANSCRIPTION FACTOR FOX P-3 M-RNA IN 
CAMPATH-1H AND DONOR HEMATOPOETIC STEM CELL 
TREATED KIDNEY TRANSPLANT RECIPIENTS
R. Cirocco, J. Mathews, T. Valone, G. Burke, V. Esquinazi, J. Miller, 
P. Ruiz, A. Tzakis
University of Miami School of Medicine
Donor Hematopoetic Stem Cells (DHSC) introduced after C1H treatment may 
increase the number of regulatory T-cells (FOX-P3 levels) and facilitate long 
term engraftment. FOX P-3 mRNA copy numbers in CD3+ cells of fi ve different 
groups were measured: 1. Normal laboratory volunteers and dialysis patient 
(found to be equivalent-‘Normals’) (N=21); 2. C1H and DHSC treated kidney 
recipients (N=2); 3. C1H treated kidney recipients (n=13); 4. Thymoglobulin 
treated kidney recipients (Thy) (n=10) Zenopax treated kidney recipients 
(Ze) (n=9); 5. Immunosuppressive regimens in groups 2 and 3 (tacrolimus or 
sirolimus and mycophenolate) contained half the dose levels of groups 4 and 
5. Lymphocytes were isolated from whole and the the RNA was extracted, 
C-DNA was produced, and analyzed for levels of m-RNA transcripts for FOX 
P-3 by real time PCR. These levels were standardized to the housekeeping 
gene GAPDH. 
FOX P-3 COPIES/5000 CD3+ CELLS
Groups  Mean copy # ±SE Days post Tx (range) P Value between
1 ‘Normals’ 44. 9 ±5. 0  2 vs 1 p=. 002
2 C1H + DHSC* 248. 8 ±39. 3 225-335 2 vs 3 p=. 025
3 C1H  112. 7 ±16. 5  180-482 2 vs 3 p=. 025
4 Thy  50. 2 ±12. 5  213-463 3 vs 4 p=. 038
5 Ze  78. 7 ±14. 7  110-418 
* n=11, number of samples serially tested in the two patients. 
There was a statistically signifi cant difference in the FOX P-3 copies between 
CD3+ cells from the C1H + DHSC patients vs the C1H patients (p=. 025). 
There was also a difference when the CD3+ cells of the C1H + DHSC patients 
or C1H patients were compared to those from ‘Normals’ (p=. 009 and p=. 002 
respectively). CD3+ cells of the C1H patients had signifi cantly higher FOX P-3 
levels when compared to those of the Thy patients (p=. 038). All other statistical 
comparisons were not signifi cant. In conclusion the use of C1H and (more so) 
of C1H + DHSC signifi cantly increases the levels of Fox P-3 transcripts in 
kidney transplant recipients, indicating a unique effect in inducing FOX P-3 in 
T regulatory cells. This supports the rationale of using of C1H and DHSC as a 
tolerogenic regimen in kidney transplant recipients. 
POSTER BOARD NUMBER P2 – 409
COMPARISON OF LUNG AND KIDNEY ALLOGRAFTS 380 
IN INDUCTION OF TOLERANCE BY A MIXED-CHIMERISM 
APPROACH IN CYNOMOLGUS MONKEYS
A. Aoyama, C. Ng, T. Millington, S. Boskovic, T. Murakami, S. Houser, 
J. Wain, J. Madsen, T. Kawai, J. Allan
Massachusetts General Hospital Transplant Center, Massachusetts General 
Hospital
Background: We have previously reported successful induction of renal 
allograft tolerance in nonhuman primates using a nonmyeloablative 
conditioning regimen to produce a mixed-chimeric state in the recipient. In 
this current study, we applied this same technique to lung allotransplantation 
in cynomolgus monkeys. 
Methods: Nine pairs of cynomolgus monkeys were used for left single-lung 
transplantation. Donors and recipients were selected for compatible ABO 
blood types and were mismatched at the MHC class I and class II loci. The 
pre-transplant conditioning regimen consisted of total body irradiation (1. 5 
Gy×2), thymic irradiation (7Gy), and anti-thymocyte globulin. The recipients 
underwent combined lung and bone marrow transplantation on day 0, followed 
by anti-CD154 mAb (6 doses over 12 days) and a one-month course of 
cyclosporine to maintain therapeutic serum levels. Because moderate or severe 
acute cellular rejection was found in three of the initial four lung recipients, the 
regimen was modifi ed by adding anti-CD8 mAb (days 0 and 2) in the subsequent 
two recipients. Post-transplant administration of α1-antitripsin was also added 
in the last 3 recipients (reported to limit neutrophil infi ltration and ischemia/
reperfusion injury in small animal models). The results were compared with 8 
recipients that received kidney allografts using the same conditioning regimen. 
Chimerism in peripheral blood was determined with fl ow cytometry. 
Results: Two lung recipients were excluded from analysis because of graft loss 
not related to rejection. Multilineage granulocyte chimerism developed in 87. 
5 ± 7. 3% (max) in the lung recipients and 69. 8 ± 23. 5% (max) in the kidney 
recipients (p= 0. 1036; data not available in one lung recipient). Slightly higher 
levels of lymphocyte chimerism were found in lung recipients than in kidney 
recipients (8. 4 ± 4. 9% [max] vs. 4. 1 ± 2. 2% [max], p= 0. 499). Nonetheless, 
all seven lung recipients rejected their allografts by day 85 (85, 68, 55, 35, 26, 
22, and 21 days), while the same regimen induced long-term allograft survival 
without the need for maintenance immunosuppression in the kidney recipients 
(>2500, >2000, 837, 755, 401, 373, 206, and 58 days) (p<0. 01). 
Conclusions: Despite the successful induction of mixed chimerism in 
recipients of fully mismatched lung allografts, we have not observed long-term 
graft survival, as has been seen in an analogous kidney model. We suspect that 
this organ-specifi c difference in the ability to induce graft tolerance relates to 
the fact that the lung, being a barrier organ, exists in a more infl amed state, 
which exerts a deleterious infl uence on the antigenicity, inmmunogenicity, 
and tolerogenicity of this organ. Strategies to overcome this problem include 
organ-specifi c modifi cations of the preparative regimen and the induction of 
chimerism/tolerance in a delayed fashion, after the graft has been sustained for 
several months with conventional immunosuppression. 
POSTER BOARD NUMBER P2 – 410
DIFFERENT FOXP3 EXPRESSING REGULATORY 381 
T CELLS IN THE LIVER CONTRIBUTE TO PORTAL 
TOLERANCE
K. Carper1, W. Wang2, J. Perkins1, J. Reyes1, W. Li1
1University of Washington, Seattle, Washington, USA, 2JiLin University, 
Changchun, China
The liver has long been considered a tolerogenic organ that favors the induction 
of peripheral tolerance. Portal venous injection (p. v. ) of allogeneic donor cells 
has been shown to prolong the survival of subsequently transplanted allografts 
(portal tolerance). However, the underlying mechanisms still remain undefi ned. 
Accumulating data indicate that liver-residing leukocytes play an important 
role in regulating self- and transplantation tolerance. In this study, we adopted 
a mouse model of portal tolerance to characterize the liver leukocytes and their 
contributions. 
Methods: Gamma-irradiated C3H (H2k) spleen cells (SCs) were injected into 
the B6 (H2b) recipients through i. v. or p. v. , and the liver nonparenchymal 
cells (NPCs) and SCs were characterized phenotypically by fl ow cytometry 
and functionally by MLR, ELISPOT, and immunohistochemistry assays. 
Heterotopic heart transplantation was performed from C3H donors to B6 
recipients at day 7 post-treatment. 
Results: Heart allograft survival was signifi cantly prolonged in the donor 
antigen p. v. treated recipients. Mean graft survival time was 50. 2+/-30. 5 
days (p<0. 01) vs 16. 5+/-3. 4 days in the i. v. treated recipients. The tolerance 
induced by donor SC p. v. treatment was antigen-specifi c, demonstrated by 
rejection of a skin graft from third party, but not donor mice in long-term 
surviving heart allograft recipients. The TCR-alpha-beta+NK1. 1+ cells (NKT) 
were signifi cantly increased in the livers, and CD4+Foxp3+ regulatory T cells 
(Treg) were markedly increased in both livers and spleens after p. v. but not i. 
v. injection of C3H SCs. The CD4+Foxp3+ Treg expressed higher intracellular 
CTLA4 and PD-1 and PD-L1 molecules on the surface. Interestingly, liver 
NKT cells showed similar phenotypes as Treg, which were also Foxp3+, and 
expressed high PD-L1 and moderate CTLA4 and PD-1. The T cells from 
the p. v. treated mice demonstrated signifi cantly suppressed antigen-specifi c 
proliferative responses. Moreover, ELISPOT assay revealed that the T cells 
from p. v. treated mice produced decreased IL-2, increased IL-4 and IL-10 
in the livers and spleens, but decreased IFN-gamma in the spleens under 
allostimulation in vitro, suggesting that the role of the Treg may contribute to 
these responses. Further, signifi cantly increased IL-4, IL-10, and IFN-gamma 
production were detected from liver NPC under alphaGalCer stimulation, 
suggesting the role of liver NKT cells. 
Conclusions: Both NKT cells and CD4+ Treg appear to constitute Foxp3 
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expressing-Treg, and underpin portal tolerance in this model. The two types of 
Treg may function differently, demonstrated by their varied cytokine profi les.
 POSTER BOARD NUMBER P2 – 411
MESENCHYMAL STEM CELLS ATTENUATE ACUTE 382 
REJECTION AND SYNERGIZE WITH RAPAMYCIN LEADING 
TO CARDIAC ALLOGRAFT TOLERANCE
W. Ge1, J. Jiang2, M.L. Baroja1, J. Arp1, R. Zassoko1, W. Liu3, 
A.M. Jevnikar2, B. Garcia3, H. Wang1,2
1Department of Surgery, University of Western Ontario, 2Multi-Organ 
Transplant Program, London Health Sciences Centre, 3Department of 
Pathology, University of Western Ontario
Mesenchymal stem cells (MSCs) exhibit many unique immunoregulatory 
properties in vitro, however their immunosuppressive potential in preventing 
allograft rejection is poorly defi ned. The present study was undertaken to 
determine whether treatment with MSCs can prevent allograft rejection and 
in combination with Rapamycin (Rapa) can induce graft tolerance in a mouse 
cardiac transplant model. MSCs (1 million, i. v. ) from C57BL/6 donor mice 
were injected into BALB/c recipients 24 hours after receiving a heterotopic 
C57BL/6 heart graft. Heart grafts in untreated recipients were rejected by 
severe acute humoral and cellular rejection within 7. 8±0. 5 days. Notably, 
MSC treatment signifi cantly attenuated graft rejection, doubling graft survival 
to 15±0. 8 days which was comparable to the prolonged survival of 16. 5±0. 
9 days achieved with Rapa (2mg/kg, orally, POD0-13). In marked contrast, 
the combination therapy of MSCs and Rapa achieved indefi nite heart graft 
survival (>100 days) with normal histology and undetectable levels of 
anti-donor antibodies. Splenocytes from long-term surviving recipients 
demonstrated allo-specifi c hyporesponsiveness, indicating donor-specifi c 
graft tolerance had been achieved. Compared with rejecting mice, splenic 
dendritic cells isolated from tolerant recipients exhibited signifi cantly 
decreased expression of MHC II, CD40, CD80 and intracellular IL-12, as well 
as a reduced ability to stimulate donor T cell proliferation as measured by 
MLR that was accompanied by an increased Th2, but decreased Th1 cytokine 
profi le. In addition, tolerant recipients demonstrated signifi cantly higher levels 
of CD4+CD25+Foxp3+ regulatory T cells. Furthermore, MSCs from GFP 
transgenic C57BL/6 mice appeared to home and persist within the recipient, 
gradually increasing their presence in the bone marrow, lymphoid organs 
and heart grafts of long-term surviving recipients when monitored on POD7, 
30 and 100. We conclude that donor MSCs maintained within the recipient 
long after infusion, attenuate acute graft rejection and synergize with Rapa 
leading to heart allograft tolerance. This study suggests that MSCs may offer 
various attractive therapeutic applications to the fi eld of clinical solid organ 
transplantation. 
POSTER BOARD NUMBER P2 – 412
CD4+CD25+ REGULATORY T CELLS COMBINED 383 
WITH LOW-DOSE SIROLIMUS, BUT NOT CALCINEURIN 
INHIBITORS, PRESERVES SUPPRESSIVE FUNCTION 
OF REGULATORY T CELLS AND PROLONGS HEART 
ALLOGRAFT SURVIVAL IN MICE
A. Ma1, S. Qi1, Z. Wang1, L. Liu1, D. Xu1, E. Massicotte2, M. Dupuis2, 
D. Zhang3, P. Daloze4, H. Chen1
1Laboratory of Experimental Surgery, Research Centre, Center hospitalier de 
l’Université de Montréal (CHUM)&#61485;Hôpital Notre-Dame, Montréal, 
Québec, Canada. , 2Institut de recherches cliniques de Montréal, Montréal, 
Québec, Canada. , 3WHO Collaboration Centre of Immunogenetics and 
Immunopathology, School of Medicine, Shanghai Jiaotong University, China, 
4Department of Surgery, Hôpital Notre-Dame, Université de Montréal, 
Montreal, Canada
CD4+CD25+ regulatory T (Treg) cells, like immunosuppressant, are potent 
suppressors, play an important role in organ transplantation and autoimmune 
diseases. Our previous study demonstrated that CD4+CD25+ regulatory 
T cells induced donor-alloantigen-specifi c transplantation tolerance, and 
maintained both anergic and suppressive function on cell proliferation in cell 
dose-dependent and donor-alloantigen-specifi c manner in vitro. In this study, 
our objective focused on whether a combination therapy of CD4+CD25+ 
regulatory T cells with different immunosuppressant, sirolimus, tacrolimus, or 
cyclosporine A, could prolong survival time of totally MHC-mismatched heart 
allografts in mice. 
The study showed that sirolimus could permit the expansion of CD4+CD25+ 
regulatory T cells in vitro. The suppressive function was neutralized when 
CD4+CD25+ T cells co-cultured with tacrolimus (1. 0 nM) or cyclosporine A 
(1. 0 nM), but not with sirolimus in vitro. When the concentration of sirolimus 
was increased more than 100 nM, inhibitive effi ciency was fallen. Based on the 
ability of sirolimus to target effective T and B cells, but permit the suppressive 
function of regulatory T cells in vitro and in vivo, an adoptive infusion of 
donor-alloantigen-specifi c CD4+CD25+ regulatory T cells combined with a 
14-day short postoperative course of low-dose sirolimus (1. 0 mg/kg) was 
found to prolong heart allograft survival time (>60 days) in Balb/c to C57 
mice. Even though the cell numbers of CD4+ T cell subsets were found to 
decrease in sirolimus treated mice, sirolimus selectively enhanced the ratios 
of CD4+CD25+ T cells to CD4+ T cells in spleens and peripheral blood, 
respectively. However, combined therapy of CD4+CD25+ T cells with 
low-dose cyclosporine A (5. 0 mg/kg) or tacrolimus (1. 0 mg/kg) reduced 
signifi cantly the population of CD4+CD25+ regulatory T cells and failed to 
prolong the survival of heart allograft survival, compared to treatment with 
immunosuppressant alone. 
This study indicates that CD4+CD25+ T cells are more resistant to sirolimus 
than other T cells. Sirolimus, but not tacrolimus or cyclosporine A, does not 
block the proliferation of CD4+CD25+ regulatory T cells in vitro. Sirolimus 
rather than calcineurin inhibitors, cyclosporine A and tacrolimus, preserves 
suppressive function of regulatory T cells in pathologic immune responses to 
alloantigens in transplantation, and calcineurin-dependent signals are required 
for induction of CD4+CD25+ regulatory T cells. 
POSTER BOARD NUMBER P2 – 413
INVOLVEMENT OF PDCS IN THE TOLEROGENIC 384 
FUNCTION OF CD8+CD45RCLOW TREG AFTER CD40-CD40L 
BLOCKADE IN A RAT HEART ALLOTRANSPLANTATION 
MODEL
X.L. LI, S. Ménoret, D. Chabannes, M. Hill, M. Heslan, C. Usal, M. Angin, 
R. Josien, B. Le Mauff, I. Anegon
INSERM U643, CHU de Nantes, Institut de Transplantation et de Recherche 
en Transplantation (ITERT) et Université de Nantes, Faculté de Médecine, 
Nantes, France. ianegon@nantes. inserm. fr
Introduction: We have shown that CD8+CD45RClow T regulatory cells 
(CD8+ Tregs) mediate tolerance to allografts after blockade of CD40-
CD40L interactions by CD40Ig. Tolerance was dependant on IFNγ;-induced 
indoleamine 2, 3-dioxygenase (IDO) expression but the exact mechanism of 
action of CD40Ig CD8+ Tregs remains unknown. The aim of this work was to 
analyze the regulatory mechanisms and migratory profi le of tolerogenic CD8+ 
Tregs, and the role of plasmacytoid dendritic cells (pDCs) in this process. 
Results: By adoptive transfer and FACS analysis, we confi rmed that tolerogenic 
CD8+ Tregs were present in the spleen as early as 1 week after initiation of 
CD40Ig treatment, and subsequently accumulated in spleen and graft but not 
in lymph nodes (LN). The spleen was not necessary for generating tolerogenic 
CD8+ Tregs since splenectomy on D0 or 3 months after transplantation did not 
abrogate tolerance. In splenectomized recipients, accumulation of tolerogenic 
CD8+ Tregs was found in grafts and bone marrow but not in lymph nodes, 
and adoptive transfer of bone marrow cells but not those from lymph nodes 
signifi cantly prolonged graft survival. Nevertheless, the spleen was the main 
storage organ of tolerogenic CD8+ Tregs since splenectomy after 6 months of 
treatment triggered rejection. Thymus was also not necessary for the generation 
of tolerogenic CD8+ Tregs since allografts were accepted long-term after 
thymectomy on D0. 
By using PKH-labeled CD8+ Tregs, we observed that tolerogenic CD8+ Tregs 
homed to the graft and spleen whereas naïve CD8+ Tregs homed to spleen to a 
lesser degree and not to the graft. There was less migration and no differences 
between tolerogenic CD8+ Tregs and naïve CD8+ Tregs cells in the thymus, 
LN, or bone marrow. 
Tolerogenic CD8+CD45RClowTregs were FoxP3+ (10%), CD62L+ (60%), 
and MHCII+ (40%). Contrary to mouse CD8+ Tregs, CD122 was weakly 
expressed in CD8+CD45RClow T cells. 
Inhibition of MLRs using CFSE-labeled CD4+CD25- T cells by tolerogenic 
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and naïve CD8+ Tregs was observed when using immature allogeneic pDCs 
and myeloid CD4-OX62+ DCs, but less when using immature myeloid 
CD4+OX62+ DCs and mature pDCs. Suppression of MLRs by tolerogenic 
CD8+ Tregs was stronger vs. naïve CD8+ Tregs when using pDCs. Suppression 
of MLRs by tolerogenic CD8+ Tregs was donor alloantigen-specifi c when 
alloantigen was presented by both immature donor pDCs or recipient pDCs 
loaded with donor antigens. 
Suppression of CD4+CD25- T cells in MLRs by tolerogenic CD8+ Tregs was 
cell contact independent. Contact between tolerogenic CD8+ Tregs and pDCs 
was critical for their suppressive function. IDO and iNOS were involved since 
the use of specifi c inhibitors abrogated MLR inhibition in vitro and triggered 
rejection of tolerated grafts in vivo. 
Conclusion: Tolerogenic CD8+ Tregs are generated as early as in 1 week after 
CD40Ig treatment in the spleen, which is the main storage organ, and from 
where they migrate into the graft. Bone marrow is an alternative generation 
site for tolerogenic CD8+ Tregs. In vitro, the alloantigen-specifi c suppression 
by tolerogenic CD8+ Tregs is preferentially mediated by immature pDCs. 
Cell contact between pDCs and CD8+ Tregs is necessary for the tolerogenic 
function through the induction of IDO and iNOS. 
POSTER BOARD NUMBER P2 – 414
ALLOGRAFT TOLERANCE MEDIATING CD4+T CELLS 385 
DEPEND UPON INTERLEUKIN-5 (IL-5), NOT IL-4. 
B. Hall, K. Plain, M. Nomura, N. Verma, G. Tran, R. Boyd, C. Robinson, 
S. Hodgkinson
Faculty of Medicine, University of NSW, Sydney, Australia
CD4+CD25+T cells in CD4+T cells are required to mediate antigen specifi c 
allograft tolerance and can transfer tolerance. We found tolerance transferring 
CD4+T cells lose their capacity to transfer tolerance when cultured in MLC 
unless supplemented with T cell derived cytokines. Which cytokines are required 
to support these cells is unknown. We examined if the Th2 cytokines IL-5 and 
IL-4 could promote survival of CD4+T cells from DA rats that tolerated a fully 
allogeneic PVG heart graft over 100 days after a short course of non-specifi c 
immunosuppression, usually anti-CD3 mAb. These cells were cultured with 
PVG alloantigen in media supplemented with either IL-5 or IL-4 for 3 days 
before transfer to irradiated DA hosts grafted with either specifi c donor PVG 
or third party Lewis grafts. These hosts do not reject their grafts unless restored 
with naïve CD4+T cells, which reject in 11-20 days (n=11). 2x106 fresh tolerant 
CD4+T cells transferred tolerance to PVG grafts (7 of 9 survived >150 days) 
but not to Lewis, all 5 rejected. Culture of tolerant CD4+T cells in MLC with 
donor antigen leads to loss of tolerance transferring capacity in that all 7 PVG 
grafts were rejected. Culture with ConA supernatant promotes the survival of 
antigen specifi c tolerance transferring cells with 8 of 10 PVG grafts accepted 
long term (>150 days) but only 1 of 10 Lewis grafts accepted with rejection in 
10-20 days. Culture with IL-5 also produced cells that transferred tolerance to 
PVG grafts (7 of 9 accepted) but not to Lewis grafts (2 of 7 accepted). Cells 
cultured with IL-4 rapidly rejected all PVG in days 7-9 days (n=10) and also 
rapidly rejected Lewis grafts in 7-10 days (n=10). Rejection times with IL-4 
cultured cells were faster that restoration with fresh naïve CD4+T cells where 
rejection occurred in 10-20 days. Culture of tolerant CD4+T cells with IL-5 
partially retained the capacity to suppress rejection mediated by naïve cells 
(n=10) with many grafts having only a transient rejection from day 12-20. 
We found that naïve CD4+CD25+T cells cultured with alloantigen and IL-4 
develop into alloantigen specifi c regulatory cells that express IL-5Rα, the 
cytokine specifi c receptor subunit for IL-5. Also, that tolerant CD4+CD25+T 
cells proliferate to donor antigen in the presence of IL-5 and express IL-5Rα. 
These fi ndings suggest that IL-5 acts directly on alloantigen specifi c 
CD4+CD25+T cells and may be a key cytokine required to promote induction 
and maintenance of allograft tolerance. Further, IL-5 appears to act on antigen 
specifi c CD4+CD25+T regulatory cells, that have been originally activated by 
IL-4 during a Th2 response. We have found human CD4+CD25+T cells when 
activated by alloantigen and IL-4 also express IL-5Rα suggesting IL-5 may 
also promote tolerance induction in man. 
POSTER BOARD NUMBER P2 – 415
INFILTRATION OF REGULATORY T CELLS IN THE 386 
TOLERANT SKIN OF ALLOGRAFT IN A RAT HIND-LIMB 
TRANSPLANTATION MODEL
M.J. Elliott, S. Wu1, L. Adamson1, D. Rahhal1, W-C. Huang1, Y. Wen1, W. 
Breidenbach2, S. Ildstad1
1Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
2Division of Hand and Microsurgery, Christine M. Kleinert Institute, Jewish 
Hospital, Louisville, KY
Background: Over 30 hand transplants have been performed worldwide. 
Contrary to prior predictions, control of acute rejection has been readily 
achieved. Foxp3+ regulatory T cells (Tregs) has been shown to act as an 
immunomodulator in peripheral transplant tolerance induction. The expression 
of the transcriptional regulator Foxp3 is specifi c to Tregs. We examined 
whether Tregs infi ltrated the transplanted skin in a rat model of composite 
tissue allotransplantation. 
Methods: WF rats (RT1Au) were conditioned with 600 cGy total body 
irradiation (day -1) and transplanted with 100×106 T cell-depleted bone marrow 
cells from MHC-mismatched ACI donors (RT1Aabl) on day 0. Tacrolimus 
was administered (days 0-10), as well as one dose of anti-lymphocyte serum 
(day 10). Mixed chimerism in peripheral blood was confi rmed by fl ow 
cytometry on day 28 and then monthly. On day 29 the chimeras received 
an ACI osteomyocutaneous hind-limb transplant (n=10). Six months post-
transplantation, specimens of tolerant, rejected, and naïve skin were snap 
frozen and immunostained with fl uorochrome conjugated anti-Foxp3 and anti-
CD4 monoclonal antibodies. Stained slides were visualized under Leica TCS 
SP5 confocal microscopy, and the number of Foxp3+ cells per high-power 
fi eld (HPF) was calculated. Twenty HPFs were randomly selected from each 
skin specimen and counted by a blinded observer. Results were expressed as 
average number of Foxp3+ cells/HPF.
Results: Six of ten animals exhibited long-term acceptance of the hind-limb 
fl ap allotransplant. There is no difference in the chimerism kinetics between 
the rats with tolerant graft and the rats with rejected graft. The overall average 
chimerism level in these rats is 41.62% one month after transplantation and 
decreased with time. Six months post-transplantation, all of them lost donor 
chimerism in peripheral blood. At this time, Foxp3-CD4+ cells could be found 
in tolerant skin, rejected skin and naïve skin, while Foxp3+CD4+ were only 
detected in tolerant skin [fi gure1]. The number of Foxp3+ cells/HPF in three 
tolerant skin samples examined to date is 14.8/HPF, 11/HPF and 7.6/HPF. 
Conclusion: Although donor chimerism in peripheral blood was lost in all 
rats with the present tolerance induction protocol by six months, 60% of them 
exhibited long-term acceptance of the hind-limb allotransplants, which may 
be associated with the infi ltration of Foxp3+ Tregs into transplanted donor 
skin. Numerous CD4+ T cells that infi ltrated tolerant skin expressed Foxp3, 
indicating predominance of Tregs over T effector cell function. Studies are 
underway to deplete Tregs in vivo to confi rm Tregs action as a mechanism of 
promoting graft acceptance. These studies suggest that infi ltration of T cells 
in the skin of the composite tissue allografts may be benefi cial and may not 
always herald rejection.
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MINI-ORAL SESSION 13: 
RENAL 4 – SURGICAL COMPLICATIONS
POSTER BOARD NUMBER P2 – 416
MINIMALLY INVASIVE VIDEO-ASSISTED KIDNEY 387 
TRANSPLANTATION (MIVAKT)
S.P. Mun1, S.H. Kim2
1Department of Surgery, Chosun University, School of Medicine, Gwangju, 
Korea, 2Department of Surgery, Chosun University, School of Medicine, 
Gwangju, Korea
Background: Minimally invasive surgery has been applied to nearly all fi elds of 
surgery due to its advantages such as reduced morbidity, a better cosmetic outcome, and 
early recovery. The recent advances in its technique have allowed us to use modifi ed 
minimally invasive surgical technique in the fi eld of kidney transplantation. 
Materials and methods: From January 2004 to March 2006, minimally 
invasive video-assisted kidney transplantation (MIVAKT) was carried out in 
20 patients. Many clinical variables were compared with the conventional 
method. The length of skin incision was equal to the diameter of grafted 
kidney, usually 7-8 cm. The incision was made between external iliac vessel 
and bladder marked pre-operatively with ultrasound. Laparoscopic balloon 
dissector was used to create the retroperitoneal space for the placement of the 
grafted kidney. The external iliac vessels were lifted as much as possible and 
surgical retractor was used. Sometimes intraluminal vascular anastomosis was 
needed and the kidney was suspended to both neighboring sites of the vascular 
anastomosis. Vascular anastomosis was performed under direct vision and with 
video-assisted TV monitoring for the assistant surgeon. Ureteroneocystostomy 
was carried out under direct vision. The grafted kidney was inserted into the 
previously made retroperitoneal space. 
Results: The total length of the MIVAKT incision was shorter than that for the 
CKT (7. 8 cm versus 21. 2 cm, P < 0. 001). The degree of pain was also lower 
in MIVAKT (5. 8 versus 7. 9, P < 0. 05). The operation time was 178 min, and 
this was longer than coventional technique by 18 min, but the difference was 
not statistically signifi cant (P=0. 78). There was no difference between the two 
methods as to the complications, graft function and episode of rejection. All 
patients were discharged at 2 weeks postoperatively. 
Conclusions: MIVKT is technically feasible and may offer benefi ts in terms of 
better cosmetic outcomes, less pain, and quicker recuperation than conventional 
kidney transplantation. 
POSTER BOARD NUMBER P2 – 417
ADDITIONAL VASCULAR RECONSTRUCTION AND 388 
SPECIAL VASCULAR ANASTOMOTIC TECHNIQUES – AN 
IMPACT FACTOR IN EARLY GRAFT DYSFUNCTION?
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, D. Tacu, 
E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni 
Clinical Institute
Purpose: The aim of this study was to investigate the one week graft function 
consecutive to additional arterial and venous reconstruction combining with 
special anastomotic techniques during renal transplantation. 
Material and Methods: 11 years renal transplant experience (1997 – 2008) 
was assessed considering 855 renal transplantations (710 living and 145 
cadaver, 807 adults and 48 pediatric) with an average of 81/year (116 in 2007). 
In all cases, general preoperative evaluation, immunological and vascular 
anatomy study was performed. 266 cases (31%) had vascular graft anomalies, 
165 abnormal arteries and 101 abnormal veins. 
Results: Special anastomotic and reconstruction techniques were used as 
followed: double T-T anastomosis – 96 cases, T-L anastomosis – 9 cases 
(cadaver donors), combined anastomosis – 3 cases; single trunk made by two 
branches – 27 cases and we used the epigastric artery for small branches in 
4 cases. 26 minor aberrant vessels were excluded, feeding a minor area of 
parenchyma. Cava patch and venous reconstruction were used in 32 cases (11 
from cadaver donors). Abnormal venous drainage was managed by classical 
T-L anastomosis to the external iliac vein. One week graft failure (vascular 
reason) occurred in one arterial reconstructed graft (0. 6%) and one venous 
reconstructed pedicle (0. 6%) proving a reasonable result. Graft function was 
96% – one year, 84% – 5 years and 80% – 10 years. 
Conclusions: Vascular anomalies of renal pedicle were founded in 31% but 
transplantation was performed due to special reconstruction and anastomotic 
techniques which did not signifi cantly increase the ischemia time and vascular 
complications. Arterial and venous reconstruction combined with special 
anastomotic procedures did not increase the risk of early graft failure. One 
week graft function remained in very good condition. Accepting the borderline 
vascular donor the number of transplantation could increase with 30%. 
POSTER BOARD NUMBER P2 – 418
EVALUATION OF INFLUENCE OF NEPHRECTOMY 389 
BEFORE AND AFTER KIDNEY TRANSPLANTATION ON 
COMPLICATION INCIDENCE IN PATIENTS WITH ESRF IN 
THE COURSE OF ADPKD
T. Sulikowski1, K. Tejchman1, Z. Zietek1, J. Rozanski2, L. Domanski2, 
M. Kaminski1, M. Romanowski1, K. Ciechanowski1, A. Ciechanowicz3, 
M. Ostrowski1
1Department of General Surgery And Transplantation, Pomeranian 
Medical University, 2Depratment of Nephrology, Transplantology And 
Internal Diseases, Pomeranian Medical University, 3Department of Clinical 
Biochemistry and Laboratory Diagnostics, Pomeranian Medical University
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is 
the entity characterized by the presence of multiple cysts in the both kidneys. 
Symptoms of the disease may arise either from the presence of cysts or increasing 
loss of kidney function. First symptoms appear usually in the third decade of 
life: lumbar pain, urinary tract infections, arterial hypertension or renal colic 
due to rupture of a cyst or coexisting nephrolithiasis. An early diagnosis, male 
sex, large kidneys in sonography, arterial hypertension, hematuria and urinary 
tract infections are predicting factors of the faster progress of the disease. 
Aims: The aim of the study was to establish the indications for nephrectomy in patients 
with symptomatic ADPKD bfefore kidney transplantation, and the assessment of 
possible risk after renal transplantation without ADPKD nephrectomy. 
Material and methods: The observed group consisted of 183 patients with 
ADPKD from among 50 (27, 3%) underwent kidney transplantation during 
7-years observation (2000-2007). Among those we observed 3 groups: 
I –; patients with nephrectomy preceding transplantation; II –; patients 
with nephrectomy during kidney transplantation; III –; patients without 
nephrectomy. 
Results: In the group I before Tx we observed: arterial hemorrhages, cases of 
wound infections, splenectomy performed 4 weeks after ADPKD nephrectomy; 
after Tx we observed: urinary tract infections, cysts infection on the other 
side. In the group II we observed only 1 case of wound infection. In the group 
III we observed: ascending urinary tract infections, infections of cysts, cyst 
hemorrhage. Cysts hemorrhages and cysts infections lead mainly to ADPKD 
kidney nephrectomy. 80, 95% of grafts were functioning correctly during 
observation time. 
Conclusions: 1. Unilateral nephrectomy seems to be well-founded preliminary 
surgical treatment preparing the patients for kidney transplantation. 
2.  Bilateral nephretomy before or during transplantation eliminates ADPKD 
complications and non signifi cantly increase general complications. 
3.  The highest numer of complications was observed in group without 
pretransplant nephrectomy, including graft loss. 
POSTER BOARD NUMBER P2 – 419
PERIOPERATIVE ANTICOAGULATION AND 390 
ANTIPLATELET THERAPY IN RENAL TRANSPLANT: IS 
THERE AN INCREASE IN BLEEDING COMPLICATION?
M. Marvin, M. Eng, R. Kadiyala, R. Ouseph, R. Nagubandi, J. Gleason, 
J. Buell
Transplant Center, Jewish Hospital, Louisville, Kentucky, United States. 
Renal transplant recipients often have comorbidities requiring anticoagulation 
or antiplatelet therapy. The effects of Warfarin may be reversed with plasma, 
but those of Aspirin (ASA) and Clopidogrel are not easily reversed. We 
evaluated the risk of bleeding complications of patients taking perioperative 
ASA, Clopidogrel, Enoxaparin, Heparin or Warfarin. 
Methods: Charts of renal transplant between July 2005 to June 2007 were 
reviewed. Patients receiving perioperative anticoagulation and antiplatelet 
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therapy were identifi ed. The need for blood transfusion, reoperation for bleed 
and decrease in serum hemoglobin (Hgb) were compared to those on no 
anticoagulation or antiplatelet therapy. 
Results: 179 patients were identifi ed. Pre-operatively, 37 were on ASA, 15 
on Warfarin, 4 on Clopidogrel, 2 on ASA and Warfarin and 1 patient was on 
Enoxaparin. Indication for therapy include prior deep venous thrombosis, 
coronary artery disease, peripheral vascular disease, prior cerebral vascular 
accident, valve replacement, prior endocarditis, hypercoagulable state and atrial 
fi brillation. Indication of Warfarin use in 2 patients could not be identifi ed. 
Post-operatively, 19 were on ASA, 4 on Heparin drip, 2 on Heparin drip and 
Warfarin, 1 on Enoxaparin, 5 on Enoxaparin and Warfarin, 3 on Warfarin, 2 on 
ASA and Warfarin, 1 on Clopidogrel and 1 was on ASA and Clopidogrel. 
Pre-operative anticoagulation and antiplatelet therapy did not increase 
the incidence of reoperation for bleed. Pre-operative ASA, Clopidogrel or 
Enoxaparin did not increase the need for transfusion. Despite correction with 
plasma, Warfarin resulted in a greater Hgb (p=0. 02) although the number of 
transfusion was not increased. 
Post-operative Heparin drip was associated with an increased incidence of 
bleeding complications. There was an increased number of transfusion (p=0. 
001), an increased incidence of return to the operating suite for bleeding (p=0. 
001) and a greater Hgb (p=0. 01) and%Hgb (p=0. 04). This occurred in all 
patients with an elevated prothrombin time (PTT) >80 seconds. Although there 
was a trend towards increased Hgb of patients on ASA and Warfarin post-
operatively, the number of transfusion was not increased. 
Conclusion: No signifi cant risk of bleeding with pre-operative anticoagulation 
was noted, although signifi cant risk was present with post-operative Heparin 
drip, especially with a supratherapeutic PTT. 
POSTER BOARD NUMBER P2 – 420
COAGULOPATHY ASSOCIATED WITH 391 
THYMOGLOBULIN INDUCTION THERAPY FOLLOWING 
RENAL TRANSPLANTATION
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
Subsequent to the development of two postoperative hemorrhagic complications 
on day 5 after renal transplantation associated with unexplained coagulopathy 
(INR > 2. 5 ), we began to check the INR on postoperative day 2 in all renal 
transplant recipients, beginning January 2005. Between Jan. 1st, 2005 and 
Nov. 30th, 2007, 167 renal transplants were performed at our institution. All 
patients received induction therapy with either Thymoglobulin (deceased-
donor and live-unrelated donor recipients) initiated within 24-hours of renal 
revascularization at a mean daily dose of 1mg/kg continued through day 6 
(Group A, n=154) or simulect (live-related donor recipients) 20 mg initiated 
prior to revascularization and repeated on postoperative day 4 (group B, n=13). 
All patients with an INR of > 1. 5 on postoperative day 2 were treated with 
fresh frozen plasma (FFP) and/or vitamin K 1 mg intravenously to reverse the 
coagulopathic parameters. Demographics between the two recipient groups 
were noted to be similar for age, gender, ethnicity, diabetes and postoperative 
serum albumin level. 
The mean immediate preoperative INR was 1. 0 in both group A and B patients. 
On postoperative day 2 the mean INR was 1. 2 in group A (range 0. 9-4. 8) 
and 1. 0 (range 0. 9-1. 2) in group B recipients (P=NS). However, twenty-two 
group A patients (14%) were noted to have an INR of > 1. 5 on postoperative 
day 2 and were treated with FFP and/or vitamin K compared to no group B 
patient (p=0. 01) No patient in either group sufferred a clinically signifi cant 
hemorrhagic complication. 
Induction therapy with Thymoglobulin, compared to simulect, after renal 
transplantation was noted to be associated with an increased rate of an elevated 
INR on day 2. This trend towards a potentially dangerous coagulopathic state 
did not reach statistical signifi cance likely due to our small patient numbers 
in group B and early treatment of the elevated INR. Nevertheless, these data 
indicate that renal transplant recipients treated with Thymoglobulin induction 
therapy should undergo careful monitoring of coagulation factor function 
postoperatively. 
POSTER BOARD NUMBER P2 – 421
THE INFLUENCE OF KIDNEY VESSEL RESISTANCE 392 
FOR FUNCTIONING GRAFT IN THE FIRST THREE MONTHS 
AFTER TRANSPLANTATION. 
M. Nowacki1, M. Kaminski1, K. Safranow1, T. Sulikowski1, 
M. Romanowski1, J. Sieñko1, E. Ignaczak3, Z. Ziêtek1, M. Drozdzik2, 
M. Ostrowski1
1Department of Surgery And Transplantation Pomeranian University of 
Medicine, Poland, 2Department of Pharmacology Pomeranian University of 
Medicine Szczecin, Poland, 3Szczecin University of Technology, Poland
Materials and methods: The aim of this study was to evaluate infl uence 
of vessel resistance for kidney function three months after transplantation 
and infl uence of changing vessel resistance for the functioning 
transplanted kidney. 
We analyzed 96 kidneys received from cadaver donors. The Kidneys were 
harvested by classical aortical cooling method with 4 liters Eurocollins solution. 
One of the kidney’s arteries was isolated by carefully dissection and prepared 
for adding calcium channel blocker (C. C. B. ). The dose of Verapamil was 0, 1 
mg in 10 ml 0, 9%NaCl solution. Two minutes before starting gravity perfusion 
we injected (by syringe) Verapamil solution directly to the one of renal artery 
(left or right) over one minute. 
On the back table just after the harvesting procedure we connected a catheter 
to each of the kidney’s artery and we measured renal fl ow of perfusion solution 
during one minute. For examination kidneys with single artery were chosen. 
Kidney function tests: levels of serum creatinine, urea and diuresis were 
measured in the fi rst and third day, after two weeks and then one and three 
months after transplantation. 
Results: 96 kidney transplants received from 48 cadaver donors had been 
performed. There were two groups of recipients. First group of 48 recipients 
that received kidneys without adding verapamil during harvesting and second 
group of 48 recipients that received kidneys with injected verapamil 2 minutes 
before starting gravity perfusion. 
The level of perfusion kidneys after adding Verapamil was signifi cantly higher 
comparing to perfusion of kidneys without adding Verapamil (SD 161 ml/min 
vs 111 ml/min). We observed negative correlation between the level of urea 
on the third day after transplantation, level of potassium on 30th day after 
transpalntation and difference of perfusion comparing both kidneys from each 
group. We also noticed positive correlation between level of perfusion kidney 
without adding Verapamil and diuresis on 90th day after transplantation [Rang 
Spearman test]. 
Summary we observed that kidneys without adding Verapamil and with lower 
level of vessel resistance functioned better during fi rst three months after 
transplantation. We also analyzed second group of recipients that received 
kidneys with adding Verapamil just before starting gravity perfusion. We 
noticed that improvement of perfusion by Calcium Channel Blocker Verapamil 
does not infl uence the functioning graft after transplantation (p<0, 05), RR = 2, 
[multivariable Cox analysis]. 
Conclusions: 1. Kidneys with lower level of vessel resistance function better 
in the fi rst period after transplantation. 
2.  Reducing level of vessel resistance by Calcium Channel Blocker does 
not infl uence signifi cantly for functioning kidneys in early period after 
transplantation. 
3.  We observed signifi cant decreasing kidney’s vessel resistance after 
administering calcium channel blocker directly to the kidney artery before 
starting gravity perfusion. 
4.  Kidneys received from donors with better biochemistry parameters of 
functioning kidneys have better reactivity of vessel for Verapamil. 
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SINGLE OR DOUBLE ARTERIES IN KIDNEY DONORS: 393 
INFLUENCE ON THE DONOR LONG-TERM OUTCOME
M. Nilsson, I. Fehrman-Ekholm1, J. Steinwall2, S. Möller2, J. Holmdahl1, 
M. Olausson1
1Transplantation Institute, 2Sahlgrenska Academy
Introduction: Today kidney with the single artery is preferred for kidney 
donation especially if laparoscopic surgery is planned. How often is the donor 
left with double or triple arteries and has this any implication on long-term 
kidney function, risk of thrombosis or hypertension?
Material and methods: All consecutive donors from 1983- 1989, who 
underwent surgery at Sahlgrenska University Hospital, was reevaluated to fi nd 
out kidney function, presence of hypertension and outcome. The project was 
approved of Ethic committee. 
Results: Total 154 donor nephrectomy was performed during these years with 
open, anterior technique. In 117 cases right kidney was removed and in 37 
cases left kidney. The medical reports showed that 98 persons were left with 
one single artery to the remnant kidney and 56 with more than one artery that is 
36%. In fact six persons were left with 3 arteries. The meanage of the donor at 
donation was 48 (SD12), range 19-73 years and present age was on the average 
68 (SD 12), range 39-92 years
In the group with single artery the preoperative p-creatinine was 86 (SD 12), at 
6 months 127 (SD 20) micromol/L and today on the average 20 years later (in 
2007) the p-creatinine was 89 (SD 22) micromol/L. The highest p-creatinine 
at six months was 176 and today 173 micromol/l. Of the total 98 from start, 96 
were available at six months and 55 were analysed in 2007. 22/55 (40%) had 
developed hypertension. Total 10 donors had died, 8 donors were living abroad, 
and 4 donors did not want to join the study. 
In the group of donors left with more than one artery the mean preoperative 
p-creatinine was 87 (SD 11) and at six months 131 (SD 20) micromol/l. Today 
in 2007 the mean p-creatinine was 100 (SD 45) micromol/l. The highest 
p-creatinine at six months was 176 and today 330 micromol/l. Of the total 56 
from start, 54 were available at six months and 35 were analysed in 2007. 10/35 
(29%) had developed hypertension. Total 11 had died, one with ESRD. Two 
were living abroad, one denied to participate and one donor had undergone 
kidney transplantation due to renal carcinoma. 
Conclusions: One third if the kidney donors are left with more than artery to 
the remnant kidney. The 20-year follow-up shows no signifi cant difference in 
renal function or hypertension between those with one artery or more than one. 
Although a small material there were two donors with ESRD in the double 
artery group. 
POSTER BOARD NUMBER P2 – 423
COMPLICATIONS OF OVERSEAS KIDNEY 394 
TRANSPLANTATION : KANGNAM ST. MARY’S HOSPITAL 
EXPERIENCE
B.J. Hyoung1, H.S. Hwang1, Y.J. Jeon1, S.Y. Lee1, H.E. Yoon1, B.S. Choi1, Y.S. 
Kim1, B.K. Bang1, C.W. Yang1
1Kangnam St. Mary’s Hospital, 2Kangnam St. Mary’s Hospital, 3Kangnam 
St. Mary’s Hospital, 4Kangnam St. Mary’s Hospital, 5Kangnam St. Mary’s 
Hospital, 6Kangnam St. Mary’s Hospital, 7Kangnam St. Mary’s Hospital, 
8Kangnam St. Mary’s Hospital, 9Kangnam St. Mary’s Hospital, 10Kangnam St. 
Mary’s Hospital
Purpose: Recipients who undergo overseas kidney transplantation lack 
medical insight regarding their perioperative and donor status. Therefore they 
need careful medical attention during their posttransplant follow-up care. We 
reviewed the surgical and medical complications of patients who went overseas 
for kidney transplantation and returned to our constitution for continued care. 
Methods: We identifi ed 66 patients who underwent kidney transplantation 
outside Korea between 2002 and 2007. The patients were transplanted in 
China (n=63) and The Philippines (n=3). The mean age was 51±10 years with 
a median follow-up of 15 months (range 9-31). We retrospectively reviewed 
surgical and medical complications in these patients. 
Results: Surgical complications were noted in fi fteen (22. 7%) patients. These 
included wound infection (n=1), wound dehiscence (n=4), lymphocele (n=4), 
hydrocele (n=1), hematoma (n=1), renal artery stenosis (n=2), ureteral stricture 
(n=2), bleeding at ureteral anastomosis site (n=1), and vesicoureteral refl ux 
(n=1). Seventeen (25. 8%) patients had medical complications, most of which 
were opportunistic infections. Six patients (9%) had cytomegalovirus (CMV) 
viremia, one of which had CMV pneumonia. Pneumocystis pneumonia was 
diagnosed in three (4. 5%) patients. Two (3%) patients experienced a signifi cant 
fungal infection including invasive pulmonary aspergillosis and aspergillus 
sinusitis. Five (7. 6%) patients had BKV infection, one of which was diagnosed 
with BKV nephropathy. In addition to infectious complication, we experienced 
thrombotic microangiopathy (TMA, n=1), and tertiary hyperparathyroidism 
(n=1). 
Conclusion: We recommend routine renal Doppler sonography and the 
monitoring of CMV and BKV viremia. To prevent fatal infection, nystatin, 
trimethoprim-sulfamethoxazole and oral gancyclovir prophylaxis are strongly 
recommended. 
POSTER BOARD NUMBER P2 – 424
RISK FACTORS FOR TRANSPLANT RENAL ARTERY 395 
STENOSIS
M.K. Heer1, P.R. Trevillian1, D. Hardy1, J. Attia2, P. Mcelduff3, D. Gillies4, S. 
Ainsworth1, A.D. Hibberd1
1Newcastle Transplant Unit, John Hunter Hospital, 2Division of Medicine, 
John Hunter Hospital, 3Hunter Medical Research Institute, University of 
Newcastle, 4Division of Surgery, John Hunter Hospital
Background Transplant Renal Artery Stenosis (TRAS) is a potentially serious 
complication after transplantation. Prevention and early management of 
TRAS may improve transplant and patient survival. The risk factors, natural 
history and indications for intervention for TRAS are poorly understood. 
Hence in this study we aimed to defi ne the risk factors and natural history 
of TRAS. 
Methods: The study population consisted of 149 consecutive renal transplant 
recipients who had 1042 duplex vascular scans at a single centre between 
1999 and 2006. Routine assessment for TRAS on all recipients was done by 
duplex vascular scanning (GE VIVID 307, multiphase transducer) at 1, 3 and 
12 months and annually thereafter. Scanning was also done when clinically 
indicated. All scans were done by one specialist. No morbidity resulted from 
the scanning. The criteria used for the diagnosis of TRAS were: absolute 
(transplant renal artery velocity to aortic velocity ratio and peak systolic 
velocity); and, relative (hilar acceleration time, parenchymal perfusion, size 
of the kidney, resistive index, presence of other vascular conditions and age 
of transplant). Recipients were divided in two groups according to the time 
at which the presence of TRAS was fi rst discovered: early stenosis occurred 
within 3 months or late stenosis occurred after 3 months from transplant. The 
risk factors studied were, for the donor: age, presence of co morbidity, live 
donor versus deceased donor, arterial injury at retrieval, CMV status and for 
the recipient: age, sex, type of anastomosis, presence of DGF, HLA mismatch, 
presence of vascular disease, vascular rejection and CMV status. Multivariate 
logistic regression analysis was done on retrospective data using the SAS 
programme. 
Results: The recipient mean age was 46. 5 ± 12. 9 years and the M: F was 
84: 65. The mean follow up period was 2. 45 yrs. The number of patients with 
TRAS was 50 with a mean age of 48. 36 ± 11. 9 years and M: F was 29: 21. The 
average time to diagnosis was 193 days. The site of stenosis was ostial (20), mid 
segment (23), hilum (1), branch (2) and entire artery (4). There were 36 (78%) 
recipients with early stenosis and 14 (28%) with late stenosis. None of the risk 
factors for TRAS in the early stenosis group reached statistical signifi cance. 
But in the late stenosis group the presence of vascular rejection [hazard ratio: 
4. 10 (95% CI 1. 12 to 15. 0)] was signifi cant risk factors for development of 
TRAS. More recipients in the early group [21/36 (58. 3%)] had resolution of 
stenosis than in the late group [3/14 (21. 4%). (p=0. 019)]. 
Conclusions: Routine duplex vascular scanning of renal transplant recipients 
detects signifi cant numbers of TRAS without causing any morbidity. Early 
stenosis usually resolved but late ones persisted implying different etiologies 
for the two groups. Presence of vascular rejection is signifi cant risk factors for 
development of late stenosis. No risk factor was found to be signifi cant for 
early stenosis. Further prospective studies are needed to defi ne the risk factors 
for TRAS. 
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OCCLUSION OF POLAR/SMALL RENAL TRANSPLANT 396 
ARTERIES SHOULD NOT BE MISDIAGNOSED AS ACUTE 
REJECTION
A.O. Mahendran, P. Veitch, J. Webster, J. Buscombe, A. Hilson, B. Fernando, 
P. Sweny
Royal Free & University College London Medical School
Aim: The investigation and management of graft dysfunction in multiple renal 
artery (MRA) allografts is not well defi ned. The use of these grafts is increasing 
with back bench arterial reconstruction being used to rescue marginal cadaveric 
kidneys and demanding implantation techniques for live donor grafts with 
multiple vessels. We have investigated the hypothesis that the late occlusion 
of small arteries should be considered in the differential diagnoses of graft 
dysfunction mainly to avoid a misdiagnosis of acute rejection in these grafts. 
Methods: Following two index cases in our unit where a decrement in graft 
function was consequent upon polar artery occlusion we designed and instituted 
a screening programme for our MRA graft recipients. 
We studied all MRA graft recipients (cadaveric and live donor) transplanted 
between January 2006 and 2008 in our unit. Operative records yielded data 
on multiple arteries, damaged vessels and the use of vascular reconstruction 
on the backbench. Data was recorded on log plots of creatinine over time, 
previous history of procoagulant state and thrombotic events, peri-operative or 
post-operative hypotension, number of antihypertensive drugs, use of aspirin/
clopidogrel and urine protein/creatinine ratio. 
Recipients were scanned using DMSA (Dimercaptosuccinic acid) imaging 
to delineate perfusion defects. Positive scans were further imaged with 
angiography. 
Patients were stratifi ed according to risk using; creeping creatinine, highest 
number of arteries and smallest caliber arteries. The high risk recipients were 
screened fi rst. 
Results: Our analysis identifi ed a total of 92 recipients with MRA grafts, of 
which 10 grafts had 3 or more discrete renal arteries and 16 had polar arteries. 
25% of the grafts had vessel damage at the time of harvesting. The complex 
vascular reconstructive techniques used included; side-to-side anastomosis of 
similar sized arteries (“trouser technique”), end-to-side anastomosis of smaller 
to larger arteries, anastomosis of polar arteries to epigastric vessels. 
To date, 16 recipients have undergone DMSA scans, with 8 grafts demonstrating 
hypoperfusion or discrete cortical defects that have been correlated to the 
entry of a smaller artery in that area. Four of these patients were noted to have 
“creeping creatinines” with infl ection points on their creatinine slopes that we 
have identifi ed as the time of occlusion of vessel. 
Conclusion: The data from our initial survey has led us to hypothesize that 
MRA grafts are at an increased risk of graft dysfunction secondary to an 
undiagnosed thrombosis or stenosis of a smaller renal artery. A creeping 
creatinine in this cohort of patients should carry a high index of suspicion 
initially for an arterial event rather than an acute graft rejection. The screening 
programme we established is unique and hitherto unreported in the literature. 
We propose a surveillance programme for MRA graft recipients; a baseline 
DMSA scan within one month of transplantation followed by repeat scans 
when clinically indicated and incorporated into the follow-up protocol for these 
patients. 
We have since expanded our study in two directions; extending the retrospective 
analysis of MRA grafts to January 2003 (fi ve years) and a prospective follow-
up of newly transplanted recipients. 
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PERSISTENT URETERAL STENOSIS AFTER KIDNEY 397 
TRANSPLANTATION: INCIDENCE AND EFFICACY OF THE 
TREATMENT WITH SELF EXPANDING METALLIC STENT. 
G. Pérez Suárez1, F.D. Romero2, D. Marrero3, J.M. Gonzalez-Posada4, 
P. Gutierrez5, H. Vallés6, T. Pérez7, A. Rodriguez8, D. Hernández9
1Department of Nephrology. Hospital Universitario De Canarias, 
2Department of Vascular Radiology. Hospital Universitario De Canarias, 
3Department of Nephrology. Hospital Universitario De Canarias, 
4Department of Nephrology. Hospital Universitario De Canarias, 
5Department of Urology. Hospital Universitario De Canarias, 6Department 
of Vascular Radiology. Hospital Universitario De Canarias, 7Department of 
Vascular Radiology. Hospital Universitario De Canarias, 8Department of 
Nephrology. Hospital Universitario De Canarias, 9Department of Nephrology. 
Hospital Universitario De Canarias
Background: Persistent Ureteral Stenosis (PUSt) is a cause of graft dysfunction 
followed kidney transplantation (KT) and the surgical treatment has been 
classically the election therapeutic approach. However the treatment by Self 
Expanding Metallic Ureteral Stent (SEMUS) can be a therapeutic alternative 
option. The aim of this study was to know the incidence of PUSt in our centre 
and described the effi cacy and safety of initial treatment with SEMUS. 
Methods: We retrospectively analysed 999 consecutive recipients of cadaver 
kidney transplantation. A double-J stent was systematically inserted at the 
time of graft implantation and removed 2 weeks later. The defi nitive diagnosis 
of PUSt was made by antegrade pyelography. Demographic and clinical 
parameters of the donor and recipient were evaluated and follow-up after 
SEMUS implantation was performed. 
Results: Twenty seven patients (2. 7%) presented a PUSt at a median of 4 
months after transplantation and in twenty two cases a SEMUS was placed as 
the fi rst therapeutic option. The remaining fi ve patients (19%) needed surgical 
treatment. Adjusted risk factors for PUSe were: donor age higher than 55 years 
(OR=4, 2; p=0. 02) and obesity of the recipient (OR=5, 3; p=0. 01). Another’s 
risk factors, such as acute rejection or cold ischemia time were not associated 
in our study. During a median time of follow-up of 41 months (range 1-52 
month), SEMUS restenosis was observed in 6 patient, two of then were treated 
by a new SEMUS and the remainder four patient needed surgical treatment. 
After SEMUS implantation, plasma creatinine levels decrease signifi cantly (4, 
5±2, 3 vs. 1, 8±0, 6 mg/dl; p<0. 0001). No severe complications in the graft or 
the recipient were observed during the follow-up. 
Conclusion: although large prospective studies are needed, the SEMUS 
implantation may be considerer the fi rst therapeutical approach for PUSt after 
kidney transplantation because it is a minimally invasive procedure, safe, 
effective and associated a low morbidity. 
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UROLOGICAL COMPLICATIONS: ANALYSIS 398 
AND MANAGEMENT OF 1525 CONSECUTIVE RENAL 
TRANSPLANTATIONS
N.P. Karidis3, G. Zavos1, P. Pappas2, T. Karatzas3, J. Bokos1, K. Stravodimos4, 
E. Theodoropoulou5, K. Diles1, G. Sotirchos1, A. Gompou6
1Transplantation Unit, Laiko General Hospital, Athens, Greece, 2Department 
of Radiology, Laiko General Hospital, Athens, Greece, 3Second Propaedeutic 
Department of Surgery, University of Athens, Medical School, Athens, Greece, 
4Department of Urology, University of Athens, Medical School, Athens, 
Greece, 5Department of Nephrology, Laiko General Hospital, Athens, Greece, 
6Hellenic National Organization of Transplantation
Urological complications after renal transplantation cause increased morbidity, 
delayed graft function and occasionally lead to graft and/or patient loss. 
Objective: The aim of this study was to analyze the causes and therapeutic 
approaches of urological complications in renal transplantation and to relate 
to patients outcome. 
Patients and Methods: A consecutive series of 1525 renal transplants were 
performed during a 24-year period. Renal grafts were provided in 814 cases from 
living-related and in 711 from cadaveric donors. A Lich-Gregoire ureterovesical 
reimplantation technique with minimal bladder wall dissection was employed 
in all cases. Ureteral stents were routinely used in cadaveric transplants and 
TU
ESD
AY
 
Oral Abstracts Tuesday 12 August 2008
1 4 1Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
exceptionally in the living-related. Urological complications were classifi ed 
according to mechanism and urinary tract site, involving: graft ureteropelvic 
junction obstruction/stenosis (A), ureteral obstruction/stenosis (B), ureterovesical 
anastomosis obstruction/stenosis (C), urinary leakage (D) and other (E). 
Results: Overall, 96 urological complications (6. 3%) were encountered. 
The rate of urological complications was expressed as the percentage of the 
overall amount of urological complications (n=96) and the total number of 
transplantations (n=1525) performed during this period. 
Urological complications after renal transplantation n % % total
Α Graft ureteropelvic junction obstruction/stenosis 12 12, 5 0. 8
Β Ureteral obstruction/stenosis 27 28, 1 1. 8
C Ureterovesical anastomosis obstruction/stenosis 29 30, 2 1. 9
D Urinary leakage 25 26, 0 1. 6
E Other 3 3, 1 0. 2
Group C complications occurred in 29 cases (30. 2%), followed by 27 cases 
(28. 1%) for group B, 25 cases (26. 0%) for group D, 12 cases (12. 5%) for 
group A and 3 cases (3. 1%) for group E. Surgical intervention was required in 
49 (51. 0%) of all urological complications and the rest (n=47, 49. 0%) were 
treated either conservatively or by minimally invasive procedures. 
Conclusions: Rapid diagnosis of urological complications in our series, assisted by 
early post-transplant DTPA scan, routine ultrasonography and especially prompt 
treatment, resulted in compensation of renal graft dysfunction in the vast majority 
(n=90, 93. 8%) of cases. Surgical technique of graft retrieval and reimplantation is 
of utmost importance in minimizing the incidence of urological complications. 
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COMBINED ISLET AND HEMATOPOIETIC STEM CELL 399 
ALLOTRANSPLANTATION: A CLINICAL PILOT TRIAL TO 
INDUCE CHIMERISM AND GRAFT TOLERANCE
D. Mineo , C. Ricordi , X. Xu , A. Pileggi , R. Garcia-Morales , 
D.A. Baidal , T. Froud , L. Inverardi , N.S. Kenyon , R. Alejandro
University of Miami, 
To prevent graft rejection and avoid immunosuppression-related side-effects, we 
attempted to induce recipient chimerism and graft tolerance in islet transplantation 
by donor CD34+hematopoietic stem cell (HSC) infusion. Six patients with brittle 
Type 1 Diabetes Mellitus received a single-donor allogeneic islet transplant (8, 
611±2, 113IEQ/kg) followed by high doses of donor HSC (4. 3±1. 9x106HSC/kg), 
at days 5 and 11 post-transplant, without ablative conditioning. An ‘Edmonton-
like’ immunosuppression was administered, with a single-dose of anti-TNFα 
antibody (Infl iximab) added to induction. Immunosuppression was weaned per 
protocol starting 12 months post-transplant. After transplantation, glucose control 
signifi cantly improved, with 3 recipients achieving insulin-independence for a short 
time (24±23days). No severe hypoglycemia or protocol-related adverse events 
occurred. Graft function was maximal at 3 months then declined. Two recipients 
rejected within 6 months due to low immunosuppressive trough levels, whereas 4 
completed 1-year follow-up with functioning grafts. Graft failure occurred within 
4 months from weaning (478±25days post-transplant). Peripheral chimerism, as 
donor leukocytes, was maximal at 1 month (5. 92±0. 48%), highly reduced at 1 
year (0. 20±0. 08%), and was undetectable at graft failure. CD25+T-lymphocytes 
signifi cantly decreased at 3 months, but partially recovered thereafter. Combined 
islet and HSC allotransplantation, using an ‘Edmonton-like’ immunosuppression, 
without ablative conditioning, did not lead to stable chimerism and graft tolerance. 
Figure: Islet graft function with metabolic control (A) and peripheral chimerism 
levels (B). 
POSTER BOARD NUMBER P2 – 429
KIDNEY FUNCTION AFTER CLINICAL ISLET 400 
TRANSPLANTATION
C.B Leitao1, P. Cure1, S. Messinger1, A. Pileggi1, O. Lenz2, T. Froud1, 
R.N Faradji1, G. Selvaggi3, C. Ricordi1, R. Alejandro1
1Diabetes Researsh Institute, University of Miami, 2Nephrology Division, 
University of Miami, 3Surgery Division, University of Miami
The aim of this study was to determine the clinical course of kidney 
function (KF) after islet transplantation (IT), identify clinical, laboratory and 
immunosuppressive factors associated and the effect of non-albumin predominant 
proteinuria in renal outcomes. A retrospective cohort study was conducted 
in 35 type 1 diabetes mellitus (T1DM) transplant subjects. Demographic, 
anthropometrical and laboratory data were recorded. KF was assessed by serum 
creatinine, albuminuria and proteinuria and estimated glomerular fi ltration rate 
(eGFR) was calculated by MDRD formula. Albuminuria/proteinuria ratio 
was calculated in those with at least one proteinuria value >300 mg/24 h (n 
= 19) and a stratifi ed analysis was performed (ratio >0. 2: glomerular pattern, 
n = 8; <0. 2: tubular pattern, n = 11). Overall eGFR remained stable during 
follow-up. Even subjects with low eGFR and/or microalbuminuria (n = 10) 
at baseline maintained stable values post-transplantation (61. 13 +/- 3. 25 vs. 
63. 32 +/- 4. 36 ml/min/1. 73 m2, P = 0. 50). Six (20%) subjects progressed to 
microalbuminuria, but sustained macroalbuminuria was not detected. A1c was 
normal after transplant (6. 09 +/- 0. 09 vs. 7. 45 +/- 0. 11%, P <0. 001), but a 
mild increment in LDL-cholesterol levels was found (101. 6 +/- 2. 3 vs. 93. 3 
+/- 3. 3 mg/dl, P = 0. 01). Blood pressure remained stable during the follow-up 
(119. 3 +/- 1. 6/71. 5 +/- 1. 0 vs. 121. 7 +/- 2. 3/71. 9 +/- 1. 6 mm Hg, P >0. 
05). After multivariate adjustments, age was the only risk factor for low eGFR 
(OR = 1. 78, 1. 22-2. 61) and LDL-cholesterol (OR = 2. 90, 1. 37-6. 12) and 
previous microalbuminuria (OR = 6. 42, 1. 42-29. 11) for macroalbuminuria. 
Tacrolimus was a protective factor against macroalbuminuria (OR = 0. 12, 0. 
06-0. 26). A higher incidence of clinical signifi cant proteinuria (>500 mg/24 
h – 100 vs. 18. 2%, P = 0. 01) and a decrease in eGFR (<60 ml/min/1. 73 m2 
-100 vs. 27%, P = 0. 01) at any time during the follow-up was found in patients 
with glomerular pattern. In conclusion, KF remained stable after IT. A high 
proportion of patients had proteinuria >300 mg/24 h, however, it seems to be 
milder and with less impact on eGFR when albumin is not the major source 
of proteinuria. Clinical IT continues to be a safe procedure for treatment of 
unstable T1DM as long as aggressive treatment of conventional risk factors for 
diabetic nephropathy is provided. 
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HYPOXIA INDUCIBLE FACTOR 1ALPHA (HIF-1ALPHA) 401 
IS REQUIRED FOR SUCCESSFUL ISLET TRANSPLANTATION 
AND INCREASING HIF-1ALPHA WITH DESFERRIOXAMINE 
MARKEDLY IMPROVES OUTCOMES
R. Stokes1, K. Cheng1, C. Scott1, S. Yim2, S. Grey1, F. Gonzalez2, 
W. Hawthorne3, P. O’Connell3, J. Gunton1
1Garvan Institute of Medical Research, Darlinghurst NSW Australia, 2NIH, 
Bethesda, Maryland USA, 3NPTU, Westmead, NSW Australia
HIF-1alpha is a transcription factor which co-ordinates a program of cellular 
response to stressors including hypoxia. In other cell types, HIF-1alpha 
increases cell survival following hypoxic challenge. HIF-1alpha functions as a 
heterodimer with ARNT, which we have previously shown to be important for 
normal beta-cell function. 
Hypothesis: HIF-1alpha is required for successful islet transplantation and 
increasing HIF-1alpha will improve transplant outcomes. 
Aim: 1. To investigate the effect of beta-cell specifi c deletion of HIF-1alpha 
upon islet transplant outcomes in mice 
2. To investigate the effects of increasing HIF-1alpha protein in human islets or 
mouse islets upon islet-transplant outcomes. 
Methods: 1. Islets were isolated from male mice with beta-cell-specifi c 
knockout of HIF-1alpha (Beta-HIF-1alpha) or fl oxed-littermate controls. These 
mice are inbred C57Bl/6. Beta-HIF1alpha mice have normal fasting glucoses. 
Islets were transplanted into STZ diabetic C57Bl/6 recipients at 1 donor to 
1 recipient (minimal mass islet transplant model). Nephrectomy on day 28 
caused recurrence of diabetes. 
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2.  Mouse islets from fl oxed-control or beta-HIF-1alpha mice were treated with 
DFO prior to transplantation. 
3.  Isolated human pancreatic islets from 9 separate donors were cultured 
overnight in control-media, or media supplemented with desferrioxamine 
(DFO), a small molecular stimulator of HIF-1alpha protein. Islets were 
transplanted into diabetic SCID mice. There were 3 transplant groups, with 
mice receiving: 
A)  Supra-physiological-mass transplant of 2000 control cultured IEQ (islet 
equivalents) 
B) Minimal mass transplant of 600 control cultured IEQ, or 
C) Minimal mass transplant of 600 IEQ cultured with DFO. 
For each human donor, at least one of each of the 3 transplant groups was 
performed to avoid the confounder of inter-donor variability. 
Results: 1. Recipients of beta-HIF-1alpha islets had markedly worse glucose 
tolerance with average random glucose 21. 2±3. 2 versus 10. 8±1. 6 mmol/L in 
control recipients (p<0. 001). 
2.  Control islets treated with DFO had signifi cantly improved islet transplant 
outcomes. DFO had no effect in transplants of beta-HIF-1alpha islets, 
demonstrating that beta-cell HIF-1alpha is required for the benefi cial effect 
of DFO. 
3.  Recipients of 2000 control IEQ were cured in 42% of cases. Minimal mass 
transplantation was ineffective: 600 IEQ cured 0% mice at 28 days. In 
contrast, minimal mass transplant of DFO treated islets had a 53% success 
rate (p<0. 001 versus group 600 IEQ control and p=ns versus 2000 IEQ). 
Blood glucose levels were markedly improved in the 600 DFO treated 
group compared to 600 IEQ control group (p<0. 0001) and did not differ 
signifi cantly from the 2000 IEQ recipients. This data demonstrates that 
increasing HIF-1alpha in human islets prior to transplantation markedly 
improves islet transplant outcomes. HIF-1alpha and DFO may have a 
therapeutic role in human islet transplantation. 
Conclusions: HIF-1alpha is a protective factor for islets after transplantation 
and is required for successful transplant outcomes. Increasing HIF-1alpha 
in islets pre-transplantation markedly improves glucose control. HIF-1alpha 
protein may have a therapeutic role in human islet transplantation. 
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NEW PANCREAS PRESERVATION STRATEGY FOR 402 
SUCCESSFUL CLINICAL ISLET TRANSPLANTATION
M. Shimoda1, H. Noguchi2, B. Naziruddin1, T. Ikemoto2, A. Jackson1, 
N. Onaca1, M. Levy1,3, P.A. Grayburn1, S. Matsumoto2,3
1Baylor University Medical Center, 2Baylor Research Institute, 3Baylor All 
Saints Islet Laboratory
Background: Islet transplantation is a promising treatment for type 1 diabetes; 
however still facing several challenges. Low success rate of clinical islet 
isolation is one such issue. Previously we have shown that improving pancreas 
preservation strategy substantially improved islet yields and success rate of islet 
isolation with non-heart-beating donors (1). We hypothesized that improving 
quality of pancreas at the time of procurement with new pancreas preservation 
strategy will improve the success rate of islet isolation using brain dead donor 
organs. 
Method: From August 2006 to January 2008, 10 clinical grade human 
pancreata were used for this study. Six pancreata were procured by transplant 
surgeons based on whole pancreas transplantation procedure and all pancreata 
were preserved by the two-layer method (standard group). Four pancreata 
were procured by islet specialist surgeons with the new pancreas preservation 
strategy (new strategy group). The new pancreas preservation strategy includes 
pancreatic ductal preservation, complete trimming of pancreas before storage, 
and oxygenated perfl uorocarbon for pancreas storage. Islets were isolated 
at our GMP facility. Isolated islets qualifi ed for transplantation based on the 
Edmonton protocol is considered as successful. 
Results: All pancreata were preserved for less than 5 hours and there were no 
signifi cant difference between the standard group and the new strategy group. 
There were no signifi cant differences in donor age, body mass index and 
pancreas weight between the standard and the new strategy groups. Average 
islet yields in the standard group were 202, 452 ± 67, 427 islet equivalents (IE) 
and in the new strategy group were 592, 023 ± 95, 586 IE. Hence islet yields 
were signifi cantly higher in new strategy group (P=0. 01). Purity was 63. 5±11. 
9 in the standard group and 58. 2±9. 3 in the new strategy. Average viability 
of isolated islets were 92. 5 ± 1. 5% in the standard group and 96. 6±2. 1% in 
the new strategy group. 2 out of 6 isolations were successfully qualifi ed all 
transplantation criteria (33%) in the standard group, while 4 out of 4 isolations 
were qualifi ed the transplantation criteria (100%) in the new strategy group. 
All transplanted islets functioned well based on serum C-peptide levels and 
improved glycemic control. Islets from the standard group transplanted into 
two type 1 diabetic patients (each patient received one preparations) and 
islets from the new pancreas preservation strategy group were transplanted 
into two type 1 diabetic patients (each patient received 2 preparations from 
the new strategy group). Both patients received islets from the new pancreas 
preservation strategy became insulin independent. 
Conclusion: New pancreas preservation strategy signifi cantly increased islet 
yields and resulted in high success of clinical islet transplantation. With the 
new pancreas preservation strategy, the issue such as low success rate of islet 
isolation might be solved. 
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ISLET TRANSPLANTATION FOR BRITTLE TYPE 1 403 
DIABETES: THE UIC PROTOCOL
A. Gangemi1, P. Salehi1, B. Hatipoglu2, J. Martellotto1, B. Barbaro1, 
J. Kuechle1, M. Qi1, Y. Wang1, E. Benedetti1, J. Oberholzer1
1Division of Transplantation/Department of Surgery/University of Illinois At 
Chicago/, 2Section of Endocrinology/Department of Medicine/University of 
Illinois at Chicago
This prospective phase 1/2 trial investigated the safety and reproducibility of 
allogeneic islet transplantation (Tx) in type 1 diabetic (T1DM) patients and 
tested a strategy to achieve insulin-independence with lower islet mass. Ten 
C-peptide negative T1DM subjects with hypoglycemic unawareness received 
1-3 intraportal allogeneic islet Tx and were followed for 15 months. Four subjects 
(Group 1) received the Edmonton immunosuppression regimen (daclizumab, 
sirolimus, tacrolimus). Six subjects (Group 2) received the University of 
Illinois protocol (etanercept, exenatide and the Edmonton regimen). All 
subjects became insulin independent. Group 1 received a mean total number of 
islets (EIN) of 1, 460, 080±418, 330 in 2 (n=2) or 3 (n=2) Tx, whereas Group 
2 became insulin independent after 1 Tx (537, 495±190, 968 EIN, p=0. 028). 
All Group 1 subjects remained insulin free through the follow-up. Two Group 
2 subjects resumed insulin: one after immunosuppression reduction during an 
infectious complication, the other with exenatide intolerance. HbA1c reached 
normal range in both groups (6. 5±0. 6 at baseline to 5. 6±0. 5 after 2-3 Tx 
in Group 1 vs. 7. 8±1. 1 to 5. 8±0. 3 after 1 Tx in Group 2). HYPO scores 
markedly decreased in both groups. Combined treatment of etanercept and 
exenatide improves islet graft function and facilitates achievement of insulin-
independence with less islets. 
POSTER BOARD NUMBER P2 – 433
COMPOSITE ISLET-KIDNEYS REVERSE DIABETES AND 404 
RENAL FAILURE ACROSS A FULLY ALLOGENEIC BARRIER 
IN NONHUMAN PRIMATES
Y. Ishikawa1, A. Griesemer1, A. Hirakata1, H. Iwaki1, V. Tchipashvili2, 
S. Moran1, A. Shimizu1, D. Sachs1, K. Yamada1
1Transplantation Biology Reserach Center, MGH, Harvard Medical School, 
2Joslin Diabetes Center, Harvard Medical School
Background: We have previously reported studies in miniature swine showing 
that transplantation (Tx) of prevascularized donor islets as part of composite 
Islet-Kidney (I-K) reversed diabetic hyperglycemia across fully allogeneic 
barriers, while the same islet-equivalents of free islets did not. In order to test 
the potential clinical applicability of this strategy, we have extended it to a fully 
allogeneic nonhuman primate model. 
Methods: I-Ks were prepared in donor baboons by isolating islets from 60% 
partial pancreatectomies and injecting them under the autologous renal capsule, 
allowing for vascularization before allogeneic transplantation. These I-Ks 
were removed at days 203 and 102 for allogeneic I-K Tx. To induce insulin-
dependent diabetes (IDDM), all recipients received streptozotocin at 2000 mg/
m2 x (Body Surface Area). One animal required total pancreatectomy to induce 
IDDM. After confi rming IDDM by fasting blood sugar (FBS) >300mg/dl for 3 
consecutive days, either I-Ks or free islets were transplanted (single donor to 
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each recipient) with ATG (day -3) followed by MMF and low-dose tacrolimus. 
Free islets were injected into the liver through the ileocolic vein. Islet function 
was assessed by FBS and renal function was assessed by serum creatinine. 
Standard CML/MLR assays were performed to determine allogeneic donor-
recipient disparities. 
Results: Two diabetic baboons received composite I-Ks and one diabetic 
baboon received free islets across fully allogeneic barriers. All three recipients 
had strong CML/MLR responses to donors pre-transplant, indicative of a fully 
allogeneic combination. In the two I-K recipients, FBS decreased immediately 
after I-K Tx and no insulin therapy was required throughout the experimental 
period (days 225 and 279). BS levels averaged 82. 2+/-15. 6 mg/dl in the fi rst 
baboon and 125. 4+/-42. 7 mg/dl in the second. Normal creatinine levels (<1. 
0mg/dl) were maintained by these life-supporting I-K grafts. In contrast, the 
recipient of allogeneic free islets had unstable BS levels and required insulin 
from day 60 (BS 400 mg/dl at day 60). 
Conclusions: Life-supporting I-Ks from single donors achieved glucose 
regulation without insulin therapy and maintained normal renal function. These 
results demonstrate the feasibility of composite I-K Tx in a non-human primate 
allogeneic model, and suggest possible clinical applicability for the cure of 
diabetic nephropathy. 
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B LYMPHOCYTE DEPENDENT REJECTION OF 405 
ISLET ALLOGRAFTS VIA INDIRECT RECOGNITION IN 
AUTOIMMUNE-PRONE NOD MICE
R.G. Gill3, T. Kupfer1, J. Beilke2, K. Pham1, J. Buhrman1
1University of Colorado Health Sciences Center, 2University of California, 
San Francisco, 3University of Alberta/Alberta Diabetes Institute
Background: Islet allografts are destroyed rapidly in spontaneously diabetic 
NOD mice. However, whether this process is more similar to conventional 
allograft immunity, islet-specifi c autoimmune pathogenesis, or both remains 
unclear. Islet allograft immunity is thought to require ‘direct’ antigen 
recognition, involving donor expression of MHC class I and/or class II 
molecules. In the present study we determined whether donor MHC expression 
and/or host B cells were required for islet allograft destruction in autoimmune-
prone NOD mice. 
Methods: Islet allograft donors were either wild-type C57Bl/6 (B6; H-2b), B6 
MHC class I defi cient (β2m-/-), B6 MHC class II-defi cient (I-Aβ-/-), or MHC 
I/II double defi cient (β2m-/- I-Aβ-/-). 450 islets from such donors then were 
grafted beneath the kidney capsule of the following recipient strains: (a) non-
autoimmune prone, streptozotocin (STZ)-induced diabetic BALB/c (H-2d), 
(b) SZT-treated, pre-diabetic NOD mice (H-2g7), (c) SZT-treated NOD B cell 
defi cient (μMT), or (d) spontaneously diabetic NOD mice.  
Results: In non-autoimmune BALB/c mice, islet allografts from wild-type B6, 
B6 β2m-/-, or B6 I-Aβ-/- rejected in < 20 days (n=5-7/group). However, B6 class 
I/II double defi cient islets were accepted long-term (>100 days) in 7/7 BALB/c 
recipients (p <. 01). However, in pre-diabetic NOD mice, B6 MHC class I/
II double-defi cient islets underwent delayed rejection in 14-90 days in 5/5 
animals. Interestingly, B lymphocytes played a signifi cant role in islet allograft 
rejection in NOD mice. B cell defi cient (μMT) mice demonstrated delayed 
rejection of wild-type B6 islet allografts relative to wild-type NOD mice (p <. 
05). Importantly, the rejection of B6 MHC class I/II double defi cient allografts 
was entirely B cell dependent in that 5/5 MHC-defi cient islet allografts survived 
>100 days in STZ-induced diabetic NOD μMT recipients. 
Spontaneously diabetic NOD mice demonstrated accelerated destruction of B6 
islet allografts regardless of donor MHC expression. That is, islets from all B6 
donor groups above were destroyed in spontaneously diabetic NOD mice in 
<20 days (n ≥ 5 in all groups). Also, anti-CD4 treatment (but not anti-CD8) 
signifi cantly delayed the rejection of MHC I/II-defi cient islets in 5/5 NOD 
mice for >50 days (p <. 02). 
Conclusion: In contrast to results using non-autoimmune mice, islet allograft 
destruction in NOD mice can be independent of donor MHC expression. The 
fi nding that rejection of such MHC-defi cient islet allografts can be CD4 T cell 
dependent and CD8 T cell independent further supports an ‘indirect’ mode of 
allograft injury. Furthermore, while B cells are known to be necessary for the 
development of autoimmune diabetes in NOD mice, they are also required 
for acute islet allograft rejection in this stain. Importantly, in the case where 
rejection is presumably dependent entirely on host indirect antigen (the 
rejection of MHC class I/II double defi cient islets), rejection appears to be 
entirely B cell dependent. We hypothesize that NOD B cells are a major APC 
for the exuberant indirect T cell reactivity demonstrated in this autoimmune-
prone strain. 
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QUANTIFYING PANCREATIC BETA-CELL 406 
REGENERATION
E. Grossman1, J. Tao1, D. Lee2, A. Chong1
1University of Chicago, 2Rush University
Introduction: We have recently described functional beta-cell regeneration 
in a mouse model of streptozotocin (STZ)-induced diabetes. We have 
extended those studies to quantify the temporal relationship between beta-
cell mass regeneration and eugylcemia. In addition, we report the use of a 
novel bio-luminescence mouse model for the real-time in vivo quantifi cation 
of beta-cell regeneration. 
Methods: C57BL/6 mice made diabetic with STZ (blood glucose >400 mg/
dl) received 200 syngenic islets under the left kidney capsule. Random blood 
glucose levels were recorded weekly for 60 or 120 days (N=10/group), after 
which the transplanted islets were removed via a left nephrectomy. Removal 
of the kidney bearing the transplanted islets allowed for assessment of 
endogenous beta-cell restoration and function. The mice were then sacrifi ced 
30 days after the removal of the transplanted islets. Non-diabetic C57BL/6 
mice and STZ-induced diabetic mice that did not receive islet transplantation 
were used as controls. 
In our bio-luminescence model, transgenic C57BL/6 mice expressing beta-
cell specifi c fi refl y luciferase (luc) under the control of the insulin promoter 
(MIP-luc) were similarly treated with STZ, islet transplantation, and 
weekly glucose level recording for 120 days. Only the recipient’s native 
pancreatic tissue express MIP-luc; the transplanted islets do not. Thus, 
photons emitted correlate to insulin production from the native pancreas. 
MIP-luc mice underwent in vivo imaging at 10-14 day intervals with the 
IVIS® 200-Series imaging system, which is capable of quantifying emitted 
bio-luminescence. 
Beta-cell mass was quantifi ed by microscopic examination of sectioned 
pancreata stained with anti-insulin polyclonal antibody. 
Results: Islet transplantation restored euglycemia (143-150 mg/dl), the 
subsequent removal of the transplanted islets at 60 days and 120 days post-
transplant resulted in a slight elevation of blood glucose levels to 230 ± 60 mg/
dl and 189 ± 31 mg/dl, respectively. The average beta-cell mass in the non-
diabetic controls and STZ-treated diabetic mice were 1. 54 ± 0. 34 mg and 0. 
094 ±0. 049 mg, respectively. There was an appreciable increase in beta cell 
mass in all STZ-induced diabetic mice receiving islet cell transplantation: 0. 
133 mg at 60 days (p = 0. 11) and 0. 914 mg (p = 0. 002) at 120 days post-
transplantation. 
In the MIP-luc mice, bio-luminescence was successfully used to quantify 
baseline beta-cell function, destruction, and regeneration. (Figure 1) After 
induction with STZ, bio-luminescence decreased to negligible levels, correlating 
with severe hyperglycemia (>500 mg/dl). After 120 days, the MIP-luc mice 
experienced an average 200% increase in photon emission compared to their 
nadir; however, this represented an achievement of only 1-10% of baseline 
intensity. Improved glycemic control correlated with an overall increase in bio-
luminescence consistent with beta-cell regeneration. 
Figure 1. 
A. Baseline.  B. STZ-treated.  C. After islet transplantation
  
Conclusion: This study confi rms that restoration of beta-cell function is time-
dependent and correlates with increased beta-cell mass. It also suggests that 
bio-luminescence imaging of beta-cells expressing luciferase may provide 
real-time quantifi cation of beta-cell regeneration. 
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LOCAL EXPRESSION OF B7-H4 BY TRANSDUCING 407 
RECOMBINANT ADENOVIRUS IN ISLET GRAFTS INHIBITS 
ALLOTRANSPLANT REJECTION
X. Wang1, J. Hao1, D. Merzger1, A. Mui1, Z. Ao1, B. Verchere1, L. Chen2, 
D. Ou1, G. Warnock1
1University of British Columbia, 2Johns Hopkins University School of 
Medicine
Allogeneic pancreatic islet transplantation has potential as a treatment option 
for type I diabetes. One of the barriers to clinical islet transplantation is the 
alloreactive T-cell response between the donors and recipients. Co-stimulatory 
molecules, which play a major role in both initiation and termination of the 
immune response to antigens during graft rejection, may be used to inhibit 
allograft destruction. B7-H4 is one such member in the B7-CD28 family of 
co-stimulatory molecules which has established negative regulation of T-cell 
responses. To determine whether local expression of B7-H4 protein can protect 
islet beta cells from damage mediated by immune rejection responses in islet 
transplantation, we have developed a recombinant adenovirus expressing 
a mouse B7-H4 cDNA (AdB7-H4). Mouse primary islet cells are mRNA-
positive by RT-PCR, but B7-H4 protein is negative in fl ow-cytometric analysis. 
Primary islet cells were infected with AdB7-H4 to express B7-H4 protein in 
a dose-dependent fashion. Treatment of fresh isolated islets by AdB7-H4 
infection at an optimized condition of 5 pfu for 24 h did not show inhibition 
of glucose-stimulated insulin secretion. To study the in vivo effects of B7-H4 
over-expression on islet graft survival, 400 adenovirus-transduced islets 
from donor BALB/C mice were transplanted under the left renal capsule of 
streptozotocin-diabetic C57BL/6 (B6) recipient mice. The B6 recipient group 
(N=12) that received AdB7-H4-transduced islet grafts established euglycemia 
for 56. 5 days, compared with the recipient group (N=12) transplanted with 
islets infected by control adenovirus (AdLacZ) for 14 days (P<0. 0001 by log-
rank test). When transplanted islets with left kidneys were removed from the 
nomoglycemic AdB7-H4-treated B6 recipients after 60 days, their glucose rose 
again, however, euglycemia restored after new islets from BALB/c donors were 
transplanted into the right kidneys of these mice, confi rming the capacity of the 
initially and secondarily transplanted islets to function. Intraperitoneal glucose 
tolerance testing confi rmed that the insulin secretion and glucose levels in the 
B6 recipients of AdB7-H4-transduced islets at 30 days post transplantation 
are similar to those of normal controls. Splenocytes and renal lymph-node 
cells isolated from the B6 recipients of AdB7H4-transduced islets showed 
clear hyporesponsiveness to alloantigenic stimulation in mixed lymphocyte 
reaction assay, compared with the control recipients of untreated islets from 
BALB/c (P<0. 00003) or from third-party CBA mice (P<0. 002), indicating 
that the inhibition of alloreactive responses is not donor tissue–specifi c. CD45+ 
leukocyte infi ltration was less in the grafts transduced with AdB7-H4 at day 60 
post-transplant, compared to that of day 10. Insulin expression remained strong 
in the islet grafts treated with AdB7-H4 at day 60 post-transplant. We conclude 
that local over-expression of B7-H4 by AdB7-H4 inhibits transplant rejection 
to allogeneic islet grafts in vivo, suggesting translational potential for beta-cell 
substitution with reduced immune injury. 
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INHIBITING DIPEPTIDYL PEPTIDASE IV ACTIVITY 408 
IMPROVES HUMAN ISLET GRAFT FUNCTION IN 
IMMUNODEFICIENT MICE WITH DIABETES
H. Yi, L. Tian, J. Hao, Y. Zhang, D. Sutherland, B. Hering, Z. Guo
Department of Surgery, University of Minnesota
Insulin secretion and beta cell differentiation, proliferation and survival are 
regulated by both glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP). However, they have extremely short half-
lives after secretion because of rapid degradation by dipeptidyl peptidase IV 
(DPP-IV). Inhibition of DPP-IV could potentially improve the therapeutic 
effi cacy of GLP-1 and GIP. In this study, we investigated whether inhibition of 
DPP-IV activity by NVP-DPP728 and by sitagliptin, the fi rst DPP-IV inhibitor 
to be approved by the FDA for treating type 2 diabetes, improves human islet 
graft function in immunodefi cient mice with diabetes. Human islets with 
purity >80% and viability >90% from different donors were used. Diabetes 
in immunodefi cient nude mice was induced by injection of STZ. Diabetic 
mice with blood glucose level >400 mg/kg for at least 2 weeks were used as 
recipients. Total 2000 IE human islets were transplanted into each diabetic 
recipient. NVP-DPP728 at 30 mg/kg was given by gavage b. i. d. for 5 days 
starting at the day of transplantation. Sitagliptin at 50 mg/kg was given by 
gavage daily for 14 days. Normglycemia was defi ned as the blood glucose level 
<200 mg/dl on 2 consecutive days. OGTT was performed in islet transplanted 
mice that had been normglycemic for at least 1 week. Mice were fastened for 4 
hours before OGTT. NVP-DPP728 at 20 mg/kg was given orally 1 hour before 
challenging orally with glucose. Blood samples were taken at 0, 15, 30, 60 
and 120 minutes after oral glucose challenge. The percentage of diabetic nude 
mice achieving normglycemia after NVP-DPP728 treatment was signifi cantly 
higher than the control mice. At 3 weeks posttransplant, the percentage of 
diabetic nude mice achieving normglycemia was 47% (N=19) without NVP-
DPP728 treatment, and 84% (N=19) with NVP-DPP728 treatment. NVP-
DPP728 treatment also signifi cantly lower blood glucose in nude mice with 
human islet grafts compared with control group after oral glucose challenge. 
Blood glucose levels in nude mice with human islet grafts after oral glucose 
challenge at 15, 30, and 60 minutes were 334±132, 305±137, 142±101 mg/
dl without NVP-DPP728 treatment; and 288±62, 215±71, and 77±36 mg/dl 
with NVP-DPP728 treatment. In sitagliptin treatment’s experiment, without 
treatment, the percentage of diabetic nude mice achieving normglycemia 
was 7% at 1 week; 31% at 2 weeks; 46% at 3 weeks; and 53% at 4 weeks 
posttransplantation (N=13). The average nonfasting blood glucose level was 
352±108 mg/dl at 1 week; 241±118 mg/dl at 2 weeks, 233±98 mg/dl at 3 
weeks; and 234±145 mg/dl at 4 weeks posttransplantation. With sitagliptin 
treatment, the percentage of diabetic nude mice achieving normglycemia was 
33% at 1 week; 58% at 2 weeks posttransplantation; 67% at 3 weeks; and 75% 
at 4 weeks posttransplantation (N=12). The average nonfasting blood glucose 
level was 283±135 mg/dl at 1 week; 225±140 mg/dl at 2 weeks, 181±142 mg/
dl at 3 weeks; and 180±131 mg/dl at 4 weeks posttransplantation. Our data 
indicate that inhibition of DPP-IV can improve human islet graft function in 
immunodefi cient mice with diabetes. 
POSTER BOARD NUMBER P2 – 438
INCREASED TOTAL INSULIN CONTENT AND 409 
RESTORATION OF FIRST-PHASE INSULIN SECRETION IN 
STANDARDIZED SMALL HUMAN PSEUDOISLETS
A. Faenza3,, G. Cavallari1,3, R. Zuellig2, R. Lehmann2, M. Weber1, 
W. Moritz1
1Clinic for Visceral and Transplant Surgery, University Hospital Zurich, 
2Division of Endocrinology and Diabetes, University Hospital Zurich, 
3Department of General Surgery and Transplantation, S. Orsola-Malpighi 
University Hospital, Bologna
Background: Pancreatic islets can be dissociated into single cells and 
reaggregated into so called “pseudoislets”, which are morphologically 
equivalent to intact islets. Small islets are potentially less susceptible to 
ischemic injury after intrahepatic islet transplantation and therefore a preferred 
subset of an islet isolate. Here we describe a method to generate standardized 
pseudosislets of small dimensions. The cytoarchitecture and in vitro function 
of rat and human pseudoislets are compared. 
Methods: Human islets were dissociated into single cells by trypsin treatment. 
Fractions with defi ned cell numbers were seeded into single drops onto cell 
culture dishes which were inverted and incubated for 6-14 days under regular 
cell culture conditions. Newly formed pseudo-islets were analyzed for 
dimensions, morphology, cellular composition and glucose stimulated insulin 
secretion (GSIS). 
Results: The volume of reaggregated pseudoislets strongly correlated with cell 
number. Morphology, cellular composition and cytoarchitecture of reaggregated 
human islets were comparable to intact islets. The insulin secretory capacity of 
small pseudoislets (250 cells/islet) reached 160% after 6 days and 246% (p<0. 
001) after 14 days of reaggregation culture compared to mixed populations 
of intact fresh islets. Compared to intact fresh islets, the stimulation index of 
small pseudoislets was improved by >2-fold (p=0. 007), partially also due to 
a reduced baseline secretion. While fi rst phase insulin secretion was nearly 
absent in freshly isolated and cultivated intact islets, it was restored in small 
pseudoislets. Total insulin content in intact and reaggregated pseudoislets was 
inversely correlated to the islet size, with small islets storing up to 4-fold more 
insulin than large islets. 
Conclusions/Interpretation: The superior biological function with respect to 
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the total insulin content, fi rst phase insulin secretion, and stimulation index 
validates small human pseudoislets as an ideal source for the improvement of 
graft function in islet transplantation. 
ORGAN DONATION AND ETHICSMINI-ORAL SESSION 15: 
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CONVERTING THE POTENTIAL FOR DONATION 410 
AFTER CARDIAC DEATH INTO ACTUAL DONORS: A 
COMPARISON BETWEEN BELGIUM AND THE U. K. 
L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
1Donor Action Foundation, 2Eurotransplant International Foundation
Study aims: To compare conversion rates of potential donation after cardiac 
death (DCD) in Belgium (opting-out system) and the U. K. (opting-in system) 
and identify areas for improvement. 
Materials: Data retrieved from a nationwide medical audit by UKT (NHS) 
between April 2005 and March 2007 in the U. K. * (24 months, 31, 077 records, 
259 records PMP/y. ) and a Donor Action Diagnostic Review in 26 Belgian 
hospitals between Nov. 2006 and Oct. 2007 (12 months, 4, 821 records, 464 
records PMP/y. , upper age limit for medical suitability: 70 yrs. )
Results: Of all patients ventilated at some point during their stay in ICU, 10. 
8% (UK) and 8. 3% (Belgium) were reported to be medically suitable for DCD 
organ donation. Signifi cantly more suitable cases (21. 3%) were identifi ed 
in the UK than in Belgium (8. 4%, P<. 0001). Whereas the approach to the 
next-of-kin was higher in the UK (88. 1% of identifi ed cases vs. 78. 1%, NS), 
consent rates were signifi cantly higher in Belgium (88. 0% of all approaches) 
compared to the UK (60. 3%, P=. 005). As a result, procurement rates were 
signifi cantly higher in Belgium (50% of all identifi ed cases) than in the UK 
(31. 2%, P=. 025). 
Conclusion: Whereas both audits demonstrate an obvious room for 
improvement within certain steps of the donation pathway (identifi cation, 
family approach, consent to donation), lower identifi cation rates in Belgium 
were compensated with higher consent rates and subsequent higher retrieval 
rates thanks to a benefi cial ‘opting-out’ legal environment. 
POSTER BOARD NUMBER P2 – 440
EVALUATING THE NON-HEART-BEATING DONOR 411 
(NHBDS) POTENTIAL IN A LARGE LEVEL-THREE 
UNIVERSITY HOSPITAL IN CHINA AND DONATION-RELATED 
ISSUE
B. Zhu, P. Yun, Z. Liu, H. Xu
Jinan City Central Hospital
The termination of current organ source and to utilize organ donors according 
to international principles is vital for the healthy development of transplantation 
in China. 
This study was designed to identify the NHBDs potential in a large level-
three hospital and donation-related issues. The charts of 502 patients who died 
during 2007 in the Emergency Department including 48 deaths in its ICU were 
reviewed. A randomized survey was conducted regarding donation. The mean 
age of death in emergency room (ER) was 61. 75¡À18. 09, and 70. 04¡À13. 
65 years in its ICU. 206 patients died in ER and 13 patients died in ICU were 
under age of 60 years. The major causes of death in patients under the age 
of 60 were sudden death (61. 64%), trauma (10. 04%), stroke (8. 68%), lung 
disease (7. 76%), and heart disease (3. 65%). 23. 08% patients in ICU showed 
abnormal liver function. The serum creatinine levels were 0. 92¡À0. 49mg/
dl when admitted into ER, and increased to 2. 04¡À0. 87 mg/dl before death. 
Life-support were terminated in 7. 57% of patients in ER and 7. 76% patients 
in its ICU under the age of 60 after receiving requests from family members. 
The mean age of patients in ICU with decision of termination of life-support 
was 41. 67¡À13. 35 years, and the duration from withdrawal of life-support to 
declaration of death was16. 17¡À21. 34 minutes. 265 patients were dead on 
the arrival at hospital, and 109 patients were documented with known duration 
between death and arrival in ER (34. 05¡À20. 84 minutes). The mean age of 
these patients was 53. 35¡À18. 78 years, and 15 patients were under the age 
of 60 years. The presumed potential availability of NHBDs in this group was 
ranged from 2. 99% (controlled) to 11. 94% (both controlled and uncontrolled). 
The randomized survey found that over 15. 7% participants have discussed 
interests in organ donation with their family members. The major issue related 
to donation was that can family members consent to organ donation following 
the death without a will from the donor. We therefore hypothesize that more 
organs would be available for transplantation after initiation of NHBDs, and 
believe that the use of NHBDs has potential in China. We are hopeful, that it 
will become a major organ source that is developed in such a way so as to be 
accepted in China and internationally. 
POSTER BOARD NUMBER P2 – 441
RESCUE ALLOCATION FOR LIVER TRANSPLANTATION 412 
WITHIN EUROTRANSPLANT: RESULTS OF A SINGLE 
CENTER EXPERIENCE
A. Nickkholgh1, P. Schemmer1, T. Gerling2, J. Weitz1, M.W. Büchler1, 
J. Schmidt1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Eurotransplant, 
Leiden, the Netherlands
Background: Organ shortage has driven many transplant centers to extend 
their criteria for organ acceptance. Graft allocation policies have been modifi ed 
accordingly. This report focuses on the impact of applying the so-called rescue 
allocation (RA) strategy for liver transplantation (LT) in a single center within 
the Eurotransplant (ET) area. 
Methods: Liver grafts are considered for RA when the regular organ allocation 
is declined by at least three centers or is averted due to donor instability/
unfavorable logistical reasons, thus entering a competitive or a single recipient 
rescue organ offer procedure, respectively. The accepting center has the 
advantage to select a recipient from its own waiting list for these RA grafts. 
Results: Among 253 livers accepted at the University of Heidelberg between 
January 2004 and December 2006, we transplanted 85 (34%) rescue allocated 
livers. The indications for LT were: hepatocellular carcinoma (HCC, 43%), 
chronic liver disease (55%), and acute liver failure (2%). Median cold ischemia 
time for RA grafts was 10 hr (range: 4-17). The MELD score (mean±SD) was 
13±7 (range: 6-40), and was 12±7 for recipients with HCC. Three (3. 5%) primary 
nonfunctions (PNF) occurred after transplantation of RA livers. One-year patient 
and graft survival were 84% and 75%, respectively. A comparison between the 
recipients of RA livers and regularly allocated livers revealed no signifi cant 
difference regarding initial poor function (IPF), PNF, and surgical complications. 
Furthermore, a median follow-up of 16 months revealed no signifi cant difference 
regarding patient and graft survival between the two groups. 
Conclusion: The use of RA organs has increased the donor pool and 
transplantation dynamics with satisfying results. The unique possibility to match 
livers with recipients, which is left to the discretion of accepting center, should 
be judged according to the center’s experience to decrease the waiting times for 
a timely rescue of organs/recipients while avoiding futile transplantations. 
POSTER BOARD NUMBER P2 – 442
UTILITY OF POLYCYSTIC KIDNEYS FROM DECEASED 413 
DONORS FOR RENAL TRANSPLANTATION
N. Gibbons, H. Rhee, V. Kanagarajah, D. Nicol
Transplant Unit
Increasing incidence of end stage renal failure (ESRF) is compounded by 
the limited number of available organs for transplantation. We report our 
experience with transplantation of cadaveric kidneys from patients with 
autosomal dominant polycystic kidney disease (ADPKD), as an option for 
selected patients with end stage renal failure. 
All fi les from deceased donors in Queensland, Australia, in the period of 
1994-2007 were reviewed to identify 5 donors with ADPKD. Data on recipients 
of polycystic kidneys was retrieved from the Australia and New Zealand 
Dialysis and Transplant (ANZDATA) registry. 
Nine patients were transplanted with follow up ranging from 6 months to 
11. 5 years. Two grafts failed due to vein thrombosis and chronic allograft 
nephropathy, both of which were unrelated to natural progression of ADPKD. 
The remaining 7 grafts all continue to function. Follow up scans of two patients 
demonstrated progressing cystic disease, whilst another showed regression. 
Kidneys from deceased donors with adult polycystic kidney disease and 
acceptable renal function can be considered for transplantation. Uncertainty 
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regarding the longevity of these kidneys and long term risks mean that they 
should be offered to carefully selected patients who would not otherwise be 
able to receive a transplant. 
POSTER BOARD NUMBER P2 – 443
DUAL VS. SINGLE KIDNEY TRANSPLANTS IN THE 414 
EUROTRANSPLANT SENIOR PROGRAM
A. Rahmel1, J. Smits1, E. de Vries1, M. Slot1, J. de Boer1, I. Tieken1, 
U. Frei2, H. de Fijter3
1Eurotransplant, 2Charite, Berlin, 3LUMC, Leiden
Background and Aim: The Eurotransplant Senior Program (ESP) is a renal 
allocation scheme based on age-matching, where organs from 65+years (yrs) 
donors are assigned with priority to 65+yrs recipients, regardless of HLA. 
The initial ESP protocol included an advice to transplant both kidneys when 
the donor creatinine clearance rate (CrCl) was below 70ml/min. The aim of this 
study is to investigate whether dual ESP kidneys have a similar graft outcome 
compared to single ESP kidney transplants. 
Patients and methods: All consecutive renal transplants performed between 
Jan 4, 1999- Dec 31, 2005 and allocated via ESP were studied [N=2261]. 
Primary end-point was graft function at 1-year. Dual kidney transplants [N=27] 
were compared to single kidney transplants (single RTX) where the donor had 
a CrCl below 70 ml/min [N=951] and single RTX with a donor CrCl ≥ 70ml/
min [N=1283]. A multivariate model was build in order to identify additional 
risk factors. 
Results: 1-Year graft survival rates for dual RTX, single RTX with a CrCl 
< 70ml/min and single RTX with a CrCL ≥ 70ml/min were 81%, 81% and 
84% respectively (p<0. 0001). The multivariate model yielded the following 
signifi cant factors. 
Variable Relative 
risk 
(95%CI)
p-value
CIT (per hour, > 11 
hours)
Cr Cl (≥ 70ml/min 
vs. < 70ml/min)
Donor age (per yr, 
>70 yr)
1. 015 (1. 001-1. 
030)
1. 260 (1. 088-1. 
459)
1. 030 (1. 013-1. 
046) 
0. 04
0. 002
<0. 0001
Factors not signifi cantly associated with 1-y graft outcome were recipient age 
(p=0. 2), retransplantation (p=0. 2), HLA mismatches (p=0. 8),%PRA (p=0. 
9), dual vs. single kidney tx (p=0. 6), donor hypertension (p=0. 9) and donor 
diabetes (p=0. 4). 
Conclusion: In this 7-year cohort of old-for-old renal transplants there is no 
evidence to advocate a dual kidney transplant in case of a donor creatinine 
clearance below 70 ml/min. Factors detrimental for 1-y graft function are 
duration of cold ischemic time (CIT) (>11 hours), creatinine clearance (< 70ml/
min) and donor age (>70 y). It still holds that the success of the ESP scheme 
relies on the reduction of cold ischemic time. 
POSTER BOARD NUMBER P2 – 444
ORGAN PROCUREMENT AFTER EUTHANASIA 415 
PROCEDURE
D. Ysebaert, G. Van Beumen, W. Van Donink, K. De Greef, G. Roeyen, 
T. Chapelle, J-L. Bosmans, P. Cras
Antwerp University Hospital
Although euthanasia is banned in almost all countries of the world, it was 
legalized in Belgium in 2002 for adults under strict conditions. Euthanasia 
is defi ned as intentionally terminating life by a physician, on the request of 
a legally competent adult, conscious at the moment making the request. The 
request must be voluntary, well-considered, repeated and not the result of 
any external pressure. The patient must be in a medically futile condition, 
of constant and unbearable physical or mental suffering that cannot be 
alleviated, resulting from a serious and incurable disorder caused by illness 
or accident. If the person is not in the terminal phase of his illness, the 2 
doctors performing the act of euthanasia must consult with a third doctor, 
either a psychiatrist or a specialist in the disease concerned. 
Between 2005-2007, 3 patients expressed their will for organ donation after 
their request for euthanasia was granted. Patients were between 43-50 y old, 
all suffering from a debilitating neurological disease, either after severe CVA 
or primary progressive multiple sclerosis. They were totally dependent on 
third parties for personal care and without quality of life. Written informed 
consent about the procedure, after extensive explanation, was given by the 
patient and their relatives. The Institutional Ethics Committee requested 
this full written scenario with informed consent, and that the organ retrieval 
should be performed as a non-heart beating donor procedure. There had 
to be clear separation between the euthanasia request, the euthanasia 
procedure and the organ procurement procedure. The procedures had to be 
performed by senior staff members and nursing staff on a voluntary basis. 
No media contact was requested by everyone involved for at least 3 months 
to maintain anonymity between donor and recipients. 
The euthanasia procedure was carried out on the requested date by the 
patient, by three physicians, in the operating room. After clinical diagnosis 
of cardiac death, the procurement team came in and performed the organ 
procurement by femoral vessel cannulation (DBTL catheter) and quick 
laparotomy for topical cooling. In 1 patients the liver, two kidneys and 
pancreatic islets were procured and transplanted, in 2 other patients there was 
additional lung procurement and transplantation. For this lung procurement 
the body was intubated after death and ventilated. Organ allocation was 
done by Eurotransplant, only in Belgium and the Netherlands, the only two 
countries with euthanasia legislation. Transplant centers were informed about 
the nature of the case and the elements of organ procurement. There was 
primary function of all organs. 
The potential in Belgium (and the Netherlands) could be substantial. 
According to the Federal Control and Evaluation Committee Euthanasia (Year 
Rapport 2006) the number patients with debilitating neurological disease that 
had their request for euthanasia granted was 22/235 (2003), 27/349 (2004) 
and 16/393 (2005). 
The involved physicians, Transplant Team and Institutional Ethics 
Committee, had the well-discussed opinion that this strong request for organ 
donation after euthanasia could not be waived. A clear separation between 
the euthanasia request, the euthanasia procedure and the organ procurement 
procedure is necessary. 
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KIDNEY TRANSPLANT LISTING FOLLOWING, LIVER, 416 
HEART AND LUNG TRANSPLANTATION
J. Schold2, T. Srinivas1, B. Stephany1, E. Poggio1, C. Miller1, M. Budev1, R. 
Fatica1, 
1Cleveland Clinic, 2University of Florida
End-stage renal disease (ESRD) frequently complicates the course of patients 
with prior non-renal solid organ transplants (liver, heart, lung;NRT) and 
adversely impacts mortality and morbidity. NRT patients who develop ESRD 
may often be referred for a kidney transplant (KT) evaluation. The principal 
study aims were 1) To assess the incidence of KT candidate listing following 
NRT and 2) To evaluate the rate of preemptive listing and donor quality among 
these candidates and recipients and 3) To evaluate the effi cacy of KT for each 
type of NRT candidate that were dialysis dependent. 
Methods: We examined data from the national SRTR transplant registry 
for all KT candidates with a prior solid organ transplant from 1988 to 2006. 
Demographic information and incidence rates of NRT candidate listing were 
calculated and compared to trends in KT patients without NRT. The effi cacy 
of kidney transplantation relative to dialysis was assessed based on time-
dependent Cox models using the population of candidates with the applicable 
prior organ transplant as a reference group. 
Results: Overall 4, 699 candidates were listed over the study period; the 
number of listings based on prior organ transplant is displayed in Figure 1. 
The proportion of all kidney transplant listings that previously had a prior NRT 
grew from <1% of candidates prior to 1990 to 3. 3% in 2006. 36% of NRT 
candidates were listed prior to dialysis initiation as opposed to 22% of other 
candidates (p<0. 001). 2, 480 patients received a kidney transplant within the 
period, 24% received a transplant from a living donor which was similar to 
non-NRTs (23%). Among deceased donor transplant recipients, NRTs and non-
NRTs received 14% and 13% ECDs respectively. KT demonstrated a survival 
advantage for each type of NRT candidate relative to maintenance dialysis. 
Conclusions: Kidney transplantation candidates listed after a non-renal 
transplant comprise a signifi cantly growing population. NRT candidates are 
listed prior to dialysis initiation more frequently than non-NRTs and receive 
similar quality organs. The more frequent pre-dialysis listing of NRTs for KT, 
likely refl ects greater access to medical management by transplant physicians 
and has implications for renal transplantation at large. Figure 1. 
POSTER BOARD NUMBER P2 – 446
APPROACH TO SOLVE ORGAN SHORTAGE IN JAPAN; 417 
FROM PERSPECTIVE OF COORDINATORS OF INTRINSIC 
MOTIVATION
Y. Uryuhara, N. Kambayashi
Graduate School of Business Administration, Kobe University
Japan has much lower level of deceased organ donation than the Western 
countries. Since this is a serious social problem in Japan, various factors have 
been considered to solve the problem of organ shortage. Although it was believed 
that the most critical factor for the organ shortage is lack of a well-established 
in-hospital system to convert potential donors into actual donors, no prior 
studies attempted to analyze the problem from the perspective of in-hospital 
coordinators f intrinsic motivation. Thus, we conducted a questionnaire survey 
in Europe and Japan to identify the characteristics of in-hospital coordinators 
who play crucial roles in organ donation. We compared their job satisfaction, 
their pride in their work, their professionalism, their job core dimensions based 
on Hackman and Oldham fs Job Characteristics Model, and job responsibilities 
between 43 European and 73 Japanese in-hospital coordinators. Our results 
demonstrated that the European coordinators have higher levels of skill 
variety, task identity, task signifi cance, autonomy, and feedback in their job 
characteristics, take more pride in their work, and do their jobs with more 
professionalism than the Japanese coordinators. These three factors also lead to 
their job satisfaction and high performance of their jobs. These fi ndings imply 
that the Japanese coordinators need to be motivated to improve the arranging 
process for potential donors to become actual donors. We suggest that redesign 
of job responsibilities of the Japanese coordinators, systematic education and 
training to foster their professionalism, recognition by healthcare professionals 
and society to boost their pride should increase organ donation in Japan. 
CARDIOTHORACICMINI-ORAL SESSION 16: 
POSTER BOARD NUMBER P2 – 447
DONOR HIGH RISK SOCIAL BEHAVIOR AND 418 
OUTCOMES IN CARDIAC TRANSPLANTATION
D. Xu1, D. Hartman2, K. Ludrosky2, J. Campbell2, R. Starling3, D. Taylor3, N. 
Smedira2, G. Gonzalez-Stawinski2
1Northwestern University Feinberg School of Medicine, Chicago, IL, United 
States, 2Department of Thoracic and Cardiovascular Surgery, Cleveland 
Clinic, Cleveland, OH, United States, 3Department of Cardiovascular 
Medicine, Cleveland Clinic, Cleveland, OH, United States
Objective: To investigate the impact of using donors with a history of high risk 
social behaviors on recipient post-transplant outcomes. 
Methods: Retrospective chart review queried cardiac transplants performed 
at a single institution from August 1994 to November 2007 involving donors 
known to have engaged in high risk social behaviors (HRSBs). Heart transplant 
recipients were stratifi ed according to the HRSB their donors had participated 
in. Kaplan-Meier methodology was used to analyze overall survival rates, and 
Cox proportional hazards regression was performed to determine the impact of 
donor HSRBs on survival. 
Results: Between August 1994 and November 2007, 143 donors were 
identifi ed with social histories containing the following HRSBs: IV drug use 
(n=21), prescription narcotic drug use (n=20), marijuana use (n=79), cocaine 
use (n=60), crack cocaine use (n=7), incarceration (n=69), multiple tattoos and/
or piercings (n=44), and alternative lifestyle participation (n=11). Viral screens 
detected 11 donors who were hepatitis B virus positive (HBV), and 10 donors 
who were hepatitis C virus positive (HCV) at the time of donation. Human 
immunodefi ciency virus (HIV) screens were negative for all patients at time of 
donation. One-year and 5 year survival were 96. 1% and 84. 2% respectively 
by Kaplan-Meier analysis. After adjusting for confounding infl uences, Cox 
proportional hazards regression model found none of the donor HRSBs to be 
signifi cant determinants of the Kaplan-Meier survival rates (p = 0. 55). At last 
follow-up, 8 patients (80%) that received a HCV positive donor converted 
positive for the virus, while 5 patients (45%) that received a HBV positive 
donor converted positive for the virus. However, no patient was detected to be 
HIV positive at their last follow-up. 
Conclusion: Using hearts for transplantation from high risk social behavior 
donors does not seem to impact long term survival. There is a considerable risk 
for viral transmission of hepatitis B and hepatitis C when these are detected by 
pre-transplant screens. However, if pre-transplant screens fail to detect HIV, 
then heart transplantation may be safely performed. 
POSTER BOARD NUMBER P2 – 448
THE EFFECT OF RECIPIENT HEPATITIS C VIRUS 419 
INFECTION ON OUTCOMES FOLLOWING HEART 
TRANSPLANTATION. 
A. Shafi i, G. Gonzalez-Stawinski
Department of Cardiothoracic Surgery, Cleveland Clinic Foundation
Background: Insuffi cient data exists on the clinical course of hepatitis C virus 
(HCV) infection in heart transplant recipients. Our study reports the outcomes 
of heart transplantation (HT) in the pre-transplant HCV-positive recipient. 
Methods: A retrospective analysis of the heart transplant database at our 
institution was conducted to identify heart transplant recipients who were 
HCV- positive prior to transplant. Demographics, serum transaminases, serum 
bilirubin, serum albumin, graft function, incidence of post-transplant acute 
hepatitis, and patient survival data were obtained by chart review. 
Results: Between 1995 and 2006 ten patients underwent HT at our center who 
at the time of transplantation were HCV seropositive. Mean age of recipients 
was 47 years-old (range 23-69). Seven recipients were male and 3 were female. 
At listing 9 patients had no cirrhosis. One patient had Childs B cirrhosis and 
was listed for combined heart-liver transplantation. Two of 10 donors were 
known to be HCV carriers. Post-transplant in-hospital survival was 100%. At 
mean follow-up of 58 months (range1. 6 -145 months) 3 deaths occurred for 
an overall survival of 70%. Only one death was linked to accelerated acute 
hepatitis, the donor in this case was HCV negative. Transplant coronary 
artery disease was detected in 2 patients at follow-up. Echocardiograms in all 
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survivors at last follow-up revealed a normal ejection fraction. In addition, 
there were no cases of hepatocellular carcinoma and all survivors were without 
evidence of hepatic dysfunction. 
Conclusions: Overall 5-year survival of this patient group was comparable to 
ISHLT survival data of HT recipients. Transplanting recipients known to have 
HCV does not seem to increase the risk of developing hepatocellular carcinoma 
or liver dysfunction. 
POSTER BOARD NUMBER P2 – 449
INFLUENCE OF ABO-COMPATIBLE 420 
TRANSPLANTATION ON LONG-TERM OUTCOME IN 
CARDIAC TRANSPLANT RECIPIENTS
A. Aliabadi, D. Dunkler, S. Mahr, M. Grömmer, M. Grimm, E. Wolner, 
A. Zuckermann
Medical University of Vienna
Background: Cardiac transplantation is best therapeutical option for end-
stage heart disease. Previous reports on the infl uence of the AB0 system on 
cardiac transplant outcome indicate that blood group identical transplants have 
a better outcome than blood group compatible transplants. As the demand for 
donor organs largely exceeds the supply, it is our policy to use blood group 
compatible local donors for transplantation if no suitable AB0 identical 
recipient is available. The aim of this study was to determine outcome after 
blood group compatible transplants. 
Patients & Methods: Between 1984-2003 a total of 915 cardiac transplants 
have been performed at our center. Median follow-up was 127 months. Patients 
were analyzed according blood group matching (AB0 identical (I) vs. AB0 
compatible (C)). Moreover subgroup analyses within the different groups were 
made to identify potential differences. Groups were analyzed for survival, graft 
rejection and graftvasculopathy (CAD). Kaplan-Meier analysis was used and 
log-rank test was performed to detect differences. 
Results: A total of 81 transplants (8. 9%) were blood group compatible. The 
majority (n=32) were 0A transplants (40%) followed by 0B (n=19; 23%), AAB 
(n=17; 21%), BAB (n=7; 9%) and 0AB (n=6; 7%). Overall survival comparison 
showed no signifi cant difference in long-term survival (10-year) between the 
two groups (I: 52. 2% vs. C: 42. 1%; p: n. s. ). Yet there was a clear trend 
towards lower survival within the C group. (10a survival: 0B: 73. 3%, AAB: 
58. 8%, BAB: 32. 1%, 0A: 27. 6%; p = 0. 0568). In contrast, Freedom from 
acute rejection was signifi cantly different between I and C groups (71. 4% vs. 
49. 9%; p<0. 0001). There was no difference in incidence of CAD (62. 5% vs. 
60. 3%) as well as severe CAD (76. 8% vs. 77. 9%). 
Conclusion: The results of our analysis show that AB0 blood group 
compatible transplants have similar outcomes in behalf of survival and CAD 
as AB0 identical transplant. Yet rejection rates are signifi cantly higher in AB0 
compatible transplants. This fi nding needs further investigation. 
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EFFECT OF DONOR GENDER ON GRAFT SURVIVAL 421 
FOLLOWING ORTHOTOPIC HEART TRANSPLANTATION
E. Lehmkuhl, H. Lehmkuhl, N. Hiemann, M. Dandel, C. Knosalla, 
V. Regitz-Zagrosek, R. Hetzer
Deutsches Herzzentrum Berlin
Objectives: Clinical outcome for women compared with men following HTX 
is assumed to be worse but is controversial. 
Methods: Based on the general observation that men who receive a female 
heart show a worse clinical outcome (48„b0, 6% vs. 46, 2„b1% for 10-year 
survival), we studied the impact of donor gender on graft survival in 1263 
patients with HTX for whom 32, 6% of donors were female. 
Results: Of 229 (18, 1%) women transplanted, 146 (63, 7%) received a female 
heart. Women suffered more often from dilated cardiomyopathy (70, 1% vs. 
62, 7%), NYHA Class IV (37, 2% vs. 31, 2%) but less often from diabetes 
(8, 7% vs. 16, 2%). Women showed a better 10-year survival rate (58% vs. 
46%). Clinical outcome in women was better when HTX was performed 
for dilated cardiomyopathy compared with ischemic heart disease and when 
women were not bridged to HTX by an assist device. Gender specifi c aspects 
of mortality showed that women died more often due to infection (30, 1% vs. 
25, 8%) and hemorrhage (4, 3% vs. 2, 9%). However, cause of death could 
less often be ascribed to rejection (7, 5% vs. 10, 7%), malignancy (7, 5% vs. 
8%) and graft failure (26, 9% vs. 31, 4%). 10-year survival for women was 
signifi cantly better compared to men (55% vs. 44%); also, 10-year survival 
was signifi cantly better for women compared to men who had received a 
female heart (60% vs. 42%). 
Conclusions: Women who received female hearts performed best. In women 
who received male hearts, clinical outcome was better compared with that of 
men who received male hearts. A partial explanation may be that lower co-
morbidity in female recipients may play an essential role since a possible 
advantage of receiving a female heart is lost in men. 
POSTER BOARD NUMBER P2 – 451
STANDARD IN SURVEILLANCE ENDOMYOCARDIAL 422 
BIOSPY (EMB) PROTOCOL IN THE FIRST MONTH AFTER 
HEART TRANSPLANTATION: TIME FOR A REAPPRAISAL?
C. d’Agostino1, A. Gambino1, G. Torregrossa1, G. Toscano1, G. Feltrin1, 
F. Tona2, A. Andreotti3, A. Angelini4, G. Thiene4, G. Gerosa1
1Cardiac Surgery Unit, 2Cardiology Unit, 3CNR, Neuroscience Institute, 
4Cardiovascular Pathology
Objective: EMB is currently the gold standard for acute rejection diagnosis in 
Htx, especially within the fi rst three monthes. We reviewed the rusults of weekly 
EMB’s performed within the fi rst month after HTx to validate their effectivness 
in directing immunosoppressor therapy procedure related complications and 
costs per patients (pts). 
Methods: We reviewed a retrospectivly 500 consecutive adult pts who 
underwent HTx from 1991 to 2007. There were 87 female and 413 male, 14 pts 
were bridged to HTx while on VAD’s. Mean ischemic time was 160 ± 50 min, 
104 pts recieved the heart from a marginal donors. Induction therapy consisted 
of: steroid bolus alone in 38 pts (7, 6%) or associated with: thymoglobuline 
(RATG) in 231 pts (46, 2%) lymphoglobulines (ALG) in 208 pts (41, 6%), 
OKT3 in 23 (4, 6%). 
Manteinance immunosuppresion therapy included: Cyclosporine (CSA) + 
Azathioprine (AZA) ± Steroids (STER) in 377 pts (83%); other associations 
of CSA or Tacrolimus and Everolimus or Mycophenolate mofetil ± STER in 
all the other pts. 
We plotted results of the fi rst four EMB’s according to ISHLT grading. 
Following our policy, all EMB’s greater than 3A were considered positive 
for acute rejection and thus treated with 3-day steroids bolus. Our data were 
analyzed with SAS statistical software. In order to evaluate if there was an 
association between the observed variables, we have performed a Chi-squared 
(÷2) test. 
Results: None of the positive presented hemodynamic failure. 
EMB 1st week: 30 positive (6%) and 6 inadequate (1, 2%);
EMB 2nd week: 113 positive (24, 5%) and 19 inadequate (3, 8%);
EMB 3rd week: 103 positive (20, 6%) and 32 inadequate (6, 4%);
EMB 4th week: 101 positive (20, 2%) and 34 inadequate (6, 8%). 
EMB1 was negative in all RATG pts. Results of EMB1 are related to 
induction therapy (p=0. 0043; á=0, 05) independently from manteinance 
immunosoppression therapy. There was a highly signifi cant relation between 
usage of RATG and results of EMB1 (p<0. 0001, á=0, 05). 
Conclusion: In our experience, EMB1 is strongly dependent on the type of 
induction therapy. EMB1 was negative in all pts treated with RATG. EMBs 
2, 3, 4 are indeed infl uenced by maintenaince immunosuppression. We 
suggest that in all RATG pts EMB1 can be safely avoided. Accordingly, our 
strategy has turned into a reduced surveillance protocol with EMBs performed 
weekly starting from the second week, thus implementing early post operative 
managment of HTx pts. 
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ANEMIA IS A RISK FACTOR FOR SURVIVAL AFTER 423 
CARDIAC TRANSPLANTATION
A. Aliabadi, D. Dunkler, M. Grimm, E. Wolner, A. Zuckermann
Medical University of Vienna
Introduction: Reduced hemoglobin (Hb) levels are common after cardiac 
transplantation. The aim of this analysis is to investigate the effect of low Hb 
levels on long-term outcome in heart transplantation. 
Patients and Methods: 797 one-month survivors after cardiac transplant 
were evaluated. Average age was 51. 5±12. 7 and 82% were male. Median 
survival was 153. 44 months. Average Hb levels for different time periods 
were calculated for each patient. Patients were grouped according their gender 
specifi c Hb levels (no anemia (A): male/female >13/12mg/dl; mild (B): m/f 
12-13/11-12mg/dl; moderate (C): m/f 11-12/10-11mg/dl; severe (D): m/f 
<11/10mg/dl). Prevalence, survival, causes of death and potential risk factors 
of anemia were examined in the different groups. 
Results: Prevalence of anemia slowly decreased during long-term follow-
up after cardiac transplantation. (year 1 vs. year 5-10: A: 58% vs. 76%, B: 
22% vs. 13%, C: 13% vs. 7%; D: 7% vs. 4%). Logistic stepwise multivariate 
regression analysis revealed lower creatinine clearance, higher BUN and lower 
body mass index as independent risk factors for chronic anemia. Severe anemia 
was associated with signifi cant lower short- and long-term survival (A: B: C: 
D; 12 month survival: 98%, 96%, 90%, 67%; 120 month survival: 68%, 61%, 
58%, 42%; p<0. 0001). In a sub analysis of three-year survivors, severe anemia 
again was associated with worse long-term outcome (A vs. B vs. C vs. D: 120 
month survival: 71%, 65%, 65%, 52%; p=0. 0268). There was a signifi cant 
higher rate of death from infection in the severe anemic group (A vs. B vs. C 
vs. D: 9%, 22%, 23%, 41%; p<0. 01). 
Conclusion: Prevalence of anemia slowly decreases during follow-up after 
cardiac transplantation. Chronic anemia is associated with chronic renal 
dysfunction and low body mass index. Chronic anemia signifi cantly worsens 
long-term survival, mainly due to infections. 
POSTER BOARD NUMBER P2 – 453
REGULATORS OF COMPLEMENT ACTIVATION IN 424 
MULTIPAROUS VS. NULLIPAROUS HEART TRANSPLANT 
RECIPIENTS. 
E.R. Rodriguez1, W.M. Baldwin2, C.D. Tan1
1Cleveland Clinic, 2Johns Hopkins University
Multiparity is thought to be an important factor that increases sensitization of 
heart transplant recipients and as a corollary one may expect a higher incidence 
of Antibody mediated rejection (AMR). AMR is a type of rejection with low 
incidence but high morbidity and if unrecognized high mortality. Activation of 
the complement cascade with deposition of complement in capillaries occurs in 
AMR and is noxious to the allograft. In some patients activation and deposition 
of complement occurs but it is not associated with clinical dysfunction of the 
allograft. A protective mechanism may be the local activation of regulators of 
complement activation (RCA’s). 
Methods: Endomyocardial biopsies from 40 multiparous and 8 nulliparous heart 
transplant recipients were evaluated at 1, 6 and 12 months after transplant. The 
mean follow up was 4 years. Immunofl uorescence for complement fragments 
C4d and C3d and for 4 regulators of complement activation was performed. The 
regulators of complement tested for included: complement receptor 1 (CD35), 
membrane cofactor protein (MCP or CD46), decay accelerating factor (CD55) 
and protectin (CD59). The presence of these regulators in capillary endothelial 
cells was scored semiquantitatively from 0 to 4+. The data were correlated to 
parity, age and clinical evidence of allograft dysfunction. 
Results: Expression of CD35 and CD46 in capillary endothelial cells was 
absent or weak in most patients. Expression of CD55 and CD59 in granular 
pattern in capillaries was commonly found. Twenty seven of 40 patients (67. 
5%) had expression of CD55 in capillaries and 15 of 40 (37. 5%) showed 
expression of CD59. Only 18 of 40 patients (45%) expressed CD55 and CD59 
concomitantly. The expression of regulators of complement activation was 
variable over time. One of 5 patients with concomitant deposits of C4d and 
C3d had severe dysfunction of the allograft. Two of these 5 patients showed 
minimal expression of the regulators of complement CD55 and CD59 in 
subsequent biopsies. 
Conclusions: The presence of regulators of complement in the endothelial 
cells correlates with: 
1. Absent or low amounts of complement C4d or C3d deposition
2.  Dysfunction of the allograft was not seen in patients with expression of 
CD55 or CD59. 
3.  Either CD55 or CD59 seem to be suffi cient for protection against the 
deleterious effects of complement activation in cardiac allografts. 
4.  The absence or low local expression of regulators of complement activation 
was associated with deposition of C4d and C3d in capillaries and concomitant 
allograft dysfunction (AMR). 
5.  The overall incidence of AMR in this cohort of multiparous heart transplant 
recipients was 5%
POSTER BOARD NUMBER P2 – 454
MICROVASCULOPATHY DOES NOT AFFECT THE 425 
FAVORABLE OUTCOME IN FEMALE HEART TRANSPLANT 
RECIPIENTS
N. Hiemann1, C. Knosalla1, E. Wellnhofer2, H. Lehmkuhl1, R. Hetzer1, 
R. Meyer1
1Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular 
Surgery, 2Deutsches Herzzentrum Berlin, Department of Cardiology
Background: Women show a more favorable long-term outcome after 
heart transplantation (HTx) than men, and we tested whether stenotic 
microvasculopathy affects the more benefi cial course in female recipients. 
Patients and Methods: We studied 873 consecutive patients (35/151 pre-
menopausal women [aged <40years]; median follow-up 12. 4 (95% CI 11. 4–13. 
5) years) who received a primary heart transplant between 1986 and 2002. In 7, 
750 biopsies harvested within the fi rst post-transplant year endothelial disease 
and stenotic microvasculopathy were evaluated by light microscopy (H&E). 
Kaplan-Meier and Cox regression analyses were performed for major cardiac 
events (lethal myocardial infarction, sudden cardiac death, graft failure, cardiac 
re-transplantation). 
Results: Endothelial disease was more frequent in pre-menopausal women 
(72% vs. men 56%; p=0. 025), while stenotic microvasculopathy was found 
equally in men (38%) and women (pre-menopausal 41%, post-menopausal 
32%). Allografts from pre-menopausal female-to-male transplants more 
frequently developed endothelial disease (78% vs. 65%; p=0. 021) and stenotic 
microvasculopathy (46% vs. 28%, p=0. 024). Beyond the fi rst 5 post-transplant 
years women presented less often major cardiac events as compared to men, 
independently of donor gender and stenotic microvasculopathy (p=0. 0001). 
Multivariate regression analysis found women at lower risk for major cardiac 
events (RR 0. 38; 95%CI 0. 17–0. 81), while stenotic microvasculopathy (RR 
2. 15; 95%CI 1. 42–3. 26) and treated diabetes (RR 1. 65; 95%CI 1. 08–2. 52) 
represented a higher risk for major cardiac events. 
Conclusions: Stenotic microvasculopathy has prognostic impact on the 
survival of male and female cardiac recipients; however, it does not affect the 
more benefi cial course of women in the long-term follow-up. 
POSTER BOARD NUMBER P2 – 455
THE EXPRESSION OF CHROMOGRANIN A IN DILATED 426 
CARDIOMYOPATHY AND ITS RELATIONSHIP WITH 
MYOCARDIAL FIBROSIS
R. Chen1, Y. Xie2, Y. Yu3, Y. Zou4, C. Wang5, J. Ge6, Y. Yang7
1Shanghai Institute of Cardiovascular Diseases, Fudan University, 2Shanghai 
Institute of Cardiovascular Diseases, Fudan University, 3Shanghai Institute 
of Cardiovascular Diseases, Fudan University, 4Shanghai Institute of 
Cardiovascular Diseases, Fudan University, 5Shanghai Institute of 
Cardiovascular Diseases, Fudan University, 6Shanghai Institute of 
Cardiovascular Diseases, Fudan University, 7Shanghai Institute of 
Cardiovascular Diseases, Fudan University
Purpose: Chromogranin A (CgA) is widely distributed in the neuroendocine 
system and considered as a diagnostic marker of the whole activity of 
neuroendocrine system. A neuroendocrine activation has been described in 
the process of dilated cardiomyopathy, which promotes the myocardial cell 
apoptosis, the stimulation of myocardial interstitial collagen hyperplasia and 
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remodeling, and the imbalance of collagenI (COLI) and collagen III (COL 
III). Losing the support of collagen, the function of left ventricular coverts 
from pressure pump to capacity, and eventually lead to heart failure. The 
CgA are released by sympathetic nerve terminals and counteract the actions 
of β-adrenergic drugs. It is also showed that CgA can modulate fi broblast 
cell adhesion and spreading in a differential manner. So it is speculated that 
CgA could also contribute to regulate heart remodeling in patients with DCM. 
However, the correlation between CgA and myocardial fi brosis remained 
uncertain. In the present study, the expression and location of CgA and 
myocardial fi brosis in DCM were observed, so as to give rise to the further 
study in the role of the neuroendocrine of DCM and clinical evaluation of 
myocardial fi brosis. 
Methods; Surgical myocardial specimen from DCM patients, who were 
underwent successful orthotopic cardiac transplantation, and the normal 
myocardium were used for study objects. CgA, COLI and COL III expression 
were analyzed by RT-PCR. Location and expression of CgA were assessed 
by immunohistochemistry with anti-CgA antibody. The collagen specifi c 
picrosirus red staining was applied on slides of heart samples from controls 
and patients, and then the collagen volume fraction (CVF) was calculated. 
Results COLI-mRNA and COL III-mRNA were generated in all DCM patients, 
but not in the normal. CgA-mRNA was detected by RT-PCR in both normal 
and pathologic myocardium, while its expression was signifi cantly increased 
in DCM (P<0. 01). It is performed by immunohistochemistry that cytoplasic 
expression of CgA was showed in both normal and DCM paraffi n sections of 
myocardial samples. But a strong positive was produced in DCM slides (P<0. 
01), densely arranged in the epicardial and endocardial myocardiocytes; while 
only few sparse granules were found in the normal. Increase of CVF and COLI 
deposition were obviously observed in DCM (P<0. 001). The deposition of 
COLI was surprisingly identical with the strong positive arrangement of CgA. 
Conclusions: It is demonstrated for the fi rst time that the deposition of CgA 
is related with the myocardial fi brosis of DCM, that is, CgA may infl uence the 
process of myocardial remodeling and fi brosis. CgA may represent a key player 
in nenuroendocrine regulation of DCM and it may be a potential diagnostic and 
prognostic indicators of DCM patients. 
POSTER BOARD NUMBER P2 – 456
THE RELATIONSHIP BETWEEN ENTEROVIRUS 427 
INFECTION AND EXPRESSION OF CHEMOKINES IN 
MYOCARDIUM OF DILATED CARDIOMYOPATHY WITH 
ORTHOTOPIC CARDIAC TRANSPLANTATION
R. Chen, Y. Yang, Q. Guo, J. Ge, C. Wang, H. Chen
1Shanghai Institute of Cardiovascular Diseases, 
Purpose: Dilated cardiomyopathy (DCM), a leading cause of heart failure 
and heart transplantation in younger adults, is characterized by dilatation 
and impaired contraction of the left or both ventricles; it may be idiopathic, 
familial/genetic (20-48%), viral, and/or immune. On endomyocardial 
biopsy there is chronic infl ammation in 30-40% of cases. Myocarditis may 
be idiopathic, infectious or autoimmune and may heal or lead to DCM. 
Chemokines are the principle mediators of leukocyte infi ltration and 
infl ammation. However, the expression of chemokine in the myocardium 
has infected with viruses and its destruction function for myocardium has 
not been studied yet. To study the prevalence of viral infection and effect 
of chemokines in patients with dilated cardiomyopathy (DCM) by detecting 
Enterovirus (Evs) RNA and the expression of chemokines in myocardium 
and to evaluate the relationship among viral infection, myocardial damage 
and cardiac function in DCM patients. 
Methods: Myocardial specimens from 33 patients with DCM underwent 
orthotopic cardiac transplantation were studied and normal specimens from 
12 persons died of accident at autopsy were examined as controls. Evs-
RNA and expression of chemokines include monocyte chemoattractant 
protein-1 (MCP-1), regulated on activation normal T cell expressed and 
secreted (RANTES), γ-interferon-inducible protein 10 (IP-10), MCP-5, 
macrophage inflammatory protein-1β (MIP-1β) in these myocardial 
tissues were detected by RT-PCR. The cardiac function was studied by 
echocardiography and the level of serum cTnI of these patients was 
monitored quantitatively by using chemiluminescence method in all the 
DCM patients. 
Results: All the 33 clinically diagnosed DCM patients were proved by 
pathologic examination. Evs-RNA was found in 14 specimens and MCP-1 
mRNA expression was found markedly increased in 7 of them. Meanwhile, 
other chemokines were detected negative. Neither viral gene nor the 
expression of MCP-1 was found in myocardium of control group. The 
serum level of cTnI was found high (>0. 1ng/ml) in 2 patients with DCM 
before heart transplantation and the Evs-RNA was detected in their donee 
myocardium. The left ventricular systolic function of the DCM patients 
were found poor as their average value of EF was 29. 4±11. 3. Compared 
the virus gene postive and negative group, it was showed no signifi cant 
difference (P>0. 05). However, the left ventricular diastolic function (E/A) 
was demonstrated signifi cant statistic higher in virus gene postive group 
than that in virus gene negative group (2. 22± 0. 44 vs 1. 78± 0. 34), P < 
0. 05. 
Conclusion: Nearly half of the DCM patients with orthotopic cardiac 
transplantation were found to be infected by Enterovirus. In these patients viral 
infection may alter the expression level of MCP-1, which provide migrating 
signal, activate the cells and initiate the aggregating of the infl ammatory cells 
and then injury myocardial cells. 
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ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION 428 
|JAPANESE EXPERIENCE OF MORE THAN 1, 000 CASES 
SINCE 1989
K. Takahashi, K. Saito, K. Tanabe, S. Takahara, K. Uchida, A. Aikawa, T. 
Kinukawa, T. Kobayashi, N. Yoshimura, Y. Kamiryo
Japanese ABO Incompatible Kidney Transplantation Committee
We heve been making continuing efforts in ABO-incompatible kidney 
transplantation since 1989 to expand the opportunities for kidney transplantation 
from living donors. 
From the Japanese registry, we have reviewed the long term patient and graft 
survival of ABO-incompatible kidney transplantation. 
This survey focused on 1, 012 patients who received ABO-incompatible kidney 
grafts from January 1989 to December 2006 in whom monitoring follow-up 
could be achieved in 92 institutions all over Japan. 
The mean age of patients at surgery was 38 years (4 to 71) comprised 638 
(63%) males and 374 (37%) females. 
The overall patient survival rate at 1, 3, 5 and 10 years after transplantation 
were 95, 93, 91 and 87%, with overall graft survival rate of 90, 86, 80 and 
63%, respectively. 
The graft survival rate has been signifi cantly improved especially after 2001, 
at 1, 3 and 5 years with 96, 94 and 90% (n=567), compared with those in the 
period of 1995-2000 at 84, 79 and 76% (n=277) and in the period of 1989-1994 
at 81, 78 and 68% (n=168), respectively. 
The graft survival rate was signifi cantly higher in patients aged 29 and 
younger compared with those aged 30 and older (p<0. 01). There were no 
signifi cant differences between A-and B-incompatible recipients, number of 
HLA mismatches, induction and maintenance calcinurine inhibitors and donor/
recipient relationships with respect to clinical outcomes. 
Recent trend in Japan is the rituximab desensitization and avoidance of 
splenectomy. Among 168 cases in 2006, rituximab was used in 69 cases and 
splenectomy was avoided in 63 cases. Overall avoidance of splenectomy have 
already reached up to 148 (15%) among 1, 012 cases. 
This study confi rms that the short-term and long-term outcome of ABO-
incompatible living kidney transplantation is excellent, and are similar to that 
in ABO- compatible cases. 
ABO incompatible kidney transplantation has become one of a standard, safety 
and effective treatment choice for end-stage renal disease. 
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COMPARATIVE STUDY OF LONG-TERM OUTCOMES 429 
BETWEEN ABO INCOMPATIBLE AND COMPATIBLE LIVING 
DONOR KIDNEY TRANSPLANTATION. 
A. Aikawa, T. Kawamura, Y. Mori, M. Saneshige, J. Takasu
Department of Nephrology, Toho University
Aim: The aim of this study is to evaluate long-term outcomes of living donor 
ABO incompatible kidney transplantation (ABOINCKTx) compared with 
ABO compatible kidney transplantation (ABOCKTx). 
Methods: Fifty ABOINCKTx and 119 ABOCKTx recipients were enrolled in 
this study. All Tx underwent from1997 to 2004 (Mean follow-up ABOINCKTx 
vs. ABOCKTx; 81 vs. 82 months). Immunosuppression was similar in both 
groups except splenectomy and pre-conditioning (plasmapheresis and/or 
plasma exchange) in ABOINCKTx. Blood group matching (donor to recipient) 
in ABOINCKTx are as follows. A1 to O (n=13), B to O (n=12), A1B to A1 
(n=6), B to A1 (n=5), A1B to B (n=8), A1 to B (n=6). 
Results: Age and gender of recipients and donors, the relation of donor to 
recipient, and HLA mismatch were not different between two groups. However 
the rate of second Tx was signifi cantly higher in ABOINCKTx than ABOCKTx 
(7/50 vs. 3/119; p<0. 01). Incidence of biopsy proven acute rejection was 
signifi cantly higher in ABOINCKTx than ABOCKTx (22/50. vs. 20/119; p<0. 
001). However serum creatinine levels were not different in any post-Tx years 
between ABOINCKTx and ABOCKTx (ABOINCKTx vs. ABOCKTx; 1-yr 1. 
18 }0. 39 vs. 1. 15 }0. 56; NS, 3-yr 1. 33 }0. 66 vs. 1. 23 }0. 93; NS, 5-yr 
1. 44 }0. 84 vs. 1. 24 }0. 52; NS, 7-yr 1. 41 }0. 36 vs. 1. 51 }0. 79; NS. ) In 
ABOINCKTx, all 50 recipients have so far survived, however only one patient 
lost graft function due to chronic allograft nephropathy (CAN) 64 months post-
Tx. In ABOCKTx, 3 recipients died of cancer and infection with good renal 
function. One and 2 recipients lost graft due to antibody mediated rejection and 
CAN, respectively. Graft survival rates in ABOINCKTx and ABOCKTx were 
100% and 98. 3% at 1-yr, 100% and 97. 5% at 3-yr, 100% and 96. 6% at 5-yr, 
and 97. 4% and 91. 8% at 7-yr, respectively. 
Conclusion: Long-term outcomes including renal function in ABOINCKTx 
were excellent and seemed to be equivalent to ABOCKTx despite of higher 
rate of acute rejection. 
ELIMINATION OF SPLENECTOMY AND ANTI-430 
CD20 THERAPY DOES NOT RESULT IN INCREASED 
CHRONIC ALLOGRAFT NEPHROPATHY: A SINGLE 
CENTER EXPERIENCE IN ABO-INCOMPATIBLE RENAL 
TRANSPLANTATION
A. Singer, J. Locke, M. Haas, Z. Stewart, K. King, J.K. Melancon, D. Segev, 
D. Warren, R. Montgomery
Johns Hopkin University
Background: ABO incompatibility (ABOi) remains a signifi cant barrier to the 
expansion of live donor renal transplantation. With the advent of plasmapheresis 
(PP) and IVIg based desensitization protocols, it is now possible to perform 
successful renal transplantation in the presence of ABOi. Our experience with 
56 ABOi renal transplants suggests that elimination of splenectomy and/or anti-
CD20 therapy does not increase the extent of chronic allograft nephropathy or 
the incidence of graft loss. 
Methods: Patients were treated with a standard protocol consisting of pre- and 
post-transplant PP/CMVIg, daclizumab induction, steroids, tacrolimus, and 
MMF. Some patients also underwent splenectomy and/or anti-CD20 treatment 
prior to transplant. 
Results: Death-censored graft survival for the entire cohort at 1- and 3- years 
was 100% and 93. 4% respectively. 3 patients died with a functioning graft. 
3 graft losses have occurred secondary to recurrent disease (2) and patient 
noncompliance (1). There were no signifi cant differences in the number of 
post-operative PP treatments or the incidence of acute rejection between the 
treatment regimens. 
Conclusions: In our experience, excellent short- and long-term function of 
ABOi renal allografts can be achieved with PP/IVIg based desensitization 
without the need for long-lasting B-cell depletion. Further, this reduction in 
immune modulation has not resulted in an increase in rejection or chronicity 
scores on 1-year protocol biopsies. 
RITUXIMAB THERAPY DECREASES ACUTE 431 
REJECTION RATES AMONG SENSITIZED RENAL 
ALLOGRAFT RECIPIENTS
D. Dadhania1,2, V. Sharma1,2, K. Wang2, R. Friedlander2, A. Menon2, 
D. Serur1,2, M. Aull1, S. Kapur1, M. Fotino2, M. Suthanthiran1
1Weill Cornell Medical Center, 2Rogosin Institute
Sensitized renal allograft recipients are disadvantaged for multiple reasons – 
longer wait times, increased risk of acute rejection and compromised long-term 
kidney survival. B cell targeted therapy may not only decrease acute rejection 
rates but also improve allograft survival rates. 
Herein, we report on the impact of Rituximab therapy (one dose of 1g (n=39) 
or two 1g doses given two weeks apart (n=10)) on : (1) the depletion of 
peripheral blood B cell subsets; (2) the percentage of lymph node B cell 
subsets (the lymph nodes were retrieved from Rituximab treated patients 
at the time of transplant surgery); and (3) acute rejection rates and graft 
survival in 49 recipients with evidence donor specifi c sensitization: donor 
fl ow cytometry cross- match positive and donor specifi c anti – HLA antibody 
positive by the Luminex platform. All recipients received Thymoglobulin 
induction at the time of transplantation, and 33 received Rituximab and 16 
did not. 
Rituximab therapy effectively depleted peripheral blood naïve B cell subset. 
Data from fl ow cytometry analysis of peripheral blood cells obtained from 4 
patients and analyzed for CD19+ CD27- (naïve subset) and CD19+CD27+ 
(memory subset) are shown in Table 1. 
Table 1. In-vivo effect Rituximab on Naïve and Memory B-cell Subsets
B cell subsets Pre Rituximab (n=4) Post Rituximab (n=4) P value
CD19+CD27- 4. 8 ± 0. 54 0. 28± 0. 06 0. 005
CD19+CD27+ 0. 45 ± 0. 25 0. 17± 0. 05 0. 32
Interestingly, both B cell subsets were identifi ed in the lymph nodes retrieved at 
the time of transplantation from Rituximab treated recipients: CD19+CD27- : 
16. 5 ± 5. 0% and CD19+CD27+: 9. 9 ± 4. 1% (mean±SE, N=6 patients)
Prophylactic Rituximab therapy was associated with a signifi cantly decreased 
risk of acute rejection at 6-months and one year post-transplantation, and a 
trend towards improved allograft survival (Table 2). 
Table 2. A signifi cant reduction in AR Rates with Rituximab Treatment of 
Patients with Donor Specifi c Antibodies
Rituximab
 (n=33)
No Rituximab
 (n=16)
Odds Ratio 95% CI P-Value
6-montth AR 12% 33% 0. 23 0. 06, 0. 93 0. 039
1-year AR 16% 45% 0. 23 0. 06, 0. 87 0. 029
Graft 
Survival
95% 75% 0. 26
In a multivariable regression model, Rituximab therapy was associated with 
an OR of 0. 18 (0. 04, 0. 83; P=0. 02) for acute rejection episodes whereas 
prophylactic IVIG therapy was associated with an OR of 1. 61 (0. 35, 7. 51; 
P=0. 5). 
Our data suggest that our Rituximab treatment protocol is associated with an 
effective depletion of peripheral blood B cells but not the B cell subsets in the 
lymphoid compartment. Importantly, prophylactic Rituximab therapy reduces 
acute rejection rates in subjects with donor specifi c anti-HLA antibodies. 
Lymph node profi ling for B cell subsets may help optimize B cell targeted 
therapy for the sensitized recipient. 
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CLINICAL SIGNIFICANCE OF B-CELL POSITIVE 432 
CROSSMATCHES AND LUMINEX® DEFINED DONOR-
SPECIFIC ANTIBODIES IN WELL-MATCHED HIGHLY 
SENSITIZED PATIENTS FROM THE AUSTRALIAN 
INTERSTATE EXCHANGE
H.S. Eng1,2, S. Campbell3, G. Russ1,2,4,5, P. Toby, H. Coates1,2,5, 
P. Bardy1,5,6, G. Bennett5, S. Chang4, B. Tait7
1Medicine, University of Adelaide, SA, Australia, 2Nephrology and 
Transplantation Services, Queen Elizabeth Hospital, SA, Australia, 3Renal 
Transplant Unit, Princess Alexandra Hospital, Brisbane, Australia, 
4ANZDATA Registry, Queen Elizabeth Hospital, SA, Austrralia, 5National 
Transplant Services, Australian Red Cross Blood Service, SA, Australia, 
6Haematology-Oncology, Queen Elizabeth Hospital, SA, Austrralia, 7Victorian 
Transplantation and Immunogenetics Service, Australian Red Cross Blood 
Service, c/o Royal Melbourne Hospital, Victoria, Australia
A positive B-cell crossmatch (BXM) is controversial in kidney transplantation. 
The Australian National Interstate Exchange (ANIE) prioritises sensitized 
patients, aiming for greater HLA-matching. We retrospectively studied the 
clinical predictive value of complement-dependent cytotoxicity (CDC) BXM 
in patients with Luminex® defi ned class I (CI) and class II (CII) donor-specifi c 
antibodies (DSA). 
Ninety-one deceased donor renal transplant recipients matched at levels 1 
(zero HLA mismatch and PRA>50%), 2 (1 mismatch, PRA>80%) and 3 (2 
mismatches, PRA>80%) under the ANIE between October 2004 and December 
2006 were studied and followed to July 2007. All patients had a negative CDC 
T-cell crossmatch (TXM). Antibody specifi city was defi ned using Luminex® 
PRA and Single Antigen Bead assays. 
There were thirteen (14%) graft losses between 0-31 months. Total rejection 
rate was 40%, 92% biopsy-proven. Eighteen of 91 (20%) had humoral rejection, 
13 with C4d staining. Thirty-one patients had negative peak and current BXM 
and 29 had positive BXM with any serum. A positive BXM was not associated 
with a higher risk of total rejection (p=0. 07), cellular (p=0. 46) or glomerular 
rejection (p=0. 08) but was for vascular (p=0. 039) and humoral rejection (p=0. 
02). A trend of poorer graft function was observed in BXM positive group at 
1 year (MDRD, mean eGFR 42 vs. 53mL/min/1. 73mm2, p=0. 14). Seven of 
31 (23%, 2 surgical, 2 rejection, 2 BK, 1 unknown) graft losses occurred in the 
BXM negative group compared to 3 of 29 (10%, 1 rejection, 2 deceased) in 
BXM positive group (p=0. 3). 
Sera from 82 of 91 were analysed using Luminex®. Anti-HLA antibodies were 
absent in 11 (13%) patients. Anti-HLA DSA were found in 33 (40%) and non-
DSA in 38 patients (46%). DSA was a signifi cant predictor for overall rejection 
(p=0. 002), glomerular (p=0. 024), vascular (p<0. 001) and humoral (p<0. 001), 
but not cellular rejection (p=0. 11). The eGFR of DSA group at 3 (p=0. 36), 6 
(p=0. 5) and 12 months (p=0. 34) were not signifi cantly different from patients 
without DSA. Humoral rejection was more common in DSA-CI alone (n=14, 
5/14, 36%, p=0. 005) or DSA-CI& CII (n=10, 6/10, 60%, p<0. 001) groups, 
compared to patients without DSA (2/49, 4%). DSA-CI&CII was associated 
with higher risk of total rejection (p<0. 001), cellular (p=0. 018) and vascular 
(p<0. 001) rejection but DSA-CII alone (n=9) was not. 
DSA was found in 18 of 29 (62%) BXM positive patients and 8 of 31 (26%) 
BXM negative patients. BXM positive with DSA was associated with humoral 
rejection (p=0. 001) but positive BXM without DSA was not (p=0. 1). Two of 8 
BXM negative patients with DSA had humoral rejection (25% vs. 0%, p=0. 06). 
Positive and negative predictive values of BXM and DSA for humoral rejection 
were 31%, 93% and 41%, 96%. After adjustment for BXM, DSA remained a 
signifi cant risk factor for total (p=0. 028), vascular (p=0. 023) and humoral 
rejection (p=0. 043). After adjustment for DSA, BXM was not a signifi cant 
risk factor for rejection. 
A positive BXM in the presence of anti-HLA DSA is a predictor for vascular and 
humoral rejection in sensitized patients. Compared to BXM, Luminex antibody 
analysis allows greater predictive value for vascular and humoral rejection.
SIMULTANEOUS KIDNEY PANCREAS 433 
TRANSPLANTATION IN PATIENTS WITH POSITIVE CDC 
B-CELL AND/OR FLOW CYTOMETRY CROSSMATCH
R. Heilman, A. Moss, M. Mazur, H. Chakkera, K. Mekeel, D. Mulligan, 
K. Reddy
Mayo Clinic Arizona
We reviewed our experience with simultaneous kidney pancreas transplantation 
(SKPT) in patients with positive CDC B-cell and/or fl ow cytometry crossmatch 
and compared to SKPT recipients with negative crossmatch performed during 
a concurrent period. 
We performed 64 SKPTs from Jan 2005 to Nov 2007, 12 in patients with 
positive CDC B-cell and/or fl ow cytometry crossmatch and 52 in patients with 
negative crossmatch. Patients with positive crossmatch received induction 
with low dose IVIG (100 mg/kg x 3 doses), r-ATG (1. 5 mg/kg x 4 doses) or 
Alemtuzumab (30 mg single dose) and maintenance with tacrolimus, MMF and 
steroids while negative crossmatch recipients received r-ATG or Alemtuzumab 
and maintenance with tacrolimus, MMF and rapid steroid taper (discontinued 
on day 4). One patient in the positive crossmatch group also received high dose 
IVIG as part of desensitization protocol. Protocol biopsies were performed 
at 1, 4 and 12 months and every year thereafter. Acute cellular rejection was 
treated with solumedrol or r-ATG depending upon the severity of rejection and 
antibody mediated rejection (AMR) episodes were treated with solumedrol, 
plasmapharesis, IVIG and rituximab. 
Transplant characteristics, incidence of acute rejection, infection rates, graft 
and patient survival rates are shown in the table. 
 positive 
crossmatch 
SKPT (n=12)
Negative 
crossmatch 
SKPT (n=52)
p value
Previous transplant 42% 2% 0. 0006
PRA 0% 8% 94% 0. 0001
PRA >80% 42% 0% 0. 0001
Biopsy confi rmed clinical acute rejection 42% 10% 0. 015
Subclinical rejection (protocol biopsy) 8% 6% NS
Antibody mediated rejection 42% 0% 0. 0001
CMV infection 8% 17% NS
BK nephropathy 0% 4% NS
Kidney graft survival 83% 96% NS
Pancreas graft survival 67% 92% 0. 03
Patient survival 92% 100% NS
Mean followup in months (median) 20 11 (18) 17 10 (16) NS
SKPT in patients with positive CDC B-cell and/or fl ow cytometry crossmatch 
is associated with high AMR rate despite low dose IVIG and r-ATG/
Alemtuzumab induction. Pancreas graft survival is inferior in patients with 
positive crossmatch while kidney graft and patient survival are similar to that 
of negative crossmatch recipients. Majority of AMR can be reversed with 
treatment but further long-term follow-up is needed to determine the impact 
on graft survival. 
HIGHLY SENSITIZED RENAL TRANSPLANT PATIENTS: 434 
>10 YEARS SINGLE CENTRE EXPERIENCE WITHOUT 
INDUCTION THERAPY. 
M. Christiaans1, J. van Hooff1, M. Gelens1, E. van Duijnhoven1, 
E. van Heurn2, E. van den Berg-Loonen3
1Dept. Internal Medicine, University Hospital Maastricht, 2Dept. Surgery, 
University Hospital Maastricht, 3Tissue-typing laboratory, University 
Hospital Maastricht
Introduction: In Eurotransplant, highly sensitized recipients (PRA>85% in 2 
sera, excluding autoantibodies) are transplanted with XM-negative donor via 
the waiting list or via the AM (acceptable mismatch)-program. In most centres, 
these patients receive induction therapy as additional immunosuppression. 
However, in our centre we at most use triple therapy without induction therapy. 
The purpose of this single-centre study is to provide the data about rejections 
and long term graft survival. 
Methodology: Retrospectively, all hyperimmunized patients transplanted in 
our centre were studied. 
Actuarial death-censored GS (Kaplan Meier) was calculated and compared to 
the overall GS of cadaveric renal transplant recipients in our centre. 
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Results: Between March 1989 and May 2006 873 renal transplants were 
performed in our centre. Of these 47 were highly sensitized, 35 were performed 
under the auspices of the AM program and 12 via the normal waiting list (male 
21, female 26); 43% were 1st graft. Immunosuppression was CNI-based in all 
(CsA 21, Tac 26). Additional IS: low-dose (<10 mg) steroids in all + AZA (18) 
or MMF (19); no induction-therapy was given. 
HLA-mismatch 0  1 2
A  46. 8 46. 8 6. 4
B  36. 2 57. 4 6. 4
DR  46. 8 46. 8 6. 4
1st biopsy-proven rejection < 3 months occurred in 24% and was lower in Tac-
treated patients (p=0. 04). Actuarial GS (censored for death) was as follows: 
1yr 78%, 5yr 76%, and 10 yr 55%. Results were comparable to the overall 
cadaveric renal transplant recipients (GS1 yr 83%, 5yr 72%, 10yr 56%). 
Conclusion: On a single-centre level, cadaveric kidney grafts transplanted in 
highly sensitized recipients without using induction therapy have an acceptable 
rejection rate, especially in Tac treated patients, and excellent long-term graft 
survival. These results are comparable to the results of the overall transplant 
population in our centre. 
RACIAL DIFFERENCES IN THE FREQUENCIES OF HLA-435 
SPECIFIC B CELLS
A.A. Zachary, D. Kopchaliiska, M.S. Leffell, J.K. Melancon
Johns Hopkins University School of Medicine
HLA tetramers are comprised of 4 identical HLA molecules bound to 
streptavidin and have been used, traditionally, to identify T cells specifi c 
for the peptide bound to the HLA molecule. However, we have previously 
shown that HLA tetramers can be used to quantify HLA-specifi c B cells 
and that patients sensitized to the tetramer HLA antigen have signifi cantly 
higher frequencies of B cells specifi c for that antigen. We hypothesized 
that there may be racially determined differences in either the baseline or 
sensitization-provoked increases in frequencies of HLA-specifi c B cells that 
may account for differences in rates of humoral sensitization. We determined 
the frequencies of B cells specifi c for HLA-A2, -A24, and -B7 among two 
groups of blacks and whites: healthy, non-transfused males and sensitized, 
male renal transplant patients. The table shows the frequencies of tet+ cells 
among CD19+ cells and number of subjects in each group. We found higher 
frequencies of HLA-positive B cells among healthy black males which 
reached statistical signifi cance for cells specifi c for A2 and A24. The same 
pattern did not occur among sensitized patients, however, when we examined 
patients who had received a transplant mismatched for the tetramer antigen, 
the HLA-specifi c B cells were appreciably higher among blacks vs. whites for 
A2 and A24 (the antigens for which there were suffi cient patients to make a 
meaningful comparison) with the same percentage (210% for A2 and 158% 
for A24) increase occurring in both racial groups. 
Conclusion: Non-sensitized blacks have higher frequencies of HLA-specifi c 
B cells than do whites. This may account, in part, for a higher incidence 
of sensitization among blacks vs whites. However, once sensitized, the 
proportional increase in B cells appears comparable in the two groups. 
Tetramer: A2 A24 B7
Group Race Freq No. Freq No. Freq No. 
non-
sensitized
black 1. 99 25 2. 69 25 2. 86 25
white 1. 73 26 2. 14 26 2. 61 26
P 0. 01 4x10-6 0. 13
sensitized black 3. 17 12 3. 53 11 5. 29 11
white 3. 10 31 3. 89 16 4. 33 28
mismatched 
for tet 
antigen
black 4. 24 5 4. 28 6
white 3. 64 11 3. 39 5
IT IS NO LONGER ACCEPTABLE TO ALLOCATE 436 
DECEASED DONOR (DD) KIDNEYS TO SENSITISED 
RECIPIENTS (SRS) ON THE BASIS OF A NEGATIVE T CELL 
CROSSMATCH (TNEG CDC XM). 
P. Trevillian1, A. Hibberd1, M. Heer1, A. Gillies2, R. Nanra2, S. Carney2, 
B. Jones2, A. Stein1
1Newcastle Transplant Unit, John Hunter Hospital, 2Department of 
Nephrology, John hunter Hospital
Background: In Australia, DD kidneys are allocated according to an algorithm 
based on shared HLA, dialysis waiting time and a Tneg CDC XM. More 
sensitive assays for detecting anti-HLA antibodies are not routinely used pre-
transplant. In our unit 42% of our wait-listed patients are sensitised to foreign 
HLA (PRA of >20%). In only a minority of these patients is the specifi city of 
the antibodies known pre-transplant. 
Methods: We report the outcomes in 5 recipients (age 21-65, 2M: 3F) of DD 
kidneys who were transplanted across a Tneg CDC XM. Four were known to be 
broadly sensitised (PRA’s = 40, 83, 85, 88%) and one had waited 13 years for 
his fi rst kidney offer (PRA = 11%). Two had lost previous grafts from chronic 
rejection. Single antigen luminex profi les were available in 2 patients and in 
each case donor specifi c antibody (DSAb), anti-MHC class I, was known to be 
present pre-transplant. Three patients were given a single pre-transplant plasma 
exchange and high dose IVIG (500-1000mg/kg) in the hours before surgery. 
One of these was also given pre-emptive Rituximab. 
Results: All 5 grafts suffered severe, accelerated rejection within 72 hours. 
In 2 cases, hyperacute rejection was observed on the operating table (grafts 
turned pink then mottled blue). One of these was removed 24 hours later 
after the recipient developed a life threatening disseminated coagulopathy. 
Histology showed glomerular thrombosis and multiple infarcts but patent large 
vessels. The second patient had classical acute AMR on sequential biopsies and 
remained dialysis dependent until a dramatic response to Campath “rescue” on 
day 22. His function remains stably impaired after 2 years (eGFR=28ml/min). 
Three grafts suffered C4d positive, chronic active AMR and 2 were lost at 3 
and 9 months. The remaining graft continues to function poorly after 2 years 
and appears about to be lost from refractory BK nephropathy. 
All patients received a single dose of Rituximab and one patient received a 
second dose. One patient received a course of OKT3 therapy. The fi ve patients 
received a total of 166 (1- 76) plasma exchange treatments, most with low 
dose IVIG. 
Retrospective testing showed all recipients had a B+ CDC XM and DSAb 
(class I = 2, class I and II = 3) pre-transplant. All had Tpos and Bpos CDC XM 
against donor cells a week post-transplant. 
Conclusions: Organs should no longer be allocated to SR’s on the basis of 
a Tneg CDC XM alone. We call for the introduction of mandatory luminex 
screening of all potential DD transplant recipients in Australia and the 
establishment of an “acceptable mismatch” program of organ allocation. 
CONCURRENT ORAL SESSION 32: 
LIVER DONOR ALLOCATION
DONATION AFTER CARDIAC DEATH LIVER 437 
TRANSPLANTATION DOES NOT INFLUENCE EARLY 
HEPATITIS C RECURRENCE OR OUTCOMES
J. Scalea, L. Campos, B. Philosophe, R. Barth
University of Maryland School of Medicine
Donation after cardiac death liver transplantation expands the available organ 
pool but may be associated with specifi c complications. Little data exists on the 
effect of DCD LTx on recurrence and outcomes with hepatitis C virus (HCV). 
We analyzed results from 22 DCD LTx performed at our center over the last 
5 years. Eleven DCD LTx were performed for HCV cirrhosis, 2 of these were 
performed as combined liver-kidney transplants. Overall, DCD LTx median 
donor age was 24 yrs old (range 16-53), median warm ischemic time (WIT) was 
22 min, and median cold ischemic time was 6. 3 hrs. Median recipient age was 
54 yrs old and MELD score was 26. WIT was shorter for HCV recipients (26 
min vs. 20 min, p=0. 02). HCV patient and graft survival was 91% with a mean 
follow-up of 22 months. Recurrent HCV has been histologically demonstrated 
in 60% patients. Transaminases were not elevated in HCV recipients compared 
to non-HCV recipients at 1 and 6 months; however, by 12 months HCV 
recipients had signifi cant elevation of transaminases (AST 192 vs. 30 U/L, p=0. 
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06; ALT 142 vs. 26 U/L, p=0. 03). No HCV patients have developed cirrhosis 
or experienced graft loss related to recurrent HCV, and only one patient has 
required HCV therapy. Of all 22 DCD LTx, fi ve patients were retransplanted; 
three patients for hepatic artery thrombosis, one for bile duct necrosis, and one 
for hepatic necrosis. The average donor age in retransplanted patients was 40 
yrs old as compared to average donor age of 28 yrs old in other patients (p=0. 
17). Only one of fi ve liver grafts survived when donor age was above 49 yrs 
old. No HCV recipient required retransplantation (p=0. 01). Median time to 
failure in those patients requiring retransplant was 1. 2 months. Our results 
support that DCD LTx can be successfully utilized for HCV patients without 
additional risks of HCV recurrence, early cirrhosis, or graft loss. While HCV 
may be associated with more indolent forms of graft failure, this has not been 
observed with early follow-up. 
EXPANDING DONOR POOL USING STEATOTIC LIVER 438 
GRAFTS
H. Noujaim1, E. Montero2, C. Ribeiro1, R. Gomes1, L. Curvello1, 
F. Crescentini1, M. Casagrande1, J. Rodrigues1, M. de Miranda1, T. Genzini1
1HEPATO – Hospital Benefi cencia Portuguesa De São Paulo, 2UNIFESP
Introduction: The necessity of liver transplant (LTx) has increased each year 
while the number of organs available has not. Options have been developed to 
expand the donors’ liver pool, such as the use of steatotic grafts. 
Purpose: To analyse the outcome of LTx when using grafts with different 
degrees of steatosis. 
Patients and methods: Between May/02 and Feb/08, 115 LTx performed 
in 112 patients were analyzed. In all cases a liver biopsy was performed 2 
hours after graft reperfusion. The 115 LTx were divided according to their 
steatosis degrees in 4 groups: absent –ASG (n=36), mild –MSG (<30%) 
(n=36), moderate- MoSG (30-59%) (n=26), severe – SSG (≥60%) (n=17). 
The following donors´ and recipients´ data were analyzed: demographics data, 
donor body mass index (BMI), MELD score, LTx indications, cold ischemia 
time (CIT) and surgery time, hospital stay. The early (<30days LTx) causes 
of regraft and death were assessed. Patients and grafts survival rates were 
compared among 4 groups using Kaplan-Meier curves. Results signifi cant 
when p<0. 05. 
Results: There was signifi cant difference on patient survival between SSG 
vs ASG (p-0. 005) and graft survival between SSG vs ASG (p-0. 001) and 
SSG vs MSG (p-0. 01). Most of patients had MELD score between 10 and 20: 
60%-MSG, 68%-MoSG, 47%-SSG, 56%- ASG (p-0. 6). 
n- LTx/Pts MSG
 (36/35)
MoSG
 (26/24)
SSG
 (17/17)
ASG
 (36/36)
p
Donors
Age (yrs)
BMI
AST (Ui/ml)
ALT (Ui/ml)
ITU stay (days)
42, 8±15
25, 6±2. 9
115±159
80±104
5, 6±5
42, 7± 12, 3
25, 9±3, 7
98. 5±86. 7
66±47
4±3
40, 5± 14
24. 3±3. 7
105±105
77. 5±56. 7
5±3, 5
45, 5±13. 4
24, 7±2, 5
179±615
116, 10±182
7±5
0. 6
0. 2
0. 8
0. 4
0. 05
Recipients
Age (yrs)
Weigh (kg)
51, 6± 10, 4
73± 15
48±12
78± 17
54± 7, 4
71± 8
51± 10, 5
74. 5± 14. 5
0. 3
0. 4
Waiting time on list 
(days)
522± 435 513±528 682±484 519±411 0. 6
CIT (minutes) 633± 192 602±159 600±135 596± 169 0. 8
Hospital stay (days) 20± 15 17± 12, 3 32, 7± 34 29± 22 0. 04
LTx indications
End stage liver disease
Cirrhosis + Tumor
Fulminante hepatic failure
Re transplant
20 (55. 6%)
14 (38. 9%)
1 (2. 8%)
1 (2. 8%)
18 (69. 2%)
4 (15. 4%)
2 (7. 7%)
2 (7. 7%)
14 (82. 4%)
3 (17. 6%)
0
0
25 (69. 4%)
9 (25%)
2 (5. 6%)
0
0. 3
Patient Survival (%)
 (3, 6, 12m)
95, 85, 80 78, 75, 75 65, 60, 60 100, 100, 90 0. 05
Graft Survival 
 (3, 6, 12m)
95, 85, 80 78, 75, 75 60, 50, 40 100, 100, 90 0. 01
Conclusion: In this study around 69% of liver grafts presented some degree of 
steatosis. Nevertheless, only severe steatosis had negative impact on patients 
and grafts survival rates when compared with other groups´ (mild, moderate 
and absent steatosis). Future research must be carried out to further study and 
therefore improve the results of LTx when using steatotic grafts, since it would 
mean a signifi cant increase in the donors pool. 
LIVER TRANSPLANTATION FROM CONTROLLED NON-439 
HEART BEATING DONORS: A SINGLE CENTER EXPERIENCE 
OF 20 YEARS FOLLOW-UP
S. Yamamoto, H.E. Wilczek, C-G. Groth, B-G. Ericzon
Dept of Transplantation Surgery, Karolinska University Hospital Huddinge
Background: The use of liver graft from non-heart beating donor (NHBD) has 
recently gained renewed interest because of the existing severe organ shortage. 
The greatest hazard with NHBD grafts relates to a prolonged warm ischemia 
in the donor which may cause primary graft dysfunction followed by ischemic 
cholangiopathy. The fi rst liver transplantation in Sweden was done in 1984, 
but brain death criteria were not accepted until 1988. In this study, we have 
retrospectively analysed the long-term outcome in recipients of NHBD livers and 
in recipients of heart-beating donor (HBD) livers done during the same period. 
Methods: During Nov 1984 – May 1988, we performed 40 consecutive liver 
transplantations (LTx) in 32 patients. Twenty-four grafts were from NHBD 
and 16 grafts came from HBD. Eight HBD grafts were imported from other 
European countries and 8 HBD grafts were procured in Sweden. All grafts 
were preserved in Euro-Collins solution. All NHBD met the criteria of brain 
death and were in Maastricht class Category III (controlled NHBD). Donor 
and recipient parameters (gender, age, blood type, diagnosis and preoperative 
hospitalization), operative parameters (operation time, anhepatic time, cold 
ischemia time and blood transfusions), postoperative peak laboratory liver 
values, follow-up liver biopsies and supervening postoperative complications 
were analyzed. 
Results: More females and more preoperative hospitalizations were seen 
in recipients of HBD grafts. No difference regarding donor and operative 
parameters was found between the groups. The two groups had similar 
postoperative peak ASAT, ALAT and total bilirubin. However, signifi cantly 
more hepatic artery thrombosis and biliary complications occurred in the 
NHBD group (p=0. 0033 and p=0. 0345, respectively, log-rank test). Graft and 
patient survival did not differ at any time point between the groups. The one, 5, 
10 and 20 year patient survival after transplantation in non-malignant patients 
was 61. 9%, 42. 9%, 42. 9% and 38. 1% in NHBD, and 63. 6%, 54. 5%, 54. 
5% and 36. 4% in HBD, respectively. (p=N. S. ) Multivariate analysis revealed 
cold ischemia time and peak ALAT to be independent predictive factors for 
poor graft survival in the NHBD group. In 10 cases follow-up liver biopsy was 
done 18-20 years post-LTx and in one case after 6 years. Only in 3 of the 11 
cases signs of chronic rejection were seen and there was no difference of the 
occurrence between NHBD and HBD. 
Conclusion: NHBD grafts had a higher incidence of early occurring hepatic 
artery thrombosis and biliary complications. However, there was no difference 
in the long-term patient and graft survival between the groups. This analysis of 
NHBD graft recipients, with more than 20 year follow-up, makes us believe that 
controlled NHBD grafts can be a feasible option to increase the donor pool. 
OUTCOMES OF LIVER ALLOGRAFTS FROM 440 
DECEASED DONORS WITH A HISTORY OF MAJOR 
ABDOMINAL TRAUMA
D. Verran1, I. Geenen1, M. Crawford1, J. Gallagher1, A. Shun2, M. Stormon2, 
S. Strasser1, G. McCaughan1
1Australian National Liver Transplantation Unit, 2The Childrens Hospital, 
Westmead
Introduction: Major abdominal trauma in a potential organ donor may prevent 
organ donation proceeding or rule out the procurement and usage of intra-
abdominal organs for transplantation. 
Methods: Retrospective review from 1/1986-9/2007 of records of all deceased 
donors with a history of trauma where the liver was procured and transplanted. 
Also a review was performed of all declined deceased donor offers where 
trauma contributed to the donor’s death. During this time period 42/1405 
(2. 9%) of deceased donor offers were declined on the basis of either known 
extensive liver trauma and/or ongoing major intra-abdominal haemorrhage. 
Results: – in 15/312 (4. 8%) of accepted liver allografts there was evidence 
of trauma to the allograft. The recorded injuries were predominantly liver 
lacerations and were graded as Grade 1 (n=7), Grade 2 (n=1), Grade 3 (n=1), 
Grade 4 (n=2) and Grade 5 (n=2). Liver lacerations were predominantly 
managed by conservative measures at the time of allograft implantation 
including argon bean coagulation, usage of fi brin glue (n=2), and suturing 
(n=1). In 3/15 (20%) of the allografts procured major trauma to the right 
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lobe precluded usage of the liver as a whole allograft. Hence 2 left lobes 
[from back table cut down] and one left lateral segment [from in-situ split] 
were procured for transplantation. In 3/15 (20%) of the liver allografts 
intimal trauma of donor vessels required management on the back table 
(suturing of hepatic veins in 2, discarding coeliac axis proximal to the hepatic 
artery in one). The median recipient age was 43[3-69] years (2 paediatric 
recipients). The median cold ischaemic time was 9. 58 (4. 59-15. 5) hours. 
There were no cases of primary non function or initial poor graft function. 
No relaparotomies were required for haemorrhage. The median peak ALT 
and AST post transplantation were 812 (93-2170) IU/ml and 926 (161-1820) 
IU/ml. Patient and allograft survival at 1 year were 9/13 (69%) for primary 
grafts and 10/15 (66%) overall. There were 3 early deaths post transplantation 
[<3 months] from hepatopulmonary syndrome, acute rejection and cerebral 
haemorrhage. The 2 other recipient deaths were due to a cerebrovascular 
accident and renal failure. 
Conclusions: Acceptable results can be achieved using allografts from 
deceased donors with a history of abdominal trauma. Management of the liver 
trauma is dictated by the severity of the trauma. Consideration should be given 
to discarding the right lobe and using the left lobe in cases of severe trauma to 
the right lobe of the liver. 
DOMINO LIVER TRANSPLANTATION (LT) IN 441 
CHILDREN AND ADULTS WITH MAPLE SYRUP URINE 
DISEASE (MSUD)
G. Mazariegos1, A. Khanna2, H. Morton3, K. Strauss3, L. Cropcho4, 
K. Gibson5, Z. Machaidze1, K. Soltys1, G. Bond1, R. Sindhi1
1Hillman Center for Pediatric Transplantation, Children’s Hospital of 
Pittsburgh of UPMC, Pittsburgh, PA, United States, 2University of California 
San Diego, San Diego, CA, United States, 3The Clinic for Special Children, 
Strasburg, PA, United States, 4Clinical Chemistry, University of Pittsburgh, 
Pittsburgh, PA, United States, 5Medical Genetics, University of Pittsburgh, 
Pittsburgh, PA, United States
Background: Classic MSUD has been treated successfully by LT. Extra-
hepatic expression of branched-chain (BC) keto acid dehydrogenase complex 
in non-MSUD patients allows for the consideration of domino LT of MSUD 
livers into these recipients. 
Aim: Data from MSUD patients whose livers were domino transplanted were 
analyzed to develop guidelines for consideration of MSUD livers for domino LT. 
Results: 5 patients underwent LT for MSUD and had their livers transplanted into 
5 non-MSUD patients. Demographic and outcome data are presented in Table 1. 
Table 1. 
MSUD Pt Age (yr)/WT (kg) Domino 
Recipient 
Age/WT
Domino 
Recipient 
Diagnosis
Current 
Follow-Up 
(mo)
25/69 51/61 HCC/HCV 42. 3
31/67. 8 65/83. 8 PSC 18. 2
9/38. 5 22/45. 6 PFIC 5. 5
16/83. 4 18/59 CF 1. 7
21/52. 5 20/90 Congenital Hepatic 
Fibrosis
0. 5
Patient and graft survival is 100% at a mean of 13. 6 months and liver 
function is normal in all. 4/5 MSUD donors received veno-venous bypass 
and hepatic vein back table reconstruction with donor iliac vein. Implantation 
was by piggyback technique in all non-MSUD patients and 2/5 MSUD 
patients. Mean leucine, isoleucine, and valine levels (M/L +/- SD) in 
MSUD patients were 333 +/-159. 9, 125+/-64, 290 +/-119 (Pre) and 205. 
3+/-49. 3, 130. 5 +/-46. 5, and 310 +/-98. 1 (Post) respectively. Non-MSUD 
domino recipient values were normal (138. 3 +/-36. 8, 60+/-28. 1 and 247. 
2+/-58. 1) post LT and BC homeostasis has been maintained on unrestricted 
diet in all pts. One domino recipient underwent successful angioplasty 
of the hepatic venous anastamosis; there were no other complications 
noted related to the domino procedure in either donor or recipient. 
Conclusion: The selected use of explanted livers from MSUD patients 
undergoing LT results in excellent outcomes and additional utility of a scarce 
resource. Technical considerations include the consideration of veno-venous 
bypass and/or reconstruction of the cava to facilitate anastamosis. 
OPTN DATABASE ANALYSIS SUGGESTS THAT THE USE 442 
OF DRI AND MELD AS INSTRUMENTS TO OPTIMIZE THE 
DONOR-RECIPIENT MATCH IN LIVER TRANSPLANTATION
A.W. Avolio1, R. Barbarino1, M. Siciliano1, R. Gaspari2, V. Perilli2, 
S. Agnes1
1Dpt of Surgery – Transplantation Service, Catholic University of Rome, 
Rome, Italy, 2Dpt of Anaesthesiology and Intensive Care Unit, Catholic 
University of Rome, Rome, Italy 
Body: Donor Risk Index (DRI) has been introduced to predict and quantify 
post-transplant graft survival on the basis of donor data. However, also 
recipient conditions strongly infl uence graft survival. Since the MELD has 
been recognized as the best method to score liver disease in liver transplant 
candidates, its prognostic signifi cance has been taken in consideration also for 
the evaluation of the post-transplant graft survival. 
Patients Methods: In order investigate the role of both DRI and MELD in 
predicting 4 year graft survival (4yGS), we retrospectively analyzed the Organ 
Procurement Transplantation Network (OPTN) database relative to 16. 877 
cases in the MELD era. Patients with hepatocarcinoma and re-transplants were 
not included. 
Results: Our results confi rm those reported in the literature on 3yGS (DRI > 
2: 4yGS=61%; DRI 1. 8-2. 0: 4yGS=64%; DRI 1. 6-1. 8: 4yGS=69%; DRI 
1. 4-1. 6: 4yGS=73%; DRI 1. 2-1. 4: 4yGS=78%; DRI <1. 2: 4yGS=84%) 
demonstrating a signifi cant difference between classes (Log-rank, p<0. 01). 
All cases were also stratifi ed in 5 MELD classes: MELD 7-12 (N=2087); 
MELD 13-15 (N=2388); MELD 16-25 (N=8443); MELD 26-39 (N=3695); 
MELD > 39 (N=1264); Log-rank between classes: p<0. 01. For cases with 
MELD < 16 the discrimination power of DRI was week, while for cases with 
MELD 16, DRI put in evidence signifi cant differences in graft survival. In 
other words, patients in the MELD class 16-25 receiving organs with DRI > 2 
achieved 66% 4yGS, while patients in the MELD class > 39 receiving organs 
with the same DRI (> 2) achieved a 4yGS lower than 50%. 
Discussion: Our analysis of 16. 877 OPTN cases demonstrates that to improve 
overall graft survival we should take in consideration the combination of DRI 
and MELD. In particular, high DRI organs should not be transplanted in high 
MELD score patients. 
THE APPLICATION OF MELD SCORE IN PATIENTS 443 
SUBMITTED TO LIVER TRANSPLANTATION – A 
RETROSPECTIVE ANALYSIS OF SURVIVAL AND THE 
PREDICTIVE FACTORS IN THE SHORT AND LONG TERM. 
I. Boin, R. Stucchi, M. Leonardi, J. Almeida, T. Seva-Pereira, E. Udo, 
I. Pereira, C. Portugal, A. Cardoso, C. Caruy
Unit of Liver Transplantation – Unicamp
Introduction: – The model for end-stage liver disease (MELD) was developed 
to predict short-term mortality in patients with cirrhosis. There are few reports 
studying the correlation between meld and long-term posttransplantation survival. 
Aim: The aim was to assess the value of pretransplant MELD in the prediction 
of posttransplant survival. 
Methods: -The adult patients (age > 18 years) who underwent liver 
transplantation were examined in a retrospective longitudinal cohort of 
patients, through the prospective data base. We excluded acute liver failure, 
retransplantation and reduced or split-livers. The liver donors were evaluated 
according to: age, sex, weight, orotracheal intubation time (tracheal-i), 
creatinine, bilirubin, sodium, aspartate aminotransferase, personal antecedents, 
brain death cause, steatosis, expanded criteria donor number and index donor 
risk (IDR – Feng et al. , 2006). The recipients’ data were: sex, age, weight, 
chronic hepatic disease, Child-Turcotte-Pugh (CTP) points, pretransplant 
and initial MELD score, pre and posttransplant creatinine clearance, sodium, 
cold and warm ischemia times, hospital length of stay, surgical time, blood 
requirements, and alanine aminotransferase (ALT > 1, 000UI/l = liver 
dysfunction). The Kaplan-Meier method with the log-rank test was used for the 
univariable analyses of posttransplant patient survival. For the multivariable 
analyses the Cox proportional hazard regression method with the stepwise 
procedure was used with stratifying sodium and MELD as variables. ROC 
curve was used to defi ne AUC for MELD and CTP. 
Results: A total of 232 patients with ten years follow up were analised. Overall 
survival rate was 62. 3%, 47. 7% and 40% respectively for one, fi ve and 10 
years. The MELD cutoff was 20 and CTP cutoff was 11. 5. For MELD score 
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> 20, the risk factors for death were: red cell requirements, liver dysfunction 
and donor’s sodium. For the patients with hyponatremia the risk factors 
were: negative delta-MELD score, red cell requirements, liver dysfunction, 
tracheal-i, and donor’s sodium. The regression univariated analyses came up 
with the following risk factors for death: female sex, warm ischemia time, ICU 
time, score MELD >25, glycemia, blood requirements, tracheal-i, recipient 
creatinine clearance pre and posttransplant and age donor >50. After stepwise 
analyses, only red cell requirement was predictive. Patients with MELD 
score < 25 had a 68. 86%, 50, 44% and 41, 50% chance for one, fi ve and 
ten-year survival and > 25 were 39. 13%, 29. 81% and 22. 36% respectively. 
Patients without hyponatremia were 65. 16%, 50. 28% and 41, 98% and with 
hyponatremia 44. 44%, 34. 28% and 28. 57% respectively. Patients with IDR 
> 1. 7 showed 53. 7%, 27. 71% and 13. 85% and IDR < 1. 7 was 63. 62%, 51. 
4% and 44. 08% respectively. Age donor > 50 years showed 38. 4%, 26. 21% 
and 13. 1% and age donor < 50 years showed 65. 58%, 26. 21% and 13. 1%. 
Association with delta-MELD score did not show any signifi cant difference. 
Expanded criteria donors were associated with primary non-function and 
severe liver dysfunction. Predictive factors for death were blood requirements, 
hyponatremia, liver dysfunction and donor’s sodium. 
Conclusion: MELD over 25, recipient’s hyponatremia, massive blood 
requirements and high donor’s sodium were associated with poor survival. 
EVEROLIMUS AND CONCURRENT ORAL SESSION 33: 
SIROLIMUS IN RENAL TRANSPLANTATION
A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE 444 
THE SAFETY AND EFFICACY OF TWO DIFFERENT 
SIROLIMUS (SRL) REGIMENS WITH TACROLIMUS (TAC) + 
MYCOPHENOLATE MOFETIL (MMF) IN DE NOVO RENAL 
ALLOGRAFT RECIPIENTS: PRELIMINARY 2-YEAR SAFETY 
RESULTS FROM THE ORION TRIAL
S. Flechner1, S. Cockfi eld2, J. Grinyo3, G. Russ4, K.M. Wissing5, 
C. Legendre6, J.B. Copley, for the ORION Trial Investigators7
1Cleveland Clinic Foundation, Cleveland, OH, 2University of Alberta, 
Edmonton, Alberta, 3Hospital Bellvitge, Barcelona, Spain, 4Queen Elizabeth 
Hospital, Woodville South, Australia, 5Hôpital Erasme, Brussels, Belgium, 
6Hôpital Necker, Paris, France, 7Wyeth Pharmaceuticals, Collegeville, PA
Purpose: Compare the safety of 2 SRL regimens with TAC + MMF in renal 
transplant recipients. 
Methods: This open-label, randomized, multinational study enrolled 451 
renal transplant recipients. Group 1: SRL (8-15 ng/mL, 12-20 ng/mL after 
week 13) + TAC (6-15 ng/mL) with elimination at week 13 (n=155); Group 
2: SRL (10-15 ng/mL through week 26, 8-15 ng/mL thereafter) + MMF (up 
to 2 gm/day) (n=155); or Group 3: TAC (8-15 ng/mL through week 26, 5-15 
ng/mL thereafter) + MMF (up to 2 gm/day) (n=141). All patients received 
corticosteroids and daclizumab. Because of increased acute rejection rates, 
Group 2 was terminated in June 2006 (after all patients were accrued). Off-
therapy adverse events were collected for 1 month in all subjects after off-
therapy date and after group 2 termination. 
Results: At 2 years, investigator-reported AEs that were more frequent in 
Group 1 included abnormal liver function tests, acne, generalized edema, 
hyperkalemia, and proteinuria. In Group 2, these AEs were delayed wound 
healing, hyperlipidemia, and thrombocytopenia. In Group 3, dysuria, 
nervousness, sweating, and tremor were reported more frequently. Serum 
potassium levels were signifi cantly higher in Group 3 through most of the 
study. Incidence of malignancies and anemia were similar among groups. 
Group 11
 (SRL+TAC-
Elim)
Group 21
 (SRL+MMF)
Group 31
(TAC+MMF)
Overall 
p-Value
Anemia, 
(%)
63/155 
(40. 6)
73/155 
(47. 1)
50/141 
(35. 5)
0. 126
Erythropoietin use, 
2 (%) 
55/155 (35. 5) 64/155 (41. 3) 36/141 (25. 5) 0. 015
Delayed wound 
healing, (%)
26/155 (16. 8) 39/155 (25. 2) 8/141 (5. 7) <0. 001
Hyperkalemia, (%) 37/155 (23. 9) 18/155 (11. 6) 24/141 (17. 0) 0. 017
Hyperlipidemia, 
(%)
55/155 (35. 5) 64/155 (41. 3) 30/141 (21. 3) <0. 001
Lipid lowering 
medication use, 
2 (%)
94/155 (60. 6) 90/155 (58. 1) 69/141 (48. 9) 0. 106
Lymphoceles, (%) 23/155 (14. 8) 22/155 (14. 2) 11/141 (7. 8) 0. 121
All malignancies, 
3 (%)
7/155 (4. 5) 3/155 (1. 9) 4/141 (2. 8) 0. 435
Median UPr/Cr 
(range), n4
 0. 21 
 (0. 04-1. 78), (44)
0. 14 
 (0. 02-2. 10), (4)
0. 13 
 (0. 00-1. 33), (59)
0. 037
Tremor, (%) 34/155 (21. 9) 12/155 (7. 7) 34/141 (24. 1) <0. 001
1Collected for 2 years in groups 1 and 3; to time of study termination in group 2. 
2 Concomitant, not prior to study enrollment; cumulative to completion or subject discontinuation
3Collected for 2 years in all groups. 42-year data
Conclusion: Overall, SRL immunotherapy appears safe and well tolerated, 
with a safety profi le similar to TAC+MMF. In patients receiving SRL+MMF, 
delayed wound healing and hyperlipidemia were more frequent. Tremor was 
more frequent in the TAC-MMF group, which also had higher levels of serum 
potassium. While proteinuria was signifi cantly greater in Group 1, it was 
minimal in all groups. 
CARDIOVASCULAR RISK PROFILE OF RENAL 445 
TRANSPLANT RECIPIENTS ENROLLED IN AN OPEN-
LABEL, RANDOMIZED STUDY COMPARING 2 SIROLIMUS 
(SRL) REGIMENS WITH A TACROLIMUS (TAC) + 
MYCOPHENOLATE REGIMEN (MMF): PRELIMINARY 
RESULTS FROM THE ORION TRIAL
G. Russ1, S.M. Flechner2, S. Cockfi eld3, J. Grinyo4, K.M. Wissing5, 
C. Legendre6, J.B. Copley, for the ORION Trial Investigators7
1Queen Elizabeth Hospital, Woodville South, Australia, 2Cleveland Clinic 
Foundation, Cleveland, OH, 3University of Alberta, Edmonton, Alberta, 
4Hospital Bellvitge, Barcelona, Spain, 5Hopital Erasme, Brussels, Belgium, 
6Hôpital Necker, Paris, France, 7Wyeth Research, Collegeville, PA
Purpose: We analyzed cardiovascular (CV) risk factors in renal transplant 
patients receiving 2 SRL regimens versus TAC+MMF. 
Methods: 451 patients were randomly assigned to receive SRL (8-15 ng/mL, 
then 12-20 ng/mL after week 13) + TAC (6-15 ng/mL) with elimination at 
week 13 (n=155); SRL (10-15 ng/mL, 8-15 ng/mL after week 26) + MMF 
(up to 2 gm/day) (n=155); or TAC (8-15 ng/mL, 5-15 ng/mL after week 26) 
+ MMF (up to 2 gm/day) (n=141). All patients received corticosteroids and 
daclizumab. SRL+MMF group was terminated in June 2006 (after all patients 
were accrued) due to higher rates of acute rejection. 
Results: The table shows 18-month on-therapy blood pressure, laboratory, and 
ESA data. Blood pressure and use of antihypertensive medications were similar 
among groups. Total cholesterol and triglycerides were signifi cantly higher in 
both SRL groups; LDL cholesterol was signifi cantly higher in SRL+TAC-Elim 
group; HDL cholesterol and use of lipid-lowering medications were similar 
among groups. Hemoglobin differences were not clinically signifi cant between 
groups. New-onset diabetes mellitus was signifi cantly higher in SRL+TAC-
Elim group (p<0. 001 vs SRL+MMF; p<0. 05 vs TAC+MMF). Of note, 21/120 
patients in SRL+TAC-Elim group were receiving TAC at time of onset of 
diabetes. Proteinuria, although signifi cantly higher in SRL+TAC-Elim group, 
was minimal in all groups. 
SRL+TAC-Elim SRL+MMF TAC+MMF
Mean systolic BP, 
mmHg (n)
134. 5 (64) 132. 9 (52) 134. 2 (94)
Mean diastolic BP, 
mmHg (n)
78. 4 (64) 75. 7 (52) 79. 0 (94)
Antihypertensive agents, 
1 n (%)
136 (87. 7) 133 (85. 8) 126 (89. 4)
Mean total cholesterol, 
mg/dL (n)
222. 0 (65)*** 213. 1 (52)** 188. 0 (86)
Mean HDL cholesterol, 
mg/dL (n)
57. 9 (62) 59. 1 (52) 54. 4 (80)
Mean LDL cholesterol, 
mg/dL (n)
120. 5 (56)** 115. 1 (51) 101. 9 (80)
Mean triglycerides, mg/
dL (n)
228. 3 (64)*** 221. 2 (52)**  153. 1 (85)
Lipid-lowering agents, 
1 n (%)
94 (60. 6) 90 (58. 1) 69 (48. 9)
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Mean hemoglobin, g/
dL (n)
13. 5 (65) 13. 0 (52)* 13. 7 (93)
ESA, n 6 7 3
New-onset diabetes 
mellitus, 2
27/120*† 7/117 12/110
Median UPr/Cr (range) 
(n)
 0. 28 (0. 06-2. 60), 
(44)**
0. 20 (0. 04-1. 15), (47) 0. 15 (0. 00-1. 21), (58)
1Concomitant, not prior to study enrollment; cumulative to completion or subject discontinuation
2Defi ned: >30 days on oral hypoglycemic agents, insulin, or their combination and no pre-existing 
diabetes; data cutoff in June 2006. 
*p<0. 05, **p<0. 01, ***p<0. 001 vs TAC+MMF; †p<0. 001 vs SRL+MMF. 
Conclusion: CV risk profi le at 18 months varies among groups. Lipids were 
adversely affected by SRL use. New-onset diabetes mellitus was more common 
when SRL was combined with TAC; and numerically lowest with SRL+MMF. 
Whether anti-atherogenic properties of SRL offset adverse effects on lipid 
panels remains to be studied. 
A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE 446 
THE SAFETY AND EFFICACY OF CYCLOSPORINE (CSA) 
DOSE REDUCTION WITH CSA ELIMINATION IN DE NOVO 
RENAL ALLOGRAFT PATIENTS RECEIVING SIROLIMUS
H. Tedesco-Silva1, J.M. Pestana1, F. Alfi eri2, S. See-Tai3, for the Brazilian 
Rapamune Study Group
1Hospital do Rim e Hipertensão, São Paulo, Brazil, 2Wyeth Brazil, São Paulo, 
Brazil, 3Wyeth Research, Collegeville, PA, USA
Purpose: The safety and effi cacy of concentration-controlled sirolimus (SRL) 
combined with reduced cyclosporine (CsA) exposure or CsA elimination at 3 
months was compared. 
Methods: This phase 4, open-label trial enrolled 207 patients at 9 centers in 
Brazil between March 2004 and November 2005. Renal transplant recipients 
were randomly assigned (1: 1) after transplantation to Group I: SRL (8-12 ng/
mL) + CsA minimization (125-250 ng/mL weeks 1-12, 50-100 ng/mL weeks 
13-21, then 50-75 ng/mL thereafter); or Group II: SRL (8-12 ng/mL weeks 1-12, 
12-20 ng/mL weeks 13-21, then 10-20 ng/mL thereafter) + CsA elimination 
(125-250 ng/mL weeks 1-12, then 25% taper/week beginning at week 13). 
All patients received corticosteroids. Antibody induction was permitted. The 
primary endpoint was renal function at 12 months. 
Results: Demographic characteristics were similar between groups. A similar 
percentage of patients received living donor kidneys (70% Group I, 69% Group 
II) and antibody induction (9. 5% Group I, 12. 7% Group II). The incidence of 
delayed graft function was not signifi cantly different between groups. At 12 
months, renal function was similar between groups. Slope analysis of Nankivell 
GFR (day 5 to month 12) showed improvement in both groups, with a higher 
mean annual GFR change in Group II (12. 96 mL/min/yr) versus Group I (6. 
74 mL/min/yr); the difference between groups was not statistically signifi cant 
(p=0. 06). Rates of biopsy-confi rmed acute rejection (BCAR) at 3 months were 
12. 4% in Group I versus 16. 7% in Group II (p=0. 43), and 14. 3% versus 22. 
5% at 12 months (p=0. 152). Patient and graft survival were not signifi cantly 
different (ITT) between groups at 12 months. Patient discontinuation was 
similar between Groups I and II (32. 4% and 36. 3%, respectively), although 
more Group II patients discontinued because of lack of effi cacy/graft loss (4. 
8% vs 14. 7%, p=0. 018). Polycythemia and pneumonia were reported more 
frequently in Group I, whereas abdominal pain and acne were more frequent 
in Group II. 
Group I (SRL+CsA 
minimization)
Group II (SRL+CsA 
elimination) p-Value
Nankivell GFR, on 
therapy, mL/min (n)
61. 1 (71) 65. 2 (65) 0. 132
Nankivell GFR, ITT, * 
mL/min (n)
49. 5 (105) 51. 6 (102) 0. 603
Serum creatinine, ITT, 
μmol/L (n)
146. 2 (87) 148. 3 (86) 0. 831
BCAR, ITT, n (%) 15/105 (14. 3) 23/102 (22. 5) 0. 152
Graft survival, including 
death, n (%)
92/105 (87. 6) 90/102 (88. 2) 1. 000
Patient survival, n (%) 94/105 (89. 5) 94/102 (92. 2) 0. 632
Delayed graft function, 
n (%)
14/105 (13. 3) 17/102 (16. 7) 0. 562
*GFR=0 for graft loss, death, or missing values
Conclusion: The comparative safety and effi cacy of SRL immunotherapy 
combined with low-dose CsA or CsA elimination was similar regarding renal 
function, patient and graft survival, BCAR, and patient discontinuations from 
treatment. 
EXPOSURE TO EVEROLIMUS, AND NOT TO 447 
CYCLOSPORINE, IS ASSOCIATED WITH FREEDOM FROM 
ACUTE REJECTION IN DE NOVO RENAL RECIPIENTS
G. Corbetta1, M. Salvadori2, M.P. Scolari3, F. Citterio4, P. Rigotti5, M. Cossu6, 
A. Dal Canton7, G. Tisone8, D. Bonucchi9, F. Pisani10, G. Gubbiotti11, 
G. Piredda12, E. Minetti13, V. Sparacino14, V. Goepel15, P. Messa16, 
P.B. Berloco17, D. Montanaro18, P. Veroux19, S. Federico20 and M. Bartezaghi1. 
1Novartis Farma SpA, Origgio (Va); 2Careggi Policlinico Hospital, Florence; 
3S. Orsola-Malpighi University Hospital, Bologna; 4A. Gemelli University 
Hospital, Rome; 5Policlinico University Hospital, Padua; 6SS Annunziata 
Civile Hospital, Sassari; 7IRCCS Policlinico S. Matteo University Hospital, 
Pavia; 8Tor Vergata University, Rome; 9Policlinico University Hospital, 
Modena; 10S. Salvatore Civile Hospital, Coppito (Aq); 11S. Maria della 
Misericordia Hospital, Perugia; 12S. Michele Hospital, Cagliari; 13Niguarda 
Cà Granda Hospital, Milano; 14Civico Hospital, Palermo; 15S. Bortolo 
Hospital, Vicenza; 16IRCCS Fondazione Policlinico Hospital, Milano; 
17Policlinico Umberto I University Hospital, Rome; 18S. Maria della 
Misericordia Hospital, Udine; 19Policlinico University Hospital, Catania; 
20Federico II University Hospital, Naples. 
Background: Concentration-controlled everolimus (EVRL) is highly effective 
in preventing acute rejection (AR) after renal transplantation (Rtx) when 
used in combination with reduced-exposure cyclosporine (CsA). Previous 
analyses showed that low EVRL trough blood levels (BL) correlate with 
the risk of AR, and a C0 of 3ng/mL (HPLC) was identifi ed as the lower 
therapeutic limit for EVRL when used with conventionally dosed CsA. Since 
reduced calcineurin inhibitor (CNI) exposure may provide long-term clinical 
benefi ts, the EVEREST (the upper target EVErolimus RandomizEd STudy) 
trial investigated whether concentration-controlled EVRL targeting ‘upper’ 
BL (8–12ng/mL) allows a further reduction in CsA exposure without loss of 
effi cacy. The present analysis examined how EVRL and CsA BL affect the risk 
of biopsy-proven AR (BPAR). 
Methods: A 6-month, multicenter, randomized, parallel-group study in Rtx 
patients (n=285) compared two immunosuppressive regimens: A) upper EVRL 
(C0 8–12ng/mL) with very low-dose CsA (C2 600ng/mL, tapered to 300ng/mL 
at M3); B) standard EVRL (C0 3–8ng/mL) with low-dose CsA (C2 600ng/mL, 
tapered to 500ng/mL at M3). All centers determined EVRL C0 locally with the 
FPIA immunoassay (Seradyn). A hazard model with time-dependent covariates 
was used to conduct a survival analysis examining the infl uence of EVRL and 
CsA BL on the risk of BPAR. Hazard rates (HR) for BPAR were determined 
for several combinations of EVRL C0 and CsA C2 at four time points (D8, 
D14, M1 and M3). 
Results: Actual mean drug BL changed with time (EVRL from 6. 1 to 8. 2ng/
mL; CsA from 734 to 511ng/mL; see Table 1). The overall proportion of BPAR 
(Kaplan-Meier) increased from 0. 03 at D8 to 0. 11 at M3. At M1 and M3 there 
was a statistically signifi cant correlation between a low EVRL C0 and increased 
risk of BPAR (p<0. 05). On the other hand, there was no signifi cant correlation 
between CsA C2 levels and BPAR (p=NS). At M1, the simulation showed that 
the risk of BPAR would signifi cantly decrease if EVRL C0 was increased by 
50% (HR 0. 31, p<0. 05) and increase if it were reduced by 25% (HR 1. 79, 
p<0. 05). However, decreasing the CsA exposure by 25% would not change the 
risk of BPAR (HR 1. 07, p=NS). A similar pattern was evident at M3. 
Conclusions: Targeting an EVRL C0 between 8 and 12 ng/mL (FPIA) would 
allow CsA C2 levels to be reduced even further, without compromising effi cacy 
and safety in de novo renal transplant recipients. Further studies are needed 
to investigate if this approach of early and marked CsA minimization may 
translate into improved long-term renal function. 
Table 1. Hazard rates (HR) for BPAR in relation to EVRL (C0) and CsA (C2) 
exposure. 
 Mean BL (ng/mL) Calculated HR for 
BPAR 
 EVRL 
C0
CsA C2 Overall 
BPAR 
rate
Increase 
EVRL 
by 50%
Increase 
CsA by 
50%
Decrease 
EVRL 
by 25%
Decrease 
CsA by 
25%
D8 6. 1 734 0. 03 0. 71 0. 39 1. 19 1. 59
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D14 7. 0 679 0. 05 0. 55 0. 83 1. 35 1. 10
M1 8. 1 631 0. 07 0. 31* 0. 9 1. 79* 1. 07
M3 8. 2 511 0. 11 0. 44* 0. 74 1. 51* 1. 16
TARGETING UPPER EVEROLIMUS BLOOD LEVELS 448 
WITH VERY LOW-DOSE CYCLOSPORINE IS EFFECTIVE AND 
SAFE IN DE NOVO RENAL TRANSPLANTATION
M. Salvadori1, M. Scolari2, E. Bertoni1, F. Citterio3, P. Rigotti4, M. Cossu5, A. 
Dal Canton6, G. Tisone7, G. Cappelli8, F. Pisani9
1Renal Unit Careggi University Hospital, 2S. Orsola-Malpighi University 
Hospital, Bologna, 3A. Gemelli University Hospital, Rome, 4Policlinico 
University Hospital, Padua, 5SS Annunziata Civile Hospital, Sassari, 6IRCCS 
Policlinico S. Matteo University Hospital, Pavia, 7Tor Vergata University, 
Rome, 8Policlinico University Hospital, Modena, 9S. Salvatore Civile 
Hospital, Coppito (Aq)
Background: Everolimus (EVRL), a proliferation signal inhibitor, is highly 
effective in preventing acute rejection (AR) after renal transplantation (Rtx) 
and allows calcineurin inhibitor (CNI) reduction without loss of effi cacy. In 
patients treated with standard EVRL and low-dose cyclosporine (CsA), higher 
trough EVRL blood levels (C0) were associated with a reduced risk of AR. 
The lower therapeutic concentration limit for EVRL was set at 3ng/mL. No 
dose-limiting toxicities were observed up to the highest C0 of 15ng/mL. The 
EVEREST (the upper target EVErolimus RandomizEd STudy) trial investigated 
whether increased EVRL exposure targeting upper EVRL C0 (8–12ng/mL), in 
combination with a further reduction in CsA exposure, would maintain effi cacy 
for prevention of AR whilst improving renal function. 
Methods: In a 6-month, prospective, randomized, multicentre, open-label trial, 
de novo Rtx patients (Table 1) received either (1) upper EVRL blood levels 
(8–12ng/mL) plus very low-dose CsA (C2 600ng/mL, tapered to 250ng/mL 
by M6) or (2) standard EVRL (C0 3–8ng/mL) with low-dose CsA (C2 600ng/
mL, tapered to 400ng/mL by M6). All patients received basiliximab (20mg i. 
v. D0, D4) and low-dose steroids. Primary endpoints were biopsy-proven acute 
rejection (BPAR) and 6-month renal function (GFR, Nankivell). EVRL blood 
levels were measured locally with Seradyn® immunoassay (FPIA). 
Results: In the upper EVRL group there was a signifi cantly reduced rate of 
graft loss compared to standard EVRL, with both regimens having a low 
rate of BPAR and excellent renal function (p=NS) as early as 1 month after 
transplantation (Table 2). There were no signifi cant differences between 
groups regarding main adverse events (including hyperlipidemia, leucopenia 
or infections), biochemical parameters or vital signs. 
Table 1: Patient characteristics
 Upper EVRL Standard EVRL
No. of patients 142 143
Recipient age (years) 45. 4±12 45. 8±11
Deceased donor (%) 97. 2 97. 9
Donor age (years) 43. 8±14 44. 6±13
Mean PRA (%) 1. 6±6. 5 2. 1±7. 2
Mean no. of HLA mismatches 3. 4±1. 2 3. 5±1. 2
Cold ischemia time 13. 8±4. 9 14. 5±4. 7
Table 2: 6-month results
 Upper EVRL Standard EVRL P
Delayed graft function 
requiring dialysis (%) 23. 2 30. 8 NS
Probability of patient 
survival (%) 98. 6 98. 6 NS
Probability of graft 
survival (death 
censored) (%)
97. 9 90. 2 <0. 05
Probability of graft 
survival (not censored 
for death) (%)
96. 5 88. 8 <0. 01
Probability of BPAR 
(%) 11. 9 14. 7 NS
Steroid-resistant AR (%) 2. 1 6. 3 NS
BPAR ≥Grade II (%) 2. 8 7. 7 0. 07
Probability of treatment 
failure (death, graft loss, 
BPAR, LFUP)
14. 8 21. 0 NS
1-month GFR (mL/min) 58. 9±22. 2 56. 7±23. 2 NS
6-month GFR (mL/min) 60. 0±16. 4 62. 3±15. 6 NS
Conclusions: In de novo Rtx patients, increased EVRL C0 (8–12ng/mL) 
combined with early reduction to very low-dose CsA was associated with a 
reduced risk of graft loss in comparison with the control group. Both groups 
had a low rate of BPAR and excellent renal function. Concentration-controlled 
EVRL targeting a higher trough level (8–12ng/mL by FPIA) allows a marked 
early reduction in CNI exposure without loss of effi cacy, which may provide 
long-term clinical benefi ts through further minimization of CNI side effects. 
A PHASE II RANDOMIZED PHARMACOKINETIC 449 
(PK) STUDY OF TACROLIMUS (TAC)-EVEROLIMUS (EVL) 
COMBINATION FOR KIDNEY TRANSPLANTATION (KT)
D. Del Castillo1, J. Pascual2, M. Cabello3, L. Pallardó4, J.M. Grinyó5, 
A.M. Fernández2, M. Brunet6
1Servicio de Nefrología, Hospital Reina Sofía, 2Hospital Ramón y Cajal, 3Hospital 
Carlos Haya, 4Hospital Dr Peset, 5Hospital de Bellvitge, 6Hospital Clínic
Tac-sirolimus combination in KT yields worse results than Tac-MMF. 
However, the antiproliferative and antifi brotic effects of mTOR inhibitors 
are promising in prevention of chronic allograft damage, and new strategies 
for early use are justifi ed. The combination Tac-EVL is attractive but 
scarcely developed to date. An investigator driven phase II PK study was 
done in 5 Spanish centers randomly comparing two fi xed EVL dosages (0. 
75 vs 1. 5 mg bid) in combination with Tac (0. 075 mg/kg bid for trough 
levels 10-15 two weeks and then 5-10 ng/ml). No antibody induction was 
allowed and all patients received steroid therapy. Complete 12-h PK curves 
of both drugs (HPLC) were performed at days 4, 14 and 42 post-KT. After 
day 42, EVL trough levels were adjusted at 3-8 and Tac at 5-8 ng/ml. 
Thirty-fi ve patients were randomized; in 34 (17 vs 17) full PK curve was 
performed at day 4, in 27 (13 vs 14) at day 14 and in 26 (15 vs 11) at day 
42. Doses, trough and maximal levels (Cmin, Cmax) and area under the 
curve (AUC) are summarized [*signifi cantly higher 1. 5 vs 3 EVL dose 
groups, p<0. 01] 
 DAY 4 DAY 14 DAY 42
EVL 
Daily 
Dose 
(mg)
1. 5 3 1. 5 3 1. 5 3
Tac Daily 
Dose (mg)
12 12 10 12. 5 6 9
EVL Cmin 
(ng/ml)
1. 1 1. 7* 1. 9 2. 6* 2. 4 3. 2
EVL Cmax 
(ng/ml)
4. 1 10. 1* 6 13. 4* 5. 9 12. 4*
EVL AUC 
(ng x h/ml)
26. 5 40. 9* 30. 3 49. 9* 36. 3 57. 2*
Tac Cmin 
(ng/ml)
10. 6 8. 1 11. 4 10. 1 11. 4 10. 1
Tac Cmax 
(ng/ml)
32. 9 36. 6 27. 4 36 26. 4 25. 9
Tac AUC (ng 
x h/ml)
192. 2 154. 2 159. 4 214. 3 159. 6 177. 6
Tac AUC/
dose
16. 0 12. 8 15. 9 17. 1 26. 6 19. 7
Treated acute rejection rate was 17% (3 cases with each dosage), wound 
healing was uneventful in 100% and linfocele was diagnosed in 2 cases (6%). 
Including all PK points, a higher Tac Cmin was observed with the low EVL 
dose of 1. 5 mg/d (Tac 11. 16. 4 with EVL 1. 5 vs 9. 45. 0 ng/ml with EVL 3, 
p=0. 03), with equivalent Tac AUCs (16261 vs 17175, p=0. 70). EVL Cmin, 
Cmax and AUC were very low with the initial dose of 0. 75 mg bid when 
combined with Tac. The EVL 1. 5 mg bid seems to be the minimal initial 
advisable dose for phase III trials. This dose is low to achieve >3 ng/ml during 
the fi rst 2 weeks, thus therapeutic drug monitoring is necessary to adjust it 
after day 4th, especially in Tac-minimization regimens. This low exposure 
EVL plus normal exposure Tac allowed 0% wound healing problems with 
good effi cacy. For Tac-minimization strategies, everolimus dosages above 3 
mg/day are needed. 
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COMPARISON AT ONE YEAR OF INTERSTITIAL 450 
FIBROSIS (IF) BY AUTOMATIC QUANTIFICATION IN RENAL 
TRANSPLANT RECIPIENTS (RTR) WITH CYCLOSPORINE 
(CSA) DISCONTINUATION AND SIROLIMUS (SRL) 
INTRODUCTION 
E. Thervet1, A. Servais1, V. Meas-Yedid2, Y. Lebranchu3, I. Etienne4, 
G. Touchard5, C. Legendre1, P.F. Westeel6, C. Olivo-Marin2
1Department of Transplantation, Hopital Necker, 2Laboratoire analyse image 
quantitative, Institut Pasteur, 3Service de Nephrologie, Hopital Bretonneau, 
Tours, 4Service de Nephrologie, Hopital Bois Guillaume, Rouen, 5Service 
de Nephrologie, Hopital Jean Bernard, Poitiers, 6Service de Nephrologie, 
Hopital Sud, Amiens
Introduction: CsA conversion to SRL at week (W) 12 is associated with a 
signifi cant improvement in renal function. The aim of this study was to investigate 
the effect of this conversion on interstitial fi brosis (IF), landmark of chronic 
allograft nephropathy (CAN), in patients included in this prospective study. 
Methods: The multicenter, prospective, randomized trial included 235 renal 
recipients randomized at W12 to be switched from CsA to SRL (group A) or 
to continue CsA (group B), in association with MMF. Routine allograft biopsy 
(RB) was performed at W52 and a section imaged using a colour video camera 
was analyzed by a program of colour segmentation image analysis which 
automatically extract green colour areas characteristic of IF. Results were 
expressed of% of IF and using Banff classifi cation (grade I : <25%, grade II : 
25-50% and grade III, > 50%). 
Results: Despite signifi cant improvement of renal function at W52, we 
observed no difference on RB. On the other hand, there was a positive 
correlation between renal function and the%IF on RB. HIgher than grade I IF 
was diagnosed in more than 50% of patients. 
Conclusion: Despite signifi cant improvement in renal function after CsA 
to SRL conversion at 3 months, we found no improvement of IF on RB at 
W52. This may be due to a longer delay to observe histological improvement. 
Improved renal function may be due to a hemodynamic effect. Finally, the 
higher IF score than the one previously reported by others may be explained by 
the use of expanded criteria donors. This urges the need for a better description 
of the chronic lesion on RB. 
Mean IF (%) Grade I (%) Grade II (%) Grade III (%)
Intent to treatment
Sirolimus (n=58) 27±15  47. 5% 45. 8%  6. 8%
Cyclosporine (n = 59) 27±15  44. 8% 48. 3%  6. 9%
On treatment
Sirolimus (52)  26±15  50%  44%  6%
Cyclosporine (n=56) 27±15  46%  46%  8%
THE INCIDENCE OF DELAYED GRAFT FUNCTION 451 
(DGF) FOLLOWING KIDNEY TRANSPLANTATION IS NOT 
AFFECTED BY DE NOVO EVEROLIMUS THERAPY
C. Legendre5, E. Cassuto1, L. Rostaing2, F. Berthoux3, M.C. Moal4, 
F. di Giambatttista6, J. Dantal7
1Hôpital Pasteur, 2Hôpital de Rangueil, 3Hôpital Nord – CHU, 4Hôpital La 
Cavale Blanche, 5Hôpital Necker, 6Novartis Pharma SAS, 7Hôpital Hôtel Dieu
Introduction: The proliferation signal inhibitor (PSI) everolimus combines 
effective immunosuppressive and anti-proliferative modes of action. The 
early post-operative course of kidney transplant patients at risk of delayed 
graft function (DGF) was evaluated with de novo everolimus versus delayed 
everolimus after one month of mycophenolic acid (MPA). 
Methods: We report a planned primary 3-month analysis from a multicenter, 
open-label, 12-month study. Patients were de novo deceased-donor kidney 
transplant recipients at protocol-specifi ed risk of DGF, with one or more 
of the following characteristics: donor age >55 years, cold ischemia time 
≥24 hours and <40 hours, or second/subsequent transplant. Patients were 
randomized to receive de novo (E) or delayed everolimus (DE) after 1 month 
of MPA treatment. The target trough range for everolimus was 3-8ng/mL. 
For E patients, everolimus was initiated ≤48 hours post-transplant, with low-
exposure cyclosporine (CsA, C2 target: weeks 0-8, 500-700ng/mL; thereafter 
350-450ng/mL). The DE group received de novo MPA with standard CsA (C2 
target 1100-1500ng/mL); after 4 weeks, MPA was replaced by everolimus 
and CsA target C2 range was reduced. All patients received anti-IL-2 receptor 
induction and steroids. 
Results: In total, 139 patients were enrolled (65 E, 74 DE). In the E and DE 
groups, respectively, donor age was >55 years in 80. 0% and 90. 5%, cold 
ischemia time was ≥24 hours in 30. 8% and 33. 8%, and 10. 8% and 2. 7% 
of patients had undergone one previous transplant. The primary endpoint (a 
composite of biopsy-proven acute rejection [BPAR], graft loss, death, DGF 
defi ned as 1 dialysis session during days 2-7 post-transplant, wound healing 
events or lost to follow-up at month 3) occurred in 36 E patients (55. 4%) and 
42 DE patients (56. 8%). There were 8 graft losses (5 E, 3 DE) and 6 deaths (4 
E, 2 DE) by month 3. There was a similar rate of BPAR with E (10. 8%) or DE 
(9. 5%). The incidence of DGF was also similar in the E and DE groups (24. 
6% and 24. 3%, respectively). At month 3, creatinine clearance (Cockcroft-
Gault) was 43. 117. 6mL/min in the E group versus 41. 817. 0mL/min in the 
DE group (n. s. ). Wound healing events occurred in 38. 5% E patients and 35. 
1% DE patients, most of which were fl uid collections (25/25 and 24/26 events 
in E and DE patients, respectively). Prior to MPA discontinuation at week 4, 
no signifi cant differences in fl uid collections were detected on ultrasound: 
18/49 (36. 7%) E patients and 19/55 (34. 5%) DE patients. The incidence of 
adverse events and infections was similar between groups at month 3. Study 
drug was discontinued due to adverse events in 18. 5% E patients and 20. 3% 
DE patients. 
Conclusions: In kidney recipients at risk of DGF, the rate of DGF, and effi cacy 
and safety profi les at month 3, were similar between de novo versus delayed 
initiation of everolimus after 1 month of MPA. 
POST-TRANSPLANT PROTEINURIA INDUCED BY 452 
EVEROLIMUS (E). DEFINITION OF MAIN FEATURES BASED 
ON COMBINED PATHOLOGY AND PROTEOMICS APPROACH. 
E. Bertoni1, A. Larti1, L. Musante2, G.M. Ghiggeri2, R. Gusmano2, 
M. Salvadori1
1Renal Unit Careggi University Hospital, 2Laboratory on Pthophysiology of 
Uremia Gaslini Hospital
Little is known on the mechanism (s) of proteinuria linked to everolimus 
(E) and reports on the clinical outcome are limited. Aim of this study was to 
characterize the E induced proteinuria and to verify whether proteinuria was 
linked to apoptosis of renal cells. 
We report clinical, pathology and laboratory features of 24 recipients of renal 
Tx who were treated with E as fi rst line drug and were followed for at least 6 
months without changes of the therapy (median follow-up 8 months). Urinary 
proteins were characterized by an integrated proteomics approach (quantitative 
assays, two-dimensional electrophoresis, MALDI-TOFF, western blot). 
Detection of renal cells apoptosis was performed by analysis of renal biopsies 
with caspase 3 antibodies. 
All but 3 recipients presented rapid normalization of renal function; 2 patients 
were treated with steroid boluses because of acute rejection. After 6 months 
renal function was normal in all. Proteinuria developed in all but 2 patients, 
in concomitance with the recovery of renal function and persisted over 
time. After 6 months, 4 patients still presented massive proteinuria (>3 g/24 
hours), while the remaining 18 patients had intermediate levels (0. 5-2 g/24 
hours). Composition of proteinuria was characterized by 2D-electrophoresis 
and MALDI-TOFF spectrometry. A mixed tubular-glomerular pattern of 
proteinuria was found in both high and low proteinuric patients with presence 
of albumin, IgG, beta1 macroglobulin, alfa1 macroglobulin and free lambda 
chains. All urines were also characterized by the presence of anti protease 
inhibitors such as alfa 1 antitrypsin and alfa1 chimotripsin and by products of 
tubular degradation never identifi ed in other tubular diseases. Finally nephrotic 
urines didn’t contain fragments of albumin and alfa 1 antitrypsin that are 
normal urinary components in other nephrotic states. Analysis of renal biopsies 
showed variable degrees of tubular apoptosis. Glomerular staining was limited 
to cases with highest proteinuria. 
E induces sudden increase of proteinuria of mixed glomerular and tubular 
origin that reaches in some cases a nephrotic range and persists over time. 
Composition of urinary proteins refl ects structural changes characterized by 
diffuse apoptosis of tubular epithelia and, more limited, of podocytes. 
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CONCURRENT ORAL SESSION 34: 
HAEMOPOETIC CELL TRANSPLANTATION
SOLUBLE LYMPHOTOXIN PLAYS A CRITICAL ROLE IN 453 
GRAFT-VERSUS-HOST DISEASE. 
K. Markey1,2, A. Burman1, R. Kuns1, N. Raffelt1, E. Morris1, T. Banovic1, 
H. Korner3, K. MacDonald1,2, G. Hill1,2
1Queensland Institute of Medical Research, 2The University of Queensland, 
3Comparative Genomics Centre, James Cook University
TNF is a key cytokine in the effector phase of both graft-versus-host disease 
(GVHD) and the graft-versus leukaemia (GVL) effect after bone marrow 
transplantation (BMT). TNF neutralising antibodies are now established as 
effective therapeutic adjuncts for the treatment of severe acute GVHD but are 
not utilised for GVHD prophylaxis because of concern regarding leukaemic 
relapse. TNF signals through the p55 and p75 TNF cell surface receptors 
(TNFR), which also act as receptors for the soluble lymphotoxin homotrimer 
(LTα3). The membrane-bound lymphotoxin heterotrimeric molecule (LTα1β2) 
signals through the LTβ receptor. The function of these molecules in GVHD 
remains unknown. Pharmacological agents are available which block either 
TNF alone, or both TNF and LT and elucidating the roles of these molecules in 
GVHD is essential for the design of rational therapeutic strategies. 
We have employed well established preclinical models of GVHD to investigate 
the roles of these molecules. We fi rst utilised TNF-/- mice as donors and treated 
recipients with a TNFR: Fc construct to neutralise both soluble TNF and LTα3 
molecules post-transplant. The TNFR: Fc provided signifi cant protection from 
GVHD mortality in the absence of donor derived TNF (P<0. 0002). To examine 
this further, we performed experiments using wild-type (WT), LTα-/- or LTβ 
-/- donor grafts. Recipients of LTα-/- grafts were protected from GVHD (P<0. 
009) while LTβ-/- grafts induced GVHD equivalent to WT grafts. LTα was 
generated primarily by donor CD4+ T cells after BMT as determined by real-
time PCR. This data confi rms soluble LTα3 but not membrane bound LTα1β 
2 as a key pathogenic molecule in GVHD. Using this transplantation system 
in the presence of luciferase-expressing, host-type leukaemia, we confi rm that 
GVL is maintained in the absence of soluble LTα3. Thus the neutralisation of 
LTα3, in addition to TNF may represent an important therapeutic intervention 
in transplant medicine. 
CD154 BLOCKADE IMPAIRS GENERATION OF 454 
CD8+ CD44HIGH/CD62LLOW/- EFFECTOR/MEMORY 
T-CELLS INDUCED BY BOTH ALLOANTIGEN EXPOSURE 
AND LYMPHOPENIA AND RESULTS IN PREVENTION OF 
SENSITIZATION
M.J. Elliott, H. Xu, Y. Huang, L-R. Hussain, S. Ildstad, 
 Institute for Cellular Therapeutics, University of Louisville
Recipient sensitization to MHC alloantigens is among the most critical 
challenges facing clinical transplantation. Effector/memory T cells (TEM) 
are generated after exposure to alloantigens and identifi ed as CD44high/
CD62Llow/−. T-cell depletion leads to lymphopenia-induced homeostatic 
proliferation, driving naive T-cells to differentiate directly into memory T-cells. 
These cells share not only the TEM phenotype but also function in allograft 
rejection. We found that CD8+ TEM were detected in B6 mice (H2b) at 11 
to 13 days after exposure to alloantigens by BALB/c (H2d) bone marrow cell 
(BMC) infusion (Fig. A). The percentage of CD8+ TEM in the CD8+ cell gate 
was signifi cantly higher than in naïve mice (11.0 ± 1.6% vs. 2.7± 1.5%; P < 
0.0001). Blockade of CD154 completely inhibited the generation of CD8+ 
TEM (3.1± 2.2%) and the level of CD8+ TEM was similar to naïve controls (P 
= 0.59). When αβ-TCR+ T cells in B6 mice were depleted with anti-αβ-TCR 
(day -3) and BMCs were infused (day 0), more CD8+ TEM (22.7 ± 10.8%, 
P = 0.02) were detected at day +11 to +13 (Fig. B) compared with mice that 
received BMC only (Fig. A). The level of CD8+ TEM in mice treated with 
anti-αβ-TCR remained higher even 30 days after BMT (7.2 ± 1.0%). The levels 
of CD8+ TEM were signifi cantly lower in the mice treated with anti-αβ-TCR 
plus anti-CD154 at day +11 to +13 (11.9 ± 8.1%, p = 0.04) or day +30 (2.6 ± 
1.0%, p = 0.005; Fig. B) compared with CD8+ TEM in mice treated with anti-
αβ-TCR alone. These results suggest that the generation of CD8+ TEM T-cells 
in the context of homeostatic proliferation and alloreactivity was decreased by 
CD154 blockade. Moreover, the production of anti-donor-MHC antibody was 
prevented in mice treated with anti-CD154 mAb, suggesting a specifi c role for 
the CD154:CD40 pathway in B-cell activation. These sensitization-preventive 
strategies also enhanced alloengraftment from same donor in sequential bone 
marrow transplantation. Our fi ndings may have important implications in the 
design of immune-based therapies in management of immune memory induced 
by alloantigen exposure or lymphopenia. 
 
SEGREGATION OF A GRAFT-VERSSUS-LEUKEMIA 455 
EFFECT FROM GRAFT-VERSUS-HOST DISEASE BY THE 
MODULATION OF DONOR CD8+ T CELL ACTIVITY
H.R. Cho1,2, B. Kwon2,3, J.S. Lee2,4, J. Kim2
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical 
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea, 
3Deapartment of Biological Science, University of Ulsan, Ulsan, Ulsan, 
Korea, 4Internal Medicine, Ulsan University Hospital, Ulsan, Ulsan, Korea
In the DBA/2unirradiated (C57BL/6 x DBA/2)F1 model of systemic lupus 
erythematosus-like chronic graft-vs-host disease (cGVHD), donor CD4+ T 
cells play a critical role in breaking host B cell tolerance, while donor CD8+ 
T cells are removed after transfer into the host and the remaining cells fall 
into anergy. Previously we have demonstrated that in vivo ligation of GITR, a 
costimulatory receptor, can activate donor CD8+ T cells, which subsequently 
result in converting the disease pattern from cGVHD to an acute form (aGVHD). 
In this study, we investigated the effect of an agonistic mAb against CD40 
on cGVHD. Treatment of anti-CD40 mAb inhibited the production of anti-
DNA IgG1 autoantibody and the development of glomerulonephritis, typical 
symptoms of cGVHD. The inhibition of cGVHD occurred because anti-CD40 
mAb prevented donor CD8+ T cell anergy such that subsequently activated 
donor CD8+ T cells deleted host cells including host CD4+ T cells and host B 
cells involved in autoantibody production. In addition, functionally activated 
donor CD8+ T cells induced full engraftment of donor hematopoietic cells and 
exhibited an increased graft-vs-leukemia (GVL) effect. However, induction of 
aGVHD by donor CD8+ T cells seemed to be not so apparent. Further CTL 
analysis indicated that there were lower levels of donor CTL activity against 
host cells in mice that received anti-CD40 mAb, compared with mice that 
received anti-GITR mAb. Taken together, our results suggest that a different 
intensity of donor CTL activity is required for removal of host hematopoietic 
cells including leukemia vs induction of aGVHD. Therefore, it is possible to 
segregate a GVL effect from GVHD by modulating the cytotoxic activity of 
donor CD8+ T cells. 
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ALLOREACTIVITY OF HUMAN T CELLS IS 456 
ASSOCIATED TO A HIGH LEVEL OF CD45RC EXPRESSION: 
THERAPEUTIC PROSPECTS FOR HEMATOPOIETIC STEM 
CELL TRANSPLANTATION
L. Ordonez1, M. Chabod1, I. Bernard1, J. Damoiseau2, A. Saoudi1
1INSERM U563, 2University Hospital of Maastricht
CD45 is a transmembrane phosphatase, which regulates the signaling in 
immune cells. On T lymphocytes, it is expressed as different isoforms (such 
as CD45RC, CD45RB, CD45RA, CD45RO) which result from alternative 
splicing. In the rat, the level of expression of the CD45RC isoform divides 
both CD4 and CD8 T lymphocytes into two subsets with different alloreactive 
properties. The CD4 and CD8 CD45RChigh subsets contain alloreactive 
effector lymphocytes, responsible for graft-versus-host disease (GvHD) 
while the CD45RClow subsets regulate this disease. Studies in the rat have 
established that the CD45RChigh/CD45RClow ratio among CD4 and CD8 T 
cells varies according to the rat strain and is genetically controlled. A major 
locus of control of CD45RC expression on CD4 and CD8 T cells has been 
localized on rat chromosome 9, in a ~1 centiMorgan region which also controls 
the susceptibility to various immune diseases. 
The present study aims to investigate CD45RC T cell populations in humans 
and to determine their alloreactive properties. We have shown that the level of 
CD45RC expression on human peripheral blood T cells defi nes, as in the rat, 
subsets of CD4 and CD8 T cells, which exhibit different cytokine profi les after 
allogeneic stimulation. Particularly, we showed that under allogeneic stimulation 
the majority of infl ammatory cytokines are produced by CD45RChigh T cells. 
In agreement with this result, SCID/beige mice humanized by human peripheral 
blood leucocytes (PBL) enriched in CD45RChigh T cells succumbed to a 
GvHD. By contrast mice injected with PBL enriched in CD45RClow T cells 
remained healthy. 
As the analysis of CD45RC expression on T cells subsets of 150 healthy donors 
revealed a large heterogeneity between individuals, we hypothesize that the 
CD45RChigh/CD45RClow ratio among T cells of donors could predict the 
risk to develop a GvHD for the recipient. If so, further studies will look for 
association between GvHD and polymorphisms of genes located within the 
human syntenic region of the rat locus. 
MECHANISM OF FC ACTION: FACILITATING 457 
CELLS ENHANCE THE CLONOGENICITY OF HUMAN 
HEMATOPOIETIC STEM CELLS IN VITRO
M.J. Elliott, T. Miller, F. Rezzoug, I. Fugier-Vivier, S. Ildstad
University of Louisville
CD8+/TCR- graft facilitating cells (FC) enhance engraftment of purifi ed 
hematopoietic stem cells (HSC) in allogeneic and syngeneic mouse recipients. 
FC also enhance the clonogenicity of HSC in an in vitro assay for FC. The 
majority of cells in the FC are tolerogenic precursor plasmacytoid dendritic 
cells. In the present studies, we evaluated whether a similar FC exists in human 
marrow. We recently developed a novel in vitro assay for FC function and found 
that FC signifi cantly enhance the clonogenicity and promote the generation of 
more primitive multipotent HSC progenitors in vitro using a mouse model. The 
CFC assay is used as an in vitro surrogate to enumerate primitive multipotent 
HSC progenitors. In the present studies, we evaluated whether a similar FC 
population exists in human bone marrow. CD34+ HSC were sorted from human 
mobilized or vertebral bone marrow samples and placed in colony-forming cell 
(CFC) assays in methylcellulose with or without FC immediately or after 18 
hours of pre-incubation. Sorted CD8+ T cells were also incubated with HSC as 
a control. Colonies were counted at day 14. Without preincubation, there was 
no signifi cant difference in the number of colonies generated by HSC alone 
vs. HSC plus FC. Strikingly, when HSC were co-incubated with HSC for 18 
hours prior to placement in the CFC assay, FC signifi cantly enhanced colony 
formation compared to HSC alone and HSC co-incubated with CD8+ T cells 
(*P < 0. 005; Figure). These results suggest that FC exert a protective effect 
on HSC and promote the generation of more primitive multipotent progenitors 
from HSC. FC may therefore have a signifi cant impact on initiatives to expand 
and culture human HSC while maintaining their ability to retain their totipotent 
“stem” properties. 
REDUCED INTENSITY CONDITIONING FOR 458 
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 
DETERMINES THE KINETICS OF ACUTE GVHD
M. Kambouris1, B. Turner1, L. Sinfi eld1, J. Lange1, A-M. Burns1, R. Lourie2, 
K. Atkinson1, D. Hart1, D. Munster1, A. Rice1
1Mater Medical Research Institute, 2Mater Adult Hospital
Allogeneic haematopoietic stem cell transplant (HSCT) can be curative for 
haematological and non-haematological malignancies but complications such 
as graft versus host disease (GVHD) and transplant related mortality (TRM) 
limit its widespread application. Preparative myeloablative conditioning 
(MAC) controls malignancy and facilitates donor engraftment but contributes 
to TRM by initiating cytokine release which drives acute GVHD. Reduced 
intensity conditioning (RIC) regimens are replacing MAC. They attenuate 
TRM and whilst GVHD onset is delayed, it is as severe and as frequent as 
seen after MAC HSCT. There are currently no allogeneic murine models of 
RIC HSCT limiting mechanistic studies. We developed murine models of 
RIC-associated delayed-onset GVHD. In contrast to GVHD observed in 
MAC HSCT recipients, we found that delayed-onset GVHD in RIC recipients 
is characterised by low TNF-alpha production, “phenotypic activation” of 
dendritic cells (DC), maintenance of functional host DC, increased regulatory 
T cells (T-reg), functionally attenuated donor DC early post HSCT, rising TNF-
alpha and delayed emergence of activated donor DC which heralded GVHD 
onset. The excess “activated” host DC that we observed after RIC might be 
expected to drive earlier GVHD if they were found in a MAC HSCT setting, but 
this was not the case. These fi ndings underscore the fact that knowledge about 
GVHD mechanisms gained in a MAC environment may not be applicable to the 
RIC HSCT setting. Delineating the mechanism of delayed onset GVHD in RIC 
HSCT recipients should generate opportunities to monitor and predict GVHD 
in these transplant recipients, providing a window for early intervention. 
PROPHYLACTIC INFUSION OF CMV SPECIFIC 459 
CYTOTOXIC T-LYMPHOCYTES FOLLOWING ALLOGENEIC 
HAEMOPOIETIC STEM CELL TRANSPLANTATION
E. Blyth1, K. Micklethwaite1, L. Clancy2, U. Sandher2, D. Gottlieb1,2,3
1Westmead Millennium Institute, Westmead, Sydney, Australia, 2Sydney 
Cellular Therapies Laboratory, Westmead Hospital, Sydney, Australia, 3Blood 
and Marrow Transplant Service, Westmead Hospital, Westmead, Sydney, 
Australia
Introduction: Cytomegalovirus (CMV) remains an important cause of non-
relapse morbidity and mortality in the setting of allogeneic haemopoietic stem 
cell transplantation. Pharmacological treatments are associated with various 
complications and treatment failure with CMV reactivation only adequately 
controlled when immune reconstitution occurs. We report the results of a phase 
I clinical trial of prophylactic infusion of CMV specifi c CD4+ and CD8+ 
T-lymphocytes generated by stimulation with adenovirus vector Ad5f35pp65 
gene modifi ed dendritic cells. 
Methods: Cytotoxic CD4+ and CD8+ T-lymphocytes specifi c for the 
immunodominant CMV pp65 antigen were generated by stimulation of donor 
peripheral blood mononuclear cells with adenoviral vector AD5f35pp65 gene 
modifi ed dendritic cells. A cell dose of 2x107m2 was infused into 12 patients 
on or after day 28 post allogeneic stem cell transplantation. The patients were 
monitored for infusion safety and CMV reactivation, antiviral treatment, 
graft versus host disease (GVHD), infection and disease relapse. They were 
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compared with 54 historical controls who did not receive any form of adoptive 
immunotherapy. Pre- and post-infusion CMV specifi c immune reconstitution 
directed against pp65 CMV epitope was assessed by immunophenotype and 
tetramer binding. Immune reconstitution to whole pp65, IE-1 and adenoviral 
proteins was assessed with interferon ELISPOT analysis. CMV reactivation 
was monitored with whole blood quantitative CMV PCR. 
Results: Rapid reconstitution to pp65 with minimal or no increase in IE-1 
immunity occurred in 5/12 participants. In 3/12 participants the IE-1 immune 
response either matched pp65 or dominated the immune response. In the 
remaining 4 participants, CMV immunity either remained unchanged or 
decreased after T-cell infusion. 
After a median follow-up of 218 days post T-cell infusion 6 episodes of CMV 
reactivation in 4 participants occurred. All of these were associated with low 
level viraemia and only 2 patients required pharmacological therapy in the 
form of oral valaiclovir. None of these episodes were associated with evidence 
of end-organ damage by CMV and none required treatment with intravenous 
antiviral medications. 
When compared with the historical controls the trial participants had less CMV 
reactivation (33% vs 52%), markedly lower peak CMV viral load (mean of 
669 copies/ml in trial participants vs 4394 copies/ml) and reduced need for 
pharmacological therapy (50% of control group with CMV reactivation 
required ganciclovir or foscarnet vs none of the study participants). Rates of 
GVHD were similar (58% for trial participants vs 52% for controls). 
There were no infusion related safety issues identifi ed. 4/12 patients developed 
graft versus host disease post T-cell infusion. These cases were all associated 
with sub-therapeutic doses of Cyclosporine A or deliberate weaning of 
immunosuppression. One participant developed secondary graft failure related 
to sulphamethoxazole/trimethoprim therapy. 
Discussion: This study confi rms the safety of infusion of CMV specifi c 
T-lymphocytes and the ability to detect T-cells with CMV specifi c immunity 
in the early period post-infusion where the risk of CMV reactivation is highest. 
The reduction of peak CMV viral load and the success of low intensity 
pharmacotherapy is encouraging and suggests the effi cacy of prophylactic viral 
specifi c T-cell infusion. 
BONE MARROW TRANSPLANTATION TEMPORARILY 460 
IMPROVES THE FUNCTION OF PANCREAS IN 
STREPTOZOTOCIN-INDUCED DIABETES
M.J. Elliott1, Y. Huang1, M. Kucia2, L-R. Hussain1, H. Xu1, M. Ratajczak2, 
S. Ildstad1, 
1Institute For Cellular Therapeutics, 2James Graham Brown Cancer Center
The role of bone marrow-derived cells in pancreatic β-cell regeneration remains 
unresolved. Under certain circumstances regeneration of insulin-producing 
tissue has been detected. In the present studies we examined whether bone 
marrow-derived cells are recruited to the site of moderate pancreatic injury 
and contribute to β-cell regeneration. In mouse bone marrow, the majority of 
cells which express the mRNA for pancreatic developmental markers (NKx6.1, 
Pdx1, and Ptfl ) are detected in the CD45-Sca-1+Lin- stem cell (SC) population. 
In response to pancreatic damage, we have found that these cells are mobilized 
from bone marrow to peripheral blood (PB), with peak in PB at day 5. These 
cells are highly enriched in the pancreas on day 10 and 15 after streptozotocin 
(STZ)-treatment. To test the hypothesis that pancreatic tissue injury induces an 
SDF-1 gradient to chemo attract the SC, which express its receptor, CXCR4, 
we evaluated the expression of mRNA for SDF-1 in the damaged pancreatic 
tissue. SDF-1 was signifi cantly increased in the pancreas after damage, with a 
peak on day 10. These data suggest that damaged pancreatic tissue produces the 
chemokine SDF-1 and that pancreatic damage is associated with mobilization 
of bone marrow-derived cells containing mRNA for pancreas developmental 
markers. To confi rm a role for bone marrow-derived stem cells, we prepared 
EGFP+ B6 → B6 bone marrow chimerism. In the EGFP+ chimeras, EGFP+ 
cells were detected around duct and islets and were positive for insulin after 
STZ-treatment. However, STZ-induced hyperglycemia was reduced only short-
term for 49 to 77 days after pancreatic injury (Figure 1). These data suggested 
that bone marrow-derived cells are mobilized into injured pancreatic tissue 
and contribute to β-cell regeneration. Transplantation of bone marrow-derived 
cells improves the function of injured pancreas, although the response is not 
suffi cient to restore normoglycemia.
SUSTAINED EFFECT OF AUTOLOGOUS BONE 461 
MARROW MONONUCLEAR CELL TRANSPLANTATION IN 
PATIENTS WITH DIABETES 12 MONTH FOLLOW-UP
L. Chen, J. Dong, W. Hou, X. Hou, L. Sun, M. Dong, X. Zhang, K. Tang, 
Y. Sun, Y. Fu
Endocrinology Department of Qilu Hospital
Diabetes is modern epidemics and a cure will have a global health impact. 
Bone marrow stem cells (BMSCs) can transdifferentiate into insulin-producing 
cells or induce endogenous ¦Â-cell expansion under certain conditions hence 
offers a major therapeutic potential. We developed a prospective study to assess 
therapeutic effi cacy of autologous BMSC transplantation with one-year follow-
up in patients with type 1 (T1DM) or 2 (T2DM) diabetes receiving autologous 
BMSC transplantation or standard medical therapy. We treated 53 diabetic 
patients (T1DM: 
n=22, T2DM: n=31) with autologous BMSC transplantation, and 52 age-
matched diabetic patients (T1DM: n=27, T2DM: n=25) with regular oral 
hypoglycemia agents (OHA) and/or insulin; these patients were followed up 
for 12 months. Bone marrow mononuclear cells (BMMCs) from the bone 
marrow aspirates of each patient were directly delivered to pancreas via 
splenic artery with the distal luminal occlusion through an arterial catheter. 
At 1 year, we observed improved glycaemic control in both transplantation 
(T) and medical treatment (C) groups. The fasting blood glucose, 2-h 
postprandial glucose, the area under the curve (AUC) during standard mixed 
meal tolerance
test and HbA1c were reduced comparing with the baseline levels (P<0. 05). 
However, patients received BMMC transplantation sustained better glycemic 
control accompanied by the reduction in the exogenous insulin requirement 
(P<0. 05). In contrast, the control group showed an increased daily insulin 
requirement for the same follow-up period. Fifteen of the fi fty-three 
transplantation patients (28. 3%) established complete insulin independence. 
This was accompanied by increased levels in C-peptide and its AUC in the 
T group (P<0. 05). None of these parameters were changed in the C group 
(P>0. 05). Comparing to conventional medical treatment, our study shows that 
autologous BMMC transplantation has a sustained effect on glycaemic control 
accompanied
by improved ¦Â-cell function with nearly 1/3 patients established complete 
insulin independence. By overcoming the transplant rejection and donor 
shortage, our protocol of autologous transplantation is safe and readily 
applicable other clinical settings. 
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CONCURRENT ORAL SESSION 35: 
EXPERIMENTAL IMMUNOSUPPRESSION
CARDIAC ALLOGRAFT VASCULOPATHY IN 462 
CYCLOSPORINE-TREATED MONKEYS DEPLETED OF CD20 
B-CELLS
S. Kelishadi, T. Zhang, T. Stoddard, E. Welty, C. Avon, A. Laaris, X-F. Cheng, 
A. Azimzadeh, R. Pierson
University of Maryland Baltimore School of Medicine
Rationale: Over 50% of clinical cardiac allograft recipients develop cardiac 
allograft vasculopathy (CAV). Peri-transplant depletion of B-cells might inhibit 
chronic rejection by reducing the precursor pool for anti-donor antibody-
producing plasma cells or by blunting antigen presentation to donor-specifi c 
T-helper cells. 
Methods: Thirteen cynomologus monkeys received MLR-mismatched 
heterotopic cardiac allografts and “therapeutic” cyclosporine (CsA: target 
trough >500ng/ml); fi ve also received anti-CD20 therapy (á-CD20: 20mg/kg 
IV on days 0, 7, 14, and 21). Anti-donor alloantibody was quantifi ed by fl ow 
cytometry. Surviving grafts were censored at 90 days. 
Results: Three animals (2 with CsA alone and one with CsA+áCD20) were 
excluded from analysis with beating grafts due to non-immune related 
complications. Primary graft survival with CsA+áCD20 (median >90d) and 
proportion of grafts surviving to 90 days (4/4) was increased relative to CsA 
alone (median 71d, 3/6 >90d; p=0. 035). CsA+áCD20 inhibited CAV (median 
CAV score 0. 2; range 0. 1-0. 34) relative to CsA alone (median 2. 1; range 
1. 5-2. 4; p=0. 0013). Anti-donor alloantibody was detected in a minority of 
animals in either treatment group. 
Conclusions: When used with a dose of conventional CsA immunosuppression 
that is “therapeutic” in this species, depletion of CD20+ B cells at the time of 
engraftment attenuates chronic rejection (as CAV) and signifi cantly decreases 
the incidence of graft loss. Interestingly, attenuation of CAV occurred 
independent of a measurable effect on anti-donor antibody incidence or titer. 
This approach to attenuate CAV could be readily evaluated in the clinic. 
Whether synergy exists (effi cacy with reduced CsA exposure/toxicity) and 
durability of the effect as B-cells recover over longer follow-up remain to be 
determined. 
INHIBITORY EFFECTS OF ATACICEPT (TACI-IG) ON 463 
CIRCULATING ANTIBODIES, B CELLS AND PLASMA CELLS 
IN ALLOSENSITIZED CYNOMOLGUS MONKEYS
S. Boskovic, R-N. Smith, T. Kawai, O. Nadazdin, D. Sachs, A.B. Cosimi, 
R. Colvin
Massachusetts General Hospital
Purpose: To evaluate the effects of atacicept (TACI-Ig; Transmembrane 
Activator and Calcium-modulator and cyclophilin ligand Interactor 
-immunoglobulin) treatment on B cell/plasma cell function in sensitized 
cynomolgus monkeys. 
Background: Organ transplantation for sensitized patients has been limited 
by the lack of specifi c therapy to control alloantibody production and plasma 
cell function. Atacicept (ZymoGenetics/Merck-Serono) is a recombinant 
human soluble receptor that acts as an antagonist to BAFF (B cell Activation 
Factor of the TNF Family) and APRIL (A Proliferation-Inducing Ligand), two 
stimulatory ligands responsible for B cell maturation and survival. In mice, 
TACI-Ig inhibits antibody response, survival of plasma cells and development 
of autoimmune disease. 
Methods: Cynomolgus monkeys that developed donor specifi c alloantibody 
(DSA) after rejecting heterotopic heart allograft received 8 doses of atacicept 
at 10 mg/kg S. C. , twice a week. Recipients were monitored over 3 months for 
levels of DSA, antibodies to ABO blood group and gal[ƒÑ1, 3 gal] antibodies, 
and peripheral B cells. Spleen biopsy was performed at one month to evaluate 
splenic plasma cells by staining for immunoglobulin light chains via in situ 
hybridization. 
Results: After a one-month course of atacicept, all three recipients 
demonstrated a reduction in DSA levels by 36. 3„b11% in anti-T and 24. 
3„b11% in anti-B cell DSA, compared to pre-treatment levels. Similarly, 
gal[ƒÑ1, 3 gal] xenogeneic antibody levels decreased by 55„b4. 4% in IgG 
and by 60. 7„b27. 5% in the IgM fraction. Antibody levels to ABO blood 
group antigens tested on two subjects with blood group A also showed 
marked reduction in IgM (from 1: 32 to 1: 4 and from 1: 64 to 1: 16) and in 
IgG antibodies (1: 16 to 1: 8, 1: 64 to 1: 32). Two of three subjects showed 
signifi cant reduction of CD20+CD3- B cells transiently, with nadir one 
month after last dose (83% and 73%). Splenic plasma cells were decreased in 
all three subjects by 75% (mean of 103„b45 cells/mm2) when compared to 
controls (mean of 293„b21). 
Conclusions: Atacicept decreased B cell and plasma cell numbers and 
reduced alloantibody levels, as well as gal[ƒÑ1, 3 gal] xenogeneic 
antibodies and anti-ABO blood group antibodies, in sensitized cynomolgus 
monkeys. Further testing of the effi cacy of atacicept to lower pathogenetic 
antibodies in transplantation is warranted by the encouraging results of this 
pilot trial. 
IMPACT OF IMMUNOSUPPRESSION ON UV-INDUCED 464 
SKIN-TUMORS IN MICE: RAPAMYCIN IMPAIRS TUMOR 
OUTGROWTH AND SHIFTS THE MUTATION TYPES IN THE 
P53 GENE
G. Koehl1, P. Voskamp2, H. Rebel2, A. Gaumann3, J.B. Bavinck2, 
H.J. Schlitt2, F. de Gruijl2, E. Geissler1
1Department of Surgery, University of Regensburg, , 2Dermatology, Leiden 
University Medical Center, Leiden, NL, 3Institute of Pathology, University of 
Regensburg
Background: A signifi cant complication in transplant patients is skin 
tumors development under the necessary immunosuppression. It has been 
shown that cyclosporine can inhibit DNA repair, may promote UV-induced 
DNA mutations and thus enhance formation of skin carcinomas. Since some 
immunosuppressants have recently shown antitumor-activities and affect 
pathways involved in cell cycle progression and expression of DNA repair 
genes (e. g. BRC1), we have tested if long-term treatment with the DNA-
synthesis inhibitor mycophenolate mofetil (MMF) and in particular the mTOR 
inhibitor rapamycin inhibits the development UV-induced tumors and affects 
p53 mutations within the tumors. 
Methods: We exposed hairless SKH1 mice to longterm UV-irradiation (250 
J/m2/day from TL12 lamps). Typical immunosuppressive doses of Rapa or 
MMF were fed to these mice during the whole experiment, while control mice 
received no drug. Blood levels of these drugs were verifi ed in sentinel mice. 
Tumor occurrence and tumor load over time were monitored. 
Sequence analysis was performed to assess DNA mutations in the p53 gene of 
skin tumors. 
Results: As expected in this model almost all tumors were classifi ed 
histologically as squamous cell carcinomas (or precursor lesions). Although 
none of the groups showed a signifi cant difference in the development of 
tumors <2 mm in diameter, larger tumors took signifi cantly longer to develop 
in the Rapa group (n=10; median latency time of 190 days for tumors >4 
mm) than in the MMF (n=10), or control (n=10) groups (140 days, and 125 
days, respectively). Moreover, the average multiplicity of tumors >4 mm was 
signifi cantly lower in Rapa-treated mice (1. 5 vs. 4. 0 in controls at 200 days). 
Mutational analysis of the p53 gene revealed that 100% of tumors from control 
mice had mutations, while mutations were only detected in 67% and 70% of 
tumors from Rapa and MMF-treated mice, respectively. Most interestingly, 
however, while 88% and 90% of the mutations found in tumors of the control 
and MMF mice, respectively, were classic C>T UV-signature mutations, these 
mutations were less frequently detected (39%) in tumors from Rapa-treated 
mice (p=0. 01; Fisher exact test; n=10-16 tumors/group). 
Conclusions: While Rapa does inhibit tumor outgrowth, it does not appear 
to affect the early onset of tumors (initiation). MMF does not affect tumor 
development in this UV-skin cancer model signifi cantly. Interestingly tumors 
in Rapa-treated mice clearly show a reduced frequency of UV-signature 
mutations in the p53 gene, which could be indicative of a selective mechanism 
on the outgrowth of skin tumors. 
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GENERATING EFFECTIVE LOCAL 465 
IMMUNOSUPPRESSION : PROTECTION OF ISLET 
ALLOGRAFTS WITHOUT COMPROMISING SYSTEMIC 
IMMUNITY
S. Londrigan, R. Sutherland, J. Brady, Y. Zhan, E. Carrington, A. Lew
The Walter And Eliza Hall Institute
Local immunosuppression during islet transplantation is clinically desirable, 
as it would reduce the requirement for systemic immunosuppression 
to prevent graft rejection. We tested the effi cacy of locally produced 
immunomodulatory molecules to prevent islet allograft rejection by 
transducing islets with Adv secreting molecules to deplete T cells or 
block T cell activation. Transduced islets were transplanted under the 
kidney capsule of diabetic mice, and graft survival was assessed by 
normalisation of blood glucose levels. Adenoviruses delivering a CD4 T 
cell depleting antibody (Adv-anti-CD4) or CTLA4Ig to block CD28/B7 
T cell co-stimulation (Adv-CTLA4Ig), enhanced islet allograft survival 
(up to 40% and 80% respectively). Importantly, we established that the 
allograft protection afforded by both of these molecules occurred as a 
result of immunosuppression that is locally restricted. Mice transplanted 
with Adv-anti-CD4 treated islets or Adv-CTLA4Ig treated islets on one 
kidney, were able to reject control islets grafted on the contralateral kidney. 
This indicates that the systemic immunity in these mice remained intact. 
Immunosuppressive effects can be restricted locally by our strategy. 
In a mouse model, prolonged local blockade of T cell co-stimulation by 
CTLA4Ig appears to be an effective way to educe signifi cant protection 
of islet allografts without compromising systemic immunity. The effi cacy 
afforded by local depletion of CD4 T cells may be improved using a 
combination of antibodies to deplete other T lymphocyte subsets. 
COMBINING SOCS1 OVEREXPRESSION WITH 466 
DEFICIENCY IN IL-1 SIGNALLING PROTECTS ISLETS FROM 
IMMUNE-MEDIATED DESTRUCTION. 
K.L. Graham, C-Y. Lee, H.E. Thomas and T.W.H. Kay
St Vincent’s Institute of Medical Research, Fitzroy, Victoria, Australia, 3065. 
A combination of inventions against allo- and auto-reactive CD4+ and CD8+ 
T cells is likely to be required to protect islets from immune mediated attack 
following transplantation. Suppressor of cytokine signalling 1 (SOCS1) 
blocks signalling by several cytokines that use the Jak/STAT pathway 
including IFNgamma. Overexpression of SOCS1 in beta cells of diabetes-
prone NOD mice (RIP-SOCS1) decreases spontaneous diabetes by half. 
Previous work suggests that SOCS1 overexpression controls the CD8+ T cell 
response by reducing beta cell antigen presentation. IL-1R defi ciency has 
been shown to increase the ability of regulatory CD4+ T cells to suppress 
expansion of CD4+ T effector cells. In this study we have used a combination 
of SOCS1 overexpression with IL-1R defi ciency (RIP-SOCS1/IL-1R mice) 
in an attempt to control both CD8+ and CD4+ T cell-mediated destruction of 
islets. RIP-SOCS1/IL-1R mice were completely protected from spontaneous 
diabetes development and have signifi cantly reduced insulitis compared 
to control mice or either parental strain. Reduction in insulitis was due to 
an overall decrease in all cell types invading the islets. Transfer of CFSE-
labelled autoreactive CD8+ T cells demonstrated that T cell priming and 
activation in the pancreatic lymph node of RIP-SOCS1/IL-1R mice was 
comparable to control mice however progression of these cells to the islet 
and subsequent proliferation was reduced. This suggests migration and/or 
function of effector cells could be impaired resulting in decreased beta cell 
killing and protection from diabetes development. Because of the increased 
protection with SOCS1 overexpression and IL-1R defi ciency than with either 
intervention alone, we are investigating the use of RIP-SOCS1/IL-1R and 
RIP-SOCS1 islets in combination with soluble IL-1Ra in transplantation 
studies to overcome allograft rejection. 
PREVENTION OF CHRONIC ALLOGRAFT REJECTION 467 
BY BLOCKING OX40 COSTIMULATORY PATHWAY IN 
CARDIAC TRANSPLANT RECIPIENTS
W. Ge1, J. Jiang2, J. Arp1, M.L. Baroja1, W. Liu3, Z. Lan1, D. Lian2, 
B. Garcia3, X.C. Li4, H. Wang1,2
1Department of Surgery, University of Western Ontario, 2Multi-Organ 
Transplant Program, London Health Sciences Centre, 3Department of 
Pathology, University of Western Ontario, 4Department of Medicine, Harvard 
Medical School
Memory T cells (Tmem) endanger allograft survival by causing not only acute 
rejection, but also chronic rejection (CR), which is the major cause of late allograft 
loss. However, the precise role of Tmem in CR is poorly defi ned, and therefore, 
effective treatments for preventing CR are still lacking. The present study was 
undertaken to determine whether functionally blocking the OX40 pathway would 
prevent Tmem-mediated CR in a mouse cardiac transplant model. Tmem were generated 
using a homeostatic proliferation (HP) model. Lymph node T cells (2x106) from 
CD40LKO mice adoptively transferred into congenic immunodefi cient Rag-1KO 
mice were allowed to undergo HP for 6 weeks. Upon undergoing HP, CD40LKO 
T cells (i. e. CD44lo) acquired a memory-like CD44hi phenotype with high level 
of OX40 expression measured by fl ow cytometry, suggesting that this novel 
costimulatory molecule may support the effector function of Tmem. To determine 
the role of Tmem in mediating CR, RAG-1KO mice harboring post-HP generated 
Tmem were transplanted with fully MHC-mismatched BALB/c heart allografts. 
Heart grafts in untreated recipients developed typical pathological features of 
CR, characterized by interstitial fi brosis, arteriosclerosis, cellular infi ltrates and 
IgG deposition on POD100, indicating the establishment of a transplant model 
with Tmem-mediated CR. In contrast, blocking OX40 signal by anti-OX40L mAb 
(0. 25mg/mouse/day, days 0, 1, 3, 5, 10) completely prevented CR in this model 
and heart grafts showed normal histology. Compared with untreated recipients 
with graft CR, anti-OX40L mAb treated recipients demonstrated signifi cant 
downregulation of the Tmem population with lower OX40 expression and decreased 
anti-donor cytotoxic T-lymphocyte activity, as well as reduced IgG deposition and 
decreased IFN-γ, TNF-α and TGF-β expression in heart grafts. We conclude that 
functionally blocking the OX40 pathway inhibits Tmem-mediated CR in a mouse 
heart transplant model. This study identifi es a key molecular pathway in targeting 
Tmem in prevention of CR and may of value in clinical transplantation. 
TARGETING ACTIVATED HUMAN LYMPHOCYTES AND 468 
MONOCYTES WITH A NEW GENERATION OF POLYCLONAL 
RABBIT ANTI-HUMAN LEUKOCYTE ANTIBODY (NEWRALG)
H. Xu1, Z. Liu1, A. Kirk2
1Jinan City Central Hospital, 2Department of Transplantation, Emory 
University Hospital, Emory University, Atlanta, USA
Thymoglobulin® was made by inoculating rabbits with human thymocytes, 
and therefore, its effects in targeting activated lymphocytes and monocytes 
may be limited. In light of this we have developed a new polyclonal rabbit 
anti-human leukocyte antibody (newRALG) that specifi cally targets activated 
T-cells and monocytes. newRALG was generated by inoculation of rabbits 
with activated human lymphocytes and monocytes expressing high levels of 
adhesion and costimulatory molecules followed by antibody purifi cation and in 
vitro evaluation. FACS found that newRALG blocked monocyte-derived CD40, 
CD80, and CD86 and T cell-derived CD28 and CD154 with greater specifi city 
than thymoglobulin®. HLA class I and II-DR, cytokine receptors and adhesion 
molecules were blocked as well as endothelial cell (EC)-derived CD54. 
newRALG blocked all known major molecules expressed on both resting T-cell 
and monocyte surface. newRALG depleted human and rhesus lymphocytes 
and monocytes in a dose dependent manner after incubation with blood for 60 
minutes. newRALG effectively inhibited mixed lymphocyte-endothelial cell 
reactions (MLER). Additionally, newRALG-treated T cells upregulated multiple 
molecules suggestive of a T-regulatory phenotype including CD25, CTLA-4, 
GITR, OX40, CD25, Foxp3, and IL-10 as determined by RT-PCR and FACS. 
In summary, newRALG blocks adhesion molecules, co-stimulatory molecules, 
cytokine receptor molecules and other major molecules involved in allo-immune 
responses in vitro more effectively than thymoglobulin®. newRALG inhibits 
human lymphocyte proliferation and depletes human and rhesus lymphocytes 
and monocytes ex vivo. This preparation results in a distinct residual T-cell 
phenotype skewed toward a regulatory population. These results suggest that 
this new polyclonal antibody will exhibit higher specifi city for the relevant cell 
populations mediating allograft rejection then currently available reagents. 
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ACTIVATION OF TIM-3-GALECTIN-9 PATHWAY 469 
IMPROVES SURVIVAL OF FULLY ALLOGENEIC SKIN 
GRAFTS
W. Feng, H. Wentao, Y. Jin, W. Ke, Z. Hongmin, Z. Weina
K.C. Zhonghua7
Institute of Organ Transplantation
Background: T cell immunoglobulin and mucin domain (Tim)-3 is a molecule 
expressed on terminally differentiated murine Th1 cells but not on Th2 cells. 
Identifi cation of galectin-9 as a ligand for Tim-3 has now fi rmly established 
the Tim-3- Galectin-9 pathway as an important regulator of Th1 immunity, 
which results in apoptosis of Th1 cells. Thus, we want to test the hypothesis 
whether activation of Tim-3-Galectin-9 pathway can improve survival of fully 
allogeneic skin grafts. 
Methods: The skin transplantation recipients (BALB/c to C57BL/6) were 
treated with 100 μg of Galectin-9 or PBS from day 0 to day 7 consecutively 
post-transplant. The mean survival time (in days) was indicated. Furthermore, 
the recipients treated with Galectin-9 were sacrifi ced at days 7. The draining 
Lymph nodes were harvested and Tim-3 and Tim-1 positive cells were 
analyzed by FACScan fl ow cytometer. The recipient blood was collected and 
the production of cytokine was detected by Enzyme-linked immunosorbent 
assay (ELISA). In vitro experiment, responder spleen cells were labeled with 
CFSE. T cell proliferation induced by anti-CD3 and anti-CD28 was analyzed 
for CFSE intensities. 
Results: We conclude that (1) binding of Tim-3 to its ligand Galectin-9 
signifi cantly inhibits rejection and prolongs the survival of fully allogeneic 
skin graft in vivo. (2) Galectin-9 dose-dependently inhibits TCR crossing link 
induced T cells proliferation in vitro. (3) interaction Tim-3 with galectin-9 
selectively deletes Tim-3+ Th1 cells to dampen Th1 immunity and result in 
prolongation of skin graft survival. (4) Galectin-9 signifi cantly decreases 
production of IFN-γ both in vivo and vitro. (5) CD8+ T cells subset was down 
regulated by using Galectin-9 in vivo after skin transplantation. 
Conclusions: Our results demonstrated that activation of Tim-3-galectin-9 
pathway can remarkably suppress allograft rejection and increase survival of 
major histocompatibility antigen mismatching skin grafts. These observations 
suggest that Tim3 -Galectin-9 pathway plays an important role in the 
termination of productive Th1-immune response and could lead to developing 
novel therapies in transplant medicine. 
A NOVEL NF-KAPPA B INHIBITOR, DHMEQ, 470 
ATTENUATES ARTERIAL VASCULOPATHY. 
M. Uno1, K. Yamashita1, T. Shibata1, R. Goto1, T. Oura1, M. Watanabe1, 
S. Haga1, K. Umezawa2, M. Ozaki1, S. Todo1
1Department of General Surgery, 2Department of Applied Chemistry, Keio 
University
Background: Previously, we have shown that a novel NF-kappa B inhibitor, 
DHMEQ signifi cantly attenuated cardiac allograft vasculopathy on chronic 
rejection model in the murine heterotopic heart allo-transplantaion. 
Aim: In this study, we further evaluated the effect of DHMEQ in vitro using 
rat vascular smooth muscle cells (VSMCs) and in vivo using murine vascular 
injury models. 
Methods: In vitro: Primary LEW rat VSMCs from the thoracic aorta were isolated 
and cultured by the explant method. We examined proliferation (3H-thymidine 
incorporation), NF-kB nuclear translocation (immunofl uorescence), apoptosis, 
cell cycle progression (Flow cytometry), and their regulators (Oligo array and 
Western blotting method) with or without DHMEQ treatment. 
In vivo: Balloon injured vasculopathy model: The common carotid artery was 
injured by balloon infl ation in Sprague-Dawley rats. Pluronic F127 gel (20%) 
containing with or without DHMEQ (100 μg) was administered to perivascular 
lesion of the injured vessel. Cuff injured vasculopathy model: A polyethylene 
cuff with LPS (1 μg/ml) was placed around the femoral artery in C57BL/6 
mice. DHMEQ (20 mg/kg/day) was given i. p. daily until the time of sacrifi ce. 
The injured vessels of rats and mice were assessed histopathologically on days 
14 and 28, respectively. 
Results: DHMEQ signifi cantly suppressed proliferation of VSMCs after 
10% FBS stimulation in a dose-dependent manner as compared to the control 
(Fig. 1A). In VSMCs, p50 and p65 translocated into the nucleas at 8 hrs after 
FBS activation, while that was inhibited by DHMEQ (15 μg/ml). Apoptosis 
was not induced, however, cell cycle progression was arrested at G0/1 phase 
by DHMEQ supplementation. This cell cycle inhibition by DHMEQ was 
associated with suppression of genes such as Itgb1, Cdkn1a (p21) and PCNA. 
Further, DHMEQ inhibited CDK1, Cyclin A, Cyclin B, Cyclin D3, p21, and 
p36 protein expressions. In vivo, treatment with DHMEQ signifi cantly inhibited 
development of arteriosclerosis as assessed by intima to media ratio in both rat 
balloon arterial injury (0. 51±0. 06 vs 0. 13±0. 02, p<0. 0001: Fig. 1B) and cuff 
arterial injury models (0. 62±0. 14 vs 0. 27±0. 06 p<0. 01: Fig. 1C). In the cuff 
injured artery, DHMEQ reduced the number of F4/80 positive macrophags in 
the adventitia as compared to that of the control groups. 
Conclusion: Inhibition of NF-kappa B activation by DHMEQ suppresses 
VSMC proliferation and ameliorates arterial vasculopathy. DHMEQ would 
be a useful agent to prevent development of transplant arteriosclerosis during 
chronic graft rejection. 
CONCURRENT ORAL SESSION 36: 
CLINICAL AND EXPERIMENTAL LUNG TRANSPLANTATION
LIVING-DONOR LOBAR LUNG TRANSPLANTATION 471 
FOR PULMONARY COMPLICATIONS AFTER BONE MARROW 
TRANSPLANTATION
M. Yamane1, Y. Sano1, S. Toyooka1, M. Okazaki1, T. Oto1, H. Date2
1Department of Cancer And Thoracic Surgery, Okayama University, School 
of Medicine, 2Department of Thoracic Surgery, Kyoto University
Objective: We report on our experiences in living-donor lobar lung 
transplantation for patients with bronchiolitis obliterans as a complication after 
bone marrow transplantation (BMT). 
Methods: Between October 1998 and February 2008, living-donor lobar lung 
transplantation (LDLLT) was performed in 49 patients with various end-stage 
lung diseases at Okayama University Hospital. Among these, 6 patients with 
pulmonary complications following BMT, aged 6 to 45 years (mean 23. 3 
years), including 2 children were assessed. Diagnoses for BMT included acute 
lymphocyte leukemia (n=3), aplastic anemia (n=1), myelodysplastic syndrome 
(n=1) and acute promyelocystic leukemia (n=1). Bilateral living-donor 
lobar lung transplantation was performed in 4 patients and right single lobar 
transplantation was performed for a 13-year-old boy and a 6-year-old girl. 
Results: Of 49 patients with LDLLT, 45 are currently alive (overall survival 
of 91. 7%). On the contrary, in this cohort of 6 patients with LDLLT for 
bronchiolitis obliterans after BMT, there were 1 early and 1 late death, and 4 of 
6 patients are currently alive without recurrence of hematological diseases with 
a follow-up period of 14 to 94. 3 months (mean, 48. 0 months). All donors have 
returned to their previous lifestyles. 
Conclusions: Living-donor lobar lung transplantation can be applied to severe 
pulmonary complications including bronchiolitis obliterans and pulmonary 
fi brosis after BMT. This type of procedure can be an effective approach and 
alternative to conventional cadaveric lung transplantation for both pediatric 
and adult patients who suffers from pulmonary complication following BMT 
and would die soon otherwise. 
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ASSOCIATION BETWEEN DONOR MBL PROMOTER 472 
HAPLOTYPE AND GRAFT SURVIVAL AND THE 
DEVELOPMENT OF BOS AFTER LUNG TRANSPLANTATION
J.M. Munster1, W. van der Bij1, M.B. Breukink1, G. van der Steege2, 
M.W. Zuurman1, B.G. Hepkema3, E.A.M. Verschuuren1, W.J. van Son1, 
M.A.J. Seelen1
1UMC Groningen, The Netherlands, department of Internal Medicine, 
2UMC Groningen, The Netherlands, department of Medical Genetics, 3UMC 
Groningen, The Netherlands, department of Transplantation Immunology
Background: Lung transplantation is a well accepted therapy for end-stage 
lung disease, despite relatively high mortality rates in the fi rst years after 
transplantation. Mannose binding lectin (MBL) is one of the recognition 
molecules of innate immunity. In many populations, polymorphisms in the 
gene encoding the MBL protein are common. Seven different haplotypes have 
been described (HYPA, LYQA, LYPA, LXPA, HYPD, LYPB and LYQC), 
in which those with exon polymorphisms or an LX promoter variant are 
associated with absent or low levels of the protein, whereas the HY promoter 
haplotype has been related to high MBL serum levels. In other solid organ 
transplantation, genotype or serum levels of MBL, has been associated with 
transplant outcome. Since there is some evidence that the MBL protein is, 
besides largely produced in the liver, partly produced in the lung alveolar cells, 
we were interested in both recipient and donor MBL genotype and their effect 
on lung transplant outcome. 
Material and Methods: All lung transplantations performed in our center, except 
from retransplantations and combined lung-liver or heart-lung transplantations, 
were included. Genotyping of the six known MBL2 variants (promoter: L/H, 
Y/X and P/Q allele and exon: A/D, A/B and A/C allele) was performed in 
both recipient and donor DNA. Univariate and multivariate analyses on graft 
survival and the development of bronchiolitis obliterans syndrome (BOS) was 
performed with Kaplan Meier (log rank) and Cox regression analysis. 
Results: Of the 277 included cases, DNA was available from 200 recipients and 
189 donors and genotyping of all three promoter SNPs was successful in 187 
recipients and 184 donors and of the three exon SNPs in 191 recipients and 181 
donors. Patients who received a graft from a donor with an X-allele (hetero- 
or homozygote Y/X promoter polymorphism) had a statistically signifi cant 
better graft survival (N=184, p=0. 007, fi gure 1) and BOS-free survival (N=60, 
p=0. 007). This association was still present after adjustment for recipient and 
donor sex and age, time on the waiting list, immunosuppressive protocol, HLA 
mismatches and the recipient X-allele (p=0. 034 and p=0. 008 for graft survival 
and BOS, respectively). Recipient MBL genotype was not associated with 
transplant outcome. 
Conclusion: The donor X-allele, which corresponds to the LXPA haplotype 
and is related to low serum MBL levels, was associated with superior lung 
transplant outcome. Our fi ndings might prove to be important in fi nding ways 
to optimize outcome after lung transplantation. 
Figure 1. Kaplan Meier survival curves including censored cases. 
Y/Y = homozygote Y-allele, Y/X = heterozygote Y- and X-allele, X/X = 
homozygote X-allele. 
SHOULD LUNG TRANSPLANT RECIPIENTS 473 
ROUTINELY PERFORM AIRWAY CLEARANCE TECHNIQUES? 
A RANDOMIZED CONTROLLED TRIAL
P.E. Munro1, M. Bailey 2, H. Whitford 1, S.J. Ellis 1, B.M. Button 1, G.I. Snell 1
1The Alfred Hospital, 2Monash University. 
Background: Interventions such as thoracic expansion exercises, postural 
drainage, forced expiration technique (huffi ng) and positive expiratory pressure 
(PEP) have been used to assist airway clearance and improve lung function in 
a variety of patient populations. These techniques are also widely used in the 
management of lung transplant recipients both in the immediate post-operative 
phase and in the presence of acute or chronic chest infection, however very little 
is known about their effi cacy. Clinical practice varies considerably, with some 
clinicians recommending the routine use of airway clearance as a “proactive” 
strategy, while others recommend a “reactive” approach with treatment only 
when patients have a chest infection. 
Objective: The aim of this study was to compare the effects of two commonly 
used airway clearance strategies (proactive vs reactive) on a range of clinical 
outcomes following lung transplant. 
Methods: A prospective randomized trial design was used. Consecutive 
patients at one month post lung transplant at The Alfred Hospital, Melbourne 
were eligible for inclusion. Subjects were excluded if they were medically 
unstable, ventilator dependent or had a contraindication to performing positive 
expiratory pressure (PEP) therapy. Patients performed airway clearance using 
PEP therapy either twice daily (proactive strategy) or only in the presence chest 
infection (reactive strategy). Lung function (FEV1 and FVC), chest radiography 
(Brasfi eld score), bronchoscopic airway characteristics (anastomotic healing, 
patency and secretions) were assessed at one, two and three months post lung 
transplant. Adherence was also measured. 
Results: Of 60 consecutive patients, 36 (18 proactive, 18 reactive) were 
recruited and completed the study. Both groups improved lung function (FEV1 
72 ± 4% to 81 ± 4% p<0. 0001; FVC 69 ± 3% to 81± 3% p<0. 0001) and 
Brasfi eld scores (17. 8 ± 0. 5 to 19. 8 ± 0. 5 p<0. 002) over the study period. No 
signifi cant differences between groups for any outcome were found. The vast 
majority had fully healed, 100% patent anastomoses without secretions at three 
months. There were no signifi cant differences between airway characteristics 
and incidence of chest infection. Adherence to both strategies was high (84% 
proactive, 100% reactive). 
Conclusions: Proactive airway clearance following lung transplantation was not 
associated with a reduced incidence of respiratory infection, alteration of chest 
radiographic fi ndings, or improvement in airway characteristics and cannot be 
recommended as part of routine clinical practice at this time. A further study 
using these baseline measures would be appropriate to evaluate the effi cacy 
of regular airway clearance in the subgroup of lung transplant recipients who 
have recurrent chest infections. The inclusion of a no treatment control group in 
future airway clearance studies in the lung transplant population is warranted. 
Supported by an Alfred Trusts Grant
LUNG TRANSPLANTATION IN RECIPIENTS 70 YEARS 474 
OF AGE AND OLDER
Y. Toyoda, C. Bermudez, M. Zenati, B. Hattler, M. Crespo, J. Pilewski, 
K. McCurry
University of Pittsburgh Medical Center
Objective: Controversy exists regarding the appropriate age limit for lung 
transplantation. We present our data of lung transplantation for patients 70 
years and older.
Methods: Retrospective analysis was performed for 257 consecutive lung 
transplant recipients from 3/05 to 9/07. There were 17 patients aged 70 and 
older at the time of transplant (Group A), 72 patients aged 61 to 69, and 168 
patients aged 60 and younger (Group B). Peri-transplant factors and outcomes 
were compared between Group A and B.
Results: The mean age of Group A was 73±1 years (range 70 – 81, 15 male 
and 2 female) whereas Group B 48±1 (17-60, 85 male and 83 female) (p<0.01). 
All patients in Group A had idiopathic pulmonary fi brosis (p<0.01) whereas 
diagnoses in Group B included emphysema in 31%, pulmonary fi brosis 
in 21%, cystic fi brosis in 15%, scleroderma in 10%, re-transplant in 7%, 
primary pulmonary hypertension in 6%, sarcoidosis in 5% and others in 5%. 
Lung allocation score was higher (p<0.01) in Group A (51±3) vs. B (41±1). 
Preoperative mean pulmonary artery pressure was lower (p=0.02) in Group 
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A vs. B (23±2 vs. 31±1 mmHg). All patients in Group A received single lung 
transplant whereas 76% of Group B double lung transplant (p<0.01). There 
were no signifi cant differences between Group A vs. B in donor age (41±1 vs. 
39±1) and gender (65% male vs. 47%). Cardiopulmonary bypass was used in 
6% of Group A vs. 35% of Group B (p=0.01). Graft ischemic time was shorter 
(p<0.01) in Group A vs. B (269±12 vs. 345±6 min). Duration of postoperative 
mechanical ventilatory support was within 48 hours and within 5 days in 
53% and 76% in Group A vs. 55% and 71% in Group B (p=NS). Signifi cant 
rejection was less common (p<0.01) in Group A vs. B. There was no signifi cant 
difference in over-all survival between groups (p=0.137, Log Rank).
Conclusion: Lung transplantation can be performed for carefully selected 
patients 70 years of age and older with acceptable morbidity and mortality. 
These patients have less rejection compared to younger patients, suggesting 
that they may benefi t with less immunosuppression.
Grade 2 and greater 
rejection (per biopsy) 
Grade 3 and 4 
rejection (per biopsy) 
30-day survival 1-year survival 
Group A 2/53 (4%) 0/53 (0%) 93% 80%
Group B 134/1097 (12%) 55/1097 (5%) 97% 86%
p-value <0. 01 <0. 01 NS NS
THE IMPORTANCE OF DEFINING WARM ISCHAEMIC 475 
TIME (WIT) WHEN UTILISING CONTROLLED DONATION 
AFTER CARDIAC DEATH (DCD)LUNG DONORS
B. Levvey1, T. Oto2, A. Griffi ths1, K. Jones1, G. Westall1, H. Whitford1, 
T. Kotsimbos1, T. Williams1, G. Snell1
1Lung Transplant Service, The Alfred & Monash University, 2Okayama 
University Hospital, Okayama, Japan
Donation after Cardiac Death (DCD) donor organs have potential to alleviate 
the shortage of transplantable lungs. Our institution commenced using 
controlled (Maastricht Category 3& 4) DCD lung donors in 2006, following 4 
years of clinical research and protocol development. Currently there remains 
a lack of detailed information regarding the clinical limits of Warm Ischaemic 
Time (WIT) as a refl ection of graft ischaemia and allograft damage. Similarly 
the relevance of WIT to early and late outcomes for DCD lung transplantation 
(LTx) is unknown. Published data refers to uncontrolled (Sweden, Spain) and 
controlled (USA, UK & Europe) DCD lung donation experience, but rarely 
reports WIT or defi nes how WIT is calculated. 
Methods: Between May 2006 & December 2007, 22 referred DCD donors led 
to 11 attempted retrievals resulting in 8 bilateral LTx (2 donors did not arrest 
within prescribed time and 1 donor had unacceptable lungs). We documented 
BP, HR, O2 sat at specifi c intervals from time of treatment withdrawal until 
Pulmonary Artery (PA) fl ush preservation of lungs, then defi ned WIT in 3 ways: 
A= extubation to PA fl ush, B=systolic BP<50 to PA fl ush, C=arrest to PA fl ush. 
Early recipient outcomes (PF ratios, PGD grade, ICU & hospital stay) and long 
term outcomes (rejection, readmission rates) have been closely monitored. 
Results: DCD lungs from 3 lung-only donors and 5 multi-organ donors were 
transplanted; mean donor age 26yrs (16-36), 5 were males. LTx recipients 
consisted of 2 PPH bridged on IV prostacycline, 3 COPD, 1 LAM & 2 CF (1 
re-LTx), with mean recipient age 42yrs (19-60). 1 PPH recipient required 24hrs 
ECMO for PGD 3, otherwise mean PGD grade at 24rs =2, and mean PGD 
grade at 72hrs =1. 
Mean group PF ratio at 24hr was 307 (240-507); mean ICU stay was 9days 
(2-21) & hospital stay was 22days (11-76). Mean WIT’s for all DCD donors are 
listed in table below. All 8 recipients survive at a mean 251days (10-573) with 
good performance status and lung function.  
WIT A  WIT B WIT C
3 lung-only donors 60 mins  54 mins 48 mins
5 multiorgan donors 38 mins  27 mins 23 mins
Conclusions: WIT probably impacts on both early and long term LTx outcomes 
thus accurate defi nitions are required to determine the true association of WIT 
and these outcome measures, plus enable comparisons with other centres. 
Considering all of these issues, we believe a WIT defi nition utilising only the 
time of treatment withdrawal (eg. WIT A) is unlikely to accurately refl ect the 
true onset of DCD lung allograft ischaemia. 
A SIGNIFICANT ASSOCIATION BETWEEN PRIMARY 476 
GRAFT DYSFUNCTION AMONG LUNG, KIDNEY AND HEART 
TRANSPLANT RECIPIENTS FROM THE SAME MULTI-ORGAN 
DONOR
T. Oto1, L. Excell2, A. Griffi ths3, B. Levvey3, S. Marasco3, P. Macdonald4, G. 
Snell3
1Okayama University Hospital, Thoracic surgery, Japan, 2Australia & New 
Zealand Dialysis and Transplant Registry (ANZDATA), Adelaide, Australia, 
3Lung Transplant Service, The Alfred Hospital and Monash University, 
Melbourne, Australia, 4Cardiopulmonary Transplant Unit, St. Vincent’s 
Hospital, Sydney, Australia
Background: Even organs from an ideal donor will occasionally develop post-
transplant Primary Graft Dysfunction (PGD) causing a signifi cant morbidity and 
mortality after solid organ transplantation. It is likely this situation represents 
subtle undetectable levels of ongoing donor organ dysfunction. The aim of this 
study is to investigate the association of PGD between lung and kidney and/or 
heart recipients from the one donor. 
Methods: From 202 multi-organ donors, contributed 231 consecutive lung 
transplants at the Alfred Hospital, 378 kidney and 114 heart transplants 
were subsequently performed at multiple centers across Australia and New 
Zealand. 
Results: From 202 multi-organ donors, 875 organs were used for 723 
transplants. The incidence of PGD after lung, kidney and heart transplants 
was 20% (47/231), 24% (92/378) and 20% (23/114), respectively. In paired 
single organ recipients, PGD in one of the pair was a signifi cant risk factor for 
development of PGD in the other [lung: odds ratio=5. 63 (1. 72-18. 43), p=0. 
004], [kidney: 3. 19 (1. 90-5. 35), p<0. 0001]. In multivariate analysis, same 
donor heart PGD [3. 37 (1. 19-9. 50), p=0. 02] was an independent risk factor 
for lung PGD, and same donor lung PGD was signifi cant risk factor for kidney 
PGD [1. 94 (1. 01-3. 73), p=0. 04], if the PGD status of the paired kidney was 
not known. 
Conclusion: There was an association for the development of PGD across 
different organs transplanted from the same donor. Sharing the early allograft 
outcome between the different transplant teams might create a window of 
opportunity to intervene with therapeutic strategies to protect against the 
subsequent development of PGD in other organ recipients. 
STEPPING UP TO TAKE CONTROL: EARLY POST-477 
TRANSPLANT REGULATORY T CELL DYNAMICS IN LUNG 
ALLOGRAFT RECIPIENTS
N. Mifsud1, T. Higuchi2, D. Abud3, R. Meani2, M. Bailey1, G. Westall1,2, 
G. Snell2, C. McLean2, T. Kotsimbos1,2
1Monash University, 2The Alfred Hospital, 3Victorian Transplantation and 
Immunogenetics Service, ARCBS
Experimental transplantation models have elucidated the importance of 
tolerance in maintaining allograft function. Phenotypic advances for detection 
of immunoregulatory T cells (Treg) enable characterization of Treg dynamics 
in lung transplant recipients (LTR) and relate this to clinical outcomes. 
All LTR, recruited from Jan 2006 to July 2007 (n=63), underwent standard 
calcineurin-based immunosuppression. During routine post-transplant (PTx) 
bronchoscopic evaluation (1 and 3 months PTx) both peripheral blood (PB) and 
bronchoalveolar lavage (BAL) samples were collected for Treg enumeration. 
The%Treg were measured by fl ow cytometry following staining with cell 
surface expression biomarkers CD4, CD25, CD127 and intracellular FOXP3 
expression. Histopathological acute rejection (AR) episodes were identifi ed 
in 29 LTR. Early PTx Treg dynamics in PB and BAL varied substantially in 
individual LTR. Multivariate analysis revealed that%Treg in PB at both 1 and 
3 months PTx [r =-0. 26, p=0. 04; r =-0. 34, p=0. 009 respectively] inversely 
correlated with AR episodes but not in BAL. To date, CD4, CD8 and FOXP3 
immunostaining has been performed on 28 transbronchial biopsies from 20 
LTR with AR. CD4 T cells dominated the lymphocytic infi ltrate in all but one 
of the early AR episodes but CD4+FOXP3+ Treg (less than 5%) were detected 
in only 17/28 AR episodes from 14 LTR (59% vs 63% at 1 and 3 months, 
respectively). This study suggests that histopathological AR in LTR is not 
necessarily all the same early PTx and that its diagnosis is inversely related to 
the%Treg in PB. The mechanisms driving this relationship are highly clinically 
relevant but as yet remain to be fully elucidated. 
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DONOR BRAIN DEATH INHIBITS TOLERANCE 478 
INDUCTION IN MINIATURE SWINE LUNG 
TRANSPLANTATION
G. Veillette, A. Meltzer, A. Aoyama, M. Cochrane, S. Houser, J. Wain, 
J. Madsen, D. Sachs, J. Allan, B. Rosengard
Transplantation Biology Research Center, Massachusetts General Hospital
Introduction: A short course of high-dose tacrolimus induces tolerance to 
fully-MHC mismatched lung allografts in miniature swine. Prior research on 
the induction of transplantation tolerance has utilized this model in which the 
donor is a healthy animal. We now present results suggesting that donor brain 
death inhibits tolerance induction. 
Methods: All transplants were performed across a fully disparate MHC barrier 
with 12 days of high-dose tacrolimus (target level 35-55 ng/ml). Donor brain 
death was induced by intracranial infl ation of a 30cc Foley catheter. Five hours 
later, orthotopic left lung transplants were performed. Recipients received 12 
days of high-dose tacrolimus. Animals were followed with daily routine labs, 
weekly chest X-rays, and scheduled biopsies. In vitro studies (CML, MLR, 
ELISA, and QPCR) were performed. 
Results: We have previously reported a series of orthotopic lung transplants 
in miniature swine performed across a full MHC-mismatch with a 12-day 
course of tacrolimus (n=6). Five animals (83%) accepted their grafts and were 
sacrifi ced with viable grafts after one year. One animal acutely rejected its graft 
by POD 103. We performed a series (n=4) of transplants after inducing brain 
death in the donor. None of these animals survived more than 45 days and all 
had evidence of ISHLT 4/4 acute cellular rejection at necropsy. In vitro studies 
(CML, MLR) indicated persistent response to donor (by MLR) despite the 
immunosuppressive regimen. ELISA and QPCR were performed to evaluate 
cytokine changes in donor sera and lung tissue after brain death induction. 
Serum ELISA demonstrated statistically signifi cant increases in concentrations 
of IL-1 (p=0. 041), TNF-a (p=0. 0005), and IL-10 (p=0. 0132) following 5 
hours of brain death. IL-4, TGF-B, and IFN-g concentrations were unchanged. 
Quantitative PCR was performed on lung biopsy specimens before brain death 
induction and at the time of implantation. There was a consistent two-fold 
upregulation of IFN-g expression after brain death. IL-1 expression in lung 
tissue also increased signifi cantly (6 to 20 fold). There was no change in IL-4, 
TNF-a, or MHC Class I expression following brain death induction. 
Conclusion: Donor brain death appears to abrogate tolerance induction in a 
swine model of orthotopic lung transplantation, along with signifi cant changes 
in donor cytokine levels and gene expression. Further studies are planned to 
better characterize the mechanism of this induced rejection and to attempt to 
fi nd ways of avoiding it. 
CHRONIC GASTRIC ASPIRATION LEADS TO 479 
AUTOIMMUNITY AND AN AUGMENTED INDIRECT 
ALLOIMMUNE RESPONSE FOLLOWING LUNG 
TRANSPLANTATION IN MINIATURE SWINE
G. Veillette, A. Meltzer, M. Weiss, M. Cochrane, S. Houser, J. Madsen, 
D. Sachs, B. Rosengard, J. Wain, J. Allan
Transplantation Biology Research Center, Massachusetts General Hospital
Introduction: Clinical evidence suggests that lung transplant recipients with 
documented gastroesophageal refl ux disease (GERD) are at increased risk for 
graft dysfunction. Here, we present a large-animal model of gastric aspiration 
following allogeneic lung transplantation, and test whether chronic aspiration 
can lead to the development of autoimmunity (type V collagen) and/or the 
augmentation of indirect alloimmunity (class I allopeptides). 
Methods: Orthotopic lung transplants (n=3) were performed in miniature swine 
across an MHC class I mismatch, followed by 12 days of high-dose CyA. We 
have previously reported that this regimen induces long-term allograft survival 
in 67% (n=6) of similarly treated animals. At the time of transplantation, trans-
tracheal bronchial catheters were placed distal to the bronchial anastomosis. A 
gastric tube was placed for daily gastric aspiration. Graft lungs were instilled 
with gastric aspirate daily (3cc/hr x 8hr/day) for 50 days. Animals were 
followed with daily CBC, and scheduled chest radiographs and biopsies. In 
vitro studies, including CML, MLR, and peptide proliferation assays (PPA), 
were performed. 
Results: Two animals were sacrifi ced with non-viable lungs by POD 50. In 
both cases the native lung was normal. The third animal survived 180 days 
without evidence of chronic rejection. After immunosuppressive treatment, all 
animals demonstrated donor-specifi c hyporesponsiveness by CML and MLR. 
Response to collagen V developed in both animals that rejected their allografts. 
The surviving animal, apparently tolerant, had no response to collagen V by 
in vitro assay. In all animals, a signifi cant response to synthetic donor-derived 
class I peptides developed. The most marked response was seen in the animals 
rejecting their grafts. 
Conclusion: A large-animal model of GERD following lung transplantation 
resulted in a spectrum of clinical outcomes. The in vitro data suggest that acid 
refl ux promotes the exposure of antigenic type V collagen epitopes and also 
enhances the indirect alloresponse to processed donor class I antigen, giving 
mechanistic insight into the manner in which GERD may be deleterious to the 
transplanted lung. 
CONCURRENT ORAL SESSION 37: 
LONG-TERM OUTCOMES IN RENAL TRANSPLANTATION
FORTY YEARS EXPERIENCE OF PREGNANCIES 480 
AMONG KIDNEY TRANSPLANT WOMEN; PREGNANCY, 
MATERNAL AND GRAFT OUTCOMES FROM THE 
AUSTRALIAN AND NEW ZEALAND DIALYSIS AND 
TRANSPLANT REGISTRY
V. Levidiotis1, S. Chang2, A. McDonald2
1Royal Prince Alfred Hospital, Sydney, NSW, 2ANZDATA Registry, Adelaide, 
SA, Australia
Fertility rates, pregnancy and maternal outcomes over 40 years in women aged 
15 to 49, were investigated in 28329 patient-years of follow-up, in kidney 
transplant women using data from the Australian and New Zealand Dialysis and 
Transplant (ANZDATA) Registry. Fertility rates were 16 per 1000 patient-years 
in women with a functioning transplant and 1 per 1000 person-years among 
women receiving dialysis; relative rates to the Australian population were 0. 19 
for transplant and 0. 01 for dialysed women. Absolute but not relative fertility 
rates have fallen over time. Among women with transplant function, 577 
pregnancies and 444 LB were reported. Of women becoming pregnant beyond 
their fi rst transplant year, 73% achieved a LB. Among transplant recipients, the 
proportion of live births (LB) doubled. In a further analysis, matching parous 
with nulliparous women, a fi rst LB event was not associated with poorer 20 
year graft (adjusted HR 1. 04 [0. 63-1. 70], P=0. 89) or patient survival. Twenty 
years after a LB, 75% of transplant women remained alive; among the 69 
who died, median duration to death was 12. 2 years. Maternal complications 
included superimposed pre-eclampsia [27% (N=22 of 71) and graft loss (N=5, 
1. 3%). After adjusting for age and decade, pregnancies in transplant women 
were 7. 1 [3. 6-13. 7] times more likely to result in a LB compared to dialyzed 
women (P<0. 001). Temporally, LB consistently increased in transplant 
women, whereas surgical termination (SxT) declined. These data confi rm a LB 
event longitudinally, in transplant women, does not adversely impact graft and 
patient survival. Nonetheless transplant women have very low pregnancy rates 
and the absolute rate has declined over the last 40 years. 
NEW HORIZON FOR OLDER PATIENTS WITH ESRD. 481 
ECD PREEMPTIVE RENAL TRANSPLANTATION OFFERS THE 
SAME LIVE EXPECTANCY AS THE STANDARD CRITERIA 
DONOR (SCD) KIDNEY TRANSPLANTATION ON DIALYSIS. 
P. Witkowski, A. Rana, M. Goldstein, K. Halazun, M. Hardy, L. Ratner
Department of Surgery, Columbia University
Background: Preemptive renal transplantation has a positive impact on both 
patient and graft survival. Although studies have demonstrated the benefi t of 
preemptive renal transplantation, such analyses included mostly high quality 
organs from living donors. There has been no research, however, examining 
the role of preemptive ECD transplantation on patient and graft outcome. This 
study aims to investigate whether preemptive ECD renal transplantation offers 
an advantage over SCD kidney transplant in patients on dialysis. 
Methods: 93, 806 adult UNOS de-identifi ed patients who underwent renal 
transplantation between 1995 and 2005 were analyzed. Living donor and 
multiorgan transplants were excluded. 86, 176 patients which received deceased 
organs were divided into two groups according to age. 
Results: Among 66, 085 (79%) recipients younger then 60yo, 48, 474 (77%) 
were on dialysis and received SCD kidneys, while preemptive transplants with 
ECD kidneys were performed in 1, 204 (2%) patients. There were 20, 082 
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(23%) recipients ≥60yo included. 12, 156 (60%) of these patients received 
SCD kidneys on dialysis, other 850 (4%) recipients received ECD kidneys 
preemptively. Survival of the patients ≥60yo after ECD preemptive renal 
transplantation did not differ statistically from survival after SCD kidney 
transplantation on dialysis (p<0. 05) (Fig. 1), whereas in younger recipients, 
their survival after preemptive ECD transplantation was signifi cantly worse 
than with SCD transplants (p <0. 05) (Fig. 2). Graft survival was found to 
be signifi cantly shorter in preemptive ECD recipients when compared to SDC 
organ transplantation, in both young and old patients (p<0. 05). 
Figure 1.  Figure 2. 
Conclusions: ECD preemptive renal transplantation offers the same life 
expectancy as SDC transplantation in patients ≥60yo on dialysis but not in 
younger ones. Such preemptive procedures allow patients to avoid the morbidity 
and additional mortality associated with waiting on dialysis for a suitable graft. 
ECD kidneys should be used preemptively in older donors therefore extending 
the repertoire of renal replacement therapies as well as organ pool in those 
patients without compromising their survival. 
ESTIMATED GFR AFTER TREATMENT OF ACUTE 482 
REJECTION: A SURROGATE MARKER FOR LONG-TERM 
GRAFT SURVIVAL AFTER KIDNEY TRANSPLANTATION
M. Cantarovich, S. Paraskevas, P. Chaudhury, D. Baran, D. Keith, M. 
Hassanian, D. Vrochides, M. Lipman, R. Mangel, P. Metrakos, 
J. Tchervenkov, M. Ladouceur. 
Departments of Medicine and Surgery, Multi-Organ Transplant Program, 
and Department of Epidemiology and Biostatistics, McGill University Health 
Center, Montréal, Quebec, Canada. 
Purpose: To determine the usefulness of the estimated GFR (eGFR) after 
treatment of acute rejection (AR) as a surrogate of long-term graft survival 
after kidney transplantation (KTx). 
Methods: We analyzed 603 pts (49±13 yrs-old), recipients of KTx between 
05/1997 and 03/2007. Eighty pts with a fi rst biopsy-proven AR were divided 
into 2 groups (Gr. ), based on the post-AR eGFR (MDRD equation). Gr. 1 
included pts whose eGFR returned to within 10% of pre-AR values within 3 
months post-AR treatment. Gr. 2 included pts whose eGFR did not improve to 
within 10% of pre-AR values. In a separate analysis, pts were divided according 
to the baseline CNI. 
Results: Pt survival at 1, 5 and 10 yrs was 96%, 90% and 82% in non-rejectors, 
and 98%, 91% and 76% in rejectors. Pt survival at 1, 5 and 10 yrs was 100%, 
90% and 80% in rejectors Gr. 1 and 97%, 93%, 65% in rejectors Gr. 2. Graft 
survival at 1, 5 and 10 yrs was 92%, 85%, 73% in non-rejectors and 91%, 73% 
and 51% in rejectors (P<0. 001). Graft survival at 1, 5 and 10 yrs was 94%, 
81% and 66% in rejectors Gr. 1 and 84%, 58% and 19% in rejectors Gr. 2 
(P=0. 04). A multivariate time-dependent graft survival analysis showed that 
AR status (HR 4. 00, 95% CI [2. 23-7. 2], P<0. 001), age at treatment of AR 
(HR 1. 03, 95% CI [1. 01-1. 05], P=0. 001), and Tac vs. CsA (HR 2. 54, 95% CI 
[0. 92-2. 85], P=0. 094) had an important effect on graft survival. 
Table 1. Age-adjusted hazard ratio (HR) for patient and graft survival
Patient Survival Graft Failure
HR [95%CI] P-value HR [95%CI] P-value
Rejectors vs. Non-
rejectors 
1. 74 [0. 84-3. 61] 0. 14 4. 33 [2. 64-7. 10] <0. 001
Rejectors Gr. 1 vs. 
Non- rejectors
1. 99 [0. 78-5. 10] 0. 15 2. 11 [0. 90-4. 97] 0. 09
Rejectors Gr. 1 vs. 
Gr. 2
0. 77 [0. 20-3. 02] 0. 77 0. 42 [0. 18-0. 96] 0. 04
Rejectors CsA 
vs. Tac 
N/A N/A 1. 57 [0. 63-3. 89] 0. 33
Conclusion: Pt survival was not infl uenced by AR status. An episode of AR 
portends a poor prognosis for long-term kidney graft survival. There was no 
signifi cant difference in graft survival after AR in pts on Tac vs. CsA. In pts 
whose eGFR post-treatment of AR returned to within 10% of baseline, there 
was no signifi cant difference in graft survival compared to pts that did not 
experience AR. The eGFR post-treatment of AR may be a useful surrogate 
marker of long-term kidney graft survival. 
ATRICONTINENTAL ANALYSES OF KIDNEY 483 
TRANSPLANT OUTCOMES FROM THREE NATIONAL 
REGISTRIES. 
R.M. Merion1,2, J. Moore2,3, R.J. Johnson4, C.J. Rudge4, S. MacDonald5, 
G. Russ5, G. Fant6, D. Collett4. 
1University of Michigan, Ann Arbor, USA; 2Scientifi c Registry of Transplant 
Recipients, Ann Arbor, USA; 3Arbor Research Collaborative for Health, 
Ann Arbor, USA; 4UK Transplant/NHS Blood and Transplant, Bristol, UK; 
5Australia and New Zealand Dialysis and Transplant Registry, Adelaide, 
Australia; 6US Health Resources and Services Administration, Rockville, USA. 
Introduction: Standardized comparisons of kidney transplant outcomes 
in different parts of the world have been challenging to undertake and very 
infrequently performed. In this collaborative study, three large registries 
undertook separate identical unadjusted analyses of short and long term kidney 
transplant outcomes as a fi rst step toward harmonization of analytic methods 
across registries and to determine whether differences in major outcomes after 
kidney transplantation were observed. 
Methods: Separate cohort analyses of the outcomes of all fi rst single organ 
kidney transplants performed from 1988-2005 in the United States (US), 
United Kingdom (UK) and Australia/New Zealand (ANZ) were performed 
by the US Scientifi c Registry of Transplant Recipients, UK Transplant, and 
the Australia and New Zealand Dialysis and Transplant Registry, respectively. 
Unadjusted (Kaplan-Meier) patient and graft survival rates were calculated. 
Patient survival analyses included all deaths (including those after loss of graft 
function). Comparisons of unadjusted Kaplan-Meier point estimates from 
the three separate models were made using normal approximation methods 
to compare group survival proportions at one, fi ve, 10, and 15 years post-
transplant. 
Results: There were 184553, 25095, and 9231 kidney transplants performed in 
the US, UK, and ANZ, respectively, from 1988-2005. The proportions of living 
donor transplants were 36%, 14%, and 30%, respectively. Male recipients 
predominated (60-62%) in all three registries. Recipient age distribution was 
comparable (6-7% pediatric and 5-8% >65 years). A much higher proportion 
of recipients received transplants for diabetic nephropathy in the US cohort 
(22%) compared to the UK (5%; 10% among cases where primary diagnosis 
was reported) and ANZ (10%). There was a higher proportion of 0 HLA 
mismatched transplants in the US (12%) vs. the UK (9%) and ANZ (6%), but 
also a higher proportion of 4-6 HLA mismatched transplants (45% vs. 18% and 
29%, respectively). Unadjusted deceased donor (DD) and living donor (LD) 
graft and patient survival rates were signifi cantly lower in the US compared 
to the UK and to ANZ at fi ve, 10, and 15 years post-transplant (all P<0. 0001) 
(Figure). Deceased donor graft survival rates in ANZ were signifi cantly higher 
than in the UK at fi ve, 10, and 15 years (P<0. 0005). Deceased donor patient 
survival rates in ANZ were modestly but signifi cantly higher than in the UK at 
10 and 15 years (P<0. 05). Patient survival rates after living donor transplants 
in ANZ were also modestly but signifi cantly higher than in the UK at fi ve and 
10 years (P<0. 05) but not at 15 years. Within the more recent 10-year cohorts 
(1996-2005), deceased donor graft survival rates at fi ve years among recipients 
with diabetic nephropathy were signifi cantly lower in the US compared to the 
UK and ANZ (61. 5 vs. 67. 8 and 70. 1; P<0. 0003 for both comparisons), and 
not signifi cantly different in the UK vs. ANZ (P=0. 42). 
Conclusions: Preliminary analyses of data from three national transplant 
registries have highlighted important differences in kidney transplant graft and 
patient outcomes between the US, UK, and Australia/New Zealand. The next 
step in this important collaboration is to undertake risk-adjusted analyses in 
order to explore the role of case mix differences. 
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THE IMPACT OF PROCEDURAL VOLUME AND 484 
OTHER TRANSPLANT HOSPITAL CHARACTERISTICS ON 
THE OUTCOMES OF KIDNEY TRANSPLANTATION IN THE 
UNITED STATES
J. Kim1, T. Louis2, B. Astor2,3, E. Boulware2,3, N. Powe2,3
1Toronto General Hospital, University Health Network, University of 
Toronto, 2Johns Hopkins Bloomberg School of Public Health, Johns Hopkins 
University, 3Welch Center for Prevention, Epidemiology and Clinical 
Research, Johns Hopkins University
Background: A larger volume of surgical procedures performed by a hospital 
has been linked to improved patient outcomes. The relation between transplant 
center/hospital characteristics (including volume) and allograft/patient survival 
has received limited attention in the current era of kidney transplantation. 
Objective: To determine the impact of transplant center volume and other 
hospital characteristics (including profi t status, total number of beds, and 
academic status) on the survival of kidney transplant recipients (KTR) and 
their allografts. 
Design and Setting: A retrospective cohort study of incident KTR in the 
United States Renal Data System from 1 Jan 1994 to 31 Dec 2003 with follow-
up to 31 Dec 2004. Characteristics of transplant hospitals were retrieved from 
the 1994, 1997, and 2000 Provider of Services fi les of the Center for Medicare 
and Medicaid Services. 
Main Outcomes: Graft failure (including death), death-censored graft failure, 
and patient mortality at 1-year, 3-years, 5-years, and total study follow-up. 
Results: Transplant center volume was defi ned as the average number of kidney 
transplants performed by a hospital over the study period. The relative hazard 
of graft failure for the fourth vs. the fi rst volume quartile was 0. 87 (95% CI 
0. 80-0. 96), after covariate and cluster adjustment (see Table). Similar results 
were observed for all other outcomes and at 1-, 3-, and 5-years post-transplant. 
Higher-order center volume quantiles revealed a consistent reduction in graft 
failure and patient mortality at approximately 100 transplants per year. After 
adjustment for center characteristics, the volume-outcome relation persisted. 
Hospitals affi liated with medical schools and offering residency programs 
showed a trend toward lower rates of graft failure but no associations were 
observed for other center-level covariates. The fi ndings were robust to various 
subgroup and sensitivity analyses. 
Conclusions: The highest quartile of transplant center volume was associated 
with a consistent reduction in the risk of graft failure and patient mortality among 
KTR. This fi nding persisted after adjustment for other center characteristics. 
Future research to better understand the patient and provider factors underlying 
this phenomenon should be made a priority in order to improve outcomes for 
all KTR. 
Table: Results of Cox Proportional Hazards Models for Transplant Center 
Volume Quartiles
Study Outcomes Follow-Up Times for 
Cox Models
Volume 
Quartile 
1
 (0-51. 
1 per 
yr) 
N = 27, 
126 
121 
centers 
Volume 
Quartile 
2 
 (51. 
2-82. 8 
per yr) 
N = 27, 
107 
50 
centers 
Volume 
Quartile 
3 
 (82. 
9-140 
per yr) 
N = 27, 
080 
30 
centers 
Volume 
Quartile 
4 
 (140. 
1-280 
per yr) 
N = 26, 
303 
16 
centers 
P Value 
(Trend)
Graft 
Failure
Total 
follow-
up
1. 00 
(Referent)
0. 99 
(0. 
93-1. 
06)
0. 95 
(0. 
88-1. 
03)
0. 87 
(0. 
80-0. 
96)
0. 010
1-year 1. 00 
(Referent)
1. 00 (0. 
90-1. 10)
0. 94 (0. 
85-1. 05)
0. 85 (0. 
74-0. 97)
0. 011
3-years 1. 00 
(Referent)
1. 01 (0. 
93-1. 09)
0. 95 (0. 
87-1. 03)
0. 88 (0. 
78-0. 99)
0. 015
5-years 1. 00 
(Referent)
1. 00 (0. 
93-1. 08)
0. 94 (0. 
87-1. 02)
0. 89 (0. 
80-0. 99)
0. 012
Death-
Censored 
Graft Failure
Total follow-
up
1. 00 
(Referent)
1. 00 (0. 
93-1. 08)
0. 97 (0. 
89-1. 06)
0. 88 (0. 
80-0. 96)
0. 038
1-year 1. 00 
(Referent)
1. 02 (0. 
91-1. 14)
1. 01 (0. 
89-1. 14)
0. 86 (0. 
75-0. 99)
0. 047
3-years 1. 00 
(Referent)
1. 03 (0. 
94-1. 11)
1. 02 (0. 
92-1. 12)
0. 89 (0. 
78-1. 00)
0. 060
5-years 1. 00 
(Referent)
1. 02 (0. 
94-1. 10)
0. 99 (0. 
91-1. 09)
0. 90 (0. 
81-1. 00)
0. 054
Patient 
Mortality
Total follow-
up
1. 00 
(Referent)
0. 98 (0. 
91-1. 07)
0. 94 (0. 
86-1. 02)
0. 89 (0. 
80-0. 99)
0. 027
1-year 1. 00 
(Referent)
0. 97 (0. 
85-1. 11)
0. 88 (0. 
78-0. 99)
0. 86 (0. 
72-1. 01)
0. 034
3-years 1. 00 
(Referent)
1. 02 (0. 
92-1. 12)
0. 91 (0. 
83-0. 99)
0. 90 (0. 
78-1. 03)
0. 045
5-years 1. 00 
(Referent)
1. 00 (0. 
91-1. 09)
0. 91 (0. 
83-0. 99)
0. 89 (0. 
78-1. 01)
0. 029
GENETIC TESTING IN FOCAL SEGMENTAL 485 
GLOMERULOSCLEROSIS (FSGS) IS MANDATORY BEFORE 
RENAL TRANSPLANTATION: RESULTS FROM THE ECOFTS 
(EUROPEAN COLLABORATIVE FSGS TRANSPLANTATION 
STUDY)
T. Jungraithmayr1, P. Cochat2, P. Pagel3, T. Knueppel4, G. Cortina1, 
T. Neuhaus5, T. Seeman6, B. Toenshoff4, M. Winn7, B. Zimmerhackl1
1Pediatrics, Medical University, Innsbruck, Austria, 2Pediatrie, Hopital 
Herriot, Lyon, France, 3Genome Oriented Bioinformatics, TU, Munich, 
Germany, 4Pediatrics, University, Heidelberg, Germany, 5Pediatrics, 
University, Zuerich, Switzerland, 6Pediatrics, University, Prague, Czech 
Republic, 77Medical Center, Duke University, Durham, North Carolina, 
United States
Renal transplantation (RTx) in steroid resistant FSGS is complicated by high risk 
of disease recurrence (DR). DR seems to be infl uenced by genetic background. 
In this international survey a genotype-phenotype correlation is studied. 
83 patients (P) with childhood onset of biopsy proven FSGS who had been 
transplanted at least once were evaluated by standardized questionnaire. 75 P 
were Caucasians, 6 Arabs and 2 Asians. Genetic analysis was performed in 53 P 
for NPHS2 (mechanoreceptor) and in 7 P for TRPC6 (Ca++-channel). 
Mean age at diagnosis was 6. 8 + 0. 7 years (y). The fi rst RTx was performed 
at age 12. 8 + 0. 8 y. 30 P (36%) recurred after a mean time of 152 + 55 days. 
29P lost their graft, 41% of those due to DR. A second RTx was performed in 
22 P with LRD in 5 P. 50% recurred after a mean time of 96 + 53 days. 11/22 
lost their graft, in 72% due to DR. Screening for NPHS2 reveiled 11 P with 
mutation, 7 P who were tested for TRPC6 mutations were all negative. P with 
a homozygous or compound heterozygous NPHS2 mutation showed no DR 
after RTx compared to 43% without mutation (p<0. 05, no results of 30 P, see 
fi gure 1). 
Mathematical modelling of the interaction between NPHS2 and TRPC6 
indicates strong interaction between these two proteins. Mutations of NPHS2 
seem to change the predicted confi guration of Podocin with potential interaction 
sites to TRPC6. 
In conclusion, patients with NPHS2 mutations had a lower risk of DR. 
Modelling indicates an infl uence of NPHS2 on TRPC6 with the potential to 
change Ca-channel function. Thus, genetic testing for underlying mutations 
is mandatory to improve long term outcome in FSGS. A prospective study for 
optimization of treatment in recurring disease is urgently needed. 
Supported by ESPN, APN, Universities Innsbruck and Heidelberg. http://
ecofts. uki. at
LONG-TERM FOLLOW-UP OF SOLITARY RENAL 486 
ALLOGRAFTS FROM PEDIATRIC DECEASED DONORS 2 
YEARS OF AGE OR LESS TRANSPLANTED INTO ADULT 
RECIPIENTS
F. Wright, P. Foster, J. Palma-Vargas, A. Bingamam
Texas Transplant Institute
Background: Since 1986 our center has performed over 250 transplants in 
adult recipients using single kidneys from donors less than 5 years of age. Our 
previous reports (Ref 1) have shown that results of these transplants can equal 
those of ideal adult donors. We also identifi ed that kidneys from donors less than 
24 months of age were more subject to technical failures and more vunerable 
to acute rejection episodes. Here we report updated results on this higher-risk 
group of adult recipients of kidneys from donors aged less than 24 months. 
Methods: From May 1996 to May 2006, 50 solitary renal allografts from 
donors < 24 months of age (median 14. 5 months, range 8-24 months) were 
transplanted into adult recipients. Mean donor weight was 11 kg (range 
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8-15kg). Technical details were previously reported (Ref 1). Induction 
immunosuppression with tacrolimus, mycophenolate and steroid maintainance 
was used. Steroid-free immunosuppression has been used since Nov. 2003. 
OPTN/SRTR renal transplant data from deceased donors 18-34 years of age 
nationally was used for comparison. 
Results: One year graft survival for recipients of a solitary pediatric kidney 
was 80%, compared with 92% for recipients of adult kidneys from “ideal” 
donors aged 18-34 (p=0. 005). Of the allografts from pediatric donors which 
failed within the fi rst year, 8/10 failures resulted from vascular thrombosis, with 
5/8 (62. 5%) thrombosis episodes from donors 8-10 months of age, compared 
with 3/42 (7%) from donors 11-24 months of age (p=0. 001). However, long-
term follow up demonstrates overall allograft survival of 72% for recipients of 
single kidneys from pediatric donors less than 24 months of age (mean follow 
up time 6. 4 years) compared with 73% 5 year survival for recipients of kidneys 
from donors aged 18 – 34 years nationally (p value not signifi cant). 
Conclusions: Single kidneys from pediatric donors less than 24 months of 
age transplanted into adult recipients result in excellent long term outcomes, 
comparable to outcomes from “ideal” deceased donors aged 18-34 reported in 
SRTR data. Solitary kidneys from donors less than 10 months of age have an 
increased risk of early graft failure due to vascular thrombosis. Pediatric donor 
kidneys from even the youngest donors should be transplanted as single units to 
increase organ availability and optimally utilize donor resources. 
Ref. 1: Transplantation Reviews, 13: 148-156, July 1999
PRETRANSPLANT MONOCLONAL GAMMOPATHY OF 487 
UNDETERMINED SIGNIFICANCE (MGUS) AS A HIGH RISK 
FACTOR FOR KIDNEY TRANSPLANTATION
H. Adrogue2, H. Carbajal1, L. Solter1, O. Gaber1
1The Methodist Hospital, Weill Medical College of Cornell, 2Baylor College 
of Medicine, 3The Kidney Institute
Introduction: Monoclonal gammopathy of undetermined signifi cance 
(MGUS) has an estimated prevalence of 3% in the general population, and 
a 1% annual risk of transformation to myeloma or other lymphoproliferative 
malignancy. Serum electrophoresis is part of the standard workup of kidney 
transplant (KT) candidates in our center. Currently, guidelines do not exist for 
transplant patients with MGUS. The incidence of MGUS and its impact on 
patient and graft survival is unknown. 
Methods: Retrospective, matched pair case-control study. Starting in the year 
2000, all patients undergoing evaluation for a KT found to have MGUS were 
included. Clinical and hematological data were collected, as well as current status 
of the grafts and patients. MGUS patients who received a KT were matched with 
controls at a 1: 2 ratio by age, gender, race, diabetes, type of donor, and date of 
transplant. Kaplan Meier survival analysis was done using Wilcoxon testing. 
Hazard rate plots were used to analyze the force of death for MGUS patients that 
received a KT and for MGUS patients that remained waiting for a KT. 
Results: Of the 501 kidney transplant candidates evaluated since 2000, 34 
patients were found to have MGUS (6. 8%). Patients were 58% male, age 63. 
2 SD10. 3; 52. 8% Caucasian, 38. 9% African-American, 8. 4% other. The 
type of paraproteinemia was IgG in 83% of the patients. All the patients that 
received a KT had a pretransplant Hematology evaluation, which was negative 
for malignant disease. The presence of MGUS was not considered in itself a 
contraindication for KT. Nine patients were transplanted. 8 patients received a 
deceased donor kidney and 1 patient had a living non-related donor. Median 
patient follow-up time after transplant was 18. 7 SD 15. 4 Seven patients (78%) 
died in the MGUS group. The median time to patient death was 12. 8 SD 5. 8 
months. Causes of death were cerebral abscess, lung cancer, sepsis, melanoma, 
bacterial meningitis, myocardial infarction, and one unknown. There were 18 
patients in the control group with a median follow-up 33. 4 months, and one 
patient (5. 5%) died due to post-transplant lymphproliferative disease. Three 
year survival was markedly decreased in the MGUS group: 22% vs. 94% in the 
Matched control group (p = 0. 0013). 
Conclusion: In our center, MGUS was a common fi nding in patients 
undergoing evaluation for a kidney transplant. There were no cases of myeloma 
or other lymphroliferative disease in the MGUS group. However, the early 
post-transplant mortality compared to matched control patients was unsettling. 
The causes of early death after transplant in the MGUS group are suggestive 
of an important immune system dysfunction that may be exacerbated by 
transplantation. These fi ndings obviate the need for further accrual of data. A 
survey is underway querying other kidney transplant centers about MGUS. 
RENAL TRANSPLANTATION FROM HCV-INFECTED 488 
DONORS INTO HCV-INFECTED RECIPIENTS: SINGLE 
CENTER EXPERIENCE. 
A. Amato, V. Sparacino, S. Calabrese, F. Caputo, R. Mongiovi, B. Oliva, 
R. Turdo, V. Vinti
UO Nefrologia E Trapianto Renale Ospedale CIVICO Palermo
Background: Renal transplantation from HCV-infected donors into 
HCV-infected recipients represents one among the potential strategies 
to overcome organ shortage and to further the number of patients having 
timely access to renal transplantation. Its rationale lies in the idea that 
the risk of transmission of HCV is less relevant and clinically harmful 
in a subject who has already a chronic infection by the same virus. Some 
criticism has been opposed to this viewpoint, because different genotypes 
of HCV exist and it is not possible to rule out that infection with a different 
genotype could behave as a new or different one and eventually worsen 
hepatic prognosis. 
Methods: 42 HCV-infected patients with end-stage-renal-disease have been 
transplanted between 2000 to 2007 at our institution. 21 of them received a 
kidney from an HCV-positive donor and the remaining 21 received a kidney 
from an HCV-negative donor. They have been regularly followed-up for an 
average time of 2, 3 and 3, 3 years respectively. 
Group D+ (recipients of HCV-
positive donors)
Group D- (recipients of HCV-
negative donors)
Number of patients 21 21
Male/Female 13/8 10/11
Dialysis duration (yrs) 9, 0 8, 0
Dialysis duration (axcluding 
those > 15 yrs) (yrs)
5, 26 5, 50
Age at transplantation (yrs) 48, 9 52, 8
HLA Mismatch 3, 7 3, 5
Follow-up (yrs) 2, 3 3, 3
Living donor 0 1
Second transplantation 2 3
Anti-HBc positive donors 2 3
HBV coinfection 1 2
Results: One-year patient and organ survival proved to be identical for both 
patients who had been grafted with HCV kidneys and those who had been grafted 
with negative ones. Subsequent follow-up did not reveal signifi cant differences. 
Group D+ (recipients of HCV-
positive donors)
Group D- (recipients of HCV-
negative donors)
One-year Organ Survival (death 
censored)
85, 7% 85, 7%
One-year Patient Survival 95, 2% 95, 2%
Organ Survival so far (Death 
censored) 
76, 2% * 76, 2% **
Patient Survival so far 90, 5% * 95, 2% **
* Mean follow-up 2, 3 years
** Mean follow-up 3, 3 years
The majority of patients in both groups developed HCV-RNA positivity after 
transplantation, though only few have shown signs of active hepatic disease, 
generally with mild elevation of liver enzymes. Interestingly, one patient in 
the HCV-positive donor group died as a consequence of a HCV-related severe 
acute hepatitits whose onset occurred early after transplantation. 
In conclusion the consequences of renal transplantation from HCV-infected 
donors into HCV-infected recipients remain only scarcely known, especially 
in the long-term. 
The major, yet uncommon, short-term adverse event reported is acute hepatitis, 
which might be probably due to re-infection with a different HCV genotype 
(thus specifi c for patients receiving from HCV donors) or reactivation of the 
pre-existing infection. 
However, as shown in this study, the short-term results are encouraging showing 
a closely similar organ and patient survival of HCV-patients transplanted both 
with kidneys from HCV-donors and with HCV-negative ones, suggesting 
that, in this era of organ shortage, HCV-matching strategy should deserve 
consideration as an alternative feasible source of kidneys for transplantation. 
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CONCURRENT ORAL SESSION 38: 
ISCHAEMIA – REPERFUSION INJURY
DONOR DOPAMINE FOR THE PREVENTION 489 
OF DELAYED GRAFT FUNCTION AFTER RENAL 
TRANSPLANTATION: A RANDOMIZED CONTROLLED TRIAL
P. Schnuelle1, U. Goettmann1, S. Hoeger1, P. Brinkkoetter1, D. Boesebeck2, W. 
Lauchart3, M. Smith4, A. Rahmel4, F. van der Woude1, B. Yard1
1University Hospital Mannheim, 2German Organ Procurement Organisation 
(DSO), Region of Bavaria, 3Organ Procurement Organisation (DSO), Region 
of Baden-Wuerttemberg, 4Eurotransplant International Foundation
Background: Retrospective clinical data indicate that donor dopamine (DA) 
may ameliorate cold preservation injury and improve initial graft function after 
kidney transplantation. This RCT investigates a standardized regimen of donor 
preconditioning with dopamine in human renal transplant recipients from a 
brain dead donor. 
Methods: Heart beating donors were randomized to receive or not to receive DA 
(4μg/kg*min) after confi rmation of brain death and given consent for donation. 
Eligibilty criteria included hemodynamic stability with low dose noradrenaline 
(<0. 4μg/kg*min), a serum-creatinine <1. 3mg/dl on admission and an increase 
<2. 0 mg during intensive care. Allocation of organs was centrally directed 
according to current Eurotransplant standards. DGF defi ned by the requirement 
of >1 dialysis session post-transplant was the primary endpoint. Study analysis 
was done on intent-to-treat. 
Results: Donor DA infusion was given with an average duration of 368±268 
min before harvesting of the kidneys (range 0-1929 min). Treated and untreated 
donors were very similar in demographics, s-creatinine, and 24hr urine 
production. 505 subsequent kidney transplants from 61 collaborating centers 
were available for study analysis (DA treated n=234, Ctrls n=271). Baseline 
characteristics of the recipients were well balanced. There were no signifi cant 
group differences in antigen mismatches, panel reactive antibodies, cold 
ischemia time, and immunosuppressive therapies, which were administered 
according to the local center’s practice. DA resulted in less DGF after 
transplantation (25. 2% vs. 35. 1%, p=0. 02). Donor age (OR 1. 03; 95%CI 1. 
01-1. 04), cold-ischemia time (OR 1. 07, 95%CI 1. 03-1. 11), and recipient’s 
body weight (OR 1. 02; 95%CI 1. 003-1. 03) were signifi cant determinants 
of an increased risk in the multivariate analysis, but the benefi cial effect of 
DA was remained (OR 0. 58; 95%CI 0. 39-0. 87). DA mediated effects on 
hemodynamics and urine production had no measurable effect on the primary 
endpoint despite a marginal increase in systolic blood pressure (132 vs. 128 
mmHg, p=0. 02) and last hour urine production (207 vs. 176ml, P=0. 005) in 
treated donors. 
Conclusion: Donor DA ameliorates DGF after kidney transplantation. It 
remains to be seen if the benefi cial effect translates in improved long-term 
graft survival. 
THE IMPACT OF PURINERGIC SIGNALLING IN RENAL 490 
ISCHAEMIA-REPERFUSION INJURY
B. Lu, E. Lee, S. Robson1, S. Crikis, S. Rajakumar, A. d’Apice, P. Cowan, 
K. Dwyer
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, Australia 
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 
MA, USA
Background: Adenosine (ADO) signalling via the adenosine 2A receptor 
(A2AR) imparts protection in mouse models of renal ischaemia-reperfusion 
injury (IRI). ADO is generated by the sequential hydrolysis of extracellular 
nucleotides by CD39 and CD73. CD39 and CD73 are recognised as integral 
immune and vascular nucleotidases and essential components of regulatory T 
cells (Treg). We have previously shown that mice transgenic for human CD39 
(hCD39tg) are protected from renal IRI and that this protection is abrogated by 
A2AR antagonists. The aim of the present study was to further delineate the 
role of ADO in mediating this protective effect using mice defi cient in CD39, 
CD73 or A2AR, thereby disrupting each tier of the protective adenosinergic 
axis. We anticipated that mice defi cient in CD39, CD73 or A2AR would exhibit 
more severe renal injury than WT mice in this model. 
Methods: CD39 null, CD73 null, A2AR null, hCD39tg and wild type (WT) 
controls (all on a C57BL/6 background) underwent right nephrectomy 
followed by left renal ischemia for 18 min and reperfusion for 24 hrs. Mouse 
core body temperature was maintained at 37ºC for the duration of ischaemia. At 
the conclusion of the experiment kidney function was assessed by measuring 
serum creatinine (SeCr) and urea (SeU) and the kidney was removed for 
histological analysis. 
Results: In this model of IRI, WT mice exhibited marked renal injury with a 
signifi cant increase in SeCr and SeU. Histologically, the WT kidneys showed 
extensive cortical injury characterised by tubular cell oedema and necrosis. 
In keeping with the protective role of ADO, mice defi cient in A2AR had 
an elevated SeCr (82. 5 μmol/L) and SeU (32. 9 mmol/L) following IRI. 
In contrast, hCD39tg mice displayed only minor injury, with a SeCr (45. 7 
μmol/L) and SeU (17. 6 mmol/L) comparable to sham animals with minimal 
histological changes (n=9). Administration of apyrase (a soluble form of CD39) 
to WT mice resulted in a similar phenotype to that of the hCD39tg mice (Se Cr 
49. 3 μmol/L, Se U 18. 4 mmol/L, n=3). Despite a lower SeCr in CD39 null 
mice (51. 2μmol/L, n=9, P=0. 450) compared to WT mice (77. 8μmol/L, n=25) 
the histological changes were similar. Interestingly, there was a trend towards 
improved outcome in the CD73 null mice following renal IRI with lower SeCr 
(53. 4μmol/L, n=9, P=0. 099) and injury score of kidneys from CD73 null mice 
were less than that observed in WT mice. 
Conclusion: We have established a valid model of renal IRI and can demonstrate 
protection by the administration of apyrase or the expression of hCD39 both 
biochemically and histologically, which was abrogated with deletion of the 
A2AR. Unexpectedly, renal injury was not exacerbated in mice defi cient in 
CD39 or CD73, suggesting a complex interaction between infi ltrating immune 
cells, the vasculature and parenchymal expression of these receptors. Adoptive 
transfer experiments will be performed to further investigate this interaction. 
EPO AND ASIALOEPO PROTECT INTESTINAL 491 
ISCHEMIA REPERFUSION INJURY IN RAT
T. Sawada, S. Mori, K. Kubota
Dokkyo University School of Medicine
Objective: Ischemia/reperfusion injury (I/R) in the small intestine is a serious 
obstacle in intestinal transplantation. The protective effect of erythropoietin 
(EPO) and its non-hematopoietic derivative, asialoEPO (aEPO), against (I/RI) 
was investigated in a rat model. 
Methods: The superior mesenteric artery of Wistar rats was clamped for 60 min, 
and then released. The rats were divided into four groups (n=15 in each group): 
sham operation (Sham), vehicle treatment (Vehicle), EPO treatment (EPO), 
and asialoEPO treatment (AsialoEPO). EPO and asialoEPO were administered 
subcutaneously at a dose of 1000 units/kg 10 min before clamping, 30 min after 
the start of clamping, and just before declamping, followed by determination of 
72-h survival rates, serum TNF-α and IL-6 levels. 
Results: The survival rates at 72 h after I/R injury in the Sham, Vehicle, EPO, 
and AsialoEPO groups were 100%, 33. 3%, 75. 0%, and 83. 3%, respectively 
(P<0. 05). Blood TNF-α concentrations in the Vehicle, EPO, and AsialoEPO 
groups at 6 h after I/RI were 4. 8 ± 1. 4 pg/mL, 1. 2 ± 0. 5 pg/mL, and 1. 0 ± 
0. 5 pg/mL, respectively (P<0. 019). The concentrations of IL-6 in the Vehicle, 
EPO, and AsialoEPO groups at 6 h after I/RI injury were 3867 ± 1103 pg/mL, 
880 ± 253 pg/mL, and 937 ± 283 pg/mL, respectively (P<0. 034)
Conclusions: EPO and asialoEPO exert a strong protective effect against 
intestinal I/R injury by inhibiting TNF-α and IL-6. 
DONOR PRE-TREATMENT WITH AN HIF-492 
PPROLYLHYDROXYLASE-INHIBITOR IMPROVES FUNCTION 
AND INCREASES LONG-TERM GRAFT SURVIVAL IN AN 
ALLOGENIC RAT TRANSPLANT MODEL
M. Wiesener1,2, W. Bernhardt1, U. Gottmann4, F. Doyon4, B. Bucholz1, V. 
Campean3, 
S. Klaus5, B. Yard4, K-U. Eckardt1
1Dept. Nephrology & Hypertension, Univ. Erlangen, 2Interdisciplinary Centre 
of Clinical Research, Univ. Erlangen, 3Dept. Pathology, Univ. Erlangen, 4Dept. 
Nephrology, Univ. Mannheim, 5FibroGen Inc. , South San Francisco
Besides immunological aspects, the long-term survival of a renal allograft 
depends on the initial injury caused by the sequence of cold ischemia, warm 
ischemia and reperfusion and is thus already determined at the time of 
transplantation. Hypoxia-inducible transcription factors (HIF) are essential 
for adaptation to low oxygen. Normoxic inactivation of HIF is regulated by 
oxygen-dependent hydroxylation of HIF by prolyl-hydroxylases (PHD). 
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Pharmacological inhibition of the PHD results in HIF accumulation with 
subsequent activation of nephroprotective genes. We examined the effect 
of donor treatment with a specifi c inhibitor of the PHD (FG-4497) on graft-
function in a rat model of allogenic kidney transplantation (KTx). 
The Fisher-Lewis rat model of KTx was used. Isogenic transplantations served 
as controls. Orthotopic transplantation of the left donor-kidney was performed 
after 24h of cold storage. The right kidney was removed at the time of KTx 
(acute) or at day 10 (chronic). 6h prior to kidney explantation, donor animals 
were treated with a single dose of FG 4497 (40mg/kg i. v. ) or vehicle (Veh) 
Recipients were followed up for 10 days (acute, n=6-8) or 24 weeks (chronic, 
n=13-14). 
Donor-preconditioning with FG 4497 resulted in HIF accumulation and induction 
of HIF target genes, which persisted beyond cold storage. It reduced acute renal 
injury (Serum creatinine FG-4497: 0. 66±0. 20 vs Veh 1. 49±1. 36; p<0. 05) and 
improved histomorphology at 10 days. Donor-preconditioning improved long 
term survival of recipient animals (mortality after 24 wks: 7/13 Veh vs. 3/14 
FG-4497; 0/13 of the isogenic controls; p<0. 05 FG-4497 vs. Veh). 
Pretreatment of organ donors with FG-4497 improves short- and long-term 
outcome after prolonged cold storage and subsequent allogenic KTx. These 
fi ndings may have signifi cant clinical implications. 
PREVENTING KIDNEY INJURY BY PERFUSING DONOR 493 
ORGAN WITH SIRNA-SOLUTION
X. Zheng1, J. Jiang, X. Zhang, M. Beduhn, H. Sun, M. Suzuki, N. Kubo, 
B. Garcia, A.M.J. Jevnikar, W-P. Min
1University of Western Ontario, 2University of Western Ontario, 3University 
of Western Ontario, 4University of Western Ontario, 5University of Western 
Ontario, 6University of Western Ontario, 7University of Western Ontario, 
8University of Western Ontario, 9University of Western Ontario, 10University 
of Western Ontario
Background: Renal ischemia-reperfusion (I/R) injury occurs in kidney 
transplantation, and has no current clinical cure. Gene silencing using siRNA 
to specifi cally knock down I/R-associated genes, such as infl ammatory, 
complement and apoptosis genes, may effectively prevent I/R injury. This 
study was designed to prevent renal I/R injury by perfusing donor kidney 
organs using siRNA solution. 
Methods: C57/BL6 kidneys were excised and perfused with 200 μl of HTK 
that contains 100 μg/ml siRNAs targeting Fas, TNFα, and complement 3 
(C3) genes. siRNA-solution-perfused kidneys were implanted into syngenic 
recipients. Forty-eight hours after transplantation, the grafted kidneys were 
harvested. The I/R injury was assessed by renal function, histopathology and 
immunohistochemistry. 
Results: Perfusion procedure resulted in effective incorporation of siRNA 
into kidney tissues, demonstrated by fl uorescence-labelled siRNA that was 
observed 30 min after perfusion. Gene expression of Fas, TNF-α, and C3 was 
signifi cantly knocked down 24 hours after perfusion with siRNA solution. 
Perfusion with siRNA prior to transplantation remarkably reduced BUN and 
serum creatinine levels. Furthermore, protection of I/R injury by perfusion with 
siRNA was demonstrated by improved histopathology, attenuated apoptosis, 
and decreased infl ammatory cytokine secretion
Conclusion: This is the fi rst demonstration that perfusing donor organs with 
siRNA solution effectively delivers siRNA and induces gene silencing in 
kidney. Silencing Fas, ΤΝF-α, and C3 using siRNA solution prevented renal 
I/R injury, highlighting the promise of clinical application using siRNA-
based therapy. 
PROTECTION OF RENAL ISCHEMIA INJURY BY RENAL 494 
ARTERY INFUSION OF ICAM-1SIRNA
Y.P. lu, G.H. Luo, J. song, L. yang, L. luo, X. Ma, Y.P. li
Transplantation Institute
Aim: Studies have proven that ICAM-1 plays an important role in Ischemia/
reperfusion injury (IRI) of renal transplant. RNA interference (RNAi) with 
Chemical modifi cation has shown a strong silencing effect. This study is to 
investigate the potential preventing role of infusion small interfering RNA 
(siRNA) targeting ICAM-1 through renal artery in rat cold ischemia injury 
(IRI) renal transplant model. 
Methods: F344 rats underwent renal isografting. The recipients were divided 
into three groups (each group n=9): (1)Normal saline (NS); (2)control siRNA; 
(3)siRNA. Before transplant, the kidneys in three groups were infused either 
with Ns or Control siRNA or ICAM-1siRNA (0. 1mg/kg) through the renal 
artery with the renal vein clamped ex vivo. siRNA delivering was observed 
through Light tools and fl uorescence microscope in vivo. SCr was measured 
and the expressions of ICAM-1 mRNA and Protein were accessed by real-
time RT PCR and Western blot at 6h, 12, 24h, 48h and 72h post-transplant. 
The severity of tubular necrosis and infl amed cells infi ltration was assessed by 
histologic evaluation. 
Results: siRNA successfully reached rat graft through renal artery. The 
immunohistochemistry (IHC) stain of ICAM-1 was observed in renal 
tubular and blood vessel. Comparing with the NS and control siRNA group, 
the histologic changes of IRI and IHC positive stain were less severe in 
siRNA group. The expression of ICAM-1 mRNA/protein and SCr levels in 
the isografts increased in a time dependent manner. However, Comparing 
with the NS and control siRNA group, the expressions of ICAM-1 mRNA 
and protein in siRNA group were signifi cantly down-regulated from 12 to 
48h post-transplant (p< 0. 01), especially at 24h (p< 0. 001). The values of 
ICAM-1 mRNA/protein (DQ ratio) in NS, control siRNA and siRNA group 
were 22. 83±0. 21/1. 37±0. 02, 23. 17±0. 21/1. 48±0. 07 and 21. 31±0. 21/0. 86±0. 04, 
respectively. The values of SCr in siRNA group were lower than those in 
other two groups in all time points, the differences from 12h to 48h were 
statistically signifi cant (p<0. 01), and the peak effect also appeared at 24h (p< 
0. 001). At 24h, SCr (umol/L) in NS, control siRNA and siRNA group was 
203. 54±39. 47, 216. 9±61. 65 and 100. 0±25. 80, respectively. The survival 
rates in the fl ethal I/R injury rats after treatment with ICAM-1 siRNA 
increased from 50% to 80%. 
Conclusions: ICAM-1siRNA can signifi cantly prevent and attenuate the renal 
damage secondary to ischemia. It is the fi rst demonstration that the siRNA can 
be applied through renal artery infusion. 
NEW TRENDS IN CLINICAL CARDIAC PRESERVATION 495 
– COLD ISCHEMIA VS. WARM PERFUSION - BENEFICIAL 
EFFECTS FOR THE ENDOTHELIUM -
G. Tenderich, A. El Banaousy, S. Schulte-Eistrup, U. Schulz, M. Tenderich, 
M. Morshuis, L. Arusoglu, T. Kahayal, S. Stille, R. Koerfer
Dpt. Thoracic- And Cardiovascularsurgery
Background: Coronary transplant vasculopathy (TVP) is known to be 
associated with an impairment of endothelium-dependent vasoreactivity after 
heart tranplantation (HTx). Regarding the etiology of TVP, antigendependant 
and independant factors (AIF) are responsible for injury of the endothelium. 
Ischemic- and the resulting reperfusion injury are thought to play a major role 
regarding AIF, with the initial leason to the endothelium. Warm donorblood 
perfusion in a beating state of the heart using the organ care system (OCS) 
leads to a dramatic decrease of ischemic time and is supposed to minimize the 
resulting injury. 
Methods and Results: Evaluation of the overall coronary vasodilator capacity 
– coronary fl ow reserve (CFR) assessed by positron emission tomography 
(PET) at rest andunder dipyeidamole stress was performed for noninvasively 
investigation of 4 different groups of patient (pts): 
A: 28 HTx-ed patients (24 men/4 women aged between 19 and 67 years (mean: 
52. 5 + 12. 8) follow-up 365 – 483 days post HTx (median: 387d)
Recipient diagnosis: 18 CAD, 8 DCM, 2 VD
13 men and 15 women, aged 11 to 58 years (mean 33. 8 + 11. 1)
Diagnosis: 9 SHT, 8 SAB, 6 ICB, 4 Hypox. , 1 brain neoplasm
Ischemic time:
142 –285 min. (mean: 200 + 35)
B: 7 patients (2 men, 5 women, aged 59 + 8 years with atypical angina pectoris) 
with normal CFR and without angiographic coronary artery disease
C: 23 patients (10 men, 13 women aged 58. 7 + 10. 3 years, regulary coronary 
angiogram n = 9, minor angiographic coronary artery disease; stenosis < 
25% n = 14; hypertension n = 15) with angina pectoris without/with minor 
angiographic coronary disease
D: Group D: 
10 HTx-ed pts. 375+/-56 days post HTx 
Recipient age: 47+/-14y. 
Donor age: 33+/-9y. Ischemic time: 
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 42+/-12min. 
OCS warm perfusion time: 
 250+/- 76 min. 
Results: Coronary fl ow reserve was different in all 4 groups with different 
levels of signifi cance : 
A: 1. 5+/-0. 4
B: 2. 5+/-0. 7
C: 4. 7+/-0. 8
D: 3. 7+/-0. 9
Conclusion: Warm perfusion of the heart using oxigenated nutrientenriched 
donorblood may have a positive impact on the functional status of coronary 
arteries regarding CFR. 
POLYPHARMACEUTICAL SURVIVAL KINASE 496 
ACTIVATION PROVIDES SIGNIFICANT CARDIAC 
PROTECTION AFTER PROLONGED HYPOTHERMIC 
STORAGE. 
L. Gao2, J. Kwan2, A. Jabbour2, P. Macdonald1, M. Hicks1
1St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: Three processes important to the preservation of donor heart 
function after storage and reperfusion are maintenance of nitric oxide fl ux, 
minimisation of intracellular calcium levels and minimisation of energy 
depletion. We showed pharmacological modulation of these processes by 
supplementing cardioplegic and storage solutions with either the nitric 
oxide donor glyceryl trinitrate (GTN), sodium-hydrogen exchange inhibitor 
cariporide and the poly (ADP-ribose) polymerase inhibitor INO1153 improved 
post storage cardiac function1, 2 and was associated with activation of pro-
survival kinases at reperfusion (ERK 1/2 by cariporide or GTN and Akt by 
INO1153). The aim of this study was to examine the cardio-protective effect of 
a protocol incorporating combination these approaches on the preservation of 
haemodynamic function in the isolated rat heart after prolonged hypothermic 
storage. 
Methods: Pre-arrest indices of cardiac function were measured in isolated 
working rat hearts after 25 minutes. Hearts were arrested and stored for 10 
hours at 2-3°C in Celsior supplemented with either: 1) GTN (0. 1mg/ml); 2) 
cariporide (10μM); 3) INO 1153 (1μM) alone or in combination (see Table 
below). Hearts were remounted on the perfusion apparatus after storage and 
indices of cardiac function were remeasured, then hearts were frozen in liquid 
nitrogen for Western blot analysis. 
Results: The values in the following table are post-storage recovery as 
percentage of pre-arrest values (mean ± SEM): 
Supplement; n Heart 
Rate
 (beats/
min)
Coronary 
Flow
 (ml/min)
Aortic 
Flow
 (ml/min)
Cardiac 
Output
 (ml/min)
GTN# 
alone; 5
9. 9 ± 9 8. 0 ± 
1. 7
0. 8 ± 
0. 5
3. 0 ± 
0. 7
Car# alone; 6 17. 4 ± 10. 2 21. 0 ± 4. 3 1. 4 ± 0. 8 5. 8 ± 1. 2
INO# alone; 4 21. 5 ± 12. 5 7. 0 ± 2. 9 1. 1 ± 0. 6 1. 7 ± 0. 7
GTN + INO; 6 40. 2 ± 18. 7 15. 3 ± 10. 5 12. 1 ± 9. 5 15. 3 ± 10. 5
Car + INO; 7 28. 2 ± 12. 2 18. 8 ± 8. 7 3. 0 ± 1. 5 7. 3 ± 3. 4
GTN+ Car; 6 54. 5 ± 14. 7 48. 6 ± 12 17. 8 ± 10. 3 25. 7 ± 10. 6
GTN+Car+INO; 6 86. 4± 4. 4§ 66. 9 ± 4. 5† 42. 2±10. 7* 49. 2 ± 8. 8¶
#GTN: Glyceryl trinitrate, Car: Cariporide, INO: INO1153; * P < 0. 02, † P < 0. 006, 
¶ P < 0. 04 vs all doubly supplemented groups; § P < 0. 02 vs GTN+INO & Car+INO 
The functional improvement in the triple supplementation was accompanied 
by signifi cant activation of Akt and ERK 1/2 as well as phosphorylation and 
activation of their downstream target, GSK-3beta. 
Conclusion: These data show supplementing a commercial storage solution 
with multiple pharmacological agents targeted to activate different pro-survival 
signalling pathways may be a useful approach to increasing the cold ischemic “shelf 
life” of the donor heart and maximising function of “marginal” donor hearts. 
SERUM ANGIOPOIETIN 1 AND 2 ARE ELEVATED IN 497 
DECEASED BRAIN DEAD DONORS AND PREDICT RENAL 
FUNCTION AFTER TRANSPLANTATION. 
H. Leuvenink, L. Koudstaal, M. Nijboer, H. Burgerhof, V. Nieuwenhuijs, J. 
Homan van der Heide, H. van Goor, R. Ploeg
University Medical Center Groningen
Organs retrieved from deceased brain dead (DBD) donors show worse organ 
function and more acute rejection episodes post-transplant than those derived 
from living donors. To date, no relevant serum markers are available to predict 
kidney function after transplantation. Angiopoietin 1 (Ang-1) and Angiopoietin 
2 (Ang-2) are regulatory proteins that play an important role in vascular 
infl ammation. Ang-1 dampens the infl ammatory response while Ang-2 boosts 
it. In this respect, Angiopoietins could refl ect the immunogenic state of the 
organ and could be used as predictors of donor organ quality. Therefore, we 
measured Ang-1 and Ang-2 levels in serum from 21 human multi-organ brain 
dead donors and compared them to 20 living kidney donors. Serum samples 
were obtained from DBD organ donors immediately after diagnosis of brain 
death (T0) and just prior to actual organ retrieval (T1). Serum from living 
kidney donors was used as a control. Serum Ang-1 and Ang-2 were measured 
by ELISA. 
In the serum of DBD donors, a profound rise in both Ang-1 and Ang-2 levels 
were seen compared to living donors. Serum Ang-1 was signifi cantly elevated 
at T0 (T0: 360 ± 57 pg/mL vs. T1 158 ± 18 pg/mL) compared to living donors 
(T0: 197 ± 32 pg/mL vs. T1: 156 ± 45 pg/mL. Serum Ang-2 levels in DBD 
donors were higher at both time points (T0: 978 ± 159 ng/mL vs. T1: 873 ± 177 
ng/mL) compared to living donors (T0: 295 ± 30ng/mL T1: 340±175ng/mL). 
Ang-1 levels decreased signifi cantly during the brain dead period comparable 
to levels in living donors, suggesting a shift of the infl ammatory balance 
towards the direction of activation. 
Interestingly, higher Ang-2 levels in the donor were associated with an 
increased risk of rejection (T0 vs. T1 odds ratio (OR) 1. 003/1. 002 p=0. 03/
p=0. 049). Rejection was defi ned as biopsy proven rejection in the fi rst year 
post-transplant including all grades of interstitial and vascular rejection. Most 
strikingly, the shift of Ang-1/Ang-2 ratio towards Ang-2 increased the risk of 
delayed graft function (DGF) (T0 vs. T1 OR 0. 003/0. 003 p=0. 036/0. 051). 
DGF was defi ned as the need for dialysis in the fi rst week. 
This study shows for the fi rst time that both Ang-1 and Ang-2 are indicators in 
the DBD donor of kidney (dys)function after transplantation. The Ang-1/Ang-2 
ratio expresses immune activation of the renal graft-to-be and angiopoietins 
appear to predict delayed graft function and rejection after transplantation. To 
restore the Ang-1/Ang-2 balance may therefore be of great therapeutical value 
to improve transplantation outcome of DBD donors. In this respect, Ang-2 
neutralizing agents, which have recently been developed as anti-angiogenic 
tumor drugs, could be of great value for that purpose. 
CONCURRENT ORAL SESSION 39: 
PAEDIATRIC LIVER TRANSPLANTATION
OUTCOMES OF LIVER TRANSPLANTATION FOR 498 
UNRESECTABLE MALIGNANT LIVER TUMORS IN 
CHILDREN: A MULTICENTER REVIEW
M. Nadler1, R. Shepherd2, J. Lowell3, G. Tiao4, L. Smith5, R. Anand6, 
C. Song6, Split Group6
1St. Louis Children’s Hospital, 2Department of Pediatrics, Washington 
University School of Medicine, 3Department of Surgery, Washington 
University School of Medicine, 4Pediatric Surgery, Cincinnati Children’s 
Hospital, 5Department of Pediatrics, New York Presbyterian Hospital, 
6EMMES Corporation, Rockville, MD
Background: Treatment of hepatic malignancies in children is complex and 
challenging. Because of their rarity, treatment is not standardized and outcomes 
from large cohorts are not well documented. Complete surgical resection appears 
essential for cure and with adjunctive chemotherapy, is the mainstay of therapy, 
although many tumors are unresectable. In recent years, liver transplantation 
has been performed successfully in children with unresectable tumors. 
Purpose: To help focus on areas where treatment might be improved, 
outcomes and risk factors for poor outcome were studied in a large, multicenter 
cohort of children with primary hepatic malignancies who underwent liver 
transplantation. 
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Methods: Data from 2605 children listed for liver transplant in the Studies in 
Pediatric Liver Transplantation (SPLIT) Registry between 1996 and 2006 was 
studied. Patient and graft survival were compared amongst the types of hepatic 
malignancies, and with non-tumor outcomes, and risk factors for poor outcome 
for each tumor type such as timing of transplant from listing, donor type, age, 
gender, and era of transplant were evaluated. 
Results: A total of 176 children had hepatic malignancies, including 
hepatoblastoma (HB, n=124), hepatocellular carcinoma (HCC, n=21), 
hemangioendothelioma (HE, n=18), and ‘other’ tumor (n=13; undifferentiated 
embryonal sarcoma (UES, n=5/13). Recipient age and gender were not 
statistically signifi cant in terms of outcomes. All deaths on the waiting list 
(HB, n=3, HCC, n=2, HE, n=3) occurred prior to 2002. Five year patient and 
graft survival rates from transplant were lower compared to non-tumor patients 
(71% patient, 66% graft vs. 87% and 79%, p<0. 01), mainly related to tumor 
metastases/recurrence: of 34 reported patient deaths in all hepatic malignancies, 
24 were tumor related (HB, n=20, HCC, n=4). Two of fi ve reported deaths in 
patients with HE were related to severe cardiomyopathy. Five year survival 
rates were improved in patients who received live donor transplants when 
compared to deceased donor transplants (84% patient, 76% graft vs. 68% and 
64%, p<0. 001). Five year patient and graft survival in the ‘other’ tumor type 
category were better (100%, 92%, respectively) when compared to HB (69%, 
64%), HCC (63%, 63%), and HE (65%, 65%) tumor types. 
Discussion: Long term survival after liver transplantation for unresectable 
hepatic malignancies in children compares favorably with reported survival 
after primary resection. Timing of transplant may play a role in outcome: all 
waiting list deaths occurred prior to use of the current UNOS PELD scoring 
system; the improved outcomes in those receiving living donor transplants may 
also refl ect on the ability to time transplantation more effectively. However, the 
majority of patient deaths after transplant were due to recurrence, particularly in 
HB, where close attention to resectability vs. transplantation at diagnosis, and 
effects of adjunctive chemotherapy, while beyond the scope of this analysis, 
deserves detailed further study. In HE, the focus should be on preventing cardiac 
mortality. Outcomes for ‘other’ rare tumors such as UES were uniformly good, 
suggesting that primary liver transplant may be the preferred modality for 
surgery for these multicentric hepatic malignancies. 
DOES LIVING DONATION OFFER AN ADVANTAGE IN 499 
SURVIVAL AFTER PEDIATRIC LIVER TRANSPLANTATION IN 
THE MELD ERA? – ANALYSIS OF OPTN/UNOS DATA
Y. Cho1,2, T. Steljes2, J. Cicciarelli1,2, I. Hutchinson1,2, M. Stapfer2, 
R. Mateo2, L. Sher2, R. Selby2, Y. Genyk2
1National Institute of Transplantation, 2USC School of Medicine
Background: Recent studies demonstrated better outcomes of graft and patient 
survival in living donor liver transplantation (LDLT) compared with those of 
whole liver (WLT) and split liver transplantation (SLT). However their results 
often utilize recipients from both pre and post model-for-end-stage- liver-
disease (MELD/PELD) implementation. 
Aims: This study retrospectively compares LDLT, SLT, and WLT in pediatrics 
in the MELD/PELD era by examining the OPTN/UNOS database with the 
intent to identify recipient factors that may impact outcomes. 
Materials and Methods: From January 1, 2002 to December 31, 2006, 1, 976 
liver transplant (LT) in recipients age<12 years old were reported to the OPTN/
UNOS. Of these, 298 LDLTs, 384 SLTs, and 1, 294 WLTs were identifi ed. 
Multiple organ transplants were excluded from the study. The log-rank test was 
used for comparison of the two survival curves. 
Results: Unadjusted graft survival rates of LDLT (85% at 1-yr and 82% 3-yr) 
were not signifi cantly different to those of SLT (81% at 1-yr and 75% 3-yr, 
P=0. 11) and WLT (81% at 1-yr and 75% 3-yr, P=0. 08) (Figure). Patient 
survival rates of LDLT (91% at 1-yr and 90% 3-yr) were also not signifi cantly 
different to those of SLT (90% at 1-yr and 86% 3-yr, P=0. 54) and WLT (88% 
at 1-yr and 84% 3-yr, P=0. 12) (fi gure). Incidence of primary graft failure was 
3. 4% for LDLT compared with 3. 9% for SLT (P=0. 70) and 3. 5% WLT 
(P=0. 91). Incidence of graft loss due to vascular thrombosis in LDLT group 
(6. 0%) also was not signifi cantly different than those of SLT (6. 0%, P=0. 
98) and WLT group (5. 1%, P=0. 91). Incidence of biliary tract complications 
was the highest in SLT (2. 1%) among 3 group, but the differences were not 
statististically signifi cant (0. 7% in LDLT, P=0. 13 and 0. 7% WLT, P=0. 96). 
In multivariate analyses, both adjusted graft and patient survival rates of LDLT 
were not signifi cantly different than those of SLT (Relative Risk (RR)=0. 79 
(95% CI: 0. 59-1. 07), P=0. 13 for graft and RR=0. 77 (0. 52-1. 14), P=0. 19 
patient) and WLT group (RR=0. 92 (0. 71-1. 18), P=0. 50 for graft and RR=0. 
75 (0. 53-1. 06), P=0. 10 patient) after adjusting for confounding factors such 
as PELD and regraft. 
Conclusion: In the MELD era, both SLT and WLT in pediatrics yielded 
comparable graft and patient survival to LDLT. 
OUTCOME OF NON-HEART BEATING DONOR (NHBD) 500 
LIVERS IN PAEDIATRIC RECIPIENTS. 
A. Bartlett, R. Vara, A. Dhawan, G. Mieli-Vergani, M. Rela, N. Heaton, 
P. Muiesan
Kings College Hospital
Adult liver transplantation using grafts from non-heart beating donors (NHBD) 
is associated with acceptable short and long-term graft survival. Little is known 
about the outcome of paediatric recipients transplanted with livers from NHBD. 
From April 2001, 158 livers were retrieved from NHBD using our previously 
described rapid retrieval technique. Eighty-four were transplanted, of which 
11 were paediatric recipients. Donor characteristics of the organs transplanted 
into the paediatric recipients included a mean age 25. 5 years (10-64), intensive 
care stay of 10. 2 days (1-14) serum bilirubin level of 25 (7-86) and inotropic 
support in 4 of 11. The mean warm and cold ischaemic time was 17 (11-29) 
minutes and 7. 6 (6. 2-12) hours, respectively. Indications for transplantation 
included: various chronic liver diseases in 9, acute liver failure (ALF) in one 
and re-transplantation for hepatic artery thrombosis in one. The mean recipient 
age was 6. 4 years (8-156 months) with a median Child-Pugh score of 9 (7-13). 
Liver grafts were transplanted as whole organs (n=3), reduced grafts (n=6), 
formal split (n=1) or an auxiliary (n=1). When a NHBD graft was reduced 
the remaining liver was used for isolation and transplantation of hepatocytes 
for children with metabolic diseases. Six of the 11 grafts were reperfused 
with arterial blood and all had biliary reconstruction by Roux-en-Y hepatico-
jejunostomy. The mean post-operative follow-up was 32. 3 months (7-67. 4) 
months. Five of 11 developed biopsy proven acute rejection of which 2 had two 
episodes. The mean AST (mmol/L) at day 1, 3 months and 12 months was 2820 
(8471-489), 58. 5 (20-174) and 50. 6 (27-119). Two patients developed cut 
surface collections that required percutaneous drainage. One patient developed 
ductopenic rejection 18 months post-transplant and is being considered 
for retransplantation. To date there have been no biliary complications and 
the mean bilirubin (mmol/L) at day 7, 6 months and 12 months was 63. 2 
(12-226), 9. 9 (4-31) and 10. 7 (6-20). In summary, LT with NHBD grafts in 
paediatric recipients can be performed with low morbidity and excellent patient 
outcome. 
EFFICACY AND SAFETY OF CYTOMEGALOVIRUS 501 
PP65 ANTIGENEMIA-GUIDED PREEMPTIVE THERAPY IN 
PEDIATRIC LIVER TRANSPLANT RECIPIENTS
A. De Icaza-González, A. Hernández-Plata, J. Nieto-Zermeño, 
L. González-Jorge, C. Zalles-Vidal, G. Varela-Fascinetto
Hospital Infantil De México Federico Gómez, Transplantation Dept
Background: Cytomegalovirus (CMV) infection is a signifi cant cause of 
morbidity and mortality in liver trasplantation. Ganciclovir is considered the 
mainstay treatment for CMV infection; however, there is still controversy 
on the optimal prophylactic strategy for CMV disease after transplantation 
(universal prophylaxis vs preemptive therapy). In preemptive therapy 
ganciclovir is started and given for a limited time, based on evidence of viral 
replication using CMV-pp65 antigenemia or CMV-PCR. Preemptive approach 
limits the cost of therapy and reduces the adverse effects related to ganciclovir 
and drug resistance. The aim of this study was to analyze our experience on 
CMV disease in pediatric liver transplantation and to assess the effi cacy and 
safety of CMV antigenemia-guided preemptive therapy. Incidence of disease 
among different risk groups, survival, adherence to treatment and drug therapy 
costs were also analyzed. 
Methods: Single center, retrospective review of pediatric liver transplant 
recipients during a 9-year period. Only patients that survived a minimum of 
3 months after transplant and had an adequate CMV-antigenemia follow-up 
were included. Patients receiving antiviral therapy for reasons other than CMV 
infection were excluded. Demographics, risk for CMV disease, antigenemia 
results, and relevant clinical data were analyzed. Descriptive statistical analysis 
included Student’s t test and Pearson correlation test for continuous variables, 
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and Chi-square and Fisher’s exact test to compare nominal data. Overall 
actuarial survival was calculated using Kaplan-Meier analysis. 
Results: Forty patients were included for analysis. Twenty four had a history 
of positive antigenemia (Ag+) and 16 had negative antigenemia (Ag-) during 
their follow up. There were no demographic differences between groups. The 
incidence of a Ag+ according to risk group was 77% for D+/R-, 63% D+/R+, 
50% D-/R+ and 25% D-/R-. None of the 16 Ag- patients received ganciclovir 
after transplantation. Among the 24 Ag+ patients, only 14 received preemptive 
treatment based on clinical suspicion of CMV disease, more than 10 positive 
cells in the antigenemia and high-risk status for CMV disease. Only one patient 
with intermediate risk and 53 positive cells developed invasive CMV disease 
that ultimately responded to treatment. The 10 Ag+ patients that did not received 
treatment were asymptomatic, 5 presented one positive cell antigenemia, 3 
patients had 2 positive cells, and 2 patients had 4 and 9 positive cells, respectively, 
that reversed to Ag- under close clinical and laboratory monitoring. Actuarial 
survival at 1800-days post-transplantation was similar between groups: 95% 
for Ag+ and 100% for Ag- patients. There were no CMV-related deaths. In this 
study, preemptive treatment saved more than 150, 000 USD. 
Conclusion: CMV pp65 antigenemia-guided preemptive treatment is 
affordable, safe, and effective. This study also confi rms that positive CMV 
pp65 antigenemia in liver transplant recipients with low and intermediate risk 
for CMV disease does not mandate preemptive ganciclovir treatment, and 
some of these patients might be closely observed with repeated determination 
of antigenemia until its negativization. 
LESSONS LEARNED FROM 120 CONSECUTIVE LIVING 502 
DONOR LIVER TRANSPLANTATIONS FOR BILIARY ATRESIA 
IN A SINGLE CENTER
A.D. Concejero, C.L. Chen, C.C. Wang, S.H. Wang, C.C. Lin, Y.W. Liu, 
C.H. Yang, C.C. Yong, T.S. Lin
Liver Transplant Program, Department of Surgery, Chang Gung Memorial 
Hospital-Kaohsiung Medical Center
Background and objective: Biliary atresia (BA) is the most common 
indication for liver transplant in children. The aim of this study is to present 
our experience in living donor liver transplantation (LDLT) as a treatment for 
end-stage liver disease in children with BA. 
Patients and methods: A review of transplant records from June1994-
November 2007 was performed. One hundred-twenty (120) BA patients 
underwent primary LDLT. The mean follow-up period was 48 months. 
Results: There were 62 males and 58 females. The mean age was 3. 6 years 
(range: 6 months-19 years). The mean preoperative weight, height and computed 
GFR were 13. 9 kg, 80. 3 cm, and 117. 5 ml/min/1. 73 m2, respectively. 32 
patients were below 1 year of age, and 59 patients were below 10 kg at time of 
transplantation. 115 had had previous Kasai operation prior to transplant. The 
most common co-existing medical condition was congenital heart disease. The 
mother was the most common donor. The mean donor intraoperative blood loss 
was 70 ml. There were 4 donor complications with 2 donor reoperations. The 
mean recipient operative time was 607 min. The mean recipient intraoperative 
blood loss was 297 ml. 39 did not require blood or blood component transfusion. 
The left lateral segment (77) was the most common graft used. 22 grafts 
underwent venoplasty prior to implantation. Innovative techniques like use of 
Foley catheter to reposition the graft in outfl ow problems and use of Gore-Tex 
to approximate the abdominal fascia were employed. There were 33 operative 
complications which included 4 reoperations for postoperative bleeding, 
10 portal vein, 5 hepatic vein, 7 hepatic artery, and 7 biliary complications. 
There were 4 in-hospital mortalities and 2 retransplantations. Most major 
late complications occurred in recipients who received blood transfusion. 
The posttransplant renal function was adequate in a majority; and metabolic 
disturbances were not documented. The overall rejection rate was 20%. The 
overall graft failure rate was 4% and the overall mortality rate was 5%. The 
6-month, 1-year, and 5-year actual recipient survival rates were all 97%. 
Conclusion: LDLT is a treatment for end-stage liver disease secondary to BA 
that has yielded excellent recipient outcome and low donor morbidity. 
LIVER TRANSPLANTATION FOR SMALL CHILDREN IN 503 
CHILE: EXPERIENCE AND LONG-TERM OUTCOME
R. Busuttil
David Geffen School of Medicine At UCLA
Introduction: The outcome of orthotopic liver transplantation (OLT) in 
pediatric patients has improved in last decades, but the subgroup of small 
children, weighting 10 kilograms or less, still presents several clinical problems. 
Despite optimal results reported elsewhere, complications are more frequent 
than in older patients, specially from vascular anastomoses. The aim of this 
study is to present the experience of liver transplantation in patients weighing 
10 kilograms or less, in a multicenter liver transplantation program in Chile. 
Patients and Methods: From November 1993 to February 2008, we performed 
348 OLT, 188 of them in pediatric patients younger than 15 years. 37 patients, 
weighing 10 kilograms or less were transplanted. The data of these cases was 
reviewed. Kaplan Meier test was used for actuarial survival. 
Results: 37 children received 45 grafts. 6 patients required retransplant, 2 of 
them received a third graft. Twenty patients were males (54%). Median age and 
weight were 1. 1 years (range 8 months-6 years) and 8. 1 kg. (range 4. 8-10) 
respectively. Primary liver disease was biliary atresia in 25 patients (68%), 
Alagille syndrome in 4 (11%), fulminant hepatitis in 2 (5%), Byler disease in 
2 (5%), neonatal hepatitis in 2 (5%), hepatoblastoma in 1 (3%) and metabolic 
disease in 1 (3%). Grafts from living donor (segments II-III) were used in 
23 cases (51%); deceased donor grafts in 22 patients (49%) (11 complete 
liver, 10 reduced grafts, and 1 split-liver). Graft-to-recipient weight ratio was 
greater than 1% in all the cases. Two patients underwent delayed abdominal 
wall closure. Immunossupresion was based on cyclosporin or tacrolimus plus 
steroids. Daily hepatic ultrasound with doppler was performed in the fi rst 10 
days after OLT. 
Regarding vascular complications, 8 cases of portal vein thrombosis (PVT) 
were seen, 5 hepatic arthery thrombosis (HAT), and one patient with both 
(PVT-HAT). Of them, 10 required reoperation (7 PVT, 2 HAT and 1 PVT-
HAT). Five patients had biliary leaks, requiring surgical repair. There were 3 
biliary stenosis managed percutaneously. 
Patient survival at 1 and 5 years is 75% and 64%. Main cause of death within 
this group was infection (7 patients, 19%). 
Only 2 patients have died due to vascular complications. Of the 8 retransplants, 
1 was due to HAT and 3 to PVT. There have been no deaths due to vascular 
complications in the last 11 years, and no graft lost for this cause in the last 4 
years. 
Comments: Liver transplantation in small children is a major medical and 
surgical challenge. Our results are comparable to countries with similar 
conditions of pediatric liver transplantation, although still below large series 
published. The improvement in the surgical technique in the last years has lead 
to fewer vascular complications and trends to better outcome. This is the largest 
series in our country. 
ISOLATED LIVER TRANSPLANTATION IN CHILDREN 504 
WITH CYSTIC FIBROSIS – THE ANLTU EXPERIENCE
S. Nightingale1,2, E. O’Loughlin1, S. Dorney1, A. Shun1,4, S. Strasser3, 
G. McCaughan3,4, K. Gaskin1,2, V. Jermyn1, P. Van Asperen1,2, 
M. Stormon1,4
1Childrens Hospital At Westmead, 2Discipline of Paediatrics and Child 
Health, University of Sydney, 3Royal Prince Alfred Hospital, 4Australian 
National Liver Transplantation Unit, Sydney
Objectives: To review the experience of the Australian National Liver 
Transplant Unit (ANLTU) with isolated liver transplantation (LT) in children 
with cystic fi brosis (CF). 
Methods: Retrospective record review of all children with CF with who 
underwent LT since ANLTU began in 1986. Baseline and post-LT clinical and 
laboratory data, as well as survival and outcomes were analysed. 
Results: Eight children (6 male) were transplanted (median age 12yrs, range 
11-16) between 1993 and 2005. Complications of portal hypertension were the 
main indication for LT in four patients, with synthetic dysfunction a signifi cant 
factor in the remaining three. All patients were pancreatic insuffi cient. One 
had diabetes at the time of LT, and two developed it soon afterwards. Three 
patients had common bile duct strictures identifi ed previously (two had 
cholecystojejunostomies performed). Two patients were severely malnourished, 
with BMI <1st percentile. Seven patients had pulmonary colonisation with 
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Pseudomonas aeruginosa prior to LT. One had previous colonisation with 
Burkholderia cepacia which was eradicated before LT. Six patients had fungal 
organisms cultured from sputum or bronchoalveolar lavage pre-transplant: 
three with Aspergillus fumigatus, two with Candida albicans, and one with 
Scedosporium species. All of these patients received antifungal therapy in 
the peri-transplant period. FEV1 (% predicted) ranged from 59-116% pre-
LT, and did not deteriorate signifi cantly post-LT; indeed it improved in three 
patients. Four patients required mechanical ventilation for less than 48 hours 
post-transplant. All grafts were cadaveric: six whole livers, two split grafts. 
One required delayed abdominal closure. A jejunal roux loop was used in all 
cases for biliary-enteric anastomosis (existing loop used in the two patients 
with previous cholecystojejunostomy). Four patients received cyclosporin, 
and four tacrolimus. Six of our patients are alive, four now followed in adult 
services. None of these have any known biliary complications. Of the two 
patients who died, one succumbed to fungal sepsis on day 45 following 
severe acute rejection requiring treatment with corticosteroids followed by 
OKT3. The other died with respiratory failure on day 31, and was found to 
have A. fumigatus and multiple strains of P. aeruginosa in respiratory cultures. 
Surviving patients all have good graft function, except one patient who has 
developed portal hypertension in association with macrovesicular steatosis 
and minimal fi brosis on biopsy. 
Conclusions: Isolated LT for CF is successful. The ANLTU survival 
rate compares favourably with other published series. Roux loop biliary-
enteric anastomosis in CF patients provides good long term biliary 
drainage post-LT. Organisms colonising the lung should be determined 
pre-transplant and antibacterial/antifungal prophylaxis instituted during 
the peri-transplant period. Overall lung function does not deteriorate, 
with improvement in some after LT. CF patients may be at increased risk 
of septic complications following potent immunosuppression, as required 
for acute rejection. 
SUCCESSFUL USE OF PLASMAPHERESIS COMBINED 505 
WITH CONTINUOUS RENAL REPLACEMENT THERAPY 
(CRRT) IN TREATING CHILDREN WITH ACUTE HEPATIC 
FAILURE (AHF) AND ACUTE-ON CHRONIC HEPATIC 
FAILURE (ACHF)
G. Yanni1, D. Shores1, P. Yorgin1, S. Sahney1, D. Cutler1, M. Shah1, C. Ejike1, 
S. Abd Allah1, M. Mathur1, P. Baron2
1Loma Linda University Children’s Hospital, 2Loma Linda University 
Transplantation Institute
Aim: To assess the effi cacy of Plasmapheresis (Therapeutic Plasma Exchange, 
TPE) combined with Continuous Renal Replacement Therapy (CRRT) in 
treating children with AHF and ACHF. 
Background: Pediatric AHF is a rare and potentially fatal condition, 
characterized by the development of hepatic encephalopathy (HE) with or 
without cerebral edema, severe coagulopathy and multi-organ system failure. 
Without liver transplantation (LT), there is a great risk for morbidity and 
mortality. Hepatocyte regeneration and recovery has been demonstrated, 
especially in young children but many patients may still require LT. Medical 
therapy that can decrease the risk of neurological complications and improve 
the coagulopathy may allow time for the hepatocyte regeneration and 
also help to stabilize those patients waiting for transplantation. We report 
our experience using TPE combined with CRRT in patients with AHF and 
ACHF. 
Methods: IRB approved retrospective chart review of all children with AHF and 
ACHF who were admitted between January 1st 2004 to February 29th 2008. 
Results: Eight patients were admitted, ages ranged from 22 months to 18 
years. M: F ratio is 3: 5 Clinical presentations include acute abdominal pain, 
fever, altered mental status (HE) and jaundice. Seven patients had AHF and 
one had ACHF. Etiologies and pathology of the AHF include Acetaminophen 
Toxicity (3) with 75-80% massive hepatic necrosis, Budd-Chiari Syndrome 
(2) with central necrosis and thrombosis on the explanted liver, Idiopathic 
AHF (1), Enterovirus AHF (1) with complete hepatic collapse (explanted 
liver) and deteriorated Langerhan’s Cell Histiocytosis CHF (1) with 90% 
cirrhotic explanted liver. Seven patients had HE (1 with grade II, 3 with 
grade III and 3 with grade IV). Initial INR ranged from 2. 1 to 12. All patients 
received combination of TPE and or CRRT. Duration of treatment ranged 
from 1 to 7 days. Four patients (50%) had full spontaneous recovery with 
intact neurological function, recovered hepatic synthetic function. Four 
patients (50%) were bridged successfully to liver transplantation and three 
patients had subsequent full recovery (one had small water-shed infarct and 
had partial neurological recovery). All patients with acetaminophen toxicity 
had full recovery. 
Conclusion: 1-TPE combined with CRRT appears to be an effective modality 
for supporting children with AHF or ACHF awaiting liver transplantation. 
2-Support with this therapeutic modality allowed time for spontaneous 
recovery avoiding LT altogether in half of our patients, and in the other four 
who eventually needed LT, improved their pre-transplant clinical condition. 
3-A randomized Multi-Center trial should be considered in order to validate the 
effi cacy of this treatment modality. 
TEN YEAR EXPIERENCE WITH PREEMPTIVE 506 
APPROACH TO CMV INFECTION IN PEDIATRIC LIVER 
TRANSPLANTATION
T. Pillen1, G. Smallwood2, R. Romero2, T. Heffron2
1Children’s Healthcare of Atlanta, 2Emory University School of Medicine
Background: Cytomegalovirus (CMV) infections in solid organ transplant 
continue to be associated with increased morbidity and mortality. Currently 
there are two approaches to CMV in solid organ transplant. One approach, 
prophylaxis, consists of using ganciclovir type products (ganciclovir or 
valganciclovir) for 3 to 6 months to prevent the development of CMV. We 
know from several multicenter studies, especially liver transplant, which 
indicate that CMV is only delayed with prophylaxis and not prevented. The 
other approach is a preemptive approach which follows patients by polymerase 
chain reaction (PCR) and treats CMV infection when CMV DNA is isolated. 
Pediatric patients are considered to be at the highest risk of developing CMV 
since most pediatric patients are CMV antibody negative recipient of a CMV 
antibody positive organ. 
Purpose: To evaluate our ten year experience with preemptive PCR monitoring 
and treating CMV in pediatric liver transplantation. 
Methods: Patients were routinely followed by weekly, serial blood draws 
for CMV by PCR and did not receive prophylactic antivirals. At time of 
seroconversion, patients were started on ganciclovir IV 5mg/Kg Q12H and 
continued to be followed by PCR to monitor treatment. All patients received 
the same immunosuppressive protocol of daclizumab 1mg/kg induction, 
tacrolimus started 3-7 days following liver transplantation, mycophenolate 
and steroids. Presence of CMV was confi rmed by quantitative PCR (COBAS 
AMPLICOR CMV assay, Roche). Patients slow to respond to treatment were 
evaluated for resistance as determined by mutations of the UL54 (polymerase) 
and UL97 (phosphotransferase) genes. 
Results: From February 1997 till present, 187 pediatric patients received 210 
liver grafts. A total of 66 (35. 2%) patients seroconvert with 72. 7% (48/66) 
of patients seroconverting once, 22. 7% (15/66) seroconverting twice, and 
3 (4. 5%) patients had 3 episodes of seroconversion. Mean time to initial 
seroconversion was 51. 6 ± 62. 6 days with secondary re-conversion occurring 
177. 2 ± 206 days following transplant. Tissue invasive disease occurred 
in 22. 7% (15/66) of patients which included CMV hepatitis in 8 patients, 
6 patients with CMV gastroenteritis and one pneumonitis. Based on CMV 
seroconversion, patients were similar in respect to age at transplant (6. 9 ± 
6. 4 yr. vs 6. 7 ± 6. 6; p = 0. 876), patients with CMV seroconversion had 
longer hospitalization (36. 6 ± 30. 8 days vs. 26. 1 ± 24. 1 days; p = 0. 02), 
with similar 1 year survival (90. 8% vs, 93. 1%; p = 0. 306). A mutation in the 
UL54 gene at codon A692S was identifi ed in one patient which appeared to 
convey ganciclovir resistance. 
Conclusion: Patients can be preemptively followed by PCR for CMV 
without the use of antiviral CMV prophylaxis without increased incidence 
of mortality in our series. By utilizing a preemptive approach, all patients 
are not exposed to ganciclovir and hopefully will avoid the development of 
resistant CMV. 
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DENDRITIC CELLS AND COSTIMULATION
B7H1-OVEREXPRESSED SWINE ACCESSORY CELLS 507 
INDUCE HUMAN REGULATORY TR1 SUBSET IN MHC 
INCOMPATIBLE CONDITIONS FOR SUPPRESSION OF 
XENOGENEIC REACTIONS
G-Y. Zhou, Q. Ding, X. Zhou, J. Tao, L. Lu, Y. Zhou, Z. Jiao, N. Yang, L. Xin
Shanghai Institute of Immunology, Shanghai Jiaotong University School of 
Medicine
Type 1 regulatory T cells (Tr1) are active in induction of transplantation 
tolerance. Our previous work demonstrated that Tr1 cells can be generated 
from purifi ed mouse CD4 T cells after treated with anti-CD3 mAb plus soluble 
B7H1-Ig fusion protein. B7H1 is a member of the cosignaling molecule B7 
family. In this study, Tr1 cells were also activated from human CD4 T cells 
(hCD4 T) by B7H1-overexpressed accessory A431 cells in a way that at least 
one DR-DQ haplotype is shared between the hCD4 T and the B7H1-positive 
A431. When A431 were substituted with B7H1-transfected porcine iliac 
artery endothelial cells (PIECs), hCD4 T cells were still able to differentiate 
into human Tr1 cells if the expression of swine SLA-DR, instead of SLA-DQ, 
on the PIECs was blocked with mAb. The activated Tr1 cells were potent 
for inducing suppression of xenogeneic mixed lymphocyte-endothelial cell 
response (xeno-MLER) by secreting cytokines IL-10 and TGF-beta. This 
implicates that the MHC class II restriction might not really involved in the 
generation of regulatory Tr1 cells. Accordingly, the PIECs were cotransfected 
with genes coding for B7H1 and a class II transactivator mutant (mCIITA). 
The mCIITA is a depressor for transcription of class II genes. Again, the 
resultant B7H1-positive, SLA-DR-negative PIECs functioned well for 
human Tr1 generation. Repeat stimulating hCD4 T cells with the mCIITA/
B7H1-cotransfected PIECs left a CD4-positive, CD25-negative, FoxP3-
negative, IFN-gammaR-positive, IL-10R-positive Tr1 population at purity 
of 93. 6% (3. 8% in control), which down-regulated the xeno-MLER in a 
dose-dependent manner. This suggests that the B7H1-positive, SLA-DR-
negative PIECs might be utilized as a universal cellular reagent for inducing 
transplantation tolerance via activating the regulatory Tr1 subset even in 
histoincompatible conditions. 
THE ROLE OF THE PD-L1 SIGNAL IN THE 508 
REGULATION OF ALLOGENEIC IMMUNE RESPONSE
W. Li2, W. Wang1, K. Carper2, F. Malone3, Y. Latchman2, J. Perkins2, 
J. Reyes2
1JiLin University, Changchun, China, 2University of Washington, Seattle, WA, 
USA, 3Children’s Hospital & Regional Medical Center, Seattle, WA, USA
Background: PD-L1, a homolog to B7, has recently been identifi ed as a 
ligand for PD-1, and is expressed on a variety of tissues and cells including T 
cells (CD4, CD8, natural killer [NK] T cells, B cells, and antigen presenting 
cells (APCs). PD-L1 negatively regulates T cell function, inhibits T cell 
positive selection and development in the thymus, and plays a critical role 
in the regulation of peripheral tolerance. The exact role of the regulation of 
alloimmune responses by PD-L1 on each cell type remains unclear. In this 
study we employed PD-L1-/- mice to evaluate the role of the PD-L1: PD-1 
interaction in alloimmune responses in vivo and in vitro, and to further explore 
the underlying mechanisms. 
Methods: Heart transplantation was performed from PD-L1-/- donors or 
recipients in MHC fully mismatched mouse combinations of B6/PD-L1-/- and 
C3H strains. The immunologic function of allograft recipients was evaluated 
ex vivo by ELISPOT, MLR, CTL, and fl ow cytometry. 
Results: PD-L1 defi ciency decreased Foxp3+CD4+ T regulatory cells 
(Treg) and increased CD11b+ and CD11c+ cells in the spleens. Both T cell 
proliferative activity and allostimulatory activity of APCs from PD-L1-/- 
mice were enhanced. Heart allografts were rejected at an accelerated rate 
in both PD-L1-/- donors and recipients. The mean survival time (MST) of 
PD-L1-/- allografts in C3H recipients was 9. 3 ± 1. 1 days compared to 
36 ± 37 days in WT controls (p < 0. 05); the MST of C3H allografts in 
PD-L1-/- recipients was 8. 5 ± 0. 6 days compared to 13. 3 ± 1. 3 days in WT 
B6 recipients (p < 0. 01). This was associated with signifi cantly augmented 
donor specifi c T cell proliferation and anti-donor CTL activities, and 
enhanced Th1 or Th2 type immune responses of heart allograft recipients. 
Both Th1 (IL-2, p < 0. 05 and IFN-gamma, p < 0. 05) and Th2 (IL-4, p 
< 0. 05) cytokine production were increased signifi cantly in the T cells of 
PD-L1-/- recipients. However, the T cells from the recipients of PD-L1-/- 
donors revealed a signifi cant increase in only Th1 cytokine IFN-gamma (p 
< 0. 05). 
Conclusions: Defi ciency in the PD-L1 signal altered the balance of peripheral 
lymphocytes, augmented the allogeneic immune responses of effector T cells 
and allostimulatory activity of APCs, and accelerated heart allograft rejection 
through the enhancement of anti-donor immune responses. Engagement of the 
PD-L1 signal on either T cells or APCs may be necessary to induce transplant 
tolerance. 
COSTIMULATORY BLOCKADE-MEDIATED LUNG 509 
ALLOGRAFT ACCEPTANCE IS ASSOCIATED WITH INTRA-
GRAFT ACCUMULATION OF CD4+FOXP3+ REGULATORY T 
CELLS AND IS ABROGATED BY OVEREXPRESSION OF BCL-2 
IN THE RECIPIENT
M. Okazaki, J. Lai, S. Sugimoto, C. Kornfeld, S. Richardson, F. Kreisel, 
A. Patterson, A. Krupnick, A. Gelman, D. Kreisel
Washington University In St. Louis
Background: Lung allografts are more immunogenic than other solid organ 
grafts. This results in higher rates of graft rejection and comparatively worse 
survival rates after lung transplantation. The effi cacy of tolerogenic strategies 
after lung transplantation remains largely unexplored. We used a novel model 
of vascularized orthotopic lung transplantation in the mouse to study the effects 
of costimulatory blockade on lung allograft rejection. 
Materials and Methods: Orthotopic vascularized mouse lung transplants 
were performed in the Balb/c --> B6 strain combination. Recipients were 
either not immunosuppressed or received costimulatory blockade with 
MR1 (250 mcg, day 0) and CTLA4Ig (200 mcg, day 2). Balb/c lung 
allografts were also transplanted into vav-Bcl-2 transgenic B6 recipients. 
Lung grafts were analyzed histologically and by fl ow cytometry 7 days 
after transplantation. In addition, intragraft CD4+ T cells were isolated by 
fl ow cytometric sorting from Balb/c --> B6 transplants (day 7) that had 
received MR1 and CTLA4Ig and their regulatory potential was tested in 
mixed lymphocyte reactions in vitro. 
Results: Nonimmunosuppressed Balb/c --> B6 lung transplants had severe 
acute rejection 7 days after transplantation. The ratio of intra-graft CD8 : CD4 
T cells was 2. 82 ± 0. 3 (S. E. M. ). B6 recipients of Balb/c lungs that had 
received perioperative costimulatory blockade with MR1 and CTLA4Ig had 
only minimal infl ammation and the ratio of intra-graft CD8 : CD4 was 0. 98 
± 0. 11. 39. 75% ± 4. 89 of graft-infi ltrating CD8+ T cells expressed IFN-
gamma. 34. 25% ± 4. 41 of intragraft CD4+ T cells expressed Foxp3 indicating 
a regulatory phenotype. CD4+ T cells isolated from these grafts induced 
apoptosis of B6 CD8+ T cells that were stimulated with Balb/c splenocytes 
in vitro and suppressed their proliferation. Unlike the case for wildtype B6 
mice, by day 7 we observed severe acute rejection of Balb/c lung allografts 
after transplantation into Bcl-2 transgenic B6 recipients despite administration 
of perioperative costimulatory blockade. In these Bcl-2 transgenic recipients 
the ratio of intragraft CD8 : CD4 T cells was 3. 52 ± 0. 11, comparable to that 
observed in nonimmunosuppressed Balb/c --> B6 lung transplants. Moreover, 
only 13. 3% ± 0. 22 of intra-graft CD4+ T cells expressed Foxp3. The 
percentage of graft-infi ltrating CD8+ T cells expressing IFN-gamma was 57. 
3% ± 9. 68, which was higher than that observed in costimulation blockade-
treated wildtype B6 recipients. 
Conclusions: This study shows that acceptance of lung allografts after 
administration of perioperative costimulatory blockade is associated with a 
decreased ratio of CD8 : CD4 T cells within the grafts and with an accumulation 
of regulatory CD4+Foxp3+ T cells within the allograft. Our in vitro studies 
suggest that the regulatory function of these CD4+Foxp3+ T cells is at least in 
part due to induction of apoptosis of alloreactive CD8+ T cells. This is further 
supported by the increased ratio of intra-graft CD8 : CD4 T cells, the increased 
expression of IFN-gamma in CD8+ T cells and allograft rejection observed in 
Bcl-2 transgenic recipients. 
TU
ESD
AY
 
Oral Abstracts Tuesday 12 August 2008
1 7 9Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
DENDRITIC CELLS PLUS TGF-BETA1 510 
DIFFERENTIATED NAÏVE CD4+ T CELLS BUT NOT NATURAL 
REGULATORY T CELLS PROTECT ALLOGRAFTS 
M. Suthanthiran1, H. Yang1, V.K. Sharma1, P. Song1, M. Lagman1, C. Chang1, 
R. Weir1, E. Chang1, G. Luo1, R.M. Steinman2
1Weill Cornell Medical College, New York, NY, USA, 2Rockefeller University, 
New York, NY USA
Naturally occurring Foxp3+CD25+CD4+ regulatory T cells (nTregs) play a 
critical role in maintaining self-tolerance but their ability to prevent allograft 
rejection remains unresolved. TGF-beta 1 can convert FoxP3 negative CD4+ 
T cells to FoxP3 positive CD4+ T cells, and dendritic cells (DCs) are potent 
in generating alloreactive cells. We therefore hypothesized that a synergistic 
combination of DCs plus TGF-Beta1 would differentiate naïve CD4+ T cells 
in to alloantigen specifi c allograft protective cells. We tested our hypothesis 
by establishing mixed lymphocyte cultures (MLCs) using H-2b C57BL/6 
(B6) splenic CD11C+ DCs as stimulators and H-2d BALB/c CD4+ T cells 
as responders, and we isolated CD4+CD25+ T cells after 5-6 days of culture 
and tested their effi cacy. Our studies showed: (1) the mean ± (SE) percentage 
of CD4+Foxp3+ cells, at the time of initiation of MLCs, was 12±1% (by fl ow 
cytometry), and increased to 87±2% (N=4) following stimulation of BALB/c 
CD4+ T cells with B6 DCs plus 2ng/ml TGF-beta1. The percentage of Foxp3+ 
cells among the nTregs was 81±3% (N=4) (ex-vivo Tregs vs. nTregs, P>0. 05); 
(2) the mean level of mRNA in ex-vivo Tregs for Foxp3 mRNA was 1. 10E+07 
copies/ug RNA (N=11), and 5. 57+E06 (N=14) with nTregs (P>0. 05). In-vitro 
regulatory experiments using BALB/c CD4+ CD25- cells as responders and 
graded quantities of Tregs, proliferation was suppressed at 2 responder to 1 
by nTregs (P=0. 01), but not at 4: 1 ratio (P=0. 20); ex-vivo Tregs were more 
suppressive and suppressed up to 8: 1 ratio (P=0. 001 for 2: 1; P=0. 006 for 
4: 1; P=0. 03 for 8: 1). In a full H-2 mismatched islet allograft transplantation 
model, the mean ± (SE) survival of 500 B6 islets transplanted under the renal 
capsule of diabetic BALB/c recipient was 7±1 day (N=18 control recipients). 
Co-transplantation of 500 B6 islets with 500, 000 BALB/c nTregs did not 
signifi cantly prolong graft survival and was10 ±1 day (N=8 recipients) (P>0. 
05, nTregs vs. control). In contrast, co-transplantation of 500 B6 islets with 500, 
000 BALB/c ex-vivo generated Tregs prolonged graft survival signifi cantly and 
was 22±5 days (N=9 recipients) (P=0. 0003, ex-vivo Tregs vs. control; P=0. 
009, ex-vivo Tregs vs. nTregs). The ex-vivo generated BALB/c Tregs were 
alloantigen specifi c, and did not prolong the survival of H-2k CBA islet grafts 
in BALB/c recipients; the survival time of CBA islets in the control BALB/c 
recipients was 11 ±1 day (N=7 recipients) and 7±1 day (N=5 recipients) 
following co-transplantation of B6 DC differentiated Tregs with CBA islets 
(P>0. 05). Our data demonstrate that although the Foxp3 expression profi le is 
similar between natural Tregs and the DC plus TGF beta1 differentiated Tregs, 
ex-vivo generated Tregs but not natural Tregs protect H-2 mismatched islet 
allografts. Our study also shows that ex-vivo generated Tregs are alloantigen 
specifi c. Finally, our strategy of using easily available CD4+ T cells rather than 
the low abundant CD25+CD4+ as the cell subset to be differentiated with DCs 
plus TGF-beta1 overcomes the signifi cant challenge of generating adequate 
numbers of alloantigen specifi c Tregs for clinical trials. 
ANTIGEN PRESENTATION BY EPIDERMAL 511 
LANGERHANS CELLS INDUCES CD4 T CELL TOLERANCE IN 
VIVO
E. Shklovskaya1, D. Gracey2, B. Fazekas de St. Groth2
1Centenary Institute of Cancer Medicine And Cell Biology, Newtown, 
Australia, 2Department of Nephrology, Prince of Wales Hospital, Randwick, 
Australia
The role of dendritic cells (DC) in the initiation of graft rejection is well 
recognised. However, the function of different skin DC subsets in skin graft 
rejection remains elusive. We have developed a novel mouse model to study 
CD4 T cell responses to individual DC subsets in vivo. In this model, 5C. C7 
T cell receptor-transgenic CD4 T cells cross-react with MHC class II IAs, in 
addition to their specifi city for moth cytochrome c peptide (pMCC) in the 
context of MHC class II-IEk or IEb. 
To test the function of epidermal Langerhans cells (LC) in CD4 T cell priming, 
we constructed radiation chimeras in which IE-positive hosts were reconstituted 
with IE-negative bone marrow (termed IE-®IE+). In these chimeras 97% of 
skin LC and approximately 15% of migratory DC in cutaneous lymph nodes 
expressed IE. As a control, we replaced 25% bone marrow in IE-negative 
hosts with bone marrow from IE-positive RAG-knockout donors, to give 
approximately 20% IE+ lymph node-DC but no IE+ B cells (termed IE+®IE-). 
FACS analysis of cutaneous lymph nodes confi rmed the expected pattern of IE 
expression and indicated equivalent total numbers of IE+ DC in the two groups 
of chimeras. 
We measured the response of IE-restricted 5C. C7 CD4 T cells to subcutaneous 
administration of pMCC emulsifi ed in complete Freund’s adjuvant. Initial T 
cell proliferation was similar between the IE-®IE+ and IE+®IE- groups, as was 
the frequency of IL2-producing cells on day 6 (mean T cell recruitment into 
division, 22. 4% and 24. 9%, respectively; mean frequency of IL2-producing 
cells, 6. 7% and 5. 5%, respectively). Dramatic differences were observed after 
day 6: at the peak of the proliferative response (day 10), the absolute number 
of 5C. C7 T cells was 8. 6-fold higher and the absolute number of IFNγ+ Th1 
effector cells was 650-fold higher in IE+®IE- mice as compared to IE-®IE+ 
mice (87. 8x103 and 0. 14x103 IFNγ-producing 5C. C7 cells, respectively). 
Most importantly, by day 90, CD44high memory 5C. C7 T cells were found only 
in IE+®IE- mice. 
These studies indicate that LC do not support differentiation of Th1 effector 
cells and fail to sustain CD4 memory. We are now testing these fi ndings in 
a skin graft model in which 5C. C7 T cells in B10. BR (H-2k) hosts respond 
to IAs-bearing skin from either unmanipulated B10. S (H-2s) mice, B10. 
BR®B10. S (H-2k®H-2s) chimeras in which LC express IAs, and B10. S®B10. 
BR (H-2s®H-2k) chimeras in which dermal DC but not LC express IAs. 
EXOSOMES CAPTURED, PROCCESED AND 512 
EXCHANGED BY SPLENIC DENDRITIC CELLS SPREAD ALLO 
– PEPTIDE BETWEEN DCS AND AMPLIFY ANTI DONOR T 
CELL RESPONSE IN VIVO. 
A. Montecalvo1, W.J. Shufesky1, S.J. Di Vito1, A.T. Larregina2, D. Beer Stolz3, 
A.E. Morelli1
1Department of Surgery, T. E. Starlz, 2Department of Dermatology and 
Immunology, 3Department of Cell Biology, University of Pittsburgh
Exosomes are nanovesicles (60-100 nm) secreted by antigen-presenting cells 
(APC) such as dendritic cells (DCs) and B cells, as well as other cell types 
including T cells, mast cells, tumor cells, and intestinal epithelial cells. APC 
derived exosomes accumulate MHC II-Ag, costimulatory (CD80, CD86), and 
adhesion molecules (ICAM-1). Therefore, although the function of exosomes 
has been not yet well understood, the evidence that those molecules are 
topologically oriented facing outwards the plasma membrane, suggests the 
possible role of exosomes as a ”vehicle” to spread allo-Ags between DCs to 
prime directly anti-donor T cells response. Aims: We investigated, in vivo, 
the ability of exosomes to transport allopeptides to recipient DC in secondary 
lymphoid organs and their possible role to stimulate T cells anti-donor 
response. Moreover we investigated whether graft-infi ltrating DCs (GIDCs) 
release exosomes ex vivo and the processing of exosomes captured by different 
lineage of DC in the secondary lymphoid organs evaluating their impact on the 
anti-donor T cell response following transplantation. 
Methods: Exosomes from [C57BL/10 (B10), IAb] DC are pre-pulsed with the 
BALB/c peptide IEα;52-68, and stained with PKH67 and H2DCF. 1H3. 1 TCR 
transgenic cells were labeled with CFSE. DCs were infected with Ad/FasL/
eGFP. 
Results: We confi rmed by ultrastructural analysis that GIDCs from mouse 
cardiac allografts release exosomes ex vivo. Moreover, immunoistochemistry 
shows that exosomes are processed “in vitro and in vivo” by different DCs 
subsets: myloid CD8-, lymphoid-related CD8α;+, and plasmacytoid CD45RA+ 
DCs, as well as the presence of eGFP in the multivescicular body of CD11c/
CD45. 1 splenocytes isolated from B10 mice i. v. injected with Ad/FasL/
eGFP infected FAS-/-/CD45. 2 splenocytes. IAb-IEα;52-68 exosomes bearing 
CD80/86 elicited proliferation/activation of allospecifi c CD4+ 1H3. 1 T cells. 
Conclusions: In the context of allograft rejection exosomes in the secondary 
lymphoid organs are processed/exchanged by different DCs lineages as an 
effi cient acellular mechanism to spread allo-Ag, amplifying the anti-donor T 
cell response via indirect pathway. 
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POOR ALLOSTIMULATORY FUNCTION OF LIVER 513 
PLASMACYTOID DC IS ASSOCIATED WITH PRO-APOPTOTIC 
ACTIVITY AND DEPENDENT ON REGULATORY T CELLS
D. Tokita, T. Sumpter, G. Raimondi, A. Zahorchak, Z. Wang, A. Nakao, 
M. Abe, G. Mazariegos, A. Thomson
T. E. Starzl Transplantation Institute, University of Pittsburgh
Background: Plasmacytoid (p) DC, that are comparatively abundant in 
the liver are inherently tolerogenic. Recently, pDC have been implicated in 
tolerance induction. Since the liver is located downstream of the gut, interstitial 
hepatic DC are constantly exposed to bacterial LPS (endotoxin) resulting in 
refractory ex vivo responses to this TLR4 ligand (gendotoxin tolerance h). 
Not only are liver DC exposed continually to TLR ligands from the gut, but 
levels of LPS may be elevated following liver transplantation. In this study, 
we examined the function of liver pDC from control and LPS-stimulated mice. 
We also investigated how exposure of mouse liver pDC to LPS in vivo affected 
the outcome of their interactions with allogeneic T cells, including naturally-
occurring T reg. 
Methods: Liver and spleen pDC (mPDCA-1+) were isolated from normal 
C57BL/10 (B10) mice or animals injected (i. v. ) 2 hr previously with LPS 
(100ƒÊg). The stimulatory capacity of pDC was evaluated by quantitation of 
BALB/c CD4+ T cell proliferation and cytokine production in MLR. Cytokine 
production was assessed by intracellular staining and ELISA. NF-ƒÈB 
activation was determined by Western blot analysis. Notch ligand expression 
by pDC was measured by quantitative, real-time PCR. 
Results: Liver pDC expressed similar levels of surface TLR4 to spleen pDC, 
but unlike spleen pDC, did not undergo NF-ƒÈB activation or maturation after 
in vivo LPS stimulation. IL-10 production was greater for liver compared with 
splenic pDC, whereas the former produced less IL-12p70. Compared with 
splenic pDC, freshly-isolated liver pDC from LPS-treated mice were inferior 
stimulators of allogeneic CD4+ T cell proliferation. Addition of neutralizing 
anti-IL-10 mAb at the start of LPS-stimulated liver pDC: allogeneic T cell 
initiation, signifi cantly enhanced the proliferative response to a level similar to 
that achieved with splenic pDC. LPS-stimulated liver pDC induce allogeneic 
CD4+ T cells to produce more IFNƒÁ compared with splenic pDC. Moreover, 
liver pDC from LPS-treated mice expressed a low Delta4/Jagged1 Notch ligand 
ratio and skewed towards Th2 differentiation. Interestingly, in the absence of 
naturally-occurring CD4+CD25+ Treg, similar levels of CFSE-labeled T cell 
proliferation were induced by liver and spleen pDC. In addition, liver pDC 
from LPS-treated mice promoted allogeneic CD4+ T cell apoptosis. However, 
when naturally-occurring CD4+CD25+ Treg were removed from the responder 
T cell population, immediately before the start of MLR, the pro-apoptotic effect 
of liver pDC was reversed. These data suggest that Treg are rendered more 
effective at inhibiting effector T cell proliferation in the presence of liver than 
spleen pDC, and that naturally-occurring Treg may suppress the differentiation/
function of liver pDC. 
Conclusion: Liver pDC are resistant to LPS stimulation in vivo, and are 
inferior allogeneic T cell stimulators compared with spleen pDC. Their 
depressed function is dependent on the presence of naturally-occurring Treg. 
This property of hepatic pDC may contribute to inherent liver tolerogenicity 
and the comparative ease of liver allograft acceptance. 
GENERATION OF TOLEROGENIC DENDRITIC CELLS 514 
FOR INHIBITION OF ALLOGRAFT REJECTION: MEDIATION 
OF SUPPRESSION BY ILT3, ADRENOMEDULLIN, AND 
APOPTOSIS?
P. Terness, S. Ehser, J-J. Chuang, F. Sandra, C. Kleist, L. Jiga, G. Opelz
University of Heidelberg, Institute of Immunology, Dept. of Transplantation 
Immunology
Dendritic cells (=DCs) are strongly immunostimulatory cells. However, some 
DCs can suppress the immune response and play an important role in induction 
of tolerance to autoantigens. Studies showed that “Glucocorticoid Induced 
Leucine Zipper” (=GILZ) – a molecule upregulated by glucorticoids, IL-10, 
or TGF-beta – decides whether a DC stimulates or suppresses the immune 
response. GILZ induces the expression ILT3, a membrane protein with a 
long cytoplasmatic tail encompassing several inhibitory ITIM motifs. ILT3-
expressing DCs were shown by others to anergize CD4 T-cells or to convert 
them into Tregs. Most intriguing, previous studies revealed that human heart 
transplant recipients with stable grafts have circulating T suppressor cells which 
upregulate ILT3 in donor antigen-presenting cells. In comprehensive gene 
scans (> 47, 000 gene transcripts) we observed that Mitomycin C (=MMC) 
– an alkylating agent used in cancer therapy – upregulates GILZ and ILT-3 
in human DCs. Increase of ILT3 expression was confi rmed by quantitative 
RT-PCR and FACS analysis. In cell culture studies the functional behaviour 
of MMC-treated DCs was analyzed. DCs were briefl y treated with MMC 
(=MMC-DCs), washed and coincubated with T-cells. MMC-DCs arrested 
proliferating T-cells in the G0/G1 cell cycle phase and the suppressed cells 
could not be restimulated. T-cell suppression was antigen-specifi c. In the next 
step, we verifi ed the suppressive effect of MMC-treated DCs in a rat heart 
transplant model. Recipients were treated before transplantation with naïve 
donor DCs or donor DCs preincubated with MMC. We noted graft survival 
rates of 9+0. 2 days (untreated controls), 5+0. 2 days (naïve DCs), and 30+0. 
4 days (MMC-DCs). The induced suppression was donor-specifi c because 
no prolongation of third-party graft survival was obtained after MMC-DC 
treatment. The results clearly indicate that in contrast to untreated donor 
DCs, which induce accelerated rejection, MMC-treated DCs injected into the 
recipient inhibit acute rejection and signifi cantly prolong allograft survival. In 
addition to ILT3, MMC treatment of DCs upregulated adrenomedullin, another 
potentially suppressive molecules, and induced apoptosis. Adrenomedullin is a 
peptide which effectively controls arthritis in animal models by decreasing the 
presence of autoreactive Th1 cells, inducing regulatory T cells and inhibiting 
autoimmune and infl ammatory responses. Based on experimental data, it was 
held that apoptotic cells induce tolerance, whereas necrotic cells trigger the 
immune response. Therefore, induction of apoptosis in DCs treated with MMC 
might be another process rendering DCs suppressive. Our “in vitro” studies 
showed that blocking ILT3 and adrenomedullin with specifi c antibodies, 
and preventing induction of apoptosis in MMC-treated DCs abrogate their 
suppressive effect. In conclusion, treatment of DCs with MMC renders the 
cells immunosuppressive. MMC-treated donor DCs, injected into the recipient 
before transplantation, suppress heart allograft rejection in rats. Our fi ndings 
suggest that the suppressive effect of MMC-DCs is mediated by overexpression 
of ILT3, adrenomedullin and induction of apoptosis. 
KIDNEY SPHERE DERIVED CELLS INDUCE THE 515 
GENERATION OF IMMATURE DENDRITIC CELLS WITH A 
REGULATORY PHENOTYPE AND CAPACITY TO INHIBIT THE 
ALLORESPONSE
K. Womer, Y. Huang, P. Johnston, P. Agreda, R. Smith, E. Marban, H. Rabb,
Department of Medicine, Johns Hopkins University School of Medicine
Stem cells have great potential to regenerate damaged tissue after injury during 
organ procurement. Despite accumulating evidence supporting the potential 
of embryonic derived stem cells, substantial ethical and practical limitations 
have increased interest in adult organ stem cell research. Thus, isolation and 
characterization of adult organ stem cell function represents an important step 
in applying stem cell based therapy to organ transplantation. Bone marrow 
mesenchymal stem cells (MSC) have profound immunoregulatory effects 
on dendritic cells (DC) and T cells, two cell populations important to the 
alloresponse during kidney transplantation. As MSC have been identifi ed in 
virtually all post-natal organs, the aim of the current study was to determine 
whether stem/progenitor cells with immunoregulatory function exist 
within the adult kidney. Using a clinically applicable technique originally 
reported for isolation and expansion of cardiac progenitor cells from human 
endomyocardial biopsy specimens, we have identifi ed a population of kidney 
sphere-derived cells (KSC) from adult mouse with growth properties and 
immunophenotype consistent with MSC. KSC were CD29+, CD44+, and stem 
cell antigen-1+, while negative for hematopoietic progenitor markers (c-Kit, 
CD34, CD31, CD133, CD45). When added to incipient bone marrow-derived 
DC culture, KSC increased the generation of DC with dramatically reduced 
MHC II expression (MFI: 113±6. 5 vs 679±125; p<0. 01), increased CD80 
expression (MFI: 195±18 vs 85±4. 7; p<0. 01), and after LPS stimulation, 
increased IL-10 production (135. 7+12. 4 pg/ml vs 46. 1+6. 9 pg/ml; p<0. 01), 
and inability to stimulate CD4+ T cell proliferation in allogeneic (2. 1±0. 1% vs 
53±1. 3%; p<0. 01) and nominal antigen-specifi c cultures (16±0. 8% vs 71±4. 
4%; p<0. 01) as determined by CFSE staining. Effects on DC differentiation 
and maturation were demonstrated in mixed and transwell cultures and after 
addition of KSC conditioned medium, indicating soluble factors were active. 
Mechanistic studies using neutralizing antibodies showed that KSC production 
of IL-6 was partially responsible, although other soluble factors appear 
contributory. Finally, direct addition of KSC but not KSC conditioned medium 
to T cell culture inhibited mitogen-stimulated T cell proliferation (32±2. 1% 
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vs 59±3%; p<0. 01), indicating contact-dependent mechanisms were active. 
Thus, immunomodulatory effects of KSC on DC differentiation appear 
predominately due to soluble factors, yielding an IL-10 producing DC with 
very low expression of MHC class II, a phenotype consistent with a steady state 
DC important for maintenance of peripheral tolerance, while direct effects of 
KSC on T cell proliferation appear to require cell contact. These novel in vitro 
fi ndings provide a potential mechanism by which resident progenitor cells in 
the kidney could alter the local alloresponse in vivo after transplantation. Our 
fi ndings also raise the possibility of KSC expansion ex vivo for use as cellular 
therapy in kidney transplantation. 
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THE USE OF FLOW CYTOMETRY TO MONITOR 516 
ANTIBODY LEVELS IN ABO INCOMPATIBLE KIDNEY 
TRANSPLANTATION
N. Krishnan1,2, R. Higgins1, P. Fleetwood2, D. Zehnder1,3, D. Mitchell3, 
R. Hamer1,3, D. Briggs2
1University Hospitals Coventry & Warwickshire NHS Trust, Coventry, 
2National Blood Service, Birmingham, 3Clinical Sciences Research Institute, 
Coventry
Introduction: Current methods of measuring ABO antibody levels based on 
the haemagglutination (HA) titres has the disadvantage of being both non-
reproducible and having inter-observer variability.
Methods: We have therefore developed and validated fl ow cytometry (FC) 
as a semi quantitative method to monitor the amount of IgG and IgM ABO 
antibodies in individuals undergoing ABOi transplantation.
Results: To validate our method, we analysed plasma samples from 79 healthy 
donors using the FC method. We have shown that in healthy donors, the 
relative levels of IgG and IgM antibodies against A and B in subjects of blood 
groups O, A and B were same as previously reported using the HA technique. 
We also analysed 40 consecutive samples over 32 days from group O patient 
who received group A2 kidney. On comparison, there is a signifi cant positive 
relationship between FC RMF (relative median fl uorescence) and HA for both 
IgM (p<,0.01) and IgG (p<0.01). We are currently analysing the blood group 
IgA antibodies and its signifi cance in ABOi transplantation.
Discussion: Our data demonstrates that FC monitoring of ABO-specifi c 
antibodies in incompatible transplants is effective in terms of detecting 
quantitative changes and reproducibility. We have simplifi ed the FC method, 
by overcoming the tendency of sensitised RBCs to agglutinate by using dilute 
cells rather than use fi xation buffers. Thus, FC may be a practical method of 
measuring antibodies and monitoring changes in ABO antibody level.
POSTER BOARD NUMBER P3 – 378
IMPACT OF ANTI-ABO BLOOD-TYPE ANTIBODIES 517 
ON ACUTE ANTIBODY-MEDIATED REJECTION IN ABO-
INCOMPATIBLE KIDNEY TRANSPLANTATION
D. Toki1, H. Ishida1, H. Shirakawa1, T. Shimiza1, K. Setoguchi1, S. Iida1, 
S. Horita1, Y. Yamaguchi2, K. Tanabe1
1Department of Urology, Tokyo Women’s Medical University, 2Division of 
Pathology, Jikei University School of Medicine, Kashiwa Hospital
Background: Acute Antibody-mediated rejection (AAMR) has been recognized 
as a major problem in ABO-incompatible (ABO-I) renal transplantation (RTX). 
Anti-ABO blood-type antibodies had been thought to be the main cause of 
AAMR. However, under the current potent immunosuppressive regimen, the 
role of anti-ABO blood-type antibodies for AAMR is not clearly understood. 
The aim of this study was to assess the impact of anti-ABO blood-type 
antibodies on AAMR.
Methods: Fifty-eight patients who underwent ABO-I RTX at our 
institution between March 1999 and December 2004 under an FK-based 
immunosuppressive regimen were enrolled in this study. AAMR was diagnosed 
by biopsies within one month after transplantation in conjunction with allograft 
dysfunction. Morphological features of AAMR based on the Banff ’05 update 
and other characteristic fi ndings for AAMR previously reported, such as 
mesangiolysis, interstitial hemorrhage, and cortical infarction. C4d deposition 
for peribubular capillaries was not employed for the diagnosis of AAMR 
because C4d deposition is commonly observed in ABO-I renal allografts. 
Anti-ABO blood-type IgM titers were determined using saline agglutination 
technique, and indirect Coomb’s test was used to measure IgG titers. To remove 
anti-ABO blood-type antibodies, three or four sessions of plasmapheresis 
before transplantation were performed, until anti-ABO blood-type IgM/IgG 
titers decreased to a level of 1:32 or below. Splenectomy was performed at the 
time of transplantation. We evaluated the association between anti-ABO blood-
type antibodies and the incidence of AAMR.
Results: The association between anti-ABO blood-type antibodies and the 
incidence of AAMR is shown in Table 1. The incidence of AMR within one 
month after transplantation was 33% (19/58). There is no signifi cant difference 
between anti-ABO blood type IgM /IgG titers ≥64 before plasmapheresis and 
the incidence of AAMR. Even in the anti-ABO blood-type IgM/IgG titers ≥128 
before plasmapheresis, no signifi cant difference was seen between anti-ABO 
blood-type IgM/IgG titers and the incidence of AAMR. Moreover, anti-ABO 
blood-type IgM titers ≥32 at biopsy were not associated with the incident of 
AAMR. Meanwhile, the anti-ABO blood-type IgG titers ≥32 at biopsy were 
signifi cantly associated with the incident of AAMR.
Conclusion: In this study, we revealed that only anti-ABO blood-type IgG titers 
at biopsy were signifi cantly associated with the incidence of AAMR regardless 
of anti-ABO blood-type IgM/IgG antibodies before plasmapheresis. Careful 
observation of anti-blood type IgG titers will be needed after transplantation.
Table 1.
Anti-ABO blood-type antibodies
AMR (-)
N=39
AMR (+)
N=19
P
IgM titer ≥64 before plasmapheresis 21 (55%) 12 (63%) 0.5693
IgM titer ≥128 before plasmapheresis 10 (26%) 5 (26%) 0.9561
IgG titer ≥64 before plasmapheresis 26 (67%) 14 (74%) 0.5877
IgG titer ≥128 before plasmapheresis 19 (47%) 10 (53%) 0.7797
IgM titer ≥32 at biopsy 3 (8%) 2 (11%) 0.7182
IgG titer ≥32 at biopsy 5 (13%) 9 (47%) 0.0039
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BLOOD GROUP B PRIMARY AND REGRAFT 518 
CANDIDATES ARE TRANSPLANTED WITH A2/A2B KIDNEYS 
AT THE SAME RATE SINCE A ISOAGGLUTININS REMAIN 
LOW
J.L. Smith1, C.F. Bryan2, M.R. Wakefi eld3, B.A. Warady4, C. Wang5, 
D. Murillo6, P.W. Nelson7
1Via Christi Regional Medical Center--Wichita, Ks, 2Midwest Transplant 
Network--Kansas City, Ks, 3University of Missouri--Columbis Mo, 4Childrens 
Mercy Hospital--Kansas City, Mo, 5University of Kansas Medical Center-
-Kansas City, Ks, 6Research Medical Center--Kansas City, Mo, 7St Lukes 
Hospital--Kansas City, Mo
Introduction: It is important to know if the retransplantation rate of blood 
group B candidates with A2/A2B kidneys in the A2/A2B to B allocation 
system is equivalent to that of primary candidates. Eligibility to receive an A2/
A2B kidney is a low level of A isoagglutinins (<8). If graft loss increases A 
titers, retransplantation of B candidates would be largely restricted to non-A2/
A2B donors.
Methods: We evaluated the incidence of A2/A2B kidney transplants in 274 
consecutive blood group B candidates transplanted (225 primary, 48 second 
and 1 third) from 1994-2007 using a donor service area-wide A2/A2B to B 
deceased donor renal allocation system.
Results: The incidence of A2/A2B kidneys transplanted into blood group B 
candidates for their fi rst transplant was 27% (62/225) and was 24% (12/49) 
for retransplant patients (p=0.6). A consistently low anti-A titer history was 
exhibited before transplantation by 87% (184/212) of primary and 88% (43/49) 
of regraft B recipients (p=0.3).
Conclusion: The A2/A2B to B kidney allocation system improves access 
of primary and regraft B candidates to the same degree because anti-A IgG 
titers usually remain low after graft loss. This system could provide wait list B 
candidates in the United States with up to one-fourth more kidney transplants.
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DOUBLE FILTRATION PLASMAPHERESIS 519 
FACILITATES HLA ANTIBODY INCOMPATIBLE RENAL 
TRANSPLANTATION, BUT IS LESS EFFECTIVE DURING 
ANTIBODY RESYNTHESIS POST-TRANSPLANTATION
R. Higgins1, R. Hamer1, D. Briggs2, N. Krishnan1, S. Fletcher1, A. Short1, 
D. Lowe2, K. McSorley1, Daniel Zehnder3
1University Hospital, 2Histocompatibility Laboratory, UK Blood and 
Transplant, 3Warwick Medical School
Introduction: We used double fi ltration plasmapheresis (DFPP) in antibody 
incompatible transplantation (AIT). The use of DFPP has not been reported 
extensively in HLA antibody incompatibility, and we review its effi cacy.
Methods: 54 patients entered the AIT programme. 41 had 267 sessions of 
DFPP, 1 had 10 sessions of plasma exchange, and 3 had 13 sessions of ABO 
immunoadsorption. Some patients had more than one modality of treatment, 11 
patients had no antibody removal.
Results:In patients treated with DFPP alone, the mean number of sessions pre-
transplant was 4.8, mean of 4.6 litres per session, total treatment 325 ml/kg. 
Post-transplant, 18 received DFPP, for a mean of 3.5 sessions, mean 6.2 litres 
per session, total treatment 309 ml/kg. Mean reductions in IgA, IgG and IgM 
per treatment session were consistent with the plasma volume treated, 63.9%, 
57.8%, 70.2% pre transplant, and 59.3%, 48.4% and 65.4% post-transplant. 
70% of patients were transplanted with a fl ow cytometric (FC) relative median 
fl uorescence (RMF) >2.5, and 65% were transplanted with microbead DSA 
mean fl uorescence intensity (MFI) of >2000u. Failure to achieve negative 
crossmatch was strongly related to the starting level of donor specifi c antibody 
(DSA).
Patients who had a course of DFPP and who had complete data and no IVIg 
administered were studied in more detail. Pre-transplant, in 21 patients, the 
mean fall in IgG over the course of treatment was 70.0%, with a fall in FC RMF 
25.7%, and fall in microbead MFI 52.6%. There was variation with levels in 
some patients responding well, but others resistant to DFPP. Post transplant, in 
8 courses of treatment administered during DSA resynthesis, IgG fell by a mean 
of 45.3%, but the microbead MFI level rose by 41.2%, and no patient achieved 
a reduction in MFI to <2000 by DFPP alone. Combined DFPP and rejection 
treatment were associated with more adverse effects, including infections and 
fl uid shifts.
Discussion: Larger volumes of plasma were treated with DFPP than were 
feasible with plasma exchange. Although graft survival was excellent, most 
patients were transplanted with potentially damaging DSA levels, and DFPP 
post transplant was unable to control rising antibody levels; we have phased 
out the use of DFPP post-transplant. There is a need for improved methods of 
DSA removal.
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ABO-INCOMPATIBLE RENAL TRANSPLANTATION 520 
WITHOUT SPLENECTOMY OR RITUXIMAB – EXCELLENT 
RENAL FUNCTION AND GRAFT HISTOLOGY
S. Flint1, M. Jose3, G. Kirkland3, D. Yip1, A. Landgren2, M. Finlay2, 
S. Cohney1
1Department of Nephrology, Royal Melbourne Hospital, 2Department of 
Pathology, Royal Melbourne Hospital, 3Department of Nephrology, Royal 
Hobart Hospital
Until recently ABO incompatible renal transplantation (ABOI) included 
splenectomy and immunosuppression greater than administered in blood group 
compatible transplantation. Since December 2005 we have performed 28 
ABOI without splenectomy, using an immunosuppressive regimen similar to 
that used in our compatible transplants with the exception of antibody removal, 
and mycophenolate for 10-14 days pre-transplant. Four of 28 patients received 
rituximab.
Three patients experienced early humoral rejection (AbMR) that resolved 
clinically with treatment. In one case the AbMR was due to a concomitant 
donor specifi c anti-HLA antibody (DSAb). Overall patient and graft survival is 
100% after a median of 13 months (range 3 months to 29 months). 15 patients 
have had their transplants in excess of 12 months. Here we present an analysis 
of graft function and graft histology in this cohort; the latter based on review of 
all available post-transplant renal biopsies (n=57).
Graft function: Creatinine at 1, 3, 6 and 12 months indicates stable renal 
function except for one patient with intermittent obstruction* and compares 
favorably with donor renal function. Median creatinine is currently 140umol/L 
(range 80-240), in comparison with a median donor creatinine of 110umol/L 
(range 80-150). In all cases but one*, the differences in renal function between 
donor and recipient are predominantly attributable to differences in gender and 
body habitus (11 grafts were female to male and 4 male to female).
Graft histology: All patients underwent a biopsy at implantation with which 
subsequent biopsies were compared. Protocol biopsies are scheduled at 3 
months and 12 months, and all biopsies were assessed by Banff ’97 scoring 
criteria.
Two of the patients with AbMR have had complete histological resolution 
on 3 month biopsy, although one has mild (grade 1) CAN without transplant 
glomerulopathy (TGP). The patient with DSAb has signifi cantly improved 
histology but in view of ongoing subclinical active rejection is receiving further 
IVIG; this patient has mild early TGP.
In total, there are twenty-one “3 month protocol biopsies” and fi ve “12 month 
protocol biopsies” analysed to date. The remaining 31 biopsies were performed 
for clinical indications (from day 2 to day 246 post-transplant). There was one 
case of acute cellular rejection (ACR) (Banff 1B) and one of borderline ACR, 
both on 3 month protocol biopsies and treated with additional corticosteroid. A 
12 month biopsy from the latter patient showed no evidence of CAN.
No patient had TGP except for the patient with DSAb. This is in comparison 
with the remaining 25 patients without AbMR, in which mild CAN was 
reported in 4/18 three month protocol biopsies and in none of the twelve month 
protocol biopsies.
C4d staining was observed in 26/57 post transplant biopsies and one implantation 
biopsy (representing 13/28 patients), including all 3 with AbMR.
ABOI renal transplantation can be successfully performed without splenectomy 
and rituximab and results in good function and graft histology.
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RESULTS OF A RANDOMIZED PROSPECTIVE STUDY 521 
OF INDUCTION THERAPY WITH DACLIZUMAB VERSUS 
THYMOGLOBULIN AMONG CROSSMATCH POSITIVE RENAL 
TRANSPLANT RECIPIENTS
J. Locke, C. Simpkins, M.S. Leffell, A. Zachary, V. Collins, D. Warren, 
D. Segev, A. Singer, M. Haas, R. Montgomery
Johns Hopkin University
Background: The introduction of protocols to desensitize recipients with 
incompatible live kidney donors has been accompanied by an increased risk 
of post-transplant acute rejection. Thymoglobulin, a polyclonal anti-human 
thymocyte antibody preparation, has been shown to decrease the 1-year 
incidence of acute rejection in renal transplant recipients. While this fi nding 
is encouraging for renal transplant recipients in general, data on the use of 
thymoglobulin as an induction agent in the highly sensitized patient population 
are lacking. We report here interim results from a prospective, randomized 
controlled clinical trial in our highly sensitized patient population comparing 
renal transplant outcomes after induction with the anti-thymocyte agent, 
Thymoglobulin, or an anti-human IL2 monoclonal antibody, daclizumab.
Methods: Adult, end-stage renal disease patients with donor-specifi c anti-
HLA antibody (DSA) against their only potential live donor were eligible 
for this study. Patients were randomized to receive either Thymoglobulin or 
daclizumab induction therapy just prior to transplant. The primary endpoint 
was 6-month incidence of biopsy proven acute rejection [antibody mediated 
(AMR) and/or cellular mediated (CMR)].
Results: 33 patients with at least 6-months of follow-up are currently enrolled 
in this trial (16-Thymoglobulin; 17 daclizumab). There is no signifi cant 
difference between the two groups in mean crossmatch titer (14.0 vs. 9.9, 
P=0.61), number of current HLA mismatches (5.7 vs.5.9, P=0.73), or repeat 
mismatches (0.2 vs.0.2, P=0.98). The rate of acute clinical rejection at 6-months 
is 56% in the Thymoglobulin arm, and 41% in the daclizumab arm (p=0.4), and 
there is no statistically signifi cant difference in the rate of clinical AMR or 
CMR between the two treatment arms. However, there is an increased rate of 
subclinical CMR in the daclizumab arm compared to the Thymoglobulin arm 
(82% vs. 44%, p=0.02). Further, the severity of subclinical CMR is greater 
among patients receiving daclizumab compared to Thymoglobulin, with a 
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28% higher incidence of ≥2A rejection in the daclizumab arm. There are no 
statistically signifi cant differences at 6 months between the two treatment 
arms with regard to patient and graft survival, infection, adverse drug events, 
malignancy, delayed graft function, and length of stay.
Conclusion: The rate of acute rejection among crossmatch positive patients 
is 2-4x higher than the non-sensitized kidney transplant recipient patient 
population. While the results from our trial are preliminary, there appears to 
be a reduction in both the incidence and severity of subclinical CMR among 
patients receiving Thymoglobulin induction therapy compared to daclizumab.
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THE NEVER-ENDING ALTRUISTIC DONOR522 
M. Rees1, J. Kopke2, G. Hil3, W. Reitsma4, R. Pelletier5, J. Rogers6, 
T. Sandholm7, A. Roth8, U. Unver9, R. Montgomery10
1University of Toledo Medical Center, 2University of Cincinnati, 3National 
Kidney Registry, 4New Jersey Sharing Network, 5Ohio State University, 
6Wake Forrest University, 7Carnegie Mellon University, 8Harvard University, 
9University of Pittsburgh, 10Johns Hopkins University
Introduction: We propose a non-simultaneous form of kidney paired donation 
that starts with a living, non-directed donor (LND).
Methods: A paired donation matching algorithm was developed to allow for 
LNDs to start potentially Never-Ending Altruistic Donor (NEAD) chains in 
addition to closed loops of 2-, 3- and 4-way exchanges.
Results: In July 2007, a LND from Michigan traveled 1500 miles to donate a 
kidney to a woman whom he had never met in Arizona. The following week, 
the Arizona recipient’s husband donated one of his kidneys to a 32-year-old 
woman in Ohio. The following month, the mother of this recipient traveled to a 
city 3 hours away to donate her kidney to a patient whose incompatible donor 
simultaneously gave a kidney to the fourth patient in the chain. Five months 
later the fourth recipient’s incompatible sister donated a kidney to a patient in 
Maryland whose incompatible donor initiated a chain of three transplants two 
weeks later that ended with a recipient in North Carolina receiving a kidney. 
This patient’s incompatible donor is now scheduled to initiate another chain 
of three transplants in March 2008. Thus, one altruistic donor has allowed for 
at least 8 people to be transplanted. In the fi rst year of operation, an alliance 
of 60 US transplant programs have partnered to perform 17 paired donation 
transplants. Demonstrating the advantage of NEAD chains over classic paired 
donation, 13 of 17 transplants resulted from altruistic donor-initiated chains.
Conclusion: In order to fully realize the potential of the above approach, one 
must be willing to supplant two prevalent ideas: 1) that kidneys from altruistic 
donors should be given to the top candidate on the deceased donor waiting 
list, and 2) that paired exchanges must be done simultaneously. While there 
are certain pitfalls to using non-simultaneous NEAD chains of transplants as 
opposed to traditional “swaps” (i.e. the possibility that a donor could renege, 
or the accumulation of type AB donors who are not likely to be able to begin 
another chain), this proposed paradigm shift could result in a very signifi cant 
increase in both the number and quality of paired donation kidney transplants.
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DONOR AND RECIPIENT ATTITUDES TOWARDS 523 
ALTRUISTIC UNBALANCED PAIRED KIDNEY EXCHANGE 
AND ITS POTENTIAL IMPACT ON LIVE DONOR 
TRANSPLANTATION
L.E. Ratner, A. Rana, E.R. Ratner, V. Ernst, J. Kelly, D. Cohen, D. Kornfeld, 
I. Wiener
Columbia University/New York-Presbyterian Hospital
Background: Altruistic Unbalanced Paired Kidney Exchange (AUPKE) utilizes 
compatible live donor/recipient pairs (D/R) to exchange with incompatible live 
D/R pairs to allow all recipients to receive a compatible donor kidney. There 
has been concern about the potential coercive nature of AUPKE. However, 
AUPKE has the potential to greatly increase the likelihood of paired kidney 
exchanges, even at the single center level in the absence of large regional 
or national sharing systems. Recently we performed a complex AUPKE to 
facilitate a compatible live donor transplant for a patient (blood group O) 
whose blood group AB husband was her prospective donor (Figure 1).
Purpose: 1) To determine the impact of AUPKE if practiced in its simplest 
form using ABO compatible, but non-identical donors (ABONI) at individual 
centers. 2) To determine patients’ attitudes towards AUPKE to be able to 
effectively encourage participation.
Methods: 1) Retrospective analysis of the UNOS data of live donor transplants 
performed in 2005. 2) At initial evaluation, potential donors and recipients 
were administered a survey regarding attitudes toward AUPKE. A 5-point 
Likert Scale was utilized with the questions structured in the affi rmative so that 
a higher Likert Score supported participation in AUPKE.
Results: 1)1396 (22.8%) ABONI live donor transplants were performed in the 
US in 2005 of which 91% of the donors were blood group O. 2) 53 potential 
donors and 52 potential recipients completed the survey. Recipient survey 
respondents were more likely than donors (p=0.002) to favor participation in 
AUPKE in the absence of any advantage to themselves. However, a number 
of circumstances increased the propensity to view AUPKE favorably for both 
recipients and donors (p<0.05) (see fi gures 2 and 3 respectively) including if 
the other individual in the D/R pair wanted to participate. Both cohorts felt 
strongly that the decision to participate in AUPKE should be made jointly 
(p<0.001 for both donors and recipients).
Conclusions: 1) AUPKE can have a profound impact on the number of live 
donor renal transplants. 2) In its simplest form, utilizing ABONI donors 
AUPKE can be performed at individual centers without requiring large sharing 
networks or complex computer algorithms. 3) Blood group O recipients with 
incompatible donors are likely to be the primary benefi ciary of AUPKE. 4) 
D/R attitudes are not static, and can be infl uenced in favor of participating in 
AUPKE, particularly if there is a perceived benefi t to the recipient. 5) Both 
donors and recipients are more willing to participate in AUPKE if their intended 
recipient or donor (respectively) are enthusiastic about participating. 6) Finally, 
AUPKE refl ects a major paradigm shift for live donation, converting a private 
resource (the donor) to a shared or public one.
Figure 1 Figure 2 
Figure 3
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IL-6R BLOCKADE IN EXPERIMENTAL AUTOIMMUNE 524 
NEPHRITIS REDUCES PROTEINURIA AND IS ASSOCIATED 
WITH TREGS IN THE DRAINING 
LYMPH-NODE
G.Y. Zhang1, Y.M. Wang1, T. Polhill1, M. Hu1, D.C.H. Harris2, S.I. Alexander1
1Centre for Kidney Research, Children’s Hospital at Westmead, 2Centre for 
Transplantation and Renal Research, University of Sydney at Westmead 
Millennium Institute. Westmead, NSW 2145. Sydney, Australia
Background: Heymann nephritis (HN) is an experimental autoimmune 
model of glomerulonephritis induced in the Lewis rat by immunisation with 
a crude renal tubular Ag (Fx1A). T cell depletion studies indicated that CD4 
cells played a critical role in the pathogenesis of HN. Th17 cells have been 
identifi ed as a distinct lineage of CD4 cells and may play a decisive role in the 
pathogenesis of autoimmune disease. IL-6 and TGF-β have been identifi ed as 
critical factors for Th17 induction. Data from mice with experimental multiple 
sclerosis (EAE) suggests that IL-6 may be a major switch factor for reciprocal 
induction of Th17 and Tregs.
Aim: To investigate if blocking IL6R can attenuate HN.
Methods: Rats were given anti IL-6R antibody or IgG control antibody iv 
every 5 days (over 20 days) and immunized with Fx1A in CFA at day 2 after the 
initial administration of antibodies. An additional control group was injected 
with CFA only.
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Results: Anti IL6R therapy signifi cantly reduced proteinuria at week 6, 
8, 10 and 12 HN. Proteinuria (mg/24 h/100g bodyweight) in control Ig 
HN, anti-IL6RHN and CFA groups at Week6: 33±.36 ±11.24, 12.56 ± 2.4, 
5.17 ±0.58; Week8: 357.1±67.03, 140.4± 43.85, 5.13± 0.5; Week10: 417 
±40.28, 275.5 ±44.87, 5.8 ±0.52; Week12: 503.0 ±52.16, 355.0 ±66.58, 
3.07 ±0.4 (p<0.05). Flow cytometry at Week 10 and 12 found equivalent 
number of Foxp3+ Treg cells in spleens of all 3 groups but increased 
Foxp3+ Treg cells in draining lymph nodes in IL6R/HN group (13.2% 
±2.0) in comparison to IgG/HN group (10% ± 1.0) and CFA alone (8.5% ± 
1.1). Immunohistochemistry showed reduced glomerular IgG deposition in 
IL6R/HN group at Week10.
Conclusions: IL6-R blockade limits Heymann Nephritis and may potentially 
infl uence the Treg/Th17 axis.
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SUCCESSFUL TRANSPLANTATION OF PATIENTS WITH 525 
LOW LEVEL DONOR HLA SPECIFIC ANTIBODY WITHOUT 
DESENSITIZATION TREATMENT
M.S. Leffell, J.E. Locke, J.A. Houp, R.A. Montgomery, A.A. Zachary
Depts of Medicine and Surgery, Johns Hopkins University School of Medicine
Donor HLA specifi c antibody (DSA) is a recognized risk factor for rejection 
of renal allografts. However, solid phase immunoassays permit the detection 
of very low levels of DSA for which the clinical relevance is not known. 
We routinely treat patients with a positive fl ow cytometric crossmatch 
(FCXM) due to DSA with our desensitization protocol. We report here the 
successful transplantation, without desensitization, of 8 patients who had a 
negative FCXM but who had DSA detectable by Luminex™ assay against 
a panel of phenotypes. Eight patients comparably sensitized to third party 
(non-donor) antigens only were used as controls. The two patient groups 
were not signifi cantly different in the degree of HLA mismatch or in their 
sensitization history. Both groups included 6 primary grafts and 2 second 
transplants (Tx). The low DSA patients included 6 female and 5 black 
recipients compared to 4 females and 3 blacks in the control group. Both 
recipient groups were treated with the same immunosuppression, except 
for 4 patients in the control group who did not receive Thymoglobulin™. 
The mean pre-Tx serum creatinine (SCr) was signifi cantly higher (P=0.03) 
among the low DSA patients (9.1±4.1) than in the control patients (5.0±1.3), 
but, notably, at one month post-Tx there was no signifi cant difference in the 
SCr levels (1.5±0.6 and 1.2±0.3, respectively). SCr available for 5 patients 
in each group at longer post-Tx times were also not signifi cantly different, 
1.3±0.4 and 1.2±0.3 (9.5 and 8.9 months, respectively). The mean MFI 
for DSA was 1914±1406 pre-Tx, compared to 4085±5840 for third party 
antigens in the low DSA group. None of the low DSA patients had any 
signifi cant increase in DSA by one month post-transplant. There have been 
no graft losses in either group with follow-up times of 11.9 months (range 
1-17) for the low DSA group and 13.8 months (range 4-23) for the control 
group. Importantly, to date, there have been no rejection episodes among the 
low DSA patients, compared to two rejection incidents among the controls. 
These results suggest that low level DSA may not have an adverse effect on 
early graft survival. Expanded, longitudinal studies are needed to determine 
the long term impact.
Group N
Mean Values
Pre Tx 
PRA
1 Mo 
Post TX 
SCr
Follow-
Up SCr
Max PreTx 
MFI *
PreTx MFI 
for DSA
1 Mo Post 
Tx MFI 
for DSA
Rejection 
Episodes
Mean 
Follow-
up (mos)
Low 
DSA 8 34.5±17.8 1.5±0.6 1.3±0.4 4085±5840 1914+1406 1758+1076 0 11.9±4.9 
Controls 8 35.0±22.5 1.2±0.3 1.2±0.3 5278±5117 NA NA 2/8 (25%) 13.8±8.5
* Mean MFI to highest HLA phenotype
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TREATMENT AND PROGNOSIS OF LATE ONSET 526 
HUMORAL REJECTION IN COMPARISON WITH EARLY 
ONSET HUMORAL REJECTION IN KIDNEY TRANSPLANTS
D.J. Han, K.T. Park, S.C. Kim, J.J. Hong, E.J. Ahn
Asan Medical Center
With the advance of immunosuppressant and induction agents, incidence 
of acute cellular rejection was decreased substantially, but acute humoral 
rejection(AHR) has been diagnosed more than before due to improved 
diagnostic study and increasing number of sensitized recipients. And treatment 
of humoral rejection has not been established yet in spite of current success 
with multimodal approach, especially for the late onset humoral rejection. So, 
the purpose of this study is to compare early and late onset humoral rejection 
in kidney transplants.
From Jan. 2003 to Apr. 2007, 45 kidney recipients having renal allograft 
dysfunction were diagnosed as humoral rejection either by cross matching or 
renal biopsy or serologic evidence at out institution. They were divided into 
early and late group according to the onset of humoral rejection (within 3 
months postoperatively).
Mean onset of humoral rejection was 9.1 day and 5.7 years respectively. 
Cross matching was positive in 87.5% in early group and 19.0% in late group 
(p<0.05). C4d marker on histology was positive in 37.5% and 70% respectively. 
PRA was positive in 13 patients (54.2%) of early group and 1 patient (4.8%) of 
late group. Female gender consisted of 80% in early and 42.9% in late group. 
47% of female recipients in early group received their organs from offspring or 
spouse donor, resulting in anamnestic reaction. And other donor and recipient’s 
profi les were not different between the two groups. In early group, fi rst 
episodes of AHR were fully recovered in 96% of cases except one patient with 
multimodal treatments like plasmapheresis, steroid pulse, immunoglobulin 
and rituximab. Recurrent AHR was observed in two patients resulting in graft 
failure and impaired renal function respectively. Finally, 87.5% of early group 
remained in normal graft function. But, in late group only 2 recipients (9.5%) 
showed full response to treatment and in 19 patients (90.5%) there were no 
responses to multimodal treatment methods resulting in graft failure in 14 cases 
(73.6%). Mean duration from diagnosis to graft failure was 21 months (1.1-102 
months) and 4 recipients (19%) have experienced the episode of acute rejection 
in early postoperative period.
AHR of early onset could be treated successfully with current multimodal 
treatment and their prognosis was excellent. But humoral rejection of late onset 
couldn’t be treated with current methods and the prognosis was also poor. It seems 
to be different in pathogenesis from early onset AHR and more effective treatment 
and risk factors of late onset humoral rejection should be sought in the future.
IMMUNOSUPPRESSION 3: MINI-ORAL SESSION 18: 
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PHARMACOKINETICS (PK) OF TACROLIMUS FOR 527 
A ONCE DAILY PROLONGED RELEASE FORMULATION 
(ADVAGRAF®) VERSUS TWICE-DAILY (PROGRAF®) IN DE 
NOVO KIDNEY TRANSPLANT RECIPIENTS IN A PHASE III 
MULTICENTRE STUDY
N. Undre8, Z. Wlodarczyk1, M. Ostrowski2, M. Mourad3, B. Kramer4, 
D. Abramovicz5, F. Oppenheimer6, D. Miller7, J. Dickinson8
1Szpital Uniwersytecki im, 2Szpital Wojewodzki nr, 3UCL St-Luc University 
Hospita, 4Klinikum der Universität Regensburg, 5Hopital Erasme, 6Hospital 
Clinic I, 7Chris Barnard Memorial Hospital, 8Astellas Pharma Europe Ltd
Introduction: Advagraf® (ADV) is a prolonged release formulation of 
tacrolimus to enable once daily administration. A previous Phase II study in 
kidney transplant recipients has shown that the mean AUC of tacrolimus on 
Day 1 following administration of ADV was approximately 30% lower than 
that for Prograf (PRG); however, the exposure was comparable by Day 14. The 
objective of this study was to further describe the PK of tacrolimus for ADV 
versus PRG during the fi rst 2 weeks post-transplant.
Methods: Thirty four patients (ADV n=17, PRG n=17), participating in a 
Phase III study, provided four evaluable PK profi les. In all patients tacrolimus 
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therapy as PRG or ADV was initiated at a pre-operative dose of 0.10 mg/kg/
day; the fi rst post-operative dose was 0.2 mg/kg/day, with target whole blood 
trough levels of 10 to 20 ng/mL. PK profi les (17 samples over 24 hours) were 
obtained following the fi rst post-operative administration of tacrolimus (Day 1) 
and then on Day 3, Day 7 and Day 14. All samples were analysed using HPLC 
with tandem mass spectrometric detection.
Results: The AUC0 24 mean values for ADV were 372 (Day 1), 437 (Day 
3), 405 (Day 7) and 412 (Day 14) ng•h/mL. Corresponding values for 
PRG were 447 (Day 1), 428 (Day 3), 335 (Day 7) and 339 (Day 14) 
ng•h/mL. Dose normalised systemic exposure to tacrolimus for ADV on 
Day 1 was approximately 81% compared to PRG. On Days 3, 7 and 14 
AUC0-24 of tacrolimus for ADV compared to PRG was approximately 
106%, 107% and 116% respectively. There was good correlation between 
AUC0-24 and C24 for ADV and PRG (r=0.92 and r=0.87, respectively) 
with similar slopes.
Conclusion: This study has confi rmed that systemic exposure to tacrolimus for 
ADV normalises to that of PRG within 3 days post-transplant and that the same 
trough level monitoring concept can be used for both formulations.
POSTER BOARD NUMBER P3 – 389
A POST-HOC ANALYSIS OF THE SAFETY AND 528 
EFFICACY OF TACROLIMUS (PROGRAF) VERSUS A 
“GENERIC FORMULATION” OF TACROLIMUS (TENACRINE) 
AS PRIMARY IMMUNOSUPPRESSIVE THERAPY IN LRD 
AND CAD, ADULTS AND PEDIATRIC RENAL TRANSPLANT 
RECIPIENTS
A. Holm, M. Hernandez
Umae HGCMN La Raza IMSS
Tacrolimus (Prograf®) is a principal immunosuppressive agent used to prevent 
allograft rejection in patients undergoing renal transplantation. Generic 
formulations of Tacrolimus are available which may not be bioequivalent to the 
original formula of Prograf® ,and therefore may be detrimental to patients.
This retrospective study compared the effi cacy and safety of Prograf® with 
Tenacrine®, a Generic formulation of Tacrolimus now used in Mexico in renal 
transplant recipients.
Inclusion criteria included undergoing a fi rst renal transplant and treatment 
with Prograf® (n = 101) or Tenacrine® (n = 121) in a 3-year open-label, 
prospective, randomized, controlled study.
Although the mean blood tacrolimus level in patients treated with Prograf® 
did not change signifi cantly over time, the mean blood tacrolimus levels were 
lower in patients treated with Tenacrine® at 3 and 6 months post-transplant 
when compared to baseline.
Approximately, twice as many patients receiving Tenacrine® developed acute 
rejection compared with patients receiving Prograf® (11.8% versus 20.8%; 
p=0.080). Although the statistical analysis showed a p-value, considered 
as no signifi cant, there is a tendency to develop more acute rejection in the 
Tenacrine® group.
There was no difference in the development of acute rejection between living 
and cadaveric renal transplants in patients treated with Prograf®. However, 
patients undergoing cadaveric renal transplants were more likely to develop 
acute rejection when compared to living renal transplants if treated with 
Tenacrine® (75% of cadaveric versus 10% of living; p=0.04).
Patients receiving Tenacrine® had a median time to rejection of two months, 
compared with a median time to rejection of fi ve months in patients receiving 
Prograf®.
These study suggest that use of Tenacrine® lead to poorer clinical outcomes in 
renal transplant patients when compared to Prograf®.
POSTER BOARD NUMBER P3 – 390
PROSPECTIVE RANDOMIZED STUDY OF 529 
PHARMACOGENETIC ADAPTATION OF TACROLIMUS 
TREATMENT AFTER RENAL TRANSPLANTATION
E. Thervet1, M.A. Loriot2, S. Barbier3, M. Buchler4, B. Hurault de Ligny5, 
G. Choukroun6, C. Legendre1, C. Alberti7, P. Beaune2
1Department of Transplantation, Hopital Necker, 2Department of 
Biochemistery, Hopital Europeen Georges Pompidou, 3Department of 
Nephrology, CHU Rouen, 4Department of Nephrology, CHU Tours, 
5Department of Nephrology, CHU Cean, 6Department of Nephrology, CHU 
Amiens, 7Department of biostatitics, Hopital Robert Debre
Introduction: Retrospective studies have demonstrated that cytochromeP450 
3A5 (CYP3A5) polymorphisms are associated with tacrolimus (TAC) dose 
requirements. CYP3A5 expressors (i.e. CYPA5*1 carriers) need a higher daily 
dose to achieve therapeutic trough drug (C0) level. The aim of this study was to 
demonstrate that the use of pharmacogenetic allows a better initial adaptation 
of TAC treatment.
Patients and methods: This multicenter, prospective, randomized, open-label 
trial included 280 de novo renal recipients randomized at day 0 to receive 
TAC from day7 according to CYP3A5 genotype (group A, 0.075 mg/kg bid in 
CYP3A5*1 carriers or 0.15 mg/kg bid in CYP3A5*3/*3) vs. a control group 
with usual TAC daily dose (group B, 0.10 mg/kg bid). All patients received 
also from day0 a biological induction, MMF and steroids. Primary endpoint 
was the proportion of patients within therapeutic C0 (10 to 15 ng/ml) at day10. 
33 patients were not analyze mainly because of the use of drugs which interact 
with CYP3A.
Results: No signifi cant difference was shown between group A vs. group B 
for baseline characteristics. Genotype frequency was 79.8% CYP3A5*3/*3, 
15.8% CYP3A5*1/*3 and 4.4% CYP3A5*1/*1. The mean TAC daily dose was 
not different among the 2 groups (group A: 12.9[plusmn]3.4 vs. 15.3[plusmn]8 
mg, p=NS). A signifi cantly higher proportion of patients reached targeted 
C0 at day 10 (43% vs. 26%, p=0.009). In CYP3A*1/*1, the mean C0 was 
14,87[plusmn]2,35 in group A vs. 7,23[plusmn]2,35 in group B (p=0.035). 
In CYP3A5*1/*3, the mean C0 were respectively 14.2[plusmn]1.4 vs. 
11.8[plusmn]1.6 (p=0.26). In CYP3A5*1/*1, the mean C0 were respectively 
13.7[plusmn]0.9 vs. 18.2[plusmn]0.8 (p=0.0002).
Figure 1.
Conclusion: This is the fi rst demonstration that the prospective adaptation of 
TAC daily dose according to CYP3A5 polymorphisms is associated with a 
higher proportion of patients reaching the targeted C0. The clinical results are 
being analyzed to determine if this pharmacokinetic improvement is associated 
with clinical consequences.
POSTER BOARD NUMBER P3 – 391
THREE-YEAR EXPERIENCE WITH TACROLIMUS 530 
ONCE-DAILY PROLONGED RELEASE IN KIDNEY, 
LIVER AND HEART RECIPIENTS
J.P. Van Hooff1, R. Alloway2, P. Trunecka3, J-P. Squiffl et4
1University Hospital Maastricht, 2University of Cincinnati, 3IKEM, 4Clinique 
Universitaires Saint-Luc
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily 
formulation of tacrolimus with similar exposure and trough levels compared to 
the well-established twice-daily formulation (Prograf®, PRO). Adult transplant 
patients who had previously participated in European ADV Phase II de novo 
(kidney and liver) or conversion studies (kidney and heart, PRO to ADV) were 
entered into a follow-up open study to collect clinical data on acute rejection, 
survival, safety and daily dose requirement in the maintenance phase.
Methods: Baseline assessments were made at study entry and all patients were 
maintained on their original immunosuppressive regimen unless medical needs 
necessitated otherwise. Any medication change was recorded as were adverse 
events. Biopsy was only performed for suspected rejection. Tacrolimus whole 
blood levels at 24 hours post-dose (Cmin) were measured every 3 months. 
Effi cacy was assessed according to patient and graft survival, and acute 
rejection (graded for all indications as: none, mild, moderate, severe).
Results and conclusions: The full analysis set consisted of 240 patients: 47 de 
novo liver, 47 de novo kidney, 67 kidney conversion and 79 heart conversion 
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patients. 191/240 (79.6%) patients completed the 3-year follow up with 
33/37/57/64 patients, completing across the separate studies. Decreases in 
the mean daily tacrolimus dose and mean blood level with time were most 
pronounced in de novo patients (see table). The mean total daily doses at 34-36 
months were 4.5/5.9/5.0/4.8 mg, respectively.
Month
Liver
de novo
Kidney
de novo
Kidney
conversion
Heart
conversion
mg/kg ng/mL mg/kg ng/mL mg/kg ng/mL mg/kg ng/mL
1-3 0.17 11.6 0.15 11.6 0.08 6.3 0.07 8.2
4-6 0.12 10.6 0.12 9.9 0.08 6.7 0.07 8.9
10-12 0.09 8.7 0.10 8.9 0.07 6.7 0.07 8.7
22-24 0.07 7.7 0.09 7.8 0.07 6.5 0.07 8.2
34-36 0.06 6.6 0.08 7.6 0.07 6.4 0.06 7.7
38/240 (15.8%) patients were withdrawn mostly for adverse events (13) or 
withdrawal of consent (7). Kaplan-Meier 3-year patient and graft survival 
estimates were 90.9%/100%/92.2%/95.7%. Acute rejection occurred in 
4.3%/10.6%/0%/10.1% patients. Most rejections were mild to moderate with 
the exception of 2 severe acute rejections in 2 heart conversion patients. Mean 
creatinine clearance at 3 years was 89.8/61.3/77.6/78.3 mL/min. The adverse event 
profi le and effi cacy were consistent with that historically observed with PRO.
POSTER BOARD NUMBER P3 – 392
PRELIMINARY TWO-YEAR EFFICACY RESULTS FROM 531 
A RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY OF 
TWO DIFFERENT SIROLIMUS (SRL) REGIMENS VERSUS A 
TACROLIMUS (TAC) + MYCOPHENOLATE REGIMEN (MMF) 
IN DE NOVO RENAL ALLOGRAFT RECIPIENTS
S.M. Flechner1, S. Cockfi eld2, J. Grinyo3, G. Russ4, K.M. Wissing5, 
C. Legendre6, J.B. Copley7, for the ORION Trial Investigators
1Cleveland Clinic Foundation, Cleveland, OH, 2University of Alberta, 
Edmonton, Alberta, 3Hospital Bellvitge, Barcelona, Spain, 4Queen Elizabeth 
Hospital, Woodville South, Australia, 5Hospital Erasme, Brussels, Belgium, 
6Hôpital Necker, Paris, France, 7Wyeth Pharmaceuticals, Collegeville, PA
Purpose: To compare preliminary 2-year effi cacy results from an open-label, 
randomized, multinational trial of 2 SRL regimens versus TAC+MMF.
Methods: 451 renal transplant recipients were randomized to either Group 
1: SRL (8-15 ng/mL, 12-20 ng/mL after week 13) + TAC (6-15 ng/mL) with 
elimination at week 13 (n=155); Group 2: SRL (10-15 ng/mL through week 
26, 8-15 ng/mL thereafter) + MMF (up to 2 gm/day) (n=155); or Group 3: 
TAC (8-15 ng/mL through week 26, 5-15 ng/mL thereafter) + MMF (up to 2 
gm/day) (n=141). Corticosteroids and daclizumab were given to all patients. 
Because of increased acute rejection (AR) rates, Group 2 was terminated in 
June 2006 (after all patients were accrued); data was collected for 30 days 
beyond termination.
Results: With the exception of more females in Group 3, patient demography 
was similar among groups. Group 2 had signifi cantly higher biopsy-confi rmed 
AR (BCAR) rates compared with Groups 1 and 3, p<0.001 (Table). The majority 
of these occurred during the fi rst 6 months after transplantation (predominantly 
in the fi rst 3 months). SRL trough concentrations were subtherapeutic in a large 
number of rejectors in Group 2. In Group 1, most ARs occurred within the fi rst 
6 months, but before TAC was eliminated. All ARs were mild to moderate, 
although Group 3 had a higher incidence of grade II ARs. Rates of graft and 
patient survival were similar among groups (see Table). Renal function was 
similar between Group 1 and Group 3. The number of patients in Group 2 was 
low because of group termination.
Group 1
(SRL+TAC-Elim)
Group 2
(SRL+MMF)
Group 3
(TAC+MMF)
BCAR,a n (%) 20/148 (13.5) 43/152 (28.3)* 13/139 (9.4)
Grade I (Mild) 15/20 (75.0) 33/43 (76.7) 7/13 (53.8)
Grade II (Moderate) 5/20 (25.0) 10/43 (23.3) 6/13 (46.2)
Patient survival, n (%) 147/155 (94.8) 147/155 (94.8) 136/140 (97.1)
Graft survival,b n (%) 145/155 (93.5) 147/155 (94.8) 138/140 (98.6)
Mean Nankivell GFR, 
modifi ed ITT, mL/min (n) 64.9 (118) 72.4 (10) 66.7 (110)
Mean serum creatinine, 
modifi ed ITT, mg/dL (n) 1.68 (123) 1.35 (10) 1.61 (112)
aOn-therapy; *p<0.001
bDeath censored
Conclusion: Preliminary results show excellent patient and graft survival. 
Renal function was similar between groups 1 and 3. Adequate SRL exposure 
appears to be essential early posttransplant to achieve low BCAR rates.
POSTER BOARD NUMBER P3 – 393
MINIMIZATION OF IMMUNOSUPPRESSIVE DRUG 532 
THERAPY AT 6 MONTHS AFTER RENAL TRANSPLANTATION: 
EVEROLIMUS OR CYCLOSPORIN SUPERIOR TO 
MYCOPHENOLATE SODIUM
I.J.M. ten Berge1, E. de Maar2, R. Press3, J. Homan van der Heide2, 
H. de Fijter3, F.J. Bemelman1
1Academic Medical Centre, Amsterdam, 2University Hospital, Groningen, 
3Leiden University Medical Cantre, Leiden
Chronic allograft nephropathy is the main cause of long term renal transplant 
failure. The pathogenesis is complex involving amongst others nephrotoxic 
drugs notably cyclosporin (CsA). Therefore we performed a randomized 
multicenter trial to withdraw the calcineurin inhibitor (CNI) from a triple 
maintenance immunosuppressive regimen at 6 months after transplantation 
in a moderate risk population. Patients continued either on prednisolon (P) 
and CsA, P and mycophenolate sodium (MPS) or P and everolimus (ELS). 
All patients received induction therapy with basiliximab. Prior to withdrawal a 
surveillance transplant biopsy was done to ensure that no subclinical rejection 
was present before tapering the immunosuppressive regimen. Drug levels were 
monitored calculating drug exposure using a Bayesian model with limiting 
sample technique. Primary outcome was the degree of fi brosis and hyalinosis 
in the 2 years protocol biopsies. Secondary endpoints were patient and graft 
survival and surrogate markers for atherosclerosis. An interim analysis was 
performed after inclusion of half of the patients. 264 patients were originally 
enrolled at that time. 49 dropped out, 76 were still prior to conversion and in 
26 the immunosuppression could not be tapered due to subclinical rejection in 
their 6 months protocol biopsy. 113 patients were effectively randomized to 
continuing cyclosporin (N=39, target AUC 3250 ƒÝg/l/hr), or MPS 2 x 720 
mg (N=36) or ELS N=38, target AUC 150 ƒÝg/ml/hr). After conversion there 
was 1 rejection in the ciclosporin arm (2%), versus 8 in the MPS arm (22%) 
and none in the ELS arm. Mean plasma creatinin was 138 „b 14 ƒÝmol/l, 132 
„b 25 ƒÝmol/L and 110 „b 10 ƒÝmol/ L in the ciclosporin, MPS and ELS arm 
respectively. We conclude that an early switch to double therapy consisting of 
P and either ELS or CsA is safe. In contrast, tapering at 6 months to double 
therapy consisting of P and MPS bears a high risk of late, acute rejection.
POSTER BOARD NUMBER P3 – 394
SIROLIMUS IS ASSOCIATED WITH WORSEN OUTCOME 533 
COMPARED TO MYCOPHENOLATE MOFETIL IN HIGH 
IMMUNOLOGIC RISK RENAL TRANSPLANT RECIPIENTS 
RECEIVING TACROLIMUS COMBINED WITH ATG 
INDUCTION
M. Durlik1, O. Tronina1, T. B±czkowska1, M. Klinger2, B. Rutkowski3, 
A. Wiêcek4, M. Ostrowski5, L. P±czek6, J. Szmidt7, W. Rowiñski8
1Dept. of Transplantation Medicine And Nephrology, 2Dept. of Nephrology and 
Transplantation Medicine, 3Dept. of Nephrology, Transplantology and Internal 
Medicine, 4Dept. of Nephrology, Endokrynology and Metabolic Diseases, 
5Dept. of General and Transplantation Surgery, 6Dept. of Immunology, 
Transplantology and Internal Medicine, 7Dept. of General, Vascular and 
Transplantation Surgery, 8Dept. of General and Transplantation Surgery
Introduction and aims: Results of kidney transplantation in high immunologic 
risk are associated with increased rate of rejection and lower graft survival. 
The aim of this multicenter, randomized, prospective study was to determine 
optimal immunosuppressive regimen in this group of patients (pts).
Methods: 62 (30 males) high risk cadaveric renal transplant recipients, aged 
15-55 years, were included in the study and followed-up for 36 months. High 
immunologic risk was defi ned as retransplantation (2nd [n=34] or 3rd [n=l] 
graft) or PRA > 25%. PRA range was 0-24% (n=28), 25-36% (n=23), and 
>36% (n=11). HLA mismatches (MM) in class I (A + B) were 16.1, 26, 35.5, 
11.4, and 4.8%, for 4, 3, 2, 1 and 0 MM, respectively and in class II (DR) 
were 14.5, 5, and 26% for 2, 1 and 0 MM, respectively. Pts were randomized 
to receive ATG (3 mg/kg; 4 doses) + Steroids + Tacrolimus (Tac) and either 
mycophenolate mofetil (MMF) (n=40) or Sirolimus (Sir) (n=22). 1-year graft 
and patient survival were estimated with Kaplan-Meier method. Renal function 
(expressed as estimated GFR [eGFR calculated by Cocroft Gault’s formula] 
was monitored for 24 months.
Results: Delayed graft function was observed in 35.5% pts. In 37% pts biopsy-
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proven acute rejection episodes were diagnosed (early [up to month 3] in 17%, 
late in 20%), in 32.5% pts on MMF, and in 45.5% on Sir (NS). Signifi cantly 
higher cholesterol and trigliceryde levels, and signifi cantly lower hemoglobine 
and hematocrit were observed in Sir group. 8 kidney grafts were lost during 
follow-up 5 and 3 in MMF and Sir groups, respectively. 4 patients were 
converted from Sir to MMF due to thrombotic mieroangiopathy, 2 patients from 
MMF to Sir due to neoplasia. Rate of infectious complications was comparable 
in both groups. Two patients died during follow-up. Renal function was stable 
in both MMF and Sir groups, with eGFR slope signifi cantly more positive in 
MMF group over 2 years after transplantation (p<0.045).
Conclusions: MMF with ATG induction proved more safe and effi cacious than 
sirolimus therapy in high immunologic risk kidney transplantation, resulting 
in better graft function and lower incidence of adverse effects. Kaplan-Meier 
estimates of l-year patient and graft survival showed a trend in benefi t of 
MMF.
Graft function (GFR mL/min [CC formula]), 1-year graft and patient survival
GFR at 
Month 1
GFR at 
Month 3
GFR at 
Month 24 Graft survival
Patient 
survival
MMF group 58.88±25.8 58.2±19 62.4±21 87.5% 95.5%
Sir group 46.8±20.4 47±20.6 50.2±20.2 81.8% 90.9%
POSTER BOARD NUMBER P3 – 395
INFLUENCES OF IMMUNOSUPPRESSIVE AGENTS 534 
ON GRAFT SURVIVAL: THE IMPACT OF DE NOVO CNI 
MINIMIZATION COMBINED WITH SIROLIMUS
M.-K. Tsai, C-Y. Lee, I-R. Lai, R-H. Hu, P-H. Lee
Department of Surgery, National Taiwan University Hospital
A multivariate analysis was conducted to assess the impact of de novo sirolimus 
therapy on graft survival. We collected 100 patients of renal transplantation 
receiving sirolimus combined with a low-dose calcineurin inhibitor (CNI) (either 
cyclosporine or tacrolimus) and 104 cases on CNI-based immunosuppressive 
therapy from October 2000 to August 2007. Graft and patient survival rates 
were estimated using the Kaplan-Meier method. Univariate analysis with the 
log-rank test was used to examine the prognostic signifi cance of recipient 
age, gender, donor age, delayed function, donor type, HLA mismatch, SRL 
therapy, CNI (CsA or TAC) and acute rejection in graft survival. Prognostic 
signifi cance of 6-month estimated GFR for graft survival was determined by 
Cox¡¦s regression. Stepwise regression analysis was then applied to factors 
with statistical signifi cance in the univariate analysis to further determine the 
independent effect of each factor. On univariate analyses, 6-month estimated 
glomerular fi ltration rate (eGFR), acute rejection and sirolimus therapy were 
signifi cant for graft survival, and sirolimus therapy and tacrolimus therapy for 
rejection-free survival. Mutivariate analyses identifi ed 6-month eGFR as the 
only one prognostic factor for graft survival. Acute rejection and sirolimus, 
but not tacrolimus, therapy was signifi cant for posttransplant renal function. In 
conclusion, sirolimus de novo therapy brought about improved renal function 
and graft survival of renal transplantation.
POSTER BOARD NUMBER P3 – 396
DELAYED INTRODUCTION OF A CALCINEURIN-535 
INHIBITOR (CNI)-FREE, SIROLIMUS (SRL)-BASED 
IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION 
IS SAFE. PRELIMINARY RESULTS OF THE RANDOMISED, 
MULTICENTER SMART TRIAL
K-W. Jauch1, J. Pratschke2, C. Hugo3, B. Krämer4, O. Hakenberg5, 
J. Brockmann6, J. Andrassy1, M. Guba1
1Surgery Dpt., Ludwig-Maximilians-University, Grosshadern, 2Surgery 
Dpt., University of Berlin, Charite (Campus Virchow), 3Dpt. of Nephrology, 
University of Erlangen, 4Dpt. of Nephrology, University of Regensburg, 5Dpt. 
of Urology, University of Rostock, 6Surgery Dpt., University of Muenster
Background: The high rate of side-effects, drug discontinuation and acute 
rejection episodes seen in SRL based CNI-free immunosuppressive protocols 
may largely be due to the ill-timed early initiation of SRL post-transplantation. To 
avoid the well-known problems of mTOR-inhibitor based immunosuppression 
in the early phase after transplantation, we designed a study where CNI-free 
immunosuppression with SRL and mycophenolate mofetil (MMF) was started 
2-3 weeks after renal transplantation following a short course of cyclosporine 
(CSA) and MMF.
Methods: After ATG-F (9mg/kg bw.) induction and an initial 2-3 weeks 
immunosuppression with CSA, MMF (2g/d) and steroids (ST), 141 low 
risk renal transplant recipients were randomized to either continue on CSA 
(target C0 200-250ng/ml), MMF (2g/d) and steroids or be converted to 
CNI-free immunosuppression with SRL (target 8-12ng/ml) +MMF (1.5g/d) 
and ST.
Results: Patient characteristics were comparable in both study arms. The 
delayed introduction of SRL successfully avoided excess rates of wound 
complications in the SRL arm. The rate of postoperative wound healing 
problems was not signifi cantly different in the SRL arm as compared to the 
CSA arm (8 vs. 9%). The incidence of lymphoceles was 15% in the SRL arm 
and 24% in the CSA arm. The early conversion did not result in an increased 
risk of rejection during the conversion process. The rate of Banff 4 rejection 
episodes from the time of conversion to 3 months was not signifi cantly 
different between the SRL arm 14% and the CSA arm 9%. Therapeutic SRL 
levels were obtained within one week, reaching the intended target levels of 
>8 ng/ml at day 7 after conversion (SRL trough 8.62±3.58 ng/ml). There was 
no increased risk of infectious complications associated with the conversion 
to SRL. However, CMV viremia, as a marker infection, was more frequent in 
the CSA arm (28%) as compared to the SRL arm (6%). Although the overall 
rate of adverse events was not signifi cantly different between the study 
groups, signifi cantly more patients were withdrawn from the SRL arm 30% as 
compared to the CSA arm 13%.
Conclusion: The preliminary results from this ongoing study show that the 
delayed introduction of a CNI-free, SRL-based immunosuppression is equally 
safe as compared to a CSA-based protocol in terms of surgical, immunological 
and infectious complications. A well-timed, sequential use of SRL may 
overcome problems observed with the de novo use of mTOR inhibitors.
POSTER BOARD NUMBER P3 – 397
RESULTS OF A CALCINEURIN-INHIBITOR-536 
FREE IMMUNOSUPPRESSIVE PROTOCOL IN RENAL- 
TRANSPLANT RECIPIENTS OF EXPANDED CRITERIA 
DECEASED DONORS (ECD). 5-YEAR ANALYSIS
L.S. Re, M. Rial, D. Curcio, O. Guardia, J. Petroni, D. Casadei
Instituto De Nefrología De Buenos Aires
Introduction: The increasing number of patients on waiting lists and the 
relatively stable organ procurement rate provide the groundwork for the use 
of expanded criteria deceased donors. While calcineurin-inhibitors (CNI) are 
excellent immunosuppressive drugs, their nephrotoxicity is largely responsible 
for the lack of improvement in long-term graft survival.
Objective: The objective of this study was to analyze the results obtained with 
the use of a calcineurin inhibitor-free immunosuppressive protocol (polyclonal 
antibody induction, plus sirolimus, mycophenolate mofetil, and low doses of 
steroids) in terms of graft and patient survival as well as post-transplant clinical 
complications over a 5-year period.
Materials and methods: 75 kidney recipients of ECD performed between 
01/01/01 y 01/05/05 were treated with Thymoglobulin induction for 7-14 days, 
Sirolimus was adjusted to a level of 8-12 ng/ml during the fi rst post-transplant 
year and 6-8 ng/ml thereafter.
Results: Recipient age: 49.25 ± 18.5 years. Donor age: 56.25 ± 7.45 years. 
Delayed graft function: 80%. 1-year acute cellular rejection: 15/75 (20%) 
5-year actuarial patient survival: 85.7%. 5-year actuarial graft survival: 75.6%
5-year actuarial graft survival (death censored): 80.3%. 5-year creatinine level: 
1.57 ± 0.34 mg/dl.
The incidence of post-transplant complications was low (arterial hypertension, 
dyslipidemia, post-transplant diabetes, proteinuria, etc) and they were not 
signifi cantly different from that reported with other immunosuppressive 
schemes.
Conclusion: The use of a calcineurin inhibitor-free protocol in renal-transplant 
recipients of expanded criteria deceased donors was associated with excellent 
graft and patient survival rates and a low incidence of adverse events in a 
5-year follow-up period.
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SAFETY AND EFFICACY OF EVEROLIMUS VS 537 
MYCOPHENOLATE MOFETYL WITH CSA IN DENOVO LIVE 
RELATED RENAL TRANSPLANTATION
R.K. Sharma, P.B. Vinod, A. Saxena, A. Gupta, R. Kapoor, A. Srivastava, 
N. Prasad, A. Kumar
Department of Nephrology & Urology, Sanjay Gandhi Post Graduate Institute 
of Medical Science
To compare the renal function, safety and effi cacy parameters in everolimus vs 
MMF group with cyclosporine at 1 year. This is a prospective non randomized 
open label study in denovo live related renal transplant recipients. Total 60 
patients above 18years and fi rst renal transplant were included in the study 
(30 in each arm). CsA was started on day -2 with 8 mg/kg/day in both groups 
and tapered to achieve C2 level of 1-1.4 ƒÝgm/ml vs 1.7 ƒÝgm/ml at 1month 
and 0.55 ¡V 0.65 ƒÝgm/ml vs 1.2 ƒÝgm/ml at 3 month and 0.35-0.45 ƒÝgm/
ml vs 1.0 ƒÝgm/ ml at 6 month and 0.25-0.35 ƒÝg/ml vs 0.8 ƒÝgm/ml at 
12 months in Everolimus vs MMF group respectively. Everolimus was started 
with 0.75 mg bid adjusted the dose to trough level of 3-8 ngm/ml. MMF dose 
was started at 2 gm/day. Prednisolone 20 mg /day in both groups and reduced 
to 10 mg /day by 3rd month of transplant. Renal functions were monitored 
by serum creatinine and calculated GFR. The mean Serum creatinine (mg%) 
at 1, 3, 6, 12 month of post transplant were 0.92±0.25; 1.0±0.12; 0.90±0.18; 
0.91±0.11 in everolimus group vs 1.1±0.8; 1.2±0.34; 1.2±0.32; 1.23+0.67 in 
MMF Gr respectively (NS).The mean GFR calculated at 12 month was 72±12 
ml/mt/m2 (everolimus) vs 62±7.2ml/mt/m2 (MMF). The no: of patients with 
BPAR at 12 month was 6 patients (20%) in the everolimus group and 8 patients 
(26.6%) in the MMF group (P=NS). Graft loss occurred in 2 patients (6.6%) 
in the everolimus group and 2 patients in the MMF group. Mortality was same 
in both the groups-3.3% (1 patient in each gp). Side effect profi le includes; 
diabetes in 4 (13.3%) patients in everolimus group and 2 (6.6%) in the MMF 
group. Dyslipidemia occurred in 6/30 (20%) in the everolimus group vs 5/30 
(16.6%) in the MMF group .The average dose of CsA was 30 mg/day in the 
evrolimus group compared to 150 mg/day in the MMF gp at 12month of 
transplantation. The CsA requirement was fi ve times less in the everolimus 
group compared with MMF group at 12 month .The mean CsA drug level at 12 
month was 0.55±0.08 ngm/ml in the everolimus group vs 0.85±0.21 ngm/ml in 
the MMF group .The mean everolimus drug level at 12 month was 4.56±1.78 
ngm/ml. The cost of therapy (calculated in US dollors) shows that everolimus 
groups have signifi cantly less cost compared to MMF group (555 vs 562 at 
one month and 305 vs 417 at 3 month, 151 vs 331 at one year). There was no 
signifi cant difference in the serum creatinine level and calculated GFR at 1 year 
of transplantation. The BPAR, graft loss and mortality were similar in the both 
groups. The incidence of CMV infection or other viral infection were higher in 
the MMF group. Exposure to CsA at 1 year was signifi cantly less (1/5th dose) 
in everolimus gp compared to MMF gp. This could have benefi t in terms of 
chronic CsA nephrotoxicity.
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POST-OPERATIVE TISSUE REGENERATION IN RENAL 538 
TRANSPLANTATION: COMPARABLE OUTCOME WITH 
EVEROLIMUS OR MMF
R. Margreiter1, Š. Vitko2, J. Whelchel2, J.C. Magee2, H. Tedesco2, J. Eris2, 
J. Pascual2, B. Kahan2, Z. Wang3, H. Sollinger2
1Universitatsklinik fur Chirurgie, Innsbruck, Austria, 2On behalf of the B201, 
B251, A2306 and A2307 Study Groups, and 3Novartis Pharmaceuticals 
Corporation, East Hanover, United States
Introduction: Everolimus is a proliferation signal inhibitor that effectively 
prevents acute rejection in renal transplant recipients. Its antiproliferative effect 
has been shown to inhibit graft vasculopathy in cardiac allografts, and has been 
a focus of interest during the early post-operative phase of tissue regeneration. 
In this cross-study analysis, the infl uence of everolimus was compared with 
mycophenolate mofetil (MMF), as part of a triple immunosuppressive regimen, 
on the incidence of post-operative complications.
Methods: Pooled data from four prospective, randomized, renal transplantation 
studies were compared: (i) the MMF arms from two 36-month, randomized, 
parallel-group studies (B201, B251; n=392) in which patients received MMF 
2g/day with standard-dose cyclosporine (CsA) and corticosteroids, and (ii) the 
everolimus arms of two 12-month, prospective, randomized studies (A2306, 
A2307; n=493) in which patients received everolimus 1.5mg/day or 3.0mg/day 
within 24h of transplantation, adjusted to target trough levels of 3–8ng/mL, in 
combination with low-exposure CsA and steroids (with basiliximab induction 
therapy in A2307). The primary endpoint for B201/B251 was effi cacy, and for 
A2306/A2307 it was renal function at 6 months; secondary endpoints included 
adverse events (AEs) and serious adverse events (SAEs).
Results: In the pooled analyses, 167 (3.3%) of reported AEs in the MMF-
treated group were associated with post-operative tissue regeneration-
related complications, such as wound infection, dehiscence and lymphocele 
development, compared with 139 (2.2%) in the everolimus-treated group. 
In both comparator groups, >85% of these AEs were classifi ed as ‘mild’ 
or ‘moderate’. The two groups had comparable rates of wound infection, 
dehiscence and lymphocele development (Table).
Conclusion: Tissue regeneration is comparable in the presence of everolimus 
or MMF. The use of everolimus does not increase the post-operative risk of 
delayed tissue regeneration. 
2g/day MMF (B201/B251)
n=392
Everolimus (A2306/A2307)
n=493
Wound infection 38 (9.7%) 37 (11.4%)
Dehiscence 14 (3.6%) 30 (6.1%)
Lymphocele 33 (8.4%) 56 (7.5%)
RENAL PATHOLOGYMINI-ORAL SESSION 19: 
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PITFALLS IN THE DIAGNOSIS OF CHRONIC ANTIBODY 539 
MEDIATED REJECTION: LOSS OF PERITUBULAR 
CAPILLARIES, WIDE SPECTRUM, AND TRANSIENT NATURE 
OF C4D DEPOSITION
A.B. Collins, A.B. Farris, R.N. Smith, C.D. Adams, P.A. Della Pelle, 
W. Wong, R.B. Colvin
Departments of Pathology, Medicine and Surgery, Massachusetts General 
Hospital and Harvard Medical School, Boston MA 02114
The diagnosis of antibody mediated graft rejection is based on the extent of PTC 
C4d deposition. However, recent studies have reported a loss of peritubular 
capillaries in the setting of late graft dysfunction with fi brosis, and we have 
commonly observed that the frequency of C4d+ PTC is less in CHR. In the 
present study we performed single and two color immunohistochemistry for 
capillary endothelium (CD34) and C4d. The PTC density was quantitated by 
visual counts and compared to morphometry on digital virtual slides (Aperio). 
These fi ndings were correlated with graft function and extent of interstitial 
fi brosis (trichrome morphometry). Cases studied were those classifi ed 
according to Banff 2007 as chronic antibody mediated rejection with transplant 
glomerulopathy (CHR), transplant glomerulopathy with negative C4d (TG 
C4d-), chronic calcineurin inhibitor toxicity (CNIT), and normal transplant 
biopsies (NT). All of the CHR recipients tested had donor specifi c antibody (4 
class I only, 5 class II only and 2 both).
Capillary Density/mm2 CD34/mm2
Diagnosis N yrs post tx CD34 C4d %C4d+ p vs NT
CHR 15 8.7±5.7 233±124 117±122 43±31% 0.02
TG C4d- 7 13.9±12.6 165±138 0 0.006
CNIT 6 5.2±3.2 243±185 0 n.s
NT 7 0.4±0.7 319±188 0
The PTC density was signifi cantly decreased in the CHR group compared with 
normal transplant biopsies (TG C4d-). Within the CHR group, the density of 
C4d+ PTC correlated with the overall capillary density (p=0.001). According 
to the new Banff C4d grades, one case was C4d1 (1-10%), 9 were C4d2 
(10-50%) and 5 were C4d3 (>50%). However, there was a continuum of the% 
of C4d+ capillaries from 1-89% and there was no obvious threshold that could 
be applied to this group. Most had glomerular capillary wall C4d deposition 
(83%). One case with class I DSA and TG had only 1% C4d+ but strongly 
positive glomerular C4d deposition. One was more widespread by IHC and 
one by IF. The% fi brosis correlated with the Cr at the time of biopsy (p=0.04). 
C4d%+ and capillary density showed no statistically signifi cant correlation with 
Cr at the time of the biopsy or with the time post transplant. One question that 
has been raised is the nature of TG with C4d-. This group also had a decreased 
capillary density. Two cases had had prior acute humoral rejection and the TG 
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was probably the residual of that episode. In 2 other cases the fi ndings of CNIT 
were typical and probably the cause of the TG. Three were idiopathic. One of 
the CHR cases had a later biopsy with TG that was C4d-. Thus some cases of 
TG C4d- are due to past episodes of antibody mediated glomerular injury.
We conclude that diagnosis of CHR by C4d staining has to take into account 
the substantial decrease of capillary density and the wide range of positive PTC 
down to a low percentage not normally considered diagnostic. C4d may be 
transient and disappear or reappear in cases with TG, in keeping with the stages 
of CHR previously proposed.
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EFFECTS OF MTOR-INHIBITION ON HYPOXIC 540 
ADAPTATION BY HIF – PREFERENTIAL INFLUENCE 
ON ERYTHROPIETIN REGULATION
M. Wiesener1,2, K. Knaup1,2, K. Jozefowski2, B. Klanke1, A. Weidemann1, 
C. Warnecke1, W. Bernhardt1, K-U. Eckardt1, 
1Dept. Nephrology & Hypertension, Univ. Erlangen, 2Interdisciplinary Centre 
of Clinical Research, Univ. Erlangen
The Hypoxia-Inducible transcription Factor (HIF) and the kinase “mammalian 
Target of Rapamycin” (mTOR) both represent key regulators in their fi eld. 
The former is the master regulator of oxygen dependent gene regulation, 
enabling cells to adapt to a hypoxic environment. The latter is a central 
controlling mechanism integrating infl uences of nutrients and mitogens to 
cellular growth and proliferation. Both systems are of major importance in 
tumour growth and wound healing, amongst many others. Recent data has 
shown that both systems overlap, in that mTOR seems to activate HIF, yet the 
mechanism and the biological relevance are unknown. mTOR inhibition is 
increasingly being used in solid organ transplantation. A number of important 
side effects, such as wound healing diffi culties and posttransplant anemia, 
represent relevant clinical problems. Furthermore, experimental data suggests 
that ischemia tolerance is reduced under mTOR inhibition, which includes 
early graft survival and cardiovascular events. Since HIF is involved in all 
these processes, putative HIF repression by mTOR-inhibitors could partially 
explain these unwanted effects.
We attempted to further characterise the regulation of HIF by mTOR, both 
in cell culture and rodent models. Our studies confi rm a profound effect of 
mTOR inhibitors, such as everolimus on HIF activation amongst a broad panel 
of cells, including primary and immortalised renal cells. However, these effects 
are partially context- and cell-dependent. Interestingly, oxygen tension itself is 
an important factor, in that HIF activation under severe hypoxia seems to be 
completely independent of mTOR. HIF target genes such as VEGF or GLUT1 
were moderately infl uenced by mTOR inhibition in cell culture. However, genes 
regulated with a high amplitude, such as EPO and CA9 showed a pronounced 
repression. Erythropoiesis is a classical function of HIF, which is mediated 
by transcriptional regulation of the erythropoietin gene in the kidney, leading 
to continuous EPO secretion. Therefore, we seeked to investigate the role of 
mTOR inhibition in vivo. In rodents, pre-treatment with everolimus prior to 
hypoxic (9% O2, 8 hours) exposure did not attenuate the expression of the HIF 
targets VEGF or GLUT1 in any organ assayed, although pronounced effects on 
the phosphorylation status of the downstream effector of mTOR, rpS6, were 
observed. EPO, on the other hand, did show a signifi cant reduction of mRNA 
expression in the kidney by everolimus.
In conclusion, our data confi rm and extend the previously demonstrated 
effect of mTOR-inhibition on HIF, which appears to be a general cellular 
effect. The regulation of HIF by mTOR seems to be most relevant at mild 
hypoxia or even normoxia; which could enable a certain degree of oxygen-
independent transactivation by HIF. Our data implicate that in severe tissue 
hypoxia, mTOR inhibition may not infl uence HIF targets on a tissue level. 
However, the infl uence of mTOR on EPO regulation possibly meets a clinical 
correlate, which could at least partially explain the frequently observed 
anemia in transplanted patients treated with mTOR inhibitors. This effect 
would cause a relative defi cit of circulating EPO, which would add to the 
antiproliferative effect on the bone marrow and should encourage the use of 
recombinant EPO.
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EFFECTS OF PITUITARY ADENYLATE CYCLASE 541 
ACTIVATING POLYPEPTIDE (PACAP) ON THE SURVIVAL, 
MORPHOLOGY, APOPTOTIC SIGNALING AND OXIDATIVE 
STRESS IN RATS SUBJECTED TO RENAL ISCHEMIA/
REPERFUSION
D. Reglodi1, P. Szakaly2, P. Kiss1, A. Lubics1, T. Magyarlaki3, A. Tamas1, 
J. Nemeth4, A. Ferencz5, G. Weber5, B. Racz5
1Dept. of Anatomy, University of Pecs, 2Dept. of Surgery, Uniersity of Pecs, 
3Dept. of Laboratory Medicine, University of Pecs, 4Dept. of Pharmacology, 
University of Debrecen, 5Dept. of Surgical Research and Techniques, 
University of Pecs
PACAP was fi rst isolated from the hypothalamus based on its cAMP-increasing 
effect, but it has been shown in all parts of the central and peripheral nervous 
system. The neuropeptide has well-known protective effects in the nervous 
system, mainly through its antiapoptotic and antiinfl ammatory actions. A few 
studies have shown that it is renoprotective in models of nephrotoxicity and 
myeloma kidney injury. Our aim was to investigate the protective effects of 
PACAP in rats subjected to different times of renal ischemia/reperfusion using 
pathohistological analysis, Western blotting of apoptotic markers, biochemical 
assay of oxidative stress and radioimmunoassay for measuring endogenous 
PACAP. Rats received iv. saline or PACAP (100 μg) injection before renal 
arteries were clamped for 15, 30, 45 or 60 minutes. Histological analysis 2 weeks 
after survival showed that 15 or 30 min renal ischemia caused no morphological 
changes in either group. Mortality increased after 45 and 60 min ischemia in 
the controls with surviving rats showing severe tubular atrophy. However, 
all PACAP-treated rats survived with normal or subtle renal morphological 
alterations after 45 min ischemia, and only 1 rat died in the 60 min ischemic 
group, where surviving rats displayed subtle focal tubular atrophy. Kidneys 
were also further processed for examination of apoptotic signaling pathways 
using Western blotting. Most marked effects were found in the expression of 
mitochondrial antiapoptotic bcl-2: 45 and 60 min ischemia led to a marked 
decrease, while PACAP treatment signifi cantly increased the level of bcl-2. 
Similar results were found with the MAP kinases: the antiapoptotic ERK was 
increased while the proapoptotic JNK and p38 were decreased upon PACAP 
treatment. Determining the levels of malondialdehyde and reduced glutathion 
by biochemical assays revealed that levels of malondialdehyde were lower in 
PACAP-treated rats that underwent 45 and 60 min ischemia. Furthermore, using 
radioimmunoassay, the concentration of PACAP was determined in the kidney 
tissue in young, old male and female rats before and after ischemia. PACAP 
levels were signifi cantly higher in young rats and were strongly reduced in 
the cortex after short ischemic time, but an upregulation was observed a few 
hours after longer ischemic times. Levels returned to baseline after 24 hours. In 
summary, our results show that PACAP is endogenously present in the kidney 
and the time-course of endogenous PACAP alterations may give further insight 
to the role of PACAP in ischemia. Exogenously given PACAP prolongs the 
ischemic time, increases survival rate and attenuates the pathomorphological 
changes in a rat model of renal ischemia/reperfusion involving the upregulation 
of antioxidant and antiapoptotic pathways.
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483 DONOR KIDNEY BIOPSIES: PREDONATION RISK 542 
FACTORS AND HISTOLOGY
L. Kyllönen1, J. Kahu2, Ü. Kirsimägi2, K. Salmela1
1Kidney Transplant Unit, Helsinki University Hospital, 2Clinic of Surgery, 
Tartu University Hospital
Deceased donor quality is known to affect kidney transplantation outcome. Less 
is known how donor risk factorsduring life are associated with the histological 
fi ndings in procurement biopsies.
Methods: We studied the infl uence of predonation risk factors on histology 
of 483 deceased donor kidneys between 1995 and 2005. Mean age of the 
donors was 45.9 ± 12.8 years (range 11-72). All biopsies were taken during 
the donor operation and graded for this study according to the Banff criteria 
by one pathologist. Clinical data were collected from hospital documents and 
the national kidney transplantation registry. We analysed the cumulative effect 
of risk factors on histological lesions. We also divided the donors according 
to UNOS criteria to expanded (N=105) and non-expanded (N=378) criteria 
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donors. Histological fi ndings in these two categories were compared.
Results:
Table 1. Frequency of donor (N=483) risk factors
Risk factor %
Smoking 61
Alcohol abuse 25
Hypotonia 23
Arterial hypertension 19
Resuscitation 16
Untreated hypertension 9
Aterosclerotic vascular disease 7
Ischemic heart disease 6
Oliguria 4
Observed frequency of donor risk factors is shown in Table 1. Donor age was the 
most signifi cant risk factor affecting glomerulosclerosis (%GS), tubular atrophy 
(ct), interstitial infl ammation (ci), vascular intimal sclerosis (cv), arteriolar 
hyalinosis (ah) and the composite CADI score in donor biopsy (Table 2.)
Cardiovascular causes of death and arterial hypertension affected the donors’ 
glomerular and vascular sclerosis and CADI but not the interstitial or 
tubular compartment. Ischemic heart disease was correlated only with%GS. 
Smoking was associated with cv and ah. Periods of hypotension affected 
the tubulointerstitial compartment but otherwise the factors related to donor 
management had no signifi cant impact on biopsy fi ndings. Alcohol abuse was 
not a risk factor for donor kidney damage.
Donor creatinine was correlated only with CADI score (4 or higher), but not 
with single histological parameters.
Table 2. Association of signifi cant risk factors with donor histology.
Risk 
factors,
P value
Age
Dgn: 
Trauma 
vs other
Athero 
sclerosis
Ischemic 
heart 
disease
Hypertension Hypo tonia Smoking
%GS < 0.0001 0.0316 ns 0.0313 0.0004 ns ns
ct 0.0115 ns ns ns ns 0.0386 ns
ci 0.0458 ns 0.0345 ns ns 0.0054 ns
cv < 0.0001 0.0004 ns ns 0.0599 ns 0.0222
ah 0.0023 0.0016 0.0634 ns ns ns 0.0115
CADI <0.0001 0.0013 ns ns 0,006 ns ns
An increased number of simultaneous risk factors resulted in higher scores of 
CADI,%GS, ah, cv and ct. If no donor risk factors were present CADI 0 was 
found in 63.6% of biopsies, if there were 2 or more risk factors only in 41% 
(P = 0.033). Expanded criteria (UNOS) donors had signifi cantly higher scores 
of%GS, cv, ct, ah and CADI than non-expanded criteria donors.
Conclusions: The pre-existing histological injuries in donors with a number 
of risk factors should be taken into account during allocation (old-for-old 
programmes) and recipient management (minimal cold ischemia time, non-
nephrotoxic schemas).
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DONOR BIOPSY HISTOLOGY AND RESULTS OF 833 543 
DECEASED DONOR KIDNEY TRANSPLANTATIONS
L. Kyllönen1, J. Kahu2, Ü. Kirsimägi2, K. Salmela1
1Kidney Transplant Unit, Helsinki University Hospital, 2Clinic of Surgery, 
Tartu Univeristy Hospital
Expanded criteria donors are increasingly used for kidney transplantation. The 
aim of our study was to examine what severity of lesions in the donor kidney 
histology is acceptable for transplantation.
Methods: We evaluated baseline kidney biopsies (more than 7 glomeruli) 
taken during the donor operation from 483 deceased donors (mean age 45.9 
± 12.8, range 11-72). Kidneys from these donors were transplanted between 
1995 and 2005 to 833 recipients. Follow-up time was from 2 to 12 years. The 
biopsies were graded semiquantitatively according to the Banff classifi cation 
by one pathologist. Clinical data were collected from hospital documents and 
the national kidney transplantation registry. The effects of each histological 
parameter and the composite CADI on graft function as measured by calculated 
(Cockcroft) creatinine clearance and survival was analysed. We also analysed 
the histological fi ndings by dividing the donors according to UNOS expanded 
(N=105) and non-expanded criteria (N=378).
Results: The average number of glomeruli in biopsies was 16.4±6.7 (range 
7 - 40). The mean percentage of sclerotic glomeruli was 3.5 (95% CI: 2.9 – 4.0, 
range 0 – 43).
Table 1. Histological fi ndings in 483 donor kidney biopsies. The remaining 
histological components of the Banff schema were positive only in solitary 
cases.
Banff 97 schema components 0 1 2 3
Vasc. intimal sclerosis (cv),% 70.8 25.1 3.9 0.2
Tubular atrophy (ct),% 96.1 3.9 - -
Interstitial fi brosis (ci),% 87.4 12.2 0.2 0.2
Arteriolar hyalinosis (ah),% 80.3 9.7 9.3 0.6
CADI 0 1 2 3 ≥4
% 45.5 33.5 13.7 4.8 2.5
 
Figure 1. CADI and 3-year Creatinine clearance 
Donor biopsy variables (Table 1) did not signifi cantly affect the graft survival. 
In our material, concerning glomerulosclerosis, increasing the required number 
of glomeruli did not make it a predictor of graft survival.
The 1 and 3 year creatinine clearances were signifi cantly affected by CADI 
(Figure 1), percentage of glomerulosclerosis and the other histological 
parameters (cv, ct, ci, ah).
Rate of DGF was signifi cantly higher in CADI >3 transplantations (52% vs. 
28%). Singly, the histological variables of donor biopsy did not predict onset 
of graft function. Expanded criteria (UNOS) donors had signifi cantly higher 
scores in vascular, tubular and glomerular injury and CADI. Transplantation 
from these donors resulted in signifi cantly worse graft survival.
Conclusion: In our deceased donor kidney transplant population donor 
histology did predict the quality of graft function up to at least 3 years after 
transplantation but did not predict graft survival.
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HEPARIN BINDING EPIDERMAL GROWTH FACTOR 544 
(HB-EGF) IS DETRIMENTAL IN ISCHEMIA/REPERFUSION 
INJURY (IRI)
H. van Goor1, G.M. Mulder1, W.N. Nijboer2, M.A. Seelen3, 
W.B.W.H. Melenhorst1, L. Visser1, R. Khokha4, H.G.D. Leuvenink2, 
R.J. Ploeg2, S.W. Sunnarborg5, 
1Department of pathology and medical biology, University Medical 
Center Groningen, University of Groningen, Groningen, the Netherlands, 
2Department of surgery, University Medical Center Groningen, University 
of Groningen, Groningen, the Netherlands, 3Department of nephrology, 
University Medical Center Groningen, University of Groningen, Groningen, 
the Netherlands, 4Ontario Cancer Institute, University Health Network, 
Toronto, Canada, 5Department of Biochemistry and biophysics, University of 
North Carolina School of Medicine, Chapel Hill, NC, USA
Background: Kidneys from living-related donors have a better long-term 
survival than those from deceased donors, suggesting that ischemia is implied 
in the pathogenesis of chronic transplant dysfunction (CTD). IRI causes 
progressive deterioration of renal function. Regeneration may be accompanied 
by fi brosis and lead to CTD. The Epidermal Growth Factor Receptor (EGFrec) 
and its ligands are expressed along the nephron and involved in the development 
of renal lesions. Mice overexpressing a dominant negative isoform of EGFrec 
are protected from renal lesions during AngII infusion. We studied HB-EGF, a 
ligand for EGFrec, in experimental and human IRI.
Methods: HB-EGF mRNA and protein expression were studied in rat kidneys 
(n=6 per group) subjected to ischemia (45 min) and sacrifi ced at 30, 90 min, 
6 hrs, 1, 4, 9, 14 or 21d after reperfusion. HB-EGF mRNA was determined in 
cultured human tubular cells that were subjected to 36 hrs of hypoxia and 0, 2, 
6, 12, 24, 48 hrs of reoxygenation. In human kidneys (Brain Dead (BD)=35, 
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Living=20), HB-EGF mRNA and protein expression were studied at time of 
donation (T1), after cold ischemia (T2) and after reperfusion (T3). HB-EGF-/- 
and wild type mice (n=3-5 per group) were subjected to bilateral ischemia (30 
min) and sacrifi ced at 1,5, 6 hrs, 1 after reperfusion to study the role of HB-
EGF in renal injury.
Results: In rat IRI, HB-EGF mRNA was 13-fold upregulated (P< 0.01) after 
30 min, 90 min and 6 hrs of reperfusion, compared to sham rats. From 1 d 
onwards, HB-EGF mRNA returned to control levels. HB-EGF protein was 
expressed in distal tubules. From 30 min after reperfusion onwards de novo 
expression of HB-EGF was detected in glomerular epithelial cells, proximal 
tubules and arterial structures. One day after reperfusion the staining pattern 
of HB-EGF returned to normal. In line with in vivo data, in cultured tubular 
cells, HB-EGF mRNA was signifi cantly increased (P< 0.05) after 2, 6, 12 
and 24 hrs of reoxygenation. In human BD and living donor biopsies, HB-
EGF mRNA was signifi cantly increased at T3, compared to T1 (P<0.001). In 
human sections, predominant tubular expression of HB-EGF shifting from 
cytoplasmatic expression at T2 to luminal expression at T1 and T3 was found. 
HB-EGF-/- mice showed signifi cantly less morphological damage after 6 hrs 
(P< 0.05) and 1 day (P< 0.01) of reperfusion, compared to wild type mice.
Conclusion: Following IRI, HB-EGF is markedly upregulated in rat kidneys, 
cultured human tubular cells, and human biopsies. Most importantly, HB-EGF-/- 
mice are protected from renal damage. These results indicate that EGFrec 
blockers might prove to be protective in the early phase of transplantation.
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ASSOCIATION BETWEEN DE NOVO DONOR SPECIFIC 545 
HLA ANTIBODY, C4D STAINING IN RENAL GRAFT BIOPSY, 
AND GRAFT OUTCOME
Yong Cho1,2, J. Cicciarelli1,2, N. Kasahara1,3, M. Koss1,2, K. Houston1, 
R. Mendez1,2, Ian Hutchinson1,2, Tariq Shah1,2
1National Institute of Transplantation, 2USC School of Medicine, 3UCLA 
School of Medicine
Background: Despite improved early graft survival, long-term kidney graft 
loss rate has not been reduced. Both HLA antibodies and HLA donor specifi c 
antibodies (DSA) have been detected and may be causal in chronic allograft 
nephropathy (CAN) and, especially, in acute rejection. We evaluated the 
association between DSA, C4d staining in transplant and graft outcome.
Materials and methods: During Sep 2004-Aug 2007, HLA antibody tests usng 
the Luminex laboratory screen assay system were performed in 348 recipients. 
Of these, Cd4 deposition was assessed in the biopsies of 69 recipients with 
transplant dysfunction.
Results: In the 69 cases, 29 (42%) showed C4d negativity, 27 (39%) were 
Cd4 positive, 6 (9%) were equivocal, and 6 (9%) not diagnostic. Fourty-nine 
recipients (71%) with transplant dysfunction had HLA antibodies and 41 
(59%) had DSA. The proportion of C4d positivity was signifi cantly higher in 
patients with DSA (Class I only, II only, and I & II) in comparison with patients 
without post-transplant HLA antibodies (Table). The incidence of graft failure 
(including current SCr≥4.0) in patients with class II antibodies (Class II only 
or I & II) was signifi cantly higher than that in patients without post-transplant 
HLA antibodies (Table). In Figure, grafts of Class II DSA group continued to 
fail beyond 2 years after transplantation when compared with other 2 groups 
(None/NDSA or Class I only), however, the difference in graft survival between 
Class II and None/NDSA group did not reach to statistical signifi cant level 
(log-rank P=0.32).
Conclusions: Signifi cant association between C4d staining, de novo HLA 
Class II antibodies and graft failure strongly suggests the importance of 
post-transplant HLA antibodies. We propose that amelioration of CAN 
graft loss depends on monitoring and identifi cation of DSA and appropriate 
immunosuppression of these antibodies.
Table. C4d positivity and graft outcomes according to DSA groups
 Antibody Category N
C4d Positive
N (%)
Graft Failure
N (%)
Graft Failure or
SCr>4.0
N (%)
None (ref) 20 1 (5) (ref) 3 (15) (ref) 5 (25) (ref)
Class I only 10 8 (80) (P<0.001) 2 (20) (P=0.82) 5 (50) (P=0.10)
Class II only 22 13 (59) (P<0.001)  9 (41) (P=0.06)  13 (59) (P=0.03)
Class I & II 9 9 (100) (P<0.001) 4 (44) (P=0.09) 6 (67) (P=0.03)
NDSA 8 2 (25) (P=0.12) 1 (13) (P=0.86) 1 (13) (P=0.40)
Figure. Graft survival according to DSA groups
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COMPARISON OF BIOPSY AND CLINICAL SCORE 546 
SYSTEMS TO PREDICT OUTCOME OF EXTENDED CRITERIA 
KIDNEY DONORS
A. Faenza1, G. Fuga1, M. Tsivian1, R. Bertelli1, F. Neri1, M. Scolari2, 
G. Feliciangeli2, G.L. D’Arcangelo2, L. Ridolfi 3, S. Stefoni2
1Dept. of General Surgery And Transplantation, University of Bologna, 2Dept. 
of Nephrology, Dialysis and Transplantation, University of Bologna, 3Emilia-
Romagna Transplant Reference Center
Introduction: Advanced age, cerebrovascular death, hypertension, diabetes 
and low calculated creatinine clearance are all risk factors in deceased kidney 
donors. Subjects older than 50 with one or more risk factors or subjects older 
than 65 without any of them are considered as suboptimal or marginal donors 
and their kidneys all over Italy are rejected or accepted for single or double 
transplantation following the Biopsy Score proposed by Remuzzi (J Am Soc 
Nephrol 10,2591,1999). A different Score on simple clinical base has been 
proposed by Nyberg (Am J Transpl. 3,715,2003). The aim of the present paper 
is to verify whether the two Score systems can help predict the outcome of 
renal transplantation.
Methods: We retrospectively analyzed the clinical records of donors and 
recipients of kidney transplants of the last 4 years. Biopsy and Clinical Score 
were correlated to the transplant outcome. End points assessed were Early 
Kidney Function (primary non function, early good function for up to two 
post-op dialyses or severe post-operative malfunction) and serum creatinine 
at 1 and 6 months.
Results: In the last 4 years (2004-2007), 271 kidney transplantations were 
performed at our centre, 151 of them using “ideal” donors and 120 using 
“marginal” donors (102 as single and 18 as double kidney transplants). In 
15 cases both kidneys and in 6 cases only one kidney from marginal donors 
were discarded owing to a high Biopsy Score; in 3 other cases the organs 
were discarded because the Biopsy showed a kidney disease. The Clinical 
Score predicted well the outcome in terms of Early Graft Function and serum 
creatinine at 6 months (p<0.001). The Biopsy Score did not prove such a 
correlation since kidneys with 0, 1, 2, 3 or 4 total Score did not result in a 
signifi cantly different transplant outcome.
Discussion: Up to several years ago, a donor age over 60 and one risk factor 
were suffi cient to discard a kidney. The Biopsy Score era has given an essential 
contribution to increase the donors’ pool with results not as good as ideal 
donors kidneys, but still widely acceptable. Our study anyhow demonstrates 
that a simple Clinical Score has a better predictive value of transplantation 
results and suggests that the Biopsy should be performed in all marginal donors 
but probably should be interpreted in a less mandatory manner.
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CHRONIC TRANSPLANT GLOMERULOPATHY –; 547 
CLINICAL AND PATHOLOGICAL CORRELATES
M. Durlik1, A. Perkowska-Ptasinska1, M. Ciszek2, T. Baczkowska1, A. 
Chmura3, Z. Galazka4, L. Paczek2
1Department of Transplantology and Nephrology, Medical University in 
Warsaw, 2Department of Immunology, Transplantology and Internal Medicine, 
Medical University in Warsaw, 3Department of General and Transplantation 
Surgery, Medical University in Warsaw, Warsaw, 4Department of General, 
Vascular, and Transplantation Surgery, Medical University in Warsaw, 
Warsaw
Introduction: Chronic transplant glomerulopathy is one of the leading 
causes of severe post-transplant proteinuria and graft loss. It may develop in a 
response to several different injurious processes, such as humoral rejection or 
thrombotic microangiopathy. In the majority of cases the etiology is obscure, 
which excludes the possibility for targeted intervention. Our current knowledge 
about risk factors for the development of TG, as well as factors affecting its 
dynamics and prognosis is poor.
The aim of the study was to fi nd pathological and clinical risk factors and 
correlations of TG as well as parameters that infl uence the survival of grafts 
with that pathology.
Materials and methods: We retrospectively reevaluated all 86 kidney 
transplant cases with TG that have been recognized on the basis of indication 
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biopsy in Transplantation Institute since 1996. All the TG- as well as all pre-
TG (previous) biopsies were histologically characterized according to Banff 
classifi cation including C4d positivity in PTC and in glomeruli. Pathological 
and clinical data were subjected to detailed statistical analysis.
Results: C4d positivity was found in 52 biopsies (61%), among which in 
33 (38%) C4d was present in both localizations. Among clinical parameters 
univariate analysis revealed that younger recipient age and minimalization 
of immunosuppression (drug withdrawal or suboptimal drugs dose/blood 
level within 3-6 months preceding the biopsy) were associated with C4d 
positivity in PTC (p =0,0053 and p=0,0365 respectively). In multivariate Cox 
analysis diffuse PTC-itis (p=0.029, RR(95%CI) =3.349(1.131-9.919) and total 
interstitial infl ammation score (p=0.015, RR(95%CI) = 9.662 (1.784-52.329) 
were found to have the negative impact on the graft survival. C4d positivity 
in both analyzed localizations (PTC and glomeruli), the level of pre-Tx 
sensitization, induction therapy with ATG or daclizumab, acute rejection and 
C4d in previous (pre -TG) biopsies did not infl uence the survival of grafts with 
TG.
Conclusions: In grafts with TG younger recipient age and minimalization of 
immunosuppression are associated with C4d positivity. The survival of kidney 
grafts with TG is signifi cantly affected by the magnitude of infl ammation in 
interstitium and PTC, but not by C4d positivity in PTC and glomeruli.
MINI-ORAL SESSION 20: 
IMMUNOBIOLOGY 3: IMMUNOMODULATION 1
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EXPRESSION OF INSULIN IN THE LIVERS OF 548 
PREDIABETIC NON OBESE DIABETIC MICE MAY REDUCE 
THE DEVELOPMENT OF TYPE I DIABETES
B. Ren, B. O’Brien, M. Byrne, A. Simpson
University of Technology Sydney
Type I diabetes (TID) is characterised by the autoimmune destruction of 
the insulin-producing beta cells in the pancreas by the actions of CD4+ and 
CD8+ T cells and macrophages infi ltrating the islets. Many scenarios have 
been suggested to prevent the progression of the disease by disrupting the 
autoimmune process in the prediabetic state. Whilst no treatment has thus far 
been successful the fi nding that antibodies and T cell clones directed against 
a specifi c epitope of insulin in early diabetes has led to the suggestion that 
treatment of early diabetes with insulin might have an immunomodulatory 
effect in addition to its ability to allow the beta cells to rest. We have shown 
that introducuction of furin-cleavable human insulin (INS-FUR) to the livers 
of streptozotocin diabetic-Wistar rats (1) and non obese diabetic mice using 
a lentiviral vector (HMD) has resulted in the reversal of diabetes. The aim 
of the current study was to see if the introduction of a small amount of the 
HMD/ INS-FUR vector to the livers of prediabetic NOD mice could prevent 
the onset of T1D. The lentiviral vector was produced on 293T cells and purifi ed 
and concentrated by tangential fl ow fi ltration and ultracentrifugation (40,000g/ 
4h). Prediabetic female NOD mice (7 weeks old) were treated with the HMD/
INS-FUR vector (107 transduction units) (n=10) or saline (n=10), and mice 
were monitored for changes in body weight and blood glucose levels. After 
30 weeks, liver, pancreas, spleen, thymus and blood samples were harvested. 
The spleen, thymus and pancreas were analysed for CD4+, CD8+, CD25+ and 
T-regulated lymphocyte markers (Treg) subset CD4+/CD25+ expression by 
immunofl uorescence. Immunoperoxidase staining for insulin expression in the 
liver and pancreas was also carried out. We examined sera for GAD 67 levels 
in HMD /INS-FUR-pre-treated diabetic NOD mice and non obese resistant 
(NOR) controls by western analysis.
Fifty percent of the mice that were pretreated with the HMD /INS-FUR vector 
maintained normal blood glucose levels and weight, by comparison 80% of 
the saline-pre-treated mice developed overt diabetes. CD25 and CD4+/CD25+ 
were signifi cantly (P<0.05) higher in HMD/INS-FUR pretreated NOD mice 
compared to saline-treated controls in spleen and thymus tissues. Pancreatic 
T lymphocytes from saline pretreated NOD mice had a CD4:CD8 ratio of 
1.17 ± 0.16 (n=10) compared with 1.79 ± 0.21 in HMD/INS-FUR pre-treated 
NOD mice (P=0.037). In HMD/INS-FUR pre-treated NOD mice, we found 
signifi cant insulin-staining in the liver and pancreas and no obvious insulitis in 
the pancreas. GAD 67 was not signifi cantly different in HMD/INS-FUR pre-
treated mice, compared with controls. Liver function tests in HMD/INS-FUR 
pre-treated NOD mice were normal. These results indicate that it is possible to 
reduce or eliminate insulitis and may have the potential to prevent the onset of 
T1D in a proportion of NOD mice.
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EFFICIENT AND LONG-LASTING ADENO-ASSOCIATED 549 
VIRUS 8 (AAV8) VECTOR –MEDIATED TRANSGENE 
EXPRESSION IN HEART TRANSPLANT MYOCARDIUM
J.J. Jokinen1, A.I. Nykänen1, K. Pajusola2, R. Tuuminen1, R. Krebs1, 
J. Soronen2, K. Alitalo2, K.B. Lemström1
1Cardiopulmonary Research Group. Transplantation Laboratory, 2Molecular 
Cancer Biology Laboratory, Biomedicum, University of Helsinki and Helsinki 
University Hospital, P.O. Box 21, FIN-00014 University of Helsinki, Finland.
Introduction: Heart transplantation offers an unique milieu to perform ex 
vivo gene transfer during the cold preservation of the graft, but identifi cation 
and throughout characterization of safe and effi cient gene transfer vector is 
essential before pursuing to clinical applications. Adeno-associated virus 
(AAV) vectors are excellent candidates for heart transplant gene therapy 
because of their non-pathogenic nature, minimal immune and infl ammatory 
response and cardiomyocyte tropism. We compared the transgene expression 
kinetics, effi ciency and localization of the well-characterized AAV serotype 2 
(AAV2) and the novel and effi cient AAV8 in rat heterotopic heart transplant 
model.
Material and methods: Heterotopic heart transplantations were performed 
between syngeneic Dark Agouti (DA) rats. To investigate the kinetics and 
effi ciency of transgene expression, coronary arteries of the donor graft were 
perfused with AAV2 or AAV8 vectors encoding fi refl y luciferase (AAV2-Luc 
or AAV8-Luc, n = 6 per group, 1x1011 genomic copies). The recipients were 
subjected to non-invasive bioluminescent in vivo imaging system (IVIS®, 
Xenogen Corp, Alameda, CA, USA) at 2 days, and 1, 2, 3, 4, 8, and 12 weeks 
after transplantation. Heart transplant transgene expression was quantifi ed 
with Living Image® 2.50 and IGOR® software (Xenogen Corp, Alameda, 
CA, USA; WaveMetrics Corp, Lake Oswego, OR, USA). To localize the 
transgene expression, donor grafts were perfused with AAV2 or AAV8 vectors 
encoding enhanced green fl uorescent protein (AAV2-EGFP or AAV8-EGFP, n 
= 3 per group, 1x1011 genomic copies), and immunofl uorescent stainings with 
endothelial cell (RECA-1), smooth muscle cell (α-SMA) and cardiomyocyte 
(T-CMC) markers were performed at 8 week time-point.
Results: Bioluminescent imaging revealed luciferase activity that mainly 
localized to the heterotopic heart transplant of AAV-Luc perfused animals 
(Figure 1, arrows). AAV2 transgene expression (Figure 2, dashed line) 
increased gradually and peaked 4 weeks after transplantation whereas AAV8 
transgene expression (Figure 2, solid line) continued to increase up to 12 weeks 
after transplantation. AAV8-Luc perfusion resulted in ~4-times higher heart 
transplant transgene expression than AAV2-Luc perfusion at 12 week time-point 
(Figure 2, p = 0.025). Immunofl uorescent stainings of AAV2-EGFP and AAV8-
EGFP-perfused grafts showed control gene expression in cardiomyocytes but 
not in endothelial or smooth muscle cells.
Conclusions: Our results show that AAV vectors result in long-term transgene 
expression in heart transplant cardiomyocytes, and the novel serotype AAV8 is 
more effi cient than AAV2. The low immunogenic nature of AAV-vectors makes 
them ideal tools in future heart transplant gene therapy applications.
Figure 1. Figure 2.
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CYCLIN KINASE INHIBITOR P21-MEDIATED IMMUNE-550 
TOLERANCE: DIRECT AND INDIRECT EVIDENCE
M. Mehra, A. Khanna
University of Maryland,, Baltimore
Background: Since uncontrolled proliferation of T-cells is considered a 
barrier to the induction of transplantation tolerance by T regulatory cells, we 
hypothesized that there is a parallel between such aberrant proliferation and 
cyclin kinase inhibitor p21 defi ciency. We hypothesize that CD4+CD25+ T 
regulatory cells and p21 expressing T cells as well as CD4+CD25- T regulatory 
cells and p21-defi cient T cells share similar proliferating properties relevant to 
induction of immune tolerance.
Methods: Human CD4+CD25+ and CD4+CD25- cells were isolated from 
normal healthy blood donors (n=6), p21-/- (n=9) and wild type mice (n=9). 
Purifi cation of Treg was confi rmed by staining the cells with anti-CD4-FITC 
and PE-coupled anti-CD25 antibody. These cells; CD4+CD25+, CD4+CD25- 
alone or in combination were then activated with anti-CD3 with and without 
cyclosporine (100 ng/ml). We also studied mRNA for FoxP3 in purifi ed 
CD4+CD25+, CD4+CD25- T cells from wild type and p21-/- mice and 
human CD4+CD25+/- cells by real-time quantitative RT-PCR. We compared 
proliferation and the expression of FoxP3 in CD4+ CD25+/CD25- cells with T 
lymphocytes from wild type and p21-/- mice. We also compared the effect of 
CD4+CD25+ and p21 expressing T cells on the proliferation of CD4+CD25- 
and p21-/- T cells, respectively.
Results: The difference in proliferation (counts per minute, p<0.003) 
among CD4+CD25+ (15236 1190) and CD4+CD25- (50317 974) T-cells 
were proportionately similar to the difference in proliferation (p<0.001) of 
lymphocytes from wild type (28206 2812) and p21-/- mice (49624 2164). 
Similar to CD4+CD25- T cells, CD4+ T cells from p21-/- mice lacked FoxP3 
gene expression. The analysis indicated that the number of T regulatory cells 
in p21-/-mice were signifi cantly (p<0.002) lower (2.6 0.8) than wild type mice 
(14.5 1.6%,). T cells from wild type mice inhibited the proliferation of T cells 
from p21-/- mice in a one way MLR assay similar to the effect of CD4+CD25+ 
T cells on the proliferation of CD4+CD25- cells. The proliferation of 
CD4+CD25- T cells and p21-/- lymphocytes was resistant to the inhibition by 
CsA. Gene expression of FoxP3, ILT3 and GITR supported these fi ndings.
Conclusions: Expression of the cyclin kinase inhibitor p21 creates a milieu 
consistent with an anti-proliferative and immunosuppressive effect of 
CD4+CD25+ T-reg cells. These fi ndings support the notion that p21 could be 
used clinically in controlling allo-immune activation in an effort to prolong 
graft survival.
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REDUCED DEVELOPMENT OF TRANSPLANT 551 
ARTERIOSCLEROSIS IN ADENOSINE DIPHOSPHATE (ADP) 
RECEPTOR P2Y12-DEFICIENT RECIPIENT MICE
Y. Matsumoto, K. Umemura
Department of Pharmacology, Hamamatsu University School of Medicine, 
Hamamatsu City, Shizuoka 431-3192, Japan
Background: Transplant arteriosclerosis (TA) is characterized by an early 
endothelial loss followed by a chronic infl ammation, eventually leading to form 
occlusive¦ neointima. The neointima is mainly composed of smooth muscle 
alpha-actin (SMA)-positive cells in the grafted vessels. Although it is well-
known that adenosine diphosphate (ADP) receptor P2Y12 signaling cascade(s) 
play a fundamental role and is pivotal for the full complement of platelet 
activation, the role of the P2Y12 receptors in immune-mediated infl ammation 
and neointimal formation after transplantation is not well understood yet. We 
therefore investigated the infl uence of P2Y12 receptor¦ defi ciency (KO) on the 
development of TA.
Methods: Fully MHC-mismatched carotid arteries from C3H/He (H-2k) 
mice were orthotopically transplanted into Wild-Type (WT) or KO recipients 
(C57BL/6 x 129S, H-2b). No immunosuppression was used. Grafts were 
harvested at 8 weeks after transplantation, and the frozen cross sections were 
processed for morphometry and immunohistology. Luminal occlusion was 
calculated by the following equation: luminal occlusion (%) = intimal area/
(luminal area + intimal area) x 100. The number of CD45-positive leukocytes 
or SMA-positive cells was examined by counting their nuclei counterstained 
with 4’,6-diamidino-2-phenylindole (DAPI). Data are presented as mean ± SD. 
The statistical evaluation was carried out using the Unpaired Student’s t-test.
Results: Morphometric analysis showed that the area of the graft intima was 
signifi cantly reduced in KO recipients when compared with WT recipients 
(luminal occlusion: 23.2 ± 8.0% versus 44.9 ± 20.5% in KO and WT recipients, 
respectively, n = 10, p<0.01). In addition, immunohistological analysis revealed 
that the accumulation of CD45-positive leukocytes (24.4 ± 23.0 cells versus 
61.9 ± 48.5 cells in KO and WT recipients, respectively, n = 10, p<0.04) and 
SMA-positive cells (87.3 ± 51.7 cells versus 200 ± 144.7 cells in KO and WT 
recipients, respectively, n = 10, p<0.03) in the graft intima was also signifi cantly 
decreased in KO recipients.
Conclusion: These experiments indicate that P2Y12 receptor defi ciency 
can effectively reduce the development of TA in the murine carotid artery 
transplantation model, suggesting that P2Y12 receptor might play a role in the 
development of TA (a manifestation of chronic rejection).
POSTER BOARD NUMBER P3 – 413
THROMBOSPONDIN-1 (TSP-1) MEDIATES THE ANTI-552 
ANGIOGENIC AND IMMUNOMODULATORY EFFECTS OF 
RAPAMYCIN ON PANCREATIC ISLET ENDOTHELIAL CELLS: 
RELEVANCE FOR ISLET TRANSPLANTATION
V. Cantaluppi1, S. Beltramo2, F. Figliolini2, G.M. Romanazzi2, L. Biancone1, 
G.P. Segoloni1, G. Camussi2
1Renal Transplantation Unit, University of Torino, 2Centre for Experimental 
Medical Research (CeRMS), University of Torino
After the transplantation into the portal vein, a relevant percentage of pancreatic 
islets fail to engraft into the liver as consequence of a poor vascular support. 
Islet endothelial cells play a key role in the neo-revascularization processes by 
forming a chimeric vascular tree with recipient vessels. The identifi cation of 
factors able to enhance neoangiogenesis may increase islet engraftment. Despite 
the mTOR inhibitor rapamycin represents the central immunosuppressive drug 
used in the Edmonton protocol for islet transplantation, it has been shown 
to reduce the rate of beta-cell proliferation contributing to the progressive 
dysfunction observed in islet graft recipients. In addition, rapamycin is known 
to exert dual effects on islet endothelium inducing the simultaneous inhibition 
of angiogenesis and the down-regulation of receptors involved in lymphocyte 
adhesion and activation.
We evaluated by gene array analysis the mediators involved in the anti-
angiogenic effects of rapamycin on freshly purifi ed human islets. In presence 
of rapamycin, we found a signifi cant decrease of pro-angiogenic factors such 
as VEGF/Î±VÎ²3 integrin and the simultaneous increase of thrombospondin-1 
(TSP-1) mRNAs. Thrombospondins are a family of fi ve multidomain, 
calcium-binding extracellular glycoproteins that are synthesized by a wide 
variety of cells of both mesenchymal and epithelial origin. TSP-1 is a key 
regulator of angiogenesis and it is markedly up-regulated in tissues following 
ischemia-reperfusion injury, a common denominator of solid organ and cell 
transplantation. Gene array data were confi rmed at protein level by confocal 
microscopy, western blot analysis and ELISA test of TSP-1 concentrations in 
islet supernatants. The co-incubation with a blocking anti-TSP-1 polyclonal 
antibody reduced the inhibitory effect exerted by rapamycin on endothelial 
outgrowth from islets. Moreover, TSP-1 blockade resulted in a signifi cant 
increase of insulin secretion by rapamycin-treated islets in response to high 
glucose challenge.
We also isolated endothelial cells from human islets to confi rm the role of 
TSP-1 in rapamycin-induced inhibition of angiogenesis. Rapamycin, at doses 
similar to those detected in islet graft recipients (10-20 ng/ml) decreased 
migration, proliferation and formation of capillary-like structures in vitro 
when islet-derived endothelial cells were plated onto Matrigel-coated plates, 
with consequent appearance of apoptosis. All these biological processes were 
signifi cantly reduced by co-incubation with a blocking anti-TSP-1 polyclonal 
antibody. In vivo, TSP-1 blockade signifi cantly reduced the anti-angiogenic 
effect of rapamycin on islet endothelium xenotransplanted subcutaneously into 
Matrigel plugs in SCID mice.
TSP-1 is also known to modulate the immune response to foreign antigens 
by generating regulatory T cells (Tregs) through the specifi c binding of 
CD47 antigen located on T cells. We found that TSP-1 blockade inhibited the 
decrease of lymphocyte adhesion induced by rapamycin on islet endothelial 
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cells through the modulation of surface molecules involved in lymphocyte 
adhesion and activation.
In conclusion, TSP-1 signifi cantly inhibited the anti-angiogenic effect of 
rapamycin on islet endothelium. The conception of a therapeutic strategy 
aimed to selectively block TSP-1 in the early period after transplantation may 
enhance islet engraftment within liver sinusoids. Furthermore, our data suggest 
a potential role of TSP-1 in the long term modulation of the immune response 
therefore improving islet graft survival.
POSTER BOARD NUMBER P3 – 414
IMMUNE CELL ACTIVATION COMPARING THREE 553 
INDUCTION AGENTS (ALEMTUZUMAB, THYMOGLOBULIN 
AND BASILIXIMAB) WITH TACROLIMUS, MYCOPHENOLATE 
MOFETIL AND A RAPID STEROID WITHDRAWAL IN RENAL 
TRANSPLANTATION
J. Holman, G. Harrison, K. Vandeputte, R. First, W. Fitzsimmons
R & D Department, Astellas Pharma U.S., Deerfi eld, IL, United States
Purpose: The ImmuKnow assay (iATP) provides a quantitative measure of 
immune cell function. Previous studies have suggested an increased risk of 
infection at low (< 250 ng/ml) or rejection at high (> 350 ng/ml) values. Prior 
studies generally examined iATP values infrequently and inconsistently.
Method: We examined iATP values at Baseline, Day 14, Day 30, Day 60 and 
Day 90 following transplant in a group of 474 adults randomized based on risk 
profi le: High Risk (HR=African American (AA), PRA>=20% or re-transplants) 
were assigned to Campath (C1H) or to Thymoglobulin (Thymo). Low Risk 
(LR=non-AA, PRA<20% or primary transplant) were assigned to C1H or 
Basiliximab (Bas). Both C1H groups received 30 mg of C1H on day (D) 0; the 
Thymo group received 4 doses of Thymo (1.5 mg/kg/d) on D0-4; the Bas group 
received 2 doses of 20 mg of Bas on D 0-4. Only 1 gram of methylprednisolone 
was given prior to discharge. Tacrolimus and Mycophenolate mofetil (MMF) 
were used as maintenance immunosuppression. Occurrence of biopsy-
confi rmed acute rejection (BCAR) and any infection was correlated with iATP 
values.
Results: There were no differences between groups in mean tacrolimus blood 
levels or mean MMF doses. As expected C1H and Thymo resulted in profound 
lymphocyte depletion. Lymphocyte counts were essentially unchanged in 
Bas group. iATP values (ng/ml) decreased over time in all groups as shown 
below. There were no differences between HR-C1H and Thymo. LR-C1H was 
signifi cantly lower than Bas at all post-transplant timepoints.
HR LR
C1H* N=70 Thymo N=69 C1H* N=164 Bas N=171
Baseline 210** 251 271** 242
Day 14 203 219 221 271***
Day 30 131 190 174 246***
Day 60 124 144 151 218***
Day 90 93 101 117 192***
*HR-C1H vs LR-C1H, repeated measures ANOVA, P=0.04
**HR-C1H vs LR-C1H, P=0.05 
***LR-C1H vs LR-Bas, P=0.05
The incidence of BCAR and any infection by iATP value is shown below. 
Treatment groups were combined for this analysis. Subjects were excluded if 
clinical event occurred before Day 14 or subject had no iATP value prior to 
clinical event. 
Incidence of Clinical Event
Closest iATP Value Prior to Event* BCAR All Infection
0 – 250 ng/ml 10/341 (2.9%) 85/282 (30.1%)
251 – 350 ng/ml 4/44 (9.1%) 19/39 (48.7%)
>= 350 ng/ml 4/40 (10.0%) 22/48 (45.8%)
*For subjects without a clinical event their last iATP value used.
Summary: Immunosuppression results in a decrease in iATP value over time. 
Depletional induction agents result in a greater decrease in iATP value than a 
non-depletional agent. Although we show a positive correlation of iATP value 
and incidence of BCAR, the cutpoint was lower than previously reported. The 
positive correlation of iATP with incidence of any infection is in contrast to 
previous reports.
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INFLUENCE OF MEDICAL IMMUNOSUPPRESSION ON 554 
CMV-SPECIFIC T-CELL THERAPY: CONCLUSIONS FROM IN 
VITRO- AND CLINICAL OBSERVATIONS
G. Brestrich3,2, S. Zwinger2, A. Röhmhild3,2, M. Hammer2, A. Kurtz3,2, 
H-D. Volk2, P. Reinke3
2Department of Medical Immunology- Charité- Universitätsmedizin, 
3Department of Nephrology- Charité- Universitätsmedizin
The cytomegalovirus (CMV) is a member of the beta-herpes family. After 
primary infection the virus stays latent in the host and reactivates frequently. 
In imunocompetent hosts these reactivations are controlled effi ciently by 
virus-specifi c CD4+ and CD8+ T-lymphocytes. In transplanted patients the 
cellular immune response is diminished due to the applied immunosuppressive 
therapy. Uncontrolled CMV-reactivations often manifest in the transplanted 
organ leading to reduced graft and host survival. The incidence of CMV-
complications is strongly dependent on the type of transplantation ranging 
between 5% in hemapoetic stem cell transplantation (HSCT) and 50% in lung 
transplantation (LTX).
The adoptive transfer of in vitro manipulated CMV-reactive T cells is a 
promising option to specifi cally strengthen the hosts’ immune response. It was 
applied successfully in several clinical studies treating CMV-complications 
after HSCT. To date, clinical trials concerning solid organ transplanted (SOT) 
patients are missing as high levels of immunosuppression in this group affect 
the generation of specifi c T-cell lines and their function in vivo.
In this study the infl uence of immunosuppressive drugs on the generation of 
CMV-specifi c T-cell lines was analyzed. We used a HLA-type independent 
protocol to generate T-cell lines against two immunodominant CMV proteins 
pp65 and IE-1. Therefore, donor PBMCs were stimulated with overlapping 
peptide pools of the both proteins. Next, specifi cally activated, IFN-ã secreting 
T cells were selected and expanded. We analyzed 5 CMV seropositive healthy 
donors and 10 kidney transplanted patients under standard immunosuppression. 
Utilizing the protocol described we successfully generated both IE-1 and pp65 
specifi c T-cell lines from all healthy and 8/10 immunocompromised donors. 
Starting with 20 ml blood, T-cell lines achieved numbers > 5x107 after 4 weeks 
of expansion. Comparing Phenotype, specifi c function, epitope diversity and 
T-cell receptor beta repertoire revealed no signifi cant differences between the 
two groups.
With regard to the in vitro fi ndings, a T-cell line specifi c for pp65 and IE-1 
was generated under clinical conditions from a LTX-patient. The patient 
suffered from a CMV-reactivation with indication of resistance to ganciclovir. 
The patient was treated with two doses of 1x107/m2 specifi c T cells in a 4 
week interval. Both infusions were well tolerated and increasing numbers of 
pp65 and IE-1 specifi c T cells could be detected in the patients’ blood shortly 
after infusion. Additionally, the viral load dropped signifi cantly and patients’ 
condition advanced. After 5 weeks the viral load started to increase again going 
along with a decrease of CMV-specifi c T cells. At this time point patients’ 
condition deteriorated and the patient died 4 weeks later by CMV-pneumonia.
We could show in this study, that the generation of functional CMV-specifi c 
T-cell lines from blood of immunosuppressed donors is feasible using the 
described protocol. Since its HLA-independence it is broadly applicable to 
SOT patients suffering from CMV-complications. However data indicate that 
in the LTX-patient the infused T-cells lost their function with time. This may 
be due to the present immunosuppression that has negative effects of on the 
T-cell function or survival. Dose escalating strategies have to be performed to 
optimize the therapeutic success in these patients.
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HOW DOES THE KIDNEY FIGHT BACK? THE ROLE 555 
OF SERPINS IN RENAL ALLOGRAFT REJECTION
K. Heutinck1,2, I. ten Berge2, J. Hamann1, A. Rowshani2
1Department of Experimental Immunology, 2Department of Internal Medicine, 
Renal Transplant Unit, Academic Medical Center, Amsterdam, The Netherlands
Subclinical renal allograft rejection is defi ned as the presence of granzyme 
positive lymphocytes leading to tubulitis. However, in sharp contrast to acute 
clinical rejection, this does not immediately result in allograft dysfunction. 
Subclinical rejection is common and is associated with the development 
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of chronic rejection and long term graft failure. We recently showed that 
serine protease inhibitor 9 (SERPINB9) is overexpressed by renal tubular 
epithelial cells (TECs) during subclinical rejection. SERPINB9 specifi cally 
inhibits granzyme B; the most important effector molecule during rejection. 
Cytotoxic T lymphocytes (CTLs) are protected against self-induced apoptosis 
via expression of this serpin. We hypothesized that SERPINB9 and related 
serpins protect TECs against attacks of host infl ammatory cells. We aimed to 
investigate the role of serpins in renal transplantation.
The expression and regulation of several members of the serpin B family were 
evaluated in HK-2 cells, a human TEC-line, and in primary human TECs. 
The TECs were stimulated by several cytokines (TNFα, IFNγ, IL-1β, IL-6) 
and toll-like receptor ligands (lipoteichoic acid, poly(I:C), LPS, imiquimod, 
CpG, oligonucleotides) which are important infl ammatory mediators during 
rejection. Next, serpin expression was analyzed by quantitative RT-PCR and 
Western blotting.
Resting HK-2 cells and primary TECs constitutively express several 
members of the serpin family. Unexpectedly, serpin expression in HK-2 cells 
was not affected signifi cantly by the tested cytokines and TLR-ligands. On 
the contrary, preliminary results in primary human TECs show that serpin 
expression is regulated by these stimuli. SERPINB2, B6, B8 and B9 mRNA 
levels were downregulated by interleukin-6. On the contrary, the mRNA levels 
of SERPINB3, B8, and B9 were elevated due to stimulation of TLR3 with 
poly(I:C). Moreover, SERPINB9 expression was also induced by IFNγ and 
IL-1β.
Here, we demonstrate that several serpins are constitutively expressed by 
TECs. In primary TECs, serpin expression is regulated by several cytokines 
and TLR-ligands which are known to play a role in acute rejection. In contrast, 
these stimuli did not infl uence serpin levels in HK-2 cells, suggesting that 
this cell-line is not the best model to study serpin regulation. Currently, we 
are performing cytotoxicity assays to unravel the function of serpins in renal 
transplantation.
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RAPAMYCIN INDUCES AUTOPHAGY IN ISLETS: 556 
RELEVANCE FOR ISLETS TRANSPLANTATION
M. Tanemura1,3, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1, 
T. Nishida1, Y. Sawa1,2, T. Ito1
1Department of Surgery, Osaka University Graduate School of Medicine, 
2Medical Center for Translational Research, Osaka University Hospital, 
3Correspondence author: e-mail; tanemura@surg1.med.osaka-u.ac.jp
Objectives: Islet transplantation has recently become a clinical reality 
from the results obtained by the adoption of the Edmonton protocol, which 
is rapamycin-based glucocorticoide-free immunosuppressive regimen, 
leading to insulin independence at 1 year in 90% of the treated patients with 
Type1 diabetes. However, islets allograft recipients exhibit a gradual fall in 
insulin independence with only 10% offi nsulin at 5 years. This decline may 
refl ect drug toxicity of rapamycin on islet β-cell. The immunosuppressive 
mechanism of rapamycin is based on selective blockade of the mammalian 
target of rapamycin (mTOR) activation. Autophagy is an alternative cell death 
pathway that is induced by mTOR inhibitors such as rapamycin and Rad 
001. The relative contributions of autophagy in transplanted islets are poorly 
understood. The aim of this study is to evaluate the effects of rapamycin in 
islet such as autophagy induction, islet viability that may strongly affect the 
engraftment of islets.
Materials and methods: Isolation of pancreatic islets: Male BL6 mice 
were anesthetized. Subsequently, the bile duct was cannulated, and the 
pancreas was infl ated with 3ml of ET-Kyoto solution containing 1mg/
ml of collagenase. The infl ated pancreas was removed and cleaned of its 
lymphnodes, fat and bile duct. Tissue was digested with collagenase VIII 
and purifi ed on a discontinuous Ficoll gradient. Isolated islets were cultured 
in complete RPMI-1640 culture medium. Western blot analysis: To detect 
the accumulation of LC3-II (a LC3-phospholilated conjugate), which is a 
good early maker of autophagy, Western blot analysis was performed. Fresh 
mice islets (30islets/well) were incubated for 48 hr in culture medium in the 
absence or presence of either 1 or 10 ng/ml of rapamycin. Subsequently, 
the cells were lysed, protein samples were electrophoresed through a 15% 
SDS/PAGE and then transferred to PVDF membrane. LC3-II in the lysate 
was recognized by immunoblotting with anti-LC3 mAb (MBL). As the 
loading control for the samples, protein expression of GAPDH in mice 
islets was also detected. The relative protein expression of LC3-II in islets 
was normalized by the LC3-II/GAPDH ratio. Islet viability assay: 30 cells 
of fresh mice islets were cultured for 48hr with complete medium in the 
absence or presence of either 1 or 10 ng/ml of rapamycin. Subsequently, 
islet viability was determined using the colorimetric methyl tetrazolium 
salt (MTS) Cell Titer 96 Aqueous One Solution cell proliferation assay 
(Promega). The colorimetric reagent was added to each well, incubated for 
2hr, and the absorbance values read at 490nm. Blocking assay of autophagic 
signaling: To determine whether the rapamycin-treated islets had recovered 
their viability, the rapamycin-treated islets were assessed by MTS assay in 
the absence or presence of 10 mM 3-methladenine (3-MA), an inhibitor 
of class III phosphatidylinositol 3-kinase, which has been shown to be an 
inhibitor of autophagy.
Results: The results are summarized in the Table.
Assay
Parental 
mice 
islets
Rapamycin treatment 
for islets Blocking assay by 3-MA
1ng/ml of 
rapamycin
10ng/ml of 
rapamycin
1ng/ml of 
rapa
+
10mM 
3-MA
10ng/ml of 
rapa
+
10mM 3-MA
LC3-II/GAPDH ratio 
(LC3-II expression by 
Western blot)
0.50 1.06 1.08 0.44 0.73
% absorbance by 
MTS assay (%) (islets 
viability, recovery of 
viability)
100 
(control) 56.8±14.1 49.0±2.0 68.5±0.5 75.8±25.9 
Conclusions: Our results demonstrate that rapamycin exerts the effects on islets 
inducing autophagy and a down-regulation of islets viability. Therapeutically 
targeting this novel pathway may yield signifi cant benefi ts for long-term islet 
graft survival.
POSTER BOARD NUMBER P3 – 418
ACCELERATED RAT CARDIAC ALLOGRAFT FAILURE 557 
IS PREVENTED BY ANTI-ICOS IMMUNOTHERAPY: 
IMPLICATIONS FOR CONTROL OF CHRONIC REJECTION
L. Guo1, Y-X. Shan1, H-Y. Zhang1, H. Kimura2, M. Makuuchi3
1The First Hospital of Ji Lin University, 2Department of Experimental 
Surgery and Bioengineering, National Children’s Medical Research Center, 
Tokyo, Japan, 3Department of Artifi cial Organ and Transplantation Surgery, 
Graduate School of Medicine and Faculty of Medicine, University of Tokyo
In a DA (RT1a) to LEW (RT1l) rat model, inhibition of B7-CD28 co-stimulatory 
signal blockade by adenovirus-mediated cytotoxic T-lymphocyte-associated 
antigen 4 immunoglobulin (AdCTLA-4Ig) induces long-term acceptance of 
cardiac allografts. However, allograft tolerance is incomplete and rejection 
eventually occurs. In particular, donor-type skin grafting to recipients with 
functional cardiac allografts causes accelerated heart rejection. Here, we re-
evaluated the combined effects of anti-ICOS antibody therapy, together with 
AdCTLA-4Ig on allograft acceptance. To this end, the effect of anti-ICOS 
on preventing accelerated cardiac rejection caused by donor-strain skin 
grafting was examined, with or without AdCTLA-4Ig treatment. AdCTLA-
4Ig-treated recipients survive >100 days, and are characterized by ICOS-
positive mononuclear cell infi ltration and apparent vasculopathy. AdCTLA-
4IG treatment combined with anti-ICOS antibodies induced stable tolerance 
without chronic rejection. Anti-ICOS therapy signifi cantly reduced ICOS-
positive infl ammatory cell infi ltration, and prevented accelerated cardiac 
graft rejection following secondary skin grafting. Our results identify a 
critical role for ICOS in chronic and accelerated cardiac allograft rejection, 
and suggest a novel approach to prevent chronic rejection of vascularized 
organ allografts.
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IMMUNOREGULATORY EFFECTS OF A NEW S1P 558 
AGONIST W-061 ON RAT SMALL BOWEL TRANSPLANTATION
J. Song1,3, T. Ito2,3, T. Nishida3, M. Nozawa3, J. Wei1
1Department of General Surgery£¬Beijing Hospital, 2Department of 
Complementary and Alternative Medicine, Osaka University Graduate School 
of Medicine, 3Department of Surgery (E1),Osaka University Graduate School 
of Medicine
Aims: To prevent immunologic respond of allograft, it is necessary to 
administer systemic immunosuppressant to the recipient. A new S1P agonist 
W-061 has the molecular structure which is completely different from FTY720. 
The present study was performed to investigate the potency of W-061 in 
treatment of allograft in SBTx.
Methods: Heterotopic total SBTx was performed from Wistar-Furth (WF) rat 
to (WF x ACI) F1, or F1 to WF rats. Recipients was administered by a dose 
3 mg/kg/day) for 14 days after SBTx. The recipient survival, histology and 
subpopulation of lymphocytes in graft and target organs were evaluated.
Results: W-061 treatment signifi cantly prolonged graft survival over 60 
days in 3 out of 6 recipient of rejection group(53¡À17days, n=6) and over 
100 days in 4 out of 6 recipients of GVHD group(86¡À29 days, n=6). W-061 
strongly inhibited GVHD in histological study in comparison with untreated 
control rats. W-061 signifi cantly decreased the numbers of lymphocytes in PB 
and target organs in GVHD group, as well as the infi ltration T lymphocytes 
subpopulations in the graft of rejection group. W-061 signifi cantly decreased 
the production of IFN-¦Ã in the target organs of different models in acute 
GVHD or rejection phase.
Conclusions: A 14 days¡¯ treatment of W-061 inhibit the rejection as well as 
GVHD, resulting in the prolongation of small bowel allograft survival.
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SIGNIFICANT DECREASE OF PLASMA ADAMTS13 559 
ACTIVITY DURING ADVERSE EVENTS AFTER LIVER 
TRANSPLANTATION
E. Okano1, S. Ko1, H. Kanehiro1, M. Matsumoto2, Y. Fujimura2, K. Tanaka3, 
Y. Nakajima1
1Department of Surgery, Nara Medical University, 2Blood Transfusion 
Medicine, Nara Medical University, 3Institute of Biomedical Research and 
Innovation
Background: ADAMTS13 was discovered as a key enzyme of thrombotic 
microangiopathy (TMA) pathogenesis. ADAMTS13 specifi cally cleaves 
multimeric von Willebrand factor (VWF) which is synthesized at the site 
of vascular endothelial cell injury. Under physiological conditions VWF 
is rapidly degraded by ADAMTS13. However, insuffi cient ADAMTS13 
leads to formation of unusually large VWF multimers (UL-VWFM) which 
have potent activity of platelet aggregation/microthrombosis, that results in 
microcirculatory disturbance and organ dysfunction. Because the primary target 
of major adverse events, including ischemia-reperfusion injury and rejection, is 
vascular endothelial cell, ADAMTS13 and UL-VWFM may play a role in graft 
dysfunction during these events even without TMA. The aim of this study was 
to determine clinical implication of this enzyme in liver transplantation (LT).
Methods: Plasma ADAMTS13 and UL-VWFM were sequentially evaluated 
before and after liver transplantation in six recipients without clinical signs 
of TMA. ADAMTS13 activity was assayed by multimer and ELISA methods. 
UL-VWFM was evaluated by vertical agarose gel electrophoresis.
Results: ADAMTS13 activity decreased markedly and rapidly in all recipients 
from 75+-37% before LT to 22+-13 on day 1 after LT. The extent of decrease 
depended on the severity of graft reperfusion injury. In a patient with steatotic 
liver graft showed signifi cant drop from 110% before LT to 9% on day 1. The 
activity recovered gradually when the post LT courses were uneventful. There 
were three episodes of acute rejection among six recipients. At the onset of 
rejection, ADAMTS 13 activity decreased signifi cantly to <3, 6, and 11%, and 
increased after remission of rejection. Upregulation of UL-VWF was parallel 
to decrease of ADAMTS13 activity.
Conclusions: Plasma ADAMTS13 activity decreases very frequently and 
markedly after LT. The kinetics of the enzyme was correlated with adverse events 
including ischemia-reperfusion injury and rejection. These results suggest that 
ADAMTS13 activity may be an useful indicator of graft dysfunction in liver 
transplant recipients.
POSTER BOARD NUMBER P3 – 421
POTENTIAL RISK OF PLATELET TRANSFUSION IN 560 
VIEW OF SIGNIFICANT DECREASE OF ADAMTS13 ACTIVITY 
AFTER LIVER TRASPLANTATION
S. Ko1, E. Okano1, H. Kanehiro1, M. Matsumoto2, Y. Fujimura2,
K. Tanaka3, Y. Nakajima1
1 Deaprtment of Surgery, Nara Medical University, 2 Transfusion Medicine, 
Nara Medical University, 3 Institute of Biomedical Research and Innovation
Background: Various degrees of thrombocytopenia were commonly observed 
after liver transplantation. Clinical studies demonstrated that thrombocytopenia 
was associated with poor prognosis, while the mechanism is unclear. 
ADAMTS13 was discovered as a key enzyme of thrombotic thrombocytopenic 
purpura (TTP) pathogenesis. ADAMTS13 cleaves multimeric von Willebrand 
factor (VWF) which is synthesized at the site of vascular endothelial cell 
injury. Insuffi cient ADAMTS13 activity, as observed in TTP patients, 
lead to formation of unusually large VWF multimer (UL-VWFM) which 
is potent activator of platelet aggregation/microthrombosis, that results in 
microcirculatory disturbance and serious organ dysfunction. In such situation 
with decreased ADAMTS13 activity in TTP, platelet transfusion is thought to 
be contraindication, because it further enhances platelet aggregation/thrombus 
formation in organ microvessels and induces serious organ dysfunction. 
Because liver transplant recipients often develop adverse events with vascular 
endothelial injury including ischemia-reperfusion and acute rejection, excessive 
production of UL-VWF and consumptive decrease of ADAMTS13 may occur 
in the site of grafted liver. The aim of this study was to determine whether 
thrombocytopenia and graft dysfunction with such local TTP like mechanism 
is vital after liver transplantation (LT). 
Methods: Plasma ADAMTS13 was sequentially assayed by multimer and 
ELISA methods before and after LT in six recipients without clinical signs 
of TTP. UL-VWFM was evaluated by vertical agarose gel electrophoresis. 
Results: The mean value of ADAMTS13 activity before LT was 75+-37%, 
and the values decreased signifi cantly in all recipients after LT (the minimal 
value after LT were 13+-11% during the fi rst month after LT), while the 
extent of decrease varied among recipients. There were fi ve episodes of 
severe thrombocytopenia with platelet count of 13,000 to 26,000/uL 
in three recipients. During three of these episodes, marked decreases of 
ADAMTS13 activity to 3, 8, and 15% were observed. Simultaneously, 
upregulation of UL-VWFM was also associated. Because of the decreased 
ADAMTS13 activity, we never transfused platelet during these events. 
Thrombocytopenia in these recipients recovered after administration of 
suffi cient amount of fresh frozen plasma, which is currently an only source 
of ADAMTS13 replacement. 
Conclusions: Thrombocytopenia after LT was frequently associated with 
signifi cant decrease of ADMTS13 activity probably due to local TTP like 
mechanism. Platelet transfusion may be dangerous and deteriorate liver graft 
function when the ADAMTS13 activity is low. Our fi ndings not only suggest a 
novel mechanism of thrombocytopenia after LT, but also demonstrate critical 
importance of ADAMTS13 monitoring in liver transplant recipients.
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DOES C4D COMPLEMENT SPLIT PRODUCT 561 
EXPRESSION IN PERIOPERATIVE LIVER ALLOGRAFT 
BIOPSIES REALLY PROVE THE ACTIVATION OF 
RECIPIENT’S IMMUNOLOGICAL SYSTEM?
A. Mroz1, J. Pazik2, B. Lagiewska3, M. Pacholczyk3, M. Durlik2
1Department of Gastroenterology And Hepatology, Medical Center For 
Postgraduate Education, 2Department of Transplantation Medicine and 
Nephrology, Transplantation Institute, Warsaw, 3Department of General and 
Transplantation Surgery, Transplantation Institute, Warsaw
Background: The data concerning usefulness of C4d expression in differential 
diagnosis of rejection in transplanted liver is confl icting. There is also debated 
whether C4d deposits found in perioperative liver transplant biopsies have any 
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impact on rejection in early post-transplant period. But here one can address 
the question whether these deposits really express the activation of recipient 
immunological response or are connected only with ischemic state as it was 
proved in patients after partial hepatectomy procedures..
Aim: To compare C4d deposition in biopsies taken prior to and 30 minutes 
after engraftment of liver transplant.
Patients and methods: The perioperative biopsies from 15 patients undergoing 
liver transplantation were analyzed. The specimen were taken prior to and 
30 minutes after engraftment and these biopsies were separately assessed 
histologically as well as the expression of C4d in vessels were. This expression 
was ascribed semiquantatively as 0 (no expression) to 3 (strong and diffuse 
expression in portal and central veins endothelium).
Results: The C4d expression was found in 8 patients and in all but one case the 
intensity of expression was exactly the same in pre and postreperfusal biopsies. 
In one case C4d deposits appeared only in second specimen. 7 patients remained 
C4d negative in both biopsies.
No correlation was shown between C4d expression and grade of ischemia-
reperfusion injury.
Conclusion: As we previously described C4d deposits are present in 
perioperative biopsies. Nevertheless the expression seems to be exactly the 
same in prior to transplantation and after the recipient’s circulation is instituted. 
Taking it into account it is doubtful that C4d deposits really prove the activation 
of recipient’s humoral immunological response and may simply refl ect the 
complement activation due to ischemic changes in transplanting organ. This 
could be the reason of equivocal results investigating C4d expression in liver 
transplant rejection.
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ALLOANTIBODY MEDIATED REJECTION (AMR) IN 562 
LIVER GRAFTS: C4D STAINING AND DONOR SPECIFIC 
AANTIBODIES (DSA) IN THREE PPOSITIVE CROSSMATCH 
RECIPIENTS
T. Kozlowski, T. Rubinas, S. Zacks, R. Watson, J. Schmitz, K. Andreoni
University of North Carolina at Chapel Hill
As a follow up of our previous report defi ning histological and IF characteristics 
of AMR, we present additional data supporting our description of novel C4d 
staining of biliary sinusoids. Three liver recipients: alcoholic cirrhosis (P1), 
HCV (P2), and PSC (P3) had positive crossmatch (pos XM) with greater 
than 300 channel shifts (cs) for T and B cells. DSA levels and XM were 
tested on POD2-3, and 7. P1 and P2 had neg XM on POD2. P3 had pos B 
cell XM on POD3. All pts had pos XM on POD7 with C4d pos liver biopsy 
(bx) within 40 days. P1 had a Class I B7 DSA that persisted despite IVIG, 
Rituximab, and plasmapheresis (PP). Her graft showed severe cholestasis (all 
pts had normal hepatic artery & portal vein fl ow with no mechanical biliary 
obstruction). Multiple bx showed worsening AMR: cholangiolar proliferation, 
centrilobular hepatocyte swelling, sinusoidal neutrophils, hepatocanalicular 
cholestasis, and pos C4d staining along sinuosoidal endothelium. Pt refused 
retransplantation and died on POD 114. P2 had Class I DSA strong T cell XM 
on POD 13, and pos C4d stain with histological features of AMR on POD 
33. Rituximab was given. P2 LFTs rapidly normalized post-op. She is doing 
well 9 mos after transplant. P3 had strong T and B XM. He had several class 
I DSAs that rapidly decreased, but a persistent Class II DSA despite IVIG, 
Rituximab and OKT3. Multiple bx showed AMR with cellular component. 
Transaminases were in 300-400. Bilirubin 13.6. Due to persistent AMR he 
received 6 PP. Post PP XM and DSAs reveled decreased T cell fl ow. B cell 
XM has decrease only to 332 cs. He has severe liver dysfunction with need 
for retransplantation.
Most pts with pos XM become neg after tx with no clinical AMR. A pos XM on 
day 2-3 may be a sign of rapid antibody response.
We postulate that sensitized liver transplant candidates should undergo XM 
follow up at least for 7 days. Persistent Pos XM warrants bx for histology and 
C4d. Treatment consist of IVIG, Retuximab and PP.
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MOUSE MAMMARY TUMOUR VIRUS - LIKE VIRUS 563 
(MMTV-LV) IS PRESENT IN LIVERS OF A WIDE RANGE 
OF HEPATIC CONDITIONS
W. Rawlinson1,2,3,5, H. Johal1,3, S. Riordan4, G. Scott1,3,5, R. Jones6,
1Virology Research, POWH & UNSW Research Laboratories, Prince of Wales 
Hospital, 2Virology Division, Department of Microbiology, SEALS, Prince 
of Wales Hospital, 3School of Biotechnology and Biomolecular Sciences, 
Faculty of Sciences, University of New South Wales, 4Gastroenterology 
and Hepatology, Prince of Wales Hospital, 5School of Medical Sciences, 
University of New South Wales, Sydney, AUS, 6Liver Transplant Unit, Austin 
Hospital
Mouse mammary tumor virus (MMTV) is a hormonally regulated, oncogenic 
virus, responsible for 95% of breast cancers in mice. Previous studies suggest 
the human equivalent of MMTV, called MMTV-like virus (MMTV-LV) 
may be important in the pathogenesis of primary biliary cirrhosis (PBC), an 
autoimmune liver disease, and carcinogenesis. End-stage liver disease, as a 
precursor to hepatocellular carcinoma is often indicated for liver transplantation. 
We investigated the prevalence of MMTV-LV in liver tissue and explants from 
Australian patients with various liver diseases resulting from different etiologies 
(including PBC). The potential correlation between MMTV-LV presence 
and cellular changes associated with liver disease and cancer progression, 
namely p53 tumour suppressor protein accumulation and altered hormone 
receptor expression (estrogen receptor-alpha and progesterone receptor), was 
also examined. Polymerase chain reaction (PCR) on extracted DNA showed 
MMTV-LV envelope (env) sequences were present in 25% (53/210) of liver 
disease biopsies but not detected in normal liver tissues (0/20). Livers from 
patients with PBC were positive for MMTV-LV at a prevalence of 12% (3/26) 
whereas 22% (10/46) of explanted livers and 23% (42/138) of livers from 
patients with other liver diseases were also positive for the virus, demonstrating 
MMTV-LV is not limited to PBC and found in many non-cirrhotic and cirrhotic 
liver diseases. A higher percentage of MMTV-LV positive tissues were positive 
for p53 (84%) than MMTV-LV negative tissues (71%), with higher rates of 
p53 detection in cirrhotic versus non-cirrhotic tissue, though the association 
between MMTV-LV and p53 accumulation was not statistically signifi cant 
(p=0.08). None of the liver sections were progesterone receptor (PgR) positive 
and no signifi cant association between the virus and estrogen receptor-alpha 
(ER-a) staining was noted.
This study shows that MMTV-LV is not limited to PBC, but found in many 
non-cirrhotic and cirrhotic liver diseases, some with the potential to progress 
to hepatocellular carcinoma (HCC). Further studies demonstrating the co-
localization of the p53 protein with MMTV-LV in diseased liver tissues will 
provide further insight into this association.
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ARE POSTREPERFUSION SUBCAPSULAR WEDGE 564 
BIOPSIES USEFUL IN PREDICTING GRAFT INITIAL POOR 
FUNCTION AFTER LIVER TRANSPLANTATION?
A. Kocbiyik1, B. Demirhan1, S. Sevmis2, I. Budakoglu3, H. Karakayali2, 
M. Haberal2
1Baskent University Faculty of Medicine, Department of Pathology, 
2Baskent University Faculty of Medicine, Department of General Surgery, 
3Baskent University Faculty of Medicine, Department of Public Health
Preservation injury is a major contributing factor to primary allograft failure 
or graft initial poor function after orthotopic liver transplantation (OLT). In 
this study, we examine histopathological fi ndings on routine postperfusion 
biopsy (between graft reperfusion and the end of the surgery) specimens in 
relation to the early graft function (within fi rst week). From September 2001 
to February 2008 a total of 217 OLTs were performed in our center. 129 
liver biopsy specimens were excluded from analysis; because of poor quality 
biopsy specimens, due to complication of surgery (biliary, hepatic artery 
thrombosis,.) early mortality (< 1 month), small size graft, acute rejection. 
Subcapsular postperfusion biopsies (from 88 patients) were reanalyzed and 
histological lesions were graded. For analysis, grafts were grouped into 3 
categories: good function (GF, 73 patients), initial poor function (IPF, 14 
patients) and primary nonfunction (PNF, 1 patient). IPF was defi ned as an 
alanine aminotransferase or aspartate aminotransferase level greater than 
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1,500 IU/L during the fi rst week. PNF was defi ned as death or re-OLT because 
of hepatic insuffi ciency. There was only one patient for the last group. So the 
other two groups were compared with each other for numerous morphologic 
and clinical parameters. Istatistically there was no relationship between these 
2 groups according to clinical data; bile-duct complication, donor (cadaver 
or live-donor), graft volume, age and the type of stent. The histologic 
parameters; neutrophilic infi ltration of subcapsular region, hepatocellular 
ballooning and macro-microvesicular fatty degeneration don’t seem to be 
related to IPF. On the other hand neutrophilic infi ltration of parenchyma, 
hepatocellular necrosis were related to IPF (p<0.05). IPF rates are more in 
cadavers (50%) than live-donors (8.5%). Preservation-reperfusion injury 
(+2, +3 neutrophilic infi ltration) was found 78.6% of the patients for IPF and 
39.7% of the patients for GF. Subcapsular neutrophilic infi ltration, which 
is a sign of surgical hepatitis rather than preservation-reperfusion injury, is 
not a morphologic changing that leads to advanced information about the 
graft. Therefore, subcapsular wedge biopsies from liver allografts, which 
were taken instead of tru-cut biopsies because of some complications for 
instance bleeding, should be carefully examined for neutrophilic infi ltration 
of the parenchyma. Also presence of necrosis may be useful for defi ning 
preservation-reperfusion injury.
POSTER BOARD NUMBER P3 – 426
GRAFT PRECONDITIONING WITH LOW-DOSE 565 
TACROLIMUS (FK506) AND NITRIC OXIDE INHIBITOR (AGH) 
REDUCES ISCHEMIA/REPERFUSION INJURY AFTER LIVER 
TRANSPLANTATION IN THE RAT
E. Matevossian1, N. Hüser2, D. Doll3, M. Werner4, A. Preissel5, M. Stangl6, 
S. Thorban7
1Department of Surgery, Transplantation, Klinikum rechts der Isar, Technical 
University of Munich, 2Department of Surgery, Transplantation, Klinikum 
rechts der Isar, Technical University of Munich, 3Department of Surgery, 
Transplantation, Klinikum rechts der Isar, Technical University of Munich, 
4Department of Pathology, Klinikum rechts der Isar, Technical University 
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Background/aim: Ischemia/reperfusion (I/R) injury in the early 
postransplant period is closely associated with delayed recovery of graft 
function, increased acute rejection, and late allograft dysfunction. Recent 
evidence indicates that an increase in nitric oxide (NO) production after 
liver transplantation is associated with I/R injury. Tacrolimus (FK506) 
is a immunsuppressive drug that is a substrate of cytochrome P450 
enzymes. The aim of this study was to demonstrate that low-dose FK506 in 
combination with aminoguanidine (AGH) to reduction of nitric oxide level 
has a hepatoprotective effect by reducing I/R injury-associated necrosis 
after liver transplantation in the rat.
Materials and methods: Fortyone DA-(RT1av1) rats served as donors and 
recipients for syngenic orthotopic arterialised liver transplantation (LTx) with 
cold ischemia of 120 minutes and warm ischemia of 12 minutes (±1,2) in 
microsurgical technique. They were divided into 4 groups: group I (controls 
without pre-/tretment, n=6), group II (pre-/treatment with high-dose FK506, 
n=11), group III (pre-/treatment with only AGH, n=13), and group IV (pre-/
treatment with lowe-dose FK506 in combination with AGH, n=11). On 
postoperative days 1, 3, 5, 8 and 10 laboratory investigations and liver biopsies 
for histopathological investigations had been performed.
Results: The level of transaminase (alanine amino transferase, ALT) in groups 
I, II and III was signifi cant highly on posttransplant day 3 as in group IV with 
combinated pre-/treatment (p= 0.002, p= 0.001, p= 0.001). After low-dose 
FK506 and AGH pre/-treatment in group IV, the I/R-induced liver necrosis rate 
was reduced, and were signifi cantly decreased.
Conclusion: We demonstrated that in the liver a combinated pre-/treatment 
with lowe-dose FK506 and AGH to inhibition of inducible nitric oxide synthase 
prevented I/R-induced injury of graft after liver transplantation in rat model. 
The synergist administration of lowe-dose FK506 and AGH in transplant 
patients should be performed with caution.
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The toxin of Amanita phalloides causes liver failure by an irreversible inhibition 
of RNA polymerase. This is often the case in not pre-injured livers with a high 
regeneration potential. The clinical decision models for transplantation were 
evaluated and new parameters were identifi ed in a porcine model.
Intoxication was induced in 8 German Landrace pigs (32±2 kg) by an 
intravenous application of 5mg or 10mg amanitine in deep anesthesia (fentanyl, 
ketamine, midazolam). The animals were keep analogous to the human setting 
of a maximum intensive care (respirator, invasive blood pressure monitoring, 
hourly blood gas analysis, HES, NaCl, noradrenaline, electrolytes on demand).
The mean survival of the animals was 137 h (38,5-163,5 h). Liver synthesis 
stopped and by the end of day 2, the PT of all animals was below 40%. Four 
out of 8 animals spontaneously recovered as measured by an increase of the 
PT above 80% on day 5. The serum activities of transaminases was at no time 
predictive for liver regeneration. Values increased up to 2500 U/l for AST 
in animals that spontaneously recovered. The increase of serum creatinine 
above 106 μmol/l was observed in a transient way. In animals that recovered, 
creatinine levels decrease whereas in animals with a fatal outcome kidney 
failure became manifest.
In all animals with a regeneration of the liver, platelet count never dropped 
below a limit of 300 *10^6 per ml. The difference clearly became predictive 
(358 SD 54 versus 216 SD 56 10^6 per ml) on day 3, more than 24 hours before 
the onset of regeneration seen by synthesis parameters.
The animal model confi rmed most of the clinical observations. The platelet 
count is an easy accessible parameter to help on the decision when to 
transplant. On the background, that the role of platelets as stimulator for liver 
regeneration is currently discussed, this observation may be directly related to 
the mechanism.
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Background/introduction: Due to the growing demand for liver transplantation 
coupled with limited donor organ availability, many transplant centers have 
expanded their donor organ pool by procuring organs from extended criteria 
donors, including donation from cardiac death (DCD). While these marginal 
organs do confer some survival benefi t, they are also associated with increased 
rates of primary graft failure and complications such as biliary strictures. Biliary 
epithelial cells (BEC) may be much more sensitive to ischemia/ reperfusion 
injury (IRI) and more prone to apoptosis in the DCD scenario than hepatocytes 
and other liver cell types. The purpose of our study was to analyze apoptotic 
pathways in the setting of IRI, and to compare biliary tissue expression of 
caspase-3, a central enzyme in the apoptotic pathway, in grafts from standard 
donors with grafts from extended criteria donors.
Patients/methods: In a retrospective review of patients with available donor 
gall bladder tissue, we identifi ed 5 patients with post-transplant biliary 
complications and compared them to 5 patients without post-transplant biliary 
complications. These samples were matched for multiple variables including 
age, gender, liver disease, and disease severity (MELD score). Donor gall 
bladders in these 10 patients were removed 40-60 minutes after reperfusion 
of the donor liver. Preserved gallbladder samples from these patients were 
retrieved and stained with rabbit anti-cleaved caspase-3 antibody using 
standard immunohistochemical techniques. Apoptosis was semi quantifi ed by 
counting the percentage of BECs that stained positive for caspase-3 under high 
power magnifi cation view.
Results: On average, 7.84% of BECs in samples obtained from patients without 
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biliary complications stained positive for caspase-3. In contrast, 46.24% of 
BECs in gallbladder samples obtained from patients who developed biliary 
complications stained positive for caspase-3 (P<0.05). Caspase-3 activity was 
not detected in the other cell types.
Conclusion: This data suggests that caspase-3 mediated apoptosis, which is 
evident at a very early stage of reperfusion, is associated with development 
of biliary complications weeks and months after transplantation. These 
observations suggest that there are molecular pathways that incite/ trigger 
biliary injury, resulting in clinical disease. These pathways could be potential 
targets for intervention, thereby allowing better functioning and survival of 
marginal liver grafts.
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IN VITRO ASSESSMENT OF ALLOREACTIVITY IN 568 
LIVING RELATED LIVER TRANSPLANTATION
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Background: With the success of solid organ transplantation has come the 
realization that the post-transplant morbidity and mortality related to the use 
of immunosuppressive medications. Induction of tolerance to the transplanted 
organ would likely prevent these complications, however, the use of tolerance 
induction protocols in solid organ transplantation will require assays that refl ect 
the immune alloreactivity of the recipient towards his/her donor.
Aim: To develop an in vitro method to detect immune alloreactivity of the 
transplanted recipient towards his/her donor.
Methods: We developed a fl ow cytometry based mixed lymphocyte reaction 
assay system, involving co-culture of peripheral blood mononuclear cells 
(PBMC’s) from liver transplanted recipients (responder cells) with antigen 
presenting cells, APC’s obtained from their living related donor (LRD 
stimulator cells), APC’s from the other parent (OP stimulator cells) and APC’s 
from 3rd party donors (TP stimulator cells). Surface activation marker (CD69, 
CD25, and CD71) induction was measured in recipient CD4+ cells following 24 
and 48 hour incubations with stimulator APC’s. The responses were compared 
between recipient cells stimulated with: LRD-APC’s, OP-APC’s, and TP-
APC’s. The recipient, donor, other parent and third party donors all had HLA 
typing performed.
Results: Our preliminary observation indicate that stimulation of recipient T 
cells with PBMC from the living related donor resulted in lower activation 
marker induction in CD4+ recipient T-cells compared to the level of activation 
marker induced following stimulation with PBMC from an unrelated 3rd party 
donor; Fig 1 shows representative results of CD69.
Figure 1: median%CD4+CD69+ on y axis. 24 hour incubation. N=11.
To further investigate whether the decreased activation marker induction was 
a result of both the recipient and donor being haploidentical or a true absence 
of alloreactivity of the recipient towards his/her donor, we also looked at 
activation marker induction following stimulation with OP APC’s. Our results 
demonstrate decreased CD25 and CD71 induction following LRD stimulation 
compared to OP and TP stimulation; Fig 2 shows representative results from 
CD71.
Figure 2: median%CD4+71+ on y axis. 48 hour incubation.
Conclusion: PBMC obtained from liver-transplanted children exhibited lower 
levels of activation in response to stimulation with APC’s obtained from their 
living related donors compared to the responses obtained when stimulated with 
APC’s from the second parent and unrelated 3rd party donors. This difference 
is compelling and we are continuing to confi rm these preliminary fi ndings in a 
larger number of transplant recipients.
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Introduction: Everolimus (Certican; Eve), acts as a m-Tor-inhibitor and may 
improve acute rejection and cardiac allograft vasculopathy (CAV) in transplant 
recipients. Only limited data are available about the clinical use in pediatric 
patients. We studied the effi ciency of Eve in pediatric heart transplant patients 
in retroprospective study during 2004-2007.
Method: Patients were analyzed in regard to acute rejection (AR), CAV 
after 1, 2, 5 years, renal function, survival and possible side-effects. Through 
level monitoring was performed using mass spectrometry. Graft function was 
analyzed with echocardiography, intramyocardial electrocardiogram (IMEG) 
and heart catheterization.
Results: 13 pts. with CyA-Eve (A), 12 pts. with CyA-Aza (B), 16 pts. with 
CyA-MMF (C) were included. Survival, Age, gender and weight were not 
signifi cant different in all three groups. Median posttransplant time was for 3.2 
(A) vs. 8.1 (B) and 5,7 (C) years. Acute rejection during 1st year was signifi cant 
lower in pts. with CyA-Eve: 7% (A) vs. 23% (B) and 35% (C) (p=0.02). CAV 
after 1 year were detected in 16% (B) patients and none of the other groups 
(p=0.04). CAV after 2 years was detected in 7,7% (A), 41% (B) and 37% (C) 
(p=0.004). After 5 years in 48% (B) and 56% (C) patients, where data was not 
achieved CyA-Eve. CyA-blood level were comparable over the time: A: 101 
(78-168) B: 125 (96-247) and C: 148 (91-293) ng/ml. Creatinine values: A: 
0,67 (0,3–0.8), B: 0,92 (0.5–1,8) and C: 0,98 (0,53–1,54) mg/dl. Major side 
effects of Eve were delayed wound healing and increased blood lipids and 
triglycerides in two patients.
Conclusion: Everolimus was safe and well tolerated in pediatric patients. 
It was signifi cantly more effective in reducing the severity and incidence of 
AR and CAV (up to 2 years) if compared with Aza or MMF. Wound healing 
complications (15%) and high lipids were reasons to temporarily stop 
medication in patients with de novo Everolimus. A 5-years follow-up is near 
and may additional important information.
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Introduction: PTLD is still a major complication in pediatric patients after 
solid organ transplantation. Overall intensity of immunosuppression, EBV 
mismatch or primary infection after transplantation may be a major risk factor 
for the development of PTLD.
Method: The incidence, risk factors, and outcome of posttransplant 
lymphoproliferative disease (PTLD) were examined for 150 children 
undergoing pediatric heart transplantation.
Results: Incidence of PTLD was 8% (12 of 150). CyA-Azathioprine (Aza) 
were associated with the development of PTLD in 8/12 as compared with 
4 patients (CyA-MMF or CyA-Everolimus) (p=0.01). Three or more doses 
of ATG were associated with an increased risk for PTLD (p=0.02). PTLD 
was detected in lymph nodes (5), intestine (2), lung (1), tonsils (2) and eye 
(2). Histology was a monomorphic B-cell lymphoma (7/12), a monomorphic 
Burkitt lymphoma (4/12), polymorphic B-cell lymphoma, angiocentric 
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lymphoma (Liebow) and as reactive plasmacytic hyperplasia (early lesion), 
respectively. PTLD was EBV positive in 10/12 patients and 50% had a 
primary EBV infection after Tx. Risk factors in the comparison to patients 
without PTLD were age at time of Tx, primary EBV infection after Tx, use 
of Azathioprine and ¡Ý 3 doses of ATG. CMV mismatch and CMV infection, 
rejection episodes and steroids were not risk factors. Despite reduction of 
immunosuppression, treatment consisted of surgical procedures to remove 
tumor masses (n=6), Rituximab (n=5), polychemotherapy (n=3), antiviral 
(n=1) and autologous T-cell therapy (n=1). All patients demonstrated full 
remission without death related to PTLD or treatment at 4.3 (1.6¨C6.8) years 
median follow-up time.
Conclusion: Intense immunosuppression (ATG and Aza) was associated 
with a signifi cant increased risk of PTLD. Primary EBV infection after Tx 
further accentuated this risk. Reduction of CyA blood level alone is not 
reducing the risk of PTLD in combinative therapy with antimetabolites. 
Identifi cation of high-risk patients with screening protocols and frequent 
EBV load measurments may lead to early PTLD-interventions, including 
change and reduction of overall immunosuppression, pre-emptive antiviral 
and antitumor therapies.
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Biliary atresia (BA) is the leading indication for liver transplantation during 
childhood. Predictive clinical markers for the progression of liver cirrhosis 
are lacking in accuracy. Therefore, we investigated the correlation between 
histologically quantifi ed fi brotic changes of the liver at the timepoint of Kasai 
hepatic portoenterostomy and the clinical course of children with biliary 
atresia.
Liver tissue was obtained at the time of the Kasai hepatic portoenterostomy 
(HPE) in 53 children (median age 54 days, range 20 -122 days) with biliary 
atresia. All liver biopsies were stained with PicroSirius Red. The images 
were captured under polarization microscopy and the extent of fi brosis was 
quantifi ed by computerized analysis. The mean amount of fi brosis per number 
of periportal fi elds (Vfi b) and the Ishak score were individually calculated and 
compared.
Mean Vfi b was 3.9% (SD 3.8) and correlated positively with the risk of 
early mortality in Pearson Correlation (R= 0.991, p< 0.001). However, this 
did not correlate with the Ishak score (r=0.18, p= 0.21). Vfi b was 6.5% (SD 
4.1%) in children with early mortality as compared to 3.2% (SD 2.3%) in 
those who survived during the observation time (p=0.01, ANOVA). A Vfi b 
> 3% predicted early mortality with a sensitivity of 61% and a specifi city of 
80%. Vfi b was correlated with bilirubin 6 months after HPE (Bili6m) and a 
signifi cant elevation of Bili6m was found in those patients with Vfi b ≥; 6. In 
patients with a combination of Vfi b > 3% and an increased serum bilirubin (> 
20 μmol/l) after 6 months post HPE survival rate was signifi cantly reduced 
(58% vs 95%). This combination was highly predictive for mortality (odds 
ratio 12.9, 95% Confi dence Interval = 2.1 - 80.1, Pearsons chi-square-test 
p= 0.002).
In conclusion, our data demonstrate that the computerized quantifi cation of the 
extent of periportal fi brosis at the time of HPE visualized by PicroSirius Red is a 
valid marker in predicting the risk of death in children with BA. Therefore, this 
method should be considered as an integral part of scoring systems predicting 
the indication for liver transplantation in these patients and be subject of further 
studies to evaluate, whether quantifi cation of fi brosis in liver biopsies could 
possibly be used as a follow up parameter after HPE.
POSTER BOARD NUMBER P3 – 433
EBV SURVEILLANCE BY PLASMA RT-PCR AFTER 572 
PAEDIATRIC LIVER TRANSPLANTATION
W. Hardikar1,3,4, Z-Z.D. Tham1, L. Crellin1, K. Lee2
1Department of Gastroenterology, Royal Children’s Hospital,Melbourne, 
2Clinical Epidemiology and Biostatistics Unit,Royal Children’s 
Hospital,Melbourne, 3University of Melbourne, 4Murdoch Children’sResearch 
Institute
Background: EBV infection after liver transplantation (OLT) is the main 
cause of post-OLT lymphoproliferative disease (PTLD), particularly in patients 
who have not previously experienced EBV. At present, EBV monitoring and 
pre-emptive modulation of immunosuppression is the mainstay of management 
however the optimal method of monitoring has not yet been established. In 
particular the signifi cance of positive PCR in whole blood in patients who 
are seropositive for EBV pre-OLT is uncertain. Recent studies suggest that 
a positive plasma PCR is superior to whole blood assays as an indicator of 
active EBV replication. We therefore sought to 1. Compare plasma PCR and 
whole blood EBV PCR levels and 2. Determine the signifi cance of active EBV 
infection as defi ned by plasma PCR in our paediatric liver transplant recipients 
using PTLD as an outcome measure.
Methods: The records of all children undergoing liver transplantation between 
1995 and 2007 were reviewed for EBV status pre-OLT and EBV monitoring 
post-OLT. Real time quantitative PCR (RT-PCR) of plasma and whole blood 
samples using an in-house assay was performed in addition to EBV serology. 
Primary infection was defi ned as the appearance of VCA-IgM or positive RT-
PCR plasma or blood in patients previously VCA-IgG negative. Sustained 
infection was defi ned as + RT-PCR lasting longer than 6 months. PTLD was 
diagnosed with standard criteria.
Results: Of 53 patients identifi ed, 3 patients were excluded as they died within 
1 month of transplantation. For the 50 remaining patients, 307 samples were 
collected over a median of 45 months (range 5 months to 12 years). Of 114 
paired whole blood and plasma samples, the specifi city of plasma PCR was 
98% (52/53) compared to whole blood while the sensitivity was 57% (35/61). 
As expected plasma titres were always lower than whole blood titres. 25 
patients were seronegative (group A) and 25 seropositive (group B) prior to 
OLT. 13/25 of group A had a primary infection post transplant. 3/13 of group A 
had a sustained infection and 1 of these developed PTLD and died. In contrast 
only 1/25 of group B had a sustained infection and none developed PTLD.
Patients with sustained infection who did not develop PTLD had plasma viral 
loads from 2x 103 to 2.5x106 copies/mL over a period of up to 35 months. 
The patient with PTLD had viral loads from 3 x104 to 2.3 x109 only detected 
4months prior to death.
Conclusions: Sensitivity of plasma PCR was inferior to whole blood PCR 
however its signifi cance in terms of EBV disease remains to be determined. 
Sustained viremia is not predictive of PTLD.
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LIVING-RELATED DONOR LIVER TRANSPLANTATION 573 
FOR CHILDREN WITH FULMINANT HEPATIC FAILURE IN 
ISRAEL
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T. Shoenfeld1, Z. Ben-Ari2, R. Shamir1, E. Mor2
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Background: Conservative treatment fort fulminant hepatic failure (FHF) in 
children is associated with high mortality rates, turning liver transplantation 
into being the treatment of choice. Living-related donor liver transplantation 
(LDLT) has been suggested as an alternative to cadaveric liver transplantation 
in order to overcome the shortage of organ donors. However, experience with 
LDLT in children with FHF is limited in the western world.
Objective: To present the experience with LDLT for children with FHF in a of 
a major referral center in Israel.
Methods: The fi les of all children who underwent primary LDLT for FHF were 
reviewed for demographic, clinical and laboratory parameters before and after 
transplantation.
Results: During 1996-2007, thirteen children diagnosed with FHF 
underwent primary LDLT at our center. The median age of the patients 
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was 4 years (range 0.75-14 years), and the causes were acute hepatitis 
A in 4 and unknown in 9. Short-term complications, documented in 12 
children, included mainly hepatic artery thrombosis, which warranted re-
transplantation in 3 cases, and biliary leaks repaired either by surgery or by 
invasive radiology. Three patients died during the fi rst month after LDLT 
of uncontrolled intraoperative bleeding (n=1), sepsis (n=1) and multiorgan 
failure (n=1). Long term complications were less common, and included 
ascending cholangitis and graft rejections. Patient survival rate was 69% 
and 62% at 1 and 5 years, respectively. None of the donors had long term 
complications.
Conclusions: Although the outcomes of LDLT in children with FHF seems 
inferior to that in children after elective transplantations for chronic liver 
diseases, the procedure is timely, life-saving and could reduce the dependence 
on cadaveric donation in this setting.
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Background: The prevalence of allergic diseases is increasing in Western 
countries. In the Australian population 10% of 6-14 year old children 
have eczema, 15% allergic rhinitis, 4-6% food allergies and 28% asthma. 
Recent case reports have described the onset of diffi cult to manage 
allergic conditions, such as peanut allergy and severe eczema, following 
orthotopic liver transplant (OLT). It is unclear whether the development 
of post transplant allergic conditions is due to the transfer of sensitized 
donor T cells or alternatively loss of clonal control of oral tolerance in the 
recipient.
Aim: To assess the development of de novo allergic disease and sensitization 
in children after OLT.
Methods: Medical records of consecutive liver transplant recipients 
(1995–2006) from a single center were reviewed for evidence of allergic 
diseases before and after OLT. Criteria for diagnosis and grade of severity were 
based on published guidelines. Data were also collected on donors, family 
history of allergic disease in patients and immunosuppressant exposure.
Results: During the study period there were 51 liver transplants in children 
in Victoria. Data were ascertained for 47 patients (23 males) with a mean age 
of 4 years and 10 months at the time of liver transplant (range 7- 192 months) 
for whom a minimum follow up of 1 year was available. In the pre-transplant 
period, 2 (4.3%) had eczema, 3 (6.4%) had asthma, 1 (2.1%) had hay fever, 4 
(8.5%) had food allergy and 3 (6.38%) had other allergies for example drugs 
and tapes. Post OLT, there was a signifi cant increase in the prevalence of 
eczema 12 (25.5%) p < 0.007. The incidence of asthma 4 (8.1%), hay fever 2 
(4.3%) and food allergy 5 (10.63%) was not signifi cantly higher than for the 
pre transplant period. However the incidence of all allergies was signifi cantly 
higher in the post transplant patients than in the general population. (p< 0.001 
for eczema, p<0.007 for asthma and p< 0.04 for hay fever). Limited data on 
allergic diseases was available in only 16 donors of whom 5/16 (31%) had a 
history of mild asthma.
Conclusion: The signifi cant increase in the incidence of eczema after transplant 
together with the increased incidence of all allergies in post transplant 
patients compared to non transplant patients suggest that factors relating to 
transplantation may be important in the development of allergic diseases. The 
mechanism of allergy sensitization or loss of tolerance is unknown and requires 
further study.
POSTER BOARD NUMBER P3 – 436
PREVALENCE OF CYTOMEGALO- AND ADENOVIRUS-575 
SPECIFIC T-CELLS IN CORRELATION TO VIRUS-
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Introduction: Post-transplant immunosuppression leads to impaired 
cellular immune defense resulting in increased risk for severe virus-induced 
complications, e.g. by Cytomegalo- (CMV) and Adenovirus (ADV). Pre-
transplant virus-specifi c T cells might serve as prognostic marker for individual 
risk to develop virus-induced diseases after transplantation.
Method: We investigated 31 children at the age of 1 to 16 years (median 13 
years; 19 m, 12 f) listed for kidney transplantation. T cells were stimulated 
with CMV and ADV antigen in vitro. Based on specifi c cellular activation and 
induction of intracellular cytokines, the frequency of CMV- and ADV-specifi c 
CD4-T cells was determined using fl ow cytometry. Viral load was quantifi ed by 
PCR. Serologic studies were performed for CMV.
Results: Pre-transplant prevalence of CMV-specifi c T cells (29%) correlated 
with CMV-serology: Every CMV-seropositive child (9 out of 31) had detectable 
CMV-specifi c T cells, whereas we have not found any CMV-specifi c T cells in 
seronegative patients (22 out of 31). The frequency of CMV-specifi c T cells 
showed interindividual variation and ranged between 0.1 and 7.3% of CD4-
positive T cells. The level of CMV-IgG-titers did not correlate with quantity 
of virus-specifi c T cells. The single child with positive CMV-DNA-PCR also 
showed CMV-specifi c T cells.
ADV-specifi c T cells was detected in 77% of our pediatric study group (24 out 
of 31), among them three patients showed positive ADV-DNA-PCR. The level 
of ADV-specifi c T cells ranged between 0.1 and 1.0% of CD4-positive T cells.
Conclusion: High prevalence of ADV-specifi c T cells suggested high 
ADV-infection rate in early childhood, whereas the CMV-prevalence was 
signifi cantly lower in our pediatric study group. Children without suffi cient 
pre-transplant level of virus-specifi c T cells probably have an increased risk 
for virus-induced complications after transplantation. Therefore virus-specifi c 
T cells might serve as prognostic marker to estimate the individual risk for 
post-transplant viral diseases. Pre-transplant level of virus-specifi c T cells is 
probably helpful to optimize post-transplant monitoring, antiviral prophylaxis 
and immunosuppression after transplantation. Further studies will have to 
determine the minimal number of virus-specifi c T cells needed for effective 
protection against viruses.
POSTER BOARD NUMBER P3 – 437
ROLE OF HLA MATCHING IN ORGAN ALLOCATION: 576 
BALANCE BETWEEN GRAFT SURVIVAL AND 
SENSITIZATION IN PEDIATRIC KIDNEY TRANSPLANTS
L. Vu, L.A. Baxter-Lowe, J. Garcia, M. McEnhill, P. Stock
University of California, San Francisco
Background: Recent studies have questioned the necessity of HLA matching 
in the kidney allocation system. Even though elimination of the HLA mismatch 
criteria may shorten the deceased donor waiting time for children and create 
equity among ethnic minorities, post-transplant sensitization for children who 
will need re-transplantation is a rising concern.
Purpose: To determine the impact of HLA mismatching on rejection, graft 
survival, and subsequent sensitization in pediatric kidney transplant recipients 
in a regional allocation system that emphasizes donor quality rather than HLA 
matching.
Methods: We studied patients less than 21 years of age who had kidney 
transplant with dacluzimab induction immunosuppression between 1997 
and 2006 at a single institution. Patient-related variables and outcomes 
were ascertained by chart review. Survival analysis was used to determine 
the risk factors for rejection and graft survival. Sensitization was defi ned as 
development of Panel Reactive Antibody (PRA) > 0% in patients with pre-
transplant PRA of 0%.
Results: 172 patients were identifi ed and median follow-up time was 3.9 years 
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(interquantile range, 6 months to 9.6 years). Overall incidence of fi rst episode 
of acute graft rejection was 62%. The one- and fi ve-year incidences of graft 
survival were 91% and 79%. The Cox models identifi ed common predictors 
for graft failure and rejection: female gender, recipient’s age, and development 
of post-transplant lymphoproliferative disorder (PTLD). However, patients 
with one or two HLA-DR mismatches had 1.8 times greater hazard of rejection 
than those with zero HLA-DR mismatch (p=0.02). The presence of either one 
or two HLA-A mismatches and Hispanic race were independently protective 
against both rejection and graft failure. (Table 1) The following variables did 
not contribute signifi cantly to model: cause of renal disease, blood type, time 
on dialysis, donor type, donor’s race, and donor’s age. Overall incidence of 
sensitization was 47% among 74 patients. HLA-mismatching did not play 
a statistically signifi cant role in post-transplant sensitization. Independent 
predictors of sensitization included history of rejection (8.2, 0.002) and 
recurrence of primary renal disease (32.2, 0.02).
Conclusion: HLA-DR mismatching is associated with increased risk of 
rejection. Rejection is a strong predictor of both graft failure and post-transplant 
sensitization. Including HLA-DR matching in the organ allocation system may 
balance the concern for sensitization and graft survival in children receiving 
kidney transplant. The ultimate decision to wait for HLA-DR match will be 
dependent on the frequency of donors required to fi nd an appropriate match.
Table 1. Independent predictors of graft failure and rejection
Graft Failure Rejection
Predictors Hazard ratio p Hazard ratio p 
HLA antigen mismatch:
 1-2 HLA-A mismatch 0.3 0.04 0.5 0.02
 1-2 HLA-B mismatch 3.8 0.3 2.2 0.09
 1-2 HLA-DR mismatch 1.0 0.99 1.8 0.02
Gender: Female 2.9 0.07 1.5 0.02
Race: White (reference)
 Black 1.4 0.7 1.4 0.2
 Hispanic 0.1 0.02 0.6 0.02
 Other 1.0 0.99 1.0 0.9
Age at transplant (years): 
 < 13 years (reference)
 13 - 16 years 10.3 0.002 2.5 <0.0001
 > 16 years 9.1 0.01 2.3 0.001
Rejection 11.7 0.006
PTLD 8.2 0.02 4.4 0.01
Donor gender: female 0.4 0.04 >0.2
Renal disease recurrence > 0.2 2.1 0.01
POSTER BOARD NUMBER P3 – 438
HEPATIC ARTERY THROMBOSIS AFTER PEDIATRIC 577 
LIVER TRANSPLANTATION: IDENTIFICATION AND 
CHARACTERIZATION OF A NOVEL RISK FACTOR
J. Locke, Z. Stewart, A. Singer, D. Warren, K. Schwarz, W. Maley, 
R. Montgomery, A. Cameron
Johns Hopkin University
Background: Pediatric liver transplant (LT) recipients are at greater risk 
than adults for the development of hepatic artery thrombosis (HAT). HAT is 
associated with increased morbidity, graft loss, and patient mortality, and has 
been attributed primarily to technical complications particularly in children in 
whom small or split grafts are utilized. Despite technical improvements, there 
has been a steady increase in the incidence of HAT among pediatric recipients. 
The goal of this study was to identify and characterize additional occult factors 
predictive of the development of HAT.
Methods: We analyzed outcomes of pediatric (<18-yrs) deceased donor 
LT recipients reported to UNOS (1987-2006). Unadjusted and adjusted 
logistic regression analyses were performed to identify factors predictive of 
developing HAT. 
Results: Since 1999, the incidence of HAT among pediatric LT recipients has 
increased 2-fold, and in parallel the number of LT performed for hepatoblastoma 
has increased 3-fold (Figure). In addition to known HAT risk factors, such as 
small donors and recipients, cytomegalovirus(+), ABO-incompatibility, and 
split grafts, there is also an increased odds of developing HAT among recipients 
transplanted for hepatoblastoma (OR 3.87, 95% CI 2, 7.5, p<0.001). Historically 
HAT risk factors have been categorized as being associated with early or late 
development of the complication. Interestingly, however, hepatoblastoma is 
associated with a continuous and ongoing risk for the development of HAT 
during the post-transplant period.
Conclusion: The incidence of HAT among pediatric LT recipients is 
increasing, and parallels a rise in the number of pediatric patients transplanted 
for hepatoblastoma. Hepatoblastoma is an important and previously unreported 
risk factor for the development of HAT among pediatric LT recipients. Increased 
vigilance in the care of these patients beyond the peri-transplant period is 
warranted as HAT can develop at any time.
POSTER BOARD NUMBER P3 – 439
LONG-TERM OUTCOME OF RENAL TRANSPLAN-578 
TATION IN CHILDREN BELOW 12 KG AT TRANSPLANTATION
U. Berg1, M. Herthelius1, J. Sandberg2, G. Tydén2
1Division of Pediatrics, Dept. of Clinical Science, Intervention And 
Technology, 2Division of Transplantation Surgery, Dept of Clinical Science, 
Intervention and Technology, Karolinska University Hospital Huddinge
From 1982 to 2007, 195 transplantations (tx) were performed in children below 
16 years of age at Karolinska University Hospital Huddinge. 44 (24 boys) of 
those transplantations were done in children with a body weight <12 kg. Their 
median age was 1.4 (range 0.4-3.7) years, body weight 9.4 (3.3-11.5) kg and 
height 74 (53-85) cm, median height SDS –2.5. 65% received preoperative 
dialysis half of them after bilateral nephrectomy and half because of too low 
body weight to obtain an adult kidney graft. 79% received grafts from living 
donors (LD). The underlying diseases were congenital in 39 (89%), obstructive 
uropathies in 12 (10 urethral valves), dysplastic kidneys without obstruction 
in 5, congenital nephrotic syndrome in 12, Drash syndrome in 6, others in 4 
and 5 had acquired diseases, mostly postnatal cortical necrosis. The fi rst 29 
infants received cyclosporine-based and the last 15 tacrolimus-based triple 
immunosuppression. No induction therapy was used.
Between 1982 and 1992, 4 children died, 2 because of generalized CMV 
infection (before the prophylaxis era) and 2 after graft loss. After 1992 two 
children died, one because of recurrent HUS and one because of nonEBV-
associated lymphoma 12 years after tx. After 1992, graft survival was 93% after 
10 years. Catch-up growth was seen during the fi rst years after transplantation 
from median height SDS of -2.5 at tx to –0.93 5 years after tx. Thereafter no 
further increase in height was seen. 7 children had reached fi nal height at last 
investigation and the median height of the 5 boys was 171 cm and of the two 
girls 168 cm. Mean GFR (clearance of inulin) was 75±28 ml/min per 1.73 m2 
one year after tx, 53±22 5 years after and 45±14 10 and 15 years after tx.
We conclude that renal transplantation can be performed with excellent short- 
and long-term results in very small children.
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THE EFFICACY AND SAFETY OF VALGANCICLOVIR 579 
VS. ORAL GANCICLOVIR IN THE PREVENTION OF 
CMV INFECTION IN CHILDREN AFTER SOLID ORGAN 
TRANSPLANTATION
Y. Avitzur1, E. Lapidus-Krol2, R. Shapiro1, M. Davidovitch3, E. Mor4, J. Amir2
1Institute of Gastroenterology, Nutrition and Liver Diseases, 2Department of 
Pediatrics “C” and 3Division of Nephrology, Schneider Children’s Medical 
Center of Israel, and 4Department of Organ Transplantation, Rabin Medical 
Center, Petah-Tikva, Israel
Infection with cytomegalovirus (CMV) can lead to severe consequences in 
children after solid organ transplantation. Routine prophylactic treatment 
with valganciclovir is common in adults but data to support its use in children 
is scarce. The aim of this study was to compare the effi cacy and safety of 
valganciclovir vs. oral ganciclovir in a pediatric cohort.
Methods: Historical prospective analysis of all children who underwent 
kidney (KTx) or liver transplantation (LTx) in our center between the years 
2000-2007. Exclusion criteria included recipients with R-/D- serostatus, graft 
loss or death within six month post transplantation, combined treatment with 
acyclovir or lost to follow up. All children have received IV ganciclovir for 
2 weeks and then oral ganciclovir (TID) before 2004 or valganciclovir (OD) 
thereafter. Valganciclovir dose was determined by the following equation: 7 X 
BSA X creatinine clearance. Treatment was given for 3 months in R+/D+/ – 
recipients and for 6 months in R-/D+. Patients were followed for 1 year after 
transplantation and effi cacy and safety parameters were collected.
Results: 153 children underwent KTx or LTx between 2000-2007. 92 of them 
fulfi lled the inclusion criteria (25 LTx, 63 KTx, 4 combined LTx and KTx). 
41 children have received oral ganciclovir and 51 valganciclovir. Both groups 
were comparable in their demographic and transplant related history. In the 
valganciclovir group 13.7% of the children have developed CMV infection/
disease vs. 19.5% in the ganciclovir group (95%CI, 0.2-2, P=0.57). Sub-
analysis according to graft type demonstrated a trend towards better effi cacy of 
valganciclovir compared to ganciclovir in LTx recipients (15% infection rate 
vs.37% respectively, P-NS) but not in KTx recipients. Time-to-onset of CMV 
disease or infection was comparable in both treatment groups; rates of acute 
allograft rejection were slightly lower in the Valganciclovir group (3.9% vs. 
9.8%). Risk factors for CMV infection included young age, serostatus of R-/D+ 
and liver graft. No signifi cant side effects were noted in both groups.
Conclusions: As in adults, treatment with VAL is as effi cacious and safe as 
treatment with oral ganciclovir in children after KTx and LTx. There might be 
some advantage for valganciclovir use in children after LTx but further studies 
are needed to support this assumption.
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XENOTRANSPLANTATION OF MICROENCAPSULATED 580 
INSULIN-PRODUCING PIG CELLS
J. Foster1, S. Ratnapala1, G. Williams1, L. Mathieson1, A. Sharland2, B. Tuch1
1Diabetes Transplant Unit, Prince of Wales Hospital and University of 
New South Wales, 2Collaborative Transplantation Group, Bosch Institute, 
University of Sydney
Xenotransplantation of porcine pancreatic tissue offers a conceivable approach 
to overcome the shortage of human tissue available for transplantation. Fetal 
porcine (FP) pancreatic tissue in the form of islet-like cell clusters (ICCs) offers 
an advantage over neonatal and adult â-cells due to their resistance to adverse 
effect of human infl ammatory cytokines. The adoption of microencapsulation 
technology adds further appeal to the clinical application of such therapy. Our 
laboratory has previously demonstrated that FP ICCs will mature and function 
when placed within barium alginate microcapsules (BAM) and injected intra-
peritoneally (IP) into diabetic SCID mice to normalise blood glucose levels 
(BGL) for at least six months. Similarly, allotransplantation of barium alginate 
encapsulated mouse insulin-producing cells into diabetic BALB/c mice 
results in long-term normalisation of BGL. However, xenotransplantation of 
microencapsulated FP ICCs into immunocompetent mice does not produce 
such promising results.
Aims: To investigate strategies to overcome the xenogeneic immune response 
and following this, to characterise the nature of the xenogeneic immune 
response in order to adopt more specifi c strategies to promote adequate function 
of xenografts.
Methods: Incorporation of 0.3M mannitol into the microcapsule composition 
(TAM) was attempted in order to decrease the capsule pore size. A porcine 
endothelial cell line (13271) was placed within TAM capsules and transplanted 
into C57/BL6 mice (2 x 106 cells/mouse) (n = 6); mice were killed at day 7 
and cell viability and capsule overgrowth assessed. Co-encapsulation of FP 
ICCs with human mesenchymal stem cells (MSC) was also investigated due to 
the known immunoprotective properties of MSC. These were transplanted into 
C57/BL6 mice (1 x 106 FP ICCs and 1 x 106 MSC/ mouse) and were killed at 
day 7 and cell viability and capsule overgrowth assessed. FP ICCs encapsulated 
within BAM were injected IP into C57/BL6 (n = 36) mice and mice killed 
and capsules retrieved at days 1, 3, 7, 14, 21 and 30 post-transplantation (n 
= 6). Analysis of the xenogeneic immune response in this model included 
measuring FP ICC viability and insulin secretion and content, assessing 
capsule overgrowth, measuring levels of porcine chemokines by real-time RT-
PCR and measuring levels of porcine C-peptide in the mouse sera. Levels of 
murine peritoneal immune cells were measured by FACS analysis and murine 
cytokines by multi-plex ELISA.
Results: The incorporation of mannitol into the alginate capsule did not 
prevent the formation of cellular overgrowth surrounding the microcapsule. 
Similarly, co-encapsulation of FP ICCs with MSC did not result in enhanced 
graft function and prevention of capsule overgrowth. In all models, substantial 
cellular overgrowth was present from as early as 7 days post transplantation. 
It was further shown that insulin secretion and content and levels of porcine 
C-peptide decreased from 1 day post-transplantation of FP ICCs encapsulated 
within BAM. Increased levels of the porcine chemokines IL-8, MIP-1a, 
HMGB1 and HSP90 co-incided with increased capsule overgrowth at day 14 
post-transplantation.
Conclusion: Microencapsulation alone is not suffi cient to overcome the 
xenogeneic immune response. Further strategies must be developed and required 
to be used in conjunction with microencapsulation such as manipulation of 
capsule composition and/or transient immunosuppression.
POSTER BOARD NUMBER P3 – 442
PROLONGED SURVIVAL OF MICROENCAPSULATED 581 
NEONATAL PORCINE ISLET XENOGRAFTS IN IMMUNE-
COMPETENT MICE WITHOUT ANTI-REJECTION THERAPY 
–IN VITRO CO-CULTURE WITH BONE MARROW AND 
SERTOLI CELLS
H. Arefanian, D. Mok, K. Winton, R.V. Rajotte, G.S. Korbutt, G.R. Rayat
Alberta Diabetes Institute, Department of Surgery, University of Alberta
Background: Neonatal porcine islets (NPI) are an attractive alternative 
source of insulin-producing cells for transplantation into patients with type 
1 diabetes mellitus (T1DM). However, these islets could not immediately 
reverse hyperglycemia in diabetic recipients due to their immature nature and 
they are acutely rejected in diabetic recipients not receiving anti-rejection 
therapy. Bone marrow and Sertoli cells could potentially enhance the survival 
and function of NPI by providing growth factors and local immunoprotection 
to NPI. Our objective therefore was to assess whether in vitro co-culture of 
microencapsulated NPI with homologous bone marrow and Sertoli cells 
could accelerate the maturation and prolong the survival of NPI in diabetic 
recipients.
Method: NPI, bone marrow and Sertoli cells were isolated from 1-3 day old 
Landrace-Yorkshire pigs. After 7 days of culture, NPI were placed in alginate 
microcapsules and were cultured in HAM’s F10 media supplemented with 
10% newborn pig serum alone, or in tissue culture plates with a monolayer of 
bone marrow and/or Sertoli cells for 50 days with media changes every other 
day. After 50 days of culture, 2000 microencapsulated NPI were transplanted 
into the peritoneum of streptozotocin-induced diabetic (≥;25 mml/L) immune-
defi cient NOD.SCID and immune-competent BALB/c mice. Blood glucose 
levels of recipient mice were monitored for 100 days post-transplantation 
to assess graft function and grafts were considered functioning when blood 
glucose levels decrease to 10 mmol/L.
Results: Transplantation of microencapsulated NPI into diabetic immune-
defi cient NOD.SCID or immune-competent BALB/c mice resulted in the 
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immediate reversal of hyperglycemia within 2 days post-transplantation. 
However, NOD.SCID mouse recipients of microencapsulated NPI cultured 
in HAM’s F10 media alone or with a monolayer of Sertoli cells showed 
a gradual increase in blood glucose levels (from 11.0±0.2 to 16.1±0.2 
mmol/L and 11.7±0.1 to 14.2± mmol/L, respectively) beginning at 72 and 
86 days post-transplantation, respectively. NOD.SCID mouse recipients 
of microencapsulated NPI co-cultured with a monolayer of bone marrow 
alone or with Sertoli cells remained normoglycemic at 100 days post-
transplantation. Similarly, all immune-competent BALB/c mouse recipients 
of microencapsulated NPI co-cultured with a monolayer of Sertoli cells 
alone or with bone marrow displayed long-term graft survival (40 days and 
68 days post-transplantation, respectively) without administration of anti-
rejection therapy. In contrast, BALB/c recipients of microencapsulated NPI 
cultured in HAM’s F10 alone or with a monolayer of bone marrow had graft 
survival of 25 and 28 days post-transplantation indicating rejection of the 
NPI grafts.
Conclusion: Collectively, our results indicate that in vitro co-culture of 
microencapsulated NPI with bone marrow and Sertoli cells is benefi cial to the 
maintenance of long-term function of NPI in vivo. Further research is required 
to explore the potential of this strategy in preserving the function of NPI 
xenografts in immune-competent recipients.
POSTER BOARD NUMBER P3 – 443
TRANSPARENT IMMUNOISOLATIVE 582 
MICROCONTAINERS FOR XENOTRANSPLANTATION
B. Gimi1,2, J. Kwon2, L. Liu1, B. Vachha1, J-B. Lee2
1The University of Texas Southwestern Medical Center At Dallas, 
2University of Texas at Dallas
Xenografts can overcome the shortage of human sources of grafting, and 
have been shown to replace or alter endogenous function in a wide range of 
disease models. To date, polymer and micromachined capsules have been 
used for the immunoisolation of xenografts. However, the clinical utility of 
such encapsulation has been limited due to the inexact control over polymer 
porosity and the diffi culties in micromachining capsules that are suffi ciently 
small so as to support nutrition and oxygenation of encapsulated cells 
as well as the inability of the micromachined capsules to access various 
implant sites. To address these challenges, we have created a nanoliter-
scale cell-encapsulating microcontainer whose surface comprises nanoslots 
for immunoisolation. The microcontainers are optically transparent so as 
to facilitate image guided delivery and the evaluation of post transplant 
xenograft function.
The microcontainer was fabricated from transparent SU-8 photoresist using 
photolithography, comprising a hollow 200 x 200 x 200 micron cubic base, 
and a lid. Thin SU-8 islands were recessed within the lid and milled with 25 
nm nanoslots using focused ion beam milling so as to exclude large immune 
complement compounds. MCF7-Luc-GFP human breast cancer cells were 
loaded in the microcontainer base in the fl uid phase using a syringe and a 30 
Ga needle, and the microcontainer was closed with the nanoporous lid. Two 
microcontainers were implanted subcutaneously and proximally in nude mice, 
followed by fl uorescence imaging immediately thereafter.
Cells within the microcontainer were viable for 1 d as evidenced by 
fl uorescence imaging of the GFP cells, providing preliminary evidence of 
the feasibility of our approach for encapsulated cell therapy. Additionally it 
was possible to detect fl uorescence signal from the implantation site of the 
microcontainers. Microcontainer transparency facilitated the evaluation of 
cell viability and function and may be useful for image-guided implantation. 
The small size of our microcontainers combined with the ability to generate 
numerous nanoslots on its surfaces ensures suffi cient oxygenation and 
nutrition for the encapsulated cells while providing graft immunoisolation. 
The 8 nl microcontainers can be easily deployed through the vasculature to 
various locations within the body. The parallel lithography process resulted 
in several microcontainers from a single process run; no mechanical breach 
of the microcontainers was observed through the entire experimental 
process.
Ongoing studies are expected to ascertain the optimal porosity that supports 
immunoisolation and encapsulated-cell survival and function.
POSTER BOARD NUMBER P3 – 444
MEASURING OXYGEN CONSUMPTION AS A 583 
PREDICTOR OF ISLET CELL POTENCY PRIOR TO 
TRANSPLANTATION
A. Pepper1
1Multi Organ Transplantation Program, LHSC, 2University of Western 
Ontario, 3Robarts Research Institute
Diabetes Mellitus is steadily becoming an epidemic not only in North America 
but worldwide. Currently, only treatments are available for this continuously 
growing disease, which still results in patients suffering from both microvascular 
and macrovascular complications. However, the fi eld of islet transplantation 
seems to offer hope of curing type 1 diabetes. One of the major barriers to 
successful islet transplantation is the pre-transplant viability assessment of the 
isolated cells. Currently, there is no consensus on how to determine which islet 
preparations are able to effectively reverse diabetes based on pre-transplant 
metabolic function measurements. Presently, FDA protocol requires athymic 
nude mouse bioassays for clinical islet transplants; however this assay is 
costly, technically demanding and retrospective. Thus, we wish to explore the 
hypothesis that O2 consumption rates (OCR) will serve as a pre-transplant 
assessment of the metabolic potency of the islet isolation. By measuring 
the Fractional Viability or FV (O2 consumption rates standardized to DNA 
quantity) we have been able to develop a means to determine which preparations 
of adult pig islets should be transplanted based on this value. Our preliminary 
data shows that adult pig islets that have a FV over 300 nmol/min-mgDNA are 
able to restore euglycemia in diabetic nude mice. Similarly, human islets with 
a FV of greater that 1000 nmol/min-mgDNA are effective in reversing diabetes 
in nude mice as well. By measuring the FV of our islet preparations in culture, 
we have been able to conclude that the islets’ mitochondrial capacity and thus 
viability signifi cantly increases during a twenty-two day culture period. To 
validate this fi nding we transplanted nude mice with adult pig islets cultured for 
2 (n=4), 8(n=4), 15(n=4) and 22(n=3) days respectively. Our fi ndings suggest 
that pre-transplant culture selects highly viable porcine islets, resulting in an 
increase reversal rate and more immediate normoglycemia response. We are 
confi dent based on our future data regarding human and porcine islets, that we 
can develop OCR thresholds which will allow the determination of which islet 
preparation is most desirable for transplantation. Furthermore, it is anticipated 
that the data we collect will lead to the development of a pre-transplant islet 
potency protocol which will defi nitively assess which islet preparations will 
reverse diabetes and will restore glycemic control in Type 1 diabetic patients.
POSTER BOARD NUMBER P3 – 445
ADULT PORCINE SERTOLI CELLS SUPPRESS THE 584 
XENOGRAFT RESPONSES TO PORCINE ISLETS IN RATS 
MORE EFFECTIVELY THAN NEONATAL SERTOLI CELLS
D. White1,2, L. Copeman1, J. Melling1,2, C. Hasilo2
1University of Western Ontario, 2London Health Sciences Centre
Purpose: This study was designed to evaluate the humoral immune responses 
to xenotransplants of neonatal porcine islets, Sertoli cells or a mixture of these 
two cell types in the rat. A comparison of the immune responses generated 
when adult Sertoli cells were used in place of neonatal Sertoli was also done.
Methods: Female Lewis rats were transplanted with 400,000 neonatal or adult 
porcine Sertoli cells, 2000 neonatal porcine islet equivalents or a mixture of 
these two cell types. Transplants were done either under the kidney capsule 
or into neovascularized subcutaneous autologous collagen pouches that had 
been previously created by implanting polypropylene mesh chambers with 
central Tefl on rods 4 weeks pretransplant. No immunosuppression was given 
at any time to the recipient animals. Weekly serum samples were collected for 
5 weeks and rat anti-pig IgG responses were measured using fl ow cytometry. 
All test sample fl uorescence measurements were compared to a control serum 
and data analysed as a ratio of maximum fl uorescence of the test sample to 
maximum fl uorescence of the control.
Results: There was no signifi cant difference in the rat anti-pig IgG response 
when islets were transplanted into collagen pouches compared to under the 
kidney capsule (peak immune response ratio (pirr) kidney 4.758±1.523 vs pirr 
pouch 4.089±0.654). There was a signifi cant decrease in this immune response 
when neonatal Sertoli cells were transplanted into these two locations (pirr 
kidney 5.375±0.874 vs pir pouch 1.151±0.783, p<0.01). Cotransplanting 
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neonatal Sertoli cells with islets into collagen pouches did decrease the 
generated immune response compared to transplanting islets alone however 
this decrease failed to achieve statistical signifi cance (pirr neonatal Sertoli 
cells+islets 2.158±1.137). Rats transplanted with adult Sertoli cells alone 
into collagen pouches failed to generate a measurable immune response 
compared to their pretransplant levels (pretransplant ratio 0.049±0.011 vs pirr 
0.0536±0.009). When adult porcine Sertoli cells were cotransplanted with 
islets they were able to signifi cantly decrease the generated immune response 
compared with cotransplantation with neonatal Sertoli cells (pirr adult Sertoli 
cells + islets 0.244± 0.139, p<0.0001). Grafts survive and produce insulin for 
at least 126 days post transplant.
Conclusion: In the rat, transplanting porcine Sertoli cells into subcutaneous 
autologous collagen pouches results in a decrease in the amount of anti-pig 
IgG compared to transplanting under the kidney capsule. Adult porcine Sertoli 
cells elicit no immune response when they are transplanted into collagen 
pouches. Further, the immune response to porcine islets transplanted into 
collagen pouches is signifi cantly decreased when adult porcine Sertoli cells are 
cotransplanted. Studies of cotransplanting adult porcine Sertoli cells and islets 
in diabetic rats are in progress
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THE WESTRAN PIG: AN IDEAL AND SAFE DONOR 585 
SOURCE FOR XENOTRANSPLANTATION
D.M. Simond1, Kelly Moyle1, Chris Moran2, Olga Gargavenko3, 
P.J. O’Connell1, W.J. Hawthorne1
1The Centre for Transplant & Renal Research, Westmead Millennium 
Institute, Westmead, 2Centre for Advanced Technologies in Animal Genetics 
and Reproduction, University of Sydney, 3Living Cell Technologies, Virology 
Laboratory, Hunters Corner, New Zealand
Aims: Inbred lines of minipig are possible donor sources for xenogenic 
tissues and cells. However, the threat of Porcine Endogenous Retrovirus 
(PERV) has raised concerns regarding the safety of xenotransplant therapies. 
The Westran pig is a highly-inbred line with well charcterised features, 
included a PERV burden, level of inbreeding and SLA homozygosity. To 
further these fi ndings, a thorough study of the xenozoonotic potential of the 
Westran pig was conducted for evidence of both in vitro and in vivo PERV 
transmission, the presence of potentially zoonotic viruses and assessment of 
PERV-C in the line. PERV-C has been implicated in the generation of human-
tropic replication-competent PERV and as such should be absent in a line of 
pigs used for human donor organs.
Methods: Stimulated and lethally irradiated Westran neonatal islet cell clusters 
(NICCs) and peripheral blood mononuclear cells (PBMCs), and plasma were 
co-cultured for a period of 24 weeks with the susceptible HEK293 cell line. 
Retroviral release was assessed by C-type-RT activity and DNA and RNA 
assessed weekly for evidence of productive infection in the presence or 
absence of microchimerism. In vivo transmission of PERV from Westran 
ICCs was assessed through the transplantation of 13 SCID mice for periods of 
30-120 days. Infection in the absence of microchimerism was then assessed in 
DNA and RNA of the transplanted mice. Expression of PERV in Westran and 
commercial pig ICCs was detected by quantitative RT-PCR. PERV-C analysis 
was conducted in parallel with PERV-A and B in Westran pig herd, representing 
11 generations from the founding pair. Five suggested xenozoonotic exogenous 
viruses; Pig cytomegalovirus (PCMV), Pig lymphotropic herpesvirus (PLHV), 
Encephalomyocarditis (EMCV), Pig circovirus (PCV type2) and Hepatitis E 
virus (HEV) were evaluated.
Results: The stimulation of the Westran NICCs and PBMCs resulted in no 
increase in RT activity and no productive infection was detected at any point 
in the co-cultures of NICCs, PBMCs or plasma. No in vivo transmission, in 
the absence of microchimerism, was detected in any SCID transplanted with 
Westran NICCs irrespective of graft duration. The level of PERV expression in 
Westran NICCs was consistently lower than in NICCs from a commercial herd. 
PERV-C was identifi ed to be segregating in the early generations of the Westran 
line, however the pair selected for establishment of a core line at generation 
six were PERV-C “null”. As a result, all subsequent animals have been free 
of the PERV-C envelope insert. Only PCV type2 was detected in the Westran. 
Subsequent analysis has shown the incidence of the virus to be decreasing in 
the herd.
Conclusions: Fortuitous decisions regarding selection of breeder has resulted 
in the Westran pigs being free of PERV C. Hence, the Westran pig provides a 
xenozoonotic herd that can be considered safe as a donor source of cells and 
tissues for clinical xenotransplantation and suggests that it is possible to reduce 
the risk of PERV infection through breeding..
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ANALYSIS OF TRANSMEMBRANE FORM OF 586 
COMPLEMENT REGULATORY PROTEINS SHOULD BE 
EXPRESSED IN TRANSGENIC PIGS TO AVOID PERV 
INFECTION
S. Miyagawa1, E. Okura1, M. Okumura1, M. Okabe2, A. Ishimaru1, 
S. Nakatsu1, C. Kobayashi1, M. Fukuzawa1,
1Osaka University Graduate School of Medicine, 2Research Institute for 
Microbial Diseases, Osaka University
Transgenic pigs genetically engineered to overcome hyperacute rejection 
following xenotransplantation via expression of human complement 
regulatory proteins (CRP), such as DAF (CD55), have been produced by 
many Institutes. However, it is possible that the pig endogenous retrovirus 
(PERV) from transgenic pigs with CRP might become resistant to human 
serum, as the graft acquires resistance due to viral particles produced from 
the transgenic pig cell wall that express human CRP. In this study, we 
investigated the effect of CRP on PERV neutralization and/or lysis by human 
sera and formulated a new approach to avoid PERV that involves expression 
of human CRP on PERV.
Methods: cDNAs corresponding to human DAFs were prepared as follows: 
delta-short consensus repeat (SCR) 1 DAF (phosphatidylinositol (PI)-anchor), 
and delta-SCR2 DAF (PI-anchor). The following transmembrane (TM) domains 
were also constructed: HLA-G, modifi ed infl uenza A virus hemaggulutinin 
(HA), and MCP (delta-CYT form).
The PEC line was transduced by pseudotype infection with the LacZ gene and 
the packaging signal of the murine leukemia virus (MuLV) under control of the 
long terminal repeat of MuLV. The PEC lines were further infected with PERV 
subtype B (PERV-B) to investigate PERV infectivity using a Lac Z pseudo-
type assay.
The cDNAs of modifi ed DAFs were then transfected into the PEC/PERV-
B(Lac Z) lines using lipofection. Expression of each DAF on the cell 
surface was verifi ed by FACS analysis. Complement-dependent PEC lysis 
was used to verify the complement regulatory function of the expressed 
DAF. HEK293 cells were incubated with PEC culture supernatants with 
or without human sera. The inoculated HEK293cells were stained for 
histochemical analysis and the LacZ-positive blue foci were counted. The 
rate of reduction in LacZ-positive cells following serum addition was then 
calculated.
Results: I. While PERV from delta-SCR 2 DAF (without CRP function) 
was not resistant to human serum, PERV from delta-SCR1 DAF (with CRP 
function) showed a signifi cant increase in resistance.
II. The DAF-blocking antibody assay indicated that PERV from the DAF 
transfectants expressed DAF molecules on the surface of the retrovirus.
III. Inhibition of complement-dependent cell lysis was determined for each 
PEC/PERV-B(Lac Z) line with TM-type DAF.
IV. While delta-SCR1 DAF (PI-anchor form) signifi cantly inhibited the 
reduction in Lac Z-positive cells following treatment with human serum, the 
reduction in Lac Z-positive cells after exposure to human serum was inhibited 
to a lesser degree by transmembrane (TM)-types of DAF: DAF-TM of HLA-G, 
DAF-TM of modifi ed HA, and DAF-TM of MCP [delta-SCR1 DAF >> HLA-G 
> HA ¦ † CYT].
Conclusion: Induction of PERV resistance to human serum depends on the 
form of the CRP tail. CRP/TM hybrids that do not associate with lipid rafts are 
suitable for gene transduction
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KNOCK DOWN OF TREG FUNCTION GENE 587 
EXPRESSION BY SIRNA RESULTS IN REDUCED 
SUPPRESSIVE POTENCY OF HUMAN TREG ON PORCINE 
XENOGENEIC EFFECTOR T CELLS IN VITRO
L. Sun, S. Yi, J. Wu, P. O’Connell
CTRR Westmead Hospital
Background: Expanded human CD4+CD25+ T regulatory cells (Treg) are 
capable of suppressing T cell-mediated porcine xenogeneic immune response 
in vitro and this suppression was associated with upregulated expression of 
Foxp3 and IL-10 in Treg. In this study RNAi technology was used to identify 
the importance of the Treg function genes, Foxp3 and IL-10, in the human Treg 
suppressive effect on the human to porcine xenogeneic effector T cell response 
in vitro.
Methods: Expanded human Treg were transfected with small interfering RNA 
(siRNA) targeting Foxp3 and IL-10 genes, respectively by lipofectamine 2000. 
The transfection effi ciency, and the level of corresponding gene and protein 
expression were measured by fl uorescent microscopy, FACS, real-time PCR 
and Western-blotting. The siRNA transfected Treg were then cocultured with 
porcine PBMC-stimulated human CD4+CD25- T cells for 4 days. After co-
culture, proliferation and xeno-cytotoxicity of porcine xenogeneic human 
CD4+CD25- T cells were examined by WST-1 and Annexin V binding assay, 
respectively.
Results: A 60% transfection effi ciency in expanded Treg was achieved for the 
both the Foxp3 and IL-10 siRNAs. Real-time PCR revealed a 63.4% reduction 
in specifi c mRNA by siRNA targeting of Foxp3 genes in Treg compared to 
control transfections. When Foxp3 siRNA transfected Treg were added to 
human CD4+CD25- T cells there was a corresponding 55% reduction in the 
suppression potency in response to porcine xenogeneic stimulation, when 
compared to control transfected cells. Following transfection with IL-10-
siRNA, the mRNA was reduced by 61% and the suppression potency of the 
Treg was reduced by 43.7% when compared to the negative control. Thus 
the suppression potency of Treg was reduced after transfection with siRNA 
for Foxp3 or IL-10 when compared with Treg cells transfected with control 
siRNA.
Conclusion: Our results demonstrate that Foxp3 and IL-10 are important in the 
Treg-mediated suppression on porcine xenogeneic effector T cells in vitro.
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INTRA- AND EXTRACELLULAR REMODELING 588 
EFFECTIVELY PREVENT HUMAN CD8+ CTL-MEDIATED 
XENOCYTOTOXICITY BY COEXPRESSION OF MEMBRANE-
BOUND HUMAN FASL AND PIG C-FLIPL 
IN PIG ENDOTHELIAL CELLS
M. Tanemura1,3, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1, 
T. Nishida1, Y. Sawa1,2, T, Ito1
1Department of Surgery, Osaka University Graduate School of Medicine, 
2Medical Center for Translational Research, Osaka University Hospital, 
Objectives: Overcoming cell-mediated immunity, especially of human CD8+ 
CTLs, is important for the success of long-term xenograft survival. Our 
previous studies have reported that the cytotoxicity of human CD8+ CTLs 
against pig endothelial cells (PEC) is highly detrimental and mediated in 
major part by the Fas/FasL apoptotic pathway. To inhibit this strong CTL 
killing, we have exploited the weapon by extracellular overxepression of a 
membrane-bound human FasL that carries a deletion at the metalloproteinase 
clearvage site. In addition, wa have demonstrated that intercellular 
overexpression of pig c-FLIPlong (c-FLIPL), which are potent inhibitor of death 
receptor-mediated pro-apoptotic signals, by virtue of blocking the signaling 
pathway more upstream (before caspase-8 activation and release) can protect 
PEC from human CTL-mediated killing. In the present study, we investigated 
the cooperating effects of double remodeling of these molecules to prevent 
CD8+ CTL-mediated xenocytotoxicity.
Materials and methods: Gene construction: cDNA encording the membrane-
bound human FasL, which cannot be cleaved with metalloproteinase, was 
subcloned into the site of pEF-BOS expression vector, which carried the 
promoter of the human elongation factor 1α chromosomal gene. cDNA of 
pig c-FLIPL was subcloned into the EcoRI site of pCR3.1 expression vector, 
which carried a CMV promoter. Gene expression: 20 μg of each plasmid were 
cotransfected into PEC line by lipofection. The expression of membrane-bound 
human FasL on PEC surface was assessed by FACS analysis. The protein 
expression of pig c-FLIPL was detected by Western blot analysis. Protein 
expression levels of pig c-FLIPL in PEC transfectants were quantifi ed by Fluor-
chem image analyzer as expressed by arbitary units. Preparation of human 
CD8+ CTLs: 10 to 15 X 106 cells of separated PBMCs were cocultured for 14 
days with irradiated PEC in the presence of 50 U/ml recombinant human IL-2. 
Subsequently, CD8+ CTLs were positively isolated by magnetic beads and 
subjected to in vitro cytotoxicity assay as effector cells. In vitro cytotoxicity 
assay: The cytotoxicity of human CTLs was assessed by 51Cr release assay, 
employing parental PEC and PEC transfectants as target cells.
Results: Two single positive clones were isolated as follows: one had high 
expression of FasL and other one is high expression clone of c-FLIPL. Three 
double positive clones were established. The amelioration of CTL killing 
against these PEC transfectants was subsequently assessed by comparison 
with parental PEC, single positive and double positive PEC transfectants. The 
results are summarized in the table.
Cells
Protein expression in 
PEC transfectants
% cytotoxicity by 51Cr 
release assay (mean ± SD) 
membrane-bound 
FasL 
(Mean 
fl uorescence 
intensity)
c-FLIPL 
(Arbitaly units)
E/T 
ratio=50:1
E/T 
ratio=25:1
E/T 
ratio=12.5:1
Parental PEC not detected 6312(endogenous) 87.5±7.5 67.7±7.2 50.4±5.8
PEC-FasL 
(single, high) 127 5669(endogenous) 31.8±4.2 21.6±3.2 12.5±5.3
PEC-FLIPL 
(single, high) not detected 29166 23.6±1.2 22.6±1.7 17.1±5.7
Double1 :Fas L (high) 
+ FLIPL (low)
80.6 11649 55.2±7.5 33.2±3.5 18.4±5.5
Double2 :FasL (low)
+ FLIPL (middle)
33.1 19429 63.5±8.1 42.1±6.4 28.4±5.4
Double3 :FasL (middle) 
+FLIPL (middle)
62.0 16595 42.2±1.6 26.7±3.0 13.7±6.4
Conclusions: The double remodeling with the overexpression of both 
membrane-bound human FasL and c-FLIPL in xenograft cells effectively avoid 
innate cellular responses against xenografts.
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IN VIVO CONTROLLING OF CELLULAR RESPONSE 589 
TO PIG ISLET XENOGRAFTS BY ADENOVIRUS-MEDIATED 
EXPRESSION OF EITHER MEMBRANE-BOUND HUMAN FASL 
OR HUMAN DECOY FAS
K. Kawamoto1, M. Tanemura1, A. Saga1, H. Komoda1,2, Y. Fumimoto1, 
T. Deguchi1, T. Machida1, Y. Sawa1,2, T. Nishida1, T. Ito1
1Department of Surgery, Osaka University Graduate School of Medicine, 
2Medical Center for Translational Research, Osaka University Hospital
Objectives: Xenotransplantation of pig islets is a potential solution to the 
shortage of human donor islets for the patients with type 1 diabetes. However, 
pig islets may be rejected by cellular immune response, including CD4+ T cells, 
CD8+ CTLs, macrophages, and NK cells. Our previous studies demonstrated 
that human CD8+ CTLs are highly detrimental to pig islets and that adenovirus-
mediated transduction with both membrane-bound human FasL (mFasL), 
which carries a deletion at the metalloprotease cleavage site, and human decoy 
Fas antigen (decoy Fas), which lacks a death domain in its cytoplasmic region, 
in pig islets effectively prevented human CD8+ CTL killing in an in vitro assay. 
In this study, we assess the in vivo effectiveness of pig islets expressing these 
molecules, employing a pig-to-rat xenotransplant model.
Materials and methods: Gene construction: cDNA encoding decoy Fas 
was cloned into an expression plasmid containing CMV promoter, internal 
ribosome entry site 2 (IRES2) gene, and enhanced green fl uorescent protein 
(EGFP). Subsequently, this expression unit was inserted into the adenovirus-
based cosmid pAxcwit (Takara Bio, Otsu, Japan). Similarly, cDNA encoding 
membrane-bound human FasL and the Discosoma sp red fl uorescent protein 
DsRed coding region were also subcloned into the cosmid pAxcwit. The control 
adenovirus that contain EGFP gene without the human cDNA insert, was also 
generated. The adenoviruses were amplifi ed by infection of HEK-293 cells, 
respectively. Preparation of pig islets: Adult pig pancreata were removed at a 
slaughterhouse that handles young market weight pig. Pig islets were isolated 
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by the modifi ed Ricordi’s method. Gene expression: Freshly obtained adult pig 
islets, resuspended in 500 μl serum-free HBSS, were exposed to adenovirus 
encoding either human decoy Fas or membrane-bound FasL at a MOI of 30. 
The expression of these molecules in pig islets were determined by FACS, using 
appropriate mAbs. Transplant studies: Lewis rats were purchased from Oriental 
Yeast (Tokyo, Japan). Recipient rats were rendered diabetic by intraperitoneal 
injection of streptozotocin at a dose of 60 mg/kg, 7 days prior to pig islets 
transplantation. Then the transduced pig islets were transplanted under the 
kidney capsule of recipient rats. Rats were monitored every 6 hours for blood 
glucose levels. The grafted kidney retrieved at day 3 posttransplantation was 
subjected to immunohistochemical analysis, using anti-pig insulin antibody.
Results: Transduction effi ciency and blood glucose levels of each group 
were shown in Table 1. Both decoy Fas and mFasL were effective to improve 
metabolic outcome of the recipient rats through 12 to 18 hours posttransplant 
(p<0.05). Unfortunately, blood glucose levels of each group were not 
signifi cantly different after 24 hours posttransplant.
Discussion: Transplantation of pig islets expressing either human decoy 
Fas antigen or membrane-bound human FasL effectively improved pig islet 
xenograft survival and reduced serum blood glucose levels in recipient rats. 
Therefore, the generation of transgenic pigs, overexpressing these molecules 
may control innate cellular response to islet xenografts, creating a window of 
opportunity for prolonged xenograft survival.
Table 1.
Pig islets
Mean fl uorescent 
intensity 
(Transduction 
effi ciency)
Blood glucose levels of recipients (mg/dl) Xenograft survival
12 hr 18 hr 24 hr Day 3
Parental pig islets endogenous 430.5±38.8 462.2±52.4 478.6±42.1 rejected
Mock islets Not determined 447.8±45.0 450.3±44.3 469.5±33.3 rejected
decoy Fas 
transduced islets 403 (81.4%) 186.6±18.7* 272.5±56.5* 458.3±36.9
++ 
(survived)
mFasL 
transduced islets 79.5 (79.3%) 196.4±44.3* 304.3±42.9* 490.0±38.5
++ 
(survived)
Each values are mean±SD (n=4). *; p<0.05 compared with mock.
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COMPARISON OF WHOLE BLOOD COAGULATION 590 
ASSESSMENT USING THROMBOELASTOMETRY (ROTEM®) 
BETWEEN HUMAN AND CYNOMOLGUS MONKEYS
M. Boldrin1, D. Bertini2, L. Spiezia2, S. Gavasso2, C. Radu2, F. Fante1, 
C. Bulato2, E. Ancona1,3, P. Simioni2, E. Cozzi1,3
1CORIT, 2Department of Medical and Surgical Sciences, 2nd Chair of Internal 
Medicine, University of Padua, Padua, Italy, 3Department of Surgical and 
Gastrointestinal Sciences, University of Padua, Padua, Italy
Introduction: Microvascular thrombosis, due to activation of clotting 
cascade, is a key feature of the rejection process that takes place when pig 
organs are transplanted into primates. Such coagulopathy is viewed by some 
as the real barrier to the long-term survival of porcine xenografts in this 
species combination. To date, little is known about qualitative characteristics 
of clot formation in primates as far as strength, fi rmness and swiftness are 
concerned. The present study is aimed at better understanding the differences 
in blood coagulation between primate and human using thromboelastometry 
(ROTEM®). This system appears to be an attractive tool for studying the 
simultaneous and integrated effects of different components involved in the 
dynamic process of clot formation such as plasma factors, platelets, leucocytes, 
and red blood cells.
Materials and methods: We studied ROTEM profi les in 40 (15 males and 25 
females; age range: 3-11 years) naïve cynomolgus monkeys from Mauritius, 
China and Philippines and in 52 healthy human volunteers (22 males and 30 
females; age range 20-60 years). Thromboelastometry (InTEM®, ExTEM®, 
FibTEM®, NaTEM®) was performed from whole blood with the ROTEM® 
coagulation analyser (Pentapharm, Munich, Germany). All samples were 
analysed between 1-3 hours from collection. ROTEM® profi les were observed 
for 60 minutes. Blood samples (1.2 mL) were drawn in syringes containing 1:10 
(v/v) sodium citrate 3.8%. Four standard ROTEM® assays were performed 
according to protocols supplied by manufacturer. The main parameters obtained 
were clotting time (CT) [time (in seconds) from initiation of the measurement 
until initiation of clotting]; clot formation time (CFT) [time (in seconds) from 
initiation of clotting until a clot fi rmness of 20 mm is detected]; maximum clot 
fi rmness (MCF) [the maximum amplitude (in mm) reached by the clot]; Area 
Under Curve (AUC) [the area under the velocity curve]; and Alpha (α;) angle 
[a tangent to the clotting curve through the 2 mm point]. Statistical analysis was 
performed using unpaired t-student test.
Results: Data obtained in cynomolgus monkeys were reproducible and 
consistent with the normal range observed in human healthy subjects. Some 
important differences were, however, observed in primate blood. In monkeys 
InTEM®, ExTEM®, FibTEM®, NaTEM® showed a hypercoagulable profi le 
as compared to humans. Mean CT and mean CFT were signifi cantly lower in 
primates (-25.7% and –55.5%, respectively) than in humans. MCF, α; angle 
and AUC were signifi cantly higher in primates than in humans (+23%, +21.5% 
and +32%, respectively). Similar distribution and range in human and monkey 
platelets were observed. In addition, fi brinogen levels in monkeys were lower 
than in humans (145.4 mg/dl vs. 289.9 mg/dl).
Conclusion: Primate clot formation studied by ROTEM®, a novel technology 
to study whole blood coagulation, is consistent with a higher prothrombotic 
profi le in primates as compared to humans. These differences do not appear to 
be related to higher platelet counts or fi brinogen levels in monkeys. Together 
these data suggest that, with regard to coagulation, xenotransplantation in cynos 
represent a much more diffi cult situation than xenotransplantation in humans.
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PROFILES OF GLYCOANTIGENS OF THE CELLS FROM 591 
¿-1,3GT KNOCKOUT PIG
S. Miyagawa1, S. Takeishi2, A. Ishimaru1, E. Miyoshi1, M. Fukuzawa1
1Osaka University Graduate School of Medicine, 2Gycomics Research 
Laboratory, Moritex Co.
Species differences in glycoantigens are major obstacles to xenotransplantation. 
Even after creation of the ƒ¿1,3 galactosyltransferase (GT) gene-knockout pig 
(KO-pig), most non-Gal antigens remain on the surface of pig cells. However, 
changes in glycoantigens of the KO-pig have not been thoroughly evaluated.
In this study, endothelial cells (EC) from KO-pigs were subjected to lectin blot 
analysis, including a survey of non-Gal glycoantigens. The results were then 
compared to those obtained for EC from wild-type pigs and human EC.
Methods: First, species differences between human and pig EC glycoantigens 
were examined. Next, the differences between wild-type and knockout pig EC 
glycoantigens were studied.
The following EC were studied: ƒ¿-Gal knockout (heterozygous and homozygous); 
the ƒ¿-Gal homozygous knockout plus N-acetylglucosaminyltransferase-III 
(GnT-III) transgenic; wild-type obtained from siblings of knockout animals; 
and, human EC from HUVEC (Health Science Research Resources Bank, 
Osaka) & HAOEC (AGC Techno Glass CO.,LTD.). Cells were cultured in 
a gelatin-coated dish for several days. After centrifugation at 14,000G for 5 
min, proteins in the supernatant were labeled with Cy3, applied to the lectin 
array, scanned with an SC Profi ler, and analyzed with an Array Pro Analyzer 
(Moritex, Yokohama, Japan).
More than 40 different lectins were used in this analysis, including GSI-B4, 
GSI-A4, GSIL-II, UEA-I, BPL, WFA, HPA, SBA, etc.
Results: 
1.  In the comparison between human and pig EC, pig EC exhibited stronger 
signals for SBA, HPA, WFA, GSI-B4 and GSI-A4, while human EC showed 
strong signals for UEA-1, MAL and ECA. Expression of ƒ¿1,2 fucose and 
ƒ¿2,3 sialic acid are greater on human EC compared with pig EC. In constrast, 
pig EC expressed high levels of both ƒ¿-Gal and terminal GalNAc.
2.  A signal for GSI-B4 was observed in human EC, but signals for EEL were 
not detected. These data indicate that the GSI-B4 signals observed in human 
EC arise from ƒÀ-Gal expression.
3.  EC from the KO-pig not only lost the GSI-B4 and GSI-A4 signals, but 
expressed lower levels of SBA, HPA and BPL. Of note, EC from the KO-pig 
had lower expression of terminal GalNAc, GalƒÀ1, 3GalNAc.
4.  In contrast, SNA, SSA, and TJA-I were upregulated on EC from the KO-pig 
compared with wild-type EC, suggesting higher expression of ƒ¿2,6Sia.
Conclusion: EC from the KO-pig vanished ƒ¿-Gal, and reduced terminal 
ƒ¿-GalNAc. However, expression of both 2,3 and 2,6 sialic acid were 
upregulated.
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EXPERIMENTAL SMALL BOWEL PRESERVATION 592 
USING PACAP-38 CONTAINING UNIVERSITY OF WISCONSIN 
SOLUTION
D. Reglodi2, A. Ferencz1, B. Racz1, A. Tamas2, J. Nemeth4, K. Nedvig1, 
K. Kalmar-Nagy3, O.P. Horvath3, G. Weber1, E. Roth1
1University of Pecs, Medical School, Department of Surgical Research And 
Techniques, 2University of Pecs, Medical School, Department of Anatomy, 
3University of Pecs, Medical School, Surgical Clinic, 4University of Debrecen, 
Department of Pharmacology And Pharmacotherapy
The deleterious effects of cold ischemia and reperfusion are major problems 
that affect clinical outcomes after intestinal transplantation. Despite its 
overall acceptance as the fi rst choice for organs, UW is unable to effective 
preserve the bowel grafts. Pituitary adenylate cyclase-activating polypeptide 
(PACAP) was originally isolated from ovine hypothalamic extracts. High 
level of endogenous PACAP-38 can be detected in the intestine. The aims 
of this study were to examine changes on endogenous PACAP values in 
intestinal I/R model, and the effi cacy of exogenous PACAP-38 on the 
oxidative stress and tissue damage induced by small bowel cold preservation 
and autotransplantation.
Intestinal ischemia/reperfusion (I/R) and autotransplanted groups were 
established in Wistar rats (n=60). In I/R groups 1 hour (Group A), 2 hours 
(Group B), and 3 hours (Group C) ischemia followed by 3 hours of 
reperfusion was applied. In autotransplanted groups total orthotopic intestinal 
autotransplantation was performed. Grafts were preserved in University of 
Wisconsin (UW) solution for 1 (GI), 2 (GII), 3 (GIII), and 6 (GIV) hours and in 
UW containing 30 ug PACAP-38 for 1 (GV), 2 (GVI), 3 (GVII), and 6 (GVIII) 
hours. Reperfusion lasted 3 hours in all groups. Endogenous PACAP-38 
concentration was measured by radioimmunoassay. To determine oxidative 
stress parameters malondialdehyde (MDA), reduced glutathione (GSH), and 
superoxide dismutase (SOD) were measured in tissue samples. Tissue damage 
was analyzed by qualitative (Park¡¦s classifi cation) and quantitative (software 
Scion Image) methods on hematoxylin/eosin-stained sections. The level of 
signifi cance was set at p<0.05.
Concentration of endogenous PACAP-38 decreased during I/R compared to 
sham. It was signifi cant in Group B and C by the end of the reperfusion 
periods. Value of tissue MDA increased in GI-GIV. Signifi cant difference 
was between GIV and GVIII (GIV: 128.2„b3.1; GVIII: 112.0„b2.1 
uM/g). In GSH content signifi cant different was between GIV and GVIII 
(GIV: 289.7„b10.9; GVIII: 328.1„b11.8 uM/g). SOD activity decreased 
signifi cantly in GII and GIV. Better preservation of SOD was observed in 
GV-VIII (GVIII: 205.1„b13.4 IU/g). According to Park¡¦s classifi cation, the 
highest grade of injury was observed in GIV (grade 5), whereas the lowest 
grade of injury was found in GV (grade 0). In GI and GII histological 
fi ndings were corresponding to an injury grade 2, showing minor clefting 
with the villus epithelium adjacent to the crypts intact. In GIII the injury was 
grade 3 characterized by massive epithelial lifting and villus tip denudation. 
In GIV the injury showed denuded villi, decellularization of lamina propria 
and crypts. By contrast, in GV-VIII PACAP-38 ameliorated injury by the 
end of reperfusion periods. Scion Image quantitative analysis has supported 
these observations.
This is the fi rst report demonstrating changes on endogenous PACAP-38 
values in intestinal I/R model, and the effi cacy of exogenous PACAP-38 on the 
oxidative stress and tissue damage induced by intestinal autotransplantation. 
PACAP-38-treatment exhibited a quality of intestinal preservation superior 
to current clinical standard UW storage. The experimental setting used in our 
study has several advantages to assess the quality of intestinal preservation.
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TNF ALPHA INHIBITORS REDUCE THE 593 
INFLAMMATORY RESPONSE TO I/R INJURY IN A RAT 
INTESTINAL TRANSPLANT MODEL
S. Kohler, G. Atanasov, U. Gerlach, A. Reutzle-Selke, P. Neuhaus, 
J. Pratschke, A. Pascher
Surgery, Charité, Campus Virchow Clinic
Introduction: Ischemia/reperfusion injury is one of the major problems in 
intestinal transplantation. We have evaluated the effi cacy of TNF alpha inhibitors 
to mitigate ischemia-/reperfusion injury in a rat small bowel transplant model.
Materials and methods: Small bowel transplantation was performed as an 
orthotopic isogenic transplantation model in female Lewis rats. The graft 
was fl ushed with UW and stored for 6 hours at 4°C before implantation. 
There was no further treatment in the controls (C). The TNF-inhibitor groups 
either received pentoxifylline (P) (25 mg/kg bw i.p., prereperf., PODs 1-5) or 
etanercept (E) (1 mg/kg bw s.c.; prereperf., PODs 1,3,5,7). Tissue samples of 
the proximal and distal small bowel were taken 20min, 12hrs, 7d, and 6mth 
after reperfusion (each n=6 per time point and group) for histopathology 
(HE) and immunohistology (CD4,CD8,CD25,ED1,ZO-1,HSP70). Samples 
of the lung were stained for MPO. Statistics: multifactorial analysis/two-way 
ANOVA, Bonferroni post-test.
Results: 7day- survival in the control group was 54,5%. TNF alpha inhibition 
improved 7day-survival to 63,2% in the P treated group and to 66,7% in the group 
treated with E, both without statistical signifi cance. Survival beyond POD 7 was 
100% in all groups. TNF alpha inhibition decreased I/R mediated infl ammatory 
response in both treatment groups signifi cantly: immunohistologically assessed 
graft and lymph node infi ltration of CD4(+), CD8(+), and CD25(+)-T-cells, as 
well as macrophages (see selected data in table1), and MPO stain of the lung 
displayed signifi cant reduction of infl ammation over the whole observation 
period. No signifi cant differences could be found between both treatment 
groups. However, graft damage and cellular infi ltrates were signifi cantly 
enhanced in tissue of distal portions vs. proximal portions of the graft in all 
groups. This difference even persisted after TNF alpha inhibition, however, 
was reduced markedly (selected data table1).
Table 1: 
Control Etanercept (p-value) Pentoxifylline (p-value)
Cells/viewing fi eld (VF) Cells/VF Cells/VF
CD 25
Proximal
20 minutes 1.568 0.623 (<0.05) 0.413 (<0.01)
12 hours 2.216 0.837 (<0.001) 0.315 (<0.001)
7 days 1.693 0.468 (<0.01) 0.460 (<0.01)
6 months 0.688 0.257 (>0.05) 0.103 (>0.05)
Distal 20 minutes 5.165 1.086 (<0.001) 0.597 (<0.001)
12 hours 4.406 2.367 (>0.05) 0.685 (<0.001)
7 days 4.383 1.998 (>0.05) 0.955 (<0.05)
6 months 4.660 0.957 (<0.01) 0.328 (<0.001)
ED 1
Proximal
20 minutes 32.89 24.39 (<0.01) 20.45 (<0.001)
12 hours 42.54 22.63 (<0.001) 22.20 (<0.001)
7 days 37.80 18.79 (<0.001) 23.34 (<0.001)
6 months 41.23 45.58 (>0.05) 46.89 (>0.05)
Distal 20 minutes 53.90 35.69 (<0.001) 34.52 (<0.001)
12 hours 54.81 36.89 (<0.001) 32.28 (<0.001)
7 days 63.46 29.61 (<0.001) 27.35 (<0.001)
6 months 84.13 66.48 (<0.001) 55.31 (<0.001)
Discussion: I/R mediated infl ammatory response after rat intestinal 
transplantation is signifi cantly reduced by TNF alpha inhibitors with regard to 
short-term as well as long-term graft outcome. The distal portions of the grafts 
were effected more severely by I/R injury. The presented fi ndings may help to 
ameliorate initial graft injury after I/R, which is believed to exert long-term 
effects on graft outcome by activating innate immunity, thus contributing to 
chronic allograft enteropathy.
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EXPERIMENTAL SMALL BOWEL TRANSPLANTATION 594 
FROM NON HEART BEATING DONORS (NHBD): 
A LARGE ANIMAL STUDY
M. Alessiani1, L. Cobianchi1, S. Zonta1, R. Ciccocioppo3, T. Dominioni1, 
J. Viganò1, C. Filisetti1, E. Vicini1, A. Bottazzi2
1University of Pavia, Department of Surgery, IRCCS Fondazione Policlinico 
San Matteo, 2Anestesia and intensive care unit, IRCCS Policlinico San 
Matteo, 3Department of internal medicine University of Pavia
Introduction: The shortage of organs in the last twenty years is stimulating the 
development of new strategies to expand the pool of donors. The harvesting 
of the graft from non-heart beating donors (NHBD) has been successfully 
proposed for kidney and liver transplantation. To our knowledge, no studies are 
available for small bowel transplantation using NHBD donors.
Aim of the study: in an experimental setting of small bowel transplantation, 
we studied the feasibility of using intestinal grafts retrieved from NHBD.
Material and method: Twenty Large White piglets underwent total orthotopic 
small bowel transplantation and were randomly divided as follow: group 1 
(n=10) received grafts from NHBD; group 2 (n=10) received grafts from heart 
beating donors (HBD). In group 1, the NHBD pigs were sacrifi ced inducing 
the cardiac arrest by a lethal potassium injection. After 20 minutes (no touch 
period = worm ischemia), they underwent cardiac massage, laparotomy and 
aorta cannulation for fl ushing and cooling the abdominal organs. In group 2 the 
cardiac arrest was induced at the time of organ cold perfusion. In both groups 
immunosuppression was based on tacrolimus oral monotherapy. The animals 
were observed for 30 days. The graft absorptive function was studied at day 
15 using the D-xylose absorption test. Histological investigation included 
EE microscopical analisys, immunohistological staining for CD4/CD8, 
macrophage and dendritic cells. The complete profi le of the MAP-kinase was 
completed by western blotting.
Results: Two animals in each group died for technical complications and were 
excluded from the study. The mean survival was 19 days in group 1 and 24 days 
in group 2. Only 2 animals (25%) of the NHBD group 1 were alive at the end 
of the study compared to 4 of the HBD group 2. The causes of death in both 
groups were infection-related. The D-xylose absorption was signifi cantly lower 
in the NHBD group 1 compared to the HBD group 2 (pƒ¬0.05). The analysis 
of cytokines profi le in the serum reviled a signifi cantly higher level of IL-1£], 
TNF-£\. An increasing in the activation of p-38 and JNK MAPKs has been 
detected compare to controls.
Conclusions: This study confi rm that intestinal mucosa is very sensitive to 
ischemic injury. When the intestinal graft is harvested from NHBD, the 
infectious-related mortality is higher and the absorptive function of the graft 
is lower Histology, cytokines profi le and MAP-kines activation profi le confi rm 
a higher grade of ischemic injury in the NHBD grafts that correlates with the 
clinical data. Therefore this experimental study suggests that non-heart beating 
donation may not be indicated for small bowel transplantation.
POSTER BOARD NUMBER P3 – 456
TOLERANCE AND SUSTAINED PERIPHERAL 595 
CHIMERISM FOLLOWING MHC MATCHED AND CLASS I 
MISMATCHED INTESTINAL TRANSPLANTATION IN MGH 
MINIATURE SWINE
Y. Ishikawa, A. Griesemer, A. Hirakata, J. Etter, A. Shimizu, K. Yamada
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: There are many unresolved obstacles to intestinal 
transplantation that limit its applicability. These include inadequacy of 
immunosuppression, lack of a reliable means to maintain functional barriers 
to infection, and the insensitivity of currently available diagnostic assays 
for rejection. In order to improve clinical outcomes and eliminate the co-
morbidities associated with chronic immunosuppression, the induction 
of donor specifi c tolerance would be desirable, especially in the pediatric 
population of intestinal transplantation recipients. In this study, we examined 
the ability of the intestine to facilitate tolerance induction and analyzed 
chimerism in the peripheral blood and both native and graft lymph nodes 
following intestinal transplantation.
Methods: Five MGH-miniature swine received small intestine transplants, two 
across a minor-antigen mismatch and three across a class-I MHC mismatch, with 
12-days of CyA. Chimerism was assessed by FACS analysis. The percentage 
of donor cells was determined using class I specifi c antibodies and/or porcine 
allele-specifi c antigen antibodies. Immunohistochemistry was performed to 
determine the distribution of donor cells in the lymph nodes. CML assays were 
performed to examine anti-donor responses across class I barriers. Regulatory 
cells were detected using Foxp3 in the peripheral blood and lymph nodes.
Results: (1) Minor antigen mismatch: Both intestine grafts survived >120 
days. Only minimal cell infi ltrate was seen 1-2 weeks after cessation of 
CyA. Recipient cells assessed by allele specifi c Abs migrated to the donor 
mesenteric lymphnodes (LNs) as early as day 5 (15-25%). Greater than 15% 
peripheral blood chimerism (donor cells) persisted greater than 60 days. 
(2) Class-I mismatch: All animals accepted intestine grafts (163 days, 106 
days and >90 days) following 12 days of CyA. Immunologically, all showed 
donor specifi c unresponsiveness in vitro by CML by day 30. Although two 
of the three animals had no signs of rejection throughout the experimental 
period, one had a rejection crisis detected by graft biopsy at POD 66. At 
this point, the level of Foxp3+/CD25+ cells in the graft mesenteric LNs 
decreased markedly as compared to that at day 30. No signs of rejection 
were noted at later time points. 5-10% of myeloid as well as lymphocyte 
chimerism in the peripheral blood was observed in the fi rst 2 weeks and then 
gradually decreased, but was sustained at low levels for at least 3 months 
after intestinal transplantation.
Conclusions: All intestinal transplants were accepted across both minor-
mismatched and class I mismatched barriers with persistent myeloid and 
lymphoid chimerism. To our knowledge, this is the fi rst demonstration of 
persistence of chimerism and tolerance induction to intestinal transplants in a 
large animal. Studies to investigate the mechanisms of tolerance in this model 
are currently in progress.
POSTER BOARD NUMBER P3 – 457
RESCUE OF INTESTINAL FUNCTION IN PATIENTS 596 
REFERRED FOR MULTIVISCERAL AND INTESTINAL 
TRANSPLANTATION
E. Island, A. Manta, C. Lyssikatos, T. Kato, G. Selvaggi, J. Moon, D. Levi, 
S. Nishida, A. Tzakis
University of Miami
Multivisceral and Intestinal transplantation have become excellent primary 
treatments for many refractory intestinal disorders. However, transplantation 
is often associated with signifi cant morbidity due to the need for life long 
immunosuppression. Herein we describe our experience with patients 
referred for multivisceral or intestinal transplantation and treated with other 
modalities. From 1994 to 2008 there were 701 referrals for intestinal or 
multivisceral transplants, and 284 transplants were preformed. During the 
same time period there were 38 patients rescued from transplantation. There 
were 18 adult and 20 pediatric cases. Patient diagnoses included gastroschisis, 
volvulus, Hirschsprung’s disease, NEC, Mesenteric thrombosis, tumors, 
and other disorders. All patients were cared for by a multidisciplinary team 
that included transplant surgeons, gastroenterologists, nutritionists, and 
pharmacists. Rescue modalities included bowel rehabilitation with medical 
management alone (17), surgical intervention followed by bowel rehabilitation 
(10), surgical resection (6), and resection with auto transplantation (5). 
Overall results were excellent; all patients demonstrated improvement in 
their enteral intake and 10 patients (26%) are off TPN altogether. However, 
there were 2 deaths due to septic complications in pediatric patients being 
rehabilitated with short gut syndrome. In selected cases, multidisciplinary 
care of complex intestinal patients has resulted in rescue of intestinal function, 
and the avoidance of morbidities associated with transplantation and life long 
immunosuppression.
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TRANSPLANTATION OF THE STOMACH – 597 
CLINICOPATHOLOGICAL OUTCOMES REVIEW 
OF THE GASTRIC ALLOGRAFT INCLUDED IN 
MULTIVISCERAL GRAFT
T. Kato, G. Selvaggi, S. Nishida, E. Island, D. Weppler, M. Velasco, 
H. Takahashi, J. Gaynor, P. Ruiz, A. Tzakis
University of Miami
Background: Transplantation of the stomach has been done as part of 
multivisceral transplantation at our institution. In this study, we review 
our results of function, pathology and complications regarding the gastric 
allograft.
Methods: A retrospective review of the recipients who received allograft 
stomach as part of as part of the multivisceral graft.
Results: 146 patients received the stomach as part of the multivisceral graft 
during 1994-2007. 124 received it with a standard multivisceral graft (liver, 
stomach, pancreas and intestine) and 22 received it with a modifi ed multivisceral 
graft (stomach, pancreas and intestine). The gastric allograft was anastomosed 
to the native esophagus (esophagogastrostomy) in 78 and to the small rim of the 
native stomach (gastro-gastric anastomosis) in 68. All received pyloroplasty at 
the time of transplant. 71 patients who received gastric allograft are currently 
alive. The gastric emptying were normal to near normal in most cases except 
for 3 cases who exhibit signifi cant gastropalasis after the transplant both of 
those cases had dysmotility disease as a cause of transplant. The rejection of the 
gastric allograft was seen in xxx cases. All of those occurred concurrently with 
the intestinal rejection. No isolated gastric rejection was seen. Signifi cant gastro 
esophageal refl ux was seen in 10 patients. 8 of those had esophagogastrostomy 
and 2 gastro gastrostomy. Fudoplication surgery was performed in 3 cases. No 
anastomotic leak from the gastric anasomosis was seen in primary multivisceral 
transplant; in 2 case, leak was seen after the second multivisceral transplant.
Conclusion: The gastric allograft as part of the multivisceral graft seemed to 
show good emptying function. Gastric rejection seemed to be a rare occurrence 
and other complication rate pertaining to the gastric allograft is rare as well.
POSTER BOARD NUMBER P3 – 459
RECOVERY FROM LIVER DYSFUNCTION AFTER 598 
ADULT ISOLATED INTESTINAL TRANSPLANTATION 
WITHOUT LIVER GRAFTING
C. Zanfi 1, A. Lauro1, M. Cescon1, L. Ansaloni1, G.L. Grazi1, A. Cucchetti1, 
M. Ravaioli1, M. Zanello1, L. Pironi2, A.D. Pinna1
1U.O Chirurgia Dei Trapianti Di Fegato E Muliorgano (Dir.:Prof. A.D 
Pinna), 2Centro Riferimento Insuffi cienza Intestinale (Head:Prof .L.Pironi), 
University of Bologna - Policlinico S.Orsola-Malpighi
Purpose: Indications for intestinal transplant with liver is the cohesistence of 
liver and intestinal failure. Liver failure has been related to reversible liver 
damage from bacterial translocation or total parenteral nutrition (TPN). The 
etiology is still not clearly established but it is likely multifactorial; several 
factors correlated with its occurrence include: duration of TPN therapy, length 
of residual small bowel, presence of residual colon, composition of TPN 
macronutrients hepatotoxic factors.). Impending or overt liver failure (which 
is, according to Medicare coverage policy, one of the criteria that makes failed 
TPN therapy) is defi ned by: increased serum bilirubin and/or liver enzyme 
levels, coagulopathy, thrombocytopenia, splenomegaly, gastroesophageal 
varices, stomal bleeding and liver fi brosis or cirrhosis at biopsy.
The aim of this study is to evaluate liver function recovery after isolated 
intestinal transplantation in adults with irreversible intestinal failure.
Patients and methods: Over a 8 years period we performed 39 intestinal 
transplantation in 38 adult patients: 29 received an isolated intestinal graft, 4 a 
multivisceral graft without liver, and 5 a multivisceral graft with liver. Patients 
were divided in 2 groups: the IF-Liver disease recipient group and the control 
group; recipients for liver graft were not considered (5 patients). The fi rst group 
was composed by 16 recipients with pre-transplant liver dysfunction which 
was considered when bilirubin was superior than 2 mg/dL (N.V.: 1.2) and/or 
transaminases more than 100 IU/mL (N.V.:37/40); other inclusion criteria were: 
TPN period > 3 months, no diagnosis of portal hypertension or cirrhosis. Two 
patients had a biopsy-proven liver fi brosis. The control group was composed by 
17 patients without pre-transplant liver dysfunction.
Results: At discharge all patients recovered liver function normal values: 
mean bilirubin blood level was 0.9 ± 0.96 mg/dL (range 0.3-1.6) and mean 
transaminases was 26 ± 9/31 ± 18 IU/mL (range 10-44/27-65). After a mean 
follow-up of 1618 ± 708 days (range 2605-227) only 2 patient has elevated 
ALT without clinical signs of liver disease; one patient has high bilirubin level 
(2.3 mg/dl) because he is affected by Gilbert’s syndrome but his liver is well 
functioning. Pre-transplant liver disease didn’t impact on survival rates.
Conclusion: Liver disease associated with intestinal failure (IF-Liver disease) 
is one of the main causes of death in patients with permanent intestinal failure. 
Regression of IF-Liver disease can be achieved by combined liver-intestine 
transplant or isolated small bowel transplant without liver grafting. In selected 
cases isolated intestinal or multivisceral graft without liver can represent a “liver 
salvage therapy” for early failing liver in patients with irreversible intestinal 
failure: pre-transplant liver disease can regress after successful intestinal 
transplantation and discontinuation of intravenous therapy if liver disease is 
early referred. Pre-transplant liver disease isn’t a negative prognostic factor.
More Surgical Videos
BACTERIAL TRANSLOCATION IN ADULT INTESTINAL 599 
TRANSPLANTATION
A. Cucchetti1, C. Zanfi 1, M. Cescon1, L. Ansaloni1, A. Lauro1, A. Dazzi1, 
M. Di Simone1, A. Bagni2, A. Siniscalchi1. A.D. Pinna1
1Liver and Multiorgan Tranplant Unit (Dir.:Prof. A.D Pinna), 2Pathology ”F. 
Addarii” Institute, University of Bologna - S.Orsola-Malpighi Hospital
Introduction: The application of small bowel transplantation (SBTx) is limited 
by the relatively high rate of infectious complications that occurs; bacterial 
translocation (BT) has been suggested as being responsible for the high rate of 
infections associated with clinical transplantation.
Materials and methods: We reviewed 95 biopsies performed on 28 isolated 
SBTx recipients in order to identify histological features predictive of BT 
within the fi rst month after transplantation.
Results: At least one episode of BT was observed in 13 patients out of 28 (46.4%);
occurrence of BT led to higher one-year mortality (38.5%) in comparison to 
negative cases (6.7%; P=0.041). No clinical or surgical factors were found to 
be signifi cantly related to occurrence of BT. Of the 95 biopsies examined, 38 
were followed by BT (40%): these biopsies showed a higher degree of mucosal 
vascular alteration (Ruiz grade; P<0.05) and ischemia/reperfusion injury (Park/
Chiu grade; P<0.05) in comparison to negative cases; the presence of acute 
cellular rejection was not found to be related to BT.
Conclusion: BT seems to be closely related to mucosal vascular alteration 
and ischemia/reperfusion injury rather than acute cellular rejection; the 
measurement of the degree of these histological features could identify patients 
at high risk of potentially life-threatening infectious complications and death.
MORE SURGICAL VIDEOS
RENAL TRANSPLANT BIOPSIES: INTRODUCING THE 600 
GLIDE PATH APPROACH AND SKEWER TECHNIQUE FOR 
SAFE & EFFECTIVE BIOPSY PRACTICE
A.O. Mahendran, P.S. Veitch
Royal Free & University College London Medical School
Aim: Renal transplant biopsy remains the gold standard in the assessment of 
parenchymal causes of graft dysfunction. As such it is a widely used procedure 
amongst transplantation units. However, it is not without risk and traditionally 
has been reserved to resolve clinical uncertainty over aetiology, usually in an 
acute setting. 
In our unit we have developed a biopsy procedure that prioritises patient safety 
and comfort. 
Our video demonstrates an accessible biopsy technique that harnesses the best 
ultrasound technology to produce real time images of the needle passage. In 
addition, the method encompasses two approaches to a transplant kidney ; the 
glide path and the skewer technique. The use of either one is dependent on the 
position of the graft. 
We have devised an easy-to-follow two handed procedure that can be taught 
effortlessly to transplant physicians and surgeons in training. 
Method: The following pieces of equipment are essential for our method: 
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•  High resolution ultrasound machine with colour Doppler and a 7. 5MHz with 
general purpose probe. 
•  A disposable, spring-loaded, automated 16 guage biopsy needle. 
•  A spinal needle for deep infi ltration of tissues and renal capsule with local 
anaesthetic. 
The fi rst step of the technique is imaging the graft and visualising the “no-go” 
areas; renal medulla, any pole overlaid by bowel, areas around major vessels, 
ureter and bladder. 
The crux of the technique is in constant needle visualisation throughout the 
procedure. This is facilitated by ensuring that both the needle tip and body 
remain within the fi nite curtain of ultrasound emitted by the probe. 
The glide path approach is based on the runway principle used in aviation to 
guide an airplane to earth. The skewer technique is ideal for those kidneys that 
are placed in the upright positions. 
Results: Between January 2007 and January 2008, a total of 130 diagnostic and 
105 protocol biopsies were performed. 3 biopsies were misses which yielded 
no renal tissue. On average there were 18 glomeruli per core of biopsy tissue. 
Two minor post-procedure complications were reported; transient haematuria 
and an intracapsular haematoma. No graft was lost. In addition, 15 doctors 
were trained successfully in the procedure. 
Conclusion: In recent years we have witnessed an expanding role for transplant 
biopsies. They have rapidly become an important management strategy in 
patients with creeping creatinines, recipients of asystolic donor kidneys and in 
protocol biopsies. The loss of a graft or serious complication following biopsy 
is unpalatable. Therefore, it is imperative that a transplant unit has confi dence 
in its biopsy technique. 
We have devised a procedure with a formidable safety profi le, based on clear 
guiding principles. The success of the technique has allowed our unit to 
incorporate protocol biopsies into the routine follow-up of transplant patients. 
This has signifi cantly improved the early detection of graft dysfunction and 
subsequent graft preservation.
OUR TECHNIQUE OF OBTAINING CUFF OF 601 
INFERIOR VENA CAVA DURING RIGHT SIDED 
RETROPERITONEOSCOPIC DONOR NEPHRECTOMY
P. Modi, J. Rizvi, G. Rahul, G. Kadam, S. Patel, T. Amit
Institute of Kidney Diseases And Research Centre, Institute of Transplantation 
Sciences
Purpose: To evaluate results of retroperitoneoscopic right side donor 
nephrectomy.
Material and methods: Between September 2004 and February 2008 a 
total of 270 retroperitoneoscopic donor nephrectomy were performed; 70 
were on right side. Four ports were used for dissection and control of renal 
pedicle; 10 mm camera port was placed at tip of 12th rib by open access, 
followed by 5 mm port at posterior axillary line and 10 mm port at renal 
angle. For stapler, a 12 mm port was placed at lateral border of eractor spina 
muscle and 2 cm above the iliac crest. Renal artery was controlled by Hem 
o loc clips while vein was controlled by Endo TA stapler. The kidney was 
retrieved from iliac fossa.
Results: All procedures were completed without conversion to open surgery. 
Eight donors had two renal arteries and 10 had two and one donor had four renal 
veins. Cuff of inferior vena cava was obtained in all cases. Mean operative time, 
blood loss and warm ischemia time were 124 minutes, 84 ml and 4 minutes and 
35 seconds respectively. Intra-operative hemorrhage from inferior vena cava 
(IVC) occurred in two patients and in both cases laparoscopic repair of bleeding 
site at IVC was performed. Post operatively, mean analgesic requirement, time 
to start orally and time to ambulation were 350 mg of Tramadol, 6.2 hours and 
12.8 hours respectively. Mean hospital stay was 2.1 days. In recipients, mean 
value of drop of serum creatinine on 1st post operative day was 2.5 mg/dL. 
Delayed graft function was present in 4 patients. One year graft survival was 
93%; two patients were lost.
Conclusion: Our technique of retroperitoneoscopic right sided donor 
nephrectomy is safe and reliable method to obtain inferior vena cava cuff in 
presence of single or multiple renal veins.
LIVE DONOR KIDNEY TRANSPLANTATION 602 
FOLLOWING EXTRACOPOREAL REPAIR OF RENAL ARTERY 
ANEURYSM
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori, 
S. D’Imporzano, L. Morelli, G. Amorese, F. Mosca.
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico, 
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Aims: Complex vascular lesions, such as renal artery aneurysms, are usually 
considered a contraindication for live kidney donation. We herein show the 
video of a case of kidney transplantation from a live donor despite the presence 
of a distally located renal artery aneurysm.
Methods: Kidney transplantation was performed on March 5th, 2008. The 
LD, a 66 year old father, donated the right kidney to his 36 year old son. 
During the pre-donation work-up the donor was incidentally discovered with 
a renal artery aneurysm located the level of the primary bifurcation. Complete 
investigation showed no other cardiovascular lesions, although a mild dilation 
of the ascending aorta was noted. The dilated aortic segment showed no size 
increment during a two year period of follow-up, during which intended 
recipient did not match with any of the available deceased donors. Provided 
that unilateral nephrectomy was not deemed detrimental for the progression 
of cardiovascular disease, and that the potential donor would have required 
repair of the renal artery aneurysm irrespective of his willing to donate we 
decided that, if extracorporeal repair was satisfactory, it would have been 
worth the effort to pursue live kidney donation. As defi ned by computed 
tomography angiogram and arteriography, the right kidney was supplied 
by two arteries The aneurysm originated from the superior renal artery 
at the level of a trifurcation. The left kidney was completely normal either 
anatomically or functionally. The right kidney was procured laparoscopically 
(hand assisted technique), perfused with Celsior solution and maintained 
between 0 and 4 Celsius degrees until transplantion. The renal aneurysm 
was excised extracorporeally and reconstructed using a branched hypogastric 
artery segment retrieved from the recipient. Each of the three renal branches 
emerging from the aneurysm was reconstructed using microsurgical technique 
with the aid of loop magnifi cation. The kidney was eventually transplanted 
into the right iliac fossa of the recipient. The same surgical team cared for all 
surgical procedures (i.e. kidney procurement, extracorporeal vascular repair, 
and KTx).
Results: The kidney was reperfused after 3 hours of cold storage. Reperfusion 
was immediate and homogeneous. No signifi cant haemorrhage was noted. 
Urine production restarted promptly, with a urine volume of 4.500 cc during 
the fi rst 24 hours. 
Conclusions: This video shows that, in well selected donors, renal artery 
aneurysms may not be an absolute contraindication for live kidney donation.
WEDNESDAY – ORAL ABSTRACTS
CARDIOVASCULAR AND CONCURRENT ORAL SESSION 41: 
METABOLIC DISEASE IN RENAL TRANSPLANTATION
REDUCTION IN CARDIOVASCULAR DEATH RATES 603 
AFTER KIDNEY TRANSPLANTATION IN ANZ
H. Pilmore1, H. Dent, S. Chang, S. McDonald, S. Chadban2
1Auckland City Hospital, Auckland New Zealand, 2ANZDATA Registry
Background: Cardiovascular disease has been a leading cause of death and a 
key impediment to successful long-term outcomes after kidney transplantation. 
Strategies proven to reduce cardiovascular events in this context are lacking.
Methods: The ANZDATA (Australian and New Zealand Dialysis and 
Transplant Registry) Registry was accessed to examine the causes of death 
for all 3348 patients who died in Australia or New Zealand between 1980 and 
2006 after receiving a kidney transplant. Annualised death rates and death 
rates in 5 year time periods were examined. Poisson regression was used to 
compare death rates over the time periods with adjustments made for multiple 
confounders. In addition, the relative risk ratio (RR) for CVS death was 
analysed in 12450 patients transplanted between 1991-2006 using multinomial 
logistic regession.
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Results: There is a signifi cant reduction in the death rate since 1990 compared 
to earlier eras with an ongoing reduction in the most recent decade (Figure 
below); Incidence Rate Ratio (IRR) 0.54; p=0.000). In comparison, there is no 
change in the rate of deaths from malignancy (IRR 1.18; p=0.287).
Factors associated with cardiovascular death after transplantation are: age over 
45 years (RR 3.03, CI 1.15 – 8.0; p=0.025), diabetes as the cause of ESRF (RR 
3.56; CI 1.52 – 8.35; p=0.0035) and presence of cardiovascular disease at the 
onset of ESRF (RR 2.7, CI 1.47 – 4.97; p=0.0014).
Conclusions: The rate of death from cardiovascular disease appears to be 
declining, in contrast to malignancy. Ongoing research is required to determine 
the cause of this observation.
METABOLIC SYNDROME AND CARDIOVASCULAR 604 
DISEASE RISK IN RENAL TRANSPLANT RECIPIENTS IN THE 
ALERT TRIAL: EFFECTS OF STATIN TREATMENT
I. Soveri1, H. Holdaas2, A. Jardine3, N. Eriksson4, B. Fellström1
1Department of Medical Sciences, Uppsala University Hospital, Uppsala, 
Sweden, 2Rikshospitalet, Oslo, Norway, 3University of Glasgow, Glasgow, UK, 
4Uppsala Clinical Research Center, Uppsala, Sweden
Background: Metabolic Syndrome (MS) is a risk factor for cardiovascular 
disease (CVD) and diabetes mellitus in the general population. Renal transplant 
recipients (RTR) have unfavorable metabolic conditions, partly due to 
immunosuppression.
Aim: To study MS as CVD risk factor in RTR. To investigate the effect of 
fl uvastatin treatment in CVD prevention in RTR with MS.
Methods: In total, 1708 stable RTR without diabetes mellitus in the ALERT 
trial were randomized to treatment with fl uvastatin or placebo. Follow-up was 
7-8 years (ALERT-extension trial). MS was defi ned at baseline using ATPIII 
defi nition. Major adverse cardiac event (MACE) was the primary study end-
point.
Results: In the ALERT study, 29% of the non-diabetic RTR had MS. MACE 
risk was increased in RTR with MS [RR (95% CI)] 1.67 (1.27-2.20). RTR 
with MS also had increased RR for non-fatal myocardial infarction (MI) 1.84 
(1.20-2.88) and cardiac death 2.22 (1.44-3.42). Statin treatment was associated 
with considerable reduction in cardiovascular event probability among RTR 
patients with MS (Table).
Table. Cumulative 8-year probability of an event (%)
MS and placebo MS and statin No MS and placebo No MS and statin
MACE 27 14 12 10
Non-fatal MI 11 4.5 5 3.5
Cardiac Death 13 6 5 3.5
Conclusion: RTR with MS are at high risk for CVD. RTR with MS are easily 
identifi able group of patients who benefi t from statin treatment.
ANTIHYPERTENSIVE THERAPY FOR KIDNEY 605 
TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS
N.B. Cross1,2, A.C. Webster1,2, P. Masson3, P. O’Connell4, J.C. Craig1,2
1Centre For Kidney Research, Children’s Hospital At Westmead, 2School of 
Public Health, University of Sydney, 3Royal Prince Alfred Hospital, Sydney, 
4Westmead Hospital, Sydney
Aims: To assess the relative effects of different classes of antihypertensive 
agents on patient and graft survival, graft function, cardiovascular events, 
acute rejection, proteinuria, blood pressure and anaemia in kidney transplant 
recipients.
Data sources: A comprehensive search of MEDLINE, EMBASE, CENTRAL, 
DARE, Science Citation Registry, reference lists of identifi ed studies and 
abstracts of conference proceedings.
Methods: We included randomised trials of any antihypertensive agent in 
kidney transplant recipients which were administered for two weeks or more, 
compared with placebo/no treatment or another class of antihypertensive agent. 
Summary estimates of treatment effects were combined using a random effects 
model and expressed as relative risks for dichotomous outcomes and weighted 
mean difference for continuous outcomes, both with 95% CI.
Results: Data from a total of 60 trials of 76 intervention comparisons involving 
3627 participants were retrieved. Indication for treatment varied: hypertension 
25 trials (1407 participants), erythrocytosis six trials (111 participants), left 
ventricular hypertrophy two trials (131 participants), and chronic allograft 
nephropathy one trial (28 participants). In the majority (37 trials, 2291 
participants), the indication was not provided or treatment was investigated 
for effect on reducing concomitant cyclosporin use. Calcium channel blocker 
(CCB) therapy was the most commonly allocated treatment (1612 participants, 
49 trials), followed by ACE inhibitors (ACEi; 706 participants, 27 trials) and 
angiotensin receptor-2 blockers (ARB; 367 participants, 16 trials). As trials 
permitted use of additional agents to treat hypertension, similar blood pressure 
control was achieved among all studied drug class comparisons.
Recipients allocated to ACEi, compared to placebo or no treatment had lower 
GFR (WMD -6.0 ml/min, 95% CI -11.9 to 0.0), higher serum potassium (WMD 
0.44 mmol/L, 95% CI 0.10 to 0.78) and lower haemoglobin (WMD -8.7 g/L, 
95% CI -12.1 to -5.3). Recipients allocated to CCB, compared to placebo or no 
treatment, had lower risk of graft loss (RR 0.71, 95%CI 0.53 to 0.94), higher 
GFR (WMD 4.8 ml/min, 95%CI 1.9 to 7.6 ml/min) and lower creatinine (WMD 
-6.5 mmol/L, 95%CI -11.9 to -1.1). Recipients allocated to CCB compared to 
ACEi experienced less acute rejection (RR 0.61, 95%CI 0.46 to 0.82), had 
higher GFR (WMD -10.6 ml/min, 95% CI 6.0 to 15.2), lower creatinine (WMD 
-12.9 mmol/L, 95% CI -17.6 to -8.1), more proteinuria (WMD 0.28 g/24h, 95% 
CI 0.10 to 0.47), less hyperkalaemia (RR 0.27, 95% CI 0.13 to 0.53) and higher 
haemoglobin (WMD 11.5 g/L, 95%CI 7.2 to 15.8).
Conclusions: These data indicate that CCB should be favoured as fi rst line 
treatment in kidney recipients requiring antihypertensive treatment, and suggest 
that CCB may prevent graft loss and improve graft function in kidney transplant 
recipients, irrespective of indication. Further prospective randomised trials in 
patients receiving newer immunosuppression regimens are required.
GENETICS OF NEW-ONSET POST TRANSPLANT 606 
DIABETES MELLITUS (NOPTDM)
I.V. Hutchinson1,2, J.W. Yang1,3, K Yamamoto1, S Takemoto1, G Burckart2, 
T Shah1,2, V Pravica1,2, D.I. Min1,3
1National Institute of Transplantation, Los Angeles, CA, 2University of 
Southern California, Los Angeles, Ca, 3Western University of Health Sciences, 
Pomona, CA
Background: The development of diabetes after transplantation is a signifi cant 
problem that dramatically increases patient morbidity and mortality. The 
principle cause of NOPTDM is the use of diabetogenic drugs, especially 
steroids and calcineurin inhibitors (CNIs), and yet only a proportion of 
recipients develop the disease. This suggests an individuality in susceptibility 
that may have a genetic component.
Patients and methods: Therefore we tested the association of known genetic 
markers for type II diabetes (DM2) and mature onset diabetes of the young 
(MODY) with NOPTDM in renal transplant recipients. NOPTDM was defi ned 
as blood glucose >125 mg/dl at more than one time point, starting 30 days post-
transplant. Patients were followed for at least 1 year after grafting. We identifi ed 
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117 patients with NOPTDM and 295 controls (never hyperglycaemic) from a 
pool of 1153 patients transplanted between 01/01/2001 and 09/30/2005.
Results: Amongst the genes associated with NOPTDM were genes affecting 
beta cell K-channel function (KCNJ11, p=0.008), insulin gene activation 
(HNF1A, p=0.002) insulin response (IRS1, p=0.008) and regulatory feedback 
of insulin action (TCF7L2, p=0.001). Each of these genes is responsive 
to either NF-AT or glucocorticoid, and therefore infl uenced by CNIs or 
steroids.
Conclusions: NOPTDM genes can be defi ned as follows: (1) the gene is 
important in glucose homeostasis, (2) there are alleles of the gene that confer a 
risk of diabetes and (3) the gene is directly susceptible to the immunosuppressive 
drugs used to treat the patient. Given the strength of association, for example 
TCF7L2 has an Odds Ratio of 13.72 (95% CI 3.13-60.21), genetic information 
on the recipient may dictate the selection and dose of immunosuppressive 
agents for individual recipients.
LATE STEROID WITHDRAWAL AND CARDIOVASCULAR 607 
EVENTS IN KIDNEY TRANSPLANT RECIPIENTS
M. Arnol1, A.M. de Mattos2, J.S. Chung3, J.C. Prather3, A. Mittalhenkle3, 
D.J. Norman3
1Department of Nephrology, University Medical Center Ljubljana, Ljubljana, 
Slovenia, 2Transplant Medicine, University of California, Davis, Davis, 
California, USA, 3Transplant Medicine, Renal Transplant Program, Oregon 
Health & Science University, Portland, Oregon, USA
Introduction: Cardiovascular events (CVE) are the leading cause of morbidity 
and mortality in kidney transplant recipients. The adverse effects of long-term 
therapy with steroids on cardiovascular risk factors have motivated increasing 
interest in steroid withdrawal (SW). The objective of this study was to compare 
the incidences of CVE (fatal and non-fatal cardiac and cerebrovascular events) 
and all-cause mortality between patients who had undergone SW at 1 year post-
transplant and control patients who continued on steroids.
Methods: The study cohort included 400 consecutive adult recipients of a kidney 
transplant between January 1, 1993 and December 31, 1998 who qualifi ed for 
SW at 1 year after transplantation. Candidates for SW included those with no 
more than 2 previous acute rejections, a stable serum creatinine of less than 
2.0 mg/dl, and ability to tolerate full doses of azathioprine or mycophenolate 
mofetil, and to maintain adequate levels of cyclosporine or tacrolimus. At 1 year 
post-transplant 188 patients subsequently underwent SW, while 212 patients 
continued on steroids. Cox proportional-hazards analysis was used to estimate 
cardiac events (new-onset angina pectoris, acute myocardial infarct, coronary 
angioplasty or by-pass surgery, or cardiac death), cerebrovascular events 
(transient ischemic attack, cerebrovascular accident, carotid endarterectomy, 
or death from a cerebrovascular event) and all-cause mortality hazard ratios 
(HR) for patients who had undergone SW versus controls who continued on 
steroids beyond 1 year.
Results: The average duration of follow-up was 61 months for the entire 
cohort, with average follow-up of 63 months for SW group and 59 months 
for control patients. There were 44 (11%) cardiac events, 18 (4.5%) 
cerebrovascular events, and 41 deaths (10.3%). The composite outcome of 
CVE and all-cause mortality was reached in 26 (13.8%) subjects who had 
undergone SW and 50 (23.6%) controls (P = 0.013). In adjusted analyses, 
SW was associated with decreased risk for the composite outcome (HR 
0.46, 95% confi dence interval [CI] 0.28-0.76, P = 0.003), cardiac events 
(HR 0.48, 95% CI 0.28-0.84, P = 0.009), and all-cause mortality (HR 0.27, 
95% CI 0.12-0.59, P = 0.001). There was no association of SW with the risk 
for cerebrovascular events (HR 1.76, 95% CI 0.45-7.01, P = 0.42). Steroid 
continuation was associated with increased body mass index, increased 
frequency of newly-diagnosed hypertension, and higher cumulative rate of 
new-onset diabetes mellitus when compared with SW (+0.50 ± 0.17 kg/m2 
vs. -0.11 ± 0.18 kg/m2, 37.8% vs. 25.3%, and 8.0% vs. 1.1%, respectively; 
P < 0.05).
Conclusion: In this retrospective analysis, SW at 1 year post-transplant was 
associated with decreased risk for future CVE and all-cause mortality. Late 
SW had a positive infl uence on some of the risk factors associated with 
cardiovascular disease, specifi cally new-onset diabetes mellitus.
CARDIOVASCULAR EVENTS AND MORTALITY 608 
IN RENAL TRANSPLANT RECIPIENTS: EARLY 
CORTICOSTEROID CESSATION REGIMENS VERSUS 
CHRONIC CORTICOSTEROID THERAPY
E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, M. Cardi2, 
G. Mogilishetty1, M. Clippard1,
1University of Cincinnati, 2The Christ Hospital
Background: Cardiovascular (CV) risk reduction has been a primary reason for 
pursuing early corticosteroid withdrawal (ECSWD) in renal transplant (RTx). 
To date, actual cardiovascular event (CVE) data (rather than CV risk) has not 
been reported for ECSWD. Therefore, we analyzed and compared actual CVE, 
CV-related survival, and overall patient survival in ECSWD (≤7 days) versus 
chronic corticosteroid (CCS) therapy. 
Methods: CVE and heart failure (HF) data were prospectively collected. 
CVE were defi ned as sudden death, myocardial infarction, angina, and 
cerebrovascular accident/transient ischemic attack. HF events were defi ned 
as pulmonary edema or clinical HF diagnosis. Statistical analyses included 
Student’s t-test, Cox Proportional-hazards Regression, and Kaplan Meier (KM) 
survival estimates and time to CVE.
Results: Data on 693 RTx pts (471 ECSWD and 222 CCS pts) were analyzed. 
Demographic data and results are presented in Table 1. Mean follow-up in all 
pts was 1420 ± 958 days. No difference was observed in HF events between 
groups (5.7% ECSWD v 6.8% in CCS group, p<0.57). CCS pts experienced 
more CVE (27.5% v 13.4% in ECSWD), despite a higher proportion of pre-
existing cardiovascular disease (CVD) in ECSWD pts (15% v 7% in CCS). 
CVE-free survival was numerically greater in ECSWD pts and approached 
signifi cance on KM analysis (Figure) (p<0.08). A trend toward better pt 
survival by KM was observed for ECSWD (p<0.11).
Demographics and Results
 CS Group (n=222) CSWD group (n=471) p
Male 49% 60% 0.007
African American 27% 21% 0.08
Mean Age (yrs) 46.4 ± 12 48.7 ± 12.9 0.03
Pretxp FRS 7.8 ± 6.7 8.2 ± 7.4 0.49
Pretxp CVD 7% 15% 0.003
Pretxp DM 26% 31% 0.14
% pts w/ CVE 27.5% 13.4% <0.0001
Mean #CVE/pt 1.6 ± 1 1.3 ± 0.6 <0.0001
p < 0.08
Conclusions: RTx recipients receiving ECSWD experienced: 1) fewer CVE 
and 2) a trend toward overall better pt survival. These differences in CVE and 
pt survival do not present until at least 3 yrs PTx; therefore, require long term 
follow-up to become evident.
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USE OF CARDIOPROTECTIVE MEDICATIONS IN 609 
KIDNEY TRANSPLANT RECIPIENTS: PRELIMINARY 
OBSERVATIONS FROM THE DETERIORATION OF KIDNEY 
ALLOGRAFT FUNCTION (DEKAF) STUDY
B. Kasiske1,10, R. Gaston2, M. Cecka3, F. Cosio4, J. Grande4, F. Gourishankar5, 
P. Halloran5, L. Hunsicker6, D. Rush7, A. Matas8
1Hennepin County Medical Center, 2University of Alabama at Birmingham, 
3University of California at Los Angeles, 4The Mayo Clinic, 5University 
of Alberta, 6University of Iowa, 7University of Manitoba, 8University of 
Minnesota
Death with function causes half of late kidney transplant failure, and 
cardiovascular disease (CVD) is the most common cause of death. Chronic 
kidney disease is a CVD risk equivalent, justifying aggressive risk reduction 
with blood pressure (BP) control, statins, aspirin, and liberal use of 
angiotensin converting inhibitors (ACEI) and angiotensin receptor blockers 
(ARB). DEKAF is an ongoing, prospective, multicenter, observational study 
examining causes of kidney allograft failure at 7 transplant centers in the US 
and Canada, with current enrollment of over 2000 subjects. We examined the 
use of cardioprotective medications among patients transplanted after October 
1, 2005 and completing at least 6 months follow-up, focusing on subgroups 
with preexisting diabetes mellitus and/or CVD.
Medication use among patients with data from both 1 and 6 months 
posttransplant.
All (n=639)% Diabetes (n=263)% CVD1(n=205)%
1 mo. 6 mo. 1 mo. 6 mo. 1 mo. 6 mo.
Any BP medication 86 84 88 85 91 88
Beta blocker 67 63 73 67 80 74
Calcium blocker 49 42 52 38 46 39
ACEI or ARB 13 25 13 29 12 28
Statin 33 41 45 51 52 57
Aspirin 36 39 54 54 60 58
1Defi ned as coronary disease, peripheral vascular disease, MI, stroke, or heart failure
Overall, 86% of all subjects were receiving antihypertensive therapy 30 days 
after transplantation, and 84% were on drug therapy at 6 months. Similar usage 
was noted among diabetics and patients with CVD, despite wide variability in 
practice from center to center. The most commonly used BP medications were 
beta-blockers, followed by calcium blockers, and both were used with the same 
frequency at 1 and 6 months (Table). In contrast, the percentage of patients on 
an ACEI or ARB doubled between 1 and 6 months, suggesting that physicians 
may be reluctant to use these agents early after transplantation (a practice that 
is not necessarily evidence-based); more than 70%, regardless of grouping, did 
not receive ACEI/ARB therapy even at 6 months. Overall, fewer than half of 
all patients were treated with aspirin, and only 60% with diabetes and/or CVD 
received aspirin. Similarly, only half of patients with diabetes and/or CVD 
received a statin at 1 and 6 months. These data indicate that current management 
of kidney transplant recipients fails to utilize optimal CVD risk reduction 
measures in a timely fashion, perhaps missing an opportunity to reduce long-
term morbidity and mortality from CVD in this at-risk population.
NEW ONSET METABOLIC SYNDROME AFTER RENAL 610 
TRANSPLANTATION: EFFECTS OF MAINTENANCE STEROID 
THERAPY AND DIABETES
E.S. Woodle1, R.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1, 
G. Mogilishetty1, S. Young1
1Surgery, U of Cincinnati, 2Christ Hospital
Background: Corticosteroid therapy has been associated with several 
metabolic effects that contribute to cardiovascular complications, osteoporosis 
and increased post transplant (txp) infections complications. According to 
NCEP ATP III guidelines, metabolic syndrome (MS) is a signifi cant predictor 
of cardiovascular events (CVE). The purpose of this study was to evaluate new 
onset metabolic syndrome (NOMS) in renal txp patients (pts) receiving early 
corticosteroid withdrawal (ECSWD) (≤ 7 days) versus chronic corticosteroid 
therapy (CCS) and to identify risk factors associated with developing MS post-
txp.
Methods: Prospective data collection on 682 renal transplant pts from 1997 
to 2007 evaluating presence of MS at baseline, 6, 12, 24, 36, 48, and 60 
months post-transplant. The NCEP ATP III criteria were used to defi ne MS; 
however, the WHO criteria of body mass index (BMI) > 30 kg/m2 was used 
as an alternative to waist circumference. All patients evaluated were either on 
CCS or ECSWD regimen. Analysis was completed on 3 separate groups: No 
pre-transplant diabetes (DM), pre-transplant DM type I, and pre-transplant DM 
type II. All patients meeting the criteria for MS at baseline (pre-transplantation) 
were excluded from the study. NOMS was defi ned as MS diagnosed at any time 
point post transplantation.
Results: 365 patients (54%) without pre-transplant MS and were evaluated for 
post-transplant NOMS. 79% were non-diabetics at time of transplant. Of these 
non-diabetic patients 53% received CCS and 44% received ECSWD. Baseline 
demographics between CCS and ECSWD were similar gender (more males in 
ECSWD, p= 0.01). All characteristics that defi ne MS were similar at baseline 
between the two groups. Risk factors analyzed for NOMS in the univariate 
and multivariate models included: Baseline BMI (stratifi ed categorically: 
<18.5, 18.5-24.99, ≥ 25-29.99, ≥ 30 kg/m2), TG, HDL, race, gender, age at 
transplant, acute rejection (AR), chronic steroids, and diabetes mellitus (DM) 
type. Signifi cant factors (p<0.2) on univariate analysis for all patients included: 
BMI (18.5 –24.9 kg/m2), ECSWD group, BMI (25.0-29.9 kg/m2), BMI > 30 
kg/m2, and HDL. Of these variables, those that were signifi cant in the fi nal 
multivariate model are listed below. Further analyses excluding diabetic 
patients confi rmed these results.
Rates of NOMS
DM Status CCS (n) ECSWD (n) P-value
Non-diabetic pts 53% (103) 44% (186) 0.1
DM Type I pts 43% (7) 53% (19) NS
DM Type II pts 69% (13) 43% (37) 0.1
DM Type I and II pts 60% (20) 46% (56) NS
MVA for NOMS
Odds Ratio 95% Confi dence Interval
Pre-txp HDL 0.9 0.94-0.98
Pre-txp BMI (25-29.9 kg/m2) 2.3 1.41-3.77
Pre-txp BMI (>30 kg/m2) 4.6 2.16-9.94
Conclusion: This analysis indicates that the primary risk factors for developing 
NOMS are the degree of obesity and HDL pre-transplant. For each 1mg/dL 
increase in pre-transplant HDL, there is a ten percent decrease in risk of post 
transplant NOMS.
THE EFFECTS OF ROSUVASTATIN ON INSULIN 611 
SENSITIVITY AND SECRETION IN NON-DIABETIC RENAL 
TRANSPLANT RECIPIENTS
A. Sharif1,2, V. Ravindran2, R. Moore2, G. Dunseath3, S. Luzio3, D. Owens3, 
K. Baboolal2
1Russells Hall Hospital, Dudley, 2University Hospital of Wales, Cardiff, 
3Diabetes Research Unit, Llandough
Background: Previous studies by this group have examined the impact of 
interventions to prevent the onset of new onset diabetes after transplantation 
(NODAT). More recently statins have been demonstrated to have pleiotropic 
effects beyond lipid-lowering. It is hypothesised that statins may delay the 
onset of NODAT by improving insulin sensitivity and reducing the decline in 
insulin secretion. The aim of this study was to analyse the effect of rosuvastatin 
on insulin sensitivity and secretion in non-diabetic renal transplant recipients.
Methods: 20 non-diabetic renal transplant recipients were randomised to either 
rosuvastatin 10mg or placebo daily for 12 weeks in a randomised, double-blind, 
crossover study. Insulin sensitivity, fi rst and second phase insulin secretion 
was assessed at the end of each 12-week treatment period with a frequently 
sampled, intravenous glucose tolerance test and meal tolerance test. After a 
4-week washout, patients crossed over to the alternative therapy for a further 
12 weeks and the investigations were repeated.
Results: Rosuvastatin was a safe and effective lipid-lowering agent, lowering 
total cholesterol by 31% (p<0.001), LDL cholesterol by 48% (p<0.001) 
and triglycerides by 19% (p=0.018) when compared to placebo. It also had 
a signifi cant anti-infl ammatory effect, lowering C-reactive protein by 43% 
(p=0.042). However no signifi cant difference was observed in insulin sensitivity 
or secretion (Table 1).
Table 1. Change in insulin sensitivity and secretion: placebo vs rosuvastatin 
(mean ± standard error of the mean)
Placebo Rosuvastatin p value
First-phase insulin secretion 
(pmol/l.min) 2693 ± 365 2785 ± 455 0.875
Second-phase insulin secretion 
(pmol/l.min) 67082 ± 8937 67393 ± 11748 0.983
Insulin sensitivity 
(10-5min-1/ U/ml) 4.8 ± 0.5 4.4 ± 0.6 0.580
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Conclusion: Short-term rosuvastatin was not associated with an improvement 
in insulin sensitivity or secretion, despite signifi cant lipid-lowering and anti-
infl ammatory effects. Whether statins can attenuate the development of NODAT 
in the long-term is questionable and not addressed by this study. This study 
demonstrated no benefi t of short-term statin therapy on glucose metabolism 
post-transplantation and we should be cautious in advocating the pleiotropic 
effects of statins post-transplantation in the absence of clinical evidence.
LIVER MALIGNANCYCONCURRENT ORAL SESSION 42: 
DECREASING DISPARITY IN LIVER 612 
TRANSPLANTATION AMONG WHITE AND ASIAN PATIENTS 
WITH HEPATOCELLULAR CARCINOMA, CALIFORNIA, 
1998-;2005
M. Daily1, A. Robbins2, C. Aoki3, M. Chen3, C. Troppmann1, J. McVicar1, 
R. Perez1
1University of California, Davis Medical Center, Department of Surgery, 
2California Cancer Registry, Public Health Institute, 3University of 
California, Davis Medical Center, Department of Internal Medicine
Context: A preliminary study using national cancer surveillance data from 
1998-;2002 suggested there were signifi cant differences between non-Hispanic 
whites (¡°whites¡±) and Asian/Pacifi c Islanders (APIs) in the use of liver 
transplantation as a treatment for hepatocellular carcinoma (HCC).
Objective: To examine whether differences in liver transplantation between 
white and API HCC patients were changing over time.
Design, setting, and participants: Population-based statewide cancer registry. 
We obtained data on all HCC cases diagnosed in California between 1998 and 
2005, but limited the study to white and API patients with non-metastatic HCC, 
sized ¡Ü 5.0 cm (n = 1728).
Main outcome measures: Racial differences in odds of transplantation and 
stage at diagnosis, as well as changes in these differences between 1998-;2003 
and 2004-;2005.
Results: During 1998-;2003 (n = 1051), the odds of receiving a liver transplant 
were 2.56 times higher for white patients than for API patients (95% confi dence 
interval [CI], 1.72 to 3.80 times higher), even after adjusting for age, sex, 
marital status, year of diagnosis, TNM stage, and tumor grade. In contrast, 
during 2004-;2005 (n = 677), there were no signifi cant differences in the odds 
of receiving a transplant (odds ratio for white vs API, 1.23; 95% CI, 0.77-;1.96). 
The disappearance of a signifi cant disparity coincided with changes in liver 
transplantation policy between 2002 and 2004 that assigned priority points to 
HCC patients (initially to stage I and II, then to stage II only). After the policy 
changes, API HCC patients experienced a signifi cant 17% relative increase in 
stage II diagnoses, while white patients experienced no signifi cant increase.
Conclusions: In California, there was a large and signifi cant disparity in liver 
transplantation among white and API patients with HCC during 1998-;2003, 
but not during 2004-;2005. Changes in liver transplantation policy between 
2002 and 2004 may have played a role in decreasing this difference.
DOES THE TYPE OF PRE-TRANSPLANT 613 
ABLATIVE THERAPY AFFECT SURVIVAL AFTER 
LIVER TRANSPLANTATION FOR PATIENTS WITH 
HEPATOCELLULAR CARCINOMA (HCC)?
D. Steffi ck1,2, R Freeman3, M Guidinger1,2, R Wolfe1,2, R Merion3,4
1Arbor Research, 2SRTR, 3Tufts-New England Medical Center, and 4University 
of Michigan
Introduction: Previous liver transplant survival analyses comparing the 
effi cacy of pre-transplant trans-arterial chemoembolization (TACE) with 
radiofrequency ablation (RFA) have been subject to selection bias due to the 
tendency to use RFA for single or smaller lesions. In order to reduce this source 
of bias, the aim of this study was to examine the effect of TACE or RFA in HCC 
candidates with single tumors only.
Methods: All US deceased donor liver transplant recipients between 5/1/2003 
and 12/31/2005 with allocation exceptions for a single HCC lesion who 
received either RFA or TACE exclusively as pre-transplant ablation therapy 
were analyzed, with follow-up through 11/1/2007. Post-transplant survival was 
estimated using Cox models, adjusted for recipient (age, gender, race, diagnosis; 
creatinine, bilirubin, INR, and albumin at transplant; portal vein thrombosis, 
prior abdominal surgery, medical condition at transplant, life support), donor 
(age, gender, race, cause of death, height, donation after cardiac death), and 
transplant (partial liver, cold ischemia time, local or shared transplant) factors, 
and level of RFA vs. TACE usage at the transplant center.
Results: 707 recipients (19% of HCC exceptions) had one lesion and RFA 
or TACE ablation therapy (58% of all HCC recipients who had ablation 
therapy). There was no difference in post-transplant survival for recipients 
in centers that used only RFA, centers that used only TACE, and centers that 
used both (100% RFA vs. 100% TACE [reference]: hazard ratio [HR]= 1.38, 
p=0.36; combination of RFA and TACE vs. 100% TACE [reference]: HR=1.10, 
p=0.77). Power analyses showed that this sample size had 95% power to detect 
at least a 38% higher mortality than TACE and 80% power to detect at least 
a 29% higher mortality than TACE. In a patient-level analysis (using actual 
receipt of RFA and TACE rather than the center’s practice pattern), the HR for 
RFA vs. TACE [reference] was 1.14 (p=0.52). A sample size of 2,292 would 
be needed to detect a 15% difference in mortality risk between groups with 
power of 80%.
Conclusions: In this national sample, powered to detect a relative mortality 
difference between groups (i.e., hazard ratio) of 1.29 or larger, there was no 
signifi cant difference in the risk of post-transplant death within three years between 
HCC recipients with one lesion who received ablation at centers that used RFA vs. 
centers that used TACE. Further analyses of the effect of pre-transplant ablation 
therapy on post-transplant outcome in patients with HCC is warranted.
ABLATION OF HEPATOCELLULAR CARCINOMA AS 614 
A BRIDGE TO LIVER TRANSPLANT PROLONGS WAIT LIST 
ELIGIBILITY
L. Lilly, D. Dubay, J. Kachura, G. Therapondos, D. Grant, P. Greig
University Health Network
Background: Ablation as a bridge to transplant in patients with hepatocellular 
carcinoma (HCC) is widely utilized without signifi cant data to support the 
clinical effi cacy. The purpose of this study is to measure the effect of ablation on 
time to drop-off and overall survival in HCC patients listed for liver transplant.
Methods: Patients were stratifi ed into ablation and no treatment groups based 
upon interventions made while on the wait list. The ablation interventions 
included both radiofrequency ablation (RFA) and percutaneous ethanol 
injection (PEI). Patients with incidental tumors and those treated with TACE 
were excluded. Cox proportional hazard regression analysis was performed to 
assess time to drop-off probability.
Results: Between 1999 and 2006, 282 HCC patients were listed for 
transplantation. There were 137 patients in the ablation group (117 RFA, 5 PEI 
only, 15 both) and 145 patients in the no treatment group. The ablation group had 
a lower MELD score (11 vs 13, p=0.005) and lower UNOS stage (2.4 ± 0.9 vs. 
2.1 ± 0.8, p=0.03) but remained on the wait list twice as long as the no treatment 
group (7.4 vs. 3.7 months, p<0.001). Ablation procedures were performed 
with minimal morbidity. The overall drop-off rates were equivalent (23% vs. 
24%, p=ns). Adjusting for UNOS stage, age and gender, the time to drop-off 
analysis demonstrated an advantage for patients treated with ablation (p=0.05), 
especially those listed longer than 6 months. The actuarial 12-month wait list 
eligibility was 78% in the ablation group compared to 55% in the no treatment 
group. There were no signifi cant differences in the overall survival from the 
time of listing or the post transplant survival in only those transplanted.
Conclusions: Ablation as a bridge to transplant is safe and signifi cantly 
prolongs wait list eligibility, especially in patients listed for longer than 6 
months. Ablation does not impact overall survival or post transplant survival.
Wednesday 13 August 2008 Oral Abstracts
2 1 6
W
ED
N
ES
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
LIVING DONOR LIVER TRANSPLANTATION FOR 615 
PATIENTS WITH HEPATOCELLULAR CARCINOMA 
– EEFFECTS OF PRE-TRANSPLANT TREATMENTS
Y. Takada, T. Kaido, H. Egawa, S. Uemoto
Kyoto University
Purpose: In Japan, where deceased donor liver grafts are rarely available, 
the role of living donor liver transplantation (LDLT) in the management for 
hepatocellular carcinoma (HCC) has signifi cantly evolved. However, given the 
risks to the live donor, LDLT is indicated only for patients with HCC considered 
unsuitable for resection or ablation therapies. Most recipients had a history of 
non-transplant treatments, which were performed not as a bridge to transplant 
or for downstaging but with intent for curative ablation. When they suffered 
from uncontrolled recurrent HCC, they were referred for LDLT as a second-
line treatment. In this study, effects of pre-transplant treatments on transplant 
outcome were evaluated.
Patients and methods: Between February 1999 and August 2007, 144 patients 
with HCC underwent LDLT. Of them, 105 patients (73%) displayed a history of 
previous treatment for HCC using various non-transplant methods, including hepatic 
resection, TACE, and RFA or ethanol injection (recurrent group). For the remaining 
39 patients (27%) who had no history of pre-transplant treatment (primary group), 
conventional treatment was not indicated because of advanced liver dysfunction in 
most cases. The median follow-up period after LDLT was 32 months.
Results: 1) Overall patient survival rate at 5 years was 69%. Based on pre-
LDLT imaging studies, 79 patients met Milan criteria (MC) and 65 did not. 
Cumulative recurrence rates at 5 years were signifi cantly higher for over-MC 
than for within-MC group (32% vs. 8%, p<0.001). 2) The survival rates for 
recurrent and primary groups were 69% and 69%, respectively (p=0.919). 3) 
Of 105 patients in recurrent group, records of tumor stage at fi rst diagnosis of 
HCC were available for 92 patients. While 70 patients met MC, 22 patients 
did not. Median period between fi rst diagnosis of HCC and LDLT was 22 
months (range, 2-168 months) in these 92 patients. At the time of LDLT, tumor 
stage was up-staged in 30 patients (Group 1), down-staged in 6 (Group 2), and 
unchanged in 54: 40 patients (Group 3) remained within MC and 16 (Group 4) 
over MC. In the primary group, 26 patients met MC (Group 5) and 13 exceeded 
MC (Group 6). The recurrence rates at 5 years were 29%, 25%, 3%, 36%, 0%, 
and 34% in groups 1 to 6, respectively. Among 6 patients who were down-
staged (Group 2), 5 patients are alive without recurrence at the median follow-
up of 45 months (range, 28-85 months).
Conclusion: The survival rates were similar for recurrent and primary groups. 
The recurrence rates after LDLT appeared to be associated with tumor stage 
immediately before LDLT, irrespective of history of pre-transplant treatments.
ELEVATED PREOPERATIVE NEUTROPHIL TO 616 
LYMPHOCYTE RATIO PREDICTS OUTCOME IN PATIENTS 
WITH HCC AFTER LIVER TRANSPLANTATION
K.J. Halazun, M.A. Hardy, A. Rana, D. Woodland, P. Witkowski, A. Seigal, 
J. Emond
Columbia University - New York Presbyterian Hospital
Background: Orthotopic liver transplantation (OLT) has become the main 
treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) as 
it not only provides a cure for the cirrhosis, but also provides total neoplastic 
clearance of the HCC. Although the initial results with OLT for HCC were 
poor the emergence of the Milan has greatly improved prediction of successful 
outcomes. The Milan Criteria, rely solely on the radiographic appearance of the 
tumor, i.e size and number of lesions, but provide no measure of tumor biology. 
Therefore, despite the adoption of Milan Criteria by UNOS, the recurrence rate 
remains 20-30% in patients who fi t these criteria. The neutrophil-lymphocyte 
ratio (NLR) is an indicator of infl ammatory status that has been previously 
used as a prognostic indicator in primary colorectal malignancy and colorectal 
liver metastases. The aim of this study was to establish whether NLR is able to 
predict outcome in patients undergoing OLT for HCC.
Design: Retrospective analysis of the white cell and differential counts of 150 
patients undergoing OLT for HCC between January 2001 and January 2007 
at our institution. A NLR > 5 was considered to be elevated. Patients with 
preoperative sepsis and missing blood results were excluded from the study.
Results: 118 males and 32 females were included with an overall recurrence 
rate of 18% and 5 year survival of 60%. 13 patients (9%) had an elevated 
NLR. Of the patients with raised NLR 62% developed recurrence compared 
to 14% of patients with normal NLR. The 5 year disease free survival for 
patients undergoing OLT with high NLR was signifi cantly worse than that 
for patients with normal NLR (35% vs 75%, p<0.0001). Patients with high 
NLR were also found to have poorer overall survival compared to patients 
with normal (5year survival 31% vs 63%, p=0.006). Univariate analysis of 
factors affecting recurrence revealed raised NLR, tumor grade, presence of 
vascular invasion on explant pathology and a diagnosis other than hepatitis 
B or C affected disease free survival. However, only a raised NLR remained 
signifi cant on multivariate analysis (HR=6.289, CI=1.703-22.226, p=0.006). 
Patients categorised according to the Milan criteria with elevated NLR had 
signifi cantly poorer disease free survival that those with normal NLR who were 
both inside and outside Milan (5 year survival 35% vs 87% vs 64%, p<0.0001 
and p=0.03 respectively). Patients outside Milan who had high NLR fared 
worst of all with a median disease free survival of <1 year.
Conclusion: Elevated NLR in patients who undergo OLT for HCC appears 
to be a signifi cant marker of increased risk for both tumor recurrence and 
recipient death. Patients with high preoperative NLR who fi t the Milan criteria 
have much worse outcomes than those who have normal preoperative NLR and 
who are within Milan Criteria. Preoperative NLR measurement may therefore 
provide a simple method of identifying patients with a poorer prognosis and 
may act as an adjunct to the Milan criteria in helping determine which patients 
with HCC would benefi t most from OLT.
THE IMPACT OF MELD ON PATIENT SURVIVAL AND 617 
DISEASE FREE SURVIVAL IN PATIENTS RECEIVING LIVER 
TRANSPLANT FOR HEPATOCELLULAR CARCINOMA
D. Moonka1, E. Castillo1, S. Kumer2, M. Abouljoud1, G. Divine1, S. Pelletier2
1Henry Ford Health Systems, 2University of Michigan Medical Center
We combined data from two liver transplant centers to determine the impact of 
the Model for End-stage Liver Disease (MELD) allocation system on survival 
and disease free survival in patients listed for liver transplantation (OLT) for 
hepatocellular carcinoma (HCC).
Methods: We evaluated a total of 172 patients listed for OLT for HCC. We 
excluded patients who received live donation. 54 patients were listed in the 
pre-MELD era and 117 in the MELD era. Patients were compared for standard 
demographics and tumor characteristics. On an intention to treat (ITT) basis, 
patients were compared for likelihood of transplant, therapy while on the list 
(embolization or radio-frequency ablation (RFA)), time to transplant, patient 
survival and tumor free survival. Survival comparisons were done with Kaplan-
Meier analysis with log rank tests.
Results: There were no differences between the pre-Meld and MELD groups 
in terms of age, incidence of hepatitis C, calculated MELD and the percent 
of patients who met Milan criteria at time of listing (78% and 76%). 37 of 55 
patients listed in the pre-MELD era received a transplant (67%) vs 106 of 117 
patients (91%) in the MELD era (p < 0.001). 69% of pre-MELD patients and 
51% of MELD patients received embolization or RFA (p=0.038). Patients who 
did receive a transplant in the pre-MELD era waited a median of 258 days 
vs 26 for those in the MELD era (p < 0.001). On an ITT basis, the 1, 3 and 5 
year survival for patients in the pre-MELD era was 79%, 60% and 48% and 
in the MELD era was 84%, 73% and 73% (p=0.055). On an ITT basis, the 
1, 3 and 5 year tumor free survival in the pre-MELD era was 58%, 58% and 
55% and in the MELD era was 83%, 74% and 70% (p=0.018). In patients who 
received a transplant, there were no differences in overall survival or tumor 
free survival. In patients who received OLT, the 1, 3 and 5 year survival was 
92%, 84% and 67% in the pre-MELD era and 90%, 81% and 81% in the MELD 
era (p=0.57). On explant, there was no difference between the pre-MELD and 
MELD patients in total tumor burden (4.5 ± 2.8 cm vs 3.9 ± 2.5 cm) or the 
likelihood of meeting Milan criteria (58% vs 67%). However, patients in the 
pre-MELD era had more differentiated tumors (p=0.046).
Conclusions: The implementation of the MELD allocation system with its 
exception for HCC did result in higher and more rapid rates of transplantation 
with a nearly signifi cant increase in overall survival (p=0.055) and a signifi cant 
increase in tumor free survival (p=0.018). However, despite the markedly 
longer wait period for patients in the pre-MELD era, those who did receive 
transplants had similar survival and recurrence free survival to patients in the 
MELD era who received transplant. Patients in the pre-MELD era had more 
differentiated tumors (p=0.046). These data support the hypothesis that the 
longer wait periods of the pre-MELD era led to a drop-out of patients with 
aggressive malignancy.
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MELD PRIORITIZATION FOR PATIENTS 618 
WITH CIRRHOSIS AND SMALL UNRESECTABLE 
HEPATOCELLULAR CARCINOMA HAS A MORE POSITIVE 
IMPACT IN WAITING TIME AND POST TRANSPLANT 
RECURRENCE FREE SURVIVAL THAN LIVING DONOR 
LIVER TRANSPLANTATION
A.G. Villamil, O.A. Galdame, J.C. Bandi, P.C. Casciato, M. Reig, 
V. Ardiles, E. de Santibañes, A.C. Gadano
Liver Transplantation Unit, Hospital Italiano de Buenos Aires, Buenos Aires, 
Argentina
Introduction: A selected group of patients with cirrhosis and small 
hepatocellular carcinoma (HCC) can be cured by liver transplantation. Yet, 
organ shortage and long waiting time may preclude transplantation due to 
disease progression. 
Aim: To evaluate the impact of living donor liver transplantation (LDLT) 
and MELD prioritization on pre and post LTx outcome of patients listed for 
cirrhosis and HCC.
Patients and methods: 55 consecutive patients with small unresectable HCC 
fulfi lling the Milan Criteria (single nodule <5 cms or up to 3 nodules <3cms 
without vascular invasion) and a normal chest CT and bone scan were listed 
for LTx between Jan 2001 and Sept 2006. Outcome was analyzed in 2 different 
time periods: Jan 2001-June 2005 (Group A, all patients were offered the 
possibility of LDLT) and July 2005-Sept 2006 (Group B, all patients were given 
a MELD score of 22 and an additional point every 3 months in the waiting list). 
No differences in ethiology and severity of cirrhosis were observed between 
groups. Results were also analyzed within Group A between patients with or 
without an available living donor.
Results: In Group A only 7:32 patients had an adequate living donor and 
received a LDLT. Median waiting time was signifi cantly longer in Group A 
compared with Group B (24.3 ± 10.3 vs 2.8 ± 1.6 months, p< 0.05). Within 
Group A waiting time was signifi cantly different between patients with an 
adequate living donor compared with those without a living donor (6.8 ± 2.1 vs 
27.8 ± 13.7 months, p<0.05). Recurrence free survival was lower for patients in 
Group A compared to Group B (19/32 (59.3%) vs 19/23 (82.6%), p<0.05).
Results
Group Waiting time (months)
Died waiting 
or "drop out" 
from list
LDLT
Recurrence-free 
survival from 
inclusion
Recurrence-free 
survival from Tx
A (n=32) 24.3±10.3 11/32 (34.3%) 7/32 19/32 (59.3%) 19/21(90.5%)
A with LD 
(n=7) 6.8±2.1 0/7 (0%) 7/7 6/7 (85.7%) 6/7 (85.7%)
A without LD 
(n=25) 27.8±13.7 11/25 (44%) - 12/25 (48%) 12/14 (85.7%)
B (n=35) 2.8±1.6 2/23 (8.6%) - 19/23 (82.6%) 1/12 (91.6%)
Conclusions: LDLT is a good alternative for patients with small HCC and an 
adequate living donor, but low applicability results in a small impact in overall 
recurrence free survival. MELD prioritization has a high effi cacy, resulting in 
short waiting time and high survival rates.
INCIDENTAL HEPATOCELLULAR CARCINOMA 619 
AFTER LIVER TRANSPLANTATION: POPULATION 
CHARACTERISTICS AND OUTCOMES
D. Moonka1, E. Castillo1, S. Pelletier2, S. Kumer2, M. Abouljoud1, G. Divine1
1Henry Ford Health Systems, 2University of Michigan Medical Center
Hepatocellular carcinomas (HCC) detected in the explant after orthotopic 
liver transplantation (OLT) are not infrequent. We reviewed our experience to 
determine the tumor characteristics and patient outcomes of incidental HCC 
and to determine if their incidence is declining.
Methods: We combined data from two liver transplant centers. A total of 
970 patients who were not known to have HCC received a liver transplant. 
51 patients were found to have an incidental HCC and these patients were 
compared to 144 patients transplanted for known (nonincidental) HCC. Patients 
were compared for preoperative characteristics, type of screening modality, 
pathologic fi ndings, survival and recurrence free survival. We also compared 
the difference in frequency of incidental HCC in the pre-MELD (Model for 
End-stage Liver Disease) and MELD eras.
Results: There was no difference in age and frequency of Hepatitis C infection 
in patients with incidental vs nonincidental HCC. Patients with incidental HCC 
were more likely to be African-American than patients with nonincidental HCC 
(22% vs 11%: p=0.014), they were more likely to be screened by ultrasound 
(38% vs 8%: p<0.001) and they had a lower alpha-fetoprotein (258.1 ± 83.9 
ng/ml vs 2157.8 ± 484.2 ng/ml: p=0.004). The liver explant of patients with 
incidental HCC had smaller total tumor burden than nonincidental HCC (3.1 ± 
3.5 vs 4.1 ± 2.6: p<0.001). Liver explant of patients with incidental HCC were 
similar to nonincidental HCC in percentage of single lesions (66% vs 64%), 
percentage that met Milan criteria (76% vs 64%), vascular invasion (8% vs 
10%) and degree of histologic differentiation. Patients with incidental HCC 
had 1 and 3 year survival of 78% and 67% and 1and 3 year recurrence free 
survival of 90% and 87%. These were comparable to the 1 and 3 year survival 
of 90% and 82% and the 1 and 3 year tumor free survival (91% and 84%) in 
patients with nonincidental HCC. There were no differences in the number of 
patients with incidental HCC transplanted in the pre-MELD and the MELD era 
(5.34% vs 5.16%).
Conclusions: Patients with incidental HCC were more likely to be African-
American, to be screened by ultrasound and to have a lower AFP. Ultrasound 
does not appear to be an appropriate modality of screening patients for HCC 
while awaiting OLT. Incidental tumors differed from nonincidental tumors 
only in total tumor diameter. Patients that are found to have an incidental 
HCC have similar survival and recurrence free survival than those with 
nonincidental HCC. The incidence of incidental HCC does not appear to be 
declining in our experience.
THE PLACE OF LIVER TRANSPLANTATION 620 
IN THE TREATMENT OF HEPATIC EPITHELOID 
HAEMANGIOENDOTHELIOMA : REPORT OF THE 
EUROPEAN LIVER TRANSPLANT REGISTRY (ELTR)
J. Lerut1, G. Orlando1, R. Adam2, V. Mazzaferro3, J. Klempnauer4, D. Mirza5, 
E. Boleslawski6, A. Burroughs7, C. Fernandez Selles8, D. Jaeck9
1St-Luc University Hospital, 2CHB Paul Brousse, 3Istituto Nazionale Tumori, 
4MHH Hannover, 5Q.E. Hospital, 6Hôpital Pitié Salpétrière, 7Royal Free 
Hospital, 8Hospital Juan Canalejo, 9Hôpital Hautepierre
Background: Hepatic epitheloid haemangioendothelioma (HEHE) is a rare 
low-grade vascular tumour. Its treatment algorithm is still unclear mainly due 
to a lack of larger clinical experiences with detailed long-term follow-up .
Material and methods: 59 patients, reported to ELTR, were analyzed in order 
to defi ne the role of liver transplantation (LT) in the treatment of this disease. 
Eleven (19%) patients were asymptomatic. Eighteen (30.5%) patients had 
pre-LT surgical [hepatic (7 pts) and extra-hepatic (3 pts)] and/or systemic or 
locoregional (10 pat) medical therapy. Ten (16.9%) patients had extra-hepatic 
disease localization before or at moment of LT. Follow-up was complete for all 
patients with a median of 92.5 (range 7-369) from moment of diagnosis and a 
median of 78.5 (range 1-245) from moment of LT.
Results: The HEHE was bi-lobar in 96% of patients; 86% of patients had 
more than 15 nodules in the liver specimen. Early (< 3 mo) and late (>3 mo) 
post-LT mortality was 1.7% (1pat) and 22% (14 pat). Fourteen(23.7%) patients 
developed disease recurrence after a median time of 49 mo (range 6-98).
Nine (15.3%) patients died of recurrent disease and fi ve are surviving with 
recurrent disease. One, 5 and 10 year patient survival rates from moment of 
transplantation for the whole series are 93;83,72%. Pre-LT tumor treatment (n 
= 18) (89;89 and 68% one, 5 and 10 year survival rates from moment of LT vs. 
95;80 and 73% in case of absence of pre-LT treatment),lymph node invasion (n 
= 18) (96;81 and 71% one, 5 and 10 year survival rates vs. 83;78 and 67% in 
node negative patients) and extra-hepatic disease localization (n = 10) (90;80 
and 80% one, 5 and 10 year survival rates vs. 94,83 and 70% in case of absence 
of extra-hepatic disease) did not signifi cantly infl uence patient survival whereas 
microvascular (n = 24) (96;75,52% one, 5 and 10 year survival vs. 96;92,85% 
in case of absence of microvascular invasion) and combined micro- and macro-
vascular invasion (n = 28) (90;72 and 54% one,5 and 10 year survival vs. 96;92 
and 85% in case of absence of vascular invasion – p 0.03) did. Disease free 
survival rates at one, 5 and 10 years post LT are 90;82 and 64%.The disease 
free survival is not signifi cantly infl uenced by pre-LT treatment, lymph node 
status, extra-hepatic disease localization and vascular invasion.
Conclusion: The results of the largest reported transplant series in the treatment 
of HEHE are excellent. Pre-existing extra-hepatic disease localisation as well 
as lymph node involvement are not contraindications to LT. Microvascular or 
combined macro-microvascular invasion signifi cantly infl uence survival after 
LT. LT therefore should be offered as a valid therapy earlier in the disease 
course of these, frequently young, patients. Recurrent (allograft) disease should 
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be treated aggressively as good long-term survivals can be obtained. Long-term 
prospective follow-up multi-centre studies as well as the evaluation of anti-
angiogenic drugs are necessary in order to further optimize the treatment of this 
rare vascular hepatic disorder.
CONCURRENT ORAL SESSION 43: 
RENAL LONG-TERM IMMUNOSUPPRESSION
LONG-TERM SAFETY OF BELATACEPT: 6 YEAR 621 
RESULTS OF A PHASE II STUDY
F. Muelbacher1, B. Charpentier2, C. Larsen3, M. Agarwal4, F. Vincent5
1Univ. Klinik Für Chirurgie, General Hospital Vienna (AKH), 2Nephrologie, 
Le Kremlin Bicetre Hospital, Le Kremlin Bicetre, France, 3Transplant 
Surgery, Emory University, Atlanta, GA, 4Bristol-Myers Squibb Company, 
Princeton, NJ., 5Transplant Svc, Univ Calif San Francisco, San Francisco, CA
Belatacept is a fi rst-in-class T-cell co-stimulation blocker which inhibits 
CD28 mediated T-cell activation and provides selective immunosuppression. 
Belatacept is being evaluated in Phase 3 trials as CNI-free immunosuppression 
in renal transplant. An interim report of an open-label long-term extension 
(LTE) of the phase 2 trial is presented. 
The Phase 2 trial design and results have been described previously. For the 
LTE, Belatacept arms were dosed as either q4week or q8week maintenance 
infusions of 5mg/kg; control patients received Cyclosporine (CsA), dosed to 
target C0 levels (150-300 ng/ml). All patients continued to receive MMF and 
steroids per protocol. Results for outcomes and serious adverse events (SAE) 
are presented as incidence rates/100 patient-years of drug exposure. No formal 
comparisons or statistical testing were applied. 
128 of 218 original patients elected to participate in the LTE and remained on 
their assigned treatment; 102 received Belatacept, 26 received CsA. Among 
LTE patients enrolled, 92 (72%) patients remain (76/102, 75% Belatacept; 
16/26, 62% CsA). Median follow-up from original randomization was 60 
months (range 15 to 78 m). Results for SAE categories, acute rejection (AR), 
and death/graft loss are shown (Table 1). 
Through six years, belatacept continues to be safe with continued low rates 
of acute rejection, death and graft loss as part of a long term- CNI-free 
immunosuppression regimen in renal transplant. Phase III studies are ongoing.
Table 1. Effi cacy Outcomes and SAE for Belatacept and CsA treated patients 
for the period of LTE
 Bela Rate/100 pt-yr (95% CI) CsA Rate/100 pt-yr(95% CI)
Infections 4.0 (2.3-6.5) 7.1 (2.8- 14.6)
Neoplasms 3.0 (1.5-5.2) 3.0 (0.6-8.9)
Cardiovascular 0.5 (0.1-1.8) 3.0 (0.6-8.9)
Treated AR 3.0 (1.5-5.4) 3.2 (0.7-9.3)
Death or Graft Loss 1.0 (0.3-2.6) 2.0 (0.2-7.3)
AFRICAN-AMERICAN KIDNEY TRANSPLANT 622 
RECIPIENTS UNDERGOING EARLY CORTICOSTEROID 
WITHDRAWAL LONG TERM (5 YEAR) RESULTS SIMILAR TO 
NON-AFRICAN AMERICANS
A.H. Rike1, R.R. Alloway1, R-A. Lee1, G. Mogilishetty1, P. Roy-Chaudhury1, 
M.A. Cardi2, R. Munda1, J. Everly1, A. Tevar1, E.S. Woodle1
1University of Cincinnati, 2The Christ Hospital
Background: African Americans (AA) have traditionally been considered 
a high risk group for early corticosteroid withdrawal (ECSWD) after renal 
transplantation. Our group and others have previously reported that short term 
results (acute rejection, CV benefi ts, and survival) in AA were similar to non-
AA. Long term (5 year) results have not been previously reported. The purpose 
of this study was to examine the results of ECSWD regimens in a large group 
of AA recipients compared to non-AA recipients with long-term follow-up.
Methods: Outcomes in 102 AAs were compared to 102 non-AAs who were 
matched for age, gender, date of transplant, maintenance immunosuppression, 
and induction. Patients were prospectively enrolled in one of several IRB 
approved ECSWD trials (ie CSWD within 7 days posttransplant). Acute 
rejection (AR) episodes were biopsy proven by Banff 97 criteria. Statistics 
included chi square and Student’s t test.
Results: Results are reported as AA versus non-AA in table below. 
Demographics and immunologic risk were similar between groups; however, 
AA patients received signifi cantly more deceased donor transplants (65% 
versus 33%, p<0.0001). 
AA (n=102) Non-AA (n=102) p value
Mean length f/u (days) 1234 ± 673 1328 ± 675 NS
Repeat txp 14.7% 10.8% NS
Deceased Donor 65% 33% <0.0001
DGF 13.7% 11.8% NS
Thymo Induction 83% 85.3% NS
Mean ∆ Scr 6mth to 5yr (ng/mL) 0.4 ± 0.6 0.3 ± 0.5 NS
Mean ∆ MDRD 6mth to 2yr (mL/min) -4.1 ± 14.2 -1.8 ± 10.2 NS
Mean ∆ MDRD 6mth to 5yr (mL/min) -14.2 ± 23.6 -9.4 ± 14.4 0.08
Mean ∆ from pretxp to 5yrs
SBP (mmHg) -14.5 ± 28.2 -22 ± 28.3 0.06
#BP meds 0.7 ± 1.6 -0.3 ± 1.6 NS
Total cholesterol (TC) (mg/dL) 20.6 ± 50.2 -7.1 ± 59.7 0.0004
Triglycerides (TG) (mg/dL) 5.8 ± 89 8.1 ± 108 NS
Weight (kg) 4.4 ± 19.5 4.6 ± 10 NS
1 Yr Acute Rejection 18.6% 10.8% NS
2 Yr Acute Rejection 21.6% 12.7% 0.09
5 Yr Acute Rejection 25.5% 13.7% 0.04
1 yr DC Graft Survival 98% 98% NS
2 yr DC Graft Survival 93.1% 96.2% NS
5 yr DC Graft Survival 91.2% 94.1% NS
1 yr Patient Survival 97.1% 100% 0.08
2 yr Patient Survival 96.1% 98% NS
5 yr Patient Survival 93.1% 96.1% NS
CV Events (5 yr incidence) 15.7% 13.7% NS
New Onset DM after Txp (NODAT) 14.7% 11.8% NS
BK Nephropathy (5 yr incidence) 7.8% 5.9% NS
Conclusions: This is the fi rst reported experience with long term follow-up 
following ECSWD in AA. Our fi ndings demonstate that 5 year results in AA 
renal transplant patients compared to non-AA are associated with 1) Similar 
patient survival and death censored graft survival, 2) Similar serum creatinine; 
however, MDRD estimates showed greater reduction at 5 years in AA patients, 
3) Similar CVE, incidence of NODAT, TG, SBP (despite reduced medication 
requirements in non-AA), and weight; however, TC was substantially increased 
in AA. This study indicates that the long term risks and benefi ts of ECSWD are 
similar between AAs and non-AAs.
CNI SPARING WITH MYCOPHENOLATE MOFETIL IN 623 
DE NOVO RENAL TRANSPLANTATION: 3-YEAR RESULTS 
FROM THE SYMPHONY STUDY
H. Ekberg1, H. Tedesco-Silva2, A. Demirbas3, S. Vitko4, J. Klempnauer5, 
A. Gürkan6, R. Margreiter7, C. Hugo8, J. Grinyó9, U. Frei10, 
Y. Vanrenterghem11, P. Daloze12, P. Halloran13
1Lund University, 2Federal University Sao Paulo, 3Akdeniz University, 
4IKEM, 5Medizinische Hochschule Hannover, 6SSK Tepecik Hospital, 
7Universitätsklinik Innsbruck, 8FAU Erlangen-Nürnberg, 9Ciutat Universitaria 
de Bellvitge, 10Virchow-Klinikum, 11KU Leuven, Leuven, Belgium, 12CHUM 
Montréal, Montréal, Canada, 13University Alberta, Edmonton, Canada
Introduction: In the 1-year Symphony core study, a regimen with 2 g 
mycophenolate mofetil (MMF) + low-dose tacrolimus (3-7 ng/ml) + 
daclizumab + steroids resulted in signifi cantly fewer acute rejections and better 
glomerular fi ltration rate (GFR) compared with 2 g MMF + steroids and either 
standard-dose cyclosporine (CsA; 150-300 mg/ml for 3 months, 100-200 ng/ml 
thereafter), low-dose CsA (50-100 ng/ml) + daclizumab, or low-dose sirolimus 
(4-8 ng/ml) + daclizumab.
Methods: 954 patients were included in the ITT population of an optional 
additional 2-year follow-up. GFR data from 83% of patients included in the 
follow-up (50% of the core ITT population) were available at 3 years.
Results: At inclusion into follow-up, 48%, 34% and 17% of patients received 
standard- or low-dose CsA, tacrolimus or sirolimus, whereas about 25% had 
been randomized to each regimen, indicating that follow-up patients had been 
switched during the fi rst year, particularly from sirolimus to tacrolimus. At 3 
years, these values were 32%, 28% and 13%, respectively. At 3 years, 95% of 
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the patients were still on MMF and 70% on steroids.
In the four arms, the mean GFR change over the 2nd and 3rd year was between 
+1 and -3 ml/min. At 3 years, the low-dose tacrolimus arm still had the highest 
GFR, although the difference was not signifi cant (68 vs 62-65 ml/min, p = 
0.10). Over the 2nd and 3rd years all arms had low rates of biopsy-proven acute 
rejection (BPAR; 1-3%) and graft loss (3-6%). Non-fatal cardiovascular events 
were rare (42 cases in total until month 36): 5.2% in the standard-dose CsA, 
5.5% in the low-dose CsA 2.4% in the low-dose tacrolimus, and 4.6% in the 
low-dose sirolimus group.
Conclusions: Observational follow-up results based on approximately half of 
the core Symphony population indicate that during the 2nd and 3rd years renal 
function was stable, BPAR and graft loss rates were low, and many patients 
changed treatment regimen. The ITT arm with 2 g MMF + low-dose tacrolimus 
+ daclizumab + steroids still resulted in highest renal function and lowest graft 
loss at 3 years, but these differences were not statistically signifi cant.
STABLE TROUGH LEVELS BUT SIGNIFICANT 624 
REDUCTION OF THE AREA UNDER THE CURVE OF 
TACROLIMUS IN RENAL TRANSPLANTED PATIENTS 
CONVERTED FROM ASSOCIATED MYCOPHENOLATE 
MOFETIL TO EQUIMOLAR DOSES OF ENTERIC-COATED 
MYCOPHENOLATE SODIUM
J.M. Puig1, M. Mir1, S. Hurtado1, M. Marin2, M. Ferrer3, M. Crespo1, 
F. Barbosa1, C. Barrios1, E. Rodriguez1, J. Lloveras1
1Hospital Del Mar. Nephrology Dept., 2Hospital Del Mar, Pharmacy Dept., 
3IMIM, Pharmacology Dept.
Enteric-coated mycophenolate sodium (EC-MPS) is a delayed release 
formulation of mycophenolic acid (MPA) developed to deliver MPA to the 
small intestine with the aim to reduce the upper gastrointestinal (GI) tract 
adverse-effects reported with the administration of mycophenolate mofetil 
(MMF). The primary objective of this study is to compare the pharmacokinetics 
(PK) of tacrolimus (TAC) and MMF with the PK of TAC and EC-MPS when 
administered in either combination.
Methods: We studied a group of 32 long-term stable RT patients treated with 
TAC and MMF without steroids. 53% were men. Age: 56.5±12.8y. Time 
from RT: 5.5±4.8y. MMF doses: 1.02±0.43g/d. Target MPA Cmin: 1.5-4ng/L. 
TAC doses: 4.7±2.5mg/d. Target TAC Cmin: 7-10ng/L. The PK parameters 
considered for each drug were Cmin, Cmax, Tmax and the AUC calculated 
by the trapezoidal rule. We fi rst determined simultaneously the 12-hour 
plasma TAC and MMF PK profi le. Next, patients were switched from MMF 
to equimolar doses of EC-MPS. After 30 days a new PK profi le of TAC and 
EC-MPS was carried out. TAC and EC-MPS doses remained unchanged 
throughtout the study. No one patient was on rifampicin, acetyl salycilic acid, 
antacids, ganciclovir or cholestyramine during the study period.
Results: Serum creatinine, proteinuria, serum albumin, leukocytes, hemoglobin, 
platelets, and bilirrubin before and after conversion were without signifi cant 
differences. TAC Tmax, and Cmin were similar with MMF and with EC-MPS. 
Howewer, TAC Cmax and AUC were 22% and 19% lower with EC-MPS 
(p=0.0013). MPA Cmin, Cmax, and AUC were 28%, 36%,and 27% higher with 
EC-MPS, and as expected, EC-MPS Tmax was signifi cantly delayed. Neither 
acute rejection episodes nor new-onset GI side-effects were observed and no 
dose-adjustements were needed.
Conclusions: In long-term stable RT patients treated with TAC and MMF, if 
MMF is converted to equimolar doses of EC-MPS, TAC AUC is signifi cantly 
reduced while TAC trough levels remain invariable. In addition, at equimolar 
doses, EC-MPS provides signifi cantly higher MPA AUC, Cmax and Cmin than 
MMF. These PK discrepancies were without short term clinical signifi cance i.e. 
acute rejection, nephrotoxicity or new-onset G.I. adverse effects.
TEN-YEAR FOLLOW-UP OF A MULTICENTRE KIDNEY 625 
TRANSPLANT STUDY DISCLOSE HIGHER GRAFT SURVIVAL 
AND BETTER RENAL FUNCTION IN TACROLIMUS THERAPY
B. Dominguez-Gil, J.M. Morales1, I. Vanrenterghem2, J.P. Squiffl et3, B. 
Suwelack4, F. Pietruck5, L. Wennberg6, S. Ball7, F. Mühlbacher8, J.P. Van 
Hooff9, M. Fischereder10
1Hospital Universitario Doce De Octubre, Madrid, Spain, on behalf of the 
European Tacrolimus Study Group, 2University Hospital Gasthuisberg, 
KU Leuven, Belgium, 3Centre Hospitalier du Sart Tilman, Liège, Belgium, 
44Medizinische Klinik und Poliklinik D, Universitatsklinikum Munster, 
Munster, Germany, 5Klinik für Nieren- & Hochdruckkrankheiten, 
Universitätsklinikum Essen, Essen, Germany, 6Karolinska Institute - 
Huddinge University Hospital, Huddinge, Sweden, 7University Hospital 
Birmingham NHS Trust, Birmingham, United Kingdom, 8Allgemeines 
Krankenhaus, Wien, Austria, 9Academic Hospital Maastricht, Maastricht, The 
Netherlands, 10Medizinische Poliklinik – Innenstadt, Klinikum der Universität 
München, München, Germany
The fi rst European Phase III trial with tacrolimus conducted in the early 
90´s clearly showed advantages for tacrolimus in terms of acute rejection 
vs the original cyclosporin formulation. However, no advantages were seen 
in survival rates. The present investigator-initiated, observational follow-
up study collected data on patients included in the original cohort of 448 
patients who participated in this large study and who were randomised to a 
triple immunosuppressive regimen consisting of tacrolimus, azathioprine and 
steroids (TAC/AZA/STER, n= 303) or cyclosporine, AZA and steroids (CSA/
AZA/STER, n=145). Effi cacy and safety parameters assessed at follow-up 
included: acute rejection; patient and graft survival; renal function, vital signs, 
basic lab results and immunosuppressive regimen. The follow-up evaluation 
included the assessment of patients 10 years after completion of the original 
study.
Results: All assessments were conducted following the intent-to-treat 
principles. A higher number of patients in the TAC than in the CSA group 
remained on the randomised treatment at the 10-year assessment. While 
Kaplan-Meier (K-M) estimates for patient survival at year 11 show comparable 
(72% for tacrolimus vs 72% for CSA) results, K-M estimates for graft 
survival demonstrate an advantage for the tacrolimus cohort (51% TAC vs 
46% CSA). Graft half-life estimates (according to the method of Gjertson and 
Terasaki) yielded overall results of 14.2 years (TAC) and 11.4 years (CS). In 
both treatment groups, acute rejection was associated with inferior long-term 
results. For patients with acute rejection, half-life estimates were 11.1 and 7.8 
years for TAC and CSA, respectively, while in patients without acute rejection 
half-lives were 19.2 (TAC) and 15.8 (CS) years. Mean serum creatinine after 
10 years was signifi cantly lower in the tacrolimus cohort vs the CSA group 
(1.65mg/dL TAC vs 2.01mg/dL CSA, p<0.05). Mean glomerular fi ltration rates 
(MDRD4 estimate) were 48.7 mL/min in TAC and 41.9 mL/min in CS. After 
ten years of follow-up, mean daily dose of TAC was 4.3 mg (0.06 mg/kg) and 
mean daily dose of CS was 160 mg (2.33 mg/kg). The corresponding mean (12 
hour trough) levels were 7.6 mg/mL (TAC) and 120 mg/mL (CS). Patients in 
monotherapy were 23% TAC vs 8% CSA. Also, TAC was associated with less 
antihypertensive use, lower lipids levels while diabetes (post-trasplant) was 
similar compared with CSA.
Conclusion: Analysis of this long term follow-up of a large study confi rms 
the benefi ts of a tacrolimus-based therapy. It also confi rms the concept that 
freedom from early acute rejection is associated with superior long term 
results. In parallel, long term renal allograft function and cardiovascular profi le 
is remarkably good in TAC patients.
A THREE YEAR FOLLOW-UP STUDY OF STABLE 626 
KIDNEY TRANSPLANT RECIPIENTS CONVERTED FROM 
TWICE DAILY PROGRAF® TO ONCE DAILY ADVAGRAF 
(EXTENDED RELEASE TACROLIMUS)
R. Alloway
for the Tacrolimus Extended Release Kidney Transplant Conversion Study 
Group, University of Cincinnati, College of Medicine, Cincinnati, OH, USA
Purpose: To assess safety and effi cacy three years following conversion from 
tacrolimus twice daily (Prograf BID) to extended release tacrolimus (Advagraf, 
previously Modifi ed Release tacrolimus or MR) once daily (QD a.m.) in stable 
kidney transplant recipients.
Methods: Seventy patients were enrolled in the pharmacokinetic (PK) portion 
of the study (days 0-35). Sixty-seven patients were subsequently maintained 
on Advagraf QD a.m. Patients were evaluated for Advagraf dosing and trough 
levels, laboratory values, concomitant medications, graft survival, and adverse 
events.
Results: The results of the PK portion of the study indicated that mg:mg 
conversion from Prograf BID to Advagraf QD a.m. dosing resulted in equivalent 
tacrolimus exposure in stable kidney transplant recipients. 66 patients agreed 
to the extension portion of the study, and 51 patients completed the third year 
of the study. Attrition was due to CNI toxicity, polyoma virus nephropathy, 
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HCV, lost to follow-up/LTFU (year 1), renal dysfunction, CAN/CNI toxicity, 
bladder cancer, CNI toxicity, LTFU (year 2), and lung cancer resulting in death, 
CNI toxicity, alopecia, proliferative GN, hyperglycemia, noncompliance with 
protocol (year 3). Through three years, renal function remained stable.
Pre- Advagraf 
Baseline
N=70 
1 Year Post-
Conversion
N=62†
2 Year Post-
Conversion
N=57†
3 Year Post-
Conversion N 
=51†
Mean Dose (mg/day)
Range (mg/day)
5.7
(1-19)
6.0
(1-17)
6.0
(1-18)
5.9
(1-16)
Mean Trough Conc. (ng/mL)
Range (ng/mL)
6.6
(3-11.9)
6.5
(1.7-12.8)
6.6
(1.9-10)
6.7
(1.6-20)
Mean Serum Creatinine (mg/dL)
Range (mg/dL)
1.4
(0.7-3.6)
1.5
(0.7-3.1)
1.5
(0.7-3.8)
1.6
(0.7-5.1)
† N = completers at each year
Patient and graft survival were 99% and 97% respectively at three years 
post-conversion. Through three years, four biopsy confi rmed acute rejection 
episodes occurred in four patients: Grades IA (Day 727), IB (Day 235), IIA 
(Day 163), and IIB (Day 466). One patient had multiple rejection episodes. 
All episodes resolved with treatment. One patient died due to lung cancer. One 
patient experienced graft loss due to polyoma virus infection.
Medication use for diabetes, hypertension, and hyperlipidemia at three years 
was similar to usage at conversion. There have been twelve occurrences of 
glucose intolerance (based on fasting plasma glucose ≥126 mg/dL). None of 
these patients required insulin therapy and one required an oral hypoglycemic 
agent. There were no patients with hemoglobinA1c ≥ 6%.
Conclusions: The three year data continues to support the safety and effi cacy 
of conversion from Prograf BID to Advagraf QD a.m. in kidney transplant 
recipients.
EFFICACY, TOLERABILITY AND SAFETY OF 627 
MYCOPHENOLATE MOFETIL (CELLCEPT) + SIROLIMUS 
(RAPAMUNE) AS MAINTENANCE THERAPY AFTER 
CALCINEURIN INHIBITOR WITHDRAWAL IN LRD AND CAD, 
ADYLTS AND PEDIATRIC RENAL TRANSPLANT RECIPIENTS. 
(EXPERIENCE WITH 405 PATIENTS)
A. Holm, M. Hernandez, A. Camarena, L. Perez, M. Santos, M.A. Porras
UMAE HGCMN LA RAZA IMSS
In a 3-year open-label, prospective, randomized, controlled study, patients 
maintained on MMF and a CNI were randomized 30-180 days after 
transplantation to received MMF (1-2.0 g day) plus SRL (2-8 mg day, followed 
by 1-2 mg/day; trough 5-10 ng/mL) and, discontinued the CNI (MMF/SRL 
group) or to continued their current regimen (MMF/CNI group). All patients 
received corticosteroids in low dose regimen (5-10mg day) and discontinued 
after 12 months of transplant.
Antibody induction: Daclizumab-1mg/kg, divided in two doses (day-0 and 
7) used in high risk LRD and CAD recipients. Effi cacy endpoints included: 
clinical data of all patients (baseline, 3, 6, 9, 12, 18, 24 and 36 months) and, the 
proportion of patients with biopsy-proven acute rejection (BPAR), graft loss, 
morbidity, death, and the percent change in measured glomerular fi ltration rate 
(GFR; 99m Tc-MAG3).
Results: 405 randomized patients, within aged 24.7+-8.4 years, receiving 
either MMF/SRL (n=220) or MMF/CNI (n=185) have completed 36 months 
of follow-up. Baseline characteristics and measured GFR values were similar 
in the treatment groups. Mean time post transplantation to randomization was 
108+-72 vs 115+-65 days for MMF/SRL and MMF/CNI groups, respectively. 
BPAR was seen in 14/220 (6.3%) MMF/SRL treated patients and 29/185 
(15.7%) of those receiving MMF/CNI. Graft loss was experienced by 6/220 
(2.7%) of those in the MMF/SRL group and, 18/185 (9.7%) of those in the 
MMF/CNI group, p < 0.005. No patient in the MMF/SRL group and, 5/185 
(2.7%) in the MMF/CNI group died. Patients receiving MMF/SRL had a 
48.8+-10.2 ml/min of GFR at 1-year compared with 32.7+-5.4 ml/min in those 
treated with MMF/CNI. SRL had minor side effects: dyslipidemias in 12/220 
(5.4%) and slight proteinuria without presence of graft loss at 1-year; while 
the proteinuria in the MMF/CNI was no signifi cant. Safety outcomes were 
generally similar in the treatment groups.
Conclusions: Our center is a Multiorganic Transplant Program, which 
performed at least 140 kidney, 35 liver and 30 heart transplants per year. Based 
on a 3-year experience in 220 patients with MMF/SRL maintenance therapy, 
showed improvements in GFR, low acute rejection rate and low side effects. 
Final results will provide more defi nitive conclusions about the long-term 
effect of these regimens on renal function, but it appears that maintenance 
immunosuppression with MMF/SRL provides long-term graft protection and 
is a safe (effi cacy and tolerability) regimen.
INTERLEUKIN-2 RECEPTOR ANTAGONIST REDUCES 628 
REJECTION RATES AND GRAFT LOSS IN LIVE-DONOR 
KIDNEY TRANSPLANT RECIPIENTS
W. Lim, S. Chang, S. Campbell, S. Chadban, G. Russ, S. McDonald
ANZDATA Transplant Work Group, ANZDATA Registry, Adelaide SA, 
Australia
Aims: The use of interleukin (IL)-2 receptor antagonist (IL2RA) in live-
donor related kidney transplantation has been associated with a reduction in 
acute rejection rates. However, the impact of IL-2RA induction in live-donor 
kidney transplantation on renal function, graft and patient survival remains 
unknown.
Methods: Using ANZDATA registry, all live-donor kidney transplant 
recipients in Australia between 1991 and 2005 were analysed (n=2050). 
Multiple organ grafts, recipients’ age <16 at time of transplant, recipients 
on calcineurin-inhibitor and/or steroid-free regimens were excluded 
from analyses. Induction therapy with monoclonal and polyclonal T cell-
depleting agents was also excluded. Outcomes analysed included the 
presence of rejection at 6 months, graft and patient survival, and eGFR at 
1 and 5 years. Confounding factors include donor and recipient variables 
(including HLA-matching), as well as transplant year and type of initial 
immunosuppression.
Results: The use of IL2RA reduced the risk of acute rejection in the fi rst 6 
months post-transplant in both univariate (odds ratio [OR] 0.44, p<0.0001) 
and multivariate analyses (OR 0.49, p<0.0001). Late rejection >6 months post-
transplant was similar in both groups. There was reduced graft loss at 5 years 
(multivariate hazard ratio [HR] 0.61, p=0.03) and improved eGFR at 1 year 
(unadjusted difference of mean 2.8ml/min, p<0.01) with the use of IL2RA in 
live-donor transplantation. There was a non-signifi cant trend towards reduced 
death-censored graft loss, patient death and a superior eGFR at 5 years with the 
use of IL2RA in the multivariate model.
Conclusions: The use of IL2RA in live-donor kidney transplantation improves 
renal allograft outcomes independent of HLA-matching and the type of initial 
immunosuppression.
FINAL RESULTS OF THE SPARE THE NEPHRON TRIAL 629 
(CNI WITHDRAWAL TRIAL)
T.C. Pearson1, A. Patel2, J. Scandling3, H. Shidban4, M. Weir5, D. Patel6, 
S. Mulgaonkar7
1Emory University Hospital, 2Henry Ford Hospital, 3Stanford Univeersity, 
4National Institute of Transplantation, 5University of Maryland, 6Roche, 
7St. Barnabas Medical Center
Purpose: To evaluate the effi cacy and safety of a maintenance 
immunosuppressive regimen of mycophenoloate mofetil (MMF) and sirolimus 
(SRL) after CNI withdrawal compared with that of MMF and a CNI in renal 
allograft recipients.
Methods: This open-label, prospective, multicenter study, randomized 305 
patients (maintained on MMF and a CNI) 30-180 days post-transplant to 
receive either MMF (1-1.5 g BID) plus SRL (2-10 mg followed by at least 2 mg/
day; trough 5-10 ng/mL) and discontinue the CNI (MMF/SRL) or to continue 
their current regimen (MMF/CNI). Antibody induction and/or corticosteroids 
were administered according to individual center practice. Effi cacy endpoints 
included the proportions of patients with biopsy-proven acute rejection 
(BPAR), graft loss, and death at 12 months, and the percent change in measured 
glomerular fi ltration rate (GFR; cold iothalamate) from randomization. 
Results: Mean time from transplant to randomization in both groups was 117 
days. Baseline characteristics and measured GFR values were similar in the 
treatment groups.
BPAR was reported in 8/123 (6.5%) MMF/SRL-treated patients and 9/126 
(7.1%) receiving MMF /CNI. Graft loss occurred in 2/123 (1.6%) in the MMF/
SRL group and 3/126 (2.4%) in the MMF/CNI group.
Mean Percent Change (n) in Renal Function From Randomization (Baseline) 
to Month 12
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MMF/CNI
MMF/SRL All Subjects MMF/TAC
Measured GFR 25.8±75.0 (96) 11.3±61.5 (100) 4.7±54.4 (77)
Calculated GFR 7.1±23.0 (97) 1.4±19.8 (104) 0.4±19.1 (79)
SCr -1.8±20.9 (99) 6.8±33.0 (105) 9.2±35.1 (80)
Calculated CrCl 5.6±22.4 (99) -0.5±23.2 (105) -2.1±23.3 (80)
CrCl, creatinine clearance; SCr, serum creatinine
Conclusions: MMF-based maintenance therapy in combination with sirolimus 
appears to be associated with improved renal function when compared with 
MMF/CNI-containing regimens without increasing the risk of acute rejection 
and is tolerated in almost 80% of patients.
CONCURRENT ORAL SESSION 44: 
CMV AND OTHER VIRAL DISEASES
HUMAN CYTOMEGALOVIRUS ANTIVIRAL 630 
RESISTANCE IN IMMUNOCOMPROMISED TRANSPLANT 
RECIPIENTS
J. Iwasenko1,3, G. Scott1,2,3,4, S. Chou5,6, W. Rawlinson1,2,3,4
1Virology Research, POWH & UNSW Research Laboratories, Prince of Wales 
Hospital, Sydney, AUS, 2Virology Division, Department of Microbiology, 
SEALS, Prince of Wales Hospital, Sydney, AUS, 3School of Biotechnology and 
Biomolecular Sciences, Faculty of Science, University of New South Wales, 
Sydney, AUS, 4School of Medical Sciences, Faculty of Medicine, University 
of New South Wales, Sydney, AUS, 5Medical & Research Services, Veterans 
Affairs Medical Center, Portland, USA, 6Division of Infectious Diseases, 
Oregon Health and Science University, Portland, USA
Immunocompromised transplant recipients are at high-risk for infection 
with human cytomegalovirus (CMV) and life-threatening CMV-related 
disease. Antiviral prophylaxis or treatment with ganciclovir (GCV), and now 
valganciclovir (valGCV), has reduced the morbidity and mortality caused 
by CMV, but antiviral resistant CMV strains still emerge and contribute to 
CMV-related disease and adverse clinical outcomes in approximately 10% of 
recipients. Even more problematic is the development of multi-drug (GCV, 
foscarnet and cidofovir) resistance CMV, severely limiting the treatment 
options for individuals infected with these strains. We have been investigating 
CMV genotypes in Australian lung, liver and renal transplant recipients to 
determine the prevalence, impact and changing patterns of antiviral resistant 
CMV in treated immunocompromised patients. CMV-positive clinical 
specimens were assessed for the presence of antiviral resistant strains by 
genotypic analysis, where the genes that encode the CMV protein kinase 
(UL97) and the viral DNA polymerase (UL54) are amplifi ed by nested PCR 
and sequenced to identify mutations known to confer antiviral resistance. 
Previously unrecognized mutations identifi ed in association with clinical 
antiviral resistance are further characterized by transfer to an antiviral sensitive 
CMV strain and subsequent phenotypic antiviral susceptibility analysis of the 
recombinant virus.
Antiviral resistant CMV strains were identifi ed in 34% (18/53) of patients 
tested. Multi-drug resistant CMV strains containing mutations in both UL97 
and UL54, or dual infections with single UL97 and UL54 variants (not always 
at the same time point) were responsible for 13% (7/53) of infections. Nearly 
half (47%) of the CMV strains containing mutations in UL97 and UL54 were 
identifi ed in lung transplant recipients, despite this group accounting for only 
16% of patients studied. A previously unrecognized UL97 mutation (N597D) 
identifi ed in a heart transplant recipient was shown to confer moderate GCV 
resistance on marker transfer analysis. ValGCV treatment reduced the viral load 
to undetectable levels in this patient indicating that antiviral treatment can be 
effective against moderately resistant CMV strains. A previously unrecognized 
UL54 mutation (D485N) was also identifi ed in a CMV strain from another heart 
transplant recipient. This strain also contained a GCV-resistant UL97 mutation 
(C603F) and UL54 mutation (P522S) that confers both GCV and CDV. The 
D485N mutation occurs in a region of the UL54 DNA polymerase that is 
invariant in antiviral sensitive strains and in proximity to other known GCV 
and CDV resistance mutations, and marker transfer experiments are underway 
to characterize the antiviral susceptibility of this mutation. Interestingly, a 
different antiviral resistant strain/s with UL97 mutation C592G and UL54 
mutation P522S was identifi ed a year earlier in this patient, indicating ongoing 
mixed CMV infections with differing profi les of multi-drug resistance.
Emergence of antiviral resistance remains a signifi cant issue in 
immunocompromised patients treated with antiviral agents and emphasizes the 
relevance of regular antiviral resistance testing. Better understanding of the role 
of individual and combined mutations in the susceptibility of CMV strains to 
antiviral agents is improving diagnosis, assisting in patient management and 
treatment and will improve outcomes for transplant recipients in the long-term.
INVESTIGATIONS INTO THE PATHOGENESIS 631 
OF CYTOMEGALOVIRUS-INDUCED TRANSPLANT-
ARTERIOSCLEROSIS USING A HUMANIZED 
MOUSE MODEL
S. Ensminger1, S. Abele1, M. Leis2, M. Wollin2, M. Weyand1, T. Stamminger2
1Department of Cardiac Surgery, University of Erlangen - Nuremberg, 
Germany, 2Institute for clinical and molecular Virology, University of 
Erlangen - Nuremberg, Germany
Introduction: Recent fi ndings have emphasised an important role of human 
cytomegalovirus infection (HCMV) in the development of transplant 
arteriosclerosis. Therefore, the aim of this study was to develop a human 
peripheral blood lymphocyte (hu-PBL)/RAG-2(-/-)gc(-/-) mouse-xenograft-
model to investigate the immunological mechanisms of HCMV in the 
progression of transplant arteriosclerosis.
Methods: Sidebranches from the internal mammarian artery were harvested 
during CABG surgery, tissue-typed and infected with a clinical isolate of HCMV 
(VR1814). In a next step size-matched sidebranches were implanted into the 
infrarenal aorta of RAG-2(-/-)yc(-/-) mice. The animals were reconstituted with 
approximately 5x107 peripheral blood mononuclear cells (PBMCs) 7 days after 
transplantation. Human cell engraftment was measured by FACS and ELISA. 
HCMV Infection was confi rmed by RT-PCR and immunofl uorescence. Arterial 
grafts were harvested on day 40 after transplantation and histological analysis 
was performed.
Results: Analysis of artery grafts after HCMV infection showed signifi cant 
amounts of viral DNA on days 7 and 14 after infection and immunohistochemical 
analysis revealed IE-2 protein expression on endothelial cells of the artery 
grafts. PBMC-reconstituted RAG-2(-/-) gc(-/-) animals showed splenic 
chimerism levels ranging from 28-40% human cells. After reconstitution 
with PBMCs RAG-2(-/-)gc(-/-) developed human leukocyte infi ltrates in their 
grafts and signifi cant amounts of transplant arteriosclerosis. In addition our 
fi rst data using this model suggest that HCMV infection of the arterial graft 
resulted in elevated levels of transplant arteriosclerosis. Arterial grafts from 
unreconstituted RAG-2(-/-)gc(-/-) recipients showed no vascular lesions.
Conclusion: These data suggest that HCMV-Infection plays an important 
role in the development of transplant-arteriosclerosis in a humanised mouse 
arterial-xenograft-model.
A PROSPECTIVE STUDY OF VIRAL GENETIC 632 
POLYMORPHISMS IN CMV GLYCOPROTEIN B AND 
THEIR ASSOCIATION WITH CLINICAL AND VIROLOGIC 
OUTCOMES IN PATIENTS WITH CMV DISEASE: 
RESULTS FROM THE VICTOR STUDY
O. Manuel1, V. Emery2, A. Asberg3, A. Hartmann3, M. Pescovitz4, X. Pang1, 
H. Rollag3, A. Jardine5, A. Humar1
1University of Alberta Hospital, 2University College London, 3University of 
Oslo, 4Indiana University, 5Univesrity of Glasgow
Background: It is unknown if specifi c viral polymorphisms affect in vivo 
virulence in patients with CMV disease. Polymorphisms in the CMV UL55 
gene encoding the glycoprotein B (gB), allow discrimination of four distinct 
genotypes (gB1-4). We assessed the infl uence of gB genotypes on CMV disease 
in a prospective cohort of patients with CMV disease.
Methods: Organ transplant recipients enrolled in an international trial 
(VICTOR study) of CMV disease treatment (valganciclovir or intravenous 
ganciclovir) were included. Quantitative and sensitive CMV gB genotyping 
was performed using a real-time PCR at Day 0 (start of antiviral therapy) and 
at days 3, 7, 14, and 21 after starting antiviral therapy. Mixed infection was 
defi ned as CMV infection with more than one gB genotype in a single sample.
Results: 229 patients with CMV disease were analyzed. The prevalence of 
gB strain types at day 0 was gB1 (28%), gB2 (14%), gB3 (14%), gB4 (6%) 
and mixed-infection in 38%. Patients who were seropositive at the time of 
transplantation were more likely to have mixed gB infection compared to 
seronegative patients (41% vs. 12%, p=0.003). Mean baseline viral loads 
were similar for different gB types but were higher for mixed vs. non-mixed 
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infections (4.36 vs. 4.16 log10 copies/ml; P=0.056). Time to viral eradication 
was longer in mixed vs. non-mixed infections (median of 22.0 ± 2.0 vs. 
19.0±1.0 days, respectively, p=0.06). Patients with mixed infection displayed 
complex decay patterns but decay kinetics for all genotypes showed a bisphasic 
response with a 1st phase half-life of ~0.7 days and a 2nd phase of ~3days. 
1st phase declines were fastest for gB1 (p=0.0001 vs. gB2 and 4) while gB4 
decline was slower than gB3 during the 1st phase. 2nd phase declines were 
similar between gB1 and gB3 (3 days and 2.9 days) but were slower for gB2 
and gB4 (3.45 days; p=0.01). In a multivariate model accounting for baseline 
viral load, CMV IgG at baseline, ganciclovir resistance, and antiviral treatment 
(valganciclovir or ganciclovir), mixed gB infection was a signifi cant predictor 
of failure of therapy at Day 21 (mixed vs. non-mixed OR 2.87; 95% CI: 1.38 
to 5.95; P=0.005). No effect of gB genotype was seen on virological or clinical 
CMV recurrence.
Conclusion: No specifi c strain of CMV based on gB genotyping appears to 
confer a specifi c viral virulence advantage. However, mixed infection with 
different gB genotypes is associated with higher viral loads and delayed 
virological clearance suggesting a role for viral polymorphisms in infl uencing 
in vivo viral fi tness.
DEMONSTRATION OF HHV-6 ANTIGENS IN BIOPSIES 633 
OF KIDNEY TRANSPLANT RECIPIENTS WITH CMV 
INFECTION
I. Helanterä1,2, R. Loginov2,3, P. Koskinen1, I. Lautenschlager2,3
1Helsinki University Hospital, Dept of Medicine, Division of Nephrology, 
2Helsinki University Hospital, Transplant Unit Research Laboratory, 
3Helsinki University Hospital, Department of Virology
Introduction: In organ transplant recipients receiving immunosuppressive 
medication, highly seroprevalent human herpesvirus-6 (HHV-6) reactivates 
from latency during the fi rst posttransplant weeks, often together with 
cytomegalovirus (CMV) infection. Whereas CMV has been associated with 
signifi cant morbidity and enhanced rejection of organ transplants, the role of 
HHV-6 after transplantation is less clear. CMV is able to persist in the kidney 
allograft for a long period after viremia, and this persistence has been associated 
with histopathological changes in the graft and inferior outcome. Although the 
presence of HHV-6 in the renal allograft has been reported, not much is known 
about the HHV-6 in the kidney. We examined the presence and the possible role 
of HHV-6 and CMV in the biopsies of adult kidney transplant recipients with 
previous CMV infection.
Methods: Frozen biopsy material for the retrospective detection of HHV-6 
and CMV antigens was available from 22 adult kidney transplant recipients, 
transplanted during 1992-2000 in the Helsinki University Hospital, who all 
had had a previous CMV infection. Follow-up data of fi ve years was analyzed. 
The diagnosis of CMV infection was based on the standard CMV pp65 
antigenemia test and viral cultures from blood and urine. CMV infections were 
treated with i.v. gancyclovir. CMV and HHV-6 antigens were demonstrated in 
frozen sections of kidney allograft biopsies using immunoperoxidase staining 
and monoclonal antibodies against CMV pp65 and HHV-6B. The biopsy 
histopathology was described according to Banff ’97.
Results: CMV infection was diagnosed mean 47±27 days after transplantation 
by pp65-antigenemia in all except one patient, in whom CMV was detected 
by viral culture from urine. Biopsies used for the detection of the viruses 
were taken mean 327±364 after transplantation (range 30-1484). HHV-6 
antigens were demonstrated in biopsies of 7/22 patients 18-1330 days after 
symptomatic CMV infection (mean 215±346). HHV-6 antigens were located 
in infi ltrating leukocytes in the transplant of 6 patients, and in tubular epithelial 
cells in two patients. A positive HHV-6 fi nding was not associated with 
increased histopathological changes or reduced renal function at 5 years after 
transplantation. CMV antigens were found in the biopsies of seven patients. 
Only 1/7 of these biopsies demonstrated also HHV-6 antigens. Persistent CMV 
antigens were demonstrated in the biopsies mean 93±74 after last positive 
CMV fi nding from blood or urine.
Conclusions: HHV-6 antigens were commonly found in late kidney allograft 
biopsies, suggesting that HHV-6 may persist in the kidney allograft. The nature 
and clinical relevance of this fi nding remains to be elucidated.
ORAL VALGANCICLOVIR AND INTRAVENOUS 634 
GANCICLOVIR RESULTS IN COMPARABLE LONG-TERM 
OUTCOMES IN TRANSPLANT RECIPIENTS WITH CMV 
DISEASE: THE VICTOR STUDY
A. Åsberg1, M.D. Pescovitz2, A. Humar3, A.G. Jardine4, H. Rollag1, 
H. Mouas5, A. Hartmann1
1University of Oslo, 2Indiana University, 3University of Alberta, 4University of 
Glasgow, 5F. Hoffmann-La Roche Ltd.
In the VICTOR-trial we previously showed that 21 days of oral valganciclovir 
(900 mg twice daily) was non-inferior to intravenous ganciclovir (5 mg/kg twice 
daily), in the treatment of CMV disease. Both arms further received maintenance 
treatment with valganciclovir 900 mg once daily until Day 49. The present report 
deals with long-term outcomes during one year of follow-up in the 321 enrolled 
patients. The study population consisted of kidney (74.1%), heart (5.6%), liver 
(7.2%), lung (5.9%) and other/combined (7.2%) recipients. Blood samples 
were collected at days 0, 21, 49, month 3 and 6 and in case of recurrence for 
central analyses of anti-CMV IgG titers (Abbott Architect), plasma viral loads 
(Amplicor, cut-off 600 copies/mL) and genotypic ganciclovir resistance.
There were no signifi cant differences in either viral clearance or resolution of 
CMV disease between the two arms throughout the follow-up. Overall clinical 
treatment success was 82.6% ay Day 21 and 91.1% at Day 49. The clinical 
recurrence beyond Day 49 was 14.4% and the virologic recurrence was 28.6%.
Patients with persistent CMV viremia at day 21 were signifi cantly more 
likely to recur (absolute yearly risk: 23.2% [95% CI: 15.7-34.1%] vs. 9.6% 
[6.3-14.7%]). Patients who were CMV IgG negative at day 0 had higher 
recurrence rate: 8/29 (27.6% [15.6-48.6%]) vs. CMV IgG positive patients: 
26/200 (13.0% [9.1-18.5%]; P=0.039, chi square). Lung transplant patients 
were more likely to recur (37.5%) than kidney (14.4%), heart (6.3%) and liver 
(0%) recipients. In a multivariable logistic regression analysis including viral 
clearance at days 21 and 49, baseline viral load and CMV IgG serostatus (+ 
vs -), transplanted organ and treatment arm (valganciclovir vs ganciclovir), 
the only independent predictor for recurrence was viral eradication at day 21 
(Clinical recurrence: OR 3.9 [1.3-11.3], P=0.012; Virological recurrence: OR 
5.6, [2.5-12.6], P<0.0001).
Five patients (2.0%) had resistant strains at baseline and eight more developed 
resistance during treatment (NS). Seven out of 94 patients with viremia at day 
21 had a resistance mutation (absolute risk: 7.4% [3.7-14.9%]) while those who 
were positive at day 49 had a rate of 4/13 (30.8% [14.3-65.0%]).
Eleven (valganciclovir) and nine (ganciclovir) patients died during follow-up 
(NS): twelve due to bacterial infections, eight were organ failures.
In conclusion, there were no differences in long term outcomes in transplant 
patients initially treated with either oral valganciclovir or intravenous 
ganciclovir for CMV disease. This supports the use of oral valganciclovir 
for treatment of CMV disease. The data further indicates that the CMV IgG 
status at start determines the response. Induction therapy should be given for at 
least 21 days and viral load measured prior to reduction to maintenance dose. 
Patients with persistent viremia at 21 days should continue on treatment doses, 
but are not likely to have resistant mutations, whereas patients with viremia 
at 49 days should be evaluated for resistance. These data support a patient-
specifi c treatment regimen based on viral load at days 21 and 49, identifi cation 
of CMV resistance at day 49 and probably also baseline CMV IgG status.
DONOR-DERIVED DISEASE TRANSMISSION EVENTS 635 
IN THE UNITED STATES 2006 – 2008: A REPORT FROM THE 
OPTN/UNOS DISEASES TRANSMISSION ADVISORY GROUP 
(DTAG)
M. Ison, J. Hager, V. McEwen, E. Blumberg, K. Carney, J. Cutler, M. DiMaio, 
R. Hasz, L. Teperman, M. Nalesnik
OPTN/UNOS Diseases Transmission Advisory Group
Background: Donor-derived disease transmission is increasingly recognized 
as a source of morbidity and mortality among transplant recipients. Policy 4.0 
of the OPTN currently required reporting of donor-derived events.
Methods: All potential donor-derived transmission events (PDDTE) that were 
reported to OPTN/UNOS and the DTAG through the patient safety system 
were reviewed by the Group from January 1, 2006 - December 31, 2007 (Data 
through May 31, 2008 will be presented at the meeting). Summary data were 
prepared for presentation.
Results: Reports of PDDTE have increased from 7 in 2005, the fi rst full year 
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data was collected, to 60 in 2006, the fi rst year that electronic submission was 
available, to 97 in 2007. During the 2006-2007 period, there were 52 reports of 
malignancy PDDTE with 7 (13%) documented transmissions and 3 attributable 
deaths (Table 1; there were 72 reports of infectious diseases PDDTE with 14 
(19%) documented transmissions and 6 attributable deaths (Table 2). Many of 
the cases remain under investigation so documented transmission and deaths 
may increase.
Conclusions: PDDTE are being increasingly reported to DTAG. Documented 
transmissions occur in 13-19% of reports with 43% of confi rmed transmissions 
resulting in patient deaths. This likely under represents the true incidence and 
impact of donor-derived infections.
Table 1. Potential Donor-Derived Malignancies Transmissions Reported to 
DTAG
Disease Reports in Donors Confi rmed Cases in Recipients
Attributable Deaths 
in Recipients
Breast Cancer 1 0 0
Colon Cancer 1 0 0
Glioblastoma Multiforme 3 1 1
Hepatocellular Cancer 1 0 0
Kaposi’s Sarcoma 1 0 0
Leukemia 1 0 0
Lung 7 2 2
Lymphoma 3 2 0
Metastatic Melanoma 2 1 0
Myeloid Sarcoma 1 0 0
Ovarian Carcinoma 1 1 0
Pancreatic Adenocarcinoma 1 0 0
Prostate Adenocarcinoma 2 0 0
Renal Cell Carcinoma 24 2 0
Renal Papillary Adenocarcinoma 1 0 0
Thyroid Cancer 2 0 0
Table 2. Potential Donor-Derived Infectious Diseases Transmissions Reported 
to DTAG
Disease Reports in Donors Confi rmed Cases in Recipients
Attributable Deaths 
in Recipients
Bacteremias* 3 2 2
Bacterial Meningitis 1 0 0
Candidemia 1 0 0
Chagas 4 3 2
Cryptococcus 2 1 0
Cytomegalovirus 1 0 0
EBV 3 0 0
Hepatitis B 6 0 0
Hepatitis C 9 4 0
HIV 7 4 0
Histoplasmosis 3 0 0
HTLV 1 0 0
Infl uenza A 1 0 0
Legionella 1 0 0
Listeria 1 0 0
Mycotic Aneurysm 1 0 0
Rocky Mountain Spotted Fever 1 0 0
Schistosomiasis 2 1 0
S. aureus in transport media 1 0 0
Strongyloides 2 0 0
Syphilis 2 0 0
Toxoplasmosis 6 0 1
Tuberculosis 8 3 1
West Nile Virus 5 0 0
Zygomycetes 1 0 0
*Acinetobacter baumanii, Pseudomonas aeruginosa
NO EXCLUSION OF HHV-8 INFECTED DONORS AND 636 
RECIPIENTS FOR KIDNEY TRANSPLANTATION: 
A FRENCH PROSPECTIVE NATIONAL COHORT
C. Frances1, A-G. Marcelin2, C. Legendre3, S. Chevret4, E. Dussaix5, 
J. Lejeune4, A. Bigorie6, T. Schulz7, F. Agbalika4, C. Lebbe4
1Hopital Tenon, 2Hopital Pitie, 3Hopital Necker, 4Hopital Saint Louis, 5Hopital 
Paul Brousse, 6Drass D’ Ile-De-France, 7Hannover Medical School
Aims: The aim of this study was to appreciate the morbidity of HHV-8 
infection, preceding or transmitted by the renal graft.
Methods: A prospective French national study was conducted from 2001 to 
2006 (3 years of inclusion and 3 year of follow). Antibodies to HHV-8 latent 
nuclear antigen were detected by indirect immunofl uorescence (IF) in serum 
samples collected just before transplantation from donors and kidney recipients. 
Three groups were delineated according to the results: group A (HHV-8 + 
patients before graft), group B (HHV-8 - patients transplanted with a HHV-8 
+ donor) and group C (all other patients). HHV-8 serology of donors was 
controlled retrospectively using a lytic ELISA OrfK8.1. Blood samples were 
collected every 3 months for quantitative HHV-8 viral load (groups A and B), 
quantitative serology using a lytic ELISA OrfK8.1 (group A), detection of anti-
HHV-8 antibodies by 3 different methods. A seroconversion was defi ned by 
emergence of anti-HHV-8 antibodies detected by two different assays. All the 
statistic tests were performed using SAS (version 9.1) and R 2.5.1 softwares.
Results: The prevalence of HHV-8+ donors and recipients was 1.08% and 
3.24% leading to include 161 recipients in cohort A, 64 in cohort B and 
4,744 in cohort C. Compared to latent IF tested from donors, the sensibility 
of the lytic ELISA OrfK8.1 was 39.4% and the specifi city 98.2%. There was 
no difference in terms of survival or graft loss in the 3 groups. Among group 
A recipients, the cumulative incidences of Kaposi’s sarcoma (KS) and death 
without KS were respectively 0.13 and 0.063 at 3 years after transplantation. In 
multivariate analysis, only age > 53.5 years (p=0.025) and black skin (p=0.0054) 
were associated with development of KS. Positive HHV-8 viremia was not 
predictive of the development of KS although it was detected in 13/21 patients 
with KS and in 10/140 patients without KS. Quantitative HHV-8 serology 
showed a decrease of titers with time. Only 1 of the 64 recipients of the group B 
developed a severe clinical HHV-8 primary infection with cytopenia, fever and 
hemophagocytosis which was successfully treated with rituximab. Two other 
patients developed KS with low HHV-8 viremia concomitantly to KS. Other 
patients of group B did not have any clinical manifestations which could be 
related to HHV-8 infection although a seroconversion to positive HHV-8 status 
was documented in 24.8% of them.
Conclusions: The morbidity of HHV-8 infection during the fi rst 3 years 
after transplantation is low and does not justify actually to exclude HHV-8+ 
donors and recipients from kidney transplantation. Nevertheless, the long term 
outcome of these patients is still uncertain.
LONG TERM EXPERIENCE WITH THE USE OF 637 
KIDNEYS FROM HCV POSITIVE DONORS INTO HCV 
POSITIVE RECIPIENTS: A SPANISH COLLABORATIVE STUDY
B. Domínguez-Gil2, J.M. Morales1, N. Esforzado3, M.I. Delgado1, A. Andrés1, 
J.M. Campistol3
1Doce de Octubre Hospital, Madrid, Spain, 2Organización Nacional de 
Trasplantes, Madrid, Spain, 3Clinic i Provincial Hospital, Barcelona, Spain
The use of kidneys from donors with a positive serology for HCV into HCV 
(+) recipients still remains controversial. In 1990, our units adopted this policy, 
subsequently modifi ed in 1993, so these kidneys were limited to recipients with 
a positive RNA HCV before transplantation.
The aim of the present analysis was to review the long-term safety of our policy. 
Since January 1990 to February 2007, 474 HCV (+) patients with a negative 
HbsAg and not treated with interferon received a kidney transplant in our units. 
Three hundred and thirteen patients were transplanted from an HCV(-) donor 
(Group 1) and 161 from an HCV (+) donor (Group 2).
Median follow-up time was 65 (IR 24-117) months. Remarkably, Group 2 
showed a signifi cantly higher donor age (46.6±13.6 versus 41.1±18.8 years; 
p<0.0001) and recipient age (50.4±13.1 versus 44.9±14.6 years; p<0.0001), as 
well as a worse HLA compatibility than Group 1. Immunosuppressive therapy 
did not signifi cantly differ between the two groups.
Main Outcome Results in HCV (+) Kidney Transplant Patients
 
Group 1
HCV (-) donors
(N=313)
Group 2
HCV (+) donors
(N=161)
p 
5 year death-censored graft survival* 69.5% 62.6% 0.1433
10 year death-censored graft survival* 58.4% 45.1% 0.1433
5 year patient survival* 84.3% 81.6% 0.5631
10 year patient survival* 73% 70.4% 0.5631
Chronic liver disease** 10.5% 15.5% 0.138
Severe liver disease*** 5.5% 7.9% 0.285
*Life table analysis **ALT > 2.5 times the upper normal limit for more than 6 months ***Signs of 
hepatocelular insuffi ciency and/or portal hypertension
Notably, only 5 patients died because of a liver disease (3 in Group 1 versus 2 in 
Group 2) and only 2 patients developed a hepatocarcinoma (both in Group 1). 
In summary, no signifi cant differences were observed in HCV (+) recipients 
according to HCV serology of the donor, in terms of death censored graft 
survival, patient survival and evolution of liver disease. Therefore, our 
experience clearly demonstrates that the use of kidneys from HCV (+) donors 
into HCV (+) recipients is a safe strategy in the long-term and a wise way of 
using these kidneys, that otherwise would be lost at a moment of shortage.
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MULTIVARIATE ANALYSIS OF 81 LIVER TRANSPLANTS 638 
(LT) FROM HTLV I/II DONORS – UNOS REGISTRY DATA
M.R. Marvin1, G.N. Brock2, R. Nagubandi1, K.V. Ravindra1, M. Eng1, 
J.F. Buell1
1Division of Transplantation, University of Louisville, Louisville, KY, United 
States and 2Bioinformatics and Biostatistics, University of Louisville, 
Louisville, KY, United States. 
HTLV has been associated with leukemia/lymphoma and progressive 
neurological disease. The purpose of this study was to evaluate the results of 
LT using donors positive for HTLV.
An analysis of the UNOS database was performed and included all LTs 
performed in the United States from 11/92-5/07. Donor, recipient, and organ 
procurement logistical factors were evaluated. Statistics were performed using 
SAS software.
There were 29,667 (-) and 81 (+) donors included in the analysis. Selected 
variables are presented in table I.
UNOS data – Univariate Analysis
Variable
 
HTLV (-) 
(N=29667)
HTLV (+) 
(N=81)  p-value
N Percent N Percent
Race White 22102 75 41 51 <0.001
 Black 3479 12 30 37  
 Hispanic 3168 11 9 11  
Diabetes - Donor 1622 5 10 13 0.01
Hypertension - Donor 7114 24 35 43 <0.001
Share Type Local 21564 73 29 36 <0.001
 Regional 6401 22 13 16  
 National 1702 6 39 48  
Functional Status at Transplant Well 11383 39 34 43 <0.001
 Average 5699 19 24 30  
 Poor 535 2 10 13  
Functional Status at Last Follow Up Well 15445 56 44 57 0.002
 Average 2755 10 14 18  
 Poor 1119 4 7 9  
 Mean Mean p-value
DRI 1.7 2.1 <0.001
Creatinine - Recipient 1.5 1.6 0.7439
Bilirubin - Recipient 7.5 5.8 0.097
Age - Recipient 50.6 55.5 <0.001
MELD 20.2 18.4 0.0623
Age - Donor 38.8 45.7 <0.001
Cold Ischemia Time 7.1 6.5 0.3144
Variables affecting graft and patient survival along with survival curves are 
depicted in the fi gures below.
HTLV (+) grafts yield identical graft and patient survival with no signifi cant 
differences in functional outcome.
CYTOKINESCONCURRENT ORAL SESSION 45: 
ABSENCE OF NEUTROPHIL-MEDIATED RENAL 639 
DYSFUNCTION AND TUBULAR CELL APOPTOSIS 
FOLLOWING RENAL ISCHEMIA/REPERFUSION IN CXCR2-/- 
MICE
M. Araki1,2, H. Kumon2, R. Fairchild1
1Cleveland Clinic, 2Okayama University School of Medicine
Introduction: Ischemia/reperfusion (I/R) injury has a critical impact on 
the outcome of organs transplant. The factors directing cell infi ltration into 
parenchymal tissues during I/R injury remain unclear. Previous studies from 
this laboratory in a mouse model have shown rapid induction of neutrophil 
chemoattractant chemokine expression and parenchymal neutrophil infi ltration 
shortly following reperfusion of ischemic kidneys. The goal of the current 
study was to investigate the induction and role of chemokine receptors in this 
model of renal I/R injury.
Methods: BALB/c wild-type and CXCR2-/- mice were anesthetized and the 
renal hilum was clamped for 45 min while the temperature was maintained 
at 32°C. At various times post-reperfusion, ischemic and control kidneys 
were removed, whole cell RNA was prepared and tested for expression of 
chemokine receptor genes by ribonuclease protection assay. Frozen sections 
were prepared from kidneys and stained for the chemokines KC, MIP-2, and 
for neutrophils and macrophages by immunohistochemistry. Serum creatinine 
was measured each day post-reperfusion. In some experiments mice were 
depleted of neutrophils by treatment with anti-Ly6G mAb and/or were treated 
with goat anti-CXCR2 antiserum. Controls were treated with normal rat IgG or 
normal goat serum. TUNEL assay was done to detect apoptosis.
Results: CXCR2 was the most highly expressed receptor in ischemic kidneys 
with expression peaking 18 h after reperfusion. The ligands for CXCR2, 
KC and MIP-2, were clearly present in the tubular epithelial cells 9 h after 
reperfusion by immunocytochemistry. Renal dysfunction was abrogated in 
CXCR2-/- mice as well as in wild-type animals depleted of neutrophils before 
reperfusion. Treatment of wild-type mice with anti-CXCR2 antibodies at the 
time of reperfusion resulted in extremely high serum creatinine levels 24-48 
h after reperfusion followed by 100% loss in viability. This renal failure was 
dependent on neutrophils as it was not observed in mice depleted of neutrophils 
before renal ischemia and reperfusion.
Conclusions: CXCR2 plays an important role in kidney I/R injury. However, 
the use of CXCR2 antagonists to attenuate neutrophil infi ltration and the injury 
following reperfusion should be carefully considered.
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IL-4 TREATMENT OF THE LIVER DONOR INDUCES 640 
ALTERNATIVELY-ACTIVATED (TYPE 2) MACROPHAGES 
AND CONVERTS LIVER TRANSPLANT REJECTION TO 
ACCEPTANCE
C. Wang, S.S. Tay, A. Buchanan, J. Laurence, R. Allen, A. Sharland, 
G. McCaughan, A. Bishop
Royal Prince Alfred Hospital And University of Sydney
Background: PVG strain rat liver transplants are accepted in low responder 
DA strain recipients without requiring immunosuppression but rejected in 
high responder Lewis strain recipients. We have previously shown that IL-4 
treatment of the DA strain recipient converts acceptance to rejection and the 
aim of this study was to examine the mechanism of this conversion.
Methods: PVG to DA liver transplants were compared with PVG to Lewis 
transplants and PVG to DA liver transplants treated from day 3 to day 7 with 
recombinant IL-4 (30,000 U/day i.p). In subsequent experiments, PVG donors 
were treated with 5 daily injections of IL-4 (30,000 U/day i.p). and the liver 
was transplanted to Lewis strain recipients. In separate experiments, the time 
course of infi ltration was measured by immunohistochemistry and the pattern 
of expression of cytokine mRNA by quantitative real-time PCR
Results: IL-4-induced rejection of PVG livers in DA strain recipients was 
associated with a marked increase in macrophage infi ltration, but no detectable 
differences in T cell infi ltration or antibody deposition. Of interest, the 
extensive macrophage infi ltrate in IL-4-treated grafts was not associated with 
increased iNOS expression but instead with a marked increase of the putative 
immunosuppressive molecule indoleamine dioxygenase (IDO), suggesting 
that the IL-4-induced macrophage infi ltrate could consist of type 2 rather than 
type 1-activated macrophages. Treatment of PVG donors with IL-4 led to a 
marked infi ltration with macrophages but little or no change in expression of 
iNOS or TNF-alpha, markers of type 1 macrophages. In contrast there was a 
massive increase in IDO (0.02¡Ó0.004 in untreated versus 196.6¡Ó117 in IL-4 
treated). This suggested that IL-4 treatment of the donor induced macrophages 
with a putative immunoregulatory phenotype that could prolong transplant 
survival. Transplantation of IL-4-treated PVG livers to Lewis strain recipients 
led to marked prolongation of survival of most recipients (19, 20, 91, >130, 
>160„e2, MST >110) compared to untreated (10, 11„e2, 12, 13, 17, 19, MST 
12)(p=0.001). Acceptance of IL-4-treated PVG livers in Lewis recipients was 
compared with rejection of untreated PVG livers. There was little difference 
in the pattern of infi ltration or cytokine expression in the transplanted liver 
however there was a rapid increase of IL-2 in the recipient spleen associated 
with liver acceptance, similar to our fi ndings in spontaneous acceptance of 
unmodifi ed PVG to DA liver allografts.
Conclusion: IL-4 treatment has opposite effects depending on whether it is 
administered to the liver donor before transplantation or to the recipient 3 days 
after transplantation. Alternatively activated (type 2) macrophages appear to be 
closely associated with both phenomena, suggesting that they may induce very 
early skewing of the immune response to acceptance rather than rejection.
IL-18 DEFICIENCY IN RECIPIENTS INDUCED EARLY 641 
REJECTION OF MHC CLASS II-DISPARATE CARDIAC 
ALLOGRAFT IN MICE
H-T. Ko1,2, J-L. Yin1, B. Hambly2, V. Levidiotis1, J. Eris1, S. Chadban1
1Department of Renal Medicine, Royal Prince Alfred Hospital, and 
2University of Sydney, NSW, Australia
Introduction: Chronic rejection remains the leading cause of late allograft failure. 
Chronic allograft vasculopathy is the hallmark of chronic rejection, characterized 
by diffuse, concentric intimal-hyperplasia of the coronary vasculature. IL-18 is a 
pro-infl ammatory, pro-Th1 cytokine that plays an important role in infl ammatory 
disorders and atherosclerotic disease. Blockade of IL-18 was found to be 
protective against intimal-thickening in a murine atherosclerosis model. In this 
study, we investigate the role of IL-18 in chronic cardiac allograft rejection in a 
class II MHC-disparate murine heart transplant model.
Methods: Heterotopic cardiac transplants were performed: C57BL/6 and 
IL-18-/- mice were recipients of B6.H-2bm12 heart grafts, (minor difference within 
I-A MHCII antigens). A survival study was performed, assessed by palpation 
of the heartbeat. In a second study, hearts were harvested at day 24 and 48 
after transplantation (n=6 per group). Neointimal-hyperplasia was quantifi ed 
morphometrically in tissue sections stained with Verhoeff’s for elastin by 
tracing the luminal area and the area bound by the internal elastic lamina. 
Infi ltration of immune cells and eosinophils were assessed by H&E. CD4+ 
and CD8+ cell infi ltration were stained by immunhistochemistry. Depositions 
of collagen and graft fi brosis were demonstrated by trichrome staining. Gene 
expression of IFN-γ, IL-4, and IL-18 were determined by real-time RT-PCR.
Results: Survival study: 4/10 of IL-18-/- recipients experienced loss of heartbeat 
within 30 days of transplant, versus nil in the B6 wild-type group (p<0.001). 
1/7 of grafts in wild-type recipients experienced late graft failure at day 56. 
Time point study: Signifi cantly increased neointimal-hyperplasia was present in 
IL-18-/- recipients versus wild-type at day 24 (p<0.01) but not at day 48. IL-18-/- 
recipients showed signifi cantly increased parenchymal cell infi ltration and 
collagen deposition, versus wild-type, at day 24 and 48 (all p<0.05). Eosinophils 
were prominent within the infi ltrate in IL-18-/- but not wild-type at day 24 and 
48 (p>0.01). Infi ltration of CD4+ and CD8+ leukocytes was signifi cantly higher 
in IL-18-/- recipients than in wild-type at day 24 (all p<0.05)., and CD8+ cells 
in IL-18-/- recipients were signifi cantly increased at day 48. Gene expression of 
IFN-γ was decreased at day 24 and 48 (all p<0.01) and IL-4 increased in IL-18-/- 
group at day 24 (p<0.05) compared with wild-type.
Conclusion: Defi ciency of IL-18 in the recipient caused early graft failure in 
this chronic rejection model, which was associated with a reduction in IFN-γ 
expression but and increase in IL-4 expression and eosinophil accumulation. A 
likely mechanism is that defi ciency of IL-18 caused an imbalance of Th1-Th2 
resulting in an active and deleterious Th2 immune response.
LYMPHOCYTE, BUT NOT PARENCHYMA-DERIVED 642 
CXCL10 IS CRITICAL IN LIVER INNATE IMMUNE RESPONSE 
AGAINST ISCHEMIA AND REPERFUSION INJURY
J. Kupiec-Weglinski, Y. Zhai, R. Busuttil
Dumont-UCLA Transplant Ctr
We have shown that CXCL10 (IP-10), the TLR4-IRF3 pathway activation 
chemokine product, plays a key role in the mechanism of liver ischemia/
reperfusion injury (IRI). However, liver consists of cells derived from bone 
marrow and parenchyma, both of which are known to produce CXCL10. 
Hence, the question as to which liver cell type and resultant CXCL10 operate in 
the innate response against IR is important for better elucidation of the disease 
mechanism.
Aim: To study the impact of CXCL10 production by parenchymal vs. non-
parenchymal cells on liver IRI cascade by employing: (1) bone marrow (BM) 
chimeras; (2) T-cell defi cient “nude” mice reconstituted with either WT or 
CXCL10-defi cient splenocytes.
Methods: Four groups (n=4-5/gr) of BM chimeras were created using syngeneic 
CXCL10 KO and WT mice: 1) KO (BM donor)/WT (recipient); 2) WT/KO; 3) 
WT/WT; 4) KO/KO. The chimeras were used at 6-8 wk after successful BM 
engraftment, as determined by FACS. They were then subjected to liver partial 
warm ischemia for 90 min, followed by 6 h reperfusion. Similarly, groups of 
nude mice (n=4-5/gr), reconstituted with splenocytes (5x107 i.v.) from either 
WT or CXCL10 KO donors were used at 7 days after cell infusion in the liver 
warm IRI experiments.
Results: As expected, WT/WT mice suffered severe hepatocellular injury, 
whereas KO/KO mice were protected against IRI, as shown by sALT levels 
[Fig.1] and histology. Interestingly, WT/KO suffered severe IRI, comparable 
with WT/WT, whereas KO/WT were protected. IR-induced liver pro-
infl ammatory response was restored in WT/KO, but remained suppressed 
in KO/WT, as shown by qRT-PCR analysis of TNF-α, IL-1β, and IL-6. IR-
triggered CXCL10 induction was partially restored only in WT/KO, but not 
KO/WT livers. Furthermore, unlike WT, CXCL10 KO splenocytes failed to 
recreate liver IRI in nude mice [Fig.1].
Conclusion: The lymphocyte- but not parenchyma-derived CXCL10 is critical 
in triggering the innate immune response in liver IRI.
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IL-1643 β-DRIVEN ST2 EXPRESSION PROMOTES 
MATURATION RESISTANCE IN RAPAMYCIN-CONDITIONED 
DENDRITIC CELLS
A.W. Thomson1,4, H.R. Turnquist1, T.L. Sumpter1, A. Tsung1, A.F. Zahorchak1, 
F.Y. Liew2, G.J. Nau3, D.A. Geller1,
T. E. Starzl Transplantation Institute And Departments of 
Surgery,1Microbiology And Molecular Genetics,3And Immunology, 4University 
of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Division of 
Immunology, 2University of Glasgow, Glasgow, UK
Introduction: Tolerogenicity can be conferred on dendritic cells (DC), 
-crucial regulators of T cells, by exposure to rapamycin (RAPA), a tolerance-
sparing immunosuppressant. Myeloid (m)DC generated in clinically-relevant 
concentrations of RAPA (RAPA-DC) are phenotypically immature, particularly 
defi cient in CD86, and exhibit markedly inhibited T cell allostimulatory capacity. 
Both in vitro-generated RAPA-DC and DC from RAPA-treated mice show impaired 
responses to TLR4 and CD40 ligation. While poor stimulators of allogeneic CD4+ 
effector T cells, RAPA-DC enrich for potent alloAg-specifi c Treg. This contrasts 
with control (CTR) mDC that favor non-Treg activation/expansion, especially 
when mature. When pulsed with alloAg and infused systemically, RAPA-DC, 
but not CTR-DC render alloAg-specifi c T cells hyporesponsive to donor and 
promote indefi nite organ allograft survival. By instilling maturation-resistance, 
RAPA enables DC to act as ‘negative cellular vaccines’ with tolerogenic potential. 
However, the mechanisms underlying the resistance of RAPA-DC to infl ammatory 
stimuli have not been defi ned. Our objective was to elucidate a molecular basis for 
RAPA-induced DC maturation resistance.
Methods: RAPA administration was used to condition splenic DC in vivo and 
bone-marrow derived DC in vitro. DC maturation was monitored by assessment 
of costimulatory molecule expression, cytokine production, and allostimulatory 
capacity. To identify negative regulators of maturation, microarray analysis and 
quantitative RT-PCR was performed, and fi ndings confi rmed via Western and 
fl ow cytometric analyses.
Results: In vitro or in vivo exposure of mDC to RAPA elicited de novo production 
of IL-1β by otherwise immature DC (CD86lo). Importantly, IL-1β production 
by RAPA-DC promoted overexpression of the IL-1 receptor family member, 
ST2, and induced its surface expression. Surface ST2 acts as the receptor for 
the Th2-polarizing cytokine IL-33 and has also been implicated as a negative 
regulator of TLR signaling. Consistent with this regulatory function, RAPA-DC 
with either inhibited IL-1β responsivity, and thus failing to upregulate ST2, or 
generated from ST2-/- mice, exhibited increased maturity and allostimulatory 
capacity, and were more responsive to TLR and CD40 ligation.
Conclusion: Pro-infl ammatory stimuli often act in regulatory loops, in which 
activation of the signaling downstream from their receptors causes the induction 
of negative regulators of the same pathway. A novel aspect of our fi ndings is 
that, although RAPA-DC produce IL-1β, a potential infl ammatory signal, they 
upregulate ST2, remain immature and resistant to TLR stimulation. Thus, DC 
conditioning with RAPA, and the consequent induction of ST2, establishes 
a barrier to functional maturation of the cells, preserving their tolerogenic 
phenotype. This decreases/minimizes any potential risk of host sensitization using 
RAPA-DC as negative cellular vaccines. This work identifi es a novel mechanism 
by which a clinically-important immunosuppressant impedes the capacity of DC 
to mature and consequently stimulate effector/adaptive T cell responses.
IL-21 ALTERS IMMUNE REGULATION AND PROMOTES 644 
TH17 IN ALLORESPONSE
M Koulmanda, D. Hanidziar, Z. Fan, A. Kroemer, X. Xiao, T.B. Strom,
Departments of Surgery & Medicine, Harvard Medical School, Transplant 
Research Center, Beth Israel Deaconess Medical Center, Boston, MA
Introduction: IL-21 prevents recruitment of naive T-cells to Treg phenotype 
and simultaneously fosters commitment to pathogenic Th17 cells in vitro. 
We hypothesized that IL-21 will promote allograft rejection by adversely 
infl uencing the proportion of effector (Teff) to regulatory T-cells.
Methods: CD4+CD45.2+GFP- Teffs were isolated from both naive and TCR-
transgenic anti-bm12 (ABM) foxp3gfp knockin (KI) B57BL/6 (B6) murine 
models. CFSE-labeled naive Teffs were cultured 4 days with anti-CD3 and 
CD3-depleted B6 splenic cells. ABM Teffs were stimulated with cognate 
B6.C-H2-bm12 CD3-depleted splenic cells. CD4+GFP+ Tregs were isolated 
from foxp3gfpKI naive CD45.1 and ABM mice (B6). Effects of IL-21 on the 
cultures were analyzed by fl ow cytometry, after intracellular staining for IL-
17A and IFNγ. In vivo, IL-21 was administered subcutaneously for 28 days in 
RAG-/- DBA/2 skin recipients (B6) that were reconstituted with equal numbers 
of naive Teffs (GFP-) and Tregs (GFP+) (B6).
Results: Mixed lymphocyte reaction CFSE histograms showed enhanced 
stimulation of Teff proliferation by IL-21. When added to naive Teff-Treg 
co-cultures, IL-21 blunted Treg-mediated suppression of CFSE-labeled Teff 
proliferation. Moreover, IL-21 induced a prominent Th17 response (p<0.05). 
However, in the in vitro transgenic system, Th17 cells were induced even in 
the absence of IL-21. The addition of TCR-transgenic, but not naive Tregs, 
suppressed Th17 response (p<0.05). In contrast, neither TCR-transgenic nor 
naive Tregs suppressed Th17 induction in the presence of IL-21. IFNγ, highly 
expressed by ABM Teffs cultured alone or with naive Tregs, was signifi cantly 
suppressed by ABM TCR-transgenic Tregs (p<0.05). The adverse effects of 
IL-21 upon the allograft were confi rmed in the DBA/2 to B6 skin transplant 
model. The mean survival time of the allograft in the IL-21 treated hosts was 26 
days (n=10) compared to 41 days in the untreated controls (n=10) (p<0.01).
Conclusion: IL-21 promoted commitment of naive alloreactive T-cells to the 
Th17 phenotype and blunted the immunoregulatory effects of Tregs in vitro. 
Consistent with these results, administration of IL-21 to skin allograft recipients 
accelerated the transplant rejection.
INTERLEUKIN-13 SIGNALING THROUGH THE 645 
INTERLEUKIN-13-RECEPTOR-ALPHA2 IS INVOLVED IN THE 
INDUCTION OF TRANSFORMING GROWTH FACTOR-BETA1 
PRODUCTION AND ORGAN FIBROSIS
S. Fichtner-Feig, G. Schiech, H-J. Schlitt, E.K. Geissler
Department of Surgery, University of Regensburg, Germany
To investigate the immunopathogenesis of organ fi brosis, a detrimental long-
term complication of allograft transplantation, we analyzed bleomycin-induced 
lung fi brosis and cardiac allograft transplantation-induced graft fi brosis in 
mice. We could demonstrate that interleukin (IL)-13 is a major inducer of a 
profi brotic pathway in chronic infl ammatory responses leading towards organ 
fi brosis and remodelling. In in vitro mechanistic studies, we found that IL-13 
induces transforming growth factor (TGF)-beta1 in macrophages through 
a two-stage process involving, fi rst, the induction of a receptor formerly 
considered to function only as a decoy receptor, IL-13-receptor-alpha2. Such 
induction requires IL-13 and tumor necrosis factor (TNF)-alpha. Second, it 
involves IL-13 signaling through IL-13-receptor-alpha2 to activate an AP-1 
variant containing c-jun and Fra-2, which then activates the TGF-beta1-
promoter. Investigating this mechanism in vivo, using the bleomycin-induced 
lung fi brosis, we found that IL-13, IL-13-receptor-alpha2, and TGF-beta1 were 
upregulated on day 13 after initiation of the infl ammatory response. We found 
an increase in IL-13 expression in the bronchoalveolar fl uid from 41.2±7.9pg/
ml on day 0 to 226.5±47.3pg/ml on day 13 and expression level of TGF-beta1 
was 69.4±13.1pg/ml on day 0 and 682.4±63.6pg/ml on day 13. In concordance 
with this increase in cytokine expression we detected an increase in the amount 
of collagen deposited in the lung tissue from 374.9±31.0μg/lung on day 0 to 
812.7±237.4μg/lung on day 24. Moreover the prevention of IL-13-receptor-
alpha2 expression by IL-13-receptor-alpha2 specifi c gene silencing led to 
marked downregulation of TGF-beta1 production (977.6±57.8pg/ml in control 
siRNA group vs. 315.2±26.1pg/ml in IL-13-receptor-alpha2 siRNA group, 
p<0.01) and collagen deposition (824.1±257.3μg/lung in control siRNA group 
vs. 471.9±61.7μg/lung in IL-13-receptor-alpha2 siRNA group, p<0.05) on 
day 24 after initiation of the infl ammatory response. Studying this pathway 
in a mouse model of cardiac allograft transplantation-induced graft fi brosis, 
we could demonstrate that the key players of the profi brotic pathway, namely 
IL-13 (95.3±13.9pg/100μg allograft protein on day 0, 187.0±20.9pg/100μg 
allograft protein on day 60, 303.4±46.5pg/100μg allograft protein on day 100), 
IL-13-receptor-alpha2, and TGF-beta1 (39.5±10.7pg/100μg allograft protein 
on day 0, 87.6±9.5pg/100μg allograft protein on day 60, 133.2±12.6pg/100μg 
allograft protein on day 100) are being upregulated starting on day 60 following 
cardiac allograft transplantation (FVB donor heart to DBA/1 recipient) with 
increasing expression levels. In addition, the collagen content (50.5±19.1μg/
mg allograft protein on day 0, 105.3±26.6μg/mg allograft protein on day 
60, 138.5±22.5μg/mg allograft protein on day 100) of the cardiac allografts 
measured by sircol assay was signifi cantly increased on day 100 after cardiac 
allograft transplantation. These data are the fi rst to describe the molecular 
basis of organ fi brosis involving an IL-13-dependent induction of TGF-beta1 
through the IL-13-receptor-alpha2. In addition, specifi cally targeting the IL-13-
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receptor-alpha2 proved to be an effective strategy to prevent organ fi brosis in 
bleomycin-induced pulmonary fi brosis. The increasing expression levels of the 
key players in this profi brotic program during chronic allograft rejection give 
rise to the assumption that this pathway may be involved in graft fi brosis as a 
complication of chronic allograft rejection. Therefore, IL-13-receptor-alpha2 
could be specifi cally targetable to prevent TGF-beta1-mediated graft fi brosis.
INTERLEUKIN-21 RECEPTOR ON B-LYMPHOCYTES 646 
IS UPREGULATED IN HIGHLY SENSITIZED RENAL 
TRANSPLANT RECIPIENTS:A POTENTIAL TARGET 
FOR DESENSITIZATION
R. Tavana, J. Tchervenkov, S. Liu
Department of Surgery, McGill University
Background: Renal transplant patients who are highly sensitized linger on the 
transplant list due to HLA specifi c antibodies. Current desensitization protocols 
are unreliable. Interleukin-21 is a type I cytokine that signals through a receptor 
composed of the IL-21R and the common cytokine receptor gamma-chain 
shared by the all known T-cell growth factors (TCGFs). IL-21 is a regulator of 
anti-body production by B-cells (differentiation to plasma cells as well as for 
immunoglobulin class switching) and acts as a co-stimulator of proliferation 
and memory response in T-cells. We hypothesized that IL-21 could play a 
role in antibody production by B-lymphocytes in sensitized renal transplant 
recipients. We evaluated the effect of IL-21 on the anti-body production 
capacity of B-cells and compared the expression IL-21 Receptor (IL-21R) on 
peripheral B-cells in highly sensitized and non-sensitized patients on dialysis.
Methods: B-cells were isolated from peripheral blood of healthy individuals 
by positively selecting B-cells with anti CD-19 magnetic beads (MACS). These 
cells (purity >95%) were cultured in triplicate 96 plates and were stimulated 
with mouse anti-Human CD40 monoclonal Ab (R&D), recombinant IL-21 
or combination of both. Supernatants were collected after defi nite duration 
and levels of IgG1 and IgM were measured by ELIZA. Patients (n=19) were 
selected from the transplant waiting list based on PRA levels (non-sensitized 
<5%, sensitized >50%). After consent, 1-2 ml of peripheral blood was taken 
right before initiation of dialysis. After washing and Blocking, blood cells were 
incubated with anti-CD19, anti-IL-21 antibodies and paraffi n fi xed after RBCs 
lysis. IL-21R Expression was measured by Flowcytometry over FACScan 
machine on the same day.
Results: 
1.  In-vitro Co-stimulation of B-cells with IL-21 and anti-CD40 increased IgG1 
and IgM production signifi cantly (p<0.02) compared with Anti-CD-40 or 
IL-21 stimulation alone.
2.  In-vitro stimulation of human B-cells with anti-CD40 Antibody alone or in 
combination with rIL-21 results in increased expression of IL-21R.
3.  The expression of IL-21R is signifi cantly higher on B-cells in highly 
sensitized patients compared to non-sensitized patients.(P=0.02)
Highly sensitized pt(HS) Non-sensitized pt(NS)
intensity of IL-21r exp (orange: HS, blue: NS)
4.  There was a signifi cant correlation between PRA level and expression of 
IL-21 receptor on peripheral B-cells (r=0.6, p<0.05).
Conclusion: Il-21 and IL-21R may be an important cytokine interaction between 
T and B-cells and antibody production in highly sensitized renal transplant 
recipients. This may offer a novel target for desensitization protocols.
SMALL BOWEL ALLOGRAFT REJECTION IS 647 
ASSOCIATED WITH CCR6/MIP3A MEDIATED RECRUITMENT 
OF HOST CELL INFILTRATION INTO LAMINA PROPRIA
Z. Zhang, Y. Lu, Z. Li, K. Chen, J. Fryer
Northwestern University, Feinberg School of Medicine
Inhibition of epithelial NFkB activation delays small bowel (SB) allograft 
rejection possibly by downregulating of chemokine/cytokine production that 
infl uences recruitment of host effector cells. While binding of macrophage 
infl ammatory protein-3 (Mip-3a), a NFkB dependent chemokine, to its receptor 
CCR6 proves to be responsible for recruiting Memory/effector T cells immature 
and dendritic cells (iDCs) into infl amed tissues, the role host CCR6 bearing 
lymphocytes and iDCs in SB allograft rejection remains unknown. We utilized 
a mouse model of SB transplantation, to test our hypothesis that recruitment 
of CCR6 bearing host effector cell and iDCs into the Lamina Propria (LP) 
of SB allograft through Mip3a/ CCR6 interactions are critical steps led to 
SB allograft rejection and are initiated by MyD88 dependent TLR signaling. 
SBs from wild type B6 and MyD88 knockout mice were transplanted into 
B6 (isograft) or BALB/c (allograft) mice. We isolated epithelial cells and LP 
leukocytes from the SB isografts and allografts on POD5, and evaluated Mip3a 
mRNA expression by the real time quantitative PCR analysis and leukocytes 
compositions by fl ow cytometry. We observed that the level of Mip3 mRNA 
expression in the epithelial cells from SB isografts was similar to that of 
normal non-transplanted SBs, while there was more 10 fold increased in Mip3a 
mRNA expression in the epithelial cells of the SB allografts. Flow cytometrical 
analysis of LP infi ltrates revealed a 50% increase in the number of host CCR6 
positive cells in SB allografts compared to the isografts, and more interestingly, 
the proportion of host CCR6 bearing DCs was markedly increased from 12% 
in SB isograft to 43% in SB allografts. Furthermore, we found that abrogating 
MyD88 dependent TLR signaling by using SB from MyD88 knockout mice 
markedly decreased infi ltration of CCR6 bearing host lymphocytes and 
minimized mucosal infl ammation in the small bowel allografts compared to 
wild type allografts at one week after transplantation. Taken together, TLR 
signaling through graft derived MyD88 mediated recruitment of CCR6 bearing 
host lymphocytes and iDC into the graft LP may be a critical mechanism in 
small bowel allograft rejection.
CHIMERISMCONCURRENT ORAL SESSION 46: 
AN IRRADIATION-FREE PROTOCOL FOR MIXED 648 
CHIMERISM AND TOLERANCE THROUGH TREG-THERAPY
N. Pilat1, U. Baranyi1, C. Klaus1, E. Jaeckel2, N. Mpofu2, F. Muehlbacher1, 
T. Wekerle1
1Div of Transplantation, Dept of Surgery, Medical University of Vienna, 
Vienna, Austria, 2Dept of Gastroenterology, Hepatology and Endocrinology, 
Hannover Medical School, Hannover, Germany
Background: Routine clinical application of bone-marrow (BM) transplantation 
for induction of tolerance by the concept of mixed chimerism is inhibited by the 
requirement of cytotoxic host treatment by either irradiation or cytotoxic drugs. 
Tregs have potent effects in autoimmune and allo-transplantation models, but 
do not induce skin graft tolerance across MHC barriers on their own. Antigen-
specifi c TCR-transgenic T cells retrovirally transduced to express FoxP3 exert 
potent suppressor function in certain autoimmune disease models. However, 
little is known about the ability of polyclonal FoxP3-transduced T cells to 
suppress alloreactivity in wild-type transplantation models. We explored 
whether treatment with polyclonal FoxP3 transduced Tregs leads to permanent 
engraftment of clinically realistic doses of allogeneic BM and donor-specifi c 
tolerance without irradiation or cytotoxic drugs.
Methods: MACS-separated C57BL/6 CD4+ cells were retrovirally 
transduced to express FoxP3 and GFP under the control of an internal 
ribosomal entry site. Regulatory function and phenotype were examined in 
vitro in proliferation assays and by fl ow cytometry. Non-irradiated C57BL/6 
recipient mice received 20x106 fully mismatched Balb/c bone marrow cells 
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(d0) under the cover of costimulation blockade (anti-CD154 mAb, MR1 d0 
and CTLA4Ig d+2) and short-course rapamycin (d-1/0/+2). A separate group 
of BMT recipients was treated in addition with 2-4x106 FoxP3-transduced 
CD4 cells (d0, d+6). Multi-lineage chimerism and deletion of donor-reactive 
T cells was followed by fl ow cytometry. Tolerance was assessed by grafting 
donor and 3rd party skin.
Results: All mice receiving additional Treg treatment developed long-term 
multilineage chimerism, whereas BMT recipients without Tregs uniformly 
failed to do so (7/7 vs 0/7 at wk 19, p<0.01; e.g. 7.08% mean chimerism 
among myeloid lineage at wk 12). Notably donor chimerism among T cells, 
which is known to correlate with tolerance, was gradually rising in FoxP3-
Treg recipients. Treg treated recipients showed profound and specifi c deletion 
of donor-reactive T cells in comparison to control group (1.87% vs 3.75% 
for Vβ11+ P < 0.05, 0.86 vs 2.46 for Vβ5+ P < 0.01; 13 weeks after BMT) 
and naïve B6 mice (1.87 vs 4.96 for Vβ11+ P < 0.05, 0.86 vs 1.72 for Vβ5+ 
P < 0.05). Notably, additional treatment with FoxP3-transduced Tregs led to 
tolerance induction with this otherwise unsuccessful regimen (long-term donor 
skin graft acceptance >100days in 7/7 mice in Treg-group vs 1/6 control group, 
p<0.005).
Conclusions: These results demonstrate that polyclonal FoxP3-Tregs permit 
engraftment of achievable allogeneic BM doses without cytotoxic recipient 
treatment. FoxP3-Tregs lead to the induction of lasting mixed chimerism, 
deletion of donor-reactive T cells and donor-specifi c skin graft tolerance in 
an irradiation-free BMT protocol. Robust non-cytotoxic BMT regimens with 
clinically obtainable BM doses have been elusive so far. We think that these 
fi ndings are an important step towards the development of non-toxic BMT 
protocols.
INFLUENCE OF CHIMERISM ON TOLERANCE AFTER 649 
COMBINED HUMAN KIDNEY AND HEMATOPOIETIC CELL 
TRANSPLANTATION
S. Busque1, J. Scandling2, J. Shizuru2, M. Sarwall5, S. Jones2, C. Benike3, 
E. Engleman3, R. Lowsky2, R. Hoppe4, S. Strober2
1Department of Surgery, Stanford University School of Medicine, 
2Departement of Medicine, Stanford University School of Medicine, 
3Depatment of Pathology,Stanford University School of Medicine, 
4Department of Radiation Oncology, Stanford University School of Medicine, 
5Deparment of Pediatrics, Stanford University School of Medicine
We studied 6 patients enrolled in a tolerance induction protocol with a goal of 
complete immunosuppressive drug withdrawal after combined HLA- matched 
kidney and hematopoietic cell transplantation. Donors received a 5 day course of 
G-CSF 4-6 weeks before transplant surgery, and purifi ed CD34+ hematopoietic 
progenitor cells from the apheresis products were mixed with a fi xed number 
of donor CD3+ T cells (1x10^6) before cryopreservation. After transplantation 
surgery, recipients were conditioned with 10 doses of total lymphoid irradiation 
and 5 doses of rabbit anti-thymocyte globulin. Immediately after conditioning 
(day 10), recipients were given an intravenous injection of the donor cells in the 
outpatient clinic. Mycophenolate mofetil was given until day 30, and a tapering 
course of cyclosporine until day 180. Five of 6 recipients developed chimerism 
with at least 50% donor type cells among B cells, granulocytes, and/or NK 
cells. One patient with rapid return of focal segmental glomerulosclerosis in 
the transplant was treated with multiple plasmaphereses, and failed to develop 
chimerism.Chimerism persisted for at least 6 months in 3 of the 5 recipients, 
and all immunosuppressive drugs were either tapered to discontinuation or are 
in the midst of tapering. The fi rst patient has been off of all drugs for more than 
2 years. Two chimeric patients with early immunosuppressive drug reduction 
developed loss of chimerism associated with a rejection episode. Analysis of the 
gene array profi les of PBMC of the fi rst patient showed a “ tolerance” pattern, 
and donor specifi c unresponsivesness in the MLR after drug withdrawal. In 
conclusion,tolerance does not develop as soon as chimerism is established, 
and drug withdrawal without allograft rejection episodes was feasible several 
months after persistent chimerism. The results suggest that tolerance induction 
in this protocol is an active and dynamic process.
TOLERANCE INDUCTION IN A LARGE-ANIMAL 650 
MODEL USING TOTAL LYMPHOID IRRADIATION AND 
INTRATHYMIC BONE MARROW
P.J. Horton1, W.J. Hawthorne2, S. Walters2, T. Patel2, G.J. Stewart2, 
R.D.M. Allen2, J.R. Chapman2
1Division of Solid Organ Transplantation, University of Rochester Medical 
Center, Rochester, New York, United States and 2Centre for Transplant & 
Renal Research, Westmead Millennium Institute, Sydney, New South Wales, 
Australia
Background: Immunological unresponsiveness of T-cells to alloantigen can 
be induced by intrathymic injection of donor-specifi c antigen in small-animals. 
Intrathymic tolerance to vascularised grafts in large-animals has not previously 
been reported.
Methods: Twenty-six dogs were allocated into dog leukocyte antigen (DLA) 
DP-matched pairs. Female recipients and male donors were preferred. Tissue 
typing was based on restriction fragment length polymorphism. Recipients were 
given total lymphoid irradiation (TLI), receiving 18Gy in 16 fractions (1.125Gy 
each) over four weeks. After 6.75Gy, dogs underwent thoracotomy permitting 
perithymic (n=4) and intrathymic (n=4) injection of donor bone marrow buffy 
coat. Saline was injected in controls (n=5). Bone marrow engraftment outside 
the thymus was prevented by further irradiation.
Fifty days post-thoracotomy recipients underwent bilateral native nephrectomy 
and donor-specifi c kidney transplantation. Acute rejection was diagnosed by 
serum creatinine >600μmol/L or urea >40mmol/L and histology. Full thickness 
skin grafts followed >100 days post-RTx. Tissue samples were taken for 
Y-chromosome polymerase chain reaction (PCR).
Results: Twelve female and one male recipient, aged 6-18 months, completed 
the protocol. Control animals rejected kidneys after 8, 10, 23, 26 and 38 
days. Intrathymic bone marrow recipients rejected after 27, 32 and 54 days; 
one survived rejection-free for 288 days. Perithymic bone marrow recipients 
survived rejection-free for 419, 199, 120 and 42 days (p=0.003). Recipients 
surviving >100 days post-RTx accepted donor-specifi c and rejected DLA-DP 
identical 3rd party skin grafts. PCR detected intrathymic chimerism but not 
haematopoetic chimerism.
Conclusions: Fractionated TLI and either perithymic or intrathymic donor-
specifi c bone marrow induced tolerance to allogeneic kidney and skin grafts. 
This study demonstrates for the fi rst time that tolerance to vascularised grafts 
can be induced in large-animals using the intrathymic route.
INDUCTION OF ALLOREACTIVE CD4 TOLERANCE BY 651 
CROSS-PRESENTATION OF DONOR MHC MOLECULES BY 
RECIPIENT APC’
J. Kurtz1,2, L. Shubert2, S. LoCascio2, M. Sykes1
1Transplantation Biology Research Center, Massachusetts General Hospital 
and Harvard Medical School, 2Emmanuel College
The establishment of mixed hematopoietic chimerism across full MHC 
barriers using a non-myeloablative regimen with costimulatory blockade (anti-
CD8 mAb and 3Gy total body irradiation on day-1 and 20x106 donor bone 
marrow cells plus anti-CD154 mAb on day 0) induces rapid donor-specifi c 
CD4 T cell tolerance. We have previously demonstrated a requirement for an 
intrinsic CTLA-4 signal to recipient CD4 cells by B7.1/2 molecules expressed 
by recipient and not donor hematopoietic APCs in order to tolerize alloreactive 
CD4 cells.
In mixed chimeras prepared using this protocol, peripheral directly donor-
reactive CD4 T cells are deleted as early as one week post-BMT, and by 4 
weeks are reduced to undetectable levels. To determine the fate of indirectly 
alloreactive CD4 T cells, we created ‘syngeneic chimeras,’ whereby recipients 
contain a small population of indirectly alloreactive transgenic CD4 T cells 
specifi c for donor peptide/recipient class II MHC complexes. C5BL/6-CD45.1 
received 3GY TBI and 4x106 BMC from C57BL/6-TEa TCR transgenic mice 
(CD45.2+), which recognize a peptide of the I-E molecule presented by I-A. 
Mice were allowed to rest until stable levels of transgenic CD4 cells were 
established in peripheral blood (12 weeks). These synchimeras then received 
allo-BMT with the above protocol with BMC that was I-E+ (B10.A), I-E- 
(B10.S), or no BMT. At one week post-BMT, mice that received B10.A BMC 
showed almost complete deletion of the indirectly alloreactive transgenic cells 
(donor MHC-CD4+CD45.2+) in the peripheral blood (0.21%±0.19), whereas 
mice that received either B10.S or conditioning alone did not (2.73%±1.56 and 
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2.40%±.92, respectively). These data demonstrate rapid deletion of indirectly 
alloreactive CD4 T cells, suggesting that recipient APC rapidly acquire donor 
MHC molecules for processing/presentation on self MHC class II.
To further understand the mechanism by which peripheral directly alloreactive 
CD4 T cells are tolerized, we hypothesized that recipient APC may ‘cross-dress’ 
wherein intact donor MHC molecules are transferred from donor to recipient 
B7-expressing cells for presentation on their surface, where they interact with 
recipient CD4 cells. C57BL/6-CD45.1 recipients that received B10.A (CD45.2) 
BMT with the above protocol were sacrifi ced at 2, 4, and 7 days post-BMT, 
and various splenocyte populations (B cell, myeloid DC, lymphoid DC) were 
analyzed by fl ow cytometry. As early as 2 days post-BMT, a small, distinct 
population of recipient B cells (CD19+ CD45.1+) was found to express donor 
MHC class I and II molecules on their surface, as was a small percentage of 
dendritic cells, although not as distinct. Similar data were obtained at 4 and 7 
days post-BMT.
These data elucidate mechanisms by which BMT with CD40/CD154 blockade 
induces donor-specifi c tolerance, and strongly suggest that interactions of 
recipient APC with both indirectly and directly alloreactive CD4 T cells play 
an important role.
REQUIREMENT FOR MHC CLASS I AND II EXPRESSION 652 
ON HOST DENDRITIC CELLS TO TOLERIZE ALLOREACTIVE 
CD8 CELLS DURING INDUCTION OF MIXED CHIMERISM
J. Mollov, C. Gibbons, M. Sykes
BMT Section, Transplantation Biology Research Center, Department of 
Surgery, Massachusetts General Hospital, Harvard Medical School
Objectives: Induction of mixed hematopoietic chimerism provides an approach 
to achieving donor-specifi c tolerance. In the mouse, non-myeloablative 
conditioning with anti-CD154 (CD40L) and 3Gy total body irradiation (TBI) 
overcomes CD4 and CD8 cell-mediated resistance to allogeneic marrow 
engraftment, permitting mixed chimerism induction. A requirement for host 
dendritic cells (DC), CD4 cells, and MHC class II expression to tolerize 
alloreactive CD8 cells has been demonstrated. Both indirectly and directly 
alloreactive CD8 cells can prevent donor marrow engraftment when CD4 cells 
are depleted. We hypothesize that the requirement for host CD4 cells and DCs 
to tolerize alloreactive CD8 cells refl ects three cell (CD4, CD8, and APC) 
interactions occurring with CD40/CD40L blockade.
Methods: To generate recipient mice lacking expression of class I and II on 
DCs, we used diphtheria toxin receptor (DTR)-transgenic mice which express 
the primate DTR transgene under control of the murine CD11c promoter, so 
that intraperitoneal (i.p.) administration of diphtheria toxin (DT) selectively 
depletes CD11c+ DCs. B6 mice were lethally irradiated and reconstituted with 
a mixture of bone marrow cells (BMC) from CD11c DTR and CIITa KbDb 
class I and class II MHC-defi cient B6 mice. Additional groups of mice were 
reconstituted with a mixture of DTR and CIITa-/- or DTR and B6 BMC to 
generate recipients with DCs lacking only class II expression or with wild-
type DCs, respectively. In another experiment, we generated recipients lacking 
expression of class I on host DC by reconstituting B6 mice with a mixture of 
BMC from DTR and KbDb -/- or B6 mice. All mice received i.p. injections 
of DT for two weeks beginning one day prior to allogeneic bone marrow 
transplantation (BMT) with 3Gy TBI/anti-CD154. Chimerism was analyzed 
by FACS.
Results: Seven of seven mice lacking class I and II expression on host DCs 
rejected donor marrow by two weeks post-BMT. Rejection was prevented by 
recipient CD8 depletion; all 4 of these mice were chimeric. Four of seven mice 
lacking only class II on their DCs and 5 of 6 mice with wild-type DCs were 
mixed chimeras at 2 weeks. In the second experiment, 7 of 9 mice lacking class 
I expression on host DCs were mixed chimeras at 8 weeks compared to 4 of 5 
mice with wild-type DCs.
Conclusion: These data suggest that in the absence of both MHC class I and 
II expression on host DCs, allogeneic donor marrow was rejected by recipient 
CD8 cells. However, when host DCs lacked only class II, donor marrow was 
variably rejected, and when they lacked only class I, donor marrow was not 
rejected by CD8 cells. Our data suggest the existence of a complex tolerance 
pathway involving interactions of indirectly and directly alloreactive CD4 and 
CD8 cells on recipient DCs that may pick up and present intact donor MHC 
molecules.
CHIMERIC TOLERANCE INDUCED BY TOTAL 653 
LYMPHOID IRRADIATION AND DONOR SPECIFIC BONE 
MARROW INFUSION IN DLA-DP MATCHED DOGS
W.J. Hawthorne1, P.J. Horton2, M.L. Ferrara1, A.D. Griffi n3, G.J. Stewart1, 
R.D.M. Allen4, J.R. Chapman1
1Centre for Transplant and Renal Research, Westmead Millennium 
Institute, Sydney, New South Wales, Australia, 2Division of Solid Organ 
Transplantation, University of Rochester Medical Center, Rochester, New 
York, United States, 3Renal Transplant Unit, Princess Alexandra Hospital, 
Brisbane, Queensland, Australia and 4Department of Surgery, Royal Prince 
Alfred Hospital, Sydney, New South Wales, Australia
Background: Mixed hematopoietic chimerism depends on engraftment of 
donor bone marrow and is associated with donor-specifi c tolerance.
Aim: To determine renal allograft survival in dogs treated with fractionated 
total lymphoid irradiation (TLI) and donor-specific bone marrow 
(DSBM).
Methods: Twenty-eight pairs of dog-leukocyte-antigen (DLA) DP-matched 
spaniels were used. Tissue typing was based on restriction fragment length 
polymorphism. Female recipients and male donors were preferred. Twenty-
two dogs underwent TLI, receiving 18Gy in 16 fractions over four weeks. 
Eighteen dogs had DSBM infused post-TLI (Group 1), while four dogs 
received TLI alone (Group 2). Fifty days post-TLI recipients underwent 
bilateral native nephrectomy and donor-specifi c kidney transplantation 
(RTx) without immunosuppression. A control group received no treatment 
prior to RTx (Group 3). Acute rejection was diagnosed by serum creatinine 
>600μmol/L or urea >40mmol/L and compatible histology. Full thickness 
skin grafts followed >100 days post-RTx. Tissue samples were taken for 
karyotyping.
Results: Only dogs receiving >4x108 nucleated bone marrow cells/kg 
recipient weight developed hematopoietic chimerism and tolerance. Seven 
tolerant animals survived for median 974 days (range 185 to 1541) and 
accepted donor-specific while rejecting DLA-DP identical 3rd party skin 
grafts. Four dogs (22.2%) developed graft-versus-host-disease. Dogs 
given TLI alone (Group 2) rejected the renal allograft after median 28 
days (range 26 to 33) compared to 20 days (range 18 to 22) for control 
animals (Group 3).
Conclusions: We have defi ned the parameters necessary to induce mixed 
hematopoietic chimerism and tolerance to renal and skin allografts in DLA-DP 
matched dogs without using immunosuppressive drugs.
DONOR BONE HARBORS HIGHEST CHIMERISM AND 654 
IS SUFFICIENT TO PROMOTE ALLOGRAFT TOLERANCE 
AFTER HETEROTOPIC HINDLIMB TRANSPLANTATION 
M.J. Elliott, L.D. Bozulic1, D. Rahhal1, L. Adamson1, W-C. Huang2, H. Xu1, 
Y. Huang1, W.C. Breidenbach3, and S.T. Ildstad1. 
1Institute for Cellular Therapeutics, Louisville, KY; 2Chang Gung Memorial 
Hospital, Taipei, Taiwan; 3Kleinert, Kutz, and Associates Hand Care Center, 
Louisville, KY
The requirement for immunosuppressive agents to prevent rejection has limited 
the widespread clinical application of composite tissue allotransplantation 
(CTA). An approach to induce transplantation tolerance and avoid the toxicity 
associated with these agents would be signifi cant. Chimerism established 
with nonmyeloablative conditioning has been shown to induce tolerance to 
organ transplants. However, whether acceptance of such a highly antigenic 
tissue as CTA would occur in nonmyeloablatively conditioned recipients 
remains controversial. In the present studies we evaluated the effect of 
nonmyeloablative conditioning on the establishment of mixed chimerism 
and CTA graft acceptance. Mixed allogeneic (ACI→WF) chimeric rats were 
prepared by conditioning recipients with doses of total body irradiation (TBI) 
ranging from 100 to 600 cGy on day 0 followed by anti-lymphocyte serum (5 
mg) on day 10, FK-506 (1 mg/kg/day) days 0-10, and a single dose of anti-αβ-
TCR mAb administered on day -3. Animals received 100 x 106 T-cell depleted 
ACI bone marrow cells on day 1. An osteomyocutaneous fl ap was placed at 
29 days in animals with chimerism ≥ 1%. Nine CTA acceptors were followed 
for 6 months, then evaluated for chimerism in several hematopoietic tissue 
compartments. Seven of the nine animals did not have detectable peripheral 
blood (PB) chimerism. One animal had low donor PB chimerism (~1.33%) and 
Wednesday 13 August 2008 Oral Abstracts
2 3 0
W
ED
N
ES
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
1 had high PB chimerism (~73%) (not shown). With the exception of the latter 
animal, when bone marrow from the transplanted donor bone was collected 
and analyzed from 5 animals, signifi cantly higher levels of donor chimerism 
were observed in this compartment than in peripheral blood (P<0.01), draining 
lymph node (P<0.05), thymus (P<0.05), and spleen (P<0.05). Signifi cantly 
higher levels of donor chimerism were also observed in the transplanted bone 
vs. recipient native bone (P = .0358). A second donor skin graft challenge was 
also accepted and did not result in rejection of the CTA. These results suggest 
that homing of donor lymphocytes/stem cells to their native bone takes place 
in the absence of lasting peripheral blood chimerism and that chimerism in 
the bone is suffi cient to induce donor-specifi c tolerance. Additional studies are 
underway to determine whether transplanted vascularized bone graft provides 
a vacant niche for donor stem cells, thereby providing a continuous tolerizing 
source.
LONG-TERM ALLOGRAFT SURVIVAL IN 655 
UNMANIPULATED HOSTS BY POST-TRANSPLANT INFUSION 
OF DONOR-SPECIFIC REGULATORY T CELLS AND 
RAPAMYCIN
G. Raimondi, T.L. Sumpter, B. Matta, D. Tokita, Z. Wang, A.W. Thomson
TE Starzl Transplantation Institute, University of Pittsburgh School of 
Medicine, Pittsburgh, PA, USA, 15213
Long-term donor-specifi c acceptance of MHC-mismatched organ allografts 
in unmanipulated hosts by administration of naturally-arising regulatory T 
cells (Treg) remains an unmet goal. High frequency of alloreactive T cells and 
pro-infl ammatory condition are emerging as the two major hurdles preventing 
induction of tolerance. We report the fi rst demonstration of a tolerance-
inducing strategy based on post-transplant administration of allo-Ag-specifi c 
Treg (AAsTreg) and rapamycin (Rapa), in a fully allogeneic, unmanipulated 
mouse heart transplant model.
Enrichment of naturally-occurring AAsTreg represented the fi rst step to 
counteract the high frequency of alloreactive T cells. Selection of AAsTreg 
was achieved by co-incubation of freshly-isolated CD4+CD25+ T cells with 
donor bone marrow-derived dendritic cells (DC). This procedure rendered 
a population with a conventional regulatory phenotype: Foxp3+, GITR+, 
CTLA-4+, CCR7+, CD62L-. These cells potently inhibited in vitro effector 
T cell proliferation at 1:20 and 1:40 Treg:T cell ratios. The suppressive 
activity was Ag-specifi c; no signifi cant inhibition was evident when effector 
T cells were stimulated by third party DC. However, T cells isolated from 
the spleen of graft recipients (d7 post transplant) were less susceptible to 
AAsTreg inhibition. Such “resistance” was associated with the infl ammatory 
state arising from transplantation. This resistance to Treg suppression was 
neutralized by Rapa administration, which also prevented graft infi ltration 
by effector T cells and favored endogenous Treg activity/expansion as was 
evident in the spleens of transplanted animals.
Considering the favorable effects associated with Rapa administration, 
AAsTreg were tested for their ability to induce transplant tolerance 
employing the following protocol: B10 recipients of vascularized BALB/c 
hearts received Rapa (1mg/Kg/d; d0-9) and 2x106 AAsTreg i.v. on d7. In 
comparison to the untreated group (median survival time, MST=11d; n=14), 
Rapa alone extended MST to 30 d (n=7), with no long-term graft survival. 
AAsTreg under cover of Rapa exerted a profound tolerogenic effect: >80% 
recipients exhibited long-term graft survival (MST>150d; n=6). This effect 
was stronger than that achieved with polyclonal Treg administration: 40% 
long-term survivors (MST=45; n=5). Moreover, the tolerogenic effect was 
Ag-specifi c as AAsTreg selected against third party DC (C3H/HeJ) did 
not prolong graft survival in comparison to the Rapa-only control group. 
Signifi cantly, heart graft survival was mediated via migration of infused 
AAsTreg to graft-draining lymphoid tissues and the induction of alloreactive 
T cell anergy.
Thus, combination of the anti-infl ammatory properties of rapamycin with 
AAsTreg administration, may represent an effective, clinically-applicable 
approach to minimization of drug-based immunosuppression, and the induction 
of long-term allograft survival.
DONOR CELL INFUSION WITHOUT 656 
IMMUNOSUPPRESSION AS A NOVEL THERAPY FOR 
INDUCTION OF DONOR-SPECIFIC TOLERANCE IN ISLET 
CELL TRANSPLANTATION
X. Luo, K. Pothoven, D. McCarthy, M. DeGutes, A. Martin, G. Xia, S. Miller
Northwestern University Feinberg School of Medicine
Background: In autoimmune models, peptide-pulsed splenic antigen presenting 
cells that are chemically fi xed with ethylcarbodiimide (ECDI) have been used 
as a powerful and safe method to induce antigen specifi c T cell tolerance. ECDI 
fi xed donor cells for allo-antigen specifi c transplant tolerance has not been well 
studied.
Material and methods: C57BL/6 mice were rendered diabetic by STZ. Kidney 
subcapsular allogeneic islet transplant was performed 10 days after diabetes 
stabilization (day 0). 1x108 ECDI-treated donor splenocytes were injected i.v. 
either once (day -7) or twice (day -7 and day +1). Animals were analyzed for 
graft outcome.
Results:Control mice receiving islet graft alone rejected the graft 
between day 11 to day 18 (MST = 14 days, N=8). Mice receiving one 
dose of ECDI-treated donor splenocytes (on day -7) showed similar graft 
survival as controls (MST = 15 days, N=5). In contrast, mice receiving 2 
doses of ECDI-treated donor splenocytes (on day -7 and day +1) showed 
significant prolongation of graft survival with 72.7% functional grafts at 
day 60 (N=11), and some remained functional >100 days. This protection 
is donor-specific as mice receiving ECDI-treated SJL cells rejected Balb/c 
islet grafts as controls (MST = 18 days, N=4). Immunohistochemistry 
of protected grafts showed positive insulin staining within well-defined 
islet architecture. Peri-islet infiltrates were composed of CD4+, CD8+, 
and CD11c+ cells, with occasional Foxp3+ cells. Anti-donor antibody 
production (IgG1,G2a,b, G3) was completely abolished in long-term graft 
survivers. This tolerance was undisturbed by anti-CD25 antibody treatment 
during maintenance stage, but could not be established if treatment was 
given around the time of the first donor cell infusion. In addition, lack of 
PD-L1 also impaired tolerance induction evidenced by using PD-L1-/- as 
recpients.
Conclusion: 1. Multiple infusions of ECDI-treated donor splenocytes 
signifi cantly prolonged allo-graft survival in the islet transplant model. 2. The 
protective effect is donor-specifi c and is dependent on regulatory T cells as well 
as the PD-L1 signaling pathway. Therapy with ECDI-treated donor cells may 
emerge to be a novel and potent agent for induction of donor-specifi c transplant 
tolerance.
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CONCURRENT ORAL SESSION 47: 
ACUTE REJECTION AND HLA
RENAL ALLOGRAFT OUTCOME AMONG RECIPIENTS 657 
OF POSITIVE VS NEGATIVE CROSSMATCH COMBINED 
LIVER-KIDNEY TRANSPLANTATION: UNOS DATA ANALYSIS
R. Parasuraman1, K.K. Venkat1, D. Moonka2, A. Yoshida2, A. Kappke3, 
K. Brown2, M. Abouljoud2, D. Kim2
1Division of nephrology, Henry Ford Hospital and 2Transplant Institute, 
Henry Ford Hospital, Detroit, MI, United States
Successful combined liver kidney transplantation (CLKT) despite pre-transplant 
positive cross match (+ CXM) has been reported implying immunoprotective 
effect of liver allograft (LA) on renal allograft (RA). However, severe acute 
humoral rejection with RA loss has been documented suggesting LA may not 
always protect RA.
Aim: To examine the effects of pre-transplant + CXM on RA outcome in 
CLKT.
Method: A total of 1401 CLKT recipients for whom CXM data available were 
identifi ed from UNOS data base from 1986–2006. Of these, 242 (17.3%) had 
+CXM and data was analyzed for acute rejection rate and RA outcome. The 
signifi cant results are summarized below.
Variable Negative CXM N = 1159
Positive CXM N 
= 242 p-value
Recipient: Female 374(32%) 136 (56%) 0.001
% Class I PRA 25.9±26.5 66.3±40.5 0.001
% Class II PRA 31.0±29.3 56.4±36.3 0.013
treated for rejection 69/606 (11%) 24/150 (16%) 0.026
Length of stay: Admission to 
discharge
Days 
28.8±33.2(N=838)
Days 
37.3±46.0(N=155) 0.028
Results: The demographic and clinical data were similar between +CXM 
and Negative CXM groups. The rejection rate was signifi cantly higher and 
the length of stay was signifi cantly longer in +CXM group as shown in the 
table. The RA survival rates were 8%, 7% and 6% lower at 1, 3 and 5 years 
post transplant respectively among + CXM recipients. However, this did not 
reach signifi cance mostly due to small sample size (p=0.11). The inferior RA 
outcome is seen during the initial few years after transplantation that disappears 
after 9 years.
Conclusion: In CLKT, pre-transplant +CXM can result in higher RA 
rejection rate and longer length of stay in hospital. LA may not always confer 
immunological protection to RA in + CXM CLKT and its true burden may be 
under recognized since CXM is not routinely performed in all CLKT. Study of 
antibody specifi cities or LA volume to determine the effect of +CXM on RA 
outcome is essential.
SUCCESSFUL TRANSPLANTATION OF DONOR 658 
SPECIFIC ANTIBODY POSITIVE, CROSSMATCH NEGATIVE 
(AHG/FCXM)RENAL ALLOGRAFT RECIPIENTS
J. Lappin, J. Abraham, S. Katz, B. Kahan, E. McKissick, K. Hosek, 
A. Hoover, B. Biedermann, R. Kerman, C. Van Buren
The University of Texas Medical School-Houston
Historically, the pretransplant (Tx) crossmatch (XM) alone was used to pair 
immunologically appropriate donors and recipients (recips) for transplantation. 
Recips were then transplanted following a negative (neg) donor-recipient anti-
human globulin (AHG) XM and, more recently, following a neg, more sensitive, 
fl ow cytometry XM (FCXM). In addition, the presence of HLA antibodies (Abs) 
and their specifi cities can be identifi ed in patient sera by Luminex and single 
antigen bead technology. Would there be an increased immune and clinical risk 
if the preTx evaluation yielded neg donor specifi c AHG and FCXMs albeit 
in the presence of a positively identifi ed donor-specifi c HLA Ab (DSA) in 
patient sera? To address this question we prospectively transplanted 17 renal 
allograft recips (14 with deceased and 3 with living related donors, including 
5 ReTx and 12 primary recips, 8 females and 9 males; 6 of African American, 
8 of Caucasian, 2 of Hispanic and 1 of Asian heritage). Immunosuppression 
consisted of Thymoglobulin induction followed by Sirolimus (N=13), 
Cyclosporine, Mycophenolate Mofetil (N=4) and Prednisone maintenance 
therapy. No patients received preTx plasmapheresis. At one year post Tx there 
was a 100% patient survival. One patient experienced a resolvable acute cellular 
rejection while fi ve patients (29%) experienced antibody mediated rejection 
(AbMR). There were four graft losses with one due to a hypercoaguable 
state and three immune losses to AbMRs (yielding an immune loss of 18%). 
All three recips with AbMR and subsequent graft loss, occurred in African 
American females and two of the three AbMRs were preceded by delayed graft 
function (DGF). Two additional Caucasian female recips with immediate graft 
function that also had AbMRs responded positively to therapeutic intervention. 
The preTx DSA titers (1:2 – 1:32) and/or fl uorescence intensities (8,486 ± 
3,229) of Ab-DSA specifi c beads were not predictive of DGF, rejection or 
graft loss. The presence of DSA in preTx neg AHG and FCXM recips did not 
predict the clinical outcome. However, female recips may be at increased risk 
for developing AbMRs and experiencing graft loss. In this study specifi cally, 
African American females with DGF were at high risk (3X) of developing 
AbMR and graft loss. To our knowledge this is the fi rst report that patients with 
neg AHG and FCXMs and positive DSAs can be successfully transplanted. 
African American female recips who experience DGF could be treated more 
aggressively (Ab reduction, anti-CD20 Ab, plasmapheresis) in this subset of 
patients to guard against unresolvable AbMR and graft loss.
THE PRESENCE OF AN ANTIBODY COMPONTENT 659 
IN ACUTE CELLULAR REJECTION DECREASES RENAL 
ALLOGRAFT SURVIVAL
M. Everly, J. Everly, P. Brailey, B. Susskind, L. Arend, A. Govil, 
R.R. Alloway, P. Roy-Chaudhury, A. Tevar, E.S. Woodle
University of Cincinnati, Cincinnati, Ohio, USA
Background: Recent studies indicate that many acute rejection (AR) episodes 
are not purely acute cellular rejection (ACR), but are mixed (i.e. contain humoral 
aspects and ACR). Despite this new understanding of humoral involvement, 
data regarding long term allograft survival in patients with mixed rejection 
is unknown. The purpose of this study was to defi ne the infl uence of humoral 
components during AR (AMR or mixed) on graft survival.
Methods: Renal allograft recipients with AR by biopsy (bx) between 1/1/2003 
and 8/1/2007 were evaluated for donor specifi c anti-HLA antibodies (DSA) 
[Luminex platform/Labscreen single antigen beads] and C4d. All DSA were 
de novo, i.e., not detected prior to transplantation. Bxs were graded by Banff 
‘97 criteria (update 2003) for ACR and antibody mediated rejection (AMR). 
Mixed AR included both AMR and ACR. AMR and mixed AR were treated 
with apheresis, IVIg, rituximab, and/or thymoglobulin. Survival analysis was 
performed by Kaplan Meier (STATA/SEv9.2).
Results: 48 patients with AR and DSA evaluation were analyzed: 30 were 
classifi ed as ACR, 8 AMR, and 10 Mixed. Demographics were similar between 
groups. Median follow-up was 27.5 +/- 17.5 mos. Kaplan-Meier survival is in 
Figure 1. Pts with AMR (p<0.001; Log-rank) or mixed AR had reduced graft 
survival compared to ACR pts (p=0.002; Log-rank). GL was not observed in 
31 pts with ACR.
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 ACR(n=31)
AMR
(n=8)
Mixed
(n=10) p1 p2
Rejection Reversal, pts (%) 25 (83) 7 (88) 8 (80) NS NS
Recurrent Rejection, pts (%) 3 (10) 1 (12) 2 (20) NS NS
Overall GL, pts (%) 0 4 (50) 3 (30) 0.0009 0.0113
GL due to Chronic Rejection, pts (%) 0 3 (37) 2 (20) NS NS
GL due to Acute Rejection, pts (%) 0 1 (13) 1 (10) NS NS
Overall Graft Survival
(Kaplan-Meier: Log Rank)
100% 28.1% 64.3% <0.001 0.002
p1 = ACR vs AMR, Fischers Exact; p2=ACR vs Mixed, Fischers Exact
Conclusions: Humoral involvement in AR has a profound negative impact 
on graft survival. Therefore in all cases of rejection: (1) detection of humoral 
components is essential to defi ne a patient’s risk of graft loss, and (2) effective 
treatment of the humoral component may reduce graft loss.
SERIAL MONITORING OF ANTI HLA-ANTIBODIES 660 
IN LIVING RELATED RENAL ALLOGRAFT RECIPIENTS IN 
EARLY POST-TRANSPLANT PERIOD AND CORRELATION 
WITH PROTOCOL HISTOLOGY
M. Minz1, A. Yadav1, A. Sharma1, R. Minz2, K. Joshi3
1Dept of Transplant Surgery, PGIMER, 2Dept of Immunopathology, PGIMER, 
3Dept of Histopathology, PGIMER
Introduction: The role of antibodies in rejection of solid organ allografts is 
being increasingly recognized with development of improved techniques for the 
characterization of anti-HLA antibodies. A large number of studies analyzing 
the incidence of these anti HLA antibodies in past with patients with graft 
dysfunction have proved the usefulness of their monitoring. However, none of 
the studies have correlated presence of anti-HLA antibodies with changes in 
protocol biopsies. The present study evaluated for appearance of Class I & II 
anti HLA antibodies in immediate post renal transplant period, and correlated 
it with simultaneous changes in histology in protocol biopsies done in the fi rst 
six months after transplant
Methods: Sera of 20 consecutive living related renal transplant recipients 
[Mean age 31.0 + 8.8 yrs, M:F 13:7, Median Follow up of 6 months] were 
screened for anti HLA class 1 and 2 antibodies by commercial ELISA 
kits[GTI Inc., Waukesha, WI, USA] at 1, 3 and 6 months after transplantation. 
The results of these tests were correlated with protocol biopsies and renal 
function during the follow-up period. A total of 48 protocol biopsies were 
performed. Immunosuppression comprised of Tacrolimus, Mycophenolate and 
Prednisolone in all patients.
Results: Antibodies to class I was found in 25% of recipients included in this 
study, and class II antibodies were found in 10% of recipients. The incidence 
of acute rejection in these patients was similar to those who did not develop 
antibodies after transplant [33.3% vs. 28.5%, p=NS]. Two patients in the 
cohort had Type III Banff rejection which was associated with presence of 
antibody. Changes of early chronic allograft nephropathy were seen in 2 
patients. One of these patients had Class I antibodies in the serum. Serum 
creatinine at 6 months in patients with antibody production was 1.2+0.6mg% 
as compared to 1.4+ 0.4 mg% in those without anti-HLA antibody [p=NS].
Conclusions: Presence of anti-HLA antibody was associated with severe 
rejection episodes and may predict development of chronic allograft 
nephropathy.
ANTIBODY-MEDIATED REJECTION IN RENAL 661 
ALLOGRAFT RECIPIENTS TREATED WITH ALEMTUZUMAB 
INDUCTION
J. Pascual, J.D. Pirsch, J.R. Torrealba1, A. Djamali2, Y.T. Becker, G. Leverson, 
S.J. Knechtle, H.W. Sollinger, M.D. Samaniego2
Department of Surgery, Division of Transplantation, Department of Pathology 
and 1Laboratory Medicine and 2Department of Medicine, University of 
Wisconsin School of Medicine and Public Health, Madison, WI, USA
Alemtuzumab is a depletive agent used in induction therapy in kidney 
transplantation (KT). Prevalence, risk factors and impact of antibody-
mediated rejection in alemtuzumab-treated patients is not well-known. From 
2002 to 2005, 829 isolated KT in adults were performed at our institution. 
Alemtuzumab induction was used in 613 of them, 602 without primary non-
function. In addition to MMF and steroids, immunosuppression was based on 
CsA (n=294), tacrolimus (n=187) or CNI-free (n=121). Tacrolimus patients 
were younger, more sensitized and received more retransplantations. CNI-free 
ones were older, more frequently received a cardiac dead donor kidney and 
less frequently a living donor one. Delayed graft function was more frequent 
in CNI-free patients.
Biopsy-proven acute cellular rejection (ACR) was diagnosed in 41 (6.8%) 
patients, 13 of them before day 90th (early ACR) and 28 later (late ACR). 
Biopsy proven C4d-positive AMR was diagnosed in 128 patients (21.2%), 58 
early and 70 late cases. Donor age (HR 1.02, p=0.001), recipient age (HR 0.97, 
p=0.001), peak PRA (HR 1.008, p=0.06) and HLA-B two mismatches (HR 
1.57, p=0.02) were signifi cant risk factors for AMR in the multivariate analysis. 
Peak PRA (HR 1.017, p=0.001), pregnancies (HR 1.13, p=0.01) and CNI-free 
treatment were risk factors for Early AMR, whereas donor age (HR 1.032, 
p=0.001), recipient age (0.96, p=0.001), peak PRA (HR 1.017, p=0.001), CMV 
D+R- status (HR 1.77, p=0.03) and time on dialysis (in months, HR 1.009, 
p=0.02) were signifi cant risk factors for Late AMR.
Post-rejection graft survival was similarly affected by all types of rejection 
(Kaplan-Meier, all p<0.001 vs non-rejectors). Risk factors for graft loss in the 
multivariate analysis were pretransplant diabetes (HR 1.61, p=0.01), ACR (HR 
3.90, p<0.0001) and AMR (HR 3.83, p<0.0001). Post-rejection patient survival 
was more affected by AMR (Kaplan Meier, early AMR p=0.001, late AMR 
p=0.01, early ACR p=0.03, late ACR p=0.90, all vs non-rejectors). Risk factors 
for post-rejection death in the multivariate analysis were recipient age (HR 
1.06, p<0.001), pretransplant diabetes (HR 2.39, p<0.001), time on dialysis (in 
months, HR 1.009, p=0.006) and AMR (HR 1.74, p=0.06).
AMR is very frequent (more than ACR) in alemtuzumab treated KT recipients, 
and the reasons are not well-known. CNI-free regimens promote early AMR 
episodes, whereas young recipients receiving old kidneys are predisposed to 
late forms.
NON-HLA ANTIBODIES REACTIVE WITH 662 
ENDOTHELIAL CELLS COULD BE INVOLVED IN EARLY 
LOSS OF RENAL ALLOGRAFTS
C.R.D.S.C. Ronda1, D. Glotz5, E. Ianhez2, H. Rodrigues1, S.C. Ferreira1, 
D.S.R. David2,3, C.S. Viggiani1, M.C. Castro2, J. Kalil1,4, N. Panajotopoulos1,4
1Laboratory of Immunology, Heart Institute (InCor), School of Medicine, 
University of São Paulo, 2Renal Transplant Unit of São Paulo, 3Division 
of Pathology, University of São Paulo, 4iii – Institute for Investigation in 
Immunology, Millenium Institute, Brazil, 5Departement of Nephrology and 
transplantation, Hospital Saint-Louis, Paris, France
We investigated the presence of non-HLA antibodies in 11 patients who had 
early loss of their transplanted kidney from irreversible humoral rejection 
and 2 from renal venal thrombosis. The diagnosis was established based on 
clinical and biopsy characteristics, as described in the Banff classifi cation. 
The absence of anti-HLA antibodies against the donor was ascertained at 
transplant, at rejection, and before and after transplantectomy by the negativity 
of crossmatches performed.
Eluates from the 13 renal allografts and patient’s platelet-absorbed sera were 
negative by ELISA and were tested by fl ow cytometry against the endothelial/
epithelial hybridoma cell line EAHy.926. Non-HLA antibodies eluted from 9 
rejected kidneys (by AHR) bound to EAHy.926. These non-HLA antibodies 
were not detected in pre-transplant sera. However, 2 out of 4 pre-rejection sera 
were positive against EAHy.926 and one showed a borderline reactivity.
Positive eluates were tested against frozen sections from 4 normal kidneys in 
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order to defi ne kidney structures to which they were reactive. Binding was 
identifi ed by indirect immunofl uorescence method. Four out of 6 eluates tested 
bound to the glomerulus and arterial endothelium with intense fl uorescence but 
not to the Bowman’s capsule and tubular epithelium, ruling out any possibility 
that the eluates contained any anti-HLA antibodies. No polymorphism was 
observed in eluates reactivity.
We evaluated retrospectively C4d in 7 kidney biopsy samples available (all 
with positive eluates). All cases were negative, implicating involvement of 
non-HLA and non-complement fi xing antibodies.
Positive eluates were then tested with or without addition of an intravenous 
polyvalent immunoglobulin preparation (IVIg) to ascertain the putative effi cacy 
of IVIg to block non-HLA antibodies binding to target cells. In all 9 cases, 
addition of IVIg led to a strong decrease of non-HLA antibodies binding.
In conclusion, we have demonstrated that non-HLA antibodies may represent 
a cause of humoral rejection and that addition of IVIg can block their binding 
to the target cells. These are non-complement fi xing antibodies and probably 
recognize antigens of a non-polymorphic system in endothelial cells.
RISK FACTORS AND ASSOCIATIONS WITH 663 
ALLOANTIBODIES IN TRANSPLANT GLOMERULOPATHY
H.S. Eng1,2, G. Bennett3, E. Tsiopelas3, S. Chang4, P. Bardy1,3,5, G.R. Russ1,2,3,4, 
P.T.H. Coates1,2,3
1Department of Medicine, University of Adelaide, SA, Australia, 2Department 
of Nephrology and Transplantation Services, Queen Elizabeth Hospital, SA, 
Australia, 3National Transplant Services, Australian Red Cross Blood Service, 
SA, Australia, 4ANZDATA Registry, Queen Elizabeth Hospital, SA, Australia, 
5Department of Haematology-Oncology, Queen Elizabeth Hospital, SA, 
Australia
Introduction: The pathogenesis of transplant glomerulopathy (TG) remains 
controversial, with a rising evidence of alloantibody involvement. We 
retrospectively studied the risk factors and the association of alloantibodies in 
the development of TG.
Methods: All renal transplants (n=421) followed up in a single South Australian 
transplant centre from 1 January 1990 to 31 December 2006 were studied. 
Fifty-one biopsy-proven TG cases were identifi ed. To assess the risk factors, 
the TG group was compared with 62 grafts that were biopsy-proven without 
TG (control group). IgG anti-HLA antibodies were defi ned by Luminex® 
assays. IgG subclass (complement binding IgG1 and IgG3 subclass) of anti-
HLA antibodies were analysed using modifi ed Luminex® assays.
Results:
TG (n=51) Control (n=62) Odds R, 95% CI, p value
Graft loss 37 (73%) 22 (35%) 4.8, 2.1-10.8, p<0.001
Death censored graft loss 25 (49%) 17 (27%) 2.5, 1.2-5.6, p=0.019
Graft survival after biopsy 16.5 months 32.6 months p=0.08
Mean graft survival 80.5 months 80.8 months p=0.99
Regraft rate 18 (35%) 10 (16%) 2.8, 1.2-6.9, p=0.02
6 months cellular rejection 8/19 (42%) 6/31 (19%) p=0.09
6 months vascular rejection 4/19 (21%) 5/31 (16%) p=0.66
6 months glomerular rejection 7/19 (37%) 1/31 (3%) p=0.01
Glomerular rejection in the fi rst 6 months post transplant was a predictor for 
TG, vascular and cellular rejection were not. Other factors not statistically 
related to TG included: recipient age, gender, race, pre-transplant current 
and peak panel reactive antibody level (PRA%), donor source, age, gender, 
delayed graft function, cold ischemia time, number of HLA A, B and DR 
mismatch, 6 months acute rejection and immunosuppressive regimen at 
induction. Pre-transplant sera from all TG patients and 43 of 62 patients from 
control group were screened. 72% of TG patients had anti-HLA antibodies 
compared to 33% in control group (p≤0.001). Presence of anti-HLA CI 
antibodies was signifi cantly associated with TG (Odds ratio 5.2, 95% C.I 
2.2 – 12.5, p<0.001) but presence of anti-HLA CII was not (p=0.49). Donor-
specifi c antibodies (DSA) were found in 25% of TG patients compared to 9% 
of patients in control group prior transplantation (p=0.066). Post-biopsy sera 
from 29 TG patients who did not have DSA pre-transplant were subsequently 
screened. DSA were found in 17 (59%) of these patients. Eight TG patients 
developed class I DSA (DSA-CI), 2 developed class II DSA (DSA-CII) and 
7 developed both class I and class II DSA post-transplantation. TG patients 
with DSA pre transplantation were diagnosed earlier than patients who 
developed DSA post transplantation (mean graft survival until biopsy 35 
vs. 77 months, p=0.03). However, the timing of develop DSA did not affect 
the graft survival in TG patients (mean 53 vs. 68 months, p=0.58). Five of 7 
patients with DSA-CII and graft lost had complement binding IgG1 and IgG3 
DSA-CII antibodies.
Conclusion: Transplant glomerulopathy is associated with 6 months glomerular 
rejection and allosensitisation prior transplantation. More than 50% of TG 
patients have DSA at any time, especially complement-binding IgG subclass 
class II DSA are at high risk for graft failure.
EVALUATION OF INTRA-GRAFT B-CELL SUBSETS 664 
IN RENAL ALLOGRAFT REJECTION
M. Naesens,V. Zarkhin, N. Kambham, L. Li, S. Kwok, S. Hsieh, 
O. Salvatierra, M. Sarwal
Stanford University
Background: Intra-graft CD20+ B-cell infi ltrates in renal allograft acute 
rejection (AR) correlate with aggressive clinical course and corticosteroid 
resistance, an increased risk of graft loss, and independant of peritubular C4d 
deposition. The refi ned lineages of B-cells that are pathogenic in this aggressive 
rejection, and their traffi cking to the graft, are largely unknown. 
Aim: To study the phenotype, localization, migration and function of pathogenic 
B-cells in graft rejection.
Methods: A Tissue microarray (TMA) was generated containing 7 normal 
and 43 acute and chronic rejection nephrectomy samples from 50 patients 
(9-68 years of age) and have only been used as a source of tissue to study 
the distribution of different B-cell subsets in rejection. Immunohistohemical 
studies (IHC) of TMA were performed for B-cell lineages (CD20, CD79a, 
CD27, Pax-5, Bcl-6, Blimp-1, CD38, CD138); T-cells (CD3, CD4, CD8); 
macrophages (CD68); chemokines and growth factors (CXCL12, CXCL13, 
CXCR5, VEGF, STAT1); HLA-DR and C4d. Selected IHC stains including 
CD20, CD38, CD138, CD21, CD27, CD79a, and C4d were performed on 
37 renal allograft core biopsies from 28 patients (1-22 years age) with no 
AR (controls; n=5), AR with (n=10), or without (n=22) graft loss, and the 
results were correlated with specifi c clinical graft outcomes. XY chromosome 
fl uorescence in situ hybridization analysis was performed on 22 TMA sections 
from male recipients of a female donor kidneys with CD20 stains performed 
on consecutive sections to study the donor vs. recipient origin of infi ltrating 
B-cells.
Results: Two independant, pathogenic recipient derived B-cell subsets 
were identifi ed in rejecting renal allografts, without co-localization. 
These are activated effector (CD20+/CD79a+/Pax-5low/Bcl-6-/Blimp-1-/
CD38-/CD138-) and memory B-cells (CD27+), with capacity for antigen 
presentation (HLA-DR+), surrounded by CD4+ T-cells, and associated 
with CXCL12/13, STAT1 and VEGF. These B-cell clusters do not correlate 
with intra-graft C4d deposition or with detection of donor specifi c antibody. 
A second group of B-cells are interstitial plasmablasts and plasma cells 
(CD38+/CD138+/CD79low/Pax-5-/Bcl-6low/Blimp-1+/CD20-/HLA-DR-), 
surrounding glomeruli and arteries. These cells correlate strongly with 
circulating donor specifi c antibody, and to a lesser extent with intragraft C4d. 
Both CD20+ B-cells and CD38+ cell subsets correlate with the recalcitrant, 
steroid-resistant rejection, and CD20 positivity during rejection associates 
with reduced graft survival. No B-cells and peritubular C4d+ were seen in 
normal control tissue.
Conclusion: Two major recipient derived B-cell compartments populate 
AR grafts. In response to donor antigen, naive B-cells undergo clonal 
expansion and differentiation, developing either into memory and/or 
effector cells for antigen presentation, or plasmablasts/plasma cells for 
donor specifi c antibody production. Memory and chronically activated 
CD20+ B-cell clusters may function as effi cient antigen-presenting cells, 
supporting aggressive T-cell mediated cellular rejection. CD38+ plasma 
cells/plasmablasts characterize humoral rejection. These cells homing to 
the graft in response to different chemokines and factors, such as CXCL12, 
CXCL13, STAT1 and VEGF. As standard immunosuppressive rescue 
therapy poorly depletes B-cells, scrutiny for these cells in AR and the 
application of stratifi ed B-cell lineage specifi c treatments may be necessary 
to improve graft outcomes.
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PROBABILISTIC MODELING OF CMV INFECTION 665 
IN RENAL TRANSPLANTATION
P. Keown, S. Dmitrienko, R. Balshaw, R.J. Shapiro, P.A Keown
for the Biomarkers in Transplantation Team, University of British Columbia, 
Vancouver, BC, Canada
Introduction: Cytomegalovirus (CMV) is the most common viral pathogen 
following renal transplantation, and a major therapeutic challenge with profound 
clinical and economic implications. CMV infection results in important direct 
costs, and may incur indirect consequences and costs by increasing the risk of 
acute rejection, by secondarily reducing the probability of graft and patient 
survival, or by the combination of these events, although these effects are 
uncertain.
Methods: This study employed multi-state time-dependent multivariate 
modeling to examine the prediction, probability, consequences and treatment 
costs of CMV infection and the relationship between CMV infection and 
biopsy-proven graft rejection, graft loss and death after renal transplantation 
using Canadian consensus guidelines for CMV management, as a basis for 
comprehensive analysis of contingent consequences and costs.
Results: D+/R- patients received antiviral prophylaxis for 14 weeks; all but 
D-/R- patients were monitored weekly for CMVpp65 expression; those with 
¡Ý 4 cells/2x105 PMN received pre-emptive antiviral therapy; patients with 
CMV syndrome or disease received antiviral treatment. Case incidences of 
CMV viremia and syndrome in 270 sequential subjects were 27% (73/270) 
and 9% (23/270) respectively and only 1% had CMV disease; 91% were 
diagnosed in the fi rst 6 months. BPAR occurred in 32/174 (18%) of patients 
without CMV infection, 17/73 (23%) patients with CMV viremia and 5/23 
(22%) patients with CMV syndrome/disease (p=0.6). Only 22 patients 
experienced both events; in 4 subjects, CMV infection preceded BPAR 
(mean: 62¡À26 range 32-85 days) while in 18 it followed the diagnosis and 
treatment of BPAR (mean: 63¡À31, range 27-119 days). Time-dependent Cox 
analysis showed that neither donor/recipient CMV risk stratum (p=0.204 for 
BPAR, p=0.262 for graft loss and death) nor prior CMV infection increased 
the probability of BPAR (HR=1.098, CI=0.332-3.633, p=0.878) or of graft 
loss and death (HR=0.717, CI=0.224-2.299, p=0.576), but the risk of CMV 
infection increased signifi cantly following BPAR (HR=1.77, p=0.03). Mean 
direct costs of CMV care were $2,256/patient, and ranged from $927/
patient in the D-/R- to $7,069/patient in the D+/R- strata. Extension of 
antiviral prophylaxis to D+ (n=151, 56%), or D+ or R+ patients (n=200, 
74%) increased estimated mean costs to $3,735 or $4,405/patient for an 
absolute reduction to 4% in CMV syndrome or disease, an incremental cost 
of $42,808 (range: $28,426-54,324) and $46,850 (range: $46,166-$48,000) 
per case prevented.
Summary: Current consensus guidelines consequently appear highly cost-
effective in managing CMV infection; CMV infection does not increase the 
risk of BPAR or graft failure, but BPAR signifi cantly increases CMV risk 
which merits consideration of prophylaxis.
CONCURRENT ORAL SESSION 48: 
TRANSPLANT SURGERY VIDEOS
MINIMALLY INVASIVE KIDNEY TRANSPLANTATION 666 
(MIKT) – A 7-9 CM INCISION IS SUFFICIENT
P. Pfeffer, O. Øyen, T. Scholz, A. Hartmann
Rikshospitalet University Hospital, Oslo, Norway
Introduction: Minimally invasive surgery (MIS) has in recent years gained 
widespread acceptance, and almost all abdominal procedures have now been 
performed laparoscopically; including laparoscopic living donor nephrectomy 
(LLDN). However, no MIS technique for kidney transplantation (KT) has been 
described - untill recently.
Material/methods: A novel minimally invasive technique for kidney 
transplantation (MIKT) has been developed; restricting to a 7-9 cm incision, 
attempting minimal dissection/tissue trauma through the whole procedure. All 
anastomoses are performed with the kidney placed in its intended position; a 
fi tting retroperitoneal pouch, lateral to the incision.
Twentyone patients were transplanted by MIKT (by a single surgeon) and 
followed in a prospective manner, with matched controls.
Results:
[*: p < 0,05] MIKTn=21
Conventional KT
n=21
Skin incision length (cm) 8,1* (7 - 9) 20,5 (17-23)
Op. time (min) 118* (95-140) 187 (130-270)
Complications requiring
Reoperations/Interventions 3 8
Stay in hospital (days) 8,2* (6-13) 12,4 (7-29)
Graft loss 0 1(rejection)
Discussion/conclusion: In experienced hands, KT may be executed safe and fast 
through a minimal incision, similar to the one required for LLDN. Since our 
fi rst report of MIKT in nov. 2006, a partially video-assisted technique, through a 
same-sized incision, has been presented by a South-Chorean group (July 2007).
Considering the rapid evolution of MIS during the last decade, there is little 
reason to believe that KT in the future will be excluded from this development. 
And there are substantial reasons to believe that the very well documented MIS-
effects on pain/recovery also apply to KT. Actually, MIS seems particularly 
attractive in the immunosuppressed population, with signifi cantly retarded 
wound healing – and even more so with the recent introduction of potent 
antiproliferative drugs.
RETROPERITONEAL PLACEMENT OF PANCREAS 667 
GRAFT WITH PORTAL-ENTERIC DRAINAGE
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori, 
S. D’Imporzano, G. Amorese, I. Mosca, F. Mosca
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico, 
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Aims: Diffi culties were reported in arterial reconstruction in pancreas 
transplantation (PTx) with portal-enteric drainage (PED) especially in male 
recipients with omental obesity. Furthermore, since the graft is usually located 
intraperitoneally in a central position, graft accessibility for percutaneous biopsy 
may also be problematic We have recently described a method for PTx with 
PED, that circumvents these diffi culties, in which the pancreas graft is located 
in the retroperitoneal space behind the right colon mesentery (Transplantation 
2005; 79: 1137-42.). We herein show the video of this technique.
Methods: Between April 20th 2001 and February 29th 2008 a total of 151 
recipients were scheduled for PTx with PED. Pancreas were procured from heart-
beating deceased donors en-bloc with liver and kidneys. No venous extension 
graft was used, while a donor iliac artery bifurcation Y graft was employed 
routinely. In the recipient, the abdomen was entered through a midline incision. 
The right colon was hence mobilized, thus allowing exposure and dissection 
of both the superior mesenteric vein (SMV) and the right common iliac artery 
(CIA). The SMV was encircled as proximally as possible, usually where two 
large ileal branches merge into the main trunk of the vein. The CIA was also 
encircled as close to its aortic origin as possible. The venous anastomosis was 
created end-to-side between donor’s portal vein and recipent’s SMV. The arterial 
anastomosis was then created end-to-side between donor’s Y iliac graft (trimmed 
as short as possible in order to avoid kinking of Y limbs after reperfusion) and 
recipient’s CIA. Enteric drainage was obtained through a Roux-en-Y jejunal limb 
brought to the right fl ank region through a window made in the avascular portion 
of the right colon mesentery. The pancreas graft was eventually placed in the right 
retroperitoneal space, being covered by the ascending colon and its mesentery.
Results: Retroperitoneal PTx with PED was carried out in 150 out of 151 
recipients (99.3%), including 84 simultaneous pancreas kidney Tx (62 using 
a cadaveric kidney and 22 a live donor kidney), 57 PTx alone and 9 pancreas 
after kidney Tx, irrespectively of recipients’ body max index or size of superior 
mesenteric vein. Arterial anastomosis was always performed with ease, despite 
keeping the Y iliac artery graft extremely short. In a recipient of a pancreas 
after kidney graft, systemic drainage was preferred to portal effl uent due to 
intraoperative diagnosis of liver cirrhosis. Relaparotomy rate was 15.3%. Two 
recipients needed 2 relaparotomies, and 3 (2.0%) pancreas grafts were lost due 
to thrombosis; no additional grafts were lost because of surgical complications. 
One graft was lost due to arterial thrombosis 6 months after PTx. Percutaneous 
biopsy was always possible. Overall, 20 biopsies were performed (75% 
diagnostic) in 15 recipients. One-year patient and graft survival were 95.1% 
and 88.3%, respectively.
Conclusions: The technique shown in this video has distinctive technical 
advantages as compared to the “classical” method in which the graft is located 
intraperitoneally.
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TECHNIQUE FOR RESTORED KIDNEY 668 
TRANSPLANTATION(RKT) USING KIDNEYS REMOVED WITH 
SMALL RENAL TUMOURS.
D. Nicol, J. Preston, S. Wood, D. Wall, V. Kanagarajah, A. Griffi n
Princess Alexandra Hospital
We have recently reported the successful utilization of kidneys from patients 
with incidentally detected small renal tumours(< 3cm) for transplantation(Nicol 
et al BJU Int 2008. Following ex-vivo excision of the lesion and repair of 
the parenchymal defect the kidney is transplanted into selected recipients. 
These restored kidney transplants(RKT) appear a novel means of increasing 
the possibility of transplantation for selected patients who may otherwise not 
receive a transplant. To date we have performed 49 RKT with a median follow-
up of 40 months. The kidneys were obtained from patients who had elected 
to undergo ablative nephrectomy for small renal tumours after discussions 
with their treating urologist of the alternative treatment options of partial 
nephrectomy, percutaneous ablative techniques and observation. Recipients 
were older patients with signifi cant co-morbidities that may have prevented 
them otherwise receiving a transplant following a rigourous informed consent 
process outlining the risk of tumour recurrence(5%) as well as tchnical 
complications including bleeding and urinary fi stula. One graft failure occured 
due to recurrent FSGS after 30 months and 4 patient deaths from unrelated causes. 
The remaining transplants continue to function. Four patients experienced 
technical complications requiring re-intervention. One patient developed 
a calyceal fi stula which was successfully repaired by open exploration with 
nephrostomy drainage and ureteric stenting. An arteriovenous malformation 
occured in another case. This was managed by selective embolisation without 
compromise to graft function. A further 2 patients required re-exploration for 
evacuation of haematoma. One recipient developed a small local recurrence 9 
years following transplantation.To date the patient has declined intervention 
and the tumour remains stable at 1.2cm after 18 months of observation.
In this video we demonstrate the donor nephrectomy procedure with the 
subsequent ex-vivo surgery to excise the tumour. Repair of the parenchymal 
defect including collecting system repair is then undertaken before 
transplantation. Utilising standard techniques employed for partial nephrectomy 
kidneys removed with small renal tumours appear a viable and novel source of 
transplantation for selected recipients.
HAND-ASSISTED LAPAROSCOPIC LIVING DONOR 669 
NEPHRECTOMY AND DISTAL PANCREATECTOMY FOR 
SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT
N. Akutsu1, M. Maruyama1, C. Iwashita1, K. Ootsuki1, K. Saigo1, T. Asano2, 
T. Kenmochi1
1Department of Surgery, Chiba-East National Hospital, National Hospital 
Organization, 2Department of Surgery, Teikyo University Hospital
Background: It is seriously important for living donations to make safer 
and to reduce operating stress. Laparoscopic surgery is though to be a useful 
operating procedure for solving these problems. We have been performing 
pure retroperitoneoscopic nephrectomy for living kidney donation to decrease 
morbidity and reduce donor disincentives since April 2004. However, in 
living donor operation for simultaneous pancreas and kidney transplants 
(SPKTx), we had performed by open approach. In the last donation of SPKTx, 
We started hand-assisted laparoscopic living donor nephrectomy and distal 
pancreatectomy. In this presentation, we report a successfully completed hand-
assisted laparoscopic living donor nephrectomy and distal pancreatectomy.
Patient and method: A 58-year old woman made kidney and distal pancreas 
donation for her 25-year old daughter with severe type-1 diabetes mellitus 
and diabetic renal failure. Her height was 160cm and weight was 55kg (body 
mass index: 21.6%). In donor operation, the patient was placed in the supine 
position rotated 30 degrees to the right. Placements of working ports were 
as follows (one hand port (7cm); above umbilicus, three 12mm ports; (left 
lateral abdomen, left subcostal abdomen and left lower abdomen)). First, we 
performed left nephrectomy after dividing ureter with double clipping and 
fi nally dividing renal artery and vein by ENDO GIATM (Covidien). Next, we 
performed distal pancreatectomy. Resection position was above the left side 
edge of portal vein.
Results and conclusions: Total operation time was 448 minutes (160 minutes 
until nephrectomy and 382 minutes until distal pancreatectomy). An estimated 
blood loss was 43 mL. A warm ischemia time of kidney was 150 seconds and 
that of pancreas was 360 seconds. Renal and pancreatic functions in recipient 
were so good that urine from transplant kidney and normalizing of blood sugar 
were recognized immediately after transplantation. She discharged the hospital 
without remarkable complications. In conclusion, we demonstrated that hand-
assisted laparoscopic nephrectomy and distal pancreatectomy would have 
advantages of safeness for donor and of transplant organ function for SPKTx.
HAND-ASSISTED SCOPIC LIVING DONOR 670 
NEPHRECTOMY: A SINGLE CENTRE EXPERIENCE DURING 
THE MINIMALLY INVASIVE ERA
P. Pfeffer, O. Øyen, M. Hagness, B.H. Lien
Surgical Dep., Rikshospitalet University Hospital, Oslo, Norway
Introduction: Since 1998 we have tried out various minimally invasive 
procedures for living donor nephrectomy (LDN), including laparoscopic versus 
retroperitoneoscopic - and strictly scopic versus hand-assisted techniques. 
Several complications with the strictly laparoscopic tecnique (including two 
intestinal perforations) urged us to explore alternative/safer approaches.
Material/methods: Since 2005, 95 hand-assisted procedures have been 
performed, in most cases through a Pfannenstiel incision (7-9 cm). In the fi rst 
18 donors, the retroperitoneoscopic approach was used, (all left-sided). For 
reasons explained below, we changed to laparoscopic/transperitoneal access 
in the last 77 cases of this series, and 21 of these constituted our fi rst right-
sided nephrectomies. Lately, dissection/hemostasis with Ultracision has been 
replaced by latest generation LigaSure.
Results:
Strict laparoscopic
2001-2004
n=63; all left-sided
Retroperitoneoscopic
Hand-assisted
n=18; all left-sided
Laparoscopic
Hand-assisted
n=77; left 56 + right 21
Op. time (min.) 
[Experienced surgeon] 180 (110-295) 179 (130-240) 143 (100–185)
Periop. incidents Vascular lesions: 2Conversions: 2 Conversions: 0 Conversions: 0
PCA-Analgesia
Postop. days 0+1
(Morphine Equiv.)
28,1 (0-77) 40,2 (10-87) 33,2 (4-79)
Complications Total: 6 (10%)Serious: 2 (intest. perf.) No major No major
Conclusions: According to our experience during the minimally invasive era, 
the hand-assisted and laparoscopic procedure is simpler, safer and faster.
Hand-assistance affords increased security, both towards vascular incidents 
and gastrointestinal complications. Peroperative incidents are more easily 
solved without conversion. The laparascopic approach utilizes a large premade 
working space, while the retroperitoneoscopic space has to be created by 
extensive stripping of the peritoneum.
The development has recently been facilitated by major technical improvements, 
including ‘High Defi nition imaging’ and improved LigaSure, taking care of all 
venous branches without clips.
NON-RELATED LIVING DONOR HORSESHOE KIDNEY 671 
TRANSPLANTATION
U. Boggi, F. Vistoli, M. Del Chiaro, C. Croce, C. Moretto, S. Signori, 
S. D’Imporzano, L. Morelli, G. Amorese, F. Mosca
U.O. di Chirurgia Generale e Trapianti nell’Uremico e nel Diabetico, 
Azienda Ospedaliero Universitaria Pisana, Pisa -- Italy
Introduction: Horseshoe kidney (HK) is a rare renal congenital anomaly, 
frequently associated with vascular and ureteral abnormalities. The increasing 
organ shortage has led to consider using renal grafts with anatomical variations; 
there are reports of cadaveric HK successfully transplanted en bloc into a single 
recipient or splitted with each half transplanted into two separate recipients. 
Use of divided HK from living donors has been described in only 7 cases, all 
in related couples. We herein report the video of the fi rst case of HK splitted 
with a half harvested from a living donor and transplanted into a non-related 
recipient (wife).
Case report: Kidney transplant was performed in November 2006 from a 55 
year old donor to his 53 year old wife, who was diagnosed with polycystic 
renal disease and underwent bilateral nephrectomy due to recurrent infectious 
episodes, before to be listed. Preoperative donor ultrasonography revealed the 
presence of a HK with no hydronephrosis or calculi. Renal function, assessed 
by Tc99scintigram, was equally balanced in the two halfs, with a total glomerular 
fi ltrate of 81 ml/min. The vascular supply, as evaluated by angio-CT and 
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angiogram, consisted in two arteries and one single venous trunk on each side. 
The HK lower poles were fused together in a parenchymal bridge at the level 
of aortic carrefour and inferior vena cava, which was joined by an accessory 
vein on each side. The urographic phase of angiogram revealed the presence 
of a single ureter on the left side while the right ureter was duplicated, with 
the two pelvis clearly separated. The HK was approached through a midline 
laparotomy; the right half was isolated and a total selective vascular control 
was achieved then the parenchymal junction was divided along its midline. 
The transplant was performed in the right iliac fossa; the renal arteries and 
the vein were anastomosed to the external iliac vessels, while the connection 
between the ureter and bladder was obtained by an uretero-vesical anastomosis 
according to Gregoire-Lich and intubated by a JJ stent. Postoperative course 
was uneventful for either patients and no delayed complication has been noted 
so far. One-year donor and recipient creatinine levels are 1.7 mg/dl and 1.3 mg/
dl, respectively.
Conclusions: When vascular and urologic anatomy are suitable, live renal 
donation may still be considered even in the presence of a HK.
CONTROL OF BLEEDING COMPLICATION DURING 672 
HAND-ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMY
Z.A. Zarka, H. Haidar, A. Sadeq, H. Hayati
Saad Specialist Hospital
Background: Laparoscopic donor nephrectomy has gained wide acceptance 
among transplant surgeons as it proved to be safe and provides similar graft 
function to open nephrectomy. Minimally invasive donor nephrectomy can be 
performed either totally laparoscopic or Hand-assisted. Hand-assisted donor 
nephrectomy is thought to be safer in regards to immediate control of intra-
operative bleeding. In this video we show clips of emergency intra-operative 
arterial and venous bleeding during nephrectomy that were controlled by the 
hand.
Method: DVD recording of all donor nephrectomy patients that had intra-
operative bleeding were reviewed and representative clips were collected in 
one DVD for presentation.
Results: This video demonstrates emergency intra-operative arterial and 
venous bleeding during nephrectomy, and maneuvers used for the control of 
bleeding by the surgeon’s hand. No patient required blood transfusion and blood 
loss was minimal as control was immediate. Most bleeding was controlled by 
compression only (either by the hand or by inserting a gauze) and dissection 
was carried out uneventfully thereafter. Only one patient required conversion 
to open, but with the surgeon’s fi nger controlling bleeding from the renal artery 
stump as the team was preparing for the conversion.
Conclusion: Hand-assisted donor nephrectomy approach provides immediate 
control of bleeding which allows the surgeon ample time to reassess the 
situation and manage accordingly minimizing blood loss, the need for blood 
transfusion, and the need to convert to open nephrectomy.
HAND TRANSPLANTATION: VIDEO DESCRIPTION OF 673 
THE PROCEDURE AND SURGICAL TECHNIQUE FOR DONOR 
LIMB HARVEST
B. Amirlak1, J. Ganz1, V. Gorantla2, R. Gonzalez2, C. Kaufman2, 
W. Breidenbach2
1Department of Plastic Surgery, Case Western Reserve University, Cleveland, 
OH, USA, 2Christine M. Kleinert Institute of Hand and Microsurgery, 
Louisville, KY, USA
Hand transplantation is a multifaceted procedure that involves a specialized staff 
and support system. Because the limbs are not traumatized, the technical aspect 
of hand transplantation may not be as diffi cult as a hand replantation. However, 
hand transplantation can become increasingly complicated if the donor limb 
is not harvested and prepared appropriately or if the recipient does not have 
viable functioning tendons, vessels, and nerves. This presentation details the 
steps, skilled personnel, and instruments required for upper extremity limb 
harvest for transplantation. The video shown was recorded during our most 
recent donor limb retrieval. It demonstrates the surgical technique for harvest 
and preparation of the donor upper extremity. This presentation is based on 
the information gathered from of the latest successful hand transplantation in 
Louisville, KY, performed in November 2006.
XENOTRANSPLANTATION CONCURRENT ORAL SESSION 49: 
– PIG-TO-PRIMATE/IMMUNE RESPONSES
AVERAGE SURVIVAL GREATER THAN 50 DAYS WITH 674 
EVIDENCE FOR BABOON THYMOPOIESIS IN PORCINE 
THYMUS IN BABOON RECIPIENTS OF LIFE-SUPPORTING 
GALT-KO PIG THYMOKIDNEYS
K. Yamada, A. Griesemer, Y. Ishikawa, At. Hirakata, S. Moran, P. Schule, H. 
Iwaki, 
S. Arn, A. Shimizu, D. Sachs
Transplantation Biology Research Center, MGH, Harvard Medical School
Background: We have previously reported the initial results of pig-to-
baboon thymokidney transplants from GalT-KO miniature swine using an 
immunosuppressive regimen designed to facilitate the induction of tolerance. 
Although the results were superior to results using hDAF thymokidneys, there 
was a high rate of early post-operative complications, especially infections. 
We have now investigated whether the elimination of steroids and whole body 
irritation (WBI) from the treatment protocol would decrease the complication 
rate in the perioperative period and enable the maturation of baboon T cells in 
the porcine thymus at an earlier time point.
Methods: 7 baboons received thymokidney transplants from GalT-KO 
miniature swine. The immunosuppressive regimen was based on the previously 
published protocol, but we eliminated steroids and substituted Rituximab for 
WBI. The regimen consisted of thymectomy before transplant, splenectomy 
day 0, ATG, Rituximab, MMF and anti-CD154 mAb. Renal function was 
assessed by serum creatinine levelsBaboon thymopoiesis in the pig thymus was 
assessed by FACS and immunohistochemistry. Xenogeneic T cell responses 
were assessed by cell-mediated lympholysis assays.
Results: One animal died due to a drug reaction at POD 18 with normal renal 
function and no evidence of infection. The remaining 6 baboons showed 
no signs of rejection although IgM deposition was observed, likely due to 
preformed non-Gal nAb. There were no deaths due to rejection. Although 
early infectious complications were not seen, late complications leading to 
mortality were still observed, including systemic CMV infection (POD 28), 
pleural effusions (POD 40, 57), ARDS with pulmonary hemorrhage (POD 49, 
81) and acute myocardial infarction (POD 83). Three animals showed evidence 
for early thymopoiesis in the pig thymus by FACS and immunohistochemistry. 
CD4+/CD8+ thymocytes were seen in the thymic grafts, indicating that T cell 
development was supported by the pig thymus. No animal had an anti-porcine 
response on CML, with one animal regaining an anti-third party response by 
day 49. The average survival of the steroid-free group was 51 days including 
the animal with the drug reaction and 56 days excluding it, compared to 34.6 
days in the previous regimen that included steroids/WBI.
Conclusions: A steroid-free and WBI free regimen designed for the induction 
of tolerance across the pig-to-baboon xenogeneic barrier had fewer early 
post-operative complications than previous regimens. Greater than 50-day 
average survival of recipients of life-supporting xenogeneic thymokidneys was 
observed without rejection. This regimen was associated with more advanced 
baboon thymopoiesis in the porcine thymus at an earlier time point than was 
seen with the previous regimen.
FUNCTIONAL ANALYSES OF CD55/HHO-1 TRANSGENIC 675 
PIGS IN AN EX VIVO PERFUSION MODEL
W. Ramackers1, B. Petersen5, L. Friedrich2, A. Tiede3, R. Zimmermann1, 
W. Schuettler1, S. Bergmann1, V. Broecker4, H. Niemann5, R. Schwinzer1, 
M. Winkler1
1Tranplant Laboratory, 2Dept. of Anesthesiology, 3Dept. of Hematology, 
4Institute of Pathology, Hannover Medical School, D-30625 Hannover, 
Germany, 5Institute of animal genetics (FLI), Dept. of Biotechnology, 31535 
Neustadt, Germany
Introduction: Although the hyperacute rejection (HAR) after pig-to-human 
xenotransplantation can now be overcome by controlling complement 
activation (i.e. by expressing human complement regulators), the acute 
vascular rejection (AVR) is still an unsolved problem. Following pig to primate 
kidney transplantation, endothelial cell activation and xenogenic activation of 
the coagulation (XAC) system of the recipient leading to organ dysfunction 
and disseminated intravascular coagulation (DIC) can be observed. Human 
Hemeoxygenase-1 (hHO-1) is known to have anti-apoptotic and cell protective 
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properties. Thus, the expression of hHO-1 on porcine endothelial cells 
could have benefi cial effects on organ survival after xenotransplantation and 
could possibly interfere with XAC. In this study we analyzed porcine cells 
and kidneys expressing the human complement regulator CD55 and the cell 
protective protein hHO-1.
Methods: The protective effects of the transgenes against complement-
mediated attack were assessed by cytotoxity assays. Organ survival and 
XAC following the contact of human blood with porcine endothelium, were 
determined by using an ex-vivo perfusion circuit based on low dose heparin 
mediated anticoagulation. Porcine kidneys were recovered following in situ 
cold perfusion with HTK organ preservation solution and were immediately 
connected to a perfusion circuit utilizing freshly drawn pooled human AB 
blood.
Results: Porcine fi broblast transgenic for CD55/hHO-1 showed increased 
resistance (up to 40%) against complement mediated attack than fi broblasts from 
wildtype pigs. Survival of wildtype pig kidneys during organ perfusion with 
human blood and addition of heparin was 42 +/- 26 min. Application of soluble 
complement inhibition (C1-Inhibitor) prolonged organ survival to 126 +/- 72 
min. XAC was observed with signifi cantly elevated concentrations of d-Dimer 
and thrombin antithrombin complex (TAT) combined with consumption of 
fi brinogen and antithrombin. The histological analyses revealed numerous 
microthrombi. In contrast, the perfusion of the CD55/hHO-1 transgenic porcine 
kidneys was feasible for more than 240 min in all perfusion experiments 
(without C1-Inhibitor). Although elevated levels of d-Dimer and TAT were 
measured, no signifi cant consumption of fi brinogen and antithrombin occurred. 
In addition, no microthrombi were detectable histologically.
Conclusion: We conclude that the expression of CD55 and hHO-1 in porcine 
kidneys can prolong organ survival and is able to interfere with XAC in this 
ex vivo perfusion model. These results suggest that the expression of hHO-1 in 
combination with CD55 could play an important role in xenograft protection.
IGVH GENES ENCODING XENOANTIBODIES TO 676 
GALTKO XENOANTIGENS IN RHESUS MONKEYS 
ARE RESTRICTED
M. Kearns-Jonker1,2, I. Harnden2, K. Kiernan2, M. Gunthart1, J. Meisner2, 
C. Gregory3
1Childrens Hospital Los Angeles, 2USC Keck School of Medicine, 3University 
of California at Davis National Primate Research Center
Galactoslytransferase-defi cient (GalTKO) pig organs were developed to 
provide a solution to the shortage of human organ donors. These organs do not 
initiate hyperacute rejection but undergo acute humoral rejection mediated by 
xenoantibodies directed at non-gal xenoantigens. The structure, specifi city and 
germline origin of these antibodies has not been determined.
Methods: Three rhesus monkeys were immunized with sixty million GalTKO 
pig endothelial cells in order to induce high levels of xenoantibodies directed 
at GalTKO xenoantigens. Pre-existing levels of anti-non-gal xenoantibodies 
were signifi cantly lower than anti-gal natural antibodies in rhesus monkeys. A 
strong immune response directed at GalTKO xenoantigens was confi rmed by 
fl ow cytometry after immunization. Pre and post transplant peripheral blood B 
cells were used to prepare IgG and IgM cDNA libraries for identifi cation of the 
IgVH genes encoding xenoantibodies.
Results: IgVH genes encoding anti-non-gal xenoantibodies were restricted to 
the use of a gene most similar to human germline progenitor V3-21, a gene 
that also encodes antibodies to carbohydrates. The CDR3 region is unique and 
the J region is most similar to JH4 in 76% of the IgG sequences. The germline 
progenitors encoding anti-non-gal xenoantibodies are also 91% similar to the 
IGHV3-11 alleles that encode anti-carbohydrate xenoantibodies in primates 
transplanted with either wild type and/or hDAF transgenic pig organs. 
Expression of iGb3 synthase could not be detected by PCR in the GalTKO pig 
cells used in this study, but could be confi rmed in GalTKO mouse cells.
Conclusions: The anti-non-gal xenoantibody response is restricted to usage 
of an IgVH repertoire known to encode antibodies to carbohydrates and 
glycolipids.
HIGH TITER PRE-TRANSPLANT ANTI-PIG IGM IN 677 
PRIMATES ARE NOT NECESSARILY ASSOCIATED WITH 
EARLY PORCINE XENOGRAFT FAILURE
F. Besenzon1, M. Seveso2, M. Vadori1, E. Bosio1, L. Cavicchioli3, 
F. Calabrese4, N. Baldan5, L. Polito2, E. Ancona1,2,5, E. Cozzi1,2,5
1Dept. of Surgical And Gastroenterological Sciences, University of Padua, 
Padua, 2CORIT, Padua, Italy, 3Dept. of Public Health Comparative Pathology 
and Veterinary Hygiene, University of Padua, Padua, Italy, 4Institute of 
Pathology, University of Padua, Padua, Italy, 5Padua General Hospital, 
Padua, Italy
Introduction: In the pig-to-nonhuman primate model, anti-pig antibodies are 
responsible for Hyperacute Rejection (HAR) and Acute Humoral Xenograft 
Rejection (AHXR). However, not all antibodies (natural or elicited) are 
detrimental to the graft. In this study, we evaluated a group of primate recipients 
of porcine renal xenografts showing long-term survival despite the presence of 
high titer of anti-pig antibodies.
Materials and methods: Eight 5-year old nephrectomized females cynomolgus 
monkeys (n=8) received a kidney from hDAF transgenic pigs (Novartis). All 
recipients received GAS914 (Novartis), cyclophosphamide perioperatively, 
cyclosporine A, mycophenolate sodium and steroids. In addition, the animals 
received recombinant human activated protein C (rhaPC), (Xigris, kindly 
provided by Eli Lilly, Florence, Italy) by continuous i.v. infusion, according 
to different regimes. Due to the presence of very high anti-pig antibody titers, 
prior to transplantation, all animals were exposed for 2 hours to extracorporeal 
perfusion using the donor controlateral kidney. Sera taken before and after 
transplantation were tested for their lytic activity on porcine aortic endothelial 
cells (PAEC) and on porcine red blood cells (RBC). Isotypes of antibodies pre- 
and post-transplantation were evaluated by fl ow cytometry. Sera were analysed 
for ability to induce expression of protective and anti-apoptotic genes such as 
HO-1 and Bcl2 by Western blot analysis.
Results: Whilst in 4 primates the haemolytic anti-pig antibodies were reduced 
by the pre-operative treatment, 4 primates presented high level of anti-pig 
antibodies during all post-transplantation period. Nonetheless, these animals 
survived for 8 to 24 days. It is of interest that one of these animals with good 
graft function (Nr. 1792) survived for 24 days in the presence of high titer 
anti-pig antibodies and kidney showing only grade I AHXR at euthanasia. 
Moreover, the pre-transplant serum from this animal was able to induce HO-1 
expression in PAEC more effi ciently than sera from other animals, whilst no 
differences were observed in Bcl2 induction. Following transplantation, 3 out 
of 4 animals with high titers anti-pig IgM pre-transplant continued to produce 
an IgM response in the absence of pig- specifi c IgG. In contrast, 3 out 4 animals 
with low titers IgM pre-transplant elicited a low titer pig specifi c IgG response 
in the post-transplant period.
Conclusions: The presence of high titer pre-transplant anti-pig IgM is not 
necessarily associated with early graft rejection. Indeed, some subsets of 
natural antibodies may increase expression of protective genes or even play an 
immunomodulatory role.
B CELL PROLIFERATION AFTER Α-GAL EXPOSURE 678 
REQUIRES THE PRESENCE OF ACTIVATED 
T HELPER CELLS
T. Kandeva, S. Liu, J. Tchervenkov
McGill University Health Center, Montreal, Canada.
Background: Antibody-mediated rejection is central to ABO incompatible 
transplantation as well as to Xenotransplantation. The xeno-antigen α-Gal has 
a highly analogous carbohydrate structure to the human blood group antigens, 
and both require memory B cell activation for antibody production.
We hypothesize that B cells reactive to the α-Gal xenoantigen require the 
presence of fully activated T cells in order to survive and proliferate in vitro.
Materials and methods: Human CD19+ B cells, isolated from healthy donors, 
were exposed to pig aorta endothelial cells’ membrane proteins, which express 
the α-Gal epitope. After an incubation period of 48 hrs with different culture 
conditions, their proliferation capacity was observed using the MTT assay 
(ATCC Bioproducts, USA). The different in vitro culture conditions used were: 
the addition of IL-4 (0.02mg/ml) and anti-CD40 receptor antibody (5mg/ml). 
B cells proliferation was computed as a percentage of the proliferation of the 
control group, which represents unstimulated B cells (B cells with culture 
medium and IL-4 only)
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Carboxyfl uorescein diacetate succinimidyl ester (CFSE) dilution assay was 
performed using the CellTrace™ CFSE Cell Proliferation Kit (Invitrogen). 
Purifi ed B cells were loaded with CFSE (5μM) in order to monitor their 
proliferation profi le. B cells were then seeded with purifi ed T cells (1 B cell 
per 2 T cells). T cells were either activated or not using anti-CD-3 (5 μg/mL). 
Also, culture medium either included or not the α-Gal antigen at different 
concentrations. Proliferation was analyzed after a 5-day incubation period
Results: 
CFSE Dilution Assay
 1 μg/mL Ag 1 μg/mL Ag
 Activated T cells Resting T cells
The results from the MTT assays show that B-lymphocytes require both anti-
CD40 and IL-4 in order to proliferate in vitro, suggesting that B cells depend 
on the presence of factors usually provided by activated T helper cells. This 
fi nding is further confi rmed by our CFSE dilution results, which suggest that 
B cells are able to proliferate only in the presence of both activated T cells and 
antigenic stimulation.
Conclusion: This fi nding may have clinical implications in offering novel 
strategies at blocking proliferation, so as to reduce antibody production in 
highly sensitized models.
IN VITRO INVESTIGATION OF HUMAN CELLULAR AND 679 
HUMORAL RESPONSES TO CELLS FROM GENETICALLY-
MODIFIED PIGS
H. Hara1, C. Long1, M. Ezzelarab1, P. Yeh1, S. Ball2, C. Phelps2, I. McKenzie3, 
D. Ayares2, B. Loveland3, D.K.C. Cooper1
1Thomas E. Starzl Transplantation Institute, University of Pittsburgh, 
Pittsburgh, PA, USA, 2Revivicor, Inc., Blacksburg, VA, USA, and 3Austin 
Research Institute, Melbourne, Victoria, Australia
Purpose: (1) To compare the antibody binding and complement-mediated 
cytotoxicity (CDC) of human sera to pig peripheral blood mononuclear cells 
(PBMC) and pig aortic endothelial cells (PAEC) from (i) wild-type (WT), 
(ii) α1,3-galactosyltransferase gene-knockout (GTKO), (iii) human CD46 
(homozygous) transgenic (CD46), and (iv) GTKO/CD46 (heterozygous) pigs. 
(2) To compare the human T cell response to pig PBMC from (i) WT, (ii) 
GTKO, (iii) pig cytotoxic T-lymphocyte antigen 4 (pCTLA4)-Ig transgenic, 
and (iv) GTKO/pCTLA4-Ig pigs.
Methods: Pooled human serum was tested by fl ow cytometry for binding of 
IgM and IgG (5% serum) and CDC (25% serum) to PBMC and PAEC from 
WT, GTKO, CD46, and GTKO/CD46 pigs. PAEC from all 4 pig types were 
activated by IFN-γ, and again tested for antibody binding and CDC. In MLR, 
human PBMC and isolated CD4+T cells as responders were cocultured with 
irradiated pig PBMC from WT, GTKO, CTLA4-Ig, and GTKO/CTLA4-Ig as 
stimulators. The results were expressed as 3H-thymidine uptake.
Results: There was higher binding of IgM and IgG to WT and CD46 than to 
GTKO and GTKO/CD46 PBMC and PAEC, but there were no differences in 
binding between WT and CD46 cells or between GTKO and GTKO/CD46 
cells. CDC of WT PBMC and PAEC was signifi cantly greater than of GTKO, 
CD46, and GTKO/CD46 PBMC (WT 73%; GTKO 37%; CD46 30%; GTKO/
CD46 4%) and PAEC (WT 51%; GTKO 18%; CD46 1%; GTKO/CD46 0%) 
(both p<0.05). Importantly, there was no lysis of GTKO/CD46 PAEC. After 
activation of PAEC, although CDC was increased against WT and GTKO 
PAEC, CD46 and GTKO/CD46 PAEC continued to demonstrate signifi cant 
resistance to lysis (WT 73%; GTKO 41%; CD46 5%; GTKO/CD46 0%). 
In MLR, human PBMC and CD4+T cell responses to GTKO PBMC were 
signifi cantly less than to WT PBMC (p<0.05). The human PBMC and CD4+T 
cell responses to PBMC from CTLA4-Ig transgenic pigs were signifi cantly 
reduced compared to the responses to non-CTLA4-Ig transgenic pig cells 
(p<0.05). (Human PBMC 3H-thymidine uptake - WT 72,710, WT/pCTLA4-
Ig 30,625, GTKO 62,660, GTKO/pCTLA4-Ig 38,182. Human CD4+T cell 
3H-thymidine uptake - WT 90,636, WT/pCTLA4-Ig 34,450, GTKO 81,698, 
GTKO/pCTLA4-Ig 55,385). The mean percent suppression of human PBMC 
and CD4+T cell responses associated with pCTLA4-Ig expression was 40%.
Conclusions: (1) CDC of all 3 types of genetically-engineered PBMC and 
PAEC was signifi cantly lower than of WT PBMC and PAEC. (2) CDC was 
signifi cantly reduced by CD46 expression even after activation of PAEC, 
lysis of GTKO/CD46 cells being signifi cantly lower than of GTKO or CD46 
cells. (3) The human T cell response to GTKO PBMC was weaker than to WT 
PBMC, indicating that the GTKO pig may provide advantages with regard to 
both humoral and cellular immunity. (4) Additional expression of CTLA4-Ig 
signifi cantly reduced the human T cell response, suggesting that organs from 
GTKO/CD46/CTLA4-Ig pigs should provide considerable protection against 
both the human humoral and cellular responses.
HUMAN CD47 ON PORCINE ANTIGEN PRESENTING 680 
CELLS HAVE A POSSIBILITY OF PREVENTING T CELL-
MEDIATED XENOGRAFT REJECTION THROUGH 
INHIBITORY SIGNALING TO SIRP ALPHA
K. Ide, H. Ohdan, H.Tahara, T. Asahara
Hiroshima University
We have previously proven that genetic induction of human CD47 on porcine 
cells provides inhibitory signaling to signal regulatory protein (SIRP) alpha 
on human macrophages; this provides a novel approach to preventing 
macrophage-mediated xenograft rejection. A recent report indicated that the 
similar CD47-SIRP alpha system negatively regulates the functions of both 
T cells and antigen presenting cells (APCs) in humans. We hypothesize that 
the interspecies incompatibility of CD47 may also act as an additional barrier 
of T cell-mediated xenograft rejection. We have analyzed the frequency and 
proliferative activity of human T cells responding to either porcine or allogenic 
APCs by using in vitro mixed lymphocyte reaction (MLR) assay with a CFSE-
labeling technique. Irradiated stimulator porcine or human peripheral blood 
mononuclear cells (PBMCs) were cultured with CFSE-labeled responder 
human PBMCs. By FCM analysis, the number of division precursors was 
extrapolated from the number of daughter cells of each division and from the 
mitotic events, and precursor frequencies in CD4+ and CD8+ T cell subsets. 
Using these values, stimulation index (SI) was calculated. The frequencies of 
alloreactive and xenoreactive CD4+ T cell precursors were almost identical, 
4.5¦ }0.8% and 4.4¦ }0.9%, respectively (n=10-12, for each type of precursor). 
However, the SI of xenoreactive CD4+ T cells was signifi cantly higher than 
that of alloreactive CD4+ T cells, indicating a more vigorous human CD4+ 
T cell response to xenoantigens than that to alloantigens per a single cell. In 
the presence of human CD47-Fc(containing the extracellular domain of human 
CD47 fused to the Fc portion of human Ig), the SI of xenoreactive CD4+ T cells 
was signifi cantly reduced to a level similar to that of alloreactive CD4+ T cells 
(n=12, P<0.05), although the frequencies of their precursors were absolutely 
uninfl uenced. The frequencies of alloreactive and xenoreactive CD8+ T cell 
precursors were also identical, i.e. 3.5¦ }0.3%, 3.9¦ }0.9%, respectively 
(n=10-12). The SI of both alloreactive and xenoreactive CD8+ T cells did not 
differ: however, that of xenoreactive CD8+ T cells was signifi cantly suppressed 
in the presence of human CD47-Fc (n=12, P<0.05). These results suggest 
that the T cell responses to porcine cells are stronger than those to allogeneic 
cells because of the interspecies incompatibility of CD47. Moreover, genetic 
manipulation of porcine APCs to induce human CD47 expression might 
attenuate human T cell-mediated xenograft rejection.
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RNA MICROARRAYS OF MACROPHAGES FROM 681 
REJECTING ISLET GRAFTS IDENTIFY UNIQUE GENE 
EXPRESSION AND PATHWAY ACTIVATION PATTERNS 
FOLLOWING XENOGRAFT REJECTION
J. Wu, S. Yi, M. Vitalone, W. Hawthorne, K. Hucker, D. Simond, P. O’Connell
Center For Transplant & Renal Research, Westmead Millennium Institute, 
Westmead Hospital
Background: Macrophages have been shown to be important in priming the 
T-cell response and are direct effectors in xenograft rejection. Previously, 
we have shown that pig primed and CD4+ T cell-activated macrophages are 
able to migrate to and specifi cally destroy pig islet xenografts in mice. This 
occurs without additional signaling from T cells, however, allograft primed 
macrophages do not show the same specifi city in graft recognition and 
destruction. Our previous results also showed that xenografts microenvironment 
provides additional signaling for macrophages activation, which are absent 
following allotransplantation.
Aim: To identify the genes involved in macrophage recruitment, migration and 
recognition which are specifi c for xenograft rejection.
Methods: Macrophages were isolated from rejecting neonatal pig islet cell 
clusters (pNICC) xenografts (PM) and C57Bl/6 islet allografts (MM) in 
NODSCID mice 12 days post reconstitution with 2x 106 Balb/c CD4+ T cells. 
Macrophages isolated from the NODSCID mouse spleen (naïve, NM) were 
used as controls. mRNA was extracted then amplifi ed by Illumina TotalPrep 
RNA Amplifi cation Kit, producing biotin cRNA, which was hybridized on the 
Illumina Sentrix® Mouse-8 (24K genes) bead-array. We compared both the 
PM and MM back to NM for differential gene expression using Beadstudio 
2.0 software. The differentially expressed genes were used in DAVID gene-
annotation engine for pathway activation analysis. Altered gene expression will 
be tested by RT-PCR.
Results: DNA micro-array revealed the total number of differentially expressed 
genes for MM and PM were 3157 and 445 respectively. The DAVID gene-
annotation engine analysis showed that immune cell activation and cytokine 
production pathways were enriched and activated in both xeno- and allo-
rejecting tissue models compared to naive controls; however these pathways 
were activated to varying degrees in each model of rejection. The cytokine-
cytokine receptor interaction pathway and cytokine activity pathway were 
specifi cally activated in the PM group (EASE score=2.04), whereas no change 
was found from MM group. Various other pathways were activated to a greater 
degree in the MM group than in PM group, such as metabolism (EASE=13.5 vs 
1.8), immune related (EASE=4.9 vs 1.0) and G-protein binding (EASE=2.3 vs 
1.0). Interestingly, TLR2 gene expression was specifi cally up-regulated in the 
PM group and was absent from the MM group when compared with NM via 
bead-microarrays. Furthermore, CXCL4 and TGFB-1 showed up-regulation 
specifi cally in the MM group, but not in PM group. CXCL12 and CXCL17 
were up-regulated and CCL8 were down-regulated in both xeno- and allograft 
rejection.
Discussion: Microphages showed different gene expression patterns in 
xenogeneic and allogeneic graft rejection which may refl ect the different roles 
played by microphages in two different processes. These studies should help us 
identify the unique role microphage play in xenograft rejection.
HUMAN IMMUNE RESPONSES TO ISLET XENOGRAFTS682 
S. Safl ey, H. Cui, J. Avila, B. Holbrook, S. Cauffi el, M. Rigby, C. Weber
Emory University
Background: The long-term goal of our research is to enable islet transplants 
in patients with Type 1 diabetes. The aim of this project was to analyze human 
immune responses to porcine islet xenografts and human islet allografts in a 
“humanized” mouse model.
Methods: NOD/Scid mice and NOD/Scids harboring a null mutation of the 
common cytokine receptor γ; chain (γ; chain KO NOD-Scids, The Jackson 
Laboratory, Bar Harbor, ME) were transplanted with neonatal or adult porcine 
islets (6,000 islet equivalents) or human islets (6,000 islet equivalents) under 
the renal capsule, and graft function was monitored by random blood glucose 
levels. Human peripheral blood mononuclear cells (PBMC) were transferred 
(i.v. or i.p.), and engraftment of human PBMC was documented by fl ow 
cytometry of the murine recipient’s peripheral blood and spleen cells. Islet graft 
destruction was evaluated histologically.
Results: Following transplantation under the renal capsule, adult porcine islets 
(API) reversed diabetes in streptozotocin (STZ)-diabetic NOD/Scid mice in 2 
± 1 days (n=11), while neonatal porcine islets (NPI) reversed diabetes in 40 ± 
14 days (n=10). API and NPI functioned for life in these immunoincompetent 
NOD/Scids. Following transfer of human PBMC by either the i.v. or the i.p. 
route, human CD4+ T cells, CD8+ T cells, and CD19+ B cells engrafted in γ; 
chain KO NOD-Scids, but human macrophages, neutrophils, and eosinophils 
did not engraft. When human PBMC and API were simultaneously transferred 
to STZ-diabetic γ; chain KO NOD-Scids, the islet grafts were rejected in 
9 days, correlating with the expansion of human CD4+ and CD8+ T cells, 
but the islet grafts continued to function in control mice given no human 
PBMC. When NPI were implanted, human PBMC were transferred after islet 
grafts had reversed diabetes in all mice (>100 days). In these recipients, graft 
rejection occurred >50 days post-transfer and correlated with the expansion 
of human CD4+ and CD8+ T cells. Human islets were rejected within 40 
days after transfer with human PBMC in γ; chain KO NOD-Scids, and also 
correlated with expansion of human CD4+ and CD8+ T cells.
Conclusions: The results of our study show that human PBMC will engraft 
in γ; chain KO NOD-Scids. We found that adult and neonatal porcine islets, 
as well as human islets, will reverse diabetes in this murine model, and we 
demonstrated that the transfer of human PBMC results in the resumption of 
diabetes. Our study suggests that human CD4+ T cells, CD8+ T cells, and B 
cells may be involved in rejection of porcine islet xenografts and human islet 
allografts. In future studies, we plan to elucidate the phenotype and function 
of human CD4+ and CD8+ T cells in islet graft rejection, as well as the role 
of xeno-, allo- or islet-specifi c antibody. In addition, we will characterize the 
mechanisms of rejection of islet allografts versus xenografts using this model. 
We expect that this model will be useful in developing improved methods 
to inhibit immune responses to islet xeno- and allografts, for example islet 
immunoisolation (microencapsulation).
MAINTENANCE CONCURRENT ORAL SESSION 50: 
IMMUNOSUPPRESSION AND LONG-TERM COMPLICATIONS
RESULTS FROM THE PAN-EUROPEAN-HTX TRIAL683 
B. Meiser1, B. Reichart1, and all investigators2
1Dept. of Cardiac Surgery, 2Depts. of Cardiac Surgery and Cardiology
Purpose: Nineteen centers from 6 European countries participated in the Pan-
European-HTx Trial. This prospective, centrally randomized investigator driven 
trial (sponsored by Roche and Astellas) was initiated to compare Tacrolimus/
MMF versus (vs) cyclosporine/MMF. Unlike previous trials, MMF dosage was 
adapted to MPA trough level measurements in all patients (pts).
Methods and materials: Altogether 201 pts entering the study were 
randomized either to Tac/MMF/steroids (n=104) or CsA/MMF/steroids (n=97), 
n=91 vs. n=96 received study medication. Mean donor age (years) was 34.9 vs 
36.8, recipient age 53.6 in both groups, the male/female ratio (%) was 85/15 
vs 80/20.
Results: Comparison of the one year follow-up data between the Tac/MMF vs 
CsA/MMF group revealed: Survival of the treated pts.: 96% vs 92%, rejection 
incidence per patient: 0.32 vs 0.46,% of pts. rejection free: 73 vs 55, mean 
serum creatinine (mg/dl): 1.50 vs 1.53, blood, glucose (mg/dl): 114 vs 105, 
systol./diastol. blood pressure (mmHg): 129/81 vs 133/83, cholesterol (mg/dl) 
176 vs. 189. Mean MMF dose (g) after 1 year in the Tac vs CsA group was 1.9 
vs 2.5, achieving mean MPA levels of 2.3 μg/ml in both groups.
Conclusions: The one year analysis indicates a similar, excellent survival in 
both groups, tacrolimus treated pts had a lower rejection incidence, similar 
creatinine, slightly higher blood glucose, lower cholesterol and lower blood 
pressure than CsA treated pts.. Remarkably is the high percentage of pts. 
completely free of rejection in both groups which might be due to the MPA 
level adapted MMF application. Furthermore, the study confi rms previous 
observations in much smaller cohorts that CsA treated pts. need signifi cantly 
more MMF to achieve similar MPA trough levels.
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DECREASE OF MAJOR CARDIAC EVENTS AND 684 
HOSPITALIZATIONS IN DE NOVO HEART TRANSPLANT 
RECIPIENTS RECEIVING EVEROLIMUS: RESULTS FROM 
A 12-MONTH, MULTICENTER, RANDOMIZED TRIAL 
COMPARING EVEROLIMUS WITH MMF
H. Lehmkuhl1, J. Arizon2, L. Almenar2, C. Magelli2, G. Gerosa2, S. Varnous2, 
F. Musumeci2, M-F. Mattei2, J. Vanhaecke2, K. Mange3, G. Machnicki3, 
U. Livi2
1Deutsches Herzzentrum Berlin, Berlin, Germany, 2On behalf of the RAD 
A2411 Study Group, 3Novartis Pharmaceuticals Corporation, East Hanover, 
United States
Introduction: The risk of acute rejection and severity/incidence of cardiac 
allograft vasculopathy is signifi cantly reduced in heart transplant patients 
receiving everolimus versus azathioprine. In this analysis, we compared major 
adverse cardiac events (MACE; i.e. acute MI, CHF, PCI, CABG, AICD, 
cerebral vascular accident or peripheral vascular accident) and the number 
of hospitalization days due to MACE in heart transplant patients receiving 
everolimus or MMF.
Methods: A 12-month, multicenter, randomized, open-label study was 
undertaken in de novo heart transplant recipients. Patients were randomized to 
everolimus (target C0 3–8ng/mL) with reduced-exposure CsA or MMF 1500mg 
b.i.d. with standard-exposure CsA, both with steroids. The main endpoints 
were renal function and effi cacy. Data were captured on MACE leading to post-
transplant hospitalization and hospital days due to MACE per 1000 patient 
days of follow up were calculated. Bootstrapping was used to determine the 
mean difference in number of hospital days due to MACE/1000 patient days 
and 95% CI values.
Results: The safety population comprised 174 patients (91 everolimus, 83 
MMF). Demographics were similar between groups. 14 (15.4%) everolimus 
patients were hospitalized for a total of 65 days due to MACE (mean 4.6±2.9 
days) and 18 (21.7%) MMF patients were hospitalized for 165 days (9.2±8.8 
days). In the everolimus and MMF groups, respectively, there were 2.09 and 
5.95 MACE hospital days/1000 patient days. Everolimus patients accounted 
for 3.86 fewer hospital days due to MACE per 1000 days than MMF patients 
(95% CI -7.8, -0.33). The ratio of MACE hospital days in the everolimus/MMF 
groups was 0.35 i.e. everolimus patients experienced 65% fewer hospitalization 
days than MMF patients after accounting for follow up.
Conclusions: Everolimus-based therapy was associated with fewer MACE 
and with a 65% reduction in the number of hospital days for MACE versus 
MMF by month 12 after heart transplantation. These preliminary fi ndings 
require confi rmation, but everolimus may offer a benefi t in light of the pivotal 
prognostic role of coronary and peripheral vasculopathy in heart transplant 
patients and the associated economic burden.
CHRONIC KIDNEY DISEASE IN UK HEART 685 
TRANSPLANT RECIPIENTS
R. Johnson, H.L. Thomas1, C.L. Murphy1, N.R. Banner2
1NHS Blood and Transplant, 2Royal Brompton and Harefi eld NHS Trust
On behalf of the Steering Group, UK Cardiothoracic Transplant Audit
Background: Renal disease is a late complication of cardiothoracic 
transplantation. We investigated the incidence of chronic kidney disease (CKD) 
following heart transplantation in the UK.
Methods: Data on 1,732 fi rst adult heart transplants in the UK, April 1996 
to March 2007, were obtained from the National Transplant Database. Multi-
organ, heterotopic and domino donor transplants were excluded from the cohort. 
GFR was estimated using the 4 variable MDRD equation, and categorised 
into National Kidney Foundation CKD stages at registration, transplant and 
throughout the post-transplant period. eGFR data was only included if serum 
creatinine was reported within 2 months of the relevant transplant anniversary.
Patients who survived the fi rst post-transplant year were split into two groups: 
those with eGFR<30ml/min/1.73m2 (CKD stage 4 or 5), and those with higher 
eGFR at one year. Long-term survival was estimated using the Kaplan-Meier 
method and compared between these two groups using the log-rank test. Risk 
factors for developing CKD stage 4 or 5 at one year were identifi ed using 
logistic regression.
Results: Renal function changed very little between registration and transplant, 
but deteriorated quickly following transplant (Figure 1). 3% of patients were 
CKD stage 4 or 5 at time of transplant, rising to 7% and 11% at 3 and 12 
months post-transplant, respectively. At 5 years post-transplant 12% were CKD 
stage 4 or 5.
Risk of developing CKD stage 4 or 5 by 12 months post-transplant was higher 
for those transplanted during the earlier years of the study (p<0.0001), for 
those who received temporary haemodialysis or haemofi ltration because of 
postoperative acute renal failure within 30 days of transplant (odds ratio 2.5, 
p=0.003), and for older recipients (p=0.002) and female recipients (odds ratio 
2.7, p<0.0001). There was also a centre-specifi c effect (p<0.0001).
For those who survived at least one year post-transplant, there was a signifi cant 
difference in unadjusted long-term survival between those with CKD stage 4 
or 5 at one year and those without (Figure 2, log-rank test p=0.019). Eight 
year survival was estimated as 70% (95% CI 61-78) and 77% (95% CI 74-80), 
respectively.
Conclusion: Renal function of heart transplant recipients is impaired early in 
the post-transplant period, with 11% CKD stage 4 or 5 at 12 months post-
transplant. Earlier transplant year, older recipient age, female recipient sex and 
temporary postoperative renal replacement were associated with developing 
CKD stage 4 or 5 within the fi rst year post-transplant, and the risk also varied 
between transplant centres. In unadjusted analysis, long-term survival was 
inferior for those who develop CKD stage 4 or 5 in the fi rst year compared to 
those who do not.
Figure 1
Figure 2
LONG-TERM IMMUNOSUPPRESSION WITH ANTI-686 
CD25 MONOCLONAL ANTIBODIES IN HEART TRANSPLANT 
PATIENTS
M. Cantarovich, N. Giannetti, J-P. Routy, R. Cecere, A. Papali, J. Barkun
Medicine, Cardiovascular and Thoracic Surgery and Epidemiology and 
Biostatistics McGill University Health Center, Montreal, Quebec, Canada.
Purpose: To describe: 1- Safety of a long-term anti-CD25 mAb-based 
immunosuppression strategy. 2- Effi cacy of this strategy with respect to renal 
function salvage.
Methods: 1- We describe 17 patients (64±7 years) who developed side-effects 
secondary to either CNI (chronic kidney disease (CKD), n=10 patients) or to 
Rapa (edema n=6 patients, lymphedema n=1 patient) and in whom conversion 
to long-term anti-CD25 mAb was performed at 10±4 years post-HTx (range 
3-16). Basiliximab, (20 mg iv at baseline and 4 days thereafter, then as needed) 
was used in 3 patients and daclizumab (1.5 mg/kg/iv as needed) was used in 
14 patients. The dosing interval was based on the CD25 saturation rate of 
peripheral blood CD4 T-lymphocytes, measured q.2-weeks for 3-months and 
monthly thereafter, aiming for <2% expression. Additional immunosuppression 
included MMF and prednisone in the majority of patients. Endomyocardial 
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biopsies were usually performed within 1-month after the discontinuation of 
CNI or Rapa. 2- Of the 17 patients, the 10 who had developed CNI-induced 
CKD were matched for age, gender and date of HTx with 10 HTx patients 
whose renal function had remained stable.
Results: 1- Anti-CD25 mAb have been given over 17±13 months (range 2-32). 
Based on the CD25 saturation rate, basiliximab was given every 2 months 
and daclizumab every 2-3 months. Anti-CD25 mAb have been well tolerated. 
Three patients died, 1 of perforated diverticulitis, 1 of acute renal failure (the 
patient refused dialysis) and 1 of acute rejection (the patient refused a biopsy). 
Side-effects secondary to Rapa resolved in all patients. 2- Table 1 depicts the 
outcome of renal function in the 10 patients with CNI-induced CKD as well as 
their matched cohort.
Table 1: Outcome of the creatinine clearance (mL/min) 
1 month 
post-HTx
6 months 
pre-event
Event: CNI 
discontinuation*
3 months 
post-event
6 months 
post-event Last visit**
Long-term anti-
CD25 mAb 74±16 50±22 37±12 42±13 42±15 41±14
Controls 72±12 72±31 70±27 68±27 67±30 65±27
*CNI were not discontinued in controls. This group was selected to compare the outcome of renal 
function; **17±13 months (range 2-32) post-discontinuation of CNI and 15±10 months (range 3-31) in 
controls.
The change in slope of the CrCl was +0.335 ml/min/month in patients in whom 
CNI were discontinued, and -0.124 ml/min/month in controls (P=0.03). 
Conclusion: Our results suggest that long-term anti-CD25 mAb-based therapy 
has the potential to replace CNI- and Rapa-based immunosuppression. It is 
crucial however that routine endomyocardial biopsies be performed in all 
patients for surveillance of acute rejection. A randomized controlled trial is 
required to confi rm the benefi ts of this strategy.
LATE ONSET ANTIBODY-MEDIATED REJECTION 687 
AND ENDOTHELIAL LOCALISATION OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR ARE ASSOCIATED WITH 
DEVELOPMENT OF CARDIAC ALLOGRAFT REJECTION
J. Bayliss1, M. Bailey2, A. Leet3, N.M. Thomson1, C.A. McLean1,4
1Department of Medicine, 2Department of Epidemiology and Preventative 
Medicine, Monash University, 3Heart Transplant Service, 4Anatomical 
Pathology, Alfred Hospital, Prahran, Victoria, 3181, Australia
Background: Improvements in cardiac transplant practice and 
immunosuppressive treatment have done much to curb the incidence of 
acute cellular rejection (ACR), however antibody-mediated rejection (AMR) 
and cardiac allograft vasculopathy (CAV) remain prevalent. Recent studies 
have shown that allograft rejection is governed by both allogeneic and non-
allogeneic factors such as infl ammation. Vascular endothelial growth factor 
(VEGF) is a highly specifi c mitogen for endothelial cells (ECs) produced 
by ECs and leukocytes. VEGF also acts as a monocyte chemoattractant 
and increases the production of various proinfl ammatory mediators. Initial 
studies have suggested that VEGF may play a specifi c role in not only 
leukocyte traffi cking, but in the augmentation of ACR and development of 
CAV.
Methods: 152 endomyocardial biopsies from 76 heart transplant patients 
undergoing orthotopic cardiac transplantation surgery between 1995 and 2000 
were assessed. Using immunohistochemistry, we investigated the localisation 
of VEGF protein to specifi c cell types during periods of ACR and AMR in the 
fi rst post transplant year and assessed the development of CAV.
Results: We showed a signifi cant correlation between lymphocytic localisation 
of VEGF protein and severe ACR (p<0.001). AMR positive biopsies taken 
at twelve months post transplant showed signifi cantly greater endothelial 
localisation of VEGF that time-matched AMR negative biopsies (p=0.006). 
When a subset of AMR positive biopsies with intravascular macrophage was 
assessed the signifi cance of the relationship with endothelial VEGF localisation 
increased further (p<0.001). Diffuse endothelial expression of VEGF was also 
associated with a 2.5-fold increase in the risk of developing CAV (p=0.001). 
There was universal development of CAV in patients from whom twelve month 
biopsies exhibited AMR with intravascular macrophage and endothelial VEGF 
localisation (n=8).
Conclusions: We have shown that localisation of VEGF protein to the vascular 
endothelium and intravascular macrophage during AMR is a highly signifi cant 
predictor of CAV. This study also highlights the potential pathogenic role of the 
endothelial cell in late onset AMR and the development of CAV.
MICROARRAY ANALYSIS SHOWS THAT NEUROPILIN2, 688 
ESDN, VASCULAR ENDOTHELIAL GROWTH FACTOR 
RECEPTORS 1 AND 2 (VEGFR1 AND 2) ARE DIFFERENTIALLY 
EXPRESSED IN PROLIFERATIVE CORONARY LESIONS 
FROM ATHEROSCLEROTIC AND TRANSPLANT 
VASCULOPATHY HUMAN ARTERIES
E.R. Rodriguez1, W.M. Baldwin2, C.D. Tan1
1Cleveland Clinic, 2Johns Hopkins University
Introduction: The single most important limiting factor to the longevity of 
cardiac allografts is “coronary artery vasculopathy”. This process consists 
of a cellular proliferative process which narrows the intima of the coronaries 
and eventually leads to failure of the graft. The pathology of the lesion has 
been compared to the pathology of coronary arteries in atherosclerosis. The 
main distinction is the proliferative nature of the lesion in the intima of the 
grafts. However the signals involved in this proliferative process are not well 
understood.
Methods: The epicardial coronary arteries from 24 hearts were procured and 
frozen in liquid nitrogen immediately after explanation of the heart from patients 
undergoing orthotopic heart transplant. Six were from dilated cardiomyopathy 
hearts without any evidence of coronary atherosclerosis. Six from patients 
with severe coronary atherosclerosis, and 12 from patients with failed cardiac 
allografts who were receiving a second transplant. Expression profi ling was 
studied by comparing these samples using Affymetrix HG-U133A expression 
chips. Genes of interest were subsequently quantitated by RT-PCR, localized 
in tissue samples by using antibodies to the protein encoded by these genes as 
well as in Western blots.
Results: Expression analysis showed increased expression of Neuropilin 2, 
ESDN and VEGFR2 in cardiac allograft coronary arteries. Immunofl uorescence 
demonstrated the abundant presence of these proteins in the neo-intimal 
proliferative lesion of these arteries and not in the media of allograft 
vasculopathy lesions.
Conclusions: This study shows that ESDN, Neuropilin 2 and its co-receptor 
the Vascular Endothelial Growth Factor 2 are expressed in the neointimal of 
coronary arteries with atherosclerosis and with allograft vasculopathy in a 
differential manner. This differential expression may modulate the interactions 
of VEGFR’s with other ligands that infl uence proliferation and migration of 
smooth muscle cells into the intima.
IMMUNOFLUORESCENCE DETECTION OF 689 
COMPLEMENT ACTIVATION PRODUCTS C4D AND C3D 
CORRELATES WITH CARDIAC ALLOGRAFT DYSFUNCTION 
AND DONOR SPECIFIC ANTIBODIES IN HUMAN HEART 
TRANSPLANTS
C.D. Tan, R.C. Starling, G. Tsokos, D.O. Taylor, D. Pidwell, 
G. Gonzalez-Stawinski, E.R. Rodriguez
Cleveland Clinic
Antibody mediated rejection in human heart transplantation is an 
immunopathologic process in which activation of complement with formation 
of the membrane attack complex results in allograft injury and dysfunction. 
However activation of complement in heart transplants does not always result 
in allograft dysfunction. The regulators of complement activation may play 
an important role in protecting the allograft from injury despite activation of 
complement.
Methods: We studied 1511 endomyocardial biopsies (EMBs) from 330 
patients (age: 20-73 years, 266 males and 64 females). The number of years 
after transplant was 1 year or less in 50 patients 1 to 5 years in 241 patients 
and >5 years in 39 patients. The average number of EMBs studied per patient 
was 5. Immunofl uorescence showing deposition of complement activation 
products C4d and C3d in linear pattern around capillaries was correlated 
with the presence of Cardiac allograft dysfunction defi ned as one or more of 
the following: 1. Systolic dysfunction defi ned as decreased cardiac output, 
decreased ejection fraction, need for inotropic agents. 2. Diastolic dysfunction 
defi nes as elevated fi lling pressures on right heart catheterization. 3. Sudden 
cardiac death.
Results: Thirty eight of 333 (12%) of patients showed deposition of 
complement. Group 1 included 19 patients with C4d and C3d deposits and 
Group 2 included 19 patients who were positive C4d only). In Group 1 16/19 
(86%) patients had concomitant allograft dysfunction and six of these patients 
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died. In Group only 1 of 19 (5%) patients had dysfunction. There were no cases 
of sudden death in Group 2. Donor specifi c antibodies were detected in 15/19 
patients of Group 1 and only in 3/19 patients in Group2
Conclusions: A panel of C4d and C3d is more useful than C4d alone in the 
evaluation of AMR. Presence of C4d and C3d correlates with cardiac allograft 
dysfunction and DSA. The incidence of AMR in this cohort: 5%. AMR 
can occur months to years after transplantation. The mere presence of C4d 
complement deposition alone should not be equated with AMR.
IS COMPLEMENT ACTIVATION WITHOUT ALLOGRAFT 690 
DYSFUNCTION INDICATIVE OF “ACCOMMODATION” 
IN HEART TRANSPLANT RECIPIENTS?
E.R. Rodriguez, C.D. Tan
Cleveland Clinic
The concept of “accommodation” has been used to refer to absence of injury 
in the face of humoral immunity directed against an organ graft; however, the 
mechanism(s) and concept of accommodation may extend much further. It has 
been suggested that regulators of complement activation may play a role in 
accommodation.
Methods: A cohort of 99 heart transplant recipients (81 men and 18 women) 
with and average age of 52 years was studied. Biopsies were stained with C4d 
and C3d as well as with antibodies to the regulators of complement activation 
(RCA) CD55 or Decay Acceleration Factor (DAF) and CD59 Protectin. 
Complement deposits were scored only if they were present in capillary pattern. 
RCA’s were scored if present in granular pattern in capillaries or venules.
Results: Six of 99 patients showed activation of complement with deposition of 
both C4d and C3d in capillaries. Only one of these six patient showed staining 
for RCA’s. Four out of 99 patients showed deposition of C4d in capillary 
pattern without staining for C3d. For out these four patients showed staining 
for RCA’s. In addition 64 patients without any complement deposition showed 
staining for CD55 and 44 showed staining for CD59.
Conclusion: In human heart transplants concomitant deposition of C4d and 
C3d correlates with antibody mediated rejection and absence of staining for 
CD55 or CD59
The presence of C4d deposits only does not correlate with antibody mediated 
rejection, but in contrast it is associated with concomitant expression of either 
CD55 or CD59 or both of these RCA’s
Patients without any evidence of complement deposits in the biopsy, often 
show staining with either CD55 or CD59 or both.
Thus a protective role of the RCA’s may be present in humans which is part of 
the accommodation mechanisms postulated in xenografts.
ROLE OF LIPIDS IN THE DEVELOPMENT OF STENOTIC 691 
MICROVASCULOPATHY AFTER HEART TRANSPLANTATION
N. Hiemann1, E. Wellnhofer1, C. Knosalla2, H. Lehmkuhl1, R. Hetzer1, 
R. Meyer1
1Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular 
Surgery, 2Deutsches Herzzentrum Berlin, Department of Cardiology
Background: C-reactive protein (CRP) and elevated lipid levels have been 
shown to increase the risk of epicardial vasculopathy after heart transplantation 
(HTx). We tested the effect of lipids and CRP on the development of stenotic 
microvasculopathy in biopsy, as novel prognostic factors for long-term 
survival.
Patients and methods: In 9,713 biopsies harvested within the fi rst post-
transplant year from 873 patients (83% men, mean age 49 yrs) morphologic 
alterations of endothelial cells and the media were studied by light microscopy 
(thickening with/without luminal stenosis). Total cholesterol, triglyceride and 
CRP levels were obtained during the fi rst year post-transplant. End-point for 
survival analysis was defi ned as major cardiac event (MACE: lethal myocardial 
infarction, sudden cardiac death, graft failure).
Results: Stenotic microvasculopathy was present in 379 (43%) patients. 
Endothelial disease (OR 1.96 [95%CI 1.38–2.78]; p<0.0001) and mild cellular 
rejections (1.17 [1.12–1.22]; p<0.0001) were found to increase the risk 
while statin treatment lowered the risk for stenotic microvasculopathy (0.68 
[0.47–0.96]; p=0.029). No differences were found between patients with and 
without stenotic microvasculopathy concerning total cholesterol (233±5 mg/
dL vs. 230±3 mg/dL), triglyceride (237±11 mg/dL vs. 235±7 mg/dL) or CRP 
levels (1.2±0.2 mg/dL vs. 1.7±0.3 mg/dL). MACE was correlated with stenotic 
microvasculopathy (2.56 [1.36–1.81]; p=0.003) and total cholesterol levels 
(1.01 [1.00–1.01]; p<0.001), while female gender (0.13 [0.03–0.59]; p=0.007) 
and statin treatment (0.35 [0.13–0.97]; p=0.044) were found to lower the risk 
for MACE.
Conclusions: CRP, total cholesterol and triglyceride levels do not seem to trigger 
stenotic microvasculopathy. Statins decrease the risk for MACE independently 
of cholesterol levels and should be considered in all HTx patients.
THURSDAY – ORAL ABSTRACTS
CONCURRENT ORAL SESSION 51: 
PREDICTORS OF RENAL TRANSPLANT OUTCOMES
VALIDATION OF AN ALGORITHM FOR DIAGNOSIS OF 692 
CORONARY ARTERY DISEASE AND PREDICTING CARDIAC 
EVENTS IN HIGH-RISK RENAL TRANSPLANT CANDIDATES.
J.J.G Lima1, L. Henrique Gowdak1, F.J. de Paula2, L.E. Ianhez2, 
J.A.F. Ramires1, E.M. Krieger1
1Heart Institute (InCor) University of São Paulo Medical School,, 2Renal 
Transplant Unit, Hospital das Clínicas, University of São Paulo Medical 
School.
Background: in a previous work (Hypertension 2003; 42:263) we showed that 
coronary angiography (CA) was the best predictor of cardiac events in high-
risk renal transplant candidates (RTC) compared to noninvasive testing. The 
aim of the present work was to validate these results in a larger group of similar 
individuals.
Methods: a strategy for diagnosis and risk assessment was applied in a group 
of 228 RTC (56 ± 9 years old, 71% males, 66% Caucasians) to validate an 
algorithm derivate from an initial study. Selection criteria were at least one of 
the following: age > 50 years, diabetes and cardiovascular disease. Patients 
underwent myocardial scans (SPECT) and CA, irrespective of symptoms and 
were followed-up until death, renal transplantation or the occurrence of cardiac 
events (sudden death, myocardial infarction, unstable angina, and heart failure). 
Coronary artery disease (CAD) was defi ned as stenosis > 70%.
Results: the prevalence of CAD was 47% and 1/3 of patients with important 
CAD were not detected by SPECT. The sensitivity, specifi city and positive 
and negative predictive values of SPECT for the detection of CAD were 70%, 
74%, 69%, and 71%, respectively and 31 patients (13.6%) developed cardiac 
events. The survival free of events in patients with normal and abnormal 
scans did not differ (Log-Rank= 0.247, Fig. 1) and the differences remained 
nonsignifi cant when we analyzed the results of fi xed (Log-Rank= 0.30) or 
reversible (Log-Rank= 0.14) defects separately. CAD, as defi ned by CA, was 
associated with increased probability of cardiac events (Log-Rank= 0.001; 
HR 1.90, 95% CI 1.29-2.92, Fig. 2). Multivariate analysis showed that 
diabetes (p= 0.03; HR 1.58, 95% CI 1.06-2.45) and angiographically-defi ned 
CAD (p=0.03; HR 1.69, 95% CI 1.08-2.78) were the independent predictors 
of events.
Conclusion: the results validate our observations in a smaller number of RTC and 
indicate that SPECT is not appropriate for the diagnosis of CAD or prediction of 
cardiac events in high-risk RTC. CA was an independent predictor of events but, 
because less than 50% of patients presented signifi cant CAD, it seems premature 
to recommend the test to all high-risk RTC. CA is necessary in many high-risk 
RTC and better noninvasive methods are still lacking to identify with precision 
those patients that will benefi t from invasive procedures.
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COUNTERINTUITIVE ASSOCAITION BETWEEN 693 
PRE-TRANSPLANT BODY MASS INDEX (BMI) DURING 
HEMODIALYSIS TREATMENT AND 5-YEAR POST-
TRANSPLANT MORTALITY IN 18,501 CKD PATIENTS
K.Kalantar-Zadeh1, E. Streja1, S. Bunnapradist2, J. Jing1, G.M. Danovitch2, 
C. McAllister3, 
1Harbor-UCLA Harold Simmons Center for Kidney Disease Research and 
Epidemiology, 2UCLA Kidney Transplant Center, 3DaVita Inc
Background: Confl icting results have been reported regarding the association 
of BMI and graft and patient survival in renal transplant recipients (RTR). We 
hypothesized that high pre-transplant BMI is NOT associated with greater 
mortality in RTRs. 
Methods: By linking the 5-year (7/2001-6/2006) national database of a large 
dialysis organization (DaVita Inc) to the Scientifi c Registry of Transplant 
Recipients (SRTR), we identifi ed 18,501 DaVita maintenance hemodialysis 
(MHD) patients, who underwent kidney transplantation in the USA. Quarterly 
BMI data originated from the dialysis database, and mortality data from the 
SRTR data. 
Results: The 18,501 RTR patients were 47.3±14.2 years old and included 
40% women and 24% diabetics. The pre-transplant BMI was 27.6±6.4 kg/m2. 
Unadjusted and case-mix and malnutrition-infl ammation complex syndrome 
(MICS) adjusted survival analyses showed incrementally greater survival with 
higher BMI>23 kg/m2 (see Figure):
Conclusions: A counterintuitive assocaition (or so-called “reverse epidemiology”) 
was observed between pre-transplant BMI values during hemodialysis treatment 
and post-transplant mortality, questioning the wisdom of weight reduction 
recommendations for pre-transplant waitlisted MHD patients. 
NT-PROBNP INDEPENDENTLY PREDICTS CVD AND 694 
GRAFT FAILURE IN RENAL TRANSPLANT RECIPIENTS
L.H. Oterdoom1, R.M. van Ree1, A.PJ. de Vries1, R.T. Gansevoort1, W.J. van Son1, 
J.J. Homan van der Heide1, P.E. de Jong1, R.O.B. Gans1 and S.J.L. Bakker1
1Renal Transplant Program, University of Groningen and University Medical 
Center Groningen, Groningen, Netherlands.
Manifest renal disease predisposes to cardiovascular disease (CVD). The 
concept of cardio-renal interaction implies that the opposite is also true and 
that cardiac dysfunction promotes development of renal dysfunction. Brain 
(B-type) natriuretic peptide (BNP), is released by ventricular myocytes and 
NT-proBNP is a cleaved product of BNP. It is unknown whether NT-proBNP 
predicts CVD and graft failure (GF) in renal transplant recipients (RTR).
Outpatient-clinic RTR, who had a functioning graft ≥1 year, were invited to 
participate between 2001-2003. CVD was defi ned as myocardial infarction, 
CVA, well documented TIA, PTCA, CABG, and CVD mortality. CVD events 
were retrieved by reviewing all electronic and paper charts until August 2007. 
GF was also determined until August 2007 and defi ned as the return to dialysis. 
NT-proBNP was determined using a sensitive immunoassay. Endpoints were 
analysed with Cox-regression analyses in three groups: reference group below 
the median and two groups above the median (equivalent to 3rd and 4th quartile).
NT-proBNP (median [IQR] 296 [131-669] pg/ml) was measured in 605 
RTR (aged 51±12 years, 55% male) who were at a 6.0 [2.6-11.4] years post-
transplant. Creatinine clearance was 62±22ml/min, 169 (28%) had proteinuria 
>0.5g/24h, and systolic blood pressure was 152±23 mmHg. During follow-up 
of 5.3 [4.7-5.7] years 78 had a CVD event and 42 suffered GF. In the reference 
group of NT-proBNP (range: 13-294 pmo/l, n=301), 16 (5) had CVD and 8 
(3%) suffered GF. In the 3rd quartile (296-667 pmol/l, n=152), 22 (15%) had 
CVD (Hazard Ratio 6.2 [95%CI 3.5-11.0) and 13 (9%) suffered GF (HR: 
3.5 [1.4-8.3]). In the 4th quartile (671-15392 pmol/l n=150), 40 (27%) had 
CVD (HR: 6.2 [3.5-11.0) and 21 (14%) suffered GF (HR: 6.5 [2.9-14.7) (All 
P≤0.001). After adjustment for age, sex, creatinine clearance, proteinuria, 
systolic blood pressure, and time since transplantation, the 3rd quartile of 
NT-proBNP predicted CVD (HR: 2.1 [CI 1.1-4.1], P=0.03), but the HR was 
reduced to 2.0 [0.8-4.9], P=0.2) for GF. The 4th quartile showed a HR of 3.6 
[1.8-7.0], P<0.001 for CVD and 2.8 [1.1-7.3], P=0.04 for GL in multivariate 
analyses. Results remained similar after adjustment of CVD prior to inclusion 
of the study.
NT-proBNP predicted CVD and GF independent of age, sex, renal function 
and blood pressure in RTR. That NT-proBNP predicts GF suggests that there 
is a cardio-renal interaction in RTR and that cardiac dysfunction leads to 
accelerated graft dysfunction.
METABOLIC SYNDROME INCREASES RISK OF 695 
MORTALITY IN RENAL TRANSPLANT RECIPIENTS.
A.P.J. de Vries1, L.H. Oterdoom1, R.M. van Ree1, W.J. van Son1, J.J. Homan 
van der Heide1, P.E. de Jong1, R.O.B. Gans1, S.J.L. Bakker1
1Renal Transplant Program, University Medical Center Groningen, 
Groningen, Netherlands.
Many renal transplant recipients (RTR) suffer from the metabolic syndrome 
(MS). It is unknown whether MS increases risk of mortality in RTR. We studied 
MS (ATPIII criteria) in a cohort of 606 RTR, who had a functioning graft ≥1 
year, with median [IQR] follow-up of 5.3 y [4.7-5.7]. MS was present in 63% 
of RTR, of whom 77 (21%) died compared to only 19 (9%) in RTR without 
MS (p<0.001). RTR with MS were older (53 vs 49y), more often female (50 
vs 39%), had more often central obesity (72 vs 14%), hypertension (100 vs 
95%), hypertriglyceridemia (84 vs 24%), low HDLc (83 vs 22%), and more 
often impaired fasting glucose or diabetes (26 vs 1%, all p<0.001). RTR with 
MS also had higher concentrations of fasting insulin (14 vs 9 pmol/L) and 
CRP (2.5 vs 1.4 mg/mL), used more ACE inhibitors (37 vs 27%), statins (55 
vs 40%), and had lower GFR (MDRD, 47 vs 53 mL/min, all p<0.001), whereas 
urinary protein excretion (0.2 vs 0.2 g/24h), current smoking (21 vs 24%) and 
immunosuppressive medication were similar. Figure 1 shows Kaplan Meier 
survival plots for RTR with and without MS. The crude hazard ratio (HR) of 
MS for mortality was 2.5 [1.4-4.1]. Age and sex adjusted HR was 2.2 [1.3-3.6]. 
The HR retained statistical signifi cance (HR 1.8 [1.0-3.3]) after adjustment for 
all MS criteria simultaneously. This did not change materially (HR 2.0 [1.1-3.9]) 
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after additional adjustment for GFR, insulin, proteinuria, smoking, CRP, and 
medication. Our data show that RTR with MS have a two times higher risk for 
mortality. Moreover, our data suggest that MS constitutes more than the sum 
of its parts with regard to mortality. The risk is not conferred by impaired renal 
function, hyperinsulinemia, proteinuria, infl ammation, smoking, or medication.
EFFECT OF CANDIDATE HEALTH STATUS 696 
ON INCREMENTAL YEARS OF LIFE FROM KIDNEY 
TRANSPLANTATION
A. Leichtman1, K. McCullough2, P. Stock3, M. Stegall4, R. Wolfe2
1Department of Medicine, Univ. of Michigan, 2Arbor Research Collaborative 
for Health, 3Department of Surgery, Univ. of California San Francisco, 
4Department of Surgery, Mayo Clinic College of Medicine
Introduction: The projected incremental years of life that can be achieved 
by receiving a kidney transplant v. remaining on dialysis (i.e. Life Years from 
Transplant or LYFT) is under investigation in the United States as a potential 
element of a national deceased donor kidney allocation system. Although 
candidate age is a signifi cant component in the LYFT calculation, additional 
elements refl ecting candidate health status contribute importantly to the LYFT 
score. We report the distribution of LYFT scores by age range.
Methodology: The LYFT scores for adult kidney-alone transplant candidates 
active on the national U.S. Organ Procurement and Transplantation Network 
waiting list on 1/1/2004 and receiving an average non-expanded criteria donor 
kidney were calculated. In the fi gure below the “whiskers represent the 5th and 
95th percentiles, the box edges the 25th and 75th percentiles, and the line within 
the box the median LYFT score.
Results: Median LYFT by age group ranged from 9.0 for kidney transplant 
candidates between 18-30 years to 3.7 for candidates greater than 70 years of 
age. The 5th-95th percentile for LYFT scores by age group ranged from 2.5-4.7 
for candidates over 70 to 7.6-10.1 for candidates between 18 and 30.
Discussion: Age is an important determinant, but not the sole important, 
determinant of LYFT. Within each age grouping, there is considerable variance 
in the projected incremental years of life that can be achieved by receiving a 
deceased donor kidney transplant. LYFT can be the same for candidates with 
as much as a 35 year difference in age. While age is an important determinant 
of LYFT, other factors can be as important as 30 years of aging.
PROSPECTIVE EVALUATION OF THE RISK BENEFIT 697 
RATIO OF A VITAMIN D TREATMENT DURING THE EARLY 
PERIOD AFTER RENAL TRANSPLANTATION
E. Thervet2, M. Courbebaisse1, J. Claude Couberbiellle1, J. Zuber2, 
F. Martinez2, M. F. Mamzer2, C. Legendre2, G. Friedlander1, D. Prie1
1Service d’explorations fonctionnelles, Hopital Necker, 2Department of 
Transplantation, Hopital Necker
Introduction: It has been demonstrated that 25-OH vitamin D (25OHD) levels 
are reduced in the large majority of renal transplant recipients (RTR) because 
of reduced sun exposure, and steroid therapy. The aim of this prospective 
randomized study was to investigate the risk benefi t ratio of a correction of 
25OHD during the early period after transplantation.
Patients and methods: All RTR in our center underwent a complete workup 
including Ca, P, ionized (i)Ca, PTH, calcidiol, calcitriol, calciuria and 
glomerular fi ltration rate (GFR) assessed by iohexol clairance at 3 months 
(M3). The inclusion criteria were a serum concentration of 25OHD<30 ng/
ml and a iCa<1.35 mmol/L. Between 01/2006 and 09/2006, 49 patients were 
randomized to receive 100.000 U of cholecalciferol (CLF) every other weeks 
for 2 months (4 doses) and thereafter 100.000 U every two months. The 
treatment was initiated at M4 (group A, n=23) or at M6 (groupe B, n =26) after 
transplantation. Complete PCa workups were performed at M6, 8 and 12. 
Results: No difference was found between the 2 groups regarding pre-
transplant characteristics and initial transplant evolution including steroid 
therapy. Between M4 and M6, all patients normalize their 25OHD in group 
A vs. no patient in group B (respectively 43.0±10.8 vs. 16.9±9.3, p<0.001). 
Delayed treatment at M6 in group B normalizes the 25OHD concentration at 
M8. Between M3 and M12, PTH signifi cantly improved (106±121 vs. 75±57 
pg/ml, p=0.03) without GFR modifi cation. At M12, CLF treatment was not 
associated with hypercalcemia or hypercalciuria (respectively 2.45±0.12 
mmol/L and 0.33±0.27 mmol/mmol). 
Conclusion: In RTR, 25OHD did not improve spontaneously between M4 
and M6 after successful renal transplantation. A treatment by 400 000 U 
of 25OHD allows a correction of vitD insuffi ciency, improve secondary 
hyperparathyroidism, without 25OHD intoxication, hypercalcemia nor 
hypercalciuria. The long term benefi t of this treatment and the need for chronic 
supplementation is currently being investigated.
STRATEGIES FOR DIAGNOSIS AND TREATMENT OF 698 
CORONARY ARTERY DISEASE IN RENAL TRANSPLANT 
CANDIDATES: IMPACT ON THE INCIDENCE OF POST-
TRANSPLANT CARDIAC EVENTS.
J.J.G. Lima1, L.H.W. Gowdak1, F.J. de Paula2, L.E. Ianhez2, R.L. Arantes1, 
E.M. Krieger1
1Heart Institute (InCor) University of São Paulo Medical School,, 2Renal 
Transplant Unit, Hospital das Clínicas, University of São Paulo Medical 
School
Background: coronary artery disease (CAD) is a major cause of post-transplant 
events in patients with chronic kidney disease (CKD). The best strategies for 
pre-transplant diagnosis and treatment for these patients are controversial.
Methods: 831 CKD patients were evaluated for CAD before been admitted 
to the waiting list for renal transplantation (Tx). High-risk patients (age > 
50 y, diabetes and any cardiovascular disease alone or in combination) were 
submitted to coronary angiography (CA) irrespectively of symptoms. All 
other (low-risk) patients were fi rst evaluated by myocardial scans and only 
those with abnormal scans were also submitted to CA. All patients received 
medical treatment according with the AST guidelines. Patients with signifi cant 
(> 70% stenosis) CAD were either kept on medical treatment or submitted to 
intervention (surgery/angioplasty with nonpharmacological stent) prior to Tx 
by decision of the study investigators. Survival curves were constructed using 
the Kaplan-Meier method and compared by Log-Rank method. 
Results: 580 patients completed pre-TX work-up and a fi rst cadaver Tx was 
subsequently performed in 167 patients. There were 25 post-Tx cardiac events 
(myocardial infarction, unstable angina, heart failure and sudden death). The 
incidence of cardiac events increased from 3% in the low-risk group to over 
30% in patients with signifi cant CAD (p< 0.01). Five-year event-free survival 
was (Figure 1): low risk (N= 67) – 87%; high-risk, no signifi cant CAD (N= 
66) – 75%; high-risk, signifi cant CAD, medical treatment (N= 23) – 55%; high-
risk, signifi cant CAD, intervention (N= 11) – 40% (p< 0.01 low risk versus 
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signifi cant CAD). The modality of treatment (medical/intervention) did not 
alter the prognosis.
Conclusion: clinical risk stratifi cation combined with CA is a powerful tool 
to identify patients with increased probability of post-Tx cardiac events. CAD 
strongly infl uences the prognosis. Coronary intervention did not alter the 
prognosis of patients with signifi cant CAD but the numbers are too small to 
allow a defi nitive conclusion in that respect.
NATURAL HISTORY OF PARATHYROID HORMONE 699 
(PTH) LEVELS IN THE FIRST YEAR POST KIDNEY 
TRANSPLANTATION (TX)
R. Masterson, J. Beavis, S. Cohney, R. Walker
Royal Melbourne Hospital
Introduction and Aims: The impact of abnormal bone-mineral metabolism 
pos t renal transplantation (Tx) is not well established and consequently 
there is a lack of established guidelines determining the optimal level of 
Ca 2+, P04& PTH in this patient population. The incidence of pre-Tx 
parathyroidectomy varies with local practice but is reported to be associated 
with low bone turnover, a higher incidence of fracture and potentially 
increased vascular calcifi cation post renal Tx. We carried out a retrospective 
study to examine the natural history of PTH in the fi rst year post renal Tx. 
Methods: A single centre retrospective study of 61 renal allograft recipients 
transplanted between January and December 2006 in whom 12 month (m) 
clinical and biochemical follow up was available. 
Results: Median Pre Tx 3m post Tx 6m post Tx 
12m post Tx
PTH (pmol/L) 12.5(0.4-180) 8 (0.8-32) 8 (0.6-38) 6.6 (3.4-30.6)
Ca2+ (mmol/L) 2.4 (1.9-2.9) 2.4 (1.5-3) 2.4 (1.5-3)
P04 (mmol/L) 0.87 (0.4-1.4) 0.9 (0.5-1.3) 0.9 (0.47-2.2)
Forty percent of patients had a pre-Tx PTH lower than KDOQI guidelines, with 
18% having had a pre-Tx parathyroidectomy. Hyperparathyroidism (PTH > 2.5 
times upper limit of normal) was present in 22% at 3m post-Tx, with 50% of 
this group being hypercalcaemic (Ca2+ > 2.7 mmol/l). Of this hyperparathroid 
group, 1 required parathyroidectomy at 12m for persistent hypercalcaemia & 1 
received cinacalcet for 3m post Tx. In the overall group 25% were prescribed 
calcitriol & 11.1% cholecalciferol.
Although 8 patients had a pre-Tx PTH > 65 pmol/L, in all cases the PTH fell 
signifi cantly post Tx: 81.9 (68-186) pmol/L (pre-Tx), 10 (4-32) pmol/L (3m) 
& 7.7 (5.2 –31) pmol/L (12 m). One patient in this group received cinacalcet 
for 3 months post Tx, 1 had calcitriol and none had a parathyroidectomy. The 
median GFR at 12 m in the high PTH group (54 (36-91) mls/min) did not differ 
signifi cantly from the overall group (52 (27-102) mls/min).
Conclusion: A signifi cant fall in PTH was uniformly observed post-Tx, even 
in the setting of extreme pre-Tx hyperparathyroidism. The greatest fall in PTH 
occurred within 3m of Tx, with no signifi cant change in PTH thereafter, an 
observation that may have implication for earlier intervention in the context 
of persistent hyperparathyroidism and hypercalcaemia post Tx. Forty percent 
had a pre-Tx PTH lower than KDOQI guidelines with a relatively high% 
having parathyroidectomy. The long-term implications of this on post-Tx bone 
and cardiovascular disease remain unknown. Post-Tx Ca2+ and P04 control 
was better than previously reported, a factor potentially associated with the 
relatively high percentage of patients prescribed Vitamin D. 
ADVERSE EFFECTS OF HYPERURICEMIA ON RENAL 700 
TRANSPLANT OUTCOME IN SEVERITY-DEPENDENT 
MANNER
S.I. Min1, I.J. Yun2, J.M. Kang3, Y.J. Park1, S.K. Min1, E.M. Kim6, C. Ahn4,5, 
S.J. Kim1,5, J. Ha1,5
1Department of Surgery, Seoul National University College of Medicine, 
2Department of Surgery, Konkuk University College of Medicine, 
3Department of Surgery, Gachon University Gil Medical Center, 4Department 
of Internal Medicine, Seoul National University College of Medicine, 
5Transplantation Research Institute, Seoul National University Medical 
Research Center, 6Seoul National University Hospital Transplant Center
The effects of hyperuricemia on renal transplant outcome have been 
controversial. We hypothesized that posttransplant hyperuricemia would 
induce different effects on renal transplant outcome according to the severity. 
Demographic and follow-up biochemical data were retrospectively collected on 
244 consecutive renal transplant recipients. Follow-up biochemical parameters 
were measured at the fi rst and third month after transplantation and at intervals 
of 6 months thereafter. Glomerular fi ltration rate (GFR) was estimated using 
MDRD Study Equation 7 (eGFRMDRD). Hyperuricemia was defi ned as uric 
acid (UA) level which was greater than 7.0 mg/dl in male and 6.0 mg/dl in 
female and was persistent at least two consecutive follow-up. Recipients were 
classifi ed into normouricemia, mild hyperuricemia (Group 1, UA level < 
8.0mg/dl) and moderate to severe hyperuricemia (Group 2, UA level ≥ 8.0mg/
dl). Compared to normouricemia, Group 1 had no signifi cant difference in 
graft survival rate, however, Group2 showed signifi cantly reduced transplant 
survival rate (P=0.003) (Fig. 1). In Cox proportional hazard analysis, UA level 
≥ 8.0 mg/dl and episodes of acute rejection were signifi cant risk factors for 
graft survival. Interestingly, UA level ≥ 8.0 mg/dl had more signifi cant impact 
on graft survival than episodes of acute rejection (P = 0.012; HR 7.72; CI 95% 
1.56-38.19 vs. P = 0.002; HR 3.77; 95% CI 1.61-8.79, respectively). In contrast 
to normouricemia or Group1, Group2 showed persistent decrease in eGFRMDRD 
throughout the follow-up. Twenty two patients (48.9%) of Group2 were treated 
with UA lowering therapy (ULT) drugs. Those who had ULT showed better 
transplant survival rate than those without treatment (P=0.02) (Fig. 2). ULT 
also had a benefi cial effect that halted the decline of eGFRMDRD (P<0.05). In 
conclusion, hyperuricemia induces adverse effects on renal transplant outcome 
in severity-dependent manner and moderate to severe hyperuricemia is an 
important risk factor for renal transplant dysfunction. Therefore, strict control 
of UA is warranted.
Fig. 1
Fig. 2
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LIVER OUTCOMES 2CONCURRENT ORAL SESSION 52: 
THE FAMILIAL AMYLOIDOTIC POLYNEUROPATHY 701 
WORLD TRANSPLANT REGISTER (FAPWTR) VIEW ON 
LIVER TRANSPLANTATION FOR TRANSTHYRETIN 
SYSTEMIC AMYLOIDOSIS DISORDERS
H.E. Wilczek, M. Larsson, B. Ericzon
Department of Transplantation Surgery, Karolinska University Hospital, 
Karolinska Institute
Background: Transthyretin (TTR) systemic amyloidosis disorders can be 
treated with liver transplantation (Ltx). The FAPWTR registers such patients 
since more than 15 years, most of which have the Val30Met mutation. However, 
patients with non-Val30Met mutations as well as new TTR mutations are 
continuously added to the Registry. Recently, patients with non-TTR mutations 
(ApoA1 renal amyloidosis and fi brinogen α-chain amyloidosis) have also been 
reported to have undergone combined liver and kidney transplantation.
Results: As of December 2007, a total of 68 centres from 17 different countries 
have reported patients to the Registry. Most transplants have been performed in 
Portugal (n=637), France (n=165), Sweden (n=115), USA (n=77), UK (n=66), 
Brazil (n=67) and Spain (n=60). Patients with more than 45 different variants of 
TTR mutations have been transplanted, the most common being Val30Met (83%) 
followed by Ser77Tyr, Thr60Ala and Tyr114Cys all 1-2% each. 1173 of the 
FAP patients had the Val30Met TTR mutation, 165 patients had a nonVal30Met 
variant, 10 were non-TTR variants and in 58 patients the information was missing 
or unknown. A total of 1406 patients have undergone 1521 liver transplants. 36 
patients have received a liver in combination with a kidney graft and 22 patients a 
combined liver- and heart transplantation. 68 liver transplantations were done with 
grafts from living related donors. Gastrointestinal and cardiovascular dysfunctions 
appear more often in non-Val30Met than in Val30Met patients. Approximately 
30-35% of the FAP patients are reported to have improved their sensory, motor, 
g-i and nutritional status, while only 8% improved their cardiovascular status. 
In the Val30Met group 236 patients (20%) died compared to 70 patients (42%) 
in the non-Val30Met group (p<0.0001). The overall 10-year patient survival in 
Val30Met patients was highly signifi cantly better than in nonVal30Met mutations 
(75.7% and 42.8%, respectively p<0.0001). This difference was also true when 
comparing the survival between these groups from May 1998, when the fi rst non-
Val30Met mutation patient was reported to the Register. However, no signifi cant 
survival was observed when re-analysing the data with patients transplanted 
during the last 6 years. Overall, cardiovascular related death dominated (26% of 
the cases). In 24%, sepsis was reported as the main cause of death. Certain TTR 
mutations appear to be important in relation to cardiac related deaths. 
Conclusion: Ltx in patients with TTR amyloidosis disorders continues to save lives. 
Val30Met and other TTR mutations differ clinically. NonVal30Met patients appear 
more often to require combined liver-heart transplantation. The previously observed 
highly signifi cant post-transplantation survival difference between Val30Met and 
non-Val30Met mutations has disappeared when analyzing the last 6 years, maybe 
as consequence of improved pre- and post-transplantation patient management as 
well as better selection criteria for the acceptance to transplantation.
HEREDITARY FIBRINOGEN A A ALPHA-CHAIN 702 
AMYLOIDOSIS; PHENOTYPIC CHARACTERIZATION AND 
THE ROLE OF LIVER TRANSPLANTATION
N.D. Heaton1, J. O’Grady1, M. Rela1, B. Portmann1, J. Wendon1, 
B. Hendry2, M. Buxton-Thomas3, N. Banner4, M. Benson5, A.J. Stangou1
1Institute of Liver Studies & Amyloidosis Treatment Programme, King’s 
College Hospital, London, U.K, 2Renal Medicine Department & Amyloidosis 
Treatment Programme, King’s College Hospital, London, U.K, 3Nuclear 
Medicine Department & Amyloidosis Treatment Programme, King’s College 
Hospital, London, U.K, 4Cardiology and Cardiac Transplant Medicine, 
Royal Brompton & Harefi eld Hospital, London, U.K, 5Amyloidosis Centre, 
Department of Pathology and Laboratory Medicine, Indiana University 
School of Medicine, Indianapolis, Indiana, USA
Background: Variants of fi brinogen A á-chain cause the commonest type 
of hereditary renal amyloidosis (AFib) in the U.K. Variant fi brinogen is 
produced in the liver, and solitary renal allografts fail within 1-7 years due to 
progressive amyloidosis. 
Patients and methods: We report the clinical features and outcome of 21 
patients with AFib and National Kidney Foundation stage 3-5 chronic kidney 
disease (CKD) in association with renal amyloidosis, who were assessed for 
combined liver and kidney transplantation (LKT). Median age of the patients 
was 55 (49-69) years; 20 had the E526V variant and one had R554L. 
Results: Coronary atherosclerotic disease was identifi ed in 61.9% of cases, 
and carotid and/or aortic atheromatosis in 57.1%. Vascular atheroma excised at 
endarterectomy in one patient contained amyloid derived from purely variant 
fi brinogen. Endomyocardial biopsies in 2 patients with the E526V the R554L 
variants revealed fi brinogen amyloid. Cardiac parasympathetic and gut and 
biliary autonomic neuropathy was identifi ed in half the cases. Eight patients 
have received LKT in the past 11 years, in 2 cases at stage 4 CKD preemptively 
before haemodialysis. Six patients (cumulative survival 75.0 percent) are 
alive and well with good dual allograft function, resolution of dysautonomia 
and no progressive amyloidosis after a median 43.7 (range 11-132) months’ 
follow-up. In contrast to inexorable progression to ESRF in the natural course 
of the disease, serial dynamic and static renal scintigraphy in the 2 cases of 
pre-emptive LKT, demonstrated preserved function of the native kidneys with 
stable contribution in the overall renal function by 13 and 20% respectively, 
up to current 5 years posttransplant follow-up. Four of the explanted livers 
were used successfully for subsequent domino LT in patients with cirrhosis and 
hepatocellular cancer.
Conclusions: Hereditary fi brinogen amyloidosis is a systemic disease with 
multivisceral, vascular, cardiac and neurological involvement. Hepatorenal 
transplantation removes the sole source of variant amyloidogenic fi brinogen 
and is curative, however, cardiovascular disease may confi ne successful access 
to this option. The observed salvage of native kidney function post-LKT 
encourages evaluation of pre-emptive solitary liver transplantation early in the 
course of amyloid nephropathy to obviate progression to ESRF, requirements 
for renal replacement therapy and kidney transplantation.
HEALTH-RELATED QUALITY OF LIFE AND 703 
EMPLOYMENT STATUS OF LIVER TRANSPLANT PATIENTS 
COMPARED TO THE GENERAL POPULATION
F.Åberg1, R.P. Roine2, A.M. Rissanen2, K. Höckerstedt1, H. Isoniemi1
1Transplantation And Liver Surgery Clinic, Helsinki University Hospital, 
2Group Administration, Helsinki and Uusimaa Hospital Group
Health-related quality of life (HRQoL) is a comprehensive and currently 
preferable outcome measure of medical interventions such as liver 
transplantation (LT).
Aim: To compare HRQoL and employment status of LT patients with that of 
the general population and in subgroups.
Material and methods: HRQoL was measured with the 15D instrument, which is 
a validated, generic (non-disease-specifi c), 15-dimensional, self-administered 
HRQoL instrument that can be used both as a profi le and single index score 
measure. The questionnaire was sent to all adult LT patients in Finland (401 
patients) alive in June 2007. Response rate was 89% (353 patients). Results 
were compared to 6050 age- and gender-standardized controls from the general 
population. 
Results: LT patients (mean age 55 years, range 20-82) had a slightly worse 
HRQoL total score than the general population (mean 0.889 vs 0.907, P<0.001). 
Although LT patients fared statistically signifi cantly worse on most of the 
15 dimensions of the HRQoL instrument, a clinically meaningful difference 
between the patients and the general population was observed only on the 
dimension of “usual activities” (Figure 1). Gender and retransplantation did 
not alter HRQoL. Acute liver failure and older age at LT were independent 
determinants of decreased HRQoL (P=0.03 and P<0.0001, respectively). 
Mean HRQoL was worst during the fi rst year after LT, then peaked during 
posttransplant years 1-5, after which it deteriorated linearly along with longer 
survival time in a similar manner to the HRQoL reducing effect of ageing itself. 
44% of working-aged LT patients were employed at time of study, as compared 
to 70% in the general population. Persons employed had better HRQoL than 
those unemployed (difference in HRQoL score 0.07, P<0.0001 among LT 
patients and difference in HRQoL score 0.04 among controls). 87% of patients 
felt that their working-capacity had improved after LT compared to one week 
before LT. Early retirement was the most common cause of unemployment 
(56% of unemployed patients).
Conclusion: Mean HRQoL of LT patients is only slightly worse than that of the 
general population. Older age, longer survival time and ALF decrease HRQoL. 
CLD patients are accustomed to a chronic disease already before LT, while 
ALF patients are often previously healthy with rapid disease-progression. Thus 
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ALF and CLD patients experience posttransplant HRQoL very differently. 
Employment is an indicator of HRQoL, and the association is more evident in 
the LT population than in the general population.
* P < 0.05, ** P < 0.01, *** P < 0.001
HEALTH-RELATED QUALITY OF LIFE IN ADULT 704 
TRANSPLANT RECIPIENTS MORE THAN 15 YEARS AFTER 
ORTHOTOPIC LIVER TRANSPLANTATION.
T. Becker, L. Kousoulas1, R. Bastian1, T. Becker1, M. Neipp1, H. Barg-Hock1, 
S. Jackobs1, C. Strassburg2, J. Klempnauer1
1Medical School of Hannover. Department of General-, Viszeral- And 
Transplantationsurgery., 2Medical School of Hannover. Department of 
Gastroenterology, Hepatology and Endokrinology.
Background: With continuously rising survival rates following orthotopic 
liver transplantation (OLT), health-related quality of life (HQOL) of long-term 
adult transplant survivors becomes increasingly important.
Methods: Recipients more than 15 years after OLT were studied retrospectively. 
HQOL in 104 long-term liver transplant recipients was assessed using the 
Standard German Version of the 36-Item Health Survey (SF-36). 
Results: Long-term liver transplant recipients revealed satisfactory HQOL 
that was comparable to the general healthy population in three of eight SF-36 
categories (physical pain, social functioning and mental health). Other SF-36 
categories such as physical functioning, role physical, general health and 
vitality were reduced. In contrast to patients living alone, married recipients 
or recipients living in a close relationship revealed a signifi cant improved 
HQOL in numerous SF-36 categories such as role physical (p<0.005), physical 
pain (p<0.005), vitality (p<0.005) and role emotional (p<0.005). Moreover 
recipients with full or part-time employment revealed improved HQOL in 
certain dimensions and especially in physical functioning (p<0.005) and role 
physical (p<0.005). 
Conclusions: More than 15 years after OLT, long-term survivors present 
satisfactory HQOL comparable to the general healthy population. Occupational 
rehabilitation and the presence of a stable familial environment are associated 
with improved HQOL
LIVER TRANSPLANTATION FOR ALCOHOL-INDUCED 705 
LIVER DISEASE – A 10 YEAR HISTOLOGICAL FOLLOW-UP
M. Schmeding, U.Neumann, R. Neuhaus, A. Kiessling, J. Pratschke, 
P. Neuhaus
Charite University Hospital
Background: Alcohol induced liver cirrhosis (ALC) accounts for an increasing 
number of patients on the waiting list for liver transplantation (LT). In contrast 
to potentially recurrent virally or immunogenically induced liver disease the 
primary cause of illness can be completely eliminated if patients refrain from 
alcohol abuse after LT. However, if patients develop recurrence of alcoholism 
after LT prognosis worsens signifi cantly.
In this study we analysed the liver tissue biopsies of patients who had been 
transplanted for ALC during a 10-year follow-up period, distinguishing between 
patients with strict alcohol abstinence and those with known recurrence of abuse.
Patients and Methods: 271 patients with ALC who received liver 
transplantation at our institution were included.
Biopsies were taken from each patient on a routine basis at specifi c time 
points: one year, 3, 5, 7 and 10 years after LT. Specimen were analysed by an 
experienced pathologist and graded concerning infl ammation, rejection, fatty 
involution, fi brosis or cirrhosis.
The collected data was analysed in respect to known status of alcohol abstinence 
or abuse. 
Results: 1, 3 and fi ve years afterLT the vast majority of patients (>80%) 
displayed no or minimal fi brotic tissue degradation. These fi ndings were 
regardless of alcohol consumption post LT.
In the further course fi brosis rates increased among all patients, yet individuals 
with known recurrence of abuse showed slightly more fi brosis. Contrastingly, 
fatty involution was signifi cantly more present in the group of patients with 
known alcohol abuse starting as early as one year after LT (p < 0.01). 
Survival was identical regardless of alcohol abuse 5 years after LT, however after 
10 years abstinent patients did signifi cantly better (82% vs. 68%; p = 0.017).
Conclusion: LT for alcohol induced liver cirrhosis offers excellent long term 
survival with minimal histological alteration of hepatic parenchyma. However, 
patients with recurrence of alcohol abuse experience signifi cantly increased 
risk of fatty involution and reduced survival.
PSYCHOSOCIAL RISK FACTORS AND THE IMPACT ON 706 
PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION
D. Sudan, L. Penkoski, J. Sorrell, W. Grant, J. Botha, A. Langnas
Univ Nebraska Med Ctr
Background: Substance abuse, poor coping skills, psychiatric illness, poor 
social support and a history of non-compliance all raise concern in the pre-
transplant patient regarding the potential for non-adherence to medications and 
postoperative follow-up. Very little is known however, about the prevalence and 
impact of psychosocial factors on patient survival after liver transplantation.
Methods: A retrospective review was performed of all adult patients undergoing 
primary liver transplantation between January 1, 2004 and December 31, 
2004 (excluding patient’s with perioperative death or multi-organ transplant). 
Psychosocial factors evaluated included a history of substance abuse, poor 
coping skills, psychiatric diagnosis, adequacy of support system, and compliance. 
Demographic variables were compared and patient survival evaluated by the 
Kaplan Meier method. The impact of various risk factors was compared using 
chi square analysis and survival curves compared using the log rank test.
Results: Sixty-nine patients were evaluated in this retrospective IRB approved 
study, 43% of whom had no identifi ed psychosocial risk factors during the 
transplant evaluation. Substance abuse was identifi ed in 29%, 24% had poor 
coping skills, 35% had a psychiatric diagnosis, 13% had inadequate social 
support, and 14% had a history of non-compliance. Multiple risk factors were 
present in 10, 6 and 2 patients (3, 4 or all 5 risk factors), respectively. Patient 
survival was 85% overall with mean follow-up of 3.3 + 0.96 years. 
Conclusions: At least one risk factor is present in more than 50% of liver 
transplant recipients at this center with substance abuse or psychiatric diagnosis 
being most common and 16% of liver transplant recipients demonstrate 3 or 
more risk factors. The evaluation process and postoperative support services are 
adequately compensating for these risk factors since we could not demonstrate 
any correlation between individual (or any group of) risk factors and patient 
survival after primary liver transplantation.
THE IMPACT OF POOR ADHERENCE TO MEDICAL 707 
REGIMEN IN LIVER TRANSPLANTATION (LT)
P. Burra1, G. Germani1, D. Canova1, M. Senzolo1, E. Perissinotto2, A. Masier1, 
F.P. Russo1, M. Gambato1, U. Cillo3, G.C. Sturniolo1
1Gastroenterology, Department of Surgical and Gastroenterological Sciences, 
University of Padua, Italy, 2Department of Environmental Medicine and 
Public Health, University of Padua, Italy, 3Surgical Unit, Department of 
Surgical and Gastroenterological Sciences, University of Padua, Italy
Background: adherence to medical prescription in patients with liver 
transplantation (LT) is mandatory to ensure patient and graft long term survival. 
Aim: the aim was to evaluate adherence to medical regimen in patients before 
and after LT, in order to identify risk factors of non adherence, by performing a 
longitudinal prospective study.
Materials and methods: all consecutive patients in the waiting list who 
attended our Liver Transplantation Unit in 2005-2006 were enrolled in the 
study and followed up after LT. Before and at 6 and 12 months after LT, all 
patients underwent anonymous questionnaire, locus of control test and blood 
tests. Child-Pugh score and MELD were assessed before LT. T test, χ square 
test, univariate and multivariate analysis were performed. 
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Results: 134 liver cirrhotic patients in the waiting list were enrolled. Before LT 
44%, 12.7% and 13.4% of patients were non adherent to therapy, to outpatient 
visit and to requested blood tests, respectively. Non adherent patients, compared 
to patients with good adherence, were younger (mean 52.1 vs 54 ys, p 0.09), 
unmarried (96.6% vs 71.3%, p 0.06) and with external LOC (66.7% vs 40.5%, 
p.04). 23 out of 134 (17.1%) patients underwent LT during the study period. 
When univariate and multivariate analysis was performed, being divorced and 
having a better MELD score were independent risk factors for non adherence 
to medical prescriptions (OR, 95%CI ; OR, 95% CI). At 6 months after LT 
15%, 20% and 10% of patients were non adherent to therapy, to outpatient 
visit and to blood tests, respectively. These patients, compared to patients with 
good adherence, presented better MELD at time of transplantation (mean 12.7 
vs 16.9, p 0.04), were drinking alcohol (33.3% vs 5.9%, p 0.001) and referred 
>3 side effects of immunosuppression therapy (66.7% vs 23.5%, p. 02). At 12 
months after LT 60%, 50% and 50% of patients were non adherent to therapy, 
to outpatient visit and to blood tests, respectively. These patients, compared to 
patients with good adherence, were younger (mean 55.3 vs 61, p.05), presented 
better MELD at time of transplantation (mean 13.3 vs 17.5), were drinking 
alcohol (50% vs 0%, p.001) after liver transplantation and referred >3 side 
effects of immunosuppression (83.3% vs 50%, p.02). Poor adherence after LT 
was related with poor adherence before transplant in 50% of the cases. 
Conclusions: Adherence to medical regimen is poor in patients in the waiting 
list for LT but also at 12 months after LT. Being divorced and having a better 
MELD score are independent risk factors for non adherence to medical 
prescriptions in patients on the waiting list, side effects of immunosoppression 
seem to be a risk factor of poor adherence after LT, therefore information and 
education for those patients are badly needed.
DE NOVO MALIGNANCY FOLLOWING LIVER 708 
TRANSPLANTATION – RETROSPECTIVE ANALYSIS OF 641 
LIVER TRANSPLANTATIONS
C. Graeb1, M. Franki1, M. Angele1, M. Rentsch1, M. Guba1, C. Wimmer1, 
C.C.J. Bruns1, R. Zachoval2, K-W. Jauch1, F. Loehe1
1Dept. of Surgery, 2Dept. of Medicine
Introduction: Development of de novo malignancy following liver 
transplantation represents a main course of late mortality. The ongoing 
improvement of both surgical technique and immunsuppressive regimens 
has lead to an ongoing increase in long term patient survival. Therefore, the 
individual patient’s risk for development of various forms of solid organ 
malignancy has continuously risen. In addition, the patient’s underlying 
disease, i.e. alcoholic cirrhosis, PSC, or various forms of hepatitis, may add to 
the patient’s susceptibility to cancer. Here, we analyze both the incidence and 
potential risk factors in our cohort of liver transplanted patients.
Method: Our retrospective analysis was based upon the peri- and postoperative 
data bases (including the Munich Tumor Registry) of 537 patients in a total 641 
liver transplantations.
Results: The cumulative risk for tumor development 20 years after 
transplantation with a value of 19% lay signifi cantly higher than in an age 
matched cohort (9%). 49/537 pts. developed a total 74 tumors (excluding 
pre-existent HCC) during a mean follow up of 9 years. Tumor prevalence 
increased from 1.3% in the fi rst year to 20% 15 years after transplantation. 
The median time interval from transplantation to tumor development was 6 
years (range 1-17 years). 19 pts. died as a result of malignancy, 30 pts. remain 
alive following diagnosis. 11/19 patients (57,9%) died within 2 years following 
transplantation. The most common tumours were basalioma (37%), squamous 
cell skin cancer SCC (22%), LPD (7%), ENT malignancy (7%) and urogenitary 
cancer (6%). The relative early development of basalioma (on average 52 mths) 
in comparison to SCC (72 mths) was remarkable, as well as the observation 
that squamous cell cancer (57%) was more common than adenocarcinoma 
(37%). At the time-point of evaluation, no signifi cant difference was detectable 
with respect to the form of immunosuppression with comparative numbers of 
patients treated with cyclosporine monotherapy (32%), CyA-steroids (14%), 
tacrolimus monotherapy (37%)and tacrolimus-steroids (7%) Despite the fact 
that cyclosporine had been used for a signifi cantly longer time period (124 
patient years) than tacrolimus (64 patient years), no difference was evident in 
overall tumor incidence. 
Conclusion: The more potent immunosuppressant tacrolimus seems to be 
related to a higher incidence of postoperative malignancy. In our analysis, 
the primary indication (alcoholic cirrhosis, PSC, and viral hepatitis) for liver 
transplantation was not related to a higher incidence for malignancy. The 
cumulative tumor incidence following liver transplantation makes a continuous 
surveillance of transplanted pts. necessary.
PREEMPTIVE VS. PROPHYLACTIC APPROACH TO 709 
CYTOMEGALOVIRUS IN LIVER TRANSPLANTATION
G. Smallwood1, K. Kempton2, A. Stieber1, C. Fasola1, T. Heffron1
1Emory University School of Medicine, 2Emory University Hospital
Cytomegalovirus (CMV) continues to be source of increased morbidity 
and mortality in the solid organ transplantation. Currently valganciclovir 
is FDA approved for CMV prevention in both heart transplant and kidney 
transplantation. In the pivotal PV16000 registration trial, liver transplant 
recipients, receiving valganciclovir, had an increase in tissue invasive CMV 
disease. Although not approved, many transplant centers use valganciclovir for 
CMV prophylaxis due to ease of patient compliance.
Aim: To compare the frequency of CMV viremia as determined by polymerase 
chain reaction (PCR) between liver transplant patients being followed with a 
preemptive strategy and treatment compared to patients taking valganciclovir 
for 100 days as prophylaxis.
Methods: This is an IRB approved review of patients being followed for CMV. 
Patients were routinely followed by weekly, serial blood draws for CMV by 
polymerase chain reaction (PCR). Based on time transplanted, patients may 
have received valganciclovir prophylaxis of 900mg daily or only monitored. 
At time of seroconversion, patients were started on ganciclovir IV 5mg/Kg 
Q12H and continued to be followed by PCR to monitor treatment. All patients 
received the same immunosuppressive protocol which included daclizumab 
induction. Outcomes were determined by rate of CMV viremia.
Results: Patients (n =119) receiving prophylactic valganciclvoir was similar 
in race, gender, and age to the patients being followed preemptively (n=131). 
CMV viremia within the fi rst 3 months of transplant were similar between 
groups [31.3%(41/131) vs. 26.8%(32/119); p=0.488]. Pre-emptive patients 
seroconverted earlier [52.2± 37.9 days vs. 120.9 ± 91.3 days; p<0.001] but 
had overall lower rates of conversion compared to the prophylactic group 
[35.1%(46/131) vs. 49.6%(49.6%); p = 0.022]. The prophylactic group had 
similar rates of viremia while on drug vs off drug [32/119 vs 27/119; p=0.4350). 
High-risk (-/-) had similar rates of viremia (75% vs. 70.4%; p=0.843). Patients 
taking valganciclovir had increased risk to develop viremia[RR 0.527 to 
0.951;p=0.02] with decreased viremia free survival.
Conclusions: Use of prophylactic valganciclovir in liver transplant does not 
prevent CMV viremia and break through viremia is not uncommon. Additional 
multicenter work should be done with this agent in liver transplant. 
CONCURRENT ORAL SESSION 53: 
STEROID AVOIDANCE AND MYCOPHENOLATES
STEROID IMMUNOSUPPRESSION INDUCES CHANGES 710 
IN THE GLUCOCORTICOID RECEPTOR
I. Hutchinson1,2, Y. Chen1,2, V. Pravica1,2
1University of Southern California, 2National Institute of Transplantation
Introduction: Initial high dose steroid treatment of transplant recipients 
induces changes in the cytoplasmic glucocorticoid receptor (cGR) that may 
affect the mode of action of the drug. The cGR consists of functionally distinct 
isoforms of the GR and chaperone molecules, including FK binding protein 5 
(FKBP5), that modulate GR signaling. Normal sensitivity to steroids requires 
expression of appropriate GR isoforms and the collaboration with FKBP5. 
Gene transactivation requires the GR-α isoform and is inhibited by excessive 
expression of the hGR-β isoform. Over expression of FKBP5 can attenuate 
steroid sensitivity by restraining translocation of the GR from cytoplasm to 
nucleus. We investigated the effect of bolus glucocorticoid (GC) treatment 
on the structure of the cGR complex by measuring the levels of GR isoform 
expression and FKBP5 transcription. 
Methods: Peripheral blood mononuclear cells (PBMCs) were obtained before 
renal transplantation and immediately after the initial methylprednisolone 
treatment. Gene expressions of the GR-α, -β, -P isoforms and FKBP5 were 
quantifi ed by the simplex TaqMan relative quantifi cation assay (Applied 
Biosystems). 
Results: Increased expression of FKBP5 (17.67+14.01 fold, mean+SD), 
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GR-β (5.77+6.82 fold) and GR-P (2.98+4.53) were observed after steroid 
bolus. The GR-β expression level is extremely low (1/500th) compared with 
the GR-α isoform (GR-β/GR-α ratio =(1.96+1.89)x10-3:1), so the six-fold 
increase GR-β expression after steroid bolus is small compared with GR-α 
expression. By contrast, the GR-P isoform is relatively abundant (GR-P/
GR-α ratio =0.24+0.09:1), so the three-fold post-treatment increase may be 
functionally relevant. Two individuals treated with 5mg dexamethasone for ten 
years prior to transplantation had lower constitutional expression of GR-α (0.41 
and 0.77 fold) and higher expression of GR–P (1.87 and 1.38 fold) compared 
with the other patients. Early acute rejection episodes, within the fi rst month 
after transplantation, were not associated with the relative expression of GR 
isoforms or FKBP5. 
Conclusion: Steroid treatment, acutely with high doses and chronically with 
low doses, alters the structure of the GR. In particular, the initial therapy with 
high dose steroid may induce a steroid resistance phenotype by increasing 
FKBP5 and GR-β expression. In chronic treatment (at least in two patients) 
reduced expression of GR-β and increased expression of GR-P isoforms may 
signal reduced steroid response. The modulatory role of the GR-P isoform 
is not fully defi ned but may provide another dimension in understanding the 
function of GR and the role of steroids in transplant immunosuppression. 
STEROID AVOIDANCE AFTER RENAL 711 
TRANSPLANTATION: RESULTS OF A PROSPECTIVE AND 
RANDOMIZED TRIAL USING FRESENIUS ATG
D. Cantarovich, L. Rostaing, G. Mourad
for the FRANCIA study group. Nantes University Hospital, Nantes, France
Background: Steroid withdrawal after renal transplantation (Tx) is associated 
with an increased incidence of acute rejection. We investigated the potential 
effective role of Fresenius ATG in completely avoiding steroids from the day 
of Tx.
Aim: seddomized and multicenter trial was designed in order to evaluate 
the tolerability and effi cacy of a sequential treatment based on Fresenius 
rabbit anti-T lymphocyte serum (ATG), mycophenolate mofetil (MMF) and 
cyclosporin (CsA), with and without concomitant corticosteroids (Cs), after a 
fi rst cadaveric renal Tx.
Patients and immunosuppression: This investigator origin protocol was 
conducted in 6 french centers and included 204 patients. Central randomization 
was done according to recipient’s age (> or <50 yrs) and cold ischemia time 
(CIT; > or <24 hrs). Retransplants were not included. Three patients did not 
received ATG and were excluded from analysis. Results included 201 patients, 
99 in the steroid group (66% men; mean age 48 yrs, range 18-73) and 102 
in the steroid avoidance group (71% men; mean age 48, range 19-69). ATG 
was given at 9 mg/kg the day of surgery, followed by 4 doses of 3 mg/kg on 
days 1, 3, 5 and 7. MMF was started the day of surgery at 1g/bid. CsA was 
started on postoperative day 5 at 8 mg/kg, and doses were adjusted according 
to standard C0 trough levels. 500 mg of Cs were given in all patients during 
surgery, followed by standard maintenance doses in the steroid group and no 
Cs at all in the steroid avoidance one.
Results: All patients were followed for at least one year. Mean CIT was similar 
in both groups: (23 vs 22 hrs). Clinical tolerance of ATG was excellent in both 
groups: the entire 5-day ATG course was given to 98% of patients in the steroid 
group (one interruption on day 1 due to thrombocytopenia) and 96% in the 
steroid avoidance one (2 interruptions on day 5 due to thrombocytopenia and 
tachycardia). One case of acute serum sickness was observed (steroid avoidance 
group).The number of severe side-effects did not differ in both groups (42 vs 
46%). Four malignancies were observed: 3 in the steroid group and 1 in the 
steroid avoidance one. CMV infections were 3% in the steroid group and 1% 
in the steroid avoidance one. Acute rejection (all histologically confi rmed) did 
not differ during the fi rst year: 14% in the steroid group and 22% in the steroid 
avoidance one; rejection onset was signifi cantly lower in the steroid avoidance 
group (median 14 days) as compared to the steroid group (median 49 days). 
Steroid-resistant rejections were not statistically different: 5% in the steroid group 
vs 2% in the steroid avoidance group. One-year patient and graft survival was 99 
and 96% in the steroid group and 97 and 94% in the steroid avoidance one.
Conclusion: This study demonstrates that Cs avoidance is possible and safe, 
with excellent one-year results, in recipients of primary cadaver renal Tx under 
an immunosuppressive regimen including Fresenius ATG, MMF and CsA. 
NEW ONSET DIABETES AFTER TRANSPLANT IN 712 
KIDNEY TRANSPLANT RECIPIENTS WITH AND WITHOUT 
STEROID FREE MAINTENANCE IMMUNOSUPPRESSION
F. Luan1, D. Steffi ck2, S. Norman1, A. Ojo1
1University of Michigan, 2Arbor Research Collaborative for Health
Background: New onset diabetes after transplant (NODAT) is a common and 
serious complication of kidney transplantation. Steroid-free immunosuppression 
has been shown to improve glucose homeostasis in some clinical trials. We 
studied the risk of NODAT in kidney transplant recipients discharged without 
maintenance steroids in national cohort of adult kidney transplant recipients. 
Materials and Methods: Between January 1, 2004 and December 31, 2006, 
a total of 29,534 adult solitary kidney transplant recipients without history of 
diabetes mellitus prior to kidney transplantation and with available follow-up 
information on their discharge immunosuppressive regimen were included. 
Multivariate logistic regression analysis was used to compare the odds of 
NODAT between recipients treated with steroid-free versus steroid-containing 
maintenance immunosuppression regimen. NODAT was defi ned as a report of 
diabetes mellitus at any time between transplant and 12/31/2007. 
Results: The post transplant risk of NODAT was 15.8% (n=2,713) and 11.9% 
(n=1,468) for deceased donor and living donor kidney transplant recipients 
(p=<0.0001). After adjusting for 26 variables for the deceased donor (DD) 
models and 18 for the living donor (LD) models , the adjusted odds ratio for 
the development of NODAT was 0.68 (95%CI 0.61-0.76, p < 0.0001) for both 
DD and LD kidney transplant recipients, respectively. In addition, among 
recipients discharged on steroid-free regimen, the combination of cyclosporine 
and mycophenolate mofetil maintenance regimen was associated with an OR of 
0.83 (95% CI 0.71-0.97, p = 0.020) for DD and OR of 0.84 (95% CI 0.72-0.98, 
p = 0.025) for LD kidney transplant, respectively, when compared to the 
combination of tacrolimus and mycophenolate mofetil maintenance regimen. 
Conclusions: Intention to treat steroids free maintenance immunosuppression 
is associated with signifi cantly lower risk of NODAT in both living and 
deceased donor kidney transplant recipients. 
IMPACT OF CENTER-SPECIFIC PATTERN OF USE OF 713 
STEROID FREE MAINTENANCE IMMUNOSUPPRESSION ON 
OUTCOMES IN LIVING DONOR KIDNEY TRANSPLANTATION
S. Norman1, F. Luan1, D. Steffi ck2, R. Wolfe2, A. Ojo1
1University of Michigan, 2Arbor Research Collaborative for Health
Background: Steroid-free immunosuppression is increasingly utilized in living 
donor kidney transplantation. U.S. transplant centers vary widely in their practice 
of steroid-free immunosuppression. We examined the impact of transplant center 
use of steroid-free maintenance immunosuppression on outcomes in a national 
cohort of living donor kidney transplant (LDKT)recipients. 
Materials and Methods: 39,728 U.S adult (age ≥18 years), solitary LDKT 
recipients engrafted between January1, 2000 and December 31, 2006 were 
stratifi ed according to the level of maintenance steroid use at their transplant 
center during the calendar year of their transplant. Patient and graft survival 
were estimated with Cox regression models with adjustment for multiple 
covariates including the use of induction therapy and other maintenance 
immunosuppressive drugs. 
Results: Table 1 shows the hazard ratios for the risk of graft failure or death for 
recipients in transplant center with the specifi ed level of maintenance steroid 
use compared to the reference group of near universal use of steroids (>95% of 
patients discharged on steroids). 
Percentage of Center’s Recipients Discharged with Steroid Maintenance at Time of Transplant, 
Recipients Engrafted in 2000 to 2006
Hazard Ratio <0-19% 20-49% 50-64% 65-79% 80-89% 90-94% 95-100%
1-yr graft 0.93 0.71* 0.63* 0.74* 0.77* 0.98 1.00
1-yr patient 0.72* 0.74 0.71 0.66* 0.55* 0.84 1.00
4-yr graft 0.97 0.81* 0.78* 0.89 0.88* 0.90 1.00
4-yr patient 0.79* 0.68* 0.71* 0.82 0.78* 0.82* 1.00
* p-value <0.05
LDKT recipients in transplant centers that tended towards steroid free 
maintenance regimens had lower risks of graft failure and death at both 1 and 4 
years. Recipients in transplant centers that utilized steroids in <50% of recipients 
were less likely to experience large weight gain (25kg or more) during the fi rst 
posttransplant year (OR 0.58, p <0.05) or to develop post transplant diabetes 
(PTDM; OR 0.65 p < 0.05) than in centers utilizing maintenance steroids in > 
95% of recipients). 
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Conclusions: LDKT recipients in transplant centers with substantial and 
selective utilization of steroid free maintenance immunosuppression regimens 
(20-64% of their recipients) had better short and long-term patient and graft 
survival rates when compared to recipients in transplant centers where < 20% 
or > 95% of recipients were discharged on a steroid-containing regimen. In 
addition, LDKT recipients in transplant centers with lower use of steroids had 
lower risk for PTDM and less weight gain than recipients in centers with >95% 
steroid use.
IMPDH ACTIVITY ON DAY 6 AFTER KIDNEY 714 
TRANSPLANTATION IS SIGNIFICANTLY RELATED TO THE 
RISK OF ACUTE REJECTION IN MMF TREATED PATIENTS
T. Van Gelder1, F. Sombogaard1, P. Glander2, W. Weimar1, K. Budde2, 
R. Mathot \1
1Erasmus Medical Center, Rotterdam, Netherlands, 2Charité University, 
Berlin, Germany.
Introduction: Mycophenolic acid (MPA) –the active metabolite of MMF– 
inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). 
Monitoring IMPDH activity, as a measure of the immunosuppressive effect of 
MMF, could be a target to optimize MMF therapy. A previous study reported that 
high pre-transplant IMPDH activity was associated with biopsy proven acute 
rejection (BPAR) of the graft. So far, data on post-transplant IMPDH activity 
and BPAR are not available. In this study we investigated the relationship 
between IMPDH activity and risk of BPAR in renal transplant patients.
Methods: A cohort of 100 patients, transplanted between 4/06 and 9/07, 
was prospectively monitored for pharmacokinetics (MPA plasma levels) and 
pharmacodynamics (IMPDH activity) of MMF treatment. Patients received 
triple immunosuppressive therapy, consisting of MMF, tacrolimus and steroids. 
Blood samples were taken pre transplantation and on day 6 post transplantation 
pre-morning dose and 0.5, 1, 2, 6 and 12h after MMF intake. The enzyme 
activity of IMPDH in PBMCs was measured using a validated HPLC method. 
IMPDH activity and MPA exposure was calculated as the area under the 
activity or concentration–time curve (AUECact and AUCMPA) using a linear 
trapezoidal rule. All acute rejection episodes were biopsy proven (Banff 
classifi cation grade IA or higher). This interim analysis includes patients with a 
follow-up after transplantation of at least two months. 
Results: Samples for IMPDH activity measurement were available from 
78 patients (age 19-76 years) on day 6 (range 3-11) post transplantation. 
In 16 (21%) of the patients a BPAR was documented within one year after 
transplantation. The mean AUECact of patients with BPAR was signifi cantly 
higher compared to non-BPAR patients (401±294 and 255±155 h*ìmol/s/mol 
AMP, p=0.017). No signifi cant correlation was found between IMPDH activity 
pre (51±26 vs. 53±41 h*ìmol/s/mol AMP; p=0.68) and at single time points 
post transplantation compared to BPAR. The mean AUCMPA of patients with 
BPAR was not signifi cantly different to non-BPAR patients (48.5±23.9 and 
52.1±38.9 h*mg/L; p=0.99). 
Conclusion: In the largest patient series to date, IMPDH activity, measured 
as AUECact on day 6, is signifi cantly correlated with BPAR after renal 
transplantation. Monitoring IMPDH activity is a promising and novel biomarker 
to optimize MMF treatment in renal transplant patients.
EARLY STEROID WITHDRAWAL FOLLOWING RENAL 715 
TRANSPLANTATION INCREASES THE RISK OF ACUTE 
REJECTION: A META-ANALYSIS
S. Knight1,2, L. Barcena1, P. Morris1
1Centre For Evidence In Transplantation, Royal College of Surgeons of 
England, 2Oxford Transplant Unit, Oxford, UK
Introduction: The morbidity related to long-term steroid therapy has led to 
interest in withdrawal of steroids from immunosuppressant regimens following 
renal transplantation. Previous systematic reviews have examined small 
subsets of patients, and a number of recent trials provide greater longer term 
information regarding the effects of steroid withdrawal. The present review is 
the most comprehensive and up-to-date yet, providing information regarding 
outcomes not previously reported.
Methods: A detailed literature search was performed using Ovid Medline and 
Embase, the Cochrane Library and the Transplant Library from the Centre 
for Evidence in Transplantation, which includes all randomised controlled 
trials in organ transplantation from 1970 to the present day. All trials with a 
control arm receiving maintenance steroid therapy and a study arm in whom 
steroids were withdrawn at any point following transplantation were included 
in the review. Trials were assessed for quality using the Jadad scoring system. 
Meta-analysis of extracted data was performed where appropriate using 
the statistical software R. All data are reported as summary effect and 95% 
confi dence intervals.
Results: A total of 112 publications from 34 studies met the inclusion criteria; 
these included a total of 5469 patients. Mean Jadad score was 2.2, with 
only 13 studies (38%) scoring ≥; 3 (good quality). Steroid withdrawal (SW) 
within 12 months of transplantation signifi cantly increased the risk of acute 
rejection (withdrawal within 7 days: RR 1.64, CI 1.41-1.91, p<0.0001; 7 days 
to 12 months RR 1.82, CI 1.15-2.89, p=0.01) whilst there was no signifi cant 
increase in risk with SW after 12 months (RR 1.32, CI 0.69-2.54, p=0.40). 
Creatinine clearance was signifi cantly reduced with SW within 12 months, 
although the magnitude of this reduction is small (2.98 ml/min, CI 1.29-4.66, 
p=0.00005). Serum creatinine did not differ signifi cantly. Patient survival was 
unaffected by SW, but graft loss excluding death was signifi cantly higher with 
withdrawal from 7 days to 12 months post-transplantation (Hazard Ratio 1.52, 
CI 1.06-2.18, p=0.02). Hypertension and hypercholesterolaemia were reduced 
with SW within 12 months (RR 0.88, CI 0.81-0.96, p=0.002 and RR 0.77, 
CI 0.70-0.85, p<0.0001 respectively). Serum cholesterol levels are reduced 
by 0.39 mmol/L with SW within 12 months (CI 0.18-0.62, p=0.0004). Serum 
triglycerides are reduced by 0.38 mmol/L (CI 0.28-0.48, p=0.0001) with SW 
within 7 days, but not with later SW. Risk of new onset diabetes is reduced with 
SW within 12 months (RR 0.70, CI 0.54-0.91, p=0.0009). Overall incidence of 
infection and risk of CMV infection were unaffected, but the risk of leucopenia 
is signifi cantly increased when steroids are withdrawn (RR 1.80, CI 1.46-2.22, 
p<0.0001).
Conclusion: Early steroid withdrawal (within 12 months) following renal 
transplantation signifi cantly increases the risk of acute rejection episodes, but 
the effect on graft function and long-term graft and patient survival is minimal. 
Signifi cant reductions are seen in cardiovascular risk factors (hypertension, 
serum cholesterol and triglycerides and diabetes) which may lead to a longer-
term reduction in cardiovascular morbidity and mortality.
MYFORTIC VS. CELLCEPT: A LARGE, SINGLE-CENTER 716 
COMPARISON
H. Sollinger, G. Leverson, B. Voss, J. Pirsch
University of Wisconsin Dept of Surgery/Division of Transplantation
Introduction: Myfortic (EC-MPS) was developed with the intent to reduce 
the incidence of gastrointestinal side effects. In a pivotal Phase III study 
involving patients undergoing de novo renal transplantation, effi cacy, failure, 
and adverse GI events were comparable between groups. Multi-center studies 
addressing GI adverse events are hampered by the fact that GI adverse effects 
are poorly standardized and so are the responses of the individual investigators. 
Material and Methods: We performed a retrospective review of 2,216 patients 
from DD, LRD, LURD or SPK between 2000 and 2006. 1,709 transplants 
qualifi ed for the study and were compared between a group receiving EC-MPS 
and a group receiving mycophenolate mofetil (MMF). Post-initiation of MPA 
therapy dose levels, post-transplant dose levels, and post-transplant e-GFR 
levels were compared between groups using a Wilcoxon rank-sums test. Time 
to fi rst dose reduction, drug discontinuation, anti-diarrheal use, infection, acute 
rejection, biopsy-proven acute rejection and graft loss were estimated using the 
methods of Kaplan and Meier and compared between groups using a log-rank 
test. Cox proportional hazards models were used to assess the impact of MPA 
after adjusting for covariates that were thought to have an association with the 
outcome of interest. 
Results: 
 CellCept Myfortic p-value
N 1,111 598  
Kidney graft survival 86.4% 84.4% NS
Acute kidney rejection 31% 24.7% 0.0212
Biopsy-proven kidney 
rejection 30.2% 21.9% 0.0004
Dose reduction 74.4% 64% 0.0001
Drug discontinuation 33.3% 27.9% 0.0130
Post-tx anti-diarrheal use 6.5% 3.6% 0.0132
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Infection 64.7% 59% NS
Bacterial infection 36.4% 37.3% NS
Viral infection 21.3% 19.5% NS
Fungal infection 14.3% 9.4% 0.0091
Percentages listed are based on 2-yr Kaplan-Meier estimates. P-values are 
based on a log-rank test
Conclusions: In this single-center retrospective analysis of 1,709 transplants, 
EC-MPS was found to be associated with fewer adverse GI side effects requiring 
dose reduction or discontinuation. This may have translated into the observed 
signifi cantly lower incidence of biopsy-proven rejection. EC-MPS patients 
also have a trend toward a lower incidence of infections and a signifi cantly 
lower incidence of fungal infections. Based on these observations, EC-MPS 
has become the IMPDH inhibitor of choice at this large center.
PHARMACOKINETIC AND PHARMACODYNAMIC 717 
COMPARISON OF AN INITIALLY INTENSIFIED DOSING 
REGIMEN VERSUS A STANDARD DOSING REGIMEN OF 
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN 
RENAL TRANSPLANT PATIENTS.
K. Budde1, W. Arns2, P. Glander1, C. Sommerer3, T. Ariatabar2, S. Kramer4, 
K. Eichele4, W. Fischer4, M. Zeier3
1Nephrology, Charité, Berlin, 2Nephrology, Köln-Merheim, 
3Nephrology, Heidelberg;, 4Novartis, Nuremberg, Germany
Objective: The aim of this prospective randomized trial was to investigate 
whether an intensifi ed dosing regimen of EC-MPS in comparison to a standard 
dosing regimen will lead to higher MPA exposure and stronger inhibition of 
inosine monophosphate dehydrogenase (IMPDH) early after transplantation. 
Furthermore, we examined whether an initially intensifi ed dosing regimen can 
be administered without compromising safety. 
Methods: In total, 75 de-novo kidney transplant recipients treated with 
cyclosporine (CsA) were randomized to a standard EC-MPS regimen 
(1440mg/d; n=36) or to an intensifi ed EC-MPS regimen (2 weeks: 2880 
mg/d; subsequent 4 weeks: 2160 mg/d; followed by 1440 mg/d; n=39). Full 
12hr pharmacokinetic and pharmacodynamic profi les with determination 
of IMPDH activity were taken on 6 different time points during the fi rst 3 
months. 
Results: MPA exposure was signifi cantly higher in the intensifi ed regimen 
on day 3 post-transplantation in comparison to the standard regimen (MPA-
AUC: 44.9 ± 15.2 vs. 31.8 ± 20.2 mg*h/L, p=0.022 and free-MPA-AUC: 2242 
± 1526 vs. 1162 ± 1038 ug*h/L, p=0.002). Signifi cant differences between 
both regimens were also observed for both MPA-metabolites, MPAG and 
AcMPAG (MPAG-AUC: 4424 ± 2102 vs. 2497 ± 937 mg*h/L, p=0.00002 and 
AcMPAG-AUC 47.4 ± 49.2 vs. 26.6 ± 22.7 mg*h/L, p=0.036). Regarding the 
pharmacodynamic parameters on day 3, initially intensifi ed dosing resulted in 
signifi cantly lower IMPDH-activity compared to standard regimen (IMPDH-
Area effect curve (AEC): 33.2 ± 15.8 vs. 45.1 ± 19.4 (nmol/mg protein 
*h)*h, p=0.03). During the fi rst 3 months MPA exposure in the intensifi ed 
arm remained stable with decreasing MPA doses, while MPA exposure in the 
standard arm increased over time, as expected.
An independent data review committee concluded that the overall safety profi le 
was comparable between both treatment arms. Most importantly, the intensifi ed 
dosing regimen did not lead to a higher risk of infections, gastrointestinal 
disorders, or hematological side effects. Incidence of biopsy-proven rejections 
was low in both arms.
Conclusion: Based on these data, an intensifi ed dosing regimen of EC-MPS 
in combination with CsA leads to a signifi cantly higher MPA exposure and 
signifi cantly stronger inhibition of IMPDH early post-transplantation. Since it 
has been shown that early adequate exposure is crucial for the clinical outcome, 
this approach might be of clinical importance. Larger studies are needed to 
prove the effect of an initially intensifi ed MPA regimen on effi cacy and safety.
RENAL FUNCTION AND INCIDENCE OF NODM 718 
WITH ENTERIC-COATED MYCOPHENOLATE SODIUM 
IN COMBINATION WITH REDUCED AND STANDARD 
TACROLIMUS LEVELS: RESULTS OF A 6-MONTH 
COMPARATIVE STUDY IN DE NOVO RENAL TRANSPLANT 
RECIPIENTS
L. Chan1, M. Hart2, A. Andres3, K. Gugliuzza4, S. Bunnapradist5, 
R. Parasumaran6
1University of Colorado Denver, CO, USA, 2CSD Medical Center San Diego, 
CA, USA, 3Hospital Universitario 12de Octubre, Madrid, Spain, 4University 
of Texas Medical Branch Galveston, Texas, USA, 5University of California 
Los Angeles, CA, USA, 6Henry Ford Hospital Detroit, MI, USA
This study investigated the safety and effi cacy of enteric-coated mycophenolate 
sodium (EC-MPS, myfortic) in combination with tacrolimus (tac) and 
addressed the possibility to preserve renal function by reducing exposure to tac. 
Methods: In a 6-month, multicenter, randomized trial, de novo renal transplant 
patients (n=292) were randomized (1:1) to one of two treatment regimens, all 
receiving basiliximab, EC-MPS 720 mg bid and steroids: Group A was treated 
with low-dose tac (target troughs of 5-9 ng/mL, fi rst 3 months, and 3-6 ng/mL, 
subsequent 3 months), and Group B with standard-dose tac (10-15 ng/mL, then 
8-12 ng/mL). Primary endpoint was the calculated Glomerular Filtration Rate 
(GFR) at 6 months (Nankivell formula). Key secondary effi cacy endpoint were 
the incidence of treatment failure (biopsy proven acute rejection [BPAR], graft 
loss or death), and the incidence of new onset of diabetes mellitus (NODM) 
assessed by means of oral glucose tolerance testing and/or fasting glucose 
measurements or by the need of use of hypoglycemic treatment. Results: 
Baseline characteristics were comparable between Group A and B as was the 
mean daily dose of EC-MPS (1296 and 1325 mg, respectively). In the intent-
to-treat (ITT) population, no signifi cant difference in mean GFR was observed 
between treatments (63.6 vs. 61.0 mL/min). However, since the compliance to 
the pre-specifi ed target tac levels was low and there was a poor differentiation 
between the groups, a re-classifi cation of patients consistently adhering to the 
two tac ranges was performed; this population (n=158) showed that GFR was 
signifi cantly higher in patients with reduced tac levels compared to standard 
tac concentrations (69.9 vs. 63.2 mL/min, p=0.038). Treatment failure was 
observed in 14.6% and 11.3% of patients in Group A and B, respectively, with 
a BPAR rate of 11% and 10%, respectively (ITT population). The incidence 
of NODM was signifi cantly lower in Group A than group B (17% vs. 30%; 
p=0.016). The overall safety profi le was comparable between treatments. 
Conclusions: This 6-month study showed that EC-MPS in combination with 
tac (standard or reduced doses) was overall effi cacious and safe, with well-
preserved renal function. A clinically important lower incidence of NODM 
in patients treated with EC-MPS with reduced tacrolimus was observed. In 
patients where tac levels were consistently adhered to, better renal function 
could be observed with reduced tac levels.
HISTOCOMPATIBILITYCONCURRENT ORAL SESSION 54: 
HUMORAL RESPONSES TO DONOR HLA ANTIGENS 719 
DURING ACUTE REJECTION ARE INDEPENDENT 
PREDICTORS OF RENAL ALLOGRAFT LOSS
M. Everly1, J. Everly1, P. Brailey1, B. Susskind1, R.R. Alloway1, E.S. Woodle1 
1University of Cincinnati, Cincinnati, Ohio, USA
Background: Current data suggests that at the time of graft loss a many patients 
have anti-donor specifi c HLA antibodies (DSA). However, little data exists 
regarding the effect of de novo DSA at the time of acute rejection on graft loss. 
Herein, we analyzed risk factors for graft loss including de novo DSA (detected 
by single antigen bead assay) at the time of acute rejection.
Methods: Renal transplant pts with acute rejection by biopsy between 
1/1/2003 and 8/1/2007 were evaluated for DSA [Luminex platform/Labscreen 
single antigen beads]. All DSA were de novo, ie, not detected before renal 
transplant. Acute rejection was defi ned by biopsy and Banff 97 criteria (update 
2003). Univariate analysis defi ned variables with a p<0.25, which entered the 
multivariate analysis. Multivariate analysis was performed by stepwise logistic 
regression (STATA/SE v.9.2). 
Results: Of 90 pts with acute rejection, 48 (53%) had DSA at diagnosis. Median 
follow-up was 23.1 18.5 months post acute rejection. Univariate analysis of 
risk factors for graft loss showed recipient age and gender, donor age and race, 
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transplant type, AB mismatch, time to biopsy, acute rejection reversal rate, and 
recurrent acute rejection to be insignifi cant. African American race, delayed 
graft function, mean baseline serum creatinine above 2mg/dL, DSA, and repeat 
transplants entered the multivariate analysis. In the multivariate analysis, DSA 
and repeat transplant were signifi cant. An interaction was noted between DSA 
and repeat transplant (75% of the repeat transplants had de novo DSA). Thus, 
two multivariate models were analyzed with Model 1 removing and Model 2 
including repeat transplant. Multivariate analysis results: Model 1 – graft loss 
was 5.5 times more likely in primary transplants with de novo DSA (p=0.047); 
Model 2 – repeat transplants with de novo DSA were 16 fold increased graft 
loss risk (p=0.035). 
Risk Factors for Graft Loss: Multivariate Analysis Results
Variables Odds Ratio 95% Confi dence Interval
African American recipient race 4.8 0.82 – 28
Delayed graft function 7.8 0.89 – 68
Repeat transplant recipient 30 2.5 – 360
Baseline serum creatinine >2mg/dL 5.7 0.63 – 51
De novo DSA in primary transplant 
recipient
5.5 1.02 – 29
De novo DSA in repeat transplant 16 1.22 – 209
Conclusions: De novo DSA in acute rejection is an independent predictor of 
graft loss. Additional studies are warranted to: 1) confi rm the predictive ability 
of DSA and 2) determine whether reduction/elimination of DSA will allow 
improvements in graft survival.
SUCCESSFUL DECEASED AND LIVING DONOR KIDNEY 720 
TRANSPLANTATION AFTER DESENSITIZATION THERAPY 
IN THE PRESENCE OF DONOR SPECIFIC ANTIBODIES 
(DSA): DETERMINATION OF ACCEPTABLE PRE- AND 
POSTTRANSPLANT DSA LEVELS
N. Reinsmoen, C. Lai, A. Vo, K. Cao, G. Ong, M. Naim, S. Jordan
Cedars-Sinai Medical Center
At our institution, desensitization protocols including high dose IVIG plus 
rituximab (IVIG/R) have been shown to decrease anti-HLA antibodies and 
improved rates of transplantation (tx) for patients (pts) highly sensitized to 
HLA. 
Aims: The aims of our study were to determine the strength of DSA that 
would allow for successful tx after IVIG/R and to identify pts at higher risk for 
antibody mediated rejection (AMR). 
Methods: Pre and posttx sera from 16 pts highly sensitized to HLA with DSA 
were tested. 8 pts received deceased donor txs; 8 pts received living donor 
txs after desensitization with IVIG/R. Strength of DSA was determined by 
single antigen (SA) luminex bead assay, standardized with quantiplex beads 
(One Lambda, Inc) with results expressed as Standard Florescence Intensity 
(SFI). T cell fl ow crossmatch (FXM) results were expressed as mean channel 
shift (MCS) over background. AMR was determined by biopsy and C4d 
deposition. 
Results: Of 16 pts tested, 7 had neg pretx T cell FXM (<50mcs) with a mean 
of 8,805 SFI for the highest DSA. 5 pts had FXM ranging from 78-192 MCS 
with mean DSA levels of 55,869 SFI. No pts in either group had AMR. 5 pts 
had FXM ranging from 242-333 MCS with mean DSA levels of 118,063 SFI. 
3 of these pts experienced AMR. The mean MCS and DSA levels for pts with 
AMR were signifi cantly higher than pts without (p=<0.001). 8 pts had class II 
DSA at the time of tx. The mean DSA level for the 2 with AMR was 213,428 
as compared to 74,948 SFI for those with no AMR (p=<0.001). B cell FXMs 
were not assessed due the interference of rituximab. 
Posttx samples were obtained for all pts to follow DSA strength and specifi city; 
long-term data has been obtained for 11 pts. Two major patterns were observed. 
For those pts without complications (N=7), DSA strength remained below 105 
SFI and usually decreased to ~104 SFI by 5-8 weeks posttx for both class I and 
II DSA. For 1 pt with DGF, DSA for DQ remained >105 and a gradual increase 
in DR DSA was observed. For those pts with AMR (N=3), predominant 
increases in class II DSA >105 SFI were observed. One of these pts was 
treated preemptively with IVIG before a signifi cant increase in creatinine was 
observed. All three pts continue to have DSA ~105 SFI with stable creatinine 
and no subsequent evidence of AMR. Patient and graft survival at 12 mo. were 
both 100%.
Discussion: With this approach, ~63% of pts were transplanted with a positive 
FXM. The results show that pts with DSA >105 and FCM > 200 MCS are 
at higher risk for AMR, albeit reversible. Some pts’ DSA remained >105 
subsequent to IVIG treatment for AMR yet maintained stable creatinine levels 
and no sign of AMR. This robust desensitization protocol allows for tx of pts 
with relatively high levels of DSA. Although longer term follow up is needed, 
perhaps by using this protocol accommodation can be achieved with high 
levels of DSA. 
HLA CLASS II MISSMATCHES IN RENAL 721 
TRANSPLANTATION: IMMUNOLOGICAL RISK FOR 
HUMMORAL ALLOREACTIVITY
A. Iniotaki1, I-S. Dokou1, H. Theodoropoulou2, M. Apostolaki1, A. Kostakis2, 
J. Boletis2
1National Tissue Typing Center, General Hospital of Athens, 2Nephrology 
Department and Transplantation Unit, Laikon Hospital, Athens Greece
The aim of this study was to evaluate the immunological risk for humoral 
alloreactivity development in renal transplant (RTx) recipients of an HLA class 
II incompatible graft.
The development of de novo donor specifi c antibodies (DSA) was investigated 
5.8±4.3 years post Tx in 643 RTx recipients using Luminex and single antigen 
bead analysis. The patients were divided into two groups according to HLA 
mismatched molecules (mm): Group A (n=486) patients with HLA class I and 
II mm and group B (n=157) with only HLA class I mm. All patients had been 
transplanted with a negative CDC-AHG and T/B Flow crossmatch. There was 
no difference at the level of HLA sensitization before RTx between the two 
groups.
De novo DSA post RTx were detected in 86/643 (13.4%) patients,76 
(15.6%) from group A and 10 (6.4%) from group B (p=.003).Expansion of 
alloreactivity to more than one HLA mm was found in 23/86(26.7%) cases. 
We further analyzed the molecular specifi city of DSA in group A patients. In 
65/76 (85.5%) cases only HLA class II were found while HLA class I and II 
DSA were present in 7 cases and HLA class I DSA only in 4 cases. The DSA 
were directed against 63 HLA-DQ alleles,26 HLA-DR alleles,6 HLA-A, 6 
HLA-B and 3 HLA-Cw alleles. DSA were detected earlier in patients who 
had HLA antibodies before Tx (p=.013).Creatinine levels were signifi cantly 
higher in patients with DSA (2.1 mg/dl) in comparison to patients without 
DSA (1.6 mg/dl) with p<.001.
We conclude that RTx recipients of HLA class II incompatible grafts are in 
high immunological risk for development of de novo DSA post Tx and require 
more intense follow up.
CD20 ANTIGEN COATED BEADS FOR THE SELECTIVE 722 
REMOVAL OF RITUXIMAB FROM SERUM PRIOR TO 
CROSSMATCH
B. Book1, N. Higgins2, M. Pescovitz1
1Indiana University School of Medicine, 2Clarian Health Partners
Rituximab (RIT), a human-mouse chimeric monoclonal antibody to human 
CD20 currently used in transplantation, interferes with most cell-based 
crossmatch techniques including complement dependent cytotoxicity and 
fl ow cytometric B cell crossmatches. We have sought methods to remove RIT 
interference by immunoabsorption. RIT has been reported to bind to a cyclic 
peptide representing an extracellular epitope of CD20 composed of amino 
acids 163-187. The cyclic CD20 peptide was synthesized with the addition 
of an N-biotinyl-NH-(PEG)2-COOH conjugate to the ε;-amine group of the 
lysine. The purifi ed peptide was coupled to Dynal M-280 super-paramagnetic 
polystyrene beads (Invitrogen, Carlsbad, CA) precoated with streptavidin 
covalently attached to the hydrophobic surface. CD20 antigen coated beads 
(6.7 X 105) were incubated with 100 μ;L of normal human serum (NHS) 
containing 10 μ;g/mL RIT. Absorbed or unabsorbed sera were incubated with 
human splenocytes. Cells were washed to remove unbound RIT. Binding of 
human IgG was detected with fl uoresceinated (FITC) goat F(ab)2 anti-human 
IgG antibody (Jackson ImmunoResearch, West Grove, PA. The presence of 
CD19 or CD20 on the B cells was detected with anti-CD19 or anti-CD20 
coupled to phycoerythrin (PE) (Becton Dickinson, San Jose, CA). Samples 
were analyzed by an Epics XL fl ow cytometer. Results are expressed as 
median channel log green fl uorescence for FITC, log red fl uorescence for PE 
and percent of positive cells for each. The percent positive CD20 cells (log 
red fl uorescence) was 72.7% in NHS, 1.24% for NHS containing 10 μ;g/mL 
of RIT before absorption, and 75.6% after 5 absorptions with CD20 coated 
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beads. Median channel of log red fl uorescence detecting CD20 was 21.5 for 
NHS, 0.457 for NHS containing 10 mg/mL of RIT before absorption, and 
21.5 after 5 treatments thus indicating that the added rituximab was no longer 
blocking the binding of the anti-human CD20 PE to the CD20 on the cell 
surface. The percent positive log green fl uorescence detecting anti-human 
IgG was 0.98% in NHS, 83.1% for NHS containing 10 μ;g/mL of RIT before 
absorption, and 4.96% after 5 adsorptions. Median channel of log green 
fl uorescence detecting anti-human IgG was 0.356 for NHS, 4.83 for NHS 
containing 10 μ;g/mL of RIT before absorption, and 0.754 after 5 adsorptions 
thus indicating that most of the added rituximab had been removed. 
Alloantibody binding was not affected by absorption. With a pooled HLA 
positive sera median channel of log green fl uorescence was 4.83 before and 
4.11 after 5 treatments. No change was seen in CD19 with binding median 
channel of log red fl uorescence was 4.26 (75.2% of cell positive) before and 
4.53 (76.2% positive) after 5 treatments. This procedure shows rituximab 
can be selectively removed from serum by immunoadsorption to allow for 
crossmatching without drug interference and without loss of alloantibody.
CLINICAL IMPORTANCE OF ANTI-HLA SPECIFIC 723 
ANTIBODY CONCENTRATION IN PERFORMING 
CALCULATED PRA AND VIRTUAL CROSSMATCHES
S. Vaidya
University of Texas Medical Branch
Background: Highly sensitized patients develop multi-HLA specifi c 
antibodies. In this study we measured concentrations of anti-HLA antibodies 
in multi-specifi c sera by converting fl uorescence intensity (FI) into molecules 
of equivalent soluble fl uorocrome (MESF) units. This was used to determine 
MESF units required for a positive T and B fl ow crossmatches (FLXM). 
Methods: MESF values of negative controls and sera from patients devoid 
of HLA antibodies were measured by FLXM and FlowPRA screening 
beads. FI values of anti-HLA specifi c antibodies determined by FlowPRA 
single antigen beads of highly sensitized patients were converted in MESF 
units. In addition endpoint titers, MESF units and% PRA of 26 sera were 
established.
Results: MESF analysis accurately predicted the outcomes of 100% of T 
and B FLXM of sera with strong (MESF units>18,000) DSA. The predictive 
values of T and B FLXM declined to 95% and 88% with weak DSA (6,000 
MESF<10,000). End point titers of sera from highly sensitized patients ranged 
from 1:512 to 1:8 with corresponding MESF values of 452,596 to 20,000 units. 
However there was no statistical difference in PRA values among these sera 
(95%-100%). We successfully transplanted 5 patients who had weak donor-
specifi c HLA antibodies (MESF units >2,000). The graft survival at one year 
was 100% and there was no evidence of DSA post transplant.
Conclusion: MESF analysis is both a time and cost effi cient way of measuring 
antibody strength. The strength of the antibody present in the sera of transplant 
candidates is critical for crossmatch prediction.
A VIRTUAL CROSS-MATCH PROTOCOL 724 
SIGNIFICANTLY INCREASES ACCESS OF HIGHLY 
SENSITIZED PATIENTS TO DECEASED DONOR KIDNEY 
TRANSPLANTATION
F. Wright1, A. Bingaman1, K. Murphy2, J. Palma-Vargas1, P. Foster1
1Texas Transplant Institute, 2Southwest Immunodiagnostics Laboratory
Background: Patients with pre-existing anti-HLA antibodies (sensitized 
patients) are more likely to have a positive cross-match with possible donors, 
and have a lower likelihood of receiving a renal transplant with longer wait 
times. A virtual crossmatch protocol (VCP) utilizing solid phase technology to 
determine the specifi city of anti-HLA antibodies should improve the probability 
of identifying a cross-match negative compatible donor and increase access of 
highly sensitized patients to kidney transplantation. 
Methods: A VCP was initiated 10-1-2006 with solid phase HLA antibody 
characterization for all sensitized patients on the wait list. Transplant rates for 
the VCP period from 10-2006 through 9-2007 were compared with rates from 
10-2005 through 9-2006 when only preliminary crossmatching was used for 
screening sensitized patients. SRTR data from 2005 was used to determine 
national transplant rates for sensitized patients.
Results: During 2005-06 prior to the VCP, 52 deceased donor transplants 
were done, with 3 sensitized (PRA >80%) patients (5.8%) receiving kidneys, 
with 1 (1.9%) patient having a PRA>90%. SRTR data for 2005 showed that 
nationally 479 of 9914 transplants (4.8%) were in patients with PRA’s >80%. 
During 2006-07 after the VCP, 62 deceased donor transplants were done, 
with 9 sensitized (PRA>80%) patients (14.5%) receiving kidneys, with 6 
(9.7%) patients having a PRA>90%, (p = 0.003 compared to SRTR national 
data). The VCP was highly predictable of a negative fi nal crossmatch. The 
VCP eliminated the use of preliminary crossmatching and reduced the 
number of fi nal crossmatches performed with attendant cost savings of over 
$100,000.
Conclusion: Initiation of a virtual crossmatch protocol using solid phase 
histocompatibility techniques signifi cantly increased access of sensitized 
patients to kidney transplantation and was more cost effective. Utilization of a 
virtual crossmatch may facilitate greater sharing of kidneys to improve access 
to transplantation for highly sensitized recipients.
FINAL CLINICAL TRIAL DATA EVALUATING THE 725 
XM-ONE ENDOTHELIAL CELL CROSSMATCH TEST IN 
PREDICTING EARLY REJECTION EPISODES IN RENAL 
ALLOGRAFT RECIPIENTS.
A. Zachary1, A. M. Jackson1, D. Lucas1, J. Melancon1, M. Breimer2, 
L. Rydberg2, J. Von Visger3, R. Pelletier3, S. Saidman4, W. WilliaJr4, 
G. Klintmalm5, S. Coultrup5, J. Holgersson6, G. Tyden6, S. Holgersson6, 
P. Grufman7
1Johns Hopkins University, 2Sahlgrenska University Hospital, Goteborg, 
Sweden, 3The Ohio State University Medical Center, Columbus, United States, 
4Massachusetts General Hospital, Boston, United States, 5Transplantation 
Services, Baylor University Medical Center, Dallas, TX, United States, 
6Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 
7AbSorber, Stockholm, Sweden
Reports of antibody mediated rejection in the absence of HLA antibodies or 
in HLA identical transplants have substantiated the importance of non-HLA 
antigens in allograft rejection. An international clinical trial was conducted to 
evaluate the clinical application of the XM-ONE endothelial cell crossmatch 
test. The XM-ONE test detects antibodies reactive with donor-specifi c 
endothelial cell antigens that escape detection in conventional lymphocyte 
crossmatch assays. Endothelial cell precursors were isolated with magnetic 
beads from donor peripheral blood and incubated with recipient serum. A 
fl ow cytometric crossmatch procedure was performed, utilizing fl uorescently 
conjugated IgM- and IgG-specifi c secondary antibodies. The XM-ONE 
test was performed pre-transplant, however, the results were not released 
to the transplant physicians nor utilized in the decision to transplant. One 
hundred and forty-seven renal transplant recipients from 6 transplant centers 
were included in this evaluation. Composition of the study population was: 
59% male, 41% female and 84% Caucasiod, 8% Black, and 1% Hispanic. 
The majority of patients were transplanted with living donors (83%), were 
primary transplants (86%), and had a PRA of less than 10% (77%). Patient 
evaluation included solid phase HLA-specifi c antibody screening and clinical 
follow-up at 3, 6, or 12 months post-transplant. A positive XM-ONE test 
(IgM or IgG isotype) was detected in 24% (35/147) of the recipients prior to 
transplant. The incidence of rejection was signifi cantly higher in XM-ONE 
positive patients (46%, 16/35) as compared to patients with negative XM-
ONE results (12%, 13/112; p<0.00005). Rejection occurred within 14 days of 
transplant in 37% of patients who had a positive XM-ONE result compared 
to 5% of patients with a negative XM-ONE result. Moreover, the mean serum 
creatinine levels were signifi cantly higher in XM-ONE positive patients at 
3 and 6 months post-transplant (p<0.05). The XM-ONE endothelial cell 
crossmatch test provides an effi cient method for determining the presence 
and isotype of donor-specifi c endothelial cell-reactive antibodies that escape 
detection in lymphocyte crossmatches and identifi es recipients at greater risk 
for rejection episodes.
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ANTIBODIESS TO HLA ELICITED BY PEPTIDES FROM 726 
OTHER MOLECULES
P. Terasaki1, L. Morales-Buenrostro2, L. Marino-Vazquez2, J. Alberu2, 
M Ravindranath1
1Terasaki Foundation Laboratory, Los Angeles, 2National Institute of Medical 
Sciences and Nutrition Salvador Zubiran, Mexico City
We had assumed that HLA antibodies are produced only in response to 
immunization by HLA antigens through transfusions, pregnancies and 
transplants. However, with the new luminex single antigen technology, 
HLA antibodies are now detected in normal male donors who had not been 
alloimmunized. Antibodies to HLA were found in as many as 44% of 432 
Mexican male blood donors, 50% of 14 Japanese male laboratory personnel, 
65% of 29 male laboratory personnel, and 64% of 11 male Asian- Indian 
vegetarians. The last fi nding indicates that the stimulating agent is not in 
the histocompatibility antigens of food from cattle, pigs or chickens. Most 
remarkable is the specifi cities found were distinct and generally of low 
frequency occurrence in the random population. The most frequent specifi city 
found was from 18% down to 10% in the following order: A3002, A3101, 
B1512 (B76), B8201, CW1701, B1516, DPB1 0101. The ‘natural’ antibodies 
are not ephemeral, but are consistently found in one individual as shown by 7 
independent bleedings of some individuals as shown in the fi gure. Thus far, 
unique peptides sequences found in B8201 were found in streptococci, and 
CW1701 in herpes virus. Thus many microorganisms may share sequences 
with the HLA molecule. 
In conclusion, antibodies to HLA were found in normal males which had 
probably been stimulated by infections from various environmental agents. These 
antibodies may affect subsequent transplants from donors with these types.
A NON-ALLOGENEIC STIMULUS TRIGGERS THE 727 
PRODUCTION OF DE NOVO HLA AND MICA ANTIBODIES.
L.E. Morales-Buenrostro1, L.A. Marino-Vázquez1, A. Nguyen2, 
P.I. Terasaki2, J. Alberu3
1Department of Nephrology and Mineral Metabolism. Instituto Nacional 
de Ciencias Medicas y Nutricion SZ, 2Terasaki Foundation Laboratory, 
3Department of Transplantation. Instituto Nacional de Ciencias Medicas y 
Nutricion SZ
Background: In a previous study, we found that healthy people developed HLA 
Abs after immunization against hepatitis B virus. The aim of this prospective 
study was to establish if stimulation with infl uenza vaccine is capable of 
triggering the production of HLA and MICA Abs.
Methods: We determined the presence of HLA and MICA Abs (de novo and 
preformed Abs) in 3 groups of patients vaccinated against infl uenza: A) 42 
healthy adults, B) 40 ESRD patients, and C) 25 KTx. Additionally, we followed 
22 healthy unvaccinated people without exposure to sensitizing factor: D) 
control group. Sera samples were collected at baseline (pre infl uenza shot), 
at 1 week, and monthly up 6 months after immunization. HLA Abs were 
assessed with Labscreen Single Antigen beads for Luminex. All samples of 
each patient were tested simultaneously. A luminescence value higher than 500 
was considered positive only if it was 3 times the baseline value. We analyzed 
the data using Chi square, one way ANOVA test, and Logistic regression. 
Results: The table shows the types of Abs in each group. Interestingly, we 
found preformed Abs across all four groups, including the control group 
(which is free of any known sensitizing factors). The proportion of de novo 
Abs was higher in the group B and C. Multivariate analysis shows that the 
only independent factor associated with development of de novo Abs was the 
presence of preformed Abs.
Conclusions: We observed a nonspecifi c immunologic response triggered by 
external stimulus and it was not necessarily associated to the vaccine in people 
previously sensitized.
Table. Distribution of antibodies by group.
Antibodies Group A
Healthy n=42
Group B
ESRD n=40
Group C
KTx n=25
Group D
Controls n=22
HLA class I 0 3 (7.5%) 2 (8.0%) 0
HLA class II 1 (2.4%) 0 1 (4.0%) 0
MICA 0 4 (10.0%) 1 (4.0%) 0
HLA I & HLA II 0 0 1 (4.0%) 0
Any De Novo** 1 (2.4%) 7 (17.5%) 5 (20.0%) 0
Preformed HLA I* 21 (50.0%) 24 (60.0%) 17 (68.0%) 2 (9.1%)
Preformed HLA II* 8 (19.1%) 9 (22.5%) 16 (64.0%) 1 (4.5%)
Preformed MICA 17 (40.5%) 11 (27.5%) 6 (24.0%) 5 (22.7%)
Any Preformed* 28 (66.7%) 31 (77.5%) 22 (88.0%) 6 (27.3%)
**p=0.016 *p<0.001
CONCURRENT ORAL SESSION 55: 
TOLERANCE AND T REGULATORY CELLS
COMBINE TGF-BETA/FC AND RAPAMYCIN FOR 728 
REGULATORY T CELLS GENERATION AND ALLOGRAFT 
TOLERANCE INDUCTION.
W. Zhang, D. Zhang, Y. Liu, Y. Tian, X.X. Zheng
Starzl Transplant Institute, Division of Plastic Surgery, University of 
Pittsburgh School of Medicine
CD4+Foxp3+ T cells have been identifi ed as regulatory T cells (Tregs) that 
play important roles in the control of autoimmune and alloimmune responses. 
Recent studies, including our own, demonstrate that TGF-β; can convert naïve 
peripheral CD4+CD25- T cells into CD4+ CD25+ regulatory cells through 
induction of Transcription Factor Foxp3 in context of TCR signaling and 
costimulation. This may prove TGF-β; to be of critical importance in generating 
regulatory T cells. However, TGF- β; is secreted in a latent form and active 
TGF- β; is rapidly cleared from circulation. In this study, we test the hypothesis 
that the combination of a long-lasting active form of TGF-β; ----TGF-β;/Fc 
and Rapamycin will further shift the balance of transplant immunity toward 
tolerance by strengthening the cadre of immunoregulatory T cells. 
Methods: (1) For making TGF-β;/Fc fusion protein, all three Cystine in 
the pro region of TGF- β; precursor were mutated to Serine by site-directed 
mutagenesis and the mutant TGF-β; was fused to a mutant human IgG Fcγ;1 
component which is incapable to direct ADCC and CDC activities. The 
recombinant protein was produced in CHO cells, then western blot analysis 
and in vitro bioassay were performed to determine the TGF-β;/Fc structure 
and biological activity. (2) T cells and Naïve CD4+Foxp3- T cells from Foxp3 
knock-in mice were stimulated in the presence of TGF-β;/Fc and Rapamycin. 
The proliferation and differentiation of cells were measured by 3H-thymidine 
incorporation and Flow cytometry. (3) The MHC mismatched DBA/2 Islets 
were transplanted into C57BL/6 mice rendered diabetic by streptozotocin. The 
recipients were treated with TGF-β;/Fc, Rapamycin or combination of them for 
4 weeks and allograft function were monitored. 
Results: (1) TGF-β;/Fc was expressed as two homodimers and one heterodimer. 
Its circulating half-life in mice was 36 hours. TGF- β;/Fc inhibited IL-4 
stimulated HT-2 cell proliferation in a dose dependent manner. (2) TGF-β;/Fc 
and Rapamycin synergistically inhibited CD4+ or CD8+ T cell proliferation 
and promoted the induction of CD4+Foxp3+ T cells. (3) In islet transplantation, 
mean survival time of islet grafts was 19 days in control recipients (n=6) and 38 
days in TGF-β;/Fc treated recipients (n=5). Rapamycin prolonged islet grafts 
survival in 63% of recipients (n=8). Combined treatment with TGF-β;/Fc and 
Rapamycin produced indefi nite islet allograft survival in 83% cases (n=7). 
Conclusion: We have produced the long-lasting active mutant TGF-β;/Fc 
fusion protein. The TGF-β;/Fc is synergistic with Rapamycin to convert naïve 
CD4+Foxp3- T cells into CD4+Foxp3+ Tregs. Short course of combined 
TGF- β;/Fc and Rapamycin treatment promotes long-term islet allograft 
engraftment.
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INDUCTION OF REGULATORY T CELLS 729 
BY PERIOPERATIVE DONOR SPLENOCYTE 
COTRANSPLANTATION IN ALLOGENIC PULMONARY 
TRANSPLANTATION
S. Thissen1, B. Kruse1, G. Warnecke1, M. Avsar2, F. Länger3, V. Kaever4, 
R. Baumann5, A. Haverich1, M. Strüber1
1Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, 
Hannover Medical School, 2Division of Cardiac, Thoracic, Transplantation 
and Vascular Surgery, Hannover Medical School, 3Institute of Pathology, 
Hannover Medical School, 4Institute of Pharmacology, Hannover Medical 
School, 5Department of Nuclear Medicine and Radiation Oncology, Hannover 
Medical School
Purpose: Donor alloantigen infusion has been shown to induce T cell 
regulation and transplant tolerance in small animal models. Here, we 
wished to study the effect of a donor splenocyte infusion on the induction of 
CD4+CD25+ regulatory T cells in a porcine allogenic lung transplantation 
model. Procedures: Left-sided lung transplantation from MHC and gender 
mismatched donors was performed in 20 adult minipigs. Intravenous 
pharmacologic immunosuppression with methylprednisolone and tacrolimus 
(Tac) was maintained for 28 postoperative days (POD). 6 animals additionally 
received 1.5 Gy whole body and 7 Gy thymic irradiation on pre-operative day 
one and a perioperative donor splenocyte cotransplantation (IRR+SpTx POD 
0), the same protocol without irradiation was performed in another 5 animals 
(SpTx POD 0). 3 animals received IRR and donor splenocyte infusion 28 days 
before transplantation under and a 7 day course of tacrolimus (IRR+SpTx 
POD -28). Another 6 animals received splenocytes 28 days before lung 
transplantation without irradiation. Allograft survival was monitored by chest 
radiographs and transbronchial biopsies (TBB). The immune phenotype was 
monitored from peripheral blood samples and bronchoalveolar lavage fl uid 
(BALF) by FACS analysis. The suppressive potency of regulatory T cells was 
tested in a mixed lymphocyte reaction (MLR). 
Results: Transplant survival in the IRR+SpTx POD 0 group was signifi cantly 
prolonged compared to all other groups. All of these animals survived POD 
178 without signs of acute rejection. CD4+CD25high+ T cells which are 
supposed to be a lymphocyte subpopulation with a strong regulatory function 
were increased in the SpTx POD 0 group, both in peripheral blood and BALF. 
The presence of high levels of these regulatory T cells correlated with the 
absence of acute vascular rejection in the animals of the SpTx POD0 group. 
Purifi ed CD25+ T lymphocytes suppressed MLR response to donor and to 
third party antigen as well as control mitogen. 
Conclusion: This data shows that miniature swine conditioned with pre-
operative irradiation and a donor splenocyte infusion develop long term 
pulmonary allograft survival in the presence of high circulating levels of 
regulatory T cells.
THE REQUIREMENT OF THE B7-H1 FOR 730 
SPONTANEOUS ACCEPTANCE AFTER MOUSE LIVER 
ALLOGRAFTING
M. Morita1, M. Fujino2, L. Xie2, Y. Kitazawa2, H. Kimura2, M. Azuma3, 
X. Li2, A. Sugioka1
1Fujita Health University School of Medicine, 2Laboratory of Transplantation 
Immunology, National Research Institute for Child Health and Development, 
3Department of Molecular Immunology, Graduate School, Tokyo Medical and 
Dental University
Programmed death-1 (PD-1), an inhibitory co-stimulatory receptor induced 
on activated T, B, and myeloid cells, can modulate negative regulator of the 
immune system. B7-H1 (PD-L1), a ligand of PD-1, is expressed on resting and 
up-regulated on activated B, T, myeloid, and dendritic cells (DCs). PD-L1-
defi cient mice developed more severe EAE and autoimmune hepatitis. These 
results suggest that the PD-1/PD-L1 pathway acts as an important negative 
regulator of immune response. Therefore, we investigated here a crucial 
role of this pathway in establishing an immunological tolerance status after 
mice liver allografting. B7-H1 was high expressed on the infi ltration cells 
in the mouse allografts, consistent with the results of the mRNA expression 
assay. Strain of mouse (B10.BR, H-2Kk) liver transplanted into B10.D2 
(H-2Kd) mice developed typical rejection pathologic changes and than 
spontaneously repressed, permitting long-term survival of these allografts 
similar to that of syngeneic grafts. Strikingly, blockade of the PD-1/PD-L1 
pathway using anti-B7-H1 mAb in the same combination, was led to not only 
server cell infi ltration but also hemorrhage and necrosis, resulting no mice 
survival beyond 12 days. Furthermore, the mRNA expression of the grafts 
was assessed by quantitative real time reverse-transcription polymerase 
chain reaction (qRT-PCR), revealing the increase of IFN-ƒÁ, TNF-ƒ¿, IL-2, 
iNOS, and OPN mRNA expression in the antibody-treated group compare 
to the control fs. Our data revealed that the expression of B7-H1 on graft 
infi ltration cells might play a critical role of the spontaneous acceptance in 
mouse hepatic allografting.
NK CELLS RESTRAIN CD8 T CELLS DURING 731 
TOLERANCE INDUCTION TO ISLET ALLOGRAFTS
R.G. Gill3, J.N. Beilke1, N.R. Kuhl2, L. Edwards2
1University of California, San Francisco, 2University of Colorado Health 
Sciences Center, 3University of Alberta/Alberta Diabetes Institute
Background: Previous studies indicate an unexpected role for NK cells in 
facilitating tolerance induction to islet allografts following costimulation 
blockade (anti-CD154). Other studies indicate that CD8 T cells can contribute to 
costimulation blockade-resistant allograft rejection. Therefore, we determined 
whether host CD8 T cells were a target of NK cell regulation during tolerance 
induction in vivo. 
Methods: The impact of NK cell function on alloreactive CD8 T cell reactivity 
was analyzed in two ways:
(1) Analysis of allo-specifi c CD8 T cell receptor (TCR) transgenic (2C) T cell 
reactivity in vivo: C57Bl/6 (B6; H-2b) TCR transgenic 2C mice (specifi c for 
MHC class I Ld) were used as CD8 T cell donors. CFSE-labeled 2C T cells 
(3xe7) were adoptively transferred into wild-type B6 hosts and monitored for 
peripheral engraftment. Recipient mice then were challenged with BALB/c 
(Ld+) spleen cells in the rear footpad and the 2C T cell response was monitored 
in the draining lymph node. Challenged mice were otherwise untreated or were 
treated with anti-CD154 (MR1), anti-NK1.1 (PK136), or combined anti-CD14/
anti-NK1.1 therapy.
(2) Islet allograft immunity and tolerance in CD8 knockout (CD8KO) recipient 
mice. BALB/c islet allografts were grafted beneath the kidney capsule of 
streptozotocin-induced diabetic B6 or B6CD8KO recipient mice. Recipients 
were either untreated or treated with anti-CD154, anti-NK1.1, or combined 
anti-CD154/anti-NK1.1 as above.
Results: (1) 2C T cell reactivity: 2C T cells reacted vigorously to BALB/c 
(Ld+) spleen cells in vivo based both on total cell numbers and by CFSE 
dilution within the draining lymph node. Anti-CD154 treatment alone resulted 
in pronounced reduction of this response while anti-NK1.1 treatment alone 
had little impact or led to a modest increase in the 2C response. Importantly, 
combined anti-CD154/anti-NK1.1 treatment resulted in a marked increase in 
the 2C response relative to anti-CD154 treatment alone.
(2) Islet allograft immunity/tolerance in vivo: Both B6 wild-type (9/9) and 
CD8KO (6/6) mice acutely rejected BALB/c islet allografts (p = NS). Anti-
CD154 treatment resulted in long-term allograft survival in 10/13 wild-type B6 
mice and in 6/6 CD8KO B6 mice. As previously reported, additional depletion 
of NK1.1+ cells abrogated allograft prolongation facilitated with anti-CD154 
in 6/6 wild-type B6 mice. Importantly, in recipients defi cient in CD8 T cells 
(B6 CD8KO), NK1.1+ cells were no longer required for long-term allograft 
survival. That is, 7/9 BALB/c islet allografts survived >100 days in anti-CD154 
treated CD8KO recipients despite additional depletion of NK1.1+ cells (p < 
0.02 relative to B6 wild-type recipients). 
Conclusions: Results indicate that anti-CD154 treatment restrains alloreactive 
CD8 T cells in vivo and that NK1.1+ cells are necessary for this inhibition. 
More importantly, CD8 T cells appear to be an essential target of regulation 
by NK1.1+ cells. That is, in the absence of host CD8 T cells, regulation by 
NK1.1+ cells is no longer required for achieving allograft prolongation. Thus, 
it appears that one host MHC class I dependent pathway (NK1.1+ cells) is 
necessary to regulate another MHC class I pathway (CD8 T cells) during 
tolerance induction in vivo.
Thursday 14 August 2008 Oral Abstracts
2 5 6
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
DONOR-DERIVED TOLEROGENIC DENDRITIC CELLS 732 
(DC) ARE REPROCESSED BY RECIPIENT DC TO DOWN-
REGULATE THE ANTI-DONOR RESPONSE AND PROMOTE 
GRAFT SURVIVAL
S.J. Divito, W.J. Shufesky, Z. Wang, A. Montecalvo, A.E. Morelli
T.E. Starzl Transplantation Institute, Department of Surgery, 
University of Pittsburgh
The discovery that maturation-resistant (MR) dendritic cells (DC) down-
regulate the anti-donor response heralded the potential use of MRDC for 
therapy of transplant rejection. Although there is evidence that donor-derived 
MRDC therapy prolongs allograft survival in murine models, it remains to be 
elucidated whether these tolerogenic DC (i) interact directly with allospecifi c 
T cells or (ii) are reprocessed by recipient antigen (Ag)-presenting cells for 
indirect pathway presentation. Our study aimed to elucidate the mechanism 
by which donor-derived MRDC down-regulate the anti-donor response in 
vivo to prolong allograft survival in mice. We employed as prototypic donor 
MRDC, bone marrow-derived DC treated with the active form of vitamin D3, 
1α,25(OH)2 D3 (VD3-DC). Results: VD3-DC failed to up-regulate co-stimulatory 
molecules in response to DC-maturation stimuli (LPS, CD40 ligation, DC-
maturation cocktail) and adoptive transfer (i.v., d-7) of BALB/c-derived 
VD3-DC prolonged signifi cantly survival of BALB/c hearts in C57BL/6 (B6) 
mice without additional immunosuppression. Utilizing 1H3.1 TCRtg CD4 
T cells (specifi c for the BALB/c allopeptide IEα52-68 presented by IAb [B6]), 
we demonstrated that donor-derived VD3-DC are reprocessed into alloAg by 
recipient splenic DC which interact with anti-donor CD4 T cells via the indirect 
pathway of allorecognition. Defi cient activation of indirect pathway CD4 T 
cells led to their peripheral deletion and resulted in outgrowth of CD4 FoxP3+ 
regulatory T cells. Reprocessing of donor-derived VD3-DC was performed 
by recipient splenic CD8α+ and CD8– DC through phagocytosis of apoptotic 
cell fragments, and resulted in alloAg presentation for up to 3 days following 
administration of donor-derived VD3-DC. Interestingly, i.v. injected donor-
derived VD3-MRDC homed to splenic T cell zones but lacked the stimulatory 
capacity necessary to directly prime either alloreactive CD4 (1H3.1) or CD8 
(2C) TCRtg T cells. Our fi ndings indicate that reprocessing of donor-derived 
MRDC into alloAg by recipient DC in secondary lymphoid organs constitutes 
a key mechanism by which DC-based therapies down-regulate alloimmunity 
and prolong allograft survival. 
LOCATION AND TIME DEPENDENT CONTROL OF 733 
REJECTION BY REGULATORY T CELLS CULMINATES IN A 
FAILURE TO GENERATE MEMORY T CELLS
M.C.Gaspar, N. Jones, S. Luo, M. Laurent, B. Matthew, W. Kathryn
University of Oxford
Introduction: We have shown previously that adaptive CD25+CD4+ regulatory 
T cells (Treg) suppress skin allograft rejection. However, the location of Treg 
as they function in vivo and the mechanisms used to control donor-reactive T 
cells remain ill-defi ned. 
Methods: Treg were purifi ed from tolerant CBA mice that had accepted a 
donor-type cardiac allograft (C57BL/10; B10; H2b) following administration of 
anti-CD154 mAb. 1x105 BM3 T cells (TCR-transgenic, H2Kb-reactive CD8+ 
T cells; H2k) were CFSE labelled and transferred alone or together with 5x105 
Treg into syngeneic RAG-/- mice one day before transplantation of a B10 skin 
allograft. The response of the BM3 T cells to skin allografts was visualised 
using FACS (draining (dLN) and contralateral (cLN) lymph nodes, mesenteric 
lymph nodes and spleen), immunohistochemistry and real-time PCR for pro-
infl ammatory genes (skin graft) 5, 10, 15 and 25 days after transplantation 
(n=3/timepoint). Allografts transplanted onto naïve RAG-/- mice served as 
control for real-time PCR analysis.
Results: Mice that received BM3 T cells alone showed clear priming by 
10 days after skin grafting resulting in a dramatic increase in the number of 
CFSE- BM3 T cells (> 7 cell divisions) in the dLN compared to those in the 
cLN or in mice that did not receive a skin graft (50 fold increase). In contrast, 
in mice that also received Treg the priming of the BM3 T cells in the dLN was 
markedly attenuated. The suppression of T cell priming by Treg also resulted 
in the absence of T cell infi ltration into skin grafts and in a marked reduction 
in the intragraft mRNA expression of IFN&#61543; (84 fold), perforin (19 
fold), CCL5 (11 fold) and XCL1 (19 fold) by day 10 post-transplant compared 
to grafts undergoing rejection (BM3 T cells alone). However, with time, 
peripheral suppression waned and effector BM3 T cells were generated by day 
15 despite the presence of Treg, albeit in reduced numbers compared to mice 
that had received BM3 T cells alone (957+/-737 compared to 3300+/-768 
CFSE- BM3 T cells, respectively). The observed priming resulted in the 
infi ltration of BM3 T cells into skin grafts generating a ‘Tc1-like’ intragraft 
gene expression profi le similar to that seen during rejection. Despite effector T 
cell infi ltration, grafts were not rejected as intragraft effector cells were deleted 
by Treg, that had also infi ltrated skin allografts, which resulted in a marked 
defi cit in peripheral CD44+ BM3 memory T cells (2354+/-569 compared to 
39434+/-19365 CD44+ BM3 T cells in the spleen from mice that had received 
BM3 T cells alone).
Discussion: These data demonstrate for the fi rst time that donor-reactive Treg 
can suppress allograft rejection using distinct mechanisms at different sites in 
vivo with the overall outcome of preventing the generation of donor-reactive 
memory T cells. Extrapolation of these data to clinical transplantation suggests 
that the identifi cation of patients that have become “operationally” tolerant to 
their foreign organ grafts will require a multi-faceted approach involving both 
peripheral and perhaps more importantly analyses that focus on the transplanted 
organ itself.
GRAFT-PROTECTIVE REGULATORY T CELLS 734 
DEVELOP FROM FOXP3-NEGATIVE PRECURSORS IN VIVO
R. Francis, K. Wood, A. Bushell
Nuffi eld Department of Surgery, University of Oxford
Background & aims: Naturally-occurring FOXP3+CD4+ regulatory T cells 
(Treg) play a crucial role in the prevention of autoimmunity. The ability to 
generate similar populations of Treg against alloantigens offers the possibility 
of preventing transplant rejection without the requirement for indefi nite global 
immunosuppression. 
Pre-treatment of mice with a donor-specifi c blood transfusion (DST) combined 
with anti-CD4 antibody generates alloreactive Treg with the capacity to prevent 
rejection of cardiac, skin and islet allografts. The aim of this project was to 
investigate whether these graft-protective Treg are derived from naturally-
occurring Treg or are generated by the peripheral conversion of non-Treg 
precursors.
Methods: A novel cell sorting strategy was developed, based on the expression 
of the cell surface markers CD25 and GITR, which yields a population of CD4+ 
cells that consistently contain ≤0.5% FOXP3+ cells by FACS. The purity of 
sorted GITR−CD25− cells was confi rmed using qRT-PCR for foxp3 mRNA. 
T cell defi cient CBA.RAG−/− mice were reconstituted with this sorted 
population, devoid of naturally occurring Treg but containing potential effector 
cells prior to tolerance induction with anti-CD4/DST. Control mice did not 
receive anti-CD4 or DST. 28 days later, full thickness donor-type skin grafts 
were performed. Spleen cells were isolated from additional cohorts of mice 
given the same adoptive transfer but without skin grafting for analysis of 
FOXP3 expression. 
Results: In the absence of a skin graft, FOXP3+CD25+ T cells were readily 
detected in both control and tolerised mice almost certainly refl ecting 
FOXP3 induction resulting from homeostatic proliferation. However, whilst 
control mice rejected their skin grafts acutely (n=6, MST 19 days), mice 
given the tolerance induction protocol accepted their grafts long-term (n=9, 
MST>100 days).
Discussion: These data demonstrate that naïve CD4+ cells with the potential 
to reject an allograft can undergo peripheral conversion into graft-protective 
Treg following an alloantigen-dependent tolerising protocol. The fact that 
skin grafts were not protected by FOXP3+ cells that arose in the absence 
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of alloantigen indicates a clear qualitative difference in the two FOXP3+ 
populations and emphasises the benefi t of driving Treg selection using 
alloantigen pre-treatment. Naturally-occurring Treg are scarce (≈5% 
peripheral CD4+ cells) while the precursor frequency of alloreactive T cells 
can be as high as 10%. Tolerance induction strategies that do not rely on 
expansion of naturally-occurring Treg and are able to convert potential effector 
cells into graft-protective Treg are very attractive for the establishment of 
transplantation tolerance.
RAPID RECRUITMENT OF FOXP3+ REGULATORY 735 
T CELLS INTO CARDIAC ALLOGRAFTS FOLLOWING 
THE INDUCTION OF SPECIFIC UNRESPONSIVENESS TO 
ALLOANTIGEN IN VIVO
M.C. Gaspar, N. Jones, A. Bushell, K. Wood
University of Oxford
Introduction: The early infi ltration of regulatory T-cells (Treg) into the 
allograft may protect the allograft from rejection. The aim of this study was 
to determine the kinetics of Treg entry into cardiac allografts following the 
induction of specifi c unresponsiveness to alloantigen in vivo and to assess the 
impact of such cells on the expression of intra-graft pro-infl ammatory genes 
associated with the development of operational tolerance.
Methods: C57BL/10 (B10,H2b) cardiac allografts were transplanted into 
naïve CBA (H2k) mice (grafts rejected with a median survival time (MST) of 
8 days) or CBA mice that had received anti-CD4 mAb and a donor-specifi c 
blood transfusion (DST) i.v. (‘pretreated mice’) 28-days before transplantation 
(MST >100 days). Cardiac allografts transplanted into RAG-/- recipients (no 
functional T or B-cells) were used as controls for activation of the innate immune 
response after transplantation. Cardiac allografts were analysed 1,2,5,8 and 
10-days after transplantation by real-time PCR analysis to determine the relative 
mRNA expression of CD3, Foxp3 and a panel of different pro-infl ammatory and 
cytoprotective genes.
Results: Analysis of cardiac allografts from pretreated mice revealed a higher 
level of chemokine and chemokine receptor mRNA expression 2-days after 
transplantation, compared to that expressed in allografts transplanted into naïve 
recipients. In particular, the expression of XCL1, CXCL9 and CXCL10 was 
dramatically enhanced (276, 166 and 186-fold, respectively). The amplifi ed 
chemokine expression correlated with an increase in CD3 expression, indicating 
that T-cells had infi ltrated cardiac allografts earlier and in greater numbers in 
pretreated mice compared to naïve recipients. 
Interestingly, early T-cell infi ltration correlated with an enhanced intragraft 
mRNA expression of genes that have been associated with Treg phenotype 
and/or function such as CCR5, CCR8, CD103, IL-2, IL-27p28, IFN&#61543;, 
IDO, IL-10 and Foxp3 (by at least 10-fold). By 10-days after transplantation, 
the difference in gene expression between grafts from pretreated and naïve 
recipients was found to persist but was not as marked as at the earlier time 
point.
Depletion of CD25+ T-cells from pretreated recipients by i.v. injection of a 
depleting anti-CD25 mAb (PC61) 14-days before transplantation of a cardiac 
allograft resulted in the rejection of the grafts that otherwise would have been 
accepted (MST=27 versus >100 days). Analysis of these cardiac allografts 
2-days after transplantation revealed a decrease in Foxp3 mRNA expression 
when compared to pretreated recipients that had not received anti-CD25 
mAb. Analysis of intragraft expression of other genes associated with Treg 
phenotype and/or function that were enhanced in pretreated recipients 2-days 
after transplantation in grafts from recipients that have been depleted of Tregs 
is in progress.
Conclusions: We have shown that under conditions leading to long-term 
cardiac allograft survival, alloreactive Treg that have been generated as a result 
of anti-CD4 mAb+DST pre-treatment are recruited to the graft within 2-days, 
before the priming and infi ltration of alloreactive effector T-cells. We propose 
that the rapid, increased expression of chemokines in the grafts of pretreated 
recipients is important for the early recruitment of Treg that, via the expression 
of CCR5 and CCR8, infi ltrate the graft and suppress damaging effector T-cell 
responses within the graft itself.
GENERATING ALLOGRAFT TOLERANCE BY BAFF-736 
DEPENDANT EXPANSION OF REGULATORY T CELLS
S. Walters, K. Webster, A. Sutherland, J. Groom, D. Liuwantara, E. Marino, 
F. Mackay, J.Sprent, S. Grey
Garvan Institute of Medical Research
The B cell activation factor from the TNF family (BAFF) plays a critical role in 
B cell function and survival. T cells have been shown to express BAFF receptors 
suggesting that BAFF may also be important for T cell responses, however 
this has not been investigated. We tested allograft responses in BAFF-Tg mice 
and found that ~60% of mice accepted a full MHC-mismatched islet allograft 
(BALB/c -> C57BL/6) for >100 days. In addition, BAFF-Tg mice also showed 
delayed skin graft rejection. This tolerant phenotype was due to a T cell intrinsic 
change in allo-responsiveness as shown by a failure of purifi ed BAFF-Tg T 
cells to reject an allograft in adoptive transfer experiments or to proliferate in an 
MLR. However, BAFF-Tg T cells were not anergic per se as they proliferated 
normally to antigenic stimulation in vitro and in vivo. Intriguingly, BAFF-Tg 
mice harbored an increased frequency of FoxP3+ T regulatory cells (Tregs) in 
the periphery as compared to Wild Type mice. Elimination of CD25+ T cells 
restored normal allograft rejection to BAFF-Tg mice, demonstrating that the 
increased number of Tregs were responsible for their altered allo-immunity. 
In a second approach, BAFF-Tg T cells depleted of CD4+ CD25+ T cells by 
FACS sorting were adoptively transferred to previously transplanted RAG-/- 
recipients, and in this case the BAFF-Tg CD4+ CD25- T cells rejected their 
allograft. Therefore we show for the fi rst time that BAFF can drive the in vivo 
expansion of Tregs that allow for immunosupression free allograft tolerance. 
We next determined the mechanism by which BAFF was expanding Tregs. 
We examined whether excessive BAFF was promoting Treg expansion in the 
periphery by driving proliferation or enhancing survival and found neither to 
be the case. However we found that BAFF promoted thymic Treg output. Since 
BAFF can modify the APC activity of B cells we questioned whether the BAFF 
expansion of Tregs was T cell intrinsic or B cell dependant. We found that 
the BAFF receptors BR3 and TACI were present on Tregs in the thymus and 
periphery however only in low levels. Signaling through BR3 activates the 
NFkB2 pathway and consistent with the low expression of BR3, Tregs from 
BAFF-Tg mice showed no increase in p100 to p52 processing compared to 
Tregs from Wild Type mice, indicating BAFF was not expanding Tregs by a 
direct interaction. To determine the role of B cells we generated bone marrow 
chimeras using μMT bone marrow. This analysis revealed that in the absence 
of B cells BAFF could not expand Tregs. Together these results demonstrate 
that BAFF can play a complex role in the regulation of T and B cell immunity. 
Excessive BAFF can drive a B cell dependant expansion of Tregs that promote 
allograft tolerance. Therefore manipulating circulating BAFF levels may 
provide a means to generate immunosuppression free allograft tolerance.
T CELLS AND NK CELLSCONCURRENT ORAL SESSION 56: 
B CELLS PROMOTE GENERATION OF CD4 AND CD8 737 
ALLOREACTIVE MEMORY T CELLS
Y-H. Ng, Q. Li, A. Marlowe, R. Hoffman, G. Chalasani
Starzl Transplantation Institute and The University of Pittsburgh
B cells and memory T cells are associated with treatment-resistant acute and 
chronic allograft rejection. It is possible that B cells contribute to allograft 
rejection by mechanisms other than alloantibody production since donor 
specifi c antibodies often precede cellular rejection. We tested whether B 
cells help generation of alloreactive memory T cells and promote allograft 
rejection. 
Methods and Results: Skin allograft rejection was compared between B-cell 
defi cient μ;MT and wild-type (wt) mice and was found to be similar in both 
groups (MST 18 days, n=4/gp). Alloreactive effector and memory T cell 
responses were measured by quantitating alloreactive IFNγ; producing T cells 
at the time of rejection (effectors) and at 8 weeks after rejection (memory). As 
expected, alloreactive effector T cell numbers were similar between μ;MT and 
wt mice. However, alloreactive memory T cells in μ;MT mice were 12-fold 
fewer in the CD4 and 10-fold fewer in the CD8 populations compared to wt 
mice. Cytotoxic function of alloreactive memory T cells was measured by 
testing in vivo allogeneic target cell lysis in μ;MT and wt mice at 8 weeks 
after skin allograft rejection. Specifi c lysis of allogeneic targets in NK-cell 
depleted μ;MT mice was 13±3% in comparison to 95 ± 2% in wt mice. These 
fi ndings suggest that the function of alloreactive memory T cells that were 
Thursday 14 August 2008 Oral Abstracts
2 5 8
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
generated was signifi cantly impaired in the absence of B cells. To address how 
B cells promote generation of alloreactive memory T cells, the role of antigen 
presentation by B cells was tested. Syngeneic mixed bone marrow chimeras 
were created in irradiated μ;MT recipients by transplanting bone marrow from 
μ;MT, wt and MHCko (lack MHC I & II expression on all cells) mice. B cells 
but not other professional APCs in μ;MT+MHCko chimeras lacked expression 
of MHC I & II and therefore, antigen presentation was specifi cally disrupted 
in B cells. Skin allograft rejection was comparable between μ;MT+MHCko 
and μ;MT+wt chimeras (MST = 17 days and 16 days, respectively, p = 0.6, 
n = 5/grp). However, heart allograft rejection was signifi cantly delayed in the 
μ;MT+MHCko chimeras compared to μ;MT+wt chimeras (MST = 23 days and 
15 days, respectively, p=0.03, n = 5/grp). Alloreactive memory T cells were 
measured in chimeras at 8 weeks after skin allograft rejection and showed 
signifi cantly fewer memory T cells in μ;MT+MHCko chimeras (7-fold fewer 
CD4, p = 0.02, and 5-fold fewer CD8, p = 0.003, n = 5/grp) than in μ;MT+wt 
chimeras. These results show that in the absence of antigen presentation by 
B cells, heart but not skin allograft rejection was signifi cantly delayed and 
development of alloreactive memory T cells was signifi cantly impaired.
Conclusions: Development of alloreactive memory T cells but not effector T 
cells is dependent upon B cells. Antigen presentation by B cells accelerates 
heart allograft rejection and leads to development of alloreactive memory T 
cells. These fi ndings emphasize antibody-independent functions of B cells in 
promoting alloimmune responses and highlight the need for B-cell targeted 
therapies to improve long-term allograft survival.
IN VIVO TIME-LAPSE IMAGING OF NAÏVE T CELLS 738 
CONVERSION TO REGULATORY T CELLS IN ALLOGRAFT 
ISLET TRANSPLANTATION
M. Koulmanda1, Z. Fan1, J. Spencer2, Y. Lu1, T. Strom1, C.s Lin2
1Dept of Medicine, Transplant Research Center, Beth Israel Deaconess 
Medical Center, Harvard Medical School, 77Ave Louis Pasteur, Boston, MA 
02115, 2Advanced Microscopy Program, Wellman Center for Photomedicine, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
Purpose: To analyze the dynamic roles of effector T cells (Teff) and both 
natural (nTreg), and induced (iTreg) regulatory T cells in allograft response of 
untreated and tolerized islet allograft recipients through in vivo imaging.
Methods: nTreg (green+) from C57BL/6 Foxp3-GFP knock in (KI) mice 
and naïve Teff (red +) from C57BL/6 DsRed tg x Foxp3-GFP KI mice, in 
this hybrid mouse the induced expression of Foxp3 creates (red+, green+ 
chromophore expression -> orange iTregs) were purifi ed and adoptively 
transferred to C57BL/6 Rag1-/- recipients of DBA/2 (H2d) islets transplanted 
under the kidney capsule. Untreated control and recipients tolerized with a 14 
day course anti-CD154 + MR1 regimen were analyzed. In vivo fl ow cytometry 
of circulating blood was performed on days 1- 7 & 14. In some cases, in vivo 
confocal microscopy with three-dimensional imaging and reconstruction of the 
graft was performed on post-transplant days 7 & 14 in order to analyze the 
intensity and distribution of graft infi ltrating Teff (red), iTreg (orange), and 
nTreg (green) T cells. Mice were sacrifi ced on day 14 and fl ow cytometry of 
spleen, peripheral lymph nodes (LN) and graft draining LN was preformed. 
Results: In untreated hosts the MST was 14 days while grafts in tolerized hosts 
survived more than 100 days before sacrifi ce. In this model, naïve Teff cells (Red), 
nTreg (Green) and in vivo converted iTreg (orange) cells can be specifi cally 
identifi ed by in vivo imaging. In blood, conversion to the iTreg phenotype peaks 
3-4 days post-transplantation. In tolerized mice, there were far more iTreg (orange) 
and nTreg (green) in the grafts on both day 7 and 14 than in control mice. The 
total cell numbers are much greater in control mice, with a predominant pattern 
of graft infi ltration by Teff (predominant). On day 14, iTreg were more prevalent 
in spleen, lymph nodes and draining LN of tolerance induction mice (8-10% of 
total DsRed+ cells) than control mice (2-4% total DsRed+ cells). Moreover, the 
expression of Foxp3-GFP was higher per individual Foxp3-GFP+ iTreg cells in 
samples from the tolerant as compared to control mice. 
Conclusions: In vivo imaging is an invaluable tool to directly observe the 
pattern of graft infi ltration by Teff, iTreg and nTeg as well as study dynamics 
of iTreg conversion in vivo. This tool can aid analysis of allograft rejection 
and the effect of tolerance inducing regimens. The unique feature is the ability 
to serially analyze in vivo the same subject to give a dynamic analysis of 
the allograft response. The fi ndings indicate that graft infi ltrating iTreg and 
nTreg are more abundant in tolerant than rejecting mice. It is notable that tire 
in tolerant mice have enhanced foxp3 expression on a per cell basis than in 
rejecting mice, suggesting stronger graft protecting properties.
T-CELL HELP IS ESSENTIAL IN MEMORY B-CELL 739 
ALPHA-GAL XENOANTIBODY PRODUCTION:IMPLICATIONS 
FOR ABO INCOMPATIBLE AND XENOTRANSPLANTATION
S. Liu, J. Tchervenkov, T. Kandeva, R. Tavana
McGill University
Introduction: The interaction between preformed anti-Gal antibodies 
(anti-Gal Ab) and α-gal epitopes is a major immunologic barrier in human 
xenotransplantation. The α-gal epitopes are very similar structurally to human 
blood group A and B. In recipients of ABO incompatible grafts, much of the 
elicited anti-A and anti-B antibodies are in fact anti-Gal Ab capable of binding 
to incompatible blood group antigen. Central to the production of anti-Gal Ab 
is the presence of memory B-cells and the need for T-cell help in this process is 
not very clear. B cells can present α-gal epitopes on the highly conserved MHC 
class I like molecule CD1d to invariant Natural Killer T lymphocytes (iNKT). 
We hypothesized that human iNKT cells can provide direct help for B cell anti-
Gal Ab production through CD1d-restricted mechanism.
Methods: Glycolipid micelles with α-gal epitopes (α-gal glycolipids) were 
extracted from swine red blood cells. 7.5X104 B cells were co-cultured with non-
irradiated 15X104 CD4+ T cells for 4 days with α-Gal glycolipid stimulation. 
After 4 days specifi c α-Gal glycolipid antigen stimulation, these cells were 
washed and plated onto ELISPOT plates coated with Gal-BSA. This Assay 
utilizes a specifi c antigen stimulation of B cells followed by an antigen-specifi c 
ELISPOT for the detection of anti-Gal memory B cells that have differentiated 
into antibody secreting cells (ASC) in vitro. 5X104 human CD19 B cells were 
co-cultured with irradiated 15X104 CD4+ T cells in the medium containing 0.2 
μg/ml of anti human CD3 antibody and 100 U/ml of interleukin (IL)-2 with or 
without swine 1 μg/ml of RBC glycolipid for 12 days. Human CD4+ T cells 
provide CD1d-dependent help to B lymphocytes for immunoglobulin production. 
IgG and IgM released by B lymphocytes cultured with irradiated CD4+ T cells 
with anti human CD3 antibody and in the absent α-Gal glycolipid in vitro. Anti-
Gal antibody production was inhibited by anti-CD1d antibody. Values are the 
mean OD from six independent experiments. P values are indicated above the 
lines. Results for IgG are shown (IgM results are the same).
BT+ α-Gal BT+ α-Gal +anti-CD1d
Results: B cells produce anti-Gal antibodies only if they receive help from activated 
T cells. These immune responses can be inhibited by anti-CD1d antibody.
Conclusion: T cell help is essential in B-cell anti-Gal Ab production. 
Xenoantibody production can be blocked by inhibition of CD1d which suggests 
that iNKT cells may be central to memory B-cell help. 
ACCELERATED REJECTION OF ALLOGRAFTS 740 
FOLLOWING HOMEOSTATIC PROLIFERATION OF T 
CELLS DESPITE DISPROPORTIONATE EXPANSION OF 
REGULATORY T CELLS
W. Wong, K. Brown, T. Tapmeier, V. Moxham, J. Karegli, S. Sacks
King’s College London
Homeostatic proliferation of peripheral lymphocytes becomes the main source 
of new T cells in adults following thymic regression. This process is accelerated 
in transplant recipients that are lymphopaenic as a result of immunosuppressive 
therapy. Importantly, T cells that have undergone homeostatic proliferation 
acquire the phenotype and functions of memory T cells. However, the fate of 
the regulatory T cell component of the T cell population following homeostatic 
proliferation has so far revealed contradictory results.
To determine the effect of homeostatic proliferation on Foxp3+ regulatory T 
cells, we reconstituted RAG-/- mice with wild-type C57BL/6 splenocytes. The 
proportions of Foxp3+ cells in wild-type spleens, and RAG-/- spleens 14 days 
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following reconstitution, were analysed using fl ow cytometry. Surprisingly, 
while only 0.73% + 0.16% CD4+ T cells from spleens of naïve animals also 
stained positive for intracellular Foxp3 (n =10), 20.21% + 4.9% CD4+ T cells 
from spleens of reconstituted RAG-/- mice were double positive, representing a 
28 fold increase (n =6, p = 0.0002). To ascertain whether the increased numbers 
of Foxp3+ T cells in the spleens of reconstituted RAG-/- mice compared with 
wild type would infi ltrate subsequent renal allografts and have a bearing on the 
outcome of the alloresponse, immunohistochemistry was performed on BM12 
allografts transplanted into WT or reconstituted RAG-/- recipients. Although 
the level of CD4+ infi ltration was similar in BM12 kidney grafts transplanted 
into reconstituted RAG-/- or WT recipients, the level of Foxp3+ T cells was 
more than 2 times higher in BM12 allografts transplanted into reconstituted 
RAG-/- recipients (27.7+6.7 and 13.5+3.5 cells per HPF respectively, n = 4). 
This is despite the fact that BM12 kidneys are rejected more rapidly by RAG-/- 
reconstituted compared with WT mice. 
Foxp3+ regulatory T cells have a greater ability to undergo homeostatic 
proliferation compared with non-regulatory T cells. Despite this, rejection of 
BM12 kidney grafts are accelerated, further supporting the notion that effector 
T cells that have undergone homeostatic proliferation have enhanced “memory” 
like functional capabilities and are therefore more diffi cult to regulate.
THE ROLE OF DONOR CD4 T CELLS WITHIN SOLID 741 
ORGAN TRANSPLANTS IN GRAFT REJECTION
T.S. Win1, S. Rehakova1, K. Saeb-Parsy1, M. Negus1, M. Goddard2, 
J.A. Bradley1, E. Bolton1, G.J. Pettigrew1
1Department of Surgery, Addenbrooke’s Hospital, Cambridge, UK, 
2Department of Pathology, Papworth Hospital, Papworth, UK
Background: This study examines how donor CD4 T cells within heart 
allografts contribute to the development of chronic allograft vasculopathy 
(CAV), by providing help to recipient B cells for generating pathogenic 
autoantibody.
Methods: B6 mice were transplanted with MHC II-disparate bm12 hearts. The 
allo- and auto-antibody responses were quantifi ed, and their contribution to 
CAV assessed by serum transfer to B cell defi cient recipients. The role of donor 
CD4 T cells in providing help for autoantibody was tested by removing CD4 
T cells from donor hearts before transplantation by three approaches: treating 
with anti-CD4 depleting mAb, administering 1300Gy lethal irradiation, and 
using RAG-/- bm12 donors. 
Results: Bm12 heart grafts developed progressive vasculopathy and were 
rejected slowly (MST 95 days, n=17). The contribution of antibody-mediated 
effector mechanisms was confi rmed by histopathological examination (fi brinoid 
necrosis and vascular proliferation), by complement C4d staining, and by long-
term graft survival and signifi cantly reduced vasculopathy in B cell defi cient 
recipients. Surprisingly, no alloantibody was detected, but recipients instead 
developed autoantibody. The autoantibody response was completely dependent 
upon the provision of help from donor CD4 T cells; removing CD4 T cells from 
donors lead to complete abrogation of autoantibody response. Furthermore, 
C4d deposition was not detected in CD4 T cell depleted/defi cient bm12 
allografts. To confi rm an effector role for autoantibody in CAV, B6 mice were 
primed for humoral autoimmunity, but not for alloimmunity, by injecting highly 
purifi ed bm12 CD4 T cells prior to transplantation. Heart grafts developed 
severe vasculopathy and were rejected more rapidly (MST 29 days, n=4, 
p<0.01). Furthermore, the serum transfer of autoantibody to B cell defi cient 
recipients induced rejection (MST=40 days, n=4) and restored C4d deposition. 
Autoantibody by itself is, however, not suffi cient to cause graft rejection; 
syngeneic grafts showed disease-free survival in the presence of autoantibody 
(n=4), indicating that development of vasculopathy and rejection is dependent 
upon synergy between humoral autoimmunity and cellular alloimmunity. Finally, 
bone marrow chimeric recipients that lacked MHC class II expression specifi cally 
on B cells did not develop autoantibody, demonstrating that transplantation-
induced autoantibody response results from cognate interaction between donor 
CD4 T cells and MHC class II of recipient B cells.
Conclusions: Our results demonstrate the novel fi nding that help for 
autoantibody production is provided by graft-versus-host cognate recognition 
of recipient B cell MHC class II by donor CD4 T cells. This autoantibody 
contributes to the development of vasculopathy independently of alloantibody.
CD8+ MEMORY T CELLS ELICIT ACCELERATED 742 
REJECTION THROUGH RAPID RECRUITMENT OF GR-1+ 
NEUTROPHILS TO THE ALLOGRAFT
N. Jones, M. Brook, M. Carvalho-Gaspar, S. Luo, K. Wood
University of Oxford
Introduction: Increasing evidence suggests that memory T cells (Tm) play 
an important role in allograft rejection and may form a barrier to tolerance 
induction. We have used TCR-transgenic mice (BM3; H2Kb-reactive CD8+ T 
cells) to compare the response of naïve and memory BM3 T cells to allogeneic 
skin grafts where the number, specifi city and affi nity of alloreactive naïve and 
memory T cells was identical.
Methods: Naïve BM3 T cells were harvested from BM3 TCR-transgenic mice; 
BM3 Tm were isolated from mice that had been primed with donor splenocytes 
or a skin allograft. In all experiments 1x105 memory or naïve BM3 T cells 
were transferred to syngeneic, immunodefi cient RAG-/- mice the day before 
H2Kb+ skin transplantation. The response of the memory and naïve T cells 
was visualised using FACS (lymphoid tissues), immunohistochemistry and 
real-time PCR for pro-infl ammatory genes (skin graft).
Results: A comparison of the response of memory and naïve BM3 T cells to skin 
allografts revealed that Tm rejected grafts with an enhanced kinetic (median 
survival time (MST) of 16 days (naïve) and 26 days (memory); P=0.01). 
Surprisingly, when the response of BM3 Tm to the skin allograft was evaluated, 
we found that memory and naïve BM3 T cells proliferated to a comparable 
extent. The percentage of Tm or naïve BM3 T cells that had undergone 4 
(7.9±4.1 Vs 6.7±3.6%), 5 (8.9±4 Vs 10.6±5.5%), 6 (9.1±4.2 Vs 8.5±3.8%), 
7 (7.7±6.4 Vs 8.9±2.5%) and 8 or more (20.4±18.7 Vs 37.1±33.1%) divisions 
in the draining lymph nodes was not signifi cantly different. Furthermore, 
the resulting effector cells, whether derived from naïve or memory BM3 T 
cells, infi ltrated skin allografts with a similar kinetic (infi ltration of skin grafts 
between 5 and 10 days post transplant). The resulting graft infi ltrating effector 
cells were also found to induce a similar gene expression profi le. However, 
during accelerated rejection triggered by BM3 Tm and in marked contrast to 
rejection triggered by naïve BM3 T cells, signifi cant numbers of GR-1+ cells 
(neutrophils) were recruited to the graft as revealed by immunohistochemistry. 
To determine whether the enhanced recruitment of GR-1+ neutrophils to skin 
grafts was responsible for the rapid rejection mediated by BM3 Tm mice, a 
depleting anti-GR-1 mAb was administered to mice that had received naïve 
or memory BM3 T cells and a donor skin allograft every 3 days for 27 days 
post transplantation. We found that the anti-GR-1 mAb therapy attenuated graft 
rejection mediated by Tm such that the rejection time was identical to that 
triggered by naïve BM3 T cells in the absence of neutrophils (Tm+anti-GR-
1=MST of 30 days, naïve BM3+anti-GR-1=MST of 30 days; n=5-6/group).
Discussion: Tm are able to rapidly reject allografts through the enhanced 
recruitment of GR-1+ neutrophils to the graft. These data extend our knowledge 
of the function of alloreactive Tm in transplantation. Furthermore, we have 
identifi ed an under-appreciated role of neutrophils in transplant rejection and 
suggest that the transient depletion/manipulation of GR-1+ cells may be of 
therapeutic benefi t in the control of rejection responses elicited by Tm.
ALLOGRAFT REJECTION IN ABSENCE OF SECONDARY 743 
LYMPHOID ORGANS
C. Leduc, C. Daniel
INRS-Institut Armand-Frappier
In transplantation, the site of alloreactive response initiation is still a matter 
of debate. Some have suggested that the organized structures of secondary 
lymphoid organs (SLO) are absolutely required for T cell sensitization, whereas 
others claimed that the graft itself could constitute an appropriate environment. 
We investigated this issue in a murine model based on a single T cell clonotype 
where direct and indirect allorecognition pathways can be independently 
studied. Our previous studies showed that during direct responses, activated 
alloreactive T cells were fi rst detected inside the graft. We further investigated 
whether alloreactive responses could be initiated in the absence of SLO.
The model used in the laboratory is based on a CD4+ T cell clone (2.102), 
which recognizes I-Ep (MHC class II) molecules by the direct pathway 
and mouse hemoglobin peptide Hb(64-76) presented by I-Ek molecules by 
the indirect pathway. Purifi ed CD4+ T cells from 2.102 TCR Tg mice were 
adoptively transferred to splenectomized H-2k mice defi cient for both α;β; T 
cells and for lymphotoxin β; receptor. These mice, which lack lymph nodes and 
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Peyer’s patches, were then grafted with donor tail skin. 
Mice without SLO rejected their allograft but with a small delay in kinetics as 
compared to mice with SLO. As expected, CD4+ T cells were detected massively 
in the graft in the direct pathway at day 7. This infi ltration is associated with an 
IFN-γ; mRNA up regulation. How CD4+ T cells get activated in direct pathway 
is still unclear. Is the graft environment itself suffi cient to T cell activation 
or is the development of lymphoid structures necessary? The presence of the 
high endothelial cell restricted N-acetylglucosamine 6-O-sulfotransferase 
mRNA, an enzyme involved in PNAd synthesis, in addition to the presence 
of the CCL19 chemokine, suggest that lymphoid structures could be present in 
the graft. Immunohistochemistry analyses are under investigation to determine 
whether tertiary lymphoid organs developed in graft. Surprisingly, rejection by 
the indirect also occurred in the absence of SLO. Because only infl ammatory 
cytokines and chemokines mRNA and almost no CD4+ T cells were detected in 
the graft at that time, other organs were investigated for the presence of CD4+ 
T cells. Indeed, BrdU+CD69+CD4+ T cells were detected in the bone marrow. 
Thus this primary lymphoid organ can also serve as a surrogate SLO where T 
cell activation and proliferation occur before migration of these activated T cells 
to the graft, as suggested by intra-graft chemokine receptors expression such 
as CCR1, CCR3, CCR5 and CXCR3. Finally, different cellular mechanisms 
seem to be implicated in each pathway as seen by a neutrophil infi ltration in 
the direct pathway and a macrophage infi ltration in the indirect pathway. In 
conclusion, although different sites of T cell activation and different effector 
mechanisms, both pathways of allorecognition can lead to rejection in absence 
of SLO.
THE ROLE OF NATURAL KILLER CELLS IN 744 
LYMPHOCYTIC CHORIOMENINGITIS VIRUS (LCMV) 
INDUCED CORONARY ALLOGRAFT VASCULOPATHY (CAV)
J.Graham1, R. Wilkinson3, T. Hirohashi1, C. Chase1, J. Fishman3, J. Madsen1, 
R. Colvin2, P. Russell1
1Department of Surgery Massachusetts General Hospital, 2Department of 
Pathology Massachusetts General Hospital, 3Division of Infectious Disease 
Massachusetts General Hospital
Background: CAV is a major cause of death in cardiac transplant patients. In 
this regard, understanding the pathogenesis of CAV has become a paramount 
pursuit of the transplant community. Viruses have always been implicated in 
CAV lesion formation, but the contribution of viral infection to the pathogenesis 
of CAV remains unclear and anecdotal. Here we investigate the role of natural 
killer (NK) cells in a novel example of LCMV-induced CAV. Importantly, the 
well characterized anti-viral properties of NK cells make them relevant in this 
discourse.
Methods: To isolate the contributions of NK cells, parental C57BL/6.RAG1-/- 
(H2b) hearts were transplanted into (C57BL/6.RAG1-/- x BALB/c.RAG1-/-) 
F1 (H2bxd) recipients. This system offers an uncontrived means with which 
to eliminate B and T cell response while maintaining intact NK cell activity. 
Four recipient groups were studied; 1) no treatment, 2) viral medium injection 
(sham), 3) LCMV inoculation alone (mice were infected IP with 2.25 x 10e5 
PFU of LCMV Armstrong strain) and 4) LCMV inoculation with anti-NK1.1 
mAb administration to deplete NK cells. CB6F1.RAG1-/- recipients of 
B6.RAG1-/- hearts were treated with PK136 (anti-NK1.1) at a dose of 200 mg 
i.p. on days -6,+1 then once weekly thereafter. Recipients were sacrifi ced on 
post-operative day 56 with beating hearts. A quantitative molecular assay for 
LCMV in tissue at sacrifi ce revealed that infected hearts had a mean of 103,745 
copies of LCMV/ng tissue RNA. Transplanted hearts were rapidly frozen and 
sections were prepared from frozen tissue to determine the presence of CAV 
formation.
Results: Only 1 in 11 untreated recipients developed lesions of CAV and none 
of the 4 sham injected recipients did so. In contrast, 6 of 8 recipients infected 
with LCMV developed distinct CAV lesions. Strikingly, none of the 8 mice 
infected with LCMV and treated with anti-NK1.1 mAb developed CAV.
Conclusion: Our experiment demonstrates that LCMV can cause CAV, which 
corroborates the clinical evidence supporting the possibility of virally induced 
CAV. However more importantly, NK cell depletion was shown to abrogate 
CAV lesion formation. Therefore, NK cells appear to mediate the development 
of CAV induced by LCMV. We propose that LCMV infection causes non-self 
peptide expression on the coronary graft endothelium leading to activation of 
the NK cells, which in turn stimulate effector cells/cytokines to induce CAV. 
Through the study of LCMV in our model we hope to clarify the role of 
the innate immune system and viral infection in the post-operative period. 
Interestingly NK cells alone do not appear able to promote CAV, but rather 
need another catalyst for stimulation. Our data demonstrates that viruses may 
be germinal to the understanding of NK cell contribution to CAV and the 
vascular biology of this disease. 
NK CELLS REGULATE GRAFT-VERSUS-HOST DISEASE 745 
AND CARDIAC ALLOGRAFT REJECTION BY LIMITING THE 
ANTIGEN-DRIVEN EXPANSION OF CD4 T CELLS
M.N. Rivas, M. Hazzan, M.l Braun
Institute For Medical Immunology (IMI) – Université Libre De Bruxelles (ULB)
CD3-negative natural killer cells (NK) are granular lymphocytes capable of 
producing infl ammatory cytokines and killing malignant, infected or ‘stressed’ 
cells. We have recently observed a new role for NK cells in the control of the 
proliferation of CD4 T cells under persistent antigenic stimulation. Adoptive 
transfer of monoclonal anti-male CD4-positive T cells into sub-lethally 
irradiated male recipients induced 100% mortality after one week. On the 
contrary, non-irradiated mice survived indefi nitely after transfer and did not 
develop clinical sign of acute graft-versus-host disease (GVHD). Moreover, T 
cells transferred into non-irradiated recipients did not expand or were rapidly 
eliminated. Remarkably, T cells transferred into non-irradiated NK cell-defi cient 
hosts expanded extensively (15x10E6 cells after 28 days). Histology revealed 
their capacity to mediate chronic GVHD-like lesions in these hosts. Transferred 
T cells did not appear to develop a regulatory phenotype since they remained 
Foxp3-negative and produced high amounts of IFN-g when stimulated in vitro. 
Interestingly, even in the absence of NK, they were unable to promote acute 
GVHD after transfer into irradiated recipients. These results highlight the 
critical role played by NK cells in the control of antigen-dependent expansion 
of CD4 T cells and the development of chronic GVHD.
The role played by NK cells in the control of T cell response was also investigated 
in a vascularised cardiac allograft model. MHC class II-disparate Bm12 hearts 
transplanted into C57BL/6 recipients underwent slow rejection (mst>50 days; 
n=4). On the contrary, our preliminary results showed that the depletion of NK 
cells by antibody treatment in this model accelerated the process of rejection 
(mst=28 days; n=4). This observation is consistent with the hypothesis that the 
control of alloreactive CD4 T cells by NK cells of the innate immune system 
could limit the process of chronic rejection of solid organ transplants. We are 
currently investigating whether the accelerated rejection process observed in 
the absence of NK cells is the result of uncontrolled expansion of allograft-
specifi c CD4 T cells.
CAN AND ANTIBODIESCONCURRENT ORAL SESSION 57: 
CIRCULATING MARKERS OF ENDOTHELIAL 746 
DYSFUNCTION INTERACT WITH PROTEINURIA IN 
PREDICTING MORTALITY IN RENAL TRANSPLANT 
RECIPIENTS
R.M. van Ree, L.H. Oterdoom, A.P.J. de Vries, J.J. Homan van der Heide, 
W.J. van Son, G.J. Navis, R.O.B. Gans, S.J.L. Bakker.
Renal Transplant Program, University of Groningen and University Medical 
Center Groningen, The Netherlands.
Proteinuria is associated with increased mortality in renal transplant recipients 
(RTR). This association is considered the consequence of proteinuria refl ecting 
generalized endothelial dysfunction (ED). In RTR, however, proteinuria 
is frequently a refl ection of renal involvement. Both, soluble intercellular 
adhesion molecule type 1 (sICAM-1) and soluble vascular cellular adhesion 
molecule type 1 (sVCAM-1) are markers of ED. In this study, we investigated 
whether markers of ED can help to recognize whether proteinuria is associated 
with vascular involvement in RTR. 
Outpatient RTR, who had a functioning graft ≥1 year, were invited to participate 
between 2001-2003. Proteinuria was defi ned as urinary protein excretion ≥0.5 
g/24hr. sICAM-1 and sVCAM-1 were measured by ELISA. Mortality was 
analyzed using Cox-regression. 
We measured sICAM-1 (median [IQR] 603 [514-721] ng/ml) and sVCAM-1 
(952 [769-1196] ng/ml) in 606 RTR (aged 51±12 years, 55% male) at 6.0 
[2.6-11.4] years post-transplant. Proteinuria was present in 169 (28%) RTR. 
During follow-up for 5.3 [4.7-5.7] years, 95 (16%) RTR died.
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RTR who had proteinuria and high levels of sICAM-1 or sVCAM-1 were 
at highest risk for death (Hazard ratio (HR)=2.2, P=0.003 and HR=2.9, 
P=0.0001, respectively versus subjects without proteinuria and with low levels 
of sICAM-1 or sVCAM-1, which were considered reference groups, both 
with HR=1.0). Subjects with proteinuria but low levels of sICAM-1 (HR=0.9, 
P=0.90) or sVCAM-1 (HR=0.9, P=0.80) had a risk comparable to the reference 
groups. The same was true for subjects without proteinuria but high levels of 
sICAM-1 (HR=1.1, P=0.80). For subjects without proteinuria but high levels 
of sVCAM-1 (HR=1.5, P=0.10) there was an insignifi cant trend towards 
increased risk (fi gure 1). 
Both sICAM-1 and sVCAM-1 interact signifi cantly with proteinuria in 
predicting mortality in RTR. These results suggest that assessment of circulating 
cell adhesion molecules can help to identify RTR in which proteinuria is 
associated with vascular involvement.
Figure 1. Interactions between proteinuria and (A) sICAM-1 and (B) sVCAM-1 
concentrations on the risk of mortality. Ref. = reference.
ESTIMATION OF RENAL ALLOGRAFT HALF LIFE IN 747 
COHORTS WITH DIFFERENT FOLLOW UP
D. Serón1, M. Arias2, J.M. Campistol3, D. Hernandez4, José Morales5, 
Francesc Moreso6, Ana Sanchez-Fructuoso7
1Hospital Universitari Bellvitge, 2Hospital de Valdecillas, 3Hospital Clinic, 
4Hospital Universitario de Canarias, 5Hospital 12de Octibre, 6Hospital 
Universitari Bellvitge, 7Hospital Cínico San Carlos
Introduction: It is necessary to monitor graft and patient survival in cohorts 
of patients transplanted at different time periods, to detect as early as possible, 
the effect of different transplant policies on long term outcome. Modelling long 
term graft failure has led to overestimation of real renal allograft half life. The 
aim is to determine the minimum follow up using different statistical models to 
accurately estimate renal allograft half life in patients with a functioning graft 
at one year of follow up.
Patients and methods: Patients with a functioning graft at one year, 
transplanted in Spain during 1990, 1994, 1998 and 2002 were followed until 
December 2005. Real half life was calculated in the 1990 cohort since >50% 
of patients lost their graft at the end of follow up. Additionally, exponential, 
Weibull and Weibull method censoring the last 2 years of follow up were 
employed to estimate renal allograft half life. 
Results: During these 4 years a total of 6901 adult patients were transplanted 
in Spain and 4842 accomplishing the inclusion criteria were enrolled. Of 
these, 851 were transplanted in 1990, 1124 in 1994, 1512 in 1998 and 1355 
in 2002.
Real half in 1990 was 14.2 years and estimated half life and its 95% confi dence 
interval according to the different statistical models are shown in the table.
Exponential  Weibull  Weibull 
censoring last 2y
1990 15.8(14.2-17.5)  14.5 (13.4-15.6)
 14.0 (13.1-15.0)
1994 18.2 (16.3-20.1) 15.3 (14.1-16.6) 13.6 (12.6-14.6)
1998 27.5 (24.0-31.0) 19.0 (16.9-21.1) 14.9 (13.4-16.4)
2002 57.5 (42.3-72.7) 27.8 (21.7-34.0) 18.0 (13.7-22.4)
 P<0.0001  p<0.0001  ns
In order to estimate minimum follow up to obtain an accurate estimation of 
mean half life, this parameter was estimated in the 1990 cohort considering 
different follow up periods from 1 to 14 years. At least 9 year of follow up were 
necessary to precisely estimated real half life in the 1990 cohort.
Conclusion: half life in patient with a functioning graft at one year can be 
precisely estimated before 50% of patients have lost their graft provided these 
patients are followed for at least 9 years.
DONOR-RECIPIENT AGE MATCHING DOES NOT 748 
IMPROVE YEARS OF GRAFT FUNCTION IN DECEASED 
DONOR KIDNEY TRANSPLANTATION
W. Lim, S. Chang, H. Dent, S. Campbell, S. Chadban, G. Russ, S. McDonald
ANZDATA Transplant Working Group
Aims: It is well established that donor and recipient age in kidney transplantation 
affect graft and patient survival. The importance of age matching of deceased 
donors and recipients in kidney transplantation and the impact on years of graft 
function remains uncertain. 
Methods: Using the ANZDATA registry, all deceased donor kidney transplant 
recipients in Australia and New Zealand between 1991 and 2005 were 
analysed (n=3888). Multiple organ grafts, donor and recipient age <16 years 
at transplant were excluded. Outcomes analysed include overall graft loss, 
death-censored graft failure (DCGF) and death with functioning graft (DFG). 
We examined the associations of donor and recipient age with outcomes using 
standard Cox and competing risk models. We estimated mean years of graft 
function for donor-recipient age combinations with and without age matching. 
Donor and recipient confounding factors were adjusted for in multivariate 
models. 
Results: There were no signifi cant interactions between recipient and donor 
age for all outcomes, indicating the associations of donor age with outcomes 
was similar in younger and older recipients. Older donors were associated 
with higher hazards of overall graft loss, DCGF and DFG at 1-8 years post-
transplant (for donors >60 and recipients <55 years, adjusted hazard ratios [HR] 
of 2.03 [95%CI 1.61,2.56], 2.62 [1.95,3.52], 1.49 [1.03,2.16] respectively; 
p<0.05). Using standard Cox models, older recipients were associated with 
higher adjusted hazards of overall graft loss and DFG, but with lower hazards 
of DCGF (HR 0.60, 95%CI 0.46,0.79; p<0.01). When DCGF and DFG were 
considered as competing events, the HR of older recipient age in competing 
risk analysis were augmented but overall conclusions were similar between 
the two methods (i.e. unadjusted HR of DCGF/DFG at 1-8 years for recipient 
age ≥55 years using standard Cox and competing risk models were 0.60 
[0.46,0.79]/3.10 [2.15,3.93] and 0.20 [0.14,0.28]/5.11 [3.58,7.30]). The 
mean years of graft function obtained per patient for best (young-to-young 
and old-to-old) and worst (young-to-old and old-to-young) donor-recipient age 
combinations were similar, indicating no overall benefi ts of age matching (see 
table). 
Mean functioning graft years (up to 15 years’ follow-up)
R
ec
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nt
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ge
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up
Donor age group
TotalYoung Old
(a) Age cut-points: Recipient 55, donor 50 years
Best age-match 9.08 (8.88, 9.73)
Worst age match
9.43 (8.94, 9.92)
Young N=1806
11.44 (11.14, 11.74)
N=887
9.44 (8.94, 9.95)
Old N=700
9.41 (8.94, 9.88)
N=495
7.16 (6.61, 7.71)
(b) Age cut-points: Recipient 55, donor 60 years
Best age-match 9.04 (8.48, 11.52)
Worst age match
8.62 (8.00, 9.23)
Young N=2368
11.15 (10.88, 11.42)
N=325
8.30 (7.47, 9.12)
Old N=981
8.93 (8.52, 9.34)
N=214
6.94 (6.08, 7.80)
(c) Age cut-points: Recipient 50, donor 60 years
Best age-match 9.10 (8.56, 9.63)
Worst age match
9.06 (8.43, 9.70)
Young N=1880
11.14 (10.83, 11.44)
N=252
8.44 (7.52, 9.36)
Old N=1469
9.68 (9.33, 10.03)
N=287
7.05 (6.29, 7.81)
Conclusions: The associations of donor age with outcomes were similar in 
younger and older recipients. Lower hazard of DFG in younger recipients was 
counter-balanced by higher hazard of DCGF. Donor-recipient age matching did 
not result in higher mean years of graft function.
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URINE MAGNETIC RESONANCE SPECTROSCOPY 749 
(UMRS): PRELIMINARY OBSERVATIONS IN THE 
DETERIORATION OF KIDNEY ALLOGRAFT FUNCTION 
(DEKAF) STUDY
R. Gaston5, D. Rush1, R. Somorjai2, M. Cecka3, F. Cosio4, S. Gourishankar6, 
J. Grande4, P. Halloran6, B. Kasiske7, A. Matas8
1University of Manitoba, 2National Research Council Institute of 
Biodiagnostics, 3University of California at Los Angeles, 4The Mayo Clinic, 
5University of Alabama at Birmingham, 6University of Alberta, 7Hennepin 
County Medical Center, 8 University of Minnesota
DEKAF is an ongoing, prospective, multicenter, observational study of the 
causes of renal allograft dysfunction and loss, conducted at 7 transplant centers 
in the US and Canada, with over 1800 patients enrolled to date. At the fi rst 
sign of graft dysfunction or new-onset proteinuria a renal biopsy is obtained 
to defi ne clinico-pathological entities at their early stages before widespread 
interstitial fi brosis and tubular atrophy (IF/TA) precludes identifi cation of their 
original etiology. In addition to traditional clinical, serological and pathological 
studies, DEKAF will attempt to classify these entities with a novel non-invasive 
method, UMRS. 
For UMRS, samples are mixed with TSP/D2O. The 1H NMR spectra are 
acquired on a 360 MHz Bruker spectrometer, aligned on the TSP peak, and 
the water resonance is suppressed. The method for distinguishing patients 
with and without infl ammation, using the UMRS, is based on the multistage 
Statistical Classifi cation Strategy developed and used with success on MR, 
IR, mass spectral and genomic data1. For the urine spectra, leave-one-
out crossvalidation is used to identify maximally discriminatory spectral 
subregions. The robust classifi ers are based on least trimmed square regression 
on the magnitude spectra. 
Patients with a combination of acute infl ammation and IF/TA have decreased 
allograft survival compared to patients with IF/TA without infl ammation. 
As proof of concept that UMRS could accurately distinguish pathological 
entities, we examined urines from patients with low Banff IF scores and 
no infl ammation (class 1: ci0 or ci1; ai=0; n=78) and compared these with 
patients with low IF scores with infl ammation (class 2: ci0 or ci1; ai>0; n=46) 
(Study 1). We next analyzed patients with varying degrees of IF without 
infl ammation (class 1: ci>0; ai=0; n=63) and compared these with patients 
with varying degrees of both IF and infl ammation (class 2: ci>0; ai>0; n=39) 
(Study 2). For either Study, the small sample sizes precluded a meaningful 
splitting of the classes into training sets and independent validation sets. 
The results are based on 6 subregions for both Studies, which satisfy the 
necessary 5-10 sample to feature ratio, required for reliable classifi cation 
of unknown samples. The results show 87.2% accuracy for class 1, 87.0% 
for class 2 (Study 1), and 90.4% for class 1 and 89.7% for class 2 (Study 
2). Thus, sensitivity and specifi city were well balanced for both Studies, but 
more samples will be needed to stabilize the classifi cation accuracies and 
class assignment reliabilities. 
In future studies, independent validation sets will be used to assess the 
diagnostic/prognostic capabilities of all eventual classifi ers. We will also 
obtain UMRS and corresponding classifi ers for other entities (e.g. transplant 
glomerulopathy). The non-invasive nature of urine MRS will allow for repeat 
testing of individual patients to evaluate changes in the spectra and their 
correlation with specifi c interventions and their outcomes. 
FOUR STAGES AND LACK OF STABLE 750 
ACCOMMODATION IN CHRONIC ALLOANTIBODY 
MEDIATED RENAL ALLOGRAFT REJECTION IN 
CYNOMOLGUS MONKEYS
R.N. Smith1, T. Kawai2, S. Boskovic2, O. Nadazdin2, D. Sachs2, 
A.B. Cosimi2, R.B. Colvin1
1Department of Pathology Massachusetts General Hospital, 2Department of 
Surgery Massachusetts General Hospital
NATURAL HISTORY OF CHRONIC ALLOANTIBODY MEDIATED 
REJECTION WITHOUT ENDURING ACCOMMODATION IN 
CYNOMOLGUS MONKEYS
The etiology of chronic renal allograft failure in humans is unclear. Its diagnosis 
both clinically and pathologically is diffi cult and confounded in humans by 
non-immune mechanisms including recurrent disease, drug toxicity, transplant 
ischemia, and hypertension. One cause is thought to be alloantibodies because a 
substantial fraction of patients with chronic rejection have circulating antibodies 
and deposition of C4d, which is associated with the later development of 
transplant glomerulopathy and led us to postulate that C4d may predict later 
chronic antibody mediated rejection (CAMR). To test this hypothesis we 
have evaluated long-term renal allografts in Cynomolgus monkeys, treated 
with mixed chimerism protocols without immunosuppression after 28 days. 
To defi ne the natural history of CAMR, we reviewed 417 specimens from 
143 Cynomolgus monkeys with renal allografts, including the pathology and 
C4d immunohistochemistry and correlated these data with DSA, analyzed by 
fl ow cytometry of recipient alloantibodies against donor lymph node cells. 
Pathological review was performed by Banff criteria. A subset of animals with 
long-term survival made DSA (48%), were C4d positive (29%), developed 
transplant glomerulopathy (TG) (22%), and chronic allograft arteriopathy 
(CAA) (19%), all highly correlated (p<0.001). Acute cellular rejection, either 
Banff type 1 or 2, did not correlate with alloantibodies, C4d deposition or TG, 
however, endarteritis (Banff type 2) correlated with later CAA. A majority of 
cases of TG were associated with alloantibodies, but a small subset of TG could 
not be attributed to alloantibodies. Life table analysis showed that in long term 
surviving animals the presence of alloantibody, C4d, TG, or CAA shortened 
renal allograft survival by at least 58%, Table I.
Table I
 N Mean SD Median SD P Value
Antibody Negative 18 1056 222 770 79 
Antibody Positive 22 348 56 274 18 P <.001
C4d Negative 24 950 185 755 282   
C4d Positive 22 303 43 256 33 P <.001
TG Negative 23 964 186 755 282   
TG Positive 23 287 42 230 35 P <.001 
CAA Negative 20 912 174 508 287 
P value refers to either mean or median
We determined the time of fi rst appearance of alloantibodies, C4d, TG, and 
renal dysfunction in 18 cases with suffi cient interval sampling, Table II and 
identifi ed four progressive stages of CAMR: 1) DSA, 2) deposition of C4d, 3) 
transplant glomerulopathy, and 4) rising creatinine.
Table II
   First Appearance
  Ab C4d TG Graft Loss
Days To Mean 158 210 252 367
 SD 145 180 165 217
 Range 61-652 97-755 113-695 231-838
Cr at Days To Mean 1.4 1.9 2.2 5.8
 SD 0.6 0.8 0.9 2.0
 Range 0.9-2.9 1-3.5 1-3.7 2.3-9
These new fi ndings provide strong evidence that CAMR develops without 
enduring accommodation, progresses through four defi ned clinical pathological 
stages and shortens renal allograft survival. In addition, our results emphasize 
the importance alloantibody assays and C4d staining because these predict the 
clinically silent progressive intragraft pathological changes that can ultimately 
lead to graft loss from CAMR.
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ASSOCIATION BETWEEN DE NOVO DONOR SPECIFIC 751 
HLA ANTIBODY, C4D STAINING IN RENAL GRAFT BIOPSY, 
AND GRAFT OUTCOME.
Y. Cho1,2, J. Cicciarelli1,2, M. Koss1, K. Houston1, R. Mendez1,2, 
N. Kasahara3, I. Hutchinson1,2, T. Shah1
1National Institute of Transplantation, 2USC School of Medicine, 3UCLA 
School of Medicine
Background: Despite improved early graft survival, long-term kidney graft 
loss rate has not been reduced. Both HLA antibodies and HLA donor specifi c 
antibodies (DSA) have been detected and may be causal in chronic allograft 
nephropathy (CAN) and, especially, in acute rejection. We evaluated the 
association between DSA, C4d staining in transplant and graft outcome.
Materials and Methods: During Sep 2004-Aug 2007, HLA antibody tests usng 
the Luminex laboratory screen assay system were performed in 348 recipients. 
Of these, Cd4 deposition was assessed in the biopsies of 69 recipients with 
transplant dysfunction.
Results: In the 69 cases, 29 (42%) showed C4d negativity, 27 (39%) were 
Cd4 positive, 6 (9%) were equivocal, and 6 (9%) not diagnostic. Fourty-nine 
recipients (71%) with transplant dysfunction had HLA antibodies and 41 
(59%) had DSA. The proportion of C4d positivity was signifi cantly higher in 
patients with DSA (Class I only, II only, and I & II) in comparison with patients 
without post-transplant HLA antibodies (Table). The incidence of graft failure 
(including current SCr>4.0) in patients with class II antibodies (Class II only 
or I & II) was signifi cantly higher than that in patients without post-transplant 
HLA antibodies (Table). In Figure, grafts of Class II DSA group continued to 
fail beyond 2 years after transplantation when compared with other 2 groups 
(None/NDSA or Class I only), however, the difference in graft survival between 
Class II and None/NDSA group did not reach to statistical signifi cant level 
(log-rank P=0.32).
Conclusions: Signifi cant association between C4d staining, de novo HLA 
Class II antibodies and graft failure strongly suggests the importance of 
post-transplant HLA antibodies. We propose that amelioration of CAN 
graft loss depends on monitoring and identifi cation of DSA and appropriate 
immunosuppression of these antibodies. 
Table. C4d positivity and graft outcomes according to DSA groups
Antibody 
Category
N C4d Positive
N (%)
Graft Failure
N (%)
Graft Failure or
SCr>4.0
N (%)
None (ref) 20 1 (5) (ref) 3 (15) (ref) 5 (25) (ref)
Class I only 10 8 (80) (P<0.001) 2 (20) (P=0.82) 5 (50) (P=0.10)
Class II only 22 13 (59) (P<0.001)  9 (41) (P=0.06)  13 (59) (P=0.03)
Class I & II 9 9 (100) (P<0.001) 4 (44) (P=0.09) 6 (67) (P=0.03)
NDSA 8 2 (25) (P=0.12) 1 (13) (P=0.86) 1 (13) (P=0.40)
Figure. Graft survival according to DSA groups
THE PRESENCE OF DE NOVO DONOR SPECIFIC 752 
ANTIBODY PREDICTS POOR ALLOGRAFT SURVIVAL IN 
PATIENT WITH TRANSPLANT GLOMERULOPATHY
M. Everly1, L. Arend1, A. Govil1, B. Susskind1, H. Al-Ghawi1, J. Everly1, 
G. Mogilishetty1, R.R. Alloway1, E.S. Woodle1, P. Roy-Chaudhury1. 
1University of Cincinnati, Cincinnati, OH, USA.
Background: Recent studies indicate that renal transplant recipients with 
chronic alloantibody production are at an increased risk of developing 
transplant glomerulopathy (TG). Despite this association, many patients with 
TG do not have peritubular capillary (PTC) deposition of C4d. The aim of this 
study was to identify linkages between transplant glomerulopathy, the pattern 
of C4d deposition, the presence of donor specifi c antibody (DSA) and allograft 
survival. 
Methods: 15 patients with evidence of TG on biopsy (in the absence of a 
rejection episode in the previous 6 months) were included in this study. All 
patients had to have a Banff 97 cg score >0. Donor specifi c anti-HLA antibodies 
(DSA) [Luminex platform/Labscreen single antigen beads] and the pattern of 
C4d deposition [glomerular (G) or peritubular capillary (PTC)] at the time of 
the biopsy were assessed. All DSA were de novo, i.e., not detected prior to 
transplantation. Survival analysis was performed by Kaplan Meier (STATA/
SEv9.2).
Results: TG was associated with the presence of DSA (53%). Of the DSA 
specifi cities present, those directed against HLA class II predominated 
(88%). The majority of patients had glomerular C4d deposition (73%). The 
most common pattern was G+, PTC-, DSA- (33.3%). PTC C4d deposition 
was limited to 3 patients only (20%). All 3 patients also had glomerular C4d 
deposition and evidence of DSA. Graft loss in these patients with TG over 
almost 2 years of follow up occurred exclusively in the DSA +ve cohort (see 
Fig). Survival analysis of TG stratifi ed by DSA positivity trended toward 
statistical signifi cance (log-rank, p=0.067). 
Table 1: Relation of C4d Deposition to DSA in patients with Transplant 
Glomerulopathy
TG (n=15)
C4d: G-, PTC-, DSA-, pt (%) 5 (33.3)
C4d: G-, PTC-, DSA+, pt (%) 2 (13.3)
C4d: G+, PTC-, DSA-, pt (%) 2 (13.3)
C4d: G+, PTC-, DSA+, pt (%) 3 (20.0)
C4d: G+, PTC+, DSA+, pt (%) 3 (20.0)
Conclusions: Transplant glomerulopathy appears to be a heterogenous entity 
with regard to the pattern of C4d deposition (G versus PTC), the presence of 
DSA and the fi nal clinical outcome. In particular, patients with TG and DSA (in 
the absence of clinical and histological features of rejection) had an extremely 
poor prognosis. We suggest that patients with transplant glomerulopathy who 
also have DSA are at high risk of allograft failure. Interventions to suppress 
DSA production may be indicated in these patients, even in the absence of 
histological evidence of rejection.
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CLINICAL VALUE OF ROUTINE MONITORING OF 753 
HLA ANTIBODY AND URINE PROTEIN AFTER RENAL 
TRANSPLANTATION
H. Iwase1, T. Kobayashi2, A. Katayama2, S. Kohara3, T. Nagasaka3, 
N. Goto3, T. Ueki4, Y. Kodera1, K. Uchida3, A. Nakao1
1Nagoya University School of Medicine, Department of Surgery II, 2Nagoya 
University School of Medicine, Department of Applied Immunology, 3Nagoya 
Daini Red Cross Hospital, 4Masuko Memorial Hospital
Introduction: De novo production of HLA antibody has been reported 
to be associated with poor prognosis due to chronic antibody-mediated 
rejection. Although the practice of HLA antibody test has been advocated, no 
recommendations for follow-up monitoring have been determined yet, including 
how frequently, for what patients (all patients for screening or only patients 
with renal dysfunction), what kind of methods and how specifi cally (specifi city 
of HLA antibody should be identifi ed or not). Flow cytometry or luminex is a 
powerful tool for scrutiny test, but requires special equipment and considerable 
expense. The simple and costless assay for HLA antibody detection is ELISA. 
The test for urine protein which refl ects renal dysfunction is performed 
everywhere. The purpose of this study was to assess the clinical value of HLA 
antibody and urine protein monitoring after renal transplantation.
Methods: Total 297 serum samples were consecutively collected from renal 
transplant recipients in 2004 and 2006. Mean+/-SD in recipient age and period 
after transplantation were 44.7+/-11.6 and 8.3+/-6.5 years. All patients were 
treated with maintenance immunosuppressive therapy. Paired sera were tested 
for IgG antibody against HLA class I and II using ELISA (LAT-M). The status 
of HLA antibody before transplantation was evaluated by the clinical record or 
re-examined by fl ow cytometry (FlowPRA). Urine protein was determined to 
be positive when dipstick protein reaction was +/- or over, which was nearly 
compatible with a urine protein level of over 20mg/dL.
Results: 297 patients were divided according to the change of HLA Ab 
and urine protein status between 2004 and 2006. Patients with continuing 
positive urine protein test showed a signifi cantly higher serum creatinine level 
(2.13+/-1.31mg/dL) and deterioration over 2 years (&#8710;Cr: 0.36mg/dL). 
In contrast, patients with positive to negative or negative to positive urine 
protein test did not show any change of serum Cr. Only patients with de novo 
production, sustained detection of HLA antibody and continuous positive urine 
protein demonstrated signifi cantly higher creatinine (2.31+/-0.67mg/dL) and 
more marked deterioration over 2 years (&#8710;Cr: 1.26mg/dL). In contrast, 
patients with de novo production and sustained detection of HLA antibody, 
but with negative urine protein test did not show any deterioration of serum 
Cr. Furthermore, negative change of HLA antibody status clearly stopped the 
increase of serum Cr.
Conclusions: The positive change of HLA antibody and urine protein seems 
to precede the increase of serum Cr. As it usually takes years to progress from 
antibody production to irreversible renal dysfunction, a yearly routine HLA 
antibody test for all patients is recommended. Considering cost-benefi t and 
availability, ELISA is the screening test of choice. When both de novo HLA 
antibody and urine protein were detected, an attempt to reduce HLA antibody 
to undetectable levels would be encouraged.
CONCURRENT ORAL SESSION 58: 
ORGAN DONATION – PROGRESS AND CONTROVERSIES
DONATION PATTERNS IN 4 EUROPEAN COUNTRIES: 754 
DATA FROM THE DONOR ACTION DATABASE
L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
1Donor Action Foundation, 2Eurotransplant International Foundation
Study aims: To analyze heart-beating (HB) organ donation patterns in 4 
countries using the Donor Action (DA) Program nationally, and identify areas 
for improvement.
Materials: Retrospective Medical Record Review (MRR) of all Critical Care 
deaths between Jan. 2006 and Dec. 2007 (n=18,118) in hospitals in Belgium, 
Finland, France and Switzerland participating in DA’s Diagnostic Review 
process. Upper age limit for medical suitability: 75 years. Data were entered to 
the DA System Database for analysis.
Results: Of 6,561 patients (36.2% of all records) with no absolute contra-
indications to donation, 2,973 met pre-conditions for brain death (BD) 
diagnosis (45.3%), 2,063 had signs of severe brain damage and 1,891 
met criteria for formal BD diagnosis (=potential donors). Belgium had 
the highest number of patients with formal BD diagnosis (75.7%) and 
Switzerland (57.4%, P<.0001) the lowest. Although donor identifi cation 
rates were uppermost in France (93.6%) with the least in Finland (47.7%, 
P<.0001), Finland excelled in donor referral (93.9% of identifi ed cases) vs. 
only 63.8% in Switzerland (P<.0001), and excelled in family approach rates 
(92.7%) vs. only 70.2% in France (P<.0001). Consent rates as a% of families 
approached were superior in Belgium and Finland (89.5%) with the most 
inferior in France (65.7%, P<.0001). Conversion rates as a% of potential 
donors resulting in donation were higher in Finland (43.1%) and Belgium 
(42.9%) and signifi cantly lower in France (34.9%) and Switzerland (33.5%) 
(P=.0187). Only Belgium had a non-heart-beating donation policy during 
the study period, resulting in an addition of 11.2% donors to the country’s 
donor pool.
Conclusions: The DA MRR proved to be an excellent tool to identify areas 
of improvement within certain steps of the donation pathway, such as donor 
identifi cation, BD diagnosis, donor referral, family approach and obtaining 
consent. Moreover, DA’s MRR has shown to be applicable in different countries 
and environments and should be considered as a unique tool to measure and 
compare countries’ donation performance. 
LIVING LIVER DONATION: A QUESTION OF 755 
CREDIBILITY
B. Ringe1, R. Strong2
1Drexel University College of Medicine, 2University of Queensland
Living donor liver transplantation (LDLTx) is based on an act of altruism, 
eventually turning a healthy volunteer into a patient. Informed consent is a 
prerequisite for the candidate donor’s decision. Despite the fact that donor 
safety is universally mentioned to be of prime importance, reliable data on 
donor complications is not available – due to under-reporting, duplicate 
reporting or false information. This is an update on living liver donor mortality, 
to serve as an easy source of reference. 
The authors reviewed the medical literature since 1989. To verify the accuracy 
and source of information a certainty (C) level was assigned to each case: C1, 
direct report by member representing the transplant program where the fatality 
occurred; C2, indirect publication by author not involved in the care; and C3, 
information based on verbal presentation or personal communication. 
This update identifi ed a total of thirty-three living liver donor deaths. Eight 
fatalities each occurred in Europe and North America, fi ve in South America, 
ten in Asia, and two in Africa. Only 12 cases (36%) were classifi ed as C1: donor 
death directly reported by the transplant program involved. 64% of living liver 
donor deaths mentioned or referred to in the transplant community were left 
to speculation, including eight C2 and 13 C3 cases. Possible risk factors for 
poor outcome are: preoperative medical conditions, psychosocial behavioural 
abnormalities, right lobe donation, and postoperative surgical complications. 
Based on an estimate of over 15,000 LDLTx performed worldwide, the 
mortality rate is ranging from 0.08 to 0.22%. 
Why is this information important? As long as LDLTx continues to play a 
role for patients without access to deceased donor livers, i.e. in certain 
geographic areas or with low MELD scores, it is unacceptable that the risk of 
this procedure remains unclear. Short term, as well as long term outcomes of 
all living donors need to be documented, including complications, abandoned 
surgeries and mortality. As emphasized by the current and previous surveys, 
the discrepancy between published and unpublished donor deaths has not 
changed, and the dilemma of rumor versus facts prevails. All transplant 
centers should be encouraged to report their own complications. It may appear 
that the transplant community is not excited about these news, however, in 
order to maintain informed consent and confi dence in LDLTx it is imperative 
that everyone knows the facts. If concerns for liability would be the reason 
not to publish poor outcomes – how can we expect innovative techniques 
in transplant surgery to be implemented in our clinical practice? This is a 
question of credibility.
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SUSTAINED IMPACT OF THE DONOR ACTION 756 
METHODOLOGY ON DONATION PRACTICES: A 7-YEAR 
FOLLOW-UP IN 4 EUROPEAN COUNTRIES
L. Roels1, C. Spaight1, J. Smits2, B. Cohen1
1Donor Action Foundation, 2Eurotransplant International Foundation
Background: The Donor Action (DA) program offers Critical Care Units 
(CCUs) all the necessary tools to optimize their donation processes, including 
a standardized Medical Record Review (MRR) method and suggestions for 
tailor-made improvement measures. This study aimed to measure the long-
term impact of the implementation of the DA program in 4 European countries 
(Finland, France, Poland, and Switzerland) where the program was piloted and 
gradually implemented over a period of 7 years.
Methods: A total of 21,561 medical records from patients who had died between 
Jan. 2000 and Dec. 2001 (n=2,782, pre-intervention phase) and between Jan. 
2002 and Nov. 2006 (n=18,779, post-intervention phase) were collected from 
81 hospitals (281 CCUs) and entered to the DA Database for analysis.
Results: 9,912 ventilated patients aged <81 years were reported to have no 
absolute contraindications to donation on admission according to international 
standard exclusion criteria. Although the% of patients with no contraindications 
(theoretical potential) decreased from 51% in 2000-01 to 48.8% in 2006, the 
identifi ed/potential donor rate increased from 15.3% in 2000-01 to 31.7% in 
2006 (+16.4%, P<.0001). Referral/identifi cation rates increased from 88.5 to 
97.3% (+8.8%). Whereas consent/family approach rates decreased from 77.9% 
in 2000-01 to 66% in 2006, overall conversion rates of potential to actual donors 
increased from 9.8% to 15.7% (+5.9%, P<.0001) because of signifi cantly 
improved identifi cation and referral rates. The% of actual donors/total number 
of deaths increased from 5.0% in 2000-01 to 7.6% in 2006 (+2.6%, P<.0001).
Conclusion: Whereas in the past the DA approach has proven to signifi cantly 
increase immediate post-intervention donation rates, the data presented 
here demonstrates how this program’s sustained impact on donation rates is 
the result of improved clinical practices within certain steps of the donation 
pathway. Further efforts to increase consent rates will be needed to optimize 
the conversion of potential to actual donors.
PAIRED AND ALTRUISTIC LIVING KIDNEY DONATION 757 
IN THE UK: PAST, PRESENT AND FUTURE
R. Johnson1, C. Rudge1, J. Allen1, S. Fuggle1, A. Bradley2
1UK Transplant, Bristol, UK, 2Dept of Surgery, University of Cambridge, 
Cambridge, UK
Paired and altruistic living kidney donation became possible in the UK from 
September 2006 following the introduction of a new legal framework for organ 
and tissue donation. The regulatory authority for these types of transplant 
resides with the Human Tissue Authority and national allocation schemes 
have been established through UK Transplant which has responsibility for 
overseeing matching and allocation arrangements. 
Kidneys from altruistic, non-directed donors are allocated through the national 
scheme for kidneys from donors after brain death (DBD) and since September 
2006, 5 altruistic living donor transplants have been performed.
For paired donation, a new matching algorithm was developed. Initially, all 
potential two-way exchanges are identifi ed and possible exchanges are then 
prioritised according to a points scoring system based on four factors: geographical 
proximity between pairs (max 20 points), HLA sensitisation level of potential 
recipient (max 50 points), HLA mismatch of potential transplant (max 15 points) 
and, acting as a tie-breaker, donor-donor age difference (max 3 points). 
The fi rst pairs were registered in December 2006 and the fi rst of a regular series 
of three-monthly “matching runs” undertaken. The fi rst two matching runs 
were performed in April 2007 and July 2007, when 9 and 26 pairs respectively 
had been registered. Each matching run identifi ed one possible match between 
two donor-recipient pairs. The four transplants proceeded successfully, with 
kidneys, rather than donors, travelling between centres. A third matching run 
in October 2007 identifi ed no matches among 32 listed pairs, but in January 
2008, three possible matches among 66 pairs were identifi ed and two of the 
exchanges are set to proceed.
The scheme has identifi ed fewer matches than expected on the basis of 
simulation studies that were undertaken when planning the scheme using 
data on incompatible pairs identifi ed in the UK in 2004-05. Unfortunately the 
composition of the paired donation list has been less favourable than expected. 
Of the 66 pairs listed in January 2008, 26 were ABO incompatible (ABOi), 
33 were HLA incompatible (HLAi) and 7 were both HLAi and ABOi. Among 
the ABOi pairs, there were 21 A donor, O recipient combinations, and no O 
donor, A/AB HLA incompatible recipient pairs listed, thus making a match 
impossible. Among HLAi pairs, the average level of recipient sensitisation 
(calculated by comparing each patient’s unacceptable antigens with HLA types 
of all blood group identical donors within a pool of 10,000 UK donors) was 
very high at 82%, with 19 of the 40 pairs having a sensitisation level ≥95%.
In order to increase the transplant rate through paired donation in the UK, it 
has been agreed that both 2 and 3-way exchanges will be considered in the 
future. In addition, a protocol for domino paired donation is being developed 
whereby altruistic non-directed donors will, where possible, donate to the 
paired donation list to start a chain of additional transplants rather than donating 
directly to recipients on the deceased donor transplant waiting list.
AMOUNT OF ANTIBODY, AS EXPRESSED BY 758 
FLUORESCENCE INTENSITY, DOES NOT CORRELATE NOR 
IS PREDICTIVE OF CROSSMATCH OUTCOME
R. Kerman, S. Katz, J. Lappin, E. McKissick, K. Hosek, N. Acorda, 
B. Kahan, C. Van Buren
The University of Texas Medical School-Houston
UNOS has replaced panel reactive antibody (PRA) with a calculated PRA 
(CPRA). The CPRA should result in a more standardized defi nition of patient 
sensitization. Each transplant center can set criteria for indentifying and listing 
unacceptable antigens either based upon the amount of antibody (Ab) measured 
by the titer of donor specifi c HLA antibodies, DSA, or the fl uorescence 
intensity (FI) of the donor specifi c single antigen bead. It is unclear whether 
Abs indentifi ed by sensitive single antigen bead and solid phase assays (Flow 
PRA and Luminex) correlate with and are predictive of a clinically relevant 
end-point (a + FCXM).
We evaluated the PRA, DSA, bead specifi c Ag FI and FCXM reactivity of pre-
transplant (pre-Tx) sera from 219 recipients of a deceased donor renal allograft 
to determine whether amount of Ab (measured by FI) predicts a (+) FCXM.
Patients with a (+) DSA, a (+) FCXM and pre-Tx class I PRA 80% (N = 103, 
mean PRA of 91 6%) when compared to patients with pre-Tx PRA < 80% (N = 
58, mean PRA 53 21%) had comparable mean FIs (7,407 4,305 vs 7,483 5,380), 
FI ranges (1,000 20,243 vs 1,552 17,153) and median FIs (5,681 vs 5,670). The 
class II comparisons were of the same pattern. Surprisingly, patients with a 
(+) DSA, a (-) FCXM and pre-Tx class I PRA 80% (N = 22, mean 90 6%) 
compared to patients with pre-Tx PRA < 80% (N = 36, mean PRA 50 18%) had 
comparable mean FIs (6,758 4,841 vs 6,412 3,844), FI ranges (1,656 16,596 
vs 2,162 11,637) and median FIs (5,924 vs 5,627). Again, the class II PRA 
comparisons were of the same pattern. Of great interest is that the mean FI, FI 
range and median FI of DSA (+)/FCXM (+) and DSA (+)/FCXM (-) are not 
statistically different. 
Because the mean FIs, FI ranges and median FIs of patients who are DSA (+) 
and either FCXM (+) or (-) are not statistically different from each other the 
amount of antibody (expressed as FI) can not be used to predict a (+) FCXM. 
Other factors such as Ab avidity for the antigen epitope and consideration of 
cross reactive Abs may contribute to predicting crossmatch outcome. Therefore, 
since FI is not predictive of crossmatch results it should not be an acceptable 
criteria for identifying clinically relevant donor specifi c HLA Abs or used for 
listing unacceptable antigens as they relate to donor allocation schemes.
VOLUME-OUTCOME RELATIONSHIP IN THE 759 
PROCUREMENT OF TRANSPLANTABLE ORGANS
J. Scalea MD1, J. Miller2, C. Alexander2, B. Philosophe MD1, R. Barth MD1, 
S. Bartlett MD1, M. Cooper MD1
1University of Maryland Medical Center Dept. of Surgery, Baltimore, MD 
United States 2Living Legacy Foundation of Maryland, Baltimore, MD United 
States
Background: Every year the numbers that die waiting for a transplant 
continues to increase. Efforts at increasing the number of transplantable organs 
have received international attention. Donor management protocols have been 
developed and validated. An outcome advantage may exist if procurement 
occurs at major transplant centers with staff dedicated to critical care ensuring 
organ optimization and function.
Methods: Retrospective review of the transplant registry in a single OPO was 
completed for a 12 month period. The cause of death (COD), conversion rate 
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and number of organs transplanted per donor (OTPD) based upon referral center 
was calculated. Two high-volume (HV), urban, academic transplant centers at 
which the majority of donations occurred were compared to remaining centers 
(LV). Student’s T-test was utilized to demonstrate signifi cance. 
Results: 120 donors yielded a total of 349 abdominal and thoracic organs. 
Mean donor age was 41.2 yrs and 71.6% were male. COD was more likely 
to be due to trauma at HV centers vs. LV (24 v 10), whereas CVA and CV 
causes of death were more common at LV hospitals (20 v 10). Conversion rates 
in HV centers v LV were 68% and 47% (p<0.001) The number of potential 
donors that resulted in transplantable organs was higher (57/61) at HV centers 
than at LV centers (53/61). Total number of organs transplanted from donors 
at HV centers was also higher, 78.5% v. 65.4% at LV institutions. HV centers 
yielded 3.40 OTPD compared to 2.41 at LV institutions (p=0.007). Eliminating 
donors without transplantable organs from analysis, the OTPD was 3.64 for 
HV centers and 2.84 for LV (p=0.02). Mean cold ischemia time (CIT) for livers 
donated at HV centers was 6.25 hours (0.5-11.1) and 7.27 hours (4.9-11.9) at 
LV centers (p=0.36). Mean CIT for kidneys was 13.82 at HV centers and 16.65 
hours at LV institutions (p=0.13). 
Conclusions: High volume transplant centers had an increased number of total 
donors, an increased number of OTPD, and higher percentage of procured 
organs that result in transplantation. Cold ischemia times are shorter for liver 
and kidneys; however, these did not reach statistical signifi cance. Intensive 
care capabilities and the level of critical care training available in the donor 
institution may be partially explanatory. The location of potential donor 
management may impact upon donor numbers and organs from those donors 
prompting consideration for transfer to HV centers.
INCREASING ORGAN DONATION FROM THE 760 
EMERGENCY DEPARTMENT: A PRECIOUS RESOURCE 
WASTED!
P. Aubrey1,2, S. Arber2, J. Richardson1, S. Lister1, M. Tyler1, T. Tymkewycz1, 
M. O’Brien1, R. Evans1
1North Thames Donor Transplant Coordinators, 2Department of Sociology, 
University of Surrey, Guildford
Background: The worldwide critical shortage of donor organs commands 
that we do not have the margin to waste or ignore any department that has a 
potential to supply organs for the purpose of transplantation. The majority of 
organ donors are referred from the intensive care unit. This paper reports on 
the fi ndings of an audit of deaths undertaken in ten Emergency Departments 
in North Thames Region. The audit itself was borne out of informal anecdotal 
accounts from medical and nursing colleagues working in the Emergency 
Department who suggested that there was a potential pool of organ donors 
that were not being realised. The audit led to an educational programme for 
Emergency Department staff
Method: Between October 2004 and December 2005 a retrospective audit of 
deaths was undertaken within ten Emergency Departments. The audit fi ndings 
provided a basis to develop an education programme in each Emergency 
Department within the region. This involved assessing the educational needs of 
Emergency Department nursing and medical staff, and developing instructive 
programmes aimed at helping key clinicians to identify potential donors.
Results: The Audit identifi ed twenty potential organ donors from within 
the ten departments. If these numbers were to be replicated over the thirty 
one Emergency Departments, this would suggest as many as two potential 
donors annually from each one. The educational programme for Emergency 
Department staff resulted in a dramatic increase in the number of referrals from 
North Thames Emergency Departments. 
In 2003, there were 8 donor referrals, one donor and 3 solid organ transplants, 
while in 2006 there were 24 donor referrals, 14 donors and 45 solid organ 
transplants. 
Summary: It is becoming increasingly clear that in order to address the current 
shortage of organ donation, it is necessary to develop sound collaborative, multi 
disciplinary educational developmental strategies in this area. Organ Donor 
Transplant Coordinators play a fundamental role in ensuring all Emergency 
Departments are delivered an effi cient and effective organ donation education 
programme.
HEALTH STATUS AND RENAL FUNCTION EVALUATION 761 
OF KIDNEY VENDERS: A REPORT FROM PAKISTAN
A. Naqvi, A. Rizvi, M.N. Zafar, E. Ahmed, B. Ali, K. Mehmood, B. Mubarak, 
F. Mazhar
Sindh Institute of Urology And Transplantation
Introduction: Limited dialysis facilities and lack of cadaveric transplant 
activity has lead to proliferation of unrelated commercial transplantation in 
developing countries. Criteria for selecting unrelated donor may be less 
stringent due to commercial interest. This may put donors at higher risk of 
renal and cardiovascular disease. The main objective is to study health status 
and renal function of kidney venders.
Patients and Methods
This study on 104 venders reports demographics, history, physical and 
systemic examination, ultrasound fi ndings, renal and liver function and GFR 
by Cockcroft-gault. Results were compared with 184 age, sex and nephrectomy 
duration matched living related donors controls.
Results: Comparison of venders vs controls showed mean age of 30.55±8.1 
vs 30.65±7.85 (p=0.91) years, M:F of 4.5:1 vs 4.2:1 and nephrectomy period 
of 33.89±30 vs 32.01±29.71 (p=0.60) months respectively. Of the venders 
67% were bonded labourers earning <50$/month as compared to controls 
where 68% were skilled labourers and self employed earning >100$/month. 
History of venders revealed jaundice in 8%, stone disease in 2% and urinary 
tract symptoms in 4.8%. Post nephrectomy fi ndings between venders vs 
donors showed BMI of 21.02±2.8 vs 23.02±4.2 (p=0.0001), hypertension in 
17% vs 9.2% (p=0.04), serum creatinine (mg/dl) of 1.17±0.21 vs 1.02±0.27 
(p=0.0001), GFR (ml/min) of 70.94±14.2 vs 95.4±20.44 (p=0.0001), urine 
Protein/Creatinine of 0.150±0.109 vs 0.10±0.10 (p=0.0001), hepatitis C 
positivity in 27% vs 1.0% (p=0.0001) and Hepatitis B positive 5.7% vs 0.5% 
(p=0.04) respectively. 
Conclusion: In conclusion, venders had compromised renal function suggesting 
inferior selection and high risk for developing chronic kidney disease in long 
term.
OUTCOMES OF PATIENTS SEEKING COMMERCIAL 762 
RENAL ALLOGRAFT TRANSPLANTATION OUTSIDE OF 
AUSTRALIA
L. Garry, J. Mawson, S. Chadban, C. George, R. Allen, J. Eris, D. Verran
Renal Transplant Programme
Introduction: Organ traffi cking continues to be an issue for the transplant 
community. Here we report on our experience with patients from within our 
transplant service area who sought transplantation overseas.
Methods: Record review of 11 patients with end stage renal failure who have 
sought commercial renal transplantation from 1/2001-2/2008.
Results: Demographics of the 11 patients were 9 male, 2 female with a median 
age of 49(28-71) years. Causes of end stage renal failure were predominantly 
glomuerulonephritis (7/11). To date 10 have been transplanted and one 
was presumably transplanted but did not return from overseas (presumed 
deceased). Countries where the renal allografts were purchased are- China 6, 
Phillipines 3, Pakistan 1. Source of the donor was presumed deceased donor in 
6 and live donor in 5. Information on donor demographics and peritransplant 
course were unavailable or limited in most cases. Outcomes to date include 
patient mortality-3/11(27%) from sepsis 1(pneumocystis pneumonia), 
tumour 1(glomus tumour), unknown 1, and allograft loss in 1. Post transplant 
complications requiring management on return of patients to Australia included-
sepsis in 5 recipients (1 nocardia & cytomegalovirus, 1 cytomegalovirus, 1 
cytomegalovirus & pneumocytis, 1 BK nephropathy, 1 aquisition of Hepatitis 
B), major ureteric stricture requiring surgery 1, angioplasty transplant renal 
artery 1. One patient has been followed for a kink of the transplant renal artery 
[stable on serial imaging].
Conclusions: A small but steady number of patients, continue to seek and 
purchase renal allografts outside of Australia against advice. This activity is 
associated with a heightened morbidity and mortality rate for the recipient, 
which physicians involved in the subsequent management of such patients 
need to be aware of. The cessation of such activity would not only protect 
donors but may be of benefi t to recipients.
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CONCURRENT ORAL SESSION 59: 
ISLET TRANSPLANTATION – ALTERNATIVE STRATEGIES
EFFECT OF NF-FÈB INHIBITON BY DHMEQ ON ISLET 763 
TRANPLANTATION IN MICE
M. Watanabe1, K. Yamashita1, S. Matsumoto1, Y. Tsuruga1, T. Takahashi1, T. 
Oura1, M. Ozaki1, K. Umezawa2, M. Matsushita1, S. Todo1
1First Department of Surgery, Hokkaido University, Sapporo, Japan, 
2Department of Applied Chemistry, Keio University, Yokohama, Japan
Background: The transcription factor, nuclear factor (NF)-κB has been shown 
to be involved in immediate islet graft loss by both non-immune-mediated 
infl ammatory and allo-immune responses. In order to attain a successful long-
term engraftment, control of these responses is essential.
Aim: We examined the effect of a newly developed NF-κB inhibitor, 
dehydroxymethylepoxyquinomicin (DHMEQ) in mice islet transplantation 
(ITx).
Methods: Pancreatic islets of C57BL/6J (H-2b: syngeneic) or BALB/c (H-2d: 
allogeneic) mice were isolated, purifi ed and handpicked (1 IEQ=150 μm). 
C57BL/6J recipient mice were rendered diabetic by streptozotocin (180 mg/
kg, i.p.). In the allogeneic ITx, either 600 or 300 islets were transplanted via 
portal vein. Syngeneic 175 islets were transplanted as a marginal ITx model. 
DHMEQ at a dose of 20 mg/kg was given i.p. once or twice daily for 14 days 
after transplantation. Blood glucose levels (BGL) were monitored. Rejection 
was considered when BGL exceeded 350 mg/dl for 2 consecutive time points. 
Normoglycemia was defi ned when BGL became less than 200 mg/dl for 2 
consecutive days.
Results: In the 600 islet allogeneic transplantation model, vehicle treated 
control mice rejected allografts at a median survival time (MST) of 11 
days (Fig. 1A). In contrast, daily and twice daily treatment with DHMEQ 
signifi cantly prolonged graft MST to 21 and >30 days (still surviving), 
respectively (p<0.001 versus Control). Such effect was associated with 
suppression of donor-antigen IFN-γ producing splenocytes and graft cellular 
infi ltration as examined on POD 9. 
We then examined the effect of NF-κB inhibition on allogeneic ITx with reduced 
istlet graft numbers. In the ITx model with 300 allogeneic islets, control grafts 
did not survive at all, and the normoglycemic rate (NGR) was 0% (n=6). On 
the other hand, once daily treatment with DHMEQ allowed a successful islet 
engraftment (NGR: 100%) in all animals (n=6), and signifi cantly prolonged 
allograft MST to13 days (P<0.05).
In the syngeneic marginal ITx model, the NGR after transplantation 14.3% in 
the control animals (Fig. 1B), whereas that of DHMEQ treated (once daily) 
mice was signifi cantly attenuated to 80% (n=6; p<0.01). Animals treated with 
DHMEQ showed normal response, while control animals exhibited higher 
BGL to the intraperitoneal glucose tolerance test which was performed at 14 
days post-ITx. 
 Fig. 1A  Fig. 1B
Conclusion: A novel NF-κB inhibitor, DHMEQ prevented immediate islet graft 
loss and prolonged islet allograft survival. With having both anti-infl ammatory 
and immunosuppressive properties, inhibition of NF-κB activation by DHMEQ 
may become a new modality in ITx.
PPAR GAMMA MEDIATES THE PROTECTIVE EFFECTS 764 
OF CARBON MONOXIDE IN ISLET TRANSPLANTATION
F. Rocuts, X. Zhang, F. Bach, H. Wang
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard 
Medical School
Purpose: Exposing donor mice to carbon monoxide (CO) protects transplanted 
islets from allogeneic immune rejection. We evaluated whether CO exerts its 
protective effects by activating peroxisome proliferator-activated receptor 
gamma (PPARg) in islets.
Methods: BABL/c islets were transplanted into C57BL/6 recipients rendered 
diabetic by strepotozotocin injection (225mg/kg, i.p.). PPARg activation was 
induced in islets by intravenously injecting the donor mice with two different 
kinds of PPARg agonists, 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2, 0.3mg/
kg) and troglitazone (2mg/kg), respectively, 1 hour before islet isolation. 
PPARg antagonist, 2-Chloro-5-nitro-N-phenylbenzamide (GW9662, 1mg/kg), 
was used to block the activation of PPARg. Control animals received vehicle 
only (2% DMSO). PPARg expression was detected by Western blot using 
an anti-PPARg antibody. Cell apoptosis was quantifi ed by fl ow cytometry. 
Expressions of TNF-a and inducible nitric oxide synthase (iNOS) at mRNA 
level were analyzed by real-time RT-PCR. 
Results: Administering CO to the donor induced expression of PPARg, which 
was observed rapidly after harvest and purifi cation of the islets. Pre-exposure 
an insulinoma cell line, bTC3 cells, to CO protected those cells from cytokines 
(IL-1b plus INF-g)-induced apoptosis. Suppressing PPARg activation using 
GW9662 abrogated the anti-apoptotic effect of CO by boosting expressions 
of TNF-a and iNOS. Islets from vehicle-treated donors were rejected in 17.8 ± 
4.4 days (n=5). Blocking PPARg activation in islets with GW9662 led to graft 
rejection at 18.2 ± 3.5 days (n=3). In contrast, inducing PPARg activation with 
15d-PGJ2 led to 3 of 4 (75%) grafts surviving >273 days in the recipients, the 
other graft was rejected at 19 days. Similarly, administering troglitazone to islet 
donors led to 50% of islet allograft (n=4) surviving long-term (>199 days) in 
recipient mice. 
Conclusion: Our results indicate that PPARg activation in the donor protects 
islet allografts from immune rejection after transplantation. CO exerts its 
protective effects at least in part by up-regulating PPARg.
A SIGNIFICANT CORRELATION OF DONOR PANCREAS 765 
GENE EXPRESSION MORPHOLOGY WITH AND ISLET 
FUNCTION
O. Sabek1, L. Truong2, L. Peterson3, D. Fraga1, A. Gaber1
1Weill Medical College of Cornell, Deparatment of Surgery, The Methodist 
Hospital, Houston, TX, 2Department of Pathology,The Methodist Hospital, 
Houston, TX, 3Department of Public Health,The Methodist Hospital, Houston, 
TX
Background: Enlarging the donor pool is severely limited, mainly because of 
the poor function and high incidence of primary non-function of islets from 
less than ideal donors. This study is aimed at identifying the morphological, 
histopathological and the gene expression characteristics of the donor pancreas 
as predictor for the outcome of human islet in- vivo function. 
Methods: Islets were isolated from 39 human donor pancreata, and islet yield 
was reported as islet equivalent per gram pancreatic tissue. In-vivo function of 
islets from 39 isolations were further tested by transplantation into NOD-SCID 
mice following short-term culture (<6 days). Biopsies from the 39 human 
pancreata were obtained from the head section. Paraffi n embedded sections 
were evaluated after staining with H E, Trichome, Congo, and PAS. Correlation 
between in vivo function (y/n) and BMI and positive histology (adipose tissue, 
islet hypertrophy or hyperplasia) was done using Somers D tests for N=39 
Pancreata. We also examined the gene expression of 5 of the pancreata using 
high-density Affymetrix U133A Gene Chips® and Genespring software. 
Results: Morphological characteristics such as the content of acinar and 
interstitial adipose cells, islet hyperplasia, and islet hypertrophy per defi ned 
area were found to have a signifi cant reduction in in-vivo function (p= 0.003), 
whereas BMI was not signifi cant (p=0.44). Furthermore, in these isolation 
Long cold ischemia was the only donor characteristic that correlated with a 
signifi cant reduction of in vivo function (Z=-1.95, p=0.011). Gene analysis of 
Pancreata that yield non-function islets (3 out of 5) showed high relative levels 
of expression of pro-infl ammatory genes such as interleukin-1, toll-like receptor 
4, T-cell activation NFKB-like protein1, as well as genes that is associated with 
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insulin resistance such as SOCS-1 and 6 and nuclear factor of activated T-cells, 
cytoplasmic (NFAT), calcineurin-dependent 1 and 2. 
Conclusion: Morphological and Gene expression study of donor pancreata 
can be very instrumental in predicting in vivo function in optimal and non-
optimal donor selection. The over-expression of pro-infl ammatory and insulin 
resistance related genes may results in reduced insulin secretion and lead to 
islet destruction post-transplantation. Identifying and validating those genes 
could allow the development of a potency assay for human transplantation 
that would be very useful for screening human Pancreata before islet isolation 
and clinical transplant and the possibilities of devising strategies for early 
intervention to reverse the adverse effect of infl ammation and ischemia on 
the islet.
THE IMPORTANCE OF TRYPTIC-LIKE ACTIVITIES FOR 766 
HUMAN ISLET ISOLATION
D. Brandhorst, H. Brandhorst, O. Korsgren
Uppsala University Hospital – Department of Clinical Immunology
Objective: The insuffi cient characterization of the enzymes and the low 
standardization of the enzymatic pancreas dissociation is exemplarily 
illustrated by the diffi culties that are associated with actual efforts to replace 
Liberase HI by Serva collagenase NB1. Although Liberase HI seems to differ 
from collagenase NB1 only with regard to thermolysin, that is replaced in 
collagenase NB1 by neutral protease (NP), this seemingly minor change in the 
protocol has caused major problems worldwide in terms of isolation outcome 
and number of islet transplants performed worldwide. We hypothesize that 
beside collagenase and NP/thermolysin a third enzyme may be required for 
optimized islet release. The main objective of the present study was therefore 
to characterize the importance of neutral protease, thermolysin and tryptic-like 
activities for successful human islet isolation.
Materials and Methods: Crude collagenase was chromatographically purifi ed 
to obtain a blend consisting of Serva collagenase NB1 and different amounts 
of tryptic-like activities. Tryptic-like activities (BAEE-U) were expressed as 
the percentage of administrated collagenase activities (PZ-U). To evaluate 
the effect of proteolytic activities, Blendzyme (Roche) was supplemented 
with appropriate amounts of NP or thermolysin adjusted according to pilot 
experiments. Rat and human research grade pancreata were processed with 
current standard procedures.
Results: No signifi cant differences were observed between the supplementation 
of Blendzyme by NP or thermolysin regarding digestion time (25.5 ± 1.9 vs 
28.5 ± 2.3 min), percentage of undigested tissue (15 ± 1 vs 22 ± 7%), purity 
(53 ± 4 vs 55 ± 10%), islet equivalent number (IE) per gram (3660 ± 500 
vs 2750 ± 1220 IE/g) and stimulation index (SI) (6.2 ± 0.1 vs 7.3 ± 0.8). 
Tryptic-like activities for the digestion of human pancreata were adjusted 
to 3 and 10% relative activity (BAEE-U/20 PZ-U/g) after performing pilot 
experiments in rats suggesting that enhanced tryptic-like activities resulted 
in an enormous acceleration of islet release from exocrine tissue without 
affecting signifi cantly rat islet yield, viability and posttransplant function in 
diabetic nude mice.
Digestion time of human pancreata was signifi cantly reduced by 25% 
increasing relative tryptic-like activities from 3 to 10% (25 ± 0.8 vs 20 ± 1.5 
min, p<0.01). The amount of embedded islets was reduced from 17 ± 4 to 11 ± 
3% (NS) whereas islet yield (3840 ± 440 vs 4930 ± 290 IE/g, NS) and recovery 
after purifi cation (65 ± 6 vs 86 ± 5%, p<0.05) was enhanced. The percentage 
of undigested tissue as well as islet purity were not infl uenced by increased 
tryptic-like activities. Quality assessment of human islets revealed no reduction 
of viability (99.9 ± 0.1 vs 95.3 ± 3.6%) or stimulation index (3.3 ± 0.6 vs 4.1 
± 0.8).
Conclusions: Our preliminary experiments in human and rat pancreata 
indicate that the presence of tryptic-like activities accelerates islet release 
from acinar tissue reducing islet exposure to the harmful environment present 
during pancreas digestion. Moreover, tryptic-like activities help to reduced the 
detrimental effect of increased NP activity.
EFFECT OF TRANSPORTATION ON HUMAN ISLETS767 
E. Jimenez-Vera1, L. Mariana2, L. Willia1, T. Kay3, P.T. Coates3, 
P.J O’Connell1, T. Loudovaris2, W.J Hawthorne1
1The Centre For Transplant And Renal Research, Westmead Millennium 
Institute, 2St Vincent’s Institute, 41Victoria Pde, Fitzroy, 3065, Victoria, 3South 
Australian
Introduction: Islet transplantation is a promising treatment for type 1 diabetes. 
The limited availability of cadaveric human donor pancreata and the need to 
concentrate expertise limits islet isolation to a few dedicated isolation centres. 
In Australia this means that transportation of islets between institutions over 
large distances is essential to provide a nation wide service. The aim of this 
study was to assess the effects of transport on human islets between interstate 
centres. A number of factors including quantity and quality of the islets prior to 
and following transport were analysed.
Methods: Human islets were isolated using a modifi ed Ricordi technique using 
collagenase digestion and fi coll purifi cation. Following culture, islets were 
transported to the receiving centre by air and road, up to 48 hours post isolation. 
The islets were sent at ambient temperature or slightly chilled with refrigerated 
gel packs in 50-ml conical tubes and placed in a Styrofoam shipping box and 
were received within 12 hours of being packed. Quality assessments were 
performed at each centre at approximately the same time. The total number 
(IEQs) and purity were determined, and fl ow cytometry was performed to 
establish viability and the percentage of B cells in each shipped preparation. 
Results: There was a signifi cant exponential decay mean decrease 32.38% in 
the number of IEQs after transportation. There was also a 68.86% increase in 
the total number of dead cells which correlated with the decrease in the total 
cell number. However, there was a 37.49% increase in the number of viable 
B Cells with no signifi cant difference in the number of B cells sent. This was 
also refl ected in the viability index remaining the same despite the loss of total 
cell number.
Conclusion: Transportation of human islets to different sites in Australia 
results in a decrease in the number of IEQs and viability. Factors responsible 
include loss due to shipment time or conditions or injury sustained from organ 
ischaemic time and the islet isolation process. Further studies to investigate the 
numbers of variables that can lead to cell loss from transporting human islets 
need to be assessed.
PREVENTION OF ISLET ALLOGARFTS BY CO-768 
TRANSPLANTED HEPATIC STELLATE CELLS IS MEDIATED 
BY TREG CELL LOCAL EXPANSION
H-R. Yang1, G. Jiang2, L. Wang1, J. Fung1, L. Lu1,2, S. Qian1,2
1Department of General Surgery, Cleveland Clinic, 2Department of 
Immuology, Lerner Research Institute, Cleveland Clinic
Transplantation of solid organs has successfully practiced in clinic for 
decades, but the outcome of cell transplantation remains disappointing. 
This is the case in experimental models. Thus, liver transplants in mice are 
spontaneously accepted without the requirement of immunosuppression, 
but hepatocyte grafts in the same combination are acutely rejection. These 
observations suggest that non-parenchymal components may play a crucial 
role in attenuation of anti-graft immune response. We have demonstrated a 
profound T cell inhibitory activity of hepatic stellate cells (HpSC) in vitro, 
as well as in vivo. Thus, co-transplant with HpSC effectively protects islet 
allografts from rejection. To investigate the involved mechanisms, BALB/c 
islets (300) mixed with 3 x 105 activated HpSC (B6) were transplanted into 
STZ-induced diabetic B6 recipients. T cells were isolated from grafts and 
lymphoid organs. On POD 8, a reduction of graft infi ltrating CD4+ (30.7%) 
and CD8+ T cells (31.3%) was seen in HpSC co-transplants, as compared 
to islet alone. CD8+ T cells dropped &#61566;7 fold on POD 140, while, 
CD4+/CD8+ ratio was increased from 0.5 on POD 8 to 2.0 on POD 140. 
As to CD4+ T cells, co-transplant of HpSC was associated with a marked 
expansion of Foxp3+ cell populations predominantly in grafts (41.2% vs. 
25% in islet alone) and draining lymph nodes (LN) (35.1% vs. 15.4%), 
compared to that in spleen (32.3% vs. 25.6%) and peripheral LN (27.1% 
vs. 15.6%). The in creased incidence of Foxp3+ cells was seen on POD 12, 
but returned to control levels in long-survival animals. Interestingly, about 
40-50% of these Foxp3+ cells were CD25-. These results suggest that co-
transplanted HpSC foster markedly expansion of Treg cells in grafts and 
draining LN. To examine this in vitro, activated HpSC were cultured with 
allogeneic CD4+ T cells at 1:10 ratio for 5 days, which elicited generation of 
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CD4+CD25+FoxP3+ cells (13% vs. 5.5% in controls), with very few CD25-
Foxp3+ cells, which was different from what was seen in vivo. Addition 
of HpSC expanded CD4+CD25+ cells into the culture of syngeneic CD4+ 
cells plus anti-CD3, resulted in marked inhibition of T cell proliferation in 
a dose dependent manner. A similar effect was seen in an allogeneic MLR 
culture. These FoxP3+ Tregs were expanded from na&iuml;ve CD4+CD25+ 
population in an IL-2 dependent manner, since depletion of CD4+CD25+ 
before co-culture only small potion of CD4+CD25+ T cells were generated, 
and all of these cells are Foxp3-. This was confi rmed by using purifi ed 
CD4+CD25+ T cells from Thy1.1+ congenic mice. In conclusion, co-
transplant with HpSC can effectively protect islet allografts from rejection, 
which could be mediated by expansion of CD4+CD25+FoxP3+ Treg cells in 
the grafts and draining LN.
REAL-TIME COMPREHENSIVE HUMAN ISLET 769 
ASSESSMENT IN VITRO USING FLUORESCENCE IMAGING 
AND MICROFLUIDIC PERIFUSION SYSTEM
Y. Wang, J. Mohammed, T. Harvat, M. Qi, S. Wang, M. Enza, E. David, 
J. Oberholzer
University of Ilinois At Chicago
Introduction and hypothesis: The Edmonton Protocol introduced in 2000 
provided an increased interest in human islet transplantation as a new 
promising treatment for Type I diabetes. Evaluation of islet quality pre-
transplantation is essential to ensure successful transplantation. However, 
it has been diffi cult to predict islet in vivo outcomes based on the current 
in vitro assays. In vivo evaluation using nude mice transplantation has only 
retrospective value. Lacking reliable in vitro assays is one of main factors 
for variable success rate. We hypothesize that simultaneously quantifying 
mitochondrial integrity, dynamic insulin secretion, oxygen consumption, 
and calcium infl ux during in vitro glucose stimulation will provide a 
comprehensive analysis with a meaningful predictive value superior to 
the individual assays. Our objective was to engineer a microfl uidic device 
to combine dynamic insulin secretion and fl uorescence image for islet 
functionality and viability that would allow for an accurate real-time analysis 
prior to transplantation.
Approach: Three-layer of Polydimethylsiloxane (PDMS)-type microfl uidic 
devices with single or multiple-chamber were designed and fabricated for 
simultaneous measurement of dynamic insulin secretion with digitized 
fl uorescence microfl uorometry for measuring calcium signaling and 
mitochondrial potentials.
Results: (1) In mice islet study, the device can be used for accurate detection 
of biphasic calcium signal and insulin secretion simultaneously without fl ow 
disturbance and has capability to image multiple-islets, unlike other designs 
in which only a single islet can be observed; When measuring mitochondrial 
potential, our results illustrate a physiological decrease in mitochondrial 
potential preceding the actual insulin secretion. (2) 8 human islet preparations 
have been assessed using the device and the in vivo results from nude mice 
were used as the benchmark for the human islet potency. Our preliminary 
results indicate that the multi-functional assessment can be used for 
assessment of human islet functionality and predict in vivo outcomes. High-
potency islet preps that reversed diabetes in nude mice had better glucose-
stimulated calcium fl ux and insulin secretion, as well showed a normal 
glucose dose dependant insulin secretion pattern, which was not observed in 
the low-potency preps which failed to reverse diabetes. Interestingly, there 
were no signifi cant difference in insulin secretion as measured in standard 
static glucose incubations between high-potency and low-potency group (SI 
of high-potency group=2.07+/-0.78, SI of low-potency group=2.58+/-1.45; 
P=0.532). 
Conclusion: It is essential to develop a defi ned, accurate, real-time assessment 
of beta-cell function based on beta-cell biochemical and metabolic signals that 
can be used as a solid indicator of functional islet preparations for transplantation. 
This microfl uidic device allows us to assess islet function and integrates insulin 
secretion with calcium infl ux and mitochondrial potential. We feel multiplexing 
previously encouraging results into an all-in-one islet characterization device 
will provide a complete and thorough analysis of islet function in an easy to use 
format that can be adopted by many islet transplantation facilities and solve this 
current clinical dilemma.
TREATMENT WITH EXENATIDE REDUCES CASPASE-3 770 
ACTIVATION AND APOPTOSIS AND ENHANCES BETA CELL 
SURVIVAL IN ISOLATED HUMAN ISLETS DURING CULTURE.
Z. Ao1, M. Meloche, E. Law, L. Dai, Z. He, D. Thompson3, G. Warnock, L. 
Marzban2
1Department of Surgery, University of British Columbia, Canada, 2Division 
of Pharmacology, Faculty of Pharmaceutical Sci, University of British 
Columbia, Canada, 3Department of Medicine, University of British Columbia, 
Canada
Clinical islet transplantation is a promising approach for treatment of type 1 
diabetes but is currently limited by loss of islets during both pre-transplant 
culture period and following transplantation. Exenatide is a long acting 
analogue of glucagon-like peptide-1 that has been shown to stimulate insulin 
secretion and enhance beta-cell mass but the underlying mechanisms are not 
fully understood. Exenatide has recently been approved as an anti-diabetic 
drug for treatment of patients with type 2 diabetes and may also enhance beta-
cell mass/function in islet grafts. In the present study, we sought to determine 
whether exenatide treatment could reduce loss of beta-cells and improve 
survival of human islets during pre-transplant culture period as a potential 
approach to increase the yield of islets isolated from pancreatic donors. Freshly 
isolated human islets from cadaveric donors were cultured in CMRL (5 mM 
glucose, 10% fetal bovine serum, 37C) at different time points (1, 3, 5, or 7 
days) in the presence or absence of exenatide (1 nM). At each time point, islets 
were fi xed in 4% paraformaldehyde and paraffi n-embedded islet sections were 
used for immunohistochemistry studies. Also, some islets were frozen and islet 
lysates were used for measurement of cleaved caspase-3 by enzyme-linked 
immunosurbent assay (ELISA). As expected, culture of human islets resulted in 
loss of islet beta-cells in a time-dependent manner leading to a decrease in the 
islet beta/alpha cell ratio during culture period (d0: 1.8 ± 0.3 vs. d7: 1.3 ± 0.2, 
P<0.05) and an increase in the proportion of apoptotic (TUNEL-positive) islet 
cells (d0: 3.4 ± 1.2% vs d7: 12.1 ± 2.4%, P<0.05). Treatment with exenatide 
for 3, 5, or 7 days resulted in an increase in the islet beta/alpha cell ratio (+Ex: 
1.6 ± 0.2%, P<0.05), intensity of insulin immunostaining and a decrease in the 
proportion of TUNEL-positive islet cells (+Ex: 7.5 ± 1.5%, P<0.05). Double 
insulin/TUNEL staining revealed that the majority of TUNEL-positive cells 
were beta cells. This decrease in the number of TUNEL-positive beta cells in 
exenatide-treated islets was associated with a marked decrease in the activation 
of caspase-3 (34%) as assessed by ELISA performed on islet lysates as well 
as double immunostaining for insulin and cleaved caspase-3. These fi ndings 
suggest that short-term treatment with exenatide reduces beta-cell apoptosis 
in isolated human islets and decreases caspase-3 activation by a direct and/or 
indirect mechanism leading to an increase in the yield of islet beta cells during 
pre-transplant culture period.2690
FACTORS THAT INFLUENCE SUCCESSFUL CLINICAL 771 
ISLET ISOLATION WHEN USING A GMP COLLAGENASE AND 
NEUTRAL PROTEASE.
A. Posselt1, G. Szot, M. Lee1, J. Lang1, P. Koudria1, J. Bluestone1, P. Stock2
1Diabetes Center and 2Department of Surgery, University of California San 
Francisco, San Francisco, California, United States. 
Background: In February 2007, the islet community was notifi ed of a possible 
bovine product contamination in the collagenase enzyme (Liberase HI) used 
for human islet isolations. To eliminate this potential hazard, we successfully 
adapted our human islet processing procedure to utilize a GMP Collagenase 
NB1 and Neutral Protease NB (Nordmark/Serva). Here we describe what we 
consider the most important factors for achieving reproducible and clinically 
useable islet isolations.
Methods/Results: A standard isolation protocol involving controlled enzymatic 
digestion followed by density gradient purifi cation was used. Islets were 
maintained in culture for 24-48h prior to transplantation. Eight of 10 (80%) of 
isolations using the Nordmark/Serva Enzyme [table 1] were used for clinical 
transplantation. In contrast, only 9 of 18 (50%) isolations using the Liberase HI 
enzyme were adequate for clinical transplantation. The following factors were 
identifi ed as being important for ensuring a successful islet yield: 1) Donor 
Age and Size: male donors 17-45 years of age who were tall (>180cm) and 
heavy (>100kg), rather than all patients with high BMIs were preferred. 2) 
Cold Ischemia Time, Transport and Preparation: Cold ischemia time was kept 
at <9hrs; organs were maintained in UW solution during transport and were 
trimmed immediately upon receipt by an experienced surgeon. 3) Enzyme 
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perfusion: Pancreata were perfused with cold enzyme solution (6-10oC) 
containing 11mM CaCl2 for 10-12 minutes while increasing pressure (80 psi 
for 4 min., then 180 psi for 6-8 min). 4) Digestion/Dilution: DNAse (2.5 cc, 
Pulmozyme) was added to a 600 mL Ricordi chamber and digestion was carried 
out at 37oC. The digestate was diluted into RPMI containing 5.0% HSA at 4oC 
while keeping the chamber temperature at 30oC for the entire dilution. Digest 
was immediately centrifuged and pooled into dilution solution with 0.625% 
HSA at 4oC. 
Conclusions: Minor modifi cations to our islet isolation protocol have 
demonstrated this GMP enzyme is as functional and viable as a related product 
and can yield clinically useful isolations with greater effi cacy.
Table 1. Islet Isolation Summary
Nordmark/Serva (n=8) Transplanted IEQ % Viability Glucose Stimulation Index
Average 514,510 98.05% 3.20
Std. Dev. 140,606 0.02 2.54
Roche Liberase HI (n=9)    
Average 508,883 99.63% 4.04
Std. Dev. 115,815 0.00 5.20
CONCURRENT ORAL SESSION 60: 
MECHANICAL CIRCULATORY SUPPORT
WEANING FROM LEFT VENTRICULAR ASSIST 772 
DEVICES IN PATIENTS WITH IDIOPATHIC DILATED 
CARDIOMYOPATHY: LONG-TERM RESULTS AND 
PREDICTABILITY OF OUTCOME AFTER WEANING
M. Dandel, Y. Weng, H. Siniawski, M. Pasic, E. Potapov, C. Knosalla, 
H. Lehmkuhl, R. Hetzer
Deutsches Herzzentrum Berlin
Background: During mechanical unloading, clinical recovery which allows 
reliable weaning from VADs is possible. After 13 years of weaning experience, 
we evaluated the outcome of our weaned patients and searched for parameters 
that are predictive for post-weaning cardiac stability and thus helpful for future 
weaning decisions.
Methods: Among 82 patients weaned since 3/1995, a homogenous group of 35 
patients with idiopathic dilated cardiomyopathy (IDCM) weaned from LVADs 
were selected for evaluation. With regard to potential prediction of weaning 
success we evaluated echocardiographic parameters obtained during fi nal 
¡°off pump¡± trials before VAD explantation, histological changes, duration of 
mechanical support and duration of HF. 
Results: The 8-year and 10-year post-weaning survival reached 78.1¡À8.2% 
and 70.7¡À9.2%. Freedom from HF recurrence at 4 and 5 years after weaning 
was 69.3 ¡À8.1% and 61.3¡À9.0%, respectively. Patients with post-weaning 
cardiac stability were younger, history of HF and recovery time during 
unloading shorter, LV short/long axis ratio lower (less spherical) and systolic 
wall motion velocity higher (p< 0.05). For LVEF ¡Ý 45% at LV enddiastolic 
diameter (LVEDD) ¡Ü 55mm the positive predictive value for ¡Ý 5 years 
cardiac stability reached 87.5%. There was no HF recurrence during the fi rst 
4 years in patients with LVEF ¡Ý 45%, LVEDD ¡Ü 55% and history of HF 
< 5 years. The time course of LVEF during the fi rst 6 months also appeared 
predictive for long-term stability after weaning. History of HF > 5 years 
showed a predictive value of 90% for HF recurrence during the fi rst 3 years. 
Reduction in myocardial hypertrophy and fi brosis during unloading appeared 
not predictive for post-weaning stability. 
Conclusions: Off-pump LVEF and LVEDD, time course of LVEF during the 
fi rst 6 months after weaning and duration of HF are predictive for the outcome 
after LVAD removal in IDCM patients. Patients¡¯ age, altered LV geometry, 
low wall motion velocity and prolonged LVAD support until improvement (> 6 
months) appeared to be risk factors for HF recurrence.
ECHOCARDIOGRAPHIC PREDICTION OF SHORT-773 
TERM OUTCOME IN PATIENTS WITH IDIOPATHIC DILATED 
CARDIOMYOPATHY REFERRED FOR TRANSPLANTATION
M. Dandel, R. Jasaityte, H. Lehmkuhl, R. Hetzer
Deutsches Herzzentrum Berlin
Objective: In the light of continuous prolongation of the waiting time on heart 
transplantation (HTx) lists, the need for reliable predictors for the time course 
of heart failure (HF) has become increasingly important. 
To optimize HTx-listing decisions, we evaluated the prognostic value of 
echocardiography including 2D strain imaging in patients with end-stage 
idiopathic dilated cardiomyopathy (IDCM) 
Methods: The study population comprised 32 consecutive stable IDCM patients 
referred for HTx. At the baseline all underwent echocardiography including 
radial, circumferential and longitudinal strain and strain-rate measurements. 
Strain data were also used for quantifi cation of systolic intraventricular 
dyssynchrony. Echocardiographic parameters were tested for their value in 
predicting the time course of HF during the following 6 months.
Results: During the fi rst 6 months after inclusion in the study, 18 patients 
(56.3%) remained stable; the other 14 showed severe cardiac deterioration 
and fi nally underwent ventricular assist device implantation, although initially 
there were no differences in left ventricular (LV) size or ejection fraction 
(LVEF 20±7% vs. 22±3%) and also no signifi cant differences in peak oxygen 
consumption (VO2max) or NT-proBNP. However, at the baseline, patients who 
remained stable had less altered diastolic function in comparison to those with 
rapid HF progression: transmitral E/A-wave ratio 1.3±1 vs. 2.8±1,3 (p<0.001), 
E-wave deceleration time (DT) 139±34.5ms vs. 102±17ms (p<0.05), strain rate 
(SR) Am-wave 0.42±0.13/s vs. 0.22±0.11/s (p<0.001), SR Em/Am-ratio 1.4±0.8 
vs. 3.1±2.7 (p<0.05) and also the systolic circumferential and longitudinal 
dyssynchrony indexes were lower (p<0.05) in the group of unstable patients 
(016±0.05 vs. 0.21±0.05 and 0.21±0.07 vs. 0.32±0.15, respectively). At certain 
cut-off values, the transmitral E/A-wave ratio as well as the 2D-strain derived 
circumferential dyssynchony index and the early diastolic strain rate (Em) 
showed high predictive values (80%-92%) for cardiac stability over the next 
6 months. Highest predictive values for rapid HF progression were found for 
transmitral E-wave DT <100 ms and Em >0.3/s (80 and 84%, respectively). 
Conclusions: In IDCM patients with similar LVEF (<30%), further cardiac 
stability appeared related to the severity of alterations in LV systolic synchrony 
and diastolic function. The high predictive values of transmitral fl ow and 
2D-strain parameters for the short-term (<6 month) course of HF recommend 
echocardiography as a valuable tool for guidance of HTx-listing decisions. 
CONTINUOUS-FLOW VERSUS PULSATILE-FLOW 774 
LVADS USED AS A BRIDGE-TO-TRANSPLANTATION
A. Watson1,2, P. Jansz2, E. Granger2, A. Farnsworth2, C. Axisa2, E. Kotlyar2, A. 
Keogh1,2, C. Haryward2, P. Macdonald1,2, P. Spratt2
1Transplant Program, Victor Chang Cardiac Research Institute, 2Heart & 
Lung Transplant Unit, St Vincent’s Hospital
Introduction: Left ventricular assist devices (LVAD) are used most commonly 
to ‘bridge’ patients with intractable heart failure to heart transplantation. 
The aim of this study was to compare the survival of patients bridged with 
continuous-fl ow LVAD to those supported with a pulsatile LVAD.
Results: Between March 1994 and February 2008, 44 patients awaiting heart 
transplantation at our institution have required LVAD support for refractory 
heart failure (n= 34), acute cardiogenic shock post AMI (n = 4) or post-
cardiotomy (n = 6). 23 patients received a continuous-fl ow VAD (Group 1: 
17 Ventrassist, 6 Heartware) and 21 received a pulsatile VAD (Group 2: all 
Heartmate).
The 2 groups did not differ signifi cantly with regard to age, gender, cardiac 
diagnosis or indication for support. Average duration of support was 262 + 
50 days in Group 1 versus 162 + 27 days in Group 2 (p <0.05). 7 patients 
died during LVAD support: 3 in Group 1 and 4 in Group 2. Causes of death 
were multi-organ failure (3), stroke (2), infection (1) and pump malfunction 
(1). Transplant-free survival at 1, 3 and 6 months was 96 + 4%, 91 + 6% and 91 
+ 6% for Group 1 versus 91 + 6%, 91+6% and 80 + 11% in Group 2 (p = NS). 
Post-transplant survival was excellent in both groups.
Conclusions: Continuous-fl ow LVADs provide excellent support when used as 
a bridge-to-transplantation, with survival at least equivalent to older generation 
devices.
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BEING AN ELDERLY VAD RECIPIENT: IS IT A 775 
RISK FACTOR FOR DEATH DURING THE BRIDGE TO 
TRANSPLANTATION AND POST-HEART TRANSPLANTATION 
PERIOD?
A. Shafi i, G. Gonzalez-Stawinski, K. Zeroske, M. Hanna, N. Smedira, 
T. Buda, K. Hoercher, D. Taylor, R. Starling
The Cleveland Clinic Foundation
Background: Elderly heart failure individuals, like their younger cohorts who 
are transplant candidates, may need mechanical circulatory support (VAD) to 
be bridged to transplantation (BTT). The aim of this study was to determine 
whether age at time of VAD placement impacts mortality during the BTT and 
post- heart transplantation period. 
Methods: A retrospective chart review was conducted on all VAD patients 
listed for heart transplantation between 1997- 2006. Outcomes were compared 
between older VAD patients ( ¡Ý 60 yrs of age, n = 89 ) and younger ones ( ¡Ü 
59 yrs, n = 135). Kaplan-Meier method was used to analyze outcomes. 
Results: Following, VAD implantation there was a trend towards more deaths 
while BTT in the older VAD group when compared to younger VAD patients 
(43.8% vs. 29.6%, p = 0.32). Mean time to death was 62 days for older 
VAD patients compared to 100 days for younger VAD patients (p < 0.001). 
When analyzing for actuarial mortality rate while BTT there was a direct 
correlation between risk of death and age at which a VAD was implanted. Post-
transplantation, both groups had similar 5 year survivals (p = 0.48); however 
there was a trend towards greater deaths associated to sepsis in the older 
patients (32% vs. 20%, p = 0.37). 
Conclusion: There was a trend towards greater mortality in elderly VAD patients 
during the BTT period; however if elderly VAD patients are successfully BTT they 
may enjoy the same long-term survival benefi ts as younger BTT VAD patients.
HEART TRANSPLANTATION IN ADULT PATIENTS WITH 776 
EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
R-B. Hsu1, N-K. Chou1, N-H. Chi1, S-S. Wang1, F-Y. Lin1, S-H. Chu2
1National Taiwan University Hospital, 2Far-Eastern Memorial Hospital
Objective: Donor shortage and improved heart failure management 
increase the prevalence of patients with severe heart failure and mechanical 
circulatory support to heart transplantation. There are numerous reports of 
successful extracorporeal membrane oxygenation (ECMO) bridging to heart 
transplantation in pediatric patients and the outcomes were variable. We sought 
to evaluate the clinical outcome of heart transplantation in adult patients with 
ECMO support.
Methods: Retrospective chart review. 
Results: Between 1995 and 2007, 22 adult patients with severe heart failure 
and ECMO support underwent heart transplantation at the authors¡¦ hospital. 
Of these patients, 11 (50%) patients had a primary diagnosis of dilated 
cardiomyopathy and 6 (27%) had coronary artery disease. Six patients (27%) 
had previous cardiac operation. The median duration of ECMO support before 
heart transplantation was 9.5 days (range, 1 to 48). Four patients underwent 
combined heart and kidney transplantations. There were 8 in-hospital deaths. 
Major postoperative complications occurred in 19 patients (86%): renal failure 
requiring dialysis in 7, infection in 12, and neurological complication in 8 
patients. Diagnosis of coronary artery disease, femoral ECMO, and no left 
atrial decompression were associated with increased hospital mortality. The 
1-year, 2-year, 3-year and 4-year patient and graft survival rates were 66.7 ¡Ó 
10.3%, 60.0 ¡Ó 11.2%, 50.0 ¡Ó 13.1%, and 37.5 ¡Ó 14.6%.
Conclusions: Direct ECMO bridging to heart transplantation was associated 
with high mortality and morbidity in adult patients, and the outcome was 
especially poor in patients with diagnosis of coronary artery disease, femoral 
ECMO, and no left atrial decompression.
USE OF ECMO SALVAGE FOR PRIMARY 777 
ALLOGRAFT FAILURE FOLLOWING ADULT CARDIAC 
TRANSPLANTATION
P. Jansz2, A. Watson1,2, A. Jackson3, A. Jabbour1,2, R. Pye3,4, E. Granger2, 
D. Winlaw2,5, P. Macdonald1,2, P. Spratt2
1Transplant Program, Victor Chang Cardiac Research Institute, 2Heart & 
Lung Transplant Unit, St Vincent’s Hospital, 3Department of Anaesthetics, St 
Vincent’s Hospital, 4Cardiothoracic Intensive Care Unit, St Vincent’s Hospital, 
5Department of Cardiac Surgery, The Children’s Hospital at Westmead
Introduction: Primary allograft failure (PAF) is the leading cause of death 
within 30 days of cardiac transplantation. The aim of this study was to evaluate 
the outcome of patients with PAF managed with veno-arterial ECMO.
Methods: Data were reviewed on 53 consecutive heart transplants performed 
at our institution between 1st June 2005 and 31st January 2008. 9 patients (17%) 
who required ECMO in order to wean from cardiopulmonary bypass (Group 1) 
were compared with the remaining 44 patients in the cohort (Group 2).
Results: There were no signifi cant differences in preoperative recipient 
characteristics. Group 1 patients were more likely to receive hearts with 
abnormal ventricular function on echocardiography prior to retrieval (4/9 vs 
4/38, p=0.033). Eight (89%) patients requiring ECMO were weaned off support 
following a mean of 91.3 hours, and seven were discharged alive (78%). 
Median ICU stay was signifi cantly longer in Group 1 (205.5 hrs, IQR 144.5 
vs 74.0 hrs, IQR 49.6; p=0.003). There was a trend towards longer median 
post-operative hospital stay in surviving Group 1 patients, however this did not 
reach statistical signifi cance (28.0 days, IQR 13.3 vs 15.0, IQR 12.0; p=0.09).
All seven survivors in Group 1 remain alive and well with normal ventricular 
function after 479 days mean follow-up. There were no peri-operative deaths in 
Group 2, however there were two late deaths due to acute rejection at 225 days 
and sepsis at 500 days, respectively. In-hospital mortality was signifi cantly 
higher in Group 1 (2/9 vs 0/44, p = 0.026), however there was no difference in 
late mortality (0/7 vs 2/44, p = NS). Kaplan Meier curves show signifi cantly 
superior survival for Group 2 patients (Figure 1) however, when plotted for 
survival conditional upon survival to discharge, there is no signifi cant difference 
between the curves (Figure 2). Taken together, these data suggest that at least 
short- to medium-term outcome for patients surviving ECMO may be expected 
to be equivalent to those patients whose course is not complicated by PAF.
Figure 1. Overall survival
Figure 2. Survival conditional on survival to discharge
Conclusions: The early implementation of veno-arterial ECMO for PAF was 
associated with low early morbidity and mortality, and excellent long-term 
outcomes. It has allowed us to expand our pool of potential donors by accepting 
organs that would previously have been rejected.
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MECHANICAL CIRCULATORY SUPPORT AFTER 778 
CARDIAC TRANSPLANTATION: THE MODERN ERA
L. Vargas, M. Hanna, G. Gonzalez-Stawinski, N. Smedira, T. Buda
Cleveland Clinic
Purpose: To determine the outcome of patients who underwent heart 
transplantation and subsequently required mechanical circulatory support 
(MCS) in the post –transplant period. 
Methods: A retrospective chart review was conducted on 245 consecutive 
heart transplants performed between January 2003 and December 2006 at 
the Cleveland Clinic Foundation. Among these, 19 (7.7%) patients required 
mechanical circulatory support following heart transplantation. Short- and 
long-term outcomes were recorded. 
Results: There were 13 men and 6 women, median age 43 years (11 to 69 years). 
Among these 19 patients, 25 MCS devices were used. These included intraaortic 
balloon pump (IABP) (n=11), extracorporeal membrane oxygenation (ECMO) 
(n=12), and ventricular assist device (VAD) (n=2), one being biventricular VAD 
and the other right VAD. The main indications for MCS were acute rejection 
(n=3), right heart failure (n=4), and primary graft dysfunction (n=12). MCS 
combinations included 4 patients with IABP + ECMO, 2 patients with VAD + 
IABP, and 1 patient required support with VAD + ECMO. A total of 12 patients 
were weaned from MCS (63%) and 7 patients died (36%), including a patient 
who died intraoperatively while on ECMO. Support time ranged from 0.5 to 
480 hours (20 days). 
Conclusions: This retrospective analysis of patients who underwent cardiac 
transplant and required post transplant mechanical circulatory support reveals 
a high mortality rate. However, a good proportion of these can be weaned from 
support with good outcomes.
USE OF EXTRACORPOREAL MEMBRANE 779 
OXYGENATION IN ADULT SEVERE RESPIRATORY FAILURE 
AS A BRIDGE TO RECOVERY OR BRIDGE TO LUNG 
TRANSPLANT
E. Granger1, A. Jackson2, P. Spratt3, P. Jansz4, M. Malouf5, A. Galnville6, J. 
Cropper7, R. Pye8
1St Vincent’s Hospital, 2St Vincent’s Hospital, 3St Vincent’s Hospital, 4St 
Vincent’s Hospital, 5St Vincent’s Hospital, 6St Vincent’s Hospital, 7St Vincent’s 
Hospital, 8 St Vincent’s Hospital
Background: The use of VV ECMO to treat respiratory failure in children 
and infants is well established as a rescue therapy. The use of ECMO for adult 
respiratory failure has previously demonstrated poor survival; however recent 
experience suggests a valuable role and better outcomes in supporting the adult 
patient with potentially reversible lung injury.
Objective: To review the results of veno-venous extracorporeal membrane 
oxygenation (VV ECMO) in adult patients with severe acute respiratory failure. 
Complications including renal failure, blood product transfusion, haemorrhage, 
device thrombosis and technical failures will be analysed.
Design and Setting: Retrospective data was analysed from medical charts of 
all patients receiving VV ECMO at a tertiary care adult transplant hospital. 
From March 2004 to March 2008 15 patients with respiratory failure were 
treated with VV ECMO after failure of conventional therapy.
Results: Overall hospital survival was 80%. The average duration of support 
was 9.3 days (range 0.1 to 29 days). 80% patients were male, with the average 
age of 38.3. Primary diagnoses included adult respiratory distress syndrome 
(3, 100% survival), pneumonia(7, 86% survival), primary graft failure post 
lung transplant(3, 100% survival) and late graft failure post lung transplant 
(2, 0% survival). Only one patient developed bleeding complications on VV 
ECMO requiring thoracotomy. Three patients were successfully bridged from 
VV ECMO to lung transplant.
Conclusion: The use of VV ECMO in adult respiratory failure can achieve high 
survival and low complication rates. The patients were selected on the basis of a 
potential reversible lung injury refractory to conventional ventilation. In select 
cases patients may be successfully bridged from VV ECMO to transplant. 
BRIDGING PATIENTS FROM VENO-VENOUS 780 
EXTRACORPOREAL MEMBRANE OXYGENATION TO LUNG 
TRANSPLANT – SURGICAL IMPLICATIONS AND LESSONS 
LEARNED.
E. Granger1, P. Spratt2, P. Jansz3, A. Jackson4, A. Glanville5, M. Malouf6, 
R. Pye7, M. Plitt8
1St Vincent’s Hospital, 2St Vincent’s Hospital, 3St Vincent’s Hospital, 4St 
Vincent’s Hospital, 5St Vincent’s Hospital, 6St Vincent’s Hospital, 7St Vincent’s 
Hospital, 8 St Vincent’s Hospital
Background: Veno-venous extracorporeal membrane oxygenation (VV 
ECMO) is an increasingly utilized therapy for adults with severe respiratory 
failure that is refractory to conventional ventilation. Reports on the use 
of ECMO as a bridge to lung transplant are rare, and the outcomes remain 
poor. Many centers have considered ECMO to be a contraindication to lung 
transplantation. We present 3 consecutive, successful cases in which ECMO 
was used as a bridge to primary lung transplant. The surgical aspects of these 
procedures and future implications will be discussed.
Objective: To review the results of bridging patients from VV ECMO to 
bilateral sequential lung transplant. Complications including renal failure, 
blood product transfusion, haemorrhage, device thrombosis, technical failures, 
and anastomotic ischaemic injury will be analysed.
Design and Setting: Retrospective data was analysed from medical charts of 
three patients receiving VV ECMO prior to bilateral lung transplant at a tertiary 
care adult transplant hospital. From March 2004 to March 2008 15 patients with 
respiratory failure were treated with VV ECMO after failure of conventional 
therapy; three patients from this group were bridged to lung transplant.
Results: Overall hospital survival was 100%. The average duration of support 
was 17.3 days (range 10 to 28 days). 100% patients were male, with the average 
age of 19.6. Primary diagnoses included adult respiratory distress syndrome (1), 
and infl uenza pneumonia(2). One patient required haemodialysis on ECMO 
to correct acute hyperkaleamia, however all patients were free of multi-organ 
failure. All patients were coagulopathic following surgery and required re-
exploration in the operating theatre combined with blood product replacement. 
All patients required a tracheostomy for prolonged weaning from ventilator 
support (average 27.7 days). The average length of hospital admission was 76 
days. No anastomotic healing problems were encountered.
Conclusion: Patients can be successfully bridged from VV ECMO to lung 
transplant. They must have single organ failure only and satisfy the criteria 
otherwise for lung transplantation. Prominent surgical issues include massive 
coagulopathy requiring re-opening of the thoracotomy in the operating theatre 
and tracheostomy for prolonged ventilation.
THURSDAY – MINI ORAL ABSTRACTS
MINI-ORAL SESSION 25: 
RENAL 6: LONG-TERM OUTCOMES AND COMORBIDITIES
POSTER BOARD NUMBER P4 – 390
OUTCOME OF HEPATITIS B, C INFECTION ON 781 
TAIWANESE KIDNEY TRANSPLANT RECIPIENTS WITH 
TACROLIMUS AND MYCOPHENOLIC ACID BASED 
IMMUNOSUPPRESSANTS: A SINGLE CENTER STUDY
M-J. Wu1, K-H. Shu1, J-D. Lian2, C-R. Yang3, C-H. Cheng1, C-H. Chen1, 
D-M. Yu1
1Division of Nephrology, Taichung Veterans General Hospital, 2Division of 
Nephrology, Chung-San Medical University Hospital, 3Division of Urology, 
Taichung Veterans General Hospital
Hepatitis B and C are the most prevalent cause of chronic liver disease after 
kidney transplantation (KTx). The aim of the present retrospective study was 
to determine the outcome of tacrolimus and mycophenolic acid based regimen 
for KTx recipients with hepatitis B, C infection. Among 232 patients, 14.7% 
were HBsAg positive, and the other 9.5% patients were anti-HCV positive. 
The overall 1-year, 3-year, 5-year patient survival rates were 99.6%, 97.7%, 
and 96.5%, respectively. Chronic liver disease was an independent risk factor 
for patient death and graft failure. Compared to patients without hepatitis B 
or C infection, KTx recipients with hepatitis C infection, but not hepatitis B 
infection, had poor long term graft survival rate. The overall prevalence rate 
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of chronic liver disease was 18.5%. Hepatitis B and C infection signifi cantly 
increased the prevalence rate of chronic liver disease. The treatment of 
lamivudine obviously reduced the development of hepatitis B related fulminant 
hepatic failure. Post-transplant diabetes was diagnosed in 15.9% patients. The 
logistic regression analysis revealed that hepatitis C infection, age, and fi rst 
month the blood trough level of tacrolimus were the independent risk factor for 
post-transplant diabetes. In summary, we have demonstrated that tacrolimus 
and mycophenolic acid based regimen is effective as a primary regimen in 
KTx recipients with or without hepatitis B and C infection. KTx recipients 
with hepatitis C, but not hepatitis B, infection may have poor long term graft 
survival. The use of lamivudine can modify the natural course of hepatitis B 
infection in kidney transplant recipients.
POSTER BOARD NUMBER P4 – 391
EPIDEMIOLOGY OF VARICELLA ZOSTER INFECTION 782 
IN ADULT RENAL TRANSPALNT RECEPIENTS
M. Kaushik1, B. Swetha1, H.N. Leong2, K.P. Chan3, A. Vathsala1
1Department of Renal Medicine, Singapore General Hospital, 2Department of 
Internal Medicine, Singapore General Hospital, 3Department of Pathology, 
Singapore General Hospital
Varicella zoster virus (VZV), a Herpes virus, presents with a wide spectrum of 
disease in solid organ transplant recipients (TX). In adult recipients with prior 
exposure to VZV, reactivation of latent virus, manifests either as dermatomal 
Herpes Zoster (HZ) or as Disseminated Varicella infection with or without 
visceral involvement (DVZ). Occurrence of primary VZV infection (PVZ) 
in adult TX is less common, although associated with higher morbidity and 
mortality. The present study examined the seroprevalence of VZV immunity 
in an adult renal TX (RTX) population and evaluated the robustness of the 
immunity and its relationship to the occurrence of VZV infection post-
transplant. 
497 adults, (2 re-transplants; 51.9% Males; 85.2% Chinese; mean age, 43.2 
years; 79.4% Deceased Donor) transplanted between 1996 and 2007 constituted 
the study population. All had been on follow-up for at least 1 year post-
transplant and had undergone serological tests for VZV-IgM and IgG at 1 year 
and annually thereafter. The mean follow-up period was 5.9 years. Occurrence 
of HZ, DVZ and PVZ infections post-transplant and their outcomes were 
documented and correlated with VZV serological status. RTX with persistent 
VZV-IgG seroprevalence, unrelated to documented infections or exposure, 
were defi ned as VZV-Immune. 
Among 499 RTX, VZV-IgG seroprevalence was present at initial testing in 
91.6% and was persistent in 99.8% of this cohort throughout the follow-up 
period. In another 2.4%, VZV-IgG became seropositive only at subsequent 
testing and was unrelated to VZV infections or exposure; although in 50% 
of these, seropositivity persisted in the follow-up period, the remaining 50% 
had only transient seropositivity. Overall VZV-IgM seropositivity was noted 
in 11.2%; it was concomitant with VZV reactivation in 4% and unrelated to 
infection or exposure in the remainder. Although transient in the majority, 
notably, VZV-IgM seropositivity persisted on follow-up for >2 years in 26.8% 
of this cohort. Overall, 92.6% had robust humoral immunity to VZV, 1.4% had 
transient immunity while 6% were non-immune. 
56 of 499 RTX (11.2%) developed 59 episodes of VZV infection (3 RTX 
experienced 2 episodes each) at an interval of 34.2 months post-transplant. 
57 (96.6%) episodes were reactivation infections (79.7% HZ, 16.9% DVZ) 
occurring in VZV seropositive RTX. However, 3.4% of episodes were PVZ, 
having occurred in VZV seronegative RTX. Although overall survival in 
reactivation VZV was 100%, there was 50% mortality in the PVZ group, 
1 seronegative RTX having succumbed to severe multi-organ, visceral 
involvement, while the 2nd RTX successfully seroconverted to positive VZV-
IgG post-infection. The incidence of VZV infections was not signifi cantly 
higher in RTX receiving mycophenolate analogs (p=0.149).
These results demonstrate that VZV immunity is over 92% in adult RTX. 
Despite the robust humoral immunity, VZV infections occurred in 11.7% of 
VZV-Immune RTX. Reactivation VZV infections was 1.7-fold as common 
as primary infections (2 episodes in 30 non-immune RTX, 6.7%). Although 
reactivation infections have good outcomes, PVZ infections occurring in non-
immune RTX, appear to be associated with high mortality. Future studies 
should evaluate the role of pre-transplant vaccination in VZV seronegative 
patients in abrogating the severity of VZV infections post-transplant.
POSTER BOARD NUMBER P4 – 392
THE TEN YEARS FOLLOW UP OF KIDNEY 783 
TRANSPLANTATION FROM HBSAG POSITIVE DONORS.
V. Sumethkul, A. Ingsathit, P. Leelasa-Nguan, S. Jirasiritham
Ramathibodi Hospital
HBsAg positivity is believed to preclude kidney donation. We examined the long 
term outcome of KT from HBsAg+ donors to anti HBsAb+ recipients (Gr. 1). 
The outcome of HBsAg+ recipients who received kidneys from HBsAg negative 
donors were compared (Gr.2). End point was patient survival. 40 patients (14 in 
Gr. 1 and 26 in Gr. 2) were enrolled. Anti-HBsAb ranged from 10 to >1000 mIU/
ml. Actuarial ten year survival was 90.9% and 72% for Gr. 1 and 2. One patient 
in Gr.1 died (from acute MI) while ten in Gr. 2 died (3 hepatoma, 4 cirrhosis, 1 
acute fi brosing cholestatic hepatitis, 2 stroke). No patient in Gr. 1 had HBsAg 
seroconversion. Cox regression revealed that KT was signifi cantly associated with 
increased risk of death within 12 months after transplantation (RR=30;p=0.005) 
and decreased risk of death thereafter (RR=0.03;p=0.005) for Gr. 2 but not for Gr. 
1 (p=0.61). Our result shows no increase risk of liver disease ten years after KT 
from HBsAg+ donors to recipients with anti-HBsAb+. Positive HBsAg in donors 
can thus be allocated to immunized recipients.
POSTER BOARD NUMBER P4 – 393
IMPACT OF PRETRANSPLANT ANTIHCV ANTIBODY 784 
STATUS AND TYPE OF IMMUNOSUPPRESSION ON 
OUTCOMES IN RENAL TRANSPLANT RECIPIENTS 
INFECTED WITH HEPATITIS C VIRUS
M. Minz1, A. Sharma1, A. Das2, Y. Chawla3
1Dept of Transplant Surgery, PGIMER, 2Dept of Histology, PGIMER, 3Dept of 
Hepatology, PGIMER
Introduction And Aims: HCV infection remains an important risk factor for 
mortality and morbidity in the transplant recipients. This retrospective study 
analyzed the impact of Hepatitis C antibody status; type of immunosuppression 
in HCV infected renal allograft recipients on liver function, graft and patient 
survival.
Methods: Between Feb 1998 to Aug 2007, 933 renal transplants were performed 
at our centre. Out of these, 104 patients were identifi ed to be harboring HCV 
infection. 59 of these patients (Group I) were AntiHCV positive prior to 
transplant and 45 patients (Group II) were found to be HCV RNA/antibody 
positive in the post-transplant period. The patients transplanted in different eras 
received different immunosuppression regimes. Complete follow-up data of 
these patients was available for 72.3% (43/59) in Group I and 80%(36/45) in 
Group II. Both the groups had a similar number of patients on cyclosporine 
(62.8% vs 61.1%), tacrolimus (37.2% vs 38.8%) and MMF (58.1% vs 61.1%).
These patients were analyzed for difference in patient & graft survival by log 
rank test. The risk of developing liver dysfunction in the post transplant period 
(defi ned as SGOT/PT values 3 x normal) was also analyzed.
Results: The mean age was 35.1 + 10.4 and 32.4 + 10.4yrs, M:F 37:6 and 
31:5, mean donor age was 41.5 + 10.9yrs and 41.2 + 13.1yrs and mean follow 
up 29.4 + 24 mo (1-107.7 mo) and 32.6 + 24.2 mo (3.1-97.2mo) in Group I 
and Group II respectively. The patients in Group I had received a signifi cantly 
higher number of blood transfusions as compared to patients in Group II 
(6.2 + 5.7 vs 2.1 + 2.9) and signifi cantly more number of dialysis prior to 
transplantation (84.5 + 62. vs 33.8 + 43.2 vs) respectively. Liver function tests 
– SGOT (22.6 + 16.1 vs 18.3 + 12.1and SGPT (24.2 + 28.9 vs 20.4 + 20.2) were 
similar in the two groups in the pretransplant period respectively. The patient 
and graft survival at 5years was similar 88.6% vs 82.3% [p=0.81] and 60.1% 
vs 62.5% [p=0.75] in Group I and II respectively. The serum creatinine at last 
FU was 1.38 + 0.6 vs 1.7+ 2.4 mg% [p=NS], SGOT 33.4 + 25.6 vs 38.3 + 47 
and SGPT 39.3 + 46.7 vs 59.2 + 89 IU/L in Group I and II, respectively. Liver 
decompensation occurred in four patients, two in each group at a mean duration 
of 36.5mo.The risk of developing liver dysfunction was higher in patients 
receiving tacrolimus vs. cyclosporine [Relative risk 1.7] and mycophenolate 
vs. azathioprine[Relative risk 1.4]. 
Conclusions: Presence of HCV antibody does not offer any survival advantage 
in HCV infected renal allograft recipients undergoing renal transplantation. 
Patients on tacrolimus and mycophenolate are at higher risk of developing liver 
dysfunction in the post transplant period.
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POSTER BOARD NUMBER P4 – 394
SIGNIFICANT IMPACT OF SERUM ADIPONECTIN 785 
LEVELS ON INSULIN RESISTANCE IN NEW ONSET 
DIABETES AFTER RENAL TRANSPLANTATION
K. Nishimura, Y. Yamauchi, N. Arichi, A. Okuno, S. Tokugawa, N. Fujii, Y. 
Namba, H. Kishikawa, Y. Ichikawa
Hyogo Prefectural Nishinomiya Hospital
Aims: New onset diabetes after transplantation (NODAT) is increasingly 
recognized as a serious complication in renal transplant recipients. Previous 
studies have described incidence rates and predictors, however, the clinical 
characteristics and mechanisms underlying this metabolic disturbance have 
not been fully elucidated. Adiponectin (APN), a recently discovered adipocyte-
derived protein, may be involved in type 2 diabetes mellitus pathogenesis based 
on its relationship with insulin and glucose metabolism. The purpose of this 
study was to analyze whether serum APN levels in renal transplant patients are 
associated with insulin resistance and secretion for the development of NODAT.
Methods: A total of 98 previously non-diabetic patients who underwent renal 
transplantation between 1997 and 2007 were enrolled. NODAT was defi ned 
according to the Japan Diabetes Society guidelines based on results of an oral 
glucose tolerance test (OGTT). Post-transplant homeostasis model assessment 
for insulin resistance (HOMA-IR) and insulinogenic index (I-Index) values 
were produced from OGTT-derived indexes. In addition, pre- and post-
transplant serum APN and high-sensitivity C-reactive protein (hsCRP) levels 
were measured.
Results: Twelve (12.2%) patients were diagnosed with NODAT and 86 (87.8%) 
without (non-NODAT). For the NODAT patients, mean HOMA-IR (3.24) was 
signifi cantly higher than that for non-NODAT patients (1.35) (p=0.004), while 
mean I-Index (0.41) was signifi cantly lower (1.88) (p<0.001). In all patients, the 
mean post-transplant serum APN level (16.8 ƒÊg/ml) was signifi cantly lower 
than the pre-transplant level (20.3 ƒÊg/ml) (p=0.009). Furthermore, mean pre- 
and post-transplant serum APN levels for NODAT patients were signifi cantly 
lower than those for non-NODAT patients (13.3 vs 21.0 ƒÊg/ml and 13.0 vs 
16.4 ƒÊg/ml, p=0.01 and 0.027, respectively). In contrast, in regard to serum 
hsCRP, there were no signifi cant differences between NODAT and non-
NODAT patients for both pre- (0.128 and 0.238 mg/dl, respectively) and post-
transplant (0.566 and 0.402 mg/dl, respectively) levels (p=0.6347 and 0.0983, 
respectively). There was a signifi cant inverse correlation between mean post-
transplant serum APN level and HOMA-IR (r=-0.223, p=0.0272) and a positive 
correlation between follow-up duration after transplantation and HOMA-IR 
(r=0.283, p=0.0047) for all patients, whereas none was seen between mean 
post-transplant serum APN level and I-Index (r=0.085, p=0.4161), or between 
follow-up duration after transplantation and I-Index (r=0.054, p=0.6067).
Conclusions: Our results indicate that serum APN levels are decreased after 
transplantation and have a signifi cant impact on insulin resistance, but not on 
insulin secretion, for the development of NODAT in patients who undergo 
renal transplantation.
POSTER BOARD NUMBER P4 – 395
BLOOD PRESSURE CONTROL IN RENAL TRANSPLANT 786 
PATIENTS: ARE WE AGGRESSIVE ENOUGH?
G. Mourad 1, P. Esler 2, F. Vetromile 1, I. Szwarc 1, A. Mimran 2, J. Ribstein 2
1 Néphrologie, Transplantation et Dialyse Péritonéale, CHU Lapeyronie, 
2 Médecine Interne et HTA, CHU Lapeyronie
Objective: In renal allograft recipients, best practice guidelines recommend 
target arterial pressure <130/80 mmHg. Whether these values are achieved in 
routine clinical practice is not known. The aim of this study was to analyze the 
prevalence and identify factors associated with the presence of hypertension 
(HT, ≥; 130/80 mmHg) in a large cohort of patients followed annually in our 
center. 
Methods: Blood pressure and renal function (glomerular fi ltration rate, GFR, 
urinary 99mTC-DTPA clearance) were evaluated in 456 subjects, 66% male, 
aged 51±12 yrs (mean ± SD) after a median follow-up period of 47 months 
(range 47-335) post fi rst-kidney transplantation (Tx). 
Results: From the 456 subjects, only 33 (7.2%) were normotensivewithout 
any antihypertensive treatment, 97 (21.3%) had well-controlled HT and 325 
(71.5%) had uncontrolled HT. Among the 325 patients with uncontrolled HT, 
69 (15.1% of the whole population) had true resistant HT (at least 3 drugs 
including 1 diuretic) whereas 257 could not be considered as resistant HT 
since they received 2 or less antihypertensive drugs (1.3±0.8) . AS compared 
to controlled HT, uncontrolled HT were slightly older (53±11 vs 50±12 yrs, 
p=0.026) had received grafts from older donors (45±16 vs 38±16 yrs, p=0.001), 
had lower GFR (51±21 vs 56±19 mL/min/1.73m²), and higher albuminuria (34 
vs 19 μg/mL, p<0.001 after log-transformation) and fasting blood glucose 
(5.85±2.61 vs 5.31±1.35 mmol/L, p=0.053). No difference was found for 
gender, duration of dialysis before TX, delay after Tx, steroïd doses or type 
of immunosuppressive treatment (cyclosporine vs tacrolimus). In multivariate 
logistic regression analysis, using controlled HT as the reference category, the 
presence of resistant HT was independently associated with higher body mass 
index, albuminuria and higher donor age. 
Conclusion: After kidney Tx, the main factor associated with persistent 
hypertension is the inadequation of antihypertensive therapy. However, obesity, 
albuminuria as well as older donor age are the main factors associated with true 
resistant HT.
POSTER BOARD NUMBER P4 – 396
STRESS ECHOCARDIOGRAPHY FOR ASSESSMENT OF 787 
RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF CARDIAC 
OUTCOMES.
C.Hood1, J. Dunlop2, H. Pilmore3
1The Alfred Hospital, 2Middlemore Hospital, 3Auckland City Hospital
Background: Pre-operative screening for coronary artery disease (CAD) is 
recommended in high risk renal transplant candidates. Myocardial perfusion 
studies are less invasive than coronary angiography but there are few studies 
correlating the results of stress tests with subsequent decisions regarding 
transplant listing and clinical events. In our programme, high risk patients 
undergo yearly or two yearly stress echocardiography (SE) as assessment for 
the active transplant list. 
Aims: To evaluate the clinical utility of SE as a means of screening potential 
renal transplant recipients. 
Methods: Analysis of 210 SE undertaken for transplant assessment in high 
risk patients was performed for the period October 2002 until Oct 2007 (185 
dobutamine, 15 exercise). Patient records were analysed for the subsequent 
development of cardiac events defi ned as angiographically proven signifi cant 
CAD (>70% stenosis), non-ST elevation myocardial infarction (NSTEMI), 
ST-elevation myocardial infarction (STEMI), or new regional wall motion 
abnormality on echocardiography. 
Results: Of 210 tests, only 18 (8.6%) were positive. 155 (73.8%) tests were 
negative. 37 (17.6%) of tests were equivocal or suboptimal. Mean follow-up 
was 24.6 months. Of the 210 tests, 22 cases (10.5%) subsequently demonstrated 
a signifi cant cardiac event, as previously defi ned. 
Positive tests: 75% of patients with a positive SE were declined listing for 
transplantation on the basis of the initial test result alone or subsequent coronary 
angiographic fi ndings of severe CAD (>70% stenoses). 2 of these patients were 
found to have signifi cant but treatable CAD and were subsequently accepted 
for listing after coronary artery stenting. 2 positive tests were considered 
“false positives” for signifi cant CAD as subsequent angiography revealed zero 
or mild CAD only. 2 patients (12.5%) developed additional co-morbidities 
contraindicating transplantation and further cardiac investigation was therefore 
withheld. Therefore the positive predictive value of SE for signifi cant cardiac 
disease either precluding transplantation or requiring revascularisation was 
85.7%. Of the 18 patients with a positive SE, 8 (44%) had reached a cardiac 
endpoint or died within 24 months of follow up. 
Negative tests: 155 patients had negative SE screening. Of these, 8 (5%) 
experienced signifi cant cardiac events within the next 24 months. The negative 
predictive value NPV for screening SE was 94.8%. In comparison with patients 
with a positive SE, there were signifi cantly fewer cardiac events in those with 
a negative SE (p<0.001). 
Equivocal tests: 37 patients (17%) had equivocal tests. 13 of these were 
further investigated with 2 being found to have signifi cant CAD resulting in 
the patients being excluded from transplantation. 
Conclusion: Our fi ve year experience of 210 SE tests has yielded 14 (6.6%) 
positive or equivocal results that have ultimately resulted in the identifi cation 
of signifi cant CAD and withholding of listing for transplantation. Negative 
screening SE had a high NPV of 94.8% for cardiac events in the next 24 
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months. The percentage of positive SE was low; however these patients had 
a signifi cantly worse outcome clinically suggesting that SE is a useful tool in 
predicting CAD prior to transplantation.
POSTER BOARD NUMBER P4 – 397
POST TRANSPLANTATION DIABETES MELLITUS: 788 
ROLE OF INSULIN-RESISTANCE AND PRO-INFLAMMATORY 
CYTOKINES IN FIRST YEAR POST-TRANSPLANT
M. Carmellini1, V. Bonato2, A. Collini1, D. Cataldo2, G. Ruggieri1, L. Nigi2, 
M. Bernini1, F. Dotta2
1UOC Chirurgia dei Trapianti – Azienda Ospedaliera Universitaria Senese, 
2UOC Diabetologia – Azienda Ospedaliera Universitaria Senese
Post Transplantation Diabetes Mellitus (PTDM), a common complication of 
kidney tranplant, has a negative impact on graft and patient prognosis. Age, 
ethnicity, type 2 diabetes family history, and Hepatitis C were identifi ed as non 
modifi able risk factors of PTDM. Modifi able risk factors are type of immune-
suppressive therapy, and overweight. Several study demonstrated that MCP-1 
and IL-6, pro-infl ammatory molecules, are involved in the pathogenesis of 
type 2 diabetes. In a retrospective analysis, we found that 17% of 250 kidney 
transplant recipients developed an altered fasting glucose (PTDM 12.2% and 
impaired fasting glucose, IFG, 4.8%), interestingly with a major incidence in 
fi rst year post transplant. We aimed to evaluate the role of insulin-resistance 
and proinfl ammatory molecules in PTDM and IFG. 
Materials and methods: Fifty-three non diabetic consecutive patients were 
included in this study, the day of renal transplantation. At the baseline the 
following data were collected: age, sex, body mass index (BMI), prevalence 
of overweight (BMI≥;25 Kg/m2), hepatitis C status, prevalence of diabetes 
mellitus family history, prevalence of hypertension, dyslipidemia and smoke. 
At follow up a blood sample was collected to determine glycaemia, lipid 
profi le, basal insulin, creatinine, and serum MCP-1 and IL-6. HOMA-IR and 
QUICKI were calculated to determine insulin-resistance and insulin-sensitivity. 
Type of immune-suppression (cyclosporine vs tacrolimus) and acute rejection 
was evaluated at follow up. Patients were classifi ed as PTDM, IFG or normal 
glucose (NG). 
Results: 9% of patients developed PTDM, il 28.3% IFG. PTDM and IFG 
patients were older than NG (p<0.05 and p<0.03). In IFG patients HOMA-IR 
resulted higher than in NG group (3.10±2.72 and 1.96±2.37 p=0.0082), while 
QUICKI was lower (0.34 ± 0.03 and 0,36±0,03 p=0.0113). PTDM and IFG 
prevalence was higher in tacrolimus-treated recipients than in cyclosporine-
treated (p=0.002 and p=0.07). No differences were observed in pro-
infl ammatory molecules, MCP-1 and IL-6. Multivariate analysis confi rmed 
tacrolimus as independent risk factors for PTDM (p<0.02).
Conclusions: Our data confi rm the role, in PTDM development, of known 
risk factors, in particular age and tacrolimus treatment, during fi rst year post 
transplant. In our experience PTDM is only in part associated with insulin 
resistance, which is a characteristic of IFG patients. In this patients insulin 
secretion failure is necessary to develop PTDM.
POSTER BOARD NUMBER P4 – 398
REVERSAL OF METABOLIC SYNDROME POST-KIDNEY 789 
TRANSPLANTATION IN CHRONIC CORTICOSTEROID 
VERSUS EARLY CORTICOSTEROID WITHDRAWAL 
REGIMENS
E.S. Woodle1, R-A. Lee1, A.H. Rike2, R.R Alloway1, J.J. Everly1, P. Roy-
Chaudhury1, L. Cole1
1Surgery, U of Cincinnati, 2Christ Hospital
Background: Prolonged use of steroids has been associated with several 
metabolic side effects that can contribute to cardiovascular complications, 
osteoporosis and increased post transplant infections complications. According 
to NCEP ATP III guidelines, metabolic syndrome (MS) is a signifi cant 
predictor of cardiovascular events (CVE). The purpose of this study was to 
evaluate the effects of maintenance corticosteroid therapy on rates of reversal 
of pre-transplant (txp) MS in renal transplant patients (pts) receiving early 
corticosteroid withdrawal (ECSWD) versus chronic corticosteroids (CCS).
Methods: Prospective data collection from 1997 to 2007 on 317 renal transplant 
pts identifi ed with MS at the time of transplant. Pts were evaluated post-
transplant at 6, 12, 24, 36, 48, and 60 months for presence of MS. The NCEP 
ATP III criteria was used to defi ne MS with WHO criteria of body mass index 
(BMI) > 30kg/m2 used as an alternative for waist circumference. All pts met 
the criteria for MS at the time of transplant. Time of MS reversal was defi ned 
as the point in which criteria of MS was no longer met post transplantation 
and remained reversed until the time of last follow-up. Statistics included chi-
square, Student’s t-test, and Kaplan Meier time to event analysis.
Results: 
317 pts had metabolic syndrome at time of transplantation and were evaluated 
for reversal of MS. Of these 317 pts, 97 pts (31%) were in CCS regimen versus 
220 pts (69%) in ECSWD regimen. Baseline demographics for MS were similar 
between the two groups. There was no difference in the overall reversal rates of 
MS (36% in CCS group v. 33% in ECSWD, p=ns). KM analysis of time to MS 
reversal revealed no signifi cant difference between ECSWD v. CCS patients. 
Surprisingly, non-diabetic patients with CCS had a higher MS reversal rate than 
non-diabetics with ECSWD. Analysis of HDL data indicates that corticosteroid 
mediated increases in HDL were responsible for a signifi cant portion of MS 
reversal with non-diabetics.
MS Reversal Rates
CCS (n) CSWD (n) p-value
All patients 36% (97) 33% (220) NS
Non-diabetic patients 50% (60) 34% (123) 0.03
DM Type I 19% (16) 38% (21) NS 
DM Type II 9% (21) 28% (76) 0.07
Conclusions: 1) A substantial proportion of patients (34%) experienced MS 
reversal after kidney transplantation regardless of steroid therapy. 2) Pts with 
pre-transplant DM Type II have signifi cantly higher reversal rates of MS with 
ECSWD. 3) Corticosteroid induced increases with HDL were responsible in 
part for high MS reversal rates in non-diabetics receiving chronic corticosteroid 
therapy.
POSTER BOARD NUMBER P4 – 399
DETERMINANTS OF BONE DENSITY IN RENAL 790 
TX RECEPIENTS AND ITS CORRELATION WITH VIT D, 
CALCIUM AND BISPHOSPHONATES – A SOUTH INDIAN 
EXPERIENCE
P. Govindan1, G. Abraham1, B. Pratap1, M. Matthew2, S. Bhaskar2, 
N. Leslie2, N. Fathima2
1Sri Ramachandra University, Madras, India, 2Madras Medical Mission, 
Madras, India
AIM: To correlate bone disease with Vitamin D therapy, bisphosphonates, 
calcium and CKD duration.
METHODS: The study was conducted in two tertiary care centers in Chennai. 
It consisted of 307 patients. Among this, males were 222(72%) and females 
85(28%), diabetics numbered 109 (35.5%) and smokers number 76(24.8%). 
Calcium containing phosphate binders and supplemental Vitamin D analogues 
were being used by 111(36.2%) and 70 patients (22.8%), respectively. 
Bisphosphonates were given to 64(20.8%) of the post transplant patients. The 
bisphosphonates used were oral alendronate 70mg once a week. Injection 
Palmidronate 60mg IV was given on discharge and followed up once in 6 
months, along with oral 1,25-dihydroxy Vitamin D3 0.25mcg daily and calcium 
carbonate 500mgOD. The baseline IS included prednisolone, azathioprine and 
microemulsion form of cyclosporine (neoral). Lately, patients were converted 
to mycophenolate mofetil, tacrolimus and rapamycin for rejection episodes 
who were not included in the analysis. 
Bone mineral density was measured by DEXA (Lunar IDXA system) at the 
spine (L1-L4 mean density of 0.691g/cm2), neck of femur (mean density of 
0.631g/cm2) and total body (mean density of 0.758g/cm2) within 15 – 45 
days in 307 patients(fi rst follow-up). A second and third follow-up was done. 
This was correlated with anthropometry, various biochemical parameters, 
CKD duration smoking, diabetic status, immunosuppressive therapy, dietary 
habits and supplemental vitamin D and calcium therapy. The mean age of the 
population was 44+/-12.7 years. The mean CKD duration was 19.4+/- 24.3 
months.
RESULTS: Vitamin D therapy prior to transplantation increased femur 
(p=0.013) and total body BMD (p=0.018). Prior calcium intake increased BMD 
at spine (p=0.001), femur (p=0.00) and total (p=0.00). Bisphosphonate therapy 
increased BMD at spine (p=0.001), femur (p=0.003) and total (p=.0.00).The 
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mean ALP value was 112+/- 63.7IU which correlated negatively with BMD 
at the spine (p=0.001), femur (p=0.00) and total (p=0.00). The longer CKD 
duration prior to transplant showed greater loss of BMD in femur (p=0.013). 
There was a positive correlation between BMI and BMD in spine (p=0.003), 
femur (p=0.004 and total body (p=0.005). Ten patients sustained fractures; hip 
joint replacement was done in 4 patients. 
DISCUSSION: Renal transplantation is associated with osteodystrophy. 
Osteopenia is frequent and the fracture risk is increased. Glucocorticoids 
play a role by decreasing calcium absorption, increasing renal excretion 
of calcium and reducing the secretion of sex hormones. They also inhibit 
osteoblast differentiation and induce apoptosis in mature osteoblasts as 
well as in osteocytes. Though glucocorticoids have a key role all other 
immunosuppressives also contribute with the exception of mycophenolate 
mofetil which is neutral with regard to post transplant bone disease. 
In a developing country like India, avoiding steroids altogether from 
the very beginning and steroid withdrawal later cannot be practiced in 
organ transplant due to fear of rejection and the augmented cost of other 
immunosuppression. 
CONCLUSION: Calcium and vitamin D therapy pre-transplantation and 
bisphosphonate therapy post-transplantation, prevented bone loss. BMI had 
a positive correlation with BMD. Those with loss of BMD had higher ALP 
values. The vintage of CKD correlated with a higher bone loss.
T-SCORE – SPINE
T-SCORE – FEMUR
T-SCORE – TOTAL BODY
TABLE 1 – Age, CKD duration and IS dosage at baseline
VARIABLES Mean Std. Deviation
Age in years 44.0656 12.76285
CKDDuration in months 19.4109 24.37840
BMI in kg/m2 22.5156 4.05642
Pred mg/kg 0.4062 0.20822
Azo mg/kg 1.7420 0.57683
Neo mg/kg 2.7770 1.18662
TABLE 2 – Average biochemical Parameters at Baseline
VARIABLES MEAN
 S.Calcium1 8.60
Bicarbonate1 22.
Phosphorus1 3.2
iPTH1 112.6
eGFR1 74.72
S.Calcium 2 8.6
POSTER BOARD NUMBER P4 – 400
TRANSPLANT ERYTHROCYTOSIS: A DISAPPEARING 791 
PHENOMENA?
B. Kiberd
Dalhousie University
Erythrocytosis is relatively common post kidney transplantation and may 
have adverse consequences. This study examines whether erythrocytosis has 
remained stable over time and explores the outcomes associated with this 
condition.
This is a single center retrospective review of an incidence (transplanted from 
1993-2005) and a prevalence cohort (cross section) of kidney and kidney 
pancreas recipients. Predictors of erythrocytosis and hemoglobin levels and 
patient and allograft survival were examined.
Erythrocytosis (defi ned as >170 g/L for >1 month) occurred in 59 of 511 
recipients. Erythrocytosis occurred in only 8.1% of recipients transplanted 
between 1997-2005 compared to 19.7% of recipients transplanted between 
1993-1996 (p=0.0005). Independent predictors of erythrocytosis were prior 
use of ACE inhibitors/ARBs (HR 0.172, 95% CI 0.042-0.734, p=0.017), male 
gender (3.9, 95% CI 1.7-8.7, p=0.001), and use of mycophenolic acid agents 
(0.49, 95% CI 0.25-0.97, p=0.041). Multivariate linear regression analysis of the 
2 cohorts showed that ACEi/ARB use was associated with lower hemoglobin 
levels. Patients with erythrocytosis had superior patient survival (HR for death 
0.105, 95% CI 0.014-0.76, p=0.026) (see fi gure below), similar graft survival 
but a trend for lower death censored graft survival (HR for graft loss 2.06, 
95% CI 0.91-4.65, p=0.084). The comparison group were patients with graft 
survival >1 year with a peak hemoglobin level >120 g/L but <170 g/L, and not 
requiring ESAs. Most patients with erythrocytosis were eventually treated with 
ACEi/ARBs and none required phlebotomy.
The incidence of erythrocytosis is falling and is likely related to greater use of 
ACEi/ARB and possibly more antiproliferative immunosuppression. Patient 
survival is excellent in those with erythrocytosis however long term graft 
survival may be compromised.
MINI-ORAL SESSION 26: 
IMMUNOSUPPRESSION 4: INDUCTION
POSTER BOARD NUMBER P4 – 401
RITUXIMAB INDUCTION IN HIGH RISK KIDNEY 792 
TRANSPLANT RECIPIENTS MAY DECREASE THE 
INCIDENCE AND SEVERITY OF RECURRENCE OF FOCAL 
SEGMENTAL GLOMERULOSCLEROSIS.
J. Sageshima, G. Ciancio, A. Fornoni, L. Chen, C. Abitbol, J. Chandar, 
W. Kupin, D. Roth, G. Zilleruelo, G.W. Burke III
University of Miami, Miller School of Medicine
Background: Disease recurrence is a major obstacle of kidney transplant for 
focal segmental glomerulosclerosis (FSGS). AntiCD20 antibody (rituximab) 
has been used for nephrotic syndrome of native kidney. The signifi cant 
reduction of proteinuria in transplant recipients with FSGS recurrence was also 
reported after rituximab use for posttransplant lymphoma. We hypothesized that 
rituximab induction could alter the posttransplant course of FSGS recipients, 
particularly in those patients with rapid progression to end-stage renal disease 
who are higher risk of recurrence. 
Methods: We compared the outcome of transplants for primary FSGS 
treated with and without rituximab. From Jan. 2000 to Dec. 2003, 11 FSGS 
patients (6-21 yo) received renal allografts along with our “standard” 
immunosuppressive protocol, consisting of tacrolimus, mycophenolate, 
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corticosteroids, antithymocyte globulin and/or daclizubab. From Jan. 2004 to 
Dec. 2007, 18 other FSGS recipients (7-24 yo) received rituximab in addition 
to the “standard” immunosuppression. Posttransplant proteinuria was treated 
with plasmapheresis (PP) and maintenance angiotensin blockade (AB). 
Results: There was no adverse event related to rituximab infusion. The overall 
incidence of posttransplant proteinuria was signifi cantly lower in recipients 
with rituximab induction (p < 0.05). Four recipients treated with “standard” 
immunosuppression developed massive proteinuria (u-protein/creat. > 10) 
immediately following transplantation; they responded poorly to PP and AB. 
Four other recipients had moderate proteinuria. In contrast to this, of the 18 
patients induced with rituximab, only 2 had massive proteinuria and 4 had mild 
to moderate proteinuria which responded well to PP and AB. With a median 
follow-up of 26 months, there was no signifi cant difference of graft survival 
between 2 groups (2-year survival: 81% without rituximab vs. 84% with 
rituximab). A half of the graft loss was related to noncompliance. 
Conclusion: While the mechanism of action is unclear, our observation 
indicates that rituximab induction may decrease the incidence and severity of 
recurrence of FSGS following kidney transplantation. A larger-scale study is 
desirable to confi rm this observation.
POSTER BOARD NUMBER P4 – 402
200 LIVING DONOR KIDNEY TRANSPLANTATIONS 793 
UNDER ALEMTUZUMAB PRETREATMENT AND WEANING 
OF TACROLIMUS MONOTHERAPY: 3 YEAR FOLLOW UP
H. Tan, J. Donaldson, A. Basu, M. Unruh, P. Randhawa, V. Sharma, C. 
Morgan, J. McCauley, C. Wu, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Alemtuzumab has been used in off-label studies of solid organ transplantation. 
We extend our report of the fi rst 200 consecutive living donor solitary kidney 
transplantations under alemtuzumab pretreatment with tacrolimus monotherapy 
and subsequent spaced weaning to 3 years of follow up. We focused especially 
on the causes of recipient death and graft loss, and the characteristics of rejection. 
The actuarial 1, 2, and 3 year patient and graft survivals were 99.0% and 
98.0%, 96.4% and 90.8%, and 93.3% and 86.3%, respectively. The incidence 
of acute cellular rejection (ACR) at the following months was 2% <6, 9.0% 
<12, 16.5% <18, 19.5% <24, 23.5% <30, 24.0% <36, and 25% <42. The mean 
serum creatinine (mg/dL) and glomerular fi ltration rate (mL/min/1.73m2) at 
1 and 3 years were 1.43+0.55 and 58.7+21.6, and 1.50+0.71 and 54.5+21.3, 
respectively. 50 (25%) recipients had a total of 89 episodes of ACR. 88.7% of 
ACR episodes were Banff 1, and of those, 82% were steroid-sensitive. Nine 
(4.5%) recipients had antibody mediated rejection (AMR). 76.5% were weaned 
to spaced dose (qod or less) tacrolimus monotherapy, and 94.4% were still 
steroid-free from the time of transplantation. Infectious complications was low. 
This experience confi rms the 3-year effi cacy of this approach.
POSTER BOARD NUMBER P4 – 403
ANTIBODY INDUCTION REGIMENS IN RENAL 794 
TRANSPLANT PATIENTS DISPLAY DIFFERENCES IN TOTAL 
T CELL AND B CELL BUT NOT T-REGULATORY CELL 
RECOVERY- ASSOCIATION WITH REJECTION AND GRAFT 
SURVIVAL
M.R. Carreño, P. Ruiz, H. Takahashi, T. Cordovilla, G. Ciancio, G.W. Burke, 
A.Tzakis
Departments of Surgery and Pathology, University of Miami-L. Miller School 
of Medicine,
Introduction: We evaluated early and long-term (two year) immunophenotypic 
peripheral blood profi les in renal transplant patients receiving single agent 
induction therapy with Thymoglobulin (T), Campath-1H (alemtuzumab) (C) 
or Daclizumab (D) versus combined T and D (T-D) or T and C (T-C) with 
steroid avoidance. The focus was to identify specifi c peripheral blood targets of 
cytoablation that might help reduce the incidence of renal allograft dysfunction. 
Methods: Patients used were enrolled in a single (T) (n=44), (D) (n=45), (C) 
(n=64) or combined (T-D) (n=75) and (T-C) (n=75) induction protocols with a 
mean follow-up of >1200 days and 457 + 131 days respectably. Maintenance 
immunosuppression (IS) consisted of Tacrolimus and Mycophenolate but no 
corticosteroids for C, T-D and T-C, in contrast to T and D which included 
steroids. Flow cytometric assessment of percentage and absolute number 
of several cell subpopulations including CD3, CD4, CD8, CD19, CD56/16, 
CD4/25 bright (n T-regulatory cells) were measured pre-transplant and 
thereafter serially in all patients.
Results: The recovery of CD4+ cells from cytoablation was more rapid within 
the 1st, 4th and 8th months (24.7, 38.8, and 37.3% respectively) in the T-D vs. 
the T-C group (1.6, 8.3 and 16.9%). The percent recovery, at 8th months, for 
T (27.6%) and C (14.0%) were not different. No differences were found in the 
nTreg recovery at 8 months in T-D (22.7%) and T-C (20.1%) vs. T (38.9%) and 
C (20.3%). The earlier T cell recoveries were not associated with signifi cantly 
increased acute cellular rejections (T-D n=5 and T-C n=3) over the 1st year, 
and not higher than (T n=5 and C n=5) in the previous study. The T-D group 
had a minimal effect on B cells at 1 month (recovery 69.6%) in contrast to the 
T-C (2.4%) and was within normal ranges by the 4th month. Humoral rejection 
was not signifi cantly different between T-D (n=3) and T-C (n=2) in the 1st year. 
Patient and graft survivals at one year were T-D (96% and 94.6%, respectfully), 
T-C (96% and 93.3%), T (95.1% and 92.9) and C (97.3% and 97.3%) in the 
stand alone during the 1st year.
Conclusions: Cytofl uorographic analysis of peripheral blood profi les in 
renal transplant patients receiving various induction modalities revealed that 
Campath has the most profound cytoablative long-term effects on overall 
CD4+ T cells and B cells. Interestingly, nTreg cells are not comparably affected 
by Campath and show recovery similar to other induction profi les. The rate 
of rejections, graft and patient survival was not notably different between the 
groups. These results raise the possibility that selective sparing of nTreg cells 
by induction reagents may ultimately infl uence the capacity of the recipient 
to manifest clinically apparent rejection episodes and this may facilitate 
operational tolerance induction.
POSTER BOARD NUMBER P4 – 404
CALCINEURIN INHIBITORS-FREE 795 
IMMUNOSUPPRESSION IN EXPANDED CRITERIA 
DONOR KIDNEYS: COMPARISON BETWEEN TWO 
INDUCTION ERAS.
L. Santiago Re, D. Curcio, S. Cuevas, J. Goldberg, M. Rial, D. Casadei
Instituto de Nefrología de Buenos Aires
Calcineurin inhibitor avoidance and antibody induction are the main 
pharmacologic strategies to improve outcomes when using ECD kidneys 
for transplantation. Our group reported previously the results of an 
immunosuppressive protocol using rATG+ sirolimus+ MMF+ Pred. In 
december 2005, we started to use Campath 1H (alemtuzumab) as induction 
agent in ECD kidneys with the same maintenance therapy. In the present study 
we report the comparative results between these two different induction eras.
rATG (n=41) Campath (n=25) P value
Donor Age 55.07 ± 4.36 53.87 ± 18.02 0.49
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Recipient age 50.68 ± 15.10 45.6 ± 19.35 0.26
DDS score 19.65 ± 7.4 22.54 ± 6.1 0.07
Remuzzi score 4.1 ± 2.3 3.75 ± 2.7 0.05
CIT (minutes) 1338 ± 546 1452 ± 834 0.504
DGF occurrence 17/41 (43.9%) 18/25 (72%) 0.20
DGF duration 12.8 ± 13.5 14.2 ±12.3 0.534
1 yr-acute rejection 7/41 (17.07%) 0/25 0.20
CNI conversion 2/41 (4.87%) 5/25 0.06
Urinary tract infection 16/41 (39.02%) 8/25 0.37
CMV infection 6/41 (13.9%) 0/25 0.04
Hb level (g/dl) 10.6 ± 1.5 10.2 ± 2.9 0.85
Epo use 5/41 (10.8%) 19/25 0
WBC (mm3) 6473 ± 1815 4154 ± 1327 0.05
G-CSF use 0/41 4/25 0.01
Cholesterol (mg/dl) 206 ± 29 149 ± 57 0.008
Statins use 21/41 (51.21%) 9/25 0.17
Triglycerides (mg/dl) 146±89 131± 78 0.484
Fibrates use 12/41 (27.8%) 10/25 0.263
1-yr creatinine 1.50 ± 0.70 1.38 ± 0.65 0.778
1-year patient survival  35/41 (85%) 23/25 (92%) 0.489
1-year graft survival  33/41 (82%) 18/25 (72%) 0.245
1-year death censored graft survival 39/41 (95.12%) 20/25 (80%) 0.367
Campath 1H treatment was associated with a more frequent use of G-CSF, lower 
levels of WBC, minor cholesterol levels and less incidence of CMV infection. 
Both induction agents were associated with excellent 1-year outcomes in terms 
of graft function and patient survival. Due to the fact that Campath 1H is less 
expensive, it constitutes a cost-effective alternative to rATG as induction agent.
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A PROSPECTIVE RANDOMIZED TRIAL OF 796 
ALEMTUZUMAB VERSUS RABBIT ANTI-THYMOCYTE 
GLOBULIN INDUCTION IN KIDNEY AND PANCREAS 
TRANSPLANTATION: MINIMUM 6 MONTHS FOLLOW-UP
A. Farney, R. Singh, J. Rogers, E. Ashcroft, E. Hartmann, L. Hart, W. Doares, 
M. Gautreaux, P. Adams, R. Stratta
Wake Forest University
Alemtuzumab (Alem) and rabbit anti-thymocyte globulin (rATG) are the most 
commonly used T-cell depleting induction agents in kidney (K) and pancreas 
(P) transplantation (tx). 
Methods: We conducted an IRB approved prospective randomized study 
comparing single dose Alem (30mg) to alternate day rATG induction in Ktx and 
Ptx patients (pts). Pts received FK and MMF. A risk stratifi cation (PRA>20%, 
re-tx, African Americans <40 years old) defi ned high immunologic risk and 
determined steroid maintenance or elimination. Expanded criteria donors 
(ECD) were included. 
Results: Between 2/1/05 and 8/24/07 225 pts enrolled and 222 pts were 
transplanted. Of 222 pts, 180 (81%) had Ktx alone, 38 (17%) KPtx, and 4 
(2%) PAKtx. Of 180 Ktx alone, 152 (84%) were deceased donor, and 61 (34%) 
were ECDs. Recipient age, race, re-tx, HLA match, PRA titer, ECDs, CMV 
status, and immunologic risk were similar for Alem (n=113) and rATG (n=109) 
groups.
Group(n) Ktx Ptx(KPtx) ECD Re-tx PRA(>20%) Race(AA) Low Immunologic Risk
Alem(113) 85 28(24) 33 12 34 34 72
rATG(109) 95 14(14) 28 10 32 36 71
Overall pt, Ktx, and Ptx survival are 96, 90, and 86% at 18 months median 
follow-up. Actuarial survival rates, initial length of stay, delayed graft function, 
steroid free rates, major infection, and incidence of PTLD (1 rATG pt) were 
similar for Alem and rATG groups. Overall, treated acute rejection (AR) 
occurred in 20 (18%) Alem pts compared to 30 (28%) rATG pts (p=0.11) and 
biopsy proven rejection (BPAR) in 15 (13%) Alem pts compared to 26 (24%) 
rATG pts (p=0.06). Amongst Ktx alone, treated AR occurred in 11 (13%) Alem 
pts compared to 25 (26%) rATG pts (p=0.04) and BPAR in 9 (11%) Alem pts 
compared to 21 (22%) rATG pts (p=0.06).
Group 1, 2 yr Pt Survival
1, 2 yr Ktx 
Survival
1, 2 yr Ptx 
Survival Treated AR BPAR CAN
Alem 96, 95% 92, 88% 82, 82% 20(18%) 15(13%) 19(17%)
rATG 99, 98% 94, 88% 100, 88% 30(28%) 26(24%) 32(29%)
Only 1 Alem BPAR has occurred after 12 months. Total daily MMF doses were 
similar for Alem and rATG groups at 3 months (1570±460 mg vs 1670±510 mg). 
Neupogen use was greater in the Alem group, 26 (23%), than in the rATG group 
(14 (13%), p=0.03). Excluding PAK, chronic allograft nephropathy (CAN) was 
observed in 19 (17%) Alem pts compared to 32 (29%) rATG pts. (p=0.04). 
Conclusions: Alem and rATG induction both provide excellent 1 and 2 yr pt, 
Ktx, and Ptx survival. Alem is associated with lower acute rejection rates and 
less CAN, but requires increased Neupogen administration to help maintain 
MMF dosing.
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IMMUNE RECONSTITUTION IN HUMAN RENAL 797 
ALLOGRAFT RECIPIENTS TREATED BY SIROLIMUS OR 
CYCLOSPORIN AFTER THYMOGLOBULIN INDUCTION 
THERAPY
E. Morelon1, N. Lefrançois1, C. Besson2, J. Prévautel2, M.N. Kolopp-Sarda2, 
M. Brunet1, J.L. Touraine1, L. Badet1, F. Touraine-Moulin2, C. Malcus2
1Tranplantation Unit, Edouard Herriot Hospital, 2Immunology Unit, Edouard 
Herriot Hospital
Background: Little is known regarding the impact of the maintenance 
immunosuppressive regimen on the immune reconstitution following induction 
therapy by depleting antibodies. The aim of this study was to compare the 
peripheral blood lymphocyte subsets time course in ATG-treated patients that 
received either cyclosporin A (CsA) or sirolimus (Sir) in a phase IV monocenter 
randomized open trial.
Patients and Methods: Nineteen renal allograft recipients received a short 
(4 days) initial dose of ATG, and were randomized to receive either 5mg/kg 
CsA (n=10; CsA group [CsAG]) or Sir (J0-J1 15mg, J2 10mg and thereafter 
5mg/d; n=9; Sir group [SirG]). All patients received mycophenolate mofetil 
and steroids. Absolute CD3, CD4, CD8 T lymphocytes were enumerated by 
fl ow cytometry (Flow-Count, FC500 Beckman-Coulter) every 3 days after 
transplantation for 15 days and at D30, D90, D180 and D365. B, NK and 
NKT cell count was assessed by the same method at day 0 and from D30 to 
D365.
Results: Four patients were excluded for adverse events at week 3, month 2.5, 
7, 8 and at month 2, 3, 6 and 8 in SirG and in CsAG respectively. Following 
ATG induction, total lymphocytes, CD3, CD4 and CD8 cells were deeply 
depleted without any difference between the 2 groups. From D5 to D30, a 
gradually increase of every T cell subsets was observed in both groups but 
was signifi cantly higher in CsAG than in SirG. At D30, the mean values of 
lymphocytes, CD3, CD4 and CD8 cells/L are 306±173 vs 157±76, 107±149 vs 
35±44, 46±67 vs 13±18, 60±85 vs 23±29 in the CsAG and SirG respectively 
(p<0.01). No difference between the two groups remains at later time points 
(D30 to D365): both groups displayed stable reduced (by 50%) number of 
total, CD4+, and CD8+ lymphocytes as compared with the initial values. NK 
and NKT cells were similarly depleted from D30 to D180 in the 2 groups and 
increased slightly at D365. B cell count was not affected by ATG induction in 
the 2 groups.
Conclusion: ATG depletion is not different on CsA and Sir. However, the nature 
of the maintenance regimen infl uences the kinetic of the immune reconstitution 
that is delayed on Sir as compared with CsA. The intensity of the reconstitution 
appears similar on the two drugs after the fi rst month.
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5 YEAR OUTCOMES IN A RANDOMIZED TRIAL 798 
COMPARING RABBIT ANTITHYMOCYTE GLOBULIN AND 
BASILIXIMAB IN KIDNEY TRANSPLANT RECIPIENTS: 
LINKING CLINICAL TRIAL DATA WITH REGISTRY DATA
D.C. Brennan1, M. Schnitzler2
1Washington University in St. Louis, 2Saint Louis University
Background: A prospective, randomized, comparative, international clinical 
study recently reported that induction treatment with rabbit anti-thymocyte 
globulin was as safe as and more effective in preventing acute rejection in 
deceased donor kidney transplant patients than basiliximab at 1 year. To assess 
the 5 year long-term outcomes of patients enrolled in this study, we employed a 
novel technique of linking clinical study records to registry data.
Methods: In the United States (US), transplant centers are mandated to 
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enter solid organ transplant recipients’ clinical data into Organ Procurement 
and Transplantation Network (OPTN) database. To obtain 5 year follow-
up data, each US-enrolled patient was identifi ed from the OPTN database 
using date of birth, date of transplant, gender, and transplant center. Matches 
were verifi ed using recipient and donor human leukocyte antigen, blood 
group and cross-referenced with Social Security Death records. Clinical 
outcomes at 5 years were obtained from the OPTN database and compared 
between groups.
Results: All US-enrolled patients (n=183) were matched uniquely to their 
OPTN records. The 5 year cumulative incidence of acute rejection was 
signifi cantly lower in patients treated with rabbit antithymocyte globulin 
group (15/91, 15.96%) than patients treated with basiliximab (28/92, 30.04%), 
P=0.029. At 5 years, rabbit antithymocyte treated patients also had the lowest 
composite endpoint of acute rejection, graft loss, and death than basiliximab 
treated patients, 38.85% and 51.95%, respectively, P=0.037. There were no 
differences in the incidences of opportunistic infections and post-transplant 
malignancies between groups.
Conclusions: Using this novel approach, we observed that the 12 months 
benefi ts of antithymocyte globulin over basiliximab induction were 
sustained through 5 years follow up without the penalties of increase 
risks of post-transplant complications. While most clinical studies provide 
only short-term effi cacy and safety results, this methodology provides an 
effi cient way to monitor long-term effi cacy and safety of patients enrolled 
in clinical studies. 
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LONG-TERM IMMUNOLOGICAL EFFECTS OF ATG 799 
INDUCTION THERAPY
R. Weimer1, S. Deisz1, H. Dietrich1, C. Süsal2, F. Renner1, S. Kamali-Ernst3, 
W. Ernst4, W. Padberg5, G. Opelz2
1Department of Internal Medicine, University of Giessen, 2Institute of 
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar, 
4Dialysis Center, Langenselbold, 5Department of Surgery, University of 
Giessen
We showed previously that rabbit ATG induction therapy induces a strong 
decrease of CD4+ T cells, impaired CD28 expression and IL-2 secretion 
up to 1 year posttransplant. To analyze long-term immunological effects of 
ATG induction, we used sensitive intracellular cytokine analysis at 2 years 
posttransplant in the same prospective study of 84 renal transplant recipients 
(ATG, n=44). 
ATG induction was associated with an increased frequency of severe 
infectious disease (46% versus 23%, p=0.03) but not CMV disease. The 
persistent decrease of CD4+ T cell counts (p<0.0001) 2 years after ATG 
induction treatment coincided with signifi cantly suppressed T cell functions 
(T cell proliferation, p=0.01; intracellular CD4 cell cytokine responses: IL-2, 
p=0.04; IL-10, p=0.004). Profoundly diminished CD4 cell IL-10 responses 
were in part counterregulated by a signifi cant increase in IL-10R expression 
which was found on CD4+ T cells only (p=0.002). These associations 
were confi rmed by multivariate logistic regression. The occurrence of 
severe infections was related to a low CD4/CD8 ratio (¡Ü0.5; p=0.002), 
elevated CD8 cell counts (p=0.01) and low CD8 cell IL-2 production 
(p=0.02). Interestingly, we found no long-term effects on production of the 
lymphoma growth factors IL-6/IL-10, IL-4 responses, CD4 helper activity 
or sCD30 levels. 
Our data show that ATG induction is associated with long-term immunological 
effects 2 years posttransplant. Decreased T cell proliferation, CD4 cell 
counts and IL-2 responses may account for an increased risk of severe 
infectious disease and of PTLD after ATG induction because of inadequate 
T cell control. Previously shown benefi cial effects of low CD4 cell IL-10 
responses on graft outcome may provide long-term graft protective effects 
after ATG treatment.
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ATG VERSUS BASILIXIMAB INDUCTION THERAPY 800 
IN KIDNEY ALLOGRAFT RECIPIENTS RECEIVING A DUAL 
IMMUNOSUPPRESSIVE REGIMEN: SIX-YEAR RESULTS
A. Pascher1, F. Ulrich1, S. Kohler1, S. Weiss1, S. Tullius2, P. Reinke3, 
P. Neuhaus1, J. Pratschke1
1Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow, 
Berlin, Germany, 2Division of Transplant Surgery, Brigham and Women’s 
Hospital, Boston, MA, United States, 3Dept. of Nephrology, Charité, Campus 
Virchow,Berlin, Germany
Purpose: The aim of this prospective randomized study was the comparison 
of effi cacy and incidence of adverse events in two induction therapy regimens 
(ATG versus basiliximab) in patients receiving a dual immunosuppression.
Methods: 120 recipients of fi rst or second deceased donor kidney transplants 
were prospectively randomized to receive either ATG (Fresenius) or 
basiliximab (Novartis) as induction therapy. Dual immnosuppression consisted 
of tacrolimus (Astellas) and methylprednisolone. CMV prophylaxis was not 
applied on a regular basis. Statistical analysis was performed with Fisher’s 
exact or chi-squared test, ANOVA or Mann-Whitney U test, Kaplan Meier 
curves and log-rank test.
Results: Patient characteristics of populations treated with ATG versus 
basiliximab were similar concerning average age (48 years), gender and 
dialysis time prior to transplantation (78 vs. 82 months). Average donor age and 
cold ischemia were also comparable (43 vs. 41 years and 832 vs. 852 minutes). 
The actuarial 5-year patient survival for the ATG subpopulation is 91,7% in 
comparison to 85% in the basiliximab group (n.s.). Analyzing graft survival 
after 5 years, rates of 88,3% in ATG patients compared to 75% in the basiliximab 
group can be observed (n.s.). The incidence of acute rejection episodes was 
similar in both groups (ATG: n=20 vs. basiliximab: n=16). 18 (30%) patients 
in the ATG group and 20 (33,3%) in the basiliximab group showed a delayed 
graft function. Serum creatinine was not signifi cantly different at 1 and 5 years 
(ATG: 1,4±0,6 mg/dl and 1,4±0,8 mg/dl vs. basiliximab: 1,3±0,7 mg/dl and 
1,5±0,9 mg/dl). Patients in the ATG group had a higher rate of CMV infections 
(n=13 vs. n=3; p=0,05) and signifi cantly more hematological complications 
like anaemia, leukopenia and thrombocytopenia.
Conclusion: Comparing induction therapy with ATG and basiliximab, our data 
shows similar patient and graft survival rates with slightly better results in the 
ATG group. Patients treated with ATG had a higher rate of CMV infections and 
more hematological complications.
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LOW DOSE THYMOGLOBULIN VERSUS SIMULECT 801 
INDUCTION IN ADULT KIDNEY TRANSPLANT WITH CNI 
TRIPLE IMMUNOSUPPRESSION: EFFICACY AND SAFETY
M.R. Laftavi1, S. Sharma1, L. FIng1, R. Koholi2, I. Min2, D.M. Danek1, J. 
Tullock1, M. Dayton1, D. Dunn1, O. Pankewycz2
1Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at 
Buffalo
Signifi cant improvements in patient and graft outcomes following kidney 
transplantation have been made over the past decade. However, the role 
of induction therapy in these advances remains uncertain. Moreover, the 
type of induction therapy, whether lymphocyte depleting therapies such as 
Thymoglobulin (TGL) or non-depleting agents such as anti-IL2R antibodies, 
is also controversial. In the recent reports, full dose TGL (7-10 mg/kg) was 
associated with higher rates of infection and cancer compared to anti-IL2R 
antibody induction. In this retrospective study, we compare the effi cacy and 
safety of a lower dose TGL induction therapy (3-5mg/kg total dose, mean dose 
= 3.64 mg/kg) to Simulect (SM) (20mg given 4 d apart) induction therapy. 
Between 2000 and 2007, 355 kidney transplant recipients received TGL and 
93 patients (Pt.)received SM for induction. Both groups received equal triple 
immunosuppression therapy consisting of a calcineurin inhibitor, MMF and 
low-dose prednisone. Demographic data including sex, donor type, age, race, 
HTN, DM, PRA> 30% and HLA matching was similar in both groups. Mean 
CIT was longer in TGL group (15+9 vs. 13+9 hours, p=0.04). Both groups 
had equal hospital stays (TGL 8.3 vs. SM 7.6 days, p= 0.44) and delayed graft 
function (TGL 28% vs. SM 26%, p= 0.49). 
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Pt.1y Pt.5y Gft.1y Gft.5y Ca. BK virus Other infections
TGL 98% 88% 96% 87% 2 6  76 (21%)
SM 93% 85% 95% 90% 1 0  14 (15%)
p value NS NS NS NS NS NS  NS
Table I. Pt.=patient survival,Gft.=graft survival, y=year, Ca=Cancer, *Graft 
survival is death censored. 
Over the past 7 years, 43 patients in the TGL group and 14 patients in the SM 
group died (p=0.44). Of the 43 deaths in the TGL group, 6 died from infection/
sepsis compared to 1 in the SM group (p= 0. 67). All deaths due to infection 
occurred after 4 months post-transplant and 80% occurred after 2 years. Acute 
graft rejection occured in 11% and 13% in TGL and SM group respectively 
(p=0.6). Graft lost (death censored) occurred in 43 pts in TGL group compared 
to 9 pts who received SM (p=0.51). Conclusion: low dose TGL and SM were 
equally effective in promoting graft survival and preventing acute rejection. 
There was no increased risk of death, infection or cancer in the low-dose (3-5 
mg/kg total dose) TGL group.
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THYMOGLOBULIN DOSING INTENSITY AND 802 
DENSITY: EFFECTS ON INDUCTION EFFICACY IN EARLY 
CORTICOSTEROID WITHDRAWAL REGIMENS
E.S. Woodle1, R-A.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1, 
P. Roy-Chaudhury1, A. Govil1, M. Clippard2
1Surgery, U of Cincinnati, 2Christ Hospital
Thymoglobulin (TMG) induction reduces acute rejection (AR) risk in early 
corticosteroid withdrawal (ECSWD) regimens in kidney transplantation (KTx). 
However, inadequate data exists regarding dosing strategies (fi xed versus CD3 
based), intensity, and density of dosing on TMG effi cacy. The purpose of this 
study was to evaluate TMG dosing intensity and density on AR.
Methods: Data was collected prospectively in 334 pts who received TMG 
induction and ECSWD. Variables with a p<0.20 entered the multivariate 
(MVA) stepwise logistic regression model. TMG dose was 1.5 mg/kg. TMG 
regimens were: fi xed dosing (days 0,2,4,6) and CD3 based (dose given when 
CD3+ cells > 25/ul). 
Results: Data is presented as CD3 dosing/fi xed dosing: Total # pts 194 
/140, mean follow-up (days) 1526±699/898±609 (p<0.01). AR rate was 
higher with CD3 based dosing (16%/8%, p<0.03). Univariate analysis 
(UVA) of AR risk factors (gender, African American (AA) recipient race, 
PRA >25%, delayed graft function (DGF), DR mismatches, diabetes, repeat 
transplant) and TMG dosing data (dosing regimen type (fi xed v CD3-
based), total dose (mg/kg), total dose by categories (£6 mg/kg and > 6 mg/
kg), and # of doses) was performed. Signifi cant UVA factors (p<0.2) that 
entered the MVA model are in the table below. In the fi nal MVA model, 
signifi cant risk factors included CD3 dosing regimen and AA recipient race. 
Additional MVA analyses that excluded DGF pts (33/334 pt) confi rmed 
these observations.
UVA for AR Odds Ratio 95% Confi dence Interval
African American 1.9 1.0-4.0
Repeat Transplant 1.8 0.8-4.3
Fixed dosing 0.4 0.2-0.9
Fixed dosing (total dose £6 mg/kg) 1.9 0.7-5.2
CD3 dosing 2.3 1.1-4.8
CD3 dosing (total dose >6 mg/kg) 3.0 1.3-7.4
MVA for AR Odds Ratio 95% Confi dence Interval
CD3 dosing 2.5 1.3-6.1
African American 2.2 1.2-5.6
Conclusion: These analyses indicate that fi xed TMG dosing which provides 
greater dosing density is associated with decreased AR in ECSWD. 
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EFFICACY OF A NOVEL RABBIT ANTI-HUMAN 803 
LEUKOCYTE POLYCLONAL ANTIBODY IN PREVENTING 
ACUTE RENAL ALLOGRAFT REJECTION IN NONHUMAN 
PRIMATES
H. Xu1, Z. Liu1, A. Kirk2
1Jinan City Central Hospital, 2Department of Transplantation, Emory 
University Hospital, Emory University, Atlanta, USA
Thymoglobulin® is generated using thymocytes and thus has broad depleting 
activity focused primarily on naïve T-cell populations. However, acute rejection 
is mediated by activated T cells and monocytes. We have therefore developed 
an anti-human leukocyte polyclonal antibody (newRALG) by immunizing 
rabbits with activated lymphocytes and monocytes to specifi cally target these 
activated cells. newRALG depletes lymphocytes and monocytes in vitro, 
and targets multiple molecules on activating lymphocytes and monocytes to 
a greater degree than thymoglobulin®. Surviving newRALG-treated human T 
cells upregulate CTLA4, CD25, and Foxp3 molecules suggestive of regulatory 
function. To evaluate the effi cacy of newRALG in preventing allograft 
rejection, rhesus macaques were treated with newRALG at 0, 1, 2.5, 5, or 20 
mg/kg, and thymoglobulin® at 5mg/kg for 5 days. Fifteen animals underwent 
renal transplantation. Lymphocyte and monocyte counts were decreased 
following newRALG infusion, and reduced lymphocyte proliferative response 
in MLR. The allograft survival in untreated monkeys (n=6) was 6.5±1.4 days. 
Thymoglobulin® treated monkeys (n=3) rejected renal allografts between 
11 to 27 days (mean=17±8.7). Monkeys treated with 2.5 mg/kg newRALG 
rejected allograft in a mean of 16.7±10.8 days, and those treated with 5 mg/
kg rejected allograft in a mean of 26.3±7.1 days (p=0.01, vs thymoglobulin®). 
Rabbit antibody was cleared within 14 days of infusion as determined by 
FACS analysis of peripheral lymphocytes. Thus, newRALG inhibits rhesus 
lymphocyte proliferation in MLR in vitro and in vivo, depletes monocytes 
and lymphocytes including memory T cells in vivo, and signifi cantly prolongs 
renal allograft survival in rhesus. This strategy for generating memory selective 
polyclonal antibodies may offer a better means of depleting alloreactive cells 
than current, non-selective polyclonal strategies.
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POST-TRANSPLANT TUBERCULOSIS: SINGLE CENTER 804 
EXPERIENCE FROM THE DEVELOPING WORLD
U. Hegde, K. Gogel, S. Gang, M. Rajapurkar
Muljibhai Patel Urological Hospital, Nadiad,Gujarat,India
Tuberculosis incidence is high in the transplant recipients especially in the 
developing countries. Objective: The aim of our study is to study the prevalence 
and to predict the risk factors for post-Transplant (Tx) Tuberculosis(TB)
Methods: This retrospective study is based on 498 renal allograft recipients 
transplanted during the period January 2000 to December 2004. TB was 
diagnosed AFB +vein fl uid or tissue/histology suggestive of TB/ exudative 
lymphocytic effusion/PUO with therapeutic response to anti-tubercular 
therapy (ATT). Kaplan-Meier survival analysis and log rank statistics were 
used to study the association between explanatory variables and post-Tx TB. 
Cox proportional hazard model was used to measure the risk factors for TB in 
the early (<18 Months) and late (>18 Months) post-Tx. period. The variables 
considered were age, gender, donor type, MMF, HBV and HCV, DM, PTDM, 
CMV, rejection and dialysis duration in months were analyzed using SPSS
Results: M/F: 388/110 with age 37.9 + 11.2 years .The prevalence of TB 12.85% 
(64/ 498) over median (range) 39 (1, 90) months follow up. 46 had an early 
while 18 had late onset post-Tx. TB. In the early TB; age (p=0.02) and other 
than related donors (p=0.01) while in the late TB age (p=0.03), MMF (p=0.007), 
PTDM (p=0.02) and duration of dialysis (p=0.04) were found to be the pre-
disposing factors. No difference in the graft survival and patient survival in those 
who suffered and not suffered the tuberculosis in the post transplant period.
Conclusion: Age, other than related donor in the early post-ttransplant period; 
Age, MMF, PTDM, dialysis duration in the late post-transplant period were 
pre-disposing factors for the occurrence of the post-transplant tuberculosis.
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HIGHER RISK OF TUBERCULOUS INFECTIONS AND 805 
COMPLICATIONS IN HEPATITIS B OR C TRANSPLANT 
RECIPIENTS THAN NON-CARRIER
B.Y. Choy, D. Yap, K.C. Tse, S.L. Lui, T.M. Chan, K.N. Lai
Department of Medicine
To determine the prevalence and risk factors for tuberculous infection (TB) 
among the Chinese transplant recipients, we retrospectively analyzed all 
renal transplant recipients who had been followed up in our centre from 
1995 to 2007. Of the 436 patients, 21 patients (4.8%) were diagnosed to 
have tuberculous infection. Seven patients were hepatitis B carrier and 3 
were hepatitis C carrier. Seven patients were diabetic. The median interval 
between transplant and diagnosis of TB was 89.5 months (range 3.8 to 247 
months) and the mean age was 48.5 ± 8.3 years. Immunosuppressive therapy 
consisted of triple therapy with cyclosporine A/tarcolimus, prednisolone 
and azathioprine/mycophenolate mofetil. Hepatitis carriers were on double 
therapy with omission of azathioprine. All except one hepatitis B carrier were 
on lamivudine. Majority of patient had pulmonary involvement (71.4%). 
Other site of involvement included disseminated disease 14.5%, laryngeal 
9.5%, urological 9.5% and skin 9.5%. All patients were treated with standard 
4 drugs regime with isoniazid, rifampicin, levofl oxacin/moxifl oxacin and 
pyrazinamide/ethambutol with reduction to 2 drugs after 3 months if stable. 
Doses of cyclosporine A /tarcolimus were adjusted according to serum level 
and the treatment course was 9 to 12 months. Hepatitis B carrier status (OR 
5.27, p<0.01), hepatitis C carrier status (OR 7.9, p<0.01) and DM (OR 3.65, 
p<0.01) were independent risk factors for TB infection. Hepatitis B and C 
carriers were also associated with higher liver related complications. Two 
hepatitis B patients had fl are up of the viral hepatitis needing replacement of 
lamivudine with adefovir /entecavir. One hepatitis B patient had rifampicin 
related hepatitis and another with rifampicin related thrombocytopenia. One 
hepatitis C patient had isoniazid related hepatitis. Complications in non-
carriers included gouty arthritis in two and isoniazid related neuropathy in 
one. Two patients (1 hepatitis C and 1 non carrier) died due to uncontrolled 
co-infections. All other patients recovered. In summary, tuberculous infection 
was associated with signifi cant morbidity and mortality in renal transplant 
recipients. Hepatitis B and C carriers are more prone to TB infection 
and development of liver related complications. Close monitoring of the 
liver function and the level of viral replication of the hepatitis carriers are 
important during the treatment course for proper diagnosis and treatment of 
any liver dysfunction.
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RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS 806 
WITH PALIVIZUMAB IN PEDIATRIC LIVER TRANSPLANT 
RECIPIENTS
A. Campbell1,2, N. Kerkar1
1Mount Sinai School of Medicine, 2Abbott
Background: Respiratory syncytial virus (RSV) lower respiratory tract 
infection (LRTI) in the post-transplant period is associated with signifi cant 
morbidity and mortality. Palivizumab, a RSV-specifi c monoclonal antibody, 
has been shown to reduce the incidence of RSV hospitalization and the severity 
of breakthrough disease in preterm infants with and without chronic lung 
disease and infants with hemodynamically signifi cant congenital heart disease. 
As part of a comprehensive immunization program in pediatric liver transplant 
(PLT) candidates and recipients at Mount Sinai, palivizumab (15 mg/kg IM 
monthly during RSV season) was recommended for PLT recipients <4 years 
of age beginning 2003. 
Objective: To describe the impact of palivizumab prophylaxis on RSV 
infections in PLT recipients at Mount Sinai School of Medicine. 
Methods: Retrospective chart review of PLT recipients <4 years of age 
transplanted between 01/01/2000 and 12/31/2005 was performed. 
Results: 76 PLT recipients were identifi ed; 36 received palivizumab 
prophylaxis and 40 did not. Demographics did not differ between PLT 
recipients who received palivizumab and those that did not with respect to 
gender (55.6% and 60.0% female, p=0.814), race (63.9% and 57.5% non-
white, p=0.150) mean age at transplant (0.94 years and 1.2 years, p=0.600) and 
indication for transplantation (61.1% and 60.0% extrahepatic biliary atresia, 
p=0.641). The rate of RSV infections did not differ between the PLT recipients 
who received palivizumab and those who did not (8.3% and 10%, p=0.802); 
however, the rate of RSV hospitalization did differ (0% palivizumab and 10% 
no palivizumab, p=0.05). RSV infections manifested more frequently as a 
LRTI in children who did not receive palivizumab prophylaxis compared to 
those who did (75% and 0%, p=0.047). The mean hospital length of stay was 
7.5 days (range, 3-13 days). Two children required admission to the intensive 
care unit and mechanical ventilation; all required supplemental oxygen. There 
were no deaths attributed to RSV. 
Conclusion: This retrospective review suggests that palivizumab may prevent 
progression of a RSV URTI to a LRTI and prevent hospitalization when 
administered prophylactically in PLT recipients. To understand the full extent 
of the benefi t of palivizumab prophylaxis in this population prospective studies 
are necessary.
POSTER BOARD NUMBER P4 – 416
BENEFITS OF ISONIAZID CHEMOPROPHYLAXIS IN 807 
RENAL TRANSPLANT RECIPIENTS
A. Naqvi, M. Hussain, R. Naqvi, S. Akhtar, F. Akhtar, E. Ahmed, A. Rizvi
Sindh Institution of Urology And Transplantation
Purpose: The incidence of post transplant tuberculosis is 15% in the 
developing world. The aim of this study was to evaluate effect of Isoniazid 
(INH) chemoprophylaxis on post transplant TB infection. 
Methods: Four hundred and two patients were randomized and 187 received 
INH prophylaxis at 300mg/day for one year and 215 without prophylaxis were 
taken as controls prior to transplantation. Primary disease and co-morbidities 
were similar in both groups. Immunosuppression was by triple drug. All 
patients were followed for 1 year. 
Results: The exposure risk factors in treated group A and controls group B 
were, past TB 5.3% A vs 5.5% B, TB in close contacts 3.2% A vs 2.7% B, 
acute rejection 10.1% A vs 10.2% B, smoking 12.7% A vs 9.6% B. At one 
year follow-up 1 (0.62%) patient from group A and 10 (5.9%) from group B 
developed TB. Site of TB was pulmonary in 9, joint in 1 and lymph node in 1. 
The average duration of TB development was 32 weeks (range 11 64).
Conclusion: The study has shown that INH prophylaxis reduces post transplant 
tuberculosis. Chemoprophylaxis may thus play an important role especially in 
developing centres where TB is endemic.
POSTER BOARD NUMBER P4 – 417
TRANSPLANTATION OF KIDNEYS FROM ANTI HCV 808 
POSITIVE DONORS – RESULTS
A. Paul1, K. Nowak1, A. Gallinat1, F. Pietruck2, F. Saner1, O. Witzke2, J. 
Treckmann1
1University Hospital Essen, Clinic for General, Visceral and Transplantation 
Surgery, 2University Hospital Essen, Clinic for Nephrology
Strategies for increasing the pool of kidney donors include acceptance of 
donors with chronic infections like hepatitis c virus (HCV) infection. 5% of 
all potential donors in Europe are positive for antibodies to HCV. Only few 
centres in Europe include acceptance of kidneys of HCV positive donors 
in their centre profi le leading to the fact that most of the organs from HCV 
positive donors in the Eurotransplant region are transplanted at the University 
of Essen (Germany). The outcome of the recipients of kidneys of anti HCV 
positive donors is analysed in this study. 
Patients and Methods: Between September 2002 and May 2007 51 patients 
(25 women, 26 men) were transplanted with kidneys of anti HCV positive 
donors. 30 recipients had a chronic HCV infection before transplantation. 
The remaining 21 recipients were HCV negative. 20 of them were 
transplanted after HCV PCR was performed with negative result. One patient 
(age 70) was transplanted with a PCR positive kidney and infected. All 
patients signed an informed consent concerning the risk of new infection 
and possible deterioriation of the underlying HCV infection. Peripoperative 
data as well as data concerning graft function, liver function and serological 
examinations (anti HCV antibodies, HCV PCR) were collected and 
analyzed prospectively.
Results: Graft survival after one year was 87% and patient survival 95%. 
Thursday 14 August 2008 Oral Abstracts
2 8 2
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
One patient was newly infected with HCV without actual consequences 
concerning liver function but received a well functioning graft of a 25 year 
old donor (s. patient and methods). Two patients with underlying HCV 
infection showed deterioriation of liver function one without correlation to 
transplantation one with genotype crossing. Of the 20 recipients without 
HCV infection transplanted with kidneys of anti HCV positive donors with 
negative HCV PCR none got infected. Mean waiting time of the study 
group was 12 months shorter than mean waiting time in the Eurotransplant 
region. 
Conclusion: Acceptance of kidneys of anti HCV positive donors increases 
the donor pool and is safe for recipients with chronic HCV infections. Also 
recipients without HCV infection can be transplanted safely if PCR is negative. 
In rare cases especially in old recipients HCV infection can be accepted as 
consequence of transplantation.
POSTER BOARD NUMBER P4 – 418
SYK, A NOVEL THERAPEUTIC TARGET FOR PTLD, 809 
DRIVES EPSTEIN BARR VIRUS (EBV)+ B CELL LYMPHOMA 
GROWTH AND SURVIVAL THROUGH ACTIVATION OF THE 
PI3K/AKT PATHWAY
O. Hatton1,2, S. Lambert1,2, M. Vaysberg1,2, J. Sharman3, S. M. Krams1,2, C. O. 
Esquivel1, O. M. Martinez1,2
1Department of Surgery/Division of Transplantation, Stanford University 
School of Medicine, 2Program in Immunology, Stanford University School 
of Medicine, 3Department of Medicine/Division of Hematology/Oncology, 
Stanford University School of Medicine
Post-transplant lymphoproliferative disorder (PTLD)-associated Epstein Barr 
Virus (EBV)+ B cell lymphomas are a serious, and often fatal, complication 
of solid organ and bone marrow transplantation. Currently, therapeutic 
options are limited and, apart from reducing immunosuppression, there is no 
consensus regarding treatment strategies. EBV+ B cell lymphomas associated 
with PTLD express several viral genes including latent membrane protein 
2A (LMP2A). LMP2A mimics a constitutively active B cell receptor (BCR) 
and provides survival signals to latently infected host cells in part by the 
recruitment of the Syk tyrosine kinase and activation of downstream signalling 
pathways, such as the PI3K/Akt pathway. We hypothesized that inhibition of 
Syk activity would diminish growth of EBV+ B cell lymphoma lines derived 
from patients with PTLD. Treatment with R406, an orally available inhibitor 
of Syk, decreased proliferation and induced apoptosis of these lymphomas, 
as assayed by 3H-thymidine incorporation and Annexin-V/PI staining, 
respectively. Western Blot analysis for total Syk and autophosphorylated 
Syk (Y525/526) revealed that Syk is constitutively activated in these 
PTLD lines. Additionally, treatment with R406 led to a decrease in Syk 
autophosphorylation at Y525/526, suggesting that Syk is the target of 
the small molecule inhibitor R406. Syk is the tyrosine kinase exclusively 
responsible for the phosphorylation of B cell linker protein (BLNK, SLP-65), 
an important component of the BCR signalling pathway. Treatment of Ramos 
cells, a human Burkitt’s lymphoma line, with R406 led to a decrease in the 
phosphorylation of BLNK upon BCR ligation as determined by intracellular 
staining. Together, these data verify that Syk is the target of R406. The PI3K/
Akt pathway plays a crucial role in cell growth and survival; in EBV+ B 
cell lymphomas, activation of the PI3K/Akt pathway leads to, among other 
things, secretion of the autocrine growth factor IL-10. Akt is constitutively 
activated in EBV+ B cell lymphoma lines; however, treatment with R406 
or Syk siRNA resulted in a signifi cant decrease in levels of phosphorylated 
Akt, as determined by Western Blot. Additionally, treatment of PTLD lines 
with R406 or Syk siRNA led to decreased autocrine IL-10 production. These 
data indicate that Syk mediates its effects on EBV+ B cell lymphoma growth 
and survival in part through activation of the PI3K/Akt pathway. Thus, these 
results provide mechanistic insight into how targeting Syk with inhibitors 
such as R406 may serve as an effective therapeutic strategy for the treatment 
of EBV-associated PTLD.
POSTER BOARD NUMBER P4 – 419
GUIDELINES AND PHYSICIAN PRACTICES IN 810 
RELATION TO VACCINATION OF BONE MARROW 
TRANSPLANT (BMT) RECIPIENTS – THE AUSTRALIAN 
PERSPECTIVE
A. Torda1, J. Alexander1, N. Gilroy2
1Prince of Wales Hospital, Sydney, 2Westmead Hospital, Sydney
Background: Following BMT, not only are patients at risk of infection because 
of immunosuppression, they also lose immunity acquired from previous 
immunisation against vaccine preventable infections. As a result of this, bone 
marrow transplant recipients need re-vaccination against a number of vaccine 
preventable. The aim of this project is to review available guidelines for the 
vaccination of bone marrow transplant recipients and examine knowledge of 
and compliance with local guidelines in a local group of transplant physicians 
and recipients. 
Method: A questionnaire was administered to physicians involved in bone 
marrow transplantation and bone marrow transplant recipients. This physician 
questionnaire examined their knowledge of and practices in relation to 
vaccination of BMT recipients. A questionnaire was also sent out to BMT 
recipients to examine what vaccinations they had received and how these had 
been organised.
Results: Two major international guidelines were most commonly used by BMT 
physicians to guide their practice. There are no national Australian guidelines 
specifi cally for this group of patients, and some hospitals have even developed 
their own. In relation to vaccination practices, there was signifi cant variation 
amongst physicians. Most physicians felt that vaccinations were important, but 
did not initiate them or have a system for ensuring that patient vaccinations 
were carried out. Patient responses echoed this variability even more, and 
confi rmed that many patients had not received appropriate vaccination.
Conclusion: This study highlights the need for national post-BMT vaccination 
guidelines in Australia. It also suggests that systems need to be developed 
for ensuring that appropriate post-BMT vaccinations are actually performed 
regularly.
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SILENCING OF HLA CLASS I EXPRESSION BY 811 
LENTIVIRUS VECTOR-MEDIATED RNA INTERFERENCE 
RESULTS IN RESISTANCE OF PRIMARY HUMAN CELLS TO 
ALLOREACTIVE T CELL-MEDIATED CYTOTOXICITY
N. Kasahara1,2, N. Lemp1, K. Houston2, C. Rhodes2,S. Musa2, K. Haga1, R. 
Stripecke1,3, R. Mendez2,4, C. Kruse5, J. Cicciarelli2,4
1University of California Los Angeles (UCLA), 2National Institute of 
Transplantation, 3Hannover Medical School, 4University of Southern 
California (USC), 5Sidney Kimmel Cancer Center
Background: Recent advances in vector technology now allow the 
possibility of genetically engineering graft tissues to express reduced 
levels of HLA. Reducing HLA expression could help to overcome the 
limitations imposed by polymorphisms which restrict availability of 
suitable donors, complicate logistics of procuring and delivering matched 
tissues and organs, and necessitate life-long immunosuppression. We 
have previously shown that lentiviral vectors can be used to deliver short 
hairpin RNAs (shRNA) that knock down HLA expression in a class- or 
allele-specifi c manner in established human cell lines, and thereby allow 
evasion from immune recognition by alloreactive T cells. Here we have 
further characterized and quantitated the effects of dose-dependent gene 
transfer and shRNA-mediated knockdown of HLA in human cell lines and 
primary cells on their ability to be recognized by alloreactive cytotoxic T 
lymphocytes (alloCTL). 
Materials & Methods: Lentiviral vectors for shRNA targeting Class I-specifi c 
and HLA-A0201 allele-specifi c sequences were employed to transduce 293T 
human embryonic kidney cells and CD34+ human primary hematopoietic 
progenitor cells. Transduced target cells were analyzed for sensitivity to 
cytolysis by incubation with HLA A2-activated alloCTL at an E:T ratio of 10:1. 
Oral Abstracts Thursday 14 August 2008
2 8 3
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Interferon-gamma production from the alloCTLs was measured by ELISA, and 
viability of target cells was determined by MTS assay, annexin V staining, and 
complement-mediated cytotoxicity assay.
Results: With higher multiplicities of infection (MOI=10-30), cell surface 
expression of HLA-A2 and HLA-ABC was reduced in a dose-dependent 
manner by 50% or >80%, respectively, compared to cells transduced with 
control vector. Additionally, relative to target cells transduced with control 
vector, target cells transduced with HLA-ABC shRNA and HLA-A0201 
shRNA vectors induced 2.5- and 4.5-fold less interferon production from 
alloCTL, respectively, and exhibited >2-fold enhanced resistance to alloCTL-
mediated killing (p<0.05). However, there were no signifi cant differences in 
survival of shRNA vector-transduced target cells compared to control vector-
transduced cells after incubation with non-HLA-restricted LAK cells derived 
from the same donor.
Conclusions: Reducing expression of HLA in a class- or allele-specifi c manner 
may be as effective as utilization of powerful non-specifi c immunosuppressive 
drugs, and would represent a fundamental shift in the concept of achieving 
histocompatibility, by engineering the graft rather than immunosuppressing the 
host. While effi cient gene transfer to entire solid organs remains a technical 
hurdle, application of this strategy can be readily envisioned for ex vivo 
transduction of cellular transplants such as bone marrow and stem cells, 
pancreatic islet cells, and keratinocytes.
POSTER BOARD NUMBER P4 – 421
HUMAN PLASMACYTOID DENDRITIC CELLS INDUCE 812 
PROFOUND HYPORESPONSIVENESS AND SUPPRESSIVE 
CAPACITY IN ALLOGENEIC T-CELLS
H. Metselaar1, P. Boor1, S. de Jonge1, L. van der Laan2, J. Kwekkeboom1
1Department of Gastroenterology and Hepatology, ErasmusMC -University 
Medical Center, Rotterdam, The Netherlands, 2Department of Surgery, 
ErasmusMC -University Medical Center, Rotterdam, The Netherlands
Background: A major barrier for induction of liver transplant tolerance in 
humans is their large repertoire of allo-reactive memory T-cells, which rapidly 
respond to allo-antigens, even when these are presented by non-professional 
antigen-presenting cells. We investigated whether human plasmacytoid 
dendritic cells (PDC) can induce hyporesponsiveness and suppressive capacity 
in allogeneic T-cells containing memory T-cells. 
Methods: Purifi ed PDC from human blood, were stimulated with Toll-Like 
Receptor (TLR)-7 agonist loxoribine (LOX) or TLR-9 ligand CpG A. After 20 
hours, allogeneic T-cells containing CD45RA+ naïve and CD45RO+ memory 
cells, were added. T-cell proliferation, cytokine production, CD25 and Foxp3-
expression were determined after 7 days. Hyporesponsiveness was assessed 
in re-stimulations with LPS-matured monocyte-derived DC (MoDC), and 
suppressive capacity was determined by adding graded numbers of PDC-
primed T-cells to responder T-cells stimulated by mature MoDC, either derived 
from the same donor as PDC, or from a third party.
Results: Toll-like receptor (TLR)-stimulated PDC primed allogeneic T-cells 
to produce IL10 (CpG-PDC: 668±260 pg/ml; LOX-PDC: 715±369 pg/
ml). After stimulation with CpG-PDC or LOX-PDC 13±2% and 14±2%, 
respectively, of allogeneic CD4+ T-cells acquired Foxp3 and CD25-
expression. CFSE-dilution showed that TLR-stimulated PDC induced 
proliferation of CD4+Foxp3hi T-cells. No Foxp3hi T-cells were generated 
when CD25+ T-cells were depleted from allogeneic T-cells prior to their 
stimulation with PDC, showing that their enrichment was due to expansion 
from pre-existing Treg. T-cells primed by TLR-stimulated PDC were 
hyporesponsive upon restimulation with mature MoDC derived from the 
same donor (90% decrease in proliferation compared with fresh T-cells), 
and suppressed responder T cells stimulated by mature MoDC in a dose-
dependent and donor-specifi c fashion (55% inhibition of proliferation at 
suppressor:responder ratio of 1:2). Suppression was abrogated by anti-IL10 
receptor antibody. 
Conclusion: TLR-stimulated human PDC induced profound hyporesponsiveness 
nand suppressive capacity in allogeneic T-cells, including memory T-cells. 
Cellular immunotherapy with PDC from donor blood may be considered as 
a promising approach to silence the allo-reactive repertoire of liver transplant 
recipients. 
POSTER BOARD NUMBER P4 – 422
HOST MHC CLASS I-DEPENDENT IMMUNITY IMPAIRS 813 
ISLET XENOGRAFT PROLONGATION
F. Ramirez-Victorino1, J. Beilke2, R.G. Gill3
1University of Colorado Health Sciences Center, 2University of California, 
San Francisco, 3University of Alberta/Alberta Diabetes Institute
Background: Recent studies show an unexpected role for host MHC class 
I-dependent immunity and NK cells in promoting islet allograft tolerance. In 
this study, we determined whether induced islet xenograft prolongation also 
showed a reliance on MHC class I-dependent pathways. In particular, we tested 
whether NK1.1+ NK/NKT cells and/or CD8 T cells were required for the long-
term (>100 day) survival of rat islet xenografts following a short course of 
combined anti-CD154 plus anti-LFA-1 monoclonal antibody therapy. 
Methods: 450 WF (RT1u) islets were grafted beneath the kidney capsule of 
streptozotocin-induced diabetic C57Bl/6 (B6; H-2b), B6 NKT cell-defi cient 
CD1-knockout, or CD8 T cell-defi cient CD8-knockout mice. Recipients 
were either untreated or treated with combined anti-CD154 (MR1; 250 μ;g d 
–1,2,7,9) plus anti-LFA-1 (KBA; 200ug d 0,1,7,14). In addition, some animals 
were also depleted of NK1.1+ cells prior to transplant (PK136; 500ug d –1). 
Long-term (>100 day) xenograft survival was confi rmed by nephrectomy of 
the graft-bearing kidney with subsequent return to hyperglycemia.
Results: WF rat islet xenografts were rapidly rejected in all untreated wild-type 
B6, CD1-defi cient, and CD8-defi cient recipients (all rejecting within 13 days) 
indicating that neither CD1-dependent NKT cells nor CD8 T cells are required 
for rejection. In wild-type B6 mice, anti-CD154/anti-LFA-1 treatment resulted 
in prolonged, but not indefi nite xenograft survival (6/6 grafts rejecting in 62.3 ± 
14 days). Such xenograft prolongation was not signifi cantly enhanced in treated 
CD1-defi cient mice (6/9 grafts rejecting in 57.9 ± 12 days; p = NS). In contrast, 
while anti-NK1.1 treatment itself did not prolong xenograft survival, adjunct 
depletion of NK1.1+ cells greatly enhanced the effi cacy of anti-CD154/anti-
LFA-1 therapy with 5/6 xenografts surviving >100 days (p = 0.015 relative to 
anti-CD154/anti-LFA-1 therapy alone). Furthermore, anti-CD154/anti-LFA-1 
therapy showed greater effi cacy in CD8-defi cient animals (6/6 xenografts 
surviving >100 days; p < 0.01 relative to wild-type).
Conclusions: While previous studies show that the depletion of NK1.1+ 
cells inhibits islet allograft survival, this same approach greatly augments the 
survival of islet xenografts. Thus, the role of NK1.1+ cells can play opposite 
roles in the prolongation of islet allografts versus xenografts. Also, while CD8 
T cells are not required for acute xenograft rejection, they do constitute a 
resistance to induced xenograft prolongation in this model. Thus, both NK1.1+ 
cells and CD8 T cells represent MHC class I-dependent immune pathways that 
can impede long-term islet xenograft prolongation. 
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CD300A AND CD300C ON PLASMACYTOID DENDRITIC 814 
CELLS ARE DOWN-REGULATED BY TLR7 AND TLR9 LIGAND 
INDUCED TYPE I INTERFERON
D. Hart1, G. Clark1, X. Ju1, M. Zenke2
1Mater Medical Research Institute, 2Institute for Biomedical Engineering, 
Department of Cell Biology, Aachen University Hospital, Aachen, Germany
The success of transplantation relies on the ability to control immune responses. 
The CD300 family of leukocyte surface molecules are immunoregulatory 
glycoproteins that balance the immune response. In humans, there are 6 
members of the family, CD300a-f. Both CD300a and CD300c are broadly 
expressed on leukocytes, CD300b, d, and f are expressed on myeloid cells 
and dendritic cells, whilst CD300e is restricted to monocytes. Plasmacytoid 
dendritic cells (pDC) constitute a distinct population of DC in the peripheral 
and secondary lymphoid organs. Human pDC numbers predict for the success 
of haematopoietic stem cell transplantation and acute graft versus host disease 
(GVHD). High numbers of pDC in a graft facilitate engraftment. In this study 
we analysed the expression of CD300a and CD300c on pDC. After activation 
with the ligands for Toll-like receptors (TLRs), particularly TLR7 and TLR9, 
pDC secrete large amounts of type I interferons and differentiate into mature 
DC, expressing co-stimulatory molecules and other cytokines. CD300a and 
CD300c cell surface molecules are expressed by pDC and their expression was 
down-regulated by CpG ODN binding TLR9. Because these CD300 molecules 
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play important roles in regulating immune responses, we investigated their 
contribution to pDC function in more detail. First, their down-regulation by 
CpG-ODN was confi rmed by real time PCR and RT-PCR for CD300a and 
CD300c. Using the monoclonal antibody CMRF-35, to detect both CD300a 
and CD300c, we demonstrated that both TLR7 and TLR9 ligands down-
regulated cell surface CD300a and CD300c. We showed that exogenous IFN-á 
down-regulated CD300a/c expression in pDC. This suggested that the TLR 
ligand induced down-regulation of CD300a/c might be an indirect effect and 
in subsequent experiments, we added neutralizing antibody to IFN-á and found 
that, it abolished the CpG-ODN induced CD300a/c down-regulation. The effect 
of CD300a and CD300c activation on the function of pDC was investigated by 
cross-linking CMRF-35 on pDC. This had no effect on CD80, CD83 and CD86 
expression, but decreased MHC-II expression. Signifi cant reductions in pDC 
TNF-á and IL-6 production occurred after CMRF-35 cross-linking, however, 
in marked contrast, CpG-ODN induced IFN was increased in pDC cross-linked 
with CMRF-35. Thus the immune regulators CD300a and CD300c regulate the 
cytokine production in pDC, whilst the pDC released cytokines regulated the 
CD300a/c expression. This suggests that CD300 molecules may play a pivotal 
role in fi ne tuning pDC driven immune responses. CD300a and CD300c are 
also expressed on conventional DC (cDC). Our results indicate that these 
molecules also regulate cytokine secretion by cDC. Thus members of this 
family are likely to be important regulators for controlling transplant rejection 
and might be useful therapeutic targets.
POSTER BOARD NUMBER P4 – 424
T CELLS ACQUIRE HLA-G VIA TROGOCYTOSIS FROM 815 
GENETICALLY MODIFIED HUMAN DENDRITIC CELLS 
DURING ALLOIMMUNE ACTIVATION
B. Fedoric1,2, R. Krishnan1,2
1The Queen Elizabeth Hospital, 2University of Adelaide
The Human Leukocyte Antigen (HLA-G) is expressed in the placenta and has 
a role in protecting the foetal allograft from being rejected by the maternal 
immune system. Immunomodulation mediated by HLA-G is predominantly 
due to its interaction with its inhibitory ligands, ILT2 and ILT4 which belong to 
the Immunoglobulin-like transcript (ILT) family of molecules. Recent studies 
have reported that HLA-G can transfer to T cells via membrane cell fragments 
by the process of trogocytosis using LCL cell lines expressing HLA-G. 
Since dendritic cells (DC) are the major antigen presenting cells that initiate 
allograft rejection, the ability of these cells to transfer HLA-G to allogeneic T 
cells was investigated. Due to the low levels of HLA-G on human monocyte-
derived dendritic cells, adenoviral gene constructs were used to transduce high 
expression of the protein. 
Adenoviral constructs containing the gene for the trans-membrane, HLA-G1 
(ADV-HLA-G1), and the secreted, HLA-G5 (ADV-HLA-G5) isoforms were 
used to transfect DC. Flowcytometry confi rmed that DC expressed low HLA-G 
and following transfection with ADV-HLA-G1, induction of cell surface 
expression occurred (MFI of 3000 in HLA-G1 transfectants vs. 100 in control 
transfectants). In addition, the HLA-G1 expressed on DC-transfectants showed 
binding to ILT2-Fc (87% HLA-G1 transfected DC) indicating that the HLA-G1 
was structurally functional. DC transfected with ADV-HLA-G5 and ADV-VB 
(vector-blank) showed no detectable cell surface expression of HLA-G. 
DC transfectants were then tested for their ability to transfer HLA-G to 
allogeneic T cells using two different approaches. In the fi rst approach, T 
cells were pre-activated with IL2/PHA for 72 h prior to co-incubation with the 
specifi c DC transfectants for 1 h at 370 C to allow for trogocytosis and then 
stained with the anti-HLA-G mAb, 87G. Two colour fl owcytometry analyses 
showed that 10% of T cells expressed HLA-G upon co-incubation with HLA-G1 
DC transfectants compared with 0.4% for ADV-HLA-G5 transfectants. Control 
T cells that were not pre-activated were unable to acquire HLA-G1 from DC 
transfectants. In the second approach, allogeneic T cells as responders were 
cocultured with DC transfectants as stimulators in a ratio of 10:1 in a DC-MLR 
and analysed for HLA-G transfer to T cells after 3 and 5 days, respectively. 
Under these conditions, 22% of T cells acquired HLA-G from HLA-G1 
transfectants compared to a baseline of 6% for HLA-G5 transfectants. HLA-G 
acquired by T cells was observed as early as 1 h, peaked at day 3 and was 
maintained at 5 days of culture. Functional assays of the T cells cocultured 
with HLA-G1 transfectants demonstrated hyporesponsiveness to interleukin-2 
(IL-2) stimulation (43% proliferation compared to control; p=0.05). 
In conclusion, this study demonstrates that DC genetically modifi ed to express 
only the transmembrane isoform of HLA-G were able to transfer to allogeneic 
T cells via trogocytosis. In addition, allogeneic T cells that acquire HLA-G 
by trogocytosis demonstrate hyporesponsiveness to IL-2 stimulation. These 
observations suggest that genetically modifi ed DC expressing HLA-G may 
offer a novel approach to modify the alloimmune response to facilitate organ 
allograft acceptance.
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ROLE OF HETEROLOGOUS IMMUNITY IN REJECTION 816 
OF SKIN AND ISLET GRAFTS
B.F. de St Groth1, D. Gracey2, Y.W. Loh1
1Centenary Institute of Cancer Medicine and Cell Biology, 2Prince of Wales 
Hospital
The role of naïve versus heterologously primed T cells in graft rejection 
mediated via the direct allorecognition pathway remains controversial. While 
purifi ed populations of either naïve or memory phenotype T cell receptor (TCR) 
transgenic cells can reject skin grafts after transfer to immunodefi cient hosts, 
spontaneous or homeostatic proliferation of naïve T cells in the immunodefi cient 
environment generates activated T cells, making interpretation diffi cult. As 
a direct test of the involvement of naïve versus memory cells in skin graft 
rejection, we used a model in which 5C.C7 TCR transgenic T cells recognise 
IAs, in addition to their primary specifi city for moth cytochrome c (MCC) in the 
context of IEk or IEb. The important feature of this model is that all endogenous 
T cells remain naïve in 5C.C7 TCR transgenic mice on a RAG-/- background, 
and transferred naïve 5C.C7 TCR RAG-/- cells do not undergo spontaneous 
proliferation. Fully allogeneic H-2s skin grafts were accepted indefi nitely by 
5C.C7 TCR RAG-/- mice, but were rejected promptly after transfer of memory 
but not naïve T cells from 5C.C7 TCR RAG-/- mice primed with MCC 2 months 
earlier. On the other hand, H-2s skin grafts were rapidly rejected by AND TCR 
RAG-/- mice, which share the 5C.C7 specifi city for MCC-IE and IAs but have up 
to 20% CD44hi memory cells as a result of ongoing spontaneous prolliferation. 
Thus in these monoclonal models, memory but not naïve T cells can reject skin 
grafts via the direct pathway of alloreactivity. 
To understand why naïve T cells could not reject skin grafts, we studied 
traffi cking of dendritic cells (DCs) from skin grafts to draining LN where naive 
T cells are situated. Skin from transgenic mice expressing GFP-tagged IAb was 
grafted onto syngeneic H-2b and allogeneic H-2k hosts. No GFP-expressing 
DCs could be detected in draining LN in either host. As a positive control, 
subcutaneously injected DCs from GFP-tagged IAb mice were detected in 
draining LN. As an additional control, the response of CFSE-labelled 5C.C7 
TCR RAG-/- cells to H-2s skin grafts and subcutaneously injected H-2s DCs 
was determined. T cells responded vigorously to injected DCs, but made no 
response to skin grafts. Finally we isolated the cellular infi ltrate from H-2s skin 
grafts and showed that CD44hi 5C.C7 TCR cells from unprimed mice were 
recruited into the grafts within 1 day. 
These studies indicate that heterologously primed T cells are crucial in rejection 
of skin grafts. We are now testing these fi ndings in a second nonvascularised 
graft model, in which pancreatic islets from H-2s donors are grafted under the 
kidney capsule of H-2k hosts. Given the diffi culty of inducing tolerance in 
heterologously primed T cells, these data suggest that alternative strategies to 
promote graft acceptance will be required for nonvascularised grafts. 
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INDUCTION OF IMMUNOSUPPRESSIVE DENDRITIC 817 
CELLS BY A NOVEL NUCLEAR FACTOR-KAPPA B 
INHIBITOR, DHMEQ
T. Aoyagi1,2, K. Yamashita2, Y. Yanagawa3, R. Goto2, M. Ozaki2, K. Onoe3, K. 
Umezawa4, S. Todo2
1Gastroenterology Center, Surgery Division, Hakodate Municipal Hospital, 
21st Dept of Surgery, Hokkaido Univ. School of Med., 3Division of 
Immunobiology, Institute for Genetic Med. Hokkaido Univ., 4Dept of Applied 
Chemistry, Faculty of Science and Technology, Keio Univ.
Background: Dendritic cells (DCs) have a potent property of antigen 
presentation, and play a central role in activating the immune responses. An 
ability of DCs to induce immunity or tolerance appears to be related to their 
state of functional maturation., The transcription factor, nuclear factor-kappa 
B (NF-κB) has been shown to be a key molecule in DCs upon maturation and 
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activation. 
Aim: We examined the effect of a novel NF-κB inhibitor, 
DHMEQ on ex vivo induction of immunosuppressive DCs, and 
assessed the immunosuppressive properties of these ex vivo 
derived DCs in vivo using a mouse heart transplantation model. 
Methods: DCs were propagated from BALB/c (H-2d) mouse bone marrow 
with GM-CSF. DHMEQ (1-5 μg/ml) was supplemented during DC 
generation or before stimulation with LPS or TNF-α. DC phenotype and 
cytokine profi les were examined by fl ow cytometry and ELISA. Also, their 
allostimulatory activity was assessed in vitro by a MLC. Ex vivo generated 
C3H/HeJ (C3H: H-2k) DCs (3x106) with or without DHMEQ was given 
i.v. to C3H mouse, and C57BL/6 (B6: H-2b) heart was transplanted 7 days 
later. Allograft survival was examined without any immunosuppression. 
Results: In contrast to the control DCs, DHMEQ-treated DCs expressed 
lower CD40, CD86, and MHC class II antigen (I-Ad) following LPS and 
TNF-α stimulation (Fig. 1A). This was associated with a dose-dependent 
suppression of IL-12p40 (Fig. 1B) but not IL-6 secretion. Proliferation of 
B6 T cells was inhibited by the DHMEQ-treated DCs as compared to the 
mature DCs (Fig. 1C). Untreated mice rejected B6 hearts at a mean graft 
survival time (MGST) of 11 days (no treatment: n=4). When transplant 
recipient was pretreated with C3H DCs that were pulsed with B6 splenocyte 
lysates during ex vivo generation, MGST was 15 days (control DC: n=6), 
whereas injection of DCs generated in the presence of DHMEQ at 1 and 5 
μg/ml signifi cantly prolonged MGST to 20 (n=5, p<0.005) and 23 days (n=8, 
p<0.005), respectively. 
Conclusion: Inhibition of NF-κB activation by DHMEQ during ex vivo 
generation signifi cantly inhibits phenotypical and functional maturation of bone 
marrow derived murine DCs. Such DCs acquire immunosuppressive properties 
and prolong allograft survival in mice. Use of DCs generated under DHMEQ 
supplimentation may become a new modality in immunosuppression.
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A NOVEL IMMUNOTOXIN HAS CYTOTOXICITY TO 818 
CTLA-4 POSITIVE CELLS WITH SPECIFICITY
H. Cai1, Q. Huang1, L. Wan1, L. Chen1, L. Zeng1,2, H. Yang1, S. Li1, Y. Li1, J. 
Cheng1, X. Lu1
1Key Laboratory of Transplant Engineering and Immunology, Ministry 
of Health, West China Hospital, Sichuan University,, 2Department of 
Hematology, Ayliated Hospital of Medical College of Xu Zhou
Background: Activated T cells play central role in graft rejection. An 
immunosuppressive strategy is to produce immunotoxin that could selectively 
delete activated T cells. Cytotoxic T-lymphocyte antign-4 (CTLA-4) is 
inductively expressed on surface of activated T cells and can function as a 
target molecule for immunosuppressant. 
Method: A novel immunotoxin called mST was constructed by fusing a pore-
forming antifungal peptide to the C-terminus of mouse-derived anti-CTLA4 
single-chain fragment of variable antibody (scFv). The gene was expressed in 
prokaryotic system E.coli M15 as well as eukaryotic system Pichia Pastoris 
GS115. The cytotoxicity of mST protein was detected on cell model. The 
mouse-derived anti-CTLA4 scFv (mS) was also prepared and used as a 
control.
Results: In 1 liter of prokaryotic cell culture, we collected 0.1mg of soluble 
mST protein from cytoplasm and refolded inclusion bodies separately. In 1 liter 
of eukaryotic culture induced by 3% (V/V) methanol, we collected 1mg mST. 
In vitro cytotoxicity assay showed that mST protein purifi ed from prokaryotic 
cytoplasm, inclusion bodies, and eukaryotic cytoplasm had killing rate of 
44.0%(¡À3.8%), 45.0%¡À(10.1%), and 37.5%(¡À2.2%) to CTLA4-positive 
lymphoma cell EL4 at concentration of 1¦ÌM, respectively. Furthermore, mST 
protein did not display obvious killing to CTLA-4 negative cells CEM. At the 
mean time, we found mS proteins produced by the same methods as mST did 
not show cytotoxicity to cells. 
Conclusion: Our results demonstrated that immunotoxin mST had signifi cant 
cytotoxicity to CTLA-4 positive cells. So it suggests that mST have possibility 
as a novel immunosuppressant for deleting activated T cell selectively.
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THE ALLOGENEIC REACTION CAN INDUCE 819 
GENERATION OF SEMI-MATURE REGULATORY DENDRITIC 
CELLS THROUGH CYTOKINE SECRETION: MAJOR ROLE 
FOR IFN GAMMA
A. Eljaafari7, Y-P. LI1, A. Farre2, D. Laurin3, J. Bernaud4, D. Rigal5, 
P. Miossec6, 
1Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux, 2EFS 
Rhone-Alpes, 3EFS Rhone-Alpes, 4EFS Rhone-Alpes, 5EFS Rhone-Alpes, 
6Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux, 
7Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux, 
Centaure Group
Introduction:We have previously demonstrated that the alloresponse can 
induce maturation and migration of immature dendritic cells (DC), through 
cytokine secretion (Transplantation, 2004). We have also reported its action 
on acute myeloid leukaemia blasts (Leukemia, 2006). Here we investigated its 
impact on monocyte differentiation into DCs. 
Methods: Blood monocytes were cultured for 6 days, either with supernatant 
collected from major-histocompatibility Ag-mismatched mixed lymphocyte 
reactions (MLR-Sn), or GM-CSF/IL4, as positive control. APCs were then 
exposed to TNFalpha for two additional days to induce their maturation. As 
negative control, Sn from HLA-identical MLR were used. 
Results: Analysis of monocytes, at the phenotypical level, showed that, as 
compared with HLA-identical MLR-Sn, HLA-mismatched MLR-Sn induced 
in Mo-DCs(i) increased expression of CD54, CD40, HLA-DR, CD80 and 
CD86 molecules, (ii) decreased expression of CD14, CD16 and other 
Fcgamma Rs, and (iii) increased cell size and granulosity, at day 6. However, 
further exposure to TNFalpha did not lead to maturation of these cells, as 
assessed by absence of CD83 expression, and moderate increase in CD86 and 
CD80. At the functional level, these cells were able to endocytose Dextran 
at day 6, but secreted high levels of IL-10 and low levels of IL-12, at day 8. 
Moreover, they were unable to elicit an allo-response, as assessed by CFSE, 
intra-cellular IFNgamma, CD25, and CD28 staining. Finally, upon secondary 
MLRs with these Mo-DCs, T cells expressed high levels of TGF beta, IL-10 
and Foxp3, but no IL-2 mRNAs. Addition of GM-CSF/IL-4 to MLR-Sn 
showed that the defect in maturation was not due to a lack in these cytokines, 
but to the presence of an inhibitory factor, rather. Antibodies directed against 
TNF-R, IL-6, and IFN gamma demonstrated that IFN gamma was the major 
inhibitory factor, since able to restore both CD83 and CD80 expression. 
Accordingly, when reciprocoal experiments were performed with addition 
of IFN gamma to GM-CSF/IL-4, a similar pattern of semi-mature DCs was 
observed.
Conclusion: The infl uence of IFN gamma on Tregs generation and function 
has recently been reported by others. In support with these studies, our results 
suggest a new mechanism by which IFN gamma can modulate the T cell 
response. Indeed, we show that the alloreaction can lead to the generation of 
semi-mature and regulatory DCs from monocytes, preponderantly through IFN 
gamma secretion.
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AN INNATE MEMORY RESPONSE TO ALLOANTIGEN IN 820 
RAG-/- MICE
D. Zecher, Q. Li, F. Lakkis
University of Pittsburgh, Depts. of Surgery and Immunology, Thomas E. 
Starzl Transplantation Institute
Introduction: The adaptive immune system is both necessary and suffi cient 
for the acute and chronic rejection of solid organ allografts. Little is known, 
however, about how the innate immune system triggers and perpetuates 
allograft rejection.
Methods: Using Rag-/- mice, which are devoid of T- and B-cells, we 
investigated the innate immune response to alloantigen in a footpad and ear 
swelling experiment analogous to delayed-type hypersensitivity in wild-type 
mice. We also asked whether the innate immune system is suffi cient to cause 
chronic rejection in a Rag-/- model of heterotopic heart transplantation.
Results: One week after priming Balb/c Rag-/- mice with allogeneic C57BL/6 
(B6) Rag-/- splenocytes (allo), rechallenge with allo induced signifi cantly 
more swelling than challenge with syngeneic Balb/c Rag-/- splenocytes (syn), 
peaking at 6h and gradually declining thereafter (footpad: allo vs. syn: 6h: 0.1 
± 0.02 vs. 0.03 ± 0.01; 12h: 0.08 ± 0.01 vs. 0.01 ± 0.00; 24h: 0.06 ± 0.01 vs. 
0.01 ± 0.01; all p<0.001). Challenge of immunized mice 4 weeks after priming 
also resulted in a signifi cant response to alloantigen (footpad: allo vs. syn: 6h: 
0.16 ± 0.02 vs. 0.09 ± 0.01; 12h: 0.1 ± 0.01 vs. 0.05 ± 0.00; 24h: 0.07 ± 0.01 
vs. 0.03 ± 0.01; all p<0.05). Challenge without prior sensitization resulted in a 
signifi cantly weaker response. We also found that the observed response was 
not NK cell-dependent but that depletion of F4/80+Gr-1int macrophages led to 
an abrogation of the swelling response. All results were comparable between 
ear and footpad. To test whether suffi cient priming or activation of the innate 
immune system alone leads to graft pathology, Balb/c Rag-/- mice were either 
left untreated or immunized with allo with or without complete Freund’s 
adjuvant prior to performing an allogeneic B6 Rag-/- heart transplantation. 
Analysis of the functioning hearts 50 days post-transplantation revealed no 
histopathological evidence of either acute or chronic rejection when compared 
to syngeneic control allografts.
Conclusion: These data provide evidence for a specifi c innate response 
to alloantigen in Rag-/- mice that requires prior priming and is mediated by 
macrophages. The data also suggest the presence of innate memory. Although 
this innate response was not suffi cient for the rejection of vascularized, solid 
organ allografts, it is a refl ection of early allorecognition events that contribute 
to triggering the adaptive alloimmune response. 
This work was supported by the German Research Foundation to D.Z. (ZE 
835/1-1) and NIH grant AI/064343 to F.G.L.
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PROLONGED SURVIVAL OF COMPOSITE TISSUE 821 
ALLOGRAFTS ASSOCIATED WITH POST-TRANSPLANT 
LYMPHOPROLIFERATIVE DISORDER IN A NON-HUMAN 
PRIMATE MODEL
R. Barth, E. Rodriguez, A. Nam, M. Stanwix, R. Bluebond-Langner, 
C. Drachenberg, D. Kukuruga, S. Shipley, S. Bartlett
University of Maryland School of Medicine
Introduction: Composite tissue allotransplantation (CTA) has achieved 
clinical advances in reconstructing soft tissue and bony defects. Despite 
heavy immunosuppressive therapies, signifi cant rejection episodes are still 
encountered. We developed CTA models in non-human primates to investigate 
immunosuppressive strategies to prevent rejection and prolong CTA survival.
Methods: Facial and fi bular composite allografts (bone, muscle, skin) were 
transplanted between mismatched cynomolgus monkeys. Facial CTAs were 
heterotopically transplanted with anastomoses of the carotid artery, internal & 
external jugular veins to femoral vessels. Fibular CTAs were heterotopically 
transplanted into forearm defects. Immunosuppression consisted of 28 days of 
continuous IV tacrolimus monotherapy followed by either tapered doses of IM 
tacrolimus or conversion to oral rapamycin. 
Results: Nine facial and 2 fi bular CTAs were performed. Nine facial allografts 
were transitioned to IM tacrolimus (n=6) or rapamycin (n=3) after 28 days of IV 
tacrolimus monotherapy. Animals maintained on tacrolimus demonstrated mean 
survival of 113 days. One graft rejected after blood transfusion and 5 animals 
had no rejection episodes but developed post-transplant lymphoproliferative 
disorders (PTLD) (day 60-177) resulting in experimental endpoints. Genomic 
analysis of PTLD tumors by short tandem repeat segments demonstrated donor-
origin in 3 of 4 animals. The origin of the fi fth PTLD tumor is currently under 
investigation. None of the animals had clinical evidence of rejection of skin, 
bone, or muscle. Animals converted to rapamycin after 28 days of tacrolimus 
developed rejection and graft loss on days 31 and 80, but did not develop PTLD. 
Two fi bular CTA transplants treated with tacrolimus therapy demonstrated no 
evidence of PTLD (days 30+, 100+), but did not demonstrate prolonged skin 
survival. Bone union of transplanted segments was radiologically confi rmed 
on day 70 and refl ected viability of transplanted bone. Fibular CTAs contained 
less than 5% of bone marrow cells compared to facial CTAs.
Conclusion: We have achieved predictable long-term survival of composite 
tissue allografts in non-human primates. Tacrolimus monotherapy prevented 
rejection of facial composite allografts, but was associated with donor-derived 
PTLD development in a pattern more similar to bone marrow transplantation 
than solid organ transplantation. Conversion to rapamycin failed to prevent 
CTA rejection. Fibular composite allografts had minimal vascularized bone 
marrow, and while tacrolimus monotherapy did not prevent loss of skin, no 
PTLD tumors developed. This is suggestive of association between amount of 
vascularized allogeneic bone marrow and PTLD development.
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USE OF CASPOFUNGIN AMONG RECIPIENTS OF LIVER 822 
TRANSPLANTS WITH HIGH INDEX OF SUSPICION FOR 
FUNGAL INFECTION.
C. Doria, C. Ramirez, A. Frank, C. Daskalakis, V. Kostaras, S. Vaccino, 
R. Measley
Thomas Jefferson University Hospital
Introduction: This study is a retrospective analysis of death, adverse events 
(AE), fungal infections, and hepatic function among recipients of liver 
transplantation at high risk of fungal infection who received caspofungin 
prophylactically. 
Material and Methods: After reviewing data of 105 patients who had received 
isolated liver transplant between January 2003 and April 2007, we identifi ed 
and analyzed 82 high-risk patients. High risk was defi ned by the presence of 
at least one of the following: 1) re-operation 2) fever of unknown origin 3) 
hypothermia 4) positive random culture for fungus at the time of transplant (bile 
and/or ascites) 5) sepsis 6) use of vasopressors 7) re-intubation with mechanical 
ventilation 8) prolonged intubation (>24 hrs) and 9) acute respiratory distress 
syndrome. Exact conditional logistic regression was used to compare the risk 
of death, AEs, and fungal infections in patients who received caspofungin, 
other antifungals, and no antifungals. Analyses were performed with SAS 9.1 
(SAS Institute Inc., Cary, NC).
Results: Patients were between 27 and 72 years old (mean = 55), with two 
thirds male and three quarters white. Sixteen patients were received caspofungin 
(11 prophylactically) and 32 received other antifungals (26 prophylactically). 
Mortality and AEs are shown in table 1. There were no fungal infections among 
the patients who received caspofungin prophylactically, three infections among 
patients who received other antifungals (3/26 = 12%), and fourteen infections 
among patients not treated prophylactically (14/45 = 31%). These infection 
rates were signifi cantly different across the three groups (p = 0.029), with 
caspofungin and other antifungal prophylaxis comparable (p = 0.540), and both 
better than no prophylaxis at all (estimated odds ratio OR = 0.15, p = 0.049, for 
caspofungin versus no prophylaxis; OR = 0.29, p = 0.085, for other antifungal 
versus no prophylaxis). 
Conclusions: Caspofungin appears to be an effective prophylactic agent against 
fungal infection when used in high-risk recipients of liver transplantation. There 
is no apparent increase in risk of death or acute cellular rejection, although we 
observed a signifi cantly higher risk of AEs, especially acute renal failure (p = 
0.001), in patients who received this agent.
Table 1. 
No antifungal 
therapy (N=34)
Other antifungal 
(N=32)*
Caspofungin 
(N=16)*
P
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Death, n (%) 6 (18) 5 (16) 2 (13) 1.000
Any adverse event 
(AE), n (%)
13 (38) 20 (63) 13 (81) 0.011
Acute cellular rejection 
(ACR), n (%)
5 (15) 6 (19) 3 (19) 0.865
Renal toxicity, n (%) 6 (18) 6 (19) 4 (25) 0.874
Acute renal failure, 
n (%)
0 4 (13) 6 (38) 0.001
Hepatotoxicity, n (%) 1 (3) 6 (19) 2 (13) 0.089
Respiratory symptoms 
n (%)
1 (3) 8 (25) 4 (25) 0.015
Congestive heart 
failure, n (%)
0 1  (3) 0 0.585
* Prophylactic use: n=26 for other antifungals; n=11 for caspofungin.
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SIXTY LIVING DONOR LIVER TRANSPLANTATION FOR 823 
WILSON DISEASE.
S. Gautier, O. Tsiroulnikova, E. Kim, A. Filin, E. Chekletsova, O. Malomooge
National Research Center of Surgery
The purpose of the study is to summarize the results of living donor liver 
transplantation (LDLT) in patients with end stage liver cirrhosis due to Wilson 
disease. Since December 1998 till December 2007 60 patients with verifi ed 
Wilson disease underwent 62 LDLT with right hepatic lobe. Twenty two 
patients were adults (9 males and 13 females) with mean age 22.2±1.7 (18 
– 47) years. Thirty eight patients were teenagers (17 males and 21 females) 
with mean age 14±0.4 (9 – 17) years. All patients had Child C liver cirrhosis, 
18 (30.0%) of them demonstrated urgent indications for transplantation. Ten 
patients had different degree of Wilson neurological disturbances. Donors 
were AB0-identical or compatible relatives of patients. Six patients had graft 
weight to recipient body weight ratio (GWRWr) less than 0.8%. GWRWr in 
other cases was 0.8% – 2.4%. Early mortality was observed once on the 19th 
postoperative day due to spontaneous rupture of varicose veins in splenic hilus 
and intraabdominal bleeding. All the rest recipients (98.4%) survived and were 
discharged from hospital with good liver function including 6 recipients with 
small-for-size grafts. Three patients died during the fi rst year due to stroke (1) 
and septic complications (2). One patient died after 18 mo. postoperatively 
because of melanoma. Immunosuppressive protocol in 10 patients with Wilson 
neurological disturbances included steroids and minimal doses of calcineurin 
inhibitors due to their neurotoxicity. Eight recipients demonstrated normalization 
of neurological status including 1 with severe neurological disturbances. In 
2 other patients with severe neurological changes calcineurin inhibitors were 
withdrawn and conversion to mycophenolate mofetil was performed. In one 
of them the degree of neurological symptoms decreased. The other one died 
after 3 years because of neurological deterioration. So, 48 (80.-%) of recipients 
are alive with follow-up from 6 mo. to 9 years with good function of their 
fi rst grafts. Two recipients survived pregnancy and successful delivery. Two 
patients were successfully retransplanted with other living related grafts after 3 
and 6 years because of biliary complications and chronic rejection. The results 
of LDLT for Wilson disease are generally good including patients with mild 
neurological disturbances.
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MULTIDISCIPLINARY APPROACH FOR PATIENTS 824 
WITH FULMINANT HEPATIC FAILURE IN THE ERA OF 
LIVING DONOR LIVER TRANSPLANTATION
T. Shimamura1, T. Suzuki2, M. Taniguchi2, K. Yamashita2, M. Oota1, 
H. Furukawa2, S. Todo3
1Division of Organ Transplantation, Hokkaido University Hospital, 
2Department of Transplantation and Regenerative Medicine, Hokkaido 
University, 3Department of General Surgery, Hokkaido University
Background: Liver transplantation (LTx) is a reliable therapeutic option for 
patients with fulminant hepatic failure (FHF). However, due to shortage of 
cadaveric organs and critical pretransplant condition, less than 50% of the 
patients can undergo LTx in the Unites States, and perioperative neurological 
defi cits are still problems. Recently, apheresis technology has been developed. 
In these circumstances, multidisciplinary approach including living donor 
liver transplantation (LDLTx) is considered to be mandatory for the treatment 
of FHF. 
Patients and Methods: From September 1997 to December 2006, 93 FHF 
patients were referred to our hospital. Twenty patients were not enrolled in our 
treatment protocol due to many socio-medical reasons. The remaining 73 were 
initially treated with extra-corporeal apheresis when the patients developed 
stage II coma or higher. Apheresis therapy consisted of plasma exchange and 
hemodiafi ltration (fi ltration volume:12-96L/day) in order to remove middle 
molecular-weight toxic substances such as cytokines. Intracranial pressure 
(ICP) was monitored in patients with progressive brain edema, and the mild to 
moderate hypothermic therapy (HT) were also carried out in those who had ICP 
more than 20mmHg as a bridge until the operation. Liver transplantation was 
indicated when the patients deteriorated despite of these treatments.
Results: Twenty-four out of the 73 patients (25.8%) recovered only through 
apheresis. Remaining 49 were considered to be candidates for LTx, however, 
28 died without transplant due to living donor unavailability, etc. Eventually, 
21 patients underwent LDLTx (including 6 auxilliary transplantation cases) 
with a mean period of 8.5 days after the onset of stage II coma. Among 
transplanted patients, ICP monitoring was performed in 8 and HT was applied 
perioperatively in 5 patients. One-year survival rate after LDLTx was 85.7% 
(18/21). No neurological complications were observed in survivors. Among 
those who could receive our protocol apheresis, overall survival rate reached 
57.6% (42/73). 
Conclusion: Apheresis therapy is effective not only as a conservative modality 
but also as a bridge to LTx. Multidisciplinary approach including LDLTx can 
improve the overall survival rate of patients with FHF.
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HEPATIC ANGIOSARCOMA (HAS): THE (LAST) 825 
ABSOLUTE CONTRA-INDICATION TO LIVER 
TRANSPLANTATION (LT) REPORT OF THE EUROPEAN 
LIVER TRANSPLANT REGISTRY (ELTR).
J. Lerut1, G. Orlando1, R. Adam2, A. Burroughs3, M. Colledan4, F. Filipponi5, 
J. Guggenheim6, Y. Grazadei7, D. Mirza8, F. Prevost9
1St-Luc University Hospital, Brussels, 2Hôpital Paul Brousse, Paris, 3Royal 
Free Hospital, London, 4Ospedali Riuniti, Bergamo, 5Ospedale Cisanello, 
Pisa, 6CHU Nice, 7Universitätslinik, Innsbruck, 8 Q.E. Hospital, Birmingham, 
9 Inselspital, Bern
Objectives: to defi ne the place of LT in the treatment algorithm of HAS based 
on a retrospective study from the European transplant experience.Background 
data: 
Methods: During the period 1985-2004, LT was done in 8 female and 11 male 
pts having a mean age of 38±24.8 years. Main symptoms of HAS were weakness 
(82%), upper abdominal discomfort or pain (59%), nausea (44%);main signs 
were hepato-splenomegaly (82%), weight loss (56%) and anorexia (53%).Six 
(37.5%) patients underwent neo-adjuvant treatment [chemotherapy (2x), TACE 
(1x), TIPSS (1x), attempt of liver resection (1x), IFN-steroid-radiotherapy 
(1x)]. Six patients had adjuvant therapy [chemo- (5pts) and /or radiotherapy 
(2pt)]. Exact pre-LT diagnosis was available in 6 (37.5%) of 16 histological 
documented patients. The remaining 10 patients were transplanted based on an 
erroneous diagnosis of epitheloid haemangioendothelioma (EHE) (8 pts) and 
hepatocellular cancer (HCC) (2 pts). Two (10.5%) pts had extra-hepatic disease. 
Imaging was rarely conclusive. Indications for LT were giant invalidating 
(painful) tumor (11/19 pts-58%), diagnosis of EHE (8/19 pts.-42%), HCC 
and cirrhosis (2/19pts.-10%), and liver failure after liver resection done for 
EHE (1/19pt- 5%).One (5.2%) patient had a small incidental HAS found in 
the hepatectomy specimen. Pathology of the hepatectomy specimen showed 
predominantly a multifocal diffuse pattern of HAS.
Results: Tumor recurrence was diagnosed at a mean delay of 6±2.7 mo (med. 5 
mo, range 2-11). Mean patient survival was 8±5.9 mo (med. 7 mo, range 0-23). 
One patient each died during the early (<3mo) post-LT period due to herpes 
infection , graft non-function and sepsis. The remaining 16 patients ,including 
the one with the incidentaloma, died of tumor recurrence.
Conclusions: This largest reported series clearly shows that HAS represents an 
absolute contraindication to LT. Precise pre-transplant imaging and especially 
histology is necessary in order to avoid spoiling of a scarce organ pool. 
Differential diagnosis with other vascular tumors is of particular importance 
in this context.
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SERUM CREATININE AND MELD SCORE 826 
UNDERESTIMATE RENAL DYSFUNCTION IN 
MALNOURISHED PATIENTS AWAITING LIVER 
TRANSPLANTATION
D. Ranjan, P.P. McHugh, T.D. Johnston, R. Gedaly, H. Jeon
University of Kentucky
Background: To estimate risk of pre-transplant mortality, MELD score 
weights serum creatinine (SCr) logarithmically to capture a patient’s degree of 
renal dysfunction. At our center we also calculate creatinine clearance (CrCl) 
using a 24 hour urine collection for all patients undergoing liver transplant 
evaluation. We suspected that SCr of our malnourished patients fails to 
refl ect their renal dysfunction, putting them at a disadvantage in MELD-
based liver allocation. In this study we estimated the derived creatinine (DCr) 
using an inverse calculation of the Modifi cation of Diet in Renal Disease 
(MDRD) and Cockcroft-Gault (CG) equations. We hypothesized that renal 
dysfunction is underestimated (demonstrated by a difference between DCr 
and SCr) and inversely correlates with serum cholesterol, a surrogate marker 
of malnutrition.
Methods: We reviewed clinical and laboratory data of patients who have 
undergone or are listed for liver transplantation at our institution between 
2004 and the present. CrCl was converted to GFR using previously established 
cofactors, and used for inverse calculation of MDRD to achieve DCr. Similarly 
DCr was achieved from inverse calculation in CG equation using measured 
CrCl. 
Results: We obtained data from 195 consecutive patients; 12 patients were 
excluded for incomplete records or inaccurate collections. The median DCr 
– SCr difference had an inverse correlation with decreasing cholesterol levels 
– 0.75, 0.9, 1.35, and 2.64 using MDRD and 0.4, 0.45, 0.5, and 1.2 using CG 
for patient groups with serum cholesterol level (mg/dL) breakpoints of 125, 
100, 75 and 50 respectively. Those with cholesterol <150 (n=83) had a mean 
DCr – SCr of 3 ±10.04, versus 0.95 ±2.25 for the group with cholesterol >150 
(n=100; p=0.048). 
Conclusion: There is a signifi cant difference between measured SCr and 
the DCr from measured CrCl in the context of the MDRD equation, and this 
varies inversely with serum cholesterol. With severe nutritional depletion, the 
disparity between MELD scores based on the two different creatinines could be 
large and clinically important.
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NOVEL CLINICAL MONITORING OF CELL MEDIATED 827 
IMMUNITY (CMI) USING IMMUNKNOW® IN LIVER 
TRANSPLANT RECIPIENTS PROVIDES OPTIMAL IMMUNE 
SUPPRESSION AND IMPROVED OUTCOMES
A. Sebastian, V. Kohli, Y. Huang, S-F. Li, Y. Yong, N. Jabbour, G. Sigle, 
A. Gurakar, H. Wright
Integris Baptist Medical Center
The reduction of drug toxicity with immunesuppression minimization is 
a current focus of long term patient management following solid organ 
transplantation. Clinical monitoring of alloimmune T cell activation 
status may optimize immunosuppression dosing and limit complications 
resulting from overimmunosuppression. The goal of the present research 
was to determine the impact of serial measurement of T cell activation on 
immunosuppression use and post transplant complications following liver 
transplantation.
Methods: Using the novel ImmuKnow® ATP assay (Cylex Inc), we monitored 
T cell activation in 190 patients receiving transplants between 2002 and 2005. 
Seventy-fi ve (75) recipients were HCV+; the remainder (n=115), including 
patients transplanted for autoimmune diseases, were HCV–. Dosing of 
immunosuppressive agents, hospital readmission/length of stay, event-free 
course of follow up, and the requirement for liver biopsy were evaluated 
retrospectively. 
Results: Results from three separate eras were compared: prior to use of the 
ATP T cell activation assay (pre-assay era – 2002), during the period of initiation 
of use (phase-in era – 2003), and the period in which monitoring with the ATP 
assay became routine practice in our center (routine practice era – 2004-2005). 
Compared to 2002, the median tacrolimus trough levels at 6-12 months of 
follow up in 2004-2005 decreased in both HCV– patients (8.0-10.0ng/mL 
to 4.0-5.8ng/mL) and in patients with autoimmune disease (8.2-9.0ng/mL to 
4.2ng/mL). The length of stay for hospital readmissions decreased by 53% and 
41% for rejection and infection, respectively. The liver biopsy:transplant ratio 
also declined from 1.28 in 2002 to 0.68 in 2005. 
Conclusions: Our fi ndings suggest that monitoring of CMI with the use of the 
ImmunKnow® ATP assay may allow substantial, controlled immunosuppression 
minimization without increasing the risk of rejection. Additional benefi ts may 
include reduced length of hospital readmission due to rejection and infection, 
and a reduced requirement for liver biopsy.
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LONG-TERM COMPLICATIONS IN LIVER 828 
TRANSPLANTATION FROM UNCONTROLLED NON-HEART-
BEATING DONORS
J. Kim, , W.Y. Shin, K-S. Suh, H.W. Lee, N-J. Yi, J.Y. Cho, E.M. Kim, 
K.U. Lee
Seoul National University College of Medicine, Department of Surgery
Background: Although uncontrolled non-heart-beating donors (NHBDs) 
could represent the largest potential donor pool, the safety of uncontrolled 
NHBD livers has not been proved yet. Thus, the purpose of the present study 
was to investigate the type and incidence of long-term complications in liver 
transplantation (LT) from uncontrolled NHBDs.
Patients and methods: Ninety-eight patients who underwent overseas LTs 
from uncontrolled NHBDs in China between December 2001 and December 
2004 were enrolled in this study. They were those who survived early 
postoperative period and were followed-up at Seoul National University 
Hospital in Korea. Eighty patients (81.6%) were male and 18 (18.4%) were 
female. Mean age at the time of LT was 51.1¡¾0.83 (mean¡¾SEM) years, 
with a range of 20 to 70 years. After LT, patients were followed-up for a 
median time of 38.1 months.
Results: Fifteen patients (15.3%) died of cancer recurrence (n=8), hepatic 
failure due to viral hepatitis (n=3), sepsis (n=3) or intracerebral hemorrhage 
(n=1). Retransplantations were performed in 4 patients. Excluding operation 
and hospital mortality, total patient survival was respectively 93.8%, 86.1%, 
and 82.6% at 1-, 3- and 5-year. Eighty-one (82.7%) experienced one or more 
complications. The most common complication was biliary complication 
(n=24, 24.5%), followed by viral hepatitis, recurrence of primary cancer, 
infectious complication and liver function abnormality of unknown cause. 
Intrahepatic biliary stricture (IHBS) was the most common and serious 
biliary complication (n=16, 66.7%). Among all patients with symptomatic 
IHBS, two (12.5%) died of biliary sepsis, three (18.8%) underwent 
retransplantation and the others had to receive repetitive interventional 
therapies. Nineteen patients (19.4%) had post-LT viral hepatitis. Especially, 
as many as fi ve patients (5.1%) developed de novo HCV infection and one 
of them died of fulminant hepatic failure. Twenty-six patients (26.5%) 
experienced Clavien grade 3B or 4 complications, resulting in death, 
retransplantation or residual diseases with high risk of death. Even when 
cancer recurrences were excluded, 15 patients (15.3%) experienced high 
risk long-term complications.
Conclusion: Although long-term survival of uncontrolled NHBD LTs was 
acceptable, high risk long-term complications, such as IHBS and de novo 
HCV, frequently developed, which are rare in conventional brain-dead donor 
LTs. Therefore, patients who underwent uncontrolled NHBD LT should be 
followed-up carefully.
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RENAL FUNCTION IN LIVER TRANSPLANT 829 
RECIPIENTS: THE TRY STUDY.
F. Saliba3, S. Karie1, N. Janus1, J. Dumortier2, V. Launay-Vacher1, Y. Calmus4, 
C. Duvoux5, R. Lorho6, G. Deray1, G-P. Pageaux7
1Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France, 
2Department of Digestive Diseases, Edouard Herriot Hopital, Lyon, France, 
3Department of Liver Disease and Liver Transplantation, Paul Brousse 
Hopital , Villejuif, France, 4Department of Liver Transplantation, Cochin 
Hopital, Paris, France, 5Liver Transplant Unit, Henri Mondor Hopital, 
Creteil, France, 6Department of Liver Disease, CHU Pontchaillou, Rennes, 
France., 7Liver Transplant Unit, Centre Hospitalier Universitaire (CHU) 
Saint Eloi, Montpellier, France
Kidney disease (KD) is a common complication after liver transplantation 
(LTx). Monitoring of renal function (RF) is particularly important in liver 
transplant patients receiving calcineurin inhibitor that may have renal toxic 
side effects. The TRY study aimed at determining the prevalence of KD in liver 
transplant patients before transplantation (BT), at 1 month (1M), 1 year (1Y) 
and 5 years (5Y) after LTx. 
Methods: national, retrospective, multicenter observational study. RF was 
assessed by Cockcroft-Gault (CG) and aMDRD formulae. 
Results: 1508 patients (972 males, 536 females) were included from 15 centers. 
The mean follow-up time post-LTx was 9.2 ± 3.4 years. Mean age and weight 
BT were 48.2 ± 10.6 years and 70.8 ± 13.5 kg, respectively. The mean Body 
Mass Index (BMI) was 24.7 ± 4.2 kg/m². The most common indications for 
LTx were alcoholic cirrhosis (31.1%), hepatitis C (11.2%) and primary biliary 
(5.8%) cirrhosis. The averages of biological data BT were: serum albumin 
31.8 ± 6.9 g/L, total bilirubin 74.4 ± 99.2 mg/L, AST/ALT 211/178 UI/L, 
haemoglobin 11.4 ± 2.2 g/dL. 
Mean serum creatinine was 82, 115, 115 and 122 μmol/L BT, at 1M, 1Y and 
5Y, respectively. Using CG formula, the mean creatinine clearance (CrCl) was 
101, 67, 71 and 68 mL/min BT, at 1M, 1Y and 5Y, respectively. Using aMDRD 
formula, the mean glomerular fi ltration rate (GFR) was 95, 66, 62 and 59 mL/
min/1.73m² BT, at 1M, 1Y and 5Y, respectively. Using CG formula, CrCl was 
< 60 mL/min in 9, 43, 37 and 42% of the patients, respectively BT, at 1M, 
1Y and 5Y. Using aMDRD formula, DFG was < 60 mL/min/1.73m² in 11, 
48, 51 and 58% of the patients, respectively at each time of data collection 
(cf. Table 1).
Conclusion: 5 years after LTx, 94, 58 and 5% of liver transplant recipients had 
a GFR lower than 90, 60 and 30 mL/min/1.73m² (aMDRD), respectively. In 
liver transplant patients with renal insuffi ciency at high risk for drug toxicity, 
drug dosages should be adapted to RF and the use of nephrotoxic therapies 
should be avoided whenever possible.
Table 1
CrCl mL/
min (CG) or 
GFR mL/
min/1.73m² 
(aMDRD)
Before LTx, n (%) After LTx, n (%)
At 1M At 1Y At 5Y
CG aMDRD CG aMDRD CG aMDRD CG aMDRD
< 90 617 
(59.1)
689 
(45.7)
1262 
(83.7)
1268 
(84.1)
1232 
(81.7)
1391 
(92.2)
1250 
(82.9)
1422 
(94.3)
< 60 142 (9.4) 163 
(10.8)
651 
(43.2)
719 
(47.9)
553 
(36.7)
772 
(51.2)
637 
(42.2)
870 
(57.7)
< 30 14 (0.9) 20 (1.3) 45 (3.0) 57 (3.8) 21 (1.4) 28 (2.5) 61 (4.1) 75 (5.0)
< 15 
and HD
0 (0) 3 (0.2) 3 (0.2) 4 (0.3) 1 (0.1) 2 (0.1) 15 (1.0) 19 (1.3)
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ROLE OF DCD ORGANS IN SIMULTANEOUS LIVER-830 
KIDNEY TRANSPLANTATION
W. Hewitt, H. Grewal, D. Willingham, J. Nguyen, B. Taner, T. Gonwa, A. 
Keaveny, D. Harnois, C. Hughes
Mayo Clinic Jacksonville
Since the introduction of the model for end-stage liver disease (MELD) as a 
prioritization system for listing patients for liver transplantation (LT) in the 
United States in 2002, the number of simultaneous liver and kidney transplants 
(SLK) has continued to increase. This redistribution of organs away from the 
patients with renal failure alone raises signifi cant concerns. Utilization of 
donation-after-cardiac-death (DCD) allografts could assist in alleviating this 
organ shortfall.
Methods: A retrospective review of all patients who received an LT at our center 
from 04/2000 until 02/2007 was conducted. 1361 LTs were performed during 
that time. Of these, 39 (2.9%) had a SLK transplant and 9 (0.7%) received 
DCD organs. Technical allograft complications, patient and graft survival were 
analyzed. The 9 DCD patients were compared to the 30 DBD LKT. 
Results: In the SLK recipients 41.0% were diabetic, 48.7% required renal 
replacement therapy (RRT) pre-transplant and 33.3% required RRT post-
operatively. There was no difference in donor age, recipient age, MELD 
score or cold ischemia time of the allografts between DCD vs. DBD SLK 
groups. Wait time from listing to transplant was 91 ± 107 days (mean ± SD) 
as compared to 64 ± 87 days for DBD vs. DCD, respectively. Mean follow-up 
was 658 days (7 – 1821). There were 5 deaths in the DBD group and 1 death 
in the DCD group. Length of stay was signifi cantly longer in the DCD SLK 
group. One-year graft survival for DCD vs. DBD kidney grafts was 88.9% 
vs. 83.3%, respectively (p=0.15). One-year graft survival for DCD vs. DBD 
liver grafts at 77.8% vs. 87.1%, respectively (p =0.11). The one-year patient 
survival for DCD SLK was 88.9% compared to 83.3% with DBD SLK. No 
ureteral complications were noted in either group. 2 out of 9 of the DCD livers 
developed biliary complications and 0 out of 30 DBD livers had biliary issues. 
56% of the DCD SLK group required RRT whereas only 27% required it in the 
DBD group (p=0.11)
Conclusions: The use of DCD organs for SLK provides an attractive option to 
help alleviate the pressure on an ever-expanding transplant waiting list. Despite 
the higher incidence of delayed renal graft function and longer hospital stay, the 
use of DCD donors provides comparable graft and patient survival and should 
be considered for patients requiring SLK transplants.
POSTER BOARD NUMBER P4 – 440
OUTCOME OF SAUDI AND EGYPTIAN PATIENTS 831 
RECEIVING CADAVERIC LIVER TRANSPLANTATION 
IN CHINA
N. Allam1, M. Al-saghier2, Y. Al-sheikh2, M. Al-sofayan2, H. Khalaf2, H. 
Bahili2, M.Sebayel2, Y. Medhat2, H. Abdel-dayem2, A. Abdo2
1National Liver Institute, Menofeya University, 2King Faisal Specialist 
Hospital and Research Center, Saudi Arabia
Background: Because of long waiting list times in local liver transplant programs 
in Saudi Arabia and because of unavailability of cadaveric liver transplantation 
in Egypt, an increasing number of patients have been seeking transplantation 
in foreign centers especially in China. They are especially attracted by the 
lower costs in China as well as shorter waiting time compared to other foreign 
centers. In this paper we describe the outcome of patients transplanted in China 
and followed in one center in Saudi Arabia (King Faisal Specialist hospital and 
Research Center (KFSH & RC) in Riyadh) and in Egypt. 
Methods: All patients receiving liver transplantation in China from January 
2003 to January 2007 who were followed post transplantation in the two 
centers were included. Available preoperative data before traveling to China, all 
available reports from China and their follow up charts after coming back were 
retrospectively reviewed for relevant clinical and laboratory data. Mortality 
and morbidity in this group of patients is described and compared to those 
transplanted in KFSH & RC during the same period. 
Results: Seventy four adult patients were included. Sixty were males while 
fourteen were females. Their mean age was 54 years. Thirteen patients were 
above 65 y. Forty-six patients were Saudi nationals, 27 were Egyptians and 1 
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was Lebanese. Indications for liver transplantation were as follows: hepatitis 
C cirrhosis (n=29); hepatitis B cirrhosis (n=13); cryptogenic cirrhosis (n=6); 
hepatitis B and C co-infection cirrhosis (n=1), primary biliary cirrhosis (n=1) 
and hepatocellular carcinoma (n=24). All patients were either on the KFSH 
waiting list for liver transplantation or were denied liver transplantation in 
KFSH or Egypt due to unsuitable medical condition such as old age or advanced 
hepatocellular carcinoma (HCC). One year, 3-year and 5-year cumulative 
patient survival rates were 83%, 62%, and 62% respectively compared to 92%, 
84% and 71% in KFSH. Median survival time of the patients was signifi cantly 
less than that of those transplanted in KFSH (p=0.01). One year, 3-year and 
5-year cumulative graft survival rates were 81%, 59%, and 59% respectively 
compared to 90%, 84% and 71% in KFSH. Of the surviving patients, many 
suffered from multiple other morbidities. Compared to the patients transplanted 
in KFSH, the incidence of complications was signifi cantly higher especially 
biliary complications (p=0.01), sepsis (p=0.003), rejection (p=0.04), metastasis 
(p=0.03) and acquired HBV infection posttransplant (p=0.02). In addition, 
requirement of postoperative interventions (radiologic and laparotomy) as well 
as hospital admissions, were signifi cantly higher hence constituting a higher 
burden on the resources of the hospital. 
Conclusion: Our data shows clearly that there is a high mortality and morbidity 
rate in Saudi and Egyptian patients receiving transplantation in China. This 
could be related to poor selection criteria, long warm ischemia time, or poor 
post transplant care. . Although cadaveric liver transplantation in China could 
be an option for desperate Egyptian and Saudi patients with end stage liver 
disease, patients and clinicians should be aware of the possible outcomes
LATE BREAKINGMINI-ORAL SESSION 30: 
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YSPSL (RPSGL-IG) FOR THE PREVENTION OF 832 
DELAYED GRAFT FUNCTION (DGF): RESULTS OF DOUBLE-
BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE I/
II SAFETY AND EFFICACY STUDY
A.O. Gaber1, L.W. Moore1, S. Mulgaonkar2, B. Kahan3, V. Bowers4, 
E.S. Woodle5, R. Alloway3, I. Bajjoka6, K. Butt7, S. Jensik8, N. Nezakatgoo9, 
G. Klintmalm10, P. Patton11, R. Peddi2, D. Slakey13, G. Lipshutz14, A. 
Wiseman15, E.C. Squiers16, S. Hemmerich17 
1Methodist Hospital, Houston TX; 2SBMC, Livingston NJ; 3Univ of Texas, 
Houston TX; 4Lifelink, Tampa FL; 5Univ of Cincinnati, Cincinnati OH; 
6Henry Ford Hospital, Detroit MI; 7Westchester MC, Valhalla NY; 8Rush, 
Chicago IL; 9Methodist Univ Hospital, Memphis TN; 10Baylor, Dallas TX; 
11Univ of Florida, Gainesville FL; 12CPMC, San Francisco CA; 13Tulane, New 
Orleans LA; 14UCLA, Los Angeles CA and 15Univ. of Colorado, Denver CO, 
16Pacifi c Biodevelopment LLC, San Bruno CA; and 17Y’s Therapeutics, Inc., 
Burlingame CA. 
Introduction: YSPSL (rPSGL-Ig) is a recombinant fusion protein of human 
P-selectin ligand (PSGL-1) and an Fc fragment of human Ig. Studies in 
several animal models have shown that YSPSL blocks the selectins and the 
infl ammation cascade following ischemic injury, thereby improving graft 
function posttransplant. This clinical study was designed to assess the safety 
and potential effi cacy of YSPSL in preventing delayed graft function (DGF) in 
patients receiving deceased donor kidney transplant. 
Methods: This phase I/II study was conducted as a randomized double-blind 
evaluation of two dosing strategies: a dose of 3.5mg/kg IV only (cohort 1, 
n=15), and a dose of 1 mg/kg IV plus or minus a 10mg dose administered 
directly to the donor organ prior to implantation (cohort 2, n=44). Endpoints 
for analysis included incidence of dialysis within one week posttransplant and 
early renal function parameters.
Results: No clinically signifi cant adverse events related to drug administration 
were identifi ed. When all patients receiving YSPSL (n=39) were compared to 
those who received placebo (n=20), the proportion of patients achieving a serum 
creatinine (SCr) <6.0mg/dL by day 5 posttransplant was signifi cantly higher in 
the YSPSL group (74%) compared to placebo-treated patients (45%; p=0.043). 
The incidence of DGF was 24% (11 of 45) in 13 of the 15 participating centers. 
In the remaining two centers, DGF was declared in 64% (9 of 14) of the patients 
enrolled. We determined to exclude those two sites for post hoc analyses due 
to the skewed rate of DGF. Three additional patients were excluded from the 
analysis due to technical complications. Within this “modifi ed per protocol 
patient set (mPP, n=42), the SCr in the early posttransplant period decreased 
more rapidly in the YSPSL-treated patients than the placebo group (Figure 1) 
and 78% of the YSPSL group achieved SCr <6.0mg/dL by day 5 posttransplant 
compared to only 33% of the placebo group (p=0.004). Immediate graft 
function was experienced in 81% of the patients who received only YSPSL IV, 
in 67% of those who received both YSPSL IV and YSPSL to the donor organ, 
and in only 40% of those who received placebo.
Conclusion: In this fi rst double-blind, placebo-controlled phase I/II safety 
and effi cacy study in cadaveric renal transplant recipients, YSPSL was 
found to be safe. Our data also suggest a potential benefi t of YSPSL on early 
renal function. Sponsor: Y’s Therapeutics.
Figure 1: Median serum creatine levels (normalized to post-operative Day 0 
levels) over time in mPP patient set
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NK CELL AND T-CELL DELETION CAN ACHIEVE 833 
TOLERANCE TO THE INNATE AND COGNATE IMMUNE 
RESPONSE TO HTF TRANSGENIC SKIN GRAFTS
H. Gock 1,2, L. Murray-Segal 1, P. Cowan 1,2, A. D'Apice 1,2
1 Immunolgy Research Centre, St Vincent's Hospital Melbourne, Australia, 2 
Department of Medicine, University of Melbourne, Australia
Background: An increase in H-transferase (HTF) activity occurs as a result 
of increased substrate in Gal-transferase knock-out (KO) animals used in 
xenotransplantation. The increase in HTF product was thought to be inert. 
However, we have previously found that overexpression of HTF in transgenic 
mice elicits (1) an innate immune response causing graft injury followed 
by recovery and (2) a cognate immune response resulting in complete graft 
rejection. Furthermore, the tempo of innate immune injury could be reduced by 
incomplete NK cell inhibition (NK1.1 antibody treatment and Beige recipients) 
and cognate immune-mediated graft destruction could be overcome by T-cell 
inhibition (KT3 antibody treatment). We sought to further elucidate mechanisms 
of the phenomenon and to investigate possible strategies to overcome.
Aims: (1) To investigate whether the innate immune injury could be negated by 
(i) complete NK inhibition (ii) regrafting recovered HTF skin grafts in RAG-1 
KO mice, (iii) using mannose receptor KO mice. (2) The test whether T-cell 
sensitisation can occur and conversely whether suffi cient anti-T-cell treatment 
could induce tolerance.
Methods: (1) (a) WT and HTF skin were grafted side-by-side onto RAG-2/
ƒ×c double KO mice (n=11) and observed daily. (b) HTF skin was grafted 
onto RAG-1 KO mice (n=9) and observed for 50 days. These grafts were then 
removed and re-grafted onto WT recipients and observed. (c) WT and HTF 
skin were grafted onto mannose receptor KO mice (n=3). (2) WT recipients of 
WT and HTF skin were treated with KT3 and observed. An additional third- 
HTF graft was added 100 days after the original graft.
Results: (1) (a) Graft injury was not observed in 6/11 RAG-2/ƒ×c recipients 
and seen in the remainder to affect <50% surface area. (b) HTF grafts that 
had recovered from injury in RAG-1 KO recipients completely rejected in WT 
recipients when regrafted. However, the time to rejection was prolonged (18-30 
days vs 12-16 days). (c) All HTF grafts rejected in the mannose receptor KO 
recipients in the same timeframe as WT mice. (2) HTF grafts in KT3 treated 
recipients were initially injured but recovered (day 10-14). However, 4 grafts 
rejected at days 80-100. The remaining 3 survived indefi nitely (>100days). 
Rechallenge with a new HTF graft in these mice again underwent injury but 
recovered to survive long term.
Conclusion: Overexpression of HTF could elicit an innate immune response 
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resulting in graft injury which could be overcome in only some mice by 
complete NK cell deletion. The mannose receptor does not appear to play a 
role in the graft recognition. HTF grafts do not become tolerant after recovery 
from innate immune-injury. Recipient treatment can induce tolerance to new 
HTF grafts but not to innate immune injury.
POSTER BOARD NUMBER P4 – 442
CORD BLOOD TREGS CAN BE POOLED AND 834 
EFFECTIVELY SUPPRESSIVE IN MIXED LYMPHOCYTE 
CULTURES.
D. Figueroa-Tentori 1,2, R.C. Duggleby 1, S. Querol 1,2, J.A. Madrigal 1,2
1 Anthony Nolan Research Institute, London UK., 2 Royal Free And UCL 
School of Medicine, London UK.
Regulatory T cells (Tregs) have shown in several models to be a good 
therapeutic option to achieve tolerance in transplantation. However, Tregs are a 
rare population, making it diffi cult to achieve the optimal cell numbers needed 
in clinical settings to counteract the high numbers of alloreactive T cells. From 
previous studies in hematopoietic stem cell transplantation (HSCT), some 
groups have used successfully multiple unmatched cord blood (CB) units to 
address the low nucleated cell numbers in the graft. 
The aim of this study was to examine the feasibility of pooling Tregs isolated 
from mismatch CB units and evaluate their suppressive ability in mixed 
lymphocyte cultures (MLC). 
Methods: The CD25 + populations were isolated from fresh CB mismatch 
units using anti-CD25 directly conjugated microbeads (Miltenyi Biotec). One-
way fully mismatch MLCs were done and cultured in different ratios using 
individual or pooled CD25+ populations for 6 days. Proliferation was measured 
by [3H]-Thymidine incorporation.
Results: We fi nd that pooled CB Tregs were suppressive in a dose dependent 
manner (Tregs/effectors 1:5 ~50% suppression, 1:10 ~40% suppression, 
p<0.05), showing a synergistic effect compared to individual Tregs suppression 
(p<0.05). Pooled Tregs were anergic when stimulated with allo-PBMC’s 
compared to CD25 negative fractions (p<0.005). 
Conclusions: These results shows that CB Tregs can be pooled and maintain 
effectively their individual suppressive properties as well as showing apparent 
synergy in-vitro. Pooling of CB Tregs can be a good practical option with no 
ex-vivo expansion needed to achieve the clinical cell numbers required for 
immunotherapy. Further studies should be warranted to elucidate mechanism 
of action and examine these results in in-vivo models. 
POSTER BOARD NUMBER P4 – 443
MRI ASSESSMENT OF LIVER ISCHEMIA AFTER 835 
INTRAPORTAL ISLET TRANSPLANTATION
E. Hathout, N. Sakata, A. Tan, N. Chan, P. Hayes, J. Mace, R. Peverini, 
L. Sowers, R. Chinnock, A. Obenaus, 
Loma Linda University
Background: Approximately 60% of islets fail to engraft following intraportal 
islet transplantation. There is recent focus on embolization of the portal vein 
by the islets themselves as a major cause for early graft loss. Transplanted 
islets can obstruct portal vessels and compromise blood fl ow of surrounding 
liver tissue. Resultant ischemia causes necrosis and/or apoptosis of liver 
cells which, in combination with immediate blood-mediated infl ammatory 
reaction (IBMIR), leads to injury of the islet graft. Non life-threatening 
micro-thrombosis may also occur as liver enzymes are usually elevated after 
intraportal transplantation. Early graft failure is infl uenced not only by the islet 
quality but also the condition of the transplant site. Thus, assessment of the 
liver receiving the islet transplant is important to maintain a healthy islet graft. 
In this study, we utilized a clinically applicable modality for the assessment of 
the transplant site. If post-transplant ischemic liver changes are detectable by 
MRI, the latter may serve as a noninvasive method to enhance the success of 
clinical islet transplantation. 
Methods: Balb/C female mice were used as donors and recipients. 
Streptozotocin- induced diabetic mice were transplanted with syngeneic 
islets (800 islet equivalent: IEQ) via the portal vein. We harvested the liver 
at the time of transplantation (n=2), at 12 hours, 1, 2, and 3 days (early post-
transplant stage, n=4) and 28 days after transplantation (late post-transplant 
stage, n=4). We compared the fi ndings of pre-fi xed liver, MRI and histological 
fi ndings (hematoxylene and eosin and immunohistochemistry for insulin) at 
each time point. MRI examination of liver specimens was performed by Bruker 
Advance 11.7 T MRI (8.9-cm bore) with a 3.0 cm volume radiofrequency coil 
(Bruker Biospin, Billerica, MA, USA). The conditions of MRI were T2 and 
3D sequences: T2 sequences were examined for determination of changes in 
the transplanted liver and 3D sequences aimed at assessment of the volume of 
areas captured in T2 imaging.
Results: We could fi nd ischemic / necrotic area of the liver at 12 hours after 
transplantation from the fi ndings of prefi xed liver, and the necrosis became 
more prominent 2 days after transplantation. Histological fi ndings revealed 
destruction of liver tissue and infl ammatory cells at 12 hours with changes 
becoming most prominent at 2 days after transplantation. MRI examination 
refl ected liver destruction which could be quantifi ed from high intensity areas 
on T2 sequences. The change was not seen in the whole liver and there was no 
high intensity area on T2 by day 28. 3D imaging showed a signifi cant increase 
in the volume of ischemic / necrotic area at the early stage assessments.
Conclusion: Onset and reversibility of liver changes due to intraportal islet 
transplantation are detectable using magnetic resonance imaging. We propose 
that MRI, as a noninvasive monitor of graft-related ischemia, may signifi cantly 
enhance the outcome of clinical islet transplantation. 
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GENE EXPRESSION PROFILING OF HUMAN ISLETS 836 
TO DETERMINE PREDICTORS OF CLINICAL ISLET 
TRANSPLANT OUTCOMES
S.T. Grey 1,4 , A. Weinberg 1,4, M.J. Cowley 2, S.N. Walters 1,4, 
W.J. Hawthorne3,4, A. Patel 3,4, E. Jimenez-Vera 3,4, L. Williams 3,4, 
B. Tabor 2, W. Kaplan 2, P.J. O'Connell 3,4, 
1 Gene Therapy and Autoimmunity Group, 2 Peter Wills Bioinformatics 
Centre, Garvan Institute,, 3 The Centre for Transplant and Renal Research, 
Westmead Hospital, Westmead, Australia, 4 The Australian Islet Transplant 
Consortium
Islet transplantation has the potential to cure type I diabetes and prevent the 
onset of diabetic complications. Despite these potential benefi ts, numerous 
obstacles prevent the success of clinical islet transplantation. Indeed the natural 
history of islet transplantation is a steady decline in graft function from a ~70% 
1 year success rate to ~10% success rate at 5 years. Relatively little is known 
about the underlying mechanisms of poor islet function post transplantation. 
We hypothesise that some of the causes resulting in poor graft function relate 
to islet intrinsic genetic factors present at the time of transplant, which then 
impact upon later graft function. To examine this hypothesis we have prepared 
mRNA from pancreatic islets isolated from 18 normal human cadaveric organ 
donors. Islets were isolated for clinical transplantation for the Australian Islet 
Transplant Consortium and a sample of each preparation was obtained for 
mRNA extraction. We obtained an average mRNA yield of ~48.78μg with a 
RIN ?8 for all samples. The gene expression profi le of each individual islet 
preparation was analysed on an Affymetrix HG-U133-Plus2 whole genome 
array. We found that on average ~40% of all possible ProbeSets were expressed 
by each islet sample, this compares to other tissues such as muscle and liver 
where ~30% and 40% of all ProbeSets are expressed respectively. Moreover 
we could determine that 11,000 of all possible ProbeSets were present in all 
islet samples, ~25,000 ProbeSets were absent in all samples, and the remaining 
~20,000 ProbeSets are present in at least one sample. Of the ~11, 000 present 
ProbeSets, 2, 096 were unique to islet tissue (e.g. absent in liver or skeletal 
muscle). Within this unique set, gene ontology analysis revealed an enrichment 
of genes involved in protein transport and localization (p = 1.84E-06; 1.65E-06), 
myoblast cell fate commitment (p = 0.000116), nucleic acid metabolism (p = 
8.20E-05), primary metabolism (p = 0.000124) and secretion (p = 0.000367). 
Thus our data reveals a cohort of genes that uniquely identify pre-transplant 
islets at the molecular level. Further, we found that the inter-sample variability 
of gene expression amongst individual islet preparations was very high; ~13% 
of genes exhibited a ?5-fold change between samples whereas the median fold 
change overall for all genes was 2.1. Of the 1, 058 most variably expressed 
genes (standardised SD > 3), gene ontology analysis revealed many were 
involved in glycolysis (p = 2.46E-05), response to wounding (p = 1.46E-18) 
and infl ammation (p = 3.52E-10). Thus, the variably expressed genes were 
those most essential for beta cell metabolic function, cellular stress responses 
and beta cell survival. We propose that preparation-specifi c variance in the 
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expression levels of these critical genes should predict transplant outcomes. In 
summary, we have established a methodology to analyse the transcriptome of 
islets prior to transplantation. In further analysis islet gene expression profi les 
will be compared against clinical transplant outcomes. Through this analysis 
we aim to achieve a molecular algorithm to determine the suitability of an islet 
preparation for clinical transplantation.
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THE OUTCOME OF COMMERCIAL KIDNEY 837 
TRANSPLANTATION: A QATARI STUDY ON PREOPERATIVE 
AND POST-TRANSPLANT FOLLOW-UP RECORDS 
OF PATIENTS HAVING COMMERCIAL RENAL 
TRANSPLANTATION ABROAD
R.A.S. Fadhil, Y. Almoslamani, A. Alansari, O. Alani
Hamad Medical Corporation
Lack of donors in Qatar caused many ESRD patients to seek quick affordable, 
live non-related renal transplants abroad. Qatar is a small gulf state with a 
population of 1.5 million. It has a single nephrology and transplant unit within 
Hamad Medical Corporation. Most of our patients were admitted to our centre 
shortly after having commercial transplant abroad .This central (patients Data 
Base) has enabled us to review the preoperative and the post-transplant follow-
up records of all the transplant patients that were done abroad within the last fi ve 
years with no (lost to follow-up patients). Between 2003 and 2007, 91 patients ( 
34 female and 57 male ; 73 Qatari and 18 non Qatari ; mean age 46 + 32 years) 
were Transplanted in Philippine (N=77), Pakistan(N=8), Egypt(N=2), Iran(N= 
2), UK(N=1), China(N=1). The study showed a bad selection of patients; 
17 patients had either relative or absolute contraindications to Transplant 
Surgery, 11 patients died early in the post operative period, 8 of them had 
absolute contraindication to transplantation. There was a high incidence of 
post operative complications, including infections N=35, Urological N=13, 
Surgical N=8, perigraft collections and lymphoceles N=18, immunological 
N=7, cardiovascular N=4, peripheral vascular N=3. Many patients had more 
than one complication N=18. The fi rst year patient survival is 87.9%. The fi rst 
year Graft survival is 82.4%. On reviewing the literature, we sited 17 studies on 
the outcome of commercial renal transplantation. Most of them coincide with 
our fi ndings of high mortality, poor selection of donors and recipients and high 
incidence of serious unconventional complications. Some studies appraised 
the long term results of commercial transplantation disregarding the lack of 
information that they admit on the exact number of patients gone to transplant, 
lost to follow-up patients, and lack of information on the early post operative 
period. Commercial renal transplantation is a bad stigma to medicine; we should 
resist the commercialization of the clean practice of organ transplantation which 
could start by price tagging of the donated kidneys ;a policy that is called for 
by many workers in this fi eld, we should not underestimate the impact of this 
endeavor on societies of different cultures and socio-economic status.
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VOCLOSPORIN (ISA 247): THE PHASE 2 'PROMISE' 838 
DE NOVO RENAL TRANSPLANT TRIAL DEMONSTRATES 
EFFICACY AND AN IMPROVED SAFETY PROFILE ACROSS A 
WIDE THERAPEUTIC RANGE
S. Busque 1, R. Mateo 2, S. Kapur 3, E.L. Hartmann 4, G. Klintmalm 5, 
M. Laftavi 6, A.O. Gaber 7
1 Stanford School of Medicine, Palo Alto, CA, 2 University of Southern 
California, Los Angeles, CA, 3 Cornell New York Presbyterian Hospital, New 
York, NY, 4 North Carolina Baptist Medical Center, Winston-Salem, NC, 5 
Baylor University Medical Center, Dallas, TX, 6 Buffalo General Hospital, 
Buffalo, NY, 7 The Methodist Hospital, Houston, TX
Background: Voclosporin (VCS) is a next generation calcineurin inhibitor 
(CNi), developed using a pharmacodynamic approach for use in autoimmune 
disease and solid organ transplantation. Voclosporin was previously shown 
to be effi cacious and well tolerated in stable renal transplant recipients 
when compared to cyclosporine. A Phase 2b study (PROMISE) in de novo 
renal transplant patients comparing voclosporin to tacrolimus was recently 
completed.
Methods: PROMISE was a 6 month, randomized, multicenter, open-label, 
concentration-controlled study comparing three oral voclosporin dosing groups 
(low, mid, high dose) with initial dosing ranging from 0.4 to 0.8 mg/kg BID to 
tacrolimus. De novo renal transplant recipients received induction therapy with 
an IL-2r antibody, and maintenance treatment with mycophenolate mofetil 
and steroids. Voclosporin and tacrolimus doses were titrated to target trough 
concentrations. The primary effi cacy parameter of the trial was non-inferiority 
(in at least one dose group) in biopsy proven acute rejection (BPAR) at 6 months 
as compared to tacrolimus. Secondary objectives included: proportion of 
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patients with new onset of diabetes after transplant (NODAT), hyperlipidemia, 
and hypertension; laboratory parameters; renal function; PK/PD relationships; 
patient and graft survival. NODAT was defi ned by the 2003 ADA guidelines.
Results: 334 patients were enrolled and key results are listed below:
Randomization Group BPAR Patient/Graft 
Survival
Nankivell GFR
(mL/min)
NODAT
Tacrolimus 
(n=86)
5.8% 97.6% 69 16.4%
Low dose VCS (n=84) 10.7% 100% 71 1.6%*
Mid dose VCS (n=77) 9.1% 100% 72 5.7%
High dose VCS (n=87) 2.3% 98.8% 68 17.7%
* p=0.031 vs. tacrolimus 
At 6 months, the primary effi cacy objective of non-inferiority in BPAR was 
achieved in all three voclosporin treatment groups. In all groups, patient 
and graft survival were excellent. The incidence of NODAT in the low dose 
voclosporin group was signifi cantly lower than the tacrolimus group, and was 
numerically lower in the mid dose group. Despite a doubling of concentration 
from the low to high dosing group renal function was similar in all 4 arms of 
the study. 
Conclusion: This large dose fi nding phase 2b study demonstrated that BPAR 
was non-inferior to tacrolimus in all voclosporin treatment groups. While 
effi cacy appeared to be dose dependent and numerically better in the highest 
dose voclosporin group, the safety profi le was similar or better in all voclosporin 
groups compared to tacrolimus. Kidney function was also excellent in all 
treatment groups. These results support the continuing clinical development 
of voclosporin. 
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RISK FACTORS AND INCIDENCE OF CANCER IN 839 
RENAL TRANSPLANT RECIPIENTS REPORTED BY UNOS 
BETWEEN 1988 AND 2006.
A.H. Jahromi, M. Morsy, J. Fronek, N. Kessaris
Renal Transplant Unit, St. Georges Hospital, London, UK.
Renal transplantation is the treatment of choice for most patients with end-
stage renal diseases because it confers survival and quality of life advantages 
over dialysis. However, kidney transplantation is not without disadvantages, 
as recipients are at increased risk of cardiovascular disease, infections as well 
as cancer. The aims of this study were fi rstly to establish the relative risk of 
cancer in the renal transplant recipients, and secondly to quantify how excess 
risk varied within this population. 
Methods: United Network for Organ Sharing (UNOS*) and Organ Procurement 
and Transplantation Network (OPTN) data, as of February 25, 2008, were used. 
The data included 234145 renal transplant recipients (M=140320, F=93825, 
M/F=1.49) transplanted between 1988 and 2006. Relative Risk (RR) of cancer 
was calculated for each risk factor.
Results: In total, 12120 (5.2%) recipients (M=8087, F=4043) developed 
cancer during the study period. Male recipients had higher risk of developing 
different cancers (RR=1.34). Of the reported cases, skin cancers (squamous 
cell carcinoma, basal cell carcinoma and melanoma) constituted 34.1% of all 
tumours and were the most common types of post-transplantation cancer. The 
incidence of cancer in the recipients was increasing between 1988 and 1994, but 
has been declining continuously ever since (Figure-1). Cancer was diagnosed 
in 4079 patients (33.7%) who were up to 3 years post-transplantation, and in 
4650 recipients (38.4%) who were 6 or more years post-transplantation. 
Increased RR was found for age > 50 years (RR=2.03), white ethnic background 
(RR=2.84) and previous history of cancer (RR=3.38, 581 cases out of 102759). 
While different immunosupression regiments using Muromonab (RR=1.23), 
Sandimmune (RR=1.05), Neoral (RR=1.16), Daclizumab (RR=1.42), Steroid 
(RR=1.73) and Azathioprin (RR=1.63) were associated with increased risk 
of cancer in the recipients, other regiments using ATG (RR=0.64), Gengraf 
(RR=0.72), Tacrolimus (RR=0.63), Sirolimus (RR=0.66) and Mycophenolate 
mofetil (RR=0.77) were associated with a reduction in the risk of cancer. 
Incompatible donor-recipient ABO match had a RR of 0.89.
Conclusion: Age>50 years, white ethnic background, male gender, 
immunosupression medications and history of pre-transplant malignancy were 
considered as main risk factors for cancer in the renal transplant recipients. 
Interestingly, ABO incompatible transplantation did not increase the risk of 
cancer. The decline in incidence of post-transplantation malignancy since 1994 
may be due to improvements in factors such as pre-operative cancer screening, 
treatment and detection of viral infections, immunosupression regimes, patient 
knowledge and life style. Alternatively, some cancers may not have occurred 
within the post-transplantation period represented in the data set. 
Figure 1 shows the incidence of post-transplantation malignancy 
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PREVALENCE AND SIGNIFICANCE OF 840 
LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID 
ORGAN TRANSPLANTS
T. Jie, J. Beisse, J. Harmon, B. Peterson, C. Holman, D. Sutherland, A. Matas, 
A. Humar
University of Minnesota
Introduction: Post-transplant lymphoproliferative disorders (PTLD) is 
recognized as one of the lead causes of morbidities and mortalities in solid 
organ transplant recipients. PTLD represents a collection of hematological 
disorders that were not well characterized in literature. 
Method: Retrospective review of single center solid organ transplant 
experience.
Results: Among 10,171 patients received solid organ transplants at our center 
between 1969 and 2007, 201 transplant recipients were diagnosed with PTLD 
(17.4% < 18 years old and 62.4% man). The cumulative incidence of PTLD 
in heart, lung, kidney, kidney and pancreas, pancreas, intestine, and liver 
transplant recipients are 1.6%, 4.2%, 1.7%, 3.1%, 1.6%, 9.1%, and 2.1% 
respectively. Subtypes of PTLD are as followed: 79.3% B cell lymphomas, 
19.0% T cell lymphomas, and 1.7% Hodgkin’s disease. 26% patients had more 
than one organ transplants. The onset of PTLD was 5.3 ± 0.4 (mean ± SEM) 
years after transplant for patient with only one transplant, and 4.8 ± 0.7 years 
after last transplant for patients with more than one transplant (p = 0.571). 
The average immunosuppression exposure for patients with more than one 
transplant was 17.5 ± 3.3 years, which is signifi cantly longer than those with 
only one transplant (p < 0.001). The interval of PTLD diagnosis was 5.2 ± 
0.5 years and 6.7 ± 1.2 years after transplant in patients with B cell and T 
cells lymphoma, not signifi cantly different (p = 0.264). However, the average 
survival for patients with T cell lymphoma is 4.8 months after diagnosis and 
5-year survival of 26.2%, which is signifi cantly worse then the average survival 
of 4.5 years and5-year survival of 48.6% seen in patients with B cell lymphoma 
(logrank p = 0.0129). Interestingly, despite lowering immunosuppression during 
the treatment of PTLD, only 16% of patients with B cell lymphoma lost their 
graft from rejections. In comparison, 50% of patients with T cell lymphoma 
lost their grafts after the completion of oncological treatment. 
Conclusion: PTLD is a heterogeneous group of hematologic malignancies 
with distinctly characteristics and prognoses. T cell depleting induction therapy 
may accelerate the onset of disease as more than 30% PTLD cases were 
diagnosed within one year after transplant. The outcome of T cell lymphoma is 
signifi cantly worse than B cell lymphoma. Effective treatment of PTLD has yet 
to be defi ned. Despite aggressive chemotherapy and severe immunosuppressive 
state, graft los remains a major problem. 
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RISK FOR NON-HODGKIN LYMPHOMA FOLLOWING 841 
RENAL TRANSPLANTATION IS ASSOCIATED WITH 
CURRENCY OF RECEIPT OF IMMUNOSUPPRESSION AND 
REVERTS TO NORMAL ON CESSATION
M. van Leeuwen1, C. Vajdic1, A. Webster2,3, S. McDonald2,4, M. McCredie5, J. 
Stewart5, J. Amin1, J. Kaldor1, J. Chapman2,6, A. Grulich1
1National Centre in HIV Epidemiology and Clinical Research, University 
of New South Wales, 2Australia and New Zealand Dialysis and Transplant 
Registry, Queen Elizabeth Hospital, 3School of Public Health, University of 
Sydney, 4Disciplines of Medicine and Public Health, University of Adelaide, 
5Department of Preventive and Social Medicine, University of Otago, 6Centre 
for Transplant and Renal Research, Millennium Institute, Westmead Hospital, 
University of Sydney
Purpose: Non-Hodgkin lymphoma (NHL) occurs at markedly increased rates 
following renal transplantation, as well as in other immunodefi cient states, such 
as in those with HIV/AIDS. This study examined the role of immunosuppression 
and other risk factors for NHL in a large, population-based, Australian cohort 
of renal transplant recipients. 
Methods: Diagnoses of NHL in a cohort of 8,165 renal transplant 
recipients during 1982 – 2002 were ascertained through probabilistic data 
linkage between the Australia and New Zealand Dialysis and Transplant 
(ANZDATA) Registry and the Australian National Cancer Statistics Clearing 
House (NCSCH). Only cancers within the NHL rubrics ICD10 C82-C85 
were included; post-transplant lymphoproliferative disorders (PTLD) of 
uncertain malignant potential were excluded. Person-years of follow-up 
were accrued from the date of transplantation until the diagnosis of NHL, 
transplant failure, death, or last contact. Multivariate Poisson regression 
was used to compute incidence rate ratios (IRR) for NHL during periods 
of transplantation and dialysis, and for risk factors for NHL following 
fi rst transplantation only. Given the bimodal distribution of NHL over 
time since transplantation, separate analyses were conducted to examine 
risk factors for NHL less than two years (‘early’) and two or more years 
(‘late’) following transplantation. Transplant recipients were classifi ed as 
having ‘potential primary EBV infection’ if the recipient was EBV antibody 
negative and the donor was EBV antibody positive or of unknown EBV 
status at the time of transplantation. Analysis of risk associated with antibody 
use included exposure to the lymphocyte depleting agents OKT3 and ATG 
only. To account for changes in immunosuppressive regimen over time, the 
regression models included time-dependent covariates for exposure to the 
major immunosuppressive agents.
Results: 130 diagnoses of NHL were recorded following transplantation 
(212 cases per 100,000 person-years). Incidence was significantly 
reduced (IRR 0.22, 95% CI 0.07 – 0.69, p=0.009) after transplant failure 
and resumption of dialysis, returning to near pre-transplantation levels. 
Independent risk factors for early NHL (n=32) during first transplantation 
included potential primary EBV infection (IRR 3.97, 95%CI 1.90 – 
8.33, p<0.001) and receipt of antibodies (IRR 2.48, 95%CI 1.19 – 5.13, 
p=0.015). NHL occurring late after transplantation (n=79) was associated 
with increasing age (IRR 1.02, 95%CI 1.01 – 1.04, p=0.007), greater time 
since transplantation (p<0.001), and current use of calcineurin inhibitors 
(IRR 2.66, 95%CI 1.38 – 5.12, p=0.004). For both early and late NHL, 
the point estimate for tacrolimus was non-significantly greater than 
that for cyclosporine when immunosuppressive agents were examined 
individually. 
Conclusion: Risk for NHL following transplantation refl ects the currency of 
receipt of immunosuppressive agents and returns to baseline on cessation of 
immunosuppression. NHL has a distinct aetiological profi le within and after the 
fi rst two years following renal transplantation. Early NHL appears to be driven 
largely by primary EBV infection and the intensity of immunosuppression. 
Late NHL was associated primarily with duration of immunosuppression. 
The increased risk with use of calcineurin inhibitors- especially tacrolimus- is 
consistent with previous reports.
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THE INCIDENCE AND MANAGEMENT OF KAPOSIÏ¿½S 842 
SARCOMA AFTER KIDNEY TRANSPLANTATION REPORTED 
BY UNOS BETWEEN 1994 AND 2005
M. Morsy1, N. Kessaris1, Y. Cheng2, V. DeSilva3, J. Fronek1
1Renal Unit, St George’s Hospital, Blackshaw Road, London SW170QT, UK, 
2United Network for Organ Sharing, Post offi ce Box 2484, Richmond, Virginia 
23218, USA, 3Mayday University Hospital, 530 London Road, Surrey, 
CR77YE, UK
Introduction: The primary aim of this study was to identify all cases of post-
kidney transplant Kaposi’s Sarcoma (KS) reported by the United Network for 
Organ Sharing (UNOS) and to assess their management. The secondary aim 
was to review the graft and patient survival.
Methods: Data on the incidence and treatment of KS in the US between 1994 
and 2005 were retrieved and analysed by UNOS*.
Results: Based on Organ Procurement and Transplantation Network data as of 
December 14, 2007, there were 57 (0.04%) reported cases of KS in 158,008 
kidney transplant recipients. Of these, 43 (75.4%) patients were male. The 
mean time to diagnosis was 728.1 days (SD=652, min=118, max=2817) after 
transplantation.
Almost all patients (53, 93%) were receiving a calcineurin inhibitor and/or 
an antimetabolite agent as maintenance immunosuppression. Upon diagnosis 
of KS, management was as follows: immunosuppression was stopped for 7 
(12.3%) patients, reduced for 40 (70.2%), not adjusted for 5 (8.8%) and not 
reported for 5 (8.8%). Three patients were on Rapamycin at the time KS was 
reported to UNOS. There were no data on radiotherapy or surgery.
Graft survival was 91.2% (52/57) and 56.6% (24/57) at one and 5 years 
respectively. Patient survival was 98.2% (55/57) and 75.8% (27/57) at one and 
5 years respectively. 
Conclusions: UNOS data suggest that the incidence of KS in kidney transplant 
recipients is low (0.04%) as compared to the rates of 0.5-5% found to be 
associated with organ transplants general (Marcelin et al, 2007). With respect 
to management, it is surprising only three patients were on Rapamycin as it 
has recently been shown to be a particularly effective treatment in transplant 
patients with KS (Stallone et al, 2005). 
The patient survival rates described above seem to be better than US fi gures 
published previously by the Israel Penn International Tumour Registry 
(Hannaway et al, 2001), where patient survival was 88% and 66% at one and 
fi ve years respectively. This group described 63 patients, of which 52 had 
kidney transplants that occurred between 1985 and 2001.
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CHRONOLOGICALLY DIFFERENT INCIDENCE OF 843 
POST-TRANSPLANT MALIGNANCY IN RENAL TRANSPLANT 
RECIPIENTS; 25 YEARS EXPERIENCE IN KOREAN SINGLE 
CENTER
M.S. Kim1,2, H.K. Chang1,2, M.K. Ju1,2, D.J. Joo1,2, S.J. Kim1,2, S.I. Kim1,2, Y.S. 
Kim1,2, K. Park3
1Department of Surgery Yonsei University College of Medicine, 2The 
Research Institute for Transplantation Yonsei University College of Medicine, 
3Department of Surgery, Kwandong University Myongji Hospital
The incidence of malignancy in transplant recipients is known to be higher than 
that of normal population. But the types of malignancies vary geographically 
and relative risks compared with general population are also different country 
by country. In this study, we investigated the incidence and characteristics of 
malignancy after renal transplantation in single center.
A total 2,650 renal recipients who were operated from April 1979 to June 
2007 were enrolled in this study. The accumulative and interval (per 3 years) 
incidence of malignancy was calculated by post-transplant period. Synchronous 
or metachronous malignancies were counted as different events. 
A total 190 cases of post-renal malignancy among 177 recipients (6.73%) were 
reported until June 2007. The post-transplant malignancy was detected from 
6 months to 290 months after transplantation with mean duration of 112.6 
± 66.0 months. As the post-transplant duration was prolonged, the interval 
incidence of malignancy was extremely increased [fi gure1]. Skin cancer 
(n=35,18.4%) was the most common, followed by thyroid cancer(n=25,13.2%), 
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stomach cancer(n=22,11.6%), colorectal cancer(n=22,11.6%), urologic 
cancer(n=19,10.0%), lymphoproliferative disorders (PTLD)(n=12,6.3%), 
and Kaposi’s sarcoma(n=12,6.3%). Virus-related malignancy such Kaposi’s 
sarcoma and cervix cancer developed in earlier post-transplant period, but on 
the other hand urologic cancer, colorectal cancer and PTLD developed in late 
post-transplant period [fi gure2]. 
Therefore, we should establish the strategies for post-transplant malignancy 
based on characteristics of post-transplant malignancy in each country. 
Figure 1
Figure 2
POSTER BOARD NUMBER P4 – 452
TREATMENT OF CENTRAL NERVOUS SYSTEM POST 844 
TRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH 
HIGH DOSE IV METHOTREXATE
C. Kew1, A. Przekwas1, B. Nabors2, C. Palmer2,3, B. Julian2
1Nephrology, University of Alabama at Birmingham, 2Neurology, University of 
Alabama at Birmingham, 3Pathology, University of Alabama at Birmingham
Central nervous system post-transplant lymphoproliferative disorder 
(CNSPTLD) is an uncommon complication of organ transplantation, and is 
frequently associated with Epstein Barr Virus (EBV) infection and is especially 
diffi cult to treat. The standard treatment for primary (non-transplant related) 
CNS lymphoma is high-dose IV methotrexate (MTX). Few cases of CNSPTLD 
in renal transplant recipients have been described in the literature. There is not 
consistent treatment. We report our experience treating renal transplant patients 
with CNSPTLD with IV MTX. 
Between 07/31/92 and 12/24/02, 3105 kidney transplants were perfomed. Eight 
kidney and 2 kidney pancreas transplant patients who developed CNSPTLD 
were included (0.3%). Eight received tacrolimus and 2 received cyclosporine; 
all patients received prednisone and mycophenolate. Six patients were treated 
with IV MTX. Charts were retrospectively reviewed.
Time from transplantation to diagnosis of CNSPTLD ranged from 17-167 
months (mean 74 months). On MRI all patients had contrast-enhancing lesions. 
Brain biopsy revealed showed all to have B-cell lymphoma (2 polymorphous, 
3 monomorphous, and 1 with mono- and polymorphous features). All 6 were 
EBV+ on immunohistochemical staining. Five patients received IV MTX (dose 
8 g/m2) alone and 1 patient received IV MTX plus whole brain radiation. All 
received leucovorin 24 hours after MTX. All immunosuppression was reduced. 
Mean from time of diagnosis to initiation of treatment was 11.1 days (range 
5-28 days). Mean follow-up interval was 24 months (range 2-66). At follow up, 
4 patients were in remission and had signifi cant improvement in neurological 
status. Two retained their allograft with function that was at or near baseline. 
Two were on dialysis. One patient died 38 days and another died 137 days after 
diagnosis both with stable disease.
In conclusion, high-dose IV MTX in addition to decrease in immunosuppression 
should be considered as a treatment option for CNSPTLD after kidney 
transplantation.
POSTER BOARD NUMBER P4 – 453
RATES OF HUMAN PAPILLOMAVIRUS (HPV)-RELATED 845 
CANCERS ARE INCREASED IN RENAL TRANSPLANT 
RECIPIENTS AND RETURN TO LOW LEVELS ON CESSATION 
OF IMMUNE SUPPRESSION.
A. Grulich1, M. McCredie2, M. van Leeuwen1, J. Amin1, J. Stewart2, 
S. McDonald3, A. Webster4, J. Kaldor1, J. Chapman5, C. Vajdic1
1National Centre in HIV Epidemiology and Clinical Research, University of 
New South Wales, 2University of Otago, Dunedin, New Zealand, 3Australia 
and New Zealand Dialysis and Transplant Registry, Queen Elizabeth 
Hospital, Adelaide, 4School of Public Health, University of Sydney, 5Centre 
for Tranplant and Renal Research, Westmead Millenium Institute, University 
of Sydney
Purpose: The International Agency for Research on Cancer classifi es a 
number of anogenital and oral cancers as being HPV-related. This study aimed 
to describe incidence and risk factors for these cancers in a population-based 
cohort of transplant recipients. 
Methods: Diagnoses of HPV-related cancers in a cohort of 8,162 renal 
transplant recipients during 1982-2002 were ascertained through probabilistic 
data linkage between the Australia and New Zealand Dialysis and Transplant 
Registry and the National Cancer Statistics Clearing House. HPV-related oral 
cancers included cancers of the tongue (ICD10 C01-02), mouth (C03-C06), 
tonsil (C09) and oropharynx (C10). HPV-related anogenital cancers included 
those of the cervix (C53), vulva (C51), vagina (C52), penis (C60) and 
anus (C21). Person-years (PY) of follow-up were accrued from the date of 
transplantation until the fi rst diagnosis of each specifi c cancer, death, or last 
contact. Standardized incidence ratios (SIRs) were calculated using age-, sex-, 
calendar year-, and state/territory-specifi c population cancer incidence rates. 
Multivariate Poisson regression was used to compute incidence rate ratios 
(IRR) for anogenital and oral cancers during periods of transplantation and 
dialysis following graft failure, as well as risk factors following risk factors 
during the period of fi rst transplant function only. 
Results: There were a total of 43 HPV-related cancers; 17 oral and 26 
anogenital. The rate of oral cancer after transplantation was 27.6 per 
100,000PY. SIRs were raised for cancers of the tongue (SIR 7.17, 95% CI 
4.38-11.07), mouth (SIR 4.58, 95% CI 2.51-7.69) and tonsil (SIR 2.94, 95% 
CI 0.80-7.52). During the period of fi rst transplant function, oral cancer was 
associated with a history of ever smoking (IRR 3.84, 95% CI 1.01-14.7), 
increasing age in years (IRR 1.03 95% CI 0.99-1.08), and increasing years 
since transplant (IRR 1.12, 95% CI 1.01-1.25). The rate of anogenital cancer 
after transplantation was 69.9 per 100,000PY. SIRs were raised for cancers 
of the cervix (SIR 2.49, 95% CI 1.33 – 4.27), vulva (SIR 24.5, 95% CI 14.6 
– 38.8), vagina (SIR 15.57, 95% CI 4.24 – 39.85), penis (SIR 15.9, 95% CI 
5.85 – 34.7) and anus (SIR 2.76, 95% CI 1.51 – 4.64). As there were only 5 
cases, no analysis of risk factors was performed in men. In women, 21 cases 
of anogenital cancer occurred after transplantation (83.2 per 100,000PY). 
During the period of fi rst transplant function, anogenital cancer in women was 
related to increasing years since transplant (IRR 1.12, 95% CI 1.03-1.22) and 
receipt of the anti-lymphocyte antibodies OKT3 or ATG (IRR 2.57, 95% CI 
1.06-6.23). Of the 43 HPV-associated cancers all but 1 occurred in a period of 
transplant function rather than in a subsequent period of dialysis (IRR 0.17, 
95% CI 0.02-1.22).
Conclusion: HPV-associated cancers occur at increased rates in renal 
transplant recipients. HPV-related cancer risk was raised only during periods 
of transplant function, and returned towards baseline during periods of 
dialysis subsequent to transplant failure. These data suggest that removal 
or reduction of immune suppression may reverse the increased risk of HPV-
related cancer and highlight the importance of preventive vaccination in 
this population. 
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RISK OF CUTANEOUS MELANOMA DOES NOT 846 
INCREASE OVER TIME AFTER RENAL TRANSPLANTATION
C. Vajdic1, M. van Leeuwen1, J. Amin1, S. McDonald2,3, M. McCredie4, 
J. Stewart4, A. Webster2,5, J. Kaldor1, J. Chapman2,6, A. Grulich1
1National Centre In HIV Epidemiology And Clinical Research, University 
of New South Wales, 2Australia and New Zealand Dialysis and Transplant 
Registry, 3Disciplines of Medicine and Public Health, University of Adelaide, 
4Department of Preventive and Social Medicine, University of Otago, 5School 
of Public Health, University of Sydney, 6Millennium Institute, Westmead 
Hospital, University of Sydney
Purpose: The incidence of melanoma is increased in solid organ transplant 
recipients and people with HIV/AIDS. In both immune defi cient populations the 
highest risk estimates have been observed in Australian populations, suggesting 
an interaction between immune defi ciency and sun exposure. This study aimed 
to explore the descriptive and analytical epidemiology of melanoma in a large, 
population-based, Australian cohort of renal transplant recipients.
Methods: Diagnoses of melanoma in a cohort of 8,162 renal transplant 
recipients during 1982¨C2002 were ascertained through probabilistic data 
linkage between the Australia and New Zealand Dialysis and Transplant 
(ANZDATA) Registry and the National Cancer Statistics Clearing House. 
Person-years of follow-up were accrued from the date of transplantation until 
the fi rst diagnosis of melanoma, death, or last contact. Multivariate Poisson 
regression was used to compute incidence rate ratios (IRR) for melanoma 
during periods of transplantation and dialysis, as well as risk factors during the 
period of fi rst transplant function only.
Results: 82 melanoma diagnoses were recorded after transplantation (134 per 
100,000 person-years). Incidence was signifi cantly lower after resumption 
of dialysis than during transplant function (IRR 0.18, 95% CI 0.04 ¨C 0.72, 
p=0.015). Of the 74 cases with specifi ed anatomic site, 55 (74%) were on 
the head, neck, arms and legs, sites with more chronic sun exposure than the 
trunk (n=19, 26%). Of the 40 cases with specifi ed morphology, 24 (60%) were 
superfi cial spreading melanoma, 5 (13%) were nodular and there were 1 each 
of 11 other subtypes. During the fi rst transplantation, melanoma (n=74) was 
independently associated with increasing age (IRR 1.04, 95%CI 1.02 ¨C 1.06, 
p=0.01), end-stage renal disease as a result of diabetic nephropathy relative to 
glomerulonephritis (IRR 2.16, 95%CI 1.00 – 4.65, p=0.05), and receipt of the 
anti-lymphocyte antibodies OKT3 or ATG (IRR 1.73, 95%CI 1.05 ¨C 2.83, 
p<0.03). Risk was signifi cantly lower among females (IRR 0.56, 95%CI 0.34 
¨C 0.93, p<0.001), and non-signifi cantly lower among non-Caucasians (IRR 
0.15, 95%CI 0.02 ¨C 1.10, p=0.06) and those who resided at more southerly 
latitudes at registration on ANZDATA (p=0.20); relative to latitudes <30¡ã 
the IRR was 0.61 (95% CI 0.35 ¨C 1.05) for latitudes 30-36¡ã and 0.70 (95% 
CI 0.38 ¨C 1.29) for latitudes ¡Ý36¡ã. Risk was also non-signifi cantly lower 
with increasing time since transplantation (p=0.47); relative to 0-5 years post-
transplantation the IRR was 0.91 (95%CI 0.54 – 1.52) for 5-10 years and 0.61 
(95% CI 0.27 ¨C 1.35) for ¡Ý10 years. 
Conclusion: Risk of melanoma after transplantation is associated with 
currency of immunosuppression but, unlike cancers with a viral association, 
appears unrelated to cumulative immune suppression. We also found no 
evidence of an association with exposure to specifi c immunosuppressive 
agents, with the exception of antibodies. This is consistent with the fi nding of 
excess melanocytic naevi across diverse groups of immunosuppressed patients, 
including transplant recipients, those with HIV/AIDS and those treated with 
chemotherapy. Risk of melanoma after renal transplantation appears related 
to the currency and possibly the intensity of immune suppression. Our data 
provide inconsistent evidence that sun exposure, an established risk factor in 
the general population, is also important in the renal transplant population..
POSTER BOARD NUMBER P4 – 455
CANCER MORTALITY IN KIDNEY TRANSPLANT 847 
RECIPIENTS
B. Kiberd1, C. Rose2, J. Gill2
1Dalhousie University, 2University of British Columbia
Several large registry analyses have shown that the overall incidence of cancer 
is signifi cantly increased (2.5-3.6 fold higher) compared either to the general 
or the dialysis populations. The increase in incidence is not uniform across all 
cancers but the increase is believed to be due to immunosuppression. What is 
not known is whether death from these cancers is increased to the same extent 
in the kidney transplant population. Our hypothesis is that competing risks of 
death from cardiovascular disease may diminish the fatality of malignancy in 
this population. In keeping with this hypothesis patients with diabetes mellitus 
would be expected to suffer less cancer death.
In an analysis of the UNOS database from 1995-2004, incidence rates for 
mortality attributed to cancer were calculated per 100,000 patient years of 
exposure with a fi rst time functioning kidney transplant (n = 224,590). Rates 
were stratifi ed for age, gender and race. In comparison to SEER registry of US 
cancer mortality rates, the overall incidence of cancer mortality per 100,000 
person years is increased in the kidney transplant compared to the general 
population (250 vs.198), greater in males recipients (285 vs.182 females), 
and greater in African Americans recipients (249 vs. 196 whites). However 
mortality rates were not uniformly increased in all age groups and were in fact 
lower in the oldest age group; age 20-54 (50 general vs. 149 kidney transplant), 
age 55-64 (368 general vs. 365 kidney transplant) and 65-74 (817 general vs. 
592 kidney transplant). The fi gure below shows that kidney transplant recipients 
with diabetes mellitus (DM TX) uniformly have lower cancer mortality rates 
than non-diabetic recipients (Non-DM TX). 
The fi ndings are in keeping with the hypothesis that older and diabetic patients 
suffer less from malignancy than is accounted for by incidence rates (likely 
competing risks of death) but that the younger patients are at very high risk of 
cancer mortality and may deserve greater surveillance.
POSTER BOARD NUMBER P4 – 456
IS SCREENING FOR CERVICAL CANCER IN KIDNEY 848 
TRANSPLANT RECIPIENTS COST-EFFECTIVE? THE COSTS 
AND HEALTH BENEFITS OF SCREENING FOR CERVICAL 
CANCER IN WOMEN WITH KIDNEY TRANSPLANTS
G. Wong¹, K. Howard², A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1Centre for Kidney Research, The Children’s Hospital at Westmead, 2School of 
Public Health, University of Sydney, NSW, Australia, 3Centre for Transplant 
and Renal Research, Westmead Hospital, NSW, Australia
Background: Women with kidney transplants have a higher incidence for 
cervical squamous neoplasia than women without a transplant. The optimal 
cervical cancer screening strategies for this population, however, are 
uncertain.
Aim: To estimate the costs and health outcomes for annual cytological cervical 
cancer screening in women who had kidney transplants.
Methods: A Markov model was developed to compare the costs and health 
outcomes in a cohort of women with kidney transplants aged 18-69, who 
underwent cytological screening (conventional) compared to a cohort who 
did not. A second comparison was made between annual screening using 
liquid-based cytology and conventional cytology. Baseline prevalence data for 
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cervical dysplasia, survival and cancer-specifi c mortality data were obtained 
from the Australian and New Zealand Dialysis and Transplant (ANZDATA) 
registry (1982 – 2006). Other information such as screening participation rates, 
test performance and costs of the screening tool were sourced from published 
literature in the general population. Unit costs for screening and treatment were 
converted to the 2005 Australian dollars using the Medicare component of the 
Consumer Price Index (CPI). 
Results: The average costs for a program of annual screening for women 
who had a kidney transplant were $2,761 for 50 years. The incremental cost-
effectiveness ratio (ICER) for annual conventional Pap screening compared 
to no screening was $28,711 per life year saved (LYS), with a net gain in life 
expectancy of 12.5 days. Using the newer liquid-based cytological screening, 
the average costs for annual screening increased to $3453.5 and average 
benefi ts increased from 15.0728 LYS to 15.0735 LYS. The incremental costs of 
liquid-based screening compared to conventional cytological (Pap) screening 
was $692.5, with an incremental benefi t of only 0.26 days of lives saved. 
The ICER for liquid-based screening compared to conventional cytological 
(Pap) screening was over $1,000,000/LYS. The choice of screening was 
most sensitive to the relative prevalence of disease, age at which screening 
commenced, natural history of precancerous lesions, test specifi city and costs 
of the screening test. For example, reducing the relative disease prevalence 
to half of the base-case estimates, increased the ICER from around $29,000/
LYS to over $600,000/LYS. Assuming the test specifi city of conventional 
cytological (Pap) screening decreased to only 50%, the ICER increased to over 
$70,000/LYS. 
Conclusion: Annual screening with conventional cytological (Pap) screening 
in women with kidney transplants appears good value for money. The improved 
test sensitivity and extra benefi ts obtained from liquid-based cytological 
screening do not offset the additional costs of the newer test. 
POSTER BOARD NUMBER P4 – 457
THE HEALTH AND ECONOMIC IMPACT OF HUMAN 849 
PAPILLOMAVIRUS VACCINATION IN KIDNEY TRANSPLANT 
RECIPIENTS
G. Wong¹, K. Howard², A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1Centre for Kidney Research, The Children’s Hospital at Westmead, 2School of 
Public Health, University of Sydney, NSW, Australia, 3Centre for Transplant 
and Renal Research, Westmead Hospital, NSW, Australia
Background: Quadrivalent vaccine against human papillomavirus 
HPV-6/11/16/18 for the prevention of high-grade cervical dysplasia is now 
recommended for women and girls ages 9-26 in the general population. 
It is uncertain whether vaccination in pre-pubertal girls prior to kidney 
transplantation in combination with annual cervical cancer screening, is a cost-
effective healthcare intervention for women with kidney transplants. 
Aim: To estimate the overall costs and health outcomes of HPV vaccination in 
the setting of existing annual cervical cytological screening in kidney transplant 
recipients.
Methods: We developed a static state-transition Markov model to simulate a 
cohort of kidney transplant recipients (n = 1000, aged 18-69) who received pre-
transplant HPV vaccination (prior to HPV exposure) and post-transplant annual 
conventional cytological (Pap) screening (commencing at age 18) compared to 
a cohort who did not receive vaccination but were screened annually for cervical 
cancer. Baseline prevalence data for cervical dysplasia, survival and cancer-
specifi c mortality were obtained from the ANZDATA Registry (1982-2006). 
Other information was sourced from the general population. Unit costs for 
screening and treatment were converted to the 2005 Australian dollars.
Results: In the base-case analysis, assuming a sustained vaccine effi cacy against 
HPV infection, the average costs for a program of pre-transplant vaccination 
plus annual screening over a period of 50 years were $3,032, and the average 
benefi ts were 15.0578 LYS. The incremental cost-effectiveness (ICER) ratio of 
pre-transplant vaccination plus annual screening compared to annual screening 
alone was $59,363 per life year saved (LYS), with a net gain in life expectancy 
of 1.9 days. Assuming vaccine effi cacy waned over time and a booster shot was 
required for the remaining cohort ten years after initial vaccination, the average 
costs of vaccination plus annual screening increased to $7,817, and the average 
benefi ts were15.0585 LYS. The ICER of pre-transplant vaccination plus annual 
screening compared to annual screening alone increased to $843,471/LYS, 
with a net gain in life expectancy of 2.2 days of life saved. Using a series of 
one and multi-way sensitivity analyses, the model was most sensitive to age 
at which screening commenced, cost of HPV vaccination, response to initial 
vaccination and persistence of the vaccine effi cacy. For example, the ICER 
increased to $104,481/LYS with a starting age of 30 compared with an ICER 
of $59,363/LYS at base-case (starting age at 18). Reducing the costs of initial 
HPV vaccination from $400 to $200 decreased the ICER to just below $25,000/
LYS. Assuming vaccine effi cacy waned over time, the ICER increased from 
$60,000/LYS to over $100,000/LYS, with a reduction in the net gain in life 
expectancy to just over 1.6 days.
Conclusions: Under the most optimistic assumptions where there is a 
sustained and life-long vaccine effi cacy against HPV infection, pre-transplant 
HPV vaccination to HPV naïve individuals in addition to annual cervical 
cytological screening commencing at age 18 is good value for money. Cost-
effectiveness of a HPV vaccination and annual cervical cancer screening 
program in transplanted women is strongly dependent on the response to initial 
vaccination, costs of the vaccine and persistence of the vaccine effi cacy.
POSTER BOARD NUMBER P4 – 458
CANCER SCREENING PRACTICES BY TRANSPLANT 850 
PHYSICIANS: WHAT DO PHYSICIANS SCREEN FOR AND 
WHY?
G. Wong¹, A.C. Webster¹ ² ³, J.R. Chapman³, J.C. Craig¹ ²
1Centre For Kidney Research, The Children’s Hospital At Westmead, 2School 
of Public Health, The University of Sydney, NSW, Australia, 3Centre for 
Transplant and Renal Research, Westmead Hospital, NSW, Australia
Background: Increased cancer risk is well established in the kidney transplant 
population. Cancer screening, which detects early stage diseases and allows 
effective curative treatment, reduces cancer-specifi c mortality and morbidity 
in the general population. Despite the increased risk, little is known about 
the current cancer screening practices by physicians caring for transplant 
recipients. 
Aim: To describe and determine the major factors infl uencing cancer screening 
practices by kidney transplant physicians in Australia and New Zealand.
Methods: Questionnaires were electronically posted to all physicians, who 
were in clinical practice and cared for adult transplant recipients, through 
the Australia and New Zealand Society of Nephrology (ANZSN) contact 
directory. The survey instrument assessed physicians’ knowledge of current 
recommendations, attitude and practice behaviour of colorectal, breast and 
cervical cancer screenings in the kidney transplant population. 
Results: 132 (53.3%) out of the 250 invited members from the ANZSN took part 
in the survey. Of all respondents, 88.6% offered breast, 90% offered cervical 
and 85% offered colorectal cancer screening. The majority of participants 
commenced screening at the recommended age (85%), used the recommended 
screening tools (87.7%) and intervals (82.6%) for all three cancers. Over 90% 
of respondents agreed breast and colorectal cancer screening should stop at 
age 70. 55% of all respondents would continue screening for cervical cancers 
using conventional Pap smear indefi nitely. Most (89%) would not adopt the 
newer liquid-based cytology and HPV DNA cervical screen. There was no 
association between demographic factors such as age, gender, years of practice 
in nephrology and the decisions to screen. Important factors considered by 
clinicians when making cancer screening decisions were disease prevalence 
(69.2% compared to 25.9% p< 0.001), disease-specifi c mortality benefi ts 
(70.2% compared to 18.5% p <0.001) and screening test performance (47.1% 
compared to 11.1% p = 0.01). Other factors such as the cost-effectiveness of 
screening, life-expectancy and co-morbidities of transplant recipients were not 
signifi cant. 
Conclusions: Despite the paucity of evidence for cancer screening in the 
transplant population, transplant physicians generally agree screening is 
acceptable and adopt screening practices recommended by current cancer 
surveillance guidelines in the general population. The three most infl uential 
factors affecting physicians’ decisions to screen for cancers are disease 
prevalence, cancer-specifi c mortality benefi ts from screening and performance 
of the screening tool. Other standard criteria for assessing the validity of 
recommendations such as cost-effectiveness of screening, life expectancy 
and competing risk of co-morbidities among transplant recipients were not 
considered. Clinicians should be better aware and informed of the evidence 
of benefi ts and harms that underpins the rationale behind screening guidelines 
from professional groups. 
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MINI-ORAL SESSION 32: 
IMMUNOBIOLOGY 5: INFLAMMATION AND ISCHAEMIA
POSTER BOARD NUMBER P4 – 459
CTGF RELEASED BY APOPTOTIC ENDOTHELIAL 851 
CELLS TRIGGERS FIBROGENESIS
P. Laplante, I. Sirois, M-A. Raymond, M-J. Hébert
University of Montreal
Apoptosis of endothelial cells (EC) is appreciated as a primary event in the 
development of various fi brotic diseases, such as chronic allograft rejection, 
systemic sclerosis and graft-vs-host-disease. Yet, the fi brogenic pathways 
activated by apoptosis of EC have remained, until recently, ill defi ned. Two 
important and concomitant phenotypic changes appear to be required for 
development of fi brosis: differentiation of fi broblasts into myofi broblasts and 
acquisition of a broad anti-apoptotic phenotype in fi broblasts/myofi broblasts. 
The myofi broblast, a specialised and contractile type of fi broblast, is a 
normal cellular constituent of healing tissues where it plays a central role in 
ECM deposition and tissue contraction. In fi brosis, however, myofi broblasts 
accumulate chronically due to a sustained state of resistance to apoptosis 
and represent key players in generating the pathological tissue deformations 
characteristic of fi brosis. 
Here we demonstrated that caspase activation in apoptotic EC triggers 
the release of fi brogenic mediators which in turn favour myofi broblast 
differentiation. A comparative proteomic approach identifi ed Connective 
Tissue Growth Factor (CTGF) as a novel mediator released by apoptotic EC 
downstream of caspase activation. Immunoblotting confi rmed increased levels 
of CTGF in medium conditioned by apoptotic EC (SSC) as compared with 
medium conditioned by non-apoptotic EC. Also, fi broblasts exposed to SSC 
immunodepleted of CTGF failed to differentiate, thus suggesting a pivotal role 
for CTGF in this system. Use of gene defi cient fi broblasts for Src, Fyn, Yes 
and siRNA targetting Focal adhesion kinase or Pyk2, demonstrated that CTGF 
induces myofi broblast differentiation through a Yes-Pyk2-Phosphatidylinositol 
3-kinase (PI3K) dependent pathway. Collectively these results suggest that 
apoptosis of EC presents an unrecognised potential towards CTGF production 
and initiation of fi brosis. 
POSTER BOARD NUMBER P4 – 460
ADVENTITAL VASCULAR PROGENITORS ARE MAIN 852 
SOURCE OF CELLS FOR INTIMAL HYPERPLASIA IN 
TRANSPLANT VASCULOPATHY
P. Religa1, M. Grudzinska1, K. Bojakowski2, J. Soin2, Z. Gaciong2, 
C. Soderborg-Naucler1
1Karolinska Institutet, Stockholm, Sweden, 2Warsaw Medical University, 
Warsaw, Poland
Transplant arteriosclerosis is the major factor of late organ dysfunction after 
transplantation. The pathology involves infl ammation of the vessel with 
formation of the intimal hyperplasia consisting of smooth muscle cells (SMCs) 
recruited into the vessel intima. The process results in a progressive narrowing 
of the vessel lumen, partly due to a healing reaction in the intima.
Hypothesis: Smooth muscle cells contributing to the vascular narrowing are 
in the large extension derived from grafts recipient. Evaluation of migration of 
tissue progenitor cells from surrounding tissues was the aim of the study.
Methods: Infrarenal aorta was transplanted from female F344 to male 
Lewis rats collected after different time points. Migration and activation of 
host-derived SMCs and cells from surrounding tissue were analyzed by 
immunohistochemistry and real-time polymerase chain reaction (PCR) for 
SRY gene. The samples were analyzed by immunohistochemistry with respect 
to cells present in the sections, such as: SMCs, endothelial cells, leukocytes and 
activation of the cells (SM-actin, SM-myosin, von willebrand factor, CD45, 
CD14, CD4, CD8, cyclinD1, PCNA). The samples were also analyzed by 
electron microscopy. Phenotypic analysis of adventitial progenitor cells was 
performed.
Results: Proliferating graft SMCs and infi ltrating leukocytes were observed 
in the intima and adventitia early after transplantation. The similar process 
was observed also in the adjacent vessel, however in a lower extension. With 
electron microscopy we observed also phenotypic modulation of medial SMCs 
in the adjacent vessels. The cells from the adventitia were major source of 
intimal cells migrating to the intima in our model. FACS analysis indicated that 
adventitial progentitor are sca1+.
Conclusion: The tissue progenitor cells from adjacent adventitia are important 
source of cells for the formation of intimal lesion.
POSTER BOARD NUMBER P4 – 461
RENAL ISCHEMIA REPERFUSION INJURY 853 
IS ABROGATED BY THE NOS COFACTOR 
TETRAHYDROBIOPTERIN VIA MAINTENANCE OF NO 
HOMEOSTASIS AND STRESS KINASE INHIBITION
R. Sucher1,2, P. Gehwolf2, R. Oberhuber2, M. Maglione1,2, E. Werner1, 
P. Obrist1, S. Schneeberger1,2, R. Öllinger1,2, R. Margreiter1,2, G. Brandacher1,2
1Department of General and Transplant Surgery, 2Daniel Swarovski Research 
Laboratory
Purpose: Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide 
synthases (NOS) and thus a critical determinant of NO production. BH4 
depletion during cold ischemia leads to uncoupling of NOS and contributes 
to reperfusion injury (IRI) due to increased superoxide formation. The role of 
BH4 during warm ischemia, however, is still largely unknown.
Material and Methods: Ischemic renal injury was induced by clamping the 
left renal artery for 45 min in male Lewis rats immediately after right-side 
nephrectomy. Reperfusion was studied at R0 (no reperfusion), 15min (R1), 
2hours (R2) and 7days (R3). Animals received either BH4(20mg/kg/BW) prior 
to reperfusion (GroupI) or saline (GroupII). Sham operated animals served 
as controls. Renal function was determined by plasma creatinine/urea. BH4 
tissue levels were assessed by HPLC. Morphologic changes were quantifi ed 
by H&E histology. Peroxynitrite formation was assessed by nitrotyrosine-
immunostaining and stress kinase (p38, JNK) activation was analysed using 
phosphorylation specifi c antibodies.
Results: BH4 tissue levels were slightly increased after 45min warm 
ischemia (1.0 to 1.6fold) up to two days (R1,R2) when compared to non-
ischemic controls. Additional BH4 treatment prior to ischemia signifi cantly 
improved renal function at all time points studied following reperfusion (all 
p<0.001). Furthermore, BH4 reduced ischemia induced histologic damage 
(increased infl ammation, interstitial edema, hemorrhage, tubular atrophy and 
focal areas of necrosis) and diminished peroxynitrite formation and hence 
nitrotyrosine staining (R1-R3). Subsequently, stress kinase activation was 
abrogated following BH4 treatment further limiting ischemia reperfusion 
injury (p<0.01). 
Conclusion: BH4 treatment signifi cantly improves post-ischemic renal 
function as well as histologic damage and might be a promising novel 
therapeutic strategy in attenuating IRI via maintenance of NO homeostasis and 
stress kinase inhibition in kidney transplantation. 
POSTER BOARD NUMBER P4 – 462
DAMPENING OF ALLOIMMUNITY BY TOLL-LIKE 854 
RECEPTOR 4 DESENSITIZATION
V. Nicolas, D.W. Virginie, L.J. François, P. Lemaitre, F. Lhomme, 
M. Goldman, A. Le Moine
Institute for Medical Immunology Université Libre de Bruxelles
A single does of lipopolysaccharide (LPS) activates innate immunity through 
the Toll-Like receptor (TLR) 4 whereas repeated injections of sublethal doses 
desensitize animals, a process referred as endotoxin tolerance. During organ 
transplantation, there is an early activation of innate immunity through the 
recognition of endogenous and exogenous TLR ligands, a process considered 
as boosting effector T cell differentiation and allograft rejection. Therefore, we 
wondered if a prior LPS-desensitization could favourably infl uence the fate of 
allograft. We observed that LPS-desensitization of both donors and recipients 
signifi cantly enhanced survival of male to female skin grafts, compared with 
undesensitized control mice (p<0.05, Logrank test). Next, we tried to identify a 
putative regulatory cell subtype by performing suppression assays of MLR and 
polyclonal CD4+ and CD8+ T cell activation. Among desensitized splenocytes, 
only CD11b+Gr-1+ cells were able to signifi cantly suppress T cell proliferation 
(CFSE dilution experiments and IFN-&#61543; production) whereas 
CD11b+Gr-1+ cells from control animals did not. Transwell experiments 
revealed that suppression was cell-cell contact-dependant. Moreover, 
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alloreactive T cells only marginally responded to desensitized allogeneic 
CD11b+ cells compared with undesensitized (thymidine incorporation and 
IFN-&#61543; production). In vivo, LPS-desensitization increased the 
percentage of CD11b+Gr-1+ cells up to 5 folds in bone marrow, spleen and 
lymph nodes. Adoptive transfer of CD11b+ from LPS desensitized animals 
to naïve female recipients signifi cantly prolonged male skin graft survival 
compared to untransferred controls (p<0.05, Logrank test). We conclude that 
LPS-desensitization: (1) delays allograft rejection; (2) increases the number 
of CD11b+Gr-1+ cells which are endowed with powerful cell-cell contact-
dependant immunosuppressive properties.
POSTER BOARD NUMBER P4 – 463
PROTECTION AGAINST RENAL ISCHEMIA INJURY IN 855 
DNA-REPAIR DEFICIENT COCKAYNE SYNDROME MICE
R.W.F. de Bruin1, D. Susa1, J.R. Mitchell2, M. Verweij1, H.P. Roest1, S. van 
den Engel1, 
M. van de Ven2, I.M. Bajema3, J.N.M. IJzermans1, J.H.J. Hoeijmakers2, 
1Erasmus Medical Centre Rotterdam, Department of Surgery, 2Erasmus 
Medical Centre Rotterdam, Department of Cell Biology and Genetics, 3Leiden 
University Medical Centre, Department of Pathology
The premature aging symptoms of progerias with inborn errors in DNA repair 
mechanisms, such as Cockayne syndrome, are thought to be due in part to 
hypersensitivity to oxidative DNA damage caused by reactive oxygen species. 
To assess the contribution of oxidative DNA damage to renal ischemia 
reperfusion (I/R) injury, we tested the effects of congenital DNA repair 
defi ciency using a mouse model of Cockayne syndrome B (Csb-/- mouse) on 
renal ischemia-reperfusion injury. 
Renal I/R injury was induced by placing an atraumatic microvascular clamp 
on the renal pedicle of the left kidney of Csb-/- or littermate control mice. After 
reperfusion, the right kidney was removed. Mice were sacrifi ced at specifi ed 
time-points after reperfusion, and markers of kidney function, proliferation, 
cell death, cell cycle and infl ammation were determined.
Unexpectedly, we found that Csb defi ciency was benefi cial to survival and 
kidney function following I/R injury. Mortality was signifi cantly reduced 
from 70% in controls to 40% in Csb-/- mice (p<0.01), and kidney function was 
signifi cantly improved. Acute tubular necrosis score was higher in control 
mice on days 1 and 2 (p<0.05). Proliferation, as assessed by histology, 
PCNA and KI-67 staining was signifi cantly higher in Csb-/- kidneys in the 
regenerative phase (days 1,2, and 3) following injury (p<0.05). Consistent 
with increased proliferation, we found a reduced number of p21 positive 
cells in Csb mice on day 2. Transcript levels of p-selectin and ICAM-1 were 
signifi cantly lower compared to controls at 6 and 24 hours after reperfusion, 
respectively.
In conclusion, Csb-/- mice showed and increased resistance to renal I/R injury. 
Our data suggest that certain types of unrepaired endogenous DNA damage 
activate a stress response that preconditions against acute forms of stress such 
as ischemic injury. Elucidation of this protective stress response may offer a 
new approach to protect against renal ischemia reperfusion injury. 
POSTER BOARD NUMBER P4 – 464
INTRACELLULAR SIGNALING PATHWAYS AS 856 
TARGETS FOR THE PREVENTION OF ISCHEMIA/
REPERFUSION-INDUCED DAMAGE DURING SOLID ORGAN 
TRANSPLANTATION
R. Sucher1, J. Smigelskaite1, P. Gehwolf1, A. Kuznetsov1, M. Hermann2, 
C. Doblander1, M. Maglione1, T. Ratschiller1, G. Brandacher1, R. Margreiter1, 
J. Troppmair1
1Daniel Swarovski Research Laboratory, Dept. of General and Transplant 
Surgery, Innsbruck Medical University, 2KMT Laboratory, Dept. of General 
and Transplant Surgery, IMU
Pronounced changes in intracellular signaling are observed during ischemia 
and reperfusion (I/R) in the context of solid organ transplantation. We are 
only beginning to understand the underlying physiological activators and 
the endpoints controlled by these signals. While genetic studies in mice 
have underscored the profound effects altering key signaling molecules may 
have on the outcome of I/R-induced organ injury (IRI), we have a much 
better understanding of the role of the second messengers reactive oxygen 
species (ROS) and Ca2+ in this process. In our work using isolated mouse 
cardiomyocytes and a murine heart transplant model we noticed a signifi cant 
increase in the activity of mitogen-activated protein kinases (ERK, JNK, p38) 
at the earliest time points after reoxygenation/reperfusion. These enzymes 
play key roles in the control of cell death and thus constitute prime candidates 
for possible regulators of IRI. In an attempt to establish a possible causal 
relationship between altered intracellular signaling and the previously described 
changes in mitochondrial ROS and Ca2+ we employed the cardiomyocyte cell 
line HL-1 as well as non-myocytic cells. Using the latter our experiments 
demonstrated that signaling through RAF-MEK-ERK controlled mitochondrial 
ROS production, which otherwise resulted in mitochondrial Ca2+ overload and 
apoptosis. In HL-1 cardiomyocytes undergoing hypoxia and reoxygenation 
we observed that in these cells activation of p38 was responsible for the 
increase in mitochondrial ROS and Ca2+ levels. Taken together, our data 
demonstrate that MAPK signaling, which we found early after reperfusion 
is critically involved in controlling ROS and Ca2+ levels and thus most likely 
cardiomyocyte death. Modulating these pathways, which has become feasible 
through the development of small molecular weight inhibitors may provide an 
effi cient means to interfere with the onset of IRI at a very early stage before 
irreversible damage is set.
POSTER BOARD NUMBER P4 – 465
A NOVEL SIRNA-DELIVERY METHOD THROUGH 857 
CORONAL ARTERY INFUSION OF DONOR HEARTS FOR 
PREVENTING ISCHEMIA-REPERFUSION INJURY
X. Zheng, D. Chen, X. Zhang, M. Suzuki, N. Kobu, D. Lian, J. Jiang, 
B. Garcia, A.M. Jevikar, W-P. Min
University of Western Ontario
Background: We have previously demonstrated that silencing infl ammatory, 
apoptosis and complement genes can prevent ischemia-reperfusion (I/R) 
injury occurring in heart transplantation. However, the method for effi cient 
delivering siRNA into donor organ has not been established. This study 
was designed to develop a new method to induce gene silencing by coronal 
artery infusing with siRNA solution for prevention I/R injury in heart 
transplantation. 
Methods: Multiple siRNAs that specifi cally target TNFα, Caspase 8, and 
C5a receptor (C5aR) genes were generated and selected. siRNA protection of 
donor organs was evaluated in a rat heart transplantation model. Heart grafts 
from Lawis rats were infused with siRNA solution via coronal artery and 
preserved in HKT solution at 4 0C for 18 hrs, and subsequently transplanted 
into syngeneic Lawis rats. Cardiac functions were assessed by heart beating 
rate. Gene expression at mRNA level was determined by qPCR. The I/R injury 
was assessed by immunohistochemistry. 
Results: After donor heart perfusion with siRNA solution, siRNA was found 
to enter the myocardial cells, indicated by the fl uorescence emitted from the 
dye labeled siRNA. The levels of TNFα, caspase 8 and C5aR genes were 
signifi cantly up-regulated in the grafts after ex vivo preservation for 18 hrs. 
These up-regulated TNFα, caspase 8, and C5aR genes were signifi cantly 
knocked down by siRNA infusion. Using a siRNA infused organ as a donor, 
the graft survival was signifi cantly prolonged in heart transplantation. While 
siRNA solution-treated heart grafts retained strong heartbeat up to the end point 
of observation (>10 days), the control grafts lost function within 3 days. In 
addition, an improved cardiac function was observed in the graft preserved 
in siRNA solution. The protection of graft by siRNA solution is associated 
with prevention of I/R injury. siRNA solution-treated organs exhibited almost 
normal histological structures as well as less neutrophil and lymphocyte 
infi ltration, compared with control solution-treated organs. 
Conclusions: This study developed a novel ex vivo siRNA delivery system 
using coronal artery infusion, which can effectively silencing genes in donor 
hearts and prevent cardiac I/R injury. 
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POSTER BOARD NUMBER P4 – 466
INHIBITION OF TH17 CELLS REGULATES 858 
AUTOIMMUNE DIABETES.
J. Emamaullee, J. Davis, L. Stanton, C. Toso, S. Merani, J. Shapiro
University of Alberta
Background: Type 1 diabetes (T1D) occurs following the T-cell mediated 
destruction of the insulin-producing islet β;-cells within the pancreas. Recently, 
a population of CD4+ T helper cells that secrete IL-17 (‘Th17’ cells) has 
been specifi cally linked to autoimmunity, and high levels of IL-17 have been 
associated with most autoimmune conditions. The impact of Th17 cells in T1D 
is not known, but our group has determined that neutralization of IL-17 in the 
NOD mouse, a model of T1D, signifi cantly delays autoimmunity, suggesting 
that Th17 cells play a role in this disease. It has recently been reported that IL-25, 
a cytokine in the same IL-17 cytokine family, downregulates the development 
of autoimmune infl ammation mediated by Th17 cells in a mouse model of 
multiple sclerosis. These data, combined with our previous work using anti-
IL-17, suggest that IL-25 therapy will control autoimmunity in T1D. 
Results: A series of experiments were conducted to test IL-25 therapy in 
diabetes prevention, remission, and recurrence in NOD mice. When IL-25 
was administered at 1 μ;g/day for 25 days beginning at 10 weeks of age, 
80% animals were free from diabetes at 6 months of age, vs. 10% of control 
animals (P=0.007). Histological analysis of treated animals revealed an 
absence of peri-islet infi ltrates, which was in stark contrast to the obliterative 
insulitis observed in control animals. As well, IL-25 treatment prevented the 
formation of GAD65 autoantibodies and reduced the frequency of GAD65-
responsive autoreactive T-cells (P<0.001 vs control; ELISPOT). Interestingly, 
administration of IL-25 at the time of diabetes onset resulted in remission from 
diabetes in 82% of treated animals, versus 0% of control animals (P<0.001). 
However, the remission was not always durable and hyperglycemia returned 
after 7-10 days in some animals, even while IL-25 therapy was ongoing. In 
the setting of recurrent autoimmunity following syngeneic islet transplantation, 
control animals rejected their islet grafts in 4.2±0.8 days, while IL-25 treated 
animals rejected their islets in 7.2±0.2 days (P=0.0013). Ongoing adoptive 
transfer studies should reveal the mechanism of IL-25 mediated suppression 
of autoimmune diabetes.
Conclusion: Our results suggest that further refi nement of IL-25 treatment 
regimens may lead to durable remission from new onset diabetes and prevent 
recurrent β;-cell autoimmunity following islet transplantation.
POSTER BOARD NUMBER P4 – 467
A MULTICENTER RCT OF DECEASED ORGAN DONOR 859 
PRE-TREATMENT WITH CORTICOSTEROIDS FOR THE 
PREVENTION OF POSTISCHEMIC ACUTE 
RENAL FAILURE
J. Wilfl ingseder1, A. Kainz1, C. Mitterbauer2, C. Burghuber2, P. Perco3, T. 
Meyer4, B. Mayer3, R. Langer5, R. Magreiter6, R. Oberbauer1,2
1KH Elisabethinen, Linz, Austria, 2Medical University of Vienna, Austria, 
3Emergentec Biodevelopment, Vienna, Austria, 4Department of Nephrology, 
University of Stanford, Palo Alto, CA, USA, 5Semmelweis University, 
Budapest, Hungary, 6Medical University of Innsbruck, Austria
This randomized placebo controlled study seeks to elucidate whether pre-
treatment of deceased organ donors with corticosteroids before organ retrieval 
will decrease infl ammation in the donor kidney and will reduce the rate or 
duration of postischemic acute renal transplant failure (ARTF). We have shown 
previously, that infl ammation of the donor kidney prior to transplantation is 
among the main risk factors for ARTF (Hauser P et al. Lab Invest 2004, Kainz 
A, AJT 2004).
The predetermined interim analysis of 210 recipients (calculated sample size 
420) will be presented. This analysis includes genome-wide gene expression 
profi les of donor kidney biopsies with subsequent systems biology approaches 
such as transcription factors analysis, regulatory networks, and protein-protein 
interaction data. Trajectories of GFR in the fi rst week after engraftment will be 
analyzed by mixed linear regression models for longitudinal data, the incidence 
of ARTF, defi ned as more than one post-transplant dialysis will be analyzed by 
Chi-square test. 
At the time of abstract submission 27 randomly selected biopsy samples have 
been analysed. Unsupervised hierarchical clustering of experimental data 
suggest a distinct molecular signature associated with reduction of infl ammation 
in the steroid group. Selection of twofold differentially downregulated genes 
in the steroid group yielded 94 signifi cant sequences that can be categorized 
according to PANTHER ontologies into four main biological processes: 
immunity and defense (p<0.001) protein modifi cation (p<0.001), cell cycle and 
control (p<0.003), cell proliferation and differentiation (p<0.003).
These preliminary genomics data suggest that infl ammation was reduced by 
steroid pre-treatment. The effect of this intervention on clinical endpoints of 
ARTF will be presented in the interim analysis at the meeting.
POSTER BOARD NUMBER P4 – 468
DONOR ANGIOTENSIN II RECEPTOR TYPE 1 860 
EXPRESSION CRITICALLY INVOLVES THE DEVELOPMENT 
OF ACUTE REJECTION
M. Ogawa, J-I. Suzuki, M. Isobe
Tokyo Medical and Dental University
Backgrounds: Although angiotensin II receptor type 1 (AT1) mediates 
infl ammation, little is known about the roles of AT1 in the development of 
cardiac rejection. Methods: To test the hypothesis that AT1 expression, either 
on the donor hearts or recipient cells, plays a pivotal role in the development 
of rejection, we established a murine heterotopic cardiac allograft model using 
AT1a knockout (AT1aKO) (C57BL/6 background), C57BL/6 and/or BALB/c 
mice. Total allomismatch combination was used to analyze graft survival 
(acute rejection). 
Results: The AT1aKO donor BALB recipient group signifi cantly prolonged 
graft survival compared to those of the B6 donor BALB recipient group 
(AT1aKO/BALB; 28.71 +/- 16.75 days, B6/BALB; 8.14 +/- 0.40 days, p<0.05). 
However, the BALB donor AT1aKO recipient group showed statistically 
comparable survival to that of the WT donor WT recipient group (BALB/
AT1aKO; 7.33 +/- 0.33 days, BALB/B6; 7.13 +/- 0.23 days). 10% of the mice 
in AT1aKO donor BALB recipient group showed graft survival more than 130 
days, but not induced immunological tolerance with acceptance of the skin 
graft from the donor strain. 
Conclusion: Donor AT expression plays an important role as a mediator for 
infl ammation of heart transplantation. The donor AT regulation deeply involves 
the development of acute rejection and the tissue distribution of the inhibitor 
may be critical for the treatment of rejection.
STATE-OF-THE-ART SYMPOSIUM 
CONCURRENT SESSION 33: UPDATE ON NEW 
IMMUNOSUPPRESSIVE TRIALS IN TRANSPLANTATION
A PROSPECTIVE, RANDOMISED, PLACEBO 861 
CONTROLLED,MULTICENTER STUDY OF THE EFFICACY 
AND SAFETY OF RITUXIMAB AS INDUCTION THERAPHY 
TOGETHER WITH TACROLIMUS,MYCOPHENOLATE 
MOFETIL AND STEROIDS IN RENAL TRANSPLANTATION
G. Tyden1, L. Mjornstedt2, H. Ekberg3, G. Tufveson4
1Karolinska University Hospital,Stockholm, 2Sahlgrenska University 
Hospital,Gothenburg, 3University Hospital MAS,Malmoe, 4Academic 
University Hospital, Uppsala
Purpose: There is an increasing evidence to suggest that B cells have a role 
in otherwise classic T cell-mediated rejection by their ability to act as antigen-
presenting cells and T cell activators. We therefore studied the effi cacy and 
safety of the monoclonal anti-CD20 antibody rituximab as induction therapy 
in renal transplantation. 
Methods: We performed a prospective, randomized, placebo-controlled 
multicenter study of the effi cacy and safety of rituximab as induction therapy, 
together with tacrolimus, mycophenolate mofetil and steroids, for patients 
undergoing renal transplantation. The primary end point was a composite 
end point defi ned as treatment failure including the occurrence of any of the 
following: biopsy-proven acute rejection, graft loss or death during the fi rst 
6 months following transplantation. Secondary end points were creatinine 
clearance (Cockroft-Gault formula) at 6 months, incidence of infections and 
incidence of rituximab-related adverse event. 
Results: 140 patients were enrolled (44 LD and 96 DD) and of those 69 
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rituximab patients and 68 placebo patients fulfi lled the study. In all the patients 
receiving rituximab there was a complete depletion of CD19/ CD20 cells at 3 
and 6 months, while there was no change in the number of CD19/ CD20 cells in 
the placebo group.There were 10 and 14 treatment failures in the rituximab and 
placebo groups respectively. Thus there was one patient death and one graft loss 
not related to rejection, in each group. There were 8 rejections in the rituximab 
group (11.6%) versus 12 in the placebo group (17.6%). There were more early 
C4d-positive rejections in the placebo group (4) than in the rituximab group(1). 
Furthermore, there were more steroid-resistent rejections in the placebo group 
(5) than in the rituximab group (2). However, none of these differences were 
statistically signifi cant.The creatinine clearance at 6 mos was 66 ml/min in 
rituximab treated patients and 67 ml/min in the placebo group. There was 
no difference in the number of bacterial infections, CMV infections, BKV 
infections or fungal infections. Neither was there any signifi cant difference in 
the incidence of leucopenia and anemia or in the incidence of cardiac events.
Conclusion: We performed the fi rst ever randomized, placebo-controlled study 
of the effi cacy and safety of rituximab in renal transplantation. There was a 
tendency towards fewer and milder rejections during the fi rst 6 months in the 
rituximab group compared with the placebo group. Although induction with 
one dose of rituximab induced a complete depletion of CD19/ CD20 positive 
cells there was no increase in the incidence of infectious complications, cardiac 
events, leucopenia or anemia and it appears safe therefore to conduct further 
studies on the use of rituximab in transplantation.
OPTICEPT TRIAL: EFFICACY AND SAFETY OF 862 
MONITORED MMF IN COMBINATION WITH CNI IN RENAL 
TRANSPLANTATION AT 1 AND 2 YEARS
R. Bloom1, B. Kaplan, H-U. Meier-Kriesche, L. Shaw, T. Shah, D. Patel, 
R. Gaston
1University of Pennsylvania, 2University of Illinois, 3University of Florida, 
4University of Pennsylvania, 5National Institutte of Transplantation, 6Roche, 
7University of Alabama
Purpose: To compare the effi cacy and safety of maintenance 
immunosuppression with either a concentration-controlled or fi xed-dose MMF 
regimen in combination with standard or reduced level calcineurin inhibitor 
(CNI) regimens in kidney recipients. 
Methods: In a 2-year open-label, prospective, randomized, multicenter study, 
720 single-organ kidney recipients received either: 1) concentration-controlled 
MMF and reduced level CNI (MMFCC/CNIRL); 2) concentration-controlled 
MMF and standard level CNI (MMFCC/CNISL); or 3) fi xed-dose MMF (1 g 
BID) and standard level CNI (MMFFD/CNISL). MMF dose adjustments were 
made in the MMFCC arms to target MPA levels > 1.3 and 1.8 respectively 
for patients on either cyclosporine or tacrolimus treatment. Antibody induction 
and corticosteroids were administered according to center practice. Primary 
endpoints included the percentage of patients with treatment failure (biopsy-
proven acute rejection [BPAR], graft loss, or death), and mean percent change 
in calculated glomerular fi ltration rate (GFR; Nankivell equation) after 12 
months. Safety endpoints were incidences of adverse events and serious 
adverse events. Non-inferiority (α=0.05) of MMFCC/CNIRL vs. MMFFD/
CNISL for treatment failure was tested. 
Results: 12- and 20-24 month data were analyzed for 720 participants; 82% 
received tacrolimus. Baseline characteristics were similar among groups. At 12 
months, noninferiority was established in the proportion of patients with treatment 
failure among the 3 groups (90% CI -11.8%, 1.3% for MMFCC/CNIRLvs. 
MMFFD/CNISL). Time to fi rst acute rejection was signifi cantly related to MPA 
trough (p=.0114) and MPA AUC (p=.0171) measured before the rejection episode 
when analyzed at 6 months. Despite signifi cantly higher MMF doses but lower 
CNI trough levels at most time points in those receiving MMFCC/CNIRL, 
signifi cantly fewer MMF withdrawals occurred in these patients vs. the other 
treatment groups at both 12 and 20-24 months (p=.002 for each comparison at 
each timepoint). Diarrhea within the fi rst 90 days after transplant was signifi cantly 
associated with tacrolimus levels but not with MPA or cyclosporine levels. The 
risk for diarrhea increased with higher tacrolimus levels. 
Treatment failure at 12 months and BPAR at 12 and 20-24 months
MMFCC/CNIRL MMFCC/CNISL MMFFD/CNISL p value
N 243 237 240 A vs B/C
Treatment failure 55 (22.6%) 68 (28.7%) 67 (27.9%)
BPAR (12 m)* 15 (6.2%) 23 (9.7%) 23 (9.6%) NS
BPAR (20-24 m)* 16 (6.6%) 26 (11.0%) 24 (10.0%) NS
Graft loss* 5 (2.1%) 4 (1.7%) 4 (1.7%)
Death* 4 (1.6%) 2 (0.8%) 6 (2.5%)
Regression Analysis Model to Estimate Risk for First Diarrheal Episode within 90 Days
Trough level Risk ratio 95% CI p value
MPA 1.107 0.935, 1.311 .240
Tacrolimus 1.062 1.020, 1.106 .003
Cyclosporine 0.998 0.990, 1.007 .719
*Events are mutually exclusive because only 1st event counted/patient; MPA, mycophenolic acid. 
Conclusions: The primary end point of the noninferiority of combining 
concentration -controlled doses of MMF with low doses of CNI was met. 
This study suggests that lower rejection and MMF withdrawal rates can be 
accomplished with therapeutic drug monitoring of MPA. 
A MULTICENTER, RANDOMIZED, DOUBLE 863 
BLIND, PLACEBO-CONTROLLED TRIAL OF EARLY 
CORTICOSTEROID CESSATION: FINAL FIVE YEAR REPORT
E.S. Woodle
University of Cincinnati
In fi ve decades of renal transplantation, only three double blind trials of 
corticosteroid withdrawal (CSWD) have been conducted, however, in each 
CSWD was performed well after transplantation (>3monts). The fi nal, fi ve year 
results of the fi rst double blind, randomized placebo controlled trial of the early 
CSWD in kidney transplant patients (pts) maintenance is presented.
Methods: CSWD (191 pts) was compared to chronic corticosteroid therapy 
(CCS)(195 pts) under tacrolimus /mycophenolate therapy with thymoglobulin 
(Thymo) or IL-2R antibody (Ab) induction. Prednisone dose in CCS pts was 
reduced to 5mg/day at 6 months. The composite primary endpoint included 
death, graft loss or severe acute rejection (AR) defi ned as AR requiring antibody 
treatment or Banff 95 Grade >2B or Banff 97 Grade >2A. Blinding of patients 
and investigators was maintained throughout the fi ve year study period.
Results: Data are presented as CCS/CSWD. Differences were not observed 
in demographic or immunologic risk data, or Thymoglobulin induction 
69.7%/65.4% of pts. Primary endpoint (13.3%/15.7%);death (6.2%/5.2%), 
death censored graft loss (3.6%/6.3%), and severe acute rejection (5.1%/7.9%) 
were not different. Death to infection was higher with CCS (2.6%/ 0%, p=0.06). 
Biopsy confi rmed AR approached signifi cance (10.8%/17.8%, p=0.06). 
However, serum creatinine (1.5+0.8 / 1.6+0.7 mg/dl); calculated creatinine 
clearance (60.2+20.5 / 57.1+20.2 ml/min and proportion of pts. with creatinine 
clearance <40 ml/min (7.4% / 10.8%) were not different between groups. 
Overall graft survival was similar, and a small increase in chronic allograft 
nephropathy (CAN) (4.1%/ 9.9%, p=0.03) was noted in for cause biopsies. 
CSWD provided cardiovascular risk/metabolic benefi ts including new onset 
diabetes requiring insulin (13.5% / 2.1%, p=0.005); change in triglycerides (in 
pts without hyperlipidemia at baseline (+26.1 / -69.0 mg/dl,p=0.001), and bone 
disorders (fractures/avascular necrosis) (11.3%/4.7%, p=0.02). 
Conclusions: After a fi ve year blinding period, this study demonstrates that 
early CSWD provides cardiovascular risk and bone disease benefi ts without 
a signifi cant effect in allograft survival or function compared to chronic 
maintenance low-dose prednisone therapy at 5 mg/day.
TACROLIMUS ONCE-DAILY PROLONGED RELEASE 864 
VERSUS TACROLIMUS TWICE-DAILY IN COMBINATION 
WITH STEROIDS - A PHASE III MULTICENTRE LIVER STUDY
P. Trunecka1, O. Boillot2, J. Langrehr3, A.D. Pinna4, L. Fischer5, B-G. 
Ericzon6, R. Troisi7, F. Bresadola8, J. Ortiz De Urbina9, W. Wall10
1IKEM, 2Hôpital Edouard Hérriot, 3Klinik Tranplantationschirurgie, 4Policlinico 
Sant’Orsola, 5Hepatobiliaere Chirurgie, 6Karolinska University Hospital 
Huddinge, 7Departement Heelkunde, 8Clinica Chirurgica Universitaria, 9Unidad 
de Trasplante Hepatico, 10London Health Sciences Centre
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily 
formulation of tacrolimus with similar exposure and trough levels compared to 
the well-established twice-daily formulation (Prograf®, PRO). This 12-month 
study was designed to compare the effi cacy and safety of ADV and PRO in de 
novo liver transplant recipients.
Methods: The study was performed in 48 transplant centres and 16 countries. 
This was a double-blind, double-dummy study with patients randomised 1:1 to 
PRO or ADV. The fi rst total daily dose was 0.1 mg/kg for PRO and 0.2 mg/kg 
for ADV combined with a steroid taper (0-10 mg/day after Day 42). For both 
treatment arms tacrolimus whole blood trough levels were targeted at 10-20 
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ng/mL to Day 28, then 5-15 ng/mL to Day 90 and 5-10 ng/mL thereafter. The 
primary end point was the event rate for biopsy proven acute rejection (BPAR, 
per protocol set with non-inferiority comparison set at 15%) at 24 weeks with 
a further 6-month extended open follow-up. Acute rejection, patient and graft 
survival were also assessed at 24 weeks and 12 months. Adverse events and 
safety parameters including renal function were recorded throughout.
Results: 234 PRO and 237 ADV patients received at least one dose of study 
medication with 156/234 (66.7%) PRO and 150/237 (63.3%) ADV patients 
completing the 12-month study. Key donor and recipient demographics were 
similar. Mean daily tacrolimus dose and mean whole blood trough level for 
PRO vs. ADV at Week 4 were 0.13 mg/kg and 10.7 ng/mL vs. 0.19 mg/kg and 
11.5 ng/mL, and at Month 12 were 0.06 mg/kg and 8.1 ng/mL vs. 0.08 mg/kg 
and 8.4 ng/mL. Kaplan-Meier patient survival at 12 months was 91% vs. 89% 
and graft survival 86% vs. 85% (PRO vs. ADV). Similarly, 24-week BPAR 
event rates were 29.3% vs. 32.6% (p=0.354). In the per protocol analysis 
with major protocol violators excluded (PRO N=177 & ADV N=181), 
BPAR events rates at 24 weeks were 33.9% vs. 35.9% (p=0.567; treatment 
difference 95% CI -7.9%, 11.9% ) falling within the predefi ned 15% non-
inferiority margin. The 12-month BPAR event rate was 30.5% vs. 33.8% 
(p=0.356). Mean creatinine clearance (Cockroft & Gault) at 12 months for 
study completers was 82 vs. 78 mL/min and adverse event profi les were 
similar for both regimens.
Conclusions: The study demonstrates that once-daily tacrolimus prolonged 
release Advagraf® was well tolerated and is non-inferior, conferring similar 
effi cacy and safety profi les to the established twice-daily formulation 
Prograf®.
 THURSDAY – ORAL ABSTRACTS (CONTINUED)
CONCURRENT ORAL SESSION 61: 
LIVING DONOR RENAL TRANSPLANTS
TESTING WILLINGNES FOR LIVING KIDNEY 865 
DONATION: AN OPTION FOR ALL PATIENTS?
L. Kranenburg, W. Zuidema, W. Weimar, M. Hilhorst, J. IJzermans, 
J. Passchier, J. Busschbach
Erasmus University Medical Centre
Purpose: This is the fi rst large scale in-depth interview study done in patients 
and potential donors who seem unwilling or unable to pursue living kidney 
donation. By investigating these groups we explore whether further expansion 
of the living kidney donation program is feasible.
Methods: We interviewed 90 patients on the waiting list for a kidney transplant 
who seemed unwilling or unable to pursue living kidney donation, and 
their potential donors (n = 54). We also included a comparison group of 53 
patients and 51 donors who had planned to undergo living kidney donation/
transplantation in the near future. All respondents underwent an in-depth 
interview by a psychologist about topics that could infl uence their willingness 
to pursue living kidney donation, such as: information, communication and 
risk perception.
Results: 82% of the patients on the waiting list are willing to accept the offer 
of a living donor. Main reason given for not pursuing living kidney donation 
was reluctance to discuss the issue with the potential donors. Notably, in the 
comparison group, it was always the donor who initiated the communication 
about donation. Both groups indicated that if no donor steps forward, one 
is likely to interpret this silence as a refusal to donate. We found evidence 
that this interpretation not always holds: over one third (20/54) of the 
potential donors that we interviewed were in a pre-contemplation phase, open 
to consider themselves as a potential donor. On the other hand, an in size 
comparable group of potential donors (22/54), was reluctant about donation. 
Main reasons for donor reluctance were 1) Fear for their own health, 2) The 
specifi c relationship with the intended recipient, and 3) A lack of information 
about living kidney donation. 
Conclusion: The majority of patients on the waiting list are willing to accept 
a living kidney donor, but are reluctant to discuss the issue of living donation 
with their potential donors. If potential donors do not take up the issue 
spontaneously, patients tend to interpret this as a refusal to donate. However, 
this interpretation is not necessarily true. Therefore, offering those patients 
professional assistance in fi nding a living kidney donor should be considered.
TIME 0 LIVING KIDNEY DONOR BIOPSY: A VALUABLE 866 
OPPORTUNITY TO CORRELATE PREDONATION CLINICAL 
DATA WITH HISTOLOGICAL ABNORMALITIES.
E. Mancilla 1, J. Alberu2, F. Rodríguez 1, N. Uribe2, S. Aburto 1, M. Vilatobá2, 
S. Magaña1, L. Morales2, B. Gabilondo2, C. Avila 1
1Instituto Nacional de Cardiologia “ICh”, 2Instituto Nacional de Ciencias 
Médicas y Nutrición “SZ”
Background: Living kidney donation is increasing rapidly worldwide to 
partially offer a solution (or an alternative?) for the number of ESRD pts 
waitlisted. In spite of properly following guidelines criteria for donor selection, 
current reports identify unsuspected renal pathology by time 0-biopsy. 
Purpose: Whether the fi ndings in time 0-biopsies correlate with pre-donation 
clinical data including renal function was explored in this study. 
Methods: Kidney transplant database from two institutions were reviewed. 
Time 0-biopsy started been performed routinely in recent years. Biopsies were 
done in the kidney upper pole during the back-table (Bard® Magnum® Biopsy 
System, gauge#16) and evaluated by 2 nephropathologist for: interstitial 
fi brosis, tubular atrophy, arteriolar hialinosis, mesangial increase (MI) and 
glomerulosclerosis (GS). Pre-donation data gathered from the donors were: 
demography, body weight, BMI, Systolic/Diastolic BP, SCr, proteinuria, and 
eGFR by Levey equation.
Results: At the time, a total of 231 time 0-biopsies of living donor 
nephrectomy have been performed; 219/231 (94.8%) were adequate 
specimens for pathologic analysis. Overall, 100/219 (45.6%) were absolutely 
normal. The histological fi ndings for the remaining 119 biopsies are shown 
in Table 1. Clinical data is summarized in Table 2. On bivariate analysis, 
signifi cant correlation with interstitial fi brosis were: age (r=0.22, p=.001), 
SCr (r=0.19, p=.005); Tubular atrophy with Diastolic BP (r=0.15, p=.03) and 
proteinuria (r=0.20, p=.009); Arteriolar hialinosis with SCr (r=0.15, p=.02) 
and eGFR (r= -0.16, p=.018); MI with BMI (r=0.13, p=.047); GS had no 
signifi cant correlation. Multivariate analysis failed to sustain the signifi cant 
associations found in the bivariate analysis, most likely due to a low event/
parameter relation. 
Table 1. Time 0-biopsy (one or more abnormalities)
Histological Finding n= 119 %
Interstitial Fibrosis 64 53.7
Tubular atrophy 29 24.3
Mesangial increase 26 21.8
Arteriolar hialinosis 23 19.3
GS 23 19.3
Table 2. 
Age 35.4 ± 10
Gender F/M 127 (56.7%)
Weight (Kg) 66.27 ± 10.14
BMI 25.53 ± 2.99
Systolic BP (mmHg) 115.46 ± 9.2
Diastolic BP (mmHg) 73.5 ± 6.7
SCr (mg/dl) 0.91 ± 0.25
Proteinuria (mg/24 h) 70.25 ± 62.8
eGFR (ml/min) 96 ± 16.65
Conclusions. A signifi cant correlation was established between time 0-biopsy 
fi ndings and clinical pre-donation parameters. Whether the existence of these 
histological fi ndings at the time of kidney donation might represent a higher 
burden/risk for the remaining kidney ought to be evaluated during follow-up. 
Certainly, in an era where the living kidney donation is expanded, we should at 
least advice a closer surveillance of these donors in order to modify risk factors 
that participate in kidney damage progression. 
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THE ASSESSMENT OF ELDERLY DONORS AGED OVER 867 
65 YEARS FOR LIVING RELATED KIDNEY TRASPLANTATION 
BY 99MTC MERCAPTO-ACETYL-TRIGLYCINE (MAG3)
H. Ushigome1, K. Sakai1, T. Suzuki1, S. Nobori1, A. Yoshizawa2, 
S. Sakamoto1, M. Okamoto2, N. Yoshimura1
1Department of Transplantation and Regenerative Surgery, Kyoto Prefectural 
University Graduate School of Medical Science, 2Department of Organ 
Interaction Research Medicine, Kyoto Prefectural University Graduate 
School of Medical Science
Background: Evaluating candidate donors for living donor kidney transplantation, 
age is an important factor for excellent graft function and survival. Although 
the survival of kidney grafts from elderly donors is considered to be inferior to 
younger donors, clinically successful outcomes of kidney transplantation using 
grafts from elderly donors have sometimes been seen. However, there is no 
proper criterion for elderly donors of kidney transplantation.
Patients and Methods: From February 1994 to February 2008, 46 living 
donor kidney transplantations from elderly donors aged over 65 years (mean 
age 67.7 □} 3.5 years) were performed at Kyoto Prefectural University of 
Medicine Hospital. 99mTc mercapto-acetyl-triglycine (MAG3) renal scan 
was utilized for one of some preoperative assessments of all elderly candidate 
donors. Then each of left and right kidney function was separately estimated 
by effective renal plasma fl ow (ERPF) determined by the renography. Actual 
graft survival and serum creatinine were analyzed at 1, 3, 5 and 10 years after 
kidney transplantation.
Results: Renal function, as assessed by the serum creatinine level in patients 
at 1 year after transplantation was correlated signifi cantly with ERPF x donor/
recipient (D/R) body surface area (BSA). Actual graft survival at 1, 3, 5 and 10 
years after kidney transplantation was 100%, 100%, 100% and 73%, respectively, 
from donors with ERPF x D/R BSA > 180 ml/min and 96%, 78%, 58% and 58%, 
respectively, from donors with ERPF x D/R BSA < 180 ml/min.
Conclusions: When ERPF x D/R BSA was suffi cient, the survival of kidney 
grafts even from elderly donors aged over 65 years was adequate. Our fi ndings 
indicate that age alone should not be regarded as an exclusion criterion 
for kidney graft donation. When evaluating living donors before kidney 
transplantation, ERPF x D/R BSA may be a more helpful parameter than age or 
creatinine clearance for prediction of graft survival.
RENAL OUTCOMES IN AFRICAN-AMERICAN LIVING 868 
KIDNEY DONORS
M. Cooper, A. Haririan, M. Weir, S. Jacobs, D. Klassen, S. Bartlett, 
J. Nogueira
University of Maryland Medical Center
Living donor kidney transplantation (LDKT) has been encouraged as a source 
of organs for transplantation. The transplant community has accepted the 
procedure based upon a body of literature, with multiple studies as well as 
a meta-analysis demonstrating a lack of long-term adverse health effects of 
unilateral nephrectomy performed on a healthy individual. However, long-
term safety has not been demonstrated with live kidney donation from African-
Americans, who are at increased risk for chronic kidney disease (CKD).
Methods: Upon institutional IRB approval, AALKD’s were identifi ed 
between 3/1/96 and 2/28/02 and invited to participate. A health questionnaire 
on follow-up health care, interim medical history, and current medications 
was administered. Height, weight and three blood pressures using a 
standardized technique were completed. Urine and blood samples were 
collected for measurement of urine albumin/microalbumin, urine creatinine, 
and serum creatinine. Pre-donation serum creatinine-based estimation of 
GFR was calculated using the abbreviated MDRD equation (MDRD-eGFR). 
Continuous variables are reported as mean +/- standard deviation and were 
compared using Student’s t tests. Categorical variables are reported as 
absolute numbers and/or percentages and compared using 2x2 contingency 
tables and chi-squared tests. 
Results: 107 AALKDs were recruited. 39 subjects (36.4%) completed 
evaluation at a mean of 7.1 +/- 1.6 (range 3.9-10.2) years post-donation. The 
MDRD-eGFR was 72.1 +/- 16.3 (range 42-106) ml/min per 1.73m2, and 17.9% 
of subjects had Stage 3 chronic kidney disease (eGFR 30-59). 
SBP (mmHg) 120.8 +/- 14.5 (range 92-144)
DBP (mmHg) 79.7 +/- 9.3 (62-99)
SBP ≥ 140 or DBP ≥ 90 at GCRC visit 10 (25.6%)
Diagnosed with HTN prior to GCRC visit 8 (20.5%)
Current diagnosis of HTN (BP ≥ 140/90 mmHg at 
GCRC visit or prior diagnosis of HTN)
16 (41.0%)
Undiagnosed HTN 8 (20.5%)
Microalbuminuria (30-300 mcg/mg creatinine) 6 (15.4%)
Macroalbuminuria (> 300 mcg/mg creatinine) 1 (2.6%)
Serum creatinine (mg/dl) 1.22 +/- 0.25 (range 0.8-1.7)
MDRD-eGFR <60 ml/min per 1.73m2 or 
macroalbuminuria
8 (20.5%)
Diagnosed with diabetes mellitus 1 (2.6%)
The absolute and relative decrease in MDRD-eGFR from time of donation 
to follow-up was 30.5 +/- 16.4 ml/min per 1.73m2 and 28.8%, respectively. 
Subjects whose BMI was ≥ 35 kg/m2 (n=8) were found to have a greater 
decrement in MDRD-eGFR than those with BMI < 35 kg/m2 (-40.1 +/- 7.3 and 
28.3 +/- 17.1 ml/min per 1.73m2, respectively; p = 0.009). 
Conclusion: AALKD’s may experience a high incidence of hypertension and 
a substantial drop in MDRD-eGFR over several years following donation. 
Obesity may increase the magnitude of renal decline. Further study is urgently 
needed to determine the long-term risks of AALKD’s. 
AFRICAN AMERICAN WOMEN AND OLDER PATIENTS 869 
HAVE A GREATER DECLINE IN RENAL FUNCTION 
FOLLOWING LIVING KIDNEY DONATION
M. Reza Laftavi1, S. Sharma1, R. Koholi2, J. Tolluck1, M. Danek1, 
K. Paolini1, L. Fing1, M. Dayton1, D. Dunn1, O. Pankewycz2
1Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at 
Buffalo
Living donor kidney transplantation offers many advantages to the recipient. 
Longer allograft survival, fewer postoperative complications and better 
renal function are just some of the benefi ts of receiving living donor kidneys 
compared to deceased donor organs. In contrast, the consequences to the 
donor in terms of renal function are less well defi ned. Moreover, it is not 
clear whether all donors share an equal risk to their renal function following 
donation. In this study, we calculated the estimated GFR (eGFR) by the 
MDRD formula in donors prior to and following renal donation. We compared 
the percentage decline in renal function amongst various ages and other 
demographic groups using individual patients as their own controls. Between 
4/93 and 11/07, a total of 341 living donor transplants were performed in a 
single center. Of these, 103 donor charts (38 men, 65 women) were available 
for review. Donor characteristics were: 11 African American (AA), 94 white, 
age 40.3 +/- 9.6 years of age and pre-op eGFR 93.3+/-17.7 ml/min. All 
donors had normal blood pressures without medications, normal urinalysis 
and normal urinary protein levels. On average, donors experienced a -34.7% 
fall in eGFR to 59.8+/-10.9 ml/min determined 273 days post-transplantation. 
A greater decline in eGFR was noted in the AA group -41% compared to 
white patients -34% (p=0.03). The majority of the decline in the AA group 
was accounted by AA women in whom the fall in eGFR was -46% compared 
to AA men -31% and white women -34% (p=0.02). The percent decline in 
eGFR was not different amongst the various age groups. However, donors >50 
years old had a post-donation eGFR of 55.1 ml/min vs. 60.9 ml/min in those < 
50 years old (p=0.03) refl ecting the lower eGFR pre-donation (older 84.7 vs. 
younger 95.2 ml/min, p=0.02). The percent decline in eGFR did not change 
with time after donation (0-1 month 37%, 1-12 months 34%, >1year 30%). 
These results suggest that renal function declines abruptly following kidney 
donation in all patients but remains stable or improves afterwards. AA women 
and older donors may have a higher risk because they experience a greater 
immediate fall in eGFR and have a lower post-donation eGFR respectively. 
Clearly, a larger and prospective study is required to assess the long term renal 
functional decline in healthy living kidney donors.
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CONCURRENT ORAL SESSION 62: 
EXPERIMENTAL LIVER TRANSPLANTATION
INSIGHTS INTO THE INTERACTION OF TISSUE CELLS 870 
WITH INFILTRATING CD8+ T CELLS IN LIVER TRANSPLANT 
TOLERANCE USING A TCR TRANSGENE APPROACH
G. Jiang1, Q. Zhang1, H-. Yang2, K. Brown1, J. Fung2, L. Lu1,2, S. Qian1,2
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, 
2Department of General Surgery, Cleveland Clinic
Liver allografts are spontaneously accepted without requirement of 
immunosuppression in mice. The underlying mechanisms are not completely 
understood. We hypothesized that it resulted from an abortive T cell response 
within the liver due to hyporesponsiveness or apoptosis. To test this, we 
examined the activation and fate of allo-Ag specifi c CD8+ T cells following 
liver transplants (LTX) compared with heart transplants (HTX) that were 
acutely rejected. Following transplantation [B10 (H2b)¡÷C3H (H2k)], CFSE 
labeled CD8+ T cells (10x106) from Des TCR Tg mice (H2Kb specifi c) 
were adoptively transferred into the recipients. Two days later, animals were 
sacrifi ced for analyses of T cells in the grafts or draining lymph nodes (D-LN). 
Host CD45+ leukocytes were quickly infi ltrated following LTX. Among 
CD3 population ƒî48% were CD4+ and ƒî52% CD8+. CD8+ T cells were 
further increased thereafter in grafts and D-LN, associated with high INF-ƒ× 
production. CD8+ T cells in the liver grafts rapidly reduced to 36% by POD 
14, and to 12% POD 40. However, the incidence of CD4+ T cells remained 
high. CFSE dilution assay and ELISPOT showed an active division of Des+ 
T cells in liver allografts either on POD 7 or 40. These Ag-specifi c CD8+ T 
cells functioned well evidenced by IFN-ƒ× production in response to allo-Ag. 
However, compared to HTX, the accumulation of Des+ cells in grafts was 
signifi cantly lower in LTX [9.6% (17x104/heart), and 0.59% (6.14¡Ñ104 /
liver)] on POD 7, and further dropped to 0.14% (3.14¡Ñ104/liver) on POD 
40. The expended cohorts of adoptively transferred cells followed by their 
elimination suggested elimination of Ag-specifi c CD8+ cells. To examine the 
role of liver environment, graft CD45- non-parenchymal cells (NPC) were 
isolated tested fro regulatory effect on Des+ T cell response. Liver allografts 
showed signifi cantly expansion of CD45- NPC, which were donor MHC class 
I+ (H2b+), B7-H1+, TRAIL+ and low for CD40 and CD86. These cells did 
not inhibit Des+ T cell proliferation in response to B10 spleen stimulation, but 
signifi cantly enhanced their death, which was dependent on B7-H1/TRAIL. 
This was confi rmed by using CD45- NPC from B7H1-/- or TRAIL-/- mice. 
In conclusion, activated T cells in liver grafts may stimulate tissue cells to 
express inhibitory and death inducing molecules, resulting in T cell death and 
graft acceptance.
CYTOPROTECTIVE ACTION OF A CO-RELEASING 871 
MOLECULE (CORM-3) IN A NOVEL MODEL OF PIG LIVER 
ISCHEMIA/REPERFUSION INJURY
E. Gringeri1, M. Vadori2,3, R. Motterlini4, C. Giacometti2, A. Stefani5, T. Pilla6, 
E. Tognato3, U. Cillo1,2, D. Sacerdoti1,2, E. Cozzi7,3
1Dept. of General Surgery and Organ Transplantation, 2Institute of Pathology, 
Padua, Italy, 3CORIT, Padua, Italy, 4NPIMR, Harrow, UK, 5IZSV, Legnaro, 
Italy, 6Dept. of Clinical Veterinary Sciences, Padua, Italy, 7Dept. of Surgical 
and Gastroenterological Sciences, University of Padua, Padua, Italy
Introduction: Orthotopic liver transplantation is an established treatment 
for end-stage liver disease. However, hepatic ischemia/reperfusion (IR) 
injury, an unavoidable insult occurring to the graft as a consequence of 
transplantation, often results in a higher incidence of acute/chronic 
rejection. In this light, different surgical and pharmacological approaches 
are under study to counteract IR injury and improve graft functionality. 
Recently, the administration of carbon monoxide (CO) has been proposed 
as a promising strategy to inhibit vasoconstriction and platelet aggregation, 
and reduce infl ammation and apoptosis in transplantation. In this study, 
we examined whether the administration of CORM-3, a water soluble CO-
releasing compound, protects liver tissue from IR injury in a large animal 
model.
Methods: Ten Landrace pigs (18-22 kg) were used for liver IR studies. Four 
hour warm ischemia of the left hepatic lobe was obtained by clamping the left 
hepatic artery and vein and occluding the left branch of the portal vein. The right 
lobe maintained normal perfusion. Ischemia was followed by 4 h reperfusion. A 
single dose of 4 mg/kg CORM-3 was administered i.v. to fi ve animals 30 min. 
before onset of ischemia. Five untreated pigs served as controls. Biochemical 
and hematological analyses were performed. Needle biopsies were obtained 
prior to and after ischemia and, subsequently, hourly during reperfusion. 
Edema, congestion, infl ammatory cell infi ltration and necrosis were evaluated 
by semiquantitative histological examination (expressed as percentage of the 
liver parenchyma involved). Apoptosis was detected by TUNEL and scored by 
averaging the number of TUNEL positive cells/mm2. TNF-a amounts in liver 
tissue omogenates were measured by ELISA.
Results: Following a 4 h ischemia, histological analysis revealed edema 
(37%), congestion (30%), infl ammatory cell infi ltration (9%) and necrosis 
(8%). Treatment with CORM-3 resulted in reduced edema (21%), congestion 
(13%) and cellular infi ltration (1%). Importantly, no necrotic areas were 
present in CORM-3-treated animals at the end of ischemia. Liver necrosis 
remained signifi cantly lower in CORM-3 treated animals compared to 
controls following 4 h reperfusion (18% vs. 60%). At this time point, the 
group treated with CORM-3 had a lower incidence of TUNEL positive cells 
compared to controls. A slight decrease in TNF-a levels in liver tissue of 
treated animals was noticed. AST, ALT, ALP and bilirubin were not different 
between groups. In addition, CORM-3-treated pigs showed a lower mean 
systemic blood pressure following drug administration and throughout 
the experiment.
Conclusions: This study has enabled the establishment of a novel model 
to investigate liver IR injury in large animals. Administration of CORM-3 
prior to inducing hepatic ischemia, attenuates the tissue damage occurring at 
reperfusion, primarily by reducing necrosis and apoptosis.
EFFECT OF HYPOXIA/REOXYGENATION ON TRAIL-872 
TRAIL RECEPTOR DR4 AND DR5 PATHWAY IN HUMAN 
INTRAHEPATIC CHOLANGIOCYTES
Y.P. Li, L.L. Pang, L. Feng, N. Zhao, D. Long, L.L. Li, S.F. Li, C.T. Zhang, 
L. Wei
Key Laboratory of Transplant Engineering and Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Ischemic-Type Biliary Lesion (ITBL) is one of the most serious complications, 
associated with long-term prognosis of the recipients, and is unavoidable in 
liver transplantation. The exact mechanism of human cholangiocytes injury 
remains to be studied. We wondered whether TNF-related apoptosis-inducing 
ligand(TRAIL)-mediated apoptosis can play some role in this course. This 
study aims to investigate the effect of hypoxia and reoxygenation(H/R) on the 
TRAIL -TRAIL Receptor DR4 and DR5 pathway for mechanism of ITBL and 
liver injury.
Method: Setting cholangiocytes H/R model to mimic IRI of graft liver in 
vitro. Normal cholangiocytes were exposed to hypoxia condition(1%CO2)
for 1 hour, then reoxygenated for 0,15,30,60,90min,2h,3h and 4h separately. 
DR4, DR5 mRNA were measured by RT-PCR, and the protein were 
detected by immunofl uorescence. Moreover, cholangiocytes were hypoxia/
reoxygenated and treated with exogenous TRAIL in different concentrations 
for 4h. Apoptosis of cholangiocytes were confi rmed by FCM and MTT 
analysis and compared with the apoptosis rate of hepatocytes under the same 
condition.
Result: 1. H/R signifi cantly increased DR4,DR5 expression after 1h hypoxia in 
all time points of reoxygenation, compared with the low expression of DR4,DR5 
protein and mRNA level of the normal cultured cholangiocytes, which peaked 
on 90min(about 4 times higher than control group) after reoxygenation and 
maintained until 240min(more than 3 times). DR5 expression of hepatocytes 
also increased after 6h hypoxia, and reached the peak after 2h reoxygenation. 
2. Exogenous TRAIL increased the sensitivity of the 2 kinds of cells to the 
apoptosis and increased the apoptosis rate.
Conclusion: 1. H/R upregulated the DR4, DR5 expression of human 
cholangiocytes and hepatocytes both on protein and mRNA level. 
But the expression are earlier and higher in cholangiocytes than in 
hepatocytes.2.Exogenous TRAIL increased the sensitivity of the 2 kinds 
of cells for the TRAIL mediated apoptosis induced by H/R and enhance the 
apoptosis rates£®These results suggested that the adoption of anti-apoptosis 
drugs might become a new measure for prevention of the ITBL.
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INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE 873 
(INOS) BY 1400W IMPROVES THE OUTCOME AFTER 
TRANSPLANTATION OF FATTY PARTIAL LIVER GRAFTS
Z. Zhong 1, S. He 1,2, H. Rehman 1, X-P. Chen 2, G. Wright 1
1 Medical University of South Carolina, Charleston, SC, USA, 2 Tongji 
Medical College, Huazhong University of Science and Technology, Wuhan, 
China
Background & Aims: Hepatic steatosis is present in ~30% of potential 
liver donors. Steatotic grafts are known to increase primary non-function 
and therefore excluded for use in partial liver transplantation. This study 
investigated if reactive nitrogen species (RNS) play a role in failure of fatty 
partial liver grafts. 
Methods: Fatty livers were induced in rats by feeding a high-fat high-fructose 
(HFFr) diet (50% and 30% of total calories from corn oil and fructose, 
respectively) for two weeks. Control animals received a low-fat low-fructose 
(LFFr) diet. Hepatic triglyceride was ~9-fold higher in rats fed the HFFr diet 
than those fed the control LFFr diet. Lean and fatty liver explants were reduced 
in size ex vivo to approximately 1/3 and stored in the UW solution at 0-1oC for 2 
h. 1400W (5╘ M), a specifi c iNOS inhibitor, was added to the storage solution 
and the lactated Ringer post-storage rinse solution. 
Results: Serum nitrite/nitrate level was 2-fold higher after transplantation of 
fatty partial grafts compared to lean partial grafts, and 3-nitrotyrosine adducts, 
an indicator of peroxynitrite formation, increased markedly in fatty partial grafts 
compared to lean partial grafts. Serum alanine aminotransferase (ALT) was 65, 
780, and 1420 U/L 24 h after sham operation or transplantation of lean and 
fatty partial grafts, respectively. Serum bilirubin concentrations, an indicator of 
graft function, increased from 0.1 mg/mL to 1.7 mg/mL after transplantation of 
lean partial grafts and was increased to 9.3 mg/mL after transplantation of fatty 
grafts. Hepatic cellular 5-bromo-2’-deoxyuridine (BrdU) incorporation was 
25% in lean partial grafts but only 5% in fatty grafts at 48 h after transplantation, 
indicating suppressed cell mitosis in the fatty grafts. Graft weight did not 
increase in fatty partial grafts but increased by 64% in lean partial grafts. All 
rats that received fatty partial grafts died within 4 days after transplantation, 
whereas the 7 day-survival rate was 100% after transplantation of lean partial 
grafts. 1400W largely blunted the increases of serum nitrite/nitrate and hepatic 
nitrotyrosine adducts, prevented the elevation of serum ALT and bilirubin, 
restored cell proliferation to 32% and weight gain to 66% in the fatty grafts. 
The benefi cial effect of 1400W on these preceding parameters coincided with 
improved survival rates in animals receiving fatty grafts. 
Conclusions: Taken together these results indicate that hepatic steatosis 
increases RNS production after partial liver transplantation, leading to more 
severe injury, poorer liver regeneration and lower graft survival. Therefore, 
inhibition of iNOS could be a potential therapy to improve the outcome of 
transplantation of fatty partial liver grafts (NIDDK). 
DISTINCT GENE SIGNATURES LINKED TO ACUTE 874 
PHASE INJURY AND TUMOR INVASIVENESS AFTER LIVER 
TRANSPLANTATION USING SMALL-FOR-SIZE GRAFTS 
– THE SIGNIFICANCE OF IP10 ON TUMOR INVASION-
RELATED PROPERTIES AND TUMOR-ASSOCIATED 
MACROPHAGE INFILTRATION
K. Man, C-M. Lo, K.T.P. Ng, Q. Cheng, K. Co Shih, Y. Chen, S-T. Fan
The University of Hong Kong
Background and objective: Acute phase small-for-size liver graft injury plays 
important role on late phase tumor development and invasiveness after liver 
transplantation. To develop novel therapies preventing tumor recurrence after 
LDLT, it will be worthwhile to investigate the precise mechanism and potential 
therapeutic targets. In the current study, we aim to study the gene expression 
profi les associated with acute phase graft injury and tumor invasiveness at 
early and late phase after liver transplantation using small-for-size grafts. The 
potential candidate gene is identifi ed for further functional studies.
Materials and Methods: Orthotopic liver transplantation was applied using 
whole (100%) grafts (Group W) and small-for-size (50%) grafts (Group S) in a 
rat transplantation model. The recipients were injected with hepatoma cell lines 
(CRL1601, 2„e105) via the portal vein after reperfusion, and were sacrifi ced on 
days 1, 3, 14, and 21 after transplantation for histological examination. Gene 
signatures of acute graft injury (days 1, 3) and tumor recurrence (days 21) were 
screened using cDNA microarray and confi rmed by quantitative RT-PCR. Potential 
gene candidate was selected for further functional studies to investigate its role 
both in tumor progression and tumor associated macrophage mobilization.
Results: Early development of liver tumors and signifi cantly larger tumor sizes 
were noted in Group S, accompanied by invasive growth patterns, signifi cant new 
vasculature formation and tumor-associated macrophage infi ltration. Distinct 
gene panels linked to infl ammatory responses and tumor invasiveness were found 
in small-for-size liver grafts and/or the tumor developed in small liver grafts by 
cDNA microarray screening. After confi rmation by real-time RT PCR, the gene 
IP10 was found over-expressed in the liver graft at early phase and in liver tumor at 
late phase after liver transplantation. In vitro functional studies further confi rmed 
that IP10 promoted tumor invasive properties and angiogenesis. Consistent with 
the animal study, IP10 also enhanced macrophage motility in vitro.
Conclusion: Distinct gene signature (over-expression of IP10) linked to acute 
phase injury and tumor invasiveness in the small-for-size liver graft may 
contribute to early tumor recurrence after liver transplantation. IP10 and its 
downstream signals might be the potential therapeutic targets in the prevention 
of tumor recurrence after liver transplantation using small-for-size graft. 
CONCURRENT ORAL SESSION 63: 
INDUCTION IMMUNUSUPPRESSION
ALEMTUZUMAB INDUCTION IN LIVING DONOR 875 
KIDNEY TRANSPLANTATION: AN ANALYSIS USING THE 
OPTN/UNOS DATABASE
S. Bunnapradist1, B.R. Madhira1, B. Anastasi1, T. Shah2, J. Gill1
1UCLA Medical Center, 2National Institute of Transplantation
Background: Antibody induction using IL2 receptor antagonists (IL-2RA) is 
common in living donor kidney transplantation (LDKTx). Recently, the use of 
alemtuzumab is increasing in kidney transplantation. Our objectives were to 
examine the use of alemtuzumab in LDKTx and to compare post-transplantation 
outcomes between recipients who received either IL2-RA induction therapy or 
alemtuzumab in the United States.
Methods: OPTN/UNOS data was used to identify all LDKTx performed in the 
US from 2003 – 2006 where induction therapy with alemtuzumab or IL-2RA 
(dacluzimab or basiliximab) was used. Follow-up was until November 2007. 
The primary outcome was the incidence of acute rejection and graft survival. 
The risk of graft loss was determined using Cox multivariate modeling.
Results: Of the 28,781 LDKTx identifi ed, induction therapy was used in 19, 
962 (69.4%). Among those receiving antibody induction, 2371 (11.8%) received 
alemtuzumab and 8207 (41.1%) received an IL2-RA. The use of alemtuzumab 
has increased over time (Figure 1). There were no clinically signifi cant 
differences in donor characteristics between those that received alemtuzumab 
and IL2-RA, but the proportion of recipients with prior transplantation was 
higher among recipients who received alemtuzumab.
The incidence of acute rejection at discharge was signifi cantly lower in the 
alemtuzumab group (0.6%) compared to the IL2RA group (4.3%), but was 
similar by 1 year post transplant (alemtuzumab 9.1% IL2RA 8.3%). Compared 
to the IL2-RA group, those in the alemtuzumab group had inferior overall graft 
survival (Figure 2) and a higher adjusted relative risk of graft loss (HR 1.21, 
95% CI 1.01-1.45). When the analysis was limited to re-transplant recipients, 
the hazard of graft loss was 1.62 (0.98-2.67).
Conclusion: The use of alemtuzumab in living donor transplantation is 
increasing in the United States. Analysis of OTPN/UNOS data revealed 
that the risk of graft loss among patients that received alemtuzumab was 
higher compared to those that received IL2-RA induction. The manner and 
circumstances under which these agents are utilized may signifi cantly impact 
outcomes and requires further study. 
Figure 1. Alemtuzumab use in Living Donor Kidney Tranplant (LDKTx) over time
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Figure 2. 
Overall Graft Survival among LDTx receiving Alemtuzumab or IL2RA
12 MONTH RESULTS OF A MULTICENTER, 876 
RANDOMIZED TRIAL COMPARING THREE INDUCTION 
AGENTS (ALEMTUZUMAB, THYMOGLOBULIN AND 
BASILIXIMAB) WITH TACROLIMUS, MYCOPHENOLATE 
MOFETIL AND A RAPID STEROID WITHDRAWAL IN RENAL 
TRANSPLANTATION
S. Woodle1, M. Hanaway2, S. Mulgaonkar3, R. Peddi4, G. Harrison5, 
K. Vandeputte5, W. Fitzsimmons5, R. First5, J. Holman5
1University of Cincinnati College of Medicine, 2University of Alabama, 3St. 
Barnabas Medical Center, 4California Pacifi c Medical Center, 5Astellas 
Pharma U.S.
Purpose: Induction therapy remains an important component of early 
corticosteroid withdrawal (ECSWD). We sought to compare the safety and 
effi cacy of three induction agents (Alemtuzumab (C1H), Thymoglobulin 
(Thymo) and Basiliximab (Bas) in renal transplantation, in combination 
with tacrolimus (TAC), mycophenolate mofetil (MMF) with a rapid steroid 
withdrawal.
Method: 474 adult patients were randomized and transplanted based on risk 
profi le: High Risk (HR=African American (AA), PRA>20% or re-transplants) 
were assigned to C1H or to Thymo. Low Risk (LR=non-AA, PRA<20% or 
primary transplant) were assigned to C1H or Bas. Both C1H groups received 
30mg of C1H on day (D) 0; the Thymo group received 4 doses of Thymo 
(1.5mg/kg/d) on D 0-4; the Bas group received 2 doses of 20mg of Bas on 
D 0-4. Only 1 gram of methylprednisolone was given prior to discharge. 
Tacrolimus and MMF were used as maintenance immunosuppression. Primary 
endpoint was biopsy proven acute rejection (BCAR).
Results: No cases of CAN were seen through 12 mo. Mean results at 12 mo 
are shown below. Adverse events are shown as% of patients with > 1 event 
through 12 mo.
 HR LR
Parameter C1H N=70 Thymo N=69 C1H N=164 Bas N=171
BCAR (%) 9.5 13.0 2.5 19.6*
Treated Rejections (%) 17.2 17.4 5.6 23.8*
Antibody for Acute Rejection (%) 4.8 8.0 1.9 9.2*
TAC Levels (12 mo mean, ng/mL) 7.30 7.26 7.41 7.50
MMF Daily Dosing (12 mo mean, mg/d) 1647 1582 1580 1650
Pt Survival (%) 98.6 98.6 98.7 98.7
Graft Survival (%) 97.1 95.3 98.1 95.1
All Infection (%) 41.4 68.1* 56.7 57.9
All Malignancy (%) 2.9 0.0 2.4 1.8
All CMV Infection (%) 10.0 13.0 9.0 8.1
All BK Infection (%) 2.9 8.7 4.2 2.3
Total Lymphocyte (cells/mm3) 928 974 923 1460
Creatinine Clearance (ml/min) 60 55 62 61
Serum Creatinine (mg/dL) 1.6 1.5 1.4 1.3
Study Discontinuation (%) 12.9 4.3 4.9 7.0
*P<0.05 for C1H vs Bas or Thymo
Conclusions: In high risk patients C1H provides similar effi cacy with fewer 
patients with infection than Thymo. In low risk patients C1H therapy is 
associated with fewer acute rejections and reduced use of antibody to treat 
rejection, without an increase in infection. 
411 LIVING DONOR KIDNEY TRANSPLANTS USING 877 
ALEMTUZUMAB PRE-CONDITIONING AND TACROLIMUS 
MONOTHERAPY: 5 YEAR EXPERIENCE
H. Tan, J. Donaldson, A. Basu, M. Unruh, P. Randhawa, J. McCauley, 
C. Morgan, C. Wu, N. Shah, R. Shapiro
University of Pittsburgh Medical Center, Starzl Transplantation Institute
Introduction: We have previously reported the short-term results of 
Alemtuzumab (Campath-1H) pre-conditioning with tacrolimus monotherapy 
and subsequent spaced weaning in living donor kidney transplantation. We 
report here our 5 year experience.
Methods: We performed 411 consecutive unselected living donor kidney 
transplants (donor kidneys were removed laparoscopically) from 12/11/2002 
to 11/26/2007 using 30 mg (0.5mg/kg) alemtuzumab and tacrolimus 
monotherapy. At 6 months post-transplant and every 2 to 6 months interval, 
we used clinical data (including ELISA antibody titers, Cylex T-cell activation 
assay, and identifi cation of donor specifi c antibodies) to wean tacrolimus when 
possible (bid-->qd-->qod-->tiw-->biw-->qwk). The recipients included 5 
HIV+, 35 pediatric recipients, and 60 re-transplants. The mean follow up was 
843.1+478.7 days. 
Results: Actuarial recipient survivals at 1-, 2-, 3-years were 98.4%, 95.6%, 
and 92.7%, respectively. Graft survivals at 1-, 2-, 3-years were 97.6%, 90.4%, 
and 85.4%, respectively. The mean creatinine (mg/dL) at 1-, 2-, 3-years were 
1.46+0.62, 1.56+1.08, and 1.54+0.89, respectively. The mean GFR (mL/
min/1.73m2) at 1-, 2-, 3-years were 73.0+28.5, 71.8+28.8, and 68.9+28.6, 
respectively. The cumulative incidence of acute cellular rejection (ACR) at 6-, 
12-, 18-, 24-, 30-, 36-, 42-, and >42 months were 4.4%, 10.0%, 15.3%, 17.0%, 
19.2%, 19.7%, 21.4%, and 22.1%, respectively. 23.4% of recipients had been 
weaned to spaced-dose (qod or less) tacrolimus monotherapy. The incidence 
of preweaning ACR was 10.5%, and postweaning was 24.9%. A total of 91 
recipients had ACR. Most (>80%) episodes of ACR were Banff 1 and were 
sensitive to steroid pulses. The degree of chronic allograft nephropathy score 
(cg, ci, cv, and ct, with a maximal score of 12) in pts with ACR appeared, 
as expected, to increase with time. The total CAN score for the 91 patients 
with ACR at 6-, 12-, 18-, 24-, 30-, 36-, 42-, and >42 months were 2.2+2.0, 
4.3+2.3, 3.4+2.0, 2.8+1.6, 4.1+1.2, 6.0+0.0, 5.1+1.8, and 8.3+2.1, respectively. 
At least 82.7% of recipients were still completely steroid-free on tacrolimus 
monotherapy from the time of transplantation. 
Conclusion: This report represents the largest series to date of living donor 
kidney transplantation under alemtuzumab preconditioning with tacrolimus 
monotherapy and subsequent weaning and confi rms the 5-year safety and 
effi cacy of this approach.
THYMOGLOBULIN INDUCTION IN LIVING DONOR 878 
RENAL TRANSPLANT RECIPIENTS: UPDATE OF THE TAILOR 
REGISTRY
A.O. Gaber1, A.J. Matas2, R.M. Fergusion3, S. Kapur4, D.C. Brennan5, 
R.B. Stevens6, M. Schnitzler7, K. David8
1The Methodist Hospital, Houston, TX, United States, 2University of Minnesota, 
Minnesota, Minneapolis, MN, United States, 3Ohio State University Medical 
Center, Columbus, OH, United States, 4NewYork-Presbyterian/Weill Cornell 
Medical Center, New York, NY, United States, 5Washington University, St. Louis, 
MO, United States, 6University of Nebraska Medical Center, Omaha, NE, 
United States, 7Saint Louis University, St. Louis, MO, United States, 8 ProSanos 
Corporation, Harrisburg, PA, United States
Introduction: The TAILOR (Thymoglobulin Antibody Immunosuppression in 
Living Donor Recipients) Patient Registry was established to collect data in 
conjunction with UNOS on the safety and effi cacy of Thymoglobulin (Thymo) 
induction in living donor (LD) renal transplant recipients. Excellent patient 
and graft survival and low acute rejection rates were previously reported from 
preliminary analyses of 610 TAILOR patients who had completed 12 months 
of follow-up in 2006. We now report on a larger sample of patients enrolled in 
the TAILOR registry through August 2007.
Methods: The following data are collected in TAILOR: Thymo dosing, dose 
alterations, premedications and administration, viral prophylaxis, maintenance 
immunosuppression, dialysis pre- and post-transplant, biopsy-proven (BPAR) 
or clinically diagnosed rejection, severity and treatment of rejection, serious 
adverse events (SAEs), infections, graft loss, and death. Graft and patient 
survival rates were calculated by Kaplan-Meier survival analysis.
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Results: 2681 patients from 83 centers enrolled in TAILOR as of August 2007. 
Data are presented here on 2243 patients (excluded patients: 322 received Thymo 
post-reperfusion; 116 had cumulative Thymo dose <=1.5 mg/kg or >15 mg/kg). 
Six and 12 month follow-up data were available for 1715 and 1464 patients, 
respectively. Mean age was 46.5 ± 13.4 years, 60% of patients were male, 13% 
were African-American, 13% had prior transplants, and mean peak PRA was 
10.2%. Mean Thymo cumulative dose was 5.28 mg/kg (median total dose 5 mg/
kg). 89.3% received Thymo via central line. Unplanned dose interruption occurred 
in 11.9% of patients, with leukopenia (11.1%) and/or thrombocytopenia (2.9%) 
as common reasons for interruption. 2.1% of patients experienced delayed graft 
function (i.e., dialysis within fi rst week post-transplant). Mean serum creatinine at 
post-operative day 3 was 1.97 ± 1.6mg/dL. Thymo was used as part of a steroid 
minimization regimen (i.e., no steroids at discharge) in 36.2% of patients and as 
part of a calcineurin inhibitor (CNI) avoidance regimen (i.e., no CNI at discharge) 
in 2.6% of patients. 79.7% received valganciclovir as antiviral prophylaxis, 11.9% 
received ganciclovir. Patient and graft survival rates were 99.1% and 98% at 6 
months, and 98% and 95.9% at 12 months, respectively. The incidence of BPAR 
was 8.8% (151/1715) at 6 months and 9.6% at 12 months (141/1464). BPAR 
severity (Banff) was available for 76.2% (115/151) of 6 months BPAR episodes; 
most were mild (56.5%; 65/115), followed by borderline 18.3% (21/115), 
moderate (15.7%; 18/115), and moderate-to-severe (9.6%; 11/115). BPAR 
severity was available for 81.6% (115/141) of 12 months BPAR episodes; most 
were mild (60.0%; 69/115), followed by moderate (15.7%; 18/115), borderline 
14.8% (17/115), and moderate-to-severe (9.6%; 11/115). Infection rates at 12 
months were: 4.4% (64/1464) for CMV (no invasive disease), 0.3% (4/1464) EBV, 
2.0% (29/1464) fungal, 23.1% (338/1464) bacterial, 4.9% (72/1464) viral, and 
5.6% (82/1464) for other infections. PTLD occurred in 0.4% (9/2243) patients. 
The overall incidence of SAEs prior to discharge was 3.5% (68/2243); only 11/68 
SAEs were reported as either possibly or probably related to Thymo. 
Conclusions: Thymo induction in LD renal transplantation is associated with 
excellent one year outcomes and is safe as evident with the low infection rate.
20 YEAR FOLLOW-UP RESULTS OF A RANDOMIZED 879 
CONTROLLED TRIAL COMPARING ANTI-LYMPHOCYTE 
GLOBULIN-INDUCTION TO NO INDUCTION IN RENAL 
TRANSPLANT PATIENTS
M. Cantarovich1,2, A. Durrbach2, M. Ladouceur1, C. Hiesse2, G. Benoit2, 
B. Charpentier2
1McGill Univesity Health Center, Montreal, Canada, 2Hopital de Bicetre, 
Paris, France
Background: There is a need to report on long-term follow-up results of 
randomized controlled trials in renal transplantation (Tx). 
Purpose: To determine the impact of ALG-induction on long-term outcomes 
post-renal Tx. Methods: Between January 1985 and January 1986, 123 
consecutive adult patients received a deceased donor renal Tx at a single 
institution. Patients were randomized into 2 groups (Gr.), Gr.1: 63 patients 
(40±10 yr-old) received cyclosporine A (CsA), prednisone and azathioprine 
(1.5 mg/kg/d); Gr.2: 60 patients (36±9 yr-old) received ALG (3 vials (100 
mg/vial)/day for 14 days), CsA, prednisone and delayed initiation (45 days 
post-Tx) of low-dose azathioprine (1 mg/kg/d). In both Gr., CsA was started 
prior to surgery at a dose of 4 mg/kg/iv. Thereafter, CsA was given orally 
and the dose was adjusted according to blood trough levels (150-250 ng/ml). 
Patients did not receive CMV prophylaxis. Cold ischemia time did not differ 
(Gr.1: 38±8 hr, Gr.2: 39±9 hr). There was no difference in HLA (A-B-DR) 
matching (Gr.1: 2.4±1.1, Gr.2: 2.6±1.2). 
Results: The incidence of acute rejection was lower in Gr.2 (28% vs. 75%, 
P<0.0001). The incidence of CMV infection was 10% in Gr.1 and 18% in 
Gr.2 (P=NS). The overall incidence of cancer was 22.2% in Gr.1 and 11.7% 
in Gr.2 (P=NS). The incidence of lymphoma was 3% in Gr.1 and 5% in Gr.2 
(P=NS) 
Table 1. Short and long-term outcomes
Patient survival* Graft survival* Scr (μmol/L)*
 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
1 year 100% 100% 79% 93% 155±45 153±73
5 years 91% 100% 67% 75% 144±44 150±51
10 years 83% 88% 56% 51% 190±163 140±34
15 years 71% 72% 43% 47% 146±46 151±56
20 years 64% 54% 43% 47% 128±47 144±47
*P=NS
Conclusion: The use of ALG-induction resulted in a lower incidence of 
acute rejection and improved graft survival during the fi rst year post-renal 
Tx. Patient and graft survival at 20 year follow-up was not affected by ALG-
induction. It remains to be determined whether long-term graft survival may 
improve if current maintenance immunosuppressive strategies are used. 
CONCURRENT ORAL SESSION 64: 
BIOMARKERS OF ACUTE REJECTION
DIFFERENTIAL EXPRESSION OF BMP-7, TGFÂ1 AND 880 
GRANZYME B DURING ACUTE REJECTION OF HUMAN 
RENAL ALLOGRAFTS: A PLAUSIBLE MOLECULAR LINK 
BETWEEN ACUTE REJECTION AND CHRONIC ALLOGRAFT 
INJURY
T. Muthukumar, R. Ding, C. Snopkowski, C. Chang, B. Li, V. Sharma, 
S. Seshan, D. Dadhania, M. Suthanthiran
Nephrology and Transplantation Medicine, Cornell University, New York, NY, 
USA
Progressive loss of allograft function and ultimate graft failure remain one 
of the great challenges of organ transplantation. A major cause for chronic 
allograft injury (CAI) and graft failure is acute rejection (AR). The mechanistic 
basis for acute rejection (AR) being a risk factor for CAI has not been resolved. 
Better understanding of the molecular mechanisms responsible for CAI may 
improve long-term outcome of kidney transplant recipients.
In experimental models, administration of bone morphogenetic protein-7 
(BMP-7) reduces epithelial cell to mesenchymal transition (EMT), promotes 
mesenchymal to epithelial transition (MET) and reverses interstitial fi brosis 
(IF), and the balance between the pro-fi brotic TGFβ1 and the anti-fi brotic 
BMP-7 determine whether EMT or MET is favored. Herein, we investigated 
the hypothesis that acute rejection (AR) is associated with BMP-7 defi ciency 
whereas pro-fi brotic and other tissue destructive effectors are hyperexpressed. 
We tested our hypothesis by measurement of urinary cell levels of mRNA for 
anti-fi brotic BMP-7, pro-fi brotic TGFβ1 and tissue destructive granzyme B.
We obtained 78 urine specimens from 78 renal allograft recipients at the time of 
diagnostic biopsies (N=28) or protocol biopsies (N=50), and measured urinary 
cell mRNA levels using pre-amplifi cation enhanced kinetic quantitative PCR 
assays developed in our laboratory. 
Urinary cell levels BMP-7 mRNA were lower in the urine specimens from the 
AR group compared to the Normal Biopsy group whereas mRNA levels of 
TGFβ1 and granzyme B were higher in the AR group than the Normal Biopsy 
group (Table 1). 
Table 1: Differential Expression of mRNA for BMP-7, TGFβ1 and granzyme 
B during Acute Rejection
mRNA Type Acute Rejection (N=28) Normal Biopsy (N=50) P-Value
median copies/ ug total RNA
BMP-7 279 934 0.04
TGF-β1 726500 313000 0.01
Granzyme B 62600 3180 0.001
P- Values calculated with the use of Mann-Whitney test
We also found that the TGFβ1 to BMP-7 ratio favored EMT and was higher 
in the AR group than the Normal Biopsy group (median ratio: 1635 vs. 438, 
P=0.0002).
Our data demonstrate differential expression of anti-fi brotic BMP-7 and tissue 
destructive granzyme B and pro-fi brotic TGFβ1 during an episode of AR. Our 
observations that BMP-7 is down-regulated during AR and that the balance 
between TGF-β1 and BMP-7 favors EMT over MET advances a plausible 
molecular mechanism for the linkage between AR and CAI and proffers an 
explanation for the deleterious impact of AR on the long-term outcome of 
human renal allografts.
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TIM3 MRNA QUANTIFICATION IN THE PERIPHERAL 881 
BLOOD AND URINARY SEDIMENT CELLS ALLOWS AN 
ACURATE DIGNOSIS OF ACUTE REJECTION OF KIDNEY 
ALLOGRAFTS.
R. Manfro, E. Aquino-Dias, G. Joelsons, F. Veronese, L.F. Gonçalves
UFRGS Medical School
Background: TIM3 is a molecule selectively expressed in cells of the Th1 
phenotype. Its mRNA measurement in the peripheral blood and urinary cells 
is a potentially useful tool for the non-invasive diagnosis of acute rejection 
episodes of kidney allografts. The aim of the present study is to evaluate TIM3 
mRNA expression in kidney biopsies, peripheral lymphocytes and urinary 
cells of renal transplant patients aiming at the non invasive diagnosis of acute 
rejection of kidney allografts.
Patients and Methods: mRNA was extracted from 111 graft biopsies and 
concomitantly obtained from peripheral blood leucocytes and urinary sediment 
cells of 100 kidney transplant patients. Fifty-eight were obtained from patients 
with delayed graft function, 43 from patients with graft dysfunction and 12 
from patients with normal protocol biopsies. According to the Banff 1997 
classifi cation biopsies were allocated in 6 diagnostic groups: (1) acute tubular 
necrosis (ATN; n=33); (2) acute rejection in patients with ATN (ATN-AR; 
n=25), (3) acute rejection (AR; n=17), (4) calcineurin inhibitor nephrotoxicity 
(CIN; n=8), (5) chronic graft nephropathy (CGN; n=16) and (6) normal 
protocol biopsies (PB; n=12). A real-time quantitative PCR technique (TaqMan 
EZ RT-PCR, Applied Biosystems) was used for mRNA amplifi cation and 
quantifi cation. A ROC curve was generated for choosing the cut-off for the 
calculation of the diagnostic parameters of acute rejection. 
Results: In the analyses performed in graft tissue patients with ATN-AR and 
AR presented statistically signifi cant increased amounts of TIM3 as compared 
to the other groups. Similarly, in the peripheral blood TIM3 is overexpressed 
in patients with rejection (ATN-AR and AR groups). The same pattern of 
expression was observed in the analyses of the mRNA obtained from urinary 
cells. (see table). Statistically signifi cant correlations were observed between 
the amounts in tissue and either peripheral blood and urinary cells (p < 0.01). 
The sensitivities for the diagnosis of acute rejection were 97.4% and 93.0%, 
specifi cities: 93.4% and 98.0%, predictive positive values: 90.5% and 96.3%; 
negative predictive values: 98.2% and 96.1 and accuracies: 95.0% and 96% 
respectively in the peripheral blood and urine.
ATN ATN-AR AR CIN CGN Protocol
Graft 1.04 ± 1.06 214.2±13.1 25.2±36.9 0.25±0.50 0.45±0.64 0.03±0.05
Blood 0.54 ± 0.56 171.9±80.7 13.5±18.0 0.15±0.33 0.34±0.45 0.03±0.06
Urine 0.48 ± 0.42 156.8±85.4 9.3±11.05 0.10±0.18 0.21±0.31 0.02±0.04
Conclusions: TIM3 mRNA analyses in peripheral blood and urinary sediment 
cells may provide an accurate non-invasive tool for the diagnosis of acute 
rejection in kidney transplant recipients.
IDENTIFICATION OF POTENTIAL BIOMARKER FOR 882 
ACUTE REJECTION OF RENAL TRANSPLANT IN URINARY 
CELL PELLETS
L. Ying, M. Naesens, A. Chen, T. Sigdel, S. Hsieh, H. Dai, S. Sosa
Stanford University
Purpose: Because of its noninvasive nature and ease of mRNA collection, 
urine is a signifi cant advancement for improved prediction, diagnosis and 
prognosis of acute allograft rejection (AR). Previous single gene studies for AR 
diagnosis in blood and urine have failed to conclusively diagnose all rejection 
episodes due to the underlying molecular heterogeneity of acute transplant 
rejection. We have identifi ed a gene list specifi c to AR using microarray gene 
profi le analysis in biopsy and peripheral blood of pediatric kidney transplant 
patients. In this study, we validated selected candidate genes in urine samples 
from same patients.
Method: The genes to be tested in urine for rejection diagnosis were selected 
by three strategies: highly statistically signifi cant genes (q scores <5% by 
statistical analysis of microarrays, and >2 fold change in rejection) from 
previously conducted microarray studies (Affymetrix HU133plus2.0) on 71 
peripheral blood samples (44AR, 27 stable, STA, unpublished), 51 kidney 
transplant biopsy samples (32 AR, 19 STA unpublished), and known urine-
present genes obtained from data fi ltering in Ingenuity Pathway Analysis 
(Ingenuity). Urine samples were collected from pediatrics transplant patients. 
Total RNA was extracted from urine samples. Two independent urine sample 
sets were selected for qPCR validation consists of 89 samples from patients 
with biopsy-proven AR (n=30), biopsy-proven stable grafts (STA n=40) and 
BK virus infection (BK n=19, with no AR). The extracted total RNA was then 
subjected to qPCR in 384-well plates using RT2 qPCR system (SuperArray). 
Primers were selected from cDNA sequences of the chosen genes using Primer 
3.0, a web-based software. 26 genes were chosen from array data to run qPCR 
(12 from blood data, 15 from biopsy data, some of the genes known to be preset 
in urine). qPCR were carried in RT2 qPCR Master Mix (SuperArray). Relative 
gene expression levels of each gene were calculated using the comparative 
delta-CT method and normalized to 18S ribosomal RNA. All samples were 
tested in duplicates. Student T test was applied for statistical analysis. P<0.05 
was considered signifi cant. 
Results: Of 26 genes tested, 5 genes were signifi cantly up regulated in AR 
comparing to STA (P< 0.03), all of which were originally selected from the biopsy 
array data set. 4 of which (80%) were also differentially expressed between AR 
vs BK (P<0.005), confi rming the genes are specifi c to AR. Interestingly, the 
expression level of 2 genes is even signifi cantly lower in BK comparing to STA 
(P< 0.004).
Conclusion: Urine is an excellent and non-invasive source for biomarker 
discovery and clinical monitoring. Transplant rejection may be non-invasively 
predicted by qPCR across 5 highly-selected genes. Further validation of these 
genes set across an independent blinded set of rejection and stable samples 
is underway to confi rm the robustness and applicability of this gene-set for 
outpatient clinical transplant monitoring.
LEUCOCYTE ELASTASE-Α;1PROTEASE INHIBITOR 883 
COMPLEX – NEUTROPHIL DEGRANULATION MARKER 
IN PLASMA AND URINE OF PATIENTS AFTER DECEASED 
RENAL ALLOGRAFT TRANSPLANTATION. ASSESSMENT 
OF INDUCING FACTORS AND IMPACT ON ALLOGRAFT 
FUNCTION.
M. Zynek-Litwin1, J. Kuzniar1, Z. Marchewka2, W. Kopec1, M. Kusztal1, 
D. Patrzalek3, P. Biecek4, A. Dlugosz2, M. Klinger1
1Department of Nephrology and Transplantation Medicine, Wroclaw 
Medical University, Wroclaw, Poland, 2Department of Toxicology, Wroclaw 
Medical University, Wroclaw, Poland, 3Department of Vascular, General and 
Transplantation Surgery, Wroclaw Medical University, Wroclaw, Poland, 
4Department of Genomics, Faculty of Biotechnology Wroclaw University
Introduction: Neutrophils (PMN) are mediators of ischemia/reperfusion (I/R) 
injury following deceased renal transplantation (kTx). Leucocyte elastase 
complex with α;1protease inhibitor (EL-α;1PI) is a PMN degranulation marker. 
The study&#8217;s aim was to examine the infl uence of immune and non-
immune factors on plasma EL-α;1PI (pEL) and urine EL-α;1PI (uEL) levels, 
and to assess the correlation between leucocyte activation and early post-
transplant complications.
Patients and Methods: The study was performed on 24 kidney graft recipients 
from deceased donors. Plasma and urine EL were analyzed 4 times in the fi rst 
week after kTx (in postoperative (PO) days 1, 3, 7) and in a distant period after 
kTx. This was done by ELISA test.
Results: Plasma EL was signifi cantly higher on 1st PO day (average (av): 
314,2±; 225,45) then on days 3 and 7 (av. 191,2±; 125,16, p<0,001 and av. 
99,62±; 80,3, p<0,0001 respectively), as well as in a distant measurement (av. 
127,4±; 69,92, p< 0,001).
The highest uEL was observed on 3 PO day. Early uEL after kTx on day 1, 3 
and 7 was markedly greater than in distant measurement (p<0,02; p<0,004 and 
p<0,03 respectively)
There was no signifi cant association between pEL as well as uEL and peak 
panel-reactive antibodies (PRA) in the examined patients. 
Signifi cantly important positive correlation was observed between pEL on 1, 
3, 7th PO days and overall A, B, DR mismatch (p<0,01; p<0,03; p<0,008). In 
patients with mismatch number >3 the pEL markedly decreased between fi rst 
PO day (av.416,4±; 259,7) and 3, 7th PO days (av.249,2±; 146,5 and av.136,9±; 
98,2; respectively) as well as distant measurement (p<0,03; p<0,004 and 
p<0,01 respectively).
Urine EL in fi rst PO day was signifi cantly correlated with overall A, B, DR 
mismatch number (p<0,02). 
Study showed a correlation between cold ischemia time (CIT) and uEL on 1 PO 
day (p<0,01). Signifi cantly higher uEL excretion on 1st PO day was observed 
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in patients with CIT >21,5h (av.:54,1±;26,8) than with CIT<21,5 h (av.:25,5±; 
25,5) –; p<0,007.
Plasma EL on 1 PO day was signifi cantly greater in patients with DGF 
(av.472,6±; 230,6) than in those with IGF (av.258,4±; 201,4) – p<0,02. Urine 
EL on fi rst PO day was higher in DGF group (av.74,5±; 23,7) than in IGF group 
(av.25,0±; 18,2) –; p<0,0007. 
In patients with an early graft rejection episode uEL on 1 PO day was signifi cantly 
greater (av.:67,3±; 28,4) than in group without rejection (av. 29,8±; 24,4) – p< 
0,009. Similarly, on 7 PO day there was a higher uEL in the graft rejection group 
(av.113,6±; 93,9 and av.36,1±; 35,7 respectively) –; p<0,04.
Conclusions: PMN activation after kTx caused an increase of pEL and uEL 
(max. pEL on 1 PO day). pEL level correlated markedly with an overall A, B, 
DR mismatch. There was a signifi cantly greater pEL in DGF patients. Urine 
EL was markedly higher in patients with longer CIT. Greater uEL on 1 PO day 
was observed in patients with early graft rejection. These fi ndings suggest an 
infl uence of ischemia/reperfusion-induced PMN degranulation on the kidney 
graft function.
RELIABLE AND SIMPLE DIAGNOSIS OF RENAL 884 
ALLOGRAFT REJECTION BASED ON URINARY 
GRANZYME A
A. Rowshani3, M. van Ham1, K. Heutinck2,3, M. Strik1, T. Jorritsma1, E. 
Remmerswaal2, 
I. ten Berge3
1Department of Immunopathology, Sanquin Research, Amsterdam, The 
Netherlands, 2Department of Experimental Immunology, Academic Medical 
Center, Amsterdam, The Netherlands, 3Department of Internal Medicine, 
Renal Transplant Unit, Academic Medical Center, Amsterdam, The 
Netherlands
Acute clinical rejection (ACR) is a serious complication of renal transplantation. 
Early and rapid diagnosis is important to discriminate ACR from other causes 
of graft dysfunction like acute tubular necrosis (ATN) and drug toxicity. A 
sensitive and specifi c biomarker could help bypass renal biopsy which is the 
current golden standard for the diagnosis of rejection. 
We collected 120 urine samples from 44 recipients with biopsy confi rmed 
diagnosis of: ACR [19], acute tubular necrosis [8], subclinical rejection [8], or 
stable graft function [9]. In 10 subjects with acute rejection we succeeded in 
collecting urine samples longitudinally in time before the clinically manifested 
and histologically proven rejection episode. Total RNA was isolated from urine 
cell pellets, quantifi ed and reverse transcribed to complementary DNA. Relative 
mRNA expression levels of granzyme A (GrA), granzyme B (GrB), perforin 
and SERPINB9 were measured. Afterwards, the results were normalized to the 
internal control 18S-rRNA. 
The relative urinary mRNA levels of the cytotoxic proteins GrA, GrB and 
perforin were higher in patients with acute rejection compared to stable graft 
function and ATN (p<0,014). Surprisingly, GrA levels were also signifi cantly 
elevated during sub-clinical rejection in comparison with stable function and 
ATN (p<0,016). GrA levels in stable patients and in patients with ATN are 
below the detection limit; therefore this marker is very specifi c for rejection 
in contrast to GrB and perforin. Additionally, timely obtained sequential urine 
samples showed an early rise in granzyme mRNA levels preceding the rise in 
serum creatinine.
Measurement of urinary GrA mRNA offers a sensitive and highly specifi c 
non-invasive diagnostic tool for both acute and subclinical rejection. Urinary 
GrA levels precede the rise in serum creatinine in case of ACR. Therefore, 
detection of GrA in urine provides a useful tool to support the performance 
of renal biopsy in order to detect both acute and subclinical rejection. The 
timely initiation of anti-rejection treatment may lead to a better preservation of 
allograft function in the long term.
IMMUNOBIOLOGY/HLACONCURRENT ORAL SESSION 65: 
DOUBLE-NEGATIVE REGULATORY T CELLS BASED 885 
THERAPEUTIC APPROACH TO PREVENT AND CURE TYPE I 
DIABETES IN NOD MICE.
D. Zhang, W. Zhang, Y. Liu, Y. Tian, X.X. Zheng
University of Pittsburgh Medical Center
Accumulating evidence in supporting the existence of more than one 
population of regulatory T-cells that function in immune responses. Further 
characterization of the function and development of these regulatory T-cells 
will contribute to our understanding of the intrinsic and extrinsic mechanisms 
during an acquired process that maintain the peripheral tolerance.
Recently we have reported that proliferated CD4+ T-cells could convert to 
CD4-CD8-CD3+ (DN) T-cells after either allogeneic or syngeneic mature 
DC triggered proliferation, and IL-2 and IL-15 enhanced the conversion. The 
converted DN T-cells were resistant to AICD and expressed a unique set of 
cell markers and gene profi le. Moreover, at a per cell base comparison, the 
converted DN T-cells were more potent in suppressing alloantigen trigged 
proliferation of na&#239;ve CD4+CD25- T-cells than na&#239;ve and 
proliferated CD4+CD25+ Tregs in vitro. 
In this study we further test the functional potential of the converted DN 
T-cells in autoimmune diabetic NOD models. In an adoptive transfer model 
of autoimmune diabetes, the adoptive transfer of T-cells or CD4+ T cells from 
new onset diabetic NOD mice precipitated a rapid onset of diabetes in all NOD/
SCID recipients. In contrast, all NOD/SCID recipients received DN T-cells, 
which were converted from CD4+ T-cells of new onset diabetic NOD mice, 
alone remain diabetic free for up to 30 weeks post adoptive transfer. The co-
transfer of DN T-cells with diabetogenic T-cells at 1: 1 ratio signifi cantly delay 
the onset of diabetes in NOD/SCID mice (P=0.0012). Thus, the DN T-cells 
converted from diabetogenic CD4+ T-cells from new onset diabetic NOD 
mice were capable of suppressing autoimmunity. Interestingly, the addition of 
GAD65 peptide, a beta-cell specifi c antigen, in the conversion further enhanced 
the suppressive function of DN T cells.
In a pre-diabetic NOD model, the adoptive transfer of 2 million DN T cells 
(converted from CD4+ T-cells of NOD mice by co-culture with mature NOD 
DC plus rIL-15 and GAD65 peptide in MLR for 6 days) into 5 weeks old pre-
diabetic NOD female mice resulted in signifi cantly delay of onset of diabetes. 
Only 25% NOD female mice became diabetes at 22 weeks after DN T cell 
transfer compare with 75% mice became diabetic in control group. Moreover, 
a single transfer of 4 million DN T-cells converted from diabetogenic CD4+ 
T-cells reversed new onset of diabetes, albeit transient, in autoimmune new 
onset diabetic NOD mice. We then combined low dose rapamycin with DN 
T-cells in a MHC mismatched islet allograft model in spontaneous autoimmune 
diabetic NOD recipients. The single transfer of 5 million DN T-cells plus 14 
days low dose rapamycin (0.6mg/kg) treatment signifi cantly prolonged islet 
allograft survival in comparison with untreated group (MST 40 days vs. 6 
days, p=0.002) and rapamycin alone treated group MST (40 days vs. 8 days, 
p=0.002). 
The results of using ex vivo CD4+ T-cells converted DN T-cells in NOD mouse 
models support the concept and the feasibility of potentially utilizing this novel 
cell-based therapeutic approach clinically for the treatment of autoimmune 
type I diabetes.
THE CRITICAL ROLE OF CD4 T CELLS IN CD154 886 
BLOCKADE-RESISTANT MEMORY CD8 T CELL ACTIVATION 
AND ALLOGRAFT REJECTION IN SENSITIZED RECIPIENTS
J. Kupiec-Weglinski, Y.W. Wang, R. Busuttil, Y. Zhai
Dumont-UCLA Transplant Ctr
Background: The sensitized transplant recipients may undergo a 
fulminant accelerated form of rejection, which is mediated by T cell-
dependent mechanisms. These patients often experience increased rate of 
early rejection episodes, which are diffi cult to control with currently used 
immunosuppressive agents. Methods: In our model of cardiac graft rejection 
in sensitized recipients, B6 mice are fi rst challenged with B/c skin, followed 
40-60 days later by B/c heart transplant (HTx). Unlike in naive hosts, HTx 
rejection and alloreactive CD8 activation in this model are CD154 blockade-
resistant. We fi rst performed systemic analysis at the intragraft transcriptional 
level by microarray to identify disparities in local immune responses in 
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naive vs. sensitized hosts. Aiming to improve the effi cacy of costimulation 
blockade in the sensitization settings, we then determined the role of CD4 
T cells in costimulation blockade-resistant alloimmune response by using 
CD4 depleting (GK1.5) vs. CD4 blocking (YTS177) Ab, in conjunction 
with CD154 blockade (MR1). Results: HTx harvested from groups of naive 
(day 4-6), sensitized (day 2-4), control Ig or MR1 Ab treated mice (n=3/
gr) were subjected to microarray analysis. MR1 treatment suppressed HTx 
expression of pro-infl ammatory genes (IL-1 , IL-6, TNF-a), and T cell-
targeted chemokines (RANTES, Mig, CXCL10) early after HTx in naive, but 
not sensitized recipients. Five groups of sensitized mice treated at the time of 
HTx with: (1) control Ig; (2) MR1 [day 0]; (3) GK1.5 [day -1/+1]; (4) MR1 
[day 0] + GK1.5 [day -1/+1]; (5) MR1 [day 0] + YTS177 [day -1/+1] were 
contrasted. HTx were rejected promptly in <5 days in Gr. (1), (2) (3), but 
survived ca. 30 days in Gr. (4) and (5). The CTL activation was determined by 
FACS phenotyping at day 10 and 30. The simultaneous blockade of CD154 
costimulation and CD4 help, but not a single blockade with MR1 Ab or anti-
CD4 Ab, was required to inhibit peripheral alloreactive CD8 activation in 
sensitized mice. Additionally, CD8 activation in the absence of CD4 help 
showed defective cytotoxic molecule profi le, with suppressed perforin but 
upregulated granzyme B expression at the graft site. Conclusion: CD154 
blockade-resistant CD8 activation is critically dependent on CD4 T cells. 
This study provides novel immunological basis to study the potential synergy 
between adjunctive CD4 and CD154 targeted therapies to control accelerated 
graft rejection in sensitized hosts.
DONOR-SPECIFIC ANTIBODIES ARE PRODUCED BY 887 
B220+/CD20+/ CD5-/IGM+/IGD+ B CELLS REGULATED BY TH1 
CYTOKINES: A STUDY USING A NOVEL MURINE MODEL OF 
HLA SENSITIZATION
G. Wu, Y. He, N-N. Chai, M. Toyoda, S. Jordan, A. Klein
Cedars-Sinai Medical Center
Objective: Anti-HLA antibodies are a major risk factor for antibody-mediated 
rejection (AMR). However, the nature of anti-HLA-producing B cells and 
the mechanisms that regulate their production are poorly understood. Lack 
of appropriate animal models has been an obstacle in our research efforts to 
quantify B cell production of HLA antibodies
Materials and Methods: We report a unique mouse model of HLA sensitization 
in which anti-donor HLA antibodies are generated. This model involves skin 
grafting from C57BL/6Tg/HLA-A2.1 mice to C57BL/6 mice. Due to the single 
antigen difference, the recipient mounts a vigorous antibody response against 
the donor specifi c HLA-A2 antigen. 
Results: Low titers (1:10) of IgM antibodies reactive to HLA-A2 antigens 
were detected in antisera produced at days 7-14 but not at days 21-28 post-
transplantation (Ptx). High titers (1:100) of IgG2a antibodies were detected 
in antisera at days 21 and 28 Ptx. Of interest was that the anti-HLA antibodies 
not only reacted to HLA-A2 but also bound to a panel of class I (but not class 
II) HLA antigens, as demonstrated in a Flow cytometric PRA assay. Thus, 
the DSA generated in this model exhibited characteristics of panel antibody 
reactivity that is usually observed in pre-sensitized transplant patients. On 
the other hand, IgG1 PRA was absent in DSA samples harvested before days 
21 Ptx, and occurred in less than 20% animals at day 28 Ptx, suggesting a 
weak Th2 effect. The anti-HLA.A2 sera also exhibited complement-dependent 
cytotoxicity against a HLA-A2-expressing human T-lymphoblast cell line. 
Elevations of serum IGg2a PRA correlated with vigorous proliferation of 
B220+/CD20+/CD5-/IgM+/IgD+B cells in the spleens. B cell depletion using 
a mouse-anti-mouse CD20 antibody suppressed IgG PRA production. T cell 
depletion by anti-CD3 antibody resulted in weakening of the IgM response and 
a signifi cant reduction in serum IgG PRA. Quantitative RT-PCR demonstrated 
signifi cant increases in mRNA expression of INF-γ and IL-2 but not IL-4 and 
IL-10 in the spleens following primary immunization. 
Conclusion: The data suggest that antibody responses to allogenic sensitization 
are T cell-dependent. Th1 microenvironment may dictate the early phases of the 
antibody responses while a Th2-dependent IgG1 response appears to follow amid 
persisting alloantigen stimulation. DSA are produced by CD5- B cells expressing 
a mature conventional B cell phenotype (B220+/CD20+/IgM+/IgD+). Suppression 
of HLA antibodies can be effectively achieved by either B cell depletion by anti-
CD20 antibodies or T cell depletion by anti-lymphocyte sera.
HUMAN REGULATORY T CELL THERAPY IN THE 888 
PREVENTION OF TRANSPLANT ARTERIOSCLEROSIS
K.J. Wood, J. Wieckiewicz, S.N. Nadig, D.C. Wu, G. Warnecke, W. Zhang, S. 
Luo, D. Taggart,
Transplantation Research Immunology Group, University of Oxford
Purpose: Transplant Arteriosclerosis (TA) is the main cause of chronic allograft 
loss after allograft transplantation. Additionally, CD25hiCD4+ regulatory T 
cells (Treg) have shown much promise in their ability to inhibit immunologic 
effector responses in vitro and in rodent models. In this report, we detail the 
capacity of ex vivo expanded human Treg to prevent TA in a clinically relevant 
humanized mouse model.
Methods and Materials: Human T regulatory cells have been sorted and 
expanded ex vivo with anti-CD28/anti-CD3 beads in the presence of high 
doses of IL-2 and their phenotype and in vitro suppressive capacity was 
assessed. Human arterial side-branches were procured from the internal 
mammary artery of patients undergoing coronary artery bypass grafts. These 
arterial segments were then transplanted into the abdominal aorta of RAG2/
commonãchain -defi cient BALB/c (BALB/C DKO) recipients on day 0. On 
post-operative day 1, allogeneic human peripheral blood mononuclear cells 
(PBMC) +/-Treg, were adoptively transferred into transplant recipients. Thirty 
days after transplantation, Elastin van Gieson staining was performed on the 
grafted vessels to assess the degree of TA by measuring the percentage intimal 
expansion (I.E.). Flow cytometric analysis of human CD45 stained splenocytes 
confi rmed human leukocyte chimerism.
Results: Sorted and ex-vivo expanded human CD25hiCD4+ retain phenotypic 
characteristic of T regulatory cells and are highly suppressive in vitro. Human 
arteries transplanted into BALB/c DKO mice reconstituted with human allo-
PBMC developed marked TA (n=8; mean% I.E.±SD= 45.53% ± 21.14). In 
contrast, when transplanted mice were treated with PBMC + ex vivo expanded 
Treg therapy, TA was signifi cantly attenuated (n=6; mean% I.E.±SD= 
12.45%±9.64; p=0.0013). As expected, TA did not develop in human arterial 
grafts transplanted into BALB/C DKO mice that did not receive human allo-
PBMC (n=4).
Conclusions: Ex vivo expanded CD25hiCD4+ Treg can signifi cantly reduce 
the development of transplant arteriosclerosis in a clinically applicable 
model of vascularized solid-organ transplantation. To our knowledge, 
this is the fi rst evidence showing the capacity of human Treg to prevent 
arteriosclerosis in vivo.
A NOVEL DNA VACCINATION STRATEGY FOR 889 
TRANSPLANTATION
A. Li, M. Hattori, J. Chen, O. Ojogho, Y. Iwaki, A. Escher
Loma Linda University
Background: We have previously described a DNA vaccine strategy that 
ameliorates new-onset of autoimmune diabetes in NOD mice, and which 
requires that plasmid DNA encodes the pro-apoptotic protein BAX and 
a pancreatic β-cell antigen. Injection of the vaccine induces formation of 
antigen-containing apoptotic cells in situ, recruits dendritic cells, and induces 
CD4+CD25+foxp3+ regulatory T cells. Here, we investigated whether the same 
strategy could be applied to prevention of skin allograft rejection in mice. We 
hypothesized that induction of apoptotic cells near the allograft would promote 
immunoregulation and increase graft survival. 
Materials & Methods: Groups of C57/BL6 mice (n=8/group) received full-
thickness skin allografts from BALB/c mice. All treated recipient mice received 
a single injection of anti-lymphocyte immunoglobulin (ALG, 1.6 mg/20 gr 
BW) at time of transplantation, followed by daily injections of rapamycin (1 
mg/kg BW) for 4 weeks. In addition, selected groups received a weekly i.d. 
injection of 50 μg plasmid DNA vector alone or coding for BAX. Allografts 
were scored twice per week for rejection. 
For immune analysis, draining lymph nodes of mice receiving ALG and 
rapamycin alone and from mice vaccinated with BAX-encoding DNA were 
taken 2 weeks after transplantation. Lymph nodes were cultured in presence of 
inactivated splenocytes from C57/BL6 (recipient), BALB/c (donor), or DBA 
(third party) mice as sources of antigens, and CD4+CD25+ cells were isolated for 
proliferation assay. Quantitative PCR analysis of expression of selected genes 
(Foxp3, Il-10, Tgf-β1, Tnf-α, Ifn-γ) was performed with skin allografts, cultured 
lymph nodes, and CD4+CD25+ cells isolated from proliferation assays. 
Results: Skin allograft survival. Untreated mice and mice receiving ALG and 
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rapamycin alone with or without plasmid vector alone rejected skin grafts 1-2 
and 5-6 weeks after transplantation, respectively. In contrast mice vaccinated 
with plasmid DNA coding for BAX rejected the allografts 10-11 weeks after 
transplantation. Quantitative PCR analysis. Expression of the selected genes 
was consistently higher in the skin grafts of non-vaccinated animals. Similarly, 
expression of Foxp3, Tgf-β1, and Tnf-α was higher in both cultured lymph 
nodes and cultured CD4+CD25+ cells from non-vaccinated mice. In contrast, 
increased expression of Il-10 and IFN-γ was observed in cultured lymph nodes, 
but not in cultured CD4+CD25+ cells from the same animals. Proliferation 
assay. CD4+CD25+ cells isolated from cultured lymph nodes of non-vaccinated 
mice showed similar suppressing activities after stimulation with self, donor, 
and third party antigens. In contrast, cells isolated from vaccinated mice showed 
higher suppressive activity when stimulated with donor antigens.
Conclusion: Our results indicate that “pro-apoptotic” DNA vaccination can 
be applied successfully not only to type 1 diabetes, but also to solid organ 
transplantation. Injection of plasmid DNA coding for BAX appears to induce 
a donor-specifi c immunoregulatory response that could contribute to increased 
graft survival. We hypothesize that vaccination recruits dendritic cells that 
process vaccine-induced apoptotic cells together with antigens from the 
allograft. However, considering that expression of Foxp3, Il-10 and Tgf-β1 
was consistently higher in non-vaccinated, immunosuppressed animals, other 
mechanisms of tolerance induced by our DNA vaccination strategy are likely 
to play a role in promoting graft survival.
COMPOSITE GRAFTSCONCURRENT ORAL SESSION 66: 
FIRST FACE ALLOGRAFT IN HUMAN: A TWO YEARS 890 
FOLLOW UP
E. Morelon1, S. Testelin3, P. Petruzzo2, L. Badet2, J. Kanitakis2, A. Eljafari4, 
B. Lengele5, X. Martin2, B. Devauchelle3, J.M. Dubernard2
1Transplantation Department, Hospices Civils de Lyon, INSERM U851, 
2Transplantation department, Hospices Civils de Lyon, 3University hospital, 
Amiens, France, 4Unité mixte HCL Biomérieux, Lyon France, 5Catholic 
University of Louvain, Brussels
The fi rst human face allotransplantation was successfully performed in Amiens 
(France) on November 27, 2005. We report outcomes up to two years after 
transplantation.
The recipient was a 38 year-old woman who was mutilated and disfi gured 
by a dog bite on May 31th, 2005. She received a facial allograft (nose-lips-
chin) from a brain dead female donor. A vascularized sentinel donor skin 
graft was performed under the recipient breast. Donor bone marrow was 
infused on days 4 and 11 post transplantation to improve graft acceptance. 
The immunosuppression protocol included Thymoglobulins as induction 
therapy, tacrolimus, prednisone and mycophenolate mofetil. Sequential biopsy 
specimens were taken from the sentinel skin graft, the oral mucosa and the 
facial skin. Functional progress was assessed by tests of sensory and motor 
function performed monthly.
The initial postoperative course was uneventful. 
Sensitivity to light touch, as assessed with the use of static monofi laments, 
and sensitivity to heat and cold had returned to normal at 6 months post 
transplantation. Motor recovery was slower and labial contact allowing 
complete mouth closure was achieved at 10 months. Psychological acceptance 
of the graft progressed as function improved. Two episodes of acute rejection 
occurred on days 18 and 214 post-transplant. Macroscopically the patient 
developed erythema and oedema on both skin of face and sentinel fl ap and 
oral mucosa. Biopsies revealed dense mononuclear cell infi ltrates vacuolisation 
of basal cells, occasional apoptotic keratinocytes. The two rejection episodes 
were resolved with the combination of 3 boluses of 1 g prednisolone, increasing 
tacrolimus and mycophenolate mofetil doses and topical immunosuppressants. 
Extracorporeal photochemotherapy (EPC) was started at 10 months to prevent 
recurrence of rejection without increasing the doses of the maintenance 
immunosuppression. There have been no subsequent acute rejection episodes. 
The main side effect of immunosuppressive regimen was a progressive renal 
failure that resolved after the switch from tacrolimus to sirolimus at 14 months 
post-transplant. 
Conclusion: In this patient who underwent the fi rst face transplantation, the 
functional and aesthetic results 2 years after transplantation are satisfactory.
INTERNATIONAL REGISTRY ON HAND AND 891 
COMPOSITE TISSUE TRANSPLANTATION
P. Petruzzo1, M. Lanzetta2, J.M. Dubernard1, R. Margreiter3, F. Schuind4, W. 
Breidenbach5, J. Jablecki6, L. Landin7, P. Cavadas7
1Department of Transplantation, 2Italian Institute of Hand Surgery, Monza 
(Italy), 3Universitatsklinik fur Chirurgie, Innsbruck (Austria), 4Erasme 
University Hospital, Brussels (Belgium), 5Kleinert, Kutz and Associates, and 
Christine M. Kleinert Institute for Hand and Microsurgery, Louisville (USA), 
6Pododdzial Replantacji Konczyn, Szpital sw. Jadwigi Slaskiej w Trzebnicy, 
Wroclaw (Poland), 7Pedro Cavadas Foundation at “La Fe” University 
Hospital, Valencia, (Spain)
From September 1998 to February 2008 twenty-two male and two female 
patients underwent 33 hand/forearm/digit transplantations (thirteen monolateral 
and eight bilateral hand transplantations, two bilateral forearm transplantations, 
one thumb transplantation). Patient average age was 32 years. Follow-up period 
ranged from 3 months to 109 months.
The level of amputation was mostly at the distal forearm or wrist. Time since 
hand loss ranged from two months to 30 years. 
Immunosuppressive therapy included tacrolimus, mycophenolate mofetil, 
rapamycin and steroids; polyclonal or monoclonal antibodies were used for 
induction. Topical immunosuppression was administered in some patients. 
Acute rejection episodes occurred in 85% of patients within the fi rst year. 
Rejection was completely reversible in all compliant patients. 
Side-effects included opportunistic infections and metabolic complications. No 
life-threatening complications or malignancies were reported. 
All patients developed protective sensibility, 90% of them developed tactile 
sensibility and 72% also a discriminative sensibility. Motor recovery enabled 
patients to perform most daily activities.
Patient survival was 100%. Graft survival was 100% at one and two years. 
Except for Chinese patients, current graft survival is 95.6% as only one 
hand has been lost. While in 2006 it was reported that all but one Chinese 
recipient have lost their grafts. In all cases the cause was non-compliance to the 
immunosuppressive therapy due to abstention from therapy, long distance from 
the transplantation centre, and unreported episodes of acute rejection.
MONITORING REJECTION IN HAND 892 
TRANSPLANTATION BY A “DISTANT SENTINEL SKIN 
GRAFT”
M. Lanzetta
Italian Institute of Hand Surgery
Background: Methods for monitoring rejection in human hand transplantation 
include visual inspection of skin changes and histological analysis of biopsies. 
Previous experimental studies have shown that skin allografts reject faster and 
with a greater immune response than composite tissue allografts containing 
skin. We aimed at using this differential rejection phenomenon to achieve 
earlier detection of incoming rejection. 
Methods: Three patients had their dominant right hand transplanted after 
suffering a traumatic amputation respectively 4, 22 and 10 years before. 
Additional full-thickness skin taken from the donor was simultaneously 
transplanted onto the left hip area, and used both as a source for skin biopsies 
and as an additional area for monitoring rejection (distant sentinel skin graft). 
Immunosuppression included monoclonal antibody anti-CD25, FK506, 
mycophenolate mofetil and steroids. 
Findings: In Case 1 at 76 days postoperatively, the “distant sentinel skin graft” 
showed an onset of rejection which was confi rmed histologically. Clinical and 
histological signs of rejection of the hand did not appear until day 83, when 
appropriate systemic and topical therapy was started. The skin changes resolved 
completely within 5 days at both locations. In Case 2 at postoperatively, the 
additional skin rejected while the skin of the hand was free from rejection. 
Immediate therapy reversed rejection of the monitor skin and prevented the 
hand from developing any signs of rejection. In Case 3, early clinical signs of 
rejection at the hip area were not reported by the patient, and within 72 hours 
the hand joined the monitor island in showing signs of infl ammation typical of 
rejection. They were both treated successfully with salvage therapy.
Interpretation: These fi ndings support previous experimental data showing 
that skin alone rejects faster and more aggressively than composite tissues 
containing skin. The earlier appearance of skin changes in the distant sentinel 
skin graft compared to the hand permits a precocious start of rescue therapy 
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minimizing tissue damages to the hand without interfering with rehabilitation 
program. Routine biopsies can be taken from the distal sentinel skin graft 
without disturbing the transplanted hand, minimizing aesthetic sequelae due 
to visible multiple scars. 
VASCULARIZED BONE MARROW TRANSPLANT AS 893 
AN ALTERNATIVE TO CONVENTIONAL CELLULAR BONE 
MARROW TRANSPLANTATION
I. Zegrea1, D. Zamfi rescu1, I. Lascar1, E. Owen2, M. Lanzetta2, R. Bratianu1, 
R. Sinescu1
1Carol Davila Medical University, 2Microsearch Foundation of Australia
Vascularized bone marrow transplantation (VBMT), in comparison 
with conventional marrow transplants, have the advantage of providing 
a microenvironment and immediate engraftment of both mature and 
progenitor hemopoietic cells at the time of transplantation in the absence 
of immunomodulation or irradiation. Current protocols for bone marrow 
transplantation involve removing the bone marrow component directly from 
its donor microenvironment and then injecting such components into the 
circulatory system of the recipient. This procedure is usually preceded by 
either total or partial body irradiation, pharmaceutical immune suppression, or 
both. The aim of the study was to follow the development of microchimerism 
after allogeneic (VBMT) vs conventional bone marrow transplantation (BMT). 
A VBMT model consisted of a donor (Brown Norway rat) femur that was 
harvested with its nutrient vessels, anastomozed to the right femoral vessels 
of the recipient (Lewis rat), and then placed subcutaneously in the epigastic 
area. Cellular microchimerism was investigated in recipients of VBMTx 
vs BMC. An intravenous infusion of BMC in suspension equivalent to that 
grafted in the vascularized femur limb was administrated. Donor-derived 
cells could be detected in VBMT recipients as long 60 days after cessation 
off immunotherapy but not in recipients of i.v. suspension BMC grafting. In 
the model of i.v. suspension BMC transplantation the number detected in the 
recipient at the termination of therapy was very low 7 days later. A low level 
of cellular microchimerism could be detected as long as 70 days after cessation 
of therapy. VBMT provides a theoretical alternative to conventional cellular 
bone marrow transplantation by addressing crucial clinical problems such as 
failure of engraftment. With regard to future implications, it may be possible to 
develop a new approach for bone marrow transplantation based primarily on a 
surgical procedure (transfer of vascularized blocks of bone/marrow).
INVESTIGATION OF LYMPHOCYTE ADHESION AND 894 
TRAFFICKING MARKERS IN REJECTION OF THE SKIN 
COMPONENT IN HUMAN HAND ALLOGRAFTS
S. Schneeberger5, T. Hautz1, B. Zelger2, G. Brandacher1, H-G. Mueller3, 
A. Lee4, R. Margreiter1,
1Dept. of General and Transplant Surgery, Innsbruck Medical University, 
Austria, 2Dept. of Pathology, Innsbruck Medical University, Austria, 3Dept. of 
Dermatology, Innsbruck Medical University, Austria, 4Div. of Plastic Surgery, 
UPMC, Pittsburgh, PA, USA, 5Div. of Plastic Surgery, UPMC, Pittsburgh, 
PA, USA and Dept. of General and Transplant Surgery, Innsbruck Medical 
University, Austria
Introduction: Human Hand Transplantation has become a clinical reality 
and good functional results have been achieved in most patients. The major 
remaining obstacle for wider range clinical application is skin rejection. We 
herein analyze eight key molecular markers of lymphocyte traffi cking and 
cellular as well as antibody mediated rejection in human hand transplantation. 
Methods: One-hundred and thirty skin biopsies were taken from three bilateral 
hand transplants recipients at and different time-points and graded as per 
previously a published classifi cation. Biopsies were further investigated by 
immunohistochemistry (IHC) using antibodies for Lymphocyte Function-
Associated Antigen (LFA)-1 = CD11a, Intercellular Adhesion Molecule 
(ICAM)-1 = CD54, Selectin E = CD62E, Selectin P = CD62P, VE-Cadherin 
= CD144, Human Leukocyte Antigen (HLA) II (DP, DQ, DR), Psoriasin = 
S100A7, FoxP3 and C4d. Levels of expression were analysed according to a 
4-graded classifi cation (0, +, ++, +++) and interpreted in the light of clinical 
courses, rejection as well as time after transplantation.
Results: Rejection ranged between grade 0 and IVa with an average score of 
0.9. None of the markers investigated was consistently up-regulated in healthy 
skin. Upon rejection, CD54, CD62E and CD62P staining in endothelial cells 
was signifi cantly increased. Staining for CD62E correlated well with severity 
of rejection. The majority of infi ltrating lymphocytes were CD11a positive. 
In biopsies taken at the onset of rejection, kerationcytes were highly positive 
for CD11a. While CD144 was detected on endothelial cells, its expression did 
not correlate with rejection. In contrast, FoxP3 positive T-cells were mainly 
found in samples showing severe rejection. Psoriasin expression was observed 
in keratinocytes in a basal and focal pattern and correlated well with rejection. 
For C4d, no consistent staining pattern was observed indicating that antibody 
mediated rejection did not play a role in these patients.
Conclusion: A pattern of molecular markers involved in lymphocyte traffi cking 
was found up-regulated upon skin rejection after hand transplantation. These 
molecules represent promising targets for prophylaxis and treatment of rejection 
in hand transplantation. FoxP3 expression indicates presence of T-regulatory 
cells in the skin during advanced stages of rejection.
CONCURRENT ORAL SESSION 67: 
SURGICAL DILEMMAS IN RENAL TRANSPLANTATION
ASSESSMENT FOR RENAL TRANSPLANTATION 895 
IN THE UNITED KINGDOM AND IMPACT OF PATIENT 
COMORBIDITY ON ACCESS TO THE WAITING LIST
D. Akolekar, J.L.R. Forsythe, G. Oniscu
Royal Infi rmary of Edinburgh, Edinburgh, United Kingdom
Introduction: This study evaluates the impact of comorbidity on access to the 
kidney transplant waiting list and variations in the assessment practices among 
transplant centres in the United Kingdom.
Material And Methods: 908 patients being assessed for renal transplantation 
in 10 transplant centres across the UK were included in this prospective multi-
centre study. Sociodemographic and comorbidity data were prospectively 
collected on a standard proforma over a nine month period from October 2006 
to June 2007. Effect of various comorbid conditions on the likelihood of listing 
and centre variations were ascertained using Chi square and Cox Proportional 
analyses.
Results: 720 patients (80%) have at least one comorbid condition at the time 
of assessment with wide centre variations. These include signifi cant differences 
in the incidence of ischaemic heart disease (p<0.0001) and diabetes (p<0.0001) 
among the assessed patients. Overall 41% patients were assessed pre-emptively 
but the proportion varies signifi cantly between centres (p<0.001, Chi square test). 
There are signifi cant differences in the time from assessment to listing among 
transplant centres even after adjusting for comorbidity and other sociodemographic 
covariates (p<0.0001, Cox Regression analysis). On multivariate analysis the 
other independent predictors of access to waiting list are ischaemic heart disease 
(p=0.027) and smoking (p=0.003). Furthermore, at a given time comparable 
patients are managed differently in different transplant centres.
Conclusion: This is the fi rst prospective study demonstrating signifi cant 
variations in the assessment of patients for renal transplantation across the 
United Kingdom leading to inequity in access to the waiting list. Comorbidity 
alone does not explain centre differences. Uniform assessment guidelines are 
required to ensure an equitable access to the renal transplant waiting list.
THE ORGAN SHORTAGE ON THE BALKANS- 896 
PAKISTAN, THE PROMISING LAND!
Z. Popov1, S. Dohcev1, J. Masin2, I. Rambabova-Busljetic2, V. Pusevski2, O. 
Stankov1, N. Ivanovski2
1Department of Urology, Skopje Medical Faculty, 2Department of Nephrology, 
Skopje Medical Faculty
Background: Underdeveloped cadaver renal transplantation and increase of 
organ shortage stimulate some patients not only from the Balkan region to go 
in the Far East to buy a kidney. Before it was India, but in the last years the 
promising place is Pakistan. So the organ sale continues despite the all ethical 
issues and dilemmas.
Patients and methods: 36 illegally transplanted patients in Pakistan (Lahore 
and Ravalpindi) are followed during the last 16 months in our Department: 
25 from Kosovo, 10 from Macedonia and one from Albania. The patients 
are transplanted very quickly from the large pool of donors available. The 
transplant team and the hospitals are identifi ed and some data about the 
transplant procedure, immunosuppression and HLA compatibility are sent. 
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The immunosuppressive protocol included CyA, Pred and MMF. Most of the 
patients did not pass the usual pretransplant workup and are not sent offi cially 
to the Pakistan’s centers. 80% of them are HCV or HBsAg positive.
Results: 7 patients died, 16 had wound infections with postoperative hernias. 
3 perirenal hematomas, 6 abscesses, 4 lymphocelles, and 4 urinary fi stulas 
are operated. Nephrectomy was done in 3 patients due to renal thrombosis. 
9 have an active hepatitis C, 4 severe CMV diseases with gastrointestinal 
bleeding, 3 steroid diabetes and 3 acute myocardial infarction. 9 had one or 
more rejection episodes treated with steroid pulse therapy. Five have chronic 
allograft nephropathy. Most of them have UTI with Pseudomonas or/and 
Escherichia coli. The one year patients and graft survival rate is 80% and 68%, 
respectively. 
Conclusion: In conclusion, as many times before, the authors do not recommend 
this type of transplantation not only from the ethical point of view, but also 
from frequent medical and surgical complications which are life threatening. 
FACTORS INFLUENCING THE NUMBER OF 897 
HOSPITALIZATION DAYS IN THE FIRST THREE MONTHS 
AFTER KIDNEY TRANSPLANTATION
M. Heemskerk1, A. Hemke1, B. Haase-Kromwijk1, A. Hoitsma2
1Dutch Transplant Foundation, 2Radboud University Medical Centre 
Nijmegen
Background: We analyzed the parameters that infl uence the number of 
hospitalization days in the fi rst 3 months after kidney transplantation. 
Methods: We analyzed the 3 month follow-up for kidney transplants performed 
in the Netherlands between 2000 and 2007 (n = 3317). We included both the 
hospitalization days immediately after the transplantation as well as every 
rehospitalization day in the fi rst 3 months after transplantation. Patients were 
included if they were alive with a functioning graft at three months after 
transplantation. Cases were assumed “missing” if less than 5 hospitalization 
days were reported. 
Results: The mean number of hospitalization days during the fi rst three months 
after transplantation was 24.8 days (range 5-92) within the period 2000-2007. 
A signifi cant difference was shown in the mean number of hospitalization days 
for the donor type: deceased donors (27.9 days) versus living donors (20.1 
days). For the deceased donors, signifi cantly more hospitalization days (2-4 
days) were found for recipients who received kidneys from older donors, 
recipients with a higher BMI, and recipients who received a non-heartbeating 
donor kidney. For living donors signifi cantly more hospitalization days (2-6 
days) were found for older recipients, recipients with a higher BMI, recipients 
with dialysis prior to the transplantation and recipients who received a kidney 
from an unrelated donor. However, for both the deceased donor and living 
donor transplants there was a signifi cantly larger difference in hospitalization 
days (maximum of 19 days for deceased and 12 for living donors) between 
the different transplant centers. This center effect was present in each of the 
identifi ed donor type, donor and recipient age groups, dialysis, and in all but 
one (due to small numbers) of the recipient BMI groups. The center effect thus 
seems to be independent from the different characteristics described above. 
Conclusion: From this analysis we conclude that the donor type (deceased 
vs living) and the transplant center (and therefore the hospitalization policy) 
are very strong, independent, parameters that infl uence the number of 
hospitalization days in the fi rst 3 months after kidney transplantation. Donor 
and recipient age, recipient BMI, dialysis and donor type had a signifi cant but 
smaller effect.
HEALTH-RELATED QUALITY OF LIFE OUTCOMES 898 
FOR KIDNEY DONORS DIFFER DEPENDING ON TYPE OF 
LAPAROSCOPIC DONOR NEPHRECTOMY (PURE (P-LDN) VS. 
HAND-ASSIST (HA-LDN))
M. Hughes, C. Jacobs, M. Hill, T. Jie, A. Rezcallah, T. Dunn, A. Humar, 
D. Sutherland, A. Matas, R. Kandaswamy
University of Minnesota
Introduction: P-LDN offers the advantage of scar placement in a less 
conspicuous area (supra-pubic) compared with HA-LDN. In addition, avoidance 
of hand insertion allows for a smaller incision but whether this contributes to 
greater post-donation quality of life remains unknown. 
Methods: Since 1997, we have performed 558 HA-LDN and 141 P-LDN. 
Choice of operation was at the discretion of the operating surgeon. Health-
related quality of life (HQOL) scores were determined by SF-12 survey and 
results were expressed as Physical Health Summary Scores (PCS) and Mental 
Health Summary Scores (MCS). PCS included 1) physical functioning, 2) role-
physical, 3) bodily pain, and 4) general health. MCS included 1) vitality, 2) 
social functioning, 3) role-emotional, and 4) mental health. RESULTS: Those 
patients who underwent P-LDN were younger (P-LDN 40.0 10.4 years vs. 
HA-LDN 41.9 10.4, p=0.03), thinner (25.0 3.6 vs 26.6 4.0, p<0.0001), and 
more often donated the left kidney (92.2% vs 76.9%, p<0.0001). There were 
no differences in gender (P-LDN 63.1% female vs HA-LDN 56.8%, p=0.2), 
relation to recipient (63.8% vs 61.5%, p=0.6) or number of arteries (90.0% 
single artery vs 84.0%). Length of stay was shorter for P-LDN (P-LDN 3.2 
3.5 days vs. HA-LDN 3.3 1.7, p=0.04) with no signifi cant differences between 
groups in blood transfusion (p=0.2), infection (p=0.8), pulmonary embolism 
(p=0.3), re-operation (p=0.8), or total in-hospital complications (p=0.4). There 
were no differences between groups in kidney performance for the recipient as 
measured by delayed graft function (P-LDN 2.8% vs. HA-LDN 2.9%, p=1.0), 
5-yr graft survival (85.5% vs 89.7%, p=0.7), ureteral obstruction (10.6% vs 
9.1%, p=0.6), or ureteral leak (4.4% vs 2.7%, p=0.4). Regarding HQOL, 
Mental Health Summary Scores (MCS) were greater for those donors who 
underwent P-LDN than for those who underwent HA-LDN (54.1 6.1 vs 52.1 
6.1, p=0.009). Physical Health Summary Scores (PCS) were similar (P-LDN 
55.0 6.1 vs 55.1 6.1, p=0.5). 
Conclusion: Compared with HA-LDN, P-LDN results in greater mental health-
related quality of life for donors without increasing donor risk, decreasing 
physical health or adversely impacting allograft function.
SHOULD KIDNEY TRANSPLANTATION BE 899 
CONSIDERED THE TREATMENT OF CHOICE FOR SYSTOLIC 
HEART FAILURE IN PATIENTS WITH END STAGE RENAL 
DISEASE?
R. Wali1, V. Mohanlal2, M. Weir1, S. Bartlett1
1University of Maryland School of Medicine, 2Harbor Hospital, Baltimore, 
MD USA
Among the spectrum of different cardiovascular disease events in dialysis 
dependent patients, chronic heart failure (HF) is present in almost one-third 
of patients and remains a common cause of morbidity and mortality. Due to 
the lack of randomized studies in treatment of systolic heart failure (SHF) in 
dialysis patients, at present these patients are treated on empirical basis without 
established effi cacy and safety. 
Objective: Systolic heart failure (SHF) defi ned as symptom complex of heart 
failure and left ventricular ejection fraction (LVEF) ¡Ü0.5 is associated with 
an increased morbidity and mortality. To investigate mortality in dialysis 
dependent patients with SHF after wait-listing while on dialysis and following 
transplantation and to report on the effects of dialysis duration (co-morbidity) 
on mortality after transplantation.
Design: Case-Control study of dialysis dependent patients that were wait-
listed for kidney transplantation at University of Maryland Transplant Program 
from March 2000 to December 2002. All patients aged over 18 years who had 
established diagnosis of SHF were included in this analysis. Main outcome 
measure was all cause mortality (ACM) and standardized mortality ratio 
(SMR) against the dialysis and transplant patients without SHF. Results: A 
total of 1700 patients were wait-listed during this period, and 438 patients had 
history of more than one hospitalization for HF at the time of wait- listing. Fifty 
seven percent (252/438) had SHF (LVEF ¡Ü0.5), 128/252 (51%) underwent 
kidney transplantation; four patients were lost to follow-up during the fi rst 
three months, hence excluded from this analysis. Mean age was 58.8 years, 
53% were blacks, 31% were females and 42% had diabetes mellitus. A total of 
106 (42.7%) died during the mean follow-up of 3.3 years. ACM was 23.4% in 
transplanted patient compared to 62.2% who continued to remain wait-listed 
(log rank, p<0.0001). One-year mortality in transplanted patients was 14.5%, 
and corresponding fi gures for those who remained on dialysis 42.4% (log 
rank, p=0.003). Compared with dialysis and transplanted population without 
SHF, the highest relative increase in mortality was in patients with LVEF <0.3 
(Standardized mortality ratio 10.0 for SHF who underwent transplantation, 33.8 
for those who continued on wait-list) and the lowest for general transplant and 
dialysis population (2.4 and 6.8, respectively). The mean LVEF at the time of 
transplant evaluation was 0.35, it increased to 0.49, and 0.53 at six and twelve 
months, respectively, following transplantation. We conclude that mortality 
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in dialysis patient with SHF is extremely high, and increases strongly with a 
decrease in ejection fraction. Since kidney transplantation is associated with 
increased longevity in dialysis population, this is more pronounced in those 
with SHF. Hence, dialysis patients with SHF should be offered transplantation 
at the time of diagnosis of SHF to prevent further deterioration in ejection 
fraction. In addition, there should a public policy change to allow such patients 
to have a priority score to prevent the prolonged wait-time as the best possible 
chance of survival. 
QUALITY OF LIFECONCURRENT ORAL SESSION 68: 
TRANSPLANTATION OF OLDER PATIENTS DOES 900 
NOT IMPROVE SURVIVAL COMPARED WITH THOSE WAIT 
LISTED. ANALYSIS OF 9,700 WAIT LISTED PATIENTS IN THE 
UK
D. Ansell1, J. O;Neil2, R. Johnson2, D. Collett2, C. Dudley1
1UK Renal Registry, 2UK Transplant
The survival benefi t of receiving a kidney transplant over remaining on the 
waiting list is often quoted from the American study by Wolfe. Recent USA 
papers have also supported a survival benefi t in the over 65s. In Europe survival 
on dialysis is better than the USA across all age bands and survival benefi t of 
transplantation may not be as great. Using the same statistical methodology as 
Wolfe, we have calculated the time to survival benefi t by age group in the UK, 
for patients receiving a deceased donor (DD) kidney transplantation over those 
remaining on the waiting list. 
Methods: 9739 adult patients listed for a DD fi rst kidney only transplant 
in the UK, 1995-2000, were analyzed. Patients were followed from date of 
listing to Sept 2005 or death. Of the patients analysed, 6819 received a DD 
transplant. Cox regression was used to analyze the combined effect of (age, 
ethnicity, diagnosis, waiting time, on patient survival and to evaluate the time 
to equal risk, equal survival, life years gained by transplantation for different 
age groups. We also examined the effect of periods of suspension from the 
waiting list (as a surrogate marker for comorbidity) on the survival benefi t. 
Results: Transplantation was of most benefi t to younger patients with risk of 
death at the time of transplant increasing with age, resulting in increasing time 
to equal risk and equal survival with increasing age. In contrast to the USA, 
UK patients aged over 65 years receiving a renal transplant did not show a 
signifi cant survival benefi t.
[table1]
Age band N RR of death tx vs list ** p< 0.001 Equal risk (days)
Equal survival 
(days)
Relative Risk 
immediate 
post tx
18 – 34 1956 0.3** (0.2-0.5) 34 82 3.2
35 – 44 2060 0.4** (0.3-0.5) 126 279 4.1
45 – 54 2464 0.5** (0.4-0.7) 158 362 4.5
55 – 64 2269 0.7** (0.6-0.8) 186 480 5.2
65+ 990 0.9 (0.7-1.1) 190 581 8.0
The survival benefi t associated with receiving a DD transplant was similar for 
whites, south Asians and Blacks with no reduced relative benefi t seen in ethnic 
minority groups.
Summary: In the UK patients aged over 65 years receiving a renal transplant 
did not show a signifi cant survival benefi t. As well as age, the survival benefi t 
of transplantation varied by primary diagnosis and time spent suspended. 
REMOVING FINANCIAL BARRIERS TO LIVING 901 
ORGAN DONATION: BRITISH COLUMBIA PILOTS EXPENSE 
REIMBURSEMENT
M.Y. Lorraine Gerard
Kidney Foundation of Canada, BC Branch
In British Columbia (BC), Canada (CAN) all organ transplantation surgery 
occurs in Vancouver at one three transplant centres. The reality for living organ 
donors is that regardless where they may live, if they are donating an organ to 
a resident of BC, they must travel to Vancouver for their fi nal assessments and 
for their surgery. Most donors are advised to stay close by the transplant centre 
for about a week following their hospital discharge; they are also advised to 
refrain from returning to work for a period of up to eight weeks. The fi nancial 
impact to a living organ donor can be signifi cant when travel, accommodation, 
meals and loss of income are calculated. Both the Kidney Foundation of Canada 
(KFOC) and BC Transplant (BCT) believe that living organ donors should not 
bear any costs associated with their donation. 
In July 2006, the KFOC’s BC Branch and BCT launched the Living Organ 
Donor Expense Reimbursement Program (LODERP) and as of the end of 
February 2008 had reimbursed 140 donors or potential donors for their eligible 
expenses. All donors are provided with the LODERP information through 
their transplant social worker. Estimated expenses are pre-approved whenever 
possible and donors complete an expense claim form which generates the 
reimbursement cheque. Employer information is required to calculate the 
potential loss of income. While the amount of reimbursement is higher for out 
of province or out of country donors, the average reimbursement is far less than 
was originally estimated.
Of the fi rst 140 donors, 133 were kidney donors and 7 liver donors. The fi rst 
58 fi les have been closed with no further claims expected; these donors were 
reimbursed between $56 – $3,719. Some travel costs, accommodation and 
meal reimbursements were claimed by most donors. Only 29% claimed loss 
of income and most claimed only a short wait period prior to their receipt of 
government or employer benefi ts.
A study is currently underway to determine the impact of expense reimbursement 
on living donation rates, donor perceptions about eligible expenses and 
reimbursement rates and the potential for ongoing program funding. Healthcare 
professionals involved in the program have already been interviewed and donor 
interviews are scheduled to begin shortly. 
OLDER LIVING KIDNEY DONORS: SURGICAL 902 
OUTCOME AND QUALITY OF LIFE
R. Minnee1, W. Bemelman1, B. Polle1, P. van Koperen1, S. ter Meulen2, 
K.D. van der Pant2, F. Bemelman2, M. Idu1
1Dept. of Surgery, Academic Medical Center, 2Dept. of Nephrology, Academic 
Medical Center
Background: Older living donors remain controversial because of their 
physiological decline in glomerular fi ltration rate and their increased 
susceptibility of surgical complications. Little is known about the quality of life 
(QoL) of this elderly group. The purpose of this study is to examine surgical 
outcome and the QoL in older living donors.
Patients and Methods: All 105 consecutive living donors who underwent a 
laparoscopic donor nephrectomy between June 2002 and February 2006 were 
prospectively included in the study. Intra- and postoperative complications 
were measured. QoL was recorded preoperatively and at several endpoints 
postoperatively. Older donors were defi ned as fi fty-fi ve years and older. 
Results: There were no signifi cant differences in intra- and postoperative 
complication rates and one year graft survival rate between both groups. 
Elderly donors (N=34) had both a signifi cant lower postoperative pain at rest 
at day one compared to the younger group (p=0.019) as well as a lower total 
pain score in the analysis for the whole follow-up period (p=0.002). Although 
small solitary signifi cant differences in Short Form 36 Health Survey (SF-36), 
Multidimensional Fatigue Inventory-20 (MFI-20) and visual analogue scale 
(VAS) measuring pain, between both groups were detected, in general QoL of 
older donors was not different than of younger donors. 
Conclusion: Although small solitary signifi cant differences exist with respect to 
pain, social functioning and mental health older donors have in general similar 
surgical outcome and quality of life as compared to younger donors. There is 
no need to exclude older donors in screening programmes for transplantation.
ESTABLISHING AN INDIGINOUS LIVE DONOR KIDNEY 903 
TRANSPLANT PROGRAMME IN NIGERIA
P. Lear1, S. Usman2
1Southmead Hospital, 2Aminu Kano University Hospital
Three visits have been made to a west African teaching hospital to help set up 
a locally provided kidney transplant service. The hospital (400 beds) provides 
specialist surgical services to 25M, Moslem population. The city has a total 
of 1200 hospital beds in three hospitals. Dialysis is not free and there are only 
8 dialysis machines. During each visit two live donated kidney transplants 
were performed with increasing independence of the local surgical team. 
BTS/RA guidelines were followed for donor work up, where possible. Access 
to CT (150Km away) was diffi cult due to the poor maintenance and renal 
angiography was only available for two donors. Colour doppler ultrasound 
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was offered as alternative imaging. 10 patient pairs were worked up to 
preparation for surgery. Four patients were transplanted abroad. The visits 
identifi ed signifi cant problems. Electricity power cuts are frequent (4 – 10 
per day) and last 20 minutes or more. The theatre lights were old, had few 
bulbs and could not focus. There is no back up power generator for the theatre 
suite, but sunshine is plentiful. The air-conditioning is archaic. Anaesthetics 
were given by nurses using Boyles machines, but two modern vaporisers 
were bought for the fi nal visit. Bore hole water in a large bucket and carbolic 
soap was used for hand cleansing. The gowns and drapes were perforated 
in many sites. The surgical instruments were crude but the sutures were of 
European standard. Tissue typing is unreliable and written detail requires the 
tests (including crossmatches) to be performed in Egypt. Cyclosporine is the 
only ‘modern’ immunosuppressant , and levels are measured in another city: 
the turnaround time is <24 hours. Luckily all the patients had BMIs of 20 
– 22. There were no signifi cant post-operative complications in donors or 
recipients. They have all done well. Their care was funded by a generous 
grant from the state governor and this covered all costs and drugs for 1 year 
post transplant. Historical experience suggests that training African surgeons 
in the UK will result in a skills drain, due to good opportunities in Britain 
for career advancement. These options are now reduced by competition with 
immigrant European medical staff. The available technology and facilities do 
not prepare them for the limited resources back home and therefore this form 
of training and mentorship is best provided by senior surgeons exporting 
their expertise.
DUAL KIDNEY TRANSPLANTS FROM VERY OLD OR 904 
VERY YOUNG DONORS; LONG TERM OUTCOMES AND 
COMPLICATIONS
M.R. Laftavi1, R. Stephan1, R. Koholi2, A. Robino1, K. Paolini1, I.e Min1, M. 
Dayton1, O. Pankewycz2
1Department of Surgery, SUNY at Buffalo, 2Department of Medicine, SUNY at 
Buffalo
Introduction: The disparity between the supply of cadaveric donors and the 
demand for organ transplants continues to grow steadily. In the USA, every 
year 6700 patients (pts) die while waiting for an organ transplant. To increase 
utilization of cadaveric organs we have expanded our acceptable criteria 
to include very old (VO) or very young (VY) donors. For such donors we 
transplanted both donor kidneys (Dual Transplant) into a single recipient. The 
aim of this study is to evaluate the long term outcomes and complications of 
dual kidney transplants from VO or VY donors. 
Methods: From July 2001 to December 2006, 356 kidney (kd) transplants 
were performed in our center. 22 pts received a dual ktx. 15 pts (mean age 
68, range 60-78) received kds from VO (mean age 72, range 60-79) donors 
and 7 pts (mean age 47, range 27-72) were transplanted from VY (mean age 
17 months, range 2-36) donors. 74% of these kds were imported from outside 
of our region after being deemed unacceptable by their local center due to the 
quality (extreme age) of the donor. 
Results: Three and 5 year pt survival rates were 95% and 82% respectively. 
Three and 5 years graft (gft) survival rates (death censored) in the VO 
donors were 94% and 94% and 85% and 68% in recipients of VY kidneys 
respectively. Mean hospital stay was 6 days in both groups. One pt. (8%) in 
the VY group and no pt. in the VO group experienced acute graft rejection. 
In the VO group, one patient experience early graft thrombosis of both 
kidneys, three pts experienced ureteral stenosis, one pt. developed urinary 
leak and one pt developed a lymphocele after transplantation. Three gft 
losses occurred in the VY gp: 1 due to lymphoma 11 mos post tx, 1 due 
to HUS 7 mos post tx and one due to early thrombosis on POD 2. Four 
pts experienced UTIs and 3 pts developed incisional subcutaneous seroma. 
Mean serum creatinines for the entire group at 3 and 5 years were 1.23 and 
1.38 mg/dl respectively. Mean eGFR at 3 and 5 years were 56.8 and 55.65 
ml/min respectively. 
Conclusion: Our study showed that using dual kidneys from cadaveric 
donors that fall outside the general acceptance criteria for kidney donation 
are a valuable resource and can maintain a good long term eGFR and provide 
acceptable long term outcomes compared to conventional single kidney 
transplant when properly placed.
XENOTRANSPLANTATION CONCURRENT ORAL SESSION 69: 
– IMMUNOSUPPRESSION AND PERV
LOCAL EXPRESSION OF IMMUNOMODULATORY 905 
MOLECULES INHIBITS XENOGENEIC RESPONSES IN VITRO 
AND IN VIVO
D. Christiansen1, W. Mulley1, Y.Q. Li1, J. Wee1, N. Dodge1, F. Ierino1,2, 
M. Sandrin1
1University of Melbourne, 2Austin Health
Background: It is likely that transgenic expression of multiple 
immunomodulatory molecules by a graft will be required to overcome cell-
mediated xenorejection. We examined the effects of local expression of several 
immunomodulatory molecules by a porcine cell line (PIEC) on indirect murine 
xenorejection responses in vitro and in vivo. 
Methods: PIEC stable lines expressing IDO, CTLA4Ig, CD40Ig and IL10 
as single immunomodulatory molecules, or expressing IDO in combination 
with either of the others were generated. BALB/c mice were primed with 
wild type PIEC, splenocytes were harvested for use as responder cells and 
PIEC expressing immunomodulatory molecules were used as stimulators 
in proliferation and cytokine assays. In vivo effects of modifi ed PIEC were 
examined in naïve and primed mice following cell transplantation under the 
renal capsule or subcutaneously. 
Results: Proliferation of primed BALB/c splenocytes was inhibited most 
signifi cantly by IDO compared with control cells (49%, p=0.02). In addition 
both Th1 (interferon-gamma) and Th2 (interleukin-4 and interleukin-10) 
cytokines were markedly inhibited in vitro by IDO expression. IL10 expressing 
cells did not inhibit proliferation as potently (37%, p=0.03) whilst CD40Ig 
lead to an increase in proliferative responses (59%, p=0.02). Co-expression of 
CD40Ig, IL10 and CTLA4Ig with IDO resulted in further modest reductions in 
proliferation compared with IDO expression alone. When transplanted under 
the renal capsule of BALB/c mice, those grafts expressing IDO demonstrated 
signifi cantly lower levels of lymphocyte infi ltration at days 7 and 14 than 
control grafts and those expressing CD40Ig, CTLA4Ig or IL10 alone. Grafts 
co-expressing IDO and a second molecule were no better protected than those 
expressing IDO alone. Graft cell viability (PIECs) was reduced in some IDO 
expressing grafts suggesting high levels of IDO expression may inhibit PIEC 
viability, however, grafts co-expressing IDO-CTLA4Ig and IDO-IL10 were 
not affected in this way. In the subcutaneous transplantation model, PIEC-
CTLA4Ig grafts had signifi cantly prolonged survival in naïve and primed 
mice compared with controls. Survival was associated with an expansion of 
CD4+25+ T-cells in naïve mice. Histology demonstrated signifi cantly reduced 
lymphocyte infi ltration compared with controls.
Conclusion: IDO appears to be a potent molecule for protecting xenografts 
from cell-mediated rejection responses activated via the indirect pathway. Co-
expression of IDO with both CTLA4Ig and IL10 warrants further investigation. 
Overall these fi ndings support pursuing further studies, in larger animal models, 
to determine whether increased IDO activity within the graft itself can attenuate 
xenorejection responses.
TRANSDUCTION OF NEONATAL PORCINE ISLETS 906 
BY AAV-CTLA-4-IG PROVIDED LOCAL PROTECTION OF 
PORCINE ISLET XENOGRAFTS FROM HUMAN T-CELL 
MEDIATED REJECTION IN VIVO
W. Wang, B. Ye, S. Liu, Z. Ye, Q. Tong, G. Zeng
Cell Transplant and Gene Therapy Center, 3rd Xiangya Hospital of Central 
South University
Background: Cellular rejection of xenografts is predominantly mediated by 
CD4+ T cells. CTLA-4 inhibits T-cell responses and regulates peripheral T-cell 
tolerance. In this study we used AAV-CTLA-4-Ig transduced neonatal porcine 
islet clusters (NPIs) to investigate whether CTLA-4-Ig produced by transfected 
NPIs was able to provide local protection of porcine islet xenografts from 
cellular rejection in a humanized mouse model. 
Methods: NPIs were transduced with AAV-CTLA4-Ig-GFP (1013v.g/ml). The 
transduction effi ciency and CTLA4-Iggene and protein expression in NPIs 
were assessed by fl uorescent microscopy, RT-PCR and immunohistochemistry, 
respectively. Static stimulation was performed to test transduced NPIs in vitro 
function prior to transplantation. SCID mice were i.v. reconstituted with 1 
x 108 human PBMC and made diabetes by strectozotocin. The humanized 
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diabetic SCID mice were then transplanted with 2000 non-transduced or 
CTLA-4-Ig transduced NPIs under left kidney capsule. After transplantation 
levels of human IL-2, IFN-γ and TNF-α in peripheral blood were examined 
by ELISA and xenograft survival was determined by BSL measurement and 
histological analysis. 
Results: AAV-CTLA-4-Ig transduced NPIs demonstrated high transduction 
effi ciency (>80%) and detectable expression of both CTLA-4-Ig mRNA and 
protein with intact insulin secreting function. When transplanted to human 
PBMC reconstituted diabetic SCID mice the CTLA-4-Ig transduced NPIs 
normalized BSL 7 days after transplantation and remained intact with no 
human cell infi ltration for 59.1 ± 24.0 days after transplantation. In addition, 
only low levels of human IL-2, IFN-γ and TNF-α were detected in these SCID 
recipients. In contrast, humanized diabetic SCID recipients that received non-
transduced NPIs remained hyperglycemic, showed high levels of human IL-2, 
IFN-γ and TNF-α, and rejected their islet xenografts completely at day 12.7 ± 
3.3 after transplantation. The NPI xenografts at rejecting time from these mice 
were mainly infi ltrated by human T cells. 
Conclusion: This study demonstrates that AAV-CTLA-4-Ig was capable 
of transducing NPIs effi ciently thereby providing an approach to local 
protection of porcine islet xenografts from human T-cell mediated cellular 
rejection. It suggests a potential strategy for tolerance induction in clinical islet 
xenotransplantation. 
ADENOVIRUS-MEDIATED GENE EXPRESSION OF 907 
HUMAN C-FLIPL PROTECTS PIG ISLETS AGAINST HUMAN 
CD8+ CTL-MEDIATED CYTOTOXICITY
M. Tanemura1, A. Saga1, K. Kawamoto1, T. Machida1, T. Deguchi1, 
H. Komoda2, Y. Fumimoto2, T. Nishida1, Y. Sawa1,2, T. Ito1
1Department of Surgery, Osaka University Graduate School of Medicine, 
2Medical Center for Translational Research, Osaka University Hospital
Objectives: Recent advantages in human allogenic islet transplantation have 
established β-cell replacement therapy as a potentially viable treatment option 
for individuals affected with Type 1 diabetes. However, the current shortage of 
human islet donors limits the application of this treatment to the patient with 
brittle Type 1 diabetes. Xenotransplantation of pig islets is a potential solution 
to the shortage of human donor islets provided xengraft rejection is prevented. 
Pig islets have precise advantages from glycobiological points, because they 
lack α-gal epitopes. Therefore, short-term xenograft survival of these islets 
may be successful by the reason of avoiding hyperacute rejection. However, 
cell-mediated rejection, including NK cells, macrophages and CD8+ CTLs, 
may represent another barrier preventing long-term xenograft survival. We 
have demonstrated that human CD8+ CTLs display strong cytotoxicity against 
pig islets. In this study, we assessed the cytoprotective effects of c-FLIPlong 
(c-FLIPL), which are potent inhibitor of death receptor-mediated pro-apoptotic 
signals, including Fas/FasL pathway, by overexpression of this molecule in 
pig islets.
Materials and Methods: Pig islet isolation: Adult pig pancreata were 
removed at slaughterhouse that handles young market weight pigs. Pig islets 
were isolated by the Ricordi’s method. Construction of adenovirus vector: 
The adenovirus vector, pAdex1CAwt regulated by CAG promoter, containing 
the open reading frame of the human c-FLIPL gene was purchased from 
RIKEN BioResource Center (Wako, Japan). The adenovirus was propagated 
by infection of HEK-293 cells. Subsequently, adenovirus was purifi ed on 
a Cs/Tris gradient, separated into aliquots, and stored at -80 oC until use. 
The “empty” control adenovirus that lack the human c-FLIPL insert, was 
also amplifi ed in a same manner as described above. Transduction of pig 
islets by adenovirus vector: Freshly obtained adult pig islets represented 
in 500μl serum free Medium-199 were exposed to adenovirus encoding 
human c-FLIPL at a MOI of either 10 or 30 for 1hr at 37 oC. To identify the 
expression of this molecule in pig islets, Western blot analysis was performed. 
Generation of human CD8+ CTLs: PBMCs, freshly obtained from healthy 
volunteers, were separated. These separated PBMCs were co-cultured for 
14 days with the irradiated PEC monolayers in the presence of 50 U/ml 
recombinant human IL-2. Subsequently, human CD8+ CTLs were positively 
selected by magnetic beads and subjected to an in vitro cytotoxicity assay. 
In vitro cytotoxicity assay and transplant studies: The cytotoxic activity of 
human CD8+ CTLs against pig islets was assessed by a 51Cr release assay. 
Furthermore, parental pig islets and transfected pig islets were transplanted 
under kidney capsule of Lewis rats to prove the in vivo effectiveness of this 
molecule for the prolongation of pig islet xenograft survival. Subsequently, 
immunohistochemical staining of insulin was performed to detect survived 
pig islets. 
Results: Results are summarized in the table.
Pig islets □ Protein 
expression 
in pig islets
% cytotoxicity by 51Cr 
release assay (mean ± SD)
Xenogfraft 
survival in 
transplant 
studiesAdenovirus (Arbitaly 
units by
Western 
blot)
□ □ E/T 
ratio=50:1
E/T 
ratio=25:1
Day 3
Parental pig 
islets
□ - 11422 59.3 ± 15.9 47.6 ± 8.2 Rejected
MOCK islets 
(control Ad 
transfected 
pig islets)
10 MOI 12532 64.0 ± 8.9 48.7 ± 14.8 Rejected
30 MOI 13531 59.0 ± 1.4 43.3 ± 5.5 N.D.
c-FLIPL 
transfected
pig islets
10 MOI 17105 30.5 ± 3.5 24.3 ± 1.6 +++ (Survived)
30 MOI 22276 23.6 ± 11.6 21.0 ± 11.0 N.D.
N.D.: not done
Conclusion: Adenovirus-mediated gene expression of human c-FLIPL 
effectively protected pig islets from human CD8+ CTL-mediated killing and 
prolonged xenograft survival. 
RAPAMYCIN PROMOTES THE ENRICHMENT OF 908 
CD4+CD25HIFOXP3+ T REGULATORY CELLS FROM NAÏVE 
CD4+ T CELLS OF BABOON THAT SUPPRESS ANTI PORCINE 
XENOGENIC RESPONSE IN VITRO
M. Mohiuddin, A. Singh, K. Horvath
Cardiothoracic Surgery Research Program, NHLBI, NIH, Bethesda MD, USA
The CD4+CD25+FoxP3+ regulatory T (Treg) cells play an important role in 
regulating immune response. These Treg cells are present in peripheral blood 
and lymphoid organs and have a high potential for immunotherapy in clinics. 
Adoptive Cell transfer therapy using CD4+CD25+ cells has been shown to 
prevent autoimmune diseases and has also induced transplant tolerance in 
mice. Treg cells low frequency in peripheral blood will necessitate its ex-vivo 
expansion to enable adaptive immunotherapy. Recently, it has been reported 
that rapamycin, an immunosuppressive agent, inhibits T cell proliferation 
while selectively increasing the number of Treg cells. Based on this additional 
mode of action, rapamycin can be used to expand Treg cells for ex-vivo cellular 
therapy in T-cell-mediated diseases and in transplantation. We have reported 
the ex-vivo expansion of baboon Treg cells, using irradiated pig PBMC and 
IL-2, and have demonstrated suppression of autologus CD4+CD25neg T-cell 
proliferation in response to pig PBMCs. In present study, we have expanded 
baboon CD4+ T cells in the presence or absence of rapamycin (0.1-10nM) 
using irradiated pig PBMCs and IL-2 to enrich the regulatory T cells. 
CD4+CD25+FoxP3+ Treg cells were increased up to two times in presence 
of rapamycin as compared without rapamycin in cultures. However, a higher 
dose of rapamycin (¡Ý10nM) considerably decreases the number of Treg cells. 
Purifi ed CD4+CD25+ Treg cells enriched from CD4+ cells in presence of 
rapamycin were able to suppress the baboon anti-porcine xenogeneic immune 
responses in vitro up to 90% at 1:1 ratio (T regulatory Cells: T effector cells) 
and suppression ability exists even at 1:256 ratio whereas freshly isolated 
natural Treg cells suppress only 70% at 1:1 and loose their suppressive 
ability (>50%) at 1:16. We also examined the effect of rapamycin on cytokine 
production in culture. The production of IL-4, IL-5, IL-6 and TNF-a was 
increased in the culture supernatant containing rapamycin as compared to 
cultures without rapamycin. However, IFN-g production and secretion was 
signifi cantly lower in rapamycin treated cells. Our results demonstrate that 
the addition of rapamycin to the culture enrich the Treg phenotype and induce 
functional regulatory T cells. This method may allow production of large 
number of regulatory cells for the preclinical testing of Treg cell therapy in a 
non human primate model.
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PERV FREE SWINE IN A DEFINED PATHOGEN FREE 909 
HERD
W.E. Beschorner1,2, P.E. Kudlacek1, Y. Takeuchi3, T. Schieber4, 
K.F. Lechtenberg2,4
1Ximerex, Inc., Blair, NE USA, 2Swine Biomedical Resource Centre, LLC, 
Oakland, NE USA, 3University London College, London, UK, 4Midwest 
Veterinary Services, Inc., Oakland, NE USA
Objective: Xenotransplantation of pig tissues could provide functional 
organs and tissues for many recipients. A major deterrent to using pig tissues, 
however, is the presence of porcine endogenous retrovirus (PERV), defi ned as 
three forms (A, B, C) in the porcine genome. Coculture studies with human 
cells demonstrate the presence of the PERV within the human cells. While 
no pathology or infection has yet been demonstrated in human recipients or 
animal models, the possibility PERV could become a public health hazard from 
PERV has led to extensive and prolonged suggested regulations by the FDA 
for monitoring xenotransplant recipients. A herd of 22 defi ned pathogen free 
(DPF) pigs was recently screened for PERV. One sow was found to be free of 
all three forms of PERV. Thirteen additional pigs had only PERV-B. Based on 
the relationship to the PERV free sow, 10 of the 13 have a 50 to 100% chance 
to be heterozygous for PERV-B.
Materials and Methods: The DPF herd was developed for clinical 
xenotransplantation over the past 20 years through selective breeding. The 
pigs are maintained in isolation with extraordinary husbandry and regular 
serological screening for more than 40 potential pathogens. Pigs from this 
herd have been used in two clinical trials. PERV was not passed to human 
cells in coculture tests. Blood from the 22 pigs was screened for PERV-A, 
B, and C in the DNA by PCR using the appropriate probes for the envelope 
gene. Additional studies included PCR for PERV gag-pol, and RT-PCR for 
gag-pol RNA.
Results: One sow (22-10) was negative for PERV-A, B, and C and for gag-
pol DNA on repeated assessments. Thirteen additional pigs were PERV-A and 
PERV-C negative, while being PERV-B positive. One pig was positive for 
PERV-B and PERV-C. Based on the relationships of the pigs to sow 22-10, 10 
pigs negative for PERV-A and PERV-C are believed to have a greater than 50% 
probability of being heterozygous for PERV-B, including 7 pigs with a 100% 
probability of being heterozygous for PERV-B.
Sow 22-10 was positive for RT-PCR when initially assessed for gag-pol RNA. 
She had been bred with a boar that was positive for PERV-A and B. Four weeks 
after farrowing the litter, her blood was RT-PCR negative. 
Conclusion: Through selective breeding, it should be possible to eliminate 
PERV from this herd of DPF pigs. The potential risk of a public health hazard 
due to PERV would effectively be eliminated.
MTOR INHIBITION IN CONCURRENT ORAL SESSION 70: 
CARDIOTHORACIC TRANSPLANTATION
BIOPSY-PROVEN ACUTE REJECTION AND RECURRENT 910 
REJECTION IN DE NOVO CARDIAC TRANSPLANT 
RECIPIENTS: SUPERIOR EFFICACY WITH EVEROLIMUS
H. Lehmkuhl1, G. Gerosa2, J. Arizon3, M. Viganó4, M-F. Mattei5, T. Dengler6, 
Y. Li7, U. Livi8
1Deutsches Herzzentrum Berlin, Berlin, Germany, 2Azienda Ospedaliera 
di Padova – Università degli, Padova, Italy, 3Hospital Universitario Reina 
Sofi a, Córdoba, Spain, 4Policlinico S. Matteo – IRCCS Università degli Studi 
di Pavia, Pavia, Italy;, 5CHU Hôpital de Brabois, Vandoeuvre les Nancy, 
France, 6Univ.-Klinikum Heidelberg, Heidelberg, Germany, 7Novartis Pharma 
AG, Basel, Switzerland, 8 Az. Osp. S. Maria della Misericordia, Udine, Italy
Introduction: The proliferation signal inhibitor (PSI) everolimus signifi cantly 
reduces the incidence of acute rejection and graft vasculopathy in cardiac 
allograft recipients vs. azathioprine, due to its marked immunosuppressive and 
anti-proliferative effi cacy. Here we analyzed the immunosuppressive effi cacy 
of everolimus against the anti-metabolite MMF. 
Methods: In a 12-month, multicenter, open-label trial, de novo heart transplant 
patients were randomized to (i) everolimus (target trough level 3–8ng/mL) 
with reduced-exposure cyclosporine or (ii) MMF 1500mg b.i.d with standard-
exposure cyclosporine. All patients received corticosteroids and the majority 
received induction therapy. Primary endpoints were renal function and effi cacy 
(biopsy-proven acute rejection [BPAR] ISHLT ≥3A). 
Results: The intent-to-treat population comprised 176 patients (92 
everolimus, 84 MMF). Mean (SD) number of biopsies performed per 
subject, considering time at risk, was identical between groups: 11.5 (5.2) 
for everolimus and 11.2 (4.8) for MMF. 292 BPAR events were diagnosed 
in the everolimus group vs. 339 events in the MMF cohort. Overall, 3.17 
BPAR events/patient occurred in the everolimus arm, vs. 4.03 in the MMF 
arm, a difference of 0.862 (P=0.037 [t-test]). Twenty-one (22.8%) patients 
vs. 25 (29.8%) experienced BPAR ≥3A in the everolimus and MMF groups, 
respectively (P=0.005 for non-inferiority), with 7/21 (33.3%) vs. 10/25 
(40%) of these recipients suffering from recurrent rejection. The proportion 
of subjects who developed recurrent rejection of any grade was signifi cantly 
lower for the concentration-controlled everolimus arm (62.0%) vs. MMF 
(79.8%) (P=0.013, Fishers exact). 
Conclusions: Everolimus-based immunosuppressive therapy in cardiac 
transplant recipients offers excellent anti-rejection prophylaxis with numerically 
fewer BPAR episodes, and statistically fewer recurrent BPAR events, compared 
to MMF.
EFFICACY AND SAFETY OF EVEROLIMUS SWITCHING 911 
IN HEART TRANSPLANT RECIPIENTS. A MULTICENTER 
RETROSPECTIVE STUDY
N. Manito1, J.F. Delgado, M.G. Crespo, E. Roig, J.M.a Arizón, J. Segovia, 
F. González, S. Mirabet, E. Lage
1Hosp. Bellvitge, Hospitalet de Llobregat, Spain, 2Hosp. 12de Octubre, 
Madrid, Spain, 3Hosp. Juan Canalejo, A Coruña, Spain, 4Hosp. Clínic, 
Barcelona, Spain, 5Hosp. Reina Sofía, Córdoba, Spain, 6Hosp. Puerta de 
Hierro, Madrid, Spain, 7Hosp. Marqués de Valdecilla, Santander, Spain, 8 
Hosp. Santa Creu i Sant Pau, Barcelona, Spain, 9 Hosp. Virgen del Rocío, 
Sevilla, Spain
Background: Everolimus (EVR), a proliferation signal inhibitor (PSI) with 
immunosuppressive and anti-proliferative potential, signifi cantly reduces the 
risk of acute rejection and cardiac allograft vasculopathy (CAV) in cardiac 
transplant recipients. EVR works synergistically with calcineurin inhibitors 
(CNI) and thus allows the minimization of CNIs without compromising 
effi cacy.
Methods: The effi cacy and safety of EVR has been assessed in this observational 
retrospective study in 215 maintenance heart transplant recipients after 6 month 
from EVR introduction in the Immunosuppressive regimen. 
Results: The mean recipient age was 51.13 +/- 13,21; 84.7% males; mean time 
since transplantation was 8.27¡Ó4.4 years. Main reasons for switching to EVR 
were Nephrotoxicitiy due to CNIs (47%), CAV (33.5%) and Malignancies 
(27.4%). 
At baseline, 93.5% of patients were on CNI treatment, 70.6% of patients 
were on Cyclosporine (CsA) – mean C0 121.55 ¡Ó 54.52 ng/ml – and 29.4% 
on Tacrolimus (Tac) ¡V mean C0 8.07 ¡Ó 4.16 ng/ml -. Six months after the 
initiation of EVR, only 57% of the patients were treated with CNI: 65.4% with 
CsA – mean C0 84.16 ¡Ó 49.55 ng/ml – and 34. 6% with Tac – mean C0 
5.35 ¡Ó 2.23 ng/ml -. Mean CsA C0 blood levels were reduced by 30.87%, 6 
months after introduction of EVR. Mean EVR C0 blood levels at 1 week were 
6.91¡Ó4.7 and at 6 months 5.54¡Ó2.4 ng/ml. 
Renal function improved at 6 month post conversion to EVR (s-Creatinine: 
Baseline, 1.79¡Ó0.77; Month 6, 1.68¡Ó0.97; p< 0.05). Blood pressure remained 
stable during the observational period (Baseline 135.66 ¡Ó 21.08/83.77¡Ó12.15; 
Month 6 136.64 ¡Ó 21.65/84.64¡Ó12.72 mmHg). Total cholesterol increased 
from 179.47 ¡Ó 43.47 mg/dL to 188.19 ¡Ó 45.49 mg/dL p<0.05) 
In 20.9% of the patients treatment with EVR was withdrawn due to: oedemas 
40%, leucopoenia 13.3%, diahorrea 13.3%, dermatitis 11%, lung toxicity 6.6% 
and other causes 15.8%. A total of 7 rejection episodes („d 3A ISHLT grade) 
were recorded.
Conclusion: Switching immunosuppression to EVR is safe, with good 
effi cacy in maintenance heart transplant recipients. Renal function improved 
signifi cantly 6 months after conversion. EVR allows early reduction of CNI 
exposure without signifi cant loss of effi cacy.
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IMMUNOSUPPRESSION WITH EVEROLIMUS IN 912 
PEDIATRIC HEART TRANSPLANTATION
H. Lehmkuhl, S. Schubert, N. Hiemann, C. Knosalla, M. Dandel, M. Hübler, 
F. Berger, R. Hetzer
Deutsches Herzzentrum Berlin
Introduction: Everolimus (Eve) prevents acute rejection in adult heart 
transplant (HTx) recipients. Only limited data are available in pediatric patients. 
Everolimus was introduced to the immunosuppressive protocol at our center in 
June 2004. Therefore, we present the fi rst study of pediatric heart transplant 
patients with de novo use of cyclosporine A (CyA) in combination with Eve in 
comparison to children receiving CyA in combination with either azathiprine 
(AZA) or mycophenolate mofetil (MMF).
Methods: Pediatric HTx patients were analyzed with regard to acute rejection, 
chronic graft vasculopathy (CAV) at 1 and 2 years after HTx, renal function, 
PTLD, Ebstein-Barr-virus infaction, side-effects of their medication and 
survival. Through level monitoring was performed using mass spectrometry.
Results: 11 patients with CyA-Aza (group A), 15 patients with CyA-Eve 
(group B), 16 patients with CyA-MMF (group C) were investigated. Age, 
gender, median age and body weight were not signifi cantly different between 
the groups. Median posttransplant time was 9.7, 2.9 and 5.4 years (groups A, B 
respectively C). Rejection during the fi rst year occurred in 30%, 0% (p=0.02) 
and 49% of the patients (groups A, B respectively C). CAV at 12 months was 
detected in 2/11 patients of group A and none of the other groups. CAV at 2 
years was detected in 5/11, 1/15 and 6/16 (groups A, B respectively C). PTLD 
occurred in 5/11, 1/15 and 2/16 patients (groups A, B respectively C) with 
a median post-Tx manifestation after 3,6 years. In 3/15 patients, everolimus 
was interupted during months 1 to 3 post-Tx because of wound healing 
problems. Mean CyA-blood levels were comparable between the groups with 
125 (96-247), 111 (78-218) and 148 (91-293) ng/ml at all post-HTx times. 
Signifi cant hyperlipemia was present in 3 patients with CyA-Eve. 2 children 
on CyA-Eve were switched to CyA-MMF because of gastric problems and 
insuffi cient target blood levels of both CyA and Eve (target Eve blood levels 
3 – 8 ng/ml at all times). 
Conclusions: Everolimus is safe and well tolerated in pediatric HTx patients, 
with a lower incidence of acute rejection and CAV during the fi rst 2 years 
compared with patients receiving Azathioprine or MMF. The incidence of 
PTLD is lower, if compared with CyA-Aza patients only. Wound healing 
complications (20%) and enteral resorption problems were the major reasons 
for interruption of everolimus use.
SAFETY AND EFFICACY OF STATIN THERAPY 913 
IN PATIENTS SWITCHED FROM CYCLOSPORINE A TO 
SIROLIMUS AFTER CARDIAC TRANSPLANTATION
A. Zuckermann, A. Aliabadi, D. Dunkller, D. Zimpfer, S. Mahr, M. Grömmer, 
M. Grimm
Dept. of Cardiothoracic Surgery, Medical University Vienna
Introduction: Statins are an established therapy against hyperlipidemia 
after cardiac transplantation. However their interactions with CsA bear the 
danger of rhabdomyolysis. Srl is a novel immunosuppressive drug that has 
been used successfully in cardiac transplant patients. Yet it’s interactions 
with statins are similar to CsA. Furthermore, Srl increases lipid blood 
levels in transplant patients. The aim of the study was to evaluate the 
safety and effi cacy of statin therapy after switch from Csa- to Srl-based 
immunosuppression. 
Patients & Methods: 95 long-term patients were switched from Csa to Srl. 
All patients received also MMF ± steroid therapy. Reasons for switch were 
renal dysfunction (88%), graftvasculopathy (7%) and skin cancer (5%). 
Average patient age at switch was 59.9±9.8 years and 92% were male. Patients 
were switched 7.8±4.7 years after transplant. We retrospectively examined a 
total period of 12 months before until 12 months after switch (total of 1088 
patient-months). Safety evaluation consisted of regular measurements of 
CK-levels as well as evaluation of incidence of rhabdomyolysis (CK>1000), 
myositis (CK>500), CK elevation (>200)± myalgia. Moreover, hepatoxicity 
(AST >100, ALT >140) was closely monitored. Effi cacy analysis was 
performed by serial blood lipid assessments (LDL, HDL, total cholesterol, 
triglyzerides).
Results: 43(44%) of patients received atorvastatin, 28(29%) pravastatin 
and 28 (27%) received other drugs or were converted from one statin to 
another or were therapy was paused. There were a total of 29 cases of CK 
elevations (0.03 events/person-months (EPM). 19 cases were CK elevations 
>200 without clinical signs (0.02 EPM), 9 cases of myositis (0.008EPM) 
and 1 case of Rhabdomyolysis. Incidence of EPM was similar with between 
atorvastatin (0.03) and pravastatin (0.02). Treatment consisted of reduction 
or weaning of statins. Only four cases of hepatoxicity (0.003EPM) were 
detected during follow-up. Most Lipid blood levels increased signifi cantly 
in the total patient population after switch (cholesterol: pre: 192.9±38.6 vs. 
post:219.9±42.5, p<0.01; LDL: pre:107.9±35.6 vs. post:122.5±37.6, p<0.01; 
Triglycerides: pre:178.3±88.2 vs. post:221.7±138.7, p<0.01). Only HDL 
cholsterol remained unchanged (pre: 55.2±15.4 vs. post:56.3±13.3, n.s.). 
Blood lipid levels increased signifi cantly in patients no matter if they were 
treated with either atorvastatin or pravastatin. Only in patients in whom statin 
therapy was increased after switch (pre: 13.8±5mg vs. post 31.3±12.6mg; 
p<0.01), blood lipid levels remained similar to pre-switch levels (cholesterol: 
pre: 187.5±31.8 vs. post:221.6±59.8, p=0.07; LDL: pre:110.5±46.9 vs. 
post:128.6±48.2,n.s.; Triglycerides: pre:175.4±82.2 vs. post:180.2±80.6, 
n.s.).
Conclusion: Statin therapy after switch from Csa to Srl in long-term cardiac 
transplant patients is safe. However, blood lipids increase signifi cantly after the 
switch unless statin therapy is increased. There were no differences in safety 
and effi cacy between atorvastatin and pravastatin. 
IMPACT OF ACE-INHIBITOR AND ANGIOTENSIN 914 
RECEPTOR BLOCKER THERAPY ON DEVELOPMENT OF 
PROTEINURIA AFTER SWITCH TO SIROLIMUS IN CARDIAC 
TRANSPLANT RECIPIENTS
A. Aliabadi, E. Pohanka, D. Dunkler, S. Mahr, M. Grömmer, E. Wolner, 
M. Grimm, A. Zuckermann
Medical University of Vienna
Background: Switch to Srl due to renal impairment has been shown to be 
effective and safe after cardiac transplantation. However there have been 
reports of increased incidence of proteinuria (PU) after switch to Srl, associated 
with a further decrease of renal function. ACEi/ARB are used to treat PU in the 
non-transplant setting. The aim of this analysis was to examine if ACEi/ARB 
therapy has an infl uence on development of PU after switch to Srl.
Patients & Methods: Sixty-one long-term cardiac transplant patients were 
switched from CNI-based immunosuppression to Srl based IS 8.8±4.5 years 
after transplantation. Concomitant IS consisted of MMF ±steroids. Pre- and 
serial post-switch PU measurements were performed. Patients were divided 
into two groups (ACEi/ARB group vs. conventional antihypertensive therapy 
(CAT). Differences in development of PU and renal function were compared 
between both groups.
Results: Fifty-fi ve patients (89%) received anti-hypertensive medication. Of 
these, 58% were treated with ACEi (n=32) and 4 (7%) patients received a 
combination of ACEi/ARB. Overall PU increased signifi cantly from pre-switch 
0.13 g/d (range 0-5.7) to 0.23 (0-9.88) 24 months post switch (p=0.0024). 
There was no difference in PU between the two groups before switch (ACEi/
ARB: 0.13 (0-5.7) vs. CAT: 0 (0-4.98; p=ns). After 24 months of follow-up 
there was a signifi cant difference between the two groups (ACEi/ARB: 0.18 
(range 0-7.25) vs. CAT: 0.42 (0-9.88; p<0.05). Creatinin clearance (CC) was 
similar before the switch in both groups (ACEi/ARB: 48.8ml/min (20.6-132.1) 
vs. CAT: 40.6 ml/min (17.3-120.2; p=ns). After 24 months CC was better in the 
ACEi/ARB group (58.8 ml/min (6.6-184.6)) compared to the CAT group (44.7 
ml/min (10-84) p<0.05).
Conclusion: Development of proteinuria after switch to Srl can be signifi cantly 
reduced with the use of ACEi/ARB therapy. Antihypertensive therapy of 
patients should be changed to ACEi/ARB before Srl is initiated.
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RECIPIENT-DERIVED ADJACENT ENDOTHELIAL 915 
CELLS RECONSTRUCT THE STRUCTURE AND FUNCTION OF 
REJECTED CORNEAL ALLOGRAFT
N.Q. Gong1, U. Pleyer2, T. Ritter3,4, E. Knop2, X.P. Chen1
1Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science And Technology,Wuhan,China, 2Department 
of Ophthalmology, Charit¨¦ ¨C University Medicine Berlin, Germany, 
3Institute of Medical Immunology, Charit¨¦ ¨C University Medicine Berlin, 
Germany, 4Regenerative Medicine Institute, National University of Ireland, 
Galway, Ireland
Objective: To determine corneal allograft endothelial cell (EC) replacement 
and the origin of the regenerative ECs in response to rejection, and to deduce 
new strategy to clinical human corneal transplantation.
Methods: The rejection kinetics of untreated corneal allografts was observed 
in a MHC class I/II disparate DA-Lewis combination. The EC integrity 
of rejected allografts was compared with that of normal corneas. Then the 
transparency recovery of the rejected grafts was analyzed. The recovering 
grafts were collected at different time point after rejection for EC staining to 
clarify the EC replacement and the origin of the regenerative cells. To elucidate 
the infl uence of treatment on EC replacement, adenovirus-mediated nerve 
growth factor (AdNGF) was transfected into the grafts before transplantation. 
The rejection kinetics and EC integrity of the treated grafts were documented 
after transplantation and compared with that of untreated cases.
Results: All corneal allografts without treatment were rejected and their ECs 
shed. The rejected corneas recovered clear gradually. The re-constructed graft 
endothelium was covered by recipient-derived ECs raised from the adjacent 
host cornea but not from circulation-derived ECs. The AdNGF gene therapy 
protected the grafts against transplanted-trauma, and altered the rejection 
kinetics and the EC integrity.
Conclusions: Recipient-derived adjacent ECs reconstruct the structure and 
function of rejected corneal allograft, different from other kind of grafts. EC 
replacement represents a reparative response to injury rather than a constant 
mechanism of tissue maintenance dependant on the tissue-specifi city and the 
milieu where the graft survives. Initiation of host-derived EC proliferation, 
protection of graft ECs, inducing EC chimerism of graft and recipient, and 
surgery approach improvement could contribute to the corneal allograft.
POSTER BOARD NUMBER P1 – 02
DONOR FACTORS AFFECTING CORNEAL 916 
TRANSPLANTATION
D.J. Coster1, M. Philpott2, K.A. Williams1
1Flinders University, 2Flinders Medical Centre
There can be no transplantation without donors and the status of the donor 
tissue can affect graft survival. Australia is close to the top of the international 
corneal donation table (fourth highest) with 48 corneal donations per year per 
million population. The differences in donation rates and patterns of practice 
around the world are striking and demand analysis if donation rates are to 
increase. Examination of the pattern of eye banking practice in the Eye Bank 
of South Australia (64 donations per year per million) reveals the complex 
nature of the eye banking process. A large number of notifi cations yield a 
small number of donors. Various factors account for the drop out. Once the 
donations are procured, eye bank practices might affect the outcome of corneal 
transplantation. However, donor age, cause of death, or the time in storage 
(up to the accepted limits for a given corneal storage medium) do not affect 
corneal graft survival. These fi ndings have served to increase the size of the 
potential donor pool, so that waiting times for corneal transplantation are 
low and the majority of procedures are performed on an elective basis. With 
an increased donor pool and more effective identifi cation of donors, we are 
rapidly approaching the point where there will be more donors than recipients. 
This will present ethical issues not previously encountered.
POSTER BOARD NUMBER P1 – 03
LENTIVIRAL GENE TRANSFER TO THE RAT CORNEA917 
S.L. Brice1, L.A. Mortimer1, C. Tan2, D.S. Anson2, H.M. Brereton1 and 
K.A.Williams1
1Department of Ophthalmology, Flinders University, Adelaide Australia; 
2Department of Genetic Medicine, Women’s and Children’s Hospital, 
Adelaide, Australia.
Background: The leading cause of human corneal graft failure is irreversible 
rejection. The cornea is ideal for gene transfer because it can be treated ex vivo 
prior to transplantation to prevent graft rejection. Lentiviral vectors provide 
stable, long term gene expression and have minimal immunogenicity. 
Aims: To explore the use of monogenic and multigenic lentiviral vectors in the 
rat cornea as a method of gene delivery. 
Methods: VSVG-pseudotyped HIV-1 lentiviral vectors were constructed. All 
expression cassettes were driven by the simian virus type 40 early promoter. 
Two monogenic lentiviral vectors were constructed. One such vector, LV-
CD4scFv, encoded a secreted protein, an anti-CD4 scFv antibody fragment 
and the other LV-eYFP, encoded the intracellular reporter gene, enhanced 
yellow fl uorescence protein (eYFP). A multigenic lentiviral vector, LV-
CD4scFv_F2A_eYFP, was assembled which contained the anti-CD4 scFv 
and eYFP. Genes were linked by a self-cleaving 2A sequence derived from a 
picornavirus. A furin cleavage site was situated upstream of 2A for removal of 
the remaining residues attached to the second protein in the cassette. The furin 
2A (F2A) sequence enabled expression of both genes by a single promoter. To 
monitor gene expression, HEK-293A cells and rat corneas were transduced 
with the lentiviral vectors. Anti-CD4 scFv expression was measured using 
fl ow cytometry on rat thymocytes and eYFP expression was assessed using 
fl uorescence microscopy. 
Results: Anti-CD4 scFv expression analysis: HEK-293A cells were transduced 
with the lentiviral vectors and fl ow cytometry on rat thymocytes was performed 
to detect the anti-CD4 scFv in the culture supernatant. After 6 days in culture, 
HEK-293A cells transduced with LV-CD4scFv and LV-CD4scFv_F2A_eYFP 
had produced 17 ng/ml and 47 ng/ml of anti-CD4 scFv respectively. Rat 
corneas were transduced with LV-CD4scFv_F2A_eYFP and organ cultured in 
vitro. After 6 days in organ culture, 29 ng/ml of scFv was detected in the culture 
supernatant. EYFP expression analysis: HEK-293A cells were transduced 
with lentiviral vectors and eYFP expression was observed using fl uorescence 
microscopy. EYFP was expressed by 27% of the HEK-293A cells transduced 
with LV-eYFP, whilst eYFP was expressed in 2% of HEK293A cells transduced 
with LV-CD4scFv_F2A_eYFP. Rat corneas were transduced with lentiviral 
vectors and organ cultured in vitro for up to 6 days. Fluorescence microscopy 
revealed that LV-eYFP transduced corneas showed eYFP expression in 50% 
of the corneal endothelium (n=3) and that one out of fi ve rat corneas that were 
transduced with LV-CD4scFv_F2A_eYFP showed detectable eYFP expression 
in the corneal epithelium. No eYFP expression was detected in the endothelium 
of any of the LV-CD4scFv_F2A_eYFP transduced corneas. 
Conclusion: The presence of the F2A sequence did not affect the expression of 
anti-CD4 scFv. Anti-CD4 scFv is the fi rst gene in the expression cassette and 
is situated before the F2A self-cleaving sequence. However, the F2A sequence 
may be affecting expression of the second gene in the expression cassette, 
because eYFP expression was lower in HEK-293A cells and rat corneas 
transduced with LV-CD4scFv_F2A_eYFP compared with LV-eYFP.
POSTER BOARD NUMBER P1 – 04
DEMENTIA AS AN EXCLUSION TO TISSUE DONATION918 
A. Jack1, N. Nuttall2, L. Hirst3
1Queensland Eye Bank, 2Queensland Eye Bank, 3Medical Director 
Queensland Eye Bank, Queesland Eye Institute
The risk of transmission of potentially fatal infectious diseases from donor 
to recipient via tissue transplantation cannot practically be eliminated, but 
must be minimised. Careful screening of potential and actual donors is the 
major available tool to achieve this. Screening usually involves investigation 
of patient medical records and histories for not only diagnoses, but 
risk factors or markers for disease as well. Dementia is one such marker 
identifi ed by tissue banks as it is one of the few indicators of Creutzfeldt-
Jakob Disease (CJD). However, CJD accounts for only a very small and 
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decreasing percentage of dementia cases in Australia. Disease processes 
that are believed to be non-infectious in origin, and therefore safe in a tissue 
transplantation context, such as Alzheimer’s and vascular dementia, cause 
the vast majority. In addition, dementia as a diagnosis is extremely common 
in the potential donor population. The current screening strategy employed 
by the Queensland Eye Bank (QEB) involves the exclusion from donation 
of individuals in which there is any uncertainty about the aetiology of their 
dementia, and this decision is often based on limited information. In 2007, 
of the 4053 death notifi cations received by QEB, 3575 were not considered 
suitable for donation, many because of dementia. This demonstrates that 
QEB uses a conservative risk management procedure and while it approaches 
a zero risk of CJD transmission, it also causes the exclusion of individuals to 
a level which is out of proportion to the prevalence of CJD in the potential 
donor population in Australia.
POSTER BOARD NUMBER P1 – 05
DONOR REGISTERS AND EYE DONATION; FUTURE 919 
USE AND COMPARISON WITH ORGAN DONATION
P.W. Madden
Queensland Eye Institute, 41Annerley Road, South Brisbane. QLD 4101. 
Australia.
Context: Many countries have registers to allow individuals to record their 
intent or consent for organ donation following death and these usually also 
have provision to include donation of eyes and tissues. There are many 
more eye donors compared with organ donors e.g. 5 to 1 in Australia. 
This means that Eye Banks are usually the largest users of registers, but 
government campaigns to support registers often focus on organ donation 
because of the chronic shortage of organs. Furthermore: campaigns may 
not adequately address the concerns and fears of eye donors; the primary 
age group may differ between eye and organ donation; and the method of 
approach is usually by telephone which may require different use of the 
register.
Objectives: To review the way in which the Australian Organ Donor Register 
(AODR) and other registers are, 1) being used for potential eye donors and how this 
differs from organ donation. 2) To assess how information from registers should 
best be used with next of kin of potential eye donors. 3) How use of registers may 
change with this sector and 4) how the use of registers could be improved.
Design: Statistics of the proportion of matches on organ donor registers for 
those to be approached for eye donation was reviewed and this was compared 
with similar available information on potential organ donors.
Results: National statistics were not readily available in Australia. The 
percentage of potential donors who were registered on the AODR, where 
the next of kin were approached, varied between Australian states. The 
percentage relied upon the degree of deliberate selection for registrants e.g. 
< 11% in Queensland were registered whereas in South Australia over 50%. 
In the UK the proportion approached was almost one third and this was the 
same as with organ donors, which suggests little selection. In Queensland 
the percentage of registered potential donors over 65 years old was even 
lower than for those of younger age, despite the majority of donors arising 
from the older group. It was noted that surgeons often express a preference 
for younger donors, even though there has been no demonstrated increase 
in outcomes.
Conclusions: Registers can have value to aid consent, but the proportion of 
those registered is generally low without deliberate selection. Some Eye Banks 
already select heavily based on registration status. Selection is expected to 
increase along with a rise in consent registration, especially with older donors.
Eye Banks should have written policy to: always check available registers of 
notifi ed cases; follow these cases in preference to non-registered cases; advise 
donor families of the register record and the method of such interaction; review 
statistics of the success of using the register. Use of registers for eye donation 
differs to that of organ donation, but good management of both sectors will be 
benefi cial to all donation for transplantation.
STEM CELLSCONCURRENT ORAL SESSION 72: 
POSTER BOARD NUMBER P1 – 06
APPROACHES TO AVOIDING IMMUNE RESPONSES 920 
TO REPEATED INJECTIONS OF ALLOGENEIC UMBILICAL 
CORD TISSUE-DERIVED CELLS
B. Lutton1, P. Cho1, E. Hirsh1, K. Ferguson1, A. Teague1, N. Chi2, 
S. Goldman2, D. Messina2, S. Popma2, D. Sachs1, C.A. Huang1
1Massachusetts General Hospital, 2Centocor R&D Inc.
Cellular treatment for repairing diseased tissues is a promising clinical strategy. 
Using porcine umbilical cord tissue-derived cells (pUTC) obtained from the 
Massachusetts General Hospital swine leukocyte antigen (SLA) -defi ned 
miniature pigs, we previously demonstrated that these cells can induce an 
immune response under certain conditions. Although a single subcutaneous 
injection of SLA-mismatched pUTC did not induce a detectable immune 
response, when injected in an infl amed region, injected repeatedly in the same 
region at one month intervals or stimulated with IFN-¦Ã prior to injection, 
pUTC were immunogenic. Since clinical cellular repair strategies may involve 
repeat dosing of cells to achieve a lasting therapeutic benefi t, in the current 
study we examined approaches to avoid an immune response to repeated 
injections of SLA-mismatched pUTC. pUTC derived from umbilical cords 
of SLAdd miniature swine were injected subcutaneously into SLA-disparate 
animals. Two animals were injected twice, in a separate site, with one month 
between injections. Four animals received two injections of pUTC in the same 
site with the second doses at 3 month (n=2) and at 6 month (n=2) time intervals. 
Four animals received immunosuppression prior to injections one month apart 
consisting of either Prednisolone at the time of the second dose (n=2). or 
Prednisolone plus Cyclosporine A at the time of both doses (n=2). To assess 
for sensitization, animals were evaluated by fl ow cytometry for detection of 
serum allo-antibody (SLAdd IgG) in vitro. Animals injected twice without 
immunosuppression either in a separate site one month apart or in the same site 
up to 6 months apart demonstrated rapid SLAdd IgG production within a week. 
Delayed and decreased IgG production was observed in one of two animals that 
received repeated injections of pUTC one month apart with Prednisolone at 
the time of the second dose, while no SLAdd IgG could be detected in animals 
receiving repeated injections of pUTC one month apart with Prednisolone 
and Cyclosporine A administration at each dose. To assess for sensitization in 
vivo, a pUTC haplotype-matched SLAdd skin graft was placed at least 30 days 
following the second pUTC injection. Visual assessment and histopathological 
analysis of grafts demonstrated an accelerated tempo of rejection in animals 
that produced SLAdd IgG following the second dose of pUTC, while animals 
that received Prednisolone and Cyclosporine A administration at each dose 
showed rejection identical to na&iuml;ve control animals. In this study it was 
confi rmed that the primary injection does not induce a measurable immune 
response as assessed by standard immunological methods. However, repeated 
subcutaneous injection of pUTC into a disparate site or delayed administration 
of pUTC in the same site for up to 6 months elicits a rapid secondary immune 
response and accelerated graft rejection, suggesting that animals are sensitized 
by the fi rst injection. The observed immune responses were successfully 
prevented by concurrent immunosuppression with each dose of pUTC. These 
studies may provide important considerations and guidelines for clinical 
protocols utilizing cellular therapies.
POSTER BOARD NUMBER P1 – 07
DONOR DERIVED MESENCHYMAL STEM CELLS AND 921 
THEIR SUSCEPTIBILITY TO IMMUNOSUPPRESSANTS
M. Hoogduijn1, M. Crop1, S. Korevaar1, A. Peeters1, A. Balk2, L. Maat2, 
W. Weimar1, C. Baan1
1Dept of Internal Medicine, Erasmus Medical Center, 2Thorax Center, 
Erasmus Medical Center
Introduction: Mesenchymal stem cells (MSC) are present at many body sites 
and have tissue repair and immunosuppressive capacities. They have potential 
for various therapeutic applications, such as repair of injured organs and 
control of allograft rejection. We isolated MSC from human cardiac allografts 
before and after transplantation and investigated their origin and susceptibility 
to immunosuppressants.
Methods: MSC were expanded from atrium tissue before heart transplantation 
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and from endomyocardial biopsies taken up to 6 years after transplantation. 
After expansion in culture, the MSC were phenotypically and functionally 
examined. Pre-transplantation heart MSC were exposed in vitro to therapeutic 
doses of the immunosuppressive drugs tacrolimus, MPA and rapamycin, 
whose targets are expressed in MSC, and toxicity, apoptosis, proliferation, 
differentiation and immunosuppressive characteristics examined.
Results I: MSC isolated from endomyocardial biopsies from the human 
heart taken up to 6 years after transplantation were of donor origin; we found 
no evidence for recipient MSC in endomyocardial biopsies. There was no 
change in MSC phenotype, immunosuppressive capacity or cardiomyogenic 
differentiation ability after heart transplantation, but MSC showed reduced 
adipogenic and increased osteogenic differentiation capacity.
Results II: In culture, treatment of pre-transplantation MSC with therapeutic 
concentrations of tacrolimus, MPA and rapamycin did not induce toxicity or 
apoptosis. MSC proliferation was not affected by tacrolimus, but was strongly 
inhibited by MPA and rapamycin. The immunosuppressants furthermore 
affected MSC differentiation; tacrolimus and MPA reduced osteogenic 
differentiation, whereas rapamycin induced adipogenic differentiation. Pre-
incubation of MSC with the immunosuppressants had no effect on the capacity 
of MSC to inhibit mixed lymphocyte reactions.
Conclusion: MSC of donor origin remain present in donor hearts at least 6 
years after transplantation. Their functionality changed after transplantation, 
possibly caused by effects of immunosuppressive medication. These results 
demonstrate that heart-resident MSC are responsible for repair processes of the 
heart for at least several years. Side effects of immunosuppressants may relate 
to their effects on transplanted and patients’ own MSC.
POSTER BOARD NUMBER P1 – 08
NOVEL APPROACH FOR IDENTIFICATION OF 922 
KERATINOCYTE STEM CELLS
W.L. Olszewski1,2,3, E. Sinkiewicz-Darol1, A. Domaszewska1, M. Zaleska1,
1Department of Surgical Research & Transplantology, Medical Research 
Center, Polish Academy of Sciences, Warsaw, Poland 2Central Clinical 
Hospital, Ministry of Internal Affairs, Warsaw, Poland 3The Norwegian 
Radiumhospital- Rikshospitalet, Oslo, Norway
Rationale: We documented that human skin preserved in anhydrous 
pulverized sodium chloride for months and transplanted to skin mice and 
humans is taken by the recipient (Transplantation 2006; 81: 1583-1588). 
The grafts were characterized by aggressive proliferation of keratinocytes 
(KC) seen on immunohistochemical section stained for BrdU. Clinically 
there was evident hyperkeratosis. We also noticed that dehydration in 
sodium chloride stopped proliferation of keratinocytes, and subsequent 
rehydration and transplantation brought about restarting of mitoses. This 
model allowed to identify cells that fi rst undergo mitosis after contact with 
the recipient. The question arouse whether these cells might be the spore-
like stem cells? 
Materials & methods: Fragments of normal human leg skin harvested during 
elective vascular surgery were preserved in anhydrous pulverized sodium 
chloride. After 7 to 30 days they were rehydrated, the epidermis was separated 
and KC were isolated. They were cultured for 7 and 21 days. Viability of 
cultured KC was tested in Live/Dead Viability/Cytoxicity test. BrdU was added 
to culture medium. Flow cytometry was used for characterization of mitotic 
cells. 
Results: The morphological shape of KC was totally preserved. Cells from 
all 5 epidermal layers could be identifi ed. Among the whole population single 
large cells resembling by shape those from stratum spinosum and granulosum 
revealed full enzymatic activity. No cells with other shape revealed this 
property. Since in culture KC change their shape it was not possible to 
objectively identify their site of origin. These cells slightly incorporated 
BrdU whereas other KCs did not. Further identifi cation of this population 
is needed. 
Conclusions: Preservation of KC in anhydrous pulverized sodium chloride 
doesn’t stop some single cells’ to display enzymatic activity upon setting 
in culture. The descibed method may help to identify KC of highest 
capacity providing progenies probably belonging to the so called spore-like 
stem cells.
POSTER BOARD NUMBER P1 – 09
INTERSTITIAL CELLS EXPRESSING THE CARDIAC 923 
DIFFERENTIATION MARKER GATA4 INCREASE 
FOLLOWING TRANSPLANTATION BUT DO NOT 
CONTRIBUTE TO CARDIAC REGENERATION
A. Dedja1,2, T. Zaglia3, C. Candiotto3, S. Bracco3, E. Ancona1,2,4, 
S. Schiaffi no3,5, S. Ausoni3, E. Cozzi1,2,4
1Dept. of Surgical And Gastroenterological Sciences – University of Padua, 
2CORIT, 3Dept. of Biomedical Sciences, 4Padua General Hospital, 5Venetian 
Institute of Molecular Medicine
Introduction: The heart is a terminally differentiated organ and is unable 
to regenerate after tissue damage. In the last years, several studies have 
been performed to identify a suitable stem cell population for a cell-based 
regenerative therapy. The cardiogenic properties of adult extra-cardiac and 
cardiac stem cells have been considered, but there are still confl icting results 
about their ability to provide an effi cient de novo cardiogenesis. Recent studies 
have demonstrated the possibility to convert adult cells of mesenchymal origin, 
such as pericytes and skin fi broblasts, into differentiated specialized cells, such 
as myoblasts, neurons and cardiomyocytes.
Material and Methods: Cardiac interstitial cells were studied both in the 
native heart and in heterotopically transplanted cardiac allografts in the rat. 
Sprague-Dawley wild type (n=35) and GFP+ transgenic rats (n=35) were used 
as heart donors and recipients, respectively. In this model, previously used by 
our group to study cardiac regeneration mediated by extra-cardiac circulating 
progenitor cells, transplanted hearts undergo immunological rejection, ischemia-
reperfusion damage and progressive atrophy. Heart allografts were retrieved 15 
(n=26) and 90 (n=9) days after surgery and tissue sections were analyzed by 
immunofl uorescence using specifi c antibodies for cell differentiation markers.
Results: In native hearts we identifi ed a considerable population of GFP+ 
interstitial cells expressing GATA4 and MEF2C, two transcription factors 
expressed in cardiomyocytes during development and adulthood. These cells 
were predominantly cardiac fi broblasts and pericytes. In addition, a minor cell 
population co-expressed GATA4 and the stem cell marker nestin (8 cells/section) 
and may therefore represent an endogenous cardiac stem cell population. 
The number of GATA4+ cells increased up to 5-fold in cardiac allografts, as 
compared to normal hearts, but did not convert into mature cardiomyocytes. 
The majority of GATA4+ cells proliferated as fi broblasts and myofi broblasts of 
remodelling tissue. The number of GATA4+/nestin+ cells was also signifi cantly 
higher in the allografts (45 cells/section in 15 days allografts). However, we 
never identifi ed small GATA4+ interstitial cells co-expressing markers of 
cardiac maturation, such as sarcomeric proteins. Interstitial cells, isolated from 
both native hearts and cardiac allografts, were cultured and stimulated with 
5-azacytidine, dexametasone, adult and embryonic cardiac tissue extracts. In 
no case did we observe differentiation into cardiomyocytes or smooth muscle 
cells.
Conclusion: Adult hearts home interstitial cells that already express 
early markers of cardiac differentiation but are refractory to spontaneous 
differentiation into cardiomyocytes. We aim at devising molecular strategies 
to allow their conversion into specialized cardiac cells using cardioinductive 
factors, as reported for fi broblasts of other sources.
POSTER BOARD NUMBER P1 – 10
EVALUATION OF AN HEPATOCYTE CELL LINE 924 
DERIVED FRON HUMAN AMNION STEM CELL
I. Tabei1, T. Nakahara2, O. Ishiwata3, Y. Ishida1, A. Ohyama4,5, K. Yanaga1, 
H. Ishikawa2,4
1Jikei University School of Medicine Deparment of Surgery, 2Nihon Dental 
University Dept. of Embryology and Regenerative Medical Science, 3Ishiwata 
Gynecological and Oncological Hospital, 4Nihon Dental University 
Laboratory of Regenerative Medical Science, 5ALOKA CO.,LTD
Aim: Although liver transplantation has become the ultimate therapy for 
hepatic failure patients, the lack of absolute donor organ has yet to be solved. 
One solution is the development of transplantable hepatocytes. The metabolic 
characteristics of hepatocytes (HEAC-2L cell) derived from the human amniotic 
membranes is clarifi ed. Also the cells were transplanted into chemically 
induced liver failure rats (CILFR) to confi rm function and adaptation. This 
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material was focused to solve ethical problems in producing hepatocyte from 
human origin materials.
Methods: From human amniotic membrane of early embryo, colonies of 
small spherical cell were cultured and collected as human amniotic membrane-
stem cell (HEAC-2 cell). Further differentiation in a circumfusion apparatus 
an hepatic cell line (HEAC-2L) was derived. HEAC-2L cells were cultured 
in collagen type 1 to characterize. Also CILFR were produced by carbon 
tetrachloride. HEAC-2L cells were transplanted into the spleen to observe the 
blood serum levels of prothrombin time (PT). ammonium (Anm) and bilirubin 
(TBil) as well as survival rate.
Results: HEAC-2L cell have contact inhibition, showed long term stable 
phenotype. Within the collagen sponge 3-dimention culture the cells produced 
albumin, a typical characteristic of an hepatocyte. Transplanted into the spleen 
of CILFR, it improved PT, Anm and TBil. Also survival rate improved from 
33 to 85%.
Conclusion: An albumin producing hepatocyte cell line was successfully 
derived from human amniotic membrane. With less ethical problems compared 
to ES cell, this resource may make an ideal material for artifi cial organ and cell 
transplantation.
POSTER BOARD NUMBER P1 – 11
CHEMOKINE EXPRESSION IN INFARCTED 925 
MYOCARDIUM AND COGNATE INTERACTION WITH 
CHEMOKINE RECEPTORS EXPRESSED IN MESENCHYMAL 
STEM CELLS
K. Atkinson1, K. Kollar1, G. Brooke1, C. Blair2, I.M. Ahmed2, M.P. Feneley2
1Mater Medical Research Institute, 2Victor Chang Cardiac Research Institute
The ability of a therapeutic cell therapy to aid the recovery of heart muscle is of 
great signifi cance, as heart muscle shows poor recovery after acute myocardial 
infarction and morbidity and death are common. Mesenchymal stem cells 
(MSC) are adult-derived cells that have multipotent lineage potential and an 
immuno-privileged status with therapeutic potential for repair of tissue injury. 
They have been shown in preclinical studies to improve myocardial function 
after infarction (1). Bone marrow-derived MSC migrate to sites of infl ammation 
in preference to bone marrow (3). However, the molecular mechanisms for 
this are currently unknown (2, 3, 4). After myocardial ischaemia chemokines 
including CXCL12 (stromal cell-derived factor [SDF-1]). macrophage 
infl ammatory protein (MIP) -1α/β, interleukin (IL) -8, CX3CL1 (fractalkine) 
and CCL5 (RANTES) are released and their expression is up-regulated in the 
heart (2).
We have utilised a murine myocardial infarction/reperfusion model and 
extensively analysed chemokine expression by fl ow cytometry and qRT-PCR. 
Expression of CXCL12, CCL4, CCL5, CCL8, CCL19, CCL25 and CCL27 
was signifi cantly up-regulated at 24 hours after myocardial infarction, thus 
identifying an important time point for potential therapeutic intervention with 
MSC. Furthermore, we have shown that MSC express surface and cytoplasmic 
chemokine receptors for CXCR4 (the receptor for CXCL12) CCR1, CCR7, 
CCR9, CCR10 and CCR11. Thus, MSC express specifi c chemokine receptors 
for the up-regulated chemokines, suggesting binding pairs which could 
be important in controlling preferential MSC migration and lodgement in 
infarcted myocardium. Upon treatment with IFN-γ, MSC showed to have 
up-regulated receptor expression of CXCR4, CCR1, CCR3 and CCR11 at 
the mRNA level, proposing increased migration effi ciency of MSC. MSC 
migration will be tested further using peptide agonists and antagonists in vivo 
and in vitro.
Another pathway which we postulate important in MSC migration is CD44 
and its receptor hyaluronic acid (HA). We have shown that the expression of 
CD44H isoform is expressed in MSC. CD44KO/GFP mice have been developed 
and will be used to test further the CD44/HA pathway in MSC migration to 
ischaemic myocardium.
POSTER BOARD NUMBER P1 – 12
EXPRESSION OF MARKERS CHARACTERISTIC 926 
FOR HUMAN KERATINOCYTE STEM CELLS UNDER THE 
INFLUENCE OF HUMAN LYMPH AND SERUM
A. Domaszewska1, M. Zaleska1, W.L. Olszewski1,2,3
1Department of Surgical Research & Transplantology, Medical 
Research Center, Polish Academy of Sciences, Warsaw, Poland 2Dept. of 
Transplantation Surgery, Central Clinical Hospital, Ministry of Internal 
Affairs, Warsaw, Poland
3The Norwegian Radiumhospital-Rikshospitalet, Oslo, Norway
Previous study performed in our department, using ELISA method, revealed a 
large number of growth factors, cytokines and chemokines in the human lymph 
fl uid. Moreover, we found that leg skin expressed more cells with stem cells 
antigens in comparison to other regions. Progenitor/stem cell populations of 
epithelium are known to reside in the small-sized cell population. Small-sized 
cells demonstrated the highest colony-forming effi ciency, and a highest long-
term proliferative potential. This observations prompted us to study the effect 
of lymph on proliferation potential of human epidermal cells in vitro.
Aim: To study the effect of human peripheral lymph and serum on the number 
of keratinocyte stem cells detected in the in vitro culture. The expression of 
markers characteristic for human keratinocyte stem cells, colony-forming 
effi ciency, and long-term proliferative potential allow us to determine the 
differences between observed cells populations.
Methods: Skin sections were stained using monoclonal antibodies against: 
p63, CD29 (ß-integrin) as well as CD34 and were analyzed using confocal 
microscopy and compared with healthy control. Keratinocytes were isolated 
from three parts of human extermity of different proliferative potential: sole, 
foot and groin. Cells were cultured in various concentrations of lymph and 
serum (100%, 50%, 20% of lymph and the same dilutions of serum). Lymph 
contained IL -1, IL- 6 TNF-α, KGF, EGF, VEGF, TIMP -1, TIMP-2 at levels 
signifi cantly higher levels than serum. Control cells culture were conducted in 
medium RPMI with 5% fetal bovine serum. To identify cytokines responsible 
for KC proliferation IL- 6, TNF -α, KGF and VEGF were blocked with 
neutralizing antibodies. After 1 and 7 days of culture the phenotypes were 
studied using monoclonal antibodies against CD34, p63 (stem cells). CD29 
(transient daughter cells) using confocal microscopy. Furthermore, the colony 
– forming cells were observed and proliferative potential was measured by 
detection of the markers of differentiation Ki67 and PCNA in confocal 
microscopy. Additionally BrdU incorporation rate was estimated after 7 days 
of culture using fl ow cytometry analysis. 
Results: Seven day lymph culture revealed increased number of p63 and CD29 
positive cells compared with cells cultured in RPMI with 5% FCS. There were 
no differences in expression of CD34 marker. Moreover, there was increased 
number of dividing cells in cultures supplemented with lymph.
Colony-forming effi ciency was the highest in cultures with 20% lymph 
concentration. 
Conclusion: Cells cultured in lymph expressed increased number of stem cells 
markers and the proliferating rate was also increased. Lymph cytokines and 
growth factors are participating in keratinocyte proliferation and are probably 
responsible for high number of presumptive keratinocyte stem cells.
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EFFECT OF AUTOLOGOUS BONE MARROW STEM 927 
CELLS MOBILIZATION ON INFRACTED CARDIAC 
FUNCTION
Z. Shen1, G. Yu2, Y. Hu3, M. He4, H. Huang5, Y. Yu6
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University, 4The First Affi niatied Hospital of Soochow University, 5The First 
Affi niatied Hospital of Soochow University, 6The First Affi niatied Hospital of 
Soochow University
Objectives: To study the effect of mobilization of autologous bone marrow 
stem cells on cardiac function after myocardial infarction.
Methods: 20 healthy Taihu Meishan swines were divided into four groups 
randomly to create the model of myocardial infarction. A group: control, B 
group: injected G-CSF for 5 days 3 hours after myocardial infarction. C group: 
Poster Abstracts Monday 11 August 2008
3 2 3
M
O
N
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
injected G-CSF for 5 days 1 week after myocardial infarction. D group: injected 
G-CSF four weeks after myocardial infarction. Changes of indexs of cardiac 
function were observed with MRI,Doppler£¬ VEGF and TGF-©¬ levels of 
blood serum were detected in different period after mobilized. 
Results: Compared with other groups£¬left ventricular function was 
signifi cantly improved in B group. 
Conclusions: Mobilization of autologous bone marrow stem cells immediately 
after myocardial infarction was effective£¬ feasible and safe to thearpy 
ischemic heart disease.
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TIME-WINDOW OF TRANSPLANTING AUTOLOGOUS 928 
BM-MSCS TO TREAT MYOCARDIAL INFARCTION
Z. Shen1, S. Guo2, M. He3, Y. Chen4, P. Jiao5, H. Huang6
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University, 4The First Affi niatied Hospital of Soochow University, 5The First 
Affi niatied Hospital of Soochow University, 6The First Affi niatied Hospital of 
Soochow University
Background: Myocardial infarction (MI) remains a major healthcare problem. 
Although modern medical therapy has improved its outcome, the mortality 
and morbidity rates are still very high. Recently, stem cell therapies have been 
proposed as an alternative for the treatment of MI on the basis of the damaged 
cells’replacement or enhanced regeneration of vessels. The aims of this study 
were to assess the consequence of the delay between injury and autologous bone 
marrow mesenchymal stem cells (bMSC) transplantation on the cardiac function 
in the swine model of MI and to explore the corresponding mechanism.
Methods: Thirty healthy Taihu Meishan swines were randomized into six groups 
(n=5). Myocardial infarction models were then established by embolization 
in the distal end of the left anterior descending branch (LAD) with a gelatin 
sponge through cardiac catheter. 30 milliliter bone marrow was aspirated from 
the postero-superior iliac spine and bMSCs were isolated and cultured for 
transplantation. swine¡¯s hearts were acquired 8 weeks after transplantation, 
Ultrasound cardiography, Magnetic resonance imaging and immunochemistry 
were performed to detect the cardiac function and bMSCs engraftment 
Results: Compared with the control group, indexes of cardiac function 
including EF, LVEDD, LVESD, infracted size, vascular density and VEGF 
levels were improved in experimental groups underwent bMSCs transplantation 
2 and 4 weeks after MI, and the improvement was more obvious in the group 
underwent transplantation 4 weeks after MI than that underwent transplantation 
2 weeks after MI .There were more engraftment cells in the group underwent 
transplantation 4 weeks after MI than other groups and no engraftment cells in 
the group underwent transplantation 3 hours after MI.
Conclusions: The therapeutic effect of bone marrow mesenchymal stem cells 
transplantation 4 weeks after MI is superior to that of 2 weeks and 3 hours after 
MI, the results strongly suggest that the optimal time window for stem cell 
therapy is after the early phase of the ischemic injury.
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BONE MARROW MONONUCLEAR CELL FRACTION 929 
CAN RETARD/STABILIZE PROGRESSION OF CHRONIC 
KIDNEY DISEASE IN RATS
M. Abbud-Filho1,2, H. Caldas1, I. Fernandes1, H. Ramalho1,2, M.A. Baptista1, 
D. Braile1, 
R. Kawasaki1, E. Bertelli1, E. Bertolli1
1Medical School of Sao Jose do Rio Preto, 2Instituto de Urologia e Nefrologia
The therapeutic potential of adult stem cells in the treatment of chronic diseases 
is becoming increasingly evident over the last few years. In the present study, 
we sought to assess whether the infusion of bone marrow derived mononuclear 
cells (MoSC) and mesenchymal cells (MSCs) could reduce/stabilize the rate of 
progression of chronic renal failure (CRF) in rats. 
Methods: We used the 5/6 renal mass reduction model to induce chronic renal 
failure in male Wistar rats. Renal function was assessed by measurements of 
serum creatinine (sCr). creatinine clearance (Clcr). and 24h proteinuria (PT24h) 
at baseline, days 60 and 120 after surgery. MoSC and MSCs were obtained 
from bone marrow aspirates and separated by the Ficoll-Hypaque method. 
After a 12 to 14 day culture period, 1.5x106 MSCs and the same amount of 
MoSC were injected intra renal parenchyma in the remanent kidney of rats with 
CRF at day of surgery. 
Results: In the control group, at day 120, the results were sCr= 1.31 ± 0.5mg/
dl, Clcr= 0.64±0.35ml/min, and PT24h= 140 ± 57.7mg/24h. Rats treated with 
MoSC at day 120 had sCr=0.81 ± 0.20mg/dl, Clcr= 1.05 ± 0.26ml/min, and 
PT24h= 61 ± 46.5mg/24h, while rats injected with MSC had sCr=0.95 ± 
0.1mg/dl, Clcr= 0.68 ±0.24ml/min, and PT24h=119.2 ± 50.0mg/24h. Analysis 
of the progression to CRF did show that treatment signifi cantly reduced the rate 
of decline in Clcr after treatment with MoSc (Control: – 0.0049 ± 0.0024ml/
min/day vs MSC: -0.0013 ± 0.0017ml/min/day vs MoSC: +0.0002 ± 0.0016ml/
min/day; p= 0.017). PT24h tended to be lower in treated groups. Histological 
scores of chronic damage were not different but distinct patterns of chronic 
lesions were observed in treated rats. 
Conclusion: Our results did show that progression of CRF in rats could be slowed/
stabilized by intra renal parenchyma injection of MoSC. A trend toward reduction 
in the progression rate of CRF was also observed with injection of MSC.
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RENAL PROGENITER LIKE TUBULAR EPITHELIAL 930 
CELLS CUTUED FROM INITIAL URINE INCLUDING THE 
EXFOLIATED CELLS FROM TRANSPLANTED KIDNEYS
R. Hattori1, T. Yamamoto1, T. Sugaya2, E. Noiri3, M. Gotoh1
1Department of Urology, Nagoya University School of Medicine, 2Center for 
Developmental Biology, Kobe, 3Department of Nephrology, Tokyo Univesity 
School of Medicine
Object: Mitotic cells are known to appear in post -ischemic kidneys and 
contribute to the recovery of renal function and structural restoration of 
tubules. We successfully isolated these progenitor cells from the initial urine 
of transplanted kidneys.
Material and Method: The urine sample including exfoliated cells was 
collected from 14 living related kidney transplant patients. The initial urine 
during 60 minutes after vascular declamping was washed within DEM-10% 
FBS and was cultured in DEMN/F-12-10% FBS with supernatant of mouse 
menchymal cell culture and some supplements.
Results: The primary culture of tubules with high proliferation was successful in 
11 out of 14 patients (78.6%).&#12288; The cultured cells showed cobblestone 
appearance and characteristics of proximal or distal tubular cells and collecting 
duct cells. And the cultured cells expressed Pax2 or Pax8 as immature cell 
markers relating the kidney development by Western blot method. Flow 
cytometry analysis showed the high rate (0.33%) of side population cells. 
Sixty-eight percent of the primary culture cells showed dome formation after 
2 week culture.
Conclusion: A high percentage of progenitor tubular epithelial cells were 
cultured from the initial urine in transplanted kidneys. These exfoliated cells 
possess characteristic features as progenitor like epithelial tubular cells of self-
renewal, multipotent differentiation and high rate of side population cells. The 
cultured cells may possibly contribute to the future development of cell therapy 
for renal regeneration.
POSTER BOARD NUMBER P1 – 17
MAGNETIC RESONANCE INFLUENCED (MRI) OVARIAN 931 
ORGAN FREEZING AND TRANSPLANT FOR IATROGENIC 
STERILITY OF CANCER THERAPY.
M. Mihara, S. Tainosho
Department of Plastic And Reconstructive Surgery, University of Tokyo
Background: Chemotherapy and radiotherapy are essential for treatment of 
cancer in children and young adults, but these methods often result in testicular 
failure or reduced ovarian function. One problem in this area is that the ovum 
is structurally weak, compared with sperm, and the pregnancy rate after frozen 
ovum storage is very low. Ovarian preservation might be performed before 
cancer therapy and, in particular, may offer hope for preservation of fertility in 
young women with cancer. 
Method: We hypothesize that this is due to instability of blood fl ow, and to examine 
this possibility we have focused on the vascular system and cryopreservation of 
5 rats and 2 cynomolgus monkey with MRI, magnetic resonance infl uenced, 
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whole organ freezing method. We are examining the potential of this technology 
in transplantation and cryopreservation of the ovary. 
Result: We attempted transplantation of a vascularized ovary following a certain 
period of cryopreservation. The endocrine function of the ovary and the potential 
for pregnancy were permanently re-acquired following these procedure.
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SYNCHRONOUS PROLIFERATION PROFILE OF THE 932 
NAIVE LIVERS AND ENGINEERED LIVER TISSUES UNDER 
THE KIDNEY CAPSULE
K. Ohashi1, T. Kohei2, T. Yokoyama3, H. Kuge3, A. Yoshioka2, Y. Nakajima3, 
T. Okano1
1Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s 
Medical Univeristy, 2Department of Pediatrics, Nara Medical University, 
3Department of Surgery, Nara Medical University
Background: Liver tissue engineering is a new and emerging fi eld in which a 
functional liver system is created in vivo using isolated hepatocytes. Our group 
has recently been established an approach to create liver tissues under the kidney 
capsule that undergo active regenerative growth similar to that observed with 
the naive liver. It would be essential to elucidate the proliferation profi le of the 
engineered liver tissues because such information could assess the functional 
and structural importance as a liver. For this reason, this study was undertaken 
with mice that had been engineered liver tissues under the kidney capsule to 
investigate the start, peak and termination of hepatocyte proliferation of the 
naive livers and engineered liver tissues.
Method: Donor hepatocytes were isolated from transgenic transgenic mice 
bearing the human alpha 1-antitrypsin (hAAT) reporter gene (provided by Dr. 
Bumgardner, Ohio State Univ.). Two million hepatocytes were re-suspended 
in Basement Membrane Matrix gel (Matrigel, rich with laminin and collagen 
type IV). By transplanting the hepatocyte suspension under the kidney capsule 
space, liver tissues were created to the wild type mice (syngenic to the donor). 
At day 70 of the experiments, 2/3 partial hepatectomy (PH) was performed 
to provide liver regeneration stimulus. For the analyses of cell proliferation, 
we administered 5-bromo-2-deoxyuridine (BrdU) for a period of 24 hours 
at different timing after hepatectomy (from day 0 to day 5). In each mouse, 
the BrdU labeling indices (LI) of the naive livers and the engineered liver 
tissues were histologically determined separately by counting a total of 1000 
hepatocytes.
Results: All the recipient mice receiving hepatocyte transplantation showed 
persistent serum hAAT levels by the time of PH, confi rming that engineered 
liver tissues under the kidney capsule had been functionally stable. By the 
assessment of BrdU LI of the hepatocytes in the naive livers, the proliferation 
started at the 1st post-PH 24-hour period, peaked at the 2nd period, and 
terminated at the 5th period. In the engineered livers, the hepatocyte 
proliferation started at the 2nd post-PH 24-hour period, peaked at 3rd period, 
and terminated at 6th period. The peak BrdU LI values of the naive livers and 
engineered livers were 56.2 } 6.3% and 54.3 } 7.5%, respectively (statistically 
insignifi cant).
Conclusion: Although there was a 24-hour delay in the proliferation profi le 
of the engineered liver tissues, the present studies clearly showed that the 
naive livers and the engineered livers carried out synchronous regenerative 
process after hepatectomy. This data highlighted the functional and structural 
importance of the engineered tissues that support entire regenerative 
process. In all, the present studies demonstrate that liver tissues with high 
regenerative capacity at similar levels to the naive liver can be engineered 
at a heterologous site.
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GENERATION OF HUMANIZED ANIMAL LIVERS USING 933 
STEM CELL TRANSPLANT
J. Locke, Z. Sun, D. Warren, T. Sheets, H. Holzer, M. Shamblott, 
R. Montgomery, A. Cameron
Johns Hopkin University
Objective: Animal organs engineered to be chimeric for human cells have 
the potential to contribute signifi cantly to new developments in the fi eld of 
transplant surgery, including the study of human specifi c diseases such as 
hepatitis C, treatment for in-born errors of metabolism, and development of 
a renewable source of transplantable organs via modifi ed xenotransplantation. 
We sought to use human stem cells (HSC) to populate livers in mice and rats 
for applications in transplant surgery.
Methods: SCID mice and rats underwent liver injury with either carbon 
tetrachloride exposure or partial (50%) hepatectomy. Animals received 
intrasplenic injection of 5 x 105 fl uorescently labeled HSCs. Spleen and liver 
were assessed at 2, 7, 15, and 30 days after transplant for the presence of HSCs, 
and for markers of human hepatocyte differentiation.
Results: HSCs migrate to and engraft in animal liver after splenic injection 
only under conditions of hepatic injury. HSCs are detectable at 2-days and are 
in abundance at 1-week after transplant (Figure 1A&B). HSCs persist in rodent 
liver long-term (> 1 month). and once engrafted in animal liver differentiate 
into functional human hepatocytes as assessed by the production of human 
α-FP and human albumin (Figure 1C).
Conclusions: We developed a novel animal model in which hepatic injury 
and HSC transplantation leads to the generation of chimeric humanized 
animal organs. We are currently using our model to study molecules capable 
of preventing hepatits C re-infection after liver transplantation, and as an 
alternative to whole organ transplantation for treatment of in-born errors of 
metabolism.
STEROID AVOIDANCECONCURRENT ORAL SESSION 73: 
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CHANGE TO A CALCINEURIN-INHIBITOR FREE 934 
IMMUNSUPPRESSION – SAFETY AND EFFECTS TO BLOOD 
PRESSURE PROFILE
A-E. Lison1, V. Eilts1, F.A. Zantvoort1, H.-G. Wullstein1, G.F. Hillebrand2, 
J. Gossmann3, H-G. Kachel3, E. Jochum4, H-G. Hartmann5
1Klinikum-Bremen-Mitte, 2Klinikum Großhadern, Universität München, 3KfH 
Nierenzentrum Frankfurt, 4Krankenhaus der Barmherzigen Brüder Trier, 
5Gemeinschaftspraxis Innere Med/Nephrologie Saarbrücken
Introduction: Calcineurininhibitors must be seen critical caused to the 
big spectrum of side effects. But they are still used as basic therapy in 
organtransplantation.
However, there are possible infl uences to cardiovascular morbidity and mortality 
and at least to the survival of graft and patient. To improve the long-term 
survival of graft and recipient a randomised, prospectively, two arms study was 
done in fi ve german centers. Patients after kidney transpantation got a different 
immunsuppressive treatment, calcineurin-inhibitor based immunsuppression 
and mycophenolate mofetil (MMF) based immunsuppression. These two arms 
were compared.
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Methods: Primary aim were safety, tolerability as well as calcineurin-
inhibitor associated side effects like hypertension. Corticosteroides were 
permitted in both arms. Patients became randomised (1: 2 ratio CNI: MMF). 
Patients had to be transplanted at least one year ago, graft-function had to be 
stable (serum-creatinine >2,5mg/dl) at the beginning of the study. 59 KTX 
were included.
Results: There were no more rejections neither in the early nor in longer follow 
up after change to calcineurin-inhibitor free treatment. No graft was lost since 
beginning of the study. Kidney transplanted patients with MMF based treatment 
achieved stable graft-function with improved serum-kreatinine (mean: 1,66 to 
1,51 mg/dl) and creatinine-clearance.
Signifi cant improvement of mean arterial blood pressure (MAD) was found 
from day 84 on. So it was the case with a surrogat parameter consisting of 
MAD and the daily dose of antihypertensive medication.
Conclusion: This study shows, that change to calcineurin-inhibitor free 
immunsuppression is possible and safe without increased risk for graft and 
patient. A positive effect on blood pressure profi le could be acertained in patients 
treated with MMF only. Establishment of an easy transposable and regulated 
switching-sheme with closmeshed controls in the early phase stood the test 
during the study for both, patients and physcian. The present results indicate 
that there is a possibility for our patients to change immunsuppressive regime 
and to reduce CNI associated side effects. So, CNI associated cardiovascular 
and nephrotoxic outcomes can possibly be prevented. Traditional regimes 
ought to be substituted by an individual, well matched medication for each 
patient. This interesting therapeutic alternative with MMF ought to be used as 
early as possible.
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EARLY STEROID WITHDRAWAL (DAY 6) AFTER RENAL 935 
TRANSPLANTATION, LONG-TERM RESULTS
M. Gallichio, O. Elbahloul, J. Jaber, D. Conti
Albany Medical College
Maintenance steroid therapy is associated with signifi cant morbidity. We report 
our long-term experience with early (day 6) steroid withdrawal (SW) after 
renal transplantation. Between 3/03 and 9/05, 125 patients enrolled in a SW 
protocol. Immunotherapy for all recipients included: Thymoglobulin (rATG) 
induction on days 1-5 (mean total dose 4.3 mg/kg). Prograf dosed to achieve 
a 12-hour trough level of 6- 10ng/ml until 3 months when the daily dose was 
decreased by 50% and targeted to a level of 2- 3ng/ml thereafter, Cellcept 
500 mg BID and prednisone on days 0-6 (total dose 1000 mg). Rapamune 
therapy was initiated on day 6, concomitant with prednisone withdrawal, at 
3 mg/day (no loading dose) and dosed to target a 24-hour trough level of 
7- 10 ng/ml. Recipient demographics were as follows: mean age 46 years, 
male 63%, Caucasian 82%, deceased- donor 70%, primary transplant 92%, 
diabetes 38%.
The mean follow-up at 12/1/07 is 43 months (27-57). Patient and allograft 
survival at one-year was 100% and 98% respectively. Ten patients (8%) 
have suffered an acute rejection episode. 90% developed within 2 weeks of 
transplantation. Long-term actual patient and allograft survival, as of 12/1/07, is 
96% and 89% respectively. Mortalities were due to cardiovascular events (n=4, 
at 20, 21, 30 and 40 months). and infection (n=1 at 49 months). Non-mortality 
etiologies of graft loss included; chronic nephropathy in 4 patients at 20, 22, 
26 and 30 months (3 directly related to non-compliance). recurrent disease in 2 
recipients at 11 and 35 months, infection in 2 patients at 11 and 20 months and 
cardiogenic shock in 1 recipient at 11 months. Mean serum creatinine levels at 
6 (n=125). 12 (n=122). 24 (n=116). 36 (n=87) and 48 (n=40) months were 1.5, 
1.5, 1.5, 1.4, and 1.5 mg/dl respectively.
This immunosuppressive regimen provides effective immunotherapy in renal 
transplant recipients. The rate of acute rejection was only 8% and one-year 
graft survival was 98%. Furthermore, 3 ½ year patient and renal allograft 
survival is excellent and serum creatinine levels have remained stable long-
term. Induction with rATG followed by maintenance Rapamune, Prograf and 
Cellcept therapy safely provides for the early discontinuation of steroids after 
renal transplantation.
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RAPID DISCONTINUATION OF CORTICOSTEROID IN 936 
KIDNEY TRANSPLANTATION: A JAPANESE SINGLE CENTER 
EXPERIENCE
N. Shimoda, K. Morita, K. Hotta, K. Nonomura
Hokkaido University Hospital, Department of Urology
Introduction: Corticosteroid is commonly used as an immunosuppressive 
therapy after renal transplantation, while it is associated with considerable side 
effects including hypertension, hyperlipidemia, diabetes mellitus, osteopenia, 
cataracta and cosmetic disfi gurement. The aim of this study is to investigate the 
effects of rapid discontinuation of corticosteroid on graft outcome and post-
transplant complications. 
Methods: Twenty fi ve patients underwent live donor kidney transplantation 
under induction immunosuppression with basiliximab, tacrolimus and 
mycophenolate mofetil. In addition, the patients were administered 
methylprednisolone for 3 days (250mg on day0, 125mg on day1, 2 in adults and 
125mg on day0, 40mg on day1, 2 in children). Corticosteroid was completely 
discontinued after 3 POD. Exclusion criteria were: ABO incompatible, pre-
sensitized transplantation and retrasnplantation. Mean follow-up period was 
26 months (range: 2-41). Study end points were to determine graft survival 
and function, acute rejection and complications. All allograft rejections were 
diagnosed by persistent elevation of serum creatinine and were confi rmed by 
allograft biopsy. 
Results: There was no graft loss during follow-up periods. A total of 6 
(24.0%) patients had experienced an acute rejection (Banff grade 1b: one 
patient, Borderline Change: 5 patients). All rejections could be treated by 
methylprednisolone pulse therapy and/or deoxyspergualin administration, 
following continuous oral methylprednisolone administration. Mean serum 
creatinine and creatinine clearance at 1 year after transplantation were 1.15 mg/
dl and 52.3ml/min/1.73m2. One patient with severe leukocytopenia resumed 
oral methylprednisolone due to cessation of mycophenolate mofetil. 
Conclusions: Renal transplantation utilizing a rapid discontinuation of 
corticosteroid protocol appears to be safe and effective, without increasing the 
risk of acute rejection or graft loss in short-time post-transplant period.
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IMPACT OF STEROID WITHDRAWAL ON THE IMMUNE 937 
RESPONSE OF RENAL TRANSPLANT RECIPIENTS
R. Weimer1, S. Deisz1, H. Dietrich1, F. Renner1, C. Süsal2, S. Kamali-Ernst3, 
W. Ernst4, W. Padberg5, G. Opelz2
1Department of Internal Medicine, University of Giessen, 2Institute of 
Immunology, University of Heidelberg, 3Nephrological Practice, Wetzlar, 
4Dialysis Center, Langenselbold, 5Department of Surgery, University of 
Giessen
Superior kidney graft outcome has been described after steroid withdrawal in a 
large prospective study within the CTS. To analyze effects of steroid withdrawal 
on clinically relevant immune parameters of Th1/Th2, B cell and monocyte 
responses, we assessed CD4 helper activity, sCD30, immunoglobulin-secreting 
cell formation, neopterin and intracellular cytokine production in a prospective 
randomized study of 84 renal transplant recipients (CsA/Aza, CsA/MMF, 
Tacr/Aza; steroid tapering not earlier than 6 months posttransplant) at 2 years 
posttransplant.
Two-year graft function was better in patients off steroids (creatinine clearance: 
62±7 versus 47±4 ml/min, p=0.03). Lower steroid dosage was signifi cantly 
related to lower systolic and diastolic blood pressure (p<0.0005 and p=0.002, 
respectively). and lower serum lipid levels (cholesterol, p=0.002; triglycerides, 
p<0.0005).
Multivariate logistic regression showed that steroid-free therapy was 
independently associated with enhanced T cell proliferative capacity (CD69 
expression; p=0.004) and CD4 cell IL-4 responses (p=0.07; p=0.03, univariate 
analysis). which was previously shown to predict a low risk of acute rejection. 
Enhanced CD4 cell IL-2 production on steroid-free treatment (p=0.02, 
univariate analysis) could not be confi rmed in the multivariate analysis. 
Logistic regression, however, confi rmed a downregulated IL-2R (CD25; 
p=0.02, univariate; p=0.01; logistic regression) and CD40 expression on B 
cells (p=0.03, univariate and logistic regression) in steroid-free patients. MMF 
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compared to Aza showed only a minor effect on B cell CD25 downregulation 
(p=0.05; logistic regression). Steroid-free treatment had no impact on monocyte 
activation, CD4 helper activity, sCD30 levels and immunoglobulin-secreting 
cell formation.
Compared to healthy controls, only patients on steroid-free immunosuppression 
showed decreased IL-2R (CD25) and CD40 expression on B cells (p<0.0005 
and p=0.005, respectively) together with decreased IL-6R expression on 
monocytes (p=0.02). Patients on steroid treatment, however, exhibited even 
higher IL-2R (CD25) expression on CD4 cells than healthy controls (p=0.02).
Our data show that steroid-free maintenance immunosuppression enhances 
T cell proliferation but provides graft protective immunological effects via 
suppression of IL-2R (CD25) and CD40 expression, and enhanced CD4 cell 
IL-4 production. Upregulation of IL-2R and the B cell costimulatory pathway 
by steroids might result in B cell responses against the graft during periods of 
infection-induced IL-2 release.
POSTER BOARD NUMBER P1 – 24
SUCCESSFUL STEROID WITHDRAWAL AFTER LONG-938 
TERM ADMINSTRATION IN RENAL TRANSPLANT PATIENTS
N. Amada, H. Kikuchi, I. Haga, T. Fukumori, A. Sato, T. Sato
Sendai Shakaihoken Hospital
Objective: Prolonged administration of steroids is associated with 
numerous side effects, which may have a negative impact on long-term 
patient and graft survival in renal transplant recipients. These days, steroids 
can be reduced or even withdrawn in these patients under treatment of other 
concomitant prominent immunosuppressive agents such as calcineurin 
inhibitors or anti-metabolites. This study evaluated the effect of steroid 
withdrawal after long-term administration on stable functioning renal 
transplant recipients.
Patients and Methods: Between April 2000 and October 2006, steroid 
administration was safely withdrawn in 47 patients with stable graft function 
for more than 1 year after renal transplantation. The period between renal 
transplantation and steroid withdrawal varied from 12 to 234 months (median: 
114 months). Steroids were withdrawn over a period of more than 2 months 
from 5 mg prednisolone-equivalent daily maintenance dose either by reducing 
the dose or every other day administration. We followed their clinical course 
after steroid withdrawal for 16 to 94 months (median: 51 months). We also 
investigated the current steroid doses of all 274 outpatients who had undergone 
renal transplantation in our hospital between July 1977 and October 2006. Since 
some patients receive methylprednisolone, it was converted to prednisolone-
equivalent doses.
Results: Twelve patients out of 47 had to resume steroid administration 
at 3 to 55 months (median: 13.5 months) after withdrawal, 10 (21%) 
due to acute rejection with/without recurrent glomerulonephritis, 1 due 
to treatment for subacute thyroiditis, and the other due to accompanying 
cessation of azathioprine for ovarian cancer, respectively. Thirty-five 
patients have maintained stable graft function for 12 to 90 months (median: 
49 months) after steroid withdrawal confirmed by follow-up. Laboratory 
data shows that the serum total cholesterol and HDL-C levels decreased 
significantly; however, there were no changes in body weight, systemic 
blood pressure, triglycerides or HbA1c level after steroid withdrawal. At 
present, only one patient of the 47 had to resume hemodialysis due to 
the chronic deterioration of the renal graft function at 262 months after 
transplantation, including a period of 31 months of steroid withdrawal and 
35 months of steroid re-administration thereafter. Current steroid doses 
(prednisolone-equivalent) of the 274 outpatients at our hospital are as 
follows: The number of patients for withdrawn, < 5 mg, 5mg, > 5 to 10 
mg, and > 10mg per day is 38, 20, 155, 57, and 4, respectively. Although 
steroid doses are administered per body and are not adjusted by body 
weight, 213 out of 294 (77.7%) are maintaining stable renal graft functions 
with ≤ 5 mg prednisolone per day.
Conclusion: Although further follow-up is necessary to evaluate the 
effectiveness to prevent serious adverse events, steroids may be safely 
withdrawn in renal transplant patients with stable graft functions, even after 
long-term administration, and it is effective to decrease serum cholesterol 
levels.
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THE FUNCTION OF TRANSPLANTED KIDNEY 939 
AFTER EIGHT YEARS OF TACROLIMUS (PROGRAF) 
IMMUNOSUPPRESSION WITH DISCONTINUATION OF 
CORTICOIDS
M. Kuman, P. Studenik, V. Mejzlik, J. Ondrasek, P. Nemec
Center of Cardivascular Surgery And Transplantation
Introduction: The fi rst 18 patients treated with Prograf at our centre were 
subject to long-term follow-up.
Patient group: 18 patients, of whom 5 women and 13 men, after the fi rst 
kidney transplant, recieved immunosuppressant treatment with tacrolimus, 
corticoids and, on randomised basis, either with azathioprine from 1999 to 2001 
(9 patients, i.e. 50%). or with mycophenolate (9 patients, i.e. 50%). Corticoid 
treatment was discontinued at four months post-transplant. Patients were 
monitored for eight years. Two of the monitored patients were later transferred 
from Prograf to Neoral (cyclosporine A) due to neurotoxicity. 16 patients, i.e. 
89%, continued on Prograf therapy. All patients with functioning graft at year 
eight were on Prograf and corticoidfree.
Objective: To establish long-term patient survival and quality of function of 
the kidney graft.
Results: 15 patients completed the eight-year follow up – the survival rate 
being 83.3%. Three patients with functional graft died before the end of the 
follow up period – 16.6% mortality
(lx colorectal carcinoma, lx Grawitz tumor, lx lung embolia ). Kidney grafts 
ceased to function and haemodialysis treatment was renewed in two patients 
only, i.e. in 11.1%. (both IgA nephropathy). 13 kidney grafts, i.e. 72%, were 
functional after eight years of transplant. Rejection episodes (all in fi rst 
year) were also documented (7 episodes on the total, i.e. 39%, of which 
5 corticosensitive, i.e. 28%, and 2 corticoresistant, i.e. 11%, ). More in the 
branch using azathioprine (corticosensitive 33% of all patients in the branch, 
corticoresistant 22%). The quality of graft function was assessed by trends in 
values of creatininemia (at year eight 132.8 ± 31.7 umol/l) and glomerular 
fi ltration (at year eight 1.275 ± 0.37 ml/s ).
Conclusion: The follow up has shown that immunosuppression with 
Prograf, with early discontinuation of corticoid treatment, in combination 
with mycophenolate mophetil brings from the long-term point of view 
very good survival and transplanted kidney function results and benefi ts 
transplant patients.
POSTER BOARD NUMBER P1 – 26
THE EMERGENCY OF NEPHROTOXICITY: A 940 
REVERSIBLE ADVERSE REACTION OF IVIG THERAPY IN 
RENAL TRANSPLANT PATIENTS
C. Callender, C. Thompson, A. Hernandez
Howard University
Background: Steroid avoidance and reduced dose calcineurine inhibition 
regimens have been possible by the use of potent induction agents. At Howard 
University Hospital Transplant Center, we have adopted the use of Campath-
1H induction which allows us to use low dose Prograf, MMF and steroid 
avoidance as maintenance immunosuppression.
Since May 2003, we have performed 46 kidney transplants following this 
regimen. During this period we have recognized an increased rate of acute 
antibody mediated rejection of 6.5%. (It was zero previously). In this 
setting, the initial therapy used at our center is IVIG. Blood Urea nitrogen 
and serum creatinine elevation following IVIG administration is a well 
recognized adverse event that has been described in the literature when 
IVIG is used to treat autoimmune diseases. The package insert reports a 
10% incidence of this adverse reaction. This presentation however, in the 
face of an already impaired renal function in renal transplantation is rarely 
addressed.
Objective: We describe three cases of IVIG administration followed by 
a reversible elevation of BUN and Serum creatinine as high as 88 and 8.8, 
respectively.
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Clinical Course:
Discussion: It has been theorized that the use of Sucrose or Maltose in the 
IVIG solution are the culprits for the development of a “Manitol like osmotic 
nephrosis”. In these cases we use Carimune ® NF, Nanofi ltered, human IVIG 
and reconstituted with D5W or Normal Saline, avoiding the use of the sugars 
considered implicated in the tubular toxicity.
Conclusion: Rather than the osmolality of the IVIG, we consider that other 
mechanisms may also be implicated in the etiology of these events. We 
consider these adverse events completely reversible and they are apparently 
dose dependent.
POSTER BOARD NUMBER P1 – 27
STEROID-FREE MAINTENANCE THERAPY – NOT 941 
APPROPRIATE FOR EVERYONE, BUT WORTHWILE FOR 
MANY
K. Lopau, F. Swoboda, C. Wanner
University of Wuerzburg
Introduction: Steroid free immunosuppression (IS) after kidney transplantation 
(KTx) is still considered critical due to reports of increased rejection episodes 
(AR) after steroid weaning. Since 1998 we have performed routinely 
prednisolone withdrawal after 12 months without AR >Banff °Ia under the 
coverage of MMF combined with tacrolimus or cyclosporin-microemulsion. 
Herein we report our experience with this late steroid-tapering comparing 
outcomes and side effects of patients on three different immunosuppressive 
regimens.
Methods: All patients gave informed consent for data collection aand analysis 
before extraction of their follow-up data out of the centre-database. We analyzed 
57 pts receiving Tac+MMF and compared them to 84 pts with CsA+MMF and 
94 pts receiving CsA+MMF+prednisolone (Pred). All pts were transplanted 
between 1998 and 2004 and had at least 12 months graft survival. Pts received 
Tac only in case of a second transplant, PRA´s >30% or severe CsA-related 
side effects.
Results: All groups were comparable concernig most donor and recepient 
variables (age, gender, diabetes, type and duration of dialysis, living-donation, 
donor age, CIT etc). CsA-pts had less HLA-mismatches compared to both other 
groups. S-creatinine at discharge was comparable. After 5.8 yrs of follow-up 
S-Crea was signifi cantly lower at 12 and 24 months in both steroid-free groups, 
thereafter differences diminished. S-Crea at year 5 was 2.0 vs 2.0 vs 1.9 mg/
dl (Tac vs CsA vs steroids). The same pattern was observed when using eGFR 
as surrogate. Graft loss occured in 4 vs 5 vs 14%. Biopsy-proven AR were less 
frequent in CsA-pts compared to both other groups (13.1 vs 21.1 vs 29.8%). 
Incidences of major cardiovascular events and death did not differ signifi cantly. 
There was a trend for post transplant diabetes appearing more often in the 
steroid group (14 vs 13 vs 18%). Blood pressure as well as infections and 
cancer incidences were comparable between groups.
Conclusion: Tailored immunosuppression employing a calcineurin inhibitor 
together with MMF in pts without higher-graded AR is highly successful 
with very low incidences of graft loss in the long term. This approach leads 
to similar graft function compared with pts on steroids and low incidences of 
cardiovascular events, diabetes, infections and death after 5 years. However 
these results have to be confi rmed in larger studies with longer follow-up.
THERAPEUTIC DRUG CONCURRENT ORAL SESSION 74: 
MONITORING
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TOXIC TACROLIMUS BLOOD LEVELS WITH 942 
RIFAMPICIN ADMINSTRATION IN A RENAL TRANSPLANT 
RECIPIENT
M. Halim, T. Ai-Otaibi, M. Nampoory, T. Said, P. Nair
Hamed Alessa Organ Transplantation Center
Induction of the hepatic cytochrome P450-3A4 system and intestinal 
P-glycoprotein is an unavoidable consequence of rifampicin (Rif) administration 
which require substantial increase in tacrolimus (Tac) dose when given 
concurrently. Chronic diarrhea is known to precipitate Tac toxicity irrespective 
of it’s cause in renal transplant recipients.
A 28 years old lady had a second renal transplant when she was 15 years old which 
is functioning well. She was maintained on prednisolone, azathioprine and Tac. 
She has close relatives infected with tuberculosis. She was started on isoniazide 
prophylaxis and Tac was maintained on therapeutic levels (5-7 ng/ml).
She developed intermittent fever, night sweating, nausea, vomiting, chronic 
diarrhea, and loss of weight. Detailed investigations didn’t show definite 
diagnosis. Mantoux skin test was border-line positive and antituberculous 
drugs including Rif were started 7 months later. She continued to 
have significant symptoms requiring multiple drugs to be controlled 
(omeprazole, antacids, metoclopramide, loperamide, acetaminophen and 
ondasetron hydrochloride). During the first four months of antituberculous 
treatment she had very high Tac blood levels requiring successive dose 
reduction from 7mg/day up to 0.5mg every other day with rise of serum 
creatinine from 100 to 140umol/l. Tac was changed to low dose sirolimus 
and renal function gradually improved to its baseline while still on Rif 
treatment.
We conclude that chronic diarrhea may cause toxic Tac blood levels even 
in presence of Rif, this would be possibly due to its signifi cant enzyme 
inhibitory effect.
POSTER BOARD NUMBER P1 – 29
ANALYSIS OF ALLOSPECIFIC T CELLS IN 943 
KIDNEY TRANSPLANT PATIENTS ON VARIOUS 
IMMUNOSUPPRESSIVE PROTOCOLS
M. Gasser1, I. Tsaur1, B. Avilez1, J. Lutz2, M. Grimm1, K. Lopau3, A. Thiede1, 
U. Heemann2, A. Chandraker4, A.M. Waaga-Gasser1
1University of Wuerzburg, Department of Surgery I, 2University of Munich, 
rechts der Isar, Department of Nephrology, 3University of Wuerzburg, 
Department of Nephrology, 4Transplantation Center, Brigham and Women’s 
Hospital, Harvard Medical School
Chronic allograft dysfunction remains a major clinical problem in organ 
transplantation. Morphologically it is characterized by changes suggestive 
of an alloantibody mediated mechanism such as glomerulopathy and 
vasculopathy or by non-specifi c changes such as interstitial fi brosis and tubular 
atrophy. Alloantigen dependent as well as -independent factors contribute to 
the pathogenesis of these changes. In this study we analysed allospecifi c T 
cells from the peripheral blood of kidney transplant patients under different 
immunosuppressive protocols with or without chronic allograft dysfunction. 
107 renal allograft recipients of our renal transplant clinic were screened 
at least six months after transplantation. All patients were on a calcineurin-
based immunosuppressive protocol consisting of cyclosporine (CsA) /
mycophenolate mofetil (MMF) /steroid, tacrolimus (Tac) /mycophenolate 
mofetil (MMF) /steroid, or CsA/steroid. Patients had to be mismatched for one 
or more of the fi ve canditate HLA-DR antigens for which synthetic peptides 
were available (DR1, DR2, DR3, DR4, and DR7). Patients with biopsy proven 
chronic allograft nephropathy (CAN) with an elevated serum creatinine level 
of ≥ 1.6 mg/dl were compared with patients with stable allograft function 
(serum creatinine <1.6 mg/dl. T cell lines were generated from peripheral 
blood lymphocytes of renal transplant recipients against donor-derived HLA-
DR peptides presented by self APC. T cell lines generated from patients 
with CAN produced signifi cantly IFN-γ, while those generated from stable 
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patients produced IL-10 associated with a low proliferation index in response 
to donor-derived mismatched HLA-DR allopeptide in vitro. Moreover, 
signifi cantly more CD4+CD25+Foxp3+ T cells were found in stable patients 
on Tac and MMF as compared to patients on CsA and MMF. Interestingly, 
higher gene expression profi les of CD4, CD25, CTLA-4, Foxp3, and IL-10 
were observed in those patients. Taken together a Th1 (IFN-γ) alloimmune 
response is deleterious and promotes chronic graft damage, while a Th2 
(IL-10) response seems to be associated with a lower incidence of chronic 
allograft nephropathy. An immunosuppression based on tac and MMF seems 
to favour CD4+CD25+Foxp3+ T cells and to allow long-term engraftment 
with stable renal function.
POSTER BOARD NUMBER P1 – 30
PHARMACODYNAMIC CHARACTARISTICS OF RENAL 944 
TRANSPLANT RESIPIENTS
T. Kuzuya1, T. Kobayashi2, A. Katayama2, Y. Miwa2, T. Nagasaka3, 
K. Uchida3, K. Yamada1
1Department of Hospital Pharmacy, Nagoya University School of Medicine, 
2Deaprtment of Applied Immunology, Nagoya University Gradually School of 
Medicine, 3Kidney Center, Nagoya Daini Red Cross Hopital
Aims: Inhibition of cytokine production is the main immunosuppressive 
effect of carcineurin inhibitor, which is widely used in organ transplantation. 
Pharmacodynamic (PD) assay can directly determine the drug effi cacy and is 
considered to be a realistic monitoring method of providing a more appropriate 
dosing regimen to each patient. However, such monitoring is not available 
at present. The purpose of this study was to elucidate the value of PD assay 
and to assess its clinical applicability. We examined an inhibitory effect of 
cyclosporine (CsA) on mitogen-induced cytokine mRNA expression in whole 
blood and evaluated the extent of inter-individual variations of PD and clinical 
effi cacy for PD index.
Methods: Written informed consent was obtained from renal transplant 
patients who participate in this study (n=50). The study protocol was approved 
by the Ethics Committee of the Nagoya University Hospital. Five different 
concentration mixtures of CsA (0-800 ng/ml) were added to whole blood from 
pre-transplant patients before taking immunosuppressive drugs to determine 
the relationship between CsA concentrations and the inhibitory response of 
cytokine (IL-2, 4, 6, 10, INF-g, TGF-b, TNF-a) production. The degree of 
inhibition observed at the different CsA concentrations was estimated by a 
50% inhibitory concentration (IC50) which was determined by variable slope, 
non-linear regression curve fi tting. Quantifi cation of each cytokine mRNA 
expression in the presence of PMA and Ca ionophore was performed by reverse 
transcription polymerase chain. An endogenous housekeeping gene (b-actin) 
was also quantifi ed to normalize the results and comparative threshold cycle 
method was used to quantify samples.
Results: Cytokine mRNA expressions except for TGF-b were declined in 
relation to an increase in CsA and the relationships could describe by the 
inhibitory sigmoid Emax model. Each value of IC50 of cytokine showed high 
specifi city among the patients (IL-2, 4, 6, 10, INF-g, TNF-a; 156 } 54, 166 } 
68, 165 } 64, 147 } 42, 191 } 68, 164 } 46 mg/mL) and correlated with those 
of other cytokines. Acute rejection and cytomegalovirus infection occurred in 
9 and 10 patients, respectively. There are no relationship between the value of 
IC50 of each cytokine and these events.
Conclusion: PD assay using cytokine mRNA semi-quantifi cation in whole 
blood is a simple, reliable and reproducible method of evaluating the individual 
variations in drug sensitivity. After transplantation, as patients are generally 
treated with multiple immunosuppressive agents, only single drug monitoring 
of sensitivity would be insuffi cient to provide the information on optimal dosage 
in consideration of overall patient condition. However, there is a possibility 
that such PD assay as a sensitivity test can be used for design of dosing regimen 
and/or drug selection before transplantation.
POSTER BOARD NUMBER P1 – 31
THE EFFECT OF GRAPEFRUIT JUICE ON 945 
SERUM CONCENTRATION AND BIOAVAILABILITY OF 
CYCLOSPORINE IN KIDNEY TRANSPLANT PATIENTS
A. Mehrsai, G. Pourmand, M. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: To estimate the effects of concurrent administration of grapefruit 
juice, a known inhibitor of drug metabolism, on pharmacokinetics of 
cyclosporine in transplant patients.
Materials: This is a randomized crossover clinical study performed in the renal 
transplant unit. On two study occasions 15 kidney transplant patients who had 
been transplanted at least 6 months before and had stable kidney function 
and using cyclosporine, received either 250cc grapefruit juice or water at the 
time of drug ingestion and 2 hours later. Systolic and diastolic blood pressure, 
serum concentration of cyclosporine, 3 and 11.5 hours after its ingestion were 
measured. Bioavailability was calculated using specifi c formula.
Results: Grapefruit juice increased peak (778.01 +- 241.5 vs. 595.3 +- 
146.47 p<0.005) and least (280.9 +- 78.5 vs. 234.6 +- 45.5 p< 0.01) serum 
concentration of cyclosporine and its bioavailability (15.6 +- 8.2 vs. 11.1 +- 3.6 
p< 0.05). Changes in blood pressure were not signifi cant.
Conclusions: Grapefruit juice inhibits the metabolism of cyclosporine, which 
may be explained by the inhibition of cytochrome P450 enzymes in the gut wall 
and to a lesser extent by inhibition of these enzymes in the liver. This interaction is 
of potential clinical importance in terms of mechanism, side effects and dosing.
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SIROLIMUS DOSE REQUIREMENT AND 946 
THE SIGNIFICANCE OF CYP3A5,MDR1 GENETIC 
POLYMORPHISMS
T.K. Saha1, S. Durugkar1, G.K. Gadikota1, K. Ramanjaneyulu1, V. Kiran2, 
Q. Hasan2
1Dept. of Nephrology, Kamineni Hospitals, 2Dept. of Genetics, Kamineni 
Hospitals
Introduction: Dose requirement of various immunosupressants varies in 
different races. Present study was done to determine the dose required to 
achieve therapeutic trough level of Sirolimus and to fi nd out any correlation 
between CYP3A5, MDR1 genetic polymorphisms with the dose requirement 
of Sirolimus in Indians.
Methods: Sirolimus was started in chronic allograft nephropathy patients. 
Sirolimus treated patient’s trough level was done to monitor target level. Target 
trough level was set as 3-8ng/ml for patients treated with Prenisolone, CNI/MMF 
& Sirolimus, whereas it was set as 6-12ng/ml if patients were on 2 drugs with 
Prednisolone & Sirolimus. Sirolimus level monitoring was done by Microparticle 
Enzyme immuno assay technique. The target trough level for Sirolimus and the 
dose (daily dose and dose per kg body weight) required achieving trough level of 
Sirolimus were noted. Serum creatinine and other biochemical and hematological 
parameters were noted.CYP3A5 and MDR1 genetic polymorphism was done 
in patients willing to undergo these tests. Different mutations of these genes 
were compared with the dose requirements of patients. Patients on Diltiazem, 
Rifampicin and Fluconazole were excluded from the study.
Results: Total 39 patients treated with Sirolimus were studied. 30 patients 
received three immunosuppressants. Their average dose requirement was 
1.99±0.51mg/day, 0.031mg/kg/day; the average level achieved was 5.29±2.41ng/
ml and the average creatinine was 2.0±1.04mg/dl. 9 patients were on two drugs. 
They required 1.92±0.70mg/day,0.026±0.008mg/kg/day,the level achieved was 
7.28±1.20 ng/ml and the average creatinine was 2.13±0.97 mg/dl. Out of total 39 
patients 16 patients genetic analysis could be done. 11 patients had heterozygous 
mutated CYP3A5 gene, 4 had homozygous normal and one had homozygous 
mutated CYP3A5 gene. There was no signifi cant (p= 0.7052) difference in dose 
requirement in mg/kg/day in these three CYP3A5 gene variation. 9 patients 
had CT Polymorphism of MDR1 gene, 4 had CC polymorphism another 3 
had TT polymorphism. There was no signifi cant (P=0.983) difference in dose 
requirement in mg/kg/day in MDR1 gene variation.
Conclusion: Indians require approximately 2 mg daily dose of Sirolimus to 
achieve therapeutic drug level. CYP3A5 and MDR1 genetic polymorphisms 
did not differ in dose requirement in this small pilot study in Indians.
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IMMUNOSUPPRESSIVE DRUGS AND NEW ONSET 947 
DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION 
IN RECIPIENTS OF HISPANIC ORIGIN
P.W. Baron1, R. Ben-Youssef1, O. Ojogho1, J. Weissman1, E. Franco1, A. 
Kore1, J. Limjoco1, M. DeLeon2, Z. Cordero-MacIntyre2 
1Transplantation Institute and 2Center for Health Disparities Research, Loma 
Linda University, California, United States.
Background: Calcineurin inhibitors (CNI) are established risk factors for new-
onset diabetes mellitus posttransplant (NODM). However, the diabetogenic 
effect of sirolimus (SLR) and mycophenolate mofetil (MMF) is still 
controversial. We studied the incidence of NODM under different CNI-based 
regimens in Hispanic kidney transplant patients.
Method: Data of 139 primary kidney transplant Hispanic patients performed 
between Jan 1998 and Dec 2002 were reviewed. WHO/ADA criteria were used 
to diagnose NODM. We excluded 37 patients due to pretransplant diabetes 
mellitus. The remaining 102 patients were divided into 2 groups: 37 received 
FK (Group A) and 65 received cyclosporine (CsA) (Group B). We studied the 
incidence of NODM, noncompliance, acute rejection, BK virus and CMV 
infection, patient and graft survival. Median follow-up was 71 mo (20-114). 
Antibody induction therapy was used in 28 FK (75.7%) and 32 CsA (49.2%) 
patients. All patients received steroids plus MMF or sirolimus.
Results: The groups were comparable for age, gender, BMI and family history 
of diabetes mellitus. Infection and noncompliance rates were similar in both 
groups. NODM occurred in 13 Group A, and in 8 Group B patients (p=0.006). 
NODM incidences among surviving patients at 6 mo, 1, 3, and 5 y were 24.3%, 
27%, 38.2%, and 25% in Group A, and 7.7%, 10.2%, 13%, and 14.9% in Group 
B (p = 0.02, 0.03, 0.006, and 0.36 at 6 mo, 1, 3 and 5 y, respectively). SLR was 
used in 6 FK and in 5 CsA patients: 4/6 FK-SLR patients developed NODM, 
while only 1/5 CsA-SLR patients did. Mean SLR level was 14.685.27 ng/mL in 
FK-SLR, and 12.423.42 ng/mL in CsA-SLR (p=0.13). This level was 13.75.5 
ng/mL in the 4 FK-SLR-NODM patients, and 18 ng/mL in the only CsA-SLR-
NODM patient. MMF was used in 31 FK (83.8%) and 60 CsA (92.3%) patients. 
Nine (29%) FK-MMF, and 7 (11.7%) CsA-MMF patients developed NODM 
(p=0.04). 5-y patient and graft survival were 97% and 59.5% in Group A, and 
98.3% and 76.9% in Group B (p=0.27 and 0.02, respectively).
Conclusion: Immunosuppressive drugs are associated with variable 
diabetogenic rates in Hispanics. However, the overall incidence of NODM 
was lower, and graft survival was better with the CsA-based regimens. 
Prospective studies are needed to establish a consensus regarding the choice of 
immunosuppression in Hispanics.
POSTER BOARD NUMBER P1 – 34
ABBREVIATED AUC OF CYCLOSPORINE IDENTIFY 948 
MORE ADEQUATELY THAN RECOMMENDED C2 
CONCENTRATION VALUE THE PATIENTS AT RISK 
OF ACUTE REJECTION DURING THE INDUCTION OF 
IMMUNOSUPPRESSIVE THERAPY AFTER KIDNEY 
TRANSPLANTATION.
P. Troncoso, M. Ortíz, S. Vilches
P Universidad Católica De Chile
Introduction: Monitoring of Cyclosporine (CsA) is critical during the induction 
of immunosuppressive therapy. In this period sub therapeutic exposure to CsA 
is associated to high risk of acute graft rejection. The area under the curve of 
concentration versus time (AUC) continues to be the gold standard to quantify 
drug exposure. Although most of the centers have incorporated C2 (2 hour post 
administration CsA) for dosing changes, our unit is still using an abbreviated 
AUC model which includes C1, C2 and C6 concentration levels. The objective 
of this study was to compare both strategies of CsA monitoring in the immediate 
period after kidney transplantation.
Methods: The study included all CsA concentration levels (CEDIA plus, 
Roche®) obtained during the fi rst 30 days after kidney transplantation in 89 
consecutive receptors induced with CsA (Neoral) and steroids. Abbreviated 
AUC was calculated by the formula: 196+0.82x (C1) +0.96x (C2) +9,53x 
(C6). A value between 5500 to 6000 ngxh/ml was considered to be in the 
therapeutic range. For comparison purposes a value of C2 ≥ 1500 ng/ml was 
also considered therapeutic. Biopsy proven acute rejection episodes (BPAR) 
were contrasted with the immediately previous C2 and AUC values. Changes 
in doses were done considering only AUC studies as it is usual in our unit.
Results: 20 patients were receptors of living donor kidneys and 46 were 
females. Initial induction dose of CsA was 8,26 ± 1,58 mg/day. A total of 248 
abbreviated AUC studies were done during this period and 40 of them (16%) 
were under the therapeutic range. When the analysis of these studies included 
only C2 level 164 (66%) were under the therapeutic value (p<0.001). In 
addition, the analysis of all concentration levels showed that the peak of CsA 
was in C2 in 54,5% of the studies and in C1 in 45,5%. Five patients had 
BPAR during the study period and all of these patients were out of the AUC 
therapeutic range. The average C2 in those patients was 1127 ± 383 with a 
range of 710 to 1740 ng/ml. On the other hand, the analysis of AUC studies 
in the therapeutic range showed that the average C2 was 1156 ± 276 ng/
ml with a range of 632 to 1859 ng/ml (p=0.84). C1 did not show either any 
difference between patients with BPAR and those in the therapeutic range 
according to the AUC. Only two patients experienced clinical CsA toxicity 
during the study period.
Conclusions: In this series, abbreviated AUC monitoring during the induction 
of immunosuppressive therapy was associated to a low incidence of CsA 
toxicity and identifi ed more adequately than C2 patients at risk of acute 
rejection. Recommended C2 concentration levels for this period were achieved 
in less than a half of the studies though most of them were related to therapeutic 
AUC range.
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A COMPARISON OF RADIOIMMUNOASSAY VERSUS 949 
MASS SPECTROSCOPY IN MONITORING OF EVEROLIMUS 
LEVELS
S. McGinn1, A. Caswell1, A. Jackson1, T. McGee1, D. Chesher1, R. Caterson1, 
J. Ray2
1Royal North Shore Hospital, 2St Vincent’s Hospital
Long term calcineurin inhibitor use in transplant recipients (CNIs) has 
been correlated with nephrotoxicity and reduced long term graft survival. 
Consequently CNI-sparing protocols have been developed using agents such 
as everolimus the proliferation signal inhibitor/mammalian target of rapamycin 
inhibitor (mTORi). Everolimus is extensively metabolized resulting in several 
hydroxylated and demethylated metabolites. These can interfere with the 
standard immunoassay used for measuring trough drug levels and hence 
given the small range allowed for clinical dose adjustment (3-8ng/ml) and in 
particular 5-8 ng/ml for those at increased risk of rejection, the aim of this study 
was to assess the safety of the fl uorescence polarization immunoassay (FPIA) 
for the measurement of everolimus concentrations in whole blood against the 
gold standard mass spectroscopy (LC-MS).
Methods: Whole blood samples were taken from renal transplant patients 
attending outpatient department at Royal North Shore Hospital between 
April and July 2007. and everolimus trough levels were measured using both 
immunoassay (Innofl uor, Certican Assay System) and mass spectroscopy. 
Results from the FPIA were compared with LC-MS using regression analysis, 
while the distribution of the differences in everolimus concentrations with the 
two methods was assessed using Bland Altman approach.
Results: One hundred and ten samples were analysed from thirty patients. The 
cost of analysis by FPIA was $3316.5 (AUD) versus $16500 (AUD) by LC-
MS. The everolimus levels ranged from 1-22 ng/ml (FPIA) and from 0-18.9 
ng/ml (LC-MS). Regression analysis showed a good correlation with multiple 
correlation coeffi cient of 0.95. However using Bland Altman plot, trough levels 
were consistently higher with FPIA method, the mean difference was 1.1 ng/ml 
higher with a standard error of 0.1 ng/ml (P < 0.001) suggesting interference 
from metabolites.
Conclusion: Everolimus trough levels measured by FPIA are cost effi cient but 
consistently higher than those measured by Mass Spectroscopy. Consequently 
interpretation of levels by FPIA should be made cautiously in those patients 
who are at increased risk of rejection
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IMPACT OF TIMING OF MEAL INTAKES ON THE 950 
THERAPEUTIC DRUG MONITORING OF CYCLOSPORINE-
MICROEMULSION ADMINISTRATION IN STABLE RENAL 
TRANSPLANT RECIPIENTS – IS C2 LEVELS MANAGEMENT 
THE OPTIMAL MONITORING METHOD IN STABLE RENAL 
TRANSPLANT PATIENTS?
S. Ohtsuka1, K. Uchida2, T. Nagasaka2, N. Goto2, A. Katayama3, 
T. Kobayashi3, A. Nakao3
1Toyohashi Municipal Hospital, 2Nagoya Daini Red Cross Hospital, 3Ngoya 
University School of Medicine
Background & Purpose: C2 levels monitoring of Cyclosprine-microemulsion 
(Neoral) has been published as an effective and method for optimally 
individualizing therapy for de novo and maintenance renal transplant patients. 
However, there was a serious problem related to the existence of low or slow 
absorbers causing malabsorption. The aim of this study was to evaluate the 
change of variability in C2 levels, C2/dose ratio, coeffi cient of variation (CV%) 
of intra-patients and clinical outcomes with comparing the effect of various 
timings of food intakes on variations in Cyclosporine levels in stable renal 
transplant patients.
Methods: 10 patients (age 43 }12) were enrolled in this study. Five kidney 
transplantations were from cadaver donors, 5 from living donors. The time that 
had elapsed from after the transplant to the initiation of this study was 3.3 }2.1 
years. All patient received Neoral-based triple therapy (Neoral + Steroids + 
MMF). Cyclosporine blood concentrations were measured by FPIA method 
(AxSYM analyzer). Dose adjustment of Neoral was made according to levels 
of AUC0-4 sparse-sampling that estimated using 2 sampling points (C1 and 
C2) once a month. The maintenance phase AUC0-4 was set at 2,000ng hr/ml. 
The time differences were selected two patterns, as following.
# Pattern 1: drug administered (within 10 minutes) after meal
# Pattern 2: drug administered immediately (within 10 minutes) before meal
At fi rst, all patients were enrolled in pattern 1 during 3months. Secondary, they 
were enrolled in pattern 2 next during 3 months.
Results: C2 levels were 489 }248 (241-845) in pattern 1 (3 times measurements) 
and 558 }82 ng/ml (435-670) in pattern 2.
Results of mean CV% of intra-patients of C2/dose were 48.5% in pattern1 and 
pattern 2 was 13.7% (p=0.008, CV% of pettern 1 vs pattern2).
The peak of Neoral often came to C2 with pattern 2. Moreover, absorption 
pattern (C1/C2) was different also in the same individual depending on the 
meal timing. No patient suffered from chronic rejection or nephrotoxicity 
during the study.
Conclusions: The absorption pattern of Neoral in the individual is different 
depending on the meal timing, Neoral should be monitored under the same 
meal timing. Especially, Neoral administered immediately (within 10 minutes) 
before meal pattern might be more appropriate timing of C2 monitoring 
administration than drug administered after meal.
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MYCOPHENOLATE-ASSOCIATED DIARRHEA: 951 
DOES IT AFFECT CYCLOSPORINE-A C-2 LEVELS? 
COMPARATIVE STUDY IN 41 PATIENTS. TRANSPLANT UNIT, 
HOSPITAL GENERAL SAN JUAN DE DIOS, GUATEMALA 
CITY, CENTRAL AMERICA
R.A. Garcia-Gallont, M. Toledo, A. Sojuel
Transplant Unit, Hospital General San Juan De Dios
Abstract: Mycophenolate (MMF/MPS) – associated diarrea is common, and 
may hypotetically interfere with Cyclosporin A (CyA) absorbtion. To assess 
this in a group of patients on a triple-drug immunosuppressive regimen (CyA, 
MMF or MPS, and steroids). CyA blood levels 2 hours post oral intake (C-2, 
were measured in 20 patients suffering this type of diarrhea, and in a control 
group (n=21) without diarrhea. C-2 levels dropped signifi cantly in 75% of 
patients with diarrhea (n=15). but only in 38% (n=8) of the control group 
(p=0.039). We conclude, that in the given setting, where CyA is frequently 
used in association with MMF or MPS, C-2 levels must be watched closely if 
patients develop diarrhea, to stay within therapeutic levels for CyA.
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AN OPEN LABEL SINGLE CENTRE PILOT STUDY TO 952 
CORRELATE THE PRETRANSPLANT C 2 BLOOD LEVEL (2HR 
POST SINGLE DOSE) OF TACROLIMUS AS A PREDICTOR OF 
POST TRANSPLANT TACROLIMUS DOSE IN DENOVO RENAL 
TRANSPLANTATION PATIENTS
A. Sharma1, M. Minz1, V. Shetty2
1Dept of Renal Transplant Surgery, PGIMER, 2Medical Advisor, Biocon 
Limited
Introduction: Tacrolimus is being increasingly used as a preferred calcineurin 
inhibitor for prophylaxis of rejection in organ transplant recipients. One 
of the problems associated with use of tacrolimus is a great inter-individual 
variability in dose requirement. Currently, there is no method to predict the 
dose requirement for an individual patient in the pretransplant period and the 
drug is started at a uniform dose in all the patients which places the patients at 
increased risk of underdosing or toxicity. The present study evaluated whether 
a single pretransplant peak tacrolimus blood level (2hours post dose) could 
predict the trough level obtained after transplant and help in establishing post 
transplant dose of tacrolimus.
Methods: This was an open label, nonrandomized, single arm, single centre, 
pilot study conducted in 20 patients undergoing renal transplantation. All 
patients received a single dose of Tacrolimus (Tacrograf, Biocon, India) at the 
dose of 0.1mg/kg/dose and blood level for tacrolimus was estimated 2 hr post 
dose (C2 level) 4-7 days before transplantation. All patients were started on 
0.2mg/kg/day of tacrolimus one day before transplant. After transplant, the 
patients underwent trough level monitoring on 2nd, 5th, 10th, 15th & 30th day 
of posttransplant days and additionally whenever indicated. The pretransplant 
peak tacrolimus level was correlated with the trough levels obtained and with 
the dose requirement after transplant.
Results: 20 patients were included in the study. Mean age 35.2+ 8.9 yrs, M: 
F 16: 4, Mean body weight 55.4+ 10.2 kg. The mean peak level of tacrolimus 
in the pretransplant period was 24.6 + 17.4 (Range 4.85-69.46) ng/ml. The 
mean fi rst trough level obtained 48 hours after transplant was 11.0 + 5.9 (Range 
3.7 – 22.07) ng/ml. There was a strong positive correlation [r=0.62] between 
the peak value obtained before transplant and trough level after transplant. 
There was a large variation in dose requirement at the end of two weeks in 
these patients with the dose ranging 0.05-0.42 mg/kg/day with a mean of 0.26 
+ 0.11mg/kg/day. There was a good negative correlation between peak level 
obtained before transplant and dose requirement at the end of second week [r= 
-0.57]. A peak level of more than 30 ng/ml could identify 80% (4/5) patients 
who achieved trough levels more than the desired range and all patients (4/4) 
with a peak level of less than 10ng/ml had subtherapeutic levels in the fi rst 
week after transplant.
Conclusions: A strong correlation could be observed between peak levels done 
before transplant with the trough levels and dose requirement after transplant 
Measurement of a single peak level before transplant presents a simple strategy 
to identify patients at risk of underdosing or developing toxicity.
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LOWER SERUM C953 0 AND C2 LEVELS OF CYCLOSPORIN 
A IN RENAL TRANSPLANT PATIENTS ON MYCOPHENOLATE 
MOFETIL (MMF) 
N.C.T. Kong, A.G. Halim, Z. Soehardy1, M. Rozita1 and C.Y. Loo1.
Department of Medicine, National University of Malaysia, Kuala Lumpur.
Serum C2 levels of cyclosporin A (CsA, ‘Neoral’) are the most consistent 
predictor of CsA AUC. The CONCERT consensus – performed in the era 
of steroids-CsA -azathioprine, had recommended target serum C2 levels of 
1500-2000, 1500, 1300, 1100, 900, and 800 ng/mL for months 1, 2, 3, 4-6, 7-12 
and >12 post-transplantation respectively. We report our experience with lower 
C0 and C2 targets with the steroids-CsA-MMF regimen in 15 patients (11 males, 
4 females) with a mean age of 39.9 11.7 years and a mean duration of follow-up 
of 22.7 18.4 months. Our target C2 levels were 1000-1200, 800-1000, 700-800 
and 500-700 ng/mL for 1-3, 4-6, 7-12 and >12 months respectively. C0 and 
C2 levels were categorized into 3 time periods: 1-3 months, 4-6 months and 
7-12 months post transplantation. There were 3 biopsy-proven acute rejection 
episodes, all precipitated by infection. There were no signifi cant increases in 
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serum creatinine levels (p=0.61, Table) on follow up. 68.4% patients were 
free of any acute rejection episodes up to 64 months post transplant (Figure). 
Thus we conclude that with our current immunosuppressive regimen which 
incorporates MMF, both Co and C2 levels lower than recommended are safe and 
spares chronic CsA nephrotoxicity.
 1-3 months 4-6 months 7-12 months > 12 months
Creatinine (umol/L)  106.7 29.2  104.3 27.5  116.6 40.8  118.2 40.9
C0 (ng/mL)  239.1 77.3  184.2 564.0  177.3 49.7  143.8 96.5
C2 (ng/mL) 1065.0 233.5  956.7 183.8  878.5 192.3  808.3 203.7
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IS CALCINEURIN INHIBITOR METABOLISM ALTERED 954 
IN POST RENAL TRANSPLANT RECIPIENT WITH END STAGE 
RENAL FAILURE DUE TO ADULT POLYCYSTIC KIDNEY 
DISEASE
D.M. Little, R. Manecksha, N. Pervez-Aslam, M. Eng, M. Ponnusamy, 
D.P Hickey
Beaumont Hospital
Calcineurin inhibitors, cyclosporine (CyA) or tacrolimus (tac) are the primary 
immunosuppresants used post renal transplant. Both are metabolised in the 
liver by cytochrome P450 enzyme system. Patients with end stage renal failure 
(ESRD) due to adult polycystic kidney disease (APCKD) frequently have 
associated liver cysts. We retrospectively reviewed data from 134 consecutive 
adult renal transplants in 133 recipients with ESRD due to APCKD to determine 
if they were more susceptible to calcineurin inhibitor toxicity in the immediate 
period post renal transplant.
Materials and Methods: Between Jan 1997 and December 2006, 134 patients 
(66 males and 67 females) with APCKD were transplanted in a single centre. 
1 patient died on the fi rst post-operative day and was excluded from analysis. 
Immunosuppression was achieved using a combination of mycophenolate (1g 
daily). steroids and either cyclosporine (Neoral 5mg BID) (n 54) or tacrolimus 
0.15mg/kg loading dose X2 followed by 0.1mg/kg (n 80). Pre-operative 
abdominal ultrasound confi rmed liver cysts in 45 patients, 24 received 
cyclosporine and 21 tacrolimus. All 133 patients had negative hepatitis B and 
C serology. Post-operative 12 hour drug trough levels were recorded on Days 
3, 7 and 14 post transplant using either Integra 800 EIA assay for cyclosporin 
or MEIA Abbott for tacrolimus. Liver function tests (LFTs) were also measured 
pre-operatively and at the same time intervals.
Results: Patients immunosuppressed with cyclosporine who had documented 
liver cysts pre-operatively tended to have signifi cantly higher levels of 
cyclosporine levels in the immediate post-operative period compared to those 
with no liver cysts. This trend was also evident in patients immunosuppressed 
with tacrolimus but the number of patients with sustained high levels of 
tacrolimus declined by 14 days post-operatively (Figure 1) There was no 
signifi cant alteration in LFTs in patient s with cystic liver disease and high 
calcineurin inhibitor levels.
Conclusion: Patients with APCKD tend to be more prone to developing 
calcineurin inhibitor toxicity in the early period post transplant. This trend is 
more evident in the subgroup of patients immunosuppressed with CyA and tac 
who have documented liver cysts. We recommend dose reduction in APCKD 
patients undergoing renal transplant immunosuppressed with cyclosporine.
Liver cysts 45 No liver cysts 40
Day 3 Day7 Day 14 Day 3 Day7 Day 14
CyA >300ng/mL 71% 63% 67% 52% 43% 62%
Tac > 14ng/mL 81% 67% 38% 82% 41% 47%
Figure 1
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DILTIAZEM AS A FK506-SPARING AGENT IN KIDNEY 955 
TRANSPLANT RECIPIENTS: PROSPECTIVE SELF-CONTROL 
CLINICAL TRIAL AND PHARMACOKINETIC STUDY
C. Wang1, S. Chen1, J. Li2, L. Liu1, X. Wang2, Q. Fu1, L. Teng1, C. Xiao1, 
L. Chen1, M. Huang2, 
1Kidney Transplant Department, Organ Transplant Center, The First Affi liated 
Hosp, 2School of Pharmaceutical Science, Sun Yat-sen University
Background: FK506, a fi rst-line immunosuppressant with poor oral 
bioavailability, is a substrate of Cytochrome P450 (CYP3A) and P-glycoprotein 
(P-gp). The calcium-channel blocker Diltiazem is a well-known inhibitor of 
both CYP3A4 and P-gp. We have used Diltiazem as CsA-sparing agent since 
1991 in over 1,000 kidney transplant recipients and applied it to FK506-based 
regimens since 1999 in over 300 patients. A prospective self-control clinical 
trial and pharmacokinetic study were conducted to quantitatively assess the 
FK506-sparing effect of Diltiazem in kidney transplant recipients.
Methods: Kidney transplant recipients on FK506+MMF+steroid regimen 
were recruited and Diltiazem (30mg tid) was added. Trough whole blood 
concentration of FK506 was monitored afterwards so as to adjust the FK506 
dose accordingly. Renal function, liver function, blood cell counting, urine 
analysis and adverse events were recorded in routine follow-up clinic. Intention-
to-treat (ITT) analysis is applied to these results. Pharmacokinetic study was 
conducted in participants with good compliance and volunteered to receive the 
tests. In this sub-group, the day before and 14 days after adding Diltiazem, 2ml 
venous blood sample was drawn 1 minute before, 0.5, 1, 1.5, 2, 3, 4, 6, 9 and 
12 hours after taking the morning dose of FK506. Whole blood concentration 
of FK506 was measured by liquid chromatography-tandem mass spectrometry 
(LC/MS/MS). and then two profi les of pharmacokinetic indexes (C0, Cmax, Tmax 
and AUC0-12h) were adjusted by the corresponding FK506 doses and compared.
Results: From Jan 2006 to Jan 2008, 88 kidney transplant recipients (67 males 
and 21 females) between 17 to 61 years old were recruited 1 to 103 months 
post-transplant. Ten patients (11.36%) withdrew from the study for hypotension 
(7 cases, 7.95%) and transaminase elevation (3 cases, 3.41%). Six episodes 
(6.82%) of biopsy-proved acute rejection was documented over the follow-
up period of 1-25 months (median time: 11 months) and were all reversed by 
Methylprednisolone impulse therapy. Serum creatinine level remained stable 
when compared to baseline (118±37ng/ml vs. 124±44ng/ml, p>0.05). FK506 
dose decreased from 0.11±0.05mg/kg to 0.07±0.03mg/kg (p<0.01) while the 
concentration maintained steadily within target ranges. Ten patients (7 males 
and 3 females) of 36±11 years old joined the pharmacokinetic study sub-group. 
Their body weight was 60±10 kilograms and remained constant throughout 
the 15 days. After using Diltiazem for 14 days, the dose-adjusted peak 
concentration (Cmax/Dose) signifi cantly increased from 286.1±128.1ng/ml/kg/
mg to 409.2±127.3ng/ml/kg/mg (p<0.05). while the area under the curve (AUC0-
12h) signifi cantly increased from 1703.4±597.1 ng·h/ml/kg/mg to 2559.1±821.7 
ng·h/ml/kg/mg (p<0.05). Dose-adjusted trough concentration (C0/Dose) and 
peak time (Tmax) were not signifi cantly different from baseline (p>0.05).
Conclusion: Intentionally applying Diltiazem to kidney transplant recipients 
could increase FK506 exposure and decrease the FK506 dose needed for a 
certain target level; thus may reduce the expense on immunosuppressant. Its side 
effects, though usually mild and reversible, should be taken into consideration 
when deciding to add it as a FK506-sparing agent.
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EVALUATING THE CLINICAL IMPACT OF A CHANGE IN 956 
TACROLIMUS IMMUNOASSAY
T. Cavanaugh1, J. Martin1, V. Culp1, N. Parrish1, S. Rudich2, G. Neff2
1James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, 
OH, 2Transplant Services, The University Hospital, Cincinnati, OH
Background: Due to a narrow therapeutic window, tacrolimus (TAC) is 
an immunosuppressive agent that undergoes extensive and routine drug 
therapeutic monitoring in transplant patients. Patient specifi c therapeutic 
ranges take into account individual factors and the relationship between side 
effects and effectiveness demonstrated by specifi c assay results in clinical 
practice over time. A recent change the immunoassay technology used by our 
local laboratory required an analysis and re-establishment of patient specifi c 
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TAC ranges. Fluorescence polarization immunoassay (FPIA) technology, 
which measures TAC and its metabolites, had been used for several years. New 
technology, the cloned enzyme donation immunoassay (CEDIA) measures the 
parent TAC compound, as well as approximately 37% of one metabolite, is 
currently being implemented. For two weeks, the laboratory is reporting both 
assay results. The purpose of this study is to evaluate the correlation between 
the FPIA and the CEDIA laboratory values and to determine how that impacts 
clinical decision making.
Methods: A list of liver transplant patients receiving TAC at our institution over 
the two weeks since the change in assay techniques was generated. Laboratory 
TAC values for the FPIA and CEDIA assays were collected. Descriptive 
statistics, as well as simple linear regression and a t-test were used to evaluate 
the reported TAC concentrations.
Results: Sixty-two TAC concentrations reported with both FPIA and CEDIA 
were collected from 20 liver transplant patients. The mean results for TAC 
concentration with FPIA were 7.85 ± 4.50mcg/L and CEDIA 9.37 ± 5.74 mcg/
mL (p = 0.11).The mean percent change in TAC concentrations was 21.6% ± 
29.4% and the mean absolute difference was 1.52 ± 2.01 mcg/L. Sequential 
daily TAC measurements demonstrated extensive intra-patient variability in the 
range from minimum to maximum values of 12.70% to 155.14% corresponding 
to absolute differences of 0.7 to 4.9 mcg/L (mean 11.0% ± 28.2% and 0.65 ± 
1.37). There was no evident ratio or other applicable mathematic relationship 
identifi ed to guide the development of new patient specifi c ranges. A high degree 
of correlation of FPIA and CEDIA TAC levels was determined by simple linear 
regression, R2 = 0.86. Despite this, based upon current patient specifi c target 
ranges or ± 30% from the FPIA result, a clinically different decision would 
have been made if the FPIA value had not been reported 45% of the time.
Conclusion: Change in TAC immunoassay technology resulted in considerable 
intra- and inter-patient variability causing diffi culty with interpretation of results 
for purposes of clinical decision making. Nearly half of the time, a different 
clinical decision would have been made based on the new level. It will take time 
to establish the relationship between the new assay values and patient outcome. 
Further analysis of the potential impact of these changes is warranted.
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THE INFLUENCE OF CYP3A5 GENOTYPE ON BLOOD 957 
SIROLIMUS CONCENTRATIONS FOLLOWING SWITCH 
FROM A CALCINEURIN INHIBITOR
I. MacPhee, M. Moreton, D.W. Holt
St. George’s, University of London
Background: Genotyping at the single nucleotide polymorphism CYP3A5*1 
predicts whether individuals will express cytochrome P4503A5. Individuals 
with at least one wild-type CYP3A5*1 allele are expressers while CYP3A5*3 
homozygotes do not synthesise the functional protein. CYP3A5 expressers 
require two-fold higher doses of tacrolimus to achieve target blood 
concentrations. Published studies on sirolimus have generated confl icting 
results.
Methods: A sub-group of patients from a multi-centre randomized controlled 
trial of switching patients from calcineurin inhibitor therapy to sirolimus at least 
6 months after renal transplantation consented to entry to a pharmacogenetic 
sub-study. Calcineurin inhibitor was discontinued and on the next day a loading 
dose of 12 mg sirolimus was given followed by 4 mg daily. The dose was then 
adjusted to a target blood concentration of 8-16 ng/mL. The study received 
ethical approval and subjects gave written informed consent.
Results: Of the 42 patients recruited there were 4 CYP3A5 expressers and 38 
non-expressers. Median time post-transplant was 4.26 years (range 0.6-17.8); 12 
were female and 30 male; median age was 46 years (range 26-75). Ethnic groups: 
2 Asian, 1 Black, 32 Caucasian and 1 other. When the fi rst blood concentration 
was measured on day 4 after switching 1/4 (25%) CYP3A5 expressers and 5/38 
(13%) were below the target range. None of the expressers and 9 of the non-
expressers (24%) were above target (Figure). 6 months following switch, dose 
normalized sirolimus blood concentrations for the CYP3A5 expressers were 
clustered at the lower end of the range for CYP3A5 non-expressers (median 147 
ng/mL/mg/kg (range 99.6-220) vs 225 (81-524); p=NS).
Discussion: In this small study the range of dose-normalised sirolimus blood 
concentration for CYP3A5 expressers lay within the range observed for 
CYP3A5 non-expressers. The potential utility of a pharmacogenetic approach 
to dosing sirolimus would be to identify the optimal initial dose to prevent 
under-exposure prior to optimization in respose to therapeutic drug monitoring. 
The regimen employed here with a loading dose delivered the target range for 
the CYP3A5 expressers but led to higher than planned exposure in a number 
of CYP3A5 non-expressers. Recently, practice has evolved to aiming for lower 
target blood concentrations of 5-10 ng/mL in late-stage transplant recipients 
with omission of a loading dose. The regimen from this study, with a loading 
dose, would deliver this target for CYP3A5 expressers and lower initial doses 
without a loading dose would run the risk of under-exposure in this patient 
group with increased risk of rejection at the time of switching.
MYCOPHENOLATESCONCURRENT ORAL SESSION 75: 
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DENOVO POST-RENAL TRANSPLANT INFLAMMATORY 958 
BOWEL DISEASE SUCCESSFULLY TREATED WHILE ON 
MYCOPHENOLATE MOFETIL
M. Halim, T. Al-Otaibi, M. Nampoory, P. Nair, T. Said, M. Samhan
Hamed Alessa Organ Transplantation Center
Background: Prevalence of infl ammatory bowel disease (IBD) post transplant is 
affected by the immune tolerance and modality of immunosuppression used (1).
Mycophenolate mofetil (MMF) may have a promoting effect in developing 
post transplant IBD, Crohn’s disease-like pattern (2,3). in spite that MMF is 
reported to be a reasonable alternative in treating Crohn’s disease for patients 
who do not tolerate azathioprine (4).
Case summary: A 39 years old Omani gentleman had chronic renal failure due 
to advanced nephrosclerosis.
He was on hemodialysis for 9 months till he received live unrelated renal 
transplant.
He was on prednisolone, MMF and tacrolimus which is changed to sirolimus 
when he developed diabetes mellitus two months post-transplant.
Five months post-transplant, he developed recurrent attacks of bloody diarrhea 
and ischiorectal abscesses complicated by anal fi stulae not responding to routine 
surgical treatment (incision and drainage); when he was on prednisolone 10mg/
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day, MMF 500mg twice/day, and sirolimus 4mg/d with trouph level 7.6ng/dl.
Colonoscopy showed multiple erythematous lesions in the rectum and sigmoid 
colon with aphthous ulcers and erosions.
There was mild chronic lymphoplasmacytic cell infi ltration of the lamina 
propria with cryptitis and non-caseating granulomatous lesions (fi gure1). There 
was no evidence of acid fast bacilli or viral infections and CMV antigenemia 
was negative.
He was diagnosed to have IBD, Crohn’s disease-like pattern.
He was treated with steroids and 5-aminosalicylic acid (5-ASA) in addition 
to a course of ciprofl oxacin and metronidazole. Later, he required a course of 
infl iximab.
He was continued on the same doses of MMF (500mg/d) and sirolimus (4mg/
day with trouph level of 7.6ng/dl) .
He became asymptomatic and rectal lesions healed within one month of 
treatment.
Tow years later, he was asymptomatic and maintained on the same 
immunosuppressive treatment and 5-ASA with normal graft function.
Conclusion: IBD disease can develop in renal transplant recipients 
in spite of immunosuppressive therapy especially when MMF is used 
which can be successfully treated without discontinuing this important 
immunosuppressive drug.
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HIGHER DOSE OF ENTERIC COATED 959 
MYCOPHENOLATE SODIUM (EC-MPS) IN KIDNEY 
TRANSPLANTATION; TOLERABILITY, EFFICACY AND 
PHARMACOKINETIC CORRELATION.
M. Nampoory1, T. Said1, A. Shihab-Eldeen2, T. Al-Otaibi1, K.V. Johny3, 
M.A. Halim1, M.P. Nair1, M. Al-Mousawi1
1Hamed Al-Essa Organ Transplant Center, 22Department of Pharmacology, 
Faculty of Medicine, Kuwait University, 3Department of Medicine, Faculty of 
Medicine, Kuwait University
Introduction: EC-MPS in regular dose is known to improve mycophenolic acid 
(MPA) related gastrointestinal (GI) symptoms with therapeutic equivalence to 
mycophenolate mofetil (MMF) in kidney transplant recipients (KTRs). The 
aim of the study is to assess the effect of higher dose of EC-MPS on its effi cacy, 
tolerability and pharmacokinetic properties.
Patients and Methods: Twenty two KTRs were randomly selected to 
receive either 50% increased dose of EC-MPS 1080 mg bid (study group, 
n=10) or regular dose of MMF 1000 mg bid (control group, n=12) in 
addition to prednisolone and cyclosporine as triple immunosuppressive 
therapy. Rejection in the fi rst 3 months post transplant was taken as a 
parameter of effi cacy while GI disorders, hematological abnormalities and 
presence of infections over 6 months were used to assess tolerability. A 
severity score system was used to assess GI disorders. Pharmacokinetic 
profi les were performed in 6 patients in each group to compare MPA trough 
concentration (C0). maximum concentration (Cmax). time to maximum 
concentration (Tmax) and area under the concentration curve (AUC) of 
both drugs.
Results: Four patients in EC-MPS group had acute rejection versus one in 
MMF group. None of them lost the graft. Eight patients (80%) on EC-MPS 
versus 6 patients (50%) on MMF developed GI symptoms with severity 
index of 0.32 versus 0.11 respectively. Dose reduction due to adverse 
events was attempted 1.4 times/patient for patients on EC-MPS versus 0.42 
for patients on MMF. AUC was 39 ug.h/ml for EC-MPS group versus 23 
ug.h/ml for MMF group (p=0.004). C0 (1.59 versus 0.69 ug/ml, p=0.049). 
Cmax (9.87 versus 5.85 ug/ml, p = 0.011) and Tmax (2 versus 1 hour, P 
= 0.001) were signifi cantly higher in EC-MPS compared to MMF groups 
respectively.
Conclusion: Higher dose of EC-MPS was associated with reduced tolerability 
and effi cacy. Higher AUC and/or Cmax in the study group could be the reason 
for increased adverse events.
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MYCOPHENOLIC ACID MONITORING IN RENAL 960 
ALLOGRAFT RECIPIENTS ON MMF/ENTERIC COATED MPS 
THERAPY
R.K. Sharma, G. Sreedas, S. Mehrotra, A. Saxena, A. Gupta
Sanjay Gandhi Post Graduate Institute of Medical Science
MMF, a prodrug of mycophenolic acid (MPA). is a highly effective 
immunosuppressant. Enteric coated mycophenolate sodium (EC-MPS – 
Myfortic). a formulation for delivering MPA was developed with the aim of 
improving MPA – related upper GI adverse events. Pharmacokinetic difference 
exists between the two molecules due to functional enteric coating, leading 
to delayed delivery of MPA as compared to MMF. The present study aims 
to detect (1) the pharmacokinetic difference between MMF and EC-MPS by 
the plasma time curve of MPA (2). compare side effects and effi cacy of the 2 
molecules, (3) drug interaction with concomitant immunosupression. 250 live 
related renal allograft recipients were started on MMF and 73 patients on EC-
MPS (Myfortic). The clinical profi le of these patients, their tolerance to MPA 
and serial renal function were studied and 12 hour MPA-AUC was done in 
15 patients (9 on EC MPS and 6 on MMF) with stable graft function. Blood 
samples were taken in EDTA tubes immediately before the administration of the 
drug (C0). at 30 min (C30). 75 min (C75). 2h (C2) ,4 hour (C 4h) ,6 h, 8h and 
12 hours. The concentrations of plasma MPA was measured by EMIT method. 
EC-MPS demonstrated the typical pharmacokinetic profi le of an enteric coated 
formulation with a delayed release of MPA compared to MMF. Patients on EC-
MPS had a higher (C0) level of MPA and delayed peak compared to patients 
on MMF, although the 12 hour AUC was comparable in both groups .The AUC 
ranged from 30-60mg.h/L. No single value could predict the 12 hour AUC. By 
regression analysis, abbreviated AUC (0-4). limited sampling strategy using 2 
samples (C30, C4) for EC MPS (r = 0.968, r²= 0.937) and 3 samples (C0, C30 
and C4) for MMF could predict AUC (0-12) (r = 0.968, r²= 0.937). The mean 
AUC of the patient groups studied were as follows – Myfortic + CsA = 32.4± 
6 μg/ml, MMF + CsA = 42.3±14.3 μg/ml, Myfortic +Tac = 78.4± 19.8 μg/ml. 
With CsA both EC-MPS and MMF showed comparable AUC, but there was 
delayed Cmax with EC-MPS. With Tacrolimus and EC-MPS, Cmax and AUC 
of MPA were almost double that of CsA and EC MPS. The side effect profi le 
revealed that MPA related GI side effects were more common with MMF (45%) 
than EC-MPS (6%).Herpes zoster was observed in 20% patients with MMF 
and 6% patients on EC-MPS.CMV disease developed in about 12% patients 
on MMF and 5% in EC-MPS. Cutaneous fungal infection occurred in 15% 
patients on MMF and 20% patients on EC-MPS. Neutropenia was observed in 
25% patients on MMF and 17% patients on EC-MPS. The incidence of acute 
rejection in the MMF group was 15% compared to 8% in EC-MPS group. EC 
MPS formulation is associated with less incidence of hematological and gastric 
side effects & had less evidence of acute rejection episodes.
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DOES DOSING OF MYCOPHENOLATE MOFETIL 500 MG 961 
QID VS 1000 MG BID IMPACT EFFICACY AND TOLERABILITY 
AFTER RENAL TRANSPLANTATION
J. Oberholzer6, M. Campara1, J. Thielke2, T. Ommert3, H. Herren4, 
P. West-Thielke5, E. Benedetti7, B. Kaplan8
1University of Illinois At Chicago, 2University of Illinois At Chicago, 
3University of Illinois At Chicago, 4University of Illinois At Chicago, 
5University of Illinois At Chicago, 6University of Illinois At Chicago, 
7University of Illinois At Chicago, 8University of Illinois At Chicago
Mycophenolate mofetil (MMF) reduces the incidence of acute rejection 
(AR) episodes and improves outcomes of kidney transplant (KTx) recipients. 
However, this agent is often associated with adverse events that may require 
dose reduction, interruption or withdrawal of therapy. Several investigators 
have noted that MMF dose reduction (<2 g/day) may be associated with 
suboptimal outcomes in KTx patients. In this retrospective data analysis, 
we examined if MMF dose reduction, extending dosing interval to 500 mg 
QID or conversion to mycophenolate sodium salt has had any effect on AR, 
tolerability, graft survival and glomerular fi ltration rate (GFR) in KTx patients 
vs those receiving standard dose MMF.
Between 01/99 and 12/06, 641 adult, KTx recipients will be reviewed. We 
present preliminary data on 64/641 patients; 14 non-MMF patients were 
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excluded and 9 were switched to alternate therapy. All patients received 
induction with either thymoglobulin, daclizumab or basiliximab. Steroid free 
maintenance with calcineurin inhibitors and MMF was used in 39/64 cases. 
Group A was the dose reduction group and Group B received standard dose 
MMF. Data for all Groups, including Group C (500 mg QID) and Group D 
(mycophenolate sodium). is still being collected and will be available at the 
time of presentation.
AR rate, GFR and overall graft survival at 6 and 12 months post-transplant is 
shown in the table. As previously described, signifi cant difference was noted in 
the rates of early AR (22% vs 57%, p 0.049).
Our preliminary results show that the patients in the MMF dose reduction 
Group experienced a higher rate of AR. Final conclusions are pending 
completion of data collection at which time we hope to show whether 
this effect translates into the extended interval dosing Group and the 
mycophenolate sodium Group.
Preliminary Results
 Group A n=18 (n,%) Group B n=21 (n,%) p-value
African American 3 (16.7) 12 (57.1)  
Female 9 (50) 9 (42.9)  
Age at Transplant 42.1 (16.1) 46.1 (14.3) 0.412
AR within 6 months 4 (22.2) 12 (57.1) 0.049
AR 6-12 months 2 (11.1) 1 (4.8) 0.586
GFR at 6 months 55.1 (14.8) 56.31 (18.8) 0.839
GFR at 12 months 64.55 (16.4) 61.64 (20.3) 0.681
Overall Graft Survival 18 (100) 20 (95.2) NS
Overall Patient Survival 17 (94.4) 21 (100) 0.462
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IMPDH – INHIBITION AS A KEY MARKER IN RENAL 962 
TRANSPLANTATION
M. Raggi1, M. Stangl1, S. Siebert1, S. Thorban1, D. Abendroth2
1Klinikum Rechts der Isar, TU-München, 2Universitätsklinikum Ulm
Introduction: Interpatient variability, changes of pharmacokinetic parameters 
over time and drug interactions make the systemic exposure of mycophenolic 
acid (MPA) unpredictable at a fi xed-dose regimen. There is evidence for a 
relationship between pharmacokinetic parameters, the in-/decrease of the 
AUC, and the co-medication of calcineurin-inhibitors. In this multicenter, 
prospective, longitudinal trial we have investigated the value of therapeutic 
drug monitoring for MPA in correlation to inhibition of Inosin-Monophosphat-
Dehydrogenase (IMPDH) in kidney transplant recipients.
Patients and Method: 68 renal transplant recipients receiving 720 mg of EC-
MPS twice daily and concomitant ciclosporin/tacrolimus provided a total of 
114 pharmacokinetic profi les for IMPDH. By application of an IMPDH assay 
(TDM, 2000). enzyme activity was investigated in isolated lymphocytes from 
renal transplant recipients at predose and at 30min, 60min, 2h, 4h, at week 1, 
2 and 3 months after transplantation (n=68, gender 32 f/34m; mean age: 53 
years). MPA concentrations were measured by a validated HPLC method in 
150 plasma samples collected at the identical time points.
Results: Patients with infection either bacterial or viral as well as patients on 
dialysis were excluded from the study. Finally 22 Patients were left and divided 
in two groups. Patients with rejection (G I, n=11; gender 5f/6m; mean age: 44 
years; FK= 5/CyA= 6) showed a signifi cant lower Inhibition of IMPDH starting 
in week 1 (day 3-5) irrespective the used dosage of CNI. The corresponding 
group (G II n=11; gender 5 f/6m; mean age: 53 years; FK= 5/CyA= 6) without 
rejection showed signifi cant (p<0.006) higher inhibition rates at week 1 and 
2, but no differences in MPA values. The MPA values for week 1 and 2 were 
lower in G II. There was no correlation between IMPDH-Inhibition and MPA 
levels at all timepoints of the protocol. All patients w./o. rejection and with low 
inhibition showed a high trough level of CNI. There was no difference between 
both CNIs applied.
Conclusion: The data show that the measurement of the biological response 
provides a useful adjunct to traditional therapeutic drug monitoring of MPA. 
This will be helpful for preventing rejection episodes especially because the 
discrimination between the patients suffering from a rejection and patients with 
no immunological problems was possible as early as in week one and was 
seen in general before clinical signs of rejection were visible. The therapeutical 
potential of MPA may be optimized especially under the aspects of CNI 
optimized/free immunosuppressive regimens.
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A REAL LIFE REFLECTION OF MYCOPHENOLATE 963 
SODIUM USAGE IN TURKISH RENAL TRANSPLANT 
POPULATION; AN INTERIM ANALYSIS
A. Uslu, T. Arinsoy1, S. Mir, I. Titiz, F. Gonenc, A. Celik, A. Turkmen, 
S. Apaydin, S. Kacar, N. Guvence
1Gazi University Faculty of Medicine, 2SB Bozyaka Research and 
Educational Hospital, 3Ege University Faculty of Medicine, 4Haydarpasa 
Numune Hospital, 5Yukses Ihtisas Hospital, 69Eylul University Medical 
School, 7Istanbul University Istanbul Faculty of Medicine, 8Istanbul 
University Cerrahpasa Faculty of Medicine, 9SB Tepecik Research and 
Educational Hospital, 10SB Etlik Ihtisas Hospital
Objectives: Myfortic® is an enteric coated mycophenolate sodium (EC-MPS) 
formulation developed for acute rejection prophylaxis in renal transplant 
patients. It has been shown before in clinical trials that EC-MPS is an effective 
treatment option for kidney transplant recipients. This is the fi rst observational 
EC-MPS study and also the fi rst country based renal transplant study in Turkey 
with a large patient number. The primary objectives of the study were to 
evaluate patient and graft survival, the incidence of rejection and graft function. 
The secondary objectives were to evaluate the patient compliance and side 
effects of EC-MPS in renal transplant patients who were switched from MMF 
to EC-MPS in equimolar doses or in whom EC-MPS was added to therapy.
Methods: 460 renal transplant patients who received EC-MPS as an adjunct 
therapy with/without CNIs or mTOR inhibitors ± steroids, from 23 Turkish 
transplant centers, were enrolled in this prospective, observational study. 252 
(160 de novo, 92 maintenance) of them completed the follow up period and 
were included in this interim analysis. Vital parameters, effi cacy and safety 
were monitored on 1, 3, 6 and 12th months.
Results: 85 (33.7%) of the 252 patients received cadaveric kidney transplants. 
Mean age of the patients were 31.6±13 and%57.9 were females. 94 (%61) 
patients received induction treatment with interleukin-2 receptor antagonists 
(Basiliximab or Daclizumab). In graft function analysis no change was observed 
in 3, 6 and 12 month blood creatinine, urea, BUN and GFR levels (p=0.05, 
p=0.126, p=0.202 and p=0.970, respectively). Acute rejection was seen in 14 
patients (8 de novo (%5); 6 maintenance (%7,6) and mean time to rejections 
were 2.29±1.09 and 8.67±8.02 months, respectively. Major adverse events:
de novo maintenance
anemia/thrombocytopenia 16.9% 43.5%
increase of liver enzymes 16.3% 26.1%
gastrointestinal symptoms 13.1%, 31.5%
Infection 15% 14.1%
Leucopenia 10% 8.7%
There was one graft loss due to BKV nephropathy and CMV infection and 3 
deaths due to cerebrovascular accident, respiratory failure and glioblastome 
multiforme. 47 (%29,3) de novo and 25 (%27,1) maintenance patients needed 
mycophenolate dose adjustment. 104 de novo (65%) and 38 (41%) maintenance 
patients could use full dose of EC-MPS (1440mg/day). gastrointestinal complaints 
were recorded in 16 (%15,3) and 11 (%28,9) of the patients in this group.
Conclusion: In our opinion; EC-MPS is an effective adjunct therapy for kidney 
transplant patients, successfully preserves renal function in maintenance 
patients, has a high patient compliance and is well tolerated according to this 
real life refl ection.
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CNI MINIMISATION WITH 2 G MYCOPHENOLATE 964 
MOFETIL – WHAT HAVE WE LEARNED FROM THE 
SYMPHONY STUDY?
H. Ekberg1, C. Bernasconi2, P. Halloran3
1Lund University, 2F. Hoffmann-La Roche Ltd, 3University of Alberta
Introduction: The effi cacy of calcineurin inhibitor (CNI) -based 
immunosuppression has been hampered by chronic nephrotoxicity associated 
with these agents. The CNI-minimisation studies that had been performed 
before the inception of the Symphony study had reported some positive results, 
but there was a clear need to fi nd the optimal balance between reducing toxicity 
and maintaining effi cacy. The Symphony study was therefore designed to 
determine whether the use of mycophenolate mofetil (MMF) and daclizumab 
in conjunction with low doses of CNIs or sirolimus may be benefi cial compared 
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with standard-dose cyclosporine-based immunosuppression.
Methods: The Symphony study was the largest ever prospective study in 
de novo solid organ transplant patients, designed to provide robust data 
on the relative benefi ts of the four regimens tested. A total of 1645 kidney 
recipients were enrolled from 83 sites in 15 countries for the one-year core 
study comparing a standard regimen of 2 g MMF + cyclosporine + steroids 
with regimens comprising 2 g MMF + daclizumab + steroids and low doses of 
either cyclosporine, tacrolimus or sirolimus. Approximately half of the patients 
were subsequently enrolled into an optional, observational, follow-up study of 
additionally 2 years.
Results: The results at 1 year showed that the regimen based on MMF + low-
dose tacrolimus resulted not only in signifi cantly improved renal function, 
but also in a signifi cantly lower rate of acute rejection compared with the 
other regimens. The benefi ts on renal function and acute rejection were also 
confi rmed by sub-analyses of the data stratifi ed for country (e.g. with all donors 
being living or deceased donors) or for various ages of the recipients. Similarly, 
when rejectors and non-rejectors were analysed separately, the same pattern 
remained, with MMF + low-dose tacrolimus having superior renal function, 
not only in rejectors but also in non-rejectors. Graft survival was highest in the 
MMF + low-dose tacrolimus group, and patient survival was excellent in all 
treatment groups.
In the follow-up study, many patients changed their immunosuppressive 
regimen (in particular, switching from sirolimus to tacrolimus). but the vast 
majority (95%) remained on MMF at 3 years. In all groups, graft and patient 
survival rates remained high, and acute rejection rates were low during the 
second and third years. The MMF and low-dose tacrolimus arm still had the 
highest GFR, although the difference was not statistically signifi cant.
Conclusions: The Symphony study, the largest ever prospective study 
performed in de novo solid organ transplantation, has provided robust and 
valuable data on the effi cacy and safety of CNI-minimisation regimens. 
Most signifi cantly, 2 g MMF + low-dose tacrolimus was shown to be 
highly effi cacious, without the negative effects on renal function that were 
commonly reported in patients receiving standard CNI regimens. As a result 
of the Symphony study and other data, 2 g MMF + low-dose tacrolimus has 
become the gold standard immunosuppressive regimen in de novo kidney 
transplant recipients. New standards in clinical transplant research have been 
set, and the Symphony study will serve as the benchmark for future studies 
in transplantation.
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OMISSION OF AZATHIOPRINE AND MYCOPHENOLATE 965 
MOFETIL IN IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY 
TRANSPLANTATION
M. Taherimahmoudi, G. Pourmand, A. Mehrsai, M. Nikoobakht
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: In this study effects of reduction and omission of cellcept and 
azathioprine (AZA) in standard immunosuppressive regimen on acute rejection 
,chronic rejection and graft survival has been evaluated.
Methods: During 1989-2005,1000 kidney transplantations has been 
performed in our center, 105 of them, has been followed up 1-10 years (mean 
5 years). All patients received cyclosporine A (CsA). cellcept or AZA and 
maintenance prednisolone. But with the onset of GI complication, hepatic 
toxicity or leukopenia, some alternations in Immunosuppressive regimen 
was considered and patients were divided to 4 groups. Group 1 (15 patients) 
developed severe, resistant leukopenia ,GI complications or hepatic injury, 
so AZA and cellcept were discontinued permanently. Group 2 (38 patients) 
developed leukopenia ,hepatic injury or GI complications at 3 mg/kg AZA 
or 2gr cellcept which were reduced to 1mg/kg Aza or 1 gr cellcept. In 
group 3, all 21 patients received AZA with the dose of 3 mg/kg without any 
complication. In group 4 (31 patients) received cellcept 2gr daily without any 
complication.
Results: Mean creatinine level was 1.32, 1.24, 1.31, 1.38 mg/dl in each group 
respectively. There was no signifi cant difference between mean age ,gender 
and serum creatinine level in 4 groups .Age and sex had no effect on acute or 
chronic rejection within 4 groups .
-  Acute rejection was reported 4 ,2,4,4 patients of each group, respectively (non 
signifi cant ) 
-rejection and graft loss was observed in 3 cases only in group 1 (signifi cant) 
Conclusions: In our study signifi cant increase of chronic rejection was observed 
only in group 1 .No signifi cant association between acute rejection and groups 
was observed. So if side effects due to cellcept or AZA observed, cellcept 1gr 
daily or a minimal dose of AZA (1mg/kg) with CsA and prednisolone can 
prevent leukopenia, hepatic toxicity or GI complications without any signifi cant 
rise in incidence of acute or chronic rejection and graft loss.
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AN EPIDEMIOGICAL, MULTICENTER, CROSS-966 
SECTIONAL STUDY TO ASSESS THE PREVALENCE OF 
GASTROINTESTINAL DISORDERS IN MAINTENANCE 
RENAL TRANSPLANT PATIENTS TREATED WITH 
AN IMMUNOSUPPRESSIVE REGIMEN INCLUDING 
MYCOPHENOLIC ACID (MPA) 
M.C. Rial1, E. Maggiora2, M. Vazquez3, J. Pefaur4, M. Espinosa5
1Instituto de Nefrologia Nephrology, BsAs Argentina, 2Sanatorio Mitre, BsAs 
Argentina, 3Sanatorio Parque, Rosario Argentina, 4Hospital Barros Luco, 
Santiago Chile, 5Hospital del Salvador, Santiago Chile
Introduction: Gastrointestinal (GI) disorders in maintenance renal transplant 
patients treated with mycophenolic acid (MPA) are particularly important 
due to the fact that they may lead to dose reductions or to discontinuation 
of MPA therapy, which in turn have been shown to increase the incidence 
of acute rejection and graft loss. An epidemiological, multicenter, cross-
sectional study was performed to assess the prevalence of GI disorders 
and the GI symptom burden (GSRS questionnaire) in maintenance renal 
transplant patients treated with an immunosuppressive regimen including 
MPA.
Materials and Methods: From a total of 500 patients (pat) enrolled in 
Argentina and Chile, 498 pat were analyzed, 209 received MMF and 289 
Enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Data were 
retrieved with a one visit record form including demographics, transplant 
background, immunosuppressive treatment details and GSRS questionnaire. 
Data were analyzed using descriptive statistics. T test and Chi square test were 
used to compare both treatment groups.
Results: All baseline data were similar for both arms, except: retransplant rate: 
MMF: 16/209 (8%) and EC-MPS: 57/289 (27%) (p=0.042); years post tx: MMF: 
4.79±3.85, EC-MPS: 3.49±3.64 (p=0.001) and years of MPA: MMF: 3.49±2.56, 
EC-MPS: 2.21±1.53 (p=0.001). The therapeutic combinations observed were: 
MMF+CsA: 88 pat (42%). MMF+Tac: 61 pat (29%). MMF+Sirolimus: 42 
pat (20%) and EC-MPS+CsA: 99 pat (34%). EC-MPS+Tac: 123 pat (43%). 
EC-MPS+sirolimus: 52 pat (18%). other patients received a combination with 
everolimus or only MPA+ steroids.
The prevalence of GI symptoms was 32% in the overall population (MMF: 
34%, EC-MPS: 31%; p=ns). however a signifi cantly higher proportion of 
patients on EC-MPS were on full MPA dose (MMF: 31%, EC-MPS: 44%, 
p=0.005). In patients on reduced MPA dose, the average dose (percentage 
of full dose) was higher with EC-MPS, regardless of the CNI type: MMF 
1542/2000 mg/day (77% of full dose) + CsA vs. EC-MPS 1190/1440 mg/day 
(83%) + CsA; MMF 1324/2000 mg/day (66%) + Tac vs. EC-MPS 1101/1440 
mg/day (76%) + Tac.
The GSRS scores were comparable in both treatment arms. A GSRS sub 
analysis was additionally performed according to creatinine levels (> or 
< to 1,5 mg/dl). In patients with creatinine levels >1,5 mg/dl (n=210) the 
abdominal pain score was lower with EC-MPS vs. MMF (1,63 vs 1,89 – 
p<0.05). The other items of GSRS questionnaire showed a positive trend in 
favor of EC-MPS.
Conclusions: The prevalence of GI symptoms and the GI symptom burden 
evaluated by GSRS were comparable between MMF and EC-MPS. However, 
a larger proportion of patients on EC-MPS were treated with full MPA dose vs. 
MMF. In addition, patients on reduced doses of EC-MPS received higher doses 
of MPA than those on reduced doses of MMF. The abdominal pain score was 
signifi cantly lower in the population with creatinine levels >1,5 mg/dl treated 
with EC-MPS.
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RENAL FUNCTION IMPROVEMENT IN PATIENTS WITH 967 
MAINTENANCE IMMUNOSUPPRESSION WHO INITIATE 
ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) 
A. Sánchez-Fructuoso1, J.C. Ruiz San Millán2, M. Rengel3, J.M. Morales4, 
I. Beneyto5, V. Torregrosa6, C. Cantarell7
1Hospital Clínico San Carlos, 2Hospital Marqués de Valdecilla, 3Hospital 
Gregorio Marañón, 4Hospital 12de Octubre, 5Hospital La Fe, 6Hospital 
Clinic, 7Hospital Vall d´Hebron
Introduction: Although the safety and effi cacy of the new enteric-
coated mycophenolate sodium (EC-MPS) are comparable to those of the 
mycophenolate mofetil (MMF). it still needs a lot of evaluation of its use in 
routine clinical practice.
Objective, research design and methods: The aim of the current study was 
to examine prospectively in routine clinical practice the effi cacy and safety of 
EC-MPS in 726 stable renal transplant patients at 1, 3, 6, and 12 months after 
its initiation.
Data are presented at the end of the study (12th month).
Results: Mean age was 53±13 years, 56% males.
The main causes for the switch to EC-MPS were GI intolerance to MMF (44%; due 
principally to diarrhea -30%-, abdominal pain -20%- or dyspepsia -17%-). chronic 
nephropathy (16%; toxicity attributed to calcineurin inhibitor drugs (CNI) -11%- 
and chronic rejection -5%-). or others (40%; from which 14% were for prevention 
in order to reduce or suspend the dosage of CNI -10%- or steroids -3%-).
90% started with EC-MPS after the fi rst post-transplant month (median time of 
the transplant: 6.1 years).
Basal plasma through levels (PTL) of mycophenolic acid (MPA) taken after 
conversion to EC-MPS increased from 2.0 ng/ml to 2.9 ng/ml at 12 months 
(p<0.001). And this occurred even having received slightly lower than 
equimolar doses of MPA (711 mg/d vs 648 mg/day, p<0.005). CsA and Tac 
doses were also signifi cantly reduced (163 mg/d vs 142 mg/d of CsA, p<0,001 
and 5.1 mg/d vs 3.9 mg/d of Tac).
Before conversion, the evolution of creatinine clearance showed a negative 
slope, refl ecting a progressive deterioration of renal function, (p<0.005). 
whereas after conversion the slope showed positive (p<0.05). indicating an 
improvement in renal function.
CsA (169.04 mg/d basal to 142.91 mg/d at 12 months, p<0,001) and Tac (5.18 
mg/d basal to 3.93 mg/d at 12 months, p<0,001) doses decreased along the study.
10.0% of patients quit the treatment with EC-MPS with 5.3% due to GI toxicity.
85 patients with GI intolerance to MMF were converted to EC-MPS: Among 
these patients, 80% tolerated EC-MPS and more than 40% patients tolerated 
well the drug up to doses more than 720 mg-d.
Conclusions: Treatment with EC-MPS results in signifi cant changes in renal 
function, reversing the progression of renal deterioration after 12 months after 
beginning EC-MPS treatment. This may be attributed to the lowering of the 
dose of CNI and/or a better immunosuppressive effi cacy of EC-MPS, because 
of an improvement in the GI tolerability and drug absorption.
The increased basal PTL of MPA and good tolerability could have been part of 
the reasons for the CNI dose reductions.
There are patients with MMF intolerance that can be treated with full doses of EC-
MPS. EC-MPS tolerability has been good with a low rate of GI adverse effects.
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SIGNIFICANCE OF PK STUDY OF MPA IN RENAL 968 
TRANSPLANTATION. A META-ANALYSIS AND PK STUDY
K. Yoshida1, M. Kobayashi2, Y. Miyashita2, Y. Takeuchi3, M. Arima2, 
K. Yago2, T. Hirayama1, F. Obata4, M. Ikeda1, F. Noguchi1
1Kitasato University Urology, 2Kitasato University Hospital Pharmacology, 
3Kitasato University Nephrology, 4Kitasato University Immunology
Purpose: Mycophenolate mofetil (MMF) is now widely used immunosuppressant 
in renal transplantation (RTX). To avoid rejection and adverse events, monitoring 
mycophenolic acid (MPA) level is recommended, but pharmacokinetics (PK) 
monitoring of MPA is still controversial. We studied the relationship between 
PK parameters of MPA and clinical event in RTX by meta-analysis, and 
investigated PK parameters of RTX patients in our institute.
Materials & Methods: A) META-ANALYSIS; We picked up papers by 
MEDLINE and Cochrane Library (1996 to 2006) using eighteen terms related 
to MPA, and investigated about 1) PK parameter and clinical outcome (acute 
rejection (AR) and adverse event (AE). 2) target concentration of MPA, 3) 
sampling point and frequency of monitoring, 4) method of measurement, 5) 
induction and maintenance dose control. B) PK STUDY; We conducted PK 
study of the RTX patient in our institute after obtaining patient fs consent under 
control of our ethical committee. Blood sampling was done on 7 days, 1 month 
and 3 months post transplant at before (C0) and 0.5 (C0.5). 1 (C1). 2 (C2). 3 (C3). 
4 (C4). 6 (C6). and 8 (C8) hours after MMF administration. MPA concentration 
was measured by HPLC, and data was analyzed by SPSS ver. 15.
Results: A) META-ANALYSIS; We fi nally choose eleven papers from 286 
selected papers, and combined data. Signifi cant relation was observed between 
C0 & AUC of MPA and AR & AE (p<0.05). Signifi cant increase of AR incidence 
was occurred in the group of MPA AUC0-12 less than 30 ug h/ml (p<0.05). The 
numbers of blood sampling points were between once to eight times to control 
MPA concentration estimation. MPA was measured by HPLC in six papers out 
of eleven. B) PK STUDY; We collected 205 blood samples from eleven living 
and four cadaver RTX patients. Cyclosporine was used in fi ve, and tacrolimus in 
ten patients. PK parameters of MPA in those patients were C0; 4.5+/-2.5 ug/ml, 
AUC0-12; 84.5+/-37.7 ug h/ml. AR was recognized in two patients and AE was 
observed in 21 (such as anemia and CMV infection). Two AR were recognized 
in the patients of both AUC0-12 less than 40 ug h/ml and C0 less than 1.3 ug/
ml. C0 was different in the patients of using cyclosporine from tacrolimus. AE 
(anemia) was observed in 5 patients out of 6 who showed AUC0-12 more than 
100 ug h/ml. From our PK study, calculated AUC0-12 estimation using the 
result of C0 and C3 MPA measurement was recommended (r2=0.931).
Discussion: Signifi cant relation was observed between PK parameters and AR 
& AE in RTX by meta-analysis, suggesting effi cacy to perform PK study of 
MPA in RTX. From our results of PK study of MPA in RTX patients, the target 
concentration of more than 1.3 ug/ml as C0 and 40 ug h/ml as AUC0-12 to avoid 
AR may be recommended. AUC0-12 of less than 100 ug h/ml may also have to 
maintain to avoid AE such as anemia. To estimate AUC0-12 from less frequent 
sampling points, two points of C0 and C3 measurements of MPA were effective.
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OUTSTANDING GRAFT SURVIVAL AFTER INCLUSION 969 
OF MYCOPHENOLATE MOFTIL IN INITIAL 114 RENAL 
TRANSPLANTATIONS: SINGLE CENTER STUDY FROM 
NORTHWESTERN PART OF INDIA
L.C.S. Laxmichand1, V. Malhotra2, D. Agarwal3, V. Khandelia4, J.H. Hota5, 
V.K. Binwal6
1Institute of Renal Scincies, Sms Hospital,Jaipur, 2Institute of Renal Scincies, 
Sms Hospital,Jaipur, 3Institute of Renal Scincies, Sms Hospital,Jaipur, 
4Institute of Renal Scincies ,Sms Hospital,Jaipur, 5Institute of Renal Scincies, 
Sms Hospital,Jaipur, 6Institute of Renal Scincies, Sms Hospital,Jaipur
Initial 114 renal transplants from live related donors were performed from 
Jan 1999 to Feb. 2008 at SMS Hospital, Jaipur a tertiary care Hospital of 
North West Rajasthan. Recipients were 104 males and 10 females, age 
ranged between 16-50 years. Amongst Donors 22 were males & 92 females, 
their ages were between 20 to 60 years. In 61 renal transplant; parents were 
the donors and the rest include 26 siblings, 24 spousal and 3 second degree 
relatives. All recipients received cyclosporine and prednisolone. Fiftynine 
patients received azathioprine and 55 patients received mycophenolate mofetil. 
Acute graft rejections were treated with 3 cycles of I.V. methylprednisolone. 
HLA matching & cross matching were done. All patients were negative for 
crossmatching. HLA matching was: 0 antigen matches in 10 cases, 1 in 31 
cases, 2 in 58 cases, 3 in 12 cases & 4 in 3 case. Urological complications 
occurred in 10 cases consisting of 8 urinary leaks, 2 ureteral stenosis. In 2 cases 
renal artery thrombosis took place. Out of 114 patients 17 expired, sepsis being 
the main cause of death in 15 patients followed by preumonia, CMV infection 
& hepatic failure due to hepatitis-C.
Overall patients survival for last 9 years were 85%, for last 3 years 87% and there 
was much improved graft survival in last 2 & 1 years 91%, 100% respectively. 
The mycophenolate mofetil was started as third immunosuppression replacing 
azathioprine after 2005, resulted in less number of acute rejection episodes and 
excellent graft & patient survival in last 2 years which reached to 100% in the 
year 2007.
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POSTER BOARD NUMBER P1 – 56
AZATHRIOPRINE IS BETTER THAN MYCOPHENOLATE 970 
MOFITIL IN LONG TERM KIDNEY GRAFT FUNCTION.
D. Sirivongs, U. Toimamueang, C. Pongskul, S. Reungjui
Khon Kaen University, Faculty of Medicine
Background: Azathrioprine have been replaced by mycophenolate mofitil 
in 3-drug regimen of KT for a decade, but it is still used in many centers 
in developing countries. To analyze outcome of KT patients with Aza 
compared with ones with MMF, we performed a retrospective analytic 
study.
Methods: We reviewed 204 renal transplant recipients who had the operations 
performed at our facility during 1990-2007 and who had received a primary 
immunosuppressive protocol consisting of CSA, steroid and azathioprine 
(AZAgr; 51 patients) or CSA, steroid and MMF (MMFgr; 153 patients). Only 
adult primary renal transplant recipients aged between 15 and 60 years were 
included. All cases received kidneys from cadaveric donors. The study was 
based on the long-term follow-up data of these renal transplant recipients. 
Comparative analyses included graft survival rates, rejection (acute and 
chronic). PTDM and opportunistic infection.
Results: The overall frequency of acute rejection episodes was not 
signifi cantly different between both groups. Graft survival rate was: 50% 
survival in AZAgr was 59 mo. compared to 48 mo. of MMFgr (p=0.0000). 
Four cases of AZAgr showed serious bone marrow suppression compared 
to 2 cases of MMFgr. No signifi cant differences were encountered 
between the two groups regarding post-transplant diabetes mellitus, DGF, 
or serious bacterial infections. Conclusion: AZA is still be a choice of 
immunosuppressive drugs for KT, but may need a preventive measure for 
bone marrow suppression. The survival outcome of AZAgr is quite good 
and signifi cant better than MMFgr. AZA should be reconsidered as a good 
immunosuppressive drug for KT.
POSTER BOARD NUMBER P1 – 57
TWELVE MONTH FOLLOWUP OF GASTROINTESTINAL 971 
(GI) CO-MEDICATION DISCONTINUATION OR REDUCTION 
IN RENAL TRANSPLANT PATIENTS AFTER CONVERSION 
FROM MYCOPHENOLATE MOFETIL (MMF) TO 
MYCOPHENOLATE SODIUM (EC-MPS) 
P. Bolin, P. Vos, P. Sullivan, S. Gerkin, K. Parker
Brody School of Medicine, East Carolina University
Purpose: To evaluate if successful discontinuation or reduction of GI co-
medication use is sustainable 12 months after conversion from MMF to EC-
MPS. 
Methods: Fifty-four renal transplant patients on a GI co-medication were 
recruited from a single center cohort of 93 patients who had successfully 
converted from MMF to EC-MPS in a previous study. These patients were 
placed on a protocol to reduce or discontinue their GI co-medication. 
Additional follow up was conducted at one year. At baseline, patients on twice 
a day GI co-medication were reduced to daily dosing and at 30 day visit further 
reduced to PRN. Patients on daily dosing at baseline were reduced to PRN. 
All patients were given pocket diaries to record GI co-medication use and 
potential cost savings. Assessments for GI symptoms were performed using 
Gastrointestinal Symptom Rating Scale (GSRS). Gastrointestinal Quality of 
Life Index (GIQLI) and Psychological General Well-Being Index (PGWBI) 
at each visit. 
Results: Successful discontinuation or reduction of GI co-medication 
was achieved in 42 (78%) patients after 30 days and maintained through 
day 90. There was no signifi cant change in assessments from baseline to 
day 30 or 90 despite discontinuation or reduction in GI co-medication. 
Twenty-four patients (44%) were taking Proton Pump Inhibitors (PPIs) and 
30 (56%) were taking H-2 blockers at enrollment. Twelve month follow 
up demonstrated sustained improvement in 32 (91%) of these patients. A 
balanced reduction of both PPIs and H-2 blockers was observed. Estimated 
cost savings per patient for H-2 blockers are $925-$1850 and PPIs are 
$1861-$3722 annually. 
Conclusion: This study supports successful long term minimization of GI 
co-medications in maintenance renal transplant patients after conversion 
to EC-MPS. These data suggest that after conversion to EC-MPS renal 
transplant patients can successfully reduce or discontinue GI co-medication 
without worsening of symptom burden, while maintaining their health-related 
quality of life and overall well-being. Considering graft survival rates of 72% 
at 5 years this could translate into signifi cant long term savings for renal 
transplant patients. In addition, avoidance of GI co-medication is important 
considering the multiple potential complications recently described in this 
class of medication.
POSTER BOARD NUMBER P1 – 58
50% OF THE RENAL TRANSPLANT PATIENTS THAT 972 
CAN NOT REACH THERAPEUTIC MYCOPHENOLIC ACID 
LEVELS WITH MMF BECAUSE OF GI INTOLERANCE, 
ACHIEVED THERAPEUTIC LEVELS WITH EC-MPS.
J.M. Puig, M. Mir, S. Hurtado, O. Rap, M. Crespo, C. Barrios, F. Barbosa, 
C. Estadella, E. Rodriguez, J. Lloveras
Hospital Del Mar, Nephrology Dept
Mycophenolic acid (MPA) trough levels are signifi cantly related to acute 
rejection incidence, but also to gastrointestinal (GI) and hematological 
toxicity. At equimolar doses, enteric-coated mycophenolate sodium (EC-
MPS) may provide signifi cantly higher MPA area under the curve (AUC). and 
Cmin than mycophenolate mofetil (MMF). The study objective is to analyse 
whether stable RT patients treated with tacrolimus (TAC) or cyclosporine 
(CsA) and MMF with persistently MPA Cmin levels below the therapeutic 
window (1.5ng/ml-4ng/ml) because of GI intolerance, could reach the desired 
level with equimolar or higher EC-MPS doses.
Methods: Due to the high intraindividual variability in the MMF 
absorption profile, we defined MPA undertherapeutic levels as Cmin 
under 1,5ng/ml in at least two of the last five level measurements ie: 
at least 40% of the time below the therapeutic window. We studied 40 
long-term stable RT patients. 61% men. Age: 53.4±13.4y. Time from RT: 
2.5±3.6y. Deceased donor: 95%. Second RT: 15%, highly sensitized: 10%. 
Induction treatment: policlonal antibodies: 28%, OKT3: 5%, Daclizumab: 
59%, TAC: 87%, CsA: 13% and steroids: 100%. Maintenance treatment: 
TAC+MMF: 97%, CsA+MMF: 2.5%, steroids: 23%. Target levels: TAC: 
7-10ng/ml, CsA C2: 600-850ng/ml, MPA: 1.5-4ng/ml. All patients were 
switched from MMF to equivalent EC-MPS doses. After the conversion, 
EC-MPS dose was increased by 50% in those patients that still were under 
the therapeutic level in two o more controls, provided that there were no 
GI side effects and leukocyte count was over 4000. Those patients that still 
were under the desired level despite increasing doses, EC-MPS was further 
increased by 180mg/d.
Results: When MMF maintenance dose was switched from 0.75±0.39g/d 
to the equivalent 0.54±0.22g/d of EC-MPS, 11/40 patients (28%) reached 
the objective with MPA levels of 2.58±2.1ng/ml. When EC-MPS dose 
was rised by 50% (0.81±0.37g/d). other 9/29 patients (31%) achieved and 
tolerated MPA levels of 2.63±2.3ng/ml. Of the remainig 20 patients no one 
tolerated any further increment without appearence of GI side-effects. After 
rising the EC-MPS dose by 50%, there was a non signifi cant trend towards 
a drop in the number of leukocytes, hemoglobin and platelets. In no case 
this drop lead to lowering EC-MPS doses or treatment withdrawal. No acute 
rejection episodes were observed and no dose-adjustement of TAC or CsA 
was needed.
Conclusions: In long-term stable RT patients with subtherapeutic MPA levels 
because of GI adverse-effects, 28% achieve therapeutic levels after equivalent 
dose conversion from MMF to EC-MPS. An additional 31% of the remaining 
patients, reach the desired levels after increasing EC-MPS dose by 50% without 
new-onset GI side effects.
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POSTER BOARD NUMBER P1 – 59
USE OF MYCOPHENOLATE SODIUM AND MYCO-973 
PHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS
P.F. Fernandes, G. Silva Junior, J.P. Ferreira Silva, M. Uchoa Mota, 
S. Albuquerque Andrade, C. Oliveira, J.B. Evangelista Junior
Renal Transplant Unit, Walter Cantidio University Hospital, Federal 
University of Ceara
Background/Objectives: Therapeutic equivalence of mycophenolate sodium 
and mycophenolate mofetil has been established in randomized trials. The aim 
of this study is to analyze the use of enteric coated mycophenolate sodium 
(MPS) and mycophenolate mofetil (MMF) in renal transplant recipients.
Methods: This is a case-series study, conducted a study from July 2007 to January 
2008, including 21 renal transplant recipients in Brazil. It was investigated the 
occurrence of biopsy-proven acute rejection (BPAR). infection, gastro-intestinal 
side effects, graft loss, rejection and the need for drug discontinuation or dose 
reduction. Descriptive statistical analysis was done.
Results: It was included 21 patients, with an average age of 45 years 
(range 21-68 years); 12 were male. The immunosuppressive regimens were 
Prednisone/MMF/FK (7 cases). Prednisone/MPS/FK (11 cases). Prednisone/
MPS/Ciclosporine, Prednisone/MPS/FK and MPS/Ciclosporine (1 case each). 
BPAR was observed in 4 cases (2 in Pred/MMF/FK regimen, 1 in Pred/MPS/
FK regimen); three had graft loss (1 primary non-function in Pred/MMF/FK 
regimen, 1 renal artery thrombosis in Pred/MPS/Ciclosporine regimen, 1 renal 
vein thrombosis in Pred/MPS/FK regimen). Gastro-intestinal side-effects were 
observed in 5 cases (3 using MPS, 2 using MMF). Infection occurred in 8 
cases, being more frequent in patients using MPS.
Conclusion: These are the fi rst data regarding the use of MPS in our unit. MPS 
seems to be as safe as MMF in renal transplant recipients. Further studies are 
required to better establish the main differences in using these medications in 
immunosuppressive regimens.
POSTER BOARD NUMBER P1 – 60
ANALYSIS OF CONVERSION FROM MYCOPHENOLATE 974 
MOFETIL TO ENTERIC-COATED MYCOPHENOLATE 
SODIUM (EC-MPS, MYFORTIC) IN RENAL TRANSPLANT 
PATIENT USING PATIENT-REPORTED OUTCOMES
W. Arns1, K. Budde2, B. Nonnast-Daniel3, K. Eichele4, W. Fischer4, 
P. Petersen5, D. Scholz5, H. Sperschneider5, L. Fricke5, P. Reinke2
1Cologne General Hospital, 2Berlin University Charite Berlin, 3University 
Hospital Nuernberg, 4Novartis Pharma Nuernberg, 5on behalf of the MyLife 
study group
Background: The benefi t of converting renal transplant recipients with 
gastrointestinal (GI) complaints from mycophenolate mofetil (MMF) to 
enteric-coated mycophenolate sodium (EC-MPS) has been evaluated using 
patient-reported outcomes. To our knowledge, no validated data are available 
including either patients with or without GI complications before conversion.
Methods: A multi-center, open-label, prospective study was undertaken in 
MMF-treated renal transplant recipients. Patients were converted to equimolar 
EC-MPS. At baseline and Visit 2 (6–8 weeks post-baseline). patients completed 
the Gastrointestinal Symptom Rating Scale (GSRS). Gastrointestinal Quality of 
Life Index (GIQLI) and Psychological General Wellbeing Index (PGWBI). At 
Visit 2, patients and physicians completed the Overall Treatment Effect (OTE) 
scale for GI symptoms and health-related quality of life (patients only).
Results: Of 196 patients enrolled, 100 experienced GI complications at 
baseline. These patients revealed signifi cant improvement for GSRS, GIQLI 
and PGWBI total scores as well as for the OTE scale between baseline and 
Visit 2 (all p<0.001, except p<0.01 for PGWBI). Mean improvement in GSRS 
score (-0.43) exceeds the assumed minimally clinical important difference 
in the GSRS score of 0.33. Primary endpoint analysis, i.e. change of GSRS 
in the total population revealed no signifi cant differences, however, the total 
population improved in GIQLI and OTE scales (p<0.001).
Conclusion: This study supports that converting patients with GI complaints 
to EC-MPS signifi cantly reduces GI-related symptom burden and improves 
patient health-related quality of life. Moreover, this study indicates that the 
entire population might benefi t from conversion in terms of quality of life and 
OTE for GI symptoms.
POSTER BOARD NUMBER P1 – 61
THE EFFICACY AND SAFETY OF TAILORED 975 
MYCOPHENOLATE THERAPY BASED ON BODY WEIGHT 
AND MYCOPHENOLIC ACID TROUGH LEVELS IN ASIAN 
RENAL TRANSPLANT RECIPIENTS.
T. Kee, A. Vathsala
Singapore General Hospital
Introduction: At our centre, a higher incidence of leukopenia and CMV 
infections were seen with fi xed dosing [1g twice daily (BD) ] of mycophenolate 
mofetil (MMF) compared to azathioprine treated renal transplant recipients 
(RTX). A dosing protocol based on body weight (10mg/kg/dose) was utilised 
between 2003 and 2006. Therefore, we compared in de novo RTX, the safety and 
effi cacy of MMF fi xed (FD) versus tailored dosing (TD) based on body weight 
with subsequent titration to mycophenolic acid trough level (MPA-C0).
Methods: The study population consisted of 63 RTX (26 TD-RTX, 37 FD-
RTX; Weight 56.2 kg [range 37-93 kg]) on cyclosporine (adjusted to 2-h post 
dose (C2) of 1,200-1,500 ng/mL for the fi rst month and 1,000-1,200 ng/mL up 
to six months). corticosteroids and MMF. The starting MMF dose was 10mg/
kg/dose BD and 1g BD for TD and FD-RTX respectively. Subsequent doses 
were adjusted to clinical events or to MPA-C0 of less than 4 ng/mL for TD-
RTX. MPA-C0 were obtained at day 7, 14, 30 and monthly thereafter.
Results: All TD-RTX received deceased donor kidneys (compared to 
27% [n=10/37] of FD-RTX) and 1 recipient per group were CMV D+/R-. 
Prophylaxis was pre-emptive in 88.5% [n=23/26] of TD-RTX and universal in 
67.6% [n=25/37] of FD-RTX. Mean initial MMF dose for TD-RTX and FD-
RTX were 9.6±1.2 mg/kg/dose and 17.0±4.6 mg/kg/dose respectively (TD vs. 
FD-RTX; p<0.005). During 6-month follow-up, 61.5% (n=16/26) of TD-RTX 
vs. 43.2% (n=16/37) of FD-RTX had dose reductions (p=0.15). Frequency of 
adverse events prompting dose reductions between TD-RTX and FD-RTX were 
similar (50% [n=13/26] vs. 40.5% [n=15/37]; p=0.45). Between TD and FD-
RTX, adverse events included rejections (15.4% [n=4/26] vs. 8.1% [n=3/37]; 
p=0.37], CMV disease (15.4% [n=4/26] vs. 8.1% [n=3/37]; p=0.37], bacterial 
infections (42.3% [n=11/26] vs. 40.5% [n=15/37]; p=0.88). cytopenias (7.7% 
[n=2/26] vs. 18.9% [n=7/37]; p=0.21) and gastrointestinal complications (0 vs. 
10.8% [n=4/37]; p=0.08). Compared to initial MMF dose, dose used in FD-
RTX was signifi cantly reduced at 6 months to 14.7±5.5 mg/kg/dose (p=0.01) 
whereas doses used in TD-RTX was not signifi cantly different (8.1±2.2 mg/
kg/dose at 6 months; p=0.22). Withdrawal of MMF occurred in 1 FD-RTX 
at 3 months post-transplantation for CMV disease. Within TD-RTX, MPA-C0 
were maintained below 4 ng/mL (1.8±0.7 ng/mL to 2.6±1.2 ng/mL) during 
follow-up. C2 levels were also similar between TD-RTX and FD-RTX except 
at 4 (1,010±331 ng/mL vs. 1,235±349 ng/mL; p=0.03) and 6 months (871±266 
ng/mL vs. 1,048±181 ng/mL; p=0.01) post-transplantation. At six months, 
calculated glomerular fi ltration rate were similar between TD-RTX and FD-
RTX (48.1±19.6 ml/min/1.73m2 vs. 47.2±12.4 ml/min/1.73m2; p=0.8).
Conclusions: Only 57% of FD-RTX could be maintained on 1g BD for six months 
without adverse events in an Asian RTX population. In contradistinction, TD-
RTX who were dosed by body weight and subsequently titrated to MPA-C0 had 
similar outcomes to FD-RTX. Refi nements in a titrated dosing strategy may further 
optimise mycophenolate use in a population with wide variations in body weight.
POSTER BOARD NUMBER P1 – 62
MMF 500 GENERIC FORMULATION IN KIDNEY 976 
TRANSPLANTATION
B. Abdallah 1-2, I. Helal 1, M. Ounissi 1, M. Cherif1, R. Goucha1, 
E. Abderrahim 1, A. Klouz2, M. Lakhal2, Y. Gorgi3, A. Kheder 1
1Department of Internal Medicine A Charles Nicolle Hospital, 
2Pharmacovigilance department Charles Nicolle Hospital, 3immunology 
laboratory department Charles Nicolle Hospital
Introduction: The Introduction of mycophenolate mofetil (MMF) has proven 
to be effective in the prevention of acute rejection in renal transplant recipients. 
However his prohibitive cost renders its long-term use in countries with limited 
income.This 6-month single center, prospective, randomized and open-label 
study instigated the effi cacy and safety of a new MMF generic formulation 
(MMF 500 developed by Medis – Tunisia) compared with Cellcept (Hoffman 
La Roche Switzerland) renal transplant recipients.The study enrolled 18 
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patients from February to august 2007 divided in 2 groups: 8 pts in G1 received 
MMF 500 and 10 pts in G2 received Cellcept. Their demographics data were 
similar: respectively mean age (y) 36.7 + 7.1 and 33.3±11.7, sex M/F: 2/6 
and 5/5, mean age donor 42.6 +11.9 and 43.6±3.9, mean HLA mismatchs 2.7 
±1.1 and 3.3 ±1.4, cadaveric donors 25% and 20%, warm ischemia time 40.2± 
11.9 and 38.7± 10.5 minutes.All patients received 2 gr. daily of MMF500 or 
Cellcept in combination with tacrolimus at an initial dosage of 0.15 mg/Kg/day 
and prednisolone.
Results:
Acute  creat Diarrhea Infection AUC*day 7AUC*day 30
rejection 6 months Nb
 (μmol/l) 
G1 1 120.7±24.4 2 6  25.9  34.1
G2 1 100.4±16.8 3 9  27.5  27.1
P NS  NS  NS NS  NS  NS
AUC is expressed In ng/ml/h
The graft and patient survival at months were at 100% in the 2 groups In 
conclusion, These results indicated that the use of MMF500 provided safe and 
effective immunosuppression compared with cellcept. However as the duration 
of the study was short, these results need to be confi rmed in long term.
POSTER BOARD NUMBER P1 – 63
LONG-TERM OUTCOME OF MYCOPHENOLATE 977 
MOFETIL ADDITION TO CALCINEURIN-INHIBITOR-
BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT 
RECIPIENTS WITH BIOPSY PROVEN CHRONIC GRAFT 
DYSFUNCTION
M. Durlik1, A. Urbanowicz1, E. Blazik1, E. Wazna1, A. Perkowska1, T. 
Cieciura1, 
A. Kwiatkowski2, Z. Galazka3
1Transplantation Institute, Dept. of Transplant Medicine and Nephrology, 
Warsaw Medical University, 2Dept. of General and Trasnplant Surgery, 3Dept. 
of General, Vascular and Trasnplant Surgery
Introduction: Chronic graft dysfunction, a major cause of late renal graft 
loss, is promoted in part by prolonged exposure to calcineurin inhibitor (CnI). 
Mycophenolate mofetil (MMF) addition improves renal function in short term. 
Long term outcome and safety profi le still awaits verifi cation.
Aim: Evaluation of long term MMF effect on renal graft function in recipients 
with biopsy-proven graft dysfunction, treated with cyclosporine (Cs) or 
tacrolimus (Tac). with further continuation, reduction or withdrawal of CnI.
Methods: 109 recipients with declining renal function were included, after 
addition of MMF to Cs (n=96) or Tac (n=13) at month 72 and 13 posttransplant 
for Cs and Tac, respectively. CnI was reduced (Group R, n=50 for Cs, n=6 for 
Tac). withdrawn (Group W, n=28 for Cs, n=4 for Tac) or not changed (Group 
C, n=18 for Cs, n=3 for Tac). Slopes of GFR (estimated with short MDRD 
[eGFR]). along with proteinuria, lipid profi le, mean blood pressure (MAP) and 
antihypertensives were recorded for 4-6 month run-in, and followed-up for 1 
(n=109) to 3 years (n=60).
Results: MMF improved renal function in all groups (eGFR slope [mL/month] 
-1.462 1.52 vs. -0.098 1.16, p<0.0001). independently of CnI used or group (R, 
W, C) effect. Proteinuria and lipids level did not change after MMF addition, 
however total cholesterol was lower in Tac treated recipients (212.2 vs. 179.8, 
p<0.002, for Cs and Tac, respectively). MAP lowered similarly in both CnI 
groups (102 6.3 vs. 98.4 6.8, p<0.006). with no change in antihypertensives 
use (2.82 vs. 2.62 and 1.84 vs 2.0 in Cs and Tac group, respectively). Use 
of antihypertensives tended to be lower in Tac group. 7 reversible rejection 
episodes were observed exclusively in Cs group (3, 2, and 2 in Group R, W, 
and C,respectively).
Conclusions: MMF added to CnI-based immunosuppressive regimen stably 
improves transplanted kidney function in long-term, as does blood pressure 
control in recipients with chronic graft dysfunction independently of CnI type 
or its further continuation. Risk of late rejection concerns only Cs treated 
patients, it does not exceed 10% independently of further continuation of Cs.
POSTER BOARD NUMBER P1 – 64
A OPEN-LABEL, PROSPECTIVE RANDOMIZED TRIAL 978 
TO COMPARE TOLERABILITY AND OUTCOME FOR TWO 
FORMULATIONS OF MYCOPHENOLATE
Y. Qazi1,2, S. Takemoto3, R. Mateo1, J. Alameda1, C. Romero1, S. Schroff1, 
A. Tsirunyan3, T. Shah2,3
1University of Southern California, 2MOTC, St Vincents Medical Center, 
3National Institute of Transplantation
Two formulations of mycophenolate have essentially replaced Azathioprine, and 
made antiproliferatives (AP) a cornerstone of maintenance immunosuppression. 
However, data comparing their relative effi cacy in denovo patients are lacking. 
For instance, little is known, to what extent side effects such as gastrointestinal 
irritation or anemia warrant dose reductions. The objectives of this study were 
to compare the effi cacy and tolerability of these formulations over a six month 
period.
Methods: A total of 111 subjects were enrolled at two institutions to receive 
either mycophenolate mofetil (MMF) or Enteric coated mycophenolic acid 
(EC-MPA) with a calcineurin inhibitor (tacrolimus or cyclosporine). steroids 
and induction. Target dosages were 1000 mg BID for MMF and 720 mg BID 
for EC-MPA. Doses were reduced if white blood count fell below 4,000 cells 
per ml or if a patient developed gastrointestinal or other side effects that might 
be attributable to the AP. A composite endpoint of rejection, graft loss and death 
was used to compare effi cacy with rates calculated using the Kaplan Meier 
produce limit method and signifi cance by log rank. Chi-square was used to test 
for signifi cance in the percentage of patients receiving full dose AP and the 
association of complications prior to dose change.
Results: Dose reductions occurred in 40% (n=44) of enrolled patients. Clinical 
events occurring at signifi cant rates prior to dose reduction included delayed 
graft function (9% vs. 0% with no dose reduction, p=0.01). diarrhea (11% vs. 
0%, p=0.005). urinary tract infection (14% vs. 0%, p=0.002). and anemia (7% 
vs. 0%, p=0.03). The table below illustrates the percentage of patients on full 
dose AP during the four clinic follow-up visits. Patients receiving EC-MPA 
more likely tolerated full dose AP compared to MMF, with the difference 
statistically signifi cant through 3 months. The percentage of patients reaching 
the composite rejection endpoint at the 6 month time point was similar (15%) 
for the two arms of the study.
Conclusions: This prospective randomized comparison of two anti-proliferative 
formulations indicates patients receiving enteric coated mycophenolic acid more 
likely tolerated full intended doses compared to those receiving mycophenolate 
mofetil. This better tolerability can have positive effects on clinical outcomes 
besides facilitating compliance.
Percentage of patients on full dose antiproliferative
Week 2 Month 1 Month 3 Month 6
EC-MPA 90.7 90.4 84.3 75.0
MMF 75.6 69.2 57.8 56.4
P 0.047 0.007 0.004 0.074
LIVER CONCURRENT ORAL SESSION 76: 
TRANSPLANTATION: SURGERY
POSTER BOARD NUMBER P1 – 65
BILIARY HEMORRHAGE AFTER REMOVAL OF 979 
EXPANDABLE METALLIC STENT DURING LIVER 
TRANSPLANTATION
S. Narumi, K. Hakamada, Y. Toyoki, M. Nara, S. Yoshihara, M. Sasaki
Department of Surgery, Hirosaki University School of Medicine
Introduction: The self-expandable metallic stent (SEMS) has become a 
common device for palliative treatment of malignant biliary obstructions or 
benign strictures. Despite the ease in the placement of SEMSs, their removal 
has been reported to be very diffi cult. Here, we report a case with primary 
sclerosing cholangitis (PSC) who developed massive hemorrhage after 
intraoperative removal of a SEMS. 
Case: Possible living donor liver transplantation was considered for a 
49-year-old female with PSC. However, her general condition did not meet 
the criteria for liver transplantation; therefore, she was referred back to her 
primary physician. Two years later, she developed jaundice, and multiple 
SEMSs were placed by her primary physician, one of which was placed 
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across the papilla of Vater. She was evaluated rapidly, and underwent living 
donor liver transplantation. During the operation, the common bile duct was 
examined and an incision was made. A stent was found fi rmly embedded 
in the bile duct. Each wire of the SEMS was pinched and then successfully 
pulled out one by one. Finally, all parts of the SEMS were removed. Before 
creating the Roux-en-Y limb, hemorrhage from the remnant bile duct was 
confi rmed by examination of the duodenum and bile duct stump. The bile 
duct was sewn internally with monofi lament stitches and compressed for 
10 min. Finally, hemostasis was brought about and transplantation was 
completed successfully. 
Conclusion: Despite some reports regarding successful endoscopic removal of 
SEMSs, its removal in patients with coagulopathy is risky. SEMSs should not 
be placed in patients for liver transplantation.
POSTER BOARD NUMBER P1 – 66
“BILE LEAK AFTER ADULT RIGHT LOBE SPLIT 980 
LIVER TRANSPLANTATION: ARE TOPICAL SEALANTS 
EFFECTIVE?”
L. Toti, M. Attia, T.M. Manzia, I. Lenci, B. Gunson, J. Buckels, D.F. Mirza, 
A.D. Mayer, S.R. Bramhall, S.J. Wigmore
Liver Unit – Queen Elizabeth Hospital – University of Birmingham – UK
Background: Bile leaks are a frequent complication of adult split liver 
transplantation. We compared surgical complications in patients who 
had the cut surface of the liver treated with a fi brin-collagen sponge 
(Tachosil®) and patients in whom the cut surface of the liver was treated 
with fi brin glue.
Methods: Two consecutive cohorts of 16 patients undergoing adult right lobe 
split liver transplant were compared. In the fi rst cohort the liver was treated 
with Tachosil® fi brinogen-thrombin-collagen sponge patches and in the second 
the liver surface was treated with fi brin glue. Blood usage and post operative 
complications were documented.
Results: Blood usage in both groups was equal. Patients in whom the cut 
surface of the liver was treated with Tachosil® had signifi cantly fewer bile 
leaks (1 of 16) compared with those where fi brin glue was used on the cut 
surface (7 of 16) (p<0.03). There were some differences in biliary anastomotic 
techniques used in the two groups but 7 of 8 leaks arose from the cut surface 
only and 1 from both the surface and anastomosis.
Conclusions: Using a fi brinogen-thrombin-collagen sponge patch such as 
Tachosil® may reduce bile leaks from the cut surface of adult right lobe split 
liver transplants.
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SURGICAL ANATOMY BY CORROSION CAST OF THE 981 
HEPATIC VEINS IN COLOMBIA SOUTH AMERICA
E. Lozano Marquez
Universidad Nacional De Colombia Departamento De Cirugía Y Morfología
Background: To determine if the surgical anatomy of the hepatic veins among 
Colombians is similar to the one described in the literature.
Materials & Methods: 50 normal livers ,mean age 30 (age 5-50) obtained 
from autopsies were studied.
The hepatic veins were injected retrogadely from the vena cava with colored 
acrylic resin .After hardening of the acrylic resin ,the livers were corrosioned 
in caustic soda.
Results: The 90% of the right hepatic vein drains segments VI and VII, and 
several parts of segments V and VIII. The middle hepatic vein always drains 
segments IV and V, and to some extent segment VIII. In 10% the middle hepatic 
vein also drained segment VI. The left hepatic vein drains segments II and III; 
in 12%cases, it also drained segment IV.
The right hepatic vein was single in 82% casts and double or more in 18%. 12% 
had an accessory right hepatic vein parallel to the main right hepatic vein; in 
6%, there were three right hepatic veins all of which were > 5mm.
64% have no ramifi cation within 1 centimeter from the inferior vena cava; 22% 
have one vein within less than 1 centimeter and 14% have two veins within 1 
centimeter.
The middle and left hepatic veins presented a common trunk in 90% of our 
cases,while in 10% the middle and left hepatic veins were independent.
Of the veins that presented a common trunk 15.5% there was a common trunk 
formed by the middle hepatic vein and two left hepatic veins. In 6.7%, there 
was a common trunk formed by the middle hepatic vein, the left hepatic vein, 
and a vein from segment IV. In 2.2%, there was a trunk formed by four veins: 
a middle hepatic vein, two left hepatic veins, and one independent vein from 
segment VIII.
The veins of the segment I formed a common trunk that has a diameter ranging 
from 0.5 to 0.7 centimeter.
The mean of dorsal hepatic veins entering the vena cava was 11, however up to 
28 were noted on one occasion.
Conclusions: 1- Compared with studies performed in Japan and US hepatic 
vein anatomy has similar variations in our ethnic group
2- The only difference see in our ethnic group was the presence of 3 right 
hepatic veins all largest than 0.5cms which has not been previously described 
in the literature.
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THE EFFECTS OF MICROSURGICAL BACK WALL 982 
SUPPORT SUTURE TECHNIQUE IN LIVING-DONOR LIVER 
TRANSPLANTATION
S. Miyagi, Y. Enomoto, N. Kawagishi, S. Sekiguchi, Y. Akamatsu, 
K. Fujimori, S. Satomi
Transplantation, Reconstruction And Endoscopic Surgery, Tohoku University
Objectives: Microsurgical reconstruction of hepatic artery is the essential 
but challenging technique in liver transplantation (LTx). Especially on living 
donor, compared with cadaveric donor, hepatic artery is short, the intimal 
damage is severe, and usable vessel grafts are limited. So, sometimes it 
is diffi cult to used conventional reconstruction technique, twist technique 
that turned over the hepatic artery. To overcome these diffi culties we 
performed back wall support suture technique with double needle sutures. 
The purpose of this study is to examine the effects of this technique using 
ultrasonography.
Methods: From July 1991 to January 2008, we performed 118cases of 
living-donor LTx (LDLTx). In the 88cases, we used conventional twist 
technique. In the 30cases, we used back wall support suture technique. To 
put it briefl y, we placed two sutures at the deepest, most diffi cult points in 
the artery for backside support. Each stitch was placed from inner side of 
the arterial wall to outer side with double needle sutures. We performed 
ultrasonography every day after LDLTx and examined pulsatile index (PI: 
peak systolic-end diasto!ic/mean velocities) and resistive index (RI: peak 
systolic-end diastolic/peak systolic velocities) on 1, 5, 7 and 14 days after 
operation.
Results: Total ratio of hepatic artery thrombosis (HAT) was 7.6% (9/118). 
In the conventional twist technique group, HAT occurred in eight patients 
9.1% (8/88). On the other hand, in the new technique group, it occurred 
only one patient 3.3% (1/30). This patient had intimal dissection in recipient 
original artery. So there is no case of HAT that was associated with arterial 
reconstruction in new technique group. PI in the conventional group versus 
in the new technique group on 1, 5, 7 and 14 days after operation was 1.380, 
1.852, 1.204 and 1.006 versus 1.550, 1.606, 1.570 and 1.347 respectively. RI 
in the conventional group versus in the new technique group on 1, 5, 7 and 14 
days after operation was 0.772, 0.776, 0.598 and 0.577 versus 0.722, 0.735, 
0.739 and 0.694 respectively. The values of PI on 14 day and RI on 7 and 14 
days in the new technique group were signifi cantly higher than those in the 
conventional group.
Conclusion: We think that our technique allows for safe intimal adaptation, 
because it didn ft need turning over of the artery and all stitches are carried 
from inside to outside. In conclusion, this back wall support suture technique 
might contribute to more satisfactory results.
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BILIARY RECONSTRUCTIONS AND COMPLICATIONS 983 
AFTER ADULT LIVING DONOR LIVER TRANSPLANTATION – 
FEASIBILITY OF DUCT-TO-DUCT RECONSTRUCTION WITH 
T-TUBE EXTERNAL STENT
T. Kobayashi, Y. Sato, S. Yamamoto, H. Oya, Y. Hara, T. Watanabe, H. Kokai, 
K. Hatakeyama
Division of Digestive and General Surgery, Niigata University
Objectives: Biliary complications are one of the important issues to be addressed 
after living donor liver transplantation (LDLT). Our previous preliminary study 
showed duct-to-duct biliary reconstruction (hepaticohepaticostpmy) with 
T-tube external stent (HH-T) may decrease biliary complications compared to 
other biliary reconstructions. The aim of this study is to analyze the feasibility 
of duct-to-duct biliary reconstruction with a T-tube external stent after adult 
LDLT based on long-term follow-up. 
Methods: From March in 1999 to January in 2008, 79 LDLTs were performed 
in our institution. Among these, we retrospectively evaluated 63 primary adult 
LDLTs survived more than one month. We compared the incidence of bile leaks 
and biliary strictures in three groups of patients; those who had Roux-en-Y 
hepaticojejunostomy biliary reconstruction (HJ) (n=18). those who had duct-to-
duct hepaticohepaticostomy with external stents except a T-tube (HH) (n=26). 
and those who had duct-to-duct hepaticohepaticostomy with a T-tube external 
stent (HH-T) (n=19). Bile leaks were defi ned as the leak by cholangiography 
or presence of bile juice in the free abdominal cavity. Biliary strictures were 
defi ned as the strictures by cholangiography or dilatation of intrahepatic bile 
duct with/without elevation of biochemical liver test. Median follow-up was 
longer in HJ group (63, range: 4.5-105 months) than others (32, range: 2.5-93 
months in HH group and 25, range: 1.5-59 months in HH-T group) (p=0.04). 
Results: The overall incidence of biliary complications (bile leaks and biliary 
strictures) and patient survival were 46% and 75%. Patient characteristics (age, 
gender, MELD score, Child-Pugh score, donor age, graft type (right lobe or 
left lobe). graft-to-recipient weight ratio, cold/warm ischemic time, operation 
time, blood loss, hepatic artery thrombosis, and cytomegarlovirus infections) 
were not different in three groups. Only the incidence of ABO incompatibility 
was higher in HH-T group (42%) than others (0% in HJ group, 8% in HH 
group) (p=0.0007). Bile leaks were observed in eight patients (44%) in HJ 
group and nine patients (33%) in HH group, and one patient (5%) in HH-T 
group (p=0.02). Biliary strictures were observed in four patients (22%) in HJ 
group and 12 patients (46%) in HH group, and four patients (21%) in HH-T 
group (p=0.12). Overall biliary complications were observed in 10 patients 
(56%) and 15 patients (58%). and four patients (21%). respectively (p=0.03). 
All patients of bile leaks were treated by continuous drainage and 15 (83%) of 
them were resolved. However, three grafts and patients (one in HJ group and 
two in HH group) were lost because of sepsis after bile leaks. 10 patients (56%) 
of biliary strictures were managed with endoscopic treatment. Especially, 64% 
of strictures in HH and HH-T groups were managed endoscopically. 4 patients 
(22%) of strictures were managed with percutaneous transhepatic approach. 4 
patients (22%) of strictures were managed with operative treatment. 
Conclusions: Biliary reconstruction using HH-T may be effective to prevent bile 
leaks after LDLT and lead to reduce the incidence of overall biliary complications. 
However, HH-T did not decrease the incidence of biliary strictures in this retrospective 
long term follow-up study. Endoscopic management was main treatment for biliary 
stricture after duct-to-duct biliary reconstruction after adult LDLT.
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EARLY RESULTS OF BILE DUCT RECONSTRUCTION 984 
WITHOUT STENT FOR LIVER TRANSPLANTATION
M. Haberal1, H. Karakayali1, S. Sevmis1, G. Moray1, C. Aydogan1, A. Torgay2, 
G. Arslan2
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Anesthesiology
Biliary complications are some of the most important problems in liver 
transplantation (LT). Although T tubes and stents are widely used for routine 
biliary reconstruction in LT, which lead to complications, and there is no proof 
that they are benefi cial on healing. In this report, we describe our results of 
biliary reconstruction without stenting in both deceased and living-donor 
LT. Two hundred and twelve LTs were performed between January 2001 and 
January 2008 at our center. Before December 2006, we used different drainage 
techniques for biliary reconstruction including T tubes, straight feeding tubes, 
and transhepatic catheters. Since December 2006, we have performed biliary 
reconstruction without a drainage catheter for both deceased and living-donor 
LT. After December 2006, 70 LTs (44 males, 26 females; median age, 25.2 ± 20.7 
years; range, 0.5 to 60 years) were performed, the results of which were reviewed 
retrospectively. Thirty-four of these 70 recipients were children, 17 of them were 
under the age of 1 year at the time of LT. Thirteen recipients received a whole-
liver graft, 24 received a right lobe graft, and 33 received a left-lateral lobe or left 
lobe graft. Biliary reconstruction was performed with a duct-to-duct anastomosis 
in 51 recipients and with a Roux-en-Y hepaticojejunostomy in 19. Fifty-two of 
the 70 grafts had single bile duct, 14grafts had 2 bile ducts, 3 grafts had 3 bile 
ducts, and 1 graft had 4 bile ducts. Biliary leak was seen in 3 recipients, and biliary 
stenosis was seen in 8 during the follow-up 7.7&#61617;4.7 months (range, 1 
to 16 months). All complications were treated with interventional radiological 
approach. Five recipients died, and remaining 65 (93%) recipients are alive in 
this series. We conclude that biliary reconstruction without using a stent is safe 
for both deceased and living-donor LT, even for the pediatric recipients
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LATE VASCULAR COMPLICATIONS AFTER LIVING-985 
DONOR LIVER TRANSPLANT
M. Haberal1, S. Sevmis1, F. Boyvat2, H. Karakayali1, G. Moray1, A. Torgay3, 
C. Aydogan1, G. Arslan3
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Radiology, 3Baskent 
University Faculty of Medicine, Department of Anesthesiology
The aim of this study was to assess the late vascular complications (which occurred 
> 6 months after transplant) in 168 living-donor liver transplants (LDLTs) in 
165 recipients (93 pediatric, 72 adult, 114 males, 51 females) at our center 
between September 2001 and January 2008. These 168 LDLTs were analyzed 
retrospectively. The mean age of the pediatric recipients was 6.5 &#61617; 5.4 
years (range, 2 months to 17 years). and the mean age of the adult recipients 
was 41.3 &#61617; 12.6 years (range, 18-66 years). The vascular complications 
were identifi ed by Doppler ultrasonography; then, the diagnosis was confi rmed 
by computerized tomography angiography and conventional angiography. We 
observed hepatic arterial (HA) stenoses in 2 (1.1%). an HA aneurysm in 1 
(0.6%). portal vein (PV) stenoses in 4 (2.2%). PV aneurysms in 3 (1.7%). and 
hepatic vein (HV) stenoses in 2 recipients (1.1%). At the time of diagnosis, 2 HA 
stenoses, 1 PV stenosis, and 1 HV stenosis recipient had complication-related 
symptoms such as elevated liver function test results and ascites. HA aneurysm 
recipient was admitted to the hospital with massive upper gastrointestinal 
bleeding. In 1 recipient with PV aneurysm, portal vein thrombosis occurred 
23 months after diagnosis. The remaining 6 recipients were asymptomatic. 
All late vascular complications were treated successfully using interventional 
radiological approaches except 1. A PV aneurysm with a thrombosis was 
treated with anticoagulant therapy. We did not encounter any radiology-related 
complications. None of the patients required surgery. Mean follow-up period 
after treatment of complications was 18.6 &#61617; 13.3 months (range, 3 to 37 
months). At the time of this writing, all recipients (100%) are alive with normal 
liver functioning. In conclusion, our vascular complications rates during the 
late post-operative period after LDLT are acceptable. Late arterial and venous 
complications may be managed by angioplasty and endovascular stenting with 
no signifi cant effect on mortality at our center.
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NON-STENTED DUCT TO DUCT ANASTOMOSIS IN 986 
LIVER TRANSPLANTATION: A SAFE METHOD
A. Jafarian1, M. Moeeni2, M.A. Mohagheghi1, J. Salimi2, A. Aminian1, 
A. Rabbani1
1Imam Khomeini Hospital Complex- Tehran University of Medical Sciences, 
2Sina Hospital- Tehran University of Medical Sciences
Introduction: Biliary complication has been named Achilles’ tendon of 
liver transplantation. Common bile duct (CBD) anastomosis is an important 
technical step of the procedure. Several techniques have been used since the 
introduction of liver transplantation.
Materials & Methods: 11 liver transplantations were performed from October 
2006 to December 2007. After evaluation of Oddi sphincter with number 3 and 
4 Bakes dilator, duct to duct anastomosis was performed in 10 patients using 
separate 6/0 PDS sutures. Choledochojejenostomy was done in one patient 
with diseased CBD.
Results: There were 2 early postoperative mortalities, one due to primary non 
function and another with hepatocellular carcinoma and pulmonary sepsis. The 
remaining 8 patients (M/F=5/3) with mean age of 41.7 years were followed 
for a mean of 6 months. We had only one biliary leakage in a patient with 
early hepatic artery thrombosis diagnosed at fourth week. No other biliary 
complication or canalicular enzymes abnormality occurred.
Conclusion: Non-stented end to end CBD anastomosis is a safe method for 
biliary reconstruction in liver transplantation with lower morbidity. Monitoring 
of bile quality could be replaced with other clinical and laboratory fi ndings.
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LATE SURGICAL OPERATIONS IN LIVER TRANSPLANT 987 
RECIPIENTS
K. Zieniewicz1, W. Patkowski1, T. Wroblewski1, M. Fraczek1, W. Kupis2, 
Z. Jabiry-Zieniewicz3, R. Paluszkiewicz1, P. Bojarski4, P. Nyckowski1, 
M. Krawczyk1
1Dept. of General, Transplant & Liver Surgery, Medical University of 
Warsaw, 2Dept. of Thoracic Surgery, Institute of Tuberculosis and Lung 
Diseases, 3Dept. of Gynecology and Obstetrics, Medical University of 
Warsaw, 4Dept. of Neurosurgery, Medical University of Warsaw
Liver transplant (LTx) recipients sometimes require surgery for various reasons 
unrelated directly to the transplantation procedure.
Aim: analyzis of the incidence of late operations, indications and impact on 
survival.
Materials & Methods: clinical records of 580 consecutive LTx patients 
operated on in the period 1994 -2007 were retrospectively reviewed and 
statistically analyzed to compare the subpopulations.
Results: 32 patients (5,5%). 11 males: 21 females, age 19-58, mean 40,2, 
underwent late operations performed at least 3 months post LTx. Mean period 
after LTx was 24 months (range 3 – 120 months). 37,5% procedures occurred 
within 1 year postransplant. The variety was very wide: in 7 patients (22%) 
operations were performed for gynecological indications, 4 patients (12,5%) 
underwent the abdominal or inguinal hernia repairs, 3 patients (9%) underwent 
neurosurgical operations unfortunately with fatal outcome, 4 patients (12,5%) 
– for late septic complications and 11 (34%) – were operated on for oncological 
diseases including melanoma, HCC recurrence in lungs and liver, thyroid 
cancer and esophageal cancer (colon bypass performed). 1 patient after liver 
and kidney transplantation underwent total hip replacement. 6 patients have 
two or more late operations.18 procedures (56%) were performed by the 
transplant surgery team and all occurred in the same facility as the transplant. 
The majority of operations were related to the initial disease or to the 
complications of immunosuppression. 22 patients (69%) are still alive in good 
general condition.
Conclusions: Late operations are relatively rare among liver transplant 
recipients, but their variety is very wide. Oversight by the transplantation team 
may have an important impact to the favourable outcome.
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THE USE OF RECIPIENT SUPERFICIAL FEMORAL VEIN 988 
AS A VENOUS GRAFT FOR PORTAL VEIN RECONSTRUCTION 
IN A RIGHT-LOBE LIVING DONOR LIVER TRANSPLANT 
PROCEDURE
K. Sato, S. Sekiguchi, T. Watanabe, Y. Akamastu, N. Kawagishi, A. Sato, 
K. Fujimori, S. Satomi
Advanced Surgical Science And Technology Division, Department of Surgery, 
Tohoku University School of Medicine
Aims: In living donor liver transplantation (LDLT). the presence of portal 
vein thrombosis (PVT) in the recipient is frequently regarded as a relative or 
absolute contraindication by most groups because of the poor outcomes and 
high mortality rates in addition to the technical diffi culties. To reconstruct 
the portal vein (PV) of a right-lobe liver graft (RLG) using an interposition 
graft from the splenomesenteric junction, a suffi cient length of vascular graft 
is required. In the absence of venous grafts from a deceased donor, a venous 
graft must be obtained from the LDLT recipient. A single external iliac vein or 
internal jugular vein graft coming from the recipient may sometimes be short 
as a jumping graft for PV reconstruction. Therefore, we have used the recipient 
superfi cial femoral vein (SFV) to reconstruct the PV because the size of the 
SFV makes it an excellent natural size match for the PV.
Methods: A total of 40 adult LDLT using RLG was performed at Tohoku 
university hospital. Of these, 33 patients were reconstructed PV by single end-
to-end anastomosis with right or left portal vein of the recipient. 3 patients 
were transplanted RLG with two separated portal veins and reconstructed 
by double anastomoses using both right and left portal vein of the recipient. 
The remaining 4 patients were required venous graft for portal reconstruction, 
including complete occlusion of the main PV (n=3) that was demonstrated 
prior to LDLT and sclerotic portal vein with partial thrombosis (n=1). In all 4 
cases, we adopted the use of SFV derived from recipient as an interposition or 
jumping graft from the splenomesenteric junction to the graft PV.
Results: The 1-, 3-, 5-year patient survival in 40 right-lobe LDLT patients was 
90.4, 86.1, and 72.2%, respectively. None of the patients were died due to PVT. 
There were 2 cases of anastomotic PV stenosis, which were suspected by clinical 
manifestation and then demonstrated by portography, one in portal reconstruction 
without venous graft and the other with SFV graft. Both cases were treated 
successfully by balloon angioplasty. Of the 4 patients with portal reconstruction 
using SFV graft, one died 2 months posttransplanatation due to multiple organ 
failure associated with multiple liver abscess, although the adequate portal infl ow 
was maintained. Another patient revealed partial occlusion of a SFV graft with 
residual thrombosis after a 10-month follow-up computed tomogram portography 
(CTP). Although complete occlusion of a SFV graft in this patient was confi rmed 
by a 15-month follow-up CTP, portal infl ow was maintained due to developed 
collateral vessels from the splenomesenteric junction into the intrahepatic PV 
with 28 months follow-up. The remaining 2 patients revealed excellent patency 
of main PV trunk by CTP with 37 and 55 months follow-up, respectively.
Conclusions: The recipient SFV is an excellent size match for the PV 
reconstruction as a long interposition or jumping conduit when the venous 
system from the deceased donor is not available. The indication for LDLT in 
patients with complete PVT should be carefully decided before transplantation 
in terms of the portal reconstruction.
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THE EFFECTS OF THE TIMING FOR HARVESTING 989 
VASCULAR GRAFT FOR VENOUS RECONSTRUCTION FROM 
RECIPIENT ON INTRAOPERATIVE BLOOD LOSS IN LIVING 
DONOR LIVER TRANSPLANTATION
K. Sato2, T. Iwane1, S. Sekiguchi2, N. Kawagishi2, Y. Akamastu2, S. Miyagi1, 
I. Takeda1, K. Fujimori2, A. Sato2, S. Satomi2
1Tohoku University Hospital, 2Advanced Surgical Science and Technology 
Division, Department of Surgery, Tohoku university school of medicine
Aims: Liver transplantation has been associated with signifi cant blood loss. 
The recipient hepatectomy in living donor liver transplantation (LDLT) differs 
from the deceased donor liver transplantation in that the maximum length of 
the hepatic artery, portal vein and hepatic duct (hilar dissection) and the inferior 
vena cava (IVC) have to be preserved. Blood loss usually predominates during 
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the dissection of the native liver. In the absence of venous system from deceased 
donors, right liver without middle hepatic vein transplant procedure sometimes 
needs the additional surgical procedure such as harvesting an autologous vein 
for vascular reconstruction from the recipient. In such a patient, the additional 
procedure sometimes contributes to progressive coagulopathy and cause 
unexpected bleeding from the abdomen. Therefore, we analyzed our cases to 
determine the optimal timing for harvesting an autologous vascular graft from 
the patient in terms of intraoperative blood loss (IBL).
Methods: A total of 51 adult LDLT was performed at Tohoku university hospital. 
Of these, 26 patients were not required venous graft for vascular reconstruction 
(group A). The remaining 25 patients were performed LDLT using a venous graft 
that was obtained superfi cial femoral vein (SFV) from the recipient; 12 patients 
had undergone SFV extraction after hilar dissection and liver mobilization 
from retro-hepatic area with preserving IVC were complete (group B). and 13 
patients underwent SFV extraction immediately after hilar dissection without 
liver mobilization to avoid progressive coagulopathy (group C).
Results: The actual 1- and 3-year patient survival was similar between the 
3 groups (84.8%, 78.9% in group A, 90.9%, 90.9% in group B, and 92.9%, 
84.4% in group C, respectively). The median warm ischemic time for the 3 
groups was similar (58 min in group A, 53 min in group B and 44 min in group 
C, respectively). but the median cold ischemic time (CIT) for group B (173 
min) was signifi cantly longer than that for group A (95 min) and group C (112 
min). Although the median IBL for group C patients (176 mL) was similar to 
that for group A patients who had not undergone SFV extraction (174 mL/kg). 
the median IBL for group B (381 mL/kg) was signifi cantly higher than that for 
other 2 groups. In group B patients, the additional hemostatic procedure further 
aggravated coagulopathy and signifi cantly prolonged not only the time from 
skin incision to liver graft implantation (633 min) but also the total operation 
time (1041 min) to control bleeding from the abdomen in addition to the SFV 
harvesting site, compared with other two groups (453, 861 min in group A and 
457, 870 min in group C, respectively). however the average operation time in 
group C patients was similar to that in group A in spite of SFV preparation.
Conclusions: The timing for undergoing SFV extraction in LDLT patients has 
effects on IBL associated with consumptive coagulopathy and operation time 
including CIT. Based on our experiences, we conclude that SFV preparation for 
vascular reconstruction should be performed before liver mobilization from the 
retro-hepatic area to minimize IBL in LDLT.
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FURTHER UNDERSTANDING OF ISCHEMIC-TYPE 990 
BILIARY LESIONS BY RESEARCH ON MECHANISM OF 
ISCHEMIA/REPERFUSION INJURY IN RAT BILIARY TRACT
Y.P. Li, N. Zhao, L. Feng, Y.S. Li, L.L. Pang, L. Wei, S.F. Li, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
The most troublesome biliary complications after liver transplantation is the 
ischemic-type biliary lesions (ITBL). with an incidence varying between 5% 
and 15%. Several risk factors for ITBL have been identifi ed, and ischemia-
related injury (IRI) is the main risk factor. This study is to investigate the 
mechanism of ischemia/reperfusion injury in rat biliary tract.
Methods: Male Wistar rat were devided into sham group and biliary tract IRI 
group (n=27/group). The liver was prepared as for graft removal during liver 
transplantation. At the completion of this procedure, the liver was isolated from 
all vascular supply except for the main hepatic artery, the extrahepatic peribiliary 
plexus and the portal vein. Then the biliary tract was suffered from long-term 
ischemia/reperfusion injury. Liver tissues and serum samples were harvested 
at 4h, 1d, 2d, 1w, 2w, 3w,4w, 5w and 6w after operation. The morphology, 
function, pathophysiology and immunology were observed and detected by HE 
stain, Massion stain, PAS stain, serum enzyme detection, IHC and RT-PCR.
Results: Rats developed biochemiacal signs of cholestasis exlusively after 
complete arterial depribation of bile ducts. Compared with sham group, IRI 
group had signifi cant higher level of ALT, AST, ALP, GGT and TB after 
operation, but all of them completely resolved at 6 weeks postoperation. 
Cholangiocyte proliferation and the number increase of biliary tract were 
obseved beginning at 1 week, up to peak at 4 weeks and returned to be normal 
at 6 weeks. At 1 week, fi brosis became detectable as thin deposites around 
proliferative bile ducts, and increased along with the bile ducts proliferation. 
Myofi roblasts (MFB) were around the proliferative bile ducts from 1 week 
postoperation. At later time points, moderate infl ammatory infi ltrates were 
present in portal tracts. Compared with sham group, the expression of ICAM-1, 
VEGF and TGF-¦Â1 of cholangiocytes in IRI froup were signifi cantly higher. 
Besides, we detected the RRLT, homologous to mouse RAE-1 family of 
proteins, but had no positive expression.
Conclusions: Cholangiocyte proliferation resulted from IRI is a compensation 
to impaired bile function. However, its proliferation maybe some different with 
normal cholangiocyte, lead to high expression of certain molecules and fi nally 
results in fi brosis, stenosis and increased chance to be attacted by immune 
reaction. If we can fi nd an appropriate opportunity to give interventions, maybe 
we can ease or improve ITBL after liver transplantation.
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TECHNIQUE AND RESULTS OF BILIARY 991 
RECONSTRUCTION WITH DUCT-PLASTY IN ORTHOTOPIC 
LIVER TRANSPLANTS.
S. Nishida, A. Tekin, A. Maki, E. Akpinar, J. Moon, D. Levi, G. Selvaggi, 
E. Island, T. Kato, A. Tzakis
University of Miami, Miami Transplant Institute
Backgrounds: End-to-end bile duct reconstruction without T-tube has become 
one of the preferred methods for biliary reconstruction in liver transplantation. 
Biliary complication including late phase biliary strictures has been reported in 
this method. We present the technique and results of bile duct-plasty including 
spatulated end-to-end bile duct reconstruction and cuff reconstruction using the 
common bile duct and cystic duct.
Methods: Between April 2007 and February 2008, 20 patients (26 – 68 years 
old) underwent orthotopic liver transplantation with biliary reconstruction with 
duct-plasty. Spatulated end-to-end bile duct reconstruction was performed 
for15 patients. Cuff reconstruction using the common bile duct and cystic duct 
was performed for 3 patients. Combination of spatulation of bile duct and cuff 
reconstruction using the common bile duct and cystic duct was performed for 
2 patients. Running anastomosis with 6-0 PDS was performed for all patients. 
Neither a biliary stent tube nor T-tube was used.
Results: No biliary leakage was observed within the early postoperative 
period (post operative day 0-30). No stenosis of the bile duct anastomosis 
was observed during this time. So far, no late biliary stenosis was observed 
(40-329 post operative days). Complications unrelated to the surgical technique 
including one cholestatic recurrent hepatitis C and one graft failure secondary 
to infection were observed. MRCP or ERCP was performed in 2 cases due to 
elevated liver function test and all the results were negative for biliary stricture 
or leakage. Current blood works showed as follows: median total bilirubin 0.9 
mg/dL, direct bilirubin 0.1mg/dL, AST 33U/L, ALT 33 U/L, ALKP105U/L, 
and GTTP 61U/L.
Conclusions: Biliary reconstruction with bile duct-plasty (including spatulated 
end-to-end bile duct reconstruction, cuff reconstruction using the common bile 
duct and cystic duct and combination of these) represents a safe technique of 
bile duct reconstruction and leads to a low technical complication rate after 
liver transplantation. Further follow up and randomized prospective studies are 
needed to confi rm our results.
POSTER BOARD NUMBER P1 – 78
THE USE OF A MODIFIED HEPATOJEJUNOSTOMY IN 992 
LIVER TRANSPLANTATION.
B.Gala Lopez, J. Copo Jorge, O. Clausell Wong, R. Sarría Duvergel, 
F. Gonzalez Castillo, S. Sainz Lopez, J. Gonzalez Escobar, D. Perez
Transplant Division, Hermanos Ameijeiras Hospital
Biliary complications are a major concern in liver transplantation. Several 
strategies have been developed to avoid such complications, especially when 
small caliber structures are involved.
We describe the use of a modifi ed hepatojejunostomy previously described 
by the authors in liver transplant settings. The technique was used in 3 adult 
patients undergoing whole cadaveric liver transplantation, in which the donor 
bile duct presented with a diameter below 3 mm.
The hepatojejunostomy was performed as follows: The jejunal free limb of 
a Roux-in-Y was opened through its anterior wall with a lineal incision. The 
stump of the bile duct was introduced into the jejunal lumen through and 
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opposite opening. Sutures were applied to the end of the stump interiorly, 
involving the entire bile duct wall and the jejunal mucosa and submucosa, over 
a silicone stent. The jejunal external wall close to the entering site of the bile 
duct was fi xed to the later, and the jejunal anterior opening was fi nally closed.
All 3 patients showed uneventfully recovery after a 36 months follow-
up with no evidences of stenosis. We offer this technique for the surgeon’s 
armamentarium, to be used when a very thin bile duct presents. Yet, further 
studies involving larger series may be required to ensure total validity.
POSTER BOARD NUMBER P1 – 79
SINGLE ORIFICE VEIN RECONSTRUCTION FOR 993 
MULTIPLE HEPATIC VEINS IN LIVING DONOR ADULT LIVER 
TRANSPLANTATION USING A LEFT LIVER GRAFT
Y. Yamauchi1, T. Noritomi1, K. Mikami2, S. Hoshino1, T. Shinohara1, 
Y. Takahashi1, N. Noda1, N. Yamamoto1, T. Maekawa2, Y. Yamashita1
1Fukuoka University School of Medicine, 2Fukuoka University Chikushi 
Hospital
Background: For maximum use of small liver grafts, most draining veins 
in donor graft should be reconstructed. We describe the usefulness of single 
orifi ce reconstruction for the multiple hepatic veins in living donor adult liver 
transplantation.
Methods: Six patients who underwent living donor adult liver transplantation 
using the left liver plus caudate lobe grafts were reviewed. A wide and single 
venous orifi ce was created by gathering the left, middle or its tributaries such as 
segment 4, and/or short hepatic vein using a conduit vein graft and a patch vein 
grafts. This single, newly-created orifi ce was then anastomosed to the common 
trunk created in the recipient fs hepatic veins.
Results: The mean graft volume standard liver volume ratio (GV/SLV) was 
33.5% (26.5 – 41%). Of 6 liver grafts, four included the middle hepatic vein 
trunk. Another included only the middle hepatic vein tributaries (without 
middle hepatic vein trunk). In 3 grafts, a signifi cantly-sized short hepatic 
vein was connected with the left hepatic vein concurrently with the middle or 
segment 4 hepatic veins to make a single orifi ce using a conduit vein graft. In 
another 3 grafts without signifi cantly-sized tributaries and short hepatic veins, 
two adjacent hepatic vein trunks (left and middle hepatic veins) were simply 
connected together using the septoplasty technique. The redundant vascular 
cuff was further added to elongate the orifi ce. The diameter of the new hepatic 
vein tract after venoplasty was larger than that of before venoplasty. Hepatic 
vein waveforms of all grafts showed the biphasic or triphasic pattern and graft 
congestion was not observed immediately after venoplasty. No graft was lost 
due to hepatic venous outfl ow block with the mean follow-up of 14 months.
Conclusions: The short-term results of our technique were satisfactory. Our 
techniques can simplify graft-to-recipient cava anastomosis and might be useful 
to avoid hepatic venous stenosis. Long-term outcome of our technique remained 
unclear, further follow-up is necessary to confi rm the feasibility of this method.
POSTER BOARD NUMBER P1 – 80
AUXILIARY PARTIAL ORTHOTOPIC LIVER 994 
TRANSPLANTATION FROM LIVING DONOR FOR PATIENT 
WITH ADULT-ONSET TYPE II CITRULLINEMIA
S.H. Joo1, B.S. Kim, J.I. Lee, S.H. Lee, S.M. Lee, H.C. Park
1Kyung Hee University, 2Kyung Hee University, 3Kyung Hee University, 
4Kyung Hee University, 5Kyung Hee University, 6Kyung Hee University
Introduction: Adult-onset type II citrullinemia (CTLN2) is one of inborn 
errors of metabolism in the liver. CTLN2 is an autosomal recessive disorder 
characterized by recurrent encephalopathy with hyperammonemia due to 
highly elevated plasma levels of citrulline and ammonia, and is ascribed to 
a defi ciency of argininosuccinate synthetase in the liver. We report a case of 
patient with type II citrullinemia who were treated successfully with auxiliary 
partial orthotopic liver transplantation (APOLT) from living donor. Case 
report: This patient was a 27-year-old Korean man who diagnosed as CTLN2 
3 years ago. He was 178 cm in height and 60kg in weight. He has been treated 
by low protein diet and oral administration of L-arginine, sodium benzoate, 
kanamycin, and branched amino acids. However, his plasma ammonia level 
did not decrease, and frequent irritability and consciousness disturbance were 
developed. Despite the medical treatments his condition failed to improve, 
therefore he underwent partial liver transplantation using a left lobe graft from 
his 25 year – old sister. The estimated volume of donor’s right lobe was 800ml 
compare to 180ml of the left. We eventually decided to perform APOLT using 
the left lobe of liver of the donor. Actual graft volume was 200g and the graft 
– to- recipient weight ratio (GRWR) is only 0.33%. The patient’s extended 
left lobe (including caudate lobe) was resected. The left lole graft (segments 
2–4) was transplanted orthotopically and the recipient’s right portal vein was 
narrowed by surgical clipping. The postoperative course was uneventful, 
and the neurological symptoms were resolved. The plasma concentrations of 
ammonia were upper normal limits, so only low protein diet (50g/day) was 
supplied without any specifi c medication. The estimated computed tomography 
volume of graft on postoperative day 14 was 220 ml. In conclusion, APOLT 
can be a life saving and effective treatment for patients with adult-onset type 
II citrullinemia, especially those who have no chance of receiving a deceased 
donor graft or who have candidate donors with insuffi cient graft volume. 
Careful monitoring of portal fl ow to the graft is important for detecting delayed 
graft dysfunction.
POSTER BOARD NUMBER P1 – 81
TRANSHEPATIC DILATION OF ANASTOMOTIC AND 995 
NONANASTOMOTIC BILIARY STRICTURES WITH CUTTING 
BALLOON IN LIVER TRANSPLANT RECIPIENTS
F. Boyvat1, C. Aytekin1, H. Karakayali2, A. Harman1, S. Sevmis2, 
M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent 
University Faculty of Medicine, Department of General Surgery
Purpose: To assess the outcome of a transhepatic dilation, using combined 
cutting balloon and conventional balloon to manage anastomotic and 
nonanastomotic biliary strictures in liver transplant recipients.
Materials and Methods: Between 2001 and 2008, 217 liver transplants (172 
living donor, 45 deceased donor) were done at our center. Twenty patients 
with a biliary obstruction were treated with combined cutting balloon and 
conventional balloon. Seven of these 20 patients had anastomotic stenoses 
and the rest had nonanastomotic stenoses. Percutaneous biliary drainage was 
done, and an internal-external biliary drainage catheter was routinely inserted. 
Cutting balloon dilation was followed by conventional balloon dilation, which 
was 1 mm to 2 mm larger than the cutting balloon. The diameter of the cutting 
balloon changed from 5 mm to 8 mm.
Results: The technical success was considered to be less than 20% stenoses 
after several dilations. The mean number of balloon dilation sessions needed for 
anastomotic stenoses was 2.1 and for nonanastomotic stenoses, this number was 
3.2. Recurrent strictures developed in 4 patients in the anastomotic group and 
in 9 patients in the nonanastomotic group, which is why repeated interventions 
were needed. Major hemobilia was observed in 1 patient; this patient was treated 
with embolization. Self-limiting minor hemobilia occurred in 6 patients.
Conclusions: Percutaneous treatment using a cutting balloon angioplasty 
protocol was more successful in anastomotic strictures than it was in 
nonanastomotic strictures (intrahepatic). More balloon dilation sessions and 
longer catheter drainage times were required for nonanastomotic strictures.
POSTER BOARD NUMBER P1 – 82
SIMULTANEOUS MULTIPLE PERCUTANEOUS LARGE-996 
PROFILE PLASTIC STENTS FOR RESISTANT BILIARY 
ANASTOMOTIC STRICTURES AFTER LIVER TRANSPLANT: 
PRELIMINARY REPORT
F. Boyvat1, S. Sevmis2, U. Ozyer1, A. Harman1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent 
University Faculty of Medicine, Department of General Surgery
Purpose: To evaluate the management of biliary anastomotic strictures with 
simultaneous multiple plastic stents for complicated liver transplants.
Materials and Methods: Between 2001 and 2008, 217 liver transplants (172 
living donor, 45 deceased donor) were done at our center. The study included 
4 female and 5 male patients (mean age, 25 years; age range, 11-46 years) 
with recurrent biliary anastomotic stenoses in whom prior balloon dilation and 
single plastic stent placements had failed. Percutaneous biliary drainage was 
done fi rst, and then 2 plastic stents were placed percutaneously through 1 tract 
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(percutaneous tracts were between 8F to 12F). The sizes of the 2 plastic stents 
were 16F (n=3). 20F (n=5). or 22F (n=1).
Results: Indwelling stents remained in place for a median of 3 months. 
Biochemical parameters in these patients were checked at 1 week, 1 month, and 
3 months intervals. Also, Doppler ultrasound was routinely done at the same 
time intervals. In 2 patients, the plastic stents were removed endoscopically 
because of cholangitis. In 7 patients with internal plastic stents, no cholangitis 
or obstruction was observed.
Conclusions: Sequential percutaneous insertion of 2 plastic biliary stents 
through 1 percutaneous access site effectively treats anastomotic strictures that 
occur after liver transplant. This technique lets the clinician place a large-profi le 
internal stent through a single small percutaneous hole. The technique has a high 
success rate; however, more studies with longer follow-ups are necessary.
POSTER BOARD NUMBER P1 – 83
HEPATIC ARTERY COMPLICATIONS AFTER LIVER 997 
TRANSPLANT, MANAGED WITH PERCUTANEOUS GRAFT-
COVERED STENTS
F. Boyvat1, U. Ozyer1, S. Sevmis2, G. Moray2, C. Aytekin1, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent 
University Faculty of Medicine, Department of General Surgery
Purpose: To assess the feasibility of graft-covered stent placement for treating 
hepatic artery stenoses (HAS). hepatic artery thromboses (HAT). and hepatic 
artery bleeding after liver transplants.
Materials and Methods: Between 2001 and 2008, 217 livers (172 living-
donor, 45 deceased-donor) were transplanted at our center. Six children and 
4 adults (mean age, 28.8 years) had transplant-related hepatic artery problems 
after their transplant. These problems were treated with graft-covered stents. 
Endovascular treatment indications for these patients were HAT (n=5). HAS 
(n=3). and active bleeding from the hepatic artery (n=2). Covered stents were 
placed 0 to 7 days postoperatively in 7 patients, 8 to 30 days postoperatively in 
2 patients, and more than 30 days postoperatively in 1 patient.
Results: Technical success was achieved in 9 of the 10 endovascular 
procedures. Five ruptures were seen before dilatation of the hepatic artery. 
Only 1 patient required surgical intervention. The other patients were managed 
with graft-covered stents. Continuous thrombolysis for 2 days was necessary 
in 1 patient to lyse the thrombus. Follow-up ranged from 1 month to 5 years. 
Three patients with patent hepatic arteries died during follow-up; the causes of 
death were unrelated to the hepatic artery intervention. One stent was occluded 
at 11 months without any clinical fi ndings. In 1 patient, 75% stenosis was found 
angiographically at 2-year follow-up; a percutaneous transluminal angioplasty 
was done.
Conclusion: Graft-covered stent placement in the hepatic artery is technically 
feasible. Graft-covered stent placements, specifi cally, can be done safely and 
effectively during the early postoperative period.
POSTER BOARD NUMBER P1 – 84
TREATMENT OF ARTERIAL STEAL SYNDROME IN 998 
LIVER TRANSPLANT RECIPIENTS
F. Boyvat1, U. Ozyer1, S. Sevmis2, A. Harman1, C. Aytekin1, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent 
University Faculty of Medicine, Department of General Surgery
Purpose: To describe the effect of splenic or gastroduodenal artery embolization 
in liver-transplant patients with arterial steal syndrome.
Materials and Methods: Between 2001 and 2008, 217 livers (172 living-
donor, 45 deceased-donor) were transplanted at our center. Of these, 20 
patients (14 male, 6 female; mean age, 23 years; age range, 3-52 years) had 
graft ischemia diagnosed on the basis of clinical, laboratory, ultrasonographic, 
and angiographic fi ndings. To determine diagnostic criteria, steal syndrome 
was defi ned as diminished hepatic arterial fl ow caused by a shift of hepatic 
arterial fl ow to the splenic or gastroduodenal artery. Treatment consisted of 
coil embolization of the midsplenic (n=12) or gastroduodenal artery (n=3). 
or both the midsplenic and gastroduodenal arteries (n=1) and embolization of 
midsplenic artery with an Amplatz plug device (n=4). Biochemical parameters 
were checked at 1, 7, and 30 days after the procedure.
Results: Nineteen patients improved clinically within 24 hours of the procedure 
with signifi cant changes in the biochemical parameters. Before treatment, mean 
alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels 
were 148.05 U/L, 85.43 U/L, and 6.77 U/L, respectively. The fi rst day after 
treatment, the mean alanine aminotransferase, aspartate aminotransferase, and 
total bilirubin levels were 105.12 U/L, 56.92 U/L, and 5.23 U/L, respectively. 
In 1 patient, no biochemical or clinical improvement was observed immediately 
after embolization; however, 3 weeks later, the patient’s biochemical parameters 
returned to normal levels.
Conclusions: Conventional angiography has a crucial role in diagnosing and 
treating arterial steal after liver transplant.
POSTER BOARD NUMBER P1 – 85
THE NEW METHOD OF TIME-LAG LIGATION FOR 999 
PORTOSYSTEMIC SHUNT USING CABG OCCULUDER FOR 
ADULT LDLT
H. Kokai, Y. Sato, S. Yamamoto, H. Oya, H. Nakatsuka, T. Kobayashi, 
T. Watanabe, K. Takizawa, K. Hatakeyama
Division of Digestive And General Surgery, Niigata University Graduate 
School of Medical And Dental Science
We have already reported an useful method of time-lag ligation of portosystemic 
shunt for the steal of portal venous fl ow without laparotomy after living donor 
liver transplantation (LDLT). However its method was by a manual ligation 
and somewhat invasive. In this study, we reported a less invasive and easy new 
time-lag ligation by CABG occuluder for a patient who had an end-stage liver 
failure with portal hypertension and the internal mesenteric vena-left testicular 
vein (IMV-LTV) shunt.
We performed a LDLT for a 57-years old man who had end-stage type C liver 
cirrhosis with hepatic encephalopathy and Hepatocellular carcinoma within 
Milan criteria. We used the right hepatic lobe for graft, and it had enough size. 
(graft volume was 733g, and GRWR was 1.22.) He had portal hypertension, 
and his IMV was expanded for a 2cm caliber and about 3 times wider than 
the portal vein. There was hepatofugal blood fl ow from the IMV to the left 
renal vein via the IMV-LTV shunt. We tried to clump of the IMV, then the 
portal vein pressure (PVP) became excessive high from 25.5 to 32.5cmH2O. 
So we declumped the IMV, and encircled the IMV with CABG occuluder, a 
surgical device that is used to clump of the clonally artery in bypass operation, 
and it was passed outside the body through the abdominal wall. Additionally, 
continuous portal injection of Prostagrandin E1 (PGE1) was started for the 
control of PV fl ow. We ascertained that the PV fl ow increase effect of PGE1 
by temporary interruption of it for test. On POD5, the PV fl ow decreased, so 
we clumped the IMV by clump of the CABG occuluder without re-laparotomy, 
then the PV fl ow was improved, while the PVP increased little. Post operative 
course was smooth and he discharged from our hospital on POD23.
An excessive portal hypertension leads to an excessive shear stress and prevent 
a graft liver regeneration after liver transplantation, therefore a management 
for the excessive portal hypertension immediately after inplantation is very 
important to lead to physiological graft liver regeneration. Additionally, 
portosystemic shunt decreases might portal venous fl ow after enlarged graft 
and sometimes become a cause of portal thrombus or graft liver atrophy. The 
technique of time-lag ligation of portosystemic shunt by CABG occuluder 
might be both easy and useful without invasive re-laparotomy.
POSTER BOARD NUMBER P1 – 86
USING SPLIT LIVER FOR RETRANSPLANTATION 1000 
IS A SAFE PROCEDURE: THE FIRST EXPERIENCES OF 
REGENSBURG
T-U. Tsui, C. Zülke, M.N. Scherer, H.J. Schlitt, A. Obed
Department of Surgery, University of Regensburg Medical Center
Splitting the liver is one of current procedures to expend the organ 
availability for transplantation. Encouraging results have been obtained 
in showing that the short-term and the long-term results of using split 
livers are comparable with those using whole grafts. However using the 
split liver for retransplantation remains controversial. Since the technical 
complexity and the potential risks in the increase of surgical complications, 
split liver is generally not considered for the retransplantation. Here we 
report the fi rst three cases of using right split liver (Seg V-VIII± SegI) for 
retransplantation in patients with severe sclerosing cholangitis and bile duct 
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necrosis in two cases and patient with thrombosis of hepatic artery in one 
case. Between 2005 and 2006, 11 of 90 recipients experienced allograft 
failure that required retransplantation. Eight of 11 allograft failures were 
associated with sclerosing cholangitis and bile duct necrosis. Two of these 
patients received split liver retransplantation. The graft weight/recipient 
weight ratios were 1.27%, 1.41% and 1.24% respectively. Venoplasty with 
large caval patch was performed in the reconstruction of hepatic venous 
outfl ow of the split livers in two cases. Reconstruction of middle hepatic 
vein outfl ow and caval anastomosis using standard technique in one case. 
Hepaticojejunostomy were performed in patients with bile duct necrosis. 
Hepaticocholesdochostomy was performed in patient with hepatic artery 
thrombosis. In comparison with using the whole graft, the cold ischemic 
time was slightly longer in using split liver (14hrs and 14hrs52min). 
There were not differences in terms of warm ischemic time, primary bile 
production and total operation time. In addition, the initial graft functions 
were comparable in both using split livers and using whole grafts. No acute 
rejection episode was observed in using split livers. In conclusion, split 
liver retransplantation can be performed safely in selected patients in order 
to further expend the organ availability.
POSTER BOARD NUMBER P1 – 87
EXPERIMENTAL STUDY OF ABSORBABLE AND NON-1001 
ABSORBABLE VASCULAR ANASTOMOSIS IN GROWING 
VESSELS. A TOOL FOR CLINICAL DECISIONS.
M. Uribe1,2, V. Bianchi1, A. Gallego1, M. Dib1, P. Fluxá1, M. Capetillo1, 
A. Mercado1, F. Valenzuela1, S. Cavallieri1,2
1Surgical Research Unit University of Chile Hospital del Salvador, 2Liver 
Transplantation Program Clínica Las Condes – Hospital Luis Calvo 
Mackenna
Introduction: Vascular anastomoses in growing vessels, as used in pediatric 
organ transplantation, are infl uenced by surgical technique and suture material 
used. Absorbable suture has shown to allow growing of arterial anastomoses 
with fewer stenosis rates. The aim of this study was to compare absorbable with 
non-absorbable suture material in end-to-end vascular anastomoses in growing 
lambs.
Materials and Methods: Six 4-week-old lambs weighting between 10-20 
kg were anesthesiated. Bilateral primary end-to-end continuous running 
anastomoses of femoral arteries and veins using 6/0 absorbable Polydiaxonone 
(PDS) and 6/0 nonabsorbable Polypropylene (Prolene) were performed. After 6 
months animals were euthanized. Vessels were excised and burst-tested to 300 
mmHg. Stenosis was defi ned as decrease in 50% or more of the anastomotic 
site. Vessels were evaluated macroscopically, histologically and by contrast 
angiography by specialists in a blind fashion. Fisher Test was used. P < 0.05 
was considered signifi cant*.
Results: Median original weight was 13 kg, and increased to 37,5 kg (range 
28-48). Stenosis and tissue reaction are shown in Table 1. Burst testing caused 
no disruption. Neither aneurysm nor dilatation of the anastomotic site was 
observed by angiography in any vessel. Suture material was observed in 
vessels of both groups.
TABLE 1. Stenosis and tissue reaction of vessel anastomoses.
Artery Artery Vein Vein
Prolene PDS Prolene PDS
Stenosis  4/6 2/6 0/6 0/6
Tissue No/Mild 33%* 100% 100% 100%
Reaction Mod/Severe 67%* 0% 0% 0%
Comments: In this study, we used each animal as its own control. Arteries and 
veins of both groups were resistant to burst test and showed no aneurysm or 
dilatation. PDS showed less arterial stenosis and no or only mild infl amatory 
reaction in those vessels. There were no differences in parameters studied 
in veins in either group. PDS is a better alternative for a running vascular 
anastomosis in this model.
POSTER BOARD NUMBER P1 – 88
MASSIVE HEMOBILIA AFTER PERCUTANEOUS 1002 
CHOLANGIOGRAPHY TREATED BY SUPERSELECTIVE 
EMBOLIZATION IN A LIVER TRANSPLANT RECIPIENT
I. Boin1, M. Camargo2, W. Oliveira2, M. Leonardi1
1UNIT OF LIVER TRANSPLANTATION – Unicamp, 2Faculty of Medical 
Science – HC – Unicamp
Hemobilia is a rare but potentially life-threatening cause of upper or lower 
gastrointestinal bleeding. It is most frequently a result of iatrogenic trauma. 
Transarterial embolization is considered the fi rst line of intervention to stop the 
bleeding for most causes of hemobilia. In the transplanted liver, this has only 
been reported in ten cases. We reported a 56-year-old liver transplant patient 
who was submitted to percutaneous transhepatic cholangiography as part of 
cholestasis investigation, and developed massive hemobilia 3 days later. He 
presented with delay lower gastrointestinal active bleeding and hypovolemic 
shock. Confi rmatory diagnosis and treatment was achieved through selective 
angiography and embolization. There were no rebleeding, abscess formation 
or allograft necrosis in a 6 month follow up. Transcatheter embolotherapy is 
recommended as initial treatment to control serious iatrogenic hemobilia even 
in transplanted liver patients.
POSTER BOARD NUMBER P1 – 89
FEASIBILITY OF AUXILIARY PARTIAL LIVING DONOR 1003 
LIVER TRANSPLANTATION FOR FULMINANT HEPATIC 
FAILURE AS AN AID FOR SMALL FOR SIZE GRAFT – SINGLE 
CENTER EXPERIENCE
T. Kobayashi, Y. Sato, S. Yamamoto, H. Oya, H. Kokai, K. Hatakeyama
Division of General And Digestive Surgery, Niigata University
Objectives: Auxiliary partial orthotopic liver transplantation (APOLT) or 
heterotopic auxiliary partial liver transplantation (HAPLT) was initially 
indicated as a potentially reversible fulminant hepatic failure. Kyoto group 
expanded the indication of living donor APOLT for fulminant hepatic failure 
and non-cirrhotic metabolic liver disease as an aid for small-for-size grafts to 
support the function of implanted graft during the early post-operative period. 
However, long-term survival was not observed in patients of fulminant hepatic 
failure.
Methods: From March in 1999 to January in 2008, 79 living donor liver 
transplantations (LDLT) were performed in our institution. We started 
auxiliary partial living donor liver transplantation for fulminant hepatic 
failure on May in 2002. From then, Five patients (three female and two male) 
underwent auxiliary partial LDLT (3 cases of APOLT and 2 cases of HAPLT) 
for fulminant hepatic failure. All of them received small for size graft. The 
defi nition of small for size graft in this study is an actual graft-to-recipient 
weight ratio (GRWR) of less than 1.0%. Etiology of fulminant hepatic failure 
was HBV in one, Wilson fs disease in one, and unknown origin in three. 
Three were acute type and two were subacute type. Median age was 45 
(range;14-54) years old. Blood type was identical in all cases. Left lobe graft 
was used in four cases and right lobe graft was used in one cases. Median 
GRWR was 0.74 (0.42-0.85). Median follow up was 42 months (range; 3 
days -70 months) 
Results: Three of five (60%) patients were alive (42, 67, 70 months). We 
lost two cases. One patient was lost at post-operative day three because 
of cytomegalo virus pneumonia and one patient was lost at 10 months 
after APOLT because of sepsis. Overall complications were seen in four 
patients (relaparotomy of hemostasis in two, biliary strictures in one, and 
hemostasis and biliary strictures in one case). There were no vascular 
complications. Controlled acute rejection was observed in one case, 
which achieved free of immunosuppression after sufficient recovery of 
the native liver.
Conclusion: Auxiliary partial living donor liver transplantation may be a 
choice as an aid for small for size graft in fulminant hepatic failure.
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MANAGEMENT OF SUBCAPSULAR HEMATOMA 1004 
OF THE GRAFT AFTER LIVING DONOR LIVER 
TRANSPLANTATION
J-H. Ryu, S.G. Lee, S. Hwang, K-H. Kim, C. Ahn, D-B. Moon, K. Song, 
T. Ha, K. Kim, N. Choi
Division of HBP Surgery and Liver transplantation, Department of Surgery, 
University of Ulsan College of Medicine and Asan Medical Center
Subcapsular hematoma of the graft is a serious complication of liver 
transplantation (LT). and there has been no discussion in the literature about 
optimal management except in sporadic case reports. The aim of this work 
is to review our experience of subcapsular hematoma in living donor liver 
transplantation (LDLT) and to introduce our management strategy. Among the 
1473 cases of adult-to-adult LDLT between February 1997 and November 
2007, there have been 5 cases of subcapsular hematoma. Two of these developed 
after percutaneous liver biopsy and the other 2 developed after percutaneous 
transhepatic biliary drainage (PTBD). Two developed immediately after the 
procedure, whereas the other 2 developed 8 and 12 days after the procedure, 
respectively, due to rupture of a pseudoaneurysm. Another one case developed 
immediately after LDLT without any procedure. Our management strategy 
was as follows; after performing dynamic computed tomography for initial 
diagnosis, these 3 steps were taken: 1) hepatic arteriography and selective 
embolization of bleeding focus; 2) pigtail catheter drainage (PCD) of 
subcapsular hematoma; and 3) hepatic vein stenting if there was a sign of 
outfl ow disturbance due to compression by a large hematoma. All 5 of our 
patients recovered from the insult of subcapsular hematoma. In conclusion, 
our results indicate that patients who develop subcapsular hematoma after 
LDLT can be treated nonsurgically
POSTER BOARD NUMBER P1 – 91
SPLIT LIVER TRANSPLANTATION (SLT) BETWEEN 1005 
TWO ADULTS. THE EXPERIENCE OF “OCTOBER 12” 
UNIVERSITY HOSPITAL.
J. Fundora, A. Moreno, J.C. Meneu, B. Perez, M. Abradelo, A. Gimeno, 
C. Jimenez, V. Barra, S. Jimenez, E. Moreno
Doce De Octubre University Hospital
Introduction: The split of the liver was created to expand the donor pool. In 
1989, Bismuth et al, described the fi rst SLT between two adults. Two years 
later, In Spain, we performed the fi rst SLT between two adults in our country.
The aim of this study was to show our recipients and grafts results about this 
procedure.
Methods: We designed a prospective study. We included the recipients of 
graft from SPLT between two adults, between April 1991 to September 
2006. Among 25 splitting of the liver graft, in 8 cases we used it between 
two adults recipients. In 7 of 8 cases, splited right and left lobe. In only 
one case used the segments II-III and I-IV-V-VI-VII-VIII, in the other 
recipient.
Results: The mean of the age and weight was 56±18 yo and 58±1,86 kgr, 
respectivily. The mean of Graft Recipient Weight Ratio (GRWR) was 1,39±0,7. 
We made a in situ partition in 87,6%. At the admission, 76,5% of the recipients 
was C Child -Pugh score. The most frecuent etiology was HCV cirrhosis. 
About the complications, Hepatic artery trombosis 3 patients (18,8%). 
hemoperitoneum 1 patient (6,2%). fl uid coleection 1 patient (6,2%).The 1 year 
recipient and graft survival was 75% and 68
Summarize:%. The SLT between two adults is a complex but possible 
procedure ,in references transplant center and It might possible to increase 
the do
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PROLONGED COLD ISCHEMIC TIME IS A RISK 1006 
FACTOR FOR BILIARY STRICTURES IN DUCT-TO-DUCT 
BILIARY RECONSTRUCTION IN LIVING DONOR LIVER 
TRANSPLANTATION.
J.M. Chun, J.B. Park, J.M. Kim, G.O. Jung, K.U. Jung, H.J. Park, H.T. Jung, 
S.J. Kim, J.W. Joh, S.K. Lee
Sungkyunkwan University School of Medicien Samsung Medical Center
Duct-to-duct (DD) anastomosis is a widely accepted procedure for biliary 
reconstruction in living donor liver transplantation (LDLT). However, biliary 
complication (BC) rates in LDLT recipients have been reported to be as high as 
20~30% or more. In this study, we examined various potential risk factors for 
biliary stricture (BS) that occurs in the context of DD reconstruction in a single 
active transplant center. Enrolled in this study were adults who underwent 
their fi rst LDLT with DD reconstruction between August 2002 and May 2007 
(n=283). BSs were defi ned as anastomotic strictures that required interventions 
or operative procedures to be corrected. We reviewed retrospectively the 
medical records of recipients, including medical history, surgical procedures, 
and progress, and analyzed risk factors of BS with the Kaplan Meier method. 
BS occurred in 58 of the 283 recipients (20.5%). The mean follow-up period 
was 24.4 months post-transplantation (SD=16.5). The univariate analysis 
revealed that recipient age (p=0.032). bile duct size (p=0.003). biliary 
reconstruction surgeon (p=0.023). perfusion solution (p=0.001). cold ischemic 
time (CIT) (p<0.001). biliary leakage history (p<0.001). and acute rejection 
episode (p<0.001) were signifi cant risk factors. In the multivariable analysis, 
CIT (p<0.001). biliary leakage history (p=0.002). and acute rejection episode 
(p=0.013) were signifi cant risk factors for BS. A CIT cut-off value of 71 minutes 
was calculated using the minimum p-value approach with correction by the 
Miller and Siegmund method (p=0.0186). In conclusion, efforts for reducing 
CIT are recommended in order to lower the incidence of BS in LDLT.
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LONG-TERM ASSESSMENT OF ENDOSCOPIC AND 1007 
INVASIVE RADIOLOGY TREATMENT FOR BILIARY 
STRICTURES AFTER LIVER TRANSPLANTATION
S. Eisner1, A. Belinki2, A. Geller3, E. Shaharabani1, Z. Ben-Ari4, M. Kniznik2 
and E. Mor1
Department of Transplantation1, Invasive Radiology Unit2, Department of 
Gastroenterology and the Liver Institut, Rabin Medical CenterPetah-Tiqwa, 
affi liated with Sackler School of Medicine, Tel-Aviv University, Israel
Biliary strictures (BS) after liver transplantation (LTx) are responsible for 
considerable morbidity and mortality. Endoscopic (ERCP) and invasive radiology 
(PTC) procedures are the mainstay for treatment of BS while surgical approach is 
reserved mainly for patients who failed the non-surgical measures. We evaluated 
the long-term results with non-surgical procedures to treat BS after LTx.
Material and Methods: A retrospective review of our data-base including 270 
adult LTx recipients was done searching for patients with biliary strictures. 
BS were categorized into 3 types: common bile duct (CBD) (type-1). major 
hepatic duct ± CBD (type-2) or intra-hepatic stricture (type-3). Patients with 
anastomotic strictures were treated fi rst conservatively by dilatation of an 
internal (with ERCP) or an external stent (PTC). The procedure was repeated 
as needed until reaching good radiographic result or was stopped if there was 
no response. When failed, patients with anastomotic stricture underwent Roux-
en-Y hepaticojejunostomy (HJ) or in cases with intrahepatic stricture patients 
were listed for re-transplantation. Good result was defi ned as normalization of 
liver function tests (LFT) at 6-months follow-up. Partial response was defi ned 
as slightly impaired LFT at the same interval and failure was defi ned as a need 
for surgical repair, retransplantation or patient death.
Results: Forty-one patients (15.1%) developed BS including 10 who had a bile 
leak preceding the development of BS. Of the 26 patients with type-1 stricture, 
2 underwent surgical repair by HJ; one patient survived and another patient who 
was operated with severe cholestasis and sepsis died after surgery. The other 24 
were managed by non-surgical approach of whom 11 (45.8%) achieved good 
result and 3 had a partial response; one of them died 1-year later and the other 
2 are alive at 2.5 and 3 years. Of the remaining 10 patients in whom the non-
surgical procedure failed 3 died from complications related to the procedure 
and 7 underwent delayed HJ of whom 4 patients survived and 3 died. Of the 8 
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patients with type-2 stricture, 5 patients achieved good long-term result and 3 
patients who had a partial response died at follow-up from rec. hepatitis C at 
2.5,3 and 4 years. Of the 7 patients with type-3 stricture, 3 patients responded 
well to the non-surgical procedure, 1 underwent re-transplantation and survived 
and another 3 patients died of septic complications. The overall long-term 
success rate with non-surgical approach to treat post-transplant BS was 48.7%. 
The overall graft loss and death rate directly related to BS was 26.8%.
Conclusions: Minimally invasive non-surgical procedures to treat bile duct 
strictures after liver transplantation achieve long-term success in only half 
of the patients. Earlier surgical intervention to repair anastomotic strictures 
might reduce mortality related to septic complications following the more 
‘conservative’ measures.
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THE MORPHOLOGIC ANALYSIS OF ACCESSORY 1008 
ARTERIAL SOURCES OF CAUDATE LOBE
K. Branzaniuc1, P. Matusz2, C. Copotoiu1, L. Azamfi rei1, S.M. Copotoiu1, 
A.M. Pusztai2, E. Hordovan2
1University of Medicine And Pharmacy, 2University of Medicine And 
Pharmacy
Reconsidering of the fundamental knowledge of liver intraparenchymal anatomy 
is imposed by the intense development of transplant surgery. The caudate lobe 
(CL) is considered by most anatomists like a distinct volume of parenchyma.
The objective of this study was to realize the correlations between the modalities 
of intraparenchymal distribution of the elements from the afferent and efferent 
pedicles of the CL, its external morphologic aspect and the own segmentation 
of CL parenchyma, which allows better surgical practice of hepatic resection 
and transplant.
Material and Method: The corrosion casts (150). were created by the injection 
of the vasculo-ductal systems with plastic mass, followed by the corrosion of 
the hepatic parenchyma with hydrochloric acid.
Results: In 7% of the cases we revealed the presence of supplementary sources. 
In 5% of the cases the right medial division is vascularized by the right accessory 
hepatic artery, originated from the superior mesenteric artery. In this case, from 
the right branch of the HAP originates only the posterior branch. In 2% of the 
cases, the left medial division is vascularized by the left gastric artery. In these 
cases from the left branch of the HAP originate only the lateral branch. The 
revealed accessory hepatic arteries are destined only the medial divisions. In 
11% of the cases the medial branch originates from the right branch of the HAP, 
and in 7% of the cases it continues the terminal part of the left branch of the 
HAP. Five morphological types of arterial vascularization of the liver have been 
noted. Most important were: type II (1,33%) (2/150) in which the medial branch 
proceeds from the accessory left hepatic artery; type V (5,33%) (8/150) in which 
the anterior branch originates from the accessory right hepatic artery.
Discussions: These correlations allow the assessment of the principal aspects 
of intraparenchymal distribution of the vasculo-ductal elements only based on 
the examination of the quantitative development of the parenchymal parts of 
CL at the visceral aspect of the liver.
Conclusion: The current study will prove the fact that CL is actually “a little liver”, 
based on the same principles as is based the liver on the whole (“the big liver”).
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SURGICAL TECHNIQUE TO AVOID HEPATIC VENOUS 1009 
OBSTRUCTION IN PARTIAL AND FULL PEDIATRIC LIVER 
TRANSPLANTATION
T. Heffron1, D. Solis1, T. Pillen2, G. Smallwood1, R. Romero1
1Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Background: Liver transplantation is the treatment of choice for end stage liver 
disease. In the pediatric population, the development of innovative techniques 
has allowed more transplants to be performed reducing time and mortality in 
the waiting lists. Reduced size, split and living related transplants have become 
the alternative to relieve the shortage of organs in the pediatric population 
with end stage liver disease, but in the other hand, these types of grafts are 
associated with a higher incidence of hepatic vein outfl ow obstruction. The 
size of the anastomotic orifi ce, the length and orientation of the vessels, and 
the positioning of the graft are key determinants in maintaining patency of 
the reconstructed hepatic vein. Others centers previously has described an 
incidence of hepatic venous obstruction as high as 20% when using recipients 
hepatic veins for the anastomosis. We described our technique in this series 
and showed its effi cacy avoiding hepatic venous obstruction in pediatric liver 
transplantation.
Methods: A total of 202 consecutive pediatric liver transplants, have been 
performed at Children’s Healthcare of Atlanta by a single surgeon. A triple 
hepatic venoplasty was performed in the recipient IVC to create an adequate 
outfl ow orifi ce in all recipients with partial liver transplantation. If two or more 
orifi ces were found on split and living related donor livers, a venoplasty was 
performed to create a single wide common orifi ce for anastomosis. No fi xation 
sutures to any hepatic ligament was done.
Patients with any clinical fi nding suggesting venous outfl ow obstruction 
(ascites, splenomegaly, abdominal distention) were studied with ultrasound or 
venogram.
Results: Liver transplants performed include 109 whole liver transplants 
(%). 39 left lateral lobes (%). 29 left lobes (%). 24 living related (%) and 
1 right lobe graft in 178 patients. In our series, no hepatic veins outfl ow 
obstruction was found based on ultrasound, clinical fi ndings or venogram. 
Our 1 and 3 year graft survivals were 82.3% and 77.6% for whole livers and 
80.2% and 72.5% for partial size livers. Patient survival at 1 and 3 years 
were 90.3% and 82.1% for whole size livers and 90% and 86% for partial 
livers.
Conclusion: A wide venoplasty at the recipient venous site with a single short 
wide orifi ce is the most appropriate method for hepatic vein anastomosis to 
prevent stenoses and to assure an adequate outfl ow for proper graft function 
and survival. The technique is feasible, easy, straightforward, and has led to 
excellent outcomes.
PANCREASCONCURRENT ORAL SESSION 77: 
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IS SYSTEMIC VENOUS DRAINAGE THE EXPLANATION 1010 
FOR HYPERINSULINEMIA IN PANCREAS-GRAFT 
RECIPIENTS?
M. Hartmann1, M. Bertoluci2, M.C. Guterres1, L. Diogo1, D. Saitovitch1, 
S. Gullo-Neto1, M. Falavigna1, L. Kroth1, M.A. Traesel1
1Sao Lucas Hospital- Porto Alegre- Brazil, 2Clinicas Hospital- Porto Alegre- 
Brazil
Hyperinsulinemia has been associated to systemic venous drainage as a 
reconstruction technique in pancreatic transplantation. The hypesinulinemia 
may be associated with dyslipidemia and insulin resistance (IR) and 
metabolic syndrome. However, it may be the case that IR would be 
responsible, at least in part, for the observed hypersinsulinemia. The 
prevalence of IR in patients submitted to this reconstruction technique as 
well as the beta cell functional status is not clearly known. The aim of this 
study is to evaluate glycidic metabolism after systemic venous drainage 
of pancreatic graft through fasting measurements of insulin, glucose, 
C-peptide, glucosilated hemoglobin as well as HOMA, oral glucose 
tolerance test and the corresponding curve of insulinemia. We analyzed 30 
patients after the systemic venous drainage of the graft (23 SPK, 2 PAK, 
5PTA). All of them were insulin-independent. The results (mean values and 
standard deviation) are the following: Glycemia: 85.7 (+/- 14.2) mg/dl; 
isulinemia 17.8 (+/- 8.6) mU/l; C-peptide 3.4 (+/-1.7) ng/ml; glucosilated 
hemoglobin: 6.0 (+/- 0.7)%. The HOMA index identifi ed two groups of 
patients: those who were insulin-resistant (n=20) and those who were not 
(n=10). Both groups had adequate glucose levels control despite of the 
differences in IR. Also, the levels of basal insulin and the measurements 
after the oral glucose challenge were higher in the IR group. These results 
show that hyperinsulinemia is not an universal fi nding among pancreas 
recipients submitted to systemic venous drainage of their grafts. It may be 
associated to the IR itself. Also, the data show that functional status of beta 
cells was good enough to surpass the IR, when it is present.
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IDO – A NEW REJECTION-MARKER IN SIMULTANEOUS 1011 
PANCREAS AND KIDNEY TRANSPLANTATION
D. Abendroth, M. Marzinzig
Center of Surgery, University of Ulm
Introduction: Pancreas rejection after transplantation is best monitored by 
the serum creatinine of the simultaneously transplanted kidney from the same 
donor. A specifi c pancreas graft marker for rejection would be desirable for 
monitoring isolated pancreas allografts.
Material and Methods: In 24 patients after successful simultaneous 
pancreas and kidney transplantation, serial values of indoleamine 2,3 
dioxygenase (IDO). IL-10, TNF-α, Neopterin (NPT). sHLA were determined 
(sera samples) beginning on day 0 and over a follow up period of at least 12 
weeks. Rejection was diagnosed by the clinical term and the day of treatment 
with antirejection medication (steroid bolus, polyclonal Ab). Kidney function 
was controlled by daily serum-creatinine and pancreas function by fastened 
blood sugar.
Results: 11 out of 24 patients experienced a total of 13 rejection episodes 
(2x pancreas/11x kidney and pancreas) within the fi rst 3 months after 
transplantation. Baseline values of proinfl ammatory mediators (IDO, TNF-α, 
neopterin) showed a rise during rejection (IDO: 7,9 + 1,3 μM to 17,6 + 3,4 
μM, sig.; TNF: 2,7+1,5 to 43,2+25 pg/ml, sig.; NPT: 37,8+19,2 to 354+108 
nmol/l n.s.). In parallel, immunologic markers like sHLA and IL-10 showed 
a similar profi le (IL-10: 13,2+3,1 to 87,1+23,8 pg/ml n.s.; sHLA: 1,8+ 0,6 
to 5,9+1,0 ug/ml, sig.; values given as x+SEM, p<.05 for all parameters, 
rejection vs. baseline). IDO was the only parameter showing an early 
detection of rejection as well as the grade of balance between infl ammation 
and immunsuppression.
Conclusion: There was a correlation of the determined markers with the clinical 
course of rejection, best represented by IDO, however none of the parameters 
was pancreas-specifi c. IDO as a new parameter was most sensitive in diagnose 
of rejection and further outcome.
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PREVENTION OF PANCREAS GRAFT THROMBOSIS 1012 
USING LOW-MOLECULAR-WEIGHT HEPARIN
P. Schenker, O. Vonend, A. Wunsch, M. Schaeffer, L-C. Rump, R. Viebahn
Ruhr-University-Bochum
Background: Simultaneous pancreas-kidney transplantation is the current 
treatment of choice for patients with type I diabetes and end stage renal disease, 
resulting in good short and long term patient and graft survival. Vascular graft 
thrombosis (VGT) after pancreas transplantation is the main cause of early 
graft loss. Low-molecular-weight heparins (LMWH) have been proved to be 
as safe and effective in preventing thromboembolism as unfractionated heparin 
(UFH).
Methods: 188 consecutive pancreas transplantations were performed between 
January 2000 and December 2006. A retrospective study has been carried out 
in order to compare the safety and effi cacy of once daily fi xed dose LMWH to 
dose adjusted intravenous UFH.
Results: 58 patients receiving LMWH and 129 receiving UFH were 
identifi ed. One patient was excluded since lepirudin was used. There 
were 7% (4/58) VGTs in the LMWH and 17% (22/129) in the UFH group 
(p=0.047). The mean time between transplantation and VGT was 4.2 ± 2.5 
days in LMWH and 5.6 ± 7.7 days in UFH receiving patients. The frequency 
of major bleedings requiring relaparatomy was not signifi cantly different 
in the groups related to LMWH and UFH, respectively (6.9% vs. 7.8%). 
One year patient and pancreas graft survival was 98.9/89.6% in the LMWH 
and 97.8/74.4% in the UFH group. Donor and recipient characteristics 
were similar.
Conclusion. The once daily fi xed dose low-molecular-weight heparin is 
safe and effective for initial prophylaxis of graft thrombosis after pancreas 
transplantation. There is no benefi t of dose adjusted intravenous heparin 
application.
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SIMULTANEOUS PANCREAS-KIDNEY 1013 
TRANSPLANTATION: A TEN YEARS FOLLOW-UP ANALYSIS 
FROM CLINICS HOSPITAL OF MEDICAL SCHOOL OF 
UNIVERSITY OF SAO PAULO, BRAZIL
R. Meirelles1, T. Bacchella1, C. Cocuzza2, F. Makidisi1, V. Rocha-Santos1, 
E. David-Neto2, W. Nahas2, L. Ianhez2, M. Srougi2, M. Machado1
1Disciplina de Transplante de Figado do Hospital Das Clínicas Da FMUSP, 
2Disciplina de Urologia do Hospital Das Clínicas Da FMUSP
Introduction: The pancreas transplantation is the only treatment that provides 
euglicemia and normalizes serum levels of glycosylated hemoglobin in type I 
diabetic patients [4] The transplantation of pancreas improves quality of life 
by promoting independence of exogenous insulin and preventing secondary 
complications of diabetes type I.
Aim: Our objective is to present the initial experience and patients follow-up 
undergoing to SPK in our institution.
Patients and Methods: During the period June 1997 to December 2007, 50 type 
I diabetes and end stage renal disease patients were submitted to SPK. Pancreatic 
graft implantation was performed in the right iliac fossa with systemic venous 
drainage and bladder or enteric drainage. Most enteric drainage and all drainage 
conversion were performed by Roux Y duodenojejunostomy. Immunossuppression 
protocol used was polyclonal antibodies or monoclonal anti-receptor for 
interleukin-2 induction followed by calcineurin inhibitor (Tacrolimus). associated 
with mycophenolic acid (Mycophenolate) and corticosteroids.
Results: Patients, pancreatic and renal transplants 1 year survival were 89.12%, 
87.07% and 86.71%, respectively. Patients, pancreatic and renal transplants 5 
years survival were 81.04%, 81.04% and 81.04%, respectively. Early patient 
death main cause was sepsis secondary to pancreatic graft thrombosis. Late 
patient death primary cause was cardiovascular event. Early pancreatic graft 
loss main cause was venous thrombosis. Mainly late pancreatic graft loss was 
due to chronic rejection The most frequent complication in the immediate 
postoperative period was abdominal wall infection Bladder drainage conversion 
rate to enteric drainage was 18.18%. The most frequent late complication was 
CMV infection (18%).
Conclusion: SPK remains the most effective treatment for type I diabetic with 
end stage renal disease patients. One and fi ve year patients and pancreatic 
grafts survival were similar to US pancreas transplantation programs.
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SONOGRAPHIC CONTRAST MEDIA CONTRIBUTION IN 1014 
PANCREAS TRANSPLANTATION ASSESSMENT
R. Meirelles2, A. Marcelino 1, C. Cocuzza3, E. David-Neto3, L. Ianhez3, 
T. Bacchella2, M. Srougi3, M. Machado2, G. Cerri1
1Disciplina de Radiologia do Hospital Das Clínicas Da FMUSP, 2Disciplina 
de Transplante do Hospital Das Clínicas Da FMUSP, 3Disciplina de Urologia 
do Hospital Das Clínicas Da FMUSP
Introduction: Pancreatic transplantation is the long-term therapeutic option 
for maintaining normoglycemic status in patients with type 1 diabetes mellitus. 
Sonographic contrast medium allows to evaluate tissue perfusion but there are 
no studies comparing this parameter in normal and pathologic pancreatic grafts 
in the literature at the time of this writing. The importance of assessment of 
graft perfusion and the potential role of contrast-enhanced sonography with 
microbubbles in this regard were the reasons for this research. The study 
conducted at the Instituto de Radiologia do Hospital das Clínicas da Faculdade 
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de Medicina da Universidade de São Paulo between November, 2004 and 
September, 2006 had the following 
Objectives: A) to establish patterns of graft vascularization in normal patients 
and in those with suspected abnormalities; B) to compare grayscale mode and 
contrast-enhanced sonographic fi ndings with clinical status, laboratory results, 
and need for exogenous insulin; C) to defi ne the role of contrast-enhanced 
sonography with microbubbles in the evaluation of pancreatic transplantation.
Materials and Methods: Twenty-six patients underwent a total of 30 
sonographic examinations with microbubbles, 20 (66.7%) men and 10 (33.3%) 
women. Age range was 25 to 51 years, with a mean of 40 years (+ 7.3 years). 
Time elapsed between transplantation and imaging ranged from 1 day to 63 
months (median, 24 months). Using grayscale mode, pancreas was assessed for 
echogenicity, dimensions (both quantitatively and qualitatively) and contours. 
Following intravenous contrast medium administration, time for enhancement 
of the pancreatic graft, pattern and intensity of enhancement were documented. 
A classifi cation system based on grayscale and contrast-enhanced sonographic 
fi ndings was designed, with the following categories: normal perfusion pattern, 
acute changes (rejection, pancreatitis or thrombosis) and chronic changes 
(chronic rejection). 
Results: There was a statistically signifi cant association between echogenicity 
and clinical status (p=0.010); echogenicity and need for exogenous insulin 
(p=0.021); dimensions (qualitative criteria) and clinical status (p=0.011); 
dimensions (qualitative criteria) and need for exogenous insulin (p=0.028); 
pattern (p=0.024) and intensity of enhancement versus clinical status 
(p=0.039). There was also statistically signifi cant association between need 
for exogenous insulin and graft perfusion (p=0.014). and sonography-based 
diagnosis (p=0.001). 
Conclusion: The study provided patterns of vascularization in normal pancreatic 
grafts and in patients with suspected abnormalities. Distinction of normal and 
abnormal pancreatic grafts was possible using echogenicity and qualitative 
analysis of graft size on grayscale mode. Contrast-enhanced sonography with 
microbubbles also contributed to differentiation between normal and abnormal 
pancreatic grafts, using pattern and intensity of enhancement and perfusion of 
the graft during the arterial phase.
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ACTIVATION OF PANCREASTIC STELLATE CELLS IN 1015 
THE FIBROTIC PROCESS OF GRAFT IN RAT MODEL
Y.P. Li, Y.S. Li, L.L. Li, T.C. Zhang, D. Long, N. Zhao, L.L. Pang, Z.P. Zhen, 
Y.C. Huang, S.F. Li, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Our previous study based on statistic data of 240,000 cases about solid organ 
transplantions from OPTN/UNOS suggested that pancreas transplantation 
alone (PTA) was one of the highest and earlist graft dysfunction occurred 
organ even with the committed HLA mismatch and informed treatment of 
immunosuppressive agents. The characteristic of dysfunction is mainly fi brosis 
and lack the effective intervention due to its mechanism has not been throughly 
identifi ed. Reseaches on chronic pancreastitis and pancreatic cancer found that 
actived pancreastic stellate cells (PSC) can induce the fi brotic process. The aim 
of this study was to probe the role and mechanism of PSC with pancreastic 
fi brosis in rat atopic PTA acute rejection model.
Method: Rat atopic PTA (SD-Wistar) were performed without 
immunosuppressive treatment and graft were harvested in 1d, 3d, 5d and 7d 
postoperation. The pathomorphological changes, the fi brotic extent (Masson 
staining Sirius red staining) and indicators of activated PSC on mRNA and 
protein level (RT-PCR immunohistochemistry) were conducted including 
-SMA, desmin, collagen I.
Result: The fi brosis of pancreas graft could be found in 3d postoperation, 
aggravated in 5d and almostly become fi brotic in 7d. The fi brotic area extended 
from interstitial substance to parenchymatous tissue. The number of acinus was 
decreased, and the architectonic of lobulous was destroyed along with the fi brotic 
process. The fi brosis stained positively for Sirius red and collagen <st2: place w: 
st=on>type I.</st2: place> Sirius red staining was associated with -SMA-positive 
cells. And the similar consequence could be seen in desmin-positive cells.
Conclusion: We found that actived PSC was the main source of graft fi brosis on 
rat PTA acute rejection model. It suggested that inhibited actived PSC might be 
one of available prevention and treatment measure for chronic graft dysfunction.
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TREATMENT WITH VITAMIN A ATTENUATED THE 1016 
FIBROSIS OF RAT PANCREAS GRAFT
Y.P. Li, Y.S. Li, L.L. Li, Y.C. Huang, N. Zhao, L.L. Pang, L. Wei, Z.P. Zhen, 
S.F. Li, L. Feng, 
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Our previous results suggested PTA was one of highly and early graft 
dysfunction occurred model, and actived PSC was the main source of graft 
fi brosis. Studies on vitamin A (VitA) in vitro showed that vitamin A could 
inhibit PSC activation in pancreatic fi brosis model caused by alcohol. The aim 
of this study was to explore whether Vit A could alleviate the graft fi brosis in 
rat PTA model.
Method: Rats atopic PTA (SD-Wistar) were performed without 
immunosuppressive treatment and divided into two groups: control group and 
Vit A group (4000IU/kg.d; intragastric administration). Graft pancreas were 
harvested in 1d, 3d, 5d, 7d postoperation. The pathomorphological changes, 
the fi brotic extent (Masson staining Sirius red staining) and indicators of 
activated PSC on mRNA and protein level (RT-PCR immunohistochemistry) 
were studied including -SMA, desmin, collagen I, and statistical analysis were 
applied.
Result: The graft fi brotic process could be found in 3d postoperation, 
aggravated in 5d and almost become fi brotic in 7d in both groups.The extent 
in Vit A group was signifi cantly improved in the fi brotic extent, number of 
acinus and the architectonic of lobulous in every time-point. All difference was 
signifi cant in 5d and 7d comparing with control group (P<0.05).
Conclusion: Vitamin A could signifi cantly alleviate the fi brosis and protect 
acinus and architectonic of lobulous in rats atopic PTA acute rejection model. 
Vitamin A might be used as supplemental drug for delay and decrease graft 
fi brotic process in clinical pancreas transplantation.
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EFFECTS OF OCTREOTIDE ON THE ACTIVED 1017 
PANCREATIC STELLATE CELLS IN EXPERIMENTAL 
PANCREAS GRAFT FIBROSIS
Y.P. Li, L.L. Li, Y.S. Li, D. Long, L.L. Pang, N. Zhao, C.T. Zhang, L. Feng, 
S.F. Li,
Key Laboratory of Transplant Engineering and Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Our previous results suggested that graft pancreas was one of highist and earlist 
graft dysfunction occurred organ in PTA even with committed HLA mismatch 
and informed treatment of immunosuppressive agents, and actived PSC was 
the main source of pancreatic fi brosis. Octreotide is widely used to prevent 
and treat complications after clinical pancreas transplantation. But it is unclear 
whether octreotide can play role in the graft fi brosis. The aim of this study was 
to investigate the effect of octreotide in the perioperative course of fi brotic 
process of transplanted pancreas both in vitro and in vivo.
Method: Isolated PSC from SD rat and cocultured with different dose (2.5, 5, 
10, 20, 40ng/ml) octreotide for 24h, 48h and 72h seperately. PSC proliferation 
was assessed by MTT. The expression of -SMA, desmin and collagen I of 
PSCs were determined by western blotting of cell lysates. Rat atopic PTA 
(SD-Wistar) were performed without immunosuppression treatment and 
divided into two groups: control group and Oct group (0.01mg/kg.bid; 
subcutaneouly). Graft pancreas were harvested in 1d, 3d, 5d, 7d postoperation. 
The pathomorphological changes, the fi brotic extent (Masson staining Sirius 
red staining) and indicators of activated PSC on mRNA and protein level (RT-
PCR immunohistochemistry) were studied including -SMA, desmin, collagen 
I. Finally, statistical analysis were applied.
Result: Octreotide markly inhibited PSC activation and proliferation in vitro 
with effective concentration range range frome10 to 40ng/ml in 48h and 72h. 
The expression of -SMA, desmin and collagen I of PSCs signifi cantly decreased 
(P<0.05). Infl ammatory infi ltration was clearly relieved in Oct group and the 
extent was lightly improved in the fi brosis, number of acinus and architectonic 
of lobulous, although the differences were not signifi cant comparing with 
control group (P>0.05). And the expression of -SMA, desmin and collagen I 
also were not signifi cant decreased (P>0.05).
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Conclusion: Octreotide can effectively inhibit PSC activation and proliferation in 
vitro as well as degree of infl ammatory inliltration, but not the noticeably relieved 
in the fi brotic process of pancreas graft in rat PTA acute rejection model.
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TRANSIENT DIABETES MELLITUS DUE TO 1018 
TACROLIMUS TOXICITY IN A SIMULTANEOUS PANCREAS-
KIDNEY TRANSPLANT RECIPIENT
S. Wright, J. Jamboti, H. Rhodes
Fremantle Hospital
Severe hyperglycaemia in a Simultaneous Pancreas-Kidney (SPK) transplant 
recipient is sine qua non of pancreatic allograft failure. Tacrolimus is a known 
cause of pancreatic βcell toxicity leading to decreased insulin production. 
We report a case where in Diabetes Mellitus with severe hyperglycaemia 
resulted from Tacrolimus toxicity and resolved with its withdrawal. The role of 
Tacrolimus toxicity should be considered in all SPK transplant recipients who 
become diabetic with low C-peptide levels.
The patient is a 38 year old Caucasian male who received a SPK transplant 
in 2000. His immunosuppression consisted of Tacrolimus, Mycophenolate 
Mofetil and Prednisolone. His transplant grafts had functioned well with blood 
glucose levels between 5-8mmol/L and a stable serum creatinine of 130μmol/L 
until August 2007 (Graph). His other medical history included recurrent urinary 
tract infections and ischaemic heart disease.
He presented in October 2007 with a two week history of feeling unwell 
with polydipsia, polyuria, anorexia and vomiting. His blood glucose level at 
presentation was 71mmol/L and serum creatinine 189μmol/L. He underwent an 
urgent ultrasound of pancreas and kidney allografts with doppler fl ow studies, 
which showed good blood fl ow to the grafts and no evidence of pancreatic 
vein thrombosis. C-peptide and insulin levels revealed lack of endocrine 
pancreas graft function. This was attributed to high Tacrolimus levels and he 
was switched to Cyclosporin. Following this his blood glucose levels improved 
with restoration of C-peptide and insulin production.
In SPK transplant recipients who present with Diabetes Mellitus, Tacrolimus 
toxicity should be considered as a reversible insult to the pancreatic βcells.
Graph – Blood Glucose Levels
 ↑ Tacrolimus withdrawn
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SURVIVAL OF PANCREAS ALLOGRAFTS DESPITE 1019 
PARTIAL THROMBOSIS OF THE Y-GRAFT USED FOR 
ARTERIAL RECONSTRUCTION
C. Margreiter1, W. Mark1, M. Maglione1, D. Wiedemann2, R. Sucher1, 
R. Öllinger1, H. Maier1, M. Freund3, R. Margreiter1, F. Aigner1
1Dept.of General and Transplant Surgery, Innsbruck Medical University, 
2Dept.of Heart Surgery, Innsbruck Medical University, 3Dept.of Radiology, 
Innsbruck Medical University
Background: A complex system of arterial anastomoses between the 
gastroduodenal, splenic (SA) and superior mesenteric artery (SMA) exists. 
During pancreas transplantation arterial reconstruction between the SA 
and SMA is performed by using a donor iliac Y-graft. Graft thrombosis is 
still responsible for up to 10% of graft losses. The aim of this study was to 
investigate arterial vascularization of the pancreas with special regard to the 
anastomoses within the pancreatic head.
Material and Methods: Ten pancreas grafts considered not suitable for 
transplantation were removed and a canula was inserted into the splenic artery 
and the SMA ligated. Angiography was performed with 5, 10 and 15 ml of 
contrast medium. In addition we retrospectively analyzed 15 patients with 
radiologically (multisliced CT) proven thrombosis of the SMA with stable 
graft function.
Results: Angiography showed excellent perfusion of the 
pancreaticoduodenal arcade via anastomoses in all cases after ex-vivo 
injection of 5 ml of contrast medium into the splenic artery only. All 15 
patients analyzed had normal graft function and sufficient perfusion of the 
pancreatic head.
Conclusion: This study demonstrates that the whole pancreas is suffi ciently 
perfused by the splenic artery only through a complex system of 
intraparenchymal anastomoses. This fi nding can be important not only for 
pancreas transplantation but also for all kinds of pancreatic surgery.
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SOLITARY LIVING RELATED ORTHOTOPIC PARTIAL 1020 
PANCREATIC TRANSPLANTATION WITH DUCT TO DUCT 
DRAINAGE OF PANCREATIC JUICE FOR TYPE I DIABETES 
MELLITUS
Y. Sato1, S. Yamamoto1, H. Oya1, T. Kobayashi1, H. Kokai1, K. Hatakeyama1, 
M. Hirota2
1First Dept. of Surg., School of Medicine, Niigata University, 2Dept. of Surg., 
Prefectuaral Muikamachi Hospital
In this study, we reported a complete solitary living related orthotopic partial 
pancreatic transplantation (LROPPT) with duct to duct drainage of pancreatic 
juice. (Case) A 29-year old man, who has suffered from type I diabetes 
mellitus at 2 years after his birth, underwent LROPPT on 2007 August 9th. 
He had hypoglycemia for several times per week. His preoperative HbA1c 
was 8.4%. He has little diabetic complications of 2 degree of nephropathy 
with albuminuria and slight neuropathy. The donor was a 57-year old his 
father, whose preoperative 75gOGTT and ivGTT revealed normal pattern. 
(Immunosuppression) In this case, we choose the new immunosuppresion of 
steroid free-protocol with intraportal infusion of donor specifi c antigen, which 
enable both rapid reduction of immunosuppression and macrochimerism of 
donor type of CD56+T cell in the graft liver. Induction of immunosuppression 
was by both thymoglobulin (1.5mg/kg) on day0, 4 and intraportal 
administration of donor leukocyte on day 0, 4, 7, 10 after transplantation. 
An each time of volume of Donor specifi c leukocytes separated from donor 
whole blood using Cellsorba EX (Asahikasei Co. LTD) ,which has been used 
as leukocyteapheresis therapy with leukocyte removal fi lter for ulcerative 
colitis, was about 40ml. Count of leukocytes was almost of 1-5x108. 
Maintenance of immunosuppression was by FK506 and MMF. (Operative 
Procedure) Donor was performed hand-assisted distal pancreatectomy with 
spleen. The pancreas was cut left side of portal vein that remnant pancreas 
was a half of whole pancreas by the CT volumetry. The pancreatic duct was 
repaired by the ligation and transfi xing suture. The pancreas wad closed by 
fi sh mouse with 6-0 prolene. Operative time was 5 hours and 18 min and 
intraoperative hemorrhage was 75 ml. Recipient was explored by upper 
abdominal L-shaped incision. Distal pancreatectomy with spleen with the 
enough expose of both splenic vein and artery, and main pancreatic duct. 
Both the splenic vein and the arterial anastomosis was made, thereafter, 
pancreatic duct to duct anastomosis was made by 6-0 PDS with pancreatic 
duct stent. The pancreatic duct stent lead to extra abdomen through Papilla 
Vater and duodenum. Pancreatic tissue was anastomosis by 6-0 prolene using 
fi brin-glue. Afterthat, absorbed thin mesh was rolled around the pancreatic 
anastomosis with fi brin-glue. The operative time was 10hr 10min and the 
blood loss was 435ml. Patient discharged without a pancreatic leakage and 
vessel thrombosis 16th days after transplantation.
Conclusion: LROPPT is a complete physiologic procedure. In Japan, almost 
of donor is marginal donor aged above 50 years old. The portal drainage might 
be comfortable for the stress of the partial pancreatic graft.
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APPLICATION OF FIBRIN SEALANT ON THE 1021 
PANCREATIC SURFACE DURING TRANSPLANTATION: A 
PROSPECTIVE RANDOMISED SINGLE CENTRE TRIAL
P. Pfeffer, O. Øyen, B.H. Lien, B. Lien
Rikshospitalet University Hospital, Oslo, Norway
Background: Excellent results, with long term insulin-independency, have 
in recent years been achieved by pancreas-Tx, particularly by simultaneous 
kidney-Tx (SPK). However, pancreas-Tx represents a major surgical trauma 
with a high rate of postoperative complications, particularly bleedings and 
leakage of serous fl uids (lymph/transudation/exocrine secretions).
We wanted to investigate whether the use of a fi brin sealant (“tissue glue”) 
on the pancreatic surface could reduce bleedings and/or serous leakage; and 
thereby the rate of complications/reoperations. This is the fi rst randomised trial 
addressing this issue.
Material/Methods: During 2003-2007 42 pancreas recipients [39 SPK/1 PTA 
(Pancreas-Tx Alone) /2 PAK (Pancreas- After Kidney-Tx) ] were randomised 
(1: 1) to the application of fi brin sealant or not. The fi brin sealant (Tisseal) was 
sprayed on the whole pancreatic surface, after revascularisation and hemostasis 
– i.e. under reasonably dry conditions. In the postoperative phase, drains were 
removed when secretion was below 50-100 ml/day. These parameters were 
recorded: Duration of drainage; total drainage volume; s-amylase values; 
transfusions; complications/reoperations/interventions; stay in hospital.
Results:
[mean]
Fibrin sealant +
n=19
Fibrin sealant ÷ (ctr) 
n=23
Duration of drainage (postop. days) 2,2 3,0
Total drainage volume (ml) 1338 1509
Max. s-amylase (U/l) 285 251
Reoperations (pancreas-related) 11 reop. in
4 pts (21%) 
6 reop. in
4 pts (17%) 
Transfusions (units of SAG-blood) 1,8 1,7
Stay in hospital (days) 17 18
Conclusion: Our randomised trial has not revealed any effect of using fi brin 
sealant spray on the pancreatic surface after revascularisation; neither on serous 
secretion/drainage volume, nor on complications.
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ANALYSIS FOR THE CAUSES OF GRAFT FAILURE AND 1022 
MORTALITY IN 91 PANCREAS TRANSPLANTS
D.J. Han, S.C. Kim, K.T. Park, J.J. Hong, E.J. Ahn
Asan Medical Center
The purpose of this study is to improve the graft survival rate by analyzing the 
causes of graft failure and mortality after pancreas transplants.
91 pancreas transplants have been performed from July 1992 to October 2007. 
The cases were divided into four eras by immunosuppression protocols: Era 
1 (July 1992 Dec. 1996, n=12) cyclosporine (CsA). azathioprine (AZA). 
steroid (PD) and OKT3 induction; Era 2 (Jan. 1997- Jan. 1999, n=11) 
tacrolimus (Tac). AZA, PD and OKT 3; Era 3 (Feb. 1999-July 2004, n=24) 
Tac, mycophenolate mofetil (MMF). PD, and IL-2 receptor antibody induction; 
Era 4 (Apr. 2004-present, n=44) Tac+MMF maintenance, PD early withdrawal, 
thymoglobulin induction. They consisted of PTA (41%). PAK (7%) and SPK 
(52%). 82 patients were transplanted from deceased donors and 9 patients 
from living donors. Median follow up duration was 55.9 months (range 1 180 
months).
Graft survival rates at 2 year by eras were 18%, 64%, 88% and 80% 
respectively and patient survival rates at 2 year were 60%, 90%, 92% and 96% 
respectively. Overall graft and patient survival of PTA/PAK were inferior to 
that of SPK, but 3 year graft and patient survival of PTA/PAK since era 3 
were slightly better than that of SPK (graft; 78% vs 76, patient; 96% vs 88%, 
p>0.05). The graft failure rate from era 1 to 4 were 92%, 64%, 17% and 23% 
respectively and acute rejection (AR) rate by eras were 75%, 64%, 42% and 
25% respectively. The causes of graft failure were rejection (34%). anastomotic 
leak (16%). thrombosis (9%). graft pancreatitis (9%). noncompliance to drug 
13% and death with functioning graft (DWFG) (19%). Immunological graft 
failures have decreased by eras (50%, 18%, 8%, 2% each) and technical failure 
rate by eras were 42%, 18%, 4% and 7% respectively. But other causes like 
noncompliance, DWFG have persisted by eras (0%, 27%, 4%, 14%) and 4 
cases of noncompliance in young PTA recipients and 2 cases of suicide were 
experienced in our series. Overall mortality rate was 16.4% and mortality by 
eras were 42%, 27%, 13% and 9%. The causes of mortality were mainly due 
to sepsis in (40%). bleeding (13.3%). suicide (13.3%). anoxic death (13.3%) 
and others (20%).
Immunological and technical graft failure has been markedly decreased, but 
other causes such as noncompliance, DWFG has been a problem. Therefore, 
in addition to precautious immunologic monitoring, noncompliance from 
medication or psychological problem and DWFG from already developed 
diabetic complication should be considered as important factors for preoperative 
screening and postoperative care.
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INITIAL EXPERIENCE ON PANCREAS 1023 
TRANSPLANTATION IN IRAN
S. Nikeghbalian, S.P. Ostad, H. Salahi, A. Bahador, K. Kazemi, 
S.M.R. Nejatollahi, M. Dehghani, S.A. Malek-Hosseini
Shiraz Organ Transplantation Center
Hyperglycemia is the most important factor in the development and 
progression of the secondary complications of diabetes. The only treatment that 
have been demonstrated to infl uence the progression of these complications 
is normalization or near normalization of glycosylated hemoglobin levels 
either by intensive insulin therapy or beta cell replacement therapy with 
pancreas or islet transplantation. Pancreas transplantation is superior to islet 
transplantation and intensive insulin therapy with regard to the effi cacy of 
achieving glycemic control, and its benefi cial effects on diabetes secondary 
complications. Pancreas transplantation started in Iran in May 2006. Until 
March 2008, 37 pancreas transplantations (26 males,11 females) have been 
performed at Shiraz Namazi hospital (21 SPK, 3 PAK and 13 PTA). The mean 
age of patients was 31.86 years (+/- 9.38) with a range of 16 to 50 years. The 
most common indications for transplantation was diabetic nephropathy (62%) 
followed by diabetic retinopathy and hypoglycemic unawareness (35%). 
Surgical techniques were pancreaticoduodenal allograft with exocrine enteric-
drainage and portal venous drainage. Daclizumab has been used for induction 
of immunosuppression and baseline immunosuppression has been achieved 
with Tacrolimus, Mycophenolate Mofetil and Prednisolone. Acute rejections 
have been treated with intravenous bolus of Methylprednisolone. Early death 
(within 1 month) occurred in one patient due to pulmonary emboli. One patient 
expired 2 months after transplantation due to fungal pulmonary infection. One 
patient went under pancreatectomy due to surgical complications and 3 patients 
had immunologic transplant rejection after 4 to 6 months post transplantation. 
32 patients (86.4%) are alive with normal functioning pancreas. Pancreas 
transplantation is now performed on a regular basis at Shiraz Namazi hospital 
and further experience will improve patients’ survival and quality of life.
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C2 MONITORING FOR THE EVALUATION OF DIABETIC 1024 
GASTROPARESIS
W.D. Schareck1, A. Püschel1, R. Wacke2, M. Gock1, E. Klar1
1Dept. of Surgery, University of Rostock, Germany, 2Institute of Clinical 
Pharmacology, University of Rostock, Germany
The indication for combined pancreas-kidney transplantation (PNTX) is type 
I diabetes with end-staged renal disease. This therapy is additionally effective 
in secondary diabetic complications as especially neuropathy including 
autonomic neuropathy. Therefore we questioned whether a regression of 
diabetic gastroparesis could be detected with resorption kinetics of orally 
applicated immunosuppression. 
Methods: From 10/2003 to 8/2004 we performed in our center consecutively 
10 PNTX´s immunosuppressed with single shot ATG, Ciclosporine A 
(microemulsion mCsA ). MMF and steroids. One week after transplantation 
AUC 0-12h (C0,C1,C2,C3,C4,C6,C8,C10,C12) was calculated for mCsA. 
With a mean AUC of 4431 ± 2400 ng/ml x h, the concentration maximum 
(Tmax) was measured after 3 hours (C2 582 ± 308 ng/ml, C3 590 ± 353 ng/
ml ). 
Results: In the postoperative course after 4 years, 3 patients had to be switched 
to another immunosuppressive regimen (2 tacrolimus, 1 sirolimus) one patient 
died. Of the remaining 7 patients with mCsA therapy 4 patients are alive: 3 of 
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them have excellent pancreas and kidney graft function with mCsA and MMF, 
1 patient is insulin-dependent with good kidney function. Controlling the CsA-
pharmacokinetics 4 years after PNTX revealed an AUC of 3604 ± 851 ng/ml 
x h and showed a shift of mean Tmax from C3 (496 ± 119 ng/ml) to C2 (716 
± 99 ng/ml ). 
Conclusion: These results demonstrate an improved gastrointestinal resorption 
thus indicating the amelioration of existing autonomic neuropathy. Neo-
quadruple therapy with mCsA reveals suffi cient immunosuppression in PNTX. 
In the long-term course mCsA pharmacokinetics are able to evaluate the course 
of diabetic gastroparesis.
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SURGICAL STRATEGIES IN THE USE OF SMALL 1025 
PEDIATRIC DONORS FOR SIMULTANEOUS PANCREAS AND 
KIDNEY (SPK) TRANSPLANTATION
H.G. Illanes, C.M. Quarin, R. Maurette, C. Piña, L. Reniero, H. Domingo, 
C. Casadei
Instituto de Nefrología de Buenos Aires
Pediatric donors are underutilized in pancreas transplantation due to a possible 
inadequate cell mass and increased risk of technical complications. We describe 
our different surgical approaches to deal with pediatric donors. Between 
September 2006 and February 2008, 45 SPK were performed in our institution, 
4 of them were from pediatric donors.
Case 1: A pediatric pancreas and en-bloc kidney were transplanted into an 
adult recipient.
The 3 year-old donor weighted 18 kg and the recipient was a 41 year-old female 
and weighted 36 kg with a BMI of 14. The recipient was a brittle Type 1 diabetic 
uremic with a deteriorated general condition including malnourishment. Up 
to the present, 10 months post transplant, she has sustained excellent graft 
functions and increased her BMI to 19.
Case 2: A single kidney and pancreas from a 12 year-old- donor with inborn 
neurological disorder were transplanted to a 31 year-old-female type 1 
diabetic uremic patient. The donor and recipient’s weight were 25 and 50 kg 
respectively. 9 months post transplantation, the recipient is euglycemic with 
normal renal function.
Case 3: An en-bloc dual kidneys-pancreas from a 5 year-old (25 kg) donor was 
implanted in a 28 year-old-male (49 kg) recipient. In this case, the liver was not 
retrieved, hence en-bloc kidneys, pancreas, duodenum, abdominal aorta (AA) 
and inferior cava vein (ICV) were utilized. The pancreas did not require arterial 
reconstruction. A portocaval shunt was made for venous pancreas drainage into 
the donor ICV. The proximal end of the donor ICV was anastomosed to the 
recipient ICV in a piggy back fashion. The donor distal AA was anastomosed 
end-to-side to the right common iliac artery (RCIA). The pancreas was enteric 
drained and the ureters were extravesically implanted. 5 months after the 
transplant, the patient is off dialysis and insulin.
Case 4: An en-bloc dual kidneys-pancreas from an 18 month-old pediatric 
(9.6 kg) donor was transplanted in a 30 year-old-female (60 Kg) pre-emptive 
recipient type 1 diabetic. Donor operation and the back table dissection were 
similar to case 3. During the recipient’s surgery, the proximal end of the donor 
AA was anastomosed to the recipient RCIA. The donor RCIA was included 
in the graft in order to preserve a right kidney polar artery. 4 months after 
transplantation, patient is euglycemic with normal renal function.
Conclusion: We observed that pancreas and kidney transplantation from 
donors with less than 25 kg shows excellent short term-outcomes. It seems 
that these donors reach the metabolic demand of adult recipients. No 
technical failures were displayed with these challenging donors. As far 
as we know, this is fi rst time that such a small donor (case 4) and these 
complex techniques (case 3 and 4) has been described in the transplantation 
literature.
Table 1.
Graft
Weight
Donor Recipient
Kidney & Pancreas 18 36
En Bloc Double Kidneys
& Pancreas
25 50
En Bloc Dual Kidneys-Pancreas 25 49
En Bloc Dual Kidneys-Pancreas 9.6 60
Figure 1. Piggy back venous reconstruction
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PSYCOPATHOLOGICAL ASSESSMENT OF A SAMPLE OF 1026 
PATIENTS CANDIDATES FOR TRANSPLANTATION’
U. Boggi6, A. Calderone1, A. Armani2, S. Rinaldi3, A. Romano4, G.E. Costa5, 
M. Mauri7, G.B. Cassano8
1Psychiatrist, 2Psychiatrist, 3Psychiatrist, 4Psychiatrist, 5Medical Doctor, 
6Surgeon, 7Psychiatrist, 8Psychiatrist
Background: transplant is an important surgical intervention inducing distress 
and anxiety. Psychiatric evaluation of organ transplant candidates is now 
routinely proposed. This study purposed to assess the psychological evolution 
in patients having received psychological and/or psychiatric assistance before 
the transplantation.
Objective: To evaluate the prevalence of major psychiatric Disorders (Axis 
I) and personality disorders (Axis II) in a sample of 227 patients candidates 
transplantation
Methods: 227 consecutive transplant candidates were psychically evaluated as 
part of the preoperative protocol. All patients were examined by a psychiatrist 
using the MINI-International Neuropsychiatric Interview (MINI) (Sheehan 
e coll., 1998) for mental disorder and a structured diagnostic interview for 
personality disorder (SCID II) (First e coll., 1997).
Results: 57.7% (131) of the sample was male, mean age 41.62 („b9,7). with a 
prevalence of married subjects (55%). with high school certifi cate (38%) and 
dependent job (36,5%). Diabetes Mellitus type I complicated represents 78% 
of the sample, while 22% is affected by a kidney disease. The age of onset of 
the pathology was 16.4 („b9.7) for the diabetes and 28 („b11.2) for a kidney 
disease.
A total of 30.8% of the sample met criteria for at least one Axis I disorder, 
namely for Depression 13.8% (9.8%, lifetime, 4% current) for Anxiety disorder 
10.1% (3.5% Panic Disorder lifetime, 1.3% panic disorder current, 0.45% panic 
paucisintomatic lifetime, 4.85% agoraphobia current).
The most frequently observed axis II disorder was obsessive-compulsive 
(20.25%). followed by Paranoid (5%). Oppositive (3.1%). Istrionic and 
Depressive (1.75%). at the last Borderline and Avoidant (1.3%).
Discussion: These preliminary data indicate that Mood disorders are frequent 
among individuals candidates for transplantation, their prevalence being much 
higher than in the general population. The causes for the association between 
chronic disease and mood disorders at present are not known, but we suppose 
that psychophysical distress and pharmachologic treatment may contribute to 
the development of psychiatric disorders.
There is a signifi cant association between personality disorder and kidney 
disease supporting the impact of somatic chronic disease in axis II disorders .
Implications of these fi ndings for the pre-transplant psychological and 
psychiatric evaluation are to be discussed.
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INCREASED INCIDENCE OF BONE FRACTURES IN 1027 
BLADDER-DRAINES VS ENTERIC-DRAINED SIMULTANEOUS 
PANCREAS-KIDNEY TRANSPLANT RECIPIENTS
O. Olaitan, J.A. Zimmermann, P. Mohan, W. Shields, J.G. Rodriguez, 
D.P. Hickey
Beaumont Hospital
Introduction: Several pre and post-transplant factors are known to contribute 
for the higher incidence of osteopenia-relatedfractures in both trabecular and 
cortical bone after simultaneouspancreas-kidney (SPK) recipients, including 
diabetic condition,dialysis, renal insuffi ciency, hyperparathyroidism, low 
boneturnover and steroid use; however, the infl uence of chronicmetabolic 
acidosis and its related calcium metabolism derangementsecondary to bladder 
drainage of the duodenopancreatic graft hasnot been reported as a risk factor.
Patients and Methods: To support our observation, we performed 
aretrospective study with all 80 SPKs performed at our institution from1992 
to 2005. 37 cases were bladder-drained (BD) with a conventional sideto side 
extraperitoneal duodenocystostomy for control of pancreaticexocrine fl uid and 
43 had an enteric drainage (ED) through aduodenoileostomy. Both groups had 
comparative demographic features interm of sex, age, time in dyalisis, length 
of the diabetic condition.There were not patients treated with biphosphonates 
post-transplant. Allcases received a calcineurin-inhibitor based quadruple 
immunosupressivetherapy.
Results: Four recipients with bone fractures were identifi ed in the ED group 
(9.3%) and ten cases in the BD group (27%) with a statisticalsignifi cance. 
Comparable patient and graft survival were found in bothgroups. All pancreas 
grafts except one had endocrine function at the timeof the fracture, and all 
BD recipients were on oral sodium bicarbonatereplacement. The average from 
the time of the transplant to the time ofthe fracture was 62.1 months (12-120) 
for the BD group compared to 15months (12-24) for the ED group. The most 
common site for fractures wasankle long bone (30%) followed by radius (20%). 
femur (20%). calcaneus (10%). middle foot (10%) and forefoot (10%) in the 
BD group; the mostcommon fractured bone in the ED group was the femur 
(50%). followed bythe ankle (25%) and the middle foot (25%).
Conclusions: We found bladder-drained SPKs to have a triple-foldincidence 
of bone fractures when compared to enteric drained recipients.Osteoporosis is 
prevalent in the pre-transplant population waiting for akidney or a SPK and in 
the post-transplant population regardless of theorgan involved, thus they are at 
increased risk of bone loss. Acceleratedosteopenia post-transplant is therefore 
expected as the cause for a highfracture rate in SPK recipients (as high as 49% in 
some series). Withcomparable demographics and immunosuppressive regimes 
employed for bothSPK recipient groups, we found statistically and clinically 
signifi cantthe higher incidence of bone fractures in the BD group, making 
thissubset of patients at particular risk for this condition and thereforefor the 
need of increased surveillance. Attention must be paid tostrictly correct both 
metabolic acidosis and to improve bone fi tness bothpharmacologically and 
with physiotherapy in this fragile population.
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QUALITY OF LIFE AND SPECTRUM 1028 
SYMPTOMATOLOGY IN POTENTIAL RECIPIENTS LISTED 
FOR PANCREAS TRANSPLANTATION
U. Boggi, A. Calderone, S. Rinaldi, A. Armani, A. Romano, G.E. Costa, 
S. Augusto
Psychiatrist
Background: The Spectrum Project aims to defi ne subthreshold and 
atypical conditions not suffi ciently characterized in the current diagnostic 
nomenclature.
Objective: The objective of this study was to assess the quality of life (QoL) and 
the spectrum symptoms in patients candidates to renal-pancreas transplantation. 
This study compared the prevalence of mood and panic spectrum features and 
quality of life in candidates to transplantation with kidney disease and diabetes 
mellitus.
Methods: The study was conducted at the University Hospital of Pisa. All 
patients were examined using self-report Structured Clinical Interview for the 
Spectrum of Panic Disorder (SCI-PAS) and for the spectrum of Mood Disorder 
(SCI-MOOD). QoL was measured using the ‘Quality of life Enjoyment and 
Satisfaction Questionnaire-SF (QlesQ) ’.
Results: Mean score of MOODS-SR-LF was 32.7 (± 21.5) in the total sample, 
37.4 (± 23.0) for the female group and 29.1 (± 19.7) for the male group. In 
patients with diabetes mellitus type I mean score was 33.0 (± 21.1). while in 
patients with kidney disease was 30.9 (±22.1).
Mean score of PAS-SR-LF was 18.5 (± 16.2) in the total sample, 24.8 (± 18.2) 
for the female group and 13.7 (± 12.6) for the male group. In patients with 
diabetes mellitus type I mean score was 18.5 (± 15.6). while in patients with 
kidney disease was 18.1 (±17.7).
Mean score at QLesQ was 44.6 (±8.5). 44 (±8.4) in patients with diabetes and 
46.6 (±8.4) in patients with kidney disease.
Conclusions: The total score on the mood and panic spectrum was higher in 
subjects with Diabetes Mellitus compared to those with kidney disease.
Total score on QLesQ was lower nearly signifi cantly in patients with diabetes 
mellitus, indicating a worse impairment of quality of life in those patients. 
The Q-LES-Q score in the overall sample was considerably lower than the 
community norm but similar to that of Major Depressive Disorder patients.
We believe that early onset of diabetes mellitus may contribute to the 
development of higher mood and panic spectrum psychopathology by means 
of the stigma and the associated psychological and physical suffering in 
individuals who are affected by a chronic disease. This appear to infl uence also 
quality of life of these subjects.
Subtreshold and atypical symptoms deserve attention for an optimal and 
complete management of this particular population of patients.
POSTER BOARD NUMBER P1 – 115
ENTERIC CONVERSION AFTER BLADDER DRAINAGE 1029 
IN PANCREAS TRANSPLANTS: TWO STEP APPROACH
D.J. Han, S.C. Kim, K.T. Park, J.J. Hong, E.J. Ahn
Asan Medical Center
In spite of urologic and metabolic complication, bladder drainage (BD) is 
still preferable option in pancreas transplantation alone (PTA) or pancreas 
after kidney transplant (PAK). The method of exocrine diversion in 
pancreas allograft continues to be controversial due to the advantages versus 
disadvantages of bladder versus enteric drainage. So, the purpose of this 
study is to analyze the clinical outcomes of BD and enteric conversion (EC) 
in pancreas transplants.
Among 68 pancreas transplantation from January 1999 to December 2007, BD 
was performed in 41 patients (25 PTA, 4 PAK, 12 SPK including 2 living donor 
SPK). 4 cases (9.7%) were excluded due to early death of the patient or early 
graft failure within 1 year, yielding an analysis of 37 patients. All the recipients 
with BD were maintained with oral bicarbonate to prevent metabolic acidosis 
and were monitored with checking urine amylase.
Of 37 recipients with functioning pancreas graft (BD). adverse effects of 
BD like hematuria (n=9). refl ux pancreatitis (n=6). UTI (n=9) and metabolic 
acidosis (n=4) were experienced, but which were well tolerated and 
managed with medication. For recurrent and poorly tolerated complications, 
6 enteric conversions (16.2%) were performed. The indication for enteric 
conversion (EC) were graft pancreatitis with minor leak (n=3). recurrent 
refl ux pancreatitis (n=1). recurrent UTI (n=1) and pancreatic duct obstruction 
(n=1) in segmental pancreas transplant treated by pancreaticojejunostomy at 
pancreas tail. Mean duration of EC from transplantation was 21.3 months 
(8-60 months). Mean operation time was 91minutes (80-115min) and no 
surgical morbidity or mortality was observed related to EC. In all patients, 
initial problems associated with BD were completely resolved maintaining 
pancreatic function. No graft rejection following enteric conversion was 
found and long-term renal and pancreatic function was not affected by the 
enteric conversion.
EC after pancreas transplantation is an effective and safe procedure with 
low morbidity and mortality rates. To maximize benefi ts of BD in terms of 
pancreatic monitoring and to minimize the adverse effects of BD, a strategy 
of two-step approach of primary bladder drainage followed by timely enteric 
conversion would be appropriate in PTA, PAK patients and in a selected group 
of SPK patients at least until an effective diagnostic tools monitoring pancreas 
allograft be found.
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EFFECTIVE CONTINUOUS ARTERIAL THROMBOLYSIS 1030 
AFTER PANCREAS TRANSPLANTATION
S. Nobori, M. Okamoto, T. Suzuki, K. Sakai, A. Yoshizawa, H. Ushigome, 
S. Sakamoto, N. Yoshimura
Kyoto Prefectural University of Medicine
Backgrounds: Venous thrombosis remains an important non-immunological 
cause of pancreatic graft loss. We report a case of successful continuous arterial 
thrombolytic therapy of venous graft thrombosis.
Methods/Results: A 54-year-old male with insulin dependent diabetes mellitus 
received a cadaveric pancreas transplant alone in the right iliac fossa with enteric 
exocrine drainage and standard vascular anastomosis. Immunosuppression 
consisted of induction with basiliximab and maintenance therapy with tacrolimus, 
mycophenolate mofetil and steroid. Nafamostat mesilate was used for prophylactic 
anticoagulation therapy. Six days after transplantation, venous graft thrombosis 
developed with normal graft function and mild increase of serum pancreatic enzyme. 
Doppler ultrasonography and enhanced computed tomography showed partial venous 
graft thrombus in splenic and mesenteric vein. After failed systemic anticoagulation, 
selective catheter thrombolysis was started with continuous urokinase infusion at 
the graft artery and systemic heparinization. Arterial thrombolysis achieved the 
complete recover of venous outfl ow in 9 days without any complication.
Conclusions: Graft rescue was achieved by continuous arterial thrombolysis 
of venous graft thrombosis.
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SIMULTANEOUS KIDNEY AND PANCREAS 1031 
TRANSPLANTATION AT A UNIVERSITY, GENERAL HOSPITAL 
IN ARGENTINA.
S. Hyon, R. Groppa, N. Heredia, L. Costan, O. Campi, C. Giudice, L. Barcan, 
L. Litwak, L. Algranati, P. Argibay
Pancreas And Kidney Transplantation Program, Hospital Italiano De Buenos 
Aires
Introduction: Simultaneous pancreas and kidney transplantation (SPK) is an 
established therapy for type 1 diabetes with end-stage renal disease and has 
increased the survival of patients from 50% to above 80% at 5 years. Objective. 
To describe the results of SPK at a teaching, general hospital based in a non-
US, non-European country. 
Methods: Sixty two consecutive SPKs were performed at a single, multiorgan 
transplant center in type-1 diabetic patients with end-stage renal insuffi ciency. 
Recipient characteristics were: men, 33; women, 29; mean age at transplant, 
33.0 +/- 5.0 years; mean time of diabetes pretransplant, 21.5 +/- 5.1 years; 
mean time of dialysis pretransplant, 39.9 +/- 25.2 months. All organs were 
obtained from heart-beating cadaveric donors with a mean age of 23.7 +/- 7.5 
years. All pancreatic grafts were placed intraperitoneally with systemic venous 
anastomosis and exocrine drainage to the bladder in the fi rst 22 cases, and the 
small bowel in the following 40. Pancreas and kidney cold ischemia times were 
11.0 +/- 1.8 h, and 14.1 +/- 2.1 h, respectively. Immunosuppression was induced 
with antilymphocytic globulin or daclizumab. Maintenance was done with a 
three-drug protocol, lately with tacrolimus, steroids, and mycophenolic acid. 
Results: All patients had immediate pancreatic graft function with insulin 
independence. Mortality within 3 months post-transplant was 1.6% (1/62). HbA1c 
stayed within normal range throughout follow-up (7.8% vs. 5.3% pre- vs. post-
transplant, respectively). Mean creatinine at 1 year was 1.1 mg/dL. Four kidneys 
were lost (1, primary non-function; 3, venous thrombosis). One patient from the 
last group underwent a kidney re-transplant with a living donor, with continuous 
pancreas function. Another patient returned to hemodialysis 7 years after SPK due 
to kidney loss from rejection, with preserved pancreas function. Five pancreases 
were lost from thrombosis (2, arterial; 3, venous). Patient, pancreas, and kidney 
1-year survival rates were 91%, 85%, and 88%, respectively; while 5-year 
survival rates were 87%, 76%, and 79%, respectively, with 17 patients in this 
series surviving over 5 years post-transplant and 4 over 10 years. 
Conclusions: SPK at our center may offer type 1 diabetic patients with end-
stage renal disease high probabilities of avoiding the use of exogenous insulin 
and dialysis in the mid-term and the long-term post-transplant. Although 
an important number of patients has not yet been achieved, the results are 
comparable to larger, international transplant centers.
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ACUTE REJECTION AFTER SIMULTANEOUS KIDNEY-1032 
PANCREAS TRANSPLANTATION WITH DIFFERENT 
IMMUNOSUPPRESSIVE REGIMENS.
S. Hyon, R. Groppa, L. Algranati, N. Imperiali, C. Giordani, G. Gallo, 
C. Mombelli, N. Heredia, L. Costan, P. Argibay
Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos 
Aires
Introduction: Simultaneous kidney and pancreas transplantation is an 
established therapy for type-1 diabetes mellitus with end-stage renal disease. 
However, a precise immunosuppressive regimen has not yet been well 
defi ned.
Objective: To assess the rate of acute rejection after simultaneous 
kidney-pancreas transplantation in two groups of patients with different 
immunosuppressive regimens.
Patients and methods: Forty four type-1 diabetic patients with end-stage 
renal disease undergoing simultaneous kidney and pancreas transplantation 
were included in this study. All organs were located intraperitoneally with 
arterial anastomoses to the common iliac artery and venous anastomoses to the 
external iliac vein. Exocrine drainage were established with the bladder (n=22) 
or the jejunum (n=22). A historical group (Group A, n=15) received induction 
immunosuppression with monoclonal or polyclonal anti-T cell antibodies 
and maintenance therapy with cyclosporine, prednisone and azathioprine or 
mycophenolate. A more recent group (Group B, n=29). were induced with 
anti-thymocytic antibodies or daclizumab, and maintained with tacrolimus, 
prednisone and mycophenolate. No signifi cant differences were observed 
regarding donor or recipient characteristics between both groups, including 
age, time of dialysis and time of diabetes pretransplant, cold ischemia time 
and mismatch.
Results: The rate of acute rejection for groups A and B were 57% and 24%, 
respectively. Within group B, those patients who received daclizumab for 
induction had an acute rejection rate of 30% (all responsive to steroid therapy). 
while those receiving thymoglobulin had no episodes of rejection. CMV 
infection was only observed in the group treated with thymoglobulin (rate, 
33%). At one-year, survival rates for patient, pancreas and kidney were 91%, 
85% and 88%; at 5 years 87%, 76% and 79%, respectively; one-year creatinine 
for groups A and B were 1.2 +/- 0.2 mg/dL vs. 1.2 +/- 0.3 mg/dL, respectively; 
HbA1c was 5.5 +/- 0.5% vs. 5.3 +/- 0.2%, respectively.
Conclusion: The use of newer, more potent immunosuppressive drugs 
determined a reduction of acute rejection episodes in patients undergoing 
simultaneous kidney and pancreas transplantation. However, no differences 
were observed in the immediate and the long-term post-transplantation.
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INTRAPYLORIC INJECTION OF BOTULINUM TOXIN 1033 
A AMELIORATES DIABETIC GASTROPARESIS SYMPTOMS 
AND QUALITY OF LIFE IN PANCREAS TRANSPLANT 
PATIENTS
M. Maglione, G. Brandacher, R. Öllinger, M. Biebl, W. Mark, H. Weiss, 
R. Margreiter
Department of General and Transplant Surgery, Innsbruck Medical 
University, Innsbruck, Austria
Background: Diabetic gastroparesis (DGP) represents a chronic gastrointestinal 
disorder defi ned by delayed gastric emptying in the absence of mechanical 
obstruction. However, following successful simultaneous or sequential 
pancreas kidney transplantation DGP remains a major concern in one third 
of these patients. In diabetic patients refractory to prokinetic and anti-emetic 
medication alternative options like intrapyloric injection of botulinum toxin A 
(BoTx) were recently reported. However, results regarding BoTx therapy in 
these patients still remain contradictory. Here we report on the application of 
this treatment option in four pancreas transplant recipients.
Methods: All four patients (three males) suffered from severe and persistent 
gastroparesis following successful transplantation with stable graft function. 
Cardinal symptoms of gastroparesis like nausea, vomiting, early satiety, 
bloating and abdominal pain were quantifi ed by the Patient Assessment of 
Gastrointestinal Symptom (PAGI-Sym©) Severity Index before injection and 
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during follow up. Likewise Quality of life (QoL) was assessed by the Patient 
Assessment of Gastrointestinal Disorders Quality of Life (PAGI-QoL©) Index. 
Total score varies from 0 to 5. To exclude other possible underlying causes 
gastric emptying was determined by X-ray and scintigraphic examination prior 
to BoTx treatment. BoTx therapy consisted of up to 100U which were injected 
equally distributed over the four quadrants of the pylorus. A fi rst control X-ray 
was performed 24 hours later.
Results: Substantial therapeutic effects were evident within two weeks 
following BoTx injection in all patients. While the mean symptom score before 
BoTx injection was 3.5 (range 3.14 – 4.44) after the treatment it decreased to 0.8 
(range 0.3 – 1.8). Similarly the PAGI-QoL© Index decreased from 2.8 (range 
2.37 – 3.24) to 1.1 (range 0.24 – 2.44). The fi rst patient reported a consistent 
decrease of clinical symptoms paralleled by an improvement in QoL after a 
total of 120U BoTx applied within two gastroscopies. The second and the third 
patient required a second injection (each 100U) due to recurrent symptoms 
after two and ten months, respectively. Finally, the forth patient experienced 
signifi cant ameliorations of both, symptoms and QoL, after just a single BoTx 
injection of 100U. After a mean follow up of 320 days all treated patients are 
doing well and display considerable improvements of all cardinal symptoms 
and even more important conspicuous amelioration of their reported QoL.
Conclusion: Intrapyloric BoTx injection represents a safe and straight forward 
treatment option for pancreas transplant patients suffering from severe and 
persistent DGF and should therefore be considered if they are refractory to 
prokinetic and anti-emetic medication.
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MICROSURGICAL TECHNIQUE IN SIMULTANEOUS 1034 
PANCREAS-/KIDNEY TRANSPLANTATION OF THE RAT – 
CLINICAL EXPERIENCE AND REVIEW OF LITERATURE
E. Matevossian1, N. Hüser2, T. Brill3, S. Thorban4, M. Stangl5
1Department of Surgery, Transplantation, Technical University, Munich, 
2Department of Surgery, Transplantation, Technical University, Munich, 
3Department of Preclinical Research, Technical University, Munich, 
4Department of Surgery, Transplantation, Technical University, Munich, 
5Department of Surgery, Transplantation, Technical University, Munich
Background: The special quality of technique and immunologic fi ndings in 
combined pancreas-/kidney transplantation (PNTx) requires experimental 
basic research. Therefore standardized and reproducible transplantation models 
which refl ect technical and immunologic aspects are necessary. In this article 
an experimental model with microsurgical aspects of the combined PNTx will 
be described, in detail following clinical transplantation. 
Material and Methods: For the syngenic transplantation model Lewis- (RT) 
rats were used to differentiate immunologic aspects after rejection from 
surgical technical artefacts. After organoprotective hypothermic perfusion the 
donor received en-bloc pancreatectomy with duodenal segment/aortic patch 
with mesenterial artery and nephrectomy on the right side with aortic and cava 
patch. The arterial and venous revascularization of the heterotopic transplanted 
pancreas in the recipient was performed using the aorta with mesenterial artery 
and vena cava inferior with portal vein. The exocrine drainage of the pancreas 
took place over the segment of the duodenum which has been transplanted in 
side-to-side technique to the jejunum of the recipient. The kidney has been 
transplanted over the aorto-cava segment end-to-side below the artery and vena 
renalis of the recipient. The ureter was anastomosed to the bladder by patch-
technique. The donor operation took 60 (±14.0) minutes and the transplantation 
90 (±17.5) minutes. After transplantation serum parameters have been controlled 
daily. Biopsies for histopathology were taken on day 5,10 and 12. 
Results: All 12 recipients survived the combined PNTx without serious 
surgical complications. In one recipient on postoperative day 10 a thrombosis 
of the portal vein segment of the transplanted pancreas occured, which lead to 
organ failure. The blood glucose levels were normal on the 3. postoperative 
day on. From histopathologic point of view the transplanted pancreas organs 
appeared like normal pancreas tissue on postoperative day 8. The transplanted 
duodenal segment showed slight villous atrophy. The origin in situ pancreas 
organ of the recipient with vascular exclusion showed total necrosis on day 
5 after transplantation. The transplanted kidneys were well perfused, and no 
vascular complications occured. The anastomosis between ureter and bladder 
was leakproof in all recipients. 
Conclusion: The transplantation model for combined PNTx presented is easily 
reproducible and associated with a low mortality and postoperative complication 
rate. Excellent graft function and graft survival rates are achievable due to the 
simplifi ed operation technique and the short operation time. This transplantation 
model may thus represent high clinical relevance as to answer surgical and 
immunologic questions within the scope of basic research.
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RENAL RETRANSPLANTATION IN SIMULTANEOUS 1035 
PANCREAS KIDNEY TRANSPLANT RECIPIENTS
W. Shields, F. Al-Nooh, D. Olaitn, A. Zimmerman, J.G. Navas, P. Mohan, 
D. Little, D. Hickey
National Centre of Renal And Pancreatic Transplantation, Beaumont Hospital
Objective: To examine renal retransplantation after graft loss in simultaneous 
pancreas kidney (SPK) transplant recipients.
Methods: A retrospective study was conducted on all patients with SPK 
transplants at a single centre in Ireland between 1992 and 2008. Timing of 
transplant, duration of functioning renal graft, timing of graft failure, panel 
reactive antibody (PRA). cause of graft failure, timing of second renal 
transplant, outcomes, and technical aspects of the surgery were recorded for 
analysis.
Results: In our centre, eight SPK patients underwent renal retransplantation 
after the failure of their renal graft. Cause of graft failure in all patients was 
chronic allograft nephropathy. All patients underwent transplant nephrectomy 
at the time of transplantation and received deceased donor kidneys. Kidneys 
were allocated purely on ABO compatibility only. Kidneys were transplanted 
into the left iliac fossa utilizing synthetic vascular grafts in three of the eight 
patients. All patients continued on their previous immunosuppression regime 
with a perioperative increase in intravenous corticosteroids. All kidneys 
functioned immediately and have normal renal function at follow-up (6 months 
to seven years). No deterioration in pancreatic function was noted at follow-
up.
Conclusion: Renal retransplantation represents an effective treatment option in 
SPK patients who lose their fi rst kidneys. The procedure can be accomplished 
without risk to the pancreatic graft.
ACUTE REJECTION – CONCURRENT ORAL SESSION 78: 
OTHER
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CURRENT STATUS OF TRANSPLANT NEPHRECTOMY 1036 
IN ONE INSTITUTION
M. Nakatsuka1, A. Colquhoun, M. Posner, M. Behnke
1Virginia Commonwealth University Health System, 2Virginia Commonwealth 
University Health System, 3Virginia Commonwealth University Health System, 
4Virginia Commonwealth University
Aims: The role of transplant nephrectomy after failure of kidney transplantation 
is still debatable.The routine removal of the asymptomatic allograft may not 
be recommended because of risks associated with transplant nephrectomy.We 
reviewed current status of transplant nephrectomy in our institution. 
Methods: 844 cases of kidney transplants were reviewed from 1995 to 2006 
from data bank. Number of cases who underwent transplant nephrectomy were 
evaluated. 
Results: Among 193 cases of graft failure (24.2%).82 cases (mean age of 
41.2) underwent transplant nephrectomy. 82.9%) were black and 79.3% were 
cadeveric kidney transplants. Graft loss < 1 yr (all of them within 1 month) 
were 14 (7.2%) and 9 cases among them underwent nephrectomy. More than 
81% of patients underwent transplant nephrectomy because of chronic allograft 
nephropathy with pain/fever/infection/hematuria or thrombocytopenia. 7 cases 
underwent transplant nephrectomy due to acute rejection.
Conclusion: We presented our data of transplant nephrectomy .24.2% 
of our kidney transplants ended up to have transplant nephrectomy.
We believe it is necessary to remove the kidney if the patient present with 
hematuria,fever,tenderness and swelling over the allograft, infection or tumor 
development in the kidney in addition to chronic allograft nephropathy. Gross 
specimen of removed kidney usually showed severe infl ammatory changes.
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IL-23P19 PLAYS A CRITICAL ROLE IN THE 1037 
PATHOGENESIS OF ACUTE BUT NOT CHRONIC GRAFT-
VERSUS-HOST DISEASE (GVHD.
J. Thompson, Y. Chu, J. Glass, S. Brown
VAMC And University of Kentucky
Despite recent advances in conditioning and prophylaxis, there still is no 
consistently reliable way to treat and/or prevent aGVHD and preserve GVL. 
Recently characterized cytokines involved in infl ammatory signaling pathways 
offer new experimental and potentially clinical approaches to improve GVHD 
outcome. Because the p19 dimer of IL-23 is a critical component in the 
induction of infl ammatory Th17 cells, we investigated its role in stem cell 
transplantation. BALB/c mice received 8.5 Gy TBI followed by transplantation 
of 10 x 106 bone marrow (BM) plus 2.5 x 106 T containing spleen cells (SCs) 
from syngeneic, allogeneic wild type (WT) C57BL/6 (B6) or allogeneic p19-/- 
mutant donors. In the fi rst experiment, 21/24 (87.7%) of the BALB/c mice 
transplanted with WT B6 cells died by the end of the experiment (21 days) 
in contrast to only 7/24r (24.1%) of those transplanted with p19-/- cells. In a 
second experiment, BALB/c mice transplanted with B6 or p19-/- cells were 
autopsied on days 7 and 14. Simonsen’s ratio of spleen to body weight and 
histology, particularly of the bowel, confi rmed aGVHD in the WT mice. In 
a third experiment 10/10 mice transplanted with B6 cells died by day 14 and 
all 10 of the p19-/- animals survived. By day 54, 7 of these 10 had developed 
clinical and histological signs of cGVHD. When either WT B6 or p19 KO 
mice were transplanted with BALB/c BM + SCs, there was no difference in 
the incidence or severity of aGVHD. Furthermore, p19 KO animals were no 
more radio-resistant to 8.5 Gy TBI than WT B6. In conclusion, BALB/c mice 
transplanted with IL-23p19 defi cient cells develop aGVHD less frequently and 
less severely than those transplanted with WT B6 cells. The survivors develop 
cGVHD. Although we have not yet tested for GVL, historically there is a strong 
positive correlation between cGVHD and GVL.
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MICROCHIMERISM AND RENAL TRANSPLANTATION: 1038 
DOUBT STILL PERSISTS
G. Pourmand1, A.R. Mehrsai1, M.R. Nikoobakht1, M. Taherimahmoudi1, 
B. Nikbin2
1Urology Research Center,Tehran University of Medical Sciences, 
2Department of Immunology, Faculty of Medicine, Tehran University of 
medical Sciences,Tehran,Iran.
Objectives: The Presence of donor leukocytes in recipients of organ allograft 
has been shown even several years after transplantation. However, it remains 
unclear whether this donor cell microchimerism plays an effective role in 
allograft acceptance or is simply a consequence of immunosuppression 
condition in recipients.
Materials & Methods: In this study we retrospectively evaluated the Peripheral 
Blood Microchimerism (PBM) after renal transplantation in 32 male-to-female 
recipients of living (unrelated) and cadaveric donor renal transplants. Using 
a Nested Polymerase Chain Reaction (Nested-PCR) amplifi cation specifi c 
for SRY region of the Y chromosome, microchimerism was detected with 
sensitivity up to 1: 1000000. According to the presence of PBM recipients 
were classifi ed into microchimeric and nonmicrochimeric group, and then 
acute and chronic rejection episodes, type of allotransplant (living or cadaveric 
donor). recipient and donor age at transplantation, previous male labor or blood 
transfusion, allograft function (serum creatinine level). and body mass index 
were compared between two groups.
Results: Among 32 recipients 7 (21.9) were positive for PBM in multiple 
testing at different post-transplantation times. All microchimeric recipients 
had been received kidney from living-unrelated donors. Regarding to other 
parameters mentioned above signifi cant difference was not observed. In 
addition, acute rejection rate in microchimeric group was 3 (42%) versus 4 
(16%) in nonmicrochimeric recipients (not signifi cant). 
Conclusion: Our results demonstrate better establishment of microchimerism 
after living donor kidney transplantation. But, concerning true effect of 
microchimerism after renal transplantation doubt still persists; and it seems that 
microchimerism alone has no major protective role in renal allograft survival.
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DOPAMINE TREATMENT IN BRAIN-DEAD DONOR 1039 
RATS IMPROVES KIDNEY FUNCTION EARLY AFTER 
TRANSPLANTATION AND REDUCES RENAL INFLAMMATION
S. Hoeger1, B. Yard1, A. Reisenbuechler1, U. Goettmann1, W. van Son2, 
M. Seelen2, R. Waldherr1, P. Schnuelle1, 
1Department of Nephrology, University Hospital Mannheim, University of 
Heidelberg, 2Department of Nephrology, University of Groningen
Introduction: Brain dead is associated with hemodynamic changes in the 
micro-circulation and with tissue infl ammation. Since donor dopamine 
treatment improves transplantation outcome after renal transplantation in 
human, we tested in an animal model if this treatment affects renal function 
and infl ammation in donors and recipients.
Methods: Brain death was induced in F344 rats for 6 hrs in all experiments. 
Dopamine (10μg/kg/min) was given from the onset of brain death for 6 
(DA 6) or 3 hours (DA 3). Untreated ventilated non brain dead (NBD) and 
brain dead (BD) animals served as controls. Kidneys were transplanted into 
bilaterally nephrectomized recipients. Serum creatinine was measured both 
in donors and recipients. Leukocyte infi ltration was assessed 10 days after 
transplantation.
Results: In BD donors serum creatinine was not signifi cantly different between 
dopamine treated and non-dopamine treated rats. One day after transplantation 
mean serum creatinine in recipients that received an renal allograft from BD 
vehicle treated rats was 1.7± 0.9, while in recipients receiving a renal allograft 
from dopamine treated BD or from NBD rats serum creatinine was signifi cantly 
reduced (0.8 ±0.4 (DA 3). 0.8± 0.2 (DA 6) and 0.8 ± 0.5 (NBD). (P<0.05) 
). Ten days after transplantation, the number of infi ltrating monocytes was 
signifi cantly lower in grafts obtained from dopamine treated and from NBD 
rats (P<0.05). A reduced infi ltration in these grafts was confi rmed by Banff 97 
classifi cation.
Conclusions: Administration of dopamine to brain dead donors improves 
early renal function after transplantation and reduces renal infl ammation. 
Hence this may explain the salutary effect of donor dopamine treatment in 
renal transplantation.
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THE EFFECT OF LOW LEVEL HE -NE LASER 1040 
RADIATION (4 J/CM2) 632.8 NM ON THE SECRETION OF 
EFFECTIVE CYTOKINE ON CHRONIC GRAFT REJECTION – 
AN IN VITRO STUDY
A. Mehrsai1, M. Afsharpad1, G. Pourmand1, B. Nikbin2, H. Wahhabaghai1, 
M. Taherimahmoudi1
1Urology Research Center,Tehran University of Medical Sciences, 
2Immunology department; Medical Faculty,Tehran University of medical 
sciences, Tehran, Iran
Introduction: Basically Chronic graft rejection is a type four hypersensitivity 
process, also known as delayed type hypersensitivity (DTH).the role of 
cytokines secreted from T cell lymphocytes is known in this process. Among 
these cytokines the biggest role belongs to TGFâ and IL2. Many studies on 
the effect of low level lasers on DTH have been published, but not many 
studies have focused on mechanism of low power lasers effect on DTH 
which is also the mechanism of chronic graft rejection. If low level lasers 
are able to decrease the level of cytokines effective on this process, then it 
is possible to use this device to prevent chronic graft rejection either alone 
or combined with routine treatmentsto gain less side effects than routine 
treatments. This study was designed to evaluate the effect of low level laser 
on the amount of cytokines secreted by T cells after stimulation by foreign 
antigens in vitro.
Method and Materials: Human Peripheral Blood Mono nuclear Cells were 
cultured; the cells were divided into 4 groups (case1, case2, control1, control2). 
Control 1 group was the base group and the cells did receive neither stimulation 
nor irradiation. Group control 2 just was stimulated by PHA, group case 1 
started receiving irradiation prior to stimulation and case 2, started receiving 
irradiation after the stimulation. Both case groups were irradiated by the same 
laser device and on days 3, 5 and 8 the level of the cytokines were checked in 
all the groups and later was analyzed.
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Results: Our results showed that low level irradiation can decrease the level 
of cytokines which are known to be stimulator for chronic graft rejection (IL2, 
IL12, and INFã. (The changes were signifi cant but there was no signifi cant 
difference between our two case groups.
Discussion: Although this study suggests the successful role of low level 
lasers on preventing chronic graft rejection by affecting the cytokines 
known to have strong role on this process, before using these devices as a 
treatment in clinic, further experimental studies and dosage determination 
are required.
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EFFECT OF PRE-TRANSPLANT LEVEL AND POST-1041 
TRANSPLANT SERIAL CHANGE OF SOLUBLE CD30 ON THE 
INCIDENCE OF BIOPSY-PROVEN ACUTE REJECTION AFTER 
KIDNEY TRANSPLANTATION
K.H. Huh1,2, M.S. Kim1,2, S.I. Kim1,2, Y.S. Kim1,2, M.K. Ju1,2, H.J. Ahn3, 
H.K. Chang1,2, D.J. Joo1, S.J. Kim1, K. Park3
1Department of Surgery and 2The Research Institute for Transplantation, 
Yonsei University College of Medicine, Seoul, Korea 3Department of Surgery, 
Kwandong University Myongji Hospital, Goyang, Korea
Serum level of soluble form CD30 (sCD30) might be used as a marker of 
immunologic status of pre-transplant recipient. We analyze effect of pre-
transplant level and post-transplant change of sCD30 on the incidence of 
biopsy-proven acute rejection prospectively.
One hundred sixty-one recipients, who underwent kidney transplant from 
March 2006 to June 2007, were enrolled in this study. Measurement of serum 
sCD30 level was performed using enzyme-linked immunosorbent assay kit 
(Bender MedSystems, CA, U.S.A.) at pre-transplant 1 day, post-transplant 1-2 
days, 5-6 days and 14 days.
Mean score of pre-transplant sCD30 was 109.7 ± 60.0 U/ml, which was not 
correlated with conventional immunologic status parameters such as panel 
of reactivity antibodies (PRA). previous history of positive lymphocyte 
cross matching and organ transplantation. The sCD30 was rapidly 
decreased after transplantation; mean score of sCD30 at post-transplant 
1-2 days, 5-6 days and 14 days were 50.1 ± 34.7, 28.0 ± 27.3 and 14.3 ± 
17.6 U/ml respectively. The post-transplant serial change of sCD30 level 
was not affected by the pre-transplant sCD30 level. The slow decrement 
of sCD30 after transplantation was related with deceased donor, high (>2.0 
mg/dl) serum creatinine level at post-transplant 7 day and delayed graft 
function. High pre-transplant sCD30 group (≥ 100 U/ml, n=82) showed 
signifi cantly higher incidence of biopsy-proven acute rejection (17.1%, 
14/82) than low sCD30 group (5.1%, 4/79) (p=0.016). The slow decrement 
of sCD30 level after transplantation did not cause a signifi cant difference 
in incidence of biopsy-proven acute rejection in separated and combined 
analysis[fi gure1].
Pre-transplant sCD30 level, not post-transplant change of sCD30 level, is 
related with the incidence of biopsy-proven acute rejection.
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CLINICOPATHOLOGICAL REVIEW IN ALLOGRAFT 1042 
NEPHRECTOMY
H-C. Park, S-J. Park, J-H. Jang, B-S. Kim, S-H. Joo,
Department of Surgery, Kyung Hee University College of Medicine, Seoul, 
Korea
Purpose: Allograft nephrectomy is not necessary in all cases of transplant 
failure. This procedure should be reserved for the symptomatic cases. The 
aim of this study was to evaluate the causes and complications of allograft 
nephrectomy. 
Materials and Methods: Among 326 kidney transplantations performed at our 
center between 1978 and 2007, 39 patients underwent allograft nephrectomy. 
The patient records were reviewed for allograft nephrectomy indications, 
morbidity, mortality and pathologic causes. Allograft nephrectomy was 
performed by the extracapsular or intracapsular route. 
Results: A total of 39 (11.9%) allograft nephrectomies were performed in 27 
(69%) male and 12 (31%) female patients. Mean age at nephrectomy was 40.9 
years (range, 26 to 59). The mean interval between kidney transplantation and 
nephrectomy was 6.7 years (range, 1 day to 16.8 years). Allograft nephrectomy 
was performed by the extracapsular route in seven cases and intracapsular 
route in 32 cases. The pathologic causes of allograft nephrectomy were chronic 
rejection in 29 cases (74.4%). acute rejection in fi ve cases (12.8%). accelerated 
rejection in three cases (7.7%). and graft vessel thrombosis in two cases (5.1%). 
There were one wound infection and two injuries of the iliac vessels. One patient 
died of sepsis. The interval from transplantation to allograft nephrectomy was 
more than 12 months in most patients (74.4%). 
Conclusions: In our study, chronic rejection was the major pathological cause 
of allograft nephrectomy. The incidences of allograft nephrectomy due to acute 
and accelerated rejection were 12.8% and 7.7%, respectively. We suggested that 
early detection and aggressive treatment of acute rejection might be considered 
to lower the incidence of allograft nephrectomy after kidney transplantation.
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DOES MICA ANTIGEN INFLUENCE ON CELLULAR AND 1043 
VASCULAR REJECTION IN KIDNEY TRANSPLANTATION?
M. Kato1, T. Kinukawa1, R. Hattori2, Y. Tsuji1, M. Tsuyuki1, N. Kohriyama3
1Chukyo Hospital, 2Nagoya University, 3Fujita Health University
Introduction and Objective: MHC class 1-related chain A (MICA) antigens 
are polymorphic genes and are expressed on endothelial cells, dendritic cells, 
fi broblasts, and epithelial cells, but not on peripheral-blood lymphocytes. 
MICA has been reported to be recognized by specifi c antibodies in sera of 
transplanted patients. Recent paper suggested that sensitization against 
MICA was associated with poorer allograft survival. Few reports mentioned 
pathological aspects on MICA so far.
Methods: To evaluate the clinical signifi cance of allo-antibodies (HLA and 
MICA antibodies) developed after kidney transplants, 31 patients who lost 
their kidney grafts were tested for post-transplant antibodies by LABScreen 
single antigen test and preserved biopsy samples were also re-stained for this 
study. All the patients had been transplanted between 1984 and 1993 at single 
center. Theses patients followed over 10 years and the sera had been collected 
at approximately 2-month intervals throughout the transplant from the original 
transplant date. Biopsies were taken dependent on the clinical data. The patients 
sera had been stored at -20 C by the test. Graft survival of 5,10,15 years are 
77%, 56% and 42%, respectively.
Results: Of 31, 21 patients lost their graft by chronic rejection with allo-
antibody by fi rst screenig using PRA test. 12 of 21 patients developed donor 
specifi c antibodies @ (57%). On the other hand, in 1of 15 control patients @ 
(7%) maintaining good renal function over 10 years, donor specifi c antibody 
was detected (P=0.0058) Although MICA antibodies were found in several 
cases with chronic rejection, C4d staining was negative in PTC and glomerulus 
of available biopsy samples. Interestingly, one rejected case showed MICA 
antibody titer increased before graft failure and that HLA antibody was 
continuously negative for this period. Biopsy sample before graft failure 
showed mild acute cellular rejection and vascular rejection.
Conclusions: In conclusion, these data shows MICA antigen may induce 
cellular and vascular rejection on renal transplantation. HLA and MICA 
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antibodies are usually present before kidney graft failure, and their development 
post-transplantation is possibly causally related to the failure of most of living 
donor kidney transplants.
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NEUTROPHILS DEGRANULATION MARKER – 1044 
LEUCOCYTE ELASTASE-Α;1PROTEASE INHIBITOR 
COMPLEX: A COMPARATIVE STUDY WITH CLASSIC (Α;1M, 
Β;2M) AND NOVEL (NGAL, IL-18) KIDNEY GRAFT INJURY 
MARKERS.
M. Zynek-Litwin1, J. Kuzniar1, Z. Marchewka2, W. Kopec1, M. Kusztal1, 
B. Szymanska2, D. Patrzalek3, P. Biecek4, M. Klinger1
1Department of Nephrology And Transplantation Medicine, Wroclaw Medical 
Universit, 2Department of Toxicology, Wroclaw Medical University, Wroclaw, 
Poland, 3Department of Vascular, General and Transplantation Surgery, 
Wroclaw Medical University, Wroclaw, Poland, 4Department of Genomics, 
Faculty of Biotechnology Wroclaw University
Introduction: Low molecular proteins are established markers of 
kidney graft function. The peritransplant events modify serum and urine 
α;1microglobulin (α;1M). β;2microglobulin (β;2M) as well as neutrophil 
gelatinase-associated lipocalin (NGAL). interleukin18 (IL-18) release. 
The mechanism of those protein concentration changes is not completely 
clear in an early period after kidney transplantation (kTx). The aim of the 
study was to seek correlations between neutrophils (PMN) activation (EL-
α;1PI complex) and classic (α;1M, β;2M) as well as novel (NGAL, IL-18) 
kidney graft tubulo-intestinal injury markers measured in blood and urine 
of deceased renal allograft recipients.
Patients and methods: The study was performed on the 24 kidney graft 
recipients from the deceased donors. The plasma and urine EL-α;1PI were 
analyzed 3 times in the fi rst week after kTx (on postoperative (PO) days 1, 3, 
7) by ELISA test. The other kidney injury markers in serum and urine were 
measured similarly on days 1, 3, and 7. NGAL, IL-18 and β;2M were measured 
by ELISA test. Serum and urine α;1M test was done by nephelometric 
method.
Results: There was an important positive correlation between plasma EL-
α;1PI (pEL) and serum NGAL on 1 and 3rd PO day (p<0,02 and 0,002 
respectively).
Strong correlation was observe between urine EL-α;1PI (uEL) on 1st PO day 
and serum NGAL on day 3 and 7 (p<0,03 and p<0,001 respectively).
Urine EL on 1 PO day correlated with urine NGAL on 3 and 7 PO day (p<0,009 
and p<0,001 respectively).
There was no important association between EL-α;1PI (in plasma and urine) 
and IL-18 level in serum and urine.
A positive association was found between pEL on the fi rst PO day and serum 
α;1M on days 3, 7 (p<0,04 and p<0,01 respectively) and between both markers 
on 3 PO day (p<0,01).
A correlation was observed between uEL on 1st PO day and serum α;1M on 1,3 
and 7th PO day (p<0,01, p<0,01 and p< 0,02 respectively).
Urine EL on 1 PO day remained in a positive correlation with urine α;1M on 
7th PO day (p<0,04).
A positive association was found on day 3 between pEL and serum β;2M 
(p<0,02).
Urine EL on 1 PO day correlated with serum β;2M on 1, 3 and 7 PO days 
(p<0,01, p<0,001, p<0,002 respectively).
There was a signifi cant association between pEL on 1 PO day and urine β;2M 
on 1,3 and 7 PO days (p<0,003, p<0,003, p<0,04 respectively).
The association between pEL and urine β;2M was observed on 3 PO day 
(p<0,04).
Urine EL on 1 PO day correlated with urine β;2M measured on PO day 1 and 7 
(p<0,007 and p<0,04 respectively).
Conclusions: Serum and urine NGAL concentration signifi cantly correlated 
with plasma and urine EL-α;1PI –; marker of PMN activation in early period 
after kTx. Similarly, there was important association between other lipocalin 
family protein – α;1M as well as low molecular protein β;2M and EL-α;1PI. 
No such correlation has been found between serum and urine IL-18 and PMN 
degranulation marker EL-α;1PI.
ACUTE REJECTION – CONCURRENT ORAL SESSION 79: 
HLA/AMR
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CELL SENESCENCE AT THE TIME OF KIDNEY ACUTE 1045 
ANTIBODY MEDIATED REJECTION: COULD PREDICT 
FUNCTION OUTCOME?
L.E. Morales-Buenrostro3, M. Arvizu-Hernandez1, M. Vilatoba1, E. Mancilla4, 
N. Uribe-Uribe2, C. Avila-Casado5, J.L. Gonzalez2, B. Gabilondo1, 
R. Correa-Rotter3 and J. Alberu1. 
1Transplantation; 2Pathology; 3Nephrology, Inst. Nal. de Ciencias Medicas y 
Nutricion SZ; 4Transplantation and 5Pathology, Inst. Nal. de Cardiologia ICh, 
Mexico
Body: Late vs. early acute antibody mediated rejection (AAMR) episodes are 
associated with worse kidney function/graft survival. Whether cell senescence upon 
development of AAMR contributes to this outcome was explored in this analysis. 
Methods: KT databases from 2 Institutions were reviewed. Biopsies (bx) 
performed due to acute graft dysfunction from 01/2000 to 03/2007 were 
analyzed. Bx fulfi lling morphological criteria of pure AAMR (n=17) were 
reviewed by 2 board-certifi ed renal pathologists. Immunoperoxidase staining 
for p16INK4a was performed in paraffi n embedded tissue, available in 9 of the 
17 bx. Immunoreactivity for p16INK4a was only considered positive if nuclear 
expression was observed to avoid false-positive results due to background 
staining. Average number of positive cells/HPF was calculated in every case. 
AAMR events were treated in accordance to current standards. Patient, biopsy 
and donor data are shown in the Table.
RECIPIENTS/BIOPSES n=17 < 3 mo > 3 mo P
Age at KT 32.1 3.5 32.6 4.6 ns
Gender F/M 2/6 5/4  
time to AAMR (weeks) 3.2 3.6 167.2 131 0.003
AAMR grade 1/2/3 0/8/0 0/8/1  
n of bx w/p16ink4a 4 5  
Nuclear expression of p16 cells/HPF 12.2 11.3 59.8 51.3 0.116
Graft loss 1 1  
*eGFR before AAMR 48.5 7.6 43.7 4.6 0.58
*eGFR (nadir) during AAMR 24.8 5.6 20.3 7.6 0.51
*eGFR at last visit 56.7 18 30.7 10.8 0.004
* eGFR before AAMR/last visit 12.5 25.9 -13.7 12.3 0.023
time from AAMR to last visit (weeks) 143.9 94.1 69.635.1 0.057
DONORS
LD/DD 5/3 8/1  
Gender F/M 5/3 3/6  
age 36.7 4.3 39 3.7 0.53
*Levey equation
AAMR cases were grouped according to the time of presentation as early (<3 
mo) or late (>3 mo). 
Conclusions: Even though the number of biopsies analysed for p16INK4a was low, 
it is evident that the number of cells expressing this marker of cell senescence 
was higher in bx of late AAMR.This fi nding may suggest the presence of prior 
injuries to the AAMR episode.The signifi cantly lower eGFR in the late AAMR 
group may translate a reduced capacity of the repairing process to sustain 
nephron function.
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IMPORTANCE OF CD4 DEPOSITION IN ACUTE 1046 
HUMORAL REJECTION
S. Sevmis1, B. Demirhan2, H. Karakayali1, B. Bilezikci2, N. Savas3, 
M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Pathology, 3Baskent 
University Faculty of Medicine, Department of Gastroenterology
Acute humoral rejection (AHR) should be considered in patients with renal 
allograft dysfunction, as it can develop at any stage of the posttransplant course. 
In this study, we review the diagnosis, treatment, and outcomes of 8 patients. 
There were 8 patients (4 women, 4 men; mean age, 32 &#61617; 16.7 years) 
who underwent renal transplant (RT) at our center who were later diagnosed as 
having AHR at mean of 19.6 months (range, 6 days to 74 months) after RT. AHR 
was diagnosed via allograft dysfunction and allograft biopsy. Allograft biopsy 
showed a strong, diffusely distributed endothelial staining pattern of CD4 in 
the peritubular capillaries. The results of a pretransplant lymphocyte subset 
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analysis, and the results of panel reactive antibody were normal. All patients 
were treated with plasma exchange. AHR occurred in the early postoperative 
period (< 3 months) in 3 patients and in the late postoperative period (> 3 
months) in 5 patients. Before treatment, the patients’ mean serum creatinine 
level was 2.4 &#61617; 0.6 mg/dL (range, 1.4-3.4 mg/dL) and after treatment, 
the mean serum creatinine level was 1.9 &#61617; 0.6 mg/dL (range, 0.9-2.9 
mg/dL). All patients were treated successfully except 1. In that patient, a graft 
nephrectomy was performed 17 days after RT owing to total vascular occlusion 
of the graft. One patient returned to hemodialysis 3 months after treatment, and 
retransplatation was performed 2 months later. At the time of this writing, the 
remaining 6 patients are alive with good graft functioning at a mean follow-up 
of 14.1 &#61617; 6.3 months (range, 7-25 months). In conclusion; widespread 
CD4 deposition in the peritubular capillaries, as demonstrated by renal allograft 
biopsy, is an important characteristic for the diagnosis of AHR. In the patients 
studied, several plasma exchange treatments were effective in resolving AHR.
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CASE REPORT: PRETRANSPLANT SEROLOGICAL 1047 
NEGATIVITY AND HYPERACUTE REJECTION IN KIDNEY 
RETRANSPLANTATION
I.M. Titiz1, G. Isitmangil1, H. Tozkir2, I. Kilicaslan3, G. Gumrukcu1, F. 
Turkmen1, 
G. Tellioglu1, B. Yigit1, I. Berber1
1Haydarpasa Numune Research And Educational Hospital, Renal 
Transplantation and Immunology Unit, Istanbul, Turkey, 2Trakya University, 
Medical Faculty, Department of Medical Biology, Edirne, Turkey, 3Istanbul 
University, Istanbul Medical Faculty, Department of Pathology, Istanbul, 
Turkey
Hyperacute rejection (HAR) occurring within minutes after transplantation are 
due to the presence of preformed antibodies to donor organ antigens.
A 35 year-old male patient, awaiting kidney retransplantation has been performed 
hemodialysis for 13 years. His original disease is chronic glomerulonephritis. 
He has not had a history of either smoking or diabetes mellitus. He was 
immunosuppressed with mycophenolate mophetyl and steroid before surgery 
and was given anti-timosit globulin (ATG) during the operation. He has been 
grafted from cadaveric donor age-matched, ABO blood type-matched with 
22 hour cold ischemia time. Before the operation the complement-dependent 
cytotoxicity cross-match assay was negative and also fl ow cytometric cross-
match (FCXM) was negative. Furthermore ELISA-PRA class I and class II 
results were all negative serologically. This patient has undergone hyperacute 
rejection. PRA class I has become positive 3 months after the retransplantation. 
Antibodies were occurred against A1, A11, A25, A26, A29, A34, A36, A66, 
and B65 antigens.
Pathologically hematoxylen eosin (HE) staining is indicating HAR and also 
C4d is focally positive at peritubular capillary area.
This case is important to show that although all immunological markers are 
negative in pretransplantation period, it may be possible to undergo a hyperacute 
rejection and further assays may be necessary to avoid the HAR.
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THE IMPACT OF DIFFUSE C4D BIOPSY STAINING AND 1048 
SERUM DONOR SPECIFIC HLA ANTIBODIES ON KIDNEY 
TRANSPLANT GRAFT SURVIVAL
R. Vaughan2, S. De Freitas1, N. Mamode1, R. Nortley1, R. Hangartner3, 
J. Else4, O. Shaw2, P. O’Donnell3
1Department of Transplantation, Guy’s Hospital, 2Clinical Transplantation 
Laboratory, Guy’s Hospital, 3Department of Histopathology, Guy’s Hospital, 
4Department of Histopathology, St George’s Hospital
Introduction: Both C4d positive staining and serum donor specifi c antibodies 
are thought to confer a higher risk of graft failure in kidney transplant 
recipients.
Methods: This was a retrospective single centre study review outcomes in 
all adult kidney transplant recipients who had had a kidney Transplant biopsy 
taken between April 2003 and October 2006 at Guy’s Hospital. The C4d stain 
was introduced in 2003 and therefore outcomes were evaluated according 
to C4d status and the presence of donor specifi c antibodies. The presence of 
staining and the pattern of this as well as kidney function at a pre-biopsy 
baseline, the day of the biopsy, six months post biopsy, one year post biopsy 
and then yearly thereafter was collected. The abbreviated MDRD was used. 
If several biopsies had been performed in one patient the incident biopsy was 
taken as the fi rst to show C4d positive staining. For the C4d –ve patients the 
fi rst biopsy was taken as the fi rst biopsy after 2003. This group have never 
had C4d stain detected but have not had any biopsies performed prior to 2003 
re-stained.
Results: One hundred and seventy three patients had not had C4d stain detected 
on their biopsies. The biopsies were reviewed by an external Histopathologist 
from a separate centre and 45 cases with diffuse (>50%) C4d stain confi rmed 
using paraffi n sections and polyclonal antibodies. One case was then excluded 
due to detection on a biopsy post graft failure giving a diffuse C4d group of 
n=44.
Outcomes differences looked at were between those patients with diffuse 
(>50%) C4d staining, and those whose biopsies had been negative for C4d. 
The Kaplan-Meyer transplant survival curves from time of transplantation (in 
months) were signifi cantly different for these two groups (p=0.006, Mantel-
Cox and Breslow). In the C4d+ve group there were 14 graft failures within 1 
year of biopsy. Of the 12/173 C4d –ve group had graft failure and only 6 within 
a year of the biopsy.
Overall positive DSA was also associated with worse graft survival irrespective 
of whether C4d staining was positive (p=0.016). There were eight patients who 
had biopsies that were consistently C4d –ve but had +ve DSA +ve. Three out 
of eight developed graft failure.
An analysis of change in eGFR over time from either a pre-biopsy baseline or 
the day of the biopsy did show a greater reduction in function in the C4d+ve 
group however due to the excess of graft loss in this group this did not reach 
statistical signifi cance as the those with End Stage Renal Failure (ESRF) are 
removed from this analysis which relies on numerical values.
Summary: Graft survival was signifi cantly worse in the patients under follow 
up at Guy’s Hospital with a kidney transplant whether outcome was looked 
at according to diffuse C4d staining on biopsy or Donor Specifi c antibodies 
detection in the serum.
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LOW-DOSE RITUXIMAB TO SALVAGE RENAL 1049 
TRANSPLANTS FROM REFRACTORY ANTIBODY-MEDIATED 
REJECTION
J. Kanellis1, W. Mulley1, F. Hudson2, B. Tait2, A. Skene3, J. Dowling3, P. Kerr1
1Department of Nephrology, Monash Medical Centre, Clayton, Australia 
3168, 2Victorian Transplantation and Immunogenetics Service, Parkville, 
Australia 3052, 3Department of Pathology, Monash Medical Centre, Clayton, 
Australia 3168
Recent reports suggest that treatment with the monoclonal anti-CD20 
antibody, Rituximab (Rtx) may improve renal graft survival in antibody 
mediated rejection (AMR); however optimal dosing for this indication 
is unknown. We examined the effi cacy of a single low dose (500mg) of 
Rtx for treatment of refractory AMR in order to limit signifi cant infective 
complications associated with conventional dosing regimens (375mg/m2). 
Rtx was used in seven consecutive patients who had refractory AMR as 
judged by ongoing biopsy evidence of AMR after 4 weeks of standard 
therapy consisting of pulse methylprednisolone and plasma exchange with 
low dose IVIg (100mg/kg) (PE/IVIg). All patients received Tacrolimus and 
Mycophenolate Mofetil. AMR was defi ned as 1) characteristic histology 
on biopsy (Banff criteria). 2) graft dysfunction and 3) presence of a donor 
specifi c anti-HLA antibody (DSAb). B-cell counts (CD19) and serum 
creatinine (SCr) were monitored. PE/IVIg was ceased in all cases after 
Rtx dosing. The average follow-up since Rtx dosing is 16.8 months (range 
5.3-28.9 mths). All patients still have functioning grafts (100% 12 month 
graft and patient survival). with current mean SCr levels (156±17ìmol/L) 
signifi cantly lower than mean peak rejection levels (514±355ìmol/L) 
p=0.05. CD19 counts fell to zero and remained <5x106/L for >6 months 
in all patients. DSAbs remain detectable by Luminex Flow Beads in all 
patients despite stabilization of SCr. Two of 7 patients developed an 
infective complication post Rtx dosing. One patient developed bacterial 
pneumonia requiring hospital admission whilst a second patient developed 
CMV viraemia and later BK nephropathy which has not led to signifi cant 
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graft dysfunction. Hence, infectious complications are far less than those 
reported for multiple standard dose regimens in similar patient groups. 
Large clinical trials are required to confi rm the effi cacy of Rtx in treating 
AMR as well as optimal dosing. Standard dosing is based on oncology 
treatment regimens which are likely to be excessive for AMR in patients 
already markedly immunosuppressed. Our data suggests single low-dose 
Rtx for refractory AMR results in excellent patient and graft survival and 
leads to low rates of serious infective complications in the short-term.
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INFLUENCE OF CYTOKINE GENE POLYMORPHISMS 1050 
ON THE DEVELOPMENT OF ACUTE AND CHRONIC 
REJECTION IN ROMANIAN RENAL TRANSPLANTATION 
RECIPIENTS
I. Constantinescu1, D. Vasile1, D. Nedelcu1, M.A. Toader1, M. Zaharia1, 
M. Harza2, B. Stefan2, A. Iordache2, B. Serbanescu2, I. Sinescu2
1Centre For Immunogenetica And Virology, Fundeni Clinical Institute, 2Centre 
For Urology, Dialysis And Renal Transplantation
Both donor and recipient cytokine genotype infl uences the development of 
acute rejection after renal transplantation
Purpose: Acute allograft rejection remains an important cause of morbidity after 
kidney transplantation and has been shown to be a crucial determinant of long-
term graft survival. Although rejection is mediated by recipient lymphocytes, 
both donor and recipient factors contribute to the local environment that 
infl uences the nature, severity, and duration of the rejection response. Cytokine 
gene polymorphisms are important factors involved in the outcome of renal 
transplant recipients and in this study is designed to explore the impact of 
donor cytokine and cytokine gene polymorphisms on acute rejection after renal 
transplantation.
Methods: A total of 138 related donors and renal allograft recipients were 
selected according to the presence or absence of graft rejection in the fi rst 
month after transplantation. DNA was genotyped using the polymerase 
chain reaction with sequence specifi c primers. Associations were assessed 
using contingency table analysis and the [chi]2 test. The Invitrogen Cytokine 
Genotyping Kit is a PCR-based method designed to detect polymorphisms 
of thirteen cytokine genes. The Invitrogen Cytokine Genotyping Kit 
consists of various combinations of lyophilized primer mixes that are used 
to amplify genomic DNA using a 96 well tray. Setup includes mixing a 
reaction buffer with a human genomic DNA sample and Taq polymerase, 
dispensing the mixture to the 96 well tray, capping and then thermal cycling. 
After cycling is complete, the PCR products are loaded onto a 2% agarose 
gel for electrophoresis. After electrophoresis the ethidium bromide gel is 
photographed and interpreted using a worksheet for specifi c application 
patterns.
Results: Polymorphisms at position – 174 of the donors IL6 gene was associated 
with the incidence and severity of recipients acute rejection (62,3%). Acute 
rejection was not infl uenced by recipient IL6 genotype. In some pairs donor 
IL4 gene polymorphisms at position – 590 was also associated with acute 
rejection within one month after kidney transplantation (13,1%).
IL 10 gene polymorphisms at position 1082 in some of the donors (24,6%) was 
correlated with rejection episode in recipients, but the intensity of the acute 
rejection was not so strong as in the other cases. Acute rejection episodes were 
not infl uenced by recipient IL4 and IL10 genotypes. All pairs were matched 
for HLA DR
Conclusions: Our study identifi es donor IL6, IL4 and IL10 polymorphisms as 
a major genetic risk factor for the development of acute rejection after renal 
transplantation.
This provides evidence that donor-derived cytokines play a major role 
in determining outcome after transplantation, and will contribute to the 
development of the therapeutic algorithms to predict individuals at particularly 
high risk of acute rejection.
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ANTI-BODY MEDIATED REJECTION DIAGNOSED ON 1051 
CLINICAL AND HISTOPATHOLOGICAL GROUNDS MEETS 
ONLY RARELY THE FULL REVISED BANFF 97 CRITERIA.
I. ten Berge1, S. Adhin1, P. Kuin2, S. Florquin3, N.J. Lardy2, F.J. Bemelman1
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Sanquin, 
Amsterdam, Dpt of HLA diagnostics, 3Dpt Pathology, Academic Medical 
Centre, Amsterdam
Acute anti-body mediated rejection (AMR) is accompanied by rapid detoriation 
of renal function. Histological signs of (AMR) vary from relatively mild to 
fulminant allograft destruction. None of the clinical and histopathological 
symptoms are specifi c. According to the Revised Banff 97 criteria, a defi nitive 
diagnosis of humoral rejection can be made, when, apart from histopathological 
changes, the renal biopsy is positive for C4d and donor specifi c antibodies 
(DSA) can be detected.With only two of the three criteria AMR is suspected. 
However, C4d positivity can be focal, diffuse, weak or strong, possibly 
depending on the type of antibodies used and the type of tissue. Variation in 
the techniques to detect DSA is even wider. In this single center retrospective 
study we aimed to defi ne the percentage of patients treated for AMR that met 
the offi cial Revised Banff 97 Criteria for (suspicion) of AMR.
From January 2004 to July 2007 21 patients were treated for AMR diagnosed 
on clinical and histological grounds with anti-thymocyte globulins (ATG) and 
plasmapheresis. Serum and renal tissue was available in 19/21 patients. 108 
pre and posttransplantation sera were evaluated with a Luminex Screening 
and Single Antigen technique. When DSA were detected, CDC and FACs 
crossmatches were repeated. Complementary C4d staining was performed, 
when needed. Positivity was defi ned as more than 75% staining of the 
peritubular capillaries.
Results: 71 van de 108 sera were positive in the Luminex Screening. DSA MHC 
Class I and/or Class II could be detected in 7 patients. 2 out of 7 showed C4d 
positivity. 2 patients without DSA were positive for C4d. There was a complete 
overlap in detection of DSA in the FACs cross match and the Luminex.
Renal allografts were lost in 5 patients. Only one of these patients met the 
criteria for AMR. Two met the criteria for suspicious for AMR.
We conclude that only a minority of patients with a diagnosis of AMR on 
clinical and histopathological grounds met the Revised Banff 97 Criteria for 
AMR or suspicious for AMR. There was no surplus value of the FACs cross 
match.
POSTER BOARD NUMBER P1 – 138
CLINICAL IMPLICATIONS OF THE MONITORING OF 1052 
ANTI-HLA ANTIBODIES AFTER KIDNEY TRANSPLANTATION
M.C.R. Castro1, P. Souza1, N. Panajotopoulos2, D. David3, C. Ronda2, 
H. Rodrigues2, F. Agena1, L.E. Ianhez1, E. David-Neto1, J. Kalil2, 
1Urology Division- Kidney Transplant Unit, 2Laboratory of Immunology – 
Heart Institute, 3Pathology Division
Aim: To follow systematically anti-HLA antibodies (Abs) after renal 
transplantation and to evaluate their association with acute rejection, C4d 
staining and graft survival.
Methods: Between July/05 and July/06, 926 sera from 111 transplanted 
patients (pts) who completed 12mo FU or lost the graft were analyzed. Sera 
were collected before transplantation, at days 7, 14, 30, 60, 90, 180, 360 post-
transplant (PTx) and during acute rejection episodes (AR). Donor-specifi c 
antibodies (DSA) were detected by fl ow cytometry (FXCM) and NIH-CDC-
AGH technique. Panel reactive antibodies (PRA) were analyzed using ELISA 
methods; AR were classifi ed by Banff 97 criteria (updated in 2003). C4d 
staining was performed on frozen biopsies.
Results: Pre-transplant PRA was >1% in 23 pts (21%). 11 of them had 
PRA>50%. Pts were classifi ed in 5 groups according to PTx PRA: Group A 
(n=88): no evidence of Abs pre and PTx; group B (n=8): non-sensitized pts 
who developed Abs de novo; Group C (n=6): sensitized pts who remained at 
the same PRA level; Group D (n=13): sensitized pts who decreased PRA level 
and Group E (n=4): sensitized pts who increased PRA levels during the 1st 
yr. Groups C, D and E received more ATG than groups A and B (p=.001). AR 
occurred in 30/111pts (27%). Groups with appearance or increase of the PRA 
after transplantation presented 3 to 5 times more rejection episodes: B=62,5%; 
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C=66,7%, E=75% vs A=21,3% (p<.001) and D= 7,7% (p<.02). Group A, 
which had no Abs pre and PTx, had lower Banff scores than the other groups 
(p=.03). Group A had also lower rates of C4d positivity on AR biopsies (6% x 
75%, p<.001). Among pts with AR, 43,3% had Abs which appeared/increased 
during the AR episode, and 77% of them were DSA. The overall incidence of 
antibody-mediated rejection was 11,7%. One-year censored graft survival was 
lower in patients with AR, especially in those with AMR. The presence of AR 
(p<.05). C4d+ (p=.02) and DSA (p<.05) where risk factors for graft loss.
Conclusion: Our data suggest that monitoring of anti-HLA Abs after kidney 
transplantation may be a useful tool to evaluate the risk of antibody-mediated 
responses, and has also prognostic implications in terms of graft survival.
POSTER BOARD NUMBER P1 – 139
CHEMOKINES AND CHEMOKINE RECEPTORS IN 1053 
RENAL TRANSPLANTATION
L.T. Saber1, J.C.O. Crispim2, R.A. Duarte3, C.P. Soares3, R.S. Costa4, 
J.S. Silva2, C.T. Mendes-Júnior5, E.A. Donadi5
1Renal Transplant Unit, Hospital Das Clinicas, University of São Paulo-
Ribeirão P, 2Department of Biochemistry and Immunology, FMRP-USP, 
Brazil, 3Department of Clinical Analysis; School of Pharmaceutical Sciences, 
UNESP, University of São Paulo State., 4Department of Pathology, FMRP-
USP, Brazil., 5Division of Clinical Immunology, FMRP-USP, Brazil
Chemokines are potent mediators of leukocyte to the site of infl ammatory 
processes, which are produced constitutively or upon activation by a variety of 
different cell types in renal tissue, including infi ltrating leukocytes, endothelial 
and tubular epithelial cells, fi broblasts, and mesangial cells. The potential 
relationship between the expression of the chemokines IP-10, MCP-1 and 
respective receptors CCR5 and CXCR3 with histological and clinical features 
was investigated in specimes renal allograft at the time acute rejection (AR) 
and chronic allograft nephropathy (CAN) and compared with biopsies no signs 
rejection. 
Patients and Methods: Fifty-one renal specimens (7 with acute rejection 
and 11 chronic allograft nephropathy, and 33 with no signs of rejection were 
immunohistochemically evaluated for MCP-1, IP-10, CXCR3 and CCR5 
Results: Chemokine and chemokine receptor expression was observed mainly 
in mononuclear cells infi ltrating the interstitium and tubulointersticial area. In 
the group as a whole, IP-10 expression was detected in 21 cases (41.2%). 8 
out of 18 exhibited AR and CAN, and the remaining 13 exhibited no signs 
of rejection. CXCR3 expression was detected in 26 cases (51%). 9 out of 18 
exhibited AR and CAN, and the remaining 17 exhibited no signs of rejection. 
MCP-1 expression was detected in 12 cases (23%). 5 out of 18 exhibited AR 
and CAN, and the remaining 7 exhibited no signs of rejection. Considering 
only patients with AR the expression of MCP-1 was signifi cantly increased 
(p<0.0415). CCR5 expression was detected in 23 cases (45.1%). 10 out of 18 
exhibited AR and CAN, and the remaining 13 exhibited no signs of rejection. 
Conclusion: Renal allograft exhibiting AR showed increased MCP-1 
expression; however, no signifi cant differences were observed regarding the 
IP-10, CXCR3 and CCR5 expression in rejection and non-rejection groups.
POSTER BOARD NUMBER P1 – 140
CORRELATION ANALYSIS AMONG SERUM ANTI-HLA 1054 
ANTIBODIES, CD4+, CD8+, AND CD19+ CELLS IN RENAL 
ALLOGRAFTS.
F. Obata1, K. Yoshida2, Y. Takeuchi2, M. Tsuchida2, T. Endo2, S. Baba2
1Kitasato University School of Allied Health Sicences, 2Kitasato University 
School of Medicine
Objective: To know the correlation between humoral and cellular rejections 
of renal allograft.
Methods: Anti HLA-class I and -class II IgG antibodies in the serum of renal 
allograft patients were detected by fl ow cytometry using PRA screening beads 
(Flow-PRA). CD4+, CD8+, and CD19+ cells in the biopsy specimens of renal 
allografts were detected by reverse transcriptase-PCR (RT-PCR).
Results and Discussion: Thirty-four patients who were positive for any one 
of CD4, CD8, or CD19 were subjected to correlation analysis. Among the 26 
cases of CD4+, 9 (35%) were CD8+, and 11 (42%) were CD19+. Thus, in these 
cases, CD8+ killer T cells and B cells resided in renal allografts concomitantly 
with the CD4+ helper T cells, providing a favorable situation for activation of 
both cell types, each of which are involved in cellular and humoral reactions, 
respectively. On the other hand, HLA antibodies were detected in 4 (15%) of 
the CD4+ cases and in 5 (19%) of the CD4- cases. Twelve cases (46%) of the 
CD4+ cases did not produce any HLA antibody. With regard to CD19, HLA 
antibodies were detected in 3 (23%) of the 13 CD19+ cases and in 5 (38%) of 
the CD19- cases. Six cases (46%) of the CD19+ cases did not produce any HLA 
antibody. These results suggested that number of CD4 helper T cells and B cells 
in renal allograft did not correlate directly with the HLA antibody production. 
We are continuing this approach to know whether cellular accumulation in 
allograft induces future humoral immune response.
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PERITUBULAR CAPILLARY ENDOTHELIAL 1055 
INDOLEAMINE 2,3-DIOXYGENASE (IDO) IN HUMAN RENAL 
ALLOGRAFTS: CORRELATIONS WITH HUMORAL AND 
CELLULAR REJECTION AND LATE GRAFT PATHOLOGY
R. Smith1, P. Della Pelle1, A.B. Collins1, L. Cornell2, W. Wong3, T. Tatsuo 
Kawai4, C. Cook5, D. Sachs4, A.B. Cosimi4, R.B. Colvin1
1Department of Pathology, Massachusetts General Hospital, 2Department 
of Pathology, Mayo Clinic, 3Department of Medicine, Massachusetts 
General Hospital, 4Department of Surgery, Massachusetts General Hospital, 
5Department of Surgery, Ohio State University
Indolamine 2, 3-dioxygenase (IDO). induced by IFNγ in endothelial and 
dendritic cells, can inhibit the allogeneic immune response. Induction of IDO 
has been documented in endothelial cells of accepted murine kidney and heart 
allografts, but little is known about its expression in human renal allografts. 
Here we test the hypothesis that endothelial IDO in 97 human renal allografts 
might correlate with resistance to antibody-mediated rejection. Transplant 
biopsies, classifi ed by Banff criteria including C4d staining, were stained by 
immunohistochemistry with a monoclonal antibody (Serotec).
Diagnosis % Positive 
C4d
% Positive 
TG Status
N % Positive 
Cases
Acute Graft Injury
Acute Cellular Rejection 0 0 11 45%
Acute Tubular Injury 0 0 2 0%
Acute Humoral Rejection (AHR) 100 0 9 11%
Acute Cellular and Humoral 
Rejection
100 0 5 0%
Chronic Graft Injury
Chronic Humoral Rejection (CHR) 100 92 13 31%
Transplant Glomerulopathy, NOS 0 100 5 80%
Chronic Calcineurin Inhibitor 
Toxicity
0 0 2 50%
Interstitial Fibrosis & Tubular 
Atrophy, NOS
0 0 5 0%
Stable/No Pathology
Accommodation (DSA+/C4d+; No 
Pathology)
100 0 5 100%
No Diagnostic Abnormality 0 0 30 13%
Donor Kidney (one hour)
Donors 0 0 10 40%
Total 97
Endothelial IDO was not observed in normal control kidneys. Stable grafts 
without pathology or C4d, including 30 protocol biopsies, were usually 
negative for IDO in PTC (13% positive). Among cases with positive C4d, 
endothelial IDO was present infrequently in acute humoral rejection (11%). 
absent in mixed cases of acute cellular and humoral rejection, present in the 
some of cases of chronic humoral rejection (31%). and was uniformly and 
strongly expressed in cases with C4d but without rejection (accommodation) 
(100%). In C4d negative cases, acute cellular rejection, endothelial IDO was 
expressed in PTC (45%). and arterial endothelium in Banff type II rejections. 
Infi ltrating cells were also focally positive. IDO expression was not identifi ed 
in two cases of acute tubular injury. In late graft injury without C4d, IDO was 
more common in cases with transplant glomerulopathy than in those showing 
only interstitial fi brosis and tubular atrophy without glomerulopathy (80% vs 
0%). Two of the positive TG cases had prior C4d+ CHR. Among donor biopsies 
IDO was variable (40%) with the strongest expression from a donor with 
subarachnoid hemorrhage. In addition, one of two cases of chronic calcineurin 
inhibitor toxicity was positive (50%).
Poster Abstracts Monday 11 August 2008
3 6 3
M
O
N
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Conclusions: These data show frequent presence of peritubular, glomerular and 
arterial endothelial IDO expression in human renal allografts. Among those with 
antibody mediated pathogenesis, the strength and frequency of IDO correlated 
inversely with the severity of chronic graft injury (accommodation > AHR > 
CHR). Other apparent stimuli include acute cell mediated rejection, presumably 
via IFNγ, and donor status. Detection of induced IDO expression provides a 
novel and potentially useful marker of endothelial status in the graft.
POSTER BOARD NUMBER P1 – 142
INCIDENTAL BIOPSIES: AN ALTERNATIVE TO 1056 
PROTOCOL BIOPSIES IN RENAL ALLOGRAFT RECIPIENTS?
K.V. Ranga1,2, S. Sathyan2, V. Patel2, P. Niezgorski1, A. Lally1, M. Brown1, 
J. D’Avella1, D. Hull1
1Hartford Hospital, 2University of Ct Health Center
Incidental biopsies, as we would like to defi ne, are renal biopsies performed 
during the course of other surgical procedures related to the renal allograft. 
For transplant programs that do not routinely perform protocol biopsies, these 
‘incidental’ biopsies may offer a means of monitoring for sub clinical rejections 
in their allografts. Some of these biopsies may even happen to be done in the 
fi rst few days post-transplant, before most scheduled protocol biopsies, offering 
a unique look into the histology of the allograft.
This was a retrospective study performed by chart review of all renal transplants 
performed at our institution from 2002 to 2007. All these patients received 
standard triple immunosuppression with Tacrolimus, Mycophenolate mofetil 
and steroids, with IL-2 receptor antibody induction in the majority of patients, 
and lytic induction for the pancreas recipients and some ‘high-risk’ kidney 
recipients. Thirty three patients
(M: F = 21: 13, median age 46 years) who underwent abdominal surgery had 
incidental renal allograft biopsies performed, at a median of 17 days post 
transplant (range: 1 to 225 days). Biopsies were performed depending on 
preference of surgeon. Of those biopsied, 7 were operated for repair of urine 
leaks, 8 for wound dehiscence, 10 for marsupialization of lymphoceles, 3 
for questionable blood fl ow on ultrasound, 3 for evacuation of hematomas, 
and 1 each during exploratory laparotomy in a febrile simultaneous pancreas 
and kidney (SPK) reciepint, and during graft pancreatectomy. Of the 33 
biopsies performed, 4 patients (8.25%) were reported to have acute cellular 
rejection (Banff Class II in 1 patient, and class I in 3 patients) and 1 patient 
had c4d positivity with no ACR and normal renal function. A small number 
of patients had mild interstitial fi brosis and tubular atrophy. The incidence of 
acute rejection in this cohort of patients is greater than the incidence of acute 
rejections demonstrated by indicated biopsies in our patient population, thus 
making a case for protocol surveillance biopsies.
We conclude that incidental biopsies are important in assessing allograft 
histology in programs that do not perform protocol biopsies routinely. In those 
patients that do not receive an incidental biopsy by a certain period of time, 
protocol biopsies may be recommended for allograft monitoring.
BIOMARKERSCONCURRENT ORAL SESSION 80: 
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ABNORMAL PROFILE OF C-PEPTIDE AND PROINSULIN 1057 
IN NONDIABETIC KIDNEY TRANSPLANT RECIPIENTS: 
IMPACT OF RENAL FUNCTION, STEROID TREATMENT AND 
HYPERLEPTINEMIA.
A. Kagan, R. Sarafi an, N. Haran, L. Leschinsky, J. Rapoport
Department of Nephrology And Hypertension, Kaplan Medical Center 
Rehovot And Faculty of Medicine, Hebrew University, Jerusalem
Abnormal profi le of C-peptide and proinsulin in nondiabetic kidney transplant 
recipients: impact of renal function, steroid treatment and hyperleptinemia. 
Alexander Kagan, MD; Ruth Sarafi an, RN, BA; Nurit Haran PhD; Ludmila 
Leschinsky MD, PhD and Jayson Rapoport MB, BS, FRCP, Department of 
Nephrology and Hypertension, Kaplan Medical Center Rehovot and Faculty of 
Medicine, Hebrew University, Jerusalem
Background: Factors associated with kidney transplantation, including renal 
functional impairment, glucocorticoid and calcineurin inhibitor therapy, 
hyperleptinemia and insulin resistance may affect the synthesis, secretion, 
circulating levels and clearance of beta cell pancreatic hormones such 
as insulin, C-peptide and proinsulin. This issue has not been extensively 
investigated in nondiabetic transplant kidney patients (Tx). and may have an 
important bearing on the development of post-transplant diabetes mellitus 
(PTDM).
Subjects and methods. The study population was selected from 47 
subjects: 21 normal subjects (Ns) and 26 kidney transplant (Tx) patients. 
16 Tx and 16 Ns matched by gender, age, BMI, hematocrit levels, serum 
concentrations of glucose, albumin, cholesterol, C-reactive protein were 
studied. In addition, 15 males: 5 Ns, 5 cyclosporine-A (Tx-CsA) and 5 
tacrolimus (Tx-FK) treated were studied prospectively from 08.00 to 16: 00 
while fasting. Most Tx patients received triple immunosupressive therapy 
including calcineurin inhibitors (Tx-FK or Tx-CsA). anti-metabolites 
(mycophenolate mofetil or azathioprine) and steroids (prednisone). Tx 
were divided into two groups: cyclosporine-A-treated (Tx-CsA, n=9) 
and tacrolimus-treated (Tx-FK, n=7). Fasting serum levels of insulin, 
C-peptide and cortisol were measured by a chemiluminescent enzyme 
immunoassay. Fasting serum proinsulin and leptin concentrations were 
measured by radioimmunoassay. Insulin resistance was calculated using 
the homeostasis model assessment.
Results: 50% of Tx (8/16) compared to 12.5% of Ns (2/16) exhibited increased 
fasting serum C-peptide levels (>1320 pmol/l). 68% of Tx (11/16) compared to 
6% of Ns (1/16) showed increased fasting serum proinsulin levels (>9.4 pmol/l). 
Corresponding fasting values of insulin, C-peptide and proinsulin decreased 
steadily with time (08.00 versus 16.00). Serum proinsulin concentrations in 
Tx- FK were markedly higher throughout the fast than those of Ns and Tx-
CsA, but there was no statistical difference between Tx-CsA and Ns. Serum 
concentrations of C-peptide and proinsulin, but not insulin, were signifi cantly 
correlated with serum leptin, cortisol and glomerular fi ltration rate (GFR) 
levels in all subjects and in Tx.
Conclusions: We found that renal functional impairment, hyperleptinemia, 
steroids and calcineurin inhibitor treatment lead to increased circulating levels 
of proinsulin and C-peptide, especially in the Tx-FK group. We suggest that 
fasting C-peptide and proinsulin levels are better markers of pancreatic ï ¢-cell 
function in Tx patients then insulin.
The relationship observed between increased serum levels of leptin and beta 
cell polypeptides in nondiabetic transplant kidney patients Tx requires further 
evaluation.
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TRANSPLANTATION OF A KIDNEY WITH A RENAL 1058 
CELL CARCINOMA AFTER LIVING DONATION: A CASE 
REPORT
A. Ghafari
Urmia University of Medical Sciences
Abstract: Transmission of cancer is a serious risk in organ transplantation. 
We present a case of renal cell carcinoma (RCC) in a kidney obtained from 
a living donor. A 48-year-old mother was evaluated for donation to her 
12-year-old daughter. Donor renal ultrasound, intravenous pyelography, and 
angiography were normal. A 5 _ 5 mm nodule found on the surface of the 
kidney during harvesting was totally excised before transplantation. The 
histology revealed RCC with free margins at 2 weeks after transplantation. 
The immunosuppressive drugs consisted of cyclosporine, mycophenolate 
mofetil, and prednisolone.
The graft function remained stable. Donor and recipient are without evidence of 
tumor recurrence at 24 months after transplantation. This experience indicated 
that donor kidneys with small, incidental RCC may be managed with excision 
and transplantation, without tumor recurrence in recipients who are informed 
of the potential risks of recurrence and metastases.
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RENAL RE-TRANSPLANTATION: IS IT JUSTIFIED?1059 
S. Moniri, M. Samhan, T. said, M.R.N Nampoory, P. Nair, T. Al Otaibi, 
I. Al-Mezairai, M. Al-Mousawi
Member of Mesot
Introduction and Objectives: there is a dispute about the justifi cation of 
renal re-transplantation in the presence of organ shortage, and the concept 
that patients who have lost a transplanted kidney are widely recognized as a 
high risk for re-transplantation. This is a retrospective study of the outcome 
of renal re-transplantation (Re-Tx) and to fi nd out if renal re-transplantation 
is justifi ed.
Patients and Methods: Between 1993 and December 2006, 646 kidney 
transplantation procedures were performed in our centre, 39 of these (6%) were 
Re-Tx. The medical records of these patients were reviewed. They were 19 
males and 20 females, aged 10 to 62 years (mean 36 years). nine of them were 
children. Kidney grafts were obtained from 16 living and 23 cadaveric donors. 
Induction immunosuppression was with ATG in 28, and with anti-Interleukin-2 
receptor antibodies in 5 recipients.
Results: patients were followed up for 12 months to 134 months. Post 
transplantation complications were in the form of: 14 instances of surgical 
complication, 12 episodes of acute rejection, and 2 cases of malignancy. Four 
recipients died with functioning graft at 4 months to 62 months after Tx. Seven 
more grafts were lost at one day to 84 months after Tx secondary to renal vessel 
thrombosis in 3, chronic dysfunction in 3, and graft infarction secondary to 
antiphospholipid syndrome in one recipient.
Conclusion: It was observed in the present series that renal Re-Tx is associated 
with recipient survival rates which are similar, and graft survival rates which are 
10-13% lower than those in primary Tx. These results are still quite reasonable 
to justify renal re-transplantation.
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SIGNIFICANTLY HIGH RATE OF COMORBIDITY IN 1060 
RENAL TRANSPLANT RECIPIENT CANDIDATES WAITING 
FOR MORE THAN 10 YEARS
Y. Watarai, A. Kawaguchi, S. Maru, R. Ishikawa, N. Taniguchi
Kushiro City General Hospital
Purpose: Candidates on the renal transplant waiting list wait for signifi cantly 
long time, 18 years in average, in Japan and they are assumed to have increasing 
numbers of comorbidity during dialysis period. Transplant centers need to 
ensure that their candidates are acceptable for transplantation when the organ 
becomes available. We have evaluated the renal transplant waiting list in our 
institute.
Methods: 18 out of 20 candidates on our waiting list, mean age of 49.8 (28-60) 
and duration on hemodialysis of 11.2 years (1-22 years). were evaluated 1) 
complete blood tests, 2) chest X ray, 3) echocardiography and cardiac stress 
testing, 4) measurement of Pulse wave velocity (PWV) and Ankle blood pressure 
index (ABPI). 5) Plain CT scan with 3D reconstruction of the calcifi cation of 
aortic and iliac artery by maximum intensity projection.
Results: All candidates revealed normal chest X ray, echocardiography and 
cardiac stress testing. CT scan showed severe aortic calcifi cation in 8 candidates 
(44%) in which the calcifi cation occupied all around the aorta, and partial aortic 
calcifi cation in 7 (39%). But all candidates had non calcifi ed iliac artery site to 
make vascular anastomosis possible. However, 13 candidates (72%) showed 
signifi cantly high PWV in average of 1601 sec, and one showed signifi cantly 
low ABPI which consequently required the interventional treatment for the 
external iliac artery occlusion. One candidate showed ventricular tachycardia 
which needs ablation treatment. One candidate revealed thrombocytopenia 
which was due to liver cirrhosis by hepatitis C infection. Finally 3 candidates, 
which all had more than 10 years of dialysis history, were not acceptable for 
transplantation at the time of evaluations and 2 have been treated successfully. 
Among 18 candidates, 7 had more than 10 years dialysis history and 43% of these 
candidates had comorbidity which was not acceptable for transplantation.
Conclusions: Screening especially of cardiovascular and peripheral vascular 
disease is mandatory on the renal transplant candidate who is on waiting list 
for more than 10 years.
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VISFATIN, NEW ADIPOCYTOKINE IS PREDOMINANTLY 1061 
RELATED TO INFLAMMATION/ENDOTHELIAL DAMAGE IN 
KIDNEY ALLOGRAFT RECIPIENTS
J. Malyszko, J. Malyszko, E. Koc- Zorawska, M. Mysliwiec
Medical University, Department of Nephrology and Transplantation, 
Bialystok, Poland,
Visfatin, a ubiquitous adipokine, fi rstly described in 2005, was found to be 
selectively upregulated in the adipose tissue and have insulin-mimetic effects. It 
has been reported that visfatin is associated with endothelial damage in chronic 
kidney disease. We investigated plasma visfatin levels (using commercially 
available kits) in 100 clinically stable kidney allograft recipients.
We assessed visfatin markers of coagulation: TAT (thrombin-antithrombin 
complexes). prothrombin fragments 1+2; fi brinolysis: tPA (tissue plasminogen 
activator). PAI-1 (plasminogen activator inhibitor). PAP (plasmin-antiplasmin 
complexes); endothelial function/injury: vWF (von Willebrand factor). 
thrombomodulin, ICAM (intracellular adhesion molecule). VCAM (vascular 
cell adhesion molecule). infl ammation: hsCRP, TNFá and IL-6.
Visfatin is signifi cantly higher in kidney allograft recipients than in healthy 
volunteers. Visfatin did not differ signifi cantly between diabetic and non-diabetics, 
hypertensives and normotensives, patients with and without coronary artery 
disease and between males and females. Type of immunosuppressive regimen 
(CSA vs tacrolimus or MMF vs azathioprine) did not affect visfatin levels. In 
univariate analysis, visfatin correlated positively with prothrombin fragments 
1+2, VCAM, creatinine, hsCRP and negatively with albumin. In multivariate 
analysis, only VCAM was an associate of visfatin in kidney allograft recipients.
Visfatin related to markers of infl ammation may represent a novel link between 
infl ammation and adipocytokines in studied patients.
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IMPACT OF COLD ISCHEMIA TIME ON RENAL 1062 
ALLOGRAFT OUTCOME FROM YOUNG DONORS
D. Hernández1, S. Estupiñán2, G. Pérez Suárez3, M. Rufi no4, J.M. González-
Posada5, D. Luis6, P. Delgado7, D. Marrero8, A. Rodriguez9, A. Torres10
1Nephrology Section and Research Unit. Hospital Universitario De Canarias., 
2Nephrology Section. Hospital Universitario De Canarias., 3Nephrology 
Section.Hospital Universitario De Canarias., 4Nephrology Section.Hospital 
Universitario De Canarias., 5Nephrology Section and Research Unit .Hospital 
Universitario De Canarias., 6Nephrology Section. Hospital Universitario De 
Canarias., 7Research Unit. Hospital Universitario De Canarias., 8Nephrology 
Section. Hospital Universitario De Canarias., 9Nephrology Section.Hospital 
Universitario De Canarias., 10Nephrology Section and Research Unit. 
Hospital Universitario de CanariasHospital Universitario De Canarias.
Background: The chronic allograft loss, particularly those from deceased donors, 
continues to occur at an unacceptable high rate. Prolonged cold ischemia time (CIT) 
is associated with delayed graft function (DGF) and both conditions have been 
related to a poorer long term transplant outcome. However the effect of CIT on long-
term allograft survival in KT from younger donors has not been well established. 
Methods: We investigated the predictive value of CIT exposure on long-term 
death-censored graft loss in 829 KT recipients from younger donors (<50 yr) 
that were performed in our center between 1991 and 2005. According to our 
median CIT (19hr). we compared clinical data of patient with CIT exposure 
shorter or longer than 19 hr. Cox regression model was used to determine the 
relative impact of CIT on the transplant outcome. 
Results: Overall death-censored graft failure rate was signifi cantly higher in 
CIT>=19 hr group versus CIT<19 hr group (26 versus 16.5%; P=0.002). Signifi cant 
differences were also observed when patients with primary non-functioning graft 
were excluded (21 versus 14%; P=0.020) and in patients who received tacrolimus 
plus mycophenolate mofetil (12 versus 4%; P=0.05). By multivariate Cox 
analysis, CIT was independently associated with death-censored graft loss with 
a 20% increase for every 5 hr of CIT [relative risk (RR) 1.04; 95% Confi dence 
interval (CI): 1.01-1.1; P=0.021]. Likewise, graft loss risk signifi cantly increased 
in CIT>=19 hr group versus CIT<19h group (RR 1.5; 95%CI: 1.1-2.1; P=0.023).
Conclusion: Prolonged CIT is an independent predictor of graft survival in 
KT from younger donors. Efforts by minimizing CIT (<19hr) should improve 
signifi cantly transplant outcome in this population.
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DOES DONOR NEPHRON MASS HAVE ANY IMPACT ON 1063 
GRAFT SURVIVAL?
M. Taherimahmoudi, G. Pourmand, A. Mehrsai, M. Nikoobakht, 
H. Wahhabaghai
Urology Research Center,Tehran University of Medical Sciences,Tehran,Iran
Objectives: Functioning nephron mass (number of nephrons in grafted kidney) 
is one of the nonimmunologic factors that may have some impact on long- term 
graft survival.
The aim of this study was Impact of Donor Nephron mass on recipient graft 
outcome.
Methods: During 1989 – 2005, 1000 renal transplants was carried out at our 
center. 217 of them were studied and followed for an average of 8 years. All 
patients received grafts from living donors. Weight of grafted kidney (donor 
nephron mass) and also recipient BMI were measured at the time of operation 
in all cases. Nephron mass index (NMI) was defi ned as the ratio of donors’s 
nephron mass to recipient’s BMI. This ratio was calculated for all 217 cases.
Associations between variables was tested by logistic regression and pearson 
correlation .The analysis was performed with the SAS system and Splus 
statistical software.
To evaluate the graft function, serum creatinine, acute and chronic rejection 
episodes were determined.
Results: Mean NMI was 8.07 (±0.2) and mean creatinine level was 1.43 (±0.4) 
mg/dL. There were 32 cases (14.7%) of acute rejection, managed successfully 
with antithymocyte globulin (ATG) in 28 cases. Four patients lost their graft. 
There were fi ve cases of graft loss due to chronic rejection. Using Pearson 
correlation, we found no association between NMI and mean serum creatinine 
level. Logistic regression showed signifi cant relation between NMI and acute 
rejection (P < .05).with odds ratio of 2.0. There was no signifi cant correlation 
between NMI and chronic rejection.
Conclusion: The less NMI, The higher acute rejection.However, in long term, 
no signifi cant correlation between graft survival and NMI was found. Also, 
mean creatinine level was not signifi cantly different in patients regardless of 
their NMI was found.
POSTER BOARD NUMBER P1 – 150
PERIOPERATIVE MARKERS OF OXIDATIVE STRESS 1064 
CORRELATE WITH LONG TERM OUTCOME AFTER KIDNEY 
TRANSPLANTATION
J. Mayer1, S. Stracke2, F. Keller2, S. Kolodziej1
1Viseral- & Transplantation Surgery, 2Nephrology
The negative effect of oxidative stress on early kidney allograft function is well 
known. Little data exists on the correlation between perioperative oxidative 
stress and long term function in allograft kidney transplantation. We therefore 
analysed markers of oxidative stress measured at and shortly after reperfusion 
in allograft kidney recipients and correlated them with clinical long term 
follow-up data.
Clinical data from 39 kidney recipients were obtained at least 60 months after 
transplantation (mean follow-up 69.3 months). Of these, 13 had an impaired 
allograft kidney function (creatinine >200 μmol/l) and 26 a good allograft 
function (creatinine <200 μmol/l).
Some perioperative markers of oxidative stress were significantly 
different in patients with an impaired allograft function after 5 years: 
Thiobarbiturate reactive substances (TBARS). a marker of lipid 
oxidation, were higher in the systemic circulation at reperfusion and in 
the allograft vein five minutes after reperfusion. These patients also had 
more free thiols in their venous blood preoperatively and higher levels of 
4-Hydroxynonenal (4HNE). another product of lipid peroxidation, at 30 
minutes after reperfusion.
In patients with an impaired long term kidney allograft function, higher 
perioperative markers of oxidative stress both in the allograft vein and 
the systemic circulation can be found. The suggested association between 
increased perioperative oxidative stress and poorer long term function 
in kidney transplantation stresses the relevance of this perioperative 
phenomenon.
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NGAL (NEUTROPHIL GELATINASE-ASSOCIATED 1065 
LIPOCALIN) AND CYSTATIN C COULD PREDICT RENAL 
OUTCOME IN PATIENTS UNDERGOING KIDNEY 
ALLOGRAFT TRANSPLANTATION- A PROSPECTIVE STUDY
J. Malyszko1, U. Lebkowska2, E. Koc-Zorawska1, A. Lebkowska2, 
J. Malyszko1, W. Lebkowski3, M. Gacko4
1Medical University, Department of Nephrology and Transplantation, 
2Medical University, Department of Radiology, 3Medical University, 
Neurosurgical ICU, 4Medical University, Department of Vascular Surgery and 
Transplantation
Parikh et al. [Am J Transplant.2006] in a small group of kidney transplant 
recipients reported that urinary NGAL may represent early, predictive 
biomarker of delayed graft function, another model of ischemia-reperfusion 
injury. Unfortunately, creatinine is an unreliable indicator during acute 
changes in kidney function. Mishra et al. (Lancet 2005) highlighted value of 
NGAL (neutrophil gelatinase-associated lipocalin) as a novel marker for early 
detection of acute renal failure. Because of its small molecular size (25kDa) 
and resistance to degradation, NGAL is readily excreted and detected in urine 
as cystatin C. Therefore, the aim of the study was to assess whether NGAL and 
cystatin C could predict renal outcome in 35 consecutive patients undergoing 
kidney allograft transplantation in a single center.
Serum, NGAL (ANTIBODYSHOP, Gentofte, Denmark). cystatin C (Dade 
Behring, Germany) were evaluated before, and after 1, 3, 6, and 10 days after 
kidney transplantation using commercially available kits. Serum creatinine was 
assessed at the same time. ANOVA or Kruskall-Wallis ANOVA for repeated 
measurements were used in statistical analysis.
We found a signifi cant fall in serum NGAL, as early as after 1 day following 
kidney transplantation (409.9±104.4 ng/ml, vs 319.9±107.4 ng/ml, p<0.001, 
baseline vs day 1, 283.8±102.8 ng/ml, p<0.0001 vs day 3, 200.2±99.8 ng/mL, 
p<0.0001 vs day 6, 238.2±111.9 ng/ml vs day 10). Serum cystatin C decreased 
signifi cantly 3 days after transplantation, Before transplantation serum NGAL 
was related to creatinine (r=0.45,p<0.001). cystatin C (r=0.52,p<0.001). 
At each time point serum NGAL was related positively to serum creatinine, 
and negatively to urine volume. In 4 patients we observed a delayed graft 
function, in all these patients we did not observe a fall in serum NGAL and 
cystatin C (mean serum NGAL before transplantation 442.2 ±32.1 ng/ml, at 
day 10 421.5±73.1 ng/ml, NS). At any time serum NGAL and cystatin C were 
signifi cantly higher in patients with delayed graft function when compared to 
patients without delayed graft function.
Our fi ndings may have important implications for the clinical management of 
patients undergoing kidney transplantation. The “window of opportunity” is 
narrow in delayed graft function to distinguish between acute rejection and 
CNI nephrotoxicity and time is limited to introduce proper treatment after 
initiating insult. Therefore, NGAL needs to be investigated as a potential early 
marker for delayed graft function, especially in the upcoming setting of early 
dialysis treatment or antirejection therapy.
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HYPERURICEMIA IS A MEDIATOR OF ENDOTHELIAL 1066 
DYSFUNCTION AND INFLAMMATION IN RENAL 
ALLOGRAFT RECIPIENTS
M. Boratyñska, A. Karbowska, M. Kusztal, M. Klinger
Dept. af Nephrology and Transplantation Medicine, Wroclaw Medical 
University, Wroclaw, Poland
Hyperuricemia is common in renal transplant recipients treated with 
calcineurin inhibitors. Experimental studies suggest that uric acid induces 
glomerular hypertension, microvascular disease and renal interstitial 
fi brosis. Hyperuricemia is also an independent risk factor of cardiovascular 
complications. The mechanism by which uric acid injures renal allograft and 
cardiovascular system is still unclear.
The aim of this study was to assess the infl uence of serum uric acid level on 
biomarkers of endothelial dysfunction and infl ammation in renal allograft 
recipients.
Material and Methods: The study entailed 78 adult, renal transplant 
recipients (at age 19-70 years) with stable graft function (serum creatinine 
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level 0.7 – 1.4 mg/dl). The patients were transplanted between 2003 and 
2006. Exclusion criteria were abnormal renal function, proteinuria, diabetes 
mellitus, BMI above 30 and infl ammation. The immunosuppressive protocol 
consisted of CsA or tacrolimus and azathioprine or mycophenolate mofetil 
and prednisone. The patients were divided into 2 groups: group I- 48 patients 
with hyperuricemia (serum uric acid level 7.72±1.33 mg/dl) and group II 
– 30 patients with normal uric acid level 5.48±0.92 mg/dl (control group). 
Markers of endothelial function and infl ammation were assessed in both 
groups: plasma resistin level, CD146 (novel adhesion molecule) and soluble 
vascular cell adhesion molecule-1 (sVCAM-1). These markers were measured 
by enzyme immunoassay.
Results: No signifi cant differences existed in demographic data between groups 
of patients with and without hyperuricemia, such as age, gender, cause of renal 
failure, number of HLA mismatches, DGF and number of episodes of acute 
rejection per patient. Hypertension was observed in 85,4% of patients from 
hyperuricemia group and 82% without hyperuricemia. Hypercholesterolemia 
and hypertriglicerydemia were found in 45,8% of patients with hyperuricemia 
and 56,6% with normal uric acid level.
The examined biomarkers were elevated in the group of patients with 
hyperuricemia. Plasma resistin level was higher in hyperuricemic patients 
than in control group (7.15±2.42 ng/ml vs 6.29±2.76 ng/ml). and tended to 
be higher in women (7.83 ng/ml) than in men (6.58 ng/ml). Also sVCAM-1 
was signifi cantly higher in hyperuricemic patients (1126±371 ng/ml) when 
compared to patients with normal uric acid level (955±269 ng/ml) P<0.03. 
Resistin level correlated signifi cantly with sVCAM-1 (P<0.01). CD146 was 
elevated in patients with hyperuricemia (389.7±150 ug/ml). In control group 
CD146 was 330±117 ug/ml.
Conclusions: Hyperuricemia mediates endothelial dysfunction and 
infl ammation and by this pathway may contribute to chronic allograft injury 
and cardiovascular events in renal allograft recipients.
POSTER BOARD NUMBER P1 – 153
RISK FACTORS FOR LONG-TERM GRAFT LOSS IN 1067 
KIDNEY TRANSPLANTATION: EXPERIENCE OF A MEXICAN 
SINGLE-CENTER.
B. Aguilar1, R. Bernal, R. Mondragon
1Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico 
ISSEMyM
Background: There is not enough information regarding risk factors for renal 
graft loss in Mexico and Latin America. 
Aim: The purpose of this study was to analyze risk factors associated with graft 
loss in our renal transplant program. 
Pathients And Methods: Clinical records of 176 patients with renal 
transplantation performed between August of 1982 to October of 2007 in 
Centro Medico ISSEMyM were reviewed. Clinical and laboratory variables 
were recorded, as well as the fi nal patient and renal function status. Survival 
rates were analyzed by Kaplan-Meier method; mortality risk by multivariate 
Cox’s proportional hazard model. 
Results: After ten years of follow-up, 156 patients were alive and 20 were 
dead and all had functioning graft at the time of their dead. Patient survival 
rates at 1, 5 and 10 years were 94%, 91%, and 89% respectively while the 
graft survival rate at 1, 5 and 10 years were 96%, 97% and 99% respectively. 
Twelve subjects lost their graft, 5 due to chronic graft nephropathy, 3 due 
to infectious complications, 2 due to acute vascular rejection, and two due 
to vascular thrombosis. Twenty subjects died with a functioning graft, 
9 due to infections, fi ve due cardiovascular complications, four due to 
metabolic complications and two due to cancer. In the univariate analysis, 
the following were signifi cantly associated (p < 0.05) with graft loss: 
delayed graft function, acute rejection episodes, vascular and infectious 
complications. In the multivariate analysis, only acute rejection predicted 
graft loss. 
Conclusions: Some factors are related to graft lost like type of donation, HLA- 
haplotipe, delayed graft function, And the main cause of graft failure was acute 
rejection. The mortality risk to the transplant patients was related to infectious 
complications.
POSTER BOARD NUMBER P1 – 154
CHARACTERISTICS OF KIDNEY ALLOGRAFT 1068 
SURVIVORS WITH MORE THAN 10 YEARS FOLLOW-UP
A. El Agroudy, S. Al Arrayed, A. Al Arrayed, S.Ghareeb, E. Fareed
Salmaniya Medical Complex
Background/Aim: To study the characteristics and the predictors of survival 
in Bahrani renal transplant recipients with an allograft that functioned for more 
than 10 yr.
Methods: Sixty three patients underwent renal transplantation between 1979 
and 1997. Of these, 37 had functioning allografts for more than 10 yr (range, 
10–28). Characteristics of the patients, data on graft survival, and determinants 
of outcome were obtained by reviewing all medical records.
Results: The mean age at time of transplantation was 30.7±14 years. The 
donor source was 25 related and the mean age was 30.4±7 years. Thirty 
three patients received their fi rst graft. Thirty three were cyclosporine (CsA) 
treated while 4 patients were primarily immunosuppressed by steroids and 
azathioprine and 21 patients received induction therapy. Acute rejection 
episodes occurred in 7 patients (58%). out of them 2 experienced two 
acute rejection episodes. At most recent follow-up (March 2008). the mean 
serum creatinine was 137±34 mmol/l. A history of cancer was noted in one 
patient whereas; hypertension was (54%) and diabetes mellitus in 20.5%. 
We compared the surviving group with the non surviving group at the 
same time of transplantation and found that the independent determinants 
of long-term graft survival were incidence of acute rejection episodes and 
histopathological fi ndings of CAN.
Conclusions: We concluded that renal transplantation even in its earliest years 
and despite the numerous complications have provided 10 or more years of 
near normal life to patients with end stage renal disease. Patients on CsA-based 
immunosuppression clearly didn’t show any signifi cant benefi t on long-term 
graft survival than patients on azathioprine and steroids.
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IMPACT OF SLOW GRAFT FUNCTION ON RENAL 1069 
ALLOGRAFT OUTCOME AND FUNCTION.
R. Bernal1, R. Mondragon, B. Aguilar
1Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico 
ISSEMyM
Introduction: Kidney transplant patients can be divided into three groups, 
according to the initial graft function. Slow graft function (SGF) or immediate 
graft function (IGF) according to whether the day 5 serum creatinine was 
higher versus lower than 3 mg/dL, respectively. 
Aim: The purpose of this study is to analyze the impact of graft function on the 
fi rst days after the transplant and their impact in the long term renal outcome. 
Results: SGF patients showed worse graft survival, above higher incidence 
of acute rejection and lower renal function than IGF patients, although few 
reports have analyzed outcomes in these groups. We analyzed the impact 
of SGF on graft survival, fi rst-year renal function, and incidence of acute 
rejection in 176 renal transplant patients. Creatinine was signifi cantly worse 
at 12 months for SGF than for IGF patients (1.9 +/- 0.8 mg/dL, 1.5 +/- 0.5 
mg/dL, respectively; P < .05). The acute rejection rate was higher among the 
SGF than the IGF group (P < .05). Graft survival was better among IGF than 
SGF patients. 
Conclusions: Kidney transplant recipients who develop SGF have a worse 
outcome than patients with IGF, similar to DGF patients. SGF patients show 
worse graft survival, worse renal function, and higher acute rejection rates than 
IGF patients, despite not needing dialysis
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SERUM NEUTROPHIL GELATINASE-ASSOCIATED 1070 
LIPOCALIN AS A MARKER OF EARLY FUNCTION OF RENAL 
TRANSPLANTS
L. Kyllönen1, M. Hollmén1, J. Merenmies2, K. Salmela1
1Kidney Transplant Unit, Helsinki University Hospital, 2Tissue Typing 
Laboratory, Finnish Red Cross
NGAL (neutrophil gelatinase-associated lipocalin) is proposed to be a 
marker of acute renal tubular injury. We wanted to test that hypothesis 
in serum samples of our kidney transplant recipients. Sixty consecutive 
adult, dialysis dependent patients undergoing deceased donor kidney 
transplantation (TX) were prospectively enrolled between September 2007 
and January 2008. Serum samples were drawn pre TX and 1, 3 and 7 days 
post TX. S-NGAL ELISA was performed with a commercial kit and as 
recommended by the manufacturer.
Twenty-three (38.3%) patients had delayed graft function (DGF). The pre-
TX s-NGAL concentrations did not signifi cantly differ in patients who 
developed DGF (594 ng/ml) compared to those with early function (EF) 
(561 ng/ml). S-NGAL concentrations at day 1 post-TX were signifi cantly 
higher among patients with DGF (mean 466 ng/ml, range 253 to 651 ng/
ml) compared to those with EF (mean 325 ng/ml, range 81 to 638 ng/ml). 
p=0.00057. The signifi cant difference persisted in samples drawn at 3 and 
7 days post TX.
The mean change of s-NGAL from pre-TX to day 1 (Δ-NGAL) was –236 in 
EF and –129 ng/ml in DGF patients (p=0.0017). As the day 1 samples were 
drawn on the fi rst morning after TX, samples were taken from 2 to 20 hours 
after TX. The Δ-NGAL in samples taken <12 hours after TX was signifi cantly 
larger in EF (-232 ng/ml) than in DGF patients (-91 ng/ml) (p=0.008). whereas 
in samples taken >12 hrs after TX it was -241 ng/ml in EF and -176 ng/ml in 
DGF patients (N.S).
In conclusion, high serum NGAL concentrations early after TX are associated 
with renal dysfunction and NGAL determination provides a novel predictor 
of DGF.
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THE IMPACT OF DELAYED GRAFT FUNCTION ON 1071 
ACTUAL GRAFT SURVIVAL IS EQUALLY BAD IN DECEASED 
DONOR KIDNEY TRANSPLANTS FROM EXPANDED 
CRITERIA DONORS AND STANDARD CRITERIA DONORS.
J. Tchervenkov1, M. Cantarovich2, P. Metrakos1, S. Paraskevas1, D. Baran2, 
M. Fernandez1, P. Chaudary1
1Department of Surgery,McGill University,Montreal,Canada, 2Department of 
Medicine, McGill University, Montreal, Canada
Introduction: Renal Transplant waiting lists continue to grow. The use of 
expanded criteria donors (ECD) will increase the donor pool, but their use 
is still limited because of poorer graft survival compared to standard criteria 
donors (SCD). We assessed the impact of immediate renal function on renal 
graft survival in recipients of SCD and ECD.
Methods: All Cadaveric renal transplants (n=335) performed at our center 
between 1990 and 2002 were included. Immunosuppression included induction 
with Thymoglobulin (83%). Mycophenolate Mofetil (51%). Azathioprin (47%). 
Tacrolimus (55%). or Cyclosporine Neoral (45%) and Methylprednisolone. 
ECD was defi ned according to UNOS criteria. All other donors were considered 
as SCD. Delayed graft function (DGF) was defi ned as anyone who required a 
form of dialysis immediately after the kidney transplant. Slow graft function 
(SGF) was defi ned as a functioning kidney with the serum creatinine drop of 
<20% in the fi rst 24hrs after the transplant. Imediate graft function (IGF) was 
defi ned as a functioning kidney with a serum creatinine drop >20% in the fi rst 
24hrs after the transplant. Data for graft survival is Non-Death Censored Actual 
Graft Survival.
Results: Seventy two of the 335 pts (21.5%) were ECD. IGF was present in 
54.7% of pts vs SGF 16.2% and DGF 29.1%. In SCD, the SGF and DGF rates 
were 15.3% and 23.4% respectively. In ECD, the SGF and DGF rates were 19.4 
and 50% (p<0.02). Actual graft survivals at 1 and 5yrs was 86.3% and 70.4% 
respectively and although ECD pts had a slightly lower 5year graft survival 
(72.6% vs 62.5%) this was not signifi cant (p=0.13). Pts with IGF had a much 
better actual graft survival at 5yrs compared to SGF and DGF (83.5%vs74.1% 
vs 45.4%). DGF had an equally bad impact on actual 5yr graft survival in SCD 
and ECD (42.6%vs 50%). Donor age or cold ischemia time had no effect on 
5year actual graft survival in SCD or ECD except for cold ischemia >18hrs in 
ECD recipients.
Conclusion: DGF has a strong detrimental impact on 5year graft survival. 
There is a higher rate of DGF in ECD vs SCD kidneys. The detrimental impact 
on 5year actual graft survival is equal in SCD and ECD kidneys. Minimizing 
DGF should be our goal in deceased donor kidney recipients.
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RECOVERY OF GRAFT FUNCTION EARLY POST 1072 
TRANSPLANT DETERMINES LONG-TERM GRAFT SURVIVAL 
IN DECEASED DONOR (DD) RENAL TRANSPLANTS.
J. Tchervenkov1, M. Cantarovich2, S. Paraskevas1, P. Metrakos1, D. Baran2, 
M. Hussanaian1, M. Fernandez1
1Department of Surgery, McGill University, Montreal, Canada, 2Deapartment 
of Medicine, McGill University, Montreal, Canad
Introduction: Kidneys show remarkable resilience and can recover function 
even after prolonged periods of delayed graft function. We looked at the 
impact of both early graft function and the rate of renal function recovery in 
the fi rst 3 months after transplantation, on long term graft survival in DD renal 
transplants.
Methods: All Cadaveric renal transplants (n=583) performed at our center 
between 1990 and 2007 were included. Immunosuppression included 
induction with Thymoglobulin, Mycophenolate Mofetil or Azathioprin, 
Tacrolimus or Cyclosporine and Methylprednisolone. ECD was defi ned 
according to UNOS criteria. All other donors were considered as SCD. 
Delayed graft function (DGF) was defi ned as anyone who required a form of 
dialysis immediately after transplant. Slow graft function (SGF) was defi ned 
as a functioning kidney with the serum creatinine drop of <20% in the fi rst 
24hrs after the transplant. Immediate graft function (IGF) was defi ned as a 
functioning kidney with a serum creatinine drop >20% in the fi rst 24hrs after 
the transplant. Recovery of renal function (RFR) was expressed as either 
the best creatinine clearance in the fi rst 3months post-renal transplantation 
(BCrCl-3mos) as calculated using the Caulcroft-Gault formula or as a 
percentage of actual versus expected (as calculated from the donors’ CrCl 
at procurement). Data for graft survival is Non-Death Censored Graft 
Survival.
Results: 140 pts (23.6%) were ECD. IGF was present in 50.3%, SGF in 
19.8% and DGF 29.1%. Overall graft survival at 1 and 5yrs was 87.8% and 
74% respectively. Pts with IGF had a 5yr graft survival of 85%, whereas 
pts with SGF and DGF had a survival of 76% and 54% respectively 
(p<0.02). There was no difference in our cohort on the impact of early 
graft function and 5yr graft survival between ECD and SCD kidneys. The 
only difference is that ECD kidneys had twice the DGF rate (49 vs 23% 
p<0.001). RFR also had an impact on 5yr graft survival and projected half-
life. BCrCl -3mos of <30ml/min had a 1 and 5yr graft survival of 47 and 
34%; BCrCl-3mos of 30-39ml/min had a 1 and 5yr survival of 92 and 72%; 
BCrCl-3mos of 40-49 ml/min had a 1 and 5yr survival of 98 and 85%; 
BCrCl-3mos of >50 ml/min had a 1 and 5yr survival of 96 and 82% and the 
half-lives were 10mos, 9.5yrs, 13.5yrs and 13yrs respectively (p<0.0001). 
Similarly a recovery within 90% of expected CrCl in the first 3mos post-
transplant was associated with a graft survival at 1 and 5yrs of 94 and 81%; 
a recovery of 70-90% was associated with a survival at 1 and 5yrs of 91 
and 65%; a recovery of <70% was associated with a survival at 1 and 5yrs 
of 63 and 51%. The half-lives were 12.5 vs 10.5 vs 5.5 yrs respectively 
(p<0.0001).
Conclusion: Early Graft function in the fi rst 3mos has a signifi cant impact on 
long term graft survival after DD renal transplantation.
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A MODIFIED QUANTITATIVE SUBJECTIVE GLOBAL 1073 
ASSESSMENT OF NUTRITION FOR PATIENTS ON THE RENAL 
TRANSPLANT WAITING LIST
A. Demýrag, G. Kantarci, M. Kalayci, B. Ekcý, T. Gulcelýk, O. Gokce
Yeditepe Univ Hospital
Subjective Global Assessment (SGA) is widely used and validated method for 
identifying and classifying malnutrition. It has been thought that this semi-
quantitative feature restricts the SGA’s reliability and precision. Recently, 
in effort to asses nutritional status a modifi ed quantitative subjective global 
assessment systems have been devised in which scores are assigned for items 
or components of the SGA. This prospective study evaluated both conventional 
and quantitative SGA systems.
Method: Using the components of the conventional SGA, we operated a fully 
quantitative scoring system consisting of seven variables: weight changes, 
dietary intake, gastrointestinal symptoms, functional capacity, comorbidity, 
subcutaneous fat, and sign of muscle wasting. Each component was assigned a 
score from 1 (normal) to 5 (very severe). The sum of all seven components in this 
malnutrition score lies between 7 (normal) and 35 (severely malnourished). To 
evaluate nutritional status patients on renal transplantation waiting list, mid-arm 
circumference (MAC). body mass index (BMI) and laboratory parameters were 
used. Twenty-seven patients (9 women and 18 men) were randomly selected 
from the waiting list. Patient’s age were between 16 and 62 years (43,1±11,6) 
and on hemodialysis for between 1 month and 196 months (55,9±44,9).
Results: Correlation coeffi cients between the malnutrition score and duration 
of hemodialysis (r=+0.72). sex (r=+0.44). total iron binding capacity (r= -0,44) 
were signifi cant, whereas the conventional SGA had signifi cant correlation 
only with duration of hemodialysis (r=+0.42).
Multiple regression analysis showed a signifi cant correlation between 
malnutrition score and the combination of duration of hemodialysis, sex, total 
iron binding capacity (r=0.77, p<0.001).
Conclusion: The quantitative SGA scoring system may be better than the 
conventional SGA to evaluate patients on the waiting list. More comparative 
studies are required to confi rm the validity of this scoring system in nutritional 
evaluation of renal transplant candidates.
POSTER BOARD NUMBER P1 – 160
CLINICAL RELEVANCE OF PRE-TRANSPLANT 1074 
ADIPONECTIN LEVELS FOR PREDICTION OF NEW-ONSET 
DIABETES AFTER TRANSPLANTATION
A. Kazory, C. Courivaud, S. Mercier, S. Kury-Paulin, E. Toussirot, 
G. Zanetta, A. Penfornis, J-M. Chalopin, G. Dumoulin, D. Ducloux
University of Franche-Comte
Background: Adiponectin is an adipose-specifi c protein with insulin-
sensitizing and anti-atherogenic properties. It is not known if pre-transplant 
plasma adiponectin levels can be used to predict new onset diabetes after 
transplantation (NODAT).
Methods: We performed a case-control study to evaluate the potential role of 
adiponectin as a risk factor for NODAT independent of obesity, and then to 
fi nd a threshold for identifi cation of high-risk patients. Forty nine patients with 
NODAT were compared to 49 transplant patients (controls). matched for age, 
gender, body mass index at the time of transplant, and the calcineurin inhibitor 
agent used for immunosuppression. Adiponectin levels were also measured in 
thirty fi ve healthy subjects with normal renal function.
Results: Adiponectin levels were signifi cantly higher in pre-transplant 
patients compared with healthy subjects (13.9 +/- 5.8 μg/ml vs. 9.5 +/- 4.2 
μg/ml; p<0.0001). In multivariate analysis, higher plasma adiponectin level 
was protective against NODAT (incidence rate ratio 0.86 [95% CI 0.78-0.95], 
p=0.002). All patients with adiponectin levels ≤; 7 μg/ml (8.2%) developed 
NODAT. This corresponds to a positive predictive value of 100%. None of 
the patients with adiponectin values ≥; 22 μg/ml (7.1%) developed NODAT. 
For a threshold of 10 μg/ml (27.6%). more than one third of patients 
developed NODAT; the adjusted incidence ratio was 4.29 [95% CI 1.62-11.47] 
(p=0.004).
Conclusion: Low pre-transplant plasma adiponectin levels are associated with 
a higher risk for subsequent development of NODAT. These results suggest that 
a threshold of 10 μg/ml can identify high-risk patients for whom preventive 
interventions might be employed.
POSTER BOARD NUMBER P1 – 161
C-REACTIVE PROTEIN AS A PREDICTOR OF 1075 
PROGNOSIS FOLLOWING RENAL TRANSPLANTATION FOR 
DIABETIC END STAGE RENAL DISEASE
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy3
1Cairo University, Division of Nephrology, Department of Medicine, 2Cairo 
University, Department of Urology, 3Cairo University, Department of Clinical 
Pathology
Aim of Study: To analyze the impact of an elevated C-reactive protein (CRP) 
on outcome following renal transplantation for diabetic ESRD.
Method: Retrospective analysis of a prospectively gathered dataset. 70 patients 
with CRP measurements taken immediately prior to the surgery
were included in this study. Patients were followed up at the outpatient clinics 
withregular blood tests, including blood sugar, kidney function tests, serum 
cholesterol,tumor markers carcinoembryonic antigen (CEA).and liver function 
tests.In addition, regular chest abdominal sonography and echocardiography 
were performed. Patients were followed up a minimum period of 1 year post 
renal transplantation at the time of study (range 1.5 years.The data examined 
included patient demographics;number of rejetions; preoperative CRP; post-
operativemorbidity/mortality
Results: A CRP value above 10 mg/l was taken as elevated.
Results: Pre-operative CRP was elevated (!10 mg/l) in 54 (77%) patients. 
The number of ischemic cardiac episodes in patients with an elevated CRP 
was 19months (95% CI 7.5 !31.2 months) compared to 42.8 months (95% CI 
33.2 !52.5 months) for those with a normal CRP, p#0.0044.The results of a 
multivariable analysis of the predictors of survival showed that an elevated 
CRP (p#0.032) as well as uncontrolled diabetes, elevated LDL cholesterol 
predicted for poorer overall survival.
Conclusions: This study showed that an elevated CRP level,measured before 
surgery, is present in a signifi cant proportion of patients with diabetic end stage 
renal patients. This is found to predict for a poor survival outcome in patients 
who had kidney transplantation performed. The infl ammatory response, as 
refl ected by CRP, is the only factor that can be modulated pre-operatively in 
these patients and this may lead to the use of novel therapies among this group 
of patients in the future.
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POST-TRANSPLANT DIABETES MELLITUS: A SINGLE 1076 
CENTER EXPERIENCE
A. Ghafari1, V. Modaess
1Urmia University of Medical Sciences, 2Urmia University of Medical 
Sciences
Introduction: Post-transplant diabetes mellitus (PTDM) has been increasingly 
recognized as an important post-transplantation complication and a signifi cant 
contributor to inferior recipient outcomes. In this study, we assessed the 
incidence of PTDM and the factors that are associated with the development 
of this complication.
Patients and Methods: All adult patients (n = 1350) who were regularly followed 
at a single kidney transplant outpatient clinic were included in a cross-sectional 
study between April 2005 and February 2006. Among them 644 (47.7%) pts 
had no history of DM prior to transplantation and enrolled in to study. Data was 
extracted from the patient’s charts at the hospital. Demographic information 
and details of medical history were collected at enrollment when information 
about age, gender, etiology of end stage renal disease (ESRD) and presence of 
DM in fi rst-degree relatives were obtained. Among pts 97% received their graft 
from living donors. The immunosuppressive protocols included cyclosporine 
A, azathioprine or Mycophenolate mofetil and prednisolone.
Statistical Analysis: Statistical analysis was carried out using the SPSS 10.0 
software. Continuous variables were compared using Student’s t-test and 
categorical variables were analyzed with the chi-squared test or the Fisher 
exact test, as appropriate.
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Results: Among 644 non DM patients enrolled to the study 350 (54.35%) were 
male. Mean age was 41.34 ± 13.8 year (range 12-82). PTDM developed in 66 
patients (10.2%). among PTDM patients 36 were female and 40 were male (P = 
0.172). Patients divided in three groups according to age: age< 40 year, 40<60 
and age > 60. Prevalence of PTDM were 3.8%, 15.6% and 20.3% among 
different age groups respectively (P< 0001). PTDM developed in 8.3% of 
patients with and in 10.3% without past history of CMV infection (P = 0.825). 
PTDM developed in 10.2% of patients receiving fi rst transplant versus 10.2% 
receiving second or more transplant (P = 0.957). Among all patients 85 had 
history of DM in fi rst degree relatives, PTDM developed in 17 (20%) 0f them 
versus 8.8% in patients without history of DM in fi rst degree relatives (0.003). 
Patients divided in to three groups according to pretransplant dialysis duration: 
preemptive (16 ). one to 23 months (444). and more than 24 months (184). 
PTDM occurred in 25%, 9.9% and 9.8% respectively (P = 0.143).
Conclusions: the older age at the time of transplantation and family history of 
DM were the main predictors for developing PTDM.
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VIABLE YIELD OF ISLETS FROM ISCHEMIC PORCINE 1077 
PANCREATA IS IMPROVED USING TWENTY-FOUR HOUR 
HYPOTHERMIC MACHINE PERFUSION PRESERVATION .
M.J. Taylor1,3, S. Baicu1, E. Greene1, A. Vazquez1, J. Brassil2.
1Cell and Tissue Systems, N. Charleston, SC, USA, 2Organ Recovery Systems, 
Des Plaines, IL, USA. 3Dept. Surgery, Medical University of South Carolina, 
Charleston, SC. USA.
Objectives: Pancreas (Px) procurement for islet isolation and transplantation 
(Tx) is hindered due to concerns for the detrimental effects of post-mortem 
ischemia. Perfusion/preservation technology has recently been reported to 
improve the recovery of islets after 24h hypothermic machine perfusion 
(HMP) of porcine Px prior to islet isolation [1]. This technology is now 
applied to pig Px subject to a warm ischemia time (WIT) prior to HMP and 
islet isolation.
Methods: Pancreata in anesthetized Domestic Yorkshire pigs (25-30 kg) were 
surgically removed and the superior mesenteric artery and celiac trunk were 
cannulated using a proprietary seal-ring cannula.The splenic vessels and other 
arterial branches were ligated to allow uniform perfusion through the gland ex 
vivo. Px were assigned to one of four preservation treatment groups: Controls 
– processed immediately with minimum cold ischemia (<1h) [G1, n=7]. Static 
Cold Storage-fl ushed with cold UW-Viaspan and stored at 2-4ºC for 24h with 
no prior WIT [G2, n=9], Hypothermic Machine Perfusion (HMP) -perfused on 
a LifePort® machine with KPS1 solution at 2-6ºC and low pressure (10mmHg) 
for 24h either immediately after procurement (no WIT) [G3, n=7], or after 
30 min WIT in situ [G4, n=7]. Islet isolation was then accomplished by 
ductal distension of the gland with liberase enzyme, normothermic digestion 
and density gradient purifi cation. Standard, accepted product release criteria 
were used including islet quantifi cation and islet function using the glucose 
stimulated insulin secretion assay.
Results: The measured degree of glandular edema was 0%; -2.79±0.71%; 
138±18.6% and 127±21.5% for the groups respectively. Islet yield normalized 
by the weight of digested pancreas was markedly different between the 
treatment groups: G1=1673.6±697.8 IEQ/g; G2=1239.1±290.4 IEQ/g; 
G3=3113±555 IEQ/g and G4=1840.6±317.3IEQ/g. The increased yield in the 
HMP group G3 over the static cold storage in UW-Viaspan was statistically 
signifi cant (p<0.05). Functionally, the islets from each experimental group 
were equivalent and not signifi cantly different to controls (G1) with insulin 
stimulation indices of G1=4.6±1.3; G2=2.5±0.4; G3=2.8±0.4 and G4=4.2±0.4. 
However, insulin content (ng/ml/IEQ) was different between the treatment 
groups with the highest insulin content in islets harvested from HMP Px (G3) 
=11.8±3.8 compared with G1=8.5±3.7,G2=4.8±1.0 and G4=6.6±1.1. Dithizone 
staining for islets showed a consistently more uniform digestion of the Px from 
G3 and G4 compared with G1 and G2, with greater separation of the tissue and 
less entrapped islets.
Conclusion: HMP for 24h is well tolerated leading to moderate edema but no 
loss of function of the harvested islets. The edema appears to aid in enzymatic 
digestion producing a greater yield and purity of islets compared with Px 
subjected to 24h of static cold storage. The salutary effects of HMP are also 
manifest after prior warm ischemia of the donor Px.
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INCIDENCE OF THE METABOLIC SYNDROME IN 1078 
KIDNEY TRANSPLANTATION
H. Kishikawa, N. Arichi, Y. Namba, K. Nishimura, Y. Ichikawa
Department of Urology, Hyogo Prefectural Nishinomiya Hospital, Hyogo, 
Japan
Objectives: Metabolic syndrome (MS) was recently reported to be a risk factor 
for cerebrovascular disease (CVD). which is one of the leading causes of death 
following kidney transplantation. However, little is known about the incidence 
and impact of this syndrome in those patients. We investigated the prevalence of 
MS in kidney transplantation patients and assessed its development following 
that procedure by determining plasma Adiponectin levels and results of an oral 
glucose tolerance test (OGTT).
Methods: We conducted a cross-sectional study of 94 patients with stable 
graft function who underwent kidney transplantation between January 1999 
and October 2008. Those with diabetes at the time of transplantation were 
excluded. The presence of MS was determined using National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III) criteria with 
body mass index used in place of waist circumstance. In addition, plasma 
Adiponectine level was measured and a 75g oral glucose tolerance test (OGTT) 
performed. A homeostatic model assessment of insulin resistance (HOMA-R) 
was calculated using the following formula: fasting BG x fasting SI/405. In 
addition, insulinogenic index (I-Index) was calculated as ¦¤SI (30’-0’) /¦¤BG 
(30’-0’).
Results: A total of 14 (14.9%) out of 94 patients suffered from MS at a mean 
time of 46.7 months (range 1-106) after the transplantation. The rates of 
incidence of obesity (BMI > 25). triglycerides (TG) ¡Ý 150mg/dL, high-density 
lipoprotein (HDL) < 40mg/dL in men or <50 mg/dL in women, systolic blood 
pressure (SBP) ¡Ý 130mmHg or diastolic blood pressure (DBP) ¡Ý 90mmHg, 
and fasting glucose (FBG) > 100mg/dL were 8.5%, 78.7%, 33.0%, 7.4%, and 
22.3%, respectively. Age at transplantation, gender, end-stage renal disease 
(ESRD) duration, HLA mismatch, and immunosuppressive regimen were not 
signifi cantly different between the MS and non-MS group, whereas BMI at 
the time of transplantation was signifi cantly greater in the MS group (23.4+/- 
3.24 vs. 20.1 +/-2.50, p< 0.0001). In addition, the nadir creatinine (Cr) level, 
and Cr at 1 year after transplantation, and Cr at the fi nal observation were not 
signifi cantly different between the groups, while plasma Adiponectin level was 
signifi cantly lower in the MS group (11.95+/-5.13 vs. 17.71+/-8.47, p=0.0158). 
Furthermore, the I-index values was similar, whereas HOMA-R was greater in 
the MS group (2.598 +/- 1.918 vs. 1.340 +/- 0.934, p= 0.0002).
Conclusions: In this cross-sectional study, 14.9% of the subjects suffered from 
MS following kidney transplantation. The level of Adiponectin was lower in 
those with MS and found to be negatively correlated with insulin sensitivity in 
kidney transplant recipients. We concluded that a low Adiponectin level may 
correlates with the prevalence of MS in kidney transplantation in association 
with impaired insulin sensitivity.
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RELATIONSHIP BETWEEN SERUM PARAOXONASE 1079 
ACTIVITY AND ADIPOKINES LEVELS IN RENAL 
TRANSPLANTED PATIENTS
L. Locsey1, I. Seres2, F. Sztanek2, L. Szabo3, L. Asztalos3, D.G. Paragh2
1B.Braun Avitum 10. AKD , 2I.Dept.Med. DEOEC ,Univ Debrecen, 3I.Surg.
Dept. DEOEC ,Univ.Debrecen
Increased oxidative stress and infl ammation are associated with atheroscle rotic 
coronary disease in renal transplanted pts.HDL-associated paraoxonase
 (PON1) prevents LDL-C from oxidation providing protection against athero 
– sclerotic and coronary artery disease.Previous studies shown that serum 
leptin,adiponectin concentrations are elevated in pts with chronic kidney 
disease. 
Aim: our aim was to investigate the connection between serum para 
-oxonase activity ,renal function ,adiponectin and leptin levels in renal 
transplanted pts.79 transplanted pts (38 males,41 females,age: 49,01 +/-14,00 
ys) were included in the study.We examined in fasting serum creatini -ne 
cystatin C,homocysteine,CRP,glucose and lipids.Serum PON1 activity 
was determined spectrophotometrically.Serum adiponectin and lipid levels 
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were measured by ELISA method.Our pts had hypercholesterolaemia,high 
LDL and ApoB levels and paralel with improved renal function decreased 
cystatin C and homocysteine levels (p<0.001).We devided our pts into two 
group accor -ding to BMI.In obes pts (BMI>30kgm2 n=14) was siginifi cantly 
higher LDL (p<0.05) and leptin concentrations (58.06 vs.15.16 ng/ml,p<0.01) 
than in malnourished pts (n=9).We not found signifi cant difference between 
serum adiponectin levels (15,12 vs.17,34 ug/ml) and PON1 activity (91,45 
vs. 101.20U/L) in obese and malnourished renal transplanted pts.Between 
serum leptin concentrations and PON1 activity was not signifi cant negative 
corre lation.After transplantation was signifi cant negative correlation 
between serum PON1 activity and improved renal function (p < 0.01 ).In 
dyslipidaemic ,obes transplanted pts have high LDL,leptin concentrations 
and paraoxonase activity not signifi cant correlation between leptin ,adipo 
nectin and CRP levels.With improved renal function signifi cant increased 
serum PON1 activity.
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NEW ONSET DIABETES (NODAT) AFTER KIDNEY 1080 
TRANSPLANTATION IN AUTOSOMAL DOMINANT 
POLYCYSTIC KIDNEY DISEASE (ADPKD).
R. Irene, R. Walker, C. Shlomo, M. Rosemary
Department of Nephrology, Royal Melbourne Hospital
Introduction and Aims: NODAT is an important complication of solid 
organ transplantation Recognised risk factors in kidney transplants include 
increased age, obesity, family history of diabetes, high dose steroid, CMV, 
Hepatitis C and tacrolimus based immunosuppressive regimens. Several 
recent publications have reported ADPKD as a risk factor for NODAT. We 
examined the incidence of NODAT and impaired glucose tolerance (IGT) 
in patients with ADPKD compared with a matched control group in our 
transplant population.
Methods: A single center case controlled retrospective study examined the 
incidence of NODAT and IGT in 65 renal allograft recipients with ADPKD 
compared to those without ADPKD transplanted in the period January 2000 
and October 2007. NODAT defi nition: (WHO defi nition) random blood 
glucose (RBG) estimations ≥ 11.1 mmol/L on two separate days > six weeks 
post transplantation. IGT defi nition: RBG ≥ 7 mmol/L and < 11.1 mmol/L on 
two separate days > six weeks post transplantation and/or post intravenous 
methylprednisolone. Patients on oral hypoglycaemic medication or insulin 
were classifi ed as NODAT, regardless of blood glucose. Graft losses and 
deaths (n=2) within 3 months of transplantation were excluded. Intergroup 
comparisons were analysed with a paired student’s t-test. The Control group 
(n=63) were matched for gender and year of transplantation. Known diabetics 
pre-transplantation were not included.
Results: (Mean values +/-SD) 
Control n ADPKD n p value
Age (years) 50.2 +/- 8.5 63 52.1 +/- 8.1 63 n.s
Male: Female 35: 28 63 35: 28 63 n.s
Follow-up (months) 92.5 +/-73.2 63 85.8 +/- 74.8 63 ns
Weight at Tx (kg) 69.8 +/-13.6 63 77.0 _/- 14.9 63 p =.005
Height (cm) 166.8 +/- 11.2 63 172.2 +/- 9.2 63 p <.005
BMI (kg/m2) 25.0 +/- 3.7 63 25.9 +/- 3.9 63 n.s
Weight 1yr post Tx (kg) 73.0 +/- 15.7 48 79.0 +/- 13.2 45 p <.05
ΔWeight 1 year (kg) 4.9 +/- 7.7 48 4.1 +/- 8.4 45 n.s.
There were no differences between groups in the incidence NODAT: IGT. 
For ADPKD the numbers were 9: 8 (Total=17) and for Controls 8: 11 (Total 
=19) respectively. Only 2 ADPKD patients and 1 control group patient were 
on insulin. There were no differences in ethnicity, Δ weight over 1 year post 
transplant, immunosuppression regimen (prednisolone dosages and Tacrolimus 
levels). There was no difference in number of acute rejection episodes requiring 
intravenous methylprednisolone, either for the whole groups or those who 
developed either NODAT or IGT.
Conclusions: This study in a cohort of Australian patients found no evidence 
to suggest ADPKD is a risk factor for NODAT
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ABNORMAL GLUCOSE HOMEOSTASIS WITHIN FIRST 1081 
SIX MONTHS POST KIDNEY TRANSPLANTATION
S. Norman, F. Luan, D. Cibrik, A. Ojo
University of Michigan
Background: Abnormal glucose homeostasis is common in renal transplant 
recipients (RTRs) and associated with poor clinical outcomes. We studied the 
evolution of abnormal glucose homeostasis within 6 months after a kidney 
transplant using sequential standardized oral glucose tolerance test (OGTT).
Materials and Methods: Between October 1, 2006 and February 28, 2008, 60 
non-diabetic RTRs underwent sequential standard 2-hour OGTT at 10 weeks 
and 6 months post transplantation as part of institutional cardiovascular risk 
stratifi cation protocol. The demographic and clinical parameters were compared 
among the three groups of patients according to 2 hours post challenge glucose 
levels at 6 months: normal (< 140 mg/dl). impaired (140-199 mg/dl) and 
diabetic (>200 mg/dl). The fasting glucose levels and 2 hours post challenge 
glucose levels at 2 time points were compared. Univariate, including ANOVA, 
χ2 test and McNemar for paired proportion, and logistic regression analysis 
were utilized.
Results: The cumulative incidence of new onset diabetes after transplant 
(NODAT) was 15.0 and 16.6%, respectively, at 10 weeks and 6 months 
after kidney transplantation while cumulative incidence of impaired glucose 
tolerance (IGT) increased over the same time period (from 15.0% to 20.0%). 
There was good correlation between 0 and 2 hours glucose levels at 6 months 
(Pearson correlation coeffi cient = 0.502, p<0.0001). However, fasting glucose 
levels underestimate the seriousness of early abnormal glucose homeostasis at 
both 10 weeks and 6 months. Univariate analysis showed that fasting glucose 
levels prior to the transplant, fi rst three days and 10-12 weeks post transplant 
were signifi cantly different among the groups. Logistic regression analysis 
revealed fasting glucose levels at 10-12 weeks as only predictor of abnormal 
glucose homeostasis at 6 months.
Conclusions: OGTT is more sensitive in identifying impaired glucose 
homeostasis within 6 months of kidney transplantation. Fasting serum glucose 
concentration alone misses a signifi cant proportion of early impaired glucose 
homeostasis in the kidney transplant population.
POSTER BOARD NUMBER P1 – 168
RELATIONSHIPS OF SOCIO-CULTURAL AND DIETARY 1082 
FACTORS TO OBESITY AND RENAL HEALTH
S. Madhere, C. Callender, A. Campbell, E. Clark.
Howard University
Previous research has identifi ed obesity as a precursor to renal disease. As 
obesity threatens to reach epidemic scale in the United States, it is important 
to examine concomitant factors that may foster such a health risk. It is equally 
crucial to determine whether those factors can also infl uence kidney function 
through additional pathways.
The present study explores the relationships of renal health to truncal obesity 
as well as socio-cultural and dietary factors. Levels of creatinine, urine protein 
and urine glucose were recorded to assess renal health. Socio-cultural factors 
include sex, income, and cultural leverage. Cultural leverage was based on 
self-report of the degree of access and infl uence a person has when dealing 
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with major social institutions. We examined dietary habits such as inclusion 
of vegetables in a person’s meals, consumption of red meat, and a reliance on 
take-out or fast-food. Two psychological variables, relevant to eating behavior, 
were also taken into account: daily stress and reactive emotional eating.
Data were collected from a sample of 88 African Americans, part of a much 
larger group recruited for a comprehensive study on transplant education 
(MOTTEP). The average age of participants was 47 years. The statistical 
analysis was conducted in several stages. First, the pertinent dimensions of diet 
were derived from factor-analysis of a 51-item instrument, using maximum-
likelihood procedures. Second, a correlation matrix was obtained for all 
variables in the study. Finally, multivariate analysis of variance was used to 
analyze the relationships between the set of independent predictors and the 
three measures of kidney function.
Details of the analysis are summarized in the table below. It is worth 
noting that sociocultural and dietary factors together could explain 35% 
of the variance in creatinine level, 32% in urine glucose level, and 19% 
in urine protein level. Signifi cant predictors for creatinine were (in order 
of their contribution based on the value of eta-squared): emotional eating, 
sex, obesity, cultural leverage, and fast-food habit. Obesity turned out to be 
the signifi cant predictor for urine glucose, with marginal contribution from 
emotional eating and cultural leverage. Level of urine protein was dependent 
on obesity only.
Correlations of Various Indices of Renal Health with Sociocultural and Dietary 
Factors.
Predictors Indices of Renal Health
Glucose Protein Creatinine
Obesity .43* .27* .19*
Stress .21* .24* .25
Emotional Eating .17* .13 .36*
Meat Consumption .05 .14 .09
Vegetables -.13 -.14 -.11
Fast-food .09 .18 .19*
Income -.11 -.15 -.05
Leverage .18 .09 .24*
Total Variance Accounted for
 (Eta-squared) .32* .19* .35*
• p < .05
This research investigation is part of a larger study entitled, “A Research Center 
to Reduce Health Disparities in End Stage Renal Disease”, that is funded 
by The National Center on Minority Health and Health Disparities, Grant 
#1P20MD000512-04. Principle Investigator: Clive O. Callender, MD, Co-
Principal Investigators: Alfonso Campbell, Jr., PhD and Jules P. Harrell, PhD
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OBESITY AND INFLAMMATION: THEIR RESPECTIVE 1083 
ROLE IN PREDICTING THE EMERGENCE OF DIABETES IN 
HUMAN SUBJECTS
S. Madhere, C. Callender, A. Campbell
Howard University
The link between Type II diabetes and obesity has been predicated on the effect 
of increased liver triglycerides on insulin sensitivity. But recently, it has been 
proposed that obesity is responsible for a state of low-grade infl ammation 
which tends to enhance insulin resistance (Shoelson et al., 2006). The evidence 
for this is an increase in the expression of pro-infl ammatory cytokines such as 
interleukin-6 (Hirosumi et al., 2002). After demonstrating that Jun kinases may 
serve as a trigger to obesity-induced infl ammation in a mouse model, Solinas et 
al. (2007) argued that the regulation of JNK1 might be useful to the treatment 
of diabetes.
The present study tests whether a single or a dual pathway links obesity and 
diabetes in human subjects. The study was conducted with a sample of 31 
African American participants, fi ve of whom had been clinically diagnosed 
as diabetic. A measure of interleukin 6 was obtained for each participant. 
This biomarker of infl ammation was supplemented by a subjective report 
of bodily pain, using items from the Health Perception Scale F36 (Ware, 
2000). Body-mass index was also recorded. Logistic regression was used 
in order to predict diabetic status as a function of IL6, bodily pain, and 
body-mass.
While the model correctly classifi ed 87.1% of the cases, only body-mass 
emerged as a signifi cant predictor of diabetic status. The odds-ratio associated 
with this variable was 1.1 (95% CI ranging from1.01 to 1.20). Our results 
suggest that obesity stands as the more reliable contributing factor to diabetes. 
By contrast, the infl ammatory response, if measured through interleukin-6 
among human subjects, may not be as powerful a mechanism in the emergence 
of diabetes, as it reported is among animals.
This research investigation is part of a larger study entitled, “A Research 
Center to Reduce Health Disparities in End Stage Renal Disease”, that is 
funded by The National Center on Minority Health and Health Disparities, 
Grant #1P20MD000512-04. Principle Investigator: Clive O. Callender, 
MD, Co-Principal Investigators: Alfonso Campbell, Jr., PhD and Jules P. 
Harrell, PhD
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IMPACT OF POSTTRANSPLANT DIABETES MELLITUS 1084 
ON GRAFT FUNCTION AND SURVIVAL AFTER RENAL 
TRANSPLANTATION IN THAI POPULATION.
A. Ingsathit, S. Rattanasiri, P. Chatchaipun, S. Jirasiritham, V. Sumethkul
Faculty of Medicine, Ramathibodi Hospital
Introduction: Posttransplant diabetes mellitus (PTDM) is a major complication 
after kidney transplantation. We examined the impact of either condition on 
death-censored graft and patient survival in Thai population.
Materials and Methods: A cohort of consecutive ESRD patients who 
underwent fi rst kidney transplantation at a single center, university based 
hospital during June 1995 to December 2006 were examined. We studied the 
outcomes of 494 KT recipients that included 62 PTDM patients (12.5%; Gr1). 
63 patients with DM as underlying disease (12.7%, Gr2) and 369 non DM 
patients (Gr3) in a single center during a 10-year period. Diagnostic criteria 
of PTDM include: fasting blood glucose levels higher than 126 mg/dl on 
two separate occasions or the requirement of glucose-lowering medications 
(insulin or oral hypoglycemic agents). Primary end point was the death-
censored graft survival rate. Secondary end point was the patient survival 
rate. Graft failure was defi ned as when recipients returned to hemodialysis. 
Cox’s regression with time-varying covariates was used to determine the 
prognostics factors. Risk factors for PTDM were assessed by mean of multiple 
logistic regression analysis models. A p value less than 0.05 was considered 
as statistical signifi cant.
Results: Among 494 recipients during study period, 62 recipients developed 
NODM. The median follow-up time was 5.2 years (range: 0.2-10.0 years). 
The estimated incidence of PTDM was 3.7/100 patients/year. The overall 
DM-free survival rates at 1, 5, and 10 years were 91.1%, 82.8%, and 79.3% 
respectively. Tacrolimus-based immunosuppressive regimen were used in 49 
(11.6%) recipients and the average prednisolone used per day were 9.73 + 3.35 
mg/day. Only recipient’s age was signifi cantly able to explain development of 
PTDM. We found that recipients whose age were older than 40 years were 
1.83 (95%CI: 1.06-3.15) times more likely to have PTDM than recipients 
aged 40 years or younger. However, recipient’s gender, type of donor, 
HBV seropositive status, HCV seropositive status, duration of dialysis, and 
tacrolimus use were not associated with the risk for development of PTDM. 
Ten year actuarial graft survival was 78.5% for Gr. 1, 81.7% for Gr. 2 and 
74.3% for Gr. 3 (P = 0.335). And the actuarial 10 year patient survival of Gr1 
was not signifi cantly different compared with Gr2 and Gr3 (92.2% VS 96.4% 
and 86.4%) (p=0.136).
Discussion: The rate of development of PTDM was lesser than previous reports. 
Low proportion of tacrolimus used and low cumulative dosage of prednisolone 
used in our practice may explain this fi nding. No signifi cant difference in death-
censored graft survival and patient survival in renal recipients who develop 
PTDM compared with recipients with history of DM before transplantation or 
control patients.
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METABOLITES PATTERNS IN KIDNEY TRANSPLANT 1085 
PATIENTS
M. Carmellini3, H. Stenlund1, M. Calderisi2, A. Vivi2, M. Tassini2, 
G. Valensin2, M. Cocchi4, J. Trygg1
1Chemistry Department Umeå University, Sweden 2NMR Center University 
of Siena, Italy 3Department of Surgery and Bioengineering, Siena, Italy 
4Chemistry Department University of Modena and Reggio Emilia, Italy
NMR spectroscopy is an analytical platform for biological matrices; it enables 
the quick generation of spectral profi les of low molecular weights metabolites. 
Metabonomics is a system approach used to investigate the metabolic profi le 
by multivariate data analysis tools.
The goal of this work is the identifi cation of the dynamic biopatterns (individual 
patient recovery trajectories) related to the recovery progress in kidney 
transplant patients, by 1H-NMR spectroscopy. Urine samples of 14 trasplanted 
patients, with deceased donor kidney, were collected during the graft recovery 
period of 15gg after trasplantation, along with clinical data (glucose, dialysis, 
diuresis, drug therapy).
Urine NMR measurements were carried out on a Bruker DRX 600 MHz Avance 
spectrometer. The samples were measured at pH 2.50 ± 0.02.
Clinical data have been analyzed by means of Principal Components Analysis 
(PCA). Cluster Analysis (CA). while 1H-NMR spectroscopic data have been 
analyzed by means of O-PLS-DA (Orthogonal PLS Discriminant Analysis).
The diuresis data has been studied by PCA. The fi rst two components loadings 
plot shows a clear trend from the fi rst days to the last one (fi g. 1).
Figure 1
The dialysis data matrix is structured as time vs. patients (presence/absence 
data array). A cluster analysis (complete linkage and percent disagreement) 
was chosen to study this type of data.
For therapy data it is possible to build an unfolded 3 way data array; PCA give 
the most interesting results, showing relations between patients and drugs, for 
each drugs it is possible to see how dosage changed with time.
The Q residual from a PCA on glucose data showed that the sample 1325 it is 
an outlier: in fact the glucose value for 1325 was very low on day 0, very high 
on day 1 and day 2.
Referring the graft kidney recovery as a discrete two-stage progress, O-PLS-
DA analysis of NMR spectroscopy data (mean centered data, Pareto scaled). 
allow us to estimate a joint intra-person effect that is representative for the 
majority of the individuals.
Figure 2
It is moreover evident that patients 1317 didn’t produce similar O-PLS effect as 
the others (they show an opposite trajectory) and patient 1325 show only one 
stage, that is doesn’t show a clear direction (fi gure 2). The OPLS profi le (bio-
pattern) for all the patients has been tested/validated for all samples.
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NEW ONSET POSTTRANSPLANT DIABETES MELLITUS 1086 
IN HISPANIC KIDNEY TRANSPLANT RECIPIENTS
P.W. Baron1, R. Ben-Youssef1, E. Franco1, J. Weissman1, W. Baqai2, A. Kore1, 
M. DeLeon2, Z. Cordero-MacIntyre2 and O. Ojogho1. 
1Transplantation Institute and 2Center for Health Disparities Research, Loma 
Linda University, California, United States.
Background: Tacrolimus (FK) is less commonly used in Hispanic patients 
due to anticipated higher risk of new-onset diabetes mellitus posttransplant 
(NODM). We analyzed the incidence of NODM and the outcome of Hispanic 
patients treated with FK or cyclosporine (CsA).
Method: Data of 139 Hispanic patients who underwent primary kidney transplant 
between Jan 1998 and Dec 2002 were reviewed. We used WHO/ADA criteria for 
NODM diagnosis. 37 patients were excluded due to diabetes mellitus pretransplant. 
The remaining 102 patients were divided into 2 groups: 37 received FK, and 65 
received CsA. We analyzed NODM incidence, acute rejection (ACR). BK virus 
and CMV infection rates, patient and graft survival. Median follow-up was 71 
mo (20-114). All patients received FK or CsA plus steroids, MMF or rapamycin. 
Antibody induction therapy was used in 28 FK (75.7%) and in 32 CsA (49.2%) 
patients. ACR was initially treated with steroid and/or anti-thymocyte globulin.
Results: NODM incidences among surviving patients at 6 mo, 1, 3, and 
5 y were 24.3%, 27%, 38.2%, and 25% with FK, and 7.7%, 10.2%, 13%, 
and 14.9% with CsA (p=0.02, 0.03, 0.006, and 0.36 at 6 mo, 1, 3, and 5 y, 
respectively). 4/13 (30.8%) NODM FK patients and only 1/8 (12.5%) NODM 
CsA patients received rapamycin (p=0.34). BK virus infection was seen in 4 
FK and in 2 CsA patients. CMV infection was seen in 1 FK and in 2 CsA 
patients. Noncompliance was recorded in 3 FK and in 2 CsA patients. ACR 
rate was 43.2% (16/37) in FK and 27.7% (18/65) in CsA (p=0.1). 5-year graft 
and patient survival were 59.5% and 97% in FK, and 76.9% and 98.3% in CsA 
(p=0.02 and 0.27, respectively).
Table 1. Patients characteristics and outcome
 FK (n=37) CsA (n=65) p-value
Age (y) 34.615.6 31.317.5
BMI (Kg/m2) 24.75.5 26.26.8
DM family history, n (%) 12 (32.4) 16 (24.6) 
5-y ACR, n (%) 16 (43.2) 18 (27.7) 
5-y NODM incidence, n (%) 13 (35.1) 8 (12.3) 0.006
1/5-y graft survival (%) 94.6/56.8 100/72.3 0.02
MeanSD=, NS=
Conclusion: The incidence of NODM was signifi cantly higher in the FK 
group. Patients treated with CsA had lower ACR rate and better graft survival. 
Is the higher incidence of NODM contributing to worsening the long-term graft 
survival in Hispanic patients treated with FK? Large prospective studies are 
needed to guide the use of calcineurin inhibitors in Hispanics.
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THE EFFECT OF SMOKING ON KIDNEY GRAFT 1087 
FUNCTION
V. Müller1, P. Gombos1,2, R. Korbely1,2, R. Langer2
1Semmelweis University Department of Pulmonology, 2Semmelweis 
University Department of Transplantation and Surgery
Chronic graft loss represents the major problem after transplantation. Smoking is 
a well known, however often neglected risk factor of chronic kidney damage.
A survey was conducted among 402 randomly selected kidney graft recipients, 
which included questions about smoking habits, Fagerström test of nicotine 
dependence. Parallel CO measurement was performed. Clinical data in smokers 
and non smokers were compared.
Twenty fi ve% of kidney graft recipients continued smoking after transplantation. 
Demographic data did show only difference between smokers and non smokers 
in age at transplantation, showing, that smokers receives their grafts at younger 
age. Posttransplant kidney function assessed by serum creatinine was not 
different in the two groups 1 month after transplantation. Three years after 
engraftment signifi cantly decreased serum creatinine was present in the smoker 
group. Decline of kidney function correlated with smoking intensity.
Smoking is a preventable risk factor of kidney damage after transplantation. 
Effective tobacco dependence treatment is advised in this group of patients as 
smoking cessation might contribute to longer preservation of graft function.
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INFLUENCE OF ANGIOTENSINOGEN (AGT) 1088 
M235T GENOTYPE AND INSERTION/DELETION (I/D) 
POLYMORPHISM OF ANGIOTENSIN-CONVERTING ENZYME 
(ACE) GENE ON GLUCOSE METABOLISM IN KIDNEY 
TRANSPLANT RECIPIENTS
B. Grandtnerova1, O. Krizanova2
1Transplant Centre, Faculty Hospital Martin, 2Institute of Molecular 
Physiology and Genetics, Slovak Acedemy of Sciences
Objective: to assess the frequency of I/D polymorphism of ACE gene and 
AGT M235T genotype and its impact on glucose metabolism in patients after 
kidney transplantation.
Patients and Methods: Medical records of 53 adult Caucasoid patients 
covering a period 4th month – 4 years after Tx were included in a retrospective 
analysis. Immunosuppression consisted either of CsA (10 Ps) or Tac (39 Ps) or 
Rapa (4Ps). All Ps were treated with mycophenolate mofetil or sodium and 10 
mg of prednisone. Evaluated groups did not differ in acute rejection episode 
incidence and methylprednisolon treatment. PCR-RFLP was used to detect 
gene polymorphisms.
Results: Frequencies of ACE gene II: ID: DD genotypes were 34%: 36%: 30% 
and TT: TM: MM genotypes of AGT 26%: 47%: 27%. Highest fasting glucose 
level was signifi cantly different in TT homozygous individuals in comparison 
to MM genotype (mean ± SEM= 8.62 ± 0.78 vs 6.62 ± 0.31 mmol/l, p < 0.05). 
differences between I/I vs D/D were not statistically signifi cant (8.31 ± 0.65 vs 
7.2 ± 0.43 mmol/l, p= 0.15). Highest HbA1c level was signifi cantly different 
in carriers of at least one T allele in comparison to MM genotype (7.67 ± 0.27 
vs 6.94 ± 0.26%, p < 0.05). differences between I/I vs D/D were not signifi cant 
(7,4 ± 0,2 vs 7,3 ± 0,3%).
Conclusions: Our results suggest infl uence of RAS polymorphisms on 
glucose metabolism after kidney transplantation. Carriage of at least one T 
allele (M235T) of AGT was linked to increased fasting glycaemia and HbA1c 
during the follow up. If proven in a larger study, prospective genotyping of 
RAS on the waiting list could help to further individualization of posttransplant 
immunosuppressive strategy, with a special regard to metabolic syndrome, e.g. 
steroid avoidance or minimalization.
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DIFFERING INCIDENCES OF POST TRANSPLANT 1089 
DIABETES MELLITUS DEPENDING UPON DEFINITION
R. Higgins, M. Lambie, N. West, S. Fletcher, A. Anwar, P. Harrison, 
M. Clamp, 
University Hospitals of Coventry And Warwickshire
Post transplant diabetes mellitus (PTDM) is a common complication of 
transplantation with a signifi cant morbidity and mortality associated, but the 
incidence rates vary between studies from 6.5% to as high as 46%. Some of 
the variation is due to different defi nitions used, although an international 
consensus group has now published guidelines. To ascertain the incidence in 
our centre, we conducted a retrospective audit of all renal transplants between 
1998 and 2007.
Data was extracted from the computer system covering all transplants on age, 
ethnicity, weight, diabetic status at time of transplant, glucose levels, diabetic 
treatment, immunosuppression and outcome. Two or more glucose levels 
between 7.1 and 11.1 were defi ned as impaired glucose tolerance (IGT) and 
over 11.1 as PTDM. As 44 patients were transferred at 6 months to another 
centre, these were excluded from outcome data.
298 patients with a mean age of 47 (19-76) were included with 83.6% White, 
11.4% South Asian and 4.7% Black.
Normal glucose IGT Diabetic pre-transplant PTDM
Population (actual 
number) 
40.6%
 (121) 
33.6% (100) 8%
 (24) 
17.8% (53) 
Mean Age 43 49 50.2 51.2
The outcomes were slightly worse in the PTDM group compared with the 
normal glucose group – graft functioning 78.7% vs 85.7%, graft failed 4.3% vs 
9.5%, patient died 17.0% vs 4.8%.
Of the PTDM group, 19 patients (6.4% of the total) started hypoglycemic 
treatment at a median of 68 days (range 6-1399) with 15 starting sulphonylureas, 
3 starting insulin, 1 starting a biguanide and 5 subsequently converted 
to insulin. The mean age was 51.2, the mean HbA1c was 6.8, and the mean 
Tacrolimus levels over the fi rst 3 months were 12.7 vs 12.5 for the normal 
glucose population. Of these 19 patients, 6 had their hypoglycemic treatment 
successfully withdrawn, leaving 4.4% of the total group on treatment. In the 
group diagnosed as having PTDM, only 15 of 33 had their HbA1c checked, with 
a mean value of 6.1 (4.5-8.2).
This audit demonstrates the signifi cant difference in calculated incidence of 
PTDM depending upon the defi nition used. Our rates range from 17.8% for 2 
or more random glucose levels over 11.1 at any time post transplant, contrasting 
with lower rates from other units who excluded glucose levels from a variable 
time post transplant, to 6.4% for those requiring treatment, to 4.4% for those 
remaining on treatment.
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GLUCOSE METABOLISM DISORDERS IN RENAL 1090 
TRANSPLANT RECIPIENTS
L.M. Obregon, M.F. Taylor, H. Petrone, M. Baran, M.E. Menna
CRAI Sur CUCAIBA
Objectives: evaluate carbohydrate metabolism in renal transplant patients.
Materials and Methods: we evaluated adult kidney transplant recipients that 
fulfi lled these criteria of inclusion: more than six months from the transplant, 
stable renal function, no rejection in the last 90 days, no infectious episodes or 
associated diseases (myocardial infarction, vascular complications, etc.) that 
required hospital admission, without diabetes diagnosis (pre transplant diabetes 
or post transplant diabetes). and women who were not attending pregnancy, 
that acceded to participate in the study. Clinical data were considered: age, 
sex, time from transplant, type of donor, circumference of waist, relation waist/
hip, BMI and dose of steroids. An oral glucose tolerance test (OGTT) was 
performed, as well as a fasting plasma glucose (FPG) and insulin, HbA1c and 
creatinine determination. In addition, we did a retrospective analysis of the 
FPG values. Patients were divided in two groups, according to whether they 
presented or not altered FGP (GI and GII respectively). We took as reference 
values American Diabetes Association’s (ADA’s) ones and we considered as 
signifi cant a value of p<0,05.
Results: 40 renal graft recipients were evaluated. By means of OGTT, 3 
cases of intolerance to oral glucose (7,5%) and one case of diabetes (2,5%) 
were diagnosed. A 62,5% (n=25) presented two or more altered FGP (GI). 
When we compared them to the group with normal FGP (GII). we observed a 
signifi cant difference in the circumference of waist (94.36 vs 86.41 cm) and a 
non signifi cant tendency to higher values of plasma glucose two hours after the 
test in the GI. No differences in the other variables were found.
Conclusions: OGTT is a simple test, available and accessible in developing 
countries like ours. In our study a 10% with abnormal results were detected. It is 
important to consider the historical values of FPG, frequently underestimated, 
since it was altered in a 62.5% of these patients. These are signifi cant results in 
the prevention of future cardiovascular complications.
POSTER BOARD NUMBER P1 – 177
NEW ONSET DIABETES AFTER TRANSPLANTATION IN 1091 
AN AUSTRALIAN COHORT – INCIDENCE AND ASSOCIATED 
FACTORS
C.N. Naresh, K. Wyburn, J. Eris, G. Whitman, S. Chadban
Department of Renal Medicine, Royal Prince Alfred Hospital, and University 
of Sydney, Australia
Background: New Onset Diabetes After Transplantation (NODAT) is 
associated with inferior patient and graft survival after kidney transplantation. 
Uncertainty about incidence and causative factors exists and signifi cant 
variation between centres is evident. We sought to estimate the incidence and 
determine clinical factors associated with the development of NODAT at week 
10 after kidney transplantation in an Australian centre.
Methods: Prospective observational cohort study conducted at a tertiary care 
university hospital from January 2005 to December 2007. All non-diabetic 
patients undergoing kidney transplantation and local follow-up were recruited. 
Immunosuppression was determined by the treating physician and at initiation 
included steroids in all cases, a monoclonal IL-2Rα receptor antibody (n= 
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94). a calcineurin inhibitor (n=104). plus mycophenolate (n=92) or a mTOR 
inhibitor (n=13). Participants were subjected to a 2-hour oral glucose tolerance 
test (OGTT) at 10 weeks post-transplantation, except for those receiving oral 
hypoglycaemic agents or insulin. Primary outcome measure was NODAT, 
defi ned by requirement for hypoglycaemic therapy or a positive OGTT (fasting 
blood glucose > 7.0 mmol/L or a 2-hour glucose > 11.1mmol/L). A multivariate 
analysis of clinical factors associated with NODAT was undertaken.
Results: 134 patients were recruited; 3 incurred early graft loss and 131 were 
included. 48 participants (36.6%) developed NODAT. Tacrolimus usage was 
strongly associated with NODAT, ORadj 6.54, χ2 = 37.55 (6df). p <0.0001 
(95%CI 2.38 – 17.98). This increased risk was independent of recipient age, 
hepatitis C status, weight at the time of transplantation, body mass index & 
weight gain at 10 weeks post-transplantation. NODAT was observed more 
often in patients treated with tacrolimus compared to cyclosporin (58.3% vs 
21.8%; p = 0.0008).
Variables N OR 95% CI χ2 p Value Pseudo R2
At the time of Renal Transplantation
Impaired OGTT* 8 3.17 0.72 – 13.94 2.44 0.12 0.01
Age >50 years 69 1.88 0.91 – 3.89 2.96 0.09 0.02
BMI > 25 80 0.96 0.46 – 1.98 0.01 0.9 0.0001
Hepatitis C positive 3 0.68 0.06 – 7.78 0.01 0.8 0.0006
Tacrolimus use 63 3.35 1.59 – 7.81 10.61 0.001 0.06
Cyclosporin A use 41 0.44 0.19 – 1.01 4.01 0.05 0.02
At 10 weeks post Renal transplantation
Weight gain (≥4Kg increase) 51 0.19 0.08 – 0.45 16.92 <0.0001 0.1
Receiving Tacrolimus 60 6.25 2.83 – 13.77 23.01 <0.0001 0.1
Receiving Cyclosporin A 32 0.40 0.16 – 1.0 4.21 0.04 0.02
BMI>25 82 0.75 0.36 – 1.56 0.58 0.4 0.003
Tacrolimus use ◊ 60 6.54 2.38 – 17.98 37.55 <0.0001 0.3
Cyclosporin A use◊ 32 0.15 0.04 – 0.51 33.31 <0.0001 0.2
*Impaired OGTT is defi ned as 2-hour post prandial BGL > 7.8 mmol/L
◊Adjusted for HCV status, Age & weight at transplantation, BMI & weight gain at 10 weeks
Conclusions: NODAT was extremely common and strongly associated 
with the use of tacrolimus, either as initial therapy or following switch from 
cyclosporine or mTOR. This rate is higher than in other published reports and 
reasons for this require exploration. Risk of NODAT should be considered in 
initial choice of calcineurin inhibitor.
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ORAL FRUCTOSE LOAD INDUCED HYPERURICEMIA 1092 
IN RENAL TRANSPLANT PATIENTS TREATED 
WITH TACROLIMUS- OR CYCLOSPORINE BASED 
IMMUNOSUPPRESSION
M. Nowicki, A. Zawiasa, I. Kurnatowska, J.F. Morawska
Medical University of Lodz, Dept. Nephrology, Hypertension And Kidney 
Transplantation
An increase in the prevalence and incidence of hyperuricemia and gout over 
the past few decades coincided with a substantial increase in the consumption 
of fructose-sweetened soft drinks and fructose. Acute oral administration 
of fructose results in a rapid increase in serum levels of uric acid through 
accentuated degradation of purine nucleotides and increased purine synthesis. 
Hyperuricemia has been implicated in the pathogenesis of both cardiovascular 
and renal disease and is a common fi nding in organ transplant patients where 
it was found to adversely affect graft function. Hyperuricemia is also a well 
known adverse effect of cyclosporine A. Data regarding the effect of tacrolimus 
have been contradictory.
The aim of the study was to compare the effect of an acute oral fructose load 
on serum uric acid, plasma lipids and blood pressure in stable (mean GFR 55 
ml/min). long-term (5.1±;4 years post-Tx) kidney transplant patients treated 
with cyclosporine- or tacrolimus-based triple (CNI+MMF+prednisone) 
immunosuppressive protocol (25 patients in each group). All patients received 
75 g of fructose per os and the blood was withdrawn for biochemistry at 
baseline and after 60, 90, 120 and 180 minutes.
Both groups did not differ with respect to age, BMI, time after Tx, GFR, and 
plasma lipids. In both groups a signifi cant increase of serum uric acid was 
observed after an oral fructose administration (from 456±;84 to 494±;91 
μ;mol/l in CyA treated and from 438±;104 to 470±;109 μ;mol/l in Tac treated 
patients) (p<0.001 in both groups). The maximal increase of serum uric acid 
was observed 90 minutes after fructose intake (to 495±;97 and 484±;109 
μ;mol/l, respectively). Plasma total, LDL and HDL cholesterol did not change 
after the fructose load in both groups but there was a signifi cant increase of 
plasma triglycerides from baseline in both groups (0.23±;0,30 vs 0.19±;0,24 
mmol/l, respectively, p=0.02). Blood pressure tended to be lower at baseline in 
Tac than in CyA treated patients (mean arterial pressure 103±;14 and 97±;16 
mmHg, respectively, p=0.1) but no change of blood pressure was recorded after 
the fructose intake in both groups.
Conclusion: Oral fructose intake causes an acute rise of serum uric acid and 
triglycerides in kidney transplant patients that is similar in both Cya and Tac 
treated patients.
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USEFULNESS OF ORAL GTT IN PREDICTING AND 1093 
MANAGING DM ON RENAL TRANSPLANT RECIPIENTS IN A 
SOUTH INDIAN HOSPITAL SETTINGS
G. Abraham1, R. Chandran2, N. Fathima2, M. Mathew2, S. Soundarajan2
1Sri Ramachandra University, Chennai, 2Madras Medical Mission, Hospital, 
Chennai
Aim: To evaluate the usefulness of GTT, hip and waist ratio as a tool for 
screening the risk of NODAT.
Patients & Methods: Study included non diabetic (M – 57, F-20) renal 
transplant recipients from January 2005 to June 2007 with mean age of 36.9 
years. All the patients were inducted with Basiliximab or Daclizimab, base 
line IS with prednisolone (0.5mg/kg) – Aza/MMF/CSA/FK506/Rapamycin. 
Prednisolone was reduced to 2.5 to 7.5mg in 6 months. Family H/O diabetes 
and Pre and post transplant weight recorded. Oral GTT was done with Glucose 
75mg before and within 8 to 30 days after transplantation (serum creatinine 
stabilized to ≤ 1.5mg/dl). Based on GTT patients were grouped as normal, IGT 
and diabetes. Hip and waist ratio taken for all patients on before discharge from 
hospital and 2 months later. The population included Indian- 33, Srilankan – 
10, Nepalese – 19, Tanzian – 10, and Seychelles – 5.
Results: Out of 77 patients, 12 patients (15.5%) developed NODAT and 21 
(27.2%) developed IGT. 22 patients had BPAR of various BANFF grades 
requiring Inj. Methyl Prednisolone. Normal GTT (Pre Tx) in 56 (Male – 42, 
female – 14). abnormal (IGT) in 21. Out of the 56 patients who had normal 
GTT (pre Tx). post Tx normal GTT in 39 (69.6%). IGT in 7 (12.5%) and DM 
requiring therapy in 10 (17.8%) Among 21 patients with IGT (pre Tx). DM 
developed in 2 (9.52%) and IGT in 12 (57.1%).
IMMUNOSUPPRESENT REGIMENT: No. of Pts No. of DM
Cyclosporine/MMF/Steroids 57  6 (10.52%) 
Tacrolimus/MMF/Steroids 20  6 (30%) p<0.05
Hip waist ratio was 0.97 in 39 patients with normal GTT (men 29 and women 
10) and those who developed DM 0.95 (men 09 and women 03) which 
was not signifi cant. Pre and Post transplant weight of these patient showed 
insignifi cance in predicting NODAT.
Conclusion: The oral GTT was useful tool in diagnosing DM early and IGT. 
More patients in Tacrolimus group developed DM. Hip waist ratio is not 
predictive of development of DM or IGT. Pre and post weight is not predictive 
of development of DM or IGT. Steroid free immunosuppression is costly in 
Indian subcontinent, hence this data helped in modifying immunosuppressive 
therapy, dietary regimen, exercise for NODAT patients.
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RENAL TRANSPLANT OUTCOME IN DIABETIC 1094 
PATIENTS
F. Jawad, R. Shaikh, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Objectives: To compare one year’s outcome of diabetics subjected to renal 
transplantation (RTx) with matched non-diabetics as controls.
Methods: All diabetics, with a fi rst live related RTx from October 1994 to April 
2007 were included. A control group comprised of non-diabetics, matching 
with respect to time of transplant, sex, age, pre Tx dialysis period and post Tx 
immunosuppressive regime. The variables studied were one-year patient and 
graft survival, acute and chronic rejection episodes, systemic infections and 
wound status.
Results: There study included 55 diabetics (Group 1) and 55 non-diabetics 
(Group 2). having undergone Tx surgery within a span of 3 months of each 
other. There were 46 males and 9 females in each group, with a mean age of 
40.9±7.5 and 39.7±6.7 years respectively. In Group 2 Hypertension was the 
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cause of renal failure in 25 cases, stone disease in 7, Glomerulonephritis in 
3 and 20 with unknown etiology. The pre-Tx dialysis period was 12.5±10.5 
and 9.7±4.6 months, in-group 1 and 2 respectively. Hypertension was 
present in 50 diabetics and 45 non-diabetics. The acute and chronic rejection 
episodes of the two groups had no signifi cant difference. Post Tx infections 
were similar in the two groups with urinary tract infections having the 
highest frequency (24 in Group-1 and 20 in Group-2). Wound infection and 
dehiscence was signifi cant in the diabetic patients (17 and 4 respectively) 
with 5 wound infections in Group 2. Three patients from Group 1 suffered 
an acute myocardial infarction. There was no cardiovascular morbidity 
in Group 2. One-year graft survival was 84% and 94% in Group 1 and 2 
respectively. One-year patient survival was 89.6% and 94% in the two groups 
respectively.
Conclusion: One-year graft and patient survival was similar in the diabetic 
and non-diabetic control subjects. Wound infection and dehiscence were more 
in diabetic subjects.
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STEADY AND STRICTLY LINEAR RISE IN BODY MASS 1095 
INDEX AMONG RENAL TRANSPLANT RECIPIENTS AT UCLA 
FROM 2002 TO 2006
S. Bunnapradist1, B.R. Madhira1, J. Gill1, M. Low2, G. Danovitch1, 
K. Kalantar-Zadeh2
1UCLA Kidney Transplant Program, 2Harbor-UCLA Harold Simmons Center, 
Los Angeles and Torrance, CA
Background: Obesity is on the rise both in the general population and among 
renal transplant recipients (RTRs) and may lead to technical problems during 
the transplantation surgery and immediate post-operative era. Since California 
has one of the highest obesity incidence and prevalence rates in the nation, we 
examined the rate of increase in body mass index (BMI) in the 21st century 
among RTR in UCLA.
Methods: We collected data from all adult RTRs between January 1997 and 
December 2007 in the UCLA kidney transplant center.
Results: A total of 2,396 RTRs were identified at UCLA between 1997 
and 2007; 67% were deceased donor transplants, 22% living related and 
11% living unrelated. RTR age was 46.7±3.5 yrs; 59% were men, 63% 
White, 7% Black and 10% Asian. The baseline BMI, available in 994 
RTRs on the day of transplant from 2002 to 2006, was 25.9± 5.2kg/m2 
(mean±SD). A strictly linear and steady increase in BMI was noticed across 
5 years of observation (r=0.99, p<0.0001) with this regression equation: 
BMI=0.39*YEAR-766.
Conclusions: Among UCLA RTR at the dawn of the 21st century, the baseline 
BMI shows a strikingly constant and signifi cant increase of 0.39 kg/m2 per 
year. The clinical and public health implications of this constant increase in 
baseline weight at transplant on the outcomes of kidney transplantation need to 
be examined in longitudinal studies.
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DISCREPANCIES OF BODY MASS INDEX AT THE TIME 1096 
OF KIDNEY TRANSPLANT ACROSS GENDER, RACE AND 
TRANPLANT TYPE AT UCLA
S. Bunnapradist1, B.R. Madhira1, J. Gill1, M. Low2, G.M. Danovitch1, 
K. Kalantar-Zadeh2
1UCLA Kidney Transplant Program, 2Harbor-UCLA Harold Simmons Center, 
Los Angeles and Torrance, CA
Background: Confl icting results have been reported regarding the association 
of body mass index (BMI) and graft and patient survival in renal transplant 
recipients (RTR). We hypothesized that signifi cant baseline BMI discrepancies 
across gender, races/ethnicities or donor status may be a relevant factor to that 
end.
Methods: We collected data from all adult RTRs between January 2002 and 
December 2006 in the UCLA kidney transplant center.
Results: A total of 1368 RTRs at UCLA were performed at that time. RTR 
age was 46.7±3.5 yrs; 60% were men, 56% White, 17% Black and 16% Asian. 
Mean Pre-transplant dialysis time was 1,371±1,265 days (median: 848, IQR: 
472-1,784]. Using electronic data record the baseline BMI, available in 993 
RTRs on the day of transplant, was 25.9±5.1 kg/m2 (mean±SD).
Donor type Overall Men Women Whites Blacks Asians Others
Living 25.7±4.8 26.5±4.2 24.6±5.4 25.5±4.7 28.2±5.0 24.5±4.4 26.2±5.6
Deceased 26.1±5.2 26.4±5.4 25.6±5.1 26.2±5.1 27.2±5.9 24.2±4.1 25.7±5.2
Conclusions: Hence, among Black and female RTRs at UCLA, a living renal 
transplant was associated with 1.0 kg/m2 higher BMI than deceased transplant, 
whereas in Whites an opposite trend (0.7 kg/m2 lower BMI) was observed. 
Asians RTR have the lowest BMI compared to other races. Longitudinal studies 
need to examine whether the found discrepancies have signifi cant clinical and 
public health implications in RTR outcomes.
SURGICAL CONCURRENT ORAL SESSION 82: 
COMPLICATIONS
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SURGICAL COMPLICATIONS AFTER KIDNEY 1097 
TRANSPLANTATION (KT) IN CHILDREN: AN 
OBSERVATIONAL SPANISH STUDY
R. Vilalta, M. Navarro, J. Govantes, I. Zamora, G. Ariceta, A. Luque, 
A. Vila, A. Muriel, F.J. Burgos, J. Pascual
For the Spanish Paediatric Kidney Transplant Survey
Abstract Document: Surgical complications are not very frequent in 
children receiving a renal allograft. We have reviewed all the pediatric 
KidneyTransplantKT performed in Spain during the year 2004 followed-
up for one year, to assess the prevalence of vascular, urological and wound 
complications. During the study period, 65 patients (<18years.) received a KT 
and one a kidney-liver in the 7 Spanish pediatric KT units. Mean donor age 
was 19.8±13.4 years, 58 (88%) were deceased donors and 7 living donors. 
Mean pre-harvesting SCr was 0.8. The cause of donor death was trauma in 
63% of cases. Recipient age was 12.3±5 years, 61% were males, mean BMI 
was 19 kg/m2, peak PRA was 12.4±25.9%, time on dialysis had been 12±23.8 
months and 23% were retransplantations. Urinary tract anomalies were present 
before transplant in one third of cases. Immunosuppression was always based 
on Tacrolimus or CsA, MMF and steroids. Sirolimus was never used initially. 
Double J ureteral stent was used in 8 cases (12%). Six patients (9%) showed 
delayed graft function and 7 (11%) acute rejection episodes.
Surgical complications are detailed in the table.
Complication n %  CI (95% ) 
Wound problem (Non-infectious) 3  4,5  1-13
Wound infection 0
Perigraft fl uid collection 10  15,2  8-26
Lymphocele 4  6,1  2-15
Hematoma 5  7,6  3-17
Urinoma 1  1,5  0-8
Vascular 6  9,1  4-21
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Arterial or venous Thrombosis 4  6,1  2-15
Renal artery stenosis 1  1,5  0-8
Iliac artery thrombosis 1  1,5  0-8
Urinary leak 2  3,0  0-11
Bladder 1  1,5  0-8
Ureteral or ureterovesical 1  1,5  0-8
Urinary Stenosis/Obstruction 6  9,1  3-17
Ureteral or ureterovesical 4  6,1  2-15
Pyeloureteral 2  3,0  0-11
The incidences complications were not signifi cantly different to those observed 
in the adult population during the same period in Spain. Vascular thrombosis 
was more frequent in children (6.1 vs 3% in adults). Seven grafts (10.6%) were 
lost during the fi rst year ;the most frequent cause was vascular thrombosis 
(n=4). Patient survival was 100%. Surgical complications in children are 
frequent after KT, and adequate prophylactic measures are encouraged, to 
prevent vascular and urological problems.
POSTER BOARD NUMBER P1 – 184
SUCCESSFUL RENAL TRANSPLANTATÝON 1098 
AFTER ENDOVASCULAR STENT PLACEMENT OF TASC 
(TRANSATLANTÝC INTER-SOCÝETY CONSENSUS) TYPE B 
AORTOÝLÝAC OCCLUSÝVE DÝSEASE
A. Demýrag, G. Kantarci, M. Kalayci, B. Ekcý, T. Gulcelýk, O. Gokce
Yeditepe Univ Hospital
The occurrence of aortoiliac lesions with renal transplantation is an increasingly 
common combination that causes problems regarding operative strategy and 
indications for aortoiliac reconstruction and renal transplantation. Staged or 
simultaneous surgical repair of aortoiliac lesions with renal transplantation 
is possible at reasonable risk. Renal transplantation after repair of aortoiliac 
occlusive disease with traditional prosthetic vascular grafts has been shown 
to be effective.
Interventional radiology continues to rapidly evolve, most notably with the 
advancement of PTA/stent placement of aortoiliac lesions. Trials continue to 
support the trend toward the use of endovascular aortic stent grafts in patients 
with TASC type A, B, C and D aortoiliac lesions. Literature data are still scarce 
regarding renal transplantation after endovascular stent placement of TASC 
type B aortoiliac lesions. Here, we describe the fi rst renal transplant in a patient 
with disabling claudication and TASC type B aortoiliac disease which treated 
with an endovascular aortoiliac stent graft (fi gure 1). ABI (ankle-brachial 
index) before and after the stent placement were 0.6 vs. 1.2 respectively. 
No intraoperative diffi culties were encountered. At 1 year follow-up, the 
transplanted kidney is functioning well with a normal serum creatinine level 
of 1.2 mg/dl, and the patient has no worsening of peripheral vascular disease 
with ABI 1.28 (fi gure 2). We recommend that percutaneous intervention can be 
recommended for patients with TASC type B aortoiliac disease and the presence 
of an endovascular aortoiliac stent not be a contraindication to perform a renal 
transplantation.
Figure 1 Endovascular aortoiliac stent graft before renal transplantation.
Figue 2 Duplex ultrasonography transplanted kidney
POSTER BOARD NUMBER P1 – 185
DONOR AGE AFFECTS IMMEDIATE BUT 1099 
NOT LONGTERM SURVIVAL FOLLOWING KIDNEY 
TRANSPLANTATION
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy
1Cairo University, 2Cairo University, Department of Urology, 3Cairo 
University, Department of Clinical Pathology
Organ shortage has resulted in an increased use of elderly related donors 
(>55years) for kidney transplantation (RTx). The aim of this study is to 
re-examine, in a modern era of transplantation, the effect of donor age on 
outcomes following RTx. In addition, we compared the effect of old donor 
kidneys onoutcomes following transplantation between young and old 
recipients.
Methods: Data was collected in a prospective clinical database on 79 patients 
receiving live kidney transplantation between January 1998 and October 2005. 
Donor and recipient age were analyzed as continuous and categorical variables. 
Univariate and multivariate regression analysis were performed investigating 
donor and recipient age, ischemia time, recipient gender, hepatitis C infection, 
CMV status for both donor and recipients, year of transplantation,and original 
renal disease. Postoperative outcomes were assessed by development of 
acute tubular necrosis, length of hospital stay, postoperative serum creatinine, 
development of rejection, calcineurine drug toxicity, graft failure, and patient 
survival.
Results: As expected, postoperative creatinine was predicted by ischemia 
time. When the infl uence of donor and recipient age was examined, we found 
that an increased donor age was associated in univariate analysis with the max 
postoperative serum creatinine, calcineurine toxicity and degree of oliguria. 
This association held true in multivariate analysis for BUN,serum creatinine 
and GGT levels. Recipient age was associated in univariate analysis only 
with increased max ALT, an associationthat did not persist upon multivariate 
regression analysis. Combining older donor kidneys with young (<40 years) or 
old >55 years) recipients resulted in identical peri-operative outcomes. Graft 
and patient survival was identical between patients receiving from old or young 
donors. Combining old donors and old recipients did not result in worsened 
ong-tem survival.
Conclusion: The use of old donor kidneys for RTx is associated with increased 
indices of reperfusion injury and calcineurine toxicity in the immediate 
postoperative period. However, recipient survival is not affected by the age of 
the donor, and the age of the recipient receiving the older donor kidney does not 
affect short or long-term results. This study provides evidence for the safety of 
using older kidney grafts.
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NON HEARTBEATING KIDNEY DONATION AT GROOTE 1100 
SCHUUR HOSPITAL: RESULTS 2006-2007
E. Muller, D. Kahn
University of Cape Town
Background: A non heart beating kidney donation programme was started in 
January 2006 at Groote Schuur Hospital. The current head injury policy is to 
withdraw treatment in patients with irreversible brain damage and a Glasgow 
Coma Scale under 5T. The objective of the non heart beating policy is to 
address this group of patients as potential donors.
Method: After consent is given for organ donation, the patient is extubated 
while the surgeon who will do the procurement stands ready in theatre. 
If the patient has a cardiac arrest within a 2 hour time span, the patient is 
taken to theatre immediately after death and the organs are retrieved. If the 
patient does not arrest in that time span, the procedure is abandoned. After 
procurement the cold ischaemic time is kept as short as possible. Recipients 
with no previous transplants and low antibody status are used. Initially standard 
immunosuppression with Cyclosporin, Azathioprine and Medrol was used from 
day 1. Subsequently the policy in the unit has changed and Simulect induction 
therapy is now being used, with Cyclosporin started on day 3-5.
Results: In the time period between January 2006 and December 2007, 7 
referrals for non heartbeating kidney donation were made to the Transplant 
Coordinators at Groote Schuur Hospital. All the donors were male patients with 
an average age of 31. The cause of death was gunshot wounds in 3 cases, a 
stab wound in 1 case, suicide in 1 case and motor vehicle accidents in 2 cases. 
Consent for donation was given in 6 cases. Of the 6 cases, 2 did not arrest in the 
2 hour time span; 1 patient had an unexpected cardiac arrest before extubation, 
but was successfully procured in theatre within 30 minutes; and 3 patients 
arrested within the 2 hour period after extubation.
Of the 8 kidneys harvested, 2 kidneys could not be used because they were 
from a AB-blood group donor and there were no suitable recipients available. 
Six kidneys were transplanted with an average cold ischaemic time of 12 hours. 
Five patients required dialysis in the fi rst week, 4 in the second week, 2 in 
the third week and none in the fourth week post transplantation. Renograms 
were done on 5 patients in the fi rst week, 2 in the second week and 2 in the 
third week. Four of the patients required a biopsy in week 2 or 3 and 2 of 
these patients had subsequent treatment with pulsed Medrol. One patient had 
a wound infection as well as a post-operative Klebsiella pneumonia. Four 
patients were discharged on day 17, one on day 31 and one on day 63 after 
severe complications with sepsis and pneumonia. All patients had functioning 
grafts on discharge.
POSTER BOARD NUMBER P1 – 187
DGF RISK INDEX (ACCORDING SRTR) FAILS TO 1101 
PREDICT DGF REAL INCIDENCE IN A MONOCENTRIC 
EXPERIENCE WITH VERY OLD CADAVERIC DONORS.
E. Bertoni, M. Salvadori
Renal Unit Careggi University Hospital
The DGF Risk Index (0-18, with 0 being the lowest risk of DGF) was derived 
from an analysis of deceased donor renal transplants by SRTR and was based 
upon fi ve predictor variables independently associated with DGF: donor age, cold 
ischemia time, recipient race, cause of death and prior kidney transplantation.
Aim of this study was to verify whether the predicted probability of DGF fi t 
well in the case of very old kidney donors, as in our regional program.
Our regional program has the highest number of cadaveric donors in Italy and 
oneof the highest in Europe (40.9 actual donors p.m.p.). mostly because of old 
donors (>60yrs). We divided our donors in 3 periods according era (91-96 (A). 
97-02 (B). 03-08 (C) ) and evaluated for each period the incidence of donors 
>60 yrs, the predicted probability of DGF for such donors according the DGF 
Risk Index above mentioned and the observed DGF.
Overall we had 638 cadaveric renal transplantation, 126 in period A, 253 in 
period B, 259 in period C. Donors over 60 yrs were respectively 6.5%, 30%, 
39.8%; p<0.0001. The observed overall DGF incidence increased by era (19%, 
26.5%, 30.9%; p<0.01).Transplants with DGF Risk Index ³ 7 were respectively 
16/126, 107/253 and 128/259; p<0.0001. According to SRTR DGF Risk Index, 
a score ³ 7 bears a probability of DGF of 0.79 (CI 0.75-0.81). In our patients 
with such score the observed DGF rate was 37.5%, 32.7%, 42.9% according 
the period. DGF observed rate was almost the half of DGF predicted rate.
The DGF Risk Index do not predict the real DGF rate in the case of old donors. 
This fact may be ascribed to several factors. A regional allocation program may 
have several advantage with respect to a national one. Donor management in 
ICU, shorter cold ischemia time, higher surgeon skill in retrieval and transplant 
such kidneys, better management of immunosuppressant drugs cause that data 
from a large national cohort can’t fi t to a regional program.
POSTER BOARD NUMBER P1 – 188
COLD PRESERVATION INDUCES A STRONG 1102 
ADDITIONAL DAMAGE IN GRAFTS FROM BRAIN-DEAD 
DONOR RATS
B. Yard, S. Hoeger, K. Petrov, A. Reisenbuechler, R. Waldherr, P. Schnuelle, 
Department of Nephrology, University Hospital Mannheim, University of 
Heidelberg
Brain death and cold preservation are both alloantigen-independent risk factors 
which could deteriorate the graft. In the present study we addressed to what 
extent these alloantigen-independent factors could accelerate the hurtful effects 
of each other.
Experiments were performed in the allogeneic Fisher-Lewis rat model. Brain 
death (BD) was induced in F344 rats and duration of brain death was 6 hrs in all 
experiments. Either with or without 24 hours of cold preservation (Cp) grafts 
were transplanted into Lewis recipients. Living donor animals (LD) served as 
controls. In order to evaluate renal infl ammation, the transplanted kidneys were 
harvested after 10 days.
Combination of brain death and cold preservation accelerated renal infl ammation 
and the number of TUNEL-positive cells. Infi ltrating cells (ED1+ and MHCII+) 
and cytokines (e.g. VEGF, IL-10) were signifi cantly increased in grafts from 
brain dead rats which were subjected to Cp compared to directly transplanted 
grafts or grafts from LD donors.
The data indicate that cold ischemia time should be minimized in grafts from 
deceased donors to prevent drastic aggravation of graft injury.
POSTER BOARD NUMBER P1 – 189
IMPACT OF DONOR AGE IN A STANDARD DONOR 1103 
POPULATION ON THE PRESENCE OR ABSENCE OF DELAYED 
GRAFT FUNCTION IN OUR CENTER- RETROSPECTIVE 
ANALYSIS
M. Kandarpa1, S. Subramanian1, S. Aure1, K. Samindla1, R. Raja1, R. Zaki2, 
S-C. Kung1
1Kraftsow Division of Nephrology, Albert Einstein Medical Center, 2Division 
of Transplantation, Albert Einstein Medical Center
Delayed graft function (DGF) is a principal factor affecting one-year graft 
survival. It is well known from previous studies that kidneys from standard 
donors have better long-term outcomes.
We sought to fi nd out if donor age was an important determinant of DGF in the 
standard donor population pool.
We did a retrospective analysis of standard kidney transplant cadaveric donors 
and attempted to fi nd out if there was a correlation between the donor age and the 
presence or absence of DGF. We included all the patients who received a single 
kidney from a standard donor as defi ned by UNOS in our center from 2003 to 
2005. Patients who were lost to follow up, patients who received dual kidneys 
from standard donors and those that received bloc single organs were excluded.
Data from a total of 188 patients were included in this retrospective analysis. 
We found that there was a signifi cant correlation (p = 0.010) between a younger 
donor age and the absence of delayed graft function in the recipient. Of interest 
recipient’s age did not have a statistically signifi cant impact (p = 0.699) on the 
presence or absence of DGF.
This study suggests that kidney from a standard donor population, the donor 
age has a signifi cant impact on the presence or absence of DGF. The reason for 
this is unclear, further study is needed.
Correlation between Donor age and DGF
DGF (N=53)  No DGF (N=135)  P Value
Mean Age (±SD)  41.33 ± 12.33 35.60 ± 14.11 0.010
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CYSTIC CHANGES OF THE BREAST IN A FAMILY WITH 1104 
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 
(ADPKD) 
A. Ghafari
Urmia University of Medical Sciences
Background: There is no report of cystic changes of the breast in ADPKD. 
We describe three members of a family with multiple bilateral breast cysts in 
association with ADPKD.
Case Report: A 21-year-old girl referred to our center for evaluation of 
bilateral breast masses. On breast examination there were no dysmorphic 
or abnormal cutaneous findings, the patient had a 30×30×50 mm mass 
in her right and a 20×20×20 mm mass in her left breast. On the family 
history her paternal grandfather and her brother died due to renal failure. 
Her 59-year-old father and two sisters have done renal transplantation 
because of end stage renal disease due to ADPKD. One of her sisters was 
evaluated for bilateral breast masses two years after renal transplantation 
and multiple bilateral breast Cysts confirmed by mammography and 
ultrasonography. The patients refused aspiration of the cyst and accepted 
to be followed up and had no problem until now. Another transplanted 
sister has also same bilateral breast Cysts. With the known family history 
of ADPKD, an abdominal and breasts ultrasonography was obtained for 
possible association and showed renal cortical cysts, a small liver cyst and 
multiple bilateral breast Cysts leading to the diagnosis of asymptomatic 
ADPKD. Aspiration of breast cysts was considered but she refused it and 
accepted to be followed up. In her 6th month of follow-up cysts persist, 
inducing some pain in her right breast.
Conclusion: To our knowledge this is the fi rst report of familial occurrence of 
multiple bilateral breast Cysts in association with ADPKD.
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GRAFT FUNCTION IN HAND ASSISTED 1105 
RETROPERITONEOSCOPIC DONOR NEPHRECTOMIES WITH 
MULTIPLE ADHESIONS
M. Hossain, C. Kirby, J. Fronek
St George’s Hospital Department of Renal Transplantation
Introduction: In the absence of national guidelines, a retrospective audit 
was undertaken to review the current renal transplant immunosuppression 
regime. There was a perception that the new Tacrolimus target level (8–10ng/
ml) introduced in May 2007 was too low and more rejections observed. Our 
current maintenance protocol includes prednisolone, Mycophenolate Mofetil 
and Tacrolimus.
Methods: All transplant recipients (Feb 2003-Oct 2007) were reviewed for the 
highest C0 (trough) Tacrolimus level achieved within 7 days post-transplant. 
Tacrolimus level of 10ng/ml was considered a cut-of as it represents the highest 
target in the current protocol. Rejection episodes within the fi rst 10 days post-
transplant were recorded.
Results: This audit included 277 renal transplant recipients. Tacrolimus 
levels were ≥;10ng/ml (high group) in 223 (80.5%) and <10ng/ml (low 
group) in 54 (19.5%) recipients. Of the low group, 11 (20.4%) had rejection 
compared to 22 (9.9%) of the high group (p=0.03). There was a difference 
between recipients with high and low Tacrolimus levels with respect to GFR 
(MDRD) levels at one year post-transplant, with a mean of 36.7±21.2 in 
31 recipients with high Tacrolimus levels compared to 40.7±24.5 in 246 
recipients with low Tacrolimus levels (p=0.4). Lower GFR levels (31.1±22.5) 
in rejecting compared with non-rejecting (41.4±24.1) recipients observed 
(p=0.02).
Conclusion: Trough Tacrolimus level <10ng/mL was associated with more 
rejection episodes. The authors feel that the current Tacrolimus target, 8-10ng/
mL is low and needs revision. While rejection and high Tacrolimus level have 
adverse effects on the GFR at 1 year, this was not statistically signifi cant when 
comparing Tacrolimus level groups (sample size).
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DESFERRIOXAMINE DECREASES ISCHAEMIA 1106 
REPERFUSION INJURY TO THE KIDNEY
R. Stokes, K. Cheng, J. Gunton
Garvan Institute of Medical Research
A common phenomenon following whole kidney transplantation is primary 
non-function in recipients. This is due to hypoxia followed by reperfusion and 
various other stressors. Acute Tubular Necrosis (ATN) with damage to tubular 
epithelial cells is the mechanism which contributes to this acute deterioration 
of renal function. Desferrioxamine (DFO). an iron-chelator is a non-toxic 
stabilizer of HIF1-alpha, which is a transcription factor required for a protective 
response to hypoxic insult. We hypothesised that giving Desferrioxamine prior 
to organ retrieval would reduce the severity of ischaemia reperfusion injury by 
increasing protein levels of the anti-apoptotic transcription factor HIF-1alpha.
Aim: To investigate whether increasing Desferrioxamine (DFO) decreases 
renal ischaemia-reperfusion injury.
Methods: C57bl/6 mice were exposed to renal ischaemia-reperfusion injury. 
The insult was achieved by temporarily clamping the renal arterial supply to 
the left kidney for 7 minutes. One week later, the right kidney was surgically 
removed and saved for histological analysis. Two days later the mice were 
euthanased. Plasma was collected for urea and creatinine for analysis of residual 
renal function. The left kidney was also collected for histological analysis.
Two groups were used (1) control mice given a saline intraperitoneal injection 
prior to clamping and (2) mice given a single DFO injection intraperitoneally 
prior to injury.
Results: Desferrioxamine treated mice had markedly lower urea and creatinine 
levels than controls. Control mice had an average Urea of 40.6±10.8 versus 
DFO 9.7±2.0 (4.2-fold higher in controls, p<0.03). Control mice had an average 
Creatinine of 91.3±26.6 compared to DFO 14.4±3.1 (6.3-fold difference, 
p<0.03). Consistent with this, histological analysis showed markedly less 
damage and cell death in the DFO-treated mice compared to the controls. This 
data shows that DFO signifi cantly reduces the degree of kidney damage caused 
by ischaemia-reperfusion injury.
Conclusions: DFO markedly decreased ischaemia-reperfusion injury, and 
histological damage to the kidney. Increasing HIF1-alpha via DFO treatment 
of either the donor or the transplant recipient, or both may reduce the frequency 
and severity of ATN after kidney transplantation. This in turn has potential to 
improve human kidney transplant outcomes.
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DONOR RISK FACTORS FOR DELAYED 1107 
GRAFT FUNCTION (DGF) IN CADAVERIC RENAL 
TRANSPLANTATION (RTX) 
A. Amoroso1, R. Giraudi2, M. Meucci3, F. Fop2, P. Magistroni1, R. Bosco4, R. 
Giacometti1, S. Roggero1, P. Stratta5, G.P. Segoloni2
1Regional Transplantation Center of Piedmont, 2Nephrology, Dialysis 
and Transplantation- University of Turin, 3Hospital of Aosta, 4Regional 
Procurement Center- Hospital San Giovanni Battista, 5Nephrology and 
Transplantation- University of Novara
Introduction and Aims: Delayed graft function (DGF). defi ned as the need 
of dialysis within one week following rTx, is a common post-transplant 
complication. The usual rate of DGF is 10% to 40% and depends on many 
variables.
The purpose of this study is to evaluate donor risk factors for DGF, to determine 
which therapeutic strategies are correct to prevent DGF in the setting of donor 
management and to evaluated some pre-transplant recipient risk factors.
Methods: In this retrospective study, all primary deceased donor, between 
January 2000 and December 2006, were identifi ed in Oracle database of the 
Regional Transplantation Centre of Piemonte and Valle d’Aosta. We analyzed 
562 consecutive donors from 32 Intensive Care Units (ICU) and 1073 renal 
recipients transplanted in the two big Centres.
Regarding donor, DGF was compared with age, sex, cause of death, body 
max index (BMI). history of hypertension and diabete, renal function, days 
in ICU, central venous pressure, blood pressure, hypotensive period, cardiac 
resuscitation, use of catecholamine, cold ischemia time (CIT) and renal biopsy, 
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for donor over 50 yrs. In recipients, DGF was compared with age, sex, BMI, 
current and historical panel reactive antibodies (PRA%). number of transplants, 
patient hospidalization.
Results: The incidence of DGF is 30% and DGF is a signifi cant factor in 
long-term patient and graft survival (p<0,005). Predictive donor factors 
are: age (60,3±13,1 ys in DGF transplants vs 46,8±18,2 ys in non-DGF 
transplants, p<0,05). cause of death (cerebrovascular accident vs trauma, 
p<0,05). history of hypertension (58% vs 29%, p<0,05). renal function 
evaluated with Cockcroft formula (84,4±37,6 vs 99,1±39,5, p<0,05) and 
with renal biopsy (2,4±1,1 mean score vs 2,2±1,2, p<0,05). BMI in female 
gender (27,2±5 vs 23,3±3,7, p<0,05). No differences in the incidence of 
DGF is noted for: donor sex, hypotension, cardiac arrest, history of diabetes. 
Donor employement of catecholamines results in less incidence of DGF 
(p<0,05) 
As in literature, prolonged CIT is associated with increased DGF: (19,4 ± 4,9 
hours in DGF transplants vs 18,1± 5,2 in non-DGF transplants, p<0,05).
In recipients the occurrence of DGF is associated with age (54,1±10,7 ys 
in DGF recipients vs 48,5±12,9 ys in no DGF recipients). BMI in female 
gender (24,1±3,9 vs 22,4±3,6). current and historical PRA% (15,3±24,9% vs 
11,8±23,2%/5,8±17,1% vs 3,2±12,0%). previous transplants, prolonged patient 
hospitalization (31,8±30,6 vs 19,2±30,6, p>0,05).
Conclusions: DGF remains a common complication in cadaveric renal 
transplant and is important because it increases risk of graft loss and patient 
survival; in order to reduce incidence is mandatory a close cooperation between 
all the specialists involved in the multidisciplinary process of organ donation, 
in particular between anesthetists, immunologists, surgeons and nephrologists.
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MANAGEMENT AND LONG-TERM OUTCOMES OF 1108 
WOUND-HEALING COMPLICATIONS ASSOCIATED WITH 
RAPAMYCIN
T. Taner, P. Dean, N. Tran, M. Stegall
Mayo Clinic
Background: Steroid– and calcineurin inhibitor-sparing immunosuppression 
regimens are increasingly being used in allograft recipients to avoid long-term 
toxicities of these agents. Rapamycin, with its unique mechanism of action, has 
been used to facilitate these regimens. One of the well-documented side-effects 
of rapamycin is its interference with wound healing, mostly attributed to its 
inhibitory impact on fi broblast proliferation and angiogenesis. Although there 
is ample evidence for impaired wound healing in patients receiving rapamycin, 
little has been reported regarding the management and long-term outcome of 
these wounds.
Methods: Forty fi ve solid organ transplant recipients at our institution 
developed wound-healing complications while receiving rapamycin, as part of 
either de-novo or maintenance immunosuppression, between 1999 and 2006. 
A retrospective analysis of risk factors (obesity, diabetes, smoking history, 
hypoalbuminemia). treatment modalities and outcomes over a one-year follow-
up period was performed.
Results: Among 45 patients with one or more wound-healing complications, 
there were 26 incidences of cellulitis/superfi cial wound infection, 25 
superfi cial wound dehiscences, 12 incisional herniae, 10 perigraft fl uid 
collections and 8 fascial dehiscences. Body mass index (BMI) over 25 kg/
m2 was the single most common risk factor (n=36 or 80%); while serum 
albumin levels (mean=3.6 ± 0.5 g/dl). history of diabetes (n=18) or smoking 
(n=24) did not appear to be signifi cantly associated with development of 
complications. 25 patients required surgical intervention, while the rest were 
managed with traditional or vacuum-assisted dressing changes. Rapamycin 
was discontinued in 16 patients due to refractory wound complications. 
Whereas 37 patients (82%) had complete resolution, four had persistent 
healing problems at the end of one-year follow-up and four were excluded 
as they either lost follow-up or allograft was removed due to rejection. 
Among the former 37, only 12 (32%) required discontinuation of rapamycin. 
Furthermore, of the four non-healers, all had been off rapamycin for at least 
one-year at the time of last evaluation and were all noted to have BMI>25 
(mean 33.5 ± 8.3).
Conclusion: Wound-healing complications associated with rapamycin can 
be effectively managed with different modalities, although healing is often 
prolonged. In our series, treatment did not require discontinuation of rapamycin 
in most cases; conversely switching to alternative immunosuppressives did not 
always alter the outcome of complications.
POSTER BOARD NUMBER P1 – 195
EMBOLIZATION OF IATROGENIC ARTERIOVENOUS 1109 
FISTULA AFTER RENAL TRANSPLANT BIOPSY.
P. Schenker1, M. Bülles1, O. Vonend2, E. Mielke3, L. Heuser3, R. Viebahn1
1Ruhr-University-Bochum, Department of Surgery, 2Ruhr-University-Bochum, 
Department of Nephrology, 3Ruhr-University-Bochum, Department of 
Radiology
Backround: Biopsy related vascular injuries in renal transplants are rare,but 
they can lead to signifi cant clinical symptoms. Some case reports describes 
transcatheter embolization for treatment of arteriovenous fi stula (AVF) after 
renal transplant biopsy, other publications reports a high complication rate after 
embolization of AVFs. We evaluated the incidence of AVFs after renal biopsy 
and assessed the use of superselective
embolization (coiling) fot treatment.
Methods: A retrospective study was performed of all biopsy-related vascular 
injuries in renal transplants treated with transcatheter embolization over a 
period of 5 years .
Results: Between January 2002 and February 2007 434 renal biopsies were 
performed. Out of these, 25 patients with symptomatic AVFs were identifi ed. 
Indications for embolization were persistent macroscopic hematuria (n=9). 
large intrarenal pseudoaneurysm (n=4) and renal transplant dysfunction 
(n=12) after rejection was excluded. In all patients transcatheter embolization 
was performed with GDC or tornado microcoils. Mean time of angiographic 
intervention was 123 (71,5) minutes with a mean volume of contrast medium 
of 41,9ml. Technical success was achieved in 100% of cases. There where 
no serious complications. Only two minor complications were documented 
due to a coil application in the extern iliac artery and in a renal segmental 
artery, without haemodynamically relevance in both cases. Clinical symptoms 
disappeared in all patients. Serum creatinine levels decreased signifi cantly 
(p<0,05) in 18 of 25 (72%) patients 1 week after embolization.
Conclusion: Transcatheter embolization (coiling) is a safe and effective 
endovascular technique to treat biopsy-related vascular injuries in renal 
transplant patients.
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INFLUENCE OF DELAYED GRAFT FUNCTION AFTER 1110 
HAND ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMIES
R. Minnee1, W. Bemelman1, K. Donselaar van der Pant2, J. Booij3, 
S. ter Meulen2, I. ten Berge2, D. Legemate1, F. Bemelman2, M. Idu1
1Dept. of Surgery, Academic Medical Center, 2Dept. of Nephrology, Academic 
Medical Center, 3Dept. of Nuclear Medicine, Academic Medical Center
Introduction: The hand assisted laparoscopic donor nephrectomy (HALDN) 
is an alternative for a total laparoscopic donor nephrectomy. The presence of a 
hand in the abdomen has several advantages including the ability to use tactile 
feedback, less kidney traction, rapid kidney removal and shorter warm ischemic 
time. Shorter warm ischemia time is associated with a reduced frequency and 
severity of delayed graft function of the renal allograft. The objective of this 
study was to evaluate the results of the fi rst 200 consecutive HALDN in out 
institution and to investigate the occurrence of delayed graft function and 
associated factors.
Patients and Methods: All 200 consecutive living donors who underwent a 
laparoscopic donor nephrectomy between January 2002 and July 2007 were 
prospectively included in the study. Delayed graft function was defi ned as the 
need for dialysis within the fi rst postoperative week. 99mTc-MAG3 renography 
was performed in all donors prior to donor nephrectomy.
Results: The mean (± SD) donor operative time was 177 ± 41 minutes and 
the mean (± SD) hospital stay for donors was 4.8 ± 1.9 days. No conversions 
were necessary; intraoperative complications and postoperative complications 
occurred in 10 donors (5%). respectively 24 donors (13.5%). In 14 recipients 
(7.0%) there were urological complications i.e., obstruction in 10 and leakage 
in 4. One-year graft survival was 95%. Delayed graft function was diagnosed 
in 12 patients (6%). Two risk factors for delayed graft function were identifi ed: 
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lower counts per second on time to peak activity (Tmax; corrected for BMI) 
during renal donor scintigraphy (odds ratio 6.04, 95% confi dence interval (CI): 
1.24-29.45) and multiple renal veins (odds ratio 15.33, 95% CI: 2.96-79.02).
Conclusion: HALDN is a safe procedure regarding donor morbidity rates 
and graft survival. The correlation between low counts per second on Tmax 
during renal donor scintigraphy and delayed graft function may represent 
hyperfi ltration injury of a relatively small donor kidney. When renal donor 
scintigraphy shows asymmetric function between both kidneys, one should 
keep in mind that transplanting a kidney with low counts per second op Tmax 
bears an increased risk of delayed graft function.
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SCREENING FOR FUNCTIONAL ASYMMETRY IN 1111 
POTENTIAL LIVING KIDNEY DONORS
N. Suh, H. Lau, H. Pleass, B. Nankivell, P. O’Connell, J. Chapman, R. Allen, 
B. Ryan
Westmead Hospital
All potential living renal donors are thoroughly and systematically assessed 
to ensure the safety of the donor and the recipient prior to transplantation. 
The means of assessment varies according to local practice, however, much 
emphasis is placed on anatomical factors when determining which kidney is to 
be donated. As such, procurement of the left kidney is preferred by surgeons. 
We have reviewed our experience of routine assessment for renal functional 
asymmetry with Tc-99m DTPA renal scintigraphy in 124 consecutive live 
donors between 2003 and 2007 at our transplant centre. We found that in 13% 
of our donors, renal function was signifi cantly asymmetrical and that the left 
kidney showed greater function. We believe that routine renal scintigraphy 
provides a more comprehensive profi le of the potential donor whose altruistic 
intentions should not be rewarded by harm.
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A SYSTEMATIC APPROACH TO MINIMIZING WOUND 1112 
PROBLEMS FOR DE NOVO SIROLIMUS TREATED KIDNEY 
RECIPIENTS.
S.M. Flechner, H.Y. Tiong, A. Wee, L. Zhou, B. Lane, B. Mastroianni, 
K. Savas, D. Goldfarb, C. Modlin.
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 
Cleveland, OH, USA
Purpose: Posttransplant lymphoceles and wound healing problems are reported 
with greater frequency in kidney recipients given de novo sirolimus. We report 
a program to reduce these problems based on the use of patient selection; closed 
suction drains, and altered wound closure techniques.
Methods: Consecutive series of adult kidney-only recipients given antibody 
induction followed by de novo sirolimus, mycophenolate mofetil, and steroids 
were compared. Group 1- 103 patients transplanted with a weight restriction <32 
kg/m2; retroperitoneal closed suction drains placed at surgery (Jackson-Pratt or 
Blake); multilayer non-absorbable sutures, and no loading dose of sirolimus. 
Sirolimus was introduced day 0-5 at 5mg. Group 2- A control group of 204 patients 
were transplanted, many with BMI >30 kg/m2, with no drains, and various suture 
techniques. All records and imaging studies were reviewed for delayed wound 
healing and fl uid collections greater than 3.0 cm after drain removal.
Results: There was no signifi cant difference in recipient demographics 
between Group 1 and 2 groups, including mean age (47.8 vs. 48.4). BMI 
(25.7 vs. 26.6). males (63.1% vs. 68.1%). whites (69.9% vs. 78.9%). deceased 
donors (50.5% vs. 50%). Retransplants (8.7% vs. 7.3%). and diabetics (27.9% 
vs. 28.4%). Median day drain removal was 18. There was a signifi cant (P 
<0.0001) reduction in lymphoceles identifi ed, treated, and treated by surgery 
in patients with closed suction drains (Table 1). In addition there was a 
signifi cant reduction in total (P=0.0054) and non-operative (P=0.0095) wound 
healing problems. Multivariate analysis demonstrated a dramatic reduction in 
lymphoceles in drained patients (OR 0.33; 95%CI .181-.596; p<.0001); while 
acute rejections (OR 3.14). DGF (OR 1.54). and age (OR 1.16) increased the 
risk. Similarly, there was a signifi cant reduction in all wound healing problems 
in drained patients (OR 0.48; 95%CI .236-.997; p<.005).
Conclusions: A program of patient restriction by BMI, closed suction drains, 
altered surgical technique, and no loading dose of sirolimus dramatically reduces 
the incidence of lymphoceles and wound problems for patients starting de novo 
on sirolimus based immunosuppression. Using this program wound healing 
problems are similar or less than that reported with other immunosuppressive 
combinations.
Number (%) Group 1 Drained
N=103 (%) 
Group 2 Undrained
N=204 (%) 
Totals
N=307
P Value
Lymphocele identifi ed 23 (22.30) 95 (46.7) 118 (39.3) 0.0002
 Total treated 5 (4.8) 50 (24.5) 55 (18.3) <0.0001
 Operative drainage 2 (1.9) 29 (14.2) 31 (10.3) <0.0001
Wound Problems Total 8 (7.8) 40 (19.6) 48 (15.6) 0.0054
 Non Operative 3 (2.9) 29 (14.2) 32 (10.4) 0.0095
 Operative repair 5 (4.8) 11 (5.4) 16 (5.2) 0.76
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HAND-ASSISTED RETROPERITONEOSCOPIC 1113 
DONOR NEPHRECTOMY: CLINICAL OUTCOMES OF 170 
CONSECUTIVE CASES AND COMPARISON WITH OPEN 
DONOR NEPHRECTOMY
N. Ichimaru1, Y. Kakuta1, T. Abe1, M. Okumi1, R. Imamura1, T. Yoshioka2, N. 
Fujimoto3, Y. Isaka1, S. Takahara1, A. Okuyama1
1Osaka University, 2Sumitomo Hospital, 3Osaka Koseinenkin Hospital
Introduction: Although the advent of laparoscopic donor nephrectomy has 
had a positive effect on the donor pool, there is still some concern about the 
increased morbidity and safety of the laparoscopic donor nephrectomy.
Aims: To determine whether hand-assisted retroperitoneoscopic donor 
nephrectomy (RDN) is a safe and effective procedure, the clinical results of 
RDN were compared with that of ODN.
Patients and Methods: From September 2001 to February 2008, RDN was 
performed in 170 consecutive patients at our hospitals. All patients were followed 
longitudinally with offi ce visits. Perioperative and postoperative data for these 
RDNs, including postoperative kidney graft function, operative time, blood loss, 
and complications, were compared with those of open donor nephrectomies 
(ODNs) performed between January 1999 and December 2001.
Results: Conversion to open surgery was needed in four cases (renal vein 
injury in 1, lumber vein injury in 1, peritoneum injury in 1, and diaphragm 
injury in 1). The average warm ischemia times were 3.6 minutes (range 1.0-8.5 
minutes) and 2.9 minutes (range 2.3-5.5 minutes) in the RDN and ODN groups, 
respectively (P = NS). The mean donor operative time for RDN (238 min) 
was signifi cantly longer than that for ODN (192 min, P < 0.01). The mean 
blood loss for RDN (158ml) was signifi cantly less than that for ODN (280ml) 
(P < 0.01). No transfusion was needed. There was no signifi cant difference 
between the groups in number of doses of analgesics administered after the 
operation. Perioperative and early postoperative major complications occurred 
in 12 recipients (7%) in the RDN group and consisted of lymphocele in 6 (4%). 
ureteral complication in 3 (2%). and delayed graft function in 3 patients (2%). 
All of these complications were treated successfully. No postoperative major 
complications were occurred in donors. The mean recipient serum creatinine 
concentrations did not differ among the groups (P = NS).
Conclusions: The RDN is a safe and effective procedure for donors, and 
recipient fs graft function is similar to that after ODN. Although the benefi ts of 
RDN have been demonstrated, further long-term studies of graft function and 
patient survival are needed.
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SITE AND TIMING OF HAND ASSISTANCE ARE KEYS 1114 
FOR SUCCESSFUL RETROPERITONEOSCOPIC LIVE DONOR 
NEPHRECTOMY
M. Yashi1, T. Yagisawa2, A. Nukui2, N. Ishikawa2, N. Miyamoto2, Y. 
Sakuma2,T. Fujiwara2, O. Muraishi1
1St. Luke fs International Hospital, 2Jichi Medical University Hospital
Introduction: Hand assistance in laparoscopic surgery has been widely applied 
method for live donor nephrectomy, because the meticulous fi ngers action 
enables to dissect the renal vessels easier and to control accidental bleeding. 
In addition, reducing warm ischemia time (WIT) by a rapid extraction through 
the hand-port device is an important advantage. However, when used in the 
retroperitoneal approach, the hand movement is limited due to the small 
retroperitoneal space. We introduce our method for the hand assistance to 
realize an effective retroperitoneoscopic surgery.
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Methods: We performed 57 retroperitoneoscopic live donor nephrectomies, 
including 14 right-sided and 43 left-sided procedures according to the basic 
principle of transplantation, namely, leaving the better-functioning kidney 
in the donor. The hand port device (LapDisc) was placed through a 6.5 cm 
incision vertically extending the inner port sequentially after the kidney and 
renal vessels almost mobilized by pure retroperitoneoscopy using 3 ports. 
Thereafter, the ureter which is just placed under the hand port is completely 
dissected by an open procedure. The renal vessels were transected using 
EndoGIA under the pure retroperitoneoscopy and the kidney removed through 
the hand port.
Results: Hand-assisted retroperitoneoscopic surgery was accomplished 
in 55 of the 57 donors (96.5%). The median operative time, WIT, blood 
loss, and renal vein length were 244 minutes, 179 seconds, 130 ml, and 
18 mm, respectively. No delayed graft function was observed. Histological 
validation revealed only minor cortical damages: bleeding or ischemia, in 
11 kidneys (19.3%). which did not have any harmful infl uences on graft 
function.
Conclusions: The technical and functional outcomes were acceptable, and our 
strategic hand assistance made the surgery easier and safer. The site and timing 
of hand assistance we devised more than make up for the disadvantage of a 
small working space in retroperitoneoscopic procedure.
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EVALUATION OF VOLUME OVERLOAD AND BODY 1115 
COMPOSITION IN HYPERTENSIVE RENAL TRANSPLANT 
PATIENTS
A. Saxena, R.K. Sharma, A. Gupta, N. Prasad, A. Kual
Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical 
Science
After transplantation, it is expected that the transplanted kidney would restore 
near-normal renal function and correct nutritional abnormalities arising from 
pre-transplant renal insuffi ciency. Therefore, evaluation of nutritional status 
and body composition is a must in post transplant patients. 
Objectives: To evaluate body composition, volume expansion, relationship 
of hypertension with body water, nutritional depletion and dry weight in post 
renal transplant patients using bioelectrical impedance analysis (BIA).
BIA parameters of 100 well nourished, clinically non edematous post 
transplant patients (TP) were compared with 16 male patients on maintenance 
hemodialysis (MHD) and 60 healthy controls. BIA parameters included dry 
weight, total body water (TBW). extracellular water (ECW). intracellular water 
(ICW). extracellular fl uid (ECF). plasma, interstitial fl uid (IF). fat free mass 
(FFM). fat mass (FM). body cell mass (BCM). muscle mass (MM). protein, 
mineral, calcium, glycogen, potassium.
Results: There was signifi cant difference in all the parameters of TP and 
control and TP and MHD patients.
TP and Controls: TP had signifi cantly low body weight, BMI and fat compared 
to controls. TP had signifi cantly higher ECF, plasma and IF. Because of higher 
ECW fat free mass. There was signifi cant difference in the systolic (120.8±13.0 
and 116.2±6.6) and diastolic (80.5±8.0 and 77.0±3.0) blood pressure.
TP: Dry weight derived from BIA was signifi cantly less than the actual weight 
of TP (p=0.000). Transplant patients were divided into groups based on GFR 
(low GFR <40 ml/min n=33 and High GFR >40 ml/min n=67). Patients 
with low GFR had low body weight (53.0/61.5). dry weight (50.1/58.7). 
BCM (21.3/23.1). FFM (42.8/48.3). TBW (30.0/34.4). ICW (46.7/51.3). 
MM (19.8/23.4). protein (9.1/10.1). mineral (3.1/3.6). ECM (21.3/23.1). 
potassium (101.3/119.5). calcium (855/987). glycogen (388/438.7) and ECS 
(4.36/5.01) compared to patients with higher GFR. Patients with low GFR 
had higher ECW. When patients were grouped according to blood pressure 
(controlled BP<120/80 n=47, High BP >120/80 mmHg n=53) it was found 
that patients with controlled blood pressure had higher GFR (47.2 ml/min 
p=0.001) than those with high BP (40.80ml/min). To fi nd out relationship 
between fl uid overload & requirement for antihypertensive drugs (AHD). 
patients were divided into two groups (one AHD n=32, more than one AHD 
n=68). It was found that patients on one AHD had signifi cantly lower TBW 
(30.9±3.9/34.1±4.3). ECW (15.1±2.9/17.2±2.53). ICW (15.7±3.4/17.4±4.9). 
plasma (3.2±0.62/3.6±0.52) and IF (11.2±2.19/11.2±1.84) than those on more 
than one AHD.
MHD and TP: MHD patients had signifi cantly higher (p=0.000) TBW, ECW 
ECW/TBW, ECW/ICW. ECF, PF, IF, FFM but low ICW and fat.
Conclusion: In clinically non-edematous transplant patients, nutritional defi cit 
and volume expansion can be picked up by BIA. Transplant patients should be 
evaluated for expanded volume for better control of blood pressure using BIA. 
Since there is a close
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MODIFIED SURGICAL TECHNIQUE IN LIVING KIDNEY 1116 
TRANSPLANTATION
S.C. Park1, K.H. Yang2, Y.S. Won1, I.S. Moon1
1Kangnam St. Mary’s Hospital, The Catholic University of Korea, 
2Sanggyepaik Hospital, College of Medicine, Inje University
Usually, the transplanted kidney is placed into the right retroperitoneal iliac 
fossa through a right abdominal surgical skin incision. The skin incision may 
be oblique or inverted J-shaped known as the ¡°hockeystick¡±. Roughly, 
oblique or curvilinear incision, parallel to the inguinal ligament, known 
as the ¡°pelvic Gibson incision.¡±, which is also extended medially to the 
midline, just above the pubis is used. The most common incision for kidney 
transplantation in our center is a paramedian incision which is parallel to 
rectus abdominis muscle and extends medially to the midline, just above 
the pubis symphysis (¡°hockeystick¡±). which is recent years has become 
increasingly popular for kidney transplantation. Nowadays, the minimal 
invasive surgery is popular in various fi eld of surgery and the patients who 
concerned the cosmetic effect are increasing. We make the skin incision 
at lower right abdomen from laterally below the anterior superior iliac 
spine to the midline just above the pubis in fi ve young unmarried women 
whose BMI were below 25 and there were no anatomical variation. The 
lower transverse abdominal skin incision compared with the usual hockey-
stick incision suggested more favorable cosmetic result and more easily 
hidden and there is no difference in postoperative various factors including 
clinical pathway of renal function comparing with other routine renal 
transplant patients.
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THE OUTCOME OF RENAL TRANSPLANTATION IN 28 1117 
PTIENTS RECEIVING KIDNEYS WITH MULTIPLE RENAL 
VESSELS
A. Mehrsai, G. Pourmand, M. Nikoobakht, M. Taherimahmoudi, 
H. Wahhabaghai
Urology Research Center,Tehran University of Medical Sciences
Objectives: To study the renal Transplantation outcomes in the patients that 
received kidney from kidneey donor with multiple renal vessels, the receipient 
were followed for 16 years.
Materials & Methods: In a 16 years period (1989-2005). 1000 renal 
transplantation was carried out at our center. In 28 cases the transplanted kidney 
had multiple renal vessels. The patients had been followed up for average of 8 
years. Serum creatinine level, vascular complications, graft survival and patient 
survival had been studied .
Results: In 3 cases grafted kidneys had 3 arteries and one vein, 3 cases had 2 
arteries and 2 veins, one case had 2 arteries, one vein and 2 ureters and fi nally 21 
cases had 2 arteries and one vein. The mean cold ischemic time was 78 minutes 
(50-143). The surgical technique employed, Included: 1- Anastomosis of graft 
arteries and veins followed by anastomosis of common trunk to recipient iliac 
artery and vein.2- Anastomosis of graft arteries or veins separately to recipient 
iliac vessels. No venous or arterial thrombosis occurred. 4 cases developed 
acute rejection managed successfully with Antithymocyte Globulin (ATG) 
.No graft loss was seen. Mean creatinine level was 1.4 mg/dl. 2 patients were 
expired due to sepsis and myocardial infarction. The grafted kidneys functioned 
normally in both cases at the time of death .
Conclusions: Multiple arteries or veins had no adverse effect on graft survival. 
Hence due to shortage of organ donors, Using kidneys with multiple vessels 
are justifi ed.
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VENOUS THROMBOEMBOLISM IN LIVE KIDNEY 1118 
DONORS – A PROSPECTIVE STUDY
J. Wadström, A. Biglarnia, M. Johansson, D. Bergqvist
Department of Surgery, Uppsala University Hospital
Aim: To evaluate risk factors for venous thromboembolism (VTE) and deep 
vein thrombosis after living donor nephrectomy in a centre using extensive 
preoperative screening and perioperative venous duplex scan.
Material and Methods: In 130 consecutive living kidney donors (laparoscopic 
105, open 25) thrombophilia screening and pre- and postoperative 
ultrasonographies were performed. Donors were followed prospectively for at 
least 3 months. All donors received prophylaxis with the low molecular weight 
heparin enoxaparin and compression stockings. Donors with increased risk 
received the double dose of enoxaparin and the prophylaxis was continued for 
6 weeks. Donors with venous thrombosis at discharge duplex also received 
prolonged prophylaxis.
Results: The frequency of thrombophilia was similar to what can be expected 
in the Swedish population (four with factor V Leiden, one each with protein 
S defi ciency, prothrombin gene mutation and anticardiolipin antibodies). 
Preoperative duplex was normal. Three donors had small postoperative deep 
vein thrombosis. Twelve donors (9,2%) received an intensifi ed and prolonged 
prophylaxis. No further thromboembolic complications developed in three 
postoperative months.
Conclusion: With the present protocol for preoperative evaluation, 
perioperative duplex screening and prophylaxis, the risk of postoperative 
venous thromboembolism is low after living donor nephrectomy. Given that 
9,2% had risk factors or developed deep vein thrombosis and the extraordinary 
situation where an operation is performed on a healthy person who has no 
therapeutic benefi t and the low incidence of VTE in the present study, we 
recommend the presented approach to be implemented more broadly and that 
further studies should be performed in larger cohorts.
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VASCULAR PROTECTION OF ISCHEMIC 1119 
POSTCONDITIONING IN ACUTE RENAL ISCHEMIA-
REPERFUSION INJURY BY UP-REGULATION EXPRESSION 
OF DECAY-ACCELERATING FACTOR
T. Tang1, W. Wang2, S. Cui1, P. Zhang2, L. Zhang2, H. Bu2
1Affi liated Hospital of North Sichuan Medical College, NanChong, P. 
R. China, 2Key Laboratory of Transplant Engineering and Immunology, 
Ministry of Health, West China Hospital, Sichuan University, Chengdu, P. R. 
China
Introduction: Complement activation during ischemia-reperfusion injury (IRI) 
is an important reason that impacts vascular endothelium integrity after kidney 
transplantation. Recent evidences showed that ischemic postconditioning 
(Pos-con) may obviously lessen vascular injury on the acute renal IRI. We 
explored the hypothesis that the Pos-con protects vascular endothelium, at least 
in part, through inhibiting down-regulation of complement inhibitors decay-
accelerating factor (DAF). CD59, or/and membrane cofactor protein (MCP).
Methods: After right nephrectomy, the acute IRI model was established as 
described before. 30 Wistar rats were randomized into 3 groups: IRI, Pos-
con (6 cycles of 10 sec ischemia and 10 sec reperfusion before reperfusion) 
and control. After 24h reperfusion without control, the blood samples were 
taken through the vena cava and the renal samples were taken too. The mRNA 
and protein expression of DAF, MCP and CD59 were examined by real-time 
PCR, western blot and immunohistochemistry, and C3d deposition in tissue 
will be detected by immunofl uorescence, further vascular endothelial integrity 
destruction was also observed by histological examination. In addition, 
blood urea nitrogen (BUN) and serum creatinine (Scr) values were measured 
commercially by quantitative colorimetric assay by Antec Diagnostics.
Results: Compared with Pos-con and control, the mRNA transcription/protein 
expression of DAF and C3 deposition in the IRI group were signifi cantly 
decreased and increased evidently, respectively (P<0.05, n=10). and the BUN/Scr 
of IRI group were increased remarkably (P<0.01, n=10). However, no statistical 
difference of DAF expression, C3d deposition and BUN/Scr values between Pos-
Con and control has been found. Moreover, the injury of kidney was attenuated and 
the pathological scale was reduced signifi cantly in the Pos-Con group compared 
with IRI group (P<0.05, n=10). Of interest, the mRNA and protein expression of 
MCP and CD59 among all groups have not statistical difference.
Conclusion: These observations provide evidence that down-regulation of 
DAF, not CD59 or MCP, plays a key role in complement-mediated vascular 
endothelium dysfunction resulted by IRI, and this cytolysic effect would be 
inhibited, at least in part, through Pos-Con.
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MODIFIED APPROACH TO MINI-INCISION LIVE 1120 
DONOR NEPHRECTOMY: A SAFE PROCEDURE THROUGH A 
SMALLER INCISION
L. Wales1121 1, N. Hakim1, T. Dosani1, N. Mustafa1, R. Canelo1, V. Papalois1
1The West London Renal And Transplant Centre, 2The West London Renal 
And Transplant Centre, 3The West London Renal and Transplant Centre, 4The 
West London Renal and Transplant Centre, 5The West London Renal and 
Transplant Centre, 6The West London Renal and Transplant Centre
Objective: To determine operative parameters and complications, using a 
modifi ed approach to mini-incision live donor nephrectomy.
Methods: 161 consecutive live donor procedures performed at the West 
London Renal and Transplant Centre between October 2005 and January 2008, 
using a modifi ed approach to open mini-incision live donor nephrectomy, were 
included in the study. Patient demographics, intra-operative parameters and 
post-operative complications were prospectively recorded.
Results: Mean donor age was 43.2±11.6 years, with an average body mass 
index of 27.1±5.1. Right-sided donor nephrectomies were performed on 
16 patients (9.9%) and 26 donors (16%) were found to have multiple renal 
arteries. Median incision length was 7.0cm (range, 3.5-15cm). Average 
operative time was 120 minutes (range, 50-265 minutes). with a median blood 
loss of 120mL (range, 20-500mL) and an average warm ischaemia time of 4.3 
minutes (range, 1.5-10 minutes). Three patients (1.9%) required peri-operative 
blood transfusions. There were no other intra-operative complications, no re-
explorations and no donor deaths. Ten patients (6.2%) developed minor post-
operative complications, but no patients developed chronic wound pain, over 
a median follow-up period of 14 months (range, 1-28 months).
Conclusion: This prospective series demonstrates that a modifi ed approach to 
open mini-incision live donor nephrectomy can result in a smaller incision length 
whilst maintaining patient safety, and has few post-operative complications.
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VASCULAR RECONSTRUCTION PRIOR TO KIDNEY 1122 
TRANSPLANTATION IN PATIENTS WITH SEVERE 
ATHEROSCLEROSIS
J. Szmidt, Z. Galazka, S. Nazarewski, T. Grochowiecki, T. Jakimowicz, 
B. Solonynko
Department of General, Vascular And Transplant Surgery, Medical University 
of Warsaw, Poland
Atherosclerosis or severe calcifi cation of recipient iliac arteries is considered 
contraindication for kidney transplantation. On the other hand it is common 
in end stage renal disease patients on dialysis. Nowadays, since renal 
transplantation is increasingly successful, extended indications are accepted 
on the waiting list including patients with severe atherosclerosis. This requires 
vascular procedure prior or during kidney transplantation.
The aim of the study was to present our experience with aorto-iliac reconstruction 
prior to kidney transplantation.
There were eight atherosclerotic, uremic patients refereed to our Department as 
a candidates for kidney transplantation. All were refused waiting list inclusion 
due to occlusive lesions of iliac arteries or distal part of the aorta. There were 
7 male and 1 female, age 45-62 years, all current or past smokers. Preoperative 
assessment consisted of Doppler ultrasound and angio-CT scan.
Reconstruction of blood supply was performed with aorto-bi-iliac in 5, aorto-
bi-femoral in 2 and ilio-femoral graft in 1 patient under general anesthesia. 
There was no major postoperative complications. Patients were discharged and 
placed on a special waiting list.
Six of them received kidney allograft including one living-related 
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transplantation. All procedures were made with transplanted kidney artery 
anastomosis to the side of the prosthesis. No patient developed signs of arterial 
graft infection. In postoperative period there was no arterial or renal allograft 
related complications except delayed kidney function in 2 cases.
Remaining two patients are still on waiting list 4 and 6 months after vascular 
procedure.
Adequate vascular reconstruction in uremic patients with severe atherosclerotic 
lesions of iliac vessels allows safe and durable kidney transplantation.
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DETECTION OF LOCAL METABOLIC CHANGES AFTER 1123 
INCREASING RENAL ISCHEMIA IN PIGS
A.K. Keller1, T.M. Jorgensen2, L.H. Olsen2, L.B. Stolle3
1Institute of Clinical Medicine, Aarhus University, Denmark, 2Department 
of Urology, Aarhus University Hospital, Denmark, 3Department of Plastic 
Surgery, Aarhus University Hospital, Denmark
Purpose: Vascular complication after renal transplantation causing initially 
only partial renal ischemia can be diffi cult to discover in time to save the 
kidney. Our aim was to design an animal model of gradually increasing renal 
ischemia and investigate whether microdialysis could detect the subsequent 
metabolic changes.
Microdialysis is based on simple diffusion over a semipermeable membrane. 
It is a minimally invasive technique for monitoring of local metabolism or 
drug distribution. Clinically it is used in reconstructive surgery for detection of 
postoperative ischemia in free microvascular fl aps.
Materials and methods: Eight pigs of 37 kg were used. Two microdialysis 
catheters were placed, one in the lateral renal cortex and one just outside the renal 
capsule. During steady state conditions, baseline measurements were obtained for 
two hours. Then fi ve repeated injections of 100μ-Polyvinyl alcohol (PVA) particles 
were administered through an angiographic catheter placed in the renal artery in 
order to make a gradual decrease of the renal arterial blood fl ow, monitored by 
a fl ow probe. There was one hour between each injection. Every thirty minutes 
the microdialysis samples were collected and analyzed for glucose, glutamate, 
glycerol and lactate. GFR was continuously estimated by 51Cr-EDTA.
Results: GFR, renal blood fl ow and all metabolites measured by microdialysis 
remained stable during baseline (ANOVA: p>0.05). The fi rst injection of 26 
mg PVA particles caused within thirty minutes a reduction of the blood fl ow to 
40±13% of the baseline fl ow (t-test: p<0.001 vs. baseline) and signifi cant changes 
of cortical lactate and glutamate as well as extracapsular glutamate as indicators 
of the resulting ischemia. Cortical glucose changed 60 minutes after baseline.
Furthermore we demonstrated a strong correlation between decrease in renal 
blood fl ow and change in concentrations of metabolites. This was in particular 
seen when the fl ow is depicted on a logarithmic axis. The association was 
strongest for lactate (R=0.95, p<0.001). glucose (R=0.94, p<0.001) and 
glutamate (Cortical: R=0.93, p<0.001; Extracapsular: R=0.93, p<0.001).
Conclusion: We present a model of acute stepwise reduction of the renal blood 
fl ow by injection of PVA particles and demonstrate that microdialysis can be 
suitable for monitoring of local metabolic changes in the kidney. An early 
warning of ischemia is provided – with possible improvement of survival of 
transplanted renal grafts suffering from postoperative ischemia.
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MICRODIALYSIS FOR DETECTION OF 1124 
POSTOPERATIVE ISCHEMIA IN EXPERIMENTAL RENAL 
TRANSPLANTATION
A.K. Keller1, T.M. Jorgensen2, K. Ravlo1, T.K. Nielsen1, L.H. Olsen2, 
L.B. Stolle3
1Institute of Clinical Medicine, Aarhus University, Denmark, 2Departmant 
of Urology, Aarhus University Hospital, Denmark, 3Departmant of Plastic 
Surgery, Aarhus University Hospital, Denmark
Purpose: Vascular thrombosis is a feared and devastating complication 
after renal transplantation because it most often leads to loss of the renal 
graft. Furthermore it can be diffi cult to monitor the primary non functioning 
kidney graft – a situation which is clinically important in children. A previous 
published article has shown that microdialysis is a fast and reliable detector of 
renal ischemia in a porcine model. However this has only been demonstrated 
in a normal healthy kidney in situ. The aims of this study was thus to make a 
model of transplantation in order to see how much warm and cold ischemia 
would affect the subsequent microdialysis measurements after reperfusion. 
Furthermore we evaluated if the technique could still detect induced 
postoperative ischemia.
Materials and methods: Sixteen pigs with a weight of 57±3 kg were used. In 
the left kidney one microdialysis catheter was placed superfi cially in the lateral 
renal cortex and one was fi xated with a 5-0 suture outside the kidney, on the 
lateral side of the renal capsule. After two hours of baseline measurements the 
kidney was removed and subjected to warm ischemia for 5 minutes and cold 
ischemia for 145 minutes. The kidney was subsequently reanastomosed end 
to end in situ, reperfused for fi ve hours and randomized into two groups: one 
subjected to total occlusion of the renal artery and one group with controls. 
After additionally two hours the experiment ended. Throughout the study the 
local renal metabolism was monitored by microdialysis, with samples changed 
every thirty minutes.
Results: One pig from the controls was excluded due to thrombosis of the 
renal artery 240 minutes after reperfusion. In this case the microdialysis 
measurements showed early detection of ischemia.
Mean arterial blood pressure, temperature, systemically glucose and lactate 
did not differ signifi cantly between the two groups during the 690 minutes the 
experiment lasted (ANOVA, p>0.15).
Signifi cant changes of glucose, glutamate, glycerol and lactate in the renal 
cortex and of glutamate and glycerol on the renal capsule were seen during 
induced postoperative ischemia compared to the period of reperfusion, while 
no changes were seen over time in control pigs. (ANOVA on Ranks; p<0.05 for 
ischemia and p>0.05 for controls) 
Conclusion: In a porcine model of renal transplantation we found microdialysis 
a reliable and early detector of induced postoperative ischemia, while no 
metabolic changes were observed in the control group without ischemia. In the 
future, microdialysis may be a valuable tool for postoperative observation of 
transplanted kidneys in selected cases.
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INFLUENCE OF PERIOPERATIONAL ACID-BASE 1125 
BALANCE AND ION DISORDERS ON GRAFT FUNCTION IN 
KIDNEY TANSPLANTATION
K. Tejchman1, L. Domañski2, T. Sulikowski1, M. Romanowski1, J. Sieñko1, K. 
Ciechanowski2, M. Ostrowski1
1Department of General Surgery And Transplantation, Pomeranian Medical 
University, 2Department of Nephrology, Transplantology and Internal 
Diseases, Pomeranian Medical University
The study&#8217;s purpose was analysis of infl uence of acid-base and ion 
balance disorders during 30 minutes of reperfusion and 4 hours after operation 
on graft early function in patients after kidney transplantation.
The examined group consisted of 53 recipients: 32 men, 21 women in 
average age 47&#61617;14 years. Arterialised blood samples for analysis 
in each patient were taken 9 times during operation using catheter placed in 
arteriovenous fi stula: 0, 1, 3, 5, 10, 15, 20, 25, 30 minutes after unclamping 
renal vessels and fi ngertip capillary blood 1, 2, 3, 4 hours after last stich 
on the wound was placed. Every of those 13 measurements consisted 
data about temporary acid-base balance state, which was evaluated on the 
basis of common parameters: pH, pCO2, [HCO3-], BE, sO2c and TCO2. 
9 intraoperational test were extended by ion concentrations (Na, K, Ca). 
glycaemia, hematocrite, lactates concentrations and vital parameters 
(expiratory pCO2, O2 saturation, heart rate, blood pressure, tidal volume 
and rate) recorded with Ohmeda 5250 RGM and Dräger Sulla 909V/
Julian apparatus. Blood samples were analysed using Corning 278 and 
248 apparatus. Assay of graft function was based on parameters of urine 
output, serum concentrations of creatinine, urea, uric acid and ions (Na, 
K). which were analysed during postoperative hospitalization and 1-year 
observation. Additional parameters like blood morphology, urinalysis, 
serum concentration of glucose, aminotransferases, ions (Cl, Ca, P) were 
also taken into consideration. Statistical signifi cance was analyzed using 
repeated-measures ANOVA followed by Tukey post-hoc test as well as U 
Mann-Whitney&#8217;s and Spearman&#8217;s ranges correlation tests.
The analysis showed increasing parameters of metabolic acidosis with 
compensative blood and expiratory pCO2 growth. Dynamics proved to be 
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repeatable phenomenon independently from initial values, correlating with 
risk of graft loss and renal function. Some alterations in vital parameters 
were observed, especially in circulatory response. Analysis of postoperative 
acid-base balance also showed increasing parameters of metabolic acidosis 
corresponding with initial state and course of reperfusion. Ion balance was 
characterized by higher stability, notwithstanding potassium concentrations 
dynamics also showed repeatable alterations. Basing on analysed group there 
was unable to separate acid-base and ion balance disorders as an independent 
risk factor of function worseing, however they seem to have predictive value in 
the course of kidney transplantation.
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LIVING DONOR RENAL TRANSPLANTATIONS THAT 1126 
USES PURE TRANS-ABDOMINAL LAPAROSCOPIC DONOR 
NEPHRECTOMY ~ SINGLE CENTER EXPERIENCE ~
K. Kozaki, K. Yuzawa
Department of Organ Transplantation, Mito Medical Center
The increased acceptance of laparoscopic nephrectomy (LN) has been a 
driving force for living donor renal transplantation (LRTx). Since organ 
donors undergo an operation without any physical benefi t for them, donor 
safety and preservation of graft function must be respected. Not to harm 
a graft function in the LRTx, in principle we shorten graft ischemic time, 
namely preservation time as much as possible. Therefore the parallel 
operation of donor and recipient is performed generally in Japan, and the 
graft kidney is transplanted after perfusion and cooling promptly. As a result, 
although graft preservation time shortens, either waiting time under general 
anesthesia of donor or recipient arise till both donor and recipient get ready 
for starting operation. In April 2006, renal transplant program has been 
started in our center. In our center, since the reduction of patient fs waiting 
time under general anesthesia and the purpose of using the operation room 
effectively, recipient enters in the same operating room after donor operation 
end and donor return to the ward. Therefore renal graft was preserved for 
about 4 hours. In addition, donor nephrectomy was performed by pure trans-
abdominal laparoscopic procedure and used UW solution as preservative 
solution. In Japan, there are extremely few transplant centers performing 
LRTxin this procedure.
Objective: To investigate effi cacy of this procedure in LRTx.
Methods: FFrom April 2006 to December 2007, 22 LRTx were performed 
by pure trans-abdominal laparoscopic procedure in our center. To investigate 
time of immediate diuresis and postoperative day 1, 7 and 28 transplant kidney 
function in recipients, and to investigate complications of perioperative period 
in donor.
Results: Mean warm ischemic time was 6.9 min, mean total ischemic 
time was 234.2 min, immediate diuresis was occurred in all recipients 
and mean time of immediate diuresis was 10.6 min. Postoperative mean 
plasma creatinine value in recipient was 5.00 (mg/dl) on POD 1, 1.36 
on POD 7 and 1.42 on POD 28. No patients needed hemodialysis after 
transplantation. No complication occurs in donor, and although surgical 
complications including postoperative hemorrhage, lymphocele and 
urinary extravasation occurred in recipients, all recipients get good renal 
function so far.
Conclusions: FIn 2006, we mailed to 124 centers, and 100 (80.6%) centers 
responded. These centers carried out 695 living donor nephrectomies. In 
these centers, 52 (52.0%) centers performed total 589 LN donors. In 589 LN 
donors, 2 had life-threatening complications by bowel injury and bleeding and 
both survived. In 589 laparoscopic donated recipients, 1 case was reported 
as primary nonfunction and 28 (4.8%) recipients needed hemodialysis after 
transplantation because of delayed graft functions Moreover, according to 
this nationwide total investigation about living donor LN in Japan, mean 
warm ischemic time was 7.0 min, mean total ischemic time was 96 min and 
mean time of immediate diuresis was 13 min. In comparison with this survey, 
no postoperative hemodialysis and good posttransplant renal functions in all 
recipients and no complications in donor by our procedure, which is excellent 
procedure in LRTx.
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OUTCOME OF LAPAROSCOPIC LIVE DONOR 1127 
NEPHRECTOMY IN 2007: NATIONAL SURVEY OF 
TRANSPLANTATION CENTERS IN JAPAN
K. Yuzawa1, K. Kozaki1, M. Shinoda2, K. Fukao3
1National Hospital Organization Mito Medical Center, 2University of Tsukuba, 
3Chiba Rousai Hospital
In Japan, the number of cadaveric kidney available for transplantation has 
not increased and the number of living donor has increased. Laparoscopic 
nephrectomy (LN) for live kidney donation offers an alternative for a less 
invasive surgical access, better cosmetic, and a shorter hospital stay for donor. 
In many countries, the increased acceptance of LN has been a driving force 
for live donor kidney transplantation. Outcome of LN in live donors must be 
surveyed nationwide.
In this study, we surveyed 138 Japanese kidney transplantation centers to 
investigate current status of live donor LN, including morbidity, mortality, and 
various methods in the donors underwent nephrectomies.
Of 138 centers, 106 (76.8%) responded. These centers carried out 822 live 
donor nephrectomies. In these centers, 48 (45.3%) centers performed LN. In 
all donors underwent nephrectomies in all responded centers, 623 (75.8%) 
donors had LN and 199 (24.2%) had open nephrectomies. In 47 centers, 23 
were performed hand-assisted (HA) LN, 18 non-HA, 3 both HA and non-HA, 
and 3 laparoscope-assisted. And 17 centers carried out peritoneal approach, 26 
retro-peritoneal and 4 both.
In 623 LN donors, 2 had life-threatening complications by colon injury and 
bleeding, and both survived. Blood transfusions were performed in 5 (0.8%) 
donors. Open conversions in LN were 8 (1.3%). Minor complications not 
requiring long-hospital stay were reported in 10 (1.8%). The mortality of LN 
was 0. On the other hand, in 623 recipients, 1 case was reported as primary 
non-function. 13 (2.1%) recipients needed hemo-dialysis after transplantation 
because of delayed graft functions. Urinary tract complications were noted in 
13 (2.0%) recipients.
We surveyed all kidney transplantation centers in Japan for 6 years on LN. 
LN increases steadily in Japan. In donor complications, the incidence of blood 
transfusion and that of open conversion decreased progressively. Organ donors 
underwent an operation have no physical benefi t, but the results of this survey 
showed the validity of LN in live donor renal transplantation. This survey 
presents current status from which complete informed consent can be taken 
from donors.
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NON-IMMUNOLOGICAL DONOR FACTORS AND THEIR 1128 
INFLUENCE ON KIDNEY FUNCTION FOLLOWING THE 
KIDNEY TRANSPLANTATION
L. Bena1, J. Rosenberger1, I. Zezula2, R. Roland1
1Transplantcenter of Teaching Hosp L Pasteur Kosice, 2Faculty of Natural 
Sciences of Universty of PJ Safarik Kosice
Objective: To analyse the infl uence of donor age, age-related diseases, factors 
related to donor brain death, management, perfusion and preservation factors 
on the offset of kidney function following the transplantation. Comparing 
the infl uence of antigen–independent factors of deceased and living kidney 
donors on the offset of kidney function following the transplantation and 
assess possibilities of affecting the offset of kidney function by modifi cation 
of affectable donor factors.
Material and Methods: We analysed 279 consecutive donor-recipient pairs 
transplanted in Transplantcentre Kosice during the period of 1995-2005. 
Data were statistically treated by ordinal regression, the offset of kidney 
function (IGF – immediate graft function, SGF – slow graft function, DGF 
– delayed graft function, PNF – primary non-function) was a dependent 
variable, independent variables were as follows: CIT, WIT II, cold storage 
solution type, donor age, donor-recipient age difference, donor sex, 
existence of extended donor acceptance criteria, diagnosis leading to the 
brain death and donor management. Diuresis in the fi rst eight hours after 
the transplantation, administration of dopamine, calcium channels blockers 
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and furosemide following the transplantation were the factors assessed on 
the recipient side.
Results: In 46% of cases IGF or SGF following the transplantation was present, 
in 42% temporary dialysis treatment was needed because of DGF and in 12% 
primary non-function was registered being more frequent in fi rst years of 
studied period of time (16% vs 11% in 1995-1997 vs 2003-2005, no statistical 
signifi cance). Donor mean age was 37,46y. (5-70y.). 75,99% of donors were of 
male sex, mean CIT was 17h24m (5h00m – 30h40m). mean WIT II was 41m 
(15m – 1h35m). UW or HTK solution was used in 52,19% of procedures, in 
26,16% of all cases donor was more than 5y. older than the recipient, in 13,98% 
of all the cases kidney from female donor was transplanted into the male 
recipient. On the recipient side, in 66,08% diuresis was present immediately 
following the surgery, in 19,04% dopamine was administered, in 29,04% 
calcium channels blockers were administered and in 77,77% furosemide was 
administered.
Conclusion: In multivariate analysis, no correlation between donor age 
and offset of kidney function was found, though statistically non-signifi cant 
prevalency of DGF comparing to IGF/SGF is present in the donor age group 
>50y. Presence of extended criteria in donor appraisal as well as cause of 
donor brain death or donor management itself did not reach statistically 
signifi cant level, but in multivariate analyses combining more independed 
variables in ECD importance of short CIT as well as of age-matching started 
to be of signifi cance when dealing with offset of kidney function following 
the transplantation. More studies comparing given and many others non-
immunologic parameters among transplant centers are needed in the future 
to create more sophisticated algorithm for the allocation of kidney for the 
transplantation.
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CONTRAST-ENHANCED ULTRASOUND WITH 1129 
SONOVUE IN THE EVALUATION OF FUNCTION AND 
COMPLICATIONS OF KIDNEY TRANSPLANTS
L. Benozzi1, G. Cappelli1, D. Bonucchi1, D. Davoli1, A.M. Savazzi1, 
A. Albertazzi1, P. Torricelli2, M.G. Montecchi2, A. Grossi2, P. D’Alimonte2
1Nephrology, Dialysis And Kidney Transplantation. Policlinico Hospital – 
Modena, 2Radiology Department – University Hospital, Modena – Italy
Introduction and Aims: Purpose: To compare data from contrast-enhanced 
sonography versus routine color Doppler ultrasound and resistance index value 
(IR) in the study of kidney transplanted patients.
Methods: From December 2006 to August 2007 we performed both routine 
color Doppler ultrasound and contrast enhanced sonography at 5th (T0). 15th 
(T1) and 30th (T2) day post transplant on 15 patients who had undergone kidney 
transplantation. Graft function was daily monitored by standard parameters, 
immunosuppresion was controlled by therapeutic drug monitoring and in 4/15 
patients a kidney biopsy was performed due to acute graft dysfunction.
Patients data: 13 males and 2 females, aged from 17 to 70 years (mean: 
49,5yrs). weight from 47 to 98 kg (mean 70,5 Kg); 4/15 were transplanted 
from living donor, while 11/15 from cadaveric donor (a double kidney in one 
case). Immunosuppressive therapy was based, after a basiliximab induction, 
on a triple regimen with methylprednisolone tapering, calcineurin inhibitors 
(11/15 cylosporin, 4/15 tacrolimus) and mycophenolate mofetil (13/15).
Color Doppler ultrasound: evaluated kidney morphology and vascularisation 
by color Power Doppler on principal, interlobar and arcuata arterial vessels, 
providing systolic peak (MAS m/sec). diastolic peak (MIN m/sec). resistance 
index (IR) and plasticity index (IP) 
Contrast-enhanced ultrasound with SonoVue (5 ml i.v.) was used to assess 
arterial infl ow in the interlobar artery and renal cortex using a time-intensity 
curve (TIC) software analysis to obtain perfusion parameters. Time to peak 
intensity (TTP) between these two vascular territories was determined so as 
peak level (Peak). regional blood volume (RBV). regional blood fl ow (RBF) 
and time to half of peak intensity (T/2).
Results: According to post grafting renal function evolution patients were 
divided into three groups:
10/15 with a standard kidney function as control group (group C); 2/15 with a 
delayed graft function (biopsy proven in one case) (group ATN); 3/15 with an 
acute rejection (3/3 biopsy proven, 1/3 steroid resistant) (group AR) 
Mean creatinine and GFR for all pts on study is reported in following table I:
Creatinine GFR ml/min
5th day 3.7 ±2,6 mg/dl 37.65±45.34
15th day 1,9 ±1,3 mg/dl 59.94±42.10
30th day 1.7 ±1.2 mg/dl 63.16±44.42
P< 0.05 P < 0.05
Results from color Doppler IR and IP and parameters from contrast-enhanced 
sonography are reported in Table II at different scheduled times of study.
 T0 T1 T2 p P p
  (mean +/- SD)  (mean +/- SD)  (mean +/- SD) T0 vs T1 T0 vs T2 T1 vs T2
IP 2,14±0,98 1,96±0,79 1,60±0,73 - - -
IR 0,83±0,13 0,77±0,12 0,73±0,10 - 0,02* -
Peak
5,64±10,8 61,48±10,89 65,78±5,92
- --
TTP 14,87±3,71 16,34±7,27 16±5,35 - - -
RBV 3925,86±1715,59 6423,97±4146,57 7332,11±3976 0,05* 0,02* -
RBF 71,03±13,79 80,23±12,26 85,49±7,27 0,01* 0,00* -
T/2 60,22±15,13 72,64±38,84 79,61±37,55 - 0,03* -
We obtained moreover a signifi cant correlation between T/2 value at T0 from 
contrast sonography and GFR (ml/min) at 30th day post transplant (p< 0.014).
Conclusion: Our data support a role of contrast-enhanced ultrasound with 
SonoVue in the evaluation of early function and complication of kidney 
transplants and suggest also from contrast sonography a possible prognostic 
index for mid term renal function.
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COMPARISION OF PREVALENCE OF PULMONARY 1130 
ARTERY HYPERTENSION IN PRE AND POST RENAL 
TRANSPLANT RECIPIENTS
G. Abraham1, D. Lunawat1, M. Mathew2, S. Bhaskar2
1Sri Ramachandra University Hospital, 2Madras Medical Mission Hospital
Objective: The aim of this study was to compare the prevalence of pulmonary 
artery hypertension in a cohort of patients with end stage renal disease prior to 
and following renal transplantation along with other variables.
Methods: This was a retrospective study of renal transplant recipients whose 
pulmonary artery pressure was compared pre and post transplantation, in a 
tertiary care centre in South India. Of the 425 renal transplantations performed 
over 2001 to 2007, 124 patients had their Doppler Echocardiographic fi ndings 
available. The data analysed included the hypertensive, diabetic and the 
smoking status of the patient along with their BUN, Creatinine, GFR (by 
Nankivell formula). Hemoglobin, Hemodialysis duration, AV fi stula+/-,Urine 
albumin, BMI and most importantly the echocardiographic fi ndings both pre 
and post transplant – the pulmonary artery pressure, ejection fraction. Statistical 
analysis was performed using SPSS for Windows and t-test, chi-square test and 
ANOVA were used.
RESULS: There were 72%males and 28% females with mean age of 
43.3+_13.02 years. Out of this 87% were hypertensives, 30% were diabetics 
and 4% smokers. Statistical analysis revealed a signifi cant decline in 
pulmonary artery pressure (PAP) following renal transplantation (p<0.05). PAP 
had no signifi cant correlation with a patient’s hypertensive, diabetic, smoking 
status, age, gender, BUN, Creatinine, GFR, Hemoglobin, Hemodialysis 
duration, AV fi stula, Urine albumin. It was noticed that BMI had a signifi cant 
correlation (p<0.05) with Pre-transplant PAH. Of the 72% patients with nil 
Pre-PAH (<=35mmof Hg). 68% remained nil following transplantation, 2% 
developed mild PAH, 2% moderate PAH. Of the 14% patients with mild Pre-
PAH (>35and<=45mm of Hg). 9% developed nil PAH, 4% mild PAH,1% 
moderate PAH following transplantation. Amongst the 11.3% patients with 
moderate pre-PAH (>45and<=55mmof Hg). 6.5% had nil, 2.4%mild and 
2.4% moderate PAH post transplantation. Out of the 3.2% who had severe 
pre-PAH (>60mmof Hg).0.8% had nil, 1.6% moderate and 0.8% severe PAH 
post transplantation. There were no patients with moderately severe PAH in 
the study (>55and<= 60mm of Hg).
Conclusion: The fi ndings of our study reveal that pulmonary artery 
pressure declines in ESRD patients after renal transplantation as compared 
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prior to it. This emphasizes the fact that excessive pulmonary blood fl ow 
is involved in the disease pathogenesis which again could be related to 
various factors.
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THE EVALUATION OF THE EFFECT OF DONOR’S AGE 1131 
WITH DIAGNOSED BRAIN DEATH AND RECIPIENT’S AGE ON 
THE INCIDENCE OF DELAYED FUNCTION OF RENAL GRAFT
A. Caban, G. Oczkowicz, G. Budzinski, K. Zagalski, W. Wystrychowski, 
L. Cierpka
Dept.of General, Vascular And Transplant Surgery, Silesian Medical 
University
Abstract: Delayed graft function (DGF). interpreted as the necessity of 
carrying out a dialysis during the fi rst week after renal graft, remains an 
incompletely explained issue. Based on multi-centre analyses, older age 
of donor is a relevant aggravating factor. However, more and more often 
obtaining kidneys from donors aged over 60 years is not always correlated 
with the rise of incidence of DGF episodes. Nonetheless, such studies are 
frequently loaded with error resulting from the heterogeneity of groups in 
particular study centres and they lead to ambiguous fi ndings. The aim of our 
study has been the analysis of the effect of donor’s and recipient’s age on the 
incidence of DGF in the material from our clinic. Our study has involved 436 
renal recipients from 218 donors with diagnosed brain death. The necessity 
of dialysis during the fi rst week was the basis for the qualifi cation of each 
recipient for DGF group. Donors’ age and recipients’ age, the difference 
between them among both groups as well as a possible correlation with the 
incidence of DGF were compared. DGF has been recorded in 135 (31%) 
recipients. Mean age in this group was 41.2 ± 12.8 years whereas in the group 
featuring a good renal function it was estimated to 38.9 ± 11.6. No statistically 
signifi cant difference for recipients’ age between both groups has been 
observed. Similarly, no correlation was demonstrated between recipient’s 
age and DGF incidence as well as between donor’s age and delayed renal 
function. Correlation between the incidence of DGF and the absolute value 
of age difference (R = 0.19, P < 0.05) was observed. In the group of organ 
recipients from older donors R-Spearman coeffi cient was 0.20 (p = 0.01). In 
contrast, in the group of organ recipients from younger donors this coeffi cient 
was lower (R = 0.17) but still statistically signifi cant (p = 0.04). The age 
difference between donor and recipient did not correlate with the number of 
dialyses (R = -0.004, p = 0.96). Nevertheless, when it exceeded a 10-year 
threshold the number of dialyses was statistically signifi cantly higher (5.6 ± 
3.8 vs. 3.7 ± 3.0, p < 0.05 ). 
Conclusions: Donor-recipient age difference, particularly if it exceeds 10 
years, and also in such cases when a donor is older than a recipient, is an 
essential factor that increases the risk of DGF occurrence. In this group of 
patients a delayed graft function is also associated with the necessity of the 
application of signifi cantly greater amount of haemodialyses during an early 
postoperative period.
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COMPLICATIONS OF LIVING DONOR NEPHRECTOMY 1132 
OF LIVING – ONE CENTER EXPIERIENCE
P. Domagala1, M. Bieniasz1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1, 
M. Wszola1, J. Trzebicki3, M. Durlik2, W. Rowinski1, A. Chmura1
1Medical University of Warsaw, Department of General Surgery 
And Transplantology, 2Medical University of Warsaw, Department 
of Transplantology And Nephrology, 3Medical University of Warsaw, 
Department of Anaesthesiology And Intensive Care
Background: Kidney transplantation from living donors is associated with 
excellent graft and patient survival. The attention of transplantation teams 
is focused on the graft and its recipient, as well as on the safety and well-
being of healthy donors and is directed at minimizing the number of donor 
complications.
The aim of this study was to analyze the perioperative complications of living 
donor nephrectomies in our center.
Patients and method: The records of 46 live kidney donors operated on 
between 2004 and 2007 were reviewed. Mean donor age was 39 years (range 
25 – 57). The donors were predominantly female (61%). Mean hospitalization 
time was 8 days (range 4 – 22 days). Open nephrectomy was performed in all 
cases, usually left-sided (78%). Donors were followed up during hospital stay 
to assess perioperative complications. Ultrasonography was performed prior 
to discharge.
Results: Twenty complications were diagnosed in 18 (39%) donors (see table 
below). There were no deaths or thromboembolism. We noted no hemorrhage 
in the postoperative period.
Complication Number (%) 
Major complications
intraoperative hemorrhage 1 (2%) 
Minor complications
wound infection 6 (13%) 
retroperitoneal haematoma 3 (6%) 
urinary tract infections 3 (6%) 
mild hypertension 1 (2%) 
Conclusion: Nephrectomy in living kidney donors is a safe procedure burdened 
however by a range of predictable surgical complications.
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HAND-ASSISTED LAPAROSCOPIC DONOR 1133 
NEPHRECTOMY OF THE RIGHT OR LEFT KIDNEY: A 
RANDOMISED CONTROLLED TRIAL
I. ten Berge1, R.C. Minnee2, W.A. Bemelman2, F.J. Bemelman1, D.J. Gouma2, 
M.M. Idu2
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of 
Surgery, Academic Medical Centre, Amsterdam
Aims: The (hand assisted) laparoscopic approach (HLDN) is an accepted 
method in live kidney donations. The benefi ts are decreased postoperative pain 
and morbidity, a shorter convalescence for the donor and a better postoperative 
cosmetic result. Most centers prefer to use the left kidney for live kidney 
donation because of the longer renal vein. It has never been addressed which 
kidney can be used best for live kidney donation, in terms of operating time, 
morbidity, reconvalescense and transplant survival.
Methods: From April 2002 to September 2006, 60 HLDN were performed. 
Donors were randomly assigned to undergo either a right- or left-sided 
donornephrectomy. Primary outcome parameters were operating time and 
length of hospital stay. Secondary parameters were donor morbidity, conversion, 
warm ischemia time, blood loss, graft survival and urological complications.
Results: There were no conversions and no major morbidity. The median blood 
loss was respectively 60cc (range 10-1000) and 55cc (range 25-1200) for left 
and right-sides donornephrectomies. Median operating time for HLDN was 180 
minutes (range 110-274) in the left group versus 150 minutes (range 88-221) in 
the right group (p=0.027, odds ratio 1.02 (95% CI: 1.00-1.03) ). Median hospital 
stay was 4 days (range 2-7) in both HLDN groups. Warm ischemia time was 
3 minutes in both groups. Median operating time for transplantation was 138 
minutes (range 90-265) in the left group and 148 minutes (range 104-300) in 
the right group (p= 0.38). The surgical re-intervention rate due to a urological 
complication for respectively left-sided and right-sided harvested grafts were 
2% and 4% respectively (p=0.55, Chi2-test). One year graft survival rate was 
91% in the left group versus 96% in the right group (p=0.55, log rank).
Conclusions: Operating time of HLDN of the right kidney is 30 minutes 
shorter than HLDN of the left kidney. There are no differences in morbidity 
of donor and acceptor, hospital stay and transplant survival in HLDN of either 
the right or left kidney.
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HAND ASSISTED LIVNG DONOR NEPHRECTOMY 1134 
AT KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE, 
STOCKHOLM, SWEDEN
H. Gjertsen, A. Sandberg, G. Tyden, B-G. Ericzon
Karolinska University Hospital, Huddinge
Introduction: Living donor kidney transplantation accounts for about 50% of 
the total number of renal transplantations in our center. From 1999 through 
2005, 75 out of 220 living donor nephrectomies (LDN) were performed with 
laparoscopic technique (LLDN). In June 2005 we introduced the technique 
of hand assisted retroperitoneoscopic nephrectomy (HARS) for our living 
donors.
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Methods: All HARS nephrectomies were performed by one single surgeon. 
Access and hand port position was via pfannenstiel incision.
Results: Since the introduction till the end of February 2008, 73 out of 84 
LDN were performed with HARS. 42 HARS operated donors were female 
and 31 male, with an average age of 49 years. 62 left sided and 11 right 
sided nefrectomies were performed, where 67 kidneys had single artery, 
and 6 had two or more arteries. Mean operation time was 148 minutes 
compared to 244 minutes in the LLDN. In the first 10 HARS operations 
mean operation time was 168 minutes, compared to 144 minutes in 
the last 63. None were converted, but four peroperative incidents were 
experienced, one clip failure on a lumbar vein, and three failures with 
the vascular stapler, where two times clips blocked the stapler suture 
at the kidney side of the vein, and one technical failure of the stapler, 
where the stapler clips did not close when dividing the artery. No severe 
postoperative complications were experienced, but three donors developed 
wound infection and two more had wound haematoma in the pfannenstiel 
incision. We had three early graft losses, two due to venous thrombosis 
and one due to ischemia, but none were believed to be associated with 
the nephrectomy technique. One venous thrombosis was in a right kidney. 
Two recipients experienced delayed graft function, one was in need of 
reoperation early due to bleeding, and the other was from the donor with 
clip failure of a lumbar vein.
Conclusion: So far HARS in our hands is a fast and safe procedure. Compared 
to LLDN, we experienced reduced operation time together with the advantage 
of retroperitoneal access. Failure of clips and vascular stapler with potential 
bleeding complications emphasizes the advantage and increased security of a 
hand assisted technique.
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HAND-ASSISTED TRANSPERITONEAL LAPAROSCOPIC 1135 
LIVE DONOR NEPHRECTOMY: A SINGLE CENTRE 
EXPERIENCE
I. Butt, C. Vallance, C. Clayton, M.S. Melbridge, V.C. Nathan, W.S. McKane, 
P. Brown, A.T. Raftery, B.M. Shrestha
Sheffi eld Kidney Institute
Introduction: Laparoscopic live donor nephrectomy is being increasingly 
practised. It reduces the disincentives to live kidney donation and is associated 
with less post-operative pain, shorter hospital stay, early return to work and 
better cosmesis. The purpose of the study was to assess the impact of hand-
assisted laparoscopic live donor nephrectomy (HLLDN) on donor and recipient 
outcomes and compare these with the established technique of open donor 
nephrectomy (ODN).
Methods: Over a period of 7 years, commencing 2000, 75 live donor 
nephrectomies (HLLDN = 35, and ODN = 40) were performed. Data was 
retrieved from a prospectively maintained departmental computer database and 
case notes. HLLDN was performed through transperitoneal and ODN through 
retroperitoneal fl ank approaches.
Results: Donor age (HLLDN 42 ± 11 vs. ODN 43 ± 10 years) and sex (HLLDN 
17 males, 18 females vs. ODN 15 males, 25 females) was similar in both groups. 
The total anaesthetic time was longer in HLLDN group (267 ± 52 vs. 174 ± 
42 minutes, p <0.001). The mean serum creatinine of the donors at discharge 
and at 1 year was higher in the HLLDN group (116 ± 22 vs. 101 ± 21 μmol/l, 
p<0.05 and 115 ± 21 vs. 103 ± 20 μmol/l, p<0.05, respectively). which would 
correlate with higher body mass index in the HLLDN group (28 ± 3 vs. 26 ± 3 
kg/m2, p<0.05). The recipient serum creatinine at discharge and at 1 year was 
similar in both groups (140 ± 88 vs. 147 ± 66, p=0.72 μmol/l and 128 ± 52 
vs. 146 ± 41 μmol/l, p=0.17, respectively). Duration of post-operative hospital 
stay was shorter in the HLLDN group (3.7 ± 1.1 vs. 6.4 ± 1.4 days, p<0.001) as 
was time to return to work (6.0 ± 1.6 vs. 12.5 ± 4.7 weeks, p<0.001). Delayed 
graft function was observed in 4 of the HLLDN group in comparison to 3 of 
the ODN group. No signifi cant post-operative complications occurred in the 
HLLDN group. Three patients required conversion to an open procedure due to 
dense adhesions between the kidney and perinephric fat. All three were athletic 
young males.
Conclusions: HLLDN is a safe alternative to ODN. We have observed distinct 
advantages over ODN with respect to shorter hospital stay, early return to work 
and cosmesis without compromising graft function.
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RENAL TRANSPLANTATION FROM THE LIVING 1136 
DONORS/PATIENTS WITH SMALL RENAL CELL CARCINOMA 
OR URETERAL CARCINOMA (AUSTRALIA AND JAPAN 
EXPERIENCES) 
M. Mannami1, R. Mannami1, N. Mitsuhata2, M. Nishi3, K. Nannba4, 
Y. Tsutsumi5, S. Fujita6, N. David7
1Uwajima Tokushukai Hospital, 2Kure Kyosai Hospital, 3Kagawa Rosai 
Hospital, 4Rokumeisou Pathology Center, 5Fujita Health University, 
6University of Florida, 7University of Queensland
Materials and Methods: Since March 1993, sixty fi ve kidney allografts were 
obtained from 65 patients (57 small renal cancers, 8 ureteral cancers) after 
extended discussion of treatment modalities at Princess Alexandra hospital 
Brisbane, Australia, Uwajima Tokushukai Hospital, Ehime, Japan, Uwajima 
municipal hospital, Ehime, Japan, and Kure Kyosai hospital, Hiroshima, Japan. 
All patients agreed to undergo simple total nephrectomy. The lesions were 
removed on the back table, and the kidneys were transplanted into 64 recipients 
(one recipient received twice).
Results: There was one recurrence of renal cell cancer 9 years after 
transplantation. The patient remained stable under observation for 18 months. 
There was one recurrence of ureteral cancer in the transplanted kidney 15 
months after kidney transplantation, treated with partial resection of the 
tumor at the patient fs request. The patient developed fatal squamous cell lung 
cancer three years later. Eight patients (6 renal cancers, 2 ureteral cancers) 
died from unrelated illnesses. Three other grafts lost function 7 months and 6 
years following transplantation (2 renal cancers and one ureteral cancer). All 
remaining grafts continue to function with median and mean follow-ups of 25 
and 32 months.
Discussion: Based on our experience we believe that in case where nephrectomy 
is performed for small, localized, incidentally detected small renal cancer or 
ureteral cancer, the kidney should be considered for transplantation to carefully 
selected patients. In countries where deceased donors are scarce, these kidneys 
will be a last resort for patients on the kidney transplant waiting list.
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REVIEW OF JAPANESE PRACTICE FOR SMALL RENAL 1137 
CELL TUMORS: ESTIMATION OF NUMBER OF GRESTORED 
KIDNEY TRANSPLANTATION H FROM THE PATIENTS WITH 
SMALL RENAL CELL TUMORS IN JAPAN.
Y. Tsutsumi1, M. Mannami2, R. Mannami2, N. Mitsuhata3, M. Nishi4, 
K. Nannba5, S. Fujita6
1Fujita Health University, 2Uwajima Tokushukai Hospital, 3Kure Kyosai 
Hospital, 4Kagawa Rosai Hospital, 5Rokumeisou Pathology Center, 
6University of Florida
Background: Restored kidney transplant (RKTx) has a great potential to 
increase available renal allografts. In this study, we estimated the number of 
RKTx from the kidneys with small renal cell tumors (RCC) in Japan, according 
to the questionnaire sent to the representative hospitals.
Material and Methods: Questionnaire was sent to 10 various hospitals, 
representing Japanese hospitals including 2 universities, asking the numbers of 
all RCC cases, partial resection cases for RCC patients, and tumor size of each 
case in 2004 -2006. The incidence rate of renal cell carcinoma in Japan was 
estimated based on the cancer registry of Hiroshima prefecture, and we applied 
it to estimate the number of possible RKTx.
Results: All RCC surgical cases were 613 in 10 hospitals, of those the 
number of T1a cases (tumor size: not more than 4.0 cm) was 283 (46.2%). 
112 underwent partial resection out of 283 T1a cases (41.9%). Expected rate 
of total nephrectomy for T1a RCC patients out of all RCC patients is (283 – 
112) /613 = 27.9%. According to the cancer registry of Hiroshima prefecture, 
estimated surgical cases of RCC in Japan is expectedly 6660 yearly. The annual 
number of total nephrectomy for T1a RCC cases is 6660 X 0.279 = 1858.
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Discussion: Estimated number of renal allograft for Restored kidney 
transplantation is up to around 2000 yearly. This can be a great source of donor 
organ for the patients who are longing for the renal transplantation. The number 
is 10 times of current cadaveric renal allograft number in Japan.
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URINARY LEAKAGE IN RENAL TRANSPLANT 1138 
PATIENTS
A. Gurkan1, S. Kacar2, C. Varýlsuha1, C. Karaca2, F. Akman2, S. Tilif1
1GOP Hospital Organ Transplantation Center, 2Kent Hospital Organ 
Transplantation Center
Purpose: Urinary leakage is of the most diffi cult complication to deal with in 
the renal transplantation procedure. We examined the factors effecting urinal 
leakage in our renal transplant patients.
Patients and Methods: During the time period between Nov. 2005 and Feb. 
2008, 138 renal transplantations have been performed in Izmir Kent Hospital 
and Istanbul G.O.P Hospital. 94 (68.1%) of these patients are live-related 
and 44 (31.9%) deceased donor transplantations. Mean age of the donors and 
recipients were 45.7 and 38.4, respectively. 84 (60.9%) of the patients were 
male. All urinary anastomosis were performed by the method of Lich-Gregoir. 
Double-J tube was used in 81 (58.7%) of them. 13 (9.4%) of the patients had 
multiple arteries which were anastomosed with double barrel manner. The 
relation between urinary leakage and certain factors such as acute rejection, 
acute tubular necrosis, recipient gender, delayed graft function, usage of ATG, 
donor gender, number of arteries, warm ischemia time, cold ischemia time, 
usage of double-J catheter, donor type, donor age, recipient age and vascular 
complication were analyzed in this study. Chi-square and student-t tests were 
applied for statistical analysis.
Results: All the patients were followed-up during the study. 2-year graft and 
patient survival were 100%. 16 (11.6%) and 3 (2.1%) patients have experienced 
acute rejection episodes and acute tubular necrosis, respectively. 6 (4.3%) 
patients had vascular complications whose have been treated properly. 10 
(7.2%) urinary leakages were seen in this series. Only the application of double-J 
catheter and donor age (p= 0.025) were found to be statistically different in 
effecting urinary leakage. Urinary leakage rate was 2.5% (2 patients) in the 
patients whom urinary anastomosis had been performed via double-J catheter 
insertion and 14,0% of the patients in whom double-J catheter was not used 
(p= 0.016). In the double-J group, one of the leakages was seen postoperative 
15th day, probably due to severe acute rejection episode. Both leakages were 
treated with suturing the hole. Mean donor age was found to be 45.2 in the 
patients whom urinary leakage was not seen, while 52.1 in the patients with 
urinary leakage.
Conclusion: Although donor age was found to be one of the two factors 
effecting urinary leakage; insertion of double-J catheter was the only one, which 
the surgeon could be able to affect the course of the procedure. So, we suggest 
the insertion of double-J catheter in all renal transplantation procedures.
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LOW DOSE ENOXAPARIN AND ASPIRIN FOLLOWING 1139 
KIDNEY TRANSPLANTATION IN PATIENTS AT RISK FOR 
BLEEDING OR THROMBOSIS
R. Shapiro, K. Sperling, N. Shah, C. Wu, A. Basu, H. Tan, J. McCauley, 
F. Bontempo
University of Pittsburgh School of Medicine
Background: Renal transplantation in patients with a hypercoaguable state 
or on chronic anticoagulation is a potentially diffi cult clinical challenge. A 
number of strategies have been tried to reduce the risk of thrombosis, but they 
have yielded confl icting results. Some approaches have been associated with a 
high incidence of signifi cant bleeding.
Methods: We reviewed the medical records of 45 high-risk patients transplanted 
at our institution over the past 5 years who were treated with low dose aspirin 
and low dose enoxaparin post-operatively.
Results: There were no cases of allograft thrombosis. There was a 13.3% 
incidence of major bleeding in patients receiving a mean daily dose of 0.42 
mg/kg of enoxaparin and 81 mg of aspirin, although no patients required 
re-exploration for bleeding. One patient (2.2%) developed a deep venous 
thrombosis.
Conclusion: This study suggests that a reduced dose of enoxaparin in conjunction 
with aspirin is a reasonably safe and effective option for thromboprophylaxis in 
the peri-transplant period.
Demographics of study population
Age 55.1 ± 14.7 yrs (19-77) 
Male 67%
Caucasian 93%
Living donor recipients 73%
Delayed graft function 13%
Enoxaparin dose 0.42 ± 0.11 mg/kg/day
Post-op day enoxaparin started 1 ± 0.7
Number days enoxaparin continued 10.4 ± 8.3 (1-30) 
Indication for anticoagulation
Hypercoaguable state 49%
Prior allograft thrombosis 4%
Mechanical heart valve 22%
Atrial fi brillation 29%
Unknown or miscellaneous 11%
Bleeding complications
Major bleeding 13%
Hemoglobin fell by ≥ 2 g 11%
Minimum 2 units PRBC transfused 4%
Perinephric hematoma
Incidence 9%
Requiring drainage 2%
Other bleeding complications
Retroperitoneal hematoma 2%
Hematuria 4%
Re-exploration 0%
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EN BLOC LIVER AND KIDNEY TRANSPLANTATION 1140 
FOR CHILDREN
T. Kato, E. Island, J. Chander, G. Selvaggi, M. Velasco, A. Tzakis
University of Miami
Background: En bloc liver and kidney transplantation can be used for children 
who require simultaneous liver and kidney transplant.
Methods: Retrospective review of three children who received en bloc bilateral 
kidney and liver graft at our institution.
Results: Patient’s ages were 1.5, 9 and 12 years. Diagnosis was polycystic kidney 
and hepatic fi brosis in 2. Primary oxalosis in the other. Liver and bilateral kidneys 
were harvested en bloc. Arterial infl ow was from the recipient’s infra renal aorta. 
Suprahepatic vena cava of the donor was anastomosed to the recipient in a 
piggyback fashion. Age of donor was 4 yo, 5 yo and 10 mo. Imunosuppression 
regimen included tacrolimus, steroids and daclizuab. All three recipients are alive 
and well at 7 years, 5 years and 8 months from the transplant. Posttransplant liver 
and kidney function were excellent in all three of them. No surgical complication 
has been seen. Liver rejection was seen in two of them.
Conclusion: En bloc liver and kidney transplant can be safe and effective 
option for children who require simultaneous liver and kidney transplant.
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FACTORS INDUCING IMMEDIATE RENAL FUNCTION 1141 
IN TRANSPLANTATION ENGRAFTING RENAL GRAFTS 
FROM CARDIAC DEAD DONORS
K. Hayakawa, H. Sasaki, M. Kusaka, T. Maruyama, R. Shiroki, A. Sugitani, 
K. Hoshinaga
Fujita Health University
Introduction: In renal transplantation engrafting kidneys donated after cardiac 
death (DCD). the incidence of delayed graft functions (DGF) is common 
compared to that of brain dead donors. This phenomenon chiefl y depends on the 
unstable renal circulation of DCD donors before cardiac death; however in certain 
number of patients, we have immediate graft function (IGF) achieved even under 
such poor conditions. The objective of this study is to evaluate the contributable 
factors for IGF in renal transplantation engrafting kidneys from DCD donors.
Patients and Methods: From January 1983 to February 2008, we recovered 
409 kidneys from DCD donors at our center. Among them, 24 grafts have 
never had graft function. In this study, we enrolled 385 kidneys, which could 
recover functions with or without hemodialysis after transplantation. Kidneys 
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were procured from DCD donors using in situ regional cooling technique. 
After procurement, all kidneys were simply cold preserved. Grafts were 
classifi ed into 2 groups; without post-transplant hemodialysis (IGF) or with 
post-transplant hemodialysis (DGF). As risk factors, we employed donor age, 
cause of death, donor serum creatinine on admission, donor serum creatinine 
immediately before donation, recipient age, warm ischemic time (WIT) and 
total ischemic time (TIT).
Results: Fifty-seven grafts had IGF after transplantations (14.8%). and the 
other 328 grafts revealed DGF. Among several factors associate with donation 
and transplantation, serum creatinine less than 2.0 mg/dl immediately before 
donation, TIT less than 6 hours and recipient age less than 25 years old are 
signifi cantly different between IGF and DGF respectively (p<0.05). The 
multivariate logistic regression model to test associations with IGF indicated 
that serum creatinine level than 2.0 mg/dl immediately before donation, 
recipient age less than 25 years old and TIT less than 6 hours were selected as 
associate risk factors by stepwise method (P<0.01).
Conclusion: Kidneys from DCD have a chance to achieve immediate graft 
function, if donated under condition of good serum creatinine level, short TIT 
and transplanted to young recipient.
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DONOR AGE AND WARM ISCHEMIC TIME ARE RISK 1142 
FACTORS FOR PRIMARY NON-FUNCTION IN RENAL 
TRANSPLANTATION ENGRAFTING KIDNEYS FROM 
CARDIAC DEAD DONORS
K. Hayakawa, H. Sasaki, M. Kusaka, T. Maruyama, R. Shiroki, A. Sugitani, 
K. Hoshinaga
Fujita Health University
Introduction: In renal transplantation engrafting kidneys donated after cardiac 
death (DCD). the incidence of delayed graft functions and primary non-
functions (PNF) are not rare compared to that of brain dead donors.
In this study, we investigate the outcome of transplantation engrafting kidneys 
from DCD donors and evaluate the risk factors for PNF.
Patients and Methods: In this study, 409 kidneys recovered from DCD donors 
at our center were enrolled. Kidneys were procured from DCD donors using 
in situ regional cooling technique. After procurements, all kidneys were cold 
preserved. Grafts were classifi ed into 2 groups; having graft function or PNF. 
As risk factors for PNF we employed donor age, cause of death, donor serum 
creatinine on admission, donor serum creatinine immediately before donation, 
recipient age, warm ischemic time (WIT) and total ischemic time (TIT).
Results: Twenty-four grafts have never recovered the functions after 
transplantations (PNF: 5.9%). and among the other 385 grafts (functioning 
graft: FG). 57 grafts had immediate function without post-transplant 
hemodialysis (13.9%) and 328 grafts recovered the functions with post-
transplant hemodialysis (80.2%).
Between PNF and FG, there was no signifi cant difference except WIT (P<0.05) 
when the mean values were compared. @On the other hand, the multivariate 
logistic regression model to test associations with PNF indicated that donor 
age and WIT over 35 minutes were selected as signifi cant risk factors using 
stepwise method (p=0.03, <0.01).
Conclusion: Donor age and WIT over 35 minutes are signifi cant independent 
risk factors for PNF in transplantation from DCD donors.
PRESERVATIONCONCURRENT ORAL SESSION 83: 
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LIMITED PENETRATION OF PERFLUOROCARBON 1143 
IN PANCREAS PRESERVED BY THE TWO-LAYER METHOD 
FOR ISLET TRANSPLANTATION DEMONSTRATED BY 
19FLOURINE MAGNETIC RESONANCE SPECTROSCOPY AND 
HEAD SPACE GAS CHROMATOGRAPHY
A. Agrawal1, P-W. So, P. Martin, P. Steve, F. Barry, D. Brian
1Royal Free Hospital, 2Hammersmith Hospital, 3Royal Free Hospital, 4Royal 
Free Hospital, 5Royal Free Hospital, 6Royal Free Hospital
Introduction: The mechanism of action of the two-layer method (TLM) of 
pancreas preservation remains unclear. Direct measurements of pO2 in the 
core of TLM-preserved pancreas have yielded confl icting results. The degree 
of penetration of perfl uorocarbon (PFC) into the substance of pancreas during 
TLM storage has not been established.
Materials and Methods: Segments of porcine pancreas (7.5 cm in length) 
were preserved either in University of Wisconsin solution (UW) alone 
or in TLM for 24 hours and then studied using a Varian INOVA 9.4T MR 
spectrometer. Tissues were suspended in UW solution and an external standard 
of PFC was introduced for quantitation. Four consecutive transverse images 
of 4mm thickness were obtained using a spin-echo sequence: repetition time 
(TR) of 1s, echo time (TE) of 20ms, fi eld of view (FOV) of 45 x 45cm, matrix 
size 256 x 128 and 4 averages. 19F MRS was then performed with the same 
parameters. For head space chromatography 500mg of pancreatic tissue was 
transferred to 50ml Pyrex vials containing 2g anhydrous magnesium sulphate. 
The bottles were placed in a microwave oven and heated for 90s at 200°;C to 
volatilize the PFC. One ml of headspace was analyzed in a gas chromatograph 
equipped with a fl ame ionization detector.
Results: 19F MRI/MRS – In transverse 19F MR images of the porcine pancreas 
after 24h storage in TLM, PFC phantom was readily detected but no fl uorine 
signal was obtained from the pancreas. 19F MR spectra typical of PFC were 
not obtained from either UW- or TLM-preserved pancreas with non-localized 
19F MRS. GC-FID – The mean concentration of PFC in TLM pancreas (n=6) 
was 0.011nl/g (SD ±0.006). not signifi cantly different from the background 
concentration (0.012nl/g, SD ± 0.006) in UW pancreas (n=6, p = 0.42).
Conclusion: There is no evidence of penetration of perfl uorocarbon in pancreas 
preserved by the two-layer method and the mechanism of action of the TLM 
remains speculative.
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THE ADDITION OF ADENOSINE TO UW: DOES IT HELP?1144 
C. Corps1, M. Shires2, D. Crellin2, R. Smolenski3, J. Pratt2, J.P.A. Lodge1
1St. James’s University Teaching Hospital, 2LIMM, Leeds University, 
3Harefi eld Hospital, Imperial College London,
Introduction: ATP precursors are often added to preservation solutions in the 
belief that once the organ is reperfused the precursors will help to build ATP 
back up more quickly, so returning the organ back to its original metabolic 
state.
Adenosine is added to University of Wisconsin Solution (UW) to overcome 
this lack of nucleotides with the theory that it will be available at reperfusion 
for the reformation of ATP. But Adenosine has a short half in blood (<1 
second). so in practice will it be available for use following reperfusion 
or will it have been broken down further? During hypothermic organ 
preservation Adenosine Triphosphate (ATP) degrades rapidly to form 
adenosine diphosphate (ADP) and adenosine monophosphate (AMP). 
Although these are not able to diffuse across the cell membrane, when AMP 
is dephosphorylated to the nucleoside adenosine by 5’-nucleotidase, this can 
freely diffuse across the cell membrane leading to a total absence of adenine 
nucleotides in the cell.
This work studied ATP and it’s metabolites during preservation of the rat 
liver using UW, which contains Adenosine, or either Histidine Tryptophan 
Ketoglutarate (HTK) or a new phosphate based preservation solution, LS, 
under development at our institution, neither of which contains Adenosine.
Methods: Livers were perfused and at various time points, tissue samples were 
analysed for ATP and metabolites by HPLC.
Results: Although the addition of adenosine to UW did correspond to the 
expected signifi cant difference in overall adenosine levels, at no time did it 
correspond to higher levels of ATP during preservation. Similarly the addition 
of adenosine to LS did not cause a corresponding signifi cant increase in ATP 
levels.
After less than 4 hours any advantage in concentration of the adenosine in the 
UW has disappeared, which was probably due to the adenosine having a short 
half life and being broken down to its metabolites.
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Discussion: Therefore for cadaveric transplantation, when the ischaemic time 
is usually greater than 4 hours the levels of adenosine in the tissues will not 
be any higher in UW than those tissue perfused with HTK or LS. Only in live 
donor transplants where the cold ischaemic time is short may there be some 
advantage to the addition of adenosine.
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HISTOLOGICAL COMPARISON OF LIVER TISSUE 1145 
PRESERVED IN UW COMPARED TO TISSUE PRESERVED IN A 
NOVEL SOLUTION
C. Corps1, M. Shires2, S. McKenzie1, D. Crellin2, J. Pratt2, J.P.A. Lodge1
1St. James’s University Teaching Hospital, 2LIMM, Leeds University,
Introduction: Histological analysis of rat liver tissue during preservation and 
following reperfusion was done to compare the effi ciency of a novel solution, 
LS, under development at our institution.
Methods: Livers were perfused with either LS or the “Gold Standard” of 
preservation solutions UW (University of Wisconsin solution). Tissue samples 
were taken and stored in gluteraldehyde at time zero and 5 minutes, 1, 4 and 24 
hours after the start of preservation.
Other livers were stored in the same way for 24 hours, but no samples were 
taken from them during preservation. These livers were then reperfused 
with rat blood and placed on an Isolated Perfused System and underwent 
reperfusion on this system for 2 hours. After this period liver samples 
were taken and placed in gluteraldehyde for histological analysis. All the 
samples were analysed using two different histological stains: PAS and 
Gordon and Sweet.
Results: Glycogen disappears from hepatocytes of livers preserved in LS at 
a slower rate than hepatocytes of livers preserved in UW, with glycogen still 
being present after 24 hours when preserved with LS but not seen with UW.
Following 2 hours reperfusion, glycogen can be seen in many hepatocytes 
originally perfused with LS, whilst very little is seen in those perfused with UW.
Due to the large amount of cell shrinkage seen in UW preserved livers reticulin 
is seen to breakdown quickly and takes a long time to reform following 
reperfusion. In LS perfused livers there is a relatively small change in cell 
volume during perfusion and a correspondingly low amount of reticulin 
breakdown and following reperfusion reticulin is reformed quicker than with 
UW perfused tissue.
Discussion: These results show that histologically LS preserves the liver as 
well as UW or even better. Following reperfusion of the liver the damage that is 
done to the reticulin is reversed more quickly in LS preserved liver than in UW 
preserved liver and the glycogen is also seen to build up again more quickly 
in LS preserved liver. This means that the improvements seen in liver tissue 
preserved in LS over those seen in UW are followed through to reperfusion.
LS can therefore be believed to be as good a preservation solution as the Gold 
Standard of UW.
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METABOLIC AND BIOCHEMICAL ANALYSIS OF 1146 
HEARTS PRESERVED IN DIFFERENT PRESERVATION 
SOLUTIONS.
C. Corps1, M. Attia1, D.J. Potts2, J.P.A. Lodge1
1St. James’s University Teaching Hospital, 2Department of Biological Science, 
University of Leeds,
Introduction: A solution has been under development at our institute, based on 
Phosphate-Buffered Sucrose, which has shown good preservation for kidneys 
and livers. This work used a refi ned version of this solution to be used in heart 
preservation and compared it to solutions which are already widely used.
Method: Hearts were mounted initially mounted in a Langendorff confi guration 
for a washout and equilibrium period, during which cannulation of the left 
atrium took place. Hearts were then fl ushed with 15ml of the preservation 
solution and left at 4˚C to be reperfused 6 hours later in a Langendorff working 
heart model for 15 minutes followed by working perfusion for 30 minutes.
For the measurement of the enzymes the initial 1.5ml of the coronary effl uent 
was collected immediately after the storage period and tested for Creatine 
Phosphokinase (CPK) and Lactate Dehydrogenase (LDH). The hearts were then 
dropped immediately into liquid nitrogen in order to measure the Adenosine 
Triphosphate (ATP). Lactate and Creatine Phosphate (CP).
Spectrophotometric analysis was used to assess both the release of CPK and 
LDH into the coronary effl uent, and the level of ATP, Lactate and CP in the 
frozen heart tissue.
Results: Table 1:
Solutions CPK (IU/L) LDH (IU/L) Lactate (μM) ATP (μM) CP (μM) 
PBSH (n=6) 18.9 ± 2.8 26.4 ± 3.6 5.7 ± 0.4 1.7 ± 0.4 2.2 ± 0.4
STH (n=8) 19.9 ± 4.0 31.0 ± 3.3 7.5 ± 0.5 0.8 ± 0.2 0.7 ± 0.2
UW (n=7) 41.0 ± 4.9 42.1 ± 3.2 7.8 ± 0.9 0.3 ± 0.1 1.3 ± 0.5
CS (n=8) 22.9 ± 2.4 20.4 ± 7.8 6.5 ± 0.5 0.9 ±0.2 2.2 ± 0.7
Conclusion: High energy phosphate compounds, including ATP and CP, are 
markers of energy preservation within the cardiac muscle after preservation. 
The higher the level of these compounds the better the quality of the organ 
preservation, as the more energy remaining in the heart the higher the possibility 
that it will start working again. ATP was found to be higher in heart preserved 
in PBSH than in any other solution, and this reached signifi cance over the UW 
preserved hearts. Overall these results, coupled with better haemodynamic 
recovery (not shown). show that PBSH is at least as effective in cardiac 
preservation in the rat model of 6 hours cold ischaemia, as the other widely 
used solutions tested.
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OH-RADICAL SCAVENGERS AND IRON CHELATOR 1147 
IMPROVE POSTHYPOXIC CELLULAR INTEGRETY IN 
GLYCINE-PRESERVED RENAL TUBULUES
M.K. Schilling1, M.R. Moussavian1, J.E. Slotta1, O. Kollmar1, M.D. Menger2, 
1Department of General, Visceral, Vascular and Pediatric Surgery, and 
2Institute of Clinical and Experimental Surgery, University of Saarland, 
D-66421Homburg/Saar, Germany
Introduction: Cellular stress during reoxygenation is a common phenomen in 
solid organ transplanation. Reperfusion and reoxygenation are characterized by 
production of reactive oxygen spezies (ROS) and free radicals. Furthermore, 
multiple substances like benzoat (BA). salicylate (SA). manitol (MAN). 
tocopherol (TF). superoxide dismutase (SOD). catalse (CAT). ascorbid acid 
(ASS) and desferroxamine (DFO) protect against free radicals. We studied 
in tubular segments of rat kidney cortex (ITS) at 1mM concentrations of 
scavengers and 0.1-1mM iron chelator during the posthypoxic recovery 
period.
Materials and Methods: All tubules were suspended in Ringer’s solution 
containing 5mM glycine and were oxygenated for 30min with 95% O2 and 
5% CO2. There after, the ITS were gassed for 30min with 95% N2 and 5% 
CO2, followed by a 60min reoxygenation period with 95% O2 and 5% CO2. 
Untreated tubules served as controls (=100%). To investigate the oxidant 
activity, membrane leakage and lipid peroxidation were measured by the 
loss of the marker enzymes lactate dehydrogenase (LDH) and glutamate 
dehydrogenase (GLDH) and the development of thiobarbituric acid reactive 
substances (TBA-RS) in the solutions. Cell function was quantifi ed by 
gluconeogenesis (GNG) and intracellular potassium accumulation (K+).
Results: DFO, TF, ASS and BA signifi cantly decreased the loss of marker 
enzymes (LDH, GLDH). Cell function was also supported by MAN, TF, ASS 
and DFO. BA improved K+ accumulation but had no marked effect on GNG. 
Nevertheless, the observed protection by the hydroxy radical scavengers BA 
and MAN indicated that even in glycine-protected reoxygenated tubulues 
hydroxy radical (OH.) formation has deleterious effects. This hypothesis was 
supported by similar effects of DFO: reduction of free tissue iron (Fe). released 
by heme proteins, by the iron chelator DFO could have diminished the catalytic 
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reaction of Fe on OH. formation via Fenton`s reaction.
Conclusion: Antioxidants in the storage solution confer protection against 
reoxygenation damage. The most effective antioxidant was the iron chealator. 
DFO, which was effective in the solution buffer. Suppression of reperfusion injury 
in solid organ transplantation could be obtained by antioxidant therapy. However, it 
is unclear how best to deliver the antioxidants to the site of oxyradical generation.
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HEMOGLOBIN INDUCES CYTOTOXIC DAMAGE OF 1148 
GLYCINE-PRESERVED RENAL TUBULES
M.K. Schilling1, M.R. Moussavian1, J.E. Slotta1, O. Kollmar1, M.D. Menger2, 
1Department of General, Visceral, Vascular and Pediatric Surgery, and 
2Institute of Clinical and Experimental Surgery, University of Saarland, 
D-66421Homburg/Saar, Germany
Introduction: The reduction of peroxide radicals (O22-) by superoxide radicals 
(O2-.). catalysed by iron ions (Fe2+) leads to the formation of hydroxy radicals 
OH., a highly reactive biological oxidantive which may contribute to oxidant 
stress in reoxygenated renal tissue.
We studied in tubular segments of rat kidney cortex (ITS) the effect of free 
iron ions (Fe2+/Fe3+). hemoglobin (hb) and intact erythrocytes on reoxygenation 
damage. We demonstrate that apart from the ischemic damage, additional tissue 
injury evolves as a result of reoxygenation.
Materials and Methods: All ITS were suspended in Ringer’s solution 
containing 5mM glycine and oxygenated for 30min with 95% O2 and 5% 
CO2, followed by a 30 minutes period with 95% N2 and 5% CO2, and fi nal 
reoxygenation with 95% O2 and 5% CO2 for 60 minutes. Untreated tubules 
served as controls (=100%). In the fi rst series, different concentrations of free 
hb were added to the incubation medium. In the second series, we examined 
the effect of intact erythrocytes. To investigate the oxidant activity, membrane 
leakage and lipid peroxidation were measured by the loss of the marker 
enzymes lactate dehydrogenase (LDH) and glutamate dehydrogenase (GLDH) 
into the medium and the development of thiobarbituric acid reactive substances 
(TBA-RS). Cell function was analysed using gluconeogenesis (GNG) and 
intracellular potassium accumulation (K+).
Results: Hb exerted cytotoxic effects indicated by signifi cantly increased 
enzyme leakage rates, lipid peroxidation and a signifi cantly raised cell function, 
(P<0.05) in ITS during extreme hypoxia and subsequent reoxygenation. 
Moreover, we found that toxicity of both Fe2+ and Fe3+ ions increased with 
rising concentration. However Fe2+ showed a higher tissue toxicity than Fe3+.
Conclusion: Our data clearly demonstrate a massive cytotoxic effect of free hb 
in ITS, which critically depended on the reduction state of the iron ions.
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SIGNALING PATHWAY ON THE EFFECT OF 1149 
OXYGENATED WARM PERFUSION PRIOR TO COLD 
PRESERVATION OF THE LIVER GRAFTS FROM NON-
HEART BEATING DONORS, AND THE ADDITIVE EFFECT OF 
EDARAVONE
Y. Kobayashi, Y. Akamatsu, T. Iwane, A. Nakamura, S. Satomi
Division of Advanced Surgical Science And Technology, Graduate School of 
Medicine, Tohoku University
Background and Aim: We reported that oxygenated warm perfusion prior to 
cold preservation (pre-perfusion) improved energy metabolism and decreased 
apoptotic cells in the grafts from non-heart beating donors (NHBD). previously. 
In this study, we investigated the effi cacy and molecular mechanisms of pre-
perfusion and the additive effect of free radical scavenger, Edaravone (Ed).
Method: Rat liver ex vivo perfusion model was used. Liver grafts from Wistar 
Rats were divided into four groups. HB group: grafts from heart beating 
donor. NHB group: grafts from NHBD. PRE group: grafts from NHBD and 
perfused prior to cold preservation. ED group: grafts from NHBD and perfused 
with Ed containing buffer at pre-perfusion. Warm ischemic time was 30 min. 
Oxygenated Klebs-Hensereit buffer at 37 °C was perfused via portal vain 
during pre-perfusion for 30 min. and reperfusion for 60 min. Bile production 
during reperfusion and ALT in perfusate were measured. MDA, MAPK family 
and apoptosis were examined in liver tissues.
Result: Bile production in ED group was higher than that in NHB group. ALT 
and tissue MDA content were reduced in PRE and ED group (table 1). p-JNK 
and p-p38 MAPK were also reduced in PRE and ED group (table 2). In contrast, 
pre-perfusion and addition of Ed did not infl uence the ERK activity. TUNEL 
positive cells in ED group were fewer than that in NHB group (table 1).
Conclusion: Oxygenated perfusion prior to cold preservation improves 
the viability of grafts from NHBDs as represented in improvement of bile 
production, release of transaminase, and down regulation of JNK and p38 
MAPK pathway was involved in these effects. Addition of Ed to pre-perfusion 
led to increasing bile production and reducing in cell death. Pre-perfusion was 
suggested to be promising strategy in liver transplantation from NHBD, though 
further investigation should be necessary.
Table 1
Parameters HB group NHB group PRE group ED group
Bile production 
(μl/g/h) 
42.27±2.98 19.28±4.01† 21.87±9.311† 24.46±4.422*†
TUNEL positive 
cells (counts/mm2) 
3.65±1.69 110.08±52.09† 63.79±25.04† 39.83±14.86**†
ALT (IU/l) 0.12±0.07 3.88±1.63† 1.22±0.40**† 1.29±0.42**†
MDA content 
(μmol/g protein) 
0.307±0.013 0.328±0.019 0.244±0.020** 0.239±0.022**
*: P < 0.05 vs. NHB group **: P < 0.01 vs. NHB group †: P < 0.01 vs. HB group
Table 2: p-JNK and p-p38 MAPK activity (Western Blot)
HB group NHB group PRE group ED group
p-SAPK/JNK 
(p-JNK/β-Actin) 
0.24±0.18 1.08±0.59 0.38±0.12** 0.37±0.14**
p-p38 MAPK 
(p-p38 MAPK/β-
Actin) 
0.45±0.27 0.53±0.34 0.25±0.13* 0.23±0.13*
The relative band intensities were expressed as the ratio of the protein of interest to beta-Actin. Results 
were expressed as the means ± S.D.
*: P < 0.05 vs. NHB group **: P < 0.01 vs. NHB group
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PROTECTIVE EFFECT OF GLYCERYL TRINITRATE 1150 
AND CARIPORIDE IN A MODEL OF DONOR HEART 
PRESERVATION: ACTIVATION OF ERK 1/2 PATHWAY
J. Kwan2, L. Gao2, P. Macdonald1, M. Hicks1
1St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: Demonstration of the association of pharmacological pre- and 
post-conditioning with activation of pro-survival kinase pathways such the 
p42/p44 extracellular signal-related MAP kinase (ERK 1/2) and the PI3K/
Akt pathways at reperfusion has provided a paradigm shift in the approach to 
myocardial protection. We have previously demonstrated that inclusion of 
preconditioning agents such as the nitric oxide donor, glyceryl trinitrate (GTN) 
and the sodium hydrogen exchange inhibitor, cariporide (Car) in Celsior, a 
commercially available storage solution, signifi cantly improved post-storage 
function in an isolated working heart model of donor heart preservation after 6 
hours hypothermic storage1. The aim of the present study was to examine the 
extent to which the ERK 1/2 and PI3K/Akt pathways were activated by these 
agents. 
Methods: Pre-arrest indices of cardiac function were measured in isolated 
working rat hearts after 25 minutes. Hearts were arrested and stored for 6 hours 
at 2-3°C in Celsior alone or Celsior supplemented with either 0.1 mg/ml GTN, 
10μM Car alone or in combination. After storage, hearts were remounted on the 
perfusion apparatus and indices of cardiac function were remeasured. Hearts 
were then bisected and frozen in liquid nitrogen for Western blot analysis or 
fi xed for imunohistochemical processing. 
Results: The values in the following table are post-storage recovery as 
percentage of pre-arrest values (mean ± SEM) :
Supplement; n
Heart Rate
 (beats/min) 
Coronary Flow
 (ml/min) 
Aortic Flow
 (ml/min) 
Cardiac Output
 (ml/min) 
None; 8 48 ± 12 31 ± 12 15 ± 8 22 ± 9
GTN; 9 94 ± 8* 70 ± 8* 42 ± 7* 52 ± 7*
Car; 6 115 ± 6* 82 ± 3* 66 ± 4* 70 ± 3*
GTN + Car; 6 95 ± 6* 85 ± 3* 60 ± 5* 68 ± 3*
P < 0.05 vs unsupplemented Celsior control.
The observed improved post-storage function of hearts stored in Celsior 
supplemented with glyceryl trinitrate and cariporide alone or in combination 
was associated with: i) an increase in phosphorylation status of ERK 1/2, ii) an 
increase in phospho Bcl2 (Ser87). an anti-apoptotic marker and downstream 
substrate of ERK 1/2, iii) a decrease in pro-apoptotic cleaved (activated) 
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caspase 3 (P < 0.01 all celsior supplements vs unsupplemented Celsior for each 
protein) and iv) no increase in phosphorylation status of Akt. 
Conclusions: GTN and cariporide alone or in combination are able to activate 
the ERK 1/2 pro-survival pathway. Importantly for the logistics of clinical 
cardiac procurement, the heart need only be exposed to the protective agents at 
the time of arrest and hypothermic ischemic storage obviating the need for pre-
treatment of the donor or treatment (of the recipient) at reperfusion.
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SUCCESFUL TRANSPLANTATION OF ALLOGENEIC 1151 
AND XENOGENEIC ARTERIAL GRAFTS PRESERVED IN 
PULVERIZED SODIUM CHLORIDE
M. Gewartowska1, M. Maksymowicz1, H. Doleżyczek1, W.L. Olszewski1,2
1Department of Surgical Research and Transplantology, Medical Research 
Center, Polish Academy of Sciences, Warsaw, Poland 2Norwegian Radium 
Hospital, Oslo, Norway
Arterial graft patency is limited by a process of rejection at the site of 
implantation. In our previous methods dehydrated studies skin fragments 
preserved for 10 months and transplanted to SCID mice were taken by 
recipient. 
Aim: To establish a method of successful aortic preservation for long time 
periods with unchanged morphological structures and low allogeneic and 
xenogeneic reactivity. 
Methods: Freshly obtained fragments of rat aorta were fi xed in anhydric 
sodium chloride and stored at 4oC up to 3 months. Cryosections of desalinated 
aortic samples were evaluated on histology using H/E method, trichrome and 
Gomori staining and immunohistochemical staining for CD 31, factor VIII 
and actin. Group 1.Syngeneic and allogeneic transplantations of rat aorta were 
performed in a LEW to LEW or BN to LEW combination. Specimens were 
collected 1 year after transplantation. Histological evaluation was the same as 
before grafting. In group 2, fragments of small arteries of a diameter of 2-4 mm 
obtained from the amputated human legs were transplanted to LEW rats as in 
group 1. Histological evaluation was carried out with use of mAbs against rat 
and human endothelial cell, lymphocyte and macrophage antigens. 
Results: Group 1.H/E staining showed preserved anatomical structure of aortae 
after storage in NaCl. No signifi cant differences between NaCl fi xed and non-
fi xed aortae in staining against CD 31, factor VIII, actin and trichrome were 
found. The orthotopically transplanted aortae did not evoke local recipients 
reaction and pulsated up to 1 year after transplantation. Moreover, we did 
not observe signifi cant cellular infi ltrates around the graft after subcutaneous 
implantation of fi xed aorta. The tensile strength of harvested specimens did not 
differ from controls. Group 2. Grafts were remaining pulsating over a period of 
3 months. Only minor peri-graft infi ltrates composed of rat ED1 (macrophage) 
cells. Grafts retained their structure and human CD31 on endothelial cells. 
Conclusions: Perfectly preserved anatomical and molecular structure of 
transplanted aortae stored at 4oC for months, indicate that dehydration in 
anhydric NaCl may be considered as a novel method for preservation of arterial 
grafts. Moreover, limited allo- and xenogeneic reactivity of recipient to the 
graft may protect against mechanical weakning of the pulsating graft.
POSTER BOARD NUMBER P1 – 237
DANSHEN PROTECTS KIDNEY GRAFTS FROM 1152 
ISCHEMIA/REPERFUSION INJURY AFTER EXPERIMENTAL 
TRANSPLANTATION
A. Nickkholgh1, X. Guan1, G. Dei-Anane1, H. Bruns1, R. Liang1, 
M-L. Gross2, M. Kern2, J. Ludwig3, M.W. Büchler1, P. Schemmer1
1Dept. of Surgery, Ruprecht-Karls University of Heidelberg, 2Dept. of 
Pathology, Ruprecht-Karls University of Heidelberg, 3Central Laboratory, 
Ruprecht-Karls University of Heidelberg
Introduction: Ischemia/reperfusion injury (IRI) remains one of the major 
problems in transplantation. Substances with low overall toxicity that can 
ameliorate IRI are desperately needed. Hence, we investigated the effect of 
the traditional Chinese medicine Danshen (DS, Salvia miltiorrhiza) on IRI in 
experimental kidney transplantation (eKTx).
Methods: Sprague-Dawley rats underwent eKTx. Two groups were infused 
with 1.5ml DS 10 minutes before organ harvest or transplantation while 
controls received the same volume Ringer solution. After 20h of cold storage 
in HTK, eKTx was performed.
Blood and tissue samples were collected 6h after reperfusion. BUN, creatinine, 
LDH, ALT and tubular damage (TDI). caspase-3 (CI) and heat shock protein 
indexes 72 (HI). superoxide dismutase (SOD). inducible nitric oxide synthase 
(iNOS) and tumor necrosis factor (TNF) á were assessed.
Results: Donor preconditioning with DS (DS-d) signifi canty decreased BUN, 
creatinine, LDH and AST to 91%, 97%, 65% and 97% of controls while 
preconditioning of the recipient (DS-r) decreased values to 80%, 82%, 69% 
and 58%, respectively (p<0.05). TDI and CI decreased signifi cantly in both 
groups (DS-d: 96% and 67%, DS-r: 83% and 75% of controls; HI and SOD 
increased signifi cantly (DS-d: 143% and 173%, DS-r: 166% and 194% of 
controls). Further, iNOS and TNF á decreased (DS-d: 84% and 61%, DS-r: 
79% and 67%) after DS.
Conclusions: Preconditioning of both donors and recipients with DS reduces 
IRI and thus improves graft function in eKTx.
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SUCCESSFUL SOLID ORGAN TRANSPLANTATION 1153 
FROM BRAIN DEATH BY SALMONELLA ENCEPHALOPATHY
Y.S. Han, D.L. Choi, M.S. Kim, E.J. Jang, J.Y. Park, J.H. Mun
Daegu Catholic Medical Center, Catholic University of Daegu, School of 
Medicine
Systemic donor infections are largely contraindication to cadaveric organ 
donation for transplantation due to fear of transmitting the pathogenic 
organisms to the immunosuppressed recipients. Especially, Salmonella species 
infection, because of virulence, tendency to adhere to endothelial surfaces, and 
the ability of spread hematogenously to other sites, render a donor undesirable. 
However, We experienced successful organ transplantation from donor with 
negative culture after administration of adequate antimicrobial therapy.
A 53-year old man was transferred to our hospital for decision of brain death 
and organ donation. The patients had an encephalopathy following infection of 
Salmonella Group D as the cause of brain death. The donor was treated until 
blood cultures were negative. Cetotaxime was used for over 14 days in the 
intensive care unit. The liver and two kidneys were procured. All recipients 
are alive with excellent graft function at 12 months following transplantation. 
The question is whether recipients are infected by grafts from the donors even 
though all them are given prophylactic antibiotic therapy. Our experience 
suggests that donor with Salmonella infection under proper treatment can be 
considered for transplantation.
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PREDICTIVE PRESERVATION: TOWARD AN EVIDENCE-1154 
BASED ORGAN RETRIEVAL STRATEGY
L. Hostert1, J. Pratt2, S. McKenzie1, D. Potts3, P. Lodge1
1Department of Organ Transplantation Leeds Teaching Hospitals, 2Leeds 
Institute of Molecular Medicine, 3University of Leeds
In renal transplantation the choice of preservation strategy for the various 
donor types is not evidence based. This study is a fi rst attempt to match the 
effi cacy of preservation fl uids to the period of cold ischaemia using an in-depth 
assessment of functional parameters. The aim of this work is to investigate the 
effects of preservation fl uids over time to predict which fl uid should be used in 
any particular clinical scenario, so- called “Predictive Preservation”.
Male Wistar rat kidneys were fl ushed with a preservation solution (PBS140, LS, 
SLS, HOC or UW) and were stored at 4oC for 0-72 hours (n = 6/group). The 
kidneys were then maintained for 2 hours on an optimised ex vivo reperfusion 
circuit at 37oC. Physiological analyses of reperfusion fl uid and urine were 
performed at 30 minute intervals to assess ischaemia/reperfusion injury (I/RI) 
to components of the nephron.
Using the optimised ex vivo model, preservation with LS produced signifi cantly 
improved urine fl ow rate, GFR and% Na+ reabsorption (29, 44 and 25% 
increase respectively) when compared to organs preserved in PBS140, HOC 
or UW (P<0.05) after 24 hours of preservation. Compartmental assessment 
suggested LS attenuated tissue damage in the glomerulus, the proximal tubules 
and the collecting system that was supported by histological observation. Using 
percentage contribution analysis the data showed differential effects of time on 
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cold ischaemic damage in the different nephron compartments. In effect, the 
cumulative data rank scores showed that from 24 to 48 hours, LS was optimal, 
but not at either extreme. At time 0, PBS140 was best, and beyond 48 hours, 
SLS or PBS140 was optimal.
In conclusion, a global assessment of functional parameters has enabled an 
in-depth assessment of fl uids used in experimental renal cold storage. The data 
suggests different fl uids should be applied where a short (living donation). 
or longer (cadaveric) cold ischaemic time is anticipated, i.e. Predictive 
Preservation. Importantly, all fl uids which best protected the kidney from I/
RI were based on PBS140 and outperformed UW across the duration of cold 
ischaemia. To diminish I/RI and maximise post-transplant functional recovery, 
we advocate an evidence-based approach to preservation be developed in the 
future and that consideration be given to PBS based preservation for clinical 
renal transplantation.
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TOLERANCE OF THE COLD PRESERVATION OF LIVER 1155 
GRAFT IS LIVER MASS DEPENDENT
Y.L. Gu1, J.F. Schlaak2, U. Rauen3, A. Paul4
1Department of General, Visceral And Transplantation Surgery, 2Department 
ofGastroenterology and Hepatology, University Hospital of Essen, 32Institute 
of Physiological Chemistry, University Hospital of Essen, 4Department of 
General, Visceral And Transplantation Surgery
Aims: Due to the shortage of donor livers, partial liver transplantation is 
currently being used more and more frequently. The mechanisms of primary 
graft non-function and factors affecting liver regeneration after small-for-size 
(SFS) liver transplantation are not completely understood. The aim of the 
present study was to assess the effect of cold ischemia time on postoperative 
liver injury and graft regeneration after SFS liver transplantation using a rat 
model.
Methods: Inbred male Lewis rats (250-300g) were subjected to 70% liver 
resection as donors and the partial liver grafts were then transplanted into 
recipients. Livers were preserved with an HTK (histidine-tryptophan-
ketoglutarate) solution at 4°C for 5 hours (group A, n=5) or 8 hours (group 
B, n=7) before transplantation. Full-size liver transplantations with 19 hours 
cold ischemia were performed on a control group (group C, n=4). The animals 
were sacrifi ced on postoperative day 7. Survival rate, liver function and 
changes in the graft recipient body weight (GRBW) ratio of the recipients were 
investigated.
Results: All animals in group A survived. Prolonged time of cold preservation 
(8 hours) was associated with a statistically signifi cant decrease of animal 
survival in comparison to animals with 5 hours cold ischemia after SFS liver 
transplantation (42.86% vs. 100%, p<0.05). All animals receiving a full-size 
liver with a cold ischemia time of up to 19 hours survived. The initial GRBW 
ratios of the recipients in group A and B were 1.49% ± 0.14% and 1.50% ± 
0.12%, respectively (p>0.05). whereas on postoperative day 7 the GRBW ratio 
was signifi cantly lower in group B than in group A (4.27% ± 0.21% vs. 4.68% 
± 0.38%, p<0.05).
Conclusions: The animal survival and the graft regeneration were signifi cantly 
reduced after only 3 hours prolongation of the cold storage for a small-for-
size graft, suggesting that the small-for-size grafts are particularly sensitive 
to cold storage injury. The cold preservation time of a full-size graft could be 
almost 4 times longer than a SFS graft, indicating that the duration of the cold 
preservation of liver graft is liver mass dependent.
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IMPROVED CORTICAL MICROCIRCULATION OF 1156 
PORCINE KIDNEY GRAFTS USING POLYSOL FOR WASH-OUT 
AND COLD STORAGE PRESERVATION
M.C.J.M. Schreinemachers1, B.M. Doorschodt1, R.H. Tolba2, T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands, 
2House of Experimental Therapy, University Clinic of Bonn, Germany
Background: The most widely used preservation method for kidney grafts 
is cold static storage (CS) using the University of Wisconsin solution (UW). 
To date, new preservation solutions have not been able to clearly improve 
preservation quality of grafts. The aim of this study was to compare Polysol 
(PS). a recently developed low viscosity preservation solution based on the 
colloid Poly-Ethylene-Glycol, and UW solution for CS of porcine kidney grafts. 
Furthermore, we evaluated real time parameters of cortical microcirculation, 
pre-retrieval, at 10 minutes post-reperfusion and 7 days posttransplant at 
sacrifi ce using the novel Oxygen-To-See (O2C) laser Doppler fl owmetry and 
remission spectroscopy system.
Methods: German Landrace pigs underwent left nephrectomy directly after 
assessment of cortical microcirculation using the O2C. Kidneys were washed 
out with PS or UW followed by 20 hr CS in PS and UW, resp. Thereafter, 
the contralateral kidneys were removed prior to reimplantation of the 
preserved kidneys. Ten minutes after reperfusion, the cortical microcirculation 
was assessed. Renal function was measured daily. Prior to removal of the 
kidney grafts for histological evaluation seven days posttransplant, cortical 
microcirculation was reassessed and animals were sacrifi ced.
Results: All animals survived for 7 days. In the PS group, improvement of 
microcirculation was seen as expressed by higher capillary blood fl ow, higher 
blood fl ow velocity and higher tissue oxygen saturation values at 10 minutes after 
reperfusion (capillary blood fl ow p<0.001, blood fl ow velocity p<0.001, tissue 
oxygen saturation PS 88.9% vs UW 79.3%, p<0.05) as well as 7 days posttransplant 
compared to the UW group (capillary blood fl ow p<0.001, blood fl ow velocity 
p<0.001, tissue oxygen saturation PS 82.0% vs UW 66.6%, p<0.001). Overall, PS 
preserved grafts showed improved recovery of renal function demonstrated by lower 
posttransplant serum creatinine and blood urea values in the PS group in comparison 
to the UW group (p=0.041 and p=0.048 resp.). Also, peak-creatinine and peak-urea 
values were lower in PS preserved grafts (peak-creatinine, PS 4.79 ± 0.59 mg/dl, 
UW 13.01 ± 2.86 mg/dl, p=0.004 and peak-urea, PS 81.5 ± 14.3 mg/dl, UW 225.8 
± 60.2 mg/dl, p=0.015). At sacrifi ce, creatinine clearance rates in the PS preserved 
grafts were signifi cantly higher than in the UW group (33.09 ± 2.7 ml/min, vs. 
12.30 ± 8.7 ml/min, p=0.046 resp.). Glomerular shrinking and tubular injury were 
less pronounced in the PS group, compared to UW. Also, less infl ammatory cell 
infi ltrates were present in the cortical region of PS preserved grafts.
In conclusion, using Polysol, cortical microcirculation was better preserved 
and renal function was improved after 20 hr CS preservation compared to UW 
solution. This study in a clinically relevant large animal model, suggests for 
the fi rst time since the introduction of UW solution that a new preservation 
solution resulted in clearly improved preservation quality of kidney grafts.
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PRESERVATION OF KIDNEY GRAFTS WITH 1157 
THE AIRDRIVE, A NOVEL DISPOSABLE SYSTEM FOR 
OXYGENATED PERFUSION
M-C. Schreinemachers1, B.M. Doorschodt1, T.M. van Gulik1, R.H. Tolba2
1Academic Medical Center, University of Amsterdam, The Netherlands, 
2House of Experimental Therapy, University Clinic of Bonn, Germany
Body: Recently, a disposable machine perfusion (MP) system for preservation 
of kidney and liver grafts has been developed, named the Airdrive (AD). This 
air-pressure driven, hypothermic perfusion system allows for oxygenated 
pulsatile MP during the entire preservation period.
The aim of the study was to assess MP preservation with the Airdrive using 
the new low-viscosity perfusion solution Polysol (PS-AD) in comparison with 
cold storage (CS) using Polysol solution (PS-CS) or University of Wisconsin 
(UW-CS) as controls. 
Methods: German Landrace pigs (18-32 kg) underwent left nephrectomy. 
Kidneys were thereafter fl ushed with either UW (n=6) or PS (n=6) followed by 
20 hr CS using UW or PS, respectively. Machine perfused kidneys were fl ushed 
using PS followed by 20 hr of MP (n=6). Pulsatile perfusion was performed 
with a mean arterial pressure of 20 mmHg at a temperature of 2-6 C. After 
preservation, all kidneys were autotransplanted and the contralateral kidneys 
removed. Renal function was assessed daily. Seven days posttransplant, animals 
were sacrifi ced and the kidney grafts removed for histological analysis. 
Results: All animals survived for 7 days. Overall, an improved recovery 
of renal function was seen in both the PS-AD group and the PS-CS group 
compared to the UW-CS group. Also, peak creatinine and peak urea values 
were lower in PS preserved grafts for both MP and CS (peak creatinine (mg/
dl). PS- AD: 3.58 0.81, PS-CS: 4.79 0.59, UW-CS: 13.01 2.86, p=0.003, and 
peak urea (mg/dl). PS-AD: 67.2 10.7, PS-CS: 81.5 14.3, UW-CS: 225.8 60.2 
mg/dl, p=0.013). Mean posttransplant creatinine clearance rates were higher in 
the PS-AD and PS-CS groups at all timepoints with signifi cant differences at 
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posttransplant days 2 and 7 (Creatinine clearance at day 7 (ml/min): PS-AD: 
33.4 2.1, PS-CS: 33.1 2.7, UW-CS: 12.3 8.7, p=0.021). Histological evaluation 
showed less glomerular damage, less tubular injury, less infl ammatory cell 
infi ltrates and less edema in the machine perfused grafts compared to the cold 
stored grafts. Also, grafts cold stored in Polysol showed better preservation of 
structural integrity than UW preserved grafts. 
Conclusions: Renal function after 20 hr of preservation was signifi cantly 
improved with both MP using the recently developed Airdrive MP system as 
well as CS using Polysol as compared to UW-CS in a large animal model. 
Structural integrity was better preserved using oxygenated pulsatile perfusion 
compared to both PS-CS and UW-CS groups. This study in a large animal model 
demonstrates signifi cant higher quality preservation of oxygenated machine 
perfusion of heart-beating kidney grafts using the Airdrive in combination with 
Polysol, as compared to cold storage.
POSTER BOARD NUMBER P1 – 243
IMPROVED RENAL FUNCTION OF WARM 1158 
ISCHEMICALLY DAMAGED KIDNEYS USING POLYSOL
M-C. Schreinemachers1, B.M. Doorschodt1, M.M. Idu1, R.H. Tolba2, 
T.M. van Gulik1
1Academic Medical Center, University of Amsterdam, The Netherlands, 
2University Clinic of Aachen, Aachen, Germany
Background: The gold standard for preservation of warm ischemically damaged 
kidneys is cold storage (CS) using Histidine-Tryptophane-Ketoglutarate 
(HTK) solution. Recently, a new low-viscosity perfusion preservation solution, 
Polysol (PS). was developed. The effi cacy of PS has been proven in different 
small and large animal organ preservation models. In a previous study using 
a porcine renal autotransplantation model, the preservation of heart-beating 
donor kidneys using PS resulted in improved renal function compared to the 
University of Wisconsin solution.
The aim of this study was to assess the effi cacy of PS for the preservation of 
NHBD kidney grafts in a porcine autotransplantation model compared to HTK 
solution and a uninephrectomy group as control.
Methods: Pigs (25-30 kg) underwent left nephrectomy after clamping the 
renal vessels for 30 minutes. Kidney grafts were washed out with PS (n=6) 
or HTK (n=6) and cold stored for 20 hr at 4 C. After the preservation period, 
the contralateral kidney was removed and the preserved kidney was implanted 
heterotopically. Pigs which underwent uninephrectomy served as non-ischemic, 
non-transplanted controls (Uni, n=4). Renal function was assessed daily for 
seven days, after which time animals were sacrifi ced and the kidney grafts 
removed for histological analysis.
Results: All animals survived for 7 days. All PS-CS preserved grafts showed 
immediate function, as demonstrated by urine production within 24 hours after 
reperfusion as compared to 3 out of six grafts in the HTK-CS group. Overall, 
the PS-CS group showed improved renal function compared to HTK-CS (serum 
creatinine, area under the curve (AUC). p<0.01 and blood urea, AUC p<0.05, 
resp.). Blood urea values of the PS-CS group (AUC) did not differ from the Uni 
group. Serum creatinine peak-values were lower in the PS-CS group compared to 
the HTK preserved grafts (p<0.0001). but higher when compared to Uni controls 
(PS-CS vs Uni, p<0.0001 and HTK-CS vs Uni, p<0.0001; peak creatinine 
(umol/l). PS-CS 629.8 ± 64.8, HTK-CS 1016 ± 39.6, Uni 170.8 ± 27.1). In 
addition, peak-urea values provided a similar outcome. Histological evaluation 
of the warm ischemically damaged grafts showed less tubular damage, less 
edema, less infl ammatory cell infi ltrates and less necrosis in the PS-CS preserved 
grafts compared to grafts washed out and preserved using HTK.
Conclusion: Application of the new Polysol solution for wash out and 
CS preservation of warm ischemically damaged kidney grafts resulted in 
signifi cantly improved renal function and structural integrity when compared 
to wash out and CS preservation using the current clinical standard HTK.
POSTER BOARD NUMBER P1 – 244
EVALUATION OF FUNCTIONAL AND BIOCHEMICAL 1159 
EFFECTS OF WARM ISCHEMIA ON KIDNEY GRAFTS USING 
AN OPTIMIZED PORCINE EXPERIMENTAL MODEL
M. Morsy, M. Hossain, M. Nortley, N. Kessaris, R. Chang.
Renal Transplant Unit, St George’s Hospital, London, UK
Introduction: Warm ischemia negatively affects the outcome of organ 
transplantation. The length of warm ischemia time (WIT) is diffi cult to 
determine in clinical setting. Therefore, it can be diffi cult to assess the 
damage sustained by the organs and predict their viability. We report our early 
experience in developing an optimized porcine experimental model to assess 
the effect of warm ischemia on kidney grafts.
Material and Methods: Twelve female wild-white pigs were included in 
this study after obtaining a project license (PPL70/6580-UK). Additionally, 
3 pigs (controls- 0 WIT) were used to optimize the surgical procedures 
including surgical approaches, contralateral nephrectomy timing and ureter 
exteriorization. The pigs were randomized into 4 groups (3 pigs/each) according 
to the length of WIT; 30, 45, 60 and 90 minutes. The left kidney was exposed in 
situ to WI by clamping the renal artery. A T-tube was inserted in the ureter and 
exteriorized in the groin to check the urine before the contralateral nephrectomy. 
A microdialysis needle was inserted in the cortex 30 minutes before clamping. 
Microdialysis samples were collected every 15 minutes before and during 
WI for glucose, lactate, pyruvate and glycerol analysis. The left kidney was 
then reperfused. The contralateral kidney was kept in situ until the left kidney 
function was approved by (T tube urine, ~7 days). The contralateral kidney 
removal was performed after exposing it to the same WIT as the left kidney 
in the same animal with microdialysis sample collection. Then, it was cold-
perfused in a pulsatile machine. The pig was kept alive for a week to assess the 
function of the left kidney (urine output and serum potassium and creatinine).
Results: There was positive correlations between WIT and glycerol and lactate 
concentrations (R2=0.779 and 0.105) with signifi cant increase in the mean 
change from baseline; 50, 29.33, 38.06, 119.53, 136.4, 128.2, 144.7 umol/L 
for glycerol and 1.26, 1.86, 4.66, 3.82, 3.67, 2.87, 2.57 mmol/L for lactate at 
0, 15, 30, 45, 60, 75 and 90 minutes WIT respectively. There was a negative 
correlation between WIT and glucose and pyruvate concentrations (R2=0.909 
and 0.807) with signifi cant decline from baseline; 2.5, 1.89, 1.05, 0.84, 0.13, 
0.03, 0.06 mmol/L for glucose and 64.4, 36.93, 24.6, 5.53, 3.58, 3.2, 1.9 umol/L 
for pyruvate at 0, 15, 30, 45, 60, 75 and 90 minutes WIT respectively.
The perfusion fl ow was signifi cantly lower and the resistance was higher at 
60 and 90 minutes WIT compared to 0 and 30 minutes at pre-set 40 mmHg 
pressure and 2-5Co. The glycerol and lactate concentration declined constantly 
while there was no change in glucose and pyruvate during machine perfusion. 
There was no observed delayed graft function with good urine output in all 
groups.
Conclusions: We devised an optimized porcine experimental model to evaluate 
the effect of WIT on the kidney function. It enabled evaluation of microdialysis 
markers. It enabled utilizing the contralateral kidney in WIT and cold ischemia 
studies. Although the number of animals is small, it demonstrated a trend of 
change in microdialysis markers and perfusion parameters.
POSTER BOARD NUMBER P1 – 245
NITRIC OXIDE SYNTHASE (NOS) COFACTOR ACTIVITY 1160 
OF TETRAHYDROBIOPTERIN (BH4) IS ESSENTIAL IN 
ATTENUATING MICROVASCULAR REPERFUSION INJURY 
FOLLOWING MURINE PANCREAS TRANSPLANTATION
M. Maglione1, R. Oberhuber1, P. Hengster1,2, M. Hermann2, W. Mark1, P. 
Obrist3, G. Werner-Felmayer4, E.R. Werner4, R. Margreiter1, G. Brandacher1
1Department of General and Transplant Surgery, Innsbruck Medical 
University, Austria, 2Center for Islet-Cell Transplantation, Innsbruck Medical 
University, Austria, 3Institute of PathologyKrankenhaus St. Vinzenz, Zams, 
Austria, 4Division of Biological Chemistry, Biocenter, Medical University of 
Innsbruck, Austria
Purpose: Tetrahydrobiopterin (BH4) is not only an essential cofactor for nitric 
oxide synthases and thus a critical determinant of NO production but also a 
strong antioxidant. In this study we compared the recently shown protective 
effect of BH4 supplementation previous to organ retrieval with supplementation 
of 4-amino-tetrahydrobiopterin (ABH4). a pteridin analogue with similar 
chemical redox behaviour but no cofactor activity.
Material and Methods: Male syngeneic C57BL6 mice, were used as size-
matched donor and recipient pairs. Cervical heterotopic vascularized pancreas 
transplantation was performed with a modifi ed no-touch technique. Pancreatic 
grafts were subjected to 16h prolonged cold ischemia time (CIT) and different 
treatment regiments: untreated (I). BH4 50mg/kg i.m. prior to organ reperfusion 
(II) and ABH4 50mg/kg i.m. prior to organ reperfusion (III). Non transplanted 
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animals served as controls (IV). After 2h of reperfusion intravital fl uorescence 
microscopy was used for analysis of graft microcirculation by means of functional 
capillary density (FCD) and capillary diameters (CD). Quantitative assessment 
of parenchymal damage was analysed by histology (H&E) and by performing 
nitrotyrosine-immunostaining to determine peroxynitrite formation.
Results: Following prolonged CIT only pancreatic grafts treated with BH4 
prior to retrieval (II) displayed NOS stabilization and hence markedly higher 
values of FCD and CD compared to non treated animals (I) (p<0.01 and 
p<0.05 respectively). In contrast, pre-treatment of donor animals with ABH4 
(III) did not improve FCD or CD levels. However, parenchymal damage as 
well as peroxynitrite formation were signifi cantly attenuated in grafts of both 
treatment regiments (p<0.05). Acinar haemorrhage and fat necrosis as well as 
peroxynitrite formation were signifi cantly reduced by BH4 treatment compared 
to ABH4 (p<0.05).
Conclusion: The protective effect of BH4 supplementation prior to organ 
procurement on microcirculation relies on its NOS cofactor activity rather than 
on its antioxidative capacity. BH4 might therefore be a novel, promising agent 
to attenuate IRI in clinical solid organ transplantation.
INFECTIOUS DISEASE – CONCURRENT ORAL SESSION 84: 
BACTERIAL, FUNGAL AND OTHER INFECTIONS
POSTER BOARD NUMBER P1 – 246
IS PREOPERATIVE INTRAVESICALLY APPLIED 1161 
ANTIBIOUTIC SOLUTION EFFECTIVE IN THE PROPHYLASIS 
OF URINARY TRACT INFECTION COMPLICATIONS OF 
RENAL TRANSPLANTATION
M. Salehipour1, H. Jalaeian2, H. Salahi1, A. Bahador1, S. Nikeghbalian1, K. 
Kazemi1, M. Nejatollahi1, M. Dehghani1, A. Malek-hosseini1
1Shiraz University of Medical Sciences, 2Ipswich Hospital, QLD, Australia
Background: Urinary tract infection (UTI) is a major cause of morbidity and 
mortality in renal transplant recipients. The effect of intravesically applied 
antibiotic solution in the prevention of infectious complications of renal 
transplantation is still controversial. The aim of this study was to evaluate the 
effi cacy of intravesical Amikacin for the prophylaxis of the post transplant UTI 
within the fi rst three months after kidney transplantation.
Methods: In a prospective, randomized controlled trial, two hundred consecutive 
renal transplant recipients were randomly allocated to two 100 study groups. 
The bladder was fi lled preoperatively with saline solution containing Amikacin 
(1 gr in Adults or 30 mg/kg in children) in the test group, and with saline 
solution only in the controls. Patients were followed up for three months after 
the transplantation. Post operative urinary tract infection was defi ned based 
on a urine culture with a bacterial count of 100,000 CFU per mL of urine, or a 
positive nitrate test. Factors such as gender, age, the underlying kidney disease, 
receiving the fi rst graft or subsequent retransplantation, and the source of graft 
(living-related, unrelated, or deceased donor) were analysed.
Results: The overall incidence of UTI was signifi cantly lower in the test group (25% 
vs. 49%; p=0.0007). In addition, male patients, adults, fi rst kidney graft recipients, 
patients with ESRD due to glomerulonephritis, having renal transplantation for 
the fi rst time, or those patients from the test group receiving a living-related graft 
have signifi cantly lower episodes of UTI than their control counterparts. (p<0.05) 
Ecoli was the most common organism causing UTI (28.9%).
Conclusion: The addition of Amikacin to the bladder irrigation fl uid could 
have signifi cant effects on the overall incidence of UTI in the fi rst three months 
after the kidney transplantation.
POSTER BOARD NUMBER P1 – 247
INFECTIOUS COMPLICATIONS IN PATIENTS WITH 1162 
KIDNEY TRANSPLANTATION: LONG-TERM FOLLOW-UP 
RESULTS
C. M. Kang1, T.Y. Koo1, G-H. Kim1, C.H. Lee1, O.J. Kwon2
1Hanyang University Hospital, Department of Internal Medicine, 2Hanyang 
University Hospital, Department of Surgery
Background: Kidney transplantation (TX) has become a well-established, 
highly successful therapy for end-stage renal disease and is more widely 
accessible now than in previous decades. The risk of any infection is much 
greater in the immunosuppressed transplant population than in general 
population. Although the current infection-related one-year mortality has been 
reduced to less than 5%, infectious complications (Cx) remain serious threats 
to successful outcomes following transplantation. This study was undertaken 
to investigate current epidemiology of bacterial, viral and fungal infections in 
renal transplant recipients and to identify the risk factors for their occurrence.
Patients and Methods: Clinical data were retrospectively analyzed from 534 
recipients who underwent kidney TX from February 1986 to September 2006. 
Antimicrobial prophylaxis included preoperative 1st generation cephalosporin 
and trimethoprim/sulfamethoxazole and isoniazid for post-transplant six months. 
Immunosuppressive regimens were cyclosporine or tacrolimus, prednisolone, 
and mycophenolate mofetil or azathioprine. The infections were grouped into 
4 categories; infection within 1 month after transplantation, infection between 
1 to 6 months after transplantation, infection between 6 months to 1 year after 
transplantation and infection later than 1 year after transplantation.
Results: 251 recipients (47.0% of total) had 390 episodes of infectious Cx. 
Most patients (86.8%) suffer 2 or less episodes of infection. No opportunistic 
infections due to cytomegalovirus (CMV). tuberculosis (Tbc). pneumocystis 
carinii, or fungi, occurred within 1 month after TX. The skin and soft tissue 
(40.7%) infection was the most common over all post-transplant periods, and 
the most common causative organism was virus (55.2%). Among the bacterial 
infections, the urinary tract (UTI) (43.0%) was the most common sites of 
infection. The causative organisms of UTI were E.coli (41.5%) and coagulase 
negative staphylococcus (19.5%). Pneumonia occurred in 25 patients; seven 
of them had prior history of steroid pulse therapy for acute rejection, and 
two patients expired. In viral infections, varicella-zoster virus was the most 
frequent organism. 28 patients (16.9%) developed CMV diseases, and 32% of 
CMV diseases had tissue invasive diseases. 24 patients had post-TX Tbc. None 
of them died of Tbc or its Cx. Overall mortality after kidney TX was 8.0% and 
infection-related mortality was 3.2%. Female sex associated with infectious 
Cx occurring after kidney TX and ATG therapy for acute rejection and age 
at kidney TX (¡Ã40 years) were associated the risk for infection within one 
month. Steroid pulse therapy was associated with the risk for UTI and bacterial 
infection between 1 to 6 month after TX.
Conclusion: Infectious complications are the important cause of morbidity 
and mortality in the post-transplant period. Strategies to reduce the infectious 
complications are necessary for the successful kidney transplantation outcome.
POSTER BOARD NUMBER P1 – 248
SIGNIFICANCE OF POSITIVE URINE CULTURES 1163 
DURING THE IMMEDIATE POST-TRASNPLANT PERIOD IN 
RENAL TRANSPLANT RECIPINETS. RETROSPECTIVE STUDY
M. Koukoulaki1, I. Baraboutis2, E. Platsouka3, V. Papastamopoulos2, V. 
Hadjiconstantinou1, O. Paniara3, A. Skoutelis2, S. Drakopoulos1
1Transplant Unit, Evangelismos, General Hospital of Athens, 25th 
Department of Internal Medicine – Division of Infectious Diseases, 
Evangelismos, General Hospital of Athens, 3Department of Microbiology, 
Evangelismos, General Hospital of Athens
Purpose: Urinary tract infections are the commonest cause of bacterial 
infection in renal transplant recipients. Epidemiology study the immediate 
post-transplant period raises special interest because immune suppression 
treatment includes different agents and patients are in hospital environment. 
Purpose of the present retrospective study is to audit urinary tract infections the 
fi rst post-transplant month and identify potential risk factors.
Patients and Methods: During the period of September 2002 till September 
2007 renal transplant recipients who had complete data on urine culture and 
urinalysis the fi rst post-transplant month were included in the study. All 
recipients except for the induction therapy and triple immune suppressive 
regimen, were treated with prophylactic antibiotics with cephotaxim (third 
generation cephalosporin) for 10 days and then ciprofl oxacin for six weeks.
Results: 116 renal transplant recipients of mean age 50,6±9,7 years old and 
male gender 74,1% (86/116) were studied. During the follow-up period of one 
month, 50 positive urine culture were identifi ed which were derived from 38 
(38/116, 32,7%) renal transplant recipients, of whom 27 presented only one 
positive urine culture. Urinalysis identifi ed pyuria in 18 recipients with positive 
urine culture which was considered as presentation of urinary tract infection. 
More specifi cally pathogen microbes were Gram positive bacteria (22/50, 
44%) with commonest pathogen Enterococcus faecalis, Gram negative bacteria 
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(17/50, 36%) with commonest pathogen Pseudomonas aeruginosa and fi nally 
fungus (11/50, 22%) (three cases with Candida albicans and eight with Candida 
non-albicans). Mean time of identifi cation of positive urine culture 14±4,7 
days post transplantation. Preliminary statistical analysis revealed signifi cant 
relation of positive urine culture with female gender (Pearson x2, p=0,043) and 
cold ischemia time (non-parametric test Mann Whitney U, p=0,005). Further 
analysis of urinary tract infection presented with pyuria did not show signifi cant 
relations with the parameters examined.
Conclusions: Positive urine cultures were observed in 32,7% of renal transplant 
recipients with commonest pathogens Enterococcus faecalis and Pseudomonas 
aeruginosa. These fi ndings demonstrate signifi cant relation with female gender 
and cold ischemia time.
POSTER BOARD NUMBER P1 – 249
ETIOLOGICAL AGENTS OF FUNGAL INFECTIONS 1164 
IN PATIENTS AFTER SOLID ORGAN TRANSPLANTATIONS 
(SOT) – FUNGAL STRAINS AND THEIR SUSCEPTIBILITY TO 
ANTIFUNGAL DRUGS.
A. Chmura2, I. Netsvyetayeva1, E. Swoboda-Kopec1, D. Kawecki1, M. 
Sikora1, S. Blachnio1, E. Stelmach1, M. Durlik3, L. Paczek4, M. Luczak1
1Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of 
General Surgery and Transplantation Medical University of Warsaw, 3Dept. 
of Transplantation Medicine and Nephrology Medical University of Warsaw, 
4Dept. of Immunology Transplantation and Internal Medicine
Fungal infection is one of the severe complication in patients undergoing solid 
organ transplantations.
Aim: The aim of the study was to evaluate species distribution and antifungal 
susceptibilities of fungal isolates taken from patients after – SOT.
Material and methods: The study included samples of urine, blood, systemic 
fl uids and the swabs of the post-operative wounds, haematomas, drains taken 
from patients after kidney, liver or simultaneous pancreas-kidney transplantation 
hospitalized in Institute of Transplantation Medicine, Medical University of 
Warsaw and Department of General and Transplantation Surgery, Medical 
University of Warsaw in 2005 – 2007. All cultured specimens were isolated by 
using Sabouraud medium with antibacterial protection using chloramphenicol 
and gentamicin (bioMerieux, France or Oxoid, England). Yeast-like fungi was 
incubated on CHROMAgar Candida Medium (Becton Dickinson ®) and identifi ed 
by using biochemical, automatic test ID32C (bioMerieux). Susceptibility of the 
strains to the antifungal agents: amfotericin B, itraconazol, fl uconazol, voriconazol 
was tested using E-test (AB Biodisk) on RPMI agar plates (Biolife®).
Results: The positive cultures were obtained in 662 samples from 402 patients 
receiving immunosuppressive therapy. There were cultured 267 isolates of 
Candida albicans, 223- Candida glabrata, 39 strains of C. parapsilosis, 37 – C. 
krusei and 35 ofTrichosporon asahii, 20- Saccharomyces cerevisiae, 9 strains 
of Cryptococcus neoformans 5 – C. lipolytica, 6 strains of C. lusitaniae and 4 
of C. sake, 5 strain of C. quilliermondii, 3 – C rugosa and and 9 molds from 
Aspergillus fumigatus species. From cultured strains 37.3% was naturally 
fl uconazole resistant and 0.5% amphotericin B resistant. The acquired resistant 
to fl uconazole was presented by 10 isolates, to itraconazole- 26, to voriconazole- 
2 and to amphotericin B by 3 isolates.
Conclusions: 1. The most numerable groups of isolated fungal species in 
patients after SOT were Candida albicans- 40% of all isolates and Candida 
glabrata- 33,7%. 2. Molds were cultured less often and they were found only 
in 1.4% of positive cultures. 3. More than one third of isolated fungi were 
resistant to fl uconazole.
POSTER BOARD NUMBER P1 – 250
NEW THERAPEUTIC OPPORTUNITY IN MANAGMENT 1165 
OF INFECTION BY MULTIRESTENT GERMS IN PATIENTS 
UNDERGOING SOLID ORGAN TRANSPLANTATION. ROLE OF 
A NEW TETRACICLIN TIGECICLINE
G. Ferretti1, M. Rossi2, G. Novelli2, L. Poli2, G. Mennini2, S. Ferretti2, 
C. Mancini3, G. Raponi3, C. Ghezzi3, F. Pugliese4
1Azienda Policlinico Umnerto I Dip. Malattie Infettive, 2Centro Trapianti Di 
Organo, 3Servizio Di Microbiologia, 4Unita’ Intensiva Post Trapianto
The management of infections by multiresistent bacteria in patients undergoing 
solid organ transplant now be regarded as one of the greatest challenges in 
these patients.
The pathogens in particular (Staphylococci, Enterococci spp and Klebsielle 
spp) are very often with variability from center to center germs more frequently 
isolated in such patients.
And ‘understandable then as the possibility of using a new antibiotic active 
against these pathogens, with excellent tolerability and pharmacology no 
interference with drugs that would normally take these patients which represents 
Tygeciclinal for infettivologo managing such patients an excellent ally.
Materials and Methods: ten patients have been included in the study 
undergoing transplantation of solid organ (6 liver, 2 kidney, lung 2) who 
have contracted in the fi rst week after transplantation systemic or localized 
infections incurred in 8 paz. by Enterococci spp and two patient with 
kidney transplant by Klebsiella spp. The enterococci isolates showed a high 
resistance to both glicopeptidi that although to a lesser extent to linezolid 
while all had a mic <0.25 mgL to tigecycline. The two isolates of klebsielle 
spp had a good sensitivity and a carbapenem excellent sensitivity to 
tigecycline.
In all patients was used as a loading dose of 100 mg followed by a double dose 
of 50 mg daily for cycles 12-14 days total.
Results: In all patients was obtained sterilization of biological specimens 
after 3-5 days of initiation, the fever has regressed in 3 ° 4 ° day therapy 
simultaneously improving the symptoms, in all patients was obtained healing 
clinic. side effects more frequently found was nausea (3 paz) short-lived 1-2 
days regressed during the therapy.
Comment: the management of infections borne pathogen in patients 
transplanted multi the possibility of using a new antibiotic with therapeutic 
effi cacy is documented for a weapon infettivologo more available.
However, the therapeutic choice should always be done whenever possible 
on the basis of isolation microbiological to use best features of the new 
drug. Tigecycline on the basis of our experience, even if limited, offers 
interesting therapeutic possibilities for the treatment of infections by 
diffi cul germs in such diffi cult patients with the good tolerability and little 
or no interference with other drugs commonly given to these patients but 
we must remember always the Spectrum action of this drug in order to 
avoid easy enthusiasm.
POSTER BOARD NUMBER P1 – 251
URINARY TRACT INFECTIONS ASSOCIATED WITH 1166 
URETERAL STENT IN RENAL TRANSPLANT RECIPIENTS
A. Asderakis, M. Ranganathan, M. Akbar, M. Ilham, R. Chavez, N. Kumar, 
Transplant Unit, University Hospital of Wales, UK
Background: Stenting of the ureter is commonly performed during the time of 
renal transplantation in order to avoid early ureteric complications. However, it 
predisposes to infections. These infections in the immunosuppressed transplant 
recipients pose a signifi cant threat to the graft and to the patient and are a 
reason for repeated admissions.
Aim: Our study aimed to investigate the incidence of infections associated with 
stenting in renal transplant recipients.
Material and Methods: A retrospective analysis of 100 consecutive renal 
transplant recipients who received their graft in a period of one year with 
median follow up period of 6 months post-transplant. The incidence of urinary 
tract infections was recorded and associated with the use of indwelling stents.
Results: The patients median age was 46 (19-71 years). 75 patients received 
organ from deceased donors while 25 from live donors. 79 patients had stents 
and 18 patients had no stent. Three patients had vascular thrombosis that 
required early nephrectomy and were excluded from the study. There were 
2 cases of ureteric stenosis (following stent removal, one required surgical 
correction and the other was treated radiologically) and no cases of urinary leak. 
The incidence of Urinary Tract Infections (UTI) was signifi cantly higher in the 
Poster Abstracts Monday 11 August 2008
3 9 7
M
O
N
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
stent compared to the non-stent group (70% vs 39% p=0.02). New episodes of 
UTI following the removal of the stent were more common in patients who had 
infection while having a stent as compared to infection-free stented patients 
(54% vs 30% p =0.04).
Conclusion: Ureteric stents help to reduce early postoperative ureteric 
complications (leak and stricture) in kidney transplantation but increase the 
likelihood of UTI. Infection while having a ureteric stent was associated with 
high recurrence rate of UTI even after removal of the stent.
POSTER BOARD NUMBER P1 – 252
INFECTIOUS COMPLICATIONS AFTER INDUCTION 1167 
THERAPY WITH LOW-DOSE RITUXIMAB IN LIVING-DONOR 
KIDNEY TRANSPLANTATION.
H. Nishida, H. Ishida, H. Shirakawa, T. Shimizu, K. Omoto, D. Toki, S. Iida, 
M. Setoguchi, K. Tanabe
Tokyo Wemen’s Medical University
Anti-CD20 antibody (rituximab) is becoming the standard for induction 
therapy in non-splenectomized ABO-incompatible, as well as highly sensitized 
kidney transplantation, at our department. However, the infl uence of rituximab 
therapy on the risk of infections remains uncertain. In this study, we evaluated 
the infectious complications after induction therapy with low-dose rituximab 
in kidney transplant recipients.
Fifty-three patients with donor-specifi c anti-HLA antibodies and/or anti-blood 
type antibodies were treated with rituximab prior to renal transplantation from 
2005 to 2006. Of these, 33 underwent ABO-incompatible kidney transplantation 
(ABO-iLKT) and 6 of the 33 ABO-iLKT recipients underwent splenetomy at 
the time of operation. The total study population included 10 cytomegalovirus 
(CMV) Ab-negative patients and 43 CMV Ab-positive patients. The 
immunsuppressive regimen consisted of tacrolimus, mycophenolate mofetil 
(MMF). methylprednisolone and basiliximab. Rituximab (200 or 500mg/
body) was given to all 53 patients as a single dose, a few days before the 
transplantation. We investigated the incidence of bacterial, fungal and viral 
infections in the study population.
There were 7 episodes of bacterial infections in 6 patients, including urinary tract 
infections (4). pneumonia (1). surgical wound infection (1). and atheroma (1). 
There were no episodes of fungal infections. There were 41 episodes of viral 
infections in 34 patients, including CMV infection (34). infl uenza (2). zoster (2). 
adenovirus infection (1). verruca vulgaris (1). and HCV reactivation (1). Seven 
of the 10 CMV Ab (-) recipients who were CMV antigen positive developed 
prolonged CMV infection. However, the CMV antibody status in these 7 patients 
became positive after CMV infection. None of the patients developed any life-
threatening infectious disease, and all could be cured by conservative treatments.
These data suggest that there is no trend toward increase in the severity of 
infectious complications with the use of low-dose rituximab as induction 
therapy in kidney transplantation. We conclude that rituximab is an effective 
and safe anti-rejection therapy for immunologically high-risk recipients.
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CLUSTER OUTBREAK OF PNEUMOCYSTIS 1168 
PNEUMONIA (PCP) AMONG KIDNEY TRANSPLANT PATIENTS 
WITHIN A SINGLE CENTER
N. Arichi1, N. Fujii, H. Kishikawa, H. Shiina, M. Igawa, Y. Ichikawa
1Hyogo Prefectural Nishinomiya Hosipital, 2Hyogo Prefectural Nishinomiya 
Hosipital, 3Hyogo Prefectural Nishinomiya Hosipital, 4Shimane medical 
university hospital, 5Shimane medical university hospital, 6Hyogo Prefectural 
Nishinomiya Hosipital
Background: Pneumocystis pneumonia (PCP) is a life-threatening opportunistic 
infection that occurs in immunocompromised hosts and associated with a high 
mortality rate that ranges between 29% and 50% in kidney transplant recipients. 
PCP is relatively rare after kidney transplantation and there are few known 
reports about its occurrence as an epidemic. In present study, we analyzed the 
risk factors for PCP development in kidney transplant recipients.
Methods: Between 1973 and January 2008, 441 patients underwent kidney 
transplantation at Hyogo Prefectural Nishinomiya Hospital. A total of 10 petitents 
suffered from PCP in our hospital during past 35 years. 9 of those PCP cases were 
clustered within the 7 month period from June 2007 to January 2008. We studied the 
risk factors for the development of PCP and prophylaxis in transplanted patients.
Results: Of the 10 patients who developed PCP, 7 cases occurred as outpatients 
and other 3 as inpatients. The mean time between transplantation and PCP 
diagnosis was 32.1 }27.5 months, with 3 cases occurring within the fi rst 3 
months after transplantation, while 1 occurred at 6 months and the other 6 more 
than 1 year after transplantation. The cumulative incidence rate rose during 
the fi rst 3 months after transplantation. Further, the mortality rate was 33.3% 
and all cases showed rapid progress. A clustering of transplant patients within 
a single center suggests the possibility of human-to-human transmission, 
however, we didn ft fi nd any important relationships among our patients. We 
compared patients who developed PCP with those who didn ft develop PCP. 
There were no signifi cant differences in regard to gender, rejection episodes, 
episodes of virus infection, and use of a calcineurin inhibitor (CNI). Patients 
with PCP showed a higher mean age at transplantation (46.9 }11.8 vs 34.0 
}11.1, p=0.003) and longer mean duration of dialysis (146.3 }120.0 vs 51.3 
}66.6, p<0.0001). Since the outbreak of PCP in the patients within 7 months, 
all the patients have received primary prophylaxis with TMP-SMX and no 
occurrences of PCP have been noted.
Discussion and Conclusions: We found the risk of PCP in kidney transplant 
recipients to be associated with age at transplantation and duration of dialysis. 
The mortality rate in our study was nearly the same as other reports, while 
early detection and appropriate treatments for PCP were shown to be important. 
Prophylaxis with TMP-SMX administration is necessary during the fi rst 3 to 
6 months after transplantation, which is the time period that showed the high 
incidence rate of PCP.
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PULMONARY TUBERCULOSIS POST KIDNEY 1169 
TRASPLANT PROSPECTIVE STUDY 1997-2007
C.R. Miranda
Essalud
Lung Tuberculosis is a very big health problem that affects our population and 
is a priority at health politics in our country. We did a prospective study of 
266 kidney trasplants patients from cadaveric donor with a follow up of 66 
months of average from 1997 to 2006. We did interviews, clinical test and 
X Rays of lung of every one of our patients with the clinical history, cultures 
for Mycobacterium tuberculosis in sputum, and gastric juice, We report 
every clinical suspect of specifi c process for tuberculosis for unknown fever, 
lost of weigth, nocturnal sweeting, positive PPD and history of previous 
tuberculosis contact. All the patients received profi lactic treatment of 200mg of 
Isoniazida dayly for 12 months post trasplant and Piridoxine 50 mg daily. The 
patientes received de protocol induction with linfoglobulina, ciclosporine and 
metilprednisolona. Between inmunosupressor therapy received Ciclosporina, 
micofenolato of mofetil and prednisone. The men group was of 47.37% (126) 
and the women was 52.63% (140). Age average at the moment of transplant 
was 37.63 years. We report 16 cases (6%) of diagnosis of tuberculosis, wich 
only six cases were confi rmed with positive culture at 60th day. Ten cases were 
diagnosis based in clinical fi ndings, two of them without therapeutic answer 
and 8 with answer to treatment with: Isoniazide, rifampicine, pirazinamide, 
etambuthol and negative culture. Th incidency of TBC in transplant in our 
country is lower comparative with other countries like Egypto, India, Turky 
and Pakistan. This results are probably for the profi lactic measures and the 
educational level of our transplant population. Our treatment with isoniazida for 
a year have diminished dramaticaly the the incidency of TBC in our transplant 
population. Our conclusion is that incidency of TBC post transplant is going to 
be under stimated and we must consider the clinical features as like a positive 
culture of M. tuberculosis. At the same time the incidency of TBC could and 
must diminish in our countries with more carefuly evaluation of donor and 
receptor, like the social enviroment that is a big concern in our society.
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BLOOD INFECTIONS IN THE EARLY POSTOPERATIVE 1170 
COURSE AFTER LIVER TRANSPLANTATION.
G. Aguirre-Avalos1,2, M.A. Covarrubias-Velasco2, R.M. Chávez-Ramírez1, 
C. Reynoso-Lomeli1, R.I. Guzmán-Lázaro1, F. López-Cisneros1, 
R. Gutierrez-Valdez1, R. Hernández-Vidales1, L.C. Rodríguez-Sancho2, 
H. Coronado-Magaña1
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1Intensive Care Unit, Hospital Civil de Guadalajara., 2Transplant Unit, 
Hospital Civil de Guadalajara., 3Universidad de Guadalajara.
Background: Orthotopic Liver Transplantation (OLT) patients have increased 
risk for infectious complications. Blood infections (BI) is a major source of 
morbidity and mortality in OLT recipients. The present study determined the 
rate of BI in the early postoperative course of OLT.
Methods: From July 1998 to December 2004, all patients who underwent OLT 
admitted to a 14-bed medical and surgical adult Intensive Care Unit (ICU) were 
monitored for BI.
The blood-culture (BC) specimens were collected in BD BACTEC. 
Identifi cation and susceptibility to antimicrobial agents was determined using 
the MicroScan and Sensititre system.
Results: Of 101 admissions to the ICU after OLT, 78 (77%) patients had at least 
one set of BC samples. The rate of BI was 14% per 100 admissions. Of 152 BC, 
16 (10.5%) were positive. One episode of BI was present in 8 (73%) patients and 
3 (27%) had more than one episode. The median period between ICU admission 
and the acquisition of BI was 3 days. Gram-negative microorganisms were the 
most frequently isolated. E. coli, E. aerogenes and P.aeruginosa were the tree 
most frequently isolated pathogens. There were 1 episode with polymicrobial 
BI. All patients received perioperative prophylaxis.
Mortality rate for patients with BI was of 45%. The mean length of ICU stay 
was 11 days.
Conclusion: BI in OLT patients are associated with signifi cant rate of death. 
Most BI occur within in the fi rst week after transplantation.
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ANALYSIS OF FEBRILE EPISODES IN POST LIVER 1171 
TRANSPLANT RECIPIENTS DURING POST-OPERATION 
HOSPITALIZATION
S.I. Kim1, Y.J. Kim2, Y.H. Jun3, H. Jeong4, Y.R. Kim5, S.C. Park6, 
I.S. Moon7, D.G. Kim8, M.D. Lee9, M.W. Kang10
1The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2The 
Catholic University of Korea, Kangnam St. Mary’s Hospital, 3The Catholic 
University of Korea, Kangnam St. Mary’s Hospital, 4The Catholic University 
of Korea, Kangnam St. Mary’s Hospital, 5The Catholic University of Korea, 
Kangnam St. Mary’s Hospital, 6The Catholic University of Korea, Kangnam 
St. Mary’s Hospital, 7The Catholic University of Korea, Kangnam St. Mary’s 
Hospital, 8The Catholic University of Korea, Kangnam St. Mary’s Hospital, 
9The Catholic University of Korea, Kangnam St. Mary’s Hospital, 10The 
Catholic University of Korea, Kangnam St. Mary’s Hospital
Background: Fever is a common clinical occurrence in liver transplant 
recipients; infections being the predominant etiology. However, the 
exact etioloies of fever could not differentiable from infectious and non-
infectious causes. And the severity is not clear in clinical settings. We 
analyzed febrile episodes to find the clues that were strongly related 
to mortality.
Methods: One hundred seven consecutive liver transplant recipients of 
Kangnam St. Mary’s hospital were analyzed retrospectively. Fever was 
defi ned as more than 37.4 oC by axillary temperature and lasting more than 
one hour.
Results: Among them, 29.9% (32/107) patients had 40 episodes of fever during 
post-transplant hospitalization. Infectious causes were documented in 72.5% 
(29/40) of cases and non-infectious 27.5% (11/40). Non-infectious causes were 
4 bleeding, 2 rejection, 2 hematoma, 1 procedure related, and 2 unknown. 
There was no case of infectious complication without fever. Ten patients 
were died and 50% (5/10) of death were related to infectious complications. 
We compared the patients between survival (n=24) and death (n=5) who had 
episodes of infectious fever. There were no signifi cant differences in age (48.4 
vs 50.4 year-old). operation time (648.2 vs 708.0 min). white blood cell count, 
MELD score, Child-Pugh score, and the body temperature between two groups. 
Time intervals between the point of fever and the point of administration or 
change of antibiotics (756.7 vs 1062.4 min). and duration of administration 
of immune suppressive agents (2,504.8 vs 5,290.0 min) were not signifi cantly 
different, however the odd ratio were 5.3 and 5.3 with univariate logistic 
regression analysis.
Conclusion: In case the post-transplant recipients have fever presumed by 
infectious disease, administration of appropriate antibiotics as soon as possible 
and discontinuation of immune suppressive agents as possible seemed to 
improve the survival.
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FUNGAL INFECTIONS IN LIVING DONOR LIVER 1172 
TRANSPLANT RECIPIENTS: 9 YEARS SINGLE CENTER 
EXPERIENCE
S.I. Kim1, Y.J. Kim2, Y.H. Jun3, Y.R. Kim4, J.Y. Choi5, S.K. Yoon6, 
I.S. Moon7, D.G. Kim8, M.D. Lee9, M.W. Kang10
1The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2The 
Catholic University of Korea, Kangnam St. Mary’s Hospital, 3The Catholic 
University of Korea, Kangnam St. Mary’s Hospital, 4The Catholic University 
of Korea, Kangnam St. Mary’s Hospital, 5The Catholic University of Korea, 
Kangnam St. Mary’s Hospital, 6The Catholic University of Korea, Kangnam 
St. Mary’s Hospital, 7The Catholic University of Korea, Kangnam St. Mary’s 
Hospital, 8The Catholic University of Korea, Kangnam St. Mary’s Hospital, 
9The Catholic University of Korea, Kangnam St. Mary’s Hospital, 10The 
Catholic University of Korea, Kangnam St. Mary’s Hospital
Background: Fungal infection remains one of the most signifi cant infectious 
complications following living donor liver transplantation (LDLT). We analyzed 
the frequency and type of fungal infections according to the post-transplant 
periods and risk factors related to morbidity and mortality of fungal infection.
Patients and Methods: We analyzed 208 living donor liver transplant 
recipients from May 1996 to August 2005 at a single center.
Results: Mean age was 48.3 and male was predominant (M/F=148/60). 
Infectious complications were developed in 76.9% (160/208) of patients and 
the fungal infections were developed in 7.7% (16/208) of patients. Total 351 
infectious episodes of 160 patients were analyzed. Among them, 19 episodes 
were diagnosed as fungal infection. Aspergillus spp. (47.4%) was most common 
and followed by Candida spp. (36.8%). Within 1 month after transplantation, 
Candida spp. (6/11) was the most common pathogen, between 2-6 months, 
Aspergillus spp. (5/7) was the most common. The most common type of infection 
was pneumonia (36.9%). followed by intra-abdominal infection (21%). primary 
fungemia (21%). and catheter related infection (5.3%). Our study showed the 
operation time (p=0.007) was the signifi cant risk factor for fungal infection 
while age, amount of transfusion, MELD score, serum creatinine, total bilirubin, 
INR, re-operation, renal failure at post-operation, and the rejection were not 
signifi cant. The overall mortality of fungal infection was 43.8% (7/16).
Conclusion: Fungal infections in liver transplant have resulted in mortality of 43.8%. 
Candida infection was common in the fi rst month after LDLT, while mortality cases 
were more common after that period by aspergillosis. Our data showed operation 
time was the only statistically signifi cant risk factor for fungal infection.
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LATE ONSET PNEUMOCYSTIS PNEUMONIA IN 1173 
PATIENTS RECEIVING RITUXIMAB FOR ANTIBODY 
MEDIATED RENAL TRANSPLANT REJECTION
S. Cohney1, M. Yong2, E. Shelton1
1Department of Nephrology, Royal Melbourne Hospital, Parkville, Australia 
3050 2Department of Infectious Diseases, Royal Melbourne Hospital, 
Parkville, Australia 3050
Rituximab is a monoclonal antibody targeting the CD20 molecule on B cells 
and is being used on an increasing basis in solid organ transplantation and 
other areas of nephrology, despite the absence of any trial data. In addition, 
Rituximab does not target the antibody producing plasma cells. A contributor 
to the expanding “off label” use of Rituximab has been the relatively low 
morbidity associated with its use in thousands of lymphoma patients over 
many years. However, reports are now emerging of an increased incidence of 
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viral and opportunistic infections following Rituximab. Until now there have 
been no reports of specifi c infectious complications relating to its use in renal 
transplantation.
Here we report the onset of Pneumocystis pneumonia (PCP) in two patients nearly 
three years after receiving their renal transplant, both of whom had received 
rituximab for refractory antibody mediated rejection (AbMR). In 2004, a 59 year 
old female received a transplant from her husband against whom there was a 
donor specifi c anti-HLA antibody associated with a positive cytotoxic crossmatch. 
Despite “desensitization” with plasma exchange and high dose immunoglobulin 
(IVIG) pre-transplant she developed early AbMR. She received a single dose of 
Rituximab 500mg, plasma exchange and IVIG, with complete resolution of the 
AbMR both clinically and histologically. At 6 months her immunosuppressive 
therapy consisted of mycophenolate sodium 360mg mane/180mg nocte, tacrolimus 
0.5mg bd and prednisolone 5mg daily and at this time her PCP prophylaxis (daily 
Bactrim) was ceased. She remained well for the next 2½ years but in mid 2007 
presented with a respiratory illness confi rmed microbiologically as PCP infection. 
Likewise a 52 year old female recipient of a cadaveric renal transplant in 2005 
developed severe acute AbMR requiring plasma exchange, IVIG, and a single 
dose of 500mg Rituximab. Although she also completed a 6 month Bactrim course 
for PCP prophylaxis, it was not until 2 years and 8 months after administration of 
Rituximab in 2007 that she presented with clinical PCP infection.
All patients in our centre receive at least 6 months PCP prophylaxis with 
Bactrim unless there are contraindications. Since 2000, we have managed 
over 450 renal transplant recipients with only 1 other case of PCP, occurring 
in a patient whose immunosuppressive therapy was increased for late rejection 
without reinstitution of PCP prophylaxis. The two individuals described here 
are amongst 10 patients who have received Rituximab for AbMR developed a 
late infectious complication of PCP at a time when their immunosuppressive 
therapy was no different from other renal transplant recipients.
This report alerts transplant clinicians to the possibility of late opportunistic 
infections in patients who have received Rituximab and highlights the need for 
randomised clinical trials to establish the effi cacy (or otherwise) of Rituximab 
in treating and preventing AbMR in areas of nephrology and transplantation.
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EARLY COLONIZATION OF URINARY TRACT AND 1174 
RISK OF URINARY TRACT INFECTION IN TRANSPLANT 
RECIPIENTS
E. Ahmed, F. Noman, N.H. Jaffery, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Introduction: Urinary tract infection is the commonest bacterial infection in 
Renal transplant recipients. Early post-operative colonization of urinary tract 
may be a risk factor for subsequent infections.
Objective: To evaluate the role of early post-operative bacteriuria in the development 
of future symptomatic urinary tract infections in renal transplant recipients.
Patients and Methods: A prospective cohort of patients transplanted between 
January and December 2004 were studied. Urine cultures were taken twice in 
fi rst ten days post-transplant from all patients (surveillance culture). For the next 
6 months follow-up urine cultures were obtained periodically from all patients on 
OPD visits and whenever urinary tract infection was suspected on clinical grounds.
Result: 107 patients, 85 Male and 22 Females were followed.14 (13.3%) had 
positive surveillance culture. In the follow-up period, 36 (33.6%) patients 
developed symptomatic infection. Ten (71%) out of 14 in surveillance culture 
positive group, and 26 (28%) out of 94 in negative surveillance culture group 
(RR =2.5, 95% C.I 1.6 – 4.1, P=0.002). Females did not show a higher incidence 
of UTI compared to Males (36.7% vs 33%). D.J stenting and its duration did 
not increase the risk of symptomatic infection.
Conclusion: Early post transplant urine culture positivity is a risk factor for 
subsequent UTI, whether treating this will decrease the risk needs further 
evaluation.
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CRYPTOCOCCAL MENINGITIS OCCURING TO 1175 
PATIENTS SUBJECTED TO A RENAL TRANSPLANT: 
DIAGNOSTIC AND THERAPEUTIC PARTICULARITIES 
RELATING TO ONE CASE.
H. Skhiri, L. Jaafoura, T. Dalila, A. Sabra, H. Kamel, F. Mouna, B. Samia, 
F. Ameur, B. Nasr, E. Mezri
Tunisian Nephrology Society
Cryptococcus is an opportunistic fungic infection to be met particularly 
between the second and the sixth post-graft months (the period of maximum 
Tcell immune dysfunction).
Meningo encephalitis is its most frequent manifestation with an acute mortality 
rate reaching 100% with patients not yet taken in charge. The rate is around 
20% despite antifungic treatment
We report a case of Cryptococcal neuro-meningitis occurring to one 42 year-
old female patient with a kidney transplant out of 72 patients engrafted at the 
Monastir hospital-university center over eight years (1999-2007).
It‘s noteworthy that this infection had been developed in the four years 
subsequent to the graft.
The case evolution for this woman was adverse: deceased fi ve days following 
the start of a treatment based on Amphotericin B and 5-Fluorocystosin.
The Cryptococcal neuro-meningitis symptoms are not specifi c.
The symptoms for such infection have to be sought out in order to be diagnosed 
and treated precociously.
IMMUNE MONITORING CONCURRENT ORAL SESSION 85: 
AND MOLECULAR DIAGNOSIS
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THE COMPARISON ANALYSIS WITH ACUTE 1176 
CELLULAR REJECTION AND VARIOUS LIVER 
DYSFUNCTIONS USING GENE EXPRESSION PROFILING
T. Asaoka, S. Marubashi, K. Dono, N. Hama, C. Chim, S. Kobayashi, Y. 
Takeda, H. Nagano, K. Umeshita, M. Monden
Department of Surgery, Graduate School of Medicine, Osaka University, 
Osaka, Japan
Backgrounds: Recent advances in immunosuppressive therapy have 
dramatically enhanced the survival of solid organ transplantation. 
Nevertheless, acute cellular rejection (ACR) still remains a major challenge 
in liver transplantation. In addition, recurrent hepatitis C (CRC). re-
perfusion injury, infection and drug toxicity caused by administration of 
immunosuppressive drugs also contribute to graft failure. Histological 
evaluation of liver biopsy is the gold standard for diagnosing these 
various conditions, but it is often diffi cult to diagnose ACR after liver 
transplantation.
Purpose: The aim of the present study is to establish a strategy based on gene 
expression profi ling to more accurately discriminate acute rejection from 
various other liver dysfunctions.
Materials and Methods: We analyzed 35 graft liver biopsy samples 
obtained from living-donor liver transplant recipients. Among them, 13 
samples were pathologically diagnosed as ACR (moderate/mild; 5/8) 
according to Banff criteria, whereas 13 samples were diagnosed as other 
dysfunction without ACR (CHC/IRI/drug induced; 5/5/3) and 9 samples 
were protocol biopsies without liver dysfunction (ACR group/Non-ACR 
group/Protocol group: 13/13/9). A part of liver biopsy samples were frozen 
and stored at -80C. Prior to the gene profi ling analysis, we followed the 
patients and confi rmed that those pathological diagnoses matched the 
clinical course of the patients. We used an oligonucleotide microarray 
covering 44,000 human probes (Agilent; DNA Chip Research Inc, Tokyo). 
For validation of microarray results, RT-PCR was performed on selected 5 
genes. In our study, we furthermore adopted the Ingenuity computational 
pathway analysis (IPA) to identify regulatory networks of differentially 
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expressed genes.
Result: We identifi ed about 2,000 genes which were differentially 
expressed between three groups. Hierarchical clustering demonstrated 
almost good separation of each groups. This clustering revealed that there 
were specifi c gene expression pattern underlying in ACR. The data from 
RT-PCR validation confi rmed an impression from the microarray data. 
Biological interactions using the IPA tool demonstrated several genetic 
networks targeted by ACR.
Conclusion: We found gene expression patterns associated with ACR. Our 
fi ndings suggest that gene expression profi ling may be useful in diagnosing 
ACR after liver transplantation.
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IMMUNE MONITORING IN LIVER TRANSPLANT 1177 
PATIENTS WITH COMBINED MYCOPHENOLATE MOFETIL 
AND LOW DOSE CALCINEURIN INHIBITOR THERAPY
S. Beckebaum1,2, Z. Yu1,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos1, A. 
Radtke1, G. Gerken1, V.R. Cicinnati1,2
1Department of Gastroenterology and Hepatology, University Hospital Essen, 
Germany, 2Department of General, Visceral and Transplantation Surgery, 
University Hospital Essen, Germany, 3Department of Surgery, Beijing 
Tongren Hospital, Capital University of Medical Sciences, Beijing, China, 
4Institute of Immunology, University Hospital Essen, Germany
Background: Long term complications of calcineurin inhibitors (CNI) have a 
major impact on morbidity of liver transplant recipients. Immunosuppressive 
drugs are regularly used in combination to reduce the adverse effects of each 
individual drug. 
Aim: To investigate the impact of combined mycophenolate mofetil (MMF) 
and low dose CNI therapy on T cell function in vivo and in vitro. 
Methods: Peripheral blood mononuclear cells (PBMC) were isolated from 
32 liver transplant recipients at baseline and 12 months after conversion to 
MMF/low dose CNI regimen. T cell frequencies, phenotype and expression of 
activation markers were analyzed by fl ow cytometry. In in vitro studies, freshly 
isolated PBMC from healthy volunteers were treated with mycophenolic acid 
(MPA). cyclosporine A (CsA). tacrolimus (Tac) and combined CsA/MPA or 
Tac/MPA to assess the effect on T cell proliferation, expression of activation 
markers and of nuclear factor of activated T cell (NFAT) -regulated cytokines. 
Results: Combined MMF and low dose CNI therapy in vivo leads to a 
reduction of the percentages of CD8+ and CD8+CD56+ T cells, to inhibition 
of T cell activation and to an increase of circulating FOXP3+CD25+CD4+ 
regulatory T cells (Treg) as compared to CNI monotherapy. MPA stops the 
cell cycle of activated T cells at G0/G1 phase in vitro; whereas MPA and CNI 
each individually inhibit the expression of T cell activation markers, and this 
effect is enhanced by combined exposure to MPA and CNI. Low doses of 
CNI strongly inhibit interleukin (IL) -2, IL-4, IL-10 and interferon (IFN) -γ; 
production by T cells in vitro. 
Conclusions: Combined MMF and low dose CNI administration has synergistic 
effects by a) decreasing the percentages of circulating NKT and cytotoxic T 
cells, b) increasing the number of circulating Treg cells, c) blocking the T cell 
proliferation and d) decreasing NFAT-regulated gene and activation marker 
expression in T cells. Immune monitoring may facilitate optimization of the 
immunosuppressive regimen with minimization of drug related adverse effects 
without increasing the risk of cellular rejection.
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CLINICAL UTILITY OF THE NOVEL METHOD OF 1178 
IMMUNOSUPPRESSION MONITORING (IMMUKNOW ASSAY) 
IN CYTOMEGALOVIRUS INFECTIONS IN KIDNEY AND 
PANCREAS TRANSPLANT RECIPIENTS
P. Kadambi, R. Harland, M. Josephson
The University of Chicago
Cytomegalovirus (CMV) infection is the most common viral infection in solid 
organ transplant recipients. Patients are at highest risk of developing CMV 
infection if they are CMV seronegative and receive an organ from a seropositive 
donor (D+). The recipients could also be infected by reactivation of their own 
CMV or by transmission of a different strain of virus from a D+. The overall 
degree of immunosuppression may play a role in this infection.
The current tests used to detect CMV that are sensitive and specifi c are the 
pp65 antigenemia test and the Polymerase Chain Reaction (PCR) test to detect 
the viral DNA.
The Cylex ImmuKnow (IK) assay was approved by the FDA for detection of 
cell-mediated immunity in immunosuppressed patients. Immune responses are 
reported in ng/ml of ATP and divided into strong (≥525). moderate (226-524) 
or low (≤225) categories. In theory, patients in the low group are generally 
more immunosuppressed and hence might be susceptible to opportunistic 
infections.
Six patients that had CMV infection at our institution in 2007 were identifi ed. 
Of them, 4 received kidney transplants, and 2 received pancreas transplants 
alone. Two patients received induction with thymoglobulin and the rest with 
an IL2 receptor antagonist. Four patients fell in the high risk group (D+/R-) for 
CMV, and the other 2 were in the intermediate risk group. We use the PCR test 
to diagnose CMV, and the threshold for detection is <2500copies/mL of blood. 
The test is obtained when there is clinical suspicion of CMV infection. Patients 
were treated with intravenous ganciclovir (5/6) and valganciclovir (1/6) for 3 
weeks, and reduction in immunosuppression. No secondary prophylaxis with 
valganciclovir was used.
We obtained IK values after the CMV infection was diagnosed and serially 
followed the values during the course of the infection. The mean IK value of 
patients during the infection (PCR positive) was
51.08 ±36.17, and 186.45 ±127.22 when the PCR was negative (p=0.001).
In most cases the IK value prior to the onset of CMV was not known. The 
values were consistently low in patients during active CMV infection 
indicating depressed immunity, and improved during periods when CMV was 
undetectable.
Perhaps the IK assay could be utilized prospectively after transplantation to 
determine which patients may be at risk for CMV and other opportunistic 
infections and optimize the immunosuppression accordingly to prevent these 
infections.
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DETECTION OF CD4+ CELL IMMUNE ACTIVITY IN 1179 
UTERUS GRAFTED PORCINE PERIPHERAL BLOOD WITH 
IMMUKNOW ASSAY
Y. Jin1, W. De Faria1, P. Tryphonopoulos1, H. Takahashi1, D. Avison1, 
A.G. Tzakis1, P. Ruiz1,2
1Dept of Surgery,University of Miami, 2Dept of Pathology, University of 
Miami
Aim: ImmuKnow assay introduced by Cylex Inc is a useful assay to assess 
immune competency in human transplant recipients. The aim of this study was 
to determine whether this assay has the research applications for transplant 
animal model. MHC class-I and II matched or full MHC mis-matched uterus 
transplanted porcinis were included in this study.
Methods: We adopted ImmuKnow assay to measure CD4+ cell immune 
activity in PHA stimulated porcine peripheral blood pre- and post- uterus 
transplantation. Recipient to donor immune reactions were determined with a 
modifi ed ImmuKnow assay in some cases.
Results: We found that the beads coated with anti-Human CD4 antibody 
had cross reaction with porcine CD4+ cells, but the optimal dosage of 
PHA stimulation for porcine was higher than that for Human. The data 
collected from 14 pre-transplant porcinis showed ATP level variations 
from 162.2 ng/ml to 559.49 ng/ml, with an average of 305 ng/ml ±110ng/
ml. High responses to PHA stimulation had the correlation with strong 
immune reactivity against donor in most of the post-transplant tests. On 
the other hand, high PHA responses were not always associated with graft 
rejections.
Summary: In this study, we demonstrated that ImmuKnow assay has valuable 
application for animal transplant model as well.
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IN VIVO LABELING OF ACTIVATED T-CELL WITH 1180 
QUANTUM DOTS CONJUGATED ANTI-CD25 ANTIBODY 
REVEALS REJECTION IN THE MOUSE SKIN GRAFT MODEL
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H-Y. Lee1, K. Bang3, H. Ro2, J. Yang4, Y.H. Park5, K.W. Kang1, C. Ahn2
1Department of Nuclear Medicine, Seoul National Universiy, College of 
Medicine, 2Department of Internal Medicine, Seoul National Universiy, 
College of Medicine, 3Department of internal medicine, Eulji University 
College of medicine, 4Department of Internal Medicine, Gachon University 
of Medicine and Science, 5Department of Surgery, Gachon University of 
Medicine and Science
Material and Method: The tail skins from Balb/c (allograft) and B6 mice 
(isograft) were transplanted on the back of Five B6 mice (female, 6 weeks 
old). A day after transplantation, 75 ug of quantum dot (Qdot 655, Invitrogen) 
conjugated anti-CD25 antibody was intravenously injected to mice. Fluorescent 
imaging was daily acquired until 8 days after transplantation using optical in 
vivo imaging system (IVIS Lumina, Xenogen).
To confi rm the fl uorescence signal from activated T-cell, the tail skin from 
B6.CHbm12 and Balb/c were transplanted on B6 mouse, which underwent 
thymectomy and CD8 T-cell depletion. After the skin graft, the mouse followed 
the same protocol as above. Also we applied the same method to evaluating the 
effect of Tacrolimus (Astellas. co). We measured the counts of skingraft from 
each image. Then, mice were sacrifi ced, and immunohistochemistry (IHC) was 
performed to correlate their pathologic results with the fl uorescent imaging 
between the allo- and isografted skin.
Result: Quantum dot conjugated anti-CD25 was more accumulated on the 
allograft than isograft. When comparing the photon counts, allograft was 
signifi cantly brighter than isograft (allograft: 5.4E-5¡¾3.4E-6, isograft: 
3.6E-5¡¾1.3E-6, p<0.05). Comparing with IHC, the number of activated T-cell 
was correlated with the counts on image. Quantum dots were located on stained 
activated T-cells.
On the skin graft with MHC II mismatch, there was no abnormal signal was 
detected (MHC II mismatch 1.8E-5, allograft: 6.7E-5). Also, there was less 
signal intensity on the allograft with Tacrolimus, compared with the allograft 
without Tacolimus (With Tacrolimus: 3.8E-5¡¾4.8E-6, Without Tacrolimus: 
5.4E-5¡¾3.4E-6 p<0.05).
Conclusion: Activated T-cell was labeled in vivo using quantum dot conjugated 
anti-CD25 antibody. We could evaluate the rejection of skin graft with non-
invasive optical imaging.
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TRANSPLANTATION AND MONITORING THE HIGHLY 1181 
SENSITIZED HEART PATIENT.
M. Lopez-Cepero1, M. Weston2, D. Rinde-Hoffman2
1LifeLink Foundation, 2LifeLink Health Institute
The use of plasmapheresis (PP) and IVIG has been reported by an increasing 
number of transplant programs to be benefi cial in the transplantation of highly 
sensitized renal patients. This approach was followed to transplant highly 
sensitized heart patients.
Our study thus far includes 63 recipients of orthotopic heart transplants that 
had a Flow PRA > 10%. The cause of sensitization included transfusions, 
pregnancies, VAD, previous transplants and immunizations. All patients 
underwent PP and received 20g IVIG immediately prior to transplant. Class I 
and II% PRA and antibody specifi cities were determined by Flow Cytometry 
using single antigen coated beads. Flow T and B cell crossmatches were done 
prior to and after PP. Results were expressed in quantitative MESF shifts. 
Post transplant, these patients were followed at time of biopsy for quantitative 
determination of donor specifi c antibodies (DSA’s) with antigen coated beads 
and/or Flow T and B cell crossmatches. The effect of immunosuppressive 
therapy on cell mediated immunity was followed using the Immuknow assay 
(Cylex).
Forty one% (26/63) of patients had a positive FCXM prior to PP. Fifty nine% of 
patients had a negative FCXM prior to PP. Of those patients that were positive, 
PP removed DSA’s in 46% (12/26) of the cases. However, 54% (14/26) of the 
patients after PP still had a positive FCXM. Out of 63 patients, 13 patients 
have died. Nine of these had a negative FCXM prior to PP. These patients 
did not develop DSA’s and died of different causes including: primary non 
function, non compliance, bacterial pneumonia and sepsis. The other 4 patients 
had a positive FCXM prior to PP and causes of death include: GI bleed, sepsis, 
respiratory distress and pulmonary embolism. Seven% of sensitized heart 
patients show graft coronary vasculopathy when compared to 11% in an age 
and disease match control group.
Our study shows that pre-operative plasmapheresis and IVIG in sensitized 
patients awaiting heart transplantation is effective with no difference with 
controls in occurrence of rejection and graft survival at 3 years. We also have 
shown that sensitized patients with Class II antibodies are more susceptible to 
rejection; however there was not a signifi cant difference in graft survival in 
this group. When compared to a well matched control group of patients, the 
sensitized group that had plasmapheresis and IVIG prior to transplant, had no 
signifi cant difference or even less graft coronary vasculopathy. These results 
and those of others are very encouraging in the use of plasmapheresis and 
IVIG with close post transplant monitoring to transplant the highly sensitized 
patient.
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PERFORMANCE OF A FULLY AUTOMATED SIROLIMUS 1182 
ASSAY ON THE SIEMENS DIMENSION VISTA ® CLINICAL 
CHEMISTRY SYSTEM
T. Wei, A. Posey, C. Schaible
Siemens Healthcare Diagnostics Inc.
Background: Monitoring sirolimus (Rapamune®, Wyeth Laboratories) in 
whole blood is a standard practice during immunosuppressive therapy for 
transplant patients. We describe the initial performance of a fully automated 
immunoassay for sirolimus* in whole blood on the Siemens Dimension Vista 
system.
Methods: A whole blood sample (8.5 μL) is automatically lysed, incubated fi rst 
with antibody β−galactosidase conjugate and later with chrome particles coated 
with a sirolimus analog. Sirolimus in the sample forms immuno-complexes 
with the antibody conjugate, and the excess molecules of antibody conjugate 
are bound by the chrome particles, which are magnetically separated from 
the supernatant. The supernatant containing the sirolimus-antibody conjugate 
complexes is then transferred to a photometric cuvette where the enzyme tag is 
detected using a chromogenic substrate.
Results: Analytical sensitivity is 1.2 ng/mL. The method is linear to 30 ng/mL 
and calibration is stable for 30 days. Repeatability and within-lab reproducibility 
on patient pools were 2.5 and 3.9%CV at 30.3 ng/mL, 1.9 and 2.5%CV at 20.2 
ng/mL, 4.0 and 4.9% at 10.2 ng/mL, and 7.0 and 12.9% at 4.7 ng/mL sirolimus 
respectively per the CLSI EP10-A3 protocol. Split sample correlation (n=100) 
between the Dimension Vista method (DV) and the Dimension® sirolimus* 
method (DM) gave a Passing-Bablok regression fi t of: DV = 1.03×DM + 
0.5, r=0.984, range = 1.3 – 29.5 ng/mL. Metabolite cross-reactivity was 45, 
14, and 61% for 39-O-demethyl, 16-O-demethyl, and 12-hydroxy sirolimus, 
respectively. No signifi cant cross-reactivity was detected in samples spiked 
with 120 ng/mL tacrolimus, 2000 ng/mL CSA, 400 ug/mL MPA or 1000ug/mL 
MPAG. No signifi cant interference (<10%) was found for 60 mg/dL bilirubin, 
1000 mg/dL triglyceride, 500 IU/mL rheumatoid factor, type I and II HAMA, 
and 25 g/dL total protein.
Conclusion: This method provides accurate, reproducible, and fast 
measurements of sirolimus on the Dimension Vista system.
*Product under development – not available for sale.
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A REVISED NO-PRETREATMENT IMMUNOASSAY FOR 1183 
CYCLOSPORINE ON THE SIEMENS DIMENSION® CLINICAL 
CHEMISTRY SYSTEM
T. Wei, S. Kramer,
Siemens Healthcare Diagnostics Inc.
Background: Therapies combining lower dosages of cyclosporine with other 
immunosuppressant drugs to reduce nephrotoxicity require more sensitive 
methods for its therapeutic monitoring. We describe an improved, automated 
immunoassay for cyclosporine on the Dimension system.
Methods: A whole blood sample (5 μL) is automatically lysed, incubated fi rst 
with antibody β−galactosidase conjugate and later with chrome particles coated 
with a cyclosporine analog. Cyclosporine forms immuno-complexes with 
the conjugate, and the excess conjugate molecules are bound by the chrome 
particles. The chrome-conjugate complexes are then magnetically separated 
from the supernatant, which contains the cyclosporine-antibody conjugate 
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complexes. The supernatant is then transferred to a photometric cuvette where 
the enzyme tag is detected using a chromogenic substrate.
Results: Analytical and functional sensitivity are 9.5 and 25 ng/mL, respectively. 
The LoB and LoD are 15.0 and 22.5 ng/mL, respectively, based on a study per 
the CLSI EP-17A protocol. The method is linear to 500 ng/mL. Repeatability 
and within-lab reproducibility on patient pools were measured to be 5.9 and 
7.3%CV at 82.5 ng/mL, 4.2 and 6.1%CV at 132.2 ng/mL, 3.5 and 4.3%CV at 
219.4 ng/mL, and 3.6 and 3.9%CV at 369.2 ng/mL cyclosporine respectively 
per the CLSI EP5-A2 protocol over a 20 day testing interval. Split sample 
correlation between the revised method (rCSA) and the existing method (CSA) 
gave a linear regression fi t of: rCSA = 1.035×CSA – 6.5, r=0.994, n =184, 
range = 19 – 468 ng/mL. Cross-reactivity with metabolite AM9 was <2%. No 
signifi cant cross-reactivity was detected in samples spiked with 100 ng/mL 
tacrolimus, 5000 ng/mL rapamycin, 200 ug/mL MPA or 400 ug/mL MPAG. No 
signifi cant interference (<10%) was found for 60 mg/dL bilirubin, 1500 mg/dL 
triglyceride, 500 mg/dL cholesterol, 500 IU/mL rheumatoid factor, type I and 
II HAMA, 4 g/dL and 12 g/dL of total protein.
Conclusion: The revised method showed signifi cant precision improvement 
at the analyte concentrations below 100 ng/mL, and provides accurate and fast 
measurements of cyclosporine on the Dimension system.
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DIFFERENTIAL EFFECT OF DITHIOTHREITOL (DTT) 1184 
ON ANTI-A/B IGM, IGG AND IGA ANTIBODIES
L. West, M. Jeyakanthan, S. Senthilselvan
University of Alberta
Introduction: Reliable measurement of IgG isotype anti-A or anti-B antibodies 
is crucial in ABO-incompatible transplantation, but detection of IgG anti-A/B 
activity is often masked by the agglutinating IgM antibody. DTT seems to 
selectively inactivate IgM leaving IgG intact and it is widely used to measure 
anti-A/B IgG titre determined by antiglobulin technique. However its effect 
specifi cally on anti-A and anti-B antibodies has not been explored. The purpose 
of this study was to evaluate the effect of DTT on anti-A/B IgM, IgG and IgA 
antibodies.
Methods: Serum samples from volunteers of different ABO-blood types (A=2, 
B=2,O=12) were tested for anti-A and anti-B IgM, IgG and IgA by ABO-
ELISA. Antibody levels were retested after incubation of serum with 0.005M 
DTT at 37C for 30 minutes. ELISA measurements were done at least three 
times on each sample pre and post DTT treatment. The effect of DTT on anti-
A/B IgM, IgG and IgA was evaluated by comparing mean OD values for each 
sample, and the overall effect on samples from this cohort of people was also 
evaluated.
Results: Following DTT treatment, residual anti-A IgM was detectable in 
samples from 6 of 16 people; only 1 sample had residual anti-B IgM. There 
was no change in anti-A IgG with DTT, but sera from 2 people had signifi cant 
reduction in anti-B IgG. Sera from 9 people had detectable anti-A and anti-B 
IgA after DTT treatment. There was no signifi cant amount of anti-A/B IgM 
detectable when the entire cohort was analysed as a group, and also there was 
no signifi cant change in anti-A/B IgG. Both anti-A and anti-B IgA on the other 
hand were detectable at a signifi cant level after DTT treatment.
Conclusions: Our data demonstrate that overall, DTT treatment effectively 
inactivates anti-A/B IgM leaving anti-A/B IgG intact but the variability among 
different people cannot be ignored. These data suggest it is likely that sera from 
ABO-incompatible transplant recipients may differ in the response to DTT, 
and erroneous quantitation of IgG antibodies may lead to mismanagement or 
unnecessary treatment. We intend to explore all possibilities of developing a 
simple but reliable method to quantitate anti-A/B IgG and IgA which may aid 
in development of effi cient clinical protocols for the management of ABO-
incompatible transplant recipients.
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THE IMPROVEMENT OF TRANS-VIVO DTH ASSAY AND 1185 
ITS EVALUATION IN IMMUNOLOGICAL STATUS IN HEART 
TRANSPLANT RAT
T. Xu1, X. Zhang, X. Qu, H. Ye, W. Bai, X. Wang
1Peking University People’s Hospital, 2Peking University People’s Hospital, 
3Peking University People’s Hospital, 4Peking University People’s Hospital, 
5Peking University People’s Hospital, 6Peking University People’s Hospital
Trans-vivo DTH is an approach to measure the status of cell-mediated 
immunity, which is believed to be correlated with the immunological mode 
of patient after transplant. We conducted this experiment with a novel and 
improved trans-vivo DTH assay. The PBMCs and allergens from subjects were 
transferred into the footpads of mice. Measurements of footpad thickness were 
obtained immediately prior to injection and 24 h after injection with a dial 
thickness gauge. The swelling that occurs within 24 h after injection serves as 
an index of the subjects¡¯ immunological status to the specifi c antigen. But the 
precision of dial thickness gauge is considered to be relatively low, and could 
be interfered by many factors. We use Universal Toolmaker Microscope to 
replace dial thickness gauge, and compare the test-retest reliability of the two 
methods. Finally, we compare this improved Trans-vivo DTH assay with MLC 
and IL-2 mRNA level (measured by RT-PCR) to investigate its evaluation on the 
immunological status in heart transplant rat. A total of 20 C57BL/6 male mice 
were enrolled in this experiment. The ipsilateral mouse footpads were measured 
with universal toolmaker microscope and dial thickness gauge. The error of 
duplicate measurement and coeffi cients of reproducibility were calculated and 
compared. There were 4 groups: A, Control group (5); B, Shum operation group 
(20); C, Isotransplant group (20); D, allotransplant group (20, F344 to Lewis).
The improved Trans-vivo DTH assay were performed in the 1st¡¢4th¡¢7th¡¢11th 
days after operation. The error of duplicate measurement and the coeffi cients of 
reproducibility of universal toolmaker microscope£¨0.007 and 0.008£©were 
lower than those of dial thickness gauge (0.049 and 0.053 respectively). The 
test-retest reliability of universal toolmaker microscope was greater than dial 
thickness gauge. Signifi cant footpad swelling occurred in the Group D after 
injection with PBMC+ alloantigen but not in Group B and C (averaging about 
0.036mm) after operation, and the peak swelling responses in Group D were 
observed in the 11th day post operation (averaging about 0.790mm). Further 
research also demonstrates that a signifi cant difference between Group D and 
other groups in the 4th day post operation (as determined by ANOVA).The level 
of IL-2 mRNA was elevated except the Group A. The peak levels of Group B and 
C were observed in post operation, and then gradually declined. The IL-2 mRNA 
level of Group D increased till rejection. We also found that there was signifi cant 
difference between Group B and other groups in 4th day post operation, but not 
between Group C and D until the 8th day.The data may demonstrate that the 
IL-2 mRNA level was related to acute rejection, but it is prone to be infl uenced 
by many factors. There were no differences between groups in MLC assay. We 
improved Trans-vivo DTH assay by use of the universal toolmaker microscope, 
instead of dial thickness gauge. According our research result, we believe that 
the improved Trans-vivo DTH assay is an effective method in evaluating the 
immune status of patient after transplantation.
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THE EMIT® 2000 SIROLIMUS ASSAY* ON THE 1186 
V-TWIN®/VIVA E® ANALYZERS
K. Ryzewski, H. Yau, A. Dominowski, Y.F. Zheng, Y. Yang, N. Morjana
Siemens Healthcare Diagnostics Inc.
Objective: Sirolimus (Rapamycin, Wyeth) is a potent immunosuppressive 
drug used in patients undergoing organ transplantation. It has a narrow range of 
safe and effective therapy therefore, therapeutic drug monitoring is absolutely 
necessary in patients on Sirolimus.  A new Emit Sirolimus Assay is currently 
being developed on the V-Twin®/Viva E® Analyzers. The proposed assay 
design was evaluated here. Methods: Imprecision was evaluated using three 
levels of sirolimus-spiked whole blood according to CLSI EP5-A2. Recovery 
was studied by spiking sirolimus into whole blood at concentrations that span 
the assay range. Linearity was assessed using patient specimens. Calibration 
stability was assessed by testing three levels of whole blood controls over a 
30-day period. Accuracy was evaluated with specimens from renal transplant 
patients and compared to LC/MS/MS and the Abbott IMx Sirolimus Assay using 
linear regression. Cross-reactivity with sirolimus metabolites was assessed at a 
concentration of 25 ng/mL in the presence and absence of sirolimus. The effect 
of common interferences was assessed by spiking the interferents into whole 
blood in the presence of 5 and 20 ng/mL sirolimus. 
Results: Within run imprecision CVs were 11.9% for level 1 (5 ng/mL), 3.7% 
for level 2 (12.6 ng/mL) and 6.0% for level 3 (29 ng/mL). Total imprecision 
CVs were 15.5%, 7.4% and 9.2%. Spike recovery of Sirolimus into whole blood 
was within 10% of the expected values. The assay linearity range is between 
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1.5-30 ng/mL. The calibration curve is stable for at least 2-weeks. A total of 
54 specimens were evaluated. The assay showed the following comparisons: 
V-Twin = 1.26*LC/MS/MS + 1.86; correlation to LC/MS/MS, r = 0.94; V-Twin 
= 1.07*Abbott + 2.9; correlation to Abbott, r = 0.92. The cross-reactivity 
of sirolimus metabolites: 41-O-demethyl, 7-O-demethyl, 11-hydroxy, 32, 
41-O-didemethyl was 38%, 15%, 4%, and 52%, respectively.  No interference 
of >+/-10% was observed with the endogenous interferences, hematocrit 
or HAMA. The interference of the co-administered drugs Cyclosporine, 
Tacrolimus, MPA or MPAG was within +/-10%. The reagents are stable on-
board the V-Twin analyzer for at least 30 days. 
Conclusion: The new Emit Sirolimus assay will provide good assay 
performance and accurate determination of Sirolimus in whole blood samples. 
* Product under development - not available for sale.
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SENSITIVE FORENSIC MEDICINE METHODS ALLOW 1187 
TO DETECT DONOR DNA IN RECIPIENT BLOOD FOR YEARS 
AFTER KIDNEY TRANSPLANTATION
J. Rutkowska1, B. Interewicz1, R. Ginak1, A. Rydzewski1,2, M. Świętek2, A. 
Dominiak1, M. Durlik1,2, W.L. Olszewski 1,2,3
1Department of Surgical Research & Transplantology, Medical Research 
Center, Polish Academy of Sciences, Warsaw, Poland 2Central Clinical 
Hospital, Ministry of Internal Affairs, Warsaw, Poland 3The Norwegian 
Radium Hospital-Rikshospitalet, Oslo, Norway
After organ transplantation passenger cells and cellular debris from ischemia 
and rejection damaged cells disseminate in recipient and in most part are 
being taken up by macrophages and dendritic cells (DC). The most important 
question is whether donor DNA may be incorporated into recipient cell genome 
in the process of the so called “illegitimate DNA incorporation” a frequent 
phenomenon in nature. A subsequent question would be the presumptive effect 
of donor DNA on the rejection process. 
Aim: To search for donor DNA in recipient tissues and cells after allogeneic 
transplantation and immunosuppression. 
Materials: Recipient’s blood samples were collected before and after kidney 
transplantation 1, 14,28,90, 180, 360 and 720 days and genomic DNA was 
isolated using Nucleospin kit (macharey-Nagel). Quantifi cation of DNA was 
performed in capillary cuvettes on GeneQuant (Amersham Pharmacia Biotech). 
The short tandem repeats analysis (STR) was applied. The investigated 
loci were: phospholipase A2- HUMPLA2A1 (AAT) n, cytochrome P450 
HUMCYARO (AAAT) n and D1S80. This type of analysis is used in forensic 
medicine. 
Results: Donor cytochrome P450 or HUMPLA2 or D1S80 genes were detected 
in recipient blood cells up to 2 years after kidney transplantation. Positive 
results were observed in all investigated patients, 24hr after grafting in 3 out 
of 3pts and in 4 out of 4 pts after 14 days, in 28 out of 28 after 28, in 2 out of 
2after 90, in 3 after 180, in 1 after 1 and in 2 out of 2 after 2 years. All patients 
remain under further follow-up. 
Conclusions: Donor DNA can be detected in recipient blood cells 2 years after 
kidney transplantation. The question as to whether the detected donor DNA 
was contained in the surviving donor cells or in a form of apoptotic or necrotic 
bodies in recipient phagocytes or was incorporated into recipient cell genome 
remains to be answered. The role of donor DNA in recipient cells in rejection 
or acceptance is not clear, although we know from animal experiments that it 
is detected in recipient dendritic APCs (antigen presenting cells). Most recent 
study documents presence of donor DNA in nuclei of recipient APCs. The 
comparison of clinical course of transplant and level of donor DNA have so far 
not been carried out because of a low number of patients.
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STIMULATION INDEX FOR PCNA MRNA EXPRESSION 1188 
IN PERIPHERAL BLOOD AS A PREDICTIVE INDICATOR OF 
OVER-IMMUNOSUPPRESSION
T. Kobayashi1, M. Niwa1, Y. Miwa1, A. Katayama1, M. Haneda2, T. Kuzuya3, 
T. Nagasaka4, T. Ueki5, K. Uchida4, A. Nakao6
1Nagoya University School of Medicine, Department of Applied Immunology, 
2Nagoya University School of Medicine, Department of Immunology, 3Nagoya 
University School of Medicine, Department of Hospital Pharmacy, 4Nagoya 
Daini Red Cross Hospital, 5Masuko Memorial Hospital, 6Nagoya University 
School of Medicine, Department of Surgery II
Introduction: Although the use of multiple immunosuppressive agents has 
recently reduced acute rejection, drug-induced toxicity and infection due to 
over-immunosuppression occasionally become a serious problem. Change 
from uniform treatment to individualized therapy is highly desirable. However, 
therapeutic drug monitoring is generally performed only in dose adjustment 
of calcineurin inhibitors. No assay for evaluating overall patient condition is 
available at present. We have attempted to develop a simple and reliable method 
of speculating the immunosuppressive state of recipients. Our attention was 
focused on proliferating cell nuclear antigen (PCNA). which is synthesized in 
early G1 and S phases of the cell cycle, and expected to refl ect the proliferation 
capacity of T lymphocytes under the immunosuppressive condition. The 
purpose of this study was to assess the feasibility and clinical applicability of 
PCNA mRNA monitoring after renal transplantation.
Methods: Heparinized blood samples were collected from recipients 
successively until 3 months after renal transplantation. Within 24 hours after 
withdrawal, 1 mL of whole blood was incubated overnight at 37 C with and 
without PMA/Ca ionophore stimulation. Extracted mRNA was applied to real 
time RT-PCR for the semi-quantifi cation of PCNA mRNA. Immune function 
was expressed as T cell proliferation capacity which was calculated as a 
stimulation index (SI = PCNA mRNA with stimulation/PCNA mRNA without 
stimulation). SI values were compared with clinical outcome such as rejection 
and infection episodes.
Results: Mean and SD values of SI in recipients were 5.6+/-2.1 at pre-
transplantation, 3.0+/-1.3 at 1 week, 2.9+/-0.9 at 2 weeks, 3.7+/-2.3 at 3 weeks 
and 5.8+/-3.0 at 4-12 weeks. SI values in healthy volunteers are signifi cantly 
higher (10.8+/-5.0) than those in transplant recipients. Eight (72.7%) among 11 
recipients with SI below 2.0 during the early post-transplant course developed 
cytomegalovirus or herpesvirus infection. In contrast, only 3 (14.3%) of 21 
recipients with continuously high SI (>2.0) showed CMV infection. SI for 
PCNA mRNA expression seemed to be closely related to immunosuppressive 
state of recipients and preceded viral infection episodes. Relation between SI 
values and acute rejection episodes could not be evaluated, because incidence 
of acute rejection within 3 months was very low (<10%).
Conclusions: PCNA mRNA monitoring in peripheral blood can be utilized to 
give a caution for over-immunosuppression as a simple immune function assay. 
Such immune function monitoring would be essential in providing optimal 
immunosuppressive therapy to each transplant recipient.
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ALLOREACTIVITY IN LIVER AND KIDNEY 1189 
TRANSPLANT RECIPIENTS
M. Lindemann1, H. Klinkenbusch1, C. Saure1, O. Witzke2, 
C. Valentin-Gamazo3, S. Beckebaum3,4, V.R. Cicinnati4, T. Philipp2, 
C.E. Broelsch3, H. Grosse-Wilde1
1Institut für Immunologie, 2Klinik für Nephrologie, 3Klinik für Allgemein-, 
Viszeral- und Transplantationschirurgie, 4Klinik für Gastroenterologie und 
Hepatologie, Universitätsklinikum
Background: Whereas HLA compatibility between donor and recipient clearly 
impacts on graft survival in kidney transplantation, it appears as minor relevant 
in liver transplantation. “Tolerogenic” properties of the liver are one possible 
explanation for this phenomenon.
Aim: To analyze if in-vitro alloreactions differ between liver and kidney 
tranplant recipients.
Methods: In 15 liver and 10 kidney transplant recipients interferon-γ und 
granzyme B ELISpots were performed prior to transplantation, at week 2-3, 
week 4-6, month 3, month 4, and month 6 post transplantation (n=95 interferon-γ 
and n=116 granzyme B ELISpots, respectively). At each time alloreactivity 
was determined against the donor and 3 HLA-DR different controls.
Results: Mononuclear cells of recipients after liver vs. kidney transplantation 
displayed signifi cantly (p<0.05) less interferon-γ production against donor 
cells prior to and at week 4-6 post transplantation (Figure). On the contrary, 
comparable alloreactivity against donors was observed from month 3 to 6 
after liver and kidney transplantation. Similarly, a decreased interferon-γ 
production was detected against 3 HLA-DR controls prior to and initially post 
transplantation. However, granzyme B production did not differ after liver and 
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kidney transplantation.
Figure: In-vitro alloreactivity of liver and kidney transplant recipients (LTX 
and NTX, respectively) against donors.
In our cohort containing 3 HLA-identical donor/recipients pairs (2 liver, 1 
kidney) no effect of HLA compatibility on in-vitro alloreactivity could be 
observed. Comparing immunosuppressive drug therapy after liver and kidney 
transplantation (cyclosporine A, tacrolimus, rapamycin, mycophenolate mofetil, 
and prednisone). average dosages were lower after liver transplantation. Thus, 
drug therapy appears as unlikely to cause diminished alloreactivity after liver 
transplantation. In summary, the data indicate that alloresponses in liver 
transplant recipients are reduced up to week 4-6 post transplantation.
Conclusions: Reduced in-vitro alloreactivity in liver transplant recipients 
could be caused by the severity of underlying disease and surgery. Thereby, 
an impairment of immunocompetence could lead to decreased alloreactivity in 
liver transplant recipients.
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PERFORMANCE OF A FULLY AUTOMATED 1190 
CYCLOSPORINE EXTENDED RANGE ASSAY ON THE 
SIEMENS DIMENSION VISTA® CLINICAL CHEMISTRY 
SYSTEM
T. Wei, Y. Yue, A. Baylis, E. Nuzzaci, J. Mizzer, D. Clark, T. Pankratz
Siemens Healthcare Diagnostics Inc.
Background: Cyclosporine Extended Range (CSAE) monitoring has been 
shown to better correlate with AUC (area under the curve) than trough 
monitoring and adequately estimates oral adsorption in transplant patients. 
We describe the initial performance of a fully automated immunoassay for 
cyclosporine extended range assay* in whole blood drawn at 2 hours post-dose 
on the Siemens Dimension Vista System.
Methods: The method employs the same reagents as used in the Dimension 
Vista CSA method. A whole blood sample (1.1 μL) is automatically lysed, 
incubated fi rst with antibody b-galactosidase conjugate and later with chrome 
particles coated with cyclosporine A. Sample cyclosporine forms immuno-
complexes with the antibody conjugate, and the excess conjugate is bound by 
the chrome particles, which are magnetically separated from the supernatant. 
The supernatant containing the cyclosporine -antibody conjugate complexes 
is then transferred to a photometric cuvette where the enzyme tag is detected 
using a chromogenic substrate.
Results: The assay range is 350-2000 ng/mL. Time to fi rst result is about 
13 minutes. Calibration is stable for 30 days. Repeatability and within-lab 
reproducibility on whole blood patient pools and control materials from More 
Diagnostics were measured to be 1.8 and 2.7%CV at 1691 ng/mL, 2.3 and 
3.6%CV at 1030 ng/mL, 3.4 and 4.4% at 653 ng/mL, and 4.7 and 5.5% at 483 
ng/mL cyclosporine respectively per the CLSI EP 5-A2 protocol over a 20 day 
testing interval. Split sample correlation (n= 116) between the Dimension Vista 
method (DV) and the Dimension method (DM) gave a linear regression fi t of: 
DV = 0.92*DM + 38, r=0.990, Sy/x= 43, range = 349 – 1765 ng/mL.
No signifi cant cross-reactivity was detected in samples spiked with 100 ng/mL 
tacrolimus, 5000 ng/mL sirolimus, 200 ug/mL MPA or 400 ug/mL MPAG. No 
signifi cant interference (<10%) was found for 60 mg/dL bilirubin, 1500 mg/dL 
triglyceride, 500 mg/dL cholesterol, 500 IU/mL rheumatoid factor, type I and 
II HAMA, and 12 g/dL total protein.
Conclusion: This method provides accurate, reproducible, and fast 
measurements of extended range cyclosporine on the Dimension Vista system.
*Product under development – not available for sale.
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CELLULAR MARKERS PREDICTIVE FOR ACUTE 1191 
REJECTION AFTER RENAL TRANSPLANTATION
P. Van De Berg1, N. Nikolaeva1, S-L. Yong1, E. Remmerswaa1, 
A. Rowshani2, K. Donselaar2, F. Bemelman2, R. van Lier1, I. ten Berge2
1Dept. of Experimental Immunology, Academic Medical Center, 2Renal 
Transplant Unit, Academic Medical Center
Discriminating patients who are at low risk for acute allograft rejection 
from those who are at high risk would allow to adjust the amount of 
immunosuppressive drugs individually. Here, we tried to fi nd T cell properties 
of transplant-recipients that can predict the risk of acute rejection episodes 
pre-transplantation. IL-7 is important for the initiation and perpetuation of an 
immune response and polymorphism in the IL-7Rα gene is correlated with the 
clinical outcome of bone marrow transplantation. Therefore, it can potentially 
be used as marker to predict the risk of an acute rejection.
We included patients with and without a rejection after transplantation. 
Lymphocytes of recipients, collected before transplantation, were CFSE 
labeled and stimulated in a mixed lymphocyte culture by either donor spleen-
cells or HLA mismatched 3d party lymphocytes. FACS analysis was performed 
after staining with CD3, CD8, CD4 and IL-7Rα.
The precursor frequency of alloreactive CD4+ and CD8+ T cells measured 
before transplantation was higher in rejectors than in non-rejectors. In patients 
who later experienced acute cellular rejection, the precursor frequency of 
alloreactive CD8+ T lymphocytes could not signifi cantly be decreased by 
blocking CD8 mAb. These same patients showed pre-transplantation higher 
IL-7Rα expression on their alloreactive CD4+ and CD8+ T cells than non-
rejectors.
Based on the ability to down regulate IL-7Rα expression after stimulation, 
recipients may be identifi ed before transplantation as being at low risk for 
developing an acute rejection episode. To further increase the chance of having 
an immunological uncomplicated course after transplantation a transplant 
donor can be selected to which they mount a low affi nity CD8 response of low 
precursor frequency.
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IN SITU QUANTITATIVE IMMUNOPROFILING 1192 
OF REGULATORY T CELLS USING LASER SCANNING 
CYTOMETRY
H. Takahashi, P. Ruiz, C. Ricordi, A. Miki, A. Mita, S. Barker, A. Tzakis, 
H. Ichii
University of Miami
Introduction: Cytofl uorographic analysis enables to analyze suspended cell 
populations quantitatively. On the contrary, quantitative in situ analysis (i.e. in 
a tissue sections) is diffi cult because of a lack of objective methodology. Laser 
scanning cytometry (iCys; CompuCyte) is recently developed methodology 
that utilizes fl uorescence-based quantitative measurements on tissue sections 
or other cellular preparations at a single-cell level. The purpose of this study 
was to develop objective quantitative immunoprofi ling of regulatory T cells 
(T regs) on formalin-fi xed/paraffi n embedded (FPE) biopsy sample from 
transplanted allograft using iCys.
Methods: We analyzed the population of CD4 (+) Foxp3 (+) T regs among 
the entire CD4 (+) T cells and the entire T cells (the total of CD4 (+) and CD8 
(+) ) in human intestinal allograft biopsy samples to evaluate the usefulness of 
iCys. Two unstained sections of four μm in thickness were prepared from the 
routinely processed FPE tissue. After deparaffi nization and blocking, primary 
antibodies (Foxp3 and CD4) were incubated on one section. Foxp3 and CD4 
were labeled by Alexa Fluoro 488 (Alexa488) and 647 (Alexa647) using 
polymer HRP and catalyzed signal amplifi cation. Propidium iodide (PI) counter 
staining was performed to visualize nuclear. On the other section, CD8 and 
CD4 were labeled by Alexa488 and Alexa647 using the same protocol. Data 
acquisition was performed using iCys. Determination of nucleated cells was 
achieved by recognizing PI signals. Alexa488 (Foxp3 or CD8) and Alexa647 
(CD4) integrals in section were acquired at a single-cell level.
Results: The nuclear signal of each cell was well determined by the PI signal. 
The signal intensity of Alexa488 and Alexa647 was suffi cient to analyze 
by iCys. Figure A and B show an example of intestinal allograft biopsy 
which histologically showed indeterminate for acute rejection with mild 
lymphoplasmacyitc infi ltrate. Distribution of the integrals of Alexa488 and 
Alexa647 on the section in which Foxp3 and CD4 were labeled was visualized 
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and CD4 (+) cell population was gated (Fig. A: R4). The population of T reg 
(Fig. A: R5) among CD4 (+) T cell was 13.7% (Fig. A: R5/R4). Distribution of 
the integrals of Alexa488 and Alexa647 on the section in which CD8 and CD4 
were labeled was visualized (Fig. B). The population of CD4 (+) T cell (Fig. B: 
R4) among the total of CD4 (+) and CD8 (+) T cells (Fig. B: R5) was 20.9% 
(Fig. B: R4/ (R4+R5) ). Accordingly, the population of T reg among the entire 
T cells was 2.9%.
Conclusion: iCys and signal amplifi ed immunofl uorescent staining allowed 
objective quantitative immunoprofi ling of in situ T reg populations, with precise 
quantitative analysis at a single-cell level on FPE section. Combined analysis 
of various immunoprofi ling enables to investigate more detailed analysis on 
the in situ T reg profi ling. This objective method can be applied on the biopsy 
sample from various transplant organs.
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HMGB1 AND IDO AS PREDICTIVE MARKERS IN RENAL 1193 
TRANSPLANTATION
D. Abendroth1, M. Marzinzig1, J. Kaden2
1Center of Surgery, University of Ulm, 2Vivantes Hospital Friedrichshain, 
Berlin
High mobility group box 1 (HMGB1) is a nuclear factor (NF) released as 
an early mediator of infl ammation and destruction. We compared results of 
indolamine 2,3 deoxigenase (IDO) with HMGB1 in renal transplantation to 
estimate which parameter is the more predictive tool for diagnosis of rejection. 
Furthermore, we evaluated the role of HMGB1 in delayed graft function.
Material and methods: Sera from 4 different groups of patients after renal 
transplantation (Gr.I, triple drug, no rejection=10; Gr.II, induction treatment 
with ATG-F, no rejection, n=10; Gr.III, rejection, n=10; Gr.IV, delayed graft 
function, n=10) were used for measurements. Estimation of HMGB1 was 
performed by using an enzyme immunoassay, IDO by using a uv detection 
method.
Results: There was a statistical difference (p<0.001) between the group I and 
IV for IDO as well as for HMGB-1 (IDO: 5,5+1,85 μM vs. 17,93+4,27μM; 
HMGB-1: 3,23+1,28 ng/ml vs. 5,65+1,08ng/ml) showing the effects of delayed 
graft function. The days until creatinine dropped < 200μmol/l were 4,4+2,7 
(dialysis n=0) compared to Gr.IV with 12,2+5,8ng/ml (dialysis n=3+1,6). 
IDO was higher in delayed function because of the infl ammation potency of 
the dialysis treatment. Concerning rejection, there was a statistical difference 
(p<.001) for HMGB-1 for rejection between group I and II compared to III 
(3,23+1,28; 3,03+0,98 and 6,69+3,4ng/ml). These fi ndings were more accented 
with IDO (5,5+1,85; 3,2+1,13 and 22,4+5,4 μM). There was a benefi cial 
behaviour for the ATG-F group for both parameters showing the lowest values 
compared to all other groups.
Conclusion: There was a positive correlation of HMGB1 and IDO in the state 
of rejection and delayed graft function. HMGB1 was more pronounced in 
DGF compared to IDO, which was the more sensitive parameter for rejection. 
Elevated HMGB1 levels might indicating the ongoing activated innate immunity 
via TLR4. The role of HMGB-1 as a predictive marker has yet to be evaluated.
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IMPACT OF IMMUNOSUPPRESSIVE TREATMENTS 1194 
ON ENDOTHELIAL BIOMARKERS AFTER KIDNEY 
TRANSPLANTATION
H. Vacher-Coponat1,2, G. Al-Massarani2,3, P. Paul2,3, Y. Berland1, 
F. Dignat-George2,3, L. Camoin-Jau2,3
1Nephrology and transplantation unit, AP-HM, Hopital Conception, 
2Hematology unit, AP-HM, Hopital Conception, 3INSERM UMR-S608, 
Université de la Méditerranée Aix-Marseille 2
Background: Endothelial dysfunction has been reported in haemodialysis and 
kidney transplanted patients and can be enhanced by immunosuppressive therapy. 
Circulating endothelial cells (CEC). endothelial microparticles (EMP) and 
sVCAM-1 have provided information on endothelium activation and/or damage.
Material and Methods: The objective was to compare the impact of two 
immunosuppressive regimens (CsA/Aza vs Tac/MMF) on the kinetics of CEC, 
EMP and sVCAM-1 levels during the fi rst year post-graft for 52 haemodialyzed 
patients by reference to 50 healthy controls donors.
Results: One-year post transplant (M12). CEC, EMP and sVCAM-1 levels 
were signifi cantly lower than before graft regardless of the treatment. While 
EMP counts reached normal values, CEC and sVCAM-1 levels were still 
signifi cantly higher than in controls at M12. When compared to the Tac/
MMF treated group, earlier improvement of EMP and lower CEC counts 
were observed in patients treated by CsA/Aza. We further investigated 
possible relationships between endothelial markers and clinical history such as 
cardiovascular diseases (HCVD) and cytomegalovirus infection. At M12, the 
CEC and EMP levels decreased signifi cantly only in patients without HCVD. 
Also, higher levels of EMP were observed after CMV infection.
Conclusion: As evaluated through non invasive circulating endothelial 
markers, renal transplantation decrease endothelial alteration with a more 
pronounced effect in patients treated by CsA/Aza. This may refl ect the reduced 
cardiovascular risk after kidney transplant but also provide early markers 
refl ecting persistence of vascular injury in transplanted patients.
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DIRECT CYTOKINE MEASUREMENT IN URINE 1195 
AND PLASMA IN A RAT MODEL OF CHRONIC KIDNEY 
REJECTION
U. Christians3, W. Schöning1,3, A. Frazer-Abel2, G. Puhl1, V. Schmitz1, 
1Dept. of Transplantation Surgery, Charite Campus Virchow, Humboldt 
University at Berlin, 2Complement Laboratory, National Jewish Medical and 
Research Center at Denver, CO, USA, 3Dept. of Anesthesiology -Resaerch 
and Development, University of Colorado at Denver, Health Science Center, 
CO, USA
Background: Up to now cytokines were mostly indirectly measured as 
cytokine mRNA expression in tissues by RT-PCR. Recently, a novel ‘direct’ 
cytokine measurement for rat urine and plasma samples based on antibody-
beads-Luminex™-technology has become commercially available. We present 
fi rst results of sequential urine and plasma cytokine analysis during the 
development of experimental chronic kidney rejection (CR).
Material and Methods: Using the well established Fisher to Lewis CR model, 
24-h-urine and plasma samples of 10 rats (250-300g BW at transplantation) 
were collected pre-transplantation and every two weeks post-transplantation 
over a 6 months period.
500μl of urine samples were concentrated by fi lter-centrifugation using 10kDa 
Millipore Microcon centrifugal fi lter units™, whereas 25 μL of plasma samples 
were diluted fi ve times. Lincoplex™ multiplex-antibody-bead-Kits and a 
Luminex™ 100IS device were used to measure the following cytokines: IFN-g, 
IL-10, IL-12, IL-18, IL-1a, IL-2, IL-4, IL-6, MCP-1, RANTES, TNF-a.
Results: Histological analysis revealed clear signs of CR at time of harvest 6 
months post-transplantation.
Signifi cant differences in Cytokine excretion over 24 h in urine compared to 
pre-transplantation were found for IL-18, IL-1a, RANTES and MCP-1. Plasma 
levels of IL-18, IL-1a, IL-2, RANTES and MCP-1 also showed signifi cant 
differences vs. pre-transplantation.
Conclusion: The above-mentioned infl ammatory Macrophage and T-Lymphocyte 
cytokines were easily measurable with minimal volumes of plasma and urine. 
Our results also contribute to an evolving discussion about interpretation of 
mRNA derived conclusions concerning cytokine actions in CR.
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NK CELL ALTERATIONS CORRELATE WITH RENAL 1196 
FUNCTION AND IMMUNOSUPPRESSIVE REGIMEN IN 
KIDNEY-TRANSPLANTED PATIENTS
H. Vacher-Coponat1,2, T. Legris1,2, C. Brunet2, M.L. Lyonnet2, V. Moal1, 
R. Purgus1, M. Indreies1, F. Dignat-George2,3, Y. Berland1, P. Paul2,3
1Nephrology and Transplantation unit, Hopital Conception, AP-HM, 
2Hematology unit, Hopital Conception, AP-HM, 3INSERM UMR-S 608, 
Université de la méditerranée Aix Marseille 2
Background: NK cells represent the fi rst line of immune defense against viral, 
tumoral or allogenic challenge, in particular in patients with T cell defi ciency. 
Still, in contrast with hematopoietic transplantation, evaluation of their 
alloreactive, anti-infectious or anti tumoral potential is poorly documented 
in organ transplantation. The impact of immunosuppressive drugs, designed 
to target activated T cells, on post transplant NK cell reconstitution may 
indeed have implications with regards to the immune potential of long term 
transplanted patients.
Methods: We fi rst conducted a multivariate and comparative retrospective 
analysis of variables that affect lymphocyte subsets counts in a cohort of 237 
hemodialyzed patients analyzed both before graft and during the fi rst year post 
kidney transplant. These patients were included in a randomized trial comparing 
quadritherapies including rabbit anti-thymocytes induction (ATG). prednisone 
in association with either Tacrolimus/mycophenolate mofetil (Tac/MMF) or 
Cyclosporine/Azathioprine (CsA/Aza). Two control groups, undialyzed uremic 
patients and healthy control donors, were evaluated.
The impact of treatment on NK cell phenotypical and functional features was 
further analyzed one year post transplant in relation with renal function.
Results: A 32% decrease in NK cell counts was observed in hemodialyzed 
patients awaiting graft in reference to age and sex matched healthy 
controls. Early post graft NK cell depletion observed after ATG treatment 
was followed by differential reconstitution of NK cell counts in the 2 
therapeutic arms. At one year post transplant, the better NK cell counts 
reconstitution observed in the Tac/MMF group (median, 147 versus 45 in 
CsA/Aza, p<0.0001) was associated with a 10% increase in renal function 
(evaluated by MDRD clearance, p=0.02). As observed in undialyzed 
uremic patients, lower renal function was associated with lower NK cell 
counts in the Tac/MMF group (r= 0.3854, p <0.0001). This selective effect 
of immunosuppressive treatment was also associated with enhanced NK 
cell cytotoxicity in the Tac/MMF group (% K562 target lysis, median, 
25-75 percentile: CsA/Aza 5.6, 0.9-18.9 versus Tac/MMF 32, 17.11-49, p 
<0.0001) and specifi c phenotypic features that affect the NK cell subsets 
defi ned by expression of NK receptors such as NKG2D, CX3CR1, CD122 
and CD244/2B4.
Conclusions: End stage renal diseased patients already have a defect in the 
NK cell compartment, which is worsened after graft in patients under CsA/
Aza immunosuppressive regimen. In contrast, association of Tac/MMF favors 
NK cell reconstitution one-year post graft, in association with better kidney 
graft function. These data may have implications to optimize use of immune 
suppressive drugs and improve graft and patient’s survival. Some associations 
may indeed both limit rejection while preserving the innate immune response 
potential against infections and tumors in long-term immunosuppressed 
patients.
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COMPARISON OF CYTOKINE PROFILE BETWEEN PRE- 1197 
AND POSTTRANSPLANTATION 1ST YEAR
I.M Titiz1, G. Isitmangil1, G. Tellioglu1, F. Turkmen1, H. Tozkir2, S. Gulle1, 
T. Ozgezer1, B. Yigit1, I. Berber1
1Haydarpasa Numune Research and Educational Hospital, Renal 
Transplantation and Immunology Unit, Istanbul, Turkey, 2Trakya University, 
Medical Faculty, Department of Molecular Biology, Edirne, Turkey
Background: Cytokines are immune mediators indicating proinfl ammatory 
or immunosuppressive state. A balance of cytokines normally exists between 
these two states. In this study we aimed to compare cytokine levels between 
pre- and postop 1st year patients who had been immunosuppressed by 
CyA+MMF+steroid therapy regimen.
Methods and Subjects: We determined IL-1alpha, TNF-alpha, IFN-gamma, 
IL-10 and TGF-beta concentrations among totally 77 blood samples by ELISA 
(RayBiotech, Inc) performed according to manufacturers’ instructions. Group 1 
(n=35) included kidney transplant patients at postoperative 1st year and Group 
2 included the same blood samples (n=35) which were studied preoperatively. 
All were lymphocyte cross-match negative by both complement-dependent 
cytotoxicity assay and fl ow cytometry technique. Group 3 contained 7 healthy 
subjects.
Results: There was no graft loss at postoperative 1st year after renal 
transplantation. Seroconversion rates from preoperative period to postoperative 
1st year were as follows for each cytokine separately: For IL-10 from negative 
to negative 94.28%; from positive to negative 5.71%. For TGF-beta from 
negative to negative 88.57%; from negative to positive 2.85%; from positive 
to negative 8.57%. For IL-1alpha from negative to negative 54.28%; from 
negative to positive 22.85%; from positive to positive 5.71%; and from positive 
to negative 17.14%. For IFN-gamma from negative to negative 85.71%; from 
negative to positive 11.42%; from positive to positive 5.71%; from positive to 
negative 2.85%. TNF-alpha was negative in all included cases. All cytokines 
were negative in the control group.
Conclusion: We conclude that routine pre- and posttransplant cytokine 
monitoring by ELISA offers early risk assessment that is crucial for proper 
immunosuppression and for antirejection therapy choice.
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A SIMPLIFIED METHOD USING ATP 1198 
AND A LUMINOMETER FOR ASSESSMENT OF 
IMMUNOSUPPRESSION IN TRANSPLANT PATIENTS
A. Assounga, S. Omarjee
Dept of Nephrology, University of KwaZulu-Natal and Laboratory of 
Immunology, Doris Duke Medical Research Institute, Durban, South Africa.
To prevent transplant rejection patients are subjected various combinations of 
immuno suppressive agents that may have addictive synergistic antagonistic 
effect. Furthermore additional co-morbid condition (ie: CMV, HIV infection) 
may further alter patient’s immune condition. Currently most monitoring 
methods measures levels of individual drugs. Recently a method using CD4 
cells was developed by Cylex to measure immune response through ATP levels 
detected by a luminometer. In this study we have applied a simplifi ed method 
using peripheral blood mononuclear cells (PBMC) and tested kidney transplant 
patients.
Method: PBMC were separated from 30 transplant patients and fi ve control 
blood samples by fi coll hypaque gradient centrifugation. 100ul of cells in culture 
medium were plated in triplicate on white opaque 96 well microtitre plates and 
incubated for 15-18 hours with phytohemagglutinin (PHA 25μg/ml) in a 37º C/
CO2 incubator. The assay plate was assembled so as to include an ATP standard 
in duplicate that was prepared by serial dilutions to concentrations of 1000ng/
ml, 100ng/ml, 10ng/ml and 1ng/ml. The Promega CellTiter-Glo Luminescent 
Cell Viability assay which signals the presence of intracellular ATP by using the 
luciferin/luciferase enzyme reaction was used. The amount of intracellular ATP 
present was measured with the Turner Biosystem luminometer in relative light 
units (RLU). ATP concentration in PBMC wells was calculated and compared 
the published literature values. .
Results: ATP results reported in nanograms of ATP per milliliter were 
determined by constructing a standard curve. The measure of the functional 
ability of PBMCs’ response to the PHA challenge in vitro demonstrated 
lower ATP values in the immune compromised patients as compared to the 
healthy controls. The patient’s immune statuses according to ATP levels were 
comparable to Cylex published values. PBMC of patients or controls showed 
various increases in ATP following exposure to PHA
Conclusion: These preliminary results demonstrate that the use of ATP 
bioluminescence together with a luminometer for assessing immune function 
is simple and sensitive assay and has possible application to assist in the 
management of immunosuppression in kidney transplant patients.
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IN SEARCH OF NON-INVASIVE MARKERS FOR 1199 
CAUSE OF GRAFT DYSFUNCTION AFTER RENAL 
TRANSPLANTATION
R. Naqvi1, Z. Imani1, S. Ali1, K. Fatima1, S. Batool1, M. Mubarak1, J. Kazi1, 
R. Muzzafar1, A. Naqvi1, A. Rizvi1
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Sindh Institute of Urology and Transplantation (SIUT). Karachi, Pakistan.
Objective: Hyperexpression of some non invasive markers have been studied 
previously in setting of acute rejection in renal allograft recipients and 
necessitated to confi rm the observation in larger sample size.
Methods: We at our institution isolated RNA from urine samples, reverse 
transcribed to cDNA and proceeded with doing kinetic (Real Time) Quantitative 
PCR. We studied 5 genes i.e. 18S, Granzyme B, Perforin, TGF β and FOX 
P3, on all urine samples collected on day 1, day 7, 3 months and 6 months 
post transplant, and at time of graft dysfunction. Clinical setting includes acute 
rejections, UTIs, CMV, CAN and DGF.
Results: Between July 2007 – Feb 2008, 135 samples from 50 consecutive 
transplant recipients processed for above mentioned genes.
We noticed high level expression of cytokines from both cytotoxic and 
regulatory T cells on fi rst day post transplant, which showed declining pattern 
of these genes on day 7 and 3 months post transplant. (Table). We were also 
able to demonstrate again rising expression of GB, Perforin and FOX P3 with 
acute rejections. Results of these fi ndings will be analysed and presented.
gene Day 1 post tx Day 7 post tx 3month post 
tx
GB (RNA copy no. 
median) 
47000 11200 4400
Perforin (RNA copy no. 
median) 
110000 24500 8200
FOX P3 (RNA copy no. 
median) 
77000 44000 00
Conclusion: The fi ndings of our study are of importance when designing studies 
using the cytokine gene expression profi le as a marker for graft dysfunction in 
setting of renal transplantation.
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PHARMACODYNAMIC MONITORING OF DE NOVO 1200 
RENAL TRANSPLANT RECIPIENTS UNDERGOING 
CONVERSION FROM CYCLOSPORINE TO EVEROLIMUS IN 
COMBINATION WITH MYCOPHENOLATE
K. Budde1,  J. Nolting1, P. Glander1, N. Gauer1, M. Naik1, A. Sefrin2, M. Mai1, 
J. Klupp3, H-H. Neumayer1, P. Reinke2
11Medizinische Klinik m.S. Nephrologie, Charité Universitätsmedizin Berlin 
Campus Mitte, Germany, 22Medizinische Klinik m.S. Nephrologie und 
Internistische Intensivmedizin, Charité Universitätsmedizin Berlin Campus 
Virchow Klinikum, Germany, 33Centrum für Chirurgische Medizin, Charité 
Universitätsmedizin, Berlin, Germany
Pharmacodynamic monitoring has been shown to be a possible tool to 
measure immunological response in patients receiving immunosuppressive 
therapy after transplantation (TX). We investigated pharmacodynamic 
(Pd) markers in 61 de novo renal transplant recipients after TX to identify 
early changes in the immunological activity of the recipients during 
conversion from cyclosporine to everolimus (EVR). All patients received 
mycophenolate sodium maintenance therapy. Immunosuppressive induction 
therapy included basiliximab (pre-TX and day 4). corticosteroids, enteric-
coated mycophenolate sodium and cyclosporine A (CsA). After month 
4.5 patients were randomized to continue on CsA (controls) or to proceed 
with everolimus. Pharmacodynamic monitoring included measurement 
of the expression of intra-T cell cytokines (IL2, TNFa). T cell activation 
markers (CD25, CD71) and lymphocyte proliferation from whole blood 
by FACS. The activity of IMPDH in isolated peripheral mononuclear cells 
was measured by HPLC. All markers were investigated pre-TX, at day 3, 
10, 28 and at month 3, 4.5, 6, 7.5. Immediately after TX we observed a 
signifi cant (p<0.001) decrease in IMPDH activity (-52%). IL2 (-62%) and 
TNFa production (-68%). CD71 (-78%) and CD25 expression (-94%) and 
lymphocyte proliferation (-92%). Proliferation, CD25 and CD71 levels 
continuously recovered in part until M4.5 (p<0.001). The conversion from 
CsA to EVR was associated with a signifi cant (p≤;0.004) reduction of 
IMPDH activity leading to a signifi cant (p≤;0.003) difference of IMPDH 
activity between groups. The EVR treated group tended to have lower 
lymphocyte-proliferation (-45%) after conversion (n.s.). CD71 expression 
was signifi cant (p≤;0.002) lower in the EVR group when compared to 
controls. A further normalisation of CD25 (p≤;0.001). CD71 (p≤;0.001) as 
well as TNFa (p≤;0.01) and proliferation (p≤;0.05) was observed in the 
control group. IL2 remained unchanged in both groups. 
Conclusion: Investigation of PD markers may lead to a better understanding 
of immunosuppressive therapy after renal transplantation. We observed 
differences between two immunosuppressive treatments with these markers. 
Prospective research activities might link clinical events like infections and 
rejection to distinct pharmacodynamic parameters.
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IN VIVO IMAGING SYSTEM (IVIS). A NEW TECHNIQUE 1201 
FOR LYMPHOID FUNCTIONAL INSPECTION
L-J. Xu1, W-N. Zhang1, H-M. Zhou1, J-M. Huang1, X-K. Pei2, C. Liu2, 
Z-H.K. Chen1
1Instiute of Organ Transplantation, Key Lab of Ministry of Education/
Ministry of Health of China, Tongji Hospital, Huazhong University of Science 
And Technology£¬Wuhan£¬430030,China, 2Organ Transplantation Center, 
2nd Affi liated Hospital of PLA General Hospital, Beijing, 100091
Objective: To evaluate the veracity and sensitivity of In Vivo Imaging System 
(IVIS) for inspection of lymphoid function especially in vivo. 
Methods: (1) In Vitro Experiments: Mouse melanoma cells (B16-F10-luc-G5) 
in 100ul media were seeded into a 96 well plate by 1: 2 serial dilutions from 
10,000 cells (well #1) to 78 cells (well #8). The plate was imaged with IVIS 
(IVIS Lumina 100, Xenogen) to evaluate its sensitivity for luminescence. 
Mixed lymphocyte culture (MLC) system consisted of total lymphocytes 
(as effect cell) and tumor cells (B16-F10-luc-G5, as target cell). and it was 
divided into 3 groups: Group1, at a 20: 1 effector: target ratio (5×104 total 
lymphocytes: 2.5×103 tumor cells) in each well; Group2, at 10: 1 effector: 
target ratio (2.5×104 total lymphocytes + 2.5×103 tumor cells) in each well; 
Control group, only tumor cells 2.5×103 in each well. After twenty-four hours’ 
culture, 1×D-luciferin working solution (150 ug/ml) was added to cells just 
prior to imaging, and then plate was imaged with IVIS for 60s, the intensity 
indicated the sensitivity of IVIS for lymphoid functional inspection in vitro. (2) 
In Vivo Experiments: Ten Bablc mice, with melanoma cells (B16-F10-luc-G5) 
(1×105 in 100ul) injected subcutaneously into the right dorsal region near 
the thigh, were randomly divided into experimental group (n=5) and control 
group (n=5). CD4+CD25+ regulatory T cells suspension (1×106 in 100ul) 
(which suppresses immune responses against tumor, namely down-regulates 
lymphocytes’ function and prolongs tumor survival) was given to each mouse 
after tumor cells implantation on Day0 in experimental group, while media 
(100ul) was given to control group. Tumor growth is monitored by in vivo 
imaging (luminescence detection by IVIS) and caliper measurement at Day0, 
Day3, Day5, Day7 and Day9. 
Results: (1) In vitro: As few as 78 tumor cells were detectable. A strong 
correlation between number of tumor cells and bioluminescence (R2=0.99) was 
also demonstrated. In MLC system, there was signifi cant difference (P<0.01) of 
mean photon count [photon/ (cm2.ser.s) ] between Group1 and Control, Group2 
and Control [ (6.98E+03) ±66.0 vs (4.24E+05) ±5354.1, (1.15E+05) ±1070.8 
vs (4.24E+05) ±5354.1]. Moreover, with few cells, effector: target ratio at 10
¦ 1 was appropriate for lymphoid functional inspection by IVIS. (2) In vivo: A 
strong correlation (R2=0.94) between mean bioluminescence and mean tumor 
volume was also demonstrated. There was signifi cant difference (P<0.01) of 
tumor luminescence [mean photon count, photon/ (cm2.ser.s) ] detected by IVIS 
between two groups in Day3, Day5, Day7 and Day9 [ (2.36E+05) ±2270.8 vs 
(1.12E+05) ±1820.1, (2.57E+05) ±3070.0 vs (1.12E+05) ±2090.7, (3.00E+05) 
±4352.8 vs (2.40E+05) ±3515.2, (1.31E+06) ±11852.3 vs (1.18E+06) 
±11530.8]. Moreover, tumor dynamic morphology could be monitored by IVIS 
when it is invisible. 
Conclusion: Compared with conventional methods, with high veracity and 
sensitivity, IVIS System should be recommended as an effective method for 
lymphoid functional inspection especially in vivo.
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COSTIMULATION AS A GVHD PROPHYLAXIS1202 
H.R. Cho1,2, B. Kwon2,3, J.S. Lee2,4, R.J. Kim2
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical 
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea, 
3Department of Biological Science, University of Ulsan, Ulsan, Ulsan, 
Korea., 4Department of Internal Medicine, Ulsan University Hospital, Ulsan, 
Ulsan, Korea
We previously demonstrated that in vivo engagement of CD137, a member of 
TNF receptor superfamily, can delete alloreactive CD4+ T cells through the 
induction of activation-induced cell death (AICD), thus preventing chronic 
GVHD in the DBA/2unirradiated (C57BL/6 x DBA/2)F1 (BDF1) chronic 
GVHD model. In this study, we further showed that in vivo engagement of 
CD137 was highly effective in triggering AICD of donor CD8+ T cells as well 
as donor CD4+ T cells in the C57BL/7unirradiated BDF1 acute GVHD model. 
Even though CD137 stimulation facilitated lethal GVHD in mice preconditioned 
with a higher dosage of total body irradiation, CD137 stimulation rather 
completely prevented acute GVHD without impairing donor cell engraftment 
in mice preconditioned with a lower dosage of total body irradiation (200 
rad). Further analysis showed that engrafted donor T cells followed by CD137 
stimulation did not exhibit alloreactivity to host alloantigens, including skin 
graft, further demonstrating that CD137 stimulation completely removed 
alloreactive donor T cells from the mature donor T cell pool transferred into 
the host. Interestingly, however, CD137 stimulation heightened a GVL effect. 
Our result suggest that CD137 stimulation increase the activity of donor T cells 
against weak tumor antigens, while deleting donor T cells responding to strong 
alloantigens. In sum, CD137 stimulation may be used as a GVHD prophylaxis 
in a parent-into-F1 GVHD setting.
POSTER BOARD NUMBER P2 – 02
COMPARISON OF CHIMERISM INDUCTION AFTER 1203 
DONOR BONE MARROW TRANSPLANTATION INTO 
DIFFERENT RECIPIENT COMPARTMENTS
M. Siemionow, E. Sonmez, A. Klimczak
Cleveland Clinic
Purpose: This study was designed to evaluate the effi cacy of different routes 
of BMC transplantation on development of donor specifi c chimerism across 
major histocompatibility complex barrier under 7-day alpha-beta-TCR/CsA 
treatment protocol.
Methods: Thirty two BMC transplantations were performed between ACI 
(RT1a) donors and Lewis (RT11) recipients. In 8 groups (n=4 of each group) 
each receiving 100x10 6 BMC, following BMC delivery routes included: 
intravenous (Groups 1 and 2), intraosseus (Groups 3 and 4), renal intra-
capsular (Groups 5 and 6) and intra-testicular (Groups 7 and 8). Groups 1,3,5,7 
(controls) received BMC transplantation without immunosuppression, whereas 
groups 2,4,6,8 received BMC transplantation under 7 day alpha-beta-TCR/
CsA protocol. Flow cytometry monitored immunodepletion and donor specifi c 
chimerism for MHC class I for T-cells, B-cells and monocyte/granulocyte 
antigens.
Results: All animals survived without development of graft-versus-host 
disease up to 35 days. In summary: As early as 7 day post-transplant in intra-
testicular and renal intra-capsular transplanted groups under alpha-beta-
TCR/CsA therapy, chimerism was supported predominantly by T-cells, and 
monocyte/granulocyte populations. During follow-up period at day 35 post-
transplant, chimerism declined in all transplanted groups. In treatment groups 
chimerism decreased by 49% after intravenous, 22% after intraosseus, 78% 
after intracapsular, and 85% after intra-testicular BMC delivery.
Despite the fact that the highest level of chimerism decline was found after intra-
testicular and intra-capsular BMC transplantation, total level of chimerism was 
still superior compared to intraosseus and intravenous BMC transplantation, 
and was assessed as follows: 13.27% (intra-testicular), 22.71% (intra-capsular), 
11.46% (intraosseus), 7.49% (intravenous) respectively.
All animals are still under observation in good condition and long-term results 
also will be presented.
Conclusion: Our observations indicate that chimerism induction and 
maintenance is superior when BMC is delivered into privileged environment 
(intraosseus) or to barrier carrying organ such as renal intra-capsular and intra-
testicular BMC delivery compared to standard intravenous injection. This study 
has proven that BMC transplantation into immuno-privileged compartment 
may be a preferred method of transplantation and currently studies are carried 
out testing its effi cacy in composite tissue transplantation models.
POSTER BOARD NUMBER P2 – 03
ALLOGENEIC BONE MARROW TRANSPLANTATION: 1204 
CLINICAL OUTCOME AND ANALYSIS OF RISK FACTORS 
FOR MORBI-MORTALITY
I. Helal, A. Byzun, J-P. Rerolle, E. Morelon, H. Kreis, M-F. Bruneel-Mamzer
Department of renal transplantation, Necker Hospital. Paris-France
Bone marrow transplantation (BMT) has become a widely used therapy for 
malignant and nonmalignant diseases. Despite the associated high risk of 
toxicity, with high morbidity and mortality rates. The present study evaluated 
the clinical outcome and analysis risk factors for morbidity and mortality in 
patients undergoing allogeneic BMT.
We performed a retrospective cohort study including all patients who had 
received allogeneic BMTs at Necker Hospital from March 1991 to May 2002. 
These patients were reviewed to determine their baseline characteristics, the 
development of co-morbidity conditions, and mortality rates at one year. ARF 
is defi ned by the doubling of the baseline serum creatinine concentrations. 
Analysis was made using Chi-square test for qualitative parameters and non 
paired student’s t test for continuous variables.
One hundred and one patients aged 34 ± 11.8 years on average were included 
in our study. The majority of patients (95/101: 95%) had received cyclosporine 
prophylaxis and overall 67 patients (66.3%) developed an acute graft-v-
host disease (GVHD). Only 12 of the 101 patients (11.9%) developed a 
venoocclusive disease (VOD).
Of the 101 patients 40 (39.6%) were admitted to intensive care, mainly for septic 
choc in 14 cases (35%) and acute respiratory failure in 11 cases (27.5%).
Of the 101 patients, 58 (57.4%) had ARF corresponding to an incidence of 
2.6% per week during the fi rst year following BMT. The peak frequency of 
ARF occurred during the second week (29. 3%).The recourse to haemodialysis, 
a proof of the severety of ARF, was necessary in 12 cases (20.7%).
The overall mortality rate for the 101 allogeinic BMT was 35.6% at the end 
of the fi rst year.In multivariate analysis, only the aminoglycoside use (p=0.02, 
RR=0.31), admission to the intensive care unit (p < 10-3, RR=7.29) and the 
development of ARF (p=0.001, RR=8.97) were independent predictors of 
mortality.
Conclusion: We conclude that ARF is a common complication of allogeneic 
BMT. It is of early onset, of multifactorial origin and often associated with 
iatrogenic complications. As the prognosis is rather grim, it is very important 
that those associated factors be identifi ed for an effective prevention of 
this disease.
POSTER BOARD NUMBER P2 – 04
MICROSURGICAL MODELS FOR VASCULARIZED 1205 
BONE MARROW ALLOTRANSPLANTS IN RATS
D. Zamfi rescu1,2, I. Lascar1, E. Owen2, M. Lanzetta2, R. Bratianu1, 
R. Sinescu1, I. Zegrea1
1Carol Davila Medical University, 2Microsearch Foundation of Australia
It has been suggested that a limb allotransplant can be consider as a vascularized 
bone marrow transplant (VBMT). A VBMT is a live and continuous source 
of donor bone marrow cells (BMC) in their own environment (stromal 
cells, hematopoietic cytokines) that continuous seeding BMC and homing 
in recipient tissues and may be responsible for partial tolerance to MHC 
antigens. The aim of this work was to familiarize with some experimental 
animal models used in the research fi eld of Composite Tissue Allografts 
(CTAs) that can be used as vascularized bone marrow models. All these 
animal models are vascularized allotransplants from Brown Norway to Lewis 
rats. A total 92 procedures were done: orthotopic (n = 60) and heterotopic (n = 
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5) limb transplantation, femur transplantation (n = 5), limb and contralateral 
femur transplantation (n = 5), knee transplantation (n = 5), tail transplantation 
(n = 5), and sternum transplantation (n = 2). All animals received drug 
therapy (FK506, MMF and Prednisone) for 8 weeks, then treatment was 
ceased entirely. The average success rate of transplantation was 84.57%. This 
study demonstrated that vascularized bone marrow transplants could be a 
reliable new method for bone marrow transplantation based on this surgical 
approach. It is proposed that the transfer of VMB could be a better technique 
than cellular bone marrow transplantation.
POSTER BOARD NUMBER P2 – 05
IMMUNOLOGICAL EVALUATION OF THE EARLY POST 1206 
TRANSPLANT PERIOD IN PEDIATRIC BONE MARROW 
ALLOTRANSPLANTATION
H. Abdelrazik1, G. Morreale2, E. Lanino2, P. Terranova2, L. Scarso2, 
B. Cappelli2, D. Di Martino2
1Cairo University, 2Istituto Giannina Gaslini
Successful hematopoietic progenitor cell transplantation requires rapid and 
complete transfer of the donor hematopoietic and immune systems to the host. 
The kinetics of immune reconstitution following various modes of transplant 
have been previously studied and found to be impaired for up to several years. 
Most of the studies showing delayed immune reconstitution post bone marrow 
transplantation (BMT) have focused on long term reconstitution and outcome 
of the transplant. Only a few, have looked at immune reconstitution in children 
in the early (First 100 days) post-transplant period. Studies have shown that 
immune reconstitution is accelerated following autologous transplant when 
compared to allogeneic transplant. In the allogeneic setting, graft-versus-host 
disease (GvHD) and immune-suppressive therapy may interfere with recovery 
of the immune system and strategies which diminish GvHD also retard immune 
reconstitution.
To compare the different settings of allogeneic BMT;19 matched unrelated 
pediatric donor transplants with mean age of 9.6yrs (1.5-18yrs) and 13 
familial allotransplantation with mean age of 6.7yrs (0.5-14yrs) were 
evaluated for Immunological Reconstitution during the fi rst 90 days post-
transplantation. Immunoglobulin assay levels, T-cells and its subsets, B 
cells and natural killer (NK) cell numbers were assessed by fl owcytometry 
at different time points; engraftment time, day+30, day+60 and day+90 
posttransplat. Immunoglobulin (Ig) diversity was determined using heavy 
chain determining region 3 (HCDR3) fi ngerprinting. Two variable heavy 
chain (VH) gene families (VH3 and VH6) were amplifi ed by nested PCR 
and visualized on 6.5%polyacrylamide gel by silver staining. Fingerprinting 
for Ig HCDR3 was also done before transplantation for both the donor and 
the recipient in order to monitor whether the patient engrafts with the same 
memory of the donor. Pretransplant CD34 counts, neutrophil and platelet 
engraftments were also considered.
The natural limb of the immune system seems to play the major role of body 
defense during the early post-transplant period. NK cells and neutrophil 
counts showed the highest signifi cant differences between patients who had 
a familial donor than patients who had Matched Unrelated Donor (MUD), 
however most of the tested elements; B-cell counts, Ig levels and T cell counts 
showed signifi cant differences. Immunoglobulin fi ngerprinting showed that 
patients were engrafted with the same diversity pattern as the donors while 
there was no correlation between the immunoglobulin assay levels and the B 
cell number and diversity. Incidence of acute GVHD did not differ between 
the two groups. Although the intensity of the immunsuppression didn’t differ 
between the two groups, it did affect the diversity and immunoglobulin 
production of the B cells.
Familial transplanted patients had a more rapid immune reconstitution 
until Day 30 post transplant after which there was no statistical signifi cant 
differences recognized between both groups. Thus after the fi rst 30 days 
Familial transplantation is comparable with MUD transplantation regarding 
Immunological reconstitution and incidence of GvHD
POSTER BOARD NUMBER P2 – 06
ISOLATION OF CD4/CD8 DOUBLE POSITIVE HUMAN 1207 
REGULATORY T CELLS, IN THE SKIN OF A BONE MARROW 
TRANSPLANTED PATIENT SUFFERING 
FROM GVHD
A. Eljaafari1, M. Michallet2, A. Farre3, C. Ferrand4, J. Kanitakis5, J. Bernaud6, 
C. Malcus7, P. Tiberghien8, D. Rigal9, P. Miossec10
1Edouard Herriot Hospital, Immunogenomics Unit HCL BioMerieux 
,Centaure group, 2Edouard Herriot Hospital , Hematology Dept, 3EFS Rhone-
Alpes, Lyon, 4EFS France Comté, 5Edouard Herriot Hospital , Dermatology 
Dept, 6EFS Rhone-Alpes, Lyon, 7Edouard Herriot Hospital , Immunology 
Dept, 8EFS France Comté, 9EFS Rhone-Alpes Lyon, 10Edouard Herriot 
Hospital, Immunogenomics Unit
Introduction: Whereas regulatory T cells have been isolated among CD4+, 
CD8+, or CD4/CD8 double negative sub-populations in the human, the 
existence of CD4/CD8 double positive regulatory (DP) T cells is still unknown, 
as opposed to the mouse.
Methods: Skin biopsies were performed in a patient suffering from graft-
versus-host-disease(GVHD), following HLA-identical BMT. Skin infi ltrating 
T cells were isolated by culture with 25 UI/ml rhIL-2, for two weeks.
Results: At day 14 of culture, we isolated a double positive CD4/CD8 T cell 
population which expressed an oligoclonal V beta T cell repertoire. These cells 
specifi cally recognized recipient, but not donor or third-party APCs in proliferation 
assays. Anti-HLA class I mAbs blocked the allo-response. Following stimulation 
with recipient APCs, the cytokine profi le of CD4/CD8 DP T cells showed 
moderate levels of TGF beta, high levels of IL-10, intermediate levels of IL-4, 
but no IL-2 secretion. This regulatory T cell clone expressed low levels of FoxP3 
mRNAs, which specifi cally increased upon allogeneic stimulation with recipient 
APCs. Finally, the T cell clone was able to inhibit the response of third party T 
cells that were stimulated with recipient, but not with donor, or third party APCs.
Conclusion: We have identifi ed for the fi rst time, CD4/CD8 double positive 
regulatory T cells, in humans. Interestingly, we show at the clonal level, that 
these cells are specifi c for an HLA-class I-restricted minor histocompatibility 
antigen, which induces their regulatory function.
POSTER BOARD NUMBER P2 – 07
CAMPATH LYMPHODEPLETION ALLOWS REDUCED 1208 
INTENSITY CONDITIONING TO ESTABLISH DURABLE 
MIXED CHIMERISM IN PATIENTS WITH SICKLE CELL 
DISEASE
M.J. Elliott 1, S. Ildstad1, A. Cheerva 1, C. Dampier 2, S. Bertolone 1, D. 
Tollerud 1, G. Herzig 1, R. Herzig 1
1Institute for Cellular Therapeutics, University of Louisville, 2St. Christopher 
Hospital for Children, Philadelphia, PA
Bone marrow transplantation is the only curative therapy for patients with sickle 
cell disease (SCD) and thalassemia. Sensitization due to transfusion therapy 
has been a signifi cant barrier in the establishment of chimerism in patients with 
SCD. Higher intensity conditioning has been required to achieve successful 
engraftment. We recently found that humoral immunity is the dominant barrier 
in sensitization to alloantigen. As a result, we developed a conditioning approach 
to tolerize B cell as well as T cell immunity. Two cycles of Campath-1H (anti-
CD52) were administered to deplete B-cells and T-cells when preconditioning 
recipients for bone marrow transplant, with the rationale to remove memory B 
cells induced to undergo homeostatic proliferation by the fi rst round of therapy. 
Patients were conditioned with Campath-1H (cycle 1: 10 mg/day; day -53 to -50 
and cycle 2: 7 or 8 mg/day -24 to -21, respectively), fl udarabine (30 mg/m2 day 
-5 to -3), 200 cGy TBI (day -1), peripheral blood hematopoietic cell infusion 
day 0, followed by cyclosporine and mycophenolate mofetil (MMF) (day -1 
to > 6 months). Patient 1 is an eight-year-old African American female who 
experienced multiple pain crises and episodes of acute chest syndrome. She had 
been extensively treated with transfusion therapy and hydroxyurea pre-transplant. 
She received 14.5 x 106/kg CD34 cells, 43.5 x 106/kg αβ-TCR cells and 6 x 106/
kg facilitating cells from her HLA-identical sibling donor with SCD trait. She 
showed 5% donor engraftment on day 17 and 78% donor engraftment on day 30. 
Her HgbA has remained over 50% through day 754 post-transplant, with donor 
chimerism consistently > 20%. She has been asymptomatic since her transplant 
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and her immunosuppression has been discontinued. Patient 2 is a nine-year-old 
African American male who had suffered multiple pain crises and two episodes 
of acute chest syndrome prior to transplant. He had been treated with red cell 
exchange transfusions since August 1999. He received HLA-identical mobilized 
product, processed to deplete T-cells and B cells, from an HLA identical sibling 
donor with SCD trait. The graft contained 5.24 x 106/kg CD34 cells, 0.55 x 106/
kg αβ-TCR cells and 0.35 x 106/kg FC. The patient has remained transfusion-
independent, with HgbA > 50% and chimerism levels at > 25% through > 608 
days post-transplant. His immunosuppression has also been discontinued. Both 
patients have been asymptomatic since their transplant. Neither experienced graft-
versus-host disease. These data suggest that targeting of adaptive B-, as well as 
T-cell reactivity in sensitized recipients allows a signifi cant reduction in intensity 
of conditioning to establish chimerism in treatment of sickle cell disease.
POSTER BOARD NUMBER P2 – 08
DEPLETION OF CD16+ CELLS LEADS TO INCREASED 1209 
SURVIVAL OF CFSE-LABELED PERIPHERAL BLOOD STEM 
CELLS IN RHESUS MACAQUES
A. Kirk, A. Charafeddine, K. Hamby, C. Larsen, L. Kean
Emory University
The induction of donor chimerism after non-myeloablative conditioning 
and hematopoietic stem cell transplantation has potential utility for inducing 
immune tolerance to subsequently placed solid organ allografts. However, one 
of the potential barriers to success of chimerism-based approaches may be the 
large number of donor stem cells required to evade early rejection responses. 
Our previous work in mice has suggested that natural killer (NK) cells play 
an important role in early rejection, and that transient NK depletion leads to 
10-20x increased effi ciency of stem cell engraftment.
We have now developed a system to study this problem in non-human primates, 
and to test the effect that NK cell depletion has on survival of transplanted 
cells in this clinically relevant translational model. We have established a 
method to collect large quantities of peripheral blood stem cells (up to 1x1010 
nucleated cells and 5x108 CD34+ cells after leukopheresis) and to effi ciently 
label these cells with the fl uorescent marker, CFSE (>95% of cells labeled with 
>95% post-labeling viability). CFSE+ cells can then be adoptively transferred, 
allowing us to monitor traffi cking and survival of multiple cell populations (eg. 
CD45+ leukocytes, CD34+ stem cells, CD4+ and CD8+ T cell subpopulations, 
CD20+ B cells, and CD16+ NK cells).
We have performed leukopheresis, CFSE labeling and autologous adoptive transfer 
on 4 recipients and have monitored the traffi cking of labeled cells to the peripheral 
blood, the lymph nodes and the bone marrow after transfer. In addition, we have 
adoptively transferred CFSE+ cells into 6 unrelated, MHC mismatched animals, half 
of which had been previously depleted of NK cells (using the anti-CD16 antibody 
3G8). We have found that depletion of CD16+ cells led to as much as a 10-fold 
survival advantage of adoptively transferred cells within one week of transplant, 
and that this survival advantage was found in multiple hematopoietic lineages. 
We are currently expanding on these results to determine if NK depletion gives a 
similar advantage in the setting of increased MHC matching, and if the increased 
stem cell survival that occurs in the setting of NK depletion will ultimately lead to 
increased chimerism after nonmyeloablative bone marrow transplantation.
POSTER BOARD NUMBER P2 – 09
VERTEBRAL BODY RETRIEVAL AND BONE MARROW 1210 
CELL ISOLATION FOR TRANSPLANTATION
S. Schneeberger1, V.S. Gorantla1, L.R. Moore2, B. Pulikkottil1, T.E. Starzl3, 
A.W.P. Lee1, A.D. Donnenberg2
1Division of Plastic Surgery, UPMC, 2UPCI Hematopoietic Stem Cell 
Transplantation Program, 3Thomas E. Starzl Transplantation Institute
Introduction: Donor bone marrow (BM) cell infusion has been successfully 
incorporated and promotes the opportunity for reducing maintenance 
immunosuppression in recently described treatment protocols organ and composite 
tissue transplantation. The best source for BM cells in deceased donors is vertebrae.
Methods: We have performed fi ve vertebral body retrievals after perfusion 
with Custodiol in deceased donors and performed vertebral BM preparation 
in a GMP environment. Removal of soft tissue was performed using a Versajet 
system and an angled oscillating saw allowed for retrieval of the vertebral 
bodies while the remaining appendixes helped stabilizing the body. The spine 
was further stabilized with a plastic cylinder shaped to fi t into the vertebral 
canal. Vertebral bodies L4-Th8 were stored for 37h14min±36min in 1-4°C cold 
Custodiol solution and transferred to a class 10,000 GMP clean room. Cubes 
of 1-2cm were irrigated with medium containing saline, albumin, DNAse 
and gentamicin, and grinded in a bone marrow machine (Biorep Technology) 
housed in a class II bio-safety cabinet. Cells were collected through stainless 
steel sieves (425, 180u). Additional cells were eluted during 2 rounds of 
agitation using a bone marrow tumbler. Cells were pooled, fi ltered (500, 200u) 
and collected using a bone marrow collection kit. &#8232;
Results: The modifi ed technique allowed for rapid and reproducible retrieval 
of vertebral bodies. Most cells (71.9±12.5%) were eluted directly from the 
crushed bone, whereas 22.3% and 5.5% were eluted after the fi rst and second 
rounds of tumbling, respectively. Larger lumbar vertebrae yielded about 1.6 
times the cells of thoracic vertebrae. A total WBC number of 5.37±1.24E+10 
and CD34+ cell count of 5.71±1.78E+10 was retrieved. WBC and CD34+ 
cell viability were 94.3±4.7 and 98.9±0.7% respectively. A distinct population 
of CD45- CD34- CD105+ CD73+ mesenchymal stem cells constituted 
approximately 0.05% of nucleated cells. Cell yields correlated well with age 
but not body weight.
Conclusion: A modifi ed procedure for VB retrieval was established while avoiding 
instabilization of the donor body. Bone marrow cell isolation with consistently 
high yields and cell viability can be performed in a GMP environment.
POSTER BOARD NUMBER P2 – 10
CONSENT TO BONE MARROW TRANSPLANTATION: 1211 
A CONVENIENT FICTION?
C. Scanlan
Centre for Values, Ethics and the Law in Medicine (VELiM), University of Sydney
Legal and ethical doctrines of consent are essential components of contemporary 
medical practice. These doctrines assume that a competent patient can make a 
choice from a series of treatment options (including having no treatment) after 
having been suffi ciently/adequately informed by their clinician of the risks 
and benefi ts of the proposed treatment(s). These assumptions remain largely 
unquestioned in the literature, in health policy, and in practice guidelines.
We conducted a qualitative study of the experience of patients who had 
undergone autologous haematopoietic stem cell transplantation (ASCT), 
and the experience of their lay carers. Insights from the study fundamentally 
challenge common conceptions of consent and choice in medical care. 
Participants said they had ‘no choice’ but to consent to ASCT, because the 
only alternative for them was death, and for them death was not an option. 
They talked about there being a ‘correct’ course of treatment for them, which 
evolved with their clinical circumstances and that this dictated what had to be 
done. These results suggest that in clinical circumstances such as these, consent 
should not be conceptualised as an authorisation based on information delivered 
and received in order to allow choice. Instead, the paradigm should shift to the 
understanding that patients are consenting to an ongoing relationship of mutual 
trust and obligation with their doctor.
PRE-CLINICAL CONCURRENT ORAL SESSION 87: 
IMMUNOSUPRESSION
POSTER BOARD NUMBER P2 – 11
EFFECTS OF ALKALOID SINOMENINE ON CD4+ T 1212 
LYMPHOCYTES OF HUMAN PERIPHERAL BLOOD 
IN VITRO
Y. Wang1, Z. Luo, G. Qin, J. Li
1The Second Affi liated Hospital, University of South China, 2The Second 
Affi liated Hospital, University of South China, 3The Second Affi liated 
Hospital, University of South China, 4The Second Affi liated Hospital, 
University of South China
To evaluate the immunosuppressive effects of alkaloid sinomenine (SIN) on 
CD4+T lymphocytes through the study of effects of SIN on the proliferation 
and intracellular Ca2+ concentration and the expression of CD69 and apoptosis 
of CD4+ T lymphocytes of human periphory blood in vitro.
Establishment of the CD4+T lymphocytes model of human peripheral blood: 
The proliferatiosd CD4+T lymphocytes suspension were divided averagely 
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into 5 groups at random whose cell concentration was 5¡Á105 and volume was 
10 ml: 1) Group contrast: No medicine was added to cell culture medium; 2) 
Group CsA: CsA solution whose fi nal concentration was 50ng/ml was added 
to cell culture media; 3) Group genistein: Genistein solution whose terminal 
concentration was 50¦Ìmol/L was added to cell culture medium; 4) Group 
low-concentration SIN: SIN solution whose terminal concentration was 10 
¦Ìmol/L was added to cell culture media; 5) Group middle-concentration SIN: 
SIN solution whose terminal concentration was 200¦Ìmol/L was added to cell 
culture media; 6) Group high-concentration SIN: SIN solution whose terminal 
concentration was 1000¦Ìmol/L was added to cell culture media.
Results: 1.The cell proliferation inhibition ratios(%) (1)¡¢Group blank 
contrast:0.00¡À0.00;(2)¡¢Group CsA:72.62¡À0.85;(3)¡¢Group low-
concentration SIN:2.25¡À1.58;(4)¡¢Group middle- concentration SIN: 
27.65¡À1.65;(5)¡¢Group high-concentration SIN:40.12¡À1.08. 2.The 
data of intracellular Ca2+ fl uorescent intensity estimated by FCM, which 
represented intracellular Ca2+ concentration:(1)¡¢Group blank contrast: 
11.00¡À0.20;(2)¡¢Group CsA:11.90¡À0.27;(3)¡¢Group low-concentration SIN: 
11.30¡À0.26;(4)¡¢Group middle-concentration SIN: 7.57¡À0.15; (5)¡¢Group 
high-concentration SIN:6.00¡À0.10. 3. The expression of CD69 in differently 
treated CD4+Tlymphocytes estimated by FCM(%): 1) Group contrast: 
87.42¡À0.96; 2) Group genistein: 36.53¡À1.17; 3) Group low-concentration 
SIN: 85.46¡À1.52; 4) Group middle-concentration SIN: 62.45¡À1.09; 5) Group 
high-concentration SIN: 43.70¡À0.62. The expression of CD69 of group low-
concentration SIN was little changeable in contrast to that of group contrast 
(P>0.05). the expression of CD69 of Group middle-concentration SIN, Group 
high-concentration SIN, Group genistien decreased gradually, and the expression 
of CD69 of group genistein was the lowest than that of other groups (P<0.05).
4. The apoptosis in differently treated groups of CD4+T lymphocytes estimated 
by FCM: 1) Group contrast: 1.70¡À0.30; 2) Group genistein: 21.17¡À1.21; 3) 
Group low-concentration SIN: 1.83¡À0.19; 4) Group middle-concentration 
SIN: 6.90¡À0.30; 5) Group high-concentration SIN: 10.17¡À0.32.
Conclusions: The study of the immunosuppressive value of SIN in the CD4+T 
lymphocytes model of human peripheral blood suggests that this medicine 
has remarkable effi cacy in immunotherapy. The immunosuppressive effi cacy 
of SIN is probably based on inhibiting of the proliferating and intracellular 
Ca2+ concentration evaluation and the expression of CD69 and the apoptosis 
of CD4+T lymphocytes of human peripheral blood in vitro. The effi cacy is 
concentration-responsively. SIN may be a potential Chinese medicine for 
immunosuppression therapy in transplantation.
POSTER BOARD NUMBER P2 – 12
DEFICIENCY IN THE RECALL RESPONSE OF THE 1213 
SUPPRESSOR CD8 T CELL GENERATED IN THE ABSENCE OF 
THE CD4 T CELL HELP
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu 
University
Background: The suppressor CD8 T (Tsupp) cells generated in the tolerant 
animal has reported to be effi cient for the engraftment in the allogenic organ 
transplantation. Tsupp cells are reported to be generated in the recipients made 
tolerant by the Cyclophosphamide (CP)-induced tolerance (CPIT) conditioning, 
which is the mixed chimerism based tolerance induction regimen. Recent 
study reported that the CD4 T cell ghelp h is required for CD8 memory T 
cell generation under virus infection, and the ghelpless h CD8 memory T cell 
generated in the absence of CD4 T cell help is defi cient for its expansion in the 
secondary stimulation. In this study, we asked the requirement of CD4 T cell 
help for the generation of T supp cells in the tolerant animals.
Method: DBA/2 (H-2d, CD45.2) and BALB/c (H-2d, CD45.1 and CD45.2) 
were used the donor and the recipients. Recipient mice were treated with CPIT 
conditioning, which comprise the 100 millions of donor splenocyte (SC) on day 
0 and 200mg/kg CP on day 2. Recipients were received donor skin graft (SG) 
at 2 weeks to confi rm the donor SG tolerance. Donor mixed chimerism in the 
recipients was also examined by fl ow cytometry. Recipients were treated with 
anti-CD4 mAb on day -4, day 0, and then weekly, when indicated (helpless 
Tsupp mice). Secondary CD45.2 BALB/c recipients received CD8 sorted T 
cells from the CD45.1 primary mixed chimeras. Those recipients received 
donor DBA/2 heart graft (HG) within 2 days, and grafts survival was evaluated. 
The Suppressive function in the mixed lymphocyte reaction was also assessed 
in vitro. Distributed CD45.1 positive primary recipient CD8 T cells in the 
secondary CD45.2 BALB/c recipients were assessed by fl ow cytometry.
Results: Permanent donor skin grafts acceptance along with the stable donor 
mixed chimerism was observed in the primary recipient after the CPIT treatment. 
The helped and helpless Tsupp showed equivalent suppressive function in 
vitro. Donor DBA/2 HG was permanently accepted in the secondary BALB/c 
recipients, that received ghelped h Tsupp from primary mixed chimeras. In 
clear contrast, donor DBA/2 HG were rejected in the secondary recipients, 
which received ghelpless h Tsupp from primary mixed chimeras treated with 
CPIT conditioning with CD4 depletion. Consistent to the HG survival, CD45.1 
positive ghelped h Tsupp cells from tolerant recipients was clearly detected in 
the secondary recipients. However, ghelpless h Tsupp cells from CD4 depleted 
recipients were found smaller percentage in the secondary CD45.2 recipient, 
suggesting helpless Tsupp undergo death by activation-induced cell death upon 
secondary stimulation.
Conclusion: CD8 suppressor T cells were generated in the mixed chimeras. 
Our results indicated that the Tsupp cells generated in the absence of CD4 
T cell help was ineffective to suppress donor HG rejection because of its 
defi ciency in recall response.
POSTER BOARD NUMBER P2 – 13
NVP-AEB071 PHARMACOKINETICS: EFFECT OF 1214 
METABOLIC INHIBITION WITH KETOCONAZOLE
A. Slade1, J.M. Kovarik1, A. Huang1, P. Chandler2, R. Schmouder1
1Novartis Pharmaceuticals Corp., East Hanover, NJ and 2Covance, Inc, 
Dallas, TX. 
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively 
blocks early T lymphocyte activation via inhibition of protein kinase C. 
AEB071 is metabolized by CYP3A4 and is currently under development for 
the prophylaxis of organ rejection and treatment of autoimmune diseases. As 
AEB071 has potential for replacing CNIs and may be combined in future 
immunosuppressant regimens with other CYP3A4 substrates, a drug-interaction 
study was conducted with ketoconazole to quantify the pharmacokinetics (PK) 
under metabolic inhibition.
Methods: Using an open-label, two-period, single sequence design, single 
doses of 50 mg AEB071 were administered to 18 healthy volunteers alone 
and in combination with steady-state ketoconazole (200 mg bid X 7 days). 
PK samples were collected during both treatment periods through 72 h post-
dose. LC-MS methodology was used to quantify AEB071 and ketoconazole 
concentrations with a quantifi cation limit of 3 ng/mL and 10 ng/ml respectively. 
Results: All doses were well tolerated with a total of 13 adverse events reported 
by 9/18 subjects. The most common reported adverse events were headache (3) 
and nausea (2); none of them serious or severe. When dosed in combination 
(See fi gure below),
AEB071 Cmax increased 2.5-fold from 285 ± 128 to 678 ± 189 ng/ml; AUC 
increased 4.6-fold from 1666 ± 808 to 7378 ± 3011 ng*h/ml; and the elimination 
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half-life was prolonged from 5.9 ± 1.7 to 10.6 ± 2.5 hours. Based on the mean 
change in AUC, this interaction is classed as “moderate”. The increase in 
AEB071 blood levels is similar to or less than that seen with other 
immunosuppressants used in transplantation, for example, following a similar 
study design, ketoconazole elicits a 4-fold increase in cyclosporine exposure, 
but an 11-fold increase in sirolimus exposure.
Conclusion: The transplant clinician should be aware that the combination of 
strong inhibitors of CYP3A4, such as ketoconazole with AEB071 results in a 
moderate increase in systemic AEB071 exposure.
POSTER BOARD NUMBER P2 – 14
NVP-AEB071: EFFECT OF MILD AND MODERATE 1215 
HEPATIC IMPAIRMENT ON AEB071 PHARMACOKINETICS
A. Slade1, C. Liu1, J.M. Kovarik1, T. Dumortier1, R. Preston2, R. Schmouder1
1Novartis Pharmaceuticals Corp, East Hanover, NJ and 2University of Miami, 
Miami, FL.
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively 
blocks early T-cell activation via selective inhibition of protein kinase C (PKC). 
AEB071 is currently under development for the prophylaxis of organ rejection 
and treatment of autoimmune diseases. AEB071 is extensively metabolized, 
in part by CYP3A4. To measure the effect of hepatic insuffi ciency on the 
pharmacokinetics of AEB071, a study was conducted in patients with mild or 
moderate hepatic impairment.
Methods: In this open-label, parallel group, single dose study, eligible 
subjects were stratifi ed by their Child-Pugh classifi cation; mild (Class A) or 
moderate (Class B) prior to receiving a single, 50 mg, oral dose of AEB071. 
Standard laboratory assessments, ECGs and pharmacokinetic (PK) sampling 
was conducted throughout the study and follow-up periods. PK samples 
were taken through 96 hours post dose. For PK comparison, two historical, 
50 mg single dose healthy volunteer studies A2210 (n=22) and A2101 (n=6) 
were used.
Results: A total of 12 subjects, 6 each mild or moderate hepatic impairment 
were enrolled. There were no clinically relevant changes in laboratory or vital 
sign assessments and all doses were well tolerated. There was 1 adverse event, 
headache reported.
As shown above, the mild group demonstrated higher variability with a mean 
Cmax of 311 ng/ml and AUC(all) of 2134 ng*hr/mL, compared to the healthy 
volunteers (265 ng/mL and 1501 ng*hr/mL). The 30% difference in exposure 
is likely due to the inherent variability of AEB PK and the small sample size of 
6 patients. This interpretation is supported by the results of the moderate group, 
in which a mean Cmax of 235 ng/mL and AUC of 1349 ng*hr/mL is similar to 
that of healthy controls.
Conclusion: Hepatic impairment, up to Child-Pugh classifi cation B 
(moderate) has no clinically relevant effect on the pharmacokinetics of 
AEB071. These data support the further development of AEB071 in hepatic 
transplantation.
POSTER BOARD NUMBER P2 – 15
NVP-AEB071 MAXIMUM TOLERATED DOSE: SAFETY 1216 
AND TOLERABILITY OF A NOVEL T-CELL ACTIVATION 
INHIBITOR
A. Slade1, T. Jung1, T. Dumortier1, G. Stingl2, M. Seiberling3, J. Wilmer4, 
R. Schmouder1
1Novartis Pharma AG, Basel, Switzerland, 2Medical University of Vienna, 
Austria, 3Swiss Pharma Contract, Allschwil, Switzerland, 4CANTEST, 
Vancouver BC, Canada 
NVP-AEB071 (AEB071) is a novel, oral, small molecule which effectively 
blocks early T-cell activation via selective inhibition of protein kinase C 
(PKC). AEB071 is currently under development for the prophylaxis of organ 
rejection and treatment of autoimmune diseases. To assess the maximum 
tolerated dose of AEB071, single (SD) and multiple dose (MD) studies were 
conducted in healthy volunteers and psoriasis patients. Studies from 10-500 
mg SD and 25-200 mg MD showed that these doses were well tolerated 
as previously reported. Herewith we report on the results of higher dose 
studies. 
Methods: Three separate, double-blind, placebo controlled studies were 
conducted. Subjects were randomized to receive either AEB071 or placebo. 
Single doses of 750, 800 or 1100 mg AEB071 or placebo were administered to 
24 healthy volunteers. Multiple doses of 300 mg or 400 mg AEB071 or placebo 
were administered to 21 subjects, twice daily, for 14 days. Standard laboratory 
assessments, ECGs and vital signs were collected throughout the dosing and 
follow-up periods.
Results: 38 adverse events (AEs) were reported by 16/24 subjects in the 
SD cohorts; one was an SAE (sinus arrest) that resolved spontaneously. 77 
AEs were reported by 15/21 subjects in the MD cohorts. There were no 
clinically relevant changes in laboratory assessments. A transient increase 
in heart rate (sinus tachycardia) and liver function tests were noted at 
the highest doses; 1100 mg SD and 400 mg MD AEB071, respectively. 
Two subjects discontinued 400 mg bid treatment, one for persistent AEs 
and the other for a protocol violation. Otherwise, all patients completed 
treatment.
As shown in the table above, 6/6 subjects receiving a single 1100 mg dose of 
AEB071 presented with nausea, 4 of whom vomited. Similarly, 4/10 subjects 
receiving multiple, 400 mg, doses of AEB071 presented with nausea and 
multiple incidence of vomiting.
Conclusion: AEB071 800 mg SD and 300 mg MD for two weeks were well 
tolerated. GI intolerance at higher doses of 1100 mg SD and 400 mg bid 
MD limit these AEB071 dosings. These data support further development of 
AEB071 in transplantation at doses up to and including 300 mg bid.
TU
ESD
AY
 
Poster Abstracts Tuesday 12 August 2008
4 1 3Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P2 – 16
STUDY EVALUATING A NEW GENERATION OF 1217 
RABBIT ANTI-HUMAN LEUKOCYTE POLYCLONAL 
ANTIBODY IN COMBINATION WITH ANTI-CD20 
RITUXIMAB IN A NONHUMAN PRIMATE MODEL OF SKIN 
ALLOTRANSPLANTATION
P. Wang1, Z. Liu1, X. Wang1, P. Yun1, Y. Jia1, H. Xu1, A. Kirk2
1Jinan City Central Hospital, 2Department of Transplantation, Emory 
University Hospital, Emory University, Atlanta, USA
We have generated new rabbit anti-human leukocyte polyclonal antibody 
(newRALG) by immunizing rabbits with activated lymphocytes and 
monocytes to specifi cally target these activated cells. The newRALG blocks 
multiple surface molecules such as costimulatory molecules and cytokine 
receptors on both activated lymphocytes and monocytes, and inhibits acute 
renal allograft rejection in rhesus macaques. To evaluate the effects of 
newRALG in combination with monoclonal anti-CD20 antibody Rituximab 
in preventing allograft rejection, rhesus macaques were treated with 5 doses 
of newRALG at 5 mg/kg with or without 2 doses of Rituximab at 10 mg/
kg (day -1 and posttransplant day 7). Thirteen animals underwent skin 
allotransplantation. Peripheral blood lymphocyte and monocyte counts were 
decreased dramatically, and the depletion of peripheral CD4+ and CD8+ 
cells as determined by FACS was observed after newRALG infusion. FACS 
analysis revealed undetectable peripheral blood CD20+ lymphocytes following 
Rituximab infusion. The allograft survival in untreated monkeys (n=4) was 
7.5¡À0.58 days. Rituximab treated monkeys did not demonstrate prolongation 
of skin allograft survival (n=2, mean=8¡À0). Monotherapy with newRALG at 5 
mg/kg moderately prolonged rhesus skin allograft survival ranged from 10 to 11 
days (n=3, mean=10.7¡À0.6 days), and those treated with combination therapy 
(newRALG and Rituximab) rejected skin allograft in a mean of 15.5¡À0.7 
days (n=2). In additional experiments, two monkeys received rapamycin at 1 
mg/kg/day and pre-transplant donor specifi c bone marrow infusion via portal 
vein 7 days before transplantation and treated with combined therapy with 
newRALG and Rituximab after transplantation. Both monkeys rejected skin 
allograft within 7 days after transplantation. Thus, newRALG depletes rhesus 
monocytes and lymphocytes in vivo, and moderately prolongs skin allograft 
survival. Rituximab monotherapy does not prolong skin allograft survival. 
newRALG in combination with Rituximab signifi cantly prolongs skin allograft 
survival in rhesus. The effects of high dose newRALG therapy in combination 
with Rituximab and post-transplant specifi c donor bone marrow infusion in 
preventing skin allograft rejection are currently under investigation.
POSTER BOARD NUMBER P2 – 17
EFFECTS OF THE NEW IMMUNOSUPPRESSIVE AGENT 1218 
AEB071 ON HUMAN IMMUNE CELLS IN VITRO
K. Budde1, M. Matz1, U. Weber1, M-F. Mashreghi2, J. Ladhoff3, S. Kramer4, 
H.H. Neumayer1
1Department of Nephrology; Universitaetsmedizin Charité, Berlin, 
Germany, 2DRFZ; Berlin, Germany, 3Institute of Medical Immunology; 
Universitaetsmedizin Charité, Berlin, Germany, 4Novartis Pharma; 
Nuernberg, Germany
The novel immunosuppressive agent AEB071 is currently being evaluated for 
its capability to prevent rejection after kidney transplantation as a potential 
replacement for calcineurin inhibitors. AEB071 is a selective protein 
kinase C inhibitor and has been shown to be well tolerated in humans. Its 
immunosuppressive effi cacy could be demonstrated in several transplantation 
models. We here present in vitro studies based on PBMC from healthy 
volunteers (n=6) that contribute to the understanding of AEB071 effects on 
human lymphocyte activation, proliferation and NK-cell activity. Additionally 
the effect of AEB071 on human DC maturation and their capacity to stimulate 
allogeneic T-cells was studied.
We were able to show that mitogen-stimulated T-cell-proliferation rates are 
signifi cantly reduced after AEB071 administration. Also mitogen-induced 
T-cell activation characterized by expression levels of surface markers ICOS, 
CTLA-4, CD71, CD25, Ox40, PD-1 and CXCR3 could be signifi cantly 
inhibited by AEB071 treatment. In contrast the T-cell stimulatory capacity of 
AEB071-treated mature Mo-DC is not reduced and AEB071 administration 
does not prevent LPS-induced Mo-DC maturation defi ned by expression levels 
of markers CD83, CD40, CD80, CD86, B7-DC and HLA-DR. We additionally 
evaluated the effect of AEB071 on the lytic activity of human NK-cells and 
were able to show that the new immunosppressive agent signifi cantly inhibited 
their cytotoxic activity in vitro.
AEB071 has a clear and strong impact on T-cell activation and proliferation, 
NK-cell activity, but not DC-maturation and therefore functions T-cell 
and NK-cell specifi c via PKC inhibition, and is thus a highly promising 
immunosuppressive agent.
POSTER BOARD NUMBER P2 – 18
A PILOT STUDY ON SUBLINGUAL AND RECTAL 1219 
ADMINISTRATION OF TACROLIMUS
A. Van de Plas1, J. Dackus2, M. Christiaans2, L. Stolk1, K. Neef1, 
J. Van Hooff 2
1Dept of Clinical Pharmacy, 2Subdivision Nephrology of the Dept of Internal 
Medicine, Maastricht University Medical Centre, The Netherlands
Introduction: Tacrolimus has a narrow therapeutic index and high variability of 
its pharmacokinetics. Oral bioavailability is relatively low and highly variable 
(25%(4-93%)). Sublingual and rectal administration of tacrolimus were studied 
in six kidney transplant patients before transplantation as part of our search for 
a non-oral formulation. Reams et al. recently reported therapeutic blood levels 
after sublingual administration of tacrolimus in lung transplant patients. Rectal 
administration of tacrolimus has not been published yet.
Objectives: Investigation of sublingual and rectal administration of tacrolimus 
to humans.
Methods: Sublingual administration: Three kidney transplant patients were 
treated with 0,04 mg/kg tacrolimus s.l. two days before transplantation and 0,1 
mg/kg one day before transplantation. A capsule with tacrolimus was opened 
and the content was dispersed under the tongue. The patient was told not to 
swallow during 15 minutes and afterwards the saliva was spit out and the 
mouth was rinsed with 250 ml water.
Rectal administration: Three kidney transplant patients were treated rectally 
with 0,23-0,27 mg/kg tacrolimus in suppositories two days before transplantation 
and 0,1 mg/kg tacrolimus orally one day before transplantation.
Blood samples of all patients were taken at t= 0, ¼, ½, 1, 2, 4, 8, 12 and 24 hours 
post dose. Whole blood tacrolimus levels were analyzed by HPLC and tandem 
mass spectrometry (LOQ = 0.05 μg/l). Compounding of the suppositories was 
performed according to GMP rules.
Results: 
Figure 1. Tacrolimus blood levels (μg/l) against time postdose (hours). SL1, 
SL2, SL3; s.l. administration, PO1, PO2, PO3; oral administration.
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Figure 2. Tacrolimus blood levels (μg/l) against time postdose (hours). R1, R2, 
R3; rectal administration, PO1, PO2, PO3; oral administration.
Discussion: To our surprise tacrolimus was hardly absorbed after sublingual 
administration. A possible explanation for the results contradictory with the 
study of Reams et al. could be that in the study of Reams et al. patients were 
not told not to swallow and to spit out saliva and rinse the mouth. Therefore 
oral intake of tacrolimus can not be excluded. After rectal administration of 
suppositories in a dose of 0,23-0,27 mg/kg tacrolimus, blood levels seemed to 
be comparable with blood levels after oral administration of 0,1 mg/kg. Peak 
blood levels occurred later and the absorption period seems to be prolonged 
after rectal in comparison with oral administration.
Conclusion: In this pilot study tacrolimus was hardly absorbed after sublingual 
administration. After rectal administration in suppositories tacrolimus is well 
absorbed. These results indicate that sublingual administration of tacrolimus 
is no but rectal administration probably is a useful alternative for oral 
administration. Further investigation is warranted in order to establish correct 
dose and pharmacokinetic parameters for rectal administration.
POSTER BOARD NUMBER P2 – 19
PHARMACOKINETIC PROFILE OF CP-690,550 IN DE 1220 
NOVO RENAL ALLOGRAFT RECIPIENTS
S. Krishnaswami1, S. Busque2, J. Leventhal2, S. Steinberg2, G. Klintmalm2, D. 
Brennan2, V. Chow1, P. Gupta1, S. Menon1, N. Lawendy1, C. Wang1, G. Chan1
1Pfi zer, Inc., 2A3921009Study Group
Background: CP-690,550 (CP) is an orally active inhibitor of Janus kinase, 
currently in Phase 2 trials for kidney transplantation and autoimmune diseases.
Objective: To characterize the CP-690,550 pharmacokinetic (PK) profi le in de 
novo kidney transplant patients enrolled in a 6-month, Phase 2, randomized, 
open-label, multicenter, active comparator-controlled, parallel group study.
Methods: Plasma samples were collected in patients receiving 15 mg (N=19) 
and 30 mg (N=20) of CP-690,550 twice daily (BID) using a combination of 
sparse (predose samples on Days 1, 3, and 14 and Months 1, 3, and 6 post-
transplant) and dense (samples at 0.5, 1, 2, 4, 8, and 12 hours post-dose on 
Days 1 and 3 in approximately 40% of the patients) sampling strategies. PK 
data were analyzed using noncompartmental techniques, where possible, and 
population modeling techniques.
Results: The absorption of CP-690,550 on Day 1 post-transplant was decreased 
with variable time to peak concentration (Tmax) between 1 and 12 hours post-
dose. The PK profi les on Day 3 showed rapid and consistent absorption, and 
rapid elimination (Table 1), consistent with historical healthy-volunteer data. 
While increases in median area under the curve (AUC0-t) estimates were 
roughly dose proportional, Cmax increases tended to be less than proportional 
between 15 mg and 30 mg BID. Over the 6-month period, geometric mean 
trough concentrations of CP-690,550 were 17 ng/mL and 32 ng/mL for the 15 
mg and 30 mg BID doses, respectively, and were highly variable (coeffi cients 
of variation [CV] of ~100%). Concentrations at 4 hours post-dose showed 
higher correlation with AUC0-t (r=0.92) than the trough concentration (r=0.63).
Table 1: Noncompartmental PK estimates of CP-690,550 on Day 3
Parameter Cmax (ng/mL) Tmax (h) AUC0-t (ng.h/mL) Half life (h)
Dose (mg BID) 15 30 15 30 15 30 15 30
N$ 6 9 6 9 6 9 5 9
Mean
(%CV)
176
(33)
258
(51)
NC NC
678
(48)
1141
(36)
3.5
(13)
3.5
(31)
Median
(range)
173
(84-264)
260
(56-434)
1
(0.5-2)
2
(0.5-4) 
656
(239-1211)
1234
(286-1618)
3.6
(2.8-3.9)
3.3
(2.4-5.9)
BID – twice daily; NC – not calculated; $ − Subjects with at least 3 samples within a dosing interval
A one-compartment model with exponential inter-individual error (additive 
residual error on log-transformed concentrations) best described the PK 
profi le of CP-690,550. Population estimates (% relative standard error) of oral 
clearance (CL/F), volume (V/F) and absorption rate were 22.7 L/h (8%), 116 
L (15%) and 1.1 h-1 (29%), respectively. Inter-individual variability (%CV) in 
CL/F was 43%. There were no obvious trends between individual CL/F values 
and body weight, gender, race, or age. Model-based AUC estimates were in good 
agreement with the noncompartmental estimates (bias -5% and imprecision 
15%). CL/F estimates showed time dependency with an approximately 25% 
lower CL/F at Month 6 compared with earlier time points.
Conclusions: After the early post-transplant period, CP-690,550 showed rapid 
absorption, rapid elimination, and dose proportional AUC in renal allograft 
recipients. Correlation with clinical outcomes will be required to understand 
the clinical relevance of the observed inter-patient variability and the time-
dependent changes in exposure.
POSTER BOARD NUMBER P2 – 20
THE EFFECT OF CP-690,550, A JANUS KINASE 1221 
INHIBITOR, ON QTC INTERVAL AND BLOOD PRESSURE: A 
CONCENTRATION-RESPONSE ANALYSIS OF PHASE 1 DATA
S. Krishnaswami, P. Gupta, J. French, J. Cook, D. Gruben, G. Chan
Pfi zer, Inc.
Background: CP-690,550 (CP) inhibits Janus kinase 3 with nanomolar potency, 
and is currently in Phase 2 development for preventing allograft rejection in 
kidney transplant recipients. Recent experience with select investigational 
immunosuppressive agents has shown unexpected effects on vital signs (eg, 
FTY720 on heart rate). To support the ongoing Phase 2 program in kidney 
transplantation, a concentration-response analysis was performed to evaluate 
the effect of CP on QTc interval and blood pressure (BP) collected in single- 
and multiple-dose Phase 1 studies.
Methods: Time-matched ECG and corresponding plasma CP concentration 
data were pooled from 2 studies. Data included in the concentration-QTc 
analysis were derived following single doses of placebo and 0.1 mg to 100 
mg CP in 94 healthy subjects and following multiple doses (up to 14 days) 
of placebo, 5 mg to 50 mg twice daily and 60 mg once daily in 58 psoriatic 
patients. BP and corresponding plasma CP concentrations were pooled from 3 
studies. Data included in the concentration-BP analysis were derived from the 
same 2 studies used in the QTc analysis and an additional study that employed 
multiple doses (up to 14 days) of placebo and 15 mg twice daily in 33 healthy 
subjects. Concentration-QTc and concentration-BP analyses were conducted 
using the mean of triplicate ECG and BP measurements, where available, at 
baseline and at various time points during treatment. Mean Cmax at the highest 
single (100 mg) and multiple (50 mg BID) doses utilized in these analyses 
exceed that of the highest dose evaluated in Phase 2 kidney transplant studies.
Results: The Fridericia correction adequately rate-corrected the QT interval data 
(QTcF). Linear mixed effects models (with additive inter-individual random 
effects on intercept and slope and additive residual error) were used to describe 
the data. The slope (drug-effect) was essentially zero (estimate: -0.0023, 90% CI 
[-0.0077, 0.0031]). At mean steady-state Cmax of the highest therapeutic dose, a 
mean QTcF change of -0.5 msec (90% CI [-1.6, 0.6]) is predicted, a value well 
below the 5 msec threshold of potential clinical signifi cance (ICH E14 Guidance). 
The concentration-BP models yielded slope estimates of 0.0016 (-0.0013, 0.0045) 
for diastolic and 0.0018 (-0.0022, 0.0058) for systolic BP. At mean steady-state 
Cmax of the highest therapeutic dose, the predicted mean changes are 0.3 mm 
(-0.3, 0.9) for diastolic and 0.4 mm (-0.4, 1.2) for systolic BP.
Conclusion: Concentration-response analyses of pooled Phase 1 data suggest 
no unexpected, clinically relevant changes in QTcF interval or BP at therapeutic 
concentrations of CP.
Future Direction: Additional concentration-response analysis on heart rate is 
being performed. Long-term studies are needed to confi rm the BP fi ndings in 
the patient population.
POSTER BOARD NUMBER P2 – 21
A SINGLE DOSE OF TM-1 SUPPRESSES THE 1222 
DEVELOPMENT OF TRANSPLANT ARTERIOSCLEROSIS
J. Ma, .-Y. Tsui, M. Vogel, A. Obed, H. Schlitt
Department of Surgery, University of Regensburg Medical Center
Transplant arteriosclerosis is one of main features of chronic allgraft rejection 
that signifi cantly affects the long-term outcome of solid organ transplantation. 
In the study, we examined the therapeutic potentiality of a newly generated 
recombinant protein containing a cell penetrating peptide and a truncated form 
of heme oxygenase-1 (TM-1) in a rat aorta transplantation model. The cell 
penetrating peptide could pass through the wall of blood vessel. The positive 
signals for cell penetrating peptide-mediated delivery of target protein were 
detected in whole endothelial and smooth muscle cell layers of blood vessels. 
The newly generated TM-1 could signifi cantly enhance the heme oxygenase 
activities in a hypothermic condition at fi ve minutes after delivery. Intraluminal 
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application of TM-1 signifi cantly suppressed the development of transplant 
arteriosclerosis in aorta allografts using BN rats as donors and LEW rats as 
recipients. In contrast, the aorta treated with control protein showed severe 
intimal proliferation and luminal narrowing. The infi ltrating leukocytes 
including CD45, CD4, ED-1 cells were signifi cantly less in TM-1-treated aorta 
allografts as compared with control protein-treated allografts. Sera levels of 
anti-donor antibodies were signifi cantly diminished in rats bearing TM-1-treated 
allografts. In addition, suppressive effects of TM-1 were associated with less 
IL-17A production in allografts in early and late phases after transplantation. In 
conclusions, the newly generated TM-1 protein represents a novel agent for the 
treatment of transplant arteriosclerosis in clinical organ transplantation.
POSTER BOARD NUMBER P2 – 22
EFFECT OF MTOR INHIBITOR ON DYSLIPIDEMIA IN 1223 
HEART TRANSPLANT RECIPIENTS RECEIVING STATINS. IS 
THERE ANY DIFFERENCE BETWEEN SIROLIMUS 
AND EVEROLIMUS?
M.J. Paniagua, M.G. Crespo-Leiro, D. Perez, C. Naya, Z. Grille, S. Albiñana, 
M. Outeda, J.A. Rodriguez, F. Estevez, A. Castro-Beiras
Hospital Juan Canalejo
Mammalian target-of-rapamycin inhibitors (mTORi) are increasingly used in heart 
transplant (HT) recipients. Dyslipidemia is a side effect associated to mTORi but 
the magnitude of this effect, when they are used in combination with statins, is less 
known and it is also not well known if there are differences between the 2 mTORi 
currently available for clinical use: sirolimus (SIR) and everolimus (EVE).
Aim: To asses changes in lipid levels in HT recipients who received treatment 
with everolimus or sirolimus, each of them in combination with statins.
Method: Retrospective analysis of lipid profi le in HT recipients treated with 
statins and mTORi. Each recipient received statin therapy with pravastatin, 
fl uvastatin or atorvastatin. Variables: Type of mTORi: SIR or EVE; Total 
cholesterol (TC), triglycerides (TG) and HDL cholesterol (HDL) were assessed 
before (time 0) and at 6 and 12 months after initiation mTORi therapy. Statistical 
analysis: student t test for paired samples comparing lipid levels at 6 and 12 
months to basal (time 0).
Results: 52 HT recipients (92.3% male, mean age 57.9 ± 7.4 years) treated 
with mTORi, SIR (n= 43) and EVE (n=9) were analyzed. Follow-up time:27 ± 
19 months. TC and TG increased signifi cantly in patients received SIR group 
but not in EVE group. TC at 0, 6 and 12 months were 174 ±20.4, 213±35 and 
212 ± 38 p<0.001 for SIR group vs 195 ±37, 221.2±47 and 215 ± 11.5 p=NS for 
EVE group. TG at 0, 6 and 12 months were 136 ±53, 173±74 (p<0.01) and 164 
± 80.5 (p<0.03) for SIR group vs 159 ±141.7, 164±56.7 and 132.52 (p=NS) 
for EVE group. No differences between 0 and at 6 and 12 months were found 
regarding HDL neither SIR nor EVE groups.
Conclusions: In our series of HT recipients receiving statins, mTORi therapy 
is associated with a signifi cant increase of TC and TG at 6 and 12 months 
if the mTOR used is SIR while this is not observed with EVE. Although the 
smaller sample size of EVE group could limit scientifi c evidence our results, 
it seems reasonable to better study these differences between this two mTORi 
in a ranzomized trial.
IMMUNOSUPPRESSION – CONCURRENT ORAL SESSION 88: 
PHARMACOKINETICS
POSTER BOARD NUMBER P2 – 23
THE EFFECT OF LIVER REGENERATION ON 1224 
CYCLOSPORINE PHARMACOKINETICS
D. Kahn, L. Lodewijk, A. Mall, W. Spearman, E. Shepherd
University of Cape Town/Groote Schuur Hospital
In liver transplantation, the liver can be injured as a result of ischaemia, 
reperfusion, rejection and infection. The transplanted liver responds by 
undergoing liver regeneration. We know that cyclosporine is metabolised via 
the cytochrome P450 system and that cytochrome P450 is down-regulated 
during liver regeneration. In this study we investigated the effect of liver 
regeneration on cyclosporine pharmacokinetics.
Male Long Evans rats weighing 250-300gm were randomly assigned to either 
2/3 partial hepatectomy (PH) or sham operation (SH). Cyclosporine (5mg/
kg) was administered orally at 0, 24 and 96 hours postoperatively. Blood 
samples were taken at 0,2,4,6,12 and 24 hours after each dose of cyclosporine 
and the following pharmacokinetic parameters calculated: Co, Cmax, Tmax, 
AUC and T1/2.
The pharmacokinetic profi le at 96 hours postoperatively showed higher 
AUC in the PH group (5963 vs 4001), higher Cmax in the PH group (360 
vs 263), and higher Co in the PH group (235 vs 173). The pharmacokinetic 
profi le immediately after PH or SH showed higher AUC in the PH group (4754 
vs3350), and a higher Co in the PH group (88 vs72). After PH, the AUC,Cmax 
and C0 were all lower in the pharmacokinetic studies done at 0 hours compared 
to 96 hours (4754 vs 5963, 172 vs 360, and 88 vs 235, respectively). There 
was minimal change in pharmacokinetic parameters after SH at 0 and 96 hours 
postoperatively.
In conclusion, liver regeneration results in impaired metabolism of cyclosporine, 
presumably as a result of its effect on cytochrome P450. This would impact on 
cyclosporine monitoring in patients with compromised liver grafts. 
POSTER BOARD NUMBER P2 – 24
TACROLIMUS PHARMACOKINETICS IS IMPAIRED 1225 
IN LIVER REGENERATION
D. Kahn, L. Lodewijk, A. Mall, W. Spearman, E. Shepherd
University of Cape Town/Groote Schuur Hospital
Ischaemia, reperfusion, rejection, infection and drug toxicity are all potential 
causes of injury to the graft in liver transplantation. This injury results in a 
regenerative response in the liver graft. Tacrolimus is metabolised via the 
Cytochrome P450 system, and liver regeneration is associated with down-
regulation of cytochrome P450. We therefore investigated the effect of liver 
regeneration on the pharmacokinetics (PK) of tacrolimus.
Male Long Evans rats weighing 250 - 300 gm were randomly assigned to either 
66% partial hepatectomy (PH) or sham operation (SH). Tacrolimus (0,2 mg/kg) 
was administered orally at 0, 24 and 96 hours postoperatively. Blood samples were 
taken at 0, 1, 2, 4, 6, 12 and 24 hours and the Tacrolimus PK profi les calculated. 
The following PK parameters were calculated: AUC, Cmax, Co, and t1/2.
PK studies undertaken immediately after PH and SH, showed higher AUC, 
Cmax and Co in the PH group (188 vs129; 20 vs11; and 10 vs 2.9,respectively). 
Similarly the PK studies undertaken at 96 hours after PH and SH, showed 
higher AUC, Cmax and Co in the PH group (169 vs 94; 18 vs 7; and 4.3 vs 
2.3, respectively. In the animals subjected to PH, the AUC, Cmax, and Co were 
higher at 0 hours compared to 96 hours postoperatively (188 vs169; 20 vs 18 
and10 vs 4.3, respectively).
In conclusion, the PK parameters were higher in the PH group compared to 
the SH animals.The impaired metabolism of Tacrolimus in the PH group was 
probably related to the down-regulation of Cytochrome P450 associated with 
liver regeneration. This has important implications in patients transplanted 
with marginal livers.
POSTER BOARD NUMBER P2 – 25
THE EFFECT OF LIVER REGENERATION ON 1226 
RAPAMYCIN PHARMACOKINETICS
D. Kahn, L Lodewijk, A. Mall, E. Muller, W. Spearman
University of Cape Town/Groote Schuur Hospital
In liver transplantation, the donor liver is susceptible to many forms of injury, 
including ischaemia, reperfusion, rejection and infection. The liver responds to 
injury by undergoing liver rgeneration. Several of the new immunosuppressive 
agents are known to modify the regenerative response. In this study we 
investigated the effect of liver regeneration on the pharmacokinetic (PK) 
profi le of rapamycin (RAPA).
Male Long Evans rats weighing 250-300gm were randomly assigned to either 
two-thirds partial hepatectomy (PH) or sham operation (SH). Single bolus 
doses of RAPA were administered orally at 0, 24 and 96 hours postoperatively. 
Blood samples were taken at 0,1,2,4,6,12 and 24 hours after the dose of RAPA 
and used to measure RAPA levels. These were used to calculate the following 
PK parameters: AUC, Co, Cmax, and T1/2.
The PK profi les (AUC, Cmax and Co) at 24 hours after PH and SH were the 
same (63 vs 64; 5.3 vs4.5; and 1.5 vs 1.8, respectively). The PK parameters 
(AUC, Cmax and Co) at 96 hours in the PH and SH groups were also similar 
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(186 vs 149; 7.6 vs 8.2; and 5.7 vs 4.3, respectively). The PK parameters were 
higher at 96 hours after PH compared to 24 hours (186 vs 63; 7.6 vs 5.3, 5.7 
vs 5.7, respectively).
In conclusion, RAPA pharmacokinetics were not modifi ed by the 
regenerative response.
CONCURRENT ORAL SESSION 89: 
IMMUNOSUPPRESSION – RAT
POSTER BOARD NUMBER P2 – 26
HYPERBARIC OXYGEN THERAPY REDUCES 1227 
ISCHAEMIA PRESERVATION AND REPERFUSION INJURY IN 
LIVER TRANSPLANTATION
N.Q. Tran, C. Christophi, V. Muralidharan
University of Melbourne, Department of Surgery, Austin Health, Studley 
Road, Heidelberg, VIC 3084
Background: A major cause of suboptimal donor organ function after liver 
transplantation is ischaemia, preservation and reperfusion injury (IPRI). 
Hyperbaric oxygen therapy (HBO) therapy has multiple mechanisms which 
may improve IPRI. This project examines the effect of HBO on IPRI in a rat 
model of liver transplantation.
Methods: Male inbred Lewis rats were used for syngeneic liver transplantation. 
Donor organs were stored at 4oC for 24 hours for severe IPRI. HBO therapy 
was administered twice daily with matching controls for all groups until 
animals were killed and livers removed at either 12, 24 or 48 hours after 
transplant. Assessment of the effect of HBO on IPRI was performed using 
histopathological, quantitative stereological and immunohistochemical 
methods to quantify hepatocyte necrosis, proliferation and apoptosis. 
Results: HBO therapy signifi cantly reduced the percentage volume of hepatic 
necrosis at 12 hours (2.38 ± 0.41% vs. 18.74 ± 1.79%, P<0.001), 24 hours 
(3.81 ± 0.51% vs. 10.46 ± 2.61%, P<0.001) and 48 hours (3.43 ± 0.86% vs. 
8.48 ± 1.34%, P<0.05). Concurrently, HBO therapy reduced apoptosis at 12 
hours (1.59 ± 0.17% vs. 6.41 ± 0.37%, P<0.001), 24 hours (1.41 ± 0.10% vs. 
4.80 ± 0.22%, P<0.001) and 48 hours (1.04 ± 0.08% vs. 2.38 ± 0.23%, P<0.05). 
Hepatocyte proliferation was found to signifi cantly increase at all time points 
with HBO treatment, (12 hours: 4.45 ± 0.26% vs. 1.00 ± 0.08%, P<0.05; 24 
hours: 7.38 ± 0.18% vs. 2.93 ± 0.19%, P<0.01; 48hrs:18.86 ± 0.74% vs. 8.58 
± 0.46%, P<0.001,).
Conclusion: HBO therapy administered immediately following liver 
transplantation improved IPRI with a signifi cant reduction in hepatocyte 
necrosis and apoptosis. It also independently stimulated the proliferation of 
hepatocytes, accelerating recovery.
POSTER BOARD NUMBER P2 – 27
MODULATION OF ACUTE CELLULAR REJECTION 1228 
BY HYPERBARIC OXYGEN THERAPY IN A RAT MODEL OF 
LIVER TRANSPLANTATION
S. Gan, V. Muralidharan, C. Christophi
Department of Surgery, University of Melbourne Austin Health
Background: Acute cellular rejection is a common cause of post-transplantation 
morbidity. Hyperbaric oxygen (HBO) therapy has been shown to favourably 
alter immune responses and may be useful in the early post transplantation 
period.
Aim: This study investigates the effect of HBO therapy on rejection in a rat 
model of liver transplantation.
Methods: Male inbred Dark Agouti and Lewis rats were transplanted to create 
severe or mild rejection. HBO was administered twice daily for one, three and 
seven days after transplantation, after which rats were killed and liver tissue 
collected for histopathology. The total number of infi ltrating cells, and both the 
number and percentage of T cells (CD3+) were assessed in the periportal and 
perivenous regions using immunohistochemistry. A survival study in the severe 
model was conducted over 14 days with HBO and matching controls.
Results: A signifi cant survival benefi t was found using twice daily HBO 
administration in the severe model, with mean survival time of 289 ± 
17.2 hours vs 234 ± 5.5 hours in controls (p = 0.01). We have previously 
determined that the Banff scoring system is not suffi ciently sensitive for this 
rat model; control and treated animals in both the mild and severe rejection 
models received a score of severe rejection and the maximum Rejection 
Activity Index score of 9. Therefore, we used infi ltrating cell counts as a 
method to quantify the effect of HBO. In the severe model, HBO produced a 
signifi cant reduction in the total number of infi ltrating cells at Day 1 (24 ± 2 
vs 31 ± 3 cells, p = 0.036) and Day 7 (198 ± 11 vs 275 ± 19 cells, p = 0.001) 
in the perivenous region. CD3+ cell numbers were found to be signifi cantly 
reduced at Day 3 in both periportal (49 ± 5 vs 56 ± 4 cells, p = 0.025) and 
perivenous regions (14 ± 1 vs 22 ± 2 cells, p = 0.002), and at Day 7 in the 
perivenous region alone (86 ± 6 vs 124 ± 10 cells, p = 0.002). Percentage 
CD3+ cells at Day 3 in the periportal (31 ± 1 vs 36 ± 1 cells, p = 0.007) 
and perivenous regions (22 ± 1 vs 28 ± 2 cells, p = 0.002) was found to be 
decreased by HBO treatment. In the mild model at Day 7, both T cell number 
and total infi ltrating cell counts in the periportal region (322 ± 20 vs 385 ± 20 
cells, p=0.004; 551 ± 32 vs 619 ± 26 cells, p=0.008), and in the perivenous 
region (54 ± 3 vs 67 ± 3 cells, p=0.001; 96 ± 4 vs 113 ± 5 cells, p=0.007) were 
found to be decreased by HBO therapy.
Conclusion: HBO therapy after liver transplantation reduces infl ammatory cell 
infi ltration in perivenous and periportal regions. In particular T cell infi ltrates 
were found to have been decreased. Acute rejection was attenuated by HBO 
administration, producing an overall survival benefi t. This therapy may 
potentially provide therapeutic benefi ts.
CONCURRENT ORAL SESSION 90: 
IMMUNOSUPPRESSION – VIRUS
POSTER BOARD NUMBER P2 – 28
CONVERSION TO EVEROLIMUS MONOTHERAPY 1229 
DOES NOT AFFECT HCV AND CMV STATUS IN LIVER 
TRANSPLANTATION
P. Simone1, P. Carrai1, S. Petruccelli1, A. Precisi2, L. Baldoni1, J. Ducci1, 
L. Coletti1, G. Tincani1, G. Catalano1, F. Filipponi1
1Liver Transplant Unit, 2Laboratory
Aim: We prospectively investigated the impact of conversion to everolimus 
(EVL) on cytomegalovirus (CMV) and hepatitis C virus (HCV) status in 
maintenance liver transplantation (LT).
Materials and methods: Adult, consenting recipients of LT from a deceased 
donor with a minimum follow-up of 12 months were included. EVL was 
introduced at 0.75 mg b.i.d. with overnight withdrawal of antimetabolites and 
a 50%-per-week reduction of CNI to a complete stop after 4 weeks. Steroids 
were kept at pre-switch levels. EVL target levels were between 3 and 8ng/mL 
(RIA). Viral status was assessed in HCV positive patients by means of HCV-
RNA at baseline (-day 1 before EVL initiation), week 1, 2, 3, 4, month 2, 3, 
4, 5, and 6. CMV status was assessed with CMV-DNA assay in all patients at 
baseline, month 3 and 6. Effi cacy evaluable (EE) patients were those on EVL 
monotherapy at 6 months.
Results: Forty patients (mean age 54.9±11 years; M/F=28/12) were enrolled 
at a mean of 45.5±31.2 months post-l LT. Native disease was HCV-related 
in 15 patients (37.5%) with 13 (86.6%) HCV-RNA positive at baseline 
(mean log 6.2±0.7). Indications for conversion were deteriorating renal 
function in 36 (90%), CNI-related peripheral neuropathy in 3 (7.5%), and 
microangiopathy in 1 (2.5%). Six months after conversion, patient and graft 
survival were 100%. The treatment success rate was 75% with 30 patients 
on EVL monotherapy (±steroids as necessary). Incidence of biopsy-proven 
acute rejection (BPAR) was 15% (6/40). Ten patients (25%) were treatment 
failures: 1 patient (2.5%) required conversion to prior treatment for BPAR; 
3 patients (10%) needed CNI reintroduction for BPAR; 3 (7.5%) patients 
required EVL withdrawal for worsening HCV-related graft hepatitis; 
1 patient (2.5%) required EVL withdrawal for acute cholangitis; and 2 
patients (5%) withdrew consent to EVL due to persistent pruritus and oral 
ulcers, respectively. In the 30 EE patients successfully converted to EVL 
monotherapy at 6 months, mean EVL dosage was 1.7 ± 0.9 mg/day and mean 
EVL trough level 4.6±1.9 ng/mL. In such patients no CMV reactivation was 
observed as per clinical and laboratory parameters. In HCV-RNA positive 
patients successfully converted to EVL monotherapy mean change in log 
viral load at 6 months was 0.2, i.e. from a mean of 6.2±0.7 at baseline to a 
mean of 6.4±0.5 at month 6 (Table).
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Table: HCV-RNA by follow-up visit.
Evaluable 
patients Mean log
Mean change 
from baseline
Baseline 13 6.2 ± 0.7 -
Week 1 13 6.3 ± 0.6 0.1
Week 2 12 6.4 ±0.6 0.2
Week 3 12 6.3 ± 0.6 0.1
Week 4 11 6.1 ± 0.6 -0.1
Month 2 9 6.3 ±0.6 0.1
Month 3 8 6 ± 0 -0.2
Month 4 8 6.2 ± 0.4 0
Month 5 8 6.3 ± 0.4 0.1
Month 6 8 6.4 ± 0.5 0.2
Conclusions: Based on our data, conversion to EVL monotherapy is not 
associated with change in CMV and HCV viral load in LT patients.
POSTER BOARD NUMBER P2 – 29
EPSTEIN-BARR VIRUS SPECIFIC CELLULAR 1230 
IMMUNITY IN PAEDIATRIC LIVER TRANSPLANT 
RECIPIENTS
M. Lindemann1, E. Liapakis1, M. Wallot2, H. Grosse-Wilde1
1Institut für Immunologie, Universitätsklinikum Essen, 2Kinderklinik, 
Bethanien Krankenhaus Moers, Germany
Background: In paediatric liver transplant recipients the infection with Epstein 
Barr virus (EBV) is associated with a severe complication, the occurrence of 
post transplant lymphoproliferative disease (PTLD).
Aim: To analyze the therapy effects on cellular in-vitro reactions towards EBV.
Methods: Children were randomized to receive two different doses of 
methylprednisolone (15 vs. 60 mg/m2, n=16 vs. n=18) starting from the time of 
transplantation. In addition, they were treated with the same dose of cyclosporine 
A and Basiliximab. To detect EBV specifi c cellular reactions interferon-γ 
ELISpots were performed prior to and fi ve times post transplantation. Here, 
cryopreserved peripheral blood mononuclear cells (PBMC) of the recipients 
were stimulated by autologous EBV transformed B cell lines (B-LCL, n=65 vs. 
n=64). Pre-incubation of 4 x 105 PBMC was performed for two days in round 
bottom microtiter plates; then the cells were incubated for two further days in 
ELISpot plates.
Results: In the group receiving 15 mg/m2 methylprednisolone EBV specifi c 
interferon-γ production was 8-fold higher at day 28 post-transplantation 
(p=0.008, two-way ANOVA, Figure). Thus, the dose of methylprednisolone 
had a signifi cant infl uence on the strength of cellular immunity towards EBV.
Figure: Time course of EBV immunity in two treatment groups of paediatric 
liver transplant recipients
Conclusion: This fi nding indicates a mechanism how a reduced dose of 
corticosteroids could lead to the prophylaxis of PTLD.
CONCURRENT ORAL SESSION 91: 
IMMUNOSUPPRESSION – MISCELLANEOUS
POSTER BOARD NUMBER P2 – 30
EFFICACY OF MINIMAL DOSAGE OF CALCINEURIN 1231 
INHIBITOR FOR THE RECIPIENTS WITH PREOPERATIVE 
RENAL DYSFUNCTION IN LIVING DONOR LIVER 
TRANSPLANTATION
S. Marubashi, D. Keizo, C.W. Kim, T. Asaoka, N. Hama, S. Kobayashi, 
Y. Takeda, H. Nagano, K. Umeshita, M. Monden
Department of Surgery, Osaka University Graduate School of Medicine
Calcineurin inhibitor (CNI) is the main immunosuppressive agent (IS) 
and necessary for liver transplant. However, its renal toxicity is one of the 
greatest concerns and should be carefully monitored especially in patients 
with preoperative renal dysfunction. Although renal-spare IS protocol in early 
postoperative period is quite important, the standard protocol has not been 
established yet.
Objectives: To evaluate the effi cacy of minimal dosage of CNI as an induction 
IS for the recipients with preoperative renal dysfunction in living donor liver 
transplant (LDLT).
Patients and methods: Among 67 patients with end-stage liver disease who 
underwent adult-to-adult LDLT between 1999 and 2006 in our hospital, 18 
patients (26.9%), who had preoperative creatinine clearance (CCr) less than 
50 ml/min, entered this study. Low dose CNI (Cyclosporin A (CsA), C0: 
100-150ng/ml or tacrolimus (FK), 5ng/ml) combined with mycophenolate 
mofetil, corticosteroids, and basiliximab was used for the fi rst 3 months in 
6 recipients (L-bas group). As control groups, normal dosage of CNI (CsA 
250-350 ng/ml, FK 10-15 ng/ml) was used in 11 patients (N group), and low 
dose CNI as L-bas group without basiliximab was used in 3 patients (L group). 
Postoperative renal function, incidence of acute cellular rejection (ACR), 
patient survival, and other clinical data were compared among these groups.
Results: Preoperative demography was similar among three groups. 
Preoperative CCr was similar among three groups (37.1 }10.0, 44.9 }2.5, 34.4 
}10.6 ml/min in L-bas, L, N group, respectively). Incidence of ACR was similar 
among three groups (40%, 33%, 35%, in L-bas, L, N group, respectively). No 
recipient developed renal failure in L-bas group, while one (9%) did in N group. 
patient survival at 1 year in L-bas group was 100%, while patient survival at 1 
year was 58.3% in N group, and 66.7% in L group. [fi gure1]
Conclusions: Our renal spare protocol using minimal dosage of CNI as an 
induction IS was safe and might be effective for the recipients with preoperative 
renal dysfunction in LDLT.
POSTER BOARD NUMBER P2 – 31
SIROLIMUS FOR RESCUE OF STEROID AND ANTI-1232 
THYMOCYTE GLOBULIN RESISTANT RECURRENT ACUTE 
REJECTION AFTER LIVER TRANSPLANTATION. REPORT OF 
ONE CASE
A. Demýrag, M. Kalaycý, B. Ekci, O. Gökce
Yeditepe Univ Hospital
Acute liver allograft rejection episodes refractory to antilymphocyte 
preparations almost inevitably progress to transplantation loss. Sirolimus 
(SRL) rescue therapy for refractory rejection in renal transplantation has been 
reported in the literature but information regarding rescue therapy for refractory 
rejection in liver transplant scarcely. To reverse ongoing rejection processes, 
we administered SRL after failure of conventional immunosuppressive 
regimens including full courses of antilymphocyte sera. Compared with the 
calcineurin inhibitors, SRL has different mechanisms of action and side effects 
profi le. Thus, this drug offers signifi cant potential advantages over other 
immunosuppressive agents. SRL inhibits the signal of interleukin 2 at a post-
receptor level, inhibiting lymphocyte proliferation and fi broblast proliferation. 
It also has antineoplastic and antifungal effects.
We report a 26 years old man who underwent OLT due to hepatits C related 
liver failure, experiencing a biopsy-proven recurrent acute rejection (AR) 
following 2 weeks after transplant. The patient initially received two 20-mg 
doses of basiliximab (days 0 and 4 after OLT) followed by tacrolimus (0.15 
mg/kg/day; 10-15 ng/mL target trough levels), steroids (methylprednisolone 
TU
ES
D
AY
 
Tuesday 12 August 2008 Poster Abstracts
4 1 8 Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
1 g intraoperatively followed by tapering doses) and mycophenolate mofetil 
(MMF) 1 g every 12 h. Steroid resistant acute rejection episodes did not 
respond anti-thymocyte globulin treatment. The patient was rescued with SRL, 
not experiencing AR again. MMF and steroids were continued and tacrolimus 
treatment was stopped, without experiencing severe complications. SRL is a 
new and safe immunosuppressive agent for rescue in patients with OLT and 
recurrent AR.
POSTER BOARD NUMBER P2 – 32
COMBINED MYCOPHENOLATE MOFETIL AND 1233 
MINIMAL DOSE CALCINEURIN INHIBITOR THERAPY IN 
STABLE LIVER TRANSPLANT PATIENTS IS NEPHRO- AND 
HEPATOPROTECTIVE
V.R. Cicinnati1,2, Z. Yu2,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos2, A. 
Radtke2, G. Gerken1, S. Beckebaum1,2
1Department of Gastroenterology and Hepatology, University Hospital Essen, 
Germany, 2Department of General, Visceral and Transplantation Surgery, 
University Hospital Essen, Germany, 3Department of Surgery, Beijing 
Tongren Hospital, Capital University of Medical Sciences, Beijing, China, 
4Institute of Immunology, University Hospital Essen, Germany
Background: Calcineurin inhibitor (CNI)-related nephrotoxicity signifi cantly 
contributes to chronic renal failure after liver transplantation (LT).
Methods: In this prospective study, LT patients with renal dysfunction were 
randomized to either receive mycophenolate mofetil (MMF) followed by 
stepwise reduction of CNI with defi ned minimal CNI-trough levels (MMF 
group) or to continue their maintenance CNI dose (control group). Immune 
monitoring was performed in a subgroup of the patients.
Results: In the MMF group (n=50), renal function assessed by serum creatinine 
improved >10% in 62% of patients, was stable in 36% and deteriorated >10% 
in 2% after 12 months compared with baseline values. Mean serum creatinine 
levels (+/- SD) signifi cantly decreased from 1.90+/-0.44 mg/dL to 1.61+/-0.39 
mg/dL and the corresponding calculated glomerular fi ltration rate signifi cantly 
increased from 48.7+/-14.1 mL/min to 57.6+/-16.9 mL/min over a 12-month 
follow-up period. Blood presssure and levels of liver enzymes signifi cantly 
decreased. In the control group (n=25), there were no signifi cant changes with 
respect to the investigated parameters. The MMF group had signifi cantly lower 
numbers of circulating cytotoxic T cells compared with the controls; whereas 
regulatory T cells signifi cantly increased.
Conclusions: Combined MMF and minimal dose CNI therapy after LT is 
nephro- and hepatoprotective, and may also promote allograft tolerance.
POSTER BOARD NUMBER P2 – 33
MANAGEMENT OF LIVING DONOR LIVER 1234 
TRANSPLANT PATIENTS USING TWICE-DAIRY 4-HOUR 
INTRAVENOUS CYCLOSPORINE THERAPY
K. Sato, Y. Kobayashi, S. Sekiguchi, N. Kawagishi, Y. Akamatsu, 
K. Fujimori, S. Satomi
Advanced Surgical Science And Technology Division, Department of Surgery, 
Graduate School of Medicine, University of Tohoku
Aims: Oral administration of cyclosporine (CsA) is the currently favored 
route of administration in most liver transplant (LT) centers. However, in 
some LT patients with poor oral absorption during the early period after LT, 
or clinically illness who were unable to take medicine orally such as severe 
immunosuppression-associated leucoencephalopathy, intravenous CsA (IV 
CsA) is the only alternative option to achieve and maintain therapeutic blood 
levels. In this study, we evaluated our experiences with 4-hour intravenous CsA 
administration in living donor LT (LDLT) patients.
Methods: From October 1998 to January 2008, 86 LDLTs were performed in 
85 patients (46 adults and 39 children) at our institution. Of these, 73 patients 
received Tacrolimus (Tac) via a nasogastric tube immediately after LDLT, and 
12 patients intravenous CsA twice daily at a dose of 3 mg/kg/day as a 4-h 
continuous infusion, for the following indications: insulin-treated diabetes 
mellitus (n=7), hepatitis C virus infection (n=4), QT prolongation (n=1). 13 
(17.8%) of 73 Tac-based patients were switched to CsA because of Tac-related 
side effects. Of these, 5 patients were switched to intravenous CsA because they 
were unable to take the drug orally due to severe Tac-related complications. 
The remaining 6 patients switched to oral CsA administration because they 
were well enough clinically to take the drug orally. Among them, we evaluated 
a total of 14 patients (11 adults and 3 children), including 12 patients with 
induction therapy and 2 with conversion therapy within 2 weeks after LDLT, 
who were given a 4-h IV CsA at an initial dose of 3 mg/kg/day.
Results: The type of graft using in LDLT was right (n=10) and left liver (n=4). 
Of these, 5 patients were reconstructed bile duct using an external biliary stent-
tube. The median actual graft volume/recipient standard liver volume (GV/
SLV) was 47.5% (31.3 -71.8%), which corresponded to 0.94 (0.57-1.41) of 
the graft weight/body weight (GW/BW) ratio. Of 14 patients, 2 patients died 
within 1 year of LDLT, due to multiple organ failure. The median duration 
of IV CsA administration was 19 days. Stable and adequate blood CsA 
concentrations were achieved by 4-h IV CsA administration in 14 patients after 
LDLT, compared to blood levels after the conversion from IV CsA to oral CsA 
(FIGURE). Of several factors that affects blood CsA concentration, only GW/
BW ratio (r = .743, P < .0001) showed signifi cant correlations with initial blood 
CsA concentration. No adverse effects were observed after IV CsA. However, 
1 of 14 (7.1%) patients developed acute cellular rejection (ACR) during IV 
CsA therapy, whereas 4 patients developed ACR after conversion from IV CsA 
to oral CsA.
Conclusions: Stable and adequate blood CsA concentrations were achieved by 
4-h IV CsA administration at the early stage after LDLT. In our cases of LDLT, 
the initial blood CsA level could be predicted by the transplanted liver graft 
and recipient body weight. Therefore, our fi ndings suggest that the immediate 
administration of a 4-h IV CsA at an initial dose of 3 mg/kg/day would be 
practical and effective for routine clinical use.
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STEROID RESISTANCE ACUTE REJECTIONS AFTER 1235 
LIVER TRANSPLANTATION
C. Aydogan, S. Sevmis, H. Karakayali, S. Pehlivan, H. Akkoc, 
M. Haberal
Baskent University Faculty of Medicine, Department of General Surgery
Liver transplantation is the defi nitive treatment for the end stage liver disease. 
Although effective immunosupressants are available, steroid resistance acute 
rejection (SRAR) can be encountered.
Between September 2001 and January 2008, 212 adult and pediatric liver 
transplantations were perfomed from both cadeveric and living related donors 
at our center. All patients received tacrolimus based immunosuppressive 
therapy. Steroids were tapered in 3 months. Liver biopsy was performed for 
confi rmation of acute rejection after vascular or biliary complications were 
excluded. High dose methylprednisolone was administered for acute rejections. 
Acute rejection was defi ned as SRAR if there was no response to steroids. 
After confi rming SRAR by second biopsy; the patients received Antithymocyte 
globulin (ATG) for10- 14 days with ganciclovir prophylaxis. Acute rejection 
was detected in 70 patients (32.8%). SRAR were detected in 9 of 70 patients 
(12.8%).Seven patients were male and 2 were female. While 6 patients were 
pediatric, 3 were adult. The mean age of the patients were 14.6 &#61617; 
10.7 years (range 5-32 years).The mean follow up period of SRAR patients 
were 19.4 &#61617;19.1 months (range 5-53 years).The mean time from 
transplantation to SRAR was 77.3 &#61617; 66.9 days (range 20-181 days). 
SRAR therapy was successful in 7 patients (77.7%) and 2 patients did not 
respond therefore advanced to chronic rejection. They required retransplantation 
at 7th and 8th month after fi rst transplantation but they died due to sepsis and 
sudden cardiac arrest at 12nd and 32nd day after retransplantation. Mean total 
bilirubin, Aspartate aminotransferase and Alanine aminotransferase levels 
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decreased from 12.6&#61617;9.5 mg/dl, 171.6&#61617;132.1 IU/L, and 
266.7&#61617;235.2IU/L to 2.4 &#61617; 2.3 mg/dl, 45.7&#61617;30.5 
IU/L, and 56.3 &#61617; 28.8 IU/L respectively. Minor side effects were 
observed in 6 patients. We did not encounter serious infections and pulmonary 
edema. In conclusion; according to our experience ATG can be considered as a 
good therapeutic option in SRAR with acceptable side effects.
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LOW-DOSE MYCOPHENOLATE MOFETIL USE 1236 
REDUCES RISK OF LATE ACUTE REJECTION IN ADULT 
LIVING DONOR LIVER TRANSPLANTATION
C-L. Chen, A. Concejero, C.C. Wang, S.H. Wang, Y.W. Liu, C.H. Yang, 
C.C. Yong
Liver Transplant Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center
Background and objective: Mycophenolate mofetil (MMF) used in a triple-
drug regimen decrease both early and late acute rejection rates. The impact 
of low-dose MMF on acute rejection episodes has not been well described 
in living donor liver transplantation (LDLT). Our objective is to present our 
experience in low-dose MMF in adult LDLT.
Patients and methods: To investigate the risk of early acute (rejection <6 
months) and late acute (rejection >6 months) rejections, we analyzed the 
records of adult pimary LDLT recipients (n=153), between January 1999-June 
2007, with hepatitis B virus (HBV) (n=92), hepatitis C virus (HCV) (n=26), 
both hepatitis B and C viruses (HBCV) (n=8) or a non-viral (n=27) primary 
cause of liver disease who received continuous MMF+tacrolimus+steroid or 
MMF+cyclosporine+steroid for at least 6 months immediately post transplant 
using our low-dose MMF regimen (<3 gm/day).
Results: The mean starting dose of MMF was 500 mg, twice a day. The 
tacrolimus dose was 0.01-0.18 mg/kg; and the cyclosporine (C2) trough 
levels were maintained at 800-1200 for the fi rst 6 months and 640-960 for 
up to 1 year. Steroid, started as methylprednisolone 20 mg/kg intra-operative, 
was tapered and discontinued within 6 months. Basiliximab induction was 
given in 123 recipients. Ten recipients discontinued MMF due to side-effects. 
The rates of early acute rejection episode in HBV, HCV, HBCV, and non-
viral groups were 18.5%, 30.8%, 25.0%, and 33.3%, respectively; whereas, 
the rates of late acute rejection episode were 3.3%, 3.8%, 12.5%, and 11.1% 
respectively. Kaplan-Meier analysis showed freedom from acute rejection 
rates of 98.6%, 95.6%, 84.4%, 75.3%, and 64.5% at 6-months, 1-, 2-, 3-, and 
5-years, respectively.
Conclusion: Triple-drug therapy for around 6 months, using low-dose MMF, 
may offer a better treatment strategy to avoid the consequences of acute 
rejections in adult LDLT.
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MTOR INHIBITORS IN LIVER TRANSPLANTATION 1237 
– THE BUDAPEST PRACTICE
I. Fehervari, Z. Gerlei, L. Kobori, D. Gorog, B. Nemes, Z. Mathe
USN Transplantation And Surgical Dept
Aim: To investigate the results of conversion from CNI based immunosuppression 
to mTOR based immunosuppression after liver transplantation. There were 26 
pts between 2003 -2007 converted. The causes of conversion were: progressive 
renal insuffi ciency in 16 cases, de novo tumor in 4 cases and planned conversion 
in 6 pts, transplanted with known or incidental liver tumors.
Results: Median conversion time was 20 month after transplantation (2-97 
month) in whole group. In renal insuffi ciency group the median was 14 
month. Comparing the serum creatinine levels at the time of conversion 
(mean 163μ;mol/l ±;88 μ;mol/l) and 2 months after conversion (mean 123 
μ;mol/l ±;63 μ;mol/l) we found signifi cant (p=0.01)improving but no change 
in glucose intolerance or diabetes. Side effects were: mucosal ulcerations in 
3 cases-requiring hospitalizations in one case. Also peripheral edema was 
found in 5 cases. In 6 patients we found severe anemia but relation to mTOR 
inhibitors is not clear because on consecutive IFN+ RBV treatment of HCV.
Conclusions: On bases of our investigations the mTOR inhibitors seems to 
be safeand probably have place in liver transplant immunosuppression in a 
stepwise treatment
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THE IMPACT OF EVEROLIMUS MONOTHERAPY ON 1238 
RENAL FUNCTION IN LIVER TRANSPLANTATION
P. De Simone1, A. Precisi2, S. Petruccelli1, L. Baldoni1, P. Carrai1, J. Ducci1, E. 
Balzano1, G. Catalano1, F. Filipponi1
1Liver Transplant Unit, 2Laboratory
We investigated retrospectively the impact of conversion from calcineurin 
inhibitors (CNI) to everolimus (EVL) monotherapy on renal function (RF) 
in liver transplant (LT) recipients. Between January 2006 and July 2007, 70 
consenting recipients (51 M, 19 F; mean age 55.9±11 years) from a deceased 
donor were enrolled into a program of conversion to EVL monotherapy at a mean 
interval of 45±35.9 months from transplantation (range 7÷192). Indications for 
conversion were deteriorating RF in 63 (90%). Effi cacy failure was defi ned 
as persistence of CNI, EVL discontinuation, death, graft loss, loss to follow-
up, and need for dialysis at 6 months. Six months after switching, 53 effi cacy 
evaluable patients (75.7%) were on EVL monotherapy and their mean change 
of creatinine clearance (CrCl) from baseline (-day 1 before EVL introduction) 
to endpoint (6 months) was 6.3±11.1 mL/min (range: 8.6÷50.4) (Table 1). 
Breakdown analysis revealed that the mean change of CrCl was 7±11.2 mL/
min (range -4.8÷50.4) for the 35 patients with baseline CrCl between 21 and 
60 mL/min vs. 4.9±10.9 mL/min (range-8.6÷36.6) for patients with baseline 
CrCl ≥61 mL/min (p=ns) (Table 1). On univariate and multivariate analyses the 
clinical variables correlated with the greatest probability of improvement were 
age (p=0.006) and baseline CrCl (p=0.008) (Table 2).
Table 1: Mean baseline and endpoint CrCl in effi cacy evaluable patients 
converted to EVL monotherapy.
CrCl group # patients (%) Mean baseline Mean endpoint Mean change
≥20 mL/min 53 (100) 59.4±21.9 mL/min 66.1±25.3 mL/min 6.3±11.1 mL/min
20÷40 mL/min 7 (13.2) 34.9±4.5 mL/min 39.8±4.3 mL/min 4.9±6.8 mL/min
41-60 mL/min 28 (52.8) 55.5±5.5 mL/min 57.5±9.9 mL/min 7.5±12.1 mL/min*
61-80 mL/min 12 (22.6) 68.4±6.7 mL/min 69.6±7.3 mL/min 1.5±4.5 mL/min*, **
≥81 mL/min 6 (11.3) 105.34±31.8 mL/min 114.5±45.5 mL/min 11.6±16.8 mL/min**
≤60 mL/min 35 (66) 49.1±7.7 mL/min 57.2±11.5 mL/min 7±11.2 mL/min
≥61 mL/min 18 (34) 81.6±26 mL/min 85.6±34.2 mL/min 4.9±10.9 mL/min
*p = 0.049 by Mann-Whitney test; **p =0.031 by Mann-Whitney test.
Table 2: correlation analysis between change in CrCl at 6 months and selected 
patients’ clinical variables.
Univariate Multivariate
Baseline CrCl 0.0005 0.006
Age 0.0028 0.008
Interval from transplantation ns ns
Type of baseline CNI (CsA vs. TAC) ns ns
Use of antimetabolites ns ns
Sex ns ns
Native disease (HCV vs. non-HCV) ns ns
Based on our data conversion from CNI to EVL monotherapy is successful in 
75.7% of cases. The improvement in RF is correlated in a continuous rather 
than categorical way with age and baseline CrCl. These data support pre-
emptive minimization of CNI in the post-transplant course in order to delay the 
decline in renal function.
POSTER BOARD NUMBER P2 – 38
SAFETY AND EFFICACY OF CONVERSION 1239 
TO EVEROLIMUS MONOTHERAPY
P. De Simone1, P. Carrai1, A. Precisi2, S. Petruccelli1, E. Balzano1, 
L. Coletti1, L. Baldoni1, J. Ducci1, G. Catalano1, F. Filipponi1
1Liver Transplant Unit, 2Laboratory
Aims: We investigated retrospectively the safety and effi cacy of conversion 
from calcineurin inhibitors (CNI) to everolimus (EVL) monotherapy in liver 
transplant (LT) recipients.
Materials and methods: Retrospective analysis of prospectively collected 
clinical data of patients undergoing conversion to EVL monotherapy at any 
time point during follow-up. Effi cacy failure was defi ned as persistence of CNI, 
EVL discontinuation, death, graft loss, loss to follow-up and need for dialysis 
at 6 months.
Results: Between January 2006 and July 2007, 70 recipients (51 M, 19 F; 
mean age 55.9±11 years) from a deceased donor were enrolled into a program 
of conversion to EVL monotherapy at a mean interval of 45±35.9 months from 
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transplantation (range 7÷192). Indications for conversion were deteriorating 
RF in 63 (90%). Native disease was HCV-related in 28 (40%); HBV-related 
in 18 (25.7%); alcohol-related in 10 (14.3%); primary biliary cirrhosis in 4 
(5.7%); acute liver failure in 3 (4.2%); cholangiocarcinoma in 2 (2.8%); 
polycystic liver in 2 (2.8%); cryptogenic cirrhosis, idiopathic liver fi brosis and 
sclerosing cholangitis in 1 (1.4%) each. Six months after switching, 53 patients 
(75.7%) were treatment success (Table 1). Complications included 5 cases of 
worsening HCV-related graft hepatitis (Table 1 and 2) in patients on baseline 
CsA-based immunosuppression. Biopsy was performed in all such cases and 
confi rmed recurrent HCV graft hepatitis (mean grade 11.6; mean stage 2.4). 
Retrospective analysis revealed that all such patients had overexposure to EVL 
as per a mean trough level of 15.5 ng/mL 7 days after drug initiation; were 
genotype 1 and had failed to respond to previous anti-viral treatment (Table 2). 
Upon withdrawal of EVL all patients but one returned to baseline liver function 
test values.
Table 1: 6-month results.
Variable
Effi cacy (%) 53 (75.7)
Effi cacy failure (%) 17 (24.3)
BPAR 4 (5.7)
Death 1 (1.4)
Worsening HCV-related graft hepatitis 5 (7.1)
Oral ulcers (consent withdrawal) 3 (2.8)
Acute cholangitis 1 (1.4)
Intractable pruritus (consent withdrawal) 1 (1.4)
Need for dialysis 1 (1.4)
Proteinuria >1 gr/24 hr 1 (1.4)
BPAR (%) 6 (8.6)
CNI reIntroduction 3 (4.3)
EVL dose adjustment 2 (2.8)
Steroid boluses and resumption of pre-switch regimen 1 (1.4)
Mean RAI score (±SD) 7 (0.6)
Mean days after EVL introduction (±SD) 70 (14.1)
Complications (%)
Hyperlipemia 19 (27.1)
Oral ulcers/stomatitis 14 (22.5)
Worsening HCV-related graft hepatitis 5 (7.1)
Pruritus 4 (5.7)
Acne 3 (3.9)
Low tract urinary infection 2 (2.8)
Erythema 2 (2.8)
Shingles 2 (2.8)
Pharyngitis 1 (2.5)
Urticaria 1 (2.5)
Persistent headache 1 (2.5)
Eczema 1 (2.5)
Psoriasis 1 (2.5)
Oral abscess 1 (2.5)
Cholangitis 1 (2.5)
Table 7: main clinical characteristics of the patients with worsening HCV-
related graft hepatitis after EVL introduction.
1 2 3 4 5
Sex M M M M M
Age 65 68 64 59 42
Interval from LT 
(months) 25 16 15 36 49
Baseline 
immunosuppression
CsA-ME, 
MMF CsA-ME CsA-ME CsA-ME CsA-ME
Baseline CsA-ME daily 
dosage (mg/kg) 110 mg (1.5) 100 (1.7) 150 (2) 150 (2) 125 (1.6)
Baseline log HCV-RNA 7 7 6 7 7
Viral genotype 1 1 1 1 1
EVER starting dosage 
(mg/day) 1.5 1.5 1.5 3 3
EVER trough level at 7 
days (ng/mL) (RIA) 12 15.1 15.5 18 17
7-day log viral load 7 7 6 7 7
Grade (Ishak) 12/18 12/18 11/18 12/18 11/18
Stage (Ishak) 3/6 1/6 3/6 2/6 3/6
Previous attempt at 
antiviral treatment 
post-LT
Yes/failed Yes/failed Yes/failed Yes/failed Yes/failed
Endpoint liver function 
tests (AST/ALT after 
EVL withdrawal)
Within range Within range >2 upper limit Normal Normal
Conclusions: Based on our data, conversion to EVL monotherapy is safe and 
effective. However, inadvertent EVL overexposure may be associated with 
hepatitis fl ares in non-responder, HCV-RNA-positive patients on baseline 
CsA immunosuppression. Strategies to reduce the risk of EVL overexposure 
need to be implemented to expand to this category of patients the benefi t of 
antiproliferative immunosuppression.
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INDICATIONS AND MANAGEMENT OF M-TOR AFTER 1240 
LIVER TRANSPLANTATION
R. Charco1, G. Sapichosin1, C. Dopazao1, A. Escartin1, J.L. Lazaro1, 
L. Castells2, M. Caralt1, I. Bilbao1
1Department of HBP Surgery and Transplants. Hospital Vall d’Hebron, 
2Department of Hepatology. Hospital Vall d’Hebron
Aim: To asses our experience with the use and management of m-TOR after 
liver transplantation (LT).
Material: From 1988 to 2007, 783 LT has been performed in 725 patients. Fifty 
one patients (7%) received immunosuppression with m-TOR: Rapamicine 36 
and everolimus 15. Mean age was 54.8 years old (r:24-70). Indication of use, 
time between LT and introduction of m-TOR, efi cacy, side effects and survival 
were analysed .
Results: Indications were: refractory rejection in the context of renal 
insuffi ciency 20 (39%), renal insuffi ciency 5 (10%), other side effects of 
CNI 6 (12%), extended HCC in the explanted live 7 (14%), HCC recurrence 
in the follow-up 7 (14%) and the novo tumour 3 (6%). Mean time between 
LT and m-TOR were 18 ± 29 months with a median of 3 months (r:10 days-
122months). Mean follow-up after conversion was 12 months (r: 1-65), with 
a median of 7. Half of the patients converted for refractory rejection, resolved 
the event. Four required re-LT, 3 progresed to chronic rejection and 3 died 
due to non resolved rejection, overimmunosuppression and sepsis. Of 19 
patients with renal insuffi ciency at time of conversion, 10 (52%) resolved. 
Three out of 7 patients with extended HCC, died and 4 out of 7 patients with 
recurrent HCC, died. The 3 the novo tumour were operated and are perfectly 
healthy. Half of the patients presented side effects related to m-tor: diarrhea 
in 4 (8%), hematologic complications in 5 (10%), dyslipemia in 22 (43%), 
and infection in 8 (16%). Ten patients (20%) developed acute rejection after 
conversion. Nineteen patients (33%) discontinued drug: 9 due to inefi cacy, 4 
due to resolution of the cause, 3 due to intercurrent surgery and 3 due to advers 
event. Actuarial survival postconversion is 55% and 15% at 1y and 3y.
Conclusion: m-TOR are indicated in critical and irreversible situations where 
other immunosuppressants have failed: in the early period for refractory 
rejection or as prophylaxis for recurrence of extended tumors; in the late period 
for patients with serious side effects of CNI.
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IMMUNOSUPPRESSION AND RENAL DYSFUNCTION IN 1241 
LIVER TRANSPLANTATION
F. Nolasco, A.C. Ferreira, S. Sampaio, A. Baptista, E. Monteiro, 
A. Martins, E. Barroso
Hospital Curry Cabral
Renal dysfunction is a common complication of orthotopic liver transplant 
(OLT). Long term use of cyclosporine A (CyA) or tacrolimus (FK) can lead 
to nephrotoxicity. The introduction of Mycophenolate Mofetil (MMF) and 
sirolimus seems to improve renal function on these patients.
The aim of this retrospective study was to determine the incidence of renal 
complications (acute and chronic) in hepatic transplants and its association 
with immunosuppression.
Clinical data included age, gender, aetiology for hepatic failure, presence of 
diabetes mellitus, hypertension, hepatitis B and C infection, renal dysfunction 
pre transplant (RD pre), defi ned by Glomerular Filtration Rate (GFR) ¡Ü60 
ml/min or serum creatinine (Scr) ¡Ý1.5mg/dl, and immunosuppression. 
Laboratorial data included serum creatinine (Scr) at day 1, 7, 21, month 6 and 
every year. The GFR was determined by Cockcroft-Gault equation. We studied, 
retrospectively, from September 1992 to March 2007, 708 OLT recipients, 82 
being re-transplanted. Mean age 44 ¡À12.6 years, 64% males, 17% diabetic, 
18.8% with hypertension, 19.9% with C hepatitis and 3.8% B hepatitis, 30.7% 
with amyloidotic polyneurophaty. Renal dysfunction pre transplant was known 
in 21.6%. Mean follow-up was 3.6 years (0- 15). Mean transplant survival was 
75% at 12 months and 69% at 3 years. 152 patients died. Uni and multivariate 
analysis (Spearman and binary regression) were performed and a p<0.05 was 
considered signifi cant.
Acute Renal Failure (ARF) occurred in 33.8% of the patients and the 
development of Chronic Kidney Disease (CKD) according to KDIGO defi nition 
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was observed in 50% of the population: 50.2% had CKD stage 3, 29% with a 
GFR ¡Ü45ml/min, 9% had CKD stage 4 and 5.6% CKD stage 5d, by the time 
of the study.
Concerning immunosuppression, almost all were treated initially with a 
calcineurin inhibitor (CI), associated to an anti metabolite. Sirolimus was 
employed in 10.6% particularly those with renal dysfunction (r=0.16, p<0.001). 
At the time of this study, 46.4% of the population was on CyA, associated with 
azatioprine or MMF, 44.7% were on FK mostly associated with MMF and 
8.9% on sirolimus.
On univariate analysis, permanent renal dysfunction, GFR ¡Ü45 ml/min, 
was positively correlated with the use of Azatioprine (r=0.130, p=0.001), 
CyA (r=0.123, p=0.003) and sirolimus (r=0.163, p<0.001) and was inversely 
correlated with the use of tacrolimus (r=-0.125, p=0.002) and MMF (r=-0.163, 
p<0.001). On multivariate analysis, renal dysfunction was positively correlated 
with CyA (p<0.01) and sirolimus (p=0.008) and inversely correlated with the 
use of MMF (p<0.01).
In univariate analysis, mortality was correlated with the use of azatioprine 
(r=0.093, p=0.025). The use of FK had a favourable impact (r=-0.095, 
p=0.018). On multivariate analysis, mortality was correlated with the use of 
azatioprine (p=0.021).
In conclusion, in this population, some immunosuppressors are associated with 
worst outcome. The use of FK and MMF seems to have better outcome in what 
concern to renal function in contrast to CyA and Azathioprine. Sirolimus may 
be important in preventing further progression of renal failure.
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PERIOPERATIVE ACUTE RENAL FAILURE IN LIVER 1242 
TRANSPLANT RECIPIENTS IN THE MELD ERA: INFLUENCE 
OF AN INDIVIDUALIZED IMMUNOSUPPRESSIVE REGIMEN 
WITH DELAYED CNI
S. Farkas1, A. Doenecke1, A. Schnitzbauer1, M. Scherer1, M. Loss1, 
G. Kirchner3, B. Banas2, A. Obed1, H-J. Schlitt1
1Dep. of Surgery, University Clinic of Regensburg, 2Dep of Nephrology, 
University Clinic of Regensburg, 3Dep. of Internal Medicine 1, University 
Clinic of Regensburg
Background: MELD score based liver allocation selects for patients with renal 
dysfunction prior to liver transplantation (LTx). Furthermore transplantation 
of extended criteria donor organs is associated with increased rates of renal 
dysfunction. CNI therapy induces chronic renal dysfunction and other 
complications. Long-term outcomes, including patient quality of life and survival 
are thereby compromised. Reduced-CNI regimens are intensely investigated to 
reduce nephrotoxic effects, while simultaneously preventing early graft loss. 
Mycophenolate mofetil (MMF)-based CNI minimisation allows prevention of 
negative side effects of CNIs. The ReSpECT trial showed a benefi t of reducing 
CNI in kidney transplantion without compromising graft survival.
We investigated the impact of the MELD allocation system on perioperative 
kidney function of LTx recipients. Moreover, due to the MELD allocation, we 
changed our standard immunosuppressive regimen from previously starting 
CNIs at day 1 to an individualized CNI delay replaced by MMF in patients 
with increased risk of kidney failure or actual need for renal replacement 
therapy. CNI delay was continued until kidney function recovered, i.e. renal 
replacement therapy was no longer necessary or occurrence of documented 
rejection.
Material and methods: LTx patients from 2004-2006 (pre-MELD era) 
were compared to recipients allocated during the MELD era (2007) at the 
transplant center of the University of Regensburg/Germany. For analysis of 
the two patient cohorts the MELD score was also calculated retrospectively 
for patients in the pre-MELD era. We investigated the MELD score at the 
time of transplantation, the pre- and postoperative need for renal replacement 
therapy. Furthermore we investigated if the individualized CNI delay for 
patients with acute renal failure had a benefi cial effect on the duration of renal 
replacement therapy.
Results:
pre-MELD era
136 patients
Median (Range)
MELD era
57 patients
Median (Range)
MELD 
at transplantation
18 (6-40) 24 (6-40)
Number of patients needing renal replacement therapy 
pre-transplant 6 (4,4%) 4 (7%)
Number of patients needing renal replacement therapy 
post-transplant 42 (31%) 18 (31%)
Days of renal replacement therapy post transplant 
(in patients needing renal replacement therapy) 25,5 (1-206) 12,5 (1-149)
The duration of renal replacement therapy was shorter in patients receiving 
individualized CNI delay and MMF in the MELD era compared to patients on 
standard immunosuppression with CNI in the pre-MELD era.
Summary and conclusion: Our data show that perioperative renal failure 
remains a severe problem for LTX patients as one third needed renal 
replacement therapy. Although our patients had a higher MELD score at 
time of transplantation in the MELD era than in the pre- MELD era, no 
increase in need of renal replacement therapy was found. On the contrary, 
we found that patients who needed renal replacement therapy after LTX 
were shorter on dialysis in the MELD era than in the pre-MELD era. This 
may be due to our change in standard immunosuppression in the MELD era 
from a CNI based therapy to an individualized CNI delay combined with 
MMF for patients with preexisting renal insuffi ciency and/or perioperative 
renal failure. A prospective, randomized trial will be started to confi rm 
these data.
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CLINICAL EVOLUTION OF LIVER TRANSPLANT 1243 
PATIENTS IN MAINTENANCE PHASE DURING THE 
FIRST 6 MONTHS AFTER CONVERSION FROM MOFETIL 
MYCOPHENOLATE TO ENTERIC-COATED SODIUM 
MYCOPHENOLATE DUE TO GASTROINTESTINAL 
COMPLAINTS
M. Miras, J. Egea, C. Marín, A. García, A. Minguela, F. Carballo, P. Parrilla
Liver Transplant Unit, Hospital Univ. Virgen De La Arrixaca, CIBERehd
Background and objective: Enteric-coated sodium mycophenolate (EC-MPS) 
in gastro-resistant tablets is a new formulation of mycophenolic acid which 
delivers drug directly in the bowel. This may reduce gastrointestinal adverse 
effects. In previous clinical trials, EC-MPS has demonstrated similar effi cacy 
and safety to mofetil mycophenolate (MMF) in de novo patients converted 
from MMF.
Methods: Clinical data from liver transplant recipients receiving MMF for 
more than one year who were converted to EC-MPS due to gastrointestinal 
complaints was retrospectively collected. Data from 20 patients followed-up 
during a maximum of 6 months after EC-MPS initiation is presented. Visits 
were conducted at the moment of conversion (baseline), and after 1, 3 and 
6 months.
Results: Mean age (±SD) was 53±10 years, 75% men. The main reason for 
transplantation was alcoholic cirrhosis (70%), followed by hepatitis C (30%). 
At baseline visit, all patients received treatment with cyclosporine, which was 
reduced during follow up (baseline dose and levels of 179 mg/day and 90 ng/ml 
versus 143 mg/day and 86 ng/ml at 3 months [p=0.017 for paired differences 
in levels], and 85 ng/ml at 6 months). The EC-MPS administered dose was 720 
mg/day in all cases. The prevalence of gastrointestinal complaints at baseline 
visit was: diarrhoea, 60% (92% moderate-severe), abdominal discomfort, 60% 
(58% moderate), abdominal pain, 45% (44% moderate-severe), fl atulence, 
40% (38% moderate-severe), nauseas, 20% (25% moderate), dyspepsia, 20% 
(all mild). After 3 months of treatment with EC-MPS, only 2 patients (10%) 
displayed moderate diarrhoea as gastrointestinal complaint. The evolution of 
renal function was good, serum creatinine was signifi cantly reduced and 24-h 
creatinine clearance increased (creatinine: 1.78±1.6 mg/dl baseline vs 1.30±0.3 
mg/dl at 3 months, p=0.002; creatinine clearance: 72.8±18 ml/min vs 79.6±13 
ml/min, p=0.001). No signifi cant differences were found between 3 and 6 
months visits.
Conclusion: The conversion from mofetil mycophenolate to enteric-coated 
sodium mycophenolate in liver transplant recipients with gastrointestinal 
complaints reduces tolerability problems and improves renal function in the 
fi rst three months, with no changes at six months after conversion. A reduction 
in anticalcineurin dose requirements is also observed.
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SODIC MYCOPHENOLATE IN LIVER TRANSPLANT 1244 
PATIENTS WITH GASTROINTESTINAL COMPLICATIONS
G. González, B. Pulido, G. Bravo, A. Martinez, B. Bellido, S. Artacho, 
S. Diez Canedo, D. Usero, S. Martinez, P. Lopez
HH. UU. Virgen del Rocío. Seville; Spain
Introduction: Mycophenolate mofetil (MMF) causes gastrointestinal (GI) side 
effects in approximately 40% of patients, making necessary to modify the dose 
or to discontinue treatment, increasing the risk of rejection.
Myfortic®, enteric-coated mycophenolic acid sodium salt is directly absorbed 
in the small intestine. Its formulation provides an adequate exposure to the 
active ingredient and reduces the undesirable GI effects.
Objective:
•  To reduce the GI side effects of MMF by using Myfortic® in liver transplant 
patients.
•  To obtain a safe and effective immunosuppressive regimen using Myfortic® in 
monotherapy or in combination with calcineurin inhibitors (CNI) or mTOR
Material and methods: 17 patients with intolerance to MMF or who had 
discontinued its use due to undesirable effects were included.
Data on MMF intolerance were collected and its evolution in time after 
Myfortic® introduction was studied.
Different variables were recorded: CNI dose and levels, MMF/Myfortic® 
doses and levels, lipid profi le, markers of liver function, white blood cells and 
uric acid.
These variables were recorded at: visit prior to conversion, starting day, and 
months: 1, 3 and 6. Rejection episodes were collected.
Results: 17 patients analyzed: 14 males (mean age 53.5 years), 3 females (mean 
age 57.7 years).
16 patients required conversion to Myfortic® due to GI complications: 
diarrhea (76.5%), anorexia and vomiting (5.9%), nervousness related 
to taking MMF (5.9%), anorexia and diarrhea (11.8%). 17.6% received 
MMF monotherapy (due to renal dysfunction), and 5.9% received MMF 
plus Sirolimus, 58.8% plus tacrolimus, and 17.6% received MMF plus 
cyclosporine.
Daily doses of CNIs prior to conversion: Tacrolimus 3.1±2.6 mg (levels 
7.2±3.05 ng/mL), Cyclosporin 75.0±25.0 mg (levels 26.0±5.1 ng/mL).
The MMF doses administered to patients are shown in Table 1.
MMF DOSES
Frequency Valid percent
Valid No MMF 4 23.5
500mg/12h 7 41.2
500mg/8h 3 17.6
250mg/8h 1 5.9
750mg/8h 1 5.9
500mg/24h 1 5.9
Total 17 100.0
Table 1. MMF doses before switching to treatment with Myfortic®
•  One month after conversion: 63.6% of patients presented no GI complication; 
at 6 months, 66.7%.
• At month 1, 18.2% presented sporadic diarrhea; at 6 months, 11.1%.
• Patients continued with diarrhea at month 1, 18.2%; at 6 months, 11.1%
At 6 months, 11.1% presented epigastralgia and pyrosis as the only 
complication.
No signifi cant changes were observed in the remaining studied variables.
No patient experienced rejection episodes.
Myfortic® treatment was discontinued in two patients due to dyspnea and due 
to nervousness related to the fact of taking the drug.
Conclusions: The use of Myfortic® in liver transplant patients with GI 
complications resulting from the chronic use of immunosuppressive agents 
(CNI and MMF) is effective as it signifi cantly reduces the incidence of such 
complications.
Myfortic® therapy is safe as no rejection episode or liver function impairment 
have been reported during the study period.
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OUTCOMES OF 4-HOUR INTRAVENOUS 1245 
CYCLOSPORINE A IN LIVING DONOR LIVER 
TRANSPLANTATION
T. Hibi, M. Tanabe, K. Hoshino, Y. Fuchimoto, S. Kawachi, H. Obara, 
M. Shinoda, N. Shimojima, Y. Morikawa, Y. Kitagawa
Department of Surgery, Keio University School of Medicine
Background and aims: Several randomized trials have revealed the 
advantages of tacrolimus over cyclosporine A microemulsion (CsA-
ME) in cadaveric liver transplantation; however, the dose of CsA-ME is 
determined by its trough level in most of the series. Recently, CsA-ME 
administration by C2 monitoring has been described to show equivalent 
immunosuppressive effi cacy with acceptable morbidity and the selection 
of calcineurin inhibitor remains controversial. Meanwhile in living donor 
liver transplantation (LDLT), small graft size, intestinal congestion due 
to extensive operative time, and external biliary diversion all affect the 
bioavailability of CsA-ME and the data from Western countries cannot 
be simply extrapolated. This study was aimed to evaluate the outcomes 
of 4-hour intravenous cyclosporine A (CsA-IV) protocol in the early 
postoperative period of LDLT.
Material and methods: From 1997 through 2007, 53 adult patients 
underwent LDLT. They were divided into 3 groups, CsA-IV (n = 9), 
tacrolimus (Tac, n = 20), and CsA-ME (n = 24), according to the 
immunosuppression protocol. The medical records were retrospectively 
reviewed to compare the dosage, rejection rate, adverse events, and 
prognosis among the groups.
Results: Male: female = 31: 22; median age [range], 48 [21-64] years; in-
hospital mortality rate, 15%; median postoperative hospital stay [range], 
68 [31-256] days; median follow-up [range], 35[5-114] months; overall 
5-year survival rate, 76%. No signifi cant difference in patient background, 
operative procedures, and long-term prognoses was observed among the 
3 groups. In the CsA-ME group, patients with biliary output > 200 ml/
day had a signifi cantly low chance of reaching the target peak level. The 
area under the curve (AUC) at 3 days posttransplant revealed a remarkable 
difference between the CsA-ME and the CsA-IV group. Compared to the 
random distribution of the C2 levels of the CsA-ME group, the C4 levels of 
the CsA-IV group was nearly identical and the AUCs of each patient could be 
superimposed. Acute cellular rejection was signifi cantly higher in the Tac and 
the CsA-ME groups (15% and 17%, respectively) compared with the CsA-IV 
group (0%, P < 0.05). Patients in the Tac group showed higher incidence of 
renal toxicity compared with the other 2 groups, although the difference did 
not reach statistical signifi cance. Infection rate was comparable among the 3 
groups. The difference between the initial and the maintenance dose around 
7POD was the largest in the Tac group (40%) compared with the CsA-IV and 
the CsA-ME groups (5% and 10%, respectively). The Tac and the CsA-ME 
groups also required more frequent dose changes to achieve the target trough 
level compared to the CsA-IV group.
Conclusions: The pharmacokinetics of CsA-ME is complicated by the 
external biliary diversion and its immunosuppressive effect is unpredictable 
in LDLT compared to the deceased donor. CsA-IV does not require enteral 
absorption and demonstrates minor individual dose variance; thus permits 
easier control in the early postoperative period. The immunosuppressive 
effi cacy of CsA-IV appears to be equivalent to Tac with less nephrotoxicity. 
Short-term outcomes of CsA-IV were promising and it may become a rational 
alternative in LDLT.
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SAFETY AND EFFICACY OF ENTERIC COATED 1246 
MYCOPHENOLATE SODIUM (EC-MPS) IN COMBINATION 
WITH BASILIXIMAB (BSX) INDUCTION, TACROLIMUS (TAC) 
WITH OR WITHOUT CORTICOSTEROIDS (CS) IN ADULT 
LIVER TRANSPLANTATION (OLT)
C. Doria1, C.B. Ramirez1, A. Frank1, V. Navarro2, S. Herrine2, S. Rossi2, 
M. Chaballa3, S. Vaccino1, Y. Kang4, I.R. Marino
CB Ramirez1, C Doria 1, A Frank 1, V Navarro 2, S Herrine 2, S Rossi 2, M 
Chaballa 3, S Vaccino1, Y Kang 4, IR Marino
Departments of 1Surgery, 2Medicine, 3Pharmacology, and 4Anesthesiology, 
Thomas Jefferson University Hospital, Philadelphia, PA U.S.A.
Methods: From February 2006 to December 2007, 40 adult OLT recipients were 
included in our prospective, randomized trial (CS=20 vs no-CS=20). All patients 
received BSX induction (20mg intra-operatively and day 4), Tac (0.1mg/kg/
day), and EC-MPS (720mg BID). Patients randomized to CS cohort received 
methylprednisolone 1gm IV intra-operatively followed by prednisone taper to 
20mg PO QD and weaned off at 6 months. Quality of life (QoL) was assessed pre-
OLT (baseline), 3 and 6 months post-OLT using the Gastrointestinal Quality of Life 
Index (GIQLI), a 36-item questionnaire evaluating the impact of GI symptoms, 
emotional status, physical and social function, and stress of medical treatment. 
Score range: 0-144 (higher score=better QoL). Gastrointestinal (GI) intolerance 
was assessed at the discretion of the physician to be related to EC-MPS therapy.
Results: Mean age of patients was 53±9.4 years, with 1:4 female/male ratio 
and 33/40 (83%) white. EC-MPS was initiated at a mean time of 5 days post-
OLT (mean duration = 12±4.2weeks; mean daily dose at 1, 2 and 3 months = 
1224±322mg, 1247±371mg, and 1158±413mg). Mean Tac trough levels were 
10±4.8ng/ml, 8.5±3ng/ml, 8.5±4.4ng/ml at 1, 3 and 6 months, respectively. 
Six patients were switched to cyclosporine micro-emulsion (CsA-ME) due 
to neurotoxicity. No signifi cant difference in 1 year graft (84.4%) and patient 
(90%) survival was observed across groups; 1 biopsy-proven CS-responsive 
rejection occurred in each group. EC-MPS dose was maintained at 720mg BID 
in 16/40 (40%) patients; however, it was reduced in 18/40 (45%) patients: 9 
patients for GI intolerability, 8 patients for leukopenia, 1 patient for both GI 
intolerability and leukopenia. Mean duration of GI intolerability and leukopenia 
was 2.7 weeks and 3.1 weeks, respectively. GI intolerance for 6/9 patients 
resolved upon dose reduction; leukopenia resolved in 5/8 patients. EC-MPS 
treatment was either discontinued (2/40=5% patients) or withheld (4/40=10% 
patients) due to infection or change in IS. Upon improvement of adverse events 
6/22 patients had EC-MPS dose increased to baseline. No CMV or difference 
in bacterial infection rate was observed. Clinical improvement in GIQLI was 
observed across groups from baseline (mean score = 79.8) to 6 months (mean 
score=107.1), p<0.0001. All subscales were statistically signifi cant from 
baseline to 3 and 6 months except for stress of medical treatment from baseline 
to 3 months (p= 0.06).
Conclusion: EC-MPS, BSX, Tac /CsA-ME in a CS or no-CS IS regimen is 
effective and safe with improvement in QoL in adult OLT. Long term follow-up 
and a greater number of subjects are necessary to further validate this conclusion.
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COMPLETE CORTICOSTEROID (CS)-AVOIDANCE 1247 
IMMUNOSUPPRESSION (IS) REGIMEN WITH BASILIXIMAB 
(BSX) INDUCTION AND TACROLIMUS (TAC) IN ADULT LIVER 
TRANSPLANTATION (OLT)
C. Doria1, C.B. Ramirez1, A. Frank1, V. Navarro2, S. Herrine2, S. Rossi2, 
M. Chaballa3, S. Vaccino1, Y. Kang4, I.R. Marino1
Departments of 1Surgery, 2Medicine, 3Pharmacology, and 4Anesthesiology, 
Thomas Jefferson University Hospital, Philadelphia, PA U.S.A.
Background: Corticosteroids have remained a standard part of post-transplant 
IS; however, they have been shown to cause long-term adverse effects, such as 
susceptibility to infection, obesity, hypertension, hyperlipidemia, diabetes, etc. 
They have also been implicated in accelerating Hepatitis C virus re-infection 
post-OLT. The primary aim of this study is to assess the effi cacy and safety of 
a completely CS-free IS regimen in adult OLT by comparing graft and patient 
survival rates, rejection rates and treatment for rejection between recipients 
treated with and without CS. The secondary objectives are to compare the 
incidence of steroid-related complications, and Hepatitis C recurrence between 
recipients treated with and without CS.
Methods: A 2-year, prospective, randomized trial of CS or no-CS IS regimen 
with BSX at 20mg IV intra-operatively and POD 4, Tac at 0.1mg/kg/day and 
EC-MPS at 720mg BID was performed on 40 patients (CS=20; No-CS=20). 
The CS cohort received methylprednisolone at 1gm IV intra-operatively 
followed by prednisone taper to 20mg PO QD and weaned off within 6 months. 
Hepatitis C virus (HCV) patients had HCV PCR pre-OLT, .5, 1, 3, 6 months 
post-OLT. Protocol liver biopsies were performed at baseline, 2 weeks and 6 
months post-OLT and/or when clinically indicated.
Results: One patient in no-CS cohort was excluded from the analysis due to 
graft failure secondary to hepatic artery thrombosis leading to re-transplantation 
within 2 weeks of primary OLT. Patient characteristics were matched between 
groups for age, sex, ethnicity, MELD score, Cold and Warm Ischemia Time, 
and diagnosis. HCV was the primary etiology for OLT (CS:12; no-CS:14). 
Mean duration on CS was 186 days (median 151 days). Tac target trough levels 
were 8-10ng/ml. Six patients were switched to cyclosporine micro-emulsion 
(CsA-ME) due to neurotoxicity. Mean follow up time was 12.3 ± 5.9 months 
(range 3-23.4 months). No signifi cant difference was observed between groups 
for incidence of Acute Cellular Rejection (CS:1; No-CS:1), histologic HCV 
recurrence (CS:5; no-CS:8), bacterial infection (CS:10; no-CS:10), CMV 
and malignancy (none). Kaplan-Meier 12-month patient (CS: 88.89%; no-
CS: 91.67%) and graft (CS:88.89%; no-CS: 80.21%) survival rates were not 
statistically signifi cant (p=0.9, p=0.5, respectively). There were 2 deaths with 
functioning grafts due to Adult Respiratory Distress Syndrome (no-CS:1) and 
intracerebral bleeding (CS:1). Graft loss from HCV recurrence (time from OLT 
12.7 months) was observed in the no-CS group. No signifi cant difference was 
observed for new onset DM, hypertension, hypercholesterolemia, and weight 
gain during follow-up.
Conclusion: Complete CS-avoidance IS regimen with BSX, Tac/CsA-ME and 
EC-MPS is safe and effective in adult OLT recipients. Longer follow-up and an 
increased number of subjects may be needed to fully assess this conclusion.
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REPLACEMENT OF CALCINEURIN INHIBITORS WITH 1248 
MMF IN PATIENTS AFTER LIVER TRANSPLANTATION: A 
PROSPECTIVE RANDOMIZED TRIAL
U.P. Neumann, M. Schmeding, A. Kiessling, R. Neuhaus, P. Neuhaus
Charité, Virchow Clinic
Side effects related to long-term immunosuppressive therapy with calcineurin 
inhibitors (CNI) are a major cause for morbidity and mortality in patients after 
liver transplantation (OLT). Several studies have proven the benefi cial effect 
of CNI sparing in combination with introduction of mycophenolate mofetil. 
The aim of this study was to prove the feasibility of CNI withdrawal and 
replacement with MMF.
Overall 146 patients a minimum of 6 months after OLT were included 
in this prospective randomized trial. Patients received their maintenance 
CNI treatment (n=71, controls) or stepwise replacement of CNI with MMF 
(MMF group, n=75) within 3 months. Renal function, blood pressure, and 
cardiovascular combinations were monitored prior to study entry and every 3 
months thereafter. Follow up was 24 months in all patients. Liver biopsies were 
performed routinely.
A complete cessation of CNI in the MMF group was possible in 50/75 
patients. Incidence of histological proven rejection was 10.7% in the MMF 
group compared to 1.4% in controls. None of the patients developed a steroid 
resistant rejection. None of the patients showed signs of chronic rejection or 
ductopenia. All rejections occurred after complete cessation of CNI treatment. 
Renal function signifi cantly improved in the MMF group (p<0.01). In contrast 
creatinine levels increased in the control group. This effect was pronounced 
in patients with impaired renal function (creatinine levels > 1.3mg/dl) at 
study entry (p<0.05). 8 patients of the control group showed a fast signifi cant 
deterioration of renal function during the study and were switched to MMF 
monotherapy to avoid chronic dialysis. We could not identify changes in blood 
pressure and cardiovascular complications between groups.
Replacement of CNI with MMF after OLT is safe and feasible. However, in 
1/3 of the patients a complete cessation of CNI was not possible. None of the 
patients developed a severe complication. The replacement of CNI with MMF 
signifi cantly improved renal function.
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POSTOPERATIVE IMMUNOSUPPRESSANT-FREE 1249 
FOR VERY SICH PATIENTS UNDERGOING LIVER 
TRANSPLANTATION
C-F. Lee, T-J. Wu, H-S. Chou, K-M. Chan, W-C. Lee
Chang-Gung Transplantation Institute, Chang-Gung Medical Center, 
Chang-Gung University
Introduction: Very sick liver cirrhotic patients are immuno-compromized. 
Organ transplantation for very sick patients has a high mortality because 
postoperative immunosuppressive agents may further compromised immunity 
and result in profound sepsis. In this study, post-transplant immunosuppressive 
agents are suspended for very sick patients to improve the outcome of liver 
transplantation.
Materials and methods: Five very sick patients, 2 males and 3 females, 
who underwent liver transplantation were included in this study. Two 
patients had hepatitis C-, one patient had hepatitis B-, and two patients 
had hepatitis B+C-related liver failure. Among these patients, two patients 
had whole liver, one had size-reduced liver, one had split liver, and one 
had living donor liver transplantation. The administration of postoperative 
immunosuppressive agents was according to the number of CD4+ and CD8+ 
lymphocytes.
Results: The mean age of the patients was 54.4+5.7 years. The MELD score 
was 33.6+10.7. Before liver transplantation, 3 patients had bacterial infection 
under antibiotic control. The percentage of CD4+ and CD8+ lymphocytes were 
13.2+6.7% and 5.7+2.3%, respectively. According to low number of CD4+ 
and CD8+ lymphocytes, postoperative immunosuppressive agents were not 
administrated for 44.2+27.1 days. Postoperatively, 2 patients had CMV and 
bacterial infection, and 3 patients had CMV, bacterial and fungal infection. 
Immunosuppressive agents were administrated until AST and ALT were 
elevated slightly and CD8+ lymphocytes were more than 10%. Among these 
patients, 4 patients were survived and one patient who had a marginal donor 
liver died of sepsis.
Conclusion: Postoperative immunosuppressive agents can be fully suspended 
to prevent uncontrolled infection for very sick patients undergoing a liver 
transplantation. The number of CD4+ and CD8+ lymphocytes can be used as a 
guide for immunosuppressant administration.
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BASILIXMAB INDUCTION WITH DELAYED 1250 
TACROLIMUS IN ADULT LIVER TRANSPLANTATION 
– IS THERE A RENAL PROTECTIVE EFFECT? 
S. Iyer, A. Yu, S. Chang, V. Lee, K. Madhavan
National University Hospital
Introduction: Basiliximab, a chimeric monoclonal antibody directed against 
the alpha-chain of the interleukin 2 receptor (CD25), has been evaluated as an 
induction therapy for liver transplant recipients, with the aims of decreasing 
acute rejections, rapid steroid withdrawal and delaying calcineurin inhibitors. 
In this study, we assessed the effi cacy of basiliximab in combination 
with a delayed tacrolimus-based regimen for renal protection after liver 
transplantation.
Methods: We instituted use of Basiliximab induction and delayed tacrolimus 
in immunosupression protocol from Jan 2000.The study group (group I) 
consisted of 20 recipients who received induction IV Basiliximab 20mg (Day 
0, 4) with steroids and introduction of tacrolimus on day 8. The control group 
(group II) included 20 patients with early tacrolimus and steroids prior to 
Jan 2000. The patient profi les, perioperative data were compared. Creatinine 
clearance was compared pretransplant and post transplant at several time 
intervals (1, 2, 3, 4 weeks, 3 months, 6 months and 1 year). The tacrolimus 
dose and the serum levels were compared at 2, 6 weeks, 6 months and 1 year 
post transplant.
Results: The mean age, gender, Childs-Pugh status, indication for transplant 
was similar in both groups. There were no differences in the operative time, 
cold and warm ischemia time, blood transfusion in both groups (p>0.05). Pre 
preoperative creatinine clearance was 81.9 and 88.3 ml/minute respectively 
(p=0.5). There were no signifi cant differences in creatinine clearance in the 2 
groups at all time points post transplantation. There was no difference in acute 
cellular rejection rates, post transplantation diabetes mellitus, hypertension and 
renal insuffi ciency at the end of one year follow up. Moreover there was no 
difference in the tacrolimus levels and tacrolimus dosage in the two groups up 
to one year of follow up.
Conclusion: Basiliximab induction has no added advantage to prevent early 
renal dysfunction by delaying the introduction of tacrolimus. It doesn’t reduce 
the dose requirement of tacrolimus without increasing graft rejection and 
infection. This study questions the role of routine basiliximab induction in 
orthotopic liver transplantation in adults.
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DE NOVO USE OF MTOR INHIBITOR EVEROLIMUS 1251 
IN COMBINATION WITH MYCOPHANOLATE SODIUM 
IN PATIENTS UNDERGONE ORTHOTOPIC LIVER 
TRANSPLANTATION
E. Antoniou1, D. Dimitroulis1, D. Mantas1, M. Flessas1, K. Labathariou2, 
N. Nikitakis1, P. Paraskeva1, D. Karoussos, K. Tsinari, A. Kostatkis
1Laikon University Hospital -2nd Surgical Department, 2Laikon University 
Hospital - Anaesthetic Department
Introduction: We present the results from our new liver transplant centre using 
the combination treatment of everolimus (mammalian target of rapamycin 
-mTOR- inhibitor) (Certican) and mycophanolate sodium (MPS - Myfortic), as 
de novo anti-rejection treatment after orthotopic liver transplantation (OLTx).
Methods: Eight out of thirteen patients who had an OLTx in our centre, 
between July’06 – January ’08, received the above treatment. Six of them had 
hepatocellular carcinoma (HCC), one had acute hepatic failure due to epitheliod 
haemangioendothelioma (EHE), and one had PBC and a single kidney with 
borderline renal function. All patient received de novo anti-rejection therapy 
with everolimus (1.5mg bid), MPS (720mg bid) and prednisolone (10mg bid), 
except the one with single kidney and PBC cirrhosis, who received half dose of 
Myfortic due to low white cell count.
Results: All patients had an improving liver function, coming almost to 
normal by the end of the fi rst week, after starting the above treatment. Five out 
of eight patients had liver cirrhosis due to viral hepatitis and hepatocellular 
carcinoma (HCC). One had PBC cirrhosis and HCC. The patient with EHE 
died on the 14th postoperative day (POD) already being in the ward, due 
to cardiac arrest. Another one who had HCV cirrhosis, HCC (8cm) and 
portal vein thrombosis, although recovered well after her OLTx, developed 
massive brain haemorrhage on the 8th post-operative day (POD) and died. 
The one with PBC and single kidney, had also everolimus dose reduced to 
half after the fi rst week, due to very high everolimus level (22ng/ml). This 
patient had two episodes of acute rejection, fi rst treated effectively with 
high dose of steroids, second, was a steroid resistant rejection clinically, 
although liver biopsy did not supported the clinical fi ndings of rejection. 
This patient converted to Tacrolimus, keeping Everolimus and steroids, 
3 months after OLTx, with very good response. Five out eight continue 
the above combination therapy and two of them have already been treated 
for more than one and a half year. The remaining three have been treated 
for 2-5 months postransplant. Three out of seven had a moderate acute 
rejection and treated effectively with high dose of steroids for three days. 
None presented any side effect due to this treatment, and no hepatic artery 
thrombosis or wound healing problems noticed. Survival range is between 2 
-17 months. Everolimus blood level (Cmin) in all patients has been between 
4.5 to 7.1ng/ml.
Conclusion: Everolimus has been mainly used in renal transplantation and only 
in few centres in OLTx, as late conversion from CyA or FK. To our knowledge, 
it is the fi rst time of de novo use of everolimus and MPS combination, in OLTx 
patients with long term survival. Although the number of patients is small, the 
results show that the above immunosuppression combination can safely be used 
in OLTx patients, especially in those with malignancy and/or renal impairment.
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GENOTYPE AND EARLY VIRAL RESPONSE BUT NOT 1252 
RIBAVIRIN DRUG LEVEL MONITORING ARE PREDICTIVE 
FACTORS FOR RESPONSE TO TREATMENT OF HCV 
REINFECTION AFTER LIVER TRANSPLANT
B. Nashan1, M. Sterneck1, D. Benten2, L. Renders3, A. Lohse2, L. Fischer1 
1University Hospital Hamburg Transplantcenter, 2University Hospital 
Hamburg Department of Medicine, 3University Hospital Schleswig Holstein, 
Department of Nephrology
Background: Treatment of HCV reinfection after orthotopic liver 
transplantation (OLT) with interferon (IFN) and ribavirin (RIB) is poorly 
tolerated and sustained biochemical and virological response (SVR) rates are 
low. Therefore, prognostic factors have to be defi ned and treatment modalities 
need to be optimized.
Patients and methods: We retrospectively analyzed 31 OLT recipients with 
HCV reinfection treated with Peg-IFN alpha-2b (1-1.5 mg/kg BW) and RIB 
(start dose: 800-1000 mg/day) for 48 weeks. In 15 of these patients, RIB 
dosage was adjusted according to blood level monitoring (HPLC; target level 
8-12 μmol/l). In the remaining 16 patients, RIB dose was adjusted according 
to the degree of anemia.
Results: SVR was achieved in 7/31 patients (23%), with signifi cantly higher 
SVR in patients with genotype 2 or 3 (4/8; 50%) compared to patients with 
genotype 1 or 4 (2/23; 9%); p=0.029. Early virological response (EVR defi ned 
as negative HCV-PCR or 2-log decrease, 12 weeks after initiation of therapy) 
was highly predictive for SVR. No patients without EVR achieved SVR despite 
continued treatment until week 48 (100% negative predictive value). Only 5/13 
patients with EVR did not achieve end-of-treatment response or had relapse 
after completion of antiviral therapy (EVR with 62% positive predictive 
value for SVR). In 15 patients with RIB drug monitoring, 155 serum levels 
were determined which resulted in adjustment of RIB dosage in 13 patients. 
However, RIB drug level monitoring did not result in improved SVR rates or 
reduction of side effects; in particular, the need for erythropoietin was similar 
in both groups.
Conclusion: Like in non-transplant patients, infection with HCV genotype 
2/3 and EVR are predictive factors for SVR in OLT recipients with HCV 
reinfection. RIB drug level monitoring did not improve SVR nor reduce side 
effects of treatment.
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EFFICACY OF THERAPY OF RECURRENT HEPATITIS 1253 
C VIRUS INFECTION AFTER LIVING DONOR LIVER 
TRANSPLANTATION IN EGYPT
A. Salah1, M. El-Mansy2, S. Zakaria1
1Cairo University, 26th October University
In Egypt, hepatitis C viral (HCV) infection genotype 4a is a major health 
concern with a reported prevalence as high as 24.3%. It has been closely 
associated with schistosomiasis. HCV recurs in nearly all patients after liver 
transplantation (LT) and is associated with progressive fi brosis and graft loss. 
Treatment of recurrent HCV in liver transplant is controversial.
Objective: To evaluate the effi cacy of pegylated interferon alpha 2b (PEG-IFN) 
and ribavirin therapy of recurrent HCV after living donor liver transplantation 
(LDLT) in Egypt.
Methods: We retrospectively investigated the clinical progress and 
management of recurrent HCV in 32 patients who underwent living donor 
liver transplantation in Egypt from August 2003 to August 2007. Twenty six 
patients were males. The median age was 47 +/-7 (39-65) years. All patients 
had 1) a positive test for HCV- RNA in serum; 2) alanine aminotransferase 
(ALT) >45 UI/mL; and 3) a liver biopsy showing chronic hepatitis without 
rejection in the previous 2 months. Patients received PEG-IFN (1.5 microg/
kg/week) and ribavirin (800-1,000 mg/day) for 12 months. Follow-up was 
based on biochemical (ALT), virological (RNA-HCV), and histological (liver 
biopsy) examinations. Follow-up lasted a minimum of 6 months after the end 
of antiviral therapy. Sustained virological response (SVR) was achieved in 7 
(22%) patients. A total of 20 (63%) patients had normalized ALT levels at the 
end of therapy. Infl ammatory portal and lobular score declined signifi cantly 
in patients with SVR (P < 0.05) but not in non-responder patients. Fibrosis 
did not change signifi cantly in either group. SVR was signifi cantly associated 
with low gamma-glutamyltransferase GGT (P = 0.04) and HCV-RNA levels 
(P = 0.03), a virological response at 12 weeks (P = 0.002) and patient’s 
compliance (P = 0.04). Six (19%) patients were withdrawn prematurely due 
to adverse effects.
Conclusion: Therapy with PEG-IFN and ribavirin achieved SVR and a 
signifi cant histological improvement in 22% of living donor liver transplant 
recipients with recurrent HCV. Management of post-recurrent cirrhotic change 
is crucial for graft and patient survival. We think customized protocols are 
needed for every situation of recurrent hepatitis C.
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DEPRESSIVE SYMPTOMS, HOST IMMUNITY, AND 1254 
SURVIVAL IN HEPATITIS B AND/OR C PATIENTS EVALUATED 
FOR ORTHOTOPIC LIVER TRANSPLANTATION
J. Steel1, T. Clark Gamblin, M. DeVera, P. Fontes, J.W. Marsh, 
K. Chopra
1University of Pittsburgh School of Medicine, 2University of Pittsburgh 
School of Medicine, 3University of Pittsburgh School of Medicine, 
4University of Pittsburgh School of Medicine, 5University of Pittsburgh 
School of Medicine, 6University of Pittsburgh School of Medicine
Objective: Increasing evidence is accumulating regarding the association 
between depressive symptoms and increased morbidity and mortality in the 
general population as well as across several chronic diseases. The aims of 
the present study were to: (1) assess the prevalence of depressive symptoms 
in patients diagnosed with hepatitis B and C awaiting orthotropic liver 
transplantation; (2) test the association between depressive symptoms and host 
immunity; and (3) begin to explore possible associations between depressive 
symptoms, graft injury, and survival
Methods: A prospective study of 23 patients with hepatitis B and/or 
C-related chronic liver disease who were being evaluated for orthotopic 
liver transplantation were recruited between April to September 2003. 
Patients were administered the Center for Epidemiological Studies-
Depression (CES-D) scale. Immune system markers including IL-4, IL-5, 
TNF-ƒÑ, IFN-ƒ×, and Natural Killer (NK) cell number and activity were 
collected at baseline. Sociodemographic and disease-specifi c data was 
gathered from the patients¡¦ chart. Survival was measured from date of 
diagnosis to death.
Results: At the time of evaluation, 40% of patients reported depressive 
symptoms in the clinical range of the CES-D. Of the 23 patients, 44% had 
received a transplant at 5-year follow-up. The patients who did not receive a 
transplant reported a higher level of depressive symptoms (CES-D score=18) 
when compared to those patients who were transplanted (CES-D mean 
score=15). At 5-year follow-up, only 54% of those who reported depressive 
symptoms in the clinical range of the CES-D were still living whereas only 
72% of patients who reported depressive below the clinical cut-off of the 
CES-D were still alive. Although not statistically signifi cant, patients with 
depressive symptoms in the clinical range, had lower levels of NK number [75 
versus 107] and activity [11.7 versus 15.9], lower levels of IL-4 (0.02 vs. 0.04) 
and higher counts of CD4 (37 s 34), CD8 (22 vs. 18), and TNF-ƒÑ (7.5 vs. 
2.5) when compared to patents who reported depressive symptoms below the 
clinical range of the CES-D. A trend toward signifi cance (p=0.13) was found 
in patients who reported depressive symptoms in the clinical range in regard 
to portal vein infl ammation at the second biopsy subsequent to transplant (0.75 
vs. 0.17).
Conclusion: Preliminary data suggests a high prevalence of depressive 
symptoms in patients diagnosed with hepatitis B and C awaiting liver 
transplantation. Although not statistically signifi cant, a potentially clinically 
signifi cant difference may exist in regard to survival and host immunity. 
It is unclear if depressive symptoms and host immunity may play a role in 
the infl ammation process. Further research concerning the prevalence and 
association between depressive symptoms, immunity, and survival is warranted. 
Psychological evaluation and treatment should be included in standard of care 
for patients awaiting liver transplantation.
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HEPATITIS B IMMUNOGLOBULIN AND LAMIVUDINE 1255 
FOR HEPATITIS B PROPHYLAXIS AFTER LIVER 
TRANSPLANTATION
S. Sevmis1, N. Savas2, U. Yilmaz2, F. Ozcay3, H. Karakayali1, 
M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Gastroenterology, 
3Baskent University Faculty of Medicine, Department of Pediatry
Recurrence of the hepatitis B virus (HBV) after liver transplantation (LT) is a 
major risk factor affecting graft and patient survival. Short-term (ie, 1-2 years) 
HBV reactivation rates following LT range between 3% and 15%. Using 
combination prophylaxis, outcomes of LT for HBV-related liver disease have 
been improved to levels comparable with non-HBV recipients. This study 
presents the results (ie, longer than 1 year) of combination prophylaxis with 
hepatitis B immunoglobulin (HBIG) and lamivudine. Between September 
2001 and January 2008, 55 patients with HBV underwent LT at our hospital, 
34 of these patients were followed for more than 12 months. Their outcomes 
were analyzed retrospectively. Our combination protocol includes lamivudine 
(100 mg PO/day beginning the day after surgery) and HBIG (10 000 IU 
IV during the anhepatic phase, 2000 IU/day IV during the fi rst week after 
surgery, 2000 IU IV/month from the fi rst to the 12th postoperative month). 
Using our dosage of HBIG, the anti-Hbs Ab serum titer was maintained 
at approximately 100-150 IU/mL. The female: male ratio was 7:27. Two 
patients were children. The mean age of patients was 43±13.1 years (range, 
4 to 65 years). Eleven patients received grafts from cadaveric donors, and 
23 received grafts from living donors. The mean MELD score was 18.7 
&#61617; 5.5. Four patients had HDV coinfection, and 12 recipients had 
concomitant hepatocellular carcinoma. All patients were given steroids and 
low-dose tacrolimus for immunosuppression. Steroid treatment was stopped 
at the end of the third month. Four patients died of causes unrelated to HBV 
13, 15, 23, and 30 months after LT. At the time of death, their HBsAg was 
negative, and serum titers of anti-Hbs Ab were 35.3, 56.4, 79.6, and 123 
IU/mL. The mean follow-up was 26.8 &#61617; 8.1 months (range, 12-47 
months). HBsAg became positive 16 months after LT in one patient; the 
remaining 29 patients had negative evidence of HBsAg. In 9 patients, the 
serum titer of anti-Hbs Ab was 0; in the remaining 20 patients, it was 69.2 
&#61617; 133 IU/mL (range, 8-468 IU/mL). In conclusion, our combination 
protocol with HBIG and lamivudine is a safe and effective treatment modality 
for HBV prophylaxis after LT. Initial long-term follow-up of this protocol 
shows satisfactory outcomes.
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LOW-DOSE HEPATITIS B IMMUNE GLOBULIN 1256 
COMBINED WITH LAMIVUDINE IS SUCCESSFUL FOR 
PROPHYLAXIS AGAINST HEPATITIS B RECURRENCE AFTER 
ORTHOTOPIC LIVER TRANSPLANTATION
M.N. Toosi1, A. Jafarian2, M. Moini2, A. Najafi 3, Z. Ahmadinegad4, 
M. Salimi2, F. A. Ardalan5, A. Rabani2, A. Mohagheghi2, S. Irajian2
Departments of 1Internal Medicine, 2Sugery, 3Anestesiology, 4Infectious 
disease, and 5Pathology, Liver Transplantation Group, Tehran University of 
Medical Sciences, Tehran, Iran
Background: Chronic hepatitis B virus (HBV) infection is leading cause 
of end-stage liver disease in Asia. Orthotopic liver transplantation (OLT) 
for patients infected with HBV had been identifi ed as having important 
limitations because of reinfection of allograft by HBV. Introduction of 
high-dose hepatitis B immune globulin (HBIG) and nucleoside analogues 
helped in development of strategies to prevent graft reinfection. To get a 
better regimen for HBV prophylaxis after OLT, combination of HBIG 
with lamivudine was introduced. No consensus exists concerning dosage 
and duration of prophylactic HBIG for prevention of HBV recurrence after 
OLT.
Method: We report the follow-up of combination prophylaxis with low-
dose HBIG and lamivudine in four cases of HBsAg positive liver transplant 
recipient. Our prophylaxis therapy to prevent HBV recurrence was combination 
of Lamivudine plus subcutaneous and Intramuscular HBIG10,000 IU/daily for 
fi ve days and 5,000 IU/daily for ten days without any dose of IV HBIG. HBIG 
administrations were continued by IM HBIG 2,500 IU/weekly for last of the 
year. Our objectives were patient survival and tolerance, graft survival, HBV 
recurrence, HBIG requirement and HbsAb titers.
Results: Two men and 2 women HBsAg positive post HBV necrotic cirrhotic 
patients were undergone OLT. Pre-transplant HBV viral loads were negative 
with amplicore PCR method threshold of 200 copies/ml, with negative HbeAg 
and lamivudine therapy in all patients. One patient was positive for anti-HDV 
antibody. All patient tolerated well the rout of injections with no major problem. 
In 14th day after transplantation, HBsAb titer received to >2,000 mIU/ml in 
all patients. Other results of follow up are in table. The patients were HBV 
recurrence free during the follow up. Marked reduction in overall requirement 
of HBIG was produced.
Conclusion: In post HBV cirrhotic patients with negative HBV DNA before 
transplantation, low-dose subcutaneous/IM HBIG and lamivudine is safe, 
low cost, and highly effective prophylactic regimen in prevention of HBV 
recurrence after liver transplantation.
Gender/Age (yr) F/37 M/30 F/46 M/46
Blood group A+ A+ B+ O+
Duration of follow up 60 mo. 48 mo. 12 mo. 3mo.
HDV status negative negative positive negative
HBsAb titters (mIU/ml)
12 mo after OLT 412 180 1000 n/a
24 mo after OLT 122 negative n/a n/a
Negative HBsAg report 12 mo 12 mo 12 mo short follow up
Time of HBIG discontinuation 24 mo 24 mo HBIG continue
Immunosupressive protocol Neoral cellcept prednisolon prograf cellcept prednisolon
Acute rejection (during 1st yr) yes no yes no
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PREDICTIVE FACTORS OF OUTCOME IN PATIENTS 1257 
TRANSPLANTED FOR HEPATITIS B
S. Beckebaum1,2, Z. Yu1,3, M. Lindemann4, C.G. Klein1,2, G. Sotiropoulos1, A. 
Radtke1, G. Gerken2, V.R. Cicinnati1,2
1Department of General, Visceral and Transplantation Surgery, University 
Hospital Essen, Essen, Germany, 2Department of Gastroenterology and 
Hepatology, University Hospital Essen, Essen, Germany, 3Department of Surgery, 
Beijing Tongren Hospital, Capital University of Medical Sciences, Beijing, 
China, 4Institute of Immunology, University Hospital Essen, Essen, Germany
In this study, we aimed 1) to investigate the impact of variables on graft 
and patient survival in hepatitis B virus (HBV)-infected liver transplant (LT) 
recipients and 2) to identify factors associated with a higher risk of graft 
cirrhosis at 5 years post-LT. A total of 104 chronically infected HBV patients 
(76% male, mean age of 49 &#61617; 10,8 years) transplanted between 
September 1992 and November 1997 were considered for this study. The 
overall 5 year patient and graft survival was 79,8% and 72.1%, respectively. 
All patients had cyclosporine A (CSA, n=58) or tacrolimus (TAC, n=46) based 
immunosuppressive regimens. Univariate and multivariate Cox’s proportional 
hazards regression analysis indicated that recipient age and recipient BMI 
at LT and immunosuppression with CSA correlated with decreased patient 
survival. Older recipient age and higher recipient body mass index (BMI) 
at LT were associated with worse graft survival. In the log rank test, 
signifi cant risk factors for graft cirrhosis within 5 years were qualitative and 
quantitative detection of HBV DNA and antiviral therapy at LT; signifi cant 
posttransplant factors included biliary stenoses due to anastomotic strictures 
or ischemic type biliary lesions, hepatitis B recurrence, nucleos(t)id analogue 
monoprophylaxis (without hepatitis B immunoglobulin) and short term (<1 
year) mycophenolate mofetil therapy. In conclusion, our study has shown 
that various recipient factors at LT as well as post-transplant virological 
status, antiviral prophylaxis, biliary complications and immunosuppressive 
regimen are related to the outcome of HBV recipients. Prospective studies are 
warranted to defi ne the “optimal” immunosuppression in patients transplanted 
for hepatitis B.
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EFFICACY OF LAMIVUDINE MONOTHERAPY 1258 
FOLLOWING ONE-YEAR COURSE OF HEPATITIS B 
IMMUNOGLOBULIN IN PREVENTING HEPATITIS B 
VIRUS RECURRENCE AFTER LIVING DONOR LIVER 
TRANSPLANTATION
N. Kawagishi, A. Nakamura, T. Iwane, I. Takeda, S. Miyagi, K. Satoh, 
Y. Akamatsu, S. Sekiguchi, S. Satomi
Division of Transplantation, Reconstruction And Endoscopy
Background and purpose: Prophylaxis of recurrent hepatitis B virus (HBV) 
using hepatitis B immunoglobulin (HBIG) after liver transplantation is costly 
and it has some limitations. We report the effi cacy of lamivudine (LAM) 
monotherapy following one-year course of HBIG plus LAM after LDLT.
Methods: Out of 111 LDLT, we had 11 patients with chronic hepatitis B before 
Tx and 3 recipients whose donors were anti-HBc antibody positive. Ten out of 
11 chronic HB patients had LAM, 1 patient had adefovir in addition to LAM, 
and 1 patient had no nucleoside analogue before Tx. HBV DNA was detected 
in 4 patients at the time of Tx. Until the second day, total 30,000 units of HBIG 
was administered and then the level of anti-HBs Ab was maintained around 
150 IU/l for one year by monthly administration of HBIG. After 1 year, HBIG 
was stopped to use. LAM (100mg) was administered daily from just after Tx, 
and it was continued throughout this study. One recipient out of 3 anti-HBc Ab 
positive donors, who had transplanted in 1993, had no prophylaxis. Other two 
recipients of anti-HBc Ab positive donor had the same prophylaxis of chronic 
hepatitis B patients. The mean follow-up period was 42 months.
Results: Two out of 14 recipients, including one who did not receive 
prophylactic therapy, had HBV recurrence [HBs Ag (+), HBV DNA (+)]. One 
recurrent recipient, who had our prophylactic protocol, treated with entecavir 
because of YMDD mutant 3 years after Tx. Two recipients were dead; one was 
due to liver abscess 3 years after Tx and the other was due to recurrence of HCC 
3 years after Tx. The other 12 recipients were alive and in good conditions. 
One recipient, who had HB hepatitis transmitted by an HBc Ab(+)donor, was 
administered LAM and adefovir, and the HBV DNA became negative.
Conclusion: LAM monotherapy after one-year course of HBIG plus LAM is 
feasible and cost-effective in terms of the preventing HBV recurrence.
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MINIMAL COSTS AND EFFICACY OF 1259 
IMMUNOPROPHYLAXIS IN HBV TRANSPLANTED PATIENTS 
– EXPERIENCE IN THE ROMANIAN PROGRAM OF LIVER 
TRANSPLANTATION
S. Iacob1, D. Hrehoret2, B. Dorobantu2, E. Gangone2, R. Iacob1, L. Gheorghe1, 
I. Popescu2
1Fundeni Clinical Institute, Gastroenterology And Hepatology Center, 
2Fundeni Clinical Institute, General Surgery and Liver Transplantation Center
Background: HBV in transplant patients has been associated with good 
outcomes and the challenges are primarily focused around optimizing 
prophylactic regimens with hepatitis B immune globulin (HBIg) and 
minimizing related costs. HBIg is an expensive therapy, and there are wide 
practice variations at different institutions.
Aim: To evaluate the effi cacy and costs of the prophylactic regimen consisting 
of lamivudine (100 or 200mg/day) and HBIg administered in order to keep the 
anti-HBs between 50-100 IU/L.
Methods: We included in the study 42 patients (69% with hepatic cirrhosis 
secondary to HBV+HDV coinfection and 31% with HBV infection alone) 
that underwent OLT between 2000 and 2007. Chi-squared and T-Student test 
were used to compare the qualitative and quantitative variables. Survival was 
estimated using the Kaplan Meier method.
Results: There were 27 men and 15 females with a mean age at OLT of 47.2±8 
years. HBV DNA was negative (<200 copies/mL) before OLT in 97.4% and 
HBeAg was negative in 92.1% of patients. HBV recurrence rate (positivity of 
HBsAg after initial negativity) was 4.8% after a mean of 1.2±0.85 years. The 
3 year survival rate was 75.8%. No death was due to HBV recurrence and no 
patient required relisting or retransplantation for recurrent HBV infection. The 
total mean cost for HBIg and lamivudine was 10977.13 EUR and the mean 
cost for patient per month of survival was 826.08 EUR. Patients with HBV 
monoinfection received lamivudine pre-OLT in a signifi cantly higher percent 
(80%) compared to HBV+HDV infection (21.1%, p=0.01) and also HBIg in 
the anhepatic phase (86.2% HBV vs 46.2% HBV+HDV, p=0.006). The time to 
HBsAg negativity after OLT was shorter in HBV+HDV infection (51.8±55.8 
days) compared to HBV infection (73.3±65.1 days), but did not reached 
statistical signifi cance (p=0.47). There was no difference regarding survival or 
costs between HBV and HBV+HDV.
Conclusion: In our transplant center HBV recurrent infection was low and 
achieved with minimal costs. There was no signifi cant difference regarding 
survival or costs between HBV and HBV+HDV coinfection, although there is 
a trend to a more rapid negativation of HBsAg in coinfected patients.
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REAL-TIME ELASTOGRAPHY AND HISTOLOGICAL 1260 
EVALUATION IN PATIENTS WITH RECURRENT HEPATITIS C 
FOLLOWING LIVER TRANSPLANTATION
S. Iacob1, L. Gheorghe1, R. Iacob1, G. Becheanu1, V. Herlea2, D. Hrehoret2, 
C. Gheorghe1, I. Popescu2
1Fundeni Clinical Institute, Gastroenterology And Hepatology Center, 
2Fundeni Clinical Institute, General Surgery and Liver Transplantation Center
Background: HCV infection invariably recurrs after liver transplantation and 
at least 50% of recipients develop histologic evidence of recurrent disease 
within 1 year posttransplant. Yearly protocol liver biopsies are currently the 
adopted strategy in HCV patients in order to detect progression of fi brosis and 
to initiate on time antiviral therapy. Noninvasive evaluation of liver fi brosis is 
now under evaluation in chronic hepatitis C.
Aim: A pilot study to evaluate the clinical value of real-time elastography in 
patients with histologically mild posttransplant recurrent hepatitis C has been 
conducted.
Methods: Patients with histologically proven hepatitis C underwent 
transcutaneous ultrasound elastography (SonoElastography mode, HITACHI 
EUB-6500). All patients underwent liver biopsies the same day after 
elastography evaluation and METAVIR score was used to assess the degree 
of infl ammation and stage of fi brosis. Ninety-four elastography images were 
analyzed using Adobe Photoshop 7. The mean intensity of colors red, blue, 
green were measured using a semi-quantitative method. Analysis of histograms 
for each color of the sonoelastography images was performed for quantifying 
the elasticity of liver tissue. In order to investigate the predictive role of 
sonoelastography for diagnosis of hepatitis, the c-statistic parameter was used.
Results: There were analyzed 8 patients (3 females and 5 males), with a mean 
age of 51.75 ± 4 years. All patients had mild histologic liver disease (A0-A2 and 
F0-F2) on liver biopsy. Necroinfl ammation grade A1 and A2 was diagnosed in 
case of green colour >146.3, with a Se=44.8% and Sp=100% and c-statistic=0.63, 
and blue colour <90.7, with a Se=32.1%, Sp=100% and c-statistic=0.7. For fi brosis 
stage 2 the following results were obtained: green colour >157.8, Se and Sp=100%, 
c-statistic=1; blue colour >102.2, Se=100%, Sp=58.6%, c-statistic=0.74.
Conclusion: Necroinfl amation can be estimated with high specifi city using 
real time elastography but the analysis might be of better clinical usefulness 
in assessing fi brosis, possibly contributing to selection of patients best suited 
to undergo liver biopsy. Larger validation studies of the method, including all 
stages of fi brosis, are needed.
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HCV RECURRENCE ON PROTOCOL LIVER BIOPSIES 1261 
AFTER LIVER TRANSPLANTATION
P. Burra1, E. De Martin1, M. Senzolo1, M. Guido2, A. Masier1, C. Ferronato1, 
M. Gambato1, G. Germani1, G. Zanus1, U. Cillo1
1Department of Surgical and Gastroenterological Sciences, 2Institute of Pathology
Background: Histological HCV recurrence is accelerated following LT with 
the development of cirrhosis up to 30% after 5 years.
Aim: To evaluate the progression of fi brosis on protocol liver biopsies in 
patients transplanted for HCV cirrhosis.
Methods: Patients transplanted (1999-2005) for HCV cirrhosis who underwent 
protocol liver biopsies consecutively performed at our Gastroenterology Unit 
at 6, 12, 24 and 36 months after LT were included. Histological stage of fi brosis 
(S) was evaluated according to Scheuer (score 0-4). The fi brosis progression 
TU
ES
D
AY
 
Tuesday 12 August 2008 Poster Abstracts
4 2 8 Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
rate (FPR) was expressed as fi brosis unit per month (FU/mo) and compared 
over 3 periods (6-12; 12-24; 24-36 months after LT).
Results: 38 patients underwent 4 serial liver biopsies following LT, follow-up 
24-95 months. Overall, at 6, 12, 24 and 36 months after LT, S 3 or 4 was seen 
in 0%, 5.3%, 10.5% and 15.8% of patients (p=0.05, 6 vs 36 months), S (mean 
value) was 1.18, 1.18, 1.59, 1.83 (p= 0.009, 6 vs 36 months) respectively; FPR 
was 0.01, 0.04 and 0.02 FU/mo, respectively. 28/38 (74%) of patients were on 
tacrolimus and 10 (26%) on cyclosporine. Low dose of steroids were given to 
21/38 (55%) patients. (14 at month 1, 2 at month 3 and 4 at month 6 after LT). 
1 patient was treated with boluses of steroids for acute rejection following 1 
month after LT. The progression of fi brosis at 36 months after LT was similar 
in patients taking or not steroids. 8/38 (21%) underwent antiviral therapy, at 6, 
12, 24 and 36 months after LT, S 3 or 4 was 0%, 12.5%, 25%, 50% of treated 
patients and 0%, 3.3%, 6.6%, 6.6% of non-treated patients (p=0.002 at 36 mo), 
S was 1.37, 1.62, 2.12, 2.75 in treated patients (p=0.04) and 1.13, 0.98, 1.45, 
1.58 in non treated patients (p=0.003).
Conclusion: The progression of fi brosis due to HCV recurrence following LT 
is overall accelerated between the 1st and 2nd year compared to the early or 
later period after LT. Low dose of steroids does not signifi cantly increase the 
fi brosis progression. A lower stage of fi brosis and a slower progression is seen 
in patients who do not need antiviral therapy.
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OUTCOME OF 100 CONSECUTIVE PATIENTS WITH 1262 
CHRONIC HEPATITIS B TRANSPLANTED IN A SINGLE 
CENTER: EFFICACY OF SHORT-TERM, LOW DOSE 
HBIG + LAMIVUDINE (LAM) IN PREVENTING DISEASE 
RECURRENCE
L. Lilly, N. Girgrah, G. Therapondos, E. Renner, I. McGilvray, P. Greig, 
M. Cattral, D. Grant, G. Levy
University Health Network
Background: The routine use of HBIG in combination with nucleos(t)ide 
therapy has dramatically reduced the incidence and mortality of recurrent 
hepatitis B virus (HBV) following liver transplantation (LT). However, the 
most effi cacious and cost-effective protocol has yet to be determined.
Aims: To describe the results of an HBIG/LAM protocol in consecutive 
patients transplanted for chronic HBV in a large transplant program.
Patients and methods: From Sept 1998 through March 2007, 100 patients 
with chronic HBV underwent LT in our center. 60 had hepatoma complicating 
their cirrhosis. Twelve had developed lamivudine resistance (LAM-R) prior to 
transplant, and were already on ‘rescue’ nucleotide therapy at the time of LT; 
of the remaining 88, all had serum HBVDNA levels <5pg/ml or <1E4copies/
ml on no treatment (20%) or on LAM monotherapy (80%). 5/88 received LAM 
only following transplant; all are alive and free of recurrence; the remaining 
83 received LAM + one year of HBIG afterwards: fi rst dose (2000IU) given 
IV during the anhepatic phase, followed by one dose daily for seven days (IV, 
then IM with normalization of INR), an IM dose weekly for three weeks, and 
then monthly x11. Anti-HBs titers were not measured. HBsAg and HBVDNA 
were measured q3m and prn for one year, and then q6m or prn thereafter. Mean 
followup is 47m.
Results: 11 patients have died, 5 <3m after transplant, and 6 beyond 3m, one of 
a stroke at 7m, two of recurrent hepatoma (9m and 22m), two of sepsis (11m and 
47m) and one of melanoma at 94m. None had recurrent HBV. 4 patients have 
developed recurrent HBV (HBsAg (+) with detectable HBVDNA), at 1, 7, 15, 
and 24m following LT. The patient with immediate recurrence had HBVDNA 
<5pg/ml 3 months prior to LT, but had a rapidly rising ALT immediately going 
into surgery, so likely had LAM-R pre transplant; the patient who recurred at 
7m had received only 1 month of HBIG treatment. All patients with recurrence 
are alive; three are currently HBVDNA negative on LAM plus nucleotide 
therapy.
Conclusions: Patients with HBV have excellent survival following LT, with no 
graft or patient losses due to recurrent HBV. A low-dose HBIG/LAM protocol 
has proved extremely effective (failure rate <5%) in preventing recurrent HBV, 
and the short course of low dose HBIG, the absence of anti-HBs monitoring, 
and the use of LAM monotherapy make it less costly and cumbersome than 
many other protocols currently in use.
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IMMUNOSUPPRESSIVE MINIMIZATION TO ACHIEVE 1263 
EFFECTIVE TREATMENT OF RECURRENT HEPATITIS C IN 
LIVER TRANSPLANTATION
W-C. Lee, C-F. Lee, T-J. Wu, H-S. Chou, K-M. Chan
Chang-Gung Medical Center, Chang-Gung University
Introduction: Hepatitis C virus (HCV)-related liver cirrhosis is a major 
indication of liver transplantation. Recurrence of hepatitis C after liver 
transplantation is universal. Post-transplant HCV recurrence accelerates liver 
fi brosis and leads to cirrhosis. How to treat recurrent HCV effectively is an 
important issue.
Materials and methods: Thirty patients, 19 males and 11 females, undergone 
liver transplantation for HCV-related liver cirrhosis from 2001 to 2007, were 
included. Recurrence of HCV was diagnosed by elevation of HCV RNA 
and liver transaminoferases. Treatment of HCV was conducted by pegylated 
interferon and ribavirin once upon HCV recurrence was diagnosed.
Results: All 30 patients were positive for anti-HCV antibody. Ten patients had 
hepatocellular carcinoma. Seventeen patients had decreased liver transplantation 
and 13 had living donor liver transplantation. When liver transplantation was 
performed, their mean age was 53.2+6.5 years and mean MELD score was 18.7+8.8 
with a range from 6 to 40. Eight patients who were negative for HCV RNA before 
transplantation did not have HCV recurrence. All other 22 patients had HCV 
recurrence and 21 patients received anti-HCV treatment. The immunosuppressive 
regimen consisted with tacrolimus, MMF and steroid. Tacrolimus were minimized 
to keep trough blood tacrolimus level within 5 ng/ml. The dosage of MMF was only 
250mg twice a day. Steroid was discontinued within 3 months. HCV recurrence 
was treated by pegylated interferon every other week and ribavirin, 200-400 mg/
day. Nineteen patients (86.4%) were treated for HCV recurrence with 2 months 
after liver transplantation. The mean duration for pegylated interferon treatment 
was 9.6+4.4months. Till now, the end-of-treatment viral response rate was 66.7% 
(14/21) and sustained viral response (SVR) rate was 61.1% (11/18). Ten of the 14 
patients who had viral response had acute rejection during or end of HCV treatment. 
All acute rejection was treated by pulsed and recycling steroid successfully.
Conclusion: The SVR in this study is comparable to the treatment results 
of no-transplant patients. Minimization of immunosuppression and reducing 
dosage of pegylated interferon and ribavirin to prevent treatment withdrawn 
can achieve a high SVR.
POSTER BOARD NUMBER P2 – 63
PEGYLATED INTERFERON AND RIBAVIRIN: 1264 
INTERFERON FOR HCV INFECTION IN KIDNEY 
TRANSPLANTATION REVISITED
Y. Yamauchi1, N. Fujii1, A. Okuno1, N. Yoshimura2, S. Takahara3, 
Y. Ichikawa1, T. Akiyama4
1Hyogo Prefectural Hospital, Nishinomiya, 3Osaka University Hospital
Background: Although newer immunosuppressant therapies have led to 
longer survival for kidney transplant recipients, liver disease caused by chronic 
hepatitis C virus (HCV) infection has become more prevalent. Clinical trials of 
interferon have been conducted, however, it failed to achieve a suffi cient anti-
viral effect and also caused graft dysfunction.
Objectives: The aim of the present study was to elucidate the effi cacy and 
tolerance of low-dose pegylated interferon and ribavirin in long-term kidney 
transplant recipients with chronic HCV infection.
Methods: This was a single-center longitudinal interventional study. The 
subjects were outpatients enrolled in the kidney transplant center of Hyogo 
Prefectural Hospital Nishinomiya, Japan, with stable graft function and an 
estimated glomerular fi ltration rate (eGFR) of 30 ml/min/1.73 m2 or greater. 
A liver biopsy was performed in all cases, followed by low-dose pegylated 
interferon and ribavirin combinational therapy. Pegylated interferon-alpha 2b 
was administered subcutaneously at a dose of 0.25 μ;g/kg/week for the fi rst 4 
weeks, then dosed up to 0.5 μ;g/kg/week. Ribavirin was started at 200 mg/day 
with dose titration to achieve an optimal serum concentration of 2000-3000 ng/
ml, which was measured at weeks 1, 2, 4, and 8. Complete blood counts and 
blood chemistry tests were performed at every visit. HCV-RNA was measured 
every 4 weeks until week 12 and every 12 weeks thereafter.
Results: At the end of February 2008, we enrolled ten subjects (6 males, 4 females; 
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mean age 61.4 } 9.3 years) with a mean eGFR of 52.1 } 23.3 ml/min/1.73 m2. The 
post-transplant period was 19.9 } 9.7 years. Although half of the subjects showed 
normal ALT values, all had biopsy-proven hepatitis. Median baseline serum HCV-
RNA was 1700 KIU/ml [interquartile range, 830-4400 KIU/ml]. Eight subjects 
had HCV genotype 1b and the other two had 2a. On week 12, ALT returned to 
a normal level in all except for one case and four subjects (genotype 1b/2a = 
2/2) showed a remarkable decrease in HCV-RNA in the order of two digits for 
a median value at week 12 of 7.0 KIU/ml [1.5-640 KIU/ml]. In contrast, three 
(38%) subjects with genotype 1b did not show a signifi cant decrease in HCV-
RNA. The concentration of ribavirin only reached 1469 } 765 ng/ml, because of 
its adverse effect of hemolytic anemia. Graft function was preserved in all subjects 
throughout the fi rst 3 months (week 12 eGFR, 55.7 } 17.0 ml/min/1.73 m2).
Conclusions: Low-dose pegylated interferon and ribavirin given to kidney 
transplant patients with HCV infection was effective and tolerable, especially 
for those with genotype 2a. A long-term evaluation should be conducted and a 
more effective regimen for HCV genotype 1b is needed.
LIVING DONOR LIVER CONCURRENT ORAL SESSION 93: 
TRANSPLANTATION
POSTER BOARD NUMBER P2 – 64
PREVENT SMALL-FOR-SIZE SYNDROME USING DUAL 1265 
GRAFTS IN LIVING DONOR LIVER TRANSPLANTATION
L. Yan, Z. Chen, B. Li, Y. Zeng, T. Wen, J. Zhao, W. Wang, M. Xu
Division of Liver Transplantation, West China Hospital, West China Medical 
School
Background: The growing gap between the number of patients waiting 
for transplantation and available organs is still the main issue facing the 
transplant community. The major limitation of adult-to-adult living donor liver 
transplantation (LDLT) is the small-for-size problem because of the concern of 
donor safety. We report preliminary experiences for preventing small-for-size 
syndrome using dual grafts from one right lobe without the middle hepatic vein 
and one left lateral segment in adult-to-adult LDLT.
Methods: 110 cases of adult-to-adult LDLT were performed in West China Hospital 
of Sichuan University from Jan 2002 to Aug 2007, and there were sixteen small-
for-size (SFS) grafts in all grafts. Dual grafts LDLT was performed for six patients 
with end-stage liver disease, consisting of 5 cases from one right lobe without the 
middle hepatic vein and one left lateral segment, and one case from two left lobes.
Results: All living donors underwent a full recovery from the operation without 
persistent complications. Four recipients died of multiple organ dysfunction 
syndrome (MODS) induced by sepsis and one recipient was performed re-
transplantation owing to hepatic failure and three recipients were performed 
selective and transplenic artery embolization or splenic artery ligature for 
small-for-size syndrome in the recipients with SFS grafts. All recipients with 
dual grafts displayed good graft function and a majority of grafts showed 
normal triangularshape regeneration of their respective liver grafts. Only one 
left lateral segment occur atrophy, graft hepatectomy didn’t be required.
Conclusion: Dual grafts from one right lobe without the middle hepatic vein 
and one left lateral segment in adult-to-adult LDLT can prevent the small-for-
size problem and yet secure the safety of the donors.
POSTER BOARD NUMBER P2 – 65
EVALUATION OF 368 LIVING RELATED LIVER 1266 
DONORS: SINGLE CENTER EXPERIENCE
N. Allam1, M. Al-Sofayan2, A. Helmy3, H. Al-manna4, M. Faguih4, 
M. Neimatallah5, Y. Al-quaddy5, Y. Medhat2, A. Abdo2, M. Sebayel2
1Hepatology,National Liver Institute, Egypt, 2Liver Transplantation, King 
Faisal Institute and Research center, 3Gastroenterology, King Faisal Institute 
and Research center, 4Pathology,King Faisal Institute and Research center, 
5Radiology,King Faisal Institute and Research center
Background and aims: Organ shortage has been the ongoing obstacle to 
expand liver transplantation world-wide including Saudi Arabia. Living donor 
liver transplantation (LDLT) was hoped to improve this shortage. The aim of 
the present study was to analyse the results of the evaluation for a large pool of 
potential living donors at our center.
Methods: From April 2001 to June 2007, a total of 44 living donors liver 
transplantation were performed at our institution (37 patients had a right lobe, 
1 had a left lobe and 6 had left lateral grafts). 368 potential donors were worked 
up according to a step-wise evaluation protocol. Their age ranged from 18 to 60 
years, with 75% in the third and forth decades. Female: male ratio was 77: 291. 
They were all fi rst and second degree relatives of the patients.
Results: Only 44 (11%) were accepted for donation and 324 (89%) were 
rejected. 37% were excluded either at initial screening due to high body 
mass index (15%), or in the fi rst step of evaluation due to incompatible blood 
group (3%), positive hepatitis serology (7%),elevated liver enzymes (12%). 
6% were rejected due to miscellaneous systemic diseases. In 13% of cases, 
the evaluation was aborted due to recipient conditions and in 5% because of 
socioeconomic reasons. 20% were rejected because of abnormal anatomy 
and 5% due to insuffi cient volume as determined by CT volumetry. In 14%, 
abnormal histopathology primarily abnormal fat content was the reason for 
rejection. Liver density was estimated by CT imaging before liver biopsy and 
the results were in agreement with the fi nding of steatosis (ƒÛ agreement=29.2, 
p=0.001).
Conclusion: There is no doubt that LDLT has helped in alleviating the severe 
shortage of cadaveric organs in Saudi Arabia. However suitable living donors are 
not easy to fi nd especially right lobe donors. Our initial evaluation is effective in 
eliminating a large number of unsuitable donors. However, the donor evaluation 
process indeed remains to be a large burden on the resources of our program. 
Estimation of liver density by CT is useful since marked hypodensity would 
imply signifi cant steatosis and hence avoid unnecessary biopsy.
POSTER BOARD NUMBER P2 – 66
THE IMPACT OF THE PRIMARY LIVER DISEASE 1267 
ON THE EARLY OUTCOME OF LIVING RELATED LIVER 
TRANSPLANTATION: A STARTING PROGRAM
E. Hammad1, I. Marwan1, E. Soliman1, H. Konsowa2, T. Yassin1
1Surgery Department, National Liver Institute, Menoufi ya University, Egypt, 
2Paediatric Department, National Liver Institute, Menoufi ya University, Egypt
Background and aim: Living related liver transplantation (LRLT) has gained 
wide acceptance in Egypt where cadaveric transplantation is not yet allowed.
Many factors have been noted to impact the outcome of liver transplantation.
Age, sex, underlying liver disease, hepatitis viral infection, immunosuppressive 
regimen, coagulopathy and metabolic derangements can infl uence the outcome of 
liver transplantation.The aim of this work is to study the effect of the primary liver 
disease on the early outcome of the patients who underwent LRLT in the National 
Liver Institute, Menoufi ya University during the early phase of the program.
Patients and methods:This study included 20 cases of LRLT (14 children 
and 6 adults).They were HCV cirrhosis(6), biliary atresia(5), Budd Chiari 
syndrome(3), Byler disease(2), congenital hepatic fi brosis(2), hepatoblastoma(1) 
and HCC(1) patients.The demographic data,the operative details,the early 
postoperative course and regimen of immunosuppressant and the incidence of 
complications were documented.
Conclusion: The results of transplantation were better in the paediatric 
age group.The state of the portal hypertension should be considered for the 
optimum GRWR.For successful outcome selection of the donor and recipient 
should consider the socioeconomic and cultural status of the parties involved.
POSTER BOARD NUMBER P2 – 67
PRESENT STATUS AND PROSPECTS OF LIVING DONOR 1268 
LIVER TRANSPLANTATION (LDLT) IN EGYPT
H. Abdeldayem1, M. Bahaa2, N. Alam1, E. Salah1, A. Helmy1
1National Liver Institute, 2Ain Shams University
Background: In Egypt, because cadaveric liver transplantation is not allowed 
by law and hampered by religious beliefs and cultural traditions, liver 
transplantation is restricted to LDLT.
Objective: To evaluate the results of LDLT programs in Egypt and to study 
the prospects in the setting of high prevalence of HCV infection in the general 
population.
Methods: Reports from four major centers of liver transplantation in Egypt 
were reviewed during the period from August 2002 to February 2007.
Results: A total number of 326 LDLT cases were performed. While adult cases 
were 285, pediatric cases were 41. In the adult group, the main indication was 
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hepatitis C related cirrhosis (88%), other indications included: hepatocellular 
carcinoma (4%), hepatitis B related cirrhosis (3%), Budd Chiari Syndrome 
(3%), primary sclerosing cholangitis (1%) and hemochromatosis (1%). In the 
pediatric age group: congenital biliray atresia represented the main indication 
(87.5%), other indications included: hepatoblastoma (5%), Bylar disease (5%) 
and congenital hepatic fi brosis (2.5%). There were two reported donor mortality 
(0.6%). Relaparotomy was mandatory in 6 donors. The overall recipient 
survival was 68.8%. While biliary complications occurred in 95 recipients 
(29.1%), vascular complications occurred in 33 cases (10.1%).
Conclusion: LDLT in Egypt is associated with reasonable outcomes; yet, it 
carries considerable risks of mortality and morbidity to healthy donors, it lacks 
cadaveric back up, and associated with other diffi culties including fi nancial 
coverage, availability of suitable donors and technical diffi culties in some 
cases. We hope that efforts to legalize cadaveric organ donation in Egypt will 
succeed in the near future
POSTER BOARD NUMBER P2 – 68
BILIARY RECONSTRUCTION AND COMPLICATIONS 1269 
AFTER LIVING-DONOR LIVER TRANSPLANTATION
R. Saidi, P. Kennealey, N. Elias, D. Ko, T. Kawai, H. Yeh, J. Markmann, 
A.B. Cosimi, M. Hertl
Massachusetts General Hospital, Harvard Medical School
Background: The technique of biliary reconstruction is remains controversial 
in living-donor liver transplantation (LDLT). The objective of this review was 
to assess the incidence of biliary complications after LDLT .
Methods: Thirty patients underwent LDLT between 1997 and 2007. The type 
of allograft was the right lobe in 14, left lobe in 4, and left lateral sector in 12 
patients. There were 18 adults and 12 pediatric recipients. The mean follow-
up was 48 months (range 6-120 months). Biliary complications were initially 
treated by endoscopic and/or radiological modalities.
Results: Biliary reconstruction was achieved with Roux-en-Y 
choledochojejunostomy in 17 patients (Group I), and choledochocholedochostomy 
in 13 patients (Group II). A external biliary stent was placed in all patients 
(expect one) in Group I and reconstruction over a T-tube was done in 6/13 of 
patients in Group II. Twenty fi ve (83.3%) patients had one biliary anastomosis 
and the remaining 5 (16.7%) had multiple anastomoses (one in Group I and 
four in Group II).
The overall incidence of biliary complications was 30%.; 29.4% in Group I and 
30.8% in Group II. The incidence of biliary leakage was 23.5% for Roux-en-Y, 
and 15.4% for Group II (p>0.05). However, the incidence of biliary stricture 
was signifi cantly higher in Group II (15.4%) compared to Group I (5.9%) (p< 
0.01). In Group II, biliary complications occurred equally in patients with and 
without T-tube stenting. Overall, 93.3% of the strictures were managed with 
endoscopic treatment alone. One patient in each group needed revision of the 
biliary anastomosis.
Comparison between two biliary reconstruction methods
Biliary Anastomosis Bilary stent/t-Tube
Biliary 
Complications
Biliary 
Leak
Biliary 
Stricture
Need 
anastomotic 
revision
Roux-en-Y 
choledocho-jejunostomy 
(n=17)
94.1% 
(n=16)
29.4% 
(n=5)
23.5% 
(n=4)
5.9%
(n=1)
5.9% 
(n=1)
duct-to-duct 
choledochocholedochostomy 
(n=13)
46.2% 
(n=7)
30.8% 
(n=4)
15.4% 
(n=2)
15.4% * 
(n=2)
7.7% 
(n=1)
* p<0.01
Conclusions: Although there was a higher rate of biliary stricture in the 
choledochocholedochostomy group, we feel that because of physiologic 
bilioenteric continuity, comparable incidence of leakage, and easy endoscopic 
access, duct-to-duct reconstruction represents a feasible technique in LDLT. 
The endoscopic approach has been shown to be a fi rst-line therapy for the 
management of biliary complications after LDLT. Placement of T-tubes did not 
appear to be benefi cial.
POSTER BOARD NUMBER P2 – 69
POSTOPERATIVE COMPLICATIONS IN LIVE LIVER 1270 
DONORS AFTER PARTIAL HEPATECTOMY FOR LIVER 
TRANSPLANTATION
R. Saidi, P. Kennealey, N. Elias, D. Ko, T. Kawai, H. Yeh, J. Markmann, 
A.B. Cosimi, M. Hertl
Massachusetts General Hospital, Harvard Medical School
Introduction: Donor safety is the fi rst priority in living donor liver 
transplantation (LDLT). We evaluated the postoperative morbidity after partial 
hepatectomy for LDLT in our unit.
Method: Thirty patients underwent LDLT between 1997 and 2007 at our 
institution. This represented approximately 8% of the total liver transplant 
experience during that period.
The type of graft was the right lobe (segments 5-8) in 14, left lobe (segments 
1-4) in 4, and left lateral sector (segments 2 and 3) in 12 patients. There were 18 
adults and 12 pediatric recipients. Mean donor age was 36 years (26-57).
The mean follow-up was 48 months (range 6-120 months). Complications were 
classifi ed according to Clavien’s system: grade I, deviation from the normal 
postoperative course but without the need for therapy; grade II, complication 
requiring pharmacologic treatment; grade III, complication with the need for 
surgical, endoscopic or radiological intervention (IIIa/b: without/with the 
need for general anesthesia); grade IV, life-threatening complication requiring 
intensive care; grade V, death.
Results: No deaths occurred. Overall 8 (26.6%) patients experienced a total of 
14 postoperative complications. Mean length of hospitalization was 7.5 days 
(5-12 days).
Donor complications based on graft type were as follows: left lateral sector 
(16.7%), left lobe (25%), and right lobe (35.7%). Type of and grade of 
complications are summarized in the Table below.
The experience was divided into two periods 1997-2001 (15 patients) and 
2002-2007 (15 patients). Overall complications during 2 periods were 40% 
and 13.3%, respectively (p<0.001). The incidence of grade III complication 
also decreased signifi cantly, 63.6% vs 33.3 (p<0.01).
Grade of Complications: 
n(%)
Complications (1997-2001)
(n)
Complications (2002-2007)
I: 4 (28.6%) atelectasis (2), 
superfi cial phlebitis (1)
a
II: 1 (7.1%) Ileus (1) 0
IIIa: 7 (50%) Biloma (3), 
perihepatic fl uid collection (1), 
pleural effusion (1), 
GI bleeding (1) 
peripancreatic fl uid collection (1)
IIIb: 2 (14.3%) wound dehiscence (1) ventral hernia (1)
IV: 0 0 0
V: 0 0 0
Conclusion: Partial hepatectomy in living donors has a learning curve which 
appears to approximate is about 15 cases. This learning curve is not restricted 
to the surgeons performing the procedure but involves all areas of peri- and 
postoperative patient care. Our experience emphasizes that LDLT can be safely 
provided by active liver transplant programs performing only modest number 
of LDLT.
POSTER BOARD NUMBER P2 – 70
MULTIPLE BILE DUCT ANASTOMOSES WITHOUT 1271 
STENT IN LIVING-DONOR LIVER TRANSPLANT
M. Haberal1, G. Moray1, S. Sevmis1, H. Karakayali1, A. Torgay2, G. Arslan2
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Anesthesiology
It is unclear whether presence of multiple bile ducts in the graft increases the 
risk of biliary complications after living-donor liver transplant (LDLT). In this 
study we analyzed multiple bile duct anastomoses in LDLT. Since 2006, we 
did not any drainage catheter for bile duct reconstruction, and after that time 57 
LDLT were performed at our center. Eighteen (31.5%) of these 57 recipient’s 
graft had multiple bile ducts, which were analyzed retrospectively. There were 
12 male, 6 female, with mean age 30.9&#61617;22 years (range, 8 months to 54 
years). Biliary reconstruction was performed with a duct-to-duct anastomosis in 
13 recipients and with a Roux-en-Y hepaticojejunostomy in 5. Fourteen of the 
18 grafts had 2 bile ducts, 3 had 3 bile ducts, and 1 had 4 bile ducts. In 4 grafts 
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with 2 bile ducts, 2 separate anastomoses were performed. In the remaining 
10 grafts with 2 bile ducts, we create a single orifi ce at the back-table. In two 
grafts with 3 bile ducts, 2 neighboring ducts were sutured together, other bile 
duct anastomosed separately. In remaining graft with three bile ducts, 3 bile 
ducts were sutured together. In last graft with 4 bile ducts, 2 neighboring ducts 
were sutured together, remaining 2 bile ducts were anastomosed separately. 
Two biliary leakages and 1 billiary stenosis occurred in this series, which were 
treated with interventional radiological approach, successfully. In the mean 
follow-up 7.3&#61617; 4.1 months(range, 1 to 15 months), 1 patient died 3 
months after liver transplant due to pulmonary emboli, remaining 17 patients 
(94.4%) are alive with normal liver functioning. In conclusion, although our 
follow-up period was short, the presences of more than one bile duct in the 
graft do not appear to increase billiary complications after liver transplant in 
our series.
POSTER BOARD NUMBER P2 – 71
POSTSURGICAL COMPLICATIONS IN LIVING-1272 
RELATED LIVER DONORS
H. Karakayali1, S. Sevmis1, F. Boyvat2, Y. Ekici1, R. Shahmazov1, 
S. Pehlivan1, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Radiology
The crucial prerequisite to performing living-donor liver transplantation 
procedure is a minimal morbidity and mortality risk to the healthy living donor. 
In this study, we evaluate living related liver donor.
From September 2001 to January 2008, we performed 168 living-donor liver 
transplantations in our transplantation center. For each patient, we collected 
data from charts, and the Ba&#351;kent University Liver Registry and found 
the following: of 168 donors, 99 were male and 69 were female, with a mean 
donor age of 35.2 &#61617; 9.3 years (range, 20-56 years); 125 (74.2%) were 
fi rst-degree relatives, 29 (17.3%) were second-degree relatives, and 14 (8.3%) 
were spouses. We performed 28 (16.74%) left hepatic lobectomies, 62 (37.13%) 
left lateral segmentectomies, and 78 (46.1%) right hepatic lobectomies. The 
mean percentages of remnant liver to the donor’s total liver volume for right 
and left lobectomies were 41.7% and 67.8%. The mean length of patients’ 
postoperative hospital stay was 7.4 &#61617; 3.1 days (range, 3-16 days). There 
was no postoperative mortality. Eleven complications (6.5%) occurred in 8 of 
the 168 donors (4.7%); these were biliary leak (n = 3), biliary stenosis (n = 1), 
wound infection (n = 2), incisional hernia (n = 1), portal vein thrombosis (n = 
1), pulmonary thromboembolism (n = 1), deep venous thrombosis (n = 1), and 
intraabdominal collection (n=1). For the donor with portal vein thrombosis, the 
vein was recanalized, and the patient recovered without treatment. This same 
donor also developed a bile leak from the cut liver surface and an incisional hernia. 
Most complications were treated with radiologic interventions. In conclusion, 
donor safety should be the primary focus in living-donor liver transplantation. 
More experience, improved surgical techniques, and meticulous donor evaluation 
will help minimize morbidity and mortality for living liver donors.
POSTER BOARD NUMBER P2 – 72
COMPARISON OF SCINTIGRAPHIC FINDINGS 1273 
OF LEFT LOBE GRAFTS TO RIGHT LOBE GRAFTS 
IN LIVING-DONOR LIVER TRANSPLANTATION
A. Gencoglu1, S. Sevmis2, A. Aktas1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Nuclear Medicine, 
2Baskent University Faculty of Medicine, Department of General Surgery
Aim: The aim of this study was to compare the perfusion and function of left 
liver lobe grafts to right liver lobe grafts using hepatobiliary scintigraphy during 
the early postoperative period in patients receiving liver transplants from the 
living-related donors.
Material and methods: Fifty-one liver transplant recipients were 
investigated. Twenty-four patients (10 men, 14 women) received left/
extended left lobe grafts, and 27 patients (23 men, 4 women) received right 
lobe grafts from living-related donors. A graft-to-recipient weight ratio was 
calculated for each patient. In all recipients, hepatobiliary scintigraphy was 
done 7 to 10 days after the transplantation. The hepatobiliary scintigraphy 
was performed after an intravenous injection of 1.85 MBq/kg Tc-99m 
mebrofenin. A large-fi eld-of-view dual-head gamma camera with a low-
energy all-purpose collimator was used for image acquisition. To test graft 
perfusion, data were recorded every second for 1 minute. To evaluate the 
parenchymal function, data were recorded every 30 seconds for 40 minutes 
in a 64×64 matrix. Perfusion, hepatocyte uptake and excretion of liver grafts 
were evaluated visually.
Results: The mean graft-to-recipient weight ratio was 1.63%±0.57% in 
recipients who received the left lobe grafts. This value was 1.29%±0.27% in 
the right lobe graft recipients. There was no statistically signifi cant difference 
between the 2 groups in terms of graft-to-recipient weight ratio(p>0.05). On 
hepatobiliary scintigraphies, normal scintigraphic parameters were found 
in 25 of 27 right lobe graft recipients during the early postoperative period. 
However, in this group, 2 of 27 grafts showed diminished perfusion and 
function. In 19 of 24 left liver lobe graft recipients, the results of hepatobiliary 
scintigraphies were completely normal. In 3 of 24 recipients in this group, 
scintigraphy demonstrated a hypoactive area in the liver grafts due to minor 
vascular problems; however, the other areas of the grafts had normal perfusion 
and function. Similar to the right lobe grafts, the 2 left lobe grafts showed 
abnormal perfusion and function on scintigraphy.
Conclusion: In the light of these scintigraphic fi ndings, we conclude that 
although they may have some minor vascular problems, left liver lobe grafts 
have perfusion and function as good as right lobe grafts during the early 
postoperative period in living-donor liver transplant recipients who have 
suffi cient graft-to-recipient weight ratios.
POSTER BOARD NUMBER P2 – 73
SCINTIGRAPHIC COMPARISON OF CADAVERIC 1274 
LIVER GRAFTS AND LIVER GRAFTS FROM 
LIVING-RELATED DONORS
A. Gencoglu1, S. Sevmis2, A. Aktas1, H. Karakayali2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Nuclear Medicine, 
2Baskent University Faculty of Medicine, Department of General Surgery
Aim: The aim of this study was to compare the scintigraphic fi ndings of 
liver grafts during the early postoperative period in patients who received 
grafts from living-related donors versus in patients who received grafts from 
cadaveric donors.
Material and method: Thirty-fi ve liver transplant recipients were included 
in the study. Fifteen patients (6 women, 9 men; mean age: 43±18.07years; 
mean cold ischemic time: 5.88±0.86 hours) received liver grafts from 
the cadaveric donors. Twenty recipients (6 women, 14 men; mean age: 
30.35±20.15 years) received grafts from the living-related donors. A 
hepatobiliary scintigraphy was done in all recipients 7 to 10 days after the 
transplantation. The hepatobiliary scintigraphy was performed after the 
intravenous injection of 1.85 MBq/kg Tc-99m mebrofenin. A large-fi eld-of-
view dual-head gamma camera with a low-energy all-purpose collimator 
was used to acquire the images. To test graft perfusion, data were recorded 
every second for 1 minute and to evaluate the parenchymal function, data 
were recorded every 30 seconds for 40 minutes in a 64×64 matrix. Perfusion, 
hepatocyte uptake and excretion of the grafts were evaluated visually. A 
graft liver biopsy was carried out in patients with abnormal scintigraphic 
fi ndings.
Results: Hepatobiliary scintigraphies during the early postoperative period 
showed normal perfusion and function in 14 of 15 grafts (93.33%) from 
cadaveric donors. However, 1 out of 15 grafts had diminished perfusion 
and function. In that graft, a liver biopsy demonstrated hepatocyte damage/
cholestasis. During the early postoperative period, 18 of 20 grafts (90%) 
from living-related donors had normal results on scintigraphy. However, 2 
of 20 grafts in this group showed diminished perfusion and function due to 
hepatocyte damage/cholestasis.
Conclusion: These scintigraphic fi ndings indicate that perfusion and function 
during the early postoperative period in liver grafts from cadaveric donors are 
as good as those in grafts from living-related donors.
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THE IMPACT OF 1275 ٱGALL-IN-ONEٱH MDCT 
FACILITATING 3D VIRTUAL VENOGRAPHY AND 
CHOLANGIOSCOPY ON LIVING DONOR LIVER 
TRANSPLANTATION
J. Yamanaka, S. Saito, T. Sugimoto, Y. Iimuro, N. Kuroda, T. Hirano, 
T. Okada, Y. Asano, N. Uyama, J. Fujimoto
Hyogo College of Medicine
Background/aim: In living donor liver transplantation (LDLT), accurate 
assessments of liver graft volume and anatomical variation are mandatory 
for preoperative planning of safe donor hepatectomy and successful recipient 
implantation. Conventional planimetry has been used to estimate the resected and 
residual liver volumes, although considerable volumetric error has been observed. 
In addition, the volumetric evaluation of hepatic venous drainage is essential to 
avoid liver graft and donor residual liver congestion. We previously reported the 
effi cacy of virtual hepatic resection using three-dimensional (3D) image analysis 
software based on hepatic circulation (Hepatology 2005;41:1297-1304). The aim 
of this study was to evaluate the impact of multidetecter CT (MDCT) scan based 
simulation on the preoperative planning of living donor liver transplantation, with 
special reference to hepatic venous drainage and variation in biliary anatomy.
Methods: Between May 2001 and December 2007, 161 individuals, including 6 
living donors, underwent preoperative hepatectomy simulation. The simulation 
software (Hitachi Image Processing System, Version 0.7a), which was developed 
by the Department of Radiology, Hyogo College of Medicine (Nishinomiya, 
Japan) and Hitachi Medical Corporation. The software was programmed to 
reconstruct functional 3D anatomy and to calculate liver graft volume based 
on portal perfusion. Briefl y, 3D images of the portal vein, hepatic vein, hepatic 
artery, bile duct, and liver parenchyma were reconstructed by a region-growing 
technique and were overlapped to create the integrated 3D images. Clipping of 
the proposed portal branch prompted volumetric calculation of the corresponding 
liver graft volume. The predicted graft volume was compared with the actual 
weight. Moreover, we applied our simulation algorithm to the hepatic venous 
system for volumetric estimation of the hepatic vein branch drainage area. 
Virtual cholangioscopy was also used to estimate hilar bile duct anatomy.
Results: Of the 161 patients enrolled in the study, 151 (94%) had complete 
simulation data and received liver resections subsequently. Poor quality 
images were obtained in 10 patients with dyspnea and could not be used for 
the simulation. Simulation revealed a signifi cant correlation (r=0.96; p<.001) 
between the predicted and actual liver resection volumes, with mean discrepancy 
of 9.3 „bƒn6.0 mL. The drainage area by the inferior right hepatic vein and 
middle hepatic vein tributaries was quantifi ed to achieve reconstruction of the 
corresponding venous branch. The application of virtual cholangioscopy allowed 
detailed visualization of 3D biliary anatomy and facilitated intraoperative 
dissection in case with variant right posterior duct arising from left hepatic duct.
Conclusions: Hepatectomy simulation system in 3D allowed for volumetric 
estimation of liver graft and hepatic venous drainage area. Virtual cholangioscopy 
was also useful for detailed evaluation of biliary anatomy. This virtual method 
may contribute to the preoperative planning of safe donor hepatectomy and 
successful graft implantation based on the functional anatomy.
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THREE RIGHT HEPATIC VEINS RECONSTRUCTION 1276 
USING CADAVERIC ILIAC VEIN IN RIGHT LOBE 
LIVING-DONOR LIVER TRANSPLANTATION
S.C. Park, Y.S. Won, I.S. Moon, D.G. Kim, M.D. Lee, E.K. Kim
The Catholic University of Korea, Kangnam St. Mary’s Hospital
In case of various right hepatic vein anatomy, the hepatic vein reconstruction is 
one of the surgically challenging techniques. The right inferior hepatic vein is 
the most common hepatic vein abnormality during right lobe living donor liver 
transplantation. But, the three accessory right hepatic veins is a rare case of 
abnormal right hepatic veins. We had experienced 1 case of unusual right hepatic 
vein reconstruction in 247 partial liver transplantations using right lobe in our center. 
Here, we report our surgical case. The donor’s right lobe has one main right hepatic 
vein and three accessory hepatic veins at lower liver border, so the restoration of 
three accessory hepatic veins to inferior vena cava was made after forming one 
conduit from the three accessory hepatic veins using cadaveric iliac vein
POSTER BOARD NUMBER P2 – 76
VARIOUS PORTAL VEIN RECONSTRUCTIONS IN RIGHT 1277 
LOBE LIVING-DONOR LIVER TRANSPLANTATION IN ADULT
S.C. Park, I.S. Moon, D.G. Kim, M.D. Lee
The Catholic University of Korea, Kangnam St. Mary’s Hospital
The anatomical variations of the portal vein in right liver lobe for partial liver 
transplantation are common. In case of various right portal vein anatomy, the 
technical modifi cations for various portal vein are necessary and one of the 
surgically challenging techniques. We had experienced unusual portal vein 
reconstructions in 247 partial liver transplantations using right lobe in our 
center since Jan. 2000 to May 2006.The portal vein anatomy of right liver lobe 
during donor operation were examined. The portal vein anatomy of the right 
lobe graft is variable and can be changed by donor surgery, e.g. according to cut 
margin of the right lobe graft. 34 cases of 18 cases of interposition graft. The 
surgical techniques for portal vein reconstructions were analysed according to 
it’s anatomy. The portal vein anatomy was defi ned as proposal of Dr. Chen. The 
graft portal vein anatomy (type 1) was 213 (86.2%) and type 2 in 18(7.3%), 
type 3 in 14(5.7%) and type 4 in 2(0.8%). Most of type 1 portal vein was 
reconstructed with end to end direct anastomosis between portal veins. In 6 
cases of poor infl ow from recipient portal vein because of portal vein stenosis 
and/or thrombosis, jump graft using cadaveric iliac vein or autogenous iliac 
vein from superior mesenteric vein or coronary vein were used. In the 18 type 2 
portal vein anatomy cases, the venoplasty to make common ostium on the graft 
surface was made for end-to end anstomosis. 14 cases of type 3 portal vein 
anatomy, 13 ¡°Y-shaped autogenous portal vein graft¡± was made on the graft 
for end to end anastopmosis. In 1 case of type 3 and 2 cases of type 4 portal vein 
anatomy, separate portal vein anastomosis was performed. The interposition 
graft using autogenous rt. external iliac vein in one case. The four cases of 
cryopreserved cadaveric iliac vein interposition from coronary vein, superior 
mesenteric vein in portal vein thrombosis patients.
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A COMPARATIVE STUDY ON THE PEDICTABILITY 1278 
OF CT VOLUMETRY IN LIVING DONOR LIVER 
TRANSPLANTATION
D.H. Jung, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, T.Y. Ha, 
G.W. Song, E.J. Lee, E.S. Yang
Department of Surgery, Division of Hepatobiliary Surgery and Liver 
Transplantation, University of Ulsan College of Medicine and Asan 
Medical Center
Backgrounds: Accurate prediction of the functional mass of both graft and 
remnant livers is essential for proper donor selection and optimal recipient 
outcome in adult living donor liver transplantation (LDLT). The objectives of 
this study is to evaluate accuracy for determining lobar liver volumes using 
a multi-detector CT scanner in potential donors undergoing LDLT and to 
compare predictability of CT volumetry between right and left lobe.
Methods: During the period from January 2005 to December 2006, 472 donors 
who underwent hepatectomy for LDLT in our center were included this study. 
359 patients underwent right lobectomy and 113 patients underwent extended 
left lobectomy. Multi-detector CT was preoperatively performed all patients. 
The estimated volume of the grafts in two-demensional image was compared 
with actual graft weight.
Results: In right lobectomy group, preoperatively measured right lobe volume 
was 779 ± 133 mL and actual graft weight was 692 ± 107 g. There was 
signifi cant agreement between preoperatively measured right lobe volume and 
actual graft weight at surgery in right lobectomy group (r=0.838). In extended 
left lobectomy group, preoperatively measured left lobe volume was 372 ± 92 
mL and actual graft weight was 384 ± 82 g. There was signifi cant agreement 
between preoperatively measured left lobe volume and actual graft weight at 
surgery in extended left lobectomy group (r=0.841). Error ratio <=(estimated 
liver volume – actual graft weight)/actual graft weight * 100> was 12.9 ± 10.3% 
and – 2.7 ± 11.6% for right lobe graft and extended left lobe graft, respectively.
Conclusions: The relationship between the estimated CT volume and actual graft 
weight was linear. The preoperatively measured volume of right lobe is substantially 
larger than the intraoperative actual graft weight. The preoperatively measured 
volume of left lobe is smaller than the intraoperative actual graft weight.
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PATIENT CONDITION ADAPTIVE PASS SYSTEM 1279 
(PCAPS) IN MANAGEMENT OF LIVING DONOR LIVER 
TRANSPLANTATION
T. Yamada1, K. Tanaka1, K. Uryuhara2, S. Kaihara2, J.P. Raj3, T. Nakata4, 
S. Tsuru4, M. Munechika5, Y. Iizuka4
1Institute of Biomedical Research And Innovation, Transplantation Division, 
2Kobe City Medical Center General Hospital, Transplantation Division, 
3Mount Elizabeth Hospital, 4The University of Tokyo, School of Engineering, 
5Waseda University
The Patient Condition Adaptive Path System (PCAPS) is a new dynamic 
method of monitoring a patient fs clinical course during hospitalization while 
at the same time allowing and monitoring medical treatment that is being 
instituted according to the patient fs changing condition.
The PCAPS is essentially an electronic medical chart comprising, 1) a process 
chart, 2) a unit sheet, 3) a master fi le and 4) a data analyzer.
The process chart allows a complete overview or gbird fs eye view h of a 
patient receiving his treatment. It defi nes the clinical state of the patient at 
any given point of time during his stay and the effect of the treatment that is 
given at that same point of time. In effect, the process chart appears like an 
galgorithm h.
In progressing along this galgorithm h, the patient thus has to satisfy certain 
clinical criteria. This allows the patient a comprehensive overview of his 
treatment that he has been through and what he may go through should there 
be or not any complications. At the same time other medical and paraclinical 
staff have access to the process chart and can easily understand the preceding 
clinical course and subsequent plans for the patient.
The Unit Sheet component of PCAPS incorporates details of medical treatment 
and is linked to a prescription system and the patient fs medical record. Both 
the Process Chart and the Unit Sheet provide us with a visual comprehensive 
overview of the patient. By applying the PCAPS to patients in the postoperative 
course following liver transplantation, we can evaluate our knowledge and 
experience more effectively. More importantly, we can establish standards of 
clinical care in liver transplantation.
Currently, daily hospital charts evaluating the clinical status of the patient 
cannot be applied to patients requiring special care following the onset of 
complications. In contrast, any patient can be monitored with our PCAPS 
without exception. Every patient fs data is collated and can then be evaluated 
to ensure a high level of quality care.
The Data Analyzer component allows us to readily perform a cost benefi t 
analysis both in our institution as well as to benchmark ourselves against other 
institutions.
We have reviewed the clinical outcomes and perioperative courses of 150 
patients following living donor liver transplantation in Kyoto University and 
Kobe City Medical Center General Hospital. Our initial experience with PCAPS 
for liver transplant patients is that it is able to both structure and standardize the 
clinical processes very well.
We would like to present the data from PCAPS in patients with biliary 
complications following living donor liver transplantation. Currently there is 
much controversy and hence debate pertaining to biliary complications because 
of its high incidence and the fact that its cause and prevention are unknown.
In conclusion we will show that our Patient Condition Adaptive System can 
improve the quality of postoperative management of liver transplant patients 
as well as evaluate the possible causes of complications and help us take 
preventive measures.
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BILIARY RECONSTRUCTION UNDER 1280 
MIRCROSURGICAL TECHNIQUE: ANSWER TO 
THE ACHILLES’ HEEL IN LIVING DONOR LIVER 
TRANSPLANTATION?
C-L. Chen, A. Concejero, T.S. Lin, C.C. Wang, S.H. Wang, Y.W. Liu, 
C.H. Yang, C.H. Yong, Y.C. Chinag
Liver Transplant Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center
Objective: Our objective is to describe our institutional experience with 
routine biliary reconstruction using microsurgical technique in living donor 
liver transplantation.
Patients and methods: From March 22, 2006-October 3, 2007, 72 grafts 
were transplanted in 70 patients (including 2 dual graft transplants). All biliary 
reconstructions were done under microscope by a single microvascular surgeon 
who also did the hepatic artery reconstruction under microsurgical technique. 
Except for biliary atresia, duct-to-duct reconstruction was performed. Stents 
were not used. The records were analyzed retrospectively. The outcomes using 
microsurgical technique were compared with a historical cohort using the last 
71 grafts (70 patients) done by conventional method before March 2006.
Results: The indications for transplant were hepatitis B and/or C cirrhosis 
with/without hepatocellular carcinoma (48), biliary atresia (13), alcoholic 
cirrhosis (4), Wilson¡¦s disease (2), urea cycle disorder (1), glycogen storage 
disease (1), and Alagille syndrome (1). The grafts used included 54 right and 
4 left lobes, 13 left lateral and 1 extended left lateral segments. The minimum 
follow-up among surviving recipients was 4 months. There were single duct-
to-duct (37), 2-in-1 ductoplastied (9), 3-in-1 ductoplastied (1), 2-to-2 (4), and 
2-to-1 (1) anastomoses, and Roux-en-Y hepatico-jejunostomies (18). The 
average graft duct sizes were 4.4 mm for a right lobe and 3.2 mm for a left 
lobe single duct orifi ce, and 2.1 mm for multiple duct orifi ces. There was no 
relationship between occurrence of biliary complications and number of duct 
openings or liver lobe used. Most complications occurred during the fi rst 15 
cases which can be inferred as the learning curve phase. The complication rate 
in the fi rst 15 cases was 46.7%; whereas 15% in the next 20 cases, and 5.7% in 
the last 35 cases. Overall complications included 9 bile leaks and 3 strictures. 
Comparing the use of microsurgical technique with the conventional method, 
the mean graft duct opening was smaller (2.8 mm vs 3.4 mm), and the ducts 
which underwent ductoplasty reconstructions were also smaller. Considering 
the learning curve and smaller duct openings, the overall complication rate 
over time in the microsurgical group (8.9%) was signifi cantly lower than the 
conventional method (21.9%).
Conclusion: Bile duct reconstruction in small graft duct opening „T3 mm is 
technically demanding. Routine use of microsurgical biliary reconstruction is a 
technical innovation that may lead to decreased complications in the long-term.
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THE INOVATION OF HEPATIC ARTERIAL 1281 
RECONSTRUCTION IN LIVING DONOR LIVER 
TRANSPLANTATION
F. Zhang, L. Lv, X. Wang, X. Li, L. Kong, B. Sun, G. Li, F. Cheng
Liver Transplantation of The First Affi liated Hospital of Nanjing Medical 
University
Objectives: Microsurgical hepatic artery reconstruction has become an essential 
technique in living donor liver transplantation (LDLT) and helps in decreasing 
the risk of hepatic arterial thrombosis (HAT) during arterial reconstruction. 
However, microsurgical reconstruction of a hepatic artery poses signifi cant 
challenges to microsurgeons, such as vessel-size discrepancy between the 
graft and recipient hepatic arteries. We have reported herein our technique for 
hepatic artery reconstruction using a graft with tiny arteries (diameter < 1.5 
mm) to decrease the postoperation complication of hepatic artery, which is an 
obvious discrepancy from the recipient hepatic artery.
Methods: Since January 1995, 94 cases of living-donor liver transplants have 
been performed in our center. In this report, we retrospectively analyzed 9 cases 
using grafts with tiny arteries. Donor artery branch to create a patch or straight 
to reconstruction in LDLT was performed to increase infl ow since 2002.
Results: All donors were discharged without any vascular complications. One 
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donor experienced bile leakage from the dissection plane of the liver, which was 
treated by draining the abdominal cavity. Two patients with branch and seven 
with branch patch anastomosis survived without evidence of HAT during 32 
months (ranging from 11 to 72 months) of follow-up. One recipient died due to 
a cytomegalovirus infection 11 months following LDLT. Both techniques were 
successfully rescued by reanastomosing the HA. There was not statistically 
signifi cant.
Conclusions: Our arterial reconstruction technique has enabled the 
reconstruction of tiny arteries and eliminated problems of diameter discrepancy. 
This technique can be adapted for living donor liver transplantation without 
increasing donor complications.
POSTER BOARD NUMBER P2 – 81
THE USE OF INTRATHECAL MORPHINE FOR 1282 
POSTOPERATIVE PAIN RELIEF AFTER LIVING DONOR 
RIGHT HEPATECTOMY
I.H. Kim1, J. Ko2, S.J. Choi3, M.S. Gwak4, G.S. Kim5, J.W. Joh6, S-K. Lee7
1Dept of Anesthesiology And Pain Medicine, Samsung Medical Center, 2Dept 
of Anesthesiology And Pain Medicine, Samsung Medical Center, 3Dept of 
Anesthesiology And Pain Medicine, Samsung Medical Center, 4Dept of 
Anesthesiology And Pain Medicine, Samsung Medical Center, 5Dept of 
Anesthesiology And Pain Medicine, Samsung Medical Center, 6Dept of 
Surgery, Samsung Medical Center, 7Dept of Surgery, Samsung Medical Center
Introduction: The condition of healthy patients makes tolerance to pain 
particularly low in the living donor population, and thus, it is necessary to 
fi nd an analgesic technique that provides effective pain relief while ensuring 
donor safety. A single dose of intrathecal morphine, administered immediately 
before surgery, may be a useful and safe alternative in obtaining prolonged 
postoperative analgesia especially when the safety of epidural catheter is 
still in question in living liver donors. This prospective, randomized study 
compared, after right lobe liver resection and over a 72-h follow-up period, 
the effi cacy and safety of single-dose intrathecal morphine combined with 
intravenous patient-controlled analgesia (IV-PCA, fentanyl) with an IV-PCA 
alone.
Methods: Forty adult patients undergoing right donor hepatectomy were 
randomly allocated into two groups: intrathecal morphine + IV-PCA group 
(ITM group, n=20) and IV-PCA-only group (Control group, n=20). In the ITM 
group, morphine sulfates 400 μg in 0.9% saline solution 4 mL was intrathecally 
administered before general anesthesia. A visual analog scale (VAS) at rest and 
when coughing was used for pain assessment and respiratory rate, SpO2, and 
IV-PCA and supplementary demerol consumptions were assessed at 2, 4, 6, 8, 
10, 12, 18, 24, 30, 36, 42, 48 56, 64, and 72 h after surgery. Side effects such as 
nausea, vomiting, pruritus, sedation, respiratory depression, and hypotension 
were evaluated.
Results: As measured by the VAS, patients in the ITM group had signifi cantly 
less pain at rest and when coughing for up to 30 h and 24 h, respectively (P 
<0.05). The time to receive fi rst rescue demerol was signifi cantly longer in 
the ITM group (45.7 ± 23 h vs. < 1 h; P < 0.001). Cumulative postoperative 
consumptions of IV-PCA and demerol until postoperative 72 h were 
signifi cantly less in the ITM group (P < 0.001). There were no signifi cant 
differences in sedation, nausea, vomiting, repiratory rate and SpO2 between 
the groups. The incidence of pruritus was signifi cantly higher in the ITM group 
(50% vs. 5%; P < 0.01).
Conclusions: In conclusion, preoperative single-shot intrathecal morphine 
injection combined with IV-PCA provides effective postoperative pain control 
and may be considered as an alternative method of pain control in patients 
undergoing living donor right hepatectomy.
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INTRAHEPATIC BILIARY ANATOMY DERIVED 1283 
FROM RIGHT GRAFT ADULT LIVE DONOR LIVER 
TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2, 
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1Department of General and Abdominal Surgery, Johannes Gutenberg 
University Hospital, Mainz, Germany, 2Department of General, Visceral, 
and Transplantation Surgery, University Hospital Essen, Essen, Germany, 
3Department of Diagnostic and Interventional Radiology, University Hospital 
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The successful management of the bile duct in right graft adult 
live donor liver transplantation requires knowledge of both its central (hilar) 
and distal (sectorial) anatomy. The purpose of this study was to provide a 
systematic classifi cation of its branching patterns in order to enhance clinical 
decision-making.
Patients and methods: We analyzed 3-dimensional CT-imaging reconstructions 
of 139 potential live liver donors evaluated at our Institution between January 
2003 and June 2007.
Results: 1) Fifty four (n=54 or 38.8%) donor candidates had a normal (classic) 
hilar and sectorial right bile duct anatomy (type I), 2) Seventy eight (n=78 or 
56.1%) cases had either hilar or sectorial branching abnormalities (types II or 
III), 3) Seven (n=7 or 5.1%) livers, a mixed type (IV) of a rare and complex 
central and distal anatomy was encountered.
Conclusions: We believe that the classifi cation proposed herein can aid in the 
better organization and categorization of the variants encountered within the 
right-sided intrahepatic biliary system.
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PERIPHERAL ANATOMY OF THE RIGHT HEPATIC 1284 
DUCT A NEW SYSTEMATIC CLASSIFICATION EXPERIENCE 
FROM ADULT LIVE DONOR LIVER TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2, 
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1Department of General and Abdominal Surgery, Johannes Gutenberg 
University Hospital, Mainz, Germany, 2Department of General, Visceral, 
and Transplantation Surgery, University Hospital Essen, Essen, Germany, 
3Department of Diagnostic and Interventional Radiology, University Hospital 
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The peripheral intrahepatic biliary anatomy, especially at the 
sectorial level on the right side, has not been adequately described. The purpose 
of our study was to systematically describe this complex anatomy, and to make 
it clinically applicable.
Patients and methods: We analyzed 3-dimensional CT-imaging reconstructions 
of 139 potential live liver donors evaluated at our Institution between January 
2003 and June 2007.
Results: 1) Eighty nine (64%) donors had a normal right bile duct 
sectorial anatomy, 2) In the other 50/139 (36%) cases, we observed an 
abnormal sectorial branching pattern, 3) 45 of the 50 abnormalities were 
trifurcations, while the remaining ones were quadrifurcations, 4) in 22/50 
(44%) of abnormalities, a linear branching pattern (types B1/C1) and 
an early segmental origin off the right hepatic duct (types B3/C3) were 
present (this fi nding being of particular danger when performing a right 
graft hepatectomy) 5) in two cases, a mixed type (B6/C6) of a rare complex 
anatomy was seen.
Conclusions: Our proposed classifi cation of the right sectorial bile duct system 
clearly displays the “area at risk” encountered while performing right graft 
ALDLT and tumor resections involving the right lobe of the liver.
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ANATOMICAL CLASSIFICATION OF THE PERIPHERAL 1285 
RIGHT HEPATIC DUCT – EARLY IDENTIFICATION OF A 
PREVENTABLE SOURCE OF MORBIDITY AND MORTALITY 
IN ADULT LIVE DONOR LIVER TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2, 
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1Department of General and Abdominal Surgery, Johannes Gutenberg 
University Hospital, Mainz, Germany, 2Department of General, Visceral, 
and Transplantation Surgery, University Hospital Essen, Essen, Germany, 
3Department of Diagnostic and Interventional Radiology, University Hospital 
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The purpose of this study was to determine the impact of our 
classifi cation on right graft ALDLT outcomes.
Methods: Three dimensional CT reconstructions were used to classify the hilar 
and sectorial biliary anatomy of 71 consecutive live liver donors. Four possible 
clinical types were defi ned, based on the normal (N) or abnormal (A) features 
of the corresponding hilar / sectorial ducts: type I: N/N; type II: N/A; type III: 
A/N and type IV: A/A. An analysis of the operative outcomes based on the 
donor anatomy was subsequently performed.
Results: Type I was encountered in 47.9% of cases, type II in 29.6%, type 
III in 19.7%, and type IV in 2.8%. The highest incidence of biliodigestive 
anastomoses was observed with type III (50%) and type IV (100%) variants. 
Type I was associated with the highest incidence of single anastomoses (single 
versus multiple p= 0.001) and of single bile duct biliary anastomoses (single 
versus multiple p= 0.004). Type III was associated with more multi-duct 
reconstructions when compared with types I and II (p= 0.002 and p=0.05, 
respectively). There were no signifi cant differences in early (p= 0.08) or late 
(p= 0.33) biliary complications, or deaths of biliary etiology (p= 0.55) among 
the four types.
Conclusions: Complex biliary anatomy in the right liver graft usually 
requires biliodigestive anastomoses and is often associated with complicated 
biliary reconstructions. The precise delineation of the intrahepatic biliary 
anatomy provided by our clinical classifi cation contributed to acceptable 
postoperative morbidity and mortality, especially for grafts at highest 
anatomical risk.
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HEPATIC HILAR AND SECTORIAL VASCULAR AND 1286 
BILIARY ANATOMY IN RIGHT GRAFT ADULT LIVE LIVER 
DONOR TRANSPLANTATION
A. Radtke1,2, G.C. Sotiropoulos1,2, T. Schroeder3, F.H. Saner2, V.R. Cicinnati2, 
S. Beckebaum2, C.G. Klein2, A. Schenk4, M. Malago2, H. Lang1,2
1Department of General and Abdominal Surgery, Johannes Gutenberg 
University Hospital, Mainz, Germany, 2Department of General, Visceral, 
and Transplantation Surgery, University Hospital Essen, Essen, Germany, 
3Department of Diagnostic and Interventional Radiology, University Hospital 
Essen, Essen, Germany, 4MeVis Research, Bremen, Germany
Objective: The aim of this study was to analyze vascular and biliary 
variants at the hilar and sectorial level in right graft adult living donor liver 
transplantation.
Methods: From January 2003 to June 2007, 139 consecutive live liver donors 
underwent 3-D CT reconstructions and virtual 3-D liver partitioning. The portal 
(PV), arterial (HA) and biliary (BD) anatomy was evaluated.
Results: The hilar and sectorial biliary/vascular anatomy was predominantly 
normal (70-85% and 67-78%). BD and HA showed an equal incidence 
(30%) of hilar anomalies. BD and PV had a nearly identical incidence of 
sectorial abnormalities (64.7% and 66.2%). The most frequent “single” 
anomaly was seen centrally in HA (21%) and distally in BD (18%). A 
“double” anomaly involved BD/HA (7.2%) in the hilum, and HA/PV and 
BD/PV (6.5% each) sectorially. A “triple” anomaly involving all systems 
was found at the hilum in 1.4% of cases, and at the sectorial level in 9.4% 
of instances. Simultanous central and distal abnormalities were very rare. 
13.7% of all donor candidates had normal hilar and sectorial anatomy 
involving all three systems. A simultaneous central and distal “triple” 
abnormality was not encountered. A combination of “triple” hilar anomaly 
with “triple” sectorial normality was found in 2 cases (1.4%). A central 
“triple” normality associated with a distal “triple” abnormality occurred in 
7 livers (5%).
Conclusions: Our data showed a variety of “horizontal” - hilar or sectorial- 
and “vertical” - hilar and sectorial- vascular and biliary branching patterns, 
providing a comprehensive assistance in surgical decision-making for right 
graft hepatectomies.
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ANALYSIS OF HEPATIC STEATOSIS AFTER PEDIATRIC 1287 
LIVING DONOR LIVER TRANSPLANTATION
K. Wakayama1, M. Taniguchi1, T. Shimamura2, T. Suzuki3, K. Yamashita1, H. 
Furukawa3, S. Todo1
1Department of General Surgery, Hokkaido University, 2Division of Organ 
Transplantation, Hokkaido Universty, 3Department of Organ Transplantation 
and Regeneration, Hokkaido University
Background and aim: It is well known that hepatic steatosis recurs after 
liver transplantation in adult patients with pre-existing Non-Alcoholic Fatty 
Liver Disease(NAFLD). Moreover, it has been recently reported to occur after 
transplantation even in adult patients without pre-existing NAFLD. In pediatric 
liver transplantation, however, the actual situation of hepatic steatosis after 
liver transplantation is unknown. Herein, we investigated the hepatic steatosis 
in pediatric transplant cases at our center.
Patients and methods: From July 1998 to May 2007, forty pediatric patients 
underwent living donor liver transplantation (LDLT) at our center. Biliary 
atrasia was the most common indication (27 cases) for transplantation. 
Diagnosis for steatosis was obtained from liver biopsy specimens after 
transplantation. Liver biopsies were performed when the possibility of 
rejection was raised clinically. This included unexplained increases in 
liver enzyme level. Signifi cant steatosis was defi ned as steatosis >5%, and 
subdivided into mild (5-33%), moderate (>33-66%), and severe (>66%). 
Recipient characteristics, risk factors for post-transplant steatosis, change 
of post-transplant liver numbers, and histological changes of steatosis were 
analyzed.
Result: The post-transplant steatosis was observed in 24 cases (62%), 
mild in 15 cases (38%), moderate in 3 cases (8%), and severe in 6 cases 
(16%), respectively. The mean time to diagnose steatosis was 16.6 post 
operative day. The mean cumulative steroid consumption in 4 weeks after 
transplantation was signifi cantly larger in steatosis group(41.7mg/kg) than in 
non-steatosis group(28.4mg/kg). The levels of T-Bil, AST, and gamma-GTP 
revealed no signifi cant change between the two groups during 8 weeks after 
transplantation. Histologically, 7 cases showed improvement or disappearance 
of steatosis within two years after transplantation. In 2 cases whose diagnoses 
were Methylmalonic aciduria and Byler fs disease, histological fi ndings 
demonstrated the persistent severe steatosis and the progression to liver 
cirrhosis, respectively.
Conclusion: Transient hepatic steatosis caused by steroid was observed at 
early period after LDLT in two thirds of pediatric cases. In patients with Byler 
fs disease and Methylmalonic aciduria, the progressive hepatic steatosis should 
be paid attention after pediatric LDLT.
POSTER BOARD NUMBER P2 – 87
DONOR PORTAL VENOPLASTY FOR SEGMENT 4 IN 1288 
RIGHT LOBE LIVING DONOR LIVER TRANSPLANTATION
H-L. Fan, S.M. Kuo, T.W. Chen, J.C. Yu, C.B. Hsieh
Tri-Service General Hospital
Segment 4 branch of portal vein rarely comes from right portal vein. Once it is 
encountered during right lobe living donor liver transplantation, it is mandatory 
to reconstruct this branch for the proper function of the rest of liver in donor. 
A simple procedure of direct end-to-end anastomosis between the stump of 
segment 4 branch and of right portal vein is described in 3 out of 40 donors 
from May 2005 to March 2008. During the right lobectomy in the donor, a 
suffi cient length of stump of right portal vein was preserved and venoplasty 
was performed for the size match of anastomsis.
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A CASE OF PYOGENIC SPONDYLODISCITIS CAUSED 1289 
BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
(MRSA) AFTER LIVING DONOR LIVER TRANSPLANTATION
J.S. Kim, D.J. Kim, I.G. Kim, J.P. Jung, H.J. Kim, S.E. Chon, J.Y. Jeon, 
S. Lee, S.J. Hyun
From Departments of Surgery, Hallym University College of Medicine,
Methicillin-resistant Staphylococcus aureus (MRSA) infection frequently 
complicates the postoperative course of liver transplant recipients. It has been 
well described that MRSA associated bacteremia, pneumonia and surgical 
site infection are common. But, MRSA infection manifesting as pyogenic 
spondylodiscitis is very rare. To our knowledge, pyogenic spodylodiscitis due 
to MRSA in lumbar spine after living donor liver transplantation (LDLT) has 
not been previously reported. Here, we report a 50-year-old man developed 
pyogenic spondylodiscitis caused by MRSA after LDLT. Our patient underwent 
LDLT for HBV related cirrhosis in February 2004. Immnosuppressive 
treatment was administered with basiliximab, tacrolimus, corticosteroids 
and mycophenolate mofetil. He discharged on postoperative 28th day with 
uncomplicated course. At one week after discharge the patient was readmitted 
for abdominal pain and septic condition. Bile leakage at the anastomosis site 
was found by endoscopic retrograde cholangiopancreaticography (ERCP) and 
managed successfully with endoscopic nasobiliary drainage (ENBD). The 
culture of drained fl uid showed MRSA and he was treated with vancomycin 
for 4 weeks. These treatment resulted in resolution of the infection. However, 
one month later the patient presented with severe back pain. At this time, MRI 
showed massive spondylodiscitis of lumbar 2-3 spine and paraspinal abscess 
formation. Our patient was treated by surgical debridement and primary bone 
graft. MRSA was cultured from the abscess specimen. Postoperatively, the 
patient received intravenous vancomycin for 4 weeks and revealed satisfactory 
outcome with no neurological sequelae. Presently he is followed up without 
rejection and other complications.
POSTER BOARD NUMBER P2 – 89
EARLY REGULAR CHECK-UP OF BILIARY STRICTURES 1290 
BY ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY FOR 
DUCT-TO-DUCT BILIARY RECONSTRUCTION AFTER ADULT 
LIVING DONOR LIVER TRANSPLANTATION
T. Kobayashi1, Y. Sato1, S. Yamamoto1, H. Oya1, H. Kokai1, K. Shioji2, 
K. Hatakeyama1
1Division of General And Digestive Surgery, Niigata University, 2Division of 
Digestive Disease, Niigata University
Objectives: Biliary strictures (BS) are one of the important issues to be 
addressed after living donor liver transplantation (LDLT). Duct-to-duct 
biliary reconstruction allows the performance of endoscopic retrograde 
cholangiography (ERC) for evaluation and management of BS. However, 
operative biliary management is sometimes required. From September 2006, 
we started regular check-up of BS by ERC within six month after removal of 
external stents in duct-to-duct biliary reconstructed adult LDLTs. We examined 
feasibility of the routine post-operative ERCs for BS after adult LDLT.
Methods: From March in 2000 to January in 2008, 54 LDLTs with duct-to-duct 
reconstruction with external stents were performed in our institution. Among 
these, we retrospectively evaluated 45 primary adult LDLTs survived more 
than one month. We separated those cases to two groups; the early cases (from 
03/2000 to 08/2006, n=34) and the late cases (from 09/2006 to 01/2008, n=11) and 
compared the incidence of BS and success rate of endoscopic treatments in these 
two groups. BS was defi ned as the strictures by cholangiography or dilatation of 
intrahepatic bile duct with/without elevation of biochemical liver test. Median 
follow-up of the late cases (8.0 months) was shorter than that of the early cases 
(38.5 months) (p=0.0003). Characteristics of the recipients (age, gender, donor 
age, MELD score, Child-Pugh score, ABO incompatibility operation time, blood 
loss, number of biliary anastomoses) were not different in those two groups.
Results: Overall incidence of BS was 36% (16/45). The incidence of BS was 
32% (11/34) in the early cases and 45% (5/11) in the late cases. There was 
no difference of the incidence of BS in these two groups (p=0.18). BS was 
successfully treated by endoscopic management in four of fi ve (80%) in the late 
cases and three of 11 (27%) in the early cases (p=0.049). Endoscopic-related-
cholangitis developed in one patient in the early cases. Nine patients with failed 
endoscopic therapy were converted to percutaneous or surgical treatment. 
Two patients in the early cases required operative biliary reconstructions. 
No surgical treatments were not required in the late cases. Median follow-up 
period between removal of the biliary stents and diagnosis of BS were 67 days 
in the late cases and 165 days in the early cases (p=0.047).
Conclusions: It was longer period to diagnose BS in the early cases. Early 
postoperative regular check-up of BS by ERC for duct-to-duct biliary 
reconstructions may be effective to avoid surgical interventions after adult LDLT.
POSTER BOARD NUMBER P2 – 90
LIVING-DONOR LIVER TRANSPLANTATION WITH 1291 
TRANSIENT PORTOCAVAL SHUNT AND SPLENECTOMY 
FOR A SMALL-FOR-SIZE GRAFT AND BLEEDING GASTRIC 
FUNDAL VARIX
Y. You, S.K. Lee, K.K. Lee, J.H. Park, C.A. Oh, D.G. Kim, E.K. Kim
The Catholic University of Korea
Background: Excessive portal venous infl ow has been known as the 
determining factor for hepatic injury in small for size graft in living-donor liver 
transplantation. Partial diversion of portal infl ow to the systemic circulation 
by portocaval shunt has been reported as a promising treatment modality to 
prevent patient from small-for-size syndrome. Initial hyperperfusion injury 
to the graft would be the most dreadful component in the living-donor liver 
transplantation. In addition, splenectomy itself is not only a method to decrease 
portal fl ow, but also a treatment for the gastric fundal variceal bleeding.
Methods: We performed living–donor liver transplantation with transient 
portocaval shunt and splenectomy for small-for-size graft in a 50 year-old 
male who suffered from hepatitis B virus related liver cirrhosis with a bleeding 
gastric fundal varix, which was intractable to endoscopic control. The height 
and weight of recipient, donor(spouse) was 177 cm, 88kg and 160 cm, 48 Kg 
respectively. Graft to recipient body weight ratio(GRWR) was 0.65. During 
surgery, left portal vein was used for temporary portocaval shunt and the 
right portal vein was anatomosed to the graft portal vein. After all vascular 
anastomoses completed, an endoloop(OpenLoop®) was placed around 
portocaval shunt without tightening, and the knot pusher was taken out of the 
abdominal cavity placed in a silastic drain tube. Concomitant splenectomy was 
performed. 24 hours after transplantation, the loop placed around portocaval 
shunt was tightened as a bedside procedure.
Results: The recipient had an uneventful postoperative course and was 
discharged with normal graft function 26 days after transplantation.
Conclusion: Living-donor liver transplantation with transient portocaval shunt and 
splenectomy could be an acceptable surgical treatment strategy for patient with 
end-stage liver disease with small-for-size graft and bleeding gastric fundal varix.
POSTER BOARD NUMBER P2 – 91
EOSINOPHILIC INFILTRATION OF DONOR LIVER1292 
K-H. Ko, S.G. Lee, K.M. Park, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, 
T.Y. Ha, K.W. Song, D.H. Jung, J.H. Ryu, H.J. Lee, J.I. Park, K.W. Kim, 
N.K. Choi
Division of HBP Surgery and Liver transplantation, Department of Surgery, 
University of Ulsan College of Medicine and Asan Medical Center
In Korea, Cadaver Donor is rare, Living Donor Transplantation(LDLT) is 
essentail for End-stage Liver disease. The quality of Living donor is important 
for postoperative recovery of recipient and safety of donor. There are rare 
report about using donor liver with eosinophilic infi ltration. We performed 
Rt. lobe LDLT on February 2007, using with eosinophilc infi ltration of donor 
Liver. In LT donor work-up, pre-op CT shows multifocal ill-defi ned low 
attenuation lesion,such as eosinophilic infi ltration. In MRI, two ill-defi ned 
T2 high signal lesion(less than 1cm) showed at Liver S6,8. But, those lesion 
were not detected on US, Hepatic, Mescenteric Doppler. The important point is 
those were migrating lesion on CT scan and CBC and diffentail count showed 
eosinophilia 8%. After transplantation, we checked CT scan on POD 1 day, 
and the eosinophilc lesion were not detected in recipient side. We followed 
up CT scans for 3 months post-operatively and no abnormal lesion detected in 
transplant liver, and donor is recovered safely. Conclusively, in view of short 
term follow up, liver donor with eosinophilc infi ltration can be safely used for 
Liver graft in LDLT. But long term follow up is needed.
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CLINICAL ANALYSIS OF GRAFT FAILURE AFTER 1293 
ADULT LIVING DONOR LIVER TRANSPLANTATION
K.K. Lee, D.G. Kim, S.K. Lee, I.S. Moon, M.D. Lee
The Catholic University of Korea
Introduction: Graft failure after liver transplantation remains an important 
cause of graft loss and leads to patient death or retransplantation, resulting in 
lower survival rate. The purpose of this study was to evaluate the epidemiologic 
and cause of graft failure and fi nd out the risk factors infl uencing graft failure 
after adult living donor liver transplantation (LDLT).
Method: We analyzed 286 patients among 330 patients who underwent adult 
LDLT from May 1999 to Jan. 2008, in which was consisted of 28 patients in 
graft failure group and 258 patients in control group. The patient with graft 
failure was divided to two groups according to period of graft failure, early 
failure, before discharge after transplantation and later failure, after discharge. 
Result: There was no signifi cant difference between two groups in preoperative 
and operative factors. The 11 patients were suffered from early graft failure 
and their causes consisted of 7 in vascular problem and 4 in graft dysfunction 
and the only one patient survived after retransplantation. The late graft failure 
occurred in 17 patients and the biliary complications including biliary leakage 
or strictures were the main causes of failure in 9 patients, and other causes 
consisted of hepatic artery or vein stenosis and TACE complication for 
recurrent HCC. Among them, the 4 patients survived after retransplantation, 
and 1 patient died of graft dysfunction in spite of retransplantation.
Conclusion: The main causes of graft failure after LDLT originated from 
technical problem and to prevent the graft failure, meticulous surgical technique 
is required. After graft failure, considering retransplantation is important to 
increase the survival rate.
POSTER BOARD NUMBER P2 – 93
HEPATIC INFLOW INFLUENCE UPON PORTAL VEIN 1294 
COMPLICATIONS IN PEDIATRIC LIVING DONOR LIVER 
TRANSPLANTATION
S. Shibasaki1, M. Taniguchi1, T. Shimamura2, T. Suzuki3, K. Yamashita1, 
M. Ohta2, H. Furukawa3, S. Todo1
1Department of General Surgery, 2Division of Organ Transplantation, 
3Department of Organ Transplantation and Regeneration, Graduate School of 
Medicine, Hokkaido University, Sapporo, Japan
Background/aim: Portal vein (PV) complications in pediatric living donor 
liver transplantation (LDLT) are often asymptomatic in the early stages after 
transplantation and can be serious enough to lead to graft failure. There have 
ever been few reports on hepatic infl ow as risk factors for PV complications in 
LDLT. The aim of this study is to investigate the infl uence of hepatic infl ow and 
to predict patients at risk for these complications.
Material/method: From Septembar 1997 to April 2007, 40 pediatric patients 
underwent LDLT at our center. Portal venous and hepatic arterial fl ows after 
reperfusion and PV diameter were analysed.
Results: PV complications were identifi ed in 6 patients (15%), and occurred in 
lower age (the group with PV complications vs. the group without PV complications: 
0.95 ± 0.4 vs. 5.3 ± 5.3 yr, p<0.001) and lower weight (7.6 ± 1.3 vs. 18.6 ± 14.3 
kg, p<0.001). None suffered graft failure. Smaller PV diameter in recipient, larger 
donor-recipient PV diameter ratio, lower portal venous fl ow and higher hepatic 
arterial fl ow after reperfusion were risk factors for PV complications (Table.1). 
In the analysis of 21 patients under two years of age, smaller PV diameter in 
recipient, larger discrepancy of PV diameter, and higher hepatic arterial fl ow were 
risk factors, too. Portal venous fl ow was also tended to be low.
Conclusion: PV size and hepatic infl ow infl uence upon PV complications. 
Patients under two years of age were a high risk group of PV complications. 
Small PV size, great discrepancy in PV diameter between donor and recipient, 
low PV fl ow, and high HA fl ow were risk factors for PV complications.
(1) 
complications
(2) non-
complications
(3) non-
complications
(under 
2 year-old)
(A) (B)
N 6 34 15
Recipient
HA diameter (mm) 3.5 ± 0.6 3.6 ± 0.9 3.4 ± 0.6 p=0.774 p=0.637
(1) 
complications
(2) non-
complications
(3) non-
complications
(under 
2 year-old)
(A) (B)
PV diameter (mm) 3.7 ± 1.0 7.5 ± 2.6 5.7 ±1.4 p<0.001 p=0.006
Donor
PV diameter (mm) 9.3 ± 1.8 9.1 ± 1.5 8.9 ± 1.3 p=0.698 p=0.576
the PV size’s ratio of donor 
to recipient 2.8 ± 1.0 1.4 ± 0.5 1.7 ± 0.4 p=0.018 p=0.044
Hepatic infl ows after reperfusion
PV fl ow (ml/100g/min) 141.0 ± 75.7 240.3 ± 93.6 196.4 ± 48.1 p=0.019 p=0.058
HA fl ow (ml/100g/min) 54.9 ± 22.7 28.6 ± 17.6 29.6 ± 17.6 p=0.013 p=0.013
PV/HA fl ow ratio 3.1 ± 2.2 12.8 ± 14.1 9.8 ± 6.9 p=0.103 p=0.032
Table.1 univariate analysis of hepatic infl ow and vascular size
is comparision between (1) and (2) using the Student’s t-test(A) 
is comparision between (1) and (3) using the Student’s t-test(B) 
POSTER BOARD NUMBER P2 – 94
A SINGLE CENTER EXPERIENCE OF 1000 RIGHT LOBE 1295 
LIVING DONOR LIVER TRANSPLANTS
T.Y. Ha, S.G. Lee, S. Hwang, K.H. Kim, C.S. Ahn, D.B. Moon, G.W. Song, 
D.H. Jung, J.H. Ryu
Asan Medical Center
Background and purpose: Right lobe living donor liver transplantation 
(LDLT) has been increasingly performed for adults with end-stage liver 
disease. However, its application to the seriously ill patients as acute liver 
failure or acute-on-chronic liver failure is still controversial due to justifi cation 
of subjecting a healthy donor to the risk of life-threatening surgery. This study 
was aimed to evaluate 1,000 adult right lobe LDLT in a single center whether 
the early outcome is comparable to cadaveric whole-size liver transplant.
Method: One thousand consecutive adult right lobe LDLTs performed between 
15th July 1997 and 8th October 2007 were retrospectively reviewed especially 
for in-hospital mortality of recipients and major donor complications. One 
thousand right lobe liver grafts consisted of 72 right lobes (without middle 
hepatic vein reconstruction), 20 extended right lobes (with middle hepatic vein 
trunk), 902 modifi ed right lobes (with reconstruction of middle hepatic venous 
tributaries) and 6 modifi ed extended right lobes (with reconstruction of distal 
middle hepatic vein trunk and segment 8 hepatic vein). The median follow-up 
period was 31 (range, 3-123) months.
Results: Recipients’ age ranged from 17 to 69 years. Graft-to-recipient weight 
ratio ranged from 0.56 to 1.69% (mean 1.03 ¡¾ 0.25, median 1.03). MELD score 
ranged from 4 to 40 (mean 20.0 ¡¾ 9.1, median 18). According to UNOS urgency 
category, there were 57 status I, 143 status IIa, 116 status IIb, and 684 status 
III. Among 1000 recipients, 44 could not return to home because of in-hospital 
mortality. There was neither mortality nor life-long disability in donors.
Conclusion: Despite the complexity of right lobe LDLT procedure, the 
standardization of the technique of procedure and the surveillance of the post-
transplant dynamic change of the partial graft have improved the results of this 
operation comparable to the full-size cadaveric donor liver transplants.
POSTER BOARD NUMBER P2 – 95
CAUSES OF REJECTION OF POTENTIAL LIVING 1296 
DONORS FOR LIVING-RELATED LIVER TRANSPLANTATION
M. Mihaila1, L. Micu1, C. Ruscanu1, A. Berbec1, I. Popescu2, M. Voiculescu1
1Fundeni Clinical Institute, Center of Internal Medicine-Nephrology, 
2Fundeni Clinical Institute, Center of General Surgery and Liver 
Transplantation
One of the most important problems in liver transplantation programs is 
represented by the shortage of organs due to the increasing number of patients 
on the waiting lists, which is not matched by an increase of available cadaveric 
donors. For this reason many patients die while awaiting a liver transplant. In 
order to better cope with this growing problem, living donor liver transplantation 
programs have been developed.
The aim of the study is to evaluate the most frequent causes that lead to the 
rejection of potential living donors from donating a liver fragment.
Material and methods: In the Center of Internal Medicine of Fundeni 
Clinical Institute, 34 potential donors were evaluated between 2003-2007 in 
order to establish the possibility of donating a liver fragment for 13 patients 
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with end stage liver disease. The standard protocol of investigations was 
applied including compatibility of the ABO system, normal psychological 
and psychiatric examinations, absence of liver or systemic disorders, as 
well as hepatic volume. We performed biological, hematological, virological 
and imagistic examinations (CT scan for hepatic volumetry, angio- and 
cholangioMRI, angiography for evaluating hepatic vascularization), liver 
biopsy, psychological, cardiological and neurological examinations.
Results: Of the 34 potential liver donors, only 9 (26.47%) were considered 
elligible for donation. 7 patients (20.58%) were found to be HBV carriers, 1 
patient (2.94%) presented multiple hepatic cystic masses, 1 (2.94%) presented 
lung tumor, 3 patients (8.82%) presented macrovesicular steatosis > 20% at 
liver biopsy, 5 pts (14.7%) were rejected after psychological evaluation, in 3 
patients (8.82%) hepatic volumetry contraindicated donation due to the risk of 
small-for-size syndrome, 1 patient (2.94%) presented an anatomical variant of 
the hepatic artery which did not allow for hepatic resection, and 4 (11.76%) had 
biological profi les which suggested Wilson disease.
Conclusions: It is important to underline the fact that for each recipient for living 
donor liver transplantation it is usually necessary to evaluate several potential 
donors. The screening of potential donors is costly and time-consuming, while 
medical contraindications of donation are frequently encountered.
POSTER BOARD NUMBER P2 – 96
PROSPECTIVE EVALUATION OF DUCT-TO-DUCT 1297 
BILIARY RECONSTRUCTION IN ADULT LIVING DONOR 
LIVER TRANSPLANTATION
T.Y. Tsui, M.N. Scherer, M. Loss, A. Doenecke, H.J. Schlitt, A. Obed
Department of Surgery, University of Regensburg Medical Center
Background: Biliary reconstruction remains the Achilles’ heel of adult living 
donor liver transplantation (LDLT). This study aims to investigate the feasibility 
of duct-to-duct hepaticocholedochostomy in LDLT.
Methods: Perioperative data from thirty consecutive LDLT aiming at duct-
to-duct reconstruction of the biliary tract using a continuous suture technique 
were prospectively collected. Nineteen recipients (63.3%) had one graft bile 
duct. Eleven recipients (36.7%) had two or three graft bile ducts. The median 
follow up was 30 months
Results: The overall biliary complication rate was 23.3%. Two recipients 
developed biliary stricture (6.7%) and two recipients (6.7%) presented with 
biliary leakage in early posttransplant phase (< 90 days). One recipient suffered 
from bilioma (3.3%) and two recipients (6.7%) presented with biliary stricture 
in later posttransplant phase (>90 days). No correlation was found between 
the number of graft bile ducts and the incidence of biliary complications. No 
biliary complication-associated necessity for re-transplantation or mortality 
was observed. On multivariate analysis, no single risk factor associated 
with biliary complication could be identifi ed. All biliary complications were 
successfully treated with Roux-en-hepaticojejunostomy and/or with endoscopic 
interventions.
Conclusion: Duct-to-duct hepaticocholedochostomy represents a safe and 
feasible procedure for biliary reconstruction in LDLT. Recipients may be 
benefi t from aggressive management of biliary complications with Roux-en-
hepaticojejunostomy as compared to repeated endoscopic interventions in 
early posttransplant phase.
POSTER BOARD NUMBER P2 – 97
LIVER TRANSPLANTATION OF A LIVING DONOR1298 
B. Ringe, G. Xiao, D. Sass, J. Reynolds, W. Meyers
Drexel University College of Medicine
Postoperative liver failure has been identifi ed as a rare complication after living 
donor liver resection. According to a recent review of the literature the outcome 
is usually fatal. Although liver transplantation was attempted in a small number 
of patients, no survivor has been reported, so far. This is a case report of a living 
donor who was rescued with liver transplantation.
A 22-year old healthy male underwent a right hemihepatectomy including 
segments 5-8 for a patient suffering from cystic fi brosis. After an uneventful 
early recovery he had an exploratory relaparotomy four days later for clinical 
signs of acute abdomen. We found a gastric perforation with peritonitis, 
eventually leading to septic shock with acute renal and subsequent 
liver failure, necessitating support with artifi cial ventilation, multiple 
vasopressive agents, and continuous veno-venous hemodiafi ltration. After 
a liver biopsy demonstrated submassive liver necrosis, he was listed for 
transplantation as a status 1A, and received a full-size liver transplant from 
a deceased donor eleven days after his liver resection. Following a stormy 
post-transplant course, with major diffi culties to close the abdominal 
wound, the patient was fi nally discharged from the hospital after 79 days. 
Eight months later, he has fully recovered from his liver and kidney failure 
as well as peritonitis.
This is the fi rst description of a living donor who received a successful 
liver transplant. There are four additional living liver donors mentioned in 
the medical literature: three died, and in one the outcome is unknown. Our 
own patient is the only documented survivor, so far. This case demonstrates 
that even in supposedly healthy living donors postoperative complications 
cannot be completely prevented. Although liver failure is rare in these 
patients, timely transplantation may need to be considered as the only life-
saving treatment.
POSTER BOARD NUMBER P2 – 98
RISKS AND BENEFITS OF LIVING DONOR LIVER 1299 
TRANSPLANTATION
B. Ringe, R. Petrucci, J. Reynolds, D. Sass, G. Xiao
Drexel University College of Medicine
Living donor liver transplantation (LDLTx) was introduced to alleviate organ 
shortage, and to help patients who have no chance of receiving a deceased 
donor organ. The procedure has always been under intense scrutiny because 
of concerns for the safety of the donor. To assess the risks and benefi ts of 
LDLTx we have reviewed our own experience with 26 pairs of donors and 
recipients.
26 adults (age 19-54 yr; 15 m/11 f) completed evaluation as living donors, 
including assessment of preoperative medical and psychosocial risk factors 
by an independent hepatologist, psychologist, and social worker. 27% had 
no medical, 62% no psychosocial, and 19% no combined risks. Overweight, 
hypercholesterolemia, smoking, and history of alcohol or illicit drugs were 
the most frequent conditions identifi ed preoperatively. Postoperative recovery 
was completely uneventful in 11 donors. Complications were observed in 15 
patients, and graded as 1 (7), 2a (2), 2b (4), 4a (1), and 4b (1), according to the 
modifi ed Clavien classifi cation (2006). A death from illicit drug overdose was 
not related to surgery performed 57 days earlier. One donor received a liver 
transplant for multi organ failure and sepsis secondary to gastric perforation, 
and is alive after 8 months. Eighteen right, one left, and 7 left lateral lobe 
grafts from 18 genetically and 8 emotionally related living donors were 
transplanted into 14 adults (age 22-58 yr) and 11 pediatric recipients (age 5 
mo - 18 yr; one retransplant). Indications were chronic end stage liver disease 
in adults (mean MELD 14, waiting time 188 d), and in 8 children (mean PELD 
11, waiting time 40 d); four pediatric patients had acute hepatic failure, and 
were transplanted within 2-10 d after listing on status 1. 17 of 25 recipients are 
alive (follow up 8 mo - 5 yr), including 10/11 children. Two of the mortalities 
were related to the technique of LDLTx (small for size syndrome and hepatic 
artery rupture).
What can be learned from this single center analysis? It is important to 
document all risks and complications accurately. Ideally, living donors 
should be completely healthy. In our experience, 81% of liver donors had at 
least one risk factor which may have contributed to some of the postoperative 
complications. However, except one, all major complications occurred in 
low risk donors. On the recipient side there is no doubt that LDLTx had 
signifi cant benefi ts in patients with low MELD scores, selected tumors, and 
in children, including acute hepatic failure. LDLTx should not be performed 
in patients with high MELD scores, especially since they are prioritized 
to receive deceased donor organs. Suffi ced to say, but LDLTx is a delicate 
balance. By violating the principle of primum non nocere there will always 
be an unpredictable risk for the donor. Any risk-benefi t calculations involving 
both donor and recipient will not help to answer the question as to where to 
draw the line.
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EVALUATION OF 368 LIVING RELATED LIVER 1300 
DONORS: SINGLE CENTER EXPERIENCE
N. Allam1, M. Al-sofayan2, A. Helmy, M. Al-saghier, Y. Medhat, 
H. Khalaf, A. Abdo, M. Sebayel
1National Liver Institute, Menofeya University, 2King Faisal Specialist 
Hospital and Research Center
Background and aims: Organ shortage has been the ongoing obstacle to 
expand liver transplantation world-wide including Saudi Arabia. Living donor 
liver transplantation (LDLT) was hoped to improve this shortage. The aim of 
the present study was to analyse the results of the evaluation for a large pool of 
potential living donors at our center.
Methods: From April 2001 to June 2007, a total of 44 living donors liver 
transplantation were performed at our institution (37 patients had a right lobe, 
1 had a left lobe and 6 had left lateral grafts). 368 potential donors were 
worked up according to a step-wise evaluation protocol. Their age ranged 
from 18 to 60 years, with 75% in the third and forth decades. Female: male 
ratio was 77: 291. They were all fi rst and second degree relatives of the 
patients.
Results: Only 44 (11%) were accepted for donation and 324 (89%) were 
rejected. 37% were excluded either at initial screening due to high body 
mass index (15%), or in the fi rst step of evaluation due to incompatible blood 
group (3%), positive hepatitis serology (7%),elevated liver enzymes (12%). 
6% were rejected due to miscellaneous systemic diseases. In 13% of cases, 
the evaluation was aborted due to recipient conditions and in 5% because of 
socioeconomic reasons. 20% were rejected because of abnormal anatomy 
and 5% due to insuffi cient volume as determined by CT volumetry. In 14%, 
abnormal histopathology primarily abnormal fat content was the reason for 
rejection. Liver density was estimated by CT imaging before liver biopsy and 
the results were in agreement with the fi nding of steatosis (ƒÛ agreement=29.2, 
p=0.001).
Conclusion: There is no doubt that LDLT has helped in alleviating the severe 
shortage of cadaveric organs in Saudi Arabia. However suitable living donors 
are not easy to fi nd especially right lobe donors. Our initial evaluation is 
effective in eliminating a large number of unsuitable donors. However, the 
donor evaluation process indeed remains to be a large burden on the resources 
of our program. Estimation of liver density by CT is useful since marked 
hypodensity would imply signifi cant steatosis and hence avoid unnecessary 
biopsy.
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LIVING DONOR LIVER TRANSPLANTATION USING A 1301 
GRAFT FROM SITUS INVERSUS DONOR
J.M. Chun, J.M. Kim, G.O. Jung, J.B. Park, H.T. Jung, H.J. Park, K.U. Jung, 
S.J. Kim, J.W. Joh, S.K. Lee
Samsung Medical Center, Department of Surgery
Several reports have shown uneventful outcomes after liver transplantation 
performed in recipient with situs inversus and three cases of deceased donor 
of situs inversus undergoing liver transplantation were reported.we report a 
case of LDLT using a graft from situs inversus donor with successful result. 
In the recipient operation, the Glissonian pedicles were cut intrahepatically 
as high as possible using high hilar dissection technique and right hepatic 
vein was obtained long enough to perform hepatic vein anastomosis without 
tension. The reversed right hepatic vein(hepatic vein on the left side of vena 
cava)of donor was anastomosed directly to the right hepatic vein of recipient 
without vascular modifi cations and then donor portal vein was anastomosed to 
the confl uence of right anterior branch and right posterior branch of recipient 
portal vein in an end to end fashion. The reversed right hepatic artery of donor 
was anastomosed to the recipient right hepatic artery using a microvascular 
technique and thereafter intraoperative Doppler examination was performed 
to evaluate the vascular fl ow and patency. Biliary reconstruction was 
achieved using a duct to duct choledochocholedochostomy and no stent 
was placed. The graft function was excellent postoperatively and the patient 
presented in satisfactory condition at his last follow up, 6 months after liver 
transplantation.
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SUCCESSFUL USE OF EXTENDED CRITERIA DONOR 1302 
GRAFTS WITH LOW TO MODERATE MACROVESCICULAR 
STEATOSIS IN PATIENTS 
WITH BIOCHEMICAL MELD SCORE LESS THAN 26
F. Frongillo1, A.W. Avolio1, E. Nure1, R. Barbarino1, G. Pepe1, V. Perilli2, 
Salvatore Agnes1
1Catholic University of Rome, Dpt of Surgery - Transplantation Service, 
2Catholic University of Rome, Dpt of Anaesthesiology
Background: Today, liver transplantation cannot be performed without the use 
of extended criteria donor (ECD) grafts. Characteristics of ECD grafts include, 
age higher than 60, use of iv narcotics until brain death, long Intensive Care 
Unit stay, history of malignancy, and steatosis. Even if, a precise defi nition of 
extended-criteria donors remains elusive, liver grafts are frequently discarded 
for orthotopic liver tranplantation (OLT) due to steatosis. Few papers on donor 
liver steatosis have been published as yet. Steatosis could be microvescicular 
or macrovescicular. Macrovesicular steatosis, is the most relevant in terms of 
unfavourable outcome due to primary non function or primary dysfunction.
Patients and methods: From January 2000, all referred donors at our institution 
were considered potentially transplantable and they were all surgically 
evaluated using inspection and biopsy (wedge-biopsy and ago-biopsy). To 
have a unique point of view, when possible, we utilized the same pathology 
service. We basically avoid to transplant steatotic grafts in patients with severe 
decompensation of liver function as represented by high MELD score (≥26).
We defi ned steatotic liver grafts when steatosis rates higher than 5%.
A typical graft with moderate steatosis without fi brosis.
Results: We observed 30 donor grafts with steatosis higher than 5%.13 grafts 
(43%) show macrovesicular steatosis affecting more than 50% of the hepatocytes 
and were discarded. 2 grafts (7%) with macrovescicular steatosis equal to 35% 
and 47%, were discarded by our Unit, and transplanted by other Italian centres. 
The graft with 35% steatosis had favourable outcome, the one with 47% steatosis 
did not, and required urgent re-transplant because of primary non function. The 
remaining 15 grafts (50%) were transplanted in spite of their steatosis.
Regarding the 15 grafts transplanted at our institution 7 grafts (23%) had a 
macrovesicular steatosis between 5% and 10%; 6 recipients are still alive and 
one (the patient who received a fatty liver for urgent retransplant) died for 
sepsis after primary dysfunction. 4 grafts (13%) had steatosis between 10% and 
15%; all the recipients are still alive and without complications. 2 grafts (7%) 
had a steatosis between 15% and 30%; both the recipients ar alive and without 
complications. 2 grafts (7%) were transplanted with microvesicular steatosis 
beetwen 40% and 50%, in absence of macrovesicular steatosis; both recipients 
are alive and well.
Conclusions: In summary, the carefull use of ECD grafts with low to moderate 
steatosis but without fi brosis, cannot be precluded, especially if particoular care 
is reserved to avoid additional risk factors related to the recipient.
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RISK FACTORS OF ACUTE CELLULAR REJECTION 1303 
IN ADULT LIVING DONOR LIVER TRANSPLANTATION: 
POSITIVE LYMPHOCYTOTOXIC CROSS-MATCH IS NOT 
A RISK FACTOR
J.M. Chun, G.O. Jung, J.M. Kim, K.U. Jung, H.T. Jung, H.J. Park, J.B. Park, 
S.J. Kim, J.W. Joh, S.K. Lee
Samsung Medical Center, Department of Surgery
Background: The infl uence of lymphocytotoxic crossmatch on acute cellular 
rejection in adult living donor liver transplantation (LDLT) has not been 
well examined. In this study, we evaluated the risk factors of acute rejection 
including positive lymphocytotoxic cross-match.
Method: Between June 1997 and June 2007, consecutive adult 382 recipients 
who underwent 1st LDLT, were enrolled in this study. Clinical factors including 
recipient age, relation of donor, primary indications of transplantation, MELD 
score, graft to recipient body weight ratio (GRWR), donor age, human leukocyte 
antigen mismatch, lymphocytotoxic cross-match, cold ischemic time, induction 
immune suppression and incidence of biliary complication and CMV infection 
were analyzed for possible risk factors by Kaplan Meier Method.
Results: Among 382, 32 recipients were positive in lymphocytotoxic cross-
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match. Median follow-up duration was 28.0 months (0~93). And 56 recipients 
underwent one more acute rejection episodes. In univariate analysis, positive 
lymphocytotoxic cross-match was not signifi cant risk factor of acute rejection 
(p=0.625), while HCV (p=0.003), low MELD score (p=0.011), and no induction 
of anti-IL-2 receptor antibody (p=0.034) were revealed as risk factor for acute 
rejection. In multivariate analysis by Cox-Regression hazard model, younger 
recipient age (p=0.030, HR 0.965, CI 0.935~0.997), HCV (p=0.003, HR 0.268, 
CI 0.112~0.642), lower MELD score (p=0.006, HR 0.956, 0.926~0.987) were 
signifi cant risk factors.
Conclusion: Positive lymphocytotoxic cross-match is not risk factor for acute 
cellular rejection.
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OUTCOME OF CANDIDATE EVALUATION IN ADULT-1304 
TO-ADULT LIVING DONOR LIVER TRANSPLANTATION IN 
JAPAN: FROM THE COORDINATOR’S POINT OF VIEW
E. Soeda1, M. Tanabe2, S. Kawachi2, H. Obera2, M. Shinoda2, T. Hibi2, 
Y. Kitagawa2
1Keio University Hospital, 2Department of Surgery, School of Medicine, 
Keio University
Purpose: In 2004, the Japanese National Insurance began to cover medical 
expenses for Adult-to-adult Living Donor Liver Transplantation (A2ALL) and 
the number of transplant candidates increased. However, not all candidates 
could receive A2ALL for a variety reasons. We report the outcome of candidates 
evaluated in one of the metropolitan university hospitals in Tokyo, Japan. This 
university is a major hospital with a special interest and experience in ABO 
blood type incompatible living donor liver transplants.
Methods: The records of consecutive 170 candidates from 2003 to 2007 were 
reviewed and analyzed.
Outcome: Of the 170 candidates (mean age=51.6,), 41 (24.1%) underwent 
A2ALL and 129 (75.9%) did not. The primary diagnoses established were 
Hepatitis B and/or C (108, 63.5%), alcoholic liver cirrhosis (20, 11.2%), 
fuluminant hepatitis (15, 0.9%). Seventy one candidates had HCC (71, 65.7%), 
beyond Milan criteria (52.1%). Of the 129 candidates, 107 were unsuitable 
for A2ALL, 15 went overseas and 7 went other Japanese hospitals to receive 
liver transplants. The main reasons identifi ed for those who did not receive 
A2ALL were 1) too late for transplant (46, 42.9%), 2) no donor (31, 28.9%), 3) 
other reasons such as considered social factors preferred deceased donor liver 
transplant (11, 10.2%). 
Conclusion: In Japan, only one-forth of candidates underwent A2ALL. 
Because of the diffi culty of fi nding a suitable living donor, about half cases were 
assessed too late for A2ALL. As a clinical transplant coordinator, facilitating 
meaningful communication among those patients and patients’ family to make 
the right decision at the right time, it was very important to not miss the chance 
of a potentially life saving liver graft. An increase in organ donation from 
deceased donors in Japan is an urgent requirement.
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INDICATION OF PREOPERATIVE LIVER BIOPSY 1305 
IN DONOR EVALUATION FOR LIVING DONOR LIVER 
TRANSPLANTATION
Y. Koshizuka, T. Suzuki, M. Taniguchi, K. Yamashita, T. Shimamura, 
T. Kamiyama, M. Matsushita, H. Furukawa, S. Todo
First Department of Surgery, Hokkaido University, Sapporo, Japan.
Background: Living donor liver transplantation (LDLT) has become an 
acceptable alternative for orthotopic liver transplantation to resolve donor 
shortage. As donor safety should be the primary consideration, accurate 
assessment for donor evaluation is critical to ensure a successful outcome for 
both donor and recipient. Preoperative liver biopsy for donor candidates whose 
liver was suspicious of hepatic steatosis or liver dysfunction by preoperative 
examination is generally accepted. However, there are arguments both for and 
against the routine preoperative liver biopsy for donor evaluation.
Aim: The aim of this study is to investigate an expansion of the indication for 
preoperative liver biopsy in donor evaluation.
Material and method: Between October 1997 and February 2007, one hundred 
eighty six donor candidates who had completely passed preoperative evaluation 
by laboratory tests, imaging, and psychosocial examination, hospitalized 
in our institution to undergo donor operation. Preoperative liver biopsy was 
performed only for donor candidates whose liver were suspicious of hepatic 
steatosis or liver dysfunction by preoperative examination. The outcome of 
donor candidates was analyzed.
Results: Of 186 donor candidates, one hundred seventy six underwent 
successful hepatectomy for living donation. There was no donor mortality. 
Ten donor candidates, who did not undergo liver biopsy before operation, 
were cancelled their operation. Of these, fi ve donor candidates were cancelled 
because of abnormalities in liver function, or symptoms of common cold. 
Abnormalities in liver function test were caused by taking medicine, 
constitutional jaundice, and alcohol drinking. Other 5 donor candidates were 
cancelled by the fi ndings of laparotomy. Intraoperative liver biopsy showed 
hepatitis in 4 cases, and the peritoneal dissemination of a gall bladder 
cancer was revealed by laparotomy in one case. In 4 donor candidates, 
two cases, whose recipient was diagnosed primary biliary cirrhosis (PBC), 
were suspicious of PBC. Of 10 donor candidates who cancelled their 
operation, 2 cases were old donor more than 50 years old. Conclusion: 
For the donor candidates whose recipient’s primary disease is autoimmune 
hepatitis including PBC or the old donor candidates more than 50 years old, 
preoperative liver biopsy should be considered.
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GASTROINTESTINAL BLEEDING WITH ANTIPLATELET 1306 
MEDICATION IN SEVERE PORTAL HYPERTENSIVE PATIENT 
AFTER LIVING DONOR LIVER TRANSPLANTATION: A CASE 
REPORT
J.W. Park1, J.H. Kim2, W.B. Kim3, S.D. Suh4, S.Y. Choi5
1Department of Surgery, Korea University Guro Hospital, 2Department of 
Internal Medicine, Korea University Guro Hospital, 3Department of Surgery, 
Korea University Guro Hospital, 4Department of Surgery, Korea University 
Ansan Hospital, 5Department of Surgery, Korea University Guro Hospital
Background: Hepatic artery thrombosis is a catastrophic complication after 
liver transplantation leading to graft failure. For this reason, antiplatelet 
medication should be started at early postoperative day especially in living 
donor liver transplantation.
Case presentation: A 56-year old male patient with hepatitis B virus related 
and alcoholic liver cirrhosis underwent living donor liver transplantation. 
The donor was his daughter. He was suffering from severe refractory ascites 
and intermittent spontaneous bacterial peritonitis. There were no signifi cant 
comorbidities such as diabetes mellitus, hypertension, hypercholesterolemia, 
etc. He received massive transfusion because of severe bleeding during 
operation. But, his vital sign was stable perioperatively. He began to recover 
rapidly without any abnormal fi ndings after liver transplantation. We started 
anticoagulation prophylatic therapy with low molecular heparin from 
immediate postoperative day and examined liver graft by color Doppler 
sonogram at fi rst and third postoperative day. His hepatic artery fl ow was 
good with normal resistive index. At 5th postoperative day, we started 
oral antiplatelet medication with overlapping intravenous low molecular 
heparin according to protocol. Next day, his hemoglobin decreased abruptly 
from 15g/dl to 7.9g/dl with stable vital sign. We found gastrointestinal 
bleeding by esophagogastroscope over duodenal third portion suggesting 
jejunojejunostomy site. We managed this patient conservatively with packed 
RBC transfusion and stopped any anticoagulant therapy. After 3 days, he 
recovered to normal hemoglobin level. Color Doppler sonogram showed good 
hepatic artery fl ow with normal resistive index at postoperative one month. 
He discharged without any anticoagulant prophylactic medication from that 
event and had a good graft function at out-patient department. This was our 
fi rst adult living donor liver transplantation.
Conclusion: Gastrointestinal bleeding should be considered in massive 
transfused patient with antiplatelet medication at early postoperative period 
and we suggest that antiplatelet medication for prevention of hepatic artery 
thrombosis can be hold with caution in low risk patient.
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DONOR COMPLICATION AND SATISFACTION 1307 
ASSESSMENT AFTER LIVING DONOR LIVER 
TRANSPLANTATION USING RIGHT LOBE GRAFT
M.K. Ju1,2, K.H. Choi1, K.H. Huh1,2, D.J. Joo1, S.J. Kim1, J. Choi1, M.S. 
Kim1,2, S.I. Kim1,2, Y.S. Kim1,2
1Department of Surgery and 2Transplantation Institutes Yonsei University 
College of Medicine, Seoul, Korea
Risk of donor mortality and morbidity is major obstacle in living donor liver 
transplantation. The goal of this study is to assess unexpected complications 
and satisfaction after donation process.
Methods: Fifty-fi ve adult living donors who underwent right (n=45) or 
extended right lobectomy (n=10) for living donor liver transplantation between 
September 2005 and December 2007 were enrolled in this retrospective study. 
The mean age of donors was 32.1 ± 10.5 years old (16-52 years old). The mean 
follow-up time for the donors was 12.3 months (2–26 months).
Result: Majority of donor type were related donor (33 offspring and 6 siblings), 
and spouse and unrelated donor was 6 (10.9%) and 10 (18.2%), respectively. 
Mean donor operation time was 440.1 ± 86.6 minutes (362 ~ 645 minutes). Only 
one donor was needed transfusion during operation. There was no operation 
mortality. Sixteen complications (29.1%) were occurred within 1 month after 
operation. Wound complication required secondary closure (7/55; 10.9%) was 
most common complication in this study. The bile leakage was another major 
complication of donor (5/55, 9.1%), and gastric ulcer bleeding (n=3), portal 
vein stricture (n=1), post-operative atelectasis (n=1) and major depressive 
disorder (n=1) were followed. Only one patient with bile leakage was need 
the operative management, but the others were well controlled by medical or 
interventional management. The hospital days of donors with post-operative 
complication was signifi cant longer than donors free complication (18.1 ± 6.5 
days versus 13.5 ± 3.9 days)(p=0.015). In risk factor analysis for occurrence of 
donor complication, we could not defi ne the signifi cant risk factors. There was 
no difference of complication rate by demographics and donor type. Especially, 
degree of donor hepatectomy that was expressed by residual volume ratio (< 
35% or ≥ 35%) was not related with complication rate (p=0.287). We could 
obtain the reply about current status of 33 donors. Twenty-fi ve donors (25/33; 
78.8%) were satisfi ed with their donation, however, 19 donors (19/33; 57.6%) 
felt the change of daily life after operation. Unexpectedly, more than half of 
donors were satisfi ed with their surgical wound (20/33; 60.6%).
Conclusion: Though there was no donor mortality, the overall complication 
rate after adult right lobe donation for liver transplantation was 29.1% in 
our center experience. More careful and meticulous surgical techniques for 
lowering donor complication are required.
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CLINICAL OUTCOMES AFTER LIVER 1308 
TRANSPLANTATION (OLT) FROM LIVING DONORS ARE 
COMPARABLE TO THOSE FROM DECEASED DONORS
M. Almarastani, A.W. Khan, A.A. Abdulkareem
King Abdulaziz Medical City
Background: Living donors offer expansion of the donor pool in the era of 
donor shortage. The donor shortage is a serious problem in the third world 
countries. The aim of this study is to determine if the outcomes of OLT from 
deceased livers are comparable to those from living one.
Material and methods: A retrospective review of liver transplant recipients 
from deceased and living donor at a single transplant center was performed. 
Patient demographics, liver function tests, length of stay, complications, and 
patient outcomes were reviewed. Comparisons between groups were done 
with Chi-square test and two samples Student t-test with p value < 0.05 being 
signifi cant.
Results: Between January 2002 and December 2006, 82 patients underwent 
OLT. 25 were from living and 57 from deceased donors. The mean age of 
recipients in the living group was 53.24+/- 9.48 years and 53.33+/- 10.79 years 
for deceased group (p=0.96). There were 76% males in the living versus 63% 
in the cadaveric group. None of the living group underwent re-transplanted 
compared with two patients (3%) of the deceased group. The follow up 
period was between 2002- 2007, during this period 84% of living related liver 
transplant patients were still alive versus 86% in the deceased group. There 
was two out of twenty-fi ve patients (8%) in the living group developed primary 
non function versus three out of fi fty-seven patients (5%) in the deceased 
group. None of the living group had hepatic artery complications versus one 
patient (1.7%) in the deceased group. Biliary complications requiring surgery 
developed in 12% of the living group versus none in the deceased group. None 
of the living group patients had portal vein complication versus one patient in 
the cadaveric group. The mean length of stay in the living group was 26+/- 
15.73 days versus 22.62+/-17.65 days in the deceased group (P= 0.4). 4% of 
the living group SGOT>2000 vs 56% in the deceased group(p<0.05), and 4% 
of the living group SGPT>2500 vs 28% in the deceased group(p<0.05). The 
mean peak value of total bilirubin in the living was 140.45+/-81.32 mmol/l 
versus 175.41+/- 167.19 mmol/dl in the deceased group (p=0.37). The mean 
peak value of INR in the living was 2.46+/-0.86 versus 2.72+/-1.42 in the 
deceased group (p=0.44).
Conclusion: In our series, the biliary complication rate was higher in the 
living group, but otherwise there were no signifi cant differences in the other 
complication, length of stay, and graft function between liver transplant 
patients from living and cadaveric donors. This data suggests that using livers 
from living does not place patients at signifi cantly increased risks of morbidity 
and mortality. Liver transplantation from living donors provides a safe source 
of livers to expand the donor pool in the third world.
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CLINICAL OUTCOMES AFTER LIVER 1309 
TRANSPLANTATION (OLT) FROM LIVING DONORS ARE 
COMPARABLE TO THOSE FROM DECEASED DONORS
M. Almarastani, A.W. Khan, A. Abdulkareem
King Abdulaziz Medical City
Background: Living donors offer expansion of the donor pool in the era of 
donor shortage. The donor shortage is a serious problem in the third world 
countries. The aim of this study is to determine if the outcomes of OLT from 
deceased livers are comparable to those from living one.
Material and methods: A retrospective review of liver transplant recipients 
from deceased and living donor at a single transplant center was performed. 
Patient demographics, liver function tests, length of stay, complications, and 
patient outcomes were reviewed. Comparisons between groups were done 
with Chi-square test and two samples Student t-test with p value < 0.05 being 
signifi cant.
Results: Between January 2002 and December 2006, 82 patients underwent 
OLT. 25 were from living and 57 from deceased donors. The mean age of 
recipients in the living group was 53.24+/- 9.48 years and 53.33+/- 10.79 years 
for deceased group (p=0.96). There were 76% males in the living versus 63% 
in the cadaveric group. None of the living group underwent re-transplanted 
compared with two patients (3%) of the deceased group. The follow up 
period was between 2002- 2007, during this period 84% of living related liver 
transplant patients were still alive versus 86% in the deceased group. There 
was two out of twenty-fi ve patients (8%) in the living group developed primary 
non function versus three out of fi fty-seven patients (5%) in the deceased 
group. None of the living group had hepatic artery complications versus one 
patient (1.7%) in the deceased group. Biliary complications requiring surgery 
developed in 12% of the living group versus none in the deceased group. None 
of the living group patients had portal vein complication versus one patient in 
the cadaveric group. The mean length of stay in the living group was 26+/- 
15.73 days versus 22.62+/-17.65 days in the deceased group (P= 0.4). 4% of 
the living group SGOT>2000 vs 56% in the deceased group9 (p<0.05), and 4% 
of the living group SGPT>2500 vs 28% in the deceased group (p<0.05). The 
mean peak value of total bilirubin in the living was 140.45+/-81.32 mmol/l 
versus 175.41+/- 167.19 mmol/l in the deceased group (p=0.37). The mean 
peak value of INR in the living was 2.46+/-0.86 versus 2.72+/-1.42 in the 
deceased group (p=0.44).
Conclusion: In our series, the biliary complication rate was higher in the 
living group, but otherwise there were no signifi cant differences in the other 
complication, length of stay, and graft function between liver transplant 
patients from living and cadaveric donors. This data suggests that using livers 
from living does not place patients at signifi cantly increased risks of morbidity 
and mortality. Liver transplantation from living donors provides a safe source 
of livers to expand the donor pool in the third world.
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A CHANGE IN BILIARY ANASTOMOTIC TECHNIQUE 1310 
LEADS TO A SIGNIFICANT IMPACT ON COMPLICATIONS 
FOLLOWING ADULT LIVING DONOR LIVER 
TRANSPLANTATION (LDLT)
A.A. Moss1, K.L. Mekeel1, K.S. Reddy1, M.E. Harrison2, D.D. Douglas2, 
H. Vargas2, E. Carey2, T. Byrne2, D.C. Mulligan1
1Division of Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ, United 
States and 2Division of Transplant Medicine, Mayo Clinic Arizona, Phoenix, 
AZ, United States
Up to 60% of patients (pts) undergoing LDLT develop biliary complications, 
most within the fi rst 3 months postoperatively (PO).
We describe a change in anastomotic technique that signifi cantly decreased the 
incidence of biliary complications at our center. This retrospective is a longitudinal 
cohort analysis of 77 LDLT completed at our institution since 2001. For the fi rst 
59 LDLT, the biliary anastomosis, either duct-to-duct (49) or Roux-en-Y (10) 
reconstruction, were completed with a running absorbable suture (Group I). Since 
2006 all our LDLT to date (16) have been completed with a running posterior line 
and an interrupted anterior row of stitches also using absorbable sutures (Group II). 
Since then, the rate of biliary complications (leak and stricture), has signifi cantly 
decreased. In Group I bile leaks occurred in 44% of pts and strictures in 63%, 
many of the leaks occurring after endoscopic balloon dilatation of strictures. Pts 
in Group II had a 6% incidence of both biliary leaks and strictures (p=0.0068 and 
p=0.0001 respectively) (Table 1). The mean follow-up was 47 months for Group 
I and 8 months for Group II. In both groups most biliary complications occurred 
within 3 months PO, with a median of 22 days for leaks and 75 days for strictures. 
If we exclude the fi rst 20 pts of our series as a learning curve, bile leaks occurred 
in 41% (16/39) in Group I and 6% in Group II. Biliary strictures occurred in 67% 
(26/39) in Group I and 6% in Group II, (p=0.0068 and p=0.0001 respectively) 
with a mean follow-up of 35 (Group I) and 8 months (Group II).
In conclusion, employing a biliary anastomotic technique using a combination 
of running and interrupted sutures signifi cantly decreases the incidence of early 
biliary complications in LDLT.
Table 1
 Group I (Running) (n=59)
Group II (Interrupted) 
(n=16) p value
Biliary Leak 26 (44%) 1 (6%) 0.0068
Biliary Stricture 37 (63%) 1 (6%) 0.0001
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BILIARY COMPLICATIONS IN ADULT TO ADULT 1311 
LIVING DONOR RIGHT LOBE LIVER TRANSPLANTS 
– LONG TERM RESULTS
A. Cotterell1, R. Fisher1, D. Maluf1, R. Stravitz2, R. Sterling2, V. Luketic2, 
A. Sanyal2, M. Shiffman2, M. Posner1
1Department of Surgery, Virginia Commonwealth University, 2Department of 
Medicine, Virginia Commonwealth University
Living donor right lobe liver transplantation provides a functional graft for 
adults with end stage liver disease and is one means of alleviating the severe 
shortage of donor organs. However, biliary complications are a major cause of 
morbidity following this procedure. This report compares the incidence of biliary 
complications following Roux en Y versus duct to duct reconstruction. Between 
June 1998 and June 2005, 75 patients underwent 77 adult to adult living donor right 
lobe liver transplants. A Roux limb was used routinely until September 2000, when 
a duct to duct anastomosis was adopted if technically feasible. Of 50 procedures 
involving Roux en Y reconstruction, 15 patients (30%) experienced biliary 
complications including 8 cases of biliary anastomotic strictures (one requiring 
surgical revision), 3 cut surface leaks requiring intervention, 1 anastomotic leak, 
1 anastomotic obstruction and 1 excluded segmental duct. Additionally, 5 patients 
experienced episodes of cholangitis unrelated to strictures. Of 27 patients with 
duct to duct reconstruction, 9 patients (33%)experienced biliary complications 
including 6 anastomotic strictures (4 requiring surgical revision), 2 anastomotic 
leaks, 1 cut surface leak requiring intervention and 1 excluded segmental duct. 
The incidence of biliary complications after adult to adult living donor right 
lobe liver transplantation is approximately 30% regardless of the method used 
for biliary reconstruction. A duct to duct biliary anastomosis is an acceptable 
alternative to Roux en Y reconstruction if technically feasible.
CLINICAL ISLETSCONCURRENT ORAL SESSION 94: 
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FUNCTIONAL CAPACITY OF HUMAN ISLETS SHIPPED 1312 
LONG DISTANCES
V. Vaithilingam1, T. Romagnoli2, J. Oberholzer2, B. Tuch1
1Diabetes Transplant Unit, Prince of Wales Hospital/University of New South 
Wales, Sydney, Australia and Division of Transplantation, 2University of 
Illinois at Chicago, USA
Background: Human islets produced at an Isolation Centre are shipped to 
researchers, usually taking short periods of time to arrive at their destination. 
The Diabetes Transplant Unit in Sydney as part of the Chicago Project has 
received human islets from Chicago. The aim of this preliminary study was to 
investigate the functional capacity of these islets.
Methods: From September to November 2007, two human pancreatic islet 
preparations, each consisting of 100,000IEQ, were sent from the University 
of Illinois at Chicago to Sydney in CMRL at room temperature. The islets 
arrived day 4 post-isolation, and were cultured for a further 2 days before being 
encapsulated in 2.2% barium alginate (Transplantation 2007; 83: 1440-7). On 
day 11-13 post-isolation, the encapsulated islets were transplanted into the 
peritoneal cavity of streptozotocin-diabetic NOD/SCID mice in aliquots of 
3000, 2000 or 1000 IEQs. Blood glucose levels (BGLs) and weights of the 
animals were monitored and oral glucose tolerance tests (OGTTs) performed on 
animals that normalized BGLs. Blood was also collected for human C-peptide.
Results: Viability of the encapsulated islets, as assessed by the fl uorescent 
markers CFDA and PI, was 80-85%, and the average capsule diameter 588 
± 12.μm. In the fi rst preparation, normalization of BGLs was achieved in all 
6 animals that received 3000 IEQs within 24 hours of transplantation, and 
subsequent OGTTs were normal. In the 2nd preparation, normalization of BGLs 
was achieved with both 3000 and 2000 IEQs, but not 1000 IEQs, within 4 days 
of transplantation. This critical number of encapsulated IEQs is similar to the 
number of unencapsulated human islets required to normalize BGLs of diabetic 
immunodefi cient mice reported in the literature.
Conclusion: These data indicate the transportation of islets from Chicago to 
Sydney does not signifi cantly deteriorate their functional capacity.
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EVIDENCE FOR INDUCED EXPRESSION OF HLA CLASS 1313 
II ON ISOLATED HUMAN PANCREATIC ISLETS: POSSIBLE 
MECHANISM FOR HLA SENSITIZATION IN TRANSPLANT 
RECIPIENTS
B. Naziruddin1,2 , A. Jackson1,2, J. Connolly1,3, S. Matsumoto1,3, H. Noguchi1,3, 
N. Onaca2, M.F. Levy2
1Institute of Biomedical Studies, Baylor University, Waco, Tx; 2Baylor 
Regional Transplant Institute, 3Baylor Institute for Immunology Research
Objective: Pancreatic islet transplantation is a promising treatment for labile 
type 1 diabetes mellitus. However, recent reports have shown that islet transplant 
recipients develop antibodies to donor HLA class I and class II antigens. Since 
human islets do not express HLA class II normally, mechanisms underlying 
induction of the alloimmune response are unclear. We hypothesized that under 
infl ammatory conditions islets will have induced expression of HLA class II 
that leads to HLA sensitization.
Method: Human islets isolated from cadaveric donors were divided into two 
groups. Group 1 was cultured at 37 ºC for 48 hours as control; Group 2 was 
cultured at 37 ºC in presence of 1000 U/ml TNF-α and 100 U/ml IFN-γ for 48 
hours to simulate infl ammation. After treatment islets were analyzed for the 
expression of HLA class II using Real-time PCR (CIITA, HLA DRα and β 
chain), immunofl uorescence (anti-insulin and HLA class II), and fl owcytometry 
(anti-HLA class II). Furthermore, HLA class II antibody (DR7) positive serum 
from an islet transplant patient was also tested by fl owcytometry. Prior to 
testing, the serum was cross absorbed with DR7 negative islets to remove non-
specifi c antibody binding.
Results: Real-time PCR analysis for gene transcripts of HLA-DRα, CIITA, 
and HLA-DRβ1 showed 2.41, 5.94, and 1.24 fold increase respectively under 
the treated conditions when compared to control. Fluorescent imaging analysis 
revealed that islet cells express minimal HLA class II molecules on their 
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surface, while the simulation of infl ammation increased surface expression 
dramatically especially on insulin positive beta cells. Flowcytometric analysis 
confi rmed the results obtained from imaging. Patient serum containing anti-
HLA DR7 bound to class II matched islet cells from Group II showing binding 
of both IgG and IgM.
Conclusion: It is known that islets are subjected to infl ammation during the 
peri-transplant period. We conclude that infl ammation leads to induction of 
donor specifi c HLA class II molecules on islets. This increased expression may 
contribute to the development of alloimmune response, which in turn could 
lead to destruction of the islet graft. Minimizing post-transplant infl ammation 
will lead to prolongation of islet graft survival.
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SUPER-LONG DISTANCE INTERNATIONAL SHIPPING1314 
T. Ikemoto1, T. Ito5, A. Jackson4, M. Shimoda3, H. Noguchi1, 
B. Naziruddin3, Y. Yasunami5, S. Matsumoto1,2, L.F. Marlon2,3
1Baylor Institute for Immunology Research, 2Baylor All Saints Islet 
Laboratory, 3Baylor University Medical Center, 4Baylor University, 
5Department of Regenerative Medicine and Transplantation, Faculty of 
Medicine, Fukuoka University
Background: Islet cell transplantation (ICTx) is one of the promising therapies 
for type 1 Diabetes Mellitus. However, it has limited use due to certain issues 
like the diffi culty to convert to normoglycemia with islets from single donor 
pancreas. Compared to North America or European countries, there is a severe 
organ donor shortage in some countries such as Japan. If it is possible to ship 
islets internationally, these severe shortages might be solved. It has already 
been shown that it is possible to ship islet within short distance. However, it is 
still unclear whether international shipping of islet is safe and effective.
Purpose: The purpose of this study is to evaluate the safety and effi cacy 
of shipping islets internationally (from USA to Japan) and to evaluate the 
effi ciency of various islet cell containers.
Method: Three pancreata were procured for this study from January to 
February 2008. All pancreata were preserved by the two-layer method and 
isolations were performed at our institute based on the Ricordi method. Isolated 
islets were packed in gas-permeable and nongas-permeable bags (both form 
Baxter) and shipped by air to Japan. Cell numbers, recovery rate, viability, 
purity, potency based on static incubation method were investigated.
Results: Mean shipping time was 53.6 ±3.5 hours. Overall mean 
numbers,viability,purity of pre-shipping were 34,852 IEq, 92± 2.6%, 48.5± 
11.3%. The same parameters post-shipping were 8705 IEq, 92.4± 1.5%, 
37.6± 3.3%. Recovery rate of islets post-shipping in gas-permeable bags were 
signifi cantly high compared to that in nongas-permeable bags (19.6± 16.4% vs. 
60.9± 7.2%, P<0.05, t-test).
Conclusion: Long distance international shipping of islets is possible. It will 
be more advantageous when gas-permeable bags were used. This could lead to 
a new possibility of islet transplants in countries with limited organ donors and 
islet isolation technology by using islets from an international remote center.
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SHORT-TERM INFUSION OF LOW MOLECULAR 1315 
WEIGHT DEXTRAN SULFATE (LMW-DS) IS WELL 
TOLERATED IN HUMANS AND INCREASES ENDOGENOUS 
EXPRESSION OF ISLET PROTECTIVE HEPATOCYTE 
GROWTH 
FACTOR (HGF)
P. Schmidt1, C. Magnusson1, O. Korsgren2, B. Nilsson2
1TikoMed AB, 2Division of Clinical Immunology, Uppsala University
Introduction: Low Molecular Weight Dextran Sulfate (LMW-DS) attenuates 
all parts of the instant blood-mediated infl ammatory reaction and is a candidate 
drug to prevent early post-transplantation islet graft destruction. An open 
single centre study in healthy volunteers was conducted to study LMW-DS 
pharmacokinetics, safety and tolerability in humans. The effect of the drug on 
endogenous release of various growth factors was also evaluated.
Materials and methods: 34 healthy volunteers, 20 men and 14 women, 
were enrolled. In part A of the study, 6 subjects received LMW-DS as one 
i.v. bolus dose of 1.5 mg/kg followed by a 20 minutes i.v. infusion of 3 mg/
kg (simulating the procedure of islet transplantation). Monitoring of activated 
partial thromboplastin time (APTT) in whole blood was used to estimate and 
control the plasma concentration and results from part A were used to calculate 
a dosage regimen in the subsequent part B. Here, 24 subjects were divided into 
four groups and received the same treatment as in part A plus a continuous 
i.v. infusion of LMW-DS for 5 hours to reach one target APTT per group; 10s 
above baseline (i.e. ~35s), 60s, 100s and 150s, respectively. 4 subjects were 
given 5000 IU heparin as a reference treatment. Safety, including haemostasis 
parameters, was evaluated prior to proceeding to a higher target APTT-level. 
Plasma was collected continuously during the infusion and was analysed 
for APTT, additional safety markers and the presence of 6 different growths 
factors.
Results: In all evaluated subjects receiving LMW-DS, the mean peak APTT 
was 187s (SD+/-37s, n=29), obtained at the end of the 20 minutes infusion. 
In part B, the predetermined target levels of APTT were reached and kept 
without extensive dose corrections. After the 5hrs20min LMW-DS infusion, 
the subjects in the highest dose group (target APTT=150s) were back at APTT-
levels below 75s within 60 minutes. There was a good correlation between 
APTT measured in whole blood and in plasma. Plasma levels of Hepatocyte 
Growth Factor (HGF) were increased 100-fold within 20 minutes of infusion 
start and persisted more than 8 hours in the two highest dose groups (target 
APTT=100s and 150s).
Conclusion: The study demonstrated that LMW-DS, at doses that maintain 
APTT at up to 150s for 5h20min, safely could be infused without affecting 
the platelet count or revealing other signs of increased bleeding risk. 
Pharmacokinetics was determined and confi rmed to be favourable from a 
safety perspective. Bed-side monitoring of APTT in whole blood was shown to 
be a suitable technique to monitor the LMW-DS plasma concentration. Based 
on previously published in vivo data, we propose that the endogenous release 
of islet protective HGF could be an additional benefi cial effect of LMW-DS 
during the fi rst critical hours after transplantation.
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LATE EPSTEIN BARR VIRUS REACTIVATION IN ISLET 1316 
TRANSPLANT RECIPIENTS
P. Cure1, C.B. Leitão2, A. Pileggi1, T. Tharavanij3, D.A. Baidal1, D. Mineo1, K. 
Bernetti1, T. Froud1, C. Ricordi1, R. Alejandro1
1Diabetes Research Institute, University of Miami, 2Endocrine Division of 
Hospital de Clínicas de Porto Alegre, RS, Brazil, 3Department of Medicine, 
Thammasat University, Pratumthani, Thailand
Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis, 
is among the most frequent viral infections occurring after transplantation 
being associated to graft dysfunction/rejection and increasing in morbidity 
and mortality in this population. In EBV sero-positive (IgG>IgM) solid organ 
transplant recipients, the incidence of EBV reactivation might be as high as 
~60%. In islet transplantation, all potential recipients must be EBV sero-positive. 
Prophylaxis with valganciclovir is given for 3 months after transplantation 
and EBV PCR in peripheral blood is measured at least every 6 months as per 
protocol. Long-term immunosuppression represents a risk for EBV reactivation, 
with the additional risk of post-transplant lymphoproliferative disease (PTLD). 
To date, no cases of EBV reactivation and clinical disease have been reported 
in the literature in patients following islet transplantation under an Edmonton-
like immunosuppressive regimen.
Herein we present the incidence of late EBV-reactivation in recipients of islet 
transplantation (IT) under the Edmonton-like protocol. A total of 23 subjects, 
16 islet transplant alone (ITA) and 7 islet after kidney (IAK) recipients were 
included. Four patients (ITA= 2, IAK n= 2) were excluded due to short-term 
follow up (<800 days). Patients were divided in cases (n=4) and controls (n=15) 
based on EBV infection detected by PCR. Total time in months since initiation of 
immunosuppression (IS) after kidney or islet transplant was calculated. The two 
groups were compared in terms of overall exposure to maintenance IS 3 months 
prior to EBV detection measured by trough levels of sirolimus and tacrolimus 
(24 and 12 hour, respectively) as well as in terms of Hemoglobin A1c.
EBV-reactivation was observed in 4/19 (21%) patients (ITA n=1, IAK n=3). 
Two IAK cases had a second recurrence after successful treatment and negative 
EBV-PCR (total EBV episodes = 6). Total time on IS was longer in patients 
with EBV (126.4±50.5 vs 67.3±32.7 months, p=0.005), but time after IT was 
not different between groups (46.6±16.2 vs 52.7±18.9 months, p=NS). No 
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differences were observed in overall IS levels of sirolimus (11.7±0.4 vs 11.5±2 
ng/ml) and tacrolimus (4.8±0.2 vs 4.6±0.3 ng/ml) between case and control 
groups. Similarly, no differences in levels 3 months prior to EBV-reactivation 
(or equivalent time in controls) were found. HbA1c was similar (5.9±0.4 vs 
6.0±0.6%). Clinical symptoms included chronic fatigue (n=5), glucose instability 
(n=1) or no symptoms (n=1). Notably, 4 IAK recipients had history of dialysis, 
three of which developed EBV reactivation (NS). In all cases, reduction of IS (at 
least 10%) and valganciclovir therapy were required. No PTLD was observed.
Late EBV-reactivation may occur after IAK and less frequently after ITA. Long 
term IS therapy may increase the risk of EBV infection/reactivation. We did 
not observe any relationship between occurrence of EBV and other variables 
(immunosuppressive drug levels and HA1c). Furthermore, direct relationship 
between EBV reactivation/infection and islet graft dysfunction/rejection cannot 
be established at this point. In recipients of IT, long term follow-up should 
include EBV-DNA PCR at least twice a year and/or as clinically indicated.
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IMPROVED LONG-TERM HEALTH RELATED QUALITY 1317 
OF LIFE AFTER ISLET TRANSPLANTATION: A 6-YEAR 
FOLLOW-UP STUDY
T. Tharavanij1,2, A. Betancourt3, S. Messinger1,4, P. Cure1, C.B. Leitao1, 
T. Froud1,5, C. Ricordi1,5, R. Alejandro1,6
1Diabetes Research Institute, University of Miami, Miami, Florida, USA, 
2Department of Medicine, Thammasat University, Pratumthani, Thailand, 
3Departments of Psychiatry and Behavioral Science, University of Miami, 
Miami, Florida, USA, 4Department of Epidemiology and Public Health, 
5Department of Surgery, 6Department of Medicine
Objective: To evaluate long-term effects of islet transplantation (ITx) on health 
related quality of life (HRQoL) and to outline possible infl uential factors.
Research design and methods: Forty ITx recipients completed 344 Health 
Status Questionnaires (HSQ 2.0) and 384 Diabetes quality of life questionnaires 
(DQoL) between 1996-2007. Assessments were performed pre-ITx, then every 
3 months after the fi rst infusion for 18 months and every 6 months thereafter. 
The mean follow-up post-ITx was 26±19.5 (3-72) months. Clinical and 
metabolic variables, medications and adverse events were recorded.
Results: Sustained improvement in DQoL-impact score was observed at all 
time-points post-ITx (increment of 6±3 to 15.5±3, p<0.05). Similarly, worry 
and satisfaction scales were signifi cantly better than pre-ITx evaluation for 
most time-points. Four-out-of-eight HSQ 2.0 scales demonstrated a signifi cant 
improvement at several time-points (increment of 5±2 to 17±4, p<0.05). 
Longitudinal analysis, after adjustments for potential confounding factors, 
showed sustained improvement in impact scale up to 72 months (increment of 6±2 
to 11±3, p<0.05). Longer diabetes duration, higher insulin dosage and occurrence 
of adverse events had negative effects on HRQoL. Single islet infusion or islet 
after kidney transplant (IAK) recipients showed the lowest values in HSQ 2.0. In 
contrast, patients on exenatide therapy had signifi cantly higher HSQ 2.0 scores.
Conclusions: ITx is associated with long-term improvement in HRQoL. 
Exenatide usage had a positive effect while single islet infusion, IAK 
transplantation, longer diabetes duration, higher insulin dosage and adverse 
events had a negative impact on HRQoL scores.
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LONG-TERM METABOLIC AND HORMONAL EFFECTS 1318 
OF EXENATIDE ON ISLET TRANSPLANT RECIPIENTS WITH 
ALLOGRAFT DYSFUNCTION
T. Froud, R.N. Faradji, S. Messinger, P. Cure, A. Pileggi, D. Mineo, T. 
Tharavanij, A. Mendez, C. Ricordi, R. Alejandro
Clinical Islet Transplant Program, Diabetes Research Institute, University of 
Miami Leonard M. Miller School of Medicine, Miami, FL, United States
Context: The initial success of Islet Transplantation (ITx) is followed by graft 
dysfunction (GD) and insulin reintroduction. Exenatide, a GLP-1 agonist, 
increases insulin and decreases glucagon secretion and has potential for β-cell 
regeneration. To improve functional-islet-mass, exenatide treatment was given 
to ITx recipients with GD.
Objective: Assess metabolic and hormonal effects of exenatide in GD.
Design: Prospective, single-arm, 12-month duration.
Patients or other participants: Eleven type-1-diabetes recipients of ITx with GD.
Interventions: Exenatide injection.
Main outcome measures: HbA1c, weight, insulin requirements and mixed-
meal tolerance-test (MMTT; with/without exenatide given before test) at 
baseline, 3, 6 and 12 months after initiating exenatide.
Results: Baseline MMTT showed postprandial hyperglycemia and 
hyperglucagonemia. Daily exenatide treatment resulted in improved glucose, 
increased amylin and decreased proinsulin as assessed by MMTT. Glucagon 
responses remained unchanged. Exenatide administration 1-hr before MMTT 
showed decreased glucagon and glucose at 0-min and attenuation in their 
postprandial rise. Time-to-peak glucose was delayed, followed by insulin, 
proinsulin, amylin and C-peptide; indicating glucose-driven insulinsecretion.
Five subjects completed 12-month follow-up. Glucose and glucagon suppression 
responses after MMTT with exenatide were no longer observed. Retrospective 
3-month analysis of these subjects revealed higher and sustained glucagon 
levels that did not suppress as profoundly with exenatide administration, 
associated with higher glucose levels and increased C-peptide responses.
Conclusions: Exenatide suppresses the abnormal postprandial 
hyperglucagonemia and hyperglycemia observed in GD. Changes in amylin 
and proinsulin secretion may refl ect more effi cient insulin processing. Different 
degrees of responsiveness to exenatide were identifi ed. These may help guide 
the clinical management of ITx recipients.
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OPTIMISING HUMAN SERUM FOR CLINICAL ISLET 1319 
ISOLATION
M. Ståhle, A. Andersson, O. Korsgren
Clinical Immunology and Transfusion Medicine, University Hospital, 
Uppsala, Sweden
Background: Human serum is regarded as the preferred supplement throughout 
the process of clinical islet isolations and culture. However, for safety and 
regulatory purposes, mainly related to the risk of transferring infections to the 
recipient, many centers involved in clinical islet programs are required to use 
human albumin instead. The risk depends on the quality of the test used to 
detect pathogens and the epidemiology of the donors. Today the risk of viral 
contamination of blood components has been dramatically reduced as a result 
of extensive testing of blood donors for different infectious disease markers. 
However, the appearance of new pathogens in the population escaping even 
the most advanced detection protocols remains a major concern. Pathogen 
inactivation (PI) may provide a way to protect from both known and as yet 
unidentifi ed agents.
Aim: In many European countries, the Intercept technology is routinely used 
for pathogen inactivation of platelets and plasma for clinical use. Intercept 
uses small molecules of psoralen which can pass through cell membranes and 
capsids. Here, the psoralens bind to the helical regions of the nucleid acid. 
When UV-A light (300-400 nm) is applied, the psoralens crosslink to the DNA 
and RNA, both free and in the genome, thus blocks both transcription and 
replication. It has so far not been tested for inactivation of human serum. The 
aim for this study was to evaluate the use of this method on human serum used 
for culture of human islets of Langerhan.
Method: Whole blood from normal Swedish donors was allowed to coagulate 
and the serum was collected and treated with the Intercept system (PI) or 
not (control). Both groups of serum complement inactivated (57Co, 30 min). 
Human islets of Langerhan were cultured with PI serum or control serum 
(10%) for 4 days under standard conditions (37°C and 5% CO2) including a 
medium exchange on day 2.
Result: There was no difference between the two groups in terms of insulin 
stimulation index (dynamic glucose challenge) or the amount of ATP compared 
with ADP in the cells (energy content in the cells). Likewise, no difference was 
found in expression of insulin, IL-6, IL-8, Tissue Factor and MCP-1.
Conclusion: Our results demonstrate that PI provides a solution to an important 
safety and regulatory problem in modern cell therapy. PI exerts no negative 
impact on the islets and may provide a solution allowing the use human serum 
in clinical islet transplantation. A major advantage of PI is that it, due to its 
mechanism of action, eliminates also unknown emerging pathogens for which 
tests do not exist today.
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EFFECT OF 1320 IN VITRO TREATMENT OF ISOLATED 
HUMAN ISLETS WITH HUMAN ALPHA1-ANTITRYPSIN
A.N. Balamurugan1, E.C. Lewis2, A.C. Wiseman1, S. Pugazhenthi1, 
S.A. Sarkar1, C.A. Dinarello2, R.G. Gill1
1Barbara Davis Center for Childhood Diabetes, University of Colorado Health 
Sciences Center, Denver, CO, USA. 2Department of Medicine, University of 
Colorado at Denver and Health Sciences Center, Denver, CO, USA
Alpha1-antitrypsin (A1-AT) is a serine protease inhibitor that possesses anti-
infl ammatory properties. In mouse islets, A1-AT treatment protects beta cells 
from isolation-associated apoptosis and reduces cytokine-induced cell loss. 
When administered to mice, monotherapy with A1-AT prevents diabetes onset 
in the NOD model, prolongs graft survival in islet allograft transplantation and 
induces strain-specifi c allograft tolerance. The effect of A1-AT treatment on 
isolated human islets in vitro has not been reported. In the present study, we 
evaluated the effect of A1-AT on human islets. Islets from fi ve donors were 
exposed to clinical grade A1-AT from either of two sources (Prolastin® and 
Aralast) each containing comparable elastase inhibitory activity but different 
anti-infl ammatory properties, as established using human blood cytokine 
production assays. Human islets were isolated by semi-automated method 
and purifi ed with density gradients. Hand-picked human islets were cultured 
for 48-72 hours in the presence of increasing concentrations of A1-AT (0.05 
to 0.5 mg/ml, 6-replicate wells) under constitutive culture conditions, and 
in the presence of IL-1beta plus interferon gamma, which mimic the early 
infl ammatory and pro-apoptotic environment that follows human intrahepatic 
engraftment. Functional assessments included morphology, cell loss, insulin 
content, insulin release, cell viability, cytokine and chemokine secretion, 
gene expressions and in vivo beta-cell function following transplantation into 
streptozotocin-induced diabetic mice.
Although islets incubated with Prolastin® produced signifi cantly less 
constitutive IL-6 and IL-8 secretion and exhibited reduced interferon gamma 
gene expression, there was no signifi cant difference in morphology, cell loss, 
insulin secretion, insulin content or viability. Prolastin® treatment did not 
improve transplantation of human islets into diabetic mice. In contrast, islets 
incubated with Aralast produced signifi cantly less constitutive IL-8 (> 50% 
reduction) and IL-6 (> 70% reduction). Also, in cytokine-stimulated islets, 
Aralast improved morphology and signifi cantly reduced IL-6, IL-8, MCP-1 
and nitric oxide levels.
In conclusion, the effects of in vitro A1-AT treatment on human islets suggest 
that the protective activity of A1-AT is independent of protease inhibition. The 
addition of A1-AT may offer cytoprotection during cadaveric islet isolation. 
Furthermore, in light of the safety record of A1-AT in humans, A1-AT pre- and 
post-treatment may be benefi cial for islet graft survival during transplantation 
in humans.
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ISLET ALONE, ISLET-KIDNEY, AND ISLET AFTER-1321 
KIDNEY TRANSPLANTATION IN ARGENTINA
S. Hyon, M. Barbich, R. Groppa, L. Gimeno, L. Grosembacher, P. Martinez, 
R. Marenchino, N. Imperiali, L. Algranati, P. Argibay
Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos 
Aires
Introduction: Islet transplantation may be used as an alternative treatment for 
type-1 diabetic patients with metabolic instability and inadequate response to 
insulin therapy.
Objective: To describe the results with islet transplantation in the pre- and 
post-Edmonton Protocol era at a single pancreas and islet transplant center. 
Patients and methods: Twenty seven islet transplants were performed in this 
series. Twenty were done as simultaneous islet-kidney transplants (SIK), 1 
was an islet after kidney (IAK) transplant, and 6 were islet transplants alone 
(ITA). Recipients for SIK were type-1 diabetic patients on dialysis due to end-
stage renal disease who were not eligible for simultaneous vascularized grafts. 
An IAK was performed in a diabetic patient who showed loss of pancreatic 
graft function following a simultaneous kidney and pancreas transplant done 
in France several years earlier. Immunosuppression and peritransplant care for 
both SIK an IAK patients were based on the University of Giessen protocol 
(including the use of steroids). Three patients with brittle diabetes and normal 
kidney function received 1, 2 and 3 sequential islet transplants, respectively, 
under the Edmonton protocol (steroid free, sirolimus, low-dose tacrolimus, and 
daclizumab immunosuppression). Recipient mean age was 42.8 +/- 6.2 years. 
Cold ischemia time for pancreas was 7.6 +/- 2.4 h, while kidney cold ischemia 
time in SIK cases was 9.3 +/- 2.5 h. Islets were obtained after liberase digestion 
of the exocrine tissue in a Ricordi chamber and transplanted without previous 
culture into the portal circulation (n=21) or the omentum (n=6). In every case, 
90% viability was obtained. Mean islet equivalent number was 6,649.5 +/- 
4,093.3 per kilogram of recipient weight.
Results: Islet graft survival (defi ned as C-peptide levels =/>0.5 ng/dL) for 
intrahepatic transplants at 1-week, 2 months, and 1 year were 57.1%, 35.7%, 
and 21.4%, respectively. Mean HbA1c and creatinine at one year were 6.4% 
and 1.4 mg/dL, respectively. Post-transplant episodes of hypoglycemia were 
reduced in 76%. Mean insulin requirement pre- vs. post-transplantation was 
50.4 +/- 5.7 IU/d vs. 44.1 +/- 3.8 IU/d, respectively. One patient with ITA had 
an intrahepatic bleeding that required red blood cell transfusion. The presumed 
cause of graft failure in the patients with ITA was the insuffi cient islet mass. 
Conclusions: Although in this series none of the patients achieved insulin 
independence, all of them evidenced a marked improvement of the metabolic 
control, with fewer and less severe episodes of hypoglycemia. Continuing 
investigation in the fi eld of islet transplantation worldwide will defi ne its real 
role in the treatment of patients with diabetes.
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SUCCESSFUL SHIPPING OF HUMAN PANCREATA 1322 
AND ISOLATION OF PANCREATIC ISLETS BY REMOTE 
ISOLATION CENTERS — AN AUSTRALIAN PERSPECTIVE
C. Milner1,4, C. Drogemuller1,4, C. Russell1,4, T. Loudovaris2,4, 
W. Hawthorne3,4, T. Kay2,4, P. O’Connell3,4, G. Russ1,4, P. Coates1,4
1The Queen Elizabeth Hospital, Adelaide, 2Tom Mandel Islet Program, 
St. Vincent’s Hospital, Melbourne, 3Center for Transplant and Renal Research, 
Westmead Millenium Institute, Sydney, 4Australian Islet Consortium
In North America and Europe the use of central islet processing centers has been 
promoted amongst various islet transplantation programs to maximise expertise 
in islet isolation. Based on overseas success the Australian Islet Transplant 
Consortium adopted this model. Since the inception of the Consortium in 2006, 
the Adelaide Transplant Center has shipped pancreata interstate to either of the 
Australian islet isolation centers in Melbourne or Sydney. This allows the islet 
isolation expertise to be concentrated in these centers, and the isolated islets to 
be utilized in specialized transplant units outside of the isolation centers. Islets 
from these shipped pancreata, as well as islets from pancreata not procured in 
Adelaide, have been successfully returned to Adelaide.
Method: The quality and quantity of islets produced at remote isolation centers 
was evaluated. Human pancreata were shipped from Adelaide (n=32) or 
Darwin (n=2) by commercial airlines to the Melbourne (n=25) or Sydney (n=9) 
isolation centers. Pancreata were shipped using the Two-Layer-Method (TLM) 
to Melbourne (25), or preserved with University of Wisconsin (UW) solution 
to Sydney (9). The islets were isolated using a modifi ed Ricordi method, after 
initially using Roche Liberase®, and lately using Serva® Collagenase and 
Neutral Protease. Product release tests for the islets (quantity, purity, viability 
index, sterility and stimulation index) were performed at the isolation center, 
and at the islet receiving center when adequate islets were received.
Results: Between July 1st 2006 and December 31st 2007 a total of 34 donor 
pancreata were procured and shipped from Adelaide, (14M; 20F; age 53.5 
years; BMI 27.5). The average time from cross clamp to airport departure was 
4hr 7min (Melbourne) and 3hr 12min (Sydney), followed by an additional 
2 hr for transportation to Melbourne or 3hr 30min to Sydney, resulting in 
total shipping time of <8 hours. One islet preparation was used for an islet 
transplant, while 30 of the remaining 33 pancreata produced islets for research. 
An additional 5 pancreata sourced from elsewhere had islets returned to 
Adelaide (total returned = 35). The average islet yield was 176,940 (range 
23,000-366,000), with a purity of 73% (range 45-90%). We have previously 
shown that the yield of islets using the TLM with a Cold Ischemic Time (CIT) 
of >6 hours is comparable to the yield of islets without using the TLM and 
having a short CIT (average 3hr 19mins). However without the TLM and a CIT 
of >6hrs, the islet yield was on average 50% less than yields where the TLM 
was used. All returned islet products passed the sterility test except one which 
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grew Candida albicans, which was also confi rmed at the isolation center. All 
islets samples had 100% viability at the isolation centers, and all endotoxin 
levels tested were acceptable.
Conclusions: In Australia where centers are geographically remote, donor 
pancreata can be received at isolation centers using commercial airlines 
with an acceptable CIT to allow successful islet isolation. Viable islets can 
be successfully returned to interstate centers using commercial airlines. 
Shipped islets have met islet cell quality, quantity and sterility criteria for 
transplantation.
POSTER BOARD NUMBER P2 – 122
USE OF ACETAMINOPHEN LEVEL TESTING DURING 1323 
MIXED MEAL STIMULATION IN ISLET TRANSPLANT 
RECIPIENTS USING EXENATIDE
T. Froud1,2,3, R.N. Faradji1,3, D.A. Baidal1, A. Mendez1, G. Selvaggi1,2, 
C. Ricordi1,2, R. Alejandro1,4
University of Miami Miller School of Medicine, Miami, USA, 1Diabetes 
Research Institute, 2Department of Surgery, 3Department of Radiology, 
4Department of Medicine
Background: Following the approval of exenatide (Exn) its use in islet 
transplant recipients with graft dysfunction was commenced at this institution. 
Long term diabetes has the risk of neuropathic complications and gastroparesis, 
and Exn has the effect of delaying gastric emptying. This study evaluated the 
effect of Exn on gastric emptying during mixed meal testing (MMT) in this 
unique population.
Methods: 12 subjects that had received at least one islet infusion and had been 
taking exn for more than 3 months were included. 1000 mg of acetaminophen 
(Acet) were co-administered with the 12 oz liquid mixed meal stimulus and 
levels of glucose, insulin, c-peptide and acetaminophen were measured up to 
5 hours post ingestion.
Results: Evaluation of Acet levels during MMT without Exn, demonstrated a 
typical emptying pattern in 6 subjects (group 1) and an abnormal pattern in 6 
subjects (group 2). Peak Acet levels occurred ≤120 mins in group 1 compared 
to ≥180 mins in group 2. Mean peak Acet levels were 92±17.8 and 34.7±28.3 
pg/ml in groups 1 and 2 respectively. Mean time to peak was 105±16.4 and 
270±118.5 mins in groups 1 and 2 respectively. The administration of Exn 
resulted in delayed gastric emptying overall, mean time to peak without Exn 
162.5±74.0 mins, with Exn 245±69.9 mins, however subanalysis of groups 1 
and 2 demonstrated delay in peak Acet more pronounced in subjects with a 
pre-existing normal empyting pattern. Mean time to peak (group 1) without 
exn 162.5±16.43, with exn 280.0±49.0 mins and in group 2: without Exn 
270.0±118.5, with Exn 230.0±79.7 mins
Discussion: In this small group of subjects the frequency of pre-existing 
abnormal gastric emptying was high (50%). Exenatide caused a signifi cant 
delay in liquid gastric emptying in subjects that had a normal pattern of gastric 
emptying but not in subjects that had pre-existing delay. The signifi cance of 
this fi nding and its contribution to glycemic control remain to be elucidated.
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SUBCUTANEOUS TRANSPLANTATION OF EMBRYONIC 1324 
PANCREAS AND NON-INVASIVE IN-VIVO IMAGING IN MICE 
WITH TYPE 1 DIABETES
S. Gunawardana, R. Benninger, S. Head, D. Piston
Vanderbilt University
Islet transplantation, a promising treatment for type 1 diabetes, has many 
limitations. It requires millions of donor islets, initial invasive surgery and 
lifelong immuno-suppressive therapy. Success is low due to graft rejection; 
poor vascularization; and diffi culty to monitor graft viability in-vivo. We 
have developed a strategy with the potential to overcome all these problems. 
This technique includes minimally-invasive transplantation of mouse 
embryonic pancreatic tissue expressing green fl uorescent protein(GFP) into 
the subcutaneous space of recipients with diabetes, and non-invasive in-vivo 
monitoring of transplants using two-photon excitation microscopy(TPEM). 
This strategy, if successful, can be easily customized for human patients using 
stem cell-derived islet-like cell clusters.
Using embryonic pancreata instead of mature islets has many advantages. 
Embryonic tissue, being immune-privileged, can survive better within a 
foreign host. Being a built-in source of angiogenic factors, embryonic tissue 
can achieve successful vascularization even in a site with poor vascularization 
potential. Furthermore, an embryonic pancreatic bud, not much larger than 
an islet, can develop into a mature endocrine pancreas inside the recipient, 
eliminating the need for many donor islets. Unlike traditional transplantat sites, 
subcutaneous tissue is superfi cial and easily-accessible, eliminating the risks 
and inconveniences in initial invasive surgery, and can be used repeatedly if 
necessary. Transplants can be placed in a minimally invasive manner with 
minute incisions and no sutures.
Current success rate of transplantation therapy is low. A major difficulty 
in finding and addressing problems is the lack of techniques to monitor 
transplant development in-vivo. There are no suitable techniques in 
humans, and the techniques used in research animals are invasive, involving 
chronic instrumentation or repeated surgery. Confocal microscopy often 
used for imaging transplants involves high laser intensities that cause 
tissue damage. The ideal transplant-monitoring technique should be 
painless, non-invasive, and not harmful to live tissue. Imaging GFP-
expressing subcutaneous transplants by TPEM is such a technique. Our 
donor embryonic pancreata come from mice expressing GFP under 
regulation of the insulin-1 promoter, causing beta cells to emit bright green 
fluorescence. TPEM can produce optical sectioning up-to 1 mm depth 
inside the tissue, and causes minimal photo-damage. With TPEM we can 
detect subcutaneously transplanted GFP-expressing embryonic pancreata 
non-invasively from the skin surface.
We have successfully transplanted embryonic pancreata subcutaneously into 
several recipient strains, and optimized imaging parameters for non-invasive 
in-vivo graft-monitoring with TPEM. Preliminary data show survival, 
vascularization, and differentiation of transplants into insulin-containing 
islet-like structures; and considerable improvement of blood glucose 
homeostasis in diabetic mice. Provided these transplants can permanently 
reverse diabetes, this technique would eliminate many problems in current 
transplantation therapy. We hope to test its success at a larger scale in several 
models of type 1 diabetes, determining whether subcutaneously transplanted 
embryonic pancreata can a)survive within non-immune defi cient hosts 
without immuno-suppression; b)achieve vascularization comparable to renal 
subcapsular transplants; and c)reverse diabetes, with or without facilitation 
techniques to help their survival. In light of recent advances in stem cell 
research, this technique, if successful, would be applicable towards human 
transplantation therapy, and would pave the way towards a much greater 
transplant success rate.
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C5A INHIBITORY PEPTIDE COMBINED WITH 1325 
GABEXATE MESILATE IS A CLINICALLY AVAILABLE 
CANDIDATE FOR PREVENTING THE INSTANT BLOOD-
MEDIATED INFLAMMATORY REACTION
K. Tokodai1, M. Goto1.2, T. Imura2, N. Ogawa1, K. Fujiori3, Y. Kurokawa2, 
H. Okada4, S. Satomi1
1Division of Advanced Surgical Science And Technology, Tohoku University, 
Sendai, Japan, 22Tohoki University Biomedical Engineering Research 
Organization, Tohoku University, Sendai, Japan, 33Division of Surgical 
Oncology, Tohoku University, Sendai, Japan, 44Choju Medical Institute, 
Fukushimura Hospital, Toyohashi, Japan
Background: The instant blood-mediated infl ammatory reaction (IBMIR), 
characterized by activation of both the coagulation and complement cascades, 
is one of the main obstacles to successful islet engraftment. We have thus 
far shown that a low molecular weight dextran sulfate effi ciently attenuates 
xenogeneic IBMIR triggered by porcine islets (Transplantation:2004:77:741
-747). No attractive protocol, however, is clinically available yet. Therefore 
the aim of the present study was to examine whether complementary peptide 
against an active region of C5a, proved to be safe due to extremely low 
molecular mass, in combination with clinically available anti-coagulant could 
provide an effective protocol for suppressing IBMIR.
Methods: Three islet equivalents/g of syngeneic rat islet grafts were 
transplanted intraportally into 6 pairs of streptozotocin-induced diabetic rats. 
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Islets from the same donor were transplanted to each pair and for each pair, 
one rat was treated with C5a inhibitory peptide (bolus: 4 mg/kg, continuous 
infusion: 0.42 mg/kg/hr for 3 days) in addition to a continuous intravenous 
infusion of gabexate mesilate (2 mg/kg/hr) 30 minutes prior to islet infusion 
and up to 1 hour after the infusion. The other recipient was injected with 
equivalent amount of saline and served as a control. Two rats were treated 
with the same dose of gabexate mesilate. The curative rate, the duration to 
normoglycemia, insulin amount in the liver of the recipients, and in vivo 
glucose tolerance tests were evaluated.
Results: The curative rate was remarkably improved (100% vs. 33.3%, 
p=0.005) and the duration to normoglycemia in cured animals was signifi cantly 
shortened in treated group (12.2 }1.4 vs. 25.0 }0.0, p=0.039). Two rats only 
received the gabexate mesilate did not restore normoglycemia during the whole 
study period. No difference was observed between the groups in terms of 
glucose tolerance (AUC:p=0.85, Kg:p=0.35). However, insulin amount in the 
liver was considerably higher in treated group than that in control group (18.0 
}3.2 vs. 12.0 }1.0 ng/IEQs p=0.14). Notably, the increase of body weight in 
the recipients was not affected by treatment (the increase rate of body weight: 
128.6 }1.2% vs. 127.7 }3.3%, p=0.80), suggesting that C5a inhibitory peptide 
combined with the gabexate mesilate is considered to be free from the side 
effect.
Conclusions: These data suggest that C5a inhibitory peptide combined with 
gabexate mesilate could be an attractive drug candidate, without side effects, 
to control the detrimental innate immune responses induced in clinical islet 
transplantation.
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A NOVEL PREDICTIVE METHOD FOR ASSESING THE 1326 
QUALITY OF ISOLATED PANCREATIC ISLETS USING 
A SCANNING ELECTROCHEMICAL MICROSCOPY
M. Goto1, H. Abe1, T. Ito-sasaki1, M. Goto1, A. Inagaki1, N. Ogawa2, 
K. Fujimori3, Y. Kurokawa1, T. Matsue4, S. Satomi2
1Tohoku University Biomedical Engineering Research Organization, 2Division 
of Advanced Surgical Science and Technology, Tohoku University, 3Division 
of Surgical Oncology, Tohoku University, 4Graduate School Environmental 
Studies, Tohoku University
Aims: The current standard methods for evaluating islet potency are not useful 
in clinical islet transplantation. Furthermore, most tests are relatively subjective 
and time-consuming. Therefore, establishment of reliable and rapid methods 
enabling accurate prediction of islet quality is warranted.
Methods: In the present study, we have evaluated the respiratory activity 
using a scanning electrochemical microscopy (SECM), glucose stimulated 
respiratory activity, glucose stimulated insulin release, ADP/ATP assay, levels 
of insulin/DNA, and Trypan blue exclusion test as predictive methods for the 
ability of isolated rat islets which were exposed to various degrees of heat 
shock stress (0, 40, 50, 60, 80 seconds) to cure Streptozotocin-induced diabetic 
syngeneic rats.
Results: Although glucose stimulated respiratory activity, basal respiratory 
activity, ADP/ATP ratio, and glucose stimulated insulin release was 
signifi cantly correlated to the outcome of transplantation into diabetic rats 
(p<0.0001, <0.0001, <0.0001, and 0.002: ƒÏ=0.80, 0.71, -0.66, and 0.53, 
respectively), there was no correlation between islet transplantation outcome 
and insulin/DNA ratio, and Trypan blue exclusion test. The glucose stimulated 
respiratory activity in islet preparations that could cure diabetic rats was 
signifi cantly higher than in those unable to cure diabetes (1.94 }0.18 vs. 0.57 
}0.07: p<0.0001). Rat islets with the glucose stimulated respiratory activity 
more than 1.5 consistently cured diabetic rats, whereas rat islets with a value 
less than 1.5 hardly cured any rats (p<0.0001). Notably, the predictive rate 
for curing diabetic rats was 91% when glucose stimulated respiratory activity 
was employed.
Conclusions: A measurement of the glucose stimulated respiratory activity 
using a SECM technique is a novel method that could be applied as a rapid and 
potent predictor for the outcome of clinical islet transplantation.
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ADENOSINE HAS AN INHIBITORY EFFECT ON 1327 
NKT CELLS FACILITATING TO PREVENT EARLY LOSS 
OF TRANSPLANTED ISLETS IN ASSOCIATION WITH 
ENGRAFTMENTS
T. Nitta1, N. Matsuoka1,2, T. Itoh1, T. Mera1, A. Kinjo1, M. Nakano1,2, 
Y. Yamashita2, Y. Yasunami1
1Dept of Regenerative Med and Transplantation, Fukuoka University, 2Dept of 
Gastroenterol Surg, Fukuoka University
The limited success in achieving insulin-independence of a single IDDM 
recipient from one donor hampers clinical application of pancreatic islet 
transplantation. One of the major reasons for this includes early loss of 
transplanted islets in association with engraftments. Previously, we have 
shown that NKT cells play an essential role in the early loss of transplanted 
islets in the liver of mice (JEM 202:913, 2005), which prompted us to screen 
drugs which have already been introduced in clinics and have an inhibitory 
effect on NKT cells. Here we demonstrate that adenosine fulfi lls the criteria. 
A single injection of adenosine (ip, 5mg/kg) at the time of islet transplantation 
ameliorates hyperglycemia of STZ-diabetic mice (C57BL/6) receiving 200 
syngenic islets, which otherwise remained hyperglycemic by 60 days after 
transplantation. Two hundreds is a number of islets isolated from a single 
mouse pancreas. In the liver of @diabetic mice receiving islets and treated with 
saline as a control, hepatic NKT cells become activated and Gr-1+CD11b+ 
cells (neutrophils) accumulated into the liver by 6 hours after transplantation 
with up-regulation of their IFN-ƒÁ production, essential for early loss of 
transplanted islets. In marked contrast, a single injection of adenosine (ip, 
5mg/kg) at the time of islet transplantation down-regulates IFN-ƒÁ production 
not only of NKT cells but Gr-1+CD11b+ cells in the liver receiving islets, 
although accumulation of Gr-1+CD11b+ cells was similarly seen. IFN-ƒÁ 
production of NKT cells in the liver of mice treated with iv administration of 
ƒ¿-Galactosylceramide, a synthetic ligand of NKT cells was down-regulated 
by a single injection of adenosine. Inhibitors of adenosine transporter on the 
cellular membrane such as dipyridamole (persantin) and S-(4-nitrobenzyl)-6-
thioinosine (NBTI) have similar effects to adenosine with respect to prevention 
of early loss of transplanted islets. The benefi cial effect of adenosine was also 
the case in diabetic mice (C57BL/6) receiving allogeneic islets (BALB/c) when 
alloimmune rejection was prevented by anti-CD4 antibody. These fi ndings show 
that increased level of extracellular adenosine has an inhibitory effect on NKT 
cells facilitating to prevent early loss of transplanted islets. Thus, adenosine has 
a potential to increase the success rate of clinical islet transplantation when the 
benefi cial effect of adenosine holds true in humans.
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PREDICTION OF LONG-TERM CLINICAL 1328 
OUTCOME BY VIABLE DUCTAL CELL MASS IN ISLET 
ALLOTRANSPLANTATION
H. Ichii, A. Miki, A. Mita, S. Barker, T. Yamamoto, Y. Sakuma, L. Inverardi, 
R. Alejandro, C. Ricordi
Diabetes Research Institute, University of Miami
Background: Recent improvements in islet isolation and immunosuppression 
have allowed transplantation of human islets of Langerhans to become a viable 
treatment for patients with long-standing type 1 diabetes mellitus (T1DM). 
However, improving long-term islet graft function is highly desired in current 
clinical trails. It is well known that human islet preparations includes a 
substantial amount of non-endocrine cells as well as endocrine cells. Ductal 
cells could be potentially benefi cial for islet survival and expansion of 
islet cell mass, but could also adversely affect islet survival due to the pro-
infl ammatory cytokine/chemokine production. We have developed a method 
for the assessment of fractional beta and ductal cell viability and content, using 
FACS and Laser scanning cytometer (iCys). Objective of this study was to 
examine whether transplanted viable ductal cell mass affect clinical outcomes 
in islet allotransplantation.
Methods: Nineteen islet preparations transplanted in Diabetes Research Institute, 
University of Miami were retrospectively assessed. Beta-cell and ductal cell 
viability were assessed by FACS using a four-color analysis (7-AAD, Newport 
green, TMRE, CA19-9). Beta-cell and ductal cell content were assessed using 
iCys. Viable beta-cell Equivalent Number/kg (vbetaEQ/kg recipient weight) and 
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viable ductal cell Equivalent Number/kg (vdEQ/kg) were calculated using the 
formula (islet beta-cell content x beta-cell fractional viability x IEQ/kg, Viable 
beta-cell Equivalent Number/kg x%ductal cell /%beta-cell) and compared to 
clinical outcomes (exogenous insulin requirement). Recipients were divided 
into two groups based the change of insulin requirement between 3 months 
and 2 years after the last transplantation. (Group 1, n=5, insulin requirement 
increased; Group 2, n=7, decreased or no change)
Results: Average transplanted islet mass was 576,122±177,570IEQ, 9,395±2,577 
IEQ/kg, 2,766±1,199 vbetaEQ/kg and 1,793±1,156 vdEQ/kg. Beta-cell content 
and beta-cell fractional viability were 43±12 and 68±16%, respectively. Ductal 
cell content and viability were 12± 6.8 and 80± 8.8%. Three out of 5 in Group 
1 and 4 out of 7 in Group 2 became insulin independent. In transplanted Islet 
mass and viable beta-cell mass, there was no signifi cant difference between two 
groups (Group I vs. Group 2; 8,552±1,740 vs. 10,020±2,830 IEQ/kg, p=0.29; 
2,533±1,066 vs.3,027±1,261 vbEQ/kg, p=0.48, respectively). However, 
viable ductal cell mass in Group2 was signifi cantly higher than that in Group1 
(2,303±993, 976±795 vdEQ/kg, p=0.027, respectively).
Conclusions: The recipients received higher amount of viable ductal cell 
mass showed signifi cantly better long-term graft function. Our data suggest 
that integrated assessment of ductal cell mass as well as viable beta-cell mass 
might be assistance in developing the strategy to improve long-term islet graft 
function.
POSTER BOARD NUMBER P2 – 128
LOWER EXPRESSION OF ANTI-OXIDANT ENZYMES IN 1329 
HUMAN BETA CELL ACCOUNTS FOR THE VULNERABILITY 
TO REACTIVE OXYGEN SPECIES
A. Miki, C. Ricordi, A. Mita, S. Barker, R-D. Molano, L. Inverardi, 
A. Pileggi, H. Ichii
Diabetes Research Institute
Objective: Recent reports have showed wide variations in beta-cell content 
of human islet preparations, which appears substantially lower when 
compared to the „d80% reported in rodents. Reactive oxygen species (ROS) 
such as hydrogen peroxide, free radical, and superoxide have been reported 
to be noxious to human islets. During islet isolation, islets are exposed to 
ROS, causing to islet cell injury. As a defense mechanism, human tissues 
have antioxidant enzymes, such as catalase and superoxide dismutase (SOD). 
In this study, we examined the expression of these antioxidant enzymes 
in cell subsets from human islet preparations, in relation to the change of 
cellular composition observed during islet cell processing and following 
transplantation.
Materials and methods: Single human islet cell preparations (Accutase 
Dissossiation method) were double-stained with anti-catalase, anti-SOD1 
or anti-SOD2 antibody, along with either anti-C-peptide, anti-Glucagon, 
anti-Somatostatin or anti-CK19 antibodies, to quantify the expression of 
antioxidant enzymes selectively into beta-, alpha-, delta- and ductal cells. 
Human islets cultured with or without H2O2 (50£gM) for 24 hours were 
assessed to examine the ROS-mediated vulnerability of each cell subset. 
Cellular composition in pre-isolation pancreatic tissue samples was analyzed 
by confocal microscopy, while cell subpopulation analysis of isolated islets 
and renal sub-capsular islet grafts (diabetic nude mice) was performed using 
an iCys/LSC.
Results: Intracellular catalase expression in alpha- and ductal cell was 
signifi cantly much higher compared to beta cells and delta cells, which 
appeared negative. However, there was no signifi cant difference in SOD1 
and SOD2 expression among beta-, alpha-, delta- and ductal cell. H2O2 
signifi cantly reduced the beta/alpha cell ratio compared to islet without H2O2 
(beta/alpha = 1.20 vs. 0.78, P<0.05). The beta/alpha cell ratio signifi cantly 
decreased following each step of islet cell processing and transplantation 
(Pancreas vs. Post-Isolation vs. Post-Transplantation: 3.58 vs. 1.52 vs. 1.02, 
P<0.05).
Conclusion: Absence of any signifi cant catalase expression in human beta-
cells was associated with an increased vulnerability against oxidative stress, 
which was paralleled by a beta-cell loss during islet isolation and following 
transplantation. Prevention of beta-cell oxidative stress before and after 
islet transplantation may be of assistance to improving clinical transplant 
outcomes.
POSTER BOARD NUMBER P2 – 129
A REAPPRAISAL OF THE PASSENGER LEUKOCYTE 1330 
MODEL OF ISLET ALLOGRAFT IMMUNOGENICITY
R.G. Gill1, J. Beilke2
1University of Alberta / Alberta Diabetes Institute, 2University of California, 
San Francisco
Background: Donor-derived antigen presenting cells, or ‘passenger 
leukocytes’, can play a major role in triggering islet allograft rejection. This 
concept has implied that ‘direct’ (donor APC dependent) antigen presentation 
predominates in initial islet allograft immunity. However, ‘indirect’ (host APC 
dependent) CD4 T cells are known to contribute to allograft rejection. In the 
current study, we tested this long-standing passenger leukocyte model by 
determining the relative role for donor MHC expression, donor APCs, and host 
CD4 T cells for islet allograft rejection.
Methods: Streptozotocin-induced diabetic BALB/c (H-2d) recipient mice 
were grafted with 400-450 islets from either wild-type C57Bl/6 (B6, H-2b), B6 
MHC class II-defi cient (C2D), or B6 MHC class I (β2m-/-) and class II (C2D) 
double defi cient mice. In some cases, donor-derived passenger leukocytes were 
depleted using fi ve days of 95% O2 culture prior to transplant. Analysis of such 
cultured islets indicated undetectable levels of remaining donor-derived CD45+ 
cells. Finally, recipients were sometimes depleted of either CD4 or CD8 T cells 
during the peri-transplant period with monoclonal antibody treatment (GK1.5 
and 2.43, respectively).
Results: If donor APCs are required to directly activate host CD4 T cells, 
then donor-derived APCs should require MHC class II expression. However, 
C57Bl/6 (B6) MHC class II-defi cient (C2D) islet allografts (n=8) were 
acutely rejected in allogeneic BALB/c recipients within three weeks, a 
time course comparable to wild-type C57Bl/6 islets (n=10). B6 MHC I/
II double-defi cient islets were uniformly accepted >100 days in BALB/c 
mice (7/7), indicating that donor MHC expression could be rate limiting 
for allograft rejection. Furthermore, rejection of C2D islet allografts was 
CD4 T cell-dependent; anti-CD4 antibody treatment prevented rejection 
of both C2D and B6 islet allografts (5/9 versus 6/9 grafts surviving > 100 
days, respectively, p < .02). Rejection of C2D islets was also CD8 T cell in 
that anti-CD8 treatment resulted in long-term survival of C2D islets in 5/12 
recipients (p < 0.05).
Importantly, the rejection of C2D islets was nevertheless donor APC-dependent. 
Pretreatment of either C2D or B6 islets in 95% O2 culture to eliminate donor 
APCs resulted in long-term allograft acceptance (>100 days in 5/5 versus 4/4, 
respectively).
Conclusions: The fi nding that the rejection of C2D allografts is CD4 T cell 
dependent strongly suggests that ‘indirect’ (host APC dependent) antigen 
recognition can play a signifi cant role in triggering islet rejection. Conversely, 
the fi ndings that CD8 T cells and donor MHC expression also are important 
for allograft rejection supports a role for ‘direct’ alloantigen recognition. 
Importantly, CD4 T cell dependent rejection of C2D islets remains donor APC 
dependent in vivo.
Taken together, these results suggest that ‘passenger leukocytes’ are not 
merely the source of ‘direct’ donor antigen presentation to initiate immunity 
but can also be an important source of donor antigen for the indirect pathway 
of allorecognition. These results further imply that donor APCs, rather than 
islet parenchymal cells, are an important source of antigen for such indirect 
recognition in vivo.
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POTENTIAL REGULATORY EFFECT OF 1331 
NICOTINAMIDE ON EARLY ISLET FAILURE FOLLOWING 
INTRAPORTAL TRANSPLANTATION
S-J. Kim1,2, D-Y. Jung1, S-K. Lee2, J-W. Joh2, J-M. Chun2, G-O. Jung2, 
J-M. Kim2, U-J. Kyung2, H-J. Park2, H-T. Jung2
1Transplantation Research Center, Samsung Biomedical Research Institute, 
Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department 
of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea
Intrahepatic human islet transplantation has been raised as a potential cure 
for diabetes mellitus, especially in patients with type 1 diabetes. However, 
early graft failure following intraportal islet transplantation represents a 
major obstacle for successful islet transplantation. Islets exposed to blood are 
subject to an immediate blood-mediated infl ammatory reaction (IBMIR) that 
involves the activation of coagulation and complement systems. Therefore, we 
examined benefi cial effect of nicotinamide (NIC) to prevent IBMIR-induced 
islet destruction in a model of syngeneic islet transplantation in STZ-induced 
diabetic C57BL/6 mice.
Chemically induced C57BL/6 diabetic mice underwent intraportal syngeneic 
islets transplantation with various doses, such as 250, 300, 350, and 400 IEQ. 
Nonfasting serum glucose levels were evaluated after transplantation of islets 
cultured with or without 10 mM NIC. To the confi rm islet function following 
intraportal islet transplantation, intraperitoneal glucose tolerance test (IPGTT) 
and hepatectomy were carried. After 3 and 24 hours of islet transplantation, the 
effects of NIC were evaluated by blood cell count, monocyte chemoattractant 
protein-1 (MCP-1) serum level, and immnohistology.
NIC-treated islet transplantation via intraportal vein promoted to decrease high 
blood glucose level in syngeneic diabetic C57BL/6 recipients. In addition, 15 
days posttransplantation, the function of islet grafts was higher in NIC treated 
group than in the untreated. Among the various islet doses, recipient infused 
with 300 IEQ was exhibited markedly difference of the effect of NIC treatment 
on glucose tolerance. 1 day after islet 300IEQ transplantation, islets treated 
with NIC were signifi cantly well-granulate (p = 0.001), NIC-treated islet grafts 
also showed the decrease of serum MCP-1 concentration in comparison with 
those of the control. In the long-term survival graft (> 100 days), about 80% of 
liver was removed and then diabetes was recurrent.
These fi ndings clearly demonstrate that NIC may function to prevent prompting 
the deterioration of the islet grafts in syngeneic mouse model.
POSTER BOARD NUMBER P2 – 131
EXPRESSION OF CELL DEATH AND INFLAMMATORY 1332 
MEDIATORS IN HUMAN ISLETS POST ISOLATION
P. Campbell, L. Mariana, G. Jhala, S. Fynch, T. Loudovaris, J. Allison, 
H. Thomas, T. Kay
St. Vincent’s Institute
Allogeneic human islet transplantation replaces the insulin producing beta 
cells and corrects the blood glucose levels in type 1 diabetic recipients, 
replacing the need for daily insulin injections. Islets are exposed to a number 
of insults during the isolation procedure including mechanical stress, 
hypoxia, temperature variations and enzyme impurities. These insults may 
lead to functional impairment resulting in loss of viable beta cell mass. We 
hypothesize that beta-cell damage and death before, during and after islet 
isolation and transplantation are factors affecting the number of islets required 
to achieve insulin independence. Using human islets from the Tom Mandel 
human islet transplant program we aim to determine if expression and/or 
activation of genes involved in infl ammation and cell death correlate with 
islet function after transplantation. The infl ammation -regulated molecules 
class I MHC and Fas were detected on the islet cell surface by fl ow cytometry, 
but there was no signifi cant difference in these levels 3, 24 or 48 hours post 
isolation. This indicates that the types of stress experienced by islets during 
the isolation procedure do not change the levels of class I MHC or Fas. Real 
time PCR using RNA isolated from human islets revealed very low levels 
of expression of members of the Bcl-2 family that regulate apoptosis by 
controlling mitochondrial integrity. Molecules predicted to improve transplant 
engraftment including insulin, and anti-apoptotic Bcl-XL and Bcl-2, were 
observed at elevated levels in islets that normalised blood glucose in diabetic 
scid mice, while those predictive of poor graft outcome, including pro-
apoptotic Bim and Puma, were elevated in islets that did not normalize blood 
glucose in mice. These data suggest that pro- and anti-apoptotic members of 
the Bcl-2 family may be useful as predictive markers of islet function after 
transplantation.
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DEFINING THE IMMUNE RESPONSE LEVELS IN 1333 
ISLET ALLOTRANSPLANTATION BY THE IMMUNE CELL 
FUNCTION ASSAY IMMUKNOW™ CYLEX®
D. Mineo2, P. Cure1, D.A. Baidal1, T. Froud1, G. Selvaggi1, A. Khan1, 
N.S. Kenyon1, L. Inverardi1, C. Ricordi1, R. Alejandro1
1Diabetes Research Institute, Miller School of Medicine, University of Miami, 
Florida, USA and also 2Department of Internal Medicine, School of Medicine, 
Tor Vergata University of Rome, Italy
Immunosuppressive management in islet transplantation is mainly based on drug 
blood levels, metabolic parameters and clinical course. None of them is completely 
reliable in preventing rejection, infections or toxicity-related side-effects.
Immuknow™ by Cylex® is a simple and FDA-approved test, currently used 
to modify immunosuppression in solid organ recipients. It detects the immune 
cell function of immunosuppressed patients by measuring the ATP levels of 
phytohemagglutinin-stimulated CD4+ T-lymphocytes, thus defi ning 3 zones 
of immune response, as strong (>525ng/mL), moderate (226-524) and low 
(<225), signifi cantly correlated with clinical outcomes: rejection, graft stability 
or infections/side-effects, respectively.
To defi ne the immune response in islet transplantation by the Immuknow™ 
assay, to help in managing graft stability and reduce the immunological risk.
We studied 26 islet recipients with functioning allografts in different 
immunosuppressive protocols. A total of 152 samples, corresponding to at 
least 2 immunological tests for each patient during a 20-month follow-up 
period, were analyzed. Clinical status was evaluated at the time of the test 
and recipients categorized in groups according to graft function or episodes of 
infections or side-effects.
Recipients with stable islet grafts showed ATP levels (mean±SD) of 211±48ng/
mL, those with graft dysfunction of 340±95ng/mL while those with infections 
or toxic side-effects of 73±33ng/mL (the same patient may having different 
clinical events during follow-up).
Statistical analyses showed signifi cant correlations between ATP values and 
either leukocytes (r=0.40 p<0.01), CD4+ T-lymphocytes (r=0.42 p<0.01) and 
fasting plasma glucose (r=0.26 p<0.05).
This retrospective observational study has defi ned the immune response values 
in islet transplantation. ATP levels for islet graft stability (211ng/mL) were 
lower than for solid organs transplant (249ng/mL) but similar to the ones for 
whole pancreas transplantation, (194ng/mL).
Immuknow™ Cylex® assay can be of utility in islet transplant recipients, to 
reduce the risk of rejection, infections or side-effects.
Figure: Immune response levels in Islet Transplantation
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ZINC TRANSPORTER EXPRESSION IN ISOLATED 1334 
HUMAN ISLETS: HIGH VARIABILITY IN BETA CELL 
SPECIFIC ZNT8 EXPRESSION
C. Drogemuller1,6, C.R. Milner1,6, D.M. Mohanasundaram1,6, A. Kupke1,6, D.J. 
Torpy1,2,6, C. Murgia3, W. Hawthorne4,6, T. Loudovaris5,6, G.R. Russ1,6, P.T.H. 
Coates1,6
1South Australian And Northern Territory Islet Program, The Queen Elizabeth 
Hospital, 2Department of Endocrinology, Royal Adelaide Hospital, 3INRAN 
(National Research Institute on Food and Nutrition), 4Center for Transplant 
and Renal Research, Westmead Millenium Institute, 5Tom Mandel Islet 
Program, St Vincent’s Hospital, 6Australian Islet Transplant Consortium
Background: β-cells within the pancreatic islet contain the highest 
concentration of zinc (Zn) in the human body. Large quantities of Zn are 
required to form the zinc-insulin crystals in the secretion vesicles of these cells. 
Exocytosis of these vesicles and release of insulin into the circulation occurs 
in response to elevated glucose levels. Zn ions cross biological membranes 
aided by a set of specialized proteins grouped into two families based on 
their structural and functional features. ZRT/IRT-related proteins (ZIP)s are 
members of the Solute Carrier Family 39A (SLC39A) while Solute Carrier 
Family 30A (SLC30A) comprise the mammalian ZnTs. The primary role of 
ZIP proteins is to mediate Zn uptake from the extracellular environment or 
from intracellular vesicles into the cytoplasm. In contrast proteins belonging 
to the ZnT family were predominantly responsible for Zn effl ux from the 
cytoplasm towards intracellular vesicles, the extracellular space and to 
specifi c metalloproteins. The Zn transporter gene ZnT8 is expressed primarily 
by β-cells of the pancreatic islet and is required to transfer Zn into insulin 
secretory vesicles. ZnT8 is found in the membrane of insulin secretory 
granules and at the plasma membrane and is thought to play a crucial role in 
insulin synthesis, secretion and storage. A single-nucleotide polymorphism in 
the gene for ZnT8 was also recently identifi ed as a critical marker for type 2 
diabetes risk.
Aim: To compare Zn transporter expression levels between different human 
islet isolations.
Materials and methods: Human pancreatic islets from ten pancreatic donors 
(age 51±15yrs, BMI 24.3±3.4) were separated by the Ricordi method. RNA 
was isolated using Qiagen® RNA kit, prior to reverse transcription and 
real time PCR analysis using gene specifi c Taqman® primers and probe. A 
polyclonal antibody to ZnT8 was raised in rabbits and tested on human islet 
preparations.
Results: The unique polyclonal antibody to ZnT8 recognises mouse, rat and 
human protein expressed in pancreatic islets as well as being functional in 
Western Blot. RNA was purifi ed from ten individual human islet isolations 
and reverse transcribed for Q PCR analysis. Relative expression levels of 
seven Zn transporter genes, ZIP1, ZIP6, ZIP7, ZIP14, ZnT4, ZnT6 and ZnT8 
were determined. Little or no expression of ZIP6, ZnT4 and ZnT6 was seen 
in any of the preparations. There was a 16 fold difference between the highest 
and lowest expression level of ZIP1 in the ten separate isolations, a 6 fold 
difference for ZIP 7, a 41 fold difference for ZIP14 and a 25 fold difference for 
ZnT8. Although ZIP14 had the largest fold difference it was ZnT8 that showed 
the greatest variability between isolations. ZIP1 and ZnT6 expression levels 
correlated (r2= 0.8) as did ZIP6 and ZIP7 (r2= 0.83) when compared between 
the different isolations. There was no signifi cant relationship to glucose 
induced insulin stimulation (Average Stimulation Index 1.66±0.91) between 
islet preparations.
Conclusion: Human pancreatic islet preparations expressed a range of Zn 
related transporter genes. The antibody to ZnT8 showed cross reactivity with 
human islet tissues. Of the transporter genes expressed, ZnT8 gene expression 
showed the greatest variability between preparations.
POSTER BOARD NUMBER P2 – 134
AN INCREASE IN HOST FOXP31335 + REGULATORY T CELLS 
IS ASSOCIATED WITH ABROGATION OF AUTOIMMUNITY 
AND ISLET GRAFT SURVIVAL IN NOD MICE
Q. Shi, D.L. Farber, D.W. Scott, S.T. Bartlett
Department of Surgery, University of Maryland School of Medicine, 
Maryland, USA, 21201
Objective: We have developed a novel protocol for promoting long-term 
acceptance of semi-allogeneic islets in diabetic NOD hosts using anti-
lymphocyte serum (ALS) treatment coupled with injection of donor pancreatic 
lymph node-derived (PLNC) CD4 T cells from non-diabetic donors. However, 
it is not known the precise phenotypic and functional CD4 subset that mediates 
long-term islet graft survival, and whether donor or recipient FoxP3 regulatory 
T cells are required for the observed effects.
Methods: Diabetic NOD.NON/Thy1.1+ mice treated with 0.2 ml ALS QOD for 
one week were used as recipients. Two islet transplant groups were analyzed: 
1. ALS/PLNC group: received 500 fresh islets from diabetes-resistant NOR/
Thy1.2+ donors with intraportal infusion of 3×107 purifi ed NOR PLNC-derived 
CD4+CD25- T cells and 2. ALS-alone group: received 500 NOR islets without 
PLNC. Some of ALS/PLNC mice were sacrifi ced normoglycemic at 30 days 
post-transplant, while ALS-alone recipients were hyperglycemic by day 20, 
indicating islet graft loss and were subjected to immediate fl ow-cytometric 
and histologic analysis. We analyzed the frequency of FoxP3 expression on 
CD4 T cells from spleen, pancreatic-draining and non-draining lymph nodes 
by fl ow cytometry. Donor T cells were distinguished from recipient T cells 
by Thy1.2 and Thy1.1 expression respectively. Sections of graft-bearing livers 
were stained with H&E and anti-insulin.
Results: Co-administration of CD4+CD25- T cells of PLNC in ALS-treated hosts 
resulted in dramatic long-term survival of islet grafts with a MST of 93 days 
for NOR islets. However, ALS treatment alone was ineffective in preventing 
graft loss with a MST of 20 days for NOR islets. We found a signifi cant 
enhancement of FoxP3+ T cells in spleen and draining pancreatic nodes in ALS/
PLNC recipients (17%-18%) compared to the ALS-only recipients (6%-11%). 
An increased number of FoxP3+ T cells among chimeric donor CD4 T cells was 
also observed from prior to transfer (4%) compared to post-transfer (7%). Graft 
histology revealed pristine islet grafts and an absence of cellular infi ltration in 
ALS/CD4+CD25- recipients.
Conclusion: These results demonstrate that an increase of FoxP3 expression in 
host CD4 T cells is associated with long-term islet graft survival in ALS/PLNC 
treated NOD mice, and suggests that the presence of donor T cells in chimeric 
hosts with long-standing islet grafts may be required for that increased FoxP3 
expression in the host compartment.
CULTURE ON ISLETSCONCURRENT ORAL SESSION 96: 
POSTER BOARD NUMBER P2 – 135
HYPERGLYCEMIA IN VITRO UP-REGULATES 1336 
GROWTH-RELATED CELL CYCLE PROTEINS OF ADULT 
MOUSE PANCREATIC ISLETS
S. Hsu, B.R.S. Hsu, S.H. Fu
Chang-Gung Medical Center, Div of Endocrinol and Metabol
In order to study the changes of cell cycle proteins of adult pancreatic islets 
during metabolic adaptation, we cultured isolated islets of 12 week-old male 
B6 mice in RPMI-1640 complete medium containing either 5.5 mM or 20 mM 
glucose. At 0, 1, 3 and 7 days of cultivation, islets were homogenized to prepare 
cytosol for PAGE and Western blotting using antibodies against β-actin (house-
keeping), p27kip1 (G1/G0 checkpoint), cyclin D1 (G1/S), cyclin B1 (G2/M), 
and FoxM1. The cell cycle proteins were expressed as the ratio of band density 
of each protein over that of β-actin of the same batch of islet cytosol. At day 
1, protein p27 of islets cultured in 5.5 mM and 20 mM glucose was 0.48±0.11 
(n=4) and 0.63±0.10 (n=6), respectively, when comparing with that of day 
0. Meanwhile, B1 of islets cultured in 5.5 mM and 20 mM glucose elevated 
7.01±5.46 times and 11.58±6.19 times at day 1. Proteins D1 and FoxM1 of 
islets cultured in 5.5 mM and 20 mM glucose medium were 1.01±0.24 and 
1.18±0.23, and 0.98±0.22 and 1.00±0.32, respectively, at day 1 when compared 
to that of day 0. At day 3, proteins of p27, B1, D1 and FoxM1 of islets cultured 
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in 5.5 mM (n=4) and 20 mM (n=5) glucose were 0.84±0.24 and 0.84±0.12, 
3.07±1.47 and 17.16±9.14, 1.77±0.34 and 1.24±0.35, 0.36±0.12 and 0.69±0.23, 
respectively, when comparing with that of day 0. Furthermore, at day 7, 
proteins of p27, B1, D1 and FoxM1 of islets cultured in 5.5 mM (n=5) and 20 
mM (n=7) glucose were 1.20±0.45 and 1.09±0.29, 3.15±1.07 and 14.83±9.31, 
0.83±0.27 and 1.26±0.30, 0.45±0.14 and 1.08±0.53 when compared to the 
corresponding mean of that of day 0, respectively. In conclusion, (1) adult 
mouse islets response to in-vitro cultivation with rapidly reducing p27 and 
markedly increasing growth-related protein B1, (2) gradual elevation of p27 
along with cultivation days was accompanied with gradual decrease of growth-
related proteins B1, D1, and FoxM1, (3) high glucose medium attenuates p27 
elevation but enhances B1 and FoxM1 elevations. Our data suggested that 
growth-related proteins of adult mouse islet response rapidly to proliferation 
stimuli such as glucose and in-vitro cultivation.
POSTER BOARD NUMBER P2 – 136
ANTI-PRO-INFLAMMATORY EFFECTS OF SIROLIMUS 1337 
SUPPLEMENTATION TO THE PRE-TRANSPLANT CULTURE 
MEDIA ON HUMAN ISLET PREPARATIONS
A. Mita1,3, C. Ricordi1,4,5, A. Miki1, S. Barker1, R. Haertter1, 
Y. Hashikura2, S-I. Miyagawa3, L. Inverardi1, H. Ichii1,4,5
1Diabetes Research Institute, University of Miami Leonard M. Miller 
School of Medicine, 2Transplantation Center, Shinshu University School of 
Medicine, 3Department of Surgery, Shinshu University School of Medicine, 
4DeWitt Family Department of Surgery, University of Miami Leonard M. 
Miller School of Medicine, 5Jackson Memorial Hospital Transplant Institute, 
University of Miami Leonard M. Miller School of Medicine
Background: Improved islet isolation techniques and immunosuppressive 
regimens have made islet transplantation a therapeutic option for patients with 
type 1 diabetes mellitus. This success is likely attributable in part to the noble 
immunosuppression protocol. Sirolimus (SRL) plays a critical role in facilitating 
steroid-free immunosuppression, in conjunction with low dose tacrolimus, in 
current islet transplantation. Although several studies have investigated the 
effects of sirolimus on islet cells, confl icting results have been reported. In this 
study, we assessed the effects of sirolimus supplementation in culture media on 
human islet preparations, focusing on the anti-pro-infl ammatory aspects.
Methods: After purifi cation, human islet preparations were divided into four 
groups: pure (purity >90%) SRL+ (30ng/ml); pure SLR- (0ng/ml); impure (purity 
40-60%) SLR+ and impure SLR-. All groups were cultured in Miami-defi ned 
medium 1 with or without sirolimus for 3 days and assessed regarding glucose 
stimulated insulin release, fractional ƒÀ-cell viability, and ƒÀ-cell and macrophage 
content within human islet preparations. Cytokine/chemokine production from 
islet preparations and sorted pancreatic ductal cells were also examined.
Results: Stimulated insulin release in impure SRL+ group was signifi cantly 
increased when compared to impure SLR- group (static incubation index: 1.9 } 0.4 
and 1.1 } 0.3, respectively, p=0.024), as previously reported, but not in pure SRL+ 
group. Although fractional ƒÀ-cell viability showed no signifi cant differences, ƒÀ-
cell survival during culture signifi cantly increased in impure SRL+ group when 
compared to impure SLR- group (133.6 } 24.2% control, p=0.015). However, both 
fractional ƒÀ-cell viability and ƒÀ-cell survival during culture were comparable 
in pure SRL+ group. TNF-ƒ¿, IL-1ƒÀ, MCP-1 and MIP-1ƒÀ production from 
impure SRL+ group signifi cantly decreased when compared to impure SLR- 
group (64.4 } 7.3% control; p=0.003, 79.0 } 4.3% control; p =0.003, 55.9 } 18.8% 
control; p = 0.049 and 60.9 } 9.8% control; p=0.007, respectively). Furthermore, 
TNF-ƒ¿ and MIP-1ƒÀ production from sorted ductal cells signifi cantly decreased 
in SRL+ group (59.2 } 10.3% control; p=0.007, 33.5 } 14.3% control; p=0.004, 
respectively). The number of macrophages contained in islet preparations 
signifi cantly decreased in impure SRL+ group when compared to impure SRL- 
group (55.9 } 27.0% control; p = 0.048), but not in pure SRL+ group.
Conclusions: Sirolimus improved not only stimulated insulin release, but also 
ƒÀ-cell survival during culture in impure human islet preparations. In addition, 
sirolimus reduced the quantity of macrophages contained in the human islet 
preparations, and cytokine/chemokine production especially from ductal cells 
which exist more in impure human islet preparations than in pure ones. Although 
many investigators have paradoxically reported the effects of sirolimus on 
human islet preparations, reconsidering the variability in the purity of human 
islet preparations used in those experiments could more adequately elucidate 
the discrepancies and allow a better comparison with these results. The anti-
infl ammatory effects of sirolimus, also appear benefi cial to islet cells in culture 
and may be a useful strategy in improving islet transplantation outcomes.
POSTER BOARD NUMBER P2 – 137
THE INFLUENCE OF A CURRENT STYLE OF CULTURE 1338 
ON THE QUALITY OF ISOLATED PANCREATIC ISLETS
H. Takahashi1, M. Goto1,2, N. Ogawa1, Y. Saitoh1, K. Fujimori3, 
Y. Kurokawa2, H. Doi1, S. Satomi1
1Division of Advanced Surgical Science And Technology, Tohoku University, 
Sendai, Japan, 2Tohoku University Biomedical Engineering Research 
Organization, Tohoku University, Sendai, Japan, 3Division of Surgical 
Oncology, Tohoku University, Sendai, Japan
Objectives: Although one of the key factors of Edmonton protocol is 
transplanting fresh islets just after islet isolations, it has recently been reported 
that the outcome of islet transplantation with short-period culture could be 
comparable. This could be based upon the different culture media applied in 
each institution. To clarify the infl uence of a current style of culture on isolated 
pancreatic islets, in the present study, fresh islets were compared to those 
cultured with several current fashions in terms of islet quality including not 
only viability but also infl ammatory mediators expressed on the islets.
Materials and methods: The islets isolated from rats were cultured for 48 hours 
with CMRL including 10% serum, CMRL including 0.5% human serum albumin 
(HSA), and Miami medium including 0.5% HSA as one of the current most 
established media. The infl uence of culture on islet integrity was evaluated by 
survival rate of islets during culture and visual scoring. The infl uence of culture 
on islet function and viability was examined by ADP/ATP test, Insulin/DNA 
content, glucose stimulation test and transplantation of islets to homogeneous 
rats. The infl uence of culture on the expression of infl ammatory mediators in the 
islets was examined by western blotting assay for tissue factor (TF) which is the 
initiator of detrimental instant blood-mediated infl ammatory reactions (IBMIR).
Results: Although the survival rate was similar in all groups, the visual scoring 
was lower in Miami medium. Stimulation index in glucose challenge test was 
higher in fresh islets than the others (fresh;17.89 }4.93, serum;13.69 }5.44, 
HSA;5.36 }1.60, Miami;2.69 }0.82: p=0.02). Insulin/DNA revealed the same 
tendency as glucose challenge test (fresh;1.02 }0.07, serum;0.83 }0.11, HSA;0.52 
}0.07, Miami;0.37 }0.08: p=0.0005). ADP/ATP ratio was lower in both fresh and 
serum group than the others (fresh;0.047 }0.021, serum;0.054 }0.017, HSA;0.086 
}0.004, Miami;0.084 }0.026: p=0.38), suggesting that the apoptotic islets are 
relatively lower in both fresh and serum group. Most importantly, the expression 
of TF on the islets was considerably lower in fresh group, suggesting that a 
current style of culture could enhance TF-dependent IBMIR after transplantation. 
In transplantation, blood glucose level normalized earliest in a fresh group, and 
the serum group showed a good result in the culture group.
Conclusions: In conclusion, isolated islets without prior culture is benefi cial to 
the transplantation under a current style of culture. Further improvements are 
required to optimize a substitute for serum supplement.
POSTER BOARD NUMBER P2 – 138
PROLACTIN SUPPLEMENTATION TO PRE-1339 
TRANSPLANT CULTURE MEDIA IMPROVES BETA CELL 
SURVIVAL ON HUMAN ISLET PREPARATIONS
T. Yamamoto1, C. Ricordi2, A. Mita2, A. Miki2, Y. Sakuma2, R.D. Molano2, A. 
Fornoni2, L. Inverardi2, A. Pileggi2, H. Ichii2
1Fujita Health University, 2Diabetes Research Institute, University of Miami
Objectives: Apoptosis are induced in pancreatic islets during islet proceeding 
and transplantation. It is critical to prevent the islets from the apoptosis in 
culture prior to transplantation for improving islet transplantation outcomes. 
Previous studies demonstrated that PRL has cyto-protective effect on insulin-
producing cell lines and pancreatic islets in streptozotocin (STZ) treated mice.
In this study, we examined the effect of human recombinant prolactin (rh-PRL) 
supplementation to the culture media, to determine whether it could exert 
b-cell-selective proliferation and cyto-protection on human islet preparations.
Materials and methods: Pancreatic islets were isolated from 11 donors (Age 
40.1 }3.5, Gender 7 males and 4 females, BMI 28.6 }1.5, CIT 646.8 }67.1min). 
The purifi ed islets were cultured in Miami defi ned medium supplemented with or 
without 500ug/l of rhPRL for 48 hours. Non-b-cell- and b-cell-specifi c fractional 
viability and cellular composition were assessed by FACS and LSC. Islets were 
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exposed to following compounds to induce apoptosis 1h after treatment with or 
without rhPRL; S-nitroso-N-acetyl-dl-penicillamine (SNAP), hydrogen peroxide 
and cytokine cocktail (CTK;IL-1ƒÀ+TNF-ƒ¿+IFN-ƒÁ). Islet potency was 
assessed in vivo by transplantation into diabetic immunodefi cient nude mice.
Results: The relative islet b-cell content and relative viable b-cell mass in PRL 
group were signifi cantly higher than control group. All transplanted mice achieved 
normoglycemia in both groups and there was no signifi cant difference in days of 
diabetes reversal and Intraportal glucose tolerance test (IPGTT) between control 
and PRL groups, indicating PRL treatment did not alter islet function.
Conclusion: PRL treatment improves b-cell-specifi c viability and survival in 
human islets. The development of novel b-cell-specifi c cytoprotective strategies 
will be of assistance in improving islet transplantation.
POSTER BOARD NUMBER P2 – 139
EFFECTS OF INSULIN-LIKE GROWTH FACTOR-1 AND 1340 
AGE ON PORCINE NEONATAL PANCREATIC CELL CLUSTERS
J-H. Juang1, C-H. Kuo2, B.R-S. Hsu1
1Division of Endocrinology and Metabolism, Chang Gung University and 
Memorial Hospital, 2Department of Biological Science and Technology, 
National Chiao Tung University
Islet transplantation has led to insulin independence in humans with type 1 
diabetes mellitus. However, a large number of islets are needed to achieve 
normoglycemia. To overcome this supply problem, islet tissues from neonatal 
pigs have been considered for xenotransplantation. Unfortunately, it takes a 
long period to cured diabetic nude mice after transplantation with the porcine 
neonatal pancreatic cell clusters (NPCCs). To shorten the latent period 
between transplantation of these cells and the reversal of hyperglycemia, we 
investigated the effects of insulin-like growth factor-1 (IGF-1) and donor age 
on transplantation of NPCCs.
To test whether IGF-1 can modulate the proliferation and differentiation of the 
NPCCs, those isolated from 1- to 3-day-old pigs were cultured with IGF-1. The 
stimulation index was not signifi cantly different between the NPCCs cultured with 
or without IGF-1 at 1, 2 or 4 weeks. Furthermore, at 4 weeks after transplantation 
with 300 NPCCs to nondiabetic nude mice, the insulin content of the grafts were 
comparable in the recipients of NPCCs precultured with or without IGF-1.
To know whether the NPCCs isolated from 1-month-old pigs (I-B) are functioning 
better than those isolated from 1- to 3-day-old pigs (I-A), we compared their 
characteristics and effects on transplantation. Soon after isolation, I-B was larger 
than I-A. After 6-day culture, I-B contained more insulin than I-A. However, the 
stimulation indices of I-A and I-B during static incubation were not signifi cantly 
different. Furthermore, both I-A and I-B had no fi rst or second phase of insulin 
secretion during perifusion study. Three hundred and 2000 cultured NPCCs were 
transplanted to nondiabetic and diabetic nude mice, respectively. In nondiabetic 
mice received I-A or I-B, their insulin content and beta-cell mass of the graft at 4 
weeks after transplantation were comparable. In diabetic recipients with I-A or I-B, 
the blood glucose decreased after transplantation and normoglycemia was achieved 
at 8 weeks. Their insulin content of the graft at 3 months was not different.
Our data indicate that: (1) isolated NPCCs cultured with IGF-1 had no benefi cial 
effects on their in vitro function and transplantation; and (2) NPCCs isolated 
from 1- to 3-day-old and 1-month-old pigs had different characteristics but 
similar effects on transplantation.
POSTER BOARD NUMBER P2 – 140
IMPROVED HUMAN ISLET QUALITY USING STEROID 1341 
WITH EXENDIN-4 FOR PRE-TRANSPLANT CULTURE
A. Miki, C. Ricordi, T. Yamamoto, S. Barker, I. Luca, H. Ichii
Diabetes Research Institute
Objective: Defi nition of optimal culture conditions for isolated human islets 
should aim at providing suffi cient oxygen and nutrients in order to allow 
for recovery from isolation-induced damage, and preventing islet mass loss. 
A wide space for improvements still exists in the methods currently utilized 
for pre-transplant culture of human islets. Steroid is known to have an anti-
infl ammatory function to reduce the cytokine/chemokine production from 
various cells. However, the effects of steroids during culture on islet cells 
have been controversial. Exendin-4 is a GLP-1 analog, which was reported to 
enhance the glucose induced insulin secretion and improve clinical outcomes 
in islet transplantation. We examined the cyto-protective and functional effects 
of steroid and exendin-4 on human islet cells during pre-transplant culture.
Materials and methods: Human islet isolations were performed using 
automated method at Diabetes Research Institute of University of Miami. After 
isolation, islets were cultured under following conditions (Group I, Miami 
defi ned medium (MM1); Group II, MM1with 2uM methylprednisolone (MP); 
Group III, MM1 with 2uM MP and 10nM exendin- 4). Beta cell fractional 
viability, cellular composition, multiple cytokine assays, multiple protein 
assays and perifusion were performed.
Results: Fractional beta cell viability of Group II and III were better than 
Group I (106.4 } 2.7%, 105.1 } 3.7% control, p<0.05).). Islet beta-cell 
content in of Group II (27.1 } 1.0%) and Group III (31.4 } 1.0%) were 
higher than Group I (32.7 } 1.8%). In multiple cytokine assays, TNF-alpha, 
IL-1, MCP-1,IL-6 and IFN-gamma were signifi cantly lower in Group II 
(71.2 } 32.6%, 51.5 } 23.2%, 66.7 } 20.2%, 20.3 } 5.3%, 53.8 } 16.8%, 
control respectively, p<0.05) and Group III (68.9 } 14.1%, 63.1 } 22.9%, 
66.7 } 20.2%, 24.6 } 6.9%, 55.2 } 14.9% control respectively, p<0.05) when 
compared to Group I. In multiple protein assay, Erk-2 was signifi cantly 
decreased, insulin secretion in Group III was recovered to be comparable to 
Group I in perifusion assay.
Conclusion: Steroid supplementation into culture medium signifi cantly 
decreased the cytokine/chemokine production and increased the Erk-2 
expression, probably leading to increase the beta cell viability. In addition, 
Exendin-4 ameliorated the insulin secretion suppressed by steroid. The use of 
steroid and exendin-4 during culture may be a useful strategy in improving islet 
transplantation outcomes.
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EFFECTS OF PITUITARY ADENYLATE CYCLASE-1342 
ACTIVATING POLYPEPTIDE (PACAP) ON HUMAN ISLETS
H. Ichii, Y. Sakuma, A. Miki, T. Yamamoto, A. Mita, S. Barker, R.D. Molano, 
L. Inverardi, A. Pileggi, C. Ricordi
Diabetes Research Institute, University of Miami
Selected reagents may provide desirable and effective cyto-protection for 
islet cells during processing, increasing islet yield and/or viability. Pituitary 
adenylate cyclase-activating polypeptide (PACAP) is an islet substance 
serving as an intra-islet amplifi er of glucose induced insulin secretion similar 
to exendin-4. It has been reported that systemic administration of PACAP 
maintained beta-cell mass, delayed the onset of hyperglycemia and resulted 
in cyto-protection from glucose toxicity. PACAP increases glucose-stimulated 
insulin release in vitro and in vivo. In this study, the effect of PACAP on islet 
cells was tested before and after transplantation.
Methods: Human islets were cultured in the presence or absence of PACAP 
(10-9 10-14M) for 48 hours. Beta cell viability was assessed by FACS, 
cellular composition analysis was performed by iCys/LSC and glucose-
stimulated insulin secretion was tested. In vivo, islets were transplanted 
beneath the kidney capsule of streptozotocin-STZ diabetic nude mice. 
Glycemic and insulin levels were assessed by glucose tolerance test 
(IVGTT) in presence or absence with PACAP (Peptide International; 1.3 
nmol/kg).
Results: There were no signifi cant differences in terms of beta-cell viability 
and cellular composition in between islets cultured with or without PACAP. 
However, glucose stimulated insulin secretion signifi cantly improved in islets 
cultured with PACAP, compared to controls (stimulation index: 2.8 vs. 1.8, 
respectively; P<0.05). Treatment of recipient mice with PACAP resulted in 
a benefi cial effect on insulin secretion (2.2 vs. 1.9 mU/l,) following IVGTT. 
However, no signifi cant difference in glucose level was observed during 
follow-up.
Conclusions: Our study indicated that PACAP maintained islet viability 
and beta-cell content during culture, as well as improved insulin secretion 
both in vitro and in vivo. However, blood glucose levels during an IVGTT 
were not affected. Because of the known effect of PACAP on blood pressure, 
local treatment may be preferable and could be further considered in islet 
transplantation.
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POSTER BOARD NUMBER P2 – 142
THE CULTURE MEDIUM INCLUDING OXYGEN 1343 
NANO BUBBLES IS PRESENTED TO IMPROVE THE 
VIABILITY OF ISLET CELLS FROM NON-HEART BEATING 
DONOR PANCREAS
H. Nagata1,2, M. Ito1, T. Yamamoto1,2, R. Ito3, Y. Iwanaga4
1Fujita Health University, 2Diabetes Research Institute Nagoya, 3University of 
Nebraska Medical Center, 4Kyoto University Transplant Unit
Background: The consumption of oxygen has been recognized as an important 
element of isolated islets. We evaluated whether the Nano-bubble oxygen 
solution improves cell viability under the cell culture.
Materials and Methods: Nano-bubble refers to ultra-fi ne oxygen gas bubble 
of diameter less than 10ƒÊm (1ƒÊm=1/1,000,000 m). We applied gNaga-
no-shizuku h produced by Royal Electric Co., Ltd., in collaboration with 
REO Research Institute and the Naga Group. It already commercialized as 
a healthy drinking water in Japan. The Nano-bubble water was mixed with 
conventional culture medium 0, 5,10,30,50,90%, respectively. The pancreas 
was procured from non-heart beating retired pigs. The pocine pancreas 
transported with two layer method and isolated using the Kyoto isolation 
method.
The viability of islet was assessed after purifi cation (day 0) and after 1, 
7 and 28days of culture. The selected islets were dissociated for the single 
cell. The single cell suspensions are incubated with Newport Green PDX 
acetoxymethylether (NG) and Tetramethylrhodamine ethyl ester (TMRE). 
After washing, the cells are stained with 7-aminoactinomycin D (7-AAD). The 
samples are analyzed using a FACScan cytometer. The beta cell composition of 
islet also analyzed using cellular antibodies. And beta cell viability index was 
calculated using ICHII-method.
Result: 50% of Nano-bubble group was maintained viability more than 80% 
after 28days culture.
Conclusions: The oxygen nano-bubbles solution may improves that the 
adaptive capability of islet cells against into apoptosis among the cell culture 
procedures.
BK POLYOMA VIRUSCONCURRENT ORAL SESSION 97: 
POSTER BOARD NUMBER P2 – 143
A SINGLE CENTRE EXPERIENCE ON APPLICATION 1344 
OF CADAVERIC POLYCYSTIC KIDNEYS FOR 
TRANSPLANTATION
D. Nicol, H. Rhee
Transplant Unit
Increasing incidence of end stage renal failure (ESRF) is compounded by 
the limited number of available organs for transplantation. We report our 
experience with transplantation of cadaveric kidneys from patients with 
autosomal dominant polycystic kidney disease (ADPKD), as an option for 
selected patients with end stage renal failure.
All fi les from deceased donors in Queensland, Australia, in the period of 
1994-2007 were reviewed to identify 5 donors with ADPKD. Data on recipients 
of polycystic kidneys was retrieved from the Australia and New Zealand 
Dialysis and Transplant (ANZDATA) registry.
Nine patients were transplanted with follow up ranging from 6 months to 
11.5 years. Two grafts failed due to vein thrombosis and chronic allograft 
nephropathy, both of which were unrelated to natural progression of ADPKD. 
The remaining 7 grafts all continue to function. Follow up scans of two 
patients demonstrated progressing cystic disease, whilst another showed 
regression.
Kidneys from deceased donors with adult polycystic kidney disease and 
acceptable renal function can be considered for transplantation. Uncertainty 
regarding the longevity of these kidneys and long term risks mean that they 
should be offered to carefully selected patients who would not otherwise be 
able to receive a transplant.
POSTER BOARD NUMBER P2 – 144
DECLINE IN NATIVE KIDENY FUNCTION IN LIVER 1345 
TRANSPLANT RECIPIENTS IS NOT ASSOCIATED WITH BKV 
VIRUS INFECTION
P. Ferrari4 , M. Salama1, N. Boudville2, D. Speers3, G. Jeffrey1
1Department of Gastroenterology/Hepatology, Sir Charles Gairdner Hospital, 
Perth, 2Department of Nephrology, Sir Charles Gairdner Hospital, Perth, 
3PathWest, Laboratory Medicine, Sir Charles Gairdner Hospital, Perth, 
4Department of Nephrology, Fremantle Hospital, Perth
BK virus (BKV) infection is an established cause of allograft dysfunction 
in renal transplant recipients. The relationship between BKV infection and 
chronic kidney disease (CKD) post orthotopic liver transplant (OLT) has been 
poorly investigated. The aim of this study was to determine the prevalence of 
BKV infection, its relationship to CKD and renal function loss over time in 
OLT recipients.
Prevalence of BKV viruria and viraemia were studied in 41 post OLT patients 
after a mean 6.5±4.7 years post-transplantation. Renal function was assessed 
using estimated glomerular fi ltration rate (eGFR) calculated from the yearly 
serum creatinine levels using the MDRD formula and by 51Cr-EDTA clearance 
(nGFR) at the time of viral studies. Polymerase chain reaction was performed 
for detection of BKV DNA in urine and plasma.
BKV viruria was present in 24.2% of patients, but none of these OLT recipients 
had detectable BKV viraemia. Isolated positive urine cytology for decoy cells 
was found in another 9.7% patients. CKD defi ned as eGFR <60ml/min/1.73m2 
was found in 83% of OLT recipients, but only in 56% when nGFR was used. 
The yearly decline in eGFR was -6.9±17 and -9.2±18 ml/min per year in BKV 
viruria positive and negative patients, respectively (P=0.39). There was no 
relationship between the presence or absence of BKV viruria and either nGFR, 
current eGFR, yearly decline in eGFR, number and type of immunosuppressive 
agents or aetiology of liver failure.
In the setting of established BK virus reactivation, immunosuppression without 
kidney injury seems insuffi cient to cause BKV viremia and nephropathy, and 
it appears that the most probable pathways for the development of BKV 
nephropathy requires a second-hit such as kidney infl ammation, kidney 
ischemia, or donor-recipient human leukocyte antigen mismatch.
POSTER BOARD NUMBER P2 – 145
INITIATION OF A SCREENING PROTOCOL FOR 1346 
POLYOMA VIRUS RESULTS IN A DECREASED RATE OF 
OPPORTUNISTIC NON-BK VIRAL DISEASE IN RENAL 
TRANSPLANT RECIPIENTS
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
BK nephropathy (BKN) develops in 2-5% of renal transplant patients and 
is recognized as a serious complication that is associated with a high rate of 
graft dysfunction and loss. In an attempt to decrease our rate of BKN, in Jan. 
2006, we initiated a serum screening policy for all newly transplanted patients 
with recipients undergoing monthly blood testing for polyoma determination 
by PCR. Patients with a positive PCR underwent a reduction in baseline 
immunosuppression which was either a discontinuation or 50% daily dose 
reduction in mycophenolate mofetil (MMF). Between Jan 1, 2006 and Feb 28, 
2007, 66 renal transplants were performed at our center (Group A). Serum PCR 
became positive for polyoma in 11 patients (17%). Mean time to positive PCR 
post-transplant was 5 months (2-9).Following discontinuation (n=5) or 50% 
reduction (n=6) in MMF dosing, 10/11 patients became negative for polyoma 
detection by PCR and no case of BKN has developed. To identify if a positive 
polyoma PCR served as a marker for over-immunosuppression and risk for 
opportunistic infection, we examined the rates of CMV and EBV disease 
in Group A patients compared to the prior 66 consecutive renal transplant 
recipients at our institution in whom monthly polyoma screening PCR was not 
obtained (Group B, Dec.1, 2004-Dec 31, 2005). Immunotherapy for recipients 
in both groups consisted of Thymoglobulin induction followed by maintenance 
therapy with prograf, MMF and prednisone or rapamune. Recipients in both 
groups received prophylactic therapy with valcyte for the fi rst 90 days post-
transplant. Demographics were similar between the 2 groups with respect to 
age, gender, ethnicity and deceased vs. live-donor transplant. In addition, there 
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were no differences between the groups in regards to primary (D+/R-) CMV 
epidemiologic risk, 26% in Group A and 24% in Group B.
Opportunistic viral infection developed in 5 (8%) group B patients (4 
CMV, 1 EBV)) and no group A patient. CMV disease in group B patients 
manifested as 1 case of CMV colitis and 3 cases of CMV syndrome. In 
addition, 1 group B patient suffered from disseminated EBV disease 
(tonsillitis, hepatitis).
In summary, monthly screening for polyoma virus by PCR in renal transplant 
recipients, with an associated decrease in immunotherapy, effectively prevents 
the development of BKN. Furthermore, this screening protocol served as 
an effective marker for over-immunosuppression and was associated with a 
decreased incidence of other opportunistic viral disease.
POSTER BOARD NUMBER P2 – 146
MONTHLY SCREENING FOR POLYOMA VIRUS 1347 
RESULTS IN AN ELIMINATION OF BK NEPHROPATHY AND 
PRESERVATION OF RENAL FUNCTION
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
BK nephropathy (BKN) is recognized to be a serious complication after 
renal transplantation and is associated with a high rate of allograft failure. 
In 219 patients transplanted at our center between Jan. 2002 and Nov. 2005, 
there were 11 cases of biopsy proven BKN (5%). In an attempt to decrease 
our rate of BKN in Jan. 2006, we initiated a serum screening policy for 
all newly transplanted patients with recipients undergoing monthly blood 
testing for polyoma determination by PCR. Patients with a positive PCR 
underwent a reduction in baseline immunosuppression which was either 
a discontinuation or 50% daily dose reduction in mycophenolate mofetil 
(MMF). Serum PCR was repeated monthly and any patient with a 25% 
increase in serum creatinine from baseline underwent a renal transplant 
biopsy.
Between Jan 1, 2006 and Feb 28, 2007, 66 renal transplants (26 live-donor 
and 40 deceased donor) were performed at our center. Immunotherapy 
consisted of Thymoglobulin induction in all recipients, mean total dose 
of 4.6mg/kg, followed by maintenance therapy with prograf, MMF and 
prednisone (n=13) or a steroid-free regimen of prograf, MMF and rapamune 
(n=53). Serum PCR became positive for polyoma in 11 patients (17%), 4 
in the maintenance steroid- treated group (31%) and 7 in the steroid-free 
recipients (13%). Mean time to positive PCR post-transplant was 5 months 
(range 2-9 months). Following discontinuation or reduction in MMF dosing, 
10/11 patients became negative for polyoma serum detection by PCR within 
6 months. The mean time to a negative PCR was 4 months, range 2-6 months. 
Renal transplant dysfunction, 25% increase from baseline serum, developed 
in only one patient (9%) two months after discontinuation of MMF therapy. 
Renal transplant biopsy in this recipient showed acute rejection. The serum 
creatinine returned to baseline in this patient after steroid therapy, however, 
the serum polyoma PCR remains positive. No other positive PCR recipient 
required a biopsy. Mean serum creatinine values for these 11 patients at one 
month post-transplant, time of initial positive polyoma PCR, 3 (n=11), 6 
(n=11) and 12 months (n=6) after immunotherapy reduction was 1.5, 1.4, 
1.5, 1.4, and 1.5 mg/dl respectively.
A trend towards a higher rate of positive serum polyoma PCR in 
maintenance steroid- treated patients compared to steroid-free regimen 
recipients was identified. Monthly screening for polyoma virus by PCR for 
early detection, with associated immunosuppressive regimen reduction, is 
an effective way to prevent BKN. In addition, this screening protocol is 
associated with a low rate of acute rejection and preservation of excellent 
renal function.
POSTER BOARD NUMBER P2 – 147
RETRANSPLANTATION AFTER RENAL ALLOGRAFT 1348 
LOSS TO POLYOMA VIRUS-ASSOCIATED NEPHROPATHY 
(PVAN)
M.R.N. Nampoory1, T. Said1, T. Al-Otaibi1, A.S. Pacsa2, M.P. Nair1, 
M.A. Halim1, M. Balaha1, M. Samhan1, M. Al-Mousawi1
1Hamed Al-Essa Organ Transplant Center, 2Department of microbiology, 
faculty of medicine
Introduction: Polyomavirus-associated nephropathy (PVAN) is an emerging 
cause of kidney transplant failure affecting 1-10% of patients. Limited data exists 
concerning retransplant in patients who lost their fi rst graft due to PVAN.
Patients and methods: Live donor retransplantation was done in four 
recipients who lost their grafts due to PVAN at a mean of 10 months after 
graft failure. Graft nephrectomy was done in all except one who was negative 
for viraemia and viruria and did not require dialysis prior to transplantation. 
Induction immunosuppression was given for thee patients (2 monoclonal and 
one polyclonal antibody). Post transplant immunosuppression was similar 
to the current center policy during the fi rst three months (Prednisolone, 
Mycophenolate and either tacrolimus in three or cyclosporine in one patient). 
Immunosuppression was tapered over the next 3 – 9 months to the minimum 
that keeps normal graft function. Follow up to detect virus reactivation in blood 
and urine was done monthly for the fi rst 3 months then every 3 months for the 
fi rst year using polymerase chain reaction (PCR).
Results: The follow up period was 3, 6, 15 and 50 months post transplant 
with mean serum creatinine 85 umol/l. All patients tolerated reduction of 
immunosuppression without rejection episodes. Viral reactivation was observed 
in two patients one turned negative and the second remained viruric on further 
reduction of immunosuppression.
Conclusion: Reduced immunosuppression in retransplantation of patients 
who lost their fi rst graft due to PVAN remains to be an option with low virus 
reactivation rate.
POSTER BOARD NUMBER P2 – 148
BK VIRUS ASSOCIATED HEMOPHAGOCYTIC 1349 
SYNDROME IN A RENAL TRANSPLANT RECIPIENT
K. Charfeddine, S. Yaich, S. Zagdane, D. Hssairi, M. Masmoudi, J. Hachicha
Hedi Chaker Hospital University
Introduction: Hemophagocytic syndrome (HPS) is a life threatening 
hematological disorder in immuno compromised patients. Reactive HPS is 
observed in patients with systemic infection, neoplasia or auto immune disease. 
Various infectious agents have been associated with the development of HPS, 
including viruses. We report here a case of BKV – associated HPS.
Case report: A 29 – year – old male with end – stage renal disease secondary to 
chronic glomerulonephritis, received a kidney allograft from a living unrelated 
donor. His immunosuppression consisted of mycophenolate mofetil (MMF), 
Tacrolimus and corticoteroids without induction therapy. The graft functioned 
immediately with a 101 μmol/l serum creatinin on day 15.
11 months later, he presented fever, pancytopenia and a raising of serum 
creatinin (s.creat) to 398 μmol/l. We found no clinical evidence of infection, 
urine and blood cultures were negative. Cytomegalovirus virus (CMV) 
antigenemia was positive and gancyclovir treatment was instaured. Graft 
ultrasound showed no abnormality. A graft biopsy on day 7 found an acute 
rejection with viral inclusions. Gancyclovir was continued and corticosteroid 
pulses were instaured. Ten days later, CMV antigenemia was negative but his 
pancyopenia was worsening (white blood cells = 500 /mm3, platelets level 
= 62 000 /mm3). Bone marrow aspiration was negative. Thus, we prescribed 
granulocyte growth factor witch leads to rising WBC count to 4900 /mm3.
One month later, allograft function was worsening and s.creat rises to 828 
μmol/l and hemodialysis was started. Concomittely to rising of s.creat, the 
patients develops again fever with pancytopenia (WBC: 400 /mm3, platelet 
level: 18 000 /mm3, hemoglobin: 3 g/dl). CMV antigenemia was negative, 
liver enzymes level was normal. Ferritinemia level was at 2890 ng/ml and 
triglycerid level at 2,7 mmol/l. Urine sample was positive for decoy cells, BK 
virus viremia chain was at 5.1 log10 copies/ml. He underwent a second graft 
biopsy witch showed lesions suggestive of overt BKV nephropathy.
A bone – marrow aspiration was suggestive of HPS and the bone – marrow 
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biopsy disclosed typical features of hemophagocytosis. We reduced MMF and 
tacrolimus doses by half, but renal function was worsening and the patient 
return to dialysis.
Conclusion: Reactive HPS is rare after renal transplantation and must be 
suspected when fever and pancytopenia are associated especially in patients 
with viral infections. HPS was usually associated with CMV infections. In 
future, we must expected for BK virus.
POSTER BOARD NUMBER P2 – 149
LEFLUNOMIDE IMPROVES ALLOGRAFT 1350 
DYSFUNCTION IN BK-POLYOMA VIRUS NEPHRITIS IN 
RENAL TRANSPLANT RECIPIENTS
D. Samarapungavan, R. Kosuri, G. Reddy, B. Rai, I. Khan
William Beaumont Hospital
Immunosuppression reduction alone has limited success in improving renal 
function and avoiding progressive graft failure in patients with established 
graft dysfunction from BK-Polyoma nephritis (BKN). We present outcomes 
of 13 transplant recipients who developed clinically relevant BKN after 
basiliximab induction, with Cellcept and prednisone maintenance. One patient 
was on sirolimus, twelve received tacrolimus.
Diagnosis was established either by a positive biopsy (n=3), or clinically in 
the setting of an otherwise unexplained drop in GFR (by a mean of 26 ml/min) 
in conjunction with both BK viruria and viremia (n=7), or a drop in GFR with 
signifi cant viruria (≥ 15 million copies) alone (n=3). The mean tacrolimus 
level at the time of diagnosis was 6.9 ng/mL (Abbott IMX). No patient had 
received more than 2 gm of Cellcept/day. Mycophenolic Acid levels were 
available on 11 patients (mean-3.13 μg/mL, range 0.5-11.9; 4 patients were 
>3.5 μg/mL, 4 patients were <1.5 μg/mL). Mean time to diagnosis of BKN 
after transplant was 14 months (range 2-72).
Treatment consisted of changing Cellcept to lefl unomide, with a loading dose 
of 100mg/day for 3 days, then 40mg/day; targeting trough levels of the active 
metabolite terifl unomide to ≥40,000ng/mL. Tacrolimus levels were optimized to 
target trough levels of 4-6 ng/mL (Abbott IMX) or 3-5 ng/mL (LC/MS/MS).
Mean follow-up is 11 months (range 1-19). One patient developed acute rejection 
(that responded to therapy) due to non-compliance after improvement in BKN, 
and another received empiric pulse methylprednisolone for a rise in creatinine in 
the setting of urosepsis. One patient died of an unrelated cause with good graft 
function. Side effects did not limit drug usage and resolved with dose adjustments. 
Mean LFL dose and levels were 49 mg/day and 57,000 ng/mL respectively.
All patients show an excellent response with decline in viral loads (90% drops 
in viruria at a mean of 4 months) and improved GFR (at a mean of 8 months, 
range 1-15) as demonstrated in fi gure 1 and fi gure 2.
POSTER BOARD NUMBER P2 – 150
IMPACT OF PROPHYLACTIC CIPROFLOXACIN 1351 
ADMINISTRATION ON BK POLYOMA VIRUS REPLICATION
M. Koukoulaki, T. Apostolou, V. Hadjiconstantinou, S. Drakopoulos
Transplant Unit, Evangelismos, General Hospital of Athens
Purpose: BK virus has emerged as a potential pathogen in renal transplantation, 
leading to irreversible renal allograft dysfunction. Early diagnosis and appropriate 
treatment are decisive steps in prognosis of graft survival. Treatment choices include 
modifi cation of immune suppression or administration of anti-viral agents. In vitro 
evidence suggests that fl uoroquinolones inhibit polyoma virus DNA replication 
and viral cycle by interacting with the subunit of gyrase and helicase activity.
Patients and methods: We studied prospectively 32 de novo renal transplant 
recipients of median age 48.5 years old (range 22 – 76) (male: female, 23:9) 
for a period of 12 months with sequential samples of urine and blood tested 
for BK virus with real-time polymerase chain reaction. All recipients received 
induction therapy (Basiliximab: 18, Daclizumab: 14) and triple immune 
suppressive regimen with calcineurin inhibitor (cyclosporine: 19, tacrolimus: 
13), mycophenolate mofetyl and corticosteroids. Prophylactic antibiotic 
treatment was administered as follows: third generation cephalosporin, 
cefotaxim for ten day and subsequently ciprofl oxacin for six weeks. Recipients 
with concurrent positive urine cultures of pathogens resistant to quinolones 
were converted to beta-lactamic antibiotic.
Results: During the period of follow-up of the fi rst two months nine recipients 
had received for three weeks ciprofl oxacin and 23 recipients were on treatment 
with ciprofl oxacin for six weeks. The incidence of BK viremia and viruria were 
not affected by administration of ciprofl oxacin (table). The was an increasing 
tendency with a peak the third post-transplant month and subsequently declined. 
Viral load (log10) in urine showed signifi cant difference (Mann-Whitney U test, 
p=0,045) between measurements on the fi rst and the third post-transplant month 
that may be attributed to concurrent administration of ciprofl oxacin during the 
collection of samples the fi rst post-transplant month.
Conclusion: In this study it was observed that ciprofl oxacin does not protect 
from BKV re-activation. However ciprofl oxacin may exert an infl uence on 
BKV replication and viral load.
Month 0 1 3 6 9 12
Plasma Positive Samples 
(No -%) 3 - 9,4 6 - 18,7 9 - 28,1 7 - 23,3 0 - 0 3 - 12
Median Plasma Viral load* 
(range)
2,35
(1,3-3,1)
2,56
(1,6-3,9)
2,73
(0, 8-3,6)
3,4
(1,90-5,1)
3.08
(2,8-5,7)
Urine Positive Samples (No 
-%) 9 - 28,1 9 - 28,1 10 - 31,2 7 - 23,3 9 - 31,1 6 - 24
Median Urine Viral load* 
(range)
2,57
(1,0 – 6,9)
3,17
(0,7-7,6)
4,36
(1,1-9,7)
3,52
(1,4-7,5)
3,32
(0,8-5,7)
4,98
(2,4-7,4)
*log10 viral load, No: number,%: percentage
POSTER BOARD NUMBER P2 – 151
THE ROLE OF SERIAL BKV PCR ASSAY IN KIDNEY 1352 
TRANSPLANTATION
S.H. Kim1,3, H.E. Yoon1, Y.K. Kim1, S.C. Park2, B.S. Choi1, Y.S. Kim1, 
I.S. Moon2, B.K. Bang1, S.Y. Kim1, C.W. Yang1
Department of 1Internal Medicine and 2Surgery, College of medicine, 
The Catholic University of Korea, Seoul, Korea, 3Department of Internal 
Medicine, College of Medicine, Chungang University, Seoul, Korea,
Background: BK virus nephropathy (BKVN) is one of leading causes of renal 
allograft dysfunction and related with immunosuppressant. The goal of this 
study was to investigate natural course of BK virus (BKV) using BKV DNA 
polymerase chain reaction (PCR) assay after transplantation.
Methods: We measured BKV DNA PCR assay in plasma and urine at 
pretransplant, then weeks 1 and 2, month 3, 6 and 9 post-transplant in kidney 
transplant recipients.
Results: The median age at transplantation was 41 year (range: 22-58 year), 
median HLA mismatch was 3(1-6) (n=38). Transient viruria was occurred 5.3%, 
10.5%, 18.4%, 15.8%, 13.2% and 5.3% patients at pretransplant, weeks 1 and 
2, month 3, 6 and 9 post-transplant, respectively. And viruria was signifi cantly 
increased in FK506 treated group compared to CsA treated group at weeks 2 
post-transplant (9 patients in FK506 treated groups vs 0 patients in CsA treated 
groups, p=0.029). BKV viremia was occurred 4 patients within 6 months after 
kidney transplant. In the all four patients, the load of viremia was decreased 
or disappeared after consequential reduction of immunosuppressant and their 
renal function were well preserved. None of these patients developed biopsy 
proven BK nephropathy during the follow-up period. 
Conclusion: The BKV viremia and viruia is transient occurred and decreased 
or disapperaed after reduction of immunosuppressant.
POSTER BOARD NUMBER P2 – 152
BK VIRUS INFECTION IN RENAL TRANSPLANT 1353 
RECIPIENTS: DIAGNOSIS AND RISK FACTORS ANALYSIS
G. Tu, T. Zhu, Q. Tang, M. Xu, R. Rong
Department of Urology, Zhongshan Hospital, Fudan University, China
Objective To investigate methods of diagnosis and risk factors of BK virus 
infection in renal transplant recipients.
Methods 92 patients received renal transplantation in our center were 
undertaken BK virus detection and presence of decoy cells in urinary sediment, 
urine, and serum BKV-DNA. Epidemiological features and risk factors of BK 
virus infection were analyzed.
Results Among 92 patients, decoy cells were found in 29(31.5%) patients. The 
median time for the fi rst detection of decoy cells was 18.3 months after surgery. 
The sensitivity and specifi city of decoy cells to diagnose BK virus infection were 
67.7% and 86.9% respectively. 22(23.9%)patients were diagnosed as BK viruria at 
a median of 16.3 months after surgery, and 9(9.8%)recipients at a median of 39.5 
TU
ES
D
AY
 
Tuesday 12 August 2008 Poster Abstracts
4 5 6 Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
months after surgery. Decoy cells were associated with a signifi cantly higher rate of 
graft dysfunction. Of 9 renal recipients diagnosed as BK viremia, 8 demonstrated 
graft dysfunction. Risk factors of BK virus infection were analyzed by Logistic 
regression which implied that immune induction and patients without hemodialysis 
were high risk factors. Whereas, immunosuppressive regimen¦ primary kidney 
disease and post-surgery infections were found no signifi cant differences.
Table 1 Comparison of decoy cell and BKV-DNA detection facility
BKV-DNA(+) BKV-DNA(-)
Decoy cell(+) 21 8
Decoy cell(-) 10 53
Table 2 Impact of BK virus infection on graft function
Normal function Graft disfunction χ2 P value
A
Decoy cell(+) 12 17 7.61 0.006Decoy cell(-) 45 18
B
Urine BKV-DNA(+) 16 15 2.12 0.145Urine BKV-DNA(-) 41 20
C
Serum BKV-DNA(+) 1 8 9.83 0.003Serum BKV-DNA(-) 54 29
Conclusion BK virus infection is a common complication of renal 
transplantation.The infection of BK virus may result in graft dysfunction. 
Detection of decoy cells and BKV-DNA in urine samples may lead to early 
diagnosis of BK virus infection.
POSTER BOARD NUMBER P2 – 153
SURVEILLANCE FOR POLYOMA VIRUS (BK): 1354 
A USEFUL STEP TO AVOID NEPHROPATHY
W.M. Bennett, L. Meyer, J. Aman, T. Batiuk
Legacy Transplant Services, Portland, OR, USA
Renal infection with BK virus is known to be associated with poor allograft 
survival and a clinical picture diffi cult to distinguish from rejection. Diagnosis 
at the time of renal dysfunction frequently leads to graft loss despite reduction 
of immunosuppression.
We followed 58 consecutive recipients prospectively for BK infection with 
plasma and urine PCR at 1, 2, 3, 6, and 12 months post transplant. Standard 
immunosuppression was thymoglobulin (3 mg/kg) induction followed by 
tacrolimus, mycophenolate mofetil and 0.1 mg/kg prednisone. When plasma 
PCR was > 2.6 log copies, mycophenolate was stopped or reduced until there was 
no detectable viral load. The plasma PCR became positive in 11 patients (19%) 
at a mean of 1.82 months (1-5) post transplant. Viremia resolved in 3 months or 
less in 9 of 11 patients with no antiviral therapy. There were 2 patients with urine 
PCR > 7 log copies who never developed positive plasma PCR and no patient 
had viremia without > 7 log copies viriuria. Two patients had biopsy proven 
rejection episodes during reduced immunosuppression and 2 patients developed 
viremia following anti-rejection treatment. There was no graft loss due to 
rejection. Surveillance biopsies at 8 weeks in all patients showed no evidence of 
BK nephropathy histologically or with SV40 staining. Patient survival was 98% 
and graft survival was 95% with no graft lost to BK nephropathy.
Conclusion: Active surveillance for BK virus with prompt reduction of 
immunosuppression can prevent graft loss due to BK nephropathy.
POSTER BOARD NUMBER P2 – 154
BK VIRUS DETECTION AND MANAGEMENT 1355 
AT A TRANSPLANT INSTITUTE
M. Marvin, R. Nagubandi, R. Kadiyala, M. Eng, J. McConnell, R. Ouseph, 
J. Gleason, J. Buell
Division of Transplantation, Dept. of Surgery, University of Louisville, 
Louisville, Kentucky, United States. 
Objective: The incidence of BK virus has ranged from 1 to 4.6%. The presence 
of viremia appears to predict allograft nephropathy and eventual graft loss. Our 
aim is to evaluate the incidence and management strategy at our institution.
Method: Retrospective review of all transplants performed from 01/05 to 
11/07 was done. All patients with BK positive urine and or serum titers were 
identifi ed. Patient demogrphics, allograft biopsy, immunosuppression and 
outcomes were examined for these patients.
Results: A total of 2014 transplants were done at our institute between 
01/95 to 11/07 which included 1134 renal; 424 liver;87 - pancreas; 231 
heart; 138 lung transplants. A total of 13 patients had positive (mean age 
49) BK virus urine and or serum titers (10 kidney, 1 lung, 2 heart/kidney, 
1- kidney/pancreas). The overall incidence was 0.6% for our program with 
an incidence of 1.1% for kidney, 1.1% for kidney/pancreas, 0.9% for heart 
and 0.7 for lung transplants. All patients received alemtuzumab induction. 
The mean creatinine 6 months prior to and at the time of diagnosis was 
3.8 and 3.2 respectively. Treatment included elimination of antiproliferative 
drugs and minimization of calcinurin inhibitors. All viremia were followed 
by serial testing. The mean creatinine was 3.0 six months after the initial 
diagnosis.
One renal transplant patient had mild rejection and there were two renal graft 
losses. In two thoracic transplants we used the immune cell function assay 
(Immuknow) to direct the immunosuppression modulation. The heart/kidney 
patient is in need of a kidney re-transplantation and immunosuppression is 
actively being reduced.
Conclusions: BK virus infection is low in our patient population with minimal 
graft rejection stimulated by down-regulation of immunosuppression. We 
believe that the immune cell function assay may provide valuable insight into 
appropriate immunosuppresion modifi cation in patients who are at higher risk 
of graft loss following immunosuppressive down regulation
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CIDOFOVIR AND CIPROFLOXACIN FOR BK 1356 
NEPHROPATHY AFTER KIDNEY TRANSPLANTATION
M. Razavian, K. Wyburn, L. Garry, D. Verran, R.D.M. Allen, J. Eris, 
S. Chadban
Transplantation Services, Royal Prince Alfred Hospital, Sydney, Australia
Background: Polyoma BK virus (BK) is a highly prevalent DNA virus that 
causes BK nephropathy (BKN) in 1-10% of kidney transplant recipients and 
probably related to over immunosuppression. Graft dysfunction is usual and 
graft loss is not uncommon. The optimal therapeutic strategy has not been 
defi ned. We report our experience of 6 consecutive cases of BKN.
Method: Retrospective analysis of 6 patients with biopsy proven BKN, treated 
with a protocol of reduction in immunosuppression (calcineurin inhibitor 
reduction/cessation +/- reduction in anti-proliferative agent), IV cidofovir 
0.25mg/kg every 2 weeks for 6 doses, followed by oral ciprofl oxacin 250mg 
daily until clearance of BK DNA from serum.
Results: The six patients were transplanted between 2003 and 2007. Five 
patients were male and median age was 43.5 years (range 24-75). Immune-
suppression at time of transplantation included steroids (n=6), tacrolimus 
(n=3), cyclosporine (n=3), mycophenolate (n=5), basiliximab (n=4) and 
thymoglobulin (n=1). Five patients had been treated for acute rejection with 
pulse steroids (n=5) and T cell depleting antibodies (n=1). Mean baseline 
creatinine after transplantation was 112μ;mol/L (range 95- 210μ;mol/L) after 
transplantation. BKN was diagnosed at median time of 8 months (range 4-18 
months) after transplantation by PCR and biopsy (EM or immune staining 
for BK). Median creatinine at time of diagnosis of BKN was 230μ;mol/L 
(range 150-350μ;mol/L). Following therapy outlined above, all patients had 
improvement (n=5) or stabilization (n=1) in renal function. Five patients were 
followed for 6 and 12 months after initiation of therapy. Mean creatinine at 
6 months was 200μ;mol/l (125-260μ;mol/L) and at 12 months 180μ;mol/L 
(120-225μ;mol/L). There was 1 graft loss 8 weeks into treatment for BKN due 
to renal artery thrombosis. Treatment was well tolerated and all patients were 
able to complete treatment. There were no episodes of acute rejection during 
follow-up.
Conclusion: In our experience a reduction in immunosuppression, coupled with 
IV cidofovir, and followed by low dose ciprofl oxacin in cases with persistent 
BK viraemia, resulted in improvement and maintenance of function in grafts 
with biopsy proven BKN. This treatment was well tolerated and warrants 
evaluation in a randomised controlled trial.
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CROSS-SECTIONAL STUDY OF BK VIRUS INFECTION 1357 
IN KIDNEY TRANSPLANT RECIPIENTS. A SINGLE CENTRE 
EXPERIENCE
S.K. Lim, Y.L. Thye, C.M. Wong, T.C. Keng, Y.B. Chong, C.Y. Loo, S.Y. Tan
Renal Unit, Department of medicine,University Malaya Medical Centre
Introduction: Although discovered over thirty years ago, BK polyomavirus 
(BKV) was not shown to be associated with clinical disease until two decades 
later. BKV infection has now emerged as an important cause of allograft 
dysfunction and loss in kidney transplant recipients. This is closely linked to 
the usage of more potent immunosuppressive agents such as tacrolimus and 
mycophenolate mofetil in recent years. The prevalence of BKV nephropathy 
(BKVN) is estimated to be 5% to 10% in renal transplant recipients. In 
Malaysia, there is currently no epidemiological data of BKV infection and 
disease in our local transplant population
Objectives: To outline the prevalence of BKV infection and nephropathy 
among renal transplant recipients in University Malaya Medical Centre.
Methods: This is a cross sectional study which recruited renal transplant 
recipients who consented to participate in the study. Blood and urine of all 
patients were sent for quantitative BKV by Polymerase Chain Reaction (PCR). 
Renal function is determined using standard assays on sera collected from 
patients. Demographic and clinical data are collected using a questionnaire. 
For patients with BKV viraemia i.e. plasma BKV PCR > 4 log copies/ml and 
renal dysfunction i.e. rise in serum creatinine by 20% above baseline, allograft 
biopsy is performed to confi rm presence of BKVN.
Results: There were a total of 56 patients in our preliminary analysis and their 
median age was 42.5 years. Thirty nine patients (70%) were male and 17 were 
female. Majority of the patients were Chinese (66%) followed by Malays (20%) 
and Indians (13%). Fifty percent of the patients were living-related renal transplant 
recipients while the others were cadaveric recipients. The median duration post-
transplant was 69 months and majority of them (91%) had immediate graft 
function. Only 3 out of 56 patients (5.4%) were found to have low grade BKV 
viraemia as determined by PCR (100, 170 and 260 copies/ml respectively) and 
none of them had raised serum creatinine of more than 20% above baseline. 
Therefore, graft biopsy was not performed in these 3 patients but the blood 
BKV PCR and renal function were monitored closely. None of them received 
monoclonal antibody at induction or received antilymphocyte globulin as anti-
rejection therapy. There were 3 patients who were given antilymphocyte globulin 
(Atgam) for steroid resistant acute rejection but none of them had positive BKV 
PCR. Most of the patients (50%) received cyclosporine, mycophenolate mofetil 
and steroids as triple immunosuppressive therapy and another 23% of patients 
were treated with tacrolimus, mycophenolate mofetil and steroids.
Conclusion: Our preliminary results suggest that the prevalence of BKV 
infection and disease among our renal transplant recipients is relatively low. 
However, the number of patients is small and we are extending the study to 
include more patients to determine local prevalence of BKV infection in out 
transplant population. The low prevalence rate, if confi rmed, may be related to 
several issues including our choice of immunosuppresion which usually does 
not include the combination most frequently associated with BKVN.
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ABDOMINAL AORTIC ENDOANEURYSMORRHAPHY 1358 
IN A RENAL TRANSPLANT RECIPIENT
R.M. Rosete-Liquete, M.A. Mejes
National Kidney and Transplant Institute
Repair of abdominal aortic aneurysm in a renal transplant patient presents an 
important technical challenge since the allograft is placed at risk of irreversible 
renal damage due to warm ischemia. We report a case of a 61-year old male 
previously diagnosed with chronic kidney disease secondary to hypertensive 
nephrosclerosis who underwent living donor kidney transplantation last March 
2002 and was diagnosed three years later with a progressively enlarging (4 cm 
to 7 cm) infrarenal saccular aneurysm. He was maintained on cyclosporine 100 
mg twice daily, mycophenolate mofetil 500 mg twice daily and prednisone 
5mg a day with a pre-operative serum creatinine level of 1.1 mg/dL. Patient 
subsequently underwent endoaneurysmorrhaphy using a 16 mm PTFE tube 
graft with cross clamping below the native kidney renal arteries and just above 
the common iliac bifurcation lasting for 49 minutes. The inferior mesenteric 
artery was simultaneously re-implanted to the PTFE graft after converting 
to a partial side clamping of the aorta. No additional procedure such in situ 
renal perfusion or shunts were done to protect the allograft simplifying the 
surgical procedure. Post-operatively, highest creatinine level was 1.3 mg/dL 
with cyclosporine level maintained at 400-600 ng/ml. No renal replacement 
therapy was necessary during the recovery period. Therefore, standard repair 
of infrarenal abdominal aortic aneurysm can be carried out without additional 
renal protective procedures by experienced hands.
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PRESENCE OF BK VIRURIA IN HEART TRANSPLANT 1359 
PATIENTS
S. Palekar1, C. Slavov1, S. Akbar1, L. Mele2, S. Pardi2
1Division of Nephrology and Transplantation Newark Beth Israel Medical 
Center., 2Division of Cardiac Transplantation Newark Beth Israel Medical 
Center.
Introduction: BK virus (BKV) also known as Polyomavirus hominis 1, is a 
human polyomavirus in the Papovaviridae family. It is a small, non-enveloped 
virus with an icosahedral capsid and a core of circular double-stranded DNA. 
By adulthood 70% of the population have serologic evidence of prior infection. 
The relation between BK viral shedding and nephropathy is still unclear in non-
renal solid organ transplant patients. The purpose of our study was to conduct 
a prospective study that would test for the presence of BK viruria and viremia 
in Orthotopic Heart Transplant (OHT) recipients when their GFR suddenly 
declined below 60mL/min on routine follow-up visits.
Method: We tested all patients presenting to the heart transplant service 
between May and July 2007 who fi t the following criteria: s/p OHT and a sudden 
decrease in GFR to below 60mL/min unexplained by hemodynamic changes or 
medications that would affect renal function (ACEI, ARBs, diuretics). Patients 
testing positive for viruria (PCR assay) were then tested for BK viremia (PCR 
assay). Medical records were reviewed for the type of immunosuppression and 
other medications or events that would impact the GFR.
Results: Twenty-two patients met the inclusion criteria for the study. 7 out of 22 
(32%) patients were found to have BK viruria. In 5 out of 7 patients the BK viruria 
was above 10,000 copies/mL. Our report focuses on these 5 patients. 3 patients 
were within the fi rst 3 months after transplant, while 2 out of 5 were within the 
3 to 12 month period. All patients had steroid induction and were on Tacrolimus 
maintenance regimen. At the time of diagnosis 1 patient was on low dose Prednisone, 
Tacrolimus and Mycophenolate; 2 were on Tacrolimus and low dose prednisone; 1 
was on Tacrolimus and Mycophenolate, and 1 patient was on Tacrolimus alone. In 
the Tacrolimus alone patient, Mycophenolate had been discontinued 4 weeks prior 
for gastroenterological intolerance. None of the patients had detectable viremia. 
The level of BK viruria detected was between 50,000 copies/mL to greater than 39 
million copies/mL. 3 out of 5 patients had BK viruria above 1 million copies/mL.
Conclusion: BK viruria is present in a substantial number of non-renal solid 
organ transplant patients that have had cardiac transplantation. It can be seen 
with diverse immunosuppressive regimens and may be a marker of excessive 
immunosuppression. Interestingly, no BK viremia was found raising the 
possibility of a lower rate of viral replication.
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REDUCTION OF IMMUNOSUPPRESSION IN OHT 1360 
PATIENTS WITH BK VIRURIA
S. Palekar1, C. Slavov1, S. Akbar1, L. Mele2, S. Pardi2
1Division of Nephrology and Transplantation Newark Beth Israel 
Medical Center, Newark, New Jersey, United States, 2Division of Cardiac 
Transplantation Newark Beth Israel Medical Center, Newark, New Jersey, 
United States
Introduction: The relation between BK virus replication and nephropathy 
is still unclear in non-renal solid organ transplant patients. We conducted a 
prospective study to determine if a reduction in the degree of immunosuppression 
in Orthotopic Heart Transplant (OHT) patients with BK viruria would lead to 
a decline in the viral load; and also whether the use of two immunosuppressive 
agents concomitantly would infl uence the viral load.
Method: We tested all patients presenting to the heart transplant service 
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between May and July 2007 who fi t the following criteria: s/p OHT and a 
sudden decrease in GFR to below 60mL/min. Patients testing positive for 
viruria (PCR assay) were then tested for BK viremia (PCR assay). 22 patients 
met the inclusion criteria for the study. 7/22(32%) patients were found to 
have BK viruria. In 5/7 patients the BK viruria was above 10,000 copies/
mL. 5/7 patients with BK viruria were followed for Tacrolimus drug levels, 
serum creatinine/GFR and the drug regimens before and after diagnosis of BK 
viruria. Upon diagnosis the immunosuppressive regimen was adjusted by either 
stopping Mycophenolate in the patients who were on it and or by decreasing 
the Tacrolimus doses. Prednisone was either stopped or the dose decreased. BK 
viruria evaluation was repeated at a mean of 61 days after the initial diagnosis 
for follow-up.
Results: All of the 7 patients diagnosed with BK viruria had Tacrolimus and 
steroid induction. At the time of diagnosis 5/7patients had BK viruria above 10,000 
copies/mL. At the time of diagnosis 1 patient was on triple therapy (Prednisone, 
Mycophenolate, Tacrolimus), 2 were on Tacrolimus and low dose prednisone, 
1 on Tacrolimus and Mycophenolate and 1 patient was on Tacrolimus alone. 
3/5 patients had BK viruria above 1 million copies/mL. The level of BK viruria 
detected was between 50,000 copies/mL and greater than 39 million copies/
mL. At the time of diagnosis Mycophenolate was discontinued in all patients 
receiving it, the Tacrolimus dose was decreased in 4/5 patients and prednisone 
was decreased in 1 patient and stopped in another. At follow-up 2/5 patients had 
cleared the virus, while 2/5 patients remained positive for BK viruria though the 
levels reduced by a factor of at least 1 log. These 2 patients corresponded to the 
patients with the highest viral load. Meanwhile 1 patient was not retested. No 
BK viremia was detected. At follow-up all patients had an improvement in their 
GFR/serum creatinine. 2/5 returned to a GFR above 60mL/min.
Pt B & E had BK viruria<10,000 copies/mL
Conclusion: Prompt intervention to decrease the degree of immunosuppression 
at the time of initial diagnosis of BK viruria in OHT patients can lead to 
eradication of the virus. Our results suggest that the type of immunosuppressive 
regimen used did not predispose to a signifi cantly higher level of BK viruria at 
diagnosis; rather viral loads greater than 1 million copies/mL were associated 
with failure to clear the virus. We suspect that there was a correlation between 
BK viral replication and renal function as the GFR/serum creatinine improved 
in all patients at follow-up.
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LACK OF EFFICACY OF CIDOFOVIR IN THE 1361 
TREATMENT OF BK VIRUS POSITIVE RENAL TRANSPLANT 
RECIPIENT’S: ONE TRANSPLANT CENTER’S EXPERIENCE
S. Palekar, J. Madigan, S. Akbar, C. Flores
Division of Nephrology and Transplantation Newark Beth Israel Medical 
Center, Newark, New Jersey, United States
Introduction: BK Virus associated nephropathy is a commonly recognized 
cause of acute and chronic renal allograft dysfunction. Detection of BK viremia 
and / or viruria may be an occult sign of excessive immunosuppression. 
Current opinion suggests that decreasing the dose and / or frequency of 
immunosuppression may be effective. However, some patients may require 
immunosuppression withdrawal or nucleoside analogs such as Cidofovir. The 
purpose of our study was to show that Cidofovir is an ineffective therapeutic 
modality for BK virus infection.
Method: At our renal transplant center we retrospectively looked at a case 
series of 22 patients who were found to have persistent BK viruria and/
or viremia. An extensive chart review was performed observing patient 
demographics, induction and maintenance immunosuppression regimens, the 
number and dosage of Cidofovir treatments, and living versus deceased donor 
transplantation.
Results: 22 patients were found to have persistent BK viruria and / or viremia. 17/22 
(77%) patients were males and the average age was 49 years (17–71 years). All 
patients were more than one year post-transplant. 9/22 (41%) were African American, 
6/22 (27%) were Hispanics, 5/22 (23%) were Caucasian, and 2/22 (9%) were Asian 
Indian. 12/22 (55%) transplant recipients had a deceased donor, while 10/22 (45%) 
had living donors. 13/22 (59%) had received induction with Thymoglobulin, while 
8 had received Daclizumab, and 1 patient received Basiliximab. 8/22 were on a 
maintenance regimen comprising of Prednisone, Tacrolimus and Mycophenolate, 
2/22 were on Prednisone, Mycophenolate and Cyclosporine, 7/22 were on only 
Prednisone and Tacrolimus, 2/22 were on only Mycophenolate and Tacrolimus, 
2/22 were on Sirolimus and Prednisone and 1 was on Sirolimus, Prednisone and 
Mycophenolate. BK viruria ranged from less than 500 copies/mL to greater than 
39 million copies/mL, while BK viremia ranged from none detected to 754,000 
copies/ mL. The number of Cidofovir treatments ranged from 3 to 16, with the 
mean of 8 treatments, with appropriate renal dosing (0.25mg/kg-0.5mg/kg). Despite 
numerous treatments there was no signifi cant decrease in the degree of BK viruria. 
7/22 (32%) patients had an increase in the degree of BK viruria despite multiple 
Cidofovir treatments. 9/22 (41%) patients had a decrease in the BK viremia, while 
18/22 (82%) had no detected BK viremia at fi nal follow-up; and 4 had persisting 
viremia. No correlation could be made between the degree of BK viruria and the 
induction or maintenance regimens. Both African Americans and Caucasians were 
equally predisposed to BK viruria with greater than 39 million copies/mL.
Conclusion: Multiple treatments with Cidofovir to eradicate BK viruria were 
ineffective. 32% of the patients had an increase in the degree of BK viruria 
despite treatment with Cidofovir. None of the patients had undetectable urinary 
BK viral load. No signifi cant risk factors could be alluded to, that would 
predispose to persistent viruria. However, Cidofovir was effective in decreasing 
the degree of BK viremia. We suggest a further larger and prospective trial to 
decipher whether persistent BK viruria in the absence of viremia should be 
treated and if so, what level of viruria is of concern.
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BK VIRAL LOAD IN RENAL TRANSPLANT RECIPIENTS 1362 
WITHOUT CLINICAL NEPHROPATHY
S.C. Tang1, A.Y. Leung2, T.M. Chan1, W.K. Lo1, Y.L. Kwong2, K.N. Lai1
Divisions of 1Nephrology and 2Haematology, Department of Medicine, 
The University of Hong Kong, Queen Mary Hospital, Hong Kong
Polyoma BK virus (BKV)-associated nephropathy (PAN) occurs in up to 9% 
of kidney transplantation in which half will have impaired graft function due 
to reactivation of BKV infection in the transplanted kidney. PAN occurs most 
commonly in the fi rst two years after transplantation and is associated with a 
rise in serum BKV DNA. Little is known about whether BKV DNA is present in 
renal transplant recipients without clinical features of nephropathy. Quantifi cation 
of serum BKV DNA levels using real-time quantitative polymerase chain 
reactivation (Q-PCR) was performed in 23 fi rst-time kidney transplant recipients 
(9 males; mean age, 53.9±13.5 y; mean serum creatinine, 103±25.4 umol/L) who 
had normal serum creatinine (below 140 umol/L or 1.58 mg/dL) within 3 years of 
transplant and were receiving an immunosuppressive regimen comprising steroid, 
calcineurin inhibitor, and mycophenolate. The frequencies of BK viral load in 4 
log orders are shown in the table. Only 1 patient had 1.2x104 copies/mL.
Yrs after Tx BKV DNA (copies/mL)
undetectable < 102 < 103 < 104 > 104
0-1 year (N=5) 3 (60%) 3 (60%) 4 (80%) 4 (80%) 1 (20%)
1-2 years (N=6) 2 (33%) 3 (50%) 5 (83%) 6 (100%) 0 (0%)
2-3 years (N=12) 8 (67%) 11 (92%) 12 (100%) 12 (100%) 0 (0%)
Overall (N=24) 13(57%) 17(74%) 21(91%) 22(96%) 1(4%)
We conclude that among renal transplant recipients with stable and good 
graft function during the fi rst 3 posttransplant years, around half of them had 
undetectable circulating BKV DNA, and 90% had levels < 103 copies/mL. BK 
viral load is independent of the duration of transplantation.
POSTER BOARD NUMBER P2 – 162
IS ABO-INCOMPATIBLE RENAL TRANSPLANTATION 1363 
A RISK FACTOR FOR BK VIRUS INFECTION OR 
NEPHROPATHY?
T. Ueki1, A. Katayama1, K. Uchida2, T. Nagasaka2, T. Kobayashi3, A. Itoh1
1Masuko Memorial Hospital, 2Ngaoya Daini Red Cross Hospital, 3Nagoya 
University School of Medicine
Introduction: BK virus nephropathy (BKVN) is a troubling onset complication 
of renal transplantation, which may affect upwards of 8% of allografts in the 
current era of immunosuppression. Risk factors for the development of this 
condition appear to be a history of acute rejection, anti-rejection therapy 
(particularly the number of corticosteroid pulses) and possibly increased donor/
recipient HLA mismatching. However, no studies have demonstrated that 
ABO-incompatible renal transplantaion(ABOi LDRT) is a risk foctor for BK 
virus infection or BKVN due to over-immunosuppression.
Method: We have performed ABOi LDRT in 88 patients (60 patients received 
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Cyclosporine based regimen and 28 patients received Tacrolimus based 
regimen) since 1993. To minimize the risk of humoral rejection, we performed 
a splenectomy 2 weeks before transplantation, eliminated anti-A and/or anti-B 
antibodies by double-fi ltration plasmapheresis (DFPP), and administered a 
potent immunosuppressive regimen consisting of cyclophosphamide, anti-
CD25 monoclonal antibody, calcineurin inhibitor and prednisolone. The 
calcineurin inhibitor dose was adjusted by monitoring AUC0-4 target values. 
We have performed BK virus follow-up in all patients since 2005. BK virus 
DNA detection in blood samples was performed using the quantitative real time 
polymerase chain reaction (PCR) technique. The primers used for this assay are 
specifi c for BK virus and have been designed to accommodate mutated strains. 
The range of detection is 1x1000 copies/ƒÊL.
We investigated the incidence of BK virus infection between ABOi LDRT and 
ABO-compatible renal transplantation group (n=120).
Results: The incidence of BK virus infection after transplantation was 1.1% (1/88) 
in the ABOi LDRT group as compared with 5.0% (6/120) in the ABO-compatible 
renal group (p=0.127). The incidence of acute rejection during the fi rst 3 months 
after transplantation was 18.2% @(8 cellular, 1 combined type and 7 antibody-
mediated rejection) in ABOi LDRT group, as compared with 20.8% (25/120) in 
the ABO-compatible group (p=0.634). Graft survival rates were similar in both 
groups (95.6% vs 96.3%) at 1 year (p=0.296). There are 4 patients with BKVN in 
ABO-compatible renal group, but no patient in ABOi LRT group.
Conclusion: Although total immunosuppression might be generally potent in 
ABOi LDRT, Our center protocol of ABO-incompatible renal transplantation 
is not a risk factor for BK virus infection or BKVAN.
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LOW INCIDENCE OF BK VIRUS NEPHROPATHY IN 1364 
PATIENTS TREATED WITH MYCOPHENOLATE MOFETIL: A 
CUMULATIVE REVIEW OF REPORTED CASES
P. Acott1, H. Mouas2
1IWK Health Centre, Halifax, Canada, 2F. Hoffmann-La Roche Ltd, Basel, 
Switzerland
Introduction: BK virus-associated nephropathy (BKVN) develops in 1-10% of 
renal transplant patients and often leads to permanent allograft dysfunction and/
or loss. A key factor in the development to BKVN pathogenesis is the “net state 
of immunosuppression”, but other factors, including allograft infl ammation, acute 
rejection and drug toxicity, may contribute as well. In order to investigate whether 
mycophenolate mofetil (MMF) is a risk factor for BKVN, a cumulative review of 
all BK-related cases reported in patients treated with MMF was carried out.
Methods: The Roche global safety database was searched using MedDRA 
version 10. The following search terms were used: BK virus infection; 
polyomavirus-associated nephropathy; and human polyomavirus infection. In 
addition, the following text strings were used: BK; PVAN; polyoma; and PV.
Results: A total of 84 cases were retrieved from 19 countries, including 21 
cases from the USA, 17 from Germany, and 14 from Japan. The average age 
of patients was 48 years (range 1.7 to 76 years), and approximately two-thirds 
of patients were male. The use of additional immunosuppressive agents was 
reported in the majority (93%) of cases and anticipated in all. There was variation 
in the reported criteria for diagnosis of BKVN, and only 51 cases (61%) were 
confi rmed by renal biopsy. In 17 cases (20%) evidence of BK viruria only was 
reported, while 16 cases (19%) were unconfi rmed. Allograft loss was reported in 
only two of the 51 biopsy-proven cases of BKVN. Clinical suspicion of rejection 
was reported in 36 cases, and 20 cases provided pathological information about 
acute or chronic rejection prior to or at time of diagnosis of BKVN. Confi rmed 
BKVN occurred on average 249 days (median 181 days) after the fi rst dose 
of MMF was administered. The reports originated from the following sources: 
53 (63%) from clinical trials; 22 (26%) from literature cases; and 9 (11%) 
spontaneous reports. Amongst the clinical trial reports, 42 cases originated from 
Roche-sponsored studies in a total of 5712 patients. This represents a BKVN 
prevalence of 1.4%, which is below the rate seen in many clinical studies.
Conclusions: The incidence of biopsy-confi rmed BKVN in patients receiving 
MMF was low. Based on the results of this cumulative review, MMF does 
not seem to play a major role in the development of BKVN. Based on in vitro 
fi ndings that mycophenolate reduces BK virus replication and considering the 
proven benefi t of MMF in preventing allograft rejection and steroid pulsing 
in the fi rst year post renal transplant, the use of MMF may even be protective 
against the emergence of BKVN.
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COLLAPSING FOCAL SEGMENTAL 1365 
GLOMERULOSCLEROSIS DUE TO POLYOMAVIRUS 
INFECTION IN A KIDNEY TRANSPLANT PATIENT: 
SEROLOGICALLY, IMMUNOHISTOCHEMICALLY 
AND ULTRASTRUCTURALLY VERIFIED CASE
A. Colak1, B. Demirhan1, E. Baskin2, N. Haberal1, M. Haberal3
1Baskent University Faculty of Medicine, Department of Pathology, 2Baskent 
University Faculty of Medicine, Department of Pediatrc Nephrology, 
3Baskent University Faculty of Medicine, Department of General Surgery
Background: The availability of potent immunosuppressant drugs has resulted 
in an increasing incidence of viral infections in solid organ transplantation. Of 
particular interest is the occurence of polyomavirus allograft nefropathy. This 
affects%5-10 of kidney transplant recipients and is associated with a high risk 
of premature graft loss.
Case: 12 year-old-girl with end stage renal failure secondary to VUR was 
followed-up with continous ambulatury peritoneal dialysis and hemodialysis for 
3 years. She underwent renal transplantation from a deceased donor in July 2007, 
in our center. The 4th month of transplantation she was admitted to our hospital 
with fever and cough. Patient was thought to have a urinary tract infection. 
However, renal biopsy was done because of high suspicion of renal allograft 
rejection. Renal biopsy did not show any sign of acute rejection. Biopsy of the 
transplant kidney of this patient showed segmental and global collapse of the 
glomerular capillaries, marked hypertrophy and hyperplasia of podocytes. The 
biopsy revealed that the interstitium was infi ltrated by numerous lymphoÂ¬cytes. 
Tubular epithelial cells had severe injury and severe reactively changes. The light 
microscopy fi ndings which is pointing to collapsing glomerulopathy induce us to 
suggest about the possible presence of polyoma virus infection in renal allograft 
although there was no signifi cant inclusions in tubule cells. A few number of 
tubular epitelial cells were positive by SV 40 antigen-antibody (which reacts with 
BK virus) in the immunohistochemical staining.
In the mean while, the patient’s urine was sent for polyoma DNA detection by 
PCR, which was reported positive for BK virus. Electron microscopy showed 
intranuclear viral particles.
Cidofovir treatment was started for BK virus infection and Tacrolimus was 
discontinued and steroid dose was decreased. After discontinued of the 
immunosuppression, with antiviral treatment with cidofovir, renal function 
was stabilized.
Conclusion: The role of post-transplant factors such as immunosuppressive 
medication, immunological injury, microvascular disease and infection in the 
pathogenesis of collapsing focal segmental glomerulosclerosis (cFSGS) is also 
not well known. Collapsing glomerulopathy is a morphologic variant of FSGS 
characterized by segmental and global collapse of the glomerular capillaries, 
marked hypertrophy and hyperplasia of podocytes, and severe tubulointerstitial 
disease. The cause of this disorder is unknown, but nearly identical pathologic 
fi ndings are present in idiopathic collapsing glomerulopathy has been associated 
with polyomavirus and treatment with cidofovir. Polyomavirus reactivation 
can occur in the kidneys transplant recipients. The effects of PV reactivation on 
long-term transplant kidney function are not known.
POSTER BOARD NUMBER P2 – 165
BK VIRUS INFECTION IN ASSOCIATION WITH 1366 
POST-TRANSPLANT UROTHELIAL CARCINOMA
H-H. Wang1, Y-J. Chiang1, P-C. Lai2, Y-C. Tian2, S-H. Chu1, K-L. Liu1
1Department of Urology, Chang-Gung Memorial Hospital, 2Department of 
Nephrology, Chang-Gung Memorial Hospital
Background: We treated two kidney recipients with urothelial carcinoma and 
BK virus infection. We report our experiences and discuss their association.
Objectives: BK virus infection after transplantation has been associated 
with graft failure. The association with malignancies are controversial. More 
evidence on immunohisochemical staining and viral DNA had been reported.
Subject and methods: BK virus workup was performed for kidney recipients 
in our hospital under the condition of hematuria and acute deterioration of renal 
function. Two BK virus infected recipients were diagnosed urothelial caricinoma. 
We reviewed their history and report our treatment and the disease course.
Results: Two patients received kidney transplantation at Mainland China and 
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returned to our country. They had persisted painless hematuria. BK virus was 
identifi ed in their urine and cystoscopic workup showed synchronous bladder 
and upper tract TCC. They received bilateral native nephroureterectomy and 
transurethral resection of bladder tumors followed by intravesical chemotherapies. 
We reduce their immunsuppresants to minimal and shift to Sirolimus based 
regimen. Both patients had no recurrence on three-month follow up and graft 
remained functional. In our center, the incidence of urothelial carcinoma in BK 
viruremia recipients was much higher than control. Immunohistochemical stains 
in the tumors were negative of BK virus in these two patients.
Conclusion: There are more clues suggesting that BK virus infection may relate 
to malignancies. We have detected higher incidence of urothelial carcinoma in 
BK virus infected kidney recipients. We should modify our protocol for tissue BK 
virus staining and correlate to RTPCR to establish more evident association.
POSTER BOARD NUMBER P2 – 166
MONITORING CELLULAR IMMUNITY IN THE 1367 
TREATMENT OF BK VIRUS INFECTION AFTER KIDNEY 
TRANSPLANTATION: TWO CASE REPORTS
R. Olsson1, A. Sedigh1, A-K. Lidehäll2, M. Engstrand1,2, J. Henriksson1, 
A-L. Hammarin3, G. Tydén1, O. Korsgren2, L. Wennberg1
1Department of Transplantation Surgery, Karolinska University Hospital, 
Huddinge, Stockholm, 2Department of Clinical Immunology, Uppsala 
University, Uppsala, and 3Department of Virology, The Swedish Institute for 
Infectious Disease Control, Stockholm, all in Sweden.
Background: BK virus associated kidney allograft nephropathy (BKVAN) 
is regarded as an important cause of graft dysfunction or loss. Over-
immunosuppression is considered to be the major cause of BKVAN and the 
most commonly applied treatment is reduction of the immunosuppression. 
Consequently, a way to monitor the degree of immunosuppression and the specifi c 
immunological reactivity to BK virus would be of signifi cant importance.
Materials and methods: In an ongoing clinical study at our center, preemptive 
treatment of BK virus infection is evaluated as a mean to avoid subsequent 
BKVAN. Therefore, all kidney transplant recipients are monitored for BK 
viremia (defi ned as >10 000 viral copies/ml). In patients diagnosed with BK 
viremia, and therefore treated with a reduction of the immunosuppressive 
treatment, T cell reactivity to BK virus was determined at diagnosis and after 
1 month. Briefl y, after in vitro stimulation with BK virus-specifi c protein 
(protein T), the number of CD8+ T cells producing IFN γ was determined 
with FACS, and expressed per ml blood. In addition, the degree of cellular 
immunosuppression was analyzed with the ImmuKnow® assay (Cylex Inc., 
Columbia, MD, USA) and the viral load was determined by quantitative PCR.
Results: Case 1: A 45-year-old male with terminal kidney failure due to 
nefrosclerosis, who received his fi rst cadaveric kidney. Five months post-
transplantation the creatinine suddenly increased from 149 μmol/l to 178 
μmol/l. At the time, he was maintained on tacrolimus (trough level 5 ng/ml), 
mycophenolate mofetil (1 g daily) and prednisolone (10 mg daily). BK viremia 
was discovered (84 000 copies/ml) and mycophenolate mofetil was therefore 
discontinued. At diagnosis, the recipient had no BK virus specifi c CD8+ 
T-lymphocytes. One month later the creatinine had decreased to 126 μmol/l and 
the recipient had developed BK virus specifi c T-lymphocytes (600 CD8+cells/
ml). Furthermore, the BK viral load was markedly decreased (19 000 copies/ml). 
In contrast, the results of the ImmuKnow® assay indicated a progressive over-
immunosuppression (427 and 123 ng/ml ATP, respectively). Case 2: A 53-year-
old male with chronic kidney failure due to IgA-nefritis, who received his 3rd 
kidney. One year after transplantation, the creatinine increased to 141 μmol/l and 
BK viremia (80 000 copies/ml) was observed. At the time, immunosuppression 
was with tacrolimus (trough level 5 ng/ml), mycophenolate mofetil (2 g daily) 
and prednisolone (10 mg daily). At diagnosis, ImmuKnow® showed a moderate 
ATP production (340 ng/ml), and we could not detect any BK virus specifi c 
lymphocytes. One month after reducing tacrolimus (trough level 3-5 ng/ml) and 
mycophenolate mofetil (1 g daily), the creatinine was stable (143 μmol/l) and 
ImmuKnow® showed a similar ATP production (297 ng/ml). However, there was 
no longer any BK viremia (5 600 copies/ml) and we were now able to detect the 
appearance of BK virus specifi c lymphocytes (935 CD8+ cells/ml).
Conclusions: In our hands, the Immuknow® assay does not properly refl ect 
the clinical course or the degree of immunosuppression during treatment of 
BK viremia. In contrast, preliminary data indicate that monitoring BK virus 
specifi c T cells might be a more useful clinical tool.
POSTER BOARD NUMBER P2 – 167
A NOVEL REAL-TIME PCR ASSAY FOR THE 1368 
DETECTION AND QUANTIFICATION OF HUMAN 
POLYOMAVIRUS BKV AND JCV
K.K. Iwaki1, Y. Qazi2, M. Smogorzewski2, J. Garcia-Gomez1, K. Matsuda3, Y. 
Iwaki1,4
1USC Metic Transplantation Laboratory, 2Department of Nephrology, USC 
Keck School of Medicine, 3Division of Infectious Disease, Children Hospital 
of Los Angeles, 4Department of Urology, Pathology and Surgery, USC Keck 
School of Medicine
The polyomavirus, BK virus (BKV) and JC virus (JCV), are becoming 
increasingly recognized as clinically important pathogens particularly in 
transplant recipients. Recent studies have shown polymerase chain reaction 
(PCR) to be an effective tool for detecting polyomavirus in a range of 
clinical samples. A major obstacle, however, in the development of a reliable 
and consistent PCR-based assay has been the large number of intraspecies 
polymorphisms in the nucleotide sequences of naturally occurring strains of 
BKV and JCV. The goal of this study was to identify an evolutionarily stable 
genetic target and to develop of a more robust real-time PCR assay for the 
detection and quantifi cation of BKV and JCV in clinical samples.
Amino acid and nucleotide sequences from more than 10 species of 
polyomavirus were compared and evaluated for areas where: <a> the product 
of the nucleotide sequence was placed under strict biological restrictions in 
terms of form and function, <b>the product of the sequence was necessary for 
effi cient viral replication and infection, <c> the amino acid sequence was highly 
conserved within the genus polyomavirus, and <d> the interspecies variation in 
nucleotide sequence was suffi cient for accurate species discrimination.
A stable, conserved region within the C-terminus of the VP2/3 gene of the 
polyomavirus was elucidated and determined to be an effective and resilient 
target. A real-time PCR based assay was developed, which targeted the 
hydrophobic alpha-helix region within the C-terminus of the VP2/3 gene. 
Specifi city of the assay was confi rmed by testing against known amounts of 
cloned BKV DNA and JCV DNA. The assay allowed specifi c and reliable 
quantifi cation of 8 copies of viral DNA.
In conclusion, our novel molecular diagnostic assay would be very useful to 
monitor polyomavirus in transplant patients.
CAN – CELL AND CONCURRENT ORAL SESSION 98: 
BIOMARKERS
POSTER BOARD NUMBER P2 – 168
CYSTATIN C AS A RELIABLE MARKER OF KIDNEY 1369 
FUNCTION IN RENAL TRANSPLANT PATIENTS
B. Geramizadeh1, N. Azarpira, M. Ayatollahi, M. Aghdai, R. Yaghoobi, 
M. Banihashemi, Z. Malekpour
1Transplant Research Center, Pathology Department, 2Transplant Research 
Center, 3Transplant Research Center, 4Transplant Research Center, 
5Transplant Research Center, 6Transplant Research Center, 7Transplant 
Research Center, 8Transplant Research Center
Introduction: Serum creatinine (sCr) is the most commonly used biochemical 
parameter for evaluating the kidney function, but, due its limitations, it is not 
the ideal marker for glomerular fi ltration rate (GFR). Serum Cystatin C (sCyC) 
appears to be an endogenous marker of GFR.
Purpose: To assess the use of sCyC as a marker of renal function in kidney 
transplant patients, we compared it with sCr and with creatinine clearance 
(CrC) in a 24-hour urine specimen.
Methods: Among 60 patients (62.8% men, 37.2% women) undergoing kidney 
transplantation (average age: 44.87 ± 13.37 years) we determined at 1, 3, 5, and 
7 days after kidney transplantation: sCr (using the Jaffe colorimetric method), 
sCyC (ELISA method), and Cr clearance with a 24 hours urine specimen.
Results: During the fi rst 5 days following transplantation, there was a 
progressive decline in sCr levels. In the fi rst 5 days post transplantation we 
couldn’t fi nd good correlation between CrC and sCyC, but after 7 days there 
was a good correlation between CCr and sCyC which is easier to perform and 
it doesn’t need 24 hour urine specimen collection.
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Conclusion: sCyC is an endogenous marker of GFR. Its limitations relate 
to its being affected by high doses of steroids in the fi rst days following 
transplantation. After a week post transplantation, it is correlated with CrC in 
a 24-hour urine. So after a week post renal transplantation sCyC is a reliable 
marker of kidney function.
POSTER BOARD NUMBER P2 – 169
COMPARISON OF GLOMERULAR FILTRATION 1370 
RATE ESTIMATION BETWEEN CREATININE CLEARANCE, 
CREATININE BASED EQUATIONS AND CYSTATIN C BASED 
EQUATIONS IN KOREAN RENAL TRANSPLANT RECIPIENTS
Y. Yeo1, D.H. Moon2, D.J. Han3, S.B. Kim1, J.S. Park1, S.K. Park1
Division of Nephrology, 1Department of Internal Medicine, 2Department 
of Nuclear Medicine and 3Department of Surgery, Asan Medical Center, 
University of Ulsan College of Medicine, Seoul, South Korea
Background: Accurate measurement of glomerular fi ltration rate (GFR) is 
critical for the successful management of kidney transplant recipients. Since 
reference methods to measure GFR cannot be easily implemented, numerous 
equations based on creatinine have been developed to estimate GFR. However, 
these equations have not been shown to be reliable in renal transplant 
recipients. We aimed to compare the performance of creatinine clearance, 
creatinine based equations and cystatin C based equations in Korean renal 
transplant patients.
Methods: We measured 51Cr-EDTA clearance as a reference GFR in 37 
stable kidney transplant recipients. For accurate measurement of GFR, 6 
plasma samples were taken at 10, 20, 30, 60, 180 and 300 minutes after 50μCi 
51Cr-EDTA bolus injection. Serum creatinine was measured by rate-blanked 
compensated kinetic Jaffe assay. Because the creatinine concentration measured 
by compensated kinetic Jaffe assay was traceable to an isotope dilution mass 
spectrometry (IDMS) determination, we estimated GFR using the IDMS 
traceable MDRD equation in addition to the abbreviated MDRD equation. 
(Vickery et al. Nephrol Dial Transplant (2006) 21:2439-2445). Cystatin C 
was measured by particle enhanced immunonephelometric method. GFR was 
estimated using 13 creatinine based equations and 8 cystatin C based equations 
as well as creatinine clearance. The bias, precision, accuracy within 30% and 
50%, relative difference and agreement of each methods were compared.
Results: The mean 51Cr-EDTA GFR was 71.83±20.41 ml/min/1.73m2. Each 
GFR equation correlated signifi cantly with 51Cr-EDTA GFR. Abbreviated 
MDRD equation overestimated GFR signifi cantly (P=0.021) with a bias 
of 5.14 ml/min/1.73m2 and an accuracy within 30%, 50% of 81.08%, 
94.59% respectively. The IDMS traceable MDRD equation had the highest 
accuracy (accuracy within 30%, 50% of 86.49%, 97.3% respectively) with 
a bias of 0.59 ml/min/1.73m2 and a precision of 12.57 ml/min/1.73m2. The 
Walser equation based on creatinine also showed high accuracy (accuracy 
within 30%, 50% of 86.49%, 94.59% respectively) with a bias of -0.96 ml/
min/1.73m2. Among the cystatin C based equations, the MacIsaac equation 
had the highest accuracy (accuracy within 30%, 50% of 83.78%, 94.59% 
respectively) with a bias of -2.27 ml/min/1.73m2 and the least relative 
difference of -0.02%. Creatinine clearance had the lowest accuracy (accuracy 
within 30%, 50% of 33.33%, 55.56% respectively) with a bias of 3.98 ml/
min/1.73m2
Conclusion: Among the various GFR equations, IDMS traceable MDRD 
equation was the most accurate equation for GFR in Korean renal transplant 
recipients. The cystatin C based GFR equations, especially MacIsaac method 
exhibits similar diagnostic characteristics to the IDMS traceable MDRD 
equation.
Table 1. Patient characteristics
Characteristics N=37 Range
Age (yr) 44.13±9.36 27-60
Male [n(%)] 18 (48.64)
Weight (kg) 58.14±10.44 38.8-80.8
Height (cm) 163.86±9.28 144.1-182.0
Body surface area (m2) 1.62±0.17 1.24-1.89
Creatinine (mg/dl) 1.05±0.34 0.6-2.4
Cystatin-C (mg/l) 1.26±0.41 0.69-2.69
Table 2. Bias, precision, accuracy and relative difference of creatinine and 
cystatin C estimates
Mean±SD Bias Precision
Paired 
t- test 
(P value)
Correlation 
coeffi ciency
Accuracy 
(%) within
Relative 
difference
(%)30% 50%
51Cr-EDTA GFR 71.83±20.41
Creatinine 
clearance 76.20±20.78 3.96 12.52 0.66 0.817 33.33 55.56 9.03
Estimates using creatinine
Abbreviated 
MDRD 76.97±21.03 5.14 12.96 0.021 0.805 81.08 94.59 10.28
IDMS traceable 
MDRD 72.42±19.79 0.59 12.57 0.778 0.805 86.49 97.30 3.76
Walser 70.87±19.29 -0.96 13.83 0.675 0.759 86.49 94.59 1.94
Cockcroft-Gault 76.77±19.38 4.94 12.12 0.018 0.816 83.78 89.20 11.10
Jelliffe-2 76.80±21.69 4.97 14.24 0.041 0.773 81.08 91.89 10.82
Gates 87.96±20.97 7.14 13.70 0.003 0.781 81.08 89.18 13.31
Nankivell 88.15±24.67 16.32 16.65 <0.001 0.743 62.16 83.78 27.21
Salazar 53.30±20.89 -18.52 35.53 0.003 -0.480 32.43 56.76 -7.97
Estimates using cystatin C
MacIsaac 69.06±18.98 -2.77 15.67 0.289 0.686 83.78 94.59 -0.02
Le Bricon 70.62±17.50 -1.21 15.27 0.632 0.686 78.38 94.59 3.06
Orebro 71.41±22.44 -0.42 17.09 0.882 0.686 75.68 91.89 2.19
Filler 77.11±22.68 5.28 17.32 0.072 0.682 72.97 94.59 11.16
Larsson 69.44±26.10 -2.38 20.86 0.491 0.622 70.27 86.49 -0.79
Grubb 70.80±29.97 -1.03 22.79 0.784 0.650 67.57 91.89 -1.27
Hoek 64.31±18.03 -7.52 15.40 0.005 0.686 81.08 94.59 -7.04
Rule 64.20±19.49 -7.64 15.98 0.006 0.680 81.08 94.59 -7.67
Bias, mean difference between the actual measured GFR and the estimated GFR
Precision, standard deviation of the difference between the measured and estimated GFR
Accuracy, proportion of GFR estimates within 30% and 50%
Relative difference, percent difference from the measured GFR
All values expressed as ml/min/1.73m2; 51Cr-EDTA, 51Cr-Ethylene diamine tetraacetic acid.
POSTER BOARD NUMBER P2 – 170
BLOCKADE OF ADVANCED GLYCATION IN CHRONIC 1371 
ALLOGRAFT DYSFUNCTION
M. Baumann, C. Jianxing, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R.D. Isar, TU Munich
Background: Advanced glycation end products (AGEs) induce oxidative stress 
and infl ammation by activating the receptor of AGE (RAGE). Evidence exists 
that AGEs are present in chronic kidney disease and RAGE-blockade improves 
renal function in diabetes models. We hypothesize that RAGE-blocker improve 
renal transplant function.
Methods: Fisher 344 kidneys were orthotopically transplanted into Lewis 
recipients. Recipients were treated with placebo, an unspecifi c RAGE-blocker 
(aminoguanidine 100mg/kg/day), specifi c RAGE-blocker (pyridoxamine 
50mg/kg/day) and angiotensin II type 1 receptor blocker (AT1RB; candesartan 
5mg/kg/day) over 24 weeks posttransplantation. Each group consisted of 8 
rats. Before harvesting 24-h proteinuria was determined. Intra-arterial blood 
pressure and renal blood fl ow was measured under isofl urane anesthesia and 
renal vascular resistance was calculated.
Results: RAGE-blockade did not reduce proteinuria nor was glomerulosclerosis 
reduced as compared to controls. Blood pressure and renal blood fl ow were 
signifi cantly reduced by the AT1RB candesartan (P<0.05) and renal vascular 
resistance tended to be lower after RAGE-blockade (P=0.08). Heart weight/
body weight ratio was lowered by all treatments (P<0.05).
Conclusion: RAGE-blockade does not ameliorate transplant-related 
proteinuria. As cardiac hypertrophy is reduced by this treatment and renal 
vascular resistance shows a tendency to be ameliorated by RAGE-blockade, 
a benefi cial cardiovascular rather than direct renal effect may be suggested in 
this animal model.
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THE CREATININE REDUCTION RATIO BETWEEN 1372 
DAYS ONE AND TWO (CRR2) IS AN EARLY 
INDEPENDENT PREDICTOR OF POOR LONG TERM RENAL 
GRAFT SURVIVAL
R. Thuraisingham, E. VIllar, M. Varagunam, M. Yaqoob
Barts and The London NHS Trust
Introduction: Dialysis requiring delayed graft function (D-DGF) is an 
independent predictor of long-term renal transplant survival. More recently non 
dialysis requiring delayed graft function (ND-DGF) as defi ned by a creatinine 
reduction ratio between days 1 and 2 (CRR2) of < 30% has been shown to have 
similar outcomes to D-DGF. We applied this defi nition in our cohort of patients 
to examine outcomes.
Methods: All transplants between 1996 and 2004 at our centre were assessed 
of which 361 were included in this study (mean age of 44 (range 17-73), 66% 
male). Patients were divided into 3 groups: IGF (immediate graft function; 
CRR2 >30%), D-DGF and ND-DGF. Follow up was for a mean of 4.2 years 
(SE + 0.06).
Results: IGF accounted for 36% of patients, D-DGF 22% and ND-DGF 
42%. CRR2 was inversely correlated with serum creatinine on day 7 (r 
=-0.673 p <0.001), day 30 (r=-0.377 p <0.001), day 90 (r=-0.256) and 
day 365 (r=-0.186 p=0.008). Risk of graft loss was signifi cantly different 
between the groups with D-DGF > ND-DGF > IGF (shown below), having 
adjusted for recipient age and sex, donor age and sex, HLA mismatches and 
immunosuppression.
Conclusion: Our study shows that CRR2 infl uences long-term graft outcomes. 
Unlike the original description however, patients with ND-DGF carried 
an intermediate risk and hence could be considered as early as Day 2 for 
calcineurin inhibitor sparing treatment regimens.
POSTER BOARD NUMBER P2 – 172
MAST CELLS TRYPTASE IN PATIENT AFTER 1373 
RENAL TRANSPLANTATION
M. Barczyk1, M. Mysliwiec2, M. Kalinowski1, M. Rowinski1, S. Brzosko2
1Dep. Nephrology And Transplantology, Specialized Hospital Bialystok, 2Dep. 
Nephrology And Transplantology, Medical Univesity Bialystok
Mast cells are involved in the pathogenesis of interstitial fi brosis, acute 
renal transplant rejection and chronic allograft nephropathy. The aim of 
this study was to evaluate MC tryptase concentration in serum of 58 renal 
transplant recipients in different time after transplantation in relation to 
the graft function. We found for the fi rst time that patients after kidney 
transplantation had much higher serum tryptase concentration than 
healthly controls and we demonstrated positive correlation between serum 
tryptase concentration and Hgb, Hct, Rbc count and hepatic cells damage. 
We were not able to show any direct correlation between serum tryptase 
concentration and graft function. Clinical relevance of this fi ndings demand 
further investigation.
POSTER BOARD NUMBER P2 – 173
SERUM LEVEL OF PLASMINOGEN ACTIVATOR 1374 
INHIBITOR-1 (PAI-1)IS SUPERIOR TO SERUM CREATININE 
OR EGFR TO PREDICT HISTOLOGICAL CHRONIC 
ALLOGRAFT DAMAGE INDEX OF RENAL ALLOGRAFTS
H.R. Chang1,2, J.D. Lian1, S.F. Yang2, C.C. Lin3, M.C. Wen4, Y.S. Hsieh3
1Division of Nephrology, Department of Internal Medicine, Chung Shan 
Medical University Hospital, Taichung 402, Taiwan, 2Institute of Medicine, 
Chung Shan Medical University, Taichung 402, Taiwan, 3Institute of 
Biochemistry and Biotechnology, Chung Shan Medical University, 4Division 
of Pathology, Taichung Veterans General Hospital,
Background: Plasminogen activator inhibitor-1 (PAI-1) has been recognized to 
play an important role in renal fi brosis. We conduct this study to examine whether 
serum PAI-1 is with a role predicting chronic allograft nephropathy (CAN).
Methods: A total of consecutive 50 cadaveric kidney transplant recipients 
receiving graft biopsies were enrolled. The pathologic diagnosis of the graft 
biopsies were acute tubular necrosis (ATN; n=12), borderline rejection (BR; 
n=7), acute rejection (ACR; n=12), CAN (n=11), polyomavirus nephropathy 
(PVN; n=3) and others (n=5; glomerulopathy, n=4; calcineurin inhibitor 
nephropathy, n=1). The serum level of PAI-1 of each patient and chronic 
allograft damage index (CADI) score of each graft were determined.
Results: The distribution of CADI score in all patients was 4 (0-10) (median 
and range) and in each group was ATN 0.5 (0-4), BR 2.0 (1-4), ACR 4.0 (2-8), 
CAN 5.0 (4-10), PVN 7 (4-8) and others 2 (0-8). The distribution of serum 
PAI-1 level in the ATN group was 9.38 (2.35-14.52) ng/ml, in the BR group 
was 10.09 (0.61-18.06) ng/ml, in the ACR group was 11.08 (2.32-20.68) ng/ml, 
in the CAN group was 14.51 (3.66-21.12), in the PVN was 14.79 (13.94-21.94) 
and in the others group 16.35 (4.05-21.01) ng/ml. The CADI score is associated 
with the serum PAI-1 activity (r=0.405, p=0.003) and is inversely associated 
with serum creatinine (r=-0.348, p=0.011) but not with eGFR (p=0.124).
Conclusion: Serum PAI-1 level is superior to serum creatinine and eGFR to 
predict CADI score, the quantitative score of CAN.
POSTER BOARD NUMBER P2 – 174
PREDICTING THE IDEAL SERUM CREATININE OF 1375 
RENAL TRANSPLANT RECIPIENT BY SIMPLE FORMULA: 
BASED ON THE BALANCE BETWEEN METABOLIC 
DEMANDS OF RECIPIENTS AND RENAL MASS SUPPLY FROM 
DONORS
C-K. Oh1, B.M. Lee1, J.H. Kim1, H. Kim1, S.I. Kim2, Y.S. Kim2
1Ajou University School of Medicine, 2Yonsei University College of Medicine
Background: Serum creatinine (Scr) is the most useful and frequently used 
test to estimate the graft function after kidney transplantation. Our previous 
study demonstrated that the independent predictors of recipient post-transplant 
Scr included the ratio of graft weight to recipient body weight, the ratio of graft 
weight to recipient body surface area (BSA), and the ratio of graft weight to 
recipient body mass index (BMI).
Methods: This prospective analysis about the impact of the balance between 
metabolic demands and renal supply on the post-transplant Scr of recipient was 
conducted and previously reported. We plotted the scattered graph by X-axis of 
the independent predictors of Scr by linear regression and Y-axis of recipient 
Scr. To generate the predictive formula of Scr, we calculated a statistical fi t line 
of the plotted cases using a fi t method of linear regression, and two regression 
prediction lines for the upper and lower 95% confi dence interval. Each line was 
converted into the predictive formula.
Results: Scr=-0.0033*(Graft weight(g)/Recipient BSA(m2))+1.75. Under 
95% confi dence, the Scr ranges from -0.0033*(Graft weight(g)/Recipient 
BSA(m2))+1.07 to -0.0033*(Graft weight(g)/Recipient BSA(m2))+2.44.
Scr=-0.1049*(Graft weight(g)/Recipient body weight(kg))+1.72, which 
ranges from -0.1049*(Graft weight(g)/Recipient body weight(kg))+1.06 to 
-0.1049*(Graft weight(g)/Recipient body weight(kg))+2.37.
Scr=-0.0158*(Graft weight(g)/Recipient BMI(kg/m2))+1.56, which ranges 
from -0.0158*(Graft weight(g)/Recipient BMI(kg/m2))+0.75 to -0.0158*(Graft 
weight(g)/Recipient BMI(kg/m2))+2.26.
Conclusions: Prediction of post-transplant Scr could be determined by 
measuring the graft weight as well as the recipient weight and height. When 
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recipient’s Scr is signifi cantly higher than that predicted by the formula, a 
clinician should suspect the possible underlying graft injuries.
POSTER BOARD NUMBER P2 – 175
ASSOCIATION OF TGF-1376 β1 AND VEGF GENE 
POLYMORPHISMS WITH CHRONIC ALLOGRAFT 
NEPHROPATHY AND GRAFT SURVIVAL IN RENAL 
TRANSPLANT RECIPIENTS
C-D. Kim, J-H. Cho, S. Huh, H-M. Ryu, J-Y. Choi, H-J. Choi, H-J. Choi, 
S-H. Park, Y-L. Kim
Division of Nephrology, Department of Internal Medicine, Transplantation 
and Vascular surgery, Kyungpook National University School of Medicine, 
Daegu, 700-721, Korea
Purpose: Transforming growth factor-β1 (TGF-β1) has been associated 
with the promotion of renal allograft interstitial fi brosis and thereby 
chronic allograft nephropathy (CAN). Vascular endothelial growth factor 
(VEGF) has been shown to contribute to cytoprotection of the graft after 
kidney transplantation. We investigated the infl uence of single nucleotide 
polymorphisms (SNPs) of the TGF-β1 (C-509T and T869C) and the VEGF 
gene (C-2578A and C405G) on graft survival and the development of 
CAN.
Methods: Genotyping was carried out using a real-time polymerase chain 
reaction which was performed on the LightCycler480 in 221 Korean renal 
transplant recipients and 148 healthy controls. According to the typical biopsy 
proven appearances of CAN or chronic calcineurin inhibitor nephrotoxicity, 
the recipients were separated into the CAN (n=21) and the No CAN (n=200) 
groups.
Results: The genotype frequencies of the SNPs were in Hardy-Weinberg 
equilibrium. The distributions of genotypes and alleles did not differ between 
recipients and controls. No signifi cant differences were observed in the 
genotype distributions and allele frequencies between the CAN and the No 
CAN groups (Table 1). On the basis of the linkage disequilibrium coeffi cients 
between polymorphisms, which indicated that investigated polymorphisms of 
TGF-β1 (D′=0.98) and VEGF (D′=0.78) were in tight linkage, haplotypes were 
reconstructed. However, there were no signifi cant differences in the frequencies 
of the reconstructed haplotypes between the two groups. There were no 
statistically signifi cant effects of TGF-β1 and VEGF gene polymorphisms on 
graft survival.
Conclusion: This study demonstrates that four selected SNPs of the TGF-β1 
and the VEGF genes are not associated with an increased risk of development 
of CAN and graft survival in renal transplant recipients.
Table 1. TGF-β1 and VEGF genotype distributions (%) and allele frequencies 
in 200 recipients without CAN and 21 with CAN
TGF-β1 C-509→T polymorphism
C/C C/T T/T p-value C allele T allele p-value
No CAN 38 (19.0) 112 (56.0) 50 (25.0) 0.470 0.530
CAN 5 (23.8) 10 (47.6) 6 (28.6) 0.706 0.476 0.524 1.000
TGF-β1
T869→C polymorphism
T/T T/C C/C p-value T allele C allele p-value
No CAN 40 (20.0) 113 (56.5) 47 (23.5) 0.483 0.518
CAN 5 (23.8) 10 (47.6) 6 (28.6) 0.705 0.476 0.524 1.000
VEGF
C-2578→A polymorphism
C/C C/A A/A p-value C allele A allele p-value
No CAN 111 (55.5) 71 (35.5) 18 (9.0) 0.733 0.268
CAN 13 (61.9) 8 (38.1) 0 (0.0) 0.467 0.810 0.190 0.356
VEGF
C405→G polymorphism
C/C C/G G/G p-value C allele G allele p-value
No CAN 33 (16.5) 101 (50.5) 66 (33.0) 0.418 0.583
CAN 5 (23.8) 9 (42.9) 7 (33.3) 0.588 0.452 0.548 0.743
* Data were analyzed by Fisher’s exact test
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ANGIOPOIETINS AND TIE21377 ¡¯S EXPRESSION 
IN THE RAT RENAL ALLOGRAFT WITH CAN
Y.P. Lu, X. Ma, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University
Objective: Angiopoietin-1 and Angiopoietin-2 are both ligands for the 
endothelium- specifi c tyrosine kinase Tie2. Previous studies have indicated 
that the mutual regulations of Ang1, Ang2 and Tie2 play a signifi cant role 
in chronic cardiac allograft vasculopathy. We investigated the expressions of 
Ang1, Ang2 and Tie2 and their roles in rat renal allograft with chronic allograft 
nephropathy (CAN) in this study.
Methods: Renal transplant following the procedure of Kamada with our 
modifi cation was orthotopically performed by using Fisher (F344, RT1lv1) 
rats as both donor and recipient in autograft group. Fisher and Lewis (LEW, 
RT1l) were used as donor and recipient in allograft group, respectively. The 
allograft group was treated with CsA 10mg.kg-1.d-1*10d. At 4w, 8w, 12w 
post-transplant, SCr was measured and the pathologic changes were assessed 
according to Banff 97 criteria. The expression of mRNA(¦¤ct) and protein of 
Ang1, Ang2 and Tie2 was determined and localized by real-time fl uorescence 
quantitative PCR and by immunohistochemistry.
Results: The elevation of SCr and the pathologic changes of CAN were observed 
in all the allografts at 8w and 12w. The expression of Ang1 and Ang2 was localized 
in epithelial cells and endothelium of vascular bundles of glomeruli, and Tie2 was 
specifi cally expressed in endothelium of vessels both in auto- and in allografts at 
all the time points post transplant. At 4w, the difference of mRNA expression of 
Ang1, Ang2 and Tie2 between 2 groups was not signifi cant (p>0.05). Comparing 
with the autografts, the mRNA expression of Ang1 was decreased signifi cantly at 
8w and 12w post-transplant (p<0.05), and the mRNA expression of Ang2 and Tie2 
were increased signifi cantly (p<0.05). These changes of the expression of all the 3 
genes showed a signifi cant correlation with the Banff score in the allografts.
Conclusions: This study for the fi rst time shows that the abnormal expression 
and mutual regulations of Ang1, Ang2 and Tie2 are likely to play an important 
role in the development of CAN in rat renal allografts.
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ROLE OF ERK2 IN TGF-1378 ¦Â-INDUCED EPITHELIAL-
MESENCHYMAL TRANSITION OF HUMAN RENAL 
PROXIMAL TUBULAR EPITHELIAL CELLS AND CHRONIC 
ALLOGRAFT NEPHROPATHY
X.L. Chen, Z. Ding, Z.S. Chen, N.Q. Gong
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science And Technology
Objective: Transforming growth factor-¦Â (TGF-¦Â)-induced 
epithelial¨Cmesenchymal transition (EMT) in renal tubular epithelial cells 
is thought to contribute to chronic allograft nephropathy(CAN). However, 
the underlying signaling mechanism remains largely unknown. This study 
investigated the role of extracellular signal-regulated kinase-2 (ERK2) activation 
in EMT process in renal tubular epithelial cell line (HK-2) and CAN.
Methods: HK-2 cells were transfected with adenovirus-mediated antisense 
ERK2 (Adanti-ERK2) and then stimulated with 10ng/ml TGF-¦Â. The 
expression level of mesenchymal markers£¨¦Á-SMA and vimentin£©and 
epithelial markers (E-cadherin) were assessed by immunofl uorescence. Cell 
migration was measured by Boyden chamber. Furthermore, a series of human 
specimen of living-related kidney allografts with biopsy-proven CAN were 
detected by immunohistochemistry.
Results: TGF-¦Â induced a time-dependent EMT characterized by de novo 
expression of ¦Á-SMA and vimentin, loss of E-cadherin and increased 
migratory property. Transfection with Adanti-ERK2 was able to attenuate 
TGF-¦Â1-induced EMT changes in HK-2. The detection of kidney specimen 
demonstrated the expression of increased ¦Á-smooth muscle actin (¦Á-SMA) 
and vimentin coupled with reduced E-cadherin, confi rming the presence of 
EMT in CAN. Concomitantly, the up-regulation of TGF-¦Â was co-localizes on 
the tubular epithelium with sites of EMT, and the expression of phosphorylated 
ERK2-positive cells was markedly increased.
Conclusions: The results suggest the important role of ERK2 in the progression 
of TGF-¦Â1-induced EMT and provide a novel therapeutic avenue against CAN.
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CHARACTERIZATION OF CHRONIC RENAL 1379 
ALLOGRAFT DYSFUNCTION BY HUMAN SERUM 
PROTEOMIC ANALYSIS
Y. Gao, K. Wu, Y. Xu, H. Zhou, W. Zhang, Z.C. Chen, X. Lin, W. He, 
F. Wang, Z. Fang
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of 
Science And Technology
Backgroud: Most late renal allograft failure is attributed to chronic allograft 
dysfunction, but this is a clinicopathological description and not a diagnosis, 
and its pathogenesis and treatment are largely unknown. The purpose of 
this study was to apply techniques for identifying chronic renal allograft 
dysfunction biomarkers in human serum using two-dimensional differential in-
gel electrophoresis (2-DE DIGE), and characterizing the protein biomarkers 
using matrix-assisted laser desorption/ionization (MALDI) to study the 
pathogenesis and treatment strategy of chronic allograft dysfunction.
Method: Serum samples were divided into 5 groups: acute reject, chronic 
allograft dysfunction, healthy volunteers, chronic renal function failure and 
long-term stable renal function. serum samples were fi rst chromatographed 
using an immunoaffi nity HPLC column, to selectively remove albumin, 
immunoglobulins, transferrin, haptoglobin, and antitrypsin. Then they were 
processed using the immunoaffi nity column. Differential protein analysis was 
performed using DIGE. These spot features were excised, trypsin digested, and 
analyzed by MALDI.
Result: A total of 34 differential protein spot features were found. These spot 
features included apolipoprotein A-I precursor, selenium-binding protein 1, 
complement C4-A precursor, complement factor H-related protein 1 precursor, 
complement component C9 precursor, vitamin D-binding protein precursor, 
plasma retinol-binding protein precursor, clusterin precursor, hornerin, et al.
Conclusion: These biomarker candidates may provide the basis for 
understanding the pathogenesis and treatment strategy of chronic allograft 
dysfunction further.
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LOCAL PRODUCTION OF C3 IS NOT A RISK FACTOR 1380 
FOR RENAL ALLOGRAFT FUNCTION
K.M. Brown1, S.H. Sacks1, N.S. Sheerin2
1Department of Nephrology and Transplantation, Guy’s Hospital, King’s 
College London, 2School of Clinical Medical Sciences, Newcastle University
Murine studies have shown a key role for local C3 secretion in renal allograft 
rejection. In humans a structural polymorphism exists in the C3 gene that is 
based on the reactivity of the HAV4-1 monoclonal antibody. Donor-recipient 
pairs who are mismatched at the C3 HAV4-1 locus provide a unique setting for 
the quantifi cation of donor specifi c C3 in the recipient circulation. Previous 
studies suggested that secretion of HAV4-1+ C3 increased during episodes of 
acute rejection in the early post-operative phase. This study investigates how 
donor C3 allotype, and the relationship of locally secreted C3 infl uences late 
graft outcome.
We determined the HAV4-1+/- allotype of 427 pairs of adult kidney donors and 
recipients transplanted at Guy’s Hospital from 1993-2002 and then related the C3 
HAV4-1+/- polymorphism status to demographic and clinical outcome data. As 
a secondary analysis serum samples were collected from patients in this cohort 
who were still attending the renal transplant clinic in 2004 (n=89). Double ligand 
ELISA was used to quantify HAV4-1+ C3 and total C3 in these samples.
Analysis of Caucasian recipients identifi ed 93 C3 HAV4-1-/- recipients receiving 
a C3 HAV4-1+ kidney and 147 C3 HAV4-1-/- receiving C3 HAV4-1-/- kidneys. 
Kaplan-Meier analysis of graft survival suggested a trend for improved outcome 
of the C3 HAV4-1+ donor group, although the data was non-signifi cant (p=0.19, 
log rank test). HAV4-1+ C3 was detectable in serum samples collected from 
these patients up to 8 years post-transplantation. However, serum C3 HAV4-1+ 
concentration did not show a signifi cant correlation with serum creatinine as an 
estimate of graft function (r2<0.001, p=0.89).
Ongoing genetic analysis will determine the role of complement protein 
polymorphism analysis as predicators of transplant outcome. This study would 
suggest that the quantity of C3 protein produced within the graft does not 
correlate with function.
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URINARY C3 EXCRETION IS NOT A GOOD 1381 
PROGNOSTIC INDICATOR OF RENAL ALLOGRAFT 
OUTCOME
K.M. Brown1, S.H. Sacks1, N.S. Sheerin2
1Department of Nephrology and Transplantation, Guy’s Hospital, King’s 
College London, 2School of Clinical Medical Sciences, Newcastle University
Murine studies have shown a key role for local C3 secretion in renal allograft 
rejection. We know that increased levels of C3, both intact and activated, are 
found in the urine of patients with glomerulonephritis, however, there is little 
information relating to transplantation. This study prospectively investigated 
the impact of acute infl ammatory events on urinary C3 concentration as well as 
the infl uence of urinary C3 on the incidence of graft dysfunction.
A cohort of adult transplant recipients (n=88) who received a renal allograft 
between June 2003 and January 2005 were recruited from the out-patient clinic 
based at Guy’s and St Thomas’ Hospital NHS Foundation Trust. Patients were 
prospectively followed for an average of 336.2 days (range; 41 to 708 days) 
post-transplantation or until allograft failure with return to dialysis. Urine and 
serum samples were collected at the following time-points:
(a) Baseline - 2 weeks post-transplantation or when graft function was achieved, 
whichever was the latest.
(b) Stable function - 3 months and 12 months post-transplantation, with no 
evidence of graft dysfunction.
(c) Event-related - when there was evidence of acute graft dysfunction due to 
rejection, infection or drug (cylosporin / tacrolimus) -induced toxicity.
Prospective analysis of renal transplant recipients revealed that episodes 
of graft dysfunction (rejection, infection or CNI-induced toxicity) tended to 
correlate with increased urinary C3 compared to baseline samples taken at 
onset of graft function and at 3 and 12 months post-transplantation. However, 
there was no signifi cant correlation between urinary C3 concentration and 
graft function (measured by serum creatinine and eGFR). Donor-recipient 
demographics (ethnicity, cause of ESRF and C3F/S allotype), as well as time 
post-transplantation, signifi cantly infl uenced urinary C3 levels.
Despite the identifi cation of several factors that signifi cantly affect urinary C3 
levels, this study indicates that urinary C3 excretion is not a good prognostic 
indicator of renal allograft outcome.
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HORNERIN AND GALECTIN-7 ARE PROMISING 1382 
BIOMARKERS FOR CHRONIC ALLOGRAFT NEPHROPATHY
K. Wu, Y. Xu, Y. Gao, H. Zhou, Z.K. Chen
Institute of Organ Transplantation, Key Laboratory of Organ Transplantation, 
Ministry of Public Health, Ministry of Education, Tongji Hospital, Tongji 
Medical College, Huazhong University of Science A
Chronic Allograft Nephropathy (CAN) remains the leading cause of renal 
graft loss after the fi rst year following renal transplantation. Identifying 
potentially protein biomarker associated with CAN could improve recipient 
care by allowing CAN to be diagnosed non-invasively and promptly. Three 
patient groups were defi ned on the basis of allograft function, clinical course, 
and allograft biopsy result: CAN group (n=4), chronic renal failure group 
(n=4) and stable transplant group (n=4, renal transplant patients with normal 
renal function more than one year after transplantation). The control group 
included 4 normal volunteers. We attempted to identify novel biomarkers 
associated with CAN by analyzing serum proteins using differential in-
gel electrophoresis (DIGE), and characterizing the protein biomarkers 
using tandem mass spectrometry (MS/MS). Serum samples were fi rst 
chromatographed using an immunoaffi nity HPLC column, to selectively 
remove albumin, immunoglobulins, transferrin, haptoglobin, and antitrypsin. 
Differential protein analysis was performed using DIGE. A total of 40 protein 
spot-features were found to be different among these groups. These spot 
features were excised, trypsin digested, and analyzed by MALDI/TOF/TOF. 
We identifi ed 2 unique proteins that were increased and 2 unique proteins 
that were decreased signifi cantly in CAN. Western blot analysis confi rmed 
increased levels of 1 protein and decreased levels of 1 protein in the CAN 
samples. In an independent series of serum samples from 15 patients with 
CAN, 15 stable transplant patients, 15 chronic renal failure patients and 
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15 normal volunteers, increased level of Hornerin and decreased level of 
Galectin-7 were found to be associated with CAN. The results suggest that 
affi nity column enrichment and 2-D DIGE can be used to identify numerous 
proteins differentially expressed in serum from patients after transplantation. 
These two proteins have been described as playing important role in human 
immune system. And the novel role of Hornerin and Galectin-7 identifi ed 
provide a potential means of diagnosing CAN by non-invasive methods 
and also provide potentially important information about the development 
and management of CAN and possible potential targets future therapeutic 
strategies in the prevention of CAN.
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CYSTATIN C OUTPERFORMS CREATININE-BASED 1383 
EGFR IN ADULT RENAL TRANSPLANTATION
R. Cervantes1, R. Nanra1, P. Trevillian1, A. Gillies1, P. Mcelduff2, 
S. Carney1, B. Jones1, M. Heer3, G. Reeves4, A. Hibberd3
1Department of Nephrology, John Hunter Hospital, 2Hunter Medical 
Research Institute, Newcastle, Australia, 3Transplant Unit, Division 
of Surgery, John Hunter Hospital, Newcastle, Australia, 4Hunter Area 
Pathology Services, Dept. Immunology, John Hunter Hospital, Newcastle, 
Australia
Background: Cystatin C has been advocated as a more reliable marker of 
GFR than creatinine based methods for estimating native kidney function. 
The data evaluating Cystatin C performance in estimating GFR changes in 
stable renal allografts is controversial. Also the use of steroids in transplant 
recipients may affect Cystatin C level and hence its reliability as a marker of 
GFR.We have examined the reliability of Cystatin C to predict GFR, both 
in single samples, and serially in the same transplant recipient over a 5 year 
period.
Methods: 17 patients with stable renal function (51Cr EDTA GFR range 
30-90 ml/min, mean: 53 ml/min/1.73m2) were followed with prospective, 
annual 51Cr EDTA GFR (71 measurements over 5 years). Comparative 
annual Cystatin C levels were measured retrospectively from stored 
serum samples using immunonephelometric assays (Dade-Behring). Serial 
estimates of eGFR (Cockcroft-Gault, MDRD, Nanra) and the reciprocal of 
Cystatin C (1/Cys C) were compared with 51Cr EDTA GFR. Multilevel 
linear regression models were used to estimate change over time for each 
measure and to estimate the correlation of 51Cr EDTA GFR with the other 
measures within and between subjects. Additional models were fi tted 
to estimate the impact of BMI, age gender and prednisone use on these 
associations.
Results: Although 51Cr EDTA GFR did not change (-2.6 X10-3, p=0.223), 
serum creatinine levels showed steady increase over the 5 years period 
regardless of correction for age and weight (change= 1.6X10-2, p<0.001). 
1/Cystatin C change also remained stable (change= -1.9X10-5 p= 0.152). 
Correlation coeffi cients between 51Cr EDTA GFR and 1/Cystatin C, MDRD, 
Nanra and Cockcroft-Gault eGFRs were 0.77, 0.68, 0.62 and 0.60 respectively. 
Over the 5 year period the “r” value of change in 51Cr EDTA GFR compared 
with 1/Cystatin C, MDRD, Nanra and Cockcroft-Gault were 0.73, 0.63, 0.64 
and 0.66 respectively.
In a multilevel model adjusting for the repeat measures on individuals, 1/
Cystatin C measures maintained the highest correlation (as measured by R2) 
with 51Cr EDTA GFR for both within individuals effects (R2=0.37 vs 0.22 for 
Nanra, 0.25 for MDRD and 0.30 for Cockcroft-Gault) and between individuals 
effects (R2=74 vs 0.42 for Cockroft-Gault, 0.55 for Nanra and 0.64 for MDRD). 
Adjustment for BMI, gender and age did not alter the association between 51Cr 
EDTA GFR and 1/CysC.
Inclusion of prednisone in the regression models did not show any effect 
either on Cystatin C levels or creatinine based GFR estimates either within 
individuals or between individuals.
Conclusions: 51Cr EDTA GFR remains the gold standard for GFR measurement 
in renal transplants. Cystatin C is an acceptable clinical alternative and 
retains validity over the early post-transplant life of the graft. On the other 
hand,creatinine-based eGFRs appear to give a spurious decline in eGFR with 
time and this may be related to altered creatinine handling by the nephron in 
aging renal transplants.This problem is not seen with Cystatin C.
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THE USEFULNESS OF SELECTED URINARY 1384 
PROTEINS LEVELS MEASUREMENT AND PATHOLOGICAL 
EXAMINATION IN THE PREDICTION OF LONG–TERM 
RENAL TRANSPLANT FUNCTION
M. Durlik1, T. Cieciura1, E. Nowacka-Cieciura1, A. Perkowska-Ptasinska1, 
M. Sawosz1, T. B±czkowska1, O. Tronina1, A. Urbanowicz1, M. Pacholczyk2, 
M. Cieciura3
1Departament of Transplantation Medicine And Nephrology, Medical 
University of Warsaw, 2Departament of Transplantation General And 
Transplantation Surgery, Medical University of Warsaw, 3University of 
Information Technology
Chronic allograft dysfunction is the leading cause of renal loss one year after 
transplantation. There is still a need to fi nd some biomarkers identifying 
recipients with the high risk of premature renal transplant dysfunction. The 
aim of the study was to evaluate the usefulness of selected urinary proteins 
measurement and pathological examination in the prediction of chronic kidney 
disease (CKD) staging fi ve years after protocol or diagnostic renal allograft 
biopsy.
Methods: 65 renal allograft recipients, between third month and third year after 
transplantation with preserved graft function at least one year after biopsy were 
included into the study. The Cockcroft–;Gault formula was used to estimate 
initial and fi nal glomerular fi ltration rate (eGFR C–;G). Beta2–;microglobulin, 
alpha1–;microglobulin, albumin, immunoglobulin G (IgG) and total protein 
concentrations were obtained from the second morning urine specimen (just 
before the biopsy) and calculated per 1 gram of creatinine excreted in urine 
(Ucr). Pathological examinations of graft specimens were done according 
to Banff&#8217;97 schema. All data along with recipient age, time after 
transplantation, serum creatinine level (Scr), and its change over period of 2 
months prior to biopsy as well as e–;GFR were taken for analysis. Statistical 
calculations were performed using MANOVA and Stepwise Discriminant 
Analysis (SDA).
Results: We were able to predict chronic kidney disease staging fi ve years after 
biopsy in 86.15% of cases. Our methodology has allowed to correctly identify 
75% (3 of 4), 95% (19 of 20), 84.62% (22 of 26), 77.78% (7 of 9) and 83.33% 
(5 of 6) patients with chronic kidney disease stage 1, 2, 3, 4, and 5 respectively. 
Percentages of totally (0.6884) and focally (0.4804) sclerotized glomeruli as 
well as urinary excretion of IgG calculated per 1 gram of Ucr (0.5781) were 
highly indispensable parameters. Nevertheless, initial eGFR (1.6942) but not 
Scr (0.0948) was the most indispensable parameter.
Conclusion: Advanced statistical analysis of selected urinary protein levels and 
pathological parameters taking into consideration initial eGFR may be useful 
in prediction of long-term renal transplant function as well as in identifying 
recipients with the high risk of premature graft loss.
CAN – SURVIVAL AND CONCURRENT ORAL SESSION 99: 
TREATMENT
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MANAGEMENT OF CHRONIC ALLOGRAFT 1385 
NEPHROPATHY WITH SIROLIMUS -A SOUTH INDIAN 
EXPERIENCE
G. Abraham1, V. Sundaram1, V. Sundaram2, V. Sathiah1, M. Mathew3, 
S. Bhaskar3
1Sri Ramachandra University Hospital, 2Sundaram Hospitals, 3Madras 
Medical Mission Hospital
Objectives: The aim of this study was to evaluate the effi cacy of conversion 
from Calcineurin Inhibitors to a rapamycin based immunosuppressive regimen 
in renal transplant recipients who had allograft dysfunction in a South Indian 
Population
Methods: This was a retrospective analysis of renal transplant patients who 
were randomly initiated on rapamycin in a tertiary care centre in South India. 
Overall seventy fi ve of the 398 renal transplants performed over a fi ve year 
period 2002-2007 were converted from a Calcineurin based immunosuppression 
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to rapamycin whihch included patients with chronic allograft dysfunction, 
chronic allograft injury and malignancy. The data analysed included serial 
rapamycin levels, serum creatinine, eGFR by nankivel formula, lipid profi le, 
haemoglobin and serum pottasium levels. Statistical analysis was performed 
using students t test and kaplen Meyer survival curve was used to predict 
probability of survival among patients on sirolimus.
Results: Male patients formed majority of the study sample (74.6%).The mean 
age patients was 39.6+_12.2yrs. Diabetic nephropathy was the predominant 
cause (36%) of ESRD. Sataistical analysis revealed a signifi cant improvement 
in GFR of 14.6 ml and decrease in pottassium by 0.7mmol/L after initiation 
of rapamycin. There were no signifi cant differences in terms of lipid profi le, 
platelet count, hemoglobin and urine albumin levels. Rapamycin was stopped 
in one patient due to hypokalemic nephropathy and in another patient due to 
delayed wound healing.
Discussion: To our Knowledge this is the fi rst study to provide information 
on the conversion from a CNI to rapamycin based immunosuppression in 
cohort of Indian patients who recieved renal transplant .The fi ndings of 
our study confi rm that rapamycin based immmunosuppressive regimen 
improves renal function and graft survival with minimal side effects in 
comparison to CNI based immunosuppression. Withdrawal of CNI also 
resulted in slowing the progression of chronic allograft injury. Rapamycin 
based therapy with elimination of CNI is safe and results in improved renal 
function.
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THE EFFECTS OF ROSUVASTATIN ON 51CR-EDTA 1386 
MEASURD GLOMERULAR FILTRATION RATE AND 
URINARY ALBUMIN EXCRETION IN NON-DIABETIC RENAL 
TRANSPLANT RECIPIENTS
A. Sharif1,2, V. Ravindran2, R. Moore2, K. Baboolal2
1Russells Hall Hospital, Dudley, 2University Hospital of Wales, Cardiff
Background: Hyperlipidaemia contributes to chronic allograft injury, 
leading to eventual graft loss. Emerging literature from the general 
population suggests statin treatment has pleiotropic and renoprotective 
properties. This raises the possibility of using statin therapy to attenuate 
chronic allograft injury in renal transplant patients. This study aimed to 
assess the change in 51Cr-EDTA measured glomerular fi ltration rate (GFR) 
and urinary albumin excretion after short-term rosuvastatin treatment in 
renal transplant recipients.
Methods: Twenty patients were recruited into a randomised, double blind, 
placebo controlled, crossover study. 51Cr-EDTA GFR and urinary albumin 
excretion was assessed after 12 weeks of either rosuvastatin or placebo before 
patients crossed over to the opposite table and the investigations repeated after 
12 weeks. Clinical and biochemical investigations were conducted at the end 
of each 12-week period.
Results: Rosuvastatin was a safe and effective lipid-lowering agent, lowering 
total cholesterol by 31% (p<0.001), LDL cholesterol by 48% (p<0.001) 
and triglycerides by 19% (p=0.018) when compared to placebo. It also had 
a signifi cant anti-infl ammatory effect, lowering C-reactive protein by 43% 
(p=0.042). However there was no difference in creatinine, estimated GFR, 
51Cr-EDTA derived GFR or urinary albumin excretion between rosuvastatin 
and placebo (Table 1).
Table 1 – Change in renal indices between placebo and rosuvastatin (mean ± 
standard error of mean)
Placebo Rosuvastatin Change p value
Creatinine (mmol/l) 112 ± 5 109 ± 5 - 3% 0.100
Est. GFR (ml/min) 61 ± 3 63 ± 3 + 3% 0.102
51Cr EDTA GFR (ml/
min) 61 ± 3 62 ± 4 + 2% 0.612
Albumin/Creatinine 
Ratio 2.3 ± 0.8 3.3 ± 1.0 + 43% 0.274
Conclusions. Short-term rosuvastatin treatment does not affect renal allograft 
function, despite a signifi cant lipid-lowering and anti-infl ammatory effect. 
Whether long-term treatment slows the decline of GFR remains unanswered. 
The renoprotective properties of statins remain speculative and we should 
hesitate from advocating benefi ts without evidence from large, clinical studies 
specifi cally designed to answer this question.
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PREEMPTIVE LIVING-DONOR RENAL 1387 
TRANSPLANTATION: THE OUTCOME AND CLINICAL 
ADVANTAGES
O.J. Kwon1, T.S.W. Yu2, J.Y. Kwak3, C.M. Kang4
1Transplantation Center, Hanyang University Hospital, 2Transplantation 
Center, Hanyang University Hospital, 3Transplantation Center, Hanyang 
University Hospital, 4Transplantation Center, Hanyang University Hospital
Background: Kidney transplant recipients have a higher quality of life 
and consume fewer health care resources compared to patients on dialysis. 
However, optimal timing of transplantation has been controversial. Recent 
studies have clearly demonstrated that preemptive renal transplantation is 
associated with better graft survival, lower complications, and cost-effective 
option. We evaluated the differential effects on long-term outcomes according 
to dialysis type and duration, or no dialysis.
Materials and methods: We retrospectically analyzed 499 cases of fi rst living 
donor kidney transplantations performed in our center from Jan. 1990 to Jan. 
2007. We exclude retransplantation cases(n=32), follow up loss (n=60), and 
deceased donor transplant(n=20) among 611 renal transplants. We evaluated 
and compared with 3 groups according to graft survival rates, acute and chronic 
rejection rates, postoperative complication rates, and delayed graft function rate.
Results: The mean duration of follow up was 95.23¡¾54.35 months. Among 
499 cases, 81 cases were preemptive renal transplantation, and 418 cases (HD: 
343 cases, PD: 75 cases) were performed transplantation after dialysis. The 
immunosuppressant regimens were cyclosporine/ tacrolimus, azathioprine/ 
MMF, and steroid with or without antiCD25 antibody according to the period. 
The mean duration of dialysis was 29.73¡¾36.46 months. The characteristics of 
3 groups were not signifi cant differences in risk factors, such as recipient’s and 
donor’s age, sex distribution, HLA matching degree, and the cause of ESRD. 
The 1, 5, 10 year graft survival rate were 97.50%, 89.45%, 79.40% in preemptive 
renal transplantation group, respectively and those of the dialysis groups(HD, PD) 
were 91.11%, 77.55%, 69.08%, respectively (p=0.0322). The differential effect 
of pretransplant dialysis either by hemodialysis or peritoneal dialysis was not 
signifi cant. However, the graft survival rates of hemodialysis group was higher 
than peritoneal dialysis group and it is not signifi cant in statistically (p=0.6056). 
The duration of dialysis (hemodialysis or peritoneal dialysis), according to 12 
months, was not associated with graft survival rate(p=0.2424). The complication 
rate of preemptive renal transplantation group was lower than dialysis groups, 
such as infection, delayed graft function rate, and acute rejection rate.
Conclusions: The preemptive renal transplantation without initiation of 
dialysis is as safe as conventional transplantation with better graft survival 
rates and lower complication rates. It has major advantage of avoiding the 
inconvenience, and cost of dialysis. This improved survival might be the 
consequence of patient selection or the reduced severity of co-morbid diseases 
associated with avoidance of uremia and dialysis. We suggest that preemptive 
renal transplantation can be the optimal mode of renal replacement therapy for 
medical and socioeconomic reasons.
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THE FIRST YEAR RENAL FUNCTION AS PREDICTOR 1388 
OF LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER 
KIDNEY TRANSPLANTATION
I. Helal1, E. Abderrahim1, F.B. Hamida1, M. Ounissi1, S. Barbouche1, 
R. Bardi2, Y. Elgorgi2, F. Elyounsi1, T.B. Abdallah1, A. Kheder1
1Department of Nephrology-Charles Nicolle Hospital, 2Laboratory of 
immunology-Charles Nicolle Hospital
This study examined the impact of graft function, at the end of the fi rst year 
after kidney transplantation (KT), on the long-term graft survival. The role of 
serum creatinine (Scr) and other variables as predictors of graft survival were 
analyzed in 235 adult kidney transplanted patients. Patients were divided into 
three groups (G1, G2 and G3) according to their Scr at the end of the fi rst year 
following KT; G1: Scr < 100 μmol/l, G2: 100 μmol/l &#61603; Scr &#61603; 
150 μmol/l and G3: Scr > 150 μmol/l.
The annual rate of graft loss was of 0.7% (CI, 95%: 0.63-0.77) in G1, it is lower 
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than those of 2.1 (2.02-2.18, p<0.0001) and 6% (5.74-6.26, p<0.0001) observed 
in G2 and G3, respectively. Regression analysis showed the role of recipient 
age, at the time of KT, and Scr level, at the end of the fi rst year after KT, as 
independent predictors of graft loss. Graft survival was not infl uenced by any 
of other studied parameters including age of donor, year of KT, warm ischemia 
time, history of acute tubular necrosis and acute rejection. We conclude that 
one-year creatinine value predict long-term renal graft survival, it represents a 
simple practical tool to identify recipients with high risk for late graft failure.
POSTER BOARD NUMBER P2 – 188
CAN SERIAL 1389 EGFR, BODY MASS INDEX PREDICT 
RENAL ALLOGRAFT SURVIVAL IN SOUTH ASIAN PATEINTS
G. Abraham, M.A. Ali, M. Mathew, N. Fathima, S. Saravanan, S. Varun, 
N. Lesley
Sri Ramachandra Medical College and Research Institute, Madras Medical 
Mission Hospital, Chennai, India
Background: There is limited data on long-term allograft survival in South Asian 
patients in the era of modern immunosuppressive therapy. This retrospective 
analysis was undertaken to see the graft survival based on serial eGFR, 
immunosuppressive therapy, BMI and other confounding factors in patients who 
have undergone renal transplantation in a tertiary care in South India.
Materials and patients – We retrospectively analyzed the outcome of all 
patients who underwent primary renal transplantation with a graft from a 
living and deceased donor in a tertiary care center between 2001 and 2006. 
We performed 303 renal transplants (3 cadaveric and 300 live). The group was 
made up of 212 male and 92 female patients, with a mean age of 42.74 ± 
13.03 years. Among the 303 renal transplant recipients, 89 were diabetic, 234 
were hypertensive, 18 had coronary artery disease and two underwent coronary 
artery bypass grafting. One recipient was positive for Hepatitis B, 17 were 
positive for Hepatitis C and none of them were HIV positive. Acute rejection 
episode occurred in seventy-nine transplant recipients and seven were back 
on hemodialysis. The HLA matching showed 202 complete mismatches in the 
A loci, 198 in the B loci and 86 in the DR loci. Zero mismatching in the A, 
B and DR loci were 13, 7 and 14 respectively. Mismatching of two to four 
antigen at A, B and DR loci were 85, 95 and 173 respectively. Our baseline 
immunosuppressive therapy consisted of prednisone, micro-emulsion form of 
cyclosporine A, tacrolimus, mycophenolate mofetil, azathioprine or rapamycin. 
Ninety-three transplant recipients received basiliximab as induction therapy 
of which 27 had multiple doses, 102 received daclizumab of which two had 
multiple doses, and seven patients had anti-thymocyte globulin single dose.
Results: Mean graft survival after transplantation is 6.38 ± 0.11 in years, graft 
survival at one year is 95.7%, two is 92.72%, three is 91.72% and fi ve year are 
89.21%. Mean creatinine value for graft survival is 1.24 ± 0.59 and for graft not 
surviving is1.74 ± 0.94 and it is statistically signifi cant. (p <0.001). Mean BMI for 
the graft survival at 1 year is 21.63 ± 2.29, graft not surviving is 26.59 ± 3.18, and 
it is statistically signifi cant. (p <.0.05). Mean eGFR for the graft survival is 61.50 
± 17.40 and graft not surviving 43.73 ± 13.65 and it is statistically signifi cant.
Conclusion: In conclusion, this analysis has shown that serial eGFR, body 
mass index are signifi cant predictor of survival following renal transplantation 
in south Asian patients. Utilizing this information, interventions can be initiated 
to improve the outcome of patients with kidney transplantation.
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CHLAMYDIA PNEUMONIAE INFECTION IN PATIENTS 1390 
AFTER KIDNEY TRANSPLANTATION TREATED WITH 
SPIRAMYCIN
S. Fesolowicz1, A. Kwiatkowski1, M. Wszola1, E. Podsiadly2, K. Ostrowski1, 
M. Durlik3, L. Paczek4, S. Tylewska-Wierzbanowska2, W. Rowinski1, 
A. Chmura1
1Department of General and Transplantation Surgery, 2National Institute 
of Hygiene, 3Department of Transplantation Medicine and Nephrology, 
4Department of Immunology, Transplantology and Internal Diseases
Previous research pointed to a signifi cant role of C. pneumoniae infection in 
the development of chronic renal allograft dysfunction, liver chronic rejection 
and vasculopathy of the transplanted heart. The aim of the study was to 
evaluate the C. pneumoniae presence prior to and after kidney transplantation 
and to determine the role of spiramycin therapy in patients after kidney 
transplantation.
Material and methods: The study group consisted of 50 patients (25 pairs) 
who received kidney transplants from cadaveric donors. One of the two 
kidneys from one donor was transplanted to a patient randomised to spiramycin 
(dose of 2x3milion U/day orally for 3 months) (group S) and the other was 
transplanted to a patient assigned as control (group C). Markers of infection 
were assessed on day 1 post transplantation and 3 months later (average=94 
days). All (n=50) patients were examined for bacterial DNA presence in 
peripheral blood leukocytes using real-time PCR and titers of serum anti C. 
pneumoniae IgG and IgA antibodies using microimmunofl uorescence (MIF). 
C. pneumoniae infection was diagnosed as C. pneumoniae DNA presence in 
peripheral blood leukocytes or positive antibodies in both classes.
Results: C. pneumoniae infection was initially diagnosed in 14 patients 
from group S and in 8 patients from group C (p=ns) after 3 months in 12 
and 9 patients respectively (p=ns). Conversion from positive to negative C. 
pneumoniae status occured in 7 patients from group S and one patient from 
group C (p=0,04). Conversion from negative to positive C. pneumoniae status 
occured in 5 patients from group S and 2 patients from group C (p=ns).
Conclusions: The results suggest a possible role for spiramycin treatment 
of in C. pneumoniae infection in kidney allograft recipients. C. pneumoniae 
infection diagnosis and treatment should be considered as a routine at every 
patient awaiting transplantation.
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LONG TERM RENAL AND METABOLIC OUTCOMES 1391 
AFTER CONVERSION FROM CNI-BASED THERAPY TO 
SIROLIMUS IN RENAL TRANSPLANT RECIPIENTS WITH 
ALLOGRAFT DYSFUNCTION
R. Swaminathan1,2, A. Irish1
1Royal Perth Hospital, 2University of Western Australia
Background: Long term calcineurin inhibitor (CNI) therapy in renal transplant 
recipients (RTRs) is associated with allograft dysfunction. The long term renal 
and metabolic outcomes following conversion from CNI to the mTOR inhibitor 
Sirolimus (SRL) in RTRs with allograft dysfunction remains uncertain.
Aim: To compare the renal and metabolic outcomes of continuing CNI therapy 
versus conversion to SRL in RTRs with allograft dysfunction and biopsy 
proven CNI toxicity &/or chronic allograft nephropathy (CAN).
Methods: A retrospective comparison of the eGFR (absolute and rate of change), 
metabolic (lipids, glycemic control, proteinuria) and clinical outcomes in 60 
RTRs with biopsy proven CNI toxicity &/or CAN.
Results: 41/60 patients were converted to SRL (SG) and 19/60 were continued 
on CNI (CG) at the same or reduced dose according to clinicians’ discretion. 
The mean SRL level was 7.3 mcg/l (95% CI 6 .6-8.1) with a mean dose of 
1.7mg/day (95% CI 1.42 - 2) at 12 months post conversion.
There was no difference in age, duration of CNI exposure (7 vs.6 years), 
eGFR (33 vs.39ml/min), proteinuria, diabetes or histological fi ndings based on 
Bannf”97 criteria between the groups, at the time of biopsy. The rate of fall of 
eGFR during the 12 months preceding the biopsy was similar in both groups 
(-1 ml /min/month).
However, there was signifi cant improvement in the measured and slope of 
the eGFR between the groups after conversion. At 12 months the mean eGFR 
improved from 39 to 48.5ml/min (SG) vs. 33 to 39.4ml/min (CG) and the 
difference in the slopes of the eGFR was 2.3 (SG) vs. 1.2 (CG) ml/min/month. 
(P=0.02). After a mean follow-up of 32 months, the eGFR was 51.2 ml/min 
(SG) vs. 34.2 ml/min (CG), p=0.02. 2/41(SG) vs. 4/19 (CG) reached ESRF 
after a median of 18 months.
The mean protein: creatinine ratio (PCR) was signifi cantly higher after 
conversion in the SG, (21.6 vs.118.4mg/mmol (p=0.001) with no signifi cant 
change in CG.
7/41 SRL patients discontinued therapy due to new onset nephrotic range 
proteinuria which was associated with a preconversion PCR of >40mg/mmol 
(P=0.001).
In the SG, but not the CG, the glycated haemoglobin (6.1% vs. 6.7%, p=0.03) 
and the mean triglyceride level (1.7 vs. 2.4mmol/l, p=0.005) deteriorated post 
conversion, associated with an increase in the lipid lowering and anti- diabeteic 
medications. There was also less use of anti-hypertensives including ACE-I 
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and ARBs post conversion.
Conclusions: 
1.  Improvement in renal allograft dysfunction was signifi cantly greater after 
conversion to SRL compared with CNI continuation and this benefi t was 
maintained after a mean follow up of nearly 3 years.
2.  Pre-conversion PCR >40mg/mmol predicted post conversion nephrotic 
range proteinuria which limited therapy in nearly 20% of patients.
3.  Conversion to SRL was associated with a worsening lipid profi le and 
glycaemic control requiring additional therapy, but a reduced need for 
antihypertensives.
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MANAGEMENT OF CHRONIC KIDNEY DISEASE 1392 
AFTER RENAL TRANSPLANTATION. IS IT DIFFERENT FROM 
NONTRANSPLANT PATIENTS?
S. Jiménez-Alvaro, R. Marcén, J.L. Teruel, A. Fernández, J. Pascual, 
J.J. Villafruela, J. Villacorta, *F.J. Burgos, J. Ortuño
Departments of Nephrology and *Urology. Hospital Ramón y Cajal. Madrid
Background: The Kidney Disease Quality Initiative (K/DOQI) of the National 
Kidney Foundation has published guidelines for the diagnosis and management 
of chronic kidney disease (CKD). Renal transplant recipients frequently have 
CKD and complications similar to patients with native kidney disease. There are 
few publications comparing the management of these two population groups. 
The purpose of the present study was to compare the management of CKD 
complications between renal transplant recipients and nontransplant patients.
Patients and methods: 83 renal transplant recipients (RTR) with CKD stage 
4T and 5T were chosen for the study. The mean age was 57.8±13.0 years, 36 
male and 47 female, the follow-up after transplantation was 114±77 months. 
The control group (CG) consisted of 83 native CKD patients matched by CKD 
stage followed at the predialysis outpatient clinic.
Results: There were no differences between the groups in serum hemoglobin 
(12.0±1.6 in RTR vs 12.3±1.5 g/dl in CG; NS), prevalence of anemia, Hb <11g/
dl, (18% vs 19%; NS) and patients treated with erytopoiesis-stimulating agents 
(42.1% vs 40.3%), but serum ferritin levels were higher in RTR (181±159 vs 
114±108 ng/ml; p=0.003). Blood pressure was similar in both groups and 83% 
RTR and 66% had systolic blood pressure higher than 130 mmHg. However 
more patients were treated with either ACEI or ARA in the transplant group 
(43.4% vs 8.0%; p<0.001). LDL-cholesterol was lower in the transplant 
recipients (109±30 vs 120±40 mg/dl; p=0.049) and a higher percentage was 
on statin treatment (44.5% vs 27.8%; p=0.046). Serum calcium was higher in 
transplant recipients (9.6±0.8 vs 8.9±0,7 mg/dl; p<0.001) and phosphate was 
lower (3.9±0.9 vs 4.3±1.1; p=0.019) and there were no differences in iPTH 
blood levels (248±290 vs 272±27 pg/ml; NS).
Conclusions: The management of renal transplant recipients is not worse than 
that at nontransplant patients. However, in both populations some parameters 
are far from the target recommended by the guidelines.
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IT IS INDEED POSSIBLE TO SLOW THE PROGRESSION 1393 
OF RENAL ALLOGRAFT CHRONIC DISEASE AND 
TO ACHIEVE THE REMISSION OF A PROGRESSIVE 
NEPHROPATHY
X. Rocca, M. Espinoza, P. Herrera, E. Reynolds, E. Lorca, O. Espinoza, 
E. Roessler, J. Hidalgo, F. Gonzalez.
Department de Nephrology, Universidad de Chile, Hospital del Salvador, 
Santiago, Chile
Successful treatments of progressive kidney disease are those that retard the 
decrease of the glomerular fi ltration rate.
Several factors participate in the progressive loss of glomerular fi ltration of 
renal allografts; one of them could be the nephrotoxicity related to calcineurin 
inhibitors. It is desirable to search therapeutic interventions capable of improving 
the adverse prognosis of the chronic kidney disease of the allograft.
Prospective, open label clinical trial in 24 kidney transplant patients with 
more than 3 months of evolution (range 141-4249 days), progressive kidney 
function deterioration and a graft biopsy showing interstitial fi brosis and 
tubular atrophy. Immunosuppressive treatment: cyclosporine, ketoconazole 
and steroids associated or not to azathioprine or mycophenolate mofetil. After 
an IRB approved written consent form signed by the patient, cyclosporine was 
switched to sirolimus in a two weeks period until achieving a trough blood 
sirolimus concentration of 6-15 ng/ml.
Using Student’ T and Wilcoxon* tests, we compared selected clinical and 
laboratory variables in the annual period before and after the drug switch 
(Table). We did not observe any graft rejection episode. No patient or graft was 
lost in the follow up. Mean daily enalapril equivalent dose in the 12 month of 
follow up was 6.6 mg.
Baseline Period Post Switch Period p
Slope of the decreasing GFR
Crockoft-Gault (1/(ml/min/year) -6.93 ± 10.08 5.03 ± 9.10 0.0008
MDRD equation (1/(ml/min/year) -6.54 ± 9.17 8.14 ± 14.04 0.0017
Systolic Blood Pressure (mmHg) 129.1 ± 20.2 122.1 ± 16.1 0.0060
Diastolic Blood Pressure (mmHg) 78.6 ± 12.9 76.6 ± 11.5 0.1285
Doses of antihypertensive /patient 2.0 ± 1.7 1.8 ± 1.5 0.242*
Cholesterol total (mg/dL) 209 ± 51 219 ± 49 0.4270
Triglycerides (mg/dL) 196 ± 118 239 ± 135 0.0049
Doses of hypolipemic /patient 0.17 ± 0.38 0.43 ± 0.50 0.030*
Proteinuria (mg/dL) 13.7 ± 17.3 40.9 ± 90.4 0.009*
Hematocrit (%) 37.3 ± 5.3 38.1 ± 5.3 0.4133
The switch of cyclosporine to sirolimus in kidney transplant patients with 
decreasing GFR and a graft biopsy showing interstitial fi brosis and tubular 
atrophy changes the natural history of the progressive nephropathy of the graft. 
It is feasible to control proteinuria with enalapril or other similar drugs. It is 
necessary to conduct trials using clinical end points to defi nitively validate this 
therapeutic intervention.
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CLINICAL ATTITUDES ON CHRONIC GRAFT 1394 
DYSFUNCTION: THE ICEBERG STUDY
J.M. Grinyó1, N. Saval2, S. Gatell2, J.M. Campistol3, on behalf of the 
ICEBERG STUDY group
1Hospital Universitari de Bellvitge, Barcelona, Spain, 2Medical Department 
Novartis Spain, 3Hospital Clinic de Barcelona, Spain
Purpose: Renal impairment after transplant is associated to a greater risk of 
death. It is of interest to asses how and how early or late the diagnosis is made, 
in what way the clinician perceives the severity of the graft dysfunction and the 
measures adopted after the diagnosis.
The primary objective was to asses the prevalence of chronic graft dysfunction 
(CGD) in renal transplant patients; secondary objectives comprised: method 
of diagnosis, characteristics of CGD and its evolution in time, current 
immunosuppressive treatment and if the diagnosis of CGD lead to changes in 
the immunosuppressive treatment.
Methods: National, multicenter, observational, cross-sectional study including 
872 renal transplant patients with an at least two year follow-up and a 
functioning graft. Patient, transplant and fi ve cross-sectional visits data were 
collected. Clinicians were asked if they considered that the patient had CGD 
and also objective criteria were applied (objective criteria: serum creatinine >2 
mg/dl or MDRD<50 ml/min).
Results: 872 patients were analyzed, 62% male, 98,7% Caucasian, mean 
age 54 years (SD 13 years). Ethiology of end stage renal failure: 32,7% 
chronic glomerulonephritis, 19,8% unknown, 12,4% polycystic disease, 7,6% 
chronic pielonephritis, 8% diabetes, 5,9% hypertension, 15,7% other. Mean 
(SD) transplant evolution 8,2 (5,1) years. Mean (SD) donor age 42 years. 
CGD could be diagnosed according to investigators’ criteria vs. objective 
laboratory criteria. CGD was diagnosed in 35% of the patients according to 
the investigators’ criteria and in 55, 5% of the patients according to objective 
criteria. In 40% of the patients that were diagnosed of CGD by objective criteria 
the clinician had not considered this diagnosis (see table 1). Graft biopsy was 
performed in 31% of patients with investigators’ criteria of CGD. The presence 
of proteinuria conducted to a biopsy more than a rise in serum creatinine. Time 
from transplant to biopsy was greater in patients with antiproteinuric treatment 
(p=0,032). Immunosuppressive treatment changes were not associated to 
biopsy histological data. The creatinina slope showed a direct relationship with 
the total number of treated acute rejections (Pearson’s r: 0,12; p<0,001).
Conclusions: The prevalence of CGD in renal transplant patients is between 
35-55%, depending on the type of criteria applied (investigator’s or objective). 
Around of 40% of patients diagnosed of CGD by objective criteria had not 
been diagnosed by the investigator. Proteinuria is the main indication for 
TU
ESD
AY
 
Poster Abstracts Tuesday 12 August 2008
4 6 9Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
biopsy. Nephrologists are more sensitive to glomerular disease than to renal 
impairment itself. Antiproteinuric treatment delays the conduct of renal biopsy. 
Changes in the immunosuppressive treatment due to presence of CGD are 
performed late and unsatisfactory.
Table 1: Concordance among criteria (Investigator’s vs. objective):
Objective Criteria Objective Criteria
Yes No
Investigator Criteria Yes 283 (92.8%) 22 (7,2%)
Investigator Criteria No 199 (35,3%) 364 (64,7%)
Kappa index (IC95%): 0,51 (0,45 a 0,56)
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STATIN THERAPY IS ASSOCIATED WITH A LOWER 1395 
RATE OF DECLINE OF RENAL FUNCTION IN KIDNEY 
TRANSPLANT RECIPIENTS
A. Assounga, S. Harparshad, N. Madala
University of Kwazulu-Natal and Inkosi Albert Luthuli Central Hospital
Background: Statins have proven ability as antilipidaemic agents as well 
benefi t on cardiovascular survival in transplant patients. The pleiotropic 
effects on renal function in renal allograft patients is still undetermined. A 
retrospective study was done to determine the effect of statin therapy on renal 
allograft function.
Method: We monitored all transplant patients who were on statin therapy for 
more than a year. We determined their renal function before, during and after 
commencing statin therapy. Statin treatment was initiated based according to 
guidelines for cardiovascular protection. Serum creatinine and eGFR were 
analysed before and after the introduction of statins. A total of 73 patients 
were studied including those who had become dialysis requiring. The average 
monthly change in eGFR was compared before and after commencing statins 
using a Chi-square test.
Results: The average creatinine 18 months before starting statins was 160.13 
μmol/l versus an average creatinine of 172.22 μmol/l 24 months after starting 
statins .The average eGFR 18 months prior to starting statin therapy was 53.40 
ml/min. The average eGFR when starting statins was 49.43 ml/min. This 
represented a decline in renal function of 0.22 ml/min/month over 18 months. 
The eGFR 12 and 24 months after commencing statins was 52.67 ml/min and 
49.06 ml/min respectively. The rate of decline after starting statins was 0.015 
ml/min/month over a 24 month period. There was a statistically signifi cant 
reduction in the rate of decline of eGFR after starting statins (p value < 0.0001). 
A total of 4 out of 73 patients developed graft failure within 24 months .
Conclusion: Statin therapy in our setting was associated with a lower rate of 
decline of renal function in renal allograft patients within 2 years of starting 
therapy.
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SPIRONOLACTONE AMELIORATES FOCAL 1396 
GLOMERULOSCLEROSIS IN EXPERIMENTAL 
CHRONIC ALLOGRAFT NEPHROPATHY IN RATS
F. Waanders1, H. Rienstra2, J. Rozing2, G. Navis1, H. van Goor3, 
J-L. Hillebrands1
1University Medical Center Groningen, Dept . Internal Medicine, Div. 
Nephrology, 2University Medical Center Groningen, Dept . Cell Biology - 
section Immunology, 3University Medical Center Groningen, Dept . Pathology
Background: Chronic allograft nephropathy (CAN) is the leading cause of 
long-term renal graft loss. CAN is characterized by proteinuria and decreased 
renal function associated with focal glomerulosclerosis (FGS), interstitial 
fi brosis (IF), tubular atrophy and transplant arteriopathy. So far, no effective 
therapy is available to prevent CAN.
There is increasing evidence that aldosterone plays a signifi cant role in 
renal damage via the non-epithelial mineralocorticoid receptors (MR). 
Spironolactone, a competitive aldosterone antagonist, administered prior to the 
induction of renal ischemia/reperfusion injury prevented loss of renal function, 
proteinuria and oxidative stress. In this study we investigated whether MR 
blockade by spironolactone ameliorates the development of CAN.
Methods: Renal transplantations (Tx) were performed in the Dark Agouti 
(DA)-to-DA (isograft) and DA-to-Wistar Furth (allografts) combinations. After 
Tx the rats received 5 mg/kg CsA s.c. for 10 days and at day 14 unilateral 
nephrectomy of the autologous kidney was performed. Treatment with 20 mg/
kg spironolactone (+) or vehicle (-) was given daily by oral gavage and started 
at 2 days prior to Tx. 4 groups were included: isografts- (n=8), isografts+ (n=8), 
allografts- (n=9) and allografts+ (n=9).
Before and every 2 weeks after Tx systolic blood pressure and renal function 
were measured. Rats were sacrifi ced at 12 weeks and kidneys removed for 
histological analyses.
Results: All isografts survived until the end of the experiment. Of the allografts 
treated with vehicle 3 animals had to be sacrifi ced prematurely but in the 
spironolactone treated allografts only 1 animal. The survival curves reached a 
borderline signifi cant difference (p=0.07). The allografts developed proteinuria 
which was decreased after spironolactone treatment (77±28 mg/day vs 41±10 
mg/day; p=0.06). In the isografts, urinary protein excretion remained at preTx 
levels (<10 mg/d). Both the allografts and isografts showed a signifi cant 
decrease of creatinine clearance after 12 weeks. Spironolactone did not affect 
systolic blood pressure.
Compared to the isografts, the allografts showed prominent development of 
FGS and IF. FGS in allografts was signifi cantly ameliorated by spironolactone 
(100±37 vs 47±17 A.U., p<0.05), without having effects in the isografts (1±1 
vs 1±2 A.U). However, spironolactone did not affect the development of IF.
Conclusion: MR blockade by the aldosterone antagonist spironolactone 
ameliorates proteinuria and FGS in an experimental rat model for CAN. 
However, spironolactone has no effect on IF development in this model. We 
propose that the observed glomeruloprotective effect of spironolactone might 
result in improved graft survival. It should be evaluated whether spironolactone 
is a useful adjunct therapy to attenuate CAN.
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PROTOCOL BIOPSIES: AN ANALYSIS OF A SINGLE 1397 
CENTER EXPERIENCE
L. Saber1, J.C. Crispim2, R.S. Costa3, T.M.P. Garcia1, M.E.P. Nardim1, 
V.A. Muglia1
1Renal Transplant Unit, Hospital Das Clinicas, University of São Paulo-
Ribeirão Preto, São Paulo, Brazil., 22-Department of Biochemistry and 
Immunology, FMRP-USP, Brazil, 3Department of Pathology, FMRP-USP, 
Brazil
Chronic allograft nephropathy (CAN), as a result of both immunological and 
non-immunological factors, is the most prevalent cause of late kidney allograft 
losses. In this context, calcineurin inhibitor (CNI) nephrotoxicity has been 
identifi ed to play a major non-immunological role, as demonstrated by Nankivell 
et al. in protocol biopsy studies. In this study, we evaluated 57 prospective, 
protocol kidney biopsy specimens, from 49 patients, of mean age of 38.3 years, 
including 41 recipients of organs from deceased donors, taken at different time 
points from 1 to 26 months after transplantation (mean time 8.95months), 
for evidence or not of protocol biopsy utility. Written informed consent was 
obtained from all patients. The initial protocol consisted of biopsies obtained 
at 1, 3, 6, 12 and 24 months, but due to technical diffi culties were grouped in 
months 1 to 6, 7 to 12 and 13 to 26. All biopsies were evaluated according to 
97 Banff criteria. IL-2R blockage was performed as induction in 28 patients 
(62.2%) and 44 (89.8%) patients were in use of CNI at the time of biopsy. 
Only one patient had previous acute rejection and 70.4% presented delayed 
graft function (DGF), defi ned as the need of hemodialysis during the fi rst week 
post-transplant. Twenty-one biopsies (BX) were performed at the fi rst 6 months 
post-transplant, with a mean serum creatinine of 2.67mg%: 14 presented CNI 
nephrotoxicity evidence and 8 had already presented CAN. These fi ndings led 
to CNI dose reduction in 6 and sirolimus (SRL) conversion in 9 patients. From 
month 7 to 12 we could evaluate 19 BX (mean serum creatinine 1.74mg%), 7 
of them with CAN and 4 with CNI nephrotoxicity, leading to SRL conversion 
in 7 and CNI reduction in 4 patients. From month 13 to 26, 17 BX were 
evaluated (mean patient serum creatinine 1.93mg%): 10 with CAN and 4 with 
CNI nephrotoxicity, leading to SRL conversion in 8 and CNI dose reduction 
in 1 patient. No subclinical rejection was detected. Three patients presented 
post-biopsy time-limited bleeding and the mean hospitalization time required 
was 2.8days. In conclusion, 82.5% of all studied biopsies showed CAN and/
or CNI nephrotoxicity, which allowed us to perform therapeutic adjustment in 
71.43% patients, either SRL conversion in 48.98% or CNI dose reduction in 
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22.45% of patients. Therefore, we may conclude that despite its fi nancial and 
time consuming cost, protocol biopsy is an important tool in the post-transplant 
management.
POSTER BOARD NUMBER P2 – 197
SIMVASTATIN TREATMENT FAILS TO INHIBIT 1398 
CHRONIC ALLOGRAFT NEPHROPATHY IN RAT WHEN 
STARTED AFTER TRANSPLANTATION
J. Savikko1, P.K. Koskinen1,2, N.K. Malmström1, J.M. Rintala1, R. Tuuminen1,
1University of Helsinki, 2Department of Nephrology, Helsinki University 
Central Hospital
Background: The role of statins in prevention of chronic allograft nephropathy 
(CAN) is still unclear. We examined the effect of an early start of simvastatin 
treatment in a rat renal transplantation model of CAN.
Methods: Allograft recipients were treated with a suboptimal dose of 
cyclosporine A (1.5 mg/kg/d s.c.) which allows acute rejection and CAN to 
develop. Simvastatin 2 mg/kg/d was started eight days after transplantation 
(n=3) and was diluted in PEG and given orally using orogastric tube. 
Control group received an equal amount of vehicle (n=3). Syngrafts with no 
immunosupression served as an additional control group (n=3). Grafts were 
harvested 90 days after transplantation for histopathological analysis.
Results: Simvastatin treatment did not statistically inhibit the development 
of CAN changes quantitated as chronic allograft damage index (CADI) score 
(mean values: control vs. treated 5.3 vs. 6.3). The mean values of the CADI 
score components were: fi brosis (1.7 vs. 1), infl ammation (1 vs. 1.3), tubular 
atrophy (1 vs. 0.7), mesangial matrix increase (0 vs. 0), glomerular sclerosis 
(1 vs. 1.7), intimal thickening (0.7 vs 1.7). Syngrafts displayed nearly normal 
glomerular and tubular structure.
Conclusions: Simvastatin treatment failed to show a benefi cial effect on 
CAN when started 8 days after transplantation. However, our preliminary data 
indicate that donor treatment of simvastatin may possess a protective effect.
POSTER BOARD NUMBER P2 – 198
BENEFICIAL EFFECTS OF CANDESARTAN ON 1399 
REDUCTION IN PROTEINURIA IN PATIENTS WITH 
FAVORABLE RENAL ALLOGRAFT FUNCTION
M. Okumi1, N. Ichimaru1, T. Moriyama2, T. Abe1, R. Imamura1, Y. Kojima3, Y. 
Isaka4, A. Okuyama1, S. Takahara4
1Department of Urology, Osaka University Graduate School of Medicine, 
2Health Care Center, Osaka University, 3Soryukai Inoue Hospital, 
4Department of Advanced Technology for Transplantation, Osaka University 
Graduate School of Medicine
Background: Recently, in non-transplant patients with chronic kidney disease 
(CKD), blockade of the renin angiotensin system with an angiotensin-converting 
enzyme (ACE) inhibitor or angiotensin II type-1 receptor blocker (ARB) has 
been shown to reduce proteinuria and delay the progression of CKD. Although 
it has been shown that the use of the ARB in kidney transplant patients is safe 
and effective with regard to the control of hypertension, the effect of the ARB 
on urinary protein excretion and renal function in patients with unremarkable 
allograft function remains unclear. The aim of this study was to evaluate the 
effi cacy and safety of the ARB candesartan on proteinuria and renal function in 
kidney transplant patients.
Methods: 75 patients with stable allograft function were included into a 
prospective study at least 6 months posttransplantation. The patients were 
treated with increasing doses of Candesartan. The initial dose of 0 to 8 mg/day 
was increased at 2 months intervals up to a maintenance dose of 12 mg/day for 
a total of 12 months, while monitoring tolerability in individual cases. Effi cacy 
was evaluated on the basis of urinary protein level by 24-hour protein excretion, 
accompanied by evaluation of safety through analysis of blood pressure (BP), 
serum creatinine, rennin, and aldosterone levels.
Results: After 12 months of therapy with candesartan, 69 cases were analyzed. 
Doses of candesartan were safely increased from the baseline level of 2.5 mg/
day to 10.8 mg/day on average. Signifi cant decreases were seen in systolic BP 
from 125.9 to 121.7 mmHg at 12 months (p<0.003) and diastolic BP dropped 
insignifi cantly from 79.4 to 77.6mmHg at 12 months. Protein level in 24-hour 
urine decreased from 298.5 to 215.2mg/day signifi cantly (P = 0.03), while no 
changes were noted in serum creatinine level or estimated eGFR level. While 
renin level increased signifi cantly from 5.7 pg/ml to 9.7 pg/ml (P < 0.0007), 
aldosterone level maintained.
Conclusions: It is concluded that candesartan reduces systolic BP and 
proteinuria in kidney transplant patients without inducing a serious worsening 
in renal function. These fi ndings suggest that the treatment with candesartan 
exerts kidney protective effects in renal transplantation patients with regard to 
the control of proteinuria.
POSTER BOARD NUMBER P2 – 199
THE CLASSIFICATION OF DETERIORATING RENAL 1400 
GRAFT FUNCTIONS AFTER THE SERUM CREATININE 
VALUE SURPASSED THE POINT OF NO RETURN
Y. Kato, K. Iwado, K. Kai, K. Nanmoku, A. Sannomiya, I. Koyama, 
T. Tojimbara, I. Nakajima, S. Fuchinoue, S. Teraoka
Department of Surgery ‡V, Tokyo Women’s Medical University
Purpose: The transplanted renal graft is mortal yet and its end stage is still 
unclear. We have analyzed the behavior of serum creatinine (s-Cr) values of 
patients with renal grafts that survived longer than three years, both functioning 
and lost. Last year we reported that the s-Cr 3.0 mg/dl could be the point of no 
return of renal graft function mainly by observing s-Cr values of functioning 
grafts. We have further investigated the subsequent patterns of time series s-Cr 
values of the lost grafts after their s-Cr exceeded 3.0 mg/dl.
Method/material: We performed 1332 living/deceased renal transplantation 
between 1985 and 2000. After excluding death with functioning graft cases 
and those with inadequate s-Cr data, 126 cases that had been lost were studied. 
All the s-Cr values taken later than 1 year after transplantation were examined. 
They were divided into three groups according to the time needed for the s-Cr 
value to rise up form 3.0 to 6.0. Group A (n=31; 25.6%): in less than 6 months, 
Group B (n=47; 38.8%): from 6 to 18 months and Group C (n=43; 35.5%): in 
more than 18 months. Linear regression analysis was applied to the time series 
s-Cr values of each group and the mean increment of s-Cr value in 3 month 
were fi gured out.
Result: That increment in Group A was 1.16 mg/dl/3month (p<0.001), that 
in Group B, 0.622 mg/dl/3month (p<0.001) and that in Group C, 0.162 mg/
dl/3month (p<0.001), respectively.
Conclusion: The steady increase of s-Cr more than 3.0 mg/dl could indicate 
the deteriorating renal graft function. Roughly speaking, the graft might be lost 
within 6 month if the increment of s-Cr in 3 month after it exceeded 3.0 is more 
than 1.2 mg/dl/3month. On the other hand, it might continue functioning more 
than 18 month if that increment is less than 0.2 mg/dl/3month.
POSTER BOARD NUMBER P2 – 200
A STEROID-FREE MANAGEMENT STRATEGY FOR 1401 
CHRONIC TRANSPLANT GLOMERULOPATHY, USING 
RITUXIMAB IN SELECTED PATIENTS
D. Anthony1,2, J. Galliford1, K.Y. Shiu1,2, H.T. Cook1,3, P. Brookes4, 
M. England3, K. Chan1, A. Warrens1,2, D. Taube1
1Imperial College Kidney And Transplant Institute, West London Renal and 
Transplant Centre, 2Department of Immunology, Imperial College London, 
Hammersmith Hospital, 3Department of Histopathology, Imperial College 
London, Hammersmith Hospital, 4Tissue Typing, Hammersmith Hospital
Background: Transplant glomerulopathy (TG) is a form of chronic antibody-
mediated rejection. Other than a report showing 12 month stabilisation in 
3/4 patients after introduction of steroids, tacrolimus and MMF, there is little 
guidance on treatment. We report a steroid-free regimen used in 16 patients 
with chronic TG, tubular atrophy and interstitial fi brosis, diagnosed in the 
context of progressive allograft dysfunction.
Methods and results: 7 patients who presented on azathioprine and 
prednisolone ¡À ciclosporin were changed to tacrolimus [12 hr trough levels 
5-7 ng/L (LCMS)] and MMF [12 hr trough levels 1.5 ¨C 3.0 mg/ml]; steroid 
doses were not increased. 6/7 had positive C4d immunostaining on ¡Ý25% of 
peritubular capillaries and/or glomerular endothelium. 3/7 stabilised rapidly 
and remain stable 18 months later. 2/7 stabilised but then deteriorated 6-9 
months later and 2/7 failed to respond. All 4 had ongoing TG on repeat biopsy; 
3 were administered two doses of Rituximab, 1g IV two weeks apart. Of these, 
TU
ESD
AY
 
Poster Abstracts Tuesday 12 August 2008
4 7 1Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
2 continued to deteriorate and reached ESRF within 6 months. The 3rd (the 
only patient with C4d-negative TG) appears to have stabilised 3 months later. 
There were no serious adverse events. One patient with hepatitis C presented at 
13 months with an acute hepatitis that resolved spontaneously.
9 other patients, on optimal doses of tacrolimus and MMF at diagnosis, 
received Rituximab straight away. 6/9 stabilised rapidly. 4 of these had C4d-
negative TG and all remain stable 6 months later. One patient, with long-
standing chronic obstructive pulmonary disease, developed pneumonic 
consolidation 2 months post-rituximab which completely resolved after 
appropriate anti-infective therapy. The other 2 had C4d+ TG; one remains 
stable 2 years later. The second, with pre-existing bronchiectasis, presented 
with chest sepsis 9 months post-rituximab, which resolved after appropriate 
anti-infective therapy; this patient suffered fatal myocardial infarction 6 
months later. 3/9 (all with C4d+ TG) failed to stabilise after rituximab and 
reached ESRF within 6 months.
On analysis of the whole group, eGFR at presentation was highly signifi cant in 
predicting graft stability at 3 and 6 months [38.4¡À8.5 mls/min vs. 22.2¡À7.5 
mls/min; p=0.004]. Comparing the responses of those administered rituximab 
(12 patients), all 5 patients with C4d-negative TG remain stable at the time of 
follow-up (3-6 months), whereas only 2/7 of those with C4d+ TG were stable 
at 3-6 months (p<0.01). Data on the presence of donor specifi c antibodies will 
be presented.
Conclusion: It is possible to stabilise renal function in TG, without steroids, 
by optimising oral immunosuppressive therapy and using rituximab in selected 
patients. This is the fi rst report of effi cacy of rituximab in TG and overall it 
appears to be safe with few side effects; although numbers are small, our data 
suggests those with C4d-negative- may respond better than those with C4d-
positive TG. Successful treatment in both groups appears to depend on early 
diagnosis (eGFR >30 mls/min).
POSTER BOARD NUMBER P2 – 201
DURATION OF DELAYED GRAFT FUNCTION IS 1402 
AN IMPORTANT PREDICTOR OF ONE YEAR SERUM 
CREATININE
J. Dominguez1,2, F. Lira1, R. Rebolledo1, P. Troncoso1, C. Aravena2, 
M. Ortiz1, R. Gonzalez2
1Pontifi cia Universidad Catolica De Chile. Santiago, Chile, 2Hospital Sotero 
del Rio. Santiago, Chile
One year Serum Creatinine (SCr) has been shown to be a very good surrogate 
end point for kidney allograft survival. The purpose of this study is to evaluate 
the importance of different factors on one year SCr in a series of kidney 
transplant from two centers.
Methods: Two hundred and sixty consecutive renal transplants performed 
between 1997 and february 2007 with at least one year follow-up were 
included. Mean age at transplantation was 40 ± 13, 55% were male, 19% 
living donors, 96% of the patients received a CyA based immunosuppressive 
protocol. Factors considered for analysis were: donor and recipient age and 
sex, number of transplants, Panel Reactive Antibodies, Total number of HLA 
mismatches, Cold Ischemia Time (CIT), 6 month Acute Rejection (AR) 
rate and presence and duration of Delayed Graft Function (DGF) defi ned as 
the need of postoperative dialysis and time to last post transplant dialysis. 
Multiple regression analysis were performed for one year S Cr, AR rate 
and duration of DGF. All calculations were performed on the Stat View® 
software.
Results: Mean one year SCr was 1.46 ± 0.5, 6 month AR rate was 22% and 
DGF rate was 26% with a mean duration of 3 ± 8 days (range 0-38). Multiple 
regression analysis identifi ed female recipient sex, decreasing donor age, 
absence of AR within 6 months and decreasing DGF duration (but not DGF 
rate) as giving lower one year S Cr (p <0.05). Analysis of AR showed that 
the only signifi cant factor affecting AR rate was duration of DGF. Finally 
prolonged CIT was associated with a longer duration of DGF.
Conclusions: We confi rm that one year SCr is affected primarily by well 
known factors such as the incidence of AR, donor age and female recipient sex. 
However we have identifi ed the number of days on post transplant dialysis as 
a new and signifi cant factor affecting one year SCr. On the other hand AR rate 
is also affected by DGF duration which in turn is conditioned by longer CIT. 
Every effort should be made to decrease DGF duration in order to improve one 
year S Cr and possibly graft survival.
POSTER BOARD NUMBER P2 – 202
VERY LATE CONVERSION TO SIROLIMUS-1403 
BASED IMMUNOSUPPRESSION VERSUS CALCINEURIN 
INHIBITOR MINIMIZATION FOR TUBULAR ATROPHY/
INTERSTITIAL FIBROSIS AND CALCINEURIN INHIBITOR 
NEPHROTOXICITY IN RENAL TRANSPLANTS
T. Kee, Y.M. Chin, A. Vathsala
Singapore General Hospital
Objectives: Tubular atrophy/interstitial fi brosis of renal transplants (RTX) 
and calcineurin inhibitor (CNI) nephrotoxicity can be treated either with a 
switch from a CNI to a Sirolimus (SRL) based immunosuppression or CNI 
minimization (CNIM). Others have reported that switch to SRL leads to 
improved allograft function and histology than CNIM when performed within 5 
years after transplantation. We report the effi cacy and safety of these strategies 
when performed beyond 5 years after transplantation.
Methods: Twenty-seven RTX who experienced allograft dysfunction with 
biopsies showing either TA/IF or CNI nephrotoxicity were either abruptly 
switched from cyclosporine to SRL (SRL; n=11) or had cyclosporine dose 
reduced to achieve a 2-hour cyclosporine level of 400-600 ng/mL in association 
with a mycophenolate derivative (CNIM; n=16). The loading dose of SRL was 
6-20 mg with a subsequent maintaining dose titrated to a target trough level of 
8-10 ng/mL. Follow-up was for 12 months after conversion.
Results: At conversion, SRL and CNIM groups did not differ signifi cantly with 
respect to baseline renal function (serum creatinine (Cr); 215.2±56.3 μmol/L 
(SRL) vs 222.2±72.8 μmol/L (CNIM); p=0.8) or time after transplantation 
(127.8±55.9 months (SRL) vs 110.0±31.0 months (CNIM); p=0.35). However, 
after one year of treatment, a 18.9±15.3% increase from baseline Cr (p=0.01) 
was seen in 72.7% (n=8/11) of SRL versus a 6.5±5.9% increase in Cr (p=0.04) 
for 37.5% (n=6/16) of CNIM. No difference in proteinuria between SRL and 
CNIM was seen at conversion (0.2±0.3 g/d vs 0.4±0,7 g/d; p=0.3) and after 
conversion (0.9±1.1 g/d vs 0.3±0.4 g/d; p=0.06). Infections occurred in 63.6% 
(n=7/11) of SRL vs 12.5% (n=2/16) of CNIM during follow-up (p=0.006) but 
no rejections, graft loss or patient death was seen.
Conclusions: After 5 years post-transplantation, switch to SRL may not be as 
effective as CNIM and are associated with an increased rate of infections.
CVD AND SCREENINGCONCURRENT ORAL SESSION 100: 
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ARTERIAL STIFFNESS AND PROTEINURIA AFTER 1404 
KIDNEY TRANSPLANTATION
M. Baumann, C. Pan, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R.D. Isar, TU Munich
Background: Cardiovascular mortality is major cause of death after kidney 
transplantation. Arterial stiffness as measured by aortic pulse wave velocity 
(aPWV) is an accepted risk factor for blood pressure independent cardiovascular 
mortality. The role of aPWV in renal transplant patients in context with their 
renal glomerular and tubular function remains uncertain. Therefore we aimed 
to investigate in stable renal transplant patients for aPWV, estimated glomerular 
fi ltration rate (eGFR) and proteinuria.
Methods: In sixty-nine stable renal transplant recipients aPWV was measured 
in duplicate using the Complior. GFR was estimated using MDRD (Modifi cation 
of Diet in Renal Disease) and logarithmic albumin-creatinine ratio (logACR) 
were determined by morning spot urine. Adjusted correlations were performed. 
Results show median±standard deviation.
Results: Mean age was 50.6±14.1 years with an eGFR of 43.6±16.2 ml/min 
and a logACR of 2.28±0.42. Systolic blood pressure was 142.4±22.7 mmHg 
and aPWV 8.9±2.2 m/s. LogACR positively correlated with aPWV including 
adjustment for age, eGFR, heart rate and height, (r=0.32; P<0.05). The relation 
between eGFR and aPWV did not reach statistical signifi cance after adjustment 
for age, logACR, heart rate and height (r=0.26; P=0.08).
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Conclusion: Albuminuria and aortic stiffness show a signifi cant association in 
renal transplant patients, suggesting an interaction between transplant function 
and systemic vasculature. This relation is less clear for eGFR and aortic 
stiffness, mirroring the data evident in patients with chronic kidney disease.
POSTER BOARD NUMBER P2 – 204
HYPERTENSION AFTER RENAL TRANSPLANTATION 1405 
– AN INDIAN EXPERIENCE
D.S. Deepak1, V. Sakhuja2
1Dept of Nephrology,Medical Division,Command Hospital (Chandimandir), 
India, 2Dept of Nephrology, Postgraduate Institute of Medical Education and 
Research, Chandigarh, India
Hypertension after renal transplantation is quite common. The prevalence 
has been reported to be 20-80% in various studies.Multiple factors have been 
thought to be responsible for development of hypertension following renal 
transplantation .
Aim: To analyse the prevalence and risk factors associated with development 
of hypertension in renal transplant recipients.
Methods: A retrospective analysis of 324 renal transplant recipients from 
Jan 1995 to May 2001 at a tertiary care nephrology and transplant centre 
was carried out. The renal transplant recipients predominantly being live 
donors(319 in number-98.5%), followed up for at least six months, were 
selected. Hypertension was defi ned as a blood pressure of >140/90 mm of 
Hg.Risk factors like age and sex of the recipient& donor,relationship with 
donor, type of immunosuppression, details of surgical procrdure,severity of 
pretransplant hypertension, HLA match, number of donor arteries, number of 
acute rejection episodes were studied. The stastical analysis was carried out 
using chi square test and multiple logistic regression model.
Results: Out of 324 renal transplant recipients,268(82.7%) were males and 
56(17.3%) were females. The commonest underlying cause for end stage renal 
disease was noted to be Chronic Glomerulonephritis present in 215(66.4%). 
253 recipients (78.3%) were on cyclosporine based triple drug immuno 
suppression and rest were on azathioprine and prednisolone at time of last 
follow up. The patients had a mean followup of 27.93+_18.52 months(6-80 
months) after renal transplantation. Hypertension was found to be present in 
278(85.8%) patients, out of which 229(82.4%) were males and 49(17.6%) 
were females.The majority of patients(66.7%) developed hypertension within 
fi rst two weeks following renal transplantation and the prevalence peaked 
to93.1% at 3 months post transplantation. Out of 278 patients who developed 
hypertension after renal transplantation ,180(64.8%) patients required two 
or more drugs for control of blood pressure after renal transplantation.
Parent donor[ odds ratio-2.40,(95% confi dence interval-1.21-4.75) 
,p<0.01], severity of pretransplant hypertension(>1 antihypertensive drug 
to control blood pressure)[ odds ratio-2.28(95% confi dence interval-1.13-
4.61),p<0.05] and body weight of renal transplant recipient(>55 kgs) [odds 
ratio-1.5,(95% confi dence interval-0.80-2.83),p<0.05] were the factors 
found to be signifi cantly associated with development of hypertension in 
a renal transplant recipient .However left kidney implantation with end to 
end anostomosis of donor renal artery to internal iliac artery of recipient 
had a negative association with respect to development of hypertension 
after renal transplantation[ odds ratio-1.53(95% confi dence interval-1.22-
4.77),p<0.05].A total of 5(1.5%) transplant recipients were detected to have 
Transplant Renal Artery Stenosis.
Conclusion: 85.8% renal transplant recipients were found to have hypertension. 
The main factors associated with development of hypertension after renal 
transplantation were- parent donor, severity of pre-transplant hypertension in 
the transplant recipient and weight of the renal transplant recipient. However 
surgical procedure comprising of a combination of left kidney implantation 
with end to end anostomosis of donor renal artery to recipient’s internal iliac 
artery was found to be negatively associated with development of hypertension 
after renal transplantation.The prevalence of Transplant Renal Artery Stenosis 
was quite low.
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THE EFFECTIVENESS OF A RENAL TRANSPLANT 1406 
CLINIC IN DISPENSING HEALTHY LIFESTYLE ADVICE: A 
SURVEY OF PATIENTS
R. Naik
Royal Berkshire Hospital
Introduction: Several lifestyle choices are known to be important determinants 
of mortality in renal transplant recipients.  This is particularly the case for 
lifestyle factors which impact upon cardiovascular risk, as this is the most 
common cause of death among transplant patients.  Smoking not only increases 
cardiovascular risk but also adversely affects graft survival.  The UK Renal 
Association has published guidelines on the lifestyle advice which should be 
offered to all renal patients, including transplant patients.
Renal transplant patients attend clinics in secondary care more frequently than 
other patient groups, and hence may attend their primary care doctor less often. 
Thus roles which are traditionally taken on by primary care doctors - advice 
about exercise, offering help to stop smoking - need to be taken up by doctors 
on the clinic.
The aim of this study was to determine not just if healthy lifestyle advice is 
being offered in the transplant clinic, but if it is effective.  We also looked at 
rates of vaccination against Infl uenza and Pneumococcus - again, often thought 
of as the role of primary care.
Methods: Questionnaires were handed out at clinics.
Results: 9% of respondents smoked, of whom 25% felt they had not been 
advised to stop, and 50% felt they had not been offered help to stop.  33% of 
patients took no regular exercise; only 30% felt they had been advised to take 
more.  One patient admitted to alcohol consumption above the recommended 
weekly limit.  15% of patients had not received the Infl uenza vaccine, and 37% 
had not received the Pneumococcal vaccine.
Conclusions: Lifestyle advice was reasonable, but there was room for 
improvement.  A readiness on the part of clinic doctors to prescribe aids to 
smoking cessation may help, as may printed reminders to discuss smoking and 
exercise on clinic pro-formas.  Improved communication between secondary 
and primary care is needed to raise vaccination rates.
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FRAMINGHAM RISK ASSESSMENT BY ACTUAL 1407 
CARDIOVASCULAR EVENT DATA IN RENAL TRANSPLANT 
RECIPIENTS
E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, M. Cardi2, 
G. Mogilishetty1, S. Safdar2, J. Durbin1
1University of Cincinnati, 2The Christ Hospital
Background: Framingham risk score (FRS) predicts cardiovascular (CV) risk 
in the general population, but may underestimate CV risk in kidney transplant 
(txp) patients (pts). FRS has not previously been validated by prospective 
cardiovascular event (CVE) data collection in kidney txp pts. The purpose of this 
study was to validate FRS with actual observed CVE data in kidney txp pts.
Methods: CVE data was collected at routine intervals in our kidney txp 
pts and entered in a cardiovascular risk database. FRS was calculated from 
baseline to 7 yrs posttransplant (PTx). Individual FRS factors of age, sex, 
smoking, diabetes mellitus (DM), high-density lipoprotein (HDL), total 
cholesterol (TC), and blood pressure (BP) were evaluated for their ability 
to predict actual CVE occurring after kidney txp. Pts with coronary artery 
disease (CAD) were excluded from the FRS analysis. CVE were defi ned as 
sudden death, myocardial infarction, angina, and cerebrovascular accident/
transient ischemic attack. FRS factors were evaluated by Cox proportional 
hazards in univariate (UVA) and multivariate (MVA) models. 
Results: 693 renal txp pts were evaluated from 1997-2007. Demographics 
and FRS data are presented in Table 1. Mean follow-up was 1420 ± 958 days. 
123 patients (18%) experienced a CVE PTx. FRS decreased signifi cantly 
from preTx to 7 yrs PTx (p<0.05). FRS was signifi cantly correlated with CVE 
(p< 0.01) in the UVA model. MVA results for individual FRS factors are in 
Table 2.
Table 1:
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 n=693
Male 56%
African American 23%
Mean Age 47.9 ± 12.7
Pretxp CAD 12.3%
Pretxp FRS (% 10 Yr Risk) 8.1 ±7.3
FRS 1 Yr (% 10 Yr Risk) 7.8 ±7.2
FRS 2 Yr (% 10 Yr Risk) 8.2 ±6.8
FRS 3 Yr (% 10 Yr Risk) 7.1 ±6.1
FRS 5 Yr (% 10 Yr Risk) 7.6 ±6.2
FRS 7 Yr (% 10 Yr Risk) 7.2 ±5.8
Table 2:
MVA of CVE Odds Ratio 95% Confi dence Interval p
SBP>160mmHg 4 1.03 - 15.4 0.04
DM 3.5 2.1 - 5.7 0.0001
Smoking 2.4 1.4 - 4.06 0.002
TC>240mg/dL 2.3 1.06 - 5.07 0.04
HDL>40mg/dL 0.6 0.34 - 0.93 0.03
Conclusions: Individual component risk factors of the FRS were each 
demonstrated to be statistically signfi cant predictors of CVE in kidney txp pts. 
This study presents the fi rst correlation of FRS with actual CVE data collected 
prospectively in kidney txp pts.
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TRADITIONAL VERSUS NONTRADITIONAL RISK 1408 
FACTORS FOR CARDIOVASCULAR EVENTS IN KIDNEY 
TRANSPLANT RECIPIENTS
E.S. Woodle1, A.H. Rike1, J. Everly1, R.R. Alloway1, G. Mogilishetty1, 
M. Cardi2, M. Clippard, R. Munda1
1University of Cincinnati, 2The Christ Hospital
Background: The Framingham risk score (FRS) has underestimated 
cardiovascular (CV) risk in renal transplant (txp) patients (pts). Evaluation 
of additional factors may provide a means for enhancing risk prediction. The 
purpose of this study was to evaluate FRS and other txp-related factors for 
observed CV events (CVE) in kidney txp pts. 
Methods: CVE data is regularly updated in our cardiovascular risk database. 
CV risk factors (renal function (fxn), pretxp coronary artery disease (CAD), 
diabetes mellitus (DM), acute rejection (AR), blood pressure (BP), lipids, and 
corticosteroids (CS)) are assessed at baseline, 6 mths, and yearly posttransplant 
(PTx). FRS factors included age, sex, smoking, DM, high density lipoprotein 
(HDL), total cholesterol (TC), and blood pressure (BP). Renal function was 
assessed using MDRD equation. HF events were defi ned as pulmonary edema or 
clinical HF diagnosis. CVE included sudden death, myocardial infarction (MI), 
angina/unstable angina or cerebrovascular accident (CVA)/transient ischemic 
attack (TIA). Statistical analyses included Chi square, Student’s t-test, Univariate 
(UVA) and multivariate analyses (MVA) using Cox proportional-hazards.
Results: Data from 693 pts were analyzed. 471 pts received early CS withdrawal 
(ECSWD) (≤7 days) and 222 pts received chronic CS (CCS). Overall, 123 pts 
(17.7%) experienced a CVE PTx. Mean follow-up in all patients was 1420 ± 
958 days. Demographics included: 56% male, 23% African Americans, and 
mean age 47.9 ±12.7 yrs. In the MVA for HF events, patients with DM were 
2.8 times more likely to have a HF event (p<0.04). In the UVA for CVE, FRS, 
DM, CAD, MDRD, CS, smoking, AR, high-density lipoprotein (HDL), and BP 
were signifi cant. However, in the MVA for CVE, only CS, DM, and HDL were 
signifi cant (Table).
MVA for CVE
 Odds Ratio p
Chronic CS 2.7 <0.001
DM 2.8 <0.001
HDL 0.97 0.02
Conclusions: Strongest predictors of CVE included CCS, HDL, and DM. 
Other factors, including FRS, acute rejection, MDRD, BP, preTx CAD, and 
smoking were predictive only in the UVA. Since FRS does not include CS 
therapy, incorporating CS therapy as a risk factor may improve the predictive 
ability of FRS in the renal txp population.
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RELATIONSHIP BETWEEN ARTERIAL STIFNESS, 1409 
CARDIOVASCULAR DISEASE AND METABOLIC 
ALTERATIONS AFTER KIDNEY TRANSPLANTATION
L. Locsey1, L. Szabo2, R. Fedor2, A. Dan1, L. Asztalos2
1B.Braun Avitum 10AKD, 2I.Surg.Dept.DEOEC ,Univ.Debrecen
The arterial stiffness is an independent predictor cardiovascular risk fac tor,the 
associated aging,hypertension and cardiovascular disease.The aug- mentation 
index (AIx)and pulse wave velocity (PWV) are early markers for atherosclerotic 
vascular changes.We examined 81 males ,64 females (45,3+/- 11,2 ys)renal 
transplanted pts,measured systolic,diastolic blood and pulse pressure (PP)and 
AIx ,PWV with TensioClinic(TensioMed) arteriograph and cardiovascular risk 
was assessed by echocardiography and ultrasonography of carotid arteries.The 
thickness of left ventricular wall,the ejection frac- tion and stenosis of carotid 
arteries were measured.We investigated is fas-ting serum creatinine,cystatin 
C,homocysteine,CRP,iPTH ,lipids and CaxP le-vels. The serum cystatin C was 
2,1+/-0,2 mg/l,homocysteine 15,2+/-2,6umol /l, with hypercholesterolaemia,high 
LDL and ApoB levels.After transplantation signifi cantly increased BMI,FM and 
VFA (p<0,01).The AIx increased 20% of men,and 37% of females (AIx <10%).
PWV increased in 43% of men,34% of fema les (>10m/s).PP was pathological high 
12-12% of pts.The PWV was siginifi cantly related to age(r=0.52),thickness of the 
ventricular wall(r=0.46).PP ,BMI,systolic and diastolic blood pressure correlated 
positively but modestly with PWV.The was signifi cant relationship between AIx80 
and systolic (r=0.42),diastolic (r=0.39) blood pressure and PP (r=0.33).Ejection 
fraction negatively correlated with PWV and AIx.There was strong association 
between carotid arteries stenosis and PWV,AIx80.All pts with greater than 10m/s 
had carotid stenosis.The pathological high AIx80 (>10%) and PWV (>12m/s) 
can be found high BMI,FM,VFA and increased PP,systolic,diastolic blood 
pressure,MAP with dyslipidaemia ,high Ca x P (> 4,4),iPTH (>160 pmol/l).
The arteriograph an objective ,non-invasive ,convenient method for the early 
diagnosis and follow -up atherosclerosis.
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RELATIONSHIP BETWEEN VISCERAL FAT SURFACE 1410 
AND CARDIOVASCULAR COMPLICATIONS AFTER RENAL 
TRANSPLANTATION
L. Locsey1, B. Borbas1, B. Szlanka1, I. Menes1, A. Dan1, L. Szabo2, 
L. Asztalos2
1B.Braun Avitum 10AKD, 2I.Surg.Dept. DEOEC ,Univ.Debrecen
After renal transplantation signifi cant increased BMI ,FM .In chronic dialysed 
programme increased the aging ,accelarating atherosclerosis and malnourished 
complications. Aims of study: relationship between change of body different 
compartment (fat and water) and cardiovascular complications (blood and 
pulse pressure,cardiac events, arterial stiffness). We are investigated dialysed 
pts 79 males, 56 females (67,12 +/-7,26 years) and renal transplanted 81 
males, 64 females (45,51 +/- 11,27 years). Blood pressure and cardiac events 
measured with CardioTens (Meditech 04), arterial stiffness with arteriograph 
(TensioClinic-TensioMed). Bioimpedancia analysis (BIA) was performed 
with multifrequential BIA analyser (InBody 720 –BIOSPACE). We compared 
the LAP–lipid accumulation product–waist(cm) x serum triglyceride (mM/l) 
and waist/hip ratio in malnourished, and obes pts in dialysis programme and 
after renal transplantation. After renal transplantation cystatin C,homocysteine 
concentrations were 2,1 vs 5,2 mg/l and 15,21 vs. 23,78 umol/l. Dialysed pts have 
hypertriglyceridaemia, in transplanted pts were high hypercholesterolaemia, 
LDL and ApoB levels. In dialysis programme was 9,87% malnourished pts,with 
decreased FM (4,9-12,6kg), visceral fat surface area less --26,9 + 12,8 cm2 
than normal. In obes dialysed pts were 29,87%, increased FM (26,89 +/- 6,71 
kg), and VFA (92,78 –296,45cm2).Transplanted pts increased BMI, in 63,14% 
FM,VFA (98,67–278,14 cm2). LAP was 72,22 +/- 13,74 cm x mM/l (<21kg/
m2 BMI), and 227,15+/- 41,78 cm x mM/l (BMI >30kg/m2). In obes pts was 
frequently arythmia ,non dipper hypertension and negative diurnal index, and 
pulse pressure increased higher (>70 mmHg) in 38% of dialysis pts ,and 24% of 
transplanted pts. The augmentations index (AIx) increased in dialysed female 
60%, after transplantation only 18% (> 10%).The pulse wave velocity (PWV) 
was higher in dialysed males 25%, after transplantation 10% (> 12m/s). In obes 
pts increased signifi cantly BMI ,FM and VFA,with increased LAP and waist/
hip ratio increased blood and pulse pressure with cardiac events.
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LIPIDEMIC PROFILING IN RENAL TRANSPLANT 1411 
RECIPIENTS. A PROSPECTIVE STUDY
M. Koukoulaki1, D. Pistolas1, K. Balaska1, T. Apostolou1, C. Vlachopoulos2, 
E. Kyristi1, V. Hadgiconstantinou1, C. Stephanadis2, S. Drakopoulos1
1Transplant Unit, Evangelismos General Hospital of Athens, Greece, 21st 
Department of Cardiology, University of Athens, Hippokrateio General 
Hospital of Athens, Greece
Introduction: Immunosuppression has a direct impact on lipidemic profi ling 
of renal transplant recipients that affects in the long term the cardiovascular 
risk. Atherosclerosis is a systematic disease of the vessels and patients with a 
single clinical manifestation of atherosclerotic lesions have increased risk of 
identifi cation of atherosclerotic lesions at multiple sites.
Patients and methods: We studied 50 patients, non-diabetic, with end-stage 
renal disease who received a renal allograft. 37 were male and 13 female of 
mean age of 47.5±9.7 years old. Triplex ultrasonography of carotic arteries was 
performed prior to transplantation and one year later. Parameters of lipidemic 
profi ling were also monitored before transplantation, and subsequently 
on the fi rst, third, sixth and twelfth month post-renal transplantation. 
Immunesuppressive protocol included induction therapy and triple regimen 
with calcineurin inhibitor, mycophenolate mofetyl and corticosteroids. 
Recipients were not administered statins or other lipid lowering drug.
Results: Cholesterol, HDL and triglycerides present statistically signifi cant 
increase post transplantation (one way ANOVA, P<0.001) (table). Mild 
atherosclerotic lesions at carotid arteries were found in 50% of renal transplant 
recipients prior to transplantation. One year post-transplantation, 18% of renal 
graft recipients did not present atherosclerosis, 54% had mild atherosclerotic 
lesions and 28% present signifi cant stenosis. Statistical analysis showed 
signifi cant change of carotid stenotic lesions (paired t-test, p=0.0013).
Conclusions: In this study it was shown that the majority of renal transplant 
recipients during the fi rst post-transplant year presented mild or signifi cant 
atherosclerotic lesions at the carotid arteries which represented extensive 
atheromatosis including coronary arteries and increase of cardiovascular risk.
Month 0 3 6 12
Cholesterol 169.56±44.04 211.46±44.22 201.56±35.29 198.64±41.05
HDL 44.2±11.28 52.12±13.29 53.0±14.42 54.84±16.25
Triglycerides 144.2±9.82 182.58±8.28 175.36±9.71 147.76±7.77
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PREOPERATIVE CARDIOVASCULAR SCREENING 1412 
PROVIDES NO SURVIVAL BENEFIT FOR PATIENTS PLACED 
ON THE RENAL TRANSPLANT WAITING LIST
R.K. Patel1, P.B. Mark1, N. Johnston2, R. McGeoch2, M. Lindsay2, H. Dargie2, 
A.G. Jardine1
1BHFGCRC, University of Glasgow, Glasgow, UK, 2Department of 
Cardiology, Western Infi rmary, Glasgow, UK
Purpose: Premature cardiovascular (CV) death is increased in patients with 
ESRF. The benefi ts and predictive value of pre-transplant cardiac assessment 
and intervention remain uncertain. We therefore examined its the importance 
on clinical outcome.
Methods: We prospectively examined 300 patients with ESRF who underwent 
pre-transplant cardiac investigation with ECG, standard Bruce exercise testing 
(ETT) and cardiac MRI to assess left ventricular dimensions. Patients with 
high index of suspicion of coronary artery disease (CAD) underwent coronary 
angiography and percutaneous coronary intervention (PCI) if indicated.
Results: Of the 222 patients accepted onto the renal transplant waiting list; 
80 patients were transplanted during the follow-up period and 31 died (7 
following transplantation). Successful transplantation was associated with 
improved survival (transplanted mean survival 4.50.6 years vs not transplanted 
4.11.4 years; p<0.0001). 74 patients of wait listed patients underwent coronary 
angiography; 56 (25.2%) had no or mild CAD and 18 (8.1%) signifi cantly 
obstructive CAD. 15 patients (6.8%) were treated by PCI. There was no 
apparent survival difference between patients who underwent PCI or CABG 
(n=15), compared to those who underwent angiography without intervention 
or no angiography (p=0.90; Figure 1) despite higher perceived risk of CAD 
in patients referred for angiography based on clinical history and non invasive 
test results. For patients placed on the transplant waiting list, univariate Cox 
regression analyses demonstrated older age at screening, past medical history of 
IHD, cerebral vascular disease (CeVD) or hypertension and ETT performance 
as factors signifi cantly associated with death. Multivariate analysis revealed 
older age, history of diabetes, IHD and CeVD and ETT performance as 
independent predictors of death.
Conclusion: Pre transplant CV screening provides prognostic information for 
patients placed on the renal transplant waiting list. However, if the aim is to 
identify and treat CAD, it provides no benefi t.
Figure 1
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ISCHEMIC HEART DISEASE (IHD) IS THE MAJOR 1413 
CAUSE OF DEATH IN RENAL TRANSPLANT RECIPIENTS
I. Kim, V. Chestuhin, B. Mironkov, M. Gontuar, N. Tomilina
Research Institute of Transplantology And Artifi cial Organs
The aim of this study was to determine the prevalence and risk factors of 
IHD, its infl uence on the outcome of renal transplantation and the effi cacy of 
coronary revascularization.
We analyzed the data of 479 renal transplant patients (males- 332, females- 
147, age 38,69 ±11,2 years). The follow-up period was 72,78 ± 46,72 mo after 
transplantation. Diabetes mellitus was found in 68 recipients. Multivariate 
analysis was used to estimate the independent relation between IHD and its 
risk factors.
IHD was present in 14,8% of all patients (71 from 479); in 12,7% recipients it 
was found de novo during 32,4 ±18 mo after transplantation. 10-year patient 
survival rate was 39% in IHD group and 75% in patient without coronary 
artery disease (p<0,0001). Age>45 year, gender, diabetes, hyperlipidemia, 
infections, left ventricular hypertrophy and renal transplant dysfunction were 
defi ned as risk factors of de novo IHD. Coronary artery disease was found to 
be independently associated only with age (p<0,009), gender (p<0,00001) and 
hyperlipidemia (p<0,0058).
34 renal transplant recipients with IHD were undergoing percutaneous 
transluminal coronary angioplasty (PTCA) with stenting and 2- coronary artery 
bypass grafting (CABG). Follow-up after revascularization was 23mo (2 to 
74). 7 PTCA-treated patients required subsequent revascularization during 3-6 
mo. All of them had coronary stenting with bare metal stents. Long-term effect 
(>12 mo) was defi ned in 71% patients. There was only one case of myocardial 
infarction after revascularization. 1 recipient died of cardiac failure during 38 
mo after repeated revascularization. 3 PTCA-treated patients died after 28, 96 
and 146 mo of oncology, hepatic cirrhosis and cerebrovascular disease. 8-year 
patient survival rate was 91% in CABG- and PTCA- treated group and only 
38% in patients with usual course of IHD (p<0,0001).
Conclusion: IHD is found in 14,8% of renal transplant recipients and in 
12,7% patients it was defi ned as de novo disease. Coronary heart disease is 
independently associated with age>45 year, gender and hyperlipidemia. 
Coronary revascularization may be used as effective method of management in 
renal transplant recipients with IHD.
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ENDOVASCULAR REPAIR AS FIRST-CHOICE 1414 
TREATMENT OF ABDOMINAL AORTIC ANEURYSM IN 
KIDNEY TRANSPLANT RECIPIENTS
J. Szmidt1, Z. Galazka1, O. Rowinski2, T. Jakimowicz1, L. Romanowski
1Department of General, Vascular And Transplant Surgery, Medical 
University of Warsaw, Poland, 22nd Department of Radiology Medical 
University of Warsaw, Poland
Improved long term survival of kidney transplant recipients contributed to 
increase number of incidence of abdominal aortic aneurysm (AAA) in this 
group of patients. Open aneurysmectomy is technically diffi cult and burdened 
with high risk of ischemic injury to transplanted kidney upon cessation of 
aortic blood fl ow.
The aim of the study was to present results of endovascular AAA exclusion by 
stentgraft implantation in patients after kidney transplantation.
In our Department since 1998 593 patients with AAA were treated 
endovasculary. In this group eight (1,34%) were kidney transplant recipients. 
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Time between kidney transplantation and AAA management was from 3 to 19 
years. In 5 patients graft’s renal artery was anastomosed in end-to-end fashion 
to hypogastric artery, in remaining patients end-to-side to external iliac artery. 
Aneurysm diameter were 50 mm to 76 mm. Commercial bifurcated stentgrafts 
were used (Zenith, Excluder and PowerLink). All procedures were performed 
under epidural anaesthesia. All patients were followed-up with CT-scan 
performed postoperatively, in 3-rd, 6-th, 12-th month and annually thereafter 
according to Eurostar protocol. Kidney function was assessed two times a year.
Successful AAA exclusion (without any endoleak) and preserved fl ow to 
transplanted kidney was confi rmed on completion angiogram in all patients. 
Temporary deterioration of transplanted kidney function was observed in two 
patients, one of them required transient haemodialysis. In follow-up there was 
one stentragft limb thrombosis contralateraly to transplanted kidney in 9-th 
month after stentgraft implantation that required femoro-femoral by-pass. 
In one patient there was endoleak type I treated successfully with proximal 
extension. The mean observation period was 33 months (range 9-68 months).
Endovascular treatment of AAA in kidney transplant recipients is safe and effective 
method and can be performed without serious impairment of graft function.
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OUTCOME OF KIDNEY TRANSPLANTATION IN 1415 
PATIENTS WITH TYPE 2 DIABETES MELLITUS: IMPACT OF 
ROUTINE PRE TRANSPLANT CORONARY ANGIOGRAPHY 
AND REVASCULARIZATION
S. Gang, B. Kalani, K. Gohel, U. Hegde, M. Rajapurkar
Muljibhai Patel Urological Hospital
Introduction: Coronary artery disease (CAD) is the leading cause of morbidity 
and mortality in type 2 diabetic patients undergoing renal transplantation. These 
patients have a high incidence of silent CAD. We wanted to investigate the outcome 
of type 2 diabetic patients who had undergone routine coronary angiography 
prior to transplantation and if deemed necessary coronary revascularization.
Methods: Between March 2002 and May 2007, 46 type 2 diabetic patients 
underwent living donor kidney transplantation. There pre transplant work 
included dobutamine stress echocardiography and coronary angiography. 14 
patients (8 coronary artery bypass grafting and 6 percutaneous interventions) 
underwent coronary interventions prior to transplantation. Mean age was 50.5+ 
5.7 years and 89% were males. Mean follow-up since kidney transplant was 
28.8 + 20.1 months.
Results: 1, 3 and 5 year graft survival in patients who did and did not undergo 
pre transplant revascularization was 92%, 78%, 78% and 87%, 71%, 68% 
respectively. The patient survivals in these groups were 92%, 78%, 78 and 
90%, 75%, 71% respectively. The cause of death was sepsis in 7, cardiovascular 
disease in 6 and pancreatitis in 1.
Discussion: Routine coronary angiography in type 2 diabetic patients shows 
high incidence of silent CAD. Pre transplant coronary interventions possibly 
offer an opportunity to transplant these patients. Limitation of this study is that 
there is no control arm that was medically managed.
Conclusion: Type 2 diabetic patients can undergo successful kidney 
transplantation after pre transplant coronary revascularization.
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EZETIMIBE IS EFFECTIVE IN THE TREATMENT 1416 
OF PERSISTENT HYPERLIPIDEMIA OF RENAL ALLOGRAFT 
RECIPIENTS
E. Savvidaki, A. Benou, M. Roumeliotou, K. Fourtounas, P. Kalliakmani, 
E. Papachristou, D. Goumenos, J.G. Vlachojannis
University Hospital of Patras
Introduction: Ezetimibe is a hypolipidemic agent acting via inhibition of 
cholesterol absorption from small intestine. The effectiveness and safety 
of long-term administration of ezetimibe was estimated in renal allograft 
recipients with persistent hyperlipidemia.
Materials and methods: Sixty-seven renal allograft recipients with post-
transplantation hyperlipidemia resistant to statins were included in the 
study. All patients were treated by ezetimibe (10mg/day) alone (n=11) or in 
combination to statins (n=56). The effectiveness of the drug was estimated 
by determination of total cholesterol (TC), LDL cholesterol (LDL-C), HDL 
cholesterol (HDL-C) and triglycerides (TR), whereas its safety by determination 
of liver enzymes (ALT, AST), LDH, CPK, serum creatinine and blood levels of 
immunosuppressive drugs (cyclosporine, tacrolimus, everolimus, sirolimus), 
over the follow-up period of 18 }6 months.
Results: A signifi cant reduction of TC and LDL-C blood levels by 25% 
and 34% respectively was observed during the fi rst month of treatment with 
ezetimibe (TC: 230 }34 ¨172 }29 mg/dl and LDL-C:147 }25 ¨87 }22 mg/dl) 
(p<0.001). Although the TC and LDL-C blood levels of patients on ezetimibe 
monotherapy showed the same degree of reduction, they remained well above 
target levels. The renal function of all patients remained stable over the follow-
up period (Cr: 1.7 }0.5 ¨1.5 }0.5mg/dl), whereas no changes on the blood 
levels of immunosuppressive drugs were observed. The liver enzymes, LDH 
and CPK remained normal in all patients apart from a diabetic patient who 
developed rabdomyolysis. Apart from gastrointestinal symptoms in 2 patients, 
no other side - effects were observed.
Conclusion: Combination of ezetimibe with statins represents an effective and safe 
regimen for treatment of persistent hyperlipidemia of renal allograft recipients.
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48 MONTHS RESULTS OF A SPANISH MULTICENTRE 1417 
DATABASE: LEADING CARDIOVASCULAR DISEASE AFTER 
RENAL TRANSPLANTATION
B. Dominguez-Gil , J.M. Morales1, R. Marcén2, D. Del Castillo2, 
M. González-Molina2
1Hospital Universitario 12de Octubre, Madrid, Spain, 2Grupo Forum Renal
With the aim to evaluate cardiovascular disease after kidney transplantation 
(KTx) patients in Spain in the actual immunosuppressive era.
Methods: We analyzed the results of 2600 KTx patients during years 2000-2002 
in 14 Spanish units, most of them, from cadaveric donors.
Results: Donors and recipient age were 46.9 ± 17 and 49.7 ± 13.7 years, 
63% men, 16% were retransplanted and 12.5% hyperimmunized. The most 
frequent immunosuppressive protocol was Tac+MMF+St. Acute rejection 
rate at 1 year was 14.8%. Graft survival at 48 months was 85.6% (death 
censored), and 80.7% (death non censored). The fi rst cause of graft loss 
was death with functioning graft during the fi rst three years, and chronic 
allograft nephropathy at the 4th year. Mean serum creatinine was 1.57mg/
dl during the fi rst three years 1-3 and 10.83 mg/dl at the fourth year. Mean 
proteinuria was 0.4 g/d at the 1st year, 0.5 g/d at the 2nd and 3rd year 
and 1.27 g/d at the 4th year. 12.7% of patients had proteinuria at month 
48. Patient survival at four years was 91.7%.The fi rst cause of death 
was cardiovascular disease (specially, IHD and PAD) at 1st, 2nd and 3rd 
year (36, 36.7 and 39.4%). Cox regression analysis showed that time on 
dialysis (HR=1.96, CI=1.24-3.10, p=0.004) and renal function impairment 
(HR=1.52, CI=1.30-179, p<0.0001) were independent risk factors for graft 
loss at 4th year. Moreover, multivariate analysis showed that recipient age 
was the most important predictor of mortality (HR=2.5, CI=1.72-3.78, 
p<0.0001) whereas acute tubular necrosis (HR=1.5, CI=1.07-2.36, p=0.02) 
and renal function impairment (HR=1.3, CI=1.11-1.53, p=0.001) where 
other independent risk factors.
Notably, the use of statines at 12 months was a protective factor for patient 
survival at 48 months (HR=0.48, CI=0.28-0.83, p<0.001).
Conclusion: Death with functioning graft was the main cause of graft loss 
during the fi rst three years after transplantation in Spain. Nevertheless, at the 4th 
year chronic allograft nephropathy was the leading cause of graft loss. Despite 
of the age of recipients, patient survival was excellent. The most important 
cause of death was cardiovascular disease. Recipient age and concomitant 
pathology at the moment of transplantation could be related to these results. 
Therefore, in this way it would confi rm that the statines could be useful. It is 
necessary to make a big effort to control cardiovascular risk factors, before and 
after transplantation.
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ADDITION OF SPIRONOLACTONE TO DUAL 1418 
BLOCKADE OF RENIN ANGIOTENSIN SYSTEM (RAS) 
DRAMATICALLY REDUCES SEVERE PROTEINURIA IN 
RENAL TRANSPLANT PATIENTS: AN UNCONTROLLED 
PILOT STUDY AT SIX MONTHS
E. Gutierrez, J. González, E. Ramirez, E. Merida, M.J. Gutierrez, 
E. Morales, M. Praga, A. Andres, J.M. Morales
Nephrology Department, Hospital 12de Octubre, Madrid, Spain
Background: Experimental and clinical data strongly suggest that aldosterone 
may contribute to proteinuria and progressive renal disease. In fact, antagonist 
of aldosterone seems to be effective controlling proteinuria in native kidneys. 
However there is no information in renal transplant patients a population in 
whom the presence and the amount of proteinuria are risk factors for graft loss, 
cardiovascular disease and death.
The aim of the study was to evaluate if the addition of an antagonist of 
aldosterone, spironolactone, provide an additional antiproteinuric effect to 
the angiotensin converting enzyme inhibitor (ACEI) and angiotensin type 1 
receptor antagonists (ARB).
Methods: We evaluate in 9 renal transplant patients (serum creatinine < 3 mg/
dl) the six-month effects of spironolactone (25 mg/d) on severe proteinuria in 
spite of the treatment with ACEI (Enalapril or captopril) plus ARB (Losartan 
or Valsartan). Patients also received cation-exchange resins and they were 
carefully controlled (mainly renal function and serum potassium) in the renal 
transplant outpatient clinic, every week in the fi rst month and twice a month 
thereafter.
Results: The most important data are showed in the [table 1]
The reduction in proteinuria (in seven patients more than 50%, mean 61.6%)) 
was early and sustained at six months with mild non-signifi cant deterioration of 
renal function. Notably, nobody presented severe hyperkalemia.
Conclusions: This pilot study demonstratred that Spironolactone dramatically 
decreased severe proteinuria in patients treated with ACEI plus ARB without 
signifi cant changes on renal function or serum potassium. Therefore, it suggest 
that triple blockade of RAS is feasible in selected renal transplant patients to 
reduce proteinuria, although caution to avoid severe hyperkalemia is required. 
Finally, prospective and randomized studies testing the use of Spironolactone 
with or without ACEI /ARB after renal transplantation are mandatory.
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STATIN THERAPY AND CORTICOSTEROID 1419 
THERAPY IN KIDNEY TRANSPLANTATION: EFFECTS ON 
CARDIOVASCULAR EVENT AND DEATH RATES
E.S. Woodle, R.M. Lee1, A.H. Rike2, R.R. Alloway1, J.J. Everly1, A. Govil1, 
J. Durbin2, 
1Surgery, U Of Cincinnati, 2Christ Hospital
Body: Statin therapy has previously been shown to reduce acute rejection (AR) 
risk in cardiac transplant (txp) recipients. Moreover, statin therapy also reduces 
risk for cardiovascular events (CVE) in the general population. The purpose of 
this study was to evaluate the effects of statin therapy on AR, CVE, and patient 
survival in kidney txp recipients.
Methods: Patients were categorized based on statin therapy post-txp versus 
no statin therapy. Univariate analysis (UVA) and multivariate analysis (MVA) 
were conducted by stepwise logistic regression (STATA v9.2) to determine 
signifi cant risk factors for AR, CVE, and patient (pt) survival. Kaplan Meier 
time to event analysis was conducted for overall pt survival and CVE rates.
Results: 638 renal txp pts were analyzed from 1997-2007 (46% received statin 
therapy v. 54% with no statin therapy). Demographic data (not shown) and 
AR rates were similar between groups. Statin therapy post-txp was associated 
with increased pt survival (95% versus 90%, p < 0.02). CVE occurred 
signifi cantly less in pts on statin therapy versus those not on statin therapy 
(p < 0.05). There was no difference in infectious complications between the 
groups. Individual risk factors for CVE evaluated by UVA and found to be 
insignifi cant included: current PRA > 25%, HDL < 40 mg/dL, AA recipient 
race, age and gender. Signifi cant factors for CVE on UVA that entered the MVA 
model included: pre-txp diabetes (DM), statin therapy, repeat txp, deceased 
donor (DD), corticosteroid therapy (CS), and DR mismatching > 0. Factors 
that were signifi cant in the fi nal model included: DM (OR 3.2, CI 2.0-4.9) 
and CS (OR 3.2, CI 2.0-4.9. (table below). Signifi cant factors for pt survival 
on UVA that entered the MVA model included: pre-txp DM, statin therapy 
group, DD, CS, delayed graft function, and DR mismatching > 0. Factors that 
were signifi cant in the fi nal model included: DM, male gender, and CS. Statin 
therapy approaches signifi cance in the fi nal multivariate model for decreasing 
the risk of CVE (p=0.07) and death rates (p=0.08).
 Statin Therapy (n=293)
No Statin Therapy 
(n=345) p value
Mean Length of Follow Up (Days) 1282±779 1603±1040 <0.01
AR Rate 13% 12% 0.70
CVE Rate 15% 21% 0.05
Overall Pt Survival 95% 90% 0.02
MVA for CVE
Odds Ratio 95% Confi dence Interval
Pretxp DM 2.8 1.8-4.3
CCS 3.2 2.0-4.9
Conclusion: This analysis indicates that CS therapy increases CVE and death 
rates. Statin therapy offers a means for reducing cardiovascular risk in patients 
receiving corticosteroids.
Kaplan Meier Estimates for Time to CVE Stratifi ed by Statin Use and 
Steroid Group
POSTER BOARD NUMBER P2 – 219
EFFICACY AND SAFETY OF VYTORIN FOR 1420 
THE TREATMENT OF DYSLIPIDEMIA IN RENAL 
TRANSPLANT PATIENTS
H.E. Yoon, B.J. Hyoung, S.Y. Lee, H.S. Hwang, Y.J. Jeon, B.S. Choi, 
Y.S. Kim, B.K. Bang, C.W. Yang
Kangnam St Mary’s Hospital, The Catholic University of Korea
Background: Dyslipidemia affects the majority of renal transplant patients, 
and is associated with cardiovascular events and premature graft loss. Despite 
of treatment with statin, many patients do not achieve the target goal of LDL-
cholesterol and need additional lipid-lowering agents. Ezetimibe/simvastatin 
(Vytorin) is a dual cholesterol-lowering therapy that inhibits the intestinal 
absorption (ezetimibe) and synthesis (simvastatin) of cholesterol.
Methods: The effi cacy and safety of ezetimibe/simvastatin in renal transplant 
patients with dyslipidemia were assessed in an open-label, nonrandomized, 
prospective study. Seventy-fi ve renal transplant patients received the combination 
tablet of ezetimibe 10mg and simvastatin 10mg daily. Concentrations of 
fasting lipid panels, liver enzymes, serum creatinine, and C-reactive protein 
(CRP), protein-creatinine ratio from a random urine sample (UPC), and trough 
concentrations of cyclosporine (CsA), tacrolimus (FK506) or sirolimus (SRL) 
were measured before and after the initiation of ezetimibe/simvastatin.
Results: 60 patients (80%) showed good compliance on ezetimibe/simvastatin 
for 60 days (range 20-76). The concentrations of total cholesterol, triglycerides 
and LDL-cholesterol decreased signifi cantly by 33.2%, 25.9%, and 47.1% 
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respectively. There were no signifi cant changes in the concentration of HDL-
cholesterol, liver enzymes, serum creatinine and CRP, UPC, and trough 
concentrations of CsA, FK506 or SRL. Eight patients (10.7%) stopped 
ezetimibe/simvastatin because of myalgia, two patients (2.7%) because 
of elevated concentration of liver enzymes, two patients (2.7%) because of 
dizziness, and one patient (1.3%) because of skin rash.
Conclusions: The ezetimibe/simvastatin combination therapy is safe and 
effective for the treatment of dyslipidemia in renal transplant patients without 
changes in the concentration of immunosuppressants or renal allograft function.
POSTER BOARD NUMBER P2 – 220
EZETIMIBE TREATMENT AS A GREAT TOOL 1421 
FOR CONTROL OF HYPERLIPEMIA IN RENAL TRANSPLANT 
RECIPIENTS
A. Sanchez-Fructuoso2, I. Perez-Flores1, N. Calvo3, 
M.A. Moreno de la Higuera4, M. Giorgi5, S. Anaya6, A. Barrientos7
1Hospital Clinico San Carlos, 2Hospital Clinico San Carlos, 3Hospital Clinico 
San Carlos, 4Hospital Clinico San Carlos, 5Hospital Clinico San Carlos, 
6Hospital Clinico San Carlos, 7Hospital Clinico San Carlos
Aims: To evaluate the effi cacy and safety of ezetimibe as monotherapy 
or combined treatment for hyperlipemia in renal transplant recipients. To 
investigate the effect of ezetimibe in the infl ammation state and the ability to 
modify levels of proinfl ammatory lipoproteins in these patients.
Methods: One hundred and forty patients who received ezetimibe during 
six months at least in our renal transplant unit were included. Fasting lipid 
profi le [total cholesterol (TC), low-density lipoproteins (LDL), high-density 
lipoproteins (HDL), triglycerides (TG), apolipoprotein B (apoB) and 
apolipoprotein A1 (apoA1)], immunosuppressive therapy, infl ammation state 
[C-reactive protein (CRP)], body mass index (BMI), patient demographics 
[age, sex, left ventricular hypertrophy (LVH), diabetes mellitus], fasting 
glucose, renal function (serum creatinine and urea, creatinine clearance), 
creatinine kinase (CK), liver function test were collected pre- and three, six 
and twelve months post-ezetimibe therapy.
Results: Twenty-four patients (20%) were on ezetimibe after statins withdrawing 
due to adverse reactions and 112 renal transplantation received ezetimibe after 
failing statins in control of fasting lipid profi le according to NCEP III lipid 
guidelines were included. The average age was 53 years (range 25-77) and 
66% were male. Main comorbid conditions were: DM 12%, LVH 68%, cardiac 
disease 18%, hepatic disease 15% and chronic obstructive lung disease 14%. 
The maintenance immunosuppression was: tacrolimus 45%, cyclosporine 
25% and inhibitors mTOR 30%. The average serum creatinine was 1.5 mg/
dL and calculated GFR by Cockcroft –Gault was 53 ml/min. There was a 
positive correlation between apoB and CRP in all patients (r 0.42, p<0.0001). 
Seven patients (5%) received combined treatment had to be discontinued 
due to adverse event (myalgias with elevations CK in 5, diarrhea in 1 and for 
elevated cost in 1). There were no differences in serum levels of CRP pre- y 
post-ezetimibe. We did not fi nd any relationship between immunosuppression 
drugs type and levels and the ezetimibe.
Basal 3m 6m p
TC C
 A
231±50
239±45
177±37*
203±33
179±42*
180±38**
<0.0001*
0.001**
HDL C
 A
61±19
54±15
56±15
51±14
54±16*
50±13**
<0.0001*
0.008**
LDL C
 A
133±42
144±40
93±37*
114±34
93±37*
97±32**
<0.0001*
0.001**
TG C
 A
211±125
212±73
163±71*
186±80
161±79*
156±76**
<0.0001*
0.020**
ApoA1 C
 A
160±38
154±33
155±34
153±32
155±34
146±28
0.090
0.225
ApoB C
 A
114±26
122±26
91±27*
102±21
93±24*
94±24**
<0.0001*
0.004**
A/C: alone/combined with statins. Basal: pre-ezetimibe. 3m and 6m: 3 
and 6 months post-ezetimibe.
Conclusions: Ezetimibe is a safe and effective therapy for dyslipemia 
in renal transplantation. It improves lipid profi le at 3 and 6 months 
post-treatment in combined therapy with statins and at six months in 
monotherapy. Ezetimibe decreases the apoB too, a proinfl ammatory, but 
no modifi es the serum CRP.
POSTER BOARD NUMBER P2 – 221
IMPORTANCE OF WAIST/HIP (W/H) RATIO 1422 
EVALUATION IN RENAL TRANSPLANTED PATIENTS
M.F. Taylor, L.M. Obregón, H. Petrone, M. Barán, M.E. Menna
CRAI Sur CUCAIBA
Objectives: Evaluate the importance of W/H ratio measurement in renal 
transplanted patients.
Materials and methods: patients that followed the following inclusion criteria 
were evaluated: more than 6 months since transplant, stable renal function 
without rejection in the last 90 days, without hospitalization,infectious episodes 
or complications, without diabetes diagnosis before or after transplant, by 
fasting glucemia, women that were not pregnant who agreed to participate in 
the study. Clinical data (age, smoking, time since transplant, donant type, sex, 
waist circumference, w/h ratio, BMI and steroids dose) were considered. An 
oral glucose tolerance test (OGTT) was performed, an overnight fasting plasma 
glucose level, creatinine and insulin determinations, HbA1c. A retrospective 
analysis of values was carried out. Patients were divided into two groups 
according to altered values in W/H ratio (Group I and group II). As reference 
values, we took into account WHO (World Health Organization). A value of 
p 0.05 was considered signifi cative. Chi square test and two tail student test 
were used.
Results: 31 patients were evaluated. 80.64% had increased W/H ratio (group 
I). This group presented signifi cantly higher values of glucemia in time 0 
and, after two hours in OGTT. We also observed BMI higher values. In the 
retrospective analysis of FPG values, greater frequence of altered FPG in group 
I. A correlation between W/H and FPG were observed. No differences were 
observed in age, smoking, time since transplant, donant type, sex, steroids 
dose, creatinine levels, fasting insulin determinations and HbA1c .
Conclusions: W/H ratio measurement is very simple and of great usefulness in 
renal transplanted population, specially in developing countries, such as ours, 
where it does not exist great availability for many laboratory determinations. 
This simple measurement is a good parameter to evaluate insuline resistence in 
this group of patients. Prevalence is very high and frequently infravalorated.
POSTER BOARD NUMBER P2 – 222
AMBULATORY BLOOD PRESSURE MONITORING 1423 
(ABPM) AND TARGET ORGAN DAMAGE IN KIDNEY 
TRANSPLANTATION
F. Margulis, R. Schiavelli
Servicio De Nefrologia Y Trasplante Renal, Hospital Argerich
The prevalence of hypertension in patients with kidney transplantation is highly 
elevated (60-80%). Several studies have demonstrated that ABPM is a useful, 
more advantageous and effi cient technique than the measurement of BP in the 
offi ce and correlates better with target organ damage. This is a useful technique 
too for the diagnosis of white coat hypertension (WCH).
For this reason we have made a retrospective study to evaluate the prevalence 
of hypertension and WCH, the changes in circadian rhythm and its possible 
relationship with target organ damage.
Material and methods: A total of 210 patients (127 males) mean age 39 ± 
13 years and mean serum creatinine 1,6 ± 0.5 mg/dl were analysed, they were 
assigned to immunosuppresant treatment with cyclosporin, mycophenolate 
mofetil and prednisone (n=136), tacrolimus, myco phenolate mofetil and 
prednisone (n=46), sirolimus and prednisone (n=21) and azathioprine and 
prednisone (n=7), all of them were studied by ABPM 33 ± 48 months after 
transplantation without any antihypertensive treatment. ABPM was recorded 
noninvasively with an Accutraker II over 24 hr on a regular working day.
Patients were defi ned as hypertensive (HT) when mean daytime BP was higher 
than 130/80 mmHg and non-dippers (ND) those patients whose mean sleeping 
BP was 10% less than mean walking BP or rose during sleep. Patients who had 
offi ce blood pressure greater than 130/85 and mean daytime BP lesser than 
130/80 mmHg was defi ned as WCH.
Trans-thoracic m-mode echocardiograms were performed by a single operator 
who was blinded to the other results. LV mass was calculated according to the 
Penn convention and corrected for body surface area to produce the LV mass 
index (LVMI).
Independent Student´s t or Mann-Whitney test were used and P values < 0.05 were 
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considered to be statistically signifi cant. Results are expressed as mean ± SD.
Results: WCH was found in 13% of transplant patients, the prevalence of HT 
has increased after transplantation (62% to 77%) and 57% of all transplant 
patients had alteration of circadian rhythm. The loss of circadian rhythm was 
seen in both HT (53%) and NT (71%).
The HT group had greater LVMI (160,7 ± 44 vs 140 ± 47 gr/m2 p< ,004) and 
lesser renal function (60,8 ± 17 vs 71,1 ± 22 ml/min p< ,0001) than NT group.
Signifi cant differences were found with respect to the alteration of circadian 
rhythm in relation to left ventricular mass index (LVMI) 162 ± 46 vs 146,1 ± 
34 gr/m2 (p< .01) and graft function 61,7 ± 16 vs 67,2 ± 19 ml/min (p< .03) 
between ND and dippers respectively.
When the relationship between alteration of circadian rhythm with LVMI and 
graft function were analyzed, we did not fi nd any signifi cant differences in the 
normotensive group but we did in the hypertensive one.
Conclusion: The prevalence of WCH in our patients was lesser than in general 
population and the ABPM was useful to defi ned the alteration of circadian 
rhythm and its relationships with organ damage in HT patients.
POSTER BOARD NUMBER P2 – 223
CARDIOVASCULAR RISK FACTORS AND THEIR 1424 
MANAGEMENT IN RENAL TRANSPLANT RECIPIENTS
X. He1, Y. Zhao1, A. Johnston1, I.A.M. MacPhee2 on behalf of the 
Pan-Thames Renal Audit Group
1Clinical Pharmacology, William Harvey Research Institute, Barts and the 
London School of Medicine and Dentistry, University of London, 2Cellular 
and Molecular Medicine: Renal Medicine, St. George’s, University of London
Background: The commonest cause of premature death in the renal transplant 
population is cardiovascular disease. This retrospective study aimed to identify 
conventional cardiovascular risk-factors and their modifi cation in a cohort of 
229 renal transplant recipients from a group of transplant units in a single city 
who were transplanted in 1999 with fi ve years of follow-up.
Methods: Data on all adult patients transplanted in the calendar year 1999 
were collected into an Access database by one clinical research nurse who 
visited all of the units. Cardiovascular risk factors at the time of transplantation 
were recorded with annual measures of blood pressure (mean of 3 values 
closest to annual review), lipid profi le and eGFR. A blood pressure standard 
of < 130mmHg/< 80mmHg was introduced by the UK Renal Association in 
2002. There are no formal standards for lipid management in renal transplant 
recipients so those used for the general population were employed.
Results: 23% had a previous cardiovascular event. Five year graft survival 
was 84% and death censored graft survival was 94%. Mean eGFR was 
around 50 mL/min/1.73m2 for the whole study period. Only 30-40% of 
patients achieved the target systolic blood pressure of <130 mmHg and fewer 
than 10% had diastolic BP <80mmHg. The mean number of antihypertensive 
agents was between 1.7 and 1.9. Use of ACE-inhibitors or Angiotensin-II 
receptor blockers and statins increased over the follow-up period. Mean 
blood pressure for 41 patients who were on no anti-hypertensive therapy was 
130±15/79±9mmHg. Only 8 (20%) had systolic pressure less than 130mmHg. 
The percentage of patients with total cholesterol < 5.0 mmol/L increased from 
45% to 70% over the follow-up period. Mean LDL was 2.8 mmol/L in 2000 
and 2.4 mmol/L in 2005. For the 75 patients not on lipid lowering therapy, 
TC at each visit were 4.8±0.9(2.5-7.6) mmol/L, 4.7±0.9(3.1-6.9) mmol/L, 
4.6±0.9(3.0-6.9) mmol/L, 4.6±0.9(2.5-7.0) mmol/L, 4.6±0.9(2.8-7.1) mmol/L 
and 4.6±0.9(2.1-6.9) mmol/L, respectively, with 30 (40%)having total 
cholesterol less than 5 mmol/L. Aspirin was prescribed for approximately 
30% patients.
Discussion: In this cohort, over 50% of patients failed to meet the Renal 
Association blood pressure targets in spite of a mean of around two 
antihypertensive agents per patient. This suggests that there is scope for 
increasing the number of agents in an attempt to reach targets in modifying 
conventional cardiovascular risk factors. In contrast, achievement of lipid 
targets through statin use was more successfully achieved.
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SUCCESSFUL RENAL TRANSPLANTATION AFTER 1425 
PERIPHERAL AND CEREBRAL VASCULAR DISEASE
J. Bittar, P. Arenas, C. Chiurchiu, W. Douthat, J. de Arteaga, J. de la Fuente, 
G. Paladini, R. Colla, P. Massari
Hospital Privado - Centro Medico De Cordoba
Pretransplant cardiovascular disease is a known risk factor for patients survival 
after renal trasnplantation. Patients with cardiac and peripheral vascular disease 
are frequently excluded from waiting lists. The post-transplant outcome in 
patients with cardiovascular disease (CVD) is not well know in South America. 
The purpose of this single center retrospective study was to compare patient 
and graft survival of patients with cardiac disease (CD) and patients with 
cerebrovascular and peripheral vascular disease (CPV) and indentify factors 
associated to CDV outocome. From a total of 758 renal transplants done from 
1986 to 2004, 19,39% (147) were identifi ed as CVD. Of them, 116 (78,9%) 
were CD and 31 (21,1%) were CPV. There were more diabetics in CPV (25,8% 
vs 8,6%) and predominantly male (87,9% vs 63,7%) than CD [p= 0,008 and 
p= 0,009]. Inmunosupression was based on CNIs and MMF in most cases.
The donors age were 35,7 15,1 years and 41,9 17,1 years in CD and CPV 
respectively (p= 0,05). Late acute rejection (> 6 months) were more frequent 
in CPV than CD: 6,4% vs 0,86% (p= 0,05) and they had more incidence of 
graft thrombosis: 9,6% vs 0,9% (p= 0,01) respectively. Patient survival for 1, 3 
and 5 years was 94,6%, 90,8% and 89,6% in control patients. Patient survival 
for 1, 3 and 5 years was 93,8, 92,6% and 92,6% in CD vs 72,6%, 72,6% and 
63,5% in CPV (p<0.001). Graft survival for 1 and 5 years was 83,8%, 69,2%. 
Graft survival at 1 and 5 years was 86,9% and 75,4% in CD vs 73,9% and 
61,6% in CPV (p=0,05). Sepsis was the main cause of death in both groups, 
but its prevalence was higher in CD: 75,0% vs 70,0% respectively (p=0,006). 
Cardiovascular death was 12.5% and 30% in CD and CPV respectively. 
Coxs multivariated analysis showed that recipient age [RR 1,10(1,04-1,16)]
(p=0,0003); CPV 1,83(1,56-1,94)](p=0,02) and serum creatinine at year [RR 
and [RR 3,20 (1,21-8,87)](p=0,003) were an independent risk factor for patient 
survival. Diabetes was not independently associated risk factor.This series 
shows that patients with pretrasplant heart disease have a similar outcome 
than controls in terms of patient and graft survival and that only those with 
previous clinically symptomatic peripheral and cerebrovascular disease have 
signifi cantly lower graft and patient survival.
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BLOOD PRESSURE CONTROL IN RENAL TRANSPLANT 1426 
PATIENTS: ARE WE AGGRESSIVE ENOUGH?
F. Vetromile2, P. Fesler1, I. Szwarc2, A. Mimran1, J. Ribstein1, G. Mourad2
1Department of Internal Medicine and Hypertension, CHU Lapeyronie, 
2Department of Nephrology, Transplantation And Peritoneal Dialysis, CHU 
Lapeyronie
Objective: In renal allograft recipients, best practice guidelines recommend 
target arterial pressure <130/80 mmHg. Whether these values are achieved in 
routine clinical practice is not known. The aim of this study was to analyze the 
prevalence and identify factors associated with the presence of hypertension (HT, 
≥; 130/80 mmHg) in a large cohort of patients followed annually in our center.
Methods: Blood pressure and renal function (glomerular fi ltration rate, GFR, 
urinary 99mTC-DTPA clearance) were evaluated in 456 subjects, 66% male, 
aged 51±12 yrs (mean ± SD) after a median follow-up period of 47 months 
(range 47-335) post fi rst-kidney transplantation (Tx).
Results: From the 456 subjects, only 33 (7.2%) were normotensive without 
any antihypertensive treatment, 97 (21.3%) had well-controlled HT and 325 
(71.5%) had uncontrolled HT. Among the 325 patients with uncontrolled HT, 
69 (15.1% of the whole population) had true resistant HT (at least 3 drugs 
including 1 diuretic) whereas 257 could not be considered as resistant HT 
since they received 2 or less antihypertensive drugs (1.3±0.8). AS compared 
to controlled HT, uncontrolled HT were slightly older (53±11 vs 50±12 yrs, 
p=0.026) had received grafts from older donors (45±16 vs 38±16 yrs, p=0.001), 
had lower GFR (51±21 vs 56±19 mL/min/1.73m²), and higher albuminuria (34 
vs 19 μg/mL, p<0.001 after log-transformation) and fasting blood glucose 
(5.85±2.61 vs 5.31±1.35 mmol/L, p=0.053). No difference was found for 
gender, duration of dialysis before TX, delay after Tx, steroïd doses or type 
of immunosuppressive treatment (cyclosporine vs tacrolimus). In multivariate 
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logistic regression analysis, using controlled HT as the reference category, the 
presence of resistant HT was independently associated with higher body mass 
index, albuminuria and higher donor age.
Conclusion: After kidney Tx, the main factor associated with persistent hypertension 
is the inadequation of antihypertensive therapy. However, obesity, albuminuria as 
well as older donor age are the main factors associated with true resistant HT.
POSTER BOARD NUMBER P2 – 226
CORRELATION OF PULMONARY HYPERTENSION 1427 
WITH EGFR, DIABETIES, SMOKING, HD, PD IN A COHORT 
OF RENAL TRANSPLANT RECIPIENTS FROM SOUTH INDIA
G. Abraham1, D. Lunawat2, M. Mathew2, N. Fathima2, S. Soundarajan2, 
V. Sundaram2
1Sri Ramachandra University, Chennai, 2Madras Medical Mission, Hospital, 
Chennai
Objective: The aim of this study was to compare the prevalence of pulmonary 
hypertension in a cohort of patients with end stage renal disease prior to and 
following renal transplantation along with other variables.
Methods: This was a retrospective analysis of renal transplant recipients whose 
pulmonary artery pressure was compared pre and post transplantation, in a tertiary 
care centre in South India. Of the 425 renal transplantations performed over 2001 to 
2007, 124 patients had their Doppler Echocardiographic fi ndings available. The data 
analysed included the hypertensive, diabetic and the smoking status of the patient 
along with their BUN, Creatinine, GFR (by Nankivell formula),Hemoglobin, 
Hemodialysis duration, AV fi stula+/-,Urine albumin, B.M.I and most importantly 
the echocardiographic fi ndings both pre and post transplant – the pulmonary artery 
pressure, ejection fraction. Statistical analysis was performed using SPSS-Windows 
software and t-test, chi-square test and ANOVA were used.
Results: There were 72%males and 28% females with mean age of 43.3+_13.02 
years. Out of this 87% were hypertensives, 30% were diabetics and 4% 
smokers. Statistical analysis revealed a signifi cant decline in pulmonary artery 
pressure(PAP) following renal transplantation(p<0.05).PAP had no signifi cant 
correlation with a patient’s hypertensive, diabetic, smoking status, age ,gender, 
BUN, Creatinine, GFR, Hemoglobin%, Hemodialysis duration, AV fi stula, 
Urine albumin.It was noticed that BMI had a signifi cant correlation with Pre-
transplant PAH. Of the 72% patients with nil Pre-PAH(<=35mmof Hg), 68% 
remained nil following transplantation, 2% developed mild PAH, 2% moderate 
PAH. Of the 14% patients with mild Pre-PAH(>35and<=45mm of Hg), 9% 
developed nil PAH, 4% mild PAH,1% moderate PAH following transplantation. 
Amongst the 11.3% patients with moderate pre-PAH(>45and<=55mmof 
Hg), 6.5% had nil, 2.4%mild and 2.4% moderate PAH post transplantation. 
Out of the 3.2% who had severe pre-PAH(>60mmof Hg),0.8% had nil, 1.6% 
moderate and 0.8% severe PAH post transplantation. There were no patients 
with moderately severe PAH in the study(>55and<= 60mm of Hg).
Conclusion: The fi ndings of our study reveal that pulmonary artery pressure 
declines in ESRD patients after renal transplantation as compared prior to it. 
This emphasizes the fact that excessive pulmonary blood fl ow is involved in 
the disease pathogenesis which again could be related to various factors.
DONOR ALLOCATION CONCURRENT ORAL SESSION 101: 
AND ETHICS
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LEGAL ASPECTS OF ORGAN TRANSPLANTATION IN 1428 
ITALY
P. Bruzzone
University of Roma “La Sapienza”
Informed consent is of paramount importance in any fi eld of surgery, both from 
the ethical and the legal point of view.
As far as organ transplantation is concerned, potential recipients are fully 
informed before entering the waiting list. However, according to the Italian 
law, they have to sign another informed consent form before entering the 
operating rooms. It is the personal opinion of this author that not only the 
recipients should be informed of the quality of the donor and of the particular 
organ/s they are going to receive, but also that before entering the waiting list 
they should accept or refuse the future possibility of receiving an organ from a 
so called “marginal” or “Extended criteria donor” and/or a Non Heart Beating 
Donor (NHBD).
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ETHICAL ASPECTS OF LIVING DONOR LIVER 1429 
TRANSPLANTATION
P. Bruzzone
University of Roma
Living donor liver transplantation is still associated with some donor risk. 
Mortality ranges from 0.3% to 1% and morbidity from 15% to 67%. After 
donation, liver does not regenerate to 100% of its predonation mass. The 
regenerative capacity and long-term health consequences of such a resection 
are still unknown.
The technical requirements of performing and maintaining an ALDLT are 
higher than in case of deceased donor transplantation or PLDLT.The graft-to-
recipient weight ratio should be suffi ciently large to provide enough hepatic 
mass and avoid small-for-size syndrome.A living donor should not be used for 
a salvage operation in situations in which 1-year patient mortality is greater 
than 20%.
Living donors should be uses only for UNOS-approved transplantation and 
thus only for recipients with a physiological Model for End-Stage disease 
(MELD) score of <25 or >15.
Patients with a MELD<15 may have a greater mortality risk with ALDLT than 
if they would have waited for a full-sized deceased donor organ, while patients 
with MELD>25 may be too debilitated or need a larger hepatic mass.
Donor only benefi t is increased self-esteem, although in some countries fi nancial 
compensation is tolerated. There are some recipient benefi ts. Particularly, the 
waiting time is reduced. This can be important for patients with blood group 
O or A, with malignant liver tumors (advanced HCC: stage T3 and T4a and 
low-grade primary malignancies other than HCC limited to the liver, such as 
hemangioendotheliomas,small in stature, with acute hepatic necrosis and in 
certain U.S. regions of allocation. Some non-neoplastic patients may even be 
transplanted too early!
Strict requirements must be fulfi lled both from the ethical and legal point of view. 
Living donor transplantation must be performed in a center of medium to large 
size. Minimum yearly volume should be 50 to 100 OLTx,including 10% to 30% 
segmental tx within a comprehensive department of surgery performing 2000 
or more general surgery cases, 50 hepatectomies, 20 pancreaticoduonectomies 
and 10 complicated biliary cases annually, with mortality rates <5% and 
complication rates<15-20% in standard liver resection surgery.
Each surgeon should have received a full training (including a fellowship 
in visceral organ transplantation), should perform at least 30 major hepatic 
surgery cases and 20 liver transplants (including pediatric and segmental 
transplants) yearly and must have an impeccable surgical record and 
outstanding ethical behaviour.
The transplant center should avoid unnecessary liver donations, pursuing 
cadaver organ donation and a split liver transplant program for adults
POSTER BOARD NUMBER P2 – 229
IMPROVING CONSENT VIA PATIENT SUPPORT 1430 
GROUPS
Y. Kattoah
Kfshrc - Jeddah
Purpose: Consent for organ donation is a signifi cant challenge in Saudi Arabia 
with families reluctant to agree to cadaveric or living donation, preferring to 
obtain kidneys abroad. The rate of Saudis leaving the country to obtain organs 
has increased signifi cantly and in 2006, 646 unrelated living kidney transplants 
were performed outside the Kingdom while only 220 living related and 151 
cadaveric transplants were performed inside the country.
Method: A qualitative approach was used, consisting of personal interviews to 
survey potential donors and families before and after attending a support group.
Many factors infl uence decision making, including fear of effects of donation 
on the living donor, and lack of understanding about the process. To address 
this, our program has organ donors visit dialysis patient support groups to share 
experiences.
These groups provide an avenue for mutual support and exchange of 
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information between those closest to the problem. Scheduling former donors 
and their families to speak at support groups provides an opportunity for 
patients and family members to learn complex and challenging information 
ranging regarding the donation process through the fi rst hand experiences of 
other Saudis who have gone through the process.
Results: By allowing potential donors families the opportunity to address their 
concerns on an informal basis in a support group, we are improving perceptions 
and practice regarding organ donation.
Conclusion: While the program is still relatively new, notable progress has 
been made and combined with a coordinated multidisciplinary approach 
committed to promoting living organ donation within the Kingdom, has seen 
positive results with more families appearing receptive to the possibility of 
living donation after meeting with prior donors and their families in these 
patient support groups.
POSTER BOARD NUMBER P2 – 230
ACCIDENTAL HIV TRANSMITTED INFECTION FROM 1431 
HIV+ CADAVERIC DONOR IN HIV- RECIPIENTOF KIDNEY 
TRANSPLANTATION:MANAGEMENT AND FOLLOW-UP
E. Bertoni, M. Zanazzi, A. Rosati, M. Salvadori
Renal Unit Careggi University Hospital
No accidental donor transmitted HIV infection in kidney transplantation 
has been up to now described in literature. Aim of this report is to describe 
the main concerns encountered after accidental HIV transmission in kidney 
transplant recipient.
A 27 old female affected by ESRD for chronic glomerulonephritis on waiting 
list for kidney transplantation, was transplanted on february 14, 2007 in our 
center. Two other patients (kidney and liver) had been elsewhere transplanted 
by the same donor. The patient had an immediate recovery of renal function 
with fast decrease of serum creatinine. Her immunosuppressive treatment was 
IL-2R blockers, cyclosporine microemulsion, mycophenolic acid and steroids. 
5 days after transplantation the donor serum resulted HIV+ at control test by 
tissue bank. All transplanted patients resulted contaminated.
An immediate HAART regimen was started with lopinavir/ritonavir, lamivudine, 
fuzeon. Due to several genotype mutations the virue resulted resistant to the 
above mentioned therapy. Two recent new drugs not yet on the market in Italy 
(TMC 114 and TBC 125) were added. Main problems encoutered beside the 
ethical and psychological ones, were the virus resistance and the powerful 
interference with cyclosporine. After change in HAART regimen the virus 
replication became undetectable. Cyclosporine dose was reduced to 10/20 
mg every other day (0.5 mg/kgs) to obtain a C0 of 150-200 ng/ml. Eleven 
months after transplantation virus replication is still undetectable,the GFR is 
84 ml/min, serum creatinine is 0.7 mg/dl, 24 hours proteinuria is about 100 mg. 
CD4+ count has been stable above 600/mmc. No acute rejection verifi ed. Main 
post-transplantation complications were usual for a normal kidney transplant 
recipient,e.g. a CMV pneumonia (recovered with ganciclovir therapy), diabetes 
mellitus and cataract.
In this case report, a fatal human mistake caused three organ recipients to be 
infected by HIV. We can only argue that such contamination can sporadically 
happen worldwide. No case is yet reported in literature. We would like to 
stress the huge ethical and psychological problems arisen by such condition. 
On the contrary, by the transplant point of view, the problem can be rather 
easily afforded. Main concerns are the HAART and its interaction with 
calcineurin inhibitors. Data coming from a number of centers offering renal 
and liver transplants to stable HIV+ patients suggest graft and patient survival 
comparable to those for non-HIV infected recipients.
POSTER BOARD NUMBER P2 – 231
WHAT DOES A DIAGNOSIS OF BRAIN STEM DEATH 1432 
MEAN TO FAMILY MEMBERS WHO ARE APPROACHED 
ABOUT ORGAN DONATION?
T. Long, M. Sque, J. Addington-Hall
University of Southampton
Brain death, whether it be brain stem death [UK] or whole-brain death [USA] 
is a prerequisite for most cadaveric organ donation. Understanding how brain 
death is perceived by bereaved family members approached about organ 
donation, its signifi cance and acceptability to them, are therefore important 
issues to explore as biomedicine moves to expand the range of end of life 
technologies that, potentially, blur the demarcation between life and death.
To explore the concept of brain stem death and what it means to family 
members who are in receipt of this diagnosis the present study asked: i) 
What does the diagnosis of death, which is based on brain stem testing, 
mean to those family members who are asked to consider donating the 
organs and tissues of a deceased relative? and ii) How do family members 
understand this concept? To address these questions a secondary analysis 
of 28 transcripts, from two primary datasets, was carried out, applying 
Charmaz’s approach to grounded theory. Datasets consisted of interviews 
with family members who had agreed to donate the organs of a deceased 
relative.
The core pattern developed during analysis is defi ned as: Confl ict 
Rationalisation, a process whereby family members and health professionals 
appeared to engage in a series of practical and psychological activities aimed 
at rationalising real or potential emotional and cognitive confl ict resulting from 
a brain based diagnosis of death, whilst being faced with the physical image of 
a live body. Confl ict rationalisation appeared to be how family members and 
health professionals’ processed this paradoxical death, a death which, as it is 
brain-based, is contrary to received conventional opinion. These fi ndings are 
summarised and interpreted in the substantive theory of ‘Paradoxical Death’.
POSTER BOARD NUMBER P2 – 232
THE DONOR FAMILY - RECIPIENT LINK: 1433 
A COMFORT OR A HAZARD?
A. Barnwell
Australian Red Cross Blood Service
For donor families and transplant recipients, the belief that psychic, social and 
biological qualities are transferred with organs may lead to emotions ranging 
from natural curiosity to a compelling desire for contact. Recipients often 
experience an overwhelming sense of gratitude coexisting with sympathy for 
the grieving family and an inability to reciprocate in a meaningful way. Both 
parties face challenges in meeting the needs of each other within legislative 
boundaries.
Analysis of the patterns of correspondence between the families of 183 deceased 
donors and 714 transplant recipients identifi ed the frequency, patterns of fl ow 
and commonalities in dialogue.
Letters from recipients were received by 68% of donor families. Common themes 
include gratitude and the impact on their lives. Two thirds of the recipient group 
have not expressed their gratitude personally. The desire for correspondence 
remains unfulfi lled for 32% families. Only 14% of donor families corresponded 
regularly with recipients, the majority being parents of donors.
Receiving personal letters from recipients is highly valued and described as 
comforting and reassuring. Given that only 2% donor families indicated a 
preference not to hear from recipients; donation agencies play a vital role in 
providing the infrastructure necessary to facilitate the exchange of anonymous 
correspondence.
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UNRELATED LIVING DONATION IN SOUTH AFRICA: 1434 
LEGISLATION AND CHALLENGES
A. Michaelides
Netcare Transplant Division
Aim: Unrelated living donation (URLD) has been performed in South Africa 
for more than 10 years. However, URLD accounts for less than 3% of our 
national renal transplants, as opposed to related living donation (RLD)which 
accounts for 36%. In an effort to understand this, close attention was paid to the 
challenges and legislation surrounding this process.
Method: The national renal transplant statistics, as collated by the Organ Donor 
Foundation of South Africa, was analyzed from January 2001-December 2006. 
This legislation and policy guidelines were studied and a comparison made 
with the United Kingdom. A retrospective analysis of potential donors who did 
not complete the process was performed.
Results: A total of 1860 renal transplants were performed during this 6 year 
period. 1131 (60%)renal transplants were from cadaver donors. This includes 
simultaneous kidney-pancreas transplants. 675 (36.6%) were from related 
living donors and 54 (2.9%)were from unrelated living donors. Legislation 
is thorough and protective of both the donor and recipient, but the process 
is slow moving and understaffed. Donors who withdrew from the process 
cited a variety of reasons, predominantly stress, medical unsuitability and 
frustration due to delays by the authorization process. The process in South 
Africa takes approximately 3 months as opposed to 10 days in the United 
Kingdom.
Conclusion: URLD accounts for less than 3% of our national transplant 
statistics, and this fi gure could probably increase with improvements in the 
authorization process. A time frame of 3 months is considered excessive. 
Addressing the patients’ stress through extensive education and counseling 
should impact positively on the need for unrelated organ donation.
POSTER BOARD NUMBER P2 – 234
HYPOTHERMIC PRESERVATION RESULTS IN 1435 
PROFOUND PROTEOLYSIS IN VASCULAR ENDOTHELIAL 
CELLS: INFLUENCE OF DOPAMINE PRE-TREATMENT
B. Yard, B. Rudic, S. Hui, N. Ponnelies
Vth Medical Clinic, Medical Faculty Mannheim, University of Heidelberg
Prolonged hypothermia, as occurs during solid organ transplantation, severely 
affects post transplantation organ function. Proteolysis is one of the deleterious 
events that have been implicated in preservation injury of organ allografts. 
This strongly affects graft quality and hence immediate organ function. Since 
donor catecholamine treatment improves transplantation outcome after renal 
transplantation, the present study was conducted to examine the infl uence 
of dopamine (DA) pre-treatment on hypothermia induced proteolysis in 
endothelial cells subjected to prolonged cold storage.
Untreated human umbilical vein endothelial cells (HUVEC) were highly 
susceptible to cold storage, which was refl ected by morphological changes, 
loss of viability and by signifi cant changes in the cellular proteome. DA 
pre-treatment completely prevented cell death during cold storage. Western 
blot analyses demonstrated a time dependent up-regulation of calpain 1 
and 2 during cold storage, which could be prevented by addition of EDTA 
to the preservation solution. DA pre-treatment abolished auto-proteolysis 
of calpain 1. Analysis of ubiquitin and ubiquitinilated proteins revealed a 
signifi cant increase in both – free ubiquitin and ubiquitinilated conjugates 
after cold storage. This was not prevented by DA pre-treatment. Neither 
proteasome - nor calpain inhibitors prevented cell death during cold storage 
of endothelial cells.
In conclusion, these fi ndings suggest that DA-pre-treatment might inhibit 
proteolysis during organ preservation. Although activation of the calpain 
and ubiquitin pathways occur during cold storage, neither of these pathways 
are directly involved in cell death. Our data may explain the salutary effect 
of donor DA treatment on transplantation outcome and may contribute to 
comprehend the mechanisms underlying hypothermic organ preservation 
injury
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A SIMPLE AND TRANSPARENT KIDNEY ALLOCATION 1436 
SYSTEM BASED ON HLA-IDENTITY AND A 1-1-1 HLA-A, 
-B AND -MISMATCH
M. Heemskerk1, E. de Buijzer1, F. Claas2, I. Doxiadis2, B. Haase-Kromwijk1, 
G. Haasnoot2, J.H. van der Heide3, W. Weimar4, A. Hoitsma5
1Dutch Transplant Foundation, 2Leiden University Medical Centre, 
3University Medical Centre Groningen, 4Erasmus Medical Centre Rotterdam, 
5Radbout University Medical Centre Nijmegen
Recently (Transplantation. 2007;83:1207-1213), a kidney allocation system 
based on HLA-DR identity was described to be a simpler and more equitable 
way of kidney allocation. The authors described HLA-DR matched renal 
transplantation to have a superior graft survival compared to HLA-DR 
mismatched grafts. They hypothesised that with an exclusive HLA-DR matched 
allocation system all kidneys could be regionally allocated.
We tested this hypothesis in an allocation algorithm were 1416 kidneys, from 
708 Dutch donors from the period 2004-2006, were offered to a non-exhaustive 
waiting list, starting with the 1014 Dutch patients on the 1-1-2004 waiting list. 
We assumed the Netherlands to be one transplant region. All HLA antigens 
were typed on split level. Simulation of an exclusive HLA-DR matched kidney 
allocation showed that 13% of the 1416 kidneys could not be matched to a 
patient. As an extra rule, one HLA-DR with maximally one HLA-A and one 
HLA-B mismatch (1-1-1-mismatch) was allowed when no HLA-DR matched 
patient kidney combination was available. This additional rule reduced the 
percentage of non-transplantable kidneys to 2%. We questioned whether this 
modifi cation would have resulted in worse graft survival.
We analysed fi ve year graft survival (death censored) after heart beating kidney 
transplantation in the Netherlands between 1990 and 2005 with Kaplan-Meier 
curves and a Log rank test. We included 1-1-1-mismatched pairs (n= 511) and 
HLA-DR split matched pairs (N = 1305). Excluded from the analysis were 
highly immunized patients, patients within the acceptable mismatch program, 
patients younger than eighteen years, donors younger than fi ve years, combined 
transplants, and retransplants.
At 5 years after kidney transplantation, graft survival was 79% for HLA-DR 
matched patient donor pairs and 77% for pairs with a Haplomatch, which is not 
signifi cantly different (p = 0.2).
We compared these results with those in a larger cohort within the Eurotransplant 
region (n = 22090). Both cohorts were similar, except that HLA typing was on 
broad level and three year follow up was analysed in the Eurotransplant cohort. 
Graft survival was 84% for pairs with a 1-1-1-mismatch. Full house matched 
pairs (89%; p<0.000) and HLA-DR matched pairs with a single HLA class I 
mismatch (86%; p=0.013) had superior graft survival. HLA-DR matched pairs 
with more HLA class I mismatches did not have signifi cantly different graft 
survival rates compared to 1-1-1-mismatched pairs (p > 0.1).
Including 1-1-1-mismatched transplants in a kidney allocation system based 
on HLA-DR identity can lead to a simpler, faster and a more equitable way of 
kidney allocation, without affecting superior transplant results.
POSTER BOARD NUMBER P2 – 236
OPTIMAL UTILIZATION OF HTLV I/II POSITIVE 1437 
ORGANS A NATIONWIDE SURVEY
M.R. Marvin1, R. Nagubandi1, G.N. Brock2, K.V. Ravindra1, M. Eng1, 
J.F. Buell1
1Division of Transplantation, Dept. of Surgery, University of Louisville, 
Louisville, KY, United States and 2Bioinformatics and Biostatistics, University 
of Louisville, Louisville, KY, United States
Objective: We recently presented data from the UNOS database that 
demonstrated no signifi cant difference in graft or patient survival between 
HTLV I /II (+) and (-) liver recipients. Several Organ Procurement Organizations 
(OPO) including our own, do not offer HTLV I /II positive organs while many 
others fi nd it diffi cult to place them. Despite this, the number of HTLV (+) 
organs is increasing with 31 utilized in 2006 alone. This prompted us to evaluate 
the practical diffi culties in placing these organs so as to improve utilization of 
these high risk life saving organs.
Method: A telephone/email survey of all the 65 OPOs in USA was done over 
a 2 month period from October to November 2007.
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Results: Of the 65 OPOs, 42 responded. All screen patients for HTLV I/II with 
ELISA. 38 centers confi rm with repeat ELISA, 27 confi rm with Western Blot 
and 6 centers do not pursue further. 36 of the 42 centers offer the HTLV I/II 
positive organs. There were a total of 231 positive donors in the past 5 years of 
which organs from 109 donors (47.2%) were placed. 
27 centers offer all the organs while 15 offer one or more organs selectively 
based on accepting centers. None have been able to place the pancreas. Only 
liver and kidney were commonly accepted. Several centers noted a high false 
positive rate.
Based on the UNOS regional analysis data, 43% of the organs are utilized 
in NY state alone. Many OPOs did not know which particular centers accept 
these organs and consequently spend a lot of time and effort in order to 
place them. A majority wanted to have a list of transplant centers that accept 
these organs.
Conclusions: HTLV I/II organs are being underutilized. Moreover, our prior 
analysis of UNOS data shows that these life saving organs are shared more 
nationally than loco-regionally which is associated with a poorer outcome. 
Increased knowledge of successful HTLV (+) donation and the centers that are 
willing to utilize these organs in the appropriate setting will help expand the 
donor pool and decrease mortality on the waiting list.
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TAILORING HLA MATCHING FOR PATIENTS 1438 
THROUGH NATIONAL KIDNEY ALLOCATION
R. Johnson1, C. Rudge1, L. Mumford1, S. Fuggle1, J. Fosythe2
1UK Transplant, Bristol, UK, 2Royal Infi rmary of Edinburgh, Edinburgh, UK
Since national kidney allocation schemes were introduced in the UK and 
elsewhere, HLA match between donor and recipient has remained an important 
criterion in the selection of recipients for transplant. In 1995, development 
work was undertaken for the UK Kidney Allocation Scheme and this included 
investigation of the role of HLA matching in allocation.
In the UK, HLA match has long been an important consideration in allocation 
of kidneys from donors after brain death (DBD). This has resulted in 
excellent HLA match grades in kidney transplants for all patients, regardless 
of age: in 2003-2005, 72% of kidney transplants from DBD had no more 
than 2 HLA-A+B+DR mismatches, and this fi gure ranged only between 70 
and 74% across all adult age groups. In this era, median waiting times to 
transplant were two years for young adults increasing to three years for the 
oldest patients.
Analyses to inform decision-making about new allocation arrangements 
included a review of the infl uence of HLA mismatch on transplant outcome. 
This lead to a redefi nition of HLA mismatch (mm) into four levels, based on 
a risk-adjusted Cox regression analysis of fi ve-year transplant survival (deaths 
with function treated as failures):
1 - 000 mm [baseline level – relative risk (RR) = 1.0]
2 - (0 DR mm with < 2 B mm) [RR=1.06, 95% CI 0.87-1.30]
3 -  (0 DR mm with 2 B mm) or (1 DR mm with < 2 B mm) [RR=1.22, 95% 
CI 0.99-1.49]
4 - (1 DR mm with 2 B mm) or 2 DR mm), [RR=1.41, 95% CI 1.11-1.80]
These results suggested that there is no signifi cant benefi t of HLA matching 
in terms of transplant outcome, provided the fourth level of graft mismatch 
is avoided. However, another reason to HLA match is to avoid the recipient 
developing antibodies to mismatched donor antigens, thus making 
retransplantation more diffi cult due to higher levels of sensitisation.
Taking these considerations into account, the new UK Kidney Allocation 
Scheme introduced in April 2006 prioritises 000 HLA-A, B, DR mismatched 
patients and well-matched paediatric patients, does not routinely consider 
level 4 mismatched grafts for any patient and, through a new points 
scoring system where points for age and HLA match are combined, gives 
HLA match a greater weight for younger patients than for older patients. 
The rationale is that the younger the patient is, the more likely they are 
to require a retransplant in the future and the greater their need to avoid 
sensitisation.
Eighteen months after the introduction of the scheme, its effect, and in particular 
the impact of the age/HLA points, is apparent.
Through a review of evidence and new allocation arrangements, well matched 
transplants continue to be provided for younger patients while the emphasis on 
HLA matching decreases with increasing patient age.
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HLA MATCHING IN KIDNEY ALLOCATION: REVISED 1439 
CRITERIA IMPROVE EQUITY OF ACCESS TO TRANSPLANT
S. Fuggle1, R. Johnson1, L. Mumford1, C. Rudge1, J. Forsythe2
1UK Transplant, Bristol, UK, 2Royal Infi rmary of Edinburgh, Edinburgh, UK
HLA matching has been considered an important factor in deceased donor 
kidney allocation in the UK for many years. However, there are many 
criteria to consider in allocation and over-emphasis on HLA matching 
disadvantages patients with rare HLA types. The new national kidney 
allocation scheme introduced in the UK in April 2006 includes features 
to improve equity of access to transplantation for patients throughout 
the UK. One feature was to revise the definition of an HLA match, by 
defaulting antigens that are rare (frequency of <2%) in the donor pool to 
more common, related antigens based on serological and sequence data. 
For example HLA-A36 is found in 0.2% patients on the transplant list 
and in 0.05% UK donors. By mapping A36 to the serologically related 
specificity, HLA-A1, HLA-A36 patients are ‘matched’ to HLA-A1 donors, 
which represent 18% of the donor pool. HLA-A36 positive donors are 
only matched to HLA-A36 patients. 3 HLA-A, 16 HLA-B and 4 HLA-
DR specificities are defaulted in the 2006 allocation algorithm. Simulation 
studies of transplant activity predicted that by adopting this approach the 
transplant rate in difficult to match patients would increase, for example 
by 14% for ethnic minority patients.
Results from the 18 month review of the allocation scheme show that 
antigen defaulting has been a factor in patient selection in 192 of 1431 
(13%) kidney transplants performed. A single HLA-DR default was 
most likely to have influenced allocation (131 cases, 68%) and HLA-B 
antigen defaults in 49 cases, (26%). In 11 (6%) transplants resulting from 
defaulting, at least two antigen defaults contributed to the recipient being 
selected for transplant.
While HLA antigen defaulting was a factor in 13% of transplants overall, this 
rate varied signifi cantly among patient subgroups. Most noticeably there was 
variation according to patient ethnicity. 10% of transplants for White patients 
involved defaulted antigens but this fi gure was 18% in Asian patients and 
48% in Black patients (p<0.0001). The overall number of transplants in ethnic 
minority patients increased by 17% in the fi rst year of the 2006 allocation 
scheme compared with the previous year.
Antigen defaulting was of benefi t to patients with longer rather than shorter 
waiting times (p=0.0005), patients who are calculated to be diffi cult to HLA 
match (p=0.002) and to patients of blood groups B and AB rather than O and 
A (p=0.04).
While retaining HLA match as an important criterion in kidney allocation, 
the UK 2006 kidney allocation scheme strives to achieve equity of access 
to transplant for diffi cult to match patients by defaulting rare antigens to 
more common counterparts. The results of the fi rst 18 months of the scheme 
demonstrate that this approach is achieving increased access to transplant for 
ethnic minority and other diffi cult to match patients.
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THERE IS NO RIGHT TO A TRANSPLANT1440 
M. Shapiro
Touro University College of Medicine
Discussions regarding the appropriate allocation of organs have sought to 
balance the ethical principles of equity (Justice in a Rawlsian sense) and utility. 
Recent US proposals to shift the balance in a utilitarian direction, such as the 
current proposal to use “net life survival benefi t” or “life years from transplant” 
in a new kidney allocation schema have been met with consternation, and cries 
of injustice. Such a system might create winners and losers, and make more 
explicit who would receive a transplant and who would not. While this is 
likely true, to suggest that such a system is unjust is to misunderstand both the 
appropriate application of equity, and to imply that the appearance of fairness 
is more important than fairness itself.
The goal of transplantation of any organ is to save lives, and improve the 
quality of life. In order for that to occur, there must be a utilitarian basis for 
any transplant. Thus, to prioritize allocation based on who is most likely to die 
waiting (as MELD does) is only of value if those patients have a reasonable 
expectation of survival post-transplant. Similarly, there is little question that a 
kidney transplant that functions for ten years is of more value, and should take 
precedence, over that which survives one week. If one accepts that premise, 
then whether a month or a year or fi ve years is an appropriate threshold is 
merely quibbling over details.
It has been suggested that the current US kidney allocation system, based 
primarily on waiting time, is more just than one based on predicted net 
survival benefi t. This presupposes several facts, none of which are without 
serious question. These include the notion that patients have equal access 
to the waiting list, patients have equal survival while waiting, and that all 
patients have an equal right to be transplanted. This also approaches the 
problem from the perspective of the potential recipient, without regard to 
the perspective of the organ, organ donor, or donor family member. One 
might hypothesize, and data suggest, that the donor family would have the 
expectation that their gift be used in the most utilitarian manner, to “do the 
most good.” This requires a judgment be made as to how long a particular 
recipient will survive, pre-, peri- and post-transplant, and take primarily those 
factors into account in allocation.
Equity is important in organ allocation, but only to the extent that one is 
comparing like groups of patients, When differences in utilitarian outcomes 
can be demonstrated between disparate groups, utility should prevail, and 
differences in priority between such disparate groups is not un-just.
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A SURVEY OF COGNITIVE, INTENTION AND BEHAVIOR 1441 
OF THE LIVING DONORS AND GENERAL POPULATION 
IN LIVING ORGAN DONATION
Objective: To investigate the living renal transplant donors about cognitive, 
intention, behavior situation, and contrast with whom refused to be living 
organ donor and willing to be living organ donor in general population. Discuss 
the impact factors of decisions relevant to living organ donation in general 
population.
Method: Designed the questionnaire on cognitive, intention, behavior of living 
organ donors. Undergraduate anonymous surveys from July 2007 to February 
2008 among 35 cases of live donor kidney transplantation in our center, 21cases 
of general population refused to be living donor well 73 cases will in medical 
centre. The living donors also assess mental state with SCL-90 Symptom 
Rating Scale at the same time.
Results: Living kidney donors are overall psychological normal. Male:female 
ratio is 1.06£º1,those aged below 38 accounted for 60% ,under high school 
qualifi cations are 62.86%, 88.57% of the manual; and those who consciously 
on living organ donation and transplantation than understanding is 82.58%, 
the organ donation more positive effect is 97.14%, 62.86% donors think that 
the most important factors to be an organ donor is whom they will donate to; 
48.57% donors hope that their parents will be the receptors;and 45.71% of 
them hope that will be their children; 85.71%donors think that is wrong to 
ask for compensation; 64.29% donors are opposed to organ trading; the act of 
organ donation get high grade in moral evaluation from 75.71% donors;2.86% 
donors think that living organ donation do harm more than benifi t. 47.83% 
women of non organ donor refuse to donate their organs ,so do 28.57%man, 
38.10% refusers think that organ donations will cause serious health problom, 
just 33.33% think that the most important factors to be an organ donor is 
whom they will donate to;they think about 2.25 fators average when they make 
decision about organ donation,61.90% of them think the most important fator 
is their own health in future,61.90% of them agree organ trading. Compare 
with the kiney donors;54.05% of who willing to be living organ donors ask for 
compensation; the most accepted form of compensation in these three groups is 
to provided with comprehensive health insurance or Organ Transplant priority 
right.
Conclusion: In general population ,the process of decision making to free 
reward live organ donation is also the process of balancing gains and losses; 
most of living organ donors or who willing to donate their organ agree that 
they will be benefi t from the living organ transplantation more than loss. So 
to enhance public understanding of organ donation and organ transplantation, 
to improve the surgical results of both receptor and donor, strengthen the 
community recognition and insurance to organ donor may be expanded the 
pool of free reward donation, and prevent organ trading.
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ARE ETHNIC PATIENTS STILL DISADVANTAGED FROM 1442 
RECEIVING RENAL TRANSPLANTS?
R. Naik, D. Meredith, M. Mohteshamzadeh, E. Vaux, L. Barker
Royal Berkshire Hospital, London Road, Reading, RG15AN
Introduction: Renal transplantation for patients with end stage renal failure 
should be available to all patients regardless of ethnicity. There is however 
a serious shortage of organs for transplantation and there are in the United 
Kingdom over 7000 patients awaiting renal transplants. Previous reports have 
suggested that ethnic patients (Asian Indian and Pakistani) who have more 
kidney failure are less likely to get transplants compared to Caucasian patients. 
Efforts have been made to improve this with more education and appointments 
of specifi c coordinators in some units to facilitate transplantation. The aim of 
our study was to assess whether the transplant needs of an increasing ethnic 
population were being met.
Methods: We reviewed the ethnicity of all patients on Haemo or peritoneal 
dialysis at the Royal Berkshire Hospital who are currently on the transplant 
waiting list. We also assessed the ethnicity of patients who had received renal 
transplants and compared these fi gures with the ethnic distribution in the 
general population.
Results: The county of Berkshire, England (population 800,090), is 
predominately Caucasian (88.7%) with Asian (6.8%) and Black (2%) residents 
making up the largest of the minority groups. There are currently 350 patients 
receiving dialysis of whom 52 patients (15%) are from the Asian population. 
156 patients are currently on the transplant waiting list of whom 32 (20.5%) are 
ethnic. 10 out of 156 patients (6.4%) are black. Of the 325 transplant recipients, 
262 (86%) are Caucasian, 37 (11%) are Asian and 8 (2%) are Black.
Asian patients are the least likely to receive a Living Related Donor Transplant 
(14% compared to 22% of Caucasian and 25% of Black patients). A total of 38 
grafts have failed to date, with average graft survival being longest in patients 
of Asian ethnicity. Of the 21 deaths in the group, 19 were Caucasian, 2 were 
Black, and none were of Asian origin.
Conclusion: This data supports recent publications which suggest 
that patients of Asian ethnicity are least likely to receive living related 
donors or find a match for a cadaveric graft within a predominantly white 
population. Asian patients are over represented in the dialysis population 
and in the transplant waiting list. Whilst this is due in part to the availability 
of suitable blood group or HLA matches, there is still a reluctance amongst 
Asians to become kidney donors due to cultural or religious objections, 
which needs urgent addressing on a local and national level. However, 
our data suggests that once transplanted, Asian patients appear to have a 
relatively long graft survival with the lowest incidence of post transplant 
mortality.
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DONOR ANTIGENIC SPECIFICITY CD4+CD25+TREG 1443 
CELLS INDUCE IMMUNE TOLERANCE OF ALLOGRAFT 
KIDNEY TRANSPLANTATION IN RATS
S. Gu1*#, C. Huang2*, J. Zheng3#, Y. Zhang2, J. Li2, Q. Wang2, J. Feng2, 
Y. Xiao2, H. Huang3, M. Unoki1
1School of Rehabilitation Sciences, Seirei Christopher University,Hamamatsu, 
Japan, 2Xinqiao Hospital, Third Military Mcdical University, Chongqing, 
China, 3Faculty of Medical Lab,Science, Third Military Mcdical University, 
Chongqing, China, *S GU and C HUANG contributed equally to this work. 
#Corresponding authors.
Objective: It is confi rmed that CD4+CD25+Treg cells have the potent 
suppressive effect not only on responder T cells either directly via cell contract or 
secretion of IL-10 and TGF-ƒÀ1 or alternatively by infl uencing the stimulating 
APC but also on B cell Ig response directly via cell contact. Meanwhile, the 
important role of CD4+CD25+Treg cells played in transplantation immunology 
tolerance in human were take into account initially. However, there are little 
evidence to realize the role of CD4+CD25+Treg cells to induce transplantation 
tolerance in vivo. This study was designed to utilize donor antigenic specifi city 
CD4+CD25+Treg cells to induce allograft transplantation tolerance of 
kidney transplantation in rats and to study the dose-effect relationship of 
CD4+CD25+Treg cells tentatively in vivo.
Methods: To establish allograft kidney transplantation animal models with 
F344 rats as donors and Lewis rats as recepients; Separating CD4+CD25+Treg 
cells from splenic cells of Lewis rats and inducing phenotype of donor antigenic 
specifi city in vitro; According to the quantities of CD4+CD25+Treg cells inject 
through tail vein in the operation of allograft kidney transplantation, models 
were divided into four experiment groups: group1 i2X105 j Ageoup2 i5X105 j 
Ageoup3 i1X106 j Ageoup4 i2X106 j ini=12 j.
Results: The models without injection as controls (n=12); The mean survival 
time was the highest in group3 (27.3 }4.6)d and the lowest in controls (12.3 
}4.6)d. The mortality rate was highest in controls(83.3%)while all models 
survival in group 1X106 15 days after operation; The function of transplanted 
kidney were exert the most sable in group3. The semi-quantitative scores 
of histopathology had statistical difference between controls with group3 
iP<0.05 j.
Conclusions: It can be tentative confi rmation that donor antigenic specifi city 
CD4+CD25+Treg cells could induce immune tolerance of allograft kidney 
transplantation in rats and 1X106 should be the right single dosage.
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FOXP3+ REGULATORY T-CELLS PLAY A DOMINANT 1444 
ROLE OVER RORGAMMA+ TH17-CELLS IN DECEASED 
DONOR KIDNEYS
C. Baan1, A. Peeters1, J. van de Wetering1, J. IJzermans2, W. Weimar1
1Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The 
Netherlands, 2Surgery, Erasmus MC, University Medical Center Rotterdam, 
The Netherlands
Th17 cells and regulatory T-cells (Tregs) have an interactive relationship 
mediated by IL-6 and TGF-ß. Both cell types are involved in the reactivity 
against alloantigens and in response to tissue injury. Here, we studied the Th17-
Treg network in zero biopsies of kidneys from living donors with relatively 
short ischemia-reperfusion times and from deceased donors with brain death 
related infl ammation and prolonged cold ischemia-reperfusion times
Biopsies from deceased (n=13, > 14 h cold ischemia) and living (n=14, < 2 h 
cold ischemia) donors were studied at the end of cold storage and after 20-30 
min reperfusion.
In deceased donor kidneys higher mRNA expression levels of CD3 were 
measured compared to living donor kidneys demonstrating that more T-cells had 
infi ltrated these allografts (p=0.04). Moreover, in deceased donor kidneys the 
expression levels of TGF-ß, which acts as a differentiation factor for FOXP3+ 
regulatory T-cells, was abundantly present (p=0.005) compared to living donor 
kidneys. Likewise, FOXP3 mRNA was detected at signifi cantly higher levels in 
deceased than in living donor kidneys (p=0.001). In contrast, in biopsies from 
deceased donor kidneys the mRNA levels of RORgamma, the transcription 
factor that directs IL-17 transcription, was signifi cantly lower than in samples 
from living donors (p<0.001).Concurrently, no induction of the RORgamma 
inducing cytokines (IL-6, TNF-a, IL-21) and IL-17 was measured.
In conclusion, the high mRNA expression levels of CD3, TGF-ß and FOXP3 in 
deceased vs living donor kidneys suggests that regulatory T-cells, but not Th17 
cells play a role in controlling tissue injury resulting from the pathophysiologic 
events inherent to deceased donation.
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EX VIVO GENERATED TREG AMELIORATE 1445 
TRANSPLANT ARTERIOSCLEROSIS BY INHIBITING 
EFFECTOR CELL PRIMING AND GRAFT INFILTRATION
R.S. Francis1, G. Warnecke2, S.N. Nadig1, G. Feng1, K.J. Wood1, A.R. Bushell1
1Nuffi eld Department of Surgery, University of Oxford, UK, 2University of 
Hannover, Germany
Background and aims: Naturally-occurring FOXP3+CD4+ regulatory T cells 
(Treg) play a crucial role in the control of self-directed immune responses. 
Similar populations of Treg have also been shown to suppress alloimmune 
responses, offering the potential to prevent transplant rejection without the 
requirement for indefi nite global immunosuppression.
We have developed an in vitro culture system that is able to generate 
graft-protective Treg from naïve CD4+ T cells. CBA (H2k) CD4+ T cells 
are conditioned for 14 days in the presence of allogeneic B6 (H2b) bone 
marrow-derived dendritic cells (BMDCs) and interferon-γ (IFN-γ). 
Following this protocol, the conditioned T cell population (Tcon) are 
enriched for FOXP3+ cells and are able to prevent skin graft rejection by 
a defined CD4+ effector population following adoptive transfer into T cell 
deficient mice. The aim of this research was to ask whether Tcon can also 
control the development of transplant arteriosclerosis using a relevant 
mouse model of vasculopathy.
Methods: T and B cell defi cient CBA.rag−/− mice were reconstituted with 
1×105 naïve CBA CD25−CD4+ effector T cells (Teff) with or without 4×105 
Tcon on day -1. The following day, a B6.CD31−/− aortic interposition graft 
was performed. CD31−/− grafts were used so that the degree of endothelial 
repopulation could be assessed histologically as a marker of graft damage. 
On day 30, the animals were sacrifi ced and the spleen and graft harvested for 
histological, functional and phenotypic analysis.
Results: Mice that received Tcon and Teff had signifi cantly reduced 
arteriosclerotic lesions compared to mice that received Teff alone (luminal 
occlusion 11.7±13.1% vs 29.7±14.5%; p=0.04). Signifi cantly, in mice 
reconstituted with Teff alone the donor CD31−/− endothelium was entirely 
replaced by CD31+/+ recipient endothelial cells refl ecting an active immune 
response against the graft. However, co-transfer of Tcon completely prevented 
this endothelial repopulation.
To investigate the mechanisms by which Tcon attenuated transplant 
arteriosclerosis, we analysed graft infi ltrating cells by histology and splenic T 
cells by FACS and IFN-γ ELISpot. Strikingly, the frequency of primed donor-
reactive IFN-γ secreting CD4+ cells was reduced from 170±16 per 1×105 in 
mice that received Teff alone to 48±15 per 1×105 in mice that also received 
Tcon (Figure 1). This correlated with CD4+ T cell infi ltration into grafts, which 
was markedly reduced in the presence of Tcon.
Figure 1: Frequency of donor-reactive IFN-γ-secreting CD4+ cells
Representative ELISpot well imagesa) 
Enumerated spots per 1×10b) 5 input cells
Discussion: These data indicate that the mechanisms by which ex-vivo generated 
regulatory T cells control transplant associated vasculopathy include a reduction 
in both effector cell priming and infi ltration into the graft. These data emphasise 
the potential of ex-vivo generated regs to control not only acute allograft rejection 
but also vascular changes associated with chronic allograft dysfunction.
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CD4+ T LYMPHOCYTES TRANSFER TOLERANCE 1446 
INDUCED BY PORTAL VENOUS INJECTION
F. He, Z. Chen, S. Xu, M. Wu, M. Cai
Institution of Organ Transplantation, HUST
Objection: A portal venous injection of allogeneic donor cells is known to 
prolong the survival of subsequently transplanted allograft. In this study we 
analysis the role of T lymphocytes in transferring tolerance induced by portal 
venous injection.
Methods: C57BL/6 (B6) mice were used as donors. 7 days after portal venous 
injection of irradiated B6 splenocytes into BALB/c mice, the splenocytes of 
the recipient were isolate and CD4+, CD8+T lymphocytes were magnetically 
sorted respectively using an auto MACS cell sorter. The sorted CD4+ (CD8+) T 
lymphocytes were then transfused into another BALB/c mice followed by heterotopic 
implantation of a B6 heart allograft. A C3H heart allograft and normal BALB/c were 
used as controls. The rejection and survival of the allograft were observed.
Result: when transfusion with CD4+T lymphocytes from BALB/c mice 
treated with a portal injection of B6 splenocytes, the subsequent transplanted 
B6 allograft was survival longer than C3H allograft. Similar results were 
not observed for normal BALB/c or BALB/c with transfusion with CD8+T 
lymphocytes from BALB/c mice treated with a portal injection of B6 
splenocytes (data show in fi gure 1).
Conclusion: This fi nding indicates that CD4+T lymphocytes, but not CD8+T 
lymphocytes, play an important role in transferring tolerance induced by portal 
venous injection and this tolerance is antigen-specifi c.
Figure 1 Survival posttransplant of each groups
A:  Donor: B6 mice Recipient: BALB/c mice receiving transfusion with 
CD4+T lymphocytes from BALB/c mice treated with a portal injection of 
B6 splenocytes
B:  Donor: C3H mice Recipient: BALB/c mice receiving transfusion with 
CD4+T lymphocytes from BALB/c mice treated with a portal injection of 
B6 splenocytes
C:  Donor: B6 mice Recipient: BALB/c mice receiving transfusion with 
CD8+T lymphocytes from BALB/c mice treated with a portal injection of 
B6 splenocytes
D:  Donor: C3H mice Recipient: BALB/c mice receiving transfusion with 
CD8+T lymphocytes from BALB/c mice treated with a portal injection of 
B6 splenocytes
E:  Donor: B6 mice Recipient: Normal BALB/c
F:  Donor: C3H mice Recipient: Normal BALB/c
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BYSTANDER REGULATORY T CELLS PLUS SUB-1447 
OPTIMAL IMMUNOTHERAPY CONTROLS ALLOGRAFT 
REJECTION
A. Bushell, K. Wood
Nuffi eld Department of Surgery
Background and aims: Strategies that lead to the development of specifi c 
populations of regulatory T cells (Treg) could provide an active immunological 
solution to allograft rejection and promising protocols exist for Treg generation/
expansion both in vivo and ex vivo. Whilst it is not clear at present which will 
offer the greatest clinical benefi t, one attractive approach would be to induce 
antigen-driven Treg in the patient prior to transplant to provide immediate control 
of rejection responses. This can be achieved in the mouse by pre-treatment with 
donor-specifi c blood transfusion plus anti-CD4 antibody, but this approach is 
only practical clinically in the setting of living donor transplantation. To address 
this limitation, we have previously shown that bystander Treg generated by 
challenge with unrelated protein antigen in an analogous protocol can prevent 
allograft rejection in adoptive transfer models. The aim of this study was to 
ask if Treg functioning through bystander mechanisms can infl uence allograft 
rejection in primary transplant recipients.
Methods: CBA mice (H2k) mice were pre-treated with 200μg of IgG2a anti-
CD4 antibody (YTS 177.9) on days -28 and -27 plus 500μg of human gamma 
globulin (HGG) on –day -27 and re-challenged with HGG on day -1 which is 
essential for elaboration of Treg function. These mice were then transplanted 
with fully vascularised B.6 (H2b) hearts on day 0 either with no further treatment 
or were given 25μg of CTLA4-Ig (Abatacept, Orencia) i.v. on days 0 and +1. 
Graft outcome was determined by palpation.
Results: Though present at the time of transplant, bystander Treg were unable 
to control primary cardiac allograft rejection (MST 8 days, data not shown). 
However, adjunctive CTLA4-Ig therapy resulted in prolongation of cardiac 
allograft survival (MST~50 days in two separate groups). Importantly, mice 
treated with CTLA4-Ig alone rejected their grafts at essentially control rates 
(MST 13 days, n=5). Thus, when combined with minimal immunosuppression, 
in vivo generated bystander Treg can infl uence graft outcome.
Conclusion and signifi cance: Treg can be generated in vivo by antigen 
challenge combined with immunomodulation but alloantigen in the clinical 
setting is possible only in limited situations. The optimised use of specifi ed 
protein antigens may provide an alternative route to in vivo Treg generation 
and when combined with Treg-sparing immunosuppression may offer a route 
to operational transplantation tolerance.
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PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL 1448 
BY EX VIVO EXPANSION OF SELECTED FOXP3-TRANSDUCED 
CD4 REGULATORY T CELLS
M. Hu1, Y.M. Wang1, G.Y. Zhang1, D. Watson1, J. Fletcher1, T. Polhill1, 
I.E. Alexander2, S.I. Alexander1
1Centre for Kidney Research, 2Gene Therapy Research Unit, Children’s 
Hospital at Westmead, University of Sydney, NSW, Australia
Background: Treg mediated immunoregulation plays an important role in the 
induction and maintenance of transplantation tolerance. Manipulating Tregs 
has signifi cant therapeutic potential in transplantation. Retroviral gene transfer 
of Foxp3has converted naïve CD4+ T cells toward a regulatory T cell phenotype 
similar to that of naturally occurring CD4+ Tregs.
Aim: We investigated a strategy to expand the proportion of antigen specifi c Tregs 
by retroviral gene Foxp3-transduced Tregs that are capable of suppressing effector 
T cells and prevent cardiac allograft rejection across an MHC mismatch.
Methods: Retroviral supernatant was harvested from packaging cells 72 h after 
transfection of pFoxp3/MIGR1/GFP+. Naïve BALB/c CD4+ T cells were cultured 
in the coated anti-CD3 Ab plate with rIL-2 for overnight and transduced with 
Foxp3/MRGR1/GFP viral supernatant then stimulated with irradiated C57BL/6 
splenocytes for another 3 days. GFP+ cells were sorted at day 5 after transduction 
and adoptively transferred to each SCID mouse received C57BL/6 and third 
party B10.BR heterotopic cardiac allografts, then these mice were reconstituted 
with 5×106 BALB/c splenocytes at 104 days after adoptive transfer.
Results: The study demonstrated that ex vivo expanded Foxp3-transduced 
CD4+ Tregs specifi cally prolonged C57BL/6 cardiac allograft survival (n = 
4) with MST >300 days, while retaining the ability to reject third-party B10.
BR cardiac allografts (n=2) at average 137 days post transplantation. In vivo 
fl ow cytometry analysis showed that antigen specifi c Foxp3-transduced CD4+ 
T cells signifi cantly expanded in SCID mice with C57BL/6 cardiac allografts, 
compared to SCID with third party B10.BR cardiac allografts. Foxp3-
transduced CD4+ Tregs were increased in SCID mice with C57BL/6 cardiac 
allografts (1.2%±0.4) more than in mice with B10.BR third party cardiac 
allografts (0.8%±0.3) relative to total CD45+ cells after 8 days adoptive transfer. 
Moreover, the proportion of transduced cells signifi cantly increased from to 
2.1%±0.6 at day 106 to 7.5%±3.2 at day 196 after reconstitution BABL/c cells 
in SCID mice with C57BL/6 cardiac allografts (p=0.005). This compared to 
0.4% at day 106 after reconstitution and 2.3% at day 196 after reconstitution 
in a SCID mouse that had already rejected B10.BR cardiac allografts. Further, 
a higher percentage of CD127 low CD4+ T cells in splenocytes of SCID mice 
received C57BL/6 allografts (16.3% ± 4.4) was observed, compared with 
splenocytes of SCID mouse, which had rejected 3rd party B10.BR allograft 
(9.7%) and naïve BALB/c (11.3%) at 196 days after reconstitution BALB/c 
cells. This suggested that the antigen specifi c allograft itself is crucial for the 
maintenance of tolerance in vivo. Splenocytes from SCID mice with C57BL/6 
cardiac allografts showed reduced proliferation and reduced IFN-γ production in 
response to the stimulator C57BL/6 strain (PI=5.2+/-0.6, p<0.05) (34.3+/-12.9 
spots, p<0.05) compared with the third-party B10.BR (PI=6.8+/-0.5, p<0.05) 
(72.8+/-32.6 spots, p<0.05).
Conclusions: Ex vivo expanded Foxp3-transduced CD4+ Tregs are capable of 
suppressing effector T cells and specifi cally prolonged cardiac allograft survival.
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ALLOANTIGEN ACTIVATED NAIVE CD41449 +CD25+FOXP3+T 
REGULATORY CELLS EXPRESS CD8; A MARKER OF NEWLY 
ACTIVATED ANTIGEN SPECIFIC T REGULATORY CELLS
N.D. Verma, K.M. Plain, M. Nomura, G.T. Tran, R. Boyd, N. Carter, 
C. Robinson, C. Wang, G.A. Bishop, S.J. Hodgkinson, B.M. Hall.
Faculty of Medicine, University of NSW, and Department of Gastroenterology, 
University of Sydney, Sydney NSW 2006, NSW, Australia
Natural CD4+CD25+Foxp3+T regulatory cells can be activated in vitro by 
alloantigen and IL-2, and used to induce tolerance to specifi c donor bone marrow 
and allografts. We have found that both IL-2 and IL-4 induce alloantigen specifi c 
CD4+CD25+Foxp3+T regulatory cells, in that after 3-4 days culture with alloantigen 
and IL-2 or IL-4 these cells can suppress rejection at a ratio of 1:10 with naïve 
CD4+T cells. Fresh naïve CD4+CD25+Foxp3+T regulatory cells only suppress 
at a ratio of 1:1 and not at 1:10 and do so in a non antigen specifi c manner. In 
characterizing the activated CD4+CD25+Foxp3+T regulatory cells, we observed 
that within 3-4 days of culture between 11 and 30% of cells also expressed CD8, 
whereas the starting population had less than 1% CD8+T cells. These CD8+cells 
also expressed CD4 and CD25 and were amongst the Foxp3 expressing cells. We 
considered this was de novo induction of CD8 on the original CD4+CD25+Foxp3+T 
regulatory cells. This study examined if the minor CD4+CD8+CD25+Foxp3+T cells 
contained the antigen specifi c regulatory T cells.
DA rat CD4+CD25+Foxp3+T regulatory cells were cultured with fully allogeneic 
PVG stimulator cells and IL-2. After 4 days in culture, the suppressive 
capacity of these cells was compared to populations depleted of CD8. The 
CD4+CD8+CD25+Foxp3+T cells could not be directly tested as in vivo the mAb 
to CD8 opsonizes cells it binds to. The antigen specifi c potency was tested by 
transfer of 5x105 activated Tr, together with 5x106 naive CD4+T cells, to irradiated 
DA hosts grafted with either PVG or third party Lewis grafts. Severe rejection 
was prevented in 8 of 9 rats with PVG grafts but in none of 5 rats with third party 
Lewis grafts. Controls given 5x106 naïve CD4+T cells rejected PVG grafts in 
10-20 days (n=12) and 7 of 10 Lewis grafts were rejected in 9-26 days. However, 
5x105 naïve fresh CD4+CD25+T cells mixed with 5x106 naïve CD4+T cells failed 
to prevent rejection with 7 of 8 animals rejecting in 8-14 days, similar to controls 
given 5x106 naïve CD4+T cells alone. Depletion of the CD8+CD4+CD25+T cells 
from the IL-2 activated CD4+CD25+T cells removed their capacity to suppress as 
transfer of 5x105 of these cells with 5x106 naïve CD4+T cells resulted in rejection 
of 4 of 5 PVG grafts in 10-22 days, only one becoming tolerant. We are examining 
the cytokine/cytokine receptor expression of CD4+CD8+CD25+T cells compared 
to IL-2 and alloantigen activated naïve CD4+CD25+Foxp3+T cells.
These studies suggest that within days of naïve CD4+CD25+T cell activation, 
antigen specifi c clones may express CD8 and this may be a marker to select 
antigen specifi c regulatory cells for further ex vivo expansion.
POSTER BOARD NUMBER P2 – 249
ANTIGEN SPECIFIC T REGULATORY CELLS FROM 1450 
TOLERANT HOSTS EXHIBIT PHENOTYPES SIMILAR TO 
CELLS THAT WERE ACTIVATED IN VITRO AND USED TO 
INDUCE TOLERANCE
N.D. Verma, K.M. Plain, M. Nomura, C. Robinson, G.T. Tran, R. Boyd, 
S.J. Hodgkinson, B.M. Hall.
Immune Tolerance Group, University of NSW, Sydney, Australia
Aims: To examine phenotype and in vitro reactivity of T regulatory cells (Tr) 
from rats made tolerant by adoptive transfer of IL-2 and IL-4 activated T 
regulatory cells.
Background: Natural CD4+CD25+T cells that express Foxp3, regulate immune 
response with no antigen specifi city, whereas the CD4+CD25+Tr that mediate 
transplant tolerance are antigen-specifi c, but require ongoing activation 
by specifi c antigen and cytokines from activated T cells. How non-antigen 
specifi c naïve CD4+CD25+Tr develop into antigen specifi c Tr is unknown. We 
found either IL-2 or IL-4, but not other Th1 or Th2 cytokines, activate naïve 
CD4+CD25+Foxp3+Tr cultured with alloantigen. IL-2 activated CD4+CD25+Tr 
expressed IFN-γ receptor (R) and IL-5 but not IFN-γ or IL-5 receptor α mRNA. 
IL-4 induced CD4+CD25+Tr had a reciprocal profi le with increased expression 
of IL-5Rα and IFN-γ, but not IL-5 and IFN-γR mRNA. These activated 
CD4+CD25+Tr showed enhanced capacity to suppress rejection of specifi c 
donor, but not third party allografts upon transfer to adoptive hosts. This 
study compared the peripheral lymphocytes in hosts where tolerance had been 
induced by either IL-2 or IL-4 alloactivated CD4+CD25+T cells to examine if 
their CD4+CD25+T cells continued to have different phenotypes.
Methods: CD4+CD25+T cells from naïve DA rats were activated in vitro with 
fully allogeneic PVG stimulator cells supplemented with IL-2 or IL-4. They 
were transferred to irradiated DA rats that were grafted with PVG or Lewis heart 
allografts and restored with naïve CD4+T cells. Both IL-2 and IL-4 activated 
cells induced tolerance to the specifi c PVG but not the third party Lewis. We 
examined the peripheral lymphocytes from long-term tolerant hosts.
Results: Both groups of tolerant hosts had normal numbers of CD4+CD25+T 
cells (5-7% of CD4+ T cells). CD4+CD25+T cells from adoptive hosts restored 
with IL-2 activated CD4+CD25+T cells had high expression of IFNGR and 
IL-5 mRNA but not IL-5Rα. Those given IL-4 activated CD4+CD25+T cells 
expressed IL-5Rα but no IL-5 mRNA. CD4+CD25+Tr hosts given IL-4, but 
not IL-2, activated CD4+CD25+Tr responded to IL-5 in MLC with signifi cantly 
higher proliferation. This is consistent with the fi nding of IL-5Rα mRNA 
expression on IL-4 activated CD4+CD25+Tr and shows that IL-5Rα has a 
functional role in maintaining these cells. CD4+CD25-T cells from these 
tolerant rats had normal reactivity to donor specifi c or third party alloantigens 
in MLC indicating they were not clonally deleted.
Conclusion: This study showed that there are two lineages of alloantigen 
specifi c activated CD4+CD25+Tr that persist in the adoptive host and may 
contribute to long term tolerance. The persistence of the phenotypes observed 
after short-term culture suggests there may be two separate pathways of 
activation and that both can mediate long term tolerance. These regulatory cells 
do not deplete donor reactive clones of CD4+CD25-T cells.
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FOXP3, CD11B AND CD57 - LOOKING FOR MARKERS 1451 
OF SUPRESSOR SUBSET OF CD8+CD28- CELLS FROM RENAL 
ALLOGRAFT RECIPIENTS
A. Korecka1, A. Duszota1,2, P. Wierzbicki2, M. Niemczyk2, J. Wyzgal2, M. 
Durlik2, A. Chmura2, A. Gorski2, L. Paczek2, G. Korczak-Kowalska1,2
1Department of Immunology, Faculty of Biology, University of Warsaw, 
2Transplantation Institute, The Medical University of Warsaw
The induction of transplant tolerance is one of the main aims of clinical 
transplantation. Suppressor CD8+CD28- T cells (Ts) are important for the 
development and maintenance of immune tolerance to allografts. CD8+CD28- 
population is very heterogeneous and Ts subset is postulated to be FoxP3+. 
Recently, CD11b and CD57 markers were also proposed to be characteristic 
for Ts subpopulation. Although immunosuppressive drugs are used to prevent 
acute allograft rejection, they can also inhibit Ts population and therefore 
interfere with transplant tolerance achievement.
The aim of this study was to evaluate the level of CD8+CD28- cells and the 
expression of FOXP3, CD11b and CD57 markers among this population in 
renal allograft recipients.
Blood samples were obtained from patients with stable renal allograft function or 
with chronic rejection that were under CsA or RAPA treatment and from healthy 
volunteers. Peripheral blood mononuclear cells were stained with monoclonal 
antibodies conjugated with fl uorochromes and analyzed by fl ow cytometry.
The CD8+CD28- population level was higher in patients than in healthy 
individuals. Less than 1% of CD8+CD28- cells had FOXP3 marker and the level 
of CD8+CD28-FOXP3+ cells was decreased both in patients with stable allograft 
function and with chronic rejection. CD8+CD28- cells from patients treated with 
CsA showed lower amount of FOXP3 marker. The level of CD8+CD28-CD11b+ 
and CD8+CD28-CD57+ cells was higher in patients than in healthy controls. We 
observed increased CD57 marker expression on CD8+CD28- cells, but there was 
no increase in CD11b marker level. CD8+CD28-CD11b+ cells level increased 
due to the higher CD8+CD28- cells number.
We did not observe any signifi cant differences in CD8+CD28- cells level or 
CD11b, CD57 and FOXP3 expression between patients with stable allograft 
function and with chronic rejection. The FOXP3 molecule level decreased after 
transplantation, especially in patients treated with CsA. The possible reason 
for that could be inhibited activation of T cells by immunosuppressive drugs 
or diminished Ts subset level. The CD57 molecule, presented on majority of 
CD8+CD28- cells, may be the Ts subpopulation marker, but the increased 
expression of this molecule and the higher number of CD8+CD28- cells 
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might be the result of chronic alloantigen stimulation. We can assume CD11b 
molecule is not a Ts subset marker because we did not observe any changes in 
its expression after transplantation.
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INCREASED CD4+CD25+FOXP3+ REGULATORY T CELLS 1452 
IN TOLERANCE INDUCED BY PORTAL VENOUS INJECTION
F. He, Z. Chen, M. Cai, S. Xu, M. Wu
Institution of Organ Transplantation, HUST
Background and aims: A portal venous injection of allogeneic donor cells 
is known to prolong the survival of subsequently transplanted allograft. But 
the underlying mechanisms remain to be clarifi ed. In this study we examined 
the proportions and function of CD4+CD25+Foxp3+ regulatory T cells (Treg 
cells) in a tolerance modal induced by portal venous injection of alloantigen.
Methods: Irradiated C57BL/6 (B6) splenocytes were transfused into BALB/c 
mice though portal vein. 7 days after portal venous injection, the proportions of 
CD4+CD25+Foxp3+ regulatory T cells (Treg cells) were examined in blood, 
liver and spleen. CD4+CD25+ Treg cells were isolated from BALB/c mice 
treated with a portal injection of B6 splenocytes using an auto MACS cell 
sorter. These isolated Treg cells were adoptive transfused into another BALB/c 
followed by heterotropic implantation of B6 or C3H (third party) heart 
allograft. Implantations of B6 heart allograft to normal BALB/c were used 
as control group. The survival of the heart allograft was analyzed by Kaplan-
Meier Estimator. Ex vivo alloantigen-specifi c CD4+CD25- T cells proliferation 
responses were assessed by cocultured CD4+CD25- T cells isolated from B6 
mice with Treg cells from normal BALB/c or BALB/c mice treated with a 
portal injection of B6 splenocytes.
Result: After portal injection of alloantigen, CD4+CD25+Foxp3+ Treg 
proportions in liver, spleen and peripheral blood were increased signifi cantly 
compared with normal BALB/c mice (date show in fi gure 1). Treg cells 
isolated from BALB/c mice treated with a portal injection of B6 splenocytes 
suppressed antigen-specifi c CD4+CD25- T cells proliferation ex vivo (PVI: 
38.2%±3.4%,n=6; Control: 78.9%±4.4%,n=6; P<0.01). Adoptive transfusion 
of Treg cells isolated from BALB/c mice treated with a portal injection of B6 
splenocytes prolonged B6 and C3H heart allograft compared with control group. 
But the B6 allograft had the greatest mean survival among the 3 groups. (Control: 
(3±1) days, n=6; C3H: (21±3) days, n=6; B6: (40±4) days, n = 6) (fi gure 2)
Conclusion: CD4+CD25+Foxp3+ regulatory T cells are increased in tolerance 
induced by portal venous injection of alloantigen. This kind of Treg plays an 
important role in promoting antigen-specifi c tolerance.
Figure 1 Proportions of CD4+CD25+Foxp3+ regulatory T cells (Treg cells) 
are increased in portal venous injective BALB/c (PVI) than in normal BALB/c 
(Normal). CD25+FoxP3+ Treg were gated from a CD4+subset of CD3+T cells.
Figure 2: Survival curve of the three groups. Adoptive transfusion of Treg cells 
isolated from BALB/c mice treated with a portal injection of B6 splenocytes 
prolonged B6 and C3H heart allograft compared with control group. The B6 
allograft had the greatest mean survival among the 3 groups.
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PREFERENTIAL DISTRIBUTION OF FOXP3+ 1453 
REGULATORY T CELLS IN COMPOSITE TISSUE 
ALLOGRAFTS
M.J. Elliott 1, B. Swearingen 1, D. Rahhal 1, L. Adamson 1, W.C. Huang 2, 
S. Atay 1, W. Breidenbach 3, S. Ildstad 1
1Institute For Cellular Therapeutics, Univeristy of Louisville, USA, 2Plastic 
and Reconstructive Surgery, Chang Gung Memorial Hospital, Taiwan, 
3Christine M. Kleinert Research Institute, Louisville, Kentucky, USA
Background: More than 30 hand transplants have been performed. 
Despite initial concerns, graft acceptance has been achieved with standard 
immunosuppression. 
Hypothesis: Regulatory T cells (Treg) have been implicated in the maintenance 
of tolerance. Treg express the transcription factor FoxP3. Peripheral blood 
Treg have skin homing receptors to aid their translocation to CTA and assist 
in cutaneous immunity. This study evaluated whether FoxP3+ Treg infi ltrate 
specifi c CTA tissue compartments. 
Materials and Methods: An ACI WF MHC-disparate rat model was utilized. 
WF rats were conditioned with 600 cGy total body irradiation on day -1, 
transplanted with 100x106 T cell depleted bone marrow from ACI rats on day 
0, and treated with tacrolimus (FK506) (days 0 to 10) and one dose of anti-
lymphocyte serum (day 10). Mixed chimerism was evaluated by fl ow cytometry 
on day 28. Rats with 1% chimerism underwent modifi ed hind limb CTA on day 
29. Animals were analyzed for FoxP3+ cell infi ltrates in different compartments: 
spleen, lymph node, bone marrow and skin at 6 months. RESULTS: The 
percentage FoxP3+ cells in spleen, lymph node, and bone marrow in rejecters 
(33.8, 34.2, 54.8%, respectively) and acceptors (46.1, 49.4, 47.4%) of CTA 
was not signifi cantly different. Both were signifi cantly lower compared to 
naive controls (83.9%, 68.7%, 61.3%). The skin of treated rats analyzed for 
infi ltrating CD4+/CD25+/FoxP3+ Treg showed a signifi cantly higher level of 
FoxP3 expressing cells (33.4 cells/HPF and 46.5 cells/HPF) in the transplanted 
skin of CTA acceptors compared to naïve donor or host skin (0 cells/HPF). 
Discussion: CTA is becoming a viable treatment option in patients with large 
tissue and limb defects. Understanding the factors that contribute to graft 
acceptance will allow focused approaches to modulate their role in post-
transplantation therapy. The preferential presence of FoxP3+ Treg in skin of 
CTA may partially explain why acceptance of CTA has been more readily 
achieved than previously predicted. Functional studies are underway to 
corroborate the fi ndings that Treg are present in skin. These data may have 
signifi cant implications in the interpretation of clinical biopsy results since 
some cellular infi ltrates (FoxP3+) may not herald rejection.
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PROLONGATION OF HEART-ALLOGRAFT SURVIVAL 1454 
AFTER LONG-TERM EXPRESSION OF SOLUBLE-MHC CLASS 
I-ANTIGENS AND VIL-10 IN THE LIVER BY AAV-PLASMID 
MEDIATED GENE TRANSFER
A. Doenecke, E. Frank, M. Scherer, E. Geissler, H. Schlitt
University of Regensburg Medical Center
The essential prerequisite for successful gene therapy in vivo is an effective 
and long-lasting transfer of the desired gene into the respective cell type or 
tissue. Over the last decades, many different methods have been developed 
for this purpose. The use of plasmid DNA seems to be a good alternative to 
the commonly used viral vectors, since its large scale production is simple, 
and side effects are low. Unfortunately, most reports describe only short-term 
expression in vivo, probably due to the lack of genomic integration in the target 
cell. This problem can possibly be addressed by the use of adeno-associated-
virus plasmids (AAV-plasmids), where the coding sequences are cloned 
between the AAV-specifi c ITRs. Here we report our results after allogeneic 
heart transplantation, which followed AAV-plasmid mediated gene transfer of 
the rat soluble MHC class I-antigen RT1.Aa and vIL-10 in the „high“-responder 
DA to Lewis rat-strain combination.
Results: A high and stable long-term expression was achieved by in vivo 
transfection of the liver using AAV plasmids. Serum levels over 1000 ng/ml 
of soluble RT1.Aa and over 300pg of vIL-10, respectively, were achieved. 
Expression levels remained high for up to several months. A mean prolongation 
of heart allograft survival of 1 to 2 days was demonstrated after transfection of 
either RT1.Aa, or vIL-10.
POSTER BOARD NUMBER P2 – 254
CARBON MONOXIDE PREVENTS REJECTION OF 1455 
CARDIAC ALLOGRAFTS VIA ACTIVATION OF HIF1Α;
M.N. Thomas1,3, T. Macdonald3, E. Csizmadia3, F. Bösch2, F.H. Bach3, 
L.E. Otterbein3, B.Y. Chin3
1General Transplant Surgery, Medical University of Munich, Germany, 
2Medical University Innsbruck, Austria and 3Transplant Center, Beth Israel 
Deaconess Medical Center, Harvard School of Medicine, Boston, 
MA 02215, USA
Carbon monoxide (CO) at low concentrations can reduce the development 
of acute and chronic rejection of allografts. One mechanism of protection 
involves preventing the actute infl ammatory response and oxidative injury 
following transplantation. The mechanism(s) by which CO imparts protection 
is still unclear. One mechanism that we have elucidated in limiting ischemia/
reperfusion injury involves CO-induced stabilization of hypoxia inducible 
factor 1α; (HIF1α;). We tested the hypothesis that HIF1α; activation in the 
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graft would prevent rejection. Employing a strong mismatch model of heart 
heterotopic allograft transplantation in mice (BALB/c to C57BL/6) we 
show that administration of exogenous CO attenuates graft rejection and 
the development of arteriosclerotic lesions. Recipients only were exposed 
to 250ppm CO or air for one hr prior to transplantation and then 1 hr daily 
thereafter. Rejection was assessed by palpating heartbeat and quantitation 
of intimal hyperplasia histopathologically 2 weeks post transplant. Air-
treated mice showed signs of rejection as measured by intimal hyperplasia 
of the aortas by 13-15 days postoperatively, which was not observed in CO 
treated hearts. Examination of tissue sections showed signifi cant increases 
in T aggressive cell infi ltrates in air-treated controls, which was signifi cantly 
reduced in CO-treated mice. We observed a statistically signifi cant survival 
benefi t of transplanted hearts with CO vs air; with air-treated animals 
rejecting by day 8 while the hearts in CO-treated animals survived until day 
12. CO induced a marked enhancement in Treg (Foxp3) positive staining 
in the aortas of CO-treated treated animals, which was signifi cantly less in 
air-treated animals. Administration of PC61, an antibody selective for Treg 
(CD4+/CD25+), reversed the protection afforded by CO to that observed in 
air-treated controls. Additionally, we observed a greater number of monocyte/
macrophage (m&#966;) infi ltrates in CO-treated mice vs air. Employing a 
conditional macrophage specifi c knockout mouse for HIF1α; (lyz-HIF1α;-
/-cre-lox) we tested the role of macrophage-specifi c HIF1α; expression in 
recipients. Air-treated lyz-HIF mice showed similar graft survival vs wild-
type littermates. The ability of CO to impart protection as that observed 
in wild-type littermates was lost in lyz-HIF recipients. Taken together, our 
studies suggest that one mechanism by which CO enhances graft survival is 
through HIF1α; stabilization in macrophages.
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UPREGULATING CD4CD25FOXP3 T CELLS IN 1456 
PANCREATIC LYMPH NODES AND INCREASING TGF-BETA 
PRODUCTION IN DIABETIC NOD MICE BY ADJUVANT 
IMMUNOTHERAPY
L. Tian1, H. Yi1, B. Tian1, J. Hao1, Y. Zhang1, T. O’Brien2, D. Sutherland1, B. 
Hering1, Z. Guo1
1Department of Surgery, University of Minnesota, 2Department of Veterinary 
Population Medicine, University of Minnesota.
Regulatory T cells play a key role in controlling or maintaining self-
tolerance. In this study, we investigated whether adjuvant immunotherapy 
with Complete Freund’s adjuvant (CFA) up-regulates CD4+CD25+FoxP3+ 
regulatory T cells and increases TGF-beta in diabetic NOD mice. Spontaneous 
diabetic NOD mice were treated with a single dose of CFA at 0.1 mg alone or 
with CFA and exendin-4, a potent analog of Glucagon-like peptide-1. Blood 
glucose level was monitored and CD4+CD25+FoxP3+ regulatory T cells in 
the peripheral blood, spleen, thymus, and pancreatic nodes will be measured. 
Reversal of diabetes was not achieved in mice that treated with insulin only. 
However, 5 of 13 (38%) diabetic NOD mice became normoglycemic from 9 
to 42 days (mean 25±14 days) after the CFA treatment; and 12 of 14 (86%) 
diabetic NOD mice became normoglycemic from 4 to 106 days (mean: 35±29 
days) after CFA and exendin-4 treatment. One week after CFA treatment, the 
percentage of CD4+CD25+FoxP3+ regulatory T cells among the total CD4+ 
T cells of peripheral blood and thymus were 8.5±2.7% and 1.3±0.7% in 
CFA-treated NOD mice; and 5.9±1.8% and 1.0±0.4% in control NOD mice. 
However, the number of CD4+CD25+FoxP3+ regulatory T cells in spleen 
and the pancreatic lymph nodes of CFA-treated NOD mice were signifi cantly 
increased, as compared with control diabetic NOD mice. The percentages 
of CD4+CD25+FoxP3+ regulatory T cells among total CD4+ T cells in the 
spleen and pancreatic lymph nodes were 12.8±2.7% and 10.9±2.0% in CFA-
treated NOD mice; and 8.2±0.6% (P<0.05) and 6.7±1.1% (P<0.05) in control 
NOD mice. The percentage of CD4+CD25+FoxP3+ regulatory T cells in the 
total CD4+ T cells in the pancreatic lymph nodes was 15.0±1.2% in control 
nondiabetic NOD mice, 14.8±1.7% in diabetic NOD mice 5 weeks after 
CFA and exendin-4 treatment; and 7.8±1.0% in diabetic NOD mice with 
exendin-4 alone treatment. The number of CD4+CD25+FoxP3+ regulatory 
T cells was signifi cantly and persistently increased in the pancreatic lymph 
nodes of diabetic NOD mice after CFA treatment. Fifteen to seventeen weeks 
after treatment, the mean level of CD4+CD25+FoxP3+ regulatory T cells in 
pancreatic lymph nodes of NOD mice was 13.3±2.3%, which was signifi cantly 
higher than the mean level in the peripheral blood (4.6±0.9%, <0.01), thymus 
(2.4±2.3%, P<0.01), and spleen (8.5±2.4%, P<0.05). All 8 NOD.scid mice 
that received lymphocytes from control diabetic NOD mice developed 
diabetes at 5 weeks post-adoptive transfer. However, diabetes developed in 
only 1 of 7 NOD.scid mice at 5 weeks (P<0.05) after receiving lymphocytes 
from CFA-treated NOD mice. Furthermore, diabetes only developed in 1 of 
7 NOD.scid mice at 5 weeks (P<0.05) following co-transfer of lymphocytes 
from diabetic NOD mice with lymphocytes from CFA-treated NOD mice. 
The concentration of TGF-beta in the sera was 7.6±1.6 ng/ml in diabetic 
NOD mice; 18.1±9.7ng/ml in nondiabetic NOD mice; and 45.9±26.4ng/
ml in CFA treated NOD mice. Our results demonstrated that adjuvant 
immunotherapy with CFA ameliorates autoimmunity in diabetic NOD mice 
by regulating CD4+CD25+FoxP3+ regulatory T cells and increasing TGF-
beta production.
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LIVER DENDRITIC CELLS RESIST THE EFFECTS OF 1457 
RETINOIC ACID AND TRANSFORMING GROWTH FACTOR-B 
FOR THE INDUCTION OF FOXP3+ REGULATORY T CELLS
A. Thomson1,2, D. Tokita1, C.S. Gandhi1, T. Sumpter1
1University of Pittsburgh, Starzl Transplant Institute, Dept of Surgery, 
2University of Pittsburgh, Dept of Immunology
Transplanted livers are better tolerated compared to other organs. This may 
refl ect interactions between dendritic cells (DC) and Foxp3+ regulatory 
T cells (Treg) within the liver. CD103 expression on DC correlates with de 
novo induction of Foxp3 in T cells. Furthermore, Foxp3 expression in T 
cells is elevated in the presence of transforming growth factor-b (TGF-b) 
and retinoic acid (RA), both of which are produced in the liver. This study 
evaluates CD103 expression on liver plasmacytoid (p) and myeloid (m) DC 
and the potential of liver DC subsets to induce Foxp3 expression in T cells 
in the presence of TGF-b&#61472;and RA. Magnetically isolated pDC and 
mDC from livers and spleens of C57BL/10 mice and evaluated for CD103 
expression by fl ow cytometry. pDC or mDC were co-cultured with CFSE-
labeled allogeneic (BALB/c) CD4+CD25- T cells. After 4 or 5d of co-culture, 
T cells were assessed for CFSE dilution and intracellular Foxp3 expression by 
fl ow cytometry. rhTGF-b&#61472;and either all trans or cis-RA were added 
to co-cultures. Both mDC and pDC from the liver expressed higher levels 
of CD103 compared to spleen pDC or mDC, with the highest expression of 
CD103 found on liver mDC. pDC, compared to mDC, from either the liver 
or the spleen were poor inducers of Foxp3 expression in CD4+CD25- T cells. 
TGF-b enhanced the induction of Foxp3 in T cells co-cultured with splenic 
pDC, but not liver pDC. The effects of TGF-b were further enhanced when RA 
(either all trans or cis) was added to CD4+CD25- T cells when splenic pDC 
but not liver pDC were used as stimulators. TGF-b&#61472;and TGF-b with 
RA also enhanced Foxp3 induction in CD4+CD25- T cells when either spleen 
or liver mDC were used as stimulators, though splenic mDC were superior 
inducers of Foxp3 in CD4+CD25+ T cells. Our data show that liver mDC and 
pDC are poor inducers of Foxp3 in T cells, even in the presence of TGF-b and 
RA. These data suggest that the inherent tolerogenicity of liver DC subsets may 
be independent of de novo induction of Treg.
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TOLERANCE TO RAT LIVER ALLOGRAFTS AFTER 1458 
TOTAL LYMPHOID IRRADIATION IS MEDIATED BY 
CD4+CD25+FOXP3+ T REGULATORY CELLS AND THE 
APOPTOSIS OF INTRAGRAFT CD4+ T CELLS
S. Krams1, M. Fujiki1, C. Esquivel1, O. Martinez1, S. Strober2, 
1Surgery, Division of Transplantation, Stanford University, 2Medicine, 
Stanford University
Aim: We previously reported that total lymphoid irradiation (TLI) induces 
tolerance to rat liver allografts with increased CD4+CD25+ T cells in the 
peripheral blood of long-term surviving recipients. Both TLI and liver 
allotransplantation have been reported to contribute to the expansion of 
regulatory T cells (T reg) and tolerance. In this study we examined the 
mechanism of TLI-induced tolerance to liver allografts.
Methods: Lewis recipients were transplanted either with syngeneic Lewis 
(Syn) or allogeneic DA livers (Allo) and were left untreated or received 
8 doses of 240 cGy of TLI after transplantation. Graft infiltrating cells 
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were isolated and stained with Annexin V to quantitate apoptotic cells. T 
reg cells (CD4+CD25+Foxp3+ cells) in the blood, spleen and graft were 
measured by flow cytometry Specific alloresponsiveness was determined 
by MLR and adoptive transfer of splenocytes to naive recipients of heart 
allografts.
Results: TLI prolonged liver allograft survival, with 88% of recipients 
surviving >100 days without any evidence of chronic rejection. At day 
7 post-transplant, CD4+CD25+Foxp3+ cells in the graft were increased 
in the Allo TLI group as compared to the Allo control group (Allo+TLI 
10.8% vs. Allo 6.6%). Intragraft CD4+CD25+Foxp3+ cells remained 
increased in the graft (day 35) and spleen (day >100) in the Allo TLI group. 
Furthermore, apoptotic CD4+ cells were detected in markedly higher 
numbers in the Allo TLI group as compared to the Allo group (AnnexinV+/
CD4+; Allo+TLI 35.9% vs. Allo 14.0%). Apoptotic infiltrating cells were 
not observed in the Syn TLI group. CD4+CD25+ cells isolated from the 
spleen of Allo TLI recipients (day >100) inhibited the alloresponse of naive 
Lewis splenocytes to DA splenocytes in MLR, whereas CD4+CD25 -cells 
increased the alloresponse. Importantly, adoptive transfer of splenocytes 
from day >100 Allo TLI recipients prolonged the survival of donor, but 
not third-party heart grafts (MST; 33 days TLI vs.18 days control; p<0.01). 
Importantly, depletion of CD4+CD25+ cells from transferred splenocytes 
abrogated this prolongation (MST; 16 days). Cardiac graft survival was 
not prolonged by the transfer of splenocytes from day 35 recipients of 
allo TLI.
Conclusion: TLI induces tolerance to liver allografts via a mechanism 
involving concomitant apoptosis of CD4+ cells and the accumulation of 
CD4+CD25+Foxp3+ Treg cells that persist in the spleen >100 days after 
transplant.
GRAFT RESPONSES AND CONCURRENT ORAL SESSION 103: 
SIGNALLING
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BENEFICIAL EFFECT OF CANDESARTAN FOR 1459 
PREVENTING RENAL INTERSTITIAL FIBROSIS THROUGH 
PAI-1 AND TGF-BETA SUPPRESSION
A. Ishikawa1, M. Tanaka2, Y. Ishibashi3, T. Fujita3, T. Kitamura1
1Department of Urology, Faculty of Medicine, The University of Tokyo, 
2Growth Factor Division, National Cancer Center Research Institute, 
3Department of Nephrology and Endocrinology, Faculty of Medicine, The 
University of Tokyo
Introduction and objective: To elucidate the mechanism of renal preservation 
effect of angiotensin II receptor blockers (ARBs), we carried out the following 
study using cyclosporine (CyA) nephrotoxic rats.
Methods: Ten-week-old male Wistar rats were divided into four groups (fi ve 
animals each). Group 1 received a medium only. Group 2 received 30 mg/kg/
day (i.e. experimentally nephrotoxic dose) of CyA only. Group 3 received both 
30 mg/kg/day of CyA and 10 mg/kg/day of candesartan (CAN), one of ARBs. 
Group 4 received 10 mg/kg/day of CAN only. Drugs were given orally once a 
day for fourteen days. On the fi fteenth day, after blood sampling, kidneys were 
removed and processed for Western blotting (WB), reverse transcriptional-
polymerase chain reaction (RT-PCR), and immunohistochemistry (IHC) to 
examine PAI-1 and TGF-beta expression.
Results: Plasma PAI-1 levels of groups 1-4 were 22 }8, 37 }11*, 27 }10, 23 
}9 (0-50) ng/ml respectively (* p<.05 vs. Group 1). WB, RT-PCR, and IHC 
demonstrated that PAI-1 and TGF-beta were up-regulated in group 2, and 
down-regulated in group 3.
Conclusions: Our present study suggested that PAI-1 and TGF-beta might play 
important roles in nephrotoxic side effect of CyA and renal preservation effect 
of ARBs. ARBs would contribute to prevent renal interstitial fi brosis through 
PAI-1 and TGF-beta suppression.
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THE ROLE OF THE KIDNEY IN THE SYSTEMIC 1460 
ELIMINATION OF SELECTED CYTOKINES AND 
GROWTH FACTORS
M. Nowak1, Z. Wlodarczyk2, A. Wyczalkowska-Tomasik1, L. Paczek1
1Transplantation Institute, Warsaw, Poland, 2University Hospital, 
Bydgoszcz, Poland
Study goal: The aim of the study was to assess the role of kidney in systemic 
elimination of cytokines (IL-6) and growth factors (PDGF, TGF-B) by 
comparison of their concentrations and gene expression in renal artery and vein, 
peripheral vein and urine. A mathematical model of elimination of investigated 
proteins from systemic circulation was elaborated.
Material and methods: 30 kidney donors were included into the study. 
Samples were obtained during harvesting procedure. 10 healthy volunteers 
served as controls. Serum levels of investigated proteins were estimated using 
immunoenzymatic method (ELISA). Real-Time Polymerase Chain Reaction 
(RT-PCR) method was used to evaluate gene expression of investigated
proteins in mononuclear blood cells.
Results: Increased peripheral blood concentrations of all investigated proteins 
comparing to the control group were observed: IL-6 – 330-fold, PDGF 25-fold 
and TGF-B 12-fold. Renal IL-6 uptake
ratio (UR) amounted to 6.6%, elimination ratio (ER) amounted to 6.4% and 
pass ratio (PR) amounted to 0.2%. PDGF ratios amounted to 5.1%, 5.0% and 
0.1% and TGF-B ratios amounted to -9%, -9% and 0%, respectively. Mean 
IL-6 gene expression was higher in renal artery comparing to vein. Differences 
in TGF-B and PDGF genes expressions were not signifi cant.
Conclusions: Kidney donors have increased serum concentrations of cytokines 
and growth factors. The kidney takes part in the elimination of IL-6 and PDGF 
from systemic circulation. The kidney does not take part in the elimination of 
TGF-B. Mononuclear blood cells producing IL-6 are retained by the kidney. 
The above phenomenon was not observed regarding to PDGF and TGF-B.
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AUGMENTED EARLY IMMUNE RESPONSE AFTER 1461 
TRANSPLANTATION OF GRAFTS FROM AGED DONORS
C. Denecke1, X. Ge1, D. Bedi1, I. Kim1, A. Jurisch1, J. Pratschke2, 
P. Neuhaus2, S. Tullius1
1Div of Transplant Surgery, BWH, 2Dept of Surgery, Charite, Berlin, 
Germany
The discrepancy between demand and supply requests an increased utilization 
of older organs for transplantation. Advanced donor age may not only be 
associated with physiological impairments but also with a modifi ed immune 
response of the recipient. We hypothesized a more potent early immune 
response following the transplantation of elderly donor organs and analyzed 
the immune response in a mouse heart transplant model.
Young B6 mice received heart allografts from 3, 12 and 18mths old bm12 donors. 
Recipients immune response and intragraft changes were analyzed. Elderly, 
non-manipulated hearts contained overall signifi cantly elevated frequencies of 
CD4+and CD8+ T-cells and DCs (CD11c+) (18mths vs. 3mths: CD4+: 2.77% 
vs. 1.35%, CD8+: 3.90% vs 1.71%, CD11c+: 46.1% vs.11.8%, p<0.05).
Following engraftment of 18mths old heart grafts numbers of activated DCs 
(CD11c+I-Ab+and CD11c+CD40+) had signifi cantly increased in recipients 
spleens (day 14:p<0.05). In parallel, frequencies of effector/memory phenotype 
T-cells (CD4+CD44highCD62Llow and CD8+CD44highCD62Llow) 
were signifi cantly elevated with increasing age (3 vs. 12 vs, 18mths: 
CD8+CD44highCD62Llow :6.7% vs. 8.4% vs. 12.2%, respectively, p< 0.01). In 
parallel, Tregs (CD4+CD25+FoxP3+) were also elevated (3 vs. 12 vs, 18mths: 
2.9%vs.9.6%vs.11%,p<0.05). T-cell alloreactivity as measured by IFN?-
production increased with donor age (3mths vs. 12mths vs.18mths: 24.4±1.5 
vs 74.4±21.9 vs. 73.2±7.8 IFN?-producing spots/5x106 cells, p<0.05). Mixed 
Lymphocyte Reaction (MLR) at day 14 revealed a gradual incline in splenocyte 
proliferation with advancing donor age (p=0.0002) underlining an enhanced 
immunogenicity of older organs.
Immunohistochemical staining confi rmed augmented CD4+ and CD8+ T-cell 
infi ltrates in 18mths old heart grafts, emphasizing an intensifi ed immune 
response associated with the engraftment of older organs.
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In summary, old native heart transplants contain an overall increased cellularity 
with higher numbers of passenger leukocytes contributing to an increased 
immunogenicity.. Following transplantation, a more potent DC and T-cell 
activation and intragraft T-cellinfi ltration was observed in elderly organs
POSTER BOARD NUMBER P2 – 261
INTENSIFIED INNATE AND ADAPTIVE IMMUNE 1462 
RESPONSE AFTER DCD TRANSPLANTATION FROM AGED 
DONORS
C. Denecke1, I. Kim1, D. Bedi1, A. Jurisch1, X. Ge1, K. Kotsch2, J. Pratschke3, 
P. Neuhaus3, S. Tullius1
1Div of Transplant Surgery, BWH, 2Dept of Med. Immunology, Charite, 
Berlin, Germany, 3Dept of Surgery, Charite, Berlin, Germany
Introduction: Organs from DCD donors are increasingly utilized for 
transplantation. We evaluated the outcome, recovery and the recipient’s 
immune response of young and old DCD organs in an experimental model.
Methods: Young (3 months) and old F-344 donor rats (18 months) were 
anesthesized, ventilated and monitored. Following withdrawal of the ventilator, 
asystole was awaited;kidneys were engrafted into bilaterally nephrectomized 
LEW recipients after a warm ischemia time of 45min. To test organ recovery, 
DCD organs were followed under the protection of a contralateral native kidney 
in an additional set of experiments.
Survival and recovery: By 10 days survival in DCD recipients was reduced by 
50% independent of donor age compared to LD controls. H&E staining confi rmed 
extensive acute tubular necrosis of > than 80% in DCD kidneys. However, all 
DCD recipients with a supportive contralateral native kidney in place for 4 weeks 
survived long-term, demonstrating a potential for recovery after tubular injury.
In vitro analysis: 24hrs after transplantation recipients of old DCD 
grafts showed signifi cantly elevated numbers of activated CD4+CD25+T-
cells and NK-cells (CD161+TCR-) in draining lymph nodes (p<0.05). 
Signifi cantly elevated frequencies of activated DCs (OX62+ClassII+ and 
OX62+CD86+) were detected at that time (p<0.05). Moreover, recipients of 
old DCD grafts responded with an enhanced IFN? production (ELISPOT; 
p<0.01) and upregulated intragraft gene expression (TNF?, TGF-?;p<0.05). 
Immunohistochemical staining revealed signifi cantly more intragraft NK/NK-
Tcells (CD161+) in old DCD kidneys (p<0.05).
By day 10, frequencies of effector T-cells (CD4+CD45RC-), activated DCs 
(OX62+ClassII+), B-cells (CD45RA+ClassII+) but also CD4+CD25+FoxP3+ 
T-cells had increased in DCD recipients (p<0.05). Old DCD kidneys 
demonstrated a signifi cantly stronger intragraft gene expression of IFN? and 
IP10 and higher numbers of graft infi ltrating CD4+ T-cells and NK/NK-Tcells 
(CD161+) as assessed by IH (p<0.05).
Conclusion: In conclusion, DCD organs have a high potential to recover 
after extensive ATN and DGF. Engraftment of elderly DCD organs elicited 
an intensifi ed early innate and adaptive immune response. Clinically, DCD 
recipients may benefi t from a modifi ed immunosuppression.
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EVIDENCE THAT THE GRAFT PLAYS AN IMPORTANT 1463 
ROLE IN MAINTAINING TOLERANCE TO DONOR 
ALLOANTIGENS
M. Hara1, E. Chosa1, A. Watanabe1, T. Shimizu1, M. Tomita1, T. Ayabe1, 
M. Yano1, R. Sekiya1, K. Wood2, T. Onitsuka1
1Department of Cardiovascular, Thoracic And General Surgery, Faculty of 
Medicine, University of Miyazaki, Japan, 2. Nuffi eld Department of Surgery, 
University of Oxford, UK
Background: Dissecting the mechanism of transplantation tolerance is one of 
the ways to investigate the role of regulatory T cell in controlling rejection. 
Treatment with a depleting anti-CD4 mAb at time of transplantation (day-1, 
0) induces tolerance to vascularized cardiac allografts. When the primary heart 
graft is removed 50 days after transplantation, tolerance to donor alloantigen 
is maintained for 130 days even in the absence of the primary heart graft. The 
mechanism of maintenance of tolerance without antigen has not been elucidated. 
We have shown that administration of either anti-CD25 or anti-CTLA4 ab 
induces rejection of the second graft. The question is whether anti-CD25 and 
anti-CTLA4 ab induce rejection of the second graft without fi rst graft removal.
Methods: C57BL/6 hearts were transplanted into the neck of a recipient C3H 
mice treated with the depleting anti-CD4 mAb treated (YTA 3.1 0.05mgx2, 
day-1,0 iv). The primary heart graft was removed or leaved at day 50. A second 
heart graft was transplanted into the recipient fs abdomen at day 100 and graft 
survival was evaluated.
Results: The second heart graft was accepted in a strain fashion (MST=100 vs 
third party MST=16). Administration of either anti-CD25 ab (PC61; 0.25mgx1, 
d97 iv) or anti-CTLA4 ab (4F10; 0.25mgx3, d100,103,106 ip) induced rejection 
of the second graft (MST= 71, 11, respectively). @However, administration of 
either anti-CD25 ab or anti-CTLA4 ab could not induce rejection of the second 
graft without fi rst graft removal.
Conclusion: Graft itself plays an important role in maintaining tolerance.
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CYCLOSPORIN A PROMOTES EPSTEIN-BARR VIRUS 1464 
INFECTED HUMAN B CELL TRANSFORMATION ASSAYED BY 
THREE CORRELATED ASSAY METHODS
D. Ranjan, C. Chen, T.D. Johnston, H. Jeon, R. Gedaly, P. McHugh
University of Kentucky
We have reported that Cyclosporin A (CsA) has direct effect in promoting Epstein-
Barr virus (EBV) transformation of human peripheral blood B-lymphocytes. In 
this paper we report that CsA promoted EBV infected human B cell transformation 
as assayed by three methods of colony number counting, cell number counting, 
and 3H-thymidine incorporation. At fi rst, we tried to fi nd the correlation between 
the three methods in EBV infected human B cell transformation, and found that 
they are convenient and correlate with each other and only vary in the degree 
when transformed cells are compared to the controls. We found that in the EBV 
infected B cells, there were 27 +/-4 colonies/well (n=12, +/- SE) in the experiments 
after 4 weeks of culture. The number of transformed cells was at 33708+/- 990 
cells/well (n=12, +/- SE). In correlation with the transformed colony and cell 
numbers, 3H-thymidine incorporation of the EBV-B cells were at high rate, 
at 12763 +/- 368 CPM/well (n=12, +/- SE). Whereas, the non infected B cells 
had 0 in colony number, 4250 +/- 185 cell number and 152 +/- 22 CPM/well in 
3H-thymidine incorporation respectively. Based on these experiments, the three 
assay methods were then applied to CsA treated and non treated EBV-infected 
human B cells to investigate if CsA treatment promotes EBV infected human B 
cell transformation. We found that CsA treatment increased colony formation 
from control of 28 +/- 4.5/well to 49 +/- 4.3 (colonies /well) (n=5, p<0.05); CsA 
treatment increased cell number from control 33025 „b 1900 to 50925 +/- 4194 
(cells/well)(n=5, p<0.05); CsA treatment increased 3H-thymidine incorporation 
from control 12481 +/- 1341 to 26514 +/- 5464 (CPM/well) (n=5, p<0.05). In 
conclusion, CsA promotion of EBV-B cell transformation is clearly indicated 
in the three correlated assay methods in the in vitro model of post-transplant 
lymphoproliferation disorder (PTLD).
POSTER BOARD NUMBER P2 – 264
PROTEIN KINASE C-DELTA (PKC-D) AS DONOR 1465 
FACTOR DETERMINING ALLOGRAFT REJECTION
H.R. Cho1,2, B. Kwon2,3, C.W. Nam1, Y.W. Nah1
1Dept. of Surgery, Ulsan University Hospital, Ulsan, Korea, 2Biomedical 
Research Center, Ulsan University Hospital, Ulsan, Ulsan, Korea, 
3Department of Biological Science, University of Ulsan, Ulsan, Ulsan, Korea
PKC-d plays a critical role in proliferation and apoptosis of various types of 
cells. In this study, we examined the role that PKC-d plays in target organs 
or cells in alloimmune responses, using three experimental model systems. 
First, we showed that, in the C57BL/6C3H vessel transplant model, there 
was an increased neointima hyperplasia and infl ammation in PKC-d-defi cient 
allografts compared with wild-type allografts. Marked upregulation of 
molecules involved in chemotaxis and T cell activation was observed in PKC-
d-defi cient allografts. Second, in the C57BL/6 (H-2Kb)C3H.SW (H-2Kb) 
minor histocompatibility antigen-mismatched cardiac allograft model, PKC-d-
defi cient cardiac allografts exhibited more severe vasculopathy, infl ammation, 
and damage of cardiac muscles. Results from RT-PCR analysis were in 
agreement with histopathological data in that there was markedly increased 
expression of molecules involved in chemotaxis, costimulation, infl ammation, 
tissue remodeling, and cell adhesion. Finally, PKC-d-defi cient C57BL/6 
recipients that received bone marrow and T cells from C3H.SW donors had 
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more severe loss of body weight and intestinal damage, and lower survival rate 
than did wild-type littermates, indicating that defi ciency of PKC-d in recipients 
deteriorates acute graft-versus-host disease (GVHD). Taken together, our 
results clearly indicate that PKC-d functions as a host factor determining 
allograft rejection.
POSTER BOARD NUMBER P2 – 265
THE ANTI-INFLAMMATORY EFFECT OF CO 1466 
RELEASING MOLECULES IS NOT PERPETUATED BY 
INDUCTION OF HEME OXYGENASE 1
B. Yard, S. Hui, C. Bergstrasser, S. Hoeger
Vth Medical Clinic, Medical Faculty Mannheim, University of Heidelberg
Heme oxygenase-1 (HO-1) exert anti-infl ammatory effects via heme 
degradation and subsequent generation of carbon monoxide (CO). Since 
CO itself is able to up-regulate HO-1 expression, perpetuation of the anti-
infl ammatory effects is expected. We investigated how CO releasing molecules 
(CORM), i.e. CORM-3, infl uence the expression of adhesion molecules and if 
HO-1 mediated perpetuation was involved.
CORM-3 consistently inhibited the expression of VCAM-1 and E-selectin on 
TNF-α; stimulated human umbilical vein endothelial cells (HUVEC), while for 
ICAM-1 this was not observed in each line tested. CORM-3 did not infl uence 
initial NFkappaB activation by TNF-α;, however, NFkappaB activation was 
diminished after 4 hrs and completely lost after 24 hrs. CORM-3 was also 
able to down-regulate VCAM-1 expression, even when added to HUVEC that 
were prior stimulated for 24 hrs with TNF-α;. In this case, down-regulation of 
VCAM-1 was not completely paralleled by a decreased NFkappaB activation 
and VCAM-1 mRNA expression. Induction of HO-1 occurred in a dose and 
time depended manner and was mediated by Nrf-2. Neither in HO-1 – nor in 
Nrf-2 siRNA transfected HUVEC, was the effi cacy of CORM-3 lost to down-
regulate VCAM-1 expression. In Nrf-2 siRNA transfected HUVEC however 
HO-1 was no longer induced by CORM-3.
In conclusion our study demonstrates that CORM-3 mediated anti-infl ammatory 
effects are independent of HO-1 up-regulation. Although CORM-3 most 
likely exerts its effect by inhibition of sustained NFkappaB activation, down-
regulation of VCAM expression also seems to be regulated post-translationally. 
CORM-3 might have a potential clinical use to resolve ongoing infl ammation 
as occurs during ischemia/reperfusion and organ transplantation.
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THE EFFECT OF IMMUNO-SUPPRESSANT DRUGS 1467 
ON INNATE IMMUNITY
A. Bakran2, L. Hopcraft1, M. Howse2, S.W. Edwards1
1School of Biological Sciences, University of Liverpool, Crown Street, 
Liverpool, L697BZ, 2Royal Liverpool and Broadgreen University Hospitals, 
Prescot Street, Liverpool, L78XP
Introduction: Patients who undergo renal transplantation receive immuno-
suppressive drugs designed to down-regulate T-lymphocytes (T-cells) which 
mediate acute rejection episodes. Whilst immuno-suppression increases the 
risk of viral infections, bacterial infections are even more common in these 
patients, despite any obvious direct effects on innate immune cells that would 
normally combat these pathogens. This observation suggests that innate 
immunity is likely to be impaired during immuno-suppressive therapy, but few 
investigations to date have focussed on the effect of such drugs on cells of the 
innate immune system. The aim of this study was to determine whether the 
commonly prescribed immuno-suppressive drugs elicited any direct in vitro 
effects on the functions of the neutrophil, an important component of the innate 
immune response.
Methods: Neutrophils were isolated from heparinized venous blood from 
healthy volunteers by a one-step isolation method on Polymorphprep. Cells were 
incubated at 37°C in RPMI 1640 medium (+HEPES, +10% pooled human AB 
serum) in the absence (control) or presence of a variety of immuno-suppressant 
drugs (or their solvent vehicle) at concentrations representing “peak” and 
“trough” serum levels following administration. After 30 min pre-incubation, 
changes to neutrophil function were determined by measurement of reactive 
oxygen species (ROS) following activation of the respiratory burst measured 
by luminol and isoluminol-dependent chemiluminescence respectively, and 
stimulation by the phorbol ester, PMA.
Results: Under these experimental conditions, the majority of the drugs tested had 
no signifi cant effect on the magnitude or kinetics of the respiratory burst. These 
included prednisolone (100-1000 ng/mL), 6-mercaptopurine (50-150 ng/mL, 
the active ingredient of azathioprine), rapamycin (0.1-1000 ng/mL), ciclosporin 
(200-1000 ng/mL) and tacrolimus (0.1-1000 ng/ml). However, mycophenolic acid 
(MPA, the active ingredient of mycophenolate mofetil) resulted in a signifi cant 
dose-dependent inhibition of ROS production (p<0.05) measured by either 
luminol or isoluminol which measure total and secreted ROS, respectively.
Conclusions: Clinically relevant concentrations of MPA markedly impaired 
production of ROS by neutrophils. The NADPH oxidase which regulates ROS 
production plays a key role in the anti-bacterial mechanisms of neutrophils. 
This suggests that bacterial infections in renal transplant patients may result 
from direct suppression of innate immunity by immuno-suppressive drug 
regimes containing mycophenolate mofetil. At present, we cannot exclude the 
possibility that other immune-suppressants that did not affect ROS production, 
may elicit some other effects on neutrophil function. Alternatively, suppression 
of T-cells may indirectly affect neutrophil function in vivo via defi ciencies in 
cytokine production, which are known regulators of innate immunity. This 
work, however, provides the fi rst direct evidence that T-cell targeted immuno-
suppression may directly lead to enhanced susceptibility to bacterial infections 
via inhibition of neutrophil function.
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THE ERK2 SIGNAL TRANSDUCTION PATHWAY 1468 
MODULATES EPITHELIAL-MESENCHYMAL TRANSITION OF 
HK-2 CELL ACTIVATED BY CONNECTIVE TISSUE GROWTH 
FACTOR
N. Gong, Z. Ding, X. Chen, Z. Chen
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, 
Huazhong University of Science And Technology
Objective: Accumulating data show epithelial-mesenchymal transition (EMT) 
plays important role in the progress of chronic allograft nephropathy. To 
date, the effect of connective tissue growth factor (CTGF) on EMT has been 
explored but the underlying mechanism still remains unclear. In the present 
study, extracellular signal-regulated kinase 2 (ERK2) pathway was blocked by 
anti-sense adenovirus-mediated ERK2 (Adanti-ERK2) gene therapy in a model 
of EMT activated by CTGF in a HK-2 cell line culture system.
Methods: (1) The HK-2 cells were transfected by Adanti-ERK2 with 
multiplicity of infection (MOI) 50, 100 and 200, and then followed by green 
fl uorescence for 2 days observation. The alive cells ratio was calculated for 
optimal MOI for the further work. (2)The cultured HK-2 cells were divided 
into four groups: empty control group (no gene transfer); vector control 
group (transfected with Ad-LacZ); CTGF-treated group (treated with CTGF 
at a fi nal concentration of 5 ng/ml); and Adanti-ERK2 therapy group (cells 
were transfected with Adanti-ERK2 and then treated with CTGF). Cells were 
collected at 72h and then immunohistochemistry and western-blot were used 
to detect the expression of E-Cadherin£¬Vimentin, ¦Á-SMA and ERK2. In an 
additional series, boyden chamber was used to detect the migration capability 
of HK-2 cells in each group at 1d, 3d and 5d.
Results: (1) Compare with the control group, over 95% HK-2 cells expressed 
green fl uorescence after transfection of Adanti-ERK2 with MOI 100 for 48h. 
The alive cell ratio had no difference in the four groups at 48h; (2) Compared 
with the empty control group and vector control group, more Vimentin, 
¦Á-SMA, ERK2 and less E-Cadherin expressed in the CTGF-treated group 
at 72h. No signifi cant difference of expression of E-Cadherin, Vimentin and 
¦Á-SMA was observed between the Adanti-ERK2 therapy group and the empty 
control and vector control group, as well as the expression of ERK2 in Adanti-
ERK2 therapy group was down-regulated markedly. (3) the migration capability 
of HK-2 didn’t show difference in all four groups at day 1. From day 3, the 
transited cells raised and migrated through the fi lter pores of boyden chamber 
to the opposite side in the CTGF-treated group. At day 5, the transformed cells 
in the opposite side of fi lters in CTGF-treated group were markedly more than 
other groups (P<0.05). No difference of migration capability of HK-2 cells 
among the Adanti-ERK2 therapy group, the empty control and the vector 
control group (P>0.05) was obtained.
Conclusion: CTGF is one potent factor to activate EMT of HK-2 but the effect 
is modulated by ERK2 signal transduction pathway. Adanti-ERK2 gene therapy 
could be the candidate for the investigation of chronic allograft nephropathy.
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MODULATION OF URETERIC SMOOTH MUSCLE 1469 
CONTRACTILITY BY UROPATHOGENIC E.COLI (UPEC)
A. Bakran1, R. Floyd2, C. Winstanley3, S. Wray2, T. Burdyga2
1Royal Liverpool University Hospital, 2Department of Physiology, University 
of Liverpool, 3Division of Medical Microbiology and GU Medicine, University 
of Liverpool
Introduction: Urinary tract infection is a common cause of morbidity pre and 
post-transplantation. Ascending urinary tract infections can cause abnormal 
ureteric functioning but little is known about the mechanisms causing this 
modulation. UPEC produce cytotoxic necrotizing factor (CNF-1) which 
triggers infl ammation and apoptosis of urothelial cells 1. CNF-1 has also been 
shown to directly activate Rho-GTPases. There are however, no studies of this 
interaction in live ureteric tissue.
Aims: In the present study, we investigated how UPEC’s expressing CNF-1 can 
modulate phasic and agonist induced contractions in human and rat ureters.
Methods: Phasic contractions evoked by electrical fi eld stimulation (EFS) 
and stimulation by high-potassium and the cholinergic agonist carbachol 
have been investigated in the presence and absence of UPEC. Ureters were 
lumenally exposed to UPEC’s J96 or C536 or a control strain of K12 E.coli 
for 3 hours to study the effects on contractility. Sham loading procedures were 
performed using physiological saline. Tetraethylammonium (TEA) 1mM 
which specifi cally inhibits Ca-activated potassium channels was used to study 
tissue excitability.
Results: Ureters exposed to UPEC’s J96 and C536 showed no overall 
decrease in the amplitude of phasic contractions induced by electrical fi eld 
stimulation compared to sham and untreated controls but excitability of 
the tissues was markedly reduced. The impaired excitability was reversed 
by application of 1mM TEA which selectively inhibits BKCa channels. 
Carbachol-induced contractions were signifi cantly increased in tissues 
exposed to UPEC’s when compared to high-potassium induced controls. 
Sham and K12 e.coli treated tissues showed similar high-potassium and 
carbachol responses to untreated ureters. Application of the rho-kinase 
inhibitor H1152 to UPEC exposed ureters, caused a reversal in the 
elevations in carbachol-induced contractions which mimicked responses 
seen in control ureters.
Conclusions: Our studies show for the fi rst time the effects of UPEC’s on 
the intact contractile machinery of whole live ureters. These studies show that 
short exposures to UPEC’s can modulate the excitability of smooth muscle 
via a mechanism involving BKCa channels. Furthermore, there are additional 
effects of UPEC’s which our studies suggest are mediated in part by rho-kinase 
activation. Previous studies suggest that this may be as a result of CNF-1 
secretion which constitutively activates the Rho-GTPases; RhoA, Rac1, and 
Cdc42 2.
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CELLULAR CHANGES IN SPLEEN OF TRAUMA 1470 
DONORS UNDERGOING PROLONGED RESUSCITATION
W.L. Olszewski1,2,3, A. Wluka1, M. Zaleska1, M. Durlik1,2
1Department of Surgical Research and Transplantology, Medical 
Research Center, Polish Academy of Sciences, Warsaw, Poland, 2Dept. of 
Transplantation Surgery, Central Clinical Hospital, Ministry of Internal 
Affairs, Warsaw, Poland, 3The Norwegian Radiumhospital-Rikshospitalet, 
Oslo, Norway
The morphological and functional condition of spleen of trauma donors has so 
far not been thoroughly studied. Donor spleen is frequently used as a source 
of lymphocytes for in vitro histocompatibility tests. The knowledge on the 
response of spleen and other lymphoid organs to trauma and infections remains 
rudimentary.
Aim: To study the cellular composition of the functional areas of human spleen 
in trauma patients undergoing prolonged resuscitation.
Material and methods: Twenty spleen specimens from trauma patients, 
unsuccessfully resuscitated, serving as organ donors were used. Patients 
received routine treatment including fl uid replacement, antibiotics, and 
pressure-regulating drugs. Phenotypes of cells in various functional regions of 
spleen were identifi ed using monoclonal antibodies to T and B lymphocytes, 
macrophages, migrating and follicular dendritic cells. Responsiveness to 
microbial antigens was studied in culture. Normal spleens obtained from 
patients with abdominal trauma and intraoperatively ruptured spleen served 
as controls.
Results: Immunohistochemical evaluation. Spleens were depleted of 
lymphocytes and erythrocytes. Cell density was 3-5-times less than in controls. 
The white pulp contained few CD3 (CD4 and CD8) cells around the arterioles. 
There were few CD123 dendritic cells. The CD34 expression on endothelial 
cells was downregulated. A number of dendritic-like cells contained cellular 
debris. Red pulp had few erythrocytes. The responsiveness of splenocytes 
to E.coli, LPS and CpG in a 24 h culture was 5-times less than in controls. 
Staph. epidermis did not stimulate splenocytes. Only a few bacteria were 
phagocytyzed.
Conclusions: Trauma patients in terminal stages reveal depletion of 
splenocytes and their low responsiveness. This observation may partly explain 
the mechanism of immune defi ciency in traumatized patients and point to the 
necessity of mobilizing the stores of immune cells (BMC?). The low in vitro 
responsiveness of trauma donor splenocytes may be wrongly interpreted as low 
reactivity to recipient transplantation antigens.
POSTER BOARD NUMBER P2 – 270
SPLEEN DENDRITIC CELL-ENRICHED POPULATION 1471 
INNATE REACTION TO TRANSPLANTATION AND 
BACTERIAL ANTIGENS
W.L. Olszewski1,2, J. Stanislawska1, M. Maksymowicz1, M. Moscicka1, 
M. Zaleska1
1Department of Surgical Research and Transplantology, Medical Research 
Center, Polish Academy of Sciences, Warsaw, Poland, 2Norwegian Radium 
Hospital, Oslo, Norway
Transplants are accompanied by infections that enhance allogeneic reaction 
(heterologous immunity) and accelerate rejection.
Aim: To determine ability of bacterial and allogeneic antigens to stimulate 
splenic DC.
Methods: DCs were isolated from rat spleen and incubated with 
E.coliDH5αpEGF, S.epidermidis, LPS and DNA of E.coli for 24h and isolated 
after i.p. E.coliDH5αpEGFP and S.epidermidis, LPS and bacterial DNA for 6 
days. Allo- and syngeneic heart, skin and BMC were transplanted. Phenotypes 
of cells were identifi ed on fl ow cytometry.
Results: In culture stimulation of rat splenic DC by E.coli, S.epidermidis, 
LPS and CpGDNA caused increase in class II-positive cells and decrease in 
percentage of ED1, B cells and OX62 DC. LPS decreased frequency of OX62 
and NK cells. In vivo stimulation by E.coli, S.epidermidis, LPS and CpGDNA 
increased percentage of class II-positive cells. S.epidermidis decreased ED1, 
OX62 and B cell populations. Syn- and allogeneic heart, skin and BMC 
transplants caused increase in class II –positive, ED1 and W3/13 cells. OX62 
cells did not react, whereas the B cell frequency rose only after allogeneic 
transplantation. Mixed culture of DC and donor PBM showed stimulation 
of both populations. In vitro and in vivo bacterial stimulation brought about 
expression of TLR and Hsp and MLR of DC with donor PBM culture expression 
of Hsp 90 but not TLR. Recipient DC produced IFN-γ upon stimulation with 
LPS and skin but not heart and BMC. Microbial and allogeneic stimulation did 
not increase IL-12.
Conclusions: Bacteria and their components cause decrease of OX62 and 
expression of TLR and Hsp. Allogeneic antigens do not evoke evident innate 
reaction.
TU
ESD
AY
 
Poster Abstracts Tuesday 12 August 2008
4 9 3Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P2 – 271
REVISITING THE ORIGIN OF INTRAGRAFT 1472 
FIBROBLASTS: EVIDENCE FOR HETEROGENEITY OF 
FIROBLASTS IN CARDIAC ALLOGRAFTS EXPERIENCING 
CHRONIC REJECTION
G. Wu, H. Wang, Y. He, A. Klein
Cedars-Sinai Comprehensive Transplant Centre, 8635W. 3rd St., Suite 590W, 
Los Angeles, CA 90048. U.S.A
Objective: A major development in fi brosis research is the recognition that 
myofi broblasts, which are considered as the terminally-differentiated scar-
contracting cells can originate from several distinct progenitor cells. The 
development of this new concept warrants a critical investigation into the 
progenitor source of intragraft fi broblasts, which was once considered to only 
be phenotypically mesenchymal.
Materials and methods: A rat model of allograft fi brosis involving the use of 
a male F344 rat as the recipient of cardiac allograft from a female LEW rat was 
studied. The cellular sources of intragraft fi broblastic cells (IFC) were qualifi ed 
using qPCR detection of Y chromosome using DNA primers specifi c for the 
sry gene. The phenotype of IFC was studied using cell surface markers with 
fl ow cytometry and quantitative real time PCR. Myofi broblast differentiation 
potential was examined in fi broblast cultures.
Results: qPCR demonstrated that approximately 70% of IFC isolated from 
chronically rejecting cardiac allografts was sry+, indicating that the majority of 
intragraft fi broblasts are of recipient origin whereas the minority but considerable 
numbers of IFC were donor-derived fi broblasts. The population of intragraft 
fi broblastic cells includes both a CD45+ and a CD45- subset. The CD45+ subset 
expressed a phenotype CD34/CD45/αSMA/Collagen-1, which is consistent with 
the description of fi brocytes. The CD45- subset expressed a phenotype typical 
of conventional fi broblasts. Dramatic changes in the proportions of CD45+ 
and CD45- IFC was observed in fi broblast cultures. About 60% of intragraft 
fi broblastic cells were CD45+ at 24 hours in cultures and the positive cells 
decreased to 30% at day 4, 10-15% at day 7 and <1% at day 14 of cultures while 
CD45-negative fi broblasts increased inversely and proportionally, indicating 
that either the CD45+ IFC rapidly transit to CD45- fi broblasts or alternatively, 
massively undergo apoptosis while the CD45- cells proliferate swiftly. In 
fi broblast cultures stimulated with FGF2 and TGF-β, the CD45+ fi broblastic cells 
exhibited differentiation potential to become αSMA-expressing myofi broblasts. 
On the other hand, the CD45- intragraft fi broblasts readily expressed high levels 
of stress fi laments containing α-actin, indicating that these cells may derive from 
mesenchymal progenitors of bone marrow origin.
Conclusion: Taken together, the data demonstrate that intragraft fi broblasts 
are heterogeneous in origin. They may come from cardiac resident fi broblasts 
or/and recipient-derived progenitors. The latter may originate from CD45+ 
fi brocytes or/and CD45- mesenchymal progenitors from the bone marrow. The 
donor-type myofi broblasts, on the other hand, may result from transition from 
vascular endothelia or cardiomyocytes under persistent tissue hypoxia during 
chronic rejection.
POSTER BOARD NUMBER P2 – 272
INTRAGRAFT FIBROBLAST-DERIVED MCSF AND 1473 
MCP-1 PARACRINE LOOPS REGULATE MACROPHAGE 
RECRUITMENT IN CARDIAC ALLOGRAFTS DEVELOPING 
CHRONIC REJECTION
G.D. Wu, Y. He, H. Wang, A. Klein
Cedars-Sinai Comprehensive Transplant Centre, 8635W. 3rd St., Suite 590W, 
Los Angeles, CA 90048. U.S.A
Objective: Macrophage colony-stimulating factor (MCSF) is known as 
a macrophage survival factor which facilitates monocyte-to-macrophage 
maturation and proliferation. MCP-1 is a chemoattractant that mediates 
monocyte migration. In previous studies, we have found that intragraft 
fi broblasts isolated from rejecting cardiac allografts produce high levels of 
MCSF and MCP-1. The current study investigated the effects of MCSF and 
MCP-1 paracrine loops produced by intragraft fi broblasts (IF) in monocyte/
macrophage migration and proliferation.
Materials and methods: Intragraft fi broblasts derived from heart allografts 
undergoing chronic rejection were examined for production of a panel of pro-
infl ammatory / fi brosis cytokines, including MCSF and MCP-1. The effects of 
MCSF and MCP-1 produced by IF, and consequential monocyte/macrophage 
migration and proliferation were studied using a fi broblast-macrophage co-
culture system and a siRNA inhibition assay.
Results: Quantitative real-time PCR demonstrated that fi broblasts from 
chronically rejecting allografts signifi cantly increased expression of MCSF 
as well as MCP-1 when compared with that from isografts control (p<0.01, 
respectively). In serum-free condition culture, PDGF, a fi brogenic cytokine 
abundantly present in chronic rejection was able to up-regulate MCSF and 
MCP-1 expression by IF (p<0.05 and 0.01 respectively). In co-cultures, 
intragraft fi broblasts were able to activate the macrophage cell line RN8383, 
as demonstrated by signifi cant increases in expression of MCP-1 receptor 
CCR2 and MCSF receptor c-fms. The MCSF paracrine effect on macrophage 
proliferation was antagonized by treatment of the IF with siRNA against 
MCSF. On the other hand, treatment of the cultures with siRNA MCP-1 
resulted in suppressed MCP-1 secretion by IF and decreased CCR2 expression 
by RN8383 cells, resulting in signifi cant decrease in chemotactic migration of 
the macrophages (p<0.05).
Conclusion: Mononuclear cell infi ltration and fi broproliferation in chronically-
rejecting allografts are regulated by a complex network of pro-fi brogenic/
infl ammatory cytokines. This mechanistic study suggests that a pathway 
involving PDGF, MCSF, MCP-1 and their receptors play an important role in 
the pathogenesis of chronic rejection.
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INFLUENCE OF SYSTEMIC HTK PRECONDITIONING 1474 
OF DONORS IN RAT LIVER TRANSPLANTATION
V. Ariyakhagorn1,2, V. Schmitz1, P. Olschewski1, P. Neuhaus1, G. Puhl1
1Charité Campus Virchow, Department of General Visceral and 
Transplantation Surgery, Berlin, Germany, 2Chiangmai University, 
Department of Surgery, Chiangmai, Thailand
Introduction: Outcome of liver transplant patients has dramatically improved 
over the last decades. Since preservation damage has a signifi cant infl uence 
on subsequent organ function, organ preservation protocols should be further 
optimized. Many protective strategies have been shown to be effective against 
ischemic injury in animal models. In our study we investigated a protocol 
foreseeing intravenous systemic preconditioning of the donor using the well-
established preservation solution HTK in a model of rat liver transplantation.
Methods: Rats were divided into two groups. In the study group, 15 minutes 
prior to organ procurement, donors were preconditioned with systemic 
intravenous infusion of warm HTK (0.01ml/g body weight). The same amount 
of saline was given in the control group. After organ procurement with cold 
HTK, livers were stored at 4ºC for 6 hours and refl ushed with cold saline 
prior to implantation. Recipients were sacrifi ced after 4 hours, 2 and 5 days 
following transplantation to obtain liver function parameters (Bilirubin, ASAT, 
ALAT, LDH) and histology. For each time point in each group a total of 6 liver 
transplantations were performed (total number 36).
Results: Four hours after transplantation, serum transaminases ASAT 
(1900±1200U/L; p= 0.015), ALAT (789±330U/L; p=0,005) and LDH 
(5938±4415; p=0.035) were signifi cantly lower after HTK preconditioning 
compared to the control group (ASAT: 3800±1900/ ALAT: 2500±1100/ 
LDH: 17380±10346U/L). However, at later time points (2 and 5 days), 
values normalized and there was also no difference in regard of serum 
bilirubin during the entire observation period. Survival was 100% for both 
groups. For all time points, based on a semiquantitative score from 0-3, liver 
endothelial cells were less damaged following donor pre-treatment with HTK, 
whereas hepatocellular damage did not differ microscopically between the 
groups.
Discussion: Our data shows that in a rat liver transplantation model, 
preconditioning of the donor with HTK has a benefi cial infl uence on the negative 
effects of ischemia/reperfusion injury. Reduction of histological damage and 
enzyme release were found at an early period after transplantation without any 
adverse reaction to either the donor or the recipient animals. Further studies are 
warranted to elucidate the exact mechanisms.
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BENEFICIAL EFFECTS OF HYPERBARIC OXYGEN 1475 
PRETREATMENT ON MASSIVE HEPATECTOMY IN AN 
EXPERIMENTAL RODENT MODEL
H. Mori1, M. Shimada2, G. Nowak1, B-G. Ericzon1
1Division of Transplantation Surgery, CLINTEC, KAROLINSKA 
INSTITUTET, Karolinska University Hospital Huddinge, Stockholm, Sweden, 
2Department of Surgery, The University of Tokushima Graduate School, 
Tokushima, Japan
Background: The purpose of this study was to investigate the impact of 
hyperbaric oxygen (HBO) pretreatment in an extensive hepatectomy model, a 
surrogate model of small-for-size graft, using rats.
Methods: (Experiment I) Rats were divided into the following four groups: 
HBO (-), HBO-1D (day), HBO-3D, and HBO-5D. Samples were taken after 
the completion of HBO pretreatment and the following parameters were 
evaluated; RT-PCR and immunohistochemical staining for heat shock protein 
(HSP 70 and HO-1); biochemical parameters; and liver weight to body 
weight ratio (Lw/Bw ratio). (Experiment II) Rats were divided into four as 
follows; 70% hepatectomy (Hx), 70%Hx-HBO, 90%Hx, and 90%Hx-HBO 
group. Samples were taken 12, 24, 48 and 72 hours after hepatectomy and the 
following parameters were investigated: biochemical analysis; Lw/Bw ratio; 
PCNA labeling index; and survival.
Results: (Experiment I) The expression of HSP70 mRNA was signifi cantly 
increased in the HBO-3D group compared with the HBO (-) group (P<0.05). 
HSP70- and HO-1-positive hepatocytes were signifi cantly increased in the 
HBO-3D group compared with the HBO (-) group (P<0.05). (Experiment II) 
Transaminases were signifi cantly decreased in both 70% and 90%Hx-HBO 
groups compared with Hx alone group (P<0.05). The Lw/Bw ratio and PCNA 
labeling index of the 90%Hx-HBO group were signifi cantly increased compared 
with the 90%Hx group, 24, 48 and 72 hours after hepatectomy (P<0.05). The 
survival rate in the 90%Hx-HBO group was signifi cantly higher than that in the 
90%Hx group (P=0.01).
Conclusions: HBO pretreatment had benefi cial effects in an extensive 
hepatectomy model in rats via the induction of HSP70 and HO-1.
POSTER BOARD NUMBER P2 – 275
PROTECTION OF PANCREATIC ISLETS FROM 1476 
IMMUNE-MEDIATED DESTRUCTION BY OVEREXPRESSION 
OF DOMINANT NEGATIVE HUMAN FAS IN BETA CELLS
K. Graham, H.E. Thomas, L. Mariana, T.W. Kay
St Vincent’s Institute, 9Princes Street, Fitzroy, 3065, Australia
Protection of islet beta cells from immune-mediated destruction is important 
in the goal to improve islet transplantation outcome. Both allogeneic and 
autoreactive cytotoxic T lymphocytes can use the Fas death receptor as 
a mechanism of killing beta cells. While global defi ciency of Fas leads 
to dysregulated immune homeostasis in mice and humans, blocking Fas 
only on beta cells has potential for prevention of immune-mediated beta 
cell damage. We developed a model where dominant negative human Fas, 
derived from a patient with autoimmune lymphproliferative syndrome, is 
overexpressed in beta cells under control of the rat insulin promoter (RIP-
hFas). Several studies using different approaches have suggested that 
preventing Fas-FasL interaction on beta cells has only a modest effect on 
beta cell destruction and type 1 diabetes. Surprisingly, our RIP-hFas mice 
are signifi cantly protected from spontaneous type 1 diabetes. Fas can be 
cleaved from the cell surface and evidence suggests this occurs in RIP-
hFas mice. Soluble Fas is detectable by ELISA in supernatants of RIP-hFas 
islets cultured in vitro. Preliminary evidence suggests that antigen-specifi c 
CD8+ T cells labelled with CFSE proliferate in the pancreatic lymph node 
and islets of RIP-hFas mice, but the number of divisions that these cells 
undergo may be reduced. We hypothesize that production of mutant Fas in 
beta cells and its release into the local environment has inhibitory effects on 
immune cells. Our data suggest that systemic administration of soluble Fas 
or encapsulation of islets in the presence of soluble Fas are strategies that 
may be employed in islet transplantation without the need for transgenic 
islets. Therapeutics based on members of this receptor family (eg TNF 
receptors) are in clinical use.
POSTER BOARD NUMBER P2 – 276
PREVENTION OF KIDNEY ISCHEMIA-REPERFUSION 1477 
INJURY: ROLE OF P38 MAP KINASE INHIBITION
P. Gehwolf1, N. Fischler1, R. Oberhuber1, C. Margreiter1,2, R. Öllinger1,2, S. 
Schneeberger1,2, G. Brandacher1,2, J. Troppmair2, R. Margreiter1,2, R. Sucher1,2
1Daniel Swarovski Research Laboratory, 2Department of General and 
Transplant Surgery, Innsbruck Medical University
Introduction: Ischemia (I) and reperfusion (R) causes complex changes to 
the graft during solid organ transplantation. Cell death, metabolic alterations 
and infl ammation result in impairment of short- and long term function. Cells 
respond to extracellular signals by transmitting intracellular instructions to 
coordinate appropriate responses. The group of mitogen activated protein 
kinases (MAPKs) was implicated through aberrant activation in many settings 
including I/R-associated organ damage. Although MAPKs are known as critical 
proteins in cell signaling their role during I/R is controversially discussed.
Material and methods: To asses intracellular signaling and kidney function a 
rat ischemia reperfusion model was used. Ischemic renal injury was induced by 
clamping the left renal artery for 45 min in male Wistar rats immediately after 
right-side nephrectomy. Reperfusion was studied at R0 (no reperfusion), 15min 
(R1), 2hours (R2) and 7days (R3). Sham operated animals served as controls. 
Renal function was determined by plasma creatinine/urea. MAPKs (ERK, 
JNK, p38) activation was analysed using phosphorylation specifi c antibodies.
Results: In summary, reoxygenation was characterized by a dramatic 
increase in the activity of ERK (p<0.05, JNK (p<0.05) and p38 (p<0.0001) 
during early reperfusion. This was associated with a signifi cant raise in 
creatinine and urea. Data suggest that the use of small molecular weight p38-
MAPK inhibitors (SB 203580 and SB 239063) have a benefi cial effect on 
the ischemia reperfusion injury, showing a decrease in creatinine and urea as 
assessed 24 hours after reperfusion.
Conclusion: Renal I/R injury is associated with a signifi cant increase in MAPK 
activity. Isolated p38 MAPK inhibition during ischemia improves kidney 
function suggesting that p38 may provide a promising target for ameliorating 
reperfusion injury.
POSTER BOARD NUMBER P2 – 277
TOLL-LIKE RECEPTOR 4 MEDIATES HEPATOCYTE 1478 
APOPTOSIS AND ACUTE LIVER FAILURE AFTER 
INTRAPERITONEAL D-GALACTOSAMINE/LPS IN MICE
T. McKenzie1, J. Lillegard1, J. Luebke-Wheller3, G. Brunn3, S. Nyberg2
1Department of Surgery, Mayo Clinic, 2Department of Transplant Surgery, 
Mayo Clinic, 3Department of Transplantation Biology, Mayo Clinic
The purpose of this study was to elucidate the mechanistic role of TLR4 in the 
development of D-galactosamine (GaIN)/lipopolysaccharide (LPS) induced acute 
liver failure. TLR-mutant (C3H/HeJ) mice with non-functional TLR4 and TLR4 
wild-type control (C3H/HeN) mice were studied after intraperitoneal injections of a 
lethal dose of GaIN/LPS (1000mg/kg and 250mcg/kg) simultaneously (n=8/group). 
Animals were electively sacrifi ced at 6 hours post injection of GaIN/LPS. Liver 
injury was assessed by examining gross morphology, histopathology, quantifying 
apoptosis using in situ terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling assay (TUNEL) stain, and measuring serum ALT measurement 
at 6 hours. Clinical status was determined both prior to injection and 6 hours post 
injection. We found that hepatic injury of the mutant animals with non-functional 
TLR4 was greatly attenuated when compared to wild-type controls. 6 hours post 
injection of GaIN/LPS, the mutant mice were clinically healthy, without evidence 
of illness. In contrast, wild-type controls appeared moribund with limited activity 
and minimal response to stimuli. Mean ALT levels of TLR4 defi cient mice and 
wild-type controls were 707 and 6006 U/L, respectively (p<0.001, normal 7-55 
U/L). The wild-type control livers appeared non-viable on gross exam, while the 
TLR4 defi cient livers appeared grossly normal. Consistent with previous studies, 
massive hemorrhage and necrosis were seen on histologic examination of the wild-
type control livers by hematoxylin and eosin staining. Microscopic examination 
of TLR4 defi cient livers demonstrated minimal hepatic parenchymal damage, 
consistent with this group’s lower levels of serum ALT and non-impaired clinical 
status. TUNEL stain demonstrated a decreased number of apoptotic nuclei among 
the TLR4 defi cient mice when compared to wild type control mice, 88.0 +/- 41.2 
and 185.1 +/- 39.8 TUNEL positive nuclei/40x fi eld, respectively (p=0.01). The 
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percent TUNEL positive nuclei of total nuclei for each group was 14.6 and 29.4%, 
respectively (p=0.01). Furthermore, the TLR4 defi cient livers displayed less 
infl ammatory cell infi ltrate. The present study demonstrates the marked decrease 
of hepatocyte apoptosis and attenuation of acute hepatic failure in mutant mice 
with non-functional TLR4 when compared to wild-type controls. Apoptosis and 
parenchymal damage of TLR4 mutant livers after GalN/LPS suggests another, 
possibly direct, secondary pathway of injury. In conclusion, TLR4 is implicated as 
a pivotal receptor in GaIN/LPS induced apoptosis and acute liver failure in mice.
POSTER BOARD NUMBER P2 – 278
SIALIC ACID DYNAMICS BEFORE AND AFTER 1479 
COLLAGENASE ISOLATION OF PANCREATIC ISLETS WITH 
POTENTIAL IMMUNOLOGICAL EFFECTS
S. Hyon2, L. Gimeno2, C. Bernard2, P. Argibay2
1Kidney And Pancreas Transplantation Program, Hospital Italiano De Buenos 
Aires, 2Instituto de Ciencias Basicas y Medicina Experimental, Hospital 
Italiano de Buenos Aires
Introduction: Host immune response has precluded clinical islet transplantation 
from becoming a consistent therapy for type 1 diabetes. Enzymatic and mechanical 
digestion of pancreatic tissue for islet isolation may affect the molecular 
structure of cell surface. Sialic acid is a nine-carbon monosaccharide with a great 
natural diversity, being N-acetyl neuraminic acid the most common form. It is 
ubiquitously distributed on the surface of cells and certain microorganisms and 
may play a crucial immunological role in a variety of biological settings.
Objective: To assess the presence of a variety of sialic acid molecules in the 
endocrine as well as the exocrine tissue of whole pancreas and the potential 
modifi cations occurring upon isolation of pancreatic islets.
Methods: Fresh pancreas and pancreatic islets were obtained from 6 to 8 week-
old, male C57BL/6 mice. Tissue and cells were fi xed in Bouin’s solution and 4% 
formalin; paraffi n embedded, and cut in 4-micron thick slices. The presence of 
different terminal N-acetyl forms and other monosaccharides were assessed by 
specifi c ligands. For this purpose, lectins used were Aleuria aurantia, Erithrina, 
Maakia amurensis, Sambucus nigra agglutinin, Peanut agglutinin, sWGA, WGA, 
VVL, GNL, GSL-II, and lotus; revealed with the fl uorescent dye FITC and 
observed under a fl uorescence microscope. Mice colon and nervous tissue were 
used as positive controls while negative controls were done with PBS. Results. 
No changes were observed for WGA, VVL, GNL, GSL-II, or lotus on pancreatic 
islets and acinar cells before and after the isolation process. However, the following 
modifi cations were observed: sialic acid with alpha 2-3 and alpha 2-6 unions were 
lost both from islets and acini; sialic acid alpha 2-6 galactose unions were preserved 
on islets but lost on acinar tissue; galactosyl (beta 1-3) N-acetyl galactosamine 
was detached from islets but not from acini; and terminal N-acetyl glucosamine 
without sialic acid were lost from both islets and acinar cells as revealed by Maakia 
amurensis, Sambucus nigra, Peanut agglutinin, and sWGA lectins, respectively.
Conclusions: Enzymatic and mechanical factors occurring during islet 
isolation produce changes on the molecular structure of endocrine as well as 
exocrine pancreatic tissue. This phenomenon may cause a critical effect on the 
immunogenicity of cells obtained for transplantation.
POSTER BOARD NUMBER P2 – 279
NK CELL STIMULATORY RECEPTORS AND LIGANDS 1480 
ARE INDUCED IN LIVER ALLOGRAFTS EARLY POST-
TRANSPLANTATION
S. Krams, M. Fujiki, M. Zhuo, L-E. Wai, C. Esquivel, O. Martinez
Transplant Immunobiology Lab, Division of Transplantation, Department of 
Surgery, Stanford University
Background: Numerous studies suggest a role for NK cells in acute and 
chronic allograft rejection. NK cells express a variety of stimulatory receptors 
that, upon binding to their ligands, activate and/or regulate effector function. 
However, the expression and functional signifi cance of NK cell stimulatory 
receptors and ligands in the alloimmune response remain unclear. Tumor 
necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is known to 
be expressed by NK cells in the liver and can participate in effector function. 
Similarly, NK cells are a major source of IFNγ early post-transplant. The aim 
of this study was to determine the expression of receptors that can stimulate 
effector function of NK cells and their ligands post-transplantation. 
Methods: Lewis recipients were transplanted either with fully allogeneic donor 
DA rat livers or syngeneic Lewis rat livers. The stimulatory receptors, NKp30, 
NKp46, NKG2D were analyzed by quantitative real-time PCR (q-PCR). TRAIL 
receptor expression was evaluated by fl ow cytometry and q-PCR. We cloned 
two rat NKG2D ligands (RAE-1L and Rat RAE-1 like transcript (RRLT)) and 
graft expression of these ligands was analyzed by q-PCR. IFNγ expression and 
production were determined by both q-PCR and ELISA. 
Results: NKp30 expression is detected very early post-transplant and is 
specifi cally increased in allografts by the fi rst day post-transplant. NKp30 
mediates NK cell interaction with dendritic cells and contributes to induction 
of IFNγ. The stimulatory receptors NKp46 and NKG2D are increased in 
allografts, but not syngeneic grafts, by day 3 post-transplant and expression 
strongly correlated with IFNγ levels in both the graft and periphery. TRAIL 
expression on NK cells is upregulated in allografts on day 3 but is diminished 
by day 7 post-transplant. RAE-1L expression is silent in the liver and is not 
increased post-transplantation. However, expression of the NKG2D-ligand, 
RRLT is induced in the liver post- transplantation and is specifi cally increased 
in liver allografts at day 7 post-transplant. 
Conclusion: Our data demonstrate the concomitant expression of NK 
stimulatory receptors and induction of the RRLT ligand early post-transplant. 
These data suggest that NK cells are activated early in liver allografts, and 
may be a functional link between innate and adaptive immunity post-
transplantation. 
CLINICAL AND PRE-CONCURRENT ORAL SESSION 104: 
CLINICAL TOLERANCE
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PROPAGATION OF A UNIQUE V 1-BEARING T CELLS 1481 
CLONE WITHIN GRAFT INFILTRATES OF HUMAN LIVER 
TRANSPLANTATION TOLERANCE-IMMUNOPRIVILEGED 
LIVER SPECIFIC ?-
Y. Li1, Y. Tanaka2, J. Pirenne3, N. Minato2, T. Koshiba1
1 Innovation Center For Immunoregulation Technologies And Drugs, Graduate 
School of Medicine, Kyoto University, 2 Department of Immunology and 
Cell Biology, Graduate School of Medicine, Kyoto University, 3 Abdominal 
Transplant Surgery Department, University Hospital Leuven
Background: TCRVƒÂ1 ƒÁƒÂT cells (VƒÂ 1 cells) was reported to function 
as suppressors against allo-response during normal pregnancy and therefore, to 
be responsible for fetomaternal tolerance. We reported that VƒÂ 1 cells, which 
represent a minor subset of T cells in normal individuals, predominate over 
VƒÂ 2bearing T cells (VƒÂ 2 cells) in peripheral blood of tolerant patients after 
liver transplantation (LTx) (Am. J. Transplant, 2004, 4: 2118). This implies 
that there may be a common feature between fetomaternal tolerance and Ltx 
tolerance (Transplant Immunol, 2007, 17: 94). We further examined LTx 
tolerant patients for VƒÂ 1 cells/VƒÂ2 cells (VƒÂ 1/VƒÂ 2) ratio and sequence 
in VƒÂ 1 TCR chains in graft infi ltrates. To elucidate whether VƒÂ 1 cells 
are responsible for immunoprivilege of LTx, highly immunogenic intestinal 
Tx (ITx) was studied in addition. (Method) Protocol biopsy was performed in 
patients whose grafts were functioning well despite the absence of or minimum 
immunosuppression after LTx (N= 9) and intestinal Tx (ITx) (N=4) (Gr-
Tol). Total RNA was extracted to synthesize cDNA. V ƒÂ1 and V ƒÂ2 gene 
expressions were quantifi ed by real-time PCR, and CDR3 sequence in V ƒÂ1 
TCR chains was analyzed. The results were compared to those of removed 
graft as a result of chronic rejection (Gr-CR N= 7) and normal liver i. e. donor 
zero biopsy (Gr-Nor N=6) in LTx and native intestines of the patients (Gr-Nat 
N=3) in ITx. Sampling of intestinal grafts and native intestines was repeated 
twice within one year interval since the number of the ITx patients was small. 
Results: LTx; VƒÂ 1/V ƒÂ2 ratio was the highest in Gr-Tol, compared to those 
in Gr-CR and Gr-Nor (Gr-Tol, Gr-CR, and Gr-Nor; 0. 074 } 0. 063, 0. 012 } 0. 
015, and 0. 021 } 0. 043. Gr-Tol vs. Gr--Nor, p<0. 05, Gr-tol vs. Gr-CR, p<0. 
01). All the 9 recipients in Gr-Tol exhibited a common sequence among several 
CDR3 sequences of VƒÂ1 cells. In Gr-Tol, this sequence predominated over 
other sequences in 6 of 9 recipients. In contrast, the identical sequence which 
all the recipients in Gr-Tol was not observed in any recipient of Gr-CR, while it 
was observed in 5 of 6 samples in Gr-Nor. However, in Gr-Nor, this sequence 
predominated over other sequences in only 1 sample. ITx; Unlike LTx, there 
was no difference between Gr-Tol and Gr-Nat with respect to VƒÂ 1/V ƒÂ2 
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ratio. Any common sequence was observed among patients in Gr-Tol. 
Conclusions: A unique V 1 T cell clone propagated within tolerant liver graft but 
not tolerant intestinal graft. We hypothesize that this propagation is liver-antigen-
selected and associated with a mechanism of immunoprivilege of liver Tx. 
POSTER BOARD NUMBER P2 – 281
IMMUNOCOMPETENCE OF CANINE HEMATOPOIETIC 1482 
CHIMERAS WITH LONG-TERM RENAL ALLOGRAFTS
P.J. Horton1, W.J. Hawthorne2, T. Patel2, S. Walters2, G.J. Stewart2, 
R.D.M. Allen2, J.R. Chapman2
1University of Rochester Medical Center, , 2Centre for Transplant & Renal 
Research, Westmead Millennium Institute, 
Background: We developed a pre-clinical model of mixed hematopoietic 
chimerism (MC) using 18Gy fractionated total lymphoid irradiation (TLI) and 
unfractionated donor bone marrow (BM) to induce tolerance in dogs. TLI alone 
can suppress the immune system long-term
Aim: To study immune responses in canine hematopoietic chimeras that had 
accepted renal allografts from dog-leukocyte antigen (DLA)-DP matched, class 
II compatible BM donors for more than one year without immunosuppression. 
Materials and methods: Five female hematopoietic chimeras were compared 
to their fi ve male DP-matched donors and also to fi ve male and fi ve female DP-
matched 3rd party dogs. Techniques used included fl owcytometric analysis of 
lymphocyte subsets, lymphocytotoxicity assay (LCA) and mixed lymphocyte 
culture (MLC). Delayed type hypersensitivity (DTH) testing was also 
performed using a standard panel of antigens including tetanus, streptococcus, 
tuberculin, candida, trichophyton and proteus. 
The four hematopoietic chimeras and the donors were inoculated intraperitoneally 
with macerated intra-peritoneal lymph nodes taken from DP-matched 3rd party 
dogs. Each dog received three lymph node inoculations injected at two weekly 
intervals. LCAs were performed before and after each inoculation. 
Results: There was no difference between the complete blood counts and 
differential cell counts measured in peripheral blood taken from the four groups 
of dogs. Lymphocyte staining for CD3, CD4, CD8a, CD8b, CD21, CD45, 
CD45RA and class II antigen was not different. Lymphocytes from tolerant dogs 
proliferated normally in response to mitogens and stimulation by alloantigen. 
DTH testing revealed normal wheel and fl are response in three out of four 
hematopoietic chimeras. The immune response in the fourth dog was relatively 
reduced but still present. Each lymph node inoculation contained median 5. 1 
x108 cells (range 1. 5 to 12. 9). All dogs were sensitized after one lymph node 
inoculation and the humeral response as determined by the dilution titer was 
greater in three out of the four female chimeras that their respective male donor. 
Conclusion: No evidence of an impaired immune response was found in the 
hematopoietic chimeras more than one year following the TLI. The absence of 
donor-specifi c alloantibody supports the assertion that true tolerance had been 
induced in chimeric dogs. 
POSTER BOARD NUMBER P2 – 282
EFFECT OF DONOR BONE MARROW CELLS INFUSION 1483 
ON ALLOIMMUNIZATION AND KIDENY ALLOGRAFT 
OUTCME
B. Nikbin1, A. Amirzargar1, M.H. Nicknam1, G. Pormand2, A. Mehrsai2, 
M. Taheri2, E. Rad1, M. Seraji2, M. Moheydin1, G. Solgi1
1Molecular Immunology Research Center, Faculty of Medicine, Tehran 
University of Medical Sciences, 2Urology Research center, Sina Hospital, 
Tehran University of Medical Sciences
Objectives: The aim of this study was to investigate the role of donor bone 
marrow cells infusion in post transplantation anti-HLA antibody induction and 
outcome of kidney allograft patients. 
Methods: a total of 40 living unrelated donor primary kidney transplant; 20 
recipients with Donor Bone Marrow Cells infusion (2. 1× 109 ±1. 3×109 
MNCs/body including 3. 5× 107 ±1. 6×107 CD34+ progenitor cells) and 20 
without infusion as control, were entered into study and followed prospectively 
for one year. Both groups received the same baseline immunosuppressant 
consisting triple drug regimen (cyclosporine A, MMF and prednisolone). WBC 
cross match, Panel Reactive Antibody and HLA-DNA typing were performed 
for all patients before transplantation. Pre and post transplant sera samples (day 
14, 30, and 90) were screened for the presence of anti-HLA class I and class II 
antibodies, and subsequently antibody specifi city was determined for positive 
patients by ELISA method. 
Results: All patients from both groups had a negative pre-transplant WBC 
cross match. A lower incidence of acute rejection (AR) (30% vs. 40%), and 
less post-transplant percentage of PRA (27. 2% vs. 36. 7%), as well as lower 
average serum creatinine in patients with AR (2. 41 vs. 4. 0 mg/dl during fi rst 
3 months post operatively, P=0. 13) were found in DBMI patients compared 
to controls. 
Almost all patients with AR had a pre-transplant anti-HLA antibody in both 
groups. On the other hand about 50% in DBMI and 36. 3% in control had 
pretransplant antibodies without acute rejection. Post transplant antibody 
production and episodes of acute rejection was the same in both groups. 
The presence of post transplant Donor Specifi c antibody (DSA) in patients with 
acute rejection was nearly the same in DBMI and control groups (33. 3% vs. 
37. 5% respectively). A signifi cant correlation was found between AR and DGF 
in control patients (P=0. 005). 
Conclusions: Despite the small number of patients, the lower number of 
infused cells, and shorter period of follow up (meanly one year), our results 
indicate that DBMC infusion didn’t sensitize the recipients and additionally it 
has some tolergenic effects on anti donor immunity. 
POSTER BOARD NUMBER P2 – 283
IMPACT OF CREG MATCHING AND INCIDENCE OF 1484 
ANTI-HLA DONOR SPECIFIC ANTIBODY IN TOLERANT 
LIVER RECIPIENTS AND CONTROLS
R. Cirocco, P. Tryphonopoulous, D. Weppler, K. Tomaki, J. Moon, D. Levi, 
G. Selvaggi, C. Ricordi, P. Ruiz, A. Tzakis
University of Miami School of Medicine
In an attempt to understand the role of pharmacological immuno-supression 
in liver transplant tolerance, we followed twenty-two tolerant transplant 
patients that were weaned off of immuno-suppresive drugs and thirty controls 
(on immunosupresive drugs) The recipients were studied ten years post liver 
transplantation. The patients were analyzed for their HLA Cross Reactive 
antigen Group (CREG) match (donor and recipient). In addition, we looked 
for the presence of donor specifi c anti-HLA antibodies. These fi ndings may 
elucidate why certain patients are tolerant (i. e. off immunosuppressive 
therapy) and others are not (controls on immuno-suppressive drugs). HLA 
matching is thought not to improve graft survival. In the CREG analysis most 
HLA-B and HLA-C antigens fell into expected groups representative of a 
normal population. In the tolerant recipients 12 had both HLA-A antigens 
in the A-1 CREG with 22 donors having both alleles in the A-1 CREG 
versus the controls, 19 in the A1, 8 in the A-2 and ten had one antigen in 
both A-1 and A-2 CREGS. These data demonstrated a difference with a 
signifi cance of p = 0. 02. All the other CREG analysis were not signifi cant. 
In the tolerant recipients; two produced anti-HLA donor specifi c antibodies 
out of ten demonstrating any anti-HLA antibodies (20%). In the controls 
fi fteen demonstrated anti-donor specifi c HLA antibodies out of twenty-fi ve 
producing anti-HLA antibodies (60%). In conclusion: 1) The matching 
of liver recipient and donors for CREGS may improve graft survival, 2) 
The tolerant recipients produce less anti-donor HLA antibodies than the 
controls, and 3) It is surprising that in these transplant patients, the lack of 
immunosupression resulted in a blunted or reduced humoral response i. e. 
less anti-HLA antibody production in general as compared the immuno-
suppressed recipients, demonstrating true long term tolerance to mismatched 
HLA antigens on the graft. 
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TOLERANCE INDUCTION TO ABO BLOOD GROUP 1485 
ANTIGENS BY USING AUTOLOGOUS LYMPHOCYTES 
ENGINEERED TO EXPRESS THE COGNATE ANTIGEN
H. Ogawa1, T. Kobayashi2, A. Onishi3, M. Iwamoto4, Y. Miwa2, D. Liu2, 
K. Kadomatsu2, U. Galili5
1Obihiro University of Agriculture And Veterinary Medicine, 2Nagoya 
University School of Medicine, 3National Institute of Agrobiological Sciences, 
4Prime Tech LTD, 5University of Massachusetts Medical School
Objectives: ABO-incompatible transplantation is performed worldwide 
because of donor paucity and availability of living donors with mismatched 
ABO blood group antigen. Despite removal of anti-A or anti-B antibodies 
prior to transplantation and immunosuppression, graft rejection can occur by 
antibodies elicited against the incompatible blood group antigen. We have been 
developing a gene therapy method to induce tolerance to B cells that produce 
antibodies to carbohydrate antigen by using autologous lymphocytes engineered 
to express the cognate antigen (Blood 2003, 101: 2318; Transplantation 2004, 
77: 366; Gene Therapy 2004, 11: 292). The objective of this study is to 
elucidate the effi cacy of the method in inducing B cell tolerance to ABO blood 
group antigens. 
Method: Using Nucleofector (Amaxa), mouse spleen lymphocytes and 
baboon peripheral blood lymphocytes were co-transfected with human A 
or B (A/B) transferase and human H transferase genes, which encode the 
gene synthesizing blood group A/B antigen and O antigen, respectively. 
The transfected lymphocytes were in vitro cultured, and the expression of 
A/B antigen on the lymphocytes was analyzed by fl ow cytometry. In order 
to induce tolerance to A/B antigen in mice, the transfected lymphocytes were 
intravenously administered into syngeneic mice 4~5 h post transfection. The 
injection was repeated 4 times in 3-4 day intervals. Then, the mice were weekly 
immunized 4 times with human blood type A/B red cell membranes, and the 
production of antibodies against A/B antigen was analyzed by ELISA. 
Results: Mouse lymphocytes expressed A/B antigen following the transfection 
with both of H transferase and A/B transferase genes but not with A/B transferase 
gene alone. The proportion of cells expressing the antigen was approximately 
2% of the viable cells cultured in vitro for 24 h (65% viability). Control mice 
intravenously administered with mock-transfected lymphocytes developed anti-
A/B antibodies in high titers following the immunizations with human red cell 
membranes. In contrast, the mice received lymphocytes engineered to express 
A/B antigen were tolerant to the antigen. In baboon, approximately 15% of 
transfected lymphocytes expressed A/B antigen in vitro with 90% viability 24 
h post transfection. Tolerance induction in baboon is currently under study by 
injecting the transfected lymphocytes back to the own circulation. 
Conclusions: We could induce tolerance to B cells with specifi city to ABO 
antigens in mice. Further studies in baboons and/or other suitable experimental 
animals may enable us to apply this method for clinical ABO-incompatible 
transplantation. 
This work is supported by a Grant-in Aid for Scientifi c Research (18380162) 
from MEXT, Japan. 
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A CELL-BASED APPROACH TO THE MINIMISATION OF 1486 
IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION
M. Schulze1, J.A. Hutchinson1, B.G. Brem-Exner1, P. Riquelme1, D. Roelen2, 
A. Sotnikova1, L. Renders1, E. Geissler3, U. Kunzendorf1, 
F. Fändrich1
1University Hospital of Schleswig-Holstein, Kiel, Germany, 2Leiden 
University Medical Center, the Netherlands, 3Regensburg University 
Hospital, Regensburg, Germany
Transplant Acceptance-inducing Cells (TAICs) are a type of immunoregulatory 
macrophage with the capacity to specifi cally suppress allogeneic T cell responses. 
Five recipients of kidney transplants from living donors were preoperatively 
treated with TAICs in a Phase-I clinical trial. Following transplantation, these 
patients received ATG induction therapy in combination with tacrolimus and 
steroid immunosuppression. Over the course of the subsequent twelve weeks, 
steroids were withdrawn and tacrolimus therapy was minimised. Three of the 
six patients were able to tolerate low-dose tacrolimus monotherapy and one 
patient was withdrawn from all immunosuppression for over eight months. 
No acute or delayed adverse events were associated with the infusion of 
TAICs. Although these data do not prove that pre-transplant TAIC treatment 
is benefi cial, they are encouraging, in that they suggest that TAICs promote 
a state of alloantigen-specifi c hypo-responsiveness, or prope tolerance, which 
might allow safe minimisation of pharmacological immunosuppression. 
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ECONOMIC IMPACT OF TOLERANCE INDUCTION 1487 
BY COMBINED KIDNEY AND BONE MARROW 
TRANSPLANTATION
T. Kawai, D. Sachs, T. Spitzer, N. Tolkoff-Rubin, M. Sykes, M.L. Farrell, 
R. Colvin, A.B. Cosimi
Massachusetts General Hospital
Background: The primary benefi ts anticipated following successful induction 
of allograft tolerance are avoidance of the complications of long-term 
immunosuppression and prevention of chronic rejection. We have previously 
reported successful induction of renal allograft tolerance in recipients of HLA 
mismatched combined kidney and bone marrow transplantation (CKBMT). 
No evidence of chronic rejection has been observed in these recipients after 
immunosuppression-free periods of 1 to 4 years. In the current study, we have 
evaluated the longer-term economic impact of this approach. 
Method: The conditioning regimen for CKBMT included cyclophosphamide, 
thymic irradiation, anti-CD2 mAb, and a calcineurin inhibitor, which was 
discontinued after 9-12 months. 18 stable renal transplant recipients receiving 
ongoing triple or double drug immunosuppressive therapy with compatible 
follow up times were compared with the four tolerant recipients. Tolerant 
patients and stable patients on maintenance immunosuppression were also 
comparable with respect to their age, their original disease and donor-recipient 
histocompatibility. 
Results: The perioperative charges for CKBMT were approximately $90, 000 
higher than those for conventional living donor kidney transplantation. After 
9-12 months, continuing medications in CKBMT recipients included only 
occasional over-the-counter analgesics. In contrast, the stable conventionally 
treated were taking an average of 8 pills daily. These included treatments 
required for de novo diabetes (11%), hypertension (67%), hyper lipidemia 
(22%) and gastro-intestinal symptoms/prophylaxis (78%) in addition to their 
maintenance immunosuppression. These needs resulted in annual maintenance 
charges of over $15, 000/year/allograft recipient and do not include unmeasured 
costs related to issues such as quality of life or absences from employment. 
Conclusion: Even with this admittedly expensive approach to tolerance 
induction, the overall medical costs for conventional kidney transplantation 
with ongoing immunosuppression and treatment for complications will exceed 
the cost of tolerance after approximately 5 years. 
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PROPAGATION OF COMMON MARMOSET MONKEY 1488 
(CALLITHRIX JACCHUS) DENDRITIC CELLS (DC) USING 
GROWTH FACTOR MOBILISED DC PRECURSORS AND 
IDENTIFICATION OF STABLY IMMATURE DC FOR PRE-
TRANSPLANT CELLULAR IMMUNOTHERAPY
S. Prasad1,2, S. Kireta1, E. Leedham1, G. Russ1,2, P. Coates1,2,3
1Transplant Immunology Laboratory, Department of Nephrology and 
Transplantation Services, The Queen Elizabeth Hospital, Woodville, 
Australia, 2Department of Medicine, University of Adelaide, Adelaide, 
Australia, 3Center for Stem Cell Research, University of Adelaide, Adelaide, 
Australia
Background: Pre-transplant treatment with donor immature DC in small animal 
models prolongs allograft survival in the absence of immunosuppression, but 
requires further evaluation in non-human primates (NHP) before clinical 
application. The common marmoset is a New World NHP. Due to its small size 
(<400g) and easy breeding, It has lower maintenance requirements and costs 
compared to larger NHP, while retaining substantial immunological similarities 
with humans. We characterised marmoset DC to identify potentially tolerogenic 
DC subsets for transplant studies in this novel model. 
Methods: Sequence-based genotyping of Caja-MHC DRB was performed on 
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our colony (n=45) to facilitate donor-recipient pairing. Recombinant human 
granulocyte-colony stimulating factor (rhG-CSF; 10mcg/kg for 5 days) 
was administered to mobilise peripheral blood (PB) monocytes and CD34+ 
stem cells (38 mobilisations, 10 animals). DC were propagated in-vitro 
from unmobilised (n>15) and G-CSF mobilised (n>25) CD14+ monocytes 
using interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). Myeloid precursors were expanded from CD34+-enriched 
populations (n=6) using fms-like tyrosine kinase 3 (fl t3-L), stem cell factor 
and thrombopoeitin, then differentiated in IL-4/GM-CSF. Maturation stimuli 
included TNF-α ± prostaglandinE2, lipopolysaccharide, and CD40Ligand. 
The DC growth-factor fl t3-L (100mcg/kg for 10 days) was used to mobilise 
myeloid DC in-vivo (7 mobilisations, 5 animals). Cells were characterised by 
morphology, surface marker phenotype, endocytic capacity, allostimulatory 
capacity in mixed lymphocyte reaction (MLR), and NFkB/RelB mRNA 
expression, to establish DC-like features and maturation status. 
Results: Twenty-six genotypes involving 14 Caja-DRB alleles (including 2 new 
alleles) were described. DRB mismatching predicted in-vitro allo-reactivity. 
Monocyte yield from unmobilised animals was insuffi cient (< 150, 000/ml PB) 
for detailed study. rhG-CSF treatment caused a 2-26 fold-rise in monocytes 
and 4-16 fold-rise in CD34+ stem cells. Monocyte-derived DC (MODC) 
yield was 0. 8-1 million/ml of rhG-CSF mobilised PB. CD34+-enriched 
cultures gave rise to a myeloid precursor population, with 4-7 fold expansion 
of cells by 4 weeks (5-15 million/ml mobilised PB). In-vitro propagated DC 
exhibited typical morphology. MODC had immature characteristics. Low-
level co-stimulation molecule expression, high endocytic capacity, weaker 
allostimulatory ability and minimal increase in RelB expression were observed 
despite exposure to various maturation stimuli. In contrast, stem-cell derived 
DC had higher expression of mature DC surface markers which increased 
further with maturation stimuli, and greater allostimulatory capacity. In-vivo 
treatment of marmosets with fl t3-L induced a 35-93 fold rise in PB myeloid DC 
by day 14. Freshly isolated, fl ow-sorted myeloid DC had typical morphology 
and were mildly stimulatory in MLR. However, the fi nal yield was less than 
MODC (0. 4-0. 9 million/ml mobilised blood). Based on stable immaturity, 
MODC were chosen for in-vivo testing of tolerogenic ability. Two million 
immature MODC from rhG-CSF mobilised donors were given intravenously 
to two DRB-mismatched recipient monkeys, without side-effect. Durable (> 
4weeks) donor-specifi c hyporesponsiveness developed in 1 recipient, based on 
MLR and interferon-gamma production. . 
Conclusions: Marmoset DC display many functional similarities to human DC 
and can be differentiated in-vitro from in- vivo mobilised precursors to produce 
suffi cient numbers of candidate immature DC for further cellular tolerance 
studies in this unique, cost- effective new primate model. 
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IMMUNOSUPPRESSIVE EFFECT OF TOTAL LYMPHOID 1489 
IRRADIATION USED IN TOLERANCE INDUCTION 
PROTOCOLS IN DOGS
P.J. Horton 1, W.J. Hawthorne 2, T. Patel 2, S. Walters 2, G.J. Stewart 2, 
R.D.M. Allen 2, J.R. Chapman 2
1 University of Rochester Medical Center, 2 Centre for Transplant & Renal 
Research, Westmead Millennium Institute
Background: We developed pre-clinical models of mixed hematopoietic 
chimerism (MC) and intrathymic tolerance in dogs using fractionated total 
lymphoid irradiation (TLI) and donor bone marrow (BM) inducing tolerance 
to renal and skin allografts. TLI alone can suppress the immune system long-
term. 
Aim: To study the immunosuppressive effect of the TLI protocol in outbred 
dogs given unmatched renal allografts and inbred spaniels given dog-leukocyte 
antigen (DLA)-DP matched, class II compatible renal allografts. 
Materials and methods: Outbred mongrel and inbred English springer spaniel 
dogs were used. Fourteen dogs underwent median width fi eld TLI, receiving 
18Gy in 16 fractions delivered over four weeks using a designated 6MV linear 
accelerator (Phillips Sl75) emmitting gamma irradiation from a gold source. 
The mantle fi eld extended from the back of the skull to the 10th rib. The 
abdominal fi eld extended between the 11th and 12th rib to the base of the tail. 
Penumbral shielding limited beam divergence and fi eld overlap. Elbow and 
knee joints were outside irradiation fi elds. Native kidneys were shielded. Half 
treatments were given posterior-anterior and half anterior-posterior. X-rays 
ensured shielding remained adequate. Monitor units were adjusted for growth. 
Twenty-nine dogs, including those given TLI underwent bilateral native 
nephrectomy and renal transplantation. Mongrel dogs received unmatched 
renal allografts while spaniels received renal allografts from DLA-DP-matched 
dogs. Tissue typing was based on restriction fragment length polymorphism. 
Five mongrels (Group 1) and six spaniels (Group 3) received no treatment pre-
transplantation. Five mongrels (Group 2) and nine spaniels (Group 4) received 
TLI pre-transplantation. Four spaniels (Group 5) received no treatment pre-
transplantation but received renal allografts from DLA-DP matched donors that 
had undergone TLI and recipient BM infusions. Serum creatinine >600μmol/L, 
urea >40mmol/L and renal histology confi rmed acute rejection. 
Results: Graft survival in mongrel dogs was not prolonged by TLI; median 
7 days (range 5 to 8) (Group 1) compared with 8 days (range 6 to 11) (Group 
2). Spaniels receiving DLA-DP matched renal allografts (Group 3) rejected 
allografts slower than mongrels (Group 1) (p=0. 002). TLI prolonged graft 
survival of DLA-DP matched renal allografts; median 20 days (range 18 to 22) 
(Group 2) compared with 26. 5 days (range 10 to 38) (Group 4) (p=0. 005). One 
dog in groups 2 and 4 was excluded for arterial thrombosis. Renal allografts 
from DLA-DP matched chimeric donors were rejected at a similar rate to DLA-
DP matched grafts; median 20 days (range 14 to 25) (Group 5). 
Conclusion: DLA-DP matching prolonged graft survival. TLI only prolonged 
graft survival in dogs receiving DLA-DP matched grafts. Survival of DLA-DP 
matched kidneys from chimeric dogs was not prolonged. 
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EVALUATION OF TOLEROGENIC EFFECT OF DONOR 1490 
SPLENOCYTES AND DELAYED CALCINEURIN INHIBITOR IN 
A PRIMATE MODEL OF KIDNEY TRANSPLANTATION
V. Benseler, P. McKenzie, L. Weston, J. Watson, M. Dahlke, 
H-J. Schlitt, A. Hennessy, K. Allman, A. Bishop, R.D.M. Allen
Collaborative Transplant Group, University of Sydney & Royal Prince Alfred 
Hospital
Donor splenocytes in combination with a delayed course of calcineurin 
inhibitors (CNI) is a strong protocol to induce donor-specifi c tolerance in 
rodents and has the potential to be used in deceased donor transplantation. 
Heavy initial immunosuppression, particularly with CNI and steroids, is 
thought to inhibit induction of tolerance. In the clinical setting however, this 
regimen might be associated with early graft loss from acute rejection and 
graft-versus-host disease (GvHD). 
Aim: To evaluate the safety and effi cacy of intra-portal infusion of un-
fractionated donor specifi c splenocytes in a preclinical primate model of kidney 
transplantation (KT) with delayed introduction of cyclosporin A (CsA). 
Methods: Preliminary pharmacokinetic studies with CsA and mycophenolate 
mofetil (MMF) provided appropriate trough levels of both drugs. Eight adult 
female outbred baboons received ABO-matched MHC-mismatched KT from 
four adult male donors. All recipients received MMF from days 0-10. The 
four control baboons commenced CsA from day 0. They were compared with 
four study baboons who received intra-portal donor splenocytes at time of 
transplantation and CsA from 72 hours. KT was life-supporting for 2 pairs. 
Target trough CsA was 1000 ng/ml till day 50 in both groups after which CsA 
dose was weaned progressively to cease on day 90. Splenocyte distribution 
was assessed by whole-body-scan after radioactive labelling with 111In-
Oxime. Allograft rejection and function were assessed by histology, duplex 
ultrasonography, serum creatinine and nuclear scans. 
Results: All allografts functioned at the conclusion of the operative procedure. 
One control kidney was lost on day 3 for technical reasons and no kidney was 
lost from early rejection in either group. Target CsA levels were achieved. 
Weekly core biopsies and duplex ultrasound fi ndings were comparable for 
control and study animals with evidence of progressive rejection from day 
14. The remaining three control kidneys, including two life-supporting 
procedures, survived 60-85 days. Two life-supporting study animals were lost 
to overwhelming pyelonephritis day 36 and 59 and two study animals were 
followed for >200days without GvHD. 
Conclusions: This translational study in non-human primates demonstrated that 
donor specifi c splenocytes and delayed CsA are not associated with increased 
risk of early kidney transplant rejection or GvHD. However, it failed to induce 
donor-specifi c tolerance in this rigorous immunological model. 
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TOLERANCE: CONCURRENT ORAL SESSION 105: 
INDUCTION AND MECHANISM
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NEONATAL INJECTION OF ALLOGENEIC LIN-/C-KIT+ 1491 
FETAL LIVERCELLS INDUCES OPERATIONAL TOLERANCE 
TO CARDIAC ALLOGRAFTS
L. West, M. Jeyakanthan, K. Tao
University of Alberta
Introduction: We previously showed that injection of neonatal mice with 
fully allogeneic fetal liver cells (FLC) results in long-term acceptance of both 
donor-specifi c and unrelated cardiac allografts as adults. A mechanistic role for 
CD4+CD25+Foxp3+ regulatory T cells has been implicated in graft survival in 
this model. The purpose of this study was to identify specifi c cell populations 
in the FLC tolerizing inoculum that induce non-donor-specifi c cardiac allograft 
acceptance. 
Methods: BALB/c (BALB, H-2d) FLC from day 12-14 fetal pups were sorted 
by magnetic cell separation and the purity of sorted cells was assessed by fl ow 
cytometry. Neonatal C3H/He (C3H, H-2k) mice were injected iv with either Lin-
/c-Kit+ or Lin+/c-Kit- BALB FLC, followed at 6-8 weeks of age by heterotopic 
transplantation of C57BL/6 (B6, H-2b) cardiac grafts. Untreated C3H controls 
received B6 cardiac grafts. All cardiac grafts were monitored for long-term survival; 
grafts surviving longer than 60 days were considered as long-term survivors. 
Results: Purity of Lin-/c-Kit+ cells was over 90% and – Lin+/c-Kit- cells 
contained less than 3% of c-Kit+ cells. While long-term graft survival was 
achieved in 6 of 8 recipients in the 
Lin-/c-Kit+ group, acute rejection occurred in all 8 recipients in the Lin+/c-Kit- 
group and all 6 recipients in the untreated group. 
Conclusions: This study demonstrates that Lin-/c-Kit+ cells isolated from 
FLC, when injected into fully MHC-mismatched neonatal mice, induce 
non-donor specifi c cardiac allograft acceptance. These data suggest that less 
differentiated cell populations within the FLC inoculum are responsible for 
the alterations in neonatal immunity that result in graft acceptance as adults. 
We are further investigating the underlying mechanisms by which Lin-/c-Kit+ 
cells induce the regulatory T cells that mediate non-donor specifi c cardiac 
allograft acceptance. Further refi nement of this strategy may offer a useful tool 
for transplant situations in which time constraints preclude consideration of 
donor-specifi c tolerance induction, as in cardiac transplantation. 
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MODULATION OF ACUTE AND CHRONIC ALLOGRAFT 1492 
REJECTION VIA ORAL APPLICATION OF ALLOANTIGEN 
CODING DNA
S. Ensminger1, A. Bushell2, K. Goldmann3, M. Weyand1, B. Spriewald3
1Department of Cardiac Surgery, University of Erlangen – Nuremberg, 
Germany, 2Nuffi eld Department of Surgery, University of Oxford, U. K. , 
3Department of Medicine 5, University of Erlangen – Nuremberg, Germany
Introduction: Nowadays the major effort in transplant immunology is the 
development of immunomodulatory protocols that help to achieve long-term 
allograft survival. One promising approach is the pre-treatment of transplant 
recipients with donor MHC (major histocompatibility complex) –alloantigen 
under favourable immunological conditions. Therefore, the aim of this study 
was to develop a strategy for oral delivery of MHC-antigen coding genes via 
DNA-chitosan nanoparticles to induce longterm allograft survival. 
Methods: Chitosan, the deacetylated form of Chitin, is an inert, non-
toxic polycationic biopolymer that can be coacervated with DNA to form 
nanoparticles. Mice were treated with Kb-nanoparticles and anti-CD4 mAb 
for two consecutive days. 40 days later CBA (H2k) recipients recieved a 
fully MHC-mismatched C57BL/6 (H2b) cardiac allograft. Survival of cardiac 
allografts was assessed by daily palpation and intestinal uptake of nanoparticles 
was analysed by immunofl uorescence and RT-PCR. 
Results: First, we could demonstrate that nanoparticles remain stable 
throughout intestinal transport. They were taken up in the small bowel where 
the target gene was expressed in the Peyer’s patches and mesenteric lymph 
nodes. Oral treatment with Kb-nanoparticles resulted in a signifi cant increased 
cardiac allograft survival. Moreover combination of a non depleting anti-CD4 
mAb with Kb-nanoparticles resulted in long term allograft survival. Untreated 
controls acutely rejected their grafts around day 7. 
Conclusion: These data show oral delivery of MHC-antigen coding genes via 
DNA-chitosan nanoparticles resulted in signifi cantly prolonged allograft survival. 
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RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV2/8) 1493 
EXPRESSING INDOLEAMINE 2, 3-DIOXYGENASE (IDO) IN 
RAT LIVER TRANSPLANTATION
J. Laurence 1, C. Wang 1, 2, S. Cunnigham 2, 4, J. Earl 4, M. Zheng 2, 4, G. 
Mccaughan 3, R. Allen 1, I. Alexander 2, 4, A. Sharland 1, A. Bishop 1, 3
1 Collaborative Transplantation Research Group, Bosch Institute, University 
of Sydney, NSW, Australia, 2 Gene Therapy Research Unit, Children’s 
Medical Research Institute, Westmead, NSW, Australia, 3 AW Morrow Liver 
Immunobiology Laboratory, Centenary Institute, Sydney, NSW, Australia, 4 
Children’s Hospital at Westmead, Westmead, NSW, Australia
Aims: To evaluate transduction of the rat liver with rAAV2/8 vectors expressing 
transgenes under the control the human alpha 1-antitrypsin promoter and to test 
a potentially immunomodulatory vector in a normally rejecting (PVG>LEW) 
rat liver allotransplant model. 
Methods: Using a rAAV2/8 vector expressing GFP (rAAV2/8_GFP), the kinetics 
of expression and optimal dosing for transduction of PVG strain rat livers was 
determined. A rAAV2/8 vector encoding for the IDO gene (rAAV2/8_IDO) 
was constructed and tested by its ability to induce tryptophan catabolism and 
kynurenine production in vitro and in vivo. PVG strain donor rats were injected 
via the portal vein with rAAV2/8_IDO two weeks before transplantation into 
LEW strain recipients to determine if allograft rejection could be ameliorated. 
Results: By means of the rAAV2/8_GFP vector, it was determined that a dose of 
1013 vector genomes was required to attain widespread hepatocyte transduction. 
Not before two weeks after vector administration was high-level gene expression 
achieved. The rAAV2/8_IDO vector was able to induce tryptophan catabolism and 
kynurenine production by Huh7 hepatoma cells. The function of the rAAV2/8_
IDO vector was validated in vivo by confi rming tryptophan catabolism both in 
untransplanted PVG animals and in isograft (PVG>PVG) recipients where serum 
tryptophan was 64. 5±5. 3μM in recipients of livers transduced with rAAV2/8_
GFP and 28. 9±5. 7μM in recipients of livers transduced with rAAV2/8_IDO (p=0. 
001). LEW recipients of PVG liver allografts pre-treated with the rAAV2/8_IDO 
vector had a median survival time (MST) of 12 days, whilst recipients of allografts 
pre-treated with rAAV2/8_GFP had a MST of 13 days (p=0. 38). Both groups 
displayed similar histological features of acute cellular rejection. 
Conclusions: rAAV2/8 vectors produced highly effi cient hepatocyte 
transduction in vivo and provide a gene therapy tool for use in transplantation 
models. However, gene therapy using IDO was unsuccessful in prolonging rat 
liver allograft survival. 
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INDUCTION OF TOLERANCE AFTER LONG-TERM 1494 
TREATMENT OF HUMAN ENDOTHELIAL CELLS WITH 
EVEROLIMUS?
G. Koehl3, K. Lehle1, L.A. Kunz-Schughart2, S. Hirt1, T. Puehler1, C. Schmid1, 
1 Department of Cardiothoracic Surgery, 2 OncoRay - Center for Radiation 
Research in Oncology, Medical Faculty Carl Gustav Carus, TU Dresden, 
Fetscherstr. 74, PF86, D-01307 Dresden, Germany, 3 Department of Surgery, 
University of Regensburg
Cardiac allograft vasculopathy (CAV) is characterized by intimal hyperplasia 
as a result of endothelial cell (EC) injury. The anti-proliferative and anti-
infl ammatory properties of mTOR inhibitors (e. g. everolimus) were used 
to treat CAV. Our study evaluated the specifi c impact of everolimus on EC 
regeneration and conservation of its function. 
Patient-derived human saphenous vein EC (HSVEC) were incubated with 
therapeutic concentrations of everolimus. The proliverative activity and the 
infl ammatory response of the cells were analyzed. 
Treatment of HSVEC with mTOR inhibitors dose-dependently reduced EC 
proliferation by about 40%, while apoptosis or cytotoxicity was not induced. 
However, after long-term cultivation of HSVEC with 10 nM everolimus and 
repeated transfers into the next generation under immunosuppression resulted 
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in a regeneration of cell growth. In addition, long-term treatment with high 
concentrations of everolimus did not induce the basal and TNF-induced 
expression of cellular adhesion molecules (CAM). Thus, the drug per se did not 
stimulate EC. Surprisingly, everolimus inhibited the synthesis of interleukin-6 
(IL-6). 
In summary, dose-dependent inhibition of proliferation might explain a delayed 
reendothelialization of injured EC layers. However, long-term treatment 
induced a regeneration of cell growth. In addition, therapeutic concentrations 
of everolimus did not contribute to the endothelial activation during CAV.
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LIVER SUPPRESSOR FACTORS SPECIFIC TO 1495 
AUTOIMMUNITY IN LIVER TRANSPLANTATION
S. Goto1,2, T. Nakano1, L.W. Hsu1, C.Y. Lai1, S. Kawamoto3, K.C. Chiang4, T. 
Goto4, K. Ono3, S.V. Lynch5, C.L. Chen1
1Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology, 
Graduate School of Advanced Sciences of Matter, Hiroshima University, 
4Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences, 
Josai International University, 5The Queensland Liver Transplantation 
Service (QLTS)
For past 15 years at QLTS (Brisbane) and Liver Transplant Program, 
Chang Gung Memorial Hospital-Kaohsiung Medical Center (Taiwan), we 
have investigated the diagnostic and therapeutic potentials of various liver 
suppressor factors (LSFs) induced by orthotopic liver transplantation (OLT). 
Recent proteomic approach allows us to target on specifi c molecules of LSFs 
underlying the common mechanism between experimental and clinical liver 
allograft tolerance. Especially, a new insight has been given into our study 
since we found that post-transplant autoimmune responses with high titer of 
anti-nuclear antibodies against histone H1 and high mobility group box 1 
(HMGB1) play an important role in induction of liver allograft tolerance in 
OLT rats and clinical drug-free OLT patients. Our previous studies showed 
that either treatment of recipient rats with commercially available histone H1 
polyclonal Ab or immunization with calf thymus histone H1 could prolong 
allograft survival in heterotopic heart transplantation. We have also reported 
that the blockade of histone H1 modulated dendritic cells toward tolerogenic 
status, decreased the cytotoxicity of lymphokine activated killer and natural 
killer cells, and induced CD4+CD25+ T-cells. For further analysis of this 
mechanism, we generated an immunosuppressive histone H1 monoclonal Ab 
(16G9 mAb). From phage display peptide library, we have selected one peptide 
(designated SSV) that binds directly to 16G9 mAb. The binding of SSV to 
16G9 mAb was inhibited by histone H1. Furthermore, SSV binds to serum of 
both tolerogeneic OLT rats and clinical drug-free OLT patients, and the binding 
to SSV was also inhibited by histone H1. Immunization of mice with SSV 
induced immunosuppression in serum, suggesting that SSV was an epitope 
responsible for the immunosuppressive activity of 16G9 mAb. Peptide SSV 
binding will allow us to establish a novel diagnostic and therapeutic strategy 
in transplantation. 
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TH2 DEPENDENT ALLOANTIBODIES SPECIFICALLY 1496 
MODIFY RECIPIENT IMMUNE RESPONSE TOWARD 
TOLERANCE AND ATTENUATION OF CHRONIC REJECTION
N. Semiletova1, D. Edberg1, X-D. Shen1, D. Feldman1, M. Ghobrial2
1UCLA Medical School, CA, 2Methodist Hospital, TX
Cardiac transplanted recipients treated with soluble MHC class I chimeric 
proteins developed specifi c tolerance. It was characterized by the deviation of 
alloantibody (alloAb) responses and predominant expression of Th2 dependent 
anti-donor IgG1 and IgG2c immunoglobulins. This study further examines the 
immunoregulatory effect of Th2 alloAb on inhibition of chronic rejection (CR) 
in the MHC disparate cardiac allografts. 
Methods: ACI recipients of WF hearts were treated with alloIgG1 and 
alloIgG2c enriched serum (1 mL, i. v. ) from tolerant syngeneic recipients. 
Whole body irradiation (130R) was used to create temporary CD4 defi ciency. 
Results: In vitro: Endothelial cells (ECs) is a fi rst target for alloAb and most 
affected by CR. RNA turnover assay demonstrated that allogeneic serum (ACI) 
directly inhibits metabolic activity of IFN-γ activated donor (WF) ECs. Mixed 
lymphocyte reaction (MLR) was performed on LN T cells from naïve ACI 
rats (responders) stimulated with syngeneic, donor or third-party splenocytes 
in the presence of naive or modulated MHC class I serum. MHC-induced, 
but not naïve, serum signifi cantly blocked ACI proliferative responses to WF 
stimulation. In vivo: Whole-body γ-irradiation creates temporary peripheral 
CD4 lymphopenia. CD4 lymphopenic ACI hosts treated with syngeneic 
alloIgG1/IgG2c enriched serum demonstrated long-term survival of WF 
hearts for more then 120 days (MST=11314. 14, n=13). Sera from animals 
treated with high-dose CsA, which contains minimal alloAb levels, modestly 
prolonged allograft survival to MST of 51±11 (n=6) days. Treatment of not 
irradiated hosts with either naïve or MHC class I modulated serum cased 
delayed rejection (MST=40+15 & 58+21, respectively). Transfer of alloIgG1/
IgG2c has specifi c effect, ACI recipients of BN hearts promptly rejected 
grafts (ACI-BN; n=2, MST 16+1. 5). Therapy with alloIgG1/IgG2c abrogated 
CR in MHC disparate grafts. CR–free recipients demonstrated upregulated 
IgG2b serum alloAb and IgG and IgM deposits on the graft vascular intima. 
Heart tissue had a diminished number of apoptotic cells. WB analysis showed 
upregulation of antiapoptotic proteins (BcL-2/BcL-xL) and decreased 
production of p50 subunit of NF-B in compare to grafts with high-level of 
CR. CR-free grafts after allo-IgG1/IgG2c therapy were free of CD3+ cells and 
had medium level of CD4+ infi ltration. 
Conclusion: Transfer of alloIgG1/IgG2c-enriched serum develops specifi c 
tolerance and abrogates CR. Presence competent CD4 cells cancels effect 
of alloIgG1/IgG2c therapy. Th2 dependent alloAb can directly inhibit ECs 
metabolic activity. These in vitro and in vivo novel fi ndings have important 
clinical implications for inhibition of chronic rejection in transplant 
recipients.
POSTER BOARD NUMBER P2 – 296
INDUCTION OF DONOR-SPECIFIC TRANSPLANTATION 1497 
TOLERANCE BY ALLOANTIGEN-PRIMED MONOCYTE-
DERIVED PROGENITOR CELLS COMBINED WITH LOW-
DOSE IMMUNOSUPPRESSION
Z.F. Yang, P. Ngai, Y. Liu, M.N.P. Ng, C.K. Lau, W.Y. Ho, R.T.P. Poon, 
S.T. Fan
The University of Hong Kong
Background: Transplantation tolerance is the ultimate goal in the fi eld of organ 
transplantation. The present study was designed to investigate a combined 
strategy of alloantigen primed monocyte-derived progenitor cells (PCMOs) 
and low-dose immunosuppression in the induction of cardiac transplantation 
tolerance. 
Methods: PCMOs were isolated from DA spleen, and cultured with IL-3, 
M-CSF in the presence or absence of LEW antigen. Adult male DA (RT1a) 
and LEW (RT1l) rats were used as donors and recipients in a rat heterotopic 
heart transplantation model. The cultured PCMOs were injected into recipient 
rats immediately after transplantation. RAD001 (a rapamycin derivative) was 
administered at the dose of 5 mg/kg/day oral feeding for 1 week either alone or 
in combination with PCMO injection. 
Results: The non-treated cardiac allografts were rejected within 7 days. PCMO 
injection prolonged allograft survival to 12 days, whereas low-dose RAD001 
prolonged allograft survival to 11 days. When combining PCMOs with RAD001, 
half of the allografts developed indefi nite allograft survival. The injected 
PCMOs were identifi ed in the allograft, spleen and mesenteric lymph nodes of 
recipients. Histological study revealed normal cardiac structure on day 7 with 
the combined treatment, whereas the non-treated allograft displayed extensive 
areas of necrosis at the same time point. In the long-term surviving animals, 
nearly normal cardiac structure was retained. Immuno-fl uorescent staining 
detected reduced number of CD4+, CD8+ and CD68+ cells in the allografts 
with the combined treatment, compared with non-treatment group and groups 
with PCMO or RAD001 treatment on day 4 after treatment. Flow cytometry 
analysis revealed an increased number of CD4+CD25+Foxp3+ regulatory T 
(T-reg) cells in the blood, thymus and lymph nodes in the group with combined 
treatment, whereas there was no obvious change in the number of T-reg cells in 
the spleen. 
Conclusion: When combined with low-dose immunosuppression, allo-
antigen primed PCMOs could induce long-term cardiac allograft survival 
by the generation of T-reg cells and subsequent induction of transplantation 
tolerance. 
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THE EFFECT OF SELECTED IMMUNOSUPPRESSIVE 1498 
DRUGS: CSA, FK506, MMF AND RAPA ON CD8+CD28- CELLS 
LEVEL IN MIXED LYMPHOCYTE CULTURE (MLC)
A. Korecka1, K. Bocian1, J. Wyzgal2, G. Korczak-Kowalska1,2
1Department of Immunology, Faculty of Biology, University of Warsaw, 
2Transplantation Institute, The Medical University of Warsaw
Among immunosuppressive drugs we can distinguish calcineurin inhibitors 
that act by blocking cytokine production (cyclosporine A – CsA and tacrolimus 
– FK506) and cell division inhibitors (mycophenolate mofetil – MMF 
and rapamycin – RAPA). The achievement of transplant tolerance seems 
to be dependent of the presence and action of regulatory cells, including 
CD8+CD28- suppressor lymphocytes (Ts). The examination of infl uence of 
immunosuppressive drugs on regulatory cells level is essential for transplant 
immunology. 
The aim of this study was to determine how the selected immunosuppressive 
drugs: CsA, FK506, MMF and RAPA affect the level of CD8+CD28- cells in 
Mixed Lymphocyte Culture (MLC). 
Mononuclear cells were obtained from peripheral blood of healthy volunteers 
and were cultured in MLC in the presence or without investigated drugs. 
After six days CD8+CD28- cells level was evaluated using monoclonal 
antibodies conjugated with fl uorochromes and analysed by fl ow cytometry 
(FACSCalibur). 
We observed that obtained data can be grouped into two subsets. In some 
cultures with drugs the level of CD8+CD28- cells decreased signifi cantly 
but there was no decline in other cultures. This phenomenon concerns to all 
investigated drugs despite of their different mechanism of action. 
There are two possible explanations. The effect of immunosuppressive drugs on 
CD8+CD28- lymphocytes can vary with different alloantigens confi gurations 
in MLC. It can be dependent on individual variations in drug responses. In the 
other hand, population of CD8+CD28- cells is very heterogeneous. It contains 
both suppressor cells and cells without regulatory properties. It is possible that 
examined drugs affect only one of these subsets and the change in CD8+CD28- 
cells number is due to the ratio of suppressor cells to non-suppressor cells 
within CD8+CD28- population. 
POSTER BOARD NUMBER P2 – 298
BLOCKING B7-CD28 CO-STIMULATORY PATHWAY 1499 
INDUCED IMMUNE TOLERANCE AND PROLONGED 
ALLOGRAFT SURVIVAL
S. Xiong, J. Chen, P. Yu, X. Yang, Q. He
Dept. Immunology, Shanghai Medical College, Fudan University
The interaction of T cell CD28/CTLA-4 receptors with B7 on antigen-
presenting cells (APCs) represents an important co-stimulatory pathway 
in T cell activation or anergy. Our previous study indicated that recipients 
immunized with allogenic donor immature dendritic cells (DCs) or resting B 
cells could induce specifi c immune tolerance and prolong allograft survival. 
The possible mechanism for those observations is that the expression of B7 
molecules is either at a low level or lacking on these APCs. Then we tried 
to investigate whether blockade of B7 molecules on donor splenocytes with 
a B7 antisense peptide (B7AP), could have the same effect using a murine 
pinna cardiac allograft experiment model. Results showed that B7AP treatment 
did not infl uence the expression of B7 molecules on C57BL/6 splenocytes 
but dose-dependently inhibited the mixed lymphocyte reaction by up to 38. 
4%. The recipients (BALB/c) immunized with B7AP-pretreated C57BL/6 
splenocytes induced a specifi c immune hypo-response (43% versus control) 
and notably prolonged survival of the C57BL/6 cardiac allograft by up to 
20. 3 days. When bone marrow transfusion (BMT) was performed 3 days 
after B7AP-treated C57BL/6 splenocytes injection, a long-lasting allogenic 
chimerism was observed with the rate as 3. 6% even on day 100 post BMT. 
And the survival of allgenic cardiac grafts was maintained over 100 days in 
recipients. Another strategy, a B7AP-exCD40L fusion protein, consisting of 
both B7AP and exCD40L (extracellular portion of CD40L) was also used to 
treat donor splenocytes and built an allo-hypo-response state. Combining with 
BMT in such a state also generated an over-100-days allogeneic chimerism and 
an over 100-days survival of cardiac allografts. Therefore, mixed chimerism 
approach, by treating with B7-CD28 costimulatory blockade could effectively 
induce an allograft tolerance in mice. 
POSTER BOARD NUMBER P2 – 299
EFFECTS OF ATORVASTATIN ON RENAL ACUTE 1500 
REPERFUSION INJURY FOLLOWING ISCHAEMIA WITH 
FOCUSES ON APOPTOSIS, INFLAMMATION AND OXIDATION 
IN A RAT MODEL 
J. Haylor1, K.P.G. Harris2, H. Waller2, M.L. Nicholson2, B. Yang2
1Sheffi eld Kidney Institute, University of Sheffi eld; 2Department of Infection, 
Immunity and Infl ammation, University of Leicester, United Kingdom. 
HMG-CoA reductase inhibitors may have benefi cial effects on renal injury 
independent of lowing lipid effects, although the underlying mechanism 
is not fully defi ned. We examined the changes of apoptosis, infl ammation, 
oxidation and renal structure in a rat model of 45 minutes ischaemia (45mI) 
and 4 hours reperfusion (45mI/4hR) with uninephrectomy (Unx) and the 
effect of 10 mg/kg atorvastatin (45mI/4hR+AT) administered intravenously 
after clamping the renal artery (before reperfusion). Caspase-3 activity (pmol 
AMC liberated/min/μg protein) in kidneys was gradually increased from Unx 
(0. 0020 ± 0. 0003), 45mI (0. 0034 ± 0. 0003) to 45mI/4hR (0. 0041 ± 0. 
0004), but decreased by addition of AT (0. 0030 ± 0. 0001, p<0. 05). 12 kD 
active caspase-3 protein signifi cantly increased by 45mI, while the change of 
17 kD active caspase-3 occurred after 4hR. Apoptotic cells (per 400× fi eld) 
in both tubular (1. 2 ± 0. 2 vs. 2. 3 ± 0. 2) and interstitial areas (0. 7 ± 0. 3 
vs. 1. 9 ± 0. 4), necrotic cells (1. 2 ± 0. 5 vs. 4. 3 ± 1. 2) and ED1 positive 
infl ammatory cells (1. 4 ± 0. 4 vs. 5. 4 ± 1. 2) were signifi cant decreased by 
AT compared with 45mI/4hR alone. In addition, protein carbonyl in kidney 
tissues (nmol/μg protein) was signifi cantly enhanced by 45mI (0. 44 ± 0. 03) 
and eliminated by 4hR with (0. 28 ± 0. 01) or without AT (0. 28 ± 0. 01). The 
score of tubulointerstitial damage was gradually raised from Unx (0. 43 ± 0. 
08), 45mI (1. 3 ± 0. 06) to 45mI/4hR (2. 89 ± 0. 06), all p<0. 01; but reduced 
by AT (2. 14 ± 0. 18, p<0. 05). There were no signifi cant differences in the 
level of serum triglyceride, cholesterol and creatinine between the groups with 
or without AT. In conclusion, caspase-3 activation, apoptosis, infl ammation 
and oxidation were involved in renal ischemia and I/R injuries. AT might 
modulate these processes and improve reperfusion tolerance in the kidney, 
but its long-term impact on renal function following I/R injury remain to be 
determined. 
POSTER BOARD NUMBER P2 – 300
INHIBITION OF DENDRITIC CELL DIFFERENTIATION 1501 
AND MATURATION BY SOLUBLE FACTOR (S) PRODUCED BY 
LIVER STELLATE CELLS
C-C. Hsieh1, H-R. Yang2, G. Jiang1, J. Fung2, S. Qian1,2, L. Lu1,2
1Deaprtment of Immunology, Lerner Research Institute, Cleveland Clinic, 
2Department of General Surgery, Cleveland Clinic
Tolerogenic property of the liver has been demonstrated by spontaneous 
acceptance of liver allografts in many species, as well as tolerance to antigens 
that are delivered through portal vein. The involved mechanisms are not 
completely understood. It has been noticed that liver allografts are accepted in 
mice, but hepatocytes transplants in same combination are acutely rejection, 
suggesting a crucial role of liver non-parenchymal components (NPC) in 
protecting parenchymal cells from immune attacks. We have focused on 
hepatic stellate cells (HpSC) which showed potent immune suppressive 
activity. Co-transplant with HpSC effectively protected islet allografts from 
rejection. We hypothesize that liver NPC may modulate immune response 
via inhibition of liver dendritic cells (DC) which are known of bone marrow 
(BM) origin. In this study, DC were propagated from B6 BM cells with 
GM-CSF for 5 days. Irradiated HpSC isolated from B6 mouse liver were 
added at the beginning into the culture at HpSC : DC progenitor ratio of 
1: 20. The differentiation, maturation and function of propagated DC were 
determined by characterizing their surface molecule expression and T cell 
stimulatory activity at the end of culture. The results showed that addition 
of HpSC markedly blocked the differentiation of DC from BM precursors 
(most cells remained in CD11b+CD11c- precursors stages). The incidence of 
CD11c+ cells was 7% vs. 41. 6% in normal DC culture (without HpSC). The 
presence of HpSC also prevented maturation of CD11c+ DC, as evidenced 
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by low expression of CD40, CD80 and CD86, but high of B7-H1. The 
inhibitory effect appeared to be mediated by soluble factor (s) produced by 
HpSC since addition of the HpSC culture supernatant provided comparable 
inhibitory activity. Culture of allogeneic CD4+ T cells with DC propagated 
in the presence of HpSC elicited poor proliferative response in a 3d MLR 
assay, with low IL-2 and IFN-ƒ× production. This was associated with high 
expansion of CD25+Foxp3+ T cells (10. 9%, compared to 6. 7% in T cells 
stimulated by normal DC, which was associated with vigorous proliferation 
and high IL-2, IFN-ƒ× production), suggesting that HpSC inhibited DC 
were capable of inducing Treg cells. In conclusion, liver tissue cells, such as 
HpSC markedly inhibit DC differentiation and maturation, suggesting that 
the tolerogenic property of liver DC may not be intrinsic, but is altered by the 
microenvironmental factors in the liver. 
POSTER BOARD NUMBER P2 – 301
FACE TRANSPLANT SURVIVAL IS PROMOTED BY 1502 
DONOR BONE MARROW CELLS AND PRESENCE OF 
REGULATORY CD4+/CD25+ T-CELL
M. Siemionow, A. Klimczak, M. Unal, Y. Demir
Cleveland Clinic
Purpose: We have formerly achieved functional tolerance in fully MHC 
miamatched rat facial allotransplantation model under cyclosporine-A 
(CsA) monotherapy. In this study we tested the effect of donor bone marrow 
transplantation (DBMT) under short-term alpha-betaTCRmAb and CsA 7-day 
protocol on development of chimerism, allograft survival, and presence of 
regulatory T-cells in face allograft model across MHC barrier. 
Methods: Thirty six hemiface allotransplantation were performed between 
LBN (RT1l+n) donors and LEW (RT1l) recipients in 6 groups (6 rats each). 
Controls: Group 1 isograft and Group 2 allograft without treatment, Group 3 
received intraosseous DBMT only. Groups 4, 5 and 6 received alpha-betaTCR/
CsA 7-day therapy. Additionally Groups 5 and 6 were augmented with 
intraosseous DBMT of 35x106, and 100x106 of bone marrow cells (BMC) 
respectively. Before transplantation BMC were stained with PKH dye to 
evaluate engraftment and migratory process of donor BMC. 
Flow cytometry assessed immunodepletion of T–lymphocytes, donor-
specifi c chimerism for MHC class I (RT1n) antigens and presence of 
regulatory T-cells CD4+/CD25+. Grading of graft rejection was assessed 
by H+E staining. 
Results: Isograft controls survived indefi nitely, whereas controls without 
immunosuppression rejected transplanted allograft within 5 to 8 days. Group 
3 treated with only DBMT accepted transplant up to 13 days. Median survival 
time (MST) of facial allograft (Group 4) under alpha-betaTCR/CsA therapy 
was 35 days. In both Groups 5 and 6 augmented with donor BMC MST was 
48 days. However, the longest survival time in Groups receiving 35x106 or 
100x106 BMC was 465 and 498 days respectively. In long-term survaivals 
split tolerance was found as presented by acceptance of skin and intact ear and 
rejection of hair components. 
PKH-positive cells of donor origin were present within lymphoid organs 
and skin of recipients. In rejected allografts T-cell chimerism declined <1%, 
and B-cell chimerism was at 4. 5% of CD45RA/RT1n. In contrast, in long-
term survival animals T-cell chimerism was 2%-4% (RT1n) during follow-
up period and B-cell chimerism reached 12. 4% CD45RA/RT1n at day 465 
post-transplant. At day 7 post-transplant, regulatory CD4+/CD25+ T-cells 
initially were detected at 1. 8%, however in long-term survivals reached 4. 0%, 
whereas rejected allografts reveled 2. 2% of CD4+/CD25+ T-cells at the time 
of euthanasia. 
Conclusion: Long-term face allograft survival was achieved under 7-day 
alpha/beta-TCRmAb/CsA protocol augmented with DBMT without chronic 
immunosuppression. Long-term allograft acceptance was supported by 
development of regulatory T-cells and maintenance of donor T-cell and B-cell 
chimerism. 
POSTER BOARD NUMBER P2 – 302
FATE AND INTERACTIONS OF TOLERIZING CELLS IN 1503 
NEONATES 
L.J. West, R.A. Bascom, K. Tao
Departments of Pediatrics, Surgery and Immunology, University of Alberta, 
Edmonton, Canada. 
Introduction: and Methods: Injection of neonatal mice with either allogeneic 
fetal liver cells (FLC) or semi-allogeneic adult F1 splenocytes (F1SpC) induces 
acceptance of donor-type and third-party heart grafts in adults; regulatory T 
cells (Tregs) have been implicated in both models. To understand the early 
events of tolerance induction we studied the fate and cellular interactions of 
injected CFSE-labeled cells in host organs by confocal microscopy using 
monoclonal antibodies for specifi c cell surface markers. Injected cells were 
tracked for six days after injection. 
Results: The fate of injected cells depended not only on their nature but 
also on the host organ examined. F1SpC persisted over 6 days in thymus 
and spleen but not in liver. FLC were greatly reduced or absent by day 
6 in all organs examined. Both F1SpC and FLC were rare in thymus 
compared to spleen, consistent with thymic entry being gated. In the 
thymus, both F1SpC and FLC appeared to interact with cortical epithelial 
cells and cortico-medullary junction dendritic cells (DC) suggesting they 
may undergo positive and negative selection respectively. Many F1SpC 
appeared to survive both positive and negative selection processes, possibly 
because they expressed appropriate functional T cell receptors. In contrast, 
the immature allogeneic FLC, which contain few if any functional T cell 
receptors, fragmented in the thymic cortex and were detected in host 
macrophages and DC. The fate of F1SpC and FLC also differed in host 
spleen. F1SpC colonized the developing neonatal spleen before arrival of 
the bulk of host T cells. F1 T cells were detected in the PALS and B cells in 
the immediate surrounding follicular regions, and were thus positioned for 
immune regulation and tolerance induction. Three days post-injection, both 
host and donor (F1) Foxp3-expressing cells were seen in close association 
with one another and with host DC. In contrast, in the allogeneic model 
many of the FLC appeared to be fragmented three days after injection. Some 
allogeneic FLC could be seen in intimate association with host CD8+ T cells 
suggesting they were being killed. As early as day one post-injection, host 
DC containing FLC fragments were seen adjacent to host T cell, suggesting 
indirect antigen presentation may play an important role in Treg development 
in this tolerance model. 
Conclusion: The fate of tolerizing cells and their interactions with host cells 
differ signifi cantly between the allogeneic and semi-allogeneic models of 
neonatal tolerance, suggesting different events leading to Treg induction. 
POSTER BOARD NUMBER P2 – 303
EFFECT OF EARLY WITHDRAWAL OF A FIRST 1504 
ALLOGRAFT ON SURVIVAL OF A SECOND VASCULARIZED 
GRAFT. EXPERIMENTAL MODEL OF TOLERANCE?
P. Troncoso, G. Olivares, C. Parra
Pontifi cia Universidad Católica De Chile
Introduction: The critical role of the receptor alloimmune response is the main 
determinant of transplanted grafts. Experimental observations have shown 
us that interrupting the immune response during this process may increase 
survivals of subsequent grafts. The objective of the study was to develop an 
animal model to test this strategy. 
Materials and Methods: Male Lewis rats were used as receptors and Brown 
Norway as graft donors. Skin was used as fi rst grafts and heterotopic heart as 
seconds grafts. Animals in the experimental groups underwent extraction of a 
fi rst skin graft in predetermined periods of time after the implant and the second 
transplant was performed 30 days after the fi rst one. The graft was controlled in 
a daily fashion with digital examination of heart beat. The absence of beating 
was considered rejection. 
The design included the following 5 groups: 
Control Group (CG): Lewis rats with a Brown Norway heart transplant and no 
other intervention. (First set rejection). Group 1: Lewis rats with a skin graft 
and a heart transplant after 30 days (Second set rejection). Group 2: Lewis 
rats with a skin graft, withdrawal during the third day and a heart transplant 
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after 30 days. Group 3: Lewis rats with a skin graft, withdrawal during the 
second day, and a heart transplant after 30 days. Group 4: Lewis rats with 
a skin graft, withdrawal during the fi rst day and a heart transplant after 30 
days. Both cellular and humoral acute rejection components were analyzed 
according to the classifi cation of the International Society for Heart & Lung 
Transplantation (ISHLT). 
Comparisons were made using a variance analysis and the multiple comparison 
test of Bonferroni. 
Results: Mean graft survivals were: CG: 8 days ± 0, 82; Group 1: 6 days ± 0, 
5; Group 2: 6 days ± 0, 58; Group 3: 8 days ± 1 and Group 4: 7 days ± 1, 53. 
There was a tendency towards increased survival of the grafts or at least to be 
equal to that of the CG when the skin allograft was removed earlier (Groups 
3 and 4). However, this difference was not statistically signifi cant (p = 0, 8). 
In addition, there was a tendency in groups 1 and 2 to present moderate to 
severe cellular rejection compared to groups 3 and 4. On the other hand, in 
CG and group 1 a total of 5 cases presented rejection with humoral component 
compared to groups 2, 3 and 4 in which only 3 cases presented this kind of 
rejection. 
Conclusions: Though this strategy was not associated to tolerance the graft 
survival of some experimental groups and the intensity of histological rejection 
were different from those of a second set type. This model needs to be more 
explored. 
POSTER BOARD NUMBER P2 – 304
ADOPTIVE TRANSFUSION OF EX VIVO DONOR 1505 
ALLOANTIGEN INDUCED FOXP3+CD4+CD25+ REGULATORY 
T CELLS AMELIORATES REJECTION OF COMPOSITE 
FACIAL ALLOGRAFTS IN RATS AND MICE
S. Qi1, A. Ma1, Z. Wang1, L. Liu1, D. Xu1, E. Massicotte2, M. Dupuis2, 
P. Daloze3, H. Chen1
1Research Center, CHUM, Notre-Dame Hospital, University of Montreal, 
2Institut de recherches cliniques de Montréal, Montréal, Québec, Canada. 
, 3Department of Surgery, Hôpital Notre-Dame, University of Montréal, 
Montreal, Canada
Exploring new immunosuppressive strategies to induce donor-alloantigen-
specifi c hyporesponsiveness is an important challenge in transplantation. 
CD4+CD25+ regulatory T (Treg) cells have been known to play an 
important role in transplantation and autoimmune diseases. In this study, our 
study aimed at whether adoptive transfer of CD4+CD25+FoxP3+ regulated 
T cells could prolong survival of totally MHC-mismatched composite 
facial allografts in rats and mice. The composite facial allotransplantations 
including the ear and scalp were performed by the anastomosis of the 
external carotid arteries, external jugular veins and facial nerves from 
Brown Norway (RT1n) to Lewis (RT1l) rats and isotransplantation between 
Lewis rats. In rats, isograft controls and allograft controls did not receive 
adoptive transfer Treg cells. Allografts in treatment group were adoptively 
transferred with donor-specifi c Treg cells on day -3, day 0 and day 7. All 
groups did not administer any other immunosuppressants. Function to face 
allografts was evaluated clinically. In vitro, evaluation of donor-specifi c 
tolerance was performed by mixed lymphocyte reaction on day 6 after 
transplantation. In mice, allograft control group, from C57BL/6J (H-2b) 
to BALB/c (H-2d) mice, did not receive any therapy. Donor-alloantigen-
specifi c Treg cells were administered in allograft treating group at day 
-3, 0 and 7. All allograft controls rejected their grafts within 5 to 7 days 
after transplantation. Facial allograft group under the Treg cells transfer 
protocol showed prolongation of the allograft survival with mean survival 
time (MST) of 13. 7 „b 3. 4 days in rats, and 13. 0 „b 2. 2 days in mice, 
compared with untreated allograft control (MST of 6. 2 „b 0. 2). The 
mixed lymphocyte reaction assay at day 6 after transplantation revealed 
that regulatory T cells display suppressive function in cell dose-dependent 
and donor-antigen-specifi c manners. Adoptive transfusion of ex vivo donor 
alloantigen-induced CD4+CD25+FoxP3+ regulated T cells may represent a 
new strategy for preventing allograft rejection after transplantation. 
POSTER BOARD NUMBER P2 – 305
ABSENCE OF MHC CLASS II ANTIGEN EXPRESSION 1506 
IN THE TOLERIZING INOCULUM IMPAIRS ALLOANTIBODY 
PRODUCTION IN NEONATALLY-TOLERIZED MICE WITH 
ACCEPTED CARDIAC ALLOGRAFTS
L. West1, K. Tao1, L. Mai2
1University of Alberta, 2University of Toronto
Introduction: We previously showed that injection of allogeneic fetal liver 
cells (FLC) into neonates induces acceptance of donor-type and third-party 
cardiac grafts in adults. Mechanisms of operational tolerance in this model 
appear to involve non-specifi c Treg cells. In this study, C3H neonates (H-2k) 
were treated with FLC from MHC-defi cient mice to investigate the role of MHC 
antigen expression on induction of cardiac graft acceptance and production of 
alloantibodies. 
Methods: C3H neonates were injected iv with 15x106 FLC from C57BL/6 
(B6; H-2b), class II defi cient [B6/II-], or class I&II defi cient [B6/I-II-] mice. At 
8 weeks, treated and untreated mice received heterotopic B6 cardiac allografts. 
After 60 days of graft survival, sera were assessed by fl ow cytometry for 
anti-B6 antibodies. 
Results: Mice treated as neonates with B6 (n=6), B6/II- (n=9) and B6/I-II- 
(n=9) FLC accepted B6 cardiac grafts as adults with median survival time 
(MST) >60 days; graft MST in untreated mice (n=9) was 9 days. Production 
of various IgG isotypes in mice with cardiac grafts varied with the different 
treatments. Generally, B6 FLC-treated mice had signifi cantly higher antibody 
levels than untreated mice, B6/II- and B6/I-II- FLC-treated mice. The level 
of IgG1 in mice treated with B6/II- and B6/I-II- FLC was 5-fold lower than 
in untreated mice and 15-fold lower than in B6 FLC-treated mice. The level 
of IgG2a in mice treated with B6/II- and B6/I-II- FLC was 10-fold lower than 
in untreated mice and 2-fold lower than in B6 FLC-treated mice. The level 
of IgG3 was 5-fold higher in B6 FLC-treated mice than all other groups. No 
difference was observed in IgG2b production. 
Summary: Preliminary results suggest that expression of MHC class II antigen 
in the tolerizing inoculum is not essential for neonatal induction of cardiac graft 
acceptance, but appears to play a role in alloantibody production, particularly 
IgG1 and IgG3, which are important in many humoral rejection responses. The 
intact MHC class II molecules in B6 FLC may sensitize recipients such that 
transplantation of B6 cardiac grafts results in elevated antibody production 
even higher than in mice not treated as neonates. It is notable that neither 
the presence or absence of tolerizing inoculum MHC class II antigens, nor 
alloantibodies after transplant, had a discernible effect on cardiac allograft 
MST in this model. 
POSTER BOARD NUMBER P2 – 306
DONOR SENSITIZATION AS A NEW APPROACH FOR 1507 
IMMUNOMODULATION. STUDY IN A COMPOSITE TISSUE 
TRANSPLANTATION MODEL
M. Siemionow, M. Hivelin, S. Nasir, A. A Klimczak, L. Krokowicz
Plastic Surgery Department-Cleveland Clinic
Introduction: New protocols are needed for tolerance induction in composite 
tissue allograft (CTA). It is well documented that bone marrow transplantation 
induces donor–specifi c immune-tolerance through the creation of mixed 
chimerism. Donor sensitization with the recipient bone marrow before 
transplantation is a new approach to induce immunotolerance. We studied the 
effect of donor sensitization on the immune response, for vascularized skin 
allografts. 
Methods: Twenty groin fl ap transplantations were performed in 4 experimental 
groups of 5 animals each. Allograft transplants were performed between 
presensitized ACI donors and Lewis (LEW) recipients. The ACI (RT1a) donor 
rats were presensitized with Lewis (RT1l) bone marrow (80x 106 cells) and 
these donors received áâ-TCR and cyclosporine (CSA) treatment therapy 
before transplantation. At either 24 hours or 72 hours after sensitization, the 
vascularized skin allografts (VSA) were transplanted to Lewis (RT1 I) recipients. 
Group I and II were the control groups without immunosuppressive treatment 
after transplantation and 24 to 72 hours of presensitization respectively. In 
group III, and IV, animals received áâ TCR and CSA protocol for 7 days after 
transplantation, with the same duration of presensitization as in group I and 
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II. Assessment included fl ap viability, fl ow cytometry for chimerism, and 
immunohistochemistry. 
Result: In the control groups (group I, II) VSA were acutely rejected within 
2 to 10 days post transplant. The mean survival of VSA was 82 days in Group 
III and 73 days in group IV, with longest survival of 115 days. Donor specifi c 
chimerism in peripheral blood was estimated by presence of T and B cells. 
Total chimerism levels for Group III at day 7, 21, 35 and 63 were 4. 93%, 1. 
75%, 2. 46%, 1. 45% respectively and Group IV 3. 6%, 2. 37%, 
1, 87%, and 0. 48% respectively. 
Conclusions: Donor presensitization with the bone morrow cells of the 
recipient modifi es the recipient’s responsiveness and extends survival of 
vascularized skin allografts, under short-term protocol of áâ-TCR monoclonal 
antibodies and cyclosporine (CSA) therapy. 
IMMUNOLOGY AND CONCURRENT ORAL SESSION 106: 
ALLOGRAFT REJECTION
POSTER BOARD NUMBER P2 – 307
THE FISHER-LEWIS KIDNEY TRANSPLANTATION 1508 
MODEL AS TOOL TO INVESTIGATE TRANSPLANT-RELATED 
CARDIOMYOPATHY
M. Baumann, J. Chang, J. Lutz, U. Heemann
Dept. of Nephrology, Klinikum R. D. Isar, TU Munich
Background: Cardiovascular mortality is major cause of death after kidney 
transplantation. Thus, cardiovascular protection is a major concern in 
transplant patients. However, information from animal models about cardiac 
characteristics after kidney transplantation is lacking. 
Therefore we investigated in a model of chronic allograft injury cardiac 
structure and function. 
Methods: Fisher 344 kidneys were orthotopically transplanted into Lewis 
recipients. Recipients were treated with placebo, angiotensin II type 1 receptor 
blocker (AT1RB; candesartan 5mg/kg/day) over 24 weeks posttransplantation. 
Untreated matched-Lewis rats were used as healthy untransplanted controls. 
Each group consisted of 8 rats. Echocardiography was performed at 24 weeks 
posttransplantation measuring ejection fraction, fractional shortening and 
left ventricular mass in triplicate. 24-h proteinuria was determined and after 
harvesting heart weight/body weight ratio (HW/BW) measured. 
Results: Renal transplant recipients demonstrated 24 weeks posttransplantation 
signifi cantly reduced ejection fraction (58. 9±3. 2% vs. 70. 7±2. 1%) and 
fractional shortening (29. 8±2. 0% vs. 38. 3±2. 0%) and increased HW/BW and 
left ventricular mass (7. 7±0. 2cm3 vs. 6. 7±0. 2cm3) as compared to healthy 
controls. HW/BW and left ventricular mass (7. 7±0. 2cm3 vs. 6. 8±0. 2cm3) were 
signifi cantly ameliorated by AT1RB as compared to placebo-treated transplant 
recipients. In parallel, reduction of proteinuria was evident after AT1RB. 
Conclusion: The Fisher-Lewis kidney transplantation model results in 
cardiac hypertrophy and reduced cardiac function. AT1RB normalizes cardiac 
hypertrophy without improving the functional state. This demonstrates that the 
Fisher-Lewis renal transplantation model can be used to investigate transplant-
related cardiomyopathy. 
POSTER BOARD NUMBER P2 – 308
REQUIREMENT OF LFA-1 DE-ACTIVATION FOR 1509 
CARDIAC ALLOGRAFT REJECTION
N. Hüser1, M. Stangl1, V. Aßfalg1, M. Semmrich2, B. Holzmann1, 
M. Laschinger1
1Department of Surgery, Division of Transplantation, 2Department of Cell and 
Molecular Biology, Immunology Section
Background: The leukocyte-specifi c integrin LFA-1 is considered to be 
important for immune responses leading to organ transplant rejection. 
Regulating the affi nity of LFA-1 for its ligand ICAM-1 is known to be crucial 
for its function. However, the importance for de-activating LFA-1 remains 
largely unknown. A mutant mouse that locks LFA-1 in an active state (LFA-
1d/d) provides the unique opportunity to explore the function of LFA-1 de-
activation in the multifaceted immune responses leading to the rejection of 
cardiac allografts in vivo. We investigated the involvement of active LFA-1 in 
the proliferation and effector function of allo-reactive T cells as well as its role 
in the recruitment of leukocytes into the allogeneic cardiac graft in a murine 
model of heterotopic cardiac transplantation. 
Methods: Allogeneic donor hearts were transplanted heterotopically into 
wildtype or mutant mice expressing LFA-1 that cannot be de-activated (LFA-
1d/d). Mixed lymphocyte reactions were performed to study the infl uence of 
LFA-1 de-activation on T cell proliferation. Histology and fl ow cytometry were 
applied to analyze graft infi ltrating leukocytes. Cytokine or chemokine levels 
in the graft were determined by RT-PCR and ELISA. 
Results: Defect in LFA-1 de-activation ameliorates graft survival in LFA-
1d/d recipient mice. A key event in graft rejection is its infi ltration by allogen-
primed T cells. Constitutively active LFA-1 hinders activation and proliferation 
of allo-reactive T cells. We found expression of the chemokines CXCL10/
IP-10 and CCL5/RANTES to be markedly reduced in grafts of LFA-1d/d 
recipients. This defect translates into a low number of CD4 and CD8 T cells 
detected in the transplanted heart. Furthermore, leukocyte subsets initiating the 
infl ammation at early stages of graft rejection are not effi ciently recruited into 
cardiac allografts of LFA-1d/d hosts. The reduced amount of TNFα and IFNγ 
in the allograft seems to account for this defect. 
Conclusions: Constitutively active LFA-1 negatively affects different 
immunological events inducing or controlling graft-specifi c responses. Thus, 
regulating LFA-1 de-activation appears to be vital for allograft rejection, opens 
new possibilities to specifi cally interfere with immune responses and could 
encourage the development of novel therapeutic approaches to promote graft 
survival. 
POSTER BOARD NUMBER P2 – 309
IGG-MEDIATED HYDROLYSIS OF COAGULATION 1510 
FACTORS IS ASSOCIATED WITH A REDUCED RISK 
OF CHRONIC ALLOGRAFT NEPHROPATHY IN RENAL 
TRANSPLANTED PATIENTS
O. Thaunat1, B. Wootla2, C. Legendre3, A. Nicoletti2, S. Lacroix-Desmazes2
1Service de transplantation et d’immunologie clinique, Hopital Edouard 
Herriot, 2Centre de recherche des Cordeliers, INSERM UMRS872, 3Service de 
Transplantation Renale, Hopital Necker
Background: We have previously identifi ed IgG endowed with hydrolytic 
properties against coagulation factors in various infl ammatory diseases. 
Uncontrolled activation of the coagulation cascade by the stressed 
endothelium of the graft is believed to play an important role in the 
pathophysiology of chronic allograft nephropathy (CAN), a major cause of 
late allograft failure. 
Objective: To investigate whether hydrolytic IgG are detectable in renal 
transplanted patients and whether they are associated with a reduced risk of CAN. 
Material and methods: Case-control study using the sera and the graft 
biopsies from the biocollection of the renal transplantation department of 
Necker hospital. Ten patients with CAN lesions on the 2-years graft biopsy 
were randomly retrieved from the database and compared to 10 matched 
patients that displayed a normal histology at the same time point. 
The presence of hydrolytic IgG in the serum of renal transplanted patients was 
tested by incubating patients IgG with coagulation factors VIII, IX, VIIa and 
prothrombin. 
The hydrolysis of a fl uorescent synthetic substrate (PFR-MCA) was used to 
quantifyed the hydrolytic activity of patients IgG, 3 months and 2 years post-
transplantation. 
Results: Circulating IgG from renal transplanted patients are endowed with 
hydrolytic properties towards coagulation factors VIII and IX that was reliably 
quantifi ed by the measure of the hydrolysis of (PFR-MCA). 
Elevated hydrolysis rate of PFR-MCA by circulating IgG correlated with 
the absence of CAN lesion on protocol graft biopsy performed 2 years post-
transplantation. Low rates of PFR-MCA hydrolysis, measured 3 months post-
transplantation, were predictive of CAN at 2 years down the lane. 
Conclusions: High levels of circulating IgG endowed with serine protease-like 
activity are associated with a reduced occurrence of CAN in renal transplanted 
patients. 
PFR-MCA hydrolysis by circulating IgG appears as an early risk marker for 
CAN. 
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IMMUNE ACTIVE EFFECTS OF CHEMOKINE RANTES 1511 
ON HUMAN PERIPHERAL MONONUCLEAR CELLS
X. Gu1, H. Zhao2, J. Yang1, G. Zhou1, S. Gu1, T. Gu2
1Affi liated Hospital of Yangzhou University, 2University of Louisville
Objective To investigate the proliferation and phenotypes of peripheral 
mononuclear cells (PMNC) stimulated by recombinant human RANTES 
(rhRANTES) and the mechanisms involved. 
Methods: PMNC was stimulated by various concentrations of rhRANTES 
and/or anti-CD3 mAb and intervened by PDTC and CTLA4Ig. Scintillation 
counter was used to count the cpm of proliferation cells and fl ow cytometry 
was used to detect the phenotypes of lymphocytes. 
Results: rhRANTES was capable of directly stimulating purifi ed human 
PMNC proliferation and two peaks occurred with rhRANTES concentration of 
100 ng/ml and 5000 ng/ml respectively. The proliferation of PMNC stimulated 
by rhRNATES was signifi cantly higher than that in the presence of anti-CD3 
mAb (P < 0. 05). The immune active effects of rhRANTES could be inhibited 
by PDTC or CTLA4Ig in a dose dependent manner. RANTES treatment of 
PMNC in vitro increased the level of cell surface CD25 and decreased the 
CCR5 expression. But it did not infl uence the ratio of CD4/CD8 and CD28 
expression of lymphocytes. 
Conclusion: RANTES is an important stimulatory mediator in human PMNC 
activation. This special signal works depending on the activation of IL-2 signal 
pathway, CD28 costimulatory pathway and nuclear factor-¦ÊB, but independent 
of CD3 activation. 
POSTER BOARD NUMBER P2 – 311
STRUCTURAL ROLE OF RNA IN THE ORGANIZATION 1512 
OF INTERMEDIATE FILAMENTS IN IMMUNOLOGICAL 
SYNAPSE
M. Kloc, B.L. Bass, O.A. Gaber, R.M. Ghobrial
The Methodist Hospital and The Methodist Hospital Research Institute 
Immuno-Biology Laboratory
Background: The immune response in allograft rejection involves a 
cascade of molecular events leading to the formation of immunological 
synapses between T cells and the antigen-presenting cells. The migration 
and activation of T cells and the formation of immunological synapse are 
critically dependent on the re-polarization and extensive reorganization of 
T cell cytoskeleton: microtubules and intermediate fi laments, and T cell 
receptors (TCR) clustering. Thus one of the novel approaches to eliminate or 
attenuate allograft rejection would be the inhibition of the polarization and 
reorganization of T cell cytoskeleton. 
Methods: We have developed an in vitro and in vivo assay using Xenopus 
oocytes as a model system to study the structural role of various RNAs in actin 
and cytokeratin fi lament formation and the maintenance of the cytoskeleton 
organization and architecture. In in vitro assay the synthetic Texas Red 
labeled VegT RNA containing whole ORF and 21 nucleotides of 5’ UTR was 
mixed with recombinant human cytokeratin19 (Biodesign International) in 
cytokeratin assembly buffer (5mM Tris-HCl, 5mM ?-mercaptoethanol, pH 7. 
0) and incubated for 30 min and 1-2 hr at room temperature. In in vivo assay 
the same RNA and cytokeratin or antisense deoxyoligonucleotides against 
Fatvg RNA were delivered into Xenopus oocytes and incubated 30 min or 
overnight. Subsequently the whole cells or aliquots of the assembly reactions 
were incubated with anti-cytokeratin FITC conjugated antibody or Rhodamine 
conjugated phalloidin and immediately observed under the fl uorescence 
microscope. 
Results: Previously we found that noncoding (Xlsirts) and coding (VegT) 
RNAs function in maintaining the integrity of the cytokeratin network 
in Xenopus oocytes. Destruction of these transcripts with antisense 
deoxyoligonucleotides disrupts cytoskeleton in a transcript-specifi c manner. 
Analysis in live cells using molecular beacons showed that these RNAs 
are integrated into the cytoskeleton. These fi ndings demonstrated a novel 
structural role of coding and noncoding RNAs in the organization of the 
cellular cytoskeleton and architecture. In assembly reaction incubated for 30 
min-1hr we observed the presence of aggregates of Texas Red labeled VegT 
RNA and cytokeratin. Some of these aggregates showed also the presence 
of short cytokeratin fi laments, which we interpret as an initial step in 
cytokeratin fi lament polymerization. In assembly reaction incubated for 1-2 
hr we observed the presence of long cytokeratin fi laments, which emanated 
from the foci containing the aggregates of VegT RNA and cytokeratin. None 
of these were present in control samples. In in vivo assay we found that VegT 
RNA speeds up the formation of cytokeratin fi laments and incorporation of 
newly made cytokeratin fi laments into pre-existing cytokeratin network, 
and the antisense oligonucleotide-mediated destruction of Fatvg RNA 
hyperpolymerizes cytokeratin and actin. 
Conclusions: VegT RNA is able to bind unpolymerized cytokeratin and 
induce its polymerization into fi laments in vivo and in vitro, and Fatvg RNA 
is needed to maintain the proper organization and cellular architecture of 
actin and cytokeratin fi laments. The study of structural RNAs involved in the 
polarization and the maintenance of cytoskeleton in naïve and activated T cells, 
and the interference with these functions will ultimately lead to attenuation of 
graft rejection. 
POSTER BOARD NUMBER P2 – 312
PRIOR SENSITISATION LIMITS LONG TERM 1513 
ALLOGRAFT SURVIVAL ACROSS A MAJOR MHC MISMATCH 
AFTER PRUNING ALLOREACTIVE T CELLS. 
D. Watson1, M. Hu1, G. Zhang1, Y.M. Wang1, M. Sartor2, J. Fletcher1, 
S.I. Alexander1
1Children’s Hospital At Westmead, 2Millenium Institute Westmead
We have demonstrated prolonged skin allograft survival across a major 
MHC mismatch following the pruning of alloreactive T cells based on their 
proliferation following allo-stimulation. Memory T cells are known to be a 
major barrier to transplantation tolerance. Therefore the aim of this study 
was to examine the effects of memory on the proportion of allo-stimulated 
dividing cells and allograft survival in the pruning model. Our hypothesis 
was that stimulating memory cells would result in an increased number of 
cells that would proliferate and that this would be a more effective pruning 
strategy to remove alloreactive T cells. In a mixed lymphocyte culture (MLC), 
naive BALB/c (naive MLC) or memory BALB/c (memory MLC) responder 
splenocytes were stained with CFSE and stimulated with irradiated C57BL/6 
donor splenocytes. Memory BALB/c splenocytes were generated by isolating 
spleen cells from BALB/c mice that had been grafted with and that had 
rejected their donor C57BL/6 allografts (Median Survival Time (MST), 20d, 
n = 4). Flow cytometry at Day 5 of the MLC indicated an increase in the 
number of proliferating cells in the memory MLC (46%), compared to the 
naive model (12%). At day 6 of the MLC, SCID mice were injected with 
allo-stimulated non-dividing (ND) or dividing (D) CD4+ T cells from the 
naive or the memory MLC. SCID mice were grafted with C57BL/6 (donor), 
BALB/c (self) and B10. Br (third party) allografts. SCID mice reconstituted 
with allo-stimulated ND CD4+ T cells from the naive MLC demonstrate 
prolonged survival of their donor C57BL/6 allografts (MST > 65d, n = 4), 
while rejecting third party B10. BR allografts (MST, 21d, n = 4) (p = 0. 0100). 
However, mice reconstituted with allo-stimulated ND CD4+ T cells from the 
memory MLC rapidly rejected both their donor C57BL/6 (MST, 17. 5d, n = 
4) and third party B10. Br allografts (MST, 13d, n = 4) (p = NS). Histology of 
C57BL/6 skin grafts demonstrated increased cellular infi ltrates at day 8 post-
transplant for mice reconstituted with ND CD4+ T cells from the memory 
MLC. Interestingly IFN-gamma production measured using Elispot analysis 
demonstrated a signifi cant increase for memory ND cells (115. 7 +/- 0. 88 
spots per 200, 000 cells) compared to naive D cells (49. 5 +/- 6. 76 spots per 
200, 000 cells) (p = 0. 0004) in response to stimulation with donor C57BL/6 
cells, indicating the persistence of memory cells within the ND population. 
While the pruning method is an effective strategy to prolong allograft 
survival in mice reconstituted with naive ND CD4+ T cells, this was not the 
case for allo-stimulated ND CD4+ T cells from the memory MLC. This data 
indicates that while there is an increased proportion of proliferating cells in the 
memory MLC potentially increasing the number of alloreactive cells pruned, 
memory cells are maintained within the allo-stimulated ND population, and 
consequently rejection is observed. This study emphasizes the importance 
of developing strategies for tolerance induction in transplantation that can 
specifi cally account for memory T cells. 
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EXPRESSION OF ARGINASE 1 (ARG1), THE 1514 
ALTERNATIVE ACTIVATED MACROPHAGES MARKER IN 
RAT MODEL OF CARDIAC TRANSPLANTATION
Y. Chen1, Y. Liu1, Z. Yuan1, J. Lamb2, P.K.H. Tam1
1Department of Surgery, The University of Hong Kong, 22Department 
of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, 
University of Edinburgh
Introduction: Macrophages infi ltration is often correlated to the grafts lose 
especially in acute phase of transplant rejection. Meanwhile, the polarization 
capacity of the macrophages activation suggested the heterogeneity of two 
subpopulations, namely classical activated macrophage and alternative 
activated macrophage (AAM) might co-exist inside the grafts. The later 
one has been suggested maintaining anti-infl ammation activity and also 
produced TGF-beta1. Arg1 is one of the markers of AAM. In this study, 
the expression of Arg1 in grafts and the effect of PPAR-gamma agonist 
rosiglitazone (Rosi) in Arg1 expression were investigated in our rat model 
of cardiac transplantation
Materials and Methods: Heterotopic cardiac transplantations were performed 
using F344 to Lewis as donor and recipient. The acute rejection was prevented 
by 10-day course of cyclosporine A (CsA). The Rosi was applied along the 
course of transplantation (CsA+Rosi). The grafts rejection and Arg1 expression 
was examined at 30 days and 120 days after transplantation by histology and 
immunohistochemistry analysis
Results: In normal and syngeneic transplant heart, Arg1 immune positive 
(Arg1+) cells were barely detected. At 30 days after transplantation, 
when compared between rejected and survived grafts, the total number of 
macrophage (ED1+ cells) was much higher in the rejected grafts then that in 
survived grafts. Simultaneously, Arg1+ cells were great increased in rejected 
grafts, they were located around the vessels and intra myocytes space. 
Arg1+ cells can also be detected in necrosis area. In contrast, the number 
of Arg1+ cells was much less in survived grafts and mainly situated near 
the blood vessels. In the grafts survived more than 120 days, the ED1+ cells 
was reduced and the Arg1+ cells mostly found in occluded blood vessels at 
outer layer and neointimal area. The Rosi treatment largely increase the grafts 
survival time, beside the reduction of ED1+ cells, the number of the Arg1+ 
cells was 50 to 80% less then that in CsA alone group. In some necrosis 
area in this group, only few of Arg1+ cells can be detected. Similarly, in the 
grafts over 120days in CsA + Rosi group, the number of Arg1+ cells was also 
much lower than that in CsA group. Furthermore, using adjacent section, we 
showed the colocalization of Arg1 and CD163 (ED-2, another AAM marker) 
inside the grafts and the expression of TGF-beta1 was also found colocalized 
with Arg1+ cells. 
Conclusion: Our data suggested the present of alternative activated macrophage 
in chronic rejection grafts, which positively correlated to the grafts rejection. In 
grafts vasculopathy, the present of the cells which produce higher level of TGF-
beta might aggressive the vessels occlusion. Rosi treatment reduced the Arg1+ 
cells may explain the benefi cial effect of the treatment in this experimental 
transplantation model
POSTER BOARD NUMBER P2 – 314
HUMAN MONOCYTES REPRESENT A COMPETITIVE 1515 
SOURCE OF INTERFERON-ALPHA IN PERIPHERAL BLOOD
H. Hackstein, W. von Wulffen, L. Hansmann, G. Bein
University of Giessen
Interferon-alpha (IFN-á) has a critical role in anti-viral immunity and 
plasmacytoid dendritic cells (pDCs) have been demonstrated the principal 
IFN-á source after Toll-like receptor (TLR) 7 and 9 stimulation. Little is known 
about the contribution of pDC-independent IFN-á sources to total IFN-á 
production capacity of human peripheral blood. Using an array of pathogen 
associated molecular patterns (PAMPs), Poly (I: C)/Dotap represented the 
second strongest IFN-á stimulus in total PBMC. Poly (I: C)/Dotap induced 
three times more IFN-á, when compared to TLR7-stimulation (R848) and four 
times less, when compared to TLR9-stimulation. Dotap (mediator of cellular 
uptake) dramatically increased Poly (I: C)-induced IFN-á production. Sorting 
experiments and ELISpot assays revealed that monocytes and not myeloid 
DCs are the main IFN-á source after Poly (I: C)/Dotap stimulation. ELISpot 
analyses demonstrated the highest IFN-á spot numbers after Poly (I: C)/
Dotap stimulation. Although pDCs produced highest IFN-á levels per cell, 
monocytes represent a competing IFN-á source in total PBMC due to their 
high frequency. 
POSTER BOARD NUMBER P2 – 315
ROLE OF TH1/TH2 CYTOKINES IN KIDNEY 1516 
ALLOGRAFT REJECTION
M. Karczewski1, J. Karczewski2, M. Glyda1
1Szpital Wojewodzki w Poznaniu, 2Uniwersytet Medyczny w Poznaniu
Background: One of the major issues the contemporary kidney transplantation 
faces is rapid diagnosis and prevention of the acute allograft rejection (AR), 
which occurs in approximately 20% of patients, signifi cantly shortening the 
time of allograft survival. Crucial mediators of immune reaction leading to AR 
are cytokines. Understanding the role of those proteins in the AR process may 
improve survival of kidney transplants. The aim of this project was to examine 
the relation between the profi le of serum Th1/Th2 cytokines and incidents of 
AR in patients after kidney transplantation. 
Patients, Materials and Methods: The project included 44 patients 
undergoing kidney transplantation. During the three-month period following 
the surgery AR was diagnosed in 11 patients. Diagnosis was based on 
clinical signs, Doppler study and biopsy. Patients were treated with various 
immunosuppressives. Pretransplantation epidemiological and clinical 
characteristics of non-rejection (NONAR) and rejection (AR) patients were 
examined in order to ensure that patient populations in NONAR and AR groups 
were, in fact, similar. Serum samples were collected 1 day before and 2, 7, 14 
and 30 days after transplantation. Each sample was tested for concentrations 
of IL-2, IL-4, IL-5, IL-10, IFN-ã, TNF-á, using Human Th1/Th2 Cytokine 
CBA Kit (BD Biosciences Pharmingen, USA) by means of fl ow cytometry. 
Data were analyzed by Mann-Whitney U, Wilcoxon’s signed rank test and ÷2 
test using the Spss v. 15 (SPSS, USA). Values were considered statistically 
signifi cant when p<0. 05. 
Results: NONAR and AR patients did not show signifi cant differences in 
baseline characteristics (p>0, 05). The mean plasma cytokine concentration 
levels in AR and NONAR patients were: IFN-ã pretransplantation 4, 53±1, 
1 vs. 2, 64±0, 4 pg/mL (p=0, 000003); 2 days posttransplantation 4, 53±1, 1 
vs. 2, 64±0, 4 pg/mL (p=0, 003); 7 days posttransplantation 8, 02±1, 7 vs. 6, 
12±1, 3 pg/mL (p=0, 002); 14 days posttransplantation 9, 42±1, 7 vs. 6, 58±1, 
2 pg/mL (p=0, 00002); 30 days posttransplantation 9, 98±2, 3 vs. 6, 29±1, 5 
pg/mL (p=0, 000003), respectively; IL-10 pretransplantation 6, 87±0, 4 vs. 
3, 69±0, 8 pg/mL, (p=0, 000001); 2 days posttransplantation 7, 40±0, 6 vs. 
3, 95±0, 8 pg/mL (p=0, 000001); 7 days posttransplantation 8, 44±0, 9 vs. 
6, 17±0, 7 pg/mL (0, 000002); 14 days posttransplantation 10, 42±1, 4 vs. 
7, 44±0, 9 pg/mL (p=0, 000002); 10, 77±1, 5 vs. 6, 31±0, 8 pg/mL (p=0, 
000001), respectively. Cytometric analysis also showed slightly higher IL-4 
plasma levels in NONAR patients up till 7 days posttransplantation (p>0, 
05), followed by a drop in concentration in NONAR patients and continuous 
increase in AR patients (IL-4 30 days posttransplantation 4, 06±0, 9 vs. 
2, 31±1, 2 pg/mL (p=0, 0002), respectively). No signifi cant differences in 
plasma levels of IL-2, IL-5, IL-10, TNF-á between the two groups were 
observed (p > 0, 05). 
Discussion: Higher pretransplantation levels of IFN-ã and IL-10 observed 
in AR patients indicate the ongoing non-detected, probably non-specific, 
inflammatory processes able to intensify the immune response directed 
against the transplanted organ and leading to its acute rejection. Therefore, 
increased pretransplant levels of both cytokines can be considered as 
risk factors increasing the probability of AR incidents. On the contrary, 
higher level of IL-4 prior to the transplantation and shortly afterwards 
can have protective effect upon the graft. However, prolonged increased 
production of IL-4 after transplantation can also increase the number of 
AR incidents. 
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“PRUNING OF ALLOREACTIVE T CELLS PREVENTS 1517 
PANCREATIC ISLET ALLOGRAFT REJECTION ACROSS AN 
MHC MISMATCH
M. Hu1, W.J. Hawthorne2, J.M. O’Hara2, K. Hucker2, J. Wu2, S. Yi2, 
D. Watson1, G.Y. Zhang1, Y.M. Wang1, M. Sartor3, P.J. O’Connell2, 
S.I. Alexander1
1Centre for Kidney Research, Children’s Hospital at Westmead, 2National 
Pancreas Transplant Unit, Westmead Hospital, 3WICR, Millennium Institute 
Westmead, University of Sydney, NSW, Australia
Background: Islet transplantation is now a clinical therapy for diabetes. 
However successful transplants appear to have a limited survival. One of 
the potential causes is T cell mediated allorecognition. We have previously 
reported that “pruning” of alloreactive CD4+ T cells based on their proliferation 
prolongs skin allograft survival across an MHC mismatch. 
Aim: In this study our aim was to establish whether “pruning” of alloreactive 
CD3+ T cells protects pancreatic islet allograft from rejection. 
Methods: Responder BALB/c (H-2d), splenocytes stained with CFSE were 
stimulated with irradiated C57BL/6 (H-2b) splenocytes in a mixed lymphocyte 
reaction (MLR). At day 5, cells were sorted into dividing and non-dividing CD3+ 
T cells based on fl uorescent CFSE staining, then adoptively transferred into 
SCID mice (BALB/c background). At 42 days of reconstitution, streptozotocin 
inducted diabetic SCID mice were transplanted with C57BL/6 pancreatic islets 
under their right renal capsule. Successful islet function was defi ned by a BSL<10 
mmol/L and allograft rejection by a BSL>16 mmol/L. Flow cytometry analysis 
was performed for cell phenotype in the MLR, and following reconstitution. 
Results: SCID mice reconstituted with non-dividing CD3+ T cells demonstrated 
prolonged pancreatic islet allograft survival (MST>100 days) compared to the 
dividing group (MST = 8 days) (p = 0. 0022). In vitro fl ow cytometry analysis 
after 5 days MLR showed that 58% ± 2. 3 of BALB/c CD3+ T cells were 
dividing while 42% ± 2. 3 were non-dividing CD3+ T cells. Both dividing and 
non-dividing CD3+ T cells contained CD4+ and CD8+ T cells. As expected, the 
dividing CD3+ T cells had higher levels of activation markers such as CD69 
and CD25 than in the non-dividing CD3+ T cells. In vivo equivalent number 
of dividing and non-dividing CD3+ T cells was detected in peripheral blood 
(PB) of SCID mice 16 days after reconstitution. The percentage of CD3+/
CD45+ was 7% ± 1. 9 in SCID mice receiving dividing CD3+ cells and was 
9% ± 0. 9 in SCID mice receiving non-dividing CD3+ T cells. Tregs as defi ned 
by CD4+CD25+ were equivalent between both groups. However γδ T cell 
expression was higher in PB (10% ± 3. 6) and spleen (12. 1% ± 8. 6%) of long-
term pancreatic islet allograft surviving SCID mice (>100 days post transplant) 
compared with naïve mice including BALB/c (1 – 5%), and SCID mice with 
dividing CD3+ T cells at the time of rejection (2. 7% ± 0. 9%). 
Conclusions: Pruning of alloreactive T cells allows long-term pancreatic islet allograft 
survival across an MHC mismatch in a mouse model. The high number of γδ T cells 
observed, suggest that this may contribute to the mechanism of graft acceptance. 
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CD10: A POTENTIAL NON-HLA ANTIGEN IN RENAL 1518 
TRANSPLANTION
T. Polhill1, Y.M. Wang1, G.Y. Zhang1, B. Howden1, X-M. Chen3, 
C. Pollock3, D.C.H. Harris2, S. Alexander1
1University of Sydney at Children’s Hospital, Westmead, 2Centre for 
Transplant and Renal Research, University of Sydney at Westmead Hospital, 
Westmead 2145, 3Department of Medicine, University of Sydney at Royal 
North Shore Hospital, St Leonards, 2065
Background: CD10 (neutral endopeptidase (NEP)) is expressed highly in 
the glomerulus. Alloantibodies against CD10 cause a severe form of neonatal 
membranous glomerulonephritis. This occurs in rare cases of maternal CD10 
defi ciency, by feto-maternal transfer of antibodies against CD10, which bind to 
fetal CD10. We aim to create a mouse model of antigen-specifi c renal disease. 
One strategy employed to provoke an immune response is renal transplantation 
in a setting where the only genetic difference between donor and recipient is 
non-HLA linked, namely the CD10 gene. 
Methods and Results: We obtained mice heterozygous for the CD10 knockout, 
created on a C57BL/6 background by targeted deletion of Exon 13 of the CD10 
gene (C Gerard, Boston). By Western blotting, we confi rmed the absence of 
CD10 protein in homozygous knockout offspring using a polyclonal CD10 
antibody. No offspring of CD10-homozygous knockout female mice crossed with 
heterozygous males spontaneously develop renal disease, after investigation of 
colocalisation of anti-CD10 and anti-IgG under fl uorescence microscopy; urine 
protein and creatinine; and renal morphology under light microscopy at 14 days of 
age. Additionally, renal disease cannot be induced in pups by immunising female 
mice with renal extract containing CD10. Preliminary results from transplantation 
show by electron microscopy that a wild-type kidney transplanted into a CD10-
immunised, CD10-/- female provokes antibody deposition in the donor kidney. 
Conclusions: CD10 defi ciency in mice as compared to humans does not lead to 
neonatal immunisation and transfer of disease. However differences in CD10 
expression may lead to alloantibody responses in transplantation. 
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A NOVEL ROLE OF NUCLEAR PROTEIN, HISTONE H1 1519 
ON TRANSPLANTATION IMMUNOLOGY
L-W. Hsu1,3, S. Goto1,2, T. Nakano1, C-Y. Lai1, S-H. Chen3, K-C. Chiang4, 
T. Goto4, C-H. Yang1, C-C. Wang1, C-L. Chen1
1Department of Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical 
Center, 2Department of Surgery, Iwao Hospital, Yufuin, Japan, 3Department 
of Chemistry, National Cheng Kung University, Tainan, Taiwan, 4Kazusa 
Institute for Drug Discovery, Josai Internation University, Kisarazu, Japan
We previously demonstrated that liver allograft tolerance is associated with the 
immunosuppressive activity of anti-histone H1 autoreactive antibodies (Abs) 
induced in the serum of liver transplantation. Furthermore, we and others have 
shown that nuclear proteins such as histone H1 and high mobility group box 
1 (HMGB1) play an important role in maturation of DCs although the precise 
mechanisms are still unknown. 
In the present study, we focus on the signifi cance of histone H1 on DCs in terms 
of the intracellular signaling pathway of DCs. Initially, we confi rmed the DC-
specifi c morphology of cultured cells in our assay system, and that most of histone 
H1-translocating cells expressed a rat DC lineage marker OX62. Subseqeunt 
immunostaining and immunoblot studies demonstrated that histone H1 was detected 
in cytoplasm and culture supernatants upon the activation of DCs. Furthermore, the 
addition of histone H1 to DCs instead of adding with endotoxin upregulated major 
histocompatibility complex class II (MHCII), the CD80 and CD86 surface markers 
of DCs and the activation of MAPKs (p38 and ERK1/2) and IκBα. On the other 
hand, histone H1 blockage by anti-histone H1 Ab downregulated the intracellular 
activation of mitogen-activated protein kinases (MAPKs) (p38), IκBα and NF-κB 
of DCs, and inhibited DC activity in the proliferation of CD4+ T-cells. We have also 
shown that either treatment of recipient rats with commercially available histone 
H1 polyclonal Ab or immunization with calf thymus histone H1 could prolong 
allograft survival in heterotopic heart transplantation. 
These results suggest that the translocation of histone H1 from nuclei to cytoplasm 
and the release of their own histone H1 are necessary for the maturation of DCs 
and the activation for T-lymphocytes. Therefore, immunosuppressive therapy 
with anti-hitsone H1 Ab or immunization of recipients with histone H1 prior 
to transplanataion may have a great potential to be novel immunosuppressive 
therapies in organ transplantation. 
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MONOCYTES PRIMED WITH INTERFERON-Γ 1520 
DIFFERENTIATE INTO MATURATION-ARRESTED 
REGULATORY DENDRITIC CELLS THAT INDUCE T CELL 
HYPORESPONSIVENESS
D. Rojas1,2 , R. Krishnan1,2
1Transplantation Immunology Laboratory, Basil Hetzel Institute, The Queen 
Elizabeth Hospital, Woodville and 2Department of Medicine, The University 
of Adelaide, South Australia. 
Interferon-γ (IFN-γ) is a pro-infl ammatory cytokine that activates T cells 
and induces the proliferation of T-helper 1 (TH1) cells that cause allograft 
rejection. Paradoxically, cardiac allografts transplanted in IFN-γ defi cient mice 
as recipients are rejected rapidly in contrast to wild type mice. This observation 
suggests that IFN-γ has a potential role in regulating immune responses that 
lead to allograft rejection. We hypothesised that IFN-γ may act on dendritic 
cells (DC) which are the major antigen presenting cells that initiate allograft 
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rejection. Therefore we examined the effect of IFN-γ on DC differentiation and 
allostimulatory capability. 
Monocytes were primed with IFN-γ at the time of DC differentiation with IL4 
and GMCSF for 5 days and compared with un-primed cells as controls. The 
maturation of the IFN-γ DC were performed by treatment with TNF-α for 2 
days. Phenotypic analysis by fl owcytometry of the IFN-γ-primed monocytes 
demonstrated typical DC differentiation with IL4/GMCSF as indicated by 
the loss of CD14 and the expression of DC-SIGN similar to un-primed cells. 
However, upon maturation with TNF-α, the IFN-γ DC demonstrated a profound 
downregulation in the expression of the maturation marker CD83 (76-94% 
inhibition of positive cells) and CD86 (62-71% inhibition of MFI) compared to 
unmodifi ed DC. Furthermore, Rel B mRNA analysis of IFN-γ DC showed an 
87% (p=0. 0005) inhibition compared to unmodifi ed DC confi rming that these 
cells were maturation-arrested. Interestingly, IFN-γ DC showed a 95% (p=0. 
0002) reduction in interleukin-12 (IL-12) mRNA compared to unmodifi ed DC. 
Moreover, IFN-γ DC as stimulators in the DC-MLR induced allogeneic T cell 
hyporesponsiveness compared to unmodifi ed DC (27, 500 +/- 1800 cpm vs 9400 
+/-1300 cpm, respectively; p=0. 00004). To ascertain the mechanism of T cell 
hyporesponsiveness in the MLR, allogeneic T cells were cocultured with IFN-γ 
DC and assessed for FoxP3 expression by fl owcytometry. Surprisingly, IFN-γ 
DC generated approximately 3-fold reduction in FoxP3+ T cells compared to 
unmodifi ed DC (31. 5% +/- 10. 5% vs%13. 5 +/- 4%, p=0. 01). While the 
priming of monocytes with IFN-γ modifi ed the DC phenotype and function, 
treatment of DC post-differentiation demonstrated no regulatory effects. 
In conclusion, the immunomodulatory effect of IFN-γ is mediated by the 
suppression of DC maturation. The induction of T cell hyporesponsiveness by 
IFN-γ DC is not likely to be governed by suppressive mechanisms involving 
FoxP3+ T regulatory cells however, T cell anergy due to the downregulation of 
CD83 may be contributory to the effect. 
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INCREASED EXPRESSION OF TRANSGLUTAMINASE 1521 
(TG2) IN THE FISHER-TO-LEWIS RAT MODEL OF CHRONIC 
ALLOGRAFT NEPHROPATHY
B.M. Shrestha, I. Butt, M. Delbridge, B.E. Wagner, A.T. Raftery, 
M. El Nahas, T. Johnson, J.L. Haylor
Sheffi eld Kidney Institute
Introduction: Chronic allograft nephropathy (CAN), the leading cause of 
renal allograft loss, involves expansion of the extracellular matrix (ECM) and 
is associated with tubular atrophy, interstitial fi brosis, glomerulosclerosis and 
obliterative arteriolopathy. Transglutaminase (TG2) is believed to be central to 
this expansion by crosslinking proteins through the formation of å (ã-glutamyl)-
lysine dipeptide bonds that causes accelerated ECM deposition and resistance 
to proteolytic clearance. The aim of this study was to investigate the activity 
and distribution of TG2 and å (ã-glutamyl)-lysine in the Fisher-to-Lewis (F-L) 
rat model of CAN. 
Methods: Under isofl urane anaesthesia, donor kidneys obtained from Fisher 
rats (allograft) (n=7) or Lewis rats (isograft) (n=5) were transplanted into 
Lewis rats (N=12) using end-to-side anastomosis employing aortic and inferior 
venacaval conduits. Total renal TG2 activity was measured using the [14C] 
putresceine incorporation assay. TG2 protein and its cross-linked product å 
(ã-glutamyl)-lysine were detected by immunofl uoresence (FITC/DAPI) and 
quantifi ed by image analysis. 
Results: F-L allografts were hypertensive (systolic BP 124 ± 11 vs. 159 
± 11 mmHg, p<0. 05) and proteinuric (37 ± 17 vs. 303 ± 80 mg/24h, p<0. 
05) with a lower creatinine clearance (1. 57 ± 0. 19 vs. 0. 62 ± 0. 18 ml/min, 
p<0. 05) than Lewis-to-Lewis (L-L) isografts. Masson’s trichrome staining 
showed an increased expansion of the ECM in the F-L allografts together with 
tubular atrophy and tubular dilatation. Electron microscopy confi rmed the 
changes of CAN in the allografts. Kidneys from the F-L allografts had higher 
transglutaminase activity (0. 41 ± 0. 03 vs. 1. 09 ± 0. 13 nmol/h/mg protein, 
p<0. 05) than the L-L isografts. Immunofl uoresence showed a marked increase 
in FITC/DAPI ratios for both TG2 protein (glomeruli: 2. 1 ± 0. 2 vs. 64. 5 
± 17. 6, p<0. 001; interstitium: 3. 2 ± 0. 4 vs. 13. 7 ± 1. 6, p<0. 001) and å 
(ã-glutamyl)-lysine (glomeruli: 2 ± 0. 4 vs. 21. 7 ± 2. 7, p<0. 01; interstitium: 
0. 4 ± 0. 1 vs. 37. 9 ± 17. 1, p<0. 05) in the F-L allografts. 
Conclusions: An increased expression of renal TG2 and å (ã-glutamyl)-lysine 
was observed in both glomeruli and the renal interstitium in the F-L rat model of 
CAN. This therefore provides a suitable model for interventional studies using 
TG2 inhibitors to treat CAN based on the successful use of these compounds 
in slowing the development of renal scarring in other animal models of chronic 
renal failure. 
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MURINE DENDRITIC CELLS (JAWS II) EXPRESSING 1522 
SOLUBLE CTLA4IG PROLONGS FIRST AND SECOND SET 
SKIN GRAFT SURVIVAL
F. Ierino1,2, W. Mulley1, N. Dodge1, Y.Q. Li1, D. Christiansen1, M. Sandrin1
1University of Melbourne, 2Austin Health
Genetically engineered Dendritic cells (DCs) expressing immunomodulatory 
molecules have potential therapeutic application in transplantation. 
Aims: Prime mice with a murine DC cell line (JAWS II) expressing CTLA4Ig 
and determine the in vitro (proliferation assays) and vivo (skin graft) 
immunological effects. 
Methods: The mouse DC cell line, JAWSII (C57/BL6) was transduced with 
lentivirus to express either soluble CTLA4Ig or green fl uorescent protein 
(GFP control protein) These transduced DCs were then used to immunise 
BALB/c mice in vivo. After 7-10 days, splenocytes from immunised mice 
were used in proliferation assays against C57/BL6 (donor) and CBA (3rd 
party) stimulators. Mice also received skin grafts from C57/BL6 and CBA 
mice donors. Two months later, mice that had rejected their grafts were 
re-transplanted with C57/BL6 (donor) and CBA (3rd party) skin grafts to 
determine whether second-set rejection could be inhibited, and whether 
systemic immune modulation had resulted from the priming with DC. 
Splenocytes from mice primed with JAWSII-CTLA4Ig had a signifi cantly 
lower stimulation index (SI) to C57BL6 compared with JAWSII-GFP (45% 
reduction, p=0. 008) at day 3 and 28% reduction, p= 0. 07, at day 4. Third 
party responses were not signifi cantly different, confi rming the response was 
specifi c. There was an increase in ratio of CD4+25hi T-cells in the JAWSII-
CTLA4Ig C57B6/CBA cultures compared to JAWSII-GFP. In vivo, there was 
specifi c prolongation of C57/BL6 skin graft survival in the JAWS-CTLA4Ig 
primed mice in both the fi rst set (Figure: Left panel) and second-set rejection 
responses (Figure Right panel). 
The peripheral blood of mice injected with JAWSII-CTLA4Ig expressing DC 
and control DC, are being examined for markers of Regulatory T cells. 
Conclusion: These studies confi rm the potent effects of modifi ed DC in primary 
and secondary responses, and that systemic modulation of T cell responses are 
established. The mechanism of this regulation is under investigation. 
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CD4+ Ô CELL IMMUNE FUNCTION IN RENAL 1523 
TRANSPLANT RECIPIENTS UNDER SPECIFIC 
IMMUNOSUPPRESSIVE PROTOCOLS
A. Iniotaki1, A. Vitoraki1, M. Darema2, I. Synodinou2, A. Kostakis2, 
J. Boletis2, M. Apostolaki1
1National Tissue Typing Center, General Hospital of Athens, 2Nephrology 
Department And Transplantation Unit, Laikon Hospital, Athens Greece
The evaluation of the status of CD4+ T cell immune function in renal 
transplant (RTx) recipients may be useful in order to optimize the 
immunosuppression. In this study, intracellular adenosine triphosphatase 
(ATP) levels were evaluated in 392 clinically stable RTx recipients and 104 
volunteers blood donors that were used as control population (NC). Blood 
samples (n=451) were collected at various post Tx intervals and ATP (ng/
ml) levels were measured in CD4+ Ô cells following stimulation with PHA 
in whole blood culture. Regarding the immunosuppressive protocols 287 
patients, were separated in 4 groups: group A (n=125) who received MMF/
CsA/MP, group A1 (n=40) who received MMF/CsA, group B (n=97) who 
received MMF/Fk/MP and group B1 (n= 15) who received MMF/Fk. ATP 
levels were tested for the ability to discriminate patients from controls 
using receiver operating characteristic (ROC) curve. Analysis of variance 
–ANOVA with Tukey s correction was used for multiple comparisons. 
The patients (n=392) had signifi cantly lower levels of intracellular ATP with 
cut-off value 314 ng/ml compared to NC (p=. 005). Intracellular ATP levels 
were found signifi cantly lower in group A1 (284. 6 ng/ml) in comparison with 
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group A (354. 5 ng/ml) p=. 009. Creatinine levels were signifi cantly lower (p=. 
0019) in group A1 patients (1. 4 mg/ml) comparatively to group A patients (1. 
6 mg/ml). Mean time post RTx was signifi cantly higher for group A1 (8. 2y) 
and B1 (4. 4y) compared to group A (7. 2y) and B (2. 4y) patients (p=. 050 and 
p=. 016 respectively). 
The above results indicate that MP withdraw in clinically stable RTx recipients is 
followed by suppression of T cell immune status and has no effect on graft function
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EARLY GROWTH RESPONSE (EGR)-1 AND ITS TARGET 1524 
GENES CORRELATES WITH LUNG GRAFT FUNCTION IN 
RATS
O. Yoshida, M. Yamane, S. Yamamoto, S. Toyooka, T. Ohto, Y. Sano
Okayama University Graduate School of Medicine Depertment of Cancer And 
Thoracic Surgery
Background: Primary graft dysfunction (PGD) caused by ischemia reperfusion 
injury (IRI) is a major clinical problem after lung transplantation. Early growth 
response (EGR)-1 is a transcription factor induced by various stimuli including 
hypoxia and reoxigenation. It regulates the expression of proinfl ammatory cytokine, 
adhesion molecules and other genes pertinent to infl ammation, coagulation and 
proliferation associated with IRI. EGR-1 is known to play roles in IRI. Changes in 
the levels of transcripts for EGR-1 and the target genes for the duration of reperfusion 
have not yet been investigated. We examined the correlation of the pulmonary graft 
function and gene expression patterns of Egr-1 and its target genes. 
Methods: Sprague-Dawley rat lungs were harvested and stored at 4 centigrade 
degrees for 3h or 18h followed by left lung transplantation and reperfusion 
for up to 4h. Transplanted lungs were assessed with blood gas analyses 
after ligation of right pulmonary artery, and then harvested and stored at -80 
centigrade degree. Transcript levels of EGR-1, ICAM-1, IL-1beta, MIP-2 and 
PAI-1 in lung tissues were analyzed with semi-quantitative RT-PCR. 
Result: Compared with 18h cold preserved lung, 3h cold preserved lung 
displayed signifi cant higher oxygenation during 4h of reperfusion. RT-PCR 
revealed that prolonged cold preservation induced more relevant upregulation 
of EGR-1 mRNA in the lung tissues after transplantation. Maximum levels 
of EGR-1 transcript were observed after 1h of reperfusion regardless of cold 
preservation length. Cold ischemia alone did not induce mRNA for EGR-1 and 
target genes. PAI-1 and MIP-2 mRNA expression increased for up to 4hours in 
long time preserved lungs. Signifi cant change in ICAM-1 mRNA level was not 
observed during observation time regardless of preservation time. 
Conclusions: The patterns of changes in mRNA levels of EGR-1 and target 
genes after transplantation were various and related with the severity of IRI and 
prolonged cold preservation. Target genes may have other regulatory pathways 
such as a signal from tissue damage, negative feedback of cytokines and other 
MAPK cascades and so on. 
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LONG TERM ACCEPTANCE OF FULL MHC DISPARATE 1525 
LUNG ALLOGRAFTS IN MINIATURE SWINE IS NOT 
PERTURBED BY EXPOSURE TO DONOR ANTIGEN
T. Shoji1, H. Sahara1, A. Aoyama1, A. Muniappan1, D. Guenther1, J. Wain1,2, S. 
Houser1, M. Bravard1, J. Madsen1,3, J. Allan1,2
1Transplantation Biology Research Center, Massachusetts General Hospital, 
2Division of Thoracic Surgery, Massachusetts General Hospital, 3Division of 
Cardiac Surgery, Massachusetts General Hospital
Background: We have previously reported that long-term acceptance of MHC 
disparate lung allografts in miniature swine can be achieved using an intensive 
12-day course of tacrolimus. To determine whether the state of graft acceptance 
would be perturbed by exposure to donor antigen following transplantation, 
skin grafts were placed on animals with viable lung graft long term. 
Methods: Six of SLAdd (Id/IId) swine were transplanted with full MHC 
SLAaa (Ia/IIa, n=3) or SLAcc (Ic/IIc, n=3) lungs. All recipients were treated 
with a 12-day course of high-dose tacrolimus (0. 15 mg/kg/d, POD0-11). 
Recipients with long term graft acceptance (>350d) underwent skin grafting 
with frozen donor skin, donor MHC-matched (minor antigen-mismatched) 
skin, and fully mismatched SLA skin bearing third-party class I plus third-
party class II antigens. 
Results: 5 of the 6 recipients maintained their grafts long term (>350d). Isolated 
lesions of obliterative bronchiolitis (OB) were occasionally seen on open lung 
biopsy, and donor-specifi c hyporesponsiveness on MLR and CML assays was 
consistently observed. The other recipient rejected its graft on POD 103 with 
histologic fi ndings of OB. 5 animals with long term graft acceptance underwent 
skin graft and all 5 animals rejected donor skin grafts in 18, 20, 22, 22, 23 days, 
respectively. Nonetheless, all animals continued to maintain their lung grafts 
without pathological change following skin grafting. After skin grafting, MLR 
and CML responses against donor-type cells were not increased. 
Conclusions: After exposure to donor antigen following transplantation, the 
lung grafts themselves remained stably engrafted without histologic or clinical 
evidence of progression of rejection. 
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THERAPEUTIC STRATEGY FOR COUNTERACTING 1526 
COMPLEMENT IN T CELL ACTIVATION
W. Zhou, Q. Peng, K. Li, C. Farrar, R. Smith, S. Sacks
King’s College London
Our previous studies in murine acute rejection and in the analysis of human 
long term graft outcome have shown that local production of C3 in donor 
organs appears to be a major determinant of graft survival. In addition, we have 
shown that APCs prepared from C3-/- mice have reduced ability to stimulate 
alloreactive T cells in vitro and in vivo. We envisage that complement activation 
at the surface of APCs will lead to enhanced allo-stimulatory capacity of those 
cells and/or provide essential help for T cell stimulation at the immunological 
synapse. Conversely, we propose that therapeutic overexpression of complement 
regulator will lower the alloreactive T cell stimulatory capacity of APCs in 
favour of immune suppression/tolerance. 
We fi rst assessed if APT070, a membrane–localising complement regulator 
can inhibit murine complement activation and bind to murine bone marrow 
dendritic cells (DCs). Using a haemolytic assay, we show that APT070 
(20&#61549;g/mL) inhibits >75% of complement mediated cell lysis. Using 
immunochemical staining and fl ow cytometry with anti-human CD35 mAb, we 
show that APT070 effi ciently binds to DCs. 
We next determined if APT070 treatment modulates DC activation and their 
function in alloreactive T cell stimulation. APT070 (20&#61549;g/mL) or 
control molecule (APT544) was added to the DC culture medium, from the 
beginning of BM cell culture, with repeated addition every two days. We show 
that compared to control molecule treated DCs, APT070 treated DCs exhibit a 
tolerogenic cytokine profi le with a lower IL-12 and higher IL-10 production; 
when co-cultured with naïve allogeneic CD4 T cells, they elicit signifi cantly 
lower T cell responses measured by IFN-γ; production and thymidine uptake. 
Our fi ndings showing that APT070 treatment reduces the alloreactive T cell 
stimulatory capacity of donor DCs may have therapeutic potential for targeting 
the alloreactive T cell response in allograft rejection. 
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HOST ENDOTHELIAL AND MESENCHYMAL 1527 
CHIMERISM IN EXPERIMENTAL CHRONIC ALLOGRAFT 
NEPHROPATHY
J.L. Hillebrands1, H. Rienstra1, M. Boersema2, A. Zandvoort1,5, A. Smit-van 
Oosten5, J. Rozing1, H. van Goor3, G.J. Navis4
1University Medical Center Groningen, Dept. Cell Biology – Immunology, 
2University Medical Center Groningen, Dept. Pathology & Laboratory 
Medicine, Div. Medical Biology, 3University Medical Center Groningen, 
Dept. Pathology & Laboratory Medicine, Div. Pathology, 4University Medical 
Center Groningen, Dept. Internal Medicine, Div. Nephrology, 5University 
Medical Center Groningen, Central Animal Facility
Background: Vascular and interstitial remodeling are hallmarks of chronic 
allograft nephropathy (CAN). Vascular remodeling (transplant arteriopathy) 
is characterized by occlusive neointima formation resulting from uncontrolled 
smooth muscle cell (SMC) proliferation. Interstitial remodeling is characterized 
by myofi broblast recruitment and proliferation culminating in interstitial 
fi brosis. Both transplant arteriopathy and interstitial fi brosis supposedly lead to 
deterioration of graft function. The origin (graft vs. host) of neointimal ECs and 
SMCs as well as interstitial myofi broblasts in CAN still is a matter of debate. 
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We therefore determined the origin of ECs, SMCs and myofi broblasts in an 
experimental model of CAN in rats. 
Methods: Dark Agouti (DA) allografts were transplanted to human 
Placental Alkaline Phosphatase (hPAP) transgenic F344 rats. hPAP F344 
rats constitutively express hPAP in nucleated cells which can be detected by 
hPAP-specifi c immunostaining. DA isografts served as controls. Recipient 
rats received ciclosporin (5 mg/kg) on the fi rst 10 days after transplantation. 
Contralateral nephrectomy was performed 10 days after transplantation. Renal 
function was determined before transplantation and 4, 8 and 12 weeks after 
transplantation. Recipients were sacrifi ced 12 weeks after transplantation or 
earlier in case of poor condition. Grafts were processed for histological analysis 
and severity of transplant arteriopathy, glomerulosclerosis and interstitial 
fi brosis was determined. Furthermore, host EC, SMC and myofi broblast 
chimerism was determined by specifi c immunofl uorescent staining using the 
following antibodies: RECA-1 (ECs), 1A4 (á-smooth muscle actin [SMCs/
myofi broblasts]), MN4-91-6 (DA MHC class I) and anti-hPAP (transgene). 
Results: Compared with isografts, allografts presented with severe CAN 
characterized by glomerulosclerosis, tubular atrophy, transplant arteriopathy 
and interstitial fi brosis. These histological changes were associated with 
reduced renal function as indicated by proteinuria and reduced creatinine 
clearance. Graft survival was inversely correlated with the severity of 
transplant arteriopathy. Immunolabeling for hPAP, DA MHC class I and 
smooth muscle actin revealed graft origin (co-expression DA MHC class I and 
smooth muscle actin) of virtually all neointimal SMCs in allografts. Similar 
results were obtained for neointimal ECs. However, host EC-chimerism 
was detected in peritubular and glomerular capillaries; 62% of glomeruli in 
allografts contained host-derived ECs (RECA-1+hPAP+; ~2 host ECs/chimeric 
glomerulus/cross-section). Staining for smooth muscle actin revealed increased 
numbers of cortical interstitial myofi broblasts in allografts (vs. isografts), 
indicative of interstitial fi brosis. Immunolabeling for hPAP, DA MHC class I 
and smooth muscle actin revealed presence of both graft- and recipient-derived 
interstitial myofi broblasts. Quantitative analysis revealed 53% of interstitial 
myofi broblasts to be of host-origin. 
Conclusions: Neointimal SMCs and ECs in CAN are graft-derived indicating 
that endothelial repair as well as neointima formation in graft arteries are 
mediated by cells residing within the graft. In contrast to vascular remodeling 
in the larger arteries, the development of interstitial fi brosis involves both 
graft- and host-derived myofi broblasts. These results suggest that interstitial 
myofi broblasts are derived from distinct cell lineages, which may separately 
or in concert contribute to interstitial fi brosis in CAN. We propose that host-
derived mesenchymal progenitor cells are a putative target for therapeutic 
intervention. Reduced mesenchymal progenitor cell recruitment is expected to 
attenuate interstitial fi brosis resulting in prolonged graft function. 
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SPIRONOLACTONE AMELIORATES FOCAL 1528 
GLOMERULOSCLEROSIS AND TRANSPLANT 
ARTERIOPATHY IN EXPERIMENTAL CHRONIC ALLOGRAFT 
NEPHROPATHY IN RATS
J-L. Hillebrands2, F. Waanders1, H. Rienstra2, J. Rozing2, A. Zandvoort1,4, A. 
Smit-van Oosten4, G.J. Navis1, H. van Goor3
1University Medical Center Groningen, Dept. Internal Medicine, Div. 
Nephrology, 2University Medical Center Groningen, Dept. Cell Biology – 
section Immunology, 3University Medical Center Groningen, Dept. Pathology 
& Laboratory Medicine, Div. Pathology, 4University Medical Center 
Groningen, Central Animal Facility
Background: Chronic allograft nephropathy (CAN) is the leading cause of 
long-term renal allograft loss. CAN is characterized by histopathological 
changes including focal glomerulosclerosis (FGS), interstitial fi brosis, tubular 
atrophy and transplant arteriopathy (neointima formation). No effective therapy 
is available to prevent CAN. Increasing evidence indicate that aldosterone 
plays a signifi cant role in renal damage via the non-epithelial mineralocorticoid 
receptors. The aldosterone antagonist spironolactone has been shown to 
attenuate renal ischemia/reperfusion injury in rats. In this study we determined 
the effi cacy of spironolactone in attenuating CAN after experimental renal 
transplantation in rats. 
Methods: Renal transplantation was performed in the allogeneic Dark 
Agouti-to-Wistar Furth rat strain combination. Dark Agouti-to-Dark Agouti 
isografts served as controls. Transplanted rats received ciclosporin (5 mg/kg 
BW) on the fi rst 10 days after transplantation. 14 days after transplantation, 
nephrectomy of the remaining host kidney was performed. Recipients received 
either spironolactone (20 mg/kg BW) (+) or vehicle (-) daily by oral gavage 
till the end of the experiment. Treatment started 2 days before transplantation. 
4 experimental groups were included: 1) isograft- (n=8), 2) isograft+ (n=8), 
3) allograft- (n=9) and 4) allograft+ (n=9). Before, and every 2 weeks after 
transplantation systolic blood pressure and urinary protein excretion were 
determined. Grafts were retrieved 12 weeks after transplantation and processed 
for histological analyses (i. e. glomerulosclerosis, interstitial fi brosis, 
macrophage infi ltration, transplant arteriopathy). 
Results: Isografts (both + and -) survived until the end of the experiment. 
Spironolactone improved allograft survival rates (p=0. 07, borderline 
signifi cance, group 3 vs. 4). Isograft recipients did not develop proteinuria. In 
contrast, allograft recipients developed clear proteinuria which was attenuated 
by spironolactone (77±28 mg/day [group 3] vs. 41±10 mg/day [group 4]; 
p=0. 06). In time, spironolactone did not affect systolic blood pressure in both 
isograft and allograft recipients. In contrast to isografts, allografts presented 
with prominent glomerulosclerosis and interstitial fi brosis. Spironolactone 
signifi cantly attenuated severity of focal glomerulosclerosis in allografts 
(100±37 A. U. [group 3] vs 47±17 A. U. [group 4], p<0. 05) however without 
affecting interstitial fi brosis. Reduced focal glomerulosclerosis in allografts 
from spironolactone-treated recipients was accompanied by reduced glomerular 
infi ltration with ED-1+ macrophages (p<0. 05, group 3 vs. group 4). Allografts 
presented with severe neointima formation which was signifi cantly reduced 
(p<0. 05) by spironolactone. 
Conclusion: Blockade of mineralocorticoid receptors by the aldosterone 
antagonist spironolactone ameliorates proteinuria, focal glomerulosclerosis and 
transplant arteriopathy but not interstitial fi brosis in an experimental rat model 
for CAN. We propose that the observed glomerulo- and vasoprotective effects 
of spironolactone might result in improved graft survival on the long-run. 
POSTER BOARD NUMBER P2 – 328
EXPLORATION OF THE ROLE OF B7H4 IN CHRONIC 1529 
ALLOGRAFT VASCULOPATHY
J. Popoola, J. Yang, M. Sayegh, A. Chandraker
Brigham And Women’s Hospital, Children’s Hospital and Harvard Medical 
School
Introduction: The specifi c roles and signifi cance of the newer co-stimulatory 
pathways such as B7H4 (B7S1 or B7X) are not entirely clear. B7H4 is of 
particular interest in the context of transplantation because of its ubiquitous 
expression. It is speculated that the co-stimulatory regulation of T cells by 
B7H4 is infl uenced by the activation status of B cells and that BTLA may act 
as a putative ligand. 
Methods: Unmodifi ed wild-type C57BL/6 recipients of BM12 class II 
mismatched heterotopic cardiac transplants were used as a model of chronic 
allograft rejection. The treatment group received anti-B7H4 monoclonal 
antibody (mAb) or B7H4 fusion protein while the control group received 
IgM mAb administered on days 0, 2, 4, 6, 8 and 10. Graft survival and 
histopathological change were compared and assessed at 8 weeks. In-vitro 
studies were carried out at 21 and 56 days and assessed by fl ow cytometry 
for temporal variation and phenotypic differentiation of the activation status, 
regulatory T cell markers and effector cell generation to dissect the mechanisms 
of action of anti-B7H4 in the setting of development of chronic allograft 
nephropathy. 
Results: A class II mismatch was used to assess the effect of inhibiting the 
B7H4 pathway in a chronic rejection model. Graft survival was not signifi cantly 
shortened in the presence of a class II mismatch in untreated wild type 
mice (MST=53. 7+/-5. 6, n=7) compared to treatment with B7H4 antibody 
(MST=51+/-6. 3, n=5), or B7H4 fusion protein MST=54+/-2. 3. Histology 
however showed a greater degree of cellular infi ltration (haematoxylin and eosin 
staining), fi brous change (trichrome staining) and vasculopathy (elastin staining) 
signifying worsened chronic damage. Characterisation of the cellular infi ltrate 
by immunohistochemistry showed a predominance of T cells (CD4+, CD8+) 
and macrophages (CD11b+) within the allograft. B7H4 was demonstrable in 
the interstitium of the IgM control treated animals with a particular locale for 
the vascular endothelium by immunofl uorescence and confocal microscopy. 
To further confi rm the presence of B7H4 on cardiac vascular endothelium we 
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isolated and cultured endothelial cells from murine hearts un-stimulated ex-vivo 
and showed expression of B7H4 having confi rmed that these cells maintain the 
phenotypic characteristics of uncultured vascular endothelium by both fl ow 
cytometry and confocal visualization of the cytospan passaged cells. Treatment 
with anti-B7H4 mAb resulted in loss of B7H4 parenchyma expression on donor 
allografts in-vivo. The expression of B7H4 on haemopoietic cells remained at 
similar levels in both the naive and in the recipient 
Mixed lymphocyte reaction proliferaton assays from splenocytes cultured for 
4 days gave an average cpm of 21032+/-2657 compared to 10814 similarly 
with CFSE based proliferation assay – (1. 13+/-0. 21: 0. 44+/-0. 17, p 
value =0. 01) in anti-B7H4 mAb treated recipients compared to controls. 
Interestingly blockade of the B7H4 pathway did not signifi cantly affect the 
number of regulatory T cells (CD4+CD25+FoxP3+) in the periphery or within 
in the allograft target tissue using FoxP3 staining by immunohistochemistry 
compared to IgM controls. Additionally while anti-PDL1 mAb reduces the 
conversion of TGF-B induced regulatory T cells, anti-B7H4 does not lead to a 
similar effect. The effector memory population at 8 weeks was (18. 5+/-1. 5 and 
15+/-1. 8) of the CD4 T cell population and of the CD8 population (15+/-0. 9 
versus 11. 7+/-1. 3) in the anti-B7H4 mAb compared to IgM controls. Similarly 
the CD4 effector: CD4 FoxP3+ regulatory cell ratio was increased in the anti-
B7H4 treated recipients 1. 9: 1. 6. There was up-regulation of both the Th1 
(IFN-γ;) and Th2 (IL-4, IL-5) cytokine response verifi ed by ELISPOT further 
exploration of the cytokine mileu by LUMINEX showed increased production 
of 1L12 p40/70 but reduced IL6 in the antibody treated group. 
Conclusion: Here we present novel data exploring the potential role of 
the co-stimulatory pathway B7H4 in the development of chronic allograft 
vasculopathy. B7H4 serves as a negative co-stimulatory pathway in the context 
of chronic allograft rejection. Its predominant effect appears to be through an 
infl uence its expression on the endothelial parenchymal tissue and its infl uence 
on the effector cell population and its blockade results in up regulation of the 
cytokine response potentially providing a window for involvement of cells of 
both the innate (macrophages) and adaptive (T cells) immune system. B7H4 
may serve as a potential therapeutic target for enhancing acceptance of donor 
grafts by manipulation of the donor graft tissue. 
POSTER BOARD NUMBER P2 – 329
COMPARTMENTALIZATION OF PLATELET DERIVED 1530 
CD154: IMPLICATIONS FOR CLINICAL CORRELATION. 
A. Kirk1, A. Charafeddine1, T. Weaver1, D. Maynard2, W. Gahl2
1Emory University, 2National Human Genome research institute-National 
institues of Health (NIH)
CD154 plays a crucial role in allograft rejection by serving as the ligand for 
CD40, an activation molecule on APCs. Platelets have recently been found as 
a major storage compartment of CD154, and platelet-derived CD154 has been 
shown to be suffi cient to support rejection in vivo. We sought to determine the 
mechanism of CD154 release from platelets. There are two types of secretory 
granules in platelets: alpha and dense granules. Serum and platelets from 
Hermansky-Pudlak syndrome (HP, lacking dense granules), and grey platelet 
syndrome patients (GP, lacking alpha granules) were obtained. Serum samples 
(from clotted blood containing products of platelet degranulation) from GP had 
no CD154 (0+/-0pg/ml, n=3) while normal serum was rich in CD154 (10, 038 
+/- 3637pg/ml; n=71). However, HP patients had normal serum CD154 (11, 
405+/-4, 779pg/ml; n=3). Sucrose gradient alpha granule enriched subcellular 
fractions from normal platelets had higher levels of CD154 than the cytosolar 
fractions (6200 vs 254 pg/ml respectively). Platelet cytosol from alpha granule 
defi cient platelets surprisingly also had high levels of CD154 (>50, 000 pg/
ml), indicating that CD154 is present in platelets lacking alpha granules but 
cannot be released upon thrombus formation. Finally, an immuno-Electron 
microscopy using gold labeled anti-CD154 antibodies shoed alpha granule 
decoration of normal human platlets. With alpha degranulation required for 
CD154 release, plasma but not serum would represent ambient/physiologic 
CD154. Serum CD154 has been associated with several infl ammatory disease 
processes, but serum, a product of clot, is not refl ective of in vivo conditions; 
rather, plasma is. Blood from normal humans (n=100) was thus studied 
under varying collection circumstances including serum, platelet containing 
plasma, and platelet free plasma. CD154 was not found in plasma (non-clotted, 
representative of physiologic in vivo conditions), but was only evident when in 
vitro platelet activation was present. Indeed, serum CD154 levels were merely 
correlated with platelet count (p<0. 0001), and changed with changes in platelet 
content and in vitro activation. We conclude that platelet CD154 release is an 
alpha granule mediated process that is dependent on activation such as that 
involved in thrombus formation. Under physiologic circumstances in the 
absence of platelet activation, CD154 is not a normal soluble blood component. 
This mechanism of release is consistent with a regulated, locally responsive 
delivery of CD154 providing APC stimulation at sites of trauma. 
POSTER BOARD NUMBER P2 – 330
EXPLORATION OF THE ROLE OF THE NOVEL B7 1531 
FAMILY MEMBER B7H4 IN CHRONIC REJECTION
J. Popoola, J. Yang, A. Vidhyadharan, M. Sayegh, A. Chandraker
Brigham And Women’s Hospital And Harvard Medical School
B7H4 (B7S1 or B7X) is a member of the B7 family which includes (B7. 1, 
B7. 2, B7-H3, ICOS, PD-L1 (B7-H1), PD-L2 (B7-DC). The specifi c role 
and signifi cance of B7H4 in solid organ transplants in the context of other 
costimulatory pathways remains unclear. It is speculated that the co-stimulatory 
regulation of T cells by B7H4 is infl uenced by the activation status of B cells 
with BTLA being a putative ligand. 
Unmodifi ed wild-type C57BL/6 recipients of bm12 class II mismatched 
heterotopic cardiac transplants (model of chronic allograft rejection). The 
treatment groups received anti-B7H4 monoclonal antibody (mAb) or B7H4 
fusion protein while the controls received IgM mAb administered on days 0, 
2, 4, 6, 8 & 10. Graft survival, histology & in-vitro studies (fl ow cytometry, 
proliferation assays, elispot & luminex) were carried out at 3 & 8 weeks. 
Results: Graft survival was similar in controls, anti-B7H4 mAb or B7H4 fusion 
protein treated (MST=53. 7+/-5. 6, n=7), (MST=51+/-6. 3, n=5), MST=54+/-2. 
3, n=3) respectively. At 3 weeks there was increased damage to the interstitial 
compartment compared to wild type. By 8 weeks, histology showed worse fi brosis 
mean 80 vs 50 vs 57% and vasculopathy 80 vs 63 vs 55% in antiB7H4mAb vs 
controls vs B7H4 fusion protein. Expression of B7H4 was demonstrable on 
interstitium & vascular endothelium by immunofl uorescence of donor allografts 
from control animals, anti-B7H4 mAb resulted in reduced donor allograft 
expression. The effect on the alloresponse was assessed by MLR average cpm 
21032+/-2657 vs 10814 +/-4326 in anti-B7H4 mAb treated vs controls. B7H4 
blockade, did not infl uence the number of regulatory T-cells (CD4+CD25+FoxP3+) 
in the periphery. Additionally, unlike anti-PDL1 mAb, anti-B7H4 did not lead to 
reduction in conversion of TGF-B induced regulatory T cells in-vitro. At 8 weeks 
the effector-memory population was (18. 5+/-1. 5 vs 15+/-1. 8%) of the CD4 T 
cell population (15+/-0. 9 vs 11. 7+/-1. 3%) of the CD8 population in anti-B7H4 
mAb treated vs controls. There was up-regulation of both the Th1 (IFN-γ;) & Th2 
(IL-4, IL-5) cytokine response verifi ed by ELISPOT and increased production of 
1L12 p40/70 by LUMINEX in the antibody treated group. B7H4 expression is 
demonstrable on cardiac derived cultured endothelial cells un-stimulated ex-vivo. 
Blockade of B7H4 accelerates changes of allograft vascuolpathy and fi brosis. Its 
predominant effects appears to be mediated through its parenchymal expression 
and its absence appears to lead to an enhanced alloimmune response. B7H4 may 
serve as a potential therapeutic target for enhancing acceptance of donor grafts by 
manipulation of the donor graft tissue. 
POSTER BOARD NUMBER P2 – 331
THE NKG2D RECEPTOR AND LIGAND ARE INDUCED 1532 
AFTER TRANSPLANTATION. 
S. Krams, M. Zhuo, M. Fujiki, K. Piard-Ruster, O. Martinez
Stanford University School of Medicine
Background: Studies by our group and others suggest a role for NK cells 
in acute and chronic allograft rejection. Indeed we have demonstrated that 
calcineurin inhibitors do not block NK cell function. NKG2D is a C-lectin 
type molecule expressed by NK cells and subsets of NKT and T cells. NKG2D 
functions as a stimulatory receptor on NK cells and as a co-stimulatory 
receptor on CD8+T cells. Interestingly, expression of NKG2D is induced by 
DNA damage and cellular stress. The objective of this study was to determine 
the expression and functional signifi cance of NKG2D interactions after liver 
transplantation. 
Methods: We have cloned the rat homologue of NKG2D and developed 
reagents to detect NKG2D expression in rat blood and tissue by quantitative 
real-time PCR (q-PCR). Additionally two ligands of NKG2D have been 
cloned, rat RAE-1L and rat RAE-1 like transcript (RRLT). Tissue expression of 
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NKG2D and its ligands was analyzed in rat liver allografts (DA&#8594;Lewis) 
and syngeneic grafts (Lewis &#8594;Lewis) by q-PCR. A rat NK cell line 
(RNK-16) that expresses NKG2D was used to confi rm functional interactions 
of NKG2D with expressed ligands. 
Results: Ectopic expression of both RAE-1L and RRLT stimulated RNK16 
cells to produce IFNγ; (as determined by ELISA) and trigger cytotoxic activity. 
Further we show using an experimental model of rat liver transplantation, that 
NKG2D expression is increased in allografts, but not syngeneic grafts, by day 
3 post-transplant and expression strongly correlated with the IFNγ; levels in 
both the graft and periphery. The NKG2D ligand RRLT is silent in normal liver, 
induced upon liver transplantation, and specifi cally increased (25. 8 ± 6. 1 fold) 
in allografts by day 3 post-transplant. 
Conclusion: Our data indicates that the “stress’ associated with transplantation 
induces the expression of NKG2D ligands. Further since NK cells are refractory 
to standard immunosuppressive drugs, and NKG2D interactions induce IFNγ; 
production and killing, therapeutics specifi cally aimed at this receptor or its 
ligands may prove benefi cial after transplantation. 
POSTER BOARD NUMBER P2 – 332
DIFFERENTIAL IMMNOLOGICAL BEHAVIOR OF 1533 
ENHANCED GREEN FLUORESCENCE PROTEIN (EGFP) 
MINOR HISTOCOMAPTIBILITY ANTIGEN WITH A SPECIAL 
REFERENCE TO SKIN ISOGRAFTING AND SPECIFIC 
REGULATON OF LOCAL GRAFT-VERSUS-HOST REACTION
H. Kimura1, M. Miyamoto1, P. Xuan-Chao1,2, Y. Sugawara2, M. Makuuchi2, 
D. Ying-Bing2, N. Fuji-Funeshima1, R. Haba1, Y. Hattori1, X-K. Li1
1National Research Center For Child Health & Development, 2Graduate 
School of Medicine and Faculty of Medicine, Tokyo University
Backgrounds: Although enhanced green fl uorescence protein (EGFP) is widely 
used as a molecular tag in cell biology, it has become evident that transgenic or 
transduced EGFP behaves itself like minor histocompatibility antigen (s). Thus 
it appears that an in vivo application of cell, tissue and organ transplantation 
becomes limited. Furthermore immunological behavior of EGFP as minor 
histocompatibility antigen in various major histocompatibility antigen complex 
(MHC) backgrounds is not fully understood. 
Methods: Employing two lines of EGFP transgenic rats, e. g. , Green-F344 Tg 
(RT11) and Green DA Tg (RT1 a), and its F1 hybrid with non-transgenic rat, 
behavior of EGFP-transgenic antigen (s) as minor histocompatibility antigens 
was investigated. 
Accordingly immunological behavior of EGFP-transgenic skin isografts or 
EGFP-transgenic lymphocytes was examined in normal F1 hybrid rats. In 
the latter system EGFP-specifi c suppression of local graft versus host (GvH) 
reaction, i. e. , in vivo equivalence to cytotoxic assay in vitro, was developed. 
Results: In skin isografting model all EGFP-positive (Green DA x F344)
F1 donor skin isografts were rejected by non-transgenic (DA x F344)F1 
recipients (MST: 12 days). In sharp contrast, none of (DA x GreenF344) 
F1 donor skin was rejected by the same F1 recipients. This non-responder 
phenotype of F1 hybrid to EGFP transgenic F1 skin isograft was not altered 
even after immunization of normal F1 with EGFP expressing F1 APC such 
as green DCs. Nevertheless once normal F1 hybrid rats were sensitized with 
EGFP, regardless of (Green DA x F344)F1 or (DA x Green F344)F1 origin, 
the sensitized F1 recipients resisted to local and systemic GvH reaction 
induced by EGFP-expressing parental T lymphocytes. Thus (DA x F344)
F1 hybrid that had been sensitized with EGFP antigen, regardless of the 
EGFP origin, i. e. , (Green DA x F344)F1 or (DA x Green F344)F1, strongly 
resisted to GvH reaction induced by Green DA T cells and Green F344 T 
cells, respectively. 
Conclusions: Evidence is provided that differential immunological behavior 
of EGFP-transgenic minor histocompatibility antigen occurs in vivo. Thus 
immune responses to EGFP-minor histocompatibility antigen (s) become 
apparent to EGFP-specifi c suppression of local GvH reaction induced by 
EGFP-transgenic T cells only after EGFP-specifi c sensitization. However this 
was not the case where test skin isografting was applied in spite of extensive 
sensitization protocols. 
POSTER BOARD NUMBER P2 – 333
A NOVEL THERAPEUTIC STRATEGY THAT REMOVES 1534 
ACTIVATED T CELLS EXTENDS GRAFT SURVIVAL IN PRE-
SENSITISED RECIPIENTS
S. Jurcevic, R.E.G. Hargreaves, N.J. Gardner, S.H. Sacks, C.A. Farrar
King’s College London, Dept. Nephrology & Transplantation, Guy’s Hospital, 
UK
Memory T cells with their rapid and effi cient response to antigen re-challenge and 
long-term persistence are a crucial component of adaptive immunity. However, 
when re-activated upon encounter with a transplant, these cells play a central role 
in causing and perpetuating tissue damage. Furthermore, current treatments which 
effi ciently control the naive T cell response, have limited effects on primed T cells. 
We have developed a treatment based on a combination of antibodies specifi c for 
molecules expressed by activated T lymphocytes to selectively remove these cells. 
This approach, which we termed multi-hit therapy, leads to the cumulative binding 
of antibodies to the activated T cell targets and results in a striking prolongation of 
skin graft survival in pre-sensitised recipients in a stringent skin transplant model. 
We propose that CD8- and CD70-specifi c antibodies in our therapy bind 
activated, CD8+ T cells (multiple hits), thus reaching a threshold for Fc-mediated 
depletion. Similarly, CD70- and CD154-specifi c antibodies target the activated 
CD4+ T cell responders. Rapamycin functions to limit the T cellresponder 
pool size. This combination of four reagents (CD8-, CD154-, CD70-specifi c 
antibodies and rapamycin) had striking effects on skin graft survival in the pre-
sensitised HY (male to female transplant) model, with median survival time 
(MST)= 84 days compared to untreated control MST=9 days. 
Importantly, this was associated with the removal of graft-specifi c HY-
tetramer+ CD8+ T cells in sequential tail bleeds post-transplantation. 
Furthermore, this multi-hit therapy approach allows a fl exible approach with 
the potential for the replacement of individual reagents as long as the fi nal 
combination adequately targets the activated responder T cell population. 
Indeed, replacing CD154- with CD25-specifi c antibody maintained the potent 
effects of the multi-hit approach on HY skin graft survival in pre-sensitized 
recipients (MST >100 days). 
The ability to alter the antibody combination in the multi-hit therapy whilst 
maintaining selectivity for activated target cells has important implications for 
future therapeutic strategies. 
POSTER BOARD NUMBER P2 – 334
NKP30-MEDIATED INTERACTIONS BETWEEN 1535 
NATURAL KILLER CELLS AND DENDRITIC CELLS INDUCE 
IFN-GAMMA PRODUCTION BUT NOT CYTOTOXICITY
L-E. Wai, O. Martinez, S. Krams
Dept of Surgery/Division of Transplantation and Program in Immunology, 
Stanford University
Background and Aims: There is considerable interest in using dendritic cells 
(DC) to induce transplant tolerance, with animal studies showing prolonged 
heart and pancreatic islet allograft survival following treatment with immature 
DCs (iDC). Natural killer (NK) cells can mediate both maturation and killing 
of iDCs, which has implications in tolerance induction. Indeed we and others 
have demonstrated that NK cells infi ltrate solid organ allografts early after 
transplantation. Moreover, calcineurin inhibitors do not block NK cell function. 
The aim of this study was to investigate the role of the rat NK cell stimulatory 
receptor, rNKp30, in the interaction of NK cells with DCs. 
Methods: Wildtype and rNKp30-transfected RNK-16 cells (rat NK cell line) 
were co-cultured with rat bone marrow-derived DCs. IFN-gamma production by 
NK cells was analyzed by ELISA and fl ow cytometry. To determine if the cellular 
interactions are contact-dependent, transwell assays were performed. Cytotoxicity 
was measured using a fl ow cytometry-based assay. In addition, degranulation by 
NK cells was determined by CD107a surface expression and granzyme B release. 
The presence of putative rNKp30 ligands on DC was determined by analyzing 
the binding of rNKp30-Fc fusion proteins with fl ow cytometry. 
Results: Flow cytometry on DC with an rNKp30-Fc fusion protein, as compared 
to a control Fc fusion protein, indicated the presence of rNKp30 ligand (s) on 
the surface of DCs. The ligand (s) is likely a protein since trypsin treatment 
of the DCs prevented rNKp30-Fc binding. Co-culture of rNKp30+, but not 
rNKp30-, NK cells with either immature or mature DC resulted in signifi cant 
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IFN-gamma production. This interaction requires direct cell contact. However, 
both rNKp30- and rNKp30+ NK cells demonstrated similar cytotoxicity against 
DC, with iDC being more susceptible to killing than mature DC, suggesting that 
killing is mediated by receptors other than rNKp30. As a control, both rNKp30- 
and rNKp30+ NK cells kill YAC-1 targets to the same extent. Further, after 
co-culture with DC, NK cells demonstrate increased surface expression of the 
degranulation marker CD107a and decreased intracellular levels of granzyme 
B suggesting the NK cells have undergone degranulation. 
Conclusions: NK cells interact with DC in a cell contact-dependent manner 
and rNKp30-rNKp30 ligand interactions are important for inducing IFN-
gamma production by NK cells. In contrast, NK cell degranulation and killing 
is mediated by other NK cell stimulatory receptor (s). Studying the involvement 
of different NK cell receptors in NK-DC crosstalk will help us elucidate the 
role of innate immunity in allograft rejection, and could lead to new targets for 
tolerance induction. 
POSTER BOARD NUMBER P2 – 335
CHRONIC KIDNEY ALLOGRAFT REJECTION IN F344 1536 
TO LEW RATS: RELATIONSHIP OF ALLOANTIBODIES, C4D 
DEPOSITION AND GLOMERULOPATHY/INTIMAL FIBROSIS. 
W. Carmen1, L. Erickson1, F. Pan1, I-C. Hong1, T. Yamada1, L. Wu1, 
J. Ding1, G. Crew1, K. Tamura1,2, H. Jiang1,2
1Astellas Research Institute, 2Department of Medicine, Northwestern 
University
Chronic transplant glomerulopathy and intimal fi brosis are common causes 
of chronic transplant dysfunction of unknown pathogenesis. To determine 
the possible contribution of the humoral immune response, we assessed the 
relationship of alloantibody titers to C4d deposition/graft gene expression and 
to measures of glomerulopathy and intimal fi brosis during the development of 
chronic kidney allograft rejection in the F344 to LEW rat model. MM: Kidneys 
of F344 rats were orthotopically transplanted into bilaterally nephrectomized 
LEW recipients treated with a brief dose of FK506. Blood and 24 hr urine 
samples were collected once a week for determination of creatinine and allo-
specifi c antibodies. Kidney grafts were harvested on day 6, 30, or 90 after 
transplantation and subjected to histologic (Banff criteria), RT-PCR (C4d) and 
immunohistological (C4d) analysis. 
Results: 80% of kidney grafts in F344 to LEW recipients with functional and 
histological changes of chronic rejection showed a high Banff classifi cation 
for both glomerulopathy and intimal fi brosis on day 90 after transplantation. 
These recipients were associated with detectable levels of allospecifi c IgM and 
IgG at week 2 and strikingly higher levels at week 5. C4d staining was mainly 
localized in the glomeruli and the peritubular capillaries of graft kidneys. The 
staining intensity of C4d deposition was low, medium and highest on days 
6, 30, and 90 after transplantation, respectively. This pattern was consistent 
with the mRNA expression of intragraft C4 in the same time intervals. The 
remaining recipients with lower Banff classifi cation of glomerulopathy and 
intimal fi brosis demonstrated low serum alloantibodies and C4d deposition. 
Conclusion: Our results suggest that C4d is a hallmark of humoral response-
mediated chronic kidney rejection in the rat. 
POSTER BOARD NUMBER P2 – 336
CHIMERIC SOLUBLE MHC CLASS I PROTEINS CAN 1537 
INDIRECTLY PRIME RECIPIENT CD4 CELLS AND INDUCE 
SPECIFIC REGULATORY CELLS THAT INHIBIT THE 
DEVELOPMENT OF CHRONIC REJECTION
N.V. Semiletova1, D.M. Feldman1,  X-D. Shen1, D. Edberg1, M.R. Ghobrial2 
1UCLA Medical School. 2Methodist Hospital, TX. 
MHC class I soluble chimeric proteins (pMHC) that represent donor 
immunogenic epitops at α1-helical region on the recipient background able to 
modulate immune response toward donor specifi c tolerance. Tolerant recipients 
demonstrated attenuated levels of cardiac graft transplant vascular sclerosis 
(TVS). Tolerant hosts demonstrated a restricted alloreactive T cell repertoire, 
strong up-regulation of Th2 dependent IgG1 and IgG2c alloantibodies, and 
accumulation of CD4+CD25+IL10+ cells at the graft site. This study investigated 
the role of pMHC in the development of T regulatory cells (T-regs). 
Methods: Irradiated (130R) ACI hosts of WF hearts were injected with 
syngeneic splenic CD4+; CD8+; CD4+CD25+ cells (107 cells >95% purity; iv) 
from tolerant pMHC or high-dose CsA treated cardiac hosts. Indirect priming 
of CD4 recipient’s cells were tested with BM generated DC in vitro. 
Results: In vitro: pMHC can inhibit CD4 cells ability to recognize antigen 
(Ag). DCs loaded with pMHC were injected into hind footpads of ACI 
recipients. CD4 from post-lethal LN did not proliferate against donor (WF) 
or third-party (BN) Ag. Recipient DC loaded with pMHC can directly block 
proliferation of naïve ACI CD4 cells against donor Ag but failed to inhibit of 
activated CD4 cells. MHC chimeric therapy induces CDR3 size restriction in 
hosts spleen cells. Vgenes 10, 12, 18 were limited when expression of V 8. 1 and 
5 were upregulated. pMHC therapy increased population of CD4CD25FoxP3 
cells in spleens of treated rats. LN T cells from tolerant pMHC and long-
term surviving CsA treated rats inhibited proliferation of ACI naive cells 
against WF (750+100 1600+200 3H-TdR cpm/min), but not third-party BN 
(3200+500; P <0. 001) Ag. In vivo: T-regs activity from pMHC and CsA rats 
was confi rmed by their ability to prolong WF graft survival (>120 d) in ACI 
hosts (n=17 and 8, resp. ). However, only pMHC induced T-regs abrogated 
TVS, (NI=15+5) with only 26+6% of vessels affected. In contrast, allografts of 
secondary ACI hosts treated with CsA-induced T-regs, exhibited severe TVS. 
Attenuated chronic rejection was associated with diminished level of cytotoxic 
T cells. Surprisingly, both CD4 and CD8 subsets induced long-term survival 
of secondary test grafts (>100 days). However, only the CD4+ T-reg prevented 
TVS (NI=19+5, 21+6% of vessels), as compared to CD8+ T-reg (NI=40+9 in 
50+15% of vessels). Alloantibody analysis showed up-regulation IL-4/IL-12 
dependent IgG1 and IgG2c. 
Conclusion: Soluble chimeric MHC class I proteins can indirectly prime 
recipient CD4 cells, moreover, recipient DC loaded with chimeric MHC 
protein can inhibit proliferative response of naïve CD4 cells. Therapy with 
soluble MHC chimeric molecules generate CD4 and CD8 regulatory cells that 
prolong graft survival, but only CD4+ cells prevent TVS. This CD4+ T-reg may 
be responsible for long-term graft maintenance through its unique ability to 
control anti-infl ammatory and alloantibody responses. 
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IL-4 HAS TOLEROGENIC AND ALLOGENIC EFFECTS: 1538 
IT ACTIVATES CD4+CD25+ T CELLS TO INDUCE SPECIFIC 
TRANSPLANT TOLERANCE AND PROMOTES REJECTION, 
EFFECTING CD4+CD25-T CELLS TO EXPRESS CD25 BUT NOT 
FOXP3. 
K. Plain1, N. Verma1, C. Robinson1, G. Tran1, R. Boyd1, S. Hodgkinson1,2, B. 
Hall1
1University of NSW, 2Liverpool Hospital
Th2 responses, especially IL-4, have been associated with transplant tolerance 
induction. Whilst administration of IL-4 can in some cases delay rejection, 
Th2 cells induced by IL-4 effect graft rejection. To examine how IL-4 may 
have such diametrically opposed actions we examined the effect of IL-4 on 
alloimmune responses by CD4+, CD4+CD25-, CD4+CD25+T cells from both 
naïve and transplant tolerant animals. 
Responses of naïve and specifi c transplant tolerant DA cells against fully 
allogeneic PVG stimulators were examined. Tolerance in DA to PVG heart 
grafts was induced by a short course of cyclosporine. In this model, tolerance 
is maintained by CD4+CD25+ Treg cells. We have previously shown that in 
culture with PVG alloAg, IL-4 primes naïve or tolerant CD4+T cells to rapidly 
effect both PVG and third party Lewis allograft rejection when transferred to an 
irradiated adoptive host. This contrasts to freshly isolated tolerant CD4+T cells 
that transfer specifi c tolerance. Paradoxically, IL-4 induces a Th2 response that 
effects rejection, and breaks tolerance. 
Culturing naïve CD4+CD25+Foxp3+ cells with IL-4 and alloAg has a very 
different effect on naïve and tolerant cells. Naïve Treg are activated to become 
alloAg specifi c suppressor cells that can suppress the reconstitution of PVG, 
but not third party Lewis, graft rejection at ten-fold lower cell numbers than 
fresh naïve Treg. Fresh naïve Treg suppress rejection at 1: 1 ratio with naïve 
CD4+T cells, whereas those activated with IL-4 and donor alloAg suppress at 
1: 10. With tolerant CD4+CD25+T cells, the opposite effect was observed in 
that after culture with IL-4 and PVG alloAg they failed to transfer tolerance 
even at a ratio of 1: 2. However at this ratio they partially suppressed Lewis 
rejection. Both naïve and tolerant CD4+CD25+T cells cultured with IL-4 and 
alloAg proliferated to PVG or other stimulators, and retained high levels of 
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expression of both CD25 (>95%) and Foxp3 (70-80%) indicating there was not 
loss of Treg phenotype. 
Naïve and tolerant CD4+ cells cultured with IL-4 and alloAg had increased 
proliferation compared to controls without IL-4. This was associated with a 
massive up-regulation of CD25 expression (72-85% CD25+ with IL-4 compared 
to 25% CD25+ when cultured with IL-2 and 12% CD25+ in control cultures) but 
the majority of these CD25+ cells were Foxp3-, suggesting these were activated 
effectors. Both tolerant and naïve CD4+CD25- T cells cultured with IL-4 and 
alloAg for 3 days became 75% CD4+CD25+ of which <2% were Foxp3+. 
Thus, the effect of IL-4 on Treg cells is important in induction but not 
maintenance of tolerance. In parallel, IL-4 massively activates CD4+CD25-T 
cells to express CD25 but not Foxp3 and to effect rejection. These different 
actions may explain the variable effects of IL-4 on tolerance induction. 
KIDNEY CONCURRENT ORAL SESSION 107: 
TRANSPLANTATION SURGERY – DONOR SURGERY
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USE OF PELVIC KIDNEY FOR LIVING 1539 
TRANSPLANTATION. CASE REPORT AND REVIEW OF THE 
LITERATURE
K. Charfeddine, S. Zagdane, S. Yaich, M. Masmoudi, D. Hssairi, J. Hachicha
Department of Renal Transplantation
Introduction and Aim: The word-wide shortage of cadaveric kidneys for 
transplantation has result in a tendency to extend the indication for procurement 
from cadaveric donors and increased our reliance on living donors. We report 
the use of a pelvic kidney for living-related renal transplantation. 
Methods: A 58-year-old man with history of end-stage renal disease presented 
for renal transplant evaluation. Her other medical problem was medically treated 
hypertension. He weighed 85 kg and the rest of her physical examination was 
unremarkable. The donor was unremarkable, except for a palpable left-side pelvic 
kidney which has been discovered by an ultra sound examination confi rmed the 
presence of a normal right kidney. The pelvic kidney provided 39% of the overall 
renal function. The angiographic examination demonstrated the presence of three 
renal arteries arising from the aorta and the common iliac artery, two renal veins 
draining into the inferior vena cava and a single ureter. Immunologically, the 
donor and recipient were ABO compatible, had a 3/6 HLA antigen match and 
B and T-cell cross-match negative. Upon completion of this lenghly evaluation; 
living related transplantation of the pelvic kidney was performed. 
Results: The donor nephrectomy was performed through a transperitoneal lower 
mediane incision. A right sided incision was used for the recipient surgery. The 
donor vessels were anastomosed end-to-end to the recipient external iliac vein 
and artery with nonabsorbable sutures, and the graft promptly produced urine. 
The ureter was stented prior to reimplantation, using a tunneled modifi ed Lich 
neocystomy. Postoperative, tacrolimus, MMF and corticosteroids were used for 
immunotherapy. The recipient’s serum creatinine fell from 64 mg/to 48 mg/l 
by the second post operative day, and 9 mg/l at 1 month after transplantation. 
At two years post transplantation, the graft function was excellent and serum 
creatinine level was maintained at 10 mg/day. 
Conclusions: transplantation of the pelvic kidney is technically feasible, and 
therefore individuals with pelvic kidneys should be considered as extended 
renal donors. 
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THE SERIES LIVING DONOR RENAL 1540 
TRANSPLANTATIONS THAT USES PURE LAPAROSCOPIC 
DONOR NEPHRECTOMY ~SINGLE CENTER EXPERIENCE~
K. Kozaki, K. Yuzawa
Department of Organ Transplantation, Mito Medical Center
Not to harm a graft function in the living donor renal transplantation (LRTx), 
in principle we shorten graft ischemic time, namely preservation time as 
much as possible. Therefore we perform the parallel operation of donor and 
recipient generally, and the graft kidney is transplanted after perfusion and 
cooling promptly. As a result, although graft preservation time shortens, 
either waiting time under general anesthesia of donor or recipient arise till 
both donor and recipient get ready for starting operation. From April 2006 
renal transplantation has been started in our center. In our center, since 
the reduction of patient’s waiting time under general anesthesia and the 
purpose of using the operation room effectively, recipient enters in the same 
operating room after donor operation end and return to the ward. In our 
country, there are extremely few transplant centers performing the renal 
transplantation in this procedure. As a result, renal graft was preserved for 
about 4 hours. In addition, donor nephrectomy was performed by pure trans-
abdominal laparoscopic procedure and used UW solution as preservative 
solution. 
Objective: To investigate effi cacy of this procedure in LRTx. 
Methods: FFrom April 2006 to December 2007, 22 LRTx were performed by 
pure trans-abdominal laparoscopic procedure. To investigate time of immediate 
diuresis and postoperative day (POD) 1, 7 and 28 transplant kidney function. 
Results: Mean warm ischemic time (mWIT) was 6. 9 min, mean total ischemic 
time (mTIT) was 234. 2 min, immediate diuresis (IU) was occurred in all 
patients and mean time of immediate diuresis (mIUT) was 10. 6 min. 
Postoperative mean plasma creatinine value was 5. 00 (mg/dl) on POD 1, 1. 36 
on POD 7 and 1. 42 on POD 28. No patients needed hemo-dialysis (HD) after 
LRTx. 
Conclusions: FAccording to nationwide total investigation in our country 
about live donor laparoscopic nephrectomy in 2006, mWIT was 7. 0 min, mTIT 
was 96 min and mIUT was 13 min. In 589 laparoscopic donated recipients, 1 
case was reported as primary nonfunction and 28 (4. 8%) recipients needed HD 
after LRTx because of delayed graft functions. In comparison with this survey, 
no postoperative HD and good posttransplant renal functions in all patients by 
our procedure, which is excellent procedure in LRTx
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LAPAROSCOPIC DONOR NEPHRECTOMY
S. Kacar 1, A. Gurkan 2, C. Varýlsuha 3, C. Karaca 3, S. Tilif 2
1 Private Kent Hospital, Izmir, TURKEY, 2 Private Gaziosmanpasa Hospital, 
Istanbul, TURKEY, 3 SSK Tepecik Training Hospital, Izmir, TURKEY
Aim: Laparoscopic donor nephrectomy (LDN) has gained popularity 
throughout the world recently. Although LDN has many advantages over 
open donor nephrectomy such as early recovery, less long-term postoperative 
complications, better cosmesis and shorter hospital stay for the donors. The aim 
of this paper is to compare the fi rst 30 and the last 100 cases. 
Method: 130 living laparoscopic donor nephrectomies have been performed 
between November 2000 and February 2008 by the same surgical team. All the 
procedures were performed via transperitoneal approach. 
Results: The mean duration of the donor surgery was 183 min (max 420, min 
75). The mean warm ischemia time was 2 min 44 sec (4 min 14 sec in the fi rst 
30, and 2 min 17 sec in the last 100 donors). In 7 patients right sided, in 123 
patients left sided nephrectomy was performed. Laparoscopic nephrectomy 
was converted to open procedure in eight donors (6, 1%), all of them in the fi rst 
30 donors. In the last 100 cases there is no conversion. Intraoperative bleeding 
(3 major, 1 minor bleeding) was the most common cause for conversion. The 
other reasons were diffuculty in disection in 3 patients, and technical in 1 
patient. Postoperative urinary complications were seen in 7, 7% (16, 6% in the 
fi rst 30, and 5% in the last 100 donors), vasculary complications in 6, 9% (16, 
6% in the fi rst 30, and 4% in the last 100 donors)of the patients. Lengths of 
hospital stay of the donors was 1, 9 days. 
Conclusion: Laparoscopic donor nephrectomy was preferred in more and 
more patients, as experience grew, due to the charm of short hospital stay, less 
postoperative pain, scar and incision morbidity. In our transplantation clinic, 
as our surgeons gained experience in various laparoscopic general surgery 
procedures in the last ten years, LDN was started fi rst with selected patients, 
than on routine basis. 
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RIGHT KIDNEYS AND DELAYED GRAFT FUNCTION: 1541 
CLINICAL IMPLICATIONS. 
H. Vacher-Coponat1, V. Moal1, R. Purgus1, M. Indreies1, T. Legris1, 
Y. Berland1,2
1Nephrology and transplantation unit, AP-HM, Hopital Conception, 
2Université de la méditerranée Aix-Marseille 2
Background: Cold ischemic time (CIT) and delayed graft function (DGF) 
are associated with transplant outcome. Having one of the shortest CITs of 
transplant centers in France, we analyzed the relevant risk factors on DGF in 
our center. 
Methods: Risk factors for DGF were retrospectively evaluated by multivariate 
analysis for all kidneys transplanted between June 2004 and April 2006 in 
our center. Impact of four courses of organ allocation on CIT and DGF were 
compared. 
Results: Relevant DGF risk factors were CIT (OR = 1. 15, p=0. 002), lower 
donor creatinine clearance (OR = 1. 33, p= 0. 002), hemodialysis duration 
(OR= 1. 28, p= 0. 011), and kidney harvested on the right side (OR= 5. 56, p=0. 
012). Local kidneys not in the national sharing program were transplanted with 
a CIT of 12. 45 h and a DGF rate of 14. 7%. The sharing program increased CIT 
2 fold and DGF 3. 6 fold. This increase concerned not only priority recipients 
but also recipients of local kidneys used after the cancellation of a priority, due 
to positive cross match. 
Conclusion: Procurement of right kidneys is a new DGF risk factor. CIT is 
a known risk factor, which is inevitably prolonged with the national sharing 
program whether the kidneys are grafted or not in priority recipients. 
Considering the independent impact on DGF of CIT and of kidney side, we 
suggest using right kidneys locally in the fi rst instance and providing left 
kidneys for sharing. 
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UNUSUAL COMPLICATIONS FOLLOWING LIVING 1542 
DONOR NEPHRECTOMY
J. Akoh1, S. Stacey
1Plymouth Hospitals NHS Trust, 2Plymouth Hospitals NHS Trust
Introduction: The living donor programme was re-established in January 
2003, with the appointment of a living donor transplant co-ordinator, resulting 
in the introduction and meticulous assessment of all potential living donors 
in conjunction with local and national guidelines. The aim of this study is to 
highlight unusual complications following living donor nephrectomies within 
a single centre. 
Method: During the period 305 people completed the staged assessment 
process for potential kidney donors resulting in 56 nephrectomies (52 open 
and 4 laparoscopic hand assisted). All patients were followed up at 6 weeks 
and then discharged to regular yearly visits with their designated nephrologists. 
All complications were entered prospectively into a database used for this 
analysis. 
Results: Forty three (77%) had a left donor nephrectomy, whereas thirteen 
(23%)had a right nephrectomy. There were 22 males and 34 females. Donor 
average length of hospital stay was 5 days (median 4). Forty six (82%) had 
no complications and those seen in the remaining 10 (18%) are shown in the 
table below: 
Complication Number
Haemorrhage requiring blood transfusion 6
Ileus 2
Incisional hernia 1
Testicular Pain (orchidectomy) 1
Chronic Pain 1
Lymphoma 1
Two individuals presented with severe upper gastrointestinal bleeding, one 
from seven small gastric ulcers managed conservatively and the other from 
a duodenal ulcer requiring surgical intervention. Both were on non steroidal 
ant-infl ammatory agents (NSAID). A patient demanded orchidectomy to treat 
severe testicular pain following a right donor nephrectomy. 
Discussion: NSAIDs should be used with caution in patients after donor 
nephrectomy. To prevent neuropathic pain following the anterolateral 
extraperitoneal approach, dissection close to the subcostal neurovascular bundle 
should be avoided. Extensive assessment of a potential living kidney donor did 
not detect a low grade B-cell lymphoma in the donated kidney. Diagnosis was 
made due to the fortuitous development of renal vein thrombosis resulting in 
transplant nephrectomy on day zero. 
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HAND-ASSISTED RETROPERITONEOSCOPIC LIVING-1543 
DONOR NEPHRECTOMY: 106 CONSECUTIVE LEFT AND 
RIGHT SIDED CASES
N. Kessaris, J. Fronek
StGeorge’s Hospital
Background: This is a report of 106 consecutive donors nephrectomies 
using hand assisted retroperitoneoscopic live donor nephrectomy (HARS). 
Extraperitoneal approach seems to be safer than transperitoneal as less 
dissection is required. Our Unit has therefore adopted this technique for both 
right and left living-donor nephrectomies. 
Methods: All living-donor nephrectomies performed since the intoduction of 
HARS in 2005, were included in this study. Data were collected prospectively. 
In 10 cases the right kindey was retreived. The operation is performed in the 
manner described by Wadström et al 2002, with minor modifi cations. 
Results: The mean age of the donors was 46 years (20-65, median 45), the 
mean body mass index was 24. 75 (20-35, median 26). One donor had a double 
vena cava, six donors had retroaortic left renal vein and 40 donors had complex 
anatomy (multiple vessels or ureters). One of the operations was converted 
to open. The average operating time was 107 min (65-175 min, median 95). 
The mean warm ischaemic time was 104 seconds (40-300, median 90 sec). 
Moreover, the mean estimated blood loss was 40 ml (0-440, median 20 ml) 
and the mean postoperative hospital stay was 44 hours. All of the donors 
demostrated rapid recovery and had no major complications except two 
incisional hernias and one wound infection. The mean serum creatinine on 
admission was 83mmo/L (57-130, median 82) and at the time of discharge 
from hospital 120mmol/L (83-170, median 118). All donors will have long 
term follow up. All transplanted kidneys had immediate function except two 
(none of these two were related to the nephrectomy). 
Conclusions: The HARS is a very safe way of performing living-donor 
nephrectomy with minimal morbodity and fast recovery. Since the introduction 
of this technique, the number of potential living donors has increased. 
POSTER BOARD NUMBER P2 – 344
DO PERINEPHRIC ADHESIONS AFFECT DONOR’S 1544 
MORBIDITY OR RECIPIENT’S OUTCOMES?
M. Hossain, C. Kirby, J. Fronek
St George’s Renal Transplantation Unit
Background: We report of 106 consecutive donors nephrectomized with using 
the Hand Assisted RetroperitoneoScopic live donor nephrectomy (HARS) 
between Jan 2005 and Mar 2008. Extraperitoneal approach seems to be safer 
than transperitoneal as less dissection is needed. Risk of conversion to an open 
procedure is the presence of perinephric adhesions. 
Methods: All living-donor nephrectomies performed using the HARS 
were included and followed prospectively. In 10 cases the right kindey was 
retreived. We present a series of those who underwent HARS and were found 
intraoperatively to have perinephric adhesions. Donors morbidity and operation 
complexity as well as recipient’s outcomes are described. 
Results: Out of 106 cases 12 were found to have adhesions (11. 3%) all male. The 
mean (SD, range) age was 51. 9 (53, 35-64)years, operative duration 149. 8 (35. 1, 
75-192)minutes and blood loss 119 (142. 3, 0-500) mls. Anatomically, there were 
5 cases with simple anatomy, with 7 cases with complex anatomy (3 with 2 artery, 
1 vein; 3 with 1 artery, 2 vein; 1 with 2 artery and 2 vein). One operation was 
aborted as the adhesions found were considered so dense, as to render the kidney 
unretrievable and 1 other procedure was converted to an open retrieval due to 
bleeding from a gonadal vein. All other operations were performed successfully. 
Discussion: Nephrectomy on donor with perinephric adhesions has got 
signifi cantly higher blood loss and duration, although non of the donors received 
a blood transfusion. There is no signifi cant difference in donors hospital stay, 
morbidity and recipients graft function. We believe HARDN can be extended 
to cases with adhesions with no impact on donor or recipient. 
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THE OUT COME OF KIDNEY TRANSPLANTS WITH 1545 
MULTIPLE RENAL ARTERIES. 
M.R. Alam1, A. Khanam1, S.A. Khan2, M. Salauddin1, H. Rahman1, 
H.U. Rashid1
1Dept of Nephrology, BSM Medical University, 2Dept of Urology, BSM 
Medical University
Objective: To determine whether the use of kidney allograft with multiple 
renal arteries adversely affects post transplant out come and complications. 
Background: Transplantation of kidney with multiple renal arteries is generally 
avoided. The disadvantages of multiple vessel graft includes technical diffi culty 
to anastomose, longer warm ischaemia and hence increased incidence of ATN, 
early graft dysfunction, various urologic and vascular complications. 
Methods: We reviewed the records of 35 living related adult kidney transplants 
done at our centre over a period of 3 years (from January 2005 to December 
2007). 
We divided the study population into two groups: Group A –20 Patients with 
single renal artery and group B-15 patients with multiple renal arteries. 
Single, end to side anastomosis was done with recipient’s external iliac artery. 
All patients were placed on conventional immunosuppressant in the post 
operative period. We compared the incidence of post transplant complications 
like ATN, Hematoma, technical obstruction of ureter, Urine leak, lymphocele, 
sloughed ureter, graft nephrectomy etc. between two groups. 
Result: Of the 34 patients; 20 patients (57%) had single renal artery 
and 15 (43%) had multiple renal arteries. In group-A: 1 (5%) developed 
hematoma, 1 (5%) technical obstruction of ureter, 1 (5%) ATN, 1 (5%) 
developed sloughed ureter and 1 (5%) patient required graft nephrectomy 
for coagulation necrosis. 
In group B, hematoma was found in 2 (13% patients, technical obstruction of 
ureter in 1 (6%) urine leak in 3 (20%), ATN in 3 (20%) sloughed ureter in 1 
(6%) patients and 1 (6%) required graft nephrectomy. 
In Kidneys with multiple renal arteries, only the incidence of ATN, Urine leak 
and technical obstruction of ureter was higher compared to single artery grafts, 
which were also not signifi cant statistically. 
Conclusion: Although kidney grafts with multiple renal arteries carry a 
relatively higher incidence of some complications, even then it should not be 
avoided, because post transplant out come and complications are comparable 
with single artery grafts. 
POSTER BOARD NUMBER P2 – 346
SEQUENTIAL CHANGES IN COAGULATION AFTER 1546 
RENAL TRANSPLANTATION – A THROMBOELASTOGRAM 
STUDY
D. Kahn, J. Timmermans, G.H.C. Dolmans
University of Cape Town/Groote Schuur Hospital
Chronic renal failure (CRF) is associated with complex alterations in 
coagulation. The changes in coagulation which occur after renal transplantation 
have been studied only to a limited extent. The thromboelastogram (TEG) 
provides a global assessment of whole blood clotting. In this study, sequential 
changes in coagulation after renal transplantation were investigated using 
the TEG in eight patients. The controls included normal healthy controls 
(n – 6), and patients on haemodialysis (n = 5), on peritoneal dialysis (n = 6) 
and long-term after transplantation (n = 7). The TEG parameters measured 
included the R-time, K-time, alpha angle and the maximum amplitude 
(MA). 
The TEG parameters pre-transplantation demonstrated a hypercoagulable state. 
There was a trend towards normal coagulation immediately post-transplantation 
(days 2-4) and a return to hypercoagulability thereafter, compared to the normal 
controls. There was no difference in the TEG parameters between the patients 
long-term after transplantation and the normal controls. The dialysis patients 
were also hypercoagulable. 
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LIMB SALVAGE IN NON-TRANSPLANTATION AND 1547 
TRANSPLANTATION POPULATION
P. Pootracool1, J. Fletcher2, R. Allen2, J. Chapman2, H. Pleass2, J. Swinnen2, 
M. Vicaretti2
1Department of Surgery, Ramathibodi Hospital, Mahidol University, 
Bangkok, Thailand 10400, 2Westmead Hospital, Sydney, Australia
Objective: To assess the current incidence of limb salvage, and survival in 
non transplantation and transplantation group following lower extremity 
revalascularization and follow up during 6 months to one year. In addition 
cumulative limb salvage in 2, 4, 6 years were studied in Westmead Hospital 
during the last 17 years. 
Material and methods: In a retrospective review in Westmead Hospital 
from 1988-2005 of lower extremity revascularization in dialysis patients and 
functioning kidney transplantation or combined kidney-Pancreas transplantation 
for chronic critical limb ischemia (such as foot gangrene, nonhealing ulcer, rest 
pain) and disabling claudication. Follow up within 6 months to one year and 
cumulative limb salvage in 2, 4, 6 years, graft patency were studies 
Results: Between January 1988-December 2005, total 44 patients (84 limbs) in 
chronic critical limb ischaemia (CLI) and disabling claudication with end stage 
renal disease included the patients who had history of Kidney transplantation/
Kidney-Pancreas transplantation with functional or non functional of kidney 
graft were analyzed. 
Four of the patients had short distance claudication (walking distance 50to 
100 metres). Previous revascularization was 27. 3% which same side 50%, 
contralateral side 50% and previous minor amputation was 31. 7% which same 
side 24. 4%, contralateral side 7. 3%. Most of the patients were males 75% with 
a mean ± SD age of 58 ± 8. 9 years, and 25% were females with a mean ±SD 
age of 51 ± 13. 3 years. Age was not statistic signifi cant difference between 
two groups. 
A total 126 procedures were performed during presentation and follow-up for 
treatment of the primary disease. Revascularization procedure was 55. 5% 
which 32. 5% surgical revascularization, 23% endovascular intervention. Minor 
amputation 22. 2%, major amputation 16. 7%, lumbar sympathectomy 5. 5%. 
There was no mortality rate in 30-days postoperative but in 6 months follow 
–up mortality rate 4. 5%, major amputation 8. 3% (below knee amputation 6%, 
above knee amputation 2. 3%). Limb salvage in 1, 2, 4 and 5 year was 82. 9%, 
79. 5%, 78. 4%, and 76. 1% respectively. 
From the result of this study, transplantation patients had better outcomes in 
limb salvage, major amputation, and mortality rate than the patients dependent 
dialysis. Limb salvage rate in transplantation group was 90. 2% in total one to 
fi ve year
Discussion: From this study, our 30- day primary graft patency was 96%. In this 
study, the mortality rate at 4 year was 9. 1% which improving in revascularization 
outcome of historical experience. This result can be explained by age of the 
patients in this group younger than previously published results and 54. 5% 
of patients in this group had transplantation which 22. 7% combined kidney 
– pancreas transplantation, 31. 7% kidney transplantation alone. Thus, in this 
study limb salvage, mortality and amputation rate in transplantation group were 
better outcome than non-transplant group. In addition, simultaneous kidney 
and pancreas transplantation can be touted as a therapeutic advance for type I 
DM. It can improve survival rates and limit many DM-related complications. 
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DOES CLAMPING OF DISTAL PART OF ILIAC 1548 
ARTERY DURING TRANSPLANTATION IMPROVING THE 
REPERFUSION OF TRANSPLANTED GRAFT
M. Romanowski1, L. Domañski2, L. Szyd³owski3, A. Kempiñska3, 
J. Sieñko1, T. Sulikowski1, K. Tejchman1, K. Safranow2, M. Ostrowski1
1Clinic of General And Transplantation Surgery, 2Clinic of Nephrology, 
3Department of Forensic Medicine
Does the termovision imaging can help surgeon to assessing reperfusion 
transplanted kidney, does clamping of distal part of iliac artery improving the 
reperfusion of transplanted graft, does shorten time of reperfusion have an 
infl uence on early and late function after transplantation. 
60 kidneys from idem cadaveric donors were divided for 2 groups. Clamping 
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of distal part of iliac artery for 5 minutes after vascular anastomoses 
were completed was the only differences between groups. We observed 
reperfusion and recorded by termovison camera. The thermovision 
camera was focused on the renal parenchyma. The images acquired over 
the operation area were recorded intraoperatively using a thermovision 
camera ThermaCAMTM SC500 which detects infra-red radiation and 
records digital images with surface temperature distribution of tested 
objects. During the reperfusion of every graft we made 100 thermographic 
scans each acquired in one second interspaces. We started the recording 
at the moment of removal of the arterial forceps (end of rewarm time). 
The outcoming graph of thermoemission changes of the graft was nearly 
continuous this way. 
The computerized system of image analysis enables to choose the method of the 
radiation and temperature analysis (along a given line on a given surface) and 
to present the obtained results in the form of a text or a diagram. To estimate the 
emission of radiation from the area studied, one can also used such parameters 
as highest and lowest or the average temperature inside a chosen isotherm. 
Kidneys function was analyzed by creatinine and BUN level and diuresis ( 
follow up 6 months). 
Conclusion: The registered initial and continuous images of the kidney 
reperfusion enable to compare temperature distribution and make a qualitative 
analysis of the effi ciency of reperfusion. It is non-contact method that does not 
disturb during operation and it is saving for graft. 
These data demonstrate the reperfusion in a new digitally imaging and additional 
clinical study will help us to develop of this technology in investigative 
practice. 
Claping of distal part of iliac artery cut down of reperfusion time but is not 
correlated with creatinine, BUN level and diuresis. 
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RENAL FUNCTION IN RENAL TRANSPLANT 1549 
RECIPIENTS WITH RENAL ARTERY STENOSIS DURING NINE 
YEAR FOLLOW UP
H. Ronald1, S. Laime, J. van Ampting, J. Beutler, G. Stapper
1University Hospital Utrecht, 2University Hospital Utrecht, 3University 
Hospital Utrecht, 4University Hospital Utrecht, 5University Hospital Utrecht
Purpose: The aim of this prospective clinical study was a nine year follow 
up of renal function in renal transplant patients with (Peak systolic velocity 
¡Ý 200cm/sec) and without a signifi cant renal artery stenosis. In addition, the 
difference in number of rejections between these two groups is determined. 
Methods: Nineteen adult renal transplant patients, with signifi cant renal 
transplant artery stenosis (peak systolic velocity ¡Ý 200cm/s) diagnosed by 
Duplex ultrasound, were compared to eighty-one adult recipients without 
renal artery stenosis (peak systolic velocity < 200cm/s). These two groups, 
matched by age, gender, time and type of renal transplantation, were followed 
during a period of nine years post-transplantation. The peak systolic velocity 
(PSV) in the renal transplant artery, pulsatility index (PI) and resistance index 
(RI) were measured at least one year post- transplantation. Furthermore, 
serum creatinine was followed twice a year during the period of 9 year follow 
up. After nine years the recipients with renal artery stenosis (PSV ¡Ý 200cm/
sec) underwent the second duplex-Doppler for evaluation of renal artery 
stenosis. 
Results: Serum creatinine was increased over nine years in group of patients 
with renal artery stenosis (PSV ¡Ý 200cm/sec) more rapidly than the control 
group (PSV < 200cm/sec). However, the difference was insignifi cant. 
Furthermore, neither signifi cant difference in the number of rejections has been 
found between the two groups. 
Conclusion: PSV ¡Ý 200cm/sec with a normal RI or PI does not affect the 
outcome of renal function after 9 years of follow up. It could be concluded 
that an angiography and successive angioplasty in these patients seem not to 
be useful. 
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ENDOVASCULAR LIGATURE OF PRIMARY 1550 
COMPLICATED AV FISTULAS WITH AMPLATZER VASCULAR 
PLUG
F. Boyvat1, A. Harman1, F. Karakayali2, U. Ozyer1, G. Moray2, M. Haberal2
1Baskent University Faculty of Medicine, Department of Radiology, 2Baskent 
University Faculty of Medicine, Department of General Surgery
Purpose: Here, we report the fi rst use of an Amplatzer vascular plug to close 
dysfunctional or complicated primary arteriovenous fi stulas. 
Materials and Methods: From January 2007 to February 2008, 4 patients 
with primary arteriovenous (AV) fi stulas, presented at our institution with arm 
swelling and long segment venous occlusion (n=1) and ischemic steal syndrome 
(n=3). Two fi stulas were brachiocephalic and the other 2 were radiocephalic 
fi stulas. Because of arm swelling and cellulitis around the anastomosis of the 
AV fi stulas, surgical ligation was not preferred for these patients. Ultrasound-
guided venous access was gained, and a vascular sheath was guided toward the 
arterial anastomosis. We used fl uoroscopy and real-time ultrasound to visualize 
the Amplatzer vascular plug, and placed the plug exactly at the origin of the 
venous site. Two Amplatzer plugs were used in 3 patients, and 1 Amplatzer 
plug was used in 1 patient. 
Results: Complete thrombosis of the venous site of the AV fi stula was 
obtained in all patients. No migration of the Amplatzer vascular plug or arterial 
complication related with embolization was observed. The patients’ pre-
embolization symptoms diminished signifi cantly after closure of the fi stulas. 
Conclusions: These cases underscore the importance of the Amplatzer vascular 
plug as a precise occlusion device for AV fi stulas. The end result is similar to 
surgical ligation of an AV fi stula. It has been our experience that the device is 
easy to use and has a high rate of technical success. 
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PTFE GRAFT RECONSTRUCTION OF THE EXTERNAL 1551 
ILIAC ARTERY IN KIDNEY TRANSPLANT RECIPIENTS WITH 
SEVERE ATHEROSCLEROSIS
R.M. Rosete-Liquete, A. Jordan-Casupang
St. Luke’s Medical Center
Background: Arteriosclerosis and calcifi cation of iliac arteries are common 
in patients on dialysis especially those with diabetes mellitus. In such cases, 
thrombendarterectomy of the hypogastric artery is usually suffi cient to provide 
adequate blood supply to the renal graft. However, in rare cases, severe 
atherosclerosis of the iliac arteries make effective endarterectomy impossible 
hence the simultaneous PTFE (polytetrafl uoroethylene) graft reconstruction of 
the external iliac artery which we will describe here. 
Patients and Methods: Between January 1988 and December 2007, 8/845 
(1%) kidney transplantations required a vascular graft reconstruction of the 
external iliac artery due to severe arterioscleroses of the iliac vessels making 
direct anastomosis precarious. All recipients were diagnosed to have diabetes 
nephropathy. Segmental resection of the external iliac artery was done and 
replaced with a 6mm PTFE anastomosed end-to-side to the common iliac artery 
and end-to-end to the distal end of the external iliac artery. Renal scintigraphy 
was done within the fi rst postoperative week when indicated. Post transplant 
allograft status was monitored by serial serum creatinine measurement and 
urine output. The mean follow-up was 29. 6 (range: 6-114) months. 
Results: All the kidney allografts functioned immediately and six patients who 
had renal scintigraphy during the immediate post transplant period showed 
adequate graft perfusion. There were no infections related to PTFE placement. 
Two cases underwent evacuation of hematoma but this was not associated with 
PTFE graft anastomosis. Serum creatinine decreased within the fi rst week 
for all the patients. There were two mortalities at 2-months and 2-years post 
transplant due to sepsis although both still had good graft function. One-year 
survival rate was 87. 5%
Conclusions: Severe atherosclerosis is not a contraindication for kidney 
transplantation. Vascular reconstruction during kidney transplantation can be 
performed and can impact survival and kidney function. Moreso, it is a safe 
option when performed under experienced hands. 
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ANGIOPLASTY AND STENTING OF ARTERIAL 1552 
STENOSIS AFFECTING RENAL TRANSPLANT FUNCTION
P. Pappas1, G. Zavos2, S. Kaza1, P. Leonardou1, E. Theodoropoulou3, 
J. Bokos2, J. Boletis3, T. Karatzas4, A. Kostakis4
1Department of Radiology, Laiko General Hospital, Athens, Greece 
2Transplantation Unit, Laiko General Hospital, Athens, Greece 3Department 
of Nephrology, Laiko General Hospital, Athens, Greece 4Second Propaedeutic 
Department of Surgery, University of Athens, Medical School, Athens, Greece
Aim: To evaluate the effi cacy of percutaneous angioplasty and stenting 
(PTAS) in cases of artery stenosis of the transplanted kidney or proximal iliac 
artery stenosis causing graft dysfunction and/or increase of the arterial blood 
pressure. 
Materials and Methods: Between January 1999 and June 2007, we evaluated 
24 patients who had undergone renal transplantation, newly presented with 
refractory hypertension and graft dysfunction; signs of possible renal transplant 
artery stenosis. Color Doppler Ultrasonography (CDU) and Magnetic Resonance 
Angiography (MRA) preceded the intraarterial angiographic investigation, 
with false negative results in 18. 2% and 13. 6% of patients, respectively. In 
two out of the 24 patients angiography did not reveal arterial stenosis affecting 
the transplanted kidney. Two patients had severe ipsilateral iliac artery stenosis 
and the remaining 20 had transplant artery stenosis. Successful angioplasty and 
stenting was performed in these 22 patients. 
Results: The method was technically feasible in 100%. The procedure-related 
morbidity was 0%. During the follow-up period (range 3 to 104 months), two 
patients died with normal renal graft function, two suffered transplant failure, 
while the remaining 18 still have normal graft function and easily controlled 
hypertension. 
Conclusions: Percutaneous angioplasty and stenting in cases of arterial 
stenosis affecting the renal transplant function is a safe and effective procedure. 
Even more, the strong clinical suspicion must lead the patient to angiographic 
investigation regardless of the results of other imaging approaches. 
POSTER BOARD NUMBER P2 – 353
EARLY THROMBOTIC COMPLICATIONS IN KIDNEY 1553 
TRANSPLANT RECIPIENTS
W. El Kady, L.W. Moore, S. Patel, A.O. Gaber. 
The Methodist Hospital, Houston, TX
Background: Venous thrombosis is a known complication in kidney transplant 
patients, occurring in about 5. 1%. With signifi cant emphasis on decreasing 
lower venous thrombosis, these rates have been declining. However, upper 
limb thrombosis appears to be increasing in kidney transplant patients. 
Aim: The purpose of this evaluation was to assess the incidence and the factors 
associated with the occurrence of upper limb or lower limb deep venous 
thrombosis or pulmonary embolism in kidney transplant patients. 
Methods: We reviewed electronic and physical charts of 139 patients who 
received their kidney allograft in the period between September 2005 till 
December 2007. We evaluated donor and recipient characteristics and 
demographics, extended donor criteria, creatinine, sodium and central venous 
pressure, early and delayed graft function, induction therapy and recipient age, 
sex, race, transplant site, central venous access, posttransplant blood transfusion, 
length of hospital stay, complete blood count, and changes in recipient body 
mass index to determine the factors associated with thrombotic events. 
Results: The mean patient age was 51 years (range, 22-80). Thrombotic events 
occurred in 14 patients (n=19 events); mean 1. 3 ± 0. 5 events with 5 patients 
having more than one event. The mean age for patients who had thrombosis 
was 58 years (range 39-80; P<0. 03). 
Lower extremity thrombosis occurred in 10 (5. 9%) patients. Lower extremity 
DVT was ipsilateral to the side of transplant in 5 (50%) patients and was 
contralateral in 3 (30%). Two (20%) patients had a bilateral venous thrombosis. 
The mean time to lower extremity thrombosis was 90 days. Blood transfusion 
was a signifi cant risk factor in patients with lower extremity thrombosis (P < 
0. 04). 
Upper limb venous thrombosis occurred in 9 (6. 4%) patients. PICC line was 
inserted in 6/9 (66. 6%) patients who had upper limb thrombosis (P< 0. 01). 
The incidence of venous thrombosis was high in patients who had delayed 
graft function (DGF, P<0. 02), posttransplant blood transfusion (P<0. 01) or 
prolonged posttransplant hospital stay (P< 0. 0001). 
Conclusion: Recipient age and factors requiring blood transfusion, PICC lines, 
prolonged hospitalization and the occurrence of delayed graft function are high 
risks for venous thrombosis in kidney transplantation. Furthermore, upper limb 
thrombosis may be as prevalent as lower limb thrombosis. Minimization of 
these factors and use of appropriate antiplatelets may be of help in decreasing 
the incidence of venous thrombosis. 
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FATAL CATASTROPHIC ANTI-PHOSPHOLIPID 1554 
SYNDROME FOLLOWING RENAL TRANSPLANTATION
A-M. Craven1, S. Campbell1, D. Johnson1, N. Isbel1, C. Hawley1, 
V. Kanagarajah2, D. Mudge1, D. Nicol2, J. Preston2
1Department of Renal Medicine, Princess Alexandra Hospital, 2Department of 
Transplantation Surgery, Princess Alexandra Hospital
“Catastrophic Anti-phospholipid Syndrome” (CAPS) is a fulminant, often lethal 
form of the Anti-Phospholipid Syndrome fi rst defi ned in 1992. Characterised by 
arterial and venous thromboembolism in multiple organ beds, it has a mortality 
rate of almost 50%. The clinical picture is dominated by small vessel occlusions 
with rapid development of multi-organ failure, severe thrombocytopenia, 
haemolytic anaemia, disseminated intravascular coagulation and the systemic 
infl ammatory response syndrome, manifested as adult respiratory distress 
syndrome. We report on the development of CAPS in a patient in the days 
immediately following renal transplantation and the fatal outcome. 
Mr. H was a 64 year old aboriginal man from a rural area who presented to 
his nephrologist with end stage renal failure. Investigations at the time of 
presentation showed bilaterally small, echogenic kidneys on ultrasonography 
and nephrotic range proteinuria. He had a positive lupus anti-coagulant (LAC), 
but no known clinical thrombotic events. The cause of his renal failure was 
uncertain. A biopsy was not performed. He commenced on peritoneal dialysis 
and remained on this modality for two years prior to transplantation. 
At day 8 post living unrelated renal transplantation, the patient developed 
worsening renal impairment and thrombocytopaenia in the setting of a very 
high anticardiolipin antibody (ACLA) titre. Despite intravenous heparin, a 5 
day course of intravenous immunoglobulin and ongoing daily plasma exchange, 
the patient’s renal function continued to deteriorate. He became increasingly 
thrombocytopaenic, and had evidence of thrombo-embolic events in other 
organs with rapid atrial fi brillation and cardiac ischaemia, skin involvement 
and ultimately ARDS. He died 24 days post renal transplantation. His family 
declined an autopsy. 
Discussion: Although not proven with biopsy evidence, a diagnosis of 
CAPS in this case was made on the basis of thrombocytopaenia, markedly 
elevated ACLA and suspicion of thromboembolism in at least two organs. 
Several studies have shown an increased incidence of ACLA and LAC in 
patients with end stage renal disease compared with the general population. 
However the pathogenecity of these antibodies in the renal failure population 
remains unclear. To our knowledge this is the fi rst documented case of CAPS 
precipitated by organ transplantation. Consideration should be given to the use 
of prophylactic anti-coagulation in those patients with high antibody titres in 
the early post transplant period. 
POSTER BOARD NUMBER P2 – 355
AN UNUSUAL CAUSE OF ANURIA TEN YEARS AFTER 1555 
SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION
S. Nangia, E. Saad,
Medical College of Wisconsin
Case: A 48-year-old female underwent SKPT in 1997. Ten years later 
she presented with a three days history of nausea, vomiting, loose stool 
and anuria. She had base line serum creatinine of 1. 1mg/dl. On physical 
examination she was severely dehydrated, markedly hypotensive and had 
mild left lower quadrant abdominal pain. Her serum creatinine was 6. 2mg/
dl. Her pancreatic function was normal with the following levels: glucose 
93mg/dl and serum amylase 38mg/dl. A renal ultrasound scan showed 
mild pelvicaliectasis with no apparent change from a previous study two 
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years prior. Doppler sonography showed normal arterial waveforms. 
Patient was aggressively resuscitated with crystalloids. There was no 
improvement in her urine output. A renal biopsy was performed and did 
not show any signifi cant pathological changes. No rejection was evident 
on the biopsy. A CT scan of the transplanted kidney showed moderate 
degree of hydronephrosis and swelling around the kidney. An antegrade 
nephrostogram demonstrated a corkscrew like confi guration of the proximal 
ureter with neither opacifi cation of the more distal ureter nor the urinary 
bladder. A percutaneous nephrostomy tube was placed and a copious 
amount of urine returned. . The patient was taken to the operating room. 
At laparotomy the kidney was found twisted 180º around its pedicle. The 
torsion was straightened and a nephropexy of the kidney to the left colon 
and the anterior abdominal wall was performed. Post operatively her serum 
creatinine went down to 0. 9mg/dl and she was discharged from the hospital 
with excellent allograft function. 
Discussion: Renal transplant torsion around its pedicle is a rare technical 
complication of intraperitoneal renal transplantation. Intraperitoneal 
placement of SKPT is technically easier compared to extra peritoneal 
placement. However, intraperitoneal location allows more transplant mobility 
that increases the risk of torsion. One of the diagnostic diffi culties of renal 
torsion is its lack of specifi c clinical features. A high level of suspicion is 
needed to diagnose renal transplant torsion since it may mimic rejection, 
ureteric obstruction as well as venous thrombosis. Imaging studies play a 
crucial role in torsion diagnosis. Renal ultrasound is not as sensitive as CT 
scan in detecting this problem. Once the diagnosis is made, nephropexy 
to the anterior abdominal wall is indicated. Prophylactic nephropexy of 
intraperitoneally placed transplanted kidney is warranted to prevent torsion 
of the transplanted kidney. To our knowledge, this is the fi rst case of 
simultaneous kidney-pancreas transplant recipient who developed torsion of 
the transplanted kidney ten years after transplantation. 
Conclusion: Transplant torsion should be considered in the differential 
diagnosis of acute renal failure and anuria particularly in simultaneous kidney-
pancreas transplant recipients with intraperitoneal kidney. It is extremely 
important not to be committed to one diagnosis but rather explore other 
diagnoses especially if there is inadequate response to therapy or if additional 
data becomes available. 
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UNUSUAL CAUSE FOR TRANSPLANT URETERIC 1556 
OBSTRUCTION
T. Dighe, S. Shivde, J. Date, V. Gorde, P. Joshi
Deenanath Mangeshkar Hospital & Research Center, Erandawane, Pune, 
India
Introduction: Urological complications are the most common type of post-
transplant surgical problems. Transplant ureteral stenosis occurs in 3. 1–10. 
2% of patients after renal transplantation. The diagnosis is usually made by 
ultrasound and radiography with contrast media. Now a days most (95%) have 
been treated by percutaneous nephrostomy, with or without stenting. We here 
present a case where ureter was obstructed due to encasement in dense scar 
which did not responded to the PCN and antegrade stenting and has to be 
surgically explored. 
Case Report: A 24-year-old man underwent live related renal transplantation 
with mother as donor. 
Transplantation done one and half month back and was with uneventful 
recovery. He developed recurrent UTI and was treated with appropriate 
antibiotics. one month post transplant he presented with colicky pain over 
the right iliac fossa and decreased urine output. There was hydronephrosis of 
transplanted kidney on ultrasound. We elected to perform a transplant puncture 
for antegrade pyelography which showed lower ureteric stricture. It was dilated 
endoscopically followed by stent insertion. On follow up stent was removed 
but RGP showed again lower ureteric stricture. On open exploration he showed 
ureter incorporated in dense scar tissue which was released till the extravesical 
ureterocystostomy. The post-operative course was uneventful. Ultrasound 
showed no evidence of hydronephrosis and serum creatinine remained stable. 
Discussion: The most frequent urological complications include ureteral 
stenosis, urinary fi stula, renal artery stenosis and lymphocele formation. Most 
often these complications occur within 3 months after transplantation. Ureteral 
stenosis affects 3. 1–10. 2% of patients after transplantation]. Usual causes of 
ureteral stenosis are post-operative oedema, ureteral torsion or compression 
(e. g. from haematoma or lymphocele), and different implantation techniques. 
Endourological means to treat such situations are usually successful but due 
to uncommon etiology in our case we have to explore the patient to treat the 
situation. 
Conclusion: We here present a rare cause of obstruction in transplanted kidney 
which may not be treated by endourological means and needs exploration to 
treat it completely 
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EFFECTIVENESS OF PREOPERATIVE HYDROSTATIC 1557 
DILATATION OF CONTRACTED BLADDER FOR KIDNEY 
TRANSPLANTATION
J-H. Choi1, W-I. Park, J-M. Kong, J-H. Jeong
1Maryknoll Hospital, 2Maryknoll Hospital, 3Maryknoll Hospital, 4Maryknoll 
Hospital
Purpose: Chronic renal failure patients may have contracted bladder which 
is the result of disuse atrophy and fi brosis of bladder mucosa and muscle. 
Contracted bladder brings many diffi culties to conduct ureteroneocystostomy 
in kidney transplantation. So many authors have suggested that preoperative 
bladder augmentation using intestine and ureter etc. could have increased 
success rate in kidney transplantation. These methods, however, have been 
studied in pediatric transplantation in most cases and known to have many 
complications associated with medical and surgical treatments. Since the 
late 1960s, a hydrostatic dilatation of bladder used as a treatment in patients 
with urgency, urge incontinence, interstitial cystitis and bladder tumor. We 
applied this method to dilatate the bladder in recipients who had contracted 
ones. 
Methods: In our hospital, we did 462 kidney transplantations from August, 
1990 to December, 2007. Among them, we attemped the hydrostatic dilatation 
of bladder in 27 patients with contracted bladder less than 100cc in capacity. 
We inserted 18Fr-3 way Foley catheter and instilled 50-100cc normal saline 
gravitationally in 80cmH2O without any kinds of anesthesia. We repeated it 
from 5 to 10 times daily. We started this procedure to the patients 7 day before 
operation and ceased it at least 2 day before operation. 
Results: Predilatation volume ranged 60-100cc (average 86. 3cc) and 
postdilatation volume did 100-250cc (average 198. 2cc). There was no 
complication associated with hydrostatic dilatation of contracted bladder and 
ureteroneocystostomy. Double J catheter was not applied in our series. There 
was no loss of transplanted kidney. 
Conclusion: Our results suggest that pretransplant hydrostatic dilatation of 
contracted bladder can make ureteroneocystostomy more easier and increase 
success rate of kidney transplantation. 
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URETEROSCOPIC MANAGEMENT OF UROLOGICAL 1558 
COMPLICATIONS AFTER RENAL TRANSPLANTATION
M. Nikoobakht, A.R. Mehrsai, G.R. Pourmand, M.R. Taherimahmoudi
Urologu Research Center, Tehran University of Medical Sciences
Purpose: To determine the feasibility, safety, and effi cacy of diagnostic and 
therapeutic ureteroscopy in renal allograft ureters. 
Materials and Methods: We reviewed 1560 consecutive renal allograft 
performed between June 1989 and February 2002. Of these, 28 patients (1. 8%) 
had indications for endoscopic procedure of the allograft ureter. Six patients 
had obstructive ureteral calculi with a history of failed ESWL, 3 had suspected 
ureteral strictures, nine had upward migrated ureteral stents and 10 had ureteral 
stricture at ureteroneocystostomy sites. The ureters have been anastomosed to 
the bldder using the leadbetter politano (6) and lich – GreGoire (22) methods 
of the ureteric implantation. 
Ureteroscopies were performed with semirigid 9. 8F wolf ureteroscope. 
Results: Identifying and cannulating the transplant ureteral orifi ce was 
successful in 19 (68%). Four of the ureteral calculi (67%) were removed with 
ureteroscope. Seven of the migrated stent (78%) were retrieved. Four of the 
patients with ureteral strictures (40%) had successful ureteral dilatation and 
a double J ureteral catheter insertion. Diagnostic ureteroscopy was successful 
in all cases. 
TU
ES
D
AY
 
Tuesday 12 August 2008 Poster Abstracts
5 2 0 Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Complications were one urinary leakage and one symptomatic urinary tract 
infection. 
Conclusion: Transplant ureteral endoscopy was safe and effective for 
the management of urological complication after renal transplantation. 
Ureteroscopy is technically demanding in these patients. One should consider 
ureteroscopy as an alternative to percutaneous and antegrade modalities, as 
these methods carry signifi cant morbidity. 
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MANAGEMENT OF URETERAL UROLOGIC 1559 
COMPLICATIONS: EXPERIENCE AFTER 700 KIDNEY 
TRANSPLANTATION
M. Taherimahmoudi, G. Pourmand, A. Mehrsai, M. Nikoobakht
Urology Research Center, Tehran University of Medical Sciences, Tehran, 
Iran
Objectives: To evaluate the incidence, diagnosis, management, surgical 
technique, outcome and risk factors of ureteric urologic complications after 
kidney transplantation. 
Materials and Methods: Since 1989-2002, among 700 kidney transplanted 
patients, 200 patients were successfully completely followed up for 1-13 
years, by clinical examination, graft sonographic study, biochemical and if 
indicated isotope scanning of the renal graft (DTPA scanning). All transplanted 
ureters were stented and received the same immunosuppressive protocol as 
routine. Those who proved to have ureteral complications were fi rst referred 
for endourologic intervention, and if failed referred for surgical repair. This 
study didn`t included extra ureteral obstructive cause, like lymphocele or other 
pelvic collections. 
Results: 14 among 200 patients (7%), were developed ureteric complications. 
M/F ratio =10/4. ureter stenosis (6), ureteric fi stulae (5) and ureter obstruction 
(3). All of them initially treated by percutaneous nephrostomy (PNS) and if were 
possible antegrade JJ stenting. Those who failed conservative approach, were 
referred for surgical intervention (10 patients = 3 ureter obstruction + 4 stenosis+ 
3 fi stulae). (3) cases managed by Boari`s fl ap, (3) by ureteroureterostomy 
with native ureter, (3) by pyeloureterostomy with native ureter and (1) by 
ureteroneocystostomy. One case failed to respond (ureteroureterostomy) and 
was managed with proper outcome by Boari`s fl ap. Among 14 patients, 10 
were diabetics, 12 had previous history of CMV infection and 5 had acute 
rejection episodes. 
Conclusion: Post kidney transplantation ureteral complications are easily 
diagnosed and can conservatively manage by expertise radiologists. Those 
with prolonged DM, previous acute rejections and/or CMV infection, are better 
to be referred to surgical repair using native ureters. 
POSTER BOARD NUMBER P2 – 360
CONSERVATIVE SURGERY IN RENAL CELL 1560 
CARCINOMA IN TRANSPLANTED KIDNEYS
J.A. Pereira, J.R. Andrade, L.C. Pinheiro, A. Pena, A. Martins, E. Barroso
Curry Cabral – Hospital
The frequency of malignancy in organ transplant recepients is estimated 
to be 100 times higher than that in genaral population. The transplant 
patiens have an incidence 15 times higher of renal cell carcinoma than the 
general population. 
We present two clinical cases of renal carcinomas in transplanted kidneys. 
Diagnosis were made in 15 and 19 years post-transplant by routine 
ultrasonography. the tumors are unifocal with 45mm and 15mm capsulated 
and low stage (t1). The resection of the mass (nephron-sparing surgery)and of 
a layer of the tissue surrounding the tumour was perfomed, without vascular 
controle or hypothermia. 12 months after surgery the patients are alive, without 
disease recurrence and with good renal function. 
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UROLOGICAL COMPLICATIONS IN RENAL 1561 
TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 10 
YEARS. 
M. Aragon1, B. Aguilar, R. Mondragon, R. Bernal
1Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico 
ISSEMyM, 4Centro Medico ISSEMyM
Introduction: Urological complications are a cause of graft loss or morbidity 
in 2 to 20% patients. 
Aim: : The purpose of this study was to review the incidence and management 
of all urological complication in our center. 
Patients and Methods: A retrospective study of the hospital charts of 176 
consecutive transplanted patients was performed in order to analyze the 
ureteral complications and their management. Between August of 1983 to 
October of 2007, 176 renal transplantations were performed at the Centro 
Medico ISSEMYM. The ureter from the kidney graft was inserted into the 
bladder according to the technique of extravesical implantation described by 
Lich-Gregoir, and based in the criteria of the surgeon the insertion of a transient 
ureteral stent in 90% of the patients. 
Results: Urological complications occurred in 9/176 renal transplantations 
(5%). Anastomotic urine leakage was the most frequent, follow by ureteral 
estenosis. The mean time to appearance of these complications was 6 months. 
All cases were managed surgically. The most frequent surgical repair was 
ureterovesical reimplantation (n=8), ureteroureteral end-to-end anastomosis 
(native ureter-ureter transplant, n=1). The insertion of the transient ureteral 
stent was no related to infectious complications. No mortality related to any of 
the urological complications were reported. 
Conclusion: The rate of complications observed in this retrospective analysis 
is similar to the experience of other studies. If the classical extravesical ureteral 
bladder implantation is to remain an attractive technique due to its simplicity, 
the surgical team at the training center should be aware of all the means to 
prevent any ureteral complications, such as the choice of another implantation 
technique and/or insertion of a transient ureteral stent. 
POSTER BOARD NUMBER P2 – 362
UROLOGICAL COMPLICATIONS AFTER KIDNEY 1562 
TRANSPLANTATION: EXPERIENCE OF OVER 1000 
TRANSPLANTS
A. Faenza1, M. Tsivian1, R. Bertelli1, F. Neri1, G. Cavallari1, B. Nardo1, G. 
Fuga1, S. Stefoni2
1Transplant Center of Bologna, University of Bologna, Italy, 2Dept. of 
Nephrology, Dialysis and Transplantation, University of Bologna, Italy
Introduction: Urinary fi stulas and stenoses are the most common complications 
after kidney transplantation that may require surgical revision. 
The aim of this study is to assess retrospectively the incidence of and risk factors 
for early (within 30 days) or late major urological complications (stenoses and 
fi stulas) after kidney transplantation in the experience of the transplant center of 
Bologna. 
Methods: The study population comprised 1142 consecutive patients who 
underwent kidney transplantation between January 1990 and September 2007. 
End points considered were early and late urological complications (stenoses 
and fi stulas). The variables considered in multivariate and univariate analyses 
were: recipient’s age, sex, etiology of renal failure, number and type of kidney 
transplant (fi rst/second and single/double/combined with other organs), cold 
ischemia time, type of urinary reconstruction (uretero-cystostomy vs uretero-
ureterostomy), stent positioning, donor’s cause of death, sex, age, serum 
creatinine and clearance, presence of graft polar arteries, acute rejection and 
post-operative graft function. 
Results: Out of 1142 transplants 100 (8. 7%) patients experienced 107 
urological complications: 85 (79. 4%) early (56 fi stulas, 29 stenoses) and 22 
(20. 5%) late (7 fi stulas and 15 stenoses). 
Multivariate analysis for all complications revealed signifi cant association 
with male sex of the recipient (p=0. 00, HR=2) while fi rst kidney transplant 
was protective (p=0. 00, HR=0. 4). Male gender both of the recipient and of 
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the donor was signifi cantly associated with early fi stulas (p=0. 01, HR=2. 5 
and p=0. 02, HR=2, respectively). First (vs second) kidney transplantation had 
a protective effect on early stenoses (p=0. 01, HR=0. 27). Late fi stulas were 
associated with anastomosis stenting (p=0. 03) in a univariate analysis but non 
in a multivariate one. Multivariate analysis for late stenoses did not demonstrate 
any signifi cant association with the considered variables; however the late 
stenoses cases had a signifi cantly higher recipient and donor age (p<0. 05) and 
a lower donor creatinine clearance (p<0. 05). Other parameters considered did 
not reach statistical signifi cance. 
Discussion: In our experience the incidence of urinary complications have 
not decreased in the last years and remains a major issue in kidney transplant 
recipients. In this study, the type of urinary anastomosis, stenting, cold 
ischemia time, presence of polar arterial branches and type of transplant 
did not infl uence the incidence of urinary fi stulas and stenoses. Our data 
confi rm that older recipients and organs from older donors, especially of male 
gender, and re-transplants are to be considered risk factors for urological 
complications. The present analysis cannot suggest any modifi cation of the 
actual surgical strategy in order to prevent urological complications in kidney 
transplantation. 
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DIFFERENT RISK FACTORS ARE ASSOCIATED 1563 
TO DIFFEENT ANATOMICAL LOCALIZATION OF 
URINARY TRACT LEAKS AND STENOSES AFTER KIDNEY 
TRANSPLANTATION
J. Pascual1, F.J. Burgos2, J. Zamora3, A. Muriel3, N. Plana3
1Servicio de Nefrología, Hospital Ramón Y Cajal, 2Servicio de Urología. 
Hospital Ramón y Cajal, 3Unidad de Bioestadística, Hospital Ramón y Cajal
The different pathophysiology underlying the appearance of ureteral and 
ureterovesical junction leaks and ureteral or pyeloureteral stenoses after 
kidney transplantation (KT) may support different risk factor profi les for each 
anatomical localization. Ureter ischemia and anastomotic problems, specially 
healing problems may be respectively the main underlying processes in the 
two groups of leaks. We have tested this hypothesis in 1341 adult isolated 
KT performed in 26 Spanish units during 2004 and followed-up for 1 year. 
Mean donor age was 48. 4±17. 3 years, 97. 2% were deceased donors, mean 
recipient age was 51. 1±13. 5 years, 59% were males, mean BMI was 25. 
3 kg/m2, peak PRA was 8. 5±19. 9%, time on dialysis had been 33. 5±36. 
1 months and 13. 4% were retransplantations. Immunosuppression included 
steroids (99%), MMF (92%), Tacrolimus (66%), CsA (18%), and sirolimus 
(9%). Double J ureteral stent was used in 35% of cases for a mean of 21 
days. Delayed graft function was observed in 37. 4%, acute rejection in 16. 
5% and graft loss in 8. 6% and death in 3%. Urinary leaks developed in 5. 
7% and urinary stenosis in 5. 5%. The leaks were localized in the ureter in 
4. 4% and in the ureterovesical anastomosis in 1. 3%. In the multivariate 
logistic regression analysis, ureteral leak was associated with donor age (OR 
1. 027, p=0. 004), the absence of double J stent (OR 0. 455 if used, p=0. 
023), and the use of cyclosporine as opposed to tacrolimus (OR 2. 058, p=0. 
02). Bladder leaks were associated again to the absence of double J stent 
(OR 0. 250 if used, p=0. 06) and the use of sirolimus (OR 3. 53, p=0. 019). 
Regarding stenoses, ureteral ones were associated to donor age (OR 1. 04, 
p=0. 0001), warm ischemia time (OR 1. 016, p=0. 03), and direct ureteral 
reimplantation (OR 2. 67, p=0. 012). The use of ureteral stent also protected 
against pyeloureteral stenosis (OR 0. 288, p=0. 046), but had no effect on 
ureteral stenoses. 
Ureteral leaks and stenosis, of ischemic origin, develop more frequently 
with advanced age kidneys. Other pro-ischemic factors such as the use of 
cyclosporine or prolonged warm ischemia time are also related with ureteral 
leaks and stenoses respectively. Contrarily, bladder leaks are more related with 
the wound healing problems promoted by sirolimus. The use of ureteral stent 
prevents both types. 
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UROLOGICAL COMPLICATIONS OF RENAL 1564 
TRANSPLANT IN A LIVE RELATED TRANSPLANT 
PROGRAMME AT SIUT
A. Rizvi, A. Hashmi, H. Askari, M. Hussain, A.S. Hasan, A. Naqvi
Sindh Institute of Urology And Transplantation
Introduction: The incidence of urological complications after kidney 
transplant ranges from 3 to 14%. Some of these are so severe that they end up 
in graft loss. The main objective of this study is to review retrospectively the 
urological complications in living related kidney transplants. 
Patients and Methods: It is a retrospective study of renal transplantation 
which was done at SIUT between November 1985 and August 2005. All the 
urological complications encountered were recorded. Ultrasonography, renal 
scintigraphy, antegrade pyelography, CT scan and MR angiography were the 
main diagnostic tools. 
Results: 1448 patients were transplanted during this period. Out of these 97 
(6. 7%) patients had developed urological complications like urinary fi stulae 
in 21 (1. 5%) patients, distal ureteral necrosis in 5 (0. 4%) patients, ureteral 
stenosis in 13 (0. 95) patients, renal calculi in 2 patients while 3 had ureteric 
calculi, symptomatic vesico-ureteric refl ux in 13 (0. 9%) patients, lymphocele 
requiring intervention in 35 (2. 5%) patients and bladder outlet obstruction 
in 5 (0. 4%) patients. All complications were treated either conservatively or 
surgically. No graft or patient was lost due to urological complications. 
Conclusion: Many complications may occur after kidney transplant. Prompt 
diagnosis with high index of suspicion and a combination of endourological 
and open reconstructive techniques may play a major role in minimizing 
urological complications. 
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LACK OF VARIATION IN SERUM CREATININE 1565 
VALUES BETWEEN CENTRAL STUDY LABORATORY AND 
CLEVELAND CLINIC IN KIDNEY TRANSPLANT RECIPIENTS
K.C. Mange1, H. Tedesco2, T. Johnston2, G. Zibari2, Y. Li1 Z. Wang1. 
1Novartis Pharmaceuticals, East Hanover, NJ, United States and 2On behalf 
of the A2309Study Group. 
Background: Recalibration of laboratory serum creatinine assays to the 
Cleveland Clinic laboratory standard may improve the accuracy of GFR 
estimation using the abbreviated MDRD equation. It is unknown what value, if 
any, this may have for kidney transplantation. 
Methods: RAD001A2309 is a 24-month, multicenter, randomized, open-
label study of the effi cacy and safety of concentration-controlled everolimus 
with reduced-exposure cyclosporine microemulsion (CsA-ME, Neoral) vs 
enteric-coated mycophenolate sodium (myfortic) with standard-exposure 
CsA-ME in 833 de novo renal transplant recipients. Blood samples from 
469 enrolled subjects were selected from the studys central laboratory that 
were representative of the distribution of serum creatinine at any timepoint. 
These residual samples were sent to the Cleveland Clinic Laboratory, which 
was blinded to the serum creatinine values recorded by the central laboratory. 
Treatment assignment remains blinded to the clinical team and data were 
pooled across treatment groups. 
Results: 464 residual blood samples were available from the 469 selected 
subjects. There was a mean difference in serum creatinine of 0. 835mg/dL 
between the laboratories) (lower for the central laboratory versus the Cleveland 
Clinic Laboratory), equivalent to a mean difference in eGFR that was 0. 186mL/
min/1. 73m2 lower for the central laboratory. 
Conclusions: 1) The RAD001A2309 central laboratory has, on average, 
little variation in serum creatinine from the Cleveland Clinic laboratory, with 
differences being clinically irrelevant; 2) The level of variation will need to 
be explored across different NKF categories of chronic kidney disease to 
determine if the lack of difference is maintained over the full range of renal 
function. 
Serum Creatinine 
(mg/dL)
Cleveland Clinic (CC) 
Value
Central Lab (CL) Value Difference (CC value 
CL value)
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Minimum 0. 300 0. 622 -0. 322
Median (50%) 2. 980 3. 083 -0. 103
Maximum 18. 450 16. 923 1. 527
Mean 3. 790 3. 802 -0. 012
Std Deviation 3. 091 2. 979 0. 112
95% CI for Mean [3. 507, 4. 072] [3. 530, 4. 074]  
eGFR mL/min/1. 73m2    
Minimum 3. 370 3. 300 0. 070
Median (50%) 23. 785 22. 750 1. 035
Maximum 348. 350 137. 500 210. 850
Mean 34. 478 33. 643 0. 835
Std Deviation 31. 400 27. 895 3. 505
95% CI for Mean [31. 613, 37. 342]
[31. 098, 36. 
188]  
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10 YEARS SINGLE CENTER EXPERIENCE IN KIDNEY 1566 
TRANSPLANTATION CHALANGED BY ABNORMAL GRAFT 
VASCULAR ANATOMY
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, B. Stefan, 
D. Tacu, E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni 
Clinical Institute
Purpose: The aim of this study was to evaluate 10 years transplant experience, 
using normal pedicle kidney and borderline vascular graft. 
Material and Methods: From June 1997 until March 2008, 855 renal 
transplantations (710 living and 145 cadaver, 807 adults and 48 pediatric 
transplants) have been performed in our center, with an average of 81/year 
(116 in 2007). In all cases, general preoperative evaluation, immunological 
and vascular anatomy study was performed. Standard minimal lombotomy 
nephrectomy technique was preferred. 266 cases (31%) had vascular graft 
anomalies, 165 abnormal arteries and 101 abnormal veins. 
Results: No major complications appeared in 710 nephrectomies. Minor 
complications were: renal artery spasm, bleeding, minor respiratory 
complication, pneumothorax, illeus, bladder voiding problems, UTI. Long-
term complications were: persistent wound pain, parestezia and wound hernia. 
Quality of life after surgery was assessed using SF 36 Health Survey Test and it 
was normal. Special anastomotic techniques were used as followed: double T-T 
anastomosis – 96 cases, T-L anastomosis – 9 cases (cadaver donors), combined 
anastomosis – 3 cases; single trunk made by two branches – 27 cases and we 
used the epigastric artery in 4 cases. 26 minor aberrant vessels were excluded, 
feeding a minor area of parenchyma. Cava patch was used in 32 cases (11 
from cadaver donors). Abnormal venous drainage was managed by classical 
T-L anastomosis to the external iliac vein. Graft function was 96% – one year, 
84% – 5 years and 80% – 10 years. 
Conclusions: General evaluation, immunological and renal pedicle 
assessment was a must. The living donor nephrectomy respected in our 
center the international accepted morbidity. No major complication appeared. 
Mortality was 0. Vascular anomalies of renal pedicle were founded in 31% but 
transplantation was performed due to special anastomotic techniques which 
did not signifi cantly increase the ischemia time and vascular complications. 
Accepting the borderline vascular donor the number of transplantation could 
increase with 30%. 
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COLONIC PERFORATIONS AFTER RENAL 1567 
TRANSPLANTATION: RISK FACTORS ANALYSIS. 
A. Faenza, F. Catena, L. Ansaloni, L. D’Alessandro, R. Bertelli, A. Pinna
St Orsola- Malpighi University Hospital
Background: Perforation of the colon is a rare and dramatic complication in kidney 
transplanted patients (high risk population for end-stage renal failure, maintenance 
therapy with dialysis before transplantation and chronic immunosuppression) 
Methods: 1651 consecutive renal transplants performed between 1976 and 
2007 at the St Orsola- Malpighi University Hospital, Bologna, ITALY. 
21 recipients (1. 2 percent) experienced 21 episodes of colonic perforations, 7 
of which (33. 3 percent) were fatal. The medical records and clinic charts of 
each person were analyzed for variables between those who survived and those 
who died of the colon perforation. 
Results: Signifi cant differences in patients characteristics, laboratory fi ndings, 
mean corticosteroid dose, and nutritional status were noted between the two 
groups. 
Early diagnosis and intervention improved the prognosis; 18. 1% (2 out 11) 
of those operated on within 24 hours died; 50% (5 out 10) died after delayed 
intervention. (p< 0. 05). 
Excision of the lesion with end- ileostomy + transverse colon mucous fi stula (right 
colon perforations) or end-colostomy plus sigmoid colon mucous fi stula (left 
colon perforations) were performed. The incidence and outcome of posttransplant 
colonic perforations were associated with the intensity of immunosuppression. 
Conclusions: Colon perforation is a dramatic complication in immunosuppressed 
renal transplant recipients. Prompt diagnosis and treatment are critical; a high 
index of suspicion, urgent investigation, prompt surgical intervention and 
attention to the nutritional status are essential for survival. 
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IMPACT OF EARLY ADVERSE EVENTS ON 1568 
KIDNEY GRAFT SURVIVAL IN THE MODERN ERA OF 
TRANSPLANTATION
C. Süsal, B. Döhler, M. Sadeghi, J. Ovens, G. Opelz
Dept. of Transplantation Immunology, Univ. of Heidelberg
Abstract Document: In a prospective multi-center study, in which 23 centers 
are participating, we are examining the impact of serum factors on graft outcome. 
We also collect information on clinical events that occur during the early phase 
after transplantation. Here we analyzed the association of early adverse events 
with graft survival. All transplantations were performed after 2001. 
Altogether, 1437 patients were studied. Primary non-function during the fi rst 
24 hours was reported in 314 patients, acute tubular necrosis (ATN) in 360 
patients, an acute rejection episode during the fi rst 3 months in 285 patients, 
and an infection during the fi rst 3 months in 181 patients. 
Recipients with primary non-function, ATN, or acute rejection showed 3-year graft 
survival rates (± standard error) of 79±3%, 81±2%, and 81±3%, respectively. These 
rates were signifi cantly lower than the 93±1%, 94±1%, and 92±1% rates found in 
1117 patients with primary function, 1067 patients without ATN, and 1131 patients 
without rejection, respectively (log rank p<0. 001 for all 3 comparisons). The 3-year 
graft survival rate in 80 patients without primary function who also experienced 
an acute rejection during the fi rst 3 months was a poor 67±7%, as compared to a 
95±1% rate in 904 patients with primary function and without acute rejection (p<0. 
001). Importantly, however, neither primary non-function nor early rejections or 
ATN had an impact on 3-year graft survival if good graft function with a serum 
creatinine of <130 umol/L was observed at the end of the 3rd month (>94% 3-year 
graft survival for all three adverse events). Infection during the fi rst 3 months also 
had a signifi cant impact on 3-year graft survival (with infection: 86±3% vs. without 
92±2%, p=0. 024). A remarkable 3-year graft survival rate of 97±1% was observed 
in 386 patients in whom none of the 4 early adverse events were reported. 
Our results indicate that, even in the modern era of transplantation, prevention, 
early diagnosis, and consequent treatment of early adversary events, such as 
primary non-function, ATN, rejection, and infection, are of great importance 
for good outcome. 
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VACUUM-ASSISTED CLOSURE THERAPY (VACT) IN 1569 
THE MANAGEMENT OF WOUND INFECTION FOLLOWING 
RENAL TRANSPLANTATION: A SINGLE CENTRE 
EXPERIENCE
I. Butt, V.C. Nathan, M.S. Delbridge, D. Throssell, W.S. McKane, 
A.T. Raftery, B.M. Shrestha
Sheffi eld Kidney Institute, Herries Road, Sheffi eld, S57AU, UK
Introduction: Wound infection in the setting of an immunosuppressed state 
such as after renal transplantation (RT) causes signifi cant morbidity from 
sepsis, prolongs hospital stay and is expensive. Vacuum-assisted closure therapy 
(VACT) is a new technique of management of wound based on the principle of 
application of controlled negative pressure. The aim of this study was to assess 
the effi cacy of VACT in the management of wound infection following RT. 
Methods: This is a prospective study of a cohort of 237 consecutive RTs 
performed over a period of 5 years, where the data were retrieved from a 
prospectively maintained computerised database and case-notes. 
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Results: 11 of 250 (4. 4%) patients developed deep wound infection following 
RT leading to cavitations and dehiscence with copious discharge, which 
refused to heal with conventional treatment. All 11 cases were treated with 
VACT. The VACT system was removed after a median of 9 (range 3-120) days 
when discharge from the wound ceased. Six patients were discharged home 
with portable VACT device and managed on an outpatient basis, where the 
system was removed after a median of 7 days (range 3-116) days. The median 
hospital stay after initiation of VACT was signifi cantly shorter (4, range 2-12 
days) than on conventional treatment prior to VACT (11, range, 5-20 days). 
Complete healing was achieved in all cases. No complications related to VACT 
such as haemorrhage and intestinal fi stulae were observed in this series. 
Conclusions: The use of VACT is an effective and safe adjunct to conventional 
and established treatment modalities for the management of deep wound 
infection and dehiscence following RT. 
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INFECTIOUS AND NONINFECTIOUS SURGICAL WOUND 1570 
COMPLICATIONS AFTER KIDNEY TRANSPLANTATION (KT) 
IN ADULTS: A MULTICENTER RISK FACTOR ANALYSIS
J. Pascual1, F.J. Burgos2, J. Zamora3, A. Muriel3, N. Plana3
1Servicio De Nefrología, Hospital Ramón Y Cajal, 2Servicio de Urología, 
Hospital Ramón y Cajal, 3Unidad de Bioestadística, Hospital Ramón y Cajal 
The surgical complication profi le after KT is being modifi ed by the increasing 
donor and recipient age and co-morbidity, and the use of anti-proliferative 
immunosuppressive drugs that alter tissue healing. To assess prevalence and risk 
factors for such complications, we have performed an observational study in 26 
units including patients who received a KT during 2004 and were followed-up for 
1 year (n=1434). Multiple organ transplants (n=41) and patients with insuffi cient 
data (n=52) were excluded, so the fi nal studied population comprised 1341 
KTs, including 16 double KTs. We classifi ed wound complications in I) non-
infectious, two subgroups (a) not-requiring surgical repair, supra-aponeurotic 
and (b) requiring surgical repair, dehiscence or incisional hernia; II) infectious, 
either superfi cial or deep infra-aponeurotic. Mean donor age was 48. 4±17. 3 
years, 97. 2% were deceased donors, mean recipient age was 51. 1±13. 5 years, 
59% were males and 13. 4% retransplantations. Initial immunosuppression 
included tacrolimus (66%), CsA (18%), or sirolimus (9%). Overall wound 
complications developed in 10. 8% of patients: 6% had non-infectious wound 
problems (3. 5% did not require surgical repair and 2. 5% required it), and 4. 
8% wound infections. In the multivariate logistic regression analysis, detected 
risk factors for a non-infectious wound problem not requiring surgery were short 
height (OR 0. 96, p=0. 006) and treated acute rejection (OR 2. 41, p=0. 01). For 
those requiring surgical repair: recipient age (OR 1. 07, p=0. 004), body mass 
index [BMI] (OR 1. 04, p=0. 021), warm ischemia time (OR 1. 03, p=0. 002). 
For wound infection: donor age (OR 1. 032, p=0. 002), peak PRA (1. 016, p=0. 
003), use of sirolimus (OR 2. 44, p=0. 019), treated acute rejection (OR 2. 16, 
p=0. 016) and delayed graft function (OR 1. 92, p=0. 027). 
In the investigation of risk factors for wound complications it is important 
to distinguish those not requiring surgical repair from those requiring it, 
and analysing separately wound infections. In this Spanish large series, 
sirolimus use increases wound infections, but does not increase non-infectious 
complications. Advanced donor and recipient age and obesity are the other 
signifi cant factors, with different impacts in each subgroup. 
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SYMPTOMATIC LYMPHOCELES AFTER KIDNEY 1571 
TRANSPLANTATION – MULTIVARIATE ANALYSIS OF 
RISK FACTORS AND OUTCOME AFTER LAPAROSCOPIC 
FENESTRATION
A. Pascher1, F. Ulrich1, S. Weiss1, S. Kohler1, S. Tullius2, P. Reinke3, 
P. Neuhaus1, J. Pratschke1
1Dept. of Visceral And Transplant Surgery, Charité, Campus Virchow, Berlin, 
Germany, 2Division of Transplant Surgery, Brigham and Women’s Hospital, 
Boston, United States, 3Dept. of Nephrology, Charité, Campus Virchow, 
Berlin, Germany
Introduction: Lymphocele formation is a common complication after kidney 
transplantation. The aim of this study was the analysis of incidence, risk factors 
and treatment outcome. 
Methods: In a retrospective study we analyzed 426 patients who underwent 
kidney transplantation between January 2002 and December 2006. After 
basiliximab induction recipients received triple immunosuppressive therapy 
with either tacrolimus or cyclosporine combined with mycophenolate mofetil 
and methyiprednisone. Patients were analyzed for donor factors, incidence and 
symptoms of lymphocele, demographic and clinical variables and treatment 
outcome. Statistical analysis was performed with Fishers exact or chi-squared 
test, ANOVA or Mann-Whitney U test, univariate analysis and the multivariate 
Cox proportional regression model. 
Results: The incidence of lymphocele was 9, 85% (n=42) in our population. 
Patients with lymphocele were older and had a higher BMI. There was no 
signifi cant difference in donor characteristics. Diabetes, acute rejection 
episodes and tacrolimus therapy were signifi cant risk factors in univariate 
analysis. After multivariate testing only diabetes confi rmed its signifi cance. 
Laparoscopic fenestration was performed in 24 patients with a mean 
lymphocele size of 7, 8±2, 9 cm. Creatinine levels at the day of lymphocele 
diagnosis were signifi cantly higher in patients with lymphocele treated 
surgically (3, 2±0, 7 vs. 1, 7±0, 6 mg/dl), whereas albumin levels were 
signifi cantly decreased (2, 7±0, 2 vs. 1, 6±0, 5 g/dl). Both parameters 
returned to a range comparable to other patients at the end of treatment. 
Two patients presented with a recurrence after fenestration and underwent 
a secondlaparoscopic procedure. All other patients were treated successfully 
without additionalmorbidity. 
Conclusion: Diabetes is a major risk factor for lymphoceles after kidney 
transplantation, while acute rejection episodes and tacrolimus use play a minor 
role. An increase of creatinine and decrease of albumin serum levels might be 
able to indicate lymphocele formation. Laparoscopic fenestration is a safe and 
effective treatment option. 
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SURGEON YURII VORONOY (1895-1961) – A PIONEER 1572 
IN THE HISTORY OF THE CLINICAL TRANSPLANTOLOGY: 
IN MEMORIAM AND ON THE 75TH ANNIVERSARY OF THE 
FIRST HUMAN KIDNEY ALLOGRAFT
E. Matevossian1, D. Doll2, Y. Snopok3, J. Nährig4, S. Thorban5, 
M. Nichitailo6
1Department of Surgery, Transplantation, Technical University of Munich, 
2Department of Surgery, Transplantation, Technical University of Munich, 
3National institute of Transplantology, Academy of Medical Sciences, Kiev, 
Ukraine, 4Institute of Pathology, Transplantation, Technical University of 
Munich, 5Department of Surgery, Transplantation, Technical University of 
Munich, 6National institute of Transplantology, Academy of Medical Sciences, 
Kiev, Ukraine
Objective/Aim: Organ transplantation plays a common and important 
part in the clinical medicine of today and is an effective cure in most of 
organ failures occuring. Its´ history and development has been a stony and 
challenging path. After pioneeristic experimental works done by Jaboulay 
and Carrel in Lion an the beginning of the XX century. In 1933, a Soviet 
surgeon Yurii Voronoy (Kherson, Ukraine) performed as pioneer the fi rst 
human allograft transplantation of cadaveric kidney, using 6 hr anoxic 
kidneys to be reimplanted into the medial thigh. In the classic account by 
David Hume of the pioneer kidney transplants done in Boston, he gave 
credit to the surgeon Voronoy, as being the fi rst to perform an allograft 
kidney transplant upon a human being. The aim of this historical overwiew 
article was to descript, what is known of this history and can now be 
reviewed. 
Results: In spit of this priorithy in human kidney transplantation, the life and 
works of Voronoy have attracted little attention in the Western hemisphere. 
The original article of Voronoy`s fi rst kidney transplantation published in the 
Spanish journal is brief in its account of the transplantation, but more detail 
of this case was given in a recent Soviet review. Our article shows that not 
only had Voronoy carried out a fi rst human kidney transplant from a cadaver, 
but also that he had some insight into the immunologic characteristics of graft 
rejection. 
Conclusion: These milestones of organ transplantation associated to the 
broadening of knowledge in the fi eld of surgical technique, preservation of 
allografts and immunological aspects of acute rejection. Thus, Voronoy has a 
major place in the history of transplantation and the specialy history of human 
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kidney allograft. In addition to his pioneering fi rst kidney allograft operation 
upon a human being, which has been briefl y noted in the literature of the 
Western world. 
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BOWEL OBSTRUCTION CAUSED BY SCLEROSING 1573 
PERITONITIS OCCURED AFTER A KIDNEY 
TRANSPLANTATION: TWO CASE-REPORTS. 
H. Skhiri, T. Dalel, J. lamia, H. Kamel, F. Mouna, A. Sabra, B. Samia, 
F. Ameur, B. Nasr, E. Mezri
Tunisian Nephrology Society
Sclerosing peritonitis (SP) is a serious complication of chronic ambulatory 
peritoneal dialysis (CAPD). It’s carecterized by thickening of peritoneum 
that can enclse some or all of the small or large bowel. The most common 
complication of SP is the partial or complete bowel obstruction. 
We report two cases of bowel obstruction due to SP following long-term CAPD 
and that have both occurred after a kidney transplantation. 
1est case: occlusif syndrom that has occurred 3months after kidney 
transplantation and in which the patient was in CAPD for 5 years than in 
hemodialysis for 3 years. Diagnosis was a ileo-colic invagination
2sd case : occlusif syndrom that has occurred 4months after kidney 
transplantation and in which the patient was in CAPD for2 years;diagnosis was 
a volvulus of grele intestine. 
Eventheless it was described a recovery of gastrointestinal function after renal 
transplantation in a patient with sclerosing peritonitis secondary to continuous 
ambulatory peritoneal dialysis due to immunosuppressive agents used after 
kidney transplantation. 
POSTER BOARD NUMBER P2 – 374
LONG-TERM NUTRITIONAL INTERVENTION OF 1574 
POST TRANSPLANT PATIENTS – VISCERAL PROTEIN, 
BIO IMPEDANCE ANALYSIS (BIA), AND CLINICAL: AN 
OVERVIEW. 
V. Jaynthi, N. Vijayashree, G. Abraham, 
Department of Nutrition and Dietetics, Madras Medical Mission, Chennai, India
Introduction: Assessment of the patient’s nutritional status enables the clinician and 
dietitian to identify those at nutritional risk. Appropriate techniques of nutritional 
assessment can detect nutritional defi ciency in the early stage of development in 
renal transplant recipient so that appropriate nutrition can be given. BIA and DEXA 
scan are commonly used technique to assess nutritional status of renal transplant 
recipients. The present study was undertaken to correlate the biochemical parameters 
and Bioimpedence Impedance Analysis among post-renal transplant Patients. 
Methodology: 138 post-renal transplant patients (66. 67% Diabetic, 53% 
Hypertensive, 88% Nonvegeterians, 22% vegetarians) were randomly selected 
and their BIA and bio chemical parameters, clinical status were analyzed. 
Results: The mean value of visceral protein was found to be less among the 
selected population (Albumin-3. 1 g/dl, Total Protein-%. 27g/dl). Calcium 
found to be 8. 2 mg/dl. The mean Hemoglobin levels were 8. 2 g/dl. The lipid 
profi le analyzed showed normal mean values of total cholestrol-140. 3 mg/dl, 
Triglycerides-90mg/dl, HDL-42mg/dl, LDL-80. 3 mg/dl respectively. 
The average BMI of the Selected patients was 22. 7, in which 39% were over 
weight with the average of 28. 4 and 15% were underweight with average BMI 
of 17. 2. From the BIA it was identifi ed that 68. 2% of the patients were having 
higher percentage of body fat (mean-32. 83%). The percentage of patients who 
were having lesser fat percentage was 15. 9%. While assessing the Total Body 
Water (TBW) it was found that 44. 9% patients TBW was below the normal 
levels (mean-38. 34). 15. 9% were overloaded with water percentage of 60. 39. 
Nutritional defi ciencies like zinc 50%, Niacin 30%, Essential fatty acids 25% were 
clinically observed. Dehydration was found in 44. 9% of the selected population. 
Conclusion: This study gives an overview of the post transplant patient’s 
nutritional intervention is necessary for a long-term period to lead a healthy life. 
Obesity, hyperlipidemia, lower visceral proteins, zinc, niacin, Essential fatty 
acid defi ciencies were found to be common among post transplant patients. 
Bio impedance analysis is very useful and meticulous method along with other 
methods to enable the nutritionist to educate, to provide appropriate nutritional 
support to the post transplant patients. 
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CARDIO AND CORONARY CONCURRENT ORAL SESSION 108: 
PATHOLOGY
POSTER BOARD NUMBER P3 – 01
SEVERITY OF LIVER DISEASE, RATHER THAN 1575 
AETIOLOGY, REFLECTS BLOOD LEVELS OF FAT SOLUBLE 
VITAMINS IN ADULTS AWAITING LIVER TRANSPLANTATION
W. Abbott-Johnson1, P. Kerlin1, A. Clague2, R. Cuneo3
1Princess Alexandra Hospital, 2Queensland Health Pathology Service, 
3Department of Medicine, University of Queensland
Although malnutrition is common in advanced liver disease, there are limited 
data on levels of fat soluble vitamins in various diseases. The aims of this study 
were to 1) determine levels of fat soluble vitamins in patients assessed for liver 
transplantation 2) compare levels in hepatocellular and cholestatic disease 3) 
relate vitamin levels to aetiology, biochemical (albumin and bilirubin) and clinical 
indicators of disease severity (Child-Pugh and MELD scores). Plasma retinol, 
serum 25-hydroxycholecalciferol and plasma vitamin E and were measured in 107 
(76 males) consecutive patients, mean age 47 (16-64) years. Child- Pugh classes 
were A (26), B (42) and C (38). Diseases were hepatocellular 74, cholestatic 22 
and other etiologies 11. Defi ciencies of retinol, 25-hydroxycholecalciferol and 
vitamin E were present in 75% (< 1.0 μmol/L), 66% (< 50 nmol/L) and 3% (< 
11 μmol/L) of patients. Concentrations of retinol and vitamin E were lower in 
hepatocellular than cholestatic disease, (0.4 (0.01-1.6) versus 0.8 (0.2-2.2) μmol/L, 
P = 0.0004 and 21 (7-61) versus 29 (6-54), P = 0.014 μmol/L respectively). 
25-hydroxycholecalciferol concentrations were similar (42 (11-110) versus 46.5 
(26-96) nmol/L, P = 0.065) and Child-Pugh score was higher in hepatocellular 
disease than cholestatic (9 (5-14) versus 7 (5-11), P < 0.0001). For the whole 
group, levels of retinol, 25-hydroxycholecalciferol and vitamin E were inversely 
related to Child-Pugh score, MELD score and bilirubin, and directly to albumin. 
Using multivariate regression analysis, fat soluble vitamin levels were refl ected by 
albumin and disease severity rather than etiology. There was a high prevalence of fat 
soluble vitamin defi ciencies (particularly retinol) in patients with advanced disease. 
Vitamin levels were more closely related to disease severity than aetiology.
POSTER BOARD NUMBER P3 – 02
ADVANCED GLYCATION END-PRODUCTS (AGES) 1576 
IN DEVELOPMENT OF ISCHEMIC AND DILATED 
CARDIOMYOPATHY IN PATIENTS WITH DIABETES 
MELLITUS TYPE 2 (DM)
M. Zakliczynski1, J. Nozynski1, D. Konecka-Mrowka1, B. Nikiel2, 
J. Mlynarczy-Liszka2, D. Lange2, M. Zembala1
1Silesian Center For Heart Disease, Zabrze, Poland, 2Comprehensive Cancer 
Center M. Sklodowska-Curie Institute Branch, Gliwice, Poland
Background: Abnormal glycemia in diabetic subjects accelerates a process of 
non-enzymatic conjugation of glucose with proteins, nucleic acids and lipids, 
resulting in AGEs formation. AGEs are thought to be a reason of heart muscle 
stiffness and impairment of its mechanical function. The aim of the work was 
morphological evaluation of AGE in the left ventricle of the heart in patients 
with diabetes type 2, and establishing the role of AGE in development of 
ischemic (ICM) and dilated cardiomyopathy (DCM) in diabetic patients.
Material: The diabetes group consisted of 11 hearts explanted in patients with ICM 
(ICM+DM group) and 8 hearts from DCM patients (DCM+DM group) undergoing 
orthotopic heart transplantation (OHT). Two comparative subgroups were 
composed of hearts explanted from OHT recipients without DM – 41 patients with 
ICM and 41 with DCM. The groups were homogenic according to patients age and 
DM2 duration. All tissues were fi xed and processed routinely to paraffi n-wax. The 
localization of AGE was detected immunohistochemically, intensity was marked 
with a semiquantitative scale in cardiomyocytes, fi broblasts, capillaries, arterioles 
and arteries (two independent observers, double blind study). Additionally, the 
score sale for contractile cells (AGECardiocyt) and all left ventricular constituents 
(AGETOTAL) were calculated. The statistical analysis was based on nonparametric 
statistical tests (Mann-Whitney test and Spearman rank correlation).
Results: The cytoplasmic positive reaction in cardiomyocytes was predominantly 
diffuse-granular (mixed type) in both DM groups, whereas comparative groups 
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represented predominantly lack of reaction or diffuse cytoplasmic pattern. These 
dependences were statistically signifi cant. ICM and DCM groups did not differed 
in the staining pattern as both DM2 groups. Moreover, there was no statistical 
differences in the reaction intensity neither between ICM and DCM, nor between 
ICM+DM vs. DCM+DM, whereas practically all myocardial constituents and 
cells showed higher intensity range in DM groups compared with corresponding 
nondiabetic groups. The only difference between ICM+DM and DCM+DM was, 
that AGE accumulation was signifi cantly more pronounced in capillaries of patients 
from ICM+DM group, while DCM+DM group AGE occurred predominantly in 
large arteries. There was no signifi cant correlation between the AGE intensity or 
scores with patients age, whereas diabetes duration correlated signifi cantly and 
strongly with the staining intensity in subendocardial and subepicardial myocardial 
layers and with AGECardiocyt and AGETOTAL, only in ICM+DM2 group.
Conclusions: The deposition of AGE in left ventricular myocardium is 
enhanced by DM, both in ICM and DCM. Different localization of AGE in 
coronary vessels of patients with ICM and DCM suggest etiology dependent 
differentiation of its role in heart failure development.
POSTER BOARD NUMBER P3 – 03
CARDIOCYTE NUCLEAR CHROMATIN DENSITY 1577 
CORRELATES WITH TRANSPLANTED HEART LEFT 
VENTRICULAR MASS
M. Zakliczynski, J. Nozynski, D. Konecka-Mrowka, R. Przybylski, 
M. Zembala
Silesian Center For Heart Disease
Background: Cardiocyte hypertrophy is accompanied by polyploidy, seen as 
a decrease in chromatin density in enlarged nucleus. Repeated biopsies of a 
transplanted heart offer the possibility of dynamic evaluation of these phenomena. 
The aim of the work was the evaluation of cardiocyte nuclear chromatin density in 
a transplanted heart during long-term follow-up. Material encompassed myocardial 
biopsies taken in the fi rst week, fi rst month and then on an annual basis up to year 
ten after surgery. Only biopsies with no rejection were considered (grade “0” ISHLT 
– 122 biopsies). The control group consisted of seven donor hearts specimens.
Methods: The optical density – mean gray level – of cardiomyocyte nuclear 
chromatin was evaluated. Correlations of this index with nuclear area, and with 
left ventricle ultrasound measurements were determined. Statistical correlation 
analysis was performed.
Results: The chromatin mean gray level showed a decrease with the passage of 
time, and correlated positively with the interventricular septum thickness, the 
left ventricle posterior wall diameter and the left ventricular mass. The analysis 
of individual periods showed a signifi cant positive correlation of the mean 
grey level with the cardiocyte nuclear surface in the 3rd, 4th and 9th year after 
transplantation, thereby suggesting the occurrence of polyploidy within that 
time. The signifi cant negative correlation of these values (1 week and 1 year) 
indicate normalization of early cardiocyte hypertrophy.
Conclusions: With the passage of time chromatin condenses, leading to pyknosis. 
The activity of cardiocyte chromatin correlates with left ventricular hypertrophy. 
The compensatory cardiomyocyte polyploidy is a periodical phenomenon.
CARDIAC CONCURRENT ORAL SESSION 109: 
PRESERVATION AND EXPERIMENTAL 
HEART TRANSPLANTATION
POSTER BOARD NUMBER P3 – 04
ANALYSIS OF THE IMPACT OF CELSIOR® 1578 
PRESERVATION SOLUTION ON CARDIAC TRANSPLANT 
OUTCOMES: A 5-YEAR RETROSPECTIVE CASE STUDY
P. Macdonald1,2, J. Kuo1, P. Jansz1, F. Junius1, E. Grainger1, P. Spratt1
1St Vincent’s Hospital, 2Victor Chang Cardiac Research Institute
Background: The quality of donor heart preservation plays a critical role in 
determining myocardial function after heart transplantation and therefore, 
the overall success of the procedure. Many preservation solutions, both 
commercially and locally formulated solutions, are used in the different 
cardiac transplant centres. The optimal preservation solution is yet to be 
established. The aim of this study was to assess the impact of two different 
cardiac preservation solutions, Celsior and aspartate-supplemented St Thomas 
solution, on post-transplant outcomes of heart transplant recipients.
Methods: This was a retrospective case study using a historical control group 
for comparison. A total of 101 consecutive heart transplant patients were 
reviewed (Celsior, n= 51; control, n= 50). The initial 50 patients in the 5-year 
study period, between September 2002 and August 2007, constituted the Control 
group in which all donor hearts were preserved in aspartate-supplemented St 
Thomas’ Hospital solution. The subsequent 51 patients formed the Celsior 
group, in which all hearts were stored in Celsior preservation solution. Data 
from various databases and patient’s clinical notes were used to compare the 
post-operative outcomes achieved in the 2 groups.
The study groups were evenly matched for most donor and recipient base line 
characteristics, including donor and recipient ages and donor heart ischemic 
times., however, the Celsior group did contain a higher proportion of female 
donors (52 vs 24%, p<0.05). Also, patients in the Celsior group were in more 
advanced heart failure at the time of transplantation (NYHA Class IV, 66 vs 
42%, p<0.05).
Results: Both groups demonstrated excellent 30 day survival rates and did 
not differ (98±0%). There was a trend towards better one year survival in the 
Celsior group (93±4% vs 90±4%), though this difference was not statistically 
signifi cant. Median time to ICU discharge was 3 days in the Celsior group and 
4 days in the control group (p=ns). Patients in the Celsior group demonstrated 
a signifi cantly higher rate of spontaneous return to sinus rhythm post transplant 
(82 vs 55%, p<0.05). Need for mechanical support post transplant was similar 
between the 2 groups (Celsior vs control; 32 vs 34%, p=ns). Celsior patients 
had better renal function (eGFR 57±25 vs 46±21 ml/min, p<0.05) and a trend 
towards better pulmonary gas exchange (PaO2/FiO2 298±119 vs 262±82, 
p=0.08) at 24 hours post-transplant.
Conclusions: Excellent post-transplant outcomes were achieved with both 
preservation solutions, however storage of the donor heart in Celsior solution 
was associated with higher rates of spontaneous return to sinus rhythm and better 
recipient renal and lung function early post-transplant. These improvements 
in outcome were observed in the face of more adverse donor and recipient 
baseline characteristics in the transplants where Celsior was used.
POSTER BOARD NUMBER P3 – 05
ACCELERATED CARDIAC ALLOGRAFT REJECTION 1579 
AND GRAFT LOSS AMONG CIGARETTE SMOKERS, ROLE OF 
INFLAMMATION, OXIDATIVE STRESS AND TISSUE REPAIR 
MOLECULES
M. Mehra, A. Khanna, J. Xu, C. Baquet,
University of Maryland, Baltimore
Background: Cigarette smoke exposure before and after among cardiac 
transplant recipients is associated with the development of cardiac allograft 
vasculopathy and excess risk of allograft loss. However, pre-transplantation 
exposure to tobacco and its impact on cardiac transplantation outcomes has not 
been adequately studied. We undertook this animal study to discern the early 
consequences of tobacco smoke exposure in cardiac donors or recipients with 
emphasis on alloimmune mediators of graft outcome.
Methods: Allogeneic heterotopic heart transplantations were performed (n= 
18) using histocompatibility mismatched rat strains, Wistar Furth (WF) and 
Lewis (LEW), as donors (D) and recipients (R). Exposure to tobacco smoke 
occurred using a novel smoke inhalation device, for D and recipient R rats at 
a dose of four cigarettes a day for fi ve days a week for at least 1-month. We 
monitored allograft survival by a heart palpation scale. Unexposed allografts 
(n=3) and isografts (n=3) were used as controls. No animals were exposed 
to immunoprophylaxis. IL-6, TNF-ƒÑ, IL-10 and IFN-ƒnƒ× expression were 
ascertained from donor rat splenocytes while intragraft gene expression of 
MMP-2, Granzyme B, Perforin and TNF-ƒnƒÑ was studied post-transplantation 
using Real Time PCR assay., the results are expressed as relative fold expression 
with respect to ƒÒ-actin.
Results: These effects of cigarette smoke exposure was associated with a 
markedly shortened allograft survival (D and R smokers 6.7 ¡Ó 0.33 days, 
Donor smoker 4.0 ¡Ó 1.7 days and Recipient smoker 7.3 ¡Ó 4.1 days). The 
survival of either donor or recipient rats exposed to tobacco was similar 
or decreased compared to untreated allogeneic animals. Chronic tobacco 
exposure to the donor and recipient strains resulted in a marked increased 
expression of pro-infl ammatory cytokines (expressed as Mean ¡Ó SEM, 
relative fold expression compared to rats without smoke exposure; IL-6 
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(15.82 ¡Ó 0.58), TNF-ƒÑ (11.21 ¡Ó 0.63), IFN-ƒ× (9.65 ¡Ó 1.58) and a 
signifi cant decreased expression of IL-10 (0.83 ¡Ó 0.18) mRNA expression 
in splenocytes. Besides the increased infl ammation, smoke exposure also 
resulted in increased circulating levels of cotinine, a metabolite of nicotine. 
In rejected allografts derived from smoke exposed donor, recipient or both, 
mRNA expression of MMP-2, Granzyme B, perforin and TNF-ƒÑ mRNA 
was markedly increased as compared to those animals that were untreated and 
rejected without cigarette smoke exposure. Histopathological analysis reveals 
3B to 4 rejection grades among smokers compared to 1 or 2 among untreated 
rejecting allografts.
Discussion: Our fi ndings show that tobacco exposure in cardiac donors and 
recipients is associated with pro-infl ammatory cytokine upregulation that 
results in heightened allo-immune activation and accelerated allograft loss. 
This allograft loss is mediated by marked activation of alloimmune and 
infl ammatory molecular mediators. These fi ndings may provide insight into 
the danger theory of alloimmune activation and urge caution in the use of 
donors with chronic exposure to tobacco as well as development of strategies 
for supplementation of appropriate treatments in the absence of cessation of 
smoking among transplant recipients.
POSTER BOARD NUMBER P3 – 06
ADENOVIRAL EXPRESSION OF HUMAN HYPOXIA-1580 
INDUCIBLE FACTOR-1¦Á WITHOUT ODD DOMAIN IN 
MYOCARDIAL CELL EFFECTS ON ISCHEMIA REPERFUSION 
INJURY
Y.P. Li, L. Wei, J. Shan, J. Lu, D. Long, L. Feng
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
The allograft will exposure to hypoxia during ischemia reperfusion (IR) 
procedure in heart transplantation, which is a major nonimmunologic 
factor implicated in pathogenesis of chronic graft dysfunction. In 
response to hypoxic conditions, cells upregulate the activity of hypoxia-
inducible factor 1 (HIF-1) which mediates the transcription of a number 
of genes against hypoxia. However, it was reported that Cyclosporin A 
(CsA) which is a widely uesed immunodepressant inhibits the activity of 
HIF-1¦Á, so the ability against IR injury of allograft may be decreased. 
Whether overexpression of HIF-1¦Á in heart will effect on the IR injury 
as well as alteration of immunological factors are little known. HIF-1 is 
a heterodimer composed of an oxygen-regulated subunit known as HIF-
1¦Á and a constitutively expressed HIF-1¦Â subunit. In normoxia, HIF-1¦Á 
protein is rapidly degraded via ubiquitination and proteasomal digestion by 
an oxygen-dependent degradation domain (ODD). The function of HIF-1 is 
represented by HIF-1¦Á.
In this study, we deleted the nucleic acid sequence coding for ODD domain 
in human HIF-1¦Á gene, then transfected the human HIF-1¦Á¦¤ODD gene by 
adenovirus into myocardial cell of rat in vitro which is treated with or without 
CsA. After hypoxia-reoxygenation-induced injury, we examined the expression 
patterns and activities of transgenes, degree of apoptosis, cell histomorphology 
and alteration of immunological factors. These results suggest that adenoviral 
expression of human HIF-1¦Á¦¤ODD domain can help cells adapt to hypoxia 
and may effect on long-term graft survival rate.
POSTER BOARD NUMBER P3 – 07
STUDY ON THE PRESERVATION WITH CO 1581 
(PCO=5000HPA), RESUSCITATION, AND HETEROTOPIC 
TRANSPLANTATION OF AN ISOLATED RAT HEART
K. Seki1, Y. Yoshida1, N. Hatayama1
1Kanagawa University, 2Kanagawa University, 3Kanagawa University
We succeeded in an experiment in which tardigrades were desiccated using 
perfl uorocarbon (PFC), an inert fl uid that has been used in liquid breathing 
and as artifi cial blood for mammals since about the 1960s, and then they were 
exposed to high pressure at 6,000MPa for resuscitation. We decided to work 
on an experiment to preserve an isolated mammal organ by immersing it in 
this desiccated PFC. It was thus demonstrated that after an isolated rat heart 
was dry-preserved for 24 hours in an environment with 400 hPa of partially 
pressure CO2 within a hyperbaric environment compressed at 2000hPa and 
then was resuscitated, it could be heterotopically transplanted into a recipient 
rat, and the reproducibility thereof was verifi ed. When the isolated rat heart was 
aeration-dried at 100 hPa of partially pressure CO2 after being immersed in 
PFC, the preservation time could be extended to 72 hours. In this experiment, 
aiming for a further extension of the preservation time, CO was added as a 
substitute gas in place of CO2 in a gas mixed with oxygen. Inbred rats LEW/
SsN Slc (¦ ‰, 6 weeks old) that were developed for organ transplantation 
by Japan SLC Inc. were used as a donor and a recipient. After an isolated 
heart of the donor rat was created, it was exposed to a gas mixture such as 
PO2=200hPa and PCO=1800hPa, and PO2=2000hPa and PCO=5000hPa in a 
2ATA high-pressure chamber, and was preserved in a refrigerator at 4¦ ‹C. We 
herein present our fi ndings which demonstrate that signifi cant reproducibility 
has been verifi ed. The heart was removed from the refrigerator 24 hours later, 
and a heterotopic heart transplantation was performed in the right neck of the 
recipient rat, and the pulsating of the transplanted heart was detected by an 
electrocardiogram.
CLINICAL HEART CONCURRENT ORAL SESSION 110: 
TRANSPLANTATION
POSTER BOARD NUMBER P3 – 08
KIDNEY AFTER EXTRARENAL TRANSPLANTATION 1582 
– THE IMPACT OF ALEMTUZUMAB INDUCTION
R. Shapiro, A. Basu, H.P. Tan, C. Morgan, V. Sharma, D. Blisard, J. 
Donaldson, P.S. Randhawa, A. Marcos, T.E. Starzl
Thomas E. Starzl Transplantation Institute, University of Pittsburgh
Background: Calcineurin inhibitor nephrotoxicity in extrarenal allograft 
recipients can lead to end stage renal disease and the need for kidney 
transplantation. We sought to evaluate the role of alemtuzumab induction in 
this population.
Patients and methods: We evaluated 144 patients undergoing kidney 
transplantation after extrarenal transplantation between 5/18/1998 and 
10/8/2007. 72 patients transplanted between 1/15/2003 and 10/8/2007 
received alemtuzumab induction and continued their pre-transplant 
immunosuppression. 72 patients transplanted between 5/18/1998 and 
7/21/2007 did not receive alemtuzumab induction. Mean recipient age was 
52.1 ± 16.6 years, and mean time after extrarenal transplantation was 8.1 ± 
4.7 years. There were 133 (92.4%) adults and 11 (7.6%) pediatric patients. 
35 (24.3%), 16 (11.1%), 87 (60.4%), and 6 (4.2%) had undergone previous 
heart, lung, liver, or multi-visceral transplantation, respectively. There were 
100 (69.4%) deceased (mean cold ischemia time 24.7 ± 7.9 hours) and 44 
(30.6%) living donors.
Results: Mean follow-up was 35.7 ± 30.7 months, 23.3 ± 15.0 in the 
alemtuzumab and 48.1 + 36.9 months in the non-alemtuzumab groups.
1 year Survival% 3 Year Survival%
Patient
Overall 91.5% 75.3%
Alemtuzumab Group 93.0% 78.9%
Non-Alemtuzumab Group 90.0% 72.4%
Graft
Overall 88.1% 71.4%
Alemtuzumab Group 93.0% 75.2%
Non-Alemtuzumab Group 83.3% 67.0%
Mean Serum Creatinine
Overall 1.4 ± 0.7 mg/dl 1.5 ± 0.9 mg/dl
Alemtuzumab Group 1.3 ± 0.5 mg/dl 1.3 ± 0.7 mg/dl
Non-Alemtuzumab Group 1.5 ± 0.8 mg/dl 1.6 ± 1.0 mg/dl
Conclusion: Alemtuzumab induction in patients undergoing kidney after 
extrarenal transplantation represents a reasonable immunosuppressive 
strategy.
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POSTER BOARD NUMBER P3 – 09
EVALUATION OF EVEROLIMUS PHARMACOKINETIC 1583 
IN ORTHOTOPIC HEART TRANSPLANTATION FROM 
CURRENT CLINICAL PRACTICE
J.M. Arizón, C. Segura, M.D. Aumente, B. Tejada, M. Cardenas
Hospital Universitaria Reina Sofi a
Background and objective: Everolimus is a immunosuppressor drug that has 
been recently introduced to prevent acute and cronic cellular rejection of solid 
organ transplantation. The aim of this study was to report our experience with 
everolimus in heart transplant patients, assesing pharmacokinetic parameters 
from current clinical practice.
Methods: Retrospectively therapeutic drug monitoring of everolimus was 
performed in 6 de novo heart transplant. Everolimus dosing adjustment was 
made to achieve Cmin>3ng/ml. All patients also received corticosteroids 
and cyclosporine, with or without antilymphocyte induction. Samples were 
obtained before the morning drug intake to measure Cmin for everolimus. 
Blood sampling to characterize the AUC was performed at 0, 0.5, 1, 2, 3, 4, 
6, 8 and 12 hours postdose. Dosage, Cmin (ng/ml), Tmax (h), Cmax (ng/ml), 
AUC0-12(ng.h/ml), Cavg (ng/ml) were also determined. Everolimus levels 
were determined by Fluorescence Polarization Immunoassay (FPIA, TDx).
Results: Interindividual pharmacokinetic variability was high, specially Cmax 
which ranged from 7.8ng/ml to 16.77ng/ml. The AUC mean was 88.9ng.h/ml 
(69.35ng.h/ml-119.31ng.h/ml). This data can be considered similar to reference 
values published by Kovarik in a study of 634 heart transplant recipients. 
Cmin was the kinetic parameter which correlated best with AUC (r=0.855, 
r2=0.73, n=6). The mean dose to achieve therapeutic drug levels (3-8ng/ml) 
was 0.62mg/12h.
Conclusion: Interindividual pharmacokinetic variability with everolimus 
is high. Cmin is the kinetic parameter which correlates best with AUC. Our 
results agree with literature data in heart transplantation patients
POSTER BOARD NUMBER P3 – 10
INFLUENCE OF CYCLOSPORINE ON EVEROLIMUS 1584 
CONCENTRATIONS IN DE NOVO HEART TRANSPLANT 
PATIENTS
J.M. Arizón, C. Segura, D.D. Aumente, B. Isla, M. Cardenas
Hospital Universitario Reina Sofi a
Background and objective: Everolimus is a novel immunosuppressant 
intended for use with cyclosporine in acute rejection prophylaxis following 
heart transplantation. Both agents are primarily metabolized by CYP3A4 
isoenzyme located in gastrointestinal enterocytes and the liver. In this context, it 
is essential to characterize the mutual infl uence of cyclosporine and everolimus 
on each other`s concentrations.
Methods: Case report of four de novo heart transplant patients. We compared 
morning trough whole-blood levels (Cmin) and 2h post-dosis level (C2) of 
cyclosporine versus Cmin and C2 of everolimus measured at 1 to 3 days 
intervals during fi rst month post-transplant. Cyclosporine and everolimus 
levels were determined by Fluorecesce Polarization Immunoassay (FPIA, 
Axsym and TDx respectively).
Results: A graphical assessment of this interaction was observed in four 
patients. All patients were on induction with baxiliximab, cyclosprorine, 
corticosteroids and everolimus. No drug that could interact with everolimus 
kinetic behaviour was used. In all cases an increase in everolimus blood 
levels was observed, as cyclosporine blood levels were increasing. This fact 
made to stop everolimus dose intake for 1-2 days and the dose was reduced 
after that. However, the increase of everolimus levels was highly variable 
between patients, ranging Cmin from 8.15ng/ml to 17.11ng/ml, and C2 from 
19.39 to 31.8ng/ml. This suggests a possible dependence of the simultaneous 
cyclosporine levels found in each patient. Anyway, in all cases everolimus 
dose-reduction was evident with an average dose by 3-fold (from 0.75mg/12h 
to 0.25mg/12h).
Conclusion: These results suggest that the dosing of everolimus needs to be 
adjusted to take account the increase of cyclosporine levels when cyclosporine 
co-administered. Given the wide variability in the magnitude of this drug 
interaction, both everolimus and cyclosporine blood concentration need to be 
carefully monitored.
POSTER BOARD NUMBER P3 – 11
BK VIRUS NEPHROPATHY IN THE NATIVE KIDNEYS 1585 
OF A PEDIATRIC HEART TRANSPLANT RECIPIENT
R. Chinnock1, S. Sahney1, P. Yorgin1, C. Zuppan1, N. Kanbaum2, D. Cutler1
1Loma Linda University, 2Stanford University
Human BK-Polyoma virus (BK virus) is acquired by respiratory or enteric route 
during childhood. The virus may remain latent in the uroepithelium. However 
in renal transplant recipients it may be reactivated, and is an important cause 
of graft dysfunction and graft loss. Although BK virus nephritis in the native 
kidneys is rare, there have been case reports of its occurrence in native kidneys 
of adult patients with non-renal transplants.
We report a case of BK nephropathy in a seven and a half year old heart 
transplant recipient. The patient received his fi rst heart transplant at 18 months 
of age, and the second heart transplant at 6.75 years of age. Prior to the second 
heart transplant, his serum creatinine was 0.9mg/dL (estimated GFR 70ml/
min/1.73m2). He developed acute renal failure following heart transplant 
surgery and was hemodialysed for three days. At discharge, his serum creatinine 
was 1.0 mg/dL (estimated GFR 62 ml/min/1.73m2). Eight months following 
the second heart transplant the patient presented with acute deterioration of 
renal function, with a serum creatinine of 3.6mg/dl (estimated GFR 16mL/
min/1.73 m2). His blood was positive for 200,000,000 copies of BK virus by 
quantitative polymerase chain reaction. Renal biopsy showed typical features 
of BK virus nephropathy, and the renal tissue stained positive for SV40.
Treatment with Cidofovir, IVIG and reduction of immunosuppresion did not 
halt the progression to renal failure. This patient is receiving maintanence 
hemodialysis and is currently awaiting kidney transplant.
To our knowledge this is the youngest reported patient with BK virus 
nephropathy in the native kidney. We recommend that immunosuppressed 
children, and pediatric recipients of non-renal transplants with rising serum 
creatinine should have BK virus PCR testing, and a renal biopsy performed if 
there is suffi cient suspicion.
POSTER BOARD NUMBER P3 – 12
HOW TO USE SIROLIMUS IN ORDER TO INCREASE 1586 
SURVIVAL IN HEART TRANSPLANT RECIPIENTS?
M. Zakliczynski, J. Nozynski, M. Zembala
Silesian Center For Heart Disease
Aim of the study was to assess an impact of sirolimus used as a part of 
immunosuppressive therapy on survival of orthotopic heart transplantation 
(OHT) recipients.
Material and methods: We performed a retrospective case-control study 
involving all 60 OHT recipients receiving sirolimus (study group), and 60 
matched individuals treated without sirolimus (control group). In almost a half 
of pts. sirolimus was used for a short period of time early after transplant, 
or introduced late after procedure. However, we identify 31 pts. in whom 
sirolimus was introduced before the 3rd year post-transplant, and continued 
for at least 3 years, or till the end of observation (28M/3F, 45±11y/o, ischemic 
c-pathy in 15 pts.). Majority of them received a combination of sirolimus and 
low-dose cyclosporine-A, which was replaced with mycophenolate mofetil 
3 years post transplant (at the end of the observation 21 pts. were without 
calcineurin inhibitor). They were confronted with their matches from control 
group (28M/3F, 44±11y/o, ischemic c-pathy in 17 pts.). We compared survival 
time and time free from death from particular causes. Signifi cance was assessed 
using log-rank test and chi-square test, when applicable.
Results: Average follow-up was 2138±1192 days in study group and 1949±1221 
days in control group (2169±650 vs. 1872±987 days, respectively in substudy). 
14(33%) deaths occurred in study group and 25(42%) in control group 
(p=0.032) – 5(16%) deaths in study subgroup vs. 14(45%) deaths in control 
subgroup (p=0.028). Survival time was signifi cantly longer both in the whole 
study group and subgroup when compared with matched controls (p=0.044 and 
p=0.019, respectively). The same trend was observed when a time free from 
non-cardiac death was compared (p=0.036 and p=0.022, respectively).
Conclusion: Long-term therapy with sirolimus prolongs survival in heart 
transplant recipients. This effect is related to the decreased probability of non-
cardiac death in this group of pts.
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POSTER BOARD NUMBER P3 – 13
SURVIVAL BENEFIT IN HEART TRANSPLANT 1587 
RECIPIENTS WITH CORONARY ARTERY DISEASE 
CONFIRMED IN ANGIOGRAPHY RECEIVING SIROLIMUS
M. Zakliczynski, M. Swierad, M. Maruszewski, M. Zembala
Silesian Center For Heart Disease
Aim of the study was to assess effi cacy and safety of sirolimus used in heart 
transplant recipients in order to prevent development of transplanted heart 
coronary artery disease (TxCAD) confi rmed in coronary angiography.
Material and methods: We performed a retrospective case-control study 
involving all 60 heart transplant recipients receiving sirolimus in a number 
of combination with other immunosuppressive drugs (study group), and 60 
matched individuals after heart transplantation treated without sirolimus 
(control group). TxCAD was diagnosed in elective coronary angiography in 
9 pts. from study group (8M/1F, 44±11y/o, ischemic c-pathy in 4 pts.) and 15 
individuals from control group (15M, 47±7y/o, ischemic c-pathy in 8 pts.). We 
compared time to develop signifi cant TxCAD and death caused by TxCAD, 
and all-cause death in pts. with TxCAD. Signifi cance was assessed using log-
rank test and chi-square test, when applicable.
Results: Signifi cant TxCAD (critical coronary lesions, myocardial infarction 
or death) was observed in 5(56%) pts. receiving sirolimus and 11(73%) without 
sirolimus (p=NS). Time to develop signifi cant TxCAD was comparable. There 
were 2(22%) deaths in sirolimus group and 8(53%) in control group (p=NS). 
Survival time was signifi cantly longer in pts. receiving sirolimus (p=0,02). 
None of deaths in study group was caused by TxCAD compared with 6(40%) 
deaths in controls (p=0,09). Time free from death caused by TxCAD was 
signifi cantly longer in study group (p=0.023).
Conclusion: Sirolimus prolongs survival in heart transplant recipients with 
TxCAD confi rmed in coronary angiography.
POSTER BOARD NUMBER P3 – 14
SIMULTANEOUS HEART AND KIDNEY 1588 
TRANSPLANTATION FROM A SINGLE DONOR
R-B. Hsu1, N-K. Chou1, N-H. Chi1, S-S. Wang1, F-Y. Lin1, S-H. Chu2
1National Taiwan University Hospital, 2Far-Eastern Memorial Hospital
Objective: There are no guidelines to establish the indications and 
contraindications for a simultaneous heart and kidney transplantation. We 
report our single-institutional experience with simultaneous heart and kidney 
transplantation.
Methods: Retrospective chart review.
Results: Between 1995 and 2006, 13 patients with co-existing end-stage heart 
and renal failure underwent simultaneous heart and kidney transplantation at 
the authors¡¦ hospital. Heart failure was secondary to dilated cardiomyopathy 
in 5 patients, ischemic cardiomyopathy in 3, cardiac allograft vasculopathy in 
2, and congenital heart disease, cardiac allograft failure, and acute myocarditis 
each in 1. Renal failure was secondary to glomerulonephritis in 6 patients, heart 
failure in 2, cyclosporine nephropathy in 3, hypertension in 1, and systemic 
lupus erythematosus in 1. Eight patients were in UNOS status IA and 5 patients 
in UNOS status II before transplantation. The 30-days mortality rate and in-
hospital mortality rate were 15% and 38%. Of 8 patients in UNOS status IA, 7 
patients have lived beyond 30 days and 3 (38%) beyond 1 year. Of 5 patients 
in UNOS status II, 4 patients have lived beyond 30 days and 4 (80%) beyond 
1 year. Patients in UNOS status IA had high rates of previous cardiac surgery, 
cardiac allograft rejection, and major renal allograft complications.
Conclusions: Although simultaneous heart and kidney transplantation 
continues to be a viable option for patients with co-existing end-stage heart and 
renal failure, the results do not match those of isolated heart transplantation. 
The clinical outcomes were not satisfactory in UNOS status IA patients with 
previous cardiac surgery.
POSTER BOARD NUMBER P3 – 15
USE OF EVEROLIMUS FOR LATE COMPLICATION 1589 
AFTER HEART TRANSPLANTATION
N. Fukushima, G. Matsumiya, S. Kogaki, Y. Sawa
Osaka University Hospital
Background: A proliferation signal inhibitor (PSI), everolimus (EVL) 
provides attractive options in patients with cardiac allograft vasculopathy 
(CAV), malignancies and renal dysfunction, or in patients intolerant to other 
immunosuppressive agents. We reported 8 patients to be given the EVL for late 
complications after heart transplantation (HTx).
Patients and methods: Eight cardiac transplant recipients (3.8 to 44.0 years 
old; 6 male 2 female) received EVL since 0.6 to 14.1 (a mean 6.6) years 
after HTx. The reasons for the use of EVL were CAV in four, post-transplant 
lymphoproferative disorder (PTLD) in three, severe diarrhea in one and renal 
dysfunction in one (Two cases were overwrapped).
Results: No patients died from 5.2 to 37.0 (a mean 17.7) months after using 
EVL. Intravascular ultrasound (IVUS) showed no progression of CAV in two 
and mid regression of CAV in two. Although one case experienced temporal 
recurrence of PTLD, all three cases are completely free from PLTD between 
and after occurrence of PTLD. Severe diarrhea completely stopped soon after 
switching mycofenolate to EVL. Serum creatinine decreased from 3 to 1.4 mg/
ml after switching cyclosporine to EVL.
Summary: everolimus seems safe for heart transplant recipients with late 
complications and may improve long-term survival.
POSTER BOARD NUMBER P3 – 16
IMPROVEMENT OF RENAL FUNCTION AND 1590 
ITS ASSOCIATED FACTORS IN HEART TRANSPLANT 
RECIPIENTS AFTER EVEROLIMUS INTRODUCTION
L.A. Bonet1, J.A. Moro López1,2, L. Martinez-Dolz1, I. Sánchez-Lázaro1, 
J.A. Ramón-Llin1, A.S. Sanz1
1Heart Failure And Transplant Unit. Cardiology. UH La Fe, 2Research 
Foundation. UH La Fe.
Objective: to prospectively assess the evolution of renal function in 
heart transplant (HT) patients and the potential factors associated with its 
improvement after the introduction of a proliferation signal inhibitor (PSI) in 
the treatment
Patients and method: 56 HT patients who sequentially receive Everolimus to 
either withdraw (77%) or reduce the calcineurin inhibitor. The demographic 
and analytical variables prior to the change were analyzed. Renal function was 
determined by plasma creatinine levels and by the glomerular fi ltration rate 
calculated using MDRD. A favorable change above 10% in these parameters 
was defi ned as renal function improvement.
Results: the sample mean age was 52±9 years. 93% were males and the mean 
BMI was 27±4. 43% underwent transplantation for dilated cardiomyopathy, 
39% for ischemic cardiopathy. Prior to the change, 75% presented hypertension, 
34% diabetes, 69% hypercholesterolemia, and 12% hypertriglyceridemia. 61% 
were ex-smokers. Mean plasma creatinine before change was 1.75±0.5mg/dl, 
with a GFR of 47.2±18ml/min. Change was due to renal dysfunction in 67% of 
the cases and presence of tumors in 32%.
45 patients have received treatment for at least 6 months. Concerning the renal 
function basal values, signifi cant improvement is observed both in plasma 
creatinine (1.92±0.7 vs 1.67±0.6; p=0.02) and in glomerular fi ltration (43.9±17 
vs 52.5±23; p=0.003). Improvement was obtained in 32 patients.
Basal 
creatinine 
(mg/dl)
Basal 
MDRD 
(ml/min)
Creatinine 
6m 
(mg/dl)
MDRD 
6m 
(ml/min)
No improvement (N=13) 1.83±0.5 43.5±13.5 2.2±0.5 34.6±12.9
Improvement (N=32) 1.95±0.8 44.2±18.9 1.4±0.5 59.7±22.4
P 0.6 0.9 0.0001 0.0001
No differences between groups were observed in the analysis of the characteristics 
prior to the change of treatment as far as age at HT, reason for HT, age at 
change of treatment, time HT-change, drug replaced, BMI, gender, presence 
of cardiovascular risk factors at change, plasma levels of cholesterol and its 
fractions, triglycerides, hemoglobin, white blood cell count, or platelet count.
Poster Abstracts Wednesday 13 August 2008
5 2 9
W
ED
N
ESD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
After 12 months of treatment (n=30), improvement signifi cantly persisted as 
shown by the repeated measures ANOVA.
Conclusions: the use of a PSI drug to replace a calcineurin inhibitor or 
to complement this one at low doses, allows obtaining renal function 
improvement at 6 months which is maintained for the fi rst year after 
therapeutic change. None of the studied variables was shown to be useful to 
predict this improvement.
POSTER BOARD NUMBER P3 – 17
SAFETY PROFILE OF EVEROLIMUS AS A RESCUE 1591 
THERAPY FOR LONG-TERM HEART TRANSPLANT 
RECIPIENTS: EXCLUDING THE HARM, WHILE WAITING 
FOR EFFICACY
L. Potena, F. Fabbri, G. Magnani, F. Coccolo, F. Fallani, M. Masetti, A. 
Russo, G. Arpesella, F. Grigioni, A. Branzi
Cardiovascular Department, University of Bologna
In several countries, everolimus is registered for the prevention of acute 
rejection in de novo heart transplant (HT) recipients. Clinical and experimental 
studies additionally suggested a potential effect in prevention of cardiac 
allograft vasculopathy (CAV) and neoplasm, and in facilitation of cyclosporine 
minimization protocols. Thus, many transplant centers use the drug off label by 
substituting azathioprine, mycophenolate or even cyclosporine with everolimus 
as a rescue therapy for maintenance HT recipients with severe comorbidities. 
While prospective trials documented the drug safety profi le in de novo patients, 
sparse safety data are available for everolimus use as a rescue therapy. In this 
report, we compare the occurrence of drug-related adverse effects between 
patients receiving everolimus in de novo vs. long-term patients shifted from 
another immunosuppressant.
All patients treated in our center with everolimus for at least 6 months, in 
addition to low-dose cyclosporine and prednisone, were included in the study. 
We analyzed change in glomerular fi ltration rate (GFR) from baseline to 6 and 
12 months of everolimus therapy, and occurrence of peripheral edema, pleural/
pericardial/lymphatic effusions, and infections needing specifi c antimicrobial 
therapy.
Fifteen patients were treated de novo, and 30 received everolimus 4.6±3.5 
years after transplant. Shifted patients were older (62±5 vs. 49±12 y; P<0.01) 
with a lower prevalence of females (13% vs. 46%; P=0.01), and with worse 
baseline GFR (37.7±11.5 vs. 60.8±25.2 ml/min/1.73m2; P<0.01) as compared 
with de novo. Reasons for shifting to everolimus were: CAV (30%), renal 
insuffi ciency (57%), and neoplasm (13%). Of these, one CAV patient died 
suddenly, and one with severe renal insuffi ciency died for sepsis. After 12 
months, no difference in everolimus levels was noted (6.4±2.3 vs. 6.6±2.0 
ng/ml: P=0.8), but trough cyclosporine was lower in maintenance patients 
(91±30 vs. 65±29 ng/ml; P=0.01). In de novo patients, after an initial 
worsening trend at 6 months (from 60.8±25.2 to 52.5±13.2 ml/min/1.73m2; 
P=0.2), GFR remained stable at 12 months (50.6±19.1 ml/min/1.73m2). In 
shifted patients, GFR remained stable for the entire follow-up (37.8±11.5 vs. 
38.6±13.8 vs. 36.7±13.8 at baseline, 6, and 12 months respectively; P=0.7). 
Pleural/pericardial/lymphatic effusions were restricted to de novo patients 
(n=4; 27%), while peripheral edema was noted only in maintenance patients 
(n=8; 27%). The incidence of relevant infection was similar between the two 
groups (17±7 vs. 13±9%; P=0.8).
These prospective observational data suggest that, despite the higher burden 
of comorbidities, shift to everolimus as a rescue therapy in long term HT 
recipients seems to have a similar safety profi le as compared with the use of 
the drug in de novo patients. Extreme cyclosporine minimization may favor 
everolimus safety profi le in these patients. The long-term effi cacy of this 
strategy remains to be proven, but it appears unlikely if undertaken in severely 
ill patients.
POSTER BOARD NUMBER P3 – 18
CARDIAC MRI ASSESSMENT OF LV FUNCTION 1592 
IN PATIENTS POST CARDIAC TRANSPLANTATION: A 
COMPARISON WITH GATED BLOOD POOL IMAGING
C. Hamilton-Craig1,2, W. Strugnell1, T. Parry1, H. Bartlett3, R. Slaugther2
1Cardiovascular MRI Research Centre, 2Department of Cardiology, 
3School of Mathematical Sciences, Queensland University of Technology
Purpose: To determine if cardiac MRI (CMRI) could replace Gated Blood 
Pool Imaging (GBPI) for annual assessment of left ventricular (LV) function in 
the on-going review of patients post-cardiac transplantation.
Methods: Forty-nine post-cardiac transplant patients presenting for annual 
review underwent LV functional assessment with GBPI and CMRI. LV 
ejection fractions obtained from the two methods were compared and limits of 
agreement determined.
Results: The mean EF (plus and minus two standard deviations) was 58.3% 
±18 for GBPI and 57.6% ± 18 for CMRI.
Conclusions: Assessment of left ventricular ejection fraction with CMRI 
is comparable to GBPI in post-heart transplant patients. CMRI also allows 
quantitative volumetric analysis of ventricular volumes and assessment of wall 
motion and valvular function. As is now accepted in native heart assessment, 
CMRI should be considered a “gold standard” for post-transplant volumetric 
and functional evaluation and offers information over-and-above traditional 
imaging modalities.
POSTER BOARD NUMBER P3 – 19
TREATMENT OF LATE HUMORAL REJECTION WITH 1593 
ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB; 
A SINGLE CENTRE EXPERIENCE
H. Hayes1, C. Wood, L. Dembo1, G. O’Driscoll1,2
1The Advanced Heart Failure & Cardiac Transplant Service, Royal Perth 
Hospital, Perth, Western Australia, 2School of Medicine, University of Notre 
Dame, Fremantle Western Australia
Background: Humoral or vascular rejection is a B cell-mediated production 
of immunoglobulin (Ig) G antibody against a transplanted organ that results 
in immune complex deposition on the vascular endothelium, activation of 
the complement cascade, production of endothelial dysfunction and regional 
ischaemic injury.
Method: 4M, age 42.3 ± 6.2 years with dilated cardiomyopathy in 3 cases and 
aortic valvular disease in the other, underwent orthotopic cardiac transplantation. 
One patient was bridged to transplant after 156 days with a Heartmate XVE 
left ventricular device. HLA antibodies measured as a percentage of the panel 
reactive pre transplant with the patient’s serum, was 41%, 76%, 0% and 0% 
respectively. The prospective fl ow cytometric cross match was negative for 
T and B cells for all patients prior to transplant. Post transplant at 65 months, 
47 months, 22 months and 90 months respectively, the diagnosis of humoral 
rejection based on allograft dysfunction, circulating HLA or DSA antibody 
and rejection morphology on allograft biopsy was made and the patients were 
treated with Rituximab.
Results: Rituximab, a chimeric humanized monoclonal antibody directed 
against the pan-B cell surface molecule, CD20 was administered intravenously 
at a dose of 375mg/m2 for four weeks. All patients were on triple therapy 
immunosuppressant maintenance which included calcineurin inhibitors, 
antiproliferative agents, mTOR inhibitors and prednisolone. Following 
rituximab treatment, all patients improved with resolution of their symptoms 
of cardiac failure. This improvement has been maintained for 48 months, 
10 months and 5 months respectively of follow-up. One patient presented 
11 months following administration of rituximab with acute haemodynamic 
compromise secondary to severe right failure and died.
Patient Characteristics
Patient Age Age HLA Antibodies pre Transplant Immunosuppression
Rituximab 
post Transplant
1 45 M 41% CyA/MMF/Prednisolone 65 months
2 45 M 76% CyA /MMF/Prednisolone 47 months
3 33 M 0% CyA/MMF/Sirolimus 22 months
4 46 M 0% CyA/Everolimus/Prednisolone 90 months
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Conclusion: Rituximab provided rapid and full resolution of symptoms and 
objective evidence of allograft dysfunction in this patient group. There was 
no toxicity or complications following rituximab therapy. Patients successfully 
treated for humoral rejection with rituximab still require careful revaluation as 
the B-cell population can rebound with time.
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CLINICAL PROFILE IMPROVEMENT AND SAFETY 1594 
OF THE CONVERSION TO EVEROLIMUS (EVE) 
IN HEART TRANSPLANT (HT) RECIPIENTS: 
A MULTICENTER ANALYSIS
N. Manito1, E. Kaplinsky1, I. Vallejos2, J. Roca1, V. Brossa3, S. Mirabet3, 
F.P. Villa2, E. Roig2
1Heart Transplant Program, Hospital de Bellvitge, Barcelona, Spain, 
2Heart Transplant Program, Hospital Clinic, Barcelona, Spain, 
3Heart Transplant Program, Hospital de Sant Pau, Barcelona, Spain
Background: EVE is a non-nephrotoxic immunosuppressive drug with anti-
proliferative properties. Its utilization may reduce the incidence of graft vascular 
disease (GVD) and also exhibits antitumoral effects. EVE allows minimization 
or withdrawal of calcineurin inhibitors (CNIs) in HT recipients.
Methods: We present a multicenter retrospective analysis in maintenance HT 
recipients switched to EVE. Aim of this work was to assess the clinical impact 
and safety after 12 months (m) from EVE conversion.
Results: 62 patients (81% male) of mean age 59±11 years and mean time 
after transplantation 5,9±4,03 years were switched to everolimus-based 
immunosuppression because the presence of renal function impairment (RFI) 
in 28 patients (45%), GVD in 17 (27,4%), cancer in 6 (9,6%), sirolimus 
intolerance in 3 (4,8%), refractory rejection in 2 (3,2%), CNI neurotoxicity in 
2 (3,2%) and other reasons in 4 (6,4%).
Initial immunosuppression was based on cyclosporine in 36 cases (58%), 
tacrolimus in 20 (32%) and sirolimus in 6 (10%). In addition, prednisone was 
present in 51 patients, mycophenolate mofetil in 48, azathioprine in 5 and 
sodium mycophenolate in 4.
EVE mean initial dose / fi rst through level was 1,39±0,29 mg/day and 5,8±3,67 
ng/ml. Mean EVE doses (mg/day) and concentrations(ng/ml) at 6 (n: 46) and 
12 m (n: 37) were: 1,38±0,37 / 5,9±2,5 and 1,33±0,69/ 6,3±2,6. Analytical 
parameters during the 12 m follow up showed a signifi cant serum creatinine 
reduction and HDL-LDL cholesterol increase:
Item (units)
Base
(n=62)
6 m
(n=46)
12 m
(n=37)
P
6 m vs base
P
12 m vs base
Creatinine (mg/dl) 1.8±0.7 1.5±0.5 1.5±0.4 <.0001  0.0007
Cholesterol (mg/dl) 181±28 201±79 189±37 NS  NS
HDL (mg/dl) 55±20 63±25 67±23 0.2426  0.0198
LDL (mg/dl) 91±24 91±31 106±20 0.0337  0.0028
Triglycerides (mg/dl) 154±83 146±74 155±88 NS  NS
Platelets (109/L) 212±59 204±45 205±54 NS  NS
Haemoglobin (g/dl) 13±2 13±1.4 13±1.3 NS  NS
CNI withdrawal was performed in 28 patients with RFI., Glomerular Filtration 
Rate (GFR) measured by MDRD improved (ml/minute/1,73m2): baseline 
45±17 to 6 months 56±13 (p < .00001), to 12 months 55±15 (p = 0.0131). Mean 
previous cyclosporine and tacrolimus doses (mg/day) and concentrations (ng/
ml) were: 159±73,3 / 124,73±51,86 and 2,06±1,08 / 4,31±2,07.
There were 11 infections, 4 rejection episodes and 2 deaths (1 non-cardiac 
and 1 GVD-related). EVE related toxicity was present in 36 episodes: oedema 
(n:12), transitory RFI (n: 9), diarrhoea (n:5), oral aphtas (n:5), pericardial 
effusion (n:2), pneumonitis (n:1), anasarca (n:1) and 1 peripheral venous 
thrombosis.
Conclusion: EVE conversion in maintenance HT recipients is safe and 
improves renal function. CNI withdrawal in patients converted to EVE for RFI 
improved GFR. Safety and effi cacy parameters for GVD and tumors requires 
a larger experience.
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DIAGNOSIS OF TOXOPLASMOSIS IN A 1595 
SERONEGATIVE AND TREATMENT-RESPONSIVE 
HEART TRANSPLANT RECIPIENT
M. Unlukaplan1, B. Celasun1, S. Sengel2, A. Sezgin3, B. Demirhan1
1Baskent University Faculty of Medicine, Department of Pathology, 2Baskent 
University Faculty of Medicine, Department of Infectious Diseases, 3Baskent 
University Faculty of Medicine, Department of Cardiovascular Surgery
Toxoplasma gondii infections in heart transplant recipients are generally 
seen as acquired infections of the immunocompromised sero-negative patient 
from an exogenous source, usually the donor organ. We report a 19-year-
old heart transplant recipient who developed a collapse of heart functions, 
28 days after the transplantation. Histopathological examination of the 
endomyocardial biopsy revealed T. gondii infection. After the appropriate 
medical therapy regimen, the patientâ€™s ejection fraction recovered 
dramatically. The control endomyocardial biopsy of the patient revealed 
any histopathologic sign of T. gondii infection or acute rejection. In both 
preoperative and postoperative serologic tests of the recipient, T. gondii IgG 
values were negative. Altough a seroconversion of T. gondii IgG/M was not 
detected, a two fold rise was signifi cant in the titer of IgG. Unfortunately the 
serologic status of the donor was not known, but the recipient of liver of the 
same donor is known to have an infection-free course. However, the heart 
transplant recipient died on the 65th day of transplantation because of other 
reasons. Our case demonstrates that the histological diagnosis of T. gondii 
is precious for recovery. In conclusion, T. gondii infection should be kept 
in mind while interpreting endomyocardial biopsies of transplanted heart. 
It is signifi cant to distinguish its histopathologic symptoms from a possible 
rejection because the therapy of these two entities are completely different 
and depends on the pathologic diagnosis.
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PREVALENCE OF RENAL DYSFUNCTION IN HEART 1596 
TRANSPLANT PATIENTS IN MAINTENANCE TREATMENT. 
THE ICEBERG STUDY
F. González1, J.M. Arizón2, S. Gatell3, N. Saval3, on behalf of the ICEBERG 
study group
1Hosp. Marqués De Valdecilla, Santander, Spain, 2Hosp. Reina Sofía, 
Córdoba, Spain, 3Novartis Farmacéutica, S.A.
Introduction: Renal impairment after transplant has a high impact in the graft 
and/or patient survival. Since its cause is complex and multiple actors are 
involved, it is important to know the prevalence, severity and factors that may 
have infl uence, in order to help in its prevention or at least, in the instauration 
of a treatment as soon as possible. Also, it is important to evaluate the little 
changes in renal function because they can mean a severe renal impairment in 
a middle-long term period.
Methods and materials: This is a national, multicenter, observational, cross-
sectional study including 243 cardiac transplant patients in maintenance 
treatment for at least two years. The primary objective was to asses the 
prevalence of renal dysfunction in maintenance cardiac transplant patients 
and the secondary objectives was to determine the characteristics of renal 
dysfunction, its evolution and the current immunosuppressive treatment and if 
the diagnosis of renal dysfunction lead to any changes in the immunosuppressive 
treatment.
Results: 243 patients were analyzed, 81% male, 99% caucasian, age 59 years 
(SD 12 years). Etiology of cardiopathy that originated the transplant was mainly 
coronary disease, 40.33%; idiopathic, 38.27%, valvulopathy, 5.35% and other 
reasons, 16.05%. Mean time since transplantation was 7.7 ± 4.0 years. Renal 
dysfunction (RD) could be diagnosed according to clinical criteria vs. objective 
laboratory criteria (Serum Creat >2mg/dl and/or GFR <50 ml/min). Taking into 
account objective criteria 32.5% (79/243) of the patients present RD. Mean 
serum creatinine was 2.2 ± 0.6 mg/dl.
Conclusions: The incidence of Renal dysfunction in this population of 
heart transplant patients is 32.5%. No renal biopsy has been performed. The 
proteinuria determination in not used as current practice. Complete data will be 
available to be presented in the Congress.
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CAN THE EUROSCORE PREDICT MORTALITY 1597 
AFTER CARDIAC TRANSPLANT?
A. Saito, M. Quantz, N. McKenzie, B. Kiaii, S. Swinamer, G. Fisher, R. 
Novick
London Health Sciences Center
Background: The European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) is frequently used to predict outcomes following cardiac surgery. 
EuroSCORE has been validated in multiple trials, however there is no current 
evidence evaluating its value in cardiac transplant patients. This study examines 
the use of EuroSCORE in predicting outcomes following cardiac transplantation.
Method: Between June 2001 to October 2007, 83 patients underwent orthotopic 
heart transplantation at our institution. Data was complete on 78 patients and they 
represent the study group. The additive and logistic EuroSCOREs were calculated. 
The following variables were analyzed: 30-day, in- hospital and overall mortality; 
hospital Length of Stay (LOS), Intensive Care Unit LOS; prolonged ventilation 
requiring tracheostomy, mechanical support (Intra-Aortic Balloon Pump, Extra-
Corporeal Membrane Oxygenation), acute renal failure requiring hemodialysis, 
chronic renal failure, peak creatinine, and delayed sternal closure.
Observed 30-day, in-hospital, and overall mortality were compared to predicted 
mortality as determined by additive and logistic EuroSCORE. The calculated 
scores were analyzed with hospital LOS, ICU LOS, and postoperative 
morbidities. The calculated values were described as mean (95% Confi dence 
Interval:CI) and p<0.05 is deemed as of statistical signifi cance.
Results: The observed 30-day mortality rate was 12.8% (10/78), and overall 
mortality rate was 25.6% (20/78). Predicted mortality by additive EuroSCORE 
was 8.81% (CI 8.08-9.53), and logistic EuroSCORE was 18.39% (CI 
14.86-21.92). Sixty-four patients (82%) were classifi ed as high-risk (additive 
EuroSCORE >5); in this high risk group the observed 30-day mortality was 
14.1% (9/64), and overall mortality was 26.6% (17/64). EuroSCORE predicted 
mortalities were 9.6% (additive) and 21.5% (logistic). Comparison of mean 
logistic EuroSCOREs between survivors and non-survivors was lower in the 
overall survivors than non-survivors (16.2 vs 24.9, p=0.03, CI 0.8-16.6). The 
patients with acute renal failure had higher logistic EuroSCOREs than those 
without (26.6 vs 16.1, p=0.01, CI 2.2-18.7). There was no correlation between 
logistic EuroSCOREs and hospital LOS (r=0.194) or ICU LOS (r=0.285). For 
the co-mobidities of prolonged ventilation, mechanical support, chronic renal 
failure, peak creatinine, and delayed sternal closure, there was no statistical 
signifi cant difference in EuroSCORE between the patients who had these 
morbidities and those who did not.
Conclusion: This study reiterates that patients presenting for cardiac 
transplantation, even those deemed to be at ¦ glow risk¦ h represent a 
challenging cohort. The logistic EuroSCORE was able to identify patients 
at higher risk that were undergoing cardiac transplantation as well as those 
more likely to develop renal failure. EuroSCORE does not predict the length of 
stay or other complications. The logistic EuroSCORE may prove useful when 
discussing the risks of transplantation with patients. However, further studies 
with a larger sample sizes are warranted.
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PRELIMINARY EXPERIENCE ON CONVERSION FROM 1598 
CALCINEURIN INHIBITORS TO EVEROLIMUS IN CARDIAC 
TRANSPLANTATION MAINTENANCE TREATMENT
E. Lage, J.A. Sánchez-Brotons, J.M. Sobrino-Márquez, R. Hinojosa, 
A. Martínez
Cardiology Dept., Virgen Del Rocio Univ. Hospital, Sevilla, Spain
Introduction: Everolimus (Eve) has been used after cardiac transplantation 
both in initial and later maintenance therapy. We present our initial experience 
with Eve as maintenance therapy after cardiac transplantation.
Methods: We retrospectively included all those patients converted from 
calcineurin inhibitors to Everolimus from September 2006 to October 2007 in 
our centre. We analyzed their basal clinical characteristics, indications for the 
conversion into Eve as well as benefi cial and adverse effects observed.
Results: A total of 16 cardiac receptors were included. Reasons for conversion 
into Eve were: Allograft vasculopathy (n=8), renal failure (n=4) and Sirolimus 
toxicity (n=4). Treatment with Eve was initiated a mean of 79.8±52.7 
months after transplant (range: 10-163). Mean initial dose was 1.4±0.2 mg 
(range: 1-1.5), and maintenance 1±0.31 mg (range: 0.5-1.5). Mean time of 
follow-up was 7.28±3.22 months (range: 0.5-13). Side effects observed were 
hypertriglyceridemia, hypertension and edema.
Only one out of four patients included due to Sirolimus intolerance did not 
tolerated Eve. Renal dysfunction did not get worse in any of the 4 patients that 
received Eve for that reason. No cases of allograft vasculopathy were observed.
Conclusions: Renal function seems to get stabilized after conversion to Eve in 
those patients with previous progressive renal dysfunction. Security profi le was 
proven in all the patients although conclusions can not be established regarding 
allograft vasculopathy evolution.
NURSINGCONCURRENT ORAL SESSION 111: 
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VENTRICULAR FIBRILLATION IN THE PATIENT 1599 
IMPLANTED WITH A CONTINUOUS FLOW LEFT 
VENTRICULAR ASSIST DEVICE – CASE REPORT
C. Axisa, P. Jansz, E. Granger, C. Hayward, A. Keogh, E. Kotlyar, A. Tay, P. 
Macdonald, P. Spratt
St. Vincent’s Hospital Sydney
Introduction: Ventricular Fibrillation is a life threatening rapid irregular heart 
rhythm where the ventricles do not contract effectively and the heart fails to 
pump blood into the arteries and systemic circulation. If Ventricular Fibrillation 
is left untreated death results within a few minutes.
We report a case where a patient implanted with the VentrAssistTM continuous 
fl ow left ventricular assist device (LVAD) experienced Ventricular Fibrillation 
without loss of consciousness for substantial time periods and maintained 
LVAD fl ows above 3.0 Litres per minute (L/min) throughout the episode.
Case report: Patient was a 66 year old male with Ischemic Dilated 
Cardiomyopathy. While the patient was at home his implantable cardiac 
defi brillator (ICD) fi red nine shocks within a few minutes. The patient 
presented to the local hospital emergency department. An Electrocardiograph 
was performed which confi rmed a rhythm of Ventricular Fibrillation. The 
patient was conscious with device fl ows of 4.0 L/min. Antiarrthymic drugs 
and intravenous fl uids were administered and patient was transferred to the 
LVAD implanting hospital. On arrival to the coronary care unit at the LVAD 
implanting hospital the patient was externally cardioverted to a paced rhythm. 
The patient had been in Ventricular Fibrillation for 4.5 hours without loss of 
consciousness. Patient had been supported by the LVAD for 129 days at the 
time of the event and is currently awaiting heart transplantation.
Results and discussion: The VentrAssist system is preload dependent and after 
load sensitive. In the setting of Ventricular Fibrillation the patient is severely 
compromised with no cardiac output and there is increased risk of ventricular 
suck down from the continuous fl ow device. Despite these obstacles the 
VentrAssist system continued to provide circulatory support to the patient.
This was a signifi cant fi nding of the VentrAssist system. The patient ICD delivered 
six bursts of Antitachycardia Pacing (ATP) and nine shocks but was unsuccessful 
in terminating the Ventricular Fibrillation. Hence, irrespective of other technology 
the VentrAssist system continued to provide circulatory support.
Conclusion: Implantation with the VentrAssist continuous fl ow LVAD 
improves hemodynamic status and enables survival during life-threatening 
episodes of Ventricular Fibrillation.
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THE INCREASINGLY COMPLEX HEALTH CARE 1600 
ENVIRONMENT OF CARDIAC TRANSPLANTATION: 
A ROLE FOR THE NURSE PRACTITIONER
C. Wood1, H. Hayes1
1Advance Heart Failure and Cardiac Transplant Service, Royal Perth 
Hospital, Western Australia
Background: In the last 25 years cardiac transplantation has become the 
accepted treatment modality for patients with end stage heart failure. This paper 
aims to demonstrate how the implementation of the nurse practitioner role 
within the designated area of the West Australian Cardiac Transplant Service 
can improve clinical outcomes and augment the services offered to patients 
and their families whilst promoting the effi cacy of cardiac transplantation in a 
world of the “shrinking dollar.”
Key points: There are manifold challenges to be met when delivering nursing 
care to patients before and after cardiac transplant. The cardiac transplant 
domain provides diverse opportunities for the advanced practice nursing 
role where the nurse must combine the skills of clinical expert with educator, 
coordinator, researcher, manager and administrator.
Results: Implementation of the role is demonstrated in terms of professional 
autonomy and accountability, legislation, extended academic qualifi cations 
and scope of practice. The Nurse Practitioner - Cardiac Transplant provides 
and coordinates outpatient health care to individuals throughout the transplant 
process. The nurse practitioner has increased clinical responsibilities and 
emerges as an independent practitioner who delivers quality, cost effective 
patient care.
Conclusion: The role of the nurse practitioner is currently evolving in Western 
Australia to meet the needs of this increasingly complex patient population. 
Extending and empowering the nurse practitioner role will require evidence based 
research that demonstrates enhanced effectiveness in meeting the needs of cardiac 
transplant patients and communicate to the nursing profession and other health 
care providers the difference the role makes in terms of clinical outcomes.
CLINICAL LUNG CONCURRENT ORAL SESSION 112: 
TRANSPLANTATION
POSTER BOARD NUMBER P3 – 27
PULMONARY REHABILITATION FOLLOWING 1601 
LUNG TRANSPLANTATION
G.I. Snell1, P.E. Munro1, B. Button1, M. Bailey2, A.E. Holland1,3,
1The Alfred Hospital, 2Monash University, 3La Trobe University
Background: Pulmonary rehabilitation (PR) following lung transplant (LT) is 
regarded as part of best practice management, however the optimal duration 
and composition of PR programs for LTx recipients is unknown.
Objective: This study aimed to describe changes in functional outcomes of LTx 
recipients who participated in our standard outpatient post LTx PR program.
Methods: A prospective, repeated measures design was used. Functional 
exercise capacity (six minute walk distance -6MWD), lung function (FEV1, 
FVC) and quality of life (SF 36) were assessed at one, two and three months 
following LTx. Following discharge, all subjects attended a one hour outpatient 
group exercise training class three days per week until 12 weeks post LTx and 
six education sessions facilitated by the multidisciplinary team. Patients with 
post-operative complications (mechanical ventilation, major myopathy) were 
excluded. Data were analysed using descriptive statistics and ANOVA with 
repeated measures.
Results: 60 consecutive LTx recipients between Sept 2003 and March 2005 
were assessed for inclusion. 36 (50% male) subjects, 81% bilateral LTx, mean 
age 46 ± 14 years were recruited and completed the study. The most common pre 
LTx diagnoses were cystic fi brosis (33%) and chronic obstructive pulmonary 
disease (31%). Signifi cant improvements were demonstrated in 6MWD (451 
± 16m to 545 ± 16m, p<0.001), FEV1 (72 ± 4% to 81 ± 4%, p<0.0001), FVC 
(74 ± 4% to 78 ± 4%, p<0.0001) and all SF36 domains, p<0.05. The greatest 
changes in 6MWD and lung function were seen between one and two months. 
Four SF36 domains (physical functioning, role functioning- physical, role 
functioning- emotional and social functioning) signifi cantly improved between 
month two and three, p<0.01.
Conclusions: Functional exercise capacity, lung function and quality of 
life improved signifi cantly over the fi rst 3 months in LTx recipients who 
participated in a structured PR program at our institution. This data provides 
a benchmark for comparisons to be made with other centres and program 
structures.
POSTER BOARD NUMBER P3 – 28
CAN PRETRANSPLANT CONDITION OF RECIPIENTS 1602 
PREDICT OUTCOMES AFTER LIVING-DONOR LOBAR LUNG 
TRANSPLANTATION?
Y. Sano1, T. Oto1, M. Yamane1, S. Toyooka1, M. Okazaki1, H. Date2
1Okayama University Graduate School of Medicine, Department of Cancer 
And Thoracic Surgery, 2Kyoto University Graduate School and Faculty of 
Medicine, Department of Thoracic Surgery
Background: Due to the shortage of brain-dead donors, living-donor lobar 
lung transplantation (LDLLT) accounts for nearly two-thirds of the lung 
transplantation cases in Japan. Although there have been no incidences of 
donor mortality following lobectomy for LDLLT at our institution, we believe 
that LDLLT should be performed under strictly limited circumstances.
Purpose: The purpose of this study was to evaluate the impact of the 
pretransplant condition of a patient on LDLLT outcomes during the early 
postoperative period.
Patients and methods: This single-center, retrospective study was conducted 
on 47 patients (37 female and 10 male), aged 6–55 years (median: 30 years), 
who underwent LDLLT between October 1998 and May 2008 at Okayama 
University Hospital. Of these, 9 patients were children. The underlying 
diagnoses of these patients included pulmonary arterial hypertension 
(n = 15), interstitial pneumonia (n = 12), bronchiolitis obliterans (n = 8), 
lymphangioleiomyomatosis (n = 4), and bronchiectasis (n = 3). The fi ve-year 
actuarial survival rate after LDLLT was 88.6%. However, 3 patients died during 
this period; 1 just before the transplant procedure in the operating room and 2 
after the transplant procedure in the ward.
Results: All patients were dependent on continuous oxygen inhalation, of 
which 19 (40.4%) were admitted in the ICU before transplantation. Among 
all patients with end-stage lung diseases (n = 31), 25 (80.6%) were grade V 
according to Hugh-Jones classifi cation, and the remaining 6 (19.4%) were 
grade IV at the time of transplantation. Of these, 5 (16.1%) were ventilator-
dependent, and another 5 required noninvasive positive pressure ventilation. 
Nineteen (61.3%) patients were steroid-dependent. Among patients with 
pulmonary hypertensive diseases (n = 16), 12 (75%) were NYHA class 
IV, and the remaining 4 (25%) were class III at the time of transplantation. 
Patients with idiopathic pulmonary arterial hypertension were being treated 
with high-dose intravenous epoprostenol (average dosage: 60.2 ng/kg/min) 
and inotropic agents. All procedures were performed under cardiopulmonary 
bypass.
As mentioned before, two patients died post transplantation in the hospital due 
to severe acute rejection and bronchopulmonary aspergillosis. In addition, a 
patient died just before the transplant procedure in the operating room owing to 
pulmonary hypertensive crisis with massive bleeding. The underlying diseases 
of these patients included idiopathic interstitial pneumonia, bronchiolitis 
obliterans, and idiopathic pulmonary arterial hypertension. The pretransplant 
status of these patients was not severe compared with the other recipients. In 
fact, two patients were classifi ed as grades V and IV according to Hugh-Jones 
classifi cation, and the third was NYHA class III. Although all of them were 
steroid-dependent, none were ventilator- or noninvasive positive pressure 
ventilator-dependent. In addition, none of these patients were admitted in the 
ICU before transplantation.
Conclusions: Although the pretransplant condition of the recipients was 
quite severe, a strong relationship between the pretransplant condition and 
the outcomes during the early postoperative period after LDLLT was not 
observed.
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LUNG TRANSPLANTATION IN PULMONARY FIBROSIS: 1603 
CHALLENGING EARLY OUTCOMES COUNTERBALANCED 
BY SURPRISINGLY GOOD OUTCOMES BEYOND 15 YEARS.
D. Keating, B. Levvey, T. Kotsimbos, H. Whitford, G. Westall, T. Williams, 
G. Snell
Lung Transplant Service, Alergy, Immunology And Respiratory Medicine, 
Alfred Hos
Introduction: Interstitial lung disease (ILD) has been reported as having a 
poor outcome following lung transplantation (LTx). This has been based on the 
diffi culties involved in getting ill recipients to LTx and challenging early post 
operative outcomes. We looked at the results in our institution over the last 18 
years to assess longer term outcomes for this cohort.
Method: A retrospective chart review was carried out of all ILD LTx recipients 
(February 1990-February 2008). Outcomes for ILD patients with respect to 
single and double lungs were compared with all other LTx patients over the 
same time period and ISHLT registry data.
Results: From a total of 585 LTx, 90(15%) were ILD (53 single LTx, 27 
bilateral LTx). There were 67(74%) Idiopathic Pulmonary Fibrosis (IPF), 
9(10%) were sarcoidosis, 9(10%) were lymphangioleiomyomatosis and 5(6%) 
had other indications. The mean age in the ILD cohort was 52yrs (range 34-69), 
and the actuarial survival at 1, 5, 10, 15 and 18 yrs compares to all other LTx 
performed (77 Vs X, 51 Vs X, 42 Vs X, 28 Vs 22, 28 Vs 20). For the IPF cohort 
the actuarial survival at 1, 5, and 10 yrs appears superior to ISHLT registry 
data (76 Vs 72, 50 Vs 44, 34 Vs 20 respectively). There was equivocal survival 
between single (n=47) and double (n=23) LTx at 1, 5, and 10yrs (78 Vs 68%, 
49 Vs 50%, 29 Vs 50%). The incidence of BOS (as a cause of death) is low at 
7% compared to 63% for other LTx indications.
Conclusion: Our LTx fi gures for ILD compare favourably to LTx for other 
diseases and international standards, this appears to be related to a lower BOS 
mortality. In addition, survival from single LTx is as successful as double 
LTx both in the short term and longer term. Consideration should be given to 
utilising more single LTx procedures to maximise the allocation of donor lungs 
and decrease the high mortality on waiting lists associated with IPF.
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LUNG TRANSPLANTATION FROM DONORS WITH 1604 
CARDIAC DEATH – INITIAL EXPERIENCE IN NSW
L.C. Yap, A. Hamilton, I.M. Ahmed, P. Spratt, P. Jansz, A. Farnsworth, E. 
Granger, P. Macdonald, A.R. Glanville
St Vincent’s Hospital, Sydney
Introduction: Donation after cardiac death (DCD) has potential to expand the 
current limited donor pool in Australia. We illustrate the challenges of starting 
such a programme and show our early results.
Methods: Institutional guidelines were created to encompass potential ethical 
and legal issues with DCD lung transplant, and an education programme initiated 
for hospital staff and donor coordinators. Initially all donors had elective 
withdrawal of ventilation (Maastricht III) in ITU or the operating room. No 
donor treatment of any kind was permitted. Our technique involved infl ation of 
the lungs with FiO2 0.4 after re-intubation. Chest was opened simultaneously 
with the abdomen and lungs were assessed prior to fl ushing antegrade and 
retrograde with cold Celsior/GTN mix. Implantation and postoperative 
management was as per our standard protocol for all lung transplants.
Results: Since November 2007 we transplanted lungs from 3 DCD donors 
with a mean age of 46(range 33-56). Cause of death was traumatic head injury 
(n=1) and subarachnoid haemorrhage (n=2). The 3 recipients had a mean age 
of 42 (range 22-61). Indications for lung transplant were emphysema, primary 
pulmonary hypertension and late graft failure after lung transplant.
Mean time to asystole after withdrawal of treatment was 14 minutes (range 
10-19). Mean warm ischaemic time was 22 minutes (range 12-31). Mean total 
ischaemic time was 231 minutes (range 184-275).
Early function was excellent with mean PO2 on the 1st postoperative day of 
100 (range 64 to 136) on FiO2 0.4. Mean length of ITU stay was 6 days (range 
3-10) and time to discharge 30 days (range 25-36). There was no mortality.
Conclusions: Our initial experience in this new venture to expand our donor 
pool taught us some key principles in setting up such a programme and our 
preliminary results demonstrate the safety of this technique.
EXPERIMENTAL LUNG CONCURRENT ORAL SESSION 113: 
TRANSPLANTATION
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ASSOCIATION OF FLOW-RATE AND ARTERIAL 1605 
BLOOD GAS MEASUREMENT IN EX-VIVO EVALUATION OF 
THE LUNGS FROM DONATION AFTER CARDIAC DEATH 
DONOR
S. Hori, T. Oto, S. Otani, S. Yamamoto, T. Kakishita, M. Okazaki, O. Yoshida, 
M. Yamane, S. Toyooka, Y. Sano
Cancer And Thoracic Surgery, Okayama University
Background: Donation after cardiac death (DCD) has a potential to solve 
the shortage of donor lungs. Assessment of the lungs from DCD donor before 
transplant is important, therefore evaluating lungs by means of Ex-vivo lung 
perfusion or simple blood fl ush have been proposed. However, the optimal 
fl ow rate of the perfusate during ex-vivo evaluation remains unclear. This study 
aims to investigate the effect of fl ow rate on the measurement and determine 
the minimal fl ow rate acceptable for lung evaluation avoiding its adverse effect 
on the graft.
Methods: Ex-vivo lung evaluation circuit was established using a pig as 
a deoxygenator. Lungs with 6 hours warm ischemia (DCD-group) and no 
ischemia (Control-group) was evaluated (n=7 in each) in a various condition of 
the fl ow rate (ranged from 0.1 to 1.2 L/min).
Results: In the Control-group, PO2 of the effl uent perfusate was stable (ranged 
from 495 to 563 mmHg) regardless of the fl ow rate. In the DCD-group, PO2 
was stable (ranged from 39.9 to 47.8 mmHg) when the fl ow rate was more than 
0.5 L/min, whilst that increased up to 237 mmHg (at 0.1 L/min) when the fl ow 
rate was less than 0.5 L/min.
Conclusions: The fl ow rates of 0.5L/min. in minimum seemed necessary for 
Ex-vivo DCD lung evaluation. Further transplant model is needed to validate 
the results.
POSTER BOARD NUMBER P3 – 32
BLOOD MONOCYTE DIFFERENTIATION INTO 1606 
AIRWAY DENDRITIC CELLS IS CONTROLLED BY MYD88 
FOLLOWING ORTHOTOPIC LUNG TRANSPLANTATION
S. Sugimoto, M. Okazaki, J. Lai, D. Kreisel, A. Gelman
Washington University School of Medicine
In lung grafts ischemia-reperfusion (I/R) signals rapidly induce the recruitment 
and differentiation of host monocytes into macrophages and dendritic 
cells. The nature of these I/R signals are antigen-independent but have been 
hypothesized to initiate Toll-like receptor (TLR)-mediated signaling pathways 
that are thought to potentiate alloimmune responses. We asked if MyD88, an 
adaptor molecule critical for TLR-mediated infl ammatory responses, regulated 
monocyte differentiation in a novel mouse model of vascularized orthotopic lung 
transplantation. Orthotopic left lung transplants were performed in the following 
syngeneic combinations: CD45.1+ B6 Æ CD45.2 + MyD88-/- and CD45.1+ B6 Æ 
CD45.2+ B6 (WT). 24 hrs later recipient-derived dendritic cell (DCs: CD45.2+ 
CD11c+ CD11bhi IAblo-hi) and macrophage (Macs: CD45.2+ CD11c- CD11blo 
IAblo) numbers were assessed in bronchial lavage (BAL) by FACS analysis. 
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Compared to the BAL of WT recipients, MyD88-/- recipients had comparable 
numbers of Macs (10297±945/ml vs. 11419±1016/ml; p=0.4) but signifi cantly 
fewer DC’s (5563±677/ml vs. 2891±341/ml; p<0.05) in lung graft airways that 
were of recipient origin. Lower numbers of newly differentiated lung graft 
DCs was coincident with the appearance of higher numbers of undifferentiated 
monocytes (CD115+F4/80+Gr1lo CD11c-) in the lung graft airways of MyD88-/- 
recipients as compared to WT recipients (254±80/ml vs. 1341±435/ml; p<0.01). 
We also analyzed monocyte differentiation in allogeneic lung recipients by 
comparing the fate of adoptively transferred CD45.2+ CD11b+ IAb- Ly6Chi Gr1- 
bone marrow monocyte precursors (MPs) from either MyD88-/- or WT mice in 
CD45.1+ B6 mice that received Balb/c lung grafts. As in the syngeneic graft 
combinations, adoptively transferred MyD88-/- MPs were similarly defective 
at differentiation into DCs in lung allografts. In conclusion these data show 
that MyD88 regulates graft-infi ltrating monocyte differentiation and suggests 
a mechanism by which TLR signaling pathways control adaptive responses in 
lung allografts through controlling monocyte fate.
SIROLIMUSCONCURRENT ORAL SESSION 114: 
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EARLY VERSUS LATE CONVERSION OF 100 HIGH RISK 1607 
RENAL TRANSPLANT RECIPIENTS FROM CALCINEURINE 
INHIBITORS TO SIROLIMUS – LONGTERM FOLLOW UP – 
KUWAIT EXPERIENCE
M.A. Halim, T. Al-Otaibi, K.V. Johny, M.R.N. Nampoory, M.H. Hamid, T. 
Said, P. Nair, I. Al-Muzairai, M. Samhan
Hamed Alessa Organ Transplantation Center
Conversion of stable renal transplant recipients (RTR) from calcineurin 
inhibitors (CNI) to sirolimus (SRL) is safe and effective while this step is 
still under investigation for recent and high risk RTR. We studied the long 
term effect of early and late conversion of high risk RTR maintained on CNI, 
mycophenolate mofetil and steroid immunosuppressive regimen to SRL, 
mycophenolate mofetil (MMF) and steroid on the graft and patient outcome.
Over about 4 years, the fi rst 100 subjects converted to SRL in our center were 
prospectively observed. The main indications for conversion were rejection, 
CNI toxicity, CNI elimination and ATN (90% had biopsy diagnosis before 
conversion). Candidates with severe bone marrow suppression were excluded. 
Mean age was 37.5(13-70) years including 14% pediatric and 9% geriatric age 
group. Mean BMI was 28.99(8.0). Grafts from deceased donors were 40%. 
Sixty percent were having 4-6 HLA mismatches. Biopsy proven total acute 
rejection and steroid resistant rejection were documented in 31% and 14% 
respectively prior to conversion. Mean follow up period after conversion was 
45.3 months (20.3- 65.8). Forty fi ve subjects started SRL within one month of 
transplantation (mean 0.5 month, range 0-0.97 month) - (group A). Fifty fi ve 
subjects started SRL later (mean 21.9, range 1-124.2 months) - (group B). No 
signifi cant differences were noticed between the groups in the demographic 
features.
Subsequent total acute rejection and steroid rejection episodes were 17% and 
10% respectively without signifi cant difference between the groups. Proteinuria 
>2gm/day, leucopenia, hypercholesterolemia and hypertriglyceridemia 
increased signifi cantly after conversion in both groups (p 0.001, 0.0003, 
0.0001 and 0.0001 respectively). The patient and graft survival were 95% and 
90% respectively without signifi cant differences between the groups. Serum 
creatinine and calculated creatinine clearance (MDRD formula) signifi cantly 
improved after conversion in both groups (p < 0.0001). Incidence of oedema 
and lymphocele were signifi cantly higher in group A (p 0.0001). Incidence of 
discontinuation of SRL was 27% mainly due to bone marrow suppression and 
wound complication. The main side effects and complications of SRL were 
documented as generalized edema (n = 36), gastrointestinal (n = 34), headache 
(n = 20), lymphocele (n = 17), mucocutaneous (n = 14), interstitial pneumonia 
(n = 2) and wound dehiscence (n = 7). Infection episodes were signifi cantly 
high in both groups mainly respiratory(n = 49)and gastrointestinal (n = 36).
We conclude that early and late conversion from CNI to SRL was effective in 
high risk RTR during long-term follow up. High incidence of discontinuation 
of SRL was mainly due to drug complications and side effects. This was 
aggravated by the high exposure to MMF. Lower dose of MMF is advisable 
when combined with SRL. RTR with multiple medical problems may not be 
the best candidates for SRL/MMF/steroid regimen.
POSTER BOARD NUMBER P3 – 34
SIROLIMUS-BASED CALCINEURIN INHIBITOR-1608 
SPARING IMMUNOTHERAPY, 6-YEAR RESULTS
M. Gallichio, O. Elbahloul, D. Conti
Albany Medical College
The Immunosuppressive effi cacy of Sirolimus (SIRO) has stimulated efforts to 
limit calcineurin inhibitor (CNI) exposure in SIRO treated patients. We report 
our 6-year experience, patients enrolled between 5/01 and 8/02, with a CNI-
sparing protocol in 50 consecutive primary renal transplant recipients. Patient 
characteristics were as follows: mean age 46 years, male 64%, caucasian 80%, 
deceased-donor 54%, diabetes 40%. Recipients were treated with a triple drug 
regimen consisting of SIRO, tacrolimus and prednisone. SIRO dosing was 
adjusted to target a trough level of 10 ng/ml. Tacrolimus dosing in the fi rst 
three months was targeted to trough levels of 8-12 ng/ml. At 90 days tacrolimus 
dosing was decreased by 50% with subsequent maintenance dosing targeted to 
a trough level of 3 ng/ml.
The mean follow-up at 12/1/07 was 72 months (64-79 months). At 90 days 
post-transplant the mean SIRO trough level was 10.9 ng/ml (6-21) and the 
mean 12-hour trough tacrolimus level was 8.4 ng/ml (4.4-13.3). Subsequent to 
tacrolimus dose reduction at three months the mean trough tacrolimus level at 
6 months was 3.1 ng/ml (1.7-6.5).
Patient and allograft survival at 1-year was 98%. Long-term actual patient and 
allograft survival, as of 12/1/07, was 82% and 72% respectively. Mortalities 
were due to cardiovascular events (n=5, at 13, 16, 30, 36 and 48 months), 
infection (n=2, at 8 and 42 months), malignancy (n=1, at 45 months), and 
unknown causes (n=1, 49 months). Five additional grafts have been lost to, 
chronic nephropathy at 28, 58 and 68 months, recurrent disease at 66 months 
and BK nephropathy at 44 months. There have been no graft losses to acute 
rejection. Acute rejection developed in 5 patients (10%), with all episodes 
ocurring within 14 days of transplantation. No acute rejection episodes 
have been identifi ed more than 90 days post-transplant when CNI dosing 
was reduced. Mean serum creatine levels at 12 (n=49), 24(n=47), 36(n=45), 
48(n=41), 60(n=37) and 72(n=21) months were 1,5, 1.5, 1.5, 1.6, 1.6, and 1.6 
mg/dl respectively.
This SIRO, CNI-sparing and steroid regimen provided potent immunotherapy 
for primary renal transplant recipients. The incidence of acute rejection was 
only 10%. In addition, subsequent to reduced prograf dosing and target levels, 
acute rejection did not occur. Furthermore, 6-year renal allograft survival is 
excellent and serum creatinine levels have remained stable long-term. SIRO 
maintenance immunotherapy safely allows for a 50% reduction in tacrolimus 
dosing and levels at three months.
POSTER BOARD NUMBER P3 – 35
DIFFERENT PROFILE OF GENE EXPRESSION OF 1609 
CYTOKINES IN PERIPHERAL BLOOD MONONUCLEAR 
CELLS OF TRANSPLANT RECIPIENTS TREATED WITH 
M-TOR INHIBITOR AND CALCINEURIN INHIBITOR
M. Niemczyk, J. Egarska, M. Pawowska, J. Wyzga, M. Ciszek, L. Pczek
Medical University f Warsaw, Transplantation Institute
Aims: To determine how sirolimus (SRL), in comparison to calcineurin 
inhibitors (CAI), infl uences gene expression of cytokines: interleukin 1 beta, 
tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), 
and interleukin 10 (IL-10) in peripheral blood mononuclear cells (PBMC) of 
transplant recipients.
Material and methods: Twenty-two patients (13 kidney and 9 liver transplant 
recipients), in which: CAI was replaced with SRL (n=11); SRL was introduced 
additionally to CAI (n=7); or SRL was replaced with CAI (n=4), were recruited. 
PBMC were obtained before and after modifi cation of immunosuppression. 
Real-time polymerase chain reaction was used for quantitative assessment of 
expression of investigated genes.
Results: During therapy with SRL+/-CAI, the pro-infl ammatory genes 
expression was increased, and IL-10 gene expression was decreased, in 
comparison to treatment with CAI. In subgroup of patients with malignancy 
as the reason of liver transplantation, gene expression of TNF-alpha and IFN-
gamma was higher when SRL+/-CAI was used in comparison to treatment with 
CAI. Patients with viral infection receiving SRL+/-CAI had higher expression 
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of pro-infl ammatory genes than during therapy with CAI.
Conclusions: Transplant recipients during therapy with SRL+/-CAI have 
increased gene expression of Th1 cytokines, and decreased gene expression of 
Th2 cytokine, IL-10, in PBMC, compared to treatment with CAI. This effect 
is also present in subgroups of patients with malignancy or viral infection, and 
may be benefi cial in these patients.
POSTER BOARD NUMBER P3 – 36
DE-NOVO CALCINEURIN INHIBITOR MINIMIZATION 1610 
IN COMBINATION WITH SIROLIMUS FOR RENAL 
TRANSPLANTATION: A SINGLE CENTER’S REPORT 
OF 100 CASES
M-K. Tsai, C-Y. Lee, I-R. Lai, R-H. Hu, P-H. Lee
Department of Surgery, National Taiwan University Hospital
Chronic nephrotoxicity of calcineurin inhibitors (CNIs) causes irreversible 
renal dysfunction and shortens renal transplant survival. We conducted a 
retrospective cohort study to test a hypothesis that de-novo CNI minimization 
combined with sirolimus improves graft survival of renal transplantation. From 
October 2000 to August 2007, we performed 100 cases of renal transplantation 
with de-novo CNI (either cyclosporine or tacrolimus) minimization combined 
with sirolimus. The initial target trough level for cyclosporine (CsA group: 
33 patients) was between 100 to 200 ng/mL, and that for tacrolimus (TAC 
group: 67 patients) between 4 to 8 ng/mL. Sirolimus was given by a loading 
dose of 6 mg plus 2 mg/day for maintenance. The mend follow-up period was 
45.0+/-25.1 months. The incidences of delayed function were 23.8% (16/67) 
for the TAC group and 15.2% (5/33) for the CsA group. The 1-year rejection-
free survival and 5-year graft survival and 5-year patient survival rates were 
94.87%, 87.72% and 98.61%, respectively. Fifteen patients stopped taking 
sirolimus because of major infection (3 patients), liver enzyme elevation (3), 
urinary leak (2), incisional hernia (1), lymphocele (1), deep vein thrombosis 
(1), joint pain (2), patient decision (1) and malignancy (1). No interstitial 
pneumonitis was noted in this series of patients, but 7 patients had pneumonia 
with good response to antibiotics. One patient had wound disruption and graft 
incarceration, which eventually lead to graft loss. In conclusion, de-novo CNI 
minimization combined with sirolimus brought about good rejection-free graft 
survival and patient survival of renal transplantation.
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LONG-TERM FOLLOW-UP OF SIROLIMUS (SLR) 1611 
MONOTHERAPY IN KIDNEY TRANSPLANT PATIENTS
R. Pinto1, M. Arellano2, A. Franco3, J.C. Ruiz4, Y. Armendariz5, E. Granados5, 
J.M. Campistol2
1H Curry Cabral, Lisboa, Portugal, 2H Clínic, Barcelona, Spain, 3H 
Universitario, Alicante, Spain, 4H Marqués de Valdecilla, Santander, Spain, 
5Wyeth Farma
Background: Sirolimus (SRL) offers an alternative to CNIs as a maintenance 
immunosuppressive drug. Usually, the SRL monotherapy (without steroids) in 
kidney transplant recipients is the result of a reactive situation. The aim of 
this study was to analyze the safety of SRL monotherapy in kidney transplant 
recipients.
Methods: Ongoing retrospective study performed in N=97 patients from 4 
sites from Spain and Portugal, all of them followed at least 12 months. The 
analysis included acute rejection rate and other assessments at 4 and 12 months 
after SRL monotherapy initiation.
Results: Mean time after SRL monotherapy start was 6.5 years (95%CI: 
5.7; 7.2), and mean trough level was 10.3 ng/mL (9.8; 10.8). Reasons to 
start monotherapy included treatment optimization (53.8%), minimization 
(23.7%), cancer (9.7%), chronic allograft nephropaty (CAN; 8.6%). There 
was not any acute rejection episode either at 6 or 12 months after treatment 
initiation. The haemoglobin increased signifi cantly (p=0.020) from 12.1 g/dL 
(1.9) at baseline in a mean of 0.27 g/dL (1.3) after 12 month-treatment. There 
were no statistically signifi cant differences in the rest of parameters [table1]. 
There were 4 deaths (cerebrovascular accident and progression of cancer) and 
3 graft failures. The most frequently reported related adverse event was mouth 
ulceration (8 patients).
Conclusions: These preliminary data obtained from an ongoing selective 
population show that long-term maintenance SRL monotherapy in kidney 
transplant recipients is safe in terms of immunological risk.
Table 1
Parameter
Mean (Standard Deviation) Baseline 6 months 12 months
GFR (Nankivell) (mL/min) 58.3 (18.1) 58.5 (19.2) 59.6 (20.9)
GFR (MDRD-4) (mL/min) 48.7 (18.8) 48.0 (19.6) 48.6 (20.9)
Serum creatinine (μmol/L) 153.4 (65.3) 153.2 (69.0) 153.9 (77.4)
Systolic Blood Pressure (mmHg) 128.9 (14.6) 128.7 (14.5) 129.1 (15.7)
Diastolic Blood Pressure (mmHg) 74.2 (6.1) 73.9 (7.4) 73.4 (7.7)
Glycaemia (μmol/L) 5.6 (1.4) 5.6 (1.6) 5.8 (2.0)
Body weight (Kg) 68.3 (10.8) 67.3 (9.2) 67.9 (9.9)
Proteinuria (mg/24h) (Median) 115.5 147.0 159.0
Cholesterol (μmol/L) 5.4 (1.2) 5.4 (1.1) 5.5 (1.2)
Triglycerides (μmol/L) 1.9 (1.3) 1.9 (1.3) 2.0 (1.1)
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SUCCESSFUL CONVERSION TO SIROLIMUS IN 1612 
CALCINEURIN INHIBITOR(CNI) TOXICITY INDUCED GRAFT 
FAILURE COMBINED WITH HEAVY PROTEINURIA
Y.K. Son, Y.H. Shin, J.K. Kim, S.S. Lee, K. Hur
Bong Seng Memorial Hospital
Sirolimus has been shown to be as effective as CNI in maintaining allograft 
without causing nephrotoxicity. Otherwise, sirolimus might aggravate the 
proteinuria after renal transplantation and some reports do not recommend 
the sirolimus in case of heavy proteinuric graft. However, we report a case of 
successful conversion to sirolimus in calcineurin inhibitor(CNI) induced graft 
dysfunction combined with heavy proteinuria.
The present case of human renal allograft recipient documents the utility of 
switching from CNI to sirolimus therapy for a patient experiencing ongoing 
biopsy proven CNI toxicity and heavy proteinuria induced by presumed CNI 
toxicity.
The patient described herein underwent maintenance therapy with CsA/MMF/
Steroid for 3months after renal transplantation.
He was complaining to edema and poor urine volume. He was oliguric with a 
urine output less than 500ml per day (Proteinuria > 6g/day) and uremic with a 
serum creatinine(sCr) value above 4.3mg/dl.
Graft biopsy showed intact glomeruli and tubules with cytoplasmic isometric 
vacuolation, focal fl attening and several casts consistent with acute CNI 
toxicity.
Although heavy proteinuria, CsA was switched to the sirolimus to treat biopsy 
proven CNI toxicity. Within 2 weeks the patient´s sCr value decreased to 
1.4mg/dl and urine output returned to greater than 2000ml per day (proteinuria 
< 1.5g/day).
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IMMUNOSUPPRESSION BASED ON M-TOR INHIBITORS 1613 
WITHOUT STEROIDS OR CALCINEURIN INHIBITORS IN 
RENAL TRANSPLANT RECIPIENTS
A. Franco, E. Cotilla, S. Roca, L. Jimenez, J. Sanchez, J. Olivares
Hospital General Alicante
The aim of this study was to study the evolution of renal function and proteinuria 
of 28 renal transplant recipients with m-TOR based immunosuppression 
without calcineurin inhibitors or steroids.
This study was prospective and observational.They were 14 males and 14 
females, aged 49,2±± 12,1 years. The therapy on m-TOR without calcineurin 
inhibitors nor steroids was 13,2 ±15,4 months postransplant. The follow- up 
was at least 12 months, mean 23,2 ±9,4 months (ranged 13-39).
Conversion to mTOR was performed within two weeks., due to histological 
nephrotoxicity (18 cases), gingival hypertrophy (2cases), postransplant diabetes 
(2 cases), de novo haemolytic-uremic syndrome (1 case) and Kaposi sarcoma 
(1 case). Four recipients received no calcineurin inhibitors nor steroids since 
the fi rst day after transplantation.
Patients improved the renal function ,mean GRF increased from 40.8 ±15,6ml/mn 
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to 44.6 ±16.9 at 6 months and 49.9 ±18.0 at 12 months (p=n.s), while creatinine 
decreased from 1.86 ±0.6 mg/dL to1.72 ±0.6 and 1.60 ±0.5 at 6 and 12 months 
(p=n.s,T-student). The 24 h proteinuria increased from 234 mg/24h(89-280) to 
280(86-731) at 6 months and 210(66-1162)) at 12 months (p=n.s Wilcoxom,).
Most of the adverse effects such as Kaposi sarcoma, hemolityc uremic syndrome, 
gingival hypertrophy disappeared after conversion, but .postransplant diabetes 
had no change.
One patient died due to abdominal sepsis at 20 months with a functioning 
graft. One patient was switched to FK due to dermical rush. During the follow-
up no acute rejection episode was observed .Concomitant therapies were: 
hypolipemics in 16 of 27 patients (59,3%), erythropoietin and angiotensin-
converting enzyme innibitors in 5/27 patients (18,5%).
At the end of the follow-up,16 of 27 patients (59,3%),were on m-TOR 
monotherapy and 11 of 27 (40.7%)with micophenolate.
The present study supports the safety and effi cacy of calcineurin inhibitors 
and steroid withdrawal in selected renal transplant recipients with m-TOR-
based immunosuppression to solve adverse effects due to calcineurin 
inhibitors or steroids.
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PULMONARY TOXICITY INDUCED BY SIROLIMUS1614 
T. Matuck, F. Miloski, M. Graciano, L. Morgado, M.E. Gouveia, D. Carvalho
Hospital Geral De Bonsucesso
Introduction: Sirolimus is an immunosuppressive agent used increasingly 
in kidney transplant recipients for initial and long-term maintenance therapy. 
It is also being used as maintenance therapy in patients following with 
chronic allograft nephropathy to stop the use of the calcineurin-inhibtor and 
avoid nefrotoxicity. Pulmonary toxicity has been recognized as a potential 
complication associated to this medication.
Objective: To report a case of intersticial pneumonitis and organizing pneumonia 
associated with the administration of sirolimus after renal transplant:
A 58-year-old African American woman, who underwent a cadaveric renal 
transplant 57 months before. Initially she received, as immunosuppressive 
regimen, tacrolimus, mycophenolate mofetil and prednisone, but 10 months 
before hospitalisation the tacrolimus was discontinued and sirolimus 
was introduced, as there was a graft biopsy suggesting chronic allograft 
nephropathy. She was hospitalised presenting a 4-week history of dyspnea 
and cough. Fever appeared only 3 weeks later, when dyspnea worsened. She 
also referred hyporexia and weight loss during this period. Chest radiography 
and CT scan revealed bilateral ground-glass alveolar infi ltrate, suggesting 
intersticial pneumonitis and organizing pneumonia. She was initially treated 
with antibiotics for atypical pneumonia with no response. Bronchoscopy 
was performed and bronchoalveolar lavage (BAL) culture was negative for 
bacteria and fungus and cytology revealed marked lymphocytosis. Arterial 
blood gas studies showed severe hypoxemia with mild respiratory alkalosis. 
Hematology was without leucytosis and the biochemistry showed only 
hypercholesterolemia, while creatinine and urea remained normal. One week 
after the initial treatment, sirolimus was discontinued, as the hypotesis of 
pneumonities secondary to the drug was suspected. Fever, dyspnea, fatigue 
and lung infi ltrates resolved rapidly when sirolimus therapy was stopped. 
After two weeks a high resolution chest CT scan showed a good radiologic 
evolution, but her chest X-ray and CT scan resolved completely only 6 
months later.
Conclusions: The temporal relationship between sirolimus exposure and 
onset of pulmonary symptoms in the absence of infectious causes and other 
alternative pulmonary disease suggested that sirolimus was the cause of the 
pulmonary changes. The associated clinical and radiological improvement 
after it was discontinued confi rmed a causal relationship. Because the use of 
sirolimus in kidney transplantation has become more widespread, clinicians 
must remain vigilant to this potential pulmonary complication.
POSTER BOARD NUMBER P3 – 41
A FOLLOW-UP AFTER CONVERSION THERAPY 1615 
FROM CALCINEURIN INHIBITOR(CNI) TO LOW DOSE 
SIROLIMUS(SRL) IN RENAL TRANSPLANTATION 
RECIPIENTS
M. Yu, T. Zhu
Zhongshan Hospital, Fudan University
Purpose: To Evaluate the short-term effi cacy and safety of conversion therapy 
from Calcineurin Inhibitor(CNI) to Sirolimus(SRL) in renal transplantation 
recipients, fi nding the appropriate SRL trough blood level for Chinese.
Methods: In a prospective study, we evaluated the short-term effi cacy 
and safety parameters in 19 renal transplantation recipients who had been 
operated for 4 months to 10 years. They were switched from CNI to SRL for 
allograft dysfunction. A kidney biopsy was done in 12 of the patients prior 
to conversion, and showed either chronic allograft nephropathy (n=3) or CNI 
nephrotoxicity (n=9). Conversion was abrupt. The patients received SRL at a 
starting dose of 3mg/d twice, then 2mg/d£¬ target trough blood level 4-7ng/
ml, with CNI withdrawal in the evening before starting SRL. The concomitant 
immunosuppression remained unchanged. Patient data were recorded at 
baseline(Day 0), and at month 1, 3, 6, 9, 12 post-conversion.
Results: After a mean post-conversion follow-up of 7.8¡À3.4 months, the 
survival of the patients and grafts was 100%. One patient had to stop SRL due 
to fi nancial limitations. No acute rejection was found. No signifi cant change in 
hepatic function, while dyslipidemia was induced in three patients and major 
pneumonia was observed in one. One patient required erythropoietin therapy 
because of the low hemoglobin level. De novo proteinuria of >1g/day appeared 
in another one. There was signifi cant amelioration of the renal function with 
Creatinine Clearance increasing from 47.0¡À15.0 baseline to 55.3¡À16.9 ml/
min post-conversion(P<0.001).
Conclusion: Conversion from CNI to low dose SRL in renal transplantation 
patients with allograft dysfunction was associated with improved renal function. 
It decreased the appearance of side reaction such as anemia, dyslipidemia, 
hepatic dysfunction and medical expense as well. So the conversion therapy 
is feasible and safe in short term. Long-term follow-up will be necessary to 
confi rm the preliminary data.
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EARLY CONVERSIO CNI-BASED TO SIROLIMUS-BASED 1616 
TRIPLE IMMUNOSUPRESSION IN PATIENTS WITH CHRONIC 
CNI TOXICITY: A PROSPECTIVE PROTOCOL BIOPSY 
MANDATED STUDY
A. Uslu1, H. Töz3, F.A. Taþlý2, A. Nart1, S Þen4, A. Nart1, M. Doðan1, 
T. Þahin2, H. Postacý2
1Izmir Teaching Hospital Organ Transplantation Center, 2Izmir Teaching 
Hospital Department of Pathology, 3Ege University Medical Faculty 
Department of Nephrology, 4Ege University Medical Faculty Department of 
Pathology
Background: There is emerging consensus on conversion from calcineurin 
(CNI)-based regimens to proliferation signal inhibitor (PSI)-based protocols 
for the prevention of progressive graft dysfunction due to CNI toxicity.
Methods: 31 primary renal transplant patients were enrolled in this double-
center study. Eligible patients were those having zero-hour biopsy and 
completed at least twelve months of follow-up after transplantation with 
current deteriorating graft function indicative of chronic CNI toxicity on biopsy 
specimen. Fast conversion protocol, being defi ned as complete withdrawal of 
CNI drug in two weeks, was attempted.
The primary endpoint of this study was the assessement of renal function by 
mGFR and renal histology by protocol biopsy at one year of conversion.
Results: The mean follow-up after conversion was 21.6 months. The 
difference between mean GFR before conversion and at the last follow-
up (40.8¡À2.36ml/min vs 53.8¡À2.96ml/min, p<0.000) was signifi cant, 
indicating a sustained improvement in graft function. The change in CAN 
scores between conversion period and the fi rst year of follow-up (-0.38¡À0.27) 
was indicative of a mild but unsignifi cant progression. Multivariate 
regression analyses revealed three independant factors (SCr<2.34¡À0.16mg/
dl, mGFR¡Ý40.6¡À3.0ml/min and CAN score<3.1¡À0.3 at conversion) with 
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signifi cant impact on mGFR and CAN score one year after conversion. The 
incidence of acute rejection and the patient and graft loss was 0% in this 
group.Moreover, SCr and mGFR was improved in 21 of the 29 patients 
(%72), remained stable in 4 (%14) and decreased in 4 (%14) patients.Study 
drug was withdrawn in two patients due to severe infections. The most 
frequent adverse event was abnormal lipid profi le observed in 23 patients 
(%74) after conversion.
Conclusion: Late conversion protocol from CNI- to SRL,particularly in 
patients with mGFR¡Ý40.6ml/min and mild CAN is safe and having excellent 
graft outcomes
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CONVERSION FROM TADCROLIMUS TO SIROLIMUS-1617 
BASED PROTOCOL IN RENAL TRANSPLANT RECIPIENTS: A 
LONG-TERM COMPERATIVE STUDY
R. Rahamimov1, A. Yusim2, J. Winkler1, T. Mashraki2, U. Gafter1, E. Mor2
1Department of Nephrology, and 2Department of Transplantation, Rabin 
Medical Center, Petah-Tiqwa affi liated with Sackler School of Medicine 
Tel-Aviv University, Israel
Sirolimus has been advocated in patients with chronic allograft nephropathy 
to replace the traditional calcineurine-inhibitor protocols. We conducted a 
comparative study to assess the effi cacy of conversion from tacrolimus to 
sirolimus in recipients with renal dysfunction.
Material and methods: Twenty-nine of 60 designed study population 
were enrolled in a randomized open label prospective manner to stay on 
Tacrolimus-based protocol (Tac) with MMF and steroids or to change to 
Sirolimus-based protocol (Sir) with the same medications. The inclusion 
criteria included patients who were > 6-months after transplant with stable 
serum creatinine levels (Cr.) ranging between 2-3 mg/dL with no clinical 
evidence of rejection. To exclude any vascular or uro-mechanical problem 
Renal Doppler ultrasound was performed before enrolment. All patients were 
followed every 3-month up to 3 years or until return to dialysis with serum 
Cr. and 24-hr. urine protein (U-Pr). Statistical method: A Person Chi square 
and Fisher Exact Test were used to compare the two groups for age, sex, 
time from transplant, serum Cr. and U-Pr at enrolment. These parameters 
were included in a stepwise Cox regression model to compare graft survival 
between the two groups.
Results: The study was discontinued by the researchers before the designed 
number of patients (60) were enrolled with literature reports advising not to 
use Sir in patients with advanced renal impairment and proteinuria. Three 
patients from the control arm were excluded from analysis (two refused their 
randomization and one who was found with RCC at enrolment). Twenty-six 
patients (11 - Tac arm, 15 - Sir arm) completed a median follow-up of 31 
months (7-44 months). At enrolment the two groups were not different by age, 
sex and interval after transplant (median 31 months). The mean Cr. and U-Pr at 
base line and follow-up were not different between the two groups (table). In 
intention to treat analysis graft survival at 36 month were 52% in the Tac group 
and 72% in the Sir arm (p=ns). In the Cox regression model the parameters 
affecting survival were Cr. (<0.02) and Ur. protein (p<0.02) at base line but not 
the immunosuppressive protocol.
Conclusion: Progression of recipients with moderate degree of renal 
insuffi ciency after transplant to graft failure depends mostly on the severity of 
functional changes and not on the immunosuppressive protocol.
Cr. baseline 
mg/dL
U-Pr 
baseline
g/24-hr
Cr
1y.
mg/dL
U-Pr
1y.
g/24-hr
Cr.
2y.
mg/dL
U-Pr
2y.
g/24-hr
SIR 2.5+0.4 1.1+1.2 3.1+1.1 2.6+2.4 2.4+0.6 2.7+1.5
TAC 2.5+0.4 1.4+1.9 2.5+0.8 2.9+2.7 2.7+1.5 2.1+2.0
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INCREASED FREQUENCY OF ANGIOEDEMA UNDER 1618 
COMBINED TREATMENT WITH MTOR – AND ACE-
INHIBITOR IN KIDNEY TRANSPLANTED PATIENTS
M. Duerr, P. Glander, F. Diekmann, H-H. Neumayer, K. Budde
Nephrology, Charité University Hospital
Angioedema is a potential life threatening swelling of the face, lips mouth and 
throat. The pathology is driven through infl ammatory mediators that cause 
dilatation and increased permeability of capillaries additionally. The etiology is 
unknown, but under treatment with ACE-I a frequency of 0,1-0,5% developing 
angioedema is described in literature, but also may rapid develop with ARBs.
Because we observed some cases of angioedema we therefore screened our 
electronic patient database for all cases of angioedema under mTOR-therapy 
systematically. We identifi ed 112 patients receiving both ACE-I and mTOR-
therapy (169 patient treatment years). Out of these 27 discontinued ACE-
therapy, of whom six patients (4,5%) developed angioedema after a mean period 
of 98 days (17-255d) under combined therapy. For control group we found 73 
patients receiving ARBs and mTOR-I combined (124 patient treatment years). 
No event of angioedema was reported in control group.
Five patients developed angiodema after initiation of mTOR-therapy, although they 
had been on ACE for 2,75 years (1,3-3,9y) already before the onset of symptoms 
started. One patient developed angioedema 255 days after initiation of ACE-I while 
he had been on Sirolimus for 430 days. All patients recovered rapidly after steroid 
bolus (n=3) and stop of ACE-I therapy (n=6). After the event of angioedema in four 
out of six patients, treatment with ARBS was initiated instead.
Conclusion: Angioedema occurs with a frequency of approximately 4,5% 
under combined therapy with mTOR and ACE-I. Therefore the preferential use 
of ARBs in patients under mTOR-therapy could be justifi ed.
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TREATMENT WITH SIROLIMUS RESULTS IN LESS 1619 
WEIGHT GAIN AFTER KIDNEY TRANSPLANTATION
F. Diekmann1, J. Rovira2, M. Arellano2, J.T. Burke3, Y. Brault3, 
J.M. Campistol2
1Nephrology, Charité Campus Mitte, Berlin, Germany, 2Nephrology and Renal 
Transplantation, Hospital Clínic, Barcelona, Spain, 3Wyeth Research, Paris, 
France
Immunosuppressive treatment after kidney transplantation has been associated 
with undesirable weight gain and obesity. Sirolimus (SRL), as the archetypal 
inhibitor of the mTOR pathway, has demonstrated in experimental models 
signifi cant downregulation of this critical regulatory pathway of nutrient 
signalling and cell growth.The aim of this analysis was to evaluate if treatment 
with SRL results in less weight gain compared with conventional calcineurin 
inhibitor-based treatment.
Methods: Data on body weight and body mass index was pooled from four 
de novo randomized prospective kidney transplant trials. 1421 patients were 
included in the study and were randomized at transplantation to receive 
either a conventional immunosuppressive treatment consisting of a CNI, an 
antimetabolite (MMF or Azathioprine) and steroids or sirolimus plus either 
CsA or an antimetabolite and steroids. Data were analyzed at 1, 6, 12, 24 
months post-transplant.
Results: Results on renal function and transplant outcome were reported earlier 
(Groth et al. Transplantation 1999; Kreis et al. Transplantation 2000; Kahan et 
al. Transplantation Proceedings 2003). Of the 1421 patients 586 completed the 
study phase of two years. At baseline patient weight in the CNI-based and the 
SRL-based groups were 74.6±17.2 and 75.0±16.5 kg. The mean weight gain 
was 8.6±8.6 vs. 5.8±9.3 kg after 24 months in the CNI and the SRL group 
respectively (p<0.001). Mean BMI at baseline was 25.7±5.1 and 25.6±4.7. 
The mean increase of BMI after 24 months was 3.0±3.0 vs.2.0±3.2 (p<0.001). 
In a multivariate analysis signifi cant risk factors related to BMI change were: 
Ethnic origin, treatment based on SRL or CNI, cumulative steroid dose, 
baseline triglycerides, recipient age and gender.
Conclusions: SRL-based treatment is associated with signifi cantly less weight 
gain after kidney transplantation. This could have clinical implications, since 
obesity is an important risk factor for insulin resistance and for cardiovascular 
diseases, which are the main cause of death after kidney transplantation.
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THERAPY OF CALCINEURIN INHIBITOR-INDUCED 1620 
THROMBOTIC MICROANGIOPATHY IN RENAL 
ALLOGRAFTS
N.C.T. Kong1, C.Y. Loo1, A.G. Halim1, M. Rozita1, S. Rashidi1, K.S. Phang1
1Faculty of Medicine, National University of Malaysia, Kuala Lumpur, 
Malaysia
Although thrombotic microangiopathy (TM) is a well recognized albeit rare 
complication of calcineurin inhibitor (CNI) therapy, its treatment is not well 
established. We report a case of tacrolimus (Tac)-induced TM and propose a 
course of treatment for this entity.
Mr MN, a 32 year old teacher developed ESRD due to obstructive uropathy and 
hypertension and was commenced on CAPD in June 2006. In March 2007, he 
received a kidney donated by his spouse. Basiliximab and methylprednisolone 
(MP) were used for induction followed by prednisolone-Tac-mycophenolate 
mofetil. He was discharged 10 days post-surgery with a serum creatinine of 95 
umol/L and a daily urine output of 5-7 L. On follow-up, his serum creatinine 
vascillated between 120-145 umol/L depending on hydration status and serum 
Tac levels were kept within therapeutic ranges. On the 95th day post-transplant, 
his serum creatinine rose steeply from 132 to 162 umol/L despite euvolaemia. 
Physical examination was unremarkable and his blood pressure was 117/63 
mmHg, lying and standing. Results of the usual investigations were all within 
normal limits. However, echodoppler ultrasound of the graft showed a rise 
in the resistive index from 0.68 (fi rst week post-transplant) to 0.8. IV pulse 
methylprednisolone (500 mg daily x3 days) was commenced whilst awaiting 
results of the urgent graft biopsy and Tac was reduced. Graft biopsy showed 9 
glomeruli, 4 of which demonstrated capillary occlusion by microthrombi. The 
tubules, interstitium and other blood vessels were normal and C4d staining 
was negative. A diagnosis of thrombotic microangiopathy (TM) consistent with 
CNI nephrotoxicity was made.
Tacrolimus was substituted with sirolimus. The 3-day course of pulse IV MP 
was completed. Plasmapheresis daily for 3 days was instituted followed by IV 
Gammaglobulins at 10 gm daily for 3 days. Aspirin and dipyridamole were 
also added. His serum creatinine held at 162 umol/L for 2 days then dropped 
progressively to 126 umol/L by 2 weeks post- and 114 umol/L by 50 days post-
event. At last review in February 2008, his serum creatinine was 123 umol/L.
Given our extensive experience with this sequential protocol for the remission-
induction treatment of severe lupus nephritis, we are emboldened to propose 
that this may indeed be a reasonable solution for CCNI-induced TM. Early 
diagnosis is the key to success.
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RETROSPECTIVE COMPARATIVE ANALYSIS OF 1621 
CYCLOSPORINE AND SIROLIMUS BASED TRIPLE DRUG 
IMMUNOSUPPRESSION
A.K. Gupta1, V. Verma1, S. Jasuja1
1Apollo Hospitals, Delhi
Introduction: Calcineurin toxicity signifi cantly contributes to chronic allograft 
dysfunction. We retrospectively analyzed patients who were shifted from 
cyclosporine-MMF- steroid to sirolimus (SRL)-MMF-steroid regimen.
Methods: There were total of 16 patients. Repeated measure ANOVA design 
was done to fi nd signifi cant difference between s. creatinine at conversion and 
six time points 2, 7, 30, 91,182 and 365 days post conversion. Patients were 
divided into 3 sub groups: period of post transplant at conversion (less than or 
equal to 200 weeks (n=11) v/s more than 200 weeks (n=5)); diabetics (n=7) v/s 
non diabetics (n=9); and pre-conversion s. creatinine (less than or equal to 2.2 
(n=10) v/s more than 2.2 mg/dl (n=6)).
Results: Mean (±SD) donor age was 40.14 ± 13.4 years; mean post 
transplant weeks at conversion 109.81 ±13.92; mean post transplant lowest 
s. creatinine (in 2 weeks) 1.5 ± 0.33 mg/dl; mean s. creatinine at conversion 
2.17 ± 0.76 mg/dl, mean s. creatinine post conversion: 2 days 2.02 ± 0.73; 
7 days 1.81 ± 0.44 ; 30 days 1.74 ± 0.46 ; 91days 1.74 ± 0.55;182 days 
1.73 ± 0.81 ; 365 days 1.78 ± 0.64 ; and s. creatinine at last follow up 1.94 
± 1.16 mg/dl. Mean s. cholesterol was 188.31 ± 50.5 mg/dl(all patients 
were on statins pre as well as post conversion). On repeated measure 
ANOVA analysis all values of s. creatinine post conversion (2,7,30,91,182 
and 365 days) were signifi cantly lower as compared to s. creatinine at 
conversion (p<0.05).Mean s. creatinine at conversion and all time points 
post conversion was signifi cantly lower in less than or equal to 200 weeks 
group as compared to more than 200 weeks group. Intra group comparison 
showed that signifi cantly lower s. creatinine at 30,91,182 & 365 days in less 
than or equal to 200 weeks and at 7,30 & 91 days in more than 200 weeks 
group when compared to s. creatinine at conversion. Mean s. creatinine in 
diabetics at conversion and all time points post conversion was higher than 
in non diabetics but could not reach statistical signifi cance (p=0.27). Intra 
group comparison revealed signifi cantly lower s. creatinine at 91 & 182 days 
in non diabetics and at 7, 30, 91, 182 & 365 days in diabetics as compared s. 
creatinine at conversion. Mean s. creatinine in group with s. creatinine more 
than 2.2 mg/dl at conversion remained signifi cantly higher at all time points 
post conversion as compared to group with s. creatinine less than or equal 
to 2.2 mg/dl.S. creatinine was signifi cantly lower at 91, 182 days in group 
with s. creatinine less than or equal to 2.2 and at 7,30,91,812 & 365 days in 
group with s. creatinine more than 2.2 mg/dl post conversion as compared to 
s. creatinine at conversion in intra group analysis.
Conclusion: SRL-MMF-Steroid regimen signifi cantly improves graft function. 
Better results are achieved with early change over from cyclosporine to SRL. 
Diabetics have signifi cantly higher s. creatinine as compared to non diabetics 
and appear to benefi t more from SRL based regimen.
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A REVIEW OF FIVE YEARS OF EXPERIENCE WITH 1622 
SIROLIMUS IN RENAL TRANSPLANT PATIENTS AT INKOSI 
ALBERT LUTHULI HOSPITAL, DURBAN, 
SOUTH AFRICA
A. Assounga, S. Maharaj
Dept of Nephrology, University of KwaZulu-Natal, Inkosi Albert Luthuli 
Hospital, Durban South Africa
Background: Evidence of sirolimus associated nephrotoxicity has recently 
gained focus. To assess the impact of this potential problem, we performed 
a retrospective audit on renal transplant patients receiving sirolimus at Inkosi 
Albert Luthuli Hospital from 2003 until 2007.
Method: Medical records of transplant recipients were analysed.
24 hour urine protein excretion (UPE) and estimated glomerular fi ltration 
rates(eGFR) prior to initiation of sirolimus(baseline) and at their last clinic 
visit were compared. Patients were sub-categorised according to their specifi c 
indications for switching to sirolimus therapy.
Results: 30 patients were included. Average follow-up was 25 months. 
Indications for use of sirolimus were: Group 1:Ciclosporin induced biochemical 
toxicity(n= 6), Group 2: Chronic allograft nephropathy(n= 6), Group 3:Severe 
gum hypertrophy(n= 9), Group 4: Post transplant diabetes(n= 4), Group 
5:Calcineurin inhibitor(CNI) induced histologic nephrotoxicity(n= 2) and 
Group 6:CNI associated malignancy(n= 3).
Average UPE rate and eGFR prior to starting sirolimus were 0.44 ± 0.08 g/24 
hrs and 50.1±3.1 ml/min respectively, compared to 0.94 ± 0.2 g/24 hrs and 
52.1±4.8 at an average follow up of 25 months.
On subgroup analysis, eGFR was increased/unchanged in groups 1(47.3 vs. 
51.16 ml/min) and 4(60.0 ml/min vs. 60.0 ml/min) when compared to baseline, 
but decreased in groups 2(47 vs. 27.6ml/min), 3(51.3 vs. 42.2ml/min), 5(54.0 
vs. 29.5ml/min) and 6(60.0ml/min vs. 56.5ml/min).
UPE rates increased in groups 2(0.30 vs 1.44g/day), 3(0.39 vs. 1.55g/day) 
5(0.08 vs. 0.77g/day) and 6(0.17 vs. 0.53g/day) compared to baseline, but 
was unchanged in groups 1(0.25 vs 0.25g/day) and 4(0.23 vs 0.21 g/day). 
Combining the latter 2 groups, most patients(80%) received sirolimus within 1 
year of transplantation, whereas only 2 patients(10%) received the drug within 
one year of transplantation in the former groups combined.
Conclusion: Overall, sirolimus therapy was associated with an improvement 
eGFR but an increase in UPE rates. Maximum benefi t was achieved when 
patients were switched to sirolimus within the fi rst transplant year.
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TACROLIMUS/CONCURRENT ORAL SESSION 115: 
CYCLOSPORINE
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EXCELLENT RESULTS OF EARLY STEROID 1623 
WITHDRAWAL LOW DOSE TACROLIMUS 
IMMUNOSUPPRESSION IN LIVING DONOR KIDNEY 
TRANSPLANTATION
W-C. Lye
Centre For Kidney Diseases
We present our 10-year, January 1996 - December 2005, single centre 
propectively collected outcome results on an early steroid withdrawal, low 
dose tacrolimus based immunosuppression in low immunologic risk living 
donor kidney transplantation. Induction therapy consisted of either 2 doses 
of basiliximab given 4 days apart or 2 doses of daclizumab, 1 mg/kg body 
wt, given 2 weeks apart. I.v. methylprednisolone 500 mg/day was given for 
3 days beginning on day 0. Oral prednisolone was administered at a dose 
of 30/day for 3 days, 20 mg/day for 3 days, 15 mg/day for 3 days, 10 mg/
day for 3 days and continued on 5.0 mg/day until day 30 post transplant. 
Tacrolimus was started at a dose of 0.2 mg/kg body wt the night before the 
transplant, tacrolimus dose was adjuested to maintain the trough level at 8-12 
ug/L for the fi rst 3 months, 5-8 ug/L from 3-12 months and 4-6 ug/L onwards. 
Mycophenolate was given at a dose of 750 mg b.i.d. for the fi rst 3 months and 
reduced to 500 mg b.i.d. later. Protocol biopsy was performed at day 10 post 
transplant, all suspected acute rejection episodes were biopsied. The 1-year 
acute rejection rate, 1-, 5- and 10-years patient and graft survival rates were 
studied. A total of 210 patients, mean age; 55.3±12.1 years (range 8-78 years), 
males:female; 136:64 were studied. Diabetes mellitus was the cause of end-
stage renal disease in 60% of patients. Subclinical rejection was detected in 5% 
of patients on protocol biopsy but was not treated if there was no rise in serum 
creatinine. The 1-year biopsy-confi rmed acute rejection and steroid-resistant 
rejection rates were 10% and 2% respectively. The 1-, 5-, and 10-years death 
censored graft survival rates were 99%, 95% and 90% respectively. The 1-, 
5- and 10-years patient survival rates were 100%, 92% and 85% respectively. 
De novo diabetes mellitus occurred in 7% of patients at 1-year. 5/210 patients 
developed malignancy, 4 were PTLDs. In conclusion, early steroid withdrawal, 
low dose tacrolimus and mycophenolate based immunosuppression with anti-
IL2 receptor induction therapy is an effective immunosuppression regimen 
with minimal complications for living donor kidney transplantation.
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DRIED BLOOD SPOT MEASUREMENT: APPLICATION 1624 
IN TACROLIMUS MONITORING USING LIMITED SAMPLING 
STRATEGY AND ABBREVIATED AUC ESTIMATION
C.Y. Cheung1, J. van der Heijden2, K. Hoogtanders2, M. Christiaans2, 
K.F. Chau1, C.S. Li1, J. van Hooff 2, L. Stolk2
1Queen Elizabeth Hospital, Hong Kong, 2University Hospital Maastricht, the 
Netherlands
Dried blood spot sampling and high-performance liquid chromatography-
tandem mass spectrometry (HPLC-MS), has been developed in monitoring 
tacrolimus levels. Our center favors the use of limited sampling strategy and 
abbreviated formula to estimate the AUC0-12. However, it is inconvenient 
for patients because they have to wait in the center for blood sampling. We 
investigated the application of dried blood spot method in tacrolimus level 
monitoring using limited sampling strategy and abbreviated AUC estimation 
approach. Duplicate venous samples were obtained at each time point (C0, 
C2 and C4). To determine the stability of blood samples, one venous sample 
was sent to our laboratory immediately. The other duplicate venous samples, 
together with simultaneous fi ngerprick blood samples, were sent to the 
University of Maastricht in the Netherlands. Thirty six patients were recruited 
and 108 sets of blood samples were collected. There was a highly signifi cant 
relationship between AUC0-12 estimated from venous blood samples and 
fi ngerprick blood samples (r2=0.96, p<0.0001). Moreover, there was excellent 
correlation between whole blood venous tacrolimus levels in the 2 centers 
(r2=0.97; p<0.0001). The blood samples were stable after long distance 
transport. Dried blood spot sampling can be used in centers using limited 
sampling and abbreviated AUC0-12 strategy as drug monitoring.
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TACROLIMUS AND TIBOLONE: A POSSIBLE DRUG 1625 
INTERACTION OF WHICH TRANSPLANT CLINICIANS 
SHOULD BE AWARE
C.J. Clark, D.W. Mudge, C.M. Hawley
Nephrology Department, Princess Alexandra Hospital, Brisbane
Tibolone is a synthetic steroid increasingly used as a hormone replacement 
therapy. It is known to have only weak interactions with the cytochrome P450 
enzyme system. We report a case in which a patient who underwent renal 
transplantation six years previously developed acute renal failure ten days after 
starting tibolone. The likely cause of the acute renal failure was tacrolimus 
toxicity, as her tacrolimus level increased from 5 μg/l to 17 μg/l. She displayed 
symptoms of toxicity including fi ne tremor and anxiety. Both the serum 
creatinine and the tacrolimus levels returned to normal within two weeks of 
ceasing tibolone therapy, and the symptoms resolved. We believe this was a 
signifi cant drug interaction of unknown mechanism.
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CONVERSION FROM CYCLOSPORINE TO 1626 
TACROLIMUS BASED IMMUNOSUPPRESSION THRAPY IN 
RENAL TRANSPLANT RECIPIENTS
L. Bäckman
Transplant Institute
Body: This is an an interim analysis of an investigator-driven multicenter trial in 
renal transplant recipients: the Prospective Quality of life Renal Transplantation 
Switch Study; Tacrolimus-based immunosuppression (PQRST study).
Patients and methods: Patients included in the trial were initially treated 
with cyclosporine-based immunosuppression after renal transplantation. They 
experienced cyclosporine- or steroid-related side-effects, such as hypertension, 
hyperlipidemia, hypertrichosis, or other adverse reactions and were converted 
to a tacrolimus-based immunosuppressive regimen (n = 76). Steroids were 
subsequently discontinued between 3 and 6 months after the conversion. 
Follow up ranged from 2 to 24 months.
Results: One patient died from a PTLD 7 months after the conversion. This event 
was however not felt to be related to the change in immunosuppression. There 
have been no acute rejection episodes and no other grafts were lost. As of today 
19/31(60%) patients, who have completed at least 6 months, are successfully 
weaned off steroids with the remaining patients in this process. No patient 
experienced an acute rejection episode. The blood pressure and the need for 
antihypertensive medication decreased. No patient developed de novo diabetes or 
other serious side effects related to the conversion. Three patients were withdrawn 
from the trial because of bleeding, depression, and proteinuria. However, none 
of these adverse events were felt to be directly related to the change of the 
immunosuppressive regimen to tacrolimus based immunosuppression.
In conclusion, conversion from cyclosporine to tacrolimus-based 
immunosuppressive therapy was safe and well tolerated and may improve the 
cardiovascular risk profi le after kidney transplantation.
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CLINICAL AND HISTOLOGICAL ANALYSIS OF 1627 
CHRONIC TACROLIMUS (TAC) NEPHROTOXICITY IN RENAL 
ALLOGRAFTS
T. Shimizu1, H. Ishida1, K. Omoto1, H. Shirakawa1, T. Tokumoto1, K. Tanabe1, 
Y. Yamaguchi2
1Tokyo Women’s Medical University, 2Department of Pathology, Kashiwa 
Hospital, Jikei University School of Medicine, Chiba, Japan
Aim of study: Tacrolimus (TAC) is an effective primary immunosuppressive 
agent in kidney transplantation. Chronic nephrotoxicity due to TAC in kidney 
transplant patients was reported to be similar to that of cyclosporin A (CYA). 
However, the severity and infl uence of chronic TAC nephrotoxicity are not 
fully elucidated, the clinico-histological characteristics of chronic TAC 
nephrotoxicity in kidney transplants were studied.
Patients and methods: We studied retrospectively the clinico-histological 
profi les of fi fteen transplant patients under TAC-based immunosuppression, 
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who were diagnosed as chronic TAC nephrotoxicity by allograft biopsies 
showing a characteristic arteriolopathy (PAS-positive hyaline thickening 
in small arteries), which underwent at Tokyo Women’s Medical University 
between January 2004 and December 2005. Mean age of their recipients was 
37.3 years old and they consisted of 11 males and 4 females. The mean age of 
their donors was 59.4 years old.
Results: The diagnoses of chronic TAC nephrotoxicities were done at an 
average of 54.7 months postoperatively. The severities of arteriolopathy were 
moderate in 8 cases and severe in 8 cases. The mean dosage of TAC at the time 
of diagnoses was 0.054 mg/kg. Mean trough level of the whole blood TAC 
was 5.09 ng/mL which was recognized within so called recommended level. 
The moderate to severe arteriosclerosis of medium sized arteries were seen in 
twelve (80.0%).
Conclusion: The existence of moderate to severe arteriosclerosis in medium 
sized arteries would have the potential of causing chronic TAC nephrotoxicities, 
rather than the TAC dosage and the trough level of the whole blood TAC.
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TACROLIMUS ONCE-DAILY PROLONGED RELEASE 1628 
VERSUS TACROLIMUS TWICE-DAILY IN COMBINATION 
WITH MMF AND STEROIDS – A PHASE III MULTICENTRE 
RENAL STUDY
B. Banas, B. Krämer1, B. Charpentier2, L. Bäckman3, H.T. Silva Junior4, G. 
Mondragon5, E. Cassuto-Viguier6, G. Mourad7, R. Sola8, E. Ancona9, 
J. Ortuno Mirete10
1University of Regensburg, 2Hôpital Bicêtre, 3Sahlgrenska University 
Hospital, 4Fundacao Oswaldo Ramos – UNIFESP, 5Instituto Mexicano de 
Transplantes, 6Service de Nephrologie, 7Hôpital Lapeyronie, 8Servicio de 
Nefrologia, 9Azienda Ospedaliera di Padova, 10Servicio de Nefrologia
Introduction: Tacrolimus prolonged release (Advagraf®, ADV) is a once-daily 
formulation of tacrolimus with similar exposure and trough levels compared to 
the well-established twice-daily formulation (Prograf®, PRO). This 12-month 
study was designed to compare the effi cacy and safety of ADV and PRO in de 
novo renal recipients.
Methods: The study was performed in 74 transplant centres and 22 countries. 
This was a double-blind, double-dummy study with patients randomised 
1:1 to PRO or ADV. Patients received a daily tacrolimus dose of 0.2 mg/kg 
combined with MMF 2 g/day (1 g/day after Day 14) and steroid taper (0-5 mg/
day after Day 84). The fi rst dose of PRO or ADV was given within 12 hrs prior 
to reperfusion. MMF was also started pre-operatively. For both treatment arms 
tacrolimus whole blood trough levels were targeted at 10-15 ng/mL to Day 28, 
then 5-15 ng/mL to Day 168 and 5-10 ng/mL thereafter. The primary end point 
was the event rate for biopsy proven acute rejection (local BPAR, per protocol 
set with non-inferiority comparison set at 10%) at 24 weeks with a further 
6-month extended open follow-up. Acute rejection, patient and graft survival, 
and creatinine clearance (Cockroft & Gault) were also assessed at 24 weeks and 
12 months. Adverse events and safety parameters were recorded throughout.
Results: 336 PRO and 331 ADV patients received at least one dose of study 
medication with 275/336 (81.8%) PRO and 257/331 (77.6%) ADV patients 
completing the 12-month study. Reasons for withdrawal were similar in both 
arms. Key donor and recipient demographics were not signifi cantly different 
except for mean HLA-DR mismatch with higher risk for ADV (0.9) vs. PRO 
(0.8, p<0.01). Mean daily tacrolimus dose and mean whole blood trough level 
at Week 4 for PRO vs. ADV were 0.16 mg/kg and 12.9 ng/mL vs. 0.21 mg/kg 
and 12.2 ng/mL, and at Months 10-12 were 0.08 mg/kg and 9.0 ng/mL vs. 0.10 
mg/kg and 8.8ng/mL. Kaplan-Meier patient survival at 12 months was 98% 
vs. 97% and graft survival 93% vs. 92% (PRO vs. ADV). Similarly, 24-week 
local BPAR event rates were 14.9% vs. 18.7% (p=0.239); central blinded 
review rates were 14.5% vs. 18.2% (p=0.230). In the per protocol analysis 
with major protocol violators excluded (PRO N=291 & ADV N=280), local 
BPAR events rates were 15.8% vs. 20.3% (p=0.182; treatment difference 
4.5%; 95% CI -1.8%, 10.9%) and central 15.1% vs. 19.6% (p=0.165; 95% 
CI -1.6%, 10.8%) falling slightly outside the predefi ned 10% non-inferiority 
margin. When adjusted for HLA-DR mismatch non-inferiority was established 
for PRO and ADV for local BPAR event rates (treatment difference 1.9%; 
95% CI -4.4%, 8.3%). Creatinine clearance was similar for both arms (mean 
at 12 months 67 mL/min in both arms) and adverse event profi les were similar 
for both regimens.
Conclusions: The study demonstrates that once-daily tacrolimus prolonged 
release Advagraf® was well tolerated, conferring similar effi cacy and safety 
profi les to the established twice-daily formulation Prograf®.
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EFFICACY AND SAFETY OF IMMUNOSUPPRESSION 1629 
BASED ON TACROLIMUS OR CYKLOSPORINE IN PATIENTS 
AFTER KIDNEY TRANSPLANTATION – 
A RANDOMIZED PROSPECTIVE STUDY
M. Slupski, Z. Wlodarczyk, M. Tomczak, M. Masztalerz
Department of Transplantation And General Surgery, Collegium Medicum 
Nicolaus Co
Objective: The aim of this research was to evaluate the effectiveness and 
safety of cni-based immunosupression.
Methods: 150 de novo renal transplant patients were randomized to tacrolimus 
(tac group) or cyclosporine microemulsion with mycophenolic acid or 
azathioprine and steroids.
Results: There is no statistical difference in 12-month neither in graft and 
patient survival nor serum creatinine levels. Steroid-sensitive rejection rate 
was higher in cyclosporine group: 20.78% vs. 31.51% (p<0.05). A tendency to 
anaemia was observed in tac group: average hemoglobin level after 6 months 
was lower in tacrolimus group: 12.3 vs. 12.9 (p=0.047). Bilirubin and AspAT 
levels were lower in tacrolimus group (p=0.003. Patients in tacrolimus group 
have lower cholesterol and trigliceryds serum levels (p=0.0002).
Conclusion: No differences in renal function during 12-month were observed. 
In tacrolimus group we observed ten more cases of aneamia, whereas in 
cyclosporine group lipid metabolism and liver function disturbance occurred 
more frequently.
Tacrolimus group Cyclosporine group  p
12 month graft survival 95.59% 96.97% n.s.
12 month patient survival 98.53% 96.97% n.s.
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THE EFFECT OF CONVERSION FROM CYCLOSPORINE 1630 
TO TACROLIMUS IN RENAL ALLOGRAFT RECIPIENT WITH 
HYPERLIPIDEMIA
S. Lee, J.E. Park, S.Y.C. Choi, K-H. Jung, J-Y. Moon, C-G. Ihm, T-W. Lee
Dept.of Nephrology, School of Medicine, Kyunghee University
Background: Calcineurin inhibitors improved the clinical course after 
kidney transplantation. However, they have been implicated in contributing 
to increased cardiovascular risk. We evaluated the change of blood lipid 
and glucose levels and the deterioration of renal function according to the 
conversion from cyclosporine to tacrolimus in renal allograft recipient with 
hyperlipidemia.
Methods: In our single-center prospective study, 23 adult renal recipients 
who were receiving cyclosporine-based regimen with serum total cholesterol 
greater than 200 mg/dL more than 1 year after transplantation and minimal 
dose of steroid (5 mg or less a day) were enrolled. Cyclosporine was replaced 
by tacrolimus. Blood pressure, fasting lipid profi le, glucose and HbA1c were 
measured at baseline and at 3, 6, 12 months after conversion. The change of 
estimated GRF was also compared using data recorded from 1 year before and 
after conversion.
Results: There was a signifi cant improvement in total cholesterol (205.5 +/- 
24.3 to 186 +/- 29.6 mg/dL, P < 0.01)) and low-density lipoprotein cholesterol 
(119.6 +/- 20.1 to 109.1 +/- 16.8 mg/dL, P < 0.01) after conversion. No new 
onset or worsening of diabetes mellitus was observed after conversion. There 
were no signifi cant differences in HDL cholesterol, triglycerides, fasting blood 
glucose and HbA1c levels.
The deterioration of renal function was signifi cantly stabilized with tacrolimus 
(change of eGFR -7.3 +/- 13.5 mL/min under cyclosporine versus -2.9 +/- 13.4 
mL/min under tacrolimus).
Conclusion: Our study susggests that conversion to tacrolimus may be 
preferable over cyclosporine for chronic maintenance immunosuppression in 
renal recipient with hyperlipidemia because it improves cardiovascular risk 
factors and leads to stabilization of transplant function.
Poster Abstracts Wednesday 13 August 2008
5 4 1
W
ED
N
ESD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P3 – 57
FIVE YEARS FOLLOW-UP OF RENAL TRANSPLANT 1631 
RECIPIENTS ON ADVAGRAF MONOTHERAPY: A SINGLE 
CENTRE EXPERIENCE
M. Christiaans1, M. Gelens1, N. Undre2, M. Mullens1, J. van Hooff1
1Departement of Internal Medicine, University Hospital Maastricht, 
The Netherlands, 2Astellas, London, UK
Introduction: The immunosuppressive protocol for low and intermediate 
immunological risk renal transplant recipients in our centre consists of 
tacrolimus and low dose corticosteroids. In non-rejectors corticosteroids are 
withdrawn within the fi rst 3 months. Therefore almost 70% of our patients 
are on one drug, only tacrolimus, as maintenance therapy (ref: Boots et al. 
Transplant Int. 2001; 14: 370-83).
Our centre participated in a open label, multicentre study in which stable renal 
transplant patients were converted from twice daily formulation of tacrolimus 
(Prograf) into a once-daily formulation of tacrolimus prolonged release 
(Advagraf).
In this analysis we present the 5-year clinical data of our patients on Advagraf 
monotherapy.
Methods: Clinical and laboratory data such as immunosuppressive therapy, 
serum Creatinine (median and range), and causes of death, graft failure or 
treatment failure were prospectively collected. Time data are given relative 
towards time of conversion, unless otherwise stated.
Results: Thirty-two patients on Advagraf monotherapy were included.
Patient characteristics at inclusion were: age 54 year, range 21-64 yr, time 
posttransplant 4.6 yr, range 1.3-11.2 yr, serum creatinine 141micromol/L, 
range 79-203micromol/l, and donor type: postmortal n=20; living n=10 (4 
related,6 unrelated).
Patient survival is 97%. One patient died because of lung cancer with a good 
functioning graft (month 28).
There were 4 treatment failures: 2 patients withdraw their consent (resp at month 
3 and 6). In the other two patients their immunosuppression was changed (month 
24 recurrent squamous cell skin cancer and month 22 recurrent disease).
Graft survival censored for death and treatment failure is 100%.
There were no acute rejections.
In 4 patients serum creatinine increased slowly (10-30%).The cause was in 2 
patients a biopsy proven recurrence of IgA nephropathy; in the 2 other patients 
the cause is (still) unknown.
Conclusion: In low – and intermediate immunological risk renal transplant 
patients with stable renal function 4 years after transplantation on Prograft 
monotherapy, conversion towards a single dosage of Advagraf in the morning 
as their only immunosupressant, 5-year patient survival is 97% and 5-year graft 
survival censored for death and treatment failure 100%.
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OPTIMIZING TACROLIMUS THERAPY IN 1632 
MAINTENANCE RENAL ALLOGRAFTS: A SINGLE CENTER 
ASSESSMENT OF CARDIOVASCULAR RISK FACTORS AT 36 
MONTHS
P. Bolin, R. Mirza, P. Sullivan, D. Holbert, K. Parker
Brody School of Medicine, East Carolina University
Purpose: To determine the effect of conversion from Cyclosporine (CsA) 
to Tacrolimus (TAC) based therapy on cardiovascular risk factors and renal 
function at 36 months assessed by cholesterol, low density lipoprotein (LDL) 
and Cystatin C.
Methods: OPTIMA, a 12 month randomized, open label, multi-center study of 
323 stable renal transplant recipients currently receiving CsA were randomized 
1:1:1 to continue CsA (50-250ng/mL); or convert to reduced TAC (3.0-5.9ng/
mL) or standard TAC (6.0-8.9ng/mL). Improvement in total cholesterol 
(p<0.004) and LDL cholesterol (p<0.004) was observed in both TAC groups 
compared with CsA group at 12 months. Renal function improved in the 
reduced TAC group compared to CsA (p<0.001). Sixty patients from our center 
completed the 12-month OPTIMA trial and were followed for an additional 
2 years to determine if these benefi ts could be sustained for 3 years. Patients 
were assessed for renal function and cardiovascular risk factors at year 24 and 
36 months.
Results: Our population consisted of 70% males, 53% African American (AA), 
43% Caucasian and 42% diabetic. Mean transplant vintage was 7.5 years. An 
improvement in total cholesterol, LDL cholesterol and Cystatin C was seen in 
each TAC group over the course of 36 months compared to CsA group.
Conclusion: Results seen in the multi-center trial at 12 months were sustained 
in our single center trial at 36 months. Improvement in renal function was 
maintained at 36 months in patients converted from CsA to TAC. These 
data suggest that reduced TAC dosing provides long term improvement in 
cardiovascular risk factors to renal transplant patients. These benefi ts were seen 
in a cohort of patients who were 53% AA and 42% diabetic and more than 7 
years post transplant.
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A RETROSPECTIVE REVIEW OF TACROLIMUS 1633 
LEVELS IN RENAL TRANSPLANT RECIPIENTS AND GRAFT 
REJECTION
M. Hossain, D. Magrill, M. Morsy, N. Kessaris, R. Chang
St George’s Renal Transplantation Unit
Introduction: In the absence of national guidelines, a retrospective audit 
was undertaken to review the current renal transplant immunosuppression 
regime. There was a perception that the new Tacrolimus target level (8–10ng/
ml) introduced in May 2007 was too low and more rejections observed. Our 
current maintenance protocol includes prednisolone, Mycophenolate Mofetil 
and Tacrolimus.
Methods: All transplant recipients (Feb 2003-Oct 2007) were reviewed for the 
highest C0 (trough) Tacrolimus level achieved within 7 days post-transplant. 
Tacrolimus level of 10ng/ml was considered a cut-of as it represents the highest 
target in the current protocol. Rejection episodes within the fi rst 10 days post-
transplant were recorded.
Results: This audit included 277 renal transplant recipients. Tacrolimus levels 
were ≥;10ng/ml (high group) in 223(80.5%) and <10ng/ml (low group) in 
54(19.5%) recipients. Of the low group, 11(20.4%) had rejection compared to 
22(9.9%) of the high group (p=0.03). There was a difference between recipients 
with high and low Tacrolimus levels with respect to GFR (MDRD) levels at 
one year post-transplant, with a mean of 36.7±21.2 in 31 recipients with high 
Tacrolimus levels compared to 40.7±24.5 in 246 recipients with low Tacrolimus 
levels (p=0.4). Lower GFR levels (31.1±22.5) in rejecting compared with non-
rejecting (41.4±24.1) recipients observed (p=0.02).
Conclusion: Trough Tacrolimus level <10ng/mL was associated with more 
rejection episodes. The authors feel that the current Tacrolimus target, 8-10ng/
mL is low and needs revision. While rejection and high Tacrolimus level have 
adverse effects on the GFR at 1 year, this was not statistically signifi cant when 
comparing Tacrolimus level groups (sample size).
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COST EFFECTIVENESS COMPARISON FOR 1634 
TWO IMMUNOSUPPRESSIVE REGIMENTS IN KIDNEY 
TRANSPLANTATION
H. Vacher-Coponat1, M. Indreies1, V. Moal1, R. Purgus1, J.F. Moussi1, B. 
Dussol1, P. Brunet1, Y. Berland1,2
1Nephrology and transplantation Unit, AP-HM, Hopital Conception, 
Marseille, France, 2Centre d’investigation clinique, AP-HM, Hôpital 
Conception, Marseille, France, 3Université de la méditerranée Aix-Marseille 
2, Marseille, France
Background: Used since the 1990s, tacrolimus (Tac) and mycophenolate mofetil 
(MMF) became the principal immunosuppressive drugs used in transplant 
centers. Their superiority for acute rejection prevention, but not in term of 
renal survival, has been showed when compared with the more older molecules 
cyclosporine (CsA) and azathioprine (Aza). Rates of acute rejections (AR) 
having diminished these last years for more than 40% to about 10% for various 
causes, we have evaluated the real impact of this expensive drugs today. So, we 
have conduced a randomized trial for compare two sequential quadritherapies 
associating rabbit anti-thymocytes, steroids, anticalcineurine and antimetabolic 
drugs (Cisclosporine microemulsion associated with Azathioprine (CsA/Aza) 
or Tacrolimus with Mycophenolate Mofetil (Tac/MMF)). We report here the 
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cost-effi ciency analysis for this two immunosuppressive regiments
Patients and methods: 289 patients were included in this prospective, open-
label, randomize, monocentric study after written consent. The primary end 
point was the rate of clinical suspected acute rejections during the fi rst year, 
with an expected rate to 25% in the CsA/Aza group and an envisaged reduction 
risk to 50% with Tac/MMF
Results:
CSA/Aza
nb (%)
Fk/MMF
nb (%° p
Acute Rejection
Clinically suspected
patients number 21(14,4%) 11 (7,7%) ns
events number 26 13 ns
Biopsy confi rmed
Patients number 21(14.4%) 8 (5.6%) <0.05
total 23 9 <0.02
Kidney death 6 (4.1%) 10 (6.9%) ns
Patient death 2 (1.4%) 4 (2.8%) ns
Creatinine (mmol/l) 148.9 ±55.59 134.9 ±56.08 0.044
DGFe (MDRD) 47.7 ±1.4 52.7 ±1.4 0,0106
Hemoglobin (g/dl) 12.8 ±1.7 13.4 ±1.6 0.008
Delayed Graft Function 23.4% 30.9% ns
Treatment at M12
CsA/Tac posology (mg/J) 234.2 ±5.9 5.8 ±0.2 NA
Aza/MMF posology (mg/J) 83.9 ±8.9 1263 ±61.1 NA
Withdrawal/switch CsA/Tac 5.11% 5.51% ns
Withdrawal/switch Aza/MMF 17.2% 16.4% ns
Cost for immunosuppressive drugs (day)
Antimetabolic agents (€ /j) 7.97 ±0.38 0.54 ±0.06 <0.0001
anticalcineurine (€/j) 10.25 ±0.31 15.17 ±0.72 <0.0001
Secondary effects
CMV Diseases 27.6% 39.6% 0.034
Cancers 5 3 ns
Skin 2 1
PTLD 2 1
Miscellaneous 1 1
Diabetes at M12 (Treatment)
Total de novo 8% 12.61% ns
Treated with insulin 4.80% 5.88% ns
HbA1C >6% 41.5% 44% ns
HTA (treated) at M12 86.86% 74.22% <0.01
Hyperlipidemia at M12
Treated with statins 56.93% 41.41% <0.02
Cholesterol (mg/l) 2.10 ±0.48 2.04 ±0.43 ns
LDL (g/l) 1.27 ±0.78 1.35 ±1.32 ns
Triglycerids (g/l) 1.59 ±0.87 1.57 ±1.00 ns
Conclusions: The primary end point, clinical suspected acute rejection, was not 
signifi cantly different between the two groups. With Tac/MMF, renal function 
was improved for 5 ml/min and the biopsies confi rmed acute rejection rate was 
slightly lowered. These results are obtained with more CMV infections and an 
additional cost of 320 € (480$ US) each month. So, with rabbit antithymocyte 
induction, CsA/Aza remains a valid alternative to more expensive treatments 
Tac/MMF.
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LONG-TERM CARDIOVASCULAR RISK IN RENAL 1635 
TRANSPLANTED PATIENTS RECEIVING CALCINEURIN 
INHIBITORS DRUGS: EXPERIENCE OF A SINGLE CENTER
I. R. Vicente1, J.V. Torregrosa1, J. Cantoni2, F. Oppenheimer1, 
J.M. Campistol1
1Renal Transplant Unit. Department of Nephrology and Renal Transplant. 
University Clinic Hospital, 2Bioclever. Barcelona
Introduction: Cardiovascular (CV) pathology is the fi rst cause of death after 
kidney transplantation. The estimated CV risk usually used in the general 
population is not usefull to the transplant recipient. The objective of this study 
is to know the risk factors that contribute to the high CV in our area.
Methodology: This is a retrospective study of patients receiving calcineurin 
inhibitors with a follow-up of 5 years. We collected epidemiologic and clinical 
data related to CV (familiar and personal history, medication, blood pressure, 
and metabolic profi le) before and after transplantation and immunosuppressive 
therapy, renal function and graft and patient survival. Univariant analysis 
of Cox, the Bonferoni test and multivariate analysis (automatic method for 
selection of variables “stepwise”, for logistic method “Likelihood “ and “wald” 
test) were applied (SAS vs 9.1)
Results: 189 patients with a mean age of 50.8 ± 16,03 years were included 
(62.23% males). The mean follow up was 98.81 ± 89.13 months. 12.7% had pre 
transplant CV disease. The incidence of CV events after transplantation was of 
15.34% (18 with ischemic heart disease, 6 with cerebrovascular disease and 9 
with peripheral vascular disease). We fi nd that age, etiology of renal disease, 
CV disease, arterial hypertension, vascular calcifi cation, hyperlipidemia and 
obesity, and levels of glycoside hemoglobin before transplantation, were 
signifi cantly related to CV risk after transplantation. During the follow-up, 
new-onset diabetes mellitus (NODM), renal function, use of the antiplatelet, 
lipid- lowering and antihypertensive drugs, and levels of lipids and uric acid, 
were signifi cantly related to CV risk. Immunosuppressive therapy and arterial 
hypertension (43,39% had a good control of blood pressure) did not show 
statistical signifi cance relation with CV risk.
Conclusion: In transplanted patients receiving anticalcineurinic drugs, renal 
function, lipid profi le and NODM are the main modifi cable CV risk factors.
EVEROLIMUSCONCURRENT ORAL SESSION 116: 
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EVEROLIMUS-ASSOCIATED PNEUMONITIS1636 
J. Otton1, C. Hayward1, A. Keogh1, E. Kotlyar1, P. Macdonald1, M. Malouf1, 
A.R. Glanville1
1Heart and Lung Transplant Unit, St Vincent’s Hospital, Sydney
Although pulmonary toxicity from sirolimus was fi rst reported in 2000, the 
biochemically homologous everolimus has been thought to be free from this 
side effect. Indeed, everolimus has been proposed as an alternative agent to 
sirolimus in some cases of sirolimus pulmonary toxicity.
We report two cases of acute onset and one case of sub-acute onset 
pneumonitis in association with everolimus therapy for heart transplantation 
immunosuppression. Serum everolimus levels were within or below 
typical therapeutic range at the time of onset of pneumonitis. In each case 
marked dyspnoea manifested as the primary symptom and was mirrored by 
hypoxia and the radiological appearance of bilateral pulmonary interstitial 
infiltrates on chest x-ray and computed tomography. The pneumonitis 
was associated with a normal white cell count but raised serum c-reactive 
protein. Symptoms and imaging improved or normalised after cessation 
of everolimus.
Investigations for alternative diagnoses were negative. The bronchoalveolar 
lavage (BAL) in the two acute cases showed an increased neutrophil count in 
the absence of a signifi cantly raised lymphocyte count. Culture of the BAL was 
negative as was indirect fl uorescent assay (IFA) and serology for viruses and 
other respiratory pathogens. Left ventricular function on echocardiography and 
endomyocardial biopsies were normal.
Pt Age Time from transplant
Everolimus 
level 
Time to 
onset
Time to
recovery
Negative investigations 
for other causes
1 32 3 days 7.9 ng/ml 2 weeks 2 weeks
BAL, IFA, serology, 
echocardiogram, 
endomyocardial biopsy
 2 69 13 years 2.8 ng/ml 2 weeks 8 weeks
BAL, IFA, serology, 
echocardiogram, 
endomyocardial biopsy
 3 60 15 years 5.5 ng/ml 6 months 3 months
Echocardiogram, 
endomyocardial 
biopsy.
We consider that these cases provide evidence to support an everolimus-
induced pneumonitis based on the temporal course, radiographic features and 
absence of other causative factors despite extensive investigation. We conclude 
that everolimus-induced pneumonitis should be considered as part of the 
differential diagnosis of pulmonary infi ltrates and dyspnoea in the transplanted 
patient receiving everolimus therapy.
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METABOLIC CHANGES FOLLOWING CONVERSION 1637 
FROM AN ANTICALCINEURINC BASED THERAPY TO AN 
EVEROLIMUS BASED ONE. A SINGLE CENTER EXPERIENCE
J. Morales, M. Ayala, A. Fierro, C. Herzog, L. Calabran, E. Buckel
Centro de Trasplante Clínica Las Condes
Everolimus (EVL) a mammalian target of rapamycin antagonist has been 
recently introduced into solid organ transplantation either associated to 
low dose of anticalcineurincs (CNI) or replacing them in order to avoid 
nephrotoxicity and chronic allograft nephropathy. Due to molecular similarities 
with Sirolimus it has been expected the same incidence of metabolic changes 
and adverse events; this is intensively investigated at the present time. We 
studied retrospectively recipients of kidney allograft converted from CNI to 
EVL during a 12 months period. Patients received a standard dose of EVL 
starting with 1.5 mg/day, afterwards titrating the dose in order to get trough 
levels in the range of 3 to 5 ug/ml. Patients effectively achieved mean EVL 
trough levels of 5.2 ug/ml, 4.0 ug/ml and 4.5 ug/ml at 1, 6 and 12 months 
respectively. One year following conversion calculated creatinine clearance 
increased from 57 to 63 ml/min and proteinuria did not change. Fasting blood 
glucose levels decreased signifi cantly following conversion to EVL. During 
the same time period no signifi cant changes were observed in body weight, 
body mass index, serum albumin, cholesterolemia, triglyceridemia, HDL 
cholesterol, LDL cholesterol, lowering lipid medication requirements, blood 
magnesium and uric acid. We conclude that EVL does not negatively infl uence 
different nutritional parameters.
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EVEROLIMUS-BASED SEQUENTIAL 1638 
IMMUNOSUPPRESSION IN EXTENDED-CRITERIA DONORS 
RENAL TRANSPLANTATION: ONE-YEAR RESULTS OF AN 
OBSERVATIONAL STUDY
L. Benozzi, D. Bonucchi, G. Cappelli, F. Ravera, D. Davoli, V. Albertazzi, 
Z. Gissara, G. Mori, A. Albertazzi
Nephrology, Dialysis and Kidney Transplantation. Policlinico Hospital – 
Modena
Introduction and aims: According to Everest Study, suggesting the usefulness 
of high-dose everolimus (Ev) in combination with low-dose Cyclosporine 
(CyA), we started an observational, not randomized, single center study 
aimed to protect patient (pt) and graft (G) against early and late transplant 
complications. Due to the increasing utilization of extended criteria donors 
(ECD), it is very hard to face at once delayed graft function (DGF), acute 
rejection (AR), wound healing problems (WHP), chronic allograft nephropathy 
and long-term CNI toxicity.
Methods: HPK2 includes basiliximab on POD 0 and 4, Mycophenolic Acid 
720 mg bid from POD 0 till switch to Ev (maximum overlap allowed 7 days), 
delayed Cyclosporin A (CyA) at 2 mg/kgBW bid since serum creatinine (SCr) 
is < 3 mg/dl (target C2 around 1000 ng/ml). On POD 21 Ev is started (0.75 
mg bid) and targeted to TLC between 8-10 ng/ml, while CyA is reduced to C2 
around 350 ng/ml. Steroid is started at 16 mg/day, after a 500 mg bolus during 
surgery and 200 mg on POD 1. Steroid is tapered to 4 mg/day within 45 days. 
After 6 mos, target levels are 6-8 for Ev and 250 for CyA C2. 
ECD donors accounted for 13/20 G: 6 double G with a mean Karpinsky score 
(Ks) of 4.5 and 7 single G (mean Ks 2.7).
Here we present results of 20 pts followed-up for a mean of 12 mos (range 
3-25). Outcomes were Ev TLC, CyA C2 and SCr from POD 25 to 365, pts and 
G survival, drop-outs, prevalence of post-transplant diabetes (PTDM).
Results: Four out of 24 patients were excluded before switch to Ev because 
of WHP. We observed 3 DGF (15%), 4 biopsy proven AR (3 Banff 1a and 1 
Banff 1b) at 7,70,90 (drop-out) and 100 POD (20%). Two acute miocardial 
infarctions (1 fatal after 3 mos) occurred (Pts survival 95%); death-censored G 
survival was 95%. PTDM occurred in 3 pts (15%).
High protection K2 - Drugs levels and graft function by Post-Operative Day 
(POD) after transplantation
HPK2 POD 25 30 90 180 210 365
TX n 20 20 19 17 12 10
ECD n (%) 13 (65) 13 (65) 13 (68) 13 (76) 9 (75) 8 (80)
C2 CyA m±sd 543±174 269±162 264±97 285±115 266±96 282±72
Evero m±sd 5.5±2.6 7.9±3.7 9.2±3.1 9.2±2.7 9.8±1.9 7.8±1.9
SCrm±sd 1.74±.87 1.51±.65 1.61±.42 1.57±.37 1.75±.42 1.89±.44
Drugs levels are ng/ml; SCr is mg/dl - ECD: Extended Criteria Donors
After one year, one pt is off CyA (85 years old donor) and one is off steroid 
(PTDM); the mean daily doses of drugs are: Ev 1.3 mg, CyA 67 mg and steroid 
3.8 mg.
Conclusions: In a cohort of grafts with a high proportion of ECD donors, the 
sequential HPK2 protocol gave satisfactory results. This drug combination is 
easy to handle, since Ev and CyA target levels are reached within 10 days after 
switch. In our serie, WHP don’t seem to be linked to Ev. The slight increase in 
SCr after six mos could be explained by drugs levels above the target and/or by 
the increasing prevalence of ECD donors over time. Increasing our case-load 
and closer tapering of drugs will allow a comparison of these different factors. 
Protocol biopsy around 9-12 mos could address the question of sub-clinical 
rejection.
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THE RISK OF WOUND HEALING COMPLICATIONS IS 1639 
COMPARABLE IN PATIENTS TREATED BY EVEROLIMUS 
VERSUS MPA IN THE EARLY PHASE AFTER KIDNEY 
TRANSPLANTATION
C. Legendre5, M-C. Moal1, E. Cassuto2, L. Rostaing3, F. Berthoux4, 
F. di Giambattista6, J. Dantal7
1Hôpital La Cavale Blanche, Brest, France, 2Hôpital Pasteur, Nice, France, 
3Hôpital de Rangueil, Toulouse, France, 4Hôpital Nord – CHU, Saint Etienne, 
France, 5Hôpital Necker, Paris, France, 6Novartis Pharma SAS, Rueil-
Malmaison, France, 7Hôpital Hôtel Dieu, Nantes, France
Introduction: The proliferation signal inhibitor (PSI) sirolimus has been 
associated with delayed tissue regeneration following initial transplant surgery. 
After the introduction of everolimus (EVL), a PSI with a more favorable 
pharmacokinetic profi le, markedly fewer post-surgical complications have 
been observed in de novo cardiac transplantation compared with mycophenolic 
acid (MPA). We report here a post-hoc analysis of the incidence and type of 
wound healing complications in kidney transplant patients randomized to EVL 
or MPA during the fi rst 4 weeks post-transplant.
Methods: CALLISTO was a multicenter, open-label, 12-month study in de 
novo deceased-donor kidney transplant patients at protocol-specifi ed risk of 
delayed graft function (donor age >55 years, cold ischemia time ≥24 hours 
and <40 hours, or second/ subsequent transplant). For the fi rst 4 weeks post-
transplant, patients were randomized to receive (a) EVL initiated ≤48 hours 
post-transplant at a starting dose of 1.5mg/day, adjusted to target trough level 
3-8ng/mL, with low-exposure cyclosporine (CsA; C2 target 500-700ng/mL) or 
(b) MPA according to local practice with standard CsA (C2 target 1100-1500ng/
mL). All patients received steroids and anti-IL-2 receptor induction. Wound 
healing complications were classifi ed as fl uid collection, wound dehiscence 
or urine leak. 
Results: 65 EVL and 74 MPA patients were recruited. Demographics were 
similar, including risk factors for wound healing complications (recipient age 
57.3±10.5 years versus 58.4±9.9 years; BMI 24.0±3.4kg/m2 versus 24.6±3.5kg/
m2, respectively). EVL exposure was within target range of 3-8ng/mL. Mean 
MPA dose at week 4 was 1427±175mg/day. Mean CsA C2 at week 4 was 
854±213ng/mL and 1105±281ng/mL in the EVL and MPA groups, respectively. 
Biopsy-proven acute rejection occurred in 3 EVL patients (4.6%) and 1 MPA 
patient (1.4%) by week 4. Study drug was discontinued due to wound healing 
complications in 1 EVL patient (1.5%) and 2 MPA patients (2.7%). Wound 
healing complications reported as serious adverse events within 4 weeks 
occurred in 2 (3.1%) and 4 (5.4%) patients in the EVL and MPA groups, 
respectively. Overall, wound healing complications reported as adverse events 
were distributed equally between groups at 4 weeks (Table).
Conclusions: EVL with low-exposure CsA or MPA with standard-exposure 
CsA as initial immunosuppression after kidney transplantation are associated 
with a similar profi le of wound healing complications. 
Incidence at week 4 Everolimus (n=65) MPA (n=74)
Wound dehiscence 0 (0.0%) 2 (2.7%)
Urine leak 2 (3.1%) 3 (4.1%)
Total wound healing complications 14 (21.5%) 17 (23.0%)
Fluid collection on protocol ultrasound 18/49 (36.7%) 19/55 (34.5%) 
Wednesday 13 August 2008 Poster Abstracts
5 4 4
W
ED
N
ES
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P3 – 66
MULTI-CENTER, OPEN-LABEL, PROSPECTIVE, 1640 
RANDOMIZED, PARALLEL GROUP STUDY INVESTIGATING 
AN EVEROLIMUS-BASED CNI-FREE REGIMEN IN 
COMPARISON TO A CYCLOSPORINE-BASED STANDARD 
THERAPY IN DE NOVO RENAL TRANSPLANT PATIENTS 
(ZEUS STUDY)
K. Budde1, J. Klempnauer2, W. Arns3, C. Sommerer4, P. Reinke5, 
U. Eisenberger6, W. Fischer7, S. Kramer7, F. Pietruck8
1Nephrology, Charité, Berlin, Germany, 2Department of Visceral and 
Transplantation Surgery, Hannover Medical School, Hannover, Germany, 
3Cologne General Hospital, Merheim Medical Centre, Cologne, Germany, 
4Department of Nephrology, University Hospital, Heidelberg, Germany, 
5Department of Nephrology and Internal Intensive Care, Campus Virchow 
Clinic, Charité University Medicine, Berlin, Germany, 6Department of 
Nephrology and Hypertension, University Hospital of Bern, Switzerland, 
7Novartis, Nuernberg, Germany, 8Department of Nephrology, University 
Hospital, School of Medicine, Essen, Germany
The ultimate aim of immunosuppressive therapy in transplantation is to 
provide an effi cacious regimen while minimizing non-immune toxicities. 
By combining synergistic drugs, it may be possible to reduce the exposure 
to individual agents and therefore avoid adverse effects whilst maintaining 
favorable clinical outcomes. Until now, no therapy has been recognized 
as being effi cient in the prevention of long-term allograft loss due to 
chronic allograft dysfunction (CAD) refl ecting an unmet medical need in 
transplantation. Therefore, the use of antiproliferative drugs like Everolimus 
in combination with the withdrawal of CNI has become an interesting concept 
in treating calcineurin inhibitor toxicity leading to chronic slow deterioration 
of renal allograft function.
Therefore, the purpose of the here presented ZEUS study was to assess whether 
an Everolimus-based CNI-free regimen is as safe and well-tolerated as the 
Cyclosporine-based standard regimen but results in a better renal function. 
This 1-year, prospective, open-label, randomized, parallel group, controlled 
study compared the effi cacy, safety and tolerability of an immunosuppressive 
regimen with Everolimus and EC-MPS to that of Cyclosporine (CsA) and EC-
MPS in renal allograft recipients.
The study population consisted of a representative group of 300 de novo 
kidney transplant recipients. For the fi rst 4.5 months post transplantation, all 
patients were treated with Basiliximab as induction therapy, CsA, EC-MPS 
and corticosteroids. 4.5 months post-transplant patients were randomized 
1:1 to either a) (n=150) continue the current regimen of CsA and EC-MPS 
(720mg BID) or b) (n=150) to convert from CsA to Everolimus over a 4 
week period and continue with Everolimus (adjusted according to trough 
levels of 6-10 ng/ml) and EC-MPS (720mg BID). Corticosteroids were 
prescribed according to center practice with a minimum dose of 5 mg/day. 
The effi cacy of the two treatment arms was assessed by the determination 
of Glomerular Filtration Rate (GFR), calculated according to Nankivell-
method (primary endpoint), Cockcroft-Gault method, and MDRD method, 
Serum creatinine and slope of creatinine and rejection episodes (treated 
and biopsy proven), graft loss, death, lost to follow up, as well as treatment 
failure as a composite endpoint. The patients will be followed-up for safety 
and graft survival for additional 4 years. At the ICTS we will present the 
data on the primary and secondary endpoints, safety and effi cacy of 285 
randomized patients.
In summary, the ZEUS study results are adequate for investigating the infl uence 
of different immunosuppressive regimens with or without CNI on short- and 
long-term renal function. Our data – which will be presented at ICTS - will 
contribute to the knowledge about CNI-free regimens in renal transplantation. 
Furthermore, the study will shead some light to the important question about 
the time point of switching the immunosuppressive regimen from a CNI-based 
to a CNI-free therapy.
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EFFICACY AND SAFETY OF EVEROLIMUS 1641 
WITH LOW DOSE CYCLOSPORINE A COMPARED 
WITH MYCOPHENOLATE MOFETIL AND FULL DOSE 
CYCLOSPORINE A IN DE NOVO RENAL TRANSPLANT 
RECIPIENTS
G. Miserlis, V. Papanikolaou, G. Vergoulas, N. Antoniadis, I. Fouzas, D. 
Vrochidis, A. Papagiannis, G. Imvrios, D. Giakoustidis, D. Takoudas
Organ Transplant Unit,Hippokration General Hospital, Thessaloniki, Greece
Proliferation signal inhibitors (mTOR inhibitors) are used in combination with 
calcineurin inhibitors for acute rejection prophylaxis and prevention of chronic 
rejection in renal transplantation.
The purpose of the study was to evaluate and compare the effi cacy and safety 
of two different immunosuppressive protocols (Group A: steroids, everolimus, 
reduced dose CsA, basiliximab vs. Group B: steroids, MMF, full dose CsA, 
basiliximab) in de novo renal transplant recipients (RTR).
The analysis included 74 RTR (Group A: 33 pts, Group B: 41 pts) transplanted 
between January 2005 and March 2007. Recipients and donors mean age 
were 44.5 and 57.8 years respectively. Sixteen patients (48.5%) from group 
A and 27 pts (65.9%) from group B had received the kidney allograft from 
deceased donors. Everolimus and CsA starting dose in group A were 2mg/d 
and 2mg/KgBW/d while MMF and CsA dose in group B were 2g/d and 5mg/
KgBW/d respectively. The mean (±SD) GFR was higher in group A than in 
group B patients (60.3±14.7 vs 51.3±15.8 ml/min/1.73m2 ,p<0.05) six months 
post transplantation. There was not noticed any signifi cant difference of GFR 
between the two groups 1 and 12 months after transplantation. Serum creatinine 
and urine albumin did not differ signifi cantly between the two groups 1, 6 and 
12 months post transplantation. Total and LDL cholesterol were statistically 
signifi cant increased in RTR on immunosuppressive regimen with everolimus 
at 6 and 12 months after transplantation. (T-cholesterol of group A, 6 and 12 
months post transplantation: 278.48±70.98mg/dl and 259.29±84.67mg/dl vs 
T-cholesterol of group B: 217.37±76.39mg/dl and 202.6±59.21mg/dl, p<0.05 
and LDL of group A, 6 and 12 months post transplantation: 187.66±56.97mg/
dl and 178.47±50.31mg/dl vs LDL of group B: 131.39±35.58mg/dl and 
126.18±30.54mg/dl, p<0.05). The incidence of biopsy proven acute rejection 
(BPAR) was 12.1% (4 pts) in group A vs 22% (9pts) in group B. CMV infection 
occurred in 3 RTR of group A and in 5 of group B. Everolimus trough levels 
ranged from 3.35 to 9.18ng/ml in group A. CsA dose was reduced by 27.5% 
and 31.3% at 12 and 18 months post transplantation in group A and this was 
resulted in reduction of CsA C2 levels by 38.21% and 45.5% at the same time 
intervals. In conclusion, although mTOR inhibitors are associated with several 
class specifi c adverse reactions (hyperlipidemia), concentration-controlled 
everolimus therapy of de novo renal transplant recipients provide effective 
protection against rejection with good renal allograft function when used in 
combination with reduced dose CsA, steroids and basiliximab.
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EARLY DIAGNOSIS OF HEPATIC ARTERY THROMBOSIS 1642 
AFTER LIVER TRANSPLANTATION WITH AN ICG-
CLEARANCE NON-INVASIVE TECHNIQUE
F. Saliba, E. Levesque, S. Benhamida, P. Ichaï, D. Azoulay, R. Adam, 
D. Castaing, D. Samuel
Hopital Paul Brousse, Centre Hépato-Biliaire, Université Paris Sud, Unité 
INSERM N°785, Villejuif-FRANCE
Hepatic artery thrombosis (HAT) is a life threatening complication that occurred 
in 2 to 12% of liver transplant recipients. The diagnostic performance of Doppler-
ultrasonography (D-US) is reported to be excellent with 91% sensitivity. False 
positive results, i.e. non-visualization of fl ow, are considered to be a limitation of 
this exam and an angiography or a CT angio-scan is usually required.
Methods Indocyanine green clearance (Cl-ICG) is used to measure the hepatic 
function and the hepatic blood fl ow. Recently, with the LiMON® system, the 
Plasma Disappearance Rate of Indocyanine Green (PDR-ICG) assessment is 
available by a non-invasive pulse-densitometric method. Serial daily D-US and 
PDR-ICG measurements were performed after liver transplantation. For each 
measurement, 0.25 mg/Kg of ICG was given through a peripheral vein.
In a routine screening of 72 liver transplant recipients for PDR-ICG (299 
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measurements), D-US revealed in seven patients a complete stop of blood 
fl ow in the hepatic artery. The characteristics of these 7 patients, PDR-ICG 
and angiography results are shown in the table. In patients 4 to 7, the presence 
of HAT (early post-OLT), confi rmed by angiography, was associated with 
extremely low values of PDR-ICG. Moreover, the treatment of hepatic artery 
thrombosis (surgical repair or retransplantation) was followed with a PDR-ICG 
increase. In one delayed HAT after OLT, the same result was obtained. In the 
three other patients (patients 1 to 3), the HAT diagnosis has been eliminated 
either by angiography (patient n°1), CT angio-scan (patient n°2) or by a second 
D-US showing the presence of fl ow in the hepatic artery the following days 
(patient n°3). In these three cases, the PDR-ICG remained normal.
Conclusion In this report, we suggest that Green Indocyanine elimination 
refl ected by the PDR-ICG as measured by a non-invasive technique, may be of 
major help in the diagnosis of HAT when the D-US is diffi cult to interpret and 
allow a rapid salvage decision.
Patient 1 2 3 4 5 6 7
Age / Gender 46/M /M 45/M 49/M 28/F 32/M 63/M 
Etiology of Liver 
Disease
HBV 
cirrhosis 
+ HIV 
Alcoholic 
Cirrhosis
HCV 
cirrhosis
HCV 
Cirrhosis 
+ HIV 
Acute 
Liver 
Failure
FAP FAP
Absence of fl ow on 
D-US (days post LT) Day 2 Day 3 Day 4 Day 3 Day 2 Day 22 Day 2
ASAT/ALAT (IU/l)
Total Bilirubin (μmol/l)
Gamma GT (IU/l)
Prothrombine time (%)
PDR-ICG (%/min)
512/589
20
33
42
24
65/163
43
125
69
28.9
21/45
29
103
84
17.2
253/378
25
50
50
0.4
4079/2281
578
43
15
9.5
287/237
69
595
75
1.1
35/56
18
59
66
8.7
Angiography results No HAT HAT
PDR-ICG: Plasma Disappearance Rate of Indocyanine Green, HAT: Hepatic Artery Thrombosis
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COMPARISON OF RADIOIMMUNOASSAY VERSUS 1643 
MASS SPECTROSCOPY IN MONITORING OF EVEROLIMUS 
LEVELS
S. McGinn1, A. Caswell1, A. Jackson1, T. McGee1, D. Chesher1, J. Ray2
1Royal North Shore Hospital, 2St Vincent’s Hospital
Long term calcineurin inhibitor use in transplant recipients (CNIs) has 
been correlated with nephrotoxicity and reduced long term graft survival. 
Consequently CNI-sparing protocols have been developed using agents such 
as everolimus the proliferation signal inhibitor/mammalian target of rapamycin 
inhibitor (mTORi). Everolimus is extensively metabolized resulting in several 
hydroxylated and demethylated metabolites. These can interfere with the 
standard immunoassay used for measuring trough drug levels and hence 
given the small range allowed for clinical dose adjustment (3-8ng/ml) and in 
particular 5-8 ng/ml for those at increased risk of rejection, the aim of this study 
was to assess the safety of the fl uorescence polarization immunoassay (FPIA) 
for the measurement of everolimus concentrations in whole blood against the 
gold standard mass spectroscopy (LC-MS).
Methods: Whole blood samples were taken from renal transplant patients 
attending outpatient department at Royal North Shore Hospital between 
April and July 2007. and everolimus trough levels were measured using both 
immunoassay (Innofl uor, Certican Assay System) and mass spectroscopy. 
Results from the FPIA were compared with LC-MS using regression analysis, 
while the distribution of the differences in everolimus concentrations with the 
two methods was assessed using Bland Altman approach.
Results: One hundred and ten samples were analysed from thirty patients. 
The cost of analysis by FPIA was $3316.5(AUD) versus $16500(AUD)by LC-
MS. The everolimus levels ranged from 1-22 ng/ml(FPIA) and from 0-18.9 
ng/ml(LC-MS). Regression analysis showed a good correlation with multiple 
correlation coeffi cient of 0.95. However using Bland Altman plot, trough levels 
were consistently higher with FPIA method, the mean difference was 1.1ng/ml 
higher with a standard error of 0.1ng/ml (P < 0.001) suggesting interference 
from metabolites.
Conclusion: Everolimus trough levels measured by FPIA are cost effi cient but 
consistently higher than those measured by Mass Spectroscopy. Consequently 
interpretation of levels by FPIA should be made cautiously in those patients 
who are at increased risk of rejection
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EVEROLIMUS WITH LOW TACROLIMUS DOSE IS AN 1644 
EFFECTIVE AND SAFE IMMUNOSUPPRESSIVE REGIMEN IN 
RENAL ALLOGRAFT RECIPIENTS
E. Savvidaki, D. Goumenos, K. Fourtounas, P. Kalliakmani, E. Papachristou, 
A. Belas, J.G. Vlachojannis
University Hospital of Patras
The signifi cant improvement of the short-term graft survival, observed in renal 
transplantation over the last decades with the development of new and effective 
immunosuppressive agents, is not followed by improvement of the long-term 
graft survival. One of the leading causes of graft loss is the development of 
chronic allograft nephropathy that is related to long-term administration of 
calcineurin inhibitors (CNIs). Everolimus, a proliferating signal inhibitor 
targeting on m-TOR, is a non-nephrotoxic new immunosuppressive drug. The 
combination of everolimus with low cyclosporin dose (target C2 blood levels 
200-250ng/ml) represents an effective and safe regimen followed by better 
preservation of renal function than regimens using higher doses of cyclosporin. 
In this study the effectiveness and safety of combination of everolimus with 
low tacrolimus dose (target trough levels 3-5ng/ml) is investigated.
Fourteen renal allograft recipients, 8 males and 6 females, aged 42„b11 years old 
were included in the study. All patients received induction therapy with basiliximab 
and combination of methylprednisolone, tacrolimus and mycophenolate mofetil 
(MMF) (850„b400 g/day). MMF was replaced by everolimus after a mean 
period of 20 months because of the development of signifi cant side-effects 
(leucopenia and gastrointestinal intolerance). In 7 patients the tacrolimus dose 
remained unchanged after the commencement of everolimus (trough blood 
levels 8„b1 ng/ml) for a period of 12„b5 months and then it was reduced by 
50% (trough blood levels 4„b1 ng/ml). In the rest 7 patients low tacrolimus dose 
was used from the beginning of everolimus administration. Everolimus blood 
levels were maintained between 3 and 8 ng/ml over the period of treatment of 
18„b13 months. No rejection episodes were observed in patients treated with 
higher or lower tarcolimus doses. A signifi cant improvement of renal function 
was observed in 7 patients treated with higher tacrolimus dose after reduction 
of the dose (calculated GFR (MDRD6) 44„b17 ¡÷ 51„b18 ml/min, p=0.005). 
Furthermore a trend towards improvement of glomerular fi ltration rate was 
noted in the 7 patients treated by low tacrolimus dose from the beginning of 
everolimus administration (GFR 61„b24 ¡÷ 67„b21 ml/min). Overall the renal 
function of 14 renal allograft recipients was signifi cantly improved during the 
period of treatment with everolimus (GFR 52„b22 ¡÷ 61„b25 ml/min, p=0.01). 
Leukopenia disappeared and gastrointestinal intolerance showed remission in 
all patients after MMF discontinuation. No serious side-effects were observed 
with everolimus. The drug was discontinued only in 1 patient because of skin 
infection. Antilipemic agents were necessary in 12 of 14 everolimus treated 
patients because of increase of triglykerides, Total and LDL cholesterol by 24%, 
27% and 41% respectively. In 3 patients anemia (Hb<12g/dl) was observed that 
was managed by administration of erythropoetin.
In conclusion, everolimus with low tacrolimus dose represents an effective and 
safe therapeutic regimen leading to improvement of renal function of renal 
allograft recipients and it is not followed by serious side-effects.
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CLINICAL EXPERIENCE IN THE FIRST YEAR AFTER 1645 
CONVERSION TO AN EVEROLIMUS-BASED COMBINATION 
REGIMEN IN RENAL TRANSPLANT RECIPIENTS
J.C. Ruiz1, A. Sánchez-Fructuoso2, M. Rengel3, D. Ramos4, J.J. Plaza5, 
S. Zárraga6, A. Andrés7, P. Errasti8, A. Fernández9
1Hospital Universitario Marqués De Valdecilla, 2Hospital Clínico San 
Carlos, 3Hospital Gregorio Marañón, 4Hospital La Fe, 5Fundación Jímenez 
Díaz, 6Hospital Cruces, 7Hospital 12 de Octubre, 8Clínica Universitaria de 
Navarra, 9Hospital Ramón y Cajal
Introduction: While clinical trials have shown the effi cacy of everolimus 
(EVL) in combination with CsA, there is little experience in other combinations 
or with complete calcineurin inhibitor (CNI) elimination, in rutine clinical 
practice. We describe the clinical experience in a large series of patients (from 
23 transplant centers in Spain) converted to EVL in stable phase and the follow-
up for the 12-month period after conversion.
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Methods: 429 stable renal transplant patients, who initiated EVL in clinical 
practice, were reviewed in a prospective, longitudinal, observational study with 
cross sections at basal, and 1, 3, 6, and 12 months after EVL initiation. Results 
are presented at the end of the study (12th month).
Results: Mean age of patients at conversion was 57¡À13 years (23¨C80) and 
68% were male. Mean time since transplant was 7.9¡À5.7 years (0.3¨C26.0). 
13.8% of patients had at least one previous failed kidney transplant.
Main indications for the introduction of EVL were: the diagnosis of a malignant 
neoplasm (37.1%), nephrotoxicity & chronic allograft nephropathy (26.1%), and 
elective prevention (26.3%). 96% of patients were under a CNI-based regimen. 
At the end of the follow-up period CNI had been eliminated in 83% of patients, 
being EVL the main immunosuppressor. In 11 cases (2.5%) an acute rejection 
was reported but in all cases this was Banff-tipe I (a or b) and steroid sensitive
Before conversion a trend to progressive renal function deterioration was evident 
(p=0.04), after conversion a trend to a better renal function, at 12-months, 
(p=0,002) was observed. This fi ndings were also seen in the sub-group of 
patients converted due to chronic allograft nephropathy. The improvement in 
renal function was more evident in those patients converted during the fi rst 
3 years after transplantation. In patients with proteinuria ¡Ý500mg/day at 
baseline there was no improvement in renal function. However in those cases 
with proteinuria <500mg/day, even in patients with a creatinine clearance ¡Ü 
40ml/min there was an improvement in renal function.
Transplant recipients demonstrated a manageable toxicity profi le. In 21.0% 
of patients was eliminated. Edema (18%), hematologic (15%) and renal/graft-
related (27%) causes were the most frequent causes for withdrawal.
During the study 12 patients died, (2.8%). Mortality was due mainly to 
neoplasia (11; 2.6%). Graft loss occurred in 35 patients
Conclusions: This study shows the patterns of use and the effi cacy and safety of 
EVL in rutine clinical practice in Spain. Conversion with complete elimination of 
CNI is the most frequently used strategy and this study shows that it is safe with a 
very low rejection rate. The benefi ts on renal function should probably be attributed 
to the reduction of CNI nephrotoxicity. Nevertheless the presence of proteinuria 
pre-conversion is a predictor of bad outcome of renal function. Early conversion 
(during the fi rst three post-transplant years) seems to be more benefi cial.
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ASSESSMENT OF EVEROLIMUS IN MAINTENANCE 1646 
RENAL TRANSPLANT RECIPIENTS: THE ASCERTAIN STUDY
H. Holdaas1, K. Midtvedt1, D. Seron2, P. O’Connell3, C. Thiagrajan4, 
R. Fassett5, J. Dantal6, R. Sharma7, E. Cole8, J. Chapman3, L. Rostaing9
1Rikshospitalet, Oslo, Norway, 2Ciutat Sanitaria I Universitaria De Bellvitge, 
Hospitalet de Llobregat, Barcelona, Spain, 3Westmead Hospital, Westmead, 
Australia, 4Devaki Hospital Limited, Chennai, India, 5Launceston General 
Hospital, Launceston, Australia, 6Hopital Hotel Dieu, Nantes Cedex, France, 
7Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India, 
8Toronto General Hospital, Toronto, Canada, 9CHU de Rangueil, Toulouse 
Cedex 4, France
Background: Calcineurin inhibitors (CNI) contribute to chronic allograft 
nephropathy (CAN) and are also associated with an adverse cardiovascular risk 
profi le. Everolimus, a proliferation signal inhibitor (PSI) immunosuppressant 
with an anti-proliferative potential may allow for minimization or 
discontinuation of CNI exposure in renal transplant recipients. This ongoing 
study was undertaken to evaluate the effect of everolimus on renal function, 
measured as glomerular fi ltration rate (mGFR), and atherosclerosis, assessed 
by carotid intima media thickness (IMT).
Design: ASCERTAIN is a 24-month, open-label, multicentre, randomized, 
controlled study in which maintenance renal transplantation patients are 
randomized to one of three parallel treatment groups: continuation of current 
immunosuppressive regimen without everolimus (Group A); initiation of 
everolimus (C-0h 8–12ng/mL; initial dose 4mg/day) with discontinuation of CNI 
(Group B); or initiation of everolimus (C-0h 3–8ng/mL; initial dose 3mg/day) 
with reduction of CNI blood levels by 70–90% (Group C). CNIs (tacrolimus or 
cyclosporine) and adjunctive therapies (mycophenolate mofetil or azathioprine) 
are used according to local centre practices with patients stratifi ed by centre to 
ensure similar numbers in each group. All groups receive steroids.
Objectives: The primary objective is to compare mGFR at 24 months. 
Secondary objectives are to compare the groups at 24 months in terms of 
patient and graft survival, the progression of CAN (protocol biopsy fi ndings) 
and atherosclerosis (ultrasonography), biopsy-proven acute rejection (BPAR), 
safety (including hypertension, hyperlipidaemia and diabetes), and drug blood 
levels (everolimus C-0h, cyclosporine C-2h, tacrolimus C-0h).
Population: A total of 398 patients (65.8 male; mean age = 48.9 years) from 
71 centres worldwide, at a mean of 5.5 ± 4.1 years after transplantation, were 
enrolled between February 2005 and August 2007. Key inclusion criteria 
were: age >18 years, primary or secondary renal transplant >6 months ago, 
unchanged immunosuppressive regimen for the previous 3 months, and renal 
impairment defi ned as GFR 30–70mL/min/1.73m2. Last patient last visit will 
be in August 2009, with data available in the fall of 2009.
Discussion: ASCERTAIN is a pivotal study that will assess the feasibility of 
clinically relevant CNI reduction/discontinuation in renal maintenance patients, 
and its impact on renal function and cardiovascular risk.
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LONG-TERM BENEFITIS OF MTORI CONVERSION 1647 
ON RENAL FUNCTION IN STABLE RENAL TRANSPLANT 
PATIENTS
J.C. Ruiz1, A. Sanchez-Fructuoso2, C.G. Alamillo1, I. Pérez-Flores2, 
G. Fernandez-Fresnedo1, N. Ridao2, T. Giménez1, N. Calvo2, A. Barrientos2, 
M. Arias1
1Hospital Universitario Valdecilla, Santander, Spain, 2Hospital Clinico 
Universitario, Madrid, Spain
Introduction: The use of mTOR inhibitors (mTORi) is a real option in the 
management of renal transplant patients but their role has not been clearly 
established and their unique toxicity profi le has delayed its large scale 
utilization. We describe our experience with conversion to mTORi in two 
Spanish transplant centres.
Patients and methods: Between Oct-98 and Dec-07 279 renal transplant 
patients were converted from a calcineurin inhibitor (CNI) to an mTORi 
for different indications after the third month postransplant.(128, 46% to 
Rapamycin [SRL] and 151, 54% to Everolimus [EVE]). We analyze our results 
with respect to indications of use, drug-tolerance and impact of conversion on 
renal function and proteinuria.
Results: Median postransplant time of conversion was 81 months and indications 
were: chronic allograft nephropathy (40%), malignant neoplasms (36.5%) and 
less frequently cardiovascular disease (10.5%) and others (13%). In 59 cases 
(21%) the drug had to be prematurely eliminated and the main reasons for 
that were: non-infectious pneumonitis (3.2%), severe infection (2.9%), renal 
function deterioration (2.2%), dermal eruption (2.2%), proteinuria (1.8%) and 
anemia (1.1%). Dermal eruption was more frequent in patients taking EVE (3.3 
vs 0.8%) and pneumonitis in those receiving SRL (3.9 vs 2.6%) although the 
differences were not statistically signifi cant. In 62% of cases drug elimination 
was made in the fi rst three months after initiation.
In the whole group renal function was progressively deteriorating with a mean 
loss of 3.7 mL/min (eGFR-Cockcroft formula) in the year before conversion 
(p=0.04) whereas in the year following conversion this parameter increased 
by 2.1 mL/min (p=0.01). Long-term analysis of renal function was performed 
in the 28 patients that reached 4 years of follow-up. In this subgroup eGFR 
increased from 38.9±3.9 to 56.7±3.3 mL/min and in the 17 patients followed 
for more than 5 years eGFR increased from 33.8±5.0 to 64.9±5.6 mL/min.
With respect to proteinuria in the whole group, mean values where 0.55±.0.06 
g/24h at conversion and 1.00±0.13 g/24h one year after conversion. The 
predictors for the development or increase of proteinuria were: the presence 
of proteinuria at the moment of conversion (>0.5 g/24h; OR 21.9, CI95%: 
6.4-74.4) and late conversion considered as that preformed beyond the third 
year postransplant (OR 4.8, CI95% 1.1-20.7).
Twenty three patients lost their grafts (9.8%) and 16 dead during follow-up 
(6.8%)
Conclusions: Conversion to mTORi in renal transplant patients is followed by a 
clear long-term benefi t in terms of renal function improvement in our series and 
it should be considered a realistic therapeutic option. Nevertheless this benefi t 
can only be obtained in those patients who tolerate the drug in the long-term. 
An adequate selection of candidates to conversion is essential to maximize this 
benefi t, especially with respect to proteinuria and time after transplantation.
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EVEROLIMUS AS PRIMARY IMMUNOSUPPRESSANT IN 1648 
STABLE KIDNEY TRANSPLANTS WITH CNI ELIMINATION: A 
SUCCESSFUL STRATEGY
A. Sanchez-Fructuoso1, J.C. Ruiz2, I. Pérez-Flores1, C.G. Alamillo2, 
N. Ridao1, R. Palomar2, N. Calvo1, J. Ruiz-Criado2, M. Arias2, A. Barrientos1
1Hospital Clinico Universitario, Madrid, Spain, 2Hospital Universitario 
Valdecilla, Santander, Spain
Introduction: Everolimus (EVL) was approved as immunosuppressive drug 
in 2005 but almost all clinical trials before approval were in combination with 
Cyclosporin A (CyA), for that reason experience in conversion with calcineurin 
inhibitor (CNI) elimination was very limited. We report the combined experience 
of two renal transplant centres in conversion of stable transplant patients from a 
CNI-based regimen to an EVE-based regimen for different indications.
Patients and methods: Between Mar/05 and Dec/07 155 patients were 
converted from a CNI to EVL with rapid and complete elimination of CNI (98 
patients in HCM and 57 in HUMV). All patients were converted in the same 
way (Initial dose between 2 and 4 mg/day of EVL divided in two doses and half 
dose of CNI until EVL through level in the desired range and then suspension). 
EVL through levels were measured at 4 and 8 days after initiation and then 
monthly up to three months and every three months thereafter.
Results: Indications for conversion were: Chronic allograft nephropathy/CNI 
nephrotoxicity (36.8%), malignant neoplasm (29.0%), cardiovascular disease 
(16.8%), and other reasons in 13.5% of patients. In 6 patients (3.9%) conversion 
was performed as a preventive strategy in the fi rst year postransplant in order to 
minimize the long-term CNI toxic effects. Two thirds of patients were males. 
Mean age at conversion was 55.8±12.6y and median time from transplant to 
conversion was 78 months (range 3-286m). Approximately the same proportion 
of patients were under CyA and Tacrolimus. Mean initial dose was 2.94±0.7 mg/
day and mean through levels at four days were 9±5.4 ng/mL (range: 1.8-28.5). 
In 92.4% this fi rst level was over 3 ng/mL and in 78.6 over 5 ng/mL. Mean time 
to CNI complete elimination was 5 days (p25-75 4-8 days).
EVL had to be prematurely eliminated in 33 patients (21.3%) due to drug 
intolerance/toxicity (8.9%), poor graft evolution (5.1%), severe infection 
(1.9%) or other reasons (5.2%). Among drug toxicity, dermal eruption (3.2%) 
and non-infectious pneumonitis (2.6%) were the most frequent reasons for EVL 
withdrawal. Median time for EVL suspension in this subgroup was 3.7 months 
(p25-75 1.4-11.1m). Among poor graft evolution the reasons were proteinuria 
(2.6%), deterioration of renal function (1.9%) and acute rejection (0.6%).
Renal function was analyzed in the 87 patients with a functioning graft and continuing 
on EVL at twelve months postconversion. Creatinine clearance (Cockcroft-Gault 
formula) signifi cantly improved at six months (57.0±21.4 vs 59.9±23.4 mL/min; 
p=0.001) but that difference decreased at 12 months (58.3±22.9mL/min; p=0.15)
Conclusions: Conversion to EVL with complete suspension of CNI is a safe 
procedure in terms of risk of graft rejection. Approximately 10% of patients do 
not tolerate EVL due to drug toxicity and in an additional 10% of it must be 
eliminated for different reasons, specially poor graft evolution. This might be 
reduced with a more adequate selection of candidates. Progressive deterioration of 
renal function before conversion was apparently detained with this intervention.
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EVEROLIMUS (EVE)IN MAINTENANCE TREATMENT 1649 
IN RENAL TRANSPLANT RECIPIENTS SWITCHED FROM 
CALCINEURIN INHIBITORS (CNI)
M. Rengel, A. Mossé, Ú. Verdalles, S. Abad, A. Vega, E. Verde
Hospital General Universitario “Gregorio Marañón”
Everolimus is a proliferation signal inhibitor utilized in combination with CNI as 
immunosuppression therapy. This approach resulted in excellent effi cacy when 
EVE is combined with reduced exposure to CNI. The present paper reports the 
results with patients who were switched from CNI to EVE, allowing cessation of 
CNI related toxicities and maintaining effi cacy. From february 2005, 120 cadaver 
kidney grafted patients (82 men and 38 women), were switched from CNI to 
EVE. The age of patients was 55 15 years, with 8.5 6 (1-23) years follow-up 
period. The basal immunosuppressant was Prednisone, Mycophenolate Mofetil 
(MMF)/ Mycophenolic acid (MPA) and Neoral Cyclosporine/Tacrolimus. 
Everolimus blood levels were maintained between 3-5 ng/ml. CNI was stopped 
using an abrupt conversion protocol. CsA /Tac treatment was stopped after the 
morning dose and EVE was started at 1.0 mg/day. MMF/MPA-based therapy 
was continued as well as prednisone while target EVE trough blood levels (3-5 
ng/ml) were achieved. At 1 year, graft and patient survival was 100% and there 
was no acute rejection. Blood pressure remained unchanged and there were not 
changes in glucose metabolism. Lipids increased silghtly during fi rst 3 months 
after EVE treatment. Proteinuria appears in patients with previous glomerular 
lesion. GFR improved in 55% of patients.
Conclusion: Conversion of renal transplant recipients from CNI-based 
immunosuppressive regimen to EVE in renal transplant recipients is safe and 
affect slightly to lipid metabolism.
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USE OF EVEROLIMUS IN DE NOVO RENAL 1650 
RECIPIENTS: INITIAL EXPERIENCE IN THE GREEK 
POPULATION
D. Vrochides, V. Papanikolaou, G. Imvrios, A. Papagiannis, D. Giakoustidis, 
I. Fouzas, N. Antoniadis, G. Vergoulas, G. Miserlis, D. Takoudas
Organ Transplant Unit, Aristotle University, Thessaloniki, Hellas
Although everolimus has proven to be as clinically effi cacious as MMF, there 
are reports that proliferation signal inhibitors have resulted in poor tolerability. 
This study aims to report the experience of a Greek transplant center using either 
everolimus or MMF in de novo renal transplant recipients. In this retrospective 
study a cohort of 40 patients who received everolimus after renal transplant 
was matched for 10 descriptive parameters with a cohort of another 40 patients 
who received MMF. The primary endpoint was renal function measured by 
creatinine and its clearance as well as wound dehiscence and opportunistic 
infections. The mean creatinine clearance for month 3 was 61.03 ± 16.99 ml/
min and 60.99 ± 8.03 for the living related recipients on everolimus and MMF 
respectively. The mean creatinine clearance for month 3 was 71.24 ± 12.61 ml/
min and 62.61 ± 20.24 for the cadaveric recipients on everolimus and MMF 
respectively. In addition, the incidence of wound dehiscence was 33.34% and 
3.92% and the incidence of CMV infection was 8.33% and 17.64% for the 
same two groups respectively.
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PROLONGED EFFECTS OF EVEROLIMUS ON WOUND 1651 
HEALING IN EXPERIMENTAL INTESTINAL ANASTOMOSES
M. Willems1, J.A. van der Vliet1, B. de Man2, J. van der Laak3, R. Lomme2, 
H. Thijs2
1Radboud University Medical Centre Nijmegen, vascular and transplantation 
surgery, 2Radboud University Medical Centre Nijmegen, Surgical Research 
Laboratory, 3Radboud University Medical Centre Nijmegen, department of 
Pathology
Introduction: Minimizing cyclosporine and steroid exposure has been the main 
reason to introduce mTOR inhibitors, such as Everolimus, in transplantation 
surgery, the ultimate goal being reduction of side effects of the post-transplant 
poly-drug regime. However, the use mTOR inhibitors in the solid organ 
recipient, has shown a worrying increase in surgical complications, which 
warranted further investigation. In an animal model of bowel anastomoses that 
is frequently validated for measurement of wound healing, Everolimus proved 
to have a negative, dose related effect on early wound healing. The duration of 
the effect is not known because previous experiments were limited to the fi rst 7 
days after operation. Here, we have investigated the effect of Everolimus over 
a longer postoperative period.
Materials and methods: Three groups of 48 Wistar rats received a daily oral 
dose of Everolimus of 1 mg/kg (E-1)or 2 mg/kg (E-2), or saline (controls) form 
the day of operation onwards. In each rat a resection of 1 cm ileum and 1 cm 
colon was performed, and end-to-end anastomoses were constructed using 8 
interrupted sutures. On day 7, 14 and 28 the animals were killed and wounds, 
also those in the fascia, were analysed for mechanical (bursting pressure BP, 
breaking strength BS and histological (collagen) parameters.
Results: In both ileum and colon, a diminished (p<0,05 vs controls) BP was 
seen in the E-2 group after 7 days. The ileal BS at 14 days did not signifi cantly 
differ between groups. However, after 28 days, ileal BS was signifi cantly lower 
in both groups that received Everolimus (p=0,0001). In colon anastomoses a 
signifi cantly reduced BS was seen in both experimental groups after 7 (p<0,0001 
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for E-1 and E-2) and 14 (p< 0,0001 for E-1 and E-2) days, if compared to the 
controls. After 28 days the effect remained non-signifi cant, although average 
values were still lower. Hydroxyproline content and concentration were 
measured after 7 days and show a dose dependent decline. The difference 
between the experimental groups and control group was signifi cant (p< 0,05), 
the difference between E-1 and E-2 for ileum and colon anastomoses was not 
signifi cant. Histological parameters did not show any apparent differences 
between groups. Fascial wounds were less strong in both experimental groups 
at all three points measured.
Conclusion: Everolimus interferes with wound repair. Fibroblast collagen 
synthesis and deposition of new collagen fi bers are essential to the proliferation 
phase of normal wound repair. Most likely, impaired cellular proliferation 
is responsible for the effect seen here. Even after 4 weeks, wound strength 
appears to remain below normal. Such a prolonged effect may have clinical 
consequences and cause surgical morbidity. The possibility of prevention 
of surgical complications, or diminishing the negative effect, is an exciting 
incentive for further investigation.
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A SHORT DELAY IN ADMINISTRATION OF 1652 
EVEROLIMUS RESULTS IN NORMALIZED WOUND HEALING 
IN A RAT-BOWEL ANASTOMOSIS MODEL
M. Willems1, T. Hendriks2, B. de Man2, R. Lomme2, J.A. van der Vliet1
1Radboud University Medical Centre Nijmegen, vascular and transplantation 
surgery, 2Radboud University Medical Centre Nijmegen, Surgical Research 
Laboratory
Introduction: Everolimus, used in post-transplant medical therapy, is 
related to an increased incidence of surgical complications in the early 
postoperative phase. In previous experiments the negative effect on wound 
healing of Everolimus was demonstrated in a dose dependent fashion. 
While the interest in Everolimus in transplantation surgery is mainly 
based on attempts to decrease side effects, this is considered an important 
phenomenon. Delaying the administration of Everolimus might prevent 
surgical complications as shown in other drug studies. In this study, we have 
analysed the effect of delayed administration of Everolimus after bowel 
resection and anastomoses in the rat, a model that is frequently validated for 
measurement of wound healing.
Materials and methods: In 143 male Wistar rats a resection of 1 cm 
ileum and 1 cm colon was performed, and end-to-end anastomoses were 
constructed using 8 interrupted sutures. Thirteen rats per group started 
Everolimus after 0, 1, 2, 3 or 4 days postoperatively, in an orally daily dose 
of 1 mg/kg (groups E1-0, E1-1, E1-2, E1-3 and E1-4). Five other groups 
of rats received Everolimus in a daily dose of 2 mg/kg (E2-0, E2-1, E2-2, 
E2-3, E2-4). A control group existed of 13 rats. On day 7 the animals were 
killed and analysed using mechanical tests (bursting pressure BP, breaking 
strength BS), biochemical tests (collagen content and gelatinase activity) and 
histological parameters.
Results: Mean BS of the ileum after 7 days in the control group was 99 
± 47,2 g. A signifi cant decrease of strength was seen in the E2-0 group 
(p<0,001). BS of the ileum reached control values after a delay of 
administrating Everolimus of 3 days in the low dose, and 4 days in the high 
dose group. BS of the colon followed the same pattern. BP of the ileum in 
the control group was 261 ± 75 mm Hg, this was signifi cantly lower in the 
E1-0 group as well as the E2-0 group (p<0,05). More importantly, a very 
signifi cant difference was seen in precentage of the anastomoses bursting 
outside the suture line, representing a stronger anastomosis. All the groups 
of rats using Everolimus had a signifi cantly lower percentage of bursting 
outside the suture line (p<0,0001). The colon anastomoses showed a similar 
pattern. In the groups of delayed strength a decreased collagen disposition 
was noted.
Discussion: Delaying administration of Everolimus until the third postoperative 
day clearly diminishes wound-healing disturbance in colon and ileum 
anastomoses of the rat. In the post-transplantation poly drug regime, delaying 
the administration of mTOR inhibitors could be of important clinical benefi t.
EXPERIMENTAL BASIC CONCURRENT ORAL SESSION 117: 
SCIENCES IN LIVER TRANSPLANTATION
POSTER BOARD NUMBER P3 – 79
CONTRIBUTION OF THE LIVER TO ELIMINATION OF 1653 
PRO-INFLAMMATORY CYTOKINES AND GROWTH FACTORS 
FROM PORTAL CIRCULATION
D. Porowski1, A. Wirkowska1, M. Pacholczyk2, L. Paczek1
1Transplantation Institute, Department of Immunology, Transplantology 
And Internal Diseases, Medical University of Warsaw, Warsaw, Poland, 
2Transplantation Institute. Department of General and Transplant Surgery, 
Medical Universiy of Warsaw, Warsaw, Poland
Study goal: To evaluate the contribution of liver to elimination of cytokines 
and growth factors from portal circulation. Additionally, a mathematical model 
of liver elimination of cytokines and growth factors was designed. The design 
of the elimination ratio was based on defi nition of the fi rst pass effect and 
existing formula of drug extraction ratio.
Material and methods: 20 liver transplant donors and 20 patients with end-
stage liver failure, were included into the study. Their blood was collected 
during surgery from portal vein, hepatic vein, artery and peripheral vein. 
Concentrations of cytokines and growth factors were determined using 
ELISA.
Results: In donors, signifi cantly lower levels of IL-6, TNF-alpha, HGF, and 
TGF-beta were detected in portal vein compared to liver vein. In cirrhotic 
patients, there were no signifi cant differences in levels of IL-6, TNF-alpha, 
and TGF-beta between portal and hepatic vein. However, signifi cantly 
higher level of HGF in liver vein compared to portal vein was observed. The 
observations were proven by values of the designed elimination ratio. In donors 
the elimination ratio was between 0.2 and 0.4, and in recipients between -0.5 
and 0.1. Positive values suggest predominance of intra-liver elimination over 
synthesis of these mediators. Negative values suggest predominance of intra-
liver synthesis over the elimination.
Conclusions: Healthy liver takes part in elimination of growth factors and pro-
infl ammatory cytokines in humans. In cirrhotic liver, the elimination ability is 
disturbed. However, cirrhotic liver is able to produce some cytokines and growth 
factors, therefore impacts the profi le of mediators and their concentrations in 
circulation.
POSTER BOARD NUMBER P3 – 80
THE NEW STRATEGY OF LIVER TRANSPLANTATION 1654 
FROM MARGINAL DONORS USING SERINE PROTEASE 
INHIBITOR
S. Miyagi, A. Okada, S. Tsukamoto, K. Fujimori, S. Satomi
Advanced Surgical Science And Technology, Tohoku University
Objectives: The purpose of this study is to establish the safety manner of 
procurement of liver grafts from marginal donors such as non-heart-beating 
donors (NHBD).
Materials and methods: Male Wistar rats were divided into fi ve groups: i) 
HB group, livers were retrieved from heart-beating donors; ii) NHB group, 
livers were retrieved from uncontrolled NHBD that were experienced apnea 
induced agonal condition; iii) NM group, retrieved the same manner as 
NHBD pretreated with nafamostat mesilate (NM) (0.2mg/kg/hour); iv) PG 
group, retrieved the same manner as NHBD pretreated with prostaglandin 
I2 (PG) (33ng/kg/hour, for 30min.); v) NM+PG group, retrieved the same 
manner as NHBD pretreated with NM and PG. After 1hr cold preservation, 
those were transplanted according to the Kamada methods. We examined 
AST, ALT, LDH, IL-1beta, TNF-alpha and thromboxane B2 (TXB2) 24hours 
after transplantation. And we also performed histological examination using 
an electron microscope.
Results: The number of survivals on 9 days after liver transplantation from 
group i) to v) was 9/9, 0/9, 1/9, 1/9, and 3/9. The values of AST 24hours 
after transplantation in the HB, NHB, NM, PG and NM+PG groups were 
3446¦ }1810, 5316¦ }985, 5914¦ }789, 5323¦ }1158, and 4193¦ }1019 
respectively. The values of ALT 24hours after transplantation in the HB, 
NHB, NM, PG and NM+PG groups were 3842¦ }902, 9126¦ }2001, 
9878¦ }790, 7268¦ }1644, and 7354¦ }2889 respectively. The values of 
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LDH 24hours after transplantation in the HB, NHB, NM, PG and NM+PG 
groups were 6644¦ }1902, 20758¦ }7631, 16068¦ }5095, 17802¦ }9977 
and 14062¦ }4714 respectively. The values of IL-1beta 24hours after 
transplantation in the HB, NHB, NM, PG and NM+PG groups were 
2895¦ }2240, 4257¦ }5514, 4444¦ }6547, 4199¦ }5016, and 3544¦ }2877 
respectively. The values of TNF-alpha 24hours after transplantation in the 
HB, NHB, NM, PG and NM+PG groups were 2854¦ }3322, 5765¦ }3537, 
5244¦ }4072, 3879¦ }4101, and 2817¦ }3472 respectively. The values of 
TXB2 24hours after transplantation in the HB, NHB, NM, PG and NM+PG 
groups were 2982¦ }2648, 4807¦ }3776, 4511¦ }2685, 3123¦ }2592 and 
2903¦ }2477 respectively. In the NM+PG group all of those values are slightly 
lower than those in the NHB group, but there are no signifi cant differences 
between those groups. On the histological exam, in the NM+PG group the 
sinusoidal endothelial cells were well preserved.
Conclusion: The strong serine protease inhibitor, NM, and PG supported 
sinusoidal endothelial cells. This method is promising strategy on liver 
transplantation from marginal donors.
POSTER BOARD NUMBER P3 – 81
EARLY EXPRESSION OF HGF, IL-6, TGF-BETA 1 AND 1655 
TGF-BETA 2 IN SYMPTOMATIC INFECTION IN PATIENTS 
WHO HAVE UNDERGONE LIVER TRANSPLANTATION
K. Dudek1, K. Koziak2, M. Kotulski1, J. ¯urakowski1, K. Zieniewicz1, 
M. Krawczyk1
1Department of General, Transplant And Liver Surgery, Medical University 
of Warsaw, 2Department of Internal Medicine, Hypertension and Angiology, 
Medical University of Warsaw
Early septic complications are still a deciding factor for successful recovery 
in patients who have undergone orthotopic liver transplantation. Therefore, 
monitoring liver function parameters plays an important role in post-operative 
treatment, where it can be used in the early diagnosis of post-surgical 
complications.
Aim: 1) to measure standard liver function parameters and the levels of 
expression for selected cytokines in patients exhibiting symptoms of infection 
after orthotopic liver transplantation.
Materials and methods: The study was carried out on thirty patients who 
had received orthotopic liver transplants. The patients were divided into two 
groups: SI-0 consisted of those patients who showed no symptoms of infection, 
and SI-1 of those who did. Standard liver function parameters were measured, 
including ALT, AST, bilirubin and prothrombin time. The levels of expression 
of the following cytokines were also determined: HGF, IL-6, TGF-ƒÒ1 and 
TGF-ƒÒ2.
Gene expression in circulating lymphocytes was determined two hours before 
surgery, 24 hours after re-perfusion, and two, six and ten days after surgery. 
mRNA was isolated from the lymphocytes using the PAXgene Blood RNA 
Tube test kit (Qiagen). Reverse transcription was carried out, followed by Real-
Time PCR.
All results were statistically elaborated using the SAS System ver. 8.02 software 
package (SAS Institute,Cary NC, USA).
Results: 1) There were no signifi cant differences in standard liver function 
parameters between the two groups of patients. 2) There were no signifi cant 
differences in the levels of expression for the cytokines in question between the 
two groups of patients.
Conclusions: 1) Although monitoring standard liver function parameters 
provides diagnostically valuable information on the condition of the patient, 
it cannot be used to determine the extent of systematic infection in patients 
showing signs of infection after liver transplantation. 2) Determining gene 
expression levels in circulating lymphocytes is a very sensitive method which 
can be used to monitor the condition of patients who have undergone liver 
transplantation. 3) The levels of expression of HGF, IL-6, TGF-beta 1 and 
TGF-beta 2 and IL-6 in circulating lymphocytes is are not specifi c enough 
to diagnose transitory post-surgical complications such as symptomatic 
infection.
POSTER BOARD NUMBER P3 – 82
THE GASTRIC SUBMUCOSA AS THE SAFER 1656 
AND REPEATABLE SITE FOR THE CELLULAR 
TRANSPLANTATION
K. Takeshita1, N. Kakihara2, S. Naka3, H. Ishibashi4
1Minami Shiga Clinic, 2Kyoto Second Red Cross Hospital, Department of 
Surgery, 3Shiga University of Medical Science, Department of Surgery, 
4Notogawa Hospital, Department of Surgery
In order to establish a safely repeatable method for cell-transplantation avoiding 
serious complications, such as portal thrombosis in the case of hepatocellular 
transplantation into the portal vein, we tried liver-cell transplantation into the 
submucosal layer of stomach wall.
Hepatocytes were isolated from the Lewis rats by a two-step collagenase 
perfusion method. Final hepatocyte suspension contained 2x107 viable 
hepatocytes in 1 ml of 0.2% collagen gel solution. Recipient rats underwent 
20% partial hepatectomy and the hepatocyte suspension (2x107 cells) was 
injected into the submucosal layer at the anterior wall of stomach. Rats were 
sacrifi ced and histologically examined at days 1, 3, 7, 30, and 180. The most 
of transplanted hepatocytes were remained in submucosal layer until day 7. 
The PAS positive cells were observed at the peripheral area of the transplanted 
hepatocyte-mass. The survived hepatocytes made clusters in the submucosa on 
day 30, and BrdU positive cells were observed. The transplanted hepatocytes 
proliferated and reconstructed the liver-tissue like structure in the gastric 
submucosa on day 180.
The gastric submucosa is easily and repeatedly accessible by the gastro-
endoscope. Thus, these results suggest that the gastric submucosa is a possible 
site for the safely repeatable cell-transplantation, using endoscopic injection.
POSTER BOARD NUMBER P3 – 83
NO SEPTICAL COMPLICATIONS IN AN ANHEPATIC 1657 
PIG MODEL WITH PROLONGED SURVIVAL
A. Etspueler1, C. Thiel2, K. Knubben2, K. Unertl1, M. Morglla3, 
A. Koenigsrainer2, M. Schenk2
1University of Tuebingen, Department of Anethesiology, 2University of 
Tuebingen, Department of General, Visceral And Transplant Surgery, 
3University of Tuebingen, Department of Neurosurgery
Introduction: Despite the progress in intensive care therapy the acute liver 
failure (ALF) has still a high mortality. Due to a depression of the immune 
system the risk of septical complications increases during anhepatic survival 
time. Aim of the present study was to investigate the course of infl ammatory 
parameters in an anhepatic pig model.
Methods: 20 female pigs of the German landrace (30-35kg) underwent a 
total hepatectomy under fully sterile conditions. Animals were kept under 
deep narcosis with pressure controlled ventilation and received intensive care 
therapy including volume substitution with sodium chloride 0.9% and glucose 
20%, hydroxyethylstarch 6%, fresh frozen plasma and erythrocyte units. All 
animals received daily 2g Ceftriaxon. Blood samples were taken every eight 
hours in order to measure leucocytes, TNF-α; and IL-6. Body core temperature 
was recorded continuously by a rectal tube. Endotoxin (LPS) was measured by 
a modifi ed LAL-Assay.
Results: All pigs died due to multi organ failure after a median of 49.5 ± 20.1 
hours. Clinical signs of sepsis were not noticed in any case. Body temperature 
and leucocytes remained stable until death at 37.3 ± 0.93°C and 22661 ± 5645/
μl (normal up to 22000/μl), respectively. Values of IL-6 and TNF-α; showed no 
increase over the critical value of 1000 mg/L and 1000 ng/L. Endotoxin levels 
remained at the detection limit and increased the last 20 hours before exitus.
Conclusion: In our anhepatic pig model no direct or indirect signs of 
septical complications were observed. It can be postulated that a “protective 
hepatectomy” could prevent septical complications in ALF-syndrome.
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HISTOLOGICAL STUDIES IN VARIOUS MODELS OF 1658 
ACUTE HEPATIC FAILURE
M. Schenk1, K. Knubben1, C. Thiel1, M.H. Morgalla2, A. Etspüler3, 
A. Königsrainer1, 
1University Hospital Tuebingen – General, Visceral and Transplant Surgery, 
2University Hospital Tuebingen – Neurosurgery, 3University Hospital 
Tuebingen – Anaesthesiology
Objective: Several animal models have been developed for evaluation of acute 
hepatic failure. A differentiation of liver damage and regeneration is needed to 
evaluate the different models.
Methods: In 12 German landrace pigs (30-35 kg) hepatic failure was induced 
by acetaminophen 1g/kg b.w. (n=6), amanitin 0,15 mg/kg b.w. (n=2) or 0,35 
mg/kg b.w. (n=2) or extended liver resection (n=2) with 3h hypoxia of the 
remaining segments. Hemalum-Eosin and immunohistochemistry staining 
(Ki67 for regeneration and TUNEL-apoptosis staining) were performed in 
liver biopsies taken every 24 hours. Albumin, ALT, AST and liver depending 
clotting factors were measured every 8 hours.
Results: Liver biopsies of acetaminophen induced liver failure showed massive 
centrolobular necrosis 24 to 48 hours after intoxication which was confi rmed 
by a signifi cant decline of PT and albumin and a worsening clinical course. In 
the liver of surviving pigs a diffuse Ki67 expression in all over the periportal 
fi elds (positive cells per fi eld: 24h: 5, 48h: 27 and 72h: 93) and a focal apoptosis 
was shown.
After amanitin intoxication liver necrosis was seen between 48 and 72 hours, 24 
hours later compared to acetaminophen. In animals with low toxin administration 
20% Ki67-positive hepatocytes were observed 96h after intoxication, which 
leads to a functional recovery of liver depending clotting factors. In animals 
with high amanitin dosage, less than 5% Ki67-postive hepatocytes and massive 
congestion were observed. Disseminated apoptosis was detected.
In the resection model, liver architecture in the remaining tissue was restored 
within 3 days after injury. No signs of liver cell necrosis were observed.
Conclusions: Maximum necrosis and localisation of liver damage and the 
potential of regeneration is specifi c to the mechanism of liver injury. This fact 
must be taken into consideration before therapeutic strategies and liver support 
devices will be tested.
POSTER BOARD NUMBER P3 – 85
THE DAMAGE ASSOCIATED MOLECULAR PATTERN 1659 
MOLECULE [DAMP] HMGB1 ENHANCE TLR AND RAGE 
EXPRESSION ON HEPATIC STELLATE CELL (HSC), 
STIMULATES ACTIVATION AND PROLIFERATION
X. Liang1,2,3, A.M. Farkas3, M.T. Lotze2,3, M.E. DeVera1,2
1Starzl Transplantation Institute, 2Department of Surgery, 3Hillman Cancer 
Institute, University of Pittsburgh
Activation of HSC, the major profi brogenic cell type in the liver, is associated 
with severe hepatitis C virus (HCV) recurrence after liver transplantation 
(LTx). We previously showed that levels of HMGB1, a DAMP molecule, 
decrease with time after LTx. HMGB1 is released by necrotic cells as well 
as activated macrophages and hepatocytes during oxidative stress and chronic 
infl ammation, a milieu that exists in the HCV-infected liver. We hypothesized 
that HMGB1 would promote HSC activation and examined its effects on 
the expression of toll-like receptor TLR4, TLR9 and receptor for advanced 
glycation end-products (RAGE) [All receptors for HMGB1], receptors which 
may play a role in fi brogenesis.
Methods: Human HSC were obtained from non-parenchymal cells isolated 
from portions of donor or resected livers using collagenase perfusion and 
Percoll density centrifugation under an IRB approved protocol. HSC were 
cultured overnight in complete RPMI medium then stimulated with HMGB1 
(10£gg/ml), LPS (1£gg/ml), IFN£^ (100IU/ml), and TGF-£] (4ng/ml) for 
48 hours. HSC proliferation was measured by MTT while their activation 
was assessed by alpha-smooth muscle actin expression detected by indirect 
immunofl uorescence (IF) staining and Western blot as well as by NF-£eB 
translocation measured by single cell immunofl uorescent imaging analysis. 
TLR 4 and RAGE expression were also assessed by IF.
Results: HSC expressed high levels of alpha-smooth muscle actin expression 
in response to HMGB1 (++), LPS (++), TGF-£] (+++) and IFN-ƒ× (+). IF 
staining demonstrated low-level expression of TLR 4 and RAGE in quiescent 
HSC. HSC activation with LPS, TGF-£], and HMGB1 all signifi cantly induced 
TLR 4, TLR9 and RAGE expression (LPS > TGF-£] > IFN£^). Compare to 
no stimulation control, HSC proliferation was increased more than 2.5 folds 
after stimulated by HMGB1 and other stimuli. NF-£eB nuclear localization 
was demonstrated with HMGB1, LPS and TGF-£] stimulation, while STAT1 
signaling occurred with IFN£^ stimulation.
Summary: HMGB1 markedly stimulates HSC activation through NF-£eB 
signaling and induces TLR 4, TLR9 and RAGE expression. Strategies to limit 
HMGB1 release in chronic infl ammatory states in the liver may be a novel 
means to slow down fi brosis progression in patients with hepatitis C in the 
transplant setting.
POSTER BOARD NUMBER P3 – 86
PROLONGATION OF COLD PRESERVATION 1660 
DRAMATICALLY DECREASES THE SURVIVAL RATE AND 
SYNTHESIS FUNCTION AFTER SMALL-FOR-SIZE LIVER 
TRANSPLANTATION IN THE RAT
Y. Gu1, O. Dirsch, Q. He, U. Dahmen
1Department of General, Visceral And Transplantation Surgery, University 
Hospital of Essen, Essen, Germany, 2Institute of Pathology, University 
Hospital of Köln, Köln, Germany, 3Department of General, Visceral And 
Transplantation Surgery, University Hospital of Essen, Essen, Germany, 
4Department of General, Visceral And Transplantation Surgery, University 
Hospital of Essen, Essen, Germany
Aims: The aim of the present study was to assess the infl uence of cold ischemia 
time on small-for-size liver transplantation using a rat model.
Methods: Inbred male Lewis rats were subjected to 50% or 70% liver resection 
in donors and the partial liver grafts were transplanted into recipients. Grafts 
were preserved with Ringer’s solution at 4 degrees for 3 hours and 5 hours 
before transplantation, respectively (n=10/group). Animals were sacrifi ced on 
postoperative day 7. Study outcomes included survival time and liver function 
were investigated.
Results: Transplantation of a 50% partial liver graft underwent 3 hours cold 
ischemia were well tolerated by all animals. Prolonging the period of cold 
preservation to 5 hours was associated with an obvious decrease of animal 
survival (60%). Transplantation with a 30% liver graft underwent 3 hours 
cold ischemia reduced the survival rate signifi cantly as compared to 50% liver 
transplantation (50% vs. 100%, p<0.05). Prolonging the cold preservation of a 
30% graft (5 hours) dramatically decreased the survival again (30%, p<0.05). 
Total protein and fi brinogen levels were signifi cantly decreased in recipients 
with 5 hours cold ischemia compared to recipients with 3 hours cold ischemia 
in both 50% partial liver Transplantation group and 30% liver transplantation 
group, p<0.05).
Conclusions: Sustained periods of cold preservation signifi cantly impaired the 
animal survival and synthesis function of the grafts. Cold ischemia tolerance of 
the liver grafts is associated with the liver mass.
POSTER BOARD NUMBER P3 – 87
APOPTOSIS IS NOT THE MAIN RESPONSIBLE BY 1661 
ISCHEMIA-REPERFUSION INJURY AFTER HUMAN 
LIVER TRANSPLANT
H. Noujaim1, E.F.S. Montero2, C. Ribeiro1, V.L. Cappellozzi3, R. Gomes1, 
L. Curvello1, M. De Miranda1, F. Crescentini1, M. Casagrande1, T. Genzini1
1HEPATO - Hospital Benefi cencia Portuguesa De São Paulo, 2UNIFESP, 
3LAB IMINUNO-HISTOQUIMICA - FMUSP
Introduction: Apoptosis is a key mechanism of reperfusion injury in normal 
liver; however, the pathway of cell death in steatotic grafts after liver transplant 
(LTx) is unknown.
Purpose: to analyse the cold ischemia and warm reperfusion (CI/WR) using 
steatotic and non steatotic grafts after LTx.
Patients and methods: this is a prospective study performed between May/02 
and Feb/08. Liver biopsies were collected 2 hours after graft reperfusion in 115 
LTx performed in 112 patients. The biopsies were assessed for the following 
histological features (hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3), 
portal infl ammation (degree 0 - absent, I- mild, II- moderate, III– severe), 
parenchymal neutrophilic infi ltration (degree 0- absent, I –rare around zone 3, 
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II-moderate in zone 3, III- since zone 3 to1) and presence of apoptotic cells; 
steatosis was classifi ed in macro and/or microvesicular, and its degree classifi ed 
as absent, mild (<30%), moderate (30to59%), severe(≥60%). Apoptosis was 
assessed by the apoptosis index (TUNEL and Caspase-3 cleaved assays). 
The 115LTx were divided according to their steatosis degree in 4 groups: 
absent –ASG (n=36), mild –MSG (n=36), moderate- MoSG(n=26), severe – 
SSG(n=17). Macrosteatosis were predominantly present in mild – G1(n=10) 
and moderate+severe- G2+3 (n=12), and microsteatosis in mild-G1 (n=29) and 
moderate+severe- G2+3 (n=24), and 4 cases presented macro and microsteatosis 
simultaneously. Preservation solutions, cold ischemia time (CIT),surgery 
time and grafts functions were assessed during the 7 days after LTx by serum 
levels of AST, ALT, GGT, Bilirubine, Protrombin time and creatinine. Results 
signifi cant when p<0.05.
Results: There was no difference among the groups when comparing 
preservation solutions, CIT and surgery time. Comparing among the 4 groups 
(ASG, MSG, MoSG, SSG), the SSG had signifi cant increase of AST level (2nd 
day LTx) p-0.02 and creatinine level (2nd to 7th day LTx) p-0.04.
No LTx MSG(n=36) MoSG(n=26) SSG(n=17) ASG(n=36) p
Suzuki score (2+3) 6% 13.5% 20% 8% 0.3
neutrophilic infi ltration 
(II + III) 42% 55% 68% 56% 0.4
Apoptosis index (TUNEL) 0.23±0.12 0.26±0.11 0.20±0.12 0.23±0.10 0.5
Apoptosis index 
(Caspase-3 cleaved) 0.14±0.11 0.17±0.10 0.19±0.11 0.15±0.10 0.6
Apoptosis index (TUNEL assay and caspase-3) were in macrosteatosis 
group: G1-0,23±0,11 and G2+3 -0,16±0,09,(p=0.4) and G1-0,17±0,12 
and G2+3-0.14±0,09 (p=0,8),respectively and in microsteatosis group: 
G1-0.23±0.11 and G2+3- 0.27±0.12,(p=0.4) and G1-0.13±0.11 and G2+3- 
0.18±0.11(p=0.2).
Conclusion: Although there was no signifi cant difference among the groups, 
severe steatosis was associated with increased parenchymal neutrophilic 
infi ltration and decreased apoptosis index (TUNEL) when comparing with 
other degrees. Isolate macrosteatosis (degree moderate and severe) had lower 
apoptosis index than those of G1 or non-steatotic grafts´ while microsteatosis 
(>30% fat) had increased apoptosis indexes. This study demonstrates, therefore, 
that apoptosis is not the main mechanism of CI/WR injury in human LTx using 
grafts with severe and macrosteatosis.
CONCURRENT ORAL SESSION 118: 
XENOTRANSPLANTATION
POSTER BOARD NUMBER P3 – 88
INDUCTION OF DIABETES IN RHESUS MONKEY WITH 1662 
PANCREATECTOMY AND LOW-DOSE STREPTOZOTOCIN
Y.R. Lu1, L.L. Wei1, G. Mai2, B.L. Tian2, C.F. Qiao1, Y.N. Chen1, W.S. Zhang3, 
Y. Ren4, H. Pan2, X. Jin1, H-X. Li5, J.Q. Cheng*1
1Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, 2Department of Surgery, 3Department of Anesthesia, 4Department 
of Endocrinology, 5National Center for Safety Evaluation of Traditional 
Chinese Medicine, West China Hospital, Sichuan University, P. R. China 
(*Correspondence author)
Objective: This study is to develop and assess a standard technique for induction 
of diabetic rhesus monkey with C-peptide negative, and establish available 
insulin strategy, which would signifi cantly benefi t preclinical investigation 
of islet transplantation and new drug treatment for Type 1 diabetes mellitus 
(T1DM).
Methods: Four rhesus monkeys were obtained from Chengdu Ping’an 
Experimental Animal Reproduction Center. Normal pancreatic function was 
confi rmed by the intravenous glucose tolerance test (IVGTT). Each two 
monkeys were assigned into two groups. Group 1: total pancreatectomy to 
induce T1DM; Group 2: 75% partial pancreatectomy combined with low-dose 
(15mg/Kg) streptozotocin (STZ). Spiral CT of the pancreas and eyeground 
examination were carried out before and after the operation. Fasting and 
postprandial blood glucose (BG) levels were monitored twice daily after the 
operation and the last STZ injection via fi nger or toe. Different types and 
doses of insulin were administered twice daily in order to maintain fasting BG 
<200mg/dL. Throughout the experimental period, the animals were regularly 
assessed for food intake, water intake, urine, blood hematological parameters, 
serum biochemistry, insulin, C-peptide and glycated hemoglobin.
Results: The fasting BG increased signifi cantly (>400mg/dL) with reduced 
insulin and negative C-peptide in serum in two groups after operation, and 
no apparent adverse effects were observed. One monkey didn’t develop 
diabetes after 75% pancreatectomy plus injection with 15mg/Kg STZ, and was 
given 3 more doses of STZ, which did induce diabetes. Except for C-peptide 
and insulin, clinical parameters associated with T1DM of monkeys showed 
no signifi cant difference with normal status. During the exogenous insulin 
treatment, hypoglycemia was happened for two times about 1 hour after 
Humulin® N (1.78U/kg/day) injection; but was not happened during treated 
with Humulin® R (1.25 U/kg/day) and LANTUS® Insulin Glargine Injection 
(1.43 U/kg/day) or porcine insulin (1.07U/kg/day Insulin Injection and 2.14U/
kg/day Protamine Zine Insulin Injection).
Conclusions: The results showed that total pancreatectomy could successfully 
result in T1DM in rhesus monkeys. STZ injection after 75% pancreatectomy 
may be a safer and reproducible method, while the dose of STZ showed 
interindividual variation. Porcine insulin is a safe and economical application 
to control the blood glucose for diabetic rhesus monkey before islet 
transplantation.
POSTER BOARD NUMBER P3 – 89
PIG PANCREATIC ISLETS TRANSPLANTATION 1663 
IN SPONTANEOUSLY DIABETIC DOGS
M. Bacqué2, A.G. Abalovich1, D. Grana3, J. Milei4
1Escuela de Ciencia y Tecnología de la Universidad Nacional de San Martín, 
Argentina- ININCA, Fac. Medicina and Department of Transplantation, 
Hospital de Clínicas, Fac.Medicina, UBA, 2Department of transplantation, 
Hospital de Clínicas Fac.Medicina UBA, 3Instituto de Investigaciones 
cardiológicas, Fac. Medicina, UBA, Conicet, 4Instituto de investigaciones 
cardiológicas, Fac. Medicina UBA, Conicet
Pig islets xenotransplantation represents an attractive way of resolve the human 
organ shortage problem.
Porcine islets are frequently considered in xenotransplantation because they 
produce insulin similar to the human´s insulin.
To avoid immediate rejection of porcine cells, many strategies are being 
developed, between them, we fi nd the microencapsulation.
In this protocol, in preclinical phase, we implanted microencapsulated adult 
porcine islets in alginate-polylisine, to insulin-dependent diabetic dogs. We 
hypothesized that porcine islets act as insulin sensors and improve the metabolic 
control of the disease, even though the diabetes is not completely cured.
Methods: Pancreases were obtained from the slaughterhouse, from animals 
weighing 100-150 kg. The islets were isolated by collagenase digestion without 
using purifi cation.
The encapsulation technique was a modifi cation of Sun´s method.
Isolated islets (150.000 IE) were mixed with 1.6% low viscocity alginate 
(Keltone ®,UK).The alginate solution was converted into droplets using an air 
driven droplet generator.
Microcapsules were cultured in RPMI supplemented 10% BFS in 5% CO2 
atmosphere and 37ºC during 36 hs before implantation.
Islets with a viability count below 80% with trypan blue test, were discharged. 
Animals: The fi ve dogs were in well health status and with diabetes mellitus 
of at least one year of evolution. All animals were being treated witn glargine 
insulin. Under sedation, microcapsules were implanted. Insulinemia basally 
and every-3 months and glycosiled hemoglobin basally and every-4 months 
were registered in peripheral blood. In the follow-up, the glycemia was 
registered twice a day, 3 hours after morning and night meals with blood 
glucose monitoring system. 
Results: In the fi rst dog, it was observed an immediate reduction of the insulin 
dose of 19%, and a new decrease of 12% in the 5 months follow-up.
In the second dog, after the immediate decrease in 20% of the basal dose, at 
6 months the dog was almost insulin-independent, with a dose of 20% of the 
original dose.
In the other three dogs, after implantation the insuline dose show a mean 
diminution of 10%.The insuline needs were also reduced after a follow-up of 5 
or 6 months in 10 to 20%.
Animals who reached in their follow-up the glycolized hemoglobin control 
showed a decrease of 8 to 15%.
All the owners subjectively claimed that their animals are now enjoying a 
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better quality of life.
Discussion: The changes in the fi ve dogs, with better metabolic control 
and reduction of insulin requirements, let us propose the pig islets 
microencapsulation as a way of achieve the metabolic control without the risk 
of the immunosupression.
The time of insulin secretion, allows us think in the need of implant only one or 
two doses per year. We hypothesized that the improvement at 6 months, could 
be due to neogenesis from exocrine tissue microencapsulated with the islets. 
This could have important clinical implications if acinar tissue could facilitate 
the neogenesis
Although these results are preliminary, they permit a different vision about 
microencapsulated pig islet xenotransplantation to cure or ameliorate the type 
I diabetes.
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TRANSCRIPTIONAL PROFILING IN PORCINE AORTIC 1664 
ENDOTHELIAL CELL INDUCED BY INFLAMMATORY 
STIMULATOR
Y. Hye-Jun, J-S. Kim, S.Y. Hwang*
Department of Biochemistry, Hanyang University & GenoCheck Co. Ltd., 
Sangrok-gu, Ansan, Gyeonggi-do 426-791
Gene expression microarrays is the key technology can easily determine 
the expression of thousand of genes. For successful development of 
xenotransplantation, it is particularly important to study the biology and 
molecular characteristics of porcine aortic endothelial cells (PAECs) treating 
human cytokines in order to discover xenotransplantation-related expression 
genes. We developed pig oligonucleotide 13K microarray chips for elucidating 
xenotransplantation-related genome in PAEC. Quality control has been done 
from several cells based on various conditions. We analyzed differentially 
expressed transcriptomes PAEC treated with hydrogen peroxide (H2O2; 40 
uM), human tumor necrosis-alpha (hTNF-α; 20 ng/ml), Lipopolysaccharide 
(LPS; 10ug/ml) and pig interferon gamma (pIFN-γ; 100ng/ml).
We selected three time points (1hr, 6hr, 24hr) for VCAM-1 expression using 
real–time PCR. Total RNA isolated from PAEC that treated with H2O2, hTNF-α, 
LPS and p IFN-γ was used for the synthesis of fl uorescence for microarray. 
There was a distinct difference in the expression level of these genes between 
H2O2, hTNF-α, LPS and pIFN-γ of PAEC. Our results should be validated for 
elucidating their clear role and functions of xeno-immune response.
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GENERATION OF HUMAN A20 GENE TRANSGENIC 1665 
PIGS BY SOMATIC CELL NUCLEAR TRANSFER
M. Oropeza1,2, B. Petersen1, E. Lemme1, A. Lucas-Hahn1, A-L. Queisser1, 
B. Barg-Kues1, D. Herrmann1, P. Hassel1, W. Kues1, H. Niemann1
1Institute For Farm Animal Genetics, Mariensee, Neustadt, Germany, 
2University of Veterinary Medicine, Hannover, Germany
Introduction: Xenotransplantation is considered as a promising strategy 
to close the growing gap between demand and availability of appropriate 
human organs. While the hyperacute rejection response can already be reliably 
controlled, the acute vascular rejection (AVR) remains a major hurdle for 
longterm survival of xenografts in a porcine-to-primate organ transplantation. 
The human A20 (hA20) gene exhibits both anti-apoptotic and anti-infl ammatory 
properties in endothelial cells (Transplantation 82: 36-40, 2006) and could thus 
prevent endothelial cell activation leading to AVR and subsequent xenograft 
destruction.The goal of this project is to produce hA20-transgenic pigs with 
improved features in xenotransplantation.
Materials and methods: The hA20-expression vector driven by the ubiquitous 
CAGGS hybrid promoter (chicken β;-actin-/ rabbit β;-globin) with an IRES-
neomycin resistance cassette (9.1 kb) was transfected into porcine fetal 
fi broblasts (PFFs) derived from German Landrace porcine fetal explant cultures. 
Transfection of 3 x 106 cells was accomplished at 450 V and 350μF with 10 
μg plasmid DNA. G418-resistant (800 μg/mL) cell clones were screened by 
PCR with hA20 specifi c primers for hA20-integration. Somatic cell nuclear 
transfer (SCNT) was performed as recently described (Cloning Stem Cells 7: 
35-44, 2005).
Results: A total of 80 cell clones were hA20-positive in PCR screening from 
4 rounds of transfection after a 14 days G418 selection period. Thirty positive 
cell clones were re-selected for 14 days with G418. Four of these cell clones 
were used as donor cells for SCNT. Immediately after SCNT, reconstructed 
embryos were transferred to 10 synchronized recipient sows (~80 reconstructed 
embryos per recipient). Ultrasound examination on days 23-25 of pregnancy 
confi rmed established pregnancies in 7 of 10 recipient sows. Two pregnant 
animals were sacrifi ced on day 30 of pregnancy and a total of 8 fetuses were 
isolated. PCR and Southern Blot analysis showed integration of the hA20 gene 
in 6 of 8 fetuses. RT-PCR analysis conducted on transgenic PFFs derived from 
hA20-positive fetuses demonstrated mRNA expression of the hA20-gene. Six 
out of 16 piglets born recently showed integration of the hA20-gene and were 
healthy at the time of birth.
Conclusions: The hA20-vector can be integrated in PFFs and hA20 transgenic 
PFFs can successfully be used in SCNT to produce transgenic offspring. The 
selection method for transgenic PFFs needs to be optimized to ensure that all 
donor cells used for SCNT carry the transgene. Further analysis will focus on the 
expression patterns and biological function of hA20 in transgenic piglet organs. 
Another approach will be to introduce an endothelial specifi c promoter active 
in pigs to target expression of hA20 to the endothelial cell layer. Providing 
the endothelial cells with a higher anti-apoptotic potential could decrease their 
susceptibility to cell death.
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REPRODUCTION OF HOMOZYGOUS 1666 α1,3-
GALACTOSYLTRANSFERASE GENE KNOCK-OUT PIGS BY 
SOMATIC CELL CLONING
H. Matsunari1, S. Miyagawa2, Y. Takahagi3, T. Fujimura3, T. Shigehisa3, 
H. Murakami3, K. Nakano1, T. Fujiwara1, R. Shirakura2, H. Nagashima1
1Laboratory of Developmental Engineering, Department of Life Science, 
Meiji University, Kawasaki, Japan, 2Division of Organ Transplant, Osaka 
University Graduate School of Medicine, Suita, Japan, 3The Animal 
Engineering Research Institute, Tsukuba, Japan
We have produced genetically engineered pigs by heterozygous knock-
out of α1,3-galactosyltransferase gene (GalT-KO) and co-expression 
of two transgenes, human decay-accelerating factor (hDAF) and 
N-acetylglucosaminyltransferase III (GntIII), using the technology of somatic 
cell nuclear transfer (SCNT; Takahagi et al., 2005). Cells collected from 
these pigs were used to generate homozygous GalT-KO cells by means of 
spontaneous mutation phenomenon of heterozygous GalT-KO cells during 
cultivation, i.e. loss of heterozygosity. Then homozygous GalT-KO pigs have 
been successfully cloned by SCNT (Fujimura et al., 2008). Natural breeding 
of the heterozygous GalT-KO pigs also gave rise to three homozygous GalT-
KO pigs. The objective of the present study was to investigate the possibility 
of cloning the homozygous GalT-KO pigs by SCNT as an alternative approach 
for the preservation of those animals.
Primary cultures of preadipocytes (Tomii et al., 2005) were established from 
two of the homozygous Gal T-KO pigs at 6 month old (DK3-1, male and 
DK3-2, female) and cryopreserved by routine procedures. Using these cells 
as nuclear donors and in vitro matured oocytes as recipient cytoplasts, cloned 
embryos were produced as described previously (Kurome et al., 2006). Cloned 
embryos were transferred into the oviducts of estrus synchronized recipient 
gilts after in vitro culture for 1- 2 days.
Transfer of the 547 cloned embryos reconstructed with the donor cells from 
DK3-1 into 6 recipients gave rise to 6 pregnancies (100%). Although two 
miscarried at 30 and 21 days of gestation, one recipient farrowed 3 piglets, 
including one stillborn piglet (Production effi ciency: 3.3%, 3/92). The other 
3 recipients are due in March, 2008. Two to 4 fetuses were confi rmed by 
transabdominal ultrasound examination in these recipients, respectively. When 
176 cloned embryos derived from DK3-2 were transferred into 2 recipients, 
both became pregnant, and two stillborn piglets were delivered.
Homozygous knock-out of the GalT gene was confi rmed in all of the cloned 
pigs obtained by PCR and PCR-Southern (Takahagi et al., 2005). These data 
demonstrated that GalT-KO pigs can be effi ciently produced by SCNT, hence 
cloning technology is suggested to be a feasible option for clinical application 
of the GalT-KO pigs.
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ANTI-CD40L ANTIBODY NOT CTLA4IG TREATMENT 1667 
PROLONGED SURVIVAL OF XENOGENIC ISLET GRAFTS 
INDEFINITELY
I-H. Yoon1,2,3, H-Y. Nam1,2,3, J-S. Kim1,2,3, C-S. Park5, S-Y. Kim1,2,3, 
M-J. Park1,2,3, J-W. Ha2,4, S-J. Kim1,2,3, C-G. Park1,2,3
1Department of Microbiology and Immunology, Xenotransplantation 
Research Center, Tumor Immunity Medical Research Center, 2Department 
of Microbiology and Immunology, Xenotransplantation Research Center, 
Tumor Immunity Medical Research Center, 3Department of Microbiology and 
Immunology, Xenotransplantation Research Center, Tumor Immunity Medical 
Research Center, 4Department of Pathology, Asan Medical Center, University 
of Ulsan College of Medicine, 5Department of Microbiology and Immunology, 
Xenotransplantation Research Center, Tumor Immunity Medical Research 
Center
Pancreatic islet transplantation can cure insulin dependent diabetes 
mellitus (IDDM). However, the shortage of the donor graft is one of the 
major limiting factors in clinical application of islet transplantation. In 
this perspective, the porcine pancreatic islet can be used as an alternative 
donor source. In this study, we compared the effect of anti-CD40L (MR1) 
antibody with CTLA4Ig on preventing islet xenograft rejection in pig to 
mouse model. The pig islets were isolated from CMS miniature pig and 
5,000 IEQ were transplanted underneath the kidney capsule of C57BL6/J 
mouse rendered diabetic by streptozotocin. The mean survival day of the 
graft without treatment was 15 „b 2 days. Immunohistochemical analysis 
of the rejected graft showed infi ltration of CD4+ and CD8+ T cells into 
the graft from 3 days post transplantation (DPT). To control the rejection 
process, the transplanted mice were injected i.p. either with 50 ug/mouse 
of CTLA4Ig, 7 times every other day or with 500 ug/mouse of anti-
CD40L (MR1) antibody for 5 consecutive days from DPT 0. The MR1-
treated graft, but not CTLA4Ig-treated, survived longer than 200 days 
with well controlled blood glucose level in 8 out of 8 transplanted mice. 
Immunohistochemical analysis showed intact insulin containing graft 
with infi ltration of CD4+ and CD8+ T cells in peri-islet space in MR1-
treated recipient. Of note, approximately 40% of the infi ltrating CD4+ T 
cells were Foxp3+. Whereas, in CTLA4Ig treated mice, the graft site were 
infi ltrated with CD4+ and CD8+ T cells without insulin staining cells and 
only 2~3% of CD4+ T cell expressed Foxp3. The ratio of CD4+FoxP3+ 
T cells in splenocytes and peripheral blood mononuclear cells from MR1 
treated recipient was not signifi cantly different from CTLA4Ig treated 
mice. Conclusively, targeting CD40-CD40L signal pathway rather than B7-
CD28 pathway is more benefi cial in preventing pig to mouse islet xenograft 
rejection by inducing Tregs in the graft site.
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ALPHA1,3-GALACTOSYLTRANSFERASE KNOCKDOWN 1668 
IN COMBINATION WITH LOW-DOSE GAL ALPHA(1-3)GAL 
BINDING LECTIN CONFERS PORCINE ENDOTHELIAL CELL 
RESISTANCE TO AB/COMPLEMENT MEDIATED CYTOLYSIS 
BY PI3K/AKT-DEPENDENT HO-1 UP-REGULATION
M. Zhu1, W. Zhang2, F. Liu2, L. Wang1, B. Liu1, Z-S. Chen1, T. Ichim3, 
P. Zhou1, S. Chen1, G. Chen1
1Institute of Organ Transplantation, Tongji Hospital, 2Wuhan Institute of 
Burn, Wuhan No.3 hospital, 3Medistem Laboratories
Background: A major barrier to clinical xenotransplantation is preformed 
xenoreactive natural antibodies (XNA) found in higher primates which react 
to Gal¦Á(1,3)Gal (¦Á-Gal) epitopes found on lower species. Accommodation of 
organs to xenogeneic recipients involves upregulation of cytoprotective genes 
and resistance to complement dependent cytotoxicity (CDC).
Methods: To develop methods of increasing these organ-protective effects, we 
established an in vitro CDC model utilizing human serum as the source of XNA 
and porcine endothelial cells (pEC) as targets.
Results: Using this system we demonstrated that downregulation of ¦Á-Gal 
epitopes by siRNA silencing of ¦Á1,3-galactosyltransferase (¦Á-GT) led to 
marginal protection (62%~85%) from CDC while combined treatment with 
Griffonia simplicifolia isolectin B4 (GS-IB4) at low concentration (2&micro;g/
ml), led to complete protection (¡Ö100%). However, GS-IB4 alone, only upto 
24 &micro;g/ml, began to achieve a signifi cant protective effect against CDC. 
Interestingly, SiRNA silencing and GS-IB4 mediated effects were not associated 
with inhibition of IgG, IgM or C3c binding to cells, but with signifi cant 
decreased E-selectin expression and cytoprotective gene HO-1 upregulation. 
PI3K inhibitor LY294002 could block the elevation of HO-1 protein expression 
and reverse the protective effect of SiRNA and GS-IB4 against CDC.
Conclusion: These data support the use of combination approaches targeting 
independent accommodation mechanisms to synergistically enhance donor 
organ survival in a xenogeneic setting.
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EVALUATION OF CULTURED NEONATAL PORCINE 1669 
SERTOLI CELLS AND THEIR EXPRESSION OF 
IMMUNE-PRIVILEGE RELATED MOLECULES IN VITRO
Z.Z. Yin, F. Hu, L. Wang, L. Xie, Y. Xiang, G. Chen, S. Chen
Institute of Organ Transplantation of Tongji Hospital, Huazhong University of 
Science And Technology, Tongji Medical College
Background: Sertoli cells (SCs) protect co-grafted allogeneic and xenogeneic 
islets from immune destruction and reverse diabetes in immunocompetent and 
autoimmune animals. SCs are thought to confer immune privilege to the testes, 
probably by producing cytokines that act locally to inhibit immune response. 
But the mechanisms underlying immune privilege are not well understood. In 
this study, SCs isolated and identifi ed from 10 to 15 day-old landrace testes 
were evaluated the biology and detected the expression of immune privilege-
related molecules in vitro.
Methods: Testes were harvested from 10 to 15 day-old landrace pigs. SCs were 
successfully prepared by a modifi ed two-step enzymatic digestion method with 
collagenase type V, trypsin and DNase I, then cultured in DMEM/F12 with 5% 
FBS at 37¡æ,5% CO2 atmosphere, and then identifi ed by electron microscope. 
As a specifi c SCs marker, Sox9 was detected by both immunocytochemistry 
and reverse transcription-polymerase chain reaction (RT-PCR). Viability and 
apoptosis of cultured cells were measured by fl ow cytometry with annexin V 
and propidium iodide. The viability of long-term cultured porcine SCs was 
detected by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrasodium bromide 
(MTT). With RT-PCR, we investigated some immune privilege-related 
molecules expressed on the SCs, such as Fas ligand (FasL), transforming 
growth factor ¦Â (TGF-¦Â1, TGF-¦Â2, TGF-¦Â3), clusterin, CD46, CD59, DAF 
and Bcl-2. Additionally, clutserin and Bcl-2 expressed on cultured SCs were 
also measured by western bolt.
Results: With the identifi cation, the purity of SCs isolated by our modifi ed 
methods were accounted more than 90%. In this culture system, viabilities 
were more than 95% assayed by trypan blue exclusion dye. The self apoptosis 
and necrosis rate of SCs was 4.73£¥¡À1.70£¥ after 3 days culture. The viability 
of SCs were found to be the highest at the seventh day of culture, however, 
after being cultured for 21 days, the viability began to reduce rapidly. Sox9 
was found to be expressed on our cultured SCs.The expression of FasL on the 
neonatal SCs was weakly positive or nearly negative, whereas, TGF-¦Â1, TGF-
¦Â2, TGF-¦Â3, clusterin, CD46, CD59, DAF were strongly positive, but the 
Bcl-2 was negative. By western blot, we confi rmed that clusterin was indeed 
expressed and the Bcl-2 was absent, although it was found to be expressed on 
the tissue of testis.
Conclusions: Our modifi ed two step method had a yield and purity similar 
to previous reports measured with one step method, but the viability was 
much better than it. Sox9 as specifi c cell marker for identifying SCs could 
clearly identify transplanted SCs in heterotopic sites. These immune privilege-
related molecules may be useful for future investigate the mechanism of the 
immuneprivileged sites.
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RESISTANCE OF PORCINE SERTOLI CELLS 1670 
TO XENOREACTIVE ANTIBODIES MEDIATED 
COMPLEMENT LYSIS
Z.Z. Yin, L. Wang, Y. Xiang, L. Xie, F. Hu, G. Chen, S. Chen
Institute of Organ Transplantation of Tongji Hospital, Huazhong University 
of Sc
Background: Sertoli cells£¨SCs£© contain immunoprivilege properties 
which allow them to survive as allografts and to protect the co-transplanted 
islets from rejection. We have shown previously that neonatal porcine sertoli 
cells£¨NPSCs£© express clusterin and complement regulatory proteins, 
such as CD46, CD59 and DAF. Prior to the transplantation of NPSCs 
into humans, it is necessary to determine whether they can also protect 
themselves from humoral injury mediated by xenoreactive antibodies 
and complement. ¦Á-Gal has been detected in the porcine testis, however, 
whether it expresses on NPSCs is still unknown. Thereby, we examine 
¦Á-Gal expression on our isolated NPSCs and the binding capability 
with preformed xenoreactive antibodies. Furthermore, an in vitro model 
was used to assess whether NPSCs could resist xenoreactive antibodies 
mediated complement lysis.
Methods: SCs were isolated from testes of 10 to 15 day-old landrace 
pigs. ¦Á-Gal expression on SCs was measured by RT-PCR, FACS and 
cytoimmunofl uorescence. The binding of human serum IgG and IgM with 
SCs was assayed by FACS and cytohistochemistry. After the incubation of the 
cultured SCs with 20% human B serum in vitro, the cellular lysis and cytotoxicity 
assay were detected with Cyto Tox-ONETM Homogeneous Membrane 
Integrity Assay and MTT method, and then activation of the complement 
cascade was examined by immunohistochemistry and immunofl uorescence. 
The SV40-porcine endothelium cells line (SV40-PED) was served as control 
cells. Finally, the expression of clusterin on either sertoli cells or the SV40-
PED cells was detected by RT-PCR and western blot.
Results: ¦Á-Gal expression was found on SCs by FACS and 
cytoimmunofl uorescence, which was confi rmed at mRNA level by RT-PCR. 
The binding of human serum IgM and IgG with SCs was 24.59¡À9.85 and 
9.91¡À1.25 (mean fl uorescence intensity) respectively, while the binding 
with SV-40 PED was 46.45¡À4.75 (P<0.05, vs. SCs) and 12.99¡À1.26. 
After incubation with 20% human serum, cellular lysis ratio of the SV40-
PED was 53.13%¡À14.53%, while lysis ratio of the SCs was signifi cantly 
lower (24.38%¡À0.50%, P<0.01), the viability of SCs and SV40-
PED were 98.73%¡À18.84% and 52.43%¡À8.08%, respectively. With 
immunohistochemistry and immunofl uorescence, C3 and C4 were found 
binding on both the SCs and SV40-PED cells, however, C5b-9 was only 
detected on SV40-PED cells. With RT-PCR, mRNA of clusterin, CD46, CD59, 
and DAF were all found to be expressed on both SCs and SV40-PED cells. 
Among these proteins, clusterin expression on sertoli cells and SV40-PED cell 
line was further confi rmed by Western Blot.
Conclusions: ¦Á-Gal was expressed on NPSCs, and the SCs could bind 
with the human serum IgM and IgG. In vitro, Compared with the SV40-
PED, NPSCs could resist xenoreactive antibodies of human serum mediated 
complement lysis by preventing the C5b-9 formation. Furthermore, expression 
of clusterin, CD46, CD59 and DAF between NPSCs and SV40-PED has no 
difference, however, the binding of IgM with NPSCs was signifi cantly lower 
than SV-40 PED. Therefore, we presumed that NPSCs resisted xenoreactive 
antibodies mediated complement lysis may associated with their lower binding 
of the xenoreactive IgM.
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SURVIVAL OF NEONATAL PIG ISLETS IN DIFFERENT 1671 
CULTURES
M.G. Lopez-Santos2, B. Ramírez-González2, O. Ramirez-Espinosa2, 
L.M. Dorantes-Álvarez3, H. Astudillo de la Vega2, R.V. González-Salas1,3
1Departamento de cirugía, Facultad de Medicina Universidad Nacional 
Autónoma de México, 2Laboratorio de Xenotrasplantes Hospital Infantil 
de México “Federico Goméz”, 3Departamento de Endocrinología Hospital 
Infantil de México “Federico Gómez”
Xenotransplants can be an alternative for the treatment of diabetes mellitus, 
because of the lack of human donors, therefore the importance to improve the 
quality of purifi cation, viability and functionality of the islets so they can be 
used in future transplants. The main goal of this study was to determine the 
optimal conditions of viability and functionality of the cell culture (islets of 
langerhans) for a period of time of 24 h and outside optimal culture (37oC 
/ 5%CO2). Here we used the pancreas of neonatal pigs (age 7 days), the 
purifi cation of the islets was determined by enzymatic digestion (Liberase 
H) cultivated at 48 h/37oC/5%CO2. For this study we used different kind 
of medium (F-10/Alb, F-10/SFB, RPMI) and three different levels of 
temperature at (25oC, 4oC and 37oC without CO2). The viability of the 
culture was determined with Acridine Orange / Propidium iodide (AO/PI) and 
the functionality with static stimulation of glucose (SGS) at several times 0, 6, 
9, 12, and 24 h. The results show that at normal temperature (25oC) and using 
medium F-10/Alb, after 12 h, we obtain viability between 90-95% of total 
and a productivity of insulin above of 70 μIU/ml/h. With this obtained data, 
we keep the islets in optimal functionality an viability for the transplant in a 
period of no less than 12 h.
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FUNCTIONALITY AND VIABILITY AFTER ENZYM 1672 
DISAGGREGATION OF NEONATAL PIG ISLETS.
B. Ramírez-González2, M.G. López-Santos2, L.M. Dorantes-Álvarez3, 
A.L. Rodríguez-Ventura2, O. Ramírez-Espinosa2, H. Astudillo de la Vega2, 
R. Valdés-González1,2
1Departamento de Cirugía, Facultad de Medicina Universidad Nacional 
Autónoma de México, 2Laboratorio de Xenotrasplantes Hospital Infantil 
de México “Federico Gómez”, 3Departamento de Endocrinología Hospital 
Infantil de México “Federico Gómez”
The islets of Langerhans posses a system of vascular communication and 
paracrine on point communications those are critical in cellular relationship, 
regulation, production and hormone secretion. The distribution of every cell 
point settles in a specifi c microenvironment depending the cellular age.
In this study we describe the cellular micro organization of the main types of 
cellular pig islets (age between 7 to 30 days) as well as their functionality while 
being isolated and disaggregated in an in vitro system.
The disaggregated islets at 48 h were presented with a parameter of stimulation 
1(IS1) of 2.42 ± 0.49 and IS2 of 0.70 ± 0.06 with an insulin production (PI) 
of 12.62 ± 1.15 and 5.66 ± 1.26 μUI/ml/h respectively. Meanwhile, the intact 
islets show an IS1 of 20.82 ± 0.7 with a PI 137.50 ± 4.18 and an IS2 of 21.37 
± 2.81 with a PI of 121.4 ± 21.34 μUI/ml/h. The viability post-trypsin was 
greater than 95% in all cases. At 24 h, viability was of 94 ± 3.86% and 89.54 ± 
4.97% in the intact and disaggregated islets respectively, without presenting an 
important variation at 48 h of culture.
The results of the immunofl uorescence of those pigs (30 days) show 61% of 
positive cells of insulin, a 28% for glucagons and a 5% for somatostatine. 
In pigs (7 days) show a 45% of insulin, an 18% for glucagon and a 3% for 
somatostatine. Evidently it exists an important difference of functionality 
between disaggregated islets and non disaggregated islets, so we conclude 
that the percentage decreases probably because of the importance of the 
intercellular unions.
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XENOVIROLOGY LABORATORY ORGANISATION:1673 
 TASKS AND ISSUES
O. Garkavenko, D. Nathu, S. Wynyard, P. Tan, R. Elliott
Living Cell Technologies Ltd, New Zealand
Xenotransplantation is an emerging technology that aims to alleviate the 
shortage of human donors. Pigs are considered to be the most suitable donors. 
One of the main concerns in the fi eld is the risk of cross-species infection from 
donor to recipient.
Diagnostic laboratories concerned with xenovirology must be able to perform 
several key tasks. This includes the establishment of reliable and sensitive 
assays for the detection of porcine infectious agents as well as the development 
of strategies for donor safety evaluation, source herd maintenance and recipient 
follow-up. Laboratories can expect to progress through two distinctive stages. 
The fi rst, focused primarily on research and development, comprises such 
tasks as the identifi cation, evaluation and establishment of a donor herd 
and the development of a monitoring strategy for source herd maintenance. 
The following criteria should be considered essential for the establishment 
of a donor herd: the absence of xenotransplantation important pathogens 
and favourable PERV characteristics (absence of an infectious PERV, low 
PERV copy number). Diagnostic assays for recipient follow-up must also be 
developed. The second stage is the conversion of the research laboratory to a 
medical diagnostic laboratory and its certifi cation. The unique characteristic 
of a xenovirology laboratory is the synergy of knowledge and skills from 
veterinarian and human medical diagnostics as well as the ongoing search for 
new infectious agents and improvement of modern techniques for donor and 
recipient surveillance.
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WESTRAN PIGS: A UNIQUELY INBRED COLONY 1674 
SUITABLE FOR XENOTRANSPLANTATION
K. Moyle1, D.M. Simond1, P. Holyoake2, C. Moran2, P.J. O’Connell1, 
W.J. Hawthorne1
1The Centre for Transplant & Renal Research, Westmead Millennium 
Institute, Westmead, NSW, 2145, 2University of Sydney, Faculty of Veterinary 
Science, NSW, Australia
Introduction: The highly inbred Westran pig (WTP) colony is being further 
developed and characterised in order to meet the immunological & inherent 
safety criteria for clinical xenotransplantation.
Method: These isolated miniature pigs have been inbred for eleven successive 
generations with breeding directed by pig size, genetic markers and ABO 
blood group. Assessment of genetic and immunological homogeneity 
was performed using ABO blood grouping, mixed lymphocyte reaction 
(MLR), lymphocytotoxicity assay (LCA), monitoring of hyperpolymorphic 
microsatellite (HPM) markers and sequence-genotyping of the swine leucocyte 
antigen complex (SLA=MHC). Genomic DNA was extracted & PCR fragments 
analysed to identify relevant genetic loci & to sequence MHC class I & II on 
a Licor sequencer.
Results: A total of 985 live pigs have been bred from 11 generations of full 
sibling matings. Current 11th generation pigs reach an average adult weight 
of 67.9kg + /- 4.0kg at 12months of age. All are blood group O with negative 
MLR’s and LCA across the colony. There are no differences between WTP 
across MHC SLA class I 6, 7, 14 & class II DQA, DQB, DRA & DRB loci, 
however, all WTP display a heterozygous SLAI-1RFLP pattern. This level of 
functional inbreeding has been confi rmed by microsatellite analysis of highly 
polymorphic markers, which show that 52 of 53 chromosomally dispersed 
markers were fi xed by the 9th generation. This level of fi xation was consistent 
with 19 to 20 generations of full-sibling inbreeding. The calculated inbeeding 
coeffi cient at generation 10 was 0.98159. Same sex and female to male 
skin grafts between sibs are accepted long term and third party donor skin 
is rejected. However due to inbreeding fertility rates decreased with the 8th 
generation having 3.3 (SD ± 1.45, Range 1-6) live births. However, we have 
counteracted this problem and in 2007 produced an average litter size for the 
tenth generation pigs of 4.5 (SD ± 2.06, Range 1-9) live births.
Conclusion: Westran pigs are of a suitable size for transplantation into patients 
are blood group O and homozygous for 7 SLA loci. Variation at the SLA-1 locus 
appears due to gene duplication or an artifactual amplifi cation from a closely 
related locus (SLA-5), thus SLA-1 is also homozygous. HPM analysis suggests 
a highly inbred core herd approaching genetic identity at 98% inbreeding. 
This is a unique colony which is ideal to assess aspects of transplantation and 
xenotransplantation processes without the need for immunosuppression.
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EFFECT OF INTRATHYMIC INOCULATION WITH 1675 
MESENCHYMAL STEM CELLS ON DISCORDANT RODENT 
CARDIAC XENOGRAFT REJECTION
Z. Shen1, Z. Zhu2, M. He3, X. Zhu4
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University, 4The First Affi niatied Hospital of Soochow University
Objective: This study was designed to investigate the effect of ntrathymic 
inoculation with MSCs on the the recipient immunoloregulation and on the 
discordant rodent Cardiac Xenograft Rejection with the model of guinea pig to 
rat xeno- transplantation and to explore the mechanisms behind.
Materials and methods: BMSCs of guinea pig were expanded to third 
passage, then inoculated into thymuses gland of rats. After inoculation, we 
observed the change of CD4+CD25+ T regulatory cells in rats. Donors(guniea 
pig) and recipients (SD rat) were divided into four groups. Group A (Control 
group); Group B (injection with CVF); Group C (IT inoculation with MSCs); 
Group D (CVF injection plus IT inoculation with MSCs).The grafted heart 
mean survival time (MST), the proliferation of mixed lymphocyte reaction 
(MLR) ,the expression of GATA-3,CCR3 and the pathology of xenograft were 
observed.
Results: The blood CD4+CD25+ regulatory T cells were higher in experiment 
groups compared with control group, the stimulator index of MLR in group 
C much lower signifi cantly than group Control, the expression of GATA£ 3, 
CCR3 of Group D were highest and the MST of group D were the longest 
among the four groups.
Conclusions: CVF injection plus IT inoculation with MSCs could prolong the 
survival time of rats with xenograft.
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INDUCTION OF IMMUNOTOLERANCE BY MIXED 1676 
XENOGENEIC CHIMERA WITH MACROPHAGES 
CLEARANCE
Z. Shen1, Y. Zhu2, M. He3
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University
Objectives: In this study, we aimed to investigate whether macrophages 
clearance could help to establishment mixed chimeras then, we explore the 
mechanisms of immunotolerance in xenotransplantation induced by establishing 
the guinea pig to rat mixed chimeras model with a non-myeloabalative 
preparative regimen.
Methods: Recipient SD rats were conditioned with sublethal whole body 
irradiation (WBI), administered with intraperitoneal injection of cytoxan(CTX), 
then treated with clodronate-encapsulated liposomes before guinea pig bone 
marrow cells were infused .Rat spleen and liver Blood and bone marrow 
cells were collected to examine macrophage depletion and the percentage 
of labeled guinea pig bone marrow cells, Mixed lymphocyte reaction 
(MLR) was also performed. then divided randomly into 6 groups: group 
I£¨control£¬n=5£©¡¢group II£¨cobra venom factor(CVF), n=5£©¡¢group 
III£¨CVF+ clodronate-encapsulated liposomes, n=5£©¡¢group IV£¨CVF+ 
BMC, n=5£©¡¢group V£¨CVF+ BMC + blank liposomes, n=5£©¡¢group 
VI£¨CVF+ BMC + clodronate-encapsulated liposomes, n=5£©.The survive 
time of xenograft was measured and the histopathologic observation was 
carried out after the graft arrest. The changes of IgG were detected before heart 
transplantation and graft arrest by fl ow cytometry.
Results: Clodronate-encapsulated liposomes treatment resulted in complete 
depletion of both liver Kupffer cells and splenic macrophages Macrophages 
depletion increase the percentages of infused labeled guinea pig bone marrow 
cells in the rat blood Recipient SD rats were specifi cally tolerant to the guinea 
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pig as certifi ed by MLR assay. Group VI showed the longest mean survival 
time of cardiac xenograft .The level of IgG was increased slightly in every 
group after heat transplantation, but the increase of group VI was slower than 
other groups.
Conclusions: (1) Depletion of macrophages with clodronate-encapsulated 
liposomes can improve guinea pig chimerism in sublethally irradiated rats. 
(2) Mixed xenogeneic chimera can signifi cantly prolong discordant xenograft 
survival time after using Chinese Cobra Venom Factor (CVF) in guinea pig to 
rat model.
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PRODUCTION AND CHARACTERIZATION OF PIGS 1677 
TRANSGENIC FOR HUMAN HEMEOXYGENASE-1 BY 
SOMATIC NUCLEAR TRANSFER
W. Ramackers2, B. Petersen1, A. Lucas-Hahn1, D. Herrmann1, W.A. Kues1, 
S. Bergmann2, W. Baars2, J.W. Carnwath1, R. Schwinzer2, M. Winkler2, 
H. Niemann1
1Institute of animal genetics, Dept. of Biotechnology, D-31535 Neustadt, 
Germany, 2Transplant Laboratory, Hannover Medical School, D-30625 
Hannover, Germany
Introduction: The hyperacute rejection after porcine-to-human 
xenotransplantation can now be reliably overcome either by transgenic 
expression of complement regulating factors (done in this study) or by 
knocking out the gene for α1,3-galactosyltransferase in pigs. The next 
immunological hurdle is the acute vascular rejection (AVR) primarily caused 
by endothelial cell activation. Human Hemeoxygenase-I (hHO-1) is known 
to have anti-apoptotic and cell protective properties. Thus, the expression 
of hHO-1 on porcine endothelial cells could have benefi cial effects in a 
xenotransplantation setting. Here we describe transgenic pigs with expression 
of CD55 and hHO-1.
Methods: Fibroblasts were obtained by an ear punch from a CD55 
transgenic female pig and were cultured in vitro (Kues WA et al. 2005 
Biol Reprod 72:1020-1028). Cells reaching confluency of 70-80%, 
were detached with EDTA/trypsin and subsequently transfected by 
electroporation at 450V/350 μF with a vector coding for hHO-I driven by 
the SV40 promoter. Transfected cells were selected for resistance against 
G418 (800 μg/ml) for 14 days. Resistant cell clones were screened for 
integration of the vector by PCR. One positive cell clone was selected for 
somatic nuclear transfer.
In total, 205 reconstructed embryos were transferred to two synchronized 
peripuberal German Landrace gilts which gave birth to nine live piglets, 
all with normal birth weights. The expression of the transgenes (CD55 and 
hHO-1) was determined by fl owcytometry and Western blot in endothelial 
cells and peripheral blood lymphocytes. The expression pattern of the 
transgenes in different organs was shown by immunostaining, RT-PCR and 
Northern blot.
Results: PCR and Southern blot analyses revealed that all of the offspring had 
integrated the vector in their genome. Six transgenic animals were sacrifi ced 
for further characterization. In these animals, the expression of CD55 and 
hHO-1 in peripheral blood lymphocytes and cultured endothelial cells was 
shown by fl owcytometry and Western blot. In addition, though all animals were 
cloned from the same cell clone, variations in the expression pattern and levels 
could be observed in immunostaining, RT-PCR and Northern Blot. The animals 
showed only weak expression of hHO-1 in most of the xenorelevant organs like 
heart, kidney and liver.
Conclusion: These results show that hHO-1 in combination with CD55 can 
be expressed in transgenic pigs. These results are encouraging and warrant 
further studies on endothelial cell activation and the biological function of 
hemeoxygenase-I in the context of xenotransplantation.
This study was funded by the Deutsche Forschungsgemeinschaft Ni 256/ 22-1, 
-2, -3.
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XENOGENEIC CHIMERAS SUPPRESS THE ACTIVATION 1678 
OF DONATOR ENDOTHELIAL CELLS BY DECREASING THE 
EXPRESSION OF ICAM -1 AND VCAM-1
Z. Shen1, M. He2, Z. Liu3, H. Huang4, Y. Chen5
1The First Affi niatied Hospital of Soochow University, 2The First Affi niatied 
Hospital of Soochow University, 3The First Affi niatied Hospital of Soochow 
University, 4The First Affi niatied Hospital of Soochow University, 5The First 
Affi niatied Hospital of Soochow University
Objective: To observe the effects of the rat bone marrow mesenchymal stem 
cells£¨BM-MSCs£© on the prolixferation of mouse lymphocyte in a co-culture 
system. Then explore the mechanisms of tolerance in xenograft induced by 
establishing the rat BM ¨CMSCS to mouse mixed chimeras model with a non- 
myeloabalative preparative regimen.
Methods: A co-culture system with or without rat BM-MSCs was established 
to observe the result.
Results: In the co-culture system, the OD value of the co-culture system and 
the expression of ICAM-1 and VCAM-1 of the co-culture system with rat BM-
MSCs is lower than that without rat BM-MSCs£¨P <0.05£©.
Conclusions: The rat BM-MSCs can suppress the prolixferation of mouse 
lymphocyte in the co-culture system. Non-myeloablative conditioning regimens 
for xenogeneic BM-MSCs transplantation can successfully establish rat BM 
¨CMSCS to mouse mixed chimeras model. Mixed chimeras can suppress 
xenogeneic lymphocytes proliferation. Xenogeneic chimeras can suppress the 
activation of donator endothelial cells ¨C decrease the expression of ICAM -1 
and VCAM-1
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A SURVEY OF THE ATTITUDE OF SCIENTISTS 1679 
TOWARD XENOTRANSPLANTATION
S-Y. Yen1, S-M. Lee2, C-F. Tu3, S-M. Tang4, J. Tapsoba5
1Graduate Institute of Management of Technology, Feng Chia University, 
2Graduate Institute of Management of Technology, Feng Chia University, 
3Animal Technology Institute Taiwan, 4Financial & Economical Law, Asia 
University, 5Department of Applied Statistics, Feng Chia University
The progress in the pharmaceutical biotechnology and the genetic engineering 
such as the genetic modifi cation of animal and the cloning of animal has 
triggered the development of research on xenotransplantation. While 
potential benefi ts may be derived from the therapeutic technology, many 
concerns including moral, ethical and legal issues and public health risks are 
often raised. The paper presents the results of a questionnaire based survey 
study of the attitude of scientists involved in biotechnical research toward 
Xenotransplatation in Taiwan. The study population consisted of the employees 
of the Animal Technology Institute in Taiwan (ATIT). The institution 
consists of 210 scientists involved in research on veterinary medicine and 
biotechnology. The study sample is composed of 91 participants that were 
randomly selected from the population and each participant voluntarily 
completed a twenty-item questionnaire.The data from the survey was analyzed 
using SPSS 13.0 statistical software. The Cronbach’s alpha coeffi cient that 
measures the overall consistency of the questionnaire was 0.689 indicating a 
good reliability. A principal component analysis revealed seven factors that 
jointly accounted for 67.63% of the overall variation in the measures. The age 
of the respondents ranges from 20 to 63 years and 75% were younger than 
47 years old. Fifty participants are female (55%) and the majority of them 
are married (60%). Twenty-seven were Buddhist and many (43.8%) did not 
have any religious belief. 35.2% had master’s degree or doctorate and 34.1% 
completed their studies with a bachelor degree. 65.2% of the participants 
agreed that using organs harvested from genetically modifi ed pig for human 
recipients was risky. However, most of them (55.6%) disagreed that clinical 
studies on xenotransplantation should be banned through legislation. 92.3% 
agreed that ethics and morality should be considered when developing the 
xenotransplantation treatment. 85.4% thought that genetic modifi cation of 
animal organs should not violate ethical and moral rules. A clear majority 
(95.6%) believed that animal welfare should be respected in any research 
on xenotransplantation. 85.2% thought that xenotransplantation can be more 
benefi c than harmful to human society and 94.3% believed that it would solve 
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the problem of human organ shortages. The nonparametric Kruskal-Wallis 
test was used to detect variables that might have infl uenced opinions and it 
turned out that gender and education did (p-value smaller than 0.05). The 
survey highlighted a high level of awareness of xenotransplantation among 
the respondents. Despite concerns over ethics, morals and animal welfare, the 
majority of them had favorable opinions on the technology.
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REVERSE XENOTRANSPLANTATION: HUMAN TO PIG 1680 
LIVER TRANSPLANTATION
G. Xiao1, O. Devon1, M. Pakerev1, R. Huneke2, W. Meyers1
1Department of Surgery, Drexel University College of Medicne, 2University 
Animal Labarotary Resources, Drexel University College of Medicine
Introduction: The fi rst step of this study is to establish the feasible model of 
liver transplantation from human to pig. Eventually, the successful creation of 
this unique model will allow us to test a panel of experimental medications 
without subjecting human to potential side effects and to avoid potential human 
morbidity and mortality.This study is approved by IRB.
Methods: Selection of human donor liver, which is not suitable for human liver 
transplantation secondary to variable reasons, is based on size-matching, pre-
existing liver disease, overall hepatic function, and liver biopsy. A Yorkshire 
pig weighing greater than 60 kg is premedicated, intubated, and anesthestized. 
Two grams of methylprednisolone is given to the pig intravenously 10 minuts 
before incision. The abdomen is entered using midline incision combined 
with bilateral subcostal incisions. The pig liver has signifi cant amount of 
liver parenchyma embedded the whole inferior vena cava (IVC), even 10 to 
12 cm below the portal hepatis level. This special anatomy makes piggy-back 
technique impossible. We used traditional liver transplant technique without 
bypass, a small cuff of liver parenchyma is left on the infrahepatic IVC during 
the transection. We kept lower IVC transection plan as high as possible to 
benefi t the later lower IVC anastomosis so that we do not have to use venous 
graft as interposition in case human liver lower IVC can not reach the pig IVC. 
The hepatic artery, common bile duct, and portal vein are dissected, ligated and 
divided close to liver hilum. The suprahepatic IVC is clamped and three hepatic 
veins were dissected and transected closed to liver. The pig liver is removed, 
small cuff of liver tissue which is wrapped up the lower IVC is dissected off 
IVC, leaving at least 8 mm free edge for lower IVC anastomosis. The human 
liver implantation is performed in the following order: suprahepatic IVC, 
infrahepatic IVC, portal vein anastomosis.
Results: To date, we have performed two successful human to pig liver 
transplants. Three anastomoses were completed and the human liver appeared 
well-perfused.
Conclusion: This new promising technique and model of reverse liver 
xenotransplantation from human to pig may be a reasonable approach to 
produce and maintain a functioning human liver for early analysis of medication 
metabolism, drug accumulation, and dose escalation toxicity.
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EXPRESSION PATTERNS OF THE NEGATIVE 1681 
COSTIMULATORY MOLECULES PD-L1 AND PD-L2 IN 
PORCINE CELLS AND TISSUES
A. Plege, W. Ramackers, K. Borns, M. Winkler, R. Schwinzer
Transplant Laboratory, Hannover Medical School, Germany
Objectives: Triggering of programmed death 1 receptor (PD-1) by its ligands 
PD-L1 or PD-L2 delivers negative signals thereby downregulating T cell 
activation. Thus, transgenic expression of human PD-L1 in pig cells and tissues 
is regarded to be an approach to prevent T cell reactivity after pig to human 
xenotransplantation. Recent data suggest that pig PD-L1 is able to functionally 
interact with human PD-1 (Jeon et al., Xenotransplantation, 14:236, 2007) 
implying that endogenous porcine PD-L1 could as well be a target for 
immunomodulation after xenotransplantation. It was the aim of this study to 
assess the expression patterns of PD-L1 and PD-L2 in the pig.
Methods: Expression of porcine PD-L1 and PD-L2 was analyzed on mRNA 
level by semi-quantitative RT-PCR. RNA was isolated from cultured cells 
(PBMC: peripheral blood lymphocytes, B cell lines, endothelial cells) as 
well as from tissue samples (thymus, lymph nodes, spleen, heart, liver, lung, 
kidney). PD-L1, PD-L2 and ß-actin mRNA was amplifi ed by specifi c primers. 
PD-L1:ß-actin and PD-L2:ß-actin ratios (densitometric units) were calculated 
to determine the expression intensities of PD-L1 and PD-L2.
Results: PD-L1 and PD-L2 mRNA was readily detected in porcine PBMC. In 
vitro activation of the cells by mitogen stimulation resulted in signifi cant up-
regulation of PD-L1 and PD-L2 mRNA. B cell lines expressed less PD-L1 than 
the entire PBMC population suggesting preferential expression in T cells and 
monocytes. Primary endothelial cells isolated from pig aorta weakly expressed 
both, PD-L1 and PD-L2. Studying PD-L1 and PD-L2 mRNA in tissue samples 
from pig lymphoid organs revealed strong expression in lymph nodes, spleen, 
and thymus. In addition, PD-L1 and PD-L2 mRNA was found in tissue samples 
from kidney, heart, liver and lung. Markedly enhanced levels were detected in 
kidneys which had been perfused with human blood using an ex vivo perfusion 
circuit, suggesting up-regulation in response to endothelial cell activation.
Conclusion: PD-L1 and PD-L2 show very similar expression patterns in the 
pig. Since PD-L1 and PD-L2 are differentially expressed in mice and humans 
the function of these molecules might not be identical in different species. 
The strong basal expression of PD-L1 and PD-L2 in various tissues and the 
observation that further up-regulation is possible supports the assumption that 
the two molecules are interesting endogeneous regulatory elements of the pig 
to modify human T cell responses after xenotransplantation.
This work was supported by the DFG (Research Unit “Xenotransplantation”, 
FOR 535).
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REFINED ANAESTHESIA AND PERIOPERATIVE 1682 
CARE IN A PRECLINICAL TRANSPLANTATION MODEL WITH 
PRIMATES
G.M. De Benedictis1, F. Fante2, L. Bellini1, E. Tognato2,3, M. Boldrin2, 
A. Dedja2,4, L. Ravarotto5, E. Ancona2,4,6, R. Busetto1, E. Cozzi2,4,6
1Dept. of Clinical Veterinary Sciences, Padua, Italy, 2CORIT, Padua, Italy, 
3Dept. of Pathology and Veterinary Hygiene, Padua, Italy, 4Dept. of Surgical 
and Gastroenterological Sciences, Padua, Italy, 5IZSV, Legnaro, Italy, 6Padua 
General Hospital, Padua, Italy
Introduction: Improving safety and effi cacy of anaesthesia is a critical aspect 
of transplantation research with animals. Appropriate management allows 
minimization of the risk of potential adverse events, which may considerably 
impact the ultimate outcome of the study. With the aim of refi ning the procedure 
in our primate transplantation model, in this series we introduced adjustments 
to the anaesthesic protocol without modifying the selection of the drugs used 
for anaesthesia.
Materials and methods: Forty-nine cynomolgus monkeys (3-7 kg) were 
used in a xenotransplantation model as recipients of hDAF-transgenic pig 
kidney. Based on the anaesthetic protocol animals were divided into 3 groups. 
The different cocktails of drugs included sedation with ketamine 10 mg/kg 
i.m., buprenorphine 0.01 (Groups A and C) or 0.02 (Group B) mg/kg i.v. and 
induction with midazolam i.v. (1, 0.5 or 0.2 mg/kg respectively Group A, B, C) 
and propofol to effect. Anaesthesia was maintained with isofl urane in oxygen 
with (Group A) or without (Groups B and C) propofol continuous rate infusion 
(CRI). During surgery, heart rate, ECG, pulse-oxymetry, non invasive blood 
pressure, respiratory rate, capnometry, end-tidal isofl urane were measured. To 
prevent perioperative hypothermia, animals were covered with lambskin and 
transported in insulated transport cages warmed by hot water-bags; heat and 
humidity exchanger, isothermic blanket and heating pads were used to reduce 
intraoperative heat loss. Prewarmed fl uids were used both for i.v. infusion and 
for fl ushing the abdominal cavity.
Results: All animals arrived to the operating room with mild hypothermia. In 
Groups A and B mean oesophageal temperature remained almost unchanged 
during anaesthesia (35,7°C and 35,4°C, respectively). In Group C, temperature 
increased gradually from 35,6±0,6°C to 37,2±0,9°C and was 36,6±0,7°C at the 
end of the anaesthesia. Extubation time was compared in 10 animals from Group 
A and 10 animals from Group B and C with similar mean body temperature 
during surgery. After propofol CRI/isofl urane anaesthesia, the extubation 
time was 18.67±8.04 min., while in animals receiving only isofl urane it was 
6.98±0.36 min. The mean intraoperatory body temperature was analysed for 
each animal and correlated to the extubation time. Interestingly, the reduced 
body temperature was signifi cantly correlated with a longer recovery time 
(r2=0.4145).
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Conclusion: A more effective management of anaesthesia and faster 
recovery were obtained by modifying the dosages of drugs administered, 
whilst guaranteeing the maintenance of an optimal anaesthesia depth. Our 
fi ndings indicate that a higher oesophageal temperature during surgery is 
always correlated with a shorter recovery time. Continuous monitoring of 
the experimental procedures may allow the identifi cation of possible areas 
of refi nement that may contribute to enhance the scientifi c outcome and the 
ethical profi le of complex experimental animal models.
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ENHANCEMENT OF HUMAN CHIMERISM IN PIGS 1683 
THROUGH INHIBITION OF FETAL PORCINE NATURAL 
KILLER CELLS
W.E. Beschorner1, P.E. Kudlacek1, T. Schieber2, K.F. Lechtenberg2
1Ximerex, Inc., Blair, NE USA, 2Midwest Veterinary Services, Oakland, NE 
USA
Objective: A major barrier to transplantation of pig tissue is vigorous rejection 
of the xenograft. For diseases such as type 1 diabetes, autoimmunity may also 
contribute to loss of the graft. Our program has developed the production of 
chimeric donor pigs as a way to induce immune tolerance to the pig tissue. 
Tolerance is induced outside of the patient and before transplantation, sparing 
the patient considerable risk. The technology is supported by growth of human 
cells within fetal pigs, generation of functional suppressor cells, and production 
of CD4+/foxP3+ T regulatory cells. Large animal proof of principle includes 
prolonged survival of pig aorta and pig hearts within sheep and two independent 
trials of pig islet tissue into diabetic monkeys. In the diabetes studies, 5 of 6 
monkeys showed prolonged survival and function of porcine islet cell clusters 
without evidence of rejection, up to 222 days post transplant. They received no 
anti-rejection drugs.
A technical challenge for the use of chimeric donor pigs is the diffi culty in 
generating suffi cient chimerism within the pig. It is estimated that chimerism 
needs to be greater than 0.3% to generate suffi cient T regulatory cells for a 
70 kg human recipient. While variable, typically chimerism less than 0.05% 
is observed. Many procedures have been explored to enhance chimerism, 
including fetal pig infusion of growth factors, accessory cells, different sources 
of hematopoietic stem cells, and post-natal boosting with donor lymphocytes. 
It was hypothesized that resistance to human cell engraftment is due to innate 
immunity in the fetal pig. Here the natural killer cells were inhibited by 
injecting antibodies to porcine NK cells into fetal pigs along with the human 
hematopoietic cells.
Materials and methods: Human bone marrow and human cord blood from 
a commercial source were processed for injection into fetal pigs at 45 days 
gestation. Monoclonal antibodies were added to the fetal pig inoculum, 
including anti-pCD16 and anti-pCD11R3 (Serotec), 100 ug/pig. Fetal pigs 
received 1x107 bone marrow cells or 4x107 cord blood cells. Controls 
consisted of sows in which the injected fetal pigs did not receive the antibodies. 
At 7 weeks after birth, blood from the pigs was evaluated for the presence 
of chimerism by PCR. Chimerism was quantifi ed with fl ow cytometry using 
antibodies specifi c for human lymphocytes.
Results: At 7 weeks of age, two of the three pigs injected with human cord blood 
cells and anti-pig NK antibodies were chimeric, with 0.14 and 1.1% chimerism. 
Of the fi ve pigs injected with human marrow cells and anti-pig NK antibodies, 
all were chimeric, with 0.15, 0.16, 0.34, 0.40, and 1.5% chimerism.
Conclusion: Inhibition of the fetal pig NK activity with antibodies to porcine 
CD16 and porcine CD11R3 appeared to enhance the human chimerism within 
the pigs. NK cells are known to contribute to hybrid resistance in hematopoietic 
stem cell transplants and resistance to human stem cell engraftment in SCID 
mice. NK cell inhibition in the fetal pig should enhance the generation of 
specifi c T regulatory cells in donor pigs.
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ENCAPSULATED SINGLE PORCINE ISLET CELLS 1684 
CONFER LONG-TERM IN VIVO FUNCTION
I. Stuiver
MicroIslet, Inc.
Suffi cient tissue yield is a constant problem in the fi eld of islet transplantation. 
Clusters of islet cells have been shown to be highly functional in both xeno 
and allo transplantation models and tissue specimens containing islet of 
low mass, are not considered suitable for transplant. Disposal of this tissue 
results in a signifi cant loss in the islet yield and in many instances insuffi cient 
mass for transplantation. Most islets from humans, rats and mice contain a 
signifi cant outer-layer of collagen, thus provides an increased opportunity 
for intact islet isolation. Alternatively, porcine islets are encapsulated with a 
thin or non-existent collagen membrane. At most, 50% of the islet is covered. 
This leads to preparations that are more fragmented than those typically 
found in other animals. Little evidence is available that indicate whether 
fragmented or single-celled preparations function. A series of experiments 
were conducted that tested whether encapsulated single celled or fragmented 
preparations of porcine islets functioned in streptozotocin induced diabetic 
mice.
Here we demonstrate that islets that have been triturated to be fragmented or 
single cells can render diabetic mice normoglycemic for 190 days or longer. The 
ability to use fragmented islets or single cells derived from the islet increases 
the yield of useable transplant material by 30-50%. A series of experiments 
were conducted that tested whether encapsulated single celled or fragmented 
preparations of porcine islets functioned in streptozotocin induced diabetic 
mice. In the fi rst study, encapsulated single cells outperformed controls by 70 
days. In the follow-up study, 50% of the animals in the broken islets and 25% 
of the animals dosed with single cells were normoglycemic at day 290. Of the 
control animals transplanted with complete islets, 100% had grafts failed by 
day 215. In the subsequent dose response study, 1.5 and 3K IEQ single celled 
doses performed 50% longer than 0.75K IEQ per mouse and 25% longer that 
the 1.5K control arm.
These results imply that single and broken pig islet cell populations can 
adequately produce insulin and promote long-term normoglycemia in a diabetic 
in vivo setting. One question of signifi cant interest is does the encapsulation 
create an environment such that the cells are proximal enough so hormonal 
cross-talk by insulin, glucagon and others can occur? Can this hormonal cross-
talk also mediate a glucose responsive single cell? These and other questions 
are currently being explored.
POSTER BOARD NUMBER P3 – 111
XENO-TRANSPLANTATION OF SKELETAL MYOBLAST 1685 
FOR ATTENUATION OF HYPERINSULINEMIA AND 
HYPERGLYCEMIA
L. Ye1, K.O. Lee2, L-P. Su3, W.C. Toh1, H.K. Haider4, P.K. Law5, W. Zhang3, 
E.K.W. Sim6
1National University Medical Institutes, National University of Singapore, 
Singapore, 2Department of Medicine, National University Hospital, 
Singapore, 3National Heart Center, Singapore, 4Department of Pathology 
and Lab Medicine, University of Cincinnati, Ohio, USA, 5Cell Transplants 
Singapore Pte. Ltd, Singapore, Singapore, 6Department of Surgery, National 
University of Singapore, Singapore & Gleneagles JPMC Cardiac Center, 
Brunei Darussalam
Aim: Type 2 diabetes mellitus is characterized by hyperglycemia resulted 
from insulin resistance: the impaired suppression of liver glucose output 
and stimulation of muscle and adipose tissue glucose uptake in response to 
insulin The study investigates the feasibility and effi cacy of intra-muscular 
transplantation of human skeletal myoblast (hSkM) for attenuation of 
hyperglycemia and improvement of insulin sensitivity using a mouse model of 
type 2 diabetes mellitus.
Methods: KK Cg-Ay/J mice (KK mice, an animal model of Type II diabetes 
mellitus) aged 14-16 weeks after screening (fasting glucose> 6.5 mmol/L 
and glucose > 13 mmol/L at 2-hour of fasting glucose tolerance test (GTT)) 
were divided into two groups (n=16 each group): KK group-1: receiving basal 
medium only, and KK group-2: receiving hSkM transplantation. C57BL mouse 
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was used as normal control to receive hSkM transplantation. Cells were intra-
muscularly transplanted into the skeletal muscle of KK and C57BL mice with a 
transient cyclosporine treatment. Fasting GTT was performed at before and 12 
weeks after treatment. HbA1c and fasting serum adiponectin, cholesterol (TG), 
insulin and triglyceride (TG) were determined.
Results: Histochemical study demonstrated extensive survival of hSkMs 
in the skeletal muscles of all animals receiving hSkM transplantation at 
12 weeks. The nuclei of hSkM integrated into host muscle fibers. Fasting 
GTT showed significantly reduced glucose (mmol/L) (0 hour = 5.84± 0.73, 
0.5 hour= 12.69± 1.39, 1 hour= 13.6± 1.71, 2 hour = 7.26± 0.83) was 
achieved in KK mice received hSkM transplantation as compared with KK 
control mice (0 hour=7.32± 0.48, 0.5 hour= 17.47± 1.13, 1 hour=21.07± 
1.61, 2 hour=14.96± 1.79). KK mice receiving hSkM transplantation 
had reduced HbA1c, Chol, insulin, and TG, and reduced decreasing of 
adiponectin. AKT activity assay showed improved AKT activity in KK 
group-2 as compared with KK group-1. No hypoglycemia was found in 
C57BL mouse.
Conclusion: These data suggested that hSkM transfer therapy attenuated 
hyperglycemia, hyperinsulinemia, and improved glucose tolerance in a Type 2 
diabetes mouse model. This approach may be served as an alternative treatment 
for muscular insulin resistance of type 2 diabetes mellitus.
POSTER BOARD NUMBER P3 – 112
BENEFICIAL EFFECT OF LONG-TERM CULTURE 1686 
OF NEONATAL ISLET CELL CLUSTERS (NICCS)
E. Jimenez-Vera, D. Simond, K. Moyle, J. O’Hara, P.J. O’Connell, 
W.J. Hawthorne
The Centre for Transplant and Renal Research, Westmead Millennium 
Institute, Westmead Hospital, Westmead, NSW 2145, Australia
Introduction: As a means to treat patients suffering type 1 diabetes, 
transplantation of porcine neonatal islet cell clusters (NICC) have the potential 
to be used as a source for xenotransplantation. NICCs are used within the fi rst 
week following isolation; however, we do not know if outcomes will improve 
by culturing the islets before transplantation or if extended culture is possible 
to allow for pooling of preparations for clinical transplantation. In this study 
we aimed to determine which NICC culture time point was optimal for in vivo 
functional outcome.
Method: Pig pancreases from 1-3 day old pigs were used to isolate NICCs 
using mechanical and enzymatic digestion. NICCs were cultured for up to 5 
weeks post isolation at 37°C, 5% CO2. Each week for 5 weeks the number of 
IEQ were determined, FACs analysis, static stimulation, Insulin:DNA ratio, 
ATP activity, ethidium bromide and acridine orange viability staining, and 
mouse transplants, were performed.
Results: Despite maintaining appropriate culture conditions there was an 
signifi cant loss in the number of IEQs over time p-values = 0.0001. There 
was no signifi cant difference at any other time point in the other parameters 
investigated due to the high variability in number of NICCs cultured in each of 
the experiments. However, preliminary diabetic mouse transplant data indicate 
NICCs functioned better after they were cultured for two or more weeks post 
isolation compared with results achieved after only one week of culture.
Conclusion: In these preliminary studies we have found that there was a 
decrease in the number of NICCs over time. However, NICCs transplanted at 
week one had poorer in vivo function than those transplanted following 2, 3 
and 4 weeks of culture. Further experiments are required to investigate which 
culture point achieves the optimum in islet numbers and function.
INTESTINAL CONCURRENT ORAL SESSION 119: 
TRANSPLANTS
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ASSESSMENT OF ACUTE REJECTION IN INTESTINAL 1687 
TRANSPLANT PATIENTS USING A PANEL OF MINIMALLY 
INVASIVE ASSAYS
P. Tryphonopoulos, P. Ruiz, D. Weppler, R. Cirocco, M. Carreno, J. Vargas, 
Y. Jin, A. Sornaraj, A. Berlanga, T. Kato, G. Selvaggi, A. Tzakis
University of Miami
Background: Intestinal transplantation is used for the treatment of intestinal 
failure. The graft can be monitored for acute rejection early post transplantation 
through a temporary ileostomy that we use for endoscopy / biopsies. Following 
closure of the ileostomy access to the graft can be limited. Moreover, the patient 
often leaves at some distance from the Transplant Center and cannot come 
readily for a graft endoscopy and biopsy. The measure of serum citrulline on a 
dried blood spot that the patient can mail to the Transplant Center has yielded 
promising results and can serve as a warning of possible acute rejection if its 
value drops below 13 umoles/Lt; however the level of specifi city for detecting 
acute rejection is not optimal. A panel of surrogate markers alongside citrulline 
could serve to refi ne and improve specifi city in detecting acute rejection 
episodes, the latter which notably contribute to late graft loss.
Methods: Since March 2007, we studied blood or stool samples of 17 patients, 4 
adults and 13 pediatrics who had undergone an intestinal (n=2) or multivisceral 
(n=15) transplant. Ten of these patients presented 14 rejection episodes during 
this period of time (mild n=5, moderate n=5 and severe n=4). We monitored 
the intestinal graft function with 5 different tests, from the peripheral blood: 
Perforin, Granzyme B, Serum citrulline, Cylex Immunoknow assay, or from 
the feces: Calprotectin.
Results: During the rejection episodes: There was a signifi cant increase of the 
fecal calprotectin levels, a signifi cant decrease of the serum citrulline levels 
and an increase of the lymphocyte reactivity (Cylex).
Conclusions: Monitoring of the small bowel graft function with a panel of 
minimally invasive assays may allow an early detection and a timely treatment 
of a rejection episode.
POSTER BOARD NUMBER P3 – 114
THE NOVEL NF-~ ÈB INHIBITOR, 1688 
DEHYDROXYMETHYLEPOXYQUINOMICIN (DHMEQ) 
PREVENTS LOCAL AND REMOTE ORGAN INJURY 
FOLLOWING INTESTINAL ISCHEMIA/REPERFUSION 
IN RATS
T. Suzuki1, K. Yamashita1, W. Jomen1, S. Ueki1, T. Aoyagi1, M. Fukai1, 
H. Frukawa1, K. Umezawa2, M. Ozaki1, S. Todo1
1Dept. of Surgery, Hokkaido University, 2Dept. of Applied Chemistry, Keio 
University
Background: Nuclear factor-ƒÈB (NF-ƒÈB) regulates the expression of several 
genes involved in infl ammation, the immune response, apoptosis, cell survival 
and proliferation. Many of these same genes are activated during ischemia/
reperfusion (I/R) injury. Here, we examined the anti-infl ammatory effi cacy 
of a newly developed NF-ƒÈB inhibitor, dehydroxymethylepoxyquinomicin 
(DHMEQ), in the intestinal I/R injury model of rats.
Method: Intestinal ischemia was induced by occluding the superior mesenteric 
artery for 60 min. The experimental animals were divided into 2 groups: 
untreated group, control; treated group, DHMEQ-treated (20 mg/kg). DHMEQ 
were administered intraperitoneally at 60 min prior to clamping and 5 min 
prior to reperfusion. Animal survival rates, intestinal tissue blood fl ow (ITBF), 
serum levels of TNF-ƒ¿ and interleukin (IL)-6, and the histopathology of both 
the intestine and lung were analyzed.
Results: The DHMEQ-treated animals exhibited higher values of ITBF and 
suppression of TNF-ƒ¿ and IL-6 production, resulting in marked prolongation 
of their survival times. Histopathological fi ndings obtained by examining 
tissues from control animals revealed severe intestinal mucosal damage and 
disruption of the lung alveolar architecture accompanied by hemorrhage and 
marked neutrophilic infi ltration. These fi ndings were signifi cantly ameliorated 
in DHMEQ-treated animals.
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Conclusion: DHMEQ effectively prevented both intestine and lung injuries in 
rat intestinal I/R models. This agent may possess a good potency for clinical 
application in various pathological settings including intestinal I/R and/or 
infl ammatory acute lung injury.
POSTER BOARD NUMBER P3 – 115
ASPERGILLUS-INDUCED SPONDYLODISCITIS AFTER 1689 
MULTIVISCERAL TRANSPLANTATION
U. Gerlach, S. Kohler, O. Guckelberger, J. Pratschke, P. Neuhaus, A. Pascher
Charite, Universitaetsmedizin Berlin, Campus Virchow Klinikum
Although the incidence of spondylodiscitis is rare, it has increasingly 
been described in patients with low immunity, most commonly due to 
immunosuppression, malignancy or chemotherapy.
We report on a case of fungal spondylodiscitis after multivisceral-transplantation 
(MVTX). A 25-year old male patient suffering from short bowel syndrome 
due to congenital intestinal malrotation and multiple abdominal operations 
underwent MVTX and kidney transplantation (stomach, duodenum, pancreas, 
liver, intestine, right kidney and adrenal gland) in June 2007. Baseline 
immunosuppression consisted of tacrolimus and steroids with thymoglobulin 
and infl iximab added as induction therapy. The patient experienced one episode 
of fungal pneumonia caused by aspergillus fumigatus which was treated with 
Caspofungin and Voriconazole for 21 and 46 days, respectively, until complete 
recovery was achieved.
Due to recurrent lumbalgy and limited mobilization, an MRI was performed 
which revealed a spondylodiscitis between the lumbar vertebral bodies L2 
and L3. Intervertebral disc puncture provided negative results. Considering E. 
faecium and Aspergillus fumigatus as potential pathogens, calculated antibiotic 
and antifungal treatment (Linezolid and Voriconazole) was offered. The patient 
was discharged 3 months after transplantation.
He was re-admitted 2 weeks later for aggravating lumbalgy and rising CRP-levels 
and a progressive spondylodiscitis was diagnosed radiographically. Surgical 
restoration including dorsal stabilization and reconstruction with autogenous 
iliac crest graft was performed immediately. Microbiological samples taken 
intraoperatively gave evidence to invasive fungal infection with Aspergillus 
fumigatus. Consequently we initiated a triple antifungal treatment consisting 
of Caspofungin, Voriconazole and liposomal Amphotericin B, concomitant to a 
triple antibiotic regimen (Tigecycline, Ceftazidim and Metronidazole).
The patient achieved a very good response clinically and microbiologically and 
remained symptomfree afterwards. He was discharged 3 weeks later. At present, 
8 months after transplantation and 5 months after spinal surgery, there is a 
complete absence of clinical symptoms and signifi cant signs of infl ammation.
Spondylodiscitis caused by fungal infection is a rare but serious complication 
after solid organ transplantation. Early surgical treatment should be considered 
in the event of irreversible disc destruction and limited mobilization due to 
intolerable pain.
POSTER BOARD NUMBER P3 – 116
TRANSFUSION SUPPORT IN INTESTINAL 1690 
TRANSPLANTATION
S. Shariatmadar1, M.E. Barron2, A.G. Tzakis3
1University of Miami Miller School of Medicine/Jackson Memorial Hospital, 
Dept. of Pathology, 2Dept. of Anesthesiology, 3Dept.of Surgery
Introduction: The current literature lacks information on the transfusion 
requirements of patients undergoing intestinal transplantation (ITX). We report 
on the intraoperative blood product utilization and the incidence of RBC 
alloimmunization in 73 ITX patients.
Methods: Medical and transfusion records were reviewed in 73 consecutive 
patients who underwent ITX from 3/94 to 5/07. Thirty-nine were adults (age 
range: 19-61 yrs), 34 were pediatric (age range: 7 mos.-17 yrs). Blood samples 
for serologic investigation were submitted to the transfusion service no later 
than 4 hours prior to initiation of surgery. The incidence of clinically signifi cant 
RBC alloantibodies pre-transplant and subsequent transfusion requirements 
during surgery were evaluated.
Results: All patients received irradiated and CMV negative/leukoreduced 
cellular products during transplantation.
Total Intraoperative Utilization
PRBCs (Units) FFP (Units) PLTS (dose) Average Blood 
Loss (ml)Mean Range Mean Range Mean Range
Pedi (n:33) 2.4 0.5-9 0.8 0-5 0.1 0-1 618
Adult (n:31) receiving
<10 PRBC Units 3.9 1-8 1.0 0-8 0.0 0-1 1434
Adult (n:8) receiving
>10 PRBC Units 21 11-44 13 6-26 0.75 0-2 10387
A 17 year old pediatric patient re-transplanted for acute rejection required 26 
units PRBCs, 30 units FFP, and 2 doses of platelets during surgery. Eight adults 
(20%) required extensive transfusions secondary to technical and anatomic 
diffi culties attributed to multiple prior abdominal surgeries. The diagnosis 
in these included Gardner’s syndrome with extensive desmoid tumors, short 
bowel syndrome secondary to trauma, and venous thrombosis from protein 
C defi ciency. Hemostasis was achieved in all cases and ITX successfully 
completed. One of 73 patients (1.3%) had a clinically signifi cant RBC 
alloantibody (anti-Kell) prior to re-transplantation. The patient was successfully 
managed with Kell-negative PRBCs during surgery.
Conclusion: This is the fi rst reported large consecutive series of blood 
utilization in isolated intestinal transplantation. Successful ITX is associated 
with minimal blood loss in most patients with an average of 2.4 units PRBCs 
in the pediatric and 3.9 units in the adult population with minimal component 
use. Patients with extensive desmoid tumors and short gut syndrome secondary 
to trauma with a history of multiple prior surgeries were identifi ed as being a 
high utilization group with larger PRBC use and markedly increased need for 
FFP. RBC alloimmunization remains rare in this expanded series of patients as 
initially reported.
POSTER BOARD NUMBER P3 – 117
THE PREVALENCE OF VASCULAR C4D DEPOSITION IN 1691 
INTESTINAL ALLOGRAFT BIOPSIES.
E. Lerut1, J. Pirenne2, K. Geboes1, D. Monbaliu2, N. Ectors1
1Dept Morphology and Molecular Pathology, University Hospitals Leuven, 
2Dept Abdominal Transplant Surgery, University Hospitals Leuven
Aim: In renal and cardiac transplantation, C4d deposition is accepted as an 
in situ marker for acute antibody-mediated rejection. Several correlations 
with a less favourable prognosis have been described. Literature data on the 
prevalence and signifi cance of C4d deposition in intestinal allograft biopsies 
are sparse.
Methods: Between October 2000 and March 2008, 8 patients (6 
female/2male, mean age 36 years, range 2-57 years) underwent an intestinal 
transplantation (combined liver-intestinal (n=3), isolated intestinal (n=3), 
combined kidney-intestinal (n=1), multi-visceral (n=1) transplantation). 
Allograft biopsies were taken as part of a standardized clinical follow-up 
or depending on clinical indication. Out of all intestinal allograft biopsies 
(n=208; 0-2539 days post-transplantation), 159 biopsies had high-quality 
frozen tissue available, which was immunohistochemically stained for C4d. 
For each biopsy the presence of mucosa (lamina propria) and submucosa 
was noted. C4d positivity in the capillaries of the lamina propria was 
scored as ‘negative’, ‘focally positive’ (<5% of the capillaries positive), or 
‘positive’ (>5% of the capillaries positive). C4d positivity in the submucosal 
vasculature was scored as ‘negative’ or ‘positive’. Correlations with clinical 
and morphological data were studied.
Results: In the lamina propria, capillaries were C4d negative in 83 biopsies 
(52.2%), focally positive in 34 biopsies (21.4%) and positive in 41 biopsies 
(25.8%) (1 biopsy (0.6%) without assessable mucosa). The submucosal 
microvasculature was C4d positive in 77 biopsies (48.4%) and negative 
in 42 biopsies (26.4%) (40 biopsies (25.2%) without submucosal tissue). 
When only biopsies consisting of both mucosa and submucosa were studied 
(n=118), 35 biopsies (29.7%) were C4d negative in both levels and 29 
biopsies (24.6%) were C4d positive in both levels (45.7% showed other 
combinations of positive/focal positive/negative in the lamina propria and 
positive/negative in the submucosa) (X2 p≤0.0001). C4d positivity was 
observed in early as well as in late post-transplantation biopsies. Although 
some degree of C4d positivity was observed in biopsies of all 8 patients, 
an acute rejection (clinically highly suspected and biopsy-proven) was 
only diagnosed in 2 patients. In those 2 patients, who were tested for the 
presence of donor specifi c antibodies, 1 was found positive and 1 negative. 
Subclinical acute cellular rejections (clinically stable allografts with 
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histological features of acute cellular rejection) were not present in our 
patients.
Conclusion: In our unicentric cohort of intestinal allografts (n=8), 
immunohistochemical C4d deposition was present in the majority of biopsies 
without a clear correlation with allograft function or the presence of donor 
specifi c antibodies. A strong correlation between C4d positivity in the lamina 
propria and the submucosa was seen. To assess the impact of C4d deposition in 
the lamina propria and submucosa on graft function and/or outcome, a larger 
cohort with longer follow-up data is needed.
ANIMAL MODELSCONCURRENT ORAL SESSION 120: 
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EARLY HUMAN FETAL PANCREAS AS A THERAPY FOR 1692 
DIABETES
B. Tuch1, W. Wu1, K. Brands1, E. Colvin1, J. Sung1, L. Williams1, R. Lock2, 
R. Wang3
1Diabetes Transplant Unit, Prince of Wales Hospital, 2Children’s Cancer 
Institute Australia for Medical Research, 3University of Western Ontario
The use of human fetal pancreatic tissue may provide an alternative source of 
tissue for transplantation as a therapy for type 1 diabetes. Human fetal pancreas 
has a remarkable capacity to grow and differentiate in vivo and has been shown 
to reverse diabetes in rodents (Transplantation 1988; 46: 608-11). However, 
it is known that human fetal pancreas obtained from the 2nd trimester of 
gestation is immunogenic and is rejected after transplantation. Tissue obtained 
from earlier stages might prove to be immune privileged, as has been shown 
for other tissues.
In this study we determined the immunogenicity of human fetal pancreatic 
tissue obtained from the 1st trimester of gestation in a humanized mouse 
model, a NOD/SCID mouse injected with 5 x 106 human peripheral blood 
mononuclear cells (PBMCs). A microarray study of immunoregulatory 
gene expression in 1st and 2nd trimester human fetal pancreas also was 
undertaken. Finally, experiments were conducted to determine the fate of the 
1st trimester tissue if it was maintained in the humanized mice long enough 
for it to mature.
The analysis of transplanted human fetal pancreata revealed a signifi cantly 
decreased immunogenicity of the 1st trimester tissue. The 1st trimester grafts 
3 weeks after injection of PBMCs showed only limited cellular infi ltration and 
contained numerous insulin positive cells, whereas 2nd trimester tissue was 
completely infi ltrated and rejected. The%age of CD45+ human cells was 26 ± 
7 vs 43 ± 5% (P < 0.05) in 1st and 2nd trimester grafts respectively. Most of 
the CD45+ cells were T cells, with CD8 > CD4 but no differences between the 
trimesters. Grafts analysed as late as 8 wk after injection of PBMCs survived 
in 11% of mice. Humanization was confi rmed at this time, but most of the mice 
developed either a, lymphoproliferative disorder or graft-vs-host disease. To 
reduce the chance of these adverse events occurring, PBMCs were obtained 
from EBV-ve donors, with 50% long-term survival of the grafts.
Normalization of blood glucose levels was achieved in the streptozotocin-
diabetic mouse grafted with 1st trimester human fetal pancreases, both non-
humanized and humanized.
An analysis of immunoregulatory genes expressed in 1st and 2nd trimester 
human fetal pancreas by microarray demonstrated the upregulation of several 
key immunoregulatory genes in the 2nd trimester tissue, especially HLA class 
II, CCL19, C3, B7-H4, IL22Rá1 and TNFSF10. This might account for the 
reduced immunogenicity of the younger tissue.
Our results provide a fi rst indication that the use of 1st trimester human fetal 
pancreas for transplantation might increase the survival of the grafts and might 
decrease the requirement for immunosuppressive drugs.
POSTER BOARD NUMBER P3 – 119
TRANSGENIC EXPRESSION OF THREE ANTIOXIDANT 1693 
ENZYMES PROTECTS MOUSE ISLETS FROM PRO-
INFLAMMATORY CYTOKINES IN VITRO AND PROLONGS 
ISLET ALLOGRAFT SURVIVAL
T. Mysore, T. Shinke, N. Fisicaro, L. Murray-Segal, P. O’Connell, A. d’Apice, 
P. Cowan
Immunology Research Centre, St. Vincent’s Hospital, Melbourne, 
National Pancreas Transplant Unit, Westmead Hospital, Sydney
Background and aim: During islet isolation and transplantation, reactive 
oxygen species (ROS) are generated within beta cells by several mechanisms 
including the action of pro-infl ammatory cytokines (PIC). Because islet grafts 
are poorly equipped to deal with ROS, we produced transgenic C57BL/6 mice 
expressing the antioxidant enzymes glutathione peroxidase (Gpx-1), CuZn SOD 
and extracellular SOD under the control of the mouse H-2Kb (MHC Class I) 
promoter. We have previously used these mice to show that co-expression of 
the 3 enzymes improves the function of marginal islet isografts. The aim of the 
current study was (i) to further explore the mechanism of this protective effect by 
examining the resistance of transgenic islets to PIC in vitro, and (ii) to determine 
whether transgene expression prolonged islet allograft survival in vivo.
Methods: (i) 100 handpicked islets from triple-transgenic (TG) and wild type 
(WT) control mice were incubated for 72 hrs with combinations of PIC (50 
U/ml IL-1β, 1000 U/ml TNFα, 1000 U/ml IFNγ). Culture supernatants were 
assayed for nitrite using Griess reagent. Islet viability was assessed by the MTT 
assay and expressed relative to untreated islets. (ii) 450 handpicked islets were 
transplanted under the kidney capsule of diabetic CBA-RIP-Kb mice. Islet 
graft function was checked by measuring the blood glucose levels (BGLs) of 
recipient mice on alternate days until graft rejection (BGL >15 mmol/l).
Results: (i) Accumulation of nitrite was signifi cantly lower in TG versus WT 
islets under all three conditions, indicating that transgene expression inhibited 
ROS generation. The viability of WT islets was reduced to 53 ± 5.0% by IL-1/
TNF, 19 ± 2.4% by IL-1/IFN, and 8.0 ± 0.4% by IL-1/TNF/IFN treatment. The 
corresponding viability of TG islets was 54 ± 2.1% (not signifi cant versus WT), 
60 ± 3.0% (P<0.001), and 20 ± 1.2% (P<0.02). (ii) In the transplantation model, 
TG islet graft survival was signifi cantly prolonged compared to WT islet grafts 
(mean time to graft rejection 21 days versus 15 days, P<0.03).
Conclusion: Transgenic islets were signifi cantly protected from PIC toxicity, 
but only when IFNγ was a component of the cytokine cocktail. We hypothesise 
that this is at least partly due to upregulation of transgene expression by IFNγ 
activation of the H-2Kb promoter. Transgenic expression of the antioxidants 
also delayed the rejection of fully allogeneic islet grafts in mice. Investigation 
of the mechanisms by which these antioxidants mediate their effects on islet 
allograft survival is underway. Overall our results indicate that balanced 
expression of antioxidant enzymes protects mouse islets against oxidative 
and cytokine-mediated injury. This approach may be useful in both allo- and 
xenotransplantation.
POSTER BOARD NUMBER P3 – 120
A NEW SPONTANEOUSLY DIABETIC TRANSGENIC 1694 
(SDT) MOUSE LINE: A USEFUL RECIPIENT FOR ISLET 
TRANSPLANTATION
T. Mysore, L. Murray-Segal, A. d’Apice, P. Cowan
Immunology Research Centre, St. Vincent’s Hospital, Melbourne
Background: Chemically-induced diabetic mice have been used for many 
years as recipients in islet transplantation studies. However, diabetogenic 
chemicals such as streptozotocin have several disadvantages: (i) cytotoxic 
effects outside the pancreas, which may result in mortality or affect immune 
responses; (ii) variable degrees of hyperglycemia, which may affect the 
reproducibility of diabetes reversal; and (iii) incomplete deletion of beta cells, 
which may recover suffi ciently to mask suboptimal performance of islet grafts. 
Spontaneously diabetic mice offer a useful alternative, but often suffer from 
poor health or fertility. In a separate project to develop doxycycline-inducible 
expression of angiogenic factors in mouse beta cells, we noticed that mice in 
one transgenic line were polyuric, and further investigation revealed that they 
were spontaneously diabetic. The mice, on a C57BL/6 background, contained 
two transgenes: the Tet-On transactivator rtTA2 under the control of the RIP7 
Wednesday 13 August 2008 Poster Abstracts
5 6 2
W
ED
N
ES
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
beta cell-specifi c promoter, and human VEGF-A under the control of the Tet-
responsive element (TRE). The aim of the current project was to characterise 
these mice as potential islet graft recipients.
Methods: The non-fasting blood glucose level (BGL) of the spontaneously 
diabetic transgenic (SDT) mice and wild type (WT) littermate controls was 
determined weekly. Mouse pancreata were harvested for measurement of 
insulin content by ELISA and expression of rtTA2 and VEGF-A by RT-PCR 
and Western blot. 400 handpicked islets from C57BL/6 (syngeneic) WT mice 
were transplanted under the kidney capsule of SDT male mice. Islet graft 
function was monitored by measuring BGL on alternate days for 35 days, at 
which point the graft-bearing kidney was removed.
Results: Diabetes in both male and female SDT mice was predictable and early 
in onset (mean BGL 29.5 ± 1.7 and 27.3 ± 5.2 mmol/L, respectively, at 4 wks; 
WT 7.2 ± 2.1 mmol/L; P<0.01 versus WT). By 16 wks of age, diabetes remained 
severe in male mice (29.6 ± 1.2 mmol/L) but was milder in female mice (18.6 ± 
3.4 mmol/L). All SDT mice showed normal fertility, appeared healthy apart from 
polyuria, and could be maintained beyond 35 weeks of age without parenteral 
insulin. Pancreatic insulin content was lower in 10 wks old SDT mice (2.43 ± 
0.71 ng/mg protein) than in WT mice (6.62 ± 3.46 ng/mg protein). Pancreas-
specifi c expression of rtTA2 was shown by RT-PCR and Western blot; however, 
human VEGF-A could not be detected even after doxycycline treatment of the 
mice. In the transplantation model, syngeneic islet grafts (n=4) maintained 
normoglycemia for the length of the experiment (35 days), and recipients 
returned to hyperglycemia after removal of the graft-bearing kidney.
Conclusions: The SDT mice offer several advantages as islet transplant 
recipients because they reproducibly and spontaneously develop diabetes 
without overt detrimental effects. Our hypothesis is that specifi c over-expression 
of the transcription factor rtTA2 in beta cells disrupts the processing and 
secretion of insulin in particular or beta cell functions in general. Investigation 
of these potential mechanisms is underway.
POSTER BOARD NUMBER P3 – 121
BETA CELLS IN TRANSPLANTED ISLETS ISOLATED 1695 
FROM YOUNG DONORS CAN REPLICATE WITH OR 
WITHOUT EEXENDIN-4 TREATMENT
L. Tian1, H. Yi1, T. O’Brien2, D. Sutherland1, B. Hering1, Z. Guo1
1Department of Surgery, University of Minnesota, 2Department of Veterinary 
Population Medicine, University of Minnesota
The outcome of islet autotransplantation in pediatric patients was better than 
the adolescent patients. One of the possible mechanisms is that beta cells in the 
transplanted islets from young donors have the capability of regeneration. In this 
study, we investigated whether beta cells in the transplanted islets isolated from 
young donors can replicate in syngeneic diabetic mice and whether exendin-4 
(a glucagon-like peptide-1 analog) treatment can enhance beta cell replication. 
Donor islets were isolated from 8 week-old C57BL/6 mice. Diabetes in the 
C57BL/6 recipient mice was induced by streptozotocin. Diabetes was diagnosed 
when the nonfasting blood glucose level was >400 mg/dl on at least 2 consecutive 
days. Total 100 or 150 islets were transplanted under the right kidney capsule of 
each diabetic C57BL/6 mouse. Islet graft function was monitored by measuring 
the blood glucose level. These recipient mice were given bromodeoxyuridine 
(BrdU) at 100 mg/kg/day or BrdU and exendin-4 at 10nM/kg/day. All recipient 
mice achieved normglycemia after transplantation. When 100 islets were 
transplanted, the average days before achieving normglycemia were 10 days in 
exendin-4 treated mice (N=10); and 16 days in control mice (N=11). When 150 
islets were transplanted, the average days before achieving normglycemia were 
7 days in exendin-4 treated mice (N=9); and 10 days in control mice (N=5). 
At 4 weeks posttransplantion, nonfasting blood glucose level was 139±14 mg/
dl in exendin-4 treated mice, and 161±20 mg/dl in control mice that receiving 
100 islets. Nonfasting blood glucose level was 112±19 mg/dl in exendin-4 
treated mice, and 116±22 mg/dl in control mice that receiving 150 islets. 
Nephrectomy was performed to remove islet grafts for insulin and BrdU double 
immunofl uorescence staining. Both insulin+ and BrdU+ beta cells in the islet 
grafts were found in mice with and without exendin-4 treatment. An average 
of 7.2 1.8% both insulin+ and BrdU+ beta cells were detected in the untreated 
islet grafts. However, both insulin+ and BrdU+ beta cells signifi cantly increased 
in inexendin-4 treated islet grafts with an average of 16.2±5.9% insulin+ and 
BrdU+ beta cells in islet grafts (P<0.01). Our data indicated that beta cells in 
the transplanted islets isolated from young donors can replicate and exendin-4 
treatment can enhance beta cell replication.
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ENHANCEMENT OF DIABETES REVERSAL IN BALB/C 1696 
ATHYMIC NUDE MICE WITH OPTIMAL RATIOS OF ADULT 
PORCINE ISLETS OF LANGERHANS TO ADULT PORCINE 
SERTOLI CELLS
C.P. Hasilo1, G. Vilk1, C.W.J. Melling1,3, A. Pepper1, A. MacGillivary1, 
A. Sverzhinsky1, C. Gall1, D.M. Siroen1, K. Grise1, D.G. White1,2,3
1Multi-Organ Transplant Program, London Health Sciences Center, London, 
Ontario, Canada, 2Department of Xenotransplantation, Robarts Research 
Institute, London, Ontario, Canada, 3Department of Pathology, The 
University of Western Ontario, London, Ontario, Canada
Islet transplantation is a viable cell replacement therapy with great potential 
to effectively cure type 1 diabetes mellitus (T1DM). Several limitations have 
prevented islet transplantation from emerging as a standard of care for T1DM. 
The supply of high quality donor pancreata and harsh immunosuppressive drug 
regimes are two major obstacles that need to be overcome to progress the fi eld. 
Sertoli cells (SC) can provide an immune privilege to the islets of Langerhans 
when co- transplanted, thus bypassing the need for immunosuppression. The 
complexity of the immune reaction in animals with an intact immune system 
prompted us to test out the benefi ts of varying ratios of islets to SC in diabetic 
balb/c athymic nude mice. These mice have an intact innate immune system 
(antibodies, NK cells, dendritic cells, Bcells, etc.) but an absence of adaptive 
immunity (Tcell defi cient). We set out to determine an optimal range for the islet 
to SC ratio for the combined cell therapy and examine if there exists a functional 
threshold to the number of adult porcine SC that may be combined with the 
adult porcine islets (islet equivelents; IE) and still reverse diabetes. Transplants 
consisted of 4,000-8,000IE islets under the left kidney capsule alone or in 
combination with Sertoli cells. The initial test consisted of a comparison of a 
1:5,000 ratio of islets to SC with a high dose of 8,000IE and 40x106 Sertoli cells. 
None of the mice receiving the dose of 1:5,000 reversed (n=4) during the study, 
compared to 75% in the 8,000IE alone group (3/4 mice). We then established 
that 1:5,000 may effectively be too great a ratio of islets to Sertoli cells and set 
out to test the effect of varying the ratio on the rates of diabetes reversals. Three 
groups of islet to Sertoli cell ratios of 1:2,000, 1:200 and 1:20 using a standard 
dose of 4000IE adult porcine islets to prevent excessive volume loading causing 
hypoxia of the cells, combined with varying amounts of adult porcine Sertoli 
cells (corresponding to 8x106 SC, 8x105 SC, and 8x104 SC, respectively). 
The resulting non-fasting blood glucose values demonstrated dose-dependent 
rates of diabetes reversal of 25% (1/4 mice), 50% (2/4 mice) and 75% (3/4 
mice) corresponding to the ratios of 1:2,000, 1:200 and 1:20, respectively (n=4 
per group). Nephrectomizing the graft-bearing kidney in the mice achieving 
normoglycemia showed reversion to hyperglycemia. Maintenance of weight as 
an indicator of health status followed a similar pattern in all mice transplanted 
with islets and SC; mice demonstrated healthy weight gain upon reversal of 
diabetes and those that did not reverse did not drop in weight as is characteristic 
of diabetic balb/c athymic nude mice. Furthermore, even the mice that do not 
reverse their diabetes show better maintenance of weight when co-transplanted 
with SC (n=4) than those that did not reverse with islets alone (n=2). Taken 
together the results of this study demonstrate optimal ratios between 1:2000 and 
1:20 islets to SC with enhanced maintenance of animal health when combining 
adult porcine islets and SC.
ENGINEERING CONCURRENT ORAL SESSION 121: 
STRATEGIES
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ULTRAPURIFIED ALGINATE-BASED MICROCAPSULES 1697 
FOR IMMUNOPROTECTION OF HUMAN ISLET 
ALLOGRAFTS IN TYPE 1 DIABETES MELLITUS (T1DM)
G. Basta, L. Racanicchi, P. Montanucci, C. Santi, R. Calafi ore
University of Perugia
Staircase-like declining long-term success of human islet allografts in totally 
immunosuppressed T1DM patients, according to Edmonton/ITN mandates 
validation of alternative approaches for islet grafts immunoprotection, so as to 
obviate recipient’s general immunosuppression, as well as establishment of new 
insulin producing cell sources. As to the former, immunoisolatory microcapsules, 
enveloping individual islets could represent a potential solution to this specifi c 
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problem. Alginic acid (AG)-based microcapsules have encountered, so far, a 
series of technical problems, mainly due to low purity grade of the constituent 
polymers that have seriously hampered their application for transplant. In our 
laboratory we have generated a method for AG ultra-purifi cation, and obtained 
a “clinical grade” product, to be used for human as well as nonhuman islet 
cell microencapsulation. Such AG is being approved for clinical use in the US 
(IND submitted). Using this product, complexed with poly-L-ornithine (PLO) 
as an aminoacidic poly-cation coat, we have initiated our own phase-1 pilot 
clinical trial of intraperitoneal AG/PLO encapsulated human islet allografts 
into 4/10 nonimmunosuppressed patients with long-standing T1DM, upon 
approval by the Italian Ministry of Health. Out of 4 patients, 3 have been 
grafted intraperitoneally, under local anesthesia and echography guidance, 
while patient#4 has been implanted by abdominal laparoscopy, under general 
anesthesia, with the encapsulated islets being deposited beneath the liver and the 
spleen. Grafted islet mass ranged from 400,000 to 1,000,000 islet equivalents 
IEQ per patient. All cases showed graft response in terms of either appearance 
of prior inexistent serum C-peptide (CPR) levels, both in basal (range: 0.4-1.2 
ng/ml) and after glucagon test (1 mg i.v.) (range: 0.9-2 ng/ml), or signifi cant 
decline of HbA1c levels at 6 mo. post-TX, or reduced daily exogenous insulin 
requirements (transient complete insulin withdrawal was obtained only in 
pt.#4). Most importantly, microcapsules prevented allosensitization in all 
recipients, with anti-HLA Class I and II antibodies resulting negative, unlike 
reported for pharmacologically immunosuppressed islet allograft recipients. 
In conclusion and preliminarily, our microcapsules formulated with “clinical 
grade” AG and PLO were shown to immunoprotect human islet allografts and 
prevent patient’s immunosensitization without immunosuppression. Further 
adjustments in islet mass dosing per patient could result in stable insulin-
indepencency in the treated cases to come.
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EFFECT OF HEPARIN ON EARLY ISLET FAILURE 1698 
AFTER INTRAPORTAL TRANSPLANTATION IN SYNGENEIC 
AND ALLOGENEIC MODEL
S-J. Kim1,2 , D-Y. Jung1, S-K. Lee2, J-W. Joh2, J-M. Chun2, G-O. Jung2, J-I. 
Moon2, J-M. Kim2, U-J. Kyung2, H-J. Park2, H-T. Jung2
1Transplantation Research Center, Samsung Biomedical Research Institute, 
Sungkyunkwan University School of Medicine, Seoul, Korea, 2Department 
of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea
In clinical transplantation, the instant blood-mediated infl ammatory reaction 
(IBMIR) is a major factor contributing to the poor initial engraftment of the islets. 
Tissue factor (TF), MCP-1 and other infl ammatory mediators trigger an injurious 
thrombotic/infl ammatory reaction, engaging the coagulation and complement 
systems, platelets and PMNs, when islets come in contact with blood in the portal 
vein. As an anticoagulant, heparin which possesses substantial anti-infl ammatory 
properties has been in widespread clinical uses. We therefore studied the effects 
of heparin to prevent IBMIR-induced islet destruction following intraportal islet 
transplantation in syngeneic and allogeneic mouse model.
Chemically induced C57BL/6 diabetic mice underwent intraportal syngeneic 
and allogeneic mice islets transplantation (300 and 350 IEQ, respectively). 
Nonfasting serum glucose levels were evaluated in islet transplant mice; the 
islets were cultured with 10 mM NIC (or without), and saline or heparin (10 
unit) with islet was infused. After 3 and 24 hours of islet transplantation, the 
effects of heparin were evaluated by blood cell count, monocyte chemoattractant 
protein-1 (MCP-1) serum concentration, and immnohistology.
Islet transplant recipients infused with heparin (10unit) became 
normoglycemic after syngeneic and allogeneic islet transplantation (300 and 
350 IEQ, respectively), and the difference was signifi cantly exhibited when 
compared with the NIC-treated or untreated. After 3 hours of intraportal islet 
transplantation, platelet consumption and MCP-1 concentration were rapidly 
increased, while heparin treatment induced slightly to decrease, but not 
signifi cant. After 24 hour, necrosis of liver was not serious in heparin-treated 
graft compare to the control graft. In addition, islet cells in the heparin-treated 
graft were morphologically well-granulate (control vs heparin; 40% vs 75%, 
p<0.05), and stained by nitrotyrosin, biomarker of oxidative stress, less than 
those of the control group (p=0.02).
These observations indicate that heparin might play an important role to prevent 
prompting the deterioration of the islet grafts in syngeneic and allogeneic 
mouse models.
POSTER BOARD NUMBER P3 – 125
DEDIFFERENTIATION OF HUMAN PANCREATIC 1699 
ISLETS SEEDED ONTO 3D-SCAFFOLDS
G. Sundaram, V. Vaithilingam, J. Lees, W. Wu, C. Wu, H. Zreiqat, B.E. Tuch
Diabetes Transplant Unit, Prince of Wales Hospital/University of New 
South Wales, Sydney and Tissue Engineering and Biomedical Research Unit, 
University of Sydney
Attempts to expand the number of beta cells in islets have been attempted by 
culturing the islets in a two-dimensional (2D) system. The insulin positive 
cells dedifferentiate, losing insulin expression and enhancing expression of 
the ductal/progenitor marker, CK19 and mesenchymal marker, vimentin. It is 
known that mouse islets function more effi ciently in a three-dimensional (3D) 
than a 2D system. We hypothesized, therefore, that there is an advantage in 
placing human islets in a 3D environment. For this reason, we seeded human 
islets onto 3D scaffolds made of polylactic-glycolic acid (PLGA), which are 
available for clinical use. Before transplanting the seeded scaffolds, we wished 
to determine whether it would be benefi cial to culturing them in vitro.
Human islets in aliquots of 4000 or 8000 islet equivalents (IEQs) were 
seeded onto 3D porous scaffolds of PLGA of dimensions 8 x 8 x 3 mm and 
with a pore size of 300 μm. Degree of attachment, survival, morphology 
and characterization of the cells by immunofl uorescent analysis for insulin 
(endocrine marker), CK19 and vimentin (mesenchymal marker) were analysed 
at 2h, 24h, 3d and 7d post-seeding.
The islets readily attached to the scaffolds, with the cells migrating from the 
spherical islets onto the surface of the scaffolds. The cytoplasm diminished in 
size and the nuclei become slightly smaller, but the nuclear:cytoplasmic ratio 
increased. Many of the cells died after the fi rst day of culture, with the surviving 
insulin positive cells dedifferentiating into cells that expressed CK19. The 
percentage of insulin positive cells diminished from 66% at 2hr to 35% at 1 day 
with a smaller reduction to 29% by 7 days. Conversely, the percentage of CK19 
positive cells increased from 22% at 2 hr to 53% at day 7. The percentage of 
mesenchymal cells remained constant throughout at 20%.
In summary, human islets seeded onto a 3D scaffold and then cultured 
dedifferentiate, just as the islets do when cultured in a 2D environment. There 
is no advantage in culturing human islets seeded onto 3D scaffolds for > 24 
hours since many of the cells do not survive. How human islets seeded onto 3D 
scaffolds and transplanted behave remains to be determined.
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EFFECTS OF SYSTEMIC IMMUNOSUPPRESSION 1700 
ON ISLET ENGRAFTMENT AND FUNCTION INTO A 
SUBCUTANEOUS BIOCOMPATIBLE DEVICE
A. Pileggi1, S. Marzorati1, N. Bocca1, R.D. Molano1, A.R. Hogan1, M. Doni1,2, 
L. Cobianchi1,2, L. Inverardi1, C. Ricordi1
1University of Miami Miller School of Medicine - Diabetes Research 
Institute, 2Department of Surgery, Fondazione IRCCS “San Matteo” Hospital 
University of Pavia, Italy
Recent data suggests that immunosuppressive agents may adversely affect the 
engraftment and the function of transplanted islets. Tacrolimus (Tac) is known 
for its diabetogenic and toxicity leading to progressive islet cells dysfunction. 
Also sirolimus (Sir) may adversely affect islet engraftment and compromise 
ß-cell function.
Aim of the study was to explore the effect of Sir and Tac immunosuppression 
(IS) on islets implanted into a subcutaneous (SC), prevascularized device. To 
avoid the confounding elements of rejection and autoimmunity, we used a 
syngeneic transplant model in rats.
A biohybrid device was implanted subcutaneously in Lewis rats 40 days prior 
to islet transplantation to allow prevascularization of the site. To test the effects 
of the drugs on islet engraftment, animals received a 40-day treatment with 
Tac (daily SC at 1.0mg/kg), Sir (oral 3.0mg/kg on days 0, 1, 2 and every other 
day thereafter) alone or in combination. Controls received no treatment. An 
additional experiment used the same immunosuppressive protocol in animal 
with established syngeneic islet graft function (>40 days). For both group we 
performed a 40-day washout period. Nonfasting glycemia (<200mg/dL) and 
intravenous glucose tolerance tests (IVGTT) were performed to monitor graft 
function over time.
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While, 3/4 recipients achieved and maintained normoglycemia long-term 
after transplantation in the control group. Animals under any IS regimen did 
not reverse diabetes during the 40-day treatment when started at the time of 
islet transplantation. Graft dysfunction was not reversible after withdrawal 
of the IS. In the Sir group, only 1/3 animals had transient graft dysfunction 
during IS treatment that resolved during the washout period. We observed a 
persistent signifi cant difference in glucose clearance during IVGTT between 
control group and animal under FK (p=0.048 under IS; p=0.0016 after 
washout).
In the animal with established graft function, graft dysfunction (elevation 
of nonfasting glycemic values) was observed during the IS treatment, and 
dysfunction persisted after washout in 2/3 and 3/3 of the animals treated with 
Tac and Sir+Tac, respectively. In the Sir group, only 1/3 animals had transient 
graft dysfunction during IS that resolved during the washout period. Signifi cant 
differences in glucose clearance during IVGTT were measured in the Tac group 
and in the Tac+ Sir group before and after IS, when compared to controls 
(p=0.008 Tac; p=0.004 Tac+Sir).
Our data underlines the potential toxicity of Sir and Tac on islet grafts also in 
the context of islet cell transplanted into a biohybrid device.
Our data indicates that Sir and Tac have profound deleterious effects on islet 
cell engraftment and function, which may hinder the success of implantation 
into biohybrid devices. Non-diabetogenic IS protocols should be considered 
for a clinical application of islet transplantation into biohybrid devices.
POSTER BOARD NUMBER P3 – 127
ANCHORING OF GROWTH FACTORS TO SURFACE-1701 
IMMOBILIZED HEPARIN ON PANCREATIC ISLETS; 
IMPLICATIONS FOR STIMULATING ISLET ANGIOGENESIS
P.U. Magnusson1, S. Cabric, U. Johansson
1Dep of Clinical Immunology, 2Dep of Clinical Immunology, 3Dep of Clinical 
Immunology
In pancreatic islet transplantation, early revascularization is necessary 
for long-term graft function. We have recently shown in in vitro and in 
vivo models that modifi cation with surface-attached heparin protects 
the islets from acute attack by the innate immune system of the blood 
following intraportal islet transplantation. In the present study, we have 
investigated the ability of an immobilized conjugate composed of heparin 
to bind the angiogeneic growth factors VEGF-A or FGF-2 as a means 
of attracting endothelial cells (ECs) in order to induce angiogenesis an 
revascularization.
The capacity of growth factors to bind to immobilized heparin was evaluated 
using a quartz crystal microbalance with dissipation monitoring (QCM-D) 
technique and ELISA. VEGF adherence to the surface of heparin-coated islets 
and the coating of islets with ECs were visualized by confocal microscopy. The 
proliferation of ECs on heparinized surfaces in the presence of VEGF was also 
evaluated using a thymidine incorporation assay.
QCM-D and ELISA demonstrated considerable binding of VEGF and FGF to 
heparin- coated surfaces, and binding of VEGF was further verifi ed by confocal 
microscopy. Covering islets with heparin also increased the adhesion of ECs to 
the islet surface. ECs cultured on heparinized surfaces showed 2-fold reduced 
proliferation in basal conditions but responded equally upon VEGF stimulation 
as corresponding control. Also, ECs cultured on heparin-coated glass surfaces 
exhibited induced focal adhesion and stress fi ber formation.
Immobilized heparin on the islet surface may be a useful anchor molecule for 
achieving complete coverage of the islets with growth factors such as VEGF 
and FGF, ultimately improving islet revascularization and engraftment in 
pancreatic islet transplantation.
DONOR PRE-CONCURRENT ORAL SESSION 122: 
TREATMENT
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GENERATION OF FUNCTIONAL NEOISLETS OF 1702 
LANGERHANS FROM SURGICAL RESECTED PANCREATIC 
TISSUE
Y-M. Shyr
Taipei Veterans General Hospital
Objective: Type 1 diabetes is a degenerative disease in which the destruction of 
£]-cells leads to persistent hyperglycemia. Although islet cell transplantation holds 
promise for the treatment of diabetes, shortage of donor remains a major drawback. 
The aim of this study is to generate functional insulin-producing neoislets from 
adult human pancreatic cells taken from surgically-resected pancreas tissue.
Research design and methods: Procedures were developed to isolate ƒÒ-
cell stem cells from 57 surgically-resected pancreas tissues. The cells were 
cultured and propagated in conditioned medium and then differentiated in 
Matrigel. The successfulness of culture of functional neoislet was determined 
by morphological and immunofl uorescent study, characteristic pancreatic islet 
gene expression, and glucose-induced C-peptide secretion.
Results: The pancreatic stem cells grew in conditioned medium and showed 
islet-like clusters when transferred to Matrigel. Immunofl uorescent labeling 
of cultured pancreatic neoislet cells was immunopositive for neural stem cell 
marker nestin, duct cell marker CK19, and endocrine cell marker such as 
C-peptide, glucagon, and Pdx1. The expressions of pancreatic islet markers 
were also confi rmed by RT-PCR. The neoislets secreted C-peptide in response 
to glucose stimulation. The neoislet cultured from soft pancreas parenchyma 
had signifi cant higher success rate.
Conclusions: We conclude that the isolated pancreatic stem cells had 
differentiated into neoislets and showed characteristics of functional endocrine 
cells. The present study describes an alternative source and improved method 
for obtaining a constant supply of large numbers of neoislets from adult human 
pancreatic tissue.
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THE IMPACT OF DONOR, PROCUREMENT, AND 1703 
ISOLATION FACTORS ON PANCREATIC ISLET PURITY, AND 
INTEGRITY
O. Sabek1, L. Peterson2, D. Fraga1, A.O. Gaber1
1Deparatment of Surgery, The Methodist Hospital, 2Public Health Research, 
The Methodist Hospital
Background: For islet transplantation to become a successful therapy 
for diabetes, it must be possible to routinely transplant a suffi cient mass of 
purifi ed viable islets isolated from one well-matched donor pancreas to one 
diabetic recipient. To defi ne donor and isolation parameters in our center, we 
retrospectively analyzed 341 pancreases and the outcome of their isolation with 
emphases on islet yield, purity and integrity. Continuous measures of isolation 
yield in units of equivalents per gm, purity, and integrity were normalized 
to range [0, 1]. Non-parametric Somers D tests were performed to quantify 
association between yield and age, Caucasian(y/n), alcohol intake(y/n), illicit 
drugs(y/n), blood type A(y/n), blood type O(y/n), Rh+(y/n), CMV+(y/n), and 
hepatitis+(y/n), height(m), weight(kg), BMI, IBW, hospital time (h), ventilator 
time (h), max(glucose), min(glucose), well perfused (y/n), cold ischemia(h), 
pre-digestion pancreatic weight(gm), pancreatic gm digest percent, collagenase 
concentration, distention volume, digestion time (min), whole/cut distention, 
and 38 binary (y/n) variables for known medications. Signifi cant univariate 
predictors were then used in maximum likelihood multivariate models to fi t a 
2-parameter beta distribution of the yield variables.
Results: Modeling results suggest that for islet equivalents per gm, the 
following variables were signifi cant predictors: log pancreas pre-digestion 
weight (g), (Z=-2.11, p=0.04), log distension volume (Z=-2.84, p=0.01), well 
perfused (Z=-2.00, p=0.05), CMV (Z=2.17, p=0.03), and anti-arrhythmia 
medication (Z=2.94, 0.00). For purity, signifi cant predictors were log ventilator 
time (Z=-1.98, p=0.05), and log digestion time (Z-2.15, p=0.03). Finally, for 
integrity, signifi cant predictors were log hospital stay time (Z=2.22, p=0.03) 
and log cold ischemia time (Z=-1.95, p=0.05).
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Conclusion: Identifying donor and isolation variables vary from one center to 
another, which can be the result of donor management and isolation technique. 
As it is important for each center to identify the effect of donor and isolation 
variables within their center, the emphasis should be placed on donor management 
and evaluating potential therapies within the context of clinical trials.
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A META-ANALYSIS OF THE IMPACT OF THE 1704 
TWO-LAYER METHOD OF PRESERVATION ON HUMAN 
PANCREATIC ISLET TRANSPLANTATION
A. Agrawal, K. Gurusamy, S. Powis, D. Gray, B. Fuller, B. Davidson
Royal Free Hospital
Background: There are confl icting reports about the effectiveness of 
perfl uorocarbons used in the two-layer method (TLM) of pancreas preservation 
for human islet transplantation. The mechanism of action is unclear and the 
optimal role of this method uncertain.
Design: a systematic review of the literature regarding mechanism of action of TLM 
and a meta-analysis of the evidence that TLM improves islet isolation outcomes.
Data Sources: Pubmed, CENTRAL, EMBASE, Science Citation Index and 
BIOSIS were searched electronically in May 2007.
Methods: After selecting the relevant human trials for meta-analysis data 
relating to donor variables, study design, primary and secondary islet isolation 
outcomes were extracted. Publications that explained the mechanism of action 
of TLM were chosen from this search for a systematic review.
Results: Electronic searches identifi ed seven unique citations, describing 
eight human studies that were eligible for the meta-analysis. When comparing 
TLM with preservation in University of Wisconsin (UW) solution, there was 
a statistically signifi cant higher islet yield (WMD 946.22, 95% CI 485.4 to 
1407.04) in the TLM group. The number of transplantable preparations obtained 
was not signifi cantly different (OR 1.56, 95% CI 0.96 to 2.54) between the two 
groups. The rate of successful islet isolations for marginal organs was higher 
in the TLM group (OR 6.69, 95% CI 1.80 to 24.87). Improved oxygenation 
and preservation of cellular bioengertics is thought to be the main underlying 
mechanism although no single mechanism has yet been confi rmed.
Conclusion: There is currently no clear evidence that the TLM is benefi cial in 
human islet transplantation. It may improve the preservation of marginal organs.
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THE INFLUENCE OF BRAIN DEATH ON TISSUE 1705 
FACTOR EXPRESSION IN THE PANCREATIC TISSUE AND 
ISOLATED ISLETS IN RATS
Y. Saito1, M. Goto1,2, K. Maya2, N. Ogawa1, K. Fujimori3, Y. Kurokawa2, 
S. Satomi1
1Division of Advanced Surgical Science And Technology, 2Tohoku University 
Biomedical Engineering Research Organization, 3Division of Surgical 
Oncology
Background: It has been revealed that tissue factor (TF) in the islets is identifi ed 
as the main trigger of the instant blood-mediated infl ammatory reaction, and 
low expression of TF in the graft is correlated with high C-peptide values after 
clinical islet transplantation. However, the crucial procedures that directly 
induce TF remain to be determined. In the present study, we therefore focused 
upon the infl uence of brain death (BD) on TF expression in the pancreatic 
tissues and isolated islets.
Methods: BD was induced in male Lewis rats weighing 250¦ `300g by 
infl ation of a Fogarty catheter placed intracranially. The rats were mechanically 
ventilated for 6h until removal of the pancreas. The expression of TF protein 
in the pancreatic tissues was examined by western blotting assay. mRNA 
expression of TF in the isolated islets was analyzed by real-time PCR assay (BD 
n=5, control n=8). The infl uence of BD on the isolation outcome was evaluated 
by the islet yield and purity (BD n=11, control n=10). Islet viability and function 
were assessed by ATP/DNA test and respiratory activity measurement using a 
scanning electrochemical microscopy system (BD n=5, control n=6).
Results: TF protein levels in the pancreatic tissues were similar between 
the groups. However, TF mRNA in the isolated islets of BD group was 
signifi cantly higher than that of control group (TF/GAPDH BD;0.169¦ }0.033, 
control;0.119¦ }0.041: p=0.04). Islet yield was considerably lower 
(BD;2110¦ }231IEQ, control;2390¦ }528IEQ: p=0.19), and purity was 
signifi cantly lower in BD group than control group (BD;87.7¦ }7.5%, control 
97.0¦ }2.6%: p=0.002). Unexpectedly, ATP/DNA ratio and respiratory 
activity were comparable between the groups (ATP/DNA BD;51.6¦ }12.8, 
control;59.1¦ }3.47: p=0.20, respiratory activity BD;2.39¦ }0.55, 
control;2.58¦ }0.19: p=0.45).
Conclusions: Although BD per se was not enough for inducing TF expression 
in the pancreatic tissues, BD combined with subsequent warm ischemia 
(isolation procedures) remarkably up-regulated TF mRNA expression in the 
isolated islets, suggesting that BD is of great importance as an initiator of TF 
induction in the islet grafts. The present study demonstrates that the expression 
of infl ammatory mediators rather than islet viability is more susceptible to BD.
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CURRENT STATUS OF ISLET TRANSPLANTATION 1706 
FROM NON-HEART BEATING DONOR IN JAPAN~ F A REPORT 
FROM JAPAN PANCREAS ISLET TRANSPLANTATION 
REGISTRY
T. Saito1, K. Ise1, M. Gotoh1, S. Satomi2, S. Uemoto3, T. Kenmochi4, T. Itoh5, 
Y. Kuroda6, Y. Yasunami7, S. Teraoka8
1Fukushima Medical University, 2Tohoku University, 3Kyoto University, 
4National Hospital Organization Chiba-East Hospital, 5Osaka University, 
6Kobe University, 7Fukuoka University, 8Tokyo Women Medical University
Objectives: The program of islet transplantation in Japan, which was 
characterized by islet isolation from non-heart-beating (NHB) donors and 
national covering system for donation, isolation, and transplantation, had been 
started in 2004. Here, we summarize three years outcome of the islet isolation 
and transplantation outcomes in Japan.
Materials and methods: Seven transplantation centers (Tohoku, Fukushima, 
Chiba, Kyoto, Osaka, Kobe, and Fukuoka) have been enrolled as a national 
team for islet isolation and transplantation. At the beginning, recipients were 
limited only for patients who had no history of kidney transplantation. From 
September 2006, we expanded the program for IAK (islet after kidney) 
recipients maintaining stable renal function with limited steroid use (below 
10mg/day). Candidates for recipients were selected according to candidate 
evaluation system conducted by three diabetologists. Selection and listing 
criteria for transplantation includes regional priority, ABO blood type, previous 
islet transplant who can be insulin-independent, and a longer waiting time. 
Isolation and purifi cation procedures of islets from pancreas are performed 
according to an individual protocol in each institute. Immunosuppression is 
based on sirolimus/tacrolimus combined with basiliximab induction. Two 
or three times consecutive infusions of >5,000 IE/kg were planned for each 
recipient until achievement of insulin independency.
Results: One hundred fi fty seven recipients are currently registrated. Sixty 
fi ve isolations and 34 transplants were performed in 18 IDDM recipients 
including 2 IAK recipients. All but one donors (64/65) were NHB. Intervals 
between each transplantation ranged from 8 to 954 days (mean 242 days). All 
recipients were free from severe hypoglycemic episodes after transplantation. 
Of 18 recipients, all cases had partial function (C-peptide >0.3 ng/ml) at 1 year 
after transplantation, but 5 cases had graft loss (C-peptide <0.3 ng/ml) 3 years 
after transplantation. Three of these recipients attained insulin-independence 
with good glycemic control at any point during follow-up period for 14, 79, 
and 215 days, however, all of these required insulin again. The other recipients 
are currently followed up with minimal dose of exogenous insulin. Mean levels 
of HbA1c before transplant and at 1 year after 1st, 2nd and 3rd transplant were 
8.8, 7.1, 6.5, and 6.3%, respectively. The renal function remains stable in 17 
recipients including 2 IAK cases, however, one recipient who had borderline renal 
function (IIIa – IIIb) became renal failure and underwent renal transplantation. 
Diabetic retinopathy remains stable in 16 recipients, but progressed in 2 
recipients. Diabetic neuropathy remains stable in 16 recipients, and improved in 
2 recipients. Nine severe immunosuppression-related events including anemia, 
diarrhea, oral ulcer and bacterial infections were treated successfully.
One procedure-related event of intra abdominal bleeding needed open 
hemostasis without transfusion.
Conclusion: Islet transplantation from NHB donors can successfully restore 
long-term endogenous insulin production and glycemic stability in non-uremic 
IDDM as well as IAK recipients. Persistent islet function provides protection 
from severe hypoglycemia and improved levels of glycated hemoglobin.
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THE MITOCHONDRIAL K-ATP CHANNEL OPENER, 1707 
DIAZOXIDE, IMPROVES ISLET ISOLATION OUTCOME IN 
MICE COLD ISCHEMIA MODEL
Y. Wang, M. Qi, S. Wang, T. Harvart, L. Rodriguez, C. Groh, E. Marchess, 
J. Oberholzer
University of Ilinois At Chicago
Introduction and hypothesis: Human islet transplantation is a promising 
treatment alternative for Type I diabetes. One of main reasons for variable 
success rate is lacking good quality islets and insuffi cient amount to reverse 
diabetes. Ischemia-reperfusion injuries and isolation stress including enzymatic 
and mechanical contribute the islet damage. Diazoxide, a mitoKATP channel 
opener, has been extensively investigated for its impact on preconditioning 
against myocardial and neuron ischemia-reperfusion injuries, but not on the 
pancreas ischemia model and islet isolation process. Therefore, the aim of the 
present study is to investigate the islet protection of this compound in rodent 
pancreas ischemia model and the impact on the islet outcomes.
Approach: (1) Mice cold ischemia (CI) model was established by vascular 
fl ush with UW solution or other agents through lower abdominal aorta and then 
organ preserved in 4 oC for 6, 10, 14 hours. (2) Groups: 150μM Diazoxde+ 
8ml UW; 8ml UW alone, and 150μM Diazoxide +8ml UW+ 100μM 5-HD (a 
specifi c mitoKATP channel blocker). (3) After cold storage, islets were isolated 
and purifi ed by standard methods. (4) Isolated islets were assessed by islet 
yield, glucose-stimulated insulin secretion(SI), calcium signal, mitochondrial 
potential changes, and confocal mitochondrial morphology.
Results: (1) in 6 hrs CI model, Diazoxide group has signifi cant higher islet 
yields compared to UW alone (237.5+/-25.6 vs.108.7+/-48.3; p<0.05), when 
added 5-HD, Diazoxide effect dramatically diminished, 117.3+/-33.1. (2) In 
10 hrs CS model, Diazoxide group islet yield still is better than UW alone 
(95.5+/-16.7 vs. 47.5+/-27.5; p<0.05), but in 14 hrs CI model, Diazoxide did 
not show its protection (54+/-2.8 vs. 49.5+/-16.2; p>0.05). (3) SI of Diazoxide 
group is 3.67+/-0.51 vs. SI of UW 2.28+/-1.67; p<0.05. Interestingly, SI of 
Diazoxide+5-HD is 5.47+/-2.29. (4) Glucose stimulated calcium infl ux and 
mitochondrial potential change is well preserved in Diazoxide group compared 
to UW group. (5) Mitochondrial morphology assessment using confocal image 
indicate that Diazoxide group has less fragmentation, swelling, and aggregation, 
and normal distribution.
Conclusion: our results show the pharmacological mitoKATP opening protects 
against ischemia damage and mimics ischemia preconditioning, probably 
through mitochondrial protection. Since plasma KATP channels of beta-cells 
have similar structure, it is expected that Diazoxide also have effect on plasma 
KATP ,but with different affi nity and may explain the 5-HD and diazoxide 
combined group preserves insulin secretion capacity but without improved islet 
yield. To our best knowledge, it is fi rst investigation of Diazoxide effect on 
the pancrease ischemia-reperfusion and islet outcomes. However underlying 
physiological and pathological signaling events are still needed to be elucidated 
and in vivo evaluation of Diazoxde-treated islets in animal model has to be 
investigated.
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ANALYSIS OF DONOR AND ISOLATION RELATED 1708 
VARIABLES ASSOCIATED WITH VIABLE BETA-CELL INDEX
H. Ichii, A. Miki, A. Mita, S. Barker, T. Yamamoto, Y. Sakuma, A. Khan, 
L. Inverardi, R. Alejandro, C. Ricordi
Diabetes Research Institute, University of Miami
Backgrounds: The results of clinical islet transplantation have greatly 
improved due to the introduction of more effi cient methods for the separation 
of islets and more effective immunosuppressive strategies. Improved islet 
isolation has been key to the evolution of this procedure. Suitable selection of 
donors and isolation methods is critical for successful human islet isolation and 
transplantation. Donor and isolation related factors for effi cient islet isolation 
have been examined and identifi ed using the analyses based on islet yields. 
These identifi ed factors have been helpful for improving the effi ciency of 
human islet isolation. However, the quality of islets, such as beta-cell content 
and viability was not taken into consideration in many analyses. We have 
recently reported that beta-cell content in islet and beta-cell fractional viability 
as well as transplanted islet mass had a good correlation with clinical islet 
transplantation outcomes. Therefore, to identify donor and isolation related 
factors for better islet quality is highly desired.
Aims: In the present study, we have analyzed donor and isolation related 
factors for effi cient islet isolation based on beta-cell content, beta-cell fractional 
viability and viable beta-cell Index.
Methods: Between 2004 and 2006, seventy-six human islet isolations processed 
for transplantation in Diabetes research institute, University of Miami, 
retrospectively analyzed. Univariate regression analyses were performed to 
identify donor and isolation related factors associated with beta-cell content, 
fractional beta-cell viability and viable beta-cell index. Beta-cell content were 
assessed by using LSC /iCys and beta-cell fractional viability was assessed by 
FACS within 24hors after isolation. Viable beta-cell index were calculated by 
the following formula (beta-cell content x beta-cell fractional viability x islet 
yields).
Results: Beta-cell content was signifi cantly associated with donor height 
(r2 =0.228; p=0.047), digestion time (r2 =0.279; p=0.015), Fatty pancreas 
(p=0.038) and female donor (p=0.007). Fractional beta-cell viability was 
signifi cantly associated with cold ischemia time (r2 =0.287; p=0.012), total 
collection volume of media (r2 =0.316; p=0.006) and fi rm pancreas (p=0.023). 
Viable beta-cell index was associated with cold ischemia time (r2 =0.240; 
p=0.037) and total collection volume of media (r2 =0.316; p=0.006). Two-layer 
method did not show any associations with beta-cell content, fractional beta-
cell viability or viable beta-cell index.
Conclusions: These data indicate that beta-cell content and viability are 
affected by independent donor and isolation related factors, which are diffi cult 
to identify by the analysis based on only islet yield. A sequential integrated 
approach to assess potency of islet cell products could be of assistance in 
improving islet transplant outcomes.
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31PHOSPHORUS MAGNETIC RESONANCE 1709 
SPECTROSCOPY TO ASSESS MITOCHONDRIAL FUNCTION 
IN RAT PANCREAS PRESERVED BY TWO-LAYER METHOD
A. Agrawal1, A. Bainbridge, B. Fuller, B. Davidson
1Royal Free Hospital, 2University College Hospital, 3Royal Free Hospital, 
4Royal Free Hospital
Introduction: Several centres have reported improved islet isolation outcomes 
with this preservation technique. Reports of success with single donor islet 
transplants and marginal donors have also been attributed, either partially or 
wholly, to the employment of the two-layer method. However, despite two 
decades of experimental and clinical application the precise mechanism of the 
two-layer method remains a mystery.
Methods: 38 Male Sprague-Dawley rats underwent pancreas procurement (with 
associated spleen and duodenum, which was securely ligated at both ends). The 
pancreas thus retrieved was maintained in either cold Marshalls solution (M) 
or at the interface of perfl uorodecalin and Marshalls solution that had been 
pre-saturated with oxygen (two layer method – TLM). Pancreases maintained 
in TLM were assigned to one of two groups: TLMs – no further oxygen was 
bubbled through the solution; TLMc – oxygen was bubbled (0.5 litre/hour) 
through the solution for 20min at intervals of 1 hour. The preservation solution 
was randomly assigned immediately following extraction. The solutions were 
kept between 4°C and 6°C during the entire experiment. Phosphorus (31P) 
magnetic resonance spectroscopy (MRS) was performed continuously during 
the period of 1 hour to 3 hours following extraction (TR = 10s; Averages = 
256). To improve signal to noise, pancreases were scanned 2 at a time. Thus 
group numbers for the experiments were: M = 6; TLMs = 6; TLMc = 7. Spectra 
were fi tted using AMARES as implemented in the jMRUI software package. 
The following metabolite ratios were calculated and plotted against time from 
extraction: Inorganic phosphate (Pi) / g - nucleotide triphosphate (g-NTP), Pi / 
b-NTP. To facilitate comparisons between groups, these data were interplotted 
linearly and the area under each curve for each experiment was calculated 
between 1 hour and 2.75 hours following extraction. Grouped data was then 
compared using ANOVA with t-tests used for pairwise comparisons.
Results: There was no difference between the groups in the mean value of 
Pi/g-NTP and Pi/b-NTP measured between 0.5 and 1 hours from procurement 
(ANOVA; p > 0.3 and p>0.2 respectively). The data for the area under the 
Pi/g-NTP and Pi/b-NTP curves between 1hr and 2.75 hours from extraction are 
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shown in the table. The grouped mean areas for both Pi/g-NTP and Pi/b-NTP 
curves were signifi cantly different between the groups (ANOVA; p < 0.001 
and p< 0.002 respectively). The marshals group was signifi cantly different to 
the TLM groups for both Pi/g-NTP and Pi/b-NTP (see table). No signifi cant 
differences were seen between the TLM groups.
Conclusions: There was no difference between the groups for Pi/g-NTP and 
Pi/b-NTP at the start of the experiment. A larger area under the Pi/g-NTP and 
Pi/b-NTP vs time curves indicates increasing Pi/g-NTP and Pi/b-NTP over 
the course of the experiment. The data indicate that both Pi/g-NTP and Pi/b-
NTP increased in the Marshalls group during the fi rst three hours following 
procurement, presumably due to decreased NTP and consequently increased 
Pi. In contrast, Pi/g-NTP and Pi/b-NTP levels were maintained using TLM in 
both TLMs and TLMc which did not differ.
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SUITO-INDEX FOR ASSESSMENT OF ENGRAFTED 1710 
ISLET MASS IN CLINICAL ISLET TRANSPLANTATION
S. Matsumoto1,2, H. Noguchi2, B. Naziruddin3, A. Jackson4, M. Shimoda3, 
T. Ikemoto2, N. Onaca1,3, M. Levy1,3
1Baylor All Saints Islet Laboratory, 2Baylor Research Institute, 3Baylor 
University Medical Center, 4Institute of BIomedical Studies, Baylor University
Introduction: Assessment of engrafted islet mass is important for evaluation 
of clinical islet outcome. Previously we have shown that fasting C-peptide 
and blood glucose were correlated after islet transplantation and the angle of 
fi tting line of such correlation refl ected engrafted islet mass (1). We developed 
a simple formula; Fasting C-peptide [ng/dl] divided by fasting blood glucose 
(mg/dl) minus 63 multiplied by 1500 to get engrafted functional islet mass. 
This formula was designed for normal non-diabetic person resulting in 100. 
SUITO index = C-peptide/(Blood glucose – 63)x1500. The purpose of this 
study is to evaluate the relationship between mean SUITO index and insulin 
independence after islet transplantation using brain-dead organ donors.
Method: Six pancreata were procured for this study between November 2005 
and January 2008. All pancreata were preserved by the two-layer method. 
Five islet isolations were performed at Baylor research institute and one islet 
isolation was performed at remote center. All islet isolations were performed 
based on the Ricordi method. Six islet preparations were transplanted into 3 
type 1 diabetic patients at Baylor University Medical Center. Each patient 
received two islet transplantations. Medications including immunosuppression 
were based on the Edmonton protocol. SUITO index was calculated using data 
between POD 3 and 30. Insulin requirements after islet transplantation were 
compared with pre-transplantation levels and categorized more than half, less 
than half and insulin free.
Results: Among the three patients, the SUITO index and insulin requirement 
after the fi st islet transplantation were 7.9 ± 1.3; more than half, 16.9 ± 4.4; 
less than half and 24.6 ± 8.9; less than half respectively. All of SUITO indices 
were less than 26 and none of the patients achieved insulin independence. 
All three patients received second islet transplantation. After the second islet 
transplantation the mean SUITO index in each patient was 52.1 ± 8.5, 43.2 ± 
3.0, and 52.6 ± 7.3. All the three patients achieved insulin independence.
Conclusion: The mean SUITO index of greater than 26 between POD 3 and 30 
could predict insulin independence after islet transplantation using brain dead 
organ donors. SUITO index is useful in the estimation of islet engraftment and 
a tool for consideration of additional islet transplantation.
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THE EFFECT OF ANESTHETIC ADMINISTRATION 1711 
ROUTES ON FUNCTION OF RAT ISLET ISOLATION
J.Y. Kim1, J-I. Lee1, J.H. Jeong1,2, Y. Fang1,2, Y.S. Kim1,2
1The Research Institute for Transplantation, 2BK21 Team of Nanobiomaterials 
for Cell-Based Implants, Yonsei University College of Medicine, Seoul, Korea
Introduction: Intraperitoneal (IP) administration of anesthesia is most 
commonly used for rodent islet isolation. When inhaled volatile agent is 
used in rodents, many problems such as high cost and technical diffi culty of 
keeping airway are still present. Although diethyl ether is preferred because 
of simplicity and low cost, but it has explosive nature and potentially irritates 
both animal and researchers. In this study, we explored the possibility of using 
intramusclar (IM) anesthesia for rodent islet isolation procedure.
Method: Lewis (male, 250~350g) was anesthetized using the combination of 
ketmaine (75mg/kg)+xylazine (K/X, 5:2) or zoletil (30mg/kg)+xylazine (Z/X 
3:2). These drugs were injected through IM or IP route. To shot IM drugs, we 
have invented a specially designed restrainer. Lag time required to lose deep 
pain by negative pedal withdrawal responses (supposed as deep anesthesia) 
were measured in order to compare between K/X and Z/X. Islets of each 
group were isolated and function was examined within 30 minutes. Glucose 
challenging test (100mg/dl, 400mg/dl, 100mg/dl, 1 hour each) was performed 
with each group of prepared islets. Additionally, to compare the effect of 
anesthetics on primary islet and RIN-5F cell line, we investigated the viability 
of RIN-5F by MTT assay of the each combination and the amounts of insulin 
from RIN-5F with ELISA.
Result: Compared to IP route, lag time to deep anesthesia was signifi cantly 
reduced [K/X (IM: 313±66 sec versus IP: 371±84 sec): Z/X (IM: 206±76 
sec, IP: 245±92 sec)] with IM route. Yield of isolated islets by IM route was 
signifi cantly improved [K/X (IM: 1530±242 ea, IP: 1245±149 ea) and Z/X 
(IM: 1136±226 ea, IP: 511±154 ea)]. Function of fresh islet with IM route 
was better kept than of IP, which was expressed by stimulation index. The 
viability and the insulin secretion of RIN-5F treated with anesthetic agents (eg. 
ketamine, zoletil, xylazine alone and combination of K/X and Z/X) showed 
time-dependent decrease.
Conclusion: For rodent islet isolation experiments, IM route for anesthesia is 
simple and better way compared to IP route in the aspect of time and islet yield.
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HYPEREMIC ISLETS, A POSSIBLE EXPLANATION FOR 1712 
POOR YIELDS IN HUMAN AND PORCINE ISLET ISOLATION
D.E. Hilling, E. Bouwman, J.K.R.A. Rijkelijkhuizen, H.A.M. Töns, 
O.T. Terpstra, 
Department of Surgery, Leiden University Medical Center, Leiden, The 
Netherlands
Background: Transplantation of islets of Langerhans can restore insulin 
production in patients with type 1 diabetes. Although procedures have been 
improved, islet isolation is still associated with considerable loss of endocrine 
tissue and unpredictable, highly variable islet yields in both humans and pigs. 
When studying histological characteristics of human and porcine pancreases in 
relation to islet isolation, a remarkable high number of hyperemic islets (HI’s) 
was encountered, a phenomenon that has not been described in detail before. 
HI’s are characterized by dilatation of different magnitudes of islet blood vessels 
and are sometimes associated with hemorrhages extending in the surrounding 
exocrine tissue. The aim of the present study was to determine the frequency 
of HI’s in pigs and humans, the occurrence of HI’s in relation to the amount of 
endocrine tissue and the possible relevance for islet isolation outcome.
Methods: 150 porcine pancreases were harvested in different slaughterhouses. 
The population consisted of a juvenile group (6-12 months) of 69 animals 
and an adult group (>12 months) of 81 animals. Islet isolation was performed 
in 50 animals of the adult group. Human pancreases were obtained from 86 
multi-organ donors. Donor ages ranged from 16-69 years. Islet isolation was 
performed in 28 cases.
Tissue samples were stained using the Aldehyde Fuchsine-Halmi technique. 
For determination of the endocrine content, all islets (except the HI’s) in a 
tissue area of 1 cm2 were assessed. The endocrine area density was determined 
by summation of all calculated (πr2) islet areas and expressed as percentage of 
the total area. The presence of HI’s was scored semi-quantitatively. Pancreases 
were allotted to categories based on the presence and severity of the HI’s 
found.
Results: In humans we found HI’s in 48% of the pancreases. In the affected 
pancreases an average (±SD) of 4.0±2.4% (range 1.3-9.5) of the assessed islets 
was hyperemic. In pigs, HI’s were found more frequently in juvenile than in 
adult pigs (in 64% versus 31% of the pancreases, p<0.001). In both humans 
and pigs, a signifi cant increase (p<0.001) in endocrine content was found in 
the most severely affected pancreases. The higher endocrine content could be 
a consequence of islet expansion, possibly by vasodilatation, edema or both. 
When this higher endocrine content was taken into account and isolation results 
were expressed as ratio of yield and content, we found a trend towards lower 
yields in the most-affected pancreases in both humans and pigs.
Conclusions: In humans and pigs a substantial amount of the pancreases contain 
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HI’s, a phenomenon that has not been described before. In veterinary literature it is 
widely recognized that electric stunning induces a rise of blood pressure resulting 
in hemorrhages of different extent, which most likely explains the fi nding of HI’s. 
The fact that only a small fraction of the islets is visually abnormal, suggests that 
HI’s are only an indicator of the detrimental effects of blood pressure rise. Although 
the results in humans are preliminary, our data suggest that this could explain the 
generally experienced diffi culties in obtaining islets from either humans or pigs.
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ISCHEMIC PRECONDITIONING IMPROVES ISLET 1713 
RECOVERY AFTER PANCREAS COLD PRESERVATION
A.R. Hogan1, A. Pileggi1, M. Doni1,2, M.M. Ribeiro1, R.D. Molano1, L. 
Cobianchi1,2, J. Molina1, E. Zahr1, C. Ricordi1, R.L. Pastori1
1University of Miami Miller School of Medicine – Diabetes Research 
Institute, 2Department of Surgery, Fondazione IRCCS “San Matteo” Hospital 
University of Pavia, Italy
Increasing evidence supports the benefi cial effects of ischemic preconditioning 
(IPC) of organs on subsequent ischemia. IPC may result in the activation of 
cytoprotective ‘survival’ pathways resulting in improved organ preservation.
The aim of this study was to assess the effects of IPC of the pancreas on islet 
cell recovery after cold preservation.
Using a rat model to test the effects of IPC, the pancreas was deprived of 
perfusion (celiac artery and superior mesenteric artery occlusion) for 10 
minutes followed by a reperfusion period of 10 minutes, prior to 18 hours of 
cold preservation. Islet isolation was performed after cold ischemia.
Glands undergoing IPC yielded signifi cantly higher numbers of islets than 
controls (890±270 IEQ vs. 662±152 IEQ, respectively; p=0.012). Islet cell 
loss after overnight culture was used as a surrogate indicator of islet quality: 
a signifi cantly greater proportion of islets were recovered from IPC-treated 
pancreata, when compared to controls (48±12% vs. 33±10%, respectively; 
p=0.00045). In vivo functional status, assessed by reversal of diabetes in mice 
after islet transplantation, demonstrated comparable function between IPC and 
control groups. Preliminary microarray genomic analysis of pancreatic tissue 
revealed a signifi cant differential expression of 602 unique mRNA strands 
within IPC pancreata compared to only 95 unique mRNA strands within 
non-IPC pancreata (fold change >2; p<0.05). Proteomic analysis revealed a 
signifi cant differential expression for at least 5 proteins (fold change >1.5; 
p<0.05), within the IPC group versus controls.
One of the limitations of clinical islet transplantation is the inability to obtain 
a suffi cient number of islets from one donor pancreas to reverse diabetes in a 
recipient. Our data indicates that IPC of the pancreas prior to cold preservation 
is associated with improved islet cell recovery after cold ischemia. The use of 
IPC of the pancreas may represent a viable therapeutic intervention to increase 
success of islet transplantation from a single donor. A better understanding 
of the underlying mechanisms of IPC-mediated cytoprotection in this model 
may be of assistance in developing targeted interventions to maximize organ 
utilization for transplantation.
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EFFECTS OF PANCREAS COLD ISCHEMIA ON ISLET 1714 
FUNCTION AND QUALITY
A. Pileggi1, M.M. Ribeiro1, A.R.. Hogan1, R.D. Molano1, J. Embury2, 
H. Ichii1, L. Cobianchi1,3, A. Fornoni1, C. Ricordi1, R.L. Pastori1
1University of Miami Miller School of Medicine - Diabetes Research Institute, 
2Department of Pathology, University of Florida College of Medicine, 
Gainesville, FL, USA, 3Department of Surgery, Fondazione IRCCS “San 
Matteo” Hospital University of Pavia, Italy
The success of islet transplantation depends upon the quality and number of 
islets transplanted. Several variables contribute to the reduction of islet mass 
and quality that can be obtained from a donor pancreas.
We used a rat model of pancreas cold preservation to assess its effects on islets. 
Glands were surgically retrieved in UW and stored for 3hrs (Short) or 18hrs 
(Long) cold ischemia time (CIT).
Islet yield was signifi cantly lower in Long-CIT (868.3¡Ó235.8 IEQ/rat; n=14) 
than Short-CIT group (1,560.8¡Ó528.4 IEQ/rat; n=12; p=0.00004), as well 
as islet recovery after overnight culture 55¡Ó20% (n=12) vs. 82¡Ó13% (n=7; 
p=0.005). Islet cell viability after isolation was signifi cantly reduced in the 
Long-CIT group (p<0.04). Reversal of diabetes following transplantation of 
suboptimal islet grafts occurred earlier in the Short-CIT group than Long-
CIT (10.2¡Ó8.6 vs. 22.4¡Ó6.0 days; n=5/group). All animals in Short-CIT 
and 80% (4/5) in the Long-CIT group achieved euglycemia. Freshly isolated 
islets showed a signifi cant increase of JNK (2.45¡Ó0.99 vs. 1.0¡Ó0.4; p=0.016) 
and p38 (1.92¡Ó0.63 vs. 1.0¡Ó0.61; p=0.047) phosphorylation in Long-
CIT compared to Short-CIT, respectively. Histopathological assessment of 
the pancreas showed signifi cantly higher injury score overall (2.4¡Ó0.9 vs. 
1.7¡Ó1.3; p=0.004) and particularly acinar (2.4¡Ó0.9 vs. 1.6¡Ó0.3; p=0.004). 
Proteomic analysis of pancreatic tissue led to identifi cation of 5 proteins 
consistently differentially expressed (cut-off range „d1.5) between Short and 
Long-CIT.
Cold ischemia of the pancreas signifi cantly affects both islet cell yield and 
potency (viability and function) paralleled by increased phosphorylation of 
stress kinases. Better understanding of the molecular pathways involved in this 
phenomenon will be of assistance in defi ning targeted interventions to improve 
organ utilization in the clinical arena.
ENZYME AND CONCURRENT ORAL SESSION 123: 
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COLLAGENASE PENETRATES HUMAN PANCREATIC 1715 
ISLETS FOLLOWING STANDARD INTRADUCTAL 
ADMINISTRATION
P. Johnson1, S. Hughes1, C. Partridge2, D. Gray1, S. Cross1
1Islet Transplant Research Group, Nuffi eld Department of Surgery, University 
of Oxford, Oxford, UK, 2Oxford Centre for Diabetes, Endocrinology and 
Metabolism, University of Oxford, Oxford, UK
Background: To optimise human islet isolation, it is important to improve 
our understanding of the collagenase digestion phase. Considerable research 
has been undertaken to improve the reproducibility, purity and stability of 
collagenase. However, even with an optimal collagenase blend, the technique 
used for administrating collagenase into the pancreas needs to enable delivery 
of collagenase to the islet-exocrine interface without it entering the islets. The 
aim of this study was to characterise collagenase distribution in relation to 
islets in infused human pancreases.
Methods: Human pancreases were retrieved from multi-organ donors (age 
range 19-61 years) with appropriate consent and ethical approval. Tissue 
samples were taken from the pancreatic neck, body and tail regions before and 
after collagenase infusion by manual syringe-loading (n=10) or recirculating 
perfusion (n=8), and snap frozen in liquid nitrogen. Frozen sections (8mm 
thick) were immunolabelled for collagenase, insulin, CK19, collagen VI and 
CD31. Intra- and peri-islet collagenase was assessed by confocal microscopy in 
double- or triple-labelled sections, with 47±5 islets assessed per section.
Results: Collagenase labelling was widespread throughout the pancreas, 
associated with collagen VI and adjacent to CK19-labelled ducts. Collagenase 
was found within 67±2% of islets (“intra-islet”), associated with capillaries 
(CD31-positive). Intra-islet collagenase labelling was observed in 70±3% of 
islets in the pancreatic tail, compared to 58±2% and 53±2% of islets in the 
body and neck, respectively (p<0.05 tail vs neck), and was more prevalent in 
islets with diameters >150μm (98±1% of islets >150μm vs. 52±2% of islets 
<150μm, p<0.05). There was no difference in intra-islet collagenase labelling 
between perfused and syringe-loaded pancreases (65±3% vs 69±3%, ns).
Conclusions: This study shows that collagenase penetrates the islet interior 
during infusion procedures currently used routinely in most human islet 
isolation facilities. This fi nding has potentially important clinical implications. 
First, intra-islet collagenase may result in islet fragmentation either by 
enzymatic digestion of the internal structural framework of the islet or simply 
as a result of the pressure effects of fl uid entering between the islet cells. Islet 
fragmentation in turn can lead to low islet yields and islet dysfunction. Second, 
the transplantation of islets that contain bacterial collagenase within their 
cells has potential long-term safety implications. This study emphasises the 
importance of further research to determine optimal methods of collagenase 
delivery that enable optimal pancreas digestion, in order to liberate intact islets 
that do not contain collagenase.
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PERI-INSULAR COLLAGEN V AND VI WITHIN 1716 
PANCREASES OF YOUNG HUMAN DONORS ARE NOT 
RESISTANT TO COLLAGENASE DIGESTION
P. Johnson1, S. Cross1, D. Gray1, A. Clark2, S. Hughes1
1Nuffi eld Dept Surgery, University of Oxford, 2Oxford Centre for Diabetes, 
Endocrinology & Metabolism, University of Oxford
Background: Effi cient islet isolation is dependent on specifi c digestion with 
collagenase of the extra-cellular matrix (ECM) within the islet-exocrine 
interface of the human pancreas. Islets yields from young donors (<30 years) are 
usually insuffi cient for transplantation, although these islets would potentially 
provide better physiological function than those from older donors. The reason 
for the poor yields is unknown. In this study, we used a novel assay to compare 
collagenase digestion of two principle components of the ECM of the islet-
exocrine interface in young and old donors.
Methods: With appropriate consent and ethical approval, human pancreata 
were retrieved from 5 young donors (aged 19-28 years) and 6 old donors (aged 
45-60 years). Cold ischaemia time was <10 hours. Tissue blocks (~0.5 cm3) 
were snap-frozen in liquid N2. Specimens were cryo-sectioned onto slides 
at 10-15-ƒÝM thickness and stored at -25oC. Specimens were thawed and 
incubated ¡ÓLiberase at 1.4mg/mL in HBSS for 5 min. at 37oC. Digestion of 
the ECM within the islet-exocrine interface was analysed by double immuno-
labelling for insulin and Collagen V or VI and semi-quantifi ed by morphometry 
using image analysis (Zeiss KS-400). A mean number of 13¡Ó1 and 15¡Ó1 
islets were assessed in control or Liberase-treated sections respectively. Data 
were expressed as area of collagen sub-type/ islet area. Statistical analysis was 
by Mann-Whitney U-test.
Results: After 5 minutes incubation, Liberase had begun to digest the exocrine 
tissue although islets within the specimen were unaffected. The mean islet area 
was unchanged in specimens from young (14572¡Ó2400 vs 12698¡Ó1604 ƒÝm2 
in untreated) and old (11881¡Ó1095 vs 12541¡Ó806 ƒÝm2 in untreated) donors. 
In contrast ECM components were undergoing digestion. Peri-islet Collagen 
V content in young and old donors was signifi cantly reduced by 34% (from 
0.210¡Ó0.022 to0.138¡Ó0.014 /islet area) and by 35% (from 0.235¡Ó0.024 to 
0.153¡Ó0.007/islet area) respectively by Liberase treatment. Similarly peri-islet 
Collagen VI content in young and old donors was signifi cantly reduced by 29% 
(from 0.298¡Ó0.017 to 0.213¡Ó0.022/islet area) and by 34% (from 0.322¡Ó0.015 
to 0.212¡Ó0.011/islet area) respectively. Collagen VI remained signifi cantly 
higher (p<0.05) than Collagen V in specimens from both young and old donors.
Conclusions: Collagenase digestion of peri-insular Collagen V and VI 
within the pancreas of young donors is not impaired. These data suggest that 
inadequate digestion of these components of the peri-insular ECM is not the 
reason for poor islet yields from young donors. We are currently investigating 
the digestion of other components of the ECM in young donors.
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HIGHLY TOXIC ENVIRONMENT TO ISOLATED ISLETS 1717 
DURING COLLAGENASE OVERDIGESTION
M. Tsukada1, M. Gotoh1, T. Saito1, K. Ise1, A. Kenjo1, T. Kimura1, Y. Satoh1, 
T. Anazawa1, S. Suzuki2
1Surgery, Fukushima Medical University, 2Research and development division, 
Kikkoman Co. LTD
Objectives: Recovery of the entire quantity of islets contained in a pancreas 
is a goal of islet isolation for transplantation. In rodent models collagenase 
digestion can be optimized at the time point to obtain peak yield, while in human 
cases, timing of dilution is determined empirically by expertise of experienced 
persons. However, once the timing is delayed, poor result is inevitable. Various 
factors could affect quantity and quality of islets during digestion phase. In this 
study, we unclose the component which injures the isolated islets during over 
digestion and propose a new model for a study of optimal islet isolation.
Materials and methods: Wistar rat islets were isolated by stationary 
collagenase digestion in which digestion time was varied from 15, 30, 60, 
and 120 min. Measurement of adenosine nucleotides (ANs) and histological 
studies including HE and TUNEL staining of digested pancreas was performed 
for digested pancreas and isolated islets. In the next series of experiments in 
order to assess the toxic environment around the islets during digestion, freshly 
isolated islets (40 islets) were co-cultured for 30 min with the pancreatic 
digested fl uid (supernatants obtained from collagenase digestion at different 
digestion periods). Morphology and ANs of the islets were also examined.
Results: Peak yields of islets were 1316¦ }245 IEQ (n=8), obtained at 30 min 
of digestion. Yields at shorter and longer digestion periods were signifi cantly 
lower than this, and the one at 120 min of digestion was less than 10% of 
the peak yield. Histological study of digested pancreas showed that islets 
were broken into pieces at 120 min of digestion with TUNEL being positive 
at 60 and 120 min of digestion. ATP levels of 150mg of pancreatic tissue 
signifi cantly decreased at 60 and 120 min of digestion compared with the ones 
of fresh pancreas (fresh, 60 min, 120 min; 22.1+/- 4.1, 10.6 +/-1.0, 1.8 +/- 0.4, 
p<0.01).) As for the co-culture experiment, ATP levels of the islets decreased 
with co-culture with collagenase as compared with Hanks alone (Hanks, 
collagenase; 0.32 +/- 0.05, 0.24 +/-0.04, p<0.05). Furthermore, ATP levels of 
the islets after co-culture with pancreatic digested fl uid decreased markedly 
in proportion to digestion time (15, 30, 60, and 120 min; 0.17 +/-0.03, 0.13 
+/-0.02, 0.07+/-0.02, 0.03 +/- 0.02, p<0.01). Islets co-cultured with collagenase 
and pancreatic digested fl uid cracked at 60 minutes and didn’t hold circular 
shape at 120 minutes.
Conclusion: Morphological deterioration of islets as well as marked ATP 
decrease of the tissues were evident not only in whole digested pancreas, but 
also in separated islets co-cultured with pancreatic digested fl uid. Various 
factors toxic to the islets can be analyzed in the future experiments using this 
co-culture experimental model for obtaining a large scale of viable islets.
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COMPARISON OF GMP SERVA COLLAGENASE AND 1718 
LIBERASE IN CLINICAL HUMAN ISLET ISOLATONS – 
A VANCOUVER EXPERIENCE
Z. Ao1, M. Meloche, P. Ao, L. Dai, Z. He, D. Ou, D. Thompson2, G. Warnock
1Department of Surgery, University of British Columbia, Canada, 
2Department of Medicine, University of British Columbia, Canada
Collagenase is a determinant component in a successful human islet isolation 
process for clinical transplant. Recently, due to safety issues, most of clinical 
islet isolation centers have started to use Good Manufacturing Practice (GMP) 
grade enzymes, such as the GMP Serva collagenase. Many centers have been 
assessing the effi cacy of GMP Serva collagenase for human islet isolation, 
however the results are inconsistent. In this study we assess the effi cacy of 
GMP Serva collagenase for human islet isolations in comparison with our 
historic results with Liberase HI.
Materials and methods: Among 83 human islet isolations, 11 were processed 
with GMP Serva collagenase and Neutral Protease (Nordmark Arzneimlttel 
GmbH $ Co. KG, Uetersen, Germany), and 72 with Liberase HI (Roche 
Diagnostics GmbH, Mannheim, Germany). The donor age 40±16 vs 45±14 
yrs), body weight (81±8 vs 81±18 kg), pancreas weight (78±12 vs 83±20 g) 
and organ cold storage time (211±50 vs 213±90 min) in both groups are very 
similar without statistical difference. The islet isolation protocol was used as 
previously described: briefl y, continuous intraductal collagenase perfusion 
of the pancreas, gentle tissue dissociation using a Ricordi chamber, and islet 
purifi cation with continuous Ficoll density gradients using a 2991 COBE. After 
primary purifi cation, all left over impure tissue were collected for 22&#730;C 
culture over night, and re-purifi ed for more islet yields. The average islet size 
is estimated by counting all islets in a representative sample and calculated 
the size index as “total counted islet equivalents (IE) / total counted number 
of islets”. Islet viability was assessed by Syto-green staining and islet function 
assessed by glucose perifusion test.
Results: The islet yields in Serva group was 503459±271520 IE with a purity 
of 81±5%, which compared favorably with the Liberase group with a yield of 
490602±227753 IE and 83±20% of purity (P=ns). Islet size index (IE/islet) 
in Serva and Liberase group was 2.2±0.8 and 2.4±0.8 respectively (P=ns). 
Islets in both group revealed similar viability with Syto-green staining (93±4% 
vs 96±4%) and insulin secretion function by glucose perifusion. 8 of the11 
(72.7%) islet isolations using Serva collagenase met release criteria and were 
used for clinical transplant, while 52 of 72 (72.2%) of isolations in Liberase 
group were used for transplant.
Conclusions: Our initial assessment of GMP Serva collagenase has 
demonstrated it has comparable effi ciency to Liberase HI in human islet 
isolations for clinical transplant.
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THE PURIFICATION METHOD USING IODIXANOL 1719 
(OPTIPREP)-BASED DENSITY GRADIENT SIGNIFICANTLY 
REDUCE CYTOKINE/CHEMOKINE PRODUCTION FROM 
HUMAN ISLET PREPARATIONS, LEADING TO PROLONG ~ À-
CELL SURVIVAL DURING CULTURE
A. Mita1,4, C. Ricordi1,2,3, A. Miki1, S. Barker1, A. Khan1, A. Alvarez1, 
Y. Hashikura5, S. Miyagawa4, H. Ichii1,2,3
1Diabetes Research Institute, University of Miami Leonard M. Miller 
School of Medicine, 2DeWitt Family Department of Surgery, University of 
Miami Leonard M. Miller School of Medicine, 3Jackson Memorial Hospital 
Transplant Institute, University of Miami Leonard M. Miller School of 
Medicine, 4Division of Transplantation, Department of Surgery, Shinshu 
University School of Medicine, 5Transplantation Center, Shinshu University 
School of Medicine
Background: Although Ficoll-based density gradient has been widely used 
for human islet purifi cation in most islet processing centers, OptiPrep-based 
density gradient was recently used in the limited centers. It has been reported 
that Islet preparations purifi ed using OptiPrep-based density gradient provided 
better clinical outcomes. It is well known that cytokine/chemokine production 
from islet preparations widely varies. Reducing cytokine/chemokine production 
from islet preparations may be a key to improve islet transplantation outcomes. 
The aim of current study is to investigate the variability of pro-infl ammatory 
cytokine/chemokine production from human islet preparations purifi ed using 
different density gradients.
Methods: Human islet isolations were performed using automated method. 
After digestion phase, pre-purifi cation digests were divided into two groups and 
purifi ed using semi-automated cell processor with Ficoll-based or OptiPrep-
based density gradient. Human Islet preparations were cultured for 2 days, and 
assessed regarding glucose stimulated insulin release, islet cell viability (FDA/
PI), fractional ƒÀ-cell viability and ƒÀ-cell content. Cytokine/chemokine 
production from islet preparations was also examined.
Results: Between Ficoll-based and OptiPrep-based density gradient groups, 
islet purity (90.0 ¦ } 4.1% and 91.3 ¦ } 3.2%, respectively, p=0.718), post-
purifi cation IEQ (128,504.0 ¦ } 28,893.4 IEQ and 140,881.0 ¦ } 16,644.0 
IEQ, respectively, p=0.726) and islet recovery rate (46.4 ¦ } 4.2% and 69.7 ¦ } 
22.8%, respectively, p=0.390) were comparable. Although stimulated insulin 
release (stimulation index 0.5 ¦ } 0.2 and 0.8 ¦ } 0.3, respectively, p=0.123), 
FDA/PI (92.4 ¦ } 2.5% and 90.6 ¦ } 3.6%, respectively, p=0.550) and fractional 
ƒÀ-cell viability showed no signifi cant differences (88.2 ¦ } 7.7% relative to 
OptiPrep-based density gradient group, p=0.178), ƒÀ-cell survival during 
culture signifi cantly improved in OptiPrep-based density gradient group when 
compared to Ficoll-based density gradient group (130.6 ¦ } 1.8% relative, 
p<0.05). TNF-ƒ¿, IL-1ƒÀ, IFN-ƒÁ, IL-6 and MIP-1ƒÀ production from 
OptiPrep-based density gradient group signifi cantly decreased when compared 
to Ficoll-based density gradient group (22.8 ¦ } 11.8% relative, p=0.003, 27.7 
¦ } 14.0% relative, p=0.002, 37.3 ¦ } 11.2% relative, p=0.001, 45.3 ¦ } 16.2% 
relative, p=0.015, and 38.5 ¦ } 18.6% relative, p=0.016, respectively).
Conclusions: The purifi cation method using OptiPrep-based density gradient 
can signifi cantly reduce cytokine/chemokine production from islet preparations 
when compared to Ficoll-based density gradient, leading to the improvement of 
quantity of ƒÀ-cell mass. Our results suggest that the purifi cation method using 
OptiPrep-based density gradient may be of assistance in improving clinical 
outcomes, and that Cytokine/chemokine profi ling from islet preparations could 
be helpful to develop better isolation methods.
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STRONG INTER-INDIVIDUAL VARIATION OF 1720 
STRUCTURAL ELEMENTS IN THE HUMAN PANCREAS 
MIGHT BE RELEVANT TO ISLET ISOLATION
H.A.M. Töns, D.E. Hilling, O.T. Terpstra, E. Bouwman
Department of Surgery, Leiden University Center, Leiden, The Netherlands
Objectives: The outcome of the isolation of the islets of Langerhans from the 
pancreas is diffi cult to predict. Even in experienced centers, isolations often 
do not lead to transplantation due to disappointing yields. The causes of these 
differences in isolation outcome are not clear. The existence and the role of 
inter-individual differences in pancreatic anatomy are largely unknown. The 
present study examined the heterogeneity of the structural elements of the donor 
pancreata relevant to islet isolation. The amount of endocrine tissue, intra-
parenchymal fat and edema were determined. Total collagen was quantifi ed 
and the degree of encapsulation of the islets with collagen and the thickness 
of the capsule were semi-quantitatively assessed. The relation between several 
parameters was examined.
Material and methods: Tissue from 100 normal pancreata was used for 
histochemical and immunochemical analyses. Aldehyde Fuchsine staining 
was performed to evaluate the amount of endocrine tissue. One cm2 tissue was 
investigated to assess the total endocrine content and the size distribution of 
the islets. The percentage intra-parenchymal fat and pancreatic edema were 
determined by the point counting method. Collagen was stained with Sirius 
Red and quantifi ed with image analysis (KS400). A double staining of Sirius 
Red with anti-insulin was done to measure the degree of islet encapsulation 
with collagen.
Results: All factors examined showed a strong inter-individual variation. 
The total endocrine tissue varied fi vefold from 0.25 to 1.25% (mean 0.77 ± 
0.28 (SD)) with great differences in size distribution. When expressed as ratio 
‘small’ versus ‘large’ islets (50-100 and > 100 μm respectively) a range from 
0.96 to 4.9 (mean 2.25) was found. The intra-parenchymal fat varied from 0 
to 8% (mean 1.34 ± 2.1) and for pancreatic edema a variation of 2.3 to 49.6% 
(mean 18.45 ± 15.25) was found.
The total collagen content varied from 1.9 to 26.3% (mean 10.0 ± 5.2) and a 
slight but not signifi cant increase of total collagen with age was seen. There 
was a wide variety in the degree of encapsulation and thickness of the collagen 
capsule. Islets completely encapsulated varied from 0-98% (mean 57 ± 27.4) 
per pancreas and the islets with a collagen capsule less than 25% of there 
circumference varied from 0-95% (mean 19.5 ± 22.4) per pancreas. There 
was no relation between age and the presence of totally encapsulated islets 
(p=0.09) and between total collagen in the tissue and the presence of islets with 
a collagen capsule (p=0.48).
Conclusions: The strong inter-individual variation observed for all factors 
analyzed, strongly suggests their contribution to the unpredictable outcome of 
the isolation process.
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AMOUNT AND DISTRIBUTION OF COLLAGEN IN 1721 
THE PANCREAS HAVE NO EFFECT ON PORCINE ISLET 
ISOLATION OUTCOME
D.E. Hilling, E. Bouwman, J.K.R.A. Rijkelijkhuizen, H.A.M. Töns, 
O.T. Terpstra, 
Department of Surgery, Leiden University Medical Center, Leiden, 
The Netherlands
Background: Transplantation of islets of Langerhans can restore insulin 
production in patients with type 1 diabetes. Because of the shortage of human 
donor organs, transplantation of porcine islets is considered to be a suitable 
alternative solution. However, porcine islet isolation procedures have been shown 
to produce unpredictable, highly variable islet yields between pigs with similar 
backgrounds. One of the variables that could account for this is the collagen 
substrate within the pancreas. The aim of the present study was to determine 
the total amount and distribution of collagen within porcine pancreases and 
furthermore the effect of these determinants on islet isolation outcome.
Methods: 140 porcine pancreases were harvested in different slaughterhouses. 
The population consisted of a juvenile group (6–12 months) of 64 animals and 
an adult group (12–78 months) of 76 animals. Islet isolation was performed in 
58 pancreases of the adult group.
To detect collagen, tissue samples were embedded in paraffi n and stained with 
Sirius red. Quantitative measurements were made using the KS-400 image 
analysis system. The amount of the collagen stained area was quantifi ed by 
assessment of 30 random fi elds in each tissue sample. Collagen distribution 
was determined by assessing the presence of collagen in the endocrine-exocrine 
interface. Tissue samples were stained with Sirius Red in combination with 
anti-insulin to allow identifi cation of the islets. The presence of collagen in 
the islet capsule was scored semi-quantitatively in an average of 100 islets per 
tissue sample.
Both measurements were considered to be valid representations of the total 
collagen content and islet encapsulation of the whole pancreas.
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Results: The mean (± SD) collagen content in the adult group was 5.9 ± 1.8% 
(range 2.3–11.0), this was signifi cant higher (p<0.001) than in the juvenile 
group where the mean collagen content was 3.7 ± 1.3% (range 1.1–7.1). 
Apparently, the pancreas undergoes a process of fi brosis as pigs grow older. 
This was confi rmed by a signifi cant correlation between collagen content and 
age in the overall group (r=0.33, p<0.001).
In a pancreas, an average of 80.7 ± 16.4% of the islets was encapsulated less than 
50%. However, this average ranged from 23 – 100%, showing high variability 
in islet encapsulation between pancreases. Between total collagen content 
and islet encapsulation a signifi cant positive correlation (r=0.33, p<0.05) was 
found, indicating that in pancreases with high total collagen content, a larger 
number of islets are encapsulated greater than 50%.
After isolation and purifi cation, the average obtained islet yield was 545.4 ± 601.2 
IE/g pancreas (range 18–3849). We found no signifi cant correlation between 
collagen content and obtained islet yield (r =-0.004, p=0.98). Furthermore, no 
signifi cant correlation was found between the percentage of islet encapsulation 
in each pancreas and obtained islet yield (r=-0.053, p=0.69).
Conclusions: Neither the amount of collagen nor the islet encapsulation have 
effect on porcine islet isolation outcome. Possibly the amount and distribution 
of collagen subtypes (e.g. collagen type VI), rather than the total content, can 
explain some of the variability in porcine islet isolation.
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BENEFICIAL EFFECT OF HUMAN ISLET RESCUE 1722 
GRADIENT PURIFICATION ON EMBEDDED ISLET AND 
FRACTIONAL BETA CELL VIABILITY
A. Miki, C. Ricordi, T. Yamamoto, A. Mita, S. Barker, A. Kahn, R. Alejandro, 
H. Ichii
Diabetes Research Institute
Objective: It is diffi cult to consistently obtain suffi cient post-purifi cation islet 
numbers from younger donors, due to the higher proportion of trapped islets 
after pancreas digestion, even though several reports suggest islets isloated 
from younger donor pancreata present better suitability for clinical islet 
transplantation. Continuous Gradient Purifi cation, which is currently used in 
several islet processing centers, sometimes is not effi cient in the purifi cation 
of trapped islets. Rescue gradient purifi cation could improve post-purifi cation 
islet yields, resulting in an increased number of islet cell products that could 
be transplanted.
Materials and methods: Islet isolation were performed by automated method 
at Diabetes Research Institute of University of Miami. Seventy three human 
islet isolations for clinical islet transplantation, in which Continuous gradient 
purifi cation was followed by Rescue gradient purifi cation were analyzed. The 
quality of islets from Continuous gradient purifi cation and Rescue gradient 
purifi cation was assessed by beta cell fractional viability and ADP/ATP ratio 
for islet potency test. Assessment of Cellular composition using Laser Scanning 
Cyotometer /iCys was performed to assess the beta cell content.
Results: The overall percent rescue (Rescue islet IEQ/Continuous islet IEQ + 
Rescue islet IEQ) is positively correlated with the% trapped islets (R=0.584, 
P < 0.01) Donor age correlated negatively to the% islets recovered from RGP 
(R=0.440, P < 0.01) and to the% of trapped islets (R=0.511, P < 0.01).
A signifi cant age related difference (< 39 vs. > 40) was observed in pancreas 
weight (91.6 ¦ } 22.9 vs. 115.0 ¦ } 33.4g; P < 0.01), digestion time (15.1 ¦ } 
4.1 vs. 18.2 ¦ } 5.7min, P < 0.05) and islet yields from CGP (214,319 ¦ } 
131,668 vs. 296,575 ¦ } 172,509 IEQ, P < 0.05), respectively. Importantly, 
islets from Rescue gradient purifi cation had an 11% higher beta cell fractional 
viability compared to islets from Continuous gradient purifi cation. ADP/ATP 
ratio was also lower in Rescue gradient purifi cation islets vs. Continuous 
gradient purifi cation islets (0.46 ¦ } 0.17 vs. 0.86 ¦ } 0.11, P<0.05). Beta cell 
content in islet showed no signifi cant difference (48.4 ¦ } 21.0 vs. 36.0 ¦ } 
15.5, N.S)
Conclusion: RGP improved the effi ciency in the purifi cation of trapped islets, 
which often come from younger donor pancreata and did not affect islet cell 
viability, which was actually higher in Rescue gradient purifi cation fractions, 
indicating that rescued trapped islets from the pellet and lower purity layers are 
not damaged by the extra purifi cation step and may actually be more viable. 
Rescue gradient purifi cation could be used to rescue high quality islets from < 
30% pure islet fractions, which are often discarded in the clinical setting.
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THE SUCCESSFUL SWITCH TO SERVA COLLAGENASE 1723 
FROM ROCHE LIBERASE ON THE ISOLATION OF HUMAN 
ISLETS
T. Loudovaris, L. Mariana, G. Jhala, B. Krishnamurthy, N. Sanders, 
P. Campbell, S. Fynch, H. Junquan, H. Thomas, T. Kay
St. Vincent’s Institute, 41 Victoria Parade, Fitzroy Victoria 3065
The primary steps in isolating islets for transplantation into diabetic patients 
involves the use of collagenase to break up the pancreas into small pieces 
less than 500μm. March last year we were made aware that the collagenase 
source that we were using, Liberase from Roche, was produced using bovine 
brain products, whose source could not be guaranteed to be free of bovine 
spongiform encephalitis (BSE) virus. This forced a change to Collagenase from 
SERVA, Germany, which was certifi ed to be BSE free.
Aim: To compare the islet yields, function and viability obtained with SERVA 
collagenase to that obtained with Liberase.
Methods: Human islets are isolated from pancreata that are offered to the 
Tom Mandel Islet Transplantation Program in Melbourne come from Victoria, 
Tasmania and South Australia (SA). Because of limited availability, there was little 
or no donor selection, with nearly all pancreata accepted, even ones that would 
be considered to be from “poor” donors. Islets were isolated using the modifi ed 
Ricordi method. Isolated islets were evaluated functionally by static glucose 
incubations (resulting in a stimulation index as a ratio of stimulated to basal islet 
insulin release) and by transplantation into diabetic SCID mice. Viability was 
determined by fl uorescent mitochondrial dyes and fl ow cytometric analysis.
Results: Pancreata digested with Roche Liberase Lot#93401520 
(n=15) achieved the best results with average pre-purifi cation count of 
416,445+/-201,393, post-purifi cation count of 207,867+/-109,858, with 
57.1% successful mouse transplants (>67% mice had corrected blood glucose 
levels) 93.3% positive insulin stimulation index and 28.6% of preparations 
had a beta cell viability index of >0.3. Pancreata digested with SERVA GMP 
Collagenase Lot#20100005 (n=16) achieved an average pre-purifi cation count 
of 282,036+/-121,182, post-purifi cation count of 182,780+/-167,725, with 
50% successful mouse transplants, 93.8% positive insulin stimulation index 
and 27.3% of preparations had a beta cell viability index of >0.3. Digestion 
with other lots of Liberase (fi ve test lots, total of 15 isolations) produced the 
lowest average islet yields both pre and post-purifi cation.
Conclusion: Although the Roche Liberase appeared to produce better yields of 
islets and more successful mouse transplant results, the results achieved with 
SERVA collagenase were not signifi cantly different. The switch from Liberase 
to SERVA collagenase has resulted in Victoria’s fi rst successful islet transplant.
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COMPARISON OF THE EFFICACY OF AVAILABLE 1724 
COLLAGENASES ON HUMAN ISLET ISOLATION FROM 
RESEARCH GRADE PANCREATA
B. Barbaro, P. Salehi, J. Kuechle, M. Qi, S. Wang, L. Rodriguez, C. Groh, 
Y. Wang, E. Benedetti, J. Oberholzer
Department of Surgery, Division of Transplantation, University of Illinois at 
Chicago, USA
Backgorund: Islet transplantation is a promising therapeutic approach for the 
treatment of type 1 diabetes. Although progressively improved, the success 
of islet transplantation is still unpredictable. One of the major obstacles to 
successful human islet isolation has been the variability of the enzymatic 
digestion phase. The aim of this study was to compare enzyme effi ciency 
among three different collagenases: Liberase HI (Roche), Collagenase (Serva) 
and Collagenase V (Sigma) during human islet isolation.
Methods: The data from 99 human islet isolations (44 with Roche, 11 with 
Serva, and 44 with Sigma) of research grade pancreata were retrospectively 
analyzed. Enzyme effi ciency was evaluated in terms of islet yield, purity, 
recovery rate, stimulation index and viability of the fi nal product.
Results: Donor characteristics including age, sex, BMI and cause of death 
were comparable among the three groups. Cold ischemia time was 10:39±2:19 
h in Sigma, 9:05±2:45 in Serva and 8:48±2:06 h in Roche group. Isolations 
with Sigma collagenase V yielded 269,020±21,214 IE whereas isolations with 
Serva collagenase yielded 248,342±53,015 IE and Roche liberase yielded 
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314,557±29,886 IE (p=0.43 for Sigma vs Roche and p=0.94 vs Serva). Islet 
recovery rate was similar among all groups: 81.4±30.4% for Sigma, 62.7±28.9% 
for Serva and 91.5±24.4% for Roche group. Similar enzyme effi ciency was 
observed among the three groups in terms of viability, functionality and purity. 
Conclusion: Sigma V collagenase achieved similar islet isolation outcomes as 
Liberase and Serva, and represents a cost-effective alternative product. This 
result questions the validity of purifi ed enzyme blends and indicates that more 
research is needed to better understand the requirements for ideal enzymes for 
human islet isolation.
LONG TERM OUTCOMES CONCURRENT ORAL SESSION 124: 
– QOL/AGING/FERTILITY/WNKUP
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THE EFFECTS OF PHYSICAL QUALITY OF LIFE, TIME, 1725 
AND GENDER ON CHANGE IN SYMPTOMS OF ANXIETY AND 
DEPRESSION AFTER KIDNEY TRANSPLANTATION
A. Soliman1, S. Zamil2, A. Lotfy2, N. Elshimy3
1Cairo University, Division of Nephrology, Department of Medicine, 2Cairo 
University, Department of Urology, 3Cairo University, Department of 
Clinical Pathology
Introduction: Previous research demonstrated that functional performance and 
health-related quality of life (HRQOL) improve following kidney transplantation, 
but the extent to which improvement in symptoms of anxiety and depression is 
related to post-transplant physical HRQOL has not been characterized. The aim 
of this study was to test the effects of physical HRQOL, time post transplant, and 
gender on pre- to post-transplant change in symptoms of anxiety and depression.
Methods: Longitudinal HRQOL data were prospectively collected at specifi c 
times before and after kidney transplantation using Health Survey, Center for 
Epidemiologic Studies Depression Scale (CES-D), andBeck Anxiety Inventory 
(BAI). Within-subject change scores were computed to represent the longest 
follow-up for each patient. Multiple regression was used to test the effects of 
time post transplant, gender, and post-transplant physical component summary 
scores on change in BAI and CES-D scores. Baseline scores on outcome 
measures were modeled to account for and quantify their expected effects.
Summary data are reported as mean±SD.
Results: 107 patients (74% male; 51% HCV; age#5498 years) reported 474 
survey points over 43 months. Time post-transplant ranged 1 to 39 months 
(mean#998). Patients with the poorest pre-transplant HRQOL showed the 
greatest improvement on every model. Change in CES-D and PCS scores 
continued with time post transplant. Reduced post-transplant physical quality 
of life was associated with less improvement in symptoms of anxiety (model 
1) and depression (model 2). This relationship is also refl ected in model 3, 
which quantifi es the negative effect of post-transplant anxiety on change in 
PCS. Gender did not affect these outcomes.
Conclusions: Despite improvement on all HRQOL measures, there was 
less improvement in symptoms of anxiety and depression in those patients 
with reduced physical HRQOL after kidey transplantation. Awareness of the 
signifi cant relationships between physical and mental quality of life indicators 
in both men and women suggests the importance of early recognition and 
intervention strategies to promote continued improvement in mental and 
physical quality of life following kidney transplantation.
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THE EFFECT OF SPONTANEOUS TWIN PREGNANCY ON 1726 
RENAL TRANSPLANT FUNCTION AND HAEMODYNAMICS
S. Bhandari
Hull And East Yorkshire Hospitals NHS Trust And Hull York Medical School
Pregnancies after transplantation are association with an increased risk for 
both mother and fetus with higher rates of stillbirth and preterm deliveries. 
Spontaneous twin pregnancy is uncommon in renal transplant recipients and 
presents an even greater risk. The effects on transplant haemodynamics have 
not been studied. We present a case of a successful outcome for both mother 
and babies and detail the effects of the pregnancy on transplant function and 
haemodynamics within the transplant kidney.
A 27-year old woman received a cadaveric transplant in December 1995 from 
a 10year old donor, HLA 111 mismatch. She had a past history of recurrent 
urinary tract infections and hypertension and presented initially to the 
nephrologists with bilateral dysplastic kidneys requiring peritoneal dialysis 
prior to transplantation. Immunosuppression at induction was Neoral 200mg 
BD, Azathioprine 75mg and Prednisone 20mg. At the time of spontaneous 
conception (March 07) she was taking Neoral 100mg BD, Azathioprine 50 mg 
daily and Prednisolone 5 mg daily.
The course of the pregnancy was uneventful apart from a modest increase in 
proteinuria (0.3 to 1.0 g/24h) and blood pressure (121/81 baseline to 132/92 
mmHg). At 32 weeks due to increasing blood pressure a semi-elective C-section 
was performed with the delivery of two healthy babies which required minimal 
medical input.
During the pregnancy serum creatinine fell by 36% (142 to 91μmol/L), urea 
fell by 39% (9.0 to 5.5mmol/L) while eGFR (MDRD) rose by 29ml/min. 
Albumin fell by 28% (39 to 28 g/L) while there was a modest increase in 
uric acid to 0.51mmol/L. Transplant scans revealed a 21% increase in cross-
sectional area of the kidney with a 10% increase in main renal artery peak fl ow 
and a 21% reduction in resistive index. Serum creatinine rose to 199μmol/L, 
eGRF 48ml/min (baseline 40ml/min), urea 8.1mmol/L and albumin 38g/L 
post pregnancy and remained stable. The RI remained unaltered and the peak 
renal artery fl ow fell 50% while the cross-sectional area returned to baseline 
post delivery.
Twin pregnancy can be successful with no increased risk in comparison to non 
transplant females. Physiological changes in renal haemodynamics are similar 
to non transplant pregnant patients (70% rise in renal blood fl ow, 25% fall in 
urea and creatinine, 55% increase in GFR) with no detrimental effect to the 
transplant function post pregnancy.
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KIDNEY TRANSPLANTATION FROM CADAVERIC 1727 
DONORS OLDER THAN 60 YEARS OF AGE
G. Miserlis, G. Vergoulas, V. Papanikolaou, A. Dinas, N. Antoniadis, 
D. Vrochidis, I. Fouzas, G. Imvrios, D. Giakoustidis, D. Takoudas
Organ Transplant Unit, Hippokration General Hospital
Donor age was identified as a major factor that determines long term 
outcome after kidney transplantation. However, the influence of other 
parameters such as acute rejection (AR) and delayed graft function (DGF) 
both on short and long-term kidney graft survival from elderly deceased 
donors has not been well characterized. In this study we analyzed 
retrospectively the impact of the above parameters on the outcomes of 
40 kidney allograft recipients (mean age: 49.5±11.5 years) transplanted 
between March 2001 and December 2006 from elderly (mean age: 
64.9±4.6 years) deceased donors. Patient and graft survival rates at 1, 3 
and 5 years post-transplantation were 97.4%, 97.4%, 80.4% and 87.3%, 
81.5% and 69.8% respectively. Twenty (50%) of patients suffered DGF 
and 11 (27.5%) AR episodes, while 8 (20%) lost the graft. Acute rejection 
was a significant determinant for worse renal graft outcome and graft 
loss (Risk Ratio [RR] for graft loss in pts with AR vs absence of AR = 
7.0; p<0.001). DGF itself was not associated with graft loss (RR for graft 
loss in pts with DGF vs absence of DGF =1.7; p=0.11). Mean GFR levels 
(MDRD6 formula) at 6 months, 1 and 2 years were 26.6±9.1, 30.4±10.3 
and 32.0±6.5 ml/min/1.73m2 in kidney graft recipients presented AR and 
57.4±17.3, 54.6±15.8 and 54.7±18.2 ml/min/1.73m2 in patients without 
rejection episodes (p<0.05). Mean 24h proteinuria was statistically 
significant higher in patients with AR only 1 year post-transplantation 
(766.6±391.9mg/24h in pts with AR vs 253.4±239.5mg/24h in pts without 
AR, p<0.05). In conclusion, renal grafts from older deceased donors can be 
successfully transplanted to younger recipients. Acute rejection episodes in 
kidney allografts from elderly deceased donors had a significant negative 
impact both on short and long term graft function and outcome.
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KIDNEY TRANSPLANTATION, A UNIQUE CURE FOR 1728 
SEVERE LEFT VENTRICULAR DYSFUNCTION
S. Bhandari, S. Sajid, N. Nickolay
Department of Renal Medicine, Hull and East Yorkshire Hospitals NHS Trust 
and Hull York Medical School, Kingston upon Hull, UK
Cardiovascular complications are the leading cause of mortality among patients 
with end-stage renal disease, accounting for 50% of all deaths. Indeed, the 
prevalence of heart failure amongst these patients is as high as 40% and is 
responsible for 12% of the total deaths. The mechanisms underlying these cardiac 
abnormalities remain unclear. Renal transplantation is normally contra-indicated.
We present a case of a dialysis patient with severe cardiac dysfunction who 
demonstrated signifi cant functional and clinical improvement as assessed by cardiac 
MRI, symptoms and hospital admissions to highlight that patients with severe 
cardiac dysfunction should be considered for possible renal transplantation.
A 37y Caucasian male with end stage renal disease secondary to IgA 
nephropathy and signifi cant left ventricular hypertrophy from hypertension had 
been on dialysis for 4 years (6 months peritoneal and 42 months haemodialysis). 
He was on maximal ACE and ARB inhibition. Cardiac transplant assessment 
demonstrated poor LV systolic and diastolic function and evidence of mild 
diffuse coronary artery disease with no focal lesion worthy of intervention. He 
had symptomatic NYHA functional class 3 heart failure. Despite regular dialysis 
and adequate fl uid removal he had 48 admissions in the previous year. MRI 
revealed signifi cant cardiac dysfunction with an EF% of 27% (see Figure).
After successful cadaveric renal transplant, within the fi rst year there was signifi cant 
function improvement with an EF% of 43%, a 19% reduction in LV mass and 24% 
increase in stroke volume. In the 3 years since transplantation he has required no 
hospital admissions and he has NYHA functional class 1 heart failure.
This case demonstrates the benefi ts of renal transplantation on cardiac function. 
Possible mechanisms for this dramatic improvement could include
1. removal of uraemic toxins causing a uraemic cardiomyopathy
2. removal of the haemodynamic effects of dialysis
3. repletion of chronic carnitine defi ciency
4. improved fl uid balance
The main impact on a reduction on LV mass and hence hypertrophy suggests 
that transplantation can abrogate the future need for cardiac transplantation. 
Patients with cardiac failure on dialysis should be considered for renal 
transplantation and not excluded. Cardiac MRI represents a useful method of 
assessing and monitoring cardiac function in renal transplants.
2 chambers diastolic 2 chamber systolic
(Pre and post transplant) (Pre and Post transplant)
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HEALTH SCREENING OF THE RENAL TRANSPLANT 1729 
WAITING LIST
Y. Watarai, A. Kwaguchi, S. Maru, R. Ishikawa, N. Taniguchi
Kushiro City General Hospital
Purpose: Candidates on the renal transplant waiting list wait for signifi cantly 
long time, 18 years in average, in Japan and they are assumed to have increasing 
numbers of comorbidity during dialysis period. Transplant centers need to ensure 
that their candidates are acceptable for transplantation when the organ becomes 
available. We have evaluated the renal transplant waiting list in our institute.
Methods: 18 out of 20 candidates on our waiting list, mean age of 49.8(28-60) 
and duration on hemodialysis of 11.2 years(1-22 years), were evaluated 1) 
complete blood tests, 2)chest X ray, 3) echocardiography and cardiac stress 
testing, 4) measurement of Pulse wave velocity(PWV) and Ankle blood pressure 
index(ABPI), 5) Plain CT scan with 3D reconstruction of the calcifi cation of 
aortic and iliac artery by maximum intensity projection.
Results: All candidates revealed normal chest X ray, echocardiography and 
cardiac stress testing. CT scan showed severe aortic calcifi cation in 8 candidates 
(44%) in which the calcifi cation occupied all around the aorta, and partial aortic 
calcifi cation in 7(39%). But all candidates had non calcifi ed iliac artery site to 
make vascular anastomosis possible. However, 13 candidates (72%) showed 
signifi cantly high PWV in average of 1601 sec, and one showed signifi cantly 
low ABPI which consequently required the interventional treatment for the 
external iliac artery occlusion. One candidate showed ventricular tachycardia 
which needs ablation treatment. One candidate revealed thrombocytopenia 
which was due to liver cirrhosis by hepatitis C infection. Finally 3 candidates, 
which all had more than 10 years of dialysis history, were not acceptable for 
transplantation at the time of evaluations and 2 have been treated successfully. 
Among 18 candidates, 7 had more than 10 years dialysis history and 43% of these 
candidates had comorbidity which was not acceptable for transplantation.
Conclusions: Screening especially of cardiovascular and peripheral vascular 
disease is mandatory on the renal transplant candidate who is on waiting list 
for more than 10 years.
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THE EFFECT OF SUCCESSFUL RENAL 1730 
TRANSPLANTATION ON ERECTILE DYSFUNCTION
G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Objective: To evaluate the prevalence of erectile dysfunction (ED) in 
hemodialysis patients and the effect of successful renal transplantation on it.
Materials and methods: Two hundred and seventy hemodialyzed patients 
underwent live unrelated renal transplantation from Sep. 2002 to Nov. 2005 in 
Sina hospital, Tehran University of Medical Sciences, Iran.
Those who were younger than 20 years, positive history for diabetes mellitus, 
ischemic heart disease, hypercholestrolemia, pelvis trauma or prostate surgery 
cigarette smoking, previous renal transplantation and medication use with 
adverse effect on erectile dysfunction were excluded. Eighty eligible patients 
entered the study and were assessed by international index of erectile function, 
version 5(IIEF-5) pre and six-month post renal transplantation.
Results: The prevalence of ED in hemodialyzed patients was 87.5%. Aging had 
not statistically signifi cant effect on it. There was no relationship between the 
duration of dialysis and ED severity. Sixty four patients had good functioning 
graft in 6-month follow-up and completed the study.
Successful transplantation improved IIEF-5 score signifi cantly (P < 0.001).
Pretransplantation IIEF-5 score, age at the time of transplantation and 
transplant artery anastomosis to common iliac artery had statistically signifi cant 
association with ED improvement, while duration of dialysis had not.
Conclusions: ED is highly prevalent in hemodialyzed patients. It improves 
signifi cantly after successful kidney transplantation.
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FACTORS INFLUENCING THE WAITING PERIOD 1731 
FOR KIDNEY TRANSPLANTATION
M. Heemskerk1, A. Hemke1, B. Haase-Kromwijk1, A. Hoitsma2
1Dutch Transplant Foundation, 2Radbout University Medical Centre, 
Nijmegen, The Netherlands
Background: Not all patients on the waiting list for a renal transplant have 
equal chances on receiving one, nor is the waiting time for patients equally 
spread. The question is what the reason is for this imbalance and which policies 
can be changed to equalise the chances.
Methods: We performed an analysis on the kidney waiting list registrations, 
for all recipients who awaited a non-pre-emptive deceased donor fi rst kidney 
transplant in the Netherlands between 2000 and 2007. We analyzed the 
infl uence of several parameters on the average number of dialysis days prior 
to kidney transplantation (waiting time). The analysis was performed on both 
patients who received a kidney (n = 2096) as well as on patients who were still 
on the kidney waiting list at the end of 2007 (n = 682).
Results: Transplanted patients: the average waiting time for a deceased donor 
fi rst kidney transplant was 3.4 years for all recipients. A signifi cant difference in 
waiting time was found for the different blood groups (AB: 2.5, A: 3.1, B: 3.5, O: 
3.9 years, P<0.001). These differences in waiting time are probably the result of 
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years of full house identical kidney exchange of blood group O donors to other 
blood groups. This has resulted in an increase of the percentage of blood group O 
patients on the list, which is illustrated by the fact that 53% of the patients on the 
Dutch active kidney waiting list on 1-1-2006 had blood group O, in comparison to 
46% of all Dutch organ donors in 2007. The type of transplant registration center 
(<35% NHB transplants: 3.5 years, >35% NHB transplants: 3.3 years, P=0.050) 
had no important infl uence. Surprisingly, patients with peritoneal dialysis had a 
shorter waiting period than patients on haemodialysis: (3.0 years versus 3.7 years, 
P<0.001). However, this might be due to the fact that patients who are a long time 
on peritoneal dialysis have a high chance to be switched to haemodialysis due to 
complications of the peritoneal treatment before being transplanted.
Patients still on the waiting list at the end of 2007: the mean waiting time for 
these patients was 2.7 years. The waiting periods were signifi cantly different per 
blood group (AB: 2.0, A: 2.2, B: 2.8, O: 3.0 years, P<0.001) and center type, 
although for center type the difference was only 0.2 years. For patients on the 
waiting list there was no signifi cant difference between the dialysis techniques.
Conclusion: For an individual on the waiting list the actual waiting time is 
strongly infl uenced by his/her blood group; there is a disadvantage for blood 
group O patients. We might have to abandon full house identical kidney 
exchange of blood group O donors to other blood groups. The percentage of 
NHBD transplants per center had no great effect on the waiting time.
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FLUCTUATIONS OF EXERCISE CAPACITY IN PATIENTS 1732 
AFTER KIDNEY TRANSPLANTATION
M. Zakliczynski1, U. Spiechowicz2, A. Wiecek2, M. Zembala1
1Dept. of Cardiac Surgery & Transplantation, Silesian Center For Heart 
Disease, 2Dept. of Nephrology, Endocrinology & Metabolic Dis., Medical 
Univ. of Silesia, Katowice, Poland
Aim of the study was to assess changes in the exercise capacity in subjects 
with end-stage renal failure undergoing kidney transplantation (RTx). Material 
and methods: Study group consisted of 16pts. (9M/7F, 43.3±11y/o), control 
group was composed of 7 healthy subjects (4M/3F, 43.9±10y/o). 1st visit took 
place 4-8 weeks after RTx. Consecutive visits were scheduled for the 4th, 
10th, 16th, 24th, 36th, and 48th month after RTx. Heart function was assessed 
by echocardiography, and exercise test with the peak oxygen consumption 
(VO2max) analysis. Results were correlated with VO2max (Pearson). Mann-
Whitney U test was used to compare study and control group. Results: The 
results of eligible VO2max tests were as follows (median & range): 1stm. 
(n=15) 19.5 (8.8-27.5)ml/kg/min, 4thm. (n=9) 21.7 (16.0-29.3)ml/kg/min, 
10thm. (n=8) 23.3 (13.1-30.0)ml/kg/min, 16thm. (n=9) 26.6 (18.3-36.0)ml/kg/
min, 24thm. (n=9) 22.3(14.1-35.0)ml/kg/min, 36thm. (n=9) 20.9(16.4-32.1)
ml/kg/min, 48thm (n=5) 19.7(17.0-30.9)ml/kg/min, and 26.8 (26.5-42.5)ml/
kg/min in the control group. VO2max result achieved by the study group 
were signifi cantly lower than in the control group, except for the 16th, 24th, 
and 48th month after RTx. VO2max was found to be signifi cantly negatively 
correlated with the following ultrasound parameters: interventricular septum 
diastolic and systolic diameter, and left ventricle systolic volume. Conclusion: 
Exercise capacity of RTx recipients seems to be negatively affected by poor 
blood pressure control, resulting in the heart muscle hypertrophy.
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PREGNANCY AFTER RENAL TRANSPLANTATION1733 
T. Abe1, M. Okumi1, R. Imamura1, N. Ichimaru1, A. Okuyama1, Y. Isaka2, 
S. Takahara2, Y. Kokado3
1Departments of Specifi c Organ Regulation (Urology), Osaka University 
Graduate School of Medicine, 2Departments of Advanced Technology for 
Transplantation, Osaka University Graduate School of Medicine, 3Takahashi 
Clinic
Aim: We examined women with renal transplants who became pregnant and 
delivered at our hospital.
Methods: Of 26 women who underwent renal transplantation between 1977 
and 2002 and became pregnant and delivered at Osaka University Hospital, 20 
women with complete data served as subjects.
Results: The 20 women became pregnant a total of 29 times after renal 
transplantation. Spontaneous abortion occurred 3 times, and pregnancy was 
artifi cially terminated 5 times. Neonates were thus delivered in 21 of 29 
pregnancies. One woman delivered twice and 2 women delivered twins. As a 
result, a total of 23 neonates were delivered. Mean gestational period was 35.4 
weeks (range, 27-41 weeks), and mean birth weight was 2229 g (range, 724-3544 
g). Regarding fetal complications, intrauterine growth retardation was seen in 
3 cases. One child with intrauterine growth retardation died at 3 months old 
due to respiratory distress syndrome. One child displayed double-outlet right 
ventricle and another child had congenital unilateral hydronephrosis. Regarding 
maternal complications, prevalence of toxemia of pregnancy was 38.1%. In 4 
of the 21 deliveries (19.0%), renal function exacerbated after delivery. Rates of 
graft survival for the 20 women at 1, 5 and 10 years after delivery were 100%, 
85.1% and 74.4%, respectively. Prognosis for renal transplant is signifi cantly 
poorer for recipients with hypertension before pregnancy than for recipients 
without hypertension before pregnancy (log-rank test, p=0.043).
Conclusions: Rates of graft survival after delivery were mostly favorable. 
However, prognosis for renal function was poor for recipients who displayed 
hypertension prior to pregnancy.
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IMPROVEMENT IN COGNITIVE FUNCTION AFTER 1734 
KIDNEY TRANSPLANTATION
L.E. Morales-Buenrostro4, J. Alberú-Gómez, S. Sánchez-Román1,2, 
F. Ostrosky-Solís2, M.G. Nogués Vizcaíno3
1Department of Neurology and Psychiatry, Instituto Nacional de Ciencias 
Medicas y Nutricion Salvador Zubiran (INCMNSZ), Mexico City, 
2Neuropsychology and Neurophysiology Laboratory, Universidad Nacional 
Autonoma de Mexico, Mexico City, 3Department of Transplantation, 
INCMNSZ, 4Nephrology Department, INCMNSZ
Purpose: Previously, we evaluated 41 ESRD patients (pts) and found that 
35% showed impairment in attention and memory functions. This prospective, 
longitudinal study was designed to evaluate a subset of ESRD pts before and 
after KT to explore whether the impairment in cognitive areas is modifi ed upon 
restitution of renal function.
Methods: 15 KTR (11M/4F) and 13 donors -control group- (4M/9F) were 
tested twice: 24-48 hrs before and 6-10 months after KT by comprehensive 
neuropsychological battery for the evaluation of Attention and Executive 
Functions and Memory Functions, Hospital Anxiety and Depression Scale 
and Epworth Sleepiness Scale. The rate of cognitive change was defi ned by 
the difference between each neuropsychological measure (post-operative vs. 
baseline score). Renal function data was gathered for KTR and donors. Mean 
group differences were assessed with paired samples T test or X 2. Bivariate 
correlations and Linear regression analysis were used.
Results: Mean age (31±12.6) and years of education (13±3.8) of the KT group 
were not signifi cantly different from controls. A signifi cant improvement 
(p<0.01) in cognitive function, predominantly in the Attention and Executive 
Functions scale was found after KT (before KT 27% showed mild-moderate or 
severe impairment in this area; after KT all patients showed normal functioning). 
Mild memory impairment persisted in 13.3% pts after KT. Although 7% of the 
donors improved their performance, the improvement of the KT recipients was 
signifi cantly higher (p<0.05). The scores for both groups did not correlate with 
the Hospital Anxiety and Depression Scale or Sleepiness Scale. Signifi cant 
correlation between SCr and Attention and Executive Functions was found 
(r=-.433, p<0.05). SCr predicted Attention and Executive Functions (R=.433, 
p<0.05).
Conclusions: Around 30% of ESRD pts had pre-KT cognitive alterations that 
may interfere with their daily function. The results of the present study suggest 
a better quality of life through the improvement attained in cognition after KT, 
adding this to the multiple benefi cial aspects of KT.
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PSYCHIATRIC SYMPTOMS IN KIDNEY TRANSPLANT 1735 
RECIPIENTS
L.E. Morales-Buenrostro2, J. Alberú-Gómez3, S. Sánchez-Román1, 
L.N. González de Jesús1, 
1Neurology and Psychiatry Department, Instituto Nacional de Ciencias 
Medicas y Nutricion Salvador Zubiran (INCMNSZ), Mexico City, 2Nephrology 
Department, INCMNSZ, Mexico City., 3Department of Transplantation, 
INCMNSZ, Mexico City
Aim: Describe the presence of psychiatric symptoms in ESRD patients before 
and after kidney transplant (KT).
Methods: We studied 75 ESRD patients (pts) (34 males, 41 females): 31 with 
living related donors (LRD), 22 with deceased donors and 22 non transplant 
candidates. The instruments used were: the Hospital Anxiety and Depression 
Scale (HAD), which measures levels of anxiety and depression, but excludes 
somatic symptoms of physical diseases avoiding false positives; and the 
Symptom Checklist-90 (SCL-90), a self report inventory that assesses the level 
of distress recently reported by the subject (in terms of psychiatric symptoms). 
From these 31 pts with LRD, 15 were evaluated with the same scales 6 months 
after KT. Descriptive statistics were done according to the measurement level 
of the variables. We used paired T-Test, Chi-square test and paired proportions 
comparison formula.
Results: Mean age of ESRD pts was 37.12±13.03. According to the HAD, 
30.7% of the ESRD pts showed anxiety symptoms and 25.3% of them 
manifested depression symptoms. No signifi cant differences were found 
between males and females in anxiety or depression symptoms. The results 
in HAD scale of the 15 KTR (11 males, 4 females) that were followed are 
presented below. The proportion of pts with depressive symptoms after KT was 
signifi cantly lower than in the pre-transplant evaluation (26.7% before KT and 
13.3% after KT). Anxiety symptoms did not show differences in both evaluation 
times. General Severity Index of SCL-90 scale was not signifi cantly different 
before and after KT in the subset of 15 kidney recipients. However, Positive 
Symptom Distress Index (designed to measure the intensity of symptoms), 
Phobic Anxiety and Paranoid Ideation (all subscales of the SCL-90) showed a 
signifi cant improvement (p<0.05) after KT.
Conclusions: Our results show the presence of psychiatric symptoms in a group 
of ESRD patients and a decrease of some of these (depression, intensity of 
symptoms, phobic anxiety) after KT. This is probably due to the improvement 
in the quality of life and physical improvement after KT.
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NEUROLOGICAL COMPLICATION IN KIDNEY 1736 
TRANSPLANT RECIPIENTS
P. Hon1, J. Dedochova2, V. Honova3, M. Bar1, F. Vlcek1, A. Martinek2
1Department of Neurology, University Hospital Ostrava, 2Transplantation 
Center, University Hospital Ostrava, 3Department of Nephrology, City 
Hospital Novy Jicin
Background: Neurological complications after renal transplantation are 
frequent. They are related to immunosuppressive therapy, comorbidity as 
hypertension, diabetes and atherosclerosis, transplantation surgery. Analyse 
these complications should lead to improve prevention and therapy renal 
transplant recipients
Material and methods: 294 patients (from 17 to 66 year old) after renal 
transplantation were analysed. Two parallel groups were installed. Group A (152 
patients) with immunosuppressive combination cyclosporin A + mycofenolate 
mofetil + methylprednisolon, and Group B (142 patients) - combination 
tacrolimus + mycofenolate mofetil + methylprednisolon
Results: In group A: polyneuropathy was observed in 25,3%, stroke in 1,9%, 
meningoencephalitis in 3,8%, transplant surgery complication in 0,7%. In 
group B: polyneuropathy in 22,2% stroke in 2,1%, meningoencephalitis in 
4,1% patients, transplant surgery complications in 0,7% patients. Peripheral 
polyneuropathy was more frequent in patients with diabetes mellitus. 
Polyneuropathy was less frequent in patients after transplantation compared to 
them before transplantation. Stroke was observed more frequently in patients 
with large vessel disease. Meningoencephalitis infection agent was detected 
Herpes simplex virus and Listeria monocytogenes. As transplant surgery 
complication was observed femoral nerve mononeuropathy. There were no 
signifi cant differences between group A and B.
Conclusion: Both combination of immunosuppressive therapy is similar safe. 
Transplantation is important to decrease number of peripheral polyneuropathy 
in patients without diabetes mellitus.
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PREPARATION OF DIALYSIS PATIENTS FOR KIDNEY 1737 
TRANSPLANTATION
P. Zámbó, A. Varga, M. Molnar
FMC Dialysis Center, Szigetvár
Introduction and aims: A successful kidney transplantation strongly depends 
on the careful selection and thorough medical evaluation of the patients who are 
suitable for transplantation. In this work we present the method of the medical 
assessment of our patients, the results of diagnostic tests and the outcome of 
medical interventions carried out prior to enlisting the patients on the waiting 
list.
Patients and methods: In the FMC Dialysis Center, Szigetvár from 2003 to 
2007, 29 dialysis patients (14 female, 15 male, mean age 48 years, 5 pts are 
above 60 years) were added to the waiting list. All patients were screened for 
viral infections: HCV, HIV, HBsAg, CMV, EBV, VZV. We scanned patients 
for any potential source of infection, (dental, gynecological, urological, ENT 
investigation, urinary culture) for malignancy, (abdominal ultrasound, chest 
X-ray, mammography for every women above age 45 y, PSA for men age 45 y, 
dermatology, haematest of stool) for cardiovascular risk factors (family history, 
hypertension, diabetes, dyslipidemia, smoking, obesity) and for cardiovascular 
complications (ECG, echocardiography, DPD SPECT; and if necessary, cardiac 
catheterization, carotis Doppler, abdomen CT scan, pelvis X-ray)
Results: Urinary culture was positiv in 8 patients, who were treated with 
antibiotics immediately. Dental infection were found in 5 patients, they were 
treated by teeth extractions. We attenuated the effect of cardiovascular risk 
factors in patients by strong control of the followings: abandoning of smoking, 
keeping blood pressure below 130/80 Hgmm and serum LDL-cholesterol level 
below 3 mmol/l).7 pts required coronarography (5 diabetic pts).
During the course of the survey we found malignancy in 2 pts, and severe 
periferal atherosclerosis in 1 patient -they were excluded from the waiting list
15 out of 29 patient received cadaver kidney during the 5 years.
Conclusion: Potential transplant recipients require very detailed medical 
assessment before enrolling into the waiting list and the treatable conditions 
and diseases have to be managed, in order to ensure that the transplantation 
procedure is done as safely as possible and to maximize the long-term survival 
of the recipient.
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RENAL TRANSPLANTATION IN PATIENTS ABOVE 1738 
60 YEARS OF AGE: A SINGLE CENTER EXPERIENCE
A. El Agroudy, S. Al Arrayed, A. Al Arrayed, S. Ghareeb, E. Fareed
Salmaniya Medical Complex
Aim: Renal transplantation is increasingly being carried out in older patients, 
with generally acceptable results. Because we have an increasingly aging 
population, we retrospectively reviewed the results of renal transplantation in 
patients over 60 years of age at our center.
Patients and methods: A retrospective study was conducted of 212 Bahraini 
patients receiving renal transplants from January 1979 to December 2007. 
All medical records were reviewed for demographic data, graft function and 
survival. Patient and graft survival was compared for patients above and below 
the age of 60.
Results: Seventeen patients >60 years with a mean age of 64.1±3.6 years at the 
time of transplantation. Sex: 76.5% Males. Diabetic nephropathy (52%) and 
PCKD (12%) were the most common causes of ESRD. Mean donor age was 
26±6 years and most of them were unrelated (82%). Follow-up was until death 
or until 1/3/2008. Of the 17 study patients, 4 died: 3 with a functioning graft, 1 
within one year of transplantation. Cardiovascular causes (3 patients, 75%) and 
infection (1 patient, 25%) were most common. Common causes of graft loss 
were death with a functioning graft (4) and chronic rejection (1). Univariate 
analysis of risk factors showed pre transplant hypertension and diabetes mellitus 
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signifi cantly (p < 0.05) affected time of return to dialysis. Multi variate analysis 
did not show these independent variables to be signifi cant. After censoring 
patients that died with functioning grafts, difference in graft survival between 
>60 and <59 years was not signifi cant (p > 0.2). In this study, 92% of older 
patients had allografts functioning at 1 year.
Conclusions: The fact that older patients succumb over time from natural causes 
should not keep patients from transplantation. Immunosuppressive agents need to 
be limited to reduce the incidence of infection. Criteria need to be refi ned to defi ne 
those who are at prohibitive risk, who may not be candidates for transplantation.
DONOR FOLLOW-UP AND CONCURRENT ORAL SESSION 125: 
OUTCOMES
POSTER BOARD NUMBER P3 – 165
AN ATTEMPT TO EXTEND THE DONOR CRITERIA 1739 
FOR SUCCESSFUL LIVING-RELATED KIDNEY 
TRANSPLANTATION FROM A DONOR WITH MEMBRANOUS 
NEPHROPATHY
K. Akioka1,4, M. Okamoto2, H. Ushigome1, S. Nobori1, A. Yoshizawa2, 
S. Sakamoto1, K. Urasaki3, A. Yanagisawa3, N. Yoshimura1,2
1Dept. Organ Transplant and Regenenative Surgery, Kyoto Prefectural 
University of Medicine, 2Dept. of Organ Interaction Research Medicine,, 
3Department of Surgical Pathology, 4Omihachiman Community Medical 
Center
Introduction: Because of the shortage of donors for renal transplantation, 
marginally appropriate donors might be considered in order to extend the donor 
criteria. Some reports have described successful outcomes after cadaveric 
kidney transplantation from donors with pre-existing membranous nephropathy. 
Here we report a successful outcome after kidney transplantation from a living-
related donor diagnosed as having membranous nephropathy.
Case report: A 38-year-old male who had suffered proteinuria from the age of 
22 years began to receive CAPD from the age of 37. His 63-year-old father had 
mild proteinuria, and had been diagnosed as having membranous nephropathy 
by needle biopsy. However, the father was found to have normal renal function 
in a preoperative examination, except for mild proteinuria and minimal 
pathology. As these two individuals expressed a willingness to participate in 
living-related kidney transplantation, and gave adequate verbal and written 
informed consent, we transplanted a kidney from the father with membranous 
nephropathy into his son. Immunosuppression in the recipient was induced 
and maintained with a CsA-based regimen, and the postoperative course was 
good in both the recipient and the donor without rejection or infection. At 50 
months after transplantation, the serum creatine level was 1.7 mg/dl in the 
recipient and 1.4 mg/dl in the donor. Their renal functions were stable, and 
no proteinuria was evident in the recipient, but minimal proteinuria was still 
detected in the donor. The recipient underwent allograft needle biopsy at 38 
months after transplantation, and the specimen showed mild spike formation 
with partial thickening of the glomerular basement membrane (GBM) after 
staining with periodic acid-silver methenamine (PAM). Mild membranous 
glomerulonephritis was therefore diagnosed. There was no evidence of 
acute rejection, and extracapillary proliferative glomerulonephritic change 
and tubulointestinal injury, characteristic of chronic allograft change, were 
observed. Electro microscopy showed decreases of electron-dense deposits 
and electron-lucent washout lesions with thickening of the GBM. This was 
diagnosed as Stage IV membranous nephropathy, resulting from clearance of 
the immune complexes and histological repair of the GBM.
Conclusion: We have reported a favorable outcome of kidney transplantation 
from a donor with membranous nephropathy. Careful observation of the natural 
course of membranous nephropathy shows that some cases enter remission. 
For the present donor, donation of the graft did not affect his residual renal 
function. Pre-existing membranous nephropathy itself might show remission 
after transplantation and immunosuppression in the recipient. It is diffi cult to 
discriminate patients with membranous nephropathy who would be likely to 
enter remission. The present attempt to extend the donor criteria for this family 
represents an alternative choice for living-related kidney transplantation. 
Although the outcome was suffi ciently successful, careful long-term observation 
of both the donor and recipient will be required. It is suggested that marginally 
appropriate donors can be considered in order to extend the donor criteria for 
kidney transplantation.
POSTER BOARD NUMBER P3 – 166
THE APPLICATIONS OF ETHICS FOR LIVING DONOR 1740 
KIDNEY TRANSPLANTQATION
X. Meng1, J. Liu2, L. He3, L. Cao4
1Transplantation Center, The Second Affi liated Hospital, Chinese PLA 
General Hosp, 2Transplantation Center, The Second Affi liated Hospital, 
Chinese PLA General Hosp, 3Transplantation Center, The Second Affi liated 
Hospital, Chinese PLA General Hosp, 4Transplantation Center, The Second 
Affi liated Hospital, Chinese PLA General Hosp
Objective: To investigate <Provisional Administrative Regulation of Human 
Organ Transplanting Technology in the Clinical Application> with its applied 
procedure, method and signifi cance of the ethics about the liver transplantation 
in the relative living organism.
Method: Have a summary and analysis on the 6 examples of liver 
transplantation in the relative living organism carried out in our hospital 
according to <Provisional Administrative Regulation of Human Organ 
Transplanting Technology in the Clinical Application> and have an analysis 
and investigation on the receptor¡¯ reveovery and donor¡¯ physiological and 
psychological recovery after transplantation.
Result: There were no complications happening during the surgery. 5 donors 
were satisfi ed with their decisions according to the visiting a month later. Only 
one donor had a psychological pressure because of the receptor¡¯ delayed renal 
graft function. Other 5 receptor¡¯s renal function recovered as normal within 
3-5 days, in which one receptor had acute rejection at 9th day after the surgery 
and reversed by methylprednisolone pulse therapy.
Conclusion: The applications of ethics in the <Provisional Administrative 
Regulation of Human Organ Transplanting Technology in the Clinical 
Application> can as far as possible ensure the donor have safety and no 
psychological pressure, which is necessary and important in the liver 
transplantation.
POSTER BOARD NUMBER P3 – 167
EVALUATION OF RENAL FUNCTION IN KIDNEY 1741 
TRANSPLANT DONORS AFTER DONATION
T. Matuck, D. Carvalho, P. Gomes, E. Ribamar, A. Borela, F. Alvarenga
Hospital Geral De Bonsucesso
Introduction: Kidney transplant is the treatment of choice of chronic kidney 
failure, as all the native kidney functions are recovered. The risk of surgical 
complications is between 0.3 and 1%, with a per-operatory mortality around 
0.03%. Proteinuria after kidney donation appears in about 3% of subjects and, 
in some cases, severe chronic renal disease can supervene. Recent data show 
the occurrence of clinical complications as hypertension, hematuria, proteinuria 
and renal dysfunction in up to 54% of donors with long-term follow-up. The 
presence of renal dysfunction can reach 7%.
Objective: To evaluate the presence of chronic renal dysfunction (CRD) after 
kidney donation, according to DOQI/NKF criteria.
Methods: Retrospective analysis from 121 kidney transplant donors, between 
1 and 132 months after donation, with a median of 12 months. We analyzed 
weight, body mass index (BMI), blood pressure, BUN, creatinine, uric acid, 
albumin, sodium, potassium, glomerular fi ltration rate (GFR) and proteinuria, 
before and after donation. The methods used were media ± standard deviation 
or median (maximum and minimum values) and the comparative statistics tests 
were Mann-Whitney or Kruskal-Walis, according to the convenience. p values 
< 0.05 were considered statistically signifi cant.
Results: The results are listed on tables 1 and 2
Conclusions: Women were involved in 2/3 of kidney donations. After donation 
statistically signifi cant increase in SBP, BUN, creatinine, uric acid, as well as 
decreased creatinine clearance were observed. Considering GFR<60ml/min or 
proteinuria>300mg/24h, in this study, around 22% of donors presented CRD 
according to DOQI/NKF criteria, showing that the prevalence of CRD in kidney 
donors in long-term follow-up is more frequent than in general population. As 
the median follow-up time was 12 months, we intend to continue the evaluation 
in a longer period in order to have more consistent conclusions.
Table 1: Demographic, clinical and laboratorial data from 121 kidney donors 
before and after donation:
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Before donation After donation p value
Age (years) 41±10.1 - -
Sex: Male/Female 39.7% / 60.3% - -
Race W:70% / NW:30% - -
Weight (kg) 66 (114-43.7) 67.1 (104-42.2) p=0.489 (NS)
BMI (kg/m²) 24.2 (38.5-17.2) 24.8 (36.3-16.5) p=0.6057 (NS)
SBP (mmHg) 110 (160-90) 120 (170-80) p=0.0338
DBP (mmHg) 70 (90-50) 70 (110-50) p=0.842 (NS)
MBP (mmHg) 86.7 (113.3-63.3) 86.7 (126-60) p=0.319 (NS)
BUN (mg%) 25 (45-11) 30.4 (59-5) p=0.00
Creatinine (mg%) 0.9 (1.2-0.4) 1.1 (2.2-0.7) p=0.00
Uric acid (mg%) 4.6 (9.7-2) 5.1 (9.1-2.3) p=0.00798
Albumin (g%) 4.3 (5.2-2.9) 4.4 (4.9-3.2) p=0.931 (NS)
Potassium (mEq/l) 4.1 (4.8-2.8) 4.2 (5.5-27) p=0.0711 (NS)
Sodium (mEq/l) 139 (146-131) 139 (150-130) p=0.536 (NS)
GFR (ml/min) 102.1 ± 30.4 80.2 ±31.1 p<0.0001
GFR (ml/min – CG) 113.7 (237.2-64.2) 88 (217.8-41.6) p=0.00
Proteinuria(mg/24h) 102 (233-8) 102.5 (7334-10) p=0.600 (NS)
*W = white / NW = non-white; SBP = systolic blood pressure; DPP = diastolic blood pressure; 
MBP = mean blood pressure; GFR = glomerular fi ltration rate; CG = Cockroft-Gault; NS = not 
signifi cant
Table 2: Evaluation of renal function before and after donation:
Before donation After donation
GFR < 60ml/min 0 19 (15.7%)
Proteinuria: 150-300mg/24h 3(2.4%) 17 (14%)
Proteinuria > 300m/24h 0 8 (6.6%)
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NEPHRECTOMY ELICITS IMPACT OF AGE AND BMI 1742 
ON RENAL HEMODYNAMICS: LOWER POST-DONATION 
RESERVE CAPACITY IN OLDER OR OVERWEIGHT KIDNEY 
DONORS
M. Rook1, R.J. Bosma1, H.S. Hofker2, J.J. Homan van der Heide1, R.J. Ploeg2, 
P.M. ter Wee3, W.J. van Son1, G.J. Navis1
Departments of 1Nephrology and 2Surgery, University Medical Center 
Groningen, the Netherlands and 3Department of Nephrology, VUMC 
Amsterdam, the Netherlands
Renal functional reserve could be relevant for maintenance of renal function 
after kidney donation. Older age and higher body mass index (BMI) may be 
associated with reduced reserve capacity (RC). We therefore investigated RC 
in 178 consecutive living kidney donors (period 1984-2005; 39% male, age 
48±11 years, BMI 25.5±4.1). RC was determined as the rise in glomerular 
fi ltration rate (GFR; 125I-iothalamate) after constant infusion of low-dose 
dopamine, 4 months before and 2 months after donor nephrectomy.
Before donor nephrectomy, GFR was 114±20 mL/min, with a reduction to 
72±12 mL/min after donor nephrectomy. The dopamine-induced rise in GFR 
of 11±10% was reduced to 5±7% after donor nephrectomy (p<0.001). Before 
donor nephrectomy, older age and higher BMI did not affect reserve capacity. 
After donor nephrectomy, the response of GFR to dopamine independently and 
negatively correlated with older age and higher BMI.
Figure 1 shows RC before and after donation according to normal weight, 
overweight or obesity (left panel) and according to tertiles of donor age (right 
panel). # ANOVA p<0.05. Post-donation reserve capacity was absent in obese 
donors. Presence of overweight had more impact on loss of RC in younger 
donors.
In conclusion, donor nephrectomy unmasked an age- and overweight-induced 
loss of reserve capacity. Possibly, donors with advanced age and/or overweight 
address their renal reserve to maintain renal function.
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LONG TERM SURVIVAL OF 932 LIVING DONORS1743 
R. Espinoza, C. Gracida, J. Cancino, A. Ibarra, U. Cedillo
Transplant Unit, Hospital de Especialidades CMN Siglo XXI. México City, 
D.F. México
The fi rst successful renal transplant in the world was from a live donor. In 
México, also the fi rst renal transplant was from living donors. During the last 
few years, in the entire world, increasing importance has been given to the live 
donor, widening the criteria for donor selection.The reasons are well known by 
all of you: Scarcity of viable organs for transplant, and long waiting lists, Better 
graft survival rate at both short, and long term, Earlier renal function, Donor 
nephrectomy by laparoscopy, donor emotional satisfaction.
The objective of the present study is to describe our experience in a single 
transplant center in 14 years of follow up of living kidney donors with open 
nephrectomy for renal transplant, including donors with risk factors for 
donation.
Materials and methods: From january 1992 through december 2005 in our 
transplant center, were carried 932 living donor transplant. All nephrectomies 
were open.
We consider high risk patients for donation, donors older than 60, body mass 
index more than 30 kg/m2, hypercholesterolemia, hyperuricemia, hypertension 
of easy control with diet or just one drug. At the time of donation, were 
registered, age, gender, glomerular fi ltration rate (GFR), serum creatinine, 
uric acid, creatinine clearance, mean arterial pressure, number of arteries and 
anatomical variations.
morbidity, and mortality rates at the short and long term follow-up study. 
Average, mean, and standard deviation, were used.
Results: Mean follow up was of 50.9 ± 39.9 months. The groups of donors 
that had changes in their studies of renal function, such as serum creatinine, 
creatinine clearance, and glomerular fi ltration rate, were the hypertensive 
donors and those over 60 years of age. (table 1).
Table 1. Follow-up of living donors 50.9±37.9 months (N=782)
Conclusions: In our transplant unit, renal donation from living donor is safe, 
without death or morbidity increase.. Age over 60 years and arterial hypertension 
signifi cantly decrease glomerular fi ltration at the end of the follow-up. Increase 
of weight, obesity, diabetes mellitus and metabolic syndrome are frecuent after 
donation, but are comparable to the non-donor population.
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A COMPREHENSIVE PROGRAME OF CARE FOR 1744 
LIVE KIDNEY DONORS – EXPERIENCE AND PLANS 
IN ONE CENTRE
P. Domagala1, M. Bieniasz1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1, 
M. Wszo³a1, A. Chmura1
1Medical University of Warsaw, Department of General Surgery And 
Transplantology, 2Medical University of Warsaw, Department of 
Transplantology And Nephrology
Results of renal transplanatation from living donors, both related and unrelated, 
are superior to renal cadaveric transplantation. Donorship carries a risk 
associated with surgery and further life with one kidney, thus renal transplantion 
from live donors may only be performed if the donor risk is low and probability 
of a successful transplant high.
The aim of the paper is to present our own experience in introducing a 
pioneering complex program of live donor care in Poland.
Patients and method: Beginning in 2006, the Polish Ministry of Health has 
obligated transplantation centres performing live donor renal transplants to 
carry out periodical medical assessments and to report the results to a newly-
created Live Donor Registry. Between 1996 and 2007 our transplantation 
team performed ninety-one live donor nephrectomies. Beginning in 2005 we 
introduced a system of control assessments of the donors (group A). Medical 
examinations are carried out at 1, 3, 6 and 12 months following surgery and 
every 12 months thereafter. Beginning at the end of 2007, medical assessments 
of donors nephrectomized priot to 2005 were commenced (group B).
Results: Majority of group A donors responded to invitations for control 
assessments. A one-day hospitalization included medical history, physical 
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examination, abdominal US, chest X-ray, peripheral blood count, C-reactive 
protein, urine microscopy and culture and functional tests of the remaining 
kidney. Most group B donors had not been followed up before the 
commencement of the program. The fi rst program visit, a 2-3 day hospital 
stay consisted of various tests and consultations, including blood and 
urine tests, abdominal US, chest X-ray, ABPM (ambulatory blood pressure 
monitoring), renal isotope scan, ECG, ophtalmological and nephrology 
consultation. Donors in both groups had signifi cantly raised serum creatinine 
and creatinine clearance decreased by 25-35mlkg/1,73m2. About 30% of 
group B donors had previously undiagnosed hypertension and appropriate 
treatment was implemented. 15% of donors presented abnormal body weight 
or obesity, as well as disturbances in lipid profi les. Both groups of donors 
were subjected to quality of life and pro-health behavioral assessment 
of by standard questionnaires, in cooperation with a clinical psychology 
specialist.
Conclusions: Live kidney donors should be subject to obligatory long-term 
follow-up. A comprehensive system of care for live kidney donors with regular 
multidisciplinary health check-ups and, if necessary, appropriate treatment 
provides the donors with a feeling of safety and is aimed at decreasing the 
number of long-term complications of donorship. The main goal of the follow-
up team is to ensure satisfactory quality of life and health for live donors in 
the long-term.
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ASSESSMENT OF RESIDUAL KIDNEY FUNCTION 1745 
AFTER LIVING DONOR NEPHRECTOMY
M. Bieniasz1, P. Domagala1, A. Kwiatkowski1, J. Gozdowska2, K. Ostrowski1, 
M. Wszola1, J. Trzebicki3, M. Durlik2, W. Rowinski1, A. Chmura1
1Medical University of Warsaw, Department of General Surgery 
And Transplantology, 2Medical University of Warsaw, Department 
of Transplantology And Nephrology, 3Medical University of Warsaw, 
Department of Anaesthesiology And Intensive Care
Background: The number of patients on the waiting list for kidney 
transplantation is increasing as a result of cadaveric donor shortage. One of the 
ways to expand the donor pool is living donor transplantation. However, only 
2% of kidney transplants in Poland come from living related donors.
The aim of this study was to assess residual renal function, incidence of 
hypertension and proteinuria in living kidney donors.
Patients and methods: Between 2004 and 2007, 46 living donor open 
nephrectomies were performed. Physical examination, blood and urine tests 
and ultrasonography were performed prior to nephrectomy and at every follow-
up visit (1, 3, 12 and 24 months post-op). All donors underwent psychological 
assessment before donation. Donor mean age was 39 years (range 25 – 57). 
The donors were predominantly female (61%). Mean hospitalization time was 
8 days (range 4 – 22 days). Nine donors did not report for follow-up visits. 
Observation period ranged from 1 to 24 months.
Results: Mean creatinine concentration, mean creatinine clearance according 
to Cockroft-Gault formula and mean creatinine clearance according to 
abbreviated modifi cation of diet in renal disease equation (aMDRD) changes 
are presented. No cases of proteinuria were observed. Hypertension occurred 
in one donor (2.7%).
Before 3 months 12 months 24 months P
Creatinine concentration 
(mg/dl) 0.83 1.16 1.13 1.15 < 0.05
Creatinine clearance according 
to Cockroft-Gault formula 110 82 88 76 < 0.05
Creatinine clearance according 
to aMDRD formula 95 64 67 65 < 0.05
Conclusion: Living kidney donation results in a reduced creatinine clearance 
in the donor. Follow-up of living kidney donors is essential in determining risk 
factors for deterioration of residual kidney function.
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QUALITY OF LIFE OF OLDER LIVING KIDNEY DONORS1746 
I.J.M. ten Berge1, R.C. Minnee2, W.A. Bemelman2, P.J. van Koperen2, 
S.W. Polle2, S. Maartense2, K.A.M.I. van Donselaar1, F.J. Bemelman1, 
M.M. Idu2
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of 
Surgery, Academic Medical Centre, Amsterdam
Introduction: Increasing organ shortage forced transplant centers to be 
inventive in discovering new sources. They increasingly pursue living 
donor transplants and utilize marginal donors. Older living donors remains 
controversial because of decline in glomerular fi ltration rate and increased 
risks of surgical complications. In addition, little is known about quality of life 
(QoL) of older living kidney donors. The purpose of this study is to examine 
the QoL in older living donors.
Patients and methods: All consecutive donors between June 2002 and 
February 2006 were prospectively included in the study. Older donors were 
defi ned as fi fty-fi ve years or older. Results: Older donors had a signifi cant 
lower postoperative pain at rest at day 1 compared to the younger group 
(p=0.019). At other time periods no statistical signifi cant differences were 
found in postoperative pain between the two groups. Although small 
differences in Short Form 36 Health Survey (SF-36), Gastro-Intestinal 
Quality of Life Index (GIQLI) and Multidimensional Fatigue Inventory-20 
(MFI-20) between both groups were detected, in general quality of life of 
older donors was not different than of younger donors. After six months all 
items in different domains were on the same level as preoperative. In addition, 
there were no signifi cant differences in length of hospital stay, intraoperative 
and postoperative complication rate and one year graft survival rate between 
both groups.
Conclusion: Donor nephrectomy does not have an additional impact of 
quality of life of older donors compared to younger donors. Therefore we have 
to be less restraint to older donors and we can include more older donors in 
screening programmes and ultimately perform more donor nephrectomies in 
older donors.
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CROSS-SECTIONAL STUDY OF LIVING KIDNEY 1747 
DONORS FROM 1964 TO 2005
I. Fehrman-Ekholm
Transplantation Institute
Background: The number of living donors is increasing worldwide. The 
necessity of follow-up is still a debate. In this study we have gathered data from 
living donors, half of them have never been followed up after donation.
Methods: 1112 kidney donors underwent nephrectomy at Sahlgrenska 
University Hospital from 1965 to the end of 2005. All donors in Sweden were 
localized and evaluated for kidney function, blood pressure, microalbuminuria 
and parathormone (PTH) levels.
Results: Age at donation was 19-75 years, mean 47 (11). Age at investigation 
time was 61.5 (13) years. 59% were females. Of 848 still alive and living in 
Sweden we had follow-up data from 470 by the end of December 2007. Mean 
plasma creatinine was 94 (25), median 90 with range 48-330 μmol/L. Two 
donors had received a transplant, one because of nephrosclerosis and one 
because of renal tumour in the remnant kidney. Mean estimated GFR was 65 ml/
min using Levey form and 72 ml/min according to cystatin C determinations. 
20. 5% had microalbuminuira. Mean PTH levels was 5.2 (2.5) pmol/L which 
was normal. 29% had hypertension.
Conclusions: Living donors have on the average very good renal function 
with GFR 65 ml/min and only 20% microalbuminuria. Thus, all donors do not 
develop hyper fi ltration damages. The preservation of renal function seems 
very satisfactory even in “uncontrolled” cases. A few donors had developed 
ESRD but not in increased rate compared to aged matched background 
population. Living donor nephrectomy seems a safe procedure when studying 
long-term data.
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COMPLICATIONS OF 103 LIVING DONOR 1748 
NEPHRECTOMIES
R. Bernal-Maldonado, B. Aguilar-Álvarez, B. Aguilar-Álvarez, 
M. Aragón-Castro, S.R. Mondragón
From the Division of Surgery and the Transplant Unit, Centro Medico 
ISSEMYM, Metepec, State of Mexico
Introduction: Transplantation yields the best results of all renal replacement 
therapies in therms of patient and graft survival. The livings donor transplantation 
it’s the main method in many countries because of worsening patient outcomes 
due to accumulation of aged patients with long periods dialysis or hemodialysis 
and the impossibility of increased the cadaveric donors.
Aim: To analyze retrospectively the general health status and renal consequences 
of living donation, as the long-term effects of unilateral nephrectomy.
Patients and methods: A retrospective study of the hospital charts of 103 
living donors patients was performed in order to analyze complications and 
their management. The information of blood group, serological tests, blood 
tests for hematology and biochemistry, coagulation profi le, urine reports, 
nephrectomy site, duration of anesthesia, intra-operative, early and long-term 
post-nephrectomy complications, comorbid conditions, and the function on the 
kidney remain were analyze.
Results: It was noted that males donated more kidneys to their relatives (p 
< 0.05) and females had a higher prevalence of anemia (p < 0.01). The site 
of nephrectomy was similar between men and women with prevalence of 
left nephrectomy. Complications were signifi cantly greater in male donors 
(p < 0.05). Hemorrhage occurred more commonly in association with right 
nephrectomy (p < 0.05), while wound infection occurred more commonly in 
men (p < 0.05). the mean stance of the patient in the hospital were 4 days. There 
were no deaths related to this procedure.
Conclusions: Our results suggest that living donor nephrectomy is safe 
procedure because had minimal adverse effects on overall health status, we 
not found mortality related to the procedure, and a regular donor follow-up 
identifi es at-risk populations and potentially modifi able factors.
RENAL PATHOLOGYCONCURRENT ORAL SESSION 126: 
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PROGRESSION OF RENAL ALLOGRAFT HISTOLOGY 1749 
AFTER RENAL TRANSPLANTATION IN RECURRENT AND 
NON-RECURRENT IGA NEPHROPATHY
H.J. Jeong1, Y.M. Cho2, M.S. Kim3, Y.S. Kim3, S.I. Kim3, B.J. Lim4
1Yonsei University College of Medicine Department of Pathology, 2Ulsan 
University College of Medicine Department of Pathology, 3Yonsei University 
College of Medicine Department of Surgery, 4Yonsei University College of 
Medicine Department of Surgery, 5Yonsei University College of Medicine 
Department of Surgery, 6Choongnam University College of Medicine 
Department of Pathology
Little information is available regarding renal histology in cases of chronic 
allograft dysfunction and graft failure in patients with recurrent IgA nephropathy 
(IgAN). We compared 55 renal allograft biopsies of 44 patients with recurrent 
IgAN to 45 biopsies of 33 patients without IgAN recurrence. Clinical parameters 
like patient demography and biopsy indications did not differ between the two 
groups, with the exception of time to biopsy. Renal allograft injury, which was 
assessed by semi-quantitative scoring of glomerular, tubulointerstitial, and 
arteriolar changes, increased linearly over time after transplantation in both 
recurrent and non-recurrent samples. Glomerular injuries were signifi cantly 
correlated with tubulointerstitial injuries in both groups, but the correlation 
graph refl ected an increasing gap in the degrees of tubulointerstitial injury 
between the two groups over time. The levels of glomerulosclerosis, mesangial 
proliferation, and crescent formation were signifi cantly higher in recurrent 
samples, while the prevalence of chronic rejection was signifi cantly higher 
in non-recurrent samples. The presence of segmental sclerosis was associated 
with signifi cant proteinuria in recurrent samples. Graft survival was better in 
recurrent IgAN patients than in non-recurrent patients (74.4% versus 51%) at 
10 years post-transplantation. In conclusion, slow and progressive glomerular 
injury is the major cause of long-term graft failure in patients with recurrent 
IgAN. In contrast, rapidly increasing tubulointerstitial injury is responsible for 
graft failure in non-recurrent patients.
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BCL-2 PROTECTS TUBULAR EPITHELIAL CELLS 1750 
FROM ISCHEMIA REPERFUSION INJURY VIA DUAL 
MECHANISMS
T. Abe1, C. Suzuki1, Y. Isaka1, M. Okumi1, N. Ichimaru1, R. Imamura1, 
E. Imai1, H. Rakugi1, S. Shimizu2, S. Takahara1
1Osaka Universitu Graduate School of Medicine, 2Tokyo Medical and Dental 
University
Ischemia/reperfusion (I/R) injury, which induces extensive loss of tubular 
epithelial cells, is associated with delayed graft dysfunction in kidney 
transplantation. Recent reports suggested that cell death by I/R injury occurs 
by autophagy, a cellular degradation process responsible for the turnover of 
unnecessary or dysfunctional organelles and cytoplasmic proteins, as well as 
apoptosis. Accordingly we hypothesized that anti-apoptotic factor, Bcl-2 protein 
augmentation may protect tubular epithelial cells by inhibiting apoptosis as 
well as by promoting autophagy.
First, we used Bcl-2 transgenic mice (Bcl-2 TG), and their wild type litter mate 
(WT). To investigate the effect of I/R injury, the left renal artery and vein were 
clumped for 45 min, followed by reperfusion for 24hr, 48hr, 96hr. Bcl-2 TG 
showed the decreased active caspase protein in tubular cells, and thereby resulted 
in the reduction of TUNEL-positive apoptotic cells. Consequently, interstitial 
fi brosis and phenotypic changes were ameliorated in Bcl-2 TG mice. Next, we 
employed a transgenic mice model (LC3-GFP TG) in which autophagosomes 
are labeled with LC3-GFP and Bcl-2/LC3-GFP double transgenic mice (Bcl-2/
LC3-GFP TG) to examine the effect of Bcl-2 on I/R-induced autophagy. Under 
ischemic injury, Bcl-2 augmentation promoted the formation of LC3-GFP dots 
which represented autophagosomes were extensively induced. Of interest is 
that LC3-GFP dots included the texas-red-labeled mitochondria. Furthermore, 
we observed autophagy-related tubular epithelial cell death in LC3-GFP TG, 
but not in Bcl-2/LC3-GFP TG.
In conclusion, Bcl-2 augmentation protected renal tubular epithelial cells from 
I/R injury by promoting autophagosomal degradation of injured mitochondria 
as well as inhibiting tubular apoptosis.
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INFLAMMATORY MICROENVIRONMENT RESCUES 1751 
B-CELLS OF TERTIARY LYMPHOID ORGANS FROM ANTI-
CD20 THERAPY DURING CHRONIC ANTIBODY-MEDIATED 
REJECTION
O. Thaunat1, N. Patey2, C. Gautreau3, A. Nicoletti4
1Service De Transplantation Et D’Immunologie Clinique, Hopital Edouard 
Herriot, 2Service d’Anatomopathologie, Hopital Necker, Paris, France, 
3Laboratoire d’Immunologie, Hopital Saint-Louis, Paris, France, 4Centre de 
Recherche des Cordeliers, INSERM U872, Paris, France
Background: Rituximab is emerging as a potent therapeutic option in chronic 
infl ammatory diseases associated with a prominent humoral component.
Recent studies have demonstrated that chronic infl ammatory infi ltrate organize 
progressively themselves into ectopic lymphoid tissues (tertiary lymphoid 
organs; TLOs) supporting a local humoral immune response.
In the present study we evaluated the impact of rituximab therapy on TLOs 
associated with chronic active antibody-mediated rejection (CAAMR), a 
prototypic humoral chronic infl ammatory condition.
Methods: Renal allografts removed for terminal chronic rejection were 
prospectively collected in 4 transplantation centers over 4 years. Among 38 
grafts collected, 2 were explanted after rituximab therapy for CAAMR. Clinical 
characteristics and circulating B cell count were recorded for these two patients. 
The composition and the microarchitecture of the infl ammatory infi ltrate were 
analyzed by fl ow cytometry and immunohistochemistry. Organotypic cultures 
were performed to evaluate the intragraft production of alloantibody. Levels of 
expression of BAFF (Blys, CD257) were evaluated by quantitative RT-PCR.
Results: Despite the complete depletion of circulating B cells in peripheral 
blood, TLOs were evidenced in the interstitium of both explanted grafts. Their 
functionality was assessed by the demonstration of a persistent local production 
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of alloantibody.
BAFF, a potent survival factor for B cells, was found to be overexpressed (both 
at the gene and the protein levels) in chronically rejected grafts as compared 
with normal kidneys and lymph nodes.
Conclusions: In certain patients, infl ammatory microenvironment provides 
BAFF-dependent paracrine survival signal to B-cells in TLOs, allowing them to 
escape rituximab-induced apoptosis, thereby thwarting therapeutic effi ciency.
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DOES LONG GRAFT COLD ISCHEMIA TIME 1752 
INFLUENCE ARTERIAL STIFFNESS IN RENAL TRANSPLANT 
RECIPIENTS?
A. Adamowicz1, P. Stró¿ecki2, M. Koz³owski2, Z. W³odarczyk1, J. Manitius2
1Dept of Transplantation and Surgery, Collegium Medicum UMK, 2Dept of 
Nephrology, Hypertension and Internal Diseases, Collegium Medicum UMK
Introduction: Graft cold ischemia time (CIT) signifi cantly infl uences the 
outcome of renal transplant. It was also found in experimental model that 
increased CIT promotes aortic graft arteriosclerosis. Increased pulse wave 
velocity (PWV) – a marker of arterial stiffness – is associated with increased 
cardiovascular risk in renal transplant recipients (RTR). PWV depends on 
reciepints related factors (age, blood pressure, graft function) as well as donor 
related factor (donor age). The aim of the study was to evaluate whether 
relationship exist between CIT and PWV in RTR.
Patients and Methods: Carotid – femoral PWV was measured with Complior 
device in 103 cadaveric RTR (F=37, M=66), aged 45 ± 12 years. Graft CIT was 
taken from patients’ charts. Clinical data: recipient and donor age, sex, body 
mass index (BMI), systolic and diastolic blood pressure (SBP, DBP), delayed 
graft function (DGF) and immunosupressive therapy were also analysed. GFR 
was estimated using MDRD equation (eGFR). Patients were devided into 2 
groups: with CIT < 24 hours and (n=24) and with CIT ≥ 24 hours (n=79). 
Results are presented as mean ± SD.
CIT < 24 h CIT ≥ 24 h P
CIT (hours) 19,9 ± 3,3 29,3 ± 3,9 < 0,001
PWV 8,3 ± 1,6 9,2 ± 2,0 < 0,05
RTR age 42 ± 13 46 ± 12 NS
Donor age 39 ± 15 45 ± 14 NS
RTR sex (male) 58% 66% NS
BMI (kg/m2) 25,8 ± 3,8 25,3 ± 4,1 NS
SBP (mmHg) 135 ± 16 138 ± 18 NS
DBP (mmHg) 83 ± 10 85 ± 11 NS
eGFR (ml/min/1,73m2) 56,8 ± 19,7 51,5 ± 14,7 NS
DGF (%) 67% 67% NS
In all patients signifi cant positive correlation was found between PWV and: 
recipient age (r=0,49;p<0,001), SBP (r=0,38;p<0,001) and fasting blood 
glucose (r=0,32;p<0,01) and CIT (r=0,23; p<0,05) but not with eGFR, DBP, 
BMI and donor age. No signifi cant differences were found in prevalence of 
cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, azathioprine and 
prednisone therapy between study groups.
Conclusions: Long cold ischemia time is associated with increased arterial 
stiffness in renal transplant recipients. Further studies are necessary to confi rm 
it and to understand the cause-effect relationship of this fi nding.
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DONOR KIDNEY HISTOLOGICAL CHANGES AS RISK 1753 
FACTORS FOR DELAYED AND SLOW KIDNEY ALLOGRAFT 
(KAG) FUNCTION
A. Trailin, T. Nikonenko, A. Nikonenko, T.I. Ostapenko, N.N. Polyakov
Zaporizhzhya Medical Academy of Postgraduate Education, Interregional 
transplantation center
Purpose: Delayed graft function (DGF) or need for dialysis within the fi rst 
week post-transplant has adverse consequences on KAG subsequent short- 
and long-term survival. Slow graft function (SGF) or low temp of creatinine 
declining, also has negative after-effects. The aim of our current study was to 
determine morphological predictors for DGF and SGF.
Methods: Morphological predictors of DGF and SGF were investigated in 75 
recipients of cadaveric kidneys transplanted in our centre during 2005-2007. 
Paraffi n sections of pre- and post-implantation kidney biopsies were stained 
with H&E, Masson’s trichrome, PAS, and silver stain. Cellularity (0/1), increase 
of mesangial matrix (0-4), basement membrane thickening (0-4), percentages 
of glomeruli with global sclerosis or segmental sclerosis were scored in 
glomeruli. Severity of tubular atrophy, ischemic damage up to necrosis was 
quantifi ed in cortical tubules (0-4). Interstitial fi brosis in cortex and medulla 
was scored (0-4). The thickening of the wall in arteries and arterioles, refl ecting 
arteriosclerosis/arteriolohyalinosis, was estimated (0-4). DGF was defi ned as 
the requirement for dialysis within the fi rst week post-transplant. Criterion for 
SGF was serum creatinine level on the 3d day &#8805; 600 μmol/l and/or 
&#8805; 300 μmol/l on the 7th day post-transplant. Patients with acute KAG 
rejection in SGF group were considered as having an immediate graft function 
(IGF). 
Results: IGF occurred in 55 patients, SGF – in 20 patients (26,7%). Only 
patients from SGF group (N=13) were dialyzed, and 7 patients had SGF 
without need for dialysis. Hence, the frequency of DGF was 17,3%. Degree 
of interstitial fi brosis, arteriosclerosis and percentages of glomeruli with global 
sclerosis in SGF group, and the basement membrane thickening, cellularity of 
glomeruli, degree of arteriolohyalinosis in DGF group were signifi cantly higher 
than in IGF patients. The only signifi cant difference between SGF and DGF 
groups was the degree of arteriosclerosis: 2,8±1,3 vs. 1,0±0,9, respectively. 
Univariate binary logistic regression followed by multivariate analysis did 
not uncover independent predictors for DGF. Cellularity of glomeruli was 
established as an independent predictor for SGF (OR=2,47, ð=0,01). Then we 
examined histological predictors for SGF without requirement for dialysis. 
Only arteriosclerosis was uncovered as an independent predictor (OR=2,80, 
ð=0,025). 
Conclusion: Morphological predictors of DGF were not found, in contrast 
with SGF. Histological changes in SGF kidney match those in DGF kidney. It 
is part of the reason why patients with SGF are almost at the same risk of post-
transplant complications, as patients with DGF. Urgent examination of donor 
biopsies is essential for assessment of impaired initial KAG function risk and 
applying approaches for its minimizing.
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THE PATHOLOGICAL SIGNIFICANCE OF MEDULLARY 1754 
RAY INJURY (MRI) IN RENAL ALLOGRAFTS
A. Kobayashi1, I. Yamamoto1, Y. Kanetsuna1, S. Ito2, Y. Akioka3, S. Teraoka4, 
M. Hattori3, K. Tanabe5, Y. Yamaguchi1
1Jikei University, Kashiwa Hospital, Department of Pathology, 2Gifu 
University, Department of Urology, 3Tokyo Women’s Medical University, 
Department of Pediatric Nephrology, 4Tokyo Women’s Medical University, 
Department of Surgery, 5Tokyo Women’s Medical University, Department of 
Urology
One of the focuses of the 8th Banff Conference was the defi nition of chronic 
alloimmune injury/rejection, and the term ¦ echronic allograft nephropathy¦ f 
replaced the term ¦ einterstitial fi brosis and tubular atrophy without any 
specifi c etiology (IF/TA)¦ f. IF/TA has various etiologies (e.g., calcineurin 
inhibitor (CNI) toxicity, obstructive uropathy, and pyelonephritis). However 
ways to detect these etiologies are still under consideration. Medullary ray 
injury (MRI) is one candidate for the early pathological determination of 
CNI toxicity because MRI is reported to be related to arteriolar hyaline 
changes and vasospasticity preceding the striped form of interstitial 
fi brosis and tubular atrophy in an experimental model (Transplantation 
1990;49:445-452). In this study, we investigated the signifi cance of MRI 
to determine the contribution of CNI toxicity to MRI or other etiologies in 
renal allografts.
Methods: This study investigated 70 biopsies from renal allografts performed 
at Tokyo Women¦ fs Medical University and Gifu University between March 
2000 and February 2008 that showed evidence of MRI. The basic regimen 
of immunosuppressants included a CNI (tacrolimus or cyclosporine), 
mycophenolate mofetil, and prednisolone. We defi ned MRI as evidence of 
fi brosis and infl ammation that was localized exclusively to the medullary 
ray. Pathological changes of MRI with evidence of ¦ earteriolar hyaline 
nodules and/or isometric vacuolization of tubular cells¦ f, ¦ eInterstitial 
Tamm-Horsfall protein deposits and/or thyroidization¦ f, and ¦ eintratubular 
and peritubular infi ltration of predominant neutrophils¦ f were considered to 
indicate MRI related to CNI toxicity, obstructive uropathy, and pyelonephritis, 
respectively.
Results: Overall (n=70), the etiology of MRI was CNI toxicity (23 cases, 
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32.8%), obstructive uropathy (35 cases, 50%), pyelonephritis (6 cases, 8.6%), 
and others (6 cases, 8.6%). We performed voiding cystography in fi ve cases 
of MRI related to obstructive uropathy and four of the fi ve (80%) cases had 
vesicoureteral refl ux (VUR) clinically.
Conclusion: As we demonstrated here, MRI has various etiologies and is 
not specifi c to CNI toxicity. Since half of the MRI was related to obstructive 
uropathy and 80% (4/5) showed clinical VUR, MRI might predict the early 
changes of obstructive uropathy.
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UNTREATED SUBCLINICAL, BORDERLINE REJECTION 1755 
IN 12 AND 36-MONTH PROTOCOL BIOPSIES IS NOT 
ASSOCIATED WITH PROGRESSIVE LOSS OF GFR AT 
5-YEAR’S FOLLOW-UP
T. Baczkowska1, A. Perkowska-Ptasiñska1, T. Cieciura1, J. Pazik1, 
E. Nowacka-Cieciura1, Z. Lewandowski2, J. Szmidt3, A. Chmura4, M. Durlik1
1Warsaw Medical University, Dept. of Transplantation Medicine and 
Nephrology, 2Warsaw Medical University, Dept. of Epidemiology, 3Warsaw 
Medical University, Dept. of General, Vascular and Transplant Surgery, 
4Warsaw Medical University, Dept. of General and Transplantation Surgery
Introduction: Calcineurin inhibitor nephrotoxicity and clinical acute rejection 
are well-known predictors of chronic allograft dysfunction. Unclear is the 
impact of late, subclinical, borderline rejection (SCR-B) in protocol biopsies 
on graft function and survival.
Aim of the study: assessment on whether the untreatment of late SCR-B in 12 
and 36-month protocol biopsies has a deleterious effect on renal function at 60 
months after Tx.
Patients and methods: In a prospective study 42 low-risk patients were 
randomized to either a reduced/withdrawn CsA dose and daclizumab (group 
A, n=21) or to a normal CsA dose without daclizumab (group B, n=21). Both 
groups received MMF and a standard dose of prednisone. In both groups we 
performed histological assessment according to Banff¡¦97 classifi cation in 
protocol biopsies before transplantation (Tx) and then at 3, 12, 36 months after 
Tx. GFR (Cockroft-Gault formula) were assessed at 3, 12, 36 and 60 months 
after Tx. Statistical analysis was performed with the aid of Fisher¡¦s Exact test 
and CATMOD Procedure (SAS System).
Results: Protocol biopsies showed 11 late cases of SCR-B episodes in 
group A (nine at 12 month, two at 36 month) and seven cases of SCR-B 
episodes in group B (two at 12 month and fi ve at month 36). There were no 
clinically suspected acute rejection episodes between month 36 and 60. In 
50% of these late, SCR-B episodes we did not change immunosuppressive 
treatment. In the remaining 50% of late SCR-B episodes we only increased 
maintenance immunosuppression (MMF from 2.0 to 2.5/3.0g or daily dose 
of prednisone by 5 mg). No treatment with pulses of methylprednisolone was 
given. Among patients with late SCR-B episodes we observed two deaths, 
unrelated to graft function (cancer, and cardiovascular complications): both 
in group B; in one case a late SCR-B episode was untreated, in the other one 
the dose of MMF was increased. In group A one patient with a late SCR-B 
episode, in whom the dose of MMF was increased, returned to dialysis 
because of chronic graft dysfunction. In other patients with late SCR-B 
episodes, regardless of treatment or not late SCR, renal function was stable. 
However GFR values were signifi cantly higher in group A than in group 
B during all the study; at 3 month mean GFR was: 65.8mL/min/1.73m2 
+/-28.6 in group A vs. 52.9 mL/min/1.73m2 +/-14.4 in group B; at 12 
month: 73.5 mL/min/1.73m2 +/-24 in group A vs. 57.5 mL/min/1.73m2 
+/-14 in group B; at 36 month: 72.5 mL/min/1.73m2 +/-23 in group A vs. 
56.4 mL/min/1.73m2 +/-18 in group B; at 60 month: 73.6 mL/min/1.73m2 
+/-26 in group A vs. 56.4 mL/min/1.73m2 +/-18 in group B (p=0.005). 
The risk of arteriolar hyalinization was lower in group A (odds ratio 0.37; 
p<0.02). The degree of progression of chronic histopathological changes 
did not differ between groups.
Conclusions: The importance of late subclinical acute rejection and the 
necessity of its treatment are unclear. Late calcineurin inhibitors withdrawal or 
their minimization in low-risk patients may improve long term graft survival.
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“HUNGRY KIDNEY SYNDROME”: A CASE OF POST 1756 
RENAL TRANPLANT PARATHYROIDECTOMY RESULTING IN 
GRAFT CALCIFICATIONA AND DYSFUNCTION
R. Baer1, E. Jarvis2, K. Oliver3, M. Mantha1, Dr Caroline Milton4
1Cairns Base Hospital, 2Royal Brisbane and Women’s Hospital, 3Princess 
Alexandra Hospital, 4Flinders Medical Centre, Adelaide, South Australia
“Hungry Kidney Syndrome” represents a signifi cant but rare outcome 
of parathyroidectomy which must be considered when contemplating 
parathyroidectomy in the renal transplant population.
Background: Occasionally hyperparathyroidism persists beyond renal 
transplant and may require surgical treatment. The literature is not clear about 
the outcome of parathyroidectomy. Renal calcifi cation and graft dysfunction 
after parathyroidectomy have been described in a case series. In contrast, cases 
of calcifi cation in grafts related to high parathyroid hormone (PTH) levels 
with benefi t from parathyroidectomy have also been described. The following 
case highlights that extraskeletal calcifi cation may affect the graft and cause 
dysfunction – a condition aptly named “Hungry Kidney Syndrome”. This 
syndrome should be included in the differential diagnoses of nephrocalcinosis. 
The Case: This case involved a 72 year old man who received a tumourectomised 
renal allograft for autosomal dominant polycystic kidney disease.  Persistent 
severe hypercalcaemia (3.12 mmol/L corrected) and hyperparathyroidism (63 
pmol/L) indicated a total parathyroidectomy eight months after transplantation. 
Over a period of one month the patient’s serum creatinine rose from 129 to 
217 ìmol/L. The graft dysfunction was associated with hypocalcaemia in the 
postoperative period and he received oral calcium carbonate and calcitriol 1ug 
bd. The patient was also being treated with cyclosporine 100mg bd (average 
level 70 Lug/L), azathioprine, prednisolone, diltiazem, without diuretics. 
Illustrative renal biopsy images demonstrate the extent of calcifi cation within 
tubules and the interstitium, without other features of calcineurin inhibitor 
toxicity or rejection. Gradually, graft function improved (creatinine 164 ìmol/L) 
after cyclosporin dose was dropped to 50mg bd.
Discussion: The positive outcome despite the calcifi cation described here is 
reassuring and new to the literature. It is yet to be determined why the renal 
allograft is particularly sensitive to calcifi cation. In this case, one could surmise 
that this predisposition was due to calcineurin inhibitor related cellular toxicity. 
Alternatively, graft dysfunction may be due to diminished perfusion as a result 
of a rapid drop in PTH. This case illustrates the distribution and extent of 
calcifi cation within the parenchyma on biopsy, as well as suggesting potential 
calcineurin inhibitor involvement in the process. It also promotes awareness 
of the serious condition and the importance of managing hyperparathyroidism 
prior to transplantation. 
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IDIOPATHIC CRESCENTIC GLOMERULONEPHRITIS 1757 
AFTER RENAL TRANSPLANTATION ASSOCIATED WITH 
ANTIBODY MEDIATED REJECTION: A CASE REPORT
P. Gojaseni1, P. Chalermsanyakorn2, T. Pajareya1, K. Pakchotanon1
1Department of medicine, Bhumibol Adulyadej Hospital, 2Department of 
pathology, faculty of medicine, Ramathibodi hospital, Mahidol university
We experienced an unusual case of rapidly progressive glomerulonephritis 
(RPGN) in a patient after renal transplantation. A 35 year old male who underwent 
living donor renal transplantation from his younger brother in December 2003, 
presented a rapid graft function deterioration with a creatinine level at 18 mg/
dL. Renal biopsy revealed cellular crescents in two-third of the glomeruli with 
neutrophilic infi ltration. Immunofl uorescence study showed focal deposit 
of IgM (1+), C3 (2+) and fi brin (1+). Antineutrophil cytoplasmic antibody 
(ANCA) was not found in serum and workup for other causes of crescentic 
glomerulonephritis was negative. Diffuse C4d deposition in peritubular 
capillaries and circulating antibodies to donor HLA class I were detected 
resulting in the possibility of antibody-mediated rejection. He was treated with 
three consecutive methylprednisolone pulses followed by plasmapheresis and 
hemodialysis. Immunosuppressive regimen was cyclophosphamide (2 mg/
kg/day) in a combination with cyclosporine and prednisolone. Treatment was 
unsuccessful, the patient lost his graft and returned to regular hemodialysis 
2 months after diagnosis. In conclusion, we diagnosed a rare case of pauci-
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immune crescentic glomerulonephritis associated with antibody mediated 
rejection. Further studies are required to explore the causative link between 
alloantibody and glomerular process.
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INCIDENCE OF C4D DEPOSITION IN PROTOCOL 1758 
BIOPSIES IN LIVING RENAL ALLOGRAFT 
TRANSPLANTATION
M.Minz1,  T. Ahmed1, A. Sharma1, R. Minz2, K. Joshi3
1Dept of Renal Transplant Surgery, PGIMER, 2Dept of Immunopathology, 
PGIMER, 3Dept of Histopathology, PGIMER
Introduction: After the initial studies by Rush et al, subclinical cellular 
rejection has become a well defi ned entity. Recently, increasing importance is 
also being given to the humoral pathways of acute rejection and deposition of 
the complement protein C4d in renal allograft biopsies has been accepted as a 
sensitive marker of antibody-mediated acute rejection. It is not known whether 
the humoral pathways can also produce a subclinical pathology in the graft. 
The present study assessed the incidence of subclinical humoral rejection by 
C4d staining on protocol renal biopsies in living donor renal allograft recipients 
with stable renal function.
Material and methods: From April 2006 to December 2007, 50 renal allograft 
recipients who underwent protocol biopsy with in six months after transplant 
with stable renal function as defi ned by serum creatinine <1.5mg% were 
included in the study. The biopsies were assessed for c4d stain[Cat B1-RC 4D, 
Biomedica] by immunofl uorescence in addition to the standard histopathology. 
All patients were followed up for six months.
Results: Mean recipient age was 34.1+ 10.7 years, M:F 44:6, mean donor age 
was 39.8 + 11.2 yrs. 41(82%) patients were on Tacrolimus & Mycophenolate, 
8(16%) on cyclosporine & everolimus and 1 (2%) patient received cyclosporine 
& azathioprine. All patients received Prednisolone. 2(4%) of the biopsies 
however showed focal c4d positivity. None of the biopsies stained diffusely 
for c4d. Histopathologic evidence of humoral rejection i.e. PTC dilation 
and neutrophil deposition was noted in 3/50 (6%) of the biopsies .Patchy 
dilation was noted in 1/50(2%) of the biopsies.5(10%) patients had evidence 
of subclinical cellular rejection. The mean serum creatinine at the end of six 
months was 1.16+ 0.3 mg%.
Conclusions: The incidence of C4d deposition in protocol biopsies in patients 
with stable renal allograft function in the early postransplant period is very 
low. This may be especially true in low risk situations like HLA and ABO 
compatible living donor transplantation and with the use of current powerful 
immunosuppressive therapy
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KIDNEY TRANSPLANTATION FROM MARGINAL 1759 
DONORS. PREDICTIVE ROLE OF BIOPSY SCORE FOR LONG 
TERM GRAFT SURVIVAL AND TRANSPLANT OUTCOME
S. Cristino1, M.P. Scolari1, G. La Manna1, A. Faenza2, G. Mosconi1, 
L. Panicali1, O. Baraldi1, C. Fantinati1, A. Ferri1, S. Stefoni1
1University of Bologna - Nephrology, Dialysis And Renal Transplant Unit, 
2University of Bologna - Renal Transplant Surgery Section
Introduction: In the last few years, the gap between organ supply and 
demand represents a signifi cant healthcare emergency, forcing the transplant 
community to use suboptimal or “marginal” donors. In 2002 the United 
Network Organ Sharing (UNOS) delineated the Expanded Criteria Donors, 
defi ning “marginal” as a cadaveric donor either older than 60 or aged between 
50 and 59 with at least one of the following risk factors: a) hypertension, 
b) deaths caused by cerebrovascular diseases and c) serum creatinine higher 
than 1.5 mg/dL (134 micromol/L). Organ quality is also evaluated by a renal 
biopsy performed before transplant using the scoring system introduced by 
Karpinski in 1999.
Aims: This study was designed to compare graft and patient survival between 3 
groups of kidney transplant recipients divided according to the biopsy score of 
the corresponding marginal donors. We also analysed the degree of predictivity 
of total and partial biopsy score to estimate the risk of graft loss.
Patients and methods: One hundred and thirty-six cadaveric kidney 
recipients who received a transplant from a marginal donor between 
September 2001 and September 2006 were retrospectively evaluated. The 
patient population was divided into 3 groups according to the total biopsy 
score as follows: Group A = 25 double renal transplants with average total 
score between 4 and 5; Group B = 24 single renal transplants with score 4 and 
Group C = 87 single renal transplants with score lower than 4. Patients who 
received a second transplant or a combined transplant were not included. The 
average follow-up was 41.8 ± 18.6 months. The therapy distribution scheme 
was similar in all 3 groups.
Results: The 1- and 5-year patient and graft survival according to Kaplan-
Meier curves were better in Group C (single transplants with score <4) than in 
Group A (double transplants with score >4) and Group B (single transplants 
with score 4), although the differences did not meet statistical signifi cance 
(p=0.3766 for patient survival and p=0.4249 for graft survival). In particular, 
1-year patient survival was 99% in Groups A and B and 100% in Group C; 
5-year patient survival was 92% in Group A, 87% in Group B and 97% in 
Group C.
One-year kidney graft survival was 88% in Groups A and B and 95% in 
Group C; 5-year graft survival was 88% in Group A, 83% in Group B and 
91% in Group C. The total and partial biopsy score (vascular and interstitial 
compartment) does not represent a risk factor for graft loss either using the 
univariate analysis or using the multivariate analysis adjusted for donor age, 
cardiovascular comorbidities, cold ischemia time, Delayed Graft Function and 
rejection episodes.
Conclusions: The presents study suggests that total and partial biopsy score 
to evaluate organs from marginal donors has a poor predictive value for short 
and long-term kidney transplant outcomes. However this approach confi rms its 
validity as a tool it for the allocation of suboptimal organs, which demonstrate 
a good survival.
POSTER BOARD NUMBER P3 – 186
CAUSES OF RENAL GRAFT DYSFUNCTION AS 1760 
DETECTED IN RENAL ALLOGRAFT BIOPSIES IN A LIVE 
RELATED RENAL TRANSPLANT PROGRAM
M.M. Nuhari, J.I. Kazi, E. Ahmed, F. Akhtar, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Objective: To determine the spectrum of pathological changes in renal graft 
biopsies performed for evaluation of graft dysfunction in a live related renal 
transplant program.
Materials and methods: A retrospective review of 1210 biopsies from 700 
renal transplant patients was carried out. Two cores of graft biopsies are 
obtained under ultrasound guidance. Both are fi xed in formalin and processed 
for light microscopy. One additional core was obtained for IMF and EM study 
in suspected cases of glomerulonephritides. The histological changes are 
classifi ed according to Banff 1997 working classifi cation of renal allograft 
pathology.
Results: A total of 1210 graft biopsies were performed in 700 patients. Acute 
rejection was seen in 292 (24%) cases, followed by acute tubular injury and 
CyA toxicity, found in 281 (23.2%) and 134 (11%) cases respectively. Chronic 
allograft nephropathy with variable degree of tubular atrophy was seen in 
361 (29.8%) cases. Acute pyelonephritis was seen in 79 (6.5%) cases. Thirty 
(2.5%) cases of recurrent/denovo renal diseases were found. FSGS was the 
most common lesion found in 15 cases. Eight cases of IgA nephropathy were 
seen. Four cases of oxalosis were found. Two cases of MCGN and one case 
of Fabry’s disease were also noted. A number of rare lesions were found in 33 
(2.7%) cases.
Conclusion: The study defi nes the pattern of pathological lesions in a large 
cohort of live related renal transplant patients. The incidence of acute rejection 
is low in our patients and CyA toxicity is more common. Recurrent/ denovo 
renal disease occurs in a signifi cant minority of dysfunctional graft biopsies 
and among these, recurrent/denovo FSGS is the most common lesion.
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USING DNA TYPING OF HLA CLASS II GENES TO 1761 
IDENTIFY HISTIOCYTIC NECROTIZING LYMPHADENITIS 
(KIKUCHI-FUJIMOTO DISEASE: KFD)
Y. Qazi, S. Schroff, M. Smogorzewski, Y. Iwaki, S. Qazi, M. Bulbul, 
R. Mateo, L. Sher, R. Selby
University of Southern California
KFD is an uncommon, idiopathic, generally self-limited cause of 
lymphadenitis. Clinically and histologically, the disease can be mistaken for 
lymphoma but the disease runs a benign course.The disease is known to occur 
in organ transplant recipients.However, the classic histological picture may 
be altered by immunosuppressive drugs and misdiagnosed as a PTLD. We 
present a case report of a KTx recipient in whom DNA typing was used to 
identify KFD. 31 yr old HW received a 0mm, CMV D+/R+ DDKTx.. I/S 
included Basiliximab induction and cyclo, MMF, pred maintanence.4 weeks 
after the transplant, the patient developed a fever that was followed by not 
tender, rubbery, lymphadenopathy around the cervical chain and a faint 
transient body rash.Viral studies were unremarkable as was a LP and Gallium 
scan. A diagnosis of a post transplant lymphoproliferative disorder was 
considered. An excisional biopsy performed revealed no monoclonality of 
the lymphocytes areas of necrosis were noted. EBV staining of the specimen 
was negative. KD diagnosis was made. HLA associations to KFD haS been 
described in a Japanese series where a positive relationship to DPA1*01 and 
DPB1*0202 allele was noted.We sought to see if our patient shared the same 
DP antigens association.DNA typing of HLA Class II genes (HLA-DP1 AND 
HLA-DP1 was done by PCR-SSP. HLA-DP typing was performed using 
Olerup SSP HLA-DP1 and HLA-DP1 kits (Genovision/QIAGEN). Analysis 
of our patients sample showed the HLA typing to be HLA-DP1*0103 
and HLA-DP1*0402. Our patient possessed the same HLA DP antigen as 
described in the Japanese series. Though, initially described in Japan, KD 
is being recognized more frequently world wide including North America. 
Kikuchi-Fujimoto disease should be included in the differential diagnosis for 
patients presenting with cervical lymphadenopathy and fever of unknown 
origin. Early recognition of this entity can minimize unnecessary measures 
such as discontinuing immunosuppression. infact some reports describe use 
of immunosuppression as treatment. Increased awareness of KFD is needed 
to minimize the risk of confusing this entity with PTLD or other serious 
conditions. Our case demonstrates that detection of DPA1*01 or DPB1*0202 
alleles may help making a diagnosis of KD when histology is confounded by 
immunosuppression.
RENAL ABOI AND CONCURRENT ORAL SESSION 127: 
SENSITISED
POSTER BOARD NUMBER P3 – 188
IMMUNOGLOBULIN CLASS (IGG, IGM) 1762 
DETERMINATION BY DITHIOTHREITOL IN SENSITIZED 
KIDNEY TRANSPLANT CANDIDATES
K.M. Adib
Medical School.Isfahan University of Medical Sciences
Immunoglobulin class plays an important role in the histocompatibility 
crossmatch test to predict hypercube rejection in kidney transplantation. The 
existing data indicates that immunoglobulin (Ig) M antibodies, particularly 
when they are autoantibodies, are not deleterious to the renal allograft. We 
used the reducing agent dithiotreitol (DTT) to inactivate IgM but not IgG in 
the crossmatch assay to help sensitized patients have the chance for successful 
transplantation. In this descriptive study, 57 candidates for kidney transplantation 
with fi nal positive crossmatches who had a history of panel – reactive antibody 
(PRA) greater than 30% were selected. Two of 57 patients had systemic 
lupus erythematous (SLE). The sera of patients were treated by DTT and then 
measured for cytotoxicity against donor lymphocytes and a panel of 12 cells 
using the complement dependent cytotoxicity (CDC) method. Autocrossmatch 
was also performed to differentiate autoantibodies and alloantibodies by the 
CDC method. Of the 57 patients, six subjects (10.53%) had IgM and 51 patients 
(89.47%) IgG in their serum against donor lymphocytes. Also against panel 
cells, 39 of 57 patients (68.47%) had IgG, three patients (5.26%) had IgM, and 
15 patients (26.31%) had both IgG and IgM antibodies. Autolymphocytotoxic 
antibodies were detected in 1.7% patients (1 of 57) who had SLE. According to 
our results, 5.26% of the patients who were IgM – positive and IgG – negative 
for both crossmatch and PRA assays may experience successful kidney 
transplantation.
POSTER BOARD NUMBER P3 – 189
CLINICAL IMPORTANCE OF ANTI-HLA SPECIFIC 1763 
ANTIBODY CONCENTRATION IN PERFORMING 
CALCULATED PRA AND VIRTUAL CROSSMATCHES
S. Vaidya
University of Texas Medical Branch
Background: Highly sensitized patients develop multi-HLA specifi c 
antibodies. In this study we measured concentrations of anti-HLA antibodies 
in multi-specifi c sera by converting fl uorescence intensity (FI) into molecules 
of equivalent soluble fl uorocrome (MESF) units. This was used to determine 
MESF units required for a positive T and B fl ow crossmatches (FLXM).
Methods: MESF values of negative controls and sera from patients devoid of 
HLA antibodies were measured by FLXM and FlowPRA screening beads. FI 
values of anti-HLA specifi c antibodies determined by FlowPRA single antigen 
beads of highly sensitized patients were converted in MESF units. In addition 
endpoint titers, MESF units and% PRA of 26 sera were established.
Results: MESF analysis accurately predicted the outcomes of 100% of T 
and B FLXM of sera with strong (MESF units>18,000) DSA. The predictive 
values of T and B FLXM declined to 95% and 88% with weak DSA (6,000 
MESF<10,000). End point titers of sera from highly sensitized patients 
ranged from 1:512 to 1:8 with corresponding MESF values of 452,596 to 
20,000 units. However there was no statistical difference in PRA values 
among these sera (95%-100%). We successfully transplanted 5 patients 
who had weak donor-specifi c HLA antibodies (MESF units >2,000). The 
graft survival at one year was 100% and there was no evidence of DSA post 
transplant.
Conclusion: MESF analysis is both a time and cost effi cient way of measuring 
antibody strength. The strength of the antibody present in the sera of transplant 
candidates is critical for crossmatch prediction.
POSTER BOARD NUMBER P3 – 190
THE EVALUATION OF OPTIMAL DOSE OF RITUXIMAB 1764 
IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION 
WITHOUT SPLENECTOMY
H. Shirakawa, H. Ishida, K. Omoto, T. Shimizu, K. Setoguchi, S. Iida, 
D. Toki, K. Tanabe
Tokyo Women’s Medical University
Purpose: A new protocol for ABO-incompatible (ABOi) kidney transplantation 
including rituximab instead of splenectomy was introduced since January 2005 
in our institute. We started a dose of rituximab at 500mg/body at fi rst and got 
the excellent short-term results. And then, we reduced a dose of the rituximab 
to 200mg/body since January 2007. We reviewed our results and evaluated the 
optimal dose of rituximab in ABOi kidney transplantation.
Material and methods: Between January 2005 and November 2007, 33 
de novo ABOi kidney transplantations were performed at Tokyo Women’s 
Medical University. The immunosuppressive protocol, consisting of tacrolimus, 
mycophenolate mofetil and methylprednisolone, was started 1 week prior 
to the operation. All the patients received induction with basiliximab. The 
preconditioning protocol included 3-4 sessions of plasmapheresis (PP) during 
the preoperative period and a single dose of rituximab 5-7 days before the 
operation. The dose of rituximab was 500mg/body between January 2005 and 
December 2006 (Group I, n=22).
Since January 2007, the dose of rituximab was reduced to 200mg/body (Group 
II, n=11). Splenectomy was not performed in any of the patients. Anti-blood 
type antibody titers and CD 19 levels were monitored regularly. Protocol biopsy 
was performed within 1 month of the transplantation and episode biopsy was 
performed in the event of rejection.
Results:
Group I (n=22)
The mean follow-up duration of patients was 20.9 months (range 10 to 34). 
All the patients underwent successful kidney transplantation. The mean serum 
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creatinine level of all the patients was 1.2 mg/dl. In most patients, the anti-blood 
type antibody titer was maintained at ¡Ü1:32 during the postoperative period. 
Only two patients showed increase of the IgG antibody titers up to 1:256 at 3 
months post-transplantation. Nonetheless, the graft functions in these patients 
were stable and there was no evidence of rejection on biopsy.
Group II (n=11)
The mean follow-up duration of patients was 5.6 months (range 1 to 10). All 
the patients underwent successful kidney transplantation. The mean serum 
creatinine level of all the patients was 1.5 mg/dl. In all patients, the anti-blood 
type antibody titer was maintained at ¡Ü1:32 during the postoperative period.
In both group, the administration of single dose of rituximab effectively 
removed all the peripheral blood CD19- positive cells and no side effect of 
the rituximab infusion was noted, although in 6 patients of Group I, late-
onset neutoropenia was observed (Grade 2: 1 case; Grade 3: 3 cases; Grade 
4: 2 cases). Nevertheless, there was no serious infection. Except one patient 
in Group II, there was no episode of antibody-mediated rejection during the 
follow-up period.
Conclusion: We conclude that with the administration of rituximab and PP 
prior to the operation, ABOi kidney transplantation can be performed with 
excellent results without splenectomy. No serious adverse effect of rituximab 
have been observed in our experience. We suggest that the a single dose of 
200mg/body 3-5 days prior to the operation is suffi cient and optimal dose.
POSTER BOARD NUMBER P3 – 191
PLASMAPHERESIS/IVIG STANDARD DOSE IN PATIENTS 1765 
WITH HIGH IMMUNOLOGICAL RISK
F.F. Gama, G.A.M. Ramirez, T.B. Riccardelli
Instituto Mexicano De Trasplantes
Background: In the search of the immunological tolerance desensitization 
protocols directed to patients with high immunological risk have been 
developed, nevertheless not yet has become general their use, thus relegating 
the patients to the growing waiting list of an immunologically compatible 
donor, being able to last the delay up to 3 years.
Objective: To report the experience of a center of transplants in the 
desensitization of patients with high immunological risk.
Design: Descriptive, retrospective.
Material and methods: We included all the renal transplants from November 
of 1999 to January of 2008 in which we used plasmapheresis and standard dose 
of intravenous immunoglobulin (IVIG) as desensitization.
Results: The 1.5% of the renal transplants from November of 1999 to January 
of 2008 had history of alloimmunity, 7 patients had positive crossmatch 
with their donor and 1 exclusively had high Panel-Reactive of Antibodies 
(PRA >30%); a patient with positive crossmatch and high PRA received 2 
years before plasmapheresis and IVIG, whoever this was unsatisfactory. The 
schedule of the plasmapheresis was in alternating days with exchange of 1.5 
plasmatic volume, subsequent to each session we administered a standard dose 
of Intravenous Immunoglubulin (IGIV 5gr/dose). In 6 patients were made 4 
pretransplant sessions, 1 of them required a posttransplant session; in a patient 
2 sessions were made pretransplant and in another case one pretransplant 
and 2 posttransplant. The immunesuppression began equal than the fi rst 
plasmapheresis with calcineurin inhibitor (Tacrolimus) plus, 6 patients with 
Mycophenolate Mofetil and 2 with Sirolimus. In 7 cases negative crossmatch 
were obtained before the transplantation, except in the eighth case to whom 
it wasn´t made. Two patients received humanized antibodies against CD25 
(Basiliximab 20mg/dose) the day of transplantation and the fourth day. A 
patient presented Delayed Graft Function (DGF) due to Acute Humoral 
Rejection (AHR). A patient had pancreatitis the 3 months posttransplant. 
Just one patient needed a graft biopsy the 20th month which showed mild 
fi brosis. During their evolution all the patients have maintained a stable graft 
function.
Conclusions: The renal graft outcome in patients with high immunological 
risk after an adequate desensitization protocol is similar to that observed in 
nonsensitized patients at least during the fi rst year of transplantation, according 
to our experience.
POSTER BOARD NUMBER P3 – 192
INCIDENCE OF REJECTION AND LONG-TERM 1766 
OUTCOME IN B-CELL CROSSMATCH-POSITIVE KIDNEY 
TRANSPLANT RECIPIENTS TREATED WITH PREOPERATIVE 
PLASMAPHERESIS AND ONE-WEEK IMMUNOSUPPRESSION
S. Iida, H. Ishida, K. Omoto, M. Furusawa, T. Ishizuka, T. Tokumoto, 
T. Shimizu, H. Shirakawa, K. Setoguchi, D. Toki, H. Nishida, K. Tanabe
Department of Urology, Tokyo Womens Medical University, Tokyo, Japan
Introduction: B-cell crossmatch (BCXM) positivity is known to be the robust 
immunological barrier to overcome and most kidney transplant recipients 
with positive BCXM experience antibody-mediated rejection (AMR) or acute 
vascular rejection (AVR) after kidney transplantation. We report incidence of 
rejection and long-term results of BCXM-positive kidney transplant recipients 
treated with preoperative plasmapheresis and one-week tacrolimus(FK)-based 
immunosuppression.
Patients and methods: One hundred and sixty-seven patients underwent KT 
following by theimmunosuppression with tacrolimus at our institute between 
January 2001 and December 2004. BCXM positivity was determined by the 
fl ow-BCXM test. Flow-PRA was also conducted on sera collected before 
transplantation. The patients were classifi ed into the following 4 groups: 
BCXM(-)PRA(-); BCXM(+)PRA(-); BCXM(-)PRA(+); BCXM(+)PRA(+). 
Rejection episodes were diagnosed by graft biopsy only.
Results: Of the 167 patients, 13 were positive and 154 were negative for 
preoperative BCXM respectively. Graft survivals of BCXM(+) recipients were 
92% and that of BCXM(-) recipients were 98% respectively. The incidence 
of graft rejections was tabulated for following groups. Of 127 patients in 
the BCXM(-)PRA(-) group, 22(17%) and 16(16%) had antibody-related and 
cellular rejection, respectively. Of 28 patients in the BCXM(-)PRA(+) group, 
8(29%) and 4(14%) had antibody-related and cellular rejection respectively. 
Of 7 patients in the BCXM(+)PRA(-) group, 1(14%) had antibody-related 
rejection. Of 6 patients in the BCXM(+)PRA(+) group, 4(67%) and 1(14%) 
had antibody-related and cellular rejection. 
Conclusions: These results suggest that there is a correlation between the 
existence of anti-HLA antibody before renal transplantation and antibody-
related graft rejection after surgery. However, long-term graft survival was not 
signifi cantly different between BCXM positive and negative groups.
POSTER BOARD NUMBER P3 – 193
CLINICAL EXPERIENCE IN LAPAROSCOPIC 1767 
SPLENECTOMY FOR ABO-INCOMPATIBLE KIDNEY 
TRANSPLANTAION
N. Ichimaru1, T. Abe1, M. Okumi1, R. Imamura1, Y. Isaka1, S. Takahara1, 
Y. Kokado2, T. Yoshioka3, M. Kyakuno4, A. Okuyama1
1Osaka University, 2Takahashi Clinic, 3Sumitomo Hospital, 4Osaka 
Seninhoken Hospital
Introduction: The serious shortage of cadaveric organs has prompted the 
development of ABO-incompatible live donor kidney transplantation. Recently, 
laparoscopic surgeries in kidney transplantation fi eld have been spreading 
dramatically. Laparoscopic splenectomy is one of the treatment options 
for ABO-incompatible kidney transplantation or severe antibody mediated 
rejection.
Aim: To evaluate the safety and effi cacy of laparoscopic splenectomy for 
ABO-incompatible kidney transplantation, 48 laparoscopic splenectomies for 
ABO-incompatible kidney transplantation were reviewed retrospectively.
Patients and methods: From July 2000 to February 2008, 48 laparoscopic 
splenectomies for ABO-incompatible kidney transplantation were performed 
in our centers. Four-trocar technique was used in all patients. En-bloc stapling 
of the splenic hilum using EndoGIA was performed for hilar vascular control. 
Anti-ABO blood type antibody titer before and after splenectomy, operation 
time, blood loss, conversion to open surgery, and complications were evaluated 
retrospectively.
Results: The mean operative time was 113 minutes. Intraoperative blood loss 
ranged from 10 mL to 600 mL (mean 120 mL). Transfusion was not required in 
any case. One patient required open conversion because of bleeding from the 
splenic hilum. One patient required conversion to hand-assisted laparoscopic 
surgery because of severe obesity. The serum amylase value was slightly 
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elevated postoperatively in fi ve patients but normalized with no treatment. 
One patient had bleeding from a trocar port wound, which was treated 
conservatively. One pancreas tail injury occurred and the patient was treated 
with drainage and Octreotide (smatostatin analogue). No fatal complications 
were occurred.
Conclusion: Laparoscopic splenectomy is one of the safe and effective 
treatment options for ABO-incompatible kidney transplantation.
POSTER BOARD NUMBER P3 – 194
ABO INCOMPATIBLE RENAL TRANSPLANTATION 1768 
IN AN HIV-SEROPOSITIVE PATIENT
J. Oberholzer, M. Campara, P. West-Thielke, J. Thielke, T. Ommert, 
E. Benedetti, B. Kaplan
University of Illinois At Chicago
To date, there have been no reports of successful ABO blood group incompatible 
(ABOI) renal transplantation in HIV patients. We describe a case of a 47 year-
old African American male with ESRD secondary to HIV induced nephropathy 
that underwent a live unrelated (spouse) donor ABOI transplant using an 
IVIG/plasmapheresis preconditioning regimen with IL2 receptor antagonist 
induction along with tacrolimus and mycophenolate mofetil maintenance. The 
post-operative course was complicated by 2 acute cellular rejection (Banff 
Ia) episodes that were successfully managed with corticosteroid boluses and 
the addition of corticosteroids to maintenance immunosuppression. No acute 
antibody mediated rejection occurred during the fi rst 90 days. The patient 
reached a SCr nadir of 2.0 mg/dL on POD20 which has now been maintained 
for 90 days. His current CD4 count is 241 cells/μL.
Table1. ABO Anti-A titers
Date IgM IgG
Baseline 1:64 1:32
POD*-3
Pre-pheresis N/A N/A
Post-pheresis 1:8 1:8
POD-2
Pre-pheresis 1:8 1:4
Post-pheresis 1:4 1:4
POD-1
Pre-pheresis 1:8 1:4
Post-pheresis 1:1 1:1
POD0
Pre-pheresis 1:1 1:1
Post-pheresis 1:1 1:1
POD1 Pre-pheresis <1:1 <1:1
POD2 Pre-pheresis <1:1 <1:1
POD3 Pre-pheresis 1:1 <1:1
POD4 Pre-pheresis 1:1 1:1
POD5 Pre-pheresis 1:1 <1:1
POD6 Pre-pheresis 1:1 <1:1
POD7 Pre-pheresis 1:1 <1:1
POD8 Pre-pheresis 1:2 1:1
POD9 Surveillance 1:2 1:1
POD10 Surveillance 1:4 1:2
POD11 Surveillance 1:4 1:2
POD12 Surveillance 1:4 1:2
*POD - postoperative day
Table 2. CD4 Count and Viral Load 
Date Absolute CD4(cells/μL) % CD4
HIV Viral Load
(copies)
Baseline 531 N/A <50
POD* 34 595 30 <50
POD 62 564 30 <50
POD 90 241 24 <50
*POD - postoperative day
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TREATMENT OF ACUTE ANTIBODY-MEDIATED 1769 
REJECTION; SPECIFIC ANTI-T LYMPHOCYTE THERAPY 
IS EFFECTIVE, WHILE SPECIFIC ANTI-B LYMPHOCYTE 
THERAPY IS NOT
R. Higgins1, D. Zehnder2, K. Chen1, S. Fletcher1, H. Kashi1, L.C. Tan1, 
C. Imray1, F.T. Lam1, R. Hamer1, N. Krishnan1
1University Hospital, 2Warwick Medical School
Introduction: The optimal treatment regimen for acute renal transplant 
rejection associated with donor-specifi c antibodies (DSA) has not been 
established. There is a recent report of several graft failures when rejection was 
treated with plasmapheresis (PP) and Rituximab, but successful reversal after 
splenectomy. We report the outcomes of treatment with the monoclonal T cell 
antibody muromonomab-CD3 (OKT3).
Methods: Fifty one patients were transplanted, 45 with HLA antibody 
incompatibility (HLAi), 3 with blood group incompatiblity (ABOi), and 3 with 
HLAi and ABOi. 24 patients had rejection or suspicious biopsy changes in the 
fi rst 3 months. 12 were treated with 5-7 day courses of OKT3; 11 of these cases 
rejection was antibody-associated, 1 case had mixed cellular/vascular rejection 
with low antibody levels.
Results: One patient with rejection was treated with Rituximab and PP, and 
the graft failed from acute rejection (the only graft in our programme to have 
failed from acute rejection). OKT3-treated rejection had onset at mean day 
12 (range 0-16) post transplant. Mean creatinine was 230 (range 87-dialysis) 
umol/l before rejection, peaked at 367 (range 126 – dialysis) umol/l, and fell 
post-treatment to 157 (range 70-271) umol/l. 5 patients were treated with 
dialysis for severe rejection. One graft failed from thrombotic microangiopathy 
at 3 months, the others are currently functioning with mean creatinine 147 
(range 78-245) umol/l. Examination of leucocyte subsets in renal biopsies 
taken before rejection treatment showed that CD20+ cells made up <5% of 
the infi ltrate, with CD3+ and CD68+ cells predominating. Additionally, there 
is little information on the effects of OKT3 on CD3- lymphocyte populations. 
Preliminary results from peripheral leucocyte monitoring of patients during 
OKT3 treatment showed changes in CD20+ and CD56+ populations in some 
patients.
Discussion: The use of OKT3 for early rejection was associated with 92% 
graft survival and 100% patient survival. The role of CD3+ cells in antibody 
mediated rejection requires further investigation.
POSTER BOARD NUMBER P3 – 196
PROTOCOL CHANGES AND IMPROVED OUTCOMES OF 1770 
ANTIBODY INCOMPATIBLE RENAL TRANSPLANTATION
R. Higgins1, R. Hamer1, N. Krishnan1, F.T. Lam1, H. Kashi1, L.C. Tan1, 
D. Lowe2, F.T. Lam1, D. Briggs2, D. Zehnder3
1University Hospital, 2Dept Histocompatibility Laboratory, UK Blood and 
Transplant, 3Warwick Medical School
Introduction: Although antibody incompatible transplantation (AIT) appears 
reasonably successful in clinical practice, the outcomes for HLA antibody 
incompatibility (HLAi), are not well defi ned outside the USA.
Methods: From 2003-2007, 54 patients entered our programme, 48 with HLAi, 
3 with blood group incompatibility (ABOi), and 3 with HLAi and ABOi. The 
early (06/2003 – 08/2006) and later (09/2006 – 12/2007) cohorts of 27 patients 
each were compared. The initial protocol was similar to that used at the Johns 
Hopkins University. From case 16, OKT3 was used for established rejection, 
and IVIg and rituximab were not used. From case 29, ATG was used pre-
emptively in selected patients, and post-transplant plasmapheresis (PP) was 
phased out.
Results: The two cohorts were similar in respect of mean age (39.7 vs 42.6 
years), proportions of regrafts (59% vs 56%), cytotoxic crossmatches +ve 
(33% vs 22%), ABO incompatible or fl ow crossmatch +ve (41 vs 52%); >10yr 
treatment of established renal failure (56% vs 56%) and serious comorbidity 
(53% vs 41%), but differed in the proportions who had developed renal failure 
as children (37% vs7%). One case in each cohort did not proceed to transplant, 
and one case was excluded as +ve crossmatch was later found not to be due to 
donor-specifi c antibodies.
At latest follow up in the early and late cohorts respectively, patient survival 
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was 92% vs 92%, graft survival was 92% vs 100%. All losses so far have been 
in the fi rst 4 months. The mean number of pre-transplant PP sessions was 
4.3 vs 3.1 and post transplant was 3.1 vs 0.28. In the early and late cohorts 
respectively, the rates of delayed graft function were 8% and 32% (increase 
due to immunological and non-immunological risks); acute rejection in 
the fi rst 3 months 42% vs 40%; mean eGFR at 3 months 49.7 vs 74.6 ml/
min/1.73m2.
Discussion: The results of AIT improved with experience and empirical 
protocol changes, with graft function and graft survival in the later cohort 
the same as in standard transplants performed in our unit, despite a high 
rate of delayed graft function. Patient survival was less than that of standard 
transplantation. This refl ected increased comorbidity, and compared with a 
survival of only 65% in another 23 patients not accepted for AIT because the 
recipient was unfi t.
POSTER BOARD NUMBER P3 – 197
DESENSITIZATION WITH PLASMAPHERESIS AND 1771 
LOW-DOSE IMMUNOGLOBULIN ALLOWS SUCCESSFUL 
KIDNEY TRANSPLANTATION FROM LIVING DONORS IN 
HIGHLY SENSITIZED RECIPIENTS
A. Yussim1, E. Mor1, B. Makogon1, T. Klein2, J. Orlin3, M. Davidovits4, R. 
Michowicz1
1Dept Transplantation, Rabin Medical Centre, 2Tissue Typing Laboratory, 
3Blood and Apheresis Service, 4Pediatric Nephrology Unit, Schneider 
Children Medical Centre
Background: Highly sensitized patients have a markedly reduced chance 
of receiving a compatible donor organ. Herein, we present the results of our 
regimen used for the management of live kidney graft recipients with broad 
alloantibody reactivity.
Methods: The study patients consisted of seventeen live donor kidney 
transplant recipients (8 males and 9 females), aged 10-63 years, with mean 
PRA of 60% (range 26-100%), awaiting for mean 20.9 ± 18.5 months for 
their fi rst (n 5), second (n 10) or third (n 2) transplant. Crossmatch (XM) by 
CDC and AHG methods was negative in all patients, 8 patients (47%) had 
positive T and/or B fl ow cytometry with channel shift of 36-375 and donor 
specifi c antibodies (DSA) to class I (n 6) and class II (n 2) in dilutions of 
1:64-1:128. The preemptive desensitization protocol consisted of 2-3 
plasmapheresis sessions, each followed by low dose (0.5 gr/kg) IVIG infusion. 
Postoperatively, all patients were maintained with conventionally dosed and 
concentration controlled prednisone-tacrolimus-mycophenolate protocol after 
induction with four daily 1mg/kg Thymoglobulin doses (n 9, 53%) or two 
bi-weekly 1mg/kg doses of Daclizumab (n 8, 47%). In addition, two patients 
with highest DSA received a single 375mg/m2 dose of Rituximab. Suspected 
rejections were investigated by biopsy with C4d staining and repeated XM and 
DSA determination. Treatment of cellular rejection consisted of Solumedrol 
pulses followed by Thymoglobulin. Humoral rejection was treated with 
Thymoglobulin, plasmapheresis and IVIG. The patients were followed for 13.8 
± 2.1 months.
Results: 14 out of 17 patients were successfully transplanted (1 yr graft 
survival 82.3%). In comparison, 1 yr graft survival in our own series of 38 
non-sensitized, fi rst live kidney transplants, done in the same period, was only 
10% better (92%). In the desensitized patients, there were 4 cases (23.5%) 
with delayed graft function caused by acute tubular necrosis, which were 
followed with weekly biopsies and all recovered completely after 7-20 days. 
Three grafts were lost, one to thrombosis, another to primary non function, 
without rejection, and only one to refractory humoral rejection. There were 
only two episodes of rejection, one of mixed cellular-humoral type which was 
successfully reversed and another of predominantly humoral type with post-
transplant positive XM and DSA, which was irresponsive to treatment. At the 
end of follow up, all functioning grafts had excellent renal function, serum 
creatinine of 1.05±0.42 mg%.
Conclusions: Our results suggest that selected crossmatch-positive patients 
can be transplanted successfully with living-donor kidney allografts, using a 
protocol of pretransplant plasmapheresis and intravenous immunoglobulin.
POSTER BOARD NUMBER P3 – 198
SUCCESSFUL TRANSPLANTATION WITHOUT 1772 
DESENSITISATION DESPITE THE PRESENCE OF DONOR 
SPECIFIC ANTIBODIES
A. Asderakis1, M. Ilham1, T. Rees2, S. Lloyds2
1Transplant Unit, University Hospital of Wales, UK, 2Welsh Transplantation 
and Immunogenetics Laboratory
Introduction: Transplanting sensitised patients is a complicated issue involving 
fi nding a reasonably matched organ, increasing level of immunosuppression 
and also has long term implications to both patient and graft survival. In the last 
few years desensitisation protocols have found widespread application in the 
setting of live donation. Retransplanted (RTX) patients who have developed 
donor specifi c antibodies (DSA) pose a signifi cant risk for graft survival 
although their outcome is not entirely clear.
Aim: To review the outcome of all retransplants that were performed with 
negative cytotoxic crossmatch despite possessing DSA.
Method and results: From 1998 to 2003 there were 55 RTX from cadaver 
donors. As all these patients were transplanted with the knowledge of a negative 
cytotoxic crossmatch (CDCXM), no specifi c changes were made to their 
immunosuppressive management. On retrospective analysis using solid phase 
assay and then fl ow cytometry-based techniques we identifi ed 10 patients with 
DSA. On fl ow cytometry (FC) cross match out of those 10 patients, there were 
three patients T-cell positive and B-cell positive, three were T-cell positive and 
B-cell negative and four were T and B-cell negative.
Median follow up was 6 years. Two kidneys were lost early postoperatively, 
due to renal vein thrombosis (on biopsy had no sign of rejection) and recurrent 
FSGS respectively. No graft was lost due to acute rejection and no proven 
humoral rejection occurred in the 1st year post transplant.
One patient died at 6 years with a functioning graft. Two grafts failed at 6 and 
8 years, and 4 grafts are still functioning at 6 to 8 years post transplant giving a 
5-year graft survival of 80%. Functioning grafts have a mean creatinine of 175 
and median of 155 micromol/l.
Conclusion: DSA detection in the presence of negative CDCXM does not 
always predict an adverse outcome or need for desensitisation even in the 
presence of positive FC crossmatch. We present 10 patients with DSA and 
surprisingly excellent long term outcome. In the current era the level of DSA 
antibody as assessed by more sensitive/ sophisticated methods as Luminex 
technique might be more predictive than the actual FC crossmatch results.
POSTER BOARD NUMBER P3 – 199
TOWARDS A THEORETICAL BASIS FOR THE 1773 
SELECTION OF PATIENT’S OPTIMAL FOR HLA SPECIFIC 
ANTI-DONOR ANTIBODY TRANSPLANTATION
R. Vaughan1, O. Shaw2, K. Reddi2
1King’s College, London, 2Guy’s Hospital
Recipient antibodies to donor HLA antigens are regarded as a contraindication 
to solid organ transplantation, although liver transplantation is usually an 
interesting exception. The sensitive fl ow-cytometry based single HLA antigen 
bead methods that have recently become available are allowing fi ne defi nition 
of complex antisera. It is now possible to be quite precise in defi ning the list 
of HLA alleles to which a patient has raised antibodies. This can be seen as 
preventing rather than facilitating solid organ transplantation. We propose that 
antibodies to HLA are not necessarily a contraindication to transplantation if 
reduced to low titre immediately prior to transplantation, but should be placed 
in context.
It is well recognised that the T cell alloepitope, consisting of part of the HLA 
groove and it’s embedded peptide is very different from the B cell epitope, 
which may be represented by single or discrete clusters of amino acids scattered 
more peripherally over the HLA molecule. There is also good experimental and 
theoretical evidence to believe that antibodies are produced after indirect T 
cell stimulation (1). However there is little or no evidence that the processed 
alloantigen peptide presented within HLA Class II is the same as the B cell 
epitope recognised by the antibody stimulated with T cell help. So although the 
sensitising alloantigen may be the same the two epitopes will usually differ.
This gives a rational for antibody removal: a repeat HLA mismatch to which 
a patient has raised antibodies is likely to involve T and B cell memory. If 
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the antibody is crossreactive with other HLA antigens that are not direct 
mismatches then this mismatch may only challenge B cell memory, with T cell 
help being limited as the processed peptide(s) may be different. This scenario 
would therefore present less of allostimulus. This has formed the theoretical 
basis for our successful anti-donor HLA antibody removal programme and 
examples will be given of the effectiveness of this approach. Ultimately it 
is to be hoped that methods for the rapid assessment of T cell memory will 
supercede our admittedly ad hoc approach. Our take home message is that T 
cell memory is an important context in which to interpret a patient’s suitability 
for antibody removal in renal transplantation.
POSTER BOARD NUMBER P3 – 200
SCD30 IN HLA ANTIBODY INCOMPATIBLE RENAL 1774 
TRANSPLANTATION
N. Kessaris1, P. Chandak2, N. Mamode2, R. Vaughan2, G. Koffman2
1St George’s Hospital, Balckshaw Road, London SW17 0QT, UK, 
2Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK
Background: CD30 is a 120kd glycoprotein surface receptor that belongs to 
the tumour necrosis factor superfamily. This is found on activated CD30+ T 
cells that then release a soluble form of CD30 (sCD30) into the circulation. 
CD30 is a costimulator molecule and a marker in the regulation of the balance 
between Th1 and Th2 immune response.
Aims: The aim of this study was to investigate sCD30 level before and after 
HLA antibody incompatible renal transplantation. A high level of pre-transplant 
serum sCD30 in patients undergoing antibody compatible renal transplant has 
been shown to be a risk factor for acute as well as chronic rejection. There are 
no similar studies in HLA antibody incompatible renal transplantation.
Methods: The pre and post-transplant serum samples of the fi rst fi ve patients 
who underwent desensitisation in a single unit were retrieved and analysed for 
sCD30 using enzyme-linked immunosorbent assay (ELISA). All transplants 
were performed between May 2005 and January 2007. Pre-transplant sCD30 
levels were correlated with creatinine level at two months as well as biopsy 
proven rejection up to one year. Pre-transplant sCD30 levels were also 
compared with those of 22 antibody compatible renal transplant patients 
performed during 2005. Fisher’s Exact Test and Mann-Whitney U test were 
performed for categorical and numerical data respectively.
Results:
Desensitisation 
group
HLA Antibody 
compatible group
Number of cases 5 22
Mean Age (years) 45.8 43.9
Mean Pre-Plasmapheresis sCD30 (U/ml) 56.7 N/A
Mean Pre-Tx sCD30 (U/ml) 14.1 92.9
Mean 1 week Post-Tx sCD30 (U/ml) 17.0 N/A
Mean 6 month Post-Tx sCD30 (U/ml) 17.4 N/A
Number of patients with ≥1 rejection episodes at 1 year 2 (40%) 9 (41%)
There was a reduction in sCD30 after plasmapheresis in the desensitisation 
group. This was maintained over the fi rst six months. Pre-transplantation sCD30 
level was higher in the two patients that had rejection (mean 25.2U/ml) when 
compared with the other three patients (mean 6.7U/ml) in the desensitisation 
group but this difference was not signifi cant (p=0.1). The creatinine level of the 
two patients with rejection was also higher at two months (mean 241mmol/L) 
when compared with the three patients who had no rejection (mean 123mmol/L) 
but again this did not reach statistical signifi cance (p=0.1) when compared with 
pre-transplantation sCD30 level.
Moreover, pre-transplantation sCD30 level in the HLA antibody compatible 
group did not correlate with creatinine (p=0.845), graft failure (p=0.464) or 
rejection rate (p=0.393) at one year.
Interestingly, pre-transplant sCD30 levels were signifi cantly lower in the 
desensitisation group (p<0.001) compared with those of 22 antibody compatible 
renal transplant patients.
Conclusions: Even though the group samples are small, there is a trend 
between pre-transplant sCD30 and creatinine as well as pre-transplant sCD30 
and rejection in the desensitisation group. Contrary to previous studies there 
was no such relationship in the HLA antibody compatible group. Much bigger 
studies are required to investigate the signifi cance of a low pre-transplant 
sCD30 level in HLA antibody incompatible renal transplantation.
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KIDNEY RECIPIENTS’ DEMOGRAPHICAL 1775 
AND SENSITIZATION ANALYSIS IN LITHUANIAN 
TRANSPLANTATION CENTER IN VILNIUS: AN EIGHT-YEAR 
ANALYSIS
R. Dobrovolskiene1, M. Miglinas, T. Rainiene, E. Asakiene
1Vilnius University Hospital, Nephrology Center, 2Vilnius University Hospital, 
Nephrology Center, director, 3Vilnius University Hospital, Immunology 
laboratory, 4Vilnius University Hospital, Nephrology Center
Introduction: Kidney transplantation is the treatment of choice for most 
patients with end-stage renal disease (ESRD). Optimal outcomes occur when 
kidney transplantation is performed as early as possible after the onset of 
ESRD, and risk of death and graft failure increase with the length of time on 
dialysis.
Methods: We investigated 374 kidney recipients, who have been transplanted 
between 01.01.2000 and 31.12.2007 and analyzed recipient/donor gender, 
sensitization of recipients, length of time on dialysis before transplantation and 
delayed graft function.
Results: There were 374 kidneys transplanted during the observation period: 68 
(18.2%) from female donors and 306 (81,8%) from male donors. These kidneys 
were received by 163 (43,6%) female and by 211 (56,4%) male recipients. 
Duration of dialysis before transplantation was 37,45 months (0-172). 15 (4%) 
from 374 transplanted recipients were sensitizied >50% panel reactive antibody 
and 39 (10.4%) from 374 transplanted recipients were sensitizied with a panel 
reactive antibody titer of 15-49%. In 28,3% recipients a delayed graft function 
was detected.
Conclusion: We found a donor-recipient pair inadequacy in gender in our 
transplant series in the studied period. There was also a signifi cant proportion 
of sensitizied recipients, high frequency of delayed graft function and a long 
median duration of dialysis before transplantation.
POSTER BOARD NUMBER P3 – 202
EVALUTION OF IMMUNOSUPPRESSION PROTOCOL IN 1776 
ABO-INCOMPATIBLE LIVING KIDNEY TRANSPLANTATION-
SINGLE CENTAER ANALYSIS
Y. Nakagawa, K. Saito, K. Takahashi
Division of Urology, Department of Regenerative And Transplant Medicine, 
Graduate School of Medical And Dental Sciences, Niigata University
Background: Immunosuppression therapy for ABO-incompatible kidney 
transplantations have previously been more rigorously practiced than ABO-
compatible. However, we found that patients treated with this regimen developed 
a high rate of complications. In our search for optimal immunosuppression, 
we have evolved and made three major changes and one minor change in 
the induction period immunosuppressive therapy in ABO-incompatible 
kidney transplantation. We have been comparable with four induction period 
immunosuppressive therapy.
Methods: 40 kidney recipients were enrolled in our study comparing the four 
protocols. Group I (n=13) patients received a standard immunosupressants, 
calcineurin-inhibitor (CNI), azathioprine or cyclophosphamide(CPA), and 
standard-dose steroid with splenectomy during April, 1996-March, 2002. 
Group II (n=6) patients were treated with low-dose CNI with MMF, and early 
low-dose steroid and induction with Basiliximab and splenectomy during April, 
2002 - August, 2004. Group III (n=13) patients were treated with low-dose CNI 
with MMF, early low-dose steroid and Basiliximab induction with standard-
dose (375mg/m2 ¦ ~2) Rituximab without splenectomy during September, 
2004-April, 2006. Group ‡W (n=8) patients were treated with low-dose 
(100mg/m2) Rituximab in triple immunosuppressive therapy combined with 
CNI/MMF/low-dose steroid desensitization started 1 month before surgery, 
during May, 2006-february, 2008.
Results: Patient (93%versus 100%, 100% and 100%) and graft survival 
(84.6% versus 66.6%, 92.3% and 100%) at 1year were not different between 
the groups. Patients of Group III and Group ‡W experienced signifi cantly 
less acute rejections than those in Group I (36.3% and 12.5%, versus 77% 
P=0.01). And Allograft function and incidence of adverse events and infections 
were similar between the four groups. However, the early low-dose steroid 
protocol Groups (GII, GIII and G‡W) patients experienced signifi cantly less 
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peptic ulcer and NODAT (new onsed diabetes after transplant). The Rituximab 
Groups (GIII and G‡W) did not experience antibody-mediated rejection 
(AMR). In the Rituximab Groups (GIII and G‡W) patients, B cells were 
selectively suppressed. Furthermore, majority of patients of Group III evokes 
elimination of B cell in peripheral blood after 2 year. In Group III, three Patients 
developed leukocytopenia six months after rituximab treatment, but Group ‡W 
experienced signifi cantly less incidence of adverse events.
Conclusion: We have be able to improve graft survival and reduced complications, 
through we have evolved in the induction period immunosuppressive therapy 
in ABO-incompatible kidney transplantation.
POSTER BOARD NUMBER P3 – 203
COMPARISON OF ANTIBODY MONITORING SYSTEM 1777 
WITH FLOW CYTOMETRIC CROSS MATCH TEST IN RENAL 
TRANSPLANT RECIPIENT WTH HIGH PANEL REACTIVE 
ANTIBODY
H.S. Hwang, B.J. Hyoung, S.Y. Lee, Y.J. Jeon, H.E. Yoon, J.Y. Kim, 
B.S. Choi, Y.S. Kim, B.K. Bang, C.W. Yang
Departments of Internal Medicine, College of Medicine, The Catholic 
University of Korea, Seoul, Korea
Purpose: We investigated the availability of antibody monitoring system(AMS) 
which uses ELISA cross match assay to detect donor-specifi c anti HLA IgG 
antibody(DS-HLA Ab). Until now, no comparative investigation between AMS 
and fl owcytometric crossmatch test (FCXM) has been reported. The objective 
of this study was to compare the two methods in fi nding DS-HLA Abs in renal 
transplant recipient with high panel reactive antibody(PRA) defi ned as more 
than 50% reactivity.
Methods: A total of 32 sera from 17 pre-renal transplant recipients with high 
ELISA PRA were screened for DS-HLA Abs. When anti-HLA Abs were 
determined in ELISA PRA and the matched donor had the corresponding HLA 
antigen, the detected anti-HLA Abs were considered to be DS-HLA Abs. And 
all sera were screened for AMS and FCXM.
Results: DS-HLA Abs were detected in 23 serum samples (71%). Sensitivity, 
specifi city, positive predictive value and negative predictive value of AMS 
assay in detecting DS-HLA Abs was 82.6%, 88.9%, 95%, 66.7%, respectively. 
Signifi cant concordance was observed (84.3%) between AMS and FCXM 
(kappa=0.429, P<0.05). Discordance among the three tests was observed in 
8 sera. Three sera (9.3%) had DS-HLA Abs, but none of AMS and FCXM 
detected the DS-HLA Abs. In one serum sample(3.1%), DS-HLA Abs were 
correctly detected in FCXM, but not in AMS. Also, one false positive result 
was observed with AMS. However, in three sera, DS-HLA Abs which were 
not detected in FCXM, was detected in AMS assays. From the concordant 
point of view, AMS assay showed higher concordance rate (kappa = 0.649, 
P<0.05) with DS-HLA Abs than FCXM (kappa = 0.302, P<0.05). Moreover, 
higher concordance rate of AMS group was observed with DS-HLA Abs 
class I (kappa = 0.813, P<0.05) compared to the T cell FCXM(kappa = 0.438, 
P<0.05).
Conclusion: In renal transplant recipient with high ELISA PRA, AMS assay 
detected DS-HLA Abs when FCXM did not. AMS assay may be a more useful 
indicator to detect DS-HLA Abs, especially, DS-HLA Abs class I which has 
more infl uence in graft kidney.
POSTER BOARD NUMBER P3 – 204
OPTIMAL DESENSITIZATION IN SUCCESSFUL 1778 
ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION
K. Saito, Y. Nakagawa, M. Suwa, M. Tasaki, T. Tanikawa, T. Nishiyama, 
K. Takahashi
Division of Urology, Niigata University Graduate School of Medical And 
Dental Sciences
Background and aim: More than 1,000 ABO-incompatible kidney 
transplantation has been done in Japan since January 1989. Since September 
2004, we have developed the ¦ g desensitization therapy for ABO-incompatible 
kidney transplantation without splenectomy which utilizes preoperative 4 
weeks MMF/low dose steroid combined with two doses of rituximab at 375 
mg/m2. We perform two sessions of Double Filtration Plasmapheresis(DFPP) 
before operation to achieve anti-donor blood type antibody titer lower than 8 
to 16 folds, but not routinely do any postoperative antibody removal or IVIG. 
Original “Lymphoma treatment” dosage of rituximab was considered much 
enough for this purpose, so we have tried to reduce the dosage for more safe 
and effective desensitization.
Patients and methods: We have compared the high dose (375mg/m2 x 2) 
rituximab administration group (Group 1; n=13) and low dose (100mg/m2 x 2) 
group (Group 2; n=7). In Group 1, CNI was started just before surgery and two 
doses of basiliximab were also administrated. In Group 2, CNI was initiated 4 
weeks prior to surgery and basiliximab was not used. In both group, We have 
evaluated the rituximab concentration profi le, peripheral CD19, 20 positive 
lymphocyte population, serum immunoglobulin level, anti-A/B antibody titer, 
patient and graft survival, graft rejection and complication.
Results: Patient and graft survival was 100%, 92% in Group 1 and 100%, 
100% in Group 2, respectively. Acute rejection was 4(Ia 3, Ib 1) in Group 1 and 
1(IIa) in Group 2. Rituximab concentration was signifi cantly lower in Group 
2, however, there was no signifi cant difference in serum immunoglobulin 
level, anti-A/B antibody titre, peripheral CD19, 20 positive cell population and 
serum creatinine level. There were 2 adenoviral infection, 10 CMV reactivation 
and 3 late onset leucocytopenia in Group 1. In Group 2, there was 1 CMV 
viremia which was successfully treated by ganciclovir. Except for 3 cases for 
treatment of AMR, postoperative antibody removal or IVIG was not done in 
both groups.
Conclusion: In ABO incompatible kidney transplantation without splenectomy, 
low dose (100mg/m2 x 2) rituximab desensitization is safe and effective. No 
additional antibody removal or IVIG is necessary.
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LOW DOSE INTRAVENOUS IMMUNOGLOBULIN, 1779 
PLASMAPHERESIS AND RITUXIMAB FOR DESENSITIZING 
HIGHLY SENSITIZED RENAL TRANSPLANT RECIPIENTS
H.E. Yoon, B.J. Hyoung, S.Y. Lee, H.S. Hwang, Y.J. Jeon, B.S. Choi, 
Y.S. Kim, B.K. Bang, C.W. Yang
Kangnam St Mary’s Hospital, The Catholic University of Korea
Background: Highly sensitized patients have a reduced chance of undergoing 
renal transplantation, and the number of these patients is growing. Several 
desensitization protocols have been developed, but there is no standard 
treatment. This study reports our experience of living donor transplantation 
with a desensitization protocol including pretransplant plasmapheresis, low 
dose intravenous immunoglobulin (IVIG) and anti-CD20 antibody (rituximab) 
in highly sensitized patients.
Methods: Ten patients with a current or historical positive crossmatch 
test or high level (¡Ã 50%) of panel reactive antibody (PRA) underwent a 
desensitization protocol, including six times of pretransplant plasmapheresis 
and subsequent low dose IVIG (PP/IVIG). Rituximab was additionally used in 
two patients. The clinical outcome and histological fi ndings of protocol biopsy 
were retrospectively analyzed.
Results: All ten patients underwent renal transplantation after achievement 
of negative crossmatch tests or low level (<20%) of PRA. Donor-specifi c 
anti-HLA antibodies were negative at the time of transplantation. Two acute 
rejection episodes developed in early posttransplantation period, of which one 
was reversible with posttransplant PP/IVIG and methylprednisolone therapy, 
however the other resulted in allograft loss. A protocol biopsy was performed 
in four patients, and all showed nonspecifi c fi ndings with no C4d deposition 
along the peritubular capillaries. Nine patients (90%) are currently dialysis-free 
after a median follow-up of 22.6 months (range: 6.9-52.0), and there were no 
more acute rejection episodes. The last mean serum creatinine concentration is 
1.0¡¾0.2 mg/dl (range: 0.7-1.4).
Conclusions: The desensitization protocol using pretransplant PP/IVIG and 
rituximab is effective and safe in reducing preformed alloantibodies. The 
absence of donor-specifi c antibodies and stable allograft function promise a 
successful long-term outcome in highly sensitized patients.
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LIVE DONOR RENAL TRANSPLANTATION IN 1780 
RECIPIENTS WITH A POSITIVE CROSS MATCH DUE TO 
ANTIBODIES AGAINST NON-HLA ANTIGENS
A. Vathsala1, H.X. Lou1, M.L. Lai2, T. Kee1
1Singapore General Hospital, 2Health Sciences Authority
Renal transplantation across a positive HLA cross match (XM) is associated 
with a high risk of acute rejection (AR) and worse graft survival. Enhanced 
immunsuppression with Plasma exchange, anti-lymphocyte antibody preparations 
(ALP), intravenous immunoglobulin (IVIG) in varying combinations is advocated 
for renal transplant recipients (RTX) with donor-specifi c antibody (DSA) as 
identifi ed by HLA-coated beads. However, outcomes and immunosuppressive 
strategy for those with no DSA, but a positive XM, presumably due to Non-HLA 
antibodies, have not been well elucidated. The present study evaluated outcomes 
for RTX with a positive XM due to antibodies against Non-HLA antigens as 
detected by a Flow cytometric crossmatch (FCM).
From June 2005 to September 2007, 32 live donor renal transplant recipients 
(LDRT, mean age 32 years, 50% female, 50% Chinese, mean PRA 32, 19% with 
PRA>80%) with a positive (+) FCM undergoing RT at our centre were included 
in the study population. FCM between donor and recipient demonstrated +Tcell-
IgG in 4 (12.5%), +Tcell-IgM in 2 (6.2%), +Bcell-IgG and IgM in 14 (43.8%) 
and +Bcell-IgM in 15 (46.9%). Mean channel shift (MCS) was 102, 78, 231 and 
269 for those with positive Tcell-IgG, IgM and Bcell-IgG and IgM respectively. 
CDC XM was positive in 28.1% (Normal Bcell in 25%, AHG-enhanced Bcell 
in 28.1%). All FCM LDRT received IV thymoglobulin for 5 days starting 1 
day prior to RT together with Cyclosporine (CsA) starting 3 days before RT, 
MPA and steroids. Except for LDRT with a +Bcell-IgM, all received additional 
intravenous immunoglobulin (IVIG) 1 day before RT, 6 hours after the dose of 
Thymoglobulin was completed. CsA doses were adjusted to achieve C2 levels 
of 1000 ng/mL at 1 month and MPA doses were adjusted to trough levels <4 ng/
mL. All LDRT received 3 months of CMV prophylaxis.
At a median (range) follow-up of 12 (4 – 32) months, graft and patient survivals 
were 100% with the median 1- and 3-month creatinine of 105 (65 - 217) and 
113 (78-178) ìmol/L respectively. The incidence of early AR at 6 months post 
RT was 0%; however, 2 (6.2% of LDRT) with negative CDC Bcell XM RTX 
experienced late AR at 225 and 516 days post RT respectively. One LDRT each 
with +Bcell-IgG FCM and +Bcell-IgM developed Banff 2A and 1A rejection 
respectively and were successfully treated with methylprednisolone. No AR 
episodes were documented in CDC XM or FCM Tcell positive LDRT. Apart 
from one LDRT with BK viruria, no other infections or malignancy were 
documented. Our study documents a 6.2% incidence of AR, excellent survival 
and low morbidity in LDRT with a positive FCM.
These results demonstrate the effi cacy of pre-RT ALS together with CsA-
MPA in minimizing AR without an increased risk of morbidity. Depletion 
of potentially alloreactive lymphocytes prior to antigen presentation may 
contribute to this excellent outcome. The anti-idiotypic effects of IVIG may 
further prevent potentially alloreactive antibodies to non-HLA antigens from 
initiating AR. Evaluation with DSA, FCM and CDC XM should be used to 
stratify LDRT so as to optimise immunosuppression.
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PRE- AND POST-TRANSPLANT BEHAVIOUR OF DSA 1781 
IN KIDNEY TRANSPLANT RECIPIENTS WITH NEGATIVE 
CROSSMATCH TREATED BY PLAMAPHERESIS AND IVIG
L.E. Morales-Buenrostro1, C. De Leo2, M. Arvizu2, B. Gabilondo2, 
M. Vilatoba2, J. Alberu2
1Depto. Nephrology and Mineral Metabolism. Instituto Nacional de Ciencias 
Medicas y Nutricion SZ, 2Department of Transplantation. Instituto Nacional 
de Ciencias Medicas y Nutricion SZ
Background: The clinical signifi cance of pre-transplant donor specifi c 
antibodies (DSA), despite negative cytotoxicity and fl ow cytometry 
crossmatches is unknown. Recently, it was reported a 20% incidence of acute 
humoral rejection (AHR) in patients of these characteristics compared with a 
2.5% incidence in patients without DSA (AJT 2007; 7: 2371).
Aim: In this pilot study we investigate the effect of 3 pre-transplant sessions of PP 
followed by 100 mg/kg/session of IVIg on DSA detected by LABScreen® PRA 
class I and class II, and confi rmed by LABScreen® Single Antigen HLA class I 
and class II antibody detection test, and in the evolution of the renal grafts.
Patients and methods: Four adult patients (mean age 30.7 yr), 3 female (1st 
transplant), and 1 male (2nd transplant), having DSA vs. 1-3 HLA specifi cities 
despite repeatedly negative T- and B-cell CDCXMs with their prospective 
living kidney donors, received the aforementioned pre-transplant treatment 
(PP+IVIg). Immunosuppression, started the day of kidney transplantation was: 
Daclizumab 2 mg/kg, tacrolimus, MMF and steroids.
Results: DSA specifi cities detected by LABScreen® PRA and LABScreen® 
Single Antigen, at the fi rst screening (baseline), post-PP+IVIg sessions pre-
KT, and post-transplant (Post-KT) are displayed in the Table. Renal function 
remains stable and no events of AHR have occurred at 2, 8, 10, and 19 mo 
post-transplant follow-up, respectively. SCr and GFR (MDRD) at this follow-
up were: 1.18 mg/dl and 72.2 ml/min, 1.0 mg/dl and 68 ml/min, 0.74 mg/dl and 
125.9 ml/min, 0.83 mg/dl and 85.2 ml/min, respectively.
PATIENT BASELINE
 LABScreen PRA % PRA
LABSCreen Single 
Antigen LUMINESCENCE
1 A24 40% ND
2 A24, Cw7 64% A24, B73 7442, 8360
3 B35 36% ND
4 DR1, DQ5 49% DQ5 8989
PATIENT PRE-KT
 LABScreen PRA %PRA
LABScreen Single 
Antigen LUMINESCENCE
1 A24 20% A24 701
2 A24 42% A24, B73 333, 269
3 NAD  0% Cw4, DQ4 1304, 262
4 DR1,DQ5 49% DQ5 4879
PATIENT POST-KT
 LABScreen PRA %PRA
LABScreen Single 
Antigen LUMINESCENCE
1 NDSA  9% NDSA ---
2 A24 33% A24, B73 333, 107
3 NDSA 24% Cw4, DQ4 1667, 335
4 DR1,DQ5 54% DQ5 5943
ND= Not done; NAD=No antibody detected
Conclusions: DSA were detected by both, LABScreen® PRA and LABScreen® 
Single Antigen, and the specifi cities identifi ed through these tests were 
consistent at baseline, pre-, and post-transplant. These tests showed that 
PP+IVIg decrease the PRA percentage and luminescence of the identifi ed 
DSA. Persistence of DSA in the post-transplant course was observed in 3 out 
of 4 patients, although at lower levels compared to baseline. In this scenario, a 
large scale study will be necessary to demonstrate if antibody reduction offers 
a salutary effect in graft outcome of these patients.
POSTER BOARD NUMBER P3 – 208
DESENSITIZATION OF LIVING DONOR RENAL 1782 
TRANSPLANT RECIPIENTS USING RITUXIMAB AND 
ALEMTUZUMAB INDUCTION THERAPY
J. Leventhal, L. Gallon, E. Power, A. Tambur, G. Ramsay, A. Zacharia, 
J. Friedewald
Northwestern University
Sensitization to human leukocyte antigens,with resultant donor specifi c antibodies 
(DSA), as well as ABO incompatibility (ABOi) is particularly frustrating for pts 
who have a live donor (LD), as their waiting times could be extremely short 
were it not for a positive crossmatch. We have used a strategy to desensitize LD 
KTx recipients that integrates therapies to disrupt memory-dependent antibody 
responses by purging both T helper and B cells (Alemtuzumab, Rituximab).
Methods/results: 30 pts with DSA and 8 pts with ABOi received a single 
dose of Rituximab (375mg/m2) 2-4 wks pre-Tx. Plasmapheresis (PP) followed 
by IVIG (0.2gm/kg) was initiated and continued daily or on alternate days 
until DSA and/or anti-A or anti-B titers fell to < 1:8 or at least an 8 fold 
reduction of titer was observed. Pts received alemtuzumab induction (30mg 
i.v.) intraoperatively. Maintenance immunosuppression (IS) consisted of 
Tacrolimus, MMF, and steroids. DSA titers were determined before, during, 
and after desensitization using single-antigen (high defi nition) fl ow cytometry 
based analysis. Anti-A/B titers were determined using hemagglutination 
technique. The decision to transplant was based upon substantial reduction, 
but not necessarily complete elimination, of DSA and/or anti- A/B antibodies. 
Protocol biopsies were performed on Day 7 and 14 post-Tx. Elevation of 
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DSA/anti-A/B post Tx, or fi ndings of C4d+ staining on biopsy was treated 
by additional PP/IVIG cycles, until titers were substantially reduced again. 
Median follow up for DSA pts is 3 years and for ABOi pts is 6 months. 1 pt 
experienced clinically evident antibody mediated rejection. 1 pt lost her graft 
due to recurrent FSGS. 1 pt who developed recurrent, high titer DSA post-
transplant has gone on to develop chronic allograft nephropathy. Signifi cant 
infectious complications include the development of BK virus nephropathy in 
one patient. Pt survival is 100%.
Conclusions: A combination of rituximab, PP/IVIG, with alemtuzumab 
induction and triple IS maintenance is a well tolerated, highly effective, and 
durable means of antibody desensitization in renal transplantation. Consistent 
monitoring of DSA and antii-A/B titre is crucial for early detection of increased 
donor-specifi c humoral activity.
POSTER BOARD NUMBER P3 – 209
EXCELLENT GRAFT SURVIVAL USING 1783 
CYCLOPHOSPHAMIDE WITHOUT~ @RITUXIMAB 
INDUCTION IN ABO-INCOMPATIBLE RENAL 
TRANSPLANTATION
A. Katayama1, K. Uchida2, T. Kobayashi3, T. Ueki1, N. Goto2, T. Sato2, 
T. Nagasaka2, Y. Watarai2, K. Morozumi2, A. Ito4
1Transplant Surgery, Masuko Memorial Hospital, 2Kidney Center, Nagoya 
Daini Red Cross Hospital, 3Applied Immunology, Nagoya University School 
of Medicine, 4Internal Medicine, Masuko Memorial Hospital
Introduction: ABO-incompatible living donor kidney transplantation has been 
performed to expand the donor pool and curtail the universal donor shortage. 
For ABO-incompatible living kidney transplantation to be successful, the 
suppression of T-cells as well as the positive removal and inhibition of the 
production of blood type antibodies are essential. The aim of this study was to 
evaluate clinical outcome between cyclosporine (CsA) and tacrolimus (Tac) in 
ABO-incompatible kidney transplantation.
Methods: We performed ABO-incompatible living donor renal transplantation 
in 99 patients (68 patients received CsA and 31 patients received Tac) since 
1993. The mean age of patients was 38 years (11-63 years) in the CsA group 
and 44 years (17-52 years) in the Tac group. To minimize the risk of antibody 
mediated rejection, we performed a splenectomy 2 weeks before transplantation, 
eliminated anti-A and/ or anti-B antibodies by double-fi ltration plasmapheresis 
(DFPP), and administered a potent immunosuppressive regimen consisting 
of cyclophosphamide, antilymphocyte globulin or anti-CD25 monoclonal 
antibody and prednisolone in both groups. Especially, we avoided splenectomy 
in 3 cases because of low titer of blood type antibodies before DFPP. Dosing of 
calcineurin inhibitors was based on monitoring AUC0-4 target values.
Results: The incidence of acute rejection during the fi rst 3 months post 
transplantation was 19.1% (5 cellular, 7 antibody-mediated and 1 combined 
type) in the CsA group compared with 12.9% (1 cellular, 3 antibody-mediated 
type) in the Tac group (p=0.215). Graft survival rates were 98.5% in the CsA 
group and 94.7% in the Tac group at 1 year (P=0.518). In both groups, anti-
A/B IgM and IgG antibody levels were maintained at less than 45% of the 
pre-DFPP levels during 3 months after transplantation. No antibody binding to 
the transplanted kidney was detected in either group at any time (1 hour to 1 
year) posttransplantation.
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ABO-INCOMPATIBLE RENAL TRANSPLANTATION 1784 
WITHOUT SPLENECTOMY OR RITUXIMAB – LOW 
REJECTION RATES, LOW MORBIDITY AND EXCELLENT 
CLINICAL OUTCOMES
S. Flint, R. Masterson, R. Walker, I. Fraser, A. Robertson, D. Francis, 
R. Millar, S. Cohney
Department of Nephrology, Royal Melbourne Hospital
Although ABO incompatible renal transplantation no longer requires 
splenectomy, overall immunosuppression has remained greater than 
administered in blood group compatible transplantation. The added potential 
morbidity, cost and inconvenience is of particular concern in older recipients 
and patients with major comorbidities. More recently rituximab has been used 
in a number of centres, though there is no trial evidence for its effi cacy and 
continued concerns about its additional expense and the long-term consequences 
of its use. Here we report a series of 28 patients (5 over the age of 65) who 
received renal transplants from ABO blood group incompatible donors without 
splenectomy at transplantation. 24 of the 28 did not receive rituximab.
With the exception of antibody removal (plasmapheresis and/or 
immunoadsorption columns), and the commencement of mycophenolate 
mofetil (MMF) 10 to 14 days pre-transplant, immunosuppression was identical 
to that of “compatible” transplants at our institution, consisting of anti-CD25 
antibody, mycophenolate mofetil (MMF) with tacrolimus and prednisolone 
(both commenced at/after transplantation). MMF was maintained at 500mg bd 
from around week 6, and prednisolone was weaned to 5mg/day by 8-12 weeks. 
Average tacrolimus trough levels were: week 0 to 6, 10 ng/ml; week 8, 8.9ng/
ml; week 12, 7.2ng/ml; week 24, 5.6ng/ml; week 52, 4.8ng/ml.
Patients received a median of 4 exchanges pre-transplant and 3 exchanges post-
transplant. Baseline titres ranged from 1:16 to 64,000 by tube method (1:2 to 
2048 by Gelcard), though for 21 (75%) patients these were under 1:512. One 
patient had a donor specifi c class II anti-HLA antibody (DSAb) with a positive 
B cell CDC crossmatch.
At a median follow up of 13 months (range 3-29), patient & graft survival is 
100%. In total, 3 patients have developed antibody-mediated rejection (AbMR). 
In each case this occurred within the fi rst 2 weeks, and was due in one patient 
to DSAb rather than an ABO incompatibility. One patient experienced cellular 
rejection and 1 patient subclinical cellular rejection (protocol biopsy and 
concurrent with a UTI). All cases of rejection responded to treatment (biopsy 
proven) though the patient with DSAb continues to receive IVIG for residual 
AbMR. One case of AbMR was amongst the four patients who received 
rituximab, while the other 4 cases (2 cellular and 2 AbMR) were amongst the 
24 not receiving rituximab.
Recipient renal function is similar to donor renal function except in one 
patient distinguished by mechanical/ureteric complications. One patient who 
inadvertently did not receive appropriate prophylaxis developed CMV disease. 
Five patients have had one or more episodes of BK viraemia, with complete 
resolution in all cases. One patient developed post-transplant diabetes mellitus, 
which has since resolved.
ABO Incompatible Kidney Transplantation (including moderate to high titre) 
can be performed without excessive immunosupression and with low morbidity, 
dramatically increasing transplant options for ESKD patients.
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ABO-INCOMPATIBLE RENAL TRANSPLANTATION 1785 
WITHOUT SPLENECTOMY OR RITUXIMAB – A LOW RATE 
OF COMPLICATIONS
S. Flint, R. Masterson, R. Walker, D. Yip, S. Cohney
Department of Nephrology, Royal Melbourne Hospital
ABO incompatible (ABOI) renal transplantation is now routinely performed 
without splenectomy but most regimens still use immunosuppression greater 
than in blood group compatible transplantation. The added potential morbidity 
is of particular concern in older recipients and those with major comorbidities. 
Rituximab has been used in a number of centres though trial evidence is 
lacking and reports are emerging of increased/late infection associated with 
its use. Here we report a low rate of complications in a series of 28 patients 
who received ABOI renal transplants without splenectomy, 24 of whom did 
not receive rituximab. Fourteen of the patients had titres greater than or equal 
to 1:256.
Patients received standard tacrolimus, mycophenolate mofetil and prednisolone 
with anti-CD25. Antimicrobial prophylaxis was with trimethoprim/
sulfamethoxazole and valganciclovir.
At a median follow up of 13 months (range 3 to 29), patient & graft survival 
is 100%. Renal function is stable with a median creatinine at present of 
140umol/L. Three patients received treatment for antibody-mediated rejection 
(one due to DSAb) and two were treated for cellular rejection.
Bacterial infections: 3 patients developed sepsis with a urinary focus and 2 
transplant pyelonephritis, all but one during the fi rst two weeks. There has been 
one case of Staphylococcus aureus septicaemia related to a permacath and one 
permacath exit site infection. There was one case of MRSE septicaemia related 
to contaminated blood products. Two patients developed Campylobacter 
gastroenteritis.
Opportunistic infections: A patient (D+/R-) who inadvertently did not receive 
appropriate prophylaxis developed CMV disease. Five patients have had one or 
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more episodes of BK viraemia, all without nephropathy and all with complete 
resolution.
Post-transplant diabetes mellitus (PTDM): One patient had pre-existing 
T2DM and one developed insulin requiring PTDM 1 month post-transplant. 
At two years she has an HbA1c of 5.8% off all hypoglycaemic therapy. An 
additional 7 patients have recorded at least one HbA1c > 6%; none of these 
have required hypoglycaemic therapy, though 2 meet the diagnostic criteria for 
PTDM. The current mean HbA1c of the cohort is 5.6%.
Urological: Two patients required re-operation for urinary leak and 
haematoma. One needed a transurethral resection of prostate for post-operative 
urinary retention and another with underlying refl ux nephropathy has ongoing 
problems with distal ureteric stenosis.
Haematological: Eight patients recorded brief episodes of neutropaenia 
(neutrophil count < 1.0x10^9/L). Compared to living related ‘compatible’ 
transplants at our institution over the same period (n=100), ABOI transplant 
patients were more likely to be anaemic at transplant (haemoglobin (Hb) 
97.5g/L versus 117g/L, p < 0.05), a difference which became insignifi cant at 
1 month.
Other: There was one case of pulmonary emboli 10 days post-operatively
A sepsis rate of 14% compares favorably with reported rates in ABOI centers. 
The use of plasma exchange contributes to line sepsis and transient anaemia. 
Despite this, our results show ABOI Kidney Transplantation (including 
moderate to high titre) can be performed without excessive immunosupression 
and with low morbidity.
POSTER BOARD NUMBER P3 – 212
C4D STAINING IN ONE-HOUR POST-REPERFUSION 1786 
ZERO-BIOPSIES SEEMS NOT TO BE SENSITIVE ENOUGH 
TO DETECT FURTHER ACUTE ANTIBODY-MEDIATED 
REJECTION
D.S.R. David, G.F. Ginani, P.S. Souza, M.C.R. Castro, N. Panajotopoulos, 
H. Kanashiro, R. Falci Jr, I.M. Antonopoulos, A.C. Piovesan, W.C. Nahas, 
E. David-Neto
From the Renal Transplantation Unit-Division of Urology, Laboratory of 
Transplant Immunology and Division of Pathology – Hospital das Clínicas, 
University of Sao Paulo School of Medicine
Renal transplantation in sensitized patients may be followed by acute antibody-
mediated rejection (AAMR) due to undetected levels of donor specifi c antibodies 
(DSA) during pre-transplant CDC-AGH cross-matching (XM). There is some 
evidence that C4d staining in zero-biopsies could detect the early phenomena 
of antibody-mediated complement-activation in the graft. To analyze whether 
C4d staining in zero-biopsies could predict the early (<100 days) occurrence 
of AAMR, all transplants (n= 354) performed at our center between June 2005 
and December 2007 entered into a prospective study of performing one-hour 
post-reperfusion, zero-biopsies stained for C4d by immunohistochemistry 
(IH). The biopsies were performed at least one-hour after removing the arterial 
and venous clamps and before the closure of the surgical wound. All transplants 
were performed against a negative T-lymphocytes CDC-AGH XM but three 
cases that had a positive B-lymphocyte XM. Twenty patients (5,6%) developed 
AAMR (defi ned as C4d+ staining plus circulating DSA) at a median time of 14 
(5-97) days post-Tx. Pre-transplant PRA revealed that 14 (70%) were sensitized 
against HLA-class I antigens and 14 (70%) against HLA-class II, with 13 
(65%) sensitized for both. Mean pre-Tx PRA (ELISA) was 57% and 61% for 
class I and II, respectively. Patients received kidneys with a median of 3 (2-5) 
HLA-ABDR mismatches. Circulating DSA were detected after transplant by 
CDC (n=6), FACS (n=13) or Luminex (n=1) at a median time of 14 (7-23) days 
after Tx. Out of these 20 patients, 14 (70%) were submitted to zero-biopsies 
and 6 (30%) were not due to many reasons. None of the zero-biopsies stained 
positive for C4d. However, all biopsies documenting AAMR, performed at a 
mean of 18 (4-95) days after transplant, revealed peritubular capillaries stained 
by C4d either by imunofl uorescence (IF) and/or IH. By IF, C4d was positive in 
10-50% PTC in 4 patients (29%) and in >50%PTC in 10 patients (71%). These 
data show that C4d staining in one-hour post-perfusion zero-biopsies seems not 
to be sensitive enough for the early detection of AAMR when the CDC_AGH 
XM is negative. In sensitized patients, early biopsies after Tx,, performed in 
the fi rst/second week, plus the frequent search for circulating DSA is possibly 
a more sensitive procedure for the early diagnosis of AAMR.
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COMBINED ALEMTUZUMAB AND RITUXIMAB 1787 
INDUCTION ALLOWS FOR EXCELLENT RESULTS IN 
HIGHLY SENSITIZED PATIENTS FOLLOWING RENAL 
TRANSPLANTATION
G. Brandacher, C. Bösmüller, S. Schneeberger, E. Pirchner, M. Biebl, 
R. Öllinger, H. Weiss, R. Margreiter, W. Mark
Department of General and Transplant Surgery, Innsbruck Medical 
University, Austria
Background: The increasing pool of multiple kidney graft recipients requires 
refi ned immunological strategies for HLA-sensitized patients. In this context, 
high levels of pretransplant panel reactive antibodies (PRA) have been 
associated with poor outcome due to an increased risk for acute as well as 
chronic rejection. Therefore, we have investigated a novel treatment protocol 
containing combined induction with alemtuzumab and rituximab in sensitized 
renal allograft recipients.
Methods: Nineteen patients (13f / 6m; mean age: 44±13.2 years) with PRA of 
>50% (50-98%) were transplanted from 1/2005 to 12/2007 and were included 
in this study. Patients received induction therapy with alemtuzumab (30mg) 
intraop and rituximab (375mg/m2) on day 1 post renal transplantation followed 
by maintenance therapy with tacrolimus, steroids and MMF. Kidney function 
and immunological follow up (PRA levels, renal biopsy) was assessed at 
predefi ned timepoints.
Results: After a mean follow up of 334±263 days, patient and graft survival 
was 95%, respectively with excellent renal function (mean creatinine 1.7±0.8, 
mean urea 63.1±31.6). Mean cold ischemia time was 13.2±6.1 hours and 
delayed graft function as defi ned by required posttransplant dialysis was 
47.3%. Induction therapy was well tolerated and not associated with severe 
infectious complications. Acute cellular rejection episodes could be controlled 
by bolused steroids (n=3; 15.7%). In four (21.1%) cases humoral rejection was 
suspected or diagnosed by positive C4d staining upon histology and treated by 
plasmapheresis.
Conclusion: In highly immunized renal transplant candidates combined 
alemtuzumab/rituximab induction is safe and may be considered a valuable 
approach for successful transplantation in this diffi cult immunological setting.
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RISK FACTORS FOR ANTIBODY MEDIATED 1788 
REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) 
RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW 
CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE 
DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND 
RATG THERAPY
A. Moss1, R. Heilman1, H. Chakkera1, M. Mazur1, S. Petrides2, E. Wosniak1, 
K. Mekeel1, D. Mulligan1, K. Reddy1
1Divisions of Transplant Surgery and Medicine, Mayo Clinic Arizona, 
Phoenix, AZ, United States and 2AKDHC, Phoenix, AZ, United States
We reviewed our experience with ktx in patients (pts) with positive CDC B 
and/or pos fl ow T/B-cell cxm treated (rx) with low dose IVIG and rATG in 
order to determine the incidence, outcome of rx and risk factors for AMR.
From July 03 to Nov 07 we performed 69 ktx in pts that met the above criteria. 
41 pts received live donor ktx; 33 were primary, 27 second, 6 third and 3 fourth 
ktx. Panel reactive antibody (PRA) was ≥80 in 24 pts, 20-79 in 23 pts and < 20 
in 22 pts. Donor specifi c antibodies (DSA) identifi ed by ELISA were found in 26 
pts (6 Class I; 14 Class II and 6 both). The cxm results are shown in Table 1. 
Table 1
 CDC B + CDC B -
Flow B+ T+ 9 23
Flow B+ T- 14 16
Flow B- T+ 0 6
Flow not done 1 0
All pts received induction with rATG (6 mg/kg) and low dose IVIG (100 mg/kg 
x 3). Maintenance immunosup consisted of tacrolimus, MMF and prednisone. 
AMR was rx with plasmapheresis, IVIG, rituximab and steroids. Protocol 
biopsies (bx) were performed at reperfusion, 1, 4, 12 months post ktx and then 
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once a year.
22 pts developed acute rejection episodes, 14 AMR, 1 acute cellular rejection 
(ACR) and 7 both ACR and AMR. There were 14 clinical and 8 subclinical (4 
AMR, 3 ACR/AMR and 1 ACR) rejections. Graft survival was 93% (2 graft 
thrombosis, 1 HUS, 1 CAN and 1 death with function) and pt survival was 99% 
with a median follow-up of 20 months (1-46 months). There was no graft loss 
from AMR. CrCl at 1-year was similar in pts with and without AMR (55±16 
cc/min). Univariate and multivariate analysis showed that positive CDC B-cell 
and presence of DSA Class II were risk factors for AHR. Retransplantation 
was a risk factor in univariate analysis only. The incidence of rejection in the 
different groups is shown in Table 2
Table 2
 n AMR p value
Class II DSA + 20 13 (65%) 0.0004
Class II DSA - 48 8 (17%)  
CDC B-cell + 24 16 (67%) 0.0001
CDC B-cell - 46 5 (11%)  
Retransplant 36 16 (43%) 0.017
Primary Tx 33 5 (15%)  
Positive CDC B-cell cxm and presence of Class II DSA were risk factors for AMR. 
AMR can be successfully treated without compromising graft function or survival. 
Further long-term follow-up is needed to confi rm these encouraging results.
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AN EASY AND COST-EFFECTIVE DESENSITIZATION 1789 
PROTOCOL FOR HIGH PRA/ POSITIVE CROSS MATCH
P. Varma, A. Hooda, A. Kumar
Armed Forces
Introduction: Patients with high PRA or positive cross match have preformed 
humoral antibodies to class I HLA antigens and are vulnerable to acute/ 
hyperacute rejection following transplantation.To remove/suppress these 
antibodies various approaches like plasmapheresis, immunoadsorption, 
cytoxan, IVIG or rituximab have been tried with variable success. Cost of such 
desensitization protocol is unaffordable by many, in developing countries.
Aim: Present study was done to test a simple and cost effective strategy of 
desensitization with mycophenolate and plasmapheresis.
Methods: All prospective renal transplant recipients with high PRA or positive 
cross match (at-least on two occasions during previous month) were subjects 
of the present study. Patients were started on mycophenolate mofetil 1 gm 
twice a day. Twenty days after start of MMF patients underwent 5 sittings of 
plasmapheresis over 1 week period. During this period and afterwards MMF 
was continued. On day 30 PRA and Cross match was repeated. If cross match 
and PRA were negative, the patient was taken up for transplantation and MMF 
was continued through the transplantation.
Results: 11 patients with mean age 39.55 years (range 23-58 years), with 
male: female ratio 8:3 were the subjects. The mean waiting period to 
transplantation due to high PRA/ Cross match in these patients was 5 months 
(range 1-18 m). Mean PRA before therapy was 75.5 (range 40-100%) and 
mean cross match was 32% (range 10-100%). After one month of treatment, 
mean cross match dropped to <10% and PRA also to <10% in 10/11 patients 
(90.9%)[p<0.05] except in one patient. All these 10 patients underwent renal 
transplantation with triple drug immunosuppression (Tacrolimus, MMF and 
presdnisolone), in addition to induction therapy with IL-2 blockers (6 pts)/ 
ATG (4 pts). One patient developed graft venous thrombosis and required 
graft nephrectomy. The remaining 9 patients have been doing well and none 
of them have developed any episode of rejection. Their mean creatinine is 
1.38 mg/dl (range 0.8-2.3 mg/dl) after a mean follow up period of 4.6 m 
(range 2-8 m).
Conclusion: Though on small number of patients, our study shows that 
effective desensitization can be achieved by judicious use of plasmapheresis 
and MMF.
GLOBAL DONOR CONCURRENT ORAL SESSION 128: 
PROBLEMS
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PATIENTS SEEKING LIVER TRANSPLANTATION 1790 
TURN TO CHINA: OUTCOME OF 15 EGYPTIAN PATIENTS 
UNDERWENT CADAVERIC LIVER TRANSPLANTATION 
IN CHINA
H. Abdeldayem, K. Abo Elella, I. Salamah, S. Soliman, K. Gameel, A. 
AboGabal, M. Rady, A. Helmy
National Liver Institute
Introduction: In Egypt liver transplantation is restricted to living related cases. 
Many of the liver transplant candidates do not have a suitable living donor.
Increasing numbers of Egyptian patients with end stage liver disease are seeking 
cadaveric liver transplantation in China. They are attracted by the lower costs 
and shorter waiting time compared to living related liver transplantation in 
Egypt. The aim of this study was to evaluate the outcome of Egyptian patients 
who underwent cadaveric liver transplantation in China and to address our 
ethical concerns.
Material and methods: Fifteen Egyptian patients who underwent 
cadaveric liver transplantation in China were included in this study. 
Preoperative data before traveling to China, all available reports from 
China and data concerning their follow up after coming back from China 
were retrospectively reviewed.
Results: Of the 15 patients, 11 were men and 4 were women. Their mean 
age was 52 years. Indications included hepatitis C-related liver cirrhosis 
(n=9), hepatitis C-related liver cirrhosis with hepatocellular carcinoma (n=4), 
and hepatitis B-related liver cirrhosis (n=2). Nine of the 15 patients were 
evaluated for living related liver transplantation but none of their potential 
donors was considered suitable. Three patients had advanced hepatocellular 
carcinoma and were not accepted by any center in Egypt for living related liver 
transplantation. Two patients did not have any potential living related donor. 
One patient refused the option of having living related liver transplantation 
in Egypt and elected from the start to get a whole liver graft from China. 
Waiting time in China before getting liver transplantation: ranged from 5 to 
days 22, median 13 days. All our patients were told exactly when they should 
arrive at the hospital and the organs usually arrive on time. Duration of stay in 
China: ranged from 28 to 89 days, median 49 days.The cause of death of the 
donors for all cases was severe brain injury (as per reports from the Chinese 
Hospitals). Putting in mind that the method of executions in China is known to 
be by gun-shooting the back of the head of the prisoner (Guttmann, 1992),we 
suggest that all donors were executed prisoners. The overall survival rate 
was 80.0% at 6 months and 73.3% at 12 months. There were four deaths, 
two of which occurred in China. Of the 11 surviving patients, nine (82%) 
developed complications. Nineteen complications were seen in the 13 patients 
who were managed following their return from China. Infective and biliary 
complications accounted for 46% and 23% respectively. Major complications 
necessitated prolonged hospitalization occurred in 4 patients. Two patients 
required further laparotomy.
Conclusions: Increasing numbers of patients from all over the world including 
Egypt travel to China for organ transplantation.Quite how hospitals meet patient 
needs so quickly is a question with legal and medical ethics implications. 
The organs are readily available but the source of “donors” is questionable. 
Clinicians considering referral of patients to China for consideration of 
cadaveric liver transplantation as well as patients who decide to seek treatment 
in China should be aware of these ethical issues and the potential risks they 
may encounter.
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ETHICAL AND LEGAL ASPECTS OF DONATION AFTER 1791 
CARDIAC DEATH (DCD) IN ITALY
P. Bruzzone
University of Roma
In Italy death of a human being must be declared either after brain death or 
after 20 minutes of cardiac arrest, certifi ed by continuous electrocardiography 
(EKC) recording.
In Italy active or passive euthanasia is a crime and no law concerning the so 
called “living will” has been yet approved. Therefore it is impossible to perform 
Maastricht category 3 or “controlled” donation after cardiac death (DCD).
In the sixties, at the very beginning of organ transplantation in Italy, kidneys 
have been removed from DCD or Non Heart Beating Donors (NHBD) and 
subsequently transplanted. However this kind of procedure was discontinued 
after that the Italian Parliament approved the “brain death” law.
Recently, DCD has been proposed again from some Italian transplant centers 
for Maastricht category 2 or 4 “uncontrolled” NHBD. There is partial agreement 
between some experts in Legal Medicine and some judges that cannulation 
of the femoral vessels could be performed without previous family consent 
in patients having sustained cardiac arrest but under timely and effective 
cardiopulmonary resuscitation. No drugs unuseful for the patient are allowed.
After having obtained the relatives’ consent, it is required to stop resuscitation 
it is mandatory to wait for at least 20 minutes of cardiac arrest, certifi ed by 
continuous EKC recording. Only afterwards is possible to start cold perfusion 
and maybe cardiopulmonary by-pass, move the patients to the operating room 
and proceed to organ harvesting.
In Italy a “presumed consent” transplant law has been approved but not really 
enforce, mostly due to lack of information of the public opinion. Therefore I 
think that is risky to perform premortem cannulation of the femoral vessels of 
the potential donor unless he brings with himself a “donor card” or there is a 
certain proof of his willingness to donate organs and tissues.
It is my personal opinion that this procedure will allow at best only the retrieval 
of few marginal kidneys and some tissues, and therefore will not be very helpful 
for our waiting list patients. I suggest instead modifying fi rst the Italian law in 
order to be able to declare cardiac death after only 5 minutes of cardiac arrest, 
certifi ed by continuous EKC recording.
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MORAL AND ETHICAL ISSUES IN LIVER 1792 
TRANSPLANTATION IN EGYPT
H. Abdeldayem, N. Allam, N.M. Adawy, E. Salah, A. Helmy
National Liver Institute
The non-acceptance of brain death criteria in Egypt meant that, only organs 
acquired from live donors could be used.
Objective: to highlight the ethical issues caused by living related liver 
transplantation (LDLT) in Egypt.
Methods: research ethics consultation that involved collaboration between 
physicians, religion scholars and clinical ethicists.
Results: The fi rst successful LDLT in Egypt was in the National Liver Institute 
in 1991, however, this program did not continue because of poor early results. 
In August 2002, the program was revived at Dar-Al-Foaud Hospital; since 
then almost 500 cases of LDLT were performed in 9 centers. In Egypt, liver 
donors are restricted to relatives up to third degree or spouse. The donor must 
be competent, meaningfully informed, able to reiterate the risk and benefi ts for 
both donor and recipients, and the alternatives available, willing to donate, with 
no evidence of coercion. Although the donor risk is estimated to be low, there 
were 2 reported donor deaths (0.4%). To not violate the principal of physician 
do no harm requires extraordinary proof that such a procedure is required, 
The ethical principle that should best be applied to LDLT is that of equipoise 
and informed consent or understanding, not primum non nocere, as the donor 
derives emotional benefi t from donation and the opportunity to save a life. It is 
important to stress that the alternative to living-donor liver transplantation in 
Egypt is not deceased-donor liver transplantation; there are no doubts that this 
is a benefi cial procedure for the recipient with acceptable risks to the donor.
Conclusion: In absence of law that permits cadaveric organ donation, it is 
ethically appropriate to perform liver transplantation using living donors. It 
is important to maintain the highest of medical and ethical standards to obtain 
maximum benefi t for both donor and recipient.
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SUCCESSFUL DECEASED DONOR RENAL 1793 
TRANSPLANTATION USING A DONOR WITH DISSEMINATED 
INTRAVASCULAR COAGULATION 
(DIC) AND ACUTE KIDNEY INJURY (AKI)
R. Villicana, A. Peng, S. Jordan
Cedars Sinai Medical Center Kidney Transplant Program
Purpose: Due to the widening gap between available donors and the deceased 
donor renal transplant list there has been an interest in methods that expand the 
donor pool. Expanded criteria donation (ECD), donation after cardiac death 
(DCD) and marginal dual kidneys (DK) are sources used to expand the donor 
pool. Despite these methods, our current supply can not keep up with our 
increasing transplant wait list. Possible donors with acute kidney Injury (AKI) 
have traditionally been turned down. 
We report 2 cases of successful renal transplantation from a deceased donor 
with AKI due to disseminated intravascular coagulation (DIC) requiring pre 
donation hemodialysis.
Methods: Our center accepted 2 kidneys from a 19 y/o male without 
signifi cant past medical history who died from a gunshot wound to the head. 
Renal function, CBC and coagulation panel was normal on admission. Patient 
developed progressive non-oliguric AKI requiring hemodialysis and had 
laboratory evidence of DIC. Patient’s peak and terminal creatinine was 6.1. At 
procurement the kidneys had diffuse capsular petechiae. Pathology revealed 
severe ATN without evidence of glomerular thrombi or chronic changes.
Results: Recipient number one was a 58 y/o female with history of ESRD 
due to polycystic kidney disease. Patient was initially anuric and remained in 
delayed graft function (DGF) for 10 days before beginning to improve. She 
received thymoglobulin for induction and was eventually on triple therapy 
consisting of steroids, tacrolimus and MMF. Her creatinine at one month was 
1.2 mg/dl, at 6 months was 1.0 mg/dl and was 0.8 mg/dl at one year.
Recipient number two was a 63 y/o male with history of ESRD due to 
hypertension and diabetes mellitus. He also was anuric and received similar 
induction and maintenance immunosuppression. He remained in DGF for 2.5 
weeks before gradual improvement. His creatinine at 1 month was 1.6 mg/dl, 
at 6 months was 1.1 mg/dl and was 1.3 mg/dl at one year.
Conclusion: Deceased donors with DIC and AKI may be suitable donors 
assuming that there are no irreversible lesions seen on renal biopsy. Acceptance 
of donors with DIC and AKI could possibly expand the donor pool.
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CONCERNS OF ORGAN DONATION FROM PRISONS 1794 
WITH DAETH PENALTY: PERSPECTIVES OF TAIWAN S AND 
MAINLAND CHINA S HEALTH PROFESSIONALS
F-J. Shih1, S-S. Wang2, R-B. Hsu3, S-S. Chu4
1Professor & Dean, National Yang-Ming University School of Nursing, Taipei, 
Taiwan, 2,3Division of Cardiovascular Surgery, Department of Surgeon, 
National Taiwan University Hospital, Taipei, Taiwan, 4Superintendent, Far-
Eastern Memorial Hospital, Taipei, Taiwan.
Purpose: This study aimed to compare the dilemmas of the use of prisons with 
death penalty (PDP) from the perspectives of Taiwan s (TW¡¦s) and Mainland 
China s (MC s) organ transplant health professionals (OTHP).
Method: A purposive sample including Tw s OTHP (including transplant 
surgeons, nurses, researchers, social workers, medical religious and legal 
experts), and MC s team (including surgeons and nurses) was obtained in 
this qualitative research. TW s subjects received face-to-face interview, and 
MC s subjects received telephone interview due to limited communication 
opportunities. Data were analyzed by content analysis.
Results: A total of 105 subjects participated in this project (TW n = 95, MC n = 
6). They were surgeons (n = 18, TW n = 14, MC n = 4), registered nurses (n = 
42, TW n= 40, MC n = 2), OT coordinating nurses (n = 10 TW), OT researchers 
(n = 5 TW), social workers (n = 10 TW), medical religious experts (n = 15 
TW), and medical legal experts (n = 5 TW).
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The following 8 ethical dilemmas were reported: (a) questioned legitimacy 
of the PDP s motivation (TW 100%, MC 100%); (b) recipients worry about 
public’s discrimination (TW 89%, MC 50%); (c) diffi culties in approaching 
PDP (TW 100%); (d) health professionals and volunteers hesitation in 
helping PDP (TW 37%); (e) questioning social contribution of PDPs as 
donor sources (TW 32%); (f) complex legal details of PDP s OT issues (TW 
26%); (g) potential threat from PDPs families (TW 23%); and (h) diffi culties 
in helping PDP s families cope with post-organ donation syndrome (TW 
11%).
Conclusion: Finally, 5 strategies were further developed in managing these 
challenges. They were: (a) OTHPs should empower their basic and social 
science knowledge as well as empirical competence; (b) Taiwan s government 
should form a task group to work on this issue, and OTHP leaders should foster 
interdisciplinary collaboration with public within short-, middle- and long-term 
time frame; (c) establishing evidence-based center(s) to provide systematically 
literature review for clinical and policy decision making and educational 
resources; (d) improving the quality of PDP s organ harvesting and donation 
practice in jails/health institutes; and (e) developing reliable assessment tools 
and evaluation criteria for this issue.
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ETHICAL ISSUES OF ORGAN TRANSPLANTATION 1795 
IN CHINESE COMMUNITY: PERSPECTIVES OF HEALTH 
PROFESSIONALS, LEGAL PROFESSIONALS AND RELIGIOUS 
EXPERTS IN TAIWAN AND MAINLAND CHINA
F-J. Shih1, S-S. Wang2, R-B. Hsu3, S-S. Chu4
1National Yang-Ming University School of Nursing, Taipei, Taiwan, 2Division 
of Cardiovascular Surgery, Department of Surgeon, National Taiwan 
University Hospital, Taipei, Taiwan, 3Division of Cardiovascular Surgery, 
Department of Surgeon, National Taiwan University Hospital, Taipei, Taiwan, 
4Far-Eastern Memorial Hospital, Taipei, Taiwan
Purpose: This study aimed to compare the perspectives of leading ethical 
issues perceived by the health professionals (HP), legal professionals (LP) and 
religious experts (RE) from Taiwan (TW) and Mainland China (MC).
Method: A purposive sample including Tw s OTHP (including transplant 
surgeons, nurses, researchers, social workers) LP and RE, and MC s HP 
(including surgeons and nurses) was obtained in this qualitative research. TW s 
subjects received face-to-face interview, and MC s subjects received telephone 
interview due to limited communication opportunities. Data were analyzed by 
content analysis.
Results: A total of 127 subjects participated in this project (TW n = 92, MC n = 
8). They were HP (n = 92) [surgeons (n = 20, TW n = 14, MC n = 6), registered 
nurses (n = 47, TW n= 45, MC n = 2), OT coordinating nurses (n = 10 TW), OT 
researchers (n = 5 TW), social workers (n = 10 TW)], religious experts (n = 25 
TW), and legal professionals (n = 10 TW).
The following 8 ethical dilemmas were reported: (a) diffi culties in touching 
public and conveying the values of OT to various age populations (HP 
100%, LP 100%, RE 100%); (b) challenges in helping donors and their 
families cope with multidimensional crisis across recovery stages (HP 96%, 
RE 80%, LP 50%); (c) health professionals competence and availability in 
providing holistic care for cadaveric donors, recipients, and their families 
(HP 93%, RE 72%, LP 50%); (d) questioning social farewell to cadaveric 
donors, recipients, and their families (HP 92%, RE 20%, LP 100%); (e) 
questioning social farewell to cadaveric donors, recipients, and their 
families (HP 92%, RE 20%, LP 100%); (f) questioned legitimacy of the 
PDP s motivation (LP 90%, RE 64%, HP 60%); (g) recipients & families 
worry about public s discrimination (LP 90%, HP 50%, RE 20%); and (h) 
challenges to families in taking care of the recipients (HP 87%, LP 70%, 
RE 52%).
Conclusion: In order to provide holistic care, the health professionals need to 
invite religious experts to provide spiritual support systems for the cadaveric 
donors, recipients, and their families The cadaveric donors¡¦ families often feel 
helpless in dealing with sophisticated legal procedures, and became vulnerable 
populations. With the help from this triangulation collaborative team, the quality 
of OT will be more visible and appreciated by the public. Future researchers 
are suggested to explore the context contributing to these challenges and to 
develop strategies for the concerns of leading ethical issues reported by these 
three agents.
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THE ROLE OF THE COMMITTEE FOR ETHIC AND 1796 
APPLICATION OF ORGAN TRANSPLANTATION IN THE 
MEDICAL AND ETHICAL EVALUATION OF LIVING DONOR 
RENAL TRANSPLATATION
M. Cai1, L. Xu2, X. Xu3, Z. Li4, Y. Qian5, B. Shi6, G. Li7
1Transplantation Center, The Second Affi liated Hospital, Chinese PLA 
General Hospital, 2Transplantation Center, The Second Affi liated Hospital, 
Chinese PLA General Hospital, 3Transplantation Center, The Second 
Affi liated Hospital, Chinese PLA General Hospital, 4Transplantation 
Center, The Second Affi liated Hospital, Chinese PLA General Hospital, 
5Transplantation Center, The Second Affi liated Hospital, Chinese PLA 
General Hospital, 6Transplantation Center, The Second Affi liated Hospital, 
Chinese PLA General Hospital, 7Transplantation Center, The Second 
Affi liated Hospital, Chinese PLA General Hospital
Objective: To ensure the success for kidney transplantation and the feasibility 
of ethical principles, the Committee for Ethic and Application of Organ 
Transplantation (CEAOT) make the medical and ethical evaluation for living-
donor and recipient in pre-transplantion.
Methods: CEAOT was composed of the experts included physician, surgeon, 
anesthetist, pharmacologist, primary nurse, medical ethic and barrister etc. 28 
pairs of living kidney donors and recipients, that they were consisted of 16 
pairs of a lineal consanguinity, 8 pairs of a second collateral consanguinity, 
2 pairs of a tertiary collateral consanguinity, and 2 of spouses, had received 
the evaluation by CEAOT. The donors ages ranged 26 to 61 years old (mean 
54years), and the recipients years old is form24 to 51, mean 35.5 years old. The 
inverse proportion of male donors and female donors is 7:21. However, 16 of 
parents donated own kidney to their offspring, non offspring give a donation 
for their parents.
Results: 24 pairs of 28 cases were pass by CEAOT one-off, 1 case had donated 
kidney for his young brother when his overweight got banting (BMI<30kg/
m2). 3 of 28 cases were excluded by CEAOT because of suffering from 
the II-diabetes, the spouse of donor refused the inquiry for evaluation by 
CEAOT, and it is not affi rmed whether pulmonary tuberculosis (TB) had 
been cured, respectively. After transplantion both donors and recipients got 
recovered well. 
Conclusion: The Committee for Ethic and Application of Organ Transplantation 
(CEAOT) is an essential agency for Living Donor Kidney Transplantation. It 
is important signifi cance that the intervention of CEAOT makes the maximal 
benefi t for living donors, and to ensure the medical safety for donors, recipients 
and doctors. The fact of the more female and more eldership donors than males 
and junior refl ect the traditional moral and ethical outlook in our country. It 
impulses us to explore farther in the medical and ethic in the future.
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ORGAN DONATION IN GERMANY – PERSPECTIVES 1797 
TO INCREASE POST MORTEM ORGAN DONATION
F. Schaub, C. Wesslau, G. Kirste
Deutsche Stiftung Organtransplantation
Background: Organ donation in Germany is organised by the Deutsche 
Stiftung Organtransplantation (DSO) - German Transplantation Foundation. 
Covering a population of 82 million people DSO entertains seven regional 
offi ces, each responsible for eight to eighteen million inhabitants.
Analysis of potential: In order to detect the donor potential in Germany 
a retrospective study has been conducted. Data was collected on deceased 
persons on ICU’s with primary or secondary brain damage. This was done 
via data entry forms which were especially designed for this purpose. 
Through this study it could be shown that the number of potential donors 
per million population (pmp) is comparable with the international standard 
of other OPO’s with 40 donors pmp. The analysis showed that refusal of 
relatives to organ donation is the main obstacle in order to realise organ 
donation. The study revealed an increase of refusal rate over the years 
2006 to 2007 (2006 37,1%; 2007 37,8%). These fi ndings enables us to 
develop strategies in order to enhance organ donation. This strategy focuses 
primarily on measurements in order to ensure the detection and referral of 
potential donors to the OPO’s, to reduce obstacles to organ donation based 
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on medical reasons and last but not least the reduction of the family refusal 
rates.
Results: The total number of organ donors in 2007 amounted to 1.313. This 
corresponds to an augmentation of fi ve percent compared to the preceding 
year. Therewith Germany ranks among the fi rst worldwide when it comes to 
the absolute number of organ donors. But looking at the number of effective 
donors per million population being 16,0, Germany does rather poor in 
the international comparison. However the study revealed considerable 
differences regarding the organ donation rates among the German regions 
(13,3 vs. 19,7 effective donors pmp). The conversion rate in the individual 
regions covers a range from 41,5 to 57, 2%. However reasons for these 
regional discrepancies can not be explained by the lack of epidemiological 
studies.
Strategies to enhance organ donation in Germany: The analysis shows, that 
the donor potential has by far not been bailed out. Essential for the increase of 
the conversion rate in the DSO area is:
• Increase of the referral of potential donors by the donor hospital.
• Reduction of the refusal rates.
In order to realise these goals “increasing of referrals” and “decreasing of 
refusals” a concept is being elaborated to optimize communication. That 
apparently is the breakthrough in succeeding. This concept is based on two 
pillars:
• Improvement of the communication between DSO and donor hospitals
• Improvement of the communication with the relatives of the deceased
We started our Trainee-Program for hospital communication in the year 2006. 
Our coordinators are trained in specially designed workshops and coached 
individually as well as in groups. Quality management circles have been 
installed in most of the hospitals.
The training based on the newly developed concept for the family interviews 
will start in 2008.
Organ donation is a multidisciplinary task and a lot of factors infl uence the 
donation rate. Improvement of communication with hospital staff as well as 
donor families is at least one key for success.
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ETHICAL CONSIDERATIONS IN ORGAN ALLOCATION 1798 
FOR TRANSPLANTATION
A. Jafarian, S. Sadeghi, S.H. Emami Razavi
Tehran University of Medical Sciences
Organ transplantation is a standard treatment for end stage organ failure which 
has several ethical and social considerations. Deceased donor organ allocation 
in the era of organ shortage and rapidly increasing number of recipient is a 
major ethical problem.
Resource allocation theories are mainly established on the ethical principle 
of justice and the cost effectiveness issue. There are different defi nitions for 
justice in resource allocation including Fairness, Equality and Equity which are 
mainstay of any decision planning format.
Medical need is the major criterion for receiving an organ but non-medical 
indications such as age or registration priority are intervening factors that is 
discussed more. Other problematic cases are retransplantation and allocating 
an organ to a person with behavioral diseases (e.g. Alcoholic cirrhosis). 
Explanation of these viewpoints is coming in details.
Achieving justice in organ allocation not only reinforces the public trust to 
medical community but also increases the overall organ donation which is 
the rate limiting factor for transplantation. The lack of a universally accepted 
protocol forces us to have a clear decision making process to clarify the 
problems and resolve pitfalls of organ allocation. This decision is sometimes of 
nonmedical type and help of others could be effective.
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THE ENLIGHTENMENT OF THE NEUROSURGEONS 1799 
AND EMERGENCY ROOM DOCTORS WITH RESPECT TO 
THE KIDNEY DONATION UNDER CARDIAC DEATH
S-I. Yoshikai1, K. Hokao1, K. Yamamoto2, C. Kaino2, H. Anai2
1Department of Neurosurgery, Shinkomonji Hospital, 2Deparment of Intensive 
Care Unit, Shinkomonji Hospital
Backgrounds: The rate of the donation card possession is 8%, and the rate of the 
affi rmative opinions for the organ donation is 42% in the general population in 
Japan. The number of the potential donors after brain death is estimated as 7000 
and the potential donors after cardiac death is also estimated as 70000 annually 
statistically. Suppose 8% of these potential donors possess donation cards, there 
should be 560 donations after brain death (DBD) and 5600 donations after cardiac 
death (DCD) theoretically. However, only 866 donation cards were proposed and 
the DBD were done only in 56 cases for the recent 10 years in Japan eventually. 
Also the kidney DCD were done approximately 100 cases annually. This poverty 
of the donation is mainly caused by the negativism of the neurosurgeons and ER 
doctors. They are not interested in the organ transplantation medicine and they 
usually do not confi rm the donation card possession because they are afraid of the 
negative campaign by the news media.
Methods: In our hospital, we are mainly focusing on the kidney DCD. From 
March 2003 to December 2007, we confi rmed the donation card possession and 
proposed the option of the kidney donation after cardiac death to the families in 
29 potential donation candidate cases.
Results: Families of 20 cases agreed with the donation. Among the total 29 cases, 
donation cards were presented in 2 cases, donation cards were possessed but lost in 
2 cases and strong will for the donation were confi rmed in 2 cases. In the remaining 
23 cases, patients and their families had never discussed about the organ donation. 
However, 14 families agreed with the kidney donation eventually. Finally, total 20 
families agreed with the kidney donation out of all 29 cases. Three cases dropped 
out afterwards because of the HTLV-1 infection in 1 case and persistent vegetative 
state course in 2 cases. Seventeen cases donated their kidneys fi nally.
Discussions: The donation card possession rate is 7% (2/29) in our study. 
This resembles the 8% possession rate in the general population. The overall 
rate of the agreement with the kidney donation was 69% (20/29). Even in the 
patients and their families who had never discussed about the organ donation 
beforehand, the rate of the agreement was 61% (14/23). This suggests that the 
families tend to consider the donation more positively in the patients’ emergent 
critical conditions than in their usual daily life.
Conclusions: The enlightenment of the organ donation seems suffi cient in the 
general population in Japan. The issues of the kidney shortage will be solved 
only if the neurosurgeons and the ER doctors ask the donation card possession 
and propose the option of the kidney donation. Also the issues of the DBD will be 
also solved gradually if the kidney DCD is well accepted and prevails generally.
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2007, THE YEAR OF REGULATORY CHANGE1800 
J.M. Millis1, J. Huang2, A. Millis3, Y. Mao2, M. Simmerling4, Y. Liu2
1University of Chicago, 2Peking Union Medical Center, 3Rhodes College, 
4Weill Cornell Medical College
The two countries that performed the most organ transplants in 2006, US and 
China, initiated signifi cant regulatory change in 2007 that continues into 2008 
and likely several more years. The purpose of this abstract is to highlight the 
reasons behind the regulatory initiatives, document the new regulations and 
assess the impact thus far.
Methods: Review of US and China governmental regulations emphasizing the 
underlying principles and impact.
Results:
US   
Principle Regulatory Change Impact
° Equity and transparency
Objectively apply process and 
criteria for each tx Candidate and 
Recipient
Eliminates arbitrary and capricious 
evaluation and transplant candidacy 
decisions
   
° Understanding Tx Process Document Waitlist Management and Communication
Ensures appropriate allocation of 
organs
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° Field Strength
Document appropriate surgeon 
and physician coverage. Document 
availability of other associated 
services
Minimizes lack of access to 
transplantation due to lack of 
institutional commitment
   
° Informed Consent
Independent Living Donor 
Advocate team and specifi c 
information regarding deceased 
donor organs that may impact organ 
function and donor transmitted 
diseases
Separate process for living donor 
organs and deceased donor 
organs that increases the level of 
knowledge for the living donor and 
recipient
CHINA
Principle Regulatory Change Impact
   
° Equity Ban Transplant Tourism and payment for organs
Allows improved access to Chinese 
and minimizes exploitation
   
° Field Strength Defi ned criteria of institutions that are able to perform transplantation
Ensures patients undergoing 
transplants receive their transplants 
at institutions with a high level of 
commitment
   
° Donor Informed Consent Requires consent of donor and donor’s family
Decreases exploitation of Prisoner 
donors
Conclusion: Both countries have made signifi cant progress in attempting to 
improve the process for both donors and recipients. The US is a more mature 
system while China is attempting to move toward an International standard. In 
the short-term there may be decreased overall access to transplantation while 
transplant centers and policies adjust to the new regulations in both countries.
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ACCESS OF NON RESIDENTS TO TRANSPLANTATION 1801 
MEDICINE
D. Norba, G. Kirste
Deutsche Stiftung Organtransplantation
When it comes to medical treatment of non nationals or non residents limitations 
usually exist due to fi nancial reasons. In terms of transplantation another factor 
becomes important: The scarcity of organs available for transplantation purposes.
The question to be raised is: Does an increase of transplantations of non-
residents jeopardize the willingness of residents to donate? The answer is not 
simple in particular the role of the mass media must not be underestimated.
An examination of the existing regulations in Europe and the US dealing with the 
access of non-residents; respectively the restriction of access to transplantation 
medicine two general approaches can be distinguished. The fi rst one limits the access 
of non residents to the (national) waiting list. That means those who are denied access 
can not be transplanted, no matter how urgent the case might be. Usually a random 
percentage between 0 -10% is chosen. Registration for transplantation serves as a 
funnel. This approach was chosen by Eurotransplant and UNOS for example.
The alternative approach is to allow the registration on national waiting list 
for everybody who is suitable for a transplant but to consider certain groups of 
persons such as non residents subordinately in the actual allocation process. In 
this second category various differentiations are possible in particular with view 
to high urgency patients. This however leads to the consequence that due to the 
lack of organs there are few chances to receive an organ of good quality or to 
receive an organ at all. This approach was chosen by UK and Switzerland.
It is however highly doubtful whether the existing regulations would stand 
the legal proof in the light of constitutional rights in particular human rights 
assigned to every person irrespective of nationality or residency. Human rights 
that are at stake are in particular the right to life and to physical integrity but also 
the prohibition of discrimination. Hence exceptions need to be made at least for 
high urgency patients. In Europe furthermore European community law needs to 
be taken into consideration as well in particular the free movement of patients.
When stipulating a regulation for non residents in transplantation medicine the 
following questions need to be answered. Is there really a need for restricting 
regulations? Who has the competence to legislate on a national or European 
level? Does the intended regulation violate constitutional or European law?
There is no easy answer to this but it can be summarized that access of non 
residents to transplantation medicine should be given due consideration in a 
European perspective, in order to be solved on a national level from a legal 
point of view. Any regulation should however be in accordance with national 
constitutions as well as European law (e.g. Art. 12, 18, 39, 43, 49 TEC and 
Council Regulation (EC) no 1408/71).
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THE IMPACT OF TRANSPLANT COORDINATOR ON 1802 
LIVE RELATED DONORS KIDNEY TRANSPLANT PROGRAM 
AT A TERTIARY CARE HOSPITAL IN KINGDOM OF SAUDI 
ARABIA
S.E-D. Al-Horani, T. Tassadaq, S. Abdel Raouf, S. Fahim Hassan
Saad Specialist Hospital
The shortage of organs available for transplantation is a universal problem. 
There are multiple reasons for this. The role of a transplant coordinator is 
well established in increasing the number of organs in cadaveric transplant 
programme. However the impact of a transplant coordinator in an exclusive 
live donor program has not been looked in detail. We present our data and 
asses the impact of a transplant coordinator at our centre, which is exclusively 
carrying out live donor kidney transplants. We also look at the factors related to 
transplant coordinators that have contributed to an exponential increase in the 
number of transplant at our centre. 
Our transplant program started in June 2005. We managed to have four live 
related kidney transplants till December 2005. Meanwhile, another four 
cases were performed from January 2006 to November 2006. Two transplant 
coordinators were appointed in November 2006. We carried out eight live 
related kidney transplants in the last two months of year 2006. In year 2007, a 
total of forty-two live related kidney transplants were performed which elevated 
our center from the last place to the second among 13 transplant centers in 
Kingdom of Saudi Arabia.
Our experience shows that trained transplant coordinators are essential to a live 
related kidney transplant program.
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EXCELLENT LONG-TERM GRAFT SURVIVAL WAS 1803 
ACHIEVED IN KIDNEY TRANSPLANTS FROM NON-HEART 
BEATING DONORS. EXPERIENCE OF 107 CONSECUTIVE 
RENAL TRANSPLANTS AT A SINGLE CENTER
K. Hoshinaga, H. Sasaki, M. Kusaka, T. Maruyama, K. Hayakawa, R. Shiroki, 
A. Sugitani
Fujita Health University
Introduction: Although kidneys donated after cardiac death (DCD) have 
marked severe ischemic damage, they have been recently accepted as the 
optional resource in the deceased donor renal transplants because of a severe 
shortage of renal grafts. In Japan, more than 90% of the deceased donor grafts 
have been recovered from DCD donors using in situ regional cooling technique 
for more than 3 decades. In this clinical communication, the outcome of the 
107 consecutive DCD donor renal transplants at a single center is reported.
Study subjects: Since November 1990, using in situ cooling technique, 107 renal 
grafts from DCD donors were engrafted at our center. Most of donors are classifi ed 
as Maastricht, category IV. The mean follow up period is 129 months. The ages of 
donors and recipients ranged from 3 to 75 years (mean; 47.1) and 15 to 63 years 
(mean; 42.7 years), respectively. The recipients’ pretransplant dialysis periods 
ranged from 12 to 359 months (mean; 110.9 months). Warm ischemic time and total 
ischemic time were from 1 to 57 minutes (mean; 9.6 minutes) and from 325 to 2603 
minutes (mean; 967 minutes), respectively. A quadruple immunotherapy consisting 
of cyclosporine (CsA), methylprednisolone (MP), anti-human lymphocyte globulin 
(ALG) and azathioprine or mizoribine was administered in 79 recipients, and a 
triple immunotherapy consisting of CsA, MP and mycophenolate mofetil (MMF) 
was administered in 13 recipients. Other 15 patients received tacrolimus (Tac), 
basiliximab, MP and MMF. Low dose CsA (4mg/kg) or Tac (0.15 mg/kg) was 
given initially and increased after the recovery of the graft function.
Results: Following renal transplants, the immediate graft function was noted 
in 22 recipients and other 83 patients had delayed graft function necessitating 
posttransplant dialyses for one to 39 days (mean; 11.9 days). Two grafts never 
recovered renal function. The 1,3,5, and 10 year patient survival rates are 
98.1%, 95.1%, 92.8% and 85.2%, respectively, and the 1, 3,5 and 10 year graft 
survival rates are 96.2%, 93.1%, 87.7% and 66.4%, respectively.
Conclusion: The current graft survival is excellent and seems to be comparable 
to the graft survival of living donor kidney transplants. Our result indicates that 
DCD donors should be considered as an excellent resource of renal allografts 
when appropriate in situ regional cooling technique can be applied.
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NON-HEART BEATING DONATION IN EUROPE; 1804 
AN OVERVIEW
B. Haase-Kromwijk1, H. van Leiden1, F. Mühlbacher2, A. Hoitsma1
1Dutch Transplant Foundation, 2Univ. Hospital of Vienna
Background: Expanding deceased donor criteria includes the use of non-heart 
beating (NHB) donors. We studied the existence of a NHB donor program in 
27 European countries.
Methods: A questionnaire was send to all the member states of the Council of 
Europe in 2007.
Results: Only 9 out of the 27 countries that replied had a NHB donation 
program, using different NHB categories, organ types, organization, and no-
touch period after death.
The no-touch period after death ranged from 0-20 minutes. In all 9 countries 
NHB donation category II and IV was performed, in only 6 countries NHB 
category III and in 4 countries NHB category I. Besides NHB kidney donation, 
NHB liver donation was performed in 5 countries. In 3 countries there was 
also a NHB lung program, while 2 countries performed NHB pancreas 
transplantations as well. In 2006 the United Kingdom had the largest number 
of NHB donors (124), refl ecting 19% of the total number of deceased donors, 
followed by the Netherlands with 90 NHB donors, refl ecting 45% of the total 
number of deceased donors. In the 5-year period 2002-2006 these countries 
also had the largest number of transplants from NHB donors (respectively 945 
and 872). In 3 of the 9 countries with a NHB program organs were allocated 
via the national allocation program. In the other countries the NHB organs are 
kept locally or are allocated via a special program.
In the 18 countries without a NHB program NHB donation was legally not 
allowed (5) or not possible due to organizational reasons and/or lack of 
expertise (13).
Conclusion: Although NHB donation is increasingly accepted in Europe, the 
majority of the European countries has not (yet) a NHB donation program 
and if available the use of NHB donor programs differs in NHB categories of 
donors, organs used and organization and procedures.
The UK has the largest NHB donation program in numbers, the Netherlands in 
percentage of the total deceased donor pool. Evaluation of these differences in 
programmes can be useful.
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COGNITION, INTENTION AND BEHAVIOR SURVEY ON 1805 
LIVING ORGAN DONATION IN CHINESE LIVING KIDNEY 
DONORS AND GENERAL POPULATION
C. Wang, C. Xiao, S. Chen, L. Chen, J. Fei, S. Deng, J. Qiu, J. Li, G. Chen
Kidney Transplant Department, Organ Transplant Center, The First Affi liated 
Hosp
Objective: To study the cognitive, intentional and behavioral status of living 
kidney donors in comparison with general population, so as to investigate 
the relevant factors affecting decision of living organ donation in general 
population.
Method: Questionnaire on cognition, intention and behavior about living organ 
donation was designed and the anonymous survey was done from July 2007 
to February 2008 in 70 living kidney donors and 115 citizens from physical 
check-up center. Mental status of living donors were assessed with SCL-90 
Symptom Rating Scale simultaneously.
Results: Seventy living kidney donors (male:female=36:34) are overall 
psychologically normal. Among this group 60% were less than 38 years 
old, 62.86% received high school education, 88.57% were manual workers; 
82.58% believed they’ve known enough about living organ donation and 
transplantation; 97.14% gave a positive comment on the outcome of organ 
donation; 62.86% considered their relationship to recipients were the most 
important factors affecting their decision of donation while 94.28% of them 
would prefer to donate to their parents or children; 64.29% were against 
organ trading; 75.71% considered organ donation to be a noble action; 
2.86% believed that living organ donation do more harm than good. In 
the sample of general population, 36.5% refused to become living donors, 
which composed of 47.72% (21/44) of female interviewers and 28.17% 
(20/71) of the male interviewers. When compared to living donors, more 
of those refused to donate agreed with organ trading (61.90% vs. 5.71%, 
p<0.05) believed that organ donation would seriously compromise their 
health (38.10% vs. 1.43%, p<0.05); and their biggest concern when 
considering organ donation was the impact on their own health. In those 
who were willing to become living donors, 54.05% believed it appropriate 
to ask for compensation when only 14.29% of the donors agreed with 
that (p<0.05). The most accepted form of compensation in all groups is 
comprehensive health insurance or priority in receiving organs when they 
need transplants.
Conclusion: In general population, the decision-making process on non-
rewarded living organ donation is the process of balancing gains and losses. 
Most living donors and those who would accept to donate their organs believed 
they would get more benefi t than harm, when many of those refused to consider 
organ donation had an exaggerated idea about related risks. Therefore public 
education and promotion activities on organ donation and transplantation shall 
be able to enlarge the donor pool and thus prevent organ trading.
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PRISONERS AS ORGAN DONORS: IS IT WORTH THE 1806 
EFFORT? IS IT ETHICAL?
M.A. Millis1, J.M. Millis2, M. Simmerling3
1Rhodes College, 2University of Chicago, 3Cornell University
With the waiting list for organs approaching 100,000 and the impact of the 
National Collaborative leveling off, additional avenues need to be explored 
to help alleviate this shortage. Prisoners have generally been excluded 
from donation because of the ethical and infectious disease concerns. 
We propose a plan, which would address both concerns and examine the 
potential impact.
Plan: Interested inmates of State and Federal correctional facilities would 
approach the medical team at the correctional facility expressing their interest 
in living donation. The prisoner would be provided a packet of information 
explaining the process. Principle steps in the process are a consent to 
evaluation and a two-step surgical consent of the inmate (separated by at 
least three weeks) and a consent signed by the next of kin (if available). 
After the consent for evaluation, standard blood testing including antibody 
testing for HIV, HCV, HBV would be performed in addition to the usual 
organ specifi c blood testing. If the results of these tests are acceptable, 
more invasive tests CT scans, renal scans, liver biopsy, if needed, would be 
performed. If these tests are acceptable, the patient would sign the initial 
surgical consent. At this point a Nucleic Acid Amplifi cation Test (NAAT) 
for HIV, HCV, HBV would be performed and the patient would be placed 
in medical isolation for three weeks. During this period the patient would 
be isolated from all other inmates, and would be subjected to random drug 
screens. At the conclusion of the 3-week period, NAAT testing for the same 
infectious agents would be obtained. If the inmate was negative for HIV, a 
suitable recipient would be identifi ed and the inmate would be scheduled 
for living donor surgery. The inmate would be in medical isolation until the 
time of donation.
Infectious concerns: Medical advances, specifi cally, NAAT testing has 
enabled the window period to be small enough to allow close observation and 
monitoring of the prisoner, which enables safe donation.
Ethical concerns: The paternalist protection of prisoners is to ensure that 
procedures are not performed on the inmates that cannot/should not be perform 
on non-inmate populations. This is a plan to allow prisoners the opportunity 
to participate in opportunities provided non – incarcerated people. In terms 
of informed consent, allowing prisoners the opportunity to consent for organ 
transplantation has already tested this concept.
Impact: There are currently 2.2 million inmates; the incidence of HIV is 1.8 
percent, decreasing the potential pool to 2.1 million. A consent rate of 1% could 
provide 21,000 kidneys.
Conclusions: Advances in medical technology and the acknowledgement 
that prisoners can consent to complex, but standard medical procedures have 
opened up a potential pool of organ donors that could dramatically impact the 
organ shortage.
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SUCCESSFUL SOLID ORGAN TRANSPLANTATIONS 1807 
FROM SEPTISEMIC CADAVERIC DONORS
H. Sozen1, D. Erer2, E. Singin3, N. Doðucan3, A. Dalgýc1
1Gazi University General Surgery, 2Gazi University Cardiovascular Surgery, 
3Gazi University Transplantation
Systemic donor infection especially gram negative organism originated is 
regarded as being an absolute contraindication to cadaver organ donation for 
transplantation. This is largely due to fear of transmitting pathogenic organisms 
to the immunosuppressed recipient. However, due to the current shortage of 
organs available for transplantation, clinicians are faced with the option of 
using organs from infected donors. Here we report successful solid organ 
transplantation from blood cultures positive donors.
Material and method: Between 1996 to January 2006 totally 47 solid 
organs (hearts, livers and kidneys) collected. Three out of 10 donors had 
positive blood cultured microorganism. Case 1: 23 years old of female. 
Cause of brain death was intracerebral bleeding due to traffi c accident. The 
donor had stayed 9 days prior to brain death onset. Two kidneys, 2 livers 
(splited) and heart were used from this donor. Klebsiella was the organism 
yield at blood culture. Case 2: 35 years old, male, cause of brain death was 
cerebral hematoma due to traffi c accident. The donor has been stayed 6 
day prior to brain death onset. Liver and two kidneys transplantations were 
performed. Acitenobacter baumanii was organism yield at the blood culture. 
All donors were treated until the negative blood culture was guarantied 
with appropriate antibiotics. Targocit, Neutromysine and Sulperazone were 
used for at least 48 hr prior to organ procurement while recipients received 
same culture-specifi c antibiotics 10 days following transplantation. Case 
3: 5 years old boy, Intracerebral bleeding due to traffi c accident was the 
reason of brain death. Liver was not able to use because of%70 steatoz. Two 
kidneys and hearts were used. Yeast enfection was detected by PCR of the 
blood just before procurement. All recipients were received Flucanozol after 
transplantation. One of donor’s (case 1) heart and all donors’ corneas were 
not used due to infection.
Results: All recipients are alive with excellent graft function on median 192 
days following transplantation.
In conclusion, our results suggest that bacteremic donors with severe sepsis and 
septic shock under proper treatment can be considered for transplantation. In 
light of the decreasing availability of organ donors and increasing waiting lists, 
more studies such as ours which challenge conventional contraindications to 
organ transplantation are required.
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PREDICTORS OF LIVER DISEASE IN POTENTIAL 1808 
ORGAN DONORS
E. Torres1, A. Garcia-Soto2, E. Garcia-LaTorre2, L. Morales1, M. Saade1
1LifeLink of Puerto Rico, 2University of Puerto Rico School of Medicine
The shortage of livers for transplantation demands the consideration of all 
candidates as potential liver donors. Rejection of a liver-only donor at the 
operating room because of unsuspected liver disease is costly and frustrating. 
The identifi cation of predictive factors for liver disease in a liver-only donor 
may justify a pre-operative percutaneous biopsy to avoid futile recovery 
efforts.
Aim: The aim of this study is to describe risk factors for liver disease in 
potential donors and correlate these factors with the outcome of liver recovery: 
recovered (transplanted or rejected), or not recovered.
Methods: Records of all donors considered for recovery of the liver from 
2004-06 were reviewed. Risk factors were identifi ed and correlated with 
outcome of organ recovery and biopsy fi ndings. Factors evaluated were age, 
gender, weight, BMI, alcohol and illegal drug use, diabetes, history of liver 
disease, AST and ALT levels.
Results: There were 255 donors, 153 male and 102 female, with a mean age 
of 41.6 +/-18.5 yrs (range 10m – 81yr). Of these, 214 livers were recovered 
from133 males and 81 females. Mean age of liver donors was 40 +/- 18.6 
(range 10m-81y). 9/214 (4%) were rejected, 41/255 (16%) were not recovered. 
23/24 liver-only donors were transplanted. Reasons for non-transplantation 
were fatty liver, anatomical damage, Chagas + test, abnormal biopsy, and 
death of recipient. Reasons for non recovery were poor organ function, fatty 
liver, donor quality, positive serology for hepatitis, and non placement. Age 
and gender distribution were similar in liver donors and all donors. Among the 
risk factors, obesity (OR 2.00, p=0.04), diabetes (OR 6.68, p<0.0001), ALT>50 
(OR 2.65, p=0.002), but not alcohol (OR 0.93,p=0.8) or drug use (OR 0.76, 
p=0.6), nor AST>50 (OR 0.93, p=0.83), correlated with non-transplant. Of the 
36 donor livers biopsied, 22 were transplanted, 5 were rejected and 9 were not 
recovered. 5/9 livers had signifi cant fatty changes, all had BMI> 25 and one 
third had diabetes.
Conclusions: Steatosis was the major cause for non-recovery. It was more 
prevalent in donors with BMI> 25 and diabetics. These fi ndings suggest that 
liver-only donors with these factors should be considered for percutaneous 
biopsy as part of donor evaluation.
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ORGAN RECIPIENTS SUFFERING FROM 1809 
UNDIFFERENTIATED NEUROENDOCRINE SMALL-CELL 
CARCINOMA OF DONOR ORIGIN
D. Foltys1, A. Hinkelmann2, A. Heumann1, I. Ruth1, M. Heise1, A. Schad1, 
J. Schneider1, K. Bender1, D. Mauer3, G. Otto1
1University Hospital Mainz, Germany, 2University Hospital Kiel, Germany, 
3DSO Region Mitte, Germany
Background: Transmission of donor-derived cancer due to organ transplantation 
is rare, but the risk based on the aging donor pool has been increased. 
Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor 
with the tendency to spread. The origin of this tumor has clinical impact on 
further decision-making therapy. In a case study, we demonstrate the case-by-
case strategy regarding liver and kidney recipient.
Methods and results: 
Case 1: Liver transplantation (LT) was performed in a 60-year old male 
suffering from hepatocellular carcinoma. In the donor, there was no history 
of malignancy. Medical examination, chest X-ray and situs at the time of 
organ retrieval were inconspicuous. CT scan of the recipient 4 months after 
LT demonstrated hypodense nodules in the liver. Biopsy confi rmed the 
diagnosis of a small-cell carcinoma of donor origin (DNA fi ngerprinting). Re-
LT was scheduled in the case of tumour restriction to the graft, but during 
exploration extrahepatic tumour manifestation was discovered. We reduced 
immunosuppression and started chemotherapy. Despite this treatment, the 
patient died 7 months after LT.
Case 2: In a different transplantation centre a 54-year old male received a 
renal graft from the same donor. When the tumour manifestation in our patient 
became apparent, meticulous follow-up of the renal recipient was initiated. One 
year after kidney transplantation, liver metastases were discovered. Biopsy 
confi rmed the diagnosis of a small-cell carcinoma which originated from the 
same donor in DNA analysis. The kidney was removed, the immunosuppression 
was stopped and additional chemotherapy was started. Hepatic metastases 
disappeared completely.
Conclusion: In this report on two cases, we demonstrate that the strategy of 
treatment after transmission of donor-derived malignancy is strongly infl uenced 
by the transplanted organ. If the graft can be removed and if immunosuppression 
may be stopped, the outcome of recipients may be favourable as the donor-
derived tumour is rejected. In contrast to this the outcome in a liver recipient 
is dismal. Based on this, meticulous exploration during the retrieval procedure 
is mandatory and even CT scan before donation may be advisable in donors 
exceeding a certain age.
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RADIOPAQUE CONTRAST ADMINISTRATION DURING 1810 
DECEASED DONOR EVALUATION: EFFECTS ON RENAL 
TRANSPLANT OUTCOMES
A. Al-Waal, G. Li, R. Balshaw, C.Y.C. Nguan1
1UBC Department of Urologic Sciences
Introduction and objective: Coronary angiography is an important 
investigative tool in the evaluation of the deceased donor during multiorgan 
procurement for transplantation. It is a defi nitive tool for the assessment of 
atherosclerosis in the donor heart, and its use will likely only increase with 
increasing limits of acceptability of cardiac donor demographics. Although 
radiographic contrast agents used in angiography are relatively safe, adverse 
effects such as contrast induced nephropathy (CIN) can occur following 
administration. In fact, most institutions adhere to strict guidelines as to who 
is an acceptable patient for contrast studies, and use renoprotective protocols 
as additional prevention. Unlike in the typical patient undergoing contrast 
study, the deceased donor usually generates concurrent signifi cant additional 
systemic insults kidneys (i.e. – catecholamine storm, hemodynamic instability, 
etc). As such, these cumulative factors may contribute to allograft performance 
following transplantation. We present our single program experience with 
the use of radiocontrast agents in the evaluation of deceased donors for renal 
transplantation.
Methods: A retrospective review of the British Columbia renal transplant 
program was conducted comparing the clinical outcomes of 32 recipients who 
were transplanted with kidneys procured from deceased donors who received 
intravenous contrast administration during evaluation, and 64 matched control 
recipients transplanted with contrast naïve kidneys. The study period was 
between 2002 and 2006.
Results: No difference was found between the two groups in terms of frequency 
of delayed graft function, slow graft function or primary nonfunction of the 
transplanted allografts. Likewise, no signifi cant difference was determined 
between groups with regards to frequency of acute rejections. Allograft function 
between groups determined through calculated GFR failed to demonstrate a 
difference at 3, 6 and 24 months post transplantation (p = 0.38, 0.395, and 0.07 
respectively), however did demonstrate a difference at 12 months (p = 0.03). 
Multivariate analysis at 12 months showed a p value of (0.067).
Conclusions: Based on the results of this experience, there appears to be 
minimal lasting effect of pre-implant contrast administration in the donor on 
renal allograft function. It remains important to be vigilant with regards to 
evaluation and treatment of the deceased donor, as numerous interacting factors 
occur between the time of donor death and time of implantation of the donated 
organ. The continued study of these factors and development of strategies to 
minimize these detrimental effects may be crucial in extending the quality and 
longevity of the transplanted organ.
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STRATEGIES FOR MAXIMIZING HEART AND LUNG 1811 
TRANSPLANT OPPORTUNITIES IN JAPAN
M. Fukushima1, M. Minami1, T. Nakatani2, M. Ono3, 
S. Konaka4, J. Ashikari4
1Osaka University Hospital, 2National Cardiovascular Center, 3Tokyo 
University Hospital, 4Japan Organ Transplant Network
As donor shortage is extremely severe in Japan because of very strict Japanese 
Organ Transplantation Law, special strategies for maximizing heart and lung 
transplant (HTx and LTx) opportunities should be established. The purpose of 
this study is to review our special strategies to identify and manage heart and 
lung donors.
Method: Since brain dead organ transplantation was restarted in 1999, 
transplant doctors themselves assessed their own donor heart and lung function 
by echocardiography and bronchoscopy before starting procurement operation, 
and skillful staff surgeons, not resident surgeons, harvested their organ. Since 
November in 2002, a special transplant consultant doctor has been sent to donor 
hospitals. He assessed donor organ function and identifi ed which organs were 
useful. He also intensively cared the donor, stabilized the donor hemodynamics 
using anti-diuretic hormone (ADH) if required, and improved donor cardiac 
and lung function by preventing and treating lung infection before harvest 
teams arrived at the donor hospital.
Results: Only 63 brain-dead donors have been available in Japan. However, 
50 HTx (79.3%) and 40 LTx (21 bilateral and 19 single) from 37 donors 
(58.7%) have been performed. Out of 50 HTx, 24 donors were marginal. 26 
donors were treated with high-dose catecholamine. Left ventricular ejection 
fraction of 5 donors was less than 50%. 15 had a history of cardiopulmonary 
resuscitation. 5 were older than 55 years. Out of 40 lung donors, 19 donors 
had infectious sputa or showed pneumonia by chest-X-ray. None of 50 HTx 
died of primary graft function (PGF). Patient survival at 1 and 3 years after 
HTx were 97.6 and 97.6%, respectively. Although 5 of 40 LTx died early after 
Tx, two died of PGF. Patient survival at 1 and 3 years after LTx were 76.9 and 
68.2%, respectively.
Conclusion: Although the number of Tx was still very small, the availability 
of heart and lung has been very high and the outcomes of HTx/LTx were 
acceptable. These strategies may be useful to maximizing HTx/LTx 
opportunities.
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GLOBAL EXPRESSION PROFILES IN ONE 1812 
HOUR BIOPSY SPECIMENS OF HUMAN KIDNEY 
TRANSPLANTATION FROM DONORS AFTER CARDIAC 
DEATH
M. Kusaka1,2, Y. Kuroyanagi1,2, T. Mori2, K. Nagaoka2, H. Sasaki1, 
T. Maruyama1, K. Hayakawa1, R. Shiroki1, H. Kurahashi2,3, K. Hoshinaga1,2
1Department of Urology, Fujita-Health University, 2Institute for 
Comprehensive Medical Science and 21st Century COE program, 
Development Center for Targeted and Minimally Invasive Diagnosis and 
Treatment, Fujita-Health University, 3Division of Molecular Genetics, Fujita-
Health University
Because of the world-wide shortage of renal grafts, kidney transplantation 
(KTx) from donors after cardiac death (DCD) is an alternative way to 
obtain KTx from brain-dead donors. Although the prognosis of DCD KTx 
is gradually improving, the graft often undergoes delayed graft function 
(DGF) rendering the control of DGF essential for post-KTx patient care. In 
an attempt to characterize etiology of DGF, genome-wide gene expression 
profi ling was performed using renal biopsy samples performed at 1 hour after 
KTx from DCD and the data was compared with those of KTx from living 
donors (LD). A total of 526 genes were differentially expressed between 
them. Genes involved in acute infl ammation were activated, while metabolic 
pathways were consistently down-regulated in DCD. These fi ndings imply 
the inferior performance of the DCD grafts relative to LD grafts. Several 
genes were identifi ed where the expression levels were correlated well with 
parameters indicating short- and long-term prognosis of the DCD patients. To 
identify novel biomarkers that might provide an indication of the prognosis 
of the DCD recipients, the expression levels of each gene was correlated 
with the parameters that refl ect prognosis of the patients. The length of 
dialysis post DCD KTx was used as a parameter indicating short-term 
prognosis. When the expression levels of the 526 genes were examined for 
any correlation with the length of dialysis post KTx, two genes, FTHL17 
and GLA were found to be signifi cant (p<0.05). On the other hand, for a 
long-term prognosis, the lowest serum creatinine levels during 1 year post 
KTx were used. The expression levels of two genes, GJA12 and PSMB10 
were found to be correlated with the serum creatinine values (p<0.05). In 
addition, several genes encoding secretory proteins were identifi ed that might 
refl ect the performance of the graft and be potential non-invasive biomarkers. 
The identifi ed genes included REG1A, TIMP1, SLPI and LTF, which are 
not known to be associated with renal transplantation graft failures. The 
validation of the microarray experiments was performed by real-time PCR. 
All four genes were up-regulated signifi cantly in the DCD group relative to 
the LD group (p<0.05). These data provide a good source for candidates of 
biomarkers that are potentially useful for the control of DGF.
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MOTTEP: SAVING LIVES AND TAXPAYERS DOLLARS!!1813 
C. Callender
Howard University
The MOTTEP program provides organs which saves lives and over time decreases 
health care expenditures on dialysis by 236 million dollars for kidneys alone.
Since 1982 we have participated in the growth and development of a national 
donor education program which relies on a grass roots strategy that emphasizes 
community education and empowerment requiring the community to be an 
effi cient and economically appropriate change agent.
Methodology: The data presented provide compelling evidence of the 
effi ciency of a community-based grass roots approach.
Table 1: The Scientifi c Transplant Registry Data demonstrate MOTTEP sites 
had statistically signifi cantly improved donation rates when compared to 
regions in which there were no MOTTEP sites!
MOTTEP NON-MOTTEP %value
Ethnicity Donation Rate Donors Donation Rate Donors p-value
White, Non Hispanic  59.3 4,928 59.2 11,279 0.02
White, Hispanic 106.9 1,055 47.4  886 <.01
Black  43.4 1,263 32.9  1,286 <.01
Other  50.7  228 42.4  272 <.01
Table 2: (UNOS Data)
Number of Donors Donors/Million Donation%
Ethnicity 1990 2000 1990 2000 2000 2005
Black 659 1373 22.4 40.8 11.2% 14%
Hispanic/Latino 518 1319 22.9 40.2 11.2% 13.2%
Asian 73 278 10.3 26.2  2.7%  2.6%
Minority Donor Total 25.1%  30% (29.8%)
Dialysis costs are in excess of $40,000.00/yr per patient much of which are 
taxpayers dollars, and transplants which break even after 3 years would provide 
an average savings of at least $30,000.00/yr for each year the organs survives 
over 3 years. Since 50% of all kidney transplants survive from 5.3 African 
Americans (A.A.) to 12.2 (Asian) years, and most more than 9 years, it is 
clear that the fi nancial benefi t to the government supporting a national donor 
education program such as this would save millions of dollars. Assuming an 
organ survival rate of 6 years, each donor (living or deceased) organ would 
save at least $135,000.00 per donor (1.5 x $30,000.00 x 3 years).
These data are based upon the current census that identifi es 25% of the 
American population as minorities. The MOTTEP goal is by 2010 to have 35% 
of the donors being minorities and to have A.A. and Latino O.D.M. to increase 
from 41 O.D. M. to 50 O.D.M. This would allow for the recovery of 1750 
minority donor organs and save the Government 236 million dollars.
While MOTTEP has received a total of $16 million dollars from the Federal 
Government between 1992 and 2008, none of these dollars have been allocated 
for organ donation after 2007. This would mean this unique program which 
has made a national contribution to the donor shortage would cease to exist 
after midyear 2008. Currently MOTTEP exists in 11 sites; only 5 of which 
are partially funded. To optimize this unique community grass roots education 
program, funding for 15-25 sites would require 3-5 million dollars a year for an 
additional 5 years. A small amount when compared to the 236 million (kidney) 
dollars saved from kidney transplants alone and are more than 1 billion dollars 
saved when kidney, liver, hearts, and other organs are combined.
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WORKING THROUGH THE DONATION AFTER 1814 
CARDIAC DEATH (DCD) PROCESS OR HOW DID WE GET 
HERE?
S. Potdar1, L. Fields1, B. Spear, L. Racher, J. Wilson, B. Martin, R. Klaric2
1Summa Health System, 2Lifebanc OPO
The organ donation process can be complicated, controversial, and politically 
charged, especially in situations involving Donation after Cardiac Death 
(DCD). Brain death is relatively straightforward for donor hospitals as long as 
there is a working defi nition that is clinically practical. The process of organ 
donation is further complicated by the number of staff involved including 
hospital physicians, nurses, respiratory, clergy, as well as Organ Procurement 
Organizations (OPO), multiple organ receiving hospitals and their recipients 
and operating room times. A 925 bed Level 1 Trauma Center in Ohio decided 
to reorganize the process into workable sections that would improve the 
infrastructure between the hospital and the OPO. The goal of reorganization 
was to develop internal standards of practice and communication that would 
result in a smoother organ donation process, improved outcomes and increased 
organs donated. The process involved enhancing communication with the 
OPO; developing guidelines/roles and then educating all team members; 
increasing involvement of Intensivists in the entire donation process; 
developing a reference manual; revising policies and procedures in the critical 
care areas as well as surgical services; and using a debriefi ng model for process 
improvement. The tool developed to accomplish all of the above is an on-line 
and printed manual that contains hospital and OPO emergency numbers, order 
sets, policies and procedures, roles and articles. As a result, the hospital and 
the OPO enhanced their partnership and allowed the hospital to maintain their 
standing as a leading donor hospital and HRSA Medal of Honor recipient.
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10-YEAR RESULTS OF THE TRANSATLANTIC KIDNEY 1815 
TRANSPLANT AIRLIFT BETWEEN THE NETHERLANDS 
ANTILLES AND THE NETHERLANDS
R. Minnee1, N. Ajubi2, R. Kock3, M. Idu1, D. Legemate1, 
K. Donselaar van der Pant4, I. ten Berge4, F. Bemelman4
1Dept. of Surgery, Academic Medical Center, 2Dept. of Haemodialysis, 
St. Elisabeth Hospital, Curaçao, the Netherlands Antilles, 3Dept. of 
Haemodialysis Horacio E. Oduber Hospital, Aruba, the Netherlands Antilles, 
4Dept. of Nephrology, Academic Medical Center
Aim: The prevalence of end-stage renal failure in Curaçao (Caribbean) is 
one of the highest in the world. In 1998, the St. Elisabeth Hospital started 
collaboration with the Academic Medical Center (AMC) in Amsterdam, the 
Netherlands, and the Eurotransplant Foundation, aimed to achieve a structured 
transplantation programme for patients in the Netherlands Antilles. It resulted 
in an airlift between Curaçao and the AMC. The distance between both places is 
8000 km, with a travelling time of approximately nine hours. Here, we present 
the 10-year results of this transatlantic transplantation programme.
Methods: We retrospectively analysed 41 consecutive transplantations 
performed between January 1998 and April 2007. All donor kidneys were 
machine-preserved. Immunosuppressive therapy consisted of prednisone, a 
calcineurin inhibitor and mycophenolate mofetil. From 2003, basiliximab was 
added as induction therapy. One year graft survival and complication rates 
were the primary endpoints. In addition cold ischemia time and acute rejection 
episodes up to six months after transplantation were recorded.
Results: 24 Males and 17 females were transplanted with a median age of 
54 years. 36 Patients were managed with haemodialysis and 5 patients were 
on peritoneal dialysis. The median dialysis period prior to transplantation was 
6.8 years (range 1 – 20). The median body mass index was 29 kg/m2 (range 
19 - 47). 38 Patients underwent a fi rst kidney transplantation. Panel-reactive 
antibody (PRA) level was 0% in 29 (71%) patients, 1% to 10% in 7 (17%) 
patients, 11% to 25% in 2 (5%) patients, and greater than 25% in 3 (7%) 
patients. In 7% (n = 3) of the transplantations no mismatches was involved 
between the donor and recipient. 1 or 2 HLA mismatches was presented in 9 
(22%) patients, 3 or 4 HLA mismatches was presented in 20 (49%) patients and 
5 or 6 HLA mismatches was presented in 9 (22%) patients. 29 Patients (71%) 
received a graft mismatched for 1 HLA-DR allele.
Median cold ischemia time was 33 hours (range 16 – 52 hours), median 
operating time 150 minutes (range 102 – 257). Initial graft function occurred 
in 28 patients (68%); primary non function occurred in 4 patients (10%) and 
delayed graft function developed in 9 patients (22%). Acute rejection was 
diagnosed in 11 patients; in 5 of them superponed on delayed graft function. 
Eight grafts were lost within 3 months, due to therapy resistant rejection (3), 
sepsis (3) or thrombosis (2). The one-year graft survival rate was 69% (95% 
confi dence interval (CI): 52% to 80%). All patients returned to the Netherlands 
Antilles within 3 months.
Conclusion: Our transatlantic kidney transplant programme is a good 
alternative for the majority of patients with end-stage renal failure in the 
Netherlands Antilles. As compared to our centre one year graft survival of 
93%, this transatlantic graft survival rate was rather low. This may be due both 
to the long cold ischemia time and to the characteristics of the transplanted 
population: i.e. high lean body mass, negroid, high cardiovascular risk profi le, 
which are all factors known to negatively infl uence the outcome of renal 
transplantation.
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TELEHEALTH: ENGAGING NEW SOUTH WALES 1816 
REGIONAL HOSPITALS IN DONATION
M. Sgorbini
Royal Prince Alfred Hospital
Telehealth is the transmission of images, voice and data between two 
or more health units delivered by digital telecommunications to provide 
clinical consultations, case management, in-service training, education 
and administrative services. Connecting Critical Care is a research project 
by New South Wales Health looking at the use of Telehealth in Intensive 
Care and Emergency Departments. It is a multi-site project involving rural, 
regional and metropolitan hospitals along with the Medical Retrieval Unit. 
In April 2007, Telehealth was utilised by a regional hospital to consult with 
an Intensivist from Royal Prince Alfred with regards to a potential organ 
donor. Telehealth, in this particular case, was used to deliver advice regarding 
brain death examination and the process for obtaining consent to a regional 
hospital that has very limited experience in organ donation. A review and 
evaluation of the consultation was conducted by the Intensivists involved and 
the Donor Coordinator and the potentials for Telehealth in organ donation 
were explored. The review found that Telehealth provide the opportunity 
to enhance the communication between rural and metropolitan hospitals 
by providing assistance and advice to rural clinicians. The effective use of 
Telehealth in organ donation will enhance early referral to LifeGift nsw/act, 
provide outreach support to rural/regional hospitals and offer educational 
support for medical and nursing staff. The aim of the presentation is to 
describe Telehealth through a short powerpoint presentation and demonstrate 
the consultation between Orange and RPA hospitals in a re-enactment 
recorded on DVD.
POSTER BOARD NUMBER P3 – 243
VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN 1817 
(VCP) IMPROVES KIDNEY STRUCTURE AND FUNCTION 
FOLLOWING ISCHEMIA/REPERFUSION INJURY IN RATS
D. Kahn, Y.T. Ghebremariam, G. Engelbrecht, M. Tyler, Z. Lotz, 
D. Govender, G. Kotwal
University of Cape Town/Groote Schuur Hospital
Renal transplantation is performed in most major centres throughout the world. 
During the transplant procedure there is an ischemia reperfusion (I/R) injury 
that accounts for a delayed physiological recovery of the graft. This surgically 
and biologically induced injury often results in activation of the complement 
system. The vaccinia virus complement control protein (VCP) regulates 
both the classical and the alternative pathways of complement activation 
by preventing the formation of C3b, a complement component where both 
pathways converge.
The aim of the study was to investigate the effect of VCP on the I/R injury 
in the kidney. Long Evans rats were subjected to laparotomy, mobilization of 
both kidneys and clamping of the renal arteries for 60 min followed by 24 h 
reperfusion time. The rats were randomly allocated to receive natural VCP, 
humanized recombinant VCP (hrVCP) or phosphate buffered-saline (PBS) 
or sham group. Blood samples were collected at various intervals for urea 
and creatinine studies, and the kidneys removed for histopathological and 
immunohistochemical studies.
The biochemical studies showed that the PBS group displayed 2.7-fold and 
10-fold increases in the serum urea and creatinine concentrations respectively 
compared to the VCP/hrVCP groups. The renal histopathological study 
revealed focal necrosis of the tubular epithelial cells in the VCP/hrVCP treated 
rats compared to the diffuse and markedly elevated fi eld scores in the PBS 
controls. The immunohistochemical study showed signifi cant C3 deposition 
in the renal tubules of the PBS controls compared to the VCP/hrVCP treated 
groups suggesting that VCP/hrVCP has reduced ischemia/reperfusion-induced 
renal injury by inhibiting the biosynthesis of C3.
POSTER BOARD NUMBER P3 – 244
A TEN YEAR RETROSPECTIVE ANALYSIS OF 1818 
DONATION AFTER CARDIAC DEATH IN NSW
C. Alvaro, L. McKay, D. Bhonagiri, N. Seifert
LifeGift nsw/act - Australian Red Cross Blood Service
Introduction: Donation after Cardiac Death or Non- Heart Beating Organ 
Donation was the only cadaveric solid organ donation pathway in the 1960s 
before widespread acceptance of the criteria to declare death using loss of 
all brain function. Resurgence in DCD in the late 1990’s and early 2000’s in 
Europe and USA was closely monitored in Australia and low levels of DCD 
donors were reported since 1997. The “Organ Donation After Cardiac Death 
NSW Guidelines” in 2007 recognised the need for a state-wide policy on DCD 
in an era of increasing disparity between the numbers of organs available for 
transplantation and prolonged waiting times for transplant recipients.
Purpose: This review presents the profi le of DCD donors in NSW from 1997 
to 2007 and the outcomes of the recipients and transplanted organs from those 
donors. The outcomes are compared to non- DCD (donors declared dead by 
brain stem criteria and living related donors).
Method: Donor records at LifeGift nsw/act were reviewed and de-identifi ed. 
Demographic data, cause of death, time interval between extubation and 
death, organs retrieved and organs transplanted were recorded into a Microsoft 
Excel® database. Recipient outcome data held in databases by Transplant 
Coordinators in transplanting hospitals were queried and the outcomes of 
organs and recipients were obtained. No recipients were identifi ed during the 
process and all data was transferred using secure servers. Age and outcomes 
data were analysed and presented as mean and median with relevant ranges 
quoted.
Results: Analysis of the donor profi le revealed that the donor demographics 
from DCD donors closely resembled the demographics from Donation after 
Brain Death (DBD) donors. All DCD donations occurred within metropolitan 
Sydney however Westmead hospital {which was the only NSW hospital to 
develop and implement a local DCD policy in the early 1990’s}, far exceeded 
other hospitals. CVA and traumatic head injury continues to be the leading 
cause of death in both groups of patients however DCD donors are on average 
aged less than that of brain-dead donors. Early reports indicate that the long 
term kidney function and patient survival rates are not signifi cantly different 
between DCD and DBD.
Conclusion: Long term graft function and recipient outcome is not signifi cantly 
different in our cohort of patients. DCD is associated with acceptable outcomes 
for kidney transplantation in NSW. Outcomes for recipients of liver, lung and 
pancreas transplantation in multi-organ DCD will need to be reviewed and 
reported.
POSTER BOARD NUMBER P3 – 245
THE AVAILABILITY OF 99MTC-MAG3 RENOGRAPHY 1819 
IN RENAL TRANSPLANTATION FROM NON HEART BEATING 
DONORS
T. Majima, R. Hattori, S. Yamada, M. Katou, O. Kamihira, O. Matuura, 
T. Kinukawa, M. Gotou
Department of Urology, Faculty of Medicine, Nagoya University
Purpose: Seventy percent of patients who undergo renal transplantation from 
non heart beating donors (NHBD) develop acute tubular necrosis (ATN) and 
require dialysis for about 2 weeks. For the evaluation of graft function during the 
ATN period, we performed 99mTc-MAG3 renography regularly as soon after 
transplantation as possible. We estimated whether 99mTc-MAG3 renography 
can monitor the recovery of graft function during the anuria period.
Patients: Fifteen patients underwent renal transplantation from NHBD from 
2 June 2005 to 24 May 2007. One patient was excluded from the study due to 
acute rejection which developed during the dialysis period. The median ages 
of the recipient and the donor were 49 (range 8¦ ]72) and 52 (range 15¦ |68) 
years old, respectively. The medians of WIT and TIT were 6.5 (range 2¦ |57) 
and 847 minutes (range 91¦ |1835), respectively. The median dialysis period 
after transplantation was 8 days (range 0¦ |16).
Methods: The fi rst 99mTc-MAG3 renography after operation was performed 
as early as possible¦ @(within 4 days) and repeated weekly thereafter until the 
recipient was weaned from dialysis. We adopted RUNQ method to quantify 
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MAG3, and calculated the corrected Tubular Extraction Rate (cTER) (ml/
min/1.73m2), that is MAG3 clearance corrected by body surface area.
Results: Corrected TER (cTER) was low (mean 53 ml/min/1.73m2) 
immediately after transplantation, but increased gradually until 2-3 weeks after 
the operation, and then plateaued. Likewise, the change in the cTER based on 
the day of weaning showed an upward tendency during the dialysis dependent 
period, and plateaued 5-10 days after weaning.
By analyzing the relation between the early cTER and the dialysis dependent 
period, a signifi cant correlation between these two parameters was found 
(R=-0,780, p=0.001). The following regression formula was obtained: 
y=0.269x+22.024 R2¦ ¦ 0.609¦ @p=0.001.
There was no signifi cant relationship between the early cTER and best cCCr, 
donors¦ f age, WIT, and TIT.
Conclusion: Recovery of graft function can be monitored by routinely 
performing 99mTc-MAG3 renography on transplanted grafts from NHBD
POSTER BOARD NUMBER P3 – 246
LEARNING TO BE AN ORGAN DONOR – AN ORAL 1820 
HISTORY APPROACH TO UNDERSTANDING HOW PEOPLE 
FROM THREE ETHNIC BACKGROUNDS BECAME POSITIVE 
ABOUT ORGAN DONATION
G. Smith1, A. Warrens1, S. Saxena1, J. Car1, H. Dulku2, P. Reece2, N. Jain3
1Imperial College London, 2Hammersmith Hospital NHS Trust, 
3Kidney Research UK
Aim: To understand how people from a white British/Irish, African Caribbean 
and South Asian/Indo-Asian ethnic background successfully integrated the 
idea of organ donation into their lives and ethnic identity.
Objective: To increase donation rates overall and particularly from ethnic 
minorities.
Design: A United Kingdom based qualitative study using in-depth oral history 
style interviews with 56 participants (18+) from diverse social, religious and 
economic backgrounds.
Analysis: The interviews were transcribed, the data coded and emerging 
themes discussed to reach a consensus on interpretation.
Results: The ability to achieve a positive view of organ donation is hindered or 
encouraged by an interplay of family background, cultural and religious values, 
feelings about death, personal relationships, age, personality, and experiences 
of donation and identity over time. These dynamic relationships are infl uenced 
by their historical and social contexts.
The white British/Irish saw organ donation and death in practical or secular 
terms, and some older participants recalled the media coverage of the 
development of organ donation as a cultural and social advancement that 
connected with their growing sense of ethnic identity.
Developing a positive view of organ donation was more complex for the 
two ethnic minorities. The idea of organ donation generated stronger and 
more emotional confl icts concerning individual and social identities that 
were often already in a state of tension. Many participants overcame these 
issues by: emphasising religious values over religious rituals; discussing 
and thinking about organ donation over time; rationally separating out good 
publicity from bad publicity about organ donation; believing in religious 
fate; thinking of themselves or family as potential organ recipients in the 
future; real life exposure to the benefi ts of organ donation; seeing organ 
donation as another struggle against “oppression.” Some participants from 
an African Caribbean ethnic background hinted that they would like to see 
a positive shift in opinion about organ donation from people of the same 
ethnic background before fully embracing the idea of organ donation. The 
experience and perception of racism was cited by some participants from 
an African Caribbean ethnic background as tempering and changing their 
positive attitude towards organ donation.
Despite being positive about organ donation many people failed to register this 
view or sign an organ donor card.
Conclusion: Future campaigns should be grounded in peoples’ realities and 
identity politics to refl ect more openly the tensions that people face when 
deciding to be an organ donor. The public can then learn how others have 
negotiated and overcome those tensions. Unfortunately, previous campaigns 
that have highlighted the lack of donors from ethnic minorities may have 
reinforced the idea that organ donation goes against cultural “norms.” Some 
peoples’ positive views towards organ donation can become negative over 
time and so campaigns must strive to sustain an ongoing presence in our 
social environment. Developing new strategies to motivate and support people 
to embrace and maintain a positive view of organ donation alongside more 
conventional educational programmes is crucial.
POSTER BOARD NUMBER P3 – 247
VARIOUS RECONSTRUCTIONS OF PANCREAS 1821 
VASCULATURE PRIOR TO TRANSPLANTATION
Z. Galazka, T. Jakimowicz, T. Grochowiecki, S. Nazarewski, K. Grygiel, 
J. Szmidt
Department of General, Vascular And Transplant Surgery, Medical University 
of Warsaw, Poland
Approximately 40% of all organ procurements in Poland are from multiorgan 
harvesting (MOH). Pancreas and liver have joint arterial supply from celiac 
trunk which requires vessel division during simultaneous pancreas and liver 
procurement for transplantation. For the same reason reconstruction of the 
pancreas vasculature must be done to achieve usefulness of both organs.
The aim of the study was to assess various methods of vascular reconstructions 
used to prepare the pancreas for transplantation.
Between January 1999 and February 2008, 75 whole pancreas transplantations 
were performed in our Department. Of this number, 66 pancreases came from 
MOH and necessitated arterial reconstruction. The splenic artery (SA) and 
superior mesenteric artery (SMA) were sewn into a single trunk using the 
common iliac arterial bifurcation in 62/66 (94%) cases. Occasionally, the iliac 
Y-graft was unsuitable for vascular reconstruction due to atherosclerosis or 
iatrogenic injury. In 2/66 (3%) cases the SA was anastomosed to the side of 
the SMA. In another 2/66 (3%) cases the brachiocephalic trunk bifurcation was 
utilized. Portal vein elongation was done using a donor procured external iliac 
vein in all 55/66 (83%) cases.
In all 66 transplanted pancreases good blood perfusion was achieved 
intraoperatively. In the early follow-up period, 6 venous and 5 arterial 
thrombosis were noted in fi rst postoperative month. All 11 (17%) organs were 
removed. In one case unsuccessful trombectomy was performed followed by 
graftectomy in the subsequent day. In remaining cases 2-86 months follow-
up reviled no vascular complications. Vessels patency was proven by either 
Doppler ultrasound or spiral angio-CT scan.
Reconstruction of the pancreas vasculature does not affect the long-term 
function of the allograft while signifi cantly increases the available donor organ 
pool.
POSTER BOARD NUMBER P3 – 248
MULTI-ORGAN DONATION AFTER CARDIAC DEATH 1822 
– AUSTRALIAN PERSPECTIVE
C. Russell1, J. Chen2, G. O’Callaghan2, G. Snell3, C. Hannan4
1The Queen Elizabeth Hospital, Adelaide, 2Flinders Medical Centre, Adelaide, 
3The Alfred Hospital, Melbourne, 4South Australian Organ Donation Agency, 
Adelaide
Donation after cardiac death (DCD) donors have greatly increased the rate of 
kidney transplantation in various parts of the world. Both Maastricht category 
II and III donors have been utilised, depending on the country involved. An 
initial reluctance to use organs other than kidney was due to the increased 
risk because of a longer warm ischaemic time. More recently however, liver 
and pancreas have been used and lungs from DCD donors can now also be 
transplanted. Currently, this is only really a viable option in Australia with 
Maastricht category III donors, due to the amount of organisation and critical 
timing involved.
We describe here a method of multi-organ retrieval in donors after cardiac 
death, which enabled rapid retrieval and viable organs. In all cases a meeting 
was undertaken with all teams, including retrieval surgeons from each 
team, ICU and theatre staff and donor co-ordinators, such that everyone 
was aware of the process. Withdrawal of life-sustaining treatment was 
undertaken in theatre, or in ICU followed by rapid removal to the operating 
theatre, with a mandatory 5 minute stand off period. The movement to 
theatre took place within this 5 minute period. Rapid laparotomy and 
simultaneous thoracotomy were performed with cannulation of the distal 
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aorta and pulmonary artery. The thoracic aorta was clamped in the chest to 
prevent mixing of the two solutions. Venting was via the right atrium and 
inferior vena cava. Ice was packed around the organs and some dissection 
undertaken whilst perfusion was ongoing, which would normally have been 
done pre perfusion.
Two retrievals have occurred in South Australia where lungs, liver and 
kidneys were taken. Of these two cases where multi-organ retrieval occurred, 
all organs were transplanted. The kidney recipients had some initial delayed 
function, but good function was achieved with all organs. During this period, 
two other donors were considered for DCD. Unfortunately, neither proceeded 
to cardiac death in the allowable time frame of 90 minutes.
There are a number of scoring options available, to help predict the progression 
to cardiac death within 90 minutes. A more accurate method of assessing the 
likelihood of cardiac death before 90 minutes would be useful. A pre-prepared 
protocol can also help with the organisation of this procedure.
The increased utilisation of donation after cardiac death donors could lead 
to increased rates of transplantation of organs other than kidney. In order to 
increase the use of DCD’s there needs to be more acceptance of the process, 
both by the public and also by intensive care staff.
POSTER BOARD NUMBER P3 – 249
CAVAL APPROACH FOR THE SEPARATION OF THE 1823 
ARTERIS IN MULTI-ORAGAN PROCUREMENT
S. Nishida1, H. Haider1, J. Kadono2, J. Moon1, E. Island1, G. Selvaggi1, 
D. Levi1, S. Ganz1, A. Tzakis1
1University of Miami, Miami Transplant Institute, 2Kagoshima University, 
Second Department of Surgery
Purpose: The crucial step during multi-organ procurement is excision of the 
arteries including the superior mesenteric artery (SMA), renal arteries, celiac 
trunk, and any aberrant hepatic arteries. We present a caval approach technique 
in which arterial dissection is performed after dividing the inferior vena cava, 
with the goal of secure exposure and separation of each artery.
Method: In the period between December 1994 and October 2006, multi-
organ procurements were performed using the previously described technique 
of multiple organ procurements with University of Wisconsin solution in our 
program.
After dividing the inferior vena cava, the left renal vein is mobilized to the foot. 
This transection of the cava permits wide exposure of the abdominal aorta at 
the root of mesentery. The abdominal aorta, SMA, and the right renal artery 
are exposed thereafter. This secure exposure permits comfortable separation of 
SMA and renal arteries on the abdominal aorta.
Results: From July 2005 to October 2006, 23 donors including 5 pediatric and 
18 adult donors underwent organ recovery using a caval approach technique. 
Recovered graft types consisted of the following: 67 grafts including 35 kidney 
grafts, 19 liver grafts, 8 pancreas grafts, 4 multivisceral grafts (liver, stomach, 
pancreas and intestine) and 1 modifi ed multivisceral grafts(stomach, pancreas 
and intestine). Of these donors, the aberrant renal artery was visualized in 2 
donors and the right replaced hepatic artery was visualized in 3 donors. All 
the excision of the abdominal aorta was successfully performed with enough 
margins of each artery using a caval approach technique and all the transplanted 
organs functioned well.
Conclusions: A new approach to a safer and easier dissection and excision 
of the abdominal aorta for an organ recovery is attempted. We believe this 
caval approach presents several advantages: 1) it gives a wide exposure 
of the abdominal aorta at the level of the root of the mesentery and renal 
arteries, 2) this secure exposure facilitates the separation of SMA and renal 
arteries on the abdominal aorta, 3) anatomical variations of the inferior 
vena cava and renal veins are low in incidence and dissection of this 
area is technically straight forward, and 4) it is especially useful in small 
pediatric donors.
POSTER BOARD NUMBER P3 – 250
SERUM TISSUE INHIBITOR OF 1824 
METALLOPROTEINASES 1 (TIMP-1) AS A PREDICTOR OF 
ORGAN RECOVERY FROM DELAYED GRAFT FUNCTION 
AFTER KIDNEY TRANSPLANTATION FROM DONORS AFTER 
CARDIAC DEATH
M. Kusaka1,2, Y. Kuroyanagi1, M. Ichino1,2, H. Sasaki, T. Maruyama1, 
K. Hayakawa1, R. Shiroki1, A. Sugitani4, H. Kurahashi2,3, K. Hoshinaga1,2
1Department of Urology, Fujita-Health University School of Medicine, 
2Institute for Comprehensive Medical Science and 21st Century COE 
program, Development Center for Targeted and Minimally Invasive Diagnosis 
and Treatment, Fujita Health University School of Medicine, 3Division 
of Molecular Genetics, Fujita Health University School of Medicine, 
4Department of Organ Transplantation and Regenerative Medicine, Fujita-
Health University School of Medicine
Because of a world-wide shortage of renal grafts, kidneys procured from donors 
after cardiac death (DCD) have recently become an important source of renal 
transplants. However, DCD kidneys often have complications with delayed 
graft function (DGF) and recipients require hemodialysis (HD) in the early 
period after kidney transplantation (KTx). From our previous gene expression 
profi ling using renal biopsy samples performed at 1 hour after KTx from DCD, 
several genes encoding secretory proteins were identifi ed that might refl ect 
the performance of the graft and be potential non-invasive biomarkers. The 
identifi ed genes included tissue inhibitor of metalloproteinases 1 (TIMP1), 
which is not known to be associated with renal transplantation graft failures. 
This study evaluated serum TIMP-1 as a potential specifi c parameter to predict 
early functional recovery of transplanted DCD kidneys. The average serum 
TIMP-1 level in normal samples was 190 ng/ml, while that in patients with 
chronic renal failure requiring HD was almost the same level (241 ¦ } 8 ng/
ml (n=38)). In patients undergoing a living-related KTx from a living donor 
(n=26), serum TIMP-1 level had no increase after KTx (POD1: 226 ¦ } 12, 
POD2: 211 ¦ } 12 and POD3: 191 ¦ } 10 ng/ml), and only in one case, with 
serum NGAL levels over 360 ng/ml on POD1, was HD required due to DGF. In 
contrast, patients undergoing a KTx from a DCD (n=12), ten patients required 
HD due to DGF. Even in these cases required HD due to DGF, serum TIMP-1 
levels increase rapidly after a KTx (POD1: 435 ¦ } 32, POD2: 412 ¦ } 42 and 
POD3: 293 ¦ } 26 ng/ml), and in two cases, with serum TIMP-1 levels under 
370 ng/ml on both POD1 and POD2, was immediate function. These data 
suggest that monitoring of serum TIMP-1 levels on POD 1 and 2 may allow us 
to predict graft recovery and the need for HD after a KTx from a DCD.
POSTER BOARD NUMBER P3 – 251
SPLIT LIVER TRANSPLANTATION FROM A DONOR 1825 
SUPPORTED BY A BERLIN HEART
M. Misra1, L. Krawczuk1, R. Jenkins2, B. Linden1, C. Weldon1, H.B. Kim1
1Children’s Hospital Boston, 2Lahey Clinic
Introduction: Patients on cardiac assist devices are often considered to 
be high-risk solid organ donors. Factors that contribute to this perception 
include the need for anticoagulation, the potential for embolic disease, and the 
possibility of organ injury due to cardiogenic shock. We report a reduced size 
liver transplant performed using the left lateral segment of a 4-year old donor 
whose cardiac function was supported by a Berlin Heart.
Methods: This study was conducted by retrospective review of both donor and 
recipient medical records.
Patient: The donor was a 4 year-old, 16 kg girl that initially presented for 
elective repair of an atrioventricular septal defect. She developed post-
operative low cardiac output syndrome and decreased left ventricular function. 
She was transferred to a tertiary medical center where she fi rst required a left 
ventricular assist device to support cardiac function and then had a Berlin heart 
placed as a bridge to her own transplant. Her condition continued to deteriorate, 
and she eventually developed bilateral infarcts of her anterior and posterior 
cerebral circulation, suggestive of an embolic pattern. She was declared brain 
dead 17 days after her transfer. Her family made her an organ donor. Her 
liver transaminases were marginally elevated at the time of brain death. The 
recipient was a 22 day-old, 3.3 kg boy who presented in liver failure shortly 
after birth secondary to neonatal hemochromatosis. He was listed Status 1A for 
a liver transplant after medical treatment failed to slow the progression of his 
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liver failure.
Procurement and transplant: Procurement proceeded as usual with 
cannulation of the abdominal aorta and portal vein. Due to the presence of 
the Berlin Heart drive lines, full anticoagulation and a high CVP secondary to 
right heart failure, minimal dissection was performed prior to cross clamp. The 
donor liver was procured as a whole organ and reduced on the back table. There 
was no suitable recipient for the right tri-segment graft but the segment2,3 graft 
was of the appropriate size for our recipient. Interestingly, the kidneys were 
found to have multiple infarcted areas, but the liver appeared normal.
The transplant was complicated by mild delayed graft function, which required 
delayed biliary reconstruction and abdominal wall closure, as well as a bile 
leak. However, the graft function improved quickly over the fi rst week and 
the patient was discharged home with normal liver function 8 weeks after 
transplant.
Conclusions: The presence of a cardiac assist device should not be considered 
an absolute contraindication for abdominal organ donation. Normal organ 
procurement procedures may require alteration due to the unusual technical 
obstacles that are encountered when the donor has a cardiac assist device.
POSTER BOARD NUMBER P3 – 252
CALORIE RESTRICTION AND FASTING PROTECT 1826 
AGAINST ACUTE OXIDATIVE DAMAGE INDUCED BY 
ISCHEMIC INJURY IN MICE
M. Verweij1, J.R. Mitchell2, H.P. Roest1, S. van den Engel1, 
J.H.J. Hoeijmakers2, J.N.M.I. Jzermans1, R.W.F. de Bruin1
1Erasmus Medical Centre, Departments of Surgery and 2Cell Biology and 
Genetics, Rotterdam, The Netherlands
Introduction: The primary mediators of renal ischemia reperfusion (I/R) 
injury are reactive oxygen species (ROS), which cause oxidative damage to 
lipid membranes, DNA and proteins.
The only known non-invasive intervention that extends lifespan is calorie 
restriction (CR). CR is thought to prolong lifespan in part by reducing oxidative 
damage in the body, which is thought of as the most important reason why we 
age. CR reduces the production of ROS in the mitochondria, and upregulates 
antioxidant defence systems.
Aim: To investigate if CR protects against renal I/R injury in mice.
Materials and methods: Male C57BL/6 mice were subjected to either 30% 
CR for 2 or 4 weeks, 24-72 hours of fasting, or were fed ad libitum. Renal 
ischemia was induced by clamping the left renal pedicle for 37 minutes 
followed by contralateral nephrectomy. Survival, kidney function, histology 
and infl ammatory markers were assessed. Partial (70%) liver ischemia was 
induced by clamping the portal triad for 75 minutes. Liver injury was assessed 
by histology and serum ALAT levels.
Results: In the ad libitum fed group, 70% of the animals died within 2-4 days 
due to acute renal failure, whereas all animals in the four and two weeks 30% 
CR group survived. Renal function was signifi cantly better in CR animals on 
days 1, 2, and 7 than in the surviving ad libitum fed mice.
Following these striking results, we investigated whether fasting was also 
able to protect against renal I/R injury. Already 24 hours of fasting was 
signifi cantly benefi cial for survival (90% vs. 30%), with a maximal survival 
benefi t reached by 48 hours (100%). Kidney function was best in the 72 hours 
fasted group. Three day fasted animals showed signifi cantly less acute tubular 
necrosis 24 hours after reperfusion. Renal mRNA levels for IL-6 and p-selectin 
were signifi cantly reduced at 6 hours post-reperfusion in 30% CR and fasted 
animals.
We next investigated if these benefi ts were organ specifi c, by inducing 
hepatic I/R injury. Mice fasted for 48-72 hours were signifi cantly protected 
from hepatic injury as shown by signifi cantly lower ALAT levels and less 
hemorrhagic necrosis.
Conclusions: Two or four weeks of CR protects C57BL/6 mice against a 
potentially lethal ischemic insult to the kidney. Similar benefi cial effects were 
seen after 24-72 hours of water-only fasting. Benefi ts of fasting were protective 
against liver ischemia as well. These results suggest that the mechanisms 
involved in extended longevity by dietary restriction may also be tapped for 
short-term benefi ts such as protection against ischemia reperfusion injury.
POSTER BOARD NUMBER P3 – 253
CHARACTERIZATION OF LIPID TRANSFER/1827 
METABOLIC PROTEINS IN A RAT NON-ALCOHOLIC 
STEATOHEPATITIS MODEL
Y.F. Cheng1, T. Nakano1, C.Y. Lai1, L.W. Hsu1, J.L. Wong1, Y.C. Chung1, 
T.L. Huang1, H.L. Eng1, S. Goto1,2, C.L. Chen1
1Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center, 2Iwao Hospital
Aims: Non-alcoholic steatohepatitis (NASH) is becoming a big problem for 
both donors and recipients in living related liver transplantation. However, 
there is no unifi ed standard for diagnosis and therapeutics of NASH. This study 
aimed to establish a noninvasive approach for diagnosis of NASH in rats.
Methods: After 1-week acclimation period on a standard diet, LEW rats (male, 
5 weeks of age) were switched to a choline defi cient and iron supplemented 
L-amino acid defi ned (CDAA) diet for 1-12 weeks to produce livers with 
different degrees of steatosis (NASH). For histological examination, sections 
of liver tissue were stained with hematoxylin and eosin (HE). Western and 
real-time PCR analyses were performed to detect the apolipoprotein E (apo-E), 
adiponectin and its receptors.
Results: The livers of CDAA diet group indicated a serious fatty liver (40-60%) 
at 2 weeks, hepatitis (NASH) at 6 weeks and fi brosis at 12 weeks with early 
elevation of aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) and latter elevation of alkali phosphatase (ALP). Serum apo-E level 
was dramatically reduced after CDAA diet feeding. Similarly to the apo-E, 
high molecular weight adiponectin (HMW-Ad) level was gradually reduced. 
AdipoR1 mRNA level was signifi cantly elevated in the livers with the 
progression of NASH. On the other hand, low molecular weight adiponectin 
(LMW-Ad) level was dramatically elevated with the progression of fi brosis in 
CDAA diet group.
Conclusions: These results suggest that serum apo-E and adiponectin (HMW-
Ad and LMW-Ad) may be effective biomarkers for noninvasive diagnosis of 
fatty liver, NASH and fi brosis, and that proteomic approach combined with 
pathological examination has potential to distinguish NASH from normal fatty 
liver disease.
POSTER BOARD NUMBER P3 – 254
THE REASONS GIVEN TO NSW AND ACT ORGAN 1828 
DONOR COORDINATORS BY POTENTIAL DONOR FAMILIES 
FOR THEIR DECISION REGARDING ORGAN AND TISSUE 
DONATION
J. Treloggen1, G. Ross2, E. Phillips3, A. Barnwell4
1LifeGift nsw/act, 2Charles Sturt University, 3Heartbeat Trends Pty Ltd, 
4LifeGift nsw/act
The number of multi-organ donors per year in New South Wales (NSW) and 
the Australian Capital Territory (ACT) has been consistent for many years 
but refusal and selective consent nominated by the donor themselves and/
or their family, limits the number of organs and tissues made available for 
transplantation.
Most of the information known about decision making related to organ and 
tissue donation has been gained from surveys undertaken with the general 
public responding to hypothetical situations. By contrast, very little is known 
about the reasoning for decisions made at the time of approach to a potential 
donor family.
Given the sensitive nature and timing of such discussions, this research used a 
non-experimental descriptive study design, to indirectly identify the decision 
making reasons given by potential donor families. Using semi-structured 
interviews, NSW and ACT donor coordinators were asked to recall and share 
their experience working with the families of potential donors.
In NSW and ACT the initial approach to potential donor families is mostly 
undertaken by the treating clinician and the majority of families make their 
decision at this time. The donor coordinators are invited into the process and 
rarely get to meet families who refuse consent. The overwhelming feedback 
from the donor coordinators is that the primary focus of all families at the 
time approach is on their family member with reasons for declining consent 
associated with wanting to protect their loved one and to avoid confl ict within 
their family. Families who gave consent most often saw donation as a fulfi lment 
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of the donor’s wishes, a refl ection of a generous nature and way of making sense 
of a person’s death. Selective consent was related to emotional attachment or 
religious beliefs linked to specifi c organs. Of interest, there appeared to be little 
concern for recipients at this time but it was suggested that they might become 
more relevant for the donor family at a later time.
POSTER BOARD NUMBER P3 – 255
NSW ORGAN DONATION INDICATOR: OUTCOMES OF 1829 
12 MONTH AUDIT 1 JANUARY – 31 DECEMBER 2007
J. Treloggen, T. Wills
LifeGift nsw/act
The Australian Organ Donor Register (AODR) was established in 2000 to 
register the individual’s decision to donate all, some or no organs and tissue for 
transplantation at the time of their death. The decisions of families to allow or 
refuse the retrieval of organs and tissues for transplantation may be infl uenced 
by the existence of a prior directive from the potential donor.
The Australian Health Ministers Advisory Committee (AHMAC) and the 
National Health and Medical Research Council (NHMRC) advocated that the 
AODR be routinely consulted at the end of life to ascertain an individual’s 
decision. In addition to direct registration to these registries, notifi cations from 
State based drivers licence databases have been transferred to the AODR. 
However, in NSW residents still have the option to lodge a decision regarding 
organ and tissue donation with both databases.
In response to the AHMAC and NHMRC directives and the Australians Donate 
National Organ Donation Collaborative key performance indicators, the NSW 
state organ donation agency, LifeGift nsw/act now routinely search both the 
Roads and Traffi c Authority (RTA) and the AODR databases for indications 
of refusal and consent for all potential organ and tissue donors. Of note, in 
accordance with the 1983 NSW Human Tissue Act an indication of ‘refusal’ 
on the databases cannot be over ridden by the Senior Available Next of Kin 
(SANOK).
During the audit period from 1 January 2007 to 31 December 2007, 129 
database searches were conducted in NSW, requested from 27 different sites. 
The total number of NSW multi-organ donors for the same period was 53. 
Brain death was confi rmed 34% at the time of the search request; the remaining 
cases were identifi ed as either potential donor after cardiac death (DCD) 17%, 
potential tissue only donors (1.5%) or brain death was not yet confi rmed (45%). 
Occasionally the request for a search was made prior to brain death testing to 
assist decisions regarding the instigation of further treatment or diagnosis.
Consent for all or some organs was registered for 46% of the searches, 58% 
became multi-organ donors, 3 were tissue only donors and one was an intended 
DCD. Final consent was only revoked 5 times by the SANOK and once by the 
Coroner.
Overall 30% did not have a decision registered and from this group 35% became 
multi-organ donors and one was an intended DCD. Refusal was registered for 
23% of the searches with none becoming donors. However on 9 occasions the 
SANOK had already indicated provisional consent prior to the database checks 
and were reported to be surprised and disappointed to know of the ‘refusal’ 
documentation and that their family member could not be a donor.
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HORMONAL RESUSCITATION HAS BENEFICIAL 1830 
EFFECTS ON DONOR PULMONARY FUNCTION IN A 
PORCINE MODEL OF BRAIN-DEAD ORGAN DONATION
A.J. Watson1,2, M. Hicks1, L. Gao1, A. Jabbour1,2, S.C. Faddy1, 
S.H. Kesteven1,3, A.F. Sharland4, R.D.M. Allen4, P.C. Jansz2, P.S. Macdonald1,2
1Transplant Program, Victor Chang Cardiac Research Institute, Sydney 
NSW Australia, 2Heart & Lung Transplant Unit, St Vincent’s Hospital, 
Sydney NSW Australia, 3Cardiovascular Mechanics Program, Victor Chang 
Cardiac Research Institute, Sydney NSW Australia, 4Collaborative Transplant 
Research Group, University of Sydney, Sydney NSW Australia
Introduction: The benefi cial effects of hormonal resuscitation (HR) on 
cardiovascular function and systemic haemodynamics are well established. We 
sought to evaluate what effects an HR protocol had on pulmonary vascular 
function and gas exchange in a porcine model of brain death.
Methods: Brain death was induced in juvenile large white landrace pigs by 
infl ation of a subdural balloon catheter. After one hour of brain death, pigs were 
randomised to receive either HR (comprising bolus methylprednisolone, and 
infusions of tri-iodothyronine and vasopressin, n = 8) or noradrenaline infusion 
(NAd, n = 9) titrated to maintain mean arterial blood pressure (MAP) 60-70 
mmHg. Invasive systemic and pulmonary haemodynamic monitoring was 
performed in conjunction with arterial blood gas sampling. Experiments were 
terminated after 6 hours of brain death. Data are expressed as mean ± SEM.
Results: Despite the high peak noradrenaline requirements of NAd animals 
(0.485 ± 0.085 μg/kg/min), systemic haemodynamic performance was 
signifi cantly better in HR animals after 6 hours of brain death than in NAd 
animals (MAP 67 ± 5 mmHg vs 53 ± 2 mmHg, p = 0.009; heart rate 100 
± 7 bpm vs 154 ± 7 bpm, p = 0.0001). There was no signifi cant change in 
transpulmonary gradient (TPG) in HR animals (12.0 ± 3.5 to 14.0 ± 4.0 mmHg, 
p = 0.33) as opposed to a signifi cant 42% rise in NAd animals (10.8 ± 1.5 to 
15.2 ± 4.3 mmHg, p = 0.007).
Gas exchange deteriorated in both groups of animals, but to a lesser extent 
in the HR group. PaO2 declined by 13% in HR animals (413 ± 26 to 354 ± 24 
mmHg, p = 0.07) versus 28% in NAd animals (438 ± 17 to 315 ± 45, p = 0.02). 
Similarly, there was an increase in alveolar-arterial (A-a) gradient, again to a 
lesser extent in HR animals. A-a gradient increased by 32% in HR animals (250 
± 26 to 313 ± 23 mmHg, p = 0.06) versus 55% in NAd animals (224 ± 17 to 343 
± 44 mmHg, p = 0.02). Differences between the two groups at 6 hours however 
did not reach statistical signifi cance.
Conclusions: These data provide encouraging preliminary evidence that HR 
attenuates brain death induced donor pulmonary haemodynamic dysfunction 
and reduction in gas exchange. Further investigation into the effects of 
hormonal resuscitation on donor lung function is warranted.
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IT’S NOT EASY. CONSENT ISSUES SURROUNDING A 1831 
DCD DONOR: A CASE REPORT
E. Treasure, S. Brean
LifeGift - Victoria
Aim: This case report demonstrates a fundamental delay in obtaining designated 
offi cer consent after cardiac death and highlights the impact on staff and the 
effect of extended warm ischaemic time on graft function.
Body: A 19yr old male suffered extensive head and chest injuries in a high 
speed motor vehicle accident. His injuries were considered non-survivable 
and discussions were held with his family regarding withdrawal of treatment 
and palliation. The family raised organ donation. Medical staff deemed 
he was unlikely to progress to brain death and on Christmas day, the DCD 
pathway was initiated. The family consented for renal only donation as they 
did not want their son’s chest to be opened. The state coronial service and 
the designated offi cer were informed of the case including planned withdrawal 
of treatment time. The coroner provided verbal consent subject to death. The 
donor family were not present at withdrawal of treatment as they felt it would 
be too distressing. The patient was extubated in ICU and inotropic support 
ceased. One minute later the patient became apnoeic then after a further ten 
minutes - loss of cardiac output. Death was certifi ed fi ve minutes later. The 
designated offi cer was unable to be contacted following certifi cation of death. 
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This was distressing for the staff involved and discussions regarding the plan 
included abandoning organ donation. Seventeen minutes later after numerous 
attempts consent was obtained from the hospital’s CEO. The patient was rapidly 
transferred to theatre where a further delay occurred as there was no clamp 
on the setup tray for cross clamp. Prior to loss of cardiac output the patient 
had sustained a SBP > 80 for all but two minutes. Thirty fi ve minutes elapsed 
between SBP < 60 and commencement of cold perfusion – forty four minutes 
after extubation. Both kidneys were successfully procured and transplanted. 
Both recipients experienced delayed graft function and required dialysis for 
up to two weeks.
Conclusion: The processes involved for organ and tissue donation are a 
complex mix of emotional, legal and logistical factors. Given this, hospitals 
considering implementing DCD programs need to ensure extensive consultation 
of all relevant stakeholders and extensive planning and education of all relevant 
staff prior to embarking on this process. DCD may not be appropriate for all 
institutions. It is important that whilst considering DCD we don’t compromise 
patient, family or staff safety and expectations and also that we are not 
negatively impacting the brain dead donor pool. Evaluating our processes 
and improving practices is vital to meet expectations of the community, donor 
families, transplant recipients and critical care staff. In this case both grafts 
are reported to be functioning well, and the patients have returned home. The 
extended consent process, although not ideal, has not affected the outcome for 
these recipients.
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SUCCESSFUL CADAVER TRANSPLANTATION 1832 
BY SHIFTING BRAIN DEAD VICTIMS BY ROAD 
– UNIQUE EXPERIENCES FROM INDIA
R. Balasubramaniyam, J. Das, N. Soosai, S. Das
KG Hospital And Post Graduate Medical Institute
Background: Cadaver transplantation is a very common modality of organ 
transplantation in the developed countries. Organ retrieval and transportation 
are integral components of cadaver transplantation. However, the situation 
is different in Indian transplant scenario. Here majority of the transplants 
are living donor transplants and cadaver transplants happen in few selected 
centers. Organs are generally retrieved and utilized in the same center and 
organ transportations have started happening.
No where brain dead victims are transported towards organ retrieval and for 
transplantation. Here we share our unique experiences where we shifted 2 brain 
dead victims by road and performed cadaveric renal transplantation.
Aim: To share our experience where we shifted two brain dead victims by road 
and performed cadaveric renal transplantation.
Materials and methods: In the year 2003, patient Ms.D, 48 years old non 
diabetic, non hypertensive woman with no other signifi cant past medical illness 
from our town, was declared brain dead following cerebral aneurismal clipping 
surgery at another hospital located 400 miles away. In 2007,Patient S, 7 years 
old girl who met with a road traffi c accident and was admitted in a hospital, 
located 100 miles where she was declared brain dead.
In both the instances the family members wanted to shift the patient for cadaver 
transplantation. Since the base hospitals were not equipped for organ retrieval 
and the family preferred to shift the brain dead patients to their hometown 
before organ retrieval we decided to shift them to our hospital by road. (We do 
not have the facility to airlift the donors in India).
We sent our medical team in our fully equipped ambulance and transported 
both the donors. Enroute the patients were maintained hemodynamically by 
our medical team.
We identifi ed 2 adult recipients for the adult donor and transplantations were 
performed successfully. In the pediatric donor, it was decided to transplant 
both the kidneys to a single recipient. The kidneys were removed enblock and 
utilized for transplantation.
All three patients did well post transplantation.
Conclusions: In a country where cadaveric renal transplantation is a rarity, we 
could shift two cadaveric donors and perform transplantation. We have no data 
of similar events that happened across the world.
We thought of presenting these two incidences because of their uniqueness.
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DOUBLE KIDNEY COMPARED TO SINGLE KIDNEY 1833 
TRANSPLANTATION: A MULTICENTRIC ITALIAN STUDY
A. Faenza1, R. Bertelli1, E. Capocasale2, G. Cappelli3, F. Neri1, M. Tsivian1, G. 
Cavallari1, B. Nardo1, G. Fuga1, S. Stefoni1
1Transplant Center of Bologna, University of Bologna, Italy, 2Transplant 
Center of Parma, University of Parma, Italy, 3Transplant Center of Modena, 
University of Modena, Italy
Introduction: Organs from marginal donors not suitable for single kidney 
transplantation (SKT) are considered for double kidney transplantation (DKT). 
The aim of the study is to determine the outcome of DKT compared to SKT.
Methods: Between March 2001 and July 2007, 80 DKTs were performed 
in transplant centers of Bologna, Parma and Modena. 167 SKTs from 
marginal donors (SKTMD) based on United Network for Organ Sharing 
criteria and 229 SKT from ideal donors (SKTID) were performed in the 
same period in the transplant center of Bologna. All grafts from marginal 
donors underwent biopsy to decide the allocation for SKT or DKT 
(according to Remuzzi et al).
Mean follow-up was 3.2±1.7 years. Recipients’ mean age was 61.4, 42.4 and 
57.5 in DKT, SKTID and SKTMD respectively. The main indications for 
transplant were similar in all groups with glomerular nephropathy being the 
most common. Mean HLA A,B,DR mismatches were: 3.1, 2.5 and 2.8 in DKT, 
SKTID and SKTMD respectively. Donors’ mean age was: 68.8, 40.1 and 65.3 
in DKT, SKTID and SKTMD respectively. Donors’ mean creatinine clearance: 
75.1 mL/min in DKT, 111.7 in SKTID and 85 in SKTMD. The kidneys were 
perfused predominantly with Celsior solution. Mean biopsy score was 4.4 
and 2.7 in DKT and SKTMD groups respectively. Immunosuppression was 
tacrolimus or cyclosporine based.
The outcomes were assessed for early graft function, acute rejection episodes, serum 
creatinine at discharge, hospital stay, re-operations and graft and patient survival.
Results: The incidence of delayed graft function was 37.5, 28.8 and 47.9% 
in DKT, SKTID and SKTMD respectively(p=0.00). Acute rejection incidence 
was 10, 28.8 and 8.8% in DKT, SKTID and SKTMD respectively (p=0.03). 
Urological complications incidence was similar in all three groups (13.7, 11.8 
and 14.8% in DKT, SKTID and SKTMD). We found no statistical difference 
in early (within 30 days) or late re-operation rate and mean hospital stay (22.1, 
21.9 and 23.9 days in DKT, SKTID and SKTMD respectively). Mean serum 
creatinine at discharge was lower in DKT (1.5 mg/dl vs 1.6 in SKTID and 1.8 
in SKTMD; p=0.00).
At last control mean serum creatinine was lower in the DKT group (1.6 mg/dl 
vs 1.7 in SKTID and 1.9 in SKTMD).
Patient survival at 1 and 5 years was not statistically different among the groups: 
97.5% in DKT, 98,6% and 96,9% in SKTID and 98,8% and 95,8% in SKTMD.
Graft survival at 1 and 5 years was 93,7% in DKT, 92,5% and 86,9% in SKTID 
and 91% and 87,4% in SKTMD.
Discussion: DKT is a safe way to face organ shortage employing kidneys from 
suboptimal donors. The outcomes of DKT are more than satisfying both in 
short and long terms compared to SKT.
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INCREASED INTESTINAL PERMEABILITY IN 1834 
DECEASED BRAIN DEAD DONORS
H. Leuvenink, L. Koudstaal, M. Nijboer, V. Nieuwenhuijs, H. Burgerhof, H. 
van Goor, R. Ploeg,
University Medical Center Groningen
Transplantation of organs derived from deceased brain dead (DBD) 
donors results in worse organ function and more acute rejection episodes 
compared with organs derived from living donors. Over the past years, we 
and others have shown in humans and in experimental animal models that 
brain death induces infl ammation in various potential donor-organs. The 
underlying mechanism of this infl ammatory state and subsequent inferior 
transplant outcome has not been unravelled yet. In several conditions, such 
as severe burns, brain injury and acute respiratory distress syndrome, an 
increased intestinal permeability is associated with distant organ injury. 
We hypothesized that the observed infl ammation in organs from DBD 
donors may result from increased intestinal permeability. To test this 
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assumption, we measured LPS Binding Protein (LBP) as a permeability 
marker and intestinal fatty acid binding protein (I-FABP) as a marker of 
enterocyte injury, in serum of 21 DBD donors and 20 living donors. Serum 
was collected immediately after the determination of brain death (T0) and 
just before organ retrieval (T1). LBP and I-FABP levels were measured by 
ELISA. C-Reactive Protein (CRP) was measured as a general marker of 
infl ammation.
In the serum of DBD donors we found signifi cantly higher LBP levels. 
Results are expressed as median and 25-75 quartiles. Living vs. DBD donors 
at T0 (10 ng/mL [7-12 ] vs. 31 ng/ mL [25-39], at T1: 8 ng/mL [5-10] vs. 
26 ng/mL [17-37]. Serum I-FABP was non detectable in most donors. No 
differences were observed between DBD and living donors with detectable 
I-FABP levels. In addition, we found a signifi cant correlation between 
serum LBP with serum CRP levels (T0: R= 0.740 p=0.001 and T1: R=0.552 
P=0.009).
Summarizing, LBP is signifi cantly enhanced in the brain dead donors suggesting 
that the systemic infl ammatory response may be induced by an enhanced 
bacterial pressure. The absence of I-FABP in the serum of DBD donors, despite 
the higher LBP levels may be caused by the renal secretion of I-FABP. Our 
present fi ndings support the concept of early intervention and adjustment of 
management in DBD donors prior to retrieval aiming to enhance donor organ 
viability after preservation and transplantation.
POSTER BOARD NUMBER P3 – 261
DOPKI - IMPROVEMENT OF KNOWLEDGE AND 1835 
PRACTICE OF ORGAN DONATION IN EUROPE
B. Dominguez-Gil
Organizacion Nacional De Trasplantes
DOPKI is a European Union funded collaborative action on the Improvement 
of Knowledge and Practice of Organ Donation. It consists of a consortium 
of 13 transplant organizations from 16 European countries. Between them, 
these organisations are responsible for 80% of all the organ donation activity 
in the EU. The main objective of the project is to improve knowledge of 
organ donation and develop an applicable methodology to determine both the 
potential of donation and its outcome, as well as to defi ne the limits of organ s 
safety and quality. This work will lead to the development of actions that will 
improve organ availability across Europe.
The fi rst step in this project was to describe the current state of organ 
donation in the participating countries. This analysis was based on data 
returned by the individual countries on a wide range of factors concerned 
with donation activity. This included the number of potential, consented, 
actual and the utilized donors. From this data we obtained the classical 
conversion rate from potential to actual donor but also calculated the rates 
of conversion from potential to consented, consented to actual and actual to 
utilized donors.
This showed that the percentage of potential donors who were consented 
ranged from 51.5% in the UK to 92.9% in Hungary; the percentage of potential 
donors who became actual donors ranged from 50.2% in the UK to 89.9% 
in Spain. The higher rates occurred in countries with presumed consent but 
there are many other factors that may contribute to theses differences. A more 
homogeneous picture emerges from the percentage of consented donors who 
became actual donors, which varied from 80.8% in Hungary to almost 100% 
in Slovenia. Similarly the percentage of actual to utilized donors ranged from 
89% in Spain to almost 100% in a number of countries.
The lack of harmonized and complete data across the participating countries was 
apparent in this initial analysis. One of the aims of the DOPKI-Project is to develop 
a common methodology to determine the true picture regarding organ donation in 
Europe. This methodology is being piloted in 30 hospitals across Europe.
One of the highlights of projects is the development of a European Registry 
focused on the use of specifi c types of expanded criteria donor including 
neoplasia, acute intoxication and rare diseases as well as the corresponding 
transplantation outcomes. These data will help to establish the limits of safe 
transplantation in Europe.
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INITIALIZING BRAIN DEATH PRACTICE AND 1836 
STANDARD ORGAN DONATION IN CHINA – REPORT OF “A 
MISSION IMPASSIBLE”
Z.K. Chen, H.M. Zhou, F.J. Zeng, C.S. Ming
Institute of Organ Transplantation, Tongji Hospital, Huazhong University of 
Science and Technology
The unique situation of using inmate organ for transplantation in China has 
its special history and un-transparent background. It was initially clean and 
secret clinical trial started from our hospital and proved by local government 
in the 1970’s. The idea was to develop transplant technology and save life. 
As the results were poor and the program was on a small scale, no one even 
care about the organ source. However the nature of the practices dependent 
on this type of organs has dramatically changed and gradually extended 
to the whole country when modern immunosuppresant producers entered 
China and provided better clinic outcomes. Increased demand biased the 
initial nature and it soon contaminated with organ traffi cking and transplant 
tourism. It became a severe human rights issue and was widely condemned 
by international organizations and academic societies. However, confl icts 
of interest, for instance, long waiting list with high mortality and absence 
of the alternative organ source, acted as the strong resistance to discontinue 
the malpractice. Furthermore, the existing national regulations on organ 
transplantation gave no description on how the ¡°sensitive source¡± should be 
legally controlled and ethically approached as a formal resource for medical 
care. The malpractice also challenged public trust on organ donation and 
allocation. Moreover, there was no brain-death practice at all in the entire 
medical care system, so that it left no space for practicing this kind organ 
donation.
Current study demonstrated that the concept of brain death can be gradually 
accepted by the society through constant public education and brain death 
organ donation is also possible even if brain death regulation is currently a 
legal vacuum. Professional teams (the Chinese OPO) work together with a 
properly drafted protocol under the surveillance of the Red Cross Association. 
Our initial strategies were:
1.  Including the proposed program into an existed national research program 
named ¡°985 Plan¡±.
2.  Establishing the Chinese Organ Donation Website: www.organdonation.org.
cn; the Chinese Transplant Games Website: www.transplantgames.org.cn; 
and the Chinese Brain Death Website: www.braindeath.org.cn; to promote 
the concepts.
3.  Calling for a national-wide cooperation and encouraging medical professions 
to adopt brain death criteria into their practice and provide organ donation as 
one of the choices beside withdraw of ventilation.
4. Establishing OPO teams.
5. Inviting the Red Cross to join the social work and family care.
6. Releasing typical cases at regular press conferences for public education.
From 2004 to 2007, 71 deceased organ donors had been achieved and 323 
quality organs have been recovered (kidney: 130; liver: 54; heart: 18; lung: 6; 
pancreas: 2; and coniea: 113). In 2007, the organ recovery rate including eyes 
was 0.15/mp. So far, more than 40 hospitals all over the country were included 
into this pioneer action.
Conclusion: Brain-death organ donation is a potential organ source in the 
future to replace the current one related to executed prisoners. The efforts are 
crucial for healthy development of Chinese medical care system, and gain 
wider international acceptance.
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VERAPAMIL-LIDOCAINE DONOR DECREASES 1837 
ACUTE TUBULAR NECROSIS, IN CADAVERIC KIDNEY 
TRANSPLANTATION
A. López-Hernández, B. Castro, L. Solis, P. Cancino, P. Escarcega, 
J.M. Rosales, J. De-los-Santos, F. Vasquez, J. Soto, B.O. Aquino, F. Benitez
From the transplant program Centro Especialidades Médicas “ Dr.Rafael 
Lucio”, Xalapa, México
Introduction: The lidocaine is a sodium channel blocker. Other groups has 
demonstrated in papers, lidocaine administration to the donor increased the 
incidence of immediate function of the kidney after transplantation. Verapamil 
is a calcium blocker, and administration before warm ischemic provides partial 
and short-lasting functional protection renal function. The Acute tubular 
necrosis is the 30 to 50% in cadaveric graft transplantation in several reports in 
the literature. Several pathway involved in ischemia-reperfusion damage. We 
purpose is report our clinical experience with deceased donors pretreated with 
Verapamil-lidocaine to avoid Acute tubular necrosis.
Material and methods: The deceased donors received verapamil-lidocaine 
as a bolus injection systemic of 30 to 60 minutes before renal ischemic. We 
administered 5mg of verapamil clorhydrate slowly and 1-2mg/kg Lidocaine 
clorhydrate body weight IV before harvesting. All donors were managed 
similar including adequade hydratation. At the time of nephrectomy 30 000 
U of heparin was given to all patients before kidney dissection. Kidney were 
fl ushed ex vivo with University Wisconsin or in custodiol solution, and stored 
in simple hypothermia at 4oC.All recipients received 250ml mannitol 20%, 
furosemide 100mg, albumin 0.5gr/kg body weight, hydrated under the control 
of central venous pressure at 8 to 12 of water, just before clamp removal.
Results: Forty seven consecutive cadaveric kidney transplants performed 
between December 2001 and March 5, 2008. All recipients received kidneys 
from verapamil-lidocaine pretreated donors. 19 women and 28 man. Aged 
12-67 yr (37 +_ 14 average).The cold ischemia was 3 to 33hrs (9 hrs average). 
In 17kidney fl ushed ex vivo with Wisconsin solution and 30 kidney with 
custodial solution. Only two patient developed Acute tubular Necrosis, and 
time cold storage 26 and 33hrs, and recovery normal function renal after 3 
weeks of transplantation.
Conclusions: In our series Acute tubular necrosis was present only in 2 of 47 
cases, which is 4.02%. Is better than that reported in the literature. verapamil-
lidocaine clorhydrate administration to the cadaver donor before kidney 
harvesting, increased the incidence of immediate function of the kidneys after 
transplantation.The presents results suggest that the use of Verapamil-Lidocaine 
clorhydrate protects the kidney against ischemia-reperfusion injury. These 
observations may offer a novel approach for reducing the incidence of reducing 
the incidence of Acute tubular necrosis in cadaveric kidney transplantation.
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EVALUATION OF ORGAN DONATION IN SLOVENIA1838 
D. Avsec Letonja1, A. Špec-Marn2
1Institute for Transplantation of Organs and Tissues of the Republic of 
Slovenia, Ljubljana, Slovenia, 2Clinical Department of Anaesthesiology and 
Intensive Therapy, University Clinical Centre, Ljubljana, Slovenia
Objectives: To determine the number of cadaveric donors in Slovenia and the 
prevailing reason for non-donation from potential donors.
Design: An audit of all brain death in intensive care units from the 1st of 
January 2000 to 31th of December 2007.
Setting: 23 intensive care units in 10 hospitals in Slovenia.
Results:
Table 1.1 Number of cadaveric donors from 2000 to 2007
Year 2000 2001 2002 2003 2004 2005 2006 2007
No. RD 22 23 35 28 36 21 30 24
RD PMP 11 11,5 17,5 14 18 10,5 15 12
RD - realised donor, PMP – per million population
The number of realised cadaveric donors per million inhabitants in Republic 
Slovenia from 2000 to 2007 is between 10,5 to 18. In Europe in average this 
number is 14,5 PD PMP. Comparing 2000 and 2001 there was 4,5% increase 
in 2001 in number of cadaveric donors. A sharp increase was noted in 2002 
(+52,2%) in Europe (-1,1%), decrease in 2003 (-20,0%) in Europe (+ 8,7%), a 
second sharp increase in 2004 (+ 28,6%) in Europe (-4,8%), sharp decrease in 
2005 (-41,7%) in Europe (+8,4%), sharp increase in 2006 (+42,9%) in Europe 
(+4%) and again sharp decrease in 2007 (-20%).
Table1.2. Number of refusal rate for relatives of potential donors from 2000 
to 2007
Year 2000 2001 2002 2003 2004 2005 2006 2007
PD PM 15 15,6 21 17 22 13,6 17,8 15,9
% RR 37 36 20 22 23,4 30 19 33
PD- potential donors, RR – refusal rate
High percentage of refusal rate for families of PD were noticed in 2000 (37%), 
2001 (36%), 2005 (30%) and 2007 (33%).
Conclusion: The great obstacle to improve organ donation is high refusal rate 
for families of PD. When discussing this issue, we have to realize that solutions 
lies in increasing effi ciency of informing the public of organ donation.
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NON-HEART-BEATING DONORS: A RENEWED SOURCE 1839 
FOR KIDNEY GRAFTING
M. Rengel, Ú. Verdalles, A. Mossé, S. Abad, A. Vega, E. Verde
Hospital General Universitario
The use of Non-Heart-Beating Donors (NHBD)kidneys to expand transplant 
programmes offers an answer to the problem of donor shortage.Despite renewed 
interest in NHBD kidney transplantation, very few clinical programmes have 
been developed this type of grafting. We analyzed the function and outcome of 
kidney transplants performed from NHBD in our hospital.
From 1999, 30 patients were grafted with kidneys from NHBD(28 grafts 
from Hospital Clínico San Carlos of Madrid). This group was compared 
with recipients of heart beating donor (HBD) matched for age, sex, number 
of transplants and HLA.Immunosupression was performed with Basiliximab, 
Predinisone, Tacrolimus and Micophenolate Mofetil. Acute rejection episodes 
were treated with Methylprednisolone boluses, and ATG-FRESENIUS® when 
necessary.The delayed graft function rate was higher on NHBD transplants than 
in HBD graft. Serum creatinine levels was signifi cantly better in the NHBD. 
Graft survival at 1 year was 81% in NHBD and 85% in HBD. Patient survival 
in both groups was 100%. Patients grafted with NHBD were hospitalized 
longer and needed more dialysis. Acute rejection episodes were more frequent 
in NHBD.
Conclusion: This source of kidneys has evidence of equivalent graft function 
and survival, compared with standard cadaveric donor organ and may expand 
de donor pool.
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INFLUENCE OF A MODIFIED PRESERVATION 1840 
SOLUTION IN PROLONGING THE COLD ISCHEMIC PERIOD 
– A COMPARATIVE STUDY IN A PORCINE MODEL OF 
ALLOGRAFT KIDNEY TRANSPLANTATION
H. Fonouni1, A. Mehrabi1, G. Kuttymuratov1, T. Longerich2, M. Golriz1, 
M. Tahmasbi Rad1, M. Esmaeilzadeh1, P. Jarahian1, M.W. Büchler1, 
J. Schmidt1, M.M. Gebhard3
1Department of General, Visceral, and Transplantation Surgery, 2Department 
of Pathology, 3Department of Experimental Surgery, University of Heidelberg; 
Heidelberg, Germany
Introduction: One of the big challenges following kidney transplantation is the 
inevitable ischemia reperfusion (IR) injury. The prolongation of the ischemic 
period has a direct correlation with the magnitude of the IR injury. Furthermore, 
in reperfusion phase free oxygen radicals play a pivotal rule in extension of cell 
damage. One of the important factors in this regard is preservation solution. To 
minimize these problems introducing new or modifi ed solutions which contain 
new antioxidants or energy substrates seems mandatory to reduce the adverse 
metabolic changes during cold preservation.
Our aim was to evaluate a modifi ed preservation solution in improving 
the viability of kidney organs in a porcine model of allograft kidney 
transplantation.
Materials and methods: Thirty landrace pigs (mean weight=30kg) underwent 
allograft kidney transplantation (KTx). For implantation, the pigs divided into 
three identical groups; group 1 (n=10) received kidneys perfused and preserved 
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for 30hrs in standard histidine-triptophane-ketoglutarate (HTK) solution, group 
2 underwent KTx using kidneys, perfused and stored in University of Wisconsin 
solution for 30hrs, and in group 3 the pigs received kidneys which were perfused 
and preserved in a new modifi ed HTK solution for 30hrs. The technique of 
implantation was standardized, laying the kidney in right lower quadrant of 
the abdomen, performing standard vascular anastomosis and ureterocystomy 
as well as both-side nephrectomy of native kidneys. The follow-up period was 
7 days. During this period, we analyzed renal laboratory parameters including 
serum creatinine, blood urea nitrogen (BUN), hemoglobin, hematocrit, urine 
creatinine, and urine osmolality. Moreover, histopathologically, the tissues were 
assessed for the degree of tubular injury or rejection. All samples were taken in 
four steps; after explantation, before reperfusion, 20 min. after reperfusion, and 
before sacrifi cing the animals 7 days post-transplant.
Results: All laboratory data are summarized in Table 1. The kidney parameters 
of HTK-new group have a better trend specifi cally in serum creatinine as 
compared to other preservation solutions, but without reaching any signifi cance. 
The histopathological assessment shows various degrees of acute tubular 
damage in different phases in all groups, but overall the HTK-new group 
showed minimal destructive changes comparing to UW and HTK and a better 
trend toward regeneration and restoration of brush border of tubular epithelial 
cells on day 7 post-transplant.
Table 1. The laboratory parameters of three groups of allograft kidney 
transplantation 7 days after transplantation.
Group
Parameters Group 1 (HTK old) Group 2 (UW) Group 3 (HTK new)
Serum creatinine (mean±SEM) 10.46±4.25 9.53±5.71 8.46±4.87
Serum BUN (mean±SEM) 251±104 240±125 240±99
Hemoglobin (mean±SEM) 10.1±1.9 11.2±1.6 11.5±2.8
Hematocrit (mean±SEM) 27±6 31±3 31±6
Urine creatinine (mean±SEM) 49.3±25.6 51.9±23.4 61.1±19.9
Urine osmolality (mean±SEM) 319±34 318±46 294±36
Conclusion: We could show an overall improvement of renal parameters with 
the usage of new HTK, although this improvement did not reach signifi cance. It 
can be speculated that HTK could preserve the kidney organs more effi ciently 
but the real advantage of this solution should be confi rmed in clinical setting, 
where the accompanying factors including atherosclerosis, old-for-old, or long 
cold ischemia time may interfere with the outcome.
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THE ONCOSTATIN M PATHWAY PLAYS A KEY ROLE IN 1841 
THE RENAL ACUTE PHASE RESPONSE
T. Mueller, L. Cairo, C. Compson, V. Luyckx
University of Alberta
The acute phase response (APR) robustly differentiates deceased (DD) 
and living (LD) donor kidneys. To further analyze the renal APR transcript 
levels of target genes in human post-reperfusion implant biopsies, discarded 
donor kidneys (DK), nephrectomy samples (Nx), liver tissue, and cell 
lines (PTEC and HK2) were measured by real-time PCR, microarray, and 
immunohistochemistry.
Fibrinogens (FGB) and serine proteinase inhibitors (SERPINA1) were 
highly expressed in kidney tissue, refl ecting cause of brain death and 
extent of renal damage. The levels were highest in DK > DD > LD > Nx 
controls. PTECs expressed high levels of FGB and SERPINA1, which 
increased signifi cantly after serum starvation or oncostatin M (OSM) 
supplementation. On the other hand an antibody against gp130 inhibited 
the induction of FGB and SERPINA1. The results further indicated that 
OSM receptor (OSMR), rather than IL6R is the major gateway for the renal 
APR. The ratio of OSMR to IL6R was signifi cantly higher in all kidney 
versus liver tissues. OSMR mRNA levels were higher than IL6R in the cell 
lines. In HK2 cells, serum starvation or OSM administration increased the 
OSMR levels by 40 and 200% respectively. Immunohistochemistry in DK 
samples revealed OSMR expression in larger peritubular arterioles, parietal 
podocytes, and occasional proximal tubules, whereas OSM was largely 
restricted to the mesangium.
Thus the renal APR, induced by brain death and ischemia-reperfusion injury, 
is characterized by high levels of fi brinogens and serpins and most likely 
regulated through OSM OSMR rather than IL6 IL6R pathways.
POSTER BOARD NUMBER P3 – 268
QUALITY ASSESSMENT OF THE ORGAN DONOR 1842 
RETRIEVAL PROCESS
R.D.M. Allen1, M. Azanza2, T. Wills2, P. Robertson1, G. Kyd1, M. Crawford1, 
H.C.C. Pleass1, D.J. Verran1
1NSW Deceased Donor Organ Procurement Service, Sydney, Australia, 
2ARCBS Organ Donation Network NSW/ACT, Sydney, Australia
High quality organ procurement surgery is the fi rst step towards successful 
organ transplantation. However, it is essentially a nocturnal pursuit with 
inherent risk of surgical and other misadventures. Furthermore, trainee surgeons 
are attracted to donor surgery because of the scope of the surgery involved and 
the opportunity to gain surgical confi dence. When a single statewide deceased 
donor organ procurement service (DDOPS) was established in NSW in 2003 
to simplify retrieval of intra-abdominal organs for subsequent transplantation 
in 17 possible transplant centres, an Organ Retrieval Report Form (ORRF) was 
created as a communication tool between the organ donor network/retrieving 
team and the transplanting centres. The aim of the ORRF was to identify and 
rectify systemic problems in the retrieval process, as assessed by the recipient 
transplanting centre, from time of declaration of death to donor organ delivery 
at the transplanting hospital.
Methods: The surgical technique for multi-organ retrieval was standardised. ORRF 
were distributed with each kidney, whole liver, liver lobe and pancreas and returned 
to a central data co-ordinator. Identifi ed problems were collated and reviewed by 
medical advisors. Findings were fed back to all DDOPS team members for review 
and action as required. Statistical analysis was performed using Fisher’s exact test.
Results: 520 abdominal organs from 176 deceased donors (11% donation 
after cardiac death) were transplanted in the 3 year period from July 2004. 12 
organs were deemed unsuitable for transplantation arterial disease or liver fat 
content, and none because of surgical injury. Compliance with ORRF return 
from transplant centres was 98%. Donor surgeons reported an iatrogenic 
injury to kidney and liver vasculature in 7.4% (n=13) and 4.4% (n=5) of 
donors respectively (P=0.45). The annual rate of donor surgeon recognition 
of injury increased in time from 5 to 14% (P= 0.067). Transplanting teams 
reported problems in an additional 23% of donors. Combining donor and 
retrieval reported data, structural injury occurred in 12.6% of retrieved 
kidneys, no pancreases (P=0.008) and 5.3% of livers (p=0.014). 6% of organs 
had preservation, packaging and documentation concerns. Injury contributed 
to loss of one kidney graft and one fatty liver failed to function. Unsolicited 
positive comments by transplant centres were welcomed.
Conclusions: The ORRF proved a valuable quality tool for productive 
communication. Transplanting centres offered critical evaluation of the 
organ retrieval process that served to strengthen retrieval protocols. To 
reduce documentation errors, co-ordinator numbers were increased. To 
reduce packaging errors, check-lists were created. To reduce the signifi cant 
disproportion of kidney versus liver donor related injuries, the senior donor 
surgeon now remains with the donor til removal of all donor organs rather than 
retreating to the back table after liver retrieval.
QUALITY OF LIFE AND CONCURRENT ORAL SESSION 130: 
ECONOMICS
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EFFECT OF AN EDUCATIONAL INTERVENTION 1843 
ON NURSES’ KNOWLEDGE OF A PERITONEAL 
DIALYSIS CIRCLER
B.A. Markazi, A. Ghafarimoghadam, E. Ahamadnezhad, R. Erfani, N. 
Sepehrvand, S. Hatami
Introduction: After several years from the initial stage of CAPD usage, still 
the percent of those using this method is very low (15% of all patients with 
end-stage-renal disease).In this study we have tried to defi ne the impact of 
educational program of CAPD.
Methods: This is a quasi- experimental study (before-after) with educational 
investigation, include: workshop, teaching by Booklet and show the fi lm. 
Sample method is base on our aim. Study was done in Urmia .we designed a 
questionnaire for collection of data. Sample size was 35. We use descriptive 
and Friedman test for analysis.
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Results: Nurses total information about CAPD defi ned by total scoring was as 
follow: little information: 75%, Moderate 19%, and good only in 6% of patients. 
All of the information were increased after investigation and was 80%.
Conclusion: Unawareness about the existence, required facilities treatment 
method and advantages and disadvantages of CAPD among patients can be 
important factors in the very slow development of CAPD.
POSTER BOARD NUMBER P3 – 270
EXPERIENCE OF RACISM CONTRIBUTES TO RISK OF 1844 
DIABETES
S. Madhere, A. Campbell, C. Callender
Howard University
Diabetes is one of the primary precursors of renal dysfunction. Therefore, 
factors that are signifi cant to the metabolism of glucose are relevant to the 
understanding of renal disease. Previous research has examined the relationship 
of physiological variables such as obesity, lifestyle risks, to glucose metabolism 
and socioeconomic factors. But, although the death rate from diabetes is higher 
for African Americans than it is for European Americans, few researchers have 
paid attention to racism as a relevant contributor to the prevalence of diabetes 
in the black population.
This study attempts to understand variations in glucose level as a function of 
predictor variable including obesity (body-mass), lifestyle (alcohol abuse), and 
socioeconomic status (income and education), perceived racism and other daily 
stress. The relationships were studied in a community sample of 92 African 
Americans (average age of 47 years). A multiple regression was applied for 
the analysis. It was found that 17.3% of the variance in glucose level could be 
explained by this set of predictors. Among them, perceived job-related racism 
was the most signifi cant contributor, (B .236 to .282). This fi nding suggests that 
the higher the level of perceived racism, the higher the level of glucose.
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PATIENT HEALTH PERCEPTIONS: A MANDATE FOR 1845 
PHYSICIANS
J. Harrell, C. Callender, A. Campbell Jr.
Howard University
Though physicians commonly elicit from their patients a subjective report of 
symptoms, these responses are not commonly viewed as highly correlated with 
objective markers of disease. Instead, self-perceptions of health status are taken 
as indices of the patient’s sense of the seriousness of their condition or as an index 
of motivational or emotional states that may affect compliance with therapy.
The present study sought to identify the source of what patients tell doctors 
about their health and selected objective indices of disease. Specifi cally we 
tested models that proposed perceived stress and depressive symptoms mediate 
the relationship between health perceptions and cholesterol. These models 
argue that health perceptions may be related to objective indices of stress 
because they are correlated with stress and the negative affect brought on by 
poorer health.
As part of a large study of psychoneuroimmunological, factors and end-stage 
renal disease, 150 African American volunteers completed the Beck Depression 
Scale, Cohen’s Perceived Stress Inventory, and the General Health Perception 
domains of the SF-36 Health Survey. Blood samples were obtained and non-
fasting HDL and LDL levels were determined. A moderately strong relationship 
between General health Perceptions and HDL levels (r=.41) indicated that 
positive perceptions of health were associated with higher HDL levels. We tested 
the mediation model fi rst by determining that HDL levels were correlated with the 
two candidate mediators, Perceived Stress (r=-.20) and Depression (r=.23). The 
second step of the test of mediation involved demonstrating that General Health 
Perceptions were negatively related to Perceived Stress (r=-.23) and Depression 
(r=-.34). However, using multiple regression analyses, the fi nal step in testing 
mediation reviewed that the relationship between General health Perceptions and 
HDL levels persisted when depression or perceived stress were controlled.
Hence, though perceptions of one’s health status tend to be related to stress 
and depression, these emotional variables did not account for the relationship 
between health perceptions and HDL> While the underlying mechanisms 
linking these two variables are not clear, these fi ndings mandate that physicians 
attend more closely to the self-reports their patient provide.
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COMPARISON OF QUALITY OF LIFE BETWEEN 1846 
KIDNEY TRANSPLANT PATIENTS AND DIALYSIS PATIENTS
M.H. Kim, O.J. Kwon, J.Y. Kwak, C.M. Kang
Organ Transplantation Center, Hanyang University Hospital
Purpose: Kidney transplant recipients have a higher quality of life and consume 
fewer health care resources compared to patients on dialysis. The aims of this 
study are to provide basic materials necessary for enhancing quality of life 
among kidney transplant patients and dialysis patients through conducting a 
survey and comparing their perceived quality of life.
Materials and methods: The subjects of this study were 108 kidney transplant 
patients performed in our center, from 1990 to 2007, and 46 dialysis patients. 
These data have been collected from August to September in 2007 by 
questionnaire. We used a structured questionnaire consisting of 9, 5, 4, and 
42 questions about general characteristics, disease related features of kidney 
transplant patients and dialysis patients, and quality of life, respectively, as a 
study tool. We analyzed and evaluated the collected data through conducted 
T-test, frequency analysis, one way ANOVA by employing a statistics package, 
SPSS 12.0 and we used Cronbach’s Alpha Coeffi cient in order to verify 
accuracy and reliability of the measurement tools.
Results: 1) In examining the averages of quality of life with minimum 1 and 
maximum 5, attitudes toward life indicated the highest point as 3.66, followed 
by somatic symptoms, 3.50, affective state, 3.29, perceptions of health, 3.03, 
and family relationships and fi nancial situation 3.00, in both groups. 2) Kidney 
transplant patients were shown statistically signifi cant higher quality of life 
than the dialysis patients, in affective state (p=0.000), social activities (p=.001), 
somatic symptoms (p=.000), attitudes toward life (p=.000), and perceptions 
of health (p=.000). On the contrary, In the family relationship and fi nancial 
situation, kidney transplant patients were shown higher scores than dialysis 
patients, but it was not signifi cant statistically (p=.202).
Conclusion: In this study, kidney transplant patients enjoy higher quality of 
life than dialysis patients with statistically signifi cant differences, and there 
showed different levels of the quality of life according to general characteristics 
and disease-related features between the two types of patients. Therefore, we 
should help them to enjoy healthy life without complicating diseases through 
providing them the follow-up care taking individuals’ general characteristics 
and disease related features into consideration after transplantation, and also 
make efforts to enhance kidney transplant patients’ quality of life by developing 
effective self-management programs.
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QUALITY OF LIFE ASSESSED BY SF-36 HEALTH 1847 
SURVEY IN OLDER VERSUS YOUNGER AND RELATED 
VERSUS NON-RELATED LIVE KIDNEY DONORS
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, R. Varsandan, D. Tacu, 
E. Kerezsy, L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis and Renal Transplantation, Fundeni 
Clinical Institute, Bucharest, Romania
Introduction: SF-36 Health Survey is a proper assessment method of health 
status in general. This study was designed to compare and to assess the 
quality of life (QOL) in four groups of renal donors - related versus non-
related live kidney donors and younger versus older donors. We defi ned the 
border age of 65 (retirement age in Romania) in order to compare the two 
age donor groups.
Methods: From June 1997 until March 2008, 855 renal transplantations (710 
living and 145 cadaver, 807 adults and 48 pediatric transplants) have been 
performed in our center, with an average of 81 /year (116 in 2007). In all 
cases, general preoperative evaluation, immunological and vascular anatomy 
study was performed. Standard minimal lombotomy nephrectomy technique 
was preferred. The evaluation was performed before surgery, one month and 
six months after surgery. One group of 62 young donors (mean age 45) was 
compared with a group of 38 older donors (mean age 68) using SF 36 protocol 
and a group of 50 related donors were compared with a group of 50 unrelated 
donors using the same questionnaire.
Results: Eight scales of SF-36 health survey were scored in all four groups: 
physical functioning (PF), role physical functioning (RP), bodily pain (BP), 
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general health (GH), vitality (VT), social functioning (SF), role emotional 
functioning (RE), and mental health (MH). Baseline QOL was better in 
younger versus older group. Summarizing the results, PF, RP, VT and GH were 
deteriorated after one month in older group (p<0.001- 0.003) and recovered 
close to baseline after six months. Bodily pain was worst in younger group 
one month and six months after surgery, while all the other scales recovered 
close to baseline. PF, RE and MH were deteriorated signifi cantly in non related 
versus related donors after one month while BP,VT and SF follow the same 
returning in both groups. Six months after surgery non signifi cant differences 
were detected.
Conclusion: QOL in non-related versus related donors returned at a baseline 
but following a slowly curve in the fi rst group. Bodily pain scale in young 
donors recovered less effective than older donors while QOL in general return 
close to a baseline in older patients after six month following a slowly curve 
than younger donors. Considering that surgical results and graft function are 
comparable in all four groups, further expansion of borderline older donor pool 
is accepted.
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COMPARATIVE QUALITY OF LIFE ASSESSED BY 1848 
SF-36 HEALTH SURVEY IN RENAL TRANSPLANT PATIENTS, 
HEMODIALYSIS PATIENTS, ANEPHRIC PATIENTS FOR 
RENAL MALIGNANCIES AND PATIENTS WITH MALIGNANT 
UROLITHIASIS
M.A. Manu, I. Sinescu, M. Harza, B. Serbanescu, D. Tacu, E. Kerezsy, 
L. Domnisor, D. Daia
Center of Urological Surgery, Dialysis And Renal Transplantation, Fundeni 
Clinical Institute
Introduction: SF-36 Health Survey is an assessment method of health status. 
This study was designed to examine the quality of life (QOL) in four groups of 
patients: renal transplant patients, patients in hemodialysis program with native 
kidneys, anephric patients in dialysis program for renal malignancies and non-
dialysis chronic renal failure urolithiasis patients.
Patients and methods: 104 renal transplant recipients, 70 patients in 
hemodialysis program, 11 anephric patients for renal malign condition and 
25 patients suffered of severe urolithiasis complicated with chronic renal 
failure were included in this study. Eight scales of SF-36 health survey were 
scored: physical functioning (PF), role physical functioning (RP), bodily 
pain (BP), general health (GH), vitality (VT), social functioning (SF), role 
emotional functioning (RE), and mental health (MH). The scores of scales 
were compared among three groups and a correlation with clinical parameters 
was made.
Results: The scale scores of PF, RP, BP, GH, VT, SF, RE, and MH were 
as follows: 84.6, 77.4, 78.6, 56.3, 64.1, 80.2, 79.1, 68.8, for the recipients 
of renal transplant, 81.8, 65.6, 69.2, 49.8, 59.4, 72.2, 70.6, 74.2, for the 
patients receiving hemodialysis, 82.2, 68.6, 71.2, 49.9, 61.2, 73.3, 72.6, 
69.9 for anephric patients secondary to a malignancy and 80.2, 70.2, 48.6, 
50.2, 62.4, 70.1, 73.5, 71.9 for the patients suffered of renal failure due to 
urolithiasis.
Conclusion: SF-36 health survey is a proper method for evaluating the quality 
of life, PF, VT and GH scores were quite similar for the four categories 
of patients in comparison with a general population sample. They were 
signifi cantly dependent on serum creatinine level. The BP score were the 
lowest in the malignant urolithiasis.
In our study, excepting the mental health score, all the other seven scores were 
better in the transplant group. Considering a general population sample score 
as 100% (which represents in reality 76.6% of the ideal score), the quality of 
life was 96% in the Tx group, 88.6% in the hemodyalisis group, 88.5% in the 
anephric by renal malignancy group and 86% in the urolithiasis group. In our 
study, transplantation improved the quality of life.
POSTER BOARD NUMBER P3 – 275
PERCEPTIONS OF GRAFT REJECTION AMONG SOLID 1849 
ORGAN TRANSPLANT RECIPIENT – STRIVING TO CONTROL 
THE UNCONTROLLABLE
M. Nilsson1, A. Forsberg2, L-O. Persson2
1Ward 324, Queen Silvias Childrens Hospital, 2Institute of Health and Care 
Sciences, Salgrenska Academy, University of Gothenburg, Gothenburg, 
Sweden
Background: Rejection is the most common cause of graft loss and graft 
dysfunction in clinical transplantation. Little is known about organ transplant 
recipients’ own models of explanation related to graft rejection.
Aim: To investigate perceptions of experiences of graft rejection.
Method: A qualitative phenomenographic approach was chosen, since 
phenomenography is the empirical study of the different ways in which 
people experience, perceive, apprehend, understand and conceptualise various 
phenomena in and aspects of the world around them. A strategic selection 
included patients who had undergone a kidney, liver, heart or lung transplant. 
Sixteen patients, 6 males and 10 females, aged between 21-63 years, with a 
follow-up time of between 3 months to 10 years, were interviewed.
Results: The result comprised fi ve domains of variations in perceptions of graft 
rejection:
the abstract threat to life
the concrete threat to health
trust in the body
striving to control the threat
one’s identity
The inner perspective and personal explanation models involved threat, fear, 
trust, control and identity adjustment. Different approaches had the same 
purpose; ‘striving to control the uncontrollable’.
Clinical relevance: The inner perspective of graft rejection leads to several 
clinical implications in terms of patient education and recipients’ differing ways 
of obtaining knowledge about graft rejection. We suggest that patient education 
should be tailored in a different way, offering support and advice in line with 
their personal models of explanation of graft rejection as a complement to the 
explanation from the biomedical model of disease.
POSTER BOARD NUMBER P3 – 276
EXAMINATIONS CONCERNING ORGAN-INTEGRATION 1850 
AFTER LIVING KIDNEY DONATION
U. Ott2, U. Wutzler1, K. Therolf-Henke1, T. Steiner3, M. Geyer1, M. Venner4
1Clinik of Psychotherapy und Psychosomatic Medicin, University of Leipzig, 
Germany, 2Department of Internal Medicine III, Friedrich-Schiller-University 
Jena, Germany, 3Department of Urology, Friedrich-Schiller-University 
Jena, Germany, 4Institute of Psychotherapy and Psychoanalysis e.V., Jena, 
Germany
Background: In the course of an organ transplantation the recipient appropriates 
a part of the donor. As yet little is known about the necessary process of psychic 
organ integration. It is the goal of the present study to describe this process in 
the context of living kidney transplantation.
Methodology: We carried out a survey among 49 recipients (30 men, 19 
women; average age: 48 years, 19 - 70 years) concerning organ integration at 
the transplantation centre of the Friedrich Schiller University Jena (Germany). 
Among other things, participants were asked to describe their organ-related 
conceptions and fantasies.
Results: 2/3 of the sample concern themselves with the transplanted kidney. 
Half of these perceive the transplant as a foreign organ. The transplanted kidney 
is associated with a great variety of fantasies and associations by the recipient. 
The analysis of the open-end questions of the inventory makes clear a positive 
perception of the transplanted kidney. At the same time the fear of organ loss is 
perceptible. This manifests itself in exhortations to hold out and the hope of a 
long functionality of the organ.
Conclusions: A positive perception of the foreign organ helps the recipient to 
overcome existing anxieties and fears. In living organ donation the emotional 
tie to the donor appears to have a positive effect on the integration process of 
the foreign organ.
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QUALITY OF LIFE AFTER LIVER TRANSPLANTATION 1851 
IN ESTABLISHED AND INDIVIDUAL SCALES
M. Schenk, K. Landgrebe, W. Steurer, A. Königsrainer
University Hospital Tuebingen - General, Visceral and Transplant Surgery
Liver transplantation is an event that changes life radically. A lot of hopes 
for a better life are involved, some are justifi ed some are not. However, the 
individual picture of life quality is different. The current study tries to address 
this issue by comparing data of life quality using the fi xed scales of an SF-36 
questionnaire and comparing them to the results of the SEIQoL questionnaire 
an to the results of a normal population.
In an interview style 71 patients (77% male, median of age 54 years, 21 months 
from transplantation) were asked to complete the SF-36 and the SEIQoL 
questionnaire in a cross-section design after liver transplantation (Follow-up: 
0.5-159 month, Median: 21 month). The scales were calculated and compared 
to the published results of a normal population. 26 scales were set up, 5 scales 
were mentioned more than any other (family, friends, sports, partner and job). 
People with a high priority for the job reported a signifi cantly lower quality of 
life (65 SD 19) than the others (79 SD 12).
It became clear that in the SF-36 scores the total life quality of our transplant 
patients (sum score) was excellent an directly comparable to a normal 
population. The transplant recipients only were lower in two scales directly 
linked to physical strength. In the SEIQoL questionnaire resulted in 72 (SD 17) 
points compared to 77 (SD 10) in the normal population.
Comparing the age-dependency in three groups (A:≤; 40 y; B:40- 60 y; C:≥; 
60 y) it became obvious that the results of the SF-36 resulted comparable in all 
three groups (75 SD15, 72 SD17 and 76 SD17), but raised with age in the more 
individual scores (A: 66 SD21, B: 71 SD17 and C: 80 SD13 points.)
Beside many more details the results of this study can be used for interviews 
with transplants candidates. The complete analysis of the former data can make 
this large change a little bit smaller and shows more or less helpful items in the 
personal transplant preparation.
POSTER BOARD NUMBER P3 – 278
COMPARISON AND ESTIMATION OF QOL BY 1852 
SF-36 BETWEEN RENAL TRANSPLANT PATIENTS AND 
HEMODIALYSIS PATIENTS
M. Ikeda1, K. Yoshida1, T. Hyodo1, Y. Takeuchi2, H. Wakai2, M. Sueki1, 
F. Noguchi1, T. Endo1, S. Baba1
1Kitasato University Urology, 2Kitasato University Nephrology
Marked improvement of quality of life (QOL) is expected in patients of 
hemodialysis (HD) after renal transplantation (RTX). However there have been 
very few studies to investigate about change of QOL from HD to RTX. We 
estimated QOL in the patients of HD and RTX using Short Form questionair-36 
(SF-36) and compared them.
Materials and methods: We sent SF-36 questionnaire to 42 RTX patients 
(male/female: 25/17)(average age 44.4+/-12.0) who underwent renal graft in 
our hospital, and 45 HD patients (male/female: 23/22)(average age 63.3+/-10.6) 
who received HD in HD clinic nearby our institute. Average period of post 
transplant was 113.1+/-112.6 months in RTX patients, and average period 
of HD was 82.2*/-56.8 months in HD patients. SF-36 questionnaires were 
retrieved at the out-patient clinic or in the HD clinic after HD.
Results: QOL in the patients of RTX was signifi cantly better in social function 
(SF) (p=0.231) and in role-emotional (RE) (p<0.001) but no difference was 
recognized neither in vitality (VT) nor mental health (MH). Those QUL scores 
were found better in RTX patients than in HD in all subscales. However, both 
QOL scores were much worse when comparing to those of national standard.
Discussion: The improvement in QOL by RTX in end stage renal disease 
patients was recognized by SR-36 questionnaire. However, improvement 
was less then we expected. The study we conducted in this paper was cross-
sectional study. The patients in both groups were stable stage for the therapy 
and may be satisfi ed and accept their situation. On the other hand the patients 
who underwent RTX may desire much better condition than they are in now. 
We should conduct longitudinal study about QOL in each patients along the 
time course before and after RTX.
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IMMUNOSUPRESSION-FREE PROTOCOL IN SOLID 1853 
ORGAN TRANSPLANTATION YEARS FOLLOWING 
BONE-MARROW TRANSPLANTATION
E. Mor1, N. Bar-Nathan1, Y. Frishberg2, R. Becker-Cohen2, T. Klein3, 
D. Krist3, R. Shapiro4, Y. Avitzur4
1Department of Transplantation, Rabin Medical Center, Petah-Tiqwa, 
2Division of Pediatric Nephrology, Sharee Zedek Medical Center, Jerusalem, 
3The cross-match laboratory, Rabin Medical Center and 4Institute of 
Gastroenterology and Nutrition, Schneider Children’s Medical Center of 
Israel, Petach-Tiqwa, Israel
In reported cases of solid-organ transplantation immediately following bone-
marrow transplant (BMTX), immunosuppression was initially administered 
to prevent GVHD and gradually withdrawn. We report two children who 
received solid-organ grafts years after BMTX from the same donor without 
any immunosuppression.
Patients and methods: The fi rst patient is a 17-y/o boy who underwent BMTX 
for ALL from his fully HLA-matched sister at the age of 3-years. Chronic renal 
failure developed following total body irradiation. The patient underwent 
kidney transplantation from the same donor with a single i.v. steroid-bolus 
before reperfusion and without any immunosupression thereafter. The second 
patient is a 10-y/o boy who received a BMTX from his HLA-matched sister 
at the age of 7-months for SCID. Chronic liver disease associated with 
hepatopulmonary syndrome developed 9-years after BMTX. Following testing 
for chimerism, the child received a segmental-liver graft from his sister using a 
single steroid-bolus with no further immunosuppression. Chimerism was tested 
in DNA extracted from peripheral blood lymphocytes by the STR method and 
the presence of XX genotype by the FISH technique.
Results: Nine months post-transplant the fi rst child has creatinine levels of 
1.0mg/dL. The second child was weaned off oxygen 4 weeks post-transplant 
and at 3-months has normal liver function tests. Both children have had no 
episode of acute rejection or GVHD
Conclusion: Children who are full chimeras may benefi t from immunosuppressive-
free protocol when a solid organ transplant is performed from the same HLA-
matched living donor years after the bone-marrow transplant.
POSTER BOARD NUMBER P3 – 280
BILIARY STRICTURES IN PAEDIATRIC DECEASED 1854 
DONOR SPLIT LIVER TRANSPLANTS (SPLITX)
E. O’Loughlin1, M. Stormon1, A. Shun1, D. Verran2, M. Crawford2, 
L. Resurruccion1, V. Jermyn1, C. Wong1, D. Lord1
1Children’s Hospital At Westmead, 2Royal Prince Alfred Hospital
Biliary strictures are a common complication of SpliTx. While hepatic artery 
thrombosis (HAT) is a known risk factor, biliary strictures are more common 
than HAT post SpliTx.
Aim: is to review biliary strictures in SpliTx (2000-2007) and to determine 
possible risk factors for stricture.
Method: Deceased donor grafts (usually segment II and III) were split off 
site (majority insitu) and transferred to CHW and inserted using standard 
surgical procedures. Cold (CI) and warm (WI) ischemia times were measured 
during surgery. Intraoperative “Transonic” probe measurement (IO) of hepatic 
artery (HA) and portal vein (PV) fl ow was performed and post operative (PO) 
HA and PV fl ow patterns were assessed 2nd or 3rd daily for 7-10 days and 
regularly thereafter by Doppler ultrasound. Biliary strictures were identifi ed by 
abdominal ultrasound and percutaneous cholangiogram.
Results: 47 patients underwent SpliTx and 14 developed biliary strictures.
Weight 
(Kg)
PO-HA 
abnormality* CI (Hr) WI (Hr)
IO-HA 
(ml/min)
IO-PV 
(ml/min) Death/ reTx
Stricture 14 13.9±2.2 8 (3HAT) 8.5±0.7 1.1±0.3 87.5±9.0 494±104 2
No Stricture 33 13.2±1.3 3 (1HAT) 8.7±0.5 1.3±0.2 127.8±10.1 534±84 4
p ns <0.001 ns ns <0.02 ns ns
Table: Data is X±SE; *HAT or loss of HA fl ow or abnormal Doppler wave 
form.
Ten strictures were anastomotic, 5 with normal PO-HA and 4 intrahepatic, 1 
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with normal PO-HA. PV thrombosis occurred in one patient without stricture. 
Conclusions: In addition to HAT, abnormal HA fl ow patterns on Doppler 
ultrasound are associated with the development of biliary strictures. Donor 
graft factors other than ischemia may contribute to stricture formation.
POSTER BOARD NUMBER P3 – 281
SHORT-TERM OUTCOMES OF PEDIATRIC RENAL 1855 
TRANSPLANT RECIPIENTS RECEIVING A NOVEL STEROID 
MINIMIZATION IMMUNOSUPPRESSION PROTOCOL
L. Butani1, K. Lau1, G. Berg1, R. Perez2
1Department of Pediatrics, University of California, Davis, 2Department of 
Surgery, University of California, Davis
Background: Although steroid minimization regimens are commonly used in 
adult renal transplant (tx) recipients, the pediatric community has been slow to 
follow suit. At our center, we have been using a novel and convenient steroid-
minimization regimen in children after renal tx since 2004.
Objective: To determine the safety and effi cacy of a novel steroid minimization 
protocol after renal tx at our center.
Design/methods: Records of children receiving renal tx at UC Davis from 
1/04 - 11/07 were retrospectively abstracted for data. Protocol included 3 
tapering daily doses of steroids, along with 5 doses of Thymoglobulin followed 
by maintenance therapy with tacrolimus (FK) and mycophenolate mofetil. 
Surveillance renal biopsies (bx) were performed at 6 and 12 months. Student’s 
t-test was performed to compare pre-tx and last FU data.
Results: 16 pts underwent tx during the study period; 31% received preemptive 
tx. Median age at tx was 12.3 yrs with median follow up (FU) of 1.3 yrs. 
Compared to pre-tx levels, at last FU, median serum creatinine improved from 
7.8 to 1.0 mg/dL (p<0.05); hemoglobin changed from 12.3 to 11.8 g/dL (p=0.1); 
WBC changed from 8.6 to 5.8 x 103/L (p<0.05); glucose changed from 92 to 
87 mg/dL (p=0.78); cholesterol improved from 163 to 128 mg/dL (p<0.05). 
Only 1 pt switched from FK to sirolimus due to calcineurin nephropathy on 
surveillance bx. At last FU 6% and 25% of pts were on erythropoietin and 
antihypertensives respectively. No pt became diabetic. There was no clinical 
acute cellular rejection or post-tx lymphoproliferative disease. None of the bx 
showed subclinical rejection. 2 pts had recurrent FSGS and were treated with 
plasmapheresis (pp). One pt received a positive crossmatch kidney, developed 
humoral rejection and was successfully treated with pp and IVIg. There was no 
incidence of EBV infection/viremia. One CMV negative pt had asymptomatic 
virema at 9 months post-tx and is maintained on valganciclovir. 1 pt developed 
pneumonia (pna) and pleural effusion at 2 months post-tx. Another pt with 
HUS related chronic lung disease had episodes of pna. 3 pts developed stent-
related UTI. All these infections were successfully treated with antibiotics.
Conclusions: Our novel steroid-minimization immuosuppression is safe in 
children after renal tx and associated with a very low risk of rejection and 
infection. A larger number of pts and longer FU are required to further confi rm 
the effectiveness and safety of this approach.
POSTER BOARD NUMBER P3 – 282
PEDIATRIC EN-BLOC KIDNEY TRANSPLANTATION 1856 
INTO PEDIATRIC RECIPIENTS WITH STEROID 
MINIMIZATION PROTOCOL: SINGLE CENTER EXPERIENCE
L. Butani1, K. Lau1, G. Berg1, Y. Schjoneman1, R. Perez2
1Department of Pediatrics, University of California, Davis, 2Department of 
Surgery, University of California, Davis
Background: Due to the ongoing shortage in organ supply, en-bloc renal 
transplantation from small donors has become more common for children with 
ESRD. However, because of concern of higher complication rates, it is not 
being performed in every center. Its safety in the setting of steroid minimization 
immunosuppression has not been investigated.
Objectives: To determine the safety and short term outcomes of en-bloc renal 
transplantation in children at a single transplant center.
Methods: Medical records of all children (< 18 years) receiving en-bloc renal 
transplants at our institution from 1/07 - 12/07 were retrospectively abstracted for 
data. Data collected included age, sex, ethnicity, and pre-transplant mode of renal 
replacement. Donor age, cold and warm ischemic time and surgical technique were 
also recorded. Laboratory values included the serum creatinine, hemoglobin, white 
blood cell count, blood glucose and cholesterol. Post-operative immunosuppression 
included 3 tapering daily doses of steroids with 5 doses of Thymoglobulin ® 
followed by maintenance therapy with tacrolimus and mycophenolate mofetil. 
Surveillance renal biopsies were performed at 6 and 12 months.
Results: Three patients (ESRD due to HUS in 1; unknown etiology in 2) 
underwent en-bloc renal transplantation during the study period. Median age 
at transplantation was 16.7 years with a median follow-up of 0.7 years. Donor 
age ranged from 9-49 months with a body weight from 10 to 22 kg. The grafts’ 
aortas were anastomosed to either the common or external iliac artery, while 
the inferior vena cava was anastomosed to the external iliac vein. No technical 
complication was observed in the post-operative period. One patient had 
delayed graft function due to acute tubular necrosis secondary to prolonged 
hypoxia in the donor. Another patient suffered from acute deterioration of serum 
creatinine due to tacrolimus toxicity. Both patients recovered without long term 
consequences. Nuclear medicine renal scans documented good function of 
both renal allografts before hospital discharge in all patients. All grafts showed 
increased renal size at follow up ultrasound. There was no clinical rejection at 
last follow-up. Two patients underwent surveillance biopsies; neither showed 
sub-clinical rejection or chronic changes.
Conclusions: Based on our experience, albeit very limited, we feel that en-bloc 
renal transplantation from young donors is an acceptable and safe procedure 
with low complication rates in the pediatric recipient. The short term clinical 
outcomes using our steroid minimization protocol on these patients were 
satisfactory. A larger number of patients and longer term follow up are needed 
to confi rm the safety of this approach.
POSTER BOARD NUMBER P3 – 283
IMPROVED OUTCOME WITH IMMUNOSUPPRESSIVE 1857 
MONOTHERAPY AFTER RENAL TRANSPLANTATION IN 
SCHIMKE-IMMUNO-OSSEOUS DYSPLASIA
L. Pape1, N. Kanzelmeyer1, A. Baradaran-Heravi2, C. Boerkoel2, M. Burg3, 
J. Ehrich1, T. Lücke1
1Department of Pediatric Nephrology, Medical School of Hannover, Germany, 
2Centre for Molecular Medicine and Therapeutics, University of British 
Columbia, Canada, 3Nephrologic Center Lower Saxony, D- 34346 Hann. Münden
Schimke-immuno-osseous dysplasia (SIOD) is a multisystem disorder caused 
by a mutant chromatin remodeling protein. The main clinical fi ndings are 
spondyloepiphyseal dysplasia with dysproportionate growth restriction, 
defective cellular immunity, and nephrotic syndrome with focal and segmental 
glomerulosclerosis (FSGS) leading to renal failure. Concerning renal 
insuffi ciency, kidney transplantation is the therapy of choice since FSGS does 
not show recurrence in the transplanted organ. However, with respect to the 
underlying immune disorder and the increased susceptibility to life threatening 
infections, the question of the optimal immunosuppressive therapy after renal 
transplantation remains unsolved. Under conventional immunosuppressive 
regimens some SIOD patients have developed severe disseminated cutaneous 
papilloma virus infections or Epstein-Barr virus associated lymphoproliferative 
disease. We have found that immunosuppressive monotherapy results in 
a good outcome with a reduced number of severe infections. Therefore 
mild immunosuppression in SIOD may be possible due to the underlying 
immunodefi ciency without an elevated risk of acute or chronic rejections.
POSTER BOARD NUMBER P3 – 284
LONG TERMS OUTCOMES AFTER LIVER TRANSPLANT 1858 
FOR PEDIATRIC ACUTE LIVER FAILURE (ALF)
J.S. Bagia, R. Mohanka, Z. Machaidze, R. Squires, B. Schneider, 
A. Thompson, K. Soltys, G. Bond, R. Sindhi, G. Mazariegos
Childrens Hospital Pittsburgh
Aim: to report our experience in liver transplant for fulminant liver failure in 
the pediatric population with particular focus on long term outcomes and the 
impact of live donor transplantation.
Methods: Children with fulminant liver failure treated between 1997 and 
2007 were reviewed for cause of liver failure, time to treatment, treatment, 
complications and long-term immunologic and clinical outcomes.
Results: 32 children (17 boys and 15 girls) with a median age of 23 months 
(range = 2 weeks to 17 years) with fulminant liver failure underwent transplant 
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during the study period. 8 children underwent living related liver transplant 
(LRLT) with left lateral segments, and 24 received deceased donor livers 
(DDLT) with 7 split/reduced livers and 17 whole livers. Indication for transplant 
in the 8 patients who had LRLT were acute fatty liver in one, cryptogenic in 
two, enteroviral sepsis in 2, autoimmune hepatitis in one, tyrosinemia in one 
and neonatal herpes simplex hepatitis in one. Median time to transplant was 2 
(range 0-23) days in LRLT and 5 days (0-21) for deceased donor transplant.
Overall patient survival is 94% and graft survival is 90% at 84 months median 
follow up (range 1-245 months). Re transplantation was successful in 1 LRLT 
for hepatic artery thrombosis (HAT). One DDLT was retransplanted for late 
HAT (3 years). There were 2 deaths after DDLT due to PTLD in one and primary 
non function and subsequent sepsis while awaiting retransplant in the other.
Liver function is normal in all 30 survivors. Current immunosuppresion in the 
8 LRLT is once daily tacrolimus in 5, tacrolimus and prednisone in 2 and 1 is 
off immunosuppression treatment for EBV infection. In the 22 DDLT 10 are 
currently on tacrolimus and prednisone, 1 is on tacrolimus and sirolimus, 6 
are on once daily CNI (5 on tacrolimus and 1 on sirolimus) and 5 are on twice 
daily tacrolimus
Conclusions: Long term results after LT for acute liver failure are comparable 
to transplant for non-ALF indications. LRLT improves timing of transplant and 
minimization of immunosuppression may contribute to success of transplant in 
this challenging patient population.
POSTER BOARD NUMBER P3 – 285
ACCELERATED VASCULAR ALLOGRAFT 1859 
CALCIFICATION IN YOUNG TRANSPLANTATION IS NOT 
RELATED TO IMMUNE RESPONSE BUT TO ITS ACTIVE 
BONE GROWTH
H. Yamauchi1, N. Motomura1, M. Sata1, D. Takai1, U. Chung1, A. Saito2, 
S. Takamoto1
1University of Tokyo, 2University of Western Ontario
Background: Vascular allografts transplanted in youth tend towards early 
graft failure due to accelerated calcifi cation, but the etiology is still unknown. 
Immunoreactivity may promote graft calcifi cation, whereas physiological 
hyperphosphatemia resulting from active osteogenesis in youth could be 
involved in the pathogenesis. We examined the development due to youth of 
allograft calcifi cation, associated with immunoreactions and hyperphosphatemia 
in a rat model on a phosphorus control diet.
Methods: Three-week-old “young” and 10-week-old “adult” Lewis (Lew) and 
Brown-Norway (BN) rats were used and a standard diet (0.9% of phosphorus) 
was given. Fresh descending aortas of donors were transplanted under the 
abdominal skin of recipients, and were explanted 14 days later. Syngeneic 
transplantation between young Lew (“Y-syn”), between adult Lew (“A-syn”), 
and allotransplantation from young BN to young Lew (“Y-allo”), from adult BN 
to adult Lew (“A-allo”) were performed. Pre-transplant donors of young and 
adult rats were defi ned as “Preop-Y” and “Preop-A”. Then, a low phosphorus 
(LP) diet (0.2% of phosphorus) was given to recipients of Y-syn and Y-allo 
(“Y-syn-LP” and “Y-allo-LP”). Calcifi cation of all explants, serum and graft 
inorganic phosphorus (Pi) levels, and gene expression of syngeneic transplants 
were analyzed.
Results: Graft calcifi cation was severe in Y-syn and Y-allo, mild in A-allo, but 
absent in A-syn and the Preop animals in von Kossa staining. Atomic absorption 
spectroscopy revealed that the graft calcium contents of Y-syn, Y-allo, A-syn, 
A-allo, Preop-Y, and Preop-A were 4.35, 4.29, 0.16, 0.43, 0.07, and 0.04 mg/
dry&#903;g, respectively, showing signifi cantly higher levels for Y-syn and 
Y-allo than for A-syn, A-allo, and Preop (p<0.0001), but no difference between 
Y-syn and Y-allo. The serum Pi levels of Y-syn and A-syn were signifi cantly 
different (10.98 and 8.29 mg/dl, p<0.05), unlike serum calcium (10.88 and 
11.01 mg/dl). The graft Pi contents of Y-syn, A-syn, Preop-Y, and Preop-A were 
1.95, 0.14, 0.80, and 0.21 mg/dry&#903;g: signifi cantly higher in Y-syn than in 
the others (p<0.001). Electron microscopy showed phenotypic changes of graft 
media cells from the contractile to the synthetic type. Realtime RT-PCR revealed 
90% down-regulated myogenic {ƒ¿-smooth muscle actin (SMA)}, 500% up-
regulated pro-infl ammatory (tumor necrosis factor-ƒ¿), and up-regulated 
osteogenic (Runx2, 650%; osteocalcin, 250%) gene expressions in both Y-syn 
and A-syn, postoperatively. Immunohistochemistry showed reduced ƒ¿-SMA 
protein and induced CD68 (macrophage), Runx2, and osteocalcin protein in 
both Y-syn and A-syn, especially in Y-syn calcifi ed regions. Following a low Pi 
diet, Y-syn-LP and Y-allo-LP showed no graft calcifi cation. In Y-syn-LP, serum 
Pi (8.94 mg/dl, p<0.01), graft Pi (0.43 mg/dry&#903;g, p<0.001), and graft 
calcium (0.49 mg/dry&#903;g, p<0.005) were all lower than Y-syn, and similar 
relationships were seen in the Y-allo-LP and Y-allo groups.
Conclusions: These data suggested that: (1) in youth, vascular allograft 
calcifi cation was accelerated; (2) immunoreactivity did not signifi cantly 
affect acceleration of graft calcifi cation in youth, but did somewhat in adults; 
(3) osteogenic transformation of graft media cells, which may cause graft 
calcifi cation, was triggered by the infl ammatory stimulus in both young and 
adults; and (4) a suffi cient supply of tissue inorganic phosphorus was a critical 
factor in graft calcifi cation in youth.
POSTER BOARD NUMBER P3 – 286
REHABILITATION AND TRANSITION AFTER LUNG 1860 
TRANSPLANTATION IN CHILDREN
J.H. Burton, J-M. Marshall, P. Munro, W. Moule, G. Westall
Paediatric Lung Transplant Service, The Alfred, Melbourne, Australia
In 2005, a paediatric lung transplant service was established alongside the 
existing adult lung transplant program at The Alfred Hospital, Melbourne, 
Australia. This necessitated the development of an age appropriate version 
of the adult recovery and rehabilitation program by the multidisciplinary 
team to best meet the needs of children and their families following lung 
transplantation.
The aim is to describe the key components, structure and content of the 
outpatient recovery and rehabilitation programme provided by the Paediatric 
Lung Transplant Service at The Alfred Hospital.
To date the service has transplanted 5 children (age 9-15 yo; 80% female; cystic 
fi brosis n = 3, obliterative bronchiolitis n = 1, bronchiectasis n = 1) who pre-
transplant lived both locally and interstate (Queensland).
Following discharge post lung transplant, in addition to their regular transplant 
clinic reviews, all patients and families participated in a 3 month outpatient 
rehabilitation programme. This comprised of 3 physiotherapy sessions, 1 
occupational therapy session and 1 education session per week for the child and 
2 education sessions per week for parents. The overall aim of the programme 
was to comprehensively address physical rehabilitation, psychosocial and 
educational needs. Sessions were tailored to meet the individual needs of 
the children and their families and refl ected a fl exible approach with active 
participation. After each session feedback was provided to parents regarding 
issues discussed and the management plan. Dietetic reviews were carried out 
during this time as required.
Physiotherapy included a progressive aerobic and strength training program, 
postural re-education and core stability. Age appropriate play activities 
(running, dancing, jumping, ball skills, etc) were incorporated.
Occupational Therapy sessions included addressing the primary occupational 
roles of patient, student and player, through therapeutic use of play. Themes 
included returning to school, friends and the community. Issues discussed 
include adjustment to new health status, participating fully again within the 
family, strategies to manage side effects of medications and altered body image 
issues.
Education sessions for both the children and parents focussed on medications, 
infection and rejection, nutrition, physiotherapy/rehabilitation, occupational 
roles and stress management, donor issues and psychosocial readjustment. 
Information for children was presented at an appropriate age and cognitive 
level. Tools used included drawing, open ended questions, internet health 
websites and the Roche CC Care Program.
A weekly paediatric multidisciplinary team meeting was used to discuss and 
plan the rehabilitation progress, ensuring consistence in the delivery of care 
and information to the child and their family.
School liaison and visits occurred prior to school commencement and follow 
up contact and visits are also offered to review the ongoing transition process.
Patients, their families and the multidisciplinary team report a high level of 
satisfaction with this model of care. Our plan is to review this service formally 
in the near future. It is hoped that this programme will continue to promote and 
ensure appropriate recovery and rehabilitation of children and their families 
post lung transplant. In preparing them for transition, ensuring a greater quality 
and a life fi lled with increased opportunity for meaningful engagement.
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SUCCESSFUL MANAGEMENT OF RECURRENCE OF 1861 
FAMILIAL HUS POST RENAL TRANSPLANTATION
E. Ball, W. Wong, T. Kara, M. Morris, J. Ronaldson
Starship Childrens’ Hospital
Familial haemolytic uraemic syndrome (HUS) frequently leads to end stage 
kidney disease and often recurs after transplantation. Long term graft survival after 
recurrence of is very poor, with almost all grafts being lost over a period of time.
We present the case of a 20 year old girl who developed recurrent HUS in 
infancy and progressed to end stage kidney at the age of 11. An older sibling 
had died of HUS in the fi rst year of life. She has no known mutations in the 
Factor H, Factor I or MCP genes and further mutation analysis for complement 
defects is underway. She received a well matched deceased donor kidney at the 
age of 18. Her initial immunosuppression regimen consisted of basiliximab, 
methylprednisolone and mycophenolate mofetil. The introduction of 
tacrolimus was delayed until day 5 when her renal function had stabilised. She 
received fresh frozen plasma (FFP) pre operatively, then daily for one week 
post transplant, twice weekly for a further fortnight and then weekly as part of 
a recurrence prevention plan.
She had immediate graft function and the fi rst post operative month was 
uneventful. On day 49, she had a sharp rise in serum creatinine to 150μmol/L 
(baseline 80-90μmol/L). This was associated with a rise in LDH, although 
haemoglobin and platelet counts remained stable. She was commenced on high 
dose FFP infusions (30ml/kg/day) for 4 days. Transplant biopsy confi rmed early 
HUS recurrence and she began plasmapheresis with FFP on day 54. She received 
daily plasmapheresis sessions for one week, then 2-3 weekly sessions for a further 
3 weeks, then weekly sessions for a further 5 weeks. Following discontinuation 
of plasmapheresis she received daily high dose FFP for a week and the frequency 
of these infusions was weaned and fi nally stopped 6 months post transplant.
At present she has excellent allograft function with a serum creatinine of 
80μmol/L and has shown no further signs of disease recurrence.
A high level of suspicion should be maintained for recurrent HUS post 
transplantation even in the absence of typical features of thrombotic 
microangiopathy. Early diagnosis and prompt treatment with high dose FFP 
infusions, a prolonged course of plasmapheresis and slow tapering of the FFP 
infusions may have been benefi cial in retaining allograft function in our patient.
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MICRO-PLATE HEMAGGLUTINATION ASSAY: A 1862 
SIMPLE AND SENSITIVE TECHNIQUE TO MEASURE ANTI-A 
AND ANTI-B ANTIBODY TITRE IN PATIENTS UNDERGOING 
ABO-INCOMPATIBLE ORGAN TRANSPLANTATION
M. Jeyakanthan, L. Podlosky, S. Senthilselvan, S. Maier, I. Larsen, 
S. Nahirniak, L. West
University of Alberta
Introduction: Accurate and reliable measurement of anti-A and anti-B antibody 
titre is important in the management of patients undergoing or being considered 
for ABO-incompatible organ transplantation. Development of new protocols 
on the basis of clinical experience is important in improving outcomes. 
However due to lack of a standardized method for measuring antibody titres, 
results from different centres are not comparable. The purpose of this study 
was to develop a simple, reliable and sensitive method for measuring anti-A 
and anti-B antibody titre.
Methods: Serum samples from human volunteers of different ABO-blood types 
(n=20) were tested for anti-A and anti-B titre by our newly developed micro-
plate assay and the widely used tube test. Micro-plate assay was performed on 
a 96 well round bottom plate with each well containing 50uL 2-fold serially 
diluted serum (1 to 2048) incubated with 25uL of 2-4% A1 and B erythrocytes 
for 1 hour; agglutination was read using either immunospot plate reader or 
an inverted microscope. Tube tests were done according to our institutional 
protocol. Antibody titres obtained by the two methods were compared to anti-
A/B IgM measured by ABO-ELISA. Paired t-test analysis was performed by 
comparing the corresponding ELISA OD value for each titre measured by the 
two different methods.
Results: The overall anti-A titre (n=17) read by inverted microscope was 
signifi cantly higher than that measured by the tube test (difference in mean OD 
value=0.0148, p<0.005). Titre read by immunospot plate reader was higher 
overall but failed to reach signifi cance. Similar results were obtained for anti-B 
titre (n=17, difference in mean OD value=0.0094824, p<0.005). Our method 
required 200 uL of serum to complete the test as compared to the tube test that 
required 900 uL.
Conclusions: Micro-plate hemagglutination assay is an effi cient and sensitive 
technique to measure anti-A and anti-B titre and easily reproducible. This 
method can be standardized in all centres with minimal variation that will 
facilitate the development of new management protocols. Sample volume is 
also a major limiting factor especially in a growing number of infant recipients 
of ABO-incompatible heart transplantation and our method is of particular 
benefi t in this patient population.
POSTER BOARD NUMBER P3 – 289
POSTOPERATIVE CARE AFTER PEDIATRIC COMBINED 1863 
HEPATORENAL TRANSPLANTATION (CHRTX)
M.J. Kemper1, K. Helmke2, R. Ganschow3, L. Fischer4, B. Nashan4, 
D.E. Müller-Wiefel1, E. Harps5
1Pediatric Nephrology, 2Pediatric Radiology, 3Pediatric Gastroenterology, 
4Transplantation Surgery, 5Pediatric Intensive Care
CHRTx may be indicated for structural disorders involving kidney and liver 
(e.g. autosomal recessive polycystic kidney disease, ARPKD) or metabolic 
disorders where the hepatic enzyme defect results in damage of the kidney 
(e.g. primary hyperoxaluria, PH1). Since 1998 we have performed CHRTx 
in 9 children, 3 with ARPKD and 6 with PH1. This included 3 girls and 6 
boys with a median age of 8 years (range 1.5-16) and a median weight of 18 
kg (range 9.6-55). Median stay of ICU was 9 days (range 5-50). Mechanical 
ventilation varied signifi cantly: 4 children could be extubated within 24 h after 
CHRTx, while 3 required ventilation for longer than 25 Days (24, 34 and 42, 
respectively). Renal replacement therapy was necessary in 6 patients, mostly 
to decrease plasma oxalate load in PH1; median duration was 2 days (range 
0-30). Erythrocyte transfusions were necessary in a median of 2 (0-31), FFP 
in 2 (0-31) and platelet transfusion median 1 (0-12). Complications included 
bleeding, infections, primary graft failure and rejection. One patient required a 
second CHRTx and later a third liver graft. All patients were discharged from 
ICU in stable condition, there was no mortality. Long-term graft function is 
excellent in 8 patients with suffi cient follow-up (>9 months). In summary and 
conclusion CHRTx is a multidisciplinary challenge that has to face a variety of 
complications. Long-term results are excellent.
POSTER BOARD NUMBER P3 – 290
RADIATION EXPOSURE IN THE FIRST YEAR 1864 
FOLLOWING PAEDIATRIC LIVER TRANSPLANTATION
I. Diamond1, B. Ahmed2, K. Thomas2, E. Hoppe1, B. Connolly2, D. Grant1, 
V. Ng1, P. Wales1, A. Fecteau1
1Paediatric Academic Multiorgan Transplant Program, 2Department of 
Diagnostic Imaging, The Hospital for Sick Children
Introduction: As survival of children undergoing transplantation continues to 
improve greater emphasis is being placed on the potential long term sequelae 
related to therapy. There is an increasing awareness that ionizing radiation 
related to diagnostic imaging may be a risk factor for future malignancy. 
However, little is known of the cumulative effective radiation dose received 
by children undergoing transplantation. We sought to examine diagnostic and 
therapeutic radiation exposure over the fi rst year following liver transplantation 
in a cohort of paediatric patients.
Methods: All children who received a liver transplant at our institution between 
1 July 2001 and 30 June 2006 were included in this retrospective cohort study. 
Records of all diagnostic and therapeutic procedures with exposure to ionizing 
radiation, within 1 year of transplant, were obtained from our electronic 
diagnostic imaging database. Age-specifi c effective radiation dose estimates 
were assigned to each study using institutional dose data and estimates derived 
from the pediatric radiological literature. Cumulative effective dose estimates 
at 60 days and 1 year following transplant were calculated for each patient.
Results: Sixty-seven children were included in this study, with an overall 
survival of 92.5% at 1-year. Median age at transplant was 4.7 (range 0.1 – 
17.9) years. Estimated median effective dose of radiation in the fi rst 60 days 
following transplant was 8.0 (range: 0.1 – 86.6) milisieverts [mSv] and 14.2 
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(range: 0.2 – 189.6) mSv in the year following transplant. At 1-year, the median 
effective dose amongst our patients represents a 4.7 fold increase over annual 
background radiation exposure (3mSv), or a dose equivalent to approximately 
865 chest x-rays. Nineteen (28%) children had an estimated cumulative effective 
dose in excess of 10 times background exposure. Computed Tomography (CT) 
scans contributed 58.3%, Interventional procedures 23.5%, Nuclear Medicine 
studies 12.6%, Fluoroscopy 4.1%, and Plain Film Radiography 1.5% to the 
total dose. These contributions are in contrast to the relative frequency of the 
procedures: Plain Film Radiography 72.3%, Interventional procedures 11.4%, 
CT scans 8.7%, Nuclear Medicine studies 5.3%, and Fluoroscopy 2.3%.
Conclusions: Although there is wide variability in radiation exposure which is 
likely related to differences in post-transplant morbidity, children undergoing 
liver transplantation have the potential to be exposed to a substantial amount 
of iatrogenic radiation following transplantation. Clinicians should be aware 
of the potential long term risks associated with ionizing radiation and employ 
strategies to reduce exposure wherever possible. Although radiographic 
procedures are necessary for the detection and management of post-transplant 
complications, the risk benefi t ratio should always be considered when 
requesting diagnostic studies. This is especially important in children who have 
already had considerable radiation exposure. As well, alternative non-ionizing 
modalities such as ultrasound and magnetic resonance imaging should be used 
whenever feasible. When ionizing radiation is necessary, specifi c pediatric 
dose-saving protocols should be employed.
POSTER BOARD NUMBER P3 – 291
THE PING PONG BALL AS A SURGICAL AID IN LIVER 1865 
TRANSPLANTATION
V. Jones, G. Thomas, M. Stormon, A. Shun
The Children’s Hospital At Westmead
Background: Liver transplantation using split adult segmental grafts in infants 
can be a technical challenge as the small abdominal cavity cannot comfortably 
accommodate the graft, leading onto graft compression. This size mismatch can 
be a particularly diffi cult problem when the anterior-posterior (AP) diameter of 
the graft is greater than the infant’s available AP peritoneal space. We describe 
a simple and novel technique to prevent this complication.
Methods and results: Two infants with biliary atresia weighing 5 kgs and 
aged 6 and 5 months received split adult liver left lobe transplants from donors 
weighing 55 and 65 kgs respectively. Congestion of the graft and inadequate 
perfusion was prevented by placing a sterilized ping pong ball in the retro-
hepatic space to elevate the graft off the native hepatic fossa. Delayed closure 
of the wound was performed after 5 days when it was possible to remove the 
ping pong ball in one of the patients. Both patients have recovered well from 
the transplant. A follow-up of 1 year in the patient with the in-situ ping pong 
ball shows it to be well anchored and causing no symptoms.
Conclusions: In children undergoing large for size split liver grafts, delaying 
the closure of the abdominal wound along with elevating the graft using a ping 
pong ball can be a useful and simple adjunct to prevent the complications of 
graft compression.
POSTER BOARD NUMBER P3 – 292
QOL AND PROBLEMS AFFECTING RECIPIENTS 1866 
MORE THAN 10 YEARS AFTER LIVING DONOR LIVER 
TRANSPLANTATION
N. Kawagishi, A. Nakamura, T. Iwane, I. Takeda, S. Miyagi, K. Satoh, 
Y. Akamatsu, S. Sekiguchi, S. Satomi
Division of Transplantation, Reconstruction and Endoscopy
Background and purpose: We started a living donor liver transplantation 
(LDLT) program in 1991; 17 out of 21 recipients have survived for more than 
10 years. The aim of this study was to review our experience with LDLT in 
children and analyse the long-term outcome.
Methods: We have performed 116 LDLT from 1991 up to the present, and 
17 recipients have survived for more than 10 years. The long-term outcome 
of these 17 recipients was evaluated in relation to growth, immunosuppresive 
therapy, complications, and quality of life.
Results: The average age at LDLT was 5.4 years old (from 6 months to 
17 y.o.), and the present average age is 17.2 years old (from 11 y.o. to 28 
y.o.). The mean follow-up period was 12 years. The primary diseases of the 
recipients were biliary atresia in 18, Byler disease in 1, patent ductus venosus 
in 1. At the time of LDLT, 6 recipients had growth retardation and their body 
weight was low for their age by 2 SD. But 4 out of 6 recipients who underwent 
LDLT before the age of 2 caught up and reached the average height and body 
weight for their age. The average frequency of re-admission after LDLT was 
7.4 times, and one recipient was re-admitted 30 times because of biliary 
stenosis. Two recipients suffered from PTLD, they cured after withdrawal of 
immunosuppressants. Six recipients were diagnosed acute rejection by biopsy 
more than 5 years after LDLT; 5 of them improved with steroid pulse therapy. 
One recipient had steroid resistant acute rejection and was administered 
deoxyspergualin after steroids. Chronic rejection was not observed in this 
series. Three ABO-incompatible LDLT were included in this group, no one 
showed antibody mediated rejection during the long-term follow-up period. 
The present immunosuppressive therapy includes tacrolimus in 9 cases and 
cyclosporine in 6 cases. One recipient has not required immunosuppresive 
therapy for more than 4 years and her present condition is good. One recipient 
had PTDM and another had HBV hepatitis. All these recipients, except for 
one, attend a normal school or have an occupation.
Conclusion: The majority of LDLT recipients have achieved a good QOL 
during their long-term survival and are pursuing normal studies. But biliary 
complications may affect their QOL.
POSTER BOARD NUMBER P3 – 293
IPC CATHETER IMPLANTATION FOR INTRACRANIAL 1867 
PRESSURE MONITORING IN CHILDREN WITH SEVERE 
COAGULOPATHY DUE TO LIVER FAILURE
H. Ismail, M. Markiewicz-Kijewska, S. Barszcz, M. Migda³, J. Teisseyre, 
M. Szymczak, P. Nachulewicz, T. Drewniak, P. Kaliciñski, 
A. Ostoja-Chy¿yñska
The Childrens Memorial Health Institute
Neurological complications of brain edema and increased intracranial pressure 
in patients with acute liver failure are main causes of mortality and morbidity in 
these patients, both before and after successful liver transplantation. Therefore 
we include ICP probe insertion and ICP monitoring in our standard of treatment 
in all patients with acute liver failure or decompensation developing stage II 
coma, despite the risk of intracranial bleeding due to severe coagulopathy 
present in most of these children.
The aim of our study was retrospective analysis of safety and risks of ICP 
implantation in this particular group of children.
Materials and methods: Between1997-2007 we implanted 19 ICP catheters 
in 18 children with liver failure (in one two catheters were implanted). Patients 
age was between 1,7 - 20,5 yrs (mean 10.43 yrs). Before all procedures of 
catheter implantation except two, we used recombinant activated factor VII 
(rFVIIa) to improve coagulation and diminish risk of intracranial bleeding. We 
administered between 17-100 mcg/kg body mass. Six patients had done this 
procedure a few days before LTx. One patient was not transplanted due to too 
long waiting for new liver and multiorgan failure. Patients were in coma 3-11 
fays (mean 5,8).
Results: Administration of rFVIIa improved INR before ICP catheter placement 
from 2,88 - 8 (mean 3,43) to 1 - 1,6 (mean 1,3). ICP monitoring was done 2-12 
days (mean 4,53 days). ICP catheter was removed routinely when patient was 
awakning of coma. Complications related to ICP catheter insertion developed 
in 2 patients (11,1%; subdural hematoma and bleeding in to brain cavity), 
both underwent neurosurgical intervention (one during liver transplantation 
procedure). Out of 18 children 13 are alive (all after LTx), 5 died of MOF 
and brain damage due to brain oedema (4 after LTx) as the course of liver 
failure. None of survivors (including 2 children with early complications of 
ICP monitoring), developed any persistent neurological complications related 
to ICP catheter.
Conclusions: With the possibility of immediate and effective correction of 
coagulopathy before ICP catheter implantation we consider ICP monitoring 
as safe and very useful in the treatment of children with acute liver failure and 
coma.
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SINGLE CENTER EXPERIENCE IN LIVER 1868 
TRANSPLANTATION FOR FULMINANT WILSON’S DISEASE 
IN CHILDREN
J. Teisseyre, M. Markiewicz- Kijewska, H. Ismail, M. Szymczak, S. Prokurat, 
I. Jankowska, A. Ostoja-Chy¿yñska, A. Apanasiewicz, P. Kaliciñski
The Childrens Memorial Health Institute
Fulminant Wilson’s disease (FWD) is rare and has been considered as fatal 
in children without liver transplantation, however introduction of new 
technologies as albumin dialysis could change this poor prognosis.
The aim of our study was retrospective analysis of clinical course, treatment 
and outcome of children with FWD treated in our institution.
Material and methods: Between 1977-2007 we’ve treated in our hospital 13 
patients aged 4-22 yrs (mean 15,5 yrs) with FWD. We performed retrospective 
analysis of clinical course, biochemical parameters, MELD/PELD score, 
Wilson score and Kings-College criteria for LTx in ALF in all patients.
Results: The initial symptoms of FWD usually were weakness and abdominal 
pain which appeared 5-60 days (mean 20 days) before icterus. Eleven patients 
developed neurological symptoms with coma lasting for 2-11 days. Maximal 
serum bilirubin concentration at time of qualifi cation for LTx was 4,5-71,6 
mg% (mean 42,24 mg%) and INR 2,9-10,0 (mean 5,4). MELD/PELD score at 
time of qualifi cation for LTx was between 21-58 (mean 38), 9 patients fulfi lled 
King’s-College criteria for transplantation in acute liver failure ALF, Wilson’s 
score ranged between 11 and 17 points (mean 13 points).
In all except two children urgent liver transplantation was performed in 11 patients 
(in 5 with ABO incompatible grafts), One patient improved with intensive therapy 
and albumin dialysis (MARS) without the need for LTx and one died on the 
waiting list for LTx due to brain edema. Two children died in early post after 
transplantation period (pTx d3 and pTx d7). In summary 10 of children with FWD 
are alive (total survival of 76,9%): 1 without LTx (7,7% survival) and 9/11 after 
LTx (survival 81,8%). Actual follow-up of living patients is 0,5-7,5 years (mean 
2,5 yrs), all are doing well with good graft function and one with native liver.
Conclusions: FWD almost in all patients lead to death or LTx, however with 
modern intensive care with early application of albumin dialysis and chelating 
therapy occasional survival without transplantation or at least prolongation of 
time necessary for LTx can be achieved improving overall survival of these 
patients. Wilson’s score seemed to better predict need for LTx than classical 
Kings-College criteria for ALF.
POSTER BOARD NUMBER P3 – 295
BENIGN TRANSIENT HYPERPHOSPHATASIA IN A 1869 
RENAL TRANSPLANT- NOT SO BENIGN
F. Mackie1,2, S. Kennedy2, G. Kainer2, A. Rosenberg1,2
1University of N.S.W., 2Sydney Children’s Hospital
‘Benign’ transient hyperphosphatasia (BTH) with spontaneous elevation of 
alkaline phosphatase (ALP) infrequently accompanies viral infections in children. 
We report the fi rst case of ALP rise heralding primary EBV infection in a paediatric 
renal transplant recipient. A 2 year old with ESRD secondary to congenital 
nephrotic syndrome received her fi rst graft from her father. Donor was CMV and 
EBV positive, recipient negative. Immunosuppression consisted of prednisone, 
mycophenolate, tacrolimus and basiliximab. Valgancylovir prophylaxis was 
given. 7 weeks post transplant, elevation in ALP to 2789 (N. 80-300U/L) was 
noted. 4 days later isolated fever developed and resolved spontaneously. Bone 
and liver isoenzymes of ALP were elevated, consistent with a diagnosis of BTH. 
Within 1 week of valgancyclovir cessation (at 4mths) diarrhoea developed. 
Plasma EBV and CMV PCR’s were negative. 1 week later the patient presented 
with a prolonged partial seizure and encephalopathy following 3 days of fever and 
coryza. MRI demonstrated bilateral signal abnormalities in the dorsal brainstem 
and periventricular white matter. EEG was consistent with encephalopathy. ALP 
continued to rise to 4447. CSF had raised total protein and EBV PCR was positive 
(plasma negative) leading to a diagnosis of EBV encephalitis. IV gancyclovir was 
started with marked clinical improvement and decline in ALP within 2 weeks to 
944. Serology 4 weeks later was consistent with early primary EBV infection. 
Immunosuppression was reduced. Full neurological recovery was made. ALP 
levels normalised within 1 month. Elevated ALP levels after renal transplantation 
may be associated with serious viral infection.
POSTER BOARD NUMBER P3 – 296
MITOCHONDRIAL RESPIRATORY CHAIN 1870 
HEPATOPATHIES: ROLE OF LIVER TRANSPLANTATION. A 
CASE SERIES OF 5 PATIENTS
M.O. Stormon1, E. De Greef1, J. Christodoulou2, S. Dorney1, A. Shun3, 
G. McCaughan3, E.V. O’Loughlin1, V. Jermyn3
1Department of gastroenterology, Children’s Hospital at Westmead, 2Genetic 
Metabolic Disorders Service, Children’s Hospital at Westmead, 3Australian 
National Liver Transplant Unit, Royal Prince Alfred Hospital; Sydney, 
Australia
Introduction: Liver transplantation in patients with mitochondrial respiratory 
chain disorders (MRCD) remains controversial. The possibility of multi-organ 
involvement requires thorough screening before considering orthotopic liver 
transplantation (OLT). 
Aim: To report 5 patients with proven MRCD to illustrate the diversity in 
clinical presentation, the diffi culty in obtaining adequate tissue to make a 
timely and accurate diagnosis, and how this infl uences decision making for 
OLT in these patients.
Methods: Retrospective chart review over a 12 year period (1995-2007) at a 
tertiary referral paediatric liver transplant centre where 5 children with hepatic 
MRCD were identifi ed.
Results: Patient 1 was diagnosed as ‘cryptogenic’ cirrhosis and transplanted 
at 13 years of age. The explant was noted to have macrovesicular steatosis 
and the diagnosis of Complex I defi ciency was subsequently made. Five 
years after transplant there are no manifestations of extrahepatic disease 
with good graft function. Patient 2 presented with fulminant liver failure at 
3 months of age and was diagnosed with complex I defi ciency after an open 
liver biopsy with fresh frozen plasma (FFP) support. Although there were no 
extrahepatic manifestations, OLT was not considered and the patient died 
3 weeks later. Patient 3 presented with recurrent hypoglycaemia and was 
transplanted for fulminant hepatic failure at the age of 12 months. Although 
MRCD was suspected and open liver biopsy performed, results (Complex I, 
II and IV defi ciency) were not known till just after transplant. Despite good 
graft function, death occurred 9 months later due to pulmonary hypertension, 
a new manifestation of MRCD1. Patient 4 was diagnosed with Complex I, III 
and IV defi ciency at the age of 2 years because of sensorineural hearing loss, 
hypoglycaemia and liver dysfunction2. She subsequently developed severe 
renal impairment and was listed for combined liver-kidney transplantation at 
14 years of age because no new organ system was affected. Death occurred, 
while listed, after a stroke-like episode following severe sepsis. Patient 5, a 5 
year old girl with mild developmental delay and epilepsy, developed valproic 
acid induced liver failure. Mt DNA depletion syndrome was diagnosed after 
open liver biopsy with FFP support; OLT was not offered and death occurred 
4 weeks later.
Conclusion: Hepatic MRCD can present with fulminant liver failure or chronic 
liver disease. The diagnosis requires a high index of suspicion. The diagnosis 
is confi rmed by measuring respiratory chain enzymes on liver tissue which 
may necessitate open liver biopsy with FFP support. The decision to perform 
OLT in a child with MRCD is diffi cult, with a good outcome in a minority 
of cases, but MRCD should not be considered an absolute contraindication. 
Careful assessment of extrahepatic manifestations is necessary. The correlation 
between the type (enzymatic defect), the extent of multi-organ involvement, 
the natural history of MRCD and the underlying genetic aetiology is unclear 
and requires further investigation.
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THE USE OF ORAL VALGANCICLOVIR IN THE 1871 
TREATMENT OF CYTOMEGALOVIRUS IN A PAEDIATRIC 
LIVER TRANSPLANT RECIPIENT
M. Cree1, H. Miller1, C. Noble2, J. Fawcett2
1Pharmacy Department Royal Children’s Hospital, 2Liver Transplant Unit 
Royal Children’s Hospital
The use of oral valganciclovir in the treatment of cytomegalovirus in a 
paediatric liver transplant recipient
Introduction: Cytomegalovirus (CMV) is an important pathogen and a major 
cause of mortality in children following solid organ transplantation. Children 
are particularly vulnerable to CMV as many of them have not developed 
immunity to CMV at the time of transplantation.
Objective: To describe the use of valganciclovir for the treatment of CMV in a 
paediatric liver transplant recipient.
Clinical Features: In January 2007 a 9 year old female received a liver 
transplant following liver failure associated with Wilson disease. In February 
2007 the patient became unwell and CMV infection was confi rmed by 
polymerase chain reaction (PCR) testing. It was decided to treat the CMV with 
oral valganciclovir.
Intervention, progress and outcome: The standard treatment for CMV is 
intravenous ganciclovir twice a day for approximately 3 weeks; this has an 
increased risk of infection and requires hospital admission. A literature review 
was undertaken and it was proposed that oral valganciclovir be used for one 
month for treatment of the CMV infection at a dose of 520mg/m2 twice a 
day. CMV PCR samples were taken frequently to monitor the effectiveness 
of valganciclovir in treating the CMV infection. Results revealed the CMV 
infection was successfully treated with oral valganciclovir in this patient.
Conclusion: Valganciclovir is indicated for CMV prophylaxis for renal transplant 
recipients. Further studies are required to confi rm the future role of valganciclovir 
in the treatment of CMV infection in paediatric liver transplant recipients.
POSTER BOARD NUMBER P3 – 298
PEDIATRIC LIVING DONOR LIVER 1872 
TRANSPLANTATION FOR METABOLIC DISEASES OF THE 
LIVER
A.D. Concejero, C.L. Chen, C.C. Wang, S.H. Wang, Y.W. Liu, C.H. Yang, 
C.C. Yong
Liver Transplant Program, Department of Surgery, Chang Gung Memorial 
Hospital-Kaohsiung Medical Center
Objective: We reviewed our experience in living donor liver transplantation 
(LDLT) for metabolic disease of the liver in children including outcomes of 
surgery and decisive factors for post-transplant patient survival.
Methods: From June 1994-December 2007, a total of 347 LDLT were 
performed. One hundred fi fty-six (156) were performed for pediatric patients. 
Nineteen (19, 12.2%) were transplanted for metabolic disease of the liver. The 
records of these patients were reviewed.
Results: There were 13 (68%) glycogen storage disease (type I, n=10; type 
III, n=3), 2 (11%) Wilson’s disease, 2 (11%) familial intrahepatic cholestasis 
(type I, n=1; type II, n=1), 1 (5%) urea cycle disorder (hyperammonemia), 
and 1 (5%) congenital hepatic fi brosis patients. The mean age at time of 
transplant was 7.8 years (range, 0.7-18) but the liver-oriented diseases 
(urea cycle disorder, familial intrahepatic cholestasis, congenital hepatic 
fi brosis) were younger. All patients presented with metabolic abnormalities. 
In addition 8 patients presented with growth retardation. Twelve received 
left lobe, 3 left lateral segment, 1 extended left lateral segment, and 3 right 
lobe grafts. The postoperative complications included 3 bile duct strictures, 
1 bile leak, 2 hepatic vein stenoses, 1 hepatic artery thrombosis (HAT), 
and 1 refractory ascites. The single HAT case required re-exploration and 
interposition grafting using a radial artery graft. The bile duct strictures 
required revision to Roux-en-Y hepaticojejunostomy. All surviving 
recipients are living with their original grafts. There was a single mortality 
at 2 months posttransplant due to acute pancreatitis and sepsis. The 
mean overall follow-up was 35.1 months (range, 10-108). The metabolic 
abnormalities and catch-up growth were corrected; and renal function 
remained within acceptable limits.
Conclusion: Our pediatric LDLT experience in patients transplanted for 
metabolic diseases of the liver shows that normal metabolic balance and 
catch-up growth are restored posttransplant. Long-term follow-up after LT for 
shows excellent graft and patient survivals.
POSTER BOARD NUMBER P3 – 299
EATING BEHAVIOUR IN CHILDREN AFTER RENAL 1873 
TRANSPLANTATION
D.E. Mueller-Wiefel1, G. Holst1, S. Feile2, I. Landthaler3, S. Schley4, 
C. Sprengel5, U. Spiering6, S. Steinmann7
1University Children’s Hospital, Hamburg, Germany, 2University Children’s 
Hospital, Heidelberg, Germany, 3University Children’s Hospital, Munich, 
Germany, 4University Children’s Hospital, Berlin, Germany, 5University 
Children’s Hospital, Essen, Germany, 6University Children’s Hospital, 
Cologne, Germany, 7University Children’s Hospital, Hannover, Germany
Nutrition as a major life-style parameter with predominant roots in childhood 
essentially contributes to long-term survival especially in chronic renal failure 
even after renal transplantation. We therefore analyzed eating behaviour in a 
total of 238 (139 male, 99 female) children (age 2 - 18, mean 12.4 yrs) treated 
over a mean period of 4.4 (at least 0.5) yrs after RTx in 7 German transplant 
centres. 38% (60% male, 40% female) of them had been tube-fed over a mean 
period of 29 months with a maximal range up to 9 yrs. Data were retrospectively 
collected by means of a food frequency questionnaire on a vast spectrum of 
nutrients, differentiating between optimal, adequate and inadequate eating 
behaviour. Consumption of healthy nutrients like fruit was equally distributed 
between optimal (31%), adequate (33%) and inadequate (36%), however with 
a low optimal incidence in obese boys (10%), in contrast to obese girls (62%). 
Vegetable consumption was far better and optimal in 42, adequate in 36 and 
inadequate in only 23%, respectively. Dairy products served as negative example 
and their consumption was optimal in only 28, adequate in 30, but inadequate 
in 42%, with evidently better results in formerly tube-fed boys (optimal 42%) 
and girls (optimal 43%). Best results were achieved with basic nutrients (rice, 
potatoes, noodles): optimal 58, adequate 34, and inadequate only 8%, even 
better than with meat: optimal 58, adequate 16, and inadequate 35%, or even 
wholemeal bread: optimal 24, adequate 29, and inadequate 47%. The use of 
chocolate was still worse (inadequate 52%), whereas fast food consumption 
was at least adequate in 72%. Best results were achieved with the drinking 
behaviour of water and tea (optimal 82%). Data demonstrate that the eating 
behaviour of transplanted children and adolescents is scattered over a wide 
range, and is usually more unfavourable than in normals, so that nutritional 
education should play a major role in the medical care of transplanted children 
and their parents.
POSTER BOARD NUMBER P3 – 300
NUTRITIONAL STATUS IN CHILDREN AFTER RENAL 1874 
TRANSPLANTATION
D.E. Mueller-Wiefel1, G. Holst1, E. Bürkel2, I. Landthaler3, S. Schley4, 
C. Sprengel5, U. Spiering6, S. Steinmann7
1University Children’s Hospital, Hamburg, Germany, 2University Children’s 
Hospital, Heidelberg, Germany, 3University Children’s Hospital, Munich, 
Germany, 4University Children’s Hospital, Berlin, Germany, 5University 
Children’s Hospital, Essen, Germany, 6University Children’s Hospital, 
Cologne, Germany, 7University Children’s Hospital, Hannover, Germany
To evaluate the nutritional status after renal transplantation (RTx) we 
performed a multicentre cross-sectional study in a total of 238 (139 male, 99 
female) children (age 2 - 18, mean 12.4 yrs) treated over a mean period of 4.4 
(at least 0.5) yrs after RTx in 7 German transplant centres. 38% (60% male, 
40% female) of them had been tube-fed over a mean period of 29 months with 
a maximal range up to 9 yrs. Data were collected as body mass index (BMI, 
kg body weight / m2 height) and classifi ed as normal between the 10th and 
90th, as underweight below the 10th, as overweight above the 90th percentile, 
calculated by the “Working Group of Obesity in Childhood and Adolescence 
of the German Society of Obesity” and compared with a representative 
cohort of 17.641 healthy 0-17 yrs old children and adolescents in Germany 
(collected by the “Robert-Koch-Institute”) as controls (C). In 68.8% of the 
transplanted children the nutritional status was normal with 70% in males and 
68% in females, respectively, however with a 10% lower incidence compared 
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to C in males as well as in females. 12.6% of transplanted children suffered 
from underweight and 18.5% from overweight compared to 7% and 15% in 
C, respectively. In boys there was a higher incidence of underweight (15%), 
whereas in girls the incidence of overweight (23%) was higher. In formerly 
tube-fed children the normal nutritional status was comparable to the non tube-
fed children (70 vs. 68.8%), however with an overrepresentation of underweight 
(16.7 vs. 10%) but an under representation of overweight (13.3 vs. 22%). A 
change of the distribution of the nutritional status within the course of time 
could not be observed in non-tube fed children, whereas after tube-feeding no 
child had overweight within the 1st year after RTx and the highest amount of 
a normal nutritional status could be achieved after 5 yrs (82%). Taken together 
after RTx there is an increased risk for overweight in girls and underweight in 
boys, whereas tube-feeding in the pre RTx period seems to be associated with 
a positive nutritional long-term effect.
POSTER BOARD NUMBER P3 – 301
ANTIOXIDANTS, TOTAL HOMOCYSTEINE AND LIPIDS 1875 
AFTER PEDIATRIC KIDNEY TRANSPLANTATION (KTX)
M.J. Kemper, N. Rink, N. Melikyan, B. Finckh, D.E. Müller-Wiefel
Pediatric Nephrology
Experimental data indicate that oxygen free radicals, total homocysteine and 
lipids are involved in acute postoperative but also long-term tissue damage 
after KTx. Clinical data however are very scarce, especially in children. We 
hypothesized, that antioxidant mechanisms are reduced after pediatric KTx 
exposing the patient to a higher risk of ROS damage. We therefore studied 
vitamin A and E, total homocysteine and lipid profi le in 31 children after renal 
transplantation and 20 age and sex matched controls. Patients did not receive 
vitamin supplements. Median age was (range 3-18) years, and median time after 
KTx was 44 (range 10-121) months. Mean vitamin A and E plasma levels were 
signifi cantly higher after KTX than in controls (1.04±0.41 and 4.1±2.0 mg/l 
versus 0.66±21 and 9.0±2.1 mg/l, p< 0.001 and p<0.02, respectively. Vitamin 
A and E levels corrected to total lips, were similar between KTx and controls, 
however and also total homocysteine concentration did not differ between the 
groups. However fasting triglyceride levels were signifi cantly higher after 
KTx (197±152 vs 109±46 mg/dl, p<0.01), resulting in signifi cantly lower 
total lipis (p<0.002), although cholesterol, HDL and LDL were comparable. 
Vitamin A levels correlated with serum-creatinine (r=0.66, p<0.0001) and 
age (r=0.43, p<0.02) and with vitamin E (r=0.50, p<0.005). Vitamin A and E 
showed a strong association with total lipids (r=0.62 and 0.57, p<0.0001 and 
p<0.001, respectively), both, triglyceride and cholesterol levels. In summary 
and conclusion there is no defi ciency of vitamin A and E in our cohort of 
children after KTx, however this might be related to hypertrigliceridemia. 
Whether this results in antioxidant mechanisms, that may have an important 
impact on long-term graft function or is an epiphenomenon of hyperlipidemia, 
deserves further study.
POSTER BOARD NUMBER P3 – 302
LACK OF RELATIONSHIP BETWEEN EARLY DMSA 1876 
SCAN APPEARANCE AND LONG TERM FUNCTION OF RENAL 
ALLOGRAFTS
A. LePage1, S. Kennedy1, G. Kainer1, F. Mackie1,2, M. Rossleigh1,2, 
A. Rosenberg1,2
1Sydney Children’s Hospital, 2University of New South Wales, Sydney
Introduction: We previously reported the results of DMSA scans of allograft 
kidneys performed in 19 children within 2 years of transplantation:- 10 allograft 
kidneys were normal (group 1), but 9 showed striking defects in isotope uptake 
with large cortical defects (group 2) (J Nucl Med 32: 1542-4, 1991).
Aim: To determine whether early abnormal DMSA scan appearance is related 
to longterm graft function.
Methods: Serum creatinine values were obtained at longterm follow up. 
Creatinine clearance was estimated by the methods of Counahan-Barratt (for 
children) or Cockroft-Gault (for adults), as appropriate.
Results: Follow up data was available for 7 / 10 patients in group 1 and 7 / 9 
in group 2. There was no signifi cant difference in graft loss (1 in group 1, 3 in 
group 2). The median follow-up period was 8 years; there was no difference in 
mean creatinine clearance between the groups (group1 40.7 ml/min/1.73sqm 
vs 37 ml/min/1.73sqm).
Conclusion: We found no correlation between the early DMSA scan appearance 
of renal allografts and their longterm function.
POSTER BOARD NUMBER P3 – 303
SUCCESSFUL TRANSPLANTATION OF KIDNEY AND 1877 
LIVER GRAFTS FROM PEDIATRIC CARDIAC DEATH 
DONORS
W. Van der Werf1, L. Belnap1, E. Roach2, S. Bratton3
1Division of Abdominal Transplant, Department of Surgery, Intermountain 
Medical Center, 2Intermountain Donor Services, 3Department of Pediatrics, 
Primary Children’s Medical Center, Salt Lake City, Utah, United States
The shortage of cadaveric donors has led many transplant centers to expand 
their criteria for accepting life-saving organs. Utilization of donation after 
cardiac death (DCD) donors has been estimated to increase the number of 
cadaveric donors. We report our experience with a recently established DCD 
program at a pediatric hospital and the outcome with the transplanted grafts.
Methods: In 2005 to 2006 all patients undergoing withdrawal of care were 
evaluated for DCD. Patients meeting criteria for DCD underwent withdrawal 
by the critical care team and organ retrieval was initiated if asystole was reached 
in less than 60 minutes. In addition, one DCD liver was imported and was 
included in the liver results. Results: During the 2 year study period 7 patients 
(25% of total donors) underwent DCD resulting in 14 organs (11 kidneys and 
3 livers) transplanted. The 7 cases had a mean donor age of 9 yrs (range 3-16), 
WIT of 22 min (9-55), time sBP < 60 of 11 min (7-15), and time from asystole 
to aortic fl ush of 8 min (6-12). Four kidneys were transplanted locally with CIT 
5-14 hrs, no DGF, and one month creat 1.2-1.7. The remaining 7 kidneys were 
exported for transplant. Four livers were transplanted locally with donor age 7 
mth-16 yrs, WIT 12-28 min, recipient age 14 mth-61 yrs, CIT 6-15 hrs, AST 
peak 190-3630, AST day 7 33-44, INR peak 1.4-1.8, INR day 7 1.0-1.1, Total 
Bili one month 0.3-1.0, and all grafts functioning at 1.5-2.9 yrs. There were 
no vascular or biliary complications. Conclusions: A protocol for DCD at a 
pediatric hospital increased the number of pediatric cadaveric donors by 25%. 
Liver and kidney grafts from pediatric DCD donors demonstrated excellent 
graft function and survival.
POSTER BOARD NUMBER P3 – 304
BASILIXIMAB DOSE IN PEDIATRIC RENAL 1878 
TRANSPLANT BASED ON PHARMACOKINETIC DATA
T. Nagai1, Y. Goth2, K. Uchida3
1Aichi Children’s Health And Medical Center, 2Naogya Daini Red Cross 
Hospital Kidney Center Pediatrics, 3Naogya Daini Red Cross Hospital 
Kidney Center Surgery
Objective: Apart from adults, basiliximab is also being established for use 
in pediatric renal transplant worldwide. However, its pharmacokinetics in 
pediatric patients, particularly those weighing 35 kg or less, have hardly been 
investigated. This study examined the setting of the dose and maintenance of 
effi cacy and the results are hereby reported.
Methods: The subjects were 11 de novo pediatric renal transplant recipients. 
Of these, 2 underwent the transplant due to relapse of nephrosis and bleeding. 
Three (weighing 35 kg or more) received two administrations of basiliximab 
20 mg and 6 (weighing less than 35 kg) received two administrations of the 
10 mg dose. All the subjects received two administrations of basiliximab. The 
fi rst administration was on the day of the transplant (Day 0 post transplant) 
and the next one four days post transplant. Subjects weighing at least 35 kg 
received the 20 mg dose and those weighing less than 35 kg, the 10 mg dose. 
The drug was administered by intravenous drip infusion over about 20 min. 
Serum concentration of basiliximab was measured over time by enzyme-linked 
immunosorbent assay over 12 weeks. All the subjects received concomitant 
immunosuppressant therapy that consisted of cyclosporine, prednisolone, and 
mycophenolate mofetil. Serum concentration was measured by body weight 
group and the PK profi le determined.
Results: Maximum serum concentration for the three subjects that weighed at 
least 35 kg was a mean of 8.7ƒÊg /mL¦ i2.9-12.4¦ j after the fi rst administration 
and 9.7ƒÊg /mL¦ i3.6-14.1¦ j after the second administration. Although there 
was no subject where the reported effective plasma concentration of basiliximab 
of 0.2ƒÊg/mL was maintained for up to 12 or more weeks, the effective 
threshold maintenance period was 56-60 days in the subjects weighing at least 
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35 kg and 42-55 days in those weighing less than 35 kg. The dose/weight ratio 
was 0.290-0.971, which is a broad range. When divided into the low-ratio 
group (one subject), moderate-ratio group (six subjects) and high-ratio group 
(two subjects), the effi cacy maintenance period was 46-55 days with the low 
and high-ratio groups and 70-84 days with the moderate-ratio group.
Conclusion: Analysis of the PK data of basiliximab revealed that there is no 
fi xed rule regarding dose per weight and effi cacy maintenance period. The high-
ratio group will consist of children with a low age and therefore, the metabolic 
rate of IgG may have an effect. However, the low-ratio group will consist of 
children weighing about 35 kg, but in this group, the effi cacy maintenance period 
will not be shortened and adequate immunosuppressant effect can be obtained.
POSTER BOARD NUMBER P3 – 305
PREVALENCE OF POLYOMAVIRUS VIRURIA (JCV/BKV) 1879 
IN CHILDREN AFTER LIVER TRANSPLANTATION
F. Brinkert, P-M. Kaulfers, M.J. Kemper, R. Ganschow
Department of Pediatrics, University Medical Center Hamburg-Eppendorf, 
Germany, Department of Medical Microbiology, Virology and Hygiene, 
University Medical Center Hamburg-Eppendorf, Germany
BK virus infection is a known cause of morbidity and graft loss after kidney 
transplantation. But as well in nonrenal organ transplant patients, polyomavirus 
infection has potential implication in renal dysfunction. Furthermore, 
polyomaviruses are tumor inducing viruses and molecular data suggest an 
association with malignancies among solid organ transplant patients. JC virus 
is the causative agent of progressive multifocal leukoencephalopathy (PML) 
which is reported in solid organ transplant recipients.
We performed a prospective prevalence study at an average of 2187 (20-5671) 
days after transplantation in 100 consecutive children admitted for the yearly 
follow-up examination post liver transplantation. The urine was screened 
for BKV and JCV DNA by using a quantitative PCR in each case. A plasma 
analysis by PCR was added if more than 100.000 copies/ml urine were detected. 
Additional data regarding date of transplantation, immunosuppressive agents 
and kidney function (GFR) were collected.
BKV or JCV DNA was found in 19% (n=19) of our patients. 15 patients had 
BK, 4had JC viruria. Only three (2 BKV, 1 JCV) had more than 50.000 copies/
ml urine, but no DNA was detected in the plasma. All patients were free of 
clinical signs of viral infection, PML or nephropathy. GFR was normal in all 
patients and we found no statistical difference between patients with and without 
BK/JC viruria. 15 out of 19 patients had a cyclosporine or tacrolimus mono 
immunosuppressive therapy, 4of them had additional mycophenolic mofetil. 
None of the 3 patients with high viruria had an intensifi ed immunosuppression.
We found a higher prevalence of polyomavirus viruria in our pediatric liver 
transplanted children than reported in adult patients. But only more than 
100.000 copies/ml urine, (3 patients) and high plasma levels (not detected), are 
reported with renal dysfunction. The extent of immunosuppressive therapy had 
no infl uence on the polyomavirus infection. Further studies are needed to assess 
the risk of polyomavirus infection in children following liver transplantation.
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DEFINITIVE ABDOMINAL WALL CLOSURE 1880 
USING A BIODEGRADABLE MEMBRANE FROM 
PORCINE INTESTINAL SUBMUCOSA IN PEDIATRIC 
TRANSPLANTATION
J. Karpelowsky, G. Thomas, A. Shun
Department of Pediatric Surgery Children’s Hospital At Westmead, Australia
Introduction: Abdominal closure in children less than 10kg post transplantation 
can be challenging. Excessive pressure used to attain closure can result in 
abdominal compartment syndrome, graft compromise and loss. Concerns over 
using prosthetic patches are that of infection and dehiscence. We report a series 
of defi nitive abdominal wall closure using a Biodegradable Membrane from 
Porcine Intestinal Submucosa (Surgisis®-Cook Il USA)
Method: A prospective collection and follow up of liver and kidney transplant 
patients weighing less than10 kg who required abdominal wall augmentation 
with Surgisis® in order to achieve safe closure.
Results: There were 10 liver transplant patients and 2 renal transplant patients. 
The average weight of the liver transplant patients was 6.59kg(5.4-8.5Kg) and 
the renal 9.8kg. The average area od Surgisis® used was 71.2cm2 (25-160 cm2) 
and length of follow up was 15.3 months (1-27months).. Systemic complications 
were one death fro multiple organ failure at 1 month post transplant secondary to 
concomitant pathology (combined immune defi ciency syndrome) and one patient 
with hepatic artery thrombosis which was salvaged at re-look. Concomitant 
measures to aid abdominal closure were recipient nephrectomy for the renal 
patients and reduction by 33% of the lateral segments in 2 patients. Delayed 
closure occurred in all patients except one and the average days to closure from 
the fi rst surgery was 3.75 days (0-6 days). There were two wound complications 
One patient developed 2 small sinuses and some skin dehiscence which healed 
over 4 months and the second developed a skin sinus following trans patch liver 
biopsy which healed in 3 weeks. Both had positive microbial cultures but neither 
necessitated removal of the graft. There were no incisional hernias.
Conclusion: Surgisis® is a safe method for abdominal closure in transplant 
patients. It appears to have long term durability with no incisional hernias in 
the series of patients, and fairly resistant to infection.
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INTRA- AND INTERPERFORMER VARIABILITY OF 1881 
KAOLIN-ACTIVATED THROMBOELASTOGRAPHY IN 
CHILDREN
J.F. Goorhuis, S.E. Timmerman, M.J.I.J. Albers
Department of Pediatrics, Division of Pediatric Intensive Care, Beatrix 
Children’s Hospital, University Medical Center Groningen, University of 
Groningen
Introduction: Thromboelastography (TEG®) is a whole blood coagulation 
test measuring the viscoelastic properties of blood during the dynamic process 
of blood clotting and blood lysis. During hepatic surgery in adults and children 
TEG® analysis proved useful in assessment of coagulopathies allowing 
optimization and reduction of blood product selection. Performance of TEG 
® in a point of care setting has not been assessed. We therefore studied the 
intra- and inter performer variability of TEG® performed by nurses in a tertiary 
paediatric intensive care unit.
Methods: In a prospective observational study (approved by the medical ethical 
board commission) 100 paired kaolin TEG® samples (50 paired samples in 
each group) were compared for intra- and interperformer variability of reaction 
time and maximum amplitude by Bland Altman analysis.
Results: Table 1. Mean differences and 95% confi dence interval of differences of 
TEG® values reaction time (R) and maximum amplitude (MA) in both groups. 
Mean (min-max) 
measured values (n 
= 100)
Intraperformer 
variability (n=50)
Interperformer 
variability (n=50)
R (sec) 512 (70-1640) -7 (-45 – 32) 28 (-20 – 75)
MA (mm) 62 (25-88) 0,8 (-0,1 – 1,7) 1,3 (0,2 – 2,3)
Conclusions: In the setting of a tertiary paediatric intensive care unit TEG® 
performed by trained nurses has narrow limits of agreement for intra- and 
interperformer variability, that allow its clinical use to guide hemostatic 
management (after transplantation).
POSTER BOARD NUMBER P3 – 308
LONG-TERM OUTCOME OF INTENSIVE INITIAL 1882 
IMMUNOSUPPRESSION PROTOCOL IN DECEASED DONOR 
RENAL TRANSPLANTATION IN CHILDREN
O.K. Olaitan, J.A. Zimmermann, W. Shields, G. Rodriguez, P. Mohan, 
D.M. Little, D.P. Hickey
National Kidney and Pancreas Transplantation Centre, Beaumont Hospital, 
Dublin, Ireland
Aim: To report long-term outcome of deceased donor kidney transplantation in 
children using intensive initial immunosuppression protocol.
Method: All children less than 18 years that had deceased donor kidney 
only transplant between January 1991 and December 1997 were included; 
82 renal allografts were transplanted into 75 children. Mean recipient age at 
transplantation was 12.9 years and the mean follow-up period was 12.6 years. 
All patients received quadruple immunosuppression with steroid, cyclosporine, 
azathioprine and rabbit anti-thymocyte globulin (R-ATG-Fresenius®).
Results: Actual 1, 5 & 10 year patient survival rates were 99%, 97% 
& 94% respectively; only one patient (1.2%) developed post-transplant 
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lymphoproliferative disorder (PTLD). Actual 1, 5, & 10 year overall graft 
survival rates were 84%, 71% & 50% respectively; there were 5 cases (6%) of 
graft thrombosis and the actual immunological graft loss was 14.6%. The long-
term survival rates of the fi rst grafts were superior to that of the retransplant 
grafts but were not statistically signifi cant (P=0.69). The long-term graft 
survival rates of the pre-emptively transplanted patients were superior to that of 
those maintained on dialysis prior to transplantation but were not statistically 
signifi cant (P=0.66).
Conclusion: The use of R-ATG resulted in excellent immunological graft 
survival without an increase in PTLD or other neoplasms over a minimum 
10-year follow up. We conclude that R-ATG is safe and results in excellent 
long-term graft survival.
POSTER BOARD NUMBER P3 – 309
DE NOVO AUTOIMMUNE HEPATITIS AFTER 1883 
25 DAY NEWBORN BABY LIVING DONOR LIVER 
TRANSPLANTATION
H. Oya1, Y. Sato1, S. Yamamoto1, T. Kobayashi1, T. Watanabe1, H. Okajima2, 
K. Asonuma2, Y. Inomata2, K. Hatakeyama1
1Division of Digestive And General Surgery, Niigata University, 2Department 
of Transplantation and Pediatric Surgery, Kumamoto University
De novo autoimmune hepatitis has been recently described as a new type of 
graft dysfunction in pediatric patients receiving liver transplantation. We report 
a case of a boy, diagnosed as neonatal hemochromatosis, received a reduced 
left lateral graft 25 days after birth. Pretransplant autoantibodies and serological 
tests were negative. Postoperative course was smooth and the episode of 
vascular, biliary complication and acute cellular rejection was not observed. 
The immuosuppressants was tacrolimus only. Liver dysfunction occurred 13 
months after living donor liver transplantation. Liver biopsies showed no acute 
cellular rejection but apoptosis of liver cells at the centrolobular area. At that 
time, various autoantibodies including anti-nuclear antibodies, anti-double 
stranded DNA antibodies, and anti-smooth muscle antibodies. In addition, 
serum IgG was elevated. Based on these fi ndings, he was diagnosed as de novo 
autoimmune hepatitis. The treatment consisted of reducing the dose of tacrolimus 
and reinduction of steroids. After 12 months treatment, liver dysfunction was 
improved, serum autoantibodies became negative and serum IgG level had 
normalized. Presently, 26 months after liver transplantation, the patient is doing 
well with normal liver function tests and no positive antibodies. Currently his 
immunosuppressive therapy consists of low dose tacrolimus and prednisolone. 
In conclusion, the present case demonstrates that de novo autoimmune 
hepatitis can appear in living donor liver transplant patients despite appropriate 
immunosuppression. Reducing the dose of tacrolimus and reinduction of 
prednisolone could sustain the graft and prevent retransplantation.
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PRE TRANSPLANT SURGERY FOR CORRECTION OF 1884 
UPPER AND LOWER URINARY TRACT ABNORMALITIES IN 
PEADIATRIC PATIENTS IMPROVE GRAFT 
SURVIVAL/OUTCOME
S. Akhter, M.W. Iqbal, M.T. Talib, M.A. Khawaja
Shifa International Hospital
Introduction: It is well recognized that optimization of urinary tract prior 
to renal transplant has improved the graft outcome. Recurrent UTI and high 
pressure in bladder are well known to be detrimental to graft survival/outcome.
Methods: At Shifa International Hospital Islamabad, Pakistan 12 Paediatric 
Transplants were done between August 2002 and February 2008, with median 
follow up of 56 months. Age ranged between 6 - 16 years and weight between 
13-50kg. Six were male and 6 were female. The causes of ESRD included 
1 case of stone disease, 5 cases of neurogenic bladder/vesicoureteric refl ux 
with recurrent urinary tract infections, 1 focal segmental glomerulosclerosis, 
1 chronic Glomerulonephritis, 1 posterior urethral valve and 3 unknown. Five 
cases underwent pre transplant Nephrectomy among them three underwent 
nephroureterctomy and Augmentation cystoplasty with mitrofanoff. All patients 
were induced with single dose Anti Thymocytic Globulim (ATG) (9mg /kg) 
except one with simulect, who had reaction with ATG, Cellcept and Solumedrol. 
Neoral was started when the serum creatinine became less then 50%. Eleven 
patients underwent transplantation via intraperitoneal approach, renal vessels 
were anastomosed to aorta and inferior vena cava, while one transplant was 
done extraperitoneally with anastomosis with external iliac vessels. All ureteric 
reimplantations were done by standard lich gregoir technique.
Results: To date patient survival and graft survival is 100%. One patient 
had delayed graft function that resolved without the need of dialysis. Mean 
creatinine level was 1.6mg/dl.rate. Acute rejection rate was 33.3%(4), 3 were 
salvaged by ATG and one by solumederol. Two patients had urinary tract 
infections. One patient had acute pancreatitis and one patient had mitrofanoff 
failure, which had to be redone using appendix.
Conclusion: Pre Renal Transplant surgery for correction of upper and lower 
urinary tract abnormalities is a safe and effective option to improve graft 
outcome and survival in pediatric patients.
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EPSTEIN-BARR PCR IN KIDNEY-TRANSPLANTED 1885 
CHILDREN IS ANOTHER PARAMETER TO INDIVIDUALICE 
IMMUNOSUPPRESSION
R. Vilalta1, E. Lara, A. Madrid, A. Vazquez, S. Chocron, A. Casquero, J. Nieto
1Hospital Infantil Vall DHebron Barcelona, 2Id, 3id, 4id, 5id, 6id, 7id
Background: Despite “normal” blood levels of immunossuppressors, some 
kidney-transplanted children exhibits oportunistic infections by different 
pathogen agents. Between them, one of the most signifi cants is Epstein-Barr 
virus (EBV), because is related to posttransplant lymphoproliferative disorder 
(PTLD) and also with other clinical situations in which there are polyclonal 
expansion of B-lymphocytes, for exemple febrile-necrotic tonsillitis. Drastic 
reduction or withdrawal of immunosuppression added to anti-viral therapy 
with valganciclovir for EBV is the primary treatment of both entities, plus 
rituximab in PTLD.
Case report: A youg boy,(IgG EBV positive) 6 years-old received a cadaveric 
kidney transplant (EBV negative) at 5 years of age because an hemolitic-uremic 
syndrome.He was treated with basiliximab, FK, mophetil mycophenolate 
(MMF) and tappered steroids. The immediate post-trasplant period was 
uneventful. FK levels were maintained between 8 and 10 ng/ml and MMF 
between 1 and 1.5 mcgr/ml.
Evolution: At the month 8 post-transplant, he developped a febrile-necrotic 
tonsillitis with a PCR title of 77.000 copies, and an histologic study showed 
polyclonal expansion of B-lymphocites. Immnunossupresion was reduced to 
obtain FK levels of 2-2.5 and MMF of 0.8-1.2. Valganciclovir oral was started 
(400mg /m2/24h).
4 weeks later, PCR EBV title was 47.000, with no healing of tonsille lesions. 
8 weeks later, PCR EBV under 5000 copies was achieved with resolution of 
tonsille lesions. Valganciclovir was maintained for 3 months. In a 6-months 
follow-up PCR EBV tittle was maintained under 5000 copies with an optimal 
renal function (creatinine 0.4mg/100ml).
Conclusion: PCR EBV monitoring of kidney-transplanted children could 
anticipate or at less help control of non-PTLD EBV disorders, and always 
indicates valganciclovir treatment (if PCR EBV copies are over 5.000) and 
also a drastic reduction of immunossuppressor levels.
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FOLLOW-UP OF CYTOMEGALO- UND ADENOVIRUS-1886 
SPECIFIC T CELLS DURING THE FIRST YEAR AFTER 
PEDIATRIC KIDNEY TRANSPLANTATION
T. Ahlenstiel1, U. Sester2, M. Sester2, A. Heim3, L. Pape1
1Medical School of Hannover, Department of Pediatric Nephrology, 
2University of the Saarland, Department of Nephrology, 3Medical School of 
Hannover, Department of Virology
Introduction: Post-transplant immunosuppression leads to impaired 
cellular immune defense resulting in increased risk for severe virus-induced 
complications, e.g. by Cytomegalo Virus (CMV) and Adenovirus (ADV). Post-
transplant follow-up of virus-specifi c T-cells might serve as marker to estimate 
the individual risk to develop virus-induced diseases.
Method: Within a prospective longitudinal study we monitored CMV- and 
ADV-specifi c T cells in 16 pediatric patients (aged 1-16 years) during the 
fi rst year after kidney transplantation. The immunosuppression consisted of 
basiliximab, prednisolon, ciclosporin and everolimus. No antiviral prophylaxis 
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was performed independent of donor/recipient CMV-status. In case of 
detectable CMV-DNA we started preemptive intravenous antiviral therapy 
with ganciclovir.
T cells were stimulated with CMV and ADV antigen in vitro. Based on specifi c 
cellular activation and induction of intracellular cytokines, the frequency of 
CMV and ADV-specifi c CD4-T cells was determined using fl ow cytometry. 
Viral load was quantifi ed by PCR. Serologic studies were performed for CMV.
Results: Prevalence of CMV-specifi c T cells correlated with CMV-serology: 
The CMV-seronegative children never showed detectable CMV-specifi c T 
cells. In case of primary CMV-infection (2 out of 16) we found an increasing 
level of CMV-specifi c T cells simultaneously with a decrease of CMV-DNA-
load. The level of CMV-IgG-titres did not correlate with the quantity of virus-
specifi c T cells.
Asymptomatic ADV-infections were characterized by boost of ADV-specifi c T 
cells without relevant detection of ADV-DNA.
As long as the virus–specifi c T cells remained at a constant detectable level, we 
found no virus-reactivation.
Conclusion: Virus-specifi c T cells represent a parameter for control of virus 
replication. After transplantation an insuffi cient level of virus-specifi c T cells 
is probably associated with increased risk of virus-induced complications. 
Accordingly, virus-specifi c T cells might serve as prognostic marker to estimate 
the individual risk for post-transplant virus-diseases. Therefore virus-specifi c 
T cells might improve posttransplant management and optimize individual 
timing of antiviral therapy. Moreover, virus-specifi c T cells probably offer 
the possibility for effect-related drug monitoring by quantifying individual 
inhibitory effects of immunosuppressive drugs. Further studies will have to 
determine the minimal level of virus-specifi c T cells needed for effective 
protection against viral disease.
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STEROID-FREE IMMUNOSUPPRESSION IN 1887 
PEDIATRIC RENAL TRANSPLANTATION 
– LONG TERM FOLLOW-UP ANALYSIS
R. Esmeraldo1, P. Pinheiro1, M. Oliveira1, C. Ponte1, M. Donadi1, S. Costa1, F. 
Paes1, C. Soares1, R. Evangelista2
1Hospital Geral de Fortaleza, 2Universidade Federal do Ceara
Background: Despite their well-recognized adverse effects, corticosteroids 
are still the mainstay of immunosuppressive protocols for renal transplant 
recipients, but successful attempts at steroid withdrawal or steroid avoidance in 
adult and pediatric renal transplant patients were already reported. The goal of 
this study was to test the safety and effi cacy of a steroid-free immunosuppressive 
protocol in pediatric renal transplant patients, in a long-term follow-up.
Methods: In a prospective, nonrandomized clinical study 36 nonsensitized 
pediatric recipients of fi rst renal allografts (age between 3-17 years; mean = 12.5 
years) received induction therapy with daclizumab (n = 32), thymoglobulin (n = 
3) or basiliximab (n = 1), in combination with Tacrolimus and Mycophenolate 
Mofetil (MMF)or Sodic (MMS). Protocol biopsies were performed at 3, 6, and 
12 months posttransplantation. Clinical outcomes were analyzed.
Results: At a mean follow-up time of 38,2 months (range 2-79 months), patient 
and graft survival were 100% and 92%, respectively. Only 2 patients (5,5%) 
experienced biopsy proven acute rejection during the fi rst year posttransplant, 
one graded Banff borderline and the other Banff IIA. Both cases were readily 
reversed, one with methylprednisolone and the other with OKT3. Protocol 
biopsies revealed 4 patients with borderline lesions and 1 patient with mild 
chronic allograft nephropathy (Banff grade I). Mean serum creatinine was 1.0 
+/- 0.9 mg/dl at discharge, 1.0 +/- 0.4 mg/dl at 6 months, 1.1 +/- 0.4 mg/dl at 
12 months, 1.4 +/- 1.2 mg/dl at 24 months, 1.3 +/- 0.4 mg/dl at 36 months, 1.4 
+/- 0.6 mg/dl at 48 months, and 1.4 +/- 0.5 mg/dl over 5 years posttransplant. 
Lipid levels were not signifi cantly different from pre-operative levels. Four 
patients (11%) presented cytomegalovirus disease. One patient (2,8%) 
presented posttransplant Diabetes Mellitus. Despite excellent renal function, 
hemoglobin was only normalized between 6 and 12 months.
Conclusions: The use of induction therapy followed by tacrolimus and MMF 
or MMS allowed complete avoidance of steroids in this selected group of 
patients. This protocol has the advantage of avoiding the side effects of steroids 
without increasing the prevalence of acute rejection episodes, while providing 
long term graft function.
POSTER BOARD NUMBER P3 – 314
REFERENCE DEPENDENT VARIABILITY OF BONE 1888 
MINERAL DENSITY (BMD) CHANGES IN PEDIATRIC KIDNEY 
TRANSPLANT RECIPIENTS
L.A. Hamiwka, M. Hanna, J.P. Midgley, A.W. Wade, S. Grisaru
Southern Alberta Renal and Transplant Program, Alberta Children’s Hospital, 
Division of Pediatric Nephrology, Calgary, Alberta, Canada
In children, interpretation of BMD values requires estimation of z-scores related 
to an age and gender matched healthy pediatric population. Calculation of 
volumetric BMD (vBMD) is more appropriate in growing children. Currently 
there are 3 major references for lumbar spine BMD z-scores in children: Hologic 
Inc., Bachrach et al and Kalkwarf et al. We have recently reviewed a cohort of 
pediatric kidney transplant recipients who have been longitudinally followed 
before and after kidney transplant with yearly dual energy x-ray absorptiometry 
(DXA) bone mineral density measurements. We herein report the estimated 
z-score values in our cohort of 40 pediatric renal transplant recipients using the 
3 references currently available for clinical practice.
Methods: Lumbar spine BMD measurements were obtained using DXA 
(Hologic QDR 4500W) prior to transplant and yearly thereafter. vBMD values, 
vBMD z-scores and areal BMD (aBMD) z-scores were estimated as described 
in the above mentioned references.
Results: Transplantation was associated with a signifi cant and sustained decline 
in both vBMD and aBMD which was directly related to cumulative steroid 
dose. Signifi cant differences in estimated z-score values we found between the 
3 references for both vBMD and aBMD.
Conclusion: BMD z-scores in pediatric kidney transplant recipients vary 
signifi cantly depending on the reference used, but all references showed 
a decline in both vBMD and aBMD post- transplant. The negative effect of 
transplant on BMD necessitates careful longitudinal BMD monitoring and 
minimization of steroid immunosuppression.
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DIAGNOSIS AND TREATMENT OF ACUTE REJECTION 1889 
CAUSED BY DONOR SPECIFIC ANTI-MICA ANTIBODY IN 
A HIGHLY SENSITIZED, PEDIATRIC RENAL TRANSPLANT 
RECIPIENT (MAJOR-HISTOCOMPATIBILITY-COMPLEX 
(MHC) CLASS-I RELATED CHAIN A ANTIGEN)
S. Narayan1, E. Tsai1, J.Q. Zhang2, E. Reed2, R. Ettenger1
1Mattel Children’s Hospital At UCLA, Department of Pediatrics, Division of 
Nephrology, UCLA Medical Center, Los Angeles, 2Department of Pathology, 
Immunogenetics Center, UCLA Medical Center, Los Angeles
Introduction: Recent studies have demonstrated that pre-transplant 
sensitization against MICA (Major-histocompatibility-complex class-I related 
chain A) antigens are associated with renal allograft rejection and failure. 
Because MICA antigens are expressed on endothelial cells, current cross-
match measures, using donor lymphocytes, fail to detect MICA antibodies. 
Furthermore, MICA antibodies are not routinely tested prior to transplantation. 
This case report describes the clinical course and treatment of donor specifi c 
MICA antibody mediated rejection in a pediatric renal re-transplant recipient.
Methods: The patient is a 14 year old female with end stage renal disease 
secondary to Branchio-oto-renal syndrome who lost her first graft due to 
recurrent rejection. Following allograft nephrectomy, she became highly 
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sensitized with panel reactive antibody greater than ninety-five percent. 
She remained on dialysis for four years. After pre-transplant desensitization 
with high dose IVIG (2g/kg once a month for four months) and Rituximab 
750mg/m2 for two doses, she received a cross-match negative, deceased 
donor transplantation. She was induced with anti-thymocyte globulin and 
continued on prednisone, mycophenolate mofetiel and tacrolimus. She 
maintained good allograft function until post-operative day ten when she 
presented with an acute rise in creatinine and anuria. A biopsy revealed acute 
cellular type 2 and antibody-mediated rejection diagnosed by complement 
4d (C4d) positive staining. She was treated with plasmapheresis and IVIG. 
Serial donor specific HLA antibody measurements remained negative. An 
extended search for a non-HLA antibody detected donor specific *012 
MICA antibody. Donor specificity was confirmed by MICA genotyping 
of the patient and donor. Serial anti-MICA antibody titers were measured 
using luminex technology using median fluorescence intensity. (See 
Figure one)
Results: Pre-transplant serum revealed the existence of pre-formed *012 
MICA antibody, with an elevated level at pre-transplantation and at the time 
of rejection. Resolution of rejection and return of patient’s graft function 
correlated well with the decline in MICA antibody titer following treatment 
with plasmapheresis and IVIG (see fi gure one). Interestingly, the MICA 
antibody titer increased during an episode of acute gastroenteritis, but continued 
to decline following the resolution of the illness and continuation of treatment 
with plasmapheresis and IVIG.
Conclusions: Our case emphasizes the importance of screening for donor 
specifi c MICA antibodies in re-transplant recipients, specifi cally when 
donor-specifi c anti-HLA antibodies are not detected during rejection. Current 
desensitization protocols using high dose IVIG and Rituximab may not 
effectively decrease MICA antibodies. Therefore, preformed MICA antibodies 
can lead to both acute antibody mediated and acute cellular rejection (type 2). 
Plasmapheresis followed by high dose IVIG may be an effective treatment of 
acute rejection caused by MICA antibodies.
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THE OUTCOME OF RENAL TRANSPLANTATION 1890 
IN CHILDREN WITH FSGS
E. Baskin1, U.S. Bayrakci1, H. Ozdemir2, B. Demirhan2, H. Karakayali3, 
S. Sevmis3, M. Haberal3
1Baskent University Faculty of Medicine, Department of Pediatric 
Nephrology, 2Baskent University Faculty of Medicine, Department of 
Pathology, 3Baskent University Faculty of Medicine, Department of General 
Surgery
Background: The recurrence of focal segmental glomerulosclerosis (FSGS) 
after renal transplantation has a potentially detrimental impact leading to 
the loss of renal function. Although, plasmapheresis (PF) and rituximab are 
commonly recommended the treatment is still a matter of debate.
Aim: We report our single-center experience to assess the outcome of the renal 
transplantation in children with FSGS.
Patients and methods: Medical records of 10 (F/M: 4/6) renal transplanted 
patients with FSGS were evaluated. Among 10 grafts 7 were from living related 
and 3 from deceased donor. The original diagnosis of FSGS as well as recurrences 
was biopsy-proven in all patients. All patients treated with calcineurin-based 
immunosuppressive therapy. PF was done at days -3,-2,-1 and 5 consequitive 
days following transplantation to all living related donor transplanted patients. 
Patients with deceased donation had only post-transplant PF.
Results: The mean age was 12.6±4.7 years. The mean duration of follow-up 
was 23.1±16.2 months. Two patients with hyperacute rejection were followed-
up for less than 1 month. One of them had biopsy-proven humeral hyperacute 
rejection while the second was implicating recurrence of FSGS. Post-transplant 
recurrence of FSGS was confi rmed in 3 (33%) patients and all of them were 
treated with pre and post-transplant PF while 2 have also received rituximab. 
Remission was obtained in 1 of 2 patients that have received rituximab while 
the other had responded partially. The one who did not receive rituximab had a 
graft loss at the 2nd month of transplantation.
Conclusion: Recurrence of FSGS in the transplanted kidney is a severe condition 
associated with graft loss. New therapeutic regimens and the effi cacy of rituximab 
and PF should be evaluated in prospective studies with large groups.
POSTER BOARD NUMBER P3 – 317
RITIXUMAB FOR POSTTRANSPLANT RECURRENCES 1891 
OF FSGS
E. Baskin1, U.S. Bayrakci1, H. Sakalli1, H. Ozdemir2, H. Karakayali3, 
M. Haberal3
1Baskent University Faculty of Medicine, Department of Pediatric 
Nephrology, 2Baskent University Faculty of Medicine, Department of 
Pathology, 3Baskent University Faculty of Medicine, Department of General 
Surgery
The recurrence of focal segmental glomerulosclerosis (FSGS) after 
transplantation is a well-known problem. Disease recurs in 30% of patients 
with FSGS receiving a fi rst renal transplant and in over 80% of patients 
receiving a second transplant after a recurrence. The pathogenesis remains 
unknown and may involve a circulating permeability factor that initiates 
injury to the glomerular capillary. Rituximab has been used to treat several 
glomerular diseases. B cells may play a role in the pathogenesis of recurrent 
FSGS. We report a 14-year-old boy whose primary kidney disease was FSGS 
developed severe recurrence of proteinuria immediately after a second living 
related kidney transplant. Despite pre and post operative plasmapheresis and 
immunosuppressive treatment consisting of steroids, cyclosporin A (CycA), 
daclizumab and mycophenolate mofetil (MMF), daily protein excretion and 
serum creatinine increased. We therefore administered rituximab on the 4th day 
of transplantation. He received 4 weekly doses of rituximab (375mg/m2/dose) 
which resulted in a rapid clearing of circulating CD19 and CD20 positive B 
cells and remission of proteinuria was achieved 6 weeks after the fi rst rituximab 
treatment. Graft function was excellent 6 months after transplantation with 
proteinuria of 8 mg/m2/h. We conclude that rituximab may be an effective 
treatment for post-transplant recurrence of FSGS.
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SUCCESSFUL CADAVERIC RENAL TRANSPLANTATION 1892 
IN A 3.9 KG INFANT
O. Amon1, A. Bosk1, P. Szavay2, J. Fuchs2, O. Beringer1, W. Steurer3
1Pediatrics, University Hospital of Tuebingen,Germany, 2Pediatric Surgery, 
University Hospital of Tuebingen,Germany, 3General,Visceral and Transplant 
Surgery, University Hospital of Tuebingen, Germany
A preterm infant with a birth weight of 2.700 gms and end-stage renal disease 
from posterior urethral valves had to be started on peritoneal dialysis shortly 
after birth. Because of multiple obstructions of the Tenckhoff catheter by 
fi brinous plugs,he was switched to intermittent hemodialysis via a Permcath 
catheter. Two life-threatening events, presumably related to his extreme arterial 
hypertension, lead to the decision to attempt an early renal transplantation. 
Augmentation cystoplasty was performed successfully, followed 6 weeks 
later by a cadaveric kidney transplantation with a 4-year old child as donor. 
The renal artery was anastomosed to the aortic bifurcation and the renal vein 
to the inferior vena cava.The graft immediately resumed full function. Body 
weight after transplantation was 3.9 kg and length 56 cm. Immunosuppression 
consisted of methylprednisolone, tacrolimus, mycophenolate mofetil and 2 
doses of daclizumab. Steroids were tapered and eventually stopped within 2 
months.The clinical course was uneventful during the 9 months up till now and 
the boy is thriving, with a current body weight of 7.8 kg. His serum creatinine is 
stable at 0.3 mg/dl. His blood pressure is normal without any antihypertensive 
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medication.
This has been the smallest infant worldwide to undergo renal transplantation 
up till now. From this experience we draw the conclusion, that augmentation 
cystoplasty (in case of a dysfunctional lower urinary tract) and kidney 
transplantation are viable options even in very small infants, if they experience 
life-threatening complications on dialysis.
POSTER BOARD NUMBER P3 – 319
SUCCESSFUL THERAPY OF A DISSEMINATED 1893 
CYTOMEGALOVIRUS (CMV) INFECTION WITH ORAL 
VALGANCICLOVIR IN A 4 YEAR-OLD BOY AFTER KIDNEY 
TRANSPLANTATION
O. Amon1, R. Beck2, O. Beringer1, P. Szavay3, J. Fuchs3, W. Steurer
1Department of Pediatrics, University Hospital of Tuebingen, Germany, 
2Department of Medical Virology, University Hospital of Tuebingen, Germany, 
3Department of Pediatric Surgery, University Hospital of Tuebingen,Germany, 
4Department of General,Visceral and Transplant Surgery, University Hospital 
of Tuebingen, Germany
A 3 year-old boy with a complex malformation syndrome developed end-
stage renal failure as a consequence of renal abscesses caused by multiple 
urinary infections and a recto-urethral fi stula. He was started on intermittend 
hemodialysis. One year later he received a kidney transplant from a CMV-
positive donor (the recipient being CMV-negative). During the transplantation 
an ileum conduit was created with implantation of the graft ureter into the 
conduit. He received standard immunosupperssion and induction therapy 
with daclizumab x 5. For CMV prophylaxis Ganciclovir i.v., followed by oral 
Valganciclovir (11 mg/kg/day) were administered. Additionally 4 infusions of 
CMV Hyperimmune Globulin (100 mg/kg each) were given.
3 months after transplantation CMV DNA as determined by PCR could be detected 
in the patients blood. The CMV DNA copy number was 14.000/ml plasma, 
indicating disseminated CMV infection. The viral load subsequently increased 
to 25.300 /ml plasma. The Valganciclovir dose was increased to 19 mg/kg daily. 
Within 2 weeks the CMV copy number decreased to less than 600/ml plasma. Two 
weeks later Valganciclovir could be stopped with a negative CMV PCR.
All the time the boy could be treated as an outpatient. The platelet count 
decreased transiently to 95.000/μl. Otherwise he experienced no adverse 
effects of the antiviral therapy.
From this experience we draw the conclusion that - depending on the clinical 
status, which was excellent all the time in our patient - outpatient oral 
Ganciclovir treatment may be an alternative therapeutic option to inpatient 
intravenous ganciclovir treatment for disseminated CMV infection after solid 
organ transplantation. Blood level determinations of the drug might be helpful 
in further exploring this therapeutic approach, which makes hospital admission 
of two weeks for intravenous therapy unnecessary.
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LOW DOSE HEPARIN INFUSION REDUCES 1894 
VASCULAR THROMBOSIS AFTER PEDIATRIC RENAL 
TRANSPLANTATION
P. Acott, J. Crocker
IWK Health Centre and Dalhousie University
The purpose of this study was to assess if low dose continuous heparin could 
reduce the risk and outcome of thrombosis in pediatric renal transplants. 
Thrombosis is an infrequent but signifi cant complication, which often leads to 
graft loss in the pediatric population with its smaller native vessel size, lower 
mean arterial pressure, and higher rejection rates. Pediatric thrombosis rates 
are 4-10% with increased rates in children ƒq6 y, cadaveric kidneys, with acute 
tubular necrosis (ATN), and in centres <50 transplants/decade. Five allografts 
(7.2%) in 69 consecutive pediatric renal transplants were lost secondary to 
vascular thrombosis in our program from 1971 - 1992.
Low dose continuous heparin (10 units/kg/hour) was routinely implemented for 
1 wk in high risk pediatric renal transplants: 1) age ƒq 6 yr; 2) laboratory profi le 
of hypercoagulability: Anti-Thrombin III < 80%, elevated fi brinogen, elevated 
Von Willebrand¡¦s Factor, or reduction of Protein C or S availability; 3) oliguric 
ATN > 24 h; 4) surgical complications with venous or arterial anastomosis; or 
5) past patient history of access thrombosis or vasculitis. Over the past 15 years 
(1992-2007), 80 children (19 ƒq 6 yr) have been transplanted and 40 received 
low dose heparin for one week. All received antibody induction therapy 
(ATG/ALG [n=31], Daclizumab [n=1] or Basiliximab [n=48]), calcineurin 
inhibitors (CyA [n=76] or FK506 [n=4]), anti-metabolites (azathioprine or 
Mycophenolate), and steroids. Surveillance renal scans were obtained on days 
1, 3, 5 and when clinical deterioration occurred. Graft survival at 1 year was 
>97.5%.
Only two thrombotic events were noted (2.5%) and did not cause graft loss: 
1) a 2 yr male LRD transplant with a venous thrombosis confi rmed and 
removed surgically 2hr post-op which occurred on heparin with stabilization 
of renal function thereafter; 2) a 17 yr female with a double renal artery 
cadaveric graft who developed arterial thrombosis of the smaller inferior 
renal artery on day 10 with heparin discontinued 3 days prior. One patient 
on heparin infusion for Anti-Thrombin III defi ciency required laparotomy 3 
hours after surgery for thrombosis external to the anastomosis, which was 
considered our only complication of low dose heparin therapy. One other 
patient not on heparin also required laparotomy in the fi rst 24 hours post-op 
for hematoma evacuation.
The risk and outcome of thrombosis was reduced by routine heparinization 
of our high-risk patients. Identifi cation, surveillance and treatment of 
children who are at high risk of thrombosis appears warranted. We report a 
low thrombosis rate and no organ loss despite a high proportion of high-risk 
patients < 6 yr.
POSTER BOARD NUMBER P3 – 321
SIROLIMUS CONVERSION IN PEDIATRIC BIOPSY 1895 
PROVEN CHRONIC ALLOGRAFT NEPHROPATHY HAS 
NO SUB-CLINICAL REJECTION ON 3 & 12 MONTH FOLLOW-
UP BIOPSY
P. Acott, J. Crocker
IWK Health Centre and Dalhousie University
Pediatric renal transplantation has made signifi cant improvements in 1st year 
allograft survival but chronic allograft nephropathy (CAN) is a major cause 
of late allograft decline and loss. Sirolimus (SRL) has been promoted as a 
calcineurin inhibitor (CNI) sparing or replacement strategy with variable 
outcomes. This study evaluates pediatric patients with biopsy evidence of CAN 
and loss of glomerular fi ltration measured by 24 hr urine creatinine clearance 
(CrCl) that were converted from CNIs to SRL. Data is presented as mean ± 
SE.
Twelve children (6 female; 6 male; 9 LD; 3 DD) all had biopsy proven CAN and 
reduced CrCl = 34.8 +/- 3.6 ml/min/1.73 m2. The patients (age= 10.3 +/- 1.7 yr) 
were 3.2 +/- 0.9 yr post renal transplant and their baseline immunosuppressant 
therapy prior to conversion to SRL consisted of CNI (Cyclosporin A = 11; 
FK506 = 1), Cellcept or Myfortic, and alternate day prednisone. SRL dosing 
was altered to achieve SRL drug levels 5 to 15 mcg/ml. Follow-up included 
laboratory data (monthly), CrCl (3 & 12 month), and renal biopsies (3 & 12 
months) to exclude sub-clinical rejection.
No child had biopsy evidence of sub-clinical rejection (3 & 12 month post 
conversion) and improvement of CrCl by 12 months (baseline CrCl = 34.8 
+/- 3.6; 3 month CrCl = 42.0 +/- 4.2 [p = 0.188]; 12 month CrCl = 48.0 +/- 4.8 
[p=0.038] ml/min/1.73 m2). Potential SRL related side effects included vulvar 
ulceration (n=1); necrotizing pneumonitis (n=1); and progressive anemia 
requiring blood transfusion and/or erythropoietin (n=2). Baseline hemoglobin 
levels (g/l) (89.4 +/- 4.4) initially reduced at 3 months (78.3 +/- 3.1 [p=0.042]) 
but were above baseline at 12 months (100.6 +/- 4.8 [p=0.095]). No child had 
to be taken off SRL and there was no allograft loss during the observation 
period.
This is the fi rst Sirolimus conversion study documenting no increase of sub-
clinical rejection in the fi rst year post cessation of CNI therapy. In pediatric 
patients with renal biopsy established CAN with reduced CrCl, serious SRL 
side effects were infrequent and amenable to SRL dose reduction and medical 
management. Conversion from CNIs to SRL in pediatric renal transplant 
recipients with biopsy proven CAN is well tolerated with improved renal 
function and no increased risk of rejection.
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KIDNEY TRANSPLANTATION IN CHILDREN AND 1896 
ADOLESENTS - AN ANALYSIS OF OPTN/UNOS DATABASE
B. Hardy1,3, T. Shah2, J. Cicciarelli2,3, K. Lemley1, I. Hutchinson2,3, Y. Cho2,3
1Children Hospital Los Angeles, 2National Institute of Transplantation, 3USC 
School of Medicine
Background: It is very important to investigate whether specifi c pediatric 
allocation schemes can not only lead to minimization of waiting time, but also 
to better clinical outcomes for children with end-stage renal disease (ESRD).
Materials and methods: We analyzed the OPTN/UNOS data for all patients 
aged 2-20 years who received kidney transplants from living or deceased 
donors aged 5-35 years between January 1, 1994 and December 31, 2006. 
Multiple organ transplants were excluded from this study. The outcome of 4,125 
deceased donor kidney transplants (DDKT) was compared with those of 6,456 
living donor kidney transplants (LDKT) using univariate and multivariate Cox 
regression analyses.
Results: Unadjusted graft survival rates of DDKT were signifi cantly lower 
than those of LDKT (HR=1.53, P<0.001). Chronic rejection was reported 
in 416 (10.1%) of 4,125 DDKT group compared with 537 (8.3%) of 6,456 
LDKT group (P<0.001). Among black recipients, 65 (3.3%) grafts were lost 
due to non-compliance as a contributory cause of failure compared with 126 
(1.5%) among other races (P<0.001). A signifi cantly lower incidence of non-
compliance was observed in children (0.9%) compared with adolescent (2.2% 
in age 10-14, P<0.001) and high teens (2.0% age 15-20, P<0.001). Multivariate 
analysis showed that adjusted graft survival rates of LDKT were superior to 
DDKT (HR=1.22, P<0.001) after adjusting for recipient race, recipient age, 
regraft status, and HLA mismatch.
Conclusion: It is recommended that LDKT be offered fi rst to children instead 
of DDKT.
Table. Results of univariate and multivariate analyses.
Unadjusted
HR (95% CI)
P value
Adjusted
HR (95% CI)
P value
DDKT vs LDKT 1.53 (1.42-1.65) <0.001 1.22 (1.12-1.34) <0.001
Recip race Black vs others 2.01 (1.85-2.20) <0.001 1.81 (1.66-1.98) <0.001
Recip Age 10-14 vs 2-9 1.47 (1.30-1.66) <0.001 1.43 (1.27-1.62) <0.001
 15-20 vs 2-9 1.91 (1.72-2.12) <0.001 1.87 (1.68-2.08) <0.001
Regraft vs primary 1.51 91.35-1.68) <0.001 1.39 (1.24-1.56) <0.001
HLA mismatch (0-6) 1.14 (1.11-1.16) <0.001 1.07 (1.04-1.10) <0.001
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SINGLE CENTER EXPERIENCE WITH PARTIAL 1897 
LIVER GRAFTS FOR PEDIATRIC PRIMARY LIVER 
TRANSPLANTATION
E. Island, T. Kato, G. Selvaggi, J. Moon, S. Nishida, D. Levi, A. Tzakis
University of Miami
Split, reduced, and live donor liver grafts have been shown to reduce 
waiting time for pediatric liver transplantation, while at the same time 
expanding both the pediatric and adult donor pools. Retrospective analysis 
of prospectively collected data was undertaken to evaluate the long-term 
outcome of these techniques in a single center’s experience. From 1993 to 
2007 we performed 226 primary pediatric liver transplants. There were 147 
whole organs and 79 partial organs. The partial organs consisted of 11 grafts 
from living related donors, 34 grafts from split livers, 31 grafts were reduced 
at the back table, and three grafts were reduced after implantation. The 
long-term (>10 year) outcome with partial livers was excellent, however 
both patient and graft survival were diminished when compared to whole 
liver transplants (p<0.01). Partial livers were more likely to be used in 
younger recipients with lower body weights (P<0.05). However there was 
no signifi cant difference found in ischemic time or blood product usage. 
Within the partial liver group, patient and graft survival was equivalent in 
the reduction, live donor, and split liver cohorts. Partial liver grafts provide 
acceptable long-term outcomes for pediatric liver recipients, however both 
patient and graph survival are diminished when compared to whole organ 
transplant. Outcomes with split liver and size reduced grafts are equivalent; 
therefore split livers should be used whenever possible to further expand 
the donor pool.
POSTER BOARD NUMBER P3 – 324
PEDIATRIC ACUTE HEPATIC FAILURE AND 1898 
TRANSPLANTATION
T. Heffron1, T. Pillen2, G. Smallwood1, R. Romero1
1Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Purpose: It has been reported that acute hepatic failure in the pediatric liver 
transplant arena has diminished survival when compared to chronic liver failure. 
The aim of this study is to report our experience of emergent transplantation of 
20 pediatric fulminate failure patients.
Method: All patients received similar immunosuppression with induction 
therapy of daclizumab with tacrolimus, mycophenolate, and prednisone.
Results: Five of the 20 children received ABO incompatible liver allografts. 
Three with blood group A received group B, one with blood group B received 
group A, one with blood group O received group A. One year and three 
year actuarial patient survival for the 15 ABO matched grafts versus 5 ABO 
incompatible grafts was the same for both groups [(94.1% and 100%, (p = 
NS)]. There was a trend in 1 and 3 year graft survival in favor of the ABO 
incompatible group. Living donor and split liver transplant were used. A 
reduced rate of rejection was noted in the ABO incompatible group [1 of 5 
(20%) vs.12/15 (84.6%); p = 0.058]. ABO incompatible median time to fi rst 
rejection was 44 days versus 573 +/- 402 days in the ABO matched group (p 
= 0.236). There was no hepatic artery, portal vein thrombosis, or vena caval 
occlusion in the ABO incompatible group. One and three year actuarial patient 
and graft survival for the entire group was 92.1% and 88.4%, and 84.9% and 
77.1%, respectively.
Conclusion: Overall patient and graft survival was better than expected in the 
fulminant failure patient. ABO mismatched grafts, split liver transplantation 
and living donor can aggressively be utilized to enable increased patient/graft 
survival in a patient group which is at risk of poor outcomes.
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KIDNEY TRANSPLANTATION IN RECIPIENTS 1899 
YOUNGER THEN 5 YEARS
M.M. Kaabak, N.N. Babenko, A.K. Zokoyev, J.I. Kurakina, T.U. Cheprasova, 
S.V. Kirillov, A.A. Abovjan, I.D. Rotova
Russian Scientifi c Center of Surgery RAMS
When ESRD is established, the results of kidney transplantation in young 
children are as better as earlier the operation is performed. Here we analyze our 
fi rst experience with this tender cohort of patients.
At the Russian Scientifi c Center of Surgery since November 2003 till May 
2007 15 kidney transplants were performed in children aged from 7 months to 
5 years (3±1,7 years).
All transplants were fi rst and from living related donors. Opposite to general 
practice, all transplants were placed extraperitonealy.
Two patients died from the reasons not linked to graft function – one 4-years 
old boy from gelmintose 1,5 years posttransplant, another 1,5-years old boy on 
the 2-nd day after surgery from brain hemorrhage. Both patients maintained on 
dialysis 24 and 13 months. Thirteen patients followed up in our center, their 
demography presented in table 1.
Table 1. Demography of transplanted patients. 
Age at transplant 0 – 1,5 years 1,5 – 3 years 3 – 5 years
Number patients 3 3 7
Diagnosis
DMS1 1
dysplasia 2
refl ux 1
DMS1 1
Finish type 1
HUS 1
DMS1 1
FSGS 4
Unknown 1
Duration of dialysis (months)
(M±m)
2,9±3 10,7±8,8 13,1±13,6
Age at start of dialysis, years 
(M±m) 0,7±0,6
2 1,2±1,1 4,2±1,1
Follow-up posttransplant, M±m
(min - max)
327±476
(44- 867)
363±416
(90-842)
336±215
(36-643)
Height at Тх, cm (M±m) 84,7±8,9 86,0±10,7 91,2±12
Weight at Tx, kg (M±m) 11,1±3,4 11,5±3,7 13,7±4,4
Donor age, years (M±m) 30,5±8,1 33,1±8,4 32,8±10,2
1DMS – diffuse mesangial sclerosis
2One patient was transplanted preemptively
Donors were parents (12), grandparents (2), uncle (1). In all cases native 
bilateral nephrectomy were performed at the time of transplantation. Surgical 
details summarized in table 2.
Table 2. Surgical details of transplants in children under age of 5 years.
Age at transplant 0 – 1,5 years (n=3) 1,5 – 3 years (n=3)
3 – 5 years
(n=7)
Arterial infl ow aorta 100%
aorta 2
a iliaca com 2#
aorta 1
a iliaca com 1
a iliaca int 6#
Venous outfl ow
v cava inf 1
v iliaca com 2
v cava inf 2
v iliaca com 1
v cava inf 2
v iliaca com 2
v iliaca ext 3
Urology reconstruction
pelvis 4*
bladder 1
pelvis 2
bladder 1
pelvis 5
bladder 2
Side of transplantation
right 2
left 1
right 2
left 1
right 6
left 1
Graft turn over** 0 1 of 3 5 of 7
*in one recipient for urine drainage were used both native and donor ureters because of neck cystitis.
#grafts with multiple arteries were used.
** Turn over of the graft facilitate arterial reconstruction, allow ipsilateral graft placement and feasible 
when native ureter used.
All grafts have a good function at the moment. Since September 2006 Campath 
1H is used for induction with early steroid withdrawal and late conversion from 
CNIs to micophenolates or rapamycines.
Conclusion: Kidney transplantation in children under 5 years is can be 
successfully performed with adult kidneys. Extraperitoneal placement of the 
grafts is feasible in all cases, even in kids of 1-st year of life, and allows to 
create adequate blood supply and urine outfl ow. Preemptive transplantation 
will improve the results of treatment by decrease of prevalence of chronic 
uremia complications.
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INCREASE INCIDENCE OF ACUTE CELLULAR 1900 
REJECTION IN PEDIATRIC RENAL TRANSPLANT PATIENTS 
RECEIVING STEROID FREE IMMUNE SUPPRESSION
J. Johnson, E. Tsai, R. Ettenger
UCLA - Dept of Pediatrics/Division of Nephrology
Introduction: Many renal transplant centers have moved towards steroid-
free immunosuppressive regimens to avoid long-term toxicities. However, 
there have been anecdotal reports of increased acute rejection with steroid-
free regimens. Moreover the factors associated with this increase have not 
been fully elucidated. The aim of this study was to compare the risk of acute 
cellular rejection in pediatric renal transplant recipients receiving optimal 
verse suboptimal dosing of mycophenolate mofetil (MMF) on a steroid free 
regimen.
Methods: We performed a retrospective chart review of 26 steroid free 
patients transplanted at Mattel Children’s Hospital at UCLA between 9/1/2004 
and 2/25/2007. Our steroid-free regimen consisted of daclizumab induction 
(7 doses of 1mg/kg), intraoperative solumedrol (10mg/kg x1)), prograf 
(0.1 mg/kg dose bid, goal trough levels initially 8-10) and mycophenolate 
mofetil (600 mg/m2/dose bid). We examined potential factors associated 
with increased risk of acute rejection including withholding or minimizing 
MMF. Suboptimal dosing of MMF was defi ned as less than 75% of 600 
mg/m2/dose, with maximum adult dose being 1000 mg. We calculated the 
incidence of acute rejection for patients receiving optimal verse suboptimal 
dosing. Biopsy proven acute rejection was defi ned by the modifi ed 1997 Banff 
criteria. Inclusion criteria were fi rst transplants with PRA< 30%. Exclusion 
criteria were retransplants; patients induced with Thymoglobulin; patients 
with PRA>30%; and patients with recurrent disease requiring plasmapheresis 
and/or Rituximab.
Results: We found 9 patients in the defi ned control group with optimal MMF 
dosing; 22% (2/9) of these patients were found to have biopsy proven acute 
cellular rejection. We identifi ed 17 patients on suboptimal MMF: 59% (10/17) 
these had biopsy proven acute cellular rejection, one of these patients also had 
an equivocal fi ndings for antibody mediated rejection. Patients with suboptimal 
MMF dosing had a 5 fold increase (95% confi dence interval 0.79 – 31.62) risk 
of acute rejection verse patients on optimal dosing.
Conclusions: We have found that while steroid free immunosuppression 
can be effective, patients with suboptimal MMF dose may have an increased 
risk of developing acute cellular rejection. This risk maybe as high as fi ve 
fold compared to patients on optimal MMF. This study is limited due to 
the small sample size. In the future, larger studies may help further defi ne 
this risk.
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CHIMERISM IN PEDIATRIC PATIENTS WITH 1901 
ALLOGENEIC TRANSPLANT OF HEMATOPIETIC 
PRECURSORS
J. Larriba, M. Makiya, M. Tambutti, L. Molina, E. Dibar, M. Redal
Hospital Italiano De Buenos Aires
Introduction: The importance of establishing the degree of chimerism on 
haematopoietic precursor recipients has long been recognised. This allows for 
the early detection of graft dysfunction, as well as the need for appropriate 
additional immunosuppression.
Objective: To determine the degree of chimerism on peripheral blood samples 
of patients undergoing a haematopoietic precursors transplant by the specifi c 
amplifi cation of DNA microsatelites.
Methods: Nine paediatric patients (mean age, 9.44 years; range 2-17 years; 
female, 4; male, 5) were included. Cause of transplantation was acute 
lymphoid leukaemia (ALL) in 2 patients; acute myeloid leukaemia (AML), 
3; myelodisplastic syndrome (MDS), 2; acute aplasia (AA), 1; and chronic 
lymphoid leukaemia (CLL), 1. Blood samples were obtained before transplant 
and at 1, 3, and 12 months post-transplant. Peripheral blood samples were also 
obtained from the donors. In two cases, bone marrow samples were used for the 
study. Chimerism was studied on different chromosomes by polymerase chain 
reaction (PCR) of polymorphic repetitive sequences (PRS) of genetic markers. 
The microsatelites analysed were D16S539, D7S820, D13S317, CSF1PO, 
Poster Abstracts Wednesday 13 August 2008
6 2 7
W
ED
N
ESD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
TPOX, TH01, F13A01, FESFPS, vWA, LPL, F13B, and HUMPRTB. Products 
of PCR were subject to electrophoresis of polyacrilamide denaturing gels and 
visualized by staining with silver nitrate.
Results: A complete chimerism (CC) was observed at one month post-transplant 
on all patients. At 3 months post-transplant, 1 out of 9 patients (11%) showed 
mixed chimerism (MC). At one year post-transplant 2 patients (22%) showed 
MC and 7 CC (78%). All patients presented acute graft versus host disease 
(GVHD) (grade 3, n=4; grade 2, n= 4; grade 1, n=1). Chronic GVHD affected 
two patients (grades 4 and 3), who died at month 16 and 18 post-transplant, 
respectively. Additionally, one patient presented GVHD grade 3 with partial 
reversal, and 4 patients had grade 1 disease of which one had partial and three 
complete reversals.
Conclusions: PCR-PRS and staining with silver nitrate is a relatively simple 
and sensitive method that allows for the detection of chimerism on recipients 
of haematopoietic precursors.
BIOARTIFICIAL ORGANS CONCURRENT ORAL SESSION 132: 
AND TISSUE ENGINEERING
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ALBUMIN DIALYSIS IN SEVERE LIVER FAILURE: 1902 
AN ANTICOAGULANT-FREE APPROACH
H.K. Tan, W.S. Yang, H.L. Choong, K.S. Wong
Department of Renal Medicine, Singapore General Hospital, Singapore
Introduction: Severe liver failure is associated with profound coagulopathy 
and can be treated with artifi cial liver support. The molecular adsorbent 
recirculating system (MARS) is one such device. Maintaining circuit patency 
with anticoagulation increases already high bleeding risk. Our hypothesis 
was: omission of heparin-saline prime and intradialytic heparin is safe and 
effi cacious.
Method: MARS was performed with neither heparin-saline prime nor 
intradialytic heparin. Duration and ultrafi ltration were as clinically indicated. 
Intermittent saline fl ushing of blood circuit was performed. Contraindications to 
MARS were poor pre-morbid status and severe hypotension SBP≤90 mmHg.
Results: A total of 12 patients (M:F=10:2; age 49±9 years) were studied. 
Six patients had fulminant hepatic failure (FHF) and the other 6 had acute 
decompensation of chronic liver disease (CLD). Two patients underwent 
liver transplant but only one survived. Overall mortality was 92% (11/12). A 
total of 44 MARS sessions were performed (average 8±7 session per patient). 
Prescribed versus achieved MARS duration were 13±3 vs. 11±4 h, p<0.05. 
Twenty-three percent (10/44) of MARS sessions developed fi lter clotting, 11% 
(5/44) of treatments were electively terminated, and 2% (1/44) experienced 
vascular catheter blockage. Spontaneous bleeding around vascular catheter sites 
occurred in 9% (4/44) of sessions. Pre- vs. post-MARS systolic blood pressure 
(SBP): 135±23 vs.131±26, p=0.105; and, diastolic blood pressure (DBP): 
64±10 vs. 61±9, p=0.043. Pre- vs. post-MARS transmembrane pressures 
(TMP) (mmHg) were comparable: 62±32 vs. 55±36, p=0.071. Circuit pressures 
were stable: pre- vs. post-MARS Aa pressure (mmHg): 127±32 vs. 130±50, 
p=0.659; and, Ae pressure (mmHg): 261±61 vs. 248±67, p=0.128. Saline 
fl ushing was used to maintain circuit patency: 2664±2420 ml per treatment 
(range: 500 – 12800 ml). Coagulation indices were (pre- vs. post-MARS): 
prothrombin time (PT) in seconds 36±30 vs. 42±33, p=0.143; activated partial 
thromboplastin time (aPTT) in seconds 78±43 vs. 88±45, p=0.117; and, platelet 
count (x103/L) 87±40 vs. 76±48, p=0.004. Systemic blood concentrations of 
water-soluble and protein-bound solutes were all reduced: pre- vs. post-MARS 
serum urea (mmol/l) 8±7 vs. 5±3, p<0.05; serum creatinine (μmol/L) 213±176 
vs.144±115, p<0.05; total bilirubin (μmol/L) 504±150 vs. 351±87, p<0.05; 
and, plasma ammonia (μmol/L) 109±50 vs. 76±39, p<0.05.
Conclusions: Anticoagulant-free albumin liver dialysis with intermittent saline 
circuit fl ush is associated with low bleeding risk but relatively higher clotting 
episodes. Overall, neither circuit performance nor blood depurative effi cacy 
was adversely affected. Although coagulopathy did not worsen signifi cantly, 
pre-MARS thrombocytopenia signifi cantly deteriorated following MARS. 
This observation is of clinical importance but its basis and signifi cance need 
further elucidation.
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DEVELOPMENT OF A NEW TREATMENT FOR BILE 1903 
DUCT STENOSIS USING TISSUE ENGINEERING TECHNIQUES 
– DEVELOPMENT OF A BILE DUCT PATCH MADE OF 
BIOABSORPABLE POLYMER –
M. Miyazawa, M. Aikawa, Y. Toshimitsu, K. Okada, K. Okamoto, I. Koyama
Saitama Medical University International Medical Center
Purpose: Along with the recent widespread use of living-donor liver 
transplantation, complications involving the biliary system are increasing. Stent 
or T-tube insertion is a common treatment for bile duct stenosis. However, there 
are some disadvantages with both stent and T-tube, and new means of treatment 
have been called for. We investigated whether a bioabsorbable polymer patch 
that dilated the narrowed bile duct could be available for the treatment of bile 
duct stenosis.
Materials and methods: Hybrid pigs were laparotomized under general 
anesthesia and the extrahepatic bile duct was identifi ed. Then a portion of the 
duodenal side of the bile duct was resected, 3¦ ~2 cm in size and spindle in 
shape, and substituted by a patch made of bioabsorbable polymer of the same 
size. The patch was designed to degrade in six to eight weeks in the body. 
There was no prior cell seeding onto the patch. Animals were re-laparotomized 
four months after implantation to recover graft sites for gross, histological and 
blood chemical studies.
Results: All recipient pigs survived until they were sacrifi ced for collection 
of graft sites four months after implantation. All of them gained weight. On 
gross examination, the patch was found to have been absorbed and the graft 
site was indistinguishable from the native extrahepatic bile duct. Stenosis did 
not occur, adhesion to surrounding tissue was mild and the graft site could 
be freed manually. Histology revealed a neo-bile duct growing in the graft 
site with the epithelium of highly uneven thickness and increased accessory 
glands compared with the native duct. Blood chemistry data at four months 
post implantation did not show change from baseline values.
Conclusion: This study demonstrated that the patch could be used for the 
treatment of bile duct stenosis. Thus, dilation of the bile duct with this patch 
can be a substitute for T-tube insertion in transplantation surgery.
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MOLECULAR ADSORBENT RECYCLING SYSTEM AS 1904 
PREDICTIVA CRITERIA OF SURVIVAL IN PATIENTS WITH 
ACUTE LIVER FAILURE
G. Novelli, M. Rossi, V. Morabito, S. Novelli, F. Pugliese, G. Spoletini, 
A. Bussotti, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: The aim of our study is directed towards the assessment of these 
resources in our possession that could facilitate a decision to transplant or not. 
For this reason, we examined whether the Molecular Adsorbent Reciclyng 
System (MARS) can be seen as a predictor of survival in patients with IEA
Material and methods: We treated 40 patients suffering from fulminant 
hepatitis (FH) with MARS. Treatment MARS was made in exchange for 
continued kits every 8 hours, because the method can be applied in safety and 
tolerability. All patients were treated at the Intensive Care (ICU). Moreover, in 
14 patients cerebral edema was assessed by monitoring intracranial pressure 
(ICP). Univariate analysis for quantitative variables was calculated using 
the Student’s t-test and using the chi-square test for qualitative variables. 
Signifi cance was defi ned as p < 0.05. Graft and patient survival rates were 
analysed using the Kaplan– Meier; the differences between curves were 
assessed by log-rank test.
Results: Of the 40 patients, twenty six of which survived,14 went to the 
transplant within 5 days of treatment while 12 have continued extracorporeal 
method for a maximum period of 17 days indicating a positive resolution of the 
clinical condition.Fourteen patients have died, including 5 before transplant for 
multi organ failure, while nine after transplantation (5 for Primary No Fuction, 
4 for sepsis). The MARS showed a specifi city of 93% and a sensitivity of 
90%.
Conclusion: From our clinical experience, we consider the seriousness of 
the patient’s neurological status and hemodynamic instabilty an important 
negative of the disease. Where we have achieved a signifi cant improvement 
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of these factors in the fi rst 48 hours thanks to MARS and the support of ICU, 
we decided to continue the extracorporeal treatment. The results lead us to 
continue this research by adjusting the number of patients to be treated.
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MONITORING HEMODYNAMIC PARAMETERS DURING 1905 
MOLECULAR ADSORBENT RECYCLING SYSTEM SESSIONS 
IN PANTIENTS WITH PRIMARY NON FUNCTION
G. Novelli, M. Rossi, L. Poli, F. Ruberto, F. Pugliese, G. Mennini, 
V. Morabito, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: Patients with Acute Liver Failure show an aggravated 
hyperdynamic circulation. We evaluated potential changes in systemic 
haemodynamics induced by the Molecular Adsorbent Recirculating System 
(MARS) in a group of patients with Primary no Function (PNF).
Material and methods: In Intensive Care Unite we treated 18 patients with 
PNF (8 female and 10 male) after liver transplantation with a mean age 47.8 
(range 28-60). Continuous MARS treatment was carried on all patients with 
kit change every 8 hours for mean days 10(range 2-20). Veno-venous access 
(double-lumen catheter type) was used for blood supply. Blood fl ow rate was 
150-250 mL/min, depending on the hemodynamic situation of the patient. 
Blood passed through an albumin non-permeable, high fl ux dialysis membrane. 
During MARS treatment the hemodynamic condition, using a series of 
parameters such as Heart Rate (HR), Mean Arterial Pressure (MAP), Cardiac 
Index (CI), Systemic Vascular Resistance Index (SVRI), Pulmonar Vascular 
Resistance Index (PVRI), were monitored before (base value), after one hour 
(T1), after three hours (T2) and at the end of treatment (T3). Neurological 
status was value through Glasgow Coma Score (GCS).The Sequential Organ 
Failure Assessment score (SOFA) was used as predictive criteria. Univariate 
analysis for quantitative variables was calculated using the Student’s t-test and 
using the chi-square test for qualitative variables. Signifi cance was defi ned as p 
< 0.05. Graft and patient survival rates were analysed using the Kaplan– Meier; 
the differences between curves were assessed by log-rank test.
Results: There was a progressive decrease in the positive inotropic 
(dobutamine,norephinefrine) and signifi cant improvement of hemodynamic 
parameters such as MAP (p<0.001), CI (p<0.001) and SVRI (p<0.002). Eleven 
patients alive: 6 to liver transplantation (LT), 5 patients without LT. Seven 
patients dead: 4 after LT while 3 before liver transplantation for Multi-Organ 
Failure.
Conclusions: The MARS device signifi cantly improves the hemodynamic 
targets in acute liver failure that also determine patients survival (52%) with 
PNF awaiting a re-transplantation presumably by a difference in removal rate 
of certain vasoactive substances
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MONITORING CITOKINES LEVELS IN ACUTE ON 1906 
CHRONIC LIVER FAILURE PATIENTS DURING MOLECULAR 
ADSORBENT RECIRCULATING SYSTEM VERSUS STANDARD 
MEDICAL THERAPY
G. Novelli, M. Rossi, S.G. Corradini, G. Di Folco, G. Ferretti, F. Pugliese, 
F. Ruberto, V. Morabito, P. Berloco
La Sapienza Universita’ Di Roma
Introduction: The various defi nitions of Acute on Chronic Liver Failure 
(AoCHF) do not accurately refl ect the differences in clinical signs and in 
prognosis. In AoCHF physiopathology, infl ammatory and metabolic factors 
and oxidative stress seem to be considered ‘precipitating’. The aim of this 
study was to compare the effect of Molecular Adsorbent Reciculating System 
(MARS™) and Standard Medical Therapy (SMT) in the correction of these 
precipitating factors. The results of MARS patients were compared with the 
performance of cytokines in 15 patients who had performed the liver transplant 
without AoCHF.
Material and methods: We monitored cytokines changes in 30 Acute on 
Chronic Liver Failure(AoCHF) patients(Pt) with different aetiology and 
similar Model End-stage Liver Disease (score 20-30): 15 Pt with MARS and 
15 with SMT. Five patients were excluded from MARS treatment: 1 Pt to Liver 
Transplantation (4 treatments), 2 Pt death for sepsis (2 treatments), 2 Pt death 
for Multi Organ Failure (3 treatments). Two patients were excluded from SMT 
group because of death within 30 days.
All ten patients were treated for 8 hour every session and for number 9 of 
MARS treatments. All twenty-three patients were valued during 30 days from 
inclusion and follow up of patients survival at three-months. In patients of 
two group we valued: IL-1â. IL-6. IL-10. TNF-á. TNF-R1. TNF-R2. Hepatic 
Growth Factor (HGF). Nitrites and Nitrates.
Intensive Care Unite (ICU) treatment was applied to optimize regeneration and 
to prevent cardiovascular complications.
Results: In the Mars group at the end of 9 treatments we valued a signifi cant 
change for IL-1â(pre MARS 32±16.9, post MARS 20.5±13.4 p<0.002), 
IL-6(pre MARS 38.14±11.1, post MARS 23.48±9.68 p<0.01), IL-10(pre 
MARS 17.04±6.81, post MARS 10.84±4.36 p<0.05) and TNF-á(pre MARS 
19.41±7.85, post MARS 11.5±6.57 p<0.03). We observed a signifi cant 
improvement of HGF (<0.001). At the three months 5 patients on 10 were lived 
(50%). In the SMT group IL-10(<0.01) and TNF-á (<0.2) were signifi cant. At 
three months 5 patients on 13 were lived (38%). Since IL-6 plays an important 
role in both pro-infl ammatory and in regenerative, we compared the values in 
15 additional patients who had performed the liver transplant. After thirty days 
by liver transplant the values of IL-6 (23.05 ± 4.1) were similar to those found 
at the end of the cycle MARS treatments.
Conclusions: In this study, MARS therapy did show a clearly identifi able 
effi cacy at removing circulating cytokines.
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DEVELOPMENT OF RENAL COMPONENTS FROM 1907 
RAT MESENCHYMAL STEM CELLS USING A MOUSE 
XENOBIOTIC SCAFFOLD
K. Kai1,3, S. Teraoka1, T. Yokoo2, T. Murakami3, E. Kobayashi3
1Tokyo Women’s Medical University, Surgery 3, 2The Jikei University School 
of Medicine,Internal Medicine, 3Jichi Medical University, Organ Replacement 
Research
Background: The terminal goal of transplantation is to establish functional 
tissues derived from recipient autologous stem cells. Various organogenesis 
studies have been carried out using artifi cial scaffolds. We previously focused 
on fetal primordia as an ideal bioscaffold for organogenesis because fetal organs 
lack antigenicity and they have the potential to produce several cytokines that 
are essential for organogenesis. In this study, we successfully developed renal 
components from rat mesenchymal stem cells (MSCs) using mouse xenobiotic 
fetal primordia as a bioscaffold.
This technology is a new strategy for organogenesis.
Methods: Fetal renal primordia (metanephroi) of C57/B6 mice at embryonic age 
(E) 13.5 were transplanted onto the omentum of a unilaterally nephrectomized 
wild-type Lewis (LEW) rat and a LacZ transgenic (Tg) LEW rat, which enable 
us to detect the host-derived cells in the transplanted metanephroi. Each recipient 
was treated with tacrolimus (0.64 mg/kg/d) administered subcutaneously from 
day 0 to day 13 after transplantation; tacrolimus administration was then 
stopped. Bone marrow-derived MSCs (1 ¦ ~ 104/metanephroi) were cultured 
on MatrigelTM and injected into the metanephroi at transplantation. The MSCs 
were harvested from the luciferase (luc) and LacZ dual marker Tg LEW rat. 
The luc marker enabled us to chase the MSC-derived cells using an in vivo 
bioluminescent imaging system (IVISTM) without animal sacrifi ce, and the 
Lac-Z marker enabled us to evaluate the MSC-derived cells by a pathological 
assay. The transplanted metanephroi were harvested at day 14 and day 28.
Results: Harvested metanephroi grew in size from 2 mm to 8 mm, and neo-
vascularization from the recipient omentum was observed. Host-derived 
LacZ-positive tissue was not detected. Using bioluminescent imaging, MSC-
derived luminescent expression was observed at day 7, 14, and 21. Pathological 
fi ndings revealed MSC-derived LacZ-positive cells in the renal tubules. There 
was no evidence of rejection.
Summary: In this study, we succeeded in transdifferentiating autologous MSCs 
to renal cell components in a xenobiotic neokidney under the administration of 
short-term tacrolimus monotherapy.
However, the reconstruction ratio of xenobiotic fetal organs as a bioscaffold 
still remains to be evaluated; this technology has the potential to establish neo-
organs derived from recipient autologous stem cells.
Poster Abstracts Wednesday 13 August 2008
6 2 9
W
ED
N
ESD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P3 – 334
TREATMENT OF NON ALBUMIN RATS BY 1908 
TRANSPLANTATION OF IMMORTALIZED HEPATOCYTES 
USING ARTIFICIAL HUMAN CHROMOSOME
M. Ito, M. Ikeno, H. Nagata, T. Yamamoto, A. Horiguchi, S. Miyakawa
Fujita-Health University
The shortage of organ donors has impeded the development of human hepatocyte 
transplantation. Immortalized hepatocytes could provide an unlimited supply 
of transplantable cells. To determine whether immortalized hepatocytes could 
provide global metabolic support in end-stage liver disease, 42 immortalized 
rat hepatocytes clones were developed by transduction with Artifi cal Human 
Chromosome (HAC) encoding the Simian virus 40 T antigen (SV40Tag) .
The SV40Tag sequence and a suicide gene, herpes simplex virus thymidine 
kinase (HSV-tk), were fl anked by FRT sequences so that they could be excised 
by FRT recombination.
When transplanted into the spleen of retrosin treated non albumin rats with 
2/3 hepatectomy with FK506 (R-NARs), immortalized hepatocyte clones 
prevented the development of albumin. The protection was reversed by 
Ganciclovir treatment, which kills HSV-tk expressing cells.
Three experimental groups were used for alnumin analysis: (G1) non albumin 
rats with 2/3 hepatectomy only (R-NARs) (n=4); (G2) R-NARs and intrasplenic 
transplantation of 3x107 primary hepatocytes (pHTx) (n=4); (G3) R-NARs and 
intrasplenic transplantation of 3x107 immortalized hepatocytes (iHTx) (n=4)
All HTx group(G2-3) were made albumin but immortalized hepatocytes were 
not signifi cantly elevated albumin level conpared with primary hepatocyte.
Immortalized hepatocytes group were not shown up tumor after one month 
HTx.
The metabolic support provided by the immortalized cells not equalled that 
observed after transplantation of primary rat hepatocytes, but in afuthur can be 
engineered to contain safeguards that could make them clinically useful.
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SKIN PRESERVED FOR MONTHS IN ANHYDROUS 1909 
SODIUM CHLORIDE IS TAKEN BY RECIPIENT WITH ONLY 
MINOR XENOGENEIC RESPONSE
W.L. Olszewski1,2,3, M. Moscicka1, D. Zolich1
1Dept. of Surg. Res. & Transpl., Medical Research Center, Polish Academy 
of Sciences, Warsaw, Poland, 2Central Clinical Hospital, Ministry of Internal 
Affairs, Warsaw, Poland, 3Norwegian Radium Hospital-Rikshospitalet, Oslo, 
Norway
Introduction: We have been searching for methods of long-term preservation 
of skin for subsequent tx. Since epidermis and dermis are, relatively to other 
tissues, resistant to ischemia and dehydration, we tried to use dehydration 
method for preservation of skin fragments for tx. Our study revealed that 
skin fragments dehydrated in powdered sodium chloride can retain their vital 
properties and can be successfully tx. Interestingly, we found only minor 
cellular infi ltrates around the grafts.
Aim: To study the xenogeneic reaction to sodium chloride preserved human 
skin grafts.
Methods: Human skin fragments (30) from lower limbs were harvested during 
elective vascular surgery (consent of ethical committee). They were placed in 
heat-dried fi ne sodium chloride powder (1part skin 9 parts of NaCl), kept at 
room temperature for 3 to 6 months. They were desalinated and fragments 1x1 
cm were transplanted to the dorsum or recipient: in group 1 to scid mice (60)
and in group 2 to WIS rats. After 21 to 90 days, the grafts were harvested.
Results: Skin grafts were taken by the recipient. In group 1, on histology, 
keratinocytes looked normal. They were all HLA class I. Staining with mAbs 
against human p63(stem cells), CD29 (transient cells), PCNA (proliferating 
cell nuclear antigen) revealed normal pictures of basal layer cells. In mice 
receiving BdUr injection 24 h before harvesting a number of nuclei of basal 
cells were stained. Staining against mouse MHC I and II antigens, macrophages 
and granulocytes did not reveal presence of mouse antigens in the tx human 
epidermis. In dermis, fi broblasts looked normal and there were some large 
HLA DR+ cells in the intercapillary spaces. In group 2, histological pictures 
were as in group 1. There was no infi ltration of recipient cells into the grafts. 
The peri-graft mononuclear accumulations were limited to 3-4 layers of cells 
expressing classII antigens.
Conclusions: Human epidermal stem cells survive in a dehydrated state for 
months and upon transplantation give rise to keratinocyte progenies. Also, 
skin fi broblasts and some immune cells survive and can be shown in the tx 
graft. Moreover, grafts transplanted to xenogeneic recipient evoke only minor 
response. The mechanism of low responsiveness is studied.
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DOSAGE DEPENDED ACETAMINOPHEN-INDUCED 1910 
ACUTE LIVER FAILURE IN PIGS
M. Schenk1, C. Thiel1, K. Knubben1, M.H. Morgalla2, A. Etspüler3, 
A. Königsrainer1
1University Hospital Tuebingen - General, Visceral and Transplant Surgery, 
2University Hospital Tuebingen - Neurosurgery, 3University Hospital 
Tuebingen - Anaesthesiology
Objective: A reproducible pig model of acute liver failure due to intoxication 
for evaluation of therapeutic strategies and devices, omitting the variability 
induced by multiple non-liver injury sites (e.g. anaemia, cardiac failure), is 
urgently needed.
Methods: Twelve pigs underwent an intoxication with a single enteric 
acetaminophen bolus of 1500 mg/kg b.w.(n=3), 1250 mg/kg b.w (n=3),1000 
mg/kg b.w (n=6). Seven pigs received a bolus of 500 mg/kg b.w.(n=3) or 250 
mg/kg b.w. (n=4) and afterwards blood levels of 300-400 mg/l acetaminophen 
were maintained by continuous enteric administration until acute liver 
failure occurred (decline of liver depended clotting factors and albumin). 
Pigs remained under deep narcosis with pressure controlled ventilation until 
death. Sodium chloride 0,9%, hydroxyethylstarch 6% were used for volume 
substitution and noradrenalin for hemodynamic stability. Parameters like heart 
rate, mean arterial pressure, pulse oximetry were continuously monitored, blood 
gas analysis was performed hourly and corrected as required. Acetaminophen 
blood levels, albumin, AST, ALT and liver depending clotting factors were 
measured every 8 hours after intoxication.
Results: All animals receiving 1500 mg/kg b.w. or 1250 mg/kg b.w. died within 
11&#61617;10 or 13&#61617;7 hours caused by cardiocirculatory failure. 
Three of the pigs receiving 1000 mg/kg b.w. died due to acute liver failure 
within 30&#61617;8 hours, but 3 animals recovered after severe liver damage 
and were killed after 48 hours. Animals with 500 mg/kg b.w. bolus and blood 
levels of 300-400 mg/l died after 21&#61617;9 hours due to cardiac arrest. 
Pigs with 250 mg/kg b.w. bolus and blood levels of 300-400 mg/l survived 
minimum 27 and maximum 45 hours (mean 37&#61617;7) and died due to 
acute liver failure.
Conclusions: A low acetaminophen bolus and continuous enteral administration 
adjusted to blood levels delivers a well reproducible pig model of acute hepatic 
failure with defi ned survival times.
POSTER BOARD NUMBER P3 – 337
ALLOSENSITIZATION ELICITED BY AORTIC 1911 
ALLOGRAFT TRANSPLANTATION IN RATS IS PREVENTED 
BY GLUTARALDEHYDE TREATMENT
B. Laing1, I.M. Rebeyka1, C.C. Anderson1, D.R. Ross1, L.J. West1,2
1Department of Surgery, University of Alberta, Edmonton, AB, 2Department of 
Pediatrics, University of Alberta, Edmonton, AB
Introduction: Aortic and pulmonary artery allografts implanted during 
congenital heart surgery are associated with a signifi cant immune response. 
This immune sensitization can complicate future transplantation should it 
be required. Commercial xenografts used in cardiac surgery are treated with 
glutaraldehyde to enhance tissue strength and durability. The aim of this study 
was to assess the effect of glutaraldehyde on the immune response associated 
with aortic allograft implantation.
Methods: Aortic grafts were harvested from the abdomen of Brown Norway 
rats (RT1n) and treated with a 1% glutaraldehyde solution. The treated grafts 
were orthotopically transplanted into ten Lewis rats (RT11). The humoral 
immune response was assessed at 16-weeks. Donor splenocytes were exposed 
to recipient serum. Bound antibody was detected with FITC-conjugated 
F[ab]2 fragment goat anti-rat IgG. Results were compared to serum from six 
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syngeneic transplant recipients and from recipients of nine untreated allogeneic 
transplants. Immunohistochemistry of glutaraldehyde-treated tissue was 
performed to detect changes in MHC staining.
Results: Allogeneic aortic transplantation is associated with a profound donor-
specifi c antibody response. (1.4% vs. 25.0% cell antibody bound (p=0.002)). 
There was no difference between antibody development in syngeneic allograft 
recipients and glutaraldehyde-treated allograft recipients (1.4% vs. 1.7% 
cells antibody bound (p=0.74). Graft treatment with glutaraldehyde prevents 
development of this antibody (Figure).
Conclusion: Glutaraldehyde-treatment of aortic allograft prevents the 
formation of donor-specifi c antibodies in the rat. This simple technique has 
potential to prevent allosensitization in patients receiving vascular allograft 
tissue in the repair of congenital heart lesions. This has profound implications 
for patients with congenital heart lesions in which the need for future cardiac 
transplantation may become a necessity. These fi ndings correlate with 
recent preliminary work showing lower panel reactive antibody in recipients 
of glutaraldehyde-treated patches following the Norwood procedure for 
hypoplastic left heart syndrome.
Figure:
IMMUNOBIOLOGYCONCURRENT ORAL SESSION 133: 
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ENTRAPMENT OF AN INOS INHIBITOR, AMT, IN 1912 
SOL-GEL GLASSES FOR USE IN PREVENTING EARLY 
DYSFUNCTION OF ISLET TRANSPLANT
B.R.S. Hsu1, Y.T. Chen2, S.H. Fu1, J.P. Chen2
1Divsion of Endocrinology and Metabolism, Chang-Gung Medical Center, 
2Department of Chemical and Materials Engineering, College of Engineering, 
Chang-Gung University
Non-specifi c infl ammation at the islet surrounding milieu causes by-stander 
damage to the islet β-cells and results in early dysfunction of islet transplant. 
To investigate whether a locally released inhibitor of an inducible form of nitric 
oxide synthase (iNOS) protects islet β-cells from infl ammatory destruction, 
we co-transplanted islets with silica-gel powder entrapping 4H-1,3-Thiazin-2-
amine,5,6-dihydro-6-methyl (AMT) and evaluated the effect of AMT on islet 
β-cells engraftment and function. The mean diameter of silica gel particles 
is 595±275 nm. The cumulative release of AMT is about 70% at 72 hours. 
The in-vitro culture of RIN-m5F cells revealed that 4 and 20 nM AMT could 
preserve 30% more of proliferating cells from cytotoxic inhibition mediated 
by 1 ng/ml of IL-1β. Silica-gel per se did not infl uence islets survival or 
function in vitro in terms of cell proliferation assay and glucose-stimulated 
insulin secretion. At 3 days following transplantation, the serum level of nitrite 
of mice receiving 50 islets plus control silica-gel powder were signifi cantly 
higher than that of mice receiving 50 islets alone (nitrite: 84±72 μM, n=6 vs. 
46±26 μM, n=4, p<0.05) and that of mice receiving 50 islets plus silica-gel 
containing 6.4 μg AMT (84±72 μM, n=6 vs. 67±41 μM, n=6, p<0.05). When 
the transplanted mice were followed up for 13 weeks, only one of six mice 
receiving 50 islets plus control silica-gel converted to normoglycemia, while 
all of mice receiving 50 islet alone and all of mice receiving 50 islets plus 
silica-gel containing 6.4 μg AMT became normoglycemia. The temporary 
post-transplantation hyperglycemia for mice receiving 50 islets alone and 
mice receiving 50 islets plus silica-gel containing AMT was 40±5 and 39±7 
days, respectively. The insulin content of islet grafts retrieved at 13 weeks 
after transplantation was 0.17±0.16 (n=6), 1.41±0.11 (n=4), and 1.28±0.30 
μg (n=6) for mice receiving 50 islets plus control silica-gel, 50 islets alone, 
and 50 islets plus silica-gel containing AMT, respectively. The insulin content 
of pancreatic remnants did not differ signifi cantly among three groups. In 
conclusion, (1) AMT, an iNOS inhibitor protects islet isograft from a non-
specifi c infl ammatory destruction. (2) although silica gel per se is non-toxic to 
islet beta cells, it induces a nonspecifi c infl ammation and offsets the protection 
of AMT on islet grafts.
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OUTCOMES OF DONOR HEPATECTOMY IN 1913 
LIVING DONOR LIVER TRANSPLANTATION: A SINGLE 
INSTITUTION’S EXPERIENCE WITH 136 CONSECUTIVE 
CASES
S. Kawachi1, M. Tanabe1, H. Obara1, M. Shinoda1, K. Hoshino2, 
Y. Fuchimoto2, N. Shimojima2, Y. Morikawa2, Y. Kitagawa1
1Department of Surgery, Keio University School of Medicine, 2Department of 
Pediatric Surgery, Keio University School of Medicine
Aim: The aim of this study was to evaluate the morbidity and mortality of 
living liver donation and to facilitate a better understanding of donor risk in 
living donor liver transplantation (LDLT).
Methods: Living donor-morbidity was evaluated in 136 consecutive cases of 
LDLT carried out from April 1995 to December 2007 at Keio University. A left 
lateral segment (LS) graft (n=44), a left liver (LL) graft with middle hepatic 
vein (n=30), a LL plus caudate lobe (LL+CL) graft (n=28), or a right liver 
(RL) graft (n=34) was selected so that at least 0.8 of graft recipient weight ratio 
(GRWR) was ensured. RL graft harvesting was strictly limited when RL volume 
was no more than 70% of whole donor liver. Perioperative complications were 
classifi ed according to the Clavien system.
Results: Complications occurred in 36 patients (Clavien grade 1: 12 patients, 
grade 2: 13 patients, grade 3a: 8 patients, grade 3b: 3 patients). The overall 
complication rate was 26.5% and major complication rate defi ned by a Clavien 
grade >or= 3 was 8.1% (n=11). There was no death or no life-threatening 
complication in the perioperative course of our donors and no signifi cant 
difference was observed in the overall complication rate for the graft type. 
Postoperative hospital stay was 13.2±0.3 (days) in patients without morbidity, 
21.8±2.0 in those with Clavien grade =1 or 2 complications, and 33.9±5.3 
in those with Cavien grade =3 complications. Eight to 11 (73%) of major 
complications were biliary complications such as biliary leak or stricture. 
Interestingly, we experienced no major biliary complication in RL graft 
harvesting. Seven to 8 of major biliary complications occurred in LL (±CL) 
graft harvesting. A signifi cantly longer operation time and more intraoperative 
blood loss was observed in LL (±CL) graft harvesting compared to LS or RL 
graft harvesting.
Conclusion: Living liver donation is performed with a low risk of major 
morbidity in our institution. Although the hepatic functional loss was less great, 
LL (±CL) graft harvesting was technically more diffi cult and often suffered 
biliary complications compared to RL graft harvesting. Consideration of both 
merit and demerit of each graft type may be important in graft selection in 
LDLT.
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PROTECTION AND RECOVERY FROM AUTOIMMUNE 1914 
HEPATITIS BY ANTI-HISTONE H1 AUTOANTIBODY
C.Y. Lai1, T. Nakano1, S. Goto1,2, L.W. Hsu1, J.L. Wong1, S. Kawamoto3, 
T. Goto4, K. Ono3, Y.F. Cheng1, C.L. Chen1
1Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology, 
Graduate School of Advanced Sciences of Matter, Hiroshima University, 
4Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences, 
Josai International University
Aims: We previously demonstrated the immunosuppressive activity of anti-
histone H1 autoreactive antibody (auto-Ab) induced in a rat spontaneous liver 
transplantation (LTx) tolerance model (Transplantation 2004; 77: 1595) and 
a clinical drug-free patient after living related LTx (Transplantation 2007; 
83: 1122). This study aimed to explore the immunological aspects of anti-
histone H1 Ab in Concanavalin A (ConA)-induced liver injury, which is well 
characterized as a model for T-cell mediated autoimmune hepatitis.
Methods: To establish ConA-hepatitis model in rats, 20 mg/kg of ConA 
was intravenously injected and serum levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) 
were measured. To evaluate the anti-infl ammatory activity of anti-histone H1 
Ab, rabbit polyclonal Ab against histone H1 was intraperitoneally injected 
immediately after ConA injection.
Results: We found the protection from ConA-induced liver injury (elevation 
of serum AST, ALT and LDH) by anti-histone H1 Ab, and that ConA-induced 
liver injury is spontaneously recovered at 3 to 7 days after ConA injection. In 
the recovery stage from ConA-induced liver injury, anti-histone H1 auto-Ab 
was transiently induced in the sera (peak at 3 days after ConA injection).
Conclusions: These results suggest that anti-histone H1 auto-Ab, which 
possesses imunosuppressive activity in vitro and in vivo, may be natural immune 
regulative factor to protect infl amed livers suffered from autoimmune hepatitis, 
and that the induction of anti-histone H1 auto-Ab may be not associated with 
any specifi c clinical manifestations.
POSTER BOARD NUMBER P3 – 341
FUNCTIONAL IMPROVEMENT OF PRIMARY PIG ISLET 1915 
WITH EXOCRINE CAPSULATION
J.Y. Kim1, J-I. Lee1, Y. Fang2, J.H. Jeong2, C.M. Kang3, Y.S. Kim1,2,3
1The Research Institute for Transplantation, 2Department of Surgery, 3BK21 
Team of Nanobiomaterials for Cell-Based Implants, Yonsei University College 
of Medicine, Seoul, Korea
Introduction: Improved success in human islet transplantation is often 
limited by the shortage of donors. This favors utilization of pig donors for 
islet xenotransplantation in near future. However, it is diffi cult to purify the 
pig islets in the routine isolation procedure that are attributed to the intrinsic 
fragility of islets during enzymatic digestion. Porcine-specifi c diffi culties of 
islet isolation often result in low purity or contamination of exocrine tissues. To 
prevent these events, we invented new technique of capsulation with unneeded 
exocrine itself as a benefi cial material.
Method: Porcine islets were isolated from adult pig (PW Genetics) using 
COBE2991. Highly purifi ed islets (HI, > 95% purity), and low purity islets (LI, 
around 50% purity) were selected and calculated by islet equivalents (IEQ). In 
either purity islets, we performed ordinary static culture (ST) or shaking culture 
(SK). After 24 hours of the incubation, functions of islets group were investigated 
by glucose challenging test (100mg/dl, 400mg/dl, 100mg/dl, 1 hour each). Amounts 
of insulin from islets were measured for 6 days culture period by ELISA.
Result: Islets function of SK culture was better than that of ST culture after 
24 hr assessed by stimulation index. After 3 days culture, it was possible to 
examine the ideal morphology of LI after SK culture, which showed smooth 
surface of islets, and exocrine cells seemed to be reduced or eliminated from 
LI, whereas morphology of HI after SK culture was not changed. Insulin 
secretion from LI after SK culture was maintained higher than that of other 
culture conditions (LI-ST, HI-SK, HI-ST) during 6 days.
Conclusion: SK culture of low purity pig islet with exocrine tissue may enhance 
the function of islet by condensing into fi rmer islets, providing natural scaffold of 
extracellular matrix that keep the shape of islet and the ability of insulin production 
of islets. If the problems related to contamination of exocrine cells in pig islet 
isolation, the capsulation with exocrine tissue it self using SK culture, could serve 
as an essential prerequisite for successful human islet transplantation of lower 
purity, and, moreover, pig islets transplantation for type 1 diabetic recipients.
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POST-TRANSPLANT TGF- BETA AND S100A4 1916 
EXPRESSION IN RAT KIDNEY ALLOGRAFTS 
PREDICTCHRONIC REJECTION CHANGES
S. Rintala1, J. Savikko1,2, J. Rinta1, N. Malmström1, P. Koskinen1,3
1Transplantation Laboratory, 2Department of Surgery, Päijät-Häme Central 
Hospital, Lahti, 3Department of Medicine, Division of Nephrology, Helsinki 
University Hospital
Background: Chronic rejection remains the primary reason for late allograft 
loss in kidney transplantation. Chronic changes are characterized by fi brosis 
and vessel changes. Transforming growth factor beta (TGF-beta) contributes to 
renal interstitial fi brosis by epithelial to mesenchymal transition (EMT). Here 
we investigated the role of TGF-beta and S100A4 as a marker for EMT in post- 
transplant kidney allografts.
Methods: Kidney transplantations were performed from DA to WF rats 
and syngenic control transplantations between DA rats. Allografts were 
immunosupressed with CsA (1.5 mg/kg/d sc) and no immunosuppression 
was given to syngenic grafts. Grafts were harvested 3,5,7 and 90 days after 
transplantation for histology and immunohistochemistry (TGF-beta, TGF-
betaR1 and S100A4) and in situ hybridisation (TGF-beta).
Results: In syngenic grafts, no signs of acute or chronic rejection were seen 
whereas intense acute and chronic rejection were seen in CsA-treated allografts. 
In syngenic grafts only mild TGF-beta expression was seen in all time points. 
Also the number of S100A4-positive cells remained low in syngenic grafts. In 
CsA-treated allografts, moderate to intense TGF-beta expression was seen 5,7 
and 90 days after transplantation. The number of tubular S100A4-positive cells 
was signifi cantly increased at days 5 and 7 in CsA-treated allografts, but no 
difference was seen in S100A4 staining between syngenic grafts and allografts 
at 90 days after transplantation.
Conclusions: Based on our results, the TGF-beta and S100A4 expression are 
increased already after 5 days in CsA-treated allografts, which later develop 
chronic changes. The high number of S100A4 cells early after transplantation 
is a sign of active EMT, and at 90 days this transition has already reached its 
peak and slowed down. These results support that TGF-beta has an important 
role in EMT leading to subsequent chronic changes. Therefore it seems that 
early post-transplant TGF-beta inhibition could be a potential intervention in 
preventing chronic rejection changes in clinical kidney transplantation.
POSTER BOARD NUMBER P3 – 343
THE ROLE OF MACROPHAGE IN THE PATHOGENESIS 1917 
OF CHRONIC CYCLOSPORINE NEPHROPATHY
J.Y. Ghee1, H.K. Song1, D.H. Han1, W.Y. Kim2, Y.K. Kim1, S.H. Kim1, 
Y-S. Kim1, J. Kim2, C.W. Yang1
1Department of Internal Medicine, Kangnam St. Mary’s Hospital, 
2Department of Anatomy, The Catholic University
Infi ltration of macrophage is observed in chronic cyclosporine (CsA) 
nephropathy, but role of macrophage is still undetermined. This study was 
performed to evaluate the direct role of macrophage in the pathogenesis 
of CsA-induced renal injury. Chronic CsA nephropathy was induced by 
administering CsA (15mg/kg per day) for 28 days, and macrophage was 
depleted by administering liposome-encapsulated clodronate (CL, 20mg/kg 
per seven day). For weeks treatment of CsA caused intersititial fi brosis and 
infl ammation, but CL treatment decreased both parameters. At molecular 
level, upregulated proinfl ammatory (osteopontin) and profi brotic (©¬igh-3) 
cytokines in CsA-treated rats were decreased with CL treatment. In addition 
to anti-infl ammatory and anti-fi brotic effect, CL treatment decreased immune 
response, demonstrated by decreased toll-like receptor and MHC class II 
in CsA-treated rat kidney which was upregulated on renal tubular cells and 
infi ltrating infl ammatory cells. Macrophage depletion decreased oxidative 
stress, and this may be responsible for decreased apoptotic cell death in CsA-
induced renal injury. In conclusion, macrophages play a pivotal role in not only 
non-immunologic but also immunologic injury in chronic CsA nephropathy.
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IN VIVO SUPPRESSION OF THE CD8 T CELL RESPONSE 1918 
BY SELECTIVE DEPLETION OF CROSS-PRESENTING 
DENDRITIC CELLS
R.M. Sutherland, Y. Zhan, M.L. Lin, E. Carrington, J.A. Villadangos, 
A.M. Lew
Walter And Eliza Hall Institute of Medical Research
Cross-presentation, i.e. presentation of exogenous antigen by MHC class 
I molecules, is an important process for generating CD8 T cell responses. 
However, the inability to selectively manipulate cross-presentation in vivo 
has limited our understanding of its contribution to allograft and xenograft 
rejection. We have exploited the specifi c cytosolic export feature of cross-
presenting dendritic cells together with the property of cytosolic cytochrome c 
in initiating Apaf-1-dependent apoptosis to selectively deplete cross-presenting 
dendritic cells. Intravenous injection of cytochrome c in mice produced 
a selective 2 to 3-fold reduction in splenic CD8+ dendritic cells, the major 
cross-presenting population. Using Annexin V staining and Apaf-1-defi cient 
mice we showed that this depletion occurred by Apaf-1 dependent apoptosis. 
Cytochrome c-resistant dendritic cells retained the capacity to present 
exogenous antigen to CD4 T cells, and endogenous antigen directly to CD8 
T cells, but were ineffi cient at cross-presentation to CD8 T cells and had a 
reduced capacity to produce IL12 upon TLR engagement. In vivo CD8 T cell 
proliferative and cytotoxic responses to exogenous antigen were profoundly 
inhibited in cytochrome c-treated mice. Thus, cytochrome c treatment provides 
the opportunity to specifi cally target cross-presenting dendritic cells in vivo 
and manipulate the CD8 T cell response to transplants.
POSTER BOARD NUMBER P3 – 345
INDUCTION OF NRP1+T CELLS IN VITRO1919 
M. Cai1, H-M. Zhou1,2, C. Liu1, X-K. Per1, W. Huang2, J-M. Huang2, L-J. Xu2, 
B-Y. Shi1, Z-K. Chen2
1Organ Transplantation Center, 2nd Affi liatted Hospital of Great Wall 
Hospital of P.L.A. Beijing, 100091, P.R.China., 2Institute of Organ 
Transplantation, Tongji Hospital, Tongji Medical College, Huazhong 
University of Science and Technology. Key Lab of Organ Transplantation of 
Ministry of Education and Ministry of Health. Hubei, 430030, P.R.China
Background: Many kinds of ceslls expresse Neuropin-1(NRP1), It was 
reported to play an important role during Neuron development, and recent 
researches shows NRP1 takes part in the immune synaps formation, and NRP1 
+T Cells functiones as immun-regulatory cells, but the quauntity is limited. 
Some scientsts induced CD4+CD25+T cells with Estrogen, whether it can be 
used to induce NRP1+T cells has not been testifi ed. This study aimed to induce 
NRP1+T cells in vitro with Estrogen, and fi nd out the whether NRP1 and it’s 
ligands, such as VEGF, get involved in the procedure.
Methods: Spleen cells from C57BL/6 mice were stained with CFSE and 
2¡Á105 cells were seeded into 96 cell-plate at a reactor/target ration 1/1, 
cultured with mitomycin pre-treated Balb/C mice spleen cells (Bm); with the 
addition of CD3 and CD28 monoclonal antibody, 2¡Á10-7 M Estrogen was 
applied as inducor. Effects of VEGF-antibody, NRP1-antibody on induction of 
NRP1+T cells were checked. 5 days after the cells seeded, the percentage of 
CD4+CD25+NRP+T cells and the proliferation of blast cells were detected by 
FACS and analyzed by Diva and ModFit LT software.
Results: The percentage of CD4+CD25+NRP+T in blast cells increased 
when Estrogen was applied (from 11.06311¡À1.006% increase to 
42.7¡À0.5787%£¨P=0.012£©) but decreased when VEGF-antibody or Nrp1 
antibody added. (7.1859¡À0.27356, 27.73147¡À0.64089, respectly. Compared 
to Estrogen group, P<0.05). The Proliferation Index(PI) decreased when VEGF/
NRP1 antibody added (from 90.503¡À0.5 to 68.0¡À2.0 or 72.923¡À2.6053, 
compared to EstrogensP<0.05). (table 1).
Conclusion: From our preliminary data, we found that Estrogen would induce 
Nrp1+T cells from C57BL/6 mice, when added with VEGF/NRP1 antibody, 
the proliferation would be inhibited. Which implied that NRP1 involved in the 
induction and proliferation of NRP1+T cells, but not only a regulatory T cells’ 
surface marker. And the ligand VEGF got involved in these procesure.
EFFECTS OF CONCURRENT ORAL SESSION 134: 
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IMMUNOMODULATORY EFFECT OF SECONDARY 1920 
METABOLITES OF A NEWLY ISOLATED TOLYPOCLADIUM 
INFLATUM WILD STRAIN
M. Ramachandran
The American College, Madurai Kamaraj University, Madurai, India
Cyclosporine (Cys) is a potent immunosuppressive drug approved for use 
in organ transplantations to prevent graft rejection in kidney,liver and lung 
transplants. Cys is known to be produced by the soil fungi Tolypocladium 
infl atum(Ti). The present study highlights the immunomodulatory effect of the 
secondary metabolites of a newly isolated wild strain of Ti collected from the 
soil samples of Western Ghats of India (Lat.10°12’N, Long.77°30’E). HPLC 
analysis of the secondary metabolite from wild Ti isolates confi rmed the 
presence of high levels of cyclosporine when compared to Ti culture of MTCC- 
989 (Microbial Culture Collection Centre ,Chandigarh, India). The T cell, B 
cell & macrophage functional assays were performed to study the specifi c and 
nonspecifi c immunity in New Zealand white rabbits. The secondary metabolite 
(0.5mg/kg/day) was given orally for 21 days prior to the administration of SRBC 
antigen (25% PCV, 0.5ml) intraperitoneally. Experimental studies on specifi c 
and nonspecifi c immunity showed a signifi cantly higher immunosuppressive 
effects when compared to Ti culture of MTCC - 989 secondary metabolites.
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EPIDERMAL GROWTH FACTOR INHIBITION BY 1921 
ERLOTINIB PREVENTS NEOINTIMA FORMATION IN 
EXPERIMENTAL ACCLERATED ATHERIOSCLEROSIS
J. Savikko1,2, J. Rintala1, S. Rintala1, N. Malmström1, P. Koskinen1,3
1Transplantation Laboratory, University of Helsinki, and Helsinki University 
Central Hospital, 2Department of Surgery, Päijät-Häme Central Hospital, 
3Department of Medicine, Division of Nephrology, Helsinki, University 
Central Hospital
Background: In clinical transplantation chronic rejection is a major reason for 
late allograft loss. Accelerated atherosclerosis is one pathological manifestation 
of chronic allograft rejection. The typical feature in atherosclerosis is 
uncontrolled proliferation and migration of vascular smooth muscle cells 
and their deposition in the vascular intima. Neointimal formation leading to 
occlusion of arteries is believed to be a pathological response to injury. Several 
peptide growth factors, for example PDGF and IGF-1, have been identifi ed 
to be operational in the formation of atherosclerotic dysplasias in vessels of 
transplanted organs by inducing migration and proliferation of smooth muscle 
cells. Inhibition of these growth factors has been experimentally shown 
to be potential intervention site after denudation injury and in transplant 
atherosclerosis. Epidermal growth factor (EGF) is also a mitogenic growth 
factor but its’ role in transplant atherosclerosis is unknown. Here we investigated 
the effect of erlotinib, a selective EGF receptor tyrosine kinase inhibitor, on 
neointima proliferation after arterial endothelial injury in vivo.
Materials and methods: The aorta of male Wistar rats weighing 350 to 370g 
was denuded of endothelium by the intraluminal passage of a French Fogarty 
arterial embolectomy catheter introduced through the left iliaca artery. Rats 
were treated per orally either with erlotinib (1 or 5 mg/kg/d) or with vehicle 
only (polyethylene glycol). Histological changes and analysis of neointimal 
area were evaluated from midaortic sections 14 days after injury.
Results: In the vehicle-treated group, moderate neointima formation was 
detected 14 days after denudation. Erlotinib prevented the neointima formation 
after denudation in a dose-dependent way. The lower 1mg/kg/d dose slightly 
reduced neointima formation compared to controls. With the higher 5mg/kg/d 
dose a signifi cant reduction in neointima formation between erlotinib-treated 
animals and controls was seen. In these animals only mild neointima formation 
was detected in the denuded aortas. Erlotinib was well tolerated and no adverse 
effects were seen in animals treated with erlotinib.
Conclusions: Our results demonstrate that EGF plays a role in the neointima 
formation and erlotinib is a potent inhibitor of accelerated arteriosclerosis after 
arterial endothelial injury. Based on these fi ndings erlotinib could be a potential 
intervention in preventing vascular changes in chronic allograft dysfunction.
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DONOR PRE-TREATMENT WITH TACROLIMUS 1922 
EDUCES TRANSPLANT VASCULOPATHY 
R.W.F. de Bruin1, D. Susa1, S. van den Engel1, L.A. van Damme2, H.P. Roest1, 
R. Krams2, J.N.M.I. Jzermans1
1Department of Surgery, Laboratory for Experimental Surgery ,and 
2Biomedical Engineering, Thoraxcenter, Erasmus MC, Rotterdam, The 
Netherlands
Donor pre-treatment with immunosuppressive agents has been shown to preserve 
kidney function after experimental transplantation, but it is not known whether 
pre-treatment of the donor is able to protect organ grafts against long-term 
structural deterioration, such as transplant vasculopathy. We tested in an allogeneic 
rat aorta transplantation model whether transplant vasculopathy can be reduced 
by pre-treatment of the donor with commonly used immunosuppressive agents.
Male Brown-Norway donor rats received no pre-treatment, tacrolimus, 
methylprednisolone, rapamycin, or mycofenolate mofetil (MMF) 16 and 
2 hours before transplantation into WAG rats (n=5 / group). Eight weeks 
after transplantation, aorta allografts were harvested. Percent intima area 
/ intima + media area (I/I+M), infl ammatory cells and in-situ MMP-2 and 
–9 activity were determined. In pre-transplantation graft biopsies, MMP-2 
and 9 ratio, and mRNA levels for genes of interest were determined.
Aorta allografts pre-treated with tacrolimus, showed signifi cantly lower I/
I+M ratio compared to untreated controls (p<0.01). Pre-treatment with 
methylprednisolone, rapamycin or MMF did not signifi cantly reduce I/
I+M ratio. In-situ MMP-2/ MMP-9 activity was signifi cantly reduced 
in grafts treated with tacrolimus and rapamycin compared to controls 
(p<0.05). Immunohistochemistry revealed a high number of CD4+ 
cells and high CD4/CD8 ratio in grafts pre-treated with tacrolimus.
To test if the protective effect of tacrolimus was mediated by induction of 
cytoprotective genes and inhibition of apoptosis, we measured mRNA levels of 
Bcl-2, Bax, HIF-1α, HO-1, TGF-β, and p21 in pre-transplantation biopsies. No 
differences were found between controls and tacrolimus pre-treated grafts. In 
addition, we found no differences in MMP-2/9 ratio in pre-transplantation biopsies.
In conclusion, donor pre-treatment with tacrolimus signifi cantly reduces 
transplant vasculopathy. Transcriptional changes in anti-apoptotic or 
cytoprotective genes were not seen in pre-transplantation biopsies, but 
the observed reduction in vasculopathy was associated with reduced in-
situ MMP-activity and increased numbers of CD4+ cells eight weeks after 
transplantation.
POSTER BOARD NUMBER P3 – 349
PRODUCTION OF A SOLUBLE AND ACTIVE 1923 
HUMANIZED SINGLE-CHAIN VARIABLE FRAGMENT 
ANTIBODY RECOGNIZING CD25
L. Wan, H. Cai, Y. Lu, H. Yang, S. Li, J. Zhang, Y. Li, Y. Li, J. Cheng, X. Lu
Key Laboratory of Transplant Engineering And Immunology, Ministry of 
Health, West China Hospital, Sichuan University
Background: CD25, an activation marker of lymphocytes, is a potential target 
in selective depletion for alloreactive cells in transplantation. Daclizumab is a 
generally used humanized anti-CD25 antibody. We attempted here to produce 
a single-chain variable fragment antibody (scFv) derived from daclizumab to 
develop scFv-based therapeutics.
Methods: The C-terminal 6His-tagged scFv gene was synthesized based on 
the variable regions of the heavy and light chains of daclizumab and cloned 
into a yeast vector for expression in P. pastoris. The recombinant scFv with 
6His-tag was purifi ed by one step Ni-agarose affi nity chromatography and 
then labeled with fl uorescein isothiocyanate (FITC). The binding ability of the 
scFv was tested using human CD25-positive cells SNT-8 and ConA-activated 
hPBMCs. And CD25-negative cells Raji and resting hPBMCs were used as 
negative control.
Results: The soluble scFv was obtained from supernatants of P. pastoris 
culture. A strong membrane staining was observed in CD25-positive cells 
treated with the FITC-labeled scFv under fl uorescence microscope, whereas 
no obvious staining was visualized on CD25-negative cells. Flow cytometry 
(FCM) analysis showed that more than 95% of SNT-8 cells incubated with the 
FITC-labeled scFv were positive, as compared to less than 5% of Raji cells. 
Activation of hPBMCs increased the positive rate from 1.1% to 26.5%.
Conclusions: The recombinant scFv derived from daclizumab expressed 
using P. pastoris was secreted in a soluble form, which was easily purifi ed, 
and found to retain good reactivity and specifi city for target antigen CD25, 
suggesting its potential use for the development of immunosuppressants for 
allotransplantation.
POSTER BOARD NUMBER P3 – 350
THE EFFECTS OF DIFFERENT IMMUNOSUPPRESANTS 1924 
ON C4D DEPOSITION IN RATS UNDERGOING CHRONIC 
ALLOGRAFT NEPHROPATHY
Y.P. Lu, L. Yang, G.H. Luo, J. Song, Y.J. Shi, Y.P. Li
Transplantation Institute, West China Hospital
Aims: Deposition of C4d in peritubular capillaries (PTC) has been considered 
to be a marker of humoral immunity in renal transplant. This study is to 
investigate C4d deposition in rat renal allografts undergoing CAN and the 
effects of immunosuppressants on it.
Methods: Fisher344 rat renal grafts were transplanted into Lewis rats 
following the procedure of Kamada with our modifi cation. All the recipients 
were given CsA 10mg/kg-1.d-1¡Á10d and then divided into 5 groups (each 
n=9):(1)Vehicle: vehicle orally,(2)CsA: 6mg/kg-1.d-1,(3)RAPA: 0.8mg/kg-
1.d-1,(4)FK506: 0.15mg/kg-1.d-1,(5)MMF: 20mg/ kg-1.d-1. At 4w, 8w, 12w, 
the rats were sacrifi ced, renal allografts were harvested and sera were collected. 
The deposition of C4d was detected by immunofl uorescence and analyzed by 
Integrated Optical Density (IOD). The pathological changes were accessed 
according to the Banff 97 criteria.
Results: C4d deposition in PTC was found in all the allografts at 4w, while 
there was no obvious CAN in all the groups; the differences of Banff Score 
between all groups were not signifi cant (p>.05). The values of IOD in group of 
RAPA and MMF were lower than those in other 3 groups (p=.002, .006). The 
differences between RAPA and MMF, and between other 3 groups were not 
signifi cant (p>.05). The intensity of C4d increased along with the progression 
of CAN, the heaviest C4d deposits in PTC were found at 12w, and meanwhile 
the severest CAN was found. Comparing with Vehicle group, CsA and FK506 
had no effect on C4d deposition (p>.05), however, MMF and RAPA obviously 
decreased the C4d deposition (p=.000). The intensity of C4d deposition had a 
signifi cant correlation with the severity of CAN (r=.894, p=.000).
Conclusions: Our study suggests that the deposition of C4d in allografts 
appears earlier than pathological changes of CAN and has a correlation with 
the progression of CAN. MMF and RAPA can attenuate CAN by inhibiting 
humoral immunity. In contrast, CsA and FK506 have no effect on humoral 
immunity.
POSTER BOARD NUMBER P3 – 351
FK506 VERSUS RAPAMYCIN HAVE DIFFERENT 1925 
EFFECTS ON EXPRESSION OF ANGIOPOIETINS1, 2 AND TIE2 
IN RAT RENAL ALLOGRAFT WITH CAN
Y.P. Lu, X. Ma, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University
Objective: Previous studies have shown that angiopoietins-1, angiopoietins-2 
and Tie2 regulate the maintenance and integrity of blood vessels and have 
potential of anti-infl ammatory properties in cardiac allografts. This study is 
to investigate whether there is difference between Rapamycin (RAPA) and 
FK506 in the ability of affecting expressions of Ang1, Ang2 and Tie2 in the rat 
renal allografts with chronic allograft nephropathy (CAN).
Methods: Male inbred F344 to Lewis rat renal CAN model was established 
via modifi ed Kamada’s procedure. The recipients were fi rst treated with 
CsA 10mg/kg • d*10d and then allocated randomly into three oral treatment 
groups: (1)Control group: vehicle orally, (2) FK506 group: 0.15 mg/kg • d, 
(3)RAPA group: 0.8mg/ kg • d. At 4w, 8w, 12w post transplant, the rats were 
sacrifi ced and the renal allografts were harvested. The serum creatinine (SCr) 
was measured and the pathologic changes were accessed according to Banff 97 
criteria. The expression of mRNA(Äct) and protein of Ang1, Ang2 and Tie2 
was determined and localized by real-time fl uorescence quantitative PCR and 
by immunohistochemistry.
Results: The elevation of SCr and the pathologic changes of CAN were 
observed in Control and FK506 group at 8w and 12w, the differences 
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between the 2 groups were not signifi cant (p>0.05). The levels of SCr and 
Banff score in RAPA group were lower than those in other 2 groups (p<0.05). 
The expressions of Ang1 and Ang2 were localized in epithelial cells and 
endothelium of vascular bundles of glomeruli, and Tie2 was specifi cally 
expressed in endothelium of vessels in all the 3 groups. At 4w, the differences 
of mRNA expression of Ang1, Ang2 and Tie2 between 3 groups were not 
signifi cant (p>0.05). Comparing with the Control and FK506 groups, the 
mRNA expression of Ang1 was increased (p<0.05), and the mRNA expression 
of Ang2 and Tie2 were decreased (p<0.05) in RAPA group at 8w and 12w. The 
differences between groups of Control and FK506 were not signifi cant at 8w 
and 12w (p>0.05).
Conclusions: The results indicate that compared with FK506, RAPA can 
regulate benefi cially the expressions of angiopoietins/Tie2 in rat renal allograft 
with CAN. It suggests that Rapamycin may improve the long-term survival of 
renal allografts through its vasculoprotective property.
POSTER BOARD NUMBER P3 – 352
TACROLIMUS(FK506) INDUCED APOPTOTIC 1926 
SIGNALLING WITH ENDOPLASMIC RETICULUM STRESS 
PATHWAY PROTEINS
S.J.N. Choi, H.S. You, H.K. Lee, S.Y. Chung
Department of Surgery, Chonnam National University Medical School, 
Gwangju, Korea
Tacrolimus(FK506) is an effective immunosuppressive drug used for the 
prevention of graft rejection in organ transplantation. We investigated 
the effects of FK506 on apoptosis, cell viability, measurement of H2O2 
generation, intracellular accumulations of Ca2+ and NO, and western blottings 
of endoplasmic reticulum(ER) stress pathway proteins, such as phospho-
PERK, PERK, CHOP, Grp78, Grp94, Bcl-2, and Bak proteins. Cells were 
cultured with the presence or absence of FK506. Flow cytometric analysis 
was performed after PI stain. Viability of Jurkat cells were decreased by the 
addition of FK506 in a dose-dependent manner. FK506 induced cytotoxicity 
was characterized by sub G0/G1 phase arrest. FK506 induced cell death was 
confi rmed as apoptosis characterized by nuclear fragmentation and caspase-3 
protease activation. Intracellular accumulations of Ca2+ and NO production 
were identifi ed in FK506 treated Jurkat cells after 24 hours. Expression of 
iNOS protein was also noted. Generation of H2O2 was identifi ed. Deceased 
activation of procaspase-12 protease confi rmed activation of caspase-12 
after 48 hours. Activation of phospho-PERK protein peaked at 36 hours 
after FK506 treatment. Expressions of CHOP/GADD153, Grp78 and Grp94/
BiP proteins were also identifi ed after 36 hours. Expression of Bak protein 
was also noted. In conclusion, activation of caspase-12 and changes of other 
ER located proteins ascertained that ER stress mediated apoptosis. Also, 
FK506 increased NO production by iNOS expression. FK506 induced H2O2 
generation revealed that cytotoxicity was achieved by generation of H2O2 
which might modulate the expression of Bak protein. These data indicate 
that the effect of FK506 on ER stress mediated apoptosis of Jurkat cells via 
generation of H2O2. Understanding of ER stress pathway would be a new 
approach to develop immunosuppressive drugs useful in organ transplantation 
cares.
POSTER BOARD NUMBER P3 – 353
EFFECT OF MYCOPHENOLIC ACID MEDIATED 1927 
APOPTOSIS IN HUMAN JURKAT CELLS VIA REGULATION 
OF HEME OXYGENASE-1 EXPRESSION
S.Y. Chung, H.K. Lee, H.S. You, S.J.N. Choi
Department of Surgery, Chonnam National University Medical School, 
Gwangju, Korea
Mycophenolic acid (MPA) is the active agent of mycophenolate mofetil(MMF). 
MPA is a selective inhibitor of inosine monophosphate dehydrogenase. Heme 
oxygenase-1(HO-1), the rate-limiting enzyme of heme catabolism, is known 
to modulate various cellular functions, including cytokine production, cell 
proliferation, and apoptosis in stress-related conditions. However, the role 
of HO-1 in the immunosuppressive response system remains elusive. This 
study demonstrate that pharmacologic induction of HO-1 along with catalytic 
activation signifi cantly modulated apoptosis of Jurkat cells induced by MPA. 
MPA induced apoptotic cell death showing nuclear fragmentation and sub 
G0/G1 phase arrest in Jurkat cells. Caspase-3 proteases expression on MPA 
treated-Jurkat cells in a time-dependent manner. Treatment of MPA resulted 
in reactive oxygen species (ROS) generation in Jurkat cells. Decreased HO-1 
expression on MPA treated-Jurkat cells after 36 hours. Change of mitochondrial 
membrane potential transition (MPT) was also noted. Expression of Bax 
proteins was identifi ed. CoPPIX, HO-1 inducer, induced expression of HO-1 
proteins in MPA treated Jurkat cells. CoPPIX inhibited generation of H2O2. 
CoPPIX, signifi cantly inhibited the MPA induced apoptosis. In conclusion, 
HO-1 inducer suppressed ROS generation, Bax protein expression and 
mitochondrial permeability transition in MPA-treated cells. This result 
suggests that the protective mechanism of HO-1 on MPA-induced cytotoxicity 
is associated with direct inhibition of ROS generation and mitochondrial 
permeability transition.
POSTER BOARD NUMBER P3 – 354
MMF AND CSA HAVE DIFFERENT EFFECTS ON 1928 
EXPRESSION OF CTGF IN RATS KIDNEY WITH 
CHRONIC ALLOGRAFT NEPHROPATHY
Y.P. Lu, G.H. Luo, L. Yang, J. Song, L. Luo, X. Ma, Y.P. Li
Transplantation Institute, West China Hospital, Sichuan University, 
Chengdu, China
Aim: CTGF is an important mediator of fi brosis and is capable of inducing 
epithelial-mesenchymal transformation (EMT). Cyclosporine A (CsA) 
is associated with renal fi brosis in long term using. It has been proved that 
Mycophenolate Mofetil (MMF) could inhibit or attenuate fi brosis process. This 
study is designed to determine whether the difference exists between MMF and 
CsA on the expression of CTGF and the fi brosis-associated genes in rat kidney 
underwent chronic allograft nephropathy (CAN).
Methods: F344 rat renal grafts were orthotopically transplanted into 
Lewis rats following the procedure of Kamada with our modifi cation. All 
the recipient rats were given CsA 10mg/kg-1.d-1x10d and then divided into 
three oral treatment groups (each group n=9): (1) Vehicle: given vehicle 
orally, (2) CsA: 6mg/kg-1.d-1, (3) MMF: 20mg/kg-1.d-1. At 4w, 8w, 12w, 
SCr and pathological changes were measured; The expression of CTGF, 
collagen I, IV, α-SMA and E-cadherin in grafts were assessed. The urine 
CTGF concentration was detected by a competitive indirect enzyme- linked 
immunosorbent assay.
Results: SCr and Banff score were increased in a time-dependent manner in 
all the 3 groups. The differences of SCr and Banff score among 3 groups 
were not signifi cant at 4w (p>0.05). At 8w and 12w, Scr(umol/L) in Vehicle, 
CsA and MMF group were 275±23.51, 516±32.00; 281±10.59, 516±31.6 
and 138±28.48, 305±32.92, respectively. The differences between MMF 
and other two groups were statistically signifi cant (p<0.05). The histological 
lesions of CAN in Vehicle and CsA groups were more serious than those in 
MMF group. At 8w and 12w, the Banff score between MMF and other two 
groups were statistically signifi cant (p<0.01). Urine CTGF increased at 4w 
and kept in high level till 12w. At 4w, 8w and 12w, The expression of CTGF 
mRNA / protein(DQ ratio) in renal graft in Vehicle, CsA and MMF group were 
23.00±0.50/0.54±0.02, 25.16±0.76/0.81±0.01, 26.50±0.50/0.86±0.05; 22.66±0.57/0.57±0.01, 
24.66±0.76/0.78±0.02, 26.50±0.86/0.90±0.02 and 21.33±0.57/0.38±0.02, 
23.50±0.50/0.62±0.01, 24.50±0.50/0.72±0.02, respectively. The difference between 
MMF and other two groups were statistically signifi cant (4w, p<0.05; 8w/12w, 
p<0.01). The expression of collagen I, IV and α-SMA in MMF group at all 
the time points were signifi cantly down regulated, and E-cadherin’ lose was 
abated in MMF group.
Conclusion: We demonstrate that the expression of CTGF in epithelial cells 
could act as a molecular marker of interstitial fi brosis in CAN. MMF can 
ameliorate fi brogenesis in transplant kidney by inhibiting the expression of 
CTGF, down-regulating the expression of the fi brosis-associated genes and 
inhibiting the EMT. Cyclosporine A has no these effects.
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INHIBITION OF MINERALOCORTICOID RECEPTORS 1929 
WITH EPLERENONE ALLEVIATES SHORT-TERM 
CYCLOSPORINE A NEPHROTOXICITY IN THE RAT
F.T. Nielsen1, B.L. Jensen1, N. Marcussen2, O. Skøtt1, P. Bie1
1University of Southern Denmark, 2Odense University Hospital
Background: Recent data indicate that aldosterone aggravates cyclosporin A 
(CsA)-induced nephrotoxicity. We examined whether the mineralocorticoid 
receptor (MR) blocker eplerenone (EPL) antagonized early deterioration of 
renal function and blood pressure increase in CsA-treated rats.
Methods: Male Sprague-Dawley rats received CsA (15 mg/kg/day i.p.) and/or 
EPL (100 mg/kg/day p.o.) for 21 days. After two weeks, arterial, venous, and 
urinary bladder catheters were implanted and the rats were trained to accept a 
restraining device allowing arterial blood sampling and direct measurement 
of blood pressure (BP) and renal function. BP was measured on-line in 
conscious rats.
Results: CsA signifi cantly increased systolic BP: 139 ± 4 vs. 134 ± 2 
mmHg, reduced body weight gain: -5±6 vs. 36±7 g, GFR: 1.02±0.16 vs. 
2.64±0.27 ml/min, RBF: 5.3±2.4 vs. 13.5±2.1 ml/min, and lithium clearance 
(CLi+): 0.16±0.04 vs. 0.26±0.07 ml/min compared to controls. These 
changes were prevented by simultaneous EPL treatment: Systolic BP: 130±4 
mmHg, weight gain: 53±7 g, GFR: 1.67±0.26 ml/min, RBF: 12.3±2.1 ml/
min and CLi+: 0.27±0.03 ml/min. Analysis of kidney morphology after CsA 
treatment showed hyaline vacuolization in tubules and vascular depositions 
in arterioles; these changes were less pronounced after combination therapy. 
No signifi cant changes were seen regarding haemoglobin, haematocrit, 
plasma renin, and vasopressin, plasma and urinary sodium, potassium, or 
osmolality.
Conclusions: MR blockade by EPL prevented short-term alterations in GFR, 
RBF and hypertension associated with CsA nephrotoxicity. We conclude that 
the aldosterone-MR pathway contributes markedly to the renal toxicity induced 
by this calcineurin inhibitor.
POSTER BOARD NUMBER P3 – 356
A NOVEL NF-KB INHIBITOR, 1930 
DEHYDROXYMETHYLEPOXYQUINOMICIN, SUPPRESSES 
THE IMMUNOSTIMULATORY FUNCTION OF HUMAN 
DENDRITIC CELLS
K. Shinoda1, K. Nakagawa1, H. Kono1, M. Oya1, K. Umezawa2
1Department of Urology, Keio University, School of Medicine, 2Department of 
Applied Chemistry, Faculty of Science and Technology, Keio University
Background: Dendritic cells (DC) are the most potent professional antigen-
presenting cells, and mature DCs play a pivotal role in the initiation of immune 
responses including the direct and indirect pathways. In the maturation of DCs, 
nuclear factor (NF)-kB is one of the most critical regulators. We synthesized 
a novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), and 
examined its effect on DC maturation.
Method: DCs were obtained from human peripheral blood monocytes by 
culturing with granulocyte macrophage-colony stimulating factor (GM-CSF) 
and interleukin-4 (IL-4), and were then used as immature DCs (im-DCs), 
lipopolysaccharide (LPS)-stimulated mature DCs (m-DCs), LPS-stimulated 
after treatment with DHMEQ DCs (dl-DCs), and LPS-stimulated before 
treatment with DHMEQ DCs (ld-DCs). First, we evaluated cytotoxity of 
DHMEQ on DCs and determined the concentration of DHMEQ (5 ƒÊg/ml) that 
was the maximum concentration that did not raise cytotoxity. We investigated 
four forms of DCs to determine the surface molecule expressions (by fl ow 
cytometry), cytokine production (by ELISA using culture supernatants), 
endocytosis (by FITC-dextran uptake evaluated by fl ow cytometry), and 
allogenic T cell stimulation (by mixed leukocyte reaction using 5-bromo-
2¦ f deoxy-uridine labeling and detection kit). To investigate effective time 
of DHMEQ, we quantifi ed NF-kB translocation into the nuclear of dl-DCs 
from 0 to 24 hours after LPS stimulation and analyzed expression levels of an 
IL-12 p40 gene by real-time PCR (by TaqMan cytokine gene expression plates, 
Applied Biosystems).
Results: DHMEQ signifi cantly inhibited both the upregulation of DC 
surface activation markers (CD40, 80, 86, HLA-DR) and the production of 
cytokines, which were IL-6 (30686 pg/ml and 12682 pg/ml for 0 and 5 ƒÊg/
ml), TNF-a (9845 pg/ml and 4967 pg/ml for 0 and 5 ƒÊg/ml), and IL-12 p40 
(7695 pg/ml and 225 pg/ml for 0 and 5 ƒÊg/ml) in a dose-dependent manner 
(at 1.0-10 ƒÊg/ml). More interestingly, not only dl-DCs but also ld-DCs 
demonstrated an inhibition in cytokine production after the administration of 
DHMEQ. Im-DCs exhibited a higher endocytotic capacity than did m-DCs 
(56.2% and 21.6% respectively, p<0.05). DHMEQ inhibited the down-
regulation of endocytosis induced by LPS (48.6% and 21.6% for dl-DCs 
and m-DCs, p<0.05). Furthermore, the proliferation response of allogenic 
T cells was effectively suppressed by dl-DCs and ld-DCs in comparison to 
that by m-DCs (at DC: T cell ratio being 1:10, 38.8%, 27% and 100% for 
dl-DCs, ld-DCs, and m-DCs respectively, p<0.05). Finally, we confi rmed 
that DHMEQ completely inhibited the NF-kB translocation to the nuclear 
of DCs and the expression of mRNA of IL-12 p40 of DHMEQ-treated DCs 
for 24 hours.
Conclusion: DHMEQ markedly inhibits the phenotypic and functional 
maturation of DCs by inhibiting the nuclear translocation of NF-kB in the 
course of LPS-stimulation of DCs. DHMEQ-treated DCs demonstrated the 
reduced production of cytokines and have less impacts on T cell stimulation 
than m-DCs.
POSTER BOARD NUMBER P3 – 357
RAPAMYCIN DECREASES CHOLESTEROL EFFLUX 1931 
AND ABCA1 PROTEIN EXPRESSION WITHIN THP-1 
MACROPHAGES
R. Tory1, K. Sachs-Barrable2, J.S. Hill1, K.M. Wasan2
1Department of Pathology and Laboratory Medicine, Fac. of Medicine, 
University of British Columbia, 2Faculty of Pharmaceutical Sciences, 
University of British Columbia
Background: Rapamycin (RAPA) has been widely used in solid organ 
transplantations. Unfortunately, RAPA has been known to contribute directly or 
indirectly to cardiovascular disease, one of the major long-term complications 
of solid organ transplantation. Side effects such as hypercholesterolemia 
and hypertriglyceridemia are associated with RAPA, representing major risk 
factors for cardiovascular disease. The mechanism, by which RAPA causes 
dyslipidemia is not well understood. In this study, we investigated the effects 
of RAPA on cholesterol effl ux and the expression of ATP-binding cassette A1 
(ABCA1) in THP-1 macrophages. Macrophages have been implicated in the 
etiology of cardiovascular disease, especially atherosclerosis; they accumulate 
lipids and change into foam cells that later become the atherosclerotic plaque. 
In addition, ABCA1 is involved in ApoA-1 mediated cholesterol effl ux from 
these cells.
Hypothesis: RAPA treatment of THP-1 macrophages will be associated with a 
decrease in cholesterol effl ux and ABCA1 protein expression.
Methods: THP-1 cells were differentiated with 1x10-7M with phorbol-
12-myristate-13-acetate (PMA) for 3 days. Cells were then exposed to 
appropriate drug treatments (1, 5, 10 and 20 ng/mL of RAPA) for 24 hours. 
The effect of RAPA on the ABCA1 protein expression of THP-1 macrophages 
was examined by Western blotting. The effect of RAPA on cholesterol effl ux 
was investigated by loading cells with [3H] cholesterol and appropriate drug 
treatments for 24 hours. Cholesterol effl ux was performed in the presence 
and absence of ApoA1 or HDL. To calculate percent effl ux, [3H] cholesterol 
was counted in the medium and divided by the sum of the cellular and media 
counts x 100.
Results and conclusions: We observed statistically signifi cant reductions in 
cholesterol effl ux and protein expression of ABCA1 following treatment with 
increasing concentrations of RAPA. Our data showed that RAPA induced 
reduction in the percent cholesterol effl ux to ApoA1 and HDL respectively 
compared to untreated control cells: 1 ng/mL (17±1%) and (24±2%), 5 ng/mL 
(20±2%) and (14±1%), 10 ng/mL (27±2%) and (19±2%), 20 ng/mL (42±2%) 
and (34±7%), respectively. Finally, consistent with the inhibition of cholesterol 
effl ux to ApoA1, RAPA was associated with a marked decrease in ABCA1 
protein expression compared to untreated cells: 1 ng/mL (13±9%), 5 ng/mL 
(32±12%), 10 ng/mL (81±7%), 20 ng/mL (87±1%). These fi ndings suggest that 
a RAPA-mediated decrease in cholesterol effl ux and ABCA1 protein expression 
may contribute in part to an increased cardiovascular risk in transplant patients 
administered RAPA.
Wednesday 13 August 2008 Poster Abstracts
6 3 6
W
ED
N
ES
D
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P3 – 358
THE EFFECTS OF INOSINE MONOPHOSPHATE 1932 
DEHYDROGENASE INHIBITION ON OLEIC ACID-INDUCED 
FIBRONECTIN SECRETION AND CELLULAR ROS IN 
MESANGIAL CELLS
K.H. Huh1, H.J. Ahn2, M.S. Kim1, Y.S. Kim1
1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, 
and 2Department of Surgery, Korea University College of Medicine, Seoul, 
Korea
Background: Mycophenolic acid (MPA), an inosine monophosphate 
dehydrogenase (IMPDH) inhibitor, suppresses mesangial proliferation. 
However, the mechanism has not been clearly elucidated. We investigated 
the effects of MPA and IMPDH2 reduction (by using siRNA) on oleic acid 
(OA)-induced fi bronectin secretion and cellular reactive oxygen species (ROS) 
production in mouse mesangial cells (MMCs).
Methods: Cells were treated with 100 μM OA, with or without MPA (0.1-10 
μM), IMPDH2 siRNA (10-50 nM), or 5 mM N-acetylcystein (NAC). 
Fibronectin was measured by Western blot, transforming growth factor 
(TGF)-β was measured by ELISA, and levels of DCF-sensitive cellular ROS 
were measured using fl ow cytometry.
Results: OA increased fi bronectin secretion and ROS. A TGF-β neutralizing 
antibody (25 μg/ml) effectively suppressed OA-induced fi bronectin secretion. 
MPA (10 μM) and NAC totally suppressed OA-induced fi bronectin secretion, 
TGF-β synthesis, and ROS production. IMPDH2 siRNA partially inhibited 
OA-induced mesangial activation.
Conclusions: TGF-β mediated OA-induced fi bronectin synthesis, and MPA 
might have inhibited OA-induced cell activation partly through inhibiting 
IMPDH2, but other mechanisms also contributed to the MPA-mediated 
mesangial inhibition in MMCs.
POSTER BOARD NUMBER P3 – 359
IS INHALED TACROLIMUS A SAFE TREATMENT 1933 
OPTION TO PREVENT ACUTE AND CHRONIC REJECTION IN 
AN AIRWAY TRANSPLANT MODEL?
T. Deuse1, D. Weill1, J. Fink2, F. Blankenberg1, C. Peter1, R. Robbins1, 
S. Schrepfer1
1Stanford University School of Medicine, 2Nektar Therapeutics, Mountain 
View, CA, USA
Background: Tacrolimus blocks T cell activation by interfering with the 
Ca2+-dependent phosphatase, calcineurin. The airway offers a selective route 
for drug delivery in tracheal/lung transplantation achieving high tissue levels 
without systemic side-effects. Although local immunosuppression may be 
advantageous to control acute and chronic rejection after airway transplantation, 
higher graft concentrations by local tacrolimus delivery could damage the local, 
graft protective airway epithelium. Therefore, we examined its direct effects on 
airway cells in vivo and in vitro.
Methods: To investigate the effi cacy of inhaled tacrolimus to prevent 
airway graft rejection, in vivo studies using 160 orthotopic BN-Lew tracheal 
transplantations were performed and tacrolimus (4mg/kg) was administered 
via aerosol (TA) using different nebulizers. The control groups received either 
oral tacrolimus (TO) or remained untreated (UA). Donor-specifi c cellular 
and humoral responsiveness was measured after a short-term treatment (1 
week), OAD development and side-effects were determined after a long-term 
treatment (2 months). Pharmacokinetics were measured by analyzing tissue 
and blood levels after QD or TID dosings. Drug distribution was measured 
by 3D-SPECT. The drug effect on the airway epithelium was quantitated by 
histology (PAS staining of goblet cells) and quantitative real time RT-PCR for 
MUC4, MUC5AC, and MUC5B gene expression. Cell viability, proliferation, 
MUC expression and phenotyp of airway epithelial cells grown at an air-liquid 
interface were investigated in vitro.
Results: Tracheal drug deposition is higher using nebulizers creating large 
particle sizes (10.2+/-0.3um), whereas lung deposition is increased with 
smaller particles (2.8+/-0.5um). Both, TO and TA treatments markedly 
suppressed the cellular (IFN-gamma spots:TA and TO vs UA p<0.001; 
IL-4 spots:TA p=0.579 and TO p<0.001 vs UA) and humoral response 
(IgM:TA p=0.004 and TO p<0.001 vs UA; IgG:TA p=0.241 and TO 
p=0.011 vs UA). Although TO was far more effective to suppress cellular 
and humoral response, luminal obliteration was similarly inhibited with 
TO (15+/-3%) and TA (13+/-4%) vs UA (44+/-7%,p<0.001) and the airway 
epithelium was preserved (TO:96+/-7%,TA 97+/-6% vs.UA 67+/-26%). 
Quantitative real time RT-PCR showed that higher local graft tissue levels 
(peak levels for TA: 901+/-175ng/g vs. TO: 502+/-93ng/g; p<0.001) did 
not alter physiologic gene expression of MUC4, MUC5AC, MUC5B. TO 
animals showed signifi cantly higher systemic side-effects, demonstrated by 
elevated BUN, cholesterol and triglyceride levels compared to TA animals 
(p<0.041).
Conclusions: These studies indicate that aerosolized tacrolimus shows 
promising potency to protect the graft against acute and chronic rejection, and 
such local immunosuppression may not impact the respiratory epithelium.
POSTER BOARD NUMBER P3 – 360
SAIREITO, A JAPANESE HERBAL MEDICINE, INDUCES 1934 
INDEFINITE SURVIVAL OF FULLY MISMATCHED CARDIAC 
ALLOGRAFTS AND GENERATES REGULATORY CELLS IN 
MICE
Q. Zhang1, D. Iwami1, O. Aramaki2, K. Watanabe3, A. Ishige3, N. Shirasugi1, 
M. Niimi1
1Teikyo University, 2Nihon University, 3Keio University, Tokyo, Japan
Aims: Saireito (TJ114) is a Japanese herbal medicine which consists of 
Shosaikoto (TJ9) and Goreisan (TJ17). A couple of reports have previously 
shown the immunomodulatory and anti-tumor activities of orally administered 
TJ114. However, there were not any reports about the effect of TJ114 on 
alloimmune responses in experimental or clinical transplantation. Here, the 
authors examined whether TJ114 could induce unresponsiveness to fully 
mismatched cardiac allografts in mice.
Methods: CBA mice (H2k) underwent transplantation of C57BL/6 (B6, H2b) 
hearts and received oral administration of TJ114 (2g/kg/day) from day 0 to day 
7 after grafting. An adoptive transfer study was performed to determine whether 
regulatory cells were generated in the TJ114-treated recipients. Histological 
examination and cell proliferation assay were performed.
Results: Untreated CBA mice rejected B6 cardiac grafts acutely (median 
survival time [MST], 9 days). In mice given TJ114, all allografts survived 
indefi nitely (MST, >100 days). However, neither TJ9 nor TJ17 prolonged 
the allografts survival (MST, 7 and 8 days, respectively). Moreover, TJ9 is 
extracts from seven herbal materials such as Bupleuri radix, Scutellariae 
radix, Pinelliae tuber, Ginseng radix, Ginseng radix, Zingiberis rhizoma and 
Zizyphi fructus, one of which did not induce graft survival. TJ17 is extracts 
from fi ve herbal materials such as Polyporus, Poria, Rhizoma atractylodis, 
Alismatis rhizoma and Cinnamomi cortex, one of which did not induce 
graft survival. Taken together, TJ9 and TJ17 are both essential to induce 
unresponsiveness. Next, adoptive transfer study was performed. Secondary 
CBA recipients (naïve) given whole splenocytes from primary TJ114-
treated CBA recipients with B6 cardiac allografts 30 days after grafting had 
prolonged survival of B6 hearts (MST, >60 days) compared to that in the 
secondary recipients with adoptive transfer of naïve splenocytes (MST, 8 
days), suggesting that regulatory cells were generated. BALB/c (third-party) 
hearts were eventually rejected in the secondary CBA recipients with the 
adoptive transfer of whole splenocytes from TJ114-treated recipients (MST, 
11.5 days), suggesting that the regulatory function is donor specifi c. When 
CD4+ cells were purifi ed from the spleen of the TJ114-treated recipients 
and were adoptively transferred into naïve secondary CBA recipients, the 
secondary recipients enjoyed prolonged survival of cardiac allografts (MST, 
>30 days), compared to that in the recipients with adoptive transfer of naïve 
CD4+ cells (MST, 13 days).
Conclusion: Treatment with TJ114 induced unresponsiveness to fully 
allogeneic cardiac allograft and generated donor-specifi c regulatory cells. The 
regulatory cells contained CD4+ population. Neither TJ9 nor TJ17 can induce 
prolongation of allograft survival, suggesting that cocktail of TJ9 and TJ17 
works synergistically to induce regulatory cells. Traditional knowledge of 
Japanese herbal medicine may contribute to immunomodulation after modern 
transplantation surgery.
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MYCOPHENOLIC ACID-MEDIATED SUPPRESSION OF 1935 
IMPDH IN CIRCULATING CD4+ CELLS IS NOT ASSOCIATED 
WITH IMMEDIATE GTP REDUCTION: A SINGLE-DOSE 
CROSSOVER EXPOSURE-RESPONSE STUDY IN HEALTHY 
INDIVIDUALS
N.T. Vethe1,2, S. Bremer1,2, H. Rootwelt1, I. Sæves1,2, S. Bergan1,3
1Dept of Medical Biochemistry, Rikshospitalet University Hospital, Oslo, 
2Institute of Clinical Biochemistry, University of Oslo, 3School of Pharmacy, 
University of Oslo
Background: Mycophenolic acid (MPA) is an uncompetitive, tight-binding 
inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme 
in the guanine nucleotide synthesis. Due to highly variable pharmacokinetics 
and pharmacodynamics it is hypothesized that personalized MPA treatment 
may improve the clinical outcome. The aim of our study was to characterize 
the exposure-response relationship for MPA at the molecular level, in order to 
guide future strategies of individualized treatment based on pharmacodynamic 
monitoring.
Methods: A single-dose (100, 250, 500 and 1000 mg mycophenolate mofetil) 
crossover exposure-response study of MPA pharmacodynamics in CD4+ cells 
was performed in fi ve healthy individuals. IMPDH activity, IMPDH gene 
expression and purine nucleotides were examined in relation to MPA plasma 
concentration.
Results: IMPDH was strongly inhibited by MPA; median EC50 was 2.5 (range 
1.3 to 4.3) mg/L. At the standard dose of 1000 mg, the median Cmax was 27 
(range 17 to 43) mg/L. The overall IMPDH activity (area under the curve; 
AUC) approached maximum suppression at MPA AUC0-12h 22 mg*h/L 
(corresponding to the 500 mg dose), and MPA plasma concentrations exceeding 
6 mg/L did not increase the IMPDH inhibition any further. The suppression of 
IMPDH was associated with reduced IMPDH gene expression. In contrast to 
the expected reduction of guanosine triphosphate (GTP), an increasing trend 
was observed in response to MPA.
Conclusions: The standard dose of 1000 mg was in the upper range of the 
response curve. Reduced IMPDH gene expression adds to the mechanism-
of-action of MPA. The absence of GTP reduction indicates that the cells 
possess mechanisms counteracting the expected molecular effect of MPA, and 
suggests that GTP may not serve as an immediate response biomarker of MPA 
pharmacodynamics in circulating lymphocytes.
POSTER BOARD NUMBER P3 – 362
EFFECT OF SIROLIMUS ON CYCLOSPORINE-INDUCED 1936 
DIABETES MELLITUS
C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim, 
H.E. Yoon, Y.S. Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Sirolimus (SRL) is a promising drug for replacing calcineurin 
inhibitors (CNI), but the effect of SRL on CNI-induced diabetes mellitus (DM) 
remains unclear. This study was performed to investigate the infl uence of SRL 
on established CNI-induced DM.
Method: Sprague-Dawley rats were divided into four groups: Vehicle (VH 
group), conversion of VH to SRL (VH/SRL group), CsA withdrawal (CsAW 
group) and conversion of CsA to SRL (CsA/SRL group). Rats on a low salt 
diet (0.05% sodium) were treated with VH (olive oil, 1mL/kg per day) and 
CsA (15mg/kg per day) for 28 days. And then, SRL (0.3 mg/kg per day) was 
concurrently administered via subcutaneously to CsA and VH groups for 28 
days. The effect conversion of CsA to SRL was evaluated by intraperitoneal 
glucose tolerance test, plasma insulin concentrations, blood glucose level and 
immohistochemistry of insulin in pancreatic ¥â-cell.
Results: The CsAW group showed complete recovery of DM, demonstrated by 
similar blood glucose concentration, calculated AUC and plasma insulin level 
compared with the VH group. The VH/SRL group showed increased blood 
glucose concentration, calculated AUC (581¡¾37 vs. 484¡¾30 mg/dL min, 
p<0.05) and decresed plasma insulin levels (3.90¡¾0.27 vs. 4.38¡¾0.35 mg/
dL min, p<0.05) compared with the VH group. The CsA/SRL group showed 
further increased blood glucose concentration and calculated AUC (983¡¾46 
vs. 581¡¾37 mg/dL min, p<0.05) and decreased plasma insulin concentration 
(3.70¡¾0.21 vs. 3.90¡¾0.27 mg/dL min, p<0.05) compared with the VH/SRL 
group. Immunoreactivity of insulin in pancreatic beta cells in the CsAW/SRL 
group was lower than other three groups other groups.
Conclusion: CsA withdrawal improves established CsA-induced DM, but 
conversion to SRL does not improve CsA-induced DM.
POSTER BOARD NUMBER P3 – 363
SYNERGISTIC EFFECT OF CYCLOSPORINE IN 1937 
RAPAMYCIN-INDUCE DIABETIC DISEASE
C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim, 
H.E. Yoon, Y.S. Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Rapamycin (RAPA) is a new drug with both immunosuppressant and 
antiproliferative properties that has a unique mechanism of action distinct from 
that of the calcineurin inhibitor. Several studies have investigated the effect of 
immunosuppressive agents on ƒÒ-cell function and effects of RAPA on insulin 
secretion are still debated. We investigated the infl uence of RAPA on insulin 
secretion in chronic cyclosporine (CsA)-induced nephropathy.
Methods: Sprague-Dawley rats maintained on a low salt diet (0.05% sodium) 
were treated subcutaneously with vehicle (olive oil, VH, 1mL/kg per day) and 
CsA (15mg/kg per day) for 21 days. RAPA (0.3mg/kg per day) was concurrently 
administered via subcutaneously to CsA and VH groups. This study was 
performed to evaluate the effect of RAPA with or without CsA treatment on 
pancreatic and renal injury. The effect of RAPA on CsA induced pancreatic 
injury was evaluated by intraperitoneal glucose tolerance test (IPGTT), plasma 
insulin concentrations, blood glucose level and pancreatic ƒÒ-cell morphology. 
The effect of RAPA on CsA-induced renal injury was evaluated by assessing 
renal function and pathology mediators of infl ammation and fi brosis such as 
osteopontin (OPN) and apoptotic cell death.
Results: Three weeks of CsA treatment caused diabetes, renal dysfunction, 
typical pathologic lesions and apoptotic cell death. VH+RAPA group 
signifi cantly increased blood glucose concentration, Calculated AUC (806 „b 
34 vs. 599 „b 13 mg/dL min, p < 0.05) decreased plasma insulin concentration 
(0.37 „b 0.01 vs. 0.42 „b 0.01 ng/mL, p < 0.05) compared with the VH group. 
CsA+RAPA group improved renal function and histopathology compared with 
the CsA group. Also pro-infl ammatory and pro-fi brotic molecules such as OPN 
and apoptotic cell death increased compared with the CsA group. In addition 
CsA+RAPA group signifi cantly increased blood glucose concentration, 
Calculated AUC (1546 „b 38 vs. 1069 „b 49 mg/dL min, p < 0.05) and plasma 
insulin concentration (0.29 „b 0.02 vs. 0.33 „b 0.01 ng/mL, p < 0.05) compared 
with the CsA group. Immunohistochemical staining for insulin in the VH group 
and VH + RAPA group strong and uniform pattern in a large proportion of the 
islet cells. In contrast, a lower intensity of staining and vacuolization in islet 
cells in the CsA group. CsA+RAPA group higher degree of vacuolization in the 
pancreas islet cells and decreased pancreatic ƒÒ islet mass.
Conclusion: Combination of RAPA with CsA treatments reduction in insulin 
production may be the result of beta cell death coupled with impaired beta cell 
regeneration.
POSTER BOARD NUMBER P3 – 364
INFLUENCE OF RAPAMYCIN ON RENAL TUBULAR 1938 
FUNCTION IN RATS WITH OR WITHOUT CYCLOSPORINE 
TREATMENT
C.W. Yang, H.K. Song, J.Y. Ghee, D.H. Han, B.S. Choi, S.H. Kim, 
H.E. Yoon, Y.S.Kim, B.K. Bang
Department of Internal Medicine, Kangnam St. Mary’s Hospital
Purpose: Rapamycin (RAPA) is a promising drug for sparing calcineurin 
inhibitors in clinical practice. But recent studies RAPA given around the time 
of renal injury can augment injury and combined treatment with RAPA and 
CsA increase synergistic effect of nephrotoxicity. However, it is undetermined 
whether the effect of rapamycin on renal tubule is related to the preexisting 
cyclosporine-induced renal injury or rapamycin itself. We investigated the effect 
of RAPA on renal function in rats with or without cyclosporine treatment.
Methods: Sprague-Dawley rats maintained on a low salt diet (0.05% sodium) 
were treated subcutaneously with vehicle (olive oil, VH, 1mL/kg per day) 
and CsA (15mg/kg per day) for 21 days. RAPA (0.3mg/kg per day) was 
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concurrently administered via subcutaneously to CsA and VH groups. The 
effect of RAPA with or without CsA treatment was renal function measured 
by serum creatinine, creatinine clearance, histological parameters, electrolyte 
level, detection of proteinuria in 24hr-urine collection and urine osmolality 
were studies. And the infl uence of RAPA with or without CsA on the kidney¡¦s 
ability to concentrate urine was evaluated using functional parameters and 
expression of aquaporins.
Results: Three weeks of VH+RAPA group Scr and Ccr with VH group 
not different, CsA+RAPA group signifi cant increase in Scr compared with 
the CsA group (1.21 „b 0.04 vs. 0.98 „b 0.03 mg/dl, p < 0.05). VH+RAPA 
group signifi cantly increased 24hr urine concentration (28 „b 4 vs. 14 „b 4 
ml, p < 0.05) and decreased urine osmolality (1007 „b 59 vs. 1283 „b 134, 
mOsm/kg, p < 0.05) is compared with VH group. Also CsA+RAPA group 
signifi cantly increased 24hr urine concentration (60 „b 7 vs. 15 „b 2 ml, p 
< 0.05) and decreased urine osmolality (467 „b 59 vs. 717 „b 47 mOsm/
kg, p < 0.05). The level of electrolyte in VH+RAPA group signifi cantly 
decreased potassium (3.3 „b 0.05 vs. 4.0 „b 0.08 mmol/L, p < 0.05) and 
magnesium (1.3 „b 0.1 vs. 1.9 „b 0.1 mmol/L, p < 0.05) compared with VH 
group. CsA+RAPA group signifi cantly decreased potassium (2.9 „b 0.10 vs. 
3.9 „b 0.15 mmol/L, p < 0.05) and magnesium not different. In addition, 
CsA+RAPA group signifi cantly higher increased tubulointerstitial fi brosis, 
infl ammatory cell infi ltration and apoptosis cell death compared with CsA 
group. Immunoblot analysis of AQP2 protein expression, CsA+RAPA group 
signifi cantly decrease compared with CsA group (36 „b 6.2% vs. 83 „b 3.5% 
p < 0.05).
Conclusion: RAPA treatments impair renal function and combination with 
CsA augments nephrotoxicity.
POSTER BOARD NUMBER P3 – 365
SUNITINIB PREVENTS NEOINTIMA PROLIFERATION 1939 
AFTER AORTIC DENUDATION IN RATS
J. Rintala1, J. Savikko1,2, S. Rintala1, N. Malmström1, P. Koskinen1,3
1Transplantation Laboratory, University of Helsinki, 2Department of Surgery, 
Päijät-Häme Central Hospital, Lahti, Finland., 3Helsinki University Central 
Hospital; Department of Medicine, Division of Nephrology
Background: Platelet-derived growth factor (PDGF) is one of the key 
mediators of atherosclerosis. The role of vascular endothelial growth factor 
(VEGF) in atherosclerosis is somewhat controversy. However, it also may 
induce atheroma proliferation. Accelerated atherosclerosis is one pathological 
manifestation of chronic allograft rejection. Sunitinib is a potent inhibitor of 
both VEGF and PDGF receptors. Therefore sunitinib could be a potential 
intervention for chronic rejection in the future. Here we investigated the 
effect of sunitinib on neointima proliferation after arterial endothelial injury 
in vivo.
Materials and methods: The aorta of male Wistar rats weighing 350 to 
370 g was denuded of endothelium by the intraluminal passage of a French 
Fogarty arterial embolectomy catheter introduced through the left iliaca artery. 
Rats were treated eather with sunitinib (5 or 20mg/kg/d) or with vehicle only 
(polyethylene glycol). Histologic changes and analysis of neointimal area were 
evaluated from midaortic sections 14 days after injury.
Results: In the vehicle-treated group, moderate neointima formation was 
detected. Sunitinib prevented the neointima formation almost completely 
already with the lower dose. Higher dose of sunitinib decreased neointima 
formation even further altough no statistical difference was seen between these 
two sunitinib-groups. Sunitinib was well tolerated with both doses.
Conclusions: Our results demonstrate that sunitinib is a potent inhibitor of 
neointima formation after arterial endothelial injury. Based on these fi ndings 
sunitinib could prevent accelerated atherosclerosis also in experimental solid 
organ transplantation. However, to defi ne the true potential of sunitinib in the 
treatment of allograft rejection more experiments are needed.
POSTER BOARD NUMBER P3 – 366
INFLUENCE OF RENIN-ANGIOTENSIN SYSTEM ON 1940 
THE EXPRESSION OF KLOTHO, AN ANTI-AGING GENE, IN 
EXPERIMENTAL MODEL OF CHRONIC CYCLOSPORINE 
NEPHROPATHY
H.E. Yoon, H.K. Song, J.Y. Ghee, B.S. Choi, Y.S. Kim, B.K. Bang, C.W. Yang
Kangnam St Mary’s Hospital, The Catholic University of Korea
Background: Klotho gene plays an important role in suppressing aging 
process. The present study evaluated the expression of Klotho gene in chronic 
cyclosporine (CsA) nephropathy, and in CsA nephropathy with angiotensin II 
receptor blockade.
Methods: Two separate experiments were performed. In the fi rst experiment, 
mice on the normal salt diet (NSD, 0.3%) or low salt diet (LSD, 0.05%) were 
treated with vehicle (VH group, olive oil, 1 mg/kg per day) or CsA (CsA group, 
30 mg/kg per day) for one or four weeks. In the second experiment, mice on 
a NSD were given VH or CsA with losartan (LSRT, 100 mg/L per day) for 4 
weeks.
Results: Klotho protein was selectively expressed in connecting tubules in the 
VH group. The CsA group with NSD or LSD revealed decreased expression 
of Klotho mRNA and protein compared with the VH group. The CsA group 
with LSD revealed further decreased expression of Klotho mRNA and protein 
compared with the CsA group with NSD. Concomitant administration of LSRT 
in CsA group increased the expression of Klotho protein compared with the 
CSA group.
Conclusions: CsA-induced renal injury decreases the expression of Klotho 
gene, and angiotensin II blockade protects aging process by upregulating the 
expression of Klotho gene.
POSTER BOARD NUMBER P3 – 367
SIROLIMUS TREATMENT IS BENEFICIAL IF GIVEN 1941 
PROPHYLACTICALLY OR LATE AFTER RENAL 
MASS REDUCTION
J. Rovira1, E.M. Arellano1,2, J. Carreras3, E. Banon-Maneus1, 
M.J. Ramirez-Bajo1, D. Moya-Rull1, A. Sole-Gonzalez1, I. Revuelta1, 
J.M. Campistol1, F. Diekmann1,4
1LENIT. Nephrology and Renal Transplantation, Hospital Clinic i Provincial 
de Barcelona, Spain, 2Nephrology. Hospital Universitario, 3Pathology, 
Hospital Clinic i Provincial de Barcelona, Spain, 4Nephrology, Charite 
Campus Mitte, Berlin, Germany
Sirolimus (SRL) has been associated with a benefi cial effect in terms of 
proteinuria and histological damage if initiated six weeks after renal mass 
reduction (RMR) in a rat model. The aim was to evaluate the infl uence of SRL 
treatment on proteinuria and renal histology if initiated before and very late 
after RMR in a rat model.
Methods: Rats either underwent cryoablation of 2/3 of the left kidney and 
subsequent right nephrectomy (group N; n=42) or sham operations (group S; 
n=29). Two weeks before (B) or twelve weeks after (L) RMR, treatment with 
SRL or vehicle (VEH) was initiated at 1.0 mg/kg three times a week (SRL levels 
in blood 38 ng/mL). Creatinine clearance and proteinuria were evaluated in all 
8 groups. 18 weeks after RMR, glomerular hypertrophy, glomerular sclerosis, 
tubular atrophy, interstitial fi brosis and chronic infl ammatory infi ltrate in the 
left kidney were evaluated.
Results: Immediately after RMR creatinine clearance was lower in rats 
with reduced renal mass (4.48 mL/min·kg vs. 1.81 mL/min·kg; p<0.001). 
At the end of treatment, the creatinine clearance was not different between 
N+VEH and N+SRL (B and L) groups. Four weeks after RMR, a signifi cant 
increase of proteinuria was observed, the SRL administration before and 
after RMR led to a stabilization of proteinuria until the end of the study, 
whereas the group N+VEH experienced a further increase of proteinuria 
(Table 1). RMR rats treated with SRL have less structural damage in all 
evaluated parameters.
Conclusion: SRL treatment has the potential to halt progression of proteinuria 
at any time during the course of progression in a model of reduced renal mass.
Proteinuria (mg/24h) 4 weeks 8 weeks 12 weeks 18 weeks
S+VEH 20.8±2.9 15.3±7.2 17.9±4.2 16.5±4.4
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Nx+VEH 84.5±72.0# 95.9±58.0## 142.5±19.2### 231.0±56.0###
S+SRL+B 5.5±1.3 9.7±0.6 14.2±7.3 ---
Nx+SRL+B 40.5±30.2 79.3±49.1# 56.3±17.3#* ---
S+SRL+L 25.2±4.4 20.6±6.2 18.6±7.4 11.4±6.2
Nx+SRL+L 90.6±74.4 95.6±62.8# 124.0±64.2# 154.8±31.1#*
# p<0.05 versus Sham; * p<0.05 versus VEH
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IMMUNOSUPPRESSIVE AGENTS AND THEIR 1942 
INFLUENCE ON HCV RNA REPLICATION AND INFECTIVITY 
IN VITRO
S. Ciesek1,2, E. Steinmann2, M. Manns1, H. Wedemeyer1, T. Pietschmann2
1Medical School Hannover, 2Experimental Virology, Twincore, Hannover
End stage liver disease that is associated with chronic hepatitis C infection 
is one of the leading causes for liver transplantation worldwide. Moreover, 
patients with recurrent hepatitis develop cirrhosis within fi ve years of their 
transplant. Several recent data suggest that the outcome of hepatitis C 
after liver transplantation has worsened in individuals transplanted in the 
late nineties. Beside older donor age immunosuppressive regimens may 
contribute to the outcome of graft hepatitis. Single substances have been 
shown to display antiviral effects in the replicon model while others are 
believed to have antifi brotic properties. Until now, there are only limited data 
available characterizing the infl uence of immunosuppressive compounds 
on HCV replication and infection in a fully permissive cell culture system 
which reproduces the complete viral replication cycle in tissue culture. As a 
consequence, no defi nite recommendation for an “optimal” immunosuppressive 
regimen based on in vitro data can be given at this stage. Therefore, in this 
study we assessed the infl uence of different immunosuppressive compounds 
routinely used upon hepatitis c associated liver transplantation with regard to 
their effect on HCV RNA replication and infectivity.
To this end, we transfected a highly permissive human hepatoma cell line 
with HCV reporter virus genomes,and monitored HCV RNA replication 
and infection in the presence of varying doses of the respective compounds. 
Cellular toxicity of the immunosuppressive agents was analyzed utilizing a 
commercially available cytotoxicity assay.
Tacrolimus, everolimus, prednisolone and the IL-2 receptor antagonist 
basiliximab neither infl uenced HCV RNA replication nor affected the 
infectivity of released virions. In contrast, the addition of mycophenolic acid 
(MPA) at a concentration of 40 μg/ml or of 0.25 μg/ml Ciclosporin A (CsA) 
to the cell culture medium caused a 90% (IC90) reduction of HCV RNA 
replication of the genotype 2a reporter virus as compared to the untreated 
control. Moreover, when target cells were inoculated with virus particles 
prepared in the absence of the drugs, addition of MPA or CsA at concentrations 
of 5 μg/ml and 0.1 μg/ml, respectively, reduced infectivity by more than 
90% indicating that these compounds also inhibited HCV RNA replication 
in infected cells. Finally, we tested various combinations of frequently used 
immunosuppressive compounds. None of the tested combinations abrogated 
the antiviral effect of CsA on HCV replication. Further studies characterizing 
additive and/or synergistic effects between individual compounds are 
ongoing.
While we did not observe any cytotoxicity of CsA in the applied concentration 
range higher doses of MPA (≥; 50 μg/ml) inhibited proliferation of the cells.
In conclusion, CsA exerts a potent antiviral effect on HCV RNA replication 
in the cell culture model fully permissive for HCV replication. In contrast, the 
ability of MPA to inhibit HCV replication is likely at least in part attributable 
to its interference with cell proliferation. Whether the direct antiviral effect of 
CsA ameliorates fi brosis progression has to be investigated in future controlled 
randomized studies.
POSTER BOARD NUMBER P3 – 369
EFFECTS OF INHIBITING NUCLEAR FACTOR-KAPPA B 1943 
ON ACUTE VASCULAR REJECTION
Z. Shen, X. Zhu, M. He, Y. Chen, Z. Zhu, Y. Zhu, S. Guo
The First Affi niatied Hospital of Soochow University
Objective:To evaluate the effect of nuclear factor-kappa B (NF-¦ÊB) 
inhibitor pyrrolidine dithiocarbamate (PDTC) on the cell-surface expression 
of costimulatory molecules (CD80, CD86) on dendriteic cells (DC) and the 
discordant cardiac xenograft rejection with the model of heterotopic cardiac 
xenotransplantation from guinea pig.
Methods: SD rats were pretreatment with Chinese Cobra Venom Factor 
(CVF) to preclude hyperacute rejection and PDTC was injected before Cardiac 
xenograft from guinea pig into the abdomen of SD rat. mixed lymphocyte 
reaction (MLR) was performed to test the tolerance effect in vitro, NF-¦ÊB 
activation in recipients was refl ected by positive nuclear staining of NF-¦ÊB 
(p65 subunit), Expression of OX-62, CD80 and CD86 on DCs from spleen 
were detected by fl ow cytometry. The mean survival time (MST) and the 
pathology of grafted heart were also observed.
Results: The immune response was suppressed by PDTC proved by MLR 
assay. The increase of CD80 and CD86 expression was suppressed and MST 
was prolonged in experiment group.
Conclusion: Pretreatment with PDTC could inhibit the expression of 
costimulatory molecules on DCs in the recipients after transplantation, which 
also prolonged the MST and suppress AVR in some extent.
POSTER BOARD NUMBER P3 – 370
INFLUENCE OF TIMING AND DOSE OF CALCINEURIN 1944 
INHIBITORS EXPOSURE ON GRAFT ACCEPTANCE, TREGS 
GENERATION AND FOXP3 REGULATION
K. Takahashi1,4, M. Kawai1,4, T. Soma1,4, E. Lerut, H. Kitade1,4, C. Mathieu, 
M. Waer, J. Pirenne1,4
1Abdominal Transplant Surgery Department, Catholic University of Leuven, 
2Morphology and Molecular Pathology, Catholic University of Leuven, 
3Laboratory for Experimental Medicine and Endocrinology (LEGENDO), 
Catholic University of Leuven, 4Laboratory for Experimental Transplantation, 
Catholic University of Leuven
Introduction: Regulatory T cells (Treg) play a crucial role for the induction and 
maintenance of tolerance. Transcription factor FoxP3 is specifi cally expressed 
on Treg and is important for the maintenance of their function. Several studies 
report that Cyclosporine A (CsA) prevents Tregs generation by inhibiting the 
expression of FoxP3 in organ transplantation. We previously showed Tregs 
generation was not only determined by the dose but also by the timing of CsA 
exposure in vivo. Therefore, we hypothesized FoxP3 expression may also be 
infl uenced by the pattern of CsA exposure and studied that in a rat model.
Methods: PVG rat recipients of an MHC fully mismatched RA heart were 
orally exposed to an identical overall dose of CsA for 12 days (starting the day 
of transplantation). However, the pattern of CsA exposure varied according 
to three groups (Gr). Gr1: constant exposure to a low dose of 10mg/kg/day; 
Gr2: gradually increasing exposure from 0 to 40mg/kg/day; Gr3: gradually 
decreasing exposure from 40 to 0mg/kg/day. Another group (Gr4) was exposed 
to a high dose CsA at 50mg/kg/day.
Grafts were harvested on post-Tx day 3, 7, 14 and 30. mRNA was extracted and 
intragraft FoxP3 expression was measured by real time RT-PCR. In addition, 
to assess the presence of Treg in vivo, adoptive cell transfer experiments were 
performed on post-Tx day 21.
Results: 8 of 10 rats in Gr1 and 7 of 9 in Gr2 accepted grafts indefi nitely 
(median graft survival time (MST) > 90 days), while 10 of 11 rats in Gr3 
and all 10 in Gr4 underwent rejection (MST = 20 and 34 days, respectively). 
Adoptive cell transfer experiments showed the presence of Treg in vivo in low 
dose CsA group (Gr1) and ¦ gearly low/late high¦ h dose CsA group (Gr2) but 
not in ¦ gearly high/late low¦ h dose CsA group (Gr3) or high dose CsA group 
(Gr4). Intragraft FoxP3 mRNA on post-Tx day 30 was signifi cantly increased 
compared with those on post-Tx day 14 in each group (P < 0.05). However, the 
levels of FoxP3 in the low dose CsA group (Gr1) and ¦ gearly low/late high¦ h 
dose CsA group (Gr2) were signifi cantly higher than those of ¦ gearly high/late 
low¦ h dose CsA group (Gr3) and high dose CsA group (Gr4), (P < 0.05).
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Conclusion: The study shows the expression of intragraft FoxP3 is infl uenced 
by the overall dose and timing of exposure to CsA intimately corresponding 
with Treg generation. Particularly, immediate exposure to high dose CsA 
post-Tx prevents the propagation of FoxP3 in grafts and Tregs generation, 
and provokes rejection. On the contrary, starting CsA at lower doses post-Tx 
and progressively increasing it allows substantial expansion of FoxP3, Tregs 
generation and better graft outcome.
POSTER BOARD NUMBER P3 – 371
THE INFLUENCE OF CURRENT IMMUNOSUPPRESSION 1945 
ON THE GENERATION AND MAINTENANCE OF 
REGULATORY T CELLS
M. Schulze1, E. Muller2, D. Kahn2
1Department of Surgery, University Hospital of Schleswig-Holstein, 
2Department of Surgery, University of Cape Town, South Africa
The immunosuppressive drugs rapamycin, tacrolimus and cyclosporin A are 
widely used to prevent allograft rejection, although the relative merits of each 
agent in tolerance-inducing immunosuppressive protocols remain contentious. 
In part, this refl ects our limited understanding of the effect of these drugs on 
the CD4+CD25+ regulatory T cell (T reg) population in humans, which play an 
important role in the development of tolerance to allografts.
Recently, it was reported that alloantigen-driven expansion of human CD4+ 
CD25+ T regs gives rise to a distinct subset of CD27+ T regs, which are more 
potently suppressive than the CD27- subset. In the current study, we investigated 
the effect of rapamycin, tacrolimus and cyclosporin on the generation of 
CD27+ T regs after alloantigen-driven expansion in vitro and showed that, 
unlike cyclosporin, both rapamycin and tacrolimus promoted the development 
of CD27+ T regs over the development of the CD27- T regs. Likewise, the 
relative number of CD27+ T regs in the peripheral blood of patients on 
rapamycin-based immunosuppressive regimens was greater than in patients 
treated with either tacrolimus or cyclosporin. We propose that the differential 
effect of rapamycin, tacrolimus and cyclosporin on the predominance of the 
CD27+ T reg subset may favour the use of rapamycin-based regimens in 
tolerance-inducing immunosuppressive protocols.
POSTER BOARD NUMBER P3 – 372
IMMUNOMODULATORY EFFECTS OF COBALT 1946 
PROTOPORPHYRIN WHEN ADMINISTERED IN 
COMBINATION WITH IMMUNOSUPPRESSIVE DRUGS IN A 
CARDIAC RAT ALLOTRANSPLANTATION MODEL
F. Besenzon1, A. Dedja1,2, M. Vadori1, E. Bosio1, M. Seveso2, F. Calabrese3, 
C. Giacometti3, D. Ramon2, E. Ancona1,2,4, E. Cozzi1,2,4
1Dept. of Surgical And Gastroenterological Sciences, University of Padua, 
Padua, Italy, 2CORIT, Padua, Italy, 3Institute of Pathology, University of 
Padua, Padua, Italy, 4Padua General Hospital, Padua, Italy
Introduction: Immunosuppressive strategies are designed to take advantage of 
potential synergy between drugs, and ultimately decrease the risk of side-effects. 
Porphyrins have been used to upregulate expression of heme oxygenase-1 
(HO-1), a cytoprotective and anti-apoptotic protein capable of reducing ischemia/
reperfusion injury and increasing graft survival in allo- and xenotransplantation 
models. In addition, HO-1 has been shown to modulate T-cell activation and 
proliferation. Based on our preliminary in vitro results, indicating increased 
immunosuppressive effects of cyclosporine A (CsA) when combined with cobalt 
protoporphyrin (CoPP, kindly donated by Frontier Scientifi c Inc., Logan, USA), 
we investigated the capacity of such drug combination to prolong survival of 
heterotopically transplanted cardiac allografts in a rat model.
Material and methods: Heterotopic cardiac allotransplantation procedures 
were performed using D’Agouti (n=24) and Lewis rats (n=24) as heart donors 
and recipients, respectively. Postoperatively, recipients were divided into 
6 experimental groups using different dose combination of CsA (Novartis) 
(suboptimal immunosuppression: 1.5mg/kg CsA; optimal immunosuppression: 
5mg/kg CsA, once daily administered by oral gavage) and different dosages 
of CoPP (5mg/kg, 10mg/kg or 20mg/kg of subcutaneous CoPP on the day 
of surgery and twice a week thereafter). Control animals received either 
CsA or CoPP. Grafts and whole blood samples were retrieved at cessation 
of heartbeat, as detected by abdominal palpation. Tissues were sectioned to 
evaluate the presence and degree of rejection. Blood samples were collected 
for pharmacodynamic studies by quantifi cation of concanavalin A (Con 
A) stimulated lymphocyte proliferation, after carboxyfl uorescein diacetate 
succnimidyl ester (CFSE) labelling.
Results: Considerable differences in graft survival were observed between the 
different groups. In particular, animals immunosuppressed with CsA 1.5mg/kg 
only had a median survival of 7 days, whilst animals immunosuppressed with 
CsA 1.5mg/kg and CoPP 20mg/kg had a median survival of 10 days. Proliferation 
of Con A stimulated PBMC was not infl uenced by CsA treatment. In contrast, 
Con A stimulated PBMC isolated from animal treated with CsA in combination 
with CoPP (10 or 20mg/kg), showed blocked or delayed cell proliferation.
Conclusions: Our preliminary in vivo studies suggest that CoPP may potentiate 
the immunomodulatory effects of CsA and extend allograft survival.
POSTER BOARD NUMBER P3 – 373
EFFECT OF B-CELL DEPLETIONAL THERAPIES 1947 
ON ALLOIMMUNE HUMORAL RESPONSES IN A 
MURINE MODEL
B. Book, G. Martens, R. Sidner, M. Volz, M. Pescovitz
Indiana University School of Medicine
There is growing interest in B-cell-directed therapy in transplantation, yet 
there are limited data on its immunologic impact. We report the effect of two 
distinct B-cell depletion regimens on allo-antibody (Ab) responses using 
a murine model. B-cell depletion was accomplished with a BR3-Fc fusion 
protein (soluble BAFF antagonist), and anti-BR3 (dual function BAFF agonist 
and cell depleter). C57BL/6 mice received BR3-Fc or anti-BR3. Initial fl ow 
cytometric (FCM) analysis documented B-cell depletion and recovery. Cohorts 
received one dose intraperitoneal (IP) anti-BR3 (200?g/mouse). BR3-Fc (200 
?g) was given IP twice weekly for 6 weeks (wk). To examine the impact of 
B-cell depletion, immunization was performed at 7 days (D) after the dose 
of anti-BR3 and 14 D after the fi rst dose of BR3-Fc. Cohorts of mice (n=3) 
were immunized IP with BALB/c splenocytes (2x107 cells) and boosted 1 
month later. Controls included no anti-B-cell therapy (positive control, PC) and 
autologous sera for negative control. Serum samples were obtained weekly for 
6 weeks. Two-fold dilutions of sera were incubated with cells and secondary 
anti-IgG- or –IgM-FITC. Binding was detected by FCM. The sum of the 
mean fl uorescence channel was calculated after subtracting autologous serum 
control. Statistical analyses used Kruskal-Wallis one-way analysis of variance 
and Dunn’s Method of pairwise comparison. B220 expression in peripheral B 
cells was determined at baseline, 1,2,4,6,8,10 and 12 wks post therapy by FCM. 
Statistical analyses utilized Student s t-test (p<0.05 was signifi cant). Anti-BR3 
led to rapid B-cell depletion from 42% to 6% at one week with recovery to 
35% at 12 weeks(wks). BR3-Fc required 4 wks for B-cell depletion from 43% 
to 8% and continued to be low at wk 12 (7%). Both agents suppressed the allo 
Ab response. IgG, but not IgM Allo-Ab was suppressed signifi cantly with anti-
BR3 and despite recovery of peripheral B cells a booster response was delayed 
and the level reduced. There was a slight effect on antibody with BR3-Fc. This 
difference could be due to small sample size, the level of B-cell depletion at 
time of immunization, or a qualitative difference in residual B cells. From a 
clinical perspective, the more rapid and complete inhibition with anti-BR3 
makes it a more favorable agent to move into clinical trials.
POSTER BOARD NUMBER P3 – 374
TARGETED DELIVERY OF RAPAMYCIN TO DENDRITIC 1948 
CELLS USING BIODEGRADABLE MICROPARTICLES IS 
HIGHLY EFFECTIVE IN SUPPRESSING THEIR MATURATION 
AND FUNCTION
 G. Raimondi2,5, S. Jhunjhunwala1, A.W. Thomson2,3,5, S.R. Little1,3,4,6
Departments of 1Bioengineering, 2Surgery, 3Immunology, and 4Chemical 
Engineering, 5Thomas E. Starzl Transplantation Institute and 6McGowan 
Institute For Regenerative Medicine. University of Pittsburgh, Pittsburgh, PA 
15260 USA
Introduction: Degradable microparticles (MPs) have potential to protect and 
release drugs over extended periods and, if sized appropriately, can be targeted 
passively to phagocytic cells. Previously, we have shown that dendritic cells 
(DC) treated with the immunosuppressive pro-drug rapamycin (rapa) are 
resistant to maturation and prolong vascularized transplant survival in a mouse 
vascularized heart allograft model. Targeting of rapa to immature DC using 
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MPs may potentiate the tolerogenic potential of these cells and minimize the 
need for systemic immunosuppression.
Methods: Rapa was encapsulated into ~3.4 μm-sized poly-lactic-co-glycolic 
acid (PLGA) MPs (rapaMPs) and release behavior was examined under intra-
phagosomal (pH = 5) and extracellular (pH = 7.4) conditions. Bone marrow-
derived CD11c+ DC were exposed to rapaMPs. RapaMPs internalization and 
their effect on DC immuno-biology was investigated.
Results: RapaMPs are characterized by a similar biphasic release profi le at 
the two pH values tested. However, at pH=5 the amount of Rapa released 
was signifi cantly higher, suggesting a more favorable release of the drug once 
MPs are internalized. Following overnight incubation with DC, rapaMPs were 
internalized in numbers that correlated with the initial concentration of particles, 
as determined by microscopic and fl ow cytometric analyses. Internalization of 
rapaMPs did not reduce DC viability. Maturation marker expression (MHC 
class II, CD80, CD86, and CD40) confi rmed that the cells were preserved in 
an immature state. Further, DCs that took up rapaMPs had markedly reduced 
ability to activate allogeneic T cells to induce their differentiation toward 
effector T cells compared to DCs exposed to an excess of soluble rapa. 
Signifi cantly, loading of DC with rapaMPs did not prevent up-regulation of 
maturation markers following LPS exposure, but these “mature-like” cells 
remained markedly compromised in promoting alloreactive T cell proliferation 
in vitro. In vivo injection of rapaMPs-loaded DC confi rmed a reduced T cell 
stimulatory ability in vivo compared with control DC.
Conclusions: DC-targeted intracellular delivery of rapa using biodegradable 
MPs results in improved effi cacy of the drug (with respect to its ability to 
modulate DC allostimulatory capacity) when compared to treating DCs with 
extracellular rapa. These data suggest that rapaMP-loaded DCs are promising 
novel vectors for prevention of transplant rejection.
POSTER BOARD NUMBER P3 – 375
R348, A JAK3 INHIBITOR, IS IMMUNE CELL SPECIFIC 1949 
AND PRESERVES THE RESPIRATORY EPITHELIUM WHILE 
STABILIZING MUCIN GENE 4 (MUC4) EXPRESSION IN THE 
PREVENTION OF OBLITERATIVE AIRWAY DISEASE (OAD)
S. Schrepfer1, J. Velotta1, T. Deuse1, C. Peter1, V. Taylor2, E. Masuda2, G. 
Park2, D. Carroll2, R. Robbins1
1Stanford University School of Medicine, Department of Cardiothoracic 
Surgery, 2Rigel Pharmaceuticals, South San Francisco, CA
Objective: This is the fi rst study to investigate the effect of R348, a Jak3 
inhibitor, on different cell types involved in the development of obliterative 
airway disease (OAD), specifi cally investigating the respiratory epithelium, 
infl ammatory cascade, and smooth muscle cells.
Methods: Trachea from Brown-Norway (BN) donors were transplanted 
heterotopically into the greater omentum of Lewis (Lew) rats. Recipients were 
treated with either R348 (40 mg/kg/d), rapamycin (3mg/kg/d), or left untreated 
for 28 days. Trachea specimens were evaluated histologically to determine 
quantitative levels of PAS-positive respiratory epithelial cells (=goblet cells). 
Tracheal epithelial mucin gene 4 (Muc4) RNA levels were determined between 
all groups using quantitative real time reverse transcription polymerase chain 
reaction (qRT-PCR). Prevention of cellular rejection was investigated between 
all groups using enzyme-linked immunosorbent spot (ELISPOT) assays on 
day 5 and tracheal grafts were analyzed by immunohistochemistry for total 
mononuclear cell infi ltration. To assess the role of R348 on smooth muscle 
cells, platelet derived growth factor (PDGF)-stimulated human coronary 
artery smooth muscle cells (hSMCs) were incubated with each respective drug 
(100nM) for 5 days and a MTT proliferation assay was performed.
Results: R348 40 mg/kg/d treated recipients and syngeneic (Lew-Lew) 
recipients contained moderate and outstanding levels of PAS-positive goblet 
cells, respectively. Both rapamycin 3 mg/kg/d and untreated recipients 
expressed no PAS-positive goblet cells. These histological results were 
confi rmed by qRT-PCR that showed R348 40 mg/kg/d treated recipients had 
176-fold greater Muc4 RNA levels compared to untreated recipients (1.04 
± 0.9 vs. 0.0059 ± 0.003, p<0.02) and also signifi cantly expressed 16-fold 
greater Muc4 RNA levels versus rapamycin 3 mg/kg/d treated recipients (1.04 
± 0.9 vs. 0.06 ± 0.1, p<0.02). R348 40 mg/kg/d treated recipients expressed 
similar Muc4 RNA levels compared to syngeneic recipients. Both, R348 and 
rapamycin, signifi cantly reduced the Th1 (IFN- ã) and Th2 (IL-4) immune 
response as evidenced by decreased spot frequencies of IFN-ã (1064 ± 117 vs. 
366 ± 50 and 194 ± 115, p<0.0001) and IL-4 (111 ± 30 vs. 48 ± 26 and 23 ± 18, 
p<0.0001) versus untreated recipients with rapamycin producing a signifi cant 
reduction in IFN-ã and IL-4 compared to R348 treated recipients (194 ± 115 
vs. 366 ± 50 and 23 ± 18 vs. 48 ± 26, p<0.01). Both R348 and rapamycin 
treated recipients expressed signifi cantly decreased amounts of peritracheal 
mononuclear cells versus untreated recipients (1087 ± 518 cells/mm2 and 1014 
± 209 cells/mm2 vs. 8018 ± 1788 cells/mm2, p<0.0001). R348 had no effect 
on hSMC proliferation similar to untreated control cells, whereas rapamycin 
signifi cantly inhibited hSMC proliferation. 
Conclusion: R348 effectively attenuates OAD while preserving the respiratory 
epithelium and possessing immune cell specifi city, in contrast to rapamycin which 
possesses inferior epithelial preservation capability and exerts its effects on multiple 
cell types. R348 provides a favorable alternative to the current immunosuppressive 
regimen in the prevention of chronic airway allograft rejection.
POSTER BOARD NUMBER P3 – 376
THE EFFECTS OF DHMEQ, A NOBEL NF-KAPPA 1950 
B INHIBITOR ON DEVELOPMENT OF OBLITERATIVE 
BRONCHIOLITIS IN HETEROTOPIC MURINE AIRWAY ALLO-
TRANSPLANTATION
Y. Oshima1, M. Uno1, T. Shibata1, T. Oura1, M. Watanabe1, R. Goto1, 
K. Umezawa2, M. Ozaki1, K. Yamashita1, S. Todo1
1First Department of Surgery, Hokkaido University, 2Department of Applied 
Chemistry, Keio University, Yokohama, Japan.
Background: Despite use of potent immunosuppressants, obliterative 
bronchiolitis (OB) remains a major hurdle for achieving long-term graft 
survival in lung transplant recipients. The transcription factor, NF-κB plays a 
crucial role upon infl ammation and acute allograft rejection. In this study, we 
examined the effect of a novel NF-κB inhibitor, DHMEQ in combination with 
tacrolimus on OB in mice.
Method: The trachea including main bronchi from BALB/c (H-2d) mice were 
transplanted heterotopically into subcutaneous pocket in C57BL6 (H-2b) mice. 
Recipient animals were given i.p. either control vehicle, DHMEQ (20 or 40 mg/
kg/day), tacrolims (1.5 mg/kg/day) or DHMEQ (20 mg/kg/day) plus tacrolimus 
daily after transplantation, and euthanaized at 28 days post-transplantation. 
Graft histology (lumen opening and epithelium remaining) and frequency of 
alloreactive IFN-γ producing cells (ELISPOT) within splenocytes of transplant 
mice were examined.
Results: In the control animals, all trachea allografts were completely obliterated 
(Fig. A) along with epithelial destruction (Fig. B) and luminal fi brosis. Daily 
administration of DHMEQ at 20 mg/kg did not prevent graft OB (n=8). In 
contrast, twice daily DHMEQ at 20 mg/kg (n=9) signifi cantly attenuated both 
luminal obliteration and epithelial destruction (both p<0.005) in the allografts 
as compared to control (Fig. A, B). Furthermore, graft protection against OB as 
assessed by luminal opening and epithelium remaining rates (both p<0.001) was 
further enhanced when tacrolimus was combined with daily DHMEQ at 20 mg/
kg (n=10). The frequency of allo-specifi c IFN-γ producing cells (Fig. C) was not 
affected by either DHMEQ or tacrolimus alone, whereas that was signifi cantly 
reduced in the DHMEQ+tacrolimus given recipients (n=3, p<0.01).
Conclusion: Inhibition of NF-κB activation by DHMEQ attenuates development 
of OB in mice. Addition of tacrolimus to DHMEQ strengthens the protective 
effect, and such strategy may become a new modality in preventing OB.
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POSTER BOARD NUMBER P4 – 01
LOW DOSE THYMOGLOBULIN INDUCTION THERAPY 1951 
FOR KIDNEY TRANSPLANTATION IS EFFECTIVE AND WELL 
TOLERATED IN ELDERLY PATIENTS
M.R. Laftavi1, S. Sharma1, R. Koholi2, P.D.M. Danek1, L. Feng1, 
J. Toullock1, M.Dayton1, D. Dunn1, O. Pankewycz2
1Deapertment of Surgery, SUNY at Buffalo, 2Department of Medicine, 
SUNY at Buffalo
Current immunosuppressive therapies and protocols have led to signifi cant 
improvements in early (<1 year) patient and graft survival rates following 
kidney transplantation. Whether induction therapies such as Thymoglobulin 
(TGL) contribute to these improved results remains controversial. Full-
dose TGL induction therapy (7-10 mg/kg total dose) has been associated 
with increased morbidity following renal transplantation which may be 
especially true in a high risk population such as the elderly. Therefore, we 
studied the effi cacy and tolerability of a low-dose TGL induction strategy in 
older recipients (>65 years) (Gr.1, n=45). We compared their post-transplant 
outcomes to a group of patients less than 65 years old (Group 2, n=45) 
transplanted during the same period. All patients were transplanted at a single 
center between Jan. 2001 and Sept. 2007. Both groups received a similar low-
dose of TGL induction therapy (Gr.1= 2.96+/-1.29 vs. Gr.2= 3.2+/-2.11 mg/
kg). The average age in years for Gr.1 was 73.8+/-5.4 and for Gr.2, 48+/-10.7 
(p<0.001). The two groups were similar in number of men (66%), African 
Americans (28%), diabetics (35%), patients with PRA > 30% (6%), CIT (16.1 
hrs.), DGF (26%) and living donors (10%). All patients were maintained on 
a calcineurin inhibitor, mycophenolic acid and low dose prednisone (5 mg/
day). To date, none of the older patients experienced AR whereas 1 younger 
patient had AR. Initial hospital stays were equal (Gr.1= 7.8+/-3.2 vs. Gr.2= 
7.5+/-4.4 days, p=0.35). Within the fi rst 6 months, 9 older patients required re-
hospitalization compared to 15 younger patients (p=0.15). Bacterial infections 
in both groups (Gr.1 vs. Gr 2) were equal including wound (4 vs. 0), urine (20 
vs. 15), lung (1 vs. 1) and skin (0 vs. 2). There were 2 BK viral infections in 
Gr.1. Gr.2 had 3 viral infections, 2 CMV and 1 H. zooster. eGFR was equal in 
both groups (Gr.1=55.7+/-18.5 vs. Gr.2=52.7+/-18.5 ml/min). 3-year patient 
and graft survival rates were equivalent in both groups (Gr1. 86.6% vs. Gr 2. 
97.6%). In conclusion, low dose TGL induction therapy is safe and effective 
in patients >65 years of age. When compared to younger patients, low-dose 
TGL leads to equivalent graft survival and function without incurring excess 
morbidity in the older population.
POSTER BOARD NUMBER P4 – 02
EVOLUTION OF RENAL TRANSPLANT RECIPIENTS 1952 
WITH HIGH IMMUNOLOGICAL RISK
A. Franco, E. Cotilla, S. Roca, L. Jimenez, J. Sanchez, J. Olivares
Hospital General Alicante
Thymoglobulin is a polyclonal antilymphocyte agent specifi c for T-cell epitopes, 
which is included in the therapy of high immunological risk recipients due to 
its therapeutic potential.
The aim of this prospective and observational study is to evaluate the incidence 
of acute rejection, oportunistic infections and malignancies, beside of the graft 
and recipient survivals between a group of 50 high immunological risk renal 
transplant recipients and a group of 50 pacients without immunological risk, 
who received grafts from the same cadaveric donors, since 2001 to 2006.
The risk group included pacients with high rate of performed antibodies (50%), 
recipients who had lost their fi rst graft due to early acute rejection, cross-
match positive, black race or important histoincompatibility. They received 
thymoglobulin to mantein T-cell count around 10 cells/μl, FK after fi ve 
days, Mycophenolate mofetyl and steroids, with ganciclovir prophilaxis for 
CMV.The normal risk group received Cyclosporine, Mycophenolate mofetyl 
and steroids. Recipients who lost their graft due to thecnical failure were 
not included. The mean follow up was 41,7 months, always more than one 
year. Both groups were similar respect to donor and recipient gender and age, 
HLA-incompatibility, but the percentage of pacients with high rate of perform 
antibodies and second transplant recipients was higher in the high risk group.
The incidence of acute rejection, histologically proved, was signifi cantly 
higher in the normal risk group (28,6% against 6,1%, p=0,03). There 
was no difference in opportunistic infections, CMV included, or 
malignancies,although 2 recipients of the normal risk group developed 
lymphoproliferative disorders. The recipient survival was 97,9% at 1 year 
and 3 years in both groups, and the graft survival was 89,8% and 84,8% in 
the high risk group against 93,8% and 90,4% at 1 year and 3 years in the 
normal risk group (p=ns). 
We conclude that the evolution of high immunological risk renal transplant 
recipients is similar to normal risk pacients if we use a immnunossuppresion 
potent enough.The incidence of acute rejection was signifi cantly higher in the 
normal risk group.
POSTER BOARD NUMBER P4 – 03
REDUCTION OF IFN-GAMMA PLASMA LEVELS EARLY 1953 
POSTTRANSPLANT IN RENAL TRANSPLANT PATIENTS 
WITH THYMOGLOBULIN INDUCTION THERAPY
M. Sadeghi1, V. Daniel1, C. Naujokat1, J. Schmitt2, A. Mehrabi2, 
H. Fonouni2, I. Lahdou1, M. Zeier3, G. Opelz1
1Institute of Immunology, Department of Transplantation Immunology, 
University of Heidelberg, Germany, 2Department of Visceral Surgery, 
University of Heidelberg, Germany, 3Department of Nephrology, University of 
Heidelberg, Germany
Objective: Antithymocyte globulins (ATGs) are used as induction therapy. They 
contain antibodies against functional molecules on the surface of mononuclear 
blood cells and affect target cell functions. The in vivo mechanisms of ATGs 
remain largely unclear. Previous studies did not evaluate the impact of ATGs on 
plasma cytokines during the posttransplant period. In this study, we analyzed 
the association of Thymoglobulin (TG) induction therapy with posttransplant 
cytokines plasma levels in renal transplant recipients.
Material and Methods: We analyzed immediately pre- and early (7±1 and 
26±7 days) posttransplant T lymphocyte subpopulations, sIL-1RA, IL-2, sIL-
2R, IL-4, IL-6, sIL-6R, IL-10, TNF-α, TGF-ß2, IFN-γ, and neopterin plasma 
levels in patients with TG therapy (n=17). Matched patients without TG 
therapy served as controls.
Results: One week posttransplant, total lymphocyte counts (p=0.001), CD3+ 
(p=0.001), CD4+ (p=0.0002), CD4+DR+ (p=0.002), and CD16+ (p=0.001) 
cells were signifi cantly lower in TG+ than TG- patients. One month 
posttransplant, TG+ patients still had slightly lower total lymphocyte counts 
(p=0.008), CD3+ cells (p=0.017), CD4+ (p=0.006), CD3+DR+ (p=0.045), 
and CD19+ (p=0.011) cells than TG- patients. Although TG+ and TG- 
patients had similar plasma levels of the different cytokines pretransplant 
(p=n.s.), one week (p=n.s.) and one month posttransplant (p=n.s.), changes 
of cytokine plasma levels during the posttransplant course in the two patient 
groups were signifi cantly different. TG+ patients had similar cytokine levels 
pre- and one week posttransplant (p=n.s.), whereas in TG- patients sIL-1RA 
(p=0.007) decreased and sIL-6R (p=0.002) increased during that time period. 
These results suggest that posttransplant sIL-6R production is reduced in 
TG+ patients. One month posttransplant, plasma IFN-γ (p=0.003) in TG+ 
patients, and sIL-2R (p=0.003) and TGF-ß (p=0.008) plasma levels in TG- 
patients, were signifi cantly lower than pretransplant. 
Conclusion: Our data indicate that TG as induction therapy reduces T cell 
subsets and inhibits infl ammatory cytokines, including the release of IFN-γ and 
sIL-6R, during the fi rst posttransplant month. 
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T10B9 MONOCLONAL ANTIBODY: SHORT ACTING 1954 
NON-STIMULATING MONOCLONAL ANTIBODY THT SPARES 
GAMMA DELTA T-CELLS AND TREATS AND PREVENTS 
CELLULAR REJECTION.
J. Thompson, T. Waid1, M. Siemionow2, S. Brown1
1University of Kentucky, 2Cleveland Clinic
T10B9.1A-31/MEDI-500/TOLERA-101 is a non-mitogenic IgM kappa 
murine monoclonal antibody (mAb) directed against the alpha-beta (¥á-©¬) 
heterodimer of the T-lymphocyte receptor complex. The clones were fi rst 
produced by fusing spleen cells from BALB/C mice immunized with human 
peripheral blood T-lymphocytes with SP2/O-Ag14 mutant myeloma cells. 
The small mAb is produced and purifi ed using multi-step ion exchange and 
molecular sieve chromatography protocols. 
T10B9 has been used successfully to treat acute cellular rejection in renal 
transplantation and as an immunosuppression induction agent in heart and 
simultaneous kidney-pancreas transplantation. Because T10B9 is non-
mitogenic and causes minimal cytokine release, both treatment of rejection 
and induction of immunosuppression were accomplished with signifi cantly 
fewer and milder untoward effects (cytokine release syndrome) than its 
comparator OKT3.
Since T10B9 is directed against the ¥á-©¬ heterodimer of the CD3 epitope, it 
spares the gamma delta (¥ã¥ä) region. These gamma delta (¥ã¥ä) T cells have 
a unique role in the immune response controlling many serious human diseases 
and perhaps facilitating the development of immunologic tolerance. 
T10B9 has a relatively short duration of action, depleting T cells for only 
10 to 14 days, unlike the protracted depletion seen with thymoglobulin 
and CAMPATH 1-H. There is no B-lymphocyte depletion with T10B9 as 
there is with both of the aforementioned reagents. The lack of prolonged 
lymphocyte depletion may account for less infection observed with 
T10B9 treatment.
POSTER BOARD NUMBER P4 – 05
EFFICACY AND SAFETY OF SINGLE BOLUS 1955 
ANTITHYMOCYTE GLOBULIN INDUCTION TREATMENT 
AFTER RENAL TRANSPLANTATION
Z. Nikolic2, D. Radivojevic-Djokic1, R. Blagojevic-Lazic1, S. Ristic1, 
V. Lezaic1
1Clinical Centre of Serbia, Department of Nephrology, 2Fresenius Biotech
Background: Antithymocyte globulins have been used as induction agents 
after organ transplantation for many years, but there are concerns with costs, 
adverse events, and the inconvenience of repeated dosing via a central vein. 
The aim of this 1-year, open-label, randomized trial was to compare the 
safety and effi cacy of antithymocyte globulin (ATG)-Fresenius for 1- year 
graft function and prevention of acute rejection (AR) in living related renal 
transplant recipients given in different dosage. 
Method: During 2005-2006, 41 patients were randomized to single (9 mg/ kg 
b.w.) dose ATG (group 1, consisted of 8 patients) or continued ATG treatment (3 
mg/kg b.w.) for next four days (group 2, consisted of 33 patients). Maintenance 
immunosuppression consisted of cyclosporine (Neoral, CsA) or tacrolimus 
(Prograf-Tac), mycophenolate mofetil (Cell-Cept, MMF), and corticosteroids. 
CsA (6.0 mg/kg b.w.) or Tac (0.15 mg/kg/b.w.) was introduced in the fi rst 
(group 1) or the forth day (group 2) after transplantation.
Results: Demographic characteristics of both donor and recipient were 
similar between two groups (age, gender, underlying kidney disease, period 
on dialysis). Pre-emptive transplantation was performed in ten patients: one 
from group 1,and 9 from group 2. All the patients received blood transfusion 
before transplantation however 13 group 2 patients were transfusion naïve. 
Immunological risk was similar in both groups (ABO and HLA mismatches 
between donor and recipient, panel reactive antibody- PRA, and response in 
mixed lymphocyte culture). Graft function was established immediately in 
all but two patients from group 2 who had slow graft function. Nevertheless, 
graft function maintained similarly until the end of the fi rst year after 
transplantation (clearance of creatinine 57.4±17.1 ml/min for group 1 vs. 
56.7±20.8 ml/min for group 2, serum creatinine 136.0±21.4 vs 138.4±33 
micromol/L). Only one patient from group 1 had suspected AR in the fi rst 
month after transplantation (12.5%). The rate of biopsy-proven AR was 
36.4% in group 2 (the mean time to rejection was 2.9 months). All AR were 
steroid-sensitive and graft function recovered fully. Five-day ATG treatment 
was associated with leucopenia in 5 patients, which required stimulating 
agent treatment (Neupogen), while three patients had infections (CMV and 
bacterial urinary tract infection). At the end of the fi rst year, slight proteinuria 
(less than 1 g/day) was noted in four patients from group 1 and 20 patients 
from group 2. Among the latter group three patients had proteinuria above 1 
g/day (maximum 3.6 g/day). 
Conclusions: Single dose ATG is safe and equally effi cient as repeated ATG 
doses after renal transplantation. Also, it is effi cient in prevention of acute 
rejection episodes in renal transplant patients.
POSTER BOARD NUMBER P4 – 06
CLINICAL OBSERVATIONS WITH INDUCTION 1956 
REGIMENS IN RENAL TRANSPLANTATION
D. Mital, R. Nubani, S. Jensik, S. Saltzberg, M. DyLiacco, E. Chan, 
F. Dodson
Rush University Medical Center
Purpose: The use of induction therapy in our center has evolved over the past 5 
years based on results from the literature. This retrospective review is designed 
to examine and compare the short-term and long-term outcomes of various 
induction therapies in a heterogeneous group of renal transplant recipients.
Methods: This is a single center retrospective review of 151 consecutive 
unselected renal transplant recipients between 1/03/04 and 12/31/04. All 
patients have completed at least 3 year follow-up. In this cohort, 50 patients 
received alemtuzumab, 65 received Thymoglobulin, 17 received basiliximab, 
and 19 received steroids alone as induction. Baseline characteristics and 
transplant outcomes were analyzed and compared among the four groups. 
Multivariate analyses using Cox regression were performed to identify risk 
factors for acute rejection, graft loss, and death.
Results: All patients had at least one high donor or recipient risk factor. 
There were no differences in recipient and donor demographics and transplant 
characteristics among the groups except for older donors, longer cold ischemia 
times, more extended criteria donors, and more pumped kidneys in the 
Thymoglobulin group. The incidences of early (90 days) death and graft loss, 
especially from thrombosis, were higher in the alemtuzumab group compared 
to the other three groups. At 3 years, basiliximab treated patients had the highest 
rate of acute rejection and graft failure. Thymoglobulin treated patients had 
the highest graft survival rate. There were no differences in the incidence of 
infection, hospital readmissions, and serum creatinine among the three groups 
at 3 years. 
Steroids Alemtuzumab Basiliximab Thymoglobulin p-value
n=19 n=50 n=17 n=65
3 Year Outcomes
Death 5.3% 6.0% 0.0% 3.1% 0.6912
Graft loss 10.5% 16.0% 35.3% 6.2% 0.0148
Acute rejection* 31.6% 16.0% 47.1% 38.5% 0.0296
Includes both clinical and biopsy-proven acute rejection 
Multivariate analyses were performed to identify independent risk factors for 
adverse outcomes after adjustment of various cofounders. The use of extended 
criteria donor (HR 2.944, p=0.013) and DGF (HR 2.053, p=0.045) were the 
only independent risk factors that were found to be associated with increase 
risk of acute rejection. The use of ECD (HR 4.274, p=0.0399) and DGF (HR 
6.405, p<0.001) were both associated with increase risk of graft failure, while 
Thymoglobulin was associated with a decrease risk of graft failure (HR 0.318, 
p=0.028). None of the risk factors evaluated was found to be an independent 
risk factor for death. 
Conclusions: In our clinical experience, alemtuzumab induction was associated 
with an unexpectedly high incidence of early graft failure and basiliximab was 
associated with high incidence of late acute rejection and graft failure in this 
relatively high risk transplant recipients. The use of ECD was associated with 
increase risk of both acute rejection and graft failure. However, compared to 
the other induction agents, the use of Thymoglobulin appeared to reduce the 
risk of graft failure. 
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ANTITHYMOCYTE GLOBULIN VERSUS IL-2R 1957 
ANTAGONIST INDUCTION THERAPY IN FIRST CADAVERIC 
KIDNEY TRANSPLANTATION
G. Vergoulas, G. Miserlis, I. Ioannidis, S. Karaba, P. Chatzimichailidou, A. 
Papagiannis, V. Papanikolaou, D. Takoudas
Hippokrateio General Hospital of Thessaloniki
Background and objectives: Induction therapy reduces the frequency of acute 
rejection in kidney transplantation and is used in patients with high probability 
of delayed graft function (DGF). We compared retrospectively the safety 
and effi cacy of antithymocyte globulin (ATG)and antiinterleukin 2 receptor 
antagonists (IL-2R ab) in patients with high risk of DGF who received a renal 
allograft from a deceased donor.
Material and methods: From March 1989 to Sept 2004, 173 patients, 117 men, 
with mean age 48 years, received a fi rst cadaveric transplant with induction 
therapy ATG (group A: 110 pts) or IL-2R ab (daclizumab or basiliximab, Group 
B: 63 pts) and maintenance therapy involving steroids, mycophenolate mofetil/
azathioprine and CsA. Serum creatinine (Sc) of the 1st, 2nd, 3rd, 4th and 5th 
post – transplant year, delayed graft function, cold ischemia time, days of fi rst 
hospitalization, were retrospectively studied. Patients under the age of 16, as 
well as patients lost to follow up were not included in the study. End of the 
follow up was 29 February 2008. Descriptive statistics, Kaplan Meier analysis 
(Log rank, Breslow, Tarone Ware), t test, x square test and repeated measures 
analysis were used. 
Results: Patient survival at one and fi ve year was 91.82%/81.82% for group 
A and 88.89%/79.21% for group B respectively (p:NS). Graft survival at one 
and fi ve years was 83.64%/67.27% for group A and 85.71%/69.52% for group 
B respectively (p: NS). Sc of the 1st and 5th year was 1,10±0.37/1.28±0.64 
and 1,15±0.26/1.40±0.35 for group A and group B respectively (p: NS). There 
was no signifi cant difference on age, DGF, cold ischemia time and fi rst patient 
hospitalization.
Conclusions: Induction therapy with ATG and IL-2R abs does not present 
differences on fi ve year patient and graft survival. There is a tendency, not 
signifi cant, for lower Sc levels in the ATG group during time.
POSTER BOARD NUMBER P4 – 08
COMPARISON OF OUTCOME WITH LOW-DOSE ANTI-1958 
THYMOCYTE GLOBULIN, BASILIXIMAB OR NO ANTIBODY 
INDUCTION THERAPY IN ADULT LIVING DONOR KIDNEY 
RECIPIENTS
P.W. Baron, J. Weissman, R. Ben-Youssef, E. Franco, A. Kore, A. Rashid, 
O. Ojogho, 
Loma Linda University Medical Center, Transplantation Institute
Background: Low-dose anti-thymocyte globulin (cumulative dose of 3-4.5 
mg/kg of LDATG) has proven its safety and effi cacy as an induction therapy in 
both kidney and pancreas transplantation. We analyzed the clinical outcome of 
LDATG in living donor kidney recipients.
Method: We retrospectively reviewed the data of 176 adults who underwent 
living donor kidney transplant between Jan 2000 and Dec 2006. They were 
divided into 3 groups based on their induction therapy. Sixty-nine patients treated 
with LDATG were compared to 79 patients who received basiliximab (BASI) 
and 28 patients who did not receive induction therapy (NAI). Donor and recipient 
ages, and recipient ethnicity were comparable between the groups. All received 
mycophenolate mofetil, calcineurin inhibitor and prednisone. We analyzed 
PRA%, delayed graft function (DGF), serum creatinine at discharge (D/C) and 
6 mo, acute rejection rate (AR), cytomegalovirus (CMV) and Epstein-Barr virus 
(EBV) infection rates, and graft and patient survival at 1 and 6 months
Results: The number of living unrelated donor kidney recipients, cold ischemia 
time and PRA% were signifi cantly higher in the LDATG group in comparison 
to BASI and NAI groups (37.7%, 21.5%, and 10.7%, p = 0.01; 130 min, 94 min 
and 52 min, p = <0.0001; 1726%, 616%, and 1.44%, p<0.0001). The cumulative 
dose per LDATG patient was 4.050.75 mg/kg. Mean serum creatinine levels 
at D/C, 1 mo, and 6 mo, DGF, AR, CMV, and EBV infection rates were not 
signifi cantly different among the groups (Table 1). Patient and graft survival 
rates at 6 mo were 100% in all groups. No one developed posttransplant 
lymphoproliferative disease.
Table 1. Clinical outcome
 LDATG (n=69) BASI (n=79) NAI (n=28) P-value
Ser cr @ D/C (mg/dL) 1.611.72 1.561.35 1.611.14 NS
Ser cr @ 1 mo (mg/dL) 1.310.47 1.420.76 1.551 NS
Ser cr @ 6 mo (mg/dL) 1.360.4 1.390.35 1.420.56 NS
DGF, n (%) 2(2.9) 3(3.8) 1(3.6) NS
Cumulative AR @ 6 mo, n (%) 7(10.1) 5(6.3) 3(10.7) NS
EBV infection @ 6 mo, n (%) 0 2(2.5) 0 NS
CMV infection @ 6 mo, n (%) 4(5.8) 2(2.5) 2(7.1) NS
Conclusion: These data showed that high immunologic risk living donor 
kidney recipients treated with low dose anti-thymocyte globulin therapy 
achieved excellent short-term clinical outcome compared to basiliximab and no 
antibody induction therapy. Larger prospective randomized trials are warranted 
to confi rm these results.
POSTER BOARD NUMBER P4 – 09
IS INDUCTION A NECESSARY STRATEGY FOR RENAL 1959 
TRANSPLANTATION?
R.C. Madarasu, S. Hussaini, V. Reddy, H.K. Marri, L. Guri, 
S.B. Padabukkala
CARE Hospitals, The Institute of Medical Sciences
Between May 2004 and March 2008 a total of 72 renal transplants were 
performed inour unit. Of this 09 were cadaver renal transplants, 19 were 
spousal transplants and 44 were live related transplants.
There was no HLA match as expected in cadaver and spousal transplants.
All the recipients were on triple immunosuppression consisting of Tacrolimus 
(or Cyclosporine), MMF and steroid. Expect for one pt in the cadaver group 
and one who had live related Tx all other recipients received no induction 
therapy.
Seven of the 72 recipients were HCV positive before Tx. Two of the 72 
recipients were HBsAg positive before TX. Almost four years into our Tx 
programme we fi nd no added benefi t of using induction even in unmatched 
recipients and donors like cadver or spousal TX. With this strategy out of 72 
transplants during this period only three patients had acute cellular rejection 
which responded to pulse methyl prednisolone. 
we conclude that induction is not a necessary strategy to improve renal transplants 
outcomes in the fi rst few years with routine use of triple immunosuppression 
including MMF, Tacrolimus and steroid.
POSTER BOARD NUMBER P4 – 10
SINGLE-DOSE INDUCTION WITH RABBIT ANTI-1960 
THYMOCYTE GLOBULIN(RATG) SAFELY IMPROVES 
RENAL ALLOGRAFT FUNCTION AND REDUCES CHRONIC 
ALLOGRAFT NEPHROPATHY
R.B. Stevens, T. Rigley, J. Skorupa, K. Nielsen, L. Wrenshall
University of Nebraska Medical Center
We conducted a prospective, randomized trial in renal transplant recipients 
comparing two dosing protocols [single dose (6mg/kg) vs. divided doses (1.5mg/
kg for 4 doses)] of rabbit anti-thymocyte globulin (rATG; Thymoglobulin). 
We present herein the results of the fi rst 142 patients [single dose (n = 70), 
divided dose (n = 72)]. After a mean follow-up of 16.2 ± 10.9 months, there 
were no signifi cant differences between groups in adverse events related to 
rATG infusion, patient and graft survival, and biopsy-proven acute rejection. 
Estimated glomerular fi ltration rate (eGFR) on day 4 was signifi cantly higher 
in the single-dose group than in the divided-dose group (50.0 ± 24.8 vs. 41.2 
± 25.7ml/min/1.73, p = 0.05), and the rate of improvement in eGFR from day 
1 to 4 was signifi cantly greater (p = 0.02). Throughout the fi rst 6 months post-
transplantation, recipients of kidneys from non-marginal deceased donors 
derived the greatest benefi t in renal function (eGFR) from the single-dose 
regimen (p = 0.006). The incidence of chronic allograft nephropathy (CAN) 
was also lower in the single-dose group, in both clinically-indicated and 
protocol biopsies combined (p = 0.045) and in 12-month protocol biopsies 
alone (p = 0.05). This study demonstrates that administration of 6mg/kg rATG 
as a single 24-hour infusion is safe and is associated with better renal function 
than conventional administration in divided doses.
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ATG INDUCTION IN RENAL TRANSPLANTATION – 1961 
A SINGLE CENTER EXPERIENCE
D. Khullar, J. Gaikwad, M. Malik, S. Ojha, A. Gupta, A.K. Bhalla, D.S. Rana, 
S. Chadha, H. Jauhari
Sir Ganga Ram Hospital
Introduction: Polyclonal antithymocyte globulin used effectively as an 
induction agent in kidney transplantation produces a profound and durable 
lymphopenia that lasts beyond one year & has been found to be safe & 
effective.
In this prospective, randomized study we share our experience of using rabbit 
ATG (r-ATG) as induction therapy in living donor renal transplantation carried 
out at our centre between 2005 & 2007.
Material & Methods: 37 kidney transplant recipients received r-ATG in the 
dose ranging from 1-1.5 mg/kg body weight per dose in addition to maintenance 
immunosuppression consisting of tacrolimus, MMF and prednisolone.
33 patients received 2 doses each of r-ATG while 4 received 3 doses of ATG.
Tacrolimus was started in the dose of 0.1mg/kg & the dose adjusted to 
maintain target levels of 8-10 ng/ml & 6-8 ng/ml during the fi rst month post 
transplantation & 1-3 months respectively & 4-6ng/ml thereafter.
Mycophenolate mofetil was used in the dosage of 1- 1.5 gm daily in divided 
dosages while prednisolone started as 0.5 mg/kg per day was tapered to 5 mg/
day at three months. Valganciclovir and cotrimoxazole prophylaxis was started 
in all the patients as soon as the graft function normalized
Results: The mean age of recipients & donors was 42 ± 9 and 47 ± 12 years 
respectively.
Six antigen HLA mismatch was present in 9, fi ve antigen mismatch in 9, four 
in 6, while 9 were haploidentical & two antigen mismatch was found in 4 
patients. 
The mean CD3 count on Day 0 was 513.5 ± 443.9 which decreased to 36.8 ± 
54.73 on Day 3 & at one year was 186 cells ± 83.7cells/μl which suggested a 
sustained response. The mean CD4 count on Day 0 was 244 ± 249.8 which 
decreased to 17.2 ± 29.6 on Day 3 & 100 ± 97.9cells/μl at one year
The mean CD8 count on Day 0 was 227 ±180.9 which decreased to 16.1 ± 26.2 
on Day 3 and 65.3 ± 40.4cells/μl at one year.
No signifi cant leucopenia, thrombocytopenia or allergic reactions were 
encountered.
One year patient as well as graft survival was 97.2%.
Two patients (5.4%) had biopsy proven acute rejections which were steroid 
responsive.
Mean serum creatinine was 1.94 ± 1.32 on day 3, 1.50 ± 0.31 on day 30, & 
1.60 ± 0.28 mg/dl at one year. Infectious complications seen during the study 
period were CMV disease in 2 patients (5.4%), UTI in 3 patients (8.1%) & 
Herpes zoster in 2 patients (5.4%).All recovered with treatment.Six patients 
had new onset diabetes mellitus (16%). None of the patients developed cancer 
during this period.
Conclusions: Induction therapy with r-ATG is safe & effi cacious. The severity 
and incidence of acute rejection was found to be low. The risk of infective 
complications can be decreased by use of appropriate prophylaxis. It is possible 
to maintain low dosages of calcineurin inhibitors & corticosteroids under the 
effect of ATG induction without any rise in the incidence of acute rejection 
thereby possibly decreasing the incidence of long term side effects associated 
with them.
POSTER BOARD NUMBER P4 – 12
OUR EXPERIENCE OF RABBIT ANTITHYMOCYTE 1962 
GLOBULIN INDUCTION IN RENAL TRANSPLANTATION AND 
COMPARISON WITH IL-2 RECEPTOR BLOCKERS
A. Dutta1, K. Sengupta, S. Nandi
1Wockhardt Hospital & Kidney Institute, Kolkata, India, 2Wockhardt Hospital 
& Kidney Institute, Kolkata, India, 3Wockhardt Hospital & Kidney Institute, 
Kolkata, India
Introduction: Antithymocyte Globulin (ATG) induction in renal transplantation, 
have been used sparingly in India primarily due to concerns regarding infective 
risks as Gancyclovir prophylaxis is unaffordable. A recent trial (Brennan D 
C et al, NEJM 2006), which showed no major difference in the risk profi le, 
prompted us to do this study.
Aims & objectives: To study the effi cacy & safety of rATG induction in renal 
transplant recipients with particular reference to CMV & non CMV viral 
infections and compare the results with that of IL-2 receptor blockers.
Materials & Methods: We studied 22 renal allograft recipients who received 
induction therapy with rabbit ATG (Dose: 1.25 – 1.5 mg/kg, 2-3 days) between 
September 2006 and February 2008 and compared with other 2 groups (15 
patients each) who had received either Basiliximab or Daclizumab as induction 
therapy at our center. All the recipients in the ATG group received Tacrolimus, 
MMF, Prednisolone as maintenance immunosuppression. 
Results: In the rATG group, the median age of the recipients was 35.7 yrs, 
& that of the donors was 40.1 yrs. Of the donors there were 8 spouses, 12 
fi rst degree relatives and 2 were unrelated. 54.5% of patients (12/22) had 
HLA mismatch of 5 or more & 31.8% (7/22) had mismatch of 3 – 4. CMV 
seropositivity: 72.7% (16/22) were D+/R+; 18.1% (4/22) were D+/R-. The 
HLA matching & CMV seropositivity were comparable in the three groups. 
Prophylactic Acyclovir & Trimethoprim – Sulphamethoxazole were given in 
all the patients. Renal function was stable at the end of 1 month, 6 months 
& 12 months. No incidence of acute rejection or delayed graft function 
was noted. There was no incidence of thrombocytopenia or leucopenia. No 
incidence of CMV or non CMV viral infection were noted in follow up of 
total 174 patient months. Fifteen patients have completed 6 months. Among 
the adverse events, there were 5 episodes of UTI, 2 instances of PTDM. 
The observations were similar in the other 2 groups who had received either 
Basiliximab or Daclizumab as induction therapy. The overall cost of ATG is 
20% less compared to IL2 receptor blockers.
Conclusion: In our study, use of rATG as induction therapy was found to be 
effective and safe even without Gancyclovir prophylaxis despite seropositivity 
and HLA mismatches. A lower net immunosuppression (lower Tacrolimus 
dosing, steroid minimization) made possible by induction therapy may have 
contributed.
MISCELLANEOUS CONCURRENT ORAL SESSION 136: 
IMMUNOSUPPRESSION
POSTER BOARD NUMBER P4 – 13
AUTOIMMUNITY IN RENAL TRANSPLANT PATIENTS1963 
J. Klassen
Foothills Medical Centrel
The recurrence of certain putative autoimmune glomerular diseases in renal 
transplants is well known. It is also common knowledge that systemic lupus 
erythematosus does not recur to any signifi cant degree in renal patients, who 
had SLE glomerular disease as a cause of their end stage renal disease. The 
occurrence of other autoimmune diseases is not well described. I would like to 
present three such cases that had excellent renal function for 10-15 years out of 
a group of 250 long-term renal transplant patients, with functioning transplants 
who developed classical primary autoimmune disease: One with multifocal 
acquired demyelinating sensory and motor neuropathy, one with classical 
temporal arteritis, and one with mononeuritis multiplex. I also successfully 
treated a stable heart transplant recipient for leucocytoclastic vasculitis 17 
years after her heart transplant. The possible explanations for these diseases 
occurring in an immunosuppressed host will be discussed. 
Thursday 14 August 2008 Poster Abstracts
6 4 6
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P4 – 14
SUCCESSFUL RENAL TRANSPLANTATION FOR 1964 
PATIENT WITH PYODERMA GANGRENOSUM
T. Fujita, S. Ishida, T. Shimoji, T. Kimura, M. Kato, Y. Tsuji, T. Kinukawa
Chukyo Hospital
Pyoderma Gangrenosum (PG) is a rare skin disease of unknown etiology which 
forms intractable skin ulcers on surgical sites or traumatic sites. The case is a 
39 years old woman with PG who became end-stage renal disease from type 
1 diabetes mellitus. Creation of arteriovenous fi stula (AVF) and insertion of 
peritoneal dialysis catheter were considered to be diffi cult and risky, because 
severe ulceration was observed on surgical site of AVF previously. Therefore 
the patient received dialysis continuously by using central venous catheter, 
changing access points of the catheter-insertion for central venous. But it 
became diffi cult gradually due to venous stenosis because of frequent central 
venous accesses. Therefore considering of renal transplant became necessary 
as a lifesaving measure. We performed living renal transplant, after controlled 
ulcers with steroid that were formed on previous surgical sites of trigger fi nger, 
appendicitis and AVF. Induction immunotherapy was started with tacrolimus, 
mycophenolate mofetil, steroids and basiliximab. Intravenous pulse of 
methylprednisolone was performed to prevent ulceration of the surgical site on 
day 0-2. Postoperative course was good and ulceration on surgical site of renal 
transplant was not observed. To our knowledge, renal transplant for patients 
with PG has not been reported previously, but only 2 cases of liver transplant 
reported.
POSTER BOARD NUMBER P4 – 15
PHOTOPHERESIS AS PREVENTION FOR ACUTE 1965 
REJECTION AFTER KIDNEY TRANSPLANTATION – A CASE 
CONTROL STUDY WITH A 2-YEAR FOLLOW-UP
G. Kumlien1, H. Genberg2, G. Tydén2
1Dept of Clin Immunol and Transfusion Medicine, Karolinska University 
Hospital Huddinge, 2Dept of Transplantation Surgery, Karolinska University 
Hospital Huddinge
Background: We have previously published a pilot study (Photopheresis 
for the Treatment of Refractory Renal Graft Rejection, Transplantation 
2005;79(1):123-5. Kumlien G et al) with seven consecutive patients with 
ongoing biopsy-proven acute cellular kidney graft rejection that was refractory 
to treatment with steroids and monoclonal antibodies (OKT3 or ATG) but was 
successfully treated with photopheresis. 
In the present study we wanted to investigate if photopheresis can be used to 
prevent rejection after kidney transplantation.
Method: Between October 2004 and October 2005 ten patients receiving fi rst 
time kidney grafts from cadaveric donors were treated with photopheresis on 
days +5, +6, +10, +11, +17, +18, +27, and +28. No patient showed clinical 
signs of rejection at the time of the photopheresis treatment. Immunosuppression 
was given with tacrolimus, azathioprine and prednisolone. Only patients 
with existing suitable vascular access for apheresis were included in the 
photopheresis group. For the photopheresis treatment, mononuclear cells were 
collected using Cobe Spectra apheresis machine (Gambro BCT, Lakewood, 
CO, USA). Apheresis products were treated with psoralen (8-methoxypsoralen 
200 ng/ml) plus UVA-irradiation, UVA 365 nm, 2 J/cm2, (BioGenic, Vilber 
Lourmat, Marne-la-Vallée, France) and subsequently retransfused to the 
patients.
During this period ten other patients received fi rst time kidney grafts from 
cadaveric donors and the same immunosuppressive protocol (tacrolimus, 
azahioprine and prednisolone) at our center. These ten patients either lacked 
suitable vascular access for apheresis or declined to be included in the 
treatment group, and they constitute the control group. Only patients receiving 
other immunosuppressive protocols or kidneys from living donors were 
excluded from the study. We have chosen to study patients receiving kidneys 
from cadaveric donors since these patients more frequently experience acute 
rejection episodes than patients receiving kidneys from living donors.
Results: Event free survival time (time to fi rst rejection, graft loss or death) 
was not signifi cantly different in the two groups (Fishers´ two-sided exact test 
n.s., p=0.65) (see Figure). Follow-up was 28-40 months in both groups.
Photopheresis group: Two patients lost their grafts, one after 10 months due 
to BKV infection and one after 12 months due to CMV infection. Three 
patients experienced acute rejections and eight of the ten patients experienced 
one or several infectious complications. One patient discontinued all 
immunosuppressive drugs except prednisone after 34 months due to intolerable 
side effects but still maintains a good and stable graft function at 40 months 
post transplant on Prednisone 5 mg daily only.
Control group: No graft losses occurred in the control group. One patient died 
with a functioning graft 12 months post transplant. Four patients experienced 
acute rejections and seven patients experienced one or several infectious 
complications.
Conclusion: We conclude that photopheresis treatment did not prevent acute 
rejection after kidney transplantation in this group of patients. Since patients 
with ongoing acute cellular rejection that was refractory to conventional 
treatment were successfully treated with photopheresis in the pilot study, we 
also conclude that the immune system must be more activated than in the 
present group of patients in order to achieve an immunomodulatory effect from 
photopheresis treatment. 
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INDUCTION IMMUNOTHERAPY WITH RITUXIMAB IN 1966 
HIGHLY SENSITIZED KIDNEY TRANSPLANT PATIENT
S.C. Park, J.I. Kim, C-W. Yang, I.S. Moon
The Catholic University of Korea, Kangnam St. Mary’s Hospital
The transplantation in highly sensitized patient is one of the major concerns in 
kidney transplantation. The development of new immunosuppressive agents is 
designed to reduce the early acute post-transplant rejection. Recently, several 
new protocols have been developed to allow the transplantation of highly 
sensitized patients. One potential target for more specifi c immunosuppressive 
therapy with monoclonal antibodies is appeared to be effective, less toxic than 
the oral long-term maintenance agents and well-tolerated in kidney transplant 
recipients. Rituximab is a high-affi nity CD 20 specifi c antibody that depletes the 
B-cell compartment by inducing cellular apoptosis. We successfully performed 
kidney transplantation in high sensitized patients and we report our experience 
with rituximab induction protocol involving pretransplant plasmapheresis, 
intravenous immunoglobulin. One case was a 43 year-old man for third kidney 
transplantation with high panel-reactive antibodies (PRA class I: 96.4%, class 
II: 58.3%) and positive fl ow cytometric crossmatch (T: 15%, B: 10%). Another 
case was 51 year-old woman with donor specifi c antibody positive (anti-A11, 
anti-A33), high panel-reactive antibodies (PRA class I: 39.3%, class II: 33.3%) 
and positive fl owcytometric crossmatch. Preoperative Rituximab induction 
therapy is effective in high risk kidney transplant patients but we must keep in 
mind that rituximab is associated with a high rate of infectious complications.
Poster Abstracts Thursday 14 August 2008
6 4 7
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P4 – 17
ELIMINATION OF IMMUNOSUPPRESSION IN KIDNEY 1967 
TRANSPLANTATION FOLLOWING SUCCESSFUL BONE 
MARROW TRANSPLANTATION IN FANCONI’S ANEMIA
R. Kadiyala, M. Eng, R. Nagubandi, M. Marvin, J. Buell
Transplant Center, Jewish Hospital, University of Louisville, KY, USA
Introduction: Fanconi’s anemia is an autosomal recessive condition causing 
bone marrow failure and renal dysfunction with an increased incidence of 
leukemias and solid tumors. Bone marrow transplant repairs the hematological 
problem but the risks of neoplasia persist. Avoidance of immunosuppression in 
this patient population may be crucial to prevent onset of neoplasia. We report 
a case of successful elimination of immunosuppression in a patient with treated 
Fanconi’s anemia who required a subsequent kidney transplant.
Patient & Results: A 21 year old woman with Fanconi’s anemia and renal 
failure was evaluated for a live donor kidney transplant from her sibling. The 
patient had received matched stem cell transplant with cord blood transfusion 
from the same sibling at 4 years of age. She had received conditioning with 
cyclophosphamide and thoraco-abdominal radiation prior to the successful 
stem cell transplant. Her anemia was cured but the renal disease progressed 
to end stage renal failure at the age of 20 years. She was evaluated for kidney 
transplantation and the sibling who donated the stem cells was evaluated 
and found suitable to be a live donor. Bone marrow engraftment analysis by 
STR revealed the patient to have 100% donor cells. With the presence of 
complete marrow identity the patient underwent live donor renal transplant 
from her sibling in July 2006. No immunosuppression was used either in the 
perioperative period or since. The transplant procedure was successful and the 
patient has normal renal function at a follow-up of 18 months.
Conclusions: This report highlights a unique immunological situation where a 
patient with Fanconi’s syndrome had a prior stem cell transplant with complete 
engraftment of her marrow with the donor cells. This facilitated subsequent 
kidney transplantation 17 years later from the same donor without any 
immunosuppression. The elimination of immunosuppression has the potential 
benefi t of not escalating her predisposition to development of cancers due to 
the underlying Fanconi’s syndrome.
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ASSOCIATION OF HIGH IFN-G PLASMA LEVELS WITH 1968 
LOW B CELL COUNTS IN RENAL TRANSPLANT RECIPIENTS 
WITH STABLE GRAFT FUNCTION LATE POSTTRANSPLANT.
V. Daniel1, C. Naujokat1, M. Sadeghi1, R. Weimer2, F. Renner2, S. Yildiz2, G. 
Opelz1
1Department of Transplantation-Immunology, Institute of Immunology, 
University of Heidelberg, Germany, 2Department of Internal Medicine, 
University of Giessen, Germany
Objective: Recently, we reported that patients with long-term stable good graft 
function have higher interferon-gamma (IFN-g) and lower interleukin-4 (IL-4) 
plasma levels late than early posttransplant. These patients had more often 
detectable CD3+CD4+CD25+IFN-g+Foxp3+ peripheral blood lymphocytes 
(PBL) late posttransplant than patients with impaired graft function. We 
therefore speculated that high plasma IFN-g late posttransplant might contribute 
to the maintenance of graft acceptance.
Methods: Using ELISA and four-color fl ow cytometry, plasma cytokines 
and PBL subpopulations were measured in 65 renal transplant recipients with 
stable graft function late posttransplant (mean+/-SD: 1755+/-1476 days; serum 
creatinine: 2.0+/-0.8 mg/dl). 
Results: High IFN-g plasma levels were strongly associated with low CD19+ B 
PBL (r=-0.329; p=0.009) and low activated CD3+CD8+DR+ T PBL (r=-0.266; 
p=0.035). Thus our data demonstrate an association of high plasma IFN-g 
with low B cells and low levels of activated cytotoxic T cells. Plasma IFN-g 
increased with time posttransplant (r=0.288; p=0.022) and was not associated 
with the dosis of immunosuppressive drugs (p=n.s.). High plasma IFN-g 
was not associated with serum creatinine (r=0.038; p=0.765), indicating that 
high plasma IFN-g does not originate from accumulation or from an immune 
response against the graft. Serum creatinine was neither associated with 
CD19+ B PBL counts (r=0.038; p=0.764) nor with the dosis or blood levels 
of calcineurin inhibitors or MMF (p=n.s.). Five patients showed evidence 
of biopsy-proven chronic allograft nephropathy and none of them exhibited 
increased plasma IFN-g.
Conclusion: In patients with good long-term graft function, high IFN-g 
plasma levels were associated with low numbers of B PBL and activated CD8+ 
T PBL. These low B and T cell counts might be involved in preventing the 
development of an immunological alloresponse against the graft and support 
the maintenance of graft acceptance. 
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STEROID-FREE IMMUNOSUPPRESSION FOR KIDNEY 1969 
TRANSPLANTATION IN BIPOLAR DISEASE LITHIUM 
TOXICITY
M.l. Shapiro1, J. Abra2
1Touro University College of Medicine, 2Hackensack University Medical 
Center
Lithium carbonate, often used for the treatment of bipolar disorder, can 
frequently cause renal disease (nephrogenic diabetes insipidus, interstitial 
nephritis) and may occasionally result in chronic renal failure. Management of 
transplant recipients with bipolar disorder is complicated by their psychiatric 
disease, and exacerbated by chronic steroid administration. The use of a rapid 
steroid taper has permitted successful renal transplantation in these patients. 
Between 1/2000 and 2/2008, 18 patients with CKD secondary to lithium 
toxicity were listed for renal transplantation at a single center. Six patients, 
multiply listed, were transplanted elsewhere, Two patients died waiting, and 
three continue to wait. Seven patients were transplanted at our center; one has 
been lost to follow-up. The remaining six patients are the subject of this report. 
Mean age was 60 (range 56-65). Two were living donor recipients; four received 
deceased donor grafts. All were treated with an anti-IL-2 receptor antibody, 
calcineurin inhibitor (Csa, 4; tac, 2), MMF and a 5-day steroid taper (500, 250, 
125, 60, 30 mg). There were no episodes of acute rejection, and no subsequent 
use of corticosteroids. Patient and graft survival, at 2 mos to 8 years is 100%. 
Mean creatinine at one and three years is 1.3 mg/dl (range 0.7-1.9) and 1.45 
mg/dl (1.0 to 1.8). No patient has subsequently required psychiatric admission. 
Only one patient, who was taking lithium to the day of transplantation, required 
re-institution of lithium therapy post-transplantation for severe depression. All 
others have been adequately maintained on other psychotropic medications. 
Patients with renal failure secondary to lithium toxicity can be successfully 
transplanted without long-term steroid use, and without major psychiatric 
exacerbation.
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TWO DOSE DACLIZUMAB IN PREVENTION OF ACUTE 1970 
REJECTION IN LIVE DONOR KIDNEY TRANSPLANTATIONS
D.S. Ray
Armenian Church Trauma Centre
Aim: Daclizumab induction has shown to reduce incidence of acute rejection. 
Since, conventional fi ve doses of Daclizumab is expensive, we tried two doses 
of Daclizumab as induction therapy to fi nd out its effect in incidence of early 
acute rejection.
Methods: Fourteen patients received Daclizumab in a dose of 1 mg/
kg body weight on Day 0 and Day 14 as induction therapy besides their 
immunosuppressive medicines in the form of steroids, Techrolimus and 
Mycophenolate. They were compared with seventeen patients who received 
only steroids, Techrolimus and Mycophenolate. Incidence of acute rejection 
and side-effects were observed for a period of six months. 
Observation: Both the groups were more or less comparable as for the age, sex, 
aetiology of kidney disease and HLA mismatch between donors and recipients. 
In the Daclizumab induction group there was no acute rejection over a period 
of six months. But, three patients had signifi cant infections (Herpis simplex of 
G.I. tract in one, recurrent urinary tract infection in one and CMV disease in 
one).In the control group there were four acute rejections(three were steroid- 
responsive and one with acute vascular rejection did not respond to steroid or 
OKT3). One patient in the control group had CMV disease.
Conclusion: Two doses of Daclizumab (I mg/kg body weight) as induction 
therapy signifi cantly reduces the incidence of early Acute Rejection.
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TWO-DOSE DACLIZUMAB PROVIDES EFFECTIVE 1971 
INDUCTION IMMUNOSUPPRESSION IN KIDNEY 
TRANSPLANTATION
J. Wynn1, D. Siler2, R. Cannon1, T. Merchen1, M. Jagadeesan1, . Mulloy1, 
D. Willia3, D. Vasil3
1Medical College of Georgia, 2College of Pharmacy, University of Georgia, 
3MCG Health
Anti-IL2r antibody provides effective induction immunosuppression in kidney 
transplantation. Basiliximab (BAS) is generally given on transplant days 0 and 
4, while daclizumab (DAC) typically requires a much longer course of therapy. 
Two-dose DAC therapy is much less costly than BAS, but is unclear whether it 
is as effective in preventing acute rejection as BAS. We began to preferentially 
use two DAC therapy in mid-2006, and report our initial experience herein.
Methods: Patient charts and our transplant database were reviewed 
retrospectively. Differences in proportions were assessed with Chi-square while 
differences in means were assessed with one-way ANOVA. Survival analysis 
was conducted using Kaplan-Meier, and logistic and Cox proportional hazards 
regression were used to evaluate the impact of induction regimen on delayed 
graft function (DGF) and acute rejection (AR), respectively. 
Findings: 145 patients (92 white, 46 black, 5 other) received kidney transplants 
between 4/2005 and 5/2007. Anti-IL2r therapy was given to 97 low-risk 
recipients (65 BAS, 32 DAC) and thymoglobulin (THY) to 48 at higher risk of 
rejection or delayed graft function. Steroids were aggressively withdrawn in all 
patients beginning 1 month post-transplants. 
92% of THY patients received deceased donor (DD) kidneys, compared to 72% 
of BAS and 59% of DAC patients. There were no signifi cant differences in 
age, race, sex, BMI, renal failure etiology, PRA, cold ischemia time or warm 
ischemia time between DAC and BAS groups. DGF was common in DD 
recipients (47%) but did not vary among induction therapy groups. 
The overall incidence of rejection was 17% in DD and 15% in LD recipients. 
There was no association of induction therapy with rejection in either DD or 
LD recipients when analyzed by Kaplan-Meier or Cox. Serum creatinine was 
not different in the three induction groups up to 12 months, and prednisone 
withdrawal was equally successful in all between groups (mean dose at 6 
months = 3.4mg/day for BAS and 2.6mg/day for DAC).
Conclusion: A short course of daclizumab is effective in preventing acute 
kidney allograft rejection.
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KIDNEY TRANSPLANTATION WITHOUT ANTIBODY 1972 
INDUCTION THERAPY: A SINGLE CENTER EXPERIENCE
P. Patel, S. Katznelson, L. Bohannon, V.R. Peddi, W. Bry, A. Hassoun, 
H. Mahanty, V. Warvariv, K. Ueda
California Pacifi c Medical Center
Background And Aim: Although most centers currently use some form of 
antibody induction therapy for immunosuppression in kidney transplant 
recipients, it remains unclear if all patients require such therapy. Often at our 
center, low immunologic risk recipients or recipients of allografts expected 
to have immediate function (e.g. short cold ischemia times, non-ECD or 
DCD grafts) do not receive antibody induction therapy. This study aims to 
evaluate patient outcomes in recipients who did not receive antibody induction 
immunosuppression. 
Methods: From April 2002 to June 2004, 171 patients underwent kidney 
transplantation without using antibody induction for immunosuppression. All 
patients received intravenous steroids perioperatively and maintenance therapy 
using mycophenolic acid, tacrolimus or cyclosporine, and prednisone.
Results: 104 patients received deceased donor transplants and 67 received live 
donor transplants. Mean patient age at the time of transplantation was 48.5 
years. Mean kidney cold ischemia time was 9.9 hours. At a follow up period of 
one, three, and fi ve years, acute rejection rates were 13.5%, 18.1%, and 20.4%, 
respectively. Patient survival was 97.8%, 93.6%, and 89.5% at one, three, and 
fi ve years and graft survival was 95.3%, 87.7%, and 82.5% at one, three, and 
fi ve years. Mean serum creatinine levels at one, three, and fi ve years were 1.5, 1.4, 
and 1.3, respectively. At a mean follow-up of 4.6 years, 18 patients died, 11 with 
a functioning allograft. Causes of death were MI (3), stroke (1), sepsis (2), cancer 
(1), pulmonary embolus (1), pneumonia (1), ARDS (2), surgical complication (1) 
(this occurred 5 years post-transplantation), and unknown (6). 
Conclusions: The optimal induction regimen for immunosuppression remains 
controversial and most centers currently use some form of antibody induction 
for all patients. Our experience suggests that a regimen avoiding antibody 
induction therapy in a low risk population can still be a viable option, resulting 
in acceptable long-term patient and allograft survival.
ALEMTUZUNABCONCURRENT ORAL SESSION 137: 
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CAMPATH 1H PRETREATMENT OF THE LIVE DONOR 1973 
KIDNEY GRAFT RECIPIENTS. DOES IT PROMOTE DONOR-
SPECIFIC TOLERANCE?
N. Babenko, M. Kaabak, A. Maschan, A. Zokoev
Russian Scientifi c Center of Surgery RAMS
Costimulatory pathway (CD28-B7) is considered to play a key role in the 
decision of the host immune system what to do with foreign antigen-bearing 
cells – reject or accept. An attempts to create monoclonal antibodies, blocking 
this pathway, clinically failed. Having in mind, that costimulatory pathway 
is realizing mostly through the mesenhimal cells, as well as Campath-1H 
capability to deplete these cells, we tried next hypothesis: Campath-1H infusion 
2-3 week prior to transplantation will promote donor-specifi c tolerance.Patient 
population: thirty patients (18 male), age from 0,7 to 52 years (16,2±13,3), 
transplanted from September 2006 to May 2007. Diagnoses: chronic 
glomerulonephritis – 10, hypoplasia – 8, obstructive uropathy – 6, congenital 
nephritic syndrome – 4, HUS – 1, Alport syndrome – 1. Twenty-six patients 
were dialyzed before transplantation within 0,7-52 month (11,3±13,6). Patients 
were followed 282-541 days (419±79). All transplants were fi rst and from live 
donors, two were ABO incompatible (anti-A/B-antibodies titer 1:8 and 1:32 
before transplantation).
Immunosupression protocol: independently of body weight 30 mg of Campath 
1H was infused to all patients at 13-42 days prior to transplantation. Next 30 
mg was given just before graft reperfusion, after bolus of methylprednisolone 
10 mg/kg. After surgery steroids were given orally at dose 60 mg/m2 with rapid 
taper down and withdrawal at day 14. Cyclosporine was given orally within 
12 hours after surgery, with target trough level 100-200 fi rst week, thereafter 
75-150 and 50-100 ng/ml after one month. After one year CNIs considered to 
be withdrawn. Decision was made by the comparison of two protocol biopsies 
(see below). Mycophenolates were added after WBC recovery (2-6 month).
Follow up: besides routine kidney transplant patient monitoring we checked 
their blood and urine for DNAs of CMV, EBV and BKV. Rising viral load was 
a signal to decrease total amount of immunosupression. The graft biopsies were 
taken per protocol 14 days and 1 year post transplant, as well as at the time of 
graft dysfunction.
Results: one patient had delayed graft function (due to urinary tract clotting) 
– 5 dialyses 11 days after surgery with creatinine drop below 3mg% at day 
36. Eight patients developed acute rejection at 21-214 days post transplant 
(94±63), which was borderline in 1 patient, 1a in 6 and 2a in one patient. Two 
patients died 162 and 452 days post transplant from brain edema (7 month and 
7 years at transplantation), developed due to improper fl uid management during 
acute urine outfl ow disorder (parent’s noncompliance). Uncensored Kaplan-
Mayer one-year graft and patient survival is 94,7%. In one patient (graft from 
haploidentical mother) immunosupression was stepwise decreased until total 
withdrawal at day 76, and this patient lives with excellent graft function and 
without immunosupression already 16 month.
The change of graft function by comparison of CFR (Schwartz formula) and 
proteinuria at discharge (38±19 days) and at the last control (419±79) was not 
signifi cant: 82±23 and 82±32 ml per min; 221±241 and 161±139 mg per day.
Immunosupression at the last control among 28 survived patients is follows: 
CsA+MMF – 14, CsA+MMF+Pred – 4, MMF monotherapy – 3, Tacro+MMF – 2, 
Tacro+MMF+Pred – 1, CsA+Pred – 1, Tacro monotherapy – 1, CsA monotherapy 
– 1, nothing – 1. As listed above, 79% of patients are free of steroids.
Conclusion: the pretreatment of kidney allograft recipients with Campath 
1-H 13-42 days before transplantation allows to reach satisfactory short-term 
results with little immunosuppressive treatment and some patients develop 
donor-specifi c tolerance. The available tools of tolerance diagnosis in clinical 
practice need to be improved.
Poster Abstracts Thursday 14 August 2008
6 4 9
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P4 – 24
ALEMTUZUMAB (CAMPATH 1H) INDUCTION IN 1974 
EXTENDED CRITERIA DECEASED DONOR KIDNEY 
TRANSPLANTATION: A SINGLE INSTITUTION EXPERIENCE
J. Gleason Jr, M. Eng, R. Kadiyala, A. Afanasyev, D. Woo, R. Nagubandi, 
J. Buell
Transplant Center, Jewish Hospital, University of Louisville, Louisville, KY, 
United States
Introduction: Alemtuzumab (Campath 1H) reduces the incidence of Acute 
Cellular Rejection (ACR), presumably by allowing allograft tolerance, thus 
permitting steroid free maintenance of deceased donor recipients.We present 
our single institution experience with Campath 1H in Extended Criteria Donor 
(ECD) Kidney Transplantation. 
Protocol: Standard UNOS criteria were used in ECD donor selection. ECD 
recipients were fi rst time recipients over the age of 55 with a BMI under 35. 
Preoperatively, recipients were given Campath 1H 30 mg iv once, Mycophenolate 
mofetil 1gm. po bid or 1.5 gm. po bid if African American (AA). Solumedrol 
500 mg. was given iv preoperatively and daily post operatively on days 1-3. 
Tacrolimus (FK506), given bid, was started when graft function was present. 
FK506 was monitored for trough levels of 8-10 ng/ml for the fi rst three months 
and then 6-8 ng/ml thereafter. Recipients were monitored for acute rejection 
and post transplant complications by frequent laboratory evaluation and clinic 
follow-up. Renal ultrasound and biopsy were performed for any unexplained 
elevation of serum creatinine (CR). 
Results: From 11/1/2004 to 12/30/2006, 13 patients received ECD Kidneys. 
Characteristics of recipients included 11 Caucasians and 2 AA, mean age of 59 
yrs., mean wt. of 189 lbs. and mean BMI of 28.4. Characteristics of the deceased 
donors included mean age of 60 yrs. and mean terminal CR of 1.08 mg/dl. 6 of 
13 recipients had delayed graft function, with recovery of graft function. Mean 
recipient serum creatinine at twelve months was 1.78 mg/dl, with no incidence 
ACR or humeral rejection in the fi rst year of follow-up. One patient lost graft 
function at 11 months after an Aortic valve replacement and coronary artery 
bypass grafting. The biopsy showed chronic rejection. No incidence of CMV or 
BK virus infection was documented. Readmits were otherwise minor.
Discussion: In this pilot experience, Campath 1H tends to be associated with 
a lower incidence of ACR under a steroid-free regimen. Recipients of kidneys 
from extended criteria donors induced with Campath 1H had good graft 
function at 1 year.
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ALEMTUZUMAB INDUCTION WITH STEROID 1975 
SPARING IMMUNOSUPPRESSION IN HIGH RISK KIDNEY 
TRANSPLANTATION
R. Kadiyala, R. Ouseph, M. Eng, M. Marvin, J. Gleason Jr, R. Nagubandi, 
C. Stepp, J. Buell
Divisions of Transplantation and Nephrology, Jewish Hospital, University of 
Louisville, KY, USA
AIntroduction: Alemtuzumab is widely used in steroid sparing 
immunosuppression protocols. At our center a single dose of Alemtuzumab 
has been used for induction in all kidney transplant recipients since December 
2004.
Aim: To analyze the results of the use of Alemtuzumab in kidney transplantation 
with emphasis on acute rejection, infectious complications and to compare the 
low and high risk groups.
Methods: High risk was defi ned as Afro-Americans aged less than 40 years, 
PRA > 20% and re-transplantation. All kidney recipients received a single 30 
mg dose of Alemtuzumab during surgery and were maintained on Tacrolimus 
(8-10 ng/ml for 6 months and 6-8 ng/ml later on) and Mycophenolate mofetil. 
Three doses of steroids were used in the peri-operative period. A prospective 
database was maintained. Chi square test was used for analysis. 
Results: Between December 2004 and June 2007, 226 patients undergoing 
kidney transplant received Alemtuzumab induction.
Comparison of high & low risk groups
 Number DGF Acute rejection Infections Creatinine at 1 year
High risk 56 11/56 2/56 6/56 1.68
Low risk 170 30/170 8/170 6/170 1.42
p-value  0.84 1.0 0.07 0.20
There were 56 and 170 patients in the high and low risk groups. The median 
age was 44 and 53 years respectively. The median follow-up was 446 and 562 
days respectively. The median serum creatinine at 12 months was 1.68 and 1.42 
mg/dl; patient and graft survivals were 96.3 & 98.3% and 93.8% & 96.6% in 
the high and low risk groups respectively. Delayed graft function (hemodialysis 
post-transplant) was seen in 19.6% of the high risk group and in 17.6% in the 
normal risk group (p =0.84). Acute cellular rejection developed in 3.6% and 
4.7% in the two groups (p=1.0). No humoral rejection was seen.The incidence 
of viral infections (CMV/BK) was 6/56 (10.7%) and 6/170 (3.5%,p=0.07).
Conclusions: Alemtuzumab induction proved extremely effective in an 
unselected kidney transplant population with a low rate of acute rejection and 
infectious complications. There was no signifi cant difference in the patient/
graft survival, delayed graft function, acute rejection or complications between 
the normal and high risk recipients. Steroid elimination with Alemtuzumab 
induction is safe even in the immunological high risk category of patients.
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TRANSPLANTATION OF ACUTE RENAL FAILURE 1976 
KIDNEYS UNDER CAMPATH-1H INDUCTION WITH MINIMAL 
POST-TRANSPLANT IMMUNOSUPPRESSION
S. Potdar1, J. Pennington, N. Carter, D. Redovian, H. Bonilla, C. Boshkos, 
B. Eltayeb, S. Schmidt, W. Fallon
1Summa Health System- Transplant Surgery, 2Summa Health System- 
Transplant Surgery, 3Summa Health System- Transplant Surgery, 4Summa 
Health System- Transplant Surgery, 5Summa Health System- Infectious 
Disease, 6Summa Health System- Nephrology, 7Summa Health System- 
Nephrology, 8 Summa Health System- Surgical Research, 9 Summa Health 
System- General Surgery
Background: The availability of optimal kidneys for transplantation is limited. 
Most transplant surgeons will not accept kidneys from deceased donors with 
acute renal failure because traditional regimens of immunosupression can 
be problematic for outcomes using these kidneys. Prior studies have shown 
that pre-treatment of recipients transplanted with kidneys from optimal 
donors using Campath-1H induction followed by minimal post-transplant 
immunosuppression (Starzl principle), results in excellent outcomes and we 
have adopted this regimen as the standard of care in our transplant program. 
We hypothesized that using these same principles, kidneys from deceased 
donors with acute renal failure could also be successfully transplanted in 
selected recipients. This report provides early results of outcomes in patients 
transplanted with kidneys derived from donors with acute renal failure using 
the Starzl principles of immunosuppression.
Methods: Kidneys obtained from deceased donors with acute renal failure were 
considered for transplant if the following donor criterion were met: Donor age 
¡Ü 50 years; no previous history of renal disease; and, negative pre-transplant 
biopsy for structural changes except acute tubular necrosis (ATN). The 
recipients all had BMI¡¯s less than 30 and were on chronic dialysis regimens. 
The immunosuppression regimen consisted of Campath-IH (30mg x dose) for 
induction immunosuppression followed by maintenance immunosuppression 
with mycophenolate mofetil (1g every12 hours) and prednisone (20mg 
daily). The prednisone was tapered by 2.5mg/week over 8 weeks and then 
off. Mycophenolate mofetil was replaced by Tacrolimus once the recipient¡¯s 
creatinine was less than 2 mg/dl. Post-transplant biopsies were performed as 
clinically indicated.
Results: Over a 1 year period from March 2007 – March 2008, a total of 44 
kidneys were transplanted using the Starzl principles of immunosupression 
Nine (9) of these kidneys (24.5%) were obtained from donors with acute renal 
failure. Donor ages ranged from 24-46 years with mean age of 37.6 years. 
Donor creatinine on admission ranged from 0.8-2.3 mg/dl with mean of 1.26 
mg/dl. Donor creatinine clearance on admission ranged from 68-208 mg/
dl with a mean of 102 mg/dl. Donor terminal creatinine ranged from 2.7-5.7 
mg/dl with a mean of 3.63 mg/dl, and donor terminal creatinine clearance 
ranged from 21-58 mg/dl with a mean of 38.3 mg/dl. All donor biopsies were 
negative for chronic tubulointersitital disease and ATN was the most prevalent 
change noted. Patient survival and graft survival are each 100% after 9 months. 
Recipient mean serum creatinine is 1.5 mg/dl with a mean creatinine clearance 
of 62.7mg/dl. No patients have exhibited biopsy proven rejection thus far 
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during follow-up.
Conclusion: We have had excellent results transplanting kidneys from donors 
with acute renal failure using Campath-1H induction with minimal post-
transplant immunosupression. This regimen increased the availability of donor 
kidneys by 24.5%. Minimal post-transplant immunosupresion may provide 
an opportunity for these sub-optimal kidneys to recover function. Long term 
follow-up will be required to validate these conclusions.
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A PHASE III UNICENTRIC, NON-RANDOMIZED STUDY 1977 
FOR THE EVALUATION OF SECURITY AND EFFICACY OF 
CAMPATH 1H ASSOCIATED WITH SIROLIMUS, MOFETIL OR 
SODIUM MYCOPHENOLATE AND LOW DOSES OF STEROIDS 
IN ECD KIDNEY RECIPIENTS OR KIDNEYS AT RISK OF 
DELAYED GRAFT FUNCTION. 
L. Santiago Re, M. Rial, S. Cuevas, L. Reniero, D. Casadei
Instituto De Nefrología De Buenos Aires
Introduction: In the actual context of shortage of organs for transplantation, 
expanded criteria donors usage plus the nephrotoxicity associated with 
calcineurin-inhibitors drugs (CNI), we designed an immunosuppressive 
protocol using Alemtuzumab (Campath 1H) as induction agent, followed by 
a CNI-free maintenance therapy for kidney recipients of expanded criteria 
donors as defi ned by the UNOS or recipients of kidneys at high risk of DGF.
Materials and methods: 25 patients received Campath 1H 30 mg IV just 
before the surgery. Maintenance therapy consisted in Sirolimus (adjusted to 
levels between 8-12 ng/ml), Mofetil or Sodium Mycophenolate and low doses 
of steroids.
Results: 1-year patient survival: 92% (2 patients died due to septic shock)
1-year graft survival 72%: (1 primary non-function, 1 graft loss at 6 months 
due to CAN, 1 renal artery thrombosis, 1 recidive of primary glomerulopathy, 
1 loss due to discontinuation of the immunosuppression in the context of TB 
pericarditis).Death censored graft survival: 80%. 6 months-creatinine clearance: 
46.25 ml/min. 1-year creatinine clearance: 63.5 ml/min. 1-year acute cellular 
rejection incidence: 0%.
CMV: 0%. Tuberculosis 2/25 (8%). Urinary tract infection 6/25 (24%). Wound 
surgery infection 4/25 (16%).
Conclusions: The utilization of this immunosuppressive scheme was associated 
with a null incidence of 1-year acute cellular rejection and CMV infection. Graft 
losses were not associated with Campath 1-H use. The incidence of septic shock 
was not different of that observed in our previous study using Thymoglobulin 
as induction agent, but due to these results in the forthcoming patients we will 
start to minimize the immunosuppressive therapy. Campath 1-H constitutes an 
effi cacious agent as induction therapy for ECD kidney recipients. 
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BIOLOGIC EFFECTS OF ALEMTUZUMAB INDUCTION 1978 
ON HIGH RISK RENAL ALLOGRAFT RECIPIENTS: THE 
VALUE OF SERIAL CDC-PRA AND LYMPHOCYTE COUNT.
A. Hernandez, C.O. Callender, T. Newberry, D. Joyce, R. Scott, J. Coton, 
N. Kramer
Howard University Hospital
Background: The CDC-PRA test, a classical cytotoxicity assays for detecting 
antibodies relies on their ability to kill target cells by activating complement. 
This test uses lymphocytes from individuals who were chosen to represent 
a wide range of HLA antigens. However; this tests cannot determine if the 
reactive antibodies are directed against HLA or some other molecules that 
reside on the lymphocytes.
Alemtuzumab (Campath 1H), a humanized monoclonal antibody, binds 
to the CD 52 molecule present in variable concentrations on all peripheral 
mononuclear cells including lymphocytes. Alemtuzumab has a depleting effect 
on such cells and therefore its blood concentration will be refl ected on the 
CDC-PRA assay.
Objective: To analyze the effects of alemtuzumab induction on serial CDC-PRA 
and peripheral lymphocyte counts in high risk kidney allograft recipients.
Methods: We prospective collected data on serial CDC-PRA, lymphocyte 
count and renal function on 8 consecutive high risk renal allograft recipients. 
All patients received a single 30mg dose of alemtuzumab intra-operatively, and 
continued maintenance immunosuppression therapy with low dose tacrolimus 
(Target concentration: 5-10 ng/ml for 3 months and 5-8 ng/ml thereafter). 
The target MMF dose was 2 gm/day and no corticosteroids were used for 
maintenance. Results were analyzed according to patients’ outcome.
Results: Six females and 2 males, ages 29 to 64, received 4 living and 4 
deceased donor kidneys. Risk factor included PRA ≥ 25% (n=2), re-transplant 
(n=2), history of antibody mediated rejection (n=1), African Americans (n=7), 
DM (n=3) and Obesity, dylipidemia and hypertension in all cases. 
All patients presented 100% CDC-PRA and a mean absolute lymphocyte count 
of 0.2 after alemtuzumab treatment (fi g 1 and 2)
Patients with stable renal function (n=5) mean CDC-PRA dropped to 50% 
by 6 weeks and retuned to pre-transplant values 16 wks after alemtuzumab 
administration. Reciprocally, Lymphocyte mean count improved to 0.5 and 
reached the lower limit of normal after 16 weeks as well (Fig. 3)
CDC-PRAs may return to their pre-treatment values as early as 3 wks. Pre-
sensitized (n=2) and patients with ongoing AMR (n=2) may require more than 
16 wks. 
Conclusions:
Serial CDC-PRA and lymphocyte counts are informative of the remaining 
biologic activity of the depleting antibody. Once CDC-PRA has returned to 
baseline, we should assume that the depleting antibody has been removed from 
the patient’s serum. These results apparently correlate with the lymphocyte 
count recovery.
Serial CDC- PRA may be useful to guide the timing for serial doses of antibody-
lymphocyte-depleting agents.
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A CALCINEURIN INHIBITOR-FREE 1979 
IMMUNOSUPPRESSIVE STRATEGY IN OLD RECIPIENTS 
OF RENAL ALLOGRAFTS: 1-YEAR RESULTS FROM A 
PROSPECTIVE SINGLE CENTRE TRIAL
H.P. Arbogast1, J.N. Hoffmann1, W-D. Illner1, G.F. Hillebrand2, 
M. Fischereder3, K-W. Jauch1, W. Land4
1Department of Surgery, University of Munich – Grosshadern, 2Medical 
Department I, Division of Nephrology, University of Munich – Grosshadern, 
3Department of Medicine, University of Munich – City, 4Baskent University, 
Ankara, Turkey
Introduction: Recently published data from our centre demonstrated the 
feasibility of an application of a nephrotoxicity- and atherogenicity-free, 
MMF-based immunosuppressive induction/maintenance protocol in elderly 
recipients of kidneys from elderly cadaver donors. With the aim to decrease 
the potential infectious and tumorogenic potency of polyclonal antibody 
induction treatment in old recipients of cadaveric renal allografts, we applied 
and investigated a therapeutic regimen consisting of a combined polyclonal-
monoclonal induction regime and CNI-free, mycophenolate mofetil (MMF) 
– based immunosuppressive maintenance protocol. In the following, the 1 year 
Poster Abstracts Thursday 14 August 2008
6 5 1
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
results of this clinical trial are published. 
Methods: Between 1997 and 2007, a total of 118 elderly patients were treated 
with an MMF-based, CNI-free immunosuppressive protocol. In a fi nal cohort, 
30 old recipients (67.8 + 3.8 y) of renal transplants from deceased donors (69.4 
+ 13.3 y) were recruited consecutively, for this 5-year, prospective, open, single 
centre, pilot trial. Induction therapy consisted of a low-dose, single shot of 
rabbit ATG (ATG-Fresenius®) and the IL-2R-antibody Basiliximab (d0 and d4) 
in conjunction with MMF and steroids. Maintenance treatment was performed 
with MMF/steroids or MMF alone under strict therapeutic drug monitoring by 
aiming target MPA-trough levels between 2 – 6 μg/mL. 
Results: Cumulative 1-year patient and renal allograft survival was 87% and 
83%, respectively, death-censored graft survival at one year was 97%. However, 
in 46% of all patients, rejection episodes were observed, mostly being steroid 
sensitive with only 3 patients requiring serum therapy. Function of the old renal 
allografts proved to be satisfactory as refl ected by serum Creatinine-values of 
1.78 + 0.45 mg/dl and Nankivell GFR-values of 48.8 + 13.9 mg/dl, at 6 months. 
23% of all patients demonstrated CMV infections, however only in 3.3%, CMV 
disease was observed. 
Conclusions: Application of a combined polyclonal-monoclonal induction 
regime using a nephrotoxicity- and atherogenicity-free, MMF-based 
immunosuppressive maintenance protocol in elderly renal cadaver transplant 
recipients leads to acceptable short-term outcomes in old recipients of old 
organs, however at the expense of an increased rejection rate, being comparable 
to previously published data for elderly (> 50 y) recipients having received 
allografts from elderly (> 50 y) cadaver donors.
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SUCCESSFUL ALEMTUZUMAB INDUCTION AND 1980 
STEROID WITHDRAWAL IN AFRICAN AMERICAN AND 
CAUCASIAN RECIPIENTS OF RENAL TRANSPLANTS
R. Barth, C. Gurk-Turner, D. Klassen, M. Cooper, E. Schweitzer, L. Campos, 
S. Bartlett, B. Philosophe
University of Maryland School of Medicine
Alemtuzumab induction therapy has been reported to decrease early rates of 
rejection and be permissive of immunosuppressive minimization strategies. 
We have implemented a protocol for alemtuzumab induction and steroid 
withdrawal of renal transplant recipients and report on our early results with 
this strategy. We have collected data from 19 living and 119 deceased donor 
renal transplant recipients from our center with median follow-up of 11 months. 
Immunosuppression consisted of 30 mg alemtuzumab at transplant, and 
maintenance with tacrolimus, mycophenolate mofetil, and steroid withdrawal 
over 21 days. Kaplan-Meier analysis was performed to determine patient and 
graft outcomes. Of 138 renal transplant recipients, 58% were African American 
(AA), 39% female, and median age was 52 yrs old. DGF rate was 48.6% and 
median length of stay was 7 days. 1-yr graft survival was 87.8%, and patient 
survival was 93.7%. Differences in 1-yr graft survivals of 84.7% for AA and 
97.9% for non-AA and 1-yr patient survivals of 90.4% AA and 100% for 
non-AA were not statistically signifi cant. Rejection rates at 1,3, and 6 mos 
were 3.6%, 8.0%, and 12.0% and were not different between AA and non-AA 
(p=0.7). Rejection-rates were 19.0% at 1-yr for all recipients (AA 17.4% vs 
non-AA 24.7%, p=0.7). ACR was observed in 15.7% patients at 1 year (AA 
11.8%, non-AA 14.7%, p=0.7); and AMR was observed in 2.9% patients at 1 
year (AA 5.0%, non-AA 0%, p=0.06). Steroid-withdrawal was attempted in 112 
patients and accomplished and maintained in 82% of these patients. Patients 
who reached 6 and 12 months time points had median creatinines of 1.8 mg/dL 
(n=125) and 1.7 mg/dL (n=54). CMV rate was 4.6% in non-CMV mismatched 
Pts and 16% in CMV mismatched Pts. Signifi cant leukopenia (WBC<2000/
uL) was observed in 26.6% of Pts, for which 53% received therapy with 
G-CSF. Rates of leukopenia between AA (21.5%) and non-AA (34.7%) were 
not signifi cantly different (p=0.15). We have demonstrated excellent early 
results with a protocol of alemtuzumab induction and steroid withdrawal in 
both African American and non-African American renal transplant recipients. 
Alemtuzumab induction allowed for successful steroid withdrawal, low rates 
of rejection, and short lengths of stay in a population with a majority of African 
American recipients and high rates of DGF.
LIVER TRANSPLANT CONCURRENT ORAL SESSION 138: 
OUTCOMES: RENAL FUNCTION
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ETIOLOGICAL AGENTS OF URINARY TRACT 1981 
INFECTIONS (UTI’S) IN THE EARLY PERIOD AFTER LIVER 
TRANSPLANTATION.
D. Kawecki1, A. Sawicka-Grzelak1, K. Kot1, E. Swoboda-Kopec1, 
M. Pacholczyk2, B. Lagiewska2, P. Malkowski3, A. Chmura2, W. Rowinski2, 
M. Luczak1
1Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of 
General Surgery and Transplantation Medical University of Warsaw, 3Dept. 
of Surgical Nursing and Transplantation Medical University of Warsaw
Urinary Tract Infection (UTI) is a one of the common infection in liver 
transplantation (LT). 
Material and methods: The study covered 83 adult patients undergoing 
liver transplantation (piggy back technique) between September 2001 and 
October 2004. All the patients were followed prospectively for urinary tract 
infections from the LT date and during the fi rst four weeks after surgery. Basic 
immunosuppression consisted of steroids and tacrolimus (Prograf ®; Fujisawa, 
Germany). Antimicrobial prophylaxis was administered intravenously from 
the day of transpalntation: piperacillin/tazobactam (Tazocin ®, Wyeth, USA), 
fl uconazole (Difl ucan ®; Phizer, USA) and selective bowel decontamination 
(orally a liquid suspension of amikacin and nystatin) was carried out.
Samples of urine were investigated for bacteriological cultures. The 
microorganisms were cultured and identifi ed in accordance with standard 
bacteriological procedures. Susceptibility testing was carried out using National 
Committee for Clinical Laboratory Standards (NCCLS) procedures.
Results: Urine specimens were examined in 53 pre-operative recipients (63.9%) 
and in 64 patients (77.1%) during the fi rst month after transplantation. Of the 
182 samples investigated, 73 were positive. Bacterial strains were cultured 
from 17 recipients before LT and from 28 patients after surgery. Among the 
bacterial strains isolated in early period after LT (n = 71), the most common 
were Gram-negative rods n = 46 (63%) isolates, the Enterobacteriaceae family 
n = 44 (95,6%) isolates among them n = 12 (27,3%) of the Gram-negative rods 
were Extended-Spectrum Beta-Lactamases ESBL(+) strains.
Gram-positive bacteria were cultured 34% (n = 25) and fungal strains 3% 
(n=2). 
Conclusions: 1.The predominance of Gram-negative rods was caused by 
ESBL(+) and use of broad spectrum antimicrobial prophylaxis. 2.The increased 
proportion of isolation Multi-Drug-Resistant (MDR) bacteria to antimicrobial 
agents may be due to the frequent use of these agents for prophylaxis of bacterial 
infections in liver transplant patients. 3. These (MDR) bacterial strains caused 
severe UTI’s in patients after LT.
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KIDNEY TRANSPLANTATION AFTER LIVER 1982 
TRANSPLANTATION
J. Moon, A. Manta, C. Lyssikatos, A. Tzakis, T. Kato, W. Kupin, D. Roth
Miami Transplant Institute, University of Miami School of Medicine
Introduction: Liver transplantation is often complicated by chronic renal 
failure, which signifi cantly increased the risk of death. A population-based 
cohort analysis recently reported 18.1% cumulative incidence of chronic 
renal failure at 5 years after liver transplantation. Treatment of end stage renal 
disease with kidney transplantation has been proved signifi cantly lower risk of 
death than dialysis. 
Objective: We reviewed our experience of kidney transplantation in the liver 
transplant patients who developed end stage renal disease.
Material and Method: This is a retrospective study using prospectively 
maintained data base from a single center. Patient and graft survival was 
examined by Kaplan-Meier analysis. 
Result: Since 1994 we have 22 kidney transplantations (3 living and 19 
deceased donors) among 1802 adult liver transplantation patients. Mean age 
of the patient is 56 ± 13 years old (range 18 to 72). There are 13 male and 
9 female patients. The reason for liver transplantation was cryptogenic liver 
cirrhosis (8, 36.4%), hepatitis C (6, 27.3%), alcoholic liver cirrhosis (2, 9.1%), 
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and others (autoimmune hepatitis, primary sclerosing cholangitis, polycystic 
liver disease, cystic fi brosis, amyloidosis, fulminant hepatic failure). Interval 
between liver and kidney transplantation was 7.1 ± 4.0 years (range 3.1 to 16). 
Causes of end stage renal disease was calcineurin inhibitor nephrotoxicity (12, 
54.5%), diabetic nephropathy (7, 31.8%), irreversible hepatorenal syndrome 
(1, 4.5%), hypertensive nephropathy (1, 4.5%), and polycystic kidney 
disease (1, 4.5%). Mean waiting time on the kidney transplant list was 350 ± 
198 days (range 24 to 820). Induction immunotherapy was daclizumab (10, 
45.5%), daclizumab with antithymocyte globulin (6, 27.3%), corticosteroid 
(5, 22.7%), and antithymocyte globulin (1, 4.5%). Tacrolimus, mycophenolate 
mofetil, and corticosteroid were used as a maintenance immunosuppression 
in all patients. Corticosteroid was slowly tapered out at 6 to 9 months after 
kidney transplantation. Mycophenolate mofetil was stopped in 3 patients due to 
signifi cant gastrointestinal adverse effect. There were 5 mortalities at 1.8, 13.5, 
23.7, 35.7, and 86.6 months after kidney transplantation. Cause of death was 
pneumonia (2), recurrent hepatitis C (2), and cardiac failure due to underlying 
amyloidosis (1). The rest of patients maintained good kidney graft function 
without graft loss. Liver allograft function did not show signifi cant change 
after kidney transplantation. Patient and graft survival at 5 years after kidney 
transplantation was 72.6%. 
Conclusion: Kidney transplantation is an excellent renal replacement therapy 
in liver transplant patients who developed end stage renal disease. Our study 
does not fi nd liver graft deterioration after kidney transplantation. 
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PREDISPOSING FACTOR OF ACUTE RENAL FAILURE 1983 
REQUIRING CONTINUOUS RENAL REPLACEMENT 
THERAPY AFTER LIVER TRANSPLANTATION
M.S. Kim1,3, M.K. Ju1,3, G.H. Choi1, B.S. Kim2, J. Choi1, D.J. Joo1, S.J. Kim1, 
S.I. Kim1,3, Y.S. Kim1,3
1Yonsei University College of Medicine, Department of Surgery, 2Yonsei 
University College of Medicine, Department of Internal Medicine, 3Yonsei 
University College of Medicine, The Research Institute for Transplantation
Acute renal failure (ARF) is a severe complication in patients undergoing liver 
transplantation, which predicts a poor outcome. ARF increases the incidence 
of postoperative sepsis, the need for dialysis, the number of days spend in the 
intensive care unit, and poor outcomes. Continuous renal replacement therapy 
(CRRT) is widely used for treatment of ARF in liver transplantation patients. The 
aims of this study are to analyze predisposing factors for development of ARF. 
Eighty adult liver transplant recipients from September 2005 to November 2007 
were enrolled in this study. Pre-transplant and transplantation-related clinical 
manifestations were retrospectively collected. All recipients used tacrolimus-
based immunosuppression with 10-15 ng/ml of trough level.
Of the 80 recipients, 10 recipients (12.5%) experienced ARF needing 
CRRT therapy during early transplantation period. The deceased donor liver 
transplantation, presence of ascites, hepatorenal syndrome and history of using 
Molecular Adsorbents Recirculation System (MARS) were also common in 
ARF needing CRRT group (p=0.037, 0.040, 0.04, and p<0.001, respectively). 
The pre-transplant serum creatinine level, total bilirubin level, and Model for 
End-stage Liver Disease (MELD) score is signifi cantly high in ARF needing 
CRRT group than no-ARF group (p<0.001, p<0.001, p=0.022, and 0.001, 
respectively). The ARF patients needing CRRT showed higher peri-operative 
mortality rate (40%) and inferior 1-year survival rate (45.0%) than no-ARF 
group (2.9% and 97.1%)(p<0.05). 
The necessity for CRRT in patients after liver transplantation correlates with 
severity of liver disease such as Hepatorenal SD and MELD score. And it also 
directly correlated with immediate post-operative mortality.
Clinical manifestations
No-ARF ARF needing CRRT Total p-value
N 70 10 80
Age (years) 51.0±7.2 49.5±9.7 50.8±7.5 0.557
Gender (Male:Female) 56: 14
(80.0%: 20.0%)
6:4
(60.0%: 40.0%)
62: 18
(77.5%: 22.5%)
0.159
Donor type (Deceased:Living) 19: 51
(27.1%: 72.9%)
6:4
(60.0%: 40.0%)
25: 55
(31.3%: 68.8%)
0.037
Encephalopathy + 15 (21.4%) 5 (50.0%) 20: 60
(25.0%: 75.0%)
0.052
Ascites + 39 (55.7%) 9 (90.0%) 48 (60.0%) 0.040
Esophageal varix + 22 (31.4%) 3 (30.0%) 25 (31.3%) 0.928
Hepatorenal syndrome + 1 (1.4%) 2 (20.0%) 3 (3.8%) 0.004
MARS history + 3 (4.3%) 4 (40.0%) 7 (8.8%) <0.0001
BMI (kg/m2) 23.5±2.4 23.7±3.3 23.58±2.5 0.834
Serum creatinine level (mg/dl) 0.9±0.2 1.4±0.9 0.9±0.4 <0.001
Total bilirubin level (mg/dl) 5.6±8.9 13.4±15.1 6.6±10.1 0.022
MELD score 14.8±7.3 23.6±10.6 15.9±8.2 0.001
Operation time (hours) 10.8±1.9 10.7±2.2 10.8±1.9 0.925
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LIVING KIDNEY DONATION FOLLOWING PREVIOUS 1984 
RIGHT LOBE LIVER DONATION – FIRST REPORT IN WORLD 
LITERATURE
R. Kadiyala, M. Eng, R. Nagubandi, M. Marvin, J. Buell
Transplant Center, Jewish Hospital, University of Louisville, KY, USA
Introduction: The past few years have witnessed an increasing disparity 
between patients awaiting organ transplants and the deceased donor organs 
available resulting in an increase in wait list mortality. This has led to a rise in 
living donation rates particularly kidneys. We report a patient who donated a 
kidney following a previous liver donation
Case report: A 48 year old woman was evaluated as a potential kidney donor 
for a friend who had end stage renal failure from polycystic kidney disease. She 
had previously donated her right lobe of liver for transplantation to her mother 
who had cirrhosis of liver. Her liver surgery 8 years prior was uneventful and 
imaging showed regeneration of her liver remnant. She was found to be in good 
health with no medical contraindications. CT angiography revealed normal 
kidneys bilaterally with single artery and vein on either side. She underwent 
extensive screening by the psycho-social team and cleared for kidney donation. 
She underwent laparoscopic left donor nephrectomy without any peri-operative 
complications and was discharged home 2 days later. The recipient, a 46 year 
old man, had good graft function and has been off dialysis since. At a follow-
up of 2 months, both the donor and recipient are in good health with normal 
renal function
Conclusion: This is the fi rst report of living kidney donation from a previous 
liver donor. In the era of organ shortage, this patient exemplifi es the safety of 
live organ donation. Previous organ donation should not be a contraindication 
to further donation in properly screened patients
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PREDICTIVE VALUE OF PRE-TRANSPLANT 1985 
CREATININE ON RENAL IMPAIRMENT ONE YEAR AFTER 
LIVER TRANSPLANTATION
C.K. Burghuber, G.P. Gyoeri, R. Steininger, F. Muehlbacher, T. Soliman, 
G.A. Berlakovich
Dept. Transplant-Surgery, Medical University Vienna
Purpose: Chronic renal failure after orthotopic liver transplantation (OLT) is 
common and is a cause for a reduced quality of life and survival. The course 
of renal function peri- and postoperatively is diffi cult to foresee. Means to 
predict the development of postoperative renal impairment (RI) would help to 
concentrate on early minimization of nephrotoxic medication in these patients.
Methods: All adult patients who received a primary liver graft between 1999 
and 2006 and were followed at our center for at least 1 year post-OLT were 
considered for analysis (n=269). Data were collected from our prospective 
electronic database.
Postoperative RI was defi ned as a serum creatinine ≥;1.5 at 1 year post-OLT. 
We conducted an analysis of the predictive value of creatinine 3, 2, and 1 
months preoperatively and on the day of OLT. Sensitivity and specifi city as 
well as positive and negative predictive values were calculated.
Results: Renal impairment was diagnosed in 69 patients (26%) at 1 year after 
OLT.
Pre-OLT serum creatinine values at 3-, 2-, 1-month and at transplant were 
compared with renal function 1 year post-OLT. The correlation coeffi cient was 
0.43, 0.26, 0.44 and 0.33, respectively. Detection of RI post-OLT by pre-OLT 
serum creatinine at the 4 time points had a sensitivity of 25%, 27%, 33% and 
7% and a specifi city of 95%, 92%, 94% and 83%, respectively. The proportion 
of true positive test results among all the positive test results (positive predictive 
value) amounted to 44% and the negative predictive value to 75%.
Conclusion: Pre-transplant serum creatinine had no predictive value for long-
term renal function in patients listed for liver transplantation. Measuring 
serum creatinine alone does not permit to sort out patients with high risk for 
developing renal failure after OLT.
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THE IMPACT OF RENAL DISEASE IN LIVER 1986 
TRANSPLANTATION
F. Nolasco, A.C. Ferreira, S. Sampaio, A. Baptista, P. Pessegueiro, 
E. Monteiro, A. Martins, E. Barroso
Hospital Curry Cabral
Renal dysfunction often complicates the course of orthotopic liver transplant 
(OLT) recipients and is associated with an increase morbidity and mortality.
The aim of this study was to determine the incidence of renal disease (acute and 
chronic), possible risk factors and to determine the impact on the patient survival.
Clinical data included age, gender, aetiology for hepatic failure, presence of 
diabetes mellitus, hypertension, hepatitis B and C infection, renal dysfunction pre 
transplant (RD pre) and immunosuppression. Laboratorial data included serum 
creatinine at day 1, 7, 21, month 6, and every year. The glomerular fi ltration rate 
(GFR) was determined by Cockcroft-Gault equation. We studied, retrospectively, 
from September 1992 to March 2007, 708 OLT recipients, 82 being re-
transplanted. Mean age 44 ±12.6 years, 64% males, 17% diabetic, 18.8% with 
hypertension, 19.9% with C hepatitis and 3.8% B hepatitis. Renal dysfunction 
was known in 21.6%. Mean follow-up was 3.6 years (0- 15). Mean transplant 
survival was 75% at 12 months and 69% at 3 years. 152 patients died. Uni and 
multivariate analysis were performed and a p<0.05 was considered signifi cant.
Renal dysfunction in this population was observed in more than 50% and was divided 
in 2 groups: acute renal failure (ARF) in the immediate post transplant period (33.8%) 
and chronic kidney disease (CKD) according to KDIGO defi nition (50.2%).
ARF occurred in 33.8% of the patients. Only 14% recovered the renal function with 
GFR > 60 ml/min (r = 0.686, p <0.001), 15.5% did not recovered renal function 
and are on dialysis (r= 0.454, p <0.001), 30.5% died (r= 0.222, p<0.001).
In the time of this study, half of the population had CKD 3, 29% with a GFR< 
45 ml/min, 9% had CKD 4 and 5.6% CKD5d. 
Persisting renal failure (GFR < 45 ml/min) was positively correlated with age 
(r=0.199, p<0.001), diabetes (r=0.88, p=0.032), alcohol (r=0.097, p=0.015), RD 
pre (r=0.279, p<0.0001), ARF post transplant (r=0,319 p<0.0001) and with high 
mortality (r=0.188, p<0.0001). On multivariate analysis, it was positively correlated 
with age (p<0.001), RD pre (p<0.001), ARF post transplant (p=0.03) and with 
mortality (p=0.015). It was not correlated with aetiology of hepatic failure.
Mortality was also correlated, on multivariate analysis, with RD pre (p=0.006), 
ARF post transplant (p<0.001), CKD stage 3 post transplant (p=0.002), CKD 
5d (p<0.001) and haemodialysis treatment (p<0.001). There was no correlation 
between mortality and need of re transplant.
In conclusion, OLT recipients are disposed to renal complications that have a 
negative impact in the survival of these patients. Renal dysfunction seems to be 
more important than the need of re transplant in what concerns clinical prognostic.
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CHRONIC KIDNEY DISEASE FOLLOWING 1987 
ORTHOTOPIC LIVER TRANSPLANTATION.
J. Frazier1, G. Lipka1, D.W. Johnson1, C. Hawley1, S. Campbell1, 
D. Mudge1, C. Van Epps1, N. Isbel2, G. Macdonald2
1Princess Alexandra Hosital, 2CCRE, University of Queensland
Background: Chronic Kidney Disease (CKD) is a frequent complication of 
liver transplantation. It is associated with increased morbidity and mortality 
including the development of End Stage Renal Disease (ESRD) requiring 
either Chronic Renal Replacement Therapy (CRRT) or renal transplantation. 
This study examines the prevalence of CKD and its predictors in a population 
of liver transplant patients at the Princess Alexandra Hospital.
Methods: Retrospective analysis of 80 liver transplant recipients transplanted 
at the Princess Alexandra Hospital, Brisbane between 1st July 1997 and 31st 
December 2001. Median follow up time was 6.24 years. CKD was defi ned as 
MDRD Estimated Glomerular Filtration Rate (eGFR) < 30mls/min/1.73m2 or 
the development of ESRD
Results: Patients transplanted in-centre had a lower prevalence of chronic 
renal failure (6.25% vs 18.1%) than previously reported (Ojo et al,NEJM 
2003,349:931-940). One patient with CKD required CRRT and none underwent 
renal transplantation. Renal function steadily deteriorated post transplant with 
a mean eGFR loss of 1.47ml/min/year. Independent predictors of impaired 
post-transplant renal function (eGFR<60 ml/min) were eGFR<60ml/min 
at pretransplant assessment (â 0.982 95% CI 0.971-0.994 p=0.004), male 
gender (â 0.48 CI 0.253-0.909 p=0.024), low BMI at assessment (â 0.957 
CI 0.906-1.01 p= 0.11), and higher number of antihypertensive medications 
(â 1.527 CI1.164-2.002 p=0.002). eGFR <60 ml/min post transplant was 
signifi cantly associated with increased mortality (p=0.004).
Conclusions: CKD is a prevalent complication following liver transplantation 
and is associated with signifi cant morbidity and mortality. Post transplant renal 
function progressively declined with time, which with improved survival post-
liver transplantation will result in an increased burden of CKD in these patients 
in the future.
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LONG-TERM SURVIVAL AND OUTCOMES OF 1988 
COMBINED LIVER-KIDNEY (SIMULTAENOUS AND 
SEQUENTIAL) TRANSPLANTS IN SPAIN
D.D. Castillo1, A. Otero2, O. Bestard3, N. Esforzado4, M.L. González5, 
L. Capdevila6, L. Castells6, J.J. Amenábar7, S. Gatell8
1Hosp. Univ. Reina Sofía, Córdoba, Spain, 2Hosp. Juan Canalejo, A Coruna, 
Spain, 3Hosp. Bellvitge, Hospitalet de Llobregat, Spain, 4Hosp. Clínic i Univ, 
Barcelona, Spain, 5Hosp. Univ. Central de Asturias, Oviedo, Spain, 6Hosp. 
Vall d´Hebron, Barcelona, Spain, 7Hosp. de Cruces, Barakaldo, Spain, 8 
Novartis Farmacéutica, S.A.
Objective: To describe long-term survival and grafts function of all patients 
who have received simultaneous or sequential liver and kidney transplant in 
Spain in the last 15 years. 
Methods: An observational, retrospective and multicenter study was conducted, 
including all adult patients receiving double liver-kidney transplant between 
1991 and 2006 in Spain.
Results: 178 patients were analyzed: 139 with simultaneous transplant and 39 
with sequential transplant (5 kidney-liver (KL) and 34 liver-kidney (LK)). Patients 
were mainly men and mean age was 51±9, 47±5, 53±11 years, respectively. The 
most frequent reasons for renal failure were glomerulonephritis and secondary 
glomerulonephritis, whereas alcoholic cirrhosis was the main cause of liver 
disease. The prevalence of positive HBV recipients before the fi rst transplant was 
14.9%, 50.0% and 7.1% respectively, positive HCV, 42.0%, 75.0% and 35.7%, 
respectively, and positive HBC and HCV, 16.3%, 33.3% and 10.0%, respectively. 
The most common immunosuppresive regimen at discharge was anticalcineurin 
plus MMF/EC-MPS plus steroids. The mean creatinine clearance and bilirubin 
values for combined transplants were 55.7 ml/min and 1.3mg/dl at fi ve years and 
59.2 ml/min and 1.2 mg/dl at ten years, respectively. At fi ve years after double 
transplantation, 75% of patients were alive, and, at ten years, 55%. The estimated 
mean survival time was 9.2 years, 7.5 years and 6.9 years for combined, KL and 
LK, respectively. Main cause of death was infection. Post-transplant hypertension 
and hyperlipemia were the most commonly reported complications. 
Conclusion: Data from clinical practice in Spain suggests that the combined 
liver-kidney transplantation presents good survival, similar to that obtained 
with liver transplantation alone. Simultaneous or sequential liver-kidney 
transplantation can be considered a valid option for patients waiting for a liver 
who also suffer kidney disease.
POSTER BOARD NUMBER P4 – 39
THE RISK OF KIDNEY AFFECTION IN ADULT PATIENTS 1989 
WITH ORTHOTOPIC LIVER TRANSPLANTATION FROM 
CADAVERIC DONORS
M. Mihaila1, L. Micu1, I. Popescu2, M. Voiculescu1
1Fundeni Clinical Institute, Center of Internal Medicine-Nephrology, 2Fundeni 
Clinical Institute, Center of General Surgery and Liver Transplantation
Introduction: Kidney affection develops frequently (40-60%) and infl uences 
the prognosis of patients with non-kidney transplants. 
Objective. The aim of this study is to evaluate the frequency and risk factors of 
kidney affection in patients with orthotopic liver transplantation. 
Material and methods: We evaluated 61 adult patients (M=34, F=27) with 
orthotopic liver transplantation performed between 2000-2007, out of a 
total of 131 patients with liver transplantation for end stage liver disease of 
various etiologies. None of the 61 patients presented kidney affection before 
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transplantation. Standard immunosuppression protocols were used, consisting 
in tacrolimus and mycophenolat mophetil (MMF) or with ciclosporin and 
MMF in case of adverse reactions to tacrolimus.
We evaluated the risk of developing kidney affection in the absence of o pre-
existing renal conditions. Kidney affection was considered in case of: proteinuria 
> 0.3 gr/24 hours or hematuria > 2000/min (Addis-Hamburger probe), the 
presence of cilinders in urine spot or a creatinine clearance of < 90 mL/min 
calculated using the MDRD formula (Modifi cation of Diet in Renal Disease).
Results: Proteinuria > 3 gr/24 hours and hematuria (>2000/min) were present in 2 
cases (3.27%); II-nd degree chronic kidney failure in 27 cases (44,26%) and III-
rd degree chronic kidney failure in 18 cases (29.5%). Renal substitution was not 
necessary in any of the patients alter a mean follow-up period of 47.5 months. Of 
the patients with chronic kidney failure, 30 (66.66%) are treated with tacrolimus, 
and 15 (33.33%) with ciclosporin in classic immunosuppressive doses. 
Conclusions: Kidney affection occurs frequently in liver transplantation 
(73.76%). Tacrolimus, as well as Ciclosporin, may be considered as risk factors 
for kidney affection. Although kidney function was found to be signifi cantly 
restricted in these cases, renal substitution was not necessary in any patients.
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GFR ASSESSED BY MDRD FORMULE IN LIVER 1990 
TRANSPLANT PATIENTS WITH ACUTE KIDENY DISEASE
E. Varo, L. Vizcaino, C. Ponton, A. Lopez, S. Tome, M. Bustamante, 
J. Martínez, E. Otero, C. Javier, F. Segade
Abdominal Transplant Unit
Accurate assessment of Chronic and acute renal failure (AKF) results a key 
point for management of patients after liver transplantation (LT). 
Aim: To estimate the degree of renal impairment by other formules than 
Creatinin clearance like MDRD during the fi rst year after LT.
Methods: From 290 Liver transplant patients during a period of time from 1999 
to 2004 we assessed 52 patients who developed AKF.AKF has been defi ned 
as either the increase of serum creatinin up to 1.5 mgrs /dl, BUN up to 70 
mgrs/ dl or GFR assessed by creatinin clearance (Ccr (Cockroft& Gault) less 
than 50 ml/min. We performed the correlation between Ccr and formules as 
recomended the International kidney fundation(MDRD) during the different 
stages of Renal failure as well as different period of time after fi rst year after 
liver transplantation
Results: From 52 patientes (67% Males and 33% Females). Median age 52 y. 
The correlation between different estimations as well as the concordance as 
assessed by Kappa statistics can be seen on fi gure 1.
Time GFR 
(C-G)
GFR 
MDRD4
GFR 
MDRD5
GFR 
MDRD6
r Kappa p
Day 1 57.14 
±25.1*
47.59±26.1 44.55±23.06 41.09±21.5 0.748 0.667 <0.01
Day 14 85.58±33.9 71.40±33.1 61.53±28.8 56.62±25.5 0.579 1.00 <0.01
Day 30 81.00±34.1 71.28±25.4 66.29±22.9 58.13±20.0 0.634 0.480 <0.01
Day 90 81.45±42.9 68.39±30.5 62.97±26.9 63.30±25.3 0.736 0.450 <0.01
Day 
365
70.09±26.6 60.26±22.8 59.41±22.4 58.04±22.6 0.725 0.420 <0.01
*SD 
Conclusions: The estimation of AKF assessed by MDRD 4, 5 and 6 formules 
results in a very good correlation and fairly well concordance. So that it can be 
recommended as a safe method to the current clinical manage 
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COMBINED LIVER-KIDNEY TRANSPLANTATION: 1991 
MELD ERA TRENDS
R. Ruiz, H. Randall, R. Goldstein, G. Klintmalm, M. Levy, G. McKenna, N. 
Onaca, L. Jennings, E. Sanchez, S. Chinnakotla
Baylor Regional Transplant Institute
An increase in the number of combined liver-kidney transplants (CLKTs) 
performed nationwide has been well-documented since the implementation 
of the Model for End-stage Liver Disease (MELD) allocation system. While 
indications have not changed, an elevated serum creatinine (SCr) in patients 
with end-stage renal disease or renal dysfunction has been the main contributor 
to the MELD score. In this analysis, we sought to fi nd any differences in 
outcomes before and during this era.
In this study, we retrospectively examined 75 CLKTs performed at our center 
over a 23-year period. Overall, patient survival rates were 82%, 73% and 64% 
at 1, 3 and 5 years, respectively. There was no difference in survival whether 
or not a recipient was on pretransplant dialysis. However, the requirement for 
post transplant hemodialysis portended a poor overall prognosis (p=0.0006). 
Patients undergoing a liver retransplantation at the time of CLKT had a survival 
rate of 40% at 3 months. Only seven patients (9%) had biopsy-proven acute 
kidney rejection episodes.
Twenty-nine CLKTs (39%) were performed during the MELD era. Patient 
survival was poorer in the MELD era when compared to the preMELD era, 
but not statistically signifi cant (p=0.398). This was likely due to an older age 
population (p=0.003) and a greater number of Hepatitis C patients transplanted 
(p=0.04). With regard to pretransplant laboratory analysis, SCr was not 
statistically different in both groups. However, the median total bilirubin 
(Tb) was 1.6 mg/dL in the preMELD era and 0.8 mg/dL in the MELD era 
(p=0.0001). Likewise, the median prothrombin time (PT) was 13.5 seconds in 
the preMELD era compared to 12.2 seconds in the MELD era (p=0.04). The 
percentage of patients undergoing retransplantation in either group was similar. 
Hospital length of stay was signifi cantly shorter in the MELD era (p=0.005). 
There is no statistically signifi cant difference in patient survival before and 
after the implementation of the MELD system. Patients requiring a liver 
retransplantation should be excluded from an additional kidney allograft. 
Based on our data, there is a trend in allocating both a liver and kidney to 
recipients with better liver function by laboratory analysis. Should end-stage 
renal disease drive the MELD score of a patient with end-stage liver disease 
and lead to CLKT? Whether this is a result of increased referrals of patients 
with renal failure or patient selection should be further investigated. Finally, 
the liver allograft confers immunologic protection to the kidney.
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EVALUATION OF PRE-TRANSPLANT CHANGES IN 1992 
CREATININE AND GLOMERULAR FILTRATION RATE AS 
INDICATOR FOR LONG-TERM RENAL FUNCTION IN LIVER 
TRANSPLANT PATIENTS
G. Gyoeri, C. Burghuber, R. Steininger, T. Soliman, F. Muehlbacher, 
G. Berlakovich
Medical University Vienna, Dept. of Transplant Surgery
Hypothesis: Aim of this study was to analyze the predictive value of pre-
transplant changes in serum creatinine (Delta-SCr) and glomerular fi ltration rate 
(GFR) on post-transplant renal function 1 year following liver transplantation.
Methods: Included were all adult patients from a single center receiving their 
1st liver graft between 1999 and 2006 (n=269). All included patients received 
our standard immunosuppressive regimen with Thymoglobulin induction for 3 
days, low dose cyclosporine from day 4 and rapid steroid taper. Maintenance 
immunosuppression consisted of low dose cyclosporine monotherapy. An 
adaptation of the regimen by protocol was performed in case of developing 
renal impairment (RI).
SCr values 3months (mo), 2mo, 1mo pre transplant and just before OLT and 
1a after transplantation were considered for analysis. GFR was calculated 
according to the MDRD formula. Renal impairment (RI) was defi ned as SCr 
>1.5mg/dl or GFR <60ml/min.
Data were collected prospectively in our Transplant Surgery database and 
reviewed retrospectively. Sensitivity and specifi city as well as positive and 
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negative predictive values were calculated.
Results: 69 patients were identifi ed with RI defi ned by SCr 1a post-OLT. Then 
correlation of Delta SCr pre-transplant to RI after 1 year was evaluated.
Patients with a Delta-SCr >0.5 and >0.25 had a correlation coeffi cient of 0.0933 
and 0.1553, respectively. The sensitivity was 13% and 20%, the specifi city was 
97% and 91%, the positive predictive value (PPV) was 67% and 46% and the 
negative predictive value (NPV) was 74% and 74%, respectively.
132 patients were identifi ed with RI defi ned by GFR 1a post-OLT, 37 patients 
with severe RI (GFR <40) and 95 patients with moderate RI (<60- >40). The 
correlation coeffi cient comparing GFR at selected time points pre-transplant 
and 1-year post OLT are shown in Tab. 1.
Tab. 1 Patients with GFR <60ml/min at 1 year post OLT
Correlation 
coeffi cient
Sensitivity% Specifi city% PPV% NPV%
3mo pre 0.4964 29 88 75 51
2mo pre 0.4460 37 84 74 50
1mo pre 0.2925 44 90 82 62
Pre TX 0.1893 42 83 71 60
Conclusion: In this study we could not validate our hypothesis that changes in 
SCr before OLT (Delta SCr) had predictive value to identify patients at risk for 
postoperative renal impairment at 1 year after OLT.
Further GFR at 3mo, 2mo, 1mo and right before OLT neither had correlation 
with renal impairment after OLT. We conclude, that renal function after liver 
transplantation is infl uenced by many factors and further studies will be needed 
to identify patients at risk for renal impairment.
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CHRONIC RENAL INSUFFICIENCY IS ASSOCIATED 1993 
WITH INFERIOR OUTCOMES AFTER COMBINED 
ORTHOTOPIC HEART/LIVER TRANSPLANTATION
S. Kreml, C. O’Mahony, N. Sussman, J. Vierling, R. Stribling, J. Goss
Baylor College of Medicine
Introduction: Combined orthotopic heart transplantation (OHT) and orthotopic 
liver transplantation (OLT) continues to be indicated only for the rare instances 
where patients are not expected to survive transplantation of either organ alone. 
Because these cases are so infrequently performed, it is diffi cult to determine 
risk factors that may affect outcome. 
Purpose: The purpose of this study was to identify risk factors that would 
affect outcomes in patients undergoing combined OHT-OLT.
Methods: This study consisted of a retrospective review of all patients who 
underwent combined OHT-OLT at our institution from June 2004 through 
January 2008. 
Results: A total of six patients underwent OHT-OLT at our institution, including 
four male and two female patients having a mean age of 55 years (42-67) with 
a mean followup of 26.3 months (10-45.7). The indications for transplantation 
were hemochromatosis in two patients, cirrhosis secondary to hepatitis C with 
concomitant ischemic cardiomyopathy in two patients, restrictive non-ischemic 
cardiomyopathy causing cardiac cirrhosis in one patient, and cryptogenic 
cirrhosis with idiopathic cardiomyopathy in one patient. At transplant, mean 
MELD score for all patients was 13.5 (7-18) and the mean serum creatinine was 
1.4 mg/dL (1.1-1.9). None of the patients required pre-transplant mechanical 
ventilation or hemodialysis.
Five of the six patients are alive with functioning grafts. Four patients had 
uncomplicated postoperative courses with an average length of stay of 13 
days (10-15). Two patients required postoperative renal replacement therapy. 
Of these two patients, one died on postoperative day 25 from sepsis and 
complications of dialysis access and the other had a prolonged hospital course 
with a 36 day length of stay. 
The mean preoperative serum creatinine for the patients with an uncomplicated 
postoperative course was 1.2 mg/dL (1.1-1.4), while the mean preoperative 
serum creatinine was 1.8mg/dL (1.7-1.9) for the patients with prolonged hospital 
courses. Age, sex, etiology of disease, and MELD score did not appear to infl uence 
length of stay or mortality (p>0.4). However, a preoperative creatinine > 1.5 mg/
dL was associated with a tendency for a prolonged length of stay (p=0.067).
Conclusion: Based on our experience with combined OHT-OLT, worse outcomes 
are associated with preoperative renal insuffi ciency. These fi ndings emphasize 
the importance of careful patient selection for these uncommon cases.
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RENAL FUNCTION IN PIGGYBACK VERSUS CAVAL 1994 
INTERPOSITION IN ADULT LIVER TRANSPLANTATION
A. Cheaito, A. Yoshida, M. Abouljoud, D. Kim
Henry Ford Hospital
Background: Orthotopic liver transplantation has become an accepted mean to 
treat end-stage liver disease. Although the technique of LTX has been refi ned to 
a relatively standardized approach, the operation remains a formidable surgical 
challenge. As such, LTX can have numerous technical complications, in which 
the recipient’s pretransplant condition, donor and immunologic factors, may 
all contribute. Renal insuffi ciency is a common fi nding with end-stage liver 
disease. Renal insuffi ciency is generally not regarded as a contraindication 
to liver transplantation. However, the impact of RI on outcome following 
transplantation is not well understood. Acute renal failure (ARF) occurs 
in 5–50% of patients undergoing orthotopic liver transplantation (OLT). 
The aim of our study is to identify technical factors (Piggyback vs. Caval 
Interposition) that may contribute to worsening renal function in orthotopic 
liver transplantation.
Method and Results: We performed a retrospective analysis of consective 
OLT performed from 2004-early 2007. Demographic data were collected. The 
etiology of the liver disease was similar between the PT and CI cohorts, with 
hepatitis C and alcoholic liver disease accounting for more than 60%. The age, 
sex, and percentage of patients with previous abdominal surgeries were also 
similar between the two groups. Serum creatinine was measured pretransplant, 
three month post transplant, and one year post transplant. During the study 
period 237 patients were identifi ed. Eleven patients were excluded because of 
LRLT(living related liver transplant), 22 patients were excluded for receiving 
SLK(simulataneous liver-kidney), and 28 patients were lost to follow-up. One 
hundred seventy-six patients were included, Anova Stastical Analysis was 
perfomred. Of those 136 patient underwent the PT and 40 were CI. The average 
pre-transplant creatinine was 1.26 (0.7-2.8) for the PT group and 1.31 (0.7-3.8) 
for CI group. At three month the average creatine for the PT was 1.12 with an 
absolute change of 11%. For the CI group the average creatine at 3 month was 
1.29 with an absolute change of 1.5%. At one year the average creatine for the 
PT was 1.22 with an absolute change of 3%. On the other hand the CI group the 
average creatine was 1.27 with an absolute change of 3%. 
Conclusion: We concluded that surgical approach to liver transplantation 
has no direct effect on renal function at one year post transplant. However, 
the difference in the absolute reduction in the creatinine at three months post 
transplant needs to be further investigated. There may be bias in which we 
perform PB technique on and that there seems to be no obvious detrimental 
effect on renal function by PB.
LIVER CONCURRENT ORAL SESSION 139: 
TRANSPLANTATION OUTCOMES (GENERAL)
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EXPECTED NUMBER OF DEATHS IN THE LIVER 1995 
TRANSPLANTATION WAITING LIST IN THE STATE OF SÃO 
PAULO, BRAZIL
E. Chaib1, E. Massad2
1University of Sao Paulo School of Medicine, 2University of Sao Paulo School 
of Medicine
São Paulo is a pioneer Brazilian state on transplantation surgery. The biggest 
challenge facing the fi eld of transplantation is the critical shortage of donors 
organs, which has led to a dramatic increase in the number of patients on the 
waiting-list as well as in their waiting time. 
We wish to report the expected number of deaths in the waiting-list of liver 
transplantation in the State of São Paulo for a projected period of 10 years 
starting in 2005. We collected offi cial data about our liver transplantation 
program between July 1997 to October 2004. Only cadaver liver transplantation 
was recorded. Living-related liver transplantation was excluded.
The data related to the actual number of liver transplantation, Tr and the 
incidence of new patients in the list, I, in the State of São Paulo since 1997 can 
be seen in table 1.
We take the data of Tr and of I from table 1 and fi tted a continuous curve 
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by the method of maximum likelihood, in order to project the number of 
transplantations, Tr, and the incidence of new patients in the list, I, in future 
time. Next we calculated the number of deaths in the list assuming an average 
survival time in the list of 18 months and assuming also that death is the 
inexorable fate of those patients. Taking the difference between the incidence of 
new cases and the incidence of transplantations did this.The results, projected 
for 10 years from 2005 can be visualized in fi gure 1.
The gap between the number of available organs from deceased donors and 
the number of patients in the waiting-list continues to rise each year. Liver 
transplantation has increased, approximately, 1.84-fold (from 160 to 295) from 
1988 to 2004. On the other hand, the number of patients on the liver waiting-
list have jumped to 2.71 (from 553 to 1500). As a result of that the number of 
deaths on the liver waiting-list have moved to a higher level from 321 to 671 
increasing 2.09 fold.
The present study found that 4.7 liver transplantation were performed per 
million inhabitants in 2003 when we should have performed at least 33 
transplantation per million inhabitants.
In conclusion, provided the conditions of the present study remain unchanged 
the number of deaths in the liver transplantation waiting-list will grow in an 
exponential function in the years to come. Therefore there is an urgent need for 
both increasing the number of liver transplantation in the State of São Paulo 
as well as by changing the law introducing non-heart-beating donors in order 
to avoid this overwhelming number of deaths in the liver transplantation 
waiting- list.
Table 1
Year Tr I
1997 63
1998 160 553
1999 188 923
2000 238 1074
2001 244 1248
2002 242 1486
2003 289 1564
2004 295 1500
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A CORRELATION BETWEEN PRETRANSPLANTATION 1996 
MELD SCORE AND DEGREE OF HEPATIC FIBROSIS IN 
EXPLANTED LIVERS
L. Yan, H. Zuo, Y. Zeng, W.Y. Lau
Division of Liver Transplantation, West China Hospital, West China Medical 
School
Objectives: To correlate the pretransplantation MELD score with the degree of 
hepatic fi brosis using the computer imaging analysis and the Ishak pathological 
grading in the explanted livers.
Methods: A MELD score was determined on 58 patients with chronic liver 
disease before liver transplantation. The area ratios of hepatic fi brosis were 
determined using the computer imaging analysis in the explanted livers. 
Pathological grading of the degree of cirrhosis were also done on these 
specimens using the Ishak grading by two independent pathologists.
Results: The MELD score ranged from 11 to 38 (mean ¡À SD, 22.85 ¡À 9.32). 
The area ratio of hepatic fi brosis of the 58 livers ranged from 23.2% to 88.4% 
(mean: 56.7%). There were 0, 2, 7, 12, 18, 12, and 7 patients in the Ishak 
grading 0 to 6, respectively. The bigger the MELD score, the higher was the 
Ishak grading and the larger was the area ratio of hepatic fi brosis (Spearman¡¯s 
rank correlation test, p < 0.01). Linear regression analysis showed a linear 
relationship between the MELD score and the degree of hepatic fi brosis. 
Conclusions: The MELD score correlated with the area ratio of hepatic fi brosis 
as determined by computer imaging techniques, and with the Ishak pathological 
grading.
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LONG-TERM FOLLOW-UP OF PEDIATRIC ALLOGRAFT 1997 
RECIPIENTS SURVIVING FOR MORE THAN 5 YEARS. A 
SINGLE CENTER EXPERIENCE
A. Sonzogni1, M. Dremmen2, D. Alberti3, M.G. Alessio, V. Corno3, 
A. Lucianetti3, D. Pinelli3, P. Stroppa 3, G. Torre3, M. Colledan3
1Pathology Unit, Ospedali Riuniti – I 24128 Bergamo, 2Faculty of Health, 
Medicine and Life Science, University of Maastricht – NL Maastricht,3Liver 
and Lung Transplantation Center, Ospedali Riuniti – I 24128 Bergamo
Pediatric orthotopic liver transplantation (OLTx) has undergone a revolution 
over the past decades, resulting in a rising new population of long-term 
survivors with a long life-expectancy. Identifi cation of factors infl uencing 
prognosis would bring more knowledge concerning the long term outcome 
Consequently, the patients selection and management can be improved.
From October 1997 to July 2002, 166 children received a liver transplant at 
Ospedali Riuniti di Bergamo. Mean follow-up was 5.9 years. There were 83 
male (50.0%) and 83 (50.0%) female recipients. Median age at time of OLTx 
was 3.8 years (range 0.1-17.5 years). Biliary atresia was the most frequent 
indication for liver transplantation (99 patients; 59.6%). Patients received split 
livers (118; 71.1%), whole-size livers (41; 24.7%), and reduced-size livers (7; 
4.2%). Retransplantation was indicated in 22 patients (13.3%). Posttransplant 
immunosuppression was cyclosporine (CsA)-based in 50 patients (30.1%) and 
tacrolimus (TAC)-based in 116 patients (69.9%). Long-term follow-up after 
hospital discharge was scheduled and standardized. 
Overall patient survival rates at 1, 3, and 5 years were 87%, 84%, and 83%. 
Re-transplantation rate was 13.3%. Respective graft survival rates were 82%, 
78%, and 77%. Pre-transplantation variables with a signifi cant adverse effect 
on patient were United Network for Organ Sharing (UNOS) status (p<0.015) 
and CsA-based immunosuppressive therapy (p<0.001). Graft survival was 
negatively infl uenced by fulminant hepatic failure as indication for liver 
transplantation (p = 0.004), UNOS status (p<0.02), ischemia time (p = 0.016), 
CsA-based immunosuppression (p<0.001), and episodes of respectively 
PTLD, vascular complications and functional cholestasis (p = 0.001, p < 0.001, 
p < 0.001). Several risk factors were identifi ed for long-term complications 
after pediatric OLTx, as donor variables, CMV and EBV infection, developing 
auto-antibodies after transplantation, short-term complications, and type of 
immunosuppressive therapy. 
Despite the good results of pediatric liver transplantation, improvement of the 
outcome is still possible. 
Total rehabilitation with a high quality of life after transplantation can be 
attained in most children.
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TWO SUCCSESFUL ORTHOTOPIC LIVER 1998 
TRANSPLANTATIONS USING LIVER GRAFTS FROM 
DECEASED DONORS WITH OPISTHORCHIASIS
E. Bessonova, I. Serebryakov, O. Lyasnicova, O. Nikiforova, B. Fadin, M. 
Prudkov, S. Alpherev, O. Orlov, N. Osadchaya
1Ekaterinburg Regional Hospital, Regional Hepatological Centre
Introduction: Opisthorchiasis is a parasitogenic disease caused by 
Opisthirchis felineus(cat liver fl uke).Most infections are asymptomatic. In 
rare cases,cholangitis,cholecystitis with involvment of the pancreatic ducts 
may develop. Diagnosis is based on microscopic identifi cation of eggs in stool 
specimens.O.Felineus is found mainly in Asia,including the former Soviet 
Union.
Aim: To report two cases of liver transplantations using liver grafts from 
deceased donors with opisthorchiasis.
Method: Two 36 and 38-year-old women were submitted to a liver 
transplantation,one for HCV related liver disease and one for cirrhosis from 
autoimmune hepatitis.
As far as it is highly diffi cult to detect opisthorchiasis is deceased donor it is 
impossible to assess it as donor risk factor in advance. In both cases Opisthirchis 
felineus were revealed in donors during surgery. Post operative course in the 
intensive care unit was marked by massive drainage of opisthichises through 
external hepaticojejunostomy tube(hepaticojejunostomy was done in the aim to 
avoid mechanical obstraction of the bile duct).
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Results: The patients were discharged after 18 and 16 days on 
cyclosporin,prednisolone and mycophenolic acid. 24 months(in one case) 
and 21 months (in another) after transplantation both patiens are negative for 
opisthorchiasis(by serology and microscopic identifi cation of eggs in stool 
specimens). One of the patients has recurrence of chronic hepatitis C and 
receive antiviral therapy.
Conclusion: This report clearly illustrates the possibility the donor pool of 
organs for transplantation purposes in the regions endemic for opisthorchiasis.
This the fi rst case reported.
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LIVER FAILURE AND NEED FOR LIVER 1999 
TRANSPLANTATION IN PATIENTS WITH ADVANCED 
HEPATOPORTAL SCLEROSIS
B. Geramizadeh1, S.A. Malek-Hosseini, S. Nikeghbalian, H. Salahi, 
A. Bahador
1Transplant Research Center, Pathology Department, 2Transplant Research 
Center, 3Transplant Research Center, 4Transplant Research Center, 
5Transplant Research Center
Introduction: Hepatoportal sclerosis (HPS) is one of the causes of noncirrhotic 
portal hypertension. 
In general, hepatic synthetic function is preserved and treatment is aimed at 
relief of the portal hypertension.
Material and Methods: In this study, we present the clinical and pathologic 
features of HPS cases who underwent liver transplantation (LT). LT cases with 
confi rmed gross and microscopic diagnosis of HPS are included. Weight of the 
explanted liver, presence of thrombi in the main blood vessels, and gross and 
microscopic characteristics were assessed. Clinical information was gathered 
from chart review.
Results: From 2005-6 patients were diagnosed with HPS. Two of the cases 
were labeled as cryptogenic cirrhosis and one of them as primary sclerosing 
cholangitis. All the three patients had ascites, huge splenomegaly, jaundice, 
and esophageal varices. 
At the time of LT, mean values were: prothrombin time of 13 seconds, serum 
albumin 3.2 g/dL, serum bilirubin 1.6 mg/dL, alkaline phosphatase 468 IU/L,
aspartate aminotransferase 43IU/L, and alanine aminotransferase 35 IU/L. 
Explanted livers were shrunken, with weights ranging from 715 to 1199 g (mean 
934). Nonocclusive portal vein thrombosis was present in 1 patients. On histologic 
examination, there was dense portal fi brosis, and marked phlebosclerosis. 
Conclusion: In conclusion, HPS can cause hepatic synthetic dysfunction 
that may necessitate LT. Small liver volume, signifi cant portal fi brosis, and 
phlebosclerosis may contribute to hepatic parenchymal loss and subsequent 
synthetic compromise.
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DARK ADAPTATION IMPAIRMENT IN VITAMIN A 2000 
DEFICIENT ADULTS AWAITING LIVER TRANSPLANTATION-
IMPROVEMENT WITH INTRAMUSCULAR VITAMIN A.
W. Abbott-Johnson1, P. Kerlin1, G. Abiad2, A. Clague3, R. Cuneo4
1Princess Alexandra Hospital, 2Prince of Wales Hospital, 3Queensland Health 
Pathology Service, 4University of Queensland
Background and Aims: Vitamin A defi ciency and night blindness occur in 
chronic liver disease but measures of dark adaptation impairment and response to 
vitamin A administration are limited. This prospective study aimed to 1) measure 
dark adaptation in patients with chronic liver disease and vitamin A defi ciency 2) 
compare symptoms of night blindness with measured dark adaptation 3) explore 
relationships between dark adaptation and vitamin A, zinc and Child Pugh score 
4) quantify improvements in dark adaptation after intramuscular vitamin A. 
Methods: Twenty patients (15M, 5F, mean age 51 years) (alcoholic liver disease 
10, other parenchymal disease 6, cholestatic disease 4) were selected based on 
plasma retinol ≤; 0.7 μmol/L (NR 1.6-2.3). There were 15 healthy age-matched 
controls. Dark adaptation was measured using a SST-1 dark adaptometer and 
perception was assessed by questionnaire. Eight patients received 50,000 IU of 
aqueous retinyl palmitate by injection and were restudied one month later.
Results: Eight (40%) patients had impaired dark adaptation. Most (75%) 
did not perceive a problem. Impaired dark adaptation was more prevalent in 
alcoholic liver disease compared to other parenchymal aetiologies (p=0.015). 
No relationships were identifi ed between measured dark adaptation and retinol, 
retinol binding protein, zinc or Child Pugh score. Dark adaptation improved by 
2.9±3.4 dB (p=0.05) one month later. 
Conclusions: Impaired dark adaptation was commonly present in patients with 
chronic liver disease and vitamin A defi ciency, especially those with alcoholic 
aetiology, and was frequently unrecognized. Dark adaptation improved after 
vitamin A, allowing light of half the previous intensity to be seen. 
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SURGICAL MORBIDITY & MORTALITY AFTER LIVER 2001 
TRANSPLANTATION IN 87 EGYPTIANS TRANSPLANTED IN 
USA.
A. Salah1, H. Khalaf2, M. El-Mansy3
1Cairo University, 2King Faiasal Hospital, 36th October University
Objective: To study the long term outcome after liver transplantation (LT) in 
Egyptian patients who underwent LT in USA
Methods: Between May 1994 and February 2007, over 94 Egyptians underwent 
cadaveric LT in the States. Data of 87 patients were collected in Egypt through 
personal communications with the Overseas Liver Transplant Centers and 
through the records of the Egyptian Liver Transplant Association (ELTA).
Results: Of the 87 patients, there were 68 men and 19 women. Median age was 
47 (4-68 years). Hepatitis C virus (HCV) cirrhosis whether alone or mixed with 
schistosomiasis was the main indication for LT. Primary nonfunctioning (PNF) 
was encountered in eight (9.2%) patients, of whom three were retransplanted 
and only one survived. Biliary complications were encountered in 22 patients 
(25.3%); this included simple bile leak in 5 patients, biliary obstruction in 
8, and biliary peritonitis in one. Seven patients were treated by endoscopic 
stenting and dilatation, whereas surgical reconstruction was needed in the 
remaining patients. Vascular complications were encountered in 7 patients 
(8.1%): two had hepatic artery thrombosis and was successfully retransplanted 
and fi ve had venous outfl ow obstruction which were successfully treated by 
transjugular balloon dilatation. Postoperative bleeding was encountered in 
7 (9.2%) patients, only three of them required surgical exploration and one 
died due to ruptured splenic artery aneurysm. Incisional hernia occurred in 4 
patients (4.6%). Out of those 87 recepients, 68 (78.2%) survived after a median 
follow up of 4.7 years (range 1-12.5 years). Death was due to PNF & early graft 
failure in 6 patients, postoperative bleeding in one patient, recurrent HCV in 9 
patients and chronic rejection in three patients. 
Conclusion: The peculiar pattern of mixed pathology (hepatitis C and 
schistosomal periportal fi brosis), and may be the frequent use of marginal 
donor livers in Egyptian patients are factors that impair the results of LT. 
Although living donor liver transplantation has been introduced recently in 
Egypt, cadaveric liver donation is still not legalized by the government. We 
strongly believe that immediate steps should be taken to establish a cadaveric 
LT program in Egypt. This would be a convenience for patients and would save 
the money spent on treatment in foreign countries. 
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THE CLINICAL RELEVANCE OF THE ANHEPATIC 2002 
PHASE DURING LIVER TRANSPLANTATION
A.J.C. IJtsma, C.S. Van Der Hilst, E.M. TenVergert, .T. De Boer, 
K.P. De Jong, P.M.J.G. Peeters, R.J. Porte, M.J.H. Slooff
University Medical Center Groningen
The aim of this study was to assess the relation between the duration of the 
anhepatic phase and the outcome after liver transplantation in terms of patient 
and graft survival and graft dysfunction.
A single center cohort of consecutive adult primary liver transplant recipients 
transplanted with the piggyback technique using heart-beating donors without 
veno-venous bypass between 1994 and 2004 was analysed. All patients had 
at least one year follow-up. The study group consisted of 169 patients. Study 
variables were donor age and body mass index, recipient age, – body mass index, 
– diagnosis and – MELD score, peroperative RBC transfusions, blood loss and 
the duration of the cold and warm ischemia time and of the anhepatic phase.
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Fig 1. Defi nition of ischemia time and anhepatic phases
The functional anhepatic phase (FAHP) and anatomical anhepatic phase 
(AAHP) were separately analysed and defi ned as in fi gure 1. ROC curves were 
constructed to determine optimal cut-off values. Graft dysfunction was defi ned 
as either primary non function or initial poor function. Primary non function 
was defi ned as graft failure leading to either patient death or retransplantation 
within a week after transplantation. Initial poor function was defi ned by the 
Ploeg-Maring criteria as an ASAT > 2000 U/l and PT > 16 seconds at any time 
point between days 2-7 post-transplantation. 
Median AAHP was 76 minutes (37 – 321). Median FAHP was 98 minutes (45 – 
321). Graft dysfunction occurred in 27 patients (16%), consisting of 6 patients 
(4%) with primary non function and 21 patients (12%) with initial poor function.
Univariate analysis showed an AAHP over 100 mins, recipient BMI over 25 
kg/m2 and peroperative RBC transfusion to be predictive factors for graft 
dysfunction. In patients with an AAHP below 100 minutes, the incidence of 
graft dysfunction was 16 out of 135 (12%) while in patients with an AAHP over 
100 minutes this was 11 out of 33 (33%) (p < 0.003).
Multivariate analysis proved the same three variables to be independent 
predictors for graft dysfunction. Corresponding odds ratios for AAHP over 100 
minutes, recipient BMI over 25 kg/m2 and peroperative RBC transfusion were 
4.02, 3.42 and 3.22 respectively.
Graft dysfunction was the only study variable independently associated with 
patient survival. One year patient survival in patients with graft dysfunction 
was 67% versus 90% in patients without graft dysfunction (p<0.001). A 
direct relation between the AAHP duration and patient or graft survival could, 
however, not be established.
In conclusion, this study shows that liver transplant patients with an anatomical 
anhepatic phase over 100 minutes have a threefold higher incidence of graft 
dysfunction. Patients with graft dysfunction had a signifi cantly worse one year 
patient survival.
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LIVER TRANSPLANT FOR WILSON’S DISEASE2003 
S. Sevmis1, H. Karakayali1, G. Moray1, N. Savas2, F. Ozcay3, U. Yilmaz2, A. 
Torgay3, G. Arslan3, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Gastroenterology, 
3Baskent University Faculty of Medicine, Department of Anesthesiology
Wilson’s disease is an inherited disorder of copper metabolism characterized 
by reduced biliary copper excretion, which results in copper accumulation in 
the tissues with liver injury and failure. Liver transplant (LT) can be lifesaving 
for patients with Wilson’s disease who present with fulminant liver failure 
and for patients’ unresponsive to medical therapy. The aim of this study is to 
review our experience with LT for patients with Wilson’s disease. Between 
September 2001 and January 2008, 28 LTs were performed at our center in 27 
patients with Wilson’s disease. Our Wilson’s disease series comprised 7 female 
and 20 male patients (mean age, 15.6 &#61617; 9.9 years; range, 5-51 years). 
Six patients were transplanted owing to coexistent fulminant hepatic failure. 
Twenty patients presented with chronic advanced liver disease with (n = 10) 
or without (n =10) associated neurologic manifestations. We performed full-
size, deceased-donor in 3 LTs and living-related donor in the remaining 25 LTs. 
Eight patients had a family history of Wilson’s disease. We detected a Kayser-
Fleischer ring in 21 patients. All patients had a low serum ceruloplasmin level 
(mean, 27.8 mg/dL) and a high urinary copper excretion level (mean, 4119 
μg/d) before LT. Following successful LT, there was a signifi cant reduction 
in urinary copper excretion (median, 37.1 μg/d) in all patients. Mean follow-
up was 25.7 &#61617; 19.8 months (range, 2-69 months). Retransplant 
was required in 1 patient 12 days after the fi rst LT owing to primary graft 
nonfunction. Five of the 27 patients died within 4 months of the surgery. 
The remaining 21 survivors (81.5%) have remained well, with normal liver 
function and no disease recurrence. In conclusion, LT is a curative procedure 
for Wilson’s disease in patients presenting with fulminant hepatic failure and 
others with end-stage hepatic insuffi ciency. After LT, the serum ceruloplasmin 
level increases to the normal range, urinary copper excretion decreases, and 
neurologic manifestations improve. 
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LIVER TRANSPLANTATION FOR BILLIARY ATRESIA2004 
H. Karakayali1, F. Ozcay2, S. Sevmis1, G. Moray1, N. Yavuzer1, A. Torgay3, G. 
Arslan3, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Pediatry, 
3Baskent University Faculty of Medicine, Department of Anesthesiology
Biliary atresia is the most common indication for liver transplantation (LT) in 
the pediatric population. The aim of this study is to present our institutional 
experience with LT as a treatment for end-stage liver disease in children with 
biliary atresia. A retrospective review of transplant records was performed. 
Twenty –four billiary atresia recipients (11 males, 13 female; mean age, 10.3 ± 
5.4 months; range, 6 to 26 months) underwent LT. Mean preoperative weight 
and height were 11.2 kg and 72.5 cm respectively. Nineteen recipients were 
younger than 1 year of age and 18 recipients weighed less than 10 kg at the time 
of transplantation. Seventeen recipients had a previous Kasai operation prior to 
transplant. Mean serum total bilürübin level was 18.3 ± 16 mg/dL (range; 5.5 
to 59.8 mg/dL) before LT. Twenty-two left lateral segment grafts and 2 whole 
grafts were transplanted. The mean recipient operative time was 8.9 ± 1.8 hours 
(range; 6 to 10 hours). The mean recipient intraoperative blood loss was 1.5 
units. Two hepatic arterial thromboses and 2 billiary leak occurred in the early 
postoperative period. Portal vein stenosis developed in 1 recipient 16 months 
after LT. Three recipients died during follow-up 17 ± 14.6 months (range, 1 to 
45 months). The remaining 21 recipients (87.5%) are alive with a good graft 
functioning. In conclusion, our results confi rm the effectiveness of LT for the 
treatment of children with billiary atresia and failed Kasai procedure. Living-
related liver grafts represent an excellent organ supply for these patients.
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PARTIAL SPLENIC EMBOLIZATION FOR 2005 
HYPERSPLENISM AFTER LIVER TRANSPLANT
G. Moray1, F. Boyvat2, H. Karakayali1, I. Aliosmanoglu1, Y. Ekici1, N. Savas2, 
C. Aydogan1, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Gastroenterology
Partial splenic embolization has been demonstrated to be an effective alternative 
to splenectomy for patients with hypersplenism. Splenectomy in these patients can 
be associated with an increased risk of perioperative complications, overwhelming 
postsplenectomy sepsis, and mortality. Partial splenic embolization has the 
advantages of nonoperative intervention and resolution of the complications of 
hypersplenism. We report the use of this technique in patients with hypersplenism 
who had undergone liver transplant with persistent hypersplenism after surgery. 
Six patients with persistent hypersplenism after liver transplant were treated 
at our center between September 2001 and January 2008. Four patients were 
male and 2 were female. The mean age of the patients was 32.5&#61617;196 
years (range, 5 to 54 years) All 6 patients had concomitant thrombocytopenia 
and neutropenia with platelet counts below 50 000. Patients underwent selective 
arterial catheterization and embolization via 500 to 700 micron polyvinyl alcohol 
particles. The lower pole of the spleen was selectively embolized in all patients 
to achieve a 30% to 50% reduction in fl ow as determined by angiography. 
Patients were followed with routine computed tomography scans, and platelet 
and white blood cell counts for a mean of 16.6 months. All patients had persistent 
resolution of thrombocytopenia and neutropenia after embolization. One patient 
required splenectomy 12 months after treatment owing to a splenic abscess. No 
procedure-related complications occurred in any patient. In conclusion; partial 
splenic embolization appears to be a safe and effective treatment of persistent 
hypersplenism in patients with hypersplenism after liver transplant.
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CYTOMEGALOVIRUS INFECTIONS AFTER LIVER 2006 
TRANSPLANTATION: INCIDENCE, RISK FACTORS AND 
OUTCOMES
Y. Nakamura, J.C. Hong, R.M. Ghobrial, B. Nonthasoot, J.C. Kim, 
T.E. Collins, D.G. Farmer, R.W. Busuttil
Division of Liver and Pancreas Transplantation, Department of Surgery, 
David Geffen School of Medicine, UCLA
Introduction: Cytomegalovirus disease (CMV) is a common cause of 
morbidity and mortality complication after liver transplantation (LT). Females 
and over-immunosuppression, CMV D+/R- have been reported as risk factors. 
We sought to determine the incidence, risk factors and outcomes of patients 
who developed CMV after LT. 
Methods: We conducted a single center retrospective analysis on 805 LT 
performed from June 1, 2003 to Dec 31, 2006. We defi ned CMV disease 
included both CMV syndrome and tissue-invasive CMV. The criteria of CMV 
syndrome was defi ned as persistent fever (temperature>38 Ž for >2 days) and 
wasting, with or without leucopenia(WBC<3.5 ~109/L) and thrombocytopenia 
(Platelet count <100,000 ~109/L) Cwhich could not attributed to other causes 
in a patient with CMV viremia. CMV disease of the liver or gastrointestinal 
tract was diagnosed by fi nding histologic or culture evidence of CMV in a 
biopsy of the liver and gastrointestinal tract in a patient with liver dysfunction 
or gastrointestinal symptoms not explainable by other causes.
Results: Among 805 patients, 17 patients developed CMV infections (2.1%). 
In these patients, 10 patients were CMV diseases, other 7 patients were CMV 
syndrome. There were all 17 adults, 5 males (%) and 12 females%). Mean 
recipient age was 51.4 (range 28-72) years while mean donor age was 32.3 (range 
14-70) years. There were 6 patients with CMV serologic D+/R-. As preoperative 
risk factors, four patients have been taken prior liver transplantation, two patients 
have been performed liver and kidney transplantation, one patient has done liver 
and small intestinal transplantation. Mean MELD score was 33.5. All of the 
patients are alive after exprosuring CMV infection. Five patients have been 
received artifi cical hemodialysis before LT. In term of initial immunosuppression, 
14 patients have been administered consist of Tacrolimus and 2 patients were 
Tacrolimus and Predonisone, the other was Predonisone and Mycofenolate 
Mofetil. CMV on set mean time was 152 days (52-597). Prophylaxis of CMV 
disease has been continued fo 100days. 13 patients developed CMV infection 
after period of prophylaxis. Seven patients have happen acute rejection with 
need for management, Five in all were injected by Steroid pulse, the other 
two patients were only increased base line immunosuppression therapy. 
Nevertheless two patients occurred secondary acute rejection with treatment of 
increasing base line immunosuppression. 13 patients had complications with 
other bacterial infection or fungal infection. Three patients were died, because 
of multiple organ fi lure or Sepsis or disseminated fungal infection. 
Conclusion: Female must be risk factors in our patients. The further study 
is needed to identify defi nite risk factors and appropriate treatment of this 
dreadful complication.
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EXPERIENCE OF THE FIRST 20 LIVER 2007 
TRANSPLANTATIONS FAILURES AND SUCCESSES
A. Jafarian1, M.N. Toosi1, J. Salimi2, A. Najafi 2, M. Moeeni2, 
Z. Ahmadinejad1, S. Seifi 1, F.S. Ardalan1, M.A. Mohagheghi1, 
A. Rabbani1
1Imam Khomeini Hospital Complex- Tehran University of Medical Sciences, 
2Sina Hospital- Tehran University of Medical Sciences
Introduction: Liver transplantation has been accepted as the standard treatment 
for end stage liver disease since 1983. Establishment of a new program has 
specifi c problems and lessons.
Patients & Methods: From January 2002 to December 2007, 20 liver 
transplantations were done in Imam Khomeini Hospital Complex, Tehran, 
IR Iran. In the fi rst series of 9 cases which was performed within 4 years, the 
standard technique was done in all except one patient. We changed the procedure 
to piggy back hepatectomy and cavocavoplasty in the second series of 11 patients 
except for 1 case. This group was operated on in a 13 months period.
Results: Mean age of the patients in the two groups were 29 and 42.3 
respectively. Mean Child-Pough score was 10.1 in group one and 9.45 in group 
two. There were 5 female patients in the group one and 4 in the latter. The most 
common indication for transplantation was hepatitis B followed by cryptogenic 
cirrhosis. We had 5 early postop mortalities in the fi rst group and 2 in the second. 
Causes of death in the fi rst group were intra operative hemorrhage, primary non 
function, post op hemorrhage due to DIC (two patients) and Klebsiella sepsis. 
Two mortalities in the second group were due to primary non function and 
pulmonary sepsis. We had no early biliary complication. 
Conclusion: Outcome of liver transplantation could be rapidly progressed with 
judicious refi nement of technique and increasing number of transplants. 82% 
one month survival may be an indicator of passing learning curve.
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CYTOMEGALOVIRUS INFECTION AFTER LIVING 2008 
DONOR LIVER TRANSPLANTATION IN ONE INSTITUTION
Y. Tsukamoto, H. Okajima, S. Ogata, T. Murokawa, K. Lee, H. Yamamoto, T. 
Takeichi, K. Asonuma, Y. Inomata
Pediatric and transplantation surgery,Kumamoto University
Introduction: Cytomegalovirus (CMV) infection after organ transplantation 
can be well treated with antiviral drugs in the recent time, however, sometimes 
still develops fatal disease. It is necessary to take care before developing CMV 
disease after CMV infection. The aims of this study were to evaluate risk 
factors for CMV infection after living donor liver transplantation and to assess 
our strategy for CMV infection. 
Patients & Methods: One hundred and ninety-one patients who received 
living donor liver transplantation in our institution from September 2000 to 
February 2008 were enrolled in this study. There were 66 pediatric and 125 adult 
patients. Blood type combination between recipient and donor was identical or 
compatible in 172 cases and incompatible in 19. CMV infection was identifi ed 
with more than one positive cells of CMV early antigen in the peripheral blood. 
10 mg/kg/day of Ganciclovir for 2 weeks were used for patients with more than 
two positive cells of CMV early antigen. Incidence of CMV infection according 
to the combination of donor/recipient CMV-IgG serology (donor-/recipient-, 
donor-/recipient+, donor+/recipient-, and donor+/recipient+) was evaluated.
Results: CMV infection was identifi ed in 93cases (48.7%). 95% of these 
patients were identifi ed within two months after transplantation and 70 cases 
(75%) marked more than 2 positive cells. There were no signifi cant differences 
of positive ratio between pediatric and adult patients. 84% of patients with 
ABO blood type incompatible were identifi ed CMV infection. Regarding to 
the combination of donor’s and recipient’s CMV antibody, D+/R- patients had 
higher rate of CMV infection (82.4%), and the recipients with donor negative 
had very small possibility of CMV infection. Seven out of 70 recipients who 
treated with Ganciclovir needed to increase dosage of the drug and to decrease 
of immune-suppression due to initial poor response. However, none of the 
patients developed CMV disease in our series. 
Conclusion: CMV-IgG combination between the recipient negative and the 
donor positive is the risk factor for CMV infection after living donor liver 
transplantation. Our strategy for CMV infection was effective to prevent 
developing CMV disease.
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COMBINED LIVER-KIDNEY TRANSPLANTATION 2009 
ACROSS A POSITIVE FLOW CROSSMATCH: A CAUSE FOR 
CONCERN?
L. Shen, A. Agarwal, N. Turgeon, T. Pearson, C. Larsen, R. Bray, H. Gebel, 
A. Kirk, K. Kokko
Emory University
Background: The number of reported combined liver and kidney transplants 
(CLKT) across a positive (+) fl ow crossmatch (FCXM) is small. Although it is 
known that kidney transplants alone have a poor outcome with +FCXM, it is 
not considered a major risk factor for liver transplant. 
Methods: A retrospective review of CLKT between March 2003 and November 
2007 was performed to determine whether or not there was an adverse effect on 
patient or graft outcomes in transplants across a +FCXM. 
Results: A total of 29 CLKT were performed at our institution that included 
13 (45%) recipients with a +FCXM. Of the 24 patients who underwent a liver 
or kidney biopies for organ dysfunction, there were 5 instances of recurrent 
Hepatitis C, one liver biopsy with acute cellular rejection (ACR), and one 
kidney biopsy with positive C4d staining antibody mediated rejection (AMR). 
ACR was treated with high-dose steriods only. AMR was treated with two 
series of thymoglobulin, IV immunoglobulin, and plasmapheresis therapy for 
persistent humoral rejection. After therapy, both patients had good resolution 
of rejection and return to good organ function.
The median follow-up was 15 months. The overall patient survival for 
the CLKT was 96.4%, 75.9%, and 66.4% at 1 month, 1 year, and 3 years 
respectively. The survival rate for the +FCXM (91.7%, 64.2%, 32.1%) 
was lower than the negative (-) FCXM (100%, 88.9%, 66.7%) but was not 
statistically different (p=0.31) in this small group. For comparison, the survival 
for kidney transplants alone (97.9%, 91.9%, 76.3%) and liver transplans alone 
(92.3%, 72.5%, 65.6%) during the same time periods was not different.
Five (38.5% – 5/13) deaths occurred in the +FCXM versus 2 (12.5% – 2/16) 
deaths in the -FCXM. Two deaths were from liver graft failure. Three patients 
died from sepsis resulting in acute renal failure at time of death. Two deaths 
were from cardiovascular events. For those who have survived to this date, 
each has good renal and hepatic allograft function.
Conclusions: In combination with liver transplant, kidney transplant can be 
successfully performed despite a +FCXM. Although hyperacute rejection does 
not occur, complications including graft failure and infection suggest that a 
+FCXM may adversely infl uence the outcome in ways other than graft failure. 
Although a +FCXM is not considered a contraindication to liver transplantation, 
both cellular and humoral rejection can occur in CLKT but can be treated with 
aggressive therapy. CLKT may lead to adverse long term survival outcomes 
compared to single organ transplantation but this needs further study.
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BACTERIAL INFECTIONS IN THE EARLY 2010 
POSTTRANSPLANT PERIOD AFTER LIVER 
TRANSPLANTATION – ETIOLOGICAL AGENTS AND THEIR 
SUSCEPTIBILITY.
D. Kawecki1, A. Sawicka-Grzelak1, K. Kot1, E. Swoboda-Kopec1, 
A. Chmura2, M. Pacholczyk2, B. Lagiewska2, P. Malkowski3, W. Rowinski2, 
M. Luczak1
1Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of 
General Surgery and Transplantation Medical University of Warsaw, 3Dept. 
of Surgical Nursing and Transplantation Medical University of Warsaw
An analysis of bacterial infections in the early posttransplant period after liver 
transplantation in adults.
Material and methods: The study covered 83 adult patients undergoing liver 
transplantation from 2001 to the end of 2004. All the patients were followed 
prospectively for infections from the LT date and during the fi rst four weeks 
after surgery. Basic immunosuppression consisted of steroids and tacrolimus 
(Prograf®; Fujisawa, Germany). Antimicrobial prophylaxis was administered 
intravenously from the day of transpalntation: piperacillin/tazobactam 
(Tazocin®, Wyeth, USA), fl uconazole (Difl ucan®; Phizer, USA) and selective 
bowel decontamination (orally a liquid suspension of amikacin and nystatin) 
was carried out.
Samples of clinical materials (blood, urine, wound swabs, stool and other) 
were investigated. The microorganisms were cultured and identifi ed in 
accordance with standard bacteriological procedures. Susceptibility testing 
was carried out using (NCCLS) procedures. The statistical analysis was made 
by chi-square test.
Results: 913 clinical samples taken from liver recipients were investigated 
in microbiological laboratory. In total 469 strains were cultured. Among 
the bacterial strains, the most common were Gram-positive bacteria n=331 
strains (70,6%), Gram-negative bacteria n=133 strains (28,4%) and yeast 
like fungi n=5 strains (1%). In the early posttransplant period the common 
isolates were taken from Surgical Site Area n=284 (60%) with predomination 
of Gram(+) strains n=222 (78%), Gram(-) strains n=61 (21,5%). From 
blood n=99 strains (21,1%) were cultured: Gram(+) n=75 (75,8%) and 
Gram(-) n=22 (22,2%). Urine samples n=73 (15,6%): among them Gram(-) 
n=46 (63%), Gram(+) n=25 (34%), fungi n=2 (3%). Samples taken from 
respiratory tract n=13 (2,8%) strains were cultured: Gram(+) n=9 (69%), 
Gram(-) n=4 (31%). From 54 stool samples Clostridium diffi cile toxins were 
positive in 63%, only in 16,7% of samples C. diffi cile strains were detected, 
30% were negative.
We analyzed the susceptibility of cultured strains to antibacterial agents. In total 
n=10 strains of (MRSA), n=138 of (MRCNS) staphylococci were detected, 
86% of enterococci were (HLAR) strains and from Enterobacteriaceae family 
12,5% (ESBL) rods were detected. 
Conclusions: The presence of (MDR) bacterial strains after liver transplantation 
such as: methicillin-resistant staphylococci (MRSA) – 52,6%, (MRCNS) – 
81,7%, enterococci (HLAR) – 86%, enteric Gram(-) bacteria (ESBL) – 12,5% 
required better professional infection controls.
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GENETIC SIMILARITY OF CANDIDA KRUSEI STRAINS, 2011 
ISOLATED FROM LIVER TRANSPLANT RECIPIENT, ON 
THE BASE OF GENOTYPIC ANALYSIS AND PHENOTYPIC 
FEATURES – THE CLINICAL CASE OF THE PATIENT WITH 
INVASIVE FUNGAL INFECTION.
D. Kawecki1, M. Krawczyk2, M.S.M. Sikora1, E. Swoboda-Kopec1, M.S.M. 
Dabkowska1, M. Luczak1
1Dept. of Medical Microbiology Medical University of Warsaw, 2Dept. of 
General Surgery Liver and Transplantation
Introduction: The signifi cant increase of Candida krusei isolates number which 
are resistant for antifungal agents could be a serious menace for transplant 
recipiens. This fact concerns mainly immunodefi cient patients. 
Aim: of the Study: Analysis of C. krusei strains isolated from different 
parts of the body of patient with multiorgan infection who underwent liver 
transplantation procedure to compare their phenotypic features and genetic 
similarity. 
Material and Methods: The analysis was perform for the 7 strains isolated 
from: oral cavity swab (1 isolate), nose swab (1 isolate), abdominal cavity swab 
(1 isolate), drain I (1 isolate), drain II (1) and III (1 isolate) and bile (1 isolate) 
from patient after liver transplantation hospitalized in Department of General 
Surgery and Liver Diseases. Isolation and identifi cation of the isolates was 
done according to standard mycological methods of diagnostic. Determination 
of genetic similarity was performed with RAPD method. Enzymatic activity 
analysis was conducted using API-ZYM test.
Results: The RAPD analysis demonstrated the existence of 4 different genetic 
types among 7 isolates. It was established that isolates from oral cavity and 
from nose had the same band pattern – type 1. Isolates from drains: I and III 
and bile were classifi ed to type 2. But isolates from drain II and abdomen 
were distinguished as the separate types (3 and 4). Enzymatic activity analysis 
determined the occurrence of two biotypes with different hydrolytic enzymes 
synthesis profi le.
Conclusion: 1. The application of RAPD technique and phenotypic diagnostic 
of API-ZYM of Candida krusei isolates allowed for detailed identifi cation of 
the strains. 2. Candida krusei is the yeastlike species with reduced susceptibility 
for antifungal agents and it is one of the factors of heavy fungal infections in 
solid organ recipients.
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EVOLUTION OF HYPERSPLENISM AFTER LIVER 2012 
TRANSPLANT: @CT/MRI VOLUMETRY ANALYSIS
F. Chikamori1, S. Nishida2, T. Panaqiotis2, A. Maki2, A. Tekin2, J. Moon2, D. 
Levi2, T. Kato2, G. Selvaggi2, A. Tzakis2
1Kuniyoshi Hospital, 2University of Miami, Miami Transplant Institute
Objective: The aim of this study was to evaluate the effect of liver 
transplantation on the spleen size, and spontaneous spleno-renal shunt (SRS) 
by CT/MRI volumetry.
Methods: Between December 2001 and February 2007, 462 adult patients 
underwent orthotopic liver transplantations (OLTX) at our institution. Of these 
patients, CT or MRI information was reviewed retrospectively in fi fty-fi ve 
patients. Volumetory of the spleen and liver, spleen/liver volume ratio (S/L ratio), 
presence and size of SRS, platelet counts were evaluated before and after OLTX. 
Results: Mean spleen volume decreased from 827±463 cm3 to 662±376 cm3 
after OLTX (P<0.01). The distribution of normal/mild/severe splenomegaly 
changed from 8/10/37 before OLTX to 10/22/23 after OLTX (p<0.05). 
Five (11%) patients returned to normal range spleen size after OLTX. SRS 
was observed in 19 patients (35%). The diameter of SRS also signifi cantly 
decreased from 1.0±0.5 cm before OLTX to 0.7±0.5 cm after OLTX (P<0.05). 
SRS disappeared in 16% of patients (3/19). S/L ratio signifi cantly decreased 
from 0.65±0.33 to 0.38± 0.17 (P<0.01) after OLTX. Improvement of the 
platelet count in the group with postoperative S/L ratio of >0.35 was not as 
good as the group with S/L ratio <0.35 (P<0.05). Recurrent thrombocytopenia 
in the former group was more frequently observed (P<0.05). 
Conclusion: Spleen size and SRS size became signifi cantly smaller after 
OLTX. However, patients with S/L ratio >0.35 after OLTX tend to have low 
platelet counts. 
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BILIARY INDOCYANINE GREEN EXCRETION – AN 2013 
ADDITIONAL USEFUL TOOL FOR THE ASSESSMENT OF 
ALLOGRAFT FUNCTION AFTER LIVER TRANSPLANTATION
F. Rauchfuss1, E. Bärthel1, M. Paxian2, M. Siering2, A.S. Kortgen2, 
A. Kornberg1, M. Bauer2, U. Settmacher1
1Department for General, Visceral and Vascular Surgery, Friedrich-Schiller-
University Jena, Germany, 2Department of Anaesthesiology and Critical Care 
Medicine, Friedrich-Schiller-University Jena, Germany
Background: The assessment of the indocyanine plasma disappearance rate 
(ICG-PDR) is a common tool for evaluating the liver function after major liver 
surgery. The uptake of the dye (ICG) takes place at the hepatocyte’s basolateral 
membrane and ICG will be excreted into the bile.
The aim of this study was to correlate the ICG-bile excretion with the allograft 
function after liver transplantation (LT).
Methods: Eleven liver recipients were included in this study, so far. The post-
LT ICG-PDR measurement was performed in standard practice twelve hours 
after reperfusion. Moreover, we quantifi ed the dye excretion in the bile fl uid. 
Spectrophotometric assessment of the ICG concentration (wave length 800 nm) 
was read using a NanodropTM spectrophotometer (Nanodrop Technologies, 
Wilmington, USA).
The allograft function was evaluated at day one post-LT using the following 
criteria: Good liver viability: GOT max. < 1000 U/l; spontaneous PT > 50% 
and no need for clotting factor substitution; bile production > 100 ml/day; 
Fair graft function: GOT 1000-2500 U/l; clotting factor support < 2 days; bile 
production < 100 ml/day; Poor graft function GOT > 2500 U/l, clotting factor 
support > 2 days, bile production < 20 ml/day. 
Statistical analysis was performed using a MWU-Test, a p-value < 0,05 was 
considered to be signifi cant.
Results: Two patients had a good graft function (18,8%), six had a fair one 
(54,54%) and three had a poor graft function (27,27%), one of them needed a 
retransplantation.
Biliary ICG-excretion was signifi cantly different between patients with fair 
and poor graft function (fair graft function: 229,28 ng/μl ± 282,33; poor graft 
function: 8,37 ng/μl ± 14,5; p=0,024). There was no difference between patients 
with good and fair graft function (p=0,143). 
Conclusion: Our fi rst results of an ongoing study are very encouraging. We assume 
that the analysis of the biliary ICG-excretion can be a helpful additional tool for 
early identifi cation of liver transplant patients with poor initial allograft function.
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POST-TRANSPLANT EMBOLOTHERAPY FOR 2014 
INTRAPULMONARY SHUNTS IN A PATIENT WITH SEVERE 
HEPATOPULMONARY SYNDROME
K-S. Suh , H.W. Lee , W.Y. Shin , J. Kim , N-J. Yi , J.Y. Cho , E.M. Kim , 
K.U. Lee 
1Seoul National University College of Medicine, Department of Surgery
Background: Hepatopulmonary syndrome (HPS), one of the most serious 
complications of the liver disease may be improved after liver transplantation 
(LT). However, post-transplant mortality has been reported to be much higher 
in patients with severe HPS than in patients without HPS. The purpose of 
this report was to introduce our experience of post-transplant embolotherapy 
performed in a patient who had suffered from sustained dyspnea after LT. 
Methods: A 10-year-old male patient who had undergone Kasai operation for 
biliary atresia at 3 months after birth was referred for LT. He had recurrent 
variceal bleeding and severe HPS. His arterial O2 pressure (PaO2) and saturation 
(SaO2) was only 40mmHg and 70-75% in room air. A diffuse pulmonary 
ateriovenous shunt was identifi ed by saline contrast echocardiography and 
pulmonary arteriography. The calculated amount of the shunt fraction was 
44.5% on macroaggregated albumin scan. He received extended left liver graft 
including middle hepatic vein from his father. 
Results: Hypoxemia and dyspnea remained and he was still bed-ridden till post-
LT one month. We performed embolization for tortuous and dilated vascularity 
in left upper lung fi eld on post-LT 30th day. The abnormal vascularity 
markedly decreased and oxygen saturation increased by about 10% right after 
embolotherapy. The second embolotherapy was performed in right lower lung 
fi eld on 37th day. His activity got better and better and he showed some active 
movements such as wheel-chair ambulation at the time of discharge, 40th day. 
His PaO2 and SaO2 increased up to 65mmHg and 93% 3 months after LT and 
he showed the same activity as children in his age group. 
Conclusion: A patient with severe HPS may suffer from sustained hypoxemic 
symptoms for a long time even after LT. We found that embolization improved 
these symptoms by reducing the amount of the shunt. Therefore, we think 
that post-transplant embolotherapy might be useful to reduce the risk of 
postoperative mortality and morbidity and to accelerate the recovery in a 
patient with severe HPS.
POSTER BOARD NUMBER P4 – 65
POSITIVE LYMPHOCYTOTOXIC CROSS-MATCH 2015 
DOES NOT INFLUENCE LONG-TERM OUTCOME IN LIVING 
DONOR LIVER TRANSPLANTATION
A.D. Concejero1, C.L. Chen1, C.C. Wang1, S.H. Wang1, Y.W. Liu1, 
C.H. Yang1, C.C. Yong1, H.L. Eng2
1Liver Transplant Program, Department of Surgery, Chang Gung Memorial 
Hospital-Kaohsiung Medical Center, 2Liver Transplant Program, Department 
of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Center
Background and objective: The infl uence of lymphocytotoxic cross-match 
in living donor liver transplantation (LDLT) remains controversial. We 
retrospectively investigated the infl uence of lymphocytotoxic cross-match 
in our LDLT series using acute rejection episodes, and graft and patient 
survivals.
Patients and methods: The transplant records of 300 consecutive LDLT 
performed between June 1994 and March 2007 were reviewed. All live donors 
and recipients were preoperatively screened for lymphocytotoxic cross-
matching. All recipients received the protocol immunosuppression therapy 
of cyclosporine-prednisone-azathioprine in pediatric cases or tacrolimus-
prednisone-mycophenolate in adult cases. The recipients¡¦ liver enzymes and 
total bilirubin were determined during follow-up. All acute cellular rejections 
were biopsy-proven and graded according to the Banff schema. The indications 
for biopsy were based on signifi cant increase in total bilirubin and/or liver 
enzyme levels, or suspicion of sub-clinical acute rejection. Rejection episodes 
were treated with intravenous boluses of steroid, and/or increase in the current 
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calcineurin-inhibitor, and/or an increase or addition of mycophenolate. The 
recipients were grouped into: negative cross-match (control), positive T&B 
(T&B), and positive B (B) only lymphocytotoxic cross-matches. The mean 
follow-up was 45 months (range, 12-168).
Results: There were 269 (90%) patients with negative, 16 (5.4%) with positive 
T&B lymphocytotoxic, and 14 (4.6%) with positive for B cell only cross-
matches. One case with a positive cross-match for T cell only was excluded. 
The recipient characteristics were similar in all groups. Control, T&B, and B 
group rejection episodes were 42/254 (17%), 2/16 (12.5%), and 2/13 (15.4%) 
at 3 months, respectively. The actual, non-estimated one-year rejection rate 
was 50/221 (22.6%), 4/10 (40%) and 2/9 (22%) for the control, T&B, and B 
groups, respectively. Multiple rejections were 14/65 (21.5%) for the control, 
1/5 (20%) for T&B, and 2/2 (100%) for B only. Although the T&B group had 
lower incidence of rejection during the fi rst 3 months which rapidly increased 
within a year, the differences in the rejection rate in the groups were not 
statistically signifi cant (p=0.494). There were 18 steroid resistant episodes in 
this series. Seventeen came from the control group and none from the T&B 
group (p=0.458). The actuarial 5-year survival rate was 88.6%, 100%, and 
82.5% for the control, T&B, and B groups, respectively (p=0.400). No graft 
loss occurred in the positive T&B group while the graft losses in the B group 
were non-immunologic in nature.
Conclusion: Positive lymphocytotoxic cross-matching in LDLT does not 
signifi cantly worsen the rejection rates, and graft and patient survivals 
in the long-term; and should not be considered as a contraindication to 
transplantation.
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ACUTE GRAFT- VERUS- HOST- DISEASE POST 2016 
ORTHOTOPIC LIVER TRANSPLANT: 2 CASES AND THE 
NOVEL USE OF ETANERCEPT.
L. Delriviere, L. Thin, G. Jeffrey, G. MacQuillan, L. Adams, G. Garas, 
C. Seow
Sir Charles Gairdner Hospital
Acute graft-versus host disease (GVHD) following orthotopic liver transplant 
(OLT) is a rare but feared complication arising in 1-2% of cases with a high 
mortality rate of 85%. It most often presents as fever, rash, diarrhea with or 
without pancytopenia. Patients die for the complications of marrow failure 
such as sepsis or bleeding. 
There is yet no clear treatment protocol for this complication of OLT. Both 
increasing and decreasing immunosuppresion have been trialed with variable 
success. However a closer look at the immunobiology of GVHD offers a 
variety of targeted treatments which have been reported with variable success 
in the literature. These include high dose steroids, anti T-cell therapies (OKT3, 
ATG, Campath etc), anti IL-2 therapy (Basiliximab, dacluximab), and now anti 
TNF-a therapy (Etanercept, infl iximab).
Whilst anti- TNF therapy have been widely used for treatment of steroid 
resistant acute GVHD in the haematopoietic stem cell transplant (HSCT) 
setting, there has been no known reported cases of use in GVHD post OLT at 
the time this case report was written.
We report of 2 cases of GVHD post OLT ever managed at our institution.
Case1: A 57 year old Chinese man presented with febrile neutropenia 3 weeks 
post liver transplant for hepatitis C and hepatocellular carcinoma (HCC). This 
was preceded by one week of pancytopenia refractory to G-CSF and removal 
of marrow suppressing drugs. He subsequently developed a rash and severe 
diarrhoea. His bone marrow was hypocellular and his viral serologies were 
negative.The diagnosis of graft versus host disease (GVHD) was suspected and 
confi rmed on a skin biopsy and chimerism studies of his bone marrow aspirate 
which demonstrated 34% XX cells (donor was a female). 
Broad spectrum antibiotics were initiated for his febrile neutropenia. Upon 
confi rmation of GVHD, he was commenced on pulsed methylprednisolone 
and increased doses of cyclosporine. However, the pancytopaenia, fever and 
diarrhoea persisted despite supportive measures and he continued to deteriorate 
culminating in death secondary to sepsis. 
Case 2: A 65 year old Chinese man presented with rigors and neutropenia 3 
weeks post liver transplant for hepatitis B and HCC. This was preceded by 1 
week of pancytopenia refractory to drug withdrawal and G-CSF support. He 
became febrile within 24hrs of admission and developed a generalised rash 
and severe diarrhoea. Broad spectrum antibiotics were commenced and his 
immunosuppression was withdrawn on the suspicion of GVHD. 
Viral serologies were negative. GVHD was confi rmed on a skin biopsy (Grade 
II) and chimerism studies of his bone marrow trephine and skin biopsy showing 
donor lymphocytes present –XX cells (donor was female). Chimerism was also 
demonstrated in his marrow via detection of variable number tandem repeats 
(VNTR) on donor lymphocytes. 
He was re-commenced on heavy immunosuppression with methylprednisolone, 
cyclosporin, mycophenolate mofetil with the addition of etanercept. Two weeks 
later, his symptoms and pancytopaenia resolved. The patient continues to do 
well and is followed up as an outpatient
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LONG TERM FOLLOW UP OF LIVER TRANSPLANT 2017 
RECIPIENTS AFTER COMPLETE WITHDRAWAL OF 
IMMUNOSUPPRESSION
P. Tryphonopoulos, A. Tzakis, D. Weppler, J. Moon, R.G. Morales, 
G. Selvaggi, D. Levi, S. Nishida, R. Cirocco, A. Sornaraz, A. Berlanga, 
H. Takahashi, E. Island, T. Kato, P. Ruiz
University of Miami
Objective: To evaluate the long term effect of complete withdrawal of 
immunosuppression in liver transplant recipients.
Methods: We followed up liver transplant recipients that had participated in 
an immunosuppression withdrawal study. Immunosuppression was gradually 
withdrawn over a period of 3 years. At the end of the study, 20 patients 
were completely withdrawn (Group 1) and 74 patients developed rejection 
and were4 put back on maintenance immunosuppression(Group 2). There 
were no signifi cant differences in primary liver disease, donor/recipient age, 
gender combinations, and HLA allelic frequency and mismatch between the 
2 groups. 
Results: Patient/graft survival: With an average follow up of 5.48 years, there 
were 3 mortalities in Group 1 (15%) vs. 12 (16%) in Group 2. The remaining 
patients in Group 1 are stable off ISP for 5.48 years (4.8-6.9 years). There were 
no retransplants. Rejection episodes: There were no rejection episodes in Group 
1 vs 23 rejection episodes in Group 2. Other complications: In Group 1, one 
patient (5%) experienced diabetic nephropathy 6 years after drug withdrawal. 
In Group 2, 7 patients (9.5%) had hemodialysis or kidney transplantation; 15 
additional patients (20%) required renal-sparing drug conversion. There was 1 
cancer associated death in Group 1 vs. 3 in Group 2. Quality of life scores show 
a better score in Group 1 (95 vs. 88.5).
Conclusions: Patients that have achieved operational tolerance after liver 
transplantation have a better quality of life and present less ISP-associated 
complications (neoplasms, organ toxicity).
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ESTABLISHMENT OF A NEW LIVER TRANSPLANT 2018 
PROGRAM: CHALLENGES DURING THE FIRST 100 CASES.
G. Selvaggi1, E. Island1, D. Levi1, A. Taylor2, A. Lopez2, A. Tzakis2
1University of Miami, 2Broward General Medical Center
The program at Broward General Medical Center in Fort Lauderdale, FL 
offi cially started in February 2004. Over the past 4 years, up until February 
2008, we have performed 106 adult liver transplants in 99 patients. The 
initiation of an adult liver program in a public trust hospital initially faced 
multiple obstacles. At an administrative level, we had to assess competency 
and train the fi nance personnel in the specifi cs of transplant fi nances. This 
included, but was not limited to, application to Medicare/Medicaid coverage, 
fi nancial contracting with private health insurers, and generating the fi rst cost 
of organ acquisition report. Within the hospital, specifi c transplant training 
was required for the fl oor and operating room nursing staff, as well as general 
laboratory, pharmacy, nutritional services and physical therapy staff. We 
developed specifi c protocols within the radiology department, both in general 
radiology and interventional procedures, to serve the needs of the pre- and post-
transplant patient population. The department of pathology assigned dedicated 
pathologists to the reading and interpretation of liver transplant biopsies, in 
addition to the capability of providing same day service on a routine basis 
for most of the specimens submitted. Interaction with the hospital medical 
staff was on two levels: the primary care/internal medicine physicians and the 
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consulting specialties. For the primary caregivers, focused attention was given 
to the identifi cation of pre-transplant candidates who could be evaluated for 
work-up. While critical care is provided by the transplant team, specialists in 
gastroenterology, nephrology, endocrinology, cardiology, infectious diseases, 
pulmonary medicine, psychology/psychiatry, neurology were all selected 
and involved in patients’ care to provide additional care when required. 
Each of the abovementioned steps involved lectures and in-service updates, 
development of close collaboration and open communication with specialists, 
which allowed the program to grow from 12 liver transplants performed in 
2004 to 40 cases in 2007.
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MODEL FOR END-STAGE LIVER DISEASE: IMPACT OF 2019 
THE NEW DECEASED DONOR LIVER ALLOCATION POLICY 
IN SÃO PAULO, BRAZIL.
F. Monteiro12, R.N.S. Coria1, R. Boni1, L. Pereira1
11São Paulo Organ Allocation System, Health Secretariat of São Paulo, 
2Laboratory of Immunology, Heart Institute, Scholl of Medicine, University of 
São Paulo
Since July 2006, São Paulo Organ Allocation System following the Brazilian 
policy has been allocating deceased donor liver based on Meld/Peld score. 
Before July 2006, those organs were allocated to recipients based on wait-list 
timing. The aim of this study was to analyze the impact on graft survival now 
transplanted under the allocation policy for Meld/Peld–based score. All data 
were acquired from São Paulo Organ Allocation System database. The study 
involved 895 consecutive liver recipients transplanted in São Paulo, Brazil 
from Feb/05 to Dec/07. Kaplan-Meier method was used to construct graft 
survival curves and the curves were compared with log-rank test. From July 
2006 to December 2007, 501 liver grafts were transplanted in 473 recipients 
(22 were split-liver – 4,4% and 426 – 89,8% were adults and 75 – 14,8% 
were pediatric recipients, it means, under 12 years old). The graft allocations 
were in 83 (16,7%) recipients under urgency transplantation requirement 
(acute liver failure and early re-transplantation), 158 (31,5%) under “special 
situation” (recipients with hepatocelular carcinoma, hepatopulmonary 
syndrome, familial amiloidotic neuropathy, liver adenomatosis and metabolic 
diseases) and 206 (41,1%) recipients without Meld/Peld score adjustment. 
Among pediatric recipients (N=75), those transplanted with Peld score up 
to 5; between 6-10 and 11-14; and above 15 were, respectively: 6 (8,0%), 
3 (4,0%%), 10 (13,3%) and 56 recipients (74,7%). Among adult recipients 
(N=426), those transplanted with Meld score up to 10, between 11-18 
and 19-24; and above 25 were, respectively: 68 (16,0%), 106 (24,9%), 68 
(16,0%) and 184 recipients (43,2%). For those, recipients transplanted with 
Meld score up to 10 (N=67) had better 18 months recipient survival rates 
than those with 11-18 (N=32), 19-24 (N=64) and up 25 (N=177) (85,6% 
vs. 81,25% vs. 68,45% vs. 59,83% P<0.050) Regarding the Meld vs. Peld 
score recipients, the 18 months recipient survival rates between adults and 
children was not different (68,2% – n=406 vs. 66,77% – n=66, P>0.050). On 
the other hand, recipients (n=149) transplanted under special situation, had 
a better 18 months survive rates than those (n=257) not transplanted under 
special situation (76,16% vs. 63,78%, P<0.025). Also, recipients (n=199) 
without urgency transplantation requirement had a better 18 months survival 
rates than those (n=58) with urgency transplantation requirement (66,56% 
vs. 53,45%, P<0.005). Finally, the results have shown no differences in 1 
year recipient survival curves between transplanted in the fi rst 18 months 
after Jul/06 (N=473) and recipients (N=422) transplanted 18 months before 
Jul/06 (68.11% for Meld/Peld–based score vs. 72,62% based on wait-list 
timing, P>0.050). In conclusion, current allocation balances the high survival 
of recipients transplanted under special situation with the low survival of 
recipients with high Meld score.
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HEREDITARY HEMORRHAGIC TELEANGIECTASIA OF 2020 
THE LIVER: TWO PATIENTS – ONE DIAGNOSIS – DIFFERENT 
CONSEQUENCES
B. Ringe2, K. Ringe1, M. Galanski1, T. Maroney3, A. Trebelev3, B. Ringe4
1Medizinische Hochschule Hannover, Institut fuer Radiologie, 
2Medizinische Hochschule Hannover, Klinik fuer Allgemein-, Viszeral- 
und Transplantationschirurgie, 3Drexel University College of Medicine, 
Department of Interventional Radiology, 4Drexel University College of 
Medicine, Center for Liver, Biliary and Pancreas Disease
Liver involvement in hereditary hemorrhagic teleangiectasia (HHT) is 
characterized by widespread diffuse vascular malformations. Symptoms may 
occur in about 8% of these patients. Treatment depends on clinical presentation, 
and is only needed in symptomatic patients. This is a report of two interesting 
cases that we have seen within a period of over twenty-three years.
Case # 1: A female patient was 41 years old when she presented with epigastric 
pain and peripheral edema. Clinical examination revealed an epigastric and 
right upper quadrant thrill which eventually led to the diagnosis of HHT with 
high-output cardiac failure, portal hypertension and an intrahepatic biliary 
cyst. She underwent hepatic artery ligation which failed to permanently 
control her intrahepatic shunt and cholangitis, and fi nally received an 
orthotopic liver transplant in November 1985. Over 22 years later she is alive 
and well with normal liver function tests, and no sign of recurrent disease. 
According to the literature this patient is the longest survivor with a liver 
transplant for HHT.
Case # 2: A 54-year old mother volunteered to be evaluated as a living liver 
donor for her daughter suffering from end stage liver disease. She appeared 
to be healthy with a completely negative medical and surgical history. As part 
of the evaluation process she had an MRI which showed multiple enhancing 
lesions throughout the liver representing intrahepatic shunts. As confi rmed by 
hepatic arteriography this picture was consistent with HHT, and the patient was 
excluded from donation. Since she was free of any symptoms, no treatment was 
required at this time.
The spectrum of liver involvement in HHT is ranging from discrete vascular 
malformations eventually detected incidentally (case # 2), to extensive 
intrahepatic shunts, with subsequent heart failure, hepatic disintegration and 
portal hypertension (case # 1). The radiologist plays a key role in diagnosing 
HHT, especially in asymptomatic patients. Whether hepatic artery embolization 
can help to temporize or ameliorate symptoms in less advanced HHT remains 
to be seen. As has been shown repeatedly, liver transplantation may be the only 
curative treatment option in symptomatic patients.
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BODY MASS ALTERATION AFTER LIVER 2021 
TRANSPLANTATION FOR NON-ALCOHOLIC 
STEATOHEPATITIS
M. Marvin, R. Nagubandi, R. Kadiyala, M. Eng, L. Marsano, C. McClain, 
M. Cave, T. Martin, J. Buell
Division of Transplantation, Jewish Hospital, University of Louisville, 
Louisville, KY, United States
Body: Objective: The true incidence of non-alcoholic steatohepatitis (NASH) 
in chronic liver failure patients is unknown. It is not clear whether transplantation 
impacts post-operative body mass index (BMI) or NASH recurrence.
Method: Retrospective review of all liver transplants from 11/ 2000 to 11/ 
2007 was performed. Patient demographics, incidence of recurrent NASH, 
trends in the BMI and liver function were examined.
Results: 19 of 280 (6.8%) liver transplant patients had NASH confi rmed on 
explantation. Overall survival was 89.5% at one year. One patient died of 
recurrent NASH at 9 months. 7 patients underwent post-transplant biopsy of 
which 2 had evidence of recurrent NASH. The overall incidence of recurrent 
NASH was 10.5%. On examination of post-transplant BMI, all patients lost 
weight at 3 months post operatively but gradually regained to above their 
pre-transplant levels with an associated increase in the mean cholesterol 
and triglyceride levels. The mean triglyceride levels signifi cantly increased 
(p=0.005) at 2 years compared to 3 months post-operative levels.
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No signifi cant alteration in liver or renal function was noted. 
Conclusion: Transplantation for NASH is increasing. Unfortunately the true 
incidence of recurrent NASH is still unknown. A statistically signifi cant rise 
in the mean triglyceride levels associated with a rise in the mean BMI and 
cholesterol levels approaching signifi cance would make one wonder if this 
affects the risk for recurrent NASH in the transplant liver.
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PAEDIATRIC LIVER TRANSPLANTATION FOR HEPATIC 2022 
VENO-OCCLUSIVE DISEASE WITH IMMUNODEFICIENCY 
SYNDROME
S. Siew1, E. O’Loughlin1, A. Shun1,2, D. Verran2, M. Wong1, V. Jermyn1,2, 
M. Stormon1,2
1The Children’s Hospital At Westmead, 2Australian National Liver Transplant 
Unit
Introduction: Hepatic Veno-Occlusive Disease with Immunodefi ciency 
(VODI) is a rare autosomal recessive condition characterised by primary 
combined immunodefi ciency with hepatic centrilobular and sinusoidal fi brosis, 
leading to hepatic venous occlusion, portal hypertension and liver failure. 
Roscioli et al recently described the genetic basis of VODI: mutations in the 
SP110 immunoregulatory gene on chromosome 2q36.3-37.1. The majority 
of reported cases are children of consanguineous Lebanese parents, living in 
Sydney, Australia. The prognosis for children with VODI is extremely poor 
with death often occurring due to either the primary immune defi ciency and/
or liver failure.
Objective: We aim to report the poor outcomes of liver transplantation for 
VODI in two children.
Results: Both children were of consanguineous Lebanese parents and each 
presented in early infancy. Patient A was a young male infant diagnosed at 
3 months when he presented in liver failure with intractable ascites, severe 
portal hypertension and presumed Pneumocystis jiroveci infection. Patient B 
presented at 4 months with hepatosplenomegaly, ascites and thrombocytopenia. 
Her brother died at 4 months from overwhelming Pneumocystis pneumonia 
and suspected VODI. 
Immune function tests in each case showed severe hypogammaglobulinaemia 
with normal B-lymphocyte numbers. There was clinical evidence of T-cell 
immunodefi ciency but normal circulating T-lymphocyte numbers, normal CD4+ 
and CD8+ percentages, and normal T-lymphocyte proliferation assays. Both patients 
received cotrimoxazole prophylaxis and monthly immunoglobulin infusions.
Patient A: underwent orthotopic liver transplantation at 7 months using a 
deceased donor split adult graft. There were multiple surgical issues secondary 
to marked portal hypertension from hepatic venous outlet obstruction including 
an inability to perform a Roux loop because of bowel wall oedema plus inability 
to achieve primary closure of the abdomen. Other complications included 
recurrent episodes of sepsis and malnutrition. Severe haemophagocytosis led 
to multi-organ failure and death, 32 days post-transplant. 
Patient B: gradually progressed into liver failure and at 17 years of age 
underwent orthotopic liver transplantation with a reduced adult graft from a 
deceased donor. The hepatectomy was extremely diffi cult, owing to severe 
portal hypertension, dense adhesions due to previous primary peritonitis and 
a previously unrecognized Morgagni diaphragmatic hernia containing an 
accessory lobe of the right liver. The initial graft function was good. However 
the post-operative course was marked by multiple infections, graft-versus-
host disease of the gastrointestinal tract, poor nutrition, renal impairment and 
expanding intracranial lesions of suspected fungal aetiology. Death occurred 
due to these complications plus graft failure 5 months post-liver transplant.
Conclusion: The poor outcomes of liver transplantation in these two children 
with VODI suggest that this therapy should not be offered to children with 
this condition. Furthermore, other children with a primary immune defi ciency 
should be considered high risk liver transplant candidates.
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PLATELET-TRANSFUSION REFRACTORINESS 2023 
FOLLOWING LIVING RELATED LIVER TRANSPLANTATION
A. Kenjo1, T. Saito1, T. Tsuchiya1, Y. Sato1, T. Kimura1, T. Ogata2, H. Ohto2, 
H. Yasuda2, K. Kawabata2, M. Gotoh1
1Fukushima Medical University, Department of Surgery, 2Fukushima 
Medical University, Department of Blood Transfusion and Transplantation 
Immunolory
Thrombocytopenia is common fi ndings in patients with end-stage liver disease 
who need liver transplantation. Sometimes we encounter platelet-transfusion 
refractoriness (PTR) in the posttrasplant patients in whom repeated platelet 
transfusion fails to increase its count in peripheral blood enough to stop 
bleeding tendency. It is crucial to understand the mechanism in each patient 
causing PTR. In this study, we focused on PTR following living-related liver 
transplantation and discuss appropriate diagnosis and treatment.
In 22 consecutive recipients of living-related liver transplantation, a poor 
response to transfusions of random donor platelets was observed in 2 cases 
who showed the count of platelets in blood fl uctuated between 2 and 4 x 1010 
/L in spite of repeated platelet transfusion. Most of antibodies against antigens 
presented on platelets including anti-human leukocyte antigen (HLA) antibody 
and anti-human platelet antibody (HPA) were examined in the cases. 
The case 1, a 23-year-old Japanese woman with fulminant hepatitis, received a 
liver transplant from her sister with one HLA locus mismatch. Platelets from 8 
donors had been transfused by day 5 against severe thrombocytopenia. The titer 
of anti-HLA antibody was negative on day 1, but went up to x512 on day 6, and 
x4096 on day 9. These antibodies positively reacted with lymphocytes which 
showed HLA A 24, 33 or B 7, 44, 48, 51, 60, 61, 67 by panel reactive assay, but 
did not react with donor HLA. The recipient had been pregnant for 6 times prior 
to liver transplantation. HLA sensitization was not detected in the sera before 
transplantation, but came apparent as a cause of PTR after transplantation. 
The platelet count of the patient started to recover within several days after 
cessation of platelet transfusion, and recovered uneventfully.
The case 2, a 47-year-old Japanese man with hepatitis B virus-related liver 
cirrhosis, received a liver transplant from his brother with one HLA locus 
mismatch. Platelets from 21 donors had been transfused by day 8 against severe 
thrombocytopenia, however, platelet count was not increased showing PTR. 
No anti-HLA or anti-HPA antibodies, but anti-CD36 (GP IV, Naka) antibody 
was detected. The recipient and donor were negative for CD36 antigen. The 
patient was transfused effectively with platelets from CD36 negative, but HLA 
non selected, donors. After 4 months when the titer went down to x16, and the 
platelet count recovered.
In conclusion, frequent platelet transfusion or pregnancy might induce 
antibodies causing PTR. Liver transplant recipients with PRT should be 
examined for anything out of the ordinary antibodies to select an appropriate 
treatment.
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EFFECTS OF HEPATIC CYP3A4 ACTIVITY ON 2024 
DISPOSITION OF SIRORIMUSU IN LIVER TRANSPLANT 
RECIPIENT
S. Kishino1, N. Mochizuki1, K. Ohno1, T. Shimamura2, H. Furukawa2, 
S. Todo2
1Meiji Pharmaceutical University, 2First Department of Surgery, Hokkaido 
University Hospital
Sirolimus is extensively metabolized by cytochrome P450 3A (CYP3A) in 
the liver. The urinary ratio of 6b-hydroxycortisol to cortisol (6b-OHF/F) is 
considered to be the estimation of hepatic CYP3A4 activity. The aims of this 
study were to clarify the effects of hepatic CYP3A4 activity on disposition of 
sirorimusu in liver transplant recipient. The results in this study show that the 
urinary 6b-OHF/F ratio is an useful probe for estimating the inter- and intra-
individual variability of CYP3A4 activity, but not for predicting the optimal 
silorimus dose in recipients. 
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DE NOVO MALIGNANCIES AFTER LIVER 2025 
TRANSPLANTATION
R. Charco1, I. Bilbao1, G. Sapichosin1, C. Dopazo1, A. Escartin1, 
J.L. Lazaro1, L. Castells2, M. Caralt1
1Department of HBP Surgery And Transplants. Hospital Vall D’Hebron, 
2Department of Hepatology
Aim: To asses our experience with the use and management of m-TOR after 
liver transplantation (LT).
Material: From 1988 to 2007, 783 LT has been performed in 725 patients. Fifty 
one patients (7%) received immunosuppression with m-TOR: Rapamicine 36 
and everolimus 15. Mean age was 54.8 years old (r:24-70). Indication of use, 
time between LT and introduction of m-TOR, efi cacy, side effects and survival 
were analysed.
Results: Indications were: refractory rejection in the context of renal 
insuffi ciency 20 (39%), renal insuffi ciency 5 (10%), other side effects of 
CNI 6 (12%), extended HCC in the explanted live 7 (14%), HCC recurrence 
in the follow-up 7 (14%) and the novo tumour 3 (6%). Mean time between 
LT and m-TOR were 18 ± 29 months with a median of 3 months (r:10 days-
122months). Mean follow-up after conversion was 12 months (r: 1-65), 
with a median of 7. Half of the patients converted for refractory rejection, 
resolved the event. Four required re-LT, 3 progresed to chronic rejection and 
3 died due to non resolved rejection, overimmunosuppression and sepsis. 
Of 19 patients with renal insuffi ciency at time of conversion, 10 (52%) 
resolved. Three out of 7 patients with extended HCC, died and 4 out of 7 
patients with recurrent HCC, died. The 3 the novo tumour were operated and 
are perfectly healthy. Half of the patients presented side effects related to 
m-tor: diarrhea in 4 (8%), hematologic complications in 5 (10%), dyslipemia 
in 22 (43%), and infection in 8 (16%). Ten patients (20%) developed acute 
rejection after conversion. Nineteen patients (33%) discontinued drug: 9 due 
to inefi cacy, 4 due to resolution of the cause, 3 due to intercurrent surgery 
and 3 due to advers event. Actuarial survival postconversion is 55% and 
15% at 1y and 3y.
Conclusion: m-TOR are indicated in critical and irreversible situations where 
other immunosuppressants have failed: in the early period for refractory 
rejection or as prophylaxis for recurrence of extended tumors; in the late period 
for patients with serious side effects of CNI.
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IMPACT OF INTRAPORTAL DONOR SPECIFIC 2026 
LEUKOCYTES TRANSFUSION FOR ADULT ABO-
INCOMPATIBLE LIVER TRANSPLANTATION
H. Oya, Y. Sato, S. Yamamoto, T. Kobayashi, Y. Hara, H. Kokai, 
K. Hatakeyama
Division of Digestive And General Surgery, Niigata University
Adult ABO-incompatible liver transplantation is poor outcome associated 
with an extremely complicated postoperative course. We have reported that 
repeated donor specifi c transfusion via portal vein bring the rapid reduction of 
immunosuppressants and the decrease of acute cellular rejection. In this study, 
we investigated whether new strategy of immunosuppression by intraportal 
transfusion of donor specifi c leukocytes (DSLT) separated from donor whole 
blood would bring up the immunological benefi ts in adult ABO-incompatible 
living related liver transplantation.
Materials and Methods: Ten patients (age: 51 }9y.o., range 31-60y.o.) 
(MELD score: 19.4 }7.3, range 12-29) who underwent living-related donor 
liver transplantation from ABO-incompatible donors (GRWR: 0.90 }0.28, 
range 0.63-1.46) from August 2003 to November 2007, were investigated. 
The antirejection therapy included multiple perioperative plasmapheresis, 
splenectomy, quadruple immunosuppression. In addition to these conventional 
approaches, we performed 4 times of intraportal administration of DSLT 
after transplantation. The clinical effects for the immunosuppression and 
the humoral and cellular rejection, and the immunological analysis were 
studied.
Results: There was no humoral rejection in the all patients. There was only one 
mild acute cellular rejection in the all patients. Donor specifi c both IgM and IgG 
A/B antibodies of all patients have decreased following transplantation within 16 
times. In the immunological analysis by fl owcytometry, it was recognized that 
the donor type of CD56+NKT cells existed in the liver graft as macrochimerism 
one month after liver transplantation. Furthermore, IL-10 production of Th2 
type of cytokine was up regulated on the day1 after transplantation. Three 
patients died on 2months, 4months and 8months after operation respectively 
because of the sepsis caused by preoperative MRSA pyothorax, MRSA and 
MRSE catheter infection. Seven patients were discharged in condition. 4 years 
survival is 67.5% by Kaplan-Meier method.
Conclusion: Adult ABO-incompatible liver transplantation can be performed 
with acceptable patient and graft survival rates with very low risk of antibody-
mediated rejection with our new strategy of immunosuppression by intraportal 
administration of DSLT. Donor type CD56+NKT cells may induce tolerance by 
veto mechanism and anti-idiotype network mechanism.
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RISKS FACTORS AND OUTCOME OF PATIENTS WITH 2027 
ISCHEMIC-LIKE CHOLANGIOPATHY WITH SECONDARY 
SCLEROSING CHOLANGITIS (IN CRITICALLY ILL PATIENTS, 
SC-CIP) AFTER LIVER TRANSPLANTATION 
G. Kirchner1, M. Scherer2, A. Obed2, P. Ruemmele3, R. Wiest1, M. Froh1, H.J. 
Schlitt2, J. Schoelmerich1, C. Gelbmann1
1University of Regensburg, University Hospital, Dept. of Internal Medicine, 
2University of Regensburg, University Hospital, Dept. of Surgery and 
Transplantation, 3University of Regensburg, University Hospital, Institute of 
Pathology
Background: Sclerosing cholangitis in critically ill patients (SC-CIP) with 
sepsis and acute respiratory distress syndrome (ARDS) is a recently newly 
described cholestatic liver disease with a rapid progression to liver cirrhosis. 
It is defi ned by an ischemic injury of the biliary tree with formation of biliary 
casts and subsequent ongoing biliary infection due to multiresistent bacteria 
infl ammation. The exact mechanisms leading to this form of cholangiopathy 
with stricture formation and complete obliteration of bile ducts are unknown. 
Clinical and endoscopic features of SC-CIP are comparable with those of 
primary sclerosing cholangitis, but patients with SC-CIP have no prior history 
of liver disease and no known pathologic process or injury responsible for bile 
duct obstruction. Liver transplantation (LTx) is the only curative therapy option 
for patients with SC-CIP-induced liver cirrhosis. Until now, little is known 
about of liver transplantation (LTx) in patients with SC-CIP.
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Material, Methods, Results: From 2004 to 2007 eight patients (40+8 yrs; 
7m, mean MELD score: 24+5) with SC-CIP underwent LTx at our institution. 
Four patients had a severe polytrauma with multiple bone fractures, sepsis 
and ARDS. SC-CIP was diagnosed within 2+3 months after polytrauma. 
Four non-traumatic patients acquired SC-CIP in the context of long-term 
intensive care unit stays with sepsis and ARDS based on internal diseases. 
SC-CIP was diagnosed by ERCP and approved in the explanted liver. 
Early endoscopic fi ndings of severe bile duct damage were intraductal 
fi lling defects of all intrahepatic bile ducts due to extensive biliary casts. 
In patients with endoscopic examination several weeks after the beginning 
of cholestasis, intrahepatic bile ducts showed multiple irregular strictures 
of different degrees and remnants of biliary cast among the strictures. As 
far as possible, biliary cast were removed by dormia basket of a balloon 
catheter after endoscopic sphincterotomy. Primary immunosuppression 
was: anti-IL2-antibody, ciclosporin and prednisolone and/or mycophenolate 
mofetil. After LTx all patients received ursodesoxycholic acid (15-20 mg/
kg body weight per day). The three main isolated bacteria in the bile were: 
enterococcus (n=4), candida albicans (n=3), multi-resistance E. coli (ESBL) 
(n=2). The mean follow-up after LTx was 13+10.0 months. Five of 8 patients 
are still alive and have a good quality of life. One female patient (HELPP 
with sepsis) underwent LTx despite of infection. She died 26 days post-LTx 
within a sepsis. Seven of 8 patients survived the post-operative course. Two 
(non-traumatic) patients died from sepsis within 4 and 8 months after LTx. 
Five (including all 4 patients with polytrauma) of the 8 patients are still alive 
and have a good quality of life. 
Summary,Conclusion: Our prospective study shows that LTx is a curative 
therapy option in patients with SC-CIP. Patients transplanted by SC-CIP due 
to polytrauma have a signifi cant superior outcome within the fi rst year after 
LTx than patients who aquired SC-CIP in the context of non-traumatic disease. 
Without exception, sepsis was the main cause of death after LTx. Further 
reasons for sepsis after LTx need to be determined, especially in the non-
traumatic group, to improve outcome and survival in these patients.
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PREDICTORS OF SUBSTANCE ABUSE AFTER LIVER 2028 
TRANSPLANTATION IN PATIENTS WITH ALCOHOLIC LIVER 
DISEASE
D. Ranjan, P. McHugh, H. Jeon, T. Johnston, R. Gedaly
University of Kentucky Transplant Center
Background: Alcoholic liver disease (ALD) is a common, yet controversial, 
indication for liver transplantation (LT) worldwide. Many patients with 
ALD also have a history of substance abuse, with return to drugs or alcohol 
consumption further complicating their post-transplant management. The aim 
of this study was to identify predictors of relapse to drug use after LT in these 
patients. 
Methods: A retrospective analysis of LT recipients with ALD was performed 
at our institution. Demographic, socioeconomic, and laboratory data were 
reviewed. Univariate and multivariate analyses of prognostic factors for 
recurrence to drug use were performed. 
Results: Between July 1995 and November 2007, 387 patients underwent 
LT at our center. Of these, 147 patients (37.9%) were found to have ALD. 
Five patients (3.4%) were excluded due to perioperative mortality. Drug abuse 
history was identifi ed in nearly half of patients with ALD (n=65, 45.8%), most 
frequently marijuana (n=39). Twenty-eight patients (19.7%) had documented 
drug use after LT. Predictive factors of drug relapse found by univariate 
analysis included recipient age >50 (p=0.019), unemployment (p=0.019), HCV 
(p<0.001), and any history of substance abuse (p<0.001). Multivariate analysis 
revealed history of substance abuse to be the only independent predictor of 
drug abuse after LT (p=0.013) when controlling for age, working status, and 
HCV status. 
Conclusion: ALD patients with any history of drug abuse are those most likely 
to return to this behavior after LT. Substance abuse counseling during evaluation 
should be emphasized in this subgroup of patients to improve compliance.
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IMPACT OF CCR5DELTA32 MUTATION ON ISCHEMIC 2029 
TYPE BILIARY LESIONS AFTER LIVER TRANSPLANTATION
I. Ruth1, M. Hoppe-Lotichius1, A. Lautem1, M. Sprinzl2, J. Thies1, G. Otto1
1Department of Transplantation and Hepatobiliary Surgery, Johannes 
Gutenberg Univ, 2Department of Internal Medicine, Johannes Gutenberg 
University, Mainz, Germany
Background: Ischemic-type biliary lesions (ITBL) occur after orthotopic 
liver transplantation (LT) with a reported incidence of up to 26% and lead 
to considerable morbidity, graft loss, and even mortality. A multi-factorial 
etiology is assumed. CC-chemokines and their receptors have been identifi ed 
to play a key role in cell survival and proliferation. The CC-chemokine receptor 
5delta32 (CCR5delta32) mutant has been shown to be a major risk factor for 
the development of ITBL after LT. 
Method: 338 LT recipients (374 LT including 36 retransplantations) 
transplanted between September 1997 and December 2007 (116 female and 
222 male) were included in the study. The CC-chemokine receptor 5 (CCR5) 
was analyzed by PCR to identify patients with CCR5delta32. 
ITBL were identifi ed by increased parameters of cholestasis followed by 
imaging of the bile ducts. 
Results: CCR5 wild-type and CCR5delta32 (3 homocygous, 45 heterocygous) 
were identifi ed in 290 and 48 patients, respectively. ITBL occurred in 35 of 
the 322 transplantations performed in patients with wild-type and in 12 of 52 
grafts in patients with CCR5delta32 mutation (p= 0.022). Patient survival was 
reduced in patients with CCR5delta32 to 67%, 65%, 61% after 1, 3 and 5 years, 
respectively. In patients with CCR5 wild type the respective fi gures are 89%, 
80%, and 75% (p=0.011). Graft survival was equally reduced to 65%,60%, and 
52% after 1,3 and 5 years in patients with CCR5delta32 versus 85%, 73%, and 
66% in patients with wild-type (p= 0.040). 
Rate of rejection was not affected (p= 0.282). CCR5Ä32 showed no infl uence 
on reinfection, rate of retransplantation, and fi brosis (within a year) after 
liver transplantation in patients with hepatitis C (p=0.721). In patients with 
CCR5delta32 mutation the mode of perfusion was without infl uence on the 
occurrence of ITBL (p=0.366) whereas in patients with wild type arterial back-
table pressure perfusion was capable of preventing ITBL (p=0.009). 
Conclusion: In a large collective CCR5delta32 was shown to be a signifi cant 
risk factor for the development of ITBL following LT. The mutation not only 
leads to a reduction of patient and graft survival but also to an increased 
retransplantation rate.
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LIVER TRANSPLANTATION FOR SMALL CHILDREN IN 2030 
CHILE: EXPERIENCE AND LONG-TERM OUTCOME.
M. Uribe, A. Alba, G. Gonzàlez, R. Iñiguez, M. Ferrario, J. Godoy, B. Hunter, 
S. Cavallieri, E. Buckel
Liver Transplantation Program Clínica Las Condes – Hospital Luis Calvo 
Mackenna
Introduction: The outcome of orthotopic liver transplantation (OLT) in 
pediatric patients has improved in last decades, but the subgroup of small 
children, weighting 10 kilograms or less, still presents several clinical problems. 
Despite optimal results reported elsewhere, complications are more frequent 
than in older patients, specially from vascular anastomoses. The aim of this 
study is to present the experience of liver transplantation in patients weighing 
10 kilograms or less, in a multicenter liver transplantation program in Chile.
Patients and Methods: From November 1993 to February 2008, we performed 
348 OLT, 188 of them in pediatric patients younger than 15 years. 37 patients, 
weighing 10 kilograms or less were transplanted. The data of these cases was 
reviewed. Kaplan Meier test was used for actuarial survival. 
Results: 37 children received 45 grafts. 6 patients required retransplant, 2 of 
them received a third graft. Twenty patients were males (54%). Median age 
and weight were 1.1 years (range 8 months-6 years) and 8.1 kg. (range 4.8-10) 
respectively. Primary liver disease was biliary atresia in 25 patients (68%), 
Alagille syndrome in 4 (11%), fulminant hepatitis in 2 (5%), Byler disease in 
2 (5%), neonatal hepatitis in 2 (5%), hepatoblastoma in 1 (3%) and metabolic 
disease in 1 (3%). Grafts from living donor (segments II-III) were used in 
23 cases (51%); deceased donor grafts in 22 patients (49%) (11 complete 
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liver, 10 reduced grafts, and 1 split-liver). Graft-to-recipient weight ratio was 
greater than 1% in all the cases. Two patients underwent delayed abdominal 
wall closure. Immunossupresion was based on cyclosporin or tacrolimus plus 
steroids. Daily hepatic ultrasound with doppler was performed in the fi rst 10 
days after OLT. 
Regarding vascular complications, 8 cases of portal vein thrombosis (PVT) 
were seen, 5 hepatic arthery thrombosis (HAT), and one patient with both 
(PVT-HAT). Of them, 10 required reoperation (7 PVT, 2 HAT and 1 PVT-
HAT). Five patients had biliary leaks, requiring surgical repair. There were 3 
biliary stenosis managed percutaneously. 
Patient survival at 1 and 5 years is 75% and 64%. Main cause of death within 
this group was infection (7 patients, 19%). 
Only 2 patients have died due to vascular complications. Of the 8 retransplants, 1 was 
due to HAT and 3 to PVT. There have been no deaths due to vascular complications 
in the last 11 years, and no graft lost for this cause in the last 4 years. 
Comments: Liver transplantation in small children is a major medical and 
surgical challenge. Our results are comparable to countries with similar 
conditions of pediatric liver transplantation, although still below large series 
published. The improvement in the surgical technique in the last years has lead 
to fewer vascular complications and trends to better outcome. This is the largest 
series in our country.
POSTER BOARD NUMBER P4 – 81
THE PROTECTIVE EFFECTS OF ANTIOXIDANTS 2031 
OF LYCIUM BARBARUM AND ASCORBIC ACID ON THE 
REPERFUSION LIVER INJURY IN RATS
D. Wang, C-F. Chen1, R-T. Hu
1Department of Medicine, Cheng Hsin General Hospital, 2Department of 
Medicine, Fu Jen Catholic University, 3Liver Center, Cathay General Hospital
Objectives: Ischemia/reperfusion (I/R) of the rat¡¦s liver could induce liver 
injury in which oxidative stress and nitrosative stress are involved. In this study 
we used antioxidants of lyceum barbarum and ascorbic to study their protective 
effects on this reperfusion liver injury model.
Methods: Ischemia was induced by clamping off the common hepatic artery 
and portal vein for 40 minutes and reperfused for 90 minutes. Blood samples 
collected before I and after R were analyzed for ALT, LDH, hydroxyl radical, 
nitric oxide and tumor necrosis factor (TNF£\). 
Results: This protocol resulted in elevation of the blood NO (p<0.01), hydroxyl 
radical (p < 0.01), TNF£\, ALT and LDH (p < 0.01) in the I/R but not in the 
sham-operated group. Ascorbic acid (100 mg/kg) signifi cantly attenuated the 
reperfusion liver injury. Lyceum barbarum (alcoholic extract from the crude 
Gogi berries; 600 mg/100 ml of drinking water for 2 weeks) alleviated the liver 
injury but the difference was not signifi cant.
Discussion and Conclusions: This I/R protocol resulted in oxidative and 
nitrosative stress and liver injury. Ascorbic acid showed signifi cant protection 
in this reperfusion liver injury. Although the crude extract of lyceum barbarum 
had antioxidant effects but in this reperfusion liver injury model it did not show 
any protective effect.
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COMPARISON OF TWO TRANSFUSION STRATEGIES 2032 
FOR ORTHOTOPIC LIVER TRANSPLANTATION
S. Roullet, M. Biais, A. Vallet, P. Revel, F. Sztark
Service Anesthésie Réanimation, CHU Bordeaux, France
Introduction: Orthotopic liver transplantation is a hemorrhagic surgery. In 1999 
a multicenter study showed great differences in transfusion strategy for OLT in 
France (Ozier, Anesth Analg 2003). At this time, in our centre, all patients received 
fresh frozen plasma (FFP), while other centre never transfused FFP for OLT. All 
volemic compensation was done with FFP. After refl ection and evaluation we 
changed our strategy and volemic compensation was done with albumin 4%. 2005 
was the year of transition. We assess the affect of this change on our transfusion 
strategy with a two-period comparison: 1999-2001 versus 2006-2007.
Patients and methods: This is a retrospective study including all patients who 
benefi t from an OLT in our centre from 1999 to 2001 and from 2006 to 2007. 
Preoperative data noted were: sex ratio, age, and blood analysis. Albumin 
transfused during OLT and blood products transfused during OLT and the 24th 
fi rst postoperative hours were collected. We chose SAPS II (simplifi ed acute 
physiology score) as a severity marker and compared length of stay in ICU 
(intensive care unit) and death at day 7.
Results: 
1999-2001 2006-2007
 n=74 n=73 p
Sex ratio M/F 52/22 50/23 NS
Age (years) 53 (46-59) 52 (46-58) NS
Pre-transplant values
Hb (g/dl) 11.3 (9.8-12.6) 12.4 (10.4-14.2) 0.022
Platelets (/mm3) 87500 111500 NS
(61250-139250) (58750-160250)
Fibrinogen (g/l) 2.5 (1.8-3.2) 2.7 (2.0-3.4) NS
TP (%) 61 (48-73) 62 (52-78) NS
Factor V (%) 56 (41-78) 63 (46-85) NS
Blood products transfused
Albumin 4% (OLT) 1 (0-2) 6 (5-9) <0.0001
red blood cells (24h) 4 (2-7) 5 (2-9) NS
fresh frozen plasma (24h) 15 (10-19) 5 (0-12) <0.0001
platelets (24h) 0 (0-1) 0 (0-1) NS
SAPS II 30 (22-35) 33 (26-39) 0.048
Length of stay ICU 16 (10-23) 14 (7-28) NS
Death at day 7 2 6 NS
Data are in numbers or median (IQ 25-75).
Comparisons are done with a Mann-Whitney test, a χ2 test or a Fisher’s exact 
test. 
Discussion: Volemic compensation with albumin instead of FFP was not 
associated with coagulation disorder and haemorrhage. Transfusion of red 
blood cells or platelets was alike. Despite slightly higher SAPS II for the 
second period, length of stay in ICU or mortality at day 7 were not signifi cantly 
different. 
These results led us to optimize our transfusion strategy and limit the use of 
FFP for haemorrhagic syndromes.
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CAN MELD EXCEPTIONS PREDICT DEATH ON LARGE 2033 
WAITING LISTS?
S. Iacob1, L. Gheorghe1, R. Iacob1, C. Gheorghe1, I. Popescu2
1Fundeni Clinical Institute, Gastroenterology and Hepatology Center, 
2Fundeni Clinical Institute, General Surgery and Liver Transplantation 
Center
Background: Currently, the most recent MELD score available for each 
waiting list patient is used to prioritize organs, because it accurately predicts 
short-term mortality. Cirrhosis related complications, considered MELD 
exceptions, proved to add prognostic value to the MELD score in predicting 
waitlist mortality.
Aim: To identify the predictive value for death on a large waiting list (WL) 
for the complications of liver disease, current MELD and variation of MELD 
scores at certain time intervals.
Methods: During 2004-2007, 372 consecutive adult patients were listed for 
liver transplantation (OLT) in our Center. To identify the potential predictors of 
patient death, univariate and multivariate Cox’s proportional hazards regression 
model was used.
Results: We included in the study 58.1% men and 41.9% females with a mean 
age at OLT of 46.6 ± 10.9 years. The 12 months actuarial survival was 76.7%. 
OLT was performed in 9.4% of patients. In the univariate survival analysis 
the following variables were signifi cant: spontaneous bacterial peritonitis, 
refractory ascites, hepatic encephalopathy, renal failure, current MELD score, 
MELD score at inclusion on WL, maximal variation of MELD score, maximal 
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variation of INR, creatinine and bilirubin, MELD score variation in the last 3 
months (p<0.0001 for each), as well as INR (p<0.0001), creatinine (p=0.01) and 
bilirubin (p<0.0001) variation in the last 3 months. The independent predictors 
of death on our WL were: current MELD score (p=0.0006), refractory ascites 
(p=0.001), renal failure (p=0.01), hepatic encephalopathy (p=0.03). Based 
on a logistic regression analysis a new score has been developed including 
these independent predictors of death on the WL: Score= 1/(1+ exp(-(-4.59 + 
1.51 x Refractory ascites + 0.18 x Current MELD), where refractory ascites is 
registered as 1 if the event occurs. The c-statistic for the new score for prediction 
of death on the WL was 0.84 compared to 0.80 for current MELD score. 
Conclusion: Refractory ascites should add valuable points to the current 
MELD in order to better prioritize for liver transplantation patients included 
on large WL.
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SIX-YEAR FOLLOW-UP OF A DOMINO LIVER 2034 
TRANSPLANTATION USING A GRAFT FROM A DONOR WITH 
FAMILIAL HYPERCHOLESTEROLEMIA
I. Popescu1, S. Dima1, N. Hancu2, L. Gheorghe3, S. Iacob3, M. Mihaila4, E. 
Matei1, B. Dorobantu1, F. Botea5
1Center of General Surgery and Liver Transplantation, Fundeni Clinical 
Institute, Bucharest, Romania, 2Institute of Diabetes and Nutritional Diseases 
Cluj-Napoca, Cluj-Napoca, Romania, 3Center of Gastroenterology and 
Hepatology, Fundeni Clinical Institute, Bucharest, Romania, 4Department 
of Internal Medicine, Fundeni Clinical Institute, Bucharest, Romania, 53rd 
Department of Surgery, University School of Medicine – Humanitas Clinical 
Institute IRCCS, Rozzano, Milan, Italy
Background: Domino liver transplantation (DLT) has been developed as a 
method to increase the donor pool. 
Material and Method: Material and Method: We present here the case of 
a 46-year-old female with hepatocellular carcinoma (HCC) and hepatitis 
B virus liver cirrhosis, non-responsive to chemoembolization. The patient 
that was in a severe condition received a domino liver graft from a 25-year-
old female with homozygous familial hypercholesterolemia (HFHC) in 
September 2001. Before transplantation, the donor’s serum cholesterol level 
was 500 mg/dl under treatment with Simvastatin and 800 mg/dl without it, 
and after transplantation the level was maintained within the normal range. 
During follow-up examination of the graft recipient, hypercholesterolemia 
occurred within one year after the liver transplant and was partially controlled 
by atorvastatin (the highest serum cholesterol value was 410 mg/dl). Three 
years after the transplantation, an autologous CD34+ cell transplantation 
was performed in order to better control the hypercholesterolemia. In 2003 
we published only preliminary results of with this case, without a long-term 
analysis of the effects of hypercholesterolemia.
Results: Subsequent to domino liver transplantation, the average plasma 
cholesterol level in the domino donor rapidly normalized and after more than 
six years of follow-up, plasma cholesterol was 182 mg/dl. The patient was 
metabolically stable. She showed no sign of lipid imbalance and only minimal 
modifi cations in her most recent Doppler echocardiography. The domino 
recipient currently has no HCC recurrence; tumoral markers are within the 
normal range and CT is negative. Moreover, no signs of cardiovascular or 
atherosclerotic lesions were noted despite an elevated plasma cholesterol level 
(320 mg/dl after 76 months of follow-up) resistant to drug therapy and stem 
cell autotransplantation. 
Conclusion: Domino liver transplantation using a liver graft from a patient 
with homozygous familial hypercholesterolemia provides a viable option for 
marginal recipients.
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ANALYSIS OF RISK FACTOR FOR ATELECTASIS AND 2035 
THE EFFECT OF PRONE POSITION THERAPY AFTER LIVING 
DONOR LIVER TRANSPLANTATION
S. Nakahashi1, T. Shimamura2, M. Taniguchi3, T. Suzuki4, K. Yamashita5, M. 
Ota6, T. Kamiyama7, M. Matsushita8, H. Furukawa9, S. Todo10
1Department of General Surgery Hokkaido University Graduate School of 
Medicine, 2Department of General Surgery Hokkaido University Graduate 
School of Medicine, 3Department of General Surgery Hokkaido University 
Graduate School of Medicine, 4Department of General Surgery Hokkaido 
University Graduate School of Medicine, 5Department of General Surgery 
Hokkaido University Graduate School of Medicine, 6Department of General 
Surgery Hokkaido University Graduate School of Medicine, 7Department 
of General Surgery Hokkaido University Graduate School of Medicine, 8 
Department of General Surgery Hokkaido University Graduate School of 
Medicine, 9 Department of General Surgery Hokkaido University Graduate 
School of Medicine, 10Department of General Surgery Hokkaido University 
Graduate School of Medicine
Background: Pulmonary complications occur with a high rate after liver 
transplantation, resulting in the extended hospital stay and sometimes 
poor prognosis. Especially, pneumonia demonstrates high mortality. As an 
underlying condition, persistent atelectasis is considered to be a risk factor. 
However, little has been reported about the pulmonary atelectatsis after living 
donor liver transplantation (LDLT), or the effective therapy to prevent this 
unfavorable complication.
Purpose: We investigated the risk factors for atelectasis after LDLT and 
assessed the effect of prone position therapy.
Patients and methods: Fifty two adult patients underwent LDLT at our center 
from October 2003 to December 2007 were enrolled in this study. Eight and 17 
patients were excluded from the reason of bilateral thracentesis and insuffi cient 
clinical data respectively. Remaining 27 cases were retrospectively reviewed 
retrospectively. Degree and type of atelectasis were assessed with computed 
tomography at one and two weeks after LDLT. Degree of atelectasis was 
expressed as the ratio between atelectatic area and whole lung area (A/WL 
ratio). Preoperative patient’s condition, graft status, intraoperative factors were 
analyzed as risk factors for atelectasis. Postoperative patient’s condition and 
clinical course were compared between the patients who treated with prone 
position therapy (treated group; n=9) and without (control group; n=18).
Result: All patients demonstrated various degree of dorsal atelectasis (27/27, 
100%). A/WL ratio was correlated with MELD score (r= 0.5456, p= 0.0022), 
Graft Volume/Standard Liver Volume ratio (r= -0.4003, p= 0.0314), length of 
ICU stay (r= 0.5496, p= 0.0020), and intubation period (r =0.3792, p= 0.0425). 
Although the A/WL ratio at 2 weeks after the operation was signifi cantly lower 
than that at 1 week after LDLT in both groups (treated group; p= 0.0001, control 
group; p= 0.0055), atelectasis was remarkably ameliorated in the treated group 
compared to the control group (p=0.0038). Further, the treated group showed 
better postoperative condition and clinical course.
Conclusion: These results suggest that dorsal atelectasis after LDLT increases 
duration of mechanical ventilation support and prolong ICU stay. Prone position 
therapy is effective for dorsal atelectasis, and prevents deleterious pulmonary 
complications after LDLT.
CT Control (n=18) Treated (n=9)
1w Post 14.37  ± 9.306 19.98  ± 8.457
2w Post 6.969  ± 9.418* 0.3167  ± 0.95
* #
1w Post – 2w Post 7.4  ± 9.878 19.66  ± 8.325##
Outcome
Walking independence (POD)
24.57  ± 11.73 15.00  ± 3.16
Hospital stay¦ ¦ days¦
51.60  ± 18.98 43.63  ± 15.74
incidence
Thoracentesis after 14POD 2 0
Re-intubation after 14POD 3 0
Pneumonia after 14POD 2 0
*:1w Post vs. 2w post, P ¦  0.01  #: Control vs. Treated, P < 0.05  ##: Control vs. Treated, P < 0.01
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PREGNANCY OUTCOME IN LIVER TRANSPLANT 2036 
RECIPIENTS AT THE UNIT OF LIVER TRANSPLANTATION – 
UNICAMP, BRAZIL
I. Boin2 , M.L. Costa1, F. Surita1, E. Udo2, M. Leonardi2, C. Portugal2, 
R. Stuchi2, 
1Centro de Atenção a Saude da Mulher – CAISM – Unicamp, 2Unit of Liver 
Transplantation – Unicamp
Context: Transplantation has become an available and successful treatment 
option for innumerous congenital and acquired hepatic disorders. Studies 
have shown that when the pregnancy recipient graft function is stable and 
adequate,the pregnancy is normally well tolerated with favorable newborn 
outcomes. However, there are reports of increased incidences of hypertension 
and preeclampsia as well as lower birth weights and prematurity. Patients 
who were administered with tacrolimus-based therapies seem to have lower 
incidence of these complications.
Case Reports: The fi ve patients aged from 19 to 37 years, had, at the time 
of conception, 2 to 9 years since transplantation. One preterm delivery, for 
fetal distress, was the most important complication in these patients. Were 
observed one episode of acute genital herpes infection, a liver hematoma in 
an anticoagulated patient with history of deep vein thrombosis and in another 
patient an urinary tract infection. Despite complications all fi ve pregnancies 
were succesfull. The mean gestational age at delivery was 37.7 weeks. No 
structural malformations or early complications were observed in the newborns. 
All cases showed stable liver parameters and the patients and babies have been 
relating well-being.
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THE RELEVANCE OF PCT AFTER LIVER 2037 
TRANSPLANTATION
V. Müller, T. Meyer, W. Hohenberger, M. Hoffmann
Chir.Uni Klinik Erlangen/Nürnberg
Introduction: Orthotopic liver transplantation (OLT) is a treatment for end 
stage liver disease. Shortage of available organs leads to the acceptance of 
marginal grafts and increases the risk of perioperative complications like acute 
rejection, infection and graft dysfunction. PCT was shown to be a reliable 
marker for complicated course after trauma and in the course of SIRS and 
sepsis. The aim of the study was to evaluate Procalcitonin (PCT) as an early 
prognostic marker for occurrence of complication in the postoperative course 
after OLT.
Methods: We included 32 patients who underwent 33 OLTs and analysed 
the levels of PCT and clinical and paraclinical data. The highest PCT was 
defi ned as peak- PCT. Patients were stratifi ed in a non-complication and a 
complication group. Renal replacement therapy, respiratory insuffi ciency, 
postoperative bleeding, refractory ascites and pleural effusion, rejection, sepsis 
and fatal outcome were defi ned as complication. A secondary stratifi cation was 
performed using a peak- PCT of 5ng/ml in each group. Then, we analysed 
the risk of occurrence of a complication according to a peak- PCT of 5ng/ml. 
Further we analysed the course of PCT after OLT in each group.
Results: The peak- PCT occurred between the fi rst and third postoperative day 
in 30 patients, followed by halvening every second day. Nevertheless, 3 of 
them died because of sepsis. A constantly rising PCT or a secondary rise was 
seen in 2 patients and associated with fatal outcome.18 patients were stratifi ed 
in the non- complication group, 8 with peak- PCT lower than 5ng/ml and 10 
higher. 14 patients with 15 transplantations were stratifi ed in the complication 
group, only 1 patient developed a peak- PCT below 5ng/ml. The odds ratio 
of running a complication was 11.2 (10.81 – 11.59; p<0,025) when the peak- 
PCT was higher than 5ng/ml. However, the course of mean PCT levels was 
signifi cant between the complication and non- complication group not before 
the 7th postoperative day.
Discussion: PCT is a reliable marker for SIRS and sepsis and rises with the 
severity of the disease and due to operative trauma. A decline was seen in 31 
cases, in 2 cases we observed a constantly rising level, and both patients had 
a fatal outcome. This observation was described before for non transplant 
patients. In transplant patients, an elevation of PCT was only seen in bacterial 
infections, but not in rejection or wound infection. We have seen a rise of PCT 
in respiratory failure and sepsis, but not in renal replacement therapy, ascites, 
pleural effusion, rejection or bleeding. An initial high PCT is described not to 
indicate a poor prognosis, and patients of the non-complication group also had 
levels exceeding 15ng/ml. The patients of the complication group had a higher 
mean PCT, which turned signifi cant not before the 7th day, most probably 
because of the high variation of levels. Still, a peak- PCT above 5ng/ml has an 
odds ratio of 11.2 for patients to experience a complication.
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REVERSAL OF SEVERE HYPOXEMIA IN 2038 
HEPATOPULMONARY SYNDROME BY CPAP AND NON 
INVASIVE POSITIVE PRESSURE VENTILATION
J.F. Goorhuis1, R. Scheenstra2, W. Dieperink3, M.J.I.J. Albers1
1Department of Pediatrics, Division of Pediatric Intensive Care, Beatrix 
Children’s Hospital, University Medical Center Groningen, University of 
Groningen. The Netherlands., 2Department of Pediatrics, Division of Pediatric 
Gastroenterology, Beatrix Children’s Hospital, University Medical Center 
Groningen, University of Groningen. The Netherlands., 3Department of Surgery, 
Division of Surgical Intensive Care, Surgical Intensive Care Unit, University 
Medical Center Groningen, University of Groningen. The Netherlands.
Introduction: Hepatopulmonary syndrome (HPS) is characterized by advanced 
liver disease and arterial hypoxemia in the presence of intrapulmonary shunting. 
The only reported curative option is orthotopic liver transplantation. Reversal 
of severe arterial hypoxemia offers a bridge to transplantation and ameliorates 
the perioperative phase. We describe two patients with severe hypoxemia in 
HPS who are treated with CPAP and non invasive positive pressure ventilation 
(NIPPV) with an improvement in oxygenation and respiratory symptoms. 
Case reports: The fi rst patient is a 14 year old girl with HPS because of liver cirrhosis 
due to primary sclerosing cholangitis. Despite continuous oxygen supplementation 
with a ventimask FiO2 60% her oxygen saturation remained around 80% and her 
exercise tolerance was minimal one month after liver transplantation. Introduction 
of CPAP 4 cm H2O FiO2 100% using a CPAP machine and later a light weight 
Boussignac CPAP device increased her arterial pO2/oxygen saturation from 5,8 
kPa/79% to 11,5 kPa/97%. After 4 weeks continuous CPAP she was weaned. Three 
months after liver transplantation she was discharged home with 1 L/min via a 
nasal cannula with oxygen saturations > 90%. 
The second patient is a 15 year old girl with HPS of liver cirrhosis due to 
cystic fi brosis. After extubation the fi rst day after liver transplantation she 
developed progressive respiratory distress with oxygen saturations between 
80- 85% with a ventimask of 60% (without CO2 retention). After introduction 
of NIPPV with FiO2 60% her oxygen saturation increased to 96% with relieve 
of respiratory symptoms. In two weeks NIPPV was weaned and one month 
after liver transplantation she could be discharged with oxygen saturation 96% 
without supplemental oxygen. 
Conclusions: CPAP and NIPPV can reverse severe hypoxemia in 
hepatopulmonary syndrome. When supplemental oxygen does not suffi ciently 
improve oxygenation in HPS CPAP and/or NIPPV therapy should be considered 
to bridge patients to recovery of HPS after liver transplantation.
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EFFICACY OF CARDIAC OUTPUT DETERMINATIONS 2039 
BY ECHO-ESOPHAGEAL DOPPLER IN LIVER TRANSPLANT 
PATIENTS WITH LOW MELD SCORE.
V. Perilli1, A.W. Avolio2, R. Caserta1, M.T. Cazzato1, N. Martella1, E. Nure2, S. 
Agnes2, L. Sollazzi1
1Dpt of Anaesthesiology, Catholic University of Rome, Rome, Italy, 2Dpt of 
Surgery – Transplantation Service, Catholic University of Rome, Rome, Italy
Objective: The aim of this study was to evaluate the suitability of a 
transesophageal echo-Doppler device (HemosonicTM – Arrow, Reading, 
PA) (ED) as a minimally invasive device for measurement of cardiac output 
in liver transplantation. This device was compared to standard pulmonary 
artery catheter (Opticath, Abbott, Illinois, USA) (PAC), taking into account the 
disease severity of liver candidate recipients as scored by the Model for End 
stage Liver Disease score (MELD).
Materials and methods: Forty two cirrhotic patients were enrolled. At standard 
times, three thermodilution cardiac output (COPAC) measurements were taken by 
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a pulmonary artery catheter, and the most recent ED measurement (COED) was 
also recorded. Paired measurements of CO were carried out at standard times, 
unless clinical needs. Recipients were stratifi ed in three groups according to 
chemical MELD score, and a low risk group (MELD score ≤15; 14 patients), 
an intermediate risk group (15< MELD score <29; 17 patients), and a high risk 
group (MELD score ≥29; 11 patients) were identifi ed. Statistical analysis was 
performed by Bland-Altman, analysis of variance and linear regression.
Results: Four hundred ninety fi ve paired measurements of CO were carried out. 
Echo Doppler signal detection was not optimal in 55 determinations (11.1%). 
These determinations have not been considered for the comparison. Mean bias 
was 0.34± 0,9 l min-1 and limits of agreement were –1.46 l/min-1 and 2.14 
l/min-1. Variations in COPAC correlated well with those measured using ED 
(p<0,01, R=0,79). Moreover, we observed a signifi cant correlation between 
COPAC and relative error between COED and COPAC (p<0.01, R=0.15). As for the 
three patient groups (table), the low risk group exhibited signifi cantly lower 
mean bias and relative error than the other two groups. In particular patients 
with MELD score under 16 exhibited a bias of 0.12 ± 0.55 (p<0.01). 
l min-1
MELD ≤15 MELD 16-28 MELD ≥29
COED l min-1 6.73 ± 2.04 8.5 ± 3.5 7.40 ± 1.77
COPAC l min-1 6.75 ±1.87 8.85± 3.5 7.67 ±1.56
Relative error% 1.66± 8.1 4.67 ± 11.3 * 4.41± 11.05 *
Bias l min-1 0.12 ±0.55 0.38 ±1.10 * 0.33± 0.84 *
p<0.05 compared to MELD ≤15 group 
Conclusions: Even if the trend of COED was comparable with COPAC and 
variations of COED fi tted well with changes of COPAC, ED is not interchangeable 
in all cases with PAC because of the large limits of agreement. However in 
cirrhotic patients with MELD score under 16 the precision of the new method 
is quite similar to that of PAC (12,7 vs 10%), and the mean bias is close to zero 
(0,12 l min-1); thus, in this subset of patients, it may represent a reliable less 
invasive alternative to PAC.
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MOLECULAR ADSORBENT RECIRCULATING SYSTEM 2040 
(MARS) IN PATIENTS WITH PRIMARY NON-FUNCTION AND 
OTHER CAUSES OF GRAFT DYSFUNCTION AFTER LIVER 
TRANSPLANTATION IN THE ERA OF EXTENDED CRITERIA 
DONORS ORGANS
R. Gaspari1, A.W. Avolio2, L. Zileri dal Verme3, S. Agnes2, V. Perilli1, 
R. Proietti1, A. Gasbarrini3
1Dpt of Anaesthesiology and Intensive Care, Catholic University of Rome, 
Rome, Italy, 2Dpt of Surgery – Transplantation Unit, Catholic University of 
Rome, Rome, Italy, 3Dpt of Medicine, Catholic University of Rome, Rome, Italy
Background and aims: Liver Dysfunction following liver transplantation 
(LTx) is an important cause of morbidity and mortality. It can present as 
Primary Non Function (PNF) or Graft Dysfunction (GD) and it’s prevalence 
is increasing because of the more frequent use of extended criteria donor 
organs. The Molecular Adsorbent Recirculating System (MARS) is an 
albumin-based dialysis system designed to enhance the excretory function 
of a failing liver. This study is to evaluate the potential role of MARS in 
this particular setting of patients. Primary end-point: six months survival.
Methods: All cases of Liver Dysfunction following LTx during the last 6 
years were referred to our Intensive Care Unit. Patients presenting with 
progressively increasing jaundice (serum bilirubin level >15 mg/dl), and 
hepatic encephalopathy and/or renal dysfunction were treated with MARS in 
addition to standard medical therapy and included in this retrospective study.
Results: Seven patients median age of 52 years, with primary non function 
(2 cases) and graft dysfunction (5 cases) after LTx, were included in 
the study. Five patients received a extended criteria donor organ. Six 
months overall survival was 57%; 4 cases of GD (1 re-LTx) were alive 
at the end of the follow up, 2 cases of PNF (1 re-LTx) and 1 case of GD 
died. After MARS therapy we observed reductions in serum bilirubin 
(40.0±11.3 vs 29.5±7.3 mg/dL), bile acids (131±73 vs 81±38 μmol/L), 
creatinine (2.2±1.2 vs 2.0±1.5 mg/dL), and ammonia levels (152±177 
vs 143±179 γ/dL). Differences were significant for bilirubin and bile 
acids (p<.05). Liver, neurological, renal, and hemodynamic functions 
did not improve in the 2 PNF patients. The liver synthetic function 
(prothrombin time and serum albumin level) was improved in 4 out of 
5 patients with GD, while all of them showed a significant improvement 
of HE grade (defined as a reduction by > 1 grade). In 2 patients suffering 
from intractable pruritus, the symptom was effectively treated by MARS 
therapy. In one patient pruritus disappeared completely after 5 MARS 
sessions (VAS decreased from 10 to 0), allowing the discontinuation of 
symptomatic therapy; in the other patient pruritus decreased, but did not 
disappear (VAS from decreased from 10 to 4-5). In all patients, MARS 
therapy was well tolerated, and no MARS-related adverse event occurred. 
Conclusions: MARS therapy is a promising and safe therapeutic option to 
treat severe GD after LTx.
N (yrs) Causes Donor MELD SAPS 
II 
a.
SOFA 
Δt &
(days)
# 
MARS
Graft
recovery
Outcome
6 months
1 28 b. Sepsis Standard* c 38 47 11 9 1 a No b
Died
2 52 Chronic 
Rejction
ECDg 21 49 10 180 5 Yes Alive
3 59 PNF^ ECDg 32 66 15 2 7 No Died
4 50 i. Liver
hypoper-
fusion 
(shock)
ECDg 15 30 9 13 2 Yes Alive
5 58 a  Liver
abscesses
ECDg 28 44 9 50 5 No 
(re-LTx)
Alive
6 55 PNF ECDg 12 55 15 3 2 No 
(re-LTx)
Died
7 50 Hemolysis Standard 23 53 17 5 6 Yes Alive
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LEVEL OF ANXIETY DE LIVER PRE-2041 
TRANSPLANTATIONS RECIPIENTS
I. Boin, G. Santos, I. Pereira, C. Portugal, E. Udo, M. Leonardi, R. Stucchi
Unit of Liver Transplantation – Unicamp
Liver transplantation is a treatment for end-stage liver disease and represents an 
important cause of fellings for the patients.
Objective: To evaluate anxiety level of pre-transplant recipients who are in 
waiting list to liver transplant.
Methods: Thirty fi ve adult patients were following at the Unit of Liver 
Transplantation and Psychology team of Gastrocentro – HC-Unicamp, all of 
them in waiting list to liver transplantation. All of them were submitted to 
query to psychological evaluation by the Inventory of Beck.
Results: The group had 31(88.6%) men and 4(11.4%) women, average of 40.28 
years-old, MELD score value was 17. Of them, 18(51.4%) had imcomplete 
middle school, 7(20%)had superior level and the others had complete high 
school. After querying we observed that 29(54.3%) patients had light level of 
anxiety, 14(40%) had moderate level and 2(5.7%)had severe. 
Conclusion: These results have demonstrated the importance of a psychological 
team in the liver transplantation unit to command the patients and the families 
to obtain good results after surgery and the well-being of the patients.
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INFLUENCE OF MARGINAL ORGANS ON BILIARY 2042 
COMPLICATIONS AFTER LIVER TRANSPLANTATION
M. Loss1, K. Mantouvalou1, J. Rochon2, T.Y. Tsui1, A. Obed1, H.J. Schlitt1
1Departments of Surgery, University of Regensburg Medical Center, Germany, 
2Center for Clinical Studies, University of Regensburg, Germany
Introduction: Biliary complications are a signifi cant cause of morbidity, 
graft loss and mortality after orthotopic liver transplantation (OLT). The 
reported incidence of biliary complications varies substantially between 
centers (6%-40%). Due to organ shortage, marginal donors are increasingly 
used in OLT. In our center, we observed a rise in the number of major biliary 
complications over the last years. We speculated this effect may be attributable 
to the increasing use of extended donor criteria (EDC) organs. Thus, the 
objective of this study was to evaluate the incidence of biliary complications in 
a contemporary series and to study potential donor and recipient risk factors as 
well as the infl uence of marginal donor organs.
Patients And Methods: We retrospectively analyzed 115 whole organ OLT 
performed between 01/2004 and 06/2007. Patients were divided into three 
groups: no biliary complications, minor complications (anastomotic strictures, 
leakages and other complications which could be managed interventionally 
by <5 procedures), and major complications (>5 interventions, reoperation 
or retransplantation necessary) Different donor and recipient factors were 
evaluated and correlated to biliary problems. 
Results: The overall incidence of biliary complications was 41.7% (8.7% minor, 
33.0% major complications). 77/115 (67%) donor organs were classifi ed as 
EDC organs. High donor age and high donor BMI were statistically signifi cant 
risk factors for major biliary complications. However, the frequency of major 
biliary complications was not higher in EDC organs. When regarding follow-
up, minor complications did not seem to have an impact on overall outcome, 
whereas major complications increased morbidity and even mortality.
Conclusion: We here report a high incidence of biliary complications in a 
contemporary series after OLT. There is currently no international consensus as 
to what criteria defi ne “marginal organs”. Our results suggest that some donor 
characteristics are related to a higher rate of biliary complications and mortality, 
whereas other aspects linked to the defi nition of marginal organs do not seem 
to have an effect on biliary complications. Prospective studies are needed in 
order to identify signifi cant risk factors for major biliary complications, thus 
allowing for a better assessment of organ quality and improving long term 
outcome after OLT.
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SEXUAL DYSFUNCTION (SD) AND QUALITY OF LIFE 2043 
(QOL) AFTER LIVER TRANSPLANTATION (LT) IN MALE 
RECIPIENTS
P. Burra1, A. Masier1, A. Salonia2, G. Germani1, M. Gambato1, E. De Martin1, 
M. Senzolo1, F.P. Russo1, G. Zanus3, 
1Gastroenterology, Department of Surgical And Gastroenterological 
Sciences, University of Padua, Italy, 2Department of Urology, University 
Vita-Salute San Raffaele, Milan, Italy, 3Surgery, Department of Surgical and 
Gastroenterological Sciences, University of Padua, Italy
Background and aim: Sexual dysfunction is highly prevalent in men with 
liver cirrhosis and it remain highly prevalent after LT. The aim of our study 
was to determine the prevalence of sexual dysfunction in men after LT and its 
relationship with QoL. 
Methods: 44 male liver transplanted patients (mean age 56.3±3yrs) were 
enrolled. Sexual hormones (17&#61538;-estradiol, PRL, thyroid hormones, 
testosterone total and free, &#61508;4, DEAS, SHBG, 17-OH progesteron) 
were assessed in all patients. Three validated questionnaires [International 
Index Erectile Function (IIEF), Beck Depression Inventory (BDI), SF36 (for 
determination of QoL) were used. Statistical analysis: Student’s t test, data 
expressed by mean±SE.
Results: Etiology of liver disease was alcohol related in 17/44 and non-alcohol 
related in the remaining 27 patients. The hormone status in transplanted 
patients – compared to normal values – was: low DHEAS (1,6±0,5 umol/L), 
high 17&#61538;-estradiol (141,9±18,8 pmol/L). Sexual dysfunction was not 
associated with sexual hormones and etiology of liver disease. 7/44 (16%) patients 
reported mild or moderate depression. 29/37 (78%) of transplanted patients 
reported mild or moderate erectile dysfunctions (ED). No difference in age was 
seen in transplanted patients with or without ED but ED was worse in depressed 
vs non depressed transplanted patients (p<0.05). The SF36 total, Mental health 
and, among variables of SF36, Role emotional, Social function and Role-physical 
have a better score in patients without ED vs patients with ED (p<0.05). No 
difference in IIEF, ED, BDI and sexual hormone levels was observed between 28 
patients on tacrolimus confronted to 16 patients on cyclosporine. 
Conclusion: Sexual dysfunction, highly prevalent in liver transplanted patients 
is not associated with age and hormone status. However, it is associated with 
depression and consequently with impaired Qol. Prognosis of psycological 
support are badly needed.
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THERAPEUTIC DRUG MONITORING OF LIVER 2044 
TRANSPLANT PATIENTS RECEIVING EVEROLIMUS 
THERAPY BY FPIA
T. Jones1, B. Ulbricht2, M. Van der Linden3, P. de Simone4, P. Marbach2, 
L. Arabshahi1
1Thermo Fisher Scientifi c Inc., 2Novartis Pharma AG, 3Eurofi ns Medinet B.V., 
4Cisanello Hospital
Everolimus is a macrolide immunosuppressant derived by chemical modifi cation 
of the natural product rapamycin; rapamycin is produced by certain strains of 
Streptomyces hygroscopicus. The mechanism of action of everolimus consists 
of binding to the mammalian target of rapamycin (mTOR).. As the result 
everolimus is routinely used in combination with calcineurin inhibitors due to 
synergistic mechanism of action. The clinical use of everolimus/cyclosporine 
A (CsA) regimens requires blood concentration-guide dosing. The preferred 
matrix is whole blood because at therapeutic concentrations both compounds 
are predominately partitioned into membranes of erythrocytes. Liquid 
chromatography alone as well as coupled to mass spectrometry (LC/MS and 
LC/MS/MS), and fl uorescent polarization immunoassay (FPIA) have been 
used to measure concentration of everolimus in blood. 
The Innofl uor® Certican® Immunoassay System is a homogeneous fl uorescence 
polarization immunoassay used for the analysis of everolimus in whole blood 
samples. This assay has previously been validated for kidney and heart samples. 
The Innofl uor Certican Immunoassay system has been developed for use on an 
FPIA analyzer. 
Using Innofl uor Certican value assigned calibrators with the following 
target values 0, 2.5, 5.0, 10.0, 20.0, 40.0 ng/mL, a 6-point calibration curve 
is generated that is stable for at least 2 weeks. Control recovery over the 
course of the 3 month study for control level 1 (3.92 ng/mL), 2 (10.76 ng/
mL) and 3 (22.04 ng/mL) was 12, 8 and 6% CV respectively. One hundred 
and fi fty liver transplant patient samples consisting of EDTA anticoagulated 
whole blood ranging from 0 ng/mL to 16 ng/mL were tested. Results from 
the immunoassay on the FPIA system were compared with LCMS/MS data 
collected at a reference lab and resulted in a slope by Passing-Bablock 
analysis of 1.18, y-intercept of -0.29, and correlation coeffi cient 0.94. The 
immunoassay has an analytical sensitivity of 2.0 ng/mL and a functional 
sensitivity of 0.8 ng/mL. This study suggests that the Innofl uor Certican 
assay is suitable for the therapeutic drug monitoring of everolimus in liver 
transplant patients.
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LONG-TERM SURVIVAL BENEFIT IN RELATION TO 2045 
MELD CLASS CATEGORIZATION. A SINGLE INSTITUTION 
INTENTION TO TREAT ANALYSIS OF WAIT LISTING FOR 
LIVER TRANSPLANTATION.
A.W. Avolio1, M. Siciliano2, G.L. Caracciolo2, R. Barbarino1, R. Gaspari3, 
F. Frongillo1, A. Gasbarrini2, S. Agnes1
1Catholic University of Rome, Dpt of Surgery – Transplantation Service, 
2Catholic University of Rome, Dpt of Internal Medicine, 3Catholic University 
of Rome, Dpt of Anaesthesiology
Background: Survival benefi t (SB) has been designed to compare, among 
patients on the waiting list, survival of those who are transplanted to survival 
of patient who are not transplanted. As yet, SB has been evaluated only at 12 
and 36 months. 
Patients and methods: From Jannuary 2002 to December 2007, 171 
consecutive cirrhotic patients were candidates to liver transplantation at 
Catholic University of Rome, Italy. In all patients biochemical MELD score 
was calculated according to standard original formula. No correction for co-
existence of hepatocarcinoma was utilized. Patients included on the waiting 
list were retrospectively stratifi ed and arbitrarily classifi ed into 4 Intention-to-
Treat (ITT) classes according to the MELD score. Classes were MELD 6-14 
(N=85), MELD 15-18 (N=41), MELD 19-25 (N=30), MELD 26-40 (N=15). 
Patients were retrospectively stratifi ed into 2 subgroups according to stay on 
the Waiting List (LWL) or to be transplanted (LTx). 
Results: Of the 171 patients listed, 110 patients were transplanted (64%). 
The overall ITT patient survival at 12, 24, 36, 48, 60 months was 76%, 72%, 
66%, 61% and 61% respectively. The patient survival for the LWL subset at 
12, 24, 36, 48, 60 months was 66%, 58%, 47%, 34% and 34% respectively. 
The patient survival for the LTx subset was 82%, 79%, 73%, 73% and 73% 
respectively. Differences were signifi cant (log rank, p<0.01). Medium term 
(30 months) survivals range from 87% in the MELD class 6-11 to 36% in the 
MELD class 26-40. Long term (60 months) survival are similar for patients 
in the MELD classes 6-14, 15-18, and 19-25 ranging between 61% and 69%, 
while for patients in the MELD class 26-40 remains 36%. Differences between 
survival curves are signifi cant (p<0.05 to p<0.001). For each MELD class the 
outcomes of staying on the list or being transplanted is shown on fi gure. The 
differences in terms of survival benefi t is represented by the distance between 
curves. Considering survival benefi t a dynamic process, a change over time 
was observed in the different MELD classes after listing. Patients in the MELD 
class 6-14 show a SB of waiting list for the fi rst 36 month of follow up. Patients 
in the MELD class 15-18, show a SB of waiting list for the fi rst 6 months of 
follow up. There is any benefi t of waiting list for the MELD class 19-25 and for 
the MELD class 26-40 (log rank, p<0.001).
Conclusions: In summary, we demonstrated that in our series all listed patients 
present SB. SB appears late for low MELD classes than for high MELD classes 
but is always present.
POSTER BOARD NUMBER P4 – 96
ALBUMIN DIALYSIS SYSTEM PROMETHEUS (FPSA) AS 2046 
SUPPORT TREATMENT BEFORE LIVER TRANSPLANTATION 
IN PATIENTS WITH WILSON’S DISEASE.
M. Kotulski, K. Zieniewicz, M. Grodzicki, A. Mackiewicz, M. Krawczyk
Department of General, Transplant and Liver Surgery, Medical University of 
Warsa
Introduction: Wilson’s disease (Wd), also called hepatolenticular degeneration, 
is an inherited disorder of copper metabolism, which, in consequence, leads 
to its accumulation in the liver and/or brain (among other) causing damage to 
those organs. There might be several forms of liver damage in the course of the 
disease: acute or chronic liver failure and acute or chronic liver infl ammation.
Aim: The purpose of this study was to compare and evaluate the effi ciency 
of the Wd treatment, when either liver transplantation (OLTx) and/or albumin 
dialysis system Prometheus (FPSA) were employed.
Material & Method: The research is based on the data provided by the 
Department of General, Transplantation and Liver Surgery, Medical University 
of Warsaw, 1996-2007. Case histories of 33 patients (26 women and 7 men) 
with Wd, aged 33±9, who were treated in the Department either by OLTx and/
or FPSA, were analysed in a retrospective study. All patients in the examined 
group were qualifi ed for OLTx. 11 patients had periodically decompensed 
chronic liver failure (CLF) – UNOS 3, and 22 patients suffered from acute on 
chronic liver failure (AoCLF) – UNOS 1 and 2A.
Results: 11 patients with Wd in the form of CLF didn’t need FPSA treatment 
before transplantation; no deaths occurred in this group after the OLTx was 
employed (observation period: 120-20m). There were 5 transplantations before 
FPSA treatment was introduced in the group of patients with acute liver failure 
in the course of Wd; 4 patients died during the early postoperative period. 6 
patients with AoCLF UNOS 1/2A underwent FPSA treatment. However, due to 
the lack of organs, there was no transplantation. All those patients died. In the 
group of 8 patients who underwent OLTx after the preparation/the prolonging 
of possible time of anticipation of organ donation by FPSA treatment, 5 patients 
survived. Other 3 patients with AoCLF underwent OLTx without previous 
FPSA because the organ for transplantation was available within 24 hours after 
the urgent organ recipient was registered at Euro/Poltransplant.
Conclusion: The only effi cient treatment for a advanced liver form of the 
Wilson’s disease is the liver transplantation. The albumin dialysis system 
Prometheus (FPSA) is an effi cient and safe form of bridge treatment before the 
organ transplantation.
POSTER BOARD NUMBER P4 – 97
MULTIPLE LIVER RETRANSPLANTATIONS FOR 2047 
RECURRING HEPATIC GRAFT FAILURE
E. Akpinar1, R. Zamora1, T. Kato1, S. Nishida1, D. Levi1, J.G. Moon1, 
G. Selvaggi1, E. Prietto2, L. Arosemana3, A. Tzakis1
1Miami Transplant Institute, Univ of Miami, Liver-GI Transplantation, 
Miami-FL, USA, 2Dept of Anestesiology, Univ of Miami, Miami-FL, USA, 
3Dept of Hepatology, Univ of Miami, Miami-FL, USA
Background: Multiple liver retransplantation (RE-LT) for recurring 
irreversible acute or chronic liver allograft failure has not been addressed in 
the literature. Here we present our patients who received multiple RE-LTs. 
Graft# TX1 TX2 TX3 TX4 TX5
ADULT (n=2066) 1808 229 (13%) 25 (1.5%) 4 (0.2%) -
PEDIATRIC (n=305) 257 37 (14%) 8 (3%) 2 (0.8%) 1 (0.05%)
Material and Methods: A retrospective analysis was performed on patients 
who received liver transplantation in our institution. Demographics, primary 
diagnoses, indications for RE-LT, perioperative technical problems, hospital 
stay (LOS), immunosuppressive regimens, and survival data were analyzed 
and compared between patients who received fi rst (TX1), second (TX2), 
third (TX3), fourth (TX4) and fi fth (TX5) liver transplants. Non-parametric 
methods were used for statistical comparisons, Kaplan-Meier method was 
used for survival analysis and p<0.05 was considered signifi cant. Results: A 
total of 1808 adult pts received 2065 and 257 pediatric pts received 306 liver 
allografts respectively between March-1987 and July-2007 (see Table). RE-LT 
indications in adults for TX2, TX3 and TX4 were primary non-function (PNF) 
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(25%, 36% and 25%), arterial thrombosis (HAT) (21%, 14% and 0%), chronic 
rejection (CR) (21%, 14% and 25%), recurrent disease (RD) (12%, 20% and 
0%), biliary complication (BC) (4%, 0%, and 0%) and portal vein thrombosis 
(PVT) (3%, 0% and 0%) respectively.In pediatric patients, the indications for 
RE-LT were PNF (29%, 29% and 0%), HAT (42%, 29% and 50%), CR (21%, 
0% and 50%), RD (21%, 0% and 0%) and PVT (3%, 0% and 0%) for TX2, TX3 
and TX4 respectively. Mass clamping was used for allograft hepatectomy in 
the majority of patients. The mortality rate before discharge, LOS and survival 
rates were not signifi cantly different after TX2, TX3 and TX4 in pediatric 
and in adult groups respectively. Cox proportional hazard model analysis of 
survival predictors in adult RE-LT population showed that HCV+ and LOS>25 
days were signifi cant risk factors predicting graft survival. Only LOS>10 days 
was found to be a predictor risk factor for pediatric RE-LT patients. 
Conclusion: In carefully selected patients, multiple RE-LT can be life saving 
procedure and it can confer survival comparable to survival after fi rst RE-LT.
POSTER BOARD NUMBER P4 – 98
LIVER TRANSPLANTATION IN A PEDIATRIC PATIENT 2048 
WITH BILIARY ATRESIA AND POLYSPLENIA SYNDROME: A 
CASE REPORT
G-S. Choi, H-J. Park, K. Jung, J. Chun, G-O. Jung, J-M. Kim, S-J. Kim, 
J-W. Joh, S-K. Lee
Samsung Medical Center, Seoul, Korea
Background: Biliary atresia (BA) is the most common disease for which liver 
transplantation (LT) is done among pediatric patients, and, in 9-37% of cases, 
it is accompanied by another congenital anomaly. Polysplenia syndrome (PS) 
is the most common congenital anomaly occurring among patients with BA, 
and is a syndrome which consists of polysplenism, midgut malrotation, situs 
inversus, preduodenal portal vein, interrupted or absent infrahepatic vena cava 
with azygous or hemiazygous continuation, anomalous hepatic arterial supply, 
symmetric or isomeric liver, and bilobed right lung or pulmonary levoisomerism. 
The authors report a case of living donor liver transplantation (LDLT) in a 
patient with BA and PS. Case: A 5 year 11 months old boy was referred to 
the clinic for digital clubbing. He had received Kasai portoenterostomy at 2 
months for BA at another hospital. Hepatopulmonary syndrome was diagnosed 
and elective LDLT with left lateral lobe from his older sister was planned 
and undertaken. Intraoperative fi ndings showed splenomegaly along with 
polysplenia, symmetric liver, intestinal malrotation and preduodenal portal 
vein. An interrupted inferior vena cava was observed with collateral fl ow into 
the azygous vein, so the donor hepatic vein was anastomosed with the recipient 
azygous vein. The boy recovered well from the surgery and all the vessels 
showed good patency on Doppler ultrasonography. Postoperative computed 
tomography scan and Diisopropyl-iminodiacetic acid (DISIDA) scan showed 
no abnormal fi ndings and the boy was discharge in good condition on the 17th 
postoperative day. In a patient with biliary atresia and polysplenia syndorme, 
living donor liver transplantation is a safe and acceptable treatment.
POSTER BOARD NUMBER P4 – 99
COMPARABLE LIVER ALLOGRAFT SURVIVAL WITH 2049 
RIGHT LOBE SPLIT VESUS WHOLE LIVER ALLOGRAFTS IN 
ADULT RECIPIENTS
D. Verran, C. Sandroussi, . Lockwood, J. Gallagher, P. Tang, N. Shackel, 
H. Pleass, S. Strasser, M. Crawford, G. McCaughan
Australian National Liver Transplantation Unit
Comparable Liver Allograft Survival with Right Lobe Split versus Whole Liver 
Allografts in Adult Recipients
Introduction: Split liver transplantation has not been widely adopted 
internationally partly due to concerns of inferior allograft outcomes in adult 
recipients. The aim was to review our units short and longer term recipient and 
graft outcomes undertaking split liver transplantation as a means of expanding 
our static deceased donor liver allograft pool.
Methods: Retrospective analysis of outcome data on all adults who underwent isolated 
liver transplantation from 7/2002-3/2007 with a minimum recipient follow up of 6 
months. Data was obtained from the unit database/ Statistics were by Stata version 8.
Results: 43/225(19%) of transplants were with right lobe splits (RLS) versus 
182(81%) whole grafts (W). The median donor age was 39(13-61) years for RLS 
versus 47(12-79) years for W [p< 0.000]. Of the RLS donors 1/43(2.3%) were 
aged > 60 years versus 41/182(22.5%) of the W donors [p<0.00]. Only 3% of the 
RLS had > mild steatosis versus 8.4% of the W [p<0.2]. The median recipient age 
was similar at 51.9(17.2-69.3) years for W and 53.05(16.6-66.6) years for RLS 
[p<0.56]. The median MELD score was higher at 18(6-50) for W recipients versus 
13(7-23) for RLS [p<0.00]. More recipients were transplanted for hepatocellular 
carcinoma (25.6%) and primary sclerosing cholangitis (23.6%) with RLS versus 
12% and 7.7% respectively with W [p<0.05]. Overall actuarial 5 year graft survival 
was 88.4% for RLS versus 78.5% for W [p<0.3]. The retransplantation rate was 
1/43(2.3%) for RLS [hepatic artery thrombosis (HAT)] versus 9/182(4.9%) for 
W [HAT 4, primary non function 3, intrahepatic biliary stricturing 2]. There was 
no primary non function with RLS. Mortality rate was 3/43(6.9%) with RLS 
[haemorrhage 1, disease recurrence 1, sepsis 1], versus 25/182(13.7%) with W 
[disease recurrence 6, rejection 4, sepsis 4, cardiovascular disease 4, other 6].
Conclusions: Good short and long term outcomes are achievable with RLS 
versus W allografts. Application of selection criteria to both donors and 
recipients may contribute to these results with RLS allowing expansion of the 
limited deceased donor pool.
POSTER BOARD NUMBER P4 – 100
SECOND LIVER RETRANSPLANTATION: INDICATIONS 2050 
AND OUTCOME
A. Pascher, F. Ulrich, S. Kohler, S. Weiss, G. Puhl, O. Guckelberger, 
U. Neumann, P. Neuhaus, J. Pratschke
Dept. of Visceral and Transplant Surgery, Charité, Campus Virchow
Although the outcome of liver retransplantation (re-LT) is still limited, it is 
the only available therapy option for irreversible liver graft dysfunction. The 
purpose ofthis study was to evaluate the role of second re-LT and to analyze 
indications, outcome and specifi c problems.
Methods: Between 1989 and 2007, we performed 1912 (88,8%) LTs, 217 (10%) 
re-LTs and 25 second re-LTs (1,2%) in 1924 patients. Patients were analyzed 
for demographic and clinical variables, indication for re-LT, postoperative 
complications and treatment outcome. Statistical analysis was performed with 
ANOVA or Mann-Whitney U test, Kaplan Meier curves and log-rank test.
Results: The main indications for a second re-LT were thrombosis of the 
hepatic artery (24%), initial nonfunction (20%) and acute or chronic rejection 
(20%). The second re-LT was performed after a median period of 70 (2-5320) 
days and the mean age of the recipients was 41,5±10,1 years. There was no 
signifi cant difference concerning mean operation time or course of serum 
aspartate aminotransferase (AST). Merely serum alkaline phosphatase (AP) 
was signifi cantly higher 6 months after second re-LT. The main causes of death 
were cardiopulmonary complications (26,7%) as well as multiorgan failure and 
bleeding complications (13,3% each). Overall, 15 out of 25 patients (60%) died 
after second re-LT. Patient survival after second re-LT was 62% after 1 year, 
53% after 5 years and 46% after 10 years. In comparison to the patient survival 
of primary LT or fi rst re-LT, these inferior results differ signifi cantly.
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ARTIFICIAL LIVER SUPPORT SYSTEM USING HUGE 2051 
BUFFER VOLUMES REMOVES SIGNIFICANT GLUTAMINE 
FROM PATIENT PLASMA WHICH IS A IDEAL BRIDGE FOR 
LIVER TRANSPLANTATION
K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Background and aims: Bleeding tendency and brain edema are two major 
life-threatening symptoms of fulminant hepatic failure (FHF). Artifi cial liver 
support (ALS) systems should effectively treat these symptoms. Plasma 
exchange has been the prevailing method used in Japan. Although able to 
supply depleted coagulation factors, plasma exchange shows limited effi cacy 
for removing toxic substances with a large body pool such as glutamine. In vitro 
studies showed that mitochondrial function is compromised by accumulated 
glutamine, considered to mediate brain edema. We have developed a new ALS 
system that combines plasma exchange and hemodiafi ltration (HDF), and 
report here its effect on various patient symptoms and its capacity to remove 
glutamine. 
Methods: Fifty-two patients with FHF and 16 patients with severe 
acute exacerbation of chronic hepatitis B underwent plasma exchange in 
combination with HDF from 1998 to 2006. The plasma exchange used 40-60 
units of fresh frozen plasma, and HDF was carried out by conventional or 
online route using polysulphone membrane. The total buffer volume used in 
one session was 370-510 l. FHF symptoms were evaluated and the levels of 
glutamine in patient plasma and in discarded buffer were assayed using an 
automatic analyzer.
Results: Of the 68 patients who underwent combined plasma exchange/HDF, 
62 (91.2%) fully regained consciousness from their initial coma and 45 (66%) 
patients survived. Brain edema was observed in 2 patients who fell into grade 
IV coma before admission, and hepatorenal syndrome was observed in 2 
patients. One session of ALS decreased the plasma glutamine level by 40-60%, 
which represents a distribution volume of removed glutamine per HDF session 
of 30-60 l of plasma equivalent.
Conclusions: Plasma exchange in combination with HDF showed good clinical 
effects and effective removal of plasma glutamine. This ALS system appears 
promising for purifying the blood of patients with FHF. It is an ideal bridging 
therapy for liver transplantation
POSTER BOARD NUMBER P4 – 102
EFFECTIVE ARTIFICIAL LIVER SUPPORT SYSTEM 2052 
ENABLE US TO DO I LIVER TRANSPLANTATION IN 
PATIENTS WITH AHEPATIC STATE
K. Inoue, M. Yoshiba
Showa University Fujigaoka Hospital Division of Gastroenterology
Purpose: Fulminant hepatic failure is a fatal disease and its clinical course 
is variable. It is classifi ed into acute form and subacute form in Japan. Acute 
form carries favorable prognosis, however, some patients rapidly fall into an 
ahepatic state. To avoid unnecessary liver transplantation and to perform it 
safely in ahepatic patients, the establishment of a safe and effective artifi cial 
liver support system is indispensable. 
Method: The present study included four patients with fulminant hepatic 
failure. Cause of FHF was acute infection with HBV. They fell rapidly into 
an ahepatic state. We developed the artifi cial liver support system consists of 
plasma exchange in combination with hemodiafi ltration using polysulfone high 
performance membrane.
Results: All patients were diagnosed as suffering from the acute form of FHF 
due to acute HBV infection. The patients were placed on the ALS system 
immediately after their referral to ensure timely bridging to liver transplantation. 
One patient underwent living donor liver transplantation four days after the 
onset of hepatitis. No donor organ could be found for the remaining patients 
who were therefore continued on ALS for more than 2 weeks. We could 
maintain these patients by ALS treatment without any severe complications 
for the period.
Conclusion: Safe and effective ALS treatment can have suffi cient capacity 
to sustain patients through an ahepatic state and is valuable for identifying 
patients who really do need liver transplantation. 
POSTER BOARD NUMBER P4 – 103
DOES A POSITIVE CROSSMATCH AFFECT OUTCOMES 2053 
FOLLOWING LIVER TRANSPLANTATION?
S. Asthana, C. Toso, G. Meeberg, T. Kawahara, D. Bigam, J. Shapiro, 
P. Campbell, N. Kneteman
Multiorgan Transplant Unit, University of Alberta Hospital
Background: The impact of a positive crossmatch in liver transplantation 
remains controversial, with some studies reporting higher rejection rates 
(Posner et al, 1996) and worse outcomes in such patients. However, LT has 
a protective effect on other organs in multiorgan transplant recipients. The 
purpose of this study was to determine what impact a pretransplant crossmatch 
had upon the clinical outcome following liver transplantation.
Patients and methods: Preoperative crossmatch status was determined 
prospectively in 396 consecutive adult liver transplants performed between 
January 2000 and December 2006. Data was collected on demographic 
variables, as well as on pretransplant crossmatch results. The outcome variables 
studied included the number and intensity of rejection episodes, as well as the 
graft and patient survival. Chi-square tests and Mann-Whitney ‘u’ tests were 
used for categorical and continuous data, while Kaplan-Meier curves were used 
for survival outcomes.
Results: Data on 396 adult LT recipients was collected, of whom 252 (65.3%) 
were male. The median follow-up for the cohort was 36.3 months (range 
1-96 months). Twenty-nine patients (7.2%) had a positive T-cell cross match, 
while 23 patients had PRA >15%. There was no difference in rejection rates in 
the two groups, but rejection occurred earlier in patients with high PRA (1.7 
months vs 6.9 months, p<0.001). Crossmatch status did not impact patient or 
graft survival (p=0.24). 
Conclusion: The presence of cytotoxic antibodies pretransplantation is 
associated with increased early rejection. However, the presence of cytotoxic 
antibodies is not deleterious to patient or liver allograft survival
POSTER BOARD NUMBER P4 – 104
TREATMENT WITH THE ANTI-COMPLIMENT C5 2054 
ANTIBODY ECULIZUMAB ALLOWS FOR SUCCESSFUL 
LIVER TRANSPLANT IN A PATIENT WITH BUDD CHIARI 
SYNDROME SECONDARY TO PAROXYSMAL NOCTURNAL 
HEMOGLOBINURIA
J. Locke, A. Singer, J. Hamilton, Z. Stewart, P. Thuluvath, W. Maley, 
R. Brodsky, A. Cameron
The Johns Hopkins Hospital
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare cause 
of hepatic venous outfl ow thrombosis, Budd-Chiari syndrome (BCS), 
and subsequent liver failure. PNH is a uncommon, acquired hemolytic 
anemia resulting from clonal expansion of hematopoietic stem cells 
having undergone somatic mutations in the phosphatidylinositol glycan-
complementation class A (PIG-A) gene. PIG-A is necessary for the synthesis 
of glycosylphosphatidylinositol (GPI) that anchors a variety of proteins 
to the cell surface including CD59, a key complement regulatory protein. 
Affected red blood cells undergo complement-mediated lysis with resultant 
anemia, hemoglobinuria and commonly venous thromboses. The rare reports 
of outcomes in patients undergoing liver transplant for BCS secondary to 
PNH detail instances of recurrent BCS as well as early portal vein occlusion 
and hepatic artery thrombosis requiring retransplantation. Therefore, most 
regard PNH as a contraindication to liver transplantation. Here we present 
the fi rst case report of a patient with BCS resulting from PNH treated with 
Eculizumab, a humanized monoclonal antibody that blocks the activation of 
terminal complement at C5, and subsequently undergoing successful liver 
transplantation.
Case Report: In 1992, a healthy 17 year old male patient was diagnosed with 
PNH having developed severe hemoglobinuria associated with fl ank pain, 
nausea with emesis, and signifi cant anemia and thrombocytopenia. Over the 
next twelve years his disease remained relatively stable with only occasional 
bouts of PNH crisis. In 2004, he developed persistent right upper quadrant 
pain and weight loss and imaging revealed splenic vein thrombosis, marked 
splenomegaly and gastric varices, and portal vein occlusion with cavernous 
transformation. Despite therapeutic anticoagulation with Warfarin (INR 2-3), 
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in 2006 he developed BCS with hepatomegaly, caudate hypertrophy, and 
worsening ascites. With progressive liver failure his renal function deteriorated 
to the point that he required dialysis. When evaluated for liver transplant, his 
candidacy was predicated on his ability to receive Eculizumab under FDA 
compassionate use and a favorable response to treatment. In December 2006, 
he began weekly infusions of Eculizumab. He showed reduction in hemolysis 
as measured by lactate dehydrogenase (LDH) levels and had decreased 
transfusion requirements. After the fi rst month of treatment, doses were given 
twice monthly. On February 7, 2007, a high quality organ became available 
from a 55-year-old brain dead donor and our recipient underwent a classic 
orthotopic liver transplant. Given his portal vein thrombosis, an SMV jump 
graft with donor iliac vein was required. His post-operative hospital course 
was unremarkable and he was discharged on POD#9. He has continued 
maintenance Eculizumab therapy and, more than a year since transplant, has 
stable graft function, no radiographic evidence of thrombotic recurrence, has 
had no hospital readmissions, and has returned to work as an accountant.
Conclusion: Outcomes for liver transplant for BCS caused by PNH historically 
have been dismal due to recurrent thrombotic complications. With use of 
the anti-complement antibody Eculizumab, such thrombotic pitfalls have 
been avoided and the fi rst successful liver transplant without subsequent 
complications in the setting of PNH has been possible.
POSTER BOARD NUMBER P4 – 105
LIVER TRANSPLANTATION IN PATIENTS WITH LIFE 2055 
SUPPORT: SIGNIFICANT PROGNOSTIC IMPROVEMENT 
ACHIEVED IN THE PAST DECADE
E. Akpinar, E. Palaois, J. Montes de Oca, T. Kato, S. Nishida, D. Levi, 
J. Moon, G. Selvaggi, E. Island, A. Tzakis
Miami Transplant Institute, Liver-GI Transplantation, Miami-FL, USA
Background: Liver transplantation (LT) in patients who need life support in 
intensive care (ICU) was reported to have worse outcome compared to the rest 
of patients. Here we review two decades of liver transplant experience in ICU 
patients from one institution.
Material and Methods: A retrospective analysis was performed on patients 
who received LT in our institution between 1994 and 2007. Pts were divided 
into two groups: pts who were transplanted in the period of 1994-2000 
(OLD) and pts who were transplanted in the period of 2001-2007 (NEW). 
Demographics, primary diagnoses, laboratory tests, posttransplant hospital stay 
(LOS), and survival data were analyzed and compared between two groups. 
Non-parametric methods were used for statistical comparisons, Kaplan-Meier 
method was used for survival analysis and p<0.05 was considered signifi cant. 
Results: A total of 2219 adult and pediatric LT were performed between 1994 
and 2007 in our institution.
1994-2000
N= 127
2001-2007
N=73
P
Adult/Pediatric 101/26 (20%) 44/29 (40%) <0.05
LOS median (min-max) 28 (0-221) 19 (1-367) NS
Req RELT (<1mo) 14 (11%) 7 (10%) NS
MORT (1 mo) 17 (17%) 7 (10%) <0.05
Among them 336 patients were transplanted while they were under care in 
ICU. After exclusion of retransplant (RELT) patients (n=113), a total of 200 
primary LT patients were included into this evaluation. The NEW group 
consisted of 40% pediatric population which was signifi cantly higher than 
the OLD group (see Table). Overall comparison of survival between groups 
showed a signifi cant difference favoring the NEW group for pediatric and adult 
patients respectively. Univariate survival analysis of the NEW group showed 
that patients with pretransplant level of prealbumin>10 mg or pO2>60 mmHg 
or HCO3>15 had signifi cantly better survival. 
Conclusion: Prognosis after liver transplantation in patients who are on life 
support has had signifi cantly improved. Better nutritional and respiratory status 
before transplantation correlates with better posttransplant survival.
POSTER BOARD NUMBER P4 – 106
CORRELATION BETWEEN SELECTED PROGNOSTIC 2056 
FACTORS AND A POSTOPERATIVE COURSE IN LIVER 
TRANSPLANT RECIPIENTS
W. Patkowski1, M. Krawczyk2, K. Zieniewicz3
1Medical University of Warsaw, 2Medical University of Warsaw, 3Medical 
University of Warsaw
The objective was to identify the major prognostic factors infl uencing the liver 
function after the transplantation and predicting postoperative course and long-
term survival in liver transplant recipients. These factors were analyzed on the 
basis of the clinical trials, results of biochemical, microbiological, serological, 
pathological studies of the donor and recipient, as well as intraoperative data.
215 of 542 liver transplant recipients (39.7%) were analyzed in the period 1989 
– 2006. Patients with irreversible liver failure caused by hepatotropic viruses B 
and C infection were prevailing. They were divided into 3 groups:
Group I – cirrhosis caused by HCV infection (RNA virus), 80 patients (37.0%)
Group II – cirrhosis caused by HBV infection (DNA virus), 33 patients (15.0%)
Group III – cirrhosis caused by HBV and HCV infection, 13 patients (6.0%).
Another group consisted of the patients with chronic liver failure caused by 
alcoholic liver disease:
Group IV – alcoholic cirrhosis, 66 patients (31.0%).
Group V – autoimmunological hepatitis and cirrhosis, 23 patients (11.0%).
Analyzed factors affecting the long-term results after liver transplantation was 
comprised intraoperative details (type of implantation, cold and warm ischemia 
time, total operation time, post-reperfusion syndrome, bile ducts drainage), as 
well as with the data regarding the quality of transplanted liver (degree of liver 
steatosis, anatomic variations). 
It was proved that patient survival prediction based on clinical parameters had 
a better prognostic value than prediction based only on the liver function tests. 
It was also concluded application of the transplant urgency scores MELD, delta 
MELD and UNOS enables to predict early and long-term patients survival 
after liver transplantation. Update of these scores, adequately to the patient 
condition, enables to evaluate effectively pretransplantation life-threatening 
factors and urgency level. 
In case of the organ donor the highest value of predictive factors are: age, 
viral status and degree of liver steatosis. Liver transplant technique, piggy-back 
or classical has a major prognostic value. Complications are more frequent 
for classical technique. Additionally it was proved that the occurrence of 
complications during liver transplantation has a disadvantageous prognostic 
effect on patient’s fate. 
It was confi rmed that cold/warm ischemia time has been a major prognostic 
factor, and occurrence of postoperative complications, surgical or medical – 
had a negative effect on the prognosis. Routine biliary drainage resulted in 
worse long-term survival when compare to non-drained patients.
Liver transplantation for alcoholic cirrhosis was affected with the highest 
complications ratio. Chronic liver rejection occurred more frequently in the 
patients transplanted for autoimmunological cirrhosis when compare to the 
other groups of indications. 
The most useful predictive factors of 1-year survival are liver function tests 
(AST, ALT, GGTP, INR, Quick) and urea/creatinine.
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CORRELATION BETWEEN INTRAOPERATIVE 2057 
RBC, FFP, PLATELET AND RECOMBINANT ACTIVATED 
FACTOR VII TRANSFUSION AND SURVIVAL AFTER LIVER 
TRANSPLANTATION
W. Patkowski, K. Zieniewicz, P. Nyckowski, M. Krawczyk
Medical University of Warsaw
Aim: We analyzed the infl uence of intraoperative transfusion blood agents and 
factor VII (NovoSeven) on the postoperative survival and complication after 
OLTx. 
Method: In the period 1989 ¨C 2006, 542 patients underwent OLTx. Among 
them 215 liver transplant recipients were retrospectively analyzed. 80 pts (37.0%) 
were transplanted for HCV liver cirrhosis, 33 pts (15.0%) for HBV cirrhosis, 13 
pts for HBV+HCV cirrhosis (6.0%), 66 pts (31.0%) for ALD and 23 pts (11.0%) 
for AIH. Surgical blood loss and number of packed blood agents and dose of 
NovoSeven given were collected. Multivariable regression analysis was used.
Results: 70 pts received at least 10 units of red blood cells (RBC) and it was 
worse prognostic factor. An overall 1-,3- and 5-year survival in this group was 
76.6%, 67.5% and 67.5% respectively. Patients who received <10 units of RBC 
showed a trend to higher rate of posttransplant survival ¨C 1 year 92.2%, 3 
year 87.6% and 5 year 83.2% (p=0.001). 48 pts needed more than 15 units 
of fresh frozen plasma (FFP). We observed 1-, 3- and 5 year survival rates 
72.2%, 64.4% and 64.4% in that group of patients compared to 90.9%, 86.0% 
and 82.9% respectively when patients required < 15 units of FFP (p=0.0015). 
NovoSeven transfusion during transplantation was associated with higher 
mortality. 8 pts received intraoperatively activated factor VII and 6 pts of them 
died 1 week after OLTx. 27 pts were given more than 8 units of platelets. No 
signifi cance occurred between patients who required more and less units of 
platelets for long-term survival. They reached 1-,3-, and 5 year survival 88.1% 
vs 77.8%, 82.5% vs 77.8% and 79.2% vs 77.8% (for > 8 units of platelets and 
¡Ü 8 units, respectively).
Conclusion: Transfusion requirements during liver transplantation are 
multifactorial with intraoperative circumstances contributing signifi cantly. Poor 
outcome were associated with RBC, FFP and activated factor VII transfusion.
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PROGNOSIS AFTER LIVER TRANSPLANTATION 2058 
PREDICTED BY PREOPERATIVE MELD, Ä MELD AND UNOS 
SCORE
W. Patkowski, K. Zieniewicz, M. Urban, M. Krawczyk
Medical University of Warsaw
Aim: To determine patients survivals and outcomes according to prognostic 
scores and alterations of the MELD, ¦¤ MELD and UNOS during waiting 
time. 
Method: 215 liver transplant recipients were retrospectively analyzed. Among 
them 80 pts (37.0%) for HCV liver cirrhosis, 33 pts (15.0%) for HBV cirrhosis, 
13 pts for HBV+HCV cirrhosis (6.0%), 66 pts (31.0%) for ALD and 23 pts 
(11.0%) for AIH. The MELD score at time on listing and of transplantation and 
UNOS as well were gathered. Additionally the delta-MELD was calculated.
Results: Mean MELD score was 23(range 6-40), mean delta-MELD was 2.5 
(range 0 -7). 2.3% of patients were transplanted with UNOS status 1, 15.3% of 
patients with UNOS 2a, 48.9% of patients with UNOS 2b and 33.0% of all group 
with UNOS status 3. Patients with MELD < 20 had an overall 1-, 3-, 5-year 
survival rates 100.0%, 98.1% and 98.1% compared to 79.1%, 72.9% and 69.8% 
for MELD ¡Ý 20 (p<0.0001). We observed than patients with delta-MELD < 
3 had an overall survival rates higher than patients with delta-MELD ¡Ý 3 and 
it was 91.5% vs 69.6%, 85.6% vs 67.1% and 83.3% vs 67.1% (1-,3-,5-year 
respectively) (p<0.0001). According to patient¡¯s UNOS criteria we found 
1-,3-,5-year survival rates for UNS 1 20.0%, 20.0% and 20.0%, for UNOS 2a 
61.5%, 54.4%, 54.4%, for UNOS 2b 85.6%, 79.3%, 76.1% and for UNOS 3 
100.0%, 95.4% and 95.4% respectively (p=0.0013). Only one patient died for 
acute pancreatitis 21 months after OLTx from all patients reached MELD< 20. 
Conclusion: We suggest that preoperative MELD, delta-MELD and UNOS 
score can be a good predictor of short-term prognosis after OLTx. Patients 
with a substantial increase of these prognostic scores during waiting time had a 
poorer 1 year posttransplant survival. 
LIVER – MALIGNANCYCONCURRENT ORAL SESSION 140: 
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DE NOVO HEPATOCELLULAR CARCINOMA IN A LIVER 2059 
ALLOGRAFT ASSOCIATED WITH ISCHEMIC TYPE BILIARY 
LESIONS
M. Heise1, G. Otto1, C. Dueber2, M. Schuchmann3
1Department of Transplantation and Hepatobiliopancreatic Surgery, 
2Department of Radiology, 3Department of Internal Medicine I
Recurrent hepatocellular carcinoma (HCC) is well described following 
liver transplantation. However, de novo HCC in the allograft liver is rare. 
Ischemic type biliary lesions (ITBL) are a severe complication following liver 
transplantation and a source of morbidity and even mortality. De novo HCC 
arising in a cirrhotic allograft due to ITBL has not been described previously. 
This report is intended to summarize the clinical features of a case of de novo 
HCC arising in an allograft liver 17 years after the fi rst transplantation. 
Clinical History: A 23-old female received an orthotopic liver transplantation 
in 1989 for acute hepatic failure of unknown origin. The postoperative course 
was complicated by an anastomotic leakage of the bile duct. A revision and 
neo-anastomosis was performed two weeks after transplantation. The further 
postoperative course was uneventful. 
In 1993, approximately 4 years after transplantation, multiple dilatations and 
nonanastomic strictures of bile ducts occurred due to ITBL (Fig.1). 
Fig.1 Percutaneous transhepatic cholangiogram (PTD) shows multiple 
strictures and dilatations of intrahepatic ducts.
In 1994, she delivered a healthy son after an uneventful pregnancy. One year 
after the delivery portal vein thrombosis and splenomegaly were diagnosed. 
In December 1996, a liver biopsy demonstrated the histological features 
of a fi brotic liver parenchyma. At the same time, balloon dilatation of the 
biliary strictures was performed. Since October 1999, the patient was treated 
by percutaneous transhepatic drainage (PTD) for recurrent cholangitis 
and obstruction of intrahepatic bile ducts. In February 2000, a liver biopsy 
demonstrated histological appearance of liver cirrhosis due to ITBL. Between 
October 1999 and November 2003, PTD was replaced routinely every 6 to 
8 weeks or in the case of cholangitis. In April 2001, the patient experienced 
hepatic decompensation after hernioplasty of an incisional hernia. After 
recompensation, the course was characterized by the moderately impaired 
liver function but largely stable until March 2006. At that time, CT-scan 
revealed a nodule of 2.8 cm in diameter in the transitional zone of segments 4 
and 8 suspicious for HCC (Fig.2).
Poster Abstracts Thursday 14 August 2008
6 7 7
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Fig.2 Contrast enhanced CT scan shows hyperdense lesion in transition zone 
of segment 4 and 8 (arrow).
The AFP was 25 ng/ml (upper limit of normal 10 ng /ml). HCC was confi rmed 
by biopsy and histological examination. As the Milan criteria were fulfi lled, 
the patient was listed for retransplantation. During waiting time, transarterial 
chemoembolization (TACE) was performed every 6 weeks. Between May and 
November 2006, the patient received a total of 5 TACE cylces, and neither 
local tumor progress nor tumor dissemination was observed (Fig.3).
Fig.3 CT scan immediately after fi fth transarterial chemoembolization shows 
uptake in the tumour (arrow).
In November 2006, the patient was retransplanted 17 years following the previous 
transplantation. Examination of the explant disclosed a singular HCC of 2 cm 
in diameter in the aforementioned location graded as G1. The AFP was 9ng/ml 
at the time of retransplantation. The postoperative course was uncomplicated. 
An episode of acute rejection (RAI 6) 8 days after retransplantation was 
successfully treated with intravenous steroid bolus therapy. The patient was 
discharged from the hospital 3 weeks after retransplantation. 
Discussion: The increased risk of cancer in organ transplant recipients is 
well recognized. De novo malignancies after liver transplantation have been 
reported comprising particularly skin cancer, lymphoproliferative disease 
(PTLD), colon cancer, cervical cancer and vulvar/perineal cancer (1, 2). 
In the liver allograft de novo HCC is rare with most cases arising in liver 
transplantation for chronic hepatitis C and B (3-5). Cirrhosis is a major risk of 
de novo HCC and occurs in approximately 10% of allografts, usually because 
of recurrent viral hepatitis. 
ITBL are nonanastomic strictures in the absence of hepatic artery thrombosis. 
So far, the exact pathogenesis remains unclear. The incidence of ITBL ranges 
from 1.4% to 26% after liver transplantation (6-8). According to the bile duct 
involvement, ITBL may be classifi ed as type I (extrahepatic lesions), type 
II (intrahepatic lesions) and type III (extra- and intrahepatic lesions) (9). 
Several risk factors have been identifi ed, including prolonged cold ischemia 
time (7, 10-14), delayed rearterialization of the allograft (12), ischemia-
reperfusion injury (15) insuffi cient perfusion of biliary arterial vessels (16-18), 
immunological factors (10-11, 19), chronic ductopenic rejection (11, 20-21), 
ABO incompatibility (11), polymorphism in genes coding for chemokines (19) 
and pre-existing immunologically mediated diseases such as primary sclerosing 
cholangitis and autoimmunehepatitis (22-25) These risk factors may affect the 
biliary epithelium or damage the microvascularisation of the biliary tree and 
fi nally lead to secondary cirrhosis. 
De novo HCC arising in liver cirrhosis due to ITBL has not been described 
previously. The unusual case of a de novo HCC in a patient with no previous 
history of specifi c malignancy or liver disease leading to liver cirrhosis 
emphasizes the risk of malignant degeneration in liver allografts with long 
standing ITBL.
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DEPRESSIVE SYMPTOMS, IMMUNITY, AND SURVIVAL 2060 
IN HEPATOBILIARY CARCINOMA
J. Steel1, D. Geller, T.C. Gamblin, M. Olek, B. Carr
1University of Pittsburgh School of Mediicne, 2University of Pittsburgh School 
of Mediicne, 3University of Pittsburgh School of Mediicne, 4University of 
Pittsburgh School of Mediicne, 5University of Pittsburgh School of Mediicne
Purpose: The aims of the present study were to: (1) at diagnosis assess the prevalence 
of depressive symptoms; (2) test the association between depressive symptoms and 
survival; and (3) test preliminarily a mediational model of depression, immunity, 
and survival in people with hepatobiliary carcinoma (HBC). 
Patients and Methods: One hundred and one patients diagnosed with HBC 
were prospectively studied. Depressive symptoms were measured at diagnosis 
using the Center for Epidemiological Studies-Depression (CES-D) scale. 
Sociodemographic and disease-specifi c data was gathered from the patients’ 
chart. In a subsample of patients, stress; alcohol, tobacco, and drug use; sleep 
quality; physical activity; social support; natural killer (NK) cell number and 
cytotoxicity; and plasma levels of IL4, IL5, TNF-alpha, and IFN-gamma were 
measured. Survival was measured from date of diagnosis to death.
Results: At diagnosis, 37% of patients reported a CES-D score >16 (clinical 
range). Using Cox Regression analysis, sociodemographic and disease-specifi c 
variables and CES-D score signifi cantly predicted survival [Breslow Chi-
Square=32.4, p=0.006]. Only vascular invasion (p=0.001) and CES-D>16 
(p=0.03) were signifi cant predictors. In a subsample of 23 patients, those who 
reported a CES-D>16 were found to have signifi cantly lower NK cell numbers 
than those who reported a CES-D score<16 [F(1,21)=9.39, p=0.003]. A robust 
trend was found in which NK cell number was associated with survival. A 
mediational model linking depressive symptoms and survival, with NK cell 
number as a mediator, was preliminarily supported. 
Conclusion: Secondary to the high prevalence of depressive symptoms, and 
impact on survival, psychological and pharmacological interventions should be 
designed and implemented in patients diagnosed with hepatobiliary carcinoma.
POSTER BOARD NUMBER P4 – 111
COMPARASION OF LONG-TERM RATES OF 2061 
HEPATOCELLULAR CARCINOMA RECURRENCE AND 
SURVIVAL BETWEEN PATIENTS UNDERWENT PARTIAL 
HEPATECTOMY AND LIVER TRANSPLANTATION
C-M. Ho, M-C. Ho, Y-M. Wu, R-H. Hu, P-H. Lee
National Taiwan University Hospital
Background: Recurrence of hepatocellular carcinoma (HCC) is the major 
problem after curative resection. Whether partial hepatectomy alone or total 
hepatectomy and liver transplantation is/are the preferred management procedure 
for HCC in the concern of long-term recurrence and survival is unknown.
Materials and Methods: Patients with HCC underwent liver resections 
during 2000-2002 and those received liver transplantation in National Taiwan 
University Hospital were enrolled. Patients were excluded with previous liver 
surgeries for HCC. Demographic data (age and sex) and clinical parameters 
(HBV and HCV status, cirrhosis confi rmed pathologically, and pathological 
tumor staging according to AJCC version 2006) were collected for adjustment 
in Cox regression analysis of recurrence and survival. Kaplan-Meier curves for 
long-term survival and recurrence were plotted, compared with log-rank test, 
between those received partial hepatectomy and those liver transplantation. 
P<0.05 was considered signifi cant.
Results: A total of 217 patients (169 males and 48 females) received 
liver resections and 40 patients (28 males and 12 females) received liver 
transplantations were included. With adjusting the parameters of age, sex, virus 
status, cirrhosis and tumor staging, patients underwent liver transplantations 
had lower recurrence (odds ratio: 0.39, p=0.03) and longer tendency of survival 
(odds ratio: 1.9, p=0.09) than those receive partial hepatectomy only. The 3- 
and 5-year recurrent rates for patients received liver resection and those liver 
transplantation were 54 vs. 38% and 65 vs. 38%, respectively (p=0.04). The 
3-, 5-, and 7-year survival rates were 72 vs. 79%, 59 vs. 72%, and 55 vs. 72%, 
respectively (p=0.44).
Conclusion: For patients with HCC, liver transplantation had lower rates of 
recurrence than partial hepatectomy and a tendency of longer survival.
Thursday 14 August 2008 Poster Abstracts
6 7 8
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P4 – 112
LIVER TRANSPLANTATION FOR CHILDHOOD 2062 
HEPATIC TUMOR
M. Haberal1, S. Sevmis1, H. Karakayali1, G. Moray1, F. Ozcay2, 
F. Sarialioglu2, B. Demirhan3, A. Torgay4, G. Arslan4
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Pediatry, 3Baskent 
University Faculty of Medicine, Department of Pathology, 4Baskent 
University Faculty of Medicine, Department of Anesthesiology
Liver transplantation (LT) is the only treatment option for unresectable liver 
tumors. In this study, we present our experience with LT in the treatment of 
13 children with unresectable liver tumor. Between January 2001 and October 
January 2008, we performed 104 LTs in 101 children at our center. Thirteen 
of these 101 children (12.8%; mean age, 8.2 &#61617; 6.2 years; age range, 
6 months to 16 years; male-to-female ratio, 8:5) underwent an living-donor 
liver transplantation because of liver tumor. Ten children had hepatocellular 
carcinoma, 2 had hepatoblastoma, and 1 had neuroblastoma causing consumption 
coagulopathy. Liver tumor was diagnosed before transplantation in 10 children 
(76%), and in 3 children (24%), we identifi ed an incidental tumor. One child 
had combined hepatic arterial chemoembolization and systemic chemotherapy, 
and 4 had systemic chemotherapy before LT. Two children received a right lobe 
graft, 6 received a left lateral segment graft, and the remaining 5 received a left 
lobe graft. The pathological fi ndings demonstrated a mean tumor size of 3.3 ± 
2.5 cm (range, 0.5 to 8 cm). The number of tumors was < 5 in 8 children, and 
> 10 in remaining 5 children. The largest tumor size was 8 cm. Three children 
had microvascular invasion. One child who had neuroblastoma causing 
consumption coagulopathy received systemic chemotherapy after LT. The 
mean follow-up was 25.9 &#61617; 12.9 months (range, 3-42 months). There 
has been only 1 tumor recurrence, which occurred in the omentum 26 months 
after LT. One child with hepatoblastoma experienced lymphoproliferative 
disease 22 months after his LT, and he died 2 months later due to chemotherapy 
related sepsis. At the time of this writing, remaining 12 (93%) children are 
alive with good graft functioning. In conclusion, LT remains a viable option 
for pediatric patients with unresectable hepatic tumor and provides long patient 
and disease-free survival.
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POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE 2063 
IN PEDIATRIC LIVER TRANSPLANT
H. Karakayali1, S. Sevmis1, F. Ozcay2, B. Demirhan3, F. Sarialioglu2, 
F. Karakayali1, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Pediatry, 3Baskent 
University Faculty of Medicine, Department of Pathology
Posttransplant lymphoproliferative disease (PTLD) is a well-recognized 
complication of solid organ transplant and therapeutic immunosuppression, 
fi rst reported in 1968. PTLD encompasses a spectrum of abnormalities 
ranging from a benign infectious mononucleosis like illness to non-Hodgkin’s 
lymphoma with nodal and extranodal site involvement. Between September 
2001 and January 2008, 104 liver transplants were performed in 101 children 
at our center. Five recipients (4.9%) developed PTLD. This retrospective study 
examines the incidence of PTLD, reasons for the original transplants, presenting 
symptoms, radiologic fi ndings, immunosuppression regimens, and outcomes in 
these 5 recipients. The average age of these recipients at the time of transplant 
was 3.9 years (range, 6 months to 10 years), with a female-to-male ratio of 
3:2. The indications for transplant were hepatoblastoma in 1 recipient and 
cholestatic liver disease in remaining 4. PTLD was diagnosed 5, 12, 17, 22, and 
27 months after liver transplant imaging abnormalities identifi ed generalized 
lymphadenopathy in 1 recipient, multiple liver masses in 1, a large portal mass 
in 1, multiple ulcer in stomach in 1, and a large mediastinal mass in 1. At 
the time of diagnosis, 1 recipient with a large mediastinal mass had a cough; 
the remaining 4 recipients were asymptomatic. Histologic fi ndings showed 
B-cell lymphoma in 3 recipients and T-cell lymphoma in 2. The result of in 
situ hybridization for Epstein-Barr virus was negative in 1 recipient, and it was 
positive in 4. Four recipients were treated with chemotherapy; the remaining 
recipient was treated with anti-CD20 monoclonal antibodies (Rituximab). One 
recipient who had a large mediastinal mass died 2 months after diagnosis due 
to chemotherapy-related sepsis; the remaining 4 children are alive 4, 5, 18, 
and 19 months after treatment. In conclusion, our rate of PTLD is similar to 
those published in the literature. From a few months to several years after liver 
transplant, radiologists must be alert to the possibility of PTLD, and thorough 
imaging is required to detect the wide variety of potential presentations.
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LIVER TRANSPLANTATION FOR EXPANDED 2064 
HEPATOCELLULAR CARCINOMA
H. Karakayali1, G. Moray1, S. Sevmis1, N. Savas2, U. Yilmaz2, F. Ozcay3, A. 
Torgay4, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Gastroenterology, 
3Baskent University Faculty of Medicine, Department of Pediatry, 
4Baskent University Faculty of Medicine, Department of Anesthesiology
Various criteria for liver transplantation have been reported for patients with 
hepatocellular carcinoma (HCC). Although the Milan criteria are often used 
to determine which patients will benefi t from liver transplantation, many 
centers have their own criteria for patient selection. In this study, we aimed 
to evaluate the results of liver transplantation in patients with HCC beyond 
the Milan criteria. Between January 2004 and January 2008, 35 patients with 
preoperatively diagnosed or incidental HCC underwent liver transplantation 
at our center. In 20 of these 35 patients, the tumors were beyond the Milan 
criteria. We analyzed these 20 patients retrospectively. Sixteen were males and 
4 were females (mean age, 41.6 ± 20.5 years [range, 12-64 years]. Seven of the 
20 grafts were from cadaveric donors, and 13 were from living-related donors. 
Five patients had neoadjuvant chemoembolization, 2 had percutaneous ethanol 
injections, and 3 had combined chemoembolization and percutaneous ethanol 
injections before transplantation. None of our patients received adjuvant 
chemotherapy. According to the Tumor size-lymph Nodes-Metastases staging 
system, 2 patients had stage III, and the remaining 18 patients had stage IVA1 
carcinoma. The number of tumors was < 5 in 2 patient, 5 to 10 in 9 patients, and 
> 10 in 9 patients. The largest tumor size was 11 cm. At the time of this writing 
and with a mean follow-up period of 25.1 &#61617;15.9 months (range, 2-49 
months), 17 patients are well and exhibit excellent graft function. Remaning 3 
patients died 7, 15, and 23 months after transplantation because of recurrence 
of HCC, HCC, and sepsis, respectively. The longest graft survival in the study 
subjects is 49 months. There have been 5 tumor recurrences, which occurred 
3, 4, 24, 26, and 29 months after liver transplantation, respectively. Three of 
theses 5 patients are still alive with good functioning grafts. In conclusion, liver 
transplantation provides long patient and disease-free survival, even in patients 
with HCC that exceeds the Milan criteria.
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INCIDENTAL HEPATOCELLULAR CARCINOMA AFTER 2065 
LIVER TRANSPLANT
G. Moray1, S. Sevmis1, N. Savas2, H. Karakayali1, F. Ozcay3, A. Torgay4, 
G. Arslan4, M. Haberal1
1Baskent University Faculty of Medicine, Department of General Surgery, 
2Baskent University Faculty of Medicine, Department of Gastroenterology, 
3Baskent University Faculty of Medicine, Department of Pediatry, 4Baskent 
University Faculty of Medicine, Department of Anesthesiology
The incidence of detecting hepatocellular carcinoma (HCC) in a removed 
recipient liver after a liver transplant is not rare. The aim of this study was to 
evaluate incidental HCC at our center. We retrospectively analyzed 5 patients 
with incidental HCC among 35 patients whom were operated with HCC on 
between January 2004 and January 2008. The proportion of incidental HCC was 
14.2%. There were 3 children and 2 adult patients (mean age, 22.6 ± 24.5 years; 
range, 1-49 years). Two of these patients were 1 year old. The alpha-fetoprotein 
level was normal in all patients. Preoperative imaging studies demonstrated 
regenerative or dysplastic nodules or no specifi c lesion in all patients. One of 
the grafts was from a deceased donor, and 4 were from living-related donors. 
We encountered no complications after transplants. The pathological fi ndings 
showed a mean tumor size of 0.94 ± 0.2 cm (range, 0.5-1.2 cm) and multiplicity 
in 1 patient (20%). One patient with multiple tumors had microvascular 
invasion. According to the TNM staging system, 4 patients had stage-I, and 
the remaining 1 patient had stage-II, carcinoma. There were no recurrences of 
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HCC, and no mortality occurred during the follow-up (mean, 35 ± 8.5 months; 
range 26-45 months). In conclusion, the incidence of HCC in cirrhotic patients 
who underwent liver transplant is similar to that of other studies in literature. 
The incidentally found HCC showed less invasive pathological features and a 
better prognosis than preoperatively detected HCC.
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THE UCSF CRITERIA ACCORDING TO THE 2066 
PRE-TRANSPLANT RADIOLOGIC STUDY CAN NOT 
ASSURE SIMILAR POST-TRANSPLANT RESULTS OF 
HEPATOCELLULAR CARCINOMA PATIENT WITHIN MILAN 
CRITERIA
M.K. Ju1,3, M.S. Kim1,3, J. Choi1, G.H. Choi1, D.J. Joo1, S.J. Kim1, 
D.Y. Kim2, S.I. Kim1,3, Y.S. Kim1,3
1Yonsei University College of Medicine Department of Surgery, 2Yonsei 
University College of Medicine Department of Internal medicine, 3Yonsei 
University College of Medicine The Research Institute for Transplantation
The recurrence of hepatocellular carcinoma (HCC) after transplantation is 
main limitation of liver transplantation. Therefore the several selection criteria 
for liver transplantation in HCC patients are established. The objective of this 
study was to verify the clinical validity of selection criteria by pretransplant 
radiologic imaging study. 
September 2005 to May 2007, 69 recipients (49 whole liver transplant and 
20 partial liver transplant) were enrolled this study. We analyzed the post-
transplant survival and recurrence rate by radiologic selection criteria and other 
clinical factors. Grouping by pre-transplant criteria for liver transplantation, 16 
recipients (23.2%) were above Milan criteria and 7 recipients (10.1%) were 
above the UCSF (University of California, San Francisco) criteria. According 
to combined categories, nine recipients (13.0%) were grouped as above Milan/
below UCSF group. 
The recipients who met Milan criteria (below Milan) and UCSF criteria (below 
UCSF) showed 85.8% and 82.7% of 1-year survival rate respectively, which 
was comparable to that of non-HCC (91.6%) without signifi cance (p=0.767 
in below Milan, p=0.2604 in below UCSF). During post-transplant follow-
up period (1-52 months, 14.8 ± 12.0 months), 16 recurrences (23.2%) were 
diagnosed. There was a signifi cant difference in the 1-year recurrence-free 
survival rate according to the selection criteria, recipients who satisfi ed the 
Milan criteria was 78.6% and of those that did not meet these criteria was 
22.7% (p<0.0001), with regard to the UCSF criteria, 72.0% and 14.2%, 
respectively (p<0.0001). According to combined grouping, 1-year recurrence-
free survival rate was 25.4% in above Milan/below UCSF group. There was 
signifi cant difference among each groups (overall p<0.0001)(Figure) which 
was confi rmed in multivariate survival analysis. 
The application of the UCSF criteria by pre-transplant radiologic fi ndings as 
patient selection criteria for liver transplantation is limited.
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PRE-LIVER TRANSPLANT TRANSARTERIAL 2067 
CHEMOEMBOLIZATION FOR HEPATOCELLULAR 
CARCINOMA BEYOND MILAN CRITERIA
P. De Simone1, C. Vignali2, P. Carrai1, I. Bargellini2, S. Petruccelli1, 
G. Catalano1, L. Coletti1, D. Campani3, C. Bartolozzi2, F. Filipponi1
1Liver Transplant Unit, 2Radiology, 3Pathology
Background: The role of transarterial chemoembolization (TACE) for 
downsizing/downstaging of hepatocellular carcinoma (HCC) before liver 
transplantation (LT) has expanded on the assumption that TACE may allow 
for reduced dropout from waitlist and longer disease-free survival rates. We 
report here our experience with pre-transplant TACE in patients undergoing 
LT for HCC.
Materials and methods: single-center experience, prospective data collection, 
retrospective analysis of patients with histology-proven HCC beyond Milan 
criteria. Tumor necrosis on explants histology was reviewed by two blinded 
pathologists and graded as nil, minimal (≤25%), partial (≤50%), subtotal 
(≤75%), and total (75-100%). 
Results: Forty-one consecutive patients transplanted between December 
1997 and August 2006 with histology proven HCC beyond Milan criteria 
were included (M:F= 39:2; mean age 55±6.4 years). All patients underwent 
pre-transplant TACE (mean procedures 1.2±0.5). On explant histology, mean 
number of tumor nodules was 3.3±1.5, and mean total tumor diameter was 
7.3±2.7 cm. Complete tumor necrosis was present in 26.8% patients (11/41); 
subtotal in 34.1% (14/41); partial in 31.7% (15/41); and nil in 2.4% (1/41). At 
a mean follow-up of 48±33 months, 70.7% patients (29/41) patients are alive, 
7% (2/29) of them with HCC recurrence. After censoring for deaths unrelated 
to HCC, actuarial patient survival was 94.5% at 6 months; 94.5% at 1 year; 
88.7% at 2 years; 85.1% at 3 years; 81.2% at 4 and 5 years. 
Conclusions: Use of pre-transplant TACE allows to improve results of LT for 
HCC beyond Milan criteria in the presence of necrosis of the tumor mass. No 
negative impact on the risk of recurrence for partial vs. subtotal/total necrosis 
was observed in the current experience. 
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THE SILVER STUDY: AN INVESTIGATOR-INITIATED 2068 
TRIAL TO DETERMINE IF SIROLIMUS USE CAN IMPROVE 
HCC RECURRENCE-FREE SURVIVAL IN AFFECTED LIVER 
TRANSPLANT RECIPIENTS
E. Geissler, A. Schnitzbauer, C. Zuelke, P. Lamby, I. Mutzbauer, H. Schlitt
University of Regensburg, Department of Surgery, Representing the 
International SilVER Study Workgroup
Background: Hepatocellular carcinoma (HCC) recurrence after liver 
transplantation (LT) limits LT success as a treatment for this malignancy. 
Since the mTOR pathway is critical for angiogenesis and tumor development, 
it is an attractive target for cancer therapy. Considering mTOR inhibitor 
immunosuppressive activities, and potential to inhibit malignancy, we initiated 
a global, multi-center, clinical trial to evaluate sirolimus-based therapy in 
patients following LT for HCC, regarding HCC recurrence-free patient 
survival. The University of Regensburg is the study sponsor. Protocol: This 
is an open-labeled, randomized, trial comparing sirolimus-containing vs. 
mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. 
A 2-3 year enrollment period with a 5-year follow-up is planned. Patients with 
histologically confi rmed HCC are randomized into one of two groups after 
LT. The fi rst group is kept on a center-specifi c mTOR-inhibitor-free protocol. 
This control group will be compared to a second group that is maintained 
on a center-specifi c mTOR-inhibitor-free regime for the fi rst 4-6 weeks, at 
which time sirolimus is incorporated as a monotherapy, or in combination 
with non-mTOR-based immunosuppression. Patients are stratifi ed into 
statistically-independent high or low risk HCC recurrence groups, based on 
factors including Milan status and presence of cirrhosis. Status: As of February 
2008, 287 patients (482 planned) have been enrolled. Forty-two centers from 
13 countries are presently recruiting (11 in Europe + Canada and Australia). 
The fi rst Data Safety Monitoring Board meeting was held in August 2007 and 
resulted in a recommendation to continue the study. We have a current drop-out 
rate of <5%. Efforts are presently being made to include sites from the United 
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States into the study. Current recruitment is averaging 15 patients per month 
since the beginning of 2007, which is expected to increase with additional 
sites being initiated. Outlook: The positive development of this study was 
only possible with a scientifi cally motivated and energetic study group. Vital 
lessons can be learned from the setup of this trial. This initiative demonstrates 
that complex, investigator-driven, studies can be successfully organized on a 
multi-continental basis. Scientifi cally, the trial is critical because it is the fi rst 
prospectively randomized study to determine if mTOR inhibitors can improve 
HCC recurrence-free survival in affected LT patients.
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LIVER TRANSPLANTATION OR LIVER RESECTION AS 2069 
TREATMENT OF HEPATOCELLULAR CARCINOMA
K.K. Lee, D.G. Kim, S.K. Lee, I.S.M. Lee
The Catholic University of Korea
Introduction: Surgical treatment including liver resection and liver 
transplantation remains mainstay of treatment offering a hope of cure in 
hepatocellular carcinoma with cirrhosis. The authors tried to evaluate the 
indication of surgical procedure for the treatment of hepatocellular carcinoma 
by comparing the outcome of treatment between transplantation and liver 
resection. Method: Our department performed surgical treatment in 248 
patients with hepatocellular carcinoma including 129 patients in liver resection 
and 119 patients in living donor liver transplantation from Oct. 1997 to Jul. 
2007. We analyzed patients, tumor characteristics and survival and disease 
free survival according to resection group and transplantation group. Result: 
Most patients were Child A in resection group in contrast to Child B or C in 
transplantation. Other factors were not signifi cantly different between two 
groups. The patients who underwent transplantation had signifi cantly higher 
survival and disease free survival rate than the patient with surgical resection in 
all patients. According to Milan criteria, the patients who are the tumor within 
Milan criteria had better survival and disease free survival rate in transplantation 
group than surgical resection group. In contrast, in the tumor beyond Milan 
criteria, there is no signifi cant difference in survival and disease free survival 
rate in both group. The tumor size and vessel invasion infl uenced on the disease 
free survival rate in multivariate analysis. Conclusion: Liver transplantation 
and resection are appropriate treatment modalities of hepatocellular carcinoma 
and in tumor within Milan criteria, liver transplantation shows better result 
than liver resection and in cases beyond Milan criteria, the transplantation and 
resection show no signifi cant difference and liver transplantation should be 
carefully considered.
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POSITIVE EMISSION TOMOGRAPHY WITH FLUORINE-2070 
18-FLUORODEOXYGLUCOSE IS USEFUL FOR PREDICTING 
THE PROGNOSIS OF LT PATIENTS WITH HEPATOCELLULAR 
CARCINOMA
J-H. Ryu, S-G. Lee, S. Hwang, K-H. Kim, C-S. Ahn, D-B. Moon, T-Y. Ha, 
K-W. Song, K-W. Kim, N-G. Choi
Department of Surgery, Asan Medical Center
Backgrounds and aims: Positive Emission Tomography with Fluorine-18-
fl uorodeoxyglucose(FDG-PET) has established itself as a useful diagnostic 
imaging for metastatic liver tumors. However, in case of hepatocellular 
carcinoma(HCC), several investigators have reported controversial results 
and have an inadequate sensitivity of PET(50-55%). Nevertheless, a high 
positive rate of FDG accumulation has been reported in patients with high-
grade HCC. We retrospectively reviewed 110 HCC cases that received liver 
transplantation(LT) at our center between Jan 2003 and December 2005 and 
underwent whole-body PET imaging. 
Methods: FDG uptake was accessed in the liver, and its prognostic factors was 
investigated. Of 110 patients enrolled, 34 patients had positive PET scans for 
liver tumor. 
Results: When we analyzed the association between tumor factors and 
PET+(greater PET lesion uptake)in the liver, vascular invasion, number of 
tumors(>3nodules), and tumor size(>5cm) were found to be signifi cantly 
associated with PET+(P<0.001, P=0.004,and P<0.001, retrospectively). 
However, the preoperative AFP level and histological grade was not 
signifi cantly associated with PET+(P=0.418 and P=0.064). The 2-year 
recurrence-free survival rate of PET- patients was signifi cantly higher than that 
of PET+patients(89.2% vs. 61.7%)(P=0.0005). Of 18 PET+ patients who did 
not meet the Milan criteria, 12 patients(66.7%) had recurrence, but 14 PET- 
patients who did not meet the Milan criteria, 5 patients(35%) had recurrence. 
Conclusions: PET imging is useful for predicting the post-LT risk of tumor 
recurrence, because vascular invasion and histological grade cannot be 
determined preoperatively. The tumor recurrence could be highly anticipated 
for PET+ HCC patients who do not meet Milan criteria. PET+ HCC patients 
could be considered seriously for LT.
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COMBINED HEPATOCELLULAR CARCINOMA 2071 
AND CHOLANGIOCELLULAR CARCINOMA IS 
CONTRAINDICATION OF LIVER TRANSPLANTATION: 
REPORT OF A CASE
Y.S. Han, D.L. Choi, M.S. Kim, E.J. Jang, J.Y. Park, M.K. Kim
Department of Hepatobiliary Surgery and Transplantation, Daegu Catholic 
Medical
Combined Hepatocellular carcinoma and cholangiocarcinoma(cHCC-
CCC) is a rare subtype of primary liver cancer, and clinicopathological 
features have seldom been reported in detail. We report a case with liver 
transplantation for cHCC-CCC. 50-year old man received deceased donor 
liver transplantation at June 2007 because of HCC and hepatitis B & C 
related liver cirrhosis. At April 2006, HCC was diagnosed on computed 
tomography(CT) and TACE was performed. On CT performed right before 
transplantation, newly developed multiple hypervascular lesions were 
detected. His serum value of alpha-fetoprotein(aFP) and CA19-9 were 
was 65 ng/§¢ and 54 U/§¢. Transplantation was performed successfully. 
Postoperatively, acute rejection was developed and steroid pulse therapy 
was performed once. The biopsy result of explanted liver was surprisingly 
cHCC-CCC of collision type. Three months after transplantation, regardless 
of adjuvant chemotherapy with doxorubicin, multiple metastases were 
detected on both lower lung fi eld. The duration of survival was 10 months. 
Our patient with cHCC-CCC was not diagnosed before operation. And the 
progression of cHCC-CCC was more rapid than that of HCC and the patient 
had a signifi cantly worse survival outcomes. Accordingly, even though 
HCC is strongly suspected on imaging studies, if an increased CA19-9 
level, intrahepatic bile duct dilatation, or lower aFP level are detected, 
further evaluations should be performed to rule out the cHCC-CCC before 
liver transplantation.
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OUTCOME OF LIVER TRANSPLANTATION FOR 2072 
HEPATOCELLULAR CARCINOMA IN PATIENTS IN AND 
OUTSIDE THE MILAN CRITERIA – A SINGLE CENTER 
EXPERIENCE
M. Olausson, M. Sternby-Eilard, F. Badri, L. Backman, C. Cahlin, S. Friman, 
L. Hafstrom, M. Rizell, P. Lindner
Department of Transplantation
Introduction: Orthotopic liver transplantation (OLT) is increasingly being 
used in the treatment of patients with cirrhosis and concomitant hepatocellular 
carcinoma (HCC). In recipients with limited tumor burden, OLT achieves 
reasonable long-term outcome. Selection criteria for hepatocellular carcinoma 
is still under debate, where expansion of Milanocriteria has been suggested, 
an approach hampered by the lack of liver grafts. Prognosis seem to differ 
between Asian and Western countries, and might differ between Northern and 
Southern countries in Europe.
Aim: The aim of the present study was to determine survival in patients 
transplanted with HCC, to defi ne prognostic factors and compare the results in 
patients transplanted inside and outside the Milan criteria (MC).
Material and methods: From 1996 to 2007, 76 patients underwent OLT for 
cirrhosis and/or HCC. Malignancy was diagnosed in 63 patients prior to OLT 
and in 13 patients on pathologic examination of the explant. 6 patients with 
HCC were non-cirrhotic. The following clinical and pathologic variables were 
considered: TNM stage, nodularity, vascular invasion, Milan criteria, incidental 
lesion, tumor size. Based on preoperative imaging studies, 32 patients met the 
MC and 30 did not.
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Results: Overall patient survival rate at 1, 3 and 5 years was 83, 61 and 49% 
respectively. Recurrence-free survival (RFS) was 76, 53 and 41% at 1, 3, and 
5 years respectively. The overall survival rate of patients inside the MC after 
1, 3 and 5 years was 83, 64 and 48% compared to 80, 45 and 36% (0,478) 
in patients outside the MC. In patients with incidental tumors, the 1, 3 and 
5-year-survival was 92, 92 and 79%. Recurrence-free survival (RFS) inside the 
MC after 1, 3 and 5 years was 83, 55 and 44% compared to 68, 35 and 20% 
(p=0,157) outside the MC.
The preoperative staging differed from the pathologic examination concerning 
the MC in 37 out of 76 patients. Nodule size seemed more important than 
nodule number. Information about vascular invasion was often missing, but 
was an important predictive factor. After 3.5 years there was no RFS in patients 
with vascular invasion on pathology.
Our results suggest that MC is a predictive factor for survival, although in 
this study the difference was not signifi cant. The results questions if staging 
or biology differ from other reports. MC is one supporting factor for selecting 
transplantation candidates but cannot in our experience be used as the sole 
determinating factor.
POSTER BOARD NUMBER P4 – 123
PREDICTORS OF SURVIVAL FOR HEPATOCELLULAR 2073 
CARCINOMA
N. Savas1, H. Gokcan1, R. Sezer1, F. Boyvat2, H. Selcuk1, U. Yilmaz1, H. 
Karakayali3, M. Haberal3
1Baskent University Faculty of Medicine, Department of Gastroenterology, 
2Baskent University Faculty of Medicine, Department of Radiology, 3Baskent 
University Faculty of Medicine, Department of General Surgery
Introduction: Hepatocellular carcinoma (HCC) is the fi fth most common 
tumor worldwide, with an incidence equal to the death rate. 
Aim: & Methods: Our aim was to detect the prognostic factors for patients 
with hepatocellular carcinoma. We retrospectively analysed the 12 years 
(1993-2008)data of 108 patients who have biopsy proven HCC diagnosis in our 
institution. Clinical and demographic characteristics of patients with treatment 
modalities, survival rates and prognostic factors all were searched. Results
Ninety-one (84.3%) of them were male, 17 (15.7%)of them were female. 
Mean age of patients was 63.9Â±12.0 (20-94)years. Out of 108 patients 8 
(7.4%) of them had HCC without cirrhosis, 8 (7.4%) had alcoholic cirrhosis, 
7 (6.5%) had cryptogenic cirrhosis and 85 (78.7%) patients had cirrhosis 
due to viral hepatitis. Median follow-up time was 12 months (l month-7 
years) after the diagnosis of HCC. At the time of diagnosis 64 (59%) patients 
had alfa-feto protein (AFP)> normal level (range: 0-15ng/mL) with a mean 
AFP level of 391.2Â± 997.0 ng/mL. Ten (9.2%) patients had a history of 
alcohol consumption and 31 (28.7%) patients had cigarette smoking history. 
Serum HBVDNA level was positive in 20 of 64 (31.2%) patients with HBV 
infection, and serum HCVRNA level was positive in 13 of 21 (62%) patients 
with HCV infection at the time of diagnosis of HCC. Mean tumor size was 
48Â±35 mm at the time of diagnosis of HCC. Twenty-eight (26%) patients 
had been liver transplanted, 15 (14%) had HCC resection, 30 (28%) had 
only radiological treatment (chemoembolization, radiofrequence ablation, 
alcohol injection or both of them) 35 (32%) had not been treated. Tumor 
size of half of the patients in transplanted group were exceeding the Milan 
criteria. On follow up mean survival rates for fi rst and third years were 96% 
and
89% for transplantation, 90%, 52% for resection and 49%, 17% for paliative 
treatments, respectively. There were only statistically signifi cant differences 
between the age of the patients (p=0.003), hepatic resection (p=0.04) and liver 
transplantation (p=0.001) with disease free survival time. 
Conclusion: The only factors that affect the survival for patients with 
hepatocellular carcinoma are young age at the time of diagnosis of hepatocellular 
carcinoma and the treatment modalities of liver transplantation and hepatic 
resection.
POSTER BOARD NUMBER P4 – 124
BENEFIT OF NEEDLE BIOPSY BEFORE LIVER 2074 
TRANSPLANTATION
G.M. Otto1, F. Bittinger2, M. Hoppe-Lotichius1, M. Pitton3
1Department of Transplantation Surgery, University, 2Institute of Pathology, 
University, 3Department of Radiology, University
According to our treatment protocol patients with hepatocellular carcinoma 
(HCC) are repeatedly treated by transarterial chemoembolization (TACE) 
before liver transplantation (LT). Needle core biopsies (NCB) were performed 
before including the patients into protocol. As grading is a prognostic factor 
of tumor recurrence after LT and response to TACE may depend on grading, 
NCB is compared to histology of the surgical specimen (HSS) in order to assess 
its benefi t.
Patients and methods: Grading in NCB was available in 65 of 82 patients before 
TACE (median 5 cycles) followed by LT and in 15 of 52 patients without TACE 
before LT. Grading of NCB was compared to HSS and both were correlated to 
angioinvasion as assessed in HSS and to tumor progress during TACE. 
Results: Results of grading in NCB and HSS are shown in table 1 and 2. 
Table 1: Grading in patients with TACE before LT
Grading surgical specimen
NCB good mod. poor total
Good  7  9 3 19
Moderate  1 34  5 40
Poor 0  1  5 6
Total 8  44 13 65
Table 2: Grading in patients w/o TACE before LT 
Grading surgical specimen
NCB good mod. poor total
Good  1  3  0  4
Moderate  0  8  0  8
Poor  0  1  2  3
Total  1 12  2 15
In patients with TACE before LT, concordance of grading in NCB compared 
to HSS was 71%, in patients w/o TACE this fi gure was 73%. Pooling good 
and moderate grading to one group, sensitivity and specifi city to detect poorly 
diffentiated tumors are 39 and 98% in patients with TACE and 100 and 92% in 
patients w/o TACE, respectively. NCB was capable of identifying angioinvasion 
(P = 0.023) in patients with TACE, but not in patiens w/o TACE (P = 0.519). 
Both grading in NCB and HSS were incapable of predicting patients with 
tumor progress during TACE (P = 0.830, and 0.278, respectively).
Conclusions: In contrast to other studies, NCB proved useful in predicting 
defi nitive grading. The rate of concordance reaches 70%. According to 
comparable fi gures (tables), there is no signifi cant shift in grading caused by 
TACE pre-treatment. In patients with TACE, NCB may be used to predict 
angioinvasion. Tumor response to TACE is not refl ected by grading which hints 
at different factors infl uential on response during TACE.
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ADVANTAGE OF LIVER TRANSPLANT IN TERMS OF 2075 
SURVIVAL FOR PATIENTS WITH HCC AND CIRRHOSIS.
R. Verzaro, F. di Francesco, S. Li Petri, G. Vizzini, B. Gridelli
Istituto Mediterraneo Per I Trapianti E Terapie Ad Alta Specializzazione 
(ISMETT), Palermo Italy. University of Pittsburgh Medical Center Italy
Background: Liver transplantation (LTx) is considered a valid therapeutic 
option to treat patients with HCC and cirrhosis due to the possibility of curing 
both liver failure and malignancy. Loco-regional treatments, such as trans-arterial 
chemoembolization (TACE) are considered adequate options for patients that are 
not candidate to either surgical resection or liver transplantation. Loco-regional 
treatments are also used to downstage HCC or as a bridge for liver transplant. The 
advantages in terms of survival of liver transplant versus loco-regional therapies 
are well defi ned in the literature as far as the long term survival is concerned 
but little is known about the gain of survival in the fi rst one or two years after 
transplant. Moreover, HCV infection might impair patients’ survival after 
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transplant when compared to not-transplant patients. We analyze our experience 
in order to clearly defi ne survival after liver transplant for HCC patients with and 
without HCV infection in the fi rst two years after transplantation.
Patients and Methods: We compared survival of patients with HCC and 
cirrhosis that underwent liver transplant (HCC-LTx group) versus patients with 
HCC and cirrhosis on the waiting list that did not received a liver transplant 
(HCC-List group). In a 9-year period, 136 patients underwent liver transplant 
whereas 270 received several treatments of chemoembolization while on the 
waiting list. All transplanted patients were in the Milan criteria and had a 
MELD score of 22. Drop out from the list (tumor growth outside the Milan 
or criteria extremely critical clinical conditions) was considered also death of 
the patient. Actuarial survival time was calculated for both groups at 6, 12, 
24, 36, and 48 months. Patients’ survival was also calculated for HCC and 
HCV infected patients (96 patients) as compared to the same group of not-
transplanted patients receiving chemoembolization (196 patients). 
Results: At 6, 12, and 24-month survival was as follows: for HCC-LTx 
group 94.5%, 91.8% and 90.7%. For the HCC-list group 90.8%, 85,5% and 
69.4%. Survival was signifi cant different (p 0.0001) for the HCC-LTx patients 
beginning at 24 months after LTx and remained signifi cant at 36 and 48 months. 
No difference was noted before 24 months for both groups. For the HCV-
HCC patients that underwent LTx a signifi cant advantage in term of survival 
(p 0.0008) was noted as early as 6 months after transplantation and remained 
signifi cant at 12, 24, 36 and 48 months thereafter. 
Conclusions: Liver transplant offers a real advantage in terms of survival even 
in the fi rst 12-24 months post transplant for patients with HCC and cirrhosis that 
are good candidate for transplantation. Mortality related to surgical procedure 
itself does not increase mortality if compared to not-transplant patients. HCV-
HCC patients experienced a signifi cant increase in survival as early as 6 months 
after LTx when compared to HCC-HCV patients on the waiting list.
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THE TREATMENT OF SMALL HEPATOCELLULAR 2076 
CARCINOMA FULFILLING THE MILAN CRITERIA: 
HEPATIC RESECTION VERSUS LIVING DONOR LIVER 
TRANSPLANTATION
N. Kusunoki, M. Tominaga, T. Iwasaki, T. Fukumoto, M. Kido, S. Ogata, 
M. Takahashi, H. Kinoshita, K. Kuramitsu, Y. Ku
KobeUniversity Graduate School of Medical Sciences
Background: Hepatic resection (HR) is the treatment of choice for small 
hepatocellular carcinoma (HCC) in Child A patients, whereas living donor 
liver transplantation (LDLT) is usually reserved for Child B and C patients in 
Japan. However, it is still debated whether HR or LDLT in the best strategy 
for Child A patients. This study was to compare HR and LDLT for HCC within 
the Milan criteria. 
Methods: Between June 2000 and June 2007, 38 patients underwent LDLT and 
20 of 38 complicated by HCC at Kobe University. Fourteen of 20 recipients 
were within Milan criteria. During the same period, 161 patients underwent 
HR. Sixty-seven patients of 161 were within Milan criteria. In this study, we 
compared demographic data, tumor characteristics and survival of 14 LDLT 
patients and 67 HR patients with HCC within Milan criteria. All date were 
expressed by mean }SD.
Results: Mean age of LDLT and HR group were 56 }8 and 64 }14 respectively. 
Gender was similar in two groups (male/female: 12/6 vs 44/23). Rate of 
Hepatitis C virus infection was signifi cantly higher in the LDLT group (78% 
vs 56%, P<0.05). ICG R15 of LDLT group was also higher than HR group (40 
}15% vs 16 }6%, P<0.05). Tumor size, tumor number (solitary/oligonodular) 
and AFP levels were not signifi cant two groups (2.5 }1.5cm vs 2.6 }1.4cm, 
8/10 vs 37/30, 59 }55 ng/ml vs 43 }39ng/ml). Three- and 5- year patient 
survival rate were no signifi cant difference, however, 3- and 5- year disease- 
free survival rate was better for LDLT (100% and 100%) than for HR (60% and 
35%) (P<0.05). Recurrences of 67 patients treated by HR were observed in 31 
(47%). Initial recurrence of 25 patients (80%) in HR group was within Milan 
criteria and that of remaining 6 patients (9%) was without Milan criteria. 
Conclusions: Disease-free survival rate was signifi cantly better in the LDLT 
groups, whereas 5-year survival rate was similar in both groups. In HR groups, 
80% of initial recurrence was within Milan criteria. When initial recurrence 
was recognized, we usually consider rescue LDLT. We concluded that HR is the 
best initial treatment in patients with resectable HCC within Milan criteria.
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OUTCOMES OF PATIENTS WITH HEPATOCELLULAR 2077 
CARCINOMA THAT ARE TREATED VERSUS UNTREATED 
WHILE WAITING FOR LIVER TRANSPLANT
T. Heffron1, T. Pillen2, G. Smallwood1, C. Fasola1, A. Stieber1
1Emory University School of Medicine, 2Children’s Healthcare of Atlanta
Background: Hepatocellular carcinoma (HCC) is the most common 
malignant tumor originating in the liver. Current practice is to treat HCC with 
chemoembolization and/or radiofrequency oblation while the patient is awaiting 
transplant to avoid progression of the tumor. The United Network of Organ 
Sharing (UNOS) policy bases allocation of liver allografts on a calculated 
model for endstage liver disease (MELD) score. With the implementation of 
the MELD policy, the patients with HCC have been giving an infl ated MELD 
score to shorten their wait time. Current wait times nationally for HCC patients 
are 0.69 years (251 days) based on UNOS data.
Aim: The aim of this study is to report our experience and outcomes of liver 
transplant recipients with HCC that had received treatment of their tumors to 
patients that had not been treated while awaiting transplant. 
Methods: Patients were retrospectively reviewed at our center for time on 
waiting list, UNOS MELD score at time of transplant, actual MELD score at 
time of transplant, type of treatment for HCC, if any, and outcomes. 
Results: 50 patients were reviewed that received a liver transplant with HCC. 
The control group (n = 23) did not receive any type of treatment for HCC while 
the treatment group (n = 27) received chemoembolization ± radiofrequency 
oblation. The control group had similar UNOS MELD scores [25.2 (± 6.9) 
vs. 24.1 (± 2.7); p =0.774] and actual calculated MELD scores [17.6 (± 9.1) 
vs. 14.1 (± 6.8); p = 0.238] at transplant compared to the treatment group. 
The control group had longer time on the waiting list [421 (± 468) days vs. 
133 (± 183) days; p = 0.010] in part due to the longer follow-up period [617 
(± 393) days vs. 369 (± 400) days; p = 0.032]. Outcome comparisons were 
similar, 2 (8.7%) deaths in the control group compared to 4 (14.8%) deaths in 
the treatment group. In the treatment group, 4 (14.8%) patients had systemic 
effects of chemoembolization (alopecia and neutropenia) with one requiring 
total gastrectomy. There was a trend towards lower survival by Kaplan-Meier 
[81.05% (±0.1) vs. 88.9% (± 0.07); p = 0.194] in the treated group. Recurrence 
of hepatitis C (n=5) was the predominant cause of death, 2 patients in the 
control group and 3 patients in the treatment group. One died of metastatic 
breast cancer in the treatment group. 
Conclusion: Due to the short wait time prior to liver transplant and the 
possibilities of adverse events associated with chemoembolization, patients 
that did not receive treatment for HCC faired as well, if not better, than those 
receiving treatment. Further studies concerning this population are required.
LONG TERM OUTCOMES CONCURRENT ORAL SESSION 141: 
– INFECTION
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PREVALENCE AND CORRELATES OF INFLUENZA 2078 
VACCINATION AMONG RENAL TRANSPLANT PATIENTS
L. Berben1, K. Denhaerynck1, S. Schaub2, S. De Geest1
1Institute of Nursing Science, University of Basel, Switzerland, 2Division 
of Transplant Immunology and Nephrology, University Hospital Basel, 
Switzerland
Background: Immunosuppressive regimens increase kidney transplant 
patients’ risk of contracting life-threatening infl uenza. However, little 
information exists about the prevalence and correlates of infl uenza vaccinations 
in this population. 
Purpose: The purpose of this study was to determine the prevalence and 
explore correlates of infl uenza vaccination in RTx recipients.
Methods: This cross-sectional study used data of the Supporting Medication 
Adherence in Renal Transplantation (SMART) study. The convenience sample 
consisted of 356 adult RTx recipients (58.1% male; mean age 52.9 years 
(SD 13.53)) recruited from two Swiss transplant outpatient clinics. Infl uenza 
vaccination status was assessed by self-report (yes/no). Known correlates of 
vaccination in chronically ill patients (older age, cohabitation, higher education, 
higher socio-economic status, fi nancial stability, more co-morbidities, negative 
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smoking status, and follow-up center attendance) were entered into a multiple 
logistic regression. 
Results: Of the 356 patients, only 83 (23.3%) reported having been vaccinated 
against infl uenza in the previous year. Positive vaccination status was 
signifi cantly related to older age (OR: 1.04; 95% CI: 1.02-1.06). 
Conclusion: Despite national and international guidelines recommending 
infl uenza vaccination in RTx patients, infl uenza vaccination prevalence was 
low in this sample. This study’s results suggest that transplant centers need to 
implement policies to maximize infl uenza vaccination of their patients.
POSTER BOARD NUMBER P4 – 129
EFFECT OF ALEMTUZUMAB ON KIDNEY TRANSPLANT 2079 
RECIPIENTS WITH HEPATITIS C
R. Ouseph1,2, K. Ravindra2, M. Eng2, J. Gleason2, R. Nagubandi2, J. Buell2, H. 
Kumar1
1University of Louisville, 2Jewish Hospital
Kidney transplant recipients (KTR) with hepatitis C virus (HCV) have a 
higher risk of mortality and morbidity. The effect of immunosuppression on 
outcomes in HCV patients has not been well studied. Our protocol is to check 
HCV antibodies (Ab) in potential recipients. If the HCV Ab and follow up 
PCR are positive a liver biopsy is done. All HCV patients had evidence of 
fi brosis but no cirrhosis. This is a retrospective case control study of KTR 
with HCV liver disease treated with basiliximab induction, cyclosporine or 
tacrolimus (TAC), steroids, and mycophenolate mofetil (MMF) (Era 1 Jan 
1, 1994 – Oct 31, 2004) versus those treated with alemtuzumab, steroids (in 
operating room and day 1), TAC, and MMF (Era 2 11/1/2004-7/31/207). 
In addition, outcomes of KTR with and without liver disease receiving 
alemtuzumab were compared.
There was no signifi cant difference in 1 year creatinine (1.83 0.8 mg/dl and 2.00 
1.2 mg/dl) or SGOT (25.2 11.0 IU/L and 29.2 16.4 IU/L) between the recipients 
with hepatitis C liver disease in the Pre- and Post- Alemtuzumab era.
There was no signifi cant difference in 1 year creatinine (1.80 0.4, 1.60 0.9 mg/
dl) or SGOT (29.2 16, 23.6 16) in the Alemtuzumab groups with or without 
hepatitis C.
In summary, there was no signifi cant differences in 1 year data in HCV liver 
disease patients receiving alemtuzumab compared to historical control. There is 
no signifi cant differences in patients with and without HCV liver disease receiving 
Alemtuzumab. In conclusion, this preliminary data suggests alemtuzumab is safe 
in patients with liver disease from HCV. Future studies are needed to evaluate the 
effect of Alemtuzumab on HCV viral load and liver pathology.
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ADEFOVIR DIPIVOXIL IN COMBINATION WITH 2080 
LAMIVUDIN IN RENAL TRANSPLANTATION PATIENT WITH 
YMDD MUTAION. 
Y.K. Son, Y.H. Shin, J.K. Kim, S.S. Lee, K Hur
Bong Seng Memorial Hospital
Lamivudin resistant mutation in hepatitis B virus genome may occur during 
therapy. Adefovur dipivoxil has been found to be effective in patients 
with lamivudin resistant HBV, whether liver disease is compensated or 
decompensated.
We report a 22-year-old man who was normal HBV carrier (HBsAg+, HBeAb+, 
and HBcAb+) with no hepatitis activity on liver biopsy, who was transplanted for 
end-stage renal disease in 2005. Directly after transplantation he took lamivudin 
50mg qd for prophylaxis. Sixteen months posttransplant he had an HBV fl are 
with an AST of 328IU/ml. At that time his HBV DNA was > 108 copies/ml 
and virologic study showed HBeAg positive and YMDD mutation. He became 
jaundiced with peripheral edema, asictes, coagulopathy but No encephalopathy 
and hepatorenal syndrome was found. He was placed on adefovir dipivoxil 
10mg qod combined with lamivudin with initial rapid decreased in serum 
aminotransferase to < 100 IU/ml. And then 14 weeks later his HBV DNA 
became <2000 copies/ml and HBe Ag seroconversion was occurred.
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CASE REPORT: A FEMALE PATIENT FROM A COUNTRY 2081 
AREA IN COLOMBIA, WHO RECEIVED 18 YEARS AGO A 
RENAL TRASPLANT, PRESENTS WITH A DIAGNOSIS OF 
DISSEMINATED HISTOPLASMOSIS CHARACTERIZED FOR 
SEVERE CUATANEOUS INVOLVEMENT. 
FINDINGS ARE DISCUSSED AND A COMPLETE REVISION OF 
THE DISEASE IS DONE.
E.L. Marquez
Universidad Nacional De Colombia Departamento De Cirugía Y Morfología
Case report: A female patient from a country area in Colombia, who received 
18 years ago a renal trasplant, presents with a diagnosis of disseminated 
histoplasmosis characterized for severe cuataneous involvement. Findings are 
discussed and a complete revision of the disease is done.
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FULMINANT LEPTOSPIROSIS IN RENAL TRANSPLANT: 2082 
FIRST NORTH -AMERICAN CASE
D. Samarapungavan, L. Gerasymchuk, A. Swami, C. Carpenter, J. Szela, 
S. Cohn, M. Batke, B. Robinson-Dunn, R. Kanhere
William Beaumont Hospital
Leptospirosis, globally perhaps the most widespread zoonosis, results from 
infection with pathogenic spirochetes of the genus Leptospira. More common 
in the tropics, rodents, farm animals, and pets are reservoirs of this pathogen. 
Humans acquire the infection from direct exposure to infected urine, or through 
contaminated water or soil. About 100-200 cases are identifi ed annually in the 
United States with about 50% of cases occurring in Hawaii. There are only two 
prior reported cases of leptospirosis in renal transplant recipients, from Iran 
and Brazil.
A 48-year-old male with idiopathic MPGN type-I received a deceased-
donor renal transplant. At 3 months he developed transplant-glomerulopathy 
associated with donor-specifi c antibodies to Cw6 HLA antigens, treated with 
plasmapheresis & IVIg. At 6 months, Cellcept was switched to lefl unomide for 
BK-polyoma virus nephropathy. At 13 months, he developed unexplained fever, 
sweats, intermittent diarrhea, and gradual weight loss. Therapy of low-grade 
CMV viremia did not alleviate the symptoms. Over the next 5 months extensive 
investigations for infections, infl ammatory or occult malignant diseases 
were fruitless. At 18 months, he developed jaundice. Physical examination 
revealed icterus with moderate ascites, and hepato-splenomegaly. A blanching 
erythematous macular rash was noted over the pre-tibial skin. Liver tests 
showed a cholestatic pattern: total bilirubin 3.8 mg/dL, direct bilirubin 3.5 mg/
dL, alkaline phosphatase 414 IU/L, ALT 57 IU/L, AST 118 IU/L. His bilirubin 
continued to rise, peaking at 17.2 g/dl, while transaminases remained less than 
twice the upper limit of normal. Liver biopsy revealed a moderate cholestatic 
process with well preserved hepatic architecture. Scattered spirochetes, 
predominantly located in the hepatic sinuses, were identifi ed on Steiner stain 
and subsequently confi rmed as leptospira by specifi c immunoperoxidase 
staining performed at the U.S. Center for Disease Control and Prevention 
(CDC) in Atlanta. Skin biopsy of the pretibial rash also identifi ed a spirochete on 
Steiner stain. Commercial serum leptospira antibodies remained negative two 
weeks apart. He was treated with penicillin and immunosuppressant reduction. 
Unfortunately, his course was complicated by recurrent lower gastrointestinal 
bleeding, and overwhelming sepsis due to multidrug-resistant Acinetobacter 
baumannii pneumonia eventually causing his demise. Post-mortem serum was 
positive for Leptospira interrogans serovar icterohaemorrhagiae (LIsI) strain 
RGA by microscopic agglutination test performed at the CDC.
The clinical presentation of leptospirosis varies from subclinical infection 
to undifferentiated febrile illness to jaundice, renal failure and pulmonary 
hemorrhage. Colitis and vasculitis have been described in human disease. 
Molecular taxonomic studies at the CDC and elsewhere have identifi ed 13 
named and 4 unnamed species of pathogenic leptospires. Disease pathogenesis, 
poorly understood, probably includes both direct effects by leptospira and host 
immune response.
The protracted nature of our patient’s symptoms suggests a progressive 
subacute illness likely infl uenced by his immunosuppressants. Zoonotic 
exposures included two healthy outdoor dogs and a cat which died of renal 
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failure a month prior to the onset of his symptoms. There was no antecedent 
travel. Although we were unable to test his deceased cat, the dogs had negative 
leptospira titers. Rats are the typical reservoir hosts for LIsI. We suspect that 
the patient acquired the leptospira from his infected cat.
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HCV+ RENAL TRANSPLANT PATIENTS DO NOT 2083 
PROGRESS TO LIVER CIRRHOSIS FOLLOWING 
T-CELL DEPLETION
A. Sener, R. Barth, M. Cooper, L. Campos, E. Schweitzer, S. Bartlett, 
B. Philosophe
University of Maryland Medical Center
Kidney transplantation prolongs survival in hepatitis C virus-positive (HCV+) 
patients with end-stage renal disease (ESRD). However, the effects of induction 
therapy and chronic immunosuppression are unknown on the course of HCV 
infection and potential for cirrhosis in renal transplantation (RTx) recipients. 
We have retrospectively assessed parameters of liver function, Child-Pugh 
(CP) and MELD scores in HCV+ ESRD patients who received induction 
therapy with T-cell depletion (Group 1: Thymoglobulin, n=30) or an IL-2 
inhibitor (Group 2: Basiliximab, n=46). Pre-RTx liver biopsies were similar 
in Group 1 and 2. Patients were followed for a mean of 826 days (range 47 to 
2679 days) following RTx and received tacrolimus, mycophenolate mofetil, 
and sometimes steroids post-transplant. Overall graft survival was 84% in 
Group 1 and 85% in Group 2 (p > 0.05). Data were analyzed pre-RTx, at 30 
and 365 days and at time of last follow-up. Serum AST, ALT, platelets, INR, 
albumin and bilirubin did not change following RTx in either group. CP scores 
in Group 1 were not signifi cantly changed after RTx (5.5 ± 0.9 to 5.7 ± 0.9 
at last follow-up, p=0.53). Group 1 patients on steroid-free protocols (n=8) 
demonstrated declining CP scores from 6.0 ± 1.0 to 5.3 ± 0.5 at last follow-up 
that were not statistically signifi cant (p=0.31). Group 1 patients on steroids 
showed opposite trends of CP: 5.3 ± 0.6 pre-RTx vs 5.8 ± 1.1 at last follow-up 
that similarly did not reach statistical signifi cance (p=0.18). Group 2 CP scores 
declined from 5.8 ± 0.8 to 5.4 ± 0.9 at last follow-up (p=0.04). There was no 
difference between CP or MELD scores at any point between the groups. As 
expected, MELD scores improved signifi cantly following RTx and remained 
low up until the fi nal visit (p=0.001); this was attributed to the drop in serum 
creatinine post-RTx. Neither the use of Thymoglobulin or Basiliximab resulted 
in acute hepatitis resurgence or the development of cirrhosis post-transplant. 
We have not identifi ed any association between choice of induction agent or 
maintenance immunosuppression regimens, including steroid withdrawal, 
with impaired hepatic function or progression to liver cirrhosis in HCV+ 
RTx patients. T cell depletion was well-tolerated by HCV+ RTx patients and 
resulted in good graft outcomes. Interestingly, CP scores declined after renal 
transplantation in the Basiliximab induction group.
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COMPARISON OF REAL TIME PCR AND CMV 2084 
ANTIGENEMIA ASSAY IN TREATMENT OF CMV INFECTION
S.H. Kim1,4, H.E. Yoon1, E-J. Oh2, S.C. Park3, B.S. Choi1, Y.S. Kim1, 
I.S. Moon3, B.K. Bang1, S.Y. Kim1, C.W. Yang1
1Department of Internal Medicine, The Catholic University of Korea, 
2Department of Laboratory Medicine, The Catholic University of Korea, 
3Department of Surgery, The Catholic University of Korea, 4Department of 
Internal Medicine, Chung-Ang University
Background: Cytomegalovirus (CMV) infection is one of the most important 
infectious complications in the kidney transplantation. We evaluated the 
effi cacy and accuracy of CMV RT-PCR compared to pp65 CMV antigenemia 
assay which was commonly used diagnostic method for monitoring the CMV 
infection. 
Methods: We investigated all suspect CMV cases with the qualitative plasma 
DNA PCR assay (PCR) and the pp65 antigenemia assay (AG) in kidney 
transplant recipients. And if results were positive, we measured both tests 
weekly. 
Results: Ninety three patients (mean age 48 ± 13 years, 49 male) provided 139 
samples for both test. Nine patients developed symptomatic CMV infection. The 
statistically signifi cant correlation between both tests was found (R2 = 0.754, 
p <0.001). The PCR (more than 1,000 CMV DNA copies) had a sensitivity, 
specifi city and positivie value and negative predictive value of 100, 98, 81 and 
100%, respectively, compared with 56, 100, 100 and 95%, respecitively, for 
antigenemia test (more than 10 of 20,000 peripheral blood mononuclear cells). 
And antigenemia assay was rapidly decreased after ganciclovir treatment 
(median negative conversion time; 1week), but the PCR assay was more slowly 
decreased (median negative conversion time: 2.5 week). Conclusion: The PCR 
assay was more accurate refl ected the course of CMV disease compared with 
the antigenemia assay.
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INFECTIOUS COMPLICATIONS IN 142 PERSIAN 2085 
KIDNEY TRANSPLANT RECIPIENTS DURING ONE YEAR 
FOLLOW-UP
G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Introduction: Infectious complications after renal transplantation are 
associated with signifi cant morbidity and mortality. In developing countries, 
the infections spectrum, their chronological occurrence and the risk factors are 
different from developed regions. A considerable amount of time and money is 
spent on the Medicare of these patients.
Material and Methods: In a 2-year period (2002-2004), 142 patients were 
studied and followed for 1-year. Immunosuppressive regimen contained 
Cyclosporine A, Cellcept and Prednisolone. Each patient was assessed on 
regular visits according to the ward protocol then results of the investigations 
were registered.
Results: The major causes of renal failure were hypertention(41%) and diabetic 
nephropathy(15%). The overall incidence of infections was 54.2%. The most 
common site of infections was lower urinary tract (41.5%). The most common 
causes of infections were Klebsiella(22.5%) and Cytomegalovirus(17.6%). 
Wound infection occurred in 4.9% patients. There were 24.6% episodes of acute 
rejection. Of these, 14 cases were administered Anti Thymocyte Globulin and 
4 received cadaveric allografts. Overall mortality was 7.7%. Infection-related 
mortality was 3.5% with developing sepsis. Graft loss was seen in 11.2%cases, 
of whom 2 had developed Cytomegalovirus infection, 2 experienced urinary 
tract infection(UTI) and 5 developed sepsis. Female gender had no impact on 
UTI incidence. Mycobacterial and Hepatitis C infections were noticeably low, 
compared with other studies.
Conclusion: This study identifi es infections as the cause of morbidity and 
mortality in post-transplant period. Patients having higher creatinine level and 
receiving high dosage of drugs at the discharge time are considered as risky 
cases and should be evaluated more obsessively.
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EPIDEMIOLOGIC STUDY OF KDNEY TRANSPLANT 2086 
PATIENTS, SUFFERING FROM TUBERCLOSIS IN EMAM 
EDUCATIONAL SURVEY TREATMENT HOSPITAL IN URMIA 
IN 2007.
B.A. Markazi, E. Ahmadnezhad, A. Ravandi, S. Hatami, N. Sepehrvand
Introduction: Using immunosuppressive drugs in transplant patients leads to 
immune system suppress and causes intracellular infection.Mycobacterium 
Tuberculosis is one of the bacteria, hidden inside Tcells and if a person suffers 
from an immunodefi ciency problem, it will become active and the person will 
be involved.
The risk of infection in these patients is 50 times and the mortality is 10 times 
more than among the normal population and furthermore the probability of 
kidney transplant rejection is 30% more in Tuberculosis patients.
According to mentioned subjects, it’s necessary to study characteristics of 
transplant patients suffering from Tuberculosis.
Methods: The cross-section study in descriptive analytical way was done with 
studying the documents of transplant patients suffering from Tuberculosis 
in Emam hospital during 10 years from 2007-1997.Totally 33 patients were 
under study the Pierson coeffi cient and chi- score test were used for statistic 
analyses.
Conclusion: The total infection prevalence was 3.79%.The most prevalence 
rate was between the ages classes of 40 to 50.There was no sex differences 
in infection. The average duration of analysis before transplant was 8+1.5 
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months.97% of the cases have been transplanted once before. The PPD was 
negative in 100% cases.The average interval between infection of TB and 
transplantation was 19.5+4.5 months. Pulmonary, milliary and meningeal TB 
were the most found types in this group.
A disorder in kidney function occurred in 24.2% of people suffering from TB 
in the form of Cr increase. Kidney transplant rejection of 12% of patients made 
them a comeback to dialysis.
A meaningful statistic relation between infection to Tb and kidney transplant 
rejection was found (P<0/000).
The rate of mortality among patients suffering from TB was 30.3%.There’s a 
meaningful statistical relation between infection and death in these patients. 
Discussion: According to high rate of death and transplant rejection in people 
suffering from TB, It’s necessary to study all transplanted cases, treat them on 
time and continue the follow-up treatments of the patients.
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POST KIDNEY TRANSPLANT HEPATITIS C VIRUS AND 2087 
ITS IMPACT ON GRAFT AND PATIENT SURVIVAL
M. Taherimahmoudi, P.G. Pourmand, A. Mehrsai, H. Wahhabaghai, 
M. Nikoobakht
Urology Research Center, Tehran University of Medical Sciences, 
Tehran, Iran
Objectives: 1-to determine the post transplant positive anti – HCV patients 
who were negative before transplantation. 
2-Does graft and patient survival alter in whom became positive anti HCV?
Materials and Methods: From 1989 –2005, 1000 kidney transplantation were 
performed in our center. 162 anti HCV negative patients were included in this 
study. The mean age was 32 years (7- 69) (33.9% female and 66.1% male), 
and followed for 4 years. Liver function tests and viral markers measurements 
carried out every three months. During follow up period any acute or chronic 
rejection and mortality were recorded.The results were analyzed by statistical 
package SPSS using Exact, chi square and ANOVA tests.
Results: Anti HCV positive was occurred in 24 patients (14.8%), all were 
confi rmed with third generation recombinant immunoblot assay (RIBA 3)
and HCV RNA polymerase reaction. All of them had history of pre-transplant 
transfusion, and 83% of them were under hemodialysis for more than 30 
months. We found no acute or chronic rejection in Anti HCV positive patients. 
three patients (12.5%) had liver enzymes increase.Two anti HCVpositive 
patient expired.due to acute hepatitis. No chronic hepatitis C were seen.
Conclusions: Although, in our study the impact of post – transplant anti 
HCV positive on graft survival was not signifi cant, but long term evaluation 
for better prejudice is mandatory, so, we highly recommend evaluation of anti 
HCV negative patients after kidney transplantation.
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ISONIAZID PROPHYLAXIS SIGNIFICANTLY REDUCES 2088 
THE INCIDENCE OF TUBERCULOSIS IN PATIENTS AFTER 
RENAL TRANSPLANT
J. Nel1, C.S.H. Bouwens1, D.J. Nel2, M.R. Moosa1
1Division of Nephrology, Tygerberg Hospital and University of Stellenbosch, 
2Centre for biostatistical sciences, University of Stellenbosch
Tuberculosis frequently complicates renal transplantation and often leads 
to loss of graft function and even loss of life. This study undertook to 
retrospectively establish the incidence and nature of tuberculosis in our kidney 
transplant population under different immunosuppression regimens, and assess 
the effi cacy of prophylactic isoniazid against tuberculosis.
Patients and Methods: All laboratory-confi rmed cases of tuberculosis were 
identifi ed from the records of patients transplanted between April 1976 and 
31 July 2004. Recipients were categorized according to immunosuppressive 
regimen and whether they received tuberculosis prophylaxis: patients in group 
A received steroids and azathioprine (conventional therapy); those in group B 
received cyclosporine as part of triple therapy; group C received triple therapy 
and isoniazid 300 mg/day prophylaxis for the fi rst year after transplantation. 
Patients who underwent multiple transplants were counted once only and 
categorized in the group under which the primary transplant was performed. 
Three patients who contracted tuberculosis after a second transplant were 
excluded from subgroup analysis. The data collected on patients and the 
various patterns of tuberculosis was entered on Excel spreadsheet and analyzed 
statistically. The overall incidence of tuberculosis in the 3 groups was compared 
as well as the incidence at 6, 12 and 24 months post-transplant using the ML 
chi-square test. Graft- and patient survival were estimated using Kaplan-Meier 
analyses, and compared with recipients who did not develop post-transplant 
tuberculosis using the log-rank test. 
Results: Of 672 renal allograft recipients treated over 340 months, 43 (6.4%) 
developed tuberculosis. There was no difference in the cumulative incidence 
between patients on conventional and triple therapy respectively, but in patients 
on a cyclosporine-based regimen, INH prophylaxis signifi cantly reduced the 
incidence of Tuberculosis (p = 0.021). Because unfair bias would exist towards 
patients on Azathioprine, due to the longer duration of time elapsed since 
transplantation compared to the two groups on cyclosporine and cyclosporine 
with INH prophylaxis, we compared the incidence of tuberculosis in the three 
groups at 6, 12 and 24 months after kidney transplantation. We were able to 
show a trend of benefi t towards the use of INH prophylaxis at 6 and 12 months 
post-transplant, which culminated in a statistically signifi cant difference in 
the incidence of tuberculosis from 24 months post transplantation onwards 
(p=0.024).
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RENAL TRANSPLANTATION IN HCV POSITIVE 2089 
PATIENTS
S. Soni
Sathya Kidney Centre
Introduction: Hepatitis C virus (HCV) infection is highly prevalent in end 
stage renal disease patients. Effect of HCV on transplant outcome is not well 
established. The aim of the present study was to determine the effect of HCV 
infection on the outcome of kidney transplantation at a single transplant center.
Methods: The study analysed 100 patients who underwent kidney 
transplantation between 1998 to 2003. Minimum post transplant period follow 
up was of fi ve years. Of this, twenty four patients were HCV+. Complete clinical 
data including type and duration of dialysis, pre- and post- transplantation 
transfusions, donor, immunosuppression, PTDM and rejection episodes was 
collected. The patients were divided in two groups: HCV positive and negative. 
Strata 6 software was used for statistical analysis.
Results: Of 100 patients 68 were males and 32 females. Most donors were live 
related (65%) followed by live unrelated(30%) and cadaver donors(5%). All 
patients in HCV positive group were on hemodialysis while 10.4% cases were 
on CAPD in HCV negative group. Although, one year graft survival was similar 
in both groups, fi ve year graft survival as well as patient survival was higher in 
HCV negative. HCV+ patients had higher rate of acute rejection and PTDM 
Conclusion: Our results show that HCV+ patients have similar one year but 
inferior fi ve year outcome post transplant compared with HCV negative.
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HISTOPLASMOSIS IN RENAL TRANSPLANT2090 
R. Schiavelli, E. Maiolo, D. Di tullio, R. Sabbatiello, M. Raño, M. Pattin
Hospital General De Agudos “Dr Cosme Argerich” 
The prevalence of mycotic infections in solid organ transplant patients varies 
from 5to 50% and it is similar in renal and cardiac transplant patients and 
much higher in liver transplant. The most important incidence of invasive 
mycotic infections is observed in bone marrow transplant and it is the major 
morbidmortality cause in this group of patients.
In all transplants, 80% of invasive mycotic infections are caused by Candida 
and Aspergillus, and may be primary infections or reactivations. 
The main disadvantages in immunosupressed patients are the absence of signs 
and symptoms as well as the lack of detectable infections in the blood. 
Histoplasmosis in renal transplant is frequently caused by reactivation in patients 
who live in endemic areas. Enviromental exposure and immunosuppression 
determine the severity of the infection. 
In our patients the incidence of cutaneous manifestations is more frequent than 
the one that is reported.
Aim: To analyze the incidence, clinical manifestations and prognosis of renal 
transplant recipients with histoplasmosis diagnosis.
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Methods: We evaluated the clinical records of patients with histoplasmosis 
diagnosed by means of the following methods:
Giemsa stain and cultures of cutaneous lesion materials or from material 
obtained through biopsies of the skin, liver and intestine.
Blood cultures by lysis centrifugation and bone marrow, bronchoalveolar and 
cerebrospinal fl uid cultures and serological techniques of immunodifusion and 
contraimmunoelectrophoresis.
We excluded patients with superfi cial mycosis.
Results: Out of 580 transplant patients, 31 showed mycotic infections (18 
M/13 F) mean age 41.8 (19 – 69). There were 32 isolations and 1 coinfection 
episode with two different agents. Seven patients developed histoplasmosis 
(22%) Tabla 2.
The typical cutaneous manifestations were observed in 4 of the 7 patients and 
they are slightly painful reddish purple nodules with a tendency to soften and to 
develop cytosteatonecrosis and suppuration. Histopathological fi ndings reveal 
necrotic areas and neutrophilic and histiocytic infi ltrate with the presence of 
yeastlike elements, compatible with Histoplasma capsulatum. Two patients had 
pulmonary involvement, one lobar infi ltrate and the other one, miliary. 
Three cases were manifested before 180 days; two were related to the 
antirejection treatment. one of them with a reactivation of CMV and another 
one with chronic C-virus hepatopathy. All the patients received anphotericin B 
and itraconazole, and two of them died.
Conclusion: The incidence of histoplasmosis is slightly higher than the one 
reported, probably due to epidemiological reasons. The cutaneous manifestation 
was observed in more than 50% of the patients therefore enabling us to reach an 
early diagnosis of the infection.
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STATISTICAL MODEL FOR PREDICTION OF CMV 2091 
INFECTION RECURRENCE AFTER INITIAL TREATMENT IN 
KIDNEY ALLOGRAFT RECIPIENTS
B. Matlosz1, D. Dêborska-Materkowska1, M. Cieciura2, A. Sadowska1, 
A. Kwiatkowski3, T. Grochowiecki4, M. Durlik1
1Dept of Transplantation Medicine And Nephrology, 2Higher School of 
Electronic Technology, 3Dept of General and Transplantation Surgery, 4Dept 
of General Transplantation and Vascular Surgery
Introduction: CMV infection is the most prevalent opportunistic infection 
in solid organ transplantation. Although it is possible to control the infection 
easily with gancyclovir it is not rare for patients to have recurrence. There are 
several factors that can infl uence the recurrence rate.
Methods: We have analyzed retrospectively medical records of all consecutive 
kidney allograft recipients transplanted at our center since 01.03.2004 till 
01.10.2007. Out of 397 patients transplanted in this period 56 were treated 
for CMV disease. 10 were excluded from analysis because they did not meet 
criteria for CMV disease. Clinical data were collected regarding the course of 
the disease and the treatment, rejection episodes, immunosuppressive therapy, 
prophylactic antiviral treatment, recurrence of the disease. Finally 24 parameters 
were chosen for statistical analysis. In order to predict the recurrence of the 
disease after initial treatment MANOVA was used.
Results: Mean observation time was 737 days (69-1524). Out of 46 patients 
with CMV disease the recurrence was observed in 9 (19,5%). In 90% of 
cases CMV disease developed within fi rst 40 weeks after transplantation. The 
MANOVA analysis revealed that it is possible to predict CMV recurrence using 
6 of the parameters (PRA value, initial dose of steroids, dose of cyclosporine 
or tacrolimus per kg body weight, mycophenolate dose per kg body weight and 
time after transplantation) using the following equation:
DF (discriminant function) = (PRA x -0,0784) + (initial steroids x -0,1374) + 
(csa/kg x 0,6914) + (tac/kg x 45,8910) + (mmf/kg x -0,1047) + (time after tx 
x 0,0315)
The mean discriminant variables were -3,2473 and -5,6757. The sensivity of 
the test was 90,9%, specifi ty 46,1%, predictive value was 81% and accuracy 
–; 78%. 
Conclusions: The most important factors for CMV recurrence after initial 
treatment included immunosuppressive treatment used (4 out of 6 features). 
Using described statistical method it is possible to accurately defi ne the group 
of patients at high risk for recurrent disease.
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INFECTION-RELATED MORTALITY IN RENAL 2092 
TRANSPLANTATION (RT)
M. Cherif1, S. Barbouch1, R. Goucha1, M. Ounissi1, E. Abderrahim1, 
F.B. Hamida1, F. Elyounsi1, Y. Gorgi2, T.B. Abdallah1.2, A. Kheder1
1Charles Nicolle Hospital Department of internal medicine A, Charles Nicolle 
Hospital Tunis, 2Immunology Laboratory, Charles Nicolle Hospital Tunis
Infections represent a major cause of morbidity and mortality among renal 
transplant recipients. Our aim was to analyze the incidence and aetiology of 
infection-related mortality among a cohort of renal transplant recipients.
From 1986 to 2006 we collected all causes of mortality among patients receiving 
a renal transplantation. The date of transplant, the last follow-up/death, type of 
transplant, age and cause of death were tabulated into a database.
296 adults RT were performed at Charles Nicolle Hospital. 56 (18.9%) were 
cadaveric, 240 (81.08%) were living transplants. Recipients were 194 males 
(65.5%) and 102 females (34.5%), whose mean age (±SD) was 31.96 ± 9.4 
years (range 16-61 years). 
244 (82.43%) patients presented at least one episode of infection during the 
follow-up. The causes of mortality were: infection 32 (58.18%), cardiovascular 
7 (12.72%), cancer 6 (10.9%), other causes 9 (16.34%) and unknown 1 (1.81%). 
Infection-related mortality were sepsis 18 (56.25%), pneumonia 7 (21.87%), 
invasive viral infection 4 (12.5%) and invasive fungal infection 3 (9.37%).
The actuarial patients survival rates at 1, 5 and 10 years in the group of patients 
who have presented at least one infection was respectively: 95.8%, 87% and 
75.5%, whereas in the group of patient who have never presented an infection, 
was respectively 98%, 94.9% and 94.9%. The differences between the two 
groups were statistically signifi cant (P = 0.01).
This study confi rmed that infections remain a major complication in the post 
transplant period and increase the risk for death of patients.
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ANEMIA AMONG LONG-TERM RENAL TRANSPLANT 2093 
RECIPIENTS
A. Ghafari
Urmia University of Medical Sciences
Background: The effects of anemia on cardiovascular disease among the end-
stage renal disease population suggest that it may be one of the major factors 
explaining this complication among kidney transplant recipients. Systematic 
investigation into the prevalence of post transplantation anemia (PTA) is 
therefore of critical importance.
Materials and Methods: This cross-sectional study of data from 650 patients 
followed at a single outpatient transplant clinic utilized the guidelines of the 
American Society of Transplantation to defi ne anemia as a hemoglobin (Hb) 
<130 g/L in men or <120 g/L in women.
Results: Mean age was 43 ± 12 years, and included 52% of men. Mean GFR 
was 64 ± 33 mL/min, and mean time since transplantation was 63 ±51 months. 
Mean Hb for the total sample was 139 ± 32 g/L (males: 141 ± 37 g/L; females: 
129 ± 28 g/L; P <.005). Overall we defi ned 254 patients (39%) as anemic. 
Among the total population, 137 patients (21%) had mild; 78 (12%) moderate; 
and 39 (6%) severe anemia. Upon bivariate analysis, there was no correlation 
between age and Hb level. Anemia was more prevalent among women than 
men (45% vs 33%; P <.01). Among all patients, 98 (15%) were iron defi cient 
(TSAT <20%). Iron defi ciency was more prevalent among women than 
men (19% vs 12%; P <.05). Upon bivariate analysis, serum transferrin was 
positively correlated with albumin (r =.254, P <.001) and negatively with 
CRP (r =2.11, P <.001). Serum albumin levels positively correlated with Hb (r 
=.214, P <.001) and negatively with CRP (r =154, P <.001). Upon multivariate 
linear regression analysis (dependent variable: serum transferrin), CRP and 
albumin remained signifi cantly and independently associated with serum 
transferrin after controlling for potential confounding variables (P<.001). For 
the whole population, there was a signifi cant correlation between GFR and 
Hb (r =.376, P <.01). When analyzed individually, only MMF was associated 
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with more frequent anemia (P <.01; Table 1); Therapy with ACEI, which was 
prescribed in 163 patients (25%), was associated with lower mean serum Hb 
levels: 130 ± 23 vs 133 ± 15 g/L (P <.05). Multivariate Analysis To analyze 
the complex relationship between anemia (Hb as the dependent variable) 
and the multiple, potentially relevant covariables, we used linear regression 
analysis. In this model (r =.383, P <.01), serum transferrin, gender, GFR, 
serum albumin, iron defi ciency, ACEI, and MMF were signifi cantly and 
independently associated with blood Hb. Among all patients, 66 (10%) were 
given iron supplementation. Only 22 (22.5%) of the 98 iron-defi cient patients 
received iron therapy and 18 (7%) of the 254 anemic patients were treated 
with EPO.
Conclusions: PTA is a prevalent, under treated condition. Based on our results, 
we suggest that protein/energy malnutrition and/or chronic infl ammation were 
independently associated with anemia.
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PROTRACTED FEBRILE MYALGIA SYNDROME IN 2094 
A RENAL TRANSPLANT RECIPIENT WITH FAMILIAL 
MEDITERRANEAN FEVER
M.A. Halim, T. Al-Otaibi, M.R.N. Nampoory, P.A. Asif, F. Donia, T. Said, 
P. Nair, M. Samhan
Hamed Alessa Organ Transplantation Center
Background: Drug induced toxic myopathy is repeatedly reported in familial 
Mediterranean fever (FMF) patients receiving cyclosporine (CsA) and 
colchicine combination. Protracted febrile myalgia syndrome (PFMS) is a 
severe form of FMF which may need aggressive treatment including high dose 
of steroids.
Case summary: A 34 years old male who is known to have FMF for more than 
15 years. He developed renal failure due to secondary amyloidosis. He was on 
hemodialysis for 6 months till he received live unrelated renal transplant which 
is functioning normally. 
There were no acute attacks of FMF for 3 years before transplantation. He was 
on 0.5 mg colchicine once daily which was continued after transplantation. 
His immunosuppressive regime was antithymocyte globulin as induction and 
prednisolone, mycophenolate mofetil and CsA as maintenance therapy. 
After 2 months he presented with severe myopathy and muscle biopsy 
showed evidence of toxic myopathy most likely due to cyclosporine when 
it was initiated in addition to colchicine. CsA was changed to sirolimus and 
colchicine was stopped. He was gradually improving apart from residual 
chronic myalgia requiring oral analgesics. Prednisolone dose was reduced 
gradually to 5 mg daily.
Eight months posttransplant he was readmitted with severe arthralgia, 
prolonged fever, pleuritic pain, diffuse abdominal pain, macroscopic 
hematuria, protienuria and diarrhea. All investigations for infections, internal 
malignancy, hyperparathyroidism and rheumatic diseases were negative other 
than high C-reactive protein (192mg/l) and erythrocyte sedimentation rate 
(120mm/hour).
The clinical diagnosis was acute attack of FMF presenting as PFMS as he was 
not receiving colchicine for 6 months. In spite of the history of toxic myopathy 
6 months earlier he was challenged with colchicine as 0.5mg twice daily which 
was well tolerated. There was signifi cant improvement of most of his symptoms 
within days and graft function continued to be normal.
Conclusion: FMF may reactivate after renal transplantation if colchicine is 
discontinued and present as PFMS which responded to restarting colchicine in 
our case in spite of the history of toxic myopathy.
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IMPROVED BONE METABOLIC MARKERS AND 2095 
DECREASED BONE MINERAL DENSITY: ONE YEAR 
FOLLOW-UP IN A DIABETIC RENAL ALLOGRAFT RECIPIENT
R. Murakami1, N. Nakamura1, T. Fujita1, M. Shimada1, K. Okumura1, 
S. Narumi2, M. Sasaki2, T. Yoneyama3, T. Koie3, C. Ohyama3
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Bone disease in type 2 diabetes mellitus is characterized by a low rate of bone 
formation especially caused by the marked reduction in serum osteocalcin (OC) 
levels, that is a characteristic fi nding in diabetic patients both with and without 
renal dysfunction. On the other hand, metabolic bone disease leading to bone 
mineral loss is a well-recognized problem in patients with end stage renal disease 
(ESRD). Therefore, osteodystrophy which causes ostealgia or bone fracture is one 
of the most severe complications in ESRD patients with diabetes mellitus because 
ESRD and diabetes mellitus have unfavorable effects on bone metabolism. Even 
renal transplantation, which is one of the excellent renal replacement therapies, 
is not able to solve this problem completely because most patients need to be 
treated with corticosteroids which affect bone metabolism and worsen diabetes. 
In the present study, we investigated the changes of bone metabolism markers and 
bone mineral density (BMD) up to 1-year after successful renal transplantation 
with minimum administration of corticosteroids and good glycaemic control in a 
male patient with type 2 diabetes. We report the infl uence of renal transplantation 
upon the bone metabolism under both unfavorable circumstances of ESRD and 
diabetes mellitus.
A 39-year-old man received a living related renal transplantation in June 2006 
after 3 months on hemodialysis. He was treated with triple immunosuppressive 
regimen for the maintenance which consisted of tacrolimus, mycophenolate 
mofetil and predonisolone. Fortunately, he has not experienced any rejection or 
infection until one year after the surgery with stable creatinine levels of 1.8~2.0 
mg/dL. We measured plasma OC and bone specifi c alkaline phosphatase (BAP) 
levels as bone formation markers, tartrate resistant acid phosphatase (TRAP) 
and osteoprotegerin (OPG) levels as bone resorption markers and BMD from 
day 0 to 12 months, respectively.
The bone formation markers started to increase from 2 and 4 months after 
transplantation, respectively, and reached the normal range for patients 
without renal insuffi ciency at 12 months after transplantation. On the other 
hand, as for the bone resorption markers, both TRAP and OPG levels remained 
unchanged or slightly increased throughout the period. In spite of the increased 
bone formation markers and the unchanged bone resorption markers, BMD 
levels had decreased gradually throughout the period. However, his lumbar 
spine BMD remained decreased 6.9% at 12 months, which is the same rate of 
decrease as non-diabetic patients.
It is reported that in renal transplant recipients, corticosteroid withdrawal 
resulted in an increase in BMD with a corresponding increase in serum OC. 
Moreover, it is also reported that in diabetic patients without renal insuffi ciency, 
good glycaemic control improved osteoblast function with increased OC 
levels and resulted in more favorable bone metabolism. Considering above, 
even in renal allograft recipients whose primary cause of ESRD is diabetic 
nephropathy, the reduction of corticosteroid, or the withdrawal of it if possible, 
and strict glycaemic control may contribute to the prevention of metabolic bone 
disease with bone mineral loss such as ostealgia or bone fracture, which greatly 
affects their daily life.
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EARLY MEASUREMENT OF PARATHYROID HORMONE 2096 
LEVELS IN RENAL TRANSPLANT PATIENTS UNDERGOING 
ELECTIVE PARATHYROIDECTOMY FOR TERTIARY 
PARATHYROIDISM: A POTENTIAL TOOL FOR PREDICTING 
SATISFACTORY EXCISION?
S. Bhandari1, J. England2
1Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, 
2Department of ENT, Hull and East Yorkshire Hospitals NHS Trust
Background: Adequacy of parathyroid surgery to normalise PTH values 
remains problematic in terms of predicting satisfactory tissue remove without 
leading to adynamic bone disease.
Aim: To examine the utility of intra-operative and early postoperative 
parathyroid hormone (PTH) levels to predict effectiveness of parathyroid tissue 
excision in a cohort of kidney transplant patients undergoing elective primary 
parathyroidectomy for tertiary hyperparathyroidism.
Methods: Renal transplant recipients (RT) undergoing elective total 
parathyoidectomy for tertiary hyperparathyroidism were eligible for inclusion. 
Intact PTH levels were measured at induction of anaesthesia (PTH0), intra-
operatively immediately following removal of parathyroid tissue (PTH1) and 
15 minutes after tissue resection (PTH2).
PTH levels were subsequently measured 3, 6 and 12 months post-operatively. 
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Raised PTH levels at these time points were used as a measure of potential 
active remnant parathyroid tissue. Calcium, phosphate and the product were 
compared pre-operatively with measurements made at intervals following 
surgery. Data are given as means±SEM. Comparison of data at different time 
points is made using the Wilcoxon signed ranks test.
Results: Twelve patients (7 male, 5 female; mean age 58±3years) underwent 
surgery. PTH levels fell signifi cantly from baseline (PTH0 247.6±50pg/ml) 
at each of the two time points (PTH1 116.2±44pg/ml; PTH2 67.3±35pg/ml; 
p<0.001) and when the postoperative levels (PTH2) were compared to baseline 
levels (PTH0) with p<0.001. Calcium levels at baseline (2.82±0.04mmol/L) 
signifi cantly dropped at 3 and 6 months levels postoperatively (2.42±0.02 
and 2.44±0.02mmol/L; p<0.001)), while there was also a signifi cant increase 
in phosphate over the time period (0.86±0.06mmol/L to 1.15±0.07 and 
1.1±0.06mml/L respectively; p<0.05) and an increase in the calcium phosphate 
product (2.43±0.15 mmol2/L2 versus 2.79±0.18mmol2/L2; p<0.01).
Three patients had raised PTH levels at 6 months post procedure. Analysis of 
these cases showed a fall in peri-operative PTH at each of the time points. There 
was no change in renal function from baseline to 1 year post parathyroidectomy 
(161±11 at baseline versus 174+12μmol/L at 1 year, p=0.18). No rejection 
episodes occurred in the follow-up period.
Conclusion: PTH levels fall rapidly following removal of parathyroid tissue in 
transplant patients with tertiary hyperparathyroidism. Intra-operative and early 
post operative measures of PTH, although suggestive of surgical success may 
not indicate satisfactory parathyroid tissue excision. Raised PTH levels seen 
later in patients with remnant parathyroid tissue may be due to reactivation 
following removal of the suppressive effects of high circulating PTH levels 
or due to parathyroid tissue re-growth. Surgery is not detrimental to long-term 
transplant function.
POSTER BOARD NUMBER P4 – 147
CHANGES IN BONE MINERAL DENSITY AND 2097 
SELECTED METABOLIC PARAMETERS OVER 36 MONTHES 
FOLLOWING RENAL TRANSPLANTATION 
D.S. AL– Gabri1, J. Zadražil 2, K. Krejčí2, P. Horák2, P. Strebpl 2, 
V. Horcicka2, K. Baker1
1Nephrology and transplantation dep., General Military Hospital, Sanaa, 
Yemen 
23rd Department of Internal Medicine Teaching Hospital and school of 
Medicine, Palacky University, Olomouc, Czech Republic
Aim: The aim was to evaluate the changes in serum levels of selected 
bone metabolism indicators and bone density over 36 months following 
renal transplant. A partial objective was assessment of the effectiveness of 
prophylactic administration of D-vitamin and calcium preparations to prevent 
the progression of osteopathy after kidney transplantation. 
Patients and methods: The population consisted of 80 patients after kidney 
transplantation 47 males and 33 females, average age of 53,9 ± 9,4 years.All 
patients were treated after transplantation by acombination of cyclosporine-
A,mycophenolate mophetil or azathioperin and prednison.They were 
prophylactically given AD-vitamin 800 IU and calcium 1000mg a day. During 
the monitoring, the serum creatinine concentration in all recipients was < 200 
μmol/l (subgroub A with creatinine concentration <120μmol/l, subgroup B 
with creatinine 120-200μmol/l). The concentration of serum parathormon, 
serum level of bone fraction of alkaline phosphatase, serum phosphorus and 
calcium concentration and phosphorus and calcium 24 hours excretion were 
examined 2 weeks and 3 years after transplantation. In the same time period, 
radiographs of thoracic, lumbar spine and hip joints were taken and the bone 
density (BMD) of lumbar (L) spine and hip was determined by Dual – Energy-
X–Ray (Lunar Prodigy). 
Results: Three years after the transplantation- in subgroup A, there was a 
BMD decrease in 75% recipiens in L spine area and the hip. BMD increase 
was in 20% recipiens. In subgroup B, BMD decrease was in 83% recipiens, 
BMD increase was in 30% recipiens. In subgroup A three years after kidney 
transplant, the average PTH serum concentration was 94,7+-57,2pg/ml, while 
in subgroup B, the average PTH concentration was 163 ± 42,9pg/ml.
No clinical either radiographic fracture was detected in these subgroups. 
Conclusions: We conclude that prophylactically adminestration of vit.D 
and calcium is not enouph effective to prevent the progression of osteopathy 
after renal transplantation.Changes in bone density evaluated after the kidney 
transplantation is affected by graft function.
PTH concentration seems to correspond with serum creatinin. Alarge number 
of patients with low BMD in the post-transplantation period indicates the 
seriousness of the problem and is a challenge for optimal prevention and 
treatment of the metabolic complication of kidney transplantation to be found.
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LACK OF ASSOCIATION BETWEEN OSTEOPOROSIS 2098 
AND OSTEOPENIA WITH VERTEBRAL FRACTURES IN 
LONG-TERM RENAL TRANSPLANT RECIPIENTS.
R. Marcén1, N. Rodriguez1, C. Caballero2, C. Vaamonde3, A. Fernandez1, B. 
Ponte1, J.J. Villafruela1, J. Pascual1, F.J. Burgos4, J. Ortuño1
1Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal 
University Hospital – Nuclear Medicine, 3Ramón Y Cajal University Hospital 
– Radiology, 4Ramón Y Cajal University Hospital – Urology
Background: In the general population, osteoporosis is associated with an 
increased risk of vertebral fractures. Bone loss and the development of both 
osteopenia or osteoporosis frequently occurs early after transplantation. Their 
long-term prevalences and their association with the risk of fractures are not 
well kown. The objective of the present work was to determine the incidence 
of osteopenia and osteoporosis and vertebral fractures in renal transplant 
recipients with stable graft function and with a follow-up of at least 10 years.
Patients and methods: 84 renal transplant recipients, 49 male and 35 female, 
were included in the study. The mean age was 42.5±12.6 years and the follow-
up was 131±20 months (range 120-150 months). Initial immunosuppression 
consisted of cyclosporine in double or triple therapy. Measurements of 
bone mass density (BMD) were done by dual-energy X-ray absorptiometry 
(DEXA). The assessment of vertebral fractures was performed by conventional 
radiography using a semiquantitative technique.
Results: Serum creatinine at the time of the study was 1.7±0.5 mg/dl (range 
0.9-3.4), BMD at lumbar spine 0.863± 0.122 g/cm2, T-score -1.90±1.14 and 
Z-score -1.11±1.13. According to the WHO classifi cation: 23 patients (27.4%) 
had osteoporosis (T score <-2.5), 43 patients (51.2%) had osteopenia (T 
score >-2.5 and <-1) and 17 patients (20.2%) were normal. BMD was better 
preserved at femoral neck: 37 patients (44.0%) had normal BMD; 37 (44.0%) 
had osteopenia and 10 (11.9%) osteoporosis. When analyzed together, patients 
with osteoporosis or osteopenia were older at the time of transplant (37.5±11.7 
vs 43.6±12.7; p=0.061) and had lower body weight (78.6±16.9 vs 71.3±13.4 kg; 
p=0.053). There were no differences in age, sex distribution, time on dialysis, 
iPTH, calcidiol and calcitriol blood levels, or other biochemical parameters. 
Vertebral fractures (mostly mild vertebral deformities) were observed in 69.6% 
of patients with osteoporosis, in 55.2% of patients with osteopenia and in 
52.9% of patients with normal lumbar spine BMD. Peripheral fractures were 
more common in patients with osteoporosis (p=0.053)
Conclusions: Osteoporosis or osteopenia were present in about 80% of 
long-term renal transplant recipients. Lumbar spine BMD osteoporosis was 
associated with peripheral fractures. However, mild vertebral deformities were 
not associated with the presence of osteopenia or osteoporosis. The signifi cance 
of mild vertebral deformities has to be elucidated.
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THE IMPACT OF LOW CYCLOSPORINE DOSE 2099 
ASSOCIATED WITH EVEROLIMUS IN BONE LOSS AFTER 
KIDNEY TRANSPLANTATION
R. Marcén1, C. Caballero2, J. Pascual1, J.J. Villafruela1, A. Fernandez1, 
J.L. Teruel1, F.J. Burgos3, J. Ortuño1
1Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal 
University Hospital – Nuclear Medicine, 3Ramón Y Cajal University Hospital 
– Urology
Background: Bone loss is a common complication after renal transplantation. It 
has been associated with immunosuppression with steroids and anticalcineurin 
inhibitors. There are no data about the effects of sirolimus and everolimus on 
bone mineral density (BMD) in renal transplant recipients. It has been postulated 
that these agents could have a sparing effect on bone loss. The purpose of the 
present study was to prospectively investigate the impact of treatment with 
everolimus and low dose cyclosporine in BMD after renal transplantion.
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Patients and methods: 15 patients, 6 males and 9 females with a mean age of 
50.5±13.5 years and on treatment with cyclosporine, everolimus (1.5 or 3 mg/
day) and prednisone (CsA-EVE) were included in the study. The group was 
compared with another 15 renal transplant recipients transplanted immediately 
before and treated with tacrolimus, mycophenolate mofetil and prednisone 
(TAC-MMF). Measurements of BMD were done by dual-energy X-ray 
absortiometry (DEXA) at the lumbar vertebral bodies L2-L4 and in the right 
femoral neck at the time of transplant and at 1 year..
Results: In CsA-EVE patients, lumbar spine BMD decreased from 
0.860±0.201 g/cm2 at baseline to 0.822±0.199 g/cm2 at 1 year (p<0.05). 
Femoral neck BMD slightly increased, it was 0.800±0.239 g/cm2 at baseline 
and 0.787±0.179 g/cm2 at 1 year (NS). There was a tendency to higher bone 
loss with the higher everolimus dose. On the contrary, lumbar spine BMD 
did not signifi cantly change in recipients on TAC-MMF, lumbar spine BMD 
at baseline was 0.980±0.150 g/cm2 and 0.959±0.119 at 1 year. Femoral 
neck BMD increased from 0.825±0.199 at baseline to 0.866±0.166 g/cm2 
at 1 year. There were no differences between the groups in age at transplant, 
sex distribution, number of post-menopausal women, time on dialysis, body 
mass index at transplant, graft function at 12 months (SCr 1.4±0.3 mg/dl in 
TAC-MMF vs 1.6±0.7 mg/dl in CsA-Eve; NS), iPTH levels at the time of 
transplant and at 12 months.
Conclusions: Our fi ndings do not support the hypothesis that immunosuppression 
with everolimus could have bone-sparing effects. But the number of patients is 
too small to draw defi nitive conclusions.
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ANEMIA IN KIDNEY TRANSPLANTED PATIENTS. 2100 
PREVALENCE AND RISK FACTORS.
R. Marcén1, B. Ponte1, N. Rodriguez1, A. Fernandez1, J. Pascual1, 
J.J. Villafruela1, J.L. Teruel1, F.J. Burgos2, J. Ortuño1
1Ramón Y Cajal University Hospital – Nephrology, 2Ramón Y Cajal 
University Hospital – Urology
Background: Anemia after kidney transplantation is a common complication 
in the fi rst post-operative months and when graft function declines. It has been 
associated with adverse effects on patient and graft outcomes. Furthermore, the 
target hemoglobin levels recommended by the transplant clinical guidelines is 
not generally achieved. The purpose of the present study was to investigate the 
prevalence of anemia, the risk factors associated with its development and the 
adequacy of its treatment in a cohort of patients with funcioning grafts.
Patients and methods: 555 patients, 328 men and 228 women with a mean 
age at transplant of 45.9±14.6 years were included in a cross-sectional study. 
Anemia was defi ned as a serum hemoglobin (Hb) £ 13 g/dl in men and £ 12 g/
dl in women. 
Results: The mean Hb was 13.5±1.7 g/dl, serum ferritin 153±185 ng/dl 
(41.4% <100 ng/ml) and the estimated glomerular fi ltration rate (eGFR) by 
the abreviated MDRD equation 47.3±18.7 ml/min/1.72 m2. A total of 157 
patients had anemia (28.3%): mild 17.6%, moderate 6.7% and severe 4.0%. 
In the univariate analysis, Hb levels correlated with eGFR (r=0.44; p=0.000) 
and seroalbumin (r=0.29; p=0.000). Anemia was more common in the 179 
patients on treatment with angiotensin converting enzyme inhibitors (ACEI) 
or with angiotensin II receptor antagonists (ARA): 38% vs 24% (p=0.001). 
The multivariate analysis showed the same risk factors observed in the 
univariate analysis. Anemia was negatively associated with eGFR (OR=0.96; 
CI95% 0.94-0.97; p=0.000), serum albumin levels (OR=0.19; CI 95% 
0.09-0.50; p=0.000) and with the treatment with ACEI or ARA (OR=1.65; 
CI 95% 1.04-2.62; p=0.033). Anemia was not related to sex, serum ferritin 
levels or immunosuppressant agents. About 27% of anemic patients and 41% 
of those with Hb<11 g/dl were on treatment with erythropoiesis-stimulating 
agents. 
Conclusions: Anemia was common after transplantation and some patients 
were not adequately treated. The factors associated with this complication 
were graft function, protein/energy malnutrition or chronic infl ammation and 
antihypertensive agents.
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POST RENAL TRANSPLANT ERYTHROCYTOSIS – 2101 
SINGLE CENTER INDIAN EXPERIENCE.
R. Balasubramaniyam, J. Das, N. Soosairaj, S. Das
KG Hospital and Post Graduate Medical Institute
Aim: To evaluate the incidence, presentation and the outcome of ‘post renal 
transplantation erythrocytosis’ among our transplant recipients.
Materials and Methods: Patients who underwent renal transplantation in our 
center from July 1999 to Jan 2008 were retrospectively evaluated. The pre and 
post transplantation Hemoglobin, Erythropoietin usage, graft function, timing 
of the erythrocytosis, treatment and the outcome were analyzed. Persistent 
elevation of Hematocrit more than 51% was defi ned as ‘post transplantation 
erythrocytosis’.
Results: Total number of patients was 157 (M: F = 129: 28). 150 patients 
underwent live related renal transplantation and 7 were cadaver transplant 
recipients. 85 patients (54%) received Erythropoietin on dialysis, though 75% 
inadequately. (Due to fi nancial constrains). 
Pre transplant hemoglobin was < 6 gms% in 20 patients (12.7%), between 6-8 
gms% in 71 patients (45.2%), 8 – 10 gms% in 49 patients (31.2%) between 10 – 
12 gms% in 14 patient’s (9%) and > 12 gms% in 3 patients (1.9%). 13 patients 
smoked prior to their transplantation and none post transplantation. Native 
kidneys were preserved in 154 patients and 3 patients with massive polycystic 
kidneys underwent bilateral native nephrectomy. 110 patients had functioning 
grafts and 37 had graft dysfunction/loss at the end of the study period.
Total number of patients with post transplant erythrocytosis were 13 patients 
(8.2%). There were 12 men and 1 woman of which 7 had used Erythropoietin 
pre transplant. 9 patients developed erythrocytosis within the fi rst year, 3 in 
the second year and 1 patient in the third year after transplantation. 1 patient 
was symptomatic and in others erythrocytosis was detected on routine testing. 
All patients had normal graft function when they had erythrocytosis. All of 
them were treated with ARB’s and theophylline. One patient with symptomatic 
erythrocytosis underwent venesection.
11 patients responded to therapy and 2 patients who developed erythrocytosis 
recently have persistent elevation of hemoglobin at the end of the study 
period.
Conclusions: Our incidence of post renal transplantation erythrocytosis is 8.2%. 
Majority were asymptomatic and showed good response to treatment. Most of 
them were men and had good graft function. Low pre transplant hemoglobin, 
less of smoking and inadequate pre transplant erythropoietin usage are the 
possible reasons for lower incidence of erythrocytosis in our experience. 
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ANEMIA AFTER KIDNEY TRANSPLANTATION: ROLE 2102 
OF HEPCIDIN, ERYTHROPOIETIN, IRON STATUS AND RENAL 
FUNCTION.
G.F. Hillebrand, U. Schoenermarck, M. Wessely, K. Kehl, T. Wendler, 
B. Hartmann, W. Samtleben
Nephrology Division, Department I of Internal Medicine, University Hospital 
Munich – Großhadern
Aim: Anemia remains prevalent after successful kidney transplantation. Aim 
of the study was to determine the relation between the occurrance of post-
transplant anemia and hepcidin, erythropoietin, iron status and renal graft 
function. 
Patients and methods: In a cross-sectional study 102 kidney transplant 
recipients were investigated (70 men, 32 women, in average 17 months after 
kidney transplantation). Serum pro-hepcidin and erythropoietin were measured 
using commercially available kits. Creatinine and parameters of iron status 
were analysed by routine clinical laboratory methods. 20 healthy controls with 
normal renal function were analysed as control group. 
Results: Anemia was found in >50% of kidney transplant recipients, although 
mostly mild (hemoglobin in average 12,4 g/dl). There was a signifi cant negative 
correlation between haemoglobin and creatinine (r = -0,44, p<0,001), ferritin (r 
= -0,34, p<0,001), ferritin index (r = -0,43, p<0,001) and erythropoietin (-0,24, 
p<0,03). Serum pro-hepcidin was not increased in kidney transplant patients 
as compared to healthy controls (96 vs. 115 ng/ml). Pro-hepcidin correlated 
signifi cantly with ferritin (r = 0,268, p=0,007), but not with hemoglobin or 
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renal graft function. The type of immunosuppression had no signifi cant effect 
on levels of hemoglobin or pro-hepcidin. Patients with anemia as compared 
to patients without anemia had a signifi cantly higher degree of renal graft 
dysfunction (creatinine 2,3 vs. 1,4 mg/dl), a higher ferritin value (798 vs. 257 
ng/ml) and a lower ferritin index (8,9 vs. 12,3). 
Conclusions: Anemia is a frequent fi nding in kidney transplant recipients. In 
this study the presence of anemia was associated with impaired renal function 
and higher levels of ferritin, possibly refl ecting a low-grade infl ammatory state. 
There was no correlation between hepcidin and the degree of anemia or the 
type of immunosuppression. 
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ANEMIA AFTER RENAL TRANSPLANTATION – AN 2103 
UNDERESTIMATED PROBLEM?
U. Ott1, M. Busch1, T. Steiner2, G. Wolf1
1Department of Internal Medicine III, 2Department of Urology
Anemia is an underestimated disease after renal transplantation. In end stage 
renal disease anemia is known to be an independent risk factor for cardiovascular 
disease and death. However, data about anemia after renal transplantation 
are rare.
We investigated 208 stable patients who underwent fi rst renal transplantation 
during 2000 and 2006. Patients were 66 women and 142 men. Immunosuppression 
was performed with Cyclosporin A and Mycophenolate Mofetil, Tacrolimus 
and Mycophenolate Mofetil or Rapamycin with Mycophenolate Mofetil. About 
one third of the patients were treated with corticosteroids.
37.5% (78 patients) had anemia at time of investigation. 8.6% of the patients 
had severe anemia with hemoglobin level < 6.8 mmo/l in men and < 6.2 mmol/l 
in women. In 8.2% of the cases we found moderate anemia (hemoglobin 6.8 
– 7.4 mmol/l in men and 6.2 – 6.8 mmol/l in women). 20.6% (29 men and 14 
women) had mild anemia with hemoglobin level <8 mmol/l in men and less 
than 7.45 mmol/l in women. 55.5% of patients with severe anemia, 53% of 
patients with moderate and 11.6% of patients with mild anemia were treated 
with erythropoietin. We found a signifi cant correlation with the glomerular 
fi ltration rate calculated by MDRD formula (p < 0.05). Of the patients with a 
serum creatinine level > 200 μmol/l, 63% were anemic, compared with 22% 
of those with a serum creatinine level < 200 μmol/l (p < 0.05). No correlation 
was found to immunosuppressive medication or to the treatment with ACE 
inhibitors and angiotensin II receptor antagonists. Iron defi ciency may be 
another reason.
The prevalence of anemia after renal transplantation is high. Most patients 
suffer from mild anemia. We found an unexpectedly high incidence of anemia 
in patients with functioning graft, more than one third of all patients are anemic. 
Anemia as a risk factor for cardiovascular events, mortality and graft failure 
should be treated more carefully in patients after renal transplantation.
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EFFECTIVE PROPHYLAXIS OR TREATMENT WITH 2104 
BISPHOSPHONATES IN SOLID ORGAN RECIPIENTS 
NON-INVASIVELY MONITORED WITH BONE TURNOVER 
MARKERS
M. Durlik1, E. Nowacka-Cieciura1, A. Sadowska1, T. Cieciura1, T. 
Bczkowska1, 
S. Nazarewski2, A. Chmura3
1Transplantation Medicine and Nephrology Dept., Medical University of 
Warsaw, 2General, Vascular and Transplantation Surgery, Medical University 
of Warsaw, 3General and Transplantation Surgery, Medical University of 
Warsaw
Reduced bone density and fractures are common problem before and after 
solid organ transplantation (Tx). Short courses of bisphosphonates (bisph) 
are proposed as prophylaxis early after Tx or as the treatment of established 
osteoporosis. The aim of the study was to defi ne the risk factors for reduced 
bone mineral density (BMD) in organ transplant recipients, and to evaluate the 
effects of bisph therapy on BMD and bone turnover markers. Methods: This 
is a pool analysis of 125 kidney, liver or simultaneous pancreas and kidney 
(SPK) recipients, 61% of whom (group Bi, n=76) received bisph (alendronate 
or risedronate) therapy as: 1) prophylaxis in case of baseline osteopenia or 
osteoporosis early after Tx, n=54 (40 kidney, 14 liver Tx) or 2) treatment of 
established osteoporosis in the late period after Tx, n=22 (8 SPK, 14 kidney Tx). 
Group C (n=49) with normal T-score in the early period after Tx (21 kidney, 1 
SPK, 14 liver transplant recipients) and with osteopenia or normal T-score late 
after Tx (13 SPK) served as control. The recipients received corticosteroids, 
calcineurine inhibitors and in most cases mycophenolate mofetil as well as 
alphacalcidiol. BMD (DXA) and bone turnover markers (serum bone alkaline 
phosphatase – BAP, osteocalcine – OC, active isoform 5b of the tartrate-
resistant acid phosphatase 5b – TRACP5b, pyridinoline crosslinks – PYD, and 
urine deoxypyridinoline crosslinks -DPD/creat, were evaluated. The therapy 
lasted for 13,4 months. Results: The groups did not differ according to age, 
gender, menopause frequency, and the time after Tx. The number of patients 
with second or third transplant was signifi cantly higher in group Bi than in 
control group. The patients in group Bi had lower BMI at baseline and in the end 
of the treatment compared to group C. The time on dialysis in renal recipients 
was longer in group Bi than in control group. In group Bi mean lumbar T score 
improved from (-)2,42±1,04 to (-)2,08±1,04 (p<0,05). The relative changes in 
lumbar BMD under bisph therapy and in control group were: (+)5,0±10,4% 
and (-)2,4±7,3%, respectively, p<0001. Baseline BAP, OC and TRACP5b were 
signifi cantly higher in Bi than in C group. In general, baseline BAP, OC and 
DPD/creat negatively correlated with baseline BMD. Signifi cant decrease in 
OC, TRACP5b and PYD was observed under bisph therapy. The treatment was 
well tolerated, GFR was >60 ml/min. Conclusion: Low BMI, retransplantation, 
and – in renal Tx – long time on dialysis, are risk factors for posttransplant bone 
disease. Bisph prevent early bone loss in organ transplant recipients as well as 
effectively treat established osteoporosis in this population. The higher baseline 
bone turnover markers in patients with lower BMD suggest the prevalence of 
high turnover bone disease in these patients. The increase of BMD after bisph 
is paralleled by the fall in bone markers. '
LONG-TERM OUTCOMES CONCURRENT ORAL SESSION 143: 
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KIDNEY GRAFT SURVIVAL RATE DON’T IMPROVE BY 2105 
ERA: THE IMPACT OF FACTOR “AGE”
M. Salvadori, E. Bertoni
Renal Unit Careggi University Hospital
Accordin registry data on kidney transplantation, graft survival rate improves 
because of rejection rate reduction but is impaired by the increasing number 
of older donors and recipients. As the age of both donors and recipients 
dramatically increaed in our country,aim of this study was to verify in our 
center how the graft survival rate (GSR) changed by era.
We compared both the 5 year actual GSR and the 5-year death censored 
GSR of 89 recipients transplanted in 1991-1995 (period A) with 221 
recipients transplanted in 1996-2000 (period B). Due to the introduction of 
immunosuppressants such as MMF, Neoral and IL-2R inhibitors, we expected 
an improvement in GSR in period B. The two period rejection rates and the 
incidence of donors and recipients >50 years were considered. Kaplan-Meier 
Estimates and Log-Rank test were performed by the Collaborative Transplant 
Study (CTS) whom our data had been regularly sent to.
Period B 5-year GSR was lower with respect to period A (76.3% vs 82%). 
The death censored GSR was similar (87.1% vs 87.5%). The period B acute 
rejection incidence was 18% vs 40% of period A (p<0.001). Both overall donor 
and recipient age had the highest impact on 5 year GSR: for donor age 21-50 yrs 
86.2% vs 65.7% for donor age >50 yrs (p<0.0001). Similar effect was observed 
for recipient age: 84.1% for age 21-50 vs 68% for age >50 yrs (p=0.0023). In 
period A donors >50yrs were 23.6% vs 50.2% in period B (p<0.001). Similarly 
period A recipients >50 were 35.9% vs 42.9% in period B (p<0.01). 5 year GSR 
of recipients with donor <50 yrs improved in period B with respect to period 
A (89.2% vs 87.2%). Similarly the 5-year GSR of recipients <50yrs improved 
(85.2% vs 81.5%). Considering the death censored 5-year GSR for period B 
with respect to period A we observed a signifi cant improvement either for 
donor >50 yrs (82.5% vs 65.8%) and for recipient >50 yrs (90.2% vs 81.2%).
Kidney GSR of patients transplanted in 1991-1995 was higher with respect 
to 1996-2000. This data disagree with the GSR expected by the reduction of 
1-year rejection rate due to immunosuppressants. Expanded donor criteria can 
account for such discrepancy. Indeed in period B with had more donor and 
Poster Abstracts Thursday 14 August 2008
6 9 1
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
recipients >50 years. Most of graft failure were due to death with function, but 
also a poorer quality of kidneys accounts for this phenomenon. Indeed looking 
for GSR of patients <50 years we observed an improvement as expected.
POSTER BOARD NUMBER P4 – 156
EVALUATION OF RENAL TRANSPLANT RECIPIENT IN 2106 
A SINGLE CENTRE OF BANGLADESH.
S. Islam1, R. Alam1, H. Rahman1, H.U. Rashid1, F. Khan2, N.U. Chowdhury3
1Bangabandhu Sheikh Mujib Medical University, 2National Institute of kidney 
diseases and urology, 3Dhaka Medical College Hospital
Renal transplantation (Tx) is the treatment of choice for most patients with end 
stage renal disease. In our centre renal Tx started and continue from 1988, but 
post Tx patient evaluation has been not well established. In this study we tried 
to establish the evaluation of post transplant recipient 
Total 214 ESRD patients were transplanted from July 1995 to December 2005. 
Maximum number of Tx were done (33) on 2002 & minimum (7) on 1995. All 
patients were live related donors, mothers were the major donors which was 
about 33% followed by brothers (29%), sisters (16%) and fathers about 14%.
Among the transplanted patients 138 (64.48%) were survivors, 19 (8.87%) 
under went graft failure and returned on dialysis and 57 (26.73%) died. 
Among the survived patients, 115 Tx recipients were evaluated and revealed 
that, 83(72.17%) developed HTN, 32 (27.83%) chest infection (specifi c and 
non-specifi c), 29 (25.22%) graft dysfunction, 29 (25.22%) UTI, 22 (19.19%) 
diabetes, 18 (15.65%) CMV infection, 9 (7.83%) CVD, & 9 (7.83%) having 
post Tx proteinuria. 
Over all graft survival in fi rst year was 85%, third year 75%, fi fth year 65% & 
tenth year 50%
In conclusion, results of renal Tx in this center is not enough. So to increase 
number of transplantation needed to overcome the existing live related donor 
scarcity as well as increased number of transplant centers in our country.
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A NATIONAL SCREENING STUDY FOR ANDERSON-2107 
FABRY DISEASE AMONG MALE KIDNEY TRANSPLANT 
RECIPIENTS
J. Kleinert1, P. Kotanko2, M. Spada3, S. Pagliardini4, E. Paschke5, 
T. Voigtländer6, C. Schwarz7, H. Holzer8, M. Födinger9, 
G. Sunder-Plassmann1
1Division of Nephrology and Dialysis, Department of Medicine III, Medical 
University Vienna, 2Renal Research Institute, New York, USA, 3Department 
of Pediatrics, University of Torino, Italy, 4Newborn Screening Unit, Regina 
Margherita Children’s Hospital, Torino, Italy, 5Laboratory of Metabolic 
Diseases, Department of Pediatrics, Medical University Graz, Austria, 
6Institute of Neurology, Medical University Vienna, Austria, 7Krankenhaus 
der Elisabethinen, Linz, Austria, 8 Division of Nephrology, Department of 
Medicine, Medical University Graz, Austria, 9 Clinical Institute of Medical 
and Chemical Laboratory Diagnostics, Medical University Vienna, Austria
Anderson-Fabry disease is a rare X-linked lysosomal storage disorder due to the 
defi ciency of alfa-galactosidase A (AGAL), resulting in cellular accumulation 
of glycosphingolipids. Typical early symptoms include pain in the legs, cold 
intolerance, hypohidrosis and gastrointestinal complaints during childhood. 
The progression of the disease leads to cardiac, renal, and central nervous 
system complications, as well as premature demise.
The incidence of Anderson-Fabry disease is reported between 1 in 117000 and 1 
in 240000 life births. However, recent studies suggest a much higher incidence 
among male newborns. Although the awareness for this rare disease has 
increased recently, the diagnosis is often delayed for many years or even missed. 
In this context, studies among patients with cardiomyopathy, juvenile stroke, 
or chronic kidney disease on dialysis revealed a surprisingly high prevalence 
of Anderson-Fabry disease among these high-risk groups. For example, case-
fi nding studies of dialysis patients revealed a 10-times higher prevalence of 
Anderson-Fabry disease as compared to European dialysis registry data. 
We therefore hypothesized that Anderson-Fabry disease is under-recognized in 
prevalent male kidney transplant recipients. To test this hypothesis, we initiated 
a nationwide case-fi nding study for Anderson-Fabry disease in Austria. This 
nation-wide study in Austria enrolled 1306 patients (~65% of all kidney 
transplanted males) from 30 kidney centers. AGAL activity was determined 
from fi lter paper dried blood spots by a fl uorescence assay. A positive screening 
test was defi ned by an AGAL activity below 1.5 nmol/h/mL. In patients with 
a positive blood spot-screening test, AGAL activity was re-examined in 
peripheral blood leukocytes. Genetic testing for mutations in the GLA gene was 
done by sequencing to confi rm the diagnosis of Anderson-Fabry disease. Two 
previously not recognized cases with Anderson-Fabry disease were identifi ed. 
Together with three already known renal allograft recipients with Anderson-
Fabry disease, 5 out of the 1306 patients enrolled in this study suffered from 
Anderson-Fabry disease (prevalence of 0.383%; 1 per 261 patients). Our study 
is the fi rst showing that a diagnosis of Anderson-Fabry disease can be missed 
even in patients who undergo kidney transplantation. Case-fi nding strategies 
may be considered a useful tool for diagnosis of this rare disease that may be 
somewhat more prevalent among kidney transplant recipients as compared to 
dialysis populations. 
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A CASE OF GUILLAIN BARRE SYNDROME IN A 2108 
KIDNEY TRANSPLANTED PATIENT TREATED WITH 
IMMUNOSUPPRESSIVE AGENTS: IS THE CAUSE DUE TO 
DRUG COMPLICATIONS OR AN OPPORTUNISTIC VIRAL 
INFECTION?
S. Lee2, J.H. Shin1, H.K. Song1, W. Byon2, K.J. Yoon2, D.J. Kim2, 
S.J. Hyun2
1Dept. of Neurology, Hallym Univ. College of Mediciene, 2Dept. of Surgery, 
Hallym Univ. College of Mediciene
Backgrounds: The Guillain-Barre syndrome(GBS) has not only been 
commonly reported in viral infection with upper respiratory symptoms but also 
rarely in organ transplanted patients treated with immunosuppressive agents, 
especially cyclosporine.
Case: 47 year old male who had been taking immunosuppressive agents 
after kidney transplantation 6 years ago was admitted for weakness of the 
upper and lower extremities and painful discomfort on both calves starting 
from 4 days before admission. He had no previous infection history but 
immunosuppressive agents had been changed from cyclosporine to tacrolimus 
1 month prior to admission. On neurologic examination, he showed ascending 
quadriparesis and absence of deep tendon refl exes of all extremities. Despite 
the lack of albuminocytologic disproportion in the cerebrospinal fl uid(CSF), 
conduction block and decreased compound muscle action potential(CMAP) 
were revealed on nerve conduction study. After starting continuous infusion 
of Immunoglobulin G (400mg/kg) intravenously for 7 days, he showed 
improvement in motor weakness and pain.
Conclusion: Organ transplanted patients have more chance of opportunistic 
viral infection owing to immunosuppressive agents. Preceding viral infection 
may precipitate GBS or correlate with it. Furthermore, immunosuppressive 
agents may induce the Guillain-Barre-like syndrome as an acute drug 
complication in itself.
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EFFECT OF RENAL TRANSPLANTATION ON SPERM 2109 
QUALITY AND SEX HORMONES LEVEL
G. Pourmand, A.R. Mehrsai, M. Taherimahmoudi, M.R. Nikoobakht
Urology Research Center,Tehran University of Medical Sciences
Objectives: we examined the effect of successful renal transplantation on 
semen parameters, sexual function and sex hormones profi le in a clinical trial.
Material and Methods: A total of 30 patients on hemodyalysis underwent 
renal transplantation. Preoperative and postoperative sperm density, motility, 
and morphology were analyzed. Preoperative follicle-stimulating hormone 
(FSH), luteinizing hormone (LH), prolactin and testostrone levels were 
measured and compared to six months postoperative results. Sexual function 
was measured before and after transplantation using an abbreviated version of 
the International Index of Erectile Function (IIEF), with a successful outcome 
defi ned as a level of satisfaction of 4 or 5 on a 5-point scale. The paired-samples 
T-test was used to measure level of statically signifi cance in all analysis.
Results: We found that sperm motility improved signifi cantly (p<0.05) 
without concomitant signifi cant changes in morphology and density (p>0.05). 
Testostrone level increased and FSH, LH and prolactin decreased signifi cantly 
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(p<0.05) after renal transplantation. Of 30 patients 16 were impotent before 
operation and fi lled the questionnaire. There was a signifi cant positive correlation 
between baseline sexual function and postoperative sexual function.
Conclusion: Although sperm morphology and density did not improve after 
renal transplantation, there was highly signifi cant changes in motility of sperms. 
Hormonal changes in hemodyalysis patients improve after transplantation and 
return to near normal. Sexual function is also signifi cantly improved. Future 
studies need to confi rm these data.
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OUTCOME OF 18 CASES OF SIMULTANEOUS KIDNEY 2110 
AND DONOR SPECIFIC BONE MARROW TRANSPLANTATION
A. Seraji, G. Pourmand, A.R. Mehrsai, M.R. Nikoobakht, M. Taherimahmoudi
Urology Research Center,Tehran University of Medical Sciences
Objectives: To evaluate the effect of simultaneous donor specifi c bone marrow 
transplantation on patient survival.
Materials & Methods: Since 1997, 81 patients received renal transplantation 
in our center and were followed up for presence and magnitude of 
michrochimerism using DRB1 region of HLA class by PCR. 18 of these 
patients were selected to receive donor’s bone marrow. The bone marrow was 
extracted from iliac crest of the donor just prior to nephrectomy. The cell count 
was determined and enough volume containing 3-5 million celis per Kg weight 
of recipient was ingected just after the transplantation. The rest of the patients 
were regarded as control group. The blood sample of recipients were taken 
pre operatively and one week, 1, 3, 6, 12, 18, 24 months after operation.The 
blood sample donor were also taken before the operation. The samples were 
tested for urea, creatinine, sodium, potasium, calcium, phospher, blood cell 
count hemogiobin and cyclosporine A levels. Samples prior to operation were 
also tested for DRB1 alleles in both donor and recipients by PCR.Afterward the 
recipients samples taken at above mentioned intervals were tested for presence 
and persistence of donors DRB1 alleles.
Results: Our results indicates that creatinine levels at all intervals does not 
differ signifi cantly in DMBT and control group. The rate of acute rejection is, 
however, lower in patients who received DMBT as compared to the control 
group (one case, 5.6% and 6 cases, 9.5% respectively). In control group 4 of 
the patients with acute rejection episode responded to therapy. The chronic 
rejection episodes were also lower in DBMT group (1 case, 5.5%). There were 
7 cases of chronic rejection (11.1%) in control group. The graft survival rate 
was 94.4% in DBMT group and 87.3% in control group.
Conclusion: Our results shows that simultaneous DBMT and renal 
transplantation may have some positive effect on graft and patient’s survival.
POSTER BOARD NUMBER P4 – 161
TRANSPLANT NEPHRECTOMY DURING LAST 10 2111 
YEARS IN CUMC
I.S. Moon1, S.C. Park1, Y.S. Won1, J.I. Kim1, Y.B. Koh2
1The Catholic University of Korea, Kangnam St. Mary’s Hospital, 2JungAng 
University Medical Center
The transplant nephrectomy was performed in cases of nonfunctioning grafts 
due to various causes. There are increased number of kidney transplantations 
in the worldwide, and there are also increasing numbers of allograft failures. 
But the management of the failed allograft that is not immediately symptomatic 
remains controversial. The transplant nephrectomy was more common nearly 
twice in patients with early compared to late graft failure. Some reports have 
advocated against the removal of the asymptomatic failed allograft due to the 
morbidity and mortality associated with transplant nephrectomy. Other reports 
have advocated that because of a source of sepsis or chronic infl ammation of 
failed allograft, it should be routinely removed. Our study was performed by 
retrospective reviewing of medical data. Among 555 kidney transplant patients 
for 10 years between Jan 1997 and Nov 2007, there were 43 cases (7.7%) 
of transplant graft nephrectomy. The duration of interval between kidney 
transplantation and transplant nephrectomy ranges from 1 day to 168 months 
with mean 26.8 months. The main reasons of transplant nephrectomy were 
acute or hyper-acute rejection with anemia within 1 month (14 cases (32.6%)), 
for the space of 2nd kidney transplantation (12 cases (27.9%)), infection signs 
like pain, fever and pyuria (9 cases (20.9%)). In patients with early graft 
failure with acute or hyper-acute rejection or bleeding, the nephrectomy was 
associated with an increased risk of death. Except 12 cases for 2nd kidney 
transplantation, the transplant nephrectomy was not common (5.6%), but the 
number of transplant nephrectomy are gradually increasing in recent years 
(prior 5 years: 13 cases, recent 5 years: 30 cases).
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A CASE OF SPINAL CORD COMPRESSION 2112 
COMPLICATING TERTIARY HYPERPARATHYROIDISM IN A 
RENAL TRANSPLANT PATIENT
C. Milton, J Barbara
Department of Renal Medicine, Flinders Medical Centre
Introduction: Tertiary Hyperparathyroidism is commonly present in patients 
with End Stage Kidney Failure (ESKF) who have a functioning renal allograft. 
We describe renal osteodystrophy of the thoracic vertebrae leading to spinal 
cord compression in a patient with a functioning 
renal allograft. In addition, a reduction in glomerular fi ltration rate (GFR) was 
observed in the renal allograft following parathryoidectomy.
Case Report: A thirty one year old male presented with severe thoracic 
back pain and an unsteady gait four years after a renal allograft. He had 
ESKF commencing peritoneal dialysis at age twenty three and three years 
later had a deceased donor renal allograft. Renal allograft function has been 
suboptimal with best post transplant creatinine of 226 micromoles/litre. Prior to 
transplantation he had established secondary hyperparathyroidism with a PTH 
of 174 picomoles/litre. Following transplantation the hyperparathyroidism 
persisted with a PTH of 250 picomoles/litre.
At presentation, CT and MR imaging showed a lytic lesion in the twelfth 
vertebral body with extradural extension and compression of the thecal sac. 
Histopathology demonstrated a brown tumour. Subtotal parathyroidectomy 
was performed 2 months post spinal decompression. Prior to this the creatinine 
was stable at 274 micromoles/litre and post parathyroidectomy the baseline 
creatinine increased to be 386 micromoles/litre 6 months later.
Conclusion: Tertiary Hyperparathyroidism is often present in patients with a 
functioning renal allograft.  Renal osteodystrophy of the vertebral bodies leading 
to spinal cord compression is exceptionally rare in tertiary hyperparathyroidism. 
Parathyroidectomy is often delayed in patients with ESKF who are likely to 
receive a transplant in the near future as there is likely to be regression of 
the hyperparathyroidism. In patients who require parathyroidectomy post renal 
allograft there appears to be a risk of loss of GFR. This raises the question as 
to whether parathyroidectomy, either surgical or medical, should be undertaken 
routinely on patients with secondary hyperparathyroidism who are likely to 
have a renal allograft. 
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LONG TERM EXPERIENCE WITH SIROLIMUS IN 2113 
KIDNEY TRANSPLANTATION – WHAT TO DO WHEN IT 
FAILS?
J. Mayer1, F. Keller2, S. Kolodziej1, S. Stracke2
1Viseral- & Transplantation Surgery, 2Nephrology
Little data exists on the long-term adherence to a proliferation signal inhibitor 
(PSI) based immunosuppression after kidney transplantation (KTx). We 
therefore retrospectively examined 90 patients that were switched from a CNI- 
to a PSI- based immunosuppression in average 36.7 months after KTx (75 to 
sirolimus and 15 to everolimus). Reasons for the replacement of sirolimus by 
everolimus were unwanted side effects (acne, pneumonitis, proteinuria) or 
patient incompliance.
Eleven of the 75 sirolimus patients (15%) were switched within an average 
of 17 months, six to everolimus and fi ve to CNIs. After re-introducing CNIs, 
creatinine did not further increase but hemoglobine and cholesterine levels 
improved. Replacing sirolimus with everolimus reduced triglyceride and 
cholesterol blood levels but increased GOT, GPT and gGT levels. Patients that 
remained on sirolimus throughout the observation period had a lower creatinine 
and a better hemoglobine than those where sirolimus was later replaced. 
Sirolimus- based immunsosuppression is tolerated in 85% of patients over more 
than three years. The need for an unscheduled replacement of sirolimus is higher 
in patients with a worse graft function at the introduction of a CNI free regimen. 
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Replacing sirolimus by everolimus improves the blood lipid profi le. A reintroduction 
of CNIs does not further increase creatinine but improves hemoglobine. In 
conclusion, nonadherence to a sirolimus based immunosuppression is rare and 
sirolimus can safely be replaced by CNIs or everolimus.
POSTER BOARD NUMBER P4 – 164
IS IT POSSIBLE TO REDUCE THE CARDIOVASCULAR 2114 
RISK THROUGH CALCINEURIN INHIBITORS (CNI) TO 
SIROLIMUS CONVERSION IN RENAL TRANSPLANT?
R. Schiavelli, F. Margulis, C. Cuevas, R. Sabbatiello, M. Raño, D.D. Tullio, 
M. Pattin
Hospital General De Agudos
Prevalence of cardiovascular disease in transplant patients is 5 fold increased 
regarding general population and it is the most important cause of death with 
functional graft. Hypertension and left ventricular hypertrophy are independent 
risk factors of cardiovascular morbidity 
Ambulatory blood pressure monitoring (ABPM) has shown a better correlation 
with target organ damage than offi ce blood pressure (O-BP) 
Aim: To evaluate the evolution of hypertension and left ventricular mass index 
after CNI to sirolimus retrospectively.
Methods: We evaluated 10 renal transplant patients (7M/3F), mean age 38,6 
± 9 that were converted to sirolimus for different reasons (neoplasias, chronic 
allograft nephropathy)
Before conversion, a 24-hour ABPM and a Trans-thoracic m-mode 
echocardiograms (ATL ULTRAMARK) were performed and were repeated 
20± 5 months after conversion.
ABPM was recorded noninvasively with an Accutracker II (Suntech Medical 
Inc.) over 24 hs on a regular working day. We evaluated the 24 hs blood pressure 
(24-BP), the awake blood pressure (AwBP) and asleep blood pressure (AsBP) 
according to the awake/asleep report of each participant.
LV mass was calculated according to the Penn convention and corrected for 
body surface area to produce the LV mass index (LVMI), 
There were not any changes in antihypertensive treatment before and after 
conversion. 
Mann-Whitney test was used and P values < 0.05 was considered to be 
statistically signifi cant. Results are expressed as mean ± SD.
Results: There was a signifi cant decrease in diastolic 24-BP (88 ± 4 vs. 83 ± 
4 mmHg p<.001), diastolic AwBP (91 ± 5 vs. 88 ± 5 mmHg, p<.01), diastolic 
AsBP 83 ± 6 vs. 74 ± 6 mmHg p<.003) and in the diastolic O-DBP (94 ± 7 vs. 
85 ± 6 mmHg p<.007)
We also observed a signifi cant decrease of LVMI (156 ± 41 vs. 125 ± 33 g/
m2 p<.04)
Conclusion: Study fi ndings could explain a decrease in cardiovascular risk in 
these patients.
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ANALYSIS OF POST RENAL TRANSPLANT MORTALITY 2115 
– A RETROSPECTIVE, SINGLE CENTER INDIAN STUDY.
R. Balasubramaniyam, J. Das, N. Soosai, S. Das
KG Hospital and Post Graduate Medical Institute
Background: Advances in immunosuppression have improved the short-term 
survival after transplantation. Chronic graft loss secondary to ‘chronic allograft 
nephropathy’ and mortality with functioning grafts contribute to major causes 
of graft loss in the long term. Currently cardio vascular disease is the leading 
cause of death in the developed countries in the post transplant period. Not 
much data is available from the developing countries.
Aim: To retrospectively analyze the incidence, causes and the timing of post 
renal transplant mortality in our renal transplant patients.
Materials and methods: Patients who underwent renal transplantation in our 
hospital from July 1999 to Jan 2008 were retrospectively analyzed. All patients 
were followed post transplantation and the causes of their death and the time of 
death in relation to their transplantation were analyzed.
Results: Total number of renal transplantations done in this period was 157. (M: 
F = 129: 28). 150 patients underwent live related renal transplantation and 7 were 
cadaver transplant recipients. Follow-up varied from 2 months to 8 ½ years.
Basic renal diseases were chronic glomerulonephritis in 62, chronic tubulo 
interstitial nephritis in 40, Diabetic nephropathy in 23, Hypertensive 
nephrosclerosis in 20 and other causes in 12 patients.
34 patients died (21.6%) during the follow up period after transplantation. 
Of these 19 patients 3 returned to dialysis and 16 patients (47%) died due to 
chronic allograft nephropathy and inability to afford subsequent treatment is 
the commonest cause of mortality seen in our population. The other causes of 
mortality were sepsis in 6 (17.7%), Ischemic heart disease in 4 (11.8%), hepatic 
failure in 4 (11.8%), suicide in 2 (5.9%), pancreatitis in 1 (2.9%) and cerebro 
vascular disease in 1 patient (2.9%). 
11 patients (32.3%) died in the fi rst year after transplantation, 7 each in the 
second and third year (20.5%), 3 patients (8.8%) in the fourth year and 6 
patients (17.6%) died beyond the fi fth year. 
Conclusions: In our experience 21.6% died during the follow up after renal 
transplantation. In contrast to the western world, where the commonest cause 
of mortality is cardio vascular deaths, chronic graft loss and inability to afford 
further treatment is the commonest cause in our population. 
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CAPD IS A MORE SUITABLE DIALYSIS MODALITY 2116 
THAN HD FOR PATIENTS WHO WERE UNDERGOING KT: A 
MATCHED CASE STUDY
D. Sirivongs, U. Toimamueang, C. Pongskul
Khon Kaen University, Faculty of Medicine
Objective: KT is the ideal therapeutic modality for ESRD patients. However 
it was unclear whether a difference in dialysis modality could affect the KT 
outcome. To evaluate the infl uence of dialysis modality on the outcome, the 
study was performed.
Methods: Medical records of CAPD pts who were undergoing KT were 
reviewed. By matching for age, gender, and timing of KT operation, KT 
cases who were on HD before the operation were recruited in the ratio 2:1. 
Clinical data of both groups were analyzed. Analyses were performed with the 
SPSS statistical data program. Results: Since 1990, 307 KT operations were 
performed in our hospital. Twenty-nine KT adult pts (age 45.66+5.37 yr) who 
had been treated with CAPD (CAPDgr.) for 4-107 mo. (39.79+23.30 mo.) were 
compared with 58 KT pts (age 45.31+5.25 yr)who had been treated with HD 
(HDgr.) for 2 110 mo. 32.59+26.01 mo.). Regarding the immunosuppressive 
agents, 2-drug regimen was administered for living related KT and 3- drug 
regimen for cadaveric KT in both groups. The mean hospitalized duration in 
CAPDgr. Vs HDgr. was 37.04+31.77 days Vs 32.59+23.30 days. Delayed graft 
function was found in 13.8% of CAPDgr. compared to 36.2% of HDgr. (p = 
0.043). Acute allograft rejection during post-operation period was comparable 
between both groups (2 episodes Vs 3 episodes). Graft loss was found in 
3.4% of CAPDgr. compared to 15.5% of HDgr. (p=0.51). Even actuarial graft 
survival compared between CAPDgr. with HDgr. was 89% Vs 91% at one 
year and was 48% Vs 44.83% at fi ve years, there was no signifi cant difference 
between the two groups (p = 0.703).
Conclusion: Even overall outcome of both groups is quite comparable, but 
higher rate of DGF and graft loss is seen in HD group. Therefore CAPD 
might be a more suitable modality than HD for patients awaiting kidney 
transplantation.
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FACTORS INFLUENCING LONG TERM OUTCOME OF 2117 
KIDNEY TRANSPLANTATION IN A THAI MEDICAL CENTER.
D. Sirivongs, U. Toimamueang, C. Pongskul, S. Reungjui
Khon Kaen University, Faculty of Medicine
Introduction: To analyze outcome and to fi nd the factors that infl uence survival 
in kidney transplantation recipients, we conducted an analytic retrospective 
study. 
Methods: A retrospective analysis was undertaken on records of all patients 
who underwent transplantation from 1990 to 2007. Survival studies were 
calculated using the Kaplan-Meier method. The outcome endpoints were death, 
redialysis, lost to follow-up, and study termination. 
Results: Eighty-fi ve living-related KT [LRKT] and 205 cadaveric KT 
[CDKT]) were recruited. Age of patients was 40.26 + 10.21 years (range, 
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15-60 years). Male to female ratio was 1.8:1. The mean waiting time was 24.45 
+ 26.4 months. Underlying DM was in 17.7%. Mean survival of CDKT was 
46.56 +2.13 mo. compared to 58.27 + 5.75 mo. of LRKT. The 50% survival 
rate of CDKT (47.6 mo.) was slightly higher than that of LRKT(49.6 mo.) (p 
= 0.0019). The following factors were found to signifi cant negative infl uence 
on graft survival: low economical status (p=0.0000), ATN (p=0.000), DGF 
(p=0.0003), hemodialysis modality (p=0.0175), but PTDM showed positive 
infl uence (p=0.014). Surprisingly, patients who received cyclosporine (CSA), 
prednisone (Pred), and azathioprine (Aza) showed better graft survival than 
ones on CSA, Pred, and mycophenolate mofetil (MMF) (p = 0.0000). 
Conclusion: CDKT was showed better graft survival than LRKT. Factors that 
had negative infl uence on survival were low economical status, ATN, DGF, and 
HD modality, but PTDM showed the opposite infl uence. Immunosuppressive 
regimen with Aza showed better survival than the one with MMF.
POSTER BOARD NUMBER P4 – 168
LONG KIDNEY GRAFT SURVIVAL FROM 2118 
ANENCEPHALIC DONOR: CASE REPORT
C. Gracida1, R. Espinoza2, J. Cancino3, A. Ibarra4
1Transplant Unit, Hospital De Especialidades CMN SXXI, 2Transplant Unit, 
Hospital De Especialidades CMN SXXI, 3Transplant Unit, Hospital De 
Especialidades CMN SXXI, 4Transplant Unit, Hospital De Especialidades 
CMN SXXI
Introducction: Kidneys from newborn donors frecuently are discharged due to 
primary dysfunction, two decades ago in many transplant centers kidneys from 
anencephalic donors were transplanted in block.
We report a case of female 35 years old who was transplanted at 11 years old 
from anencephalic donor at august 1984. Both kidneys were used in block to 
the right comun iliac artery with aortic segment. Patient received Azathiprine 
and prednisone as initial immunosuppression. 10 years after transplantation 
was added Cyclosporine A (CsA)at 3mg/kg/day. after 20 years of follow of 
CsA was changed to MMF 2 g/day du to albuminuria.Patient have had follow 
up in our transplant unit since then, actual renal function stable. with serum 
Creatinine 1.3mg/dL, Creatinine clearance 50ml/min, albuminuria 0.5 g/L.
MRI shows both kidney well perfused, and it shows stenosis of infra renal 
comun iliac artey.
Conclusions: Follow up of this case shows that pediatric kidneys in block 
could have long survival, they can be used in pediatric patients or in small 
adult patients with good results.
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OUTCOMES OF HAEMODIALYSIS VASCULAR ACCESS 2119 
IN THE RENAL TRANSPLANT RECIPIENTS: A SINGLE 
CENTRE EXPERIENCE
I. Butt, W.S. McKane, P. Brown, A.T. Raftery, B.M. Shrestha
Sheffi eld Kidney Institute
Introduction: Maintaining the functionality of vascular access (VA) is central 
to the well-being of the haemodialysis patients. After a successful renal 
transplant (RT), the management of VA has remained a subject of dispute, 
particularly with respect to intervention for thrombotic complications. The aim 
of this study was to evaluate the fate of haemodialysis VA in our RT recipients 
and to assess whether an alternative management strategy should be adopted.
Methods: A retrospective study of a cohort 570 RT performed over a period 
of 14 years between January 1993 and October 2007 was conducted. Data 
was collected from a prospectively maintained departmental database, case 
notes and through telephone interviews. VAs presenting with thrombotic 
complications were not subjected to salvage procedures and those with 
symptomatic complications were considered for ligation.
Results: A total of 363 patients were on haemodialysis prior to undergoing 
renal transplantation. Of these, 57 patients died during the period of study. 
Out of the 306 living patients, 258 (85%) patients have a functioning RT 
whereas 48 (15%) have returned to alternative mode of renal replacement 
therapy (RRT). Of the 258 with a currently functioning transplant the fi stula 
in use prior to the transplant has stopped functioning in 78 (30%) patients 
(57 spontaneous thromboses, 21 operative ligations). Ligations were 
performed for steal syndrome, Raynaud’s syndrome, venous hypertension, 
sepsis and aneurysmal dilatation. Of the 48 patients returned to alternative 
RRT, 29 (60%) demonstrated a patent, useable fi stula and were all able to 
restart haemodialysis without disruption. Of the remaining 19 (40%) patients, 
17 (35%) of them required creation of a new VA and 2 patients opted for 
peritoneal dialysis. The distribution by anatomical site of fi stulae in use prior 
to transplantation was as follows: autogenous (wrist: 162; forearm: 79; and 
cubital fossa: 94) and PTFE grafts (groin: 11; forearm: 14 and upper arm: 3). 
Of these 56, 15, 37, 6, 4 and 1 accesses respectively were lost during the life 
of the renal allograft. The median time to failure of the VA following RT was 
651 days (range 0-4378 days).
Conclusions: Our data shows that majority of patients with failed RTs did 
have functioning VAs despite no active surveillance programme and majority 
of patients did not have signifi cant morbidity related to the presence of VAs 
after RT warranting surgical intervention. Therefore we do not recommend 
prophylactic ligation of VAs following renal transplantation.
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LONG TERM FOLLOW-UP OF RENAL TRANSPLANT 2120 
PATIENTS A SINGLE CENTER EXPERIENCE.
R. Mondragon1, R. Bernal, B. Aguilar
1Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico 
ISSEMyM
Introduction: Renal transplantation is considered the optimal form of renal 
replacement therapy for patients with end stage renal disease, the determinators 
of patient survival after renal transplantation are incompletely known, and 
confl icting results have been reported. AIM: The purpose of this study is to 
analyze retrospectively the general health status and survival rates of grafts 
and patients. 
Patients And Methods: A retrospective database analysis of the hospital 
charts of 176 kidney recipients was perform in order to analyze the effects 
of following parameters on mortality: age, sex, blood type, cause of renal 
failure, comorbid conditions, previous renal treatment, date of transplantation, 
immunosuppressive therapy, surgical and medical complications. We calculated 
1-, 5-, and 10-year Kaplan-Meier survival rates. 
Results: 176 transplants were performed in the Centro medico ISSEMyM 
from August of 1982 to October of 2007; the follow up period was 0 to 120 
months postoperatively. Age average was 30 years old (range of 12 to 62), 
106 (60%) males and 70 (40%) females. Age average of the donor was 32 
years. The related living donors was 89 (51%) cadaveric donations 73 (41%), 
non related living donors 14(8%). the average duration of substitutive renal 
therapy before transplantation was 1 to 3 years, 61% were treated with dialysis, 
31% with hemodialysis and 17.3% with booth. The most common cause of 
renal failure was glomerulonephritis, the predominant group of blood was 0+. 
The immunosuppressive include triple therapy (Ciclosporine, Micophenolate 
mofetil, Tracolimus) and all episodes of rejection were treated with pulse of 
methyl prednisolon. We had no complications in 60% of our patients, 89% 
had medical complications and 11% surgery related complications them 
had a similar distribution between urological and vascular complications, 
only one case of infectious complications required drainage of a perirrenal 
abscess. Patient survival rates at 1, 5 and 10 years were 94%, 91%, and 89% 
respectively while the graft survival rate at 1, 5 and 10 years were 96%, 97% 
and 99% respectively. These results were found to be comparable to the average 
values of others centers. The total mortality was 11%, Patient death was more 
prominent during the fi rst two years after transplantation. Most common causes 
of death were infectious (45%), cardiovascular (25%) metabolic (20%), cancer 
(10%), due to the surgical procedure non case were related. 
Conclusions: Many individual factors contributed to the risk of mortality 
incidence of renal transplant patients like infectious complications especially 
pneumonia and CMV, retard graft function or repeated rejections. 
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DEATH WITH A FUNCTIONING GRAFT INCREASES 2121 
WITH RECIPIENT AGE AT KIDNEY TRANSPLANT
R. Wolfe1, K. McCullough1, A. Leichtman2
1Arbor Research Collaborative for Health, 2Dept of Medicine, Div. of 
Nephrology, U. of Michigan
Introduction: Death with a functioning graft (DWFG) is an important cause of 
renal allograft failure in developed countries. We investigated the relationship 
between age at transplant and the probability of DWFG.
Methods: 131,225 cadaveric kidney-alone transplants reported to the Scientifi c 
Registry of Transplant Recipients database between 1987 and 2004 were 
analyzed for cause of graft loss within 3 or 5 years. Death ascertainment and 
graft failure were supplemented by data from the US Social Security Death 
Master File and the Centers for Medicare and Medicaid Services. 
Results: The percentage of kidney transplants with DWFG increases with 
recipient age at transplant. Less than 10% of graft loss at 5 years up to a 
recipient age of 40 years. By recipient age 69, fully 34% of graft loss by fi ve 
years results from DWFG.
Discussion: DWFG decreases the total number of years of graft survival that 
can be achieved from the donor pool. Kidney allocation policy to match the 
projected survival of the recipient to the estimated potential survival of the 
donated organ offers the promise of reducing DWFG, and of improving overall 
kidney graft survival.
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BODY MASS INDEX,C-REACTIVE PROTEIN, AND 2122 
BLOOD PRESSURE IN A COMMUNITY-BASED STUDY OF 
AFRICAN-AMERICAN WOMEN
D. Morehead, J. Hurrell, C. Callender, A. Campbell
Howard University
Introduction: Obesity has been declared to be the 21st century epidemic, 
a problem that is out of control, with no signs of abatement. Obesity 
disproportionately affects people of low income and socioeconomic status, 
particularly African-American, as compared to white women. Obesity is defi ned 
as an excess of body fat and is commonly measured by the body mass index 
(BMI). BMI values above 30 kg/m² denote obesity and are known correlates 
of C-reactive protein (CRP), an acute-phase infl ammatory reactant, and blood 
pressure (BP). 
Objective: To investigate the relationship between BMI, CRP, and BP in a 
community-based cohort of African-American women.
Hypotheses: 1) African-American women who have higher elevations of CRP 
will have higher BMIs; and, 2) African-American women who have higher 
blood pressures will have higher BMIs.
Methods: African-American women (N=60), 18 years of age and older, were 
the participants in this study. Weight and height measurements were assessed 
for BMI, ELISA assay procedures were performed for serum CRP, and, three 
blood pressure measurements were taken.
Results: As predicted, both hypotheses were supported. Elevated CRP levels 
were associated with higher BMIs (r=.594, p≤0.01); and, higher SBPs, but 
not DBPs, were associated with higher BMIs (1st r=.277, p≤0.05; 2nd r=.278, 
p≤0.05; 3rd r=.410, p≤0.01).
Conclusion: Obesity is an infl ammatory related disease and adverse 
physiological outcomes that can lead to kidney failure and death.
Implication: There is a need to identify the underlying biopsychosocial 
mechanisms that contribute to the problem of obesity in the African-American 
female population.
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SUCCESSFUL CALCINEURIN-INHIBITOR (CI) 2123 
DISCONTINUATION FOLLOWING EARLY STEROID 
WITHDRAWAL (ESW) IN RENAL ALLOGRAFT RECIPIENTS; 
REDUCED CHRONIC ALLOGRAFT NEPHROPATHY (CAN) 
AND IMPROVED RENAL FUNCTION WITHOUT INCREASED 
REJECTION OR GRAFT LOSS
R.B. Stevens, T. Rigley, J. Skorupa, K. Nielsen, L. Wrenshall
University of Nebraska Medical Center
We hypothesized that rATG induction would enable safe discontinuation of CI 
maintenance in renal transplant patients on steroid-free immunosuppression. 
We compared two rATG induction protocols (6/mg/kg x 1 dose vs. 1.5 mg/kg 
x 4 doses) in a prospective randomized trial of CI discontinuation (tacrolimus/
sirolimus vs. mycophenolate mofetil/sirolimus) combined with ESW in kidney 
recipients. 
We enrolled 152 patients with an average follow-up of 19.7 ± 11.7 months. 
Subjects were 19 to 65 years old and included primary and re-transplants, with 
primary endpoints of renal function and CAN. Follow-up averaged 16.6 ± 9.5 
months in 47 patients withdrawn from CI (26 single-dose rATG induction, 
21 divided-dose rATG induction). We found no increased rejection (p = 0.8) 
after CI discontinuation and that both rATG induction dosing regimen and CI 
discontinuation signifi cantly impacted renal function and the development of 
CAN (both p < 0.03). 
Conclusions: We successfully discontinued both calcineurin inhibitors and 
steroids with either single or divided-dose rATG induction, and single-dose 
rATG induction independently associated with improved renal function and 
reduced CAN.
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LATE CONVERSION TO EVEROLIMUS COMPLICATED 2124 
WITH NECROTIZING GLOMERULONEPHRITIS IN RENAL 
ALLOGRAFT RECIPIENT – CASE REPORT
M. Durlik1, E. Nowacka-Cieciura1, A. Perkowska-Ptasiñska1, A. Sulikowska-
Rowiñska2, T. Cieciura1, E. Wa¿na1
1Transplantation Medicine and Nephrology Dept, Medical University of 
Warsaw, 2Department of Pathology, Children Hospital, Medical University of 
Warsaw
Conversion from calcineurin inhibitors (CNI) to proliferation signal 
inhibitors (PSI), such as sirolimus or everolimus (EV) may improve renal 
function in patients with chronic allograft nephropathy. We present a case 
of 39-years old male kidney allograft recipient with chronic cyclosporine 
(CsA) nephrotoxicity, recognized in a biopsy performed 5,5 years after Tx. 
The patient’s proteinuria was 0,5g/day, serum creatinine (creat) was stable 
at the level of 2,3 mg/dl. Concomitant medication consisted of MMF and 
prednisone (P), as well as losartan (L). In the preconversion biopsy arteriolar 
hyalinization, chronic ischemic glomerulopathy with focal, segmental 
glomerulosclerosis, double-contouring of some glomerular capillaries, mild 
interstitial fi brosis and tubular atrophy were found. Immunofl uorescence 
(IFL) was negative for Ig, C3, C1q, and C4d. Electron microscope (EM) 
(performed on the material regained from the paraffi n block) showed focal 
glomerulosclerosis, GMB reduplication, no electron dense deposits. With the 
introduction of EV (2 mg twice a day, target blood levels 8-12 ng/ml) CsA 
was withdrawn 8 days later. The patient continued MMF in the reduced dose, 
P and L. Two months after the conversion the patient presented with rush, 
proteinuria (1,8 g/day), erythrocyturia, and mild leukocyturia with negative 
urine culture. Creat increased from 2,1 to 2,3 mg/dl, serum C3 was below 
normal range. In biopsy: focal, segmental necrosis of the glomerular tuft with 
the formation of segmental cellular crescents, an increase in endocapillary 
cellularity. IFL: granular deposits of IgG, IgM, and C3 mostly along the 
capillary walls. Negative for C4d. EM: electron dense deposits within the 
GBM and in a subendothelial region, signifi cant reduction in the capillaries 
lumen due to GBM reduplication and widening of lamina rara interna with the 
formation of fi brillary structures within it. Focal segmental glomerulosclerosis. 
EV was withdrawn, CNI (tacrolimus) concomitantly with steroid pulses were 
administered. The rush disappeared, proteinuria decreased to 0,6 g/d, there 
was no active urine sediment, creat was 2,5 mg/dl. Five months after the 
withdrawal of EV creat level increased to 3,4 mg/dl with no proteinuria. The 
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third graft biopsy showed double contouring of glomerular capillaries, some 
scanty deposits of IgG and C3 in some of glomerular segments, negative 
for C4d, more advanced glomerulosclerosis. EM (performed on the material 
regained from the paraffi n block): the reconstitution of glomerular capillary 
lumens with the decrease in endocapillary cellularity, the presence of scanty 
intramembranous and subendothelial granular electron dense deposits in some 
of glomerular capillary loops. There was subsequent decline in renal graft 
function during the next year and the patient demanded dialysis 17 months 
after conversion to EV. Conclusion: Necrotizing glomerulonephritis with 
immune complexes deposition in renal allograft was possibly induced by late 
conversion from CNI to EV. The re-conversion to CNI could be recommended 
in case of PSI-associated post-transplantation glomerulonephritis but the 
long-term prognosis is uncertain.
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LONG-TERM KIDNEY GRAFT FUNCTION AFTER 2125 
COMBINED LIVER-KIDNEY TRANSPLANTATION
R. Ruiz1, B. Fischbach2, N. Onaca1, G. McKenna1, H. Randall1, 
G. Klintmalm1, R. Goldstein1, M. Levy1, S. Chinnakotla1, E. Sanchez1
1Baylor Regional Transplant Institute, 2Dallas Transplant Institute
The number of combined liver-kidney transplants (CLKTs) has steadily 
increased in large part to the implementation of the MELD (Model for End-
stage Liver Disease) allocation system. When to include a kidney allograft has 
been debated extensively. In this study, we analyzed preoperative factors which 
may infl uence allocation. In addition, long-term graft survival and function are 
also assessed.
In this study, we retrospectively examined 75 CLKTs performed at our center 
over a 23-year period. Overall, patient survival rates were 82%, 73% and 64% 
at 1, 3, and 5 years, respectively. Kidney graft survival rates were 76%, 68% 
and 60% at 1, 3, and 5-years, respectively. There was no difference in patient 
or graft survival whether or not a recipient was on pretransplant dialysis. 
However, the requirement for post transplant hemodialysis portended a poor 
overall prognosis (p=0.0006). We prospectively assessed kidney function using 
glomerular fi ltration rates (GFR) as measured by the I125-iothalamate method 
(Glofi l) before transplant and at predetermined intervals post transplant. There 
was no difference in patient survival when GFR was greater or less than 20 ml/
min pretransplant. We retrospectively calculated creatinine clearance using the 
Modifi cation of Diet in Renal Disease (MDRD) formula and found a strong 
correlation between GFR and MDRD values after one-year post transplant 
(p=NS). Only seven patients (9%) had biopsy-proven acute kidney rejection 
episodes.
Kidney graft survival mirrors patient survival in CLKT. MDRD is a reliable 
estimate of renal function greater than one-year post transplant. The liver 
allograft is renoprotective.
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THE PROBLEM WITH COMPLIANCE IN 2126 
TRANSPLANTATION.
M. Bos
Health Council of The Netherlands- Eurotransplant
Non-compliance with the medical regimen, e.g. non-adherence to 
immunosuppressants,is described as a major factor affecting the health, 
quality of life and the graft survival in transplant patients. Many episodes of 
late acute rejection and graft loss can be retraced to non-compliant behavior of 
the recipient, resulting in erratic timing or missed doses of medication. This is 
particularly distressing in paediatric and young adult patients. Non-compliance 
not only results in a personal loss for the patient, but also in considerable 
societal and economic loss. This issue has often been observed, but has not 
been extensively studied and analyzed in the context of transplantation. This 
has resulted in rather poor defi nition of what precisely constitutes (non)
compliance and insuffi cient insight in its possible causes and predictors. 
Because of this, effi cient strategies to enhance compliance and prevent non-
adherence have not been developed and implemented widely and effectively. 
This presentation focuses on developing new concepts and fi nding practical 
solutions. The key strategy is on improving communication between doctor 
and patient.
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IS RENAL TRANSPLANTATION THE CURE TO FATAL 2127 
NEPHROGENIC SYSTEMIC FIBROSIS: A CASE SERIES OF A 
RARE DISEASE.
N. Shah, M. Ramkumar, C. Wu, M. Unruh, J. McCauley, A. Basu, H. Tan, C. 
Morgan, R. Shapiro
UPMC
Nephrogenic Systemic Fibrosis (NSF) is a recently described systemic disease 
diagnosed at increasing frequencies with a high rate of morbidity and mortality. 
This systemic disorder involves a progressive, severe expansion and fi brosis of 
the dermis and can involve vital organs with no cure. An unproven multi-hit 
hypothesis includes: kidney disease, gadolinium use, prothrombotic state, high 
erythropoietin dosing, and acidosis. Systemic NSF has been reported to be fatal 
on autopsy studies.
We describe 3 patients with biopsy proven NSF, with common risk factors, 
each with a different response with renal transplantation, suggesting a possible 
explanation.
Case 1: 37 year old female with ESRD from IgA Nephropathy, thrombophillia 
with lupus anticoagulant, on erythropoietin therapy while on HD for 1 year 
prior to a deceased donor renal transplantation. She received multiple MRI’s 
with gadolinium for workup of CVA’s, the last within 2 months of onset of skin 
tightness. She had biopsy confi rmed NSF with cutaneous involvement. She 
received as a well functioning allograft with baseline creatinine of 1.1 and no 
episodes of rejection. Within 9 months of transplant she had marked clinical 
improvement in signs and symptoms of NSF with less skin tightness and full 
mobility of extremities.
Case 2: 62 year old female with ESRD secondary to hypertension, thrombophillia 
with lupus anticoagulant, was on HD 4 years prior to transplantation. She received 
epogen on HD and had an MRI with gadolinium prior to transplant. Her NSF 
(biopsy proven) was precipitated by renal allograft vein thrombosis and acute 
allograft dysfunction after a laproscopic cholecystectomy with improvement in 
Cr to 1.2 with thrombolysis. She subsequently suffered recent ACR with baseline 
of 2.9. She describes minimal improvement cutaneous NSF and noted to have 
persistent induration and swelling but no progression of disease.
Case 3: 37 year old with ESRD from bilateral nephrectomy from Von Hippel 
Lindau with multiple MR angiograms for intracranial hemiangioma. He was on 
HD for 7 years prior to transplantation. He had severe, cutaneous NSF (biopsy 
proven) symptoms for 2 years, with resulting severe contractures in upper 
extremities. He underwent living related renal transplantation with excellent 
allograft function and creatinine of 1.2mg/dl one year from transplant with no 
improvement in chronic contractures but no progression of symptoms of NSF.
Conclusions: We present 3 patients of biopsy confi rmed NSF who are 
transplanted at different stages in disease progression. We are to fi rst to 
demonstrate that renal transplantation, if done early, with a well functioning 
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allograft, offers the best chance at halting and reversing the progression of this 
chronic progressive, potentially fatal systemic disease. 
Patients presenting for transplantation with NSF should not be delayed but 
expedited and explored for living donors if possible. In addition, as documented 
in the literature, a majority of cases of NSF have a prothrombotic condition that 
should be investigated and consideration given to of the use of perioperative 
anti-coagulation. Finally, gadolinium use in severe CKD should be avoided if 
possible.
IMMUNOSUPPRESSION – CONCURRENT ORAL SESSION 144: 
POST TRANSPLANT MALIGNANCY
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LYMPHOCYTES SUBSETS IN RENAL TRANSPLANT 2128 
RECIPIENTS WITH DE NOVO GENITOURINARY 
MALIGNANCIES
G. Guichard1, J-M. Rebibou2, D. Simula-Faivre3, D. Ducloux4, 
J.M. Chalopin5, P. Tiberghien6, H. Bittard7, P. Saas8, F. Kleinclauss9
1Urology, 2Renal transplantation
Background: Renal transplant recipients are at high risk of developing de 
novo malignancies. This increased risk has been associated with high level 
of immunosuppression. CD4 cell lymphocytopenia has been involved in skin 
cancer and non cutaneous neoplasia after renal transplantation.
The aim of this study was to investigate the role of CD4 lymphocytopenia on 
the development of de novo urological malignancies (prostate cancer, renal cell 
carcinoma, bladder cancer) in renal transplant recipients.
Methods: From January 1989 to December 2003, 434 patients were 
transplanted in our institution. All patients were followed for the development 
of urological malignancies. Lymphocytes subsets (CD3, CD4, CD8, CD19) 
were measured annually by fl ow cytometry. We considered the mean of at least 
three different values out the fi rst year post-transplant. Patients who developed 
urological cancers were compared to patients without cancer for gender, age, 
haemodialysis duration, transplant duration, immunosuppressive regimen and 
lymphocytes subsets.
Results: Fourteen patients (3,2%) developed a urological cancer after kidney 
transplantation (6 prostate cancers, 7 renal cell carcinoma and 1 bladder 
cancer). These patients were male (93% vs 63%, p=0,022) and signifi cantly 
older (55,5 +/- 6,5 vs 43,6 +/- 14, p=0,002) than patients without cancer. 
They did not differ in haemodialysis mode, haemodialysis time and serum 
creatinine concentration. No difference was observed in CD3, CD4 and CD19 
lymphocytes counts but patients with urological cancer present signifi cantly 
more CD8 than patients without cancer (672+/- 743 vs 490+/- 313, p=0,04). No 
difference was observed in immunosuppression duration, induction regimen, 
immunosppressive maintenance and acute rejection. 
Six patients presented a prostate cancer. Mean age at diagnosis was 61,4 
years and the median interval between diagnosis and transplantation was 83,3 
months [17-127]. Mean Gleason score was 7,5 [4-10]. Four patients are alive 
without recurrence and with a functional graft with a mean follow up of 48 
month [10,5-155].
Seven patients developed renal cell carcinoma on native kidneys. Mean age 
was 60,8 years and the median interval from diagnosis and transplantation 
was 56,9 months [11-113]. Four patients are alive after radical surgery with 
functioning graft. The mean follow up is 26 months [2-57].
Conclusion: Although CD4 lymphocytopenia has been involved in cutaneous 
and non cutaneous cancer development, we cannot confi rm his role on the 
development of urological cancer. Likewise no other immunologic factors 
such as immunosuppression duration, induction regimen, or acute rejection 
can be involved in the de novo urological malignancies development. Further 
investigations, with lymphocytes counts in patient who develop urological 
cancer after renal transplant, are needed to confi rm this data.
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PRE-TRANSPLANT SERUM VITAMIN D LEVELS AND 2129 
RISK OF CANCER AFTER RENAL TRANSPLANTATION
A. Kazory1, C. Courivaud1,2, J. Bamoulid1,2, G. Dumoulin4, J-M. Chalopin1,2,3, 
D. Ducloux1,2,3
1University of Franche-Comte, Besancon, France, 2INSERM, U645, 
Besançon, F-25020; University of Besançon, F-25020; IFR133, Besançon, 
F-25000,, 3CIC Biotherapy, Saint Jacques University Hospital, Besançon, 
4Laboratory of Renal and Metabolic Exploration, Jean-Minjoz University 
Hospital, Besançon
Background: Serum levels of 25-OH-D3 inversely correlate with the incidence 
of various types of cancers in the general population. Since risk factors and 
incidence of cancer in renal transplant recipients (RTRs) are different from 
the general population, this study was designed to determine whether pre-
transplant 25-OH-D3 levels could be predictive of cancer risk in RTRs.
Methods: Pre-transplant 25-OH-D3 levels were reviewed in 363 consecutive 
RTRs. The impact of 25-OH-D3 levels on development of cancer was then 
analyzed with respect to other known risk factors.
Results: One hundred twenty four patients (34.2%) showed vitamin D 
defi ciency, 185 (51%) vitamin D insuffi ciency, and 54 (14.8%) with normal 
vitamin D levels. Thirty two cancers (8.8%) occurred in 32 patients. A higher 
incidence of cancer was observed in patients with vitamin D defi ciency (13.7% 
vs. 7% for patients with vitamin D insuffi ciency [p=0.068] and 3.7% for those 
with normal vitamin D levels [p=0.007]). 25-OH-D3 levels were lower in 
patients who developed cancer after transplantation (13.7 +/- 6 vs. 18.3 +/- 
17.8 ng/ml; p=0.022). Age (HR, 1.06; 95% CI, 1.02 to 1.11, for each one year 
increase; p=0.009) and low 25-OH-D3 levels (HR, 1.12; 95% CI, 1.04 to 
1.23, for every 1 ng/ml decrease; p=0.021) were independent risk factors for 
development of cancer.
Conclusion: Pre-transplant level of 25-OH-D3 is an important determinant for 
subsequent development of cancer after renal transplantation. Future studies 
should examine whether 25-OH-D3 supplementation can effectively decrease 
the incidence of cancer in RTRs.
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SPECTRUM OF LYMPHOPROLIFERATIVE DISORDERS 2130 
FOLLOWING RENAL TRANSPLANTATION IN NORTH INDIA
V. Sakhuja1, H. Kohli1, V. Jha1, K. Gupta1, K. Joshi2
1Department of Nephrology Post Graduate Institute of Medical Education 
And Research, 2Department of Pathology Post Graduate Institute of Medical 
Education And Research
Lymphoproliferative disorder is a common and serious complication of organ 
transplantation. This study was a retrospective analysis of 1400 patients 
who underwent renal transplantation over a period of 25 years (1980-2005). 
Thirty malignancies were diagnosed in 26 patients. Nineteen patients (1.6%) 
developed post transplant lymphoproliferative disorder (PTLD) accounting 
for 63.3% of all malignancies. Diagnosis was made by biopsy of the involved 
organ in 13 patients (68.4%) and aspiration cytology in 3 patients (15.8%). 
In 3 patients the diagnosis was made only at autopsy Mean age at the time of 
diagnosis of PTLD was 40.2 years (range 21 to 62 years). The interval between 
transplantation and PTLD was less than a year in 21% and more than a year 
in 79%. Involvement was primarily extranodal in 14 patients (73.7%). Twelve 
(63.2%) patients had disseminated disease at diagnosis and 7 (36.8%) had 
localized involvement of a single organ (brain -2, allograft -1, perigraft node-1 
and retroperitoneal lymph nodes- 3). Direct infi ltration of graft was noted in 
2 patients while one patient presented with a perigraft mass. One patient was 
positive for anti-HCV antibodies, 3 had CMV antigenemia and 1 had IgG 
antibodies to EBV. PTLD was of B cell origin in 16 cases (84.2%), 2 t cells 
and 1 myeloma.. CD 20 staining was done only in 6 cases, of which 4 stained 
positive. Of the 16 patients diagnosed during life, 13 (81.3%) died within 1 
year of diagnosis. In India, PTLD is the commonest post transplant malignancy 
but occurs predominantly in the late post transplant period.
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SIROLIMUS DECREASES SERUM PSA POST-2131 
TRANSPLANT
Z. Kaposztas1, D. Hosey1, W. Etheridge2, S. Laneri1, B. Childs1, 
C. Van Buren1
1University of Texas, HSC At Houston, Division of Immunology And Organ 
Transplantation, 2St Luke`s Episcopal Hospital
Objective: Immunosuppressive medications following solid organ 
transplantation increase the risk of cancer. With improved management and 
better outcomes immediately after transplantation, complications related to 
post-transplant malignancy may become an increasingly important cause of 
death. Prostate cancer has been documented to be responsive to testosterone 
via surface receptors. Sirolimus (Sir) is a novel immunosuppressant that acts by 
blocking signal transduction, lowering the incidence of malignancies. 
Method: To test the hypothesis that Sir decreases Prostate-Specifi c Antigen 
(PSA) expression, which is correlated with prostate cancer, a cohort of 83 
male, kidney transplanted patients has been studied. We have been sought 
the relationship of Sir to PSA serum level between the ages of 50 – 65. Two 
groups have been established based on the maintenance immunosuppression 
of subjects: Group A patients who have never been treated with Sir (n=19) 
and Group B patients who have been treated with Sir based maintenance 
immunosuppression (n=64). 
Results: Data analysis revealed that the mean PSA level in Group A was 
2.18+/-2.1 and in Group B: 1.39+/-1.15 (independent samples t test; p=0.039). 
We divided the patients according to their PSA levels into 3 groups: PSA 0-2 (low 
risk for prostate cancer); PSA 2.1-3.5 (moderate risk, prostate biopsy should be 
considered) and PSA>3.5 (high risk). The distribution of PSA levels between 
the 2 groups showed signifi cant difference (Cross tabulation, Chi Square test; 
p value = 0.032). The vast majority of patients being on Sir belonged to the 
PSA level 0-2 group (n=53). There was no signifi cant difference in distribution 
of African-Americans and Whites in these PSA groups (Crosstabulation, Chi 
Square test; P=0.58). Duration for post-transplant was comparable in both 
groups (Group A: 2730±1901 days; Group B: 1761.8±1478 days; Independent 
Samples t-test; P=0.055).
Conclusion: This is the fi rst study to examine correlation of immunosuppression 
with PSA. Signifi cantly lower PSA serum levels were found among subjects in 
Group B, treated with Sir as baseline immunosuppression. If these data are 
validated in a larger study, the hypothesis that Sir reduces prostate cancer post-
transplant should be tested.
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MALIGNANCY AFTER KIDNEY TRANSPLANTATION IN 2132 
JAPAN
M. Nojima1, Y. Higuchi1, Y. Ueda1, S. Yamamoto1, H. Shima1, H. Ihara2, 
T. Yoshimoto3
1Department of Urology, Hyogo College of Medicine, 2Ihara Clinic, 
3Department of Urology, Kawanishi City Hospital
Objectives: Cancer development is a major cause of patient morbidity and 
mortality in patients after kidney transplantation, due to longer survival under 
immunosuppressive status. To determine the incidence of cancer after kidney 
transplantation, we analyzed a Japanese multicenter database.
Materials and methods: The data of 3184 kidney transplant recipients from 
13 transplant centers were collected, and the incidence of malignancies were 
analyzed.
Results: 206 out of 3184 (6.5%) recipients developed malignant tumors. The 
mean age of patients who developed cancer was 36 years old at transplantation 
and 46 years old at cancer development, showing that cancers occurred around 
10 years after transplantation. Most frequent malignancies were cutaneous (25), 
renal (22), lymphoma (22) and liver (21) cancers followed by colorectal (17), 
uterine (16), breast (15), gastric (15), tongue/ oral cavity (11) and urotherial (9) 
cancers. Twelve of 22 lymphoma occurred within 5 years after transplantation 
and the average onset time of lymphoma was 6.8 years after transplantation. On 
the other hand, the average onset time of non-lymphoma was 11.0 years after 
transplantation (p= 0.0004). Eighty-one out of 206 (39%) patients developing 
cancers died after diagnosis of cancer. The survival rates of patients associated 
lymphoma was 50%, which was slightly lower than that of non-lymphoma 
cancer patients (56%), but there was no signifi cant difference.
Conclusion: In 1990 fs, the Japanese multicenter study in regard to cancer 
incidences of renal transplant patients showed that most frequent malignancies 
were renal, liver, gastric and colorectal cancers. The results showed that the 
incidence of cutaneous cancer and lymphoma are increasing in Japanese renal 
transplant recipients in the last decade probably due to strong suppressive 
drugs of T-cell function.
POSTER BOARD NUMBER P4 – 183
CHRONOLOGICALLY DIFFERENT INCIDENCE OF 2133 
POST-TRANSPLANT MALIGNANCY IN RENAL TRANSPLANT 
RECIPIENTS; 25 YEARS EXPERIENCE IN KOREAN SINGLE 
CENTER
M.S. Kim1,2, H.K. Chang1,2, M.K. Ju1,2, D.J. Joo1,, S.J. Kim1, S.I. Kim1,2, 
Y.S. Kim1,2, K. Park3
1Yonsei University College of Medicine, Department of Surgery, 2Yonsei 
University College of Medicine, The Research Institute for Transplantation, 
3Kwandong University Myongji Hospital, Department of Surgery
The incidence of malignancy in transplant recipients is known to be higher than 
that of normal population. But the types of malignancies vary geographically 
and relative risks compared with general population are also different country 
by country. In this study, we investigated the incidence and characteristics of 
malignancy after renal transplantation in single center.
A total 2,650 renal recipients who were operated from April 1979 to June 
2007 were enrolled in this study. The accumulative and interval (per 3 years) 
incidence of malignancy was calculated by post-transplant period. Synchronous 
or metachronous malignancies were counted as different events. 
A total 190 cases of post-renal malignancy among 177 recipients (6.73%) were 
reported until June 2007. The post-transplant malignancy was detected from 
6 months to 290 months after transplantation with mean duration of 112.6 
± 66.0 months. As the post-transplant duration was prolonged, the interval 
incidence of malignancy was extremely increased [fi gure1]. Skin cancer 
(n=35,18.4%) was the most common, followed by thyroid cancer(n=25,13.2%), 
stomach cancer(n=22,11.6%), colorectal cancer(n=22,11.6%), urologic 
cancer(n=19,10.0%), lymphoproliferative disorders (PTLD)(n=12,6.3%), 
and Kaposi’s sarcoma(n=12,6.3%). Virus-related malignancy such Kaposi’s 
sarcoma and cervix cancer developed in earlier post-transplant period, but on 
the other hand urologic cancer, colorectal cancer and PTLD developed in late 
post-transplant period [fi gure2]. 
Therefore, we should establish the strategies for post-transplant malignancy 
based on characteristics of post-transplant malignancy in each country. 
Figure 1
Figure 2
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TYPE OF MALIGNANCY AMONG RENAL 2134 
TRANSPLANTATION PATIENTS IN URMIA RENAL 
TRANSPLANT CENTER
B.A. Markazi, E. Ahmadnezhad, A. Ravandi, S. Hatami, N. Sepehrvand
Background: The overall incidence of cancer in renal transplant recipients is 
greater than in dialysis patients and general population. The several reasons 
include immunosuppression and primary renal disease.
Method: In Urmia there are 1997 patients who carried out renal transplantation 
from the beginning until now (Aug 2007). Among them, 159 cases developed 
cancer. Questioner has been used for data collection.
Results: Among 1997 kidney recipient patients, 7/96% affected by cancer. 
Mean age was 46.7 year, duration of pretransplant dialysis include 1-5 year in 
53.8%, < 1 year in 42/3% and >5 year in 3.8% of cases. The immunosuppressive 
drugs include Cyclosporine plus azathioprine and Prednisolone in 84/6%. 
The detected tumors included: Kaposi sarcoma 42/3%, Lymphoma 11/5%, 
Hepatoma, Leukemia and RCC each one 3/8%.In 34/6% of patients we couldn’t 
detect malignancy.
Conclusion: Incidence of malignancy in kidney recipients in our center is 
lower than other centers. It can be due to age of patients, state of residency, type 
of immunosuppressive drugs, duration of dialysis and renal allograft survival. 
Monitoring of patients in certain interval recommended.
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INHIBITION OF MTOR KINASE ACTIVITY BY 2135 
SIROLIMUS IN THE MANAGEMENT OF MALIGNANCIES IN 
RENAL TRANSPLANT RECIPIENTS
M. Boratynska1, E. Watorek1, D. Smolska1, D. Patrzalek2, M. Klinger1
1Department of Nephrology and Transplantation Medicine Wroclaw Medical 
University, 2Department of General, Vascular and Transplantation Surgery 
Wroclaw Medical University
The mTOR kinase abundantly expressed in neoplastic cells may be a target for 
proliferation signal inhibitors in post-transplant malignancies. The infl uence 
of conversion to sirolimus after malignancy diagnosis on patient and renal 
allograft survival was investigated.
From 957 patients transplanted in Wroclaw between 1983-2006 malignancy 
was diagnosed in 50 patients (5%). In this group 28 renal allograft recipients 
(9 women, 19 men) of ages 26 to 73 years (mean 56 years), who developed 
malignancies within 6 to 168 months (mean 58 months) after transplantation 
were converted to sirolimus in dose 2 mg per day (target level 4.0-8.0 ng/
ml). Prednisone was maintained. The observation time of sirolimus therapy 
was 2-62 months (mean 21 months). Four patients developed post-transplant 
lymphoproliferative disease (PTLD), 4 Kaposi’s sarcoma, 3 lung cancer, 
4 malignant melanoma, 3 breast cancer, 4 renal cell carcinoma, 1 Merkel 
cell carcinoma, 1 larynx cancer and 1 patient gingival cancer, 2 carcinoma 
urotheliale of the bladder, in the remaining one patient metastatic planoepithelial 
carcinoma was found in the lymph node. 
Two patients with PTLD (large B-cell lymphoma) and 4 with Kaposi’s 
sarcoma had full regression. Mean remission time on sirolimus is 40 
months until now. Twenty patients (larynx cancer, melanoma, breast cancer, 
T-cell lymphoma, renal cell carcinoma, Merkel cell carcinoma and skin 
lymphoma) apart from sirolimus therapy, underwent oncologic treatment: 
surgery and/or chemotherapy. Seven patients died from disseminated 
malignancy 3-15 months after conversion. In the remaining patients, who 
achieved remission, serum creatinine levels since conversion to sirolimus 
have been stable.
In conclusion, conversion to sirolimus resulted in regression of large B-cell 
lymphoma and Kaposi’s sarcoma. In patients with advanced or disseminated 
malignancy tumor progressed. Graft function after conversion to sirolimus was 
preserved
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USEFULNESS OF EVEROLIMUS AS ALTERNATIVE 2136 
IMMUNOSUPPRESSION IN PATIENT WHO DEVELOP A 
NEOPLASIA AFTER RENAL TRANSPLANTATION.
E. González, E. Gutiérrez, E. Morales, N. Polanco, A. Hernández, 
E. Gutiérrez-Solis, D. Parés, A. Andrés, J.M. Morales
Cancer is a growing complication in renal transplant patients. Everolimus a 
new m-TOR inhibitor is an useful immunosuppressive drug with antineoplasic 
properties.
The aim of the study was to evaluate the safety of Everolimus immunosuppresion 
in patients who developed a neoplasia after renal transplantation.
In this retrospective observational single-center study we include 24 renal 
transplant patients with cancer who were transplantated during 2005-2008. 
Seventeen developed non-melanoma skin cancer, one melanoma without 
visceral involvement, two prostatic cancer, one bladder cancer, one lymphoma, 
one tongue cancer and the last one Kaposi’s sarcoma. Everolimus was 
added to immunosuppressive regimen (1mg/day), decreasing the dose 
calcineurin inhibitors (CNI) or stopping the dose of CNI drug (especially in 
non-skin cancer). 
Immunosuppressive combinations at the end of follow-up (18±11 months) 
were:steroids, tacrolimus and everolimus (37,5%), steroids, Cyclosporine and 
everolimus (20,8%), Tacrolimus, everolimus (12,5%), Cyclosporine everolimus 
(12,5%) and Everolimus monotherapy in (16,6%). Blood levels of CNI were 
signifi cant decreased (Cyclosporine 143 vs 43 ng/dl and Tacrolimus 8.9 vs 5.6 
ng/dl) during follow-up, 
Notably nobody presented acute rejection, acute worsening of renal function 
or increase of proteinuria (initial 0.3 vs 0.4 gm/d fi nal). Renal function was 
stable (serum creatinine initial 1.4 vs fi nal 1.3 mg/dl) and nobody develop 
cardiovascular complications. 
Remarkably, evolution of cancer was excellent: there was no recurrence of 
neoplasia in 21 cases, the skin Kaposi’s sarcoma improved, skin melanoma 
was stable and only bladder cancer recurred
In conclusion, these encouraging results suggest that Everolimus 
immunosuppression,with or without CNI, could be safe in patients who 
developed cancer after renal transplantation. Prospective and controlled studies 
to test this therapeutical option are mandatory.
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MALIGNANCY IN KIDNEY TRANSPLANT RECIPIENTS 2137 
IN HYOGO PREFECTURE, JAPAN
Y. Ichikawa1, H. Kishikawa1, K. Nishimura1, M. Takeda2, M. Fujisawa2, M. 
Nojima3
1Hyogo Prefectural Nishinomiya Hospital, 2Kobe University, 3Hyogo Medical 
College
Background: Organ transplantation increases the incidence of cancer because 
of immunocompromised sate and/or use of carcinogenic agents and kidney 
recipients are known to have a higher cancer risk than the general population. 
We studied the incidence of and risk factors for malignancy in a long-term 
follow-up study of patients living in Hyogo Prefecture, Japan who underwent 
kidney transplantations.
Materials and Methods: A total of 770 transplants was performed for 743 
patients between 1973 and 2007 at three medical centres in Hyogo Prefecture. 
We investigated the patient records to determine the incidence and sites of 
malignancy and computed the cumulative incidence and survival rates. The 
effects of immunosuppressant administration were also examined with the 
results divided into three groups based on the medication received azathioprine, 
cyclosporine and tacrolimus. A Kaplan-Meier method and the log-rank test 
were employed to compare survival rates between the patients with and without 
malignancy.
Results: A total of 77 malignant diseases were developed in 71 (9.5%) of the 
patients. The mean follow-up time after the initial transplantation was 14.1 } 0.4 
years. The cumulative incidence of malignancy increased yearly and the overall 
rates were 1.7% at 5, 4.6% at 10, 7.9% at 15, 10.9% at 20 and 15.4% at 25 years. 
Patients without malignancy had signifi cantly superior survival rate in the second 
and third post-transplant decades as compared to those with cancer (p<0.0001). The 
survival rates with and without malignancy were 83.8% and 89.5%, respectively, 
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at 10 years, and 60.6% and. 83.7%, respectively, at 20 years. There were no 
signifi cant differences in cancer incidence among the three inumosuppressive 
administration groups though the graft survival rate for tacrolimus group was 
signifi cantly higher. At 15 years, the rates of incidence were 8.3%, 7.9% and 5.1% 
in the azathioprine, cyclosporine and tacrolimus.groups, respectively while the 
graft survival were 47.4%, 51.0% and 70.6% in azathioprine, cyclosporine and 
tacrolimus.groups, respectively (p<0.0001). The common types of malignancy 
were skin cancer, renal cell carcinoma (RCC) in the native kidney, hepatocellular 
carcinoma (HCC) and post-transplant disease. On the other hand, lung cancer, 
breast cancer and ovarian cancer were rare in our series. 
Conclusion: The incidence of malignancy following renal transplantation was 
relatively lower in our long-term follow-up cohort as were the sites of malignancy 
as compared to the reports from other nations. RCC and HCC were characteristic 
fi ndings in our patients which were considered to result from the very long waiting 
time in regard to the former and the endemic spread of hepatitis B virus in far-east 
Asia including Japan in regard to the latter. Our results also showed that tacrolimus 
was the most powerful agent of immunosuppression for the best graft survival rate 
and had the same carcinogenic effect as azathioprine and cyclosporine.
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INCIDENCE AND BIOPSY FINDINGS OF COLORECTAL 2138 
POLYP IN KIDNEY TRANSPLANTATION RECIPIENTS
Y.J. Jeon, H. Yoon, S. Kim, J. Kim, S. Lee, B. Choi, Y. Kim, S. Kim, B. Bang, 
C. Yang
Catholic University of Korea
Purpose: The risk of colorectal malignancy after kidney transplantation is 
increasing, but incidence of colorectal polyp in these patients is rarely reported. 
We reviewed the incidence and biopsy fi ndings of colorectal polyp in renal 
transplant recipients. 
Methods: The database was queried for all cases of transplant recipients who 
underwent colonoscopy were included. Pretransplant history of colorectal 
cancer or polyp was excluded. Two hundred and forty kidney transplantation 
recipients were surveyed. The mean follow-up after kidney transplantation was 
144 months (0 to 362), and mean age was 51.2 years (21 to 77).
Results: We identifi ed 82 cases (34.2% of surveyed recipients) of colorectal 
polyps using colonoscopy or sigmoidoscopy. Biopsy fi ndings revealed tubular 
adenoma (n=52, 63.4%), infl ammatory polyps (n=22, 26.8%), hyperplastic 
polyps (n=7, 8.5%), villous adenoma (n=4, 4.9%), adenocarcinoma (n=4, 4.9%) 
and lymphoid polyps (n=3, 4.9%), in that order. Mean number of polyp was 2.1 
(1 to 13), and 52.4% of polyp was observed in patients under 50 years. In patients 
with adenocarcinoma, the mean age at diagnosis was 63.5 years (52 to 79).
Conclusion: Incidence of colorectal polyps is high in renal transplant recipients. 
Regular colonoscopy should be performed for early detection of polyps which 
have malignant potential. 
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B-CELL PTLD EPSTEIN-BARR VIRUS NEGATIVE IN 2139 
PAEDIATRIC KIDNEY TRANSPLANTATION.
R. Vilalta, E. Lara, A. Madrid, S. Chocron, A. Casquero, J. Nieto
Hospital Infantil Vall DHebron Barcelona
We report our experience with paediatric B-PTLD, PCR EBV negative after 
kidney transplantation.Ultrasonographyc study was diagnostic.
Background: Post-transplant lymphoproliferative disorder (PTLD) is the most 
common immusupression related malignancy that occurs after solid organ 
transplantation (SOT) in children. PTLD has extended its range from its initial 
description as an Epstein-Barr virus (EBV)-driven-B-cell proliferation (PCR 
positive high titer) to include EBV-negative cases in whom only protocol 
ultrasonographyc study is helpful.
Patients and evolution: Case 1, male 18 years old, transplanted 10 years before, 
abdominal PTLD B-lymphoma CD19CD20 negative, had a bimodal response to 
therapy with initial erradication of bulky nodal disease with COP regimen, but 
because persisted mesenteric disease, more intensive treatment with CHOPP 
was necessary with remision. Was converted from tacrolimus to sirolimus.
Case 2, male 19 years old, transplanted 16 years before, PTLD abdominal, B 
lymphoma CD19 CD20 negative had a satisfactory response Rituximab and 
immunosupression was switched from tacrolimus to sirolimus.
Case 3, female 20 years old, transplanted 18 years before, PTLD abdominal, 
B-lymphoma CD19 CD 20 negative had a satisfactory response to therapy with 
COP regime and switched to sirolimus-base regime.
Conclusions: Depite initial association between EBV infection and B-cell PTLD, 
development of this disease in EBV-negative kidney transplanted children is also 
observed. After reduction of immunosuppression and (and/or switch to PSI-based 
immunosuppression), CD 19-20 positivity offers a good chance to rituximab. COP 
or CHOPP theraphy could be necessary and overall survival is in the literature 
around 60%. This fact should promote an increase of ultrasonic monitoring added 
to a systematic PCR-EBV determination to early detection of PTLD cases.
POSTER BOARD NUMBER P4 – 190
SIROLIMUS CONVERSION FOR PATIENTS WITH 2140 
POSTTRANSPLANT KAPOSI’S SARCOMA
K. Charfeddine, S. Yaich, S. Zagdane, A. Bahloul, M. Masmoudi, M. Kharrat, 
J. Hachicha
University-Hospital Sfax
Introduction: Recipients ofrenal transplantation are susceptible to Kaposi’s 
Sarcoma as result of treatment with immunosuppressive drugs. Sirolimus 
(Rapamun), an immunosuprressive drug, may also have antitumor effects.This 
retrospective study aimed to evaluate the benefi t of switching from calcineurin 
inhibitors (CnI) to sirolimus in posttransplant Kaposi’s Sarcoma (KS)
Methods: Five patients who developed posttransplant KS were switched 
from CnI to sirolimus from February 2004 to May 2006.They were 1 woman 
and 4 men, their mean age at switch was 32 years (21-44).All of them were 
renal recipients. The mean time from graft to KS diagnosis was 12.3 months 
(2-24).Four patients had only cutaneous lesions ; the fi fth had a digestive 
lesion (stomach).When KS was diagnosid, switching from CnI to Sirolimus 
was abrupt for all patients(SRL: 18 mg day1;15mg day2; then 4mg daily); 
mycophenolate mofetil or azathioprin was stopped 2 week later and one dose 
of anti CD20 monoclonal antibody was administreted at d0 and d20.
Results: Three out of 5 (60%) patients had complete KS remission within 3 
months of follow-up. Two patients lost the skin lesions eight months after the 
switch and the fi fth patient had a partial remission of her cutaneous lesions at 
6 months and complete remission of both skin and digestif lesions 18 months 
after switch. The tolerance of sirolimus was excellent except for one patient 
who developed a n asymptomatic lung’s fi brosis 4 months after switch.
Conclusion: In conclusion, our observations suggests that sirolimus based 
immunosuppression brings the possibility of KS regression with concomitant 
renal function preservation in renal graft recipients. It is diffi cult to ascertain 
whether the KS regression may be attributed to sirolimus treatment or to 
reduction in immunosuppression. And what is the real role of Rituximab?
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POSTTRANSPLANT MALIGNANCY IN KIDNEY 2141 
TRANSPLANT RECIPIENTS: SINLGE CENTER EXPERIENCE
H.T. Kim1, W.H. Cho1, Y.M. Seo1, H.C. Kim2, S.B. Park2, S.Y. Han2, 
E.A. Hwang2, H.S. Jang3
1Dept. of Transplant & Vascular Surgery, Keimyung University Dongsan 
Medical Center, 2Dept. of Nephrology, Keimyung University Dongsan Medical 
Center, 3Dept. of Urology, Keimyung University Dongsan Medical Center
Introduction: Posttransplant malignancy is second leading cause of death 
among longterm survivors of organ transplant recipients. Skin cancers 
and lymphomas are reported as two most frequent malignancies in western 
countries. But little is known about the pattern of posttransplant malignancies 
in Korea. To see the patterns of posttransplant malignancies in Korean kidney 
transplant recipients, we analyzed our experience of posttransplant malignancy 
at our transplant center. 
Patients and Method: From Feb. 1984 to Feb. 2008, 792 kidney transplantations 
were performed at the Department of Surgery, Keimyung University Dongsan 
Medical Center. Among them, 761 patients followed at least 12 months were 
included. Their clinical records were analyzed retrospectively. Incidence and 
types of malignancies, intervals developing malignancy after transplantation, 
demographic characteristics, and prognosis were analyzed.
Results: There were 25 posttransplant malignancies (3.3%). Six cases of 
lymphomas, three cases of stomach, lung, liver (HCC) and thyroid cancers, 
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two cases of renal cancers, and one case of bile duct, breast, laryngeal, prostate, 
and skin cancer. There was no case of Kaposi¡¯s sarcoma. Fifteen of recipients 
and 15 of donors were male. Mean age of the recipients and donors were 40.8 
¡¾ 11 (21-58) and 38.5 ¡¾ 13.1 (17-60), respectively. Fourteen transplants 
were from living related donors, 7 from living unrelated donors and 3 from 
deceased donors. All transplantations were fi rst transplantation except one. 
Mean interval of development of malignancy after transplantation was 73.3 ¡¾ 
38.1 months. No one received lymphocyte depleting induction therapy. Main 
immunosuppressant was cyclosporine in 19 patients and was tacrolimus in 6. 
Seven patients showed far advanced state at the time of diagnosis and died 
within 1 month after diagnosis of cancer. 
Summary: Incidence of malignancy in kidney recipients is 10 times higher 
than general population. Types of posttransplant malignancy are different in 
Korea compare to western countries. Since far advanced malignancies are 
common and their prognosis is poor, regular screening of malignancy is needed 
in kidney transplant recipients.
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SURVIVAL WITHOUT IMMUNOSUPPRESSION IN POST 2142 
RENAL TRANSPLANT KAPOSI’S SARCOMA
T. Aziz, E. Ahmed, J.I. Kazi, F. Akhtar, A. Naqvi, A. Rizvi
Sindh Institute of Urology And Transplantation
Introduction: Kaposi’s sarcoma is one of the common malignancy after renal 
transplantation in some geographical regions. Withdrawl of immunosuppression 
leads to regression but predisposes to rejection and graft loss. 
Patients and Methods: We have studied the outcome of patients with Kaposi’s 
sarcoma at our center in whom immunosuppression was withdrawn. 
Results: A total of 1800 renal transplant performed between November 
1985 and December 2007. Kaposi’s sarcoma (KS) developed in 11 of 1800 
recipients (0.6%) which account for 36% of total malignancies developing in 
transplant recipients during this period. All patients were male with a mean 
age at presentation was 31.9± 8.9 years. Mucocutaneous involvement was 
present in 9 of 11 patients (82%) with visceral evidence of KS was present in 
6 of 11 patients (55%). All of sarcomas developed after one year of transplant. 
Azathioprine and cyclosporine were withdrawn after the diagnosis of tumor 
and patients were kept on low dose prednisolone only. Serum creatinine at the 
time of diagnosis of tumor was 1.87±0.77 mg/dl. Four patients had one episode 
of rejection prior to diagnosis of KS. They received pulse steroid therapy. 
But none of the patient had acute rejection episode after the withdrawal of 
immunosuppression. Three patients died due to aggressive pulmonary disease 
and two later on became dialysis dependent. Six patients had functioning graft 
with a mean creatinine 2.5 ± 1.7 mg/dl after a follow up period of 49 months 
(10-108 months) with no evidence of KS. 
Conclusion: Kaposi’s sarcoma is the 2nd most common malignancy 
after Non Hodgkin’s lymphoma in our transplant recipients. Reduction in 
immunosuppression leads to regression of KS in majority of our patients with 
relative preservation of graft function in medium term. 
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IMPACT OF HLA ANTIBODIES IN SHORT AND LONG-2143 
TERM COURSE AFTER RENAL TRANSPLANTATION
G.F. Hillebrand1, T. Kauke2, M.C. Heydenreich1, W-D. Illner3, K-W. Jauch3, 
W. Samtleben1, H. Arbogast3
1Nephrology Division, Medical Clinic I, University of Munich, Campus 
Grosshadern, 2Tissue Typing Lab, Institute of Transfusion Medicine, 
University of Munich, Campus Grosshadern, 3Surgical Clinic, Transplant 
Centre,University of Munich, Campus Grosshadern
Aim: Despite an excellent improvement in the early period after renal 
transplantation due to new powerful immunosuppressive drugs, the late outcome 
is still hampered by chronic transplant loss. The reasons for this are not fully 
understood. Chronic allograft dysfunction is considered to be a multifactor 
damage caused only partially by immunological attacks on the donated kidney. 
However, the impact of anti HLA especially donorspecifi c antibodies (ab) are 
considered to play an important role in late allograft dysfunction. They seem to 
be important to discriminate such immunological attacks from other reasons.
Patients And Methods: We examined 205 pts after renal transplantation (RT) 
in the outpatient clinic: Group I (n=66) in the early period after RT followed up 
by the transplantation unit and Group II (n= 139) in long-term follow up under 
care of the Div of Nephrology. Time from RT was 3.9±4.3 years in group I and 
12.0±7.2 years in group II. The impact of HLA- ab after RT especially in respect to 
donor-specifi c ab (DSA) was investigated. Sera were screened by Luminex® for 
the presence of HLA class I and class II IgG antibodies, and positively screened 
sera were confi rmed by an identifi cation assay (Tepnel Lifecodes,USA).
Results: 35.6% (73/205) pts showed HLA ab. In 16.6% (22/205) DSA could be 
detected. In group I 42.4% (28/66) pts were positive for HLA-ab with 12.1% 
DSA versus 37.4% (45/139) HLA ab positive pts and 10.8% detectable DSA 
in group II. There was no statistical difference between group I and group II. 
However, in group I ab against HLA class I were signifi cantly higher (31.8% 
[21/66]) than in group II (15.8% [22/139]) (p<0.001). Also, DSA against HLA 
class I was more pronounced in group I: 13.6% (9/66) as in group II: 5% (13/139) 
p>0.05. In group I with the short follow up the combination of ab against HLA 
class I and II was seen more often (12.1%) in contrast to the long-term followed 
group II (9.3%) p<0.05. The frequency of DSA against HLA class I and II was 
higher in group I (19.1%) than in group II (2.1%) p<0.05. Ab against HLA class 
II revealed no signifi cant difference between the two groups.
Conclusion: The lower frequency of HLA- class I- ab, either DSA or non donor 
specifi c (NDSA), in long-term graft survivors indicate an adverse infl uence of 
HLA-ab on graft outcome. Regular monitoring in the follow up should be an 
important tool in adjusting the immunosuppressive therapy.
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RAPAMYCIN IS LESS FIBROGENIC THAN FK506 IN RAT 2144 
MODEL OF CHRONIC ALLOGRAFT NEPHROPATHY
G.H. Luo, Y.P. Lu, L. Yang, J. Song, L.Y. Zhang, X. Ma, Y.P. Li
Transplantation Institute
Aim: FK506 is associated with signifi cant chronic nephrotoxicity, which mainly 
manifests as renal fi brosis. There have been proved that Rapamycin (RAPA) 
could inhibit or attenuate fi brosis process. This study is to determine whether 
the differences on expression of fi brosis-associated genes exist between FK506 
and RAPA in rat kidney underwent chronic allograft nephropathy (CAN).
Methods: F344 rat renal grafts were orthotopically transplanted into Lewis rats 
following the procedure of Kamada with our modifi cation. All the recipient rats 
were given CsA 10mg/kg-1.d-1×10d and then divided into three oral treatment 
groups (each group n=9): (1) Vehicle: given vehicle orally, (2) FK506: 0.15mg/
kg-1. d-1, (3) RAPA: 0.8mg/kg-1.d-1. At 4w, 8w, 12w, SCr and pathological 
changes were measured. The expression of CTGF, collagen I, IV, α-SMA and 
E-cadherin were assessed by real time PCR and Western blot.
Results: The CAN model of the rat kidney allograft, which was reinforced 
with cold ischemia injury was successfully built. The SCr and Banff score 
increased in a time dependent manner in all the three groups. The differences 
of SCr and Banff score between the three groups were not signifi cant at 4w 
(p>0.05). At 8w and 12w, SCr(μmol/L) in Vehicle, FK506 and RAPA group 
were 275±23.5,516±32.0; 230±18.01, 476±61.63 and 110±11.3, 321±59.15. 
The differences between RAPA and other two groups were statistically 
signifi cant (p<0.05). The histological lesions of CAN in Vehicle and FK506 
groups were more serious than those in RAPA group. At 8w and 12w, the 
Banff score in Vehicle, FK506 and RAPA group were 5.33±0.58, 13.33±1.52; 
5.00±1.00, 12.33±3.79 and 1.33±1.52, 7.33±3.78, respectively. The difference 
between RAPA and other two groups were statistically signifi cant (p<0.01). 
CTGF positively expressed in tubular epithelial cell (TEC) in allografts at 4w. 
Although at 8w, many tubules in allografts were damaged and vanished, the 
remained TEC still positively expressed CTGF. α-SMA was also expressed in 
TEC. Collagens I and IV were expressed in interstitium since 8w. E-cadherin 
was lost dramatically in atrophied tubules since 4w and only a few of the 
remained tubules were E-cadherin positive at 12w. Comparing with the Vehicle 
and FK506 group, the expressions of the fi brosis-associated genes in RAPA 
group were obviously weaker except E-cadherin. 
Conclusion: We demonstrate that RAPA can ameliorate fi brogenesis in 
transplant kidney by inhibiting the expression of CTGF mRNA and protein, 
down-regulating the expression of collagen I, IV and α-SMA, abating for 
E-cadherin’s lose and inhibiting the epithelial-mesenchymal transformation 
(EMT). FK506 has no these effects. 
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COMPARISON OF RAPAMYCIN VS. FK506 ON 2145 
EXPRESSION OF CYTOPROTECTIVE GENES IN THE RAT-
KIDNEY ALLOGRAFTS UNDERGOING CHRONIC REJECTION
D.H. Teng, Y. Lu, R. Gao, Y. Xin, G. Cao, X. Li, L. Wang, J. Wang
Transplantation Institute
Aims: Cytoprotective genes are named after their known anti-infl ammatory 
and anti-apoptotic function. It is increasing recognized that expression of 
cytoprotective genes in grafts can affect the progress of chronic rejection. Little 
is known about the infl uence of different immunosuppressive regimens on 
expression of cytoprotective genes in allografts undergoing chronic rejection. 
We investigate whether there is difference between rapamycin and FK506 in 
the ability of affecting expression of cytoprotective genes in the rat kidney 
allografts undergoing chronic rejection.
Methods: SD rat renal grafts were orthotopically transplanted into Wistar 
rats following the procedure of Kamada with our modifi cation. The recipients 
were divided into three oral treatment groups: (1) vehicle group (CsA 10mg/
kg.dX10d followed by vehicle), (2) rapamycin group (CsA 10mg/kg.dX10d 
followed by rapamycin 0.8mg/kg.d), (3) FK506 group (CsA 10mg/kg.dX10d 
followed by FK506 0.15mg/kg.d). At the same time points after transplantation, 
the rats were sacrifi ced and the renal allografts were harvested. The expression 
of four cytoprotective genes, A20, heme oxygenase (HO)-1, Bcl-2 and Bcl-
X/L in these grafted kidneys were analyzed by quantitative RT-PCR and 
immunohistochemistry.
Results: Four cytoprotective genes are all detected in the rat-kidney allografts 
undergoing chronic rejection. The expression of A20 in grafted kidneys is 
signifi cantly higher in rapamycin group than that in FK506 group and in vehicle 
group (P<0.05)(Table1 and 2). There is no signifi cant difference between 
rapamycin group and FK506 group in the expression of HO-1, Bcl-2 and 
Bcl-X/L (Table2). A20 is expressed in vascular structures, cellular infi ltrates 
and at very low levels in glomerular structures. Expression of HO-1 is mainly 
localized in cellular infi ltrates, but it is also detected in tubular structures. 
Expression of Bcl-2 and Bcl-X/L are mainly in tubular structures.
Table 1. Rate of positive area of A20, HO-1, Bcl-2 and Bcl-X/L in kidney allografts (%)
Group A20 HO-1 Bcl-2 Bcl-X/L
Vehicle 1.47±0.25 1.72±0.18 3.98±0.53 3.04±0.47
Rapamycin 12.43±1.04 3.37±0.49 15.04±4.26 17.29±1.58
FK506 7.92±0.87 3.34±0.51 15.18±3.97 16.94±2.26
Table 2. Expression of A20, HO-1, Bcl-2 and Bcl-X/L mRNA in kidney allografts (X±SD)
Group A20(copy×104) HO-1(copy×104) Bcl-2(copy×104) Bcl-X/
L(copy×104)
Vehicle 0.72±0.30 1.18±0.26 1.27±0.41 1.19±0.34
Rapamycin 92.17±11.26 8.92±1.04 4.87±0.69 9.87±1.12
FK506 46.37±9.92 8.89±0.73 4.91±0.53 9.84±1.04
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DETECTION OF CITRATE SYNTHASE 2146 
AUTOANTIBODIES IN RATS WITH CHRONIC ALLOGRAFT 
NEPHROPATHY
L.Y. Zhang, Y.P. Lu, Y. Li, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital
Background: There are only some sparse records of test on autoantibodies 
against mitochondria1 innermembrane enzymes in some autoimmune 
diseases and vasculopathy after heart transplantation,and the roles of those 
autoantibodies are more and more emphasized. Citrate synthase(CS) is an 
important mitochondrial autoantigen and one of the key enzymes in citric 
acid cycle,which is central to the regulation of energy homeostasis and cell 
metabolism.However,the autoimmune responses against CS have never been 
studied in chronic allograft nephropathy(CAN).In this study we aimed to 
investigate CS specifi c autoantibodies in renal allograft rats with CAN.
Methods: Fisher344 rat renal grafts were orthotopically transplanted into 
Lewis rats following the procedure of Kamada with our modifi cation.All the 
recipients were given CsA 10mg/kg-1.d-110d and then divided into 4 groups 
(each n=9):(1)Vehicle:vehicle orally;(2)CsA:6mg/kg-1.d-1;(3)FK506:0.15mg/
kg-1.d-1; (4)MMF:20mg/ kg-1.d-1. At 4w, 8w and 12w,the rats were sacrifi ced, 
renal allografts were harvested and sera were collected. The SCr was measured 
and the pathological changes were assessed according to the Banff 97 criteria.
IgM and IgG isotype CS antibodies of all the recipients were detected 
differently by binding indirect enzyme-linked immunosorbent assay(ELISA). 
Results: Both IgM and IgG isotype CS autoantibodies were found in the sera of 
all recipients before and after transplant,but the level of IgM CS autoantibodies 
are more obviously stable and higher than IgG isotype in all different blood 
samples. At 4w, the Banff scores in Vehicle, CsA,FK and MMF groups were 
1.670.58,1.330.58, 1.001.00 and 0.670.58 respectively,the differences of Banff 
score between different groups were not signifi cant (p>.05). The OD values 
of IgG isotype CS autoantibodies in Vehicle, CsA,FK and MMF groups were 
0.068±0.007, 0.081±0.009,0.0830.003 and 0.0560.006, respectively(P>.05).
With progression of CAN(Banff score:5.330.58 and 12.671.16 in vehicle group 
at 8w and 12w, respectively,P=0.001),the OD values of IgG in Vehicle group 
were increased gradually(0.1710.015,0.3350.009,at 8w,12w,P=0..005);in CsA 
group,with the progression of CAN(Banff score:4.671.53,13.331.53),CsA 
did not prevent the formation of IgG isotype autoantibodies,but the OD 
(0.1370.001,0.2790.019 respectivly at 8w,12w,p>0.5) values had no 
signifi cant difference;in FK group,with the progression of CAN(5.670.58, 
12.333.79 at 8w,12w), the OD values were 0.1510.011,0.2910.009 at 
8w,12w,respectively,p=0.005;MMF could decrease signifi cantly the formation 
of IgG(OD values:0.1330.000 and 0.0990.007 respectively at 8w,12w, 
p=0.078) and the progression of CAN(1.671.16,6.671.53) at 8w and 12w.
Conclusions: This study suggests IgG isotype CS autoantibodies may 
contribute to CAN after kidney transplantation,but IgM isotype autoantibodies 
may be physiological.
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RAPAMYCIN CAN AMELIORATE CAN IN RAT 2147 
ALLOGRAFTS BY AFFECTING RHO/ROCK SIGNAL PATHWAY
J. Song, Y.P. Lu, G. Luo, L. Yang, X. Ma, Q.J. Xia, Y.J. Shi, Y.P. Li
West of China Transplantation Institute
Aim: The small GTPase Rho and ROCK play an important role in graft 
fi brosis. This study is to investigate whether the difference exist between 
rapamycin(RAPA) and FK506 by affecting small GTPase Rho and ROCK 
signal pathway in rat renal allografts with chronic allograft nephropathy 
(CAN)
Methods: Male inbred F344 rat renal grafts were orthotopically transplanted 
into Lewis rats following the procedure of Kamada with our modifi cation. F344 
rats were also autografted. The allograft rats were fi rst treated with CsA10mg/
kg-1.d-1×10d and then divided into 3 groups (each n=9):(1)CAN:Vehicle 
orally,(2)FK506:0.15mg /kg-1.d-1,(3)RAPA:0.8mg/kg-1.d-1. At 4w, 8w, 12w, SCr 
was measured and the pathological changes were accessed according to Banff 
97 criteria. The expression of RhoA and ROCK-1 was determined by real-time 
RT-PCR and immunohistochemistry. The expression of α-SMA, CTGF were 
observed simultaneously.
Results: As showing in Table, SCR and Banff score increased since 4w 
in CAN group, and obviously increased both in CAN and FK506 group at 
8w, 12w. The differences between CAN/FK506 and autograft group were 
signifi cant(P=.000). SCR and Banff score in RAPA group increased mildly 
and moderate at 8w and 12w, respectively; but were signifi cantly lower than 
those in CAN/FK506 group(p<.05). α-SMA and CTGF were observed in 
renal epithelium and tubular cells and the expression increased along with 
progression of CAN. RhoA and ROCK-1 were observed in mesangial cells 
and tubule cells and increased gradually along with CAN. There was negative 
correlation between RhoA/ROCK-1mRNA and Banff score(r=-.637, p=.000; 
r=-.676, p=.000) and SCR(r=-.705, p=.000; r=-.756, p=.000). RAPA down-
regulated the expression of gene and protein of RhoA and ROCK-1. FK506 
had little effect on them. 
Groups
4W 8W 12W
SCr
Banff
Score
RhoA ROCK-1 SCr
Banff
Score
RhoA ROCK-1 SCr
Banff
Score
RhoA ROCK-1 
Autograft 63.44
±0.94
0 11.84 
±0.24
22.68
±0.48
62.27
±0.51
0 12.00
±0.00
22.50
±0.00
71.21
±2.01
0 11.84
±0.24
22.68
±0.47
CAN 110.97
±55.84
1.67
±0.58
4.18
±0.25
7.54
±0.75
275.23
±23.51
5.33
±0.58
3.55
±0.43
8.08
±0.83
516.78
±31.60
12.67
±1.15
2.85
±0.24
6.38
±0.65
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FK506 86.07 
±18.13
1.00
±1.00
8.05
±1.25
15.20 
±2.38
263.64 
±50.97
5.33
±0.57
5.68
±0.24
9.71
±0.64
476.93
±61.63
12.33
±3.79
5.17
±0.25
9.00
±0.00
RAPA 66.08
±4.88
0.67
±1.15
9.21
±0.64
17.20
±0.65
110.35
±11.30
1.33
±1.53
8.02
±0.42
12.72
±0.85
321.81
±59.15
7.33
±3.79
6.53
±0.42
1 0 . 5 3 
±0.42
Conclusion: We demonstrate that abnormal expression of RhoA and ROCK-1 
signal pathway may play a role in CAN. RAPA can attenuate CAN by down-
regulating the expression of RhoA and ROCK-1.
POSTER BOARD NUMBER P4 – 198
ROLE OF DIFFERENT IMMUNOSUPPRESANTS IN 2148 
VSMC BY AFFECTING THE TGF-BETA AND SMADS SIGNAL 
PATHWAY
Y.P. Lu, R. Gao, Y.P. Xin, X.H. Zhang, J. Wang, Y.P. Li
West of China Transplantation Institute
Objective: TGF-β is a key mediator in the development of CAN. It can promote 
vascular smooth muscle cell (VSMC) proliferation and has a great infl uence 
on the ECM turnover in SMC. The discovery of Smad proteins has revealed 
the intracellular signal transduction of TGF-β. We investigated the effect of 
different immunosuppresants on TGF-β1/ Smads Signal Pathway in VSMC in 
order to clarify the role of immunosuppresants in CAN. 
Methods: Vascular smooth muscle cell (VMSC) from rat aorta were incubated 
with different immunosuppresants (CsA 3μg /ml, FK506 1μg/ml, MMF 0.3μg/
ml, Rapa 10μg/ml, CsA 1μg/ml+ MMF 0.3μg/ml), respectively for 6 or 12 
hours, as control without anything. The immunohistochemistry and real-time 
fl uorescence quantitative PCR, were used to comprehend the expression of 
TGF-β1 and Smad2, 7 in VMSC. 
Results: Comparing with control groups, CsA and FK506 increased expression 
of TGF-β1 and Smad2 and inhibited expression of Smad7, whereas MMF and 
Rapa could down-regulate the expression of TGF-β1 and Smad2 and up-regulate 
expression of Smad7. We demonstrated that increased TGF-β1 was associated 
with over expression of Smad2 and down-regulated Smad7 in VSMC. There 
is no signifi cant difference between CsA group and FK506 group, as well as 
MMF group and Rapa group. We also showed that CsA and FK506 affected 
TGF-β1, Smad2 and Smad7 in VSMC in a time-dependent manner. 
Conclusion: Our data indicated that Smads proteins were expressed in 
VSMC and that they mediated TGF-β signaling in those cells. Different 
immunosuppresants can affect TGF-β1/Smads signal pathway in VSMC, CsA 
and FK506 can up-regulate the expression of Smad2 and down-regulate Smad7 
expression in VSMC, and caused the over expression of TGF-β1. This will 
contribute to arteriosclerosis. However, MMF and Rapa have an opposite role 
in VSMC compared with CsA and Fk506.
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MMF CAN PREVENT THE PROGRESSION OF CAN IN 2149 
ALLOGRAFT BY AFFECTING RHOA/ROCK-1
J. Song, Y.P. Lu, G.H. Luo, L. Yang, Q. Xia, Y.J. Shi, Y.P. Li
West of China Transplantation Institute
Aim: The small GTPase RhoA/ROCK-1 play a role in the processing of organ 
fi brosis. We studied whether MMF can prevent the progression of chronic 
allograft nephropathy (CAN) in allograft by affecting RhoA/ROCK-1 signal 
pathway.
Methods: Specifi c pathogen free animal male inbred F344 rat renal grafts were 
orthotopically transplanted into Lewis rats following the procedure of Kamada 
with our modifi cation in CAN models. F344 were autografted as control. F344 
rats were also autografted as control. The allograft rats were fi rst treated with 
CsA10mg/kg-1.d-1×10d and then divided into 3 groups (each n=3): (1) CAN: 
Vehicle orally, (2) CsA (Cyclosporin A): 6 mg/kg-1.d-1, (3) MMF: 20mg/kg-
1.d-1. After 60days, SCR was measured and the pathological changes were 
accessed. RhoA/ROCK-1 was examined by real-time PCR and fi brosis factors 
a-SMA, CTGF were observed by immunohistochemistry.
Results: Showing in Table, SCR and Banff score increased obviously 
increased both in CAN and CsA group. The differences between CAN/CsA and 
autografts were signifi cant (n=3/group, p=.000). SCR and Banff score changed 
with fi brosis factors α-SMA and CTGF in MMF group increased moderate 
at 60days, but were signifi cantly lower than those in CAN/CsA group(n=3/
group,p<.05). Seeing in Figure, the fi brosis factors a-SMA and CTGF were 
observed in renal epithelium and tubular cells. Protein of RhoA and ROCK-1 
were observed in mesangial and tubule cells and increased gradually in the 
processing of CAN. There was negative correlation between RhoA/ROCK-
1mRNA (¦ Ct values, ¦ Ct values were in inverse proportion to gene copies 
in the cells and tissues) and Banff score(r=-.637, p=.000; r=-.676, p=.000) and 
SCR(r=-.705, p=.000; r=-.756, p=.000). CsA can accelerate the expression of 
fi brosis factors gene and protein. MMF attenuated the fi brosis factors α-SMA, 
CTGF and down-regulated the expression of gene and protein of RhoA/
ROCK-1 in kidney allograft. 
Conclusion: The fi ndings of our study highlight the importance of abnormal 
expression of RhoA/ROCK-1 signal pathway in the pathogenesis of CAN. 
MMF can prevent the progression of CAN by down-regulating the expression 
of the fi brosis factors α-SMA, CTGF and GTPase RhoA/ROCK-1. 
Groups(each 
n=9) SCr(μmol/L) Banff Score RhoA(¦ Ct) ROCK-1(¦ Ct)
Autograft 62.27±0.51 0 12.00±0.00 22.50±0.00
CAN 275.23±23.50 5.33±0.58 3.55±0.43 8.08±0.83
CsA 295.26±32.07 4.67±1.52 5.68±0.24 9.71±0.64
MMF 138.26±28.45* 1.67±1.16* 8.02±0.42* 12.72±0.85*
* p<.05
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THE AUTOANTIBODY LEVEL OF CITRATE SYNTHASE 2150 
ARE CORRELATED WITH C4D DEPOSITION IN RATS WITH 
CHRONIC ALLOGRAFT NEPHROPATHY
L.Y. Zhang, Y.P. Lu, L. Yang, G.H. Luo, J. Song, Y.P. Li
Transplantation Institute, West China Hospital
Background: C4d deposition after kidney transplantation is thought to 
be associated with alloantibodies. Citrate synthase (CS) is an important 
mitochondrial autoantigen and one of the key enzymes in citric acid cycle, which 
plays a central role in regulation of energy homeostasis and cell metabolism. 
This study is to investigate the relationship between C4d deposition and anti-
CS autoantibodies in rats with CAN post renal allotransplant.
Methods: Fisher344 rat renal grafts were orthotopically transplanted into 
Lewis rats following the procedure of Kamada with our modifi cation. All 
the recipients were given CsA 10mg/kg-1.d-1×10d and then divided into three 
groups: (1)Vehicle: vehicle orally, (2)CsA: 6mg/kg-1.d-1, (3)MMF: 20mg/
kg-1.d-1. At 4w, 8w, 12w after transplant, the rats were sacrifi ced, the renal 
allografts were harvested and the sera was collected. The SCr was measured 
and the pathological changes were assessed according to the Banff 97 criteria. 
The isotype of CS antibodies, including IgM and IgG in all the recipients 
were detected by binding indirect enzyme-linked immunosorbent assay 
(ELISA) before and after transplant. The deposition of C4d was detected 
by immunofl uorescence and analyzed by Integrated Optical Density (IOD). 
Results: With progression of the CAN from 4w post-transplant, the C4d 
deposition in peritubular capillaries (PTC) increased. The level of IgM of 
CS autoantibodies was more obviously stable and higher than IgG isotype in 
all blood samples. With the progression of CAN from 4w,there was a strong 
positive correlation between the level of IgG isotype of CS and C4d deposition 
(r=0.973, p=.000) in vehicle group. CsA didn’t prevent the formation of IgG 
isotype of CS (OD: 0.1370.001 and 0.2790.019 at 8w,12w, respectively, 
p>0.5) and the deposition of C4d(IOD: 8.81040.3104 and 19.31042.1104 at 
8w,12w, respectively, p=0.016). The values of IgG isotype of CS(OD) and 
C4d (IOD) in groups of Vehicle, CsA and MMF at 12w post-transplant were 
0.3350.009, 0.2790.019, 0.1130.000, and 21.11041.3104, 19.31042.1104, 
8.21040.7104, respectively.The differences of IgG and deposition of C4d 
between MMF and other two groups were all statistically signifi cant (p=.000). 
Conclusions: This study shows that there was a strong positive correlation 
between the level of IgG isotype of CS and C4d deposition. The CS 
autoantibodies may contribute to progression of CAN. MMF may inhibit the 
progression of CAN by decreasing the formation of IgG autoantibodies of CS 
and the deposition of C4d. CsA has no these effects.
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IMPACT OF POST TRANSPLANT PANEL REACTIVE 2151 
ANTIBODIES ON LONG TERM GRAFT OUTCOMES IN 
DECEASED DONOR RENAL TRANSPLANTATION
J.C.J. Choo1, M.L. Lai2, A. Vathsala1
1Department of Renal Medicine, Singapore General Hospital, 2Health 
Sciences Authority-Centre for Transfusion Medicine
The presence of panel-reactive antibodies(PRA) prior to transplantation has 
been associated with a higher risk of graft failure in deceased donor renal 
transplantation(DDRT). However, the role of PRA occurring post-transplant 
has not been hitherto examined. Furthermore, the role of pre and post-transplant 
PRA on long term survival is unestablished. The present study examined 
the role of pre and post-transplant PRA in renal transplant recipients(RTX) 
undergoing DDRT between 1988 and 2006 at our centre. All RTX had a 
negative B and T-cell CDC crossmatch against donor lymphocytes. PRA was 
tested against a panel of lymphocytes using the CDC method. From 1988 
to 2000, RTX received Cyclosporine(CsA) and Prednisolone(Pred) with or 
without Azathioprine(AZA) as primary immunosuppression(IS). From 2000, 
AZA was substituted with Mycophenolate analogs(MPA) for RTX with PRA 
>25%. From September 2002, RTX with a functioning graft at 1 year had 
repeat PRA tested post-transplant annually. The present study examined the 
change in PRA levels, pre and post-transplant, and evaluated their impact on 
graft and patient outcomes. 
The study population included 426 RTX (52.6% Female, 89.7% Chinese, 
Mean Age 49.9 years) with at least one PRA measurement beyond 1 year post-
transplant; those with graft loss and patient death prior to 1 year were excluded 
from the study. IS consisted of CsA-Pred with or without AZA in 72.1%, CsA-
Pred-MPA in 19.7%, and other combinations in the remainder. All deaths, 
including death with a functioning graft were considered as graft failures. 
Overall actuarial graft survival at 5, 10 and 15 years was 96.3%, 90.4% and 
76.2% respectively. 42% of RTX were not sensitized pre-transplant; proportions 
with PRA of 1-10% and >10% were 12.2% and 45.8% respectively. RTX with 
pre-transplant PRA<10% had signifi cantly better graft survival to 15 years 
(82.4% vs. 67.1%, p=0.003). There were no differences in incidence of either 
early or late rejection in sensitised vs. non-sensitised RTX. 
In comparison to pre-transplant PRA, mean post-transplant PRA was 
signifi cantly higher (18% vs. 42%, pre vs. Average of all post-transplant 
PRA, p=0.000). Indeed, in relation to the pre-transplant PRA, 72.3% had an 
increase in post-transplant PRA, while 23.5% had a decrease, while 4.2% 
remaining unchanged. Furthermore, RTX with a decrease in post-transplant 
PRA or unchanged PRA, in comparison to pre-transplant PRA, had no survival 
advantage. Separate analyses evaluated the impact on graft survival of PRA at 
each of the 1st four years post-transplant as well as of averaged values during 
various post-transplant periods from the 1st to 4th years and at 5-yearly intervals 
thereafter till 19 years. Each analysis included stratifi cation for different levels 
of PRA values; none demonstrated any correlations with graft survival. 
These results demonstrate that broad sensitisation as measured by pre-transplant 
PRA has a signifi cant impact on long-term outcomes to 15 years post DDRT. 
Post-transplant, the majority of RTX experience an increase in PRA; however, 
this change neither confers benefi t nor risk to graft survival in DDRT. Identifying 
post-transplant Anti-HLA antibodies, donor specifi c antibodies or cellular 
alloreactivity may better identify RTX at risk for chronic allograft failure. 
POSTER BOARD NUMBER P4 – 202
PROSPECTIVE TESTS ON THE PREDICTIVE VALUE OF 2152 
ANTI HLA AND MICA ANTIBODIES
P. Terasaki, M. Ozawa
Terasaki Foundation Laboratory
In two prior studies involving 1329 patients and 1219 patients a strong 
predictive value on subsequent graft function was noted for HLA and MICA 
antibodies. This data was based on kidney transplants, and confi rmatory results 
on 235 heart and 150 lung transplant patients was recently published.
We have now completed the prospective testing of the sera of 4,977 functioning 
patients of 4,081 kidney, 164 liver, 456 heart, 194 lung transplants. A total of 
76 centers from 20 countries are participating in this study. This new study 
involving an entirely new set of patients should provide defi nitive evidence 
of the predictive value of these antibody tests. The new tests also incorporate 
the testing with single antigen beads, allowing for separation of donor specifi c 
antibodies from other non specifi c antibodies. 
We will report on the outcomes from the earliest study (now 6 years post 
testing), up through the recently tested patients with one year follow-up. 
Thus far we have confi rmed that transplanted patients with well functioning 
grafts, nevertheless often do have anti HLA and anti MICA antibodies. The 
frequencies in patients with more than 1 year of good function are given in 
Table 1.
In summary, 4,977 patients who have functioning transplants were tested for 
anti HLA and MICA antibodies, and then followed up for subsequent graft 
failure. We will present the predictive value of antibodies on graft survival data 
for kidneys, heart, lung, and liver transplants.
Organ HLA # HLA% MICA MICA% 
Heart 349 47% 114 15.8%
Kidney 2120 26.1% 907 20.5%
Lung 117 31.6% 56 12.5%
Liver 82 43.9% 56 12.5%
Total 2695 29.4% 1104 19.3%
POSTER BOARD NUMBER P4 – 203
THE IMPACT OF PRE-TRANSPLANT ANTI-HLA AND 2153 
MICA ANTIBODIES ON LONG-TERM GRAFT OUTCOMES
M.D. Wavamunno1, P.J. O’Connell1, C.L-S. Fung1, R.D.M. Allen2, 
N. Watson3, F. Aboud-Daher3, J.R. Chapman1, B.J. Nankivell1
1Dept Renal Medicine and Transplantation Westmead Hospital, 
2Transplantation Surgery, Westmead Hospital, 3Tissue Typing,Australian 
Redcross and Blood service
Introduction: HLA antibodies are associated with late graft loss of kidney 
transplants. Solid phase assays can detect low levels of circulating antibody 
however the clinical consequences of antibodies detected by these techniques 
are not fully understood. The aim of this project was to determine the clinical 
signifi cance of pre-transplant antibodies detected by luminex microsphere 
assays on long-term renal function, survival and graft histology.
Methods: We retrospectively screened simultaneous kidney pancreas 
recipients (n=117) transplanted at our centre for pre-transplant HLA and 
MICA antibodies where there was availability of pre-transplant sera. Sera were 
screened to determine the presence or absence of anti-HLA Class I or Class II 
and MICA antibodies using luminex. Sequential prospective protocol kidney 
biopsies (n=318) from implantation to 5 years post transplant were evaluated 
for histological parameters using the Banff schema and for deposition of C4d in 
peritubular and glomerular capillaries by immunoperoxidase staining. Findings 
were evaluated against clinical outcomes including isotopic DTPA GFR from 1 
yr to 10 yrs and graft survival.
Results: Class I and/or Class II anti-HLA antibodies were found in 60 of 117 
(52%) patients (17 Class I and II,38 Class I and 5 Class II). Of 60 patients 
with anti HLA antibodies 19(31%) had a peak PRA >25% compared with 7 
(12.2%) in the group without HLA antibodies, (÷2=6.8, P<0.02). Presence of 
anti-HLA antibodies was associated with Banff Cg score >1 beyond 2 year 
after transplantation (÷2 =6.3, P<0.02). The 1,3 and 5 year isotopic GFR 
levels were higher in the cohort without HLA antibodies compared to those 
with HLA antibodies (54.5 ±4.2 vs. 64.2±2.9, 49.5±3.4 vs. 63.6±3.6 and 
43.2±3.8 vs58.9±4.0 ml/min/1.73 respectively (P <0.05). Beyond 5 years 
after transplantation there was no difference in GFR between groups. Total 
uncensored graft loss was higher in the group with HLA antibodies 16/60 
(26%) compared to 5/57 (9%) in the group without HLA antibodies (P<0.01). 
There was a trend to higher death-censored graft loss 8/60 (13%) compared 
to 2/57(3.5%) (p=0.06). MICA antibodies were present in 28 of 105 (26%) 
patients. There was no association between peak panel reactive antibodies and 
presence of MICA antibodies. Isotopic GFR and graft loss were comparable 
in both groups. 
Conclusions: Presence of pre-transplant MICA antibodies is not associated 
with reduced GFR or graft survival. Pre- transplant Anti HLA antibodies 
detected by sensitive solid phase assays are associated with poor long-term 
histological and clinical outcomes in renal allograft recipients.
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HLA MISMATCHES AND PRA IN KIDNEY RE-2154 
TRANSPLANTS
K. Mizutani1, G. Monokazu2, P. Terasaki1
1Terasaki Foundation Laboratory, 2Nagoya University
Kidney re-transplants are increasingly performed worldwide even though they 
are considered high-risk. One reason for the extra risk is that re-transplants 
have higher PRA than fi rst transplants, giving rise to serious issues—including 
the fact that highly sensitized patients often lose their opportunity for transplant 
specifi cally because the risk of their higher PRA renders them less desirable 
candidates. Currently, there are many patients on the waiting list and those 
numbers have been increasing. Defi ning the effect of HLA mismatches and PRA 
on re-transplants will give more opportunities to patients awaiting transplants. 
Here, we examine the trends of change, over the years, in the relationships 
between PRA, HLA mismatch, and 1st, 2nd, 3rd and multiple transplants from 
deceased donors. 
Data from 1987 up to November 2007 was obtained for 163,967 deceased 
kidney transplants reported to the Organ Procurement and Transplantation 
Network/United Network for Organ Sharing (OPTN/UNOS). 
HLA mismatches have increased nearly every year with both 1st and 2nd 
transplants while the percent of low PRA with 1st transplants and high PRA 
with 2nd transplants both increased. Although high PRA levels can reduce the 
rate of graft survival, that rate with 2nd transplants improved to almost the same 
levels expected with 1st transplants. However, some difference between the two 
groups did persist for 5-year graft survival. 
In conclusion, the graft survival of all HLA mismatches and PRA levels 
improved. And effect of HLA mismatches and PRA on re-transplants has been 
decreased. However, although advances in immunosuppression during the last 
decade have resulted in better short term graft survival, our analysis suggests 
that new drug treatments may not be enough to affect long term transplant 
outcomes.
POSTER BOARD NUMBER P4 – 205
CYLEX IMMUKNOW2155 ® IN THE MANAGEMENT OF POST 
KIDNEY TRANSPLANT RECIPIENTS.
M.R. Carreño, G. Ciancio, G.W. Burke, L. Chen, J. Sageshima, P. Ruiz
Departments of Surgery and Pathology, University of Miami-L. Miller School 
of Medicine
The ImmuKnow® assay has proven to have utility in the assessment of 
immunosuppression in organ transplantation. In the present study, we 
evaluated Immuknow responses pre- and post-renal transplantation of serially 
drawn specimens obtained randomly, during quiescence, rejection, or infection 
episodes and correlated these fi ndings with other tests and clinical outcomes.
Renal transplant patients received induction therapy with depleting antibodies 
and were maintained on Prograf and low dose steroids. A total of 2096 
specimens from 339 transplants were evaluated using Immuknow. Levels of 
ATP were categorized as Low or Strong when outside the Moderate range of 
225-525 ng/ml. 
Several patterns were observed with healthy adult volunteers or patients. In 
general the mean responses of healthy adults (Controls) was 432+150 ng/mL 
(n= 20). Pre-transplant specimens from kidney transplant recipients showed 
lower levels than controls with a mean of 342.1+155 (n=91, not all tested), but 
signifi cantly higher (p<0.005) than post-transplant values at 1-30 (203.7+171 
ng/mL), 30-365 (249.1+162 ng/mL), 366-730 (278.3+147 ng/mL), or 730-1090 
(263.5+136 ng/mL) days post-transplant. Patients that tested Strong pre-Tx 
(n=10) remained Strong in subsequent testing without notable evidence of 
rejection (1st. year n=11, 2nd. year n=10, 3rd. year n=4). Of those with cellular 
(C) (n=8) or humoral (H)(n=2) rejections while monitoring, all in the C group 
had increases >200 ng/mL with rapid return 1-2 days after function was restored, 
and the H group did not have any ATP changes. Of those with infections (n=23) 
except for two, there was a tendency to go below >150 ng/ml. Stable patients 
remained within a 200 ng/ml range (quiescent zones) within Low/Moderate 
levels. Patients with persistent low levels (<100ng/ml) (n=29) did not have 
major consequences as reported by others. In addition, low absolute CD4+ T 
cells (100 cells/mm3) did not impede Strong Immuknow responses. 
Serial monitoring with ImmuKnow is crucial to establish individual patient 
baseline levels, which vary signifi cantly in clinically stable patients. 
Signifi cant changes in ImmuKnow throughout the post-transplant period helps 
individualize and tailor immunosuppression levels. Our results suggest that the 
Immuknow assay can aid signifi cantly in the clinical management of kidney 
post-transplant recipients.
POSTER BOARD NUMBER P4 – 206
OUTCOMES OF ALLOGRAFT DYSFUNCTION IN RENAL 2156 
TRANSPLANT RECIPIENTS WITH MHC CLASS I CHAIN 
RELATED PROTEIN A ANTIBODIES (MICA): SINGLE CENTER 
ANALYSIS.
Y. Qazi, V. Pradeep, E. Solbes, M. Hermes, M. Smogorzewski, M. Koss, 
R. Mateo, L. Sher, R. Selby, Y. Iwaki
University of Southern California
Antibody mediated rejection is a signifi cant contributor of allograft dysfunction 
(GD) and detection of post transplant HLA antibodies has been shown to 
correlate with poorer graft survivals. Newer techniques can now detect 
antibodies to MICA with better accuracy but the frequency and signifi cance of 
these antibodies is unclear. Aim: To evaluate sera of Kidney Tx recipients (KTx) 
with GD for the presence of MICA and to asses its impact on outcomes.
Methods: The study was a retrospective, observational study of KTx recipients 
with GD from 03/2002 – 07/2007. GD was defi ned as a clinical event requiring 
a kidney biopsy (KBx). MICA and Class I &/or Class II HLA Ab (HLA Ab) 
were detected by using Single Antigen Beads (Luminex) and analyzed with 
Labscreen software (One Lambda). A positive result was characterized by 
an increase in fl uorescent intensity of >100 raw data units. The histology of 
allografts was defi ned using the Banff classifi cation. 
Results: 200 KBx were performed during this period and concurrent serum 
samples were available for 66 biopsies on which MICA and HLA Ab antibody 
testing was performed. MICA was detected in 44/66 patients. MICA with a 
positive or equivocal C4d but no HLA Ab was detected in 5 patients (1C4d +, 
4 C4d equivocal).MICA with a negative C4d and HLA Ab was detected in 14 
patients. MICA and HLA Ab was detected in 25 patients. Of the 5 MICA(+) 
patients found to be C4d + /equivocal but HLA Ab negative, 2 had graft loss. 
Graft loss occurred in the patient who was C4d + and in another patient with a 
equivocal C4d but a recipient of a combined Liver Kidney Tx. The mean [Cr] 
at time of biopsy was 2.74 mg/dl (1.4 – 6.0 mg/dl). Of the two patients with 
graft loss, the mean duration before graft loss was lost was 41.5 months (range 
35-48 months) and the mean Cr at last follow up for the remaining grafts was 
1.57mg/dl (0.8 – 2.3 mg/dl). Of the 14 patients that were negative for C4d and 
HLA Ab, 10 were found to have mild ACR but no patient had lost a graft. At 
the time of biopsy, mean [Cr] was 2.75 mg/dl (1.4-6.9 mg/dl). Mean follow-up 
from transplant was 23.4 months (5.6 –48.9 months) with last follow-up mean 
[Cr] of 1.59 mg/dl (1-3.2 mg/dl). Since the presence of HLA Ab would make 
it diffi cult to evaluate the signifi cance of MICA, this group was not studied 
further.
Conclusion: Our study demonstrates that in KTx with allograft dysfunction, 
detection of MICA in the presence of a positive or equivocal C4d independent 
of HLA Ab is a risk factor for graft loss and that all C4d + or C4d equivocal 
biopsies without HLA Ab should be evaluated for MICA. Detection of MICA 
in the absence of C4d or HLA Ab is a risk factor for ACR and may account for 
late allograft dysfunction which may require alteration in immunosuppression. 
Data is being collected prospectively to confi rm these observations.
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DONOR ATTITUDES CONCURRENT ORAL SESSION 146: 
AND EDUCATION
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COMPARING THE DYNAMICS OF KIDNEY AND LIVER 2157 
TRANSPLANTATION WAITING LIST IN THE STATE OF SAO 
PAULO, BRAZIL.
E. Chaib1, E. Massad2
1University of Sao Paulo School of Medicine, 2University of Sao Paulo School 
of Medicine
São Paulo is a pioneer brazilian state on transplantation surgery. Kidney and 
liver transplantation was fi rst performed at Sao Paulo Medical School. Since 
then the patient waiting list for both kidney and liver transplantation has 
increased now approximately 600 and 150 new cases, respectively, per month. 
The aim of this study was to compare the performance of our state kidney and 
liver transplantation program and analyze when the number of transplantations 
for both will meet our waiting list demand.
We collected offi cial data about our kidney and liver transplantation program 
between July 1997 to October 2004. The data related to actual number of liver 
and kidney transplantation, (Tr), the incidence of new patients on the list (I), 
and the number of patients who died in the waiting list, (D) in the State of Sao 
Paulo since 1997 are shown in Table 1. We projected the size of the waiting list, 
L, by taking into account the incidence of new patients per year, I, the number 
of transplantations carried out in that year, Tr, and the number of patients that 
died in the waiting list, D. The dynamics of the waiting list is given by the 
difference equation:, that is, the list size at time t+1 is equal to the size of 
the list at the time t, plus the new patients getting into the list at time t, minus 
those patients who died in the waiting list at time t, and minus those patients 
who received a graft at time t. The variables I, and D, from 2004 onward were 
projected by fi tting an equation by maximum likelihood, in the same way that 
we did for Tr. The waiting list, compared to the number of transplantations, can 
be seen in fi gure 1.
 
In conclusion, provided the conditions of the present day, the two projected 
curves will never meet each other. In other words, the list size grows at a rate 
much higher than the number of transplantations actually done.
Table 1. Actual number of liver and renal transplantation, Tr, the incidence of 
new patients in the list, I, and the number of patients who died in the waiting 
list, D, in the State of São Paulo since 1997
  Liver   Kidney  
Year Tr I D Tr I D
1997 63 450
1998 160 553 321 541 1598 492
1999 188 923 414 787 2980 834
2000 238 1074 548 907 3430 1014
2001 244 1248 604 921 3440 1248
2002 242 1486 725 874 1910 976
2003 289 1564 723 891 2544 1080
2004 295 1500 671 1001 2146 695
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BE BLESSED: A BIOPSYCHOSOCIAL MODEL FOR 2158 
RUDUCING HEALTH DISPARITIES
A. Campbell Jr., C. Callender, M. Lofton, L. Keen, A. Turner, J. Wiley, 
L. Adams, E. Clark, D. Morehead, T. Willis
Howard University
Background: Most biopsychosocial models contend that health and wellness 
are determined by biological, psychological, and social factors. The present 
study introduces a health model that broadens the biopsychosocial view to 
include a spiritual factor that also infl uences health-related physiological 
processes. The BE BLESSED Health Model™, as it is called, is a 
biopsychosocial-spiritual model of health that has been primarily derived 
from fi ndings in an empirical study of psychosocial stress and health that 
our research group has been conducting with a community-based sample 
of adult African Americans. This conceptual model recognizes that health 
outcomes are determined by the dynamic interplay of activities across 
nine biopsychosocial-spiritual sub-domains expressed by the acrostic BE 
BLESSED. 
Objective: The current study examines the socioeconomic gradient in health 
and discusses its implications in relation to objective biomarkers of health, 
renal disease, health perception, and elements of racism. 
Methods: Participants in our study include 125 African American (males= 
60 and females=65) between the ages of 18 to 85. Each participant in the 
study provided a blood and urine sample to determine the levels of immune, 
endocrine, cardiovascular, and metabolic functions. Participants were also 
given a battery of neuropsychological tests, psychosocial measures, and a 
health related quality of life survey. 
Results: The present study focuses on those fi ndings that involve measures 
of metabolic activity (HDL, triglycerides, waist to hip ratio), cardiovascular 
functions (blood pressure), health related quality of life, and perceived racism. 
As expected, socio-economic status (SES) was inversely related to HDL levels 
and directly related to triglyceride levels, waist- to- hip- ratio, and systolic blood 
pressure. Regression analyses show that in addition to SES, perceived racism 
accounted for a signifi cant proportion of the variance in general (physical) 
health perception and mental health. 
Conclusions: These fi ndings suggest that in addition to social class, elements 
of racism are independently related to subjective impressions of physical and 
mental health. They are also consistent with other studies which show a greater 
proportion of sub-clinical markers of disease risk and chronic health conditions 
among lower SES persons. These fi ndings are examined in the context of 
the BE BLESSED model and its potential for identifying the underlying 
mechanisms that link biological, psychological, social, and spiritual factors 1) 
to the onset and progression of renal disease and other disease processes, 2) to 
physical healing and recovery, and 3) to health disparities among ethnic and 
racial minorities.
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ORGAN DONATION: ATTITUDES AND PERCEPTIONS2159 
S.E-D. Al-Horani
Saad Specialist Hospital
Introduction: The availability of organs and tissue for transplantation is driven 
by public attitudes towards transplantation. To increase organ donation, public 
awareness campaigns simply urge individuals to discuss organ donation with 
their families. A representative sample of 50 people (age range 20–57 years) 
who were registered as potential for renal transplant donors (n=26) or members 
of the general public (n=24) participated in this study. It was designed to 
explore the feelings, ideas and public attitudes towards donating a kidney for 
transplantation.
Methods: Unstructural interviews were conducted for 30-40 minutes. Analysis 
of transcripts was based on hermeneutics and focused on identifi cation of 
typical attitude patterns related to donating organs.
Findings: Thirty six respondents had positive attitudes about organ donation, 
six had negative attitudes, and eight were undecided. Respondents seemed to fi t 
into one of four typical attitude patterns regarding willingness to donate organs. 
The attitude pattern of willingness to give was characterized by a perspective 
of the body as an object or machine, where parts could easily be exchanged. 
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The focus was on functioning of organs. Respondents with a willingness not to 
give (unwilling to give) seems that their strong anxiety regarding death made 
them unwilling to donate their own or a relative’s organs. An attitude pattern 
of mixed feelings initially willing to give, preferably to family members was 
characterized by initial intention to donate and give a family member either for 
life saving or enhancing a quality of live. Respondents who had mixed feelings 
about willingness to give (undecided) focused on there was no clear idea abut 
willing to give, it is still unclear for them about for whom they can give, or 
when to donate? 
Conclusion: Four attitude patterns about organ donation seemed to refl ect 
two conceptions of the body: the body as machine, where bodies were seen as 
machine like objects that did not express personal identity or self. In this way, 
donating organs does not present an internal confl ict to the person. On the other 
hand the infl uenced body, where body parts comprised the whole, which could 
be affected by transplanted organs.
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VALUATION OF PRIORITY CRITERIA FOR 2160 
THE ALLOCATION OF DECEASED DONOR KIDNEY 
TRANSPLANTS; VIEWS OF PATIENTS, PROFESSIONALS AND 
DONOR FAMILIES
R. Higgins1 , M. Clark2, A. Gumber2, A. Szczepura2, D. Leech2, D. Moro3, 
N. West1, 
1University Hospital, 2Warwick Medical School, 3Universita’ Cattolica del 
Sacro Cuore
Aims: Those designing systems for the allocation of deceased donor kidney 
transplants need to be informed by the views of professionals and patients in 
order to produce equitable allocation algorithms. We studied a large sample 
of patients and professionals, including carers and for the fi rst time donor 
families.
Methods: Extensive piloting was used to establish criteria (attributes) that 
may be valued when prioritising patients. Discrete choice experiments 
(DCE) (using questionnaires) were used to explore the different weightings 
respondents placed on these criteria. Final analysis was undertaken using 
appropriate regression techniques, and according to respondents’ ethnicity, 
gender, transplant status, quality of life, age, dependents (adults or children), 
and stated altruism.
Results: Final priority criteria included waiting time; level of HLA matching; 
differences in the patients’ number of dependents; age of recipients; and 
illnesses affecting both length of life and quality of life. Responses came 
from 908 patients; 113 healthcare workers; 41 carers and 48 donors. All the 
attributes were statistically signifi cant. Signifi cant differences in preferences 
were observed in some categories of patients. Patients of non-white ethnicity 
had less strong preference for HLA matching. There were also differences 
by transplant status, age, respondent quality of life, altruism of responders, 
and whether patients had dependent children. Respondents’ gender and 
having adult dependents did not infl uence preferences. Compared to 
patients, healthcare workers placed more value on prioritizing young 
patients and on prioritizing those with diseases having a moderate effect on 
life expectancy.
Summary: This large study indicated that respondents valued multiple 
factors affecting the allocation of deceased donor kidneys. DCE 
methodology had not previously been used in this area, but proved very 
powerful. The results are broadly supportive of the changes made in the 
UK 2006 transplant allocation policy, in which more priority was given to 
long waiters and young adults. Despite HLA matching now only producing 
a small numerical benefi t in transplant survival, it remained an attribute 
valued by all groups of patients and professionals, though was valued less 
by patients of non-white ethnicity, who may be disadvantaged by allocation 
systems using HLA matching.
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“ORGANS TO BE TAKEN WITHOUT CONSENT”- THE 2161 
INFLUENCE OF MEDIA ON DISCUSSIONS OF THE “OPT OUT” 
SCHEME
N. Stitt, A. Bakran
Royal Liverpool University Hospital
On 13th January 2008 the Prime Minister Gordon Brown released a statement 
in a newspaper article supporting the “opt-out” scheme for organ donation and 
suggesting debate on the issue. The article made headline news and, with the 
release of the Organ Donation Task Force Recommendations two days later, it 
kept Organ donation in the news for most of that week. There was considerable 
media and public response. Five newspaper broadsheets, four tabloids and the 
BBCs news website were reviewed to assess how they managed the Prime 
Minister’s statement and subsequent discussion of the “opt-out” proposal.
60% of the media group gave a positive interpretation of the Task Force 
recommendations and discussed the “opt-in/opt-out” consent issue. Only two 
newspapers gave information about how to join the Organ Donor Register or 
details of UK Transplant website. 
30% of the media group were negative on the “opt-in/opt-out” consent issue 
and gave little or no information regarding Task Force Recommendations. The 
newspapers were politically motivated in their comments. The subject of Organ 
Donation did not seem to be the focus of their discussions and organ donation 
was used as a platform with which they could vent their objections to Prime 
Minister Gordon Brown!
The remaining 10% of newspapers were neutral in their opinion; however they 
did tend to focus again on the consent issue.
The newspapers that were positive in their reporting also had the most positive 
reader comments and those negative had the most negative reader comments. 
The Daily Mail was particularly negative and its columnist wrote the most 
disturbing article and also spoke on national Radio. Her description of brain 
stem death was not only completely inaccurate but more worryingly her 
interpretation was believed by readers. Comments posted on the Mail’s forum 
included.” I think donating one’s organs is wonderful… However I’ve heard 
too many scare stories to want to be a donor now”. This comment supports 
the theory that adverse publicity can cause enormous damage to altruistic 
organ donation. Surprisingly, no comments were sought or published from the 
Transplant Community.
The saying “There is no such thing as bad publicity” is unlikely to hold true in 
the case of organ donation. The Transplant Community has to use the media to 
its advantage and gain some control over what is written although we cannot 
control the debate. The involvement of politicians in the “opt-in/opt-out” debate, 
unfortunately, may not always be helpful and, indeed, may be harmful! 
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REGULATED UNRELATED LIVING DONATION 2162 
PROGRAM AND TRANSPLANT TOURISM: WHO IS THE 
WINNER?
E. Mor, R.N.R. Michowiz, R. Rahamimov
Dept. of Transplantation, Rabin Medical Center
Objective: In 1998, with an attempt to offer an alternative to the growing 
number of patients traveling abroad a national regulated unrelated-donation 
kidney transplant program was implemented. We sought to determine whether 
that program had any effect on transplant tourism of Israelis abroad.
Material and Methods: A chart review of 216 potential living donors 
interviewed at our pre-transplant clinic between 1/00-12/07 was performed. 
The number of transplants performed yearly at our center categorized into 
living-unrelated and living-related were recorded. Patients who discontinued 
the evaluation process before the interview at the Ministry of Health (MOH) 
committee or whose donation was disapproved were categorized into those who 
remained on the waiting list, transplanted in Israel, transplanted abroad or died. 
Results: The proportion of unrelated transplants increased over time (table). 
The approval rate of donation at the committee was 55.5% (120/216); 95/120 
underwent transplantation including 2 with a second unrelated-donor. A medical 
problem prohibited donation in 16 donors, another 3 patients underwent 
deceased-donor transplantation and 6 others underwent transplantation abroad. 
Of the remaining 96 patients whose donor discontinued the process or declined 
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at the MOH committee, 23 are still waiting, 16 were transplanted in Israel, 43 
underwent transplant abroad and 13 patients died. 
Conclusions: The Israeli regulated-unrelated living donation program failed to 
reduce transplant tourism and actually provided an alternative option to living-
related donation. 
2000 2001 2002 2003 2004 2005 2006 2007
Living Related 34 38 32 35 20 19 22 30
Living Unrelated 7 6 8 7 22 20 16 22
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FACTORS WHICH IMPACT ON ORGAN DONOR 2163 
REFERRALS IN SOUTH AFRICA
E. Muller, Z. Barday, R. Cauley, F. McCurdie, D. Kahn
University of Cape Town
The signifi cant decline in the number of cadaveric organ donors in recent years 
is a universal problem and of major concern. We undertook a retrospective 
review of all organ donor referrals to the Transplant Unit at Groote Schuur 
Hospital between 1996 and 2005, in an attempt to identify potentially remedial 
causes for the decline in the number of donors.
Hospital records of all organ donors referred to our institution were retrospectively 
reviewed, and the demographics, causes of death, outcomes, reasons for refusal 
of consent, and factors which infl uenced consent rates analyzed.
There were 824 donor referrals during the 10 year study period. The number of 
referrals has declined from n = 115/year in 1996 to n = 63 in 2005. The male 
to female ratio was 3:1, and the mean age was 26.15 years. There were 321 
black patients, 318 of mixed racial origin and 154 white patients. The decline 
in referrals was apparent in all racial groups. The cause of death was related 
to trauma in 640 donors (gunshot wounds n = 151, motor vehicle accidents n 
= 280, and assault n = 143), and medical reasons in 171 donors. A total of 315 
donors (37%) were used successfully. Consent was refused in 222 donors (27%) 
and 176 were found to be unsuitable. Nineteen (2.3%) donors were found to be 
HIV positive. The consent rate was higher in white donors (66%) compared to 
black donors (33%) and those of mixed racial origin (50%). Consent rates were 
not infl uenced by age or gender. Consent rates were higher in suicide victims 
(62%) and lower in gunshot (34%) and MVA Pedestrian victims (39%).
In conclusion, the decline in the number of referrals is a concern. Furthermore 
the overall success rate of 37% is disappointing, and the lower consent rates in 
black and mixed race donors should be addressed with public awareness and 
education programmes. The HIV crisis has not affected organ donation yet.
POSTER BOARD NUMBER P4 – 214
ORGAN DONATION WITHOUT ALTRUISM? COULD 2164 
EDUCATION HELP TO SOLVE THIS DILEMMA?
F. Cantarovich
Catholic University Argentina
Organ shortage (OS) is a “modern disease”. The solution should be to use 
every acceptable deceased donor (DD). However, stagnant DD donation 
has intensifi ed living donors; and recently paid donation has been proposed. 
Rationale for payment is to rescue dialysis patients for suffering and death. 
Public surveys were discordant. We observed that from 2321 respondents 25% 
considered payment convenient and 19% ethical. These results encourage the 
evaluation for non-economic incentives. 
Non-economic approaches proposed are: 1) “ethical incentives” such as donor 
social/medical protection, 2) improving dialysis patient’s survival and transplant 
outcome, 3) access to better healthcare systems, 4) education programs.
Education may improve OS sustaining altruism, fairness, and respect for 
autonomy. It has been argue that much money has been spent in education 
without success. Why this result? 1) The message “organ donation a gift of life” 
did not impact society. By education people should acknowledged that sharing 
DD organs more than a gift is a right and a duty for everybody. 2) Media did 
not address valid notions, e.g.: the intrinsic value of the DD, the concept that 
during life we might be more organ recipients than donors, the number of 
patients dying on the waiting lists, the standpoint of monotheist religions.
A worldwide effort is being attempted to correct these issues by school’s 
education programs. All these programs targeted high schools. The studies 
arrived to similar conclusions about the positive changes observed in students 
and the need to include information about organ donation and transplantation 
in school curriculum.
Surveys performed among well educated people n: 2320 (A) and transplant 
specialists n: 139 (B) showed: 1) 66% of A and 89% of B agreed that “sharing” 
organs might be consider as a conceptual agreement between individuals and 
society. 2) 85% of A and 82% of B were in agreement with education at schools. 
A pilot assay on school education on transplantation was performed in Canada 
and Argentina. Teaching subjects were: brain death, the DD, waiting lists, 
religious opinions, etc. Between 75% and 100% of the students (10 to 19 years) 
enjoy and agreed with the presentation
As Childress said “rationalistic policies to increase the supply of a transplantable 
organ may appear to be quite defensible but then turn out to be ineffective and 
perhaps even counterproductive” 
Ethical and legal issues regarding live paid donation have been largely 
discussed, and the controversial is sluggish. Undoubtedly a factual issue is that 
DD is the source of extra renal transplants. Potential slowing down of altruistic 
DD=death of thousand of patients or to developing a savage organ market: A 
risk of opening Pandora’s Box.
Altruism is the cornerstone of organ donation; economic incentives would turn 
into organ trade, would authenticate the exploitation of poor people and will 
dissuade the real altruist.
Organ donation should be recognized trough education as a social compromise, 
between individuals and society and the logical award for this kind of 
engagements are exclusively ethical and moral.
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RELATIVES’ REFUSAL RATE FOR ORGAN DONATION 2165 
IN RELATION TO DONOR REGISTER AND DONOR AGE
H. Van Leiden, N. Jansen, A. Hoitsma, B. Haase-Kromwijk
Dutch Transplant Foundation
Purpose: In the Netherlands consent for donation is based on an opting in 
system. Before consent for donation is requested from relatives, the national 
Donor Register (DR) must be consulted in which Dutch citizens can state their 
will to donate. Since the introduction of the DR in 1998 the number of donors 
did not increase until 2007 (~200 donors/year). In order to stimulate consent 
for donation more effi ciently, the relation between the registered donor will, the 
decision to donate given by relatives and the donor age has to be clarifi ed.
Methods: We used data from a centrally registered medical record review of 
all deceased patients from intensive care units of 73 hospitals in the years 2005 
and 2006. Out of 947 recognized medical potential organ donors, the outcome 
of DR consultation and corresponding relatives’ refusal for donation were 
analyzed. DR outcome and relatives’ refusal for organ donation were studied 
for different groups of donor age.
Results: 947 recognized medical potential organ donors fi nally resulted in 312 
referrals to the Dutch Transplant Foundation for organ donation. The DR was 
consulted in 88% of all potential organ donors. If the DR was consulted, no 
registration was present in 56% and in 18% consent was found in the DR. In 
7% donors left the decision for donation in the DR to the relatives and in 18% 
a refusal was registered. The consent/refusal ratio in the DR (51% vs. 49%) 
after consulting for these donors differed from the ratio among all registered 
people in the DR nationally (65% vs. 35%, December 2006). This is because 
the age of potential donors is on average higher than the age of all registered 
people in the DR. Among all DR consults in this study the refusal rate in the 
DR increased by donor age from 15% in donors aged 18-35 years to 36% in 
donors of 66 years or older.
When consent was present in the DR, relatives still refused donation in 6%. 
When no consent/refusal was found in the DR, relatives were not requested 
for donation in 11%, but if requested, relatives refused donation in 68% of the 
cases. The refusal rate among relatives was signifi cantly higher for potential 
donors who were not registered in the DR (68%) than for potential donors who 
were registered and left the decision in the DR to relatives (42%). Relatives’ 
refusal increased from 49% in donors aged 0-17 years to 83% in donors of 66 
years or older when the DR was not decisive.
Conclusion/ discussion: The refusal rate for organ donation in the Netherlands 
is high and increases in donors of older generations, both in the DR and among 
relatives requested for donation. 
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Donation rate could increase when people are better informed about organ 
donation and about each others will to donate. This could be improved by 
continuous stimulation of public and family discussions about donation, 
especially among the elderly.
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WHAT DONOR FAMILIES CAN TEACH US ABOUT 2166 
OBTAINING CONSENT: DONOR FAMILY VIDEO INTERVIEWS
L. Dinhofer
Hood College, KoDen, LLC
Purpose: This presentation will highlight video clips and coordinating 
educational components of a video interview project investigating: the 
experience, decision-making factors, coping mechanisms and out-comes in 
electing organ and tissue donation subsequent to homicide, suicide, pediatric 
death and multiple simultaneous loss within one family; understanding the 
impact of positive and negative death notifi cations on consent; short/long-
term perceptions of brain death and decision-making; the transformative 
power of donation on traumatic/stigmatized death during and after consent; 
the psychological/spiritual perceptions of a living host for an anatomical gift; 
presumed consent vs. an opt-in election. 
Methods/Materials: Individually videotaped interviews of Caucasian and 
African American organ and tissue donor families who had experienced 
traumatic loss through a mid-west U.S. organ procurement organization. 
Participating families were voluntarily consented verbally and in writing 
regarding the purpose, scope and educational intent of the project with release 
for application in various settings. Interviews averaged 90 minutes in length 
and were edited to accompany didactic educational training curriculums for 
state conferences, Requestors, Hospital Development and Aftercare staff, 
community healthcare professionals and college students. Individual family 
anonymity was maintained until after the project was completed when a 
reception was held for a screening and group discussion.
Results: Participating families highlighted much needed information regarding 
how to work with them from the initial notifi cation of crisis, to consent through 
to bereavement, and confi rmed the option of donation as a powerful coping 
mechanism and transformative tool for dealing with traumatic and unexpected 
loss. 
Conclusion: The project has been successful in highlighting donor family needs 
and converting negative bias, misinformation and stereotyping about donation; 
caring for families experiencing traumatic loss and the impact that care has on 
the decision-making process and outcomes. Feedback from professional and 
lay viewers in various educational settings has been overwhelmingly positive 
and educational.
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INTERNATIONAL DIVERSITY AS THE KEY TO AN 2167 
EFFECTIVE TRAINING PROGRAM
T. Coco1, G. Paez2, R. Valero2, M. Manyalich2
1Queenslanders Donate – Princess Alexandra Hospital, Australia, 2 
Transplant Procurement Management, IL3– Universitat de Barcelona, Spain
Purpose: Transplant Coordinators require a multidisciplinary profi le to 
effectively manage the organ and tissue donation process. They have to 
develop solid and comprehensive skills in technical, scientifi c, psychological 
and human capabilities by integrating the theoretical and practical knowledge 
in their daily clinical practice. Furthermore, they should be able to work with 
the everyday challenges in the fi eld and consequently, integrate their skills and 
knowledge within the work environment to refl ect international best practice. 
Method: Based on the learning-through-experience model, Transplant 
Procurement Management – TPM has been developing since 1991 a training 
methodology aimed at answering the needs of health professionals involved 
in organ and tissue donation and transplantation: face-to-face courses, on-
line modules and blended-learning programs, such as the International 
Master’s Course. Special attention is given to adapt the courses to the 
specifi c needs of the different country’s issues. In order to do so, TPM 
works closely with the partner organization in order to include local experts 
in the curriculum.
Whether organizing national or international courses, TPM considers that 
the understanding of different donation and transplantation models used 
internationally is an important consideration for training. Course programs 
are designed to facilitate the exchange of experiences among participants and 
faculty members.
Results: TPM acquired an international dimension soon after its inception, 
thanks to a vast network of qualifi ed professionals throughout the world that have 
collaborated as faculty members. Each year health professionals from all over the 
world participate in the TPM training programs, as shown in the Table 1.
Up to now, 5676 participants from 90 countries have been trained by the TPM 
considering all the training modalities.
Figure 1. Number of TPM courses participants displayed by continent and year 
of attendance.
Conclusion: The learning process has reinforced the communication amongst 
professionals, enhancing international information sharing and collaboration. 
This established network has also allowed TPM to engage health professionals 
in International Projects to analyze and improve the donation and transplantation 
activity among European countries.
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NATIONAL SURVEY OF POTENTIAL ORGAN DONORS 2168 
IN SWEDEN
C. Möller, Å. Welin
Swedish National Council For Organ And Tissue Donation
Background: Sweden has about 135 organ donors a year/9,2 millions. 
Estimated numbers implicates 250-300 annual donors. This is the fi rst 
nationwide survey to establish the number of potential donors, based on all 
reported patient deaths in Swedish Intensive Care Units (ICUs).
Methods: A potential donor is defi ned as “a patient in ICU on mechanical 
ventilation with the diagnosis of brain death”. 84 units out of 84 possible 
ICUs in Sweden, were included to report patient deaths over a period of 3 
months (October-December 2007). The protocol consisted of 10 questions. The 
majority of the protocols were reported electronically by the ICU staff to the 
“Swedish Intensive Care Registry”.
Results: 841 patient deaths were reported by all 84 participating ICUs. 6,5% 
were defi ned as potential donors. 4% became actual donors while 2,5% did not 
become donors due to refusals and medical contraindications.
Conclusions: The result of the survey shows that the number may be less than 
the estimated number of potential donors. Another interesting observation is 
the group of patients on mechanical ventilation with brain injury and were 
death was diagnosed by cardiac arrest. This group will most likely end up in 
forth coming projects.
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EDUCATION ON ORGAN DONATION AND 2169 
TRANSPLANTATION IN SCHOOLS
F. Cantarovich1, M. Cantarovich2, L. Falco3, R. Revello4, C. Legendre1, A. 
Herrera-Gayol5
1Hôpital Necker, Paris, France, 2McGill Univesity Health Center, Montreal, 
Canada, 3The Study School, Montréal, Canada, 4Catholic University, Buenos 
Aires, Argentina, 5ScienceMedAdvice, Montréal, Canada.
Purpose: To assess the impact of education on organ donation and 
transplantation (Tx) in elementary and high school students. 
Methods: Lectures about organ donation and Tx were given by the same 
speaker in one school in Argentina and one in Canada. Concepts regarding 
medical, legal, historical, and religious aspects of Tx, including brain death and 
organ shortage were presented. New concepts were discussed: “During life, we 
are at higher risk of becoming organ recipients rather than organ donors”; “The 
dead body is a source of health”; “Organ donation means that we are sharing 
a chance of life for everyone”; “Organ donation and Tx might be considered 
as a right and a duty for everybody”. Thereafter, the students were invited to 
complete the following questionnaire: 1) Before this presentation did you have 
any knowledge about organ Tx?; 2) Did you enjoy the presentation?; 3) Did 
you understand all the topics?; 4) Which ones did you not?; 5) What was the 
information you found the most interesting?; 6) What are your conclusions of 
this presentation?; 7) With whom would you discuss this topic? 
Results: 316 questionnaires were analyzed, including 108 from elementary 
school and 108 from high school students from a co-ed school in Argentina; 
and 55 and 45 from elementary and high school students, respectively, from 
a girls’ school in Canada. Students were divided into pre-adolescents (<12 
yrs) and adolescents (>13 yrs). 71% of Argentinean pre-adolescents had some 
knowledge about organ Tx vs. 45% of Canadians (P=0.02). Pre-adolescents 
enjoyed the presentation (Argentina 90% vs. Canada 89%) and understood 
the topics (80% in both countries). Adolescents were more informed vs. 
pre-adolescents (Argentina 90% vs. 71% (P=0.01) and Canada 80% vs. 
45% (P=0.008)). Argentinean adolescents enjoyed less the presentation vs. 
Canadians (74% vs. 89%, P=0.007), and vs. Argentinean pre-adolescents (74% 
vs. 90%, P=0.007). Pre-adolescents and adolescents would discuss the topics 
with their parents, friends or both (in Argentina 90% and 81% and in Canada 
75% and 80%, respectively). 
Conclusion: This study suggests that students are open to learn about organ 
donation and Tx, to accept new concepts and to discuss this with their entourage. 
Education programs on organ donation and Tx should be adapted to age and 
idiosyncrasy of students of different countries, and should be incorporated to 
school curriculum.
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FOUNDATION OF LOCAL NETWORK FOR INCREASING 2170 
ORGAN DONATION IN SOUTHERN IRAN
P. Janghorban, S. Gholami, A. Bahador, H. Salahi, S. Nikeghbalian, 
S.A. Malekhosseini
Nemazee Hospital
After decades of organ transplantation, main problem is still shortage of 
donors. In many European countries, “presumed consent” rule has facilitated 
than process. In our country that informed consent should be obtained from the 
fi rst relatives of deceased donors, the problem is complicated. To overcome 
this problem, based on Shiite cleric’s Fatwa, we established a local Network 
in southern Iran. Kidney transplantation program was started in 1988 in Shiraz 
when the national organization for organ procurement has not been founded yet. 
For 3 years, kidney transplantation was performed only with living donors. In 
1992, the fi rst consent was gained form a deceased donor family. Between 1988 
and 1993, we were able to obtain only six consents. Liver transplant program 
started in 1993. To increase the donation, we began educating ICU, ER, and 
neurosurgery wards nurses, neurosurgeons, anesthesiologists, and neurologists 
of our province and 7 other neighbor provinces in southern Iran. The necessity, 
diagnosis and reporting of deceased donor were discussed. These sessions were 
repeated every 6 months or yearly. First consent from a deceased donor family 
was obtained in 1992. During 7 years (1992-8), only 21 out of 128 deceased 
cases (16.4%) were harvested. In 1998, we educated 7 transplant coordinator 
nursed and one-hundred staff nurses for 7 other provinces. Sixty neurosurgeons, 
anesthesiologists, and neurologists, working in 20 cities, had several seminars 
about transplantation and brain-death. The consents rate increased from seven 
in 1998, to 12 in 1999, and to 264 between 2000 and 2008 (each year around 
40 consents). Repeated education of ICU, neurosurgical and ER nurses, 
neurosurgeons, anesthesiologists, and neurologists is helpful in increasing the 
issued consent rates form deceased donor families and cooperation between 
the transplant wards.
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FACTORS INFLUENCING OBTAINED CONSENT RATE 2171 
FROM THE DECEASED DONOR FAMILIES: AN ONGOING 
EXPERIENCE IN SOUTHERN IRAN
S. Gholami, P. Janghorban, A. Bahador, H. Salahi, S. Nikeghbalian, S.M. 
Dehghani, S.A Malekhosseini
Nemazee Hospital
Donor shortage is still major problem of transplantation programs. Even in 
a country with a system or an organization for transplantation, the rates of 
gained consents in different areas are not the same. At our center, we obtained 
informed consent for kidney and liver transplantation programs since 1988 and 
1993, respectively. At beginning, we encountered with diffi culty of gaining 
consents from deceased donor families. We undertook this study to evaluate 
factors infl uencing consent rate from the deceased donor families between 
1988 and 2007, 1800 kidney and 430 liver transplantation were performed 
in our center. During this period, 243 consents were obtained from the 
deceased donor families. Data of age, sex, residential place, number of family 
members, marital status, education, cause of brain death, and religious beliefs 
was collected. Statistical analysis performed by student T and Chi squire 
test. Informed consent was obtained from 293 deceased donors (194males, 
99females), with a mean age of 29.8 years. 211(72%) of cases had less than 
30 years. 198(67.5%) were single. 61(20.8%) were younger than 15 years. 21 
cases (7.1%) were older than 50. cause of brain death in 249 cases (84.9%) was 
vehicle accident. Families of 16(84.2%) brain death cases of 19, issued consent 
in private hospitals. All families of donors wit suicide attempts issued consent. 
230 brain death cases were from rural of suburb areas. 65% of cases had not 
academic education. Less consent was obtained from crowded families than 
smaller ones (38% versus 62% P<0.05). issued consents from singles, young 
cases, suicidal victims, patients admitting private hospitals, those with small 
families, or live in rural areas were higher than consents obtained from donors 
of large cities, married or those admitted in charity hospitals.
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THE EFFECTIVENESS OF ROUTINE REFERRAL 2172 
SYSTEM IN JAPAN
N. Shinozaki, K. Asamizu, Y. Matsumoto
Cornea Center & Eye Bank, Tokyo Dental College Ichikawa General Hospital
Background: In Japan, there has been a constant problem in the insuffi ciency 
of donors for all organs and tissue. Contrastingly, in the US, there have been 
many donors, particularly in the corneal donation, after the eye banks installed 
the will checking system for donation in hospitals. The system is called Routine 
Referral System, RRS. Now we have installed this system in our hospital, and 
bringing results, therefore we report the effectiveness of RRS.
Methods: The medical staff in our hospital informs our eye bank, when a patient 
died. Our eye bank fs transplant coordinator checks the patient fs both medical 
and social histories to see the donor potential. Then the coordinator meets the 
family member of the deceased and asks the will of donation.
Results: There were 1,235 death cases within 3 years from October 04 to 
September 07 in our hospital. We received 991 (80.2%) calls from the medical 
staff. Our coordinator met 456 (46.0%) families after the contraindication case 
was eliminated, and asked the will. Eventually, 82 (18.0%) families expressed 
the will to do donation.
Conclusion: Over 200,000 blind patients exist in Japan, where nearly 5,000 
patients are on the waiting lists on eye banks. With the RRS, it is possible to 
reach 18.0% of donation consent from all the potential donors. There has been 
a discussion of cultural and religious issues leading the luck of donation in 
Japan. But education of medical staff, there is high potential donors among the 
general population. 
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ORGAN DONATION AS THE’GIFT OF LIFE’:WHO ARE 2173 
WE KIDDING?
M. Sque1, T. Long1, S. Payne2
1University of Southampton, 2University of Lancaster
Background: In the United Kingdom family members’ consent is usually sought 
before organ donation from their deceased relative can proceed. The ‘gift of life’ 
is recognised as a popular discourse associated with pro-donation activists, its 
use seemingly directed at heightening public awareness about the perceived 
benefi ts of organ donation. However such rhetoric remains over simplistic as 
it does not refl ect the depth and complexity of families’ decision-making about 
organ donation. Families’ wishes to protect the dead body may stimulate tension 
between the notions of ‘gift of life’, as supported by transplant policy, and the 
decision to facilitate the removal of organs from the deceased, through post 
mortem surgical intervention upon the body. It has therefore been suggested 
that the donation event is better represented as a ‘sacrifi ce’; a discourse that 
acknowledges the suffering of the bereaved family and the possible diffi culties 
encountered in their decision-making about organ donation. 
Method: The aim of this paper was to provide insights into the relevance of 
‘gift of life’ or ‘sacrifi ce’ as discourses that inform families’ decision-making 
about organ donation. Data were interrogated, from a self selected sample 
of 26 relatives of 23 organ donors who chose not to donate organs of their 
deceased relatives, for evidence of families’ literal, symbolic or metaphorical 
representations of ‘gift of life’ or ‘sacrifi ce’ in describing their experiences of 
donation. Participants were recruited via three, geographically diverse, staged 
media campaigns in large conurbations of England and Wales, and four hospital 
intensive care units. Data were collected in 2005 via single, face to face or 
telephone interviews. 
Findings: An unexpected fi nding was how many of the participants and 
their deceased relatives, in life, held pro-donation views. The decision to 
decline donation was most infl uenced by factors related to protecting the 
body of the deceased. Participants whose pro-donation views may well have 
embraced the ‘gift of life’ notion appeared to make their decision to decline 
donation in the context of deeply distressing concerns related to the cultic 
sacrifi cial element of this gift giving. A decision to facilitate the removal of 
organs from the deceased through post mortem surgical intervention upon 
the body should therefore never be underestimated. Data revealed many 
examples of descriptions by participants, which could be linked to the ‘gift 
of life’ discourse. Similarly several explicit or metaphorical examples were 
also found, which were related to cutting and mutilation, relevant to the 
cultic notion of sacrifi ce; examples which evidenced the nature of the hard-
wrought decision-making by families and the existence of their emotional 
and physical sacrifi ce. 
Conclusions: We propose that the compelling nature of sacrifi ce and the 
manner in which it appears to impinge on families’ decision-making may help 
to explain the high refusal rates in populations that appear generally aware of 
the benefi ts of organ transplantation. Understanding that ‘sacrifi ce’ may assume 
greater signifi cance for the family at the bedside faced with a donation decision 
and could become a barrier to actualising donation may be key to the support 
offered to them, potentially increasing the incidence of donation. 
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ORGAN DONATION ETHICS – EAST EUROPEAN POINT 2174 
OF VUE
S.M. Copotoiu, L. Azamfi rei, K. Branzaniuc, R. Copotoiu, C. Copotoiu
University of Medicine and Pharmacy
Organ donation is a medical action observing philosophical principles and 
practically impossible without theological agreement. The ultimate aim is 
preserving human life of an acceptable quality, satisfying the interests of the 
survivor and of his family, direct benefi ciaries of the process. 
Living in an era on blame and litigation and being able to use medical 
technology to guarantee successful donation creates the premises to suspect 
inappropriate use of organs, abuse, unfairness, preferential prioritization of 
the recipients, shortly to incriminate donor exploitation and trauma of their 
families. No matter the type of donor, living and healthy, voluntarily donating 
and with no constraint and no remuneration, in a state of brain death or non-
heart beating donor (NHBD), the donors share some problems. The living 
donors, theoretically the most altruistic category are raising suspicions of 
interest, or constraint to donation to the extent of being abused. The donors in a 
state of brain death or NHBD have the right to being respected as to their own 
scale of values expressed during their lifetime and this respect is extended to 
the moral of the society who manipulates the organs. 
The ethical principles that apply to both the donors and the recipients are: 
autonomy, nonmalefi cience, benefi cence, confi dentiality, the right to a better 
life, justice and fairness.
Autonomy implies that the adult discerning patient fully informed on the 
benefi ts and the risks of organ donation and transplantation agrees to donate 
or to receive an organ. It is a relatively new principle derived of the principle 
of the respect own to a person. This is opposed to paternalism where any 
action a living person is to accept in his/her interest is subject to approval or 
denial by a dominant member of the family, the society, the confessor or by the 
physician himself who takes action in the name of the patient regardless of his/
her opinion. 
Benefi cence is the meaning of all medical actions, the very purpose of medicine 
that is to do good to the patient. This is an undeniable principle and as long as for 
a living donor completing an act of altruism and generosity leads to satisfaction, 
the very act of donation can be therefore benefi cial even for the donor. 
The right to a better life is a consequence of the progress medicine has 
achieved and of the societal rights modern living observes. Societies not being 
equal in terms of assistance and quality of life granted to the members, cannot 
therefore be comparable as to the level of organ transplantation, but should 
thrive to do so 
The countries of East European regions involved with organ donation are acting 
according to these medical and societal principles, but this does not necessarily 
mean that justice is being done. 
Another aspect of justice is the rightness of resource distribution, and this is 
beyond the medical reach, rarely a problem of medical management. Fairness is 
rather the term for justice applied to individuals while equity would better refl ect 
a right distribution of medical benefi ts to individuals in similar condition.
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IMPLEMENTATION OF TRANSPLANT COORDINATOR 2175 
(TC) EDUCATIONAL INITIATIVES FOCUSED ON THE 
BENEFITS OF RESEARCH DRAMATICALLY INCREASES 
RESEARCH CONSENT RATES AND THE NUMBER OF 
ORGANS PLACED FOR RESEARCH
R.D. Hasz, H.M. Nathan, S.M. West
Gift of Life Donor Program
Purpose: To demonstrate how one organ procurement organization’s (OPO’s) 
implementation of routine educational initiatives regarding utilization of organs 
for research combined with offering the opportunity for research to all donor 
families could increase the number of organs successfully placed for research. 
Methods: To enable TCs to be effective in explaining the need and benefi ts 
of research the following key educational initiatives were implemented: 
1) Information on research was incorporated into TC orientation didactics, 
immediately establishing the organization’s commitment to research 
science; 2) Local researchers and national research organizations were 
invited to be part of the continuing education curriculum. Each researcher 
was asked to discuss the goals and impact of their research, and to provide 
TCs with information that could be utilized to help families understand 
the benefi ts of research; 3) TCs practiced integrating research request into 
the donation conversation during scenario-based role-plays, conducted in 
mandatory tri-annual consent workshops; 4) TCs were provided with a 
pocket card, clipped to each consent form, describing the research projects 
that the OPO was supporting including specifi cs on how the gift could be 
used. Additionally request for research was embedded into all donation 
conversations, as a standard component of the informed consent process. 
The OPO’s consent form contained language that specifi cally requested 
research consent.
Results: Sustained increases in consent rates for research resulted in the 
placement of 1,816 organs for research in a six-year period. Comparing 2002 
to 2007, consent rates for research increased by 23% (60% vs. 83%), and the 
total number of organs placed for research increased by 55% (210 vs. 325). 
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Placed Year # Organ Donors Research Consent Rate
from Organ Donors 
# Organs for Research
 
2002 354 60% 210
2003 344 76% 236
2004 387 81% 317
2005 382 85% 367
2006 401 84% 361
2007 389 83% 325
% Change from
2002 vs. 2007 
10% 23% 55%
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EVALUATING THE IMPACT OF PRINT MEDIA 2176 
PUBLICITY ON ORGAN DONATION
K. McKay1, S. Bhonagiri, P. Wills
1LifeGift Australian Redcross and Bloodbank Service, 2LifeGift Australian 
Redcross And Bloodbank Service, 3LifeGift Australian Redcross and 
Bloodbank Service
Introduction: Organ donation has a high profi le in all forms of media- print, 
radio and television in most countries. Most media reports in Australia on 
organ donation are positive. LifeGift nsw & act monitors media related to 
organ donation in Australia. 
In probono ads negotiated with Fairfax Media, four eal life experiences of 
one organ donor family and three organ transplant recipients were reported 
in advertisements in the Sydney Morning Herald (smh) on behalf on LifeGift. 
These were published in the lead up to and during Organ Donor Awareness 
Week 2008 on Wednesday Friday and Saturday for a four week rotation which 
is still continuing. In the days following this publication a spike in internet 
activity via the LifeGift website to the Medicare Australia Australian Organ 
Donor Registry and an increase in the number of telephone call to the AODR 
were reported. 
Methods: before and after report on internet and telephone activity to assess 
effi cacy of media publicity related to organ donation. The number of internet 
hits to the AODR were recorded at the AODR from the LifeGift website and 
supplied by Medicare Australia. In addition calls to the 1800 number were 
recorded but do not differentiate the source of enquiry..
Results: The articles appeared in the smh on 1st, 2nd, 6th, 9th, 11th, 13th, 15th, 
16th, 20th, 22nd, 23/24th, 27, 29th and 1st March to date,
The no of hits and traffi c prior to the dates was less than 30 hits per week
The hits and traffi c following was 57 in the fi rst week and 43 in the second 
week
This activity continues to be greater than the 30 hits in the second week of 
March.
Discussion: Media related to organ donation is generally positive and has a 
high impact. Measuring the impact of media on the number of donors in a 
low donation environment as seen currently in Australia is diffi cult. Organ 
donation occurs in the setting of immense grief to the donor family and surveys 
of donor families to assess the impact of media on their decision to donate 
or not donate are ethically challenging. The advertisements in the smh were 
associated temporally with an increase in internet traffi c and telephone calls to 
the AODR. Organ Donation intent registration were increased too. However 
this increased activity may be due to other factors such as the Australian Organ 
Donor Awareness Week.
INFECTIOUS DISEASE – CONCURRENT ORAL SESSION 147: 
CMV AND OTHER VIRAL INFECTION
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CYTOMEGALOVIRUS PNEUMONIA AFTER SIROLIMUS 2177 
BASED KIDNEY TRANSPLANTATION: HIGH RESOLUTION 
CT FINDINGS
A. Soliman, A. Lotfy, S. Zamil, E. Ismail
Cairo University
Cytomegalovirus (CMV) pneumonia is one of the most common pulmonary 
complications after sirolimus based kidney transplantation (SBRT). We 
describe the high resolution CT (HRCT) fi ndings of 13 patients with CMV 
pneumonia diagnosed after SBRT. The study included 13 patients who 
developed CMV pneumonia after SBRT and who had HRCT of the chest 
performed within 24 h of the onset of symptoms. HRCT scans were reviewed 
by two radiologists who assessed pattern and distribution of fi ndings. There 
were eight male and fi ve female patients, ranging from 19 years to 56 years 
of age. The time elapsed until diagnosis ranged from +98 days to +425 days. 
The predominant patterns of abnormality on HRCT scans were ground-glass 
opacities (79%), small centrilobular nodules (79%) and air-space opacities 
(64%). The abnormalities were distributed in the central and peripheral 
zones of the lungs in seven cases, only in the periphery in three cases, and 
only in the central zone in three cases. In all cases the lung lesions were 
bilateral, and asymmetry was observed in six cases. We can conclude that the 
most common HRCT fi ndings in patients with CMV pneumonia after SBRT 
consist of bilateral asymmetric ground-glass, air-space opacities and small 
centrilobular nodules. 
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CAMPATH 1-H INDUCTION AND STEROID-FREE 2178 
MAINTENANCE IMMUNOSUPPRESSION IN HEPATITIS C 
POSITIVE KIDNEY RECIPIENTS
J. Ortiz1, J. Horton2, A. Bingaman1, J. Palma1, P. Foster1, F. Wright1, F. 
Membreno1
1Texas Transplant Institute, 2Beaumont Medical Center
Introduction: Safety and effi cacy of immunosuppression in hepatitis C positive 
(HCV+) kidney transplant recipients is of concern due to possible acceleration 
of disease or allograft loss. Campath 1-H has been used effectively for induction 
therapy in kidney recipients without liver disease. This paper reports results of 
Campath induction in HCV+ patients receiving tacrolimus and mycophenolate 
maintenance immunosuppression without steroids.
Methods and Materials: An IRB approved retrospective review of HCV+ 
recipients was done. Hepatitis C positivity was determined by antibody 
and PCR testing. From 2002 to 2007, 24 recipients were identifi ed with the 
following characteristics: 21 males (87%), age range 40 – 71 years (mean 59 
years), 18 fi rst transplants (75%), 4 second and 2 third transplants, 19 deceased 
donors (79%) with 14 HCV+ donors, and 5 living donors (21%) all HCV 
negative. Five patients (21%) had PRA > 30% and the mean HLA mismatch 
was 3.9 for all patients. Liver biopsies were done in 23 patients with 2 patients 
showing cirrhosis and 3 showing bridging fi brosis.
Results: Follow-up ranges from 3 to 45 months (mean 15 months). Patient 
survival is 83% with 3 deaths, 2 with allograft function: one due to accidental 
head trauma, one due to tuberculosis after a third transplant and one due to 
myocardial infarct 6 months after allograft loss due to chronic nephropathy. 
Two other graft losses occurred, both in sensitized patients, one due to acute 
rejection and one due to chronic allograft nephropathy for an overall allograft 
survival of 79%. Mean creatinine is 1.5 mg/dl (range 0.9 – 3.0 mg/dl) with a 
creatinine >2 mg/dl in 3 patients. Increased liver function tests were noted in 3 
patients (12.5%); one had fatty liver, one was treated with steroids for rejection 
and one had BK virus treated with lelunamide. No exacerbation of hepatitis C 
has been noted to date.
Conclusions: Campath 1-H induction and steroid free maintenance with 
tacrolimus and mycophenolate appears to be safe and effective in HCV+ 
kidney recipients. Wait time was signifi cantly shorter for HCV+ deceased 
donor organs. Risk factors for graft failure include previous transplant and 
sensitization. Progression of hepatitis C has not occurred in short-term follow-
up. Longer follow-up data needs to be obtained.
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SURVEY THE SEROPREVALENCE OF CMV AMONG 2179 
HEMODIALYSIS PATIENTS IN URMIA, IRAN
Z.R.Z. Khameneh1, N. Sepehrvand, F. Eslamlu, S. Masoodi, R.Y. Gharebagh
1Urmia University of Medical Sciences, 2Student Research Committee
Cytomegalovirus (CMV) causes infection in immunocompromised, transplant 
recipients and those who receive blood transfusion frequently. Risk factors for 
primary CMV infection are blood transfusion (Including clotting factors, etc), 
recipients of infected transplants, hemodialysis and the frequency of dialysis 
in a week. This study aimed to determine the prevalence of cytomegalovirus 
(CMV) antibodies in end-stage renal disease (ESRD) patients which undergo 
hemodialysis.
Material & Methods: This study has a cross-sectional design, which 
is executed in 2007 among hemodialysis patients in Urmia, Iran. Sera 
of 84 Hemodialysis patients have been investigated by CMV-specifi c 
immunoglobulin G (IgG) using a CMV IgG enzyme-labeled antigen test. 
Collected data were analyzed by descriptive statistics and chi-square test via 
SPSS software ver11.5.
Results: In our study, 84 patients who regularly underwent hemodialysis 
were studied. Forty-four patients were male and 40 female with the range 
23-82 years age. In the time of evaluation, 65 patients (77.4%) were anti-
CMV IgG positive and 6 (7.1%) were anti-CMV IgM positive. There was no 
relationship between the antibody titer and dialysis duration, or frequency of 
HD in a week. 
Conclusion: We recommend that every patient who has undergone 
hemodialysis received blood products free of CMV. Development of a vaccine 
against cytomegalovirus is essential and could be very life & cost-saving.
POSTER BOARD NUMBER P4 – 230
POPULATION PHARMACOKINETICS OF 2180 
VALGANCICLOVIR IN SOLID ORGAN TRANSPLANT 
RECIPIENTS INFECTED BY CYTOMEGALOVIRUS
A. Caldés2, H. Colom1, S. Gil-Vernet2, L. Lladó3, N. Manito4, Y. Armendariz2, 
N. Lloberas2, L. Pou5, M.J. Garrido6, J.M. Grinyó2
1Pharmacokinetics and Biopharmacy Dept. Pharmacy Faculty. Universidad 
De Barcelona, 2Nephrology Dept. Hospital of Bellvitge, 3Hepatology Dept. 
Hospital of Bellvitge, 4Cardiology Dept. Hospital of Bellvitge, 5Biochemestry 
Dept. Hospital Vall D’hebron, 6Pharmacy And Pharmaceutical Technology 
Dept. School of Pharmacy, University of Navarra
Background: Cytomegalovirus (CMV) is a leading cause of disease in 
immunocompromised subjects, such as solid organ transplant recipients. 
Valganciclovir (VGC), a L-valyl ester prodrug of ganciclovir, was developed to 
offer an alternative to long-term IV and low oral bioavailability of ganciclovir 
(GCV).
Objective: The aim of this study was to establish the population pharmacokinetics 
of GCV after iv GCV/oral VGC as treatment of CMV infection in heart, liver 
and kidney transplant recipients, and explore the infl uence of patient covariates 
on drug disposition
Patients and Methods: An open-label clinical trial was performed in twenty 
patients with solid organ transplantation (SOT) and CMV infection (11 renal, 
5 heart and 4 liver) at the Hospital Universitari de Bellvitge. The following 
demographic and clinical covariates were recorded: body weight, gender, age, 
serum creatinine, creatinine clearance, transplant type, CMV serostatus and 
concomitant immuosuppresive medication. Patients received 5 mg/kg/12 h of 
GCV for fi ve days as an 1-hour intravenous infusion, followed by oral VGC 
doses (900 mg/12 h), given for 15 days. In both cases doses were adjusted 
by creatinine clearance (CRCL). At the end of each treatment, blood samples 
were collected at 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 h post-dose. A population 
pharmacokinetic (PK) analysis was performed using NONMEM VI. 
Results: As previously reported (1), the PK of GCV was best described by a 
two compartment open model with elimination from the central compartment. 
Interindividual variability (IIV), was included in total plasma clearance 
(41.0%), central distribution volume (46.8%), absorption rate (47.2%) 
and bioavailability (24.9%). Total plasma clearance was linearly related 
to creatinine clearance (CLCR) and body weight (WGT) according to the 
following relationship: CL=7.58x(CLCR/56.3)x(WGT/66.8) (56.3 mL/min 
and 66.8 kg: mean values of CLCR and WGT, respectively, in the studied 
population). Creatinine clearance and body weight explained part of the 
interindividual variability in CL and it decreased in a 27.3% (from 68.3% 
to 41.0%). According to this relationship, total plasma clearance would 
increase with increasing body weight and renal function. The fi nal population 
estimates of the rest of the PK parameters were: VC, volume of distribution 
of the central compartment =31.8 L;VP, volume of distribution of peripheral 
compartment =32.7 L; CLD, intercompartmental clearance =10.3 L/h; KA, 
1st order rate constant of absorption=0.895 h-1; F1, bioavailability =82.6% 
and Lag time=0.38 h. 
Conclusions: A population PK model for GCV, after GCV iv and/or VGC 
po, has been developed. The effects of body weight and renal function are 
substantial and clinically relevant, making dose adjustment by both covariates 
important to achieve the required GCV exposure to assure effi cacy and avoid 
adverse events. 
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PRIMARY CMV INFECTIONS AFTER 6 MONTHS 2181 
VALGANCYCLOVIR PROPHYLAXIS IN RENAL TRANSPLANT 
RECIPIENTS
I. Helanterä1, I. Lautenschlager2, P. Koskinen1
1Helsinki University Hospital, Dept of Medicine, Division of Nephrology, 
2Helsinki University Hospital, Department of Virology
Background: Cytomegalovirus (CMV) seronegative kidney transplant 
recipients receiving an organ from seropositive donors (D+/R-) 
nowadays in most centres receive prophylaxis with valgancyclovir after 
transplantation. However, many patients develop primary CMV infection 
after the cessation of prophylaxis. The occurrence and clinical course 
of these late primary CMV infections developing after valgancyclovir 
prophylaxis are poorly described.
Material and Methods: All our university hospital district adult patients, who 
received a kidney allograft between 2004-2007 (N=175) were investigated. 
Baseline immunosuppression was usually a triple-drug regimen with 
Cyclosporine A, mycophenolate mofetil and steroids. In immunologically 
high-risk patients cyclosporine was replaced by tacrolimus. Patients with 
D+/R- CMV serostatus and at least one year follow-up were included (N=24). 
These patients received oral valgancyclovir prophylaxis for 6 months after 
transplantation (900mg once daily if normal renal function). After the cessation 
of prophylaxis, patients were monitored for CMV-DNAemia with real-time 
quantitative plasma PCR with 2-6 weeks interval, and also if CMV infection 
was suspected. Infections were treated with i.v. gancyclovir or high-dose 
valgancyclovir (900mg twice daily if normal renal function), followed by 1-3 
months secondary oral valgancyclovir prophylaxis. 
Results: CMV infection developed in 12/24 patients mean 107 days (range 
30-330) after the cessation of prophylaxis. Two were asymptomatic, and in ten 
patients symptoms included: fever (N=7), gastrointestinal (nausea, vomiting, 
diarrhea, abdominal pain) (N=4), upper respiratory tract (N=3), and elevated 
liver enzymes (N=2). One patient with infection had prophylaxis terminated 
after 5 months due to leukopenia. One patient with a non-functioning graft 
(delayed graft function) developed CMV infection 24 days after transplantation, 
before prophylaxis was started. Mean viral load at diagnosis was 49517 (range 
490-325300) copies/ml, and peak viral load 84654 (range1250-527400) 
copies/ml. Five infections were treated with oral valgancyclovir and 6 with i.v. 
gancyclovir, all resulting with negative PCR results. One mild infection with low 
viral load was treated successfully with minimization of immunosuppression. 
Infection relapse developed in 4 patients mean 31 (range 15-61) days after the 
end of the therapy. Relapses were treated with oral valgancyclovir in 3, and 
with i.v. gancyclovir in one patient.
Conclusions: CMV primary infections were common after 6 months 
valgancyclovir prophylaxis, and mostly symptomatic. Relapses commonly 
occurred. Primary infections seem to be delayed, but not effi ciently prevented 
by 6 months prophylaxis.
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LATE CYTOMEGALOVIRUS INFECTION WITH 2182 
MULTIPLE COLONIC PERFORATIONS IN RENAL 
TRANSPLANT RECIPIENT – CASE REPORT.
A. Olejnik, L. Koziol, I. Idasiak-Piechocka, A. Oko, S. Czekalski
Department of Nephrology, Transplantology and Internal Diseases, Poznan 
University of Medical Sciences, Poland
Cytomegalovirus (CMV) infection after renal transplantation is major cause 
of morbidity and mortality. Cytomegalovirus disease typically occurs in fi rst 6 
months after transplantation and causes fever, leukopenia, thrombocytopenia 
and slightly elevated transaminases. More invasive forms of CMV infections 
are rare because of prophylactic regimen in high-risk patients and early 
treatment with gancyclovir.
We report the case of 36-year-old patient who developed CMV related colonic 
multiple perforations 3 years after renal transplantation.
Initially after transplantation the immunosupressive regimen consisted 
of steroids(Metypred),calcineurin inhibitor(Prograf)and mycophenolate 
mofetil(CellCept).
CMV infection was not present.
Three weeks and 3 months after transplantation the patient presented two 
incidents of acute rejection treated successfully with antithymotic globulin(fi rst 
episode) and steroids(second episode).
Furthermore in the fi rst year after transplantation patient demonstrated recurrent 
urinal tract infections and severe Pneumocystis carinii infection treated with 
Pentamidine. 
At the same time Prograf was withdrawal.
Three years after transplantation patient presented symptoms of 
enterocolitis(abdomen pain, diarrhea, nausea, weight loss) with biochemical 
disorders hypoproteinemia, hypoalbuminemia and temporary graft 
dysfunction.
At the beginning of enterocolitis manifestation, investigation of CMV pp65 
antigenemia test and CMV-DNA polymerase chain reaction (CMV-DNA PCR)
were negative.
However CMV IgG antibodies were positive.
At that time conversion from CellCept to Myfortic was performed with 
temporary improvement of symptoms.
Six months after fi rst symptoms, colonic biopsy was performed – the histological 
investigation gave evidence of typical CMV infection. CMV infection was also 
confi rmed by positive CMV pp65 antigenemia test and CMV-DNA PCR.
Ganciclovir therapy was initiated immediately and resulted in improvement of 
symtoms. However periodically abdomen pain and diarrhea was observed.
Control examination of CMV pp65 antigenemia test and CMV-DNA PCR were 
negative.
Three months after ganciclovir therapy symptoms of colonic perforation 
occured and total colectomy was necessary. 
The relationship between CMV infection and colonic perforation has been 
confi rmed by histological examination of the resected colon.
Colonic perforationas are often fatal and life-threatening complications in 
transplant recipients with CMV infection. In such cases only rapid diagnosis 
and agressive surgical treatment can save the patient from death.
The history of our patient illustrated the need to consider CMV infection in 
patients with enterocolitis symptoms even more than 3 years after solid organ 
transplantation.
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SEVERE APLASTIC ANEMIA IN RENAL TRANSPLANT 2183 
RECIPIENTS CAUSED BY CHRONIC PARVOVIRUS B 19 
INFECTION
C.A. Bucsa1, B.D. Tacu1, C. Dobrea2, E. Kerezsy1, C. Tacu1, I. Ursuleac3, 
I. Alexiu4, V. Uscatescu3, I. Sinescu1
1Department of Renal Transplantation, Fundeni Clinical Institute, 
2Department of Hematopathology, Fundeni Clinical Institute, 3Department of 
Hematology Fundeni Clinical Institute, 4Institute of Virology Stefan Nicolau 
Bucharest
Background: Parvovirus B19 is a single – stranded DNA erythroid virus. It is a 
highly contagious community – acquired infection in children, 30-60% of people 
being sero-positive by adulthood. Most infections are asymptomatic or presenting 
as an erythema infectiosum- a mild illness also known as “fi fth disease”. In 
immunocompromised patients like renal transplant recipients, the infection may 
be prolonged and can lead to recurrent and severe aplastic anemia.
Purpose: To identify the risk factors for persistent infection, the most effi cient 
treatment and to develop a preventive strategy.
Material: 6 recipients with new onset, severe, relapsing anemia after renal 
transplantation in our center between December 2006- Oct 2007. The mean 
follow-up period was three months. Serologic status for Parvovirus before 
transplantation was not available.
Results: The diagnostic, suggested by clinical characteristics (severe and 
areticulocytotic anemia, resistant to therapy) was made by giant pronormoblasts 
in the bone marrow biopsy and the detection of viral DNA using a qualitative 
polymerase chain reaction assay. 
4/6 patients have received cadaveric renal grafts, 2 have received living related 
grafts. The medium HLA mismatches was 50%. All recipients had induction 
therapy with IL 2 receptors blockers and the maintenance immunosuppressive 
regimen included tacrolimus (through levels 8-15 ng/ml), mycophenolate 
mofetil (2 g/day) and corticosteroids for 5 patients and cyclosporine (C 2 level 
1500 ng/ml) for the last one. None of them had delayed graft function. 5/6 
experienced at least one early acute rejection episode effi ciently treated with 
metil prednisolon. The medium hemoglobin level was 7.1 g/dl. The mean 
serum clearance creatinine 57 ml/min. The evolution was complicated by CMV 
infection (pp 65 antigenemia positive) in 5/6 patients even with prophylaxis 
therapy with valganciclovir 3 months post transplant for all patients. Another 
signifi cant complication was acute venous thrombosis in 4/6, two of them being 
lupus anticoagulant positive on pro-coagulants factors screening.
Evolution: 3/6 patients experienced clinical persistent remission with presence 
of Ig G antibodies but with persistent viraemia on qualitative DNA- PCR 
at 3 months. The clinical remission was associated with decreasing the 
immunosuppression: switching the tacrolimus to sirolimus for CAN in 2 two 
cases, and the third remission has occurred to the patient on cyclosporine. 
Conclusions: Reducing the immunosupression could be the optimal treatment 
for persistent viral infection – in our experience, the switching or avoidance of 
tacrolimus was effective. 
It is necessary in our center a routine screening serology for Parvovirus B19 in 
order to identify the subjects in high risk for infection. The vaccination may be 
indicated in selected patients pre-transplantation. 
Persistent infection with CMV could have an immunomodulatory role – 
predisposition to other persistent viral infection.
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QUANTITATIVE HHV-6B ANTIGENEMIA TEST FOR THE 2184 
MONITORING OF TRANSPLANT PATIENTS
K. Höckerstedt1, I. Lautenschlager1, R. Loginov1, D. Ablashi2
1Helsinki University Hospital, 2HHV-6Foundation
Background: Human herpesvirus-6 (HHV-6) activation, mostly of the variant 
B, is common after organ transplantation. The viral activation can be detected 
from peripheral blood by PCR or by the HHV-6 antigenemia test. Here we 
report a new modifi cation of the HHV-6 antigenemia test using a HHV-6B 
glycoprotein IgG-antibody, OHV-3, and attempt to quantify the HHV-6 
antigenemia and the viral load after liver transplantation.
Patients and methods: Twenty-four adult liver transplant recipients were 
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frequently monitored by the qualitative HHV-6 antigenemia test, which 
detects the HHV-6B virion protein in peripheral blood mononuclear cells 
(PBMC). For the HHV-6 antigenemia test, PBMC were isolated by density 
gradient centrifugation and cytocentrifuged onto microscope slides. HHV-
6B antigens were now demonstrated using a glycoprotein OHV-3 IgG-
antibody in the immunoperoxidase staining from the same specimens and 
quantifi ed as positive cells/10,000 PBMC. Altogether 206 blood specimens 
were analyzed.
Results: During the fi rst six months, HHV-6 antigenemia was detected in 
17/24 (71%) recipients by using HHV-6B virion antibody. Altogether, 37% 
(77/206) of specimens were positive with the virion antibody and 39% 
(78/201) by the OHV-3 antibody. The peak number of OHV-3 positive cells 
in the PBMC`s varied from 5 to 750/10,000 (mean 140/ 10,000). 
Conclusions: The glycoprotein antibody OHV-3 was useful to quantify the 
HHV-6B antigenemia. The fi ndings of the HHV-6B quantitative antigenemia 
correlated well with the previous qualitative HHV-6 antigenemia assay, and 
can be used as a quantitative method in the monitoring of HHV-6 in transplant 
patients.
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REDUCED RESPIRATORY SYNCYTIAL VIRUS 2185 
LOWER RESPIRATORY TRACT INFECTIONS AND 
HOSPITALIZATIONS IN PEDIATRIC LIVER TRANSPLANT 
RECIPIENTS WITH PALIVIZUMAB
A. Campbell1,2, N. Kerkar1
1Mount Sinai School of Medicine, 2Abbott
Background: Respiratory syncytial virus (RSV) lower respiratory tract 
infection (LRTI) in the post-transplant period is associated with signifi cant 
morbidity and mortality. Palivizumab, a RSV-specifi c monoclonal antibody, 
has been shown to reduce the incidence of RSV hospitalization and the severity 
of breakthrough disease in preterm infants with and without chronic lung 
disease and infants with hemodynamically signifi cant congenital heart disease. 
As part of a comprehensive immunization program in pediatric liver transplant 
(PLT) candidates and recipients at Mount Sinai, palivizumab (15 mg/kg IM 
monthly during RSV season) was recommended for PLT recipients <4 years 
of age beginning 2003. 
Objective: To describe the impact of palivizumab prophylaxis on RSV 
infections in PLT recipients at Mount Sinai School of Medicine. 
Methods: Retrospective chart review of PLT recipients <4 years of age 
transplanted between 01/01/2000 and 12/31/2005 was performed. 
Results: 76 PLT recipients were identified; 36 received palivizumab 
prophylaxis and 40 did not. Demographics did not differ between PLT 
recipients who received palivizumab and those that did not with respect to 
gender (55.6% and 60.0% female, p=0.814), race (63.9% and 57.5% non-
white, p=0.150) mean age at transplant (0.94 years and 1.2 years, p=0.600) 
and indication for transplantation (61.1% and 60.0% extrahepatic biliary 
atresia, p=0.641). The rate of RSV infections did not differ between the 
PLT recipients who received palivizumab and those who did not (8.3% 
and 10%, p=0.802); however, the rate of RSV hospitalization did differ 
(0% palivizumab and 10% no palivizumab, p=0.05). RSV infections 
manifested more frequently as a LRTI in children who did not receive 
palivizumab prophylaxis compared to those who did (75% and 0%, 
p=0.047). The mean hospital length of stay was 7.5 days (range, 3-13 
days). Two children required admission to the intensive care unit and 
mechanical ventilation; all required supplemental oxygen. There were no 
deaths attributed to RSV. 
Conclusion: This retrospective review suggests that palivizumab may prevent 
progression of a RSV URTI to a LRTI and prevent hospitalization when 
administered prophylactically in PLT recipients. To understand the full extent 
of the benefi t of palivizumab prophylaxis in this population prospective studies 
are necessary.
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TRANSFER OF ADOPTIVE IMMUNITY TO HEPATITIS B 2186 
VIRUS BY LIVING LIVER TRANSPLANTATION*
M. Lindemann1, A. Schumann1,2, M. Fiedler2, C. Valentin-Gamazo3, 
D. Knop4, C.E. Broelsch3, H. Grosse-Wilde1, M. Roggendorf2
1Institut für Immunologie, 2Institut für Virologie, 3Klinik für Allgemein-, 
Viszeral- und Transplantationschirurgie, 4Institut für Transfusionsmedizin, 
Universitätsklinikum
Background: In chronically hepatitis B virus (HBV) infected patients liver 
transplantation is often the ultimate option of therapy. Despite antiviral therapy 
reinfection is still a problem. Adoptive transfer of HBV immunity with the liver 
after vaccination of living liver donors could be a new approach to prevent 
reinfection in the recipients. However, the period in which to achieve HBV 
immunity in donors is usually short (1-2 months). 
Aim: To investigate if HBV immunity from an immunized living liver donor 
can be transferred to the recipient.
Methods: In this study we vaccinated living liver donors in a short time 
immunization protocol (4 injections in two weeks intervals) using Sci-B-Vac, 
a recombinant vaccine that contains the PreS1, PreS2, and S proteins of HBV 
(SciGen Ltd., Singapore, n=39), or boosted donors with prior HBV vaccination 
using a standard vaccine (HBVAXPRO, Sanofi  Pasteur MSD, Frankfurt, 
Germany, n=7). Humoral (anti-HBs titer) and cellular (proliferation assay 
and interferon-gamma ELISpot) immune responses were examined prior to 
each immunization, pre and post transplantation. Out of 46 potential donors 
receiving HBV immunizations 14 were selected for liver donation. 
Results: In 3 out of 14 recipients adoptive immune transfer was clearly 
detectable. One HBV naive recipient developed humoral and cellular immune 
responses post transplantation (anti-HBs of 1800 IU/l and stimulation index of 
4.9), another naive recipient showed cellular immune responses (stimulation 
indices of up to 40, 22 spots increment). Furthermore, in one chronically HBV 
infected recipient specifi c immune responses were measurable at day 5 (anti-
HBs of 120 IU/l) and vigorously increased thereafter (anti-HBs of 58000 IU/l 
and stimulation index of 3.1). This fi nding most likely refl ects the boosting of 
HBV specifi c immunity by HBs antigen persisting in the host. Taken together, 
we were able to show that in principle HBV specifi c humoral and cellular 
immunity can be transferred to recipients with the liver graft. 
Conclusion: By immunization of living liver donors, the reinfection in 
chronically HBV infected recipients could be prevented.
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ACUTE NECROTIC PANCREATITIS AFTER LIVER 2187 
TRANSPLANTATION DUE TO HUMAN HERPESVIRUS 2
I. Gonzalez-Pinto, M. Rodriguez, A. Miyar, L. Gonzalez-Dieguez, 
C. García-Bernardo, V. Cadahia, L. Vazquez, P. Diaz, L. Barneo
Hospital Universitario Central de Asturias
Aim: to report a case that reminds us of the risk of severe pancreatitis in the 
course of a viral infection.
Case presentation: A 67-year-old woman affected of advanced primary biliary 
cirrhosis, with frequent decompensations, underwent liver transplantation. 
The donor was young, and the surgical procedure uneventful. However, 
postreperfussion biopsy showed a 40% alcoholic steatohepatitis, which led to 
severe graft dysfunction with non-oliguric renal insuffi ciency, but with good 
progressive recovery. Immunosuppression consisted of basiliximab and low 
level tacrolimus, with delayed introduction of mophetil mycophenolate. Since 
post-op day 3 she presented blisters in right arm which extended progressively. 
After misdiagnosis and treatment with topical steroids, culture on day 19 
revealed human herpesvirus 2. On day 33 she developed septic shock with 
renal failure due to acute necrotic pancreatitis, which required 2 reoperations 
for drainage and debridement, and 1 TC-guided percutaneous drainage. She 
was treated with acyclovir in addition to antibiotics and ICU management, 
and immunosuppression was temporarily withdrawn. Liver biopsy culture also 
showed human herpesvirus 2.
After several additional complications, the patient recovered completely, was 
discharged, and maintains a normal life.
Conclusions: – Viral cutaneous infection can produce visceral involvement in 
immunosuppressed patients. – Viral necrotic pancreatitis with renal failure in 
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transplanted patient carries a high mortality. – Viral infection as a cause of 
pancreatitis is probably underestimated. – Withdrawal of immunosupression 
should be readily considered.
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ROLE OF REGULATORY T CELLS IN ADOPTIVE 2188 
CMV-SPECIFIC T-CELL THERAPY
A. Fischer1, S. Zwinger1, G. Brestrich2, A. Roemhild2, J.P. Maciejewski3, 
M. Wlodarski1, M. Hammer2, A. Kurtz2, P. Reinke2, H-D. Volk1
1Institute of Medical Immunology, Charite-University Medicine, Berlin, 
2Department of Nephrology and Intensive Care Medicine, Charite-Unviersity 
Medicine, Berlin, 3Experimental Hematology and Hematopoiesis Section, 
Cleveland Clinic, Cleveland
Cytomegalovirus (CMV) is a major cause of morbidity and mortality after 
transplantation. In haematopoietic stem cell transplantation (HSCT) adoptive 
immunotherapy with healthy donor-derived T cells directed against CMV has 
been proven to prevent clinical manifestation of the virus. 
The aim of our study is to introduce this promising treatment option also in the 
setting of solid organ transplantation (SOT) by generating autologous T-cell 
lines from peripheral blood of the immunosuppresed organ recipients suffering 
from CMV disease. 
For this approach we established an HLA-type independent generation 
protocol to isolate and expand T cells specifi c for the immunodominant 
CMV proteins pp65 and IE-1. Analysis on surface-expression, antigen-
specifi c cytokine release and cytotoxic-activity revealed that these CMV-
specifi c T cells do not only contain Th-1 and cytotoxic T cells, but also 
cells possessing the phenotype of regulatory T cells (Treg). Regarding the 
well described involvement of Tregs in modulation of immune response to 
pathogens we studied the functional role of these CMV-specifi c Tregs on 
the control of effector T-cell response. Our data showed that after specifi c 
triggering CD4+ Tregs inhibit CMV-peptide specifi c IL-2 secretion of 
Teff cells. Detailed analysis of classical Treg-markers, cytokines, Foxp3 
expression and epigenetic signature suggest the presence of an induced 
Tr1 (T-regulatory type-1) phenotype. Our data on the clonotypic repertoire 
revealed that CMV-epitope specifi c T effector and Treg are clonally identical 
T cells. Using a TCR Vb-specifi c cell sorting we are now able to directly 
compare pure effector and reglulatory T cell clones. Furthermore, our results 
facilitated us to design a TCR Vb-CDR3 sequence-specifi c PCR to monitor 
fate and clonal distribution of ex-vivo isolated and in vitro expanded CMV-
specifi c CD4+ Tregs. 
In summary, CMV can induce both Teff and Tr1 that can be expanded in 
parallel. Using adoptive T-cell therapy we presume targeting regulatory T cells 
to improve the in vitro and in vivo effi cacy of CMV-specifi c T-cell lines.
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WHY DO WE NEED CYTOMEGALOVIRUS-SPECIFIC 2189 
MEMORY T CELLS?
I.J.M. ten Berge1, E. Remmerswaal1,2, N.A. Lages2, E.M.M. van Leeuwen1,2, 
R.A.W. van Lier2
1Renal Transplant Unit, Academic Medical Centre, Amsterdam, 2Dpt of 
Experimental Immunology, Academic Medical Centre, Amsterdam
Memory T cells are believed to protect the host against re-infection with the 
same virus or, in case of persistent viruses, to enforce viral latency. Next to 
resting IL7RƒÑ- effector cells, cytomegalovirus (CMV) carriers also possess a 
variable number of CD8+IL7RƒÑ+ T cells, which resemble long term antigen-
independent memory cells that are generated against cleared viruses. We aimed 
to clarify the putative role of IL7RƒÑ+ and IL7RƒÑ- CD8+ T cells during 
CMV latency and CMV reactivation.
IL7RƒÑ+ CMV-specifi c CD8+ cells indeed had phenotypic traits of memory 
T cells and expressed granzyme K and CXCR3 which may allow them to 
migrate to draining lymph nodes. In contrast, IL7RƒÑ- cells were resting, 
granzyme B-containing effector cells and expressed CX3CR1+ which could 
drive homing to infl amed tissue. To clarify the possible clonal relation 
between these subsets TCR repertoire analyses were performed. A highly 
diverse TCR usage in the acute response was found that narrowed down in 
both IL7RƒÑ+ and IL7RƒÑ- subsets. However, hardly any overlap in VƒÒ 
usage and CDR3 sequences was found between the populations. Upon viral 
reactivation IL7RƒÑ- cells expanded signifi cantly and acquired a broad usage 
of TCRs, that resembled the primary response, but interestingly we found no 
evidence that T cell clones from the IL7RƒÑ+ fraction were recruited to this 
expanded pool. 
Thus, IL7RƒÑ+ and IL7RƒÑ- CD8+ T cells represent separate subsets of virus-
specifi c T cells that differ in migration potential, effector functions and TCR 
usage. In addition, IL7RƒÑ+ T cells are not being recruited to the expanded 
pool during virus reactivation suggesting that they do not provide a source 
for effector cells during latency or virus reactivation. Rather, different sets 
of CMV specifi c T cells may be involved in maintaining latency in different 
compartments.
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TREATMENT OF HIGH VIRAL LOAD 2190 
CYTOMEGALOVIRUS WITH VALGANCYCLOVIR A CASE 
STUDY
M. Castle, T. Evans-Walker
Cleveland Clinic
Purpose: The severity of Cytomegalovirus ranges from asymptomatic to tissue 
invasive, organ specifi c disease, allograft failure, and death. The highest risk 
of developing subsequent CMV infection and disease is donor+/recipient-. 
Clinical practice has shifted toward oral valganciclovir for preemptive therapy 
and not surprisingly, outpatient treatment as opposed to IV gancyclovir. The 
validity of treating active CMV infection with an oral therapy was shown in 
recent studies, including the VICTOR study (2007), but in the trials reviewed, 
the median initial viral loads were modest, 19 750 copies per mL. This case 
study is to observe the course of treatment for an individual (D+/R-), eight 
months post Living-Unrelated kidney transplant, detected with 616 960 copies/
mL CMV.
Method: High Viral loads of CMV and tissue-invasive disease are more 
likely to be treated with IV gancyclovir. However, this case represents, per 
one patient’s preference (AMA), the effi cacy of outpatient oral treatment with 
an endpoint yet to be determined. All D+/R- and other high risk individuals 
have preemptive screening for CMV every 2 weeks for the fi rst year post 
kidney transplant. For symptomatic viremia or CMV disease; standard therapy 
would include (reducing or discontinuing the antimetabolite, as applicable) and 
intravenous gancyclovir 5mg/kg twice daily for 21 days and preferable until 
CMV DNA assay becomes negative, followed by valganciclovir 900 po daily 
for an additional 28 days. This individual had No CMV DNA Detected on 
16 consecutive screening tests until January of 2008 when he presented with 
616 960 copies/mL. Before his leaving from the hospital, he did receive one 
dose of gancyclovir 5mg/kg IV. The multidisciplinary team discussed the risks 
associated with CMV. The patient determined that the plan of care would need 
to be coordinated from home since his informed choice was not to be treated 
in the hospital.
Results: Oral Valganciclovir per renal dose was ordered for therapy as the 
transplant and ID team discussed PICC/home care, with local physician 
collaboration. The next CMV DNA had fallen within one week to 61 971. 
Continued oral therapy was prescribed as patient preference. The following 
CMV results were as follows; weekly, 178 960, 14,898 then No CMV DNA 
detected. The next 2 weeks; No CMV DNA detected. After three consecutive 
negative results, the Valganciclovir was discontinued. The following week 1558 
copies/mL detected and the following week 60 505. The individual remains 
free from complaints. The valcyte was reintroduced at 900mg PO BID. There 
is a test presently pending.
Conclusion: Although there was much encouragement during the course 
of treatment, follow up of recurrences and better understanding of duration 
of therapy versus resistance warrants ongoing investigation. This case 
study refl ects the importance of diligent screening to diagnose as quickly 
as possible. Ongoing trials will yield additional data in providing a true 
measure whether oral Valganciclovir is comparable in effi cacy to the IV 
gancyclovir.
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FATAL OSELTAMIVIR-RESISTANT INFLUENZA A/2191 
SOLOMAN ISLANDS/3/2006 (H1N1) INFECTION IN A CORD-
BLOOD HAEMATOPOIETIC STEM CELL TRANSPLANT 
(HSCT) RECIPIENT
P. Ferguson1,2, I. Kerridge2,3, B. Wang4, K. McPhie5, N.K. Saksena4, A. Hurt6, 
T. Sloots7, M. Nissen7, T. Sorrell1,2, D. Dwyer1,2
1Centre for Infectious Diseases and Microbiology, Westmead Hospital, 
2Centre of Clinical Research Excellence, Infection and Bioethics in 
Haematological Malignancies, 3Bone Marrow Transplant Unit, Westmead 
Hospital, Sydney, Australia, 4Westmead Millennium Institute, 5Institute of 
Clinical Pathology and Medical Research, 6WHO Collaborating Centre, 
7Queensland Paediatric Infectious Diseases Laboratory
A 21 year old woman underwent a double cord-blood HSCT for Acute 
Lymphoblastic Leukaemia in third remission during the 2007 infl uenza 
season in Sydney, Australia. She received oseltamivir on admission (75mg 
daily bd on Days -5 to +1) because of prolonged close contact with non-
vaccinated household members with infl uenza-like illness. Pneumonia with 
upper respiratory symptoms developed on Day +12 (total white cell count 0.1 
x109/L). Infl uenza A was detected by immunofl uorescence (IF) and culture of 
nose/throat swabs (NTS). Treatment with oseltamivir 75mg bd, meropenem and 
amphotericin was initiated. Infl uenza A and coronavirus OC43 were detected 
subsequently by PCR of DNA extracted from NTS. Moderate-severe acute 
GVHD developed Day +20 on cyclosporin and mycophenolate prophylaxis and 
was treated with IV methylprednisolone (2mg/kg), thence a tapering steroid 
regimen. Although a further NTS was infl uenza IF and culture negative on Day 
+25, PCR for infl uenza and OC43 remained positive and there was no clinical 
improvement. Bronchoscopy on Day +29 was IF and PCR positive for infl uenza 
A only. Aspergillus fl avus and adenovirus were cultured from the same specimen. 
Despite neutrophil recovery (>0.5 x109/L) on Day +30 and ongoing treatment 
(oseltamivir 75mg bd then 100mg bd from Day +34, liposomal amphotericin, 
voriconazole, meropenem), the patient developed respiratory failure and required 
invasive ventilation from Day +44. A bronchoscopic respiratory sample on Day 
+47 was IF and culture-negative for infl uenza, adenovirus and Aspergillus, and 
oseltamivir was ceased after a total of 34 days. The patient deteriorated rapidly. 
A bronchoscopic sample on Day +51 was positive for infl uenza A (IF, culture 
and PCR), and OC43 (PCR) but negative for other respiratory viruses and 
Aspergillus. The patient died of respiratory failure on Day +53. 
DNA from cultured Infl uenza A isolates on days +12 and +51 demonstrated 
oseltamivir resistance with the H274Y mutation being detected.. Both wild-type 
and resistant virus were present on day +12, but only resistant virus, on day +51. 
The H274Y mutation was confi rmed by rolling circle amplifi cation (RCA) applied 
directly to clinical specimens collected on days +12, +29, +42, +47 and +51.
Treatment-associated development of infl uenza A and B resistance to oseltamivir 
has been described, although the clinical signifi cance is uncertain. This is the 
fi rst report of fatal, oseltamivir-resistant, infl uenza A infection associated with 
prolonged oseltamivir treatment in an HSCT recipient. Novel molecular methods, 
such as RCA, may facilitate detection of gene mutations that confer oseltamivir 
resistance and predict therapeutic failure in patients on prolonged therapy. 
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VIRAL AND HOST FACTORS ASSOCIATED WITH CMV 2192 
INFECTION IN LIVER TRANSPLANT RECIPIENTS
W. Rawlinson1,2,3,4, G. Scott1,3,4, Z. Naing1,3, J. Pavlovic5, P. Angus5, 
N. Rismanto2, R. Jones5, 
1Virology Research, POWH & UNSW Research Laboratories, Prince of Wales 
Hospital, Sydney, AUS, 2Virology Division, Department of Microbiology, 
SEALS, Prince of Wales Hospital, Sydney, AUS, 3School of Medical Sciences, 
Faculty of Medicine, University of New South Wales, Sydney, AUS, 4School of 
Biotechnology and Biomolecular Sciences, University of New South Wales, 
Sydney, AUS, 5Liver Transplant Unit, Austin Health, Melbourne, AUS
Aims: We are investigating the effi cacy of valganciclovir (valGCV) prophylaxis 
in liver transplant recipients and the effect on cytomegalovirus (CMV) infection, 
CMV-related disease, development of antiviral resistance and other secondary 
complications of liver transplantation. We aim to determine optimum strategies 
for the prevention of these complications following liver transplantation.
Methods: Transplant recipients who are seronegative for CMV and receiving 
a liver from seropositive donor (D+/R-) are at high-risk for CMV infection 
and disease and are therefore automatically placed in the valGCV prophylaxis 
arm of the study. All other recipients (D+/R+; D-R+; D-R-) are randomised 
to receive valGCV prophylaxis at the time of transplantation or valGCV 
pre-emptive therapy if laboratory evidence of active CMV infection exists 
(increasing CMV load, CMV PCR positivity on consecutive specimens). We 
have enrolled 45 patients to date at the Austin Hospital, Melbourne.
Results: ValGCV prophylaxis reduces the incidence of active CMV infection 
in D-/R+ liver transplant recipients (0% in recipients receiving prophylaxis 
versus 50% in recipients who did not receive prophylaxis) and D+/R+ recipients 
(67% versus 25%). However, CMV infection (71%) and disease (43%) was 
still evident in seronegative recipients of a liver from a seropositive donor, 
indicating D+/R- patients are still at highest risk for CMV-related disease even 
when valGCV prophylaxis is used. 
We fi nd an association between CMV disease and severe acute or chronic 
rejection of the transplanted organ, although our data do not address whether 
CMV is causative. Antiviral resistance to valGCV was evident in two of 
the CMV strains infecting D+/R- recipients, equating to 10% of recipients 
receiving valGCV prophylaxis. These resistant strains were evident after the 
initial 100 days of valGCV prophylaxis. One of these patients (with HCV 
related liver disease) developed CMV gastritis, duodenitis and hepatitis as a 
result of this resistant CMV infection and later died from multi-organ failure 
despite subsequent change in antiviral therapy to foscarnet. The other D+/R- 
recipient with an antiviral resistant CMV infection did not develop CMV-related 
disease and remains well. The CMV infection of this patient has resolved 
without antiviral treatment, and presumably in accordance with reversal of the 
post-transplant immunosuppression and development of anti-CMV immune 
response. Mixed infections with two different CMV genotypes were evident in 
D+/R+ recipients, refl ecting concomitant reactivation of latent CMV infection 
in the recipient, and transmission of CMV from the donated organ. However, 
mixed CMV infections did not refl ect worse outcomes for these liver transplant 
recipients, as has been shown for lung transplant recipients. No association 
between CMV infection and Toll-like receptor (TLR2, TLR4) polymorphisms 
was evident in this liver transplant population.
Conclusions: Investigations to date suggest the major host factor for CMV 
infection and life threatening disease is D+/R- serostatus. The major viral 
factions associated with adverse clinical outcomes include increasing and 
sustained viral load in blood, sometimes as the result of resistant infection. 
ValGCV prophylaxis appears to provide protection to D-/R+ and D+/R+ 
recipients but improvements to prophylactic regimens (including prolonged 
prophylaxis) may be necessary to reduce the incidence of CMV disease in 
D+/R- liver transplant recipients.
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PRE-EMPTIVE TREATMENT OF CMV INFECTION 2193 
FOLLOWING RENAL TRANSPLANTATION – A SINGLE 
CENTRE CLINICAL EXPERIENCE
S. Rajakumar, F. Ierino, D. Tomlinson
Austin Health
Cytomegalovirus (CMV) infection after renal transplantation is an important 
cause of morbidity due to both direct and indirect complications and has 
been associated with higher mortality rates. Two approaches have generally 
been used to prevent CMV disease: universal prophylaxis and a pre-emptive 
treatment strategy involving serial monitoring for viraemia to allow early 
treatment. Universal prophylaxis is easier logistically but may unnecessarily 
expose a proportion of patients to the adverse effects and costs of antiviral 
therapy. A pre-emptive approach requires an effective monitoring strategy and 
is more resource-intensive. We report our experience using a PCR-based pre-
emptive treatment strategy for renal transplant recipients.
Forty-six consecutive renal transplant patients (average age 46.5 years, 73% 
male, 72% cadaveric) were managed with a pre-emptive CMV treatment 
protocol and had a minimum of 6 months follow-up (range: 6 – 39 months). 
CMV seronegative recipients receiving a graft from a seropositive donor (D+R-) 
received 3 months prophylaxis with either oral valaciclovir or valganciclovir. 
The remaining patients (D+R+, D-R+, D-D-) had plasma CMV PCR tested 
fortnightly for 6 months. Patients with a viral load > 10,000 copies/ml were 
treated with ganciclovir followed by 3 months valganciclovir. Those with < 
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10,000 copies/ml were treated with valganciclovir for 3 months. Patients with 
CMV disease were treated with 2 weeks ganciclovir followed by 3 months of 
oral therapy. Very low-level asymptomatic viraemia was treated only if rising 
rapidly. Patients receiving OKT3 were given prophylaxis. Immunosupression 
was reduced as tolereated. 
Seven of 46 patients were D-R-. During the 6 month period of fortnightly PCR 
surveillance none developed CMV infection. After follow-up of 6 – 39 months 
none had developed CMV disease. This low rate, in keeping with published 
data, suggests that prophylaxis may not be warranted in this group.
Seven of 46 patients were D+R- and received 3 months prophylaxis during 
which none developed CMV disease or viraemia. One patient developed 
CMV disease (pneumonitis) and another had subclinical viraemia 12 and 4 
months after ceasing prophylaxis respectively. The trend of later presentation 
with prophylaxis is consistent with published data and a longer period of 
prophylaxis or a period of surveillance after prophylaxis may be benefi cial.
Thirty-two transplants were with seropositive recipients. Five patients remained 
free of CMV viraemia or disease and 4 had CMV disease (1 severe). Twenty-
three (69%) developed subclinical viraemia. This occurred at an average of 
6.9 weeks after transplantation and 17 of these patients received anti-viral 
treatment. None of the patients with subclinical viraemia (treated or observed) 
developed CMV disease.
The rate of exposure to anti-viral agents with this protocol was relatively high 
(53% of R+ and 87% of all non D-R- transplants). This suggests that a universal 
prophylaxis regime may not entail a signifi cantly larger complication rate. The 
high incidence of subclinical viraemia is notable as the prognosis for this subset 
of patients has not been well-defi ned and lends itself to further research. This 
may guide the development of strategies to prevent CMV disease after renal 
transplantation.
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ADOPTIVE IMMUNOTHERAPY: FUNCTIONAL 2194 
CHARACTERISATION OF EPSTEIN-BARR-VIRUS (EBV) 
SPECIFIC T CELLS GENERATED BY SHORT TIME 
STIMULATION WITH EBV PEPTIDES
A. Roemhild1, S. Zwinger2, G. Brestrich1, I. Noack2, H-D. Volk2, P. Reinke1
1Department of Nephorology, Charite Berlin, 2Institute of Medical 
immunology
Patients undergoing an immunosuppressive treatment, e.g. after transplantation, 
have an increased susceptibility to infection and neoplasia, in general and to 
B-cell lymphomas, in particular. EBV plays an essential role in development 
of the majority of these posttransplant lymphoproliferative disorders (PTLD). 
PTLD affects 2-25% of solid organ transplant (SOT) recipients for instance and 
still carries a high morbidity and mortality. 
In healthy individuals EBV infection is controlled by EBV-specifi c cytotoxic 
T lymphocytes (CTLs). Under immunsupression some patients are unable to 
control EBV effi ciently and are therefore in risk of developing B cell tumours 
or active chronic infections with transplant damage. 
Immunotherapy with cytotoxic T cells (CTLs) as a new approach is increasingly 
used to treat such malignancies and viral infections. For re-establishing a 
functional immune response in-vitro expanded autologous virusspecifi c T cells 
are retransferred into the patient.
Currently the generation of these T cells is mostly carried out by repetitive 
stimulations with EBV-infected autologous lymphoblastoid cells (LCLs), 
which takes approximately 2-3 months. Due to this generation time many 
severe cases of patients suffering from missing viral immunity and subsequent 
viral disease are excluded from therapeutic benefi t. 
Recently our group developed a shortened generation protocol for the 
production of EBV specifi c T cells. T cells are detected via peptide stimulated 
cytokine secretion combined with immunomagnetic cell isolation. Using 
multicolour fl ow cytometry, we characterized these cells functionally after 
expansion. Besides determining diverse surface markers and intracellular 
cytokine production we also analysed the cytotoxic capacity and specifi city by 
calcein release assay.
In summary we were able to shorten the generation time for EBV specifi c T 
cells dramatically without affecting the phenotyp or the specifi city of neither 
CD8+ nor CD4+ cells in the culture. The detailed characterization of these cells 
should help to further improve the adoptive immunotherapy and its outcome.
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DETECTION OF CYTOMEGALOVIRUS (CMV) AND 2195 
HUMAN HERPESVIRUS-6 (HHV-6) DNA IN BIOPSY OF LIVER 
DONOR.
A. Guardia1, A. Sampaio1, I. Pereira2, R. Stucchi2, M. Leonardi2, I. Boin2, 
S. Costa1
1Molecular Biology Laboratory – FCM – Unicamp, 2Unit of Liver 
Transplantation – Unicamp
Introduction: Cytomegalovirus (CMV), Human Herpesvirus-6 (HHV-6) 
and Human Herpesvirus-7 (HHV-7) belong to the herpesvirus subfamily. 
These viruses remain latent or at a low level of viral replication after primary 
infection and can reactive during immunosuppressed states as following organ 
transplantation. 
Objective: Detection of Cytomegalovirus (CMV) and Human Herpesvirus-6 
(HHV-6) DNA in biopsy of liver donors’ by nested polymerase chain reaction 
(Nested-PCR).
Methods: Seventy-two liver biopsies were tested for the presence of CMV and 
HHV-6 genome using a Nested-PCR.
Results: Thirty of seventy (41,1%) liver biopsies were HHV-6 PCR positive 
and eight (11%) of seventy liver biopsies were positive CMV. Only six (8,3%) 
of seventy biopsies were both CMV and HHV-6 positive. 
Conclusions: The presence of the viruses observed in the samples of the donor, 
indicate that pretransplant HHV-6 and CMV infection may be a risk factor 
post-transplantation. They stayed aware to the neurological manifestation 
of unknown origin because they can be related to the active infection by 
HHV-6 isolated.
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CORRELATION OF TNFD MICROSATELLITE AND 2196 
HEMATOPOIETIC STEM CELL TRANSPLANTATION
K. Stingl1, Z. Grubic1, R. Zunec1, R. Serventi-Seiwerth2, E. Cecuk-Jelicic1, B. 
Labar2, V. Brkljacic-Kerhin1
1Tissue Typing Centre, University Hospital Centre Zagreb, 2Department of 
Hematology, Internal Clinic, University Hospital Centre Zagreb
Correlation between serum levels of TNFá and occurrence of posttransplantion 
complications such as acute GvHD was demonstrated in previous studies. The 
release of this proinfl ammatory cytokine is a consequence of conditioning 
regimens performed before hematopoietic stem cell transplantation (HSCT). 
Furthermore, an association between TNFá production and TNFd microsatellite 
polymorphism was also reported previously. The aim of the present study was 
to investigate the possible correlation between this polymorphism and the 
survival of patients.
Eighty patients who underwent HSCT were included in the analysis. All 
of them received a transplant from a sibling identical for HLA-A, -B, and 
-DRB1 loci. The analysis of the TNFd microsatellite was performed using 
PCR amplifi cation with specifi c primers followed by electrophoresis on a 
polyacrylamide gel in ALFexpress sequencer with the B cell lines from 10th 
Workshop as controls.
The distribution of alleles at TNFd locus among the patients did not differ 
from the results obtained for healthy individuals tested in previous studies. The 
predominance of TNFd4 allele (53.8% and 56.6% respectively) was observed 
in both groups and the frequencies of all other alleles were in agreement. The 
patients were divided according to the survival at day 100 post HSCT. No 
statistically signifi cant difference was observed between patients who survived 
longer than 100 days post HSCT (N=68) and those who have not (N=12) 
with respect to the distribution of allele and genotype frequencies at TNFd 
locus as well as to the percentage of homozygous individuals. No correlation 
with worse survival rates was observed for the presence of alleles with higher 
number of repeats as previously suggested. The only marginally signifi cant 
difference was found for TNFd3 allele, which was increased among patients 
with worse survival. Finally, this fi nding is in agreement with previous reports, 
but further studies with a larger group of patients are necessary in order to reach 
a fi nal conclusion.
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PROPHYLAXIS NOT PROTECTION!!2197 
A. Asderakis, M. Ilham, R. Egan, R. Bradley
Transplant Unit, University Hospital of Wales, UK
Introduction: 8% to 20%of renal transplant recipients experience 
symptomatic Cytomegalovirus (CMV) infection. CMV disease leads to 
reduction of patients and graft survival. This results not only from the CMV 
virus direct pathogenic effect but also from its immunomodulating effects. 
This is associated with other infections and a higher incidence of graft 
rejection and chronic fi brosis.
Therefore prophylactic and pre-emptive treatment regimes against CMV have 
been developed and are used in most transplant centers.
Aim: Identify the incidence of CMV disease in renal transplant recipients who 
had a three month course of Valganciclovir prophylaxis following completion 
of the course.
Method: All renal transplant recipients in the period between January 2004 
to December 2007, who received valganciclovir prophylaxis were eligible for 
the study. During this period Valganciclovir was given orally for 100 days post 
transplant to seronegative patients that received an organ from a seropositive 
donor and all recipients irrespective of CMV status who received T-Cell 
depleting agents. CMV disease was diagnosed on the basis of a positive CMV 
PCR in the context of clinical symptoms of viral disease, kidney dysfunction or 
tissue invasive disease (colitis, gastritis). 
Results: 361 kidney and kidney pancreas transplants were performed during 
this period. 306 of the patients received prophylaxis according to the described 
criteria.
Three patients developed CMV disease during the time they were receiving 
prophylaxis. Thirty two patients (10.5%) developed CMV disease following 
the completion of the prophylactic course. CMV developed from one week to 
7 months (median 2 months) after completing the prophylaxis. These patients 
proceeded to receive IV Ganciclovir and/or Oral Valganciclovir treatment and 
went subsequently on additional prophylaxis adding a signifi cant cost to the 
overall transplant management. All patients responded to the treatment and no 
resistance developed against Valganciclovir 
Conclusion: Valganciclovir is effective in preventing CMV disease in a cohort 
of medium and high risk patients during the 100 days that is given. 
However it does not confer satisfactory longer term protection, as 10.5% of the 
patients still developed CMV disease following completion of this prophylactic 
course. This poses along term risk that is diffi cult to quantify.
POSTER BOARD NUMBER P4 – 248
THE INFLUENCE OF STATINS ON POLYOMA VIRUS2198 
D. Brennan1, K. Hardinger2, A. Godolbo-Brooks1, R. Schuessler1, B. Lluhka1, 
M. Schnitzler3
1Washington University, 2University of Kansas City Missouri, 3Saint Louis 
University
Statins have recently been shown, in vitro, to inhibit polyomavirus uptake. The 
purpose of the study was to determine whether statins have a clinical effect 
on the incidence, timing or severity of polyoma virus infection post kidney 
transplant transplant. 
Methods: A retrospective review of data collected in a randomized, single-
center trial (n=200) that compared the infl uence of calcineurin inhibitors on 
development of polyoma and the infl uence of reduced immunosuppressive 
therapy for treatment of BK viremia. 
Results: During the twelve month trial, 70 patients (35%) developed 
viruria and 23 patients (11.5%) developed viremia. The median time to 
onset of viruria and viremia were 40 and 60 days, respectively. At the 
time of transplant 61 patients (31%) and at three months after transplant 
84 patients (42%) received a statin. Patients on statins at the time of 
transplant continued on their pre-transplant medication as soon as they are 
able to tolerate medications. There was no difference in the use of statins 
at baseline (P=0.85) or at 3 months after transplant (P=0.6) by type of 
calcineurin inhibitor used. There were no differences in the incidence of 
viruria, viremia, or the time to development of viruria or viremia based on 
statin use.
Statin use at Transplant Statin use at 3 months
No
(n=139)
Yes (n=61) P value No
(n=116)
Yes (n=84) P value
Viruria (%) 37 31 0.521 38 31 0.298
Viremia (%) 12 10 0.810 14 8 0.266
Time to Viruria (days) 37± 7 47± 11 0.467 32± 9 57± 10 0.726
Time to Viremia (days) 57± 29 60± 33 0.221 55± 9 88± 37 0.753
There were no differences in other measures of viral severity based on presence 
of a statin at the time of transplant or 3 months after transplant including the 
following: peak urine viral load (baseline use P=0.904 and 3 months P=0.962) or 
peak blood viral load (baseline use P=0.515 and 3 months P=0.789), time from 
onset of viruria to peak viruria (baseline use P=0.977 and 3 months P=0.966), or 
time from viruria to viremia (baseline use P=0.891 and 3 months P=0.538).
Conclusion: Based on the results of this study, statins do not infl uence the 
incidence, timing or severity of BK infection after renal transplantation. 
However, our lack of fi nding an effect may refl ect a type II error.
POSTER BOARD NUMBER P4 – 249
SUCCESSFUL TREATMENT OF SEVERE ADENOVIRUS 2199 
INFECTION WITH INTRAVENOUS CIDOFOVIR IN A KIDNEY 
TRANSPLANTATION PATIENT
S. Watcharananan1, S. Jirasirithum1, V. Mavichak2, C. Leenanupunth1, 
S. Dithbanchong1, V. Chantarathitaya1, K. Malathum1, R. Avery3
1Ramathibodi Hospital, Mahidol University, 2Institute of Kidney 
Transplantation, Praram 9 Hospital, 3Cleveland Clinic Foundation
Adenovirus infection following kidney transplantation is not common. Most of 
the infections are self-resolved. We present a patient who developed adenovirus 
viremia with severe urethritis and hemorrhagic cystitis 3 weeks after cadaveric 
kidney transplantation. Adenovirus was detected in the blood, urine and bladder 
tissue. Reduced dosages of immunosuppressive drugs in conjunction with oral 
ribavirin and intravenous immunoglobulin were administered without effect. 
Intravenous cidofovir was effi cacious. Patient became defervesced within 
72 hours of treatment. There was no serious side effect and no detrimental 
outcome on graft function. Reversible anterior uveitis after cidofovir use was 
observed. Blood and urine for adenovirus became undetectable 2 weeks and 5 
weeks after the initiation of cidofovir, respectively. Although the effi cacy of 
reduced dose cidofovir has not been proven in clinical trial, this is the fi rst case 
report to support the treatment of severe adenovirus infection with reduced 
dose of cidofovir in kidney transplant patient.
POSTER BOARD NUMBER P4 – 250
CURRENT STATUS OF CMV-REACTIVATIONS IN ADULT 2200 
LIVER TRANSPLANT PATIENTS MONITORED BY FREQUENT 
QUANTITATIVE PCR TESTING
K. Höckerstedt, I. Lautenschlager, R. Loginov, H. Mäkisalo
Helsinki University Hospital
Background: Cytomegalovirus (CMV) is a signifi cant infectious agent 
causing morbidity in transplant patients. CMV-infection mostly appears within 
2-3 fi rst months after transplantation. To prevent CMV, most liver centers use 
prophylaxis for high risk patients of CMV-seronegative recipients receiving 
an organ from a seropositive donor (R-/D+) and many centers even for all 
seroposive recipients (R+). Preemptive treatment is mainly used for those at a 
moderate or low risk of CMV, with a major advantage of reduced drug expose. 
Preemptive therapy is based on the screening for early evidence of CMV by 
frequent monitoring of viral load. The current status of CMV-reactivations 
demonstrated by quantitative PCR-monitoring of adult CMV-seropositive (R+) 
liver transplant patients was studied. 
Patients and methods: Altogether 211 adult patients were transplanted 
2003-2007. The basic immunosuppression consisted of CNI inhibitors, 
azathioprine/MMF plus steroids in tapered or ceased doses. High risk patients 
received valganciclovir (or ganciclovir) prophylaxis, i.v. ganciclovir was used 
for preemptive therapy for (R+) patients, and in the case of symptomatic CMV. 
Most recipients, 176 (84%), were CMV-seropositive (R+). Of those, 161 (R+) 
patients with a follow-up over six months were studied. The patients were 
frequently monitored for CMV by a real-time quantitative plasma PCR. 
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Results: In most cases, 98/161 (61%) no evidence of CMV was seen, and just 
63/161 (39%) developed CMV-DNAemia during the post transplant monitoring 
of six months. Only 25/63 reactivations exceeded 5000 copies/ml considered 
as cutoff level for preemptive treatment, and most had self-limiting, low-level 
CMV-DNAemia. Thus, low-level CMV-reactivation occurred in 38/161 (R+) 
patients (23.5%), and only 25/161 (15.5%) demonstrated signifi cant viral loads. 
No correlation to immunosuppression regimen could be found. No patient or 
graft was lost due to CMV. 
Conclusions: These results demonstrate that most CMV-seropositive liver 
recipients do not develop CMV-reactivation, and even if reactivations occur, 
most of them are temporal, low-level DNAemias. Thus, universal prophylaxis 
for all R+ patients would not seem to be reasonable in this patient population. 
Indirect effects and long term results are analyzed later. 
POSTER BOARD NUMBER P4 – 251
POLYMERASE CHAIN REACTION (PCR) NEGATIVE 2201 
CYTOMEGALOVIRUS (CMV) ENTERO-COLITIS: A 
CLINICALLY SIGNIFICANT ENTITY
P. Masson1, K. Wyburn1, J. Eris1, P. Collett2, S. Chadban1
1Royal Prince Alfred Hospital, Sydney, 2Concord Repatriation General 
Hospital, Sydney
Background: CMV infection is a common complication of solid organ 
transplantation which can be diagnosed serologically based either on 
sero-conversion, or by detection of viral DNA using a nested PCR. PCR 
is increasingly used as the ‘gold standard’ test in clinical practice as a 
sensitive and specifi c qualitative and quantitative test in the surveillance 
and detection of CMV, and in the measurement of anti-viral treatment 
effi cacy.
Methods: Retrospective analysis of four patients with symptoms of diarrhoea, 
fever and weight loss who were found to be CMV PCR negative but confi rmed 
to have CMV colitis or enteritis following histopathological examination of 
surgical or biopsy specimens. Quantitative PCR using an in-house assay of 
human whole blood was performed, with dynamic range: <1000 copies/ml – 
unlikely; 1000-5000 copies/ml – possibly; >5000 copies/ml – highly likely to 
be associated with clinical disease.
Results: All patients were recipients of primary renal allografts (3 cadaveric, 
1 living-unrelated) and three were CMV IgG antibody positive prior to 
transplant. Donor CMV serology was positive in two cases and unknown 
in two. Mean age of patient at time of transplant was 49.5 years (36 – 70) 
with PCR negative CMV disease occurring an average of 147 months 
post transplantation (10 – 212) at the mean age of 61.5 years (53 – 71). 
One patient had experienced a prior episode of serologically proven CMV 
disease. Baseline immunosuppression regimens all included Cyclosporin and 
Prednisone in combination with an anti-proliferative agent (Azathioprine 
or Mycophenolate Mofetil). Basiliximab induction was used in one case. 
One patient discontinued calcineurin inhibition and one other switched to 
Tacrolimus prior to the episode of CMV infection. One patient had ceased 
anti-proliferative therapy. Three patients experienced acute cellular rejection 
episodes, all receiving intravenous Methylprednisolone, and two receiving 
T-cell depletion therapy (OKT-3). CMV prophylaxis had been given in only 
one case. Serum CMV IgM was positive in one case, but not measured in 
three others, nor were changes in IgG titres or CMV antigenaemia studies 
performed. All responded to treatment with intravenous Gancyclovir and 
subsequent oral Valgancylclovir. 
Conclusions: PCR negative CMV infection is a clinically signifi cant entity. 
Undetectable CMV DNA by PCR does not exclude organ-invasive disease, 
specifi cally intestinal disease. In cases where clinical suspicion of CMV disease 
is high, alternative investigations should be employed and tissue diagnosis may 
be required.
POSTER BOARD NUMBER P4 – 252
EPSTEIN BARR VIRUS ENCODED LATENT MEMBRANE 2202 
PROTEIN 1 ACTIVATES THE JAK/STAT PATHWAY 
INDIRECTLY THROUGH PRODUCTION OF IFN-G
O. Martinez1,2, M. Vaysberg1,2, S. Lambert1,2, S. Kra1,2, C. Esquivel1
1Stanford University School of Medicine, Dept of Surgery, 2Program in 
Immunology
Background and Aims: Epstein Barr virus (EBV) is associated with multiple 
human malignancies including post-transplant lymphoproliferative disease 
(PTLD)-related B cell lymphomas. Latent membrane protein 1 (LMP1) is an 
EBV-encoded protein expressed in PTLD tumors that can drive tumor growth 
through constitutive activation of NFκ;B, Erk, p38, Akt, and JNK. We have 
shown that EBV+ B cell lines from PTLD patients express LMP1 and have a 
constitutively active Jak/STAT pathway. Dysregulated Jak/STAT activation has 
been observed in several B cell malignancies. Here we determine the role of the 
viral protein LMP1 in STAT activation in B cells. 
Methods: Direct interaction of LMP1 with JAK3 was analyzed by 
immunoprecipitation of PTLD cell line lysates with anti-LMP1 antibody and 
Western blotting for JAK3. NGFR-LMP1 chimeric proteins were expressed 
in the EBV negative Burkitt’s lymphoma cell line BL41 to permit inducible 
LMP1 signaling. Gel shift assays were performed with whole cell extracts 
from BL41. NGFR-LMP1 cells after 0-24 h of LMP1 activation. Additionally, 
lysates were resolved on SDS-PAGE and Western Blotting (WB) was performed 
with phospho (p) STAT1, STAT1, pSTAT3 and STAT3 antibodies. Cytokine 
secretion was assayed by pan-cytokine luminex assay and ELISA. IFNγ;R1 
and IFNγ; specifi c antibodies were used to block IFNγ; signaling in cells prior 
to pSTAT1/STAT1 WB. 
Results: Although JAK3 could associate with the common γ; chain in EBV+ 
B cell lines derived from PTLD tumors and in the BL41 B cell lymphoma line 
infected with the B95.8 strain of EBV, no interaction of LMP1 with JAK3 was 
observed. STAT/DNA complexes were detected in NGFR-LMP1 BL41 clones 
after 24 hours of LMP1 signaling but not after 20-30 minutes of LMP1 signaling, 
suggesting that STAT activation is indirect. STAT1 was the predominant STAT 
activated by LMP1. Inhibition of cytokine secretion with brefeldin A prior to 
LMP1 activation abolished STAT binding to DNA indicating that a secreted 
protein is responsible for STAT activation. IFNs are known inducers of the STAT 
pathway and cytokine luminex assays revealed that LMP1 can induce IFNγ; 
but not IFNα;. Moreover, IFNγ; receptor blockade prior to LMP1 activation 
dramatically decreased STAT1 activation. Finally, silencing of STAT1 by RNAi 
markedly inhibited proliferation of BL41 cells and diminished expression of the 
IFN-γ; inducible genes Mig1 and p21
Conclusion: Together, these data demonstrate that LMP1 does not activate the 
Jak/STAT pathway through direct interaction with JAK3 but rather through an 
indirect pathway involving IFNγ; induction. Moreover, activation of STAT1 
via this pathway contributes to tumor cell growth. Thus the oncogenic protein 
LMP1 of EBV usurps cellular cytokine pathways to augment tumor growth. 
Understanding the viral-host cell interactions that promote tumorigenesis will 
lead to novel strategies for treatment of PTLD.
POSTER BOARD NUMBER P4 – 253
EARLY POSTOPERATIVE URETERAL NECROSIS 2203 
ASSOCIATED WITH CYTOMEGALOVIRUS INFECTION
K. Malathum1, S. Jirasiritham2, W. Mawijak3, W. Kittikowit4
1Department of Internal Medicine, Faculty of Medicine, Ramathibodi 
Hospital, Mahidol University., 2Department of Surgery, Faculty of Medicine, 
Ramathibodi Hospital, Mahidol University, 3Praram 9 Hospital, 4High Tech 
Laboratories
Ureteritis associated with cytomegalovirus infection has rarely been reported in 
medical literature although other syndromes caused by this virus are quite common 
and pose a real challenge in transplantation medicine. We report here a case of 
ureteritis accidentally identifi ed in a renal transplanted recipient in Thailand.
A 57-year-old Thai man came to Praram 9 Hospital, Bangkok, Thailand in 
late December, 2007 because of fever and shaking chill. He had undergone 
cadaveric kidney transplantation one month earlier. Post-operatively, he 
developed a large hematoma at the surgical site and urinary tract infection 
caused by Klebsiella pneumoniae, which fi nally subsided. Pre-transplant 
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serologic screening revealed CMV IgG positivity both in the patient and 
the donor. Current medications included mycophenolate, prednisolone, and 
cyclosporin. A diagnosis of urinary tract infection for which broad-spectrum 
antibiotic was given was made and microbiologically confi rmed later. A large 
urinoma was found and he subsequently underwent a surgical operation. Partial 
ureteral wall necrosis was found. Histopathology revealed subacute, organizing 
ureteritis with rupture and atypical large endothelial lining possessing large 
nuclei containing basophilic intranuclear inclusion and pink cytoplasmic 
inclusions. The urothelial lining was markedly eroded. Immunohistochemical 
staining confi rmed these abnormalities as cytomegalovirus infection. CMV 
viral load in the blood and urine were determined immediately after this fi nding 
and it was 4890 copies/ml and <600 copies/ml, respectively. The patient was 
treated with a 2-week course of ganciclovir and completely recovered.
This report emphasizes the importance of CMV infection in transplantation 
recipient. Our case was in keeping with previous cases in that CMV infection 
might be under recognized.
POSTER BOARD NUMBER P4 – 254
DIFFERENTIAL BINDING OF UL-16 2204 
CYTOMEGALOVIRUS PROTEINS TO POLYMORPHIC MHC 
CLASS I CHAIN RELATED B (MICB) RELEVANT TO IMMUNE 
EVASION.
C. Leelayuwat1, K. Klumkrathok1,2, A. Jumnainsong1, W. Wongsena1,3
1The Centre for Research and Development of Medical Diagnostic 
Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University, 
2PhD Program in Medical Technology, Faculty of Medical Technology, 
Mahidol University, Bangkok, Thailand, 3Faculty of Allied Health Sciences, 
Naraesuan University, Pisanuloke, Thailand
Human cytomegalovirus causes an opportunistic infectious disease in an 
immunocompromized host. It is one of the clinical problems in transplantation 
patients. The UL16 glycoprotein is present in human cytomegalovirus infected 
cells but not in the virion envelop and down modulates NKG2D ligands by 
forming stable intracellular complex leading to immune evasion. The purpose 
of this study was to examine the functional variants of UL16 affecting the 
binding activities to a polymorphic cellular NKG2D ligand, MHC Class I chain 
related B (MICB). The soluble Fc fusion variants of the UL16 proteins from 
four human cytomegalovirus strains (AD169, Toledo, PH and TR) and allelic 
MICB expressing stable cell lines were produced. The binding activities of 
UL16 variants to allelic MICB proteins were analyzed by fl owcytometry. The 
results showed that the variants of UL16 did not affect the binding activities 
to the MICB proteins. However, the polymorphisms of MICB did affect the 
UL16 binding activities. MICB*008 containing Methionine (M) at the amino 
acid position 98 in the alpha 2 domain showed decreased binding activities to 
UL16 when compared to MICB*003 and MICB*00502 containing Isoleucine 
(I). This result suggests that the alpha 2 domain is critical to UL16 binding, 
especially the residue M98I. Differential binding of diverse MICB alleles 
could contribute to CMV immune evasion affecting immune responses to 
human cytomegalovirus.
TREGSCONCURRENT ORAL SESSION 148: 
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PROLONGATION THE MAJOR HISTOCOMPATIBILITY 2205 
COMPLEX-COMPATIBLE CARDIAC ALLOGRAFT SURVIVAL 
DURING PREGNANCY
X -K. Li1, N. Funeshima-Fuji1, L. Xie1, H. Kimura1, T. Ezaki2, S. Takahara3, 
B-T. Zhu4, 
1Lab of Transplantation Immunology, National Research Institute For Child 
Health And Development, 2Department of Anatomy & Development Biology, 
Tokyo Women fs Medical University School of Medicine, 3Department of 
Advanced Technology for Transplantation, Osaka University Graduate 
School of Medicine, 4Department of Pharmacology, The University of Kansas 
Medical Center
Background: It has been suggested that the pregnancy hormones may play a critical 
role in mediating selective immune tolerance during pregnancy. An understanding 
of how the woman’s body normally never rejects the fetus, escapes the maternal 
immune system may be relevant for the prevention of transplant rejection.
Materials & Methods: Female inbred DA (RT1a) or F344 rat (RT1lvl) hearts 
were transplanted into normal Lewis (RT1l, nLewis) or pregnancy (pLewis) 
rats, respectively. The mean survival time (MST) of the cardiac allografts 
between the pLewis and nLewis groups was statistically compared using 
unpaired student’s t test analysis. The proliferation of the PanT cells isolated 
from nLewis and pLewis rats to ConA, antibody and alloantigen stimulation 
was performed. The cytokines mRNA expression of these cells was analyzed 
with quantitative RT-PCR.
Results: The pLewis recipients on day 12 had significantly prolonged 
F344 cardiac graft survival (MST 13.3 days) compared with a group of 
the nLewis recipients (MST 8 days), while no significantly difference 
on day 6 and 18 of the pLewis (MST 10 and 10.2 days). Otherwise, 
the MST was 5.7 days for DA to nLewis, and 6 days for DA to pLewis, 
respectively. The pLewis PanT cell proliferation stimulated by alloantigen 
and antibody was reduced, while not by ConA. The Th1/Th2 cytokine 
profile of the PanT cells mRNA had no difference between the nLewis 
and pLewis rats. 
Conclusions: These results demonstrated that pregnancy hormones appeared 
to play a critical role not only in the maternal acceptance of the fetus, but 
also have therapeutic potential for prolongation the major histocompatibility 
complex (MHC)-compatible allograft survival during pregnancy.
POSTER BOARD NUMBER P4 – 256
SUPERAGONIST CD28 ANTIBODY PREFERENTIALLY 2206 
EXPAND FOXP3-EXPRESSING NTREG CELLS TO PREVENT 
GRAFT-VERSUS-HOST DISEASE
X-K. Li1, Y. Kitazawa1, L. Xie2, H. Kimura1, T. H?nig3, S. Takahara2
1Lab of Transplantation Immunology, National Research Institute for 
Child Health, 2Department of Advanced Technology for Transplantation, 
Osaka University Graduate School of Medicine, 3Institute for Virology and 
Immunobiology, University of W?rzburg,
It is well known that the naturally occurring CD4+CD25+ regulatory T 
(nTreg) cells comprise a separate lineage of T cells that are essential for 
maintaining immunological tolerance to self and represent a potential 
therapy for the treatment of autoimmune disease, infl ammation and allograft 
rejection. Therefore, reagents that are capable of expanding the pool of nTreg 
and enhancing their suppressive activity should prove to be very effi cient 
therapeutic tools. We previously presented a novel class of superagonistic 
CD28-specifi c monoclonal antibodies (supCD28 mAb, JJ316) that can 
induce the in vitro and in vivo expansion of T cells without a need for TCR 
engagement. The dramatic polyclonal T cell response after in vivo application 
of supCD28 mAb signifi cantly prolonged the full MHC mismatch (DA to 
Lewis) cardiac allografts survival. In the present study, we demonstrated that 
the nTreg cells were preferentially proliferated to a 4-fold increase within 3 
days in response to a single antibody administration. The appearance of the 
Foxp3 and CTLA-4 molecules were signifi cantly increased in the expanded 
CD4+CD25+ Treg subset and the polarization toward a Th2 cytokine profi le 
with decreased production of IFN-ƒÁ and increased production of IL-4 
and IL-10 was also observed in these expanded T cells. It was clarifi ed that 
isolated expanded Foxp3-expressing Treg cells by supCD28 mAb in vivo 
exhibited immunomodulatory properties capable of inhibiting both naive or 
activated CD4+CD25- T cell proliferation stimulated by alloantigens, anti-
CD3/CD28 mAbs, and ConA in a dose-dependent manner in vitro as well as 
nai Nve fs, and, upon adoptive transfer, suppressed local and systemic Lewis 
to F1 hybrid (Lewis x DA) GvH reaction. Furthermore, we found the Foxp3 
positive Treg cells were maintained at the high level in the peripheral blood 
of the GvHD host and immunostaining showed that the intragraft Foxp3 
positive cell were signifi cantly higher in supCD28 mAb-treated recipients. In 
summary, our data identifi ed a subpopulation of nTreg that are preferentially 
expanding in vivo by the supCD28 mAb-treatment and maintaining not only 
their phenotype but also their potent regulatory functions for suppressing 
the immune response by the conventional T cells. We also demonstrated that 
these preferentially expanded Treg are maintained in the peripheral blood 
and recruited to the grafts for suppress the local immune and infl ammatory 
response resulting the graft survival prolongation, represent a major advance 
towards the therapeutic use of these cells as cellular therapy for treatment 
allograft rejection and GvHD.
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INDUCTION OF LONG-TERM SURVIVAL OF CARDIAC 2207 
ALLOGRAFTS IN WILD-TYPE MICE BY ALLOANTIGEN 
(ALLOAG)-SPECIFIC FOXP3+CD4+CD25+ NATURAL 
REGULATORY T (NTREG) CELLS
G. Xia, J. He, J. Leventhal
Northwestern University, Dept. of Surgery – Organ Transplantation
Aims: Current study was aimed at preventing heart allograft rejection in wild-
type mice by alloAg-specifi c Foxp3+CD4+CD25+ nTreg.
Methods: Fresh naive CD4+CD25+ nTreg were isolated from congeneic B6.PL 
mice via autoMACS and enriched for alloAg specifi city by in vitro culture with 
either anti-CD3/CD28-coated Dynabeads (d0-11), then donor bone marrow-
derived dendritic cells ([DC] d11-20 (Beads/DC-expansion) or fi rst with 
donor DC (d0-8) then anti-CD3/CD28-coated Dynabeads (d8-16] (DC/Beads-
expansion) in the presence of interleukin(IL)-2, IL-2/transforming growth 
factor(TGF)- or IL-2/TGF-/retinoic acid(RA).
Results: The% of intracellular Foxp3+ nTreg quickly decreased from 96.2% 
(fresh) to 7.1% (d+18) during Beads/DC-expansion or to 6.2% (d+16) 
during DC/Beads-expansion with IL-2 alone. Addition of TGF- (2.5 ng/mL) 
signifi cantly rescued the loss with Foxp3 expressed at 21.3% (d+18) for Beads/
DC-expanded nTreg and at 66.8% (d+16) for DC/Beads-expanded nTreg, while 
total fold of expansion of nTreg remained similar (24.830.2 for Beads/DC- or 
5.27.1 for DC/Beads-expansion) regardless of the presence or absence of TGF-. 
Introducing RA (100 nM) into Bead/DC-based, TGF-/IL-2-conditioned culture 
resulted in marginal improvement with 25.3% (d+18) nTreg being Foxp3+. In 
MLR assays, nTreg expanded with TGF-/IL-2 exerted more potent suppression 
than cells conditioned with IL-2 alone. In vivo, Beads/DC-expanded, TGF-/IL-
2-conditioned nTreg synergized with transient host T cell-depletion (anti-Thy1.2 
mAb i.p. 50 g at d-3 25 g on d+1) in C57BL/6 mice to suppress BALB/c heart 
allograft rejection with 57.1% (n=7) and 100% (n=7) allografts surviving over 
100 days when 4x107 or 8x107 cells/mouse were injected immediately post-
transplant, respectively. Anti-Thy1.2 treatment alone led to only 10% long-term 
survival. Infused nTreg survived long-term (5.8% circulating T cells (8x107 cell 
dose) or 1.2% (4x107 cell dose) at d+7 post-transplant) and expressed high level 
Foxp3 (38.556.7%) in vivo. Interestingly, Beads/DC-expanded, TGF-/IL-2/RA-
conditioned nTreg expressed even higher Foxp3 (57.6~69.8%) during in vivo 
suppression of allograft rejection. However, post-transplant RA treatment did 
not enhance expansion of and/or conversion into host-derived Foxp3+ Treg (16.4% 
vs. 21.7% in controls at d+7 post-transplant). Long-term surviving allografts 
showed characteristics of acquired immune privilege with cellular infi ltrates that 
were Foxp3+, TGF-+, IL-10+ and indoleamine 2,3-dioxygenase (IDO)+, although 
signs of mild to moderate chronic rejection were still evident.
Conclusions: AlloAg-specifi c Foxp3+CD4+CD25+ nTreg synergize with 
peritransplant host T cell-depletion to induce long-term survival of allografts in 
wild-type mice. Our ongoing study has shown >50% (d+18) of ex vivo-expanded 
nTreg were Foxp3+ when cells were cultured in the presence of trichostatin A, 
an histone deacetylase inhibitor, in the aforementioned Beads/DC-based, TGF-/
IL-2/RA-conditioned protocol. The effi cacy of these cells to suppress allograft 
rejection or to induce allograft tolerance will be tested in vivo.
POSTER BOARD NUMBER P4 – 258
ALLOREACTIVE REGULATORY T CELLS CAN 2208 
CONTROL THE EARLY STAGE OF REJECTION BY THE 
DIRECT PATHWAY.
C. Daniel, M. Belghith
Inrs Institut Armand Frappier
The reactivity of the 2.102 T cell clone with two independent ligands, the 
alloantigen I-Ep and the self-restricted ligand Hb(64-76)/I-Ek, provides a unique 
opportunity to study both direct and indirect pathways of allorecognition. 
Although the two pathways have similar kinetics of rejection, the initiation 
of immune responses leading to graft rejection is different. Using ab T cell-
defi cient mice reconstituted with purifi ed CD4+ T cells from 2.102 TCR Tg 
mice, we fi rst evaluated the infi ltration of cells in grafts and lymphoid organs 
by fl ow cytometry at various times post transplantation. 2.102 CD4+ T cells 
were detected inside the graft as early as 7 days in the direct pathway and their 
frequency decreased by day 11. This infi ltration correlated with high expression 
of IFN-γ and IL-17 mRNA, as determined by qRT-PCR analyses. In contrast, 
no signifi cant infi ltration could be observed before day 11 after priming through 
the indirect pathway, infi ltration that peaked at day 15, and which correlated 
with a progressive transition from Th1 (IFN-γ) to mixed Th1/Th2 (IL-4) 
mRNA expression. These observations suggested that a regulatory mechanism 
was responsible for this delay in graft rejection by the direct pathway, in spite 
of early effector T cells infi ltration. qRT-PCR analyses showed that direct 
pathway alloreactivity was specifi cally associated with the expression of Foxp3 
in the allografts. Furthermore, depletion of the CD25+ cells in the population 
of purifi ed CD4+ T cells adoptively transferred signifi cantly accelerated 
allograft rejection by the direct pathway only, suggesting that regulatory T 
cells are able to control the early stage of allograft rejection, but these are 
eventually overwhelmed by the burst of T cell activation that occurs later in the 
draining lymph nodes. Studies are currently in progress in order to confi rm this 
hypothesis. (Supported by CIHR and Fondation Armand-Frappier).
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ISOLATION AND CHARACTERIZATION OF A 2209 
CD45+ SUBSET OF FIBROBLASTIC CELLS IN CARDIAC 
ALLOGRAFTS UNDERGOING CHRONIC REJECTION
A. Klein, G. Wu, Y. He, H. Wang
Cedars-Sinai Medical Center
Objective: Fibrocytes which express the phenotype CD34/CD45/αSMA/ 
Collagen-1 are believed to be one of the progenitors of myofi broblasts in 
healing wounds and organ fi brosis. However, their role in allograft fi brosis 
remains unclear. 
Materials and Methods: Studies have been conducted using a rat model of 
heart transplant (LEW-to-F344). Intragraft fi broblastic cells (IFC) were isolated 
and characterized to qualify 1) the presence of fi brocytes in allografts; and 2) 
phenotypic characteristics of the CD45+ and CD45- IFC. 
Results: Dish-adherent fi broblastic cells were isolated from cardiac allografts, 
native hearts and bone marrow of the recipients. These cells were then analyzed 
for CD45 expression using fl ow cytometry. Dynamic changes in the proportion 
of CD45+ and CD45- cells were observed in primary cultures. Approximately 
60% of intragraft fi broblastic cells (IFC) were CD45+ at 24 hours in culture. The 
cells dramatically decreased to 30% at day 4, 15% at day 7 and <1% at day 14 of 
cultures; while CD45-negative fi broblasts increased proportionally. CD45+ IFC 
co-expressed low levels of αSMA, displaying a CD45+/αSMAdim cytometric 
phenotype whereas CD45- cells expressed high levels of αSMA, displaying 
a CD45-/αSMAhigh phenotype. In contrast, cardiac fi broblasts isolated from 
native hearts only had 2% cells expressing CD45 at day 7 and this percentage 
diminished quickly over time. qPCR studies showed that CD45+ IFC expressed 
stem cell marker CD34, hematopoietic markers CD14, CD11b, CD45, low 
levels of αSMA and pre-collagen-α1, a phenotype characteristic of fi brocytes. 
These cells also expressed high levels of PDGFα, TGF-β, MMP-9, IL-1 and 
TNF-α, which are important infl ammatory/fi brogenic factors. In contrast, 
CD45-/αSMAhigh cells expressed high levels of pre-collagen α1, αSMA, and 
TIMP-1, a myofi broblast phenotype. Microscopic examination demonstrated 
that CD45+ IFC are small oval or spindle shaped, and co-express cytoplasmic 
non-stress α-actin. To study whether intragraft fi brocytes can give rise to 
myofi broblasts, CD45+ and CD45- fi broblastic cells isolated from primary IFC 
cultures were evaluated for myofi broblast differentiation in cultures stimulated 
with TGF-β. At 24-48 hours cultures CD45+ cells exhibited a small oval or 
spindle-shaped morphology. Few myofi broblasts were sporadically seen. A few 
polygonal cells emerged at 72-96 hours in cultures. The cells expressed αSMA, 
as demonstrated by immunofl uorescent microscopy and grew into αSMA 
expressing colonies in 7-9 days. In comparison CD45- IFC at day 2 cultures 
exhibited typical fi broblast morphology and expressed redundant stress αSMA. 
Similar patterns of CD45+ cell-to-myofi broblast transition were also observed 
in cultures of the blood fi brocytes and bone marrow stromal cells. 
Conclusion: The data demonstrate that two distinct subpopulations of 
fi broblastic cells exist in chronically rejecting allografts. The CD45- subset 
represents the end-differentiated fi broblasts (myofi broblasts). The CD45+ 
subset, on the other hand, exhibits a phenotype consistent with description 
of fi brocytes. Since the CD45+ subset has the potential to differentiate into 
myofi broblast and the ability to produce pro-infl ammatory cytokines these cells 
may play important roles in allograft fi brogenesis, either as the precursors or/
and the regulators of myofi broblasts. 
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IMMUNE RESPONSE IN OLDER TRANSPLANT 2210 
RECIPIENTS IS CHARACTERIZED BY AN IMPAIRED 
EFFECTOR AND INTACT REGULATORY T-CELL RESPONSE
C. Denecke1, X. Ge1, I. Kim1, D. Bedi1, A. Jurisch1, J. Pratschke2, 
P. Neuhaus2, S. Tullius1
1Div of Transplant Surgery, BWH, 2Dept of Surgery, Charite Berlin
Elderly recipients represent the most rapid growing segment of patients on the 
waiting list. However, little is known about age-dependent alterations of the 
immune response in organ transplantation. We examined age dependent T-cell 
functions in a transgenic mouse transplant model.
Effector T-cell phenotype, -function, cytokine production and regulatory T-cell 
function were analyzed in 3 and 18mths old B6 mice. In an in vivo transplant 
model, BL/6 nude mice were reconstituted with 2x106young or old transgenic 
alloantigen-specifi c CD4+T-cells and engrafted with bm12 skin grafts. T-cell 
phenotype and cytokine secretion were analyzed in all lymphatic compartments.
Splenocytes of naïve old B6 mice contained signifi cantly higher frequencies of 
T-cells with an effector/memory phenotype (CD4+CD44highCD62Llow and 
CD8+CD44highCD62Llow; p<0.005). However, in vitro proliferation (MLR: 
p<0.005) and IFNγ;-production (ELISPOT (p<0.001) were signifi cantly 
reduced in aged mice 
Older wild-type (WT) skin transplant recipients showed a modifi ed immune 
response. While graft survival in elderly native recipients was prolonged (11 
vs. 13 d, p= n.s.), increasing recipient age was associated with an impaired 
proliferation and IFNγ;-production. Signifi cantly diminished numbers of 
early activated (CD69+) T-cells, IFN&#61543;+ – and IL-2+ T-cells and 
CD4+ T-cells expressing CXCR3+ and CCR5+ were observed. In parallel, 
regulatory functions remained age-independent as alloantigen-specifi c 
CD4+CD25+FoxP3+ T-cells isolated from sensitized old mice demonstrated a 
dose-dependent well preserved suppressor function. 
We then examined the impact of age in a transgenic skin transplant model 
analyzing the alloantigen –specifi c CD4+ T-cell response: Rejection kinetics were 
also moderately prolonged with increasing recipient age in this model (young vs. 
old: 10.1 vs. 14.3 d, n.s.) However, the T-cell response was signifi cantly different: 
Fewer numbers of activated CD4+CD25+ (spleen and draining lymph node, 
dln) and effector/memory phenotype T-cells (CD4+CD44highCD62Llow) (dln) 
were found after transfer of old T-cells (p<0.05). In parallel, T-cell migration was 
impaired since less CXCR3+ and CCR7+ T-cells were detected in dln following 
the transfer of old T-cells (total cell numbers x104: CXCR3+: 10.9±4.2 vs.0.95 
±0.2, CCR7+: 4.7±1.0 vs. 0.35±0.2, p<0.05). As a consequence, intragraft CD4+ 
T-cell infi ltration was reduced compared to recipients of young T-cells. 
In summary, elderly mice showed an overall impaired effector T-cell response. 
In vivo allospecifi c CD4+ T-cell activation and migration was delayed in elderly 
transplant recipients while regulatory -T-cell function remained preserved.
These experimental fi ndings may have important clinical implications for an 
age-adapted immunosuppression.
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THE IMMUNOLOGICAL ASPECTS OF ANTI-HISTONE 2211 
H1 AUTOANTIBODY ON LYMPHOCYTE BIOLOGY IN LIVER 
TRANSPLANTATION TOLERANCE
T. Nakano1, S. Goto1,2, L.W. Hsu1, C.Y. Lai1, J.L. Wong1, S. Kawamoto3, 
T. Goto4, K. Ono3, Y.F. Cheng1, C.L. Chen1
1Liver Transplantation Program, Chang Gung Memorial Hospital-Kaohsiung 
Medical Center, 2Iwao Hospital, 3Department of Molecular Biotechnology, 
Graduate School of Advanced Sciences of Matter, Hiroshima University, 
4Kazusa Institute of Drug Discovery and Faculty of Pharmaceutical Sciences, 
Josai International University
Aims: We previously demonstrated the immunosuppressive activity of anti-
histone H1 autoreactive antibody (Ab) induced in a rat spontaneous liver 
transplantation (LTx) tolerance model (Transplantation 2004; 77: 1595) and 
a clinical drug-free patient after living related LTx (Transplantation 2007; 83: 
1122). This study aimed to explore the immunological aspects of anti-histone 
H1 Abs on intracellular signaling pathway via T cell receptor (TCR).
Methods: Purifi ed T-cells were cultured on anti-CD3 Ab-immobilized dishes 
with anti-histone H1 Abs or standard immunosuppressant cyclosporine (CsA) 
for 0-6 hr. Western analyses were performed to evaluate the effects of anti-
histone H1 Abs and CsA on mitogen activated protein kinase (MAPK), nuclear 
factor-kappaB (NF-kB) and calcineurin signaling pathways.
Results: Anti-histone H1 Ab possesses immunosuppressive activity with 
a comparable ability to block T-cell activation as the CsA. Western analyses 
revealed that anti-histone H1 Ab altered the phosphorylation levels of 
extracellular signal-regulated kinase (ERK), p38, and inhibitory NFkB (IkBa) via 
TCR signaling. We also found lower expression of calcineurin due to treatment 
with anti-histone H1 Ab. Intriguingly, we observed a higher phosphorylation of 
c-Jun N-terminal kinase (JNK) during TCR signaling with anti-histone H1 Ab, 
while CsA downregulated the JNK activity, suggesting the existence of different 
immune regulative mechanism(s) between anti-histone H1 Ab and CsA.
Conclusions: These results suggest a therapeutic advantage of anti-histone 
H1 Ab compared with current immunosuppressants and that the selective 
regulation of MAPK, NF-kB and calcineurin signaling may be important in the 
T-cell growth arrest led by anti-histone H1 Ab.
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THE INVOLVEMENT OF GAMMA-DELTA T 2212 
LYMPHOCYTES IN LIVER TRANSPLANT TOLERANCE
W. Li2, F. Malone1, K. Carper2, J. Reyes2
1Children’s Hospital & Regional Medical Center, Seattle, WA, 2University of 
Washington, Seattle, WA
The gamma delta T lymphocytes are considered a non-conventional T cell subset 
and are found throughout the body, but mainly located in the cutaneous, gastric 
and intestinal epithelia as reported. The role of gamma delta T cells in innate 
and adaptive immunity is just emerging; remaining poorly understood in many 
aspects. It has recently been shown that gamma delta T cells have an important 
anti-tumor and anti-infectious effect. The involvement of gamma delta T cells 
in the immunologic response to hematopoietic cell transplantation and the 
development of graft versus host disease remains controversial, with divergent 
results depending on the murine strains and model systems employed. Whether 
gamma delta T cells are involved in solid organ transplantation is understudied. 
In this study, we have characterized the gamma delta T cell population in mouse 
livers and spleens, and further evaluated their contributions in liver transplant 
tolerance throughout the time course of posttransplantation by using our unique 
model of mouse spontaneous transplant tolerance. Our studies revealed that 
gamma delta T cells mainly reside in the liver and comprise about 20% of the 
population of liver nonparenchymal cells in either naïve B6 or C3H mice. Most 
of those cells are CD4, CD8, and NK1.1 negative. The percentage of gamma 
delta T cells was decreased in the liver grafts in the spontaneous tolerance model 
from day 1 to day 100 posttransplantation; they were all below 10% in the liver 
grafts vs 20% in naïve mice. In contrast, the percentage was increased in the 
rejected liver grafts, which was induced by anti-CTLA4 and anti-CD25 mAb 
administration. The percentages of gamma delta T cells were 33% and 35% in the 
anti-CTLA4 and anti-CD25 mAb treated recipients at day 5 posttransplantation, 
respectively. There was a slightly increased frequency of CD8 expression on 
gamma delta T cells in the tolerated livers post transplantation (10-20%), but 
not in the rejected livers. Thus, the data from our preliminary study suggests that 
gamma delta T cells are involved in the liver transplant tolerance and rejection 
processes, but may favor the induction of liver graft rejection.
POSTER BOARD NUMBER P4 – 263
IL-6R BLOCKADE ENHANCES TREGS AND LIMITS 2213 
TH17 CELLS IN PROTEINURIC RENAL DISEASE
Y.M. Wang1, G.Y. Zhang1, Y. Wang2, T.P. Polhill1, M. Hu1, D.C.H. Harris2, S.I. 
Alexander1
1Centre For Kidney Disease, Children’s Hospital At Westmead, Sydney, NSW. 
Australia., 2Centre for Transplant and Renal Research, University of Sydney 
at Westmead, Sydney, NSW, Australia.
IL-17-producing T lymphocytes comprise a distinct lineage of pro-infl ammatory 
T helper cells, termed Th17 cells. IL-6 is crucial with TGF-b in the development 
of Th17 cells. Blockade of the IL-6R may shift T cells from Th17 to regulatory 
T cells (Tregs). 
Aim: The aim of this study was to evaluate whether IL-6R blockade inhibits 
Th17 and enhances Tregs in a model of chronic proteinuric renal injury. 
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Methods: Adriamycin nephropathy was induced in BALB/c mice by 
a single injection of Adriamycin. Anti-IL-6R or isotype controls were 
administered to mice one day prior to Adriamycin administration, and on 
days 6, 13 and 20. 
Results: Urinary protein excretion was reduced in ADR mice receiving anti-
IL-6R (ADR+anti-IL-6R), compared to those not receiving antibody (ADR) 
and those receiving isotype control (ADR+isotype). Serum creatinine, 
glomerular sclerosis and tubulointerstitial damage were signifi cantly lower in 
the ADR+anti-IL-6R group than in the ADR group and ADR+isotype group 
(p<0.01). Body weight was maintained in the anti-IL6R group. Enhanced 
Foxp3 expression occurred in the IL-6R blockade group. In vitro blockade 
with IL-6R inhibited TH17 cells induction and enhanced generation of Foxp3 
Tregs by TGF-β. 
Conclusions: We conclude that antibody blockade of IL-6R can be used 
to protect against renal damage in a murine model of chronic immune 
injury. Protection may be due to enhanced Treg numbers and limiting Th17 
development.
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LIVER STELLATE CELLS, AS NON-PROFESSIONAL 2214 
ANTIGEN-PRESENTING CELLS, PREFERENTIALLY EXPAND 
TREG CELLS IN AN IL-2 DEPENDENT MANNER
G. Jiang1, L. Wang2, J. Fung2, S. Qian1,2, L. Lu1,2
1Department of Immunology, Lerner Research Institute, Cleveland Clinic, 
2Department of General Surgery, Cleveland Clinic
Liver tolerance is demonstrated by spontaneous acceptance of liver allografts 
in many species, but hepatocytes are acutely rejected in the same donor-
recipient combinations, suggesting an immunosuppressive effect of liver 
nonparenchymal components. Some tissue cells, upon activation, acquire 
ability to present antigens, and act as non-professional APC leading to 
immune suppression. Thus, hepatic stellate cells (HpSC) constitutively 
express MHC class I, CD80 and ICAM-1. The expression of MHC class 
II, CD80, B7-H1 and IL-10 is upregulated following IFN-ƒ× activation, 
which conferred ability to stimulate allogeneic CD4+ T cell proliferation. 
However, activated (a) HpSC demonstrate profound immune suppressive 
activity, and effectively protect co-transplanted islet allografts from rejection. 
The underlying mechanisms remain unclear. In this study, we examined 
responses of allogeneic CD4+ T cells to aHpSC, compared to professional 
APC, dendritic cells (DC). CD4+ T cells of BALB/c (H2d) were cultured 
with irradiated B6 (H2b) aHpSC, at 10:1 for 5 days promoted CD25+ cells 
from 5% to 13%, among which 85% were FoxP3+. Addition of expanded 
CD4+CD25+ cells inhibited proliferative responses in reporter T cells (CD4+ 
or CD4+CD25- cells) in a dose dependent manner. Whereas, DC stimulated 
pronounced allogeneic CD4+ T cell proliferation with CD25+ cells 
increasing to 63.7%, but majority (81%) were Foxp3- effector cells, and did 
not show immune suppressive activity. Neutralization of IL-2 by anti-IL-2 
mAb almost totally eliminated the ability of aHpSC to expand Treg cells. To 
determine the origin of Foxp3+ T cells, aHpSC were cultured with purifi ed 
CD4+CD25+ or CD4+CD25- cells, showing that FoxP3+ cells were only 
differentiated from CD4+CD25+, which required exogenous IL-2 (100 U/
ml). This was confi rmed by using Thy1.1+ congenic mice. CD25- cells from 
normal BALB/c (Thy1.1-) were mixed with CD25+ cells from Thy1.1+ mice 
at 10:1 ratio. The CD25+FoxP3+ cells was increased to 13.8% following 
5 days culture, in which 95.2% were Thy1.1+, similar to the composition 
of the original CD4+CD25+ cells that contained 93.4% Thy1.1+ cells. In 
vivo, systemic administration of aHpSC (106) into allogeneic recipients 
resulted in signifi cant increases in CD25+FoxP3+ cells in lymph nodes and 
spleen. These results strongly suggest that professional APC generate mostly 
effector cells, whereas, non-professional APC selectively drive Tregs, which 
may explain their capacity of inducing T cell hyporesponsiveness. This may 
represent a portion of complex mechanisms by which immune responses are 
regulated in the liver.
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REGULATION OF ALLOSPECIFIC T CELL RESPONSES 2215 
BY DONOR ANTIGEN PRESENTING CELLS DEPENDS ON 
LOCAL GENERATION OF COMPLEMENT C5A
K. Li, Q. Peng, S. Sacks, W. Zhou
King’s College London
The innate system of immunity an important role in ischemia-reperfusion 
injury and allograft rejection. The early stages of infl ammatory processes 
are accompanied by complement activation. One biological consequence of 
this activation is the release of potent infl ammatory anaphylatoxins, C3a and 
C5a, which have been reported to regulate a range of infl ammatory responses. 
We previously reported that DCs express C3aR and C5aR, and C3a-C3aR 
interaction has a positive impact on murine BM DCs, in terms of activation 
phenotype and capacity for Ag uptake and allostimulation. However, the role 
of C5a in modulating DC function remains unclear. The aim of this study is 
to investigate the role of local C5aR signalling in modulating murine BM DC 
function and subsequent regulation of the allospecifi c T cell response. We fi rst 
evaluated if C5a-C5aR interaction could result from local expression of factors. 
Our results showed that C5aR mRNA was detected in WT DCs at different 
stage of DC culture by RT-PCR, and C5a was detected by ELISA in the culture 
supernatants from different stages of DC culture. We next determined if C5a-
C5aR interaction modulates DC function in allospecifi c T cell stimulation 
in vitro and in vivo. We found that BM DCs cultured from C5aR-/- mice or 
treated with C5aR antagonist (C5aRa, W54011) exhibited a less activated 
phenotype (producing signifi cantly less IL-12 and more IL-10, in response to 
LPS stimulation); both C5aR-/- and antagonist-treated DCs (LPS stimulated) 
showed reduced capacity to stimulate naïve alloreactive T cells, as measured 
by IFN-γ; production and thymidine uptake. As regards interaction in vivo, 
following i.p. administration of the C5aRa-treated DCs into allogeneic mice for 
10 days, ex vivo mixed lymphocyte reaction showed that CD4+ T cells from 
those recipients have reduced thymidine uptake, but increased IL-4 production 
compared to that with untreated DCs. Conversely, DCs treated with C5aR 
agonist (C5a) exhibited a more activated phenotype (producing more IL-12 
and less IL-10) and were more potent in allospecifi c T cell stimulation. 
Our fi ndings demonstrate that murine BM DCs can express C5aR and C5a 
can be generated locally; C5a-C5aR interaction up-regulates murine BMDC 
activation and their allostimulatory capacity. Thus, targeting C5a-mediated 
signal may be able to prevent allograft injury.
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REGULATORY T CELLS INHIBIT THE PROLIFERATION 2216 
OF LYMPHOCYTES THROUGH TIM-3-TIM-3L PATHWAY
J. Yuan1, K. Wu2, Y. Xu2, Z.K. Chen2
1Department of Nephrology, Tongji Hospital, 2Institute of Transplantation, 
Tongji Hospital
Objective: To explore the role of TIM-3-TIM-3L pathway to modify the 
immunosuppressive effect of natural Treg (nTreg) and induced Treg (iTreg).
Methods: Firstly, we separate nTreg from C57BL/6 by MACS and induce 
na&iuml;ve T cells to differentiate into iTreg by TGF-¦Â1. And then Foxp3 and 
TIM-3L expression in these Treg, and the ability of inhibiting the proliferation 
of lymphocytes were measured. The TIM-3-TIM-3L pathway was blocked 
with TIM-3.Ig and anti-TIM-3, which could combine with TIM-3L and 
TIM-3 expressed on the surface of nTreg and iTreg respectively. And then, the 
immunosuppressive ability of these Treg was measured by MLC.
Results: Both of nTreg and iTreg expressed Foxp3, and could inhibit 
proliferation of lymphocytes. TIM-3L(galectin-9) mRNA was measured in 
nTreg and iTreg with RT-PCR. The expression of galectin-9 in nTreg and 
iTreg was lower than that in splenocytes(p<0.05). Immunosuppressive effects 
of nTreg and iTreg were partially reduced with TIM-3.Ig interference. It was 
weaker than control group(p<0.05). But anti-TIM-3 did not affect nTreg and 
iTreg obviously(p>0.05).
Conclusion: TGF-¦Â1 could induce iTreg population. nTreg and iTreg could 
express TIM-3L, and inhibited the proliferation of lymphocytes through TIM-
3-TIM-3L pathway. Even while TIM-3-TIM-3L pathway was blocked, Treg 
could still inhibit the lymphocytes to proliferate partly. These results imply that 
TIM-3-TIM-3L pathway was not the only mechanism of Treg function.
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RAPAMYCIN PREFERENTIALLY BLOCKS 2217 
THE EXPANSION OF POTENTIALLY TOLEROGENIC 
PLASMACYTOID DENDRITIC CELLS IN VIVO
A.W. Thomson1,2, H.R. Turnquist1
1T. E. Starzl Transplantation Institute And Department of Surgery, University 
of Pittsburgh, Pittsburgh, PA, 2Department of Immunology, University of 
Pittsburgh
Introduction: Previously, it has been shown that rapamycin (RAPA), a novel, 
‘tolerance-sparing’ immunosuppressive pro-drug with anti-proliferative 
properties, inhibits myeloid (m) dendritic cell (DC) differentiation and 
maturation in vitro. In addition, RAPA decreases the number of CD11c+ DC 
in the mouse spleen and suppresses the massive expansion of total CD11c+ 
DC typically observed following administration of the endogenous DC growth 
factor, fms-like tyrosine kinase 3 ligand (Flt3L). However, the infl uence of 
RAPA on plasmacytoid (p) DC,- the principal type-1 IFN producers in the body, 
that regulate innate and adaptive immune responses, and promote experimental 
transplant tolerance, has not been evaluated. 
Methods: DC were propagated from bone marrow cells for 10 days (d) in 
Flt3L, in the absence or presence of a clinically-relevant concentration of 
RAPA (10 ng/ml). In addition, DC were mobilized in C57BL/10 mice by 
i.p. administration of Flt3L (10 μg/d for 10 d; d1-10). Groups of untreated 
and Flt3L-treated animals also received RAPA (0.5 mg/kg/d i.p.; d3-10). 
On d11, DC were isolated from spleen preparations by density gradient 
centrifugation and CD11c+ DC positively selected (purity >97%) using anti-
CD11c immunomagnetic beads. Identifi cation of mDC (CD11c+CD11b+) and 
pDC (CD11cloCD11b-B220+) was completed by assessment of surface Ag 
expression by fl ow cytometry.
Results: RAPA suppressed pDC and mDC generation in vitro. RAPA-DC-treated 
BM cultures had only 22% of the pDC and 40% of the mDC found under control 
conditions. RAPA also reduced the steady-state absolute numbers of splenic DC 
in normal mice. Both mDC (54% of vehicle-treated control) and pDC (24%) 
numbers were reduced signifi cantly by RAPA administration. Furthermore, 
administration of RAPA, when given concurrently with Flt3L, blunted the 
typical profound expansion of mDC. Specifi cally, Flt3L and RAPA-treated mice 
displayed a 47-fold increase over control steady state numbers compared to the 
145-fold increase in mice treated with Flt3L alone. Flt3L-induced expansion of 
pDC was impacted to a much greater extent by RAPA, as the absolute numbers 
of pDC increased only 6-fold over control steady state numbers compared to a 
51-fold increase in absolute splenic pDC in Flt3L-treated mice. 
Conclusion: These data identify RAPA as a selective suppressor of pDC 
generation. This has signifi cant clinical implications, given the use of RAPA 
following organ transplantation and the importance of pDC in IFNα production. 
Likewise, pDC have been implicated as critical antigen presenting cells in the 
secondary lymphoid tissue and instrumental in the promotion of experimental 
transplant tolerance. As such due attention to these possible disparate effects of 
RAPA on potentially immunoregulating cell populations will be necessary to 
optimize therapeutic tolerogenic regimens for safe promotion of tolerance.
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DIFFERENTIAL EXPRESSION OF FOXP3 IN 2218 
PLASMACYTOID AND MYELOID DENDRITIC CELLS (DC) 
GENERATED FROM RAT BONE MARROW CELLS (BMC)
H. Kimura1, A. Tsuji2, H. Mizuguchi3, X-K. Li1, N. Fuji-Funeshima1, R. 
Haba1, K. Matsumoto1, H. Saito1, Y. Kitazawa1, I. Nozawa4
1National Research Center For Child Health & Development, 2National 
Institute of Radiological Sciences, 3National Institute of Biomedical 
Innovation, 4RNAi Co., Ltd.
Backgrounds: Currently Foxp3 is considered to encode a transcription 
suppressor with a forkhead/winged helix motif at the carboxy terminus, a 
C2H2 zinc fi nger domain, and a 3-heptad Zip motif. 
Heretofore, numerous studies have shown that Scurfi n, a protein of FoxP3 
gene, is a master gene for regulatory T cells (Treg) that down regulate T cell 
function in general.
Thus it has been reported that Foxp3 is exclusively expressed by a sunset of 
T cells, i.e., CD4+CD25+ T cells, and currently is it representing the most 
defi nitive marker for this population.
To the best of our knowledge, there has been no single study that specialized 
antigen presenting cells (APC), dendritic cells (DCs) express Foxp3. 
Materials & Methods: Employing DCs generated from long term culture 
driven by Flt3 ligand and IL-6, i.e., currently classifi ed as plasmacytoid DCs, 
PCR cloning of cDNA obtained from rat DC was completed and real time PCR 
was applied to measure the mRNA of cytokines related to immune regulation.
Results: Sequencing of 29 cDNA clones revealed 3 isoforms of rat Foxp3, i.e., 
major isoform 1, and two additional minor forms of 2 and 3.
Real time RT-PCR analysis revealed that the level of Foxp3 expression 
was time dependent and ultimately reached the same as or higher than 
CD4+CD25+ T cells.
Although western blotting analysis revealed that isoform 1 was indeed 
expressed by a subset of DCs and the Foxp3+ DCs were found to express a high 
level of various immunoregulatory cytokines and molecules, such as IL-10, 
TGF-b, and iNOS, Foxp3+ DCs were found to be fully functional in terms of 
antigen presentation to nai Nve T cells.
In contrast to this, DC generated from a short-term culture driven by GM-CSF 
and IL-4, i.e., myeloid DCs, did not express Foxp3. 
It appears that Foxp3 is expressed differentially on a subset of DCs such as 
plasmasytoid DCs and myeloid DCs.
Conclusion: Inasmuch as Foxp3 appears to be a key element of cause and result 
of the fatal lymphoproliferative disorder of scurfy mice and a human X-linked 
autoimmune and infl ammation syndrome, our fi nding would give a new insight 
in the function of Foxp3 that plays a role of immune regulation by DCs. 
Taken together, our fi ndings indicated that Foxp3 is not only a master gene for 
the developmental program of CD4+CD25+ Treg cells rather it may represent 
a more broader function of the gene regulation responsible for a subset of 
specialized antigen presenting cells such as DCs and macrophages.
POSTER BOARD NUMBER P4 – 269
RENAL FUNCTION IS STRONGLY PREDICTIVE OF A 2219 
RENAL TRANSPLANT PATIENT’S REGULATORY T CELL (T 
REG) PHENOTYPE, USING FLOW CYTOMETRIC ANALYSIS 
OF CD127 TO IDENTIFY T REGS WITHIN THE PERIPHERAL 
BLOOD.
D. Gracey1, B. Pussell1, J. Charlesworth1, C. Zhu2, B. Fazekas de St Groth2
1Prince of Wales Hospital, 2Centenary Institute
Assessment of the role of regulatory T cells within the transplant clinic has been 
hampered by the complexity of the techniques involved in their identifi cation, 
as well as the inability to reliably distinguish between activated CD4+ cells, 
and true regulatory T cells. We have utilised a novel fl ow cytometric approach 
using the expression of interleukin (IL)-2 and IL-7 (CD 127) to discriminate 
between regulatory and activated T cells. This technique may be undertaken 
using a sample of peripheral blood, with subsequent fl ow cytometric analysis 
using a standard protocol. We wished to investigate its clinical utility amongst 
renal transplant patients. 
The immune phenotype of the renal transplant population was compared to 
those with CKD, those on dialysis and to the normal population. Clinical 
correlates were sought, with particular attention paid to the effects of renal 
function. Samples of peripheral blood (n=20 in each group) were assayed 
using six-colour fl ow cytometry to identify a highly purifi ed population of 
T regs (CD25+, CD127lo). Phenotypic analysis further classifi ed these cells 
as naïve, or effector/memory. An individual’s serum creatinine and eGFR 
were highly predictive of T reg phenotype. The relationship between renal 
function and effector/memory cell number was strongest (for serum creatinine 
R=0.587, p<0.001, for eGFR R=-0.532, p<0.001), with increasing numbers 
of effector/memory T regs demonstrated with increased creatinine. There 
was also a trend for increased numbers of naïve memory cells with declining 
renal function (for serum creatinine R=0.177, p=0.18). The renal transplant 
population demonstrated more normal T reg subset proportions, however, the 
overall number of T regs remained abnormally low compared to the normal 
population. 
This study indicates that the cell surface expression of IL-2 and IL-7 can 
be used to reliably identify a pure population of T regs in renal transplant 
patients, using a standard fl ow cytometric approach on a sample of peripheral 
blood. Additionally, we have demonstrated a strong relationship between 
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renal function and T reg phenotype, with higher numbers of both naive and 
effector/memory T regs with worsening renal function. The renal transplant 
group demonstrated proportions of regulatory subsets more reminiscent of the 
control group, possibly related to their superior renal function. The effect of 
immunosuppressive regimen upon T reg phenotype, if any, will be investigated 
using this technique.
POSTER BOARD NUMBER P4 – 270
CTLA4-IG INHIBITS THE INDUCTION OF ADAPTIVE 2220 
FOXP3+ T REGULATORY CELLS IN COCULTURES OF NAÏVE 
CD4+ T CELLS IN AN ALLOGENEIC DENDRITIC-T CELL MLR
R. Krishnan1,2, J. McIntyre1
1The Queen Elizabeth Hospital, 2University of Adelaide
Human CD4+CD25+ T regulatory cells express the transcription factor FoxP3 
and have potent immunosuppressive properties that may facilitate allograft 
tolerance. While naturally occurring CD4+CD25+ T regulatory (Treg) cells 
occur in the thymus, adaptive Treg expand in the periphery from naïve CD4+ T 
cells. In this study we investigated the ability of dendritic cells (DC) to induce 
the adaptive Treg population during an allogeneic DC-T cell MLR. The role of 
costimulation in the induction of adaptive Treg was verifi ed by fi rstly comparing 
the propensity of immature versus mature DC to generate FoxP3+ T cells and 
secondly by the blockade of costimulation with CTLA4-Ig fusion protein. 
Immature DC (iDC) were obtained by differentiating human monocytes with 
the cytokines IL-4 and GM-CSF and mature DC (mDC) were generated by the 
subsequent addition of TNF-α and prostaglandin-E2. Both iDC and mDC were 
co-cultured with immunomagnetically isolated naïve T cells (CD4+CD25-) for 
3 and 6 days in a stimulator: responder ratio of 1:100. Adaptive Treg were 
detected by fl ow cytometry by the expression of intracellular Foxp3 and the 
cell surface markers, CD4 and CD25. The FoxP3+ cells also showed low or 
no expression of the IL-7 receptor, CD127. At 3 days of co-culture, mDC 
produced higher numbers of Treg compared to iDC (14.7% vs 9.4%; p<0.001) 
however, by day 6 both populations of DC produced similar levels of Treg. 
Furthermore, immunomagnetically isolated CD25+ adaptive Treg obtained 
from both iDC and mDC co-cultures showed potent immunosuppression (74% 
inhibition compared to control; p<0.001) in the mixed lymphocyte reaction. 
CTLA4-Ig (100 ng/ml) added directly to the MLR inhibited T cell proliferation 
by 33.4±13.6% (p=0.02) and 12.1±5% (p=0.004) with iDC and mDC as 
stimulators, respectively. However, while CTLA4-Ig showed inhibition of the 
MLR it surprisingly demonstrated a reduction in the numbers of FoxP3+ Treg 
compared to untreated cocultures. 
In conclusion, this study shows that mature DC due to their increased 
costimulatory profi le are better inducers of adaptive Treg in an MLR compared 
to immature DC. Moreover, the blockade of the B7 costimulation pathway 
signalling mediated by CTLA4-Ig affects the propensity of dendritic cells to 
induce the generation of adaptive T regulatory cells.
POSTER BOARD NUMBER P4 – 271
CHRONIC ALLOGRAFT NEPHROPATHY IS 2221 
ASSOCIATED WITH REDUCED EXPRESSION OF FOXP3
T. Muthukumar, D. Dadhania, C. Snopkowski, R. Ding, C. Chang, B. Li, 
S. Seshan, V. Sharma, M. Suthanthiran
Nephrology and Transplantation Medicine, Cornell University Medical 
College, New York, NY, USA
A specialized subset of CD4+CD25+ T lymphocytes, termed regulatory 
T lymphocytes (Treg cells), is critical for suppressing autoimmunity and 
maintaining self-tolerance. Emerging data suggest that Treg cells may exert a 
cytoprotective role including protection of allograft. Treg cells express FoxP3, 
the X-linked forkhead/ winged helix transcription factor, and the non-redundant 
contribution of this specifi cation factor to immune homeostasis is vividly 
demonstrated by the occurrence of a fatal multi-focal infl ammatory disease in 
mice and humans with a loss-of-function mutation in the FoxP3 gene. 
In an experimental model of allograft tolerance, the relative levels of cytopathic 
cells and FoxP3+ Treg cells have been reported to impact allograft outcome, 
with higher levels of cytopathic cells compared to FoxP3+ Treg cells being 
associated with graft destruction whereas higher levels of Treg cells compared 
to cytopathic cells being associated with allograft tolerance (Zheng et al, 
Immunity. 2003).
Chronic allograft nephropathy (CAN) is a relentlessly progressive process. 
Both immune and non-immune mechanisms have been implicated in the 
pathogenesis of CAN. A defi ciency in Treg cells may contribute to the 
pathogenesis of CAN. Herein, we examined the novel hypothesis that Foxp3+ 
Treg cells are defi cient in renal allograft recipients with CAN and that the 
balance between cytopathic cells and Treg cells is “tipped” towards cytopathic 
T cells in subjects with CAN. 
We measured urinary cell mRNA levels for FoxP3, CD3ε, perforin and 18s 
rRNA from 76 renal allograft recipients. All urine samples were obtained 
at the time of allograft biopsy. Twenty-fi ve urine samples were obtained 
from 25 subjects with CAN and 51 urine specimens were obtained from 51 
subjects with normal protocol biopsies (Normal Biopsy). Transcript levels 
were measure by the use of pre-amplifi cation assisted real time quantitative 
PCR assay developed in our laboratory. mRNA levels were expressed as copy 
numbers per microgram of total RNA and were normalized using 18S rRNA 
copy numbers. The ratios FoxP3/ CD3ε and FoxP3/perforin were calculated 
and log transformed to reduce the skew. 
The log mean (±SE) ratio of FoxP3/ CD3ε was -3.49±0.42 in the 25 subjects 
with CAN and -1.28±0.45 in the 51 subjects with Normal Biopsy (Panel A, 
P=0.002, Mann –Whitney test); the FoxP3/ perforin ratio was -3.74±0.52 in the 
25 subjects with CAN and -0.87±0.38 in the 51 subjects with Normal Biopsy 
(Panel B, P= 0.0003, Mann –Whitney test).
Our fi ndings demonstrate that CAN is characterized by a defi ciency in Foxp3+ 
Treg cells, and that the balance between cytopathic T cells and Treg cells is 
“tipped” towards cytopathic T cells. In the BDC2.5/NOD.FoxP3 scurfy mice, 
Treg cells prevent destructive insulitis by restraining destructive T cells within 
the islets. Whether the lack of intragraft damage control by Treg cells contribute 
to CAN and whether the use of calcineurin inhibitor associated IL-2 inhibition 
contributes to Treg cell defi ciency remains unresolved. 
CHIMERISMCONCURRENT ORAL SESSION 149: 
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INTRACELLULAR RETENTION OF CD80/86 BY 2222 
DENDRITIC CELLS, UNLIKE TRYPTOPHAN CATABOLISM, 
AS A MECHANISM TO INDUCE REGULATORY T CELL-
MEDIATED DONOR-SPECIFIC TOLERANCE
A. Khan1, J. Harper1, S. Beutelspacher2, G. Lombardi3, M. McClure4, A. 
George1
1Department of Immunology, Imperial College London, 2University 
Eye Hospital, University of Heidelberg, 3Department of Nephrology 
and Transplantation, King’s College London, 4Jefferiss Research Trust 
Laboratories, Imperial College London
Background: Allogeneic T cell stimulation requires not only antigen-specifi c 
signals but also costimulatory signals, most importantly between CD80/86 on the 
antigen presenting cell (APC) and CD28 and CTLA4 on the T cell. Engagement 
of the T cell receptor in the absence of costimulation can lead to anergy and 
the subsequent induction of regulatory T cells (Tregs). T cell activation is also 
controlled by expression of the tryptophan-catabolising enzyme indoleamine 
2,3-dioxygenase (IDO). Depletion of this essential amino acid, and/or the 
production of tryptophan metabolites inhibits T cell proliferation.
Methods: In this study, a genetic approach to confer tolerogenic properties 
on murine dendritic cells (DCs) has been explored using lentiviral vectors, 
based on the Equine Infectious Anaemia Virus. Firstly, an intracellular method 
that prevents costimulation has been developed: A fusion protein consisting 
of CTLA4 and KDEL [an endoplasmic reticulum (ER) retention signal] 
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is expressed in DCs. The CTLA4-KDEL binds to CD80/86 in the ER and 
prevents expression of these proteins on the DC surface. A second approach 
uses an elevated expression of the IDO enzyme by transduced DCs.
Results: CTLA4-KDEL- or IDO-transduced DCs were unable to induce and/or 
sustain allogeneic T cell proliferation. However, using two-stage DC:T cell co-
culture assays, it was shown that CTLA4-KDEL-, but not IDO-transduced DCs, 
can induce donor-specifi c T cell anergy both in vitro and in vivo. Tolerance to 
both the direct and indirect pathways of alloantigen presentation was shown 
using CTLA4-KDEL-transduced DCs, and linked suppression was mediated 
by the generation of donor-specifi c Tregs. We have also shown reversibility of 
anergy in these T cells by the addition of exogenous IL-2 to rechallenge cultures. 
EIAV IDO-transduced DCs were unable to generate Tregs. Furthermore, it was 
demonstrated that DCs expressing IDO whilst lacking CD80/86 expression for 
potential ligation by CTLA4 (although CTLA4-CD80/86 ligation upregulates 
IDO, it downregulates T cell activation) failed to generate or sustain FoxP3+ 
Treg populations. The ability of the transduced DCs to induce tolerance to 
allografts was assessed in a corneal allograft model, in which rejection results 
predominantly from the indirect pathway. We have used strain combinations 
in which we have compared separately the effect of tolerance induction to the 
direct and indirect pathways on corneal allograft survival, and demonstrated an 
initial role of the direct pathway in corneal allograft rejection.
Conclusions: These results strongly support a clinical strategy to induce 
Treg-mediated, donor-specifi c transplantation tolerance using CTLA4-KDEL-
expressing, rather than IDO-expressing DCs.
POSTER BOARD NUMBER P4 – 273
THE SUPPRESSOR CD8 T CELL GENERATED IN THE 2223 
MIXED CHIMERA MEDIATES SUPPRESSIVE FUNCTION VIA 
IL-10 PRODUCTION IN CD4 T CELLS
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu 
University
Background: The acute and chronic rejection remain the major obstacle to the 
clinical organ transplantation. Utilization of regulatory cell populations can be 
provided for the improvement of the graft survival. Cyclophosphamide (CP) 
induced tolerance (CPIT) conditioning is a mixed chimerism based tolerance 
induction protocol, which consisted with donor splenocyte (SC) and CP. Long 
lasting donor mixed chimerism and donor skin graft tolerance were induced in the 
recipients with MHC matched and minor antigen mismatched donors. In the present 
study, we found that the CD8 T cell of the tolerance mice possess the suppressive 
function, which is mediated by the enhanced IL-10 production in CD4 T cells.
Method: DBA/2 (H-2d, Ly-5.1, Mls-a) and BALB/c (H-2d, Ly-5.2, Mls-b) mice 
were used as the donor and the recipient. IL-10 knockout (KO) recipient on BALB/c 
background was also used as the recipient. Recipient mice were treated with 100 
millions of donor splenocyte (SC) and 200mg/kg CP. Donor mixed chimerism and 
the clonal deletion on donor reactive Vb6 positive T cell population were followed 
by the fl ow cytometry. Donor skin grafting was performed on day 14. Recipients 
thymus, lymph nodes (LN) and splenocyte (SC) were harvested over 12 weeks 
after treatments, and CD8 positive cells were collected by magnetic cell sorting 
(MACS). The CD8 suppressive function was examined in vivo and in vitro. In 
vivo, secondary BALB/c recipient mice recieved donor DBA/2 or allogenic B10.
D2 (H-2d) heart grafts with 40 millions CD8 suppressor T cells from primary 
mixed chimeras. In vitro, the suppressor function on the CD4 responder T cells 
(Tresp) in mixed lymphocyte reaction was assessed by readout assay.
Results: Long lasting donor mixed chimerism and permanent acceptance of 
donor skin graft were observed in recipient mice. Permanent acceptance of 
donor DBA/2 heart grafts was observed in the secondary recipient mice with 
CD8 T cells, but not CD4 T cells, from primary chimera. If IL-10 KO mice 
were used as primary recipients, the donor mixed chimerism and the donor 
skin graft acceptance were similarly observed. CD8 T cells from IL-10 KO 
mixed chimera showed the comparable suppressive function to the CD8 T cells 
from WT chimera in vitro, suggestive that the IL-10 production from Tsupp 
cells is dispensable for the suppressive function. However, if na&#239;ve CD4 
T cells from IL-10 KO mice were used for Tresp and WT chimera for Tsupp, 
suppressive function was abrogated in vitro.
Conclusion: We found that the suppressor CD8 T cells were generated in 
the mixed chimera. Our results indicated that the suppressor T cell mediates 
suppressive function via promoting IL-10 secretion from CD4 T cells.
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INDUCTION OF THE DONOR MIXED CHIMERISM AND 2224 
TOLERANCE MEDIATED BY THE IMMATURE PHENOTYPE 
OF DONOR BONE MARROW DERIVED DENDRITIC CELLS
I. Shimizu, Y. Tomita, T. Onzuka, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu 
University
Background: The acute and chronic rejection remain the major obstacle to the 
clinical organ transplantation. Induction of donor mixed chimerism is one of 
the ideal methods to induce donor specifi c tolerance. Previously, we reported 
that the induction of donor mixed chimerism and the skin/heart graft tolerance 
in recipients with MHC matched and minor antigen mismatched donors in 
Cyclophosphamide induced tolerance (CPIT) conditioning, which consists 
with donor splenocyte (SC) on day 0 and Cyclophoshamide (CP) on day 2. To 
apply this protocol to the large animal model, the more refi ning protocol with 
less toxic conditioning may required. It was reported that the pretreatment with 
Flt3L to the donor mice expanded the feasibility of the induction of tolerance 
in MHC mismatched recipients with CPIT conditioning. In the present study, 
we evaluated the role of the immature or mature phenotype of the bone marrow 
derived dendritic cells (imBMDC) in CPIT conditioning. 
Method: C57BL/6xBALB/c F1 (CBF1, H-2b/d) and C57BL/6 (B6, H-2b) were 
used as donors and recipients. imBMDC was generated by 7 days culture of donor 
BM in the presence of GM-CSF (20ng/ml) and IL-4 (1000u/ml). To generate 
maBMDC, LPS (1ƒÊg/mL) was added in the last 8 hours of incubation. Recipient 
mice were injected of 1-3x107 imBMDC or maBMDC on day 0, 200mg/kg CP 
on day 2, followed with the whole body irradiation (3-5Gy) and 2x107 donor 
bone marrow cells (BMC) on day3. Donor skin grafting was performed on day 
14. Donor mixed chimerism was examined by fl ow cytometry.
Results: As previously reported, higher level of CD80/86 and CD40, as well 
as MHC Class I/II expression was observed in maBMDC comparing to the 
imBMDC. The maBMDC was used in the fi rst series of experiments. Donor 
mixed chimerism was not observed in the recipient mice after the treatments 
with donor maBMDC and CP, with 20 millions of BMC. Donor chimerism was 
still not observed by the additional treatment with T cell depletion on day -4, 
or 3Gy WBI on day 3. Minimal level of donor mixed chimerism was observed 
in 2 out of 6 recipient mice treated with maBMDC, CP, BMC and 5Gy WBI. 
In clear contrast, donor mixed chimerism with permanent acceptance of donor 
skin graft was observed in the all recipient mice treated with imBMDC, CP, 
3Gy WBI and BMC. The level of donor mixed chimerism was correlated with 
the amount of imBMDC, since higher level of chimerism was observed in the 
group of mice injected with 3 times more imBMDC.
Conclusion: These results indicated that the immature phenotype of DC, but not 
the mature phenotype, is able to induce tolerance in clinically corresponding F1 
into B6 model. Since large number of imBMDC can be generated from the low 
number of BMC, the newly modifi ed protocol can be appreciable to the large 
animal model.
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MYCOPHENOLIC ACID IMPEDES ANTIGEN 2225 
PRESENTING AND LYMPH NODE HOMING CAPACITIES OF 
HUMAN BLOOD MYELOID DENDRITIC CELLS
V.R. Cicinnati1,2, J. Hou2, M. Lindemann3, A. Radtke2, C.G. Klein1,2, 
G. Gerken1, S. Beckebaum1,2
1Department of Gastroenterology and Hepatology, University Hospital Essen, 
Germany, 2Department of General, Visceral and Transplantation Surgery, 
University Hospital Essen, Germany, 3Institute of Immunology, University 
Hospital Essen, Germany
Background: Mycophenolic acid (MPA) is the pharmacologically active 
compound of mycophenolate mofetil, a recently introduced immunosuppressive 
drug which inhibits the inosine monophosphate dehydrogenase and thereby 
constrains lymphocyte proliferation. Alloantigen-presenting dendritic cells (DC) 
are the key for initiating and priming the adaptive immune response leading to 
graft rejection. We investigated the effects of MPA on DC homeostasis with a 
particular emphasis on DC traffi cking properties. 
Methods: Isolated peripheral blood mononuclear cells (PBMC) from healthy 
donors were cultured in with MPA for 48 hours without the addition of exogenous 
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growth factors. Flow cytometric techniques were used for phenotypic and functional 
analysis of MDC within the cultured PBMC population. Freshly isolated MDC 
were employed for assessment of endocytotic and allostimulatory properties. 
Results: MPA exposure lowered the expression of CC chemokine receptor 
(CCR) 7 and increased the expression of CCR1 in MDC. In line with their 
CCR expression profi le, MPA treated MDC lessened their response to lymph 
node chemokines and at the same time showed an increasing migration towards 
infl ammatory chemokines. MDC cultured in the presence of MPA exhibited 
an immature phenotype with higher endocytotic capacity. MPA impaired also 
MDC activation in response to toll-like receptor 3 ligation and abrogated their 
capacity to stimulate allogenic T cells in mixed lymphocyte reaction. 
Conclusions: MPA interferes with the initiation of acquired immunity by abating 
lymph node homing and allostimulatory capacity of MDC. MPA treatment of 
patients after solid organ transplantation may promote allograft tolerance.
POSTER BOARD NUMBER P4 – 276
IMMUNE TOLERANCE INDUCED BY EXOSOMES 2226 
DERIVED FROM REGULATORY DENDRITIC CELLS
H. Fan, Y. Liu, L. Zhao
Shanghai Blood Center
Background: Exosomes are membrane nanovesicles generated by reverse 
budding of the limiting membrane of multivesicular late endosomes. Exosomes 
originating from dendritic cells are thought to play a role in either an immuno-
stimulating or suppressive manner. 
Aim: To explore the role of Exosomes derived from regulatory dendritic cells 
in induction of immune tolerance.
Methods: Immature DCs (iDC) were induced from mouse bone marrow cells 
with GM-CSF and regulatory DCs (rDC) were induced by treating iDC with 
TGF-¦Â1 and IL-10. The phenotypes of regulatory DC and normal DC were 
assayed by fl ow cytometry. Exosomes from immature DC (iDex) and regulatory 
DC (rDex) were isolated by ultracentrifugation and ultrafi ltration. The function 
associated molecules of rDex were detected by Western blotting. The inhibitory 
effect of iDex and rDex to the proliferation of T lymphocytes was analyzed 
by mixed lymphocyte reaction (MLR) in vitro. A skin transplantation model 
was established with the recipient BALB/c mice and the donor C57BL/6 
mice. Recipients were divided into PBS control group, iDex group (injection 
10¦Ìg iDex of donor C57BL/6 mice via tail vein 7 and 3 days before skin 
transplantation) and rDex group (injection 10¦Ìg rDex of donor C57BL/ 6 mice 
via tail vein 7 and 3 days before skin transplantation).
Results: TGF-¦Â1 and IL-10 might down-regulate the expression of costimulatory 
molecules on dendritic cell, such as CD80, CD86 and CD40. The inhibitory effect 
of rDex to the proliferation of T lymphocytes was signifi cantly stronger than 
iDex, and rDex might express more FasL molecules to induce potent suppression 
of MLR. The graft mean survival time (MST) in control group, iDex group and 
rDex group was 7.8, 10.7 and 18.8 days, respectively. There was signifi cant 
difference in MST between iDex group and control group (p©‚0.05), and between 
rDex group and iDex group(p©‚0.01). The results of MLR assays showed donor-
specifi c hyporeactivity especially in rDex group, while the recipient BALB/c 
mice were still immunocompetent to unrelated allogeneic DBA mice. 
Conclusion: Exosomes secreted from regulatory dendritic cells can induce 
immune tolerance in skin transplantation. It has the potential application to 
prevent allogeneic transplantation rejection in the future.
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REQUIREMENT OF INKT CELLS FOR THE 2227 
MAINTENANCE OF MIXED CHIMERISM IN 
CYCLOPHOSPHAMIDE-INDUCED TOLERANCE
T. Onzuka, Y. Tomita, I. Shimizu, R. Tominaga
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu 
University
Purpose: Cyclophosphamide (CP)-induced tolerance is a mixed chimerism-
based tolerance conditioning, which donor skin graft tolerance is achieved in 
recipients with MHC-matched minor antigen-mismatched donors. Previously, 
we have elucidated the essential role of invariant Natural Killer T (iNKT) cells 
in CP-induced tolerance. In the present study, we investigate the need of iNKT 
cells for adequate mixed chimerism in CP-induced tolerance.
Methods: DBA/2 (DBA; H-2d, Ly1.1) mice and BALB/c (BALB; H-2d, Ly1.2) 
wild type (WT), or iNKT knockout (KO) (Jα18-/-, BALB background) mice 
were used as donors and recipients.¦ To deplete recipient Thy1.2+ cells, WT or 
iNKT KO recipients were injected with 100μg of anti-Thy1.2 mAb (MAb) on 
day -4 prior to our conventional conditioning, which consist of 108 donor DBA 
spleen cells (DBA SC) on day 0 and 200 mg/kg CP on day 2. To effectively 
raise donor mixed chimerim, WT or iNKT KO recipients were treated with 
DBA SC and CP, followed by 2~10×107¦ SC from tolerant DBA mice on day 
3. Tolerant DBA SC was harvested from DBA mice that had been treated with 
1×108 BALB SC and CP two weeks earlier. Donor DBA skin grafting was 
performed at 4 weeks. The level of mixed chimerism (Ly1.1+ cells in Ly1+ 
cells) and the kinetics of donor-reactive T cells (Mls-1a-reactive CD4+Vβ6+ T 
cells) were assessed by fl ow cytometry.
Results: The skin graft tolerance with stable mixed chimerism was observed 
in WT recipients treated with DBA SC and CP. However, donor skin grafts 
were chronically rejected in iNKT KO recipients treated with DBA SC and CP 
(median 71.5 days, n=10). Donor mixed chimerism was clearly observed in 
WBC of iNKT recipients at 2 weeks but diminished (<1.0%) at 8 weeks. When 
WT or iNKT KO recipients received additional treatment with either MAb or 
tolerant donor cells, all recipients developed elevated mixed chimerism at 8 
weeks and showed permanent skin graft survival. Twenty millions of tolerant 
DBA SC was enough for the tolerance induction in iNKT KO recipients. 
The clonal deletion of CD4+Vβ6+ T cells was insuffi cient in the thymus of iNKT 
KO recipient treated with DBA SC and CP. In contrast, the intrathymic clonal 
deletion was profoundly induced in iNKT KO recipients, if the skin graft tolerance 
was induced by the additional treatment with MAb or tolerant donor cells. 
Conclusions: The skin graft survival was always correlated with the induction 
of mixed chimerism in CP-induced tolerance. Invariant NKT cells are essential 
for the maintenance of stable mixed chimerism. The additional treatment 
with either MAb or tolerant donor cells was effective alternative methods for 
the maintenance of mixed chimerism, even in the absence of the regulatory 
function of iNKT cells.
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DETERMINATION OF CYTOTOXIC T LYMPHOCYTE 2228 
ACTIVITY AGAINST HUMAN SPLEEN CELLS AND 
ESTIMATION OF MICROCHIMERISM FOR TOLERANCE 
MEASUREMENT
M. Schenk, P. Kaur-Gill, A. Königsrainer
University Hospital Tuebingen – General, Visceral and Transplant Surgery
Clinical organ transplantation between genetically disparate individuals 
presently requires non-specifi c immunosuppressive agents to prevent rejection. 
However, the use of immunosuppressive drugs caused side effects and does not 
always guarantee success of the graft. Therefore, there is a need to establish 
methods of “donor specifi c transplantation tolerance” and that could not be 
achieved directly in patients. So, aim was to establish mixed lymphocytes 
culture (MLC) and fl uorescence activated cell sorting (FACS) cytotoxicity 
assay and a very sensitive assay for microchimerism based on cytospin 
preparation of peripheral blood lymphocytes.
In this study, the spleen cells and PBMC from different patients were stimulated 
with different concentration of Con-A (2-6 μg) up to 6 days. Than, spleen cells 
were labelled (5x105 cells/ml in PBS buffer) with 3 μM of Dio18(3) for 45 
min at 37°C, 5% CO2. Dio18 dye remains stably incorporated in the membrane 
for long periods of time (20 days). The MLC were established by culturing 
different ratios (1:1, 2:1, 4:1) of unstained PBMC (effectors lymphocytes) 
with an 105-106 cells/ml irradiated (30 Gy) spleens cells in RPMI medium 
supplemented with 50 μg/ml Gentamycin, 10% FCS, 200 mM Glutamin, 10 
mM Hespes pH 7.2 and 2 μg Con-A into 96 well fl at bottom plates. After 
different time intervals, the cells suspension were harvested and by adding 
PI to samples, FACS analysis was carried out on a FACScan cytometer. By 
excitation at 488 nm with an argon laser, the emission of two fl uorochromes 
was recorded through specifi c band pass fi lter 520 nm for Dio18(3) (FL1) and > 
425 for PI (FL3). Cytospin preparations of Bw4/Bw6-different donor-recipient 
combinations were stained with the corresponding antibody. 
Maximum stimulation of spleen cells was observed with 2 μg Con-A after 24 
h. Whereas, the stimulation of peripheral blood lymphocytes (PBMC) was 
also with 2 μg Con-A, but after 8 days of activation of PBMC from different 
patients, generated markedly higher levels of cytotoxicity against targets cells. 
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Maximum reduction of spleen cells (2-3%) in the MLC was observed after 
6 days of incubation at 37°C, 5% CO2. The degree of decrease of spleen 
cells was 95% using PBMCs from healthy persons and from third-party 
immunosuppressed patient 20%. With PBMC from the recipient no decrease 
was observed. 
In conclusion, the Dio18(3) assay is a quantitative methods for the detection of 
cell- mediated cytotoxicity and providing a greater insight into the mechanisms of 
cell-mediated cytolysis by different effector populations. Cytospin preparations 
provide reproducible results in mircochimerism rates even below 1%. A clinical 
study using both methods on liver transplant recipients is on the way.
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PROLONGED TRANSPLANT SURVIVAL AFTER DONOR 2229 
MACROPHAGE TRANSFUSION IN PORCINE PULMONARY 
TRANSPLANTATION
G. Warnecke1, S. Thissen1, B. Kruse1, M. Avsar1, R. Reinhard1, F. Fändrich2, F. 
Länger3, R. Baumann4, A. Haverich1, M. Strüber1
1Division of Heart, Thoracic, Transplantation and Vascular Surgery, 
Hannover Medical School, 2Department of General and Thoracic Surgery, 
University Kiel Germany, 3Institute of Pathology, Hannover Medical School, 
4Department of Radiotherapy and Special Oncology, Hannover Medical 
School.
Objective: Cotransplantation of donor suppressor macrophages has been shown 
to prolong allograft survival in small animals models. The aim of our study was to 
analyze the effect of donor macrophage cotransplantation on transplant survival in 
a preclinical large animal model of porcine allogenic pulmonary transplantation. 
We compared the survival of porcine lung allografts after induction therapy with 
immunosuppression and immunosuppression plus irradiation with the same 
protocols extended by donor macrophage cotransplantation. 
Methods: Left sided lung transplantation from MHC and sex mismatched 
donors was performed in female 26 minipigs. Immunosuppression included 
1.5 mg/kg per day methylprednisolone and tacrolimus, adjusted to 16–26 ng/
ml. All immunosuppressive drugs were discontinued on postoperative day 28. 
Six animals received intravenous immunosuppression only. The same protocol 
extended by postoperative macrophage cotransplantations from the lung donor 
was performed in seven animals. Six pigs received preoperative irradiation 
and immunosuppression. Seven animals were treated with irradiation and 
immunosuppression combined with macrophage transplantation. Peripheral 
blood cells were screened for donor leukocyte chimerism after macrophage 
cotransplantation and CD4/CD25 expression. 
Results: In comparison between the groups, transplant survival was prolonged 
in animals that received donor macrophages in combination with irradiation 
and immunosuppression. The degree of donor cell chimerism did not increase 
after macrophage transplantation. The frequency of CD4+CD25+ T cells 
was slightly higher in the group which received irradiation and macrophage 
cotransplantation, however, the difference was not statistically signifi cant.
Conclusion: The results of our study show that donor macrophage 
transplantation in a clinically feasible manner prolongs pulmonary allograft 
survival in a large animal model, especially combined with irradiation and 
immunosuppression.
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CD26/DPPIV ENZYMATIC INHIBITION IN A MURINE 2230 
MODEL OF MIXED CHIMERISM.
E. Schwaiger1, K. Christoph1, U. Baranyi1, N. Pilat1, S. Korom2, 
V. Matheeussen3, I. De Meester3, F. Mühlbacher1, T. Wekerle1
1Medical University of Vienna, Austria, 2University Hospital Zurich, 
Switzerland, 3University of Antwerp, Belgium
Background: Methods to enhance stem cell engraftment would be important 
for the development of minimally toxic bone marrow transplantation (BMT) 
protocols. CXCL12/SDF-1α has an important role in the homing of hematopoietic 
stem cells to bone marrow (BM). The ectopeptidase CD26/dipeptidylpeptidase 
IV (DPPIV) cleaves CXCL12/SDF-1α and thus inhibits homing. Inhibition 
of CD26/DPPIV enzymatic activity would thus be an appealing strategy for 
promoting BM engraftment. The CD26/DPPIV enzymatic activity inhibitor 
diprotin A has been reported to promote engraftment of purifi ed stem cells in 
lethally irradiated recipients, but little is known about the effects of CD26/
DPPIV enzymatic inhibition in non-myeloablative allogeneic BMT protocols 
for the induction of mixed chimerism and transplantation tolerance. We therefore 
explored inhibition of CD26/DPPIV enzymatic activity with diprotin A or the 
clinically available inhibitor sitagliptin for the purpose of enhancing engraftment 
of unseparated bone marrow after non-myeloablative recipient conditioning.
Materials and methods: B6 CD45.1 mice received a non-myeloablative dose 
of total body irradiation (1Gy, day –1) and 15x106 CD45-congenic bone marrow 
cells from CD45.2 donors. Donor bone marrow of one group was incubated 
in vitro with diprotin A (Ile-Pro-Ile, for blocking CD26/DPPIV activity; for 
15 minutes). Multi-lineage macrochimerism was followed by fl ow cytometry. 
Naïve C57BL/6 mice received 200mg/kg of sitagliptin by oral gavage (0h and 
+12h). Blood samples were collected after 2 and 24 hours and serum enzymatic 
activity of CD26/DPPIV was measured by a kinetic fl uorimetric enzyme assay 
with glycyl-L-proline-4-methoxy-2-naphthylamide as substrate.
Results: Similar rates and levels of multi-lineage chimerism were observed 
with or without CD26/DPPIV enzymatic inhibition by diprotin A (10/10 with 
diprotin A vs. 9/9 mice without). After 76 days mean chimerism of the group 
treated with diprotin A reached about 26% in the CD4 T-cell, 17% in the CD8 
T-cell, 37% in the B-cell and 28% in the myeloid-cell lineage. The group 
receiving untreated bone marrow showed comparable levels of chimerism 
(30% in the CD4 T-cell, 21% in the CD8 T-cell, 44% in the B-cell and 36% 
in the myeloid cell lineage). Treatment of naïve C57BL/6 mice showed about 
72% after 2x15mg/kg sitagliptin 24 hours post treatment. Mice treated with 
the high dose sitagliptin (2x200mg/kg) showed almost complete inhibition of 
CD26 serum enzymatic activity after 2 hours and more than 90% inhibition 
after 12 hours.
Conclusion: We have found no evidence that treatment of unseparated bone 
marrow with diprotin A leads to an enhanced engraftment of unseparated bone 
marrow in a CD45-congeneic model using non-myeloablative conditioning. We 
identifi ed a dosing regimen with the clinically approved CD26/DPPIV inhibitor 
sitagliptin which virtually completely blocks CD26/DPPIV enzymatic activity 
in the murine system and which is now under investigation in congeneic and 
allogeneic BMT protocols.
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HYPERACUTE REJECTION FOLLOWING 2231 
PREOPERATIVE DONOR SPECIFIC CELL TRANSFUSION 
IS ASSOCIATED WITH A LOSS OF HEMATOPOETIC 
CHIMERISM
B. Kruse1, S. Thissen 2, G. Warnecke1, M. Avsar1, F. Länger3, V. Kaever4, 
R. Baumann5, J.H. Karstens5, A. Haverich1, M. Strüber1
1Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, 
Hannover Medical School, 2Division of Cardiac, Thoracic, Transplantation 
and Vascular Surgery, Hannover Medical School, 3Institute of Pathology, 
Hannover Medical School, 4Institute of Pharmacology, Hannover Medical 
School, 5Department of Nuclear Medicine and Radiation Oncology, Hannover 
Medical School
Purpose: Donor alloantigen infusion has been shown to induce transplantation 
tolerance in small animal models. Here, we wished to study the effect of a 
donor splenocyte infusion (SpTx) on hematopoetic chimerism and transplant 
survival in a large animal model of porcine allogenic lung transplantation.
Procedures: Left-sided lung transplantation from MHC and sex mismatched 
donors was performed in 20 adult female minipigs. All received intravenous 
pharmacologic immunosuppression with methylprednisolone and tacrolimus 
for 28 postoperative days (POD). Animals in the IRR+SpTx POD 0 group 
additionally received 1.5 Gy whole body and 7 Gy thymic irradiation (IRR) on 
pre-operative day one and a donor splenocyte cotransplantation on the day of 
lung transplantation (n=6), the same protocol without irradiation was performed 
in the SpTx POD 0 group (n=5). IRR+SpTx POD–28 animals (n=3) received 
IRR and donor splenocyte infusion 28 days before transplantation under and a 
7 day course of tacrolimus. Pigs in the SpTx POD –28 group (n=6) received the 
same protocol without irradiation. Allograft survival was monitored by chest 
radiographs and transbronchial biopsies (TBB). Peripheral blood chimerism was 
analyzed by Y-chromosomal quantitative real time polymerase chain reaction 
(RTQ-PCR). Results: Transplant survival in the IRR+SpTx POD 0 group was 
signifi cantly prolonged compared to all other groups. Median allograft survival 
was: IRR+SpTx POD0 371d, SpTx POD0 73d, SpTx POD-28 110d, IRR+SpTx 
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POD-28 64d. Chimerism following lung transplantation and SpTx was 
signifi cantly increased in irradiated groups. In all animals donor cells peaked 
one hour after reperfusion of the graft, but compared to reperfusion levels, SpTx 
only caused a small additional increase in chimerism in the IRR+SpTx POD 
0 group. Splenocytes infused 28 days before lung transplantation remained 
detectable during the fi rst seven days, but rapidly decreased after withdrawal 
of immunosuppressive drugs. Only in the IRR+SpTx POD –28 group a residual 
amount of chimerism was detectable before lung transplantation. In the SpTx 
POD –28 group hyperacute rejection occurred in two animals which was 
associated with extremely low chimerism after reperfusion of the lung. 
Conclusion: Miniature swine conditioned with irradiation and perioperative 
donor splenocyte infusion have a higher ratio of donor cells to recipient cells 
and develop long term pulmonary allograft survival. Pre-operative donor cell 
transfusion is not benefi tial for transplant survival, furthermore it bears a high 
risk of hyperacute rejection due to sensitization which is associated with a rapid 
elimination of donor cells after lung transplantation.
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LONG TERM DONOR CELL CHIMERISM INSIDE 2232 
THE LUNG IS ASSOCIATED WITH A PROLONGED GRAFT 
SURVIVAL AFTER PULMONARY TRANSPLANTATION
B. Kruse1, G. Warnecke 1, S. Thissen 1, M. Avsar 1, B. Pabst2, J. Hohlfeld 1, 
V. Kaever 3, A. Haverich 1, M. Strüber 1
1Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, 
Hannover Medical School, 2Institute of Human Genetics, Hannover Medical 
School, 3Department of Respiratory Medicine, Hannover Medical School, 
7Institute of Pharmacology, Hannover Medical School
Purpose: We have reported earlier on marked prolongation of pulmonary 
allograft survival in minipigs treated with various immunosuppressive protocols. 
Although mean survival differed somewhat among groups, long term allograft 
survival occurred under a variety of protocols and several groups revealed similar 
distributions of long term surviving and rejecting animals. Taking into consideration 
the failure of a given “tolerance induction protocol” to predict outcome, we studied 
alternative factors possibly explaining prolonged survival. Here we wished to 
examine postoperative chimerism in the peripheral blood and inside the graft 
of tolerant and rejecting animals. Groups for eventual analysis were defi ned by 
outcome, i.e. animals with acute rejection of the lung were randomized into one 
group (n=16) and animals with long term allograft survival (LTS, n=11) into the 
other group regardless of the immunosuppressive protocol. Procedures: Left-sided 
lung transplantation from gender mismatched male donors was performed in 27 
minipigs. Intravenous pharmacologic immunosuppression was maintained for 
28 postoperative days (POD). Peripheral blood chimerism was analyzed by fl ow 
cytometry and Y-chromosomal quantitative real time polymerase chain reaction 
(RTQ-PCR). For fl ow cytometry donors had prospectively been selected positive 
for the SLA I specifi c antibody 74-11-10, and recipients had been selected negative. 
To analyze intra-graft chimerism cells harvested from bronchoalveolar lavage fl uid 
were screened for their sex genotype by fl uorescence in situ hybridization (FISH). 
Results: Peripheral blood chimerism was not stable. Chimerism detected by 
the SLA I mAb 74-11-10 and RTQ-PCR peaked within 24 h of pulmonary 
transplantation. In samples drawn 1 h after reperfusion signifi cantly higher 
donor cell levels (11.7-18.2%) were detected in LTS (p<0.05). In the follow-
up period the percentage of donor cells constantly decreased, with a trend 
towards higher microchimerism in long term surviving animals. In case of 
acute rejection microchimerism was lost in all except two animals. In all long 
term surviving animals microchimerism was detectable for more than 90 
postoperative days. Later analyses demonstrated a lack of male DNA in six 
LTS. Anyhow graft function remained stable, and rejection episodes did not 
occur over an observation period of up to 36 months. FISH-analysis showed 
consistent results. The percentage of male nuclei in BALF was equally high 
in all animals under immunosuppression (median value of 86% on POD 7; 
78% on POD 28). In rejecting animals the percentage of Y-chromosomal cells 
rapidly decreased after withdrawal of immunosuppressive drugs, and was lost 
almost completely when acute rejection occurred. In tolerant pigs chimerism 
in BALF in the range of 70% was detectable for more than 100 postoperative 
days, decreased slowly in the follow up and reached a stable state of 7-12%.
Conclusion: These data seem to support an important role of peripheral blood 
cell chimerism for the induction, but not for the maintenance of tolerance in 
lung transplanted pigs. In rejecting animals the rapid decrease of donor cells 
in BALF after discontinuation of immunosuppression was predictive of acute 
rejection, but in long term surviving animals a gradual replacement occurred 
which was not associated with acute rejection.
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THE DISTINCT ROLES OF THE CD40 COSTIMULATION 2233 
PATHWAY IN DONOR AND RECIPIENT IN A MIXED 
CHIMERISM MODEL
C. Klaus, N. Pilat, E. Schwaiger, M. Gattringer, F. Muehlbacher, T. Wekerle
Vienna Medical University
Background: Bone marrow transplantation (BMT) together with costimulation 
blockade induces mixed chimerism and tolerance in various protocols with anti-
CD40L (CD154) mAb being an essential component in all of them. Unfortunately, 
it has not been possible to create a safe anti-CD154 mAb for clinical use. In the 
literature there are contradictory reports on the mechanism of anti-CD154 therapy. 
Some studies show that a signal is essential for the effect of anti-CD154, while 
others demonstrate that only its blocking properties are required. Besides, little 
is know about the separate effects of anti-CD154 therapy on donor and recipient 
APC. As the donor BM is amenable to in vitro manipulation (e.g. transfection, 
siRNA technology), it is important to delineate the role of donor CD40.
Materials & Methods: B6 recipient mice (WT or knock-out) received 
approximately 20x106 fully mismatched Balb/C (WT our knock-out) bone 
marrow (BM) cells (d0), total body irradiation (2Gy, d-1) and costimulation 
blockade consisting of CTLA4Ig (d+2) with or without anti-CD154 (d0, MR1, as 
indicated). The following donor-recipient strain combinations were used (7-8 mice/
group): Group 1: WT Balb/C and WT B6; Group 2: WT Balb/C and CD154 KO 
B6; Group 3: as group 2 but without anti-CD40L; Group 4: CD40KO Balb/C and 
CD40KO B6; Group 5: as group 3 but without anti-CD40L; Group 6: CD40KO 
Balb/C and WT C57BL/6; Group 7: as group 6 but without anti-CD40L. Multi-
lineage chimerism and deletion of donor-reactive T cells were followed by fl ow 
cytometry. Tolerance was assessed by grafting donor and 3rd party skin.
Results: Mixed chimerism developed in mice of all groups except when CD40 
KO BM was transplanted into WT recipient without using MR1 (group 7). 
Chimerism levels among myeloid and lymphoid lineages were signifi cantly 
different between group 6 vs. group 7 was p<0.05 in whereas differences between 
all other groups were not signifi cant. Chimeras in control group 6 (CD40KO 
into WT plus MR1) showed skin graft tolerance during the entire observation 
period, whereas neither chimerism nor tolerance developed in group 7. Third 
party skin was rejected in all mice. Chimerism in all groups (except group 7) 
was comparable to WT to WT combination (group 1), which is our established 
protocol for chimerism induction. When used WT donor to CD154 KO recipient 
w/o MR1 (group 3), 7/8 mice developed stable multi-lineage chimerism and 
donor skin was accepted in chimeric mice for more than 50 days with 5 continuing 
for more than 80 days (ongoing). Similar results were true for control group (2, 
with MR1). All chimeric mice in CD40 KO to CD40 KO combination were also 
tolerant for more than 80 days (ongoing), whether MR1 is added or not. 
Conclusion: We show that in a fully mismatched costimulation-blockade BMT 
model involving CTLA4Ig, anti-CD40L treatment is effective independent of 
triggering a signal or cytotoxic target cell elimination. Eliminating the CD40 
pathway in the (APC of the) donor alone is not suffi cient to replace anti-
CD40L treatment, pointing to the importance of blocking the indirect antigen 
presentation pathway through eliminating CD40 signals in recipient APC.
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PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL 2234 
BY ADMINISTRATION OF ANTIGEN-PULSED RECIPIENT 
DENDRITIC CELLS TRANSDUCED BY LENTIVIRUS-SIRNA 
TARGETING CD80 AND CD86
X. Gu1, Z. Chen1, J. Xiang1, L. Lu2, S. Qian2
1Department of General Surgery, Hua Shan Hospital, University of Fudan, 
2Department of Immunology and General Surgery, Cleveland Clinic
Dendritic cells (DC)-based therapies in transplantation using genetic engineering 
approach will reduce dependency on nonspecifi c immunosuppression. Its 
development has been limited by the inability to appropriately transfect DC 
using conventional vectors. Thus, infection of retroviruses requires cells to 
be actively dividing, as a result, many cells, including DC, are very resistant 
to retrovirus infection. Although adenovirus infects non-dividing cell, it 
does not integrate into the genome and is not replicated during cell division. 
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Lentivirus belongs to a subclass of retroviruses with ability to integrate into 
the genome of non-dividing cell, and can pass on to the progeny of the cell 
when it divides. In this study, the DC were cultured from C3H (H2k) bone 
marrow cells in the presence of GM-CSF plus IL-4, and, at day 2, exposed 
for 48 hours to lentivirus- GFP-siRNA-anti-CD80- or RFP-siRNA-anti-CD86 
at Mal of 2-20. Cells were then washed, cultured for six additional days, 
and exposed to 1ƒÝg/ml LPS for fi nal 48 hours. The infection effi ciency at 
Mal of20 was 79.78:!:4.95% without affecting cellular viability (by annexin 
V and propidium iodine staining). DC transduced with lentiviruses-anti-
CD80 or anti-CD86 siRNA expressed markedly lower CD80 and CD86 
(18.03%„b2.97% and18.61%„b3.00%,respectively, vs. 64.24%„bl.21% and 
70.02%„b0.42%in scrambled RNA controls, both p<0.05). To test effect 
oftransduction of targeting siRNA on DC function, DC transduced with anti-
CD80 and CD86 were pulsed with debris of B6 (H2b) spleen cells, and showed 
low stimulatory activity in an MLR culture in which C3H spleen T cells were 
responders, compared to DC transduced with scrambled control RNA. 2x106 
DC that were infected with lentivirus-antiCD80 and anti-CD86 siRNA were 
intravenously injected into C3H recipients 7 days before receiving a B6 heart 
allograft in the absence of immunosuppressive therapy. Survival of cardiac 
allografts was signifi cantly prolonged in treated group [median survival 
time (MST) 22days] compared with non-treat group (MST 6 days) or PBS-
treat group (MST 10 days, both p<0.05 vs. DC treat group). In conclusion, 
lentivirus vector effectively infects DC with low cytotoxicity. Use of recipient 
DC for vaccination provides a more feasible approach for deceased donor 
organ transplantation.
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TARGETED BONE MARROW RADIOABLATION 2235 
ENHANCES HEMATOPOIETIC CHIMERISM AND 
PREVENTION DIABETES ONSET IN NOD MICE.
A. Pileggi1, R.D. Molano1, S.S. Jose1, E. Zahr1, J. Molina1, W. An1, 
J. Gonzalez-Quintana1, M.A. Atkinson2, C. Ricordi1, L. Inverardi1
1University of Miami Miller School of Medicine – Diabetes Research Institute, 
2Department of Pathology, University of Florida, Gainesville, FL, USA
Transplantation of allogeneic bone marrow cells (BMC) may result in stable 
chimerism and tolerance to donor-specifi c tissues. NOD mice develop 
autoimmune diabetes spontaneously and are resistant to tolerance-inducing 
protocols proven successful in non-autoimmune strains. Stable chimerism has 
been reported in NOD mice using anti-CD3 antibody treatment and infusion of 
CD8+ splenocytes plus high doses BMC (two inocula of 200x106 each). The 
use of bone-seeking isotopes [153Samarium(153Sm)-EDTMP] has allowed 
for targeted bone marrow (BM) radioablation and enhanced hematopoietic 
chimerism in non-autoimmune mice. 
In the present study, we tested whether inclusion of 153Sm-EDTMP at 
induction would allow for BMC dose reduction in an allogeneic (FVB) BMC 
transplantation in prediabetic female NOD mice (7-8wk old). Animals received 
153Sm-EDTMP (0.5mCi i.v. on day -10), anti-CD3 antibody (0.5mg i.v. on 
day -7). Two doses of FVB BMC (50x106) and CD8+ splenocytes (20x106) 
were given on days 0 and 7. Recipients were monitored for chimerism levels 
and diabetes onset. 
Control untreated female NOD mice (n=7) invariably developed diabetes 
during the follow-up period. Animals receiving the induction protocol without 
153Sm-EDTMP did not achieve stable chimerism (n=8) developed diabetes in 
62.5% of the cases. 153Sm-EDTMP inclusion in the induction protocol resulted 
in stable chimerism in 71.5% of the animals (n=7), with only nonchimeric 
animals developing diabetes during follow-up in this group. Chimeric animals 
accepted donor-specifi c skin allografts and rejected third-party (C57BL/6) skin 
grafts. 
Targeted BM radioablation prior allows reducing substantially the mass of BMC 
inoculum needed to achieve stable chimerism and tolerance in the challenging 
NOD mouse model. The use of bone-seeking isotopes to selectively target the 
BM compartment may represent a valuable strategy to complement chimerism-
based tolerance inducing protocols for clinical use.
Supported in part by the Juvenile Diabetes Research Foundation.
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SIMULTANEOUS INJECTION OF DONOR-DERIVED 2236 
OX62+-SPLENIC DENDRITIC CELLS AND NON-DEPLETING 
ANTI-CD4 MONOCLONAL ANTIBODIES INTO A FISCHER TO 
LEWIS RAT COMBINATION GENERATES CD4+CD25+FOXP3+ 
T CELLS WHICH ABROGATE THE PRODUCTION OF DONOR-
SPECIFIC ALLO-ANTIBODIES AND INDUCE INDEFINITE 
SKIN GRAFT SURVIVAL
M. Alawieh, G. Rifl e, O. Bouchot, C. Mousson, L. Martin
University of Burgundy, IFR 100 Santé STIC
Aim: Donor-specifi c antibodies (DSA) are probably one of the main 
immunological factors involved in the genesis of chronic allograft rejection 
and one of the hurdles to overcome to achieve tolerance. This preliminary 
study tests (1) the ability of a tolerance induction protocol using donor-derived 
dendritic cells (DC) and anti-CD4 monoclonal antibodies (MoAb) to generate 
donor-specifi c CD4+CD25+ regulatory T cells (Treg) and (2) the capacity of 
these cells to abrogate the production of DSA after skin graft in rats.
Material and methods: OX62+-splenic DC (non plasmocytoid DC) were 
isolated from Fischer rats with magnetic beads (Miltenyi-Biotec) and injected 
(2.106) into Lewis recipients with or without non depleting anti-CD4 (W3/25) 
MoAb. CD4+CD25+ T cells were harvested with magnetic beads from 
“tolerized” animals and injected (1.106) into Lewis recipients at day 1 before 
they receive a skin graft from Fischer (n=4) or third party (Brown Norway, n=4) 
donors. DSA were detected in the recipient blood using fl ow cytometric cross 
matches with donor lymphocytes at several time points after transplantation 
(d0, d7, d15, d30).
Results: After injection of CD4+CD25+FOXP3+ T lymphocytes isolated from 
the “tolerized-rats”, Lewis recipients accepted skin grafts from Fischer rats 
indefi nitely (>100days), whereas skin grafts from a third party were rejected. 
DSA were detected at low levels at days 7, 15 and 30 in only one recipient 
receiving Treg prior to grafting. Treg coming from Fischer receiving DC alone 
are unable to inhibit DSA production and to prolong skin graft survival in 
Lewis rats. In addition, it was shown that DSA induced by a single injection 
of allogenic OX62+ DC are abrogated when anti-CD4 MoAb was associated 
with DC.
Conclusion: These preliminary data suggest that splenic non plasmocytoid 
DC and anti-CD4-MoAb-induced donor-specifi c Treg that can, in most cases, 
inhibit the production of DSA and indefi nitely prolong allogenic skin grafts 
survival. Experiments are now in progress in order to check if this protocol can 
inhibit chronic rejection lesions after heart transplantation in this model.
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PERSISTENT MOLECULAR CHIMERISM IS NOT 2237 
REQUIRED TO MAINTAIN NEONATALLY-INDUCED CARDIAC 
ALLOGRAFT TOLERANCE IN MICE
L. West, H. Mewhort, K. Tao, S. Maier, J. Brown 
University of Alberta
Long-term acceptance of both donor-specifi c BALB/c (BALB, H-2d) and third-
party C57BL/6 (B6, H-2b) cardiac allografts is induced by treating neonatal 
C3H/He (C3H, H-2k) mice with either semi-allogeneic BALBxC3H spleen (F1/
SP, H-2d/k) cells or fully allogeneic BALB fetal liver cells (FLC). The cellular 
mechanisms responsible for tolerance differ: the former involves alloreactive 
T-cell deletion and the latter involves induction of non-specifi c regulatory 
T-cells. Previous studies suggested that persistent chimerism is important to 
preserve neonatally-induced tolerance into adulthood. Cellular chimerism 
can be detected in the F1/SP cell model 3-100 days post-treatment, but only 
up to 10 days in the FLC model suggesting either that molecular chimerism 
is responsible for FLC-induced tolerance or that persistent chimerism is not 
required. This study assessed whether molecular chimerism persists in FLC-
treated mice. 
Female C3H neonatal mice were treated with either male F1/SP cells or FLC. 
Genomic DNA was isolated from various tissues of treated mice at 3 days and 
6-8 weeks post-treatment. PCR for the SRY gene was used to detect molecular 
chimerism. 
Molecular chimerism was detected in mice treated with F1/SP cells 3 days and 
6-8 weeks post-treatment. While molecular chimerism was detected in FLC-
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treated mice 3 days post-treatment, molecular chimerism could not be detected 
in the tissues tested 6-8 weeks post-treatment. 
These results demonstrate that molecular chimerism is lost prior to adulthood 
after neonatal FLC treatment. Chimerism at a molecular and cellular level is 
thus not required for neonatal tolerance to either donor-specifi c or third-party 
cardiac allografts, suggesting that induction of non-specifi c regulatory T-cells 
occurs early post-injection.
GENE REGULATION IN CONCURRENT ORAL SESSION 150: 
TRANSPLANTATION
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CYP3A5 GENOTYPE INFLUENCES THE BLOOD 2238 
CONCENTRATION OF TACROLIMUS IN RESPONSE TO 
INHIBITION BY KETOCONAZOLE
V. Jha, N. Chandel, P. Aggarwal, M. Minz, V. Sakhuja
Postgraduate Institute of Medical Education and Research
There is marked heterogeneity in blood concentrations of tacrolimus following 
standard body-weight-based dosing. Differences in hepatic and intestinal 
cytochrome P4503A activity have been postulated as contributing to this 
problem, probably through linkage with an SNP in the CYP3A5 gene. It has been 
shown that patients with at least one CYP3A5*1 allele achieved twofold lower 
dose-normalized tacrolimus blood concentrations compared with CYP3A5*3/*3 
homozygote. We investigated the role of this polymorphism on response to 
inhibition of the enzyme activity by ketoconazole (used to bring down the cost 
of therapy). A total of in 64 stable renal transplant recipients were started on 
100 mg/day of ketoconazole and tacrolimus dose was reduced by 40% 2 days 
later. Dose-normalized blood concentrations of tacrolimus before and 1 week 
after starting ketoconazole were related to CYP35 genotypes determined by 
polymerase chain reaction followed by restriction fragment length polymorphism 
analysis. A total of 35 and 2 patients were homozygous for the *3 and *1 alleles 
respectively whereas 27 were *1/*3 heterozygotes. Before starting ketoconazole, 
the dose-normalized concentrations were similar in *3 homozygotes and *1/*3 
heterozygotes. However, the post-ketoconazole tacrolimus trough concentration 
were higher in *3 homozygotes. Also, the magnitude of increase in the dose-
normalized concentrations was bigger in the *3 homozygotes. We conclude that 
CYP35 genotype is important in determining the dose requirement for tacrolimus 
in response to metabolic inhibitors, and determination of the CYP3A5*1/*3 
genotype could be used to predict the tacrolimus dose requirement. This fi nding is 
of value in optimizing immunosuppressive therapy in cost-constrained settings.
POSTER BOARD NUMBER P4 – 289
IS DONOR DNA INCORPORATED INTO RECIPIENT 2239 
LYMPHOID CELLS GENOME?
J. Tyszka1, W.L. Olszewski1,2,3, J. Rutkowska1
1Department of Surgical Research & Transplantation, Medical Research 
Center, Poli, 2Central Clinical Hospital, Ministry of Internal Affairs, Warsaw, 
Poland, 3The Norwegian Radium Hospital-Rikshospitalet, Oslo, Norway
Introduction: Processing and incorporation of fragments of DNA and 
oligonucleotides by mammalian and bacterial cells is a continuing physiological 
process. It is strongly intensifi ed in infl ammation, cancer and after tissue and 
organ transplantation. The outcome of DNA transfer between mammalian cells 
remains not well understood. It has been suggested that donor DNA may play 
a role in rejection or creating partial tolerance. 
Aim: to study whether donor DNA may be identifi ed in recipient immune cells 
and if so, whether it locates in cytoplasm or penetrates into nucleus.
Methods: In sex- mismatched combination male rat DNA was injected i.v. into 10 
female rats. Recipient blood (PBM), lymph node (LN) and spleen (SPL) mononuclear 
cells were examined 24 hr later for the presence of SRY gene characteristic for 
Y-chromosome. SRY was detected using polymerase chain reaction (PCR) method 
and real-time PCR. The PCR products was analyzed by electrophoresis in12,5% 
polyacrylamide gel (PAGE; Phast System, Amersham Pharmacia Biotech) and 
silver stained (Silver Staining Kit; Amersham Pharmacia Biotech). 
Results: SRY gene was detected in female PBM, LN and SPL cell cytoplasm 
in 2 out of 10 rats. Moreover, it was detected in PBM nuclei in 4 out of 10 
rats and in LN cell nuclei also in 4 out of 10 rats. Location of the incorporated 
fragments is studied. 
Conclusion: Detection of donor male DNA in nuclei isolated from female 
cells suggests its spontaneous transport into recipients cells and their nuclei. 
The question remains open whether this fi nding may have any relevance to the 
rejection or tolerance process. 
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IMPACT OF CYTOKINE GENE POLYMORPHISM ON 2240 
RENAL ALLOGRAFT OUTCOME COULD BE MODULATED BY 
IMMUNOSUPPRESSANT?
Y.J. Park1, S-K. Min1, S-H. Kim1, Y.J. Jung1, Y.S. Kim2, M.H. Park3, 
S.J. Kim1, J. Ha1
1Department of Surgery, Seoul National University College of Medicine, 
2Department of Internal Medicine, Seoul National University College of 
Medicine, 3Department of Laboratory Medicine, Seoul National University 
College of Medicine
It has been suggested that genetic polymorphisms of cytokines could affect graft 
outcome due to the different levels of cytokine produced in individual patients. 
However, there is little agreement between different research groups as to the 
functional signifi cance of each polymorphism and its role in transplantation.
To evaluate the association of tumor necrosis factor α (TNF-α) and 
transforming growth factorβ1 (TGF-β1) gene polymorphisms with renal 
allograft outcomes, TNF-α (-308 G/A) and TGF-β1 (codon 10 T/C) single 
nucleotide polymorphism (SNP) sites were evaluated using polymerase chain 
reaction (PCR) in 234 recipients and 193 donors. One hundred normal controls 
were also studied. Recipients were mismatched by at least 1 human leukocyte 
antigen (HLA), and all organs were from living donors. Of recipients, 11.3% 
were TNF-α high producers (-308 G/A), whereas 22.3% were TGF-β1 low 
producers (codon 10 C/C). Allele frequency did not differ between controls and 
patients. The acute rejection rate, recurrent rejection rate, and chronic allograft 
nephropathy in TNF-α high producers and TGF-β1 low producers were not 
different from the other group; however, if groups were subdivided according 
to immunosuppressant, the recurrent rejection rate was signifi cantly increased 
in the cyclosporine-based dual therapy group. The triple regimen group did 
not show a signifi cant difference, and the tacrolimus (TAC)-treated group 
did not show any recurrent rejection. Graft survival was better in the TNF-α 
low-producer and TGF-β1 high-producer groups than the others, respectively; 
however, only the latter group showed a signifi cant difference in CsA-based 
regimen group, of which the result was more prominent in the triple regimen 
group (Fig. 1 & 2). There was no signifi cant difference in graft survival in 
patients with TAC-based regimen with dual nor triple agents. 
Although TNF-α and TGF-β1 gene polymorphism may have an infl uence on 
graft outcomes, its signifi cance could be modulated at least in part by a more 
potent immunosuppression regimen.
Fig 1. P=0.043 Graft survival in patients with CsA-based agents according to 
TGF-β1 codon10 polymorphism. (In TAC-based group, P=NS)
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Fig 2. P=0.018 Graft survival in patients with CsA-based triple agents according 
to TGF-β1 codon10 polymorphism. (In CsA-based dual group, P=NS)
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EFFECT OF GENETIC POLYMORPHISMS OF MRP2 2241 
AND UGT2B7 ON GASTROINTESTINAL SYMPTOM RATING 
SCALE IN KIDNEY TRANSPLANT RECIPIENTS TAKING 
MYCOPHENOLIC ACID
P.H. Lee1, J.W. Yang3,5, I. Hutchinson3,4, V. Pravica3,4, T. Shah2,3, D. Min3,5
1Singapore General Hospital, 2St. Vincent Medical Center, 3National Institute 
of Transplantation, 4University of Southern California, 5Western University of 
Health Sciences
Background: Gastrointestinal (GI) symptoms are the most common 
complications with mycophenolic acid (MPA) therapy. MRP2 and UGT2B7 
which are involved in the excretion and production of the metabolites of MPA 
respectively may play a role in the presentation of GI symptoms. 
Objectives: To determine the relationship between single nucleotide 
polymorphisms in MRP2 and UGT2B7 and the incidence and severity of 
the GI symptoms in patients receiving MPA. Methods: Genotypes of MRP2 
C-24T and UGT2B7 C802T were determined and the incidence and severity 
of GI symptoms were assessed using the validated Gastrointestinal Symptom 
Rating Scale (GSRS) at baseline, 2 weeks, 1 month, 3 months and 6 months 
post transplant. The mean overall GSRS score and subscale score for diarrhea 
were compared using Student’s t-test and linear regression was performed to 
determine the predictors of GI symptoms. 
Results: Fifty-six kidney transplant recipients were included in the study. The 
overall GSRS score was not signifi cantly different between the MRP2 C-24T 
heterozygous variant and the homozygous wild type (1.6 vs 1.8, p=0.084). 
However the GSRS subscale score for diarrhea was signifi cantly lower in the 
MRP2 C-24T heterozygous variant compared to the homozygous wild type 
(1.2 vs 1.7, p=0.004). For the UGT2B7 C802T, the overall GSRS score (1.6 
vs 1.8, p=0.158) and diarrhea subscale score (1.4 vs 1.8, p=0.127) were not 
signifi cantly different between the heterozygous and homozygous variant 
and the homozygous wild type. When the genotypes for MRP2 and UGT2B7 
are considered together, the variant MRP2 C-24T and UGT2B7 C802T had 
signifi cantly lower overall GSRS (1.5 vs 1.9, p=0.032) and diarrhea subscale 
score (1.1 vs 1.8, p=0.014) compared to the wild type. There were however 
no differences in the scores between patients receiving either mycophenolate 
mofetil or enteric-coated mycophenolate sodium; and patients receiving the 
different calcineurin inhibitors. 
Conclusion: This study demonstrates that among patients receiving MPA, 
those with MRP2 C-24T and UGT2B7 C802T variant genotypes are potentially 
protected from the GI side effects, in particular diarrhea, regardless of the 
formulation administered.
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SYSTEMS BIOLOGY IN DONOR KIDNEYS OF 2242 
RECIPIENTS WITH POST-TRANSPLANT ANEMIA
J. Wilfl ingseder1,2, A. Kainz1, P. Perco2, B. Mayer2, R. Oberbauer1,3
1KH Elisabethinen, Linz, Austria, 2Emergentec Biodevelopment, Vienna, 
Austria, 3Medical University of Vienna, Austria
Post-Transplantation anemia is a common phenomenon after renal 
transplantation, and the cause is usually multi-factorial. Molecular mechanisms 
leading to anemia after renal transplantation are not fully understood. Focus of 
this present study was to further elucidate the biological processes of anemia in 
the post-transplantation setting.
The analysis of 52 renal transplant recipients (25 treated with ESAs within the 
fi rst year after transplantation and 27 without ESA treatment) will be presented. 
The analysis include genome-wide gene expression profi les of donor kidney 
biopsies with subsequent systems biology approaches such as transcription 
factors analysis, regulatory networks, and protein-protein interaction data. 
Multivariable logistic regression analysis was used to quantify the association 
of genes identifi ed in the systems biology studies with the outcome ESA use 
adjusted for clinical predictors such as donor age, biopsy confi rmed acute 
rejection (BCAR) and glomerular fi ltration rate. 
Unsupervised hierarchical clustering of experimental data suggests a distinct 
molecular signature associated with activated infl ammation in the donor kidney 
biopsies with subsequent ESA requirement. Selection of 1.5fold differentially 
upregulated genes in the ESA group yielded 28 signifi cant sequences that can 
be categorized according to PANTHER ontologies into three main biological 
processes: Cell adhesion-mediated signalling (p<0.004), immunity and defense 
(p<0.004), oncogenesis (p<0.007). In the multivariable analysis, several genes 
were found to be independent predictors of post-transplant anemia.
Our data suggest that genes involved in the infl ammation cascade predict post-
transplant anemia.
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INFLUENCE OF MRP2 AND UGT1A9 POLIMORPHISMS 2243 
IN THE MPA PHARMACOKINETICS IN RENAL TRANSPLANT 
RECIPIENTS. RESULTS OF THE PHARMACOGENETIC 
SUBSTUDY WITHIN THE SYMPHONY STUDY.
N. Lloberas1, M. Brunet2, J. Torras1, F. Oppenheimer3, J. Sanchez-Plumed4, 
M.A. Gentil5, H. Ekberg6, J.M. Grinyó1
1Nephrology Service and Laboratory of Experimental Nephrology, 
Department of Medicine, Hospital Universitari De Bellvitge, L´Hospitalet 
de Llobregat, Spain, 2Centre de Diagnostic Biomedic, Barcelona, Spain, 
3Hospital Clinic i Provincial, Barcelona, Spain, 4Hospital La Fe, Valencia, 
Spain, 5Hospital Virgen del Rocío, Sevilla, Spain, 6Malmoe, Sweeden
Introduction: Mycophenolic acid (MPA) is an effective immunosuppressant 
used in renal transplantation and is mainly metabolized by uridine diphosphate-
glucuronosytransferases (UGTs). The latter metabolites are excreted trough the 
kidney at least in part by multidrug resistance protein 2 (MRP2), which play 
an important role in the enterohepatic recirculation of the MPA. Furthermore, 
the inhibition of MRP2 by cyclosporine (CsA) is the main mechanism 
responsible for the interaction between CsA and MPA. The Symphony study 
compares 4 immunosuppressant regimens in renal transplant patients in terms 
of clinical outcomes. Patients included in the Pharmacogenetic sub-study had 
complete cyclosporine (CsA) and mycophenolic acid (MPA) pharmacokinetic 
assessments (in the Symphony PK sub-study) and they were genotyped for 
MRP2 and UGT1A9.
Objective: To determine the relationship between single nucleotide 
polymorphisms (SNPs) in the MRP2 (C-24T and C3972T) and UGT1A9 
(UGT1A9*3 and UGT1A9-2152) genes and the MPA pharmacokinetics in 
renal transplant recipients of the Symphony Pharmacogenetic sub-study.
Subjects And Methods: 70 renal transplant recipients (58.6% males; mean 
age: 47.9±11.8 years) at 8 Spanish centres were randomized to 4 branches 
of immunosuppressive regimen: low and standard dose of CsA (N=30), 
tacrolimus (Tac) (N=13) and sirolimus (SRL) (N=23) all in addition to 
mycophenolate mofetil and steroids. Low and standard dose of CsA were 
summed into one group for the present analysis. Patients were genotyped for 
SNPs in MRP2, C24T and C3972T, and for SNPs in UGT1A9, *3 and 2152. 
Pharmacokinetic sampling was done before administration and at 20, 40, 75 
min, 2, 3, 6, 8, 10 and 12 hours post-dose at scheduled intervals during the 
study (7, 30 and 90 days). Association of different Area Under Curve (AUC) 
plasma samplings with the presence of MRP2 and UGT1A9 polymorphisms 
and with the immunosuppressive regimens were studied using ANOVA 
analysis (Kruskal-Wallis). 
Results: At 90 days, MPA AUC was associated with the presence of C24T 
(CC: 82.3 ± 48.3; *T: 50.6 ± 21.0; p= 0.009; N= 48) and with treatment with 
CsA (Tac and SRL: 82.9 ± 46.9; CsA: 52.9 ± 518.5; p= 0.003; N= 54). MPAG 
AUC was associated with the presence of UGT1A9*3 at 30 days (C*: 857.3 
± 558.6; TT: 1496.9 ± 888.2; p= 0.036; N= 53) and at 90 days (C*: 321.2 ± 
22.2; TT: 972.2 ± 518.5; p= 0.024; M= 57). MPA AUC was associated with the 
presence of UGT1A9*3 at 30 days (C*: 68.3 ± 19.1; TT: 50.5 ± 26.6; p= 0.056; 
N= 53) but not at 90 days.
Conclusions: Renal transplant recipients with C-24T MRP2 SNPs were 
associated with a reduced MPA exposure in the steady-state conditions and CsA 
treated patients showed a reduction in MPA AUC in the steady-state conditions.
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POLYMORPHISMS OF THE MDR1 GENE IN RENAL 2244 
TRANSPLANT RECIPIENTS AFFECT THE PGP ACTIVITY. 
RESULTS OF THE PHARMACOGENETIC SUBSTUDY WITHIN 
THE SYMPHONY STUDY.
N. Lloberas1, I. Llaudó1, J. Torras1, A. Caldes1, J.M. Cruzado1, 
F. Oppenheimer2, J. Sanchez-Plumed3, M.A. Gentil4, H. Ekberg5, J.M. Grinyó1
1Nephrology Service and Laboratory of Experimental Nephrology, 
Department of Medi, 2Hospital Clinic i Provincial, Barcelona, Spain, 
3Hospital La Fe, Valencia, Spain, 4Hospital Virgen del Rocío, Sevilla, Spain, 
5Malmoe, Sweeden
Introduction: The human multidrug resistance gene (MDR1) encodes for 
the membrane effl ux transporter, P-glycoprotein (Pgp). The search for key 
genetic determinants that predispose individuals to drugs that are substrates or 
inhibitors of Pgp has just begun. Reports in the literature, particularly focusing 
on the C3435T polymorphism may be of interest to individualization therapy 
and has been related to nephrotoxicity drug disposition. Pgp functional studies 
may provide new insights on the relevance of Pgp polymorphisms on therapy 
individualization. The Symphony study compares 4 immunosuppressant 
regimens in renal transplant patients in terms of clinical outcomes. 
Objective: To investigate the association of 4 SNPs in MDR1 gene with Pgp 
activity as measured by means of rhodamine fl uorescence. Correlation of 
different immunosuppressive drugs with Pgp activity in vivo. 
Subjects And Methods: Patients included in the Pharmacogenetic sub-
study were genotyped for MDR1 gene. In total, 70 renal transplant 
recipients (58.6% males; mean age: 47.9±11.8 years) at 8 Spanish centres 
of the Symphony Pharmacogenetic sub-study were included. Patients were 
randomized to 4 branches of immunosuppressive regimen: low and standard 
dose of cyclosporine (CsA) (N=30), tacrolimus (TRL) (N=13) and sirolimus 
(SRL) (N=23) all in addition to mycophenolate mofetil and steroids. Low 
and standard dose of CsA were summed into one group for present analysis. 
Patients were genotyped for SNPs in MDR1 C3435T, C1236T, G2677T and 
T129C. Pgp was measured in peripheral lymphocytes by means of rhodamine 
fl uorescence and expressed as fl uorescence units (FU). 
Results: Pgp activity was infl uenced by different MDR1 polymorphisms: 
C3435T (CC: 48.8 ± 14.7 FU; CT: 40.6 ± 10.8 FU; TT: 33.1 ± 9.3 FU; 
p= 0.013), C1236T (CC: 46.4 ± 15.4; CT: 40.0 ± 9.7; TT: 32.6 ± 8.5; p= 
0.030) and G2677T: (GG: 46.0 ± 15.2; *T: 38.7 ± 9.9; p= 0.042). Pgp 
activity was lower for CsA and SRL groups than for TRL groups (p= 0.081). 
No association was found between Pgp activity and age (p=0.431) and sex 
(p=0.478). 
Regression analysis: in C3435T MDR1 gene SNP (R-squared= 0.24), 
presence of CC was associated with higher Pgp activity than CT (coef: 
-10.34; p= 0.024) and TT (coef:-20.14; p= 0.001); in C1236T MDR1 
gene SNP (R-squared= 0.20), presence of CC was associated with higher 
Pgp activity than CT (coef: -7.79; p= 0.066) and TT (coef:-17.26; p= 
0.005); and in the MDR1 gene SNP G2677T (R-squared= 0.13), presence 
of GG was associated with higher Pgp activity than *T (coef: -9.35; p= 
0.022).
Conclusions: The polymorphisms of the human multidrug resistance gene 
MDR1 (C3435T, C1236T and G2677T) were infl uenced by Pgp function in 
vivo in lymphocytes isolated from renal transplant recipients. Pgp activity in 
vivo also was modifi ed depending on the immunosuppressant drug treatment. 
Patients treated with TRL showed an increase of Pgp activity compared with 
CsA and SRL treatment. 
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IDENTIFICATION OF BIOMARKERS FOR MEDIUM 2245 
GRAFT FUNCTION IN PREIMPLANTATION KIDNEY 
BIOPSIES.
P. Perco1,2,3,4, A. Kainz1,2, M.. Wilfl ingseder2, C. Mitterbauer1, B. Mayer3,4, 
R. Oberbauer1,2
1Medical University of Vienna, 2KH Elisabethinen, Linz, 3University of 
Vienna, 4emergentec biodevelopment GmbH
Several studies investigated the association of histological scores of donor 
kidney biopsies obtained before engraftment with post transplant outcomes. 
Discrimination and goodness of fi t of these scores however is low. Thus we 
sought to identify and elucidate the performance of molecular rather than 
histological markers for this purpose. 
We identifi ed 80 unique differentially regulated genes in 82 samples showing 
no histological damage versus those with histological damage in at least one 
of the six BANFF07 categories. Main biological categories enriched with 
upregulated genes in damaged tissue were “immunity and defense”, “cell 
communication”, or “apoptosis”. Interestingly genes involved in cell structure, 
cell adhesion and protein traffi cking were specifi c for tubular atrophy.
Histology (CADI score) correctly predicted creatinine at one year in only 
14% (adjusted r2 for PRA, BCAR, MMsum) whereas a combination of four 
biomarkers without clinical covariables explained 33% of the creatinine 
variability at one year. The top two biomarkers alone still explained 29% of 
the variability. 
In summary, we identifi ed biomarkers in transplant kidney biopsies, which are 
predictive for medium term allograft function. The individual markers will be 
presented at the conference.
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ASSOCIATION OF MDR-1 AND CYP3A5 2246 
POLYMORPHISM WITH TACROLIMUS DISPOSITION IN 
KOREAN RENAL TRANSPLANTATION RECIPIENTS
Y.J. Park2, Y.J. Moon1, S-H. Kim2, H.J. Hong2, E.H. Ji1, Y.J. Joeng2, 
S-K. Min2, J. Ha2, J.M. Oh1, S.J. Kim2
1Collegy of Pharmacy, Seoul National University, 2Department of Surgery, 
Seoul National University College of Medicine
Background: Tacrolimus is a major immunosuppressant which has a narrow 
therapeutic range and wide interindividual variation. Because tacrolimus 
is a substrate of cytochrome P450 3A5 and P-glycoprotein, which play a 
key role in drug pharmacokinetics, it was expected that these gene would be 
associated with different drug response. Furthermore, studies have shown 
that there are clear ethnic differences in the prevalence of the CYP3A5 
genotypes. Therefore, the purpose of this study was to characterize the 
genetic variations of MDR1 and CYP3A5 on the tacrolimus disposition in 
Korean renal transplantation recipients.
Methods: Genotyping for MDR1 C1236T, G2677T/A, and C3435T and 
CYP3A5 were performed on 104 kidney recipients receiving tacrolimus-based 
immunosuppressant. Clinical data was collected retrospectively on 0.5, 1, 3, 6, 
and 12 months after transplantation. Dose-adjusted trough levels (ng/ml per mg/
kg) as well as doses (mg.kg) required to achieve target blood concentration was 
compared among patients according to the genotypes of CYP3A5 and MDR1.
Results: The mean dose required to achieve target concentration at 0.5, 1, 3, 
6, and 12 months was signifi cantly higher in patients with CYP3A5*1/*1 and 
*1/*3 compared to CYP3A5 *3/*3 (p<0.001). Dose-adjusted trough level at 
week 2 was signifi cantly higher in TT variant of MDR1 C3435T (p=0.01) and 
dose requirement at week 2 was signifi cantly lower in homozygous mutant of 
MDR1 G2677T/A (p=0.022), but there was no signifi cant difference in other 
SNPs of MDR1. A total of 14 patients out of 104 presented with the biopsy-
proven acute rejection within one month of transplantation, but the genetic 
variation had no effect on the incidence of acute graft rejection. 
Conclusion: Our data has identifi ed that polymorphism of CYP3A5 is 
signifi cantly associated with dose-adjusted trough levels of tacrolimus. 
Genotyping for CYP3A5*1/*1 and *1/*3 to identify CYP3A5 expressers has 
the potential to identify individuals with a high dose requirement for tacrolimus 
and may be a useful tool for individualizing immunosuppressive drug treatment 
in Korean renal transplantation recipients.
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EARLY POST TRANSPLANT ANAEMIA IS NOT 2247 
ASSOCIATED WITH THE ANGIOTENSIN II TYPE 1 
A1166C SINGLE NUCLEOTIDE POLYMORPHISM OR 
ANGIOTENSIN CONVERTING ENZYME INSERTIN/DELETION 
POLYMORPHISM IN RENAL TRANSPLANTATION
J. Irvine1, A. Pilbrow1, C. Frampton1, Z. Endre2, M. Richards1, V. Cameron1
1Cardioendocrine Reseach Group, Christchurch, 2Renal Research Group, 
Christchurch
Introduction: Post-transplant anaemia (PTA) is a common phenomenon. The 
cause of PTA is multi-factorial. ACE inhibitors can contribute to PTA and their use 
to alleviate post transplant erythrocytosis is a well-recognised management option. 
However the response can be variable and the mechanism is poorly understood
The angiotensin II type 1 receptor (AT1R) has an important role in determining 
serum erythropoietin levels. The AT1R has a single base substitution of the 
adenine to cytosine at position 1166 of the 3’ untranslated region (A1166C). 
The C-allele of this single nucleotide polymorphism (SNP) has been associated 
with increased activity of the renin-angiotensin system (RAS) with augmented 
angiotensin II activity. The angiotensin converting enzyme insertion/deletion 
(ACE I/D) polymorphism is a 287 base pair insertion of the ACE gene. The 
D-allele is associated with higher serum ACE concentration. 
The aim of this study was to investigate associations between kidney transplant 
recipient AT1R A1166C and ACE I/D genotype and PTA 6 months post 
transplantation. We hypothesised that the presence of an AT1R C-allele and/or 
ACE D-allele would be associated with a reduced prevalence of PTA.
Methods: This is a retrospective study. Recipients (n=163) were genotyped for 
the AT1R A1166C and ACE I/D polymorphisms. All recipients were older than 
18 years and had a functioning graft for more than 90 days. Anaemia was defi ned 
using the World Health Organisation criteria as a serum haemoglobin concentration 
<130 g/L in men and <120g/L in women. For statistical analyses AT1R AC and CC 
genotypes were combined, and ACE ID and DD genotypes were combined.
Results: The gene frequency of the AT1R A1166C polymorphism was 53% AA, 
40% AC and 7% CC. and the frequency of the ACE I/D polymorphism was 20% 
II, 45% ID and 35% DD. As expected, haemoglobin concentration 6-months 
post-transplant was signifi cantly associated with gender, with males having a 
higher concentration (133g/L versus 122g/L, p<0.001). In a univariate model 
adjusted for gender and use of ACE inhibitors or angiotensin receptor blockers, 
there was no signifi cant association between haemoglobin concentration 
and AT1R or ACE genotype (AT1R C-allele p=0.72, ACE D-allele p=0.82). 
Furthermore, there was no synergistic interaction between AT1R and ACE 
genotypes on haemoglobin concentration after adjustment for gender, ACE 
inhibitor and angiotensin receptor blocker treatment and genotype main effects. 
In anaemic recipients, the frequency of the AT1R C-allele or ACE D-allele did 
not differ from non-anaemic recipients (p=0.90 and p=0.70 respectively).
Conclusions: In this cohort of graft recipients, the AT1R A1166C and ACE I/D 
genotypes were not associated with early post transplant haemoglobin or the 
presence of anaemia.
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LONGITUDINAL PATTERN OF DIFFERENTIAL GENE 2248 
EXPRESSION WITHIN THE FIRST 3 MONTHS FOLLOWING 
RENAL TRANSPLANTATION
P. Keown, Z. Hollander, O. Gunther, G. Cohen-Freue, D. Lin, 
J. Wilson-McManus, R. Balshaw, R. Ng, R. McMaster, B. McManus
University of British Columbia
Introduction: Whole-genome expression analysis was used to identify patterns 
of differential expression prior to and during the fi rst 3 months following renal 
transplantation in patients with a quiescent clinical course. A longitudinal 
cohort design was employed for discovery and validation of genomic markers. 
Blood, tissue and urine samples were obtained throughout the fi rst 12 weeks 
in 106 sequential subjects receiving a renal transplant with rigorous control 
of treatment variables in a single university centre. Samples were analyzed 
using Affymetrix Human Genome U133 plus 2.0 microarrays, analysed using 
Linear Models for Microarray Data (Limma) after conventional normalization 
and pre-fi ltering. 
Results: Baseline expression was compared in 72 subjects, comprising 
52 uremic pre-transplant patients and 20 normal controls. After RMA 
normalization and prefi ltering, hierarchical clustering and multivariate 
analysis of normal subjects and uremic pre-transplant patients showed distinct 
segregation between these populations with statistically signifi cant differential 
expression in 11,156 probe sets encompassing bioamine synthesis, cellular 
metabolic processes, hormonal function, erythropoiesis, macromolecular 
processes, cell communications, neutrophil functions and other key biological 
processes. Differential expression within the pre-transplant cohort was noted 
according to primary renal disease, with discrete patterns for subjects with 
diabetic nephropathy, glomerulonephritis, polycystic disease and other 
renal disorders. Principal components analysis showed clear defi nition by 
treatment, accurately categorizing subjects who were pre-dialysis from those 
receiving hemodialysis or peritoneal dialysis therapies according to GO terms 
of cell growth and maintenance, cell communication, transcription and protein 
metabolism. Transplantation caused a profound alteration in gene expression 
even in quiescent patients, with a rapid and transient increase or decrease 
in expression of almost 200 probesets during the fi rst post-operative week 
which returned to baseline by weeks 2-4. Subjects with sustained clinical 
and immunological quiescence throughout the fi rst 3 months post-transplant 
exhibited profound suppression of probesets encompassing immunoglobulin 
genes, infl ammatory cytokines, chemokines and other mediators of 
infl ammatory injury. Subsets of these genes returned gradually to normal 
levels by 3 months post-transplant, commensurate with the gradual reduction 
in dose of immunosuppressive agents.
Summary: Monitoring gene expression in the peripheral blood identifi es 
longitudinal biological processes, and may provide the fi rst insight into the 
mechanisms of immunological accommodation permitting controlled reduction 
of immunosuppression.
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DIFFERENTIAL GENE EXPRESSION IN ACUTE 2249 
AND CHRONIC REJECTION FOLLOWING RENAL 
TRANSPLANTATION.
Z. Hollander, G. Cohen-Freue, D. Lin, J. Wilson-McManus, R. Balshaw, 
R. Ng, R. McMaster, B. McManus, P. Keown
University of British Columbia
Introduction: Whole-genome expression analysis was used to identify 
molecular mechanisms and to identify predictive biomarkers of acute and 
chronic immune injury following renal transplantation. A total of 165 sequential 
renal allograft recipients were divided into early and late-phase discovery and 
validation cohorts. RNA was collected longitudinally at weeks 1, 2, 3, 4, 8, 
12, 24, 36 and 52 and every 3 months thereafter, along with renal allograft 
tissue at the time of graft dysfunction or potential rejection. Gene expression 
was measured using Affymetrix Human Genome U133 plus 2.0 microarrays, 
analysed using Linear Models for Microarray Data (Limma) after conventional 
normalization and pre-fi ltering. 
Results: All subjects received standard quadruple immunosuppression. Graft 
function was determined using clinical, laboratory and histological (Banff 
97) criteria, and patients were selected to eliminate confounding events 
including DGF, CMV, sepsis and disease recurrence. Analysis compared gene 
expression in patient cohorts with clinical quiescence, borderline rejection, 
acute rejection (Banff grade „d1) and chronic graft injury. There was a marked 
perturbation in gene expression/inhibition during the fi rst 4 weeks refl ecting 
surgery, healing and intervention. Principal component analysis showed that 
few genes were differentially expressed in borderline rejection, but 135 genes 
were highly signifi cantly differentially expressed in acute rejection compared 
to quiescence, comprising cellular, macromolecular, regulatory and immune 
system processes. In the late phase, no genes were differentially expressed 
in classical chronic rejection and 3 key candidates were identifi ed in non-
specifi c chronic allograft nephropathy (CAN).
Summary: Gene expression is markedly perturbed post-transplant refl ecting 
concomitant processes of injury, healing and immunity. Acute rejection 
is accompanied by a characteristic signal of molecular events which may 
provide a valuable biomarker, but chronic injury appears relatively silent in 
the peripheral blood.
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THE EXPRESSION OF RENAL KLOTHO IS DECREASED 2250 
IN DECEASED DONOR KIDNEYS 
T. Mueller, P. Halloran, V. Luyckx
University of Alberta
Klotho is a gene almost exclusively expressed in renal distal tubules and 
loss of expression is associated with accelerated aging. In various models 
of acute and chronic renal injury, and with normal aging, renal klotho 
expression has been found to decrease. Increased donor age is associated 
with poorer long term allograft function. We hypothesized that klotho 
mRNA expression in renal implant biopsies would correlate with donor 
kidney quality, as determined by donor chronologic age and peri-transplant 
renal injury. 
Our recent unsupervised microarray analysis of 87 renal implant biopsies 
revealed a continuum of organ quality across all samples ranging from the 
best living donor (LD) kidneys at one end to the worst performing deceased 
donor (DD) kidneys at the other (Am J Transpl 2007, Nov 16,epub). Three 
predominant groups were identifi ed of LD, DD1 kidneys with low risk 
(9.5%) of delayed graft function (DGF) and DD2 kidneys with high risk 
(35%) of DGF (p < 0.05). Analysis of klotho gene expression among these 
groups also revealed a spectrum of expression from highest levels in LD to 
lowest in DD2 kidneys, especially those who developed DGF. Differences 
were highly signifi cant among LD vs DD kidneys (p < 0.001), although 
donor age was not different between these groups. 
Klotho transcript levels were signifi cantly different among kidneys that 
developed DGF compared to those with immediate graft function (IGF) (p < 
0.05). An additional analysis of different post-transplant complications in 114 
samples from kidney biopsies for cause showed an age-independent association 
of Klotho expression with extent of tubular damage.
In conclusion, reduced klotho gene expression is associated with grafts at risk 
of poorer function and appears to be independent of donor age. Decreases in 
klotho expression likely refl ect other factors impacting the renal tissue, which 
may impact potential for repair and ultimately allograft function.
ISCHEMIA AND CONCURRENT ORAL SESSION 151: 
REPERFUSION
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RECOVERY OF TACROLIMUS ASSOCIATED BRACHIAL 2251 
NEURITIS AFTER CONVERSION TO EVEROLIMUS IN 
A PEDIATRIC RENAL TRANSPLANT RECIPIENT; CASE 
REPORT AND REVIEW OF THE LITERATURE
S. Quader, O.A. Masri, W. Fathalla
Sheikh Khalifa Medical City
Abstract: Tacrolimus (TAC) has been shown to be a potent immunosuppressive 
agent for solid organ transplantation in pediatrics. Neurotoxicity is a 
potentially serious toxic effect. It is characterized by encephalopathy, 
headaches, seizures or neurological defi cits. Here we describe an 8 ½ -year- 
old renal transplant boy with right Brachial Neuritis (BN). MRI demonstrated 
hyperintense T2 signals in the cervical cord and right brachial plexus roots 
indicative of both myelitis and right brachial plexitis. Symptoms persisted for 
3 months despite TAC dose reduction, administration of IVIG and 4 doses of 
methylprednisolone pulse therapy. Improvement and eventually full recovery 
only occurred after TAC was completely discontinued and successfully 
replaced by Everolimus.
.POSTER BOARD NUMBER P4 – 302
DECREASED NEUTROPHIL-MEDIATED RENAL 2252 
DYSFUNCTION AND TUBULAR APOPTOSIS FOLLOWING 
RENAL ISCHEMIA-REPERFUSION IN CCR1-DEFICIENT MICE
M. Araki1,2, H. Kumon2, R. Fairchild1
1Cleveland Clinic, 2Okayama University School of Medicine
Objective: Ischemia/reperfusion (I/R) injury is an unavoidable component 
of solid organ transplantation that negatively impacts graft function and 
survival. Neutrophil infi ltration is a key mediator of I/R injury. Neutrophils 
express CCR1 which may play a role in directing this infi ltration. The goal of 
the current study was to investigate the induction and role of the chemokine 
receptor, CCR1, in a model of renal I/R injury. 
Methods: C57BL/6 wild-type and CCR1-/- mice were anesthetized and the 
renal hilum was clamped for 45 min while the temperature was maintained at 
32°C. At various times post-reperfusion, ischemic and control kidneys were 
removed, whole cell RNA was prepared and tested for expression of chemokine 
receptor genes by ribonuclease protection assay. Frozen or paraffi ne sections were 
prepared from kidneys and stained for neutrophils, macrophages, MIP-1a by 
immunohistochemistry. Serum creatinine was measured each day post-reperfusion. 
In some experiments mice were depleted of neutrophils by treatment with anti-
mouse Ly-6G rat IgG. TUNEL assay was performed to detect apoptosis. 
Results: CXCR2 and CCR1 were the most highly expressed receptors in 
ischemic kidneys with expression peaking 18 h after reperfusion and increasing 
again after 24 hr. The ligands for CCR1, MIP-1a and RANTES, were clearly 
present in the tubular epithelial cells at these time points. Renal dysfunction was 
abrogated in CCR1-/- mice and histopathology analyses indicated markedly less 
renal tissue damage and apoptosis of tubular epithelial cells when compared to 
wild-type mice. Immunohistochmistry indicated less neutrophil infi ltration in 
the renal tissue. Survival of CCR1-/- mice was signifi cantly better following 
renal I/R injury than wild-type mice. 
Conclusions: CCR1 plays an important role in kidney ischemia/reperfusion injury 
by decreasing neutrophil infi ltraion in renal tissue after reperfusion. CCR1 can be 
the target to reduce renal ischemia reperfusion injury in the clinical situation.
POSTER BOARD NUMBER P4 – 303
THE ROLE OF CALCIUM (CA2+) IN MODULATION OF 2253 
SMOOTH MUSCLE CELLS REACTIVITY TO ANGIOTENSIN II 
(ANG II) DURING ISCHEMIA/REPERFUSION (I/R).
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, M. Jasinski1, 
G. Grzesk2
1Department of Transplantation And General Surgery, Collegium Medicum 
Nicolaus Copernicus University, Bydgoszcz, Poland, 2Department of 
Pharmacology and Therapeutics, Collegium Medicum Nicolaus Copernicus 
University, Bydgoszcz, Poland
Background: The aim of this study was to examine the role of Ca2+ in reactivity 
of arteries to ANG after I/R and to determine the function of antioxidative 
system in this phenomenon.
Material and methods: Experiments were performed on male Wistar rats tail 
artery retrieved and preserved in the UW solution for 12 hours. The effects of 
ANG II were examined after I/R in the presence of catalase or aminotriazole. To 
determine the role of intra and extracellular Ca2+ experiments were performed 
in Ca2+ free PSS (FPSS) and PSS. 
Results: ANG II increased perfusion pressure in both FPSS (66mmHg) and 
PSS (91mmHg). After ischemia reactions induced by ANG II were lower 
(17mmHg in FPSS; 24mmHg in PSS), while after 120 min. of reperfusion 
were higher (117 mmHg in FPSS; 209mmHg in PSS). In the presence of 
catalase perfusion pressure was 39 mmHg in FPSS and 48 mmHg in PSS, 
after ischemia: 28 mmHg in FPSS and 30 mmHg in PSS, after 120 min of 
reperfusion: 73 mmHg in Ca2+-free PSS and 139 mmHg in PSS. In the 
presence of aminotriazole perfusion pressure was 89 mmHg in FPSS and 127 
mmHg in PSS, after ischemia: 43 mmHg in FPSS and 77 mmHg in PSS, after 
120 min of reperfusion: 124 mmHg in FPSS and 263 mmHg in PSS. 
Conclusion: Contractile effects of ANG II are mediated by both intra- and 
extracellular Ca2+. Results suggest that antioxidative system plays a role in 
modulating reactions induced by ANG II after I/R injury.
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N-ACETYL CYSTEINE HÁS A BENEFICIAL EFFECT 2254 
ON PANCREAS AND KIDNEY FOLLOWING PANCREATIC 
ISCHEMIA-REPERFUSION
R. Meirelles, T. Bacchella, M. Kubrusly, M. Machado
Disciplina de Transplante do Hospital Das Clínicas Da FMUSP – LIM37
Introduction: Simultaneous pancreas-kidney transplantation became the 
fi rst treatment option for type I diabetes patients with end stage renal failure. 
However, graft acute pancreatitis remains a frequent complication (35%) on 
immediate pos-operative time. It may contribute to pancreas graft loss and 
kidney delay graft function (KDGF). Ischemia-reperfusion injury may be 
involved in the pathogenesis of graft pancreatitis and KDGF. Glutathione-
S-transferases (GST) enzymes provide protection against reactive oxygen 
species, by catalyzing the formation of glutathione conjugates and by 
eliminating peroxides during ischemia-reperfusion injury. N-acetyl cysteine 
(NAC) has been shown to improve pancreatic microcirculation alterations and 
renal function.
AIM: Evaluate pancreatic and renal injury and expression level of isoform 
GST-á after pancreatic ischemia-reperfusion induction on rat model.
Methods: Twenty-four Wistar rats weighting 300-350g were divided into 
four groups: Group 1 – sham; Group 2 – ischemia-reperfusion; Group 3 – 
ischemia-reperfusion plus NAC iv; Group 4 – ischemia-reperfusion plus NAC 
po. Splenic pancreatic portion underwent to 1 hour ischemia followed by 4 
hours of reperfusion. Group 3 received intravenously150mg/kg body weight 
15 minutes before reperfusion followed by 50mg/kg body weight during the 
remaining time. Group 4 received NAC (4800 mg/L) ad libitum 48 hours 
before the experiment. Blood, splenic pancreatic and renal tissue samples 
were collected after 4hour of reperfusion. Serum amylase and creatinine were 
determined. Expression level of isoform GST-á was evaluated by quantitative 
real-time polymerase chain reaction (qRT-PCR) for both tissue samples. Total 
pancreatic and renal RNA (20ng) from all animals were subjected to qRT-PCR. 
Normalized qRT-PCR data were determined from the ratio of GST-á/â-actin 
values for each sample.
Results: Serum amylase level were 6.11 (sd=0.55) mg/mL/min, 10.30 
(sd=0.50) mg/mL/min, 9.77 (sd=1.24) mg/mL/min and 7.82 (sd=0.38) mg/mL/
min in Groups 1, 2, 3 and 4, respectively. There was an increase in serum 
amylase when compared group 1 with group 2 (p=0.0002) and a decrease when 
compared group 2 with group 4 (p=0.003). An increase in GST-á expression 
was observed in groups 3 and 4 when compared to group 2 (p=0.016). Serum 
creatinine level were 0.52 (0.07) mg/dL, 0.77 (0.18) mg/dL, 0.48 (0.13) mg/
dL and 0.25 (0.83) mg/dL in Groups 1, 2, 3 and 4, respectively. There was 
an increase in serum creatinine level when compared group 1 with group 2 
(p=0.012) and a decrease when compared Groups 2 and 3 (p=0.03). An increase 
in renal GST-á gene expression was observed in group 2 when compared to 
group 1 (p=0.013).
Conclusion: NAC given 48 hours before experimental ischemia-reperfusion 
injury induction normalizes hyperamilasemia. This protective effect in 
pancreatic tissue under ischemia-reperfusion injury may be due to an increase 
in expression level of GST-á gene. NAC given iv improves renal function. 
Finally, renal GST-á gene expression is already increased during pancreatic 
ischemia-reperfusion injury. NAC may have a potential benefi t in pancreas-
kidney transplantation. (FAPESP)
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THE ROLE OF G PROTEIN AND CALCIUM (CA2+) 2255 
IN THE REACTIVITY OF ARTERIES DURING ISCHEMIA/
REPERFUSION (I/R) INJURY
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, 
M. Jasinski1, G. Grzesk2
1Department of Transplantation and General Surgery, Collegium Medicum 
Nicolaus Copernicus University, Bydgoszcz, Poland, 2Department of 
Pharmacology and Therapeutics, Collegium Medicum Nicolaus Copernicus 
University, Bydgoszcz, Poland
Background: The aim of this study was to examine the role of G protein and 
Ca2+ in the reactivity of the vascular smooth muscle cells during I/R injury to 
angiotensin II (ANG II), phenylephrine (PHE) in comparison to Bay K8644.
Material and methods: Experiments were performed on isolated and perfused 
male Wistar rats tail artery retrieved and preserved in the UW solution for 12 
hours. We investigated the effects of ANG II, PHE and BAY K8644 on vascular 
tone in Ca2+- free PSS (FPSS) and PSS. The results were compared with 
reactions after I/R, without or in presence of G protein blocker – Bordetella 
pertussis toxin (P 7208). 
The constriction of the rat tail artery in response to ANG II, PHE and BAY 
K8644 was measured as an increase of perfusion pressure at a constant fl ow of 
the perfusion fl uid (about 1ml/min.). 
Results: ANG II and PHE increased perfusion pressure in FPSS (ANG II: 66 
mmHg, PHE: 61 mmHg) and PSS (ANG II: 91 mmHg; PHE: 86 mmHg). After 
ischemia, reactions were lower (ANG II: 33 mmHg in FPSS; 37 mmHg in 
PSS; PHE: 28 mmHg in FPSS; 35 mmHg in PSS), while after 120 min. of 
reperfusion were higher (ANG II: 93 mmHg in FPSS; 193 mmHg in PSS; PHE: 
84 mmHg in FPSS; 181 mmHg in PSS). In the presence of P 7208 reaction 
induced by ANG II was decreased only in FPSS to 36 mmHg, while reactions 
on PHE were inhibited in both – FPSS (36 mmHg) and in PSS (54 mmHg). 
Bay K8644 increased perfusion pressure only in PPS (74 mmHg), and it wasn’t 
infl uenced by P 7208 and I/R. 
Conclusion: Results suggest that G protein modulates effects of ANG II 
mediated by intracellular Ca2+ and plays a role in reactions of PHE mediated 
by both intra- and extracellular Ca2+.
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THE ROLE OF ENDOTHELIUM IN CONTRACTION 2256 
OF THE VASCULAR SMOOTH MUSCLE CELLS DURING 
ISCHEMIA/REPERFUSION.
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, 
L. Szadujkis-Szadurski2, M. Jasinski1
1Department of Transplantation and General Surgery, Collegium Medicum 
Nicolaus Copernicus University, 2Department of Pharmacology and 
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: The aim of this study was to examine the role of endothelium 
in contraction of the vascular smooth muscle cells induced by angiotensin II 
(ANG II) during I/R.
Material and methods: Experiments were performed on perfused male 
Wistar rats’ tail artery with or without endothelium. The infl uence of ANG II 
on vascular contraction estimated for vessels with or without endothelium was 
compared with reactions in the presence of SNP (sodium nitroprusside) and 
8Br-cGMP. Then effect of ANG II on vessels with or without endothelium was 
compared with reactions after ischemia and reperfusion. 
Results: Vascular contraction induced by ANG II (in vessels with or 
without endothelium) was decreased by SNP and 8Br-cGMP (10-100μM/l) 
respectively to 37(±14)% and 44(±14)% for SNP and 33(±12)% and 
29(±9)% for 8Br-cGMP. EC50 for ANG II were 1.22(±0.23)x10-8 and 
1.44(±0.24)x10-8, in the presence of SNP 3.33(±0.34)x10-8 and 5.92(±0.24)
x10-7, in the presence of 8BrcGMP 5.26(±0.22)x10-7 and 5.02(±0.27)x10-7. 
After ischemia CRC for ANG II was shifted to the right with reduction 
in maximal response, but this effect was not observed in vessels without 
endothelium, where after 30, 60 and 90 min. of reperfusion CRCs were 
shifted to the left with increase in maximal responses. EC50 for ANG II 
were 1.22(±0.23)x10-8, after ischemia 2.89(±0.33)x10-8, after 90 min. of 
reperfusion 2.17(±0.22)x10-9. 
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Conclusion: Reduction of the vascular contraction on ANG II caused by 
ischemia is connected with the presence of endothelium, synthesis of NO and 
activation of cGMP.
The increase of reaction on ANG II induced by reperfusion is not dependent 
on endothelium.
POSTER BOARD NUMBER P4 – 307
CHANGES IN THE CONTRACTILITY OF THE 2257 
VASCULAR SMOOTH MUSCLE CELLS IN REACTION TO ANG 
II INDUCED BY CATALASE AND AMINOTRIAZOLE DURING 
ISCHEMIA/REPERFUSION.
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, G. Grzesk2, 
M. Jasinski1
1Department of Transplantation and General Surgery, Collegium Medicum 
Nicolaus Copernicus University, 2Department of Pharmacology and 
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: The aim of this study was to examine the effect of I/R injury 
on reactivity of arteries to ANG II and to determine the role of antioxidative 
system in this phenomenon.
Material and methods: Experiments were performed on male Wistar rats tail 
artery retrieved and preserved in the UW solution for 12 hours.
The effects of ANG II on vascular tone were examined after 30 min. of 
ischemia and 30, 60 and 90 min. of reperfusion. Then infl uence of catalase and 
aminotriazole on contraction was investigated. Cumultative response curves 
(CRCs) to agonists KA and EC50, pD2 values were calculated using commonly 
approved methods.
Results: After ischemia, CRC for ANG II was shifted to the right with reduction 
in maximal response, while after 30, 60 and 90 min. of reperfusion CRCs were 
shifted to the left with increase in maximal responses. EC50 for ANG II were 1.22 
(±0.23) x 10-8, after ischemia 2.89 (±0.33) x 10-8, after 90 min. of reperfusion 2.17 
(±0.22) x 10-9. In the presence of catalase calculated EC50 values were higher, 
while in the presence of aminotriazole EC50 values were lower. EC50 for ANG II 
in the presence of catalase were 8.26 (±0.29) x 10-8, after ischemia 1.29 (±0.31) x 
10-7, after 90 min. of reperfusion 5.57 (±0.24) x 10-9.
Conclusion: Ischemia reduces, but reperfusion augments vascular tone 
induced by ANG II. Catalase inhibits, while aminotriazole increases contractile 
response of vascular smooth muscle cells to ANG II after I/R. This results 
suggest that antioxidative system modulates reactions induced by ANG II, and 
reperfusion impairs the balance between antioxidants and the production of 
reactive oxygen species.
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THE INFLUENCE OF ISCHEMIA/REPERFUSION (I/R) 2258 
INJURY ON THE REACTIVITY OF ARTERIES INDUCED BY 
ANGIOTENSIN II (ANG II) AND PHENYLEPHRINE (PHE).
M. Slupski1, K. Szadujkis-Szadurska2, R. Szadujkis-Szadurski2, 
L. Szadujkis-Szadurski2, M. Jasinski1
1Department of Transplantation and General Surgery, Collegium Medicum 
Nicolaus Copernicus University, 2of Pharmacology and Therapeutics, 
Collegium Medicum Nicolaus Copernicus University
Introduction: The aim of this study was to examine reactivity of arteries 
during I/R on ANG II and PHE in the presence of G protein blocker (Bordetella 
pertussis toxine, P 7208), phospholipase C inhibitor (D609) and antagonist of 
the IP3 receptor – xestospongin C (XeC). 
Material and methods: Experiments were performed on male Wistar rats tail 
artery retrieved and preserved in the UW solution for 12 hours. The effects of 
ANG II and PHE were examined after I/R in the presence of P 7208, D609, 
XeC. Experiments were performed in Ca2+ free PSS (FPSS) and PSS. 
Results: ANG II and PHE increased perfusion pressure in FPSS (ANG II: 66 
mmHg, PHE; 61 mmHg) and PSS (ANG II: 91 mmHg; PHE: 86 mmHg). After 
ischemia reactions were weaker (ANG II: 33 mmHg in FPSS; 37 mmHg in 
PSS; PHE: 28 mmHg in FPSS; 35 mmHg in PSS), while after 120 min. of 
reperfusion were stronger (ANG II: 93 mmHg in FPSS; 193 mmHg in PSS; 
PHE: 84 mmHg in FPSS; 181 mmHg in PSS). In the presence of P 7208 and 
D609 perfusion pressure induced by ANG II was decreased only in FPSS (36 
mmHg; 10 mmHg), while reactions on PHE were inhibited in both – FPSS (36 
mmHg; 39 mmHg) and in PSS (54 mmHg; 51 mmHg). XeC inhibited reactions 
only in FPSS (ANG II: 12 mmHg, PHE: 33 mmHg).
Conclusion: Contractile effects of ANG II and PHE are mediated by intra- 
and extracellular Ca2+. P 7208 and D609 inhibit reaction to ANG II only in 
Ca2+ free PSS. In distinction from ANG II, reaction of the smooth muscle cells 
induced by PHE is inhibited by P 7208 and D609 in both – Ca2+ free PSS and 
PSS. These results suggest that G protein and phospholipase C play a role in 
vascular contraction induced by ANG II mediated by intracellular Ca2+ and 
modulate reactions to PHE mediated by both intra- and extracellular Ca2+.
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THE INFLUENCE OF ISCHEMIA-REPERFUSION INJURY 2259 
ON THE EFFECT OF RHO-KINASE INHIBITORY-27632 ON 
CONTRACTILE ACTIVITY INDUCED BY ANG II IN HUMAN 
MESENTERIC ARTERIES RETRIEVED AND CONSERVED 
UNDER THE SAME CONDITIONS AS TRANSPLANTED 
ORGANS.
M. Slupski1, R. Szadujkis-Szadurski2, K. Szadujkis-Szadurska2, 
L. Szadujkis-Szadurski2, M. Jasinski1, Z. Wlodarczyk1
1Department of Transplantation and General Surgery, Collegium Medicum 
Nicolaus Copernicus University, 2Department of Pharmacology and 
Therapeutics, Collegium Medicum Nicolaus Copernicus University
Background: In this study the infl uence of Rho-kinase inhibitor and 
calcium on reactions of the smooth muscle cells induced by ANG II after I/R 
were investigated. 
Material and methods: Experiments were performed on perfused human 
mesenteric superior arteries. The infl uence of ANG II on vascular contraction, 
mediated by intra- or extracellular calcium, in the presence of Y-27632, 
after ischemia and reperfusion was analyzed using classical pharmacometric 
methods.
Results: Vascular contraction induced by ANG II was decreased by Y-72632. 
Maximal response was reduced after ischemia, but after reperfusion an increase 
was observed. Y-72632 reduces vascular contraction after reperfusion, mediated 
by both intra- and extracellular calcium.
Conclusion: Reperfusion augments vascular contraction in reaction to ANG 
II. Rho-kinase inhibitor – Y-27632 reduces the effect induced by ANG II after 
reperfusion.
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ERYTHROPOIETIN TREATMENT PROTECTS AGAINST 2260 
RENAL ISCHEMIA/REPERFUSION INJURY THROUGH THE 
UP-REGULATION OF SERUM AND GLUCOCORTICOID-
REGULATED KINASE-1
K. Rusai1, V. Muller2, A. Prokai1, A. Fekete1, B. Szebeni1, A. Vannay3, A. 
Treszl3, U. Heemann4, J. Lutz4, A.J. Szabo1
1Semmelweis University, I. Dept. of Pediatrics, 2Semmelweis University, Dept. 
of Pulmonology, 3Szentagothai Research Center, 4Klinikum rechts der Isar, 
Dept. of Nephrology
The serum- and glucocorticoid-inducible protein kinase 1 (SGK1) is an anti-
apoptotic serine-threonine protein kinase mainly induced through the p38 
MAPK pathway. It has been shown that the phosphorylated form mediates 
protection against various forms of cellular stress. We determined the effect of 
the erythropoietin (EPO), of which apoptosis inhibiting properties have been 
proved in several forms of ischemic injury on SGK1 expression both in an in 
vitro and in vivo models of renal ischemia/reperfusion (I/R) injury. 
In vitro, EPO exerted a protective effect on hypoxic human embryonic kidney 
(HEK) cells detected by Annexin V FACS analysis which was paralleled by 
a signifi cant overexpression of SGK1 shown by RT-PCR and Western blot 
analysis. Treatment of HEK cells with the p38 MAPK inhibitor resulted in 
a decreased induction of SGK1 after EPO administration. Downregulation of 
SGK1 expression by small interfering RNA abolished the anti-apoptotic effect 
of the EPO treatment. In renal I/R injury, pre-treatment of rats with EPO had 
a signifi cant protective effect on tissue injury and renal function. Furthermore, 
expression and phosphorylation of SGK1 were higher in EPO treated animals 
compared to vehicle treated rats assessed by real-time PCR, Western blot and 
immunofl uorescence techniques.
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In conclusion, SGK1 could mediate the protective effects of the anti-apoptotic 
EPO under ischemic conditions demonstrated in the I/R injury of the kidney.
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THE EXPRESSION OF CYSTEINYL-LT1 RECEPTOR 2261 
(CYSLT1R) IN RENAL ISCHEMIA-REPERFUSION INJURY OF 
LEWIS RAT MODEL
M. Matsuyama1,2, K. Funao1, J. Chargui2, J-L. Touraine2, T. Nakatani1, 
R. Yoshimura1
1Department of Urology, Osaka City University Graduate School of Medicine, 
2Department of Transplantation and Clinical Immunology, Claude Bernard 
University of Lyon and Lyon Hospitals, Lyon, France
Background: Renal transplantation has made substantial strides in the past few 
decades, with the introduction of improved immunosuppressive regimens, organ 
preservation, and pre- and postoperative care. Nevertheless, there is considerable 
room for improvement, particularly in terms of improving long-term outcome. 
The pathogenesis of ischemia-reperfusion (I/R) injury is known to involve 
cytokines and particularly surface adhesion molecules, the expression of which 
initiates the attachment of infl ammatory cells. Renal I/R injury is also clinically 
important problem and invariable consequence of renal transplantation. The 
problem begins at the onset of acute tubular necrosis, when the transplantation 
takes a long ischemic interval by using the cardiac arrest donor’s kidney. In 
addition, the longer the ischemic interval, the higher in the incidence rate of 
acute tubular necrosis. Generally, cysteinyl leukotriene1 receptor (CysLT1R) 
is am important mediator of human bronchial asthma and CysLT1R antagonist 
is clinically used in treating human bronchial asthma. However, no report has 
addressed the relationship between renal I/R injury and CysLT1R. In this study, 
we researched the expressions CysLT1R in renal I/R injury.
Materials and Methods: Male Lewis rats (270-320g) were used in this study. 
Under laparotomy using pentobarbital sodium anesthesia, the right kidney was 
harvested and then the left renal artery and vein were clamped with a hemostasis 
clip for 90 minutes. The clip was subsequently removed to permit reperfusion. 
The abdomen was closed during I/R. The left kidneys were reperfused, the rats 
were sacrifi ced at 0, 3, 5, 12 and 24 hours after reperfusion. The kidneys were 
harvested for HE staining and immunohistochemistry. Samples of ischemic 
and nonischemic kidney tissue were fi xed in 10% buffered formalin for 24 
hour for immunohistochemical staining.
Results: CysLT1R expression was observed only in endothelial cells of normal 
kidney. From 0 to 3 hours after reperfusion, CysLT1R expression gradually 
became stronger on endothelial cells. CysLT1R expression was most intense on 
endothelial cells at 3 hour after reperfusion. Five hours after reperfusion, internal 
spaces of the tubular epithelial cells were expanded, and slight destruction of 
the tubular epithelial cells appeared. Twelve hours after reperfusion, necrosis 
extended throughout the ischemic kidney and nearly all the tubular epithelial 
cells were destroyed, but from 3 to 12 hours after reperfusion, CysLT1R 
expression gradually became weaker on endothelial cells. Twenty-four hour after 
reperfusion, CysLT1R expression was almost normal level of normal kidney. 
Naturally, renal I/R injury gradually progressed at time fl ow after reperfusion. 
Several hours after the maximum of CysLT1R expression, the maximum of 
renal I/R injury was observed.
Conclusions: These results suggest CysLT1R play very important roles on 
renal I/R injury in rat, and CysLT1R plays very important roles on renal I/R 
injury in rat.
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SYNTHETIC OLIGOPEPTIDES RELATED TO HUMAN 2262 
CHORIONIC GONADOTROPIN AMELIORATE RENAL 
ISCHEMIA-REPERFUSION INJURY
R.W.F. de Bruin1, D. Susa1, N.A. Khan2,3, M. Huisman1, M.H. Ameling2, S. 
van den Engel1, H.P. Roest1, J.N.M. IJzermans1, R. Benner2
1Erasmus Medical Centre, Department of Surgery, Rotterdam, The 
Netherlands, 2Erasmus Medical Centre, Department of Immunology, 
Rotterdam, The Netherlands, 3Biotempt b.v., Koekange, The Netherlands
We have previously reported that small synthetic oligopeptides related to the 
primary structure of the pregnancy hormone human β-chorionic gonadotropin 
(β-hCG) can reduce infl ammation. Here we investigated whether such 
oligopeptides are able to reduce ischemia reperfusion injury (I/R) of the 
kidney. 
I/R injury was induced by clamping the left kidney of male C57BL6J mice 
for 25 minutes. After releasing the clamp, the contralateral kidney was 
removed.
Ten different oligopeptides were administered intravenously at a dosage 
of 5 mg/kg BW one minute before induction of ischemia and 1 minute 
before reperfusion. Mice were sacrifi ced at 6, 24 and 72 hours post-
reperfusion. Survival, kidney function, infl ammatory cells, proliferation, 
apoptosis, serum cytokine levels and mRNA levels for genes of interest 
were determined.
Ischemia reperfusion injury resulted in a 50% mortality in placebo treated 
mice three days after reperfusion. In contrast, mortality was signifi cantly 
reduced in mice treated with the peptide LQG (90%), and completely 
prevented in animals treated with MTRV, VLPALPQ or AQGV. AQGV was 
the most effective peptide since it not only completely prevented mortality 
but also best preserved kidney function as assessed by serum urea and 
creatinine levels. 
Upon treatment with AQGV, E-selectin mRNA levels in kidneys were 
signifi cantly decreased at 6 hours post-reperfusion. At 24 hours post-
reperfusion, a signifi cantly lower infl ux of neutrophils was found, renal tubular 
epithelial cell proliferation as assessed by KI-67 immunohistochemistry was 
signifi cantly increased, and the number of TUNEL-positive apoptotic cells was 
signifi cantly decreased. Serum levels of TNF-α, INF-γ, IL-6 and IL-10 were 
signifi cantly decreased at 24 hours post reperfusion. 
This study shows that small synthetic oligopeptides related to the primary 
structure of β-hCG, especially AQGV, are promising potential drugs for the 
treatment of ischemic renal injury.
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CONNECTIVE TISSUE GROWTH FACTOR STIMULATES 2263 
ENDOTHELIAL-MESENCHYMAL TRANSITION OF RAT 
AORTIC ENDOTHELIAL CELLS
Z. Ding, Z. Chen, X. Chen, M. Cai, H. Guo
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College
Objective: Although epithelial-mesenchymal transition has already 
been investigated in transplant area, another kind of transition, termed as 
endothelial-mesenchymal transition (EMT), fi nds few works on it. The 
present study is to explore the effect of connective tissue growth factor 
(CTGF) on EMT in rat aortic endothelial cells for the further research of 
allograft arteriosclerosis.
Methods: The rat arotic endothelial cells were primary cultured. The cells 
were randomly divided into two groups: (1) control group, the cells were 
cultured in DMEM medium supplemented with 10% fetal bovine serum 
only; (2) experimental group, the cells were cultured in DMEM medium 
supplemented with 10% fetal bovine serum, and recombinan CTGF was added 
a fi nal concentration of 5 ng/ml. The cells were collected at time points of 24h, 
48h and 72h. Immunohistochemistry and Western-blot were used to detect 
the E-Cadherin¡¢Vimentin¡¢and ¦Á-SMA for samples. In another series, the 
Boyden Chamber was used to detect the migration capability of the aortic 
endothelial cells at 1d, 3d, and 5d. 
Results: In experimental group, a process of less E-Cadherin and more 
Vimentin expression was found in the cells, indicating EMT happening. The 
¦Á-SMA was detected until 48h and was markedly expressed at 72h. On the 
other hand, no ¦Á-SMA expression was found from 0h to 72h in control group. 
In the duration of the fi rst two days the migration of the aortic endothelial cells 
in the two groups was no difference, no cells migrated through the pores to 
the opposite side of the transwell fi lters. But 2 days later, the transited cells 
emerged and began to migrate to the opposite side of fi lters in the experimental 
group. At day 5, more and more transited cells was found on the opposite side 
of fi lters in the experimental group compared with the control group (79¡À1.1 
VS 15¡À1.2 P<0.05). 
Conclusion: The aortic endothelial cells also has the transition capability to 
mesenchymal cells and the process also can be stimulated by CTGF, similar 
as epithelial cells. Our results remind that the endothelial cells EMT should be 
paid more attention in the study of allograft arteriosclerosis.
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REPERFUSION TOLERANCE OF ISOLATED ISCHEMIC 2264 
PORCINE KIDNEYS IMPROVED BY WARM PRESERVATION 
AND ERYTHROPOIETIN
B. Yang1, S. Hosgood, A. Bagul, G. Bicknell, M. Nicholson
1University Hospitals of Leicester, 2University of Leicester
Ischemia/reperfusion tolerance is important in kidney transplantation. 
Erythropoietin inhibits apoptosis and infl ammation, and provides renoprotection. 
This study investigated the effects of different preservation methods on 
reperfusion tolerance of kidneys. Porcine kidneys subjected to 10-minutes 
ischemia were preserved by four approaches: 16-hours cold storage (CS) 
followed by 2-hours warm preservation (WP) ± 5000 units/L erythropoietin; or 
18-hours CS ± 5000 units/L erythropoietin, and assessed by haemoreperfusion 
for 3 hours on an isolated organ perfusion system. All parameters were measured 
on termination of CS, WP and reperfusion. Both WP and reperfusion increased 
caspase-3 activity, the expression of heat shock protein 70, apoptosis in tubular 
areas (excluding kidneys preserved by 18-hours CS), tubular lumens and the 
interstitium compared with CS kidneys. The presence of erythropoietin in WP 
further raised caspase-3 activity and apoptosis in tubular lumens, sustained 
interstitial apoptosis and reduced tubular apoptosis; also subsequently improved 
tubular vacuolation and interstitial expansion, oxygen consumption and renal 
blood fl ow after reperfusion. Erythropoietin increased urine production more 
than renal blood fl ow. WP and erythropoietin improved reperfusion tolerance 
and early renal structure and function over that seen in CS alone. This was 
probably through caspase-3 activation, HSP70 induction and subsequently 
improved clearance of infl ammation and damaged cells.
Caspase-3 activity (pmol 
AMC liberated/min/ug 
protein)
Apoptosis in tubules 
(400× fi eld)
Apoptosis in tubular 
lumen (400× fi eld)
Apoptosis in interstitium 
(400× fi eld)
pre3hR post3hR pre3hR post3hR pre3hR post3hR pre3hR post3hR
16hCS+ WP 0.048 ± 0.017 0.045 ± 0.018 0.15 ± 0.04 1.34 ± 0.21 1.65 ± 0.33 0.58 ± 0.11 0.58 ± 0.08 1.75 ± 0.31
16hCS+ 
(WP+EPO)
0.114 ± 0.021 0.070 ± 0.018 0.03 ± 0.02 0.94 ± 0.25 2.35 ± 0.72 0.31 ± 0.06 0.52 ± 0.23 2.83 ± 0.53
18hCS 0.009 ± 0.001 0.069 ± 0.024 0.07 ± 0.03 0.27 ± 0.17 0.03 ± 0.02 0.64 ± 0.03 0.20 ± 0.09 1.58 ± 0.93
(18hCS+ 
EPO)
0.010 ± 0.003 0.09 ± 0.015 0.08 ± 0.06 1.73 ± 0.66 0.05 ± 0.04 1.73 ± 0.66 0.10 ± 0.03 1.26 ± 0.64
% of SCr 
fall
HSP70 (OD*mm2) Renal blood fl ow 
(ml/min/100g)
Oxygen consumption 
(ml/min/g)
Urine output (ml/h)
post3hR pre3hR post3hR pre3hR post3hR pre3hR post3hR pre3hR post3hR
64.3 ± 7.0 31.1 ± 2.6 18.5 ± 3.1 75.9 ± 9.6 70.5 ± 6.7 40.6 ± 5.6 39.4 ± 4.0 76.3 ± 19.6 53.7 ± 18.9
59.5 ± 4.6 31.3 ± 2.3 34.6 ± 10.7 73.6 ± 6.0 74.3 ± 6.6 41.1 ± 4.1 45.4 ± 4.0 155.0 ± 
18.2
92.5 ± 20.9
43.8 ± 5.3 11.2 ± 1.3 34.7 ± 9.5 38.2 ± 6.3 23.7 ± 4.8 36.5 ± 13.2
51.8 ± 3.3 13.3 ± 3.3 34.8 ± 8.0 60.0 ± 12.2 24.1 ± 3.7 88.8 ± 14.4
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RENAL ISCHEMIA AND REPERFUSION INJURY LEADS 2265 
TO SYSTEMIC INFLAMMATION RESPONSE INVOLVING 
PULMONAR DYSFUNCTION
G. Campanholle1, R. Landgraf1,2, V.N. Paiva1, J.O. Martins1, P.H.M. Wang1, 
R.M.M. Monteiro1, R.C. Silva2, A. Pacheco-Silva2, S. Jancar1, 
N.O.S. Camara1,2
1Universidade De São Paulo, 2Universidade Federal de São Paulo
Introduction: Renal ischemia and reperfusion injury (IRI) is the mainly 
cause of acute renal failure (ARF) in native and transplanted kidneys. The 
infl ammation plays a major role in its pathophysiology. ARF is frequently 
combined with adult respiratory distress syndrome (ARDS) and associated 
with high mortality. 
Aim: To study the pulmonary infl ammatory systemic response after renal IRI. 
Methods: Male C57Bl/6 mice were subjected to 45 min of bilateral renal 
ischemia, followed by 4, 6, 12, 24 and 48h of reperfusion. Blood was collected 
to measure serum creatinine. Bronchoalveolar lavage fl uid (BAL) was 
collected to determine the number of cells. Expressions of iNOS and COX-2 in 
lung were determined by Western blot. Gene analyses were quantifi ed by real 
time PCR. Results: Serum creatinine increased in IRI group compared to sham 
mainly at 24h after IRI, (2.57±0.16 vs 0.43±0.07, p<0.01).The total number 
of cells in BAL fl uid was higher in IRI group in comparison with sham, with 
12h (100x104 ±15.63 vs 29.5x104 ±10.5, p<0.05), 24h (117.3x104 ±8.94 vs 
30.5x104 ±3.5, p<0.05) and 48 hours (87x104 ±15.72 vs 34x104 ±4.2, p<0.05), 
mainly by mononuclear cells and neutrophils. Pulmonary COX-2 and iNOS 
were up regulated in IRI group in comparison with sham (COX-2 1084±97.09 
vs 129±10 AU; iNOS 1172±126.2 vs 529±59 AU). IRI group had an increase 
in IL-1â expression (2.97±0.57, p<0.05) and MCP-1(2.27±0.46) and a decrease 
in IL-4 (0.52±0.07, p<0.05), in comparison to sham group. 
Conclusion: Renal IRI induces an infl ammatory systemic response that 
reaches lung increasing cell infi ltration, up regulating COX-2 and iNOS and 
a Th1 cytokine profi le.
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ISCHEMIA/REPERFUSION OF THE PANCREAS 2266 
INDUCED HYPERRESPONSIVENESS OF THE AIRWAYS IN 
RATS
D. Wang, C-F. Chen1, F-J. Leu
1Department of Medicine, Cheng Hsin General Hospital, 2Department of 
Medicine, Fu Jen Catholic University, 3Department of Pathology, Catholic 
Cardinal Tien Hospital
Objectives: Ischemia-reperfusion (I/R) of the rat¡¦s pancreas induced acute 
pancreatitis with systemic infl ammatory response syndrome. Activated 
infl ammatory cells sequestered in the lung and the proteases released from the 
infl ammatory pancreas both could induce lung infl ammation and lung injury. 
Methods: Ischemia was induced by clamping off the gastroduodenal artery 
and the splenic artery for 2 hrs to induce ischemia of pancreas, followed by 
reperfusion for 6 hrs and then observed the airways reactivity to methacholine. 
Pulmonary function tests including Penh and airway resistance were used as 
parameters to refl ect the airway responses. mRNA expression of iNOS and 
TNF£\ in lung tissue were measured after the experiments.
Results: This protocol resulted in elevation of the blood NO (p<0.01), amylase 
(p < 0.001) and white cells (p<0.01) in the I/R group. The mRNA expression 
of iNOS and TNF£\ in the lung tissues were signifi cantly increased after I/R. 
Pulmonary function data showed that I/R of the pancreas induced signifi cant 
increases in the responses to methacholine challenge: Penh and airway resistance 
were signifi cant increases in I/R group when compared with sham group. 
Discussion and Conclusions: I/R of the pancreas induced systemic 
infl ammatory responses and increased white cells sequestered in the lung. 
Hyperresponsive response in the airways of the reperfusion group could be 
related the infl ammatory response, increased white cells sequestered and the 
expressions of the infl ammatory mediators of iNOS and TNF£\.
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PROTECTIVE ROLE OF MACROPHAGE STIMULATING 2267 
PROTEIN ON RENAL TUBULAR EPITHELIAL CELLS: 
RELEVANCE FOR REGENERATION AFTER DELAYED 
KIDNEY GRAFT FUNCTION
V. Cantaluppi1, F. Figliolini2, S. Beltramo2, G.M. Romanazzi2, D. Medica2, M. 
Migliori3, C. Mannari3, L. Biancone1, G.P. Segoloni1, G. Camussi2
1Renal Transplantation Unit, University of Torino, 2Centre for Experimental 
Medical Research (CeRMS), University of Torino, 3Department of 
Neuroscience, Section of Pharmacology, University of Pisa
Delayed graft function (DGF) is a form of acute renal failure in the early post-
transplantation period after ischemia-reperfusion injury that is characterized by 
histological signs of tubular injury and by an increased risk of acute rejection 
due to the enhanced cell immunogenicity. DGF, together with other immune 
and non-immune causes, represents a risk factor for the development of chronic 
allograft nephropathy. For these reasons, the identifi cation of new growth 
factor-based therapeutic strategies aimed to improve tubular regeneration may 
avoid or decrease DGF, therefore promoting long term kidney graft function. 
Macrophage stimulating protein (MSP) belongs to the plasminogen-related 
growth factors family and exerts proliferative and anti-apoptotic effects on 
different cell types after binding to its specifi c receptor, the tyrosine kinase 
RON. However, little is known about the biological activity of MSP in the adult 
human naïve and transplanted kidneys. 
In this study, we evaluated the plasmatic levels of MSP in uremic patients before 
and at different time points after kidney transplantation and the activation of 
the MSP/RON pathway in tubular regeneration in an experimental rat model 
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of kidney ischemia/reperfusion injury. In vitro, we studied the biological 
effects of MSP in human proximal tubular epithelial cells cultured in different 
experimental conditions.
MSP plasmatic levels were elevated in renal allograft recipients in the fi rst week 
after transplantation in association with tubular regeneration after ischemia/
reperfusion injury. MSP subsequently declined at basal levels after eight weeks, 
when renal function became stable. MSP and RON were markedly up-regulated 
in the regenerative phase following ischemia-reperfusion injury in rats. In vitro, 
MSP elicited proliferation and resistance to hypoxia-induced apoptosis in human 
tubular epithelial cells through the inhibition of caspases. MSP stimulated 
migration, scattering, branching morphogenesis and tubulogenesis in vitro and 
in vivo. In addition, MSP induced de-differentiation of surviving tubular cells 
leading to an enhanced expression of the mesenchymal marker vimentin and to 
the re-expression of Pax-2, an embryonic gene crucial for kidney development. 
In conclusion, the MSP/RON pathway was up-regulated during the regeneration 
of injured tubular cells. Furthermore, MSP exerted multiple in vitro biological 
effects benefi cial for the recovery from acute tubular injury. These results 
suggest a potential therapeutic application of MSP to avoid or to limit the 
duration of DGF in transplanted kidneys.
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BENEFICIAL EFFECTS OF CARBON MONOXIDE ON 2268 
ISCHEMIA-REPERFUSION INJURY OF LUNG IN MINIATURE 
SWINE
H. Sahara, M. Oku, M. Okumi, K. Setoyama, A. Shimizu, K. Yamada
Frontier Science Research Center, Kagoshima University
Background: Carbon monoxide (CO) is produced endogenously as a byproduct 
of heme catalysis, and has been shown to provide protection against ischemia-
reperfusion injury (IRI) in a variety of organs in murine models. Since CO 
is also known to be a toxic gas, translational research using large animals is 
essential prior to its use in the clinic. We developed an in situ lung model of 
warm IRI in miniature swine, and evaluated the cytoprotective effects of low-
dose inhaled CO in this model. 
Methods: Eight miniature swine were evenly divided into two groups (CO-treated 
and control group). In both groups, warm ischemia was induced for 90 minutes 
by clamping the left pulmonary artery and veins. Simultaneously, the left main 
bronchus was dissected; it was reanastomosed just prior to reperfusion. One group 
(CO-treated group) of animals was additionally treated with inhaled CO at a 
concentration of 250 ppm throughout the procedure. Lung function and structure 
were serially assessed via blood gas analysis, chest X-ray (CXR) and lung biopsy. 
Results: In the control group, 90 minutes of warm ischemia resulted in 
a signifi cant decrease PaO2, and one animal died 4 hours after reperfusion 
due to severe pulmonary edema. In the CO-treated group, COHb levels were 
maintained at 12.1 +/-0.3% without apparent adverse effects. CO inhalation 
dramatically decreased lung injury associated with ischemia and reperfusion. 
Two hours after reperfusion, the PaO2 of the CO-treated group was 454 +/-34 
mmHg, almost double the PaO2 of the control group (227 +/-57 mmHg). 
In the control group, biopsies taken at two hours after reperfusion showed 
infl ammatory cell infi ltrates, consisting mainly of neutrophils, with intra-
alveolar edema. Biopsies 2 days after transplant showed persistence of the 
neutrophil infi ltrates in alveolar capillaries and pulmonary arterioles with 
accompanying alveolar hemorrhage and fi brin deposition. In contrast, the CO-
treated group had a marked reduction in the degree of neutrophil cell infi ltrates 
and intra-alveolar edema at these time points. Electron microscopy also 
revealed decreased endothelial cell injury in the CO-treated group. Sequential 
measurements of systemic early phase cytokines IL-1ƒÀ and IL-6 showed that 
the concentrations of these proteins were markedly lower in the CO-treated 
group 2 days after reperfusion (IL-1ƒÀ: 9 +/-4 vs. 43 +/-9 pg/ml; IL-6: 2.1 
+/-1.5 vs. 30 +/-9 pg/ml). High-mobility group box 1 (HMGB1), recently 
reported to be an important early mediator of infl ammation and cell injury, was 
also signifi cantly lower in the CO-treated group 2 days after reperfusion (0.04 
+/-0.1 vs. 14 +/-6 ng/ml). 
Conclusions: To our knowledge, this is the fi rst demonstration of the benefi cial 
effects of CO on Ischemia-Reperfusion Injury of the lung in a large animal 
model. The perioperative administration of low-dose inhaled CO decreases warm 
ischemic-reperfusion injury in lungs in miniature swine. This protective effect is 
mediated in part by the downregulation of pro-infl ammatory mediators that are 
associated with infl ammatory cell infi ltration and endothelial cell damage.
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BILIRUBIN AND BILIVERDIN DI-TAURATE FOR THE 2269 
TREATMENT OF RENAL ISCHEMIA REPERFUSION INJURY
R. Öllinger1, M. Thomas2,3, F. Bösch1, C. Koidl1, P. Kogler1, R. Sucher1, 
J. Troppmair1, F. Bach2, R. Margreiter1
1D. Swarovski Research Laboratory, Surgery, Medical University of 
Innsbruck, 2Immunobiology Research Center, Surgery, Harvard Medical 
School, 3Surgery, Ludwig-Maximilians-University Munich
Introduction: Heme Oxygenase-1 (HO-1) is playing a crucial role in ischemia 
reperfusion injury (IRI). HO-1 degrades heme into carbon monoxide, free iron 
and biliverdin, which subsequently is converted to bilirubin by the enzyme 
biliverdin reductase. Experimentally both, biliverdin and bilirubin, at least in 
part, account for the protective effects mediated by HO-1. In order to develop 
strategies how to potentially clinically use the bile pigments for the treatment/
prevention of IRI, we tested conjugated, thus water soluble, forms of bilirubin 
and biliverdin at various doses and time points in a model of warm renal IRI 
and a model of kidney transplantation in rats.
Methods: Renal arteries of contralaterally nephrectomized Wistar rats were 
clamped for 45 minutes prior to reperfusion. Further, Wistar rat kidneys were 
transplanted after 18 hours of cold ischemia into isogenic recipients. Animals 
were treated with saline (as a control) or various doses of bilirubin or biliverdin di-
taurate, applied as three i.v. injections covering the perioperative period or a single 
injection given either before or after reperfusion. Serum total bilirubin was assessed 
fi ve minutes and serum urea and creatinine was assessed 24 hours after reperfusion 
(n=4 in each group). Activation of mitogen activated protein kinases (MAPK) has 
been assessed by western blot and measurement of optical densities.
Results: Perioperative and preoperative treatment with bilirubin di-taurate at 
3, 10 and 30 but not 1mg/kg resulted in a signifi cant increase in serum total 
bilirubin levels after reperfusion (p<0,0001 vs. control). Similarly, treatment 
with biliverdin di-taurate prior to reperfusion increased serum total bilirubin 
(p<0,0001 vs. control). The increase in serum total bilirubin was associated 
with signifi cantly lower serum creatinine and urea levels at 24 hours after 
reperfusion as well as substantial changes in MAPK activation in the clamp 
model when compared to the control (p<0,05) with no signifi cant difference 
within the various doses. However, when the bile pigments were applied post 
reperfusion, no effect on kidney function was being observed. In the transplant 
model, application of biliverdin di-taurate at 30mg/kg but not at 3 or 10mg/kg 
signifi cantly improved kidney function when compared to the control (p<0,05).
Summary. Intravenous application of water soluble bilirubin and biliverdin 
di-taurate is feasible and effective in improving kidney function after renal 
IRI. Bilirubin serum levels should be increased prior to reperfusion in order 
to achieve suffi cient renoprotection. Bilirubin and biliverdin di-taurate may 
become a valuable tool to improve outcome after kidney transplantation. 
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PROLONGED WARM RENAL ISCHEMIA IN RATS 2270 
UNDER CONTROLLED INHALATION ANESTHESIA 
RESULTS IN HIGHER SURVIVAL RATES THAN EXPECTED: 
IMPLICATIONS FOR RENAL ISCHEMIA-REPERFUSION 
STUDY DESIGN
R. Raman1,2, C. PIvetti3, R. Ramsamooj4, D. Matthews1,2, S. Demos1,5, C. 
Troppmann3
1University of California, Davis, Center For Biophotonics, Sacramento, CA 
95817, 2University of California, Davis, Dept of Applied Science, Davis, CA 
95616, 3University of California, Davis, Dept of Surgery, Sacramento, CA 
95817, 4University of California, Davis, Dept. of Pathology, Sacramento, CA 
95817, 5Lawrence-Livermore National Laboratory, Livermore, CA 94550
Introduction: Until now, most rat renal warm ischemia-reperfusion models have 
been designed based on expected animal survival rates of ~50% if warm ischemia 
time (WIT) exceeds 60 min (e.g., Jablonski et al., Transplantation 1983; 35:198; 
and Togashi, Acta Pathol Jpn 1982; 32:749). Most prior studies, however, relied on 
intraperitoneal anesthetic agent (e.g., pentobarbital) delivery, which is associated 
with unpredictable absorption and highly variable systemic effects. Currently, 
technological advances coupled with more stringent animal care regulatory 
requirements are leading to increased use of inhalation anesthesia—even in 
rodents. The impact of these more advanced anesthetic methods with signifi cantly 
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improved delivery control is unknown and may be associated with less signifi cant 
systemic (e.g., hemodynamic) side effects. These changes in practice may be 
particularly relevant during post-ischemic renal recovery, and may decrease animal 
mortality from renal dysfunction. We studied rat survival after prolonged WIT 
under controlled-delivery isofl urane anesthesia in several strains. 
Methods: Following laparotomy, we subjected Sprague-Dawley (SD), Wistar-
Furth (WF), Dahl salt-sensitive (DS), and Spontaneously Hypertensive Rat (SHR) 
rats to 150 min unilateral renal WIT (by complete renal vascular occlusion), 
subsequent reperfusion, and immediate contralateral nephrectomy. General 
anesthesia was induced by inhaled isofl urane delivered by a calibrated vaporizer 
(inspired maintenance isofl urane concentration: 1.25% to 2%; 90% O2). Rat survival 
was monitored for up to one month, when all surviving animals were euthanized. 
Autopsies were done to determine cause of death. Rat survival (censored for deaths 
from surgical complications) was calculated according to Kaplan-Meier.
Results: (see Table 1)
Conclusions: Advanced controlled-delivery anesthesia methods and rat strain 
both had a profound effect on long-term rat survival after extreme renal WIT. Our 
fi ndings suggest that (i) rat strain selection for experimental protocols that involve 
warm ischemic renal injury is paramount, and (ii) with increasing implementation 
of clinical anesthesia techniques, experimental protocols for inducing renal warm 
ischemia injury in rats must be re-designed. These recommendations will allow 
to continue to devise experimental protocols with intermediate survival rates 
which are necessary to conduct meaningful studies.
Table 1.
Strain n Rat Survival [# days] 30-day Survival Rate*
SD 12 4**,4, 5, 6, 8, 10, 30, 30, 30, 30, 30, 30 55%
WF 6 5, 5, 30, 30, 30, 30 67%
DS 9 8, 9, 30, 30, 30,30, 30, 30, 30 78%
SHR 10 4, 4, 5, 5, 5, 5, 5, 5, 6, 8 0%
*: p<0.01 for SHR vs. SD, WF, DS
**: death due to surgical complication
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GLYCINE PRE-TREATMENT REDUCES THE PORTAL 2271 
VEIN PRESSURE AND IMPROVES INITIAL LIVER FUNCTION 
AFTER SUBTOTAL HEPATECTOMY IN THE RAT
Y. Gu1, U. Rauen2, F. Saner3, J. Sowa4, S.Y. Shue5, J.F. Schlaak6
1Department of General, Visceral And Transplantation Surgery, 2Institute 
of Physiological Chemistry, University Hospital of Essen,, 3Department 
of General, Visceral And Transplantation Surgery, 4Department of 
Gastroenterology and Hepatology, University Hospital of Essen,, 5Institute of 
Pathology und Neuropathology, University Hospital of Essen,, 6Department of 
Gastroenterology and Hepatology, University Hospital of Essen,
Aims: It is known that Kupffer cells (KC) can be activated during liver 
resection and liver graft harvest. Activated KC releases numerous mediators of 
infl ammation and potent vasoconstrictors, leading to hepatic microcirculatory 
failure and increasing portal vein pressure. The amino acid glycine has been 
shown to inhibit the activation of KC and thus, possibly reduce KC mediated 
hepatocyte damage. We therefore investigated the infl uence of glycine pre-
treatment on the outcome after subtotal partial hepatectomy (PH) in the rat. 
Methods: Male Wistar rats (250-300g) were used. Animals were pre-treated with 
glycine (5% glycine in rat chow) 5 days prior to operation. Resection of 90% of liver 
mass was then performed. Rats receiving 90% PH without glycine pre-treatment 
and sham operation were used as control groups. Animals were sacrifi ced at 2 or 6 
hours after hepatectomy. Portal vein pressure was monitored and blood was taken 
for analysis of initial liver function prior to sacrifi ce. Liver tissue was snap-frozen 
in liquid nitrogen and fi xed in formalin for subsequent histological analysis.
Results: A signifi cant decrease in portal pressure 2 hours after PH in the glycine 
pre-treated animals was found (12.7±0.77 cmH2O in 90% PH with glycine pre-
treated group; 14.6±1.66 cmH2O in 90% PH group (p<0.05); 9.7±0.26 cmH2O 
in sham-operated group). Signifi cantly lower levels of alkaline phosphatase 
(AP) and prothrombin time (PTT) were shown in the glycine pre-treated group 
at both 2 hours and 6 hours postoperatively (p<0.05). Nuclear factor kappa B 
(NF-KB) was also less activated 6 hours after hepatectomy in the treatment 
group (p<0.05).
Conclusions: Subtotal hepatectomy induced severe liver damage and increased 
portal vein pressure. This damage can be reduced through glycine pretreatment. The 
inhibition of the activation of NF-KB in KC might contribute to the effects observed.
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ISCHEMIC KIDNEYS FOLLOWING ISCHEMIA REPERFUSION 
INJURY (IRI)
T. Matthews1, W. Sun2, N. Rogers1,3, S. Sen1,3, C. Bonder2, P. Coates1,3,4
1Department of Nephrology And Transplantation Services, The Queen 
Elizabeth Hospital, 2Hanson Institute, Institute of Medical and Veterinary 
Sciences, Adelaide, 3Department of Medicine, University of Adelade, 4Center 
for Stem Cell Research, University of Adelaide.
Introduction: EPC are a subset of peripheral blood cell stem cells that contribute 
to vascular repair and angiogenesis following vascular injury or ischemia. IRI 
is an inevitable consequence of organ transplantation contributing signifi cant 
allograft damage. Following renal transplantation IRI commonly leads to the 
development of acute tubular necrosis (ATN) which is closely associated with 
the development of delayed graft function (DGF). DGF, ATN and the onset of 
acute allograft rejection are all major predictors of poor graft outcome. Whilst 
most of the injury in the kidney has focussed on the tubular compartment, 
intra renal vascular injury is also plays a signifi cant role in the renal injury. We 
hypothesised that EPC would be recruited to murine vascular compartment of 
kidneys subjected to IRI.
Methods: EPC were derived from the tibia and femur bone marrow of C57B6 
mice and cultured in 20% fetal calf serum for 4 days on fi bronectin coated 
plates at 1.5 x 105 cells/cm2. Non-adherent cells were removed after 24 hours. 
In a typical experiment 1 mouse yielded 6 x 107 EPC. Purity was assessed by 
the presence of the lin-, sca1+ and ckit+ lineage and development into endothelial 
cells 10 days post seeding. IRI was induced in syngeneic C57B6 mice by 
occluding the left renal pedicle for 30 minutes using a microvascular clamp. 1 
x 107 EPC were labelled with CarboxyFluoroscein Succinimidyl Ester (CFSE), 
washed and injected intravenously following reperfusion. SHAM operated 
animals were injected with EPC but were not subjected to renal ischemia. After 
24 hours left and right kidneys were removed and analysed by fl ow cytometry 
following enrichment by Ficoll gradient and immunohistochemistry.
Results: Mice subjected to 30 minutes IRI developed typical changes of ATN, 
characterised by histological damage, upregulation of mRNA for heat shock 
protein 70 (HSP70) and toll like receptor 4 (TLR4). In kidneys subjected to 30 
minutes ischemia a small but distinct population of CFSE labelled cells were 
identifi ed in kidney lysate (n= 5) from ischemic but not contralateral kidneys 
(n=7). In contrast no CFSE labelled cells were identifi ed in SHAM operated 
kidneys (n=3). Using Zeiss Apotome fl uorescence microscopy, CFSE labelled 
cells were easily identifi ed within the glomeruli and peritubular regions in 
ischaemic kidneys but only occasional cells were identifi ed in contralateral 
controls. CFSE labelled cells colocalised with the vascular adhesion molecule 
PECAM, suggesting the incorporation of EPC into ischaemic damaged vessels 
both in renal cortex and medulla.
Conclusions: We show for the fi rst time EPC home to ischemic kidney 
following IRI, incorporating in both vascular and tubular compartments of 
the kidney. Manipulation of EPC recruitment may provide a novel pathway to 
modulate repair of ischemic organs following reperfusion. 
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ORGAN FUNCTION IN AN EXPERIMENTAL RAT MODEL OF 
KIDNEY ISCHEMIA REPERFUSION INJURY
S. Scheidl1, D. Wiedemann2, S. Schneeberger1, F. Peter3, N. Wick4, 
K. Zacharowski5, R. Margreiter1, G. Laufer2, P. Petzelbauer3, S. Semsroth2
1Dept. of General And Transplant Surgery, Innsbruck Medical University, 
Austria, 2Dept. of Cardiac Surgery, Innsbruck Medical University, Austria, 
3Dept. of General Dermatology, Vienna Medical University, Austria, 
4Dept. of Clinical Pathology, Vienna Medical University, Austria, 5Dept. of 
Anaesthesia, Duesseldorf University Medical Center, Germany
Backgorund: The shortage of available organs has led to widespread use of 
extended criteria and nonheart-beating donor (NHBD) grafts. Graft infi ltration 
by recipient leukocytes is one of the key mechanisms of ischemia-reperfusion 
injury (IRI). The fi brin derived peptide Bbeta15-42 has been shown to attenuate 
leukocyte infi ltration in various models by inhibiting the transmigration process. 
Previous work in experimental heart transplantation and myocardial infarction 
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models suggest that Bbeta15-42 is capable of reducing cardiac IRI. The aim of 
the current study was to assess the effects of Bbeta15-42 in rat kidney IRI.
Material and Methods: Male Lewis rats (250-300g) underwent median 
laparotomy with removal of the right kidney, followed by clamping of the 
left renal artery for 60 min. Animals were divided into two control and two 
treatment groups, with 24 hours and 7 days observation periods, respectively. 
Treatment group animals received 1,2mg Bbeta15-42 intravenously at two 
separate timepoints (, one minute prior to and one minute after removal of 
the arterial clamp). Serum samples for the evaluation of creatinine and BUN 
levels were collected at several time points. Kidneys were harvested at the end 
of the observation period for follow-up histologic, immunohistochemical and 
molecular biological analyses.
Results: Over the course of the reperfusion period we could observe, that 60 
min of ischemia leads to a pronounced increase in creatinine and BUN levels 
with values peaking at day 2. After day 2 renal function starts to recover, 
reaching normal levels on day 7 again. Administration of Bbeta15-42 led to 
a marked reduction of creatinine and BUN levels, with normal levels detected 
of which was signifi cant by day 2 and day 5. In fact, animals receiving 
Bbeta15-42 displayed normal creatinine and BUN levels over the course of the 
entire observation period.
Conclusion: Our experiments provide evidence that Bbeta15-42 is a promising 
agent for minimizing renal ischemia-reperfusion injury and for the preservation 
of early graft function.
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AMELIORATES ISCHEMIA-REPERFUSION INJURY AFTER 
HEART TRANSPLANTATION IN RATS
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Zacharovski5, P. Petzelbauer3, R. Margreiter2, G. Laufer1, S. Semsroth1
1Department of Cardiac Surgery Innsbruck Medical University, 2Department 
of General and Transplant Surgery, Daniel Swarovski Research Laboratory, 
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Purpose: Ischemia-reperfusion injury still represents one of the major problems 
in solid organ transplantation. On one hand it is associated with primary non-
function, on the other with delayed function of transplanted organs which 
goes along with increased rates of acute and chronic rejection episodes. The 
infl ammatory response after ischemia and reperfusion is caused by leukocytes 
migrating from the bloodstream into graft tissue. The fi brin derived peptide 
B-beta15-42 has been shown to reduce leukocytemigration by inhibiting 
the transmigration process. The purpose of our study was to investigate the 
protective effect of B-beta 15-42 on ischemia reperfusion injury in a rat heart 
transplant model.
Methods and Materials: Hearts of male Lewis rats (250-300g) were fl ushed 
with chilled (0-1 C) Custodiol preservation solution and either transplanted 
immediately or stored in the same solution for 4 or 8 h and then transplanted 
into syngenic recipients. 1,2mg of B-beta15-42 were given i.v. immediately 
after implantation of the heart or added to the preservation solution prior to 
harvest. At 24h and 10d hearts were retrieved for histological evaluation and 
MPO (myeloperoxidase) immunohistochemistry. At time of harvest, serum 
samples were collected for troponin T level analysis. Pumpfunction of hearts 
subjected to 8h of cold ischemia followed by 24h of reperfusion was evaluated 
in an isolated working heart model (pressure-volume). 
Results: Hearts transplanted immediately or after 4h of cold ischemia did 
not show any morphological damage. In contrast 8h of cold ischemia showed 
severe myocardial damage associated with an infl ammatory response at 24h. 
Lesions further progressed after 10d. Administration of B-beta15-42 resulted 
in a signifi cant amelioration of myocardial necrosis together with a reduced 
leukocyte infi ltration. The protective effect of the peptide was further underlined 
by reduced troponin T levels in the treatment groups. The working heart 
preparation showed poor cardial function in the control group. Administration 
of B-beta15-42 resulted in a signifi cant amelioration of graft function.
Conclusions: The fi brin derived peptide B-beta15-42 ameliorates I/R injury in 
a rat heart transplant model and represent a promising drug for a clinical use.
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P.V.B. Palma3
1UNIFESP – Federal University of Sao Paulo, 2FAMERP Sao Jose do Rio 
Preto Medical School, 3FMRPUSP – Medical School
Background: FTY720 is a new compound whose main mechanism of action 
has been associated with lymphocyte trapping in secondary limphoid organs 
[1]. Experimental models of tumors are inhibited by FTY720 administration [2]. 
However, there is no report of FTY720 action in lung adenoma development.
Objective: To evaluate whether FTY720 plays any role in urethane-induced 
lung cancer model. 
Methods: BALB/c mice (male, 8-10 weeks old) were submitted to two doses 
(1,5 mg/Kg/day) of Urethane (Ur) intraperitoneal administration. Mice received 
a fi ve-day course of FTY720 (1mg/Kg/day) orally starting immediately after 
the last dose of Ur (G2), 30 days after Ur (G3) or were not treated (G1). Four 
months after Ur administration mice were anesthetized and blood, spleen and 
lungs were harvested. Blood leucocytes were counted and fl ow cytometry 
for CD4+ splenocytes was performed. Lungs were stained (H&E) and their 
histology evaluated for presence of lesions/nodules. Using a software for image 
analysis, nodules and hyperplasia areas were measured. Lung sections were 
evaluated for VEGF staining using immunohistochemistry. 
Results: Ur-induced non-treated mice (G1) presented two deaths (34, 73 days) 
whereas no mice died in FTY720-treated Groups during 120 days. FTY720 
caused a decrease in blood lymphocytes (G2= 47.8±4.8, G3=45.9±6.5) when 
compared to Ur (G1=67.5±2.6) and Control (69.3±4.4) p<0.005. On the 
other hand, neutrophils increased in FTY720-treated mice (G2=50.4±5.1, 
G3=50.1±5.1) in comparison with G1 (31.6±3.0) p<0.005. Monocytes were 
higher in G3 (4.2±2.0) versus G1 (2.5±1.4), G2 (2.6±1.0) and Control (3.1±0.6). 
Total lung lesions were similar in all groups (G1=2.5±1.3, G2=2.9±0.9, 
G3=2.4±0.9) but nodules area was smaller in G3 (1661 ìm2) than in G1 (2184 
ìm2) and G2 (2254 ìm2). Intense VEGF staining was observed in 67% of 
nodules in G1, 16.5% in G2 and 47% in G3. 
Conclusions: FTY720 prevented death caused by Ur-induced lung tumors. The 
drug inhibited tumor area growth when administered 30 days after Ur injection 
and decreased VEGF expression by tumor cells although it did not impair 
lung nodules development. This fi nding was associated with lymphopenia and 
decrease of CD4+ T cells in spleen, whereas in blood there was increase of 
neutrophils and monocytes. 
POSTER BOARD NUMBER P4 – 326
IMPACTS OF NKT CELLS ON CD4+CD25+T AND 2276 
CD4+CD25-T CELL PROLIFERATION IN VITRO
H-M. Zhou1,2, W. Huang2, X-K. Pei1, C. Liu1, J-M. Huang2, L-J. Xu2, 
B-Y. Shi1, M. Cai1, Z-K. Chen2
1Organ Transplantation Center, 2nd Affi liatted Hospital of Great Wall 
Hospital of P.L.A., 2Institute of Organ Transplantation, Tongji Hospital, 
Tongji Medical College, Huazhong University of Science and Technology. Key 
Lab of Organ Transplantation of Ministry of Education and Health. Hubei, 
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Background: NKT Cells is a special member of immune system which 
connects the innate and adaptive immune responses. Their complicated role 
differs from case to case, according to the local and neighbor circumstances. 
Resent research reported that NKT cells may be involved in CD4+CD25+ T cell 
induction in vivo. This research focused on their impact on CD4+CD25+T cell 
induction in single-way mixed lymphocyte culture (MLC) system in vitro.
Methods: Innate CD4+CD25+T cells, CD4+CD25-T cells from C57BL/6 mice 
spleen were sorted by Flow cytometry (FacsAria, BD. LTD), as reactor, these 
cells were stained with CFSE and 2×105 cells were seeded into 96 cell-plate at 
a reactor/target ration 1/1, cultured with mitomycin pre-treated Balb/C mice 
spleen cells (Bm), with or without the addition of CD3 and CD28 monoclonal 
antibody. NKT cells from C57BL/6 mice spleen were sorted and added into 
the single-way MLC system. namely, these cells were divided in 8 groups: 
group 1, C57BL/6 CD4+CD25+T cells with Bm; group 2, NKT cell added 
to cells as group 1; group 3, and 4, CD3 and CD28 monoclonal antibody 
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added into system as group1, 2; group 5, C57BL/6 CD4+CD25-T cells with 
Bm; group 6, NKT cell added to cells as group 5; g group 7, and 8, CD3 and 
CD28 monoclonal antibody added into system as group5, 6. After 5 days, the 
percentage of CD4+CD25+T cells, CD4+CD25-T cells among reactor cells and 
the proliferation of the reactor cells were detected by FACS and analyzed by 
Diva and ModFit LT software. 
Results: The percentage of CD4+CD25+T, CD4+CD25-T cells increased 
when added with NKT cells, and got even more higher with the addition of 
CD3 and CD28 monoclonal antibody (see table 1, P<0.05); except that of 
CD4+CD25+T from group 6 (decreased to 25.1% from 40% after NKT added) 
and CD4+CD25-T cells from group 8 (decreased to 12.6% from 17.9% after 
NKT added). The proliferation index of reactor cells decreased after NKT 
addition (table 1). 
Conclusion: From our preliminary data, we found that innate NKT cells from 
C57BL/6 mice inhibited the reactor cells’ proliferation and involved in the 
transdifferantiation of CD4+CD25-T and CD4+CD25+T cells of MLC system in 
vitro, the functional impacts of NKT on these cells and the potent application 
of this character of NKT needs further observation. 
Table 1:
Percentage of CD4+CD25+T, CD4+CD25-T cells and the Proliferation Indedx of 
the reactor cells in different groups.
Group MLC system CFSE
+CD4+CD25+T/ 
(CFSE+cells)%
CFSE+CD4+CD25-T/ 
(CFSE+cells)%
PI of Reactor cells
1 25+C57,Bm 49.76±0.69 28.2±0.75 54.10±1.10
2 25+C57,Bm,NKT 51.73±0.64 (P=0.022002)
32.4±0.66 
(P=0.001897)
69.26±1.10 
(P=0.007)
Compared to 
group 1
3 25+C57,Bm,MA 65.56±2.45 19.46±3.41 67.21±3.59
4 25+C57,Bm,MA,NKT
57.63±2.22 
(P=0.014)
18±1.93 
(P=0.5526)
59.26±3.26 
(P=0.04669)
Compared to 
group 3
5 25-C57,Bm 39.1±1.64 31.2±0.56 33.44±0.51
6 25-C57,Bm,NKT 25.3±0.62 (P=0.0017)
46.27±0.80 
(P=0.001)
25.61±0.54 
(P=0.005)
Compared to 
group 5
7 25-C57,Bm,MA 66.6±3.40 12.2±2.33 8.8±1.73
8 25-C57,Bm,MA,NKT 56.63±2.97 (P=0.01877)
20.3±2.75 
(P=0.01761)
15.26±3.07 
(P=0.03366)
Compared to 
group 7
Note: 25+C57:CFSE stained C57BL/6 mice spleen CD4+CD25+ cells 25-C57:CFSE 
stained C57BL/6 mice spleen CD4+CD25- cells Bm:mitomycin pre-treated Balb/C mice 
spleen cells MA: CD3 and CD28 monoclonal antibody PI:Proliferation Index
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KINASE 1/2 (MEK1/2) INHIBITION AMELIORATES LIVER 
TRANSPLANT ISCHEMIA-REPERFUSION (I/R) INJURY.
S. Ueki1, N. Murase1, J. Yoshida1, Y. Koike1, N.G. Puttaraju1, L. Shao1, 
R. Sugimoto1, A. Nakao1, D.B. Stolz2, D.A. Geller1
1University of Pittsburgh Medical Center, Surgery, 2University of Pittsburgh, 
Center for Biologic Imaging
Background: Hepatic I/R injury is a major risk factor signifi cantly affecting 
outcome of liver transplantation (LTx). Cold liver I/R injury is a robust 
proinfl ammatory response involving a prompt activation of multiple signaling 
pathways, including p38, ERK, and JNK MAPK pathways. To elucidate the 
molecular mechanisms of hepatic I/R injury, current study investigated the 
role of ERK1/2 MAPK pathways using selective upstream MEK1/2 inhibitor, 
U0126.
Methods: Syngenic LTx was performed in LEW rats after 18-hr cold 
preservation in UW solution. U0126 (50 μg/kg) was iv injected into recipients 
at 30 min before and 5 min after reperfusion. Hepatic injury was assessed by 
serum ALT levels and graft histopathology. Proinfl ammatory cytokine mRNA 
(real time RT-PCR) and phosphorylated ERK1/2 MAPK (Western blot) were 
analyzed. To determine the effects of U0126 on Kupffer cells, rat Kupffer cells 
were isolated from the liver and stimulated with LPS (0.1 μg/ml) with and 
without U0126. 
Results: Cold preservation of liver grafts for 18 hrs resulted in severe 
hepatic I/R injury with a marked increase of serum ALT levels at 24 hrs 
and signifi cant hepatic necrosis by 48 hrs. U0126 effectively reduced ALT 
levels and hepatic necrosis (table). In untreated control liver grafts, rapid 
phosphorylation (p) of p38, ERK1/2, and JNK MAPK pathways were 
seen at 1 hr and subsided by 3 hrs. At the same time, proinfl ammatory 
cytokine mRNA (TNF-α, IL-6) levels were upregulated at 1 hr in untreated 
grafts. U0126 treatment signifi cantly suppressed p-ERK1/2 expression. 
Interestingly, however, benefi cial effects of U0126 did not associate with 
proinfl ammatory cytokine downregulation, and notably high mRNA levels 
for TNF-α and IL-6 were seen in liver grafts. In in vitro study, U0126 did not 
inhibit LPS-stimulated Kupffer cell production of NO and showed marginal 
(20%) inhibition of TNF-α production. 
Conclusions: These data suggest that ERK1/2 MAPK pathway plays a 
signifi cant role in hepatic I/R injury. As U0126 inhibits hepatic I/R injury 
without effective proinfl ammatory cytokine downregulation, further 
investigation is needed to elucidate the roles of ERK1/2 MAPK pathways in 
hepatic I/R injury. This study provides valuable insightful information on the 
molecular mechanisms of hepatic I/R injury.
Group ALT 24h (IU/l)
Necrotic area 
(%)
TNF-α mRNA
(fold increase)
IL-6 mRNA 
(fold increase)
control (DMSO) 5611±1697 30.1 10.4 28.5
U0126 1274±699 6.7 38.2 88.4
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ISCHAEMIC/WARM REPERFUSION INJURY IN HEPATIC 
TRANSPLANT
H. Noujaim1, E. Montero2, C. Ribeiro1, V. Capelozzi3, R. Gomes1, 
L. Curvello1, F. Crescentini1, M. Casagrande1, M. de Miranda1, T. Genzini1
1HEPATO – Hospital Benefi cencia Portuguesa De São Paulo, 2UNIFESP, 
3FMUSP
Introduction: Apoptosis has been considered the key mechanism of ischemia 
/reperfusion in non-steatotic liver grafts. In liver transplant (LTx), cold 
ischemia- warm reperfusion (CI/WR) injury is responsible for the release of 
infl ammatory mediators, such as ICAM-1, apoptosis and cellular necrosis.
Purpose: To analyse the mechanism of infl ammatory response after CI/WR 
injury in LTx, with special attention to apoptosis and ICAM-1 release.
Methods: Between Jan/06 and Feb/08 41 liver biopsies were performed 
on back table time (pre reperfusion) and 2 hours after reperfusion (pos 
reperfusion). The biopsies were assessed for the following histological features 
(hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3),portal infl ammation 
(degree 0 – absent, I- mild, II- moderate, III– severe), parenchymal neutrophilic 
infi ltration (degree 0- absent, I –rare around zone 3, II-moderate in zone 3, 
III- since zone 3 to1) and presence of apoptosis cells; steatosis was classifi ed in 
macro and/or microvesicular, and its degree classifi ed as absent, mild (<30%), 
moderate (30to59%), severe(≥60%). ICAM-1 and apoptosis were assessed by 
the apoptosis index (TUNEL and Caspase-3 cleaved assays). Results signifi cant 
when p<0.05.
Results: 
No biopsies Pre reperfusion(n=41)
Pos reperfusion
(n=41) p
neutrophilic infi ltration
degree 1
2+3
60%
12%
24%
72% <0.001
Suzuki score
Degree 0
100% 80% 0.02
portal infl ammation (I) 40% 52% 0.8
apoptosis 
index(TUNEL) 0.14±0.11 0.21±0.1 0.01
apoptosis index
(Caspase-3 cleaved)
0.12±0.1 0.18±0.14 0.13
ICAM-1 Index 0.20±0.12 0.22±0.17 0.7
Conclusion: In LTx, after warm reperfusion, signifi cant increases in the 
parenchymal neutrophilic infi ltration, Suzuki score and apoptosis index 
(TUNEL assay) were observed. However, the migration of neutrophils, 
presence of ICAM-1 and apoptosis process started at cold ischemia. Further 
research must be carried out to develop agents to bloc the infl ammatory 
response initiated at cold ischemia in LTx. 
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INJURY WHEN USING STEATOTIC GRAFTS IN LIVER 
TRANPLANTS
H. Noujaim1, E. Montero2, C. Ribeiro1, R. Gomes1, V. Capelozzi3, 
L. Curvello1, M. de Miranda1, T. Genzini1
1HEPATO – Hospital Benefi cencia Portuguesa De São Paulo, 2UNIFESP, 
3FMUSP
Introduction: In liver transplantation, during the cold ischemia/warm 
reperfusion (CI/WR), liberation of ROS and cytokynes occurs and adhesion 
molecules such as ICAM-1, resulting in increase of neutrophils adhesion, 
apoptosis e necrosis cellular and consequently graft dysfunction. In steatotic 
liver grafts this process is little known.
Purpose: to analyse the role of ICAM-1 in cold ischemia and warm reperfusion 
(CI/WR) using steatotic and non steatotic grafts after LTx.
Patients and methods: this is a prospective study performed between 
May/02 and Feb/08. In 115 LTx liver biopsies were collected 2 hours after 
graft reperfusion. The biopsies were assessed for the following histological 
features (hematoxylin-eosin HE): Suzuki score (degree 0, 1,2,3), portal 
infl ammation (degree 0 – absent, I- mild, II- moderate, III– severe), 
parenchymal neutrophilic infi ltration (degree 0- absent, I –rare around zone 
3, II-moderate in zone 3, III- since zone 3 to1) ; steatosis was classifi ed 
in macro and/or microvesicular, and its degree classifi ed as absent, mild 
(<30%), moderate (30to59%), severe(≥60%). ICAM-1 was assessed by 
the ICAM-1 index. The 115 LTx were divided according to their steatosis 
degree in 4 groups: absent –ASG (n=36), mild –MSG (n=36), moderate- 
MoSG(n=26), severe – SSG(n=17). Macrosteatosis were predominantly 
present in mild – G1(n=10) and moderate+severe- G2+3 (n=12), and 
microsteatosis in mild-G1 (n=29) and moderate+severe- G2+3 (n=24), 
and 4 cases presented macro and microsteatosis simultaneously. Results 
signifi cant when p<0.05.
Results: The macrosteatosis groups presented ICAM-1 index in G1= 0.20±0.14 
and G2+3 = 0.21±0.11 (p-0.8) and the microsteatosis in G1 = 0.17±0.15 and 
G2+3= 0.26±0.18 (p-0.13). 
No LTx MSG(n=36) MoSG(n=26) SSG(n=17) ASG(n=36) p
neutrophilic infi ltration 
(II + III)
42% 55% 68% 56% 0.4
ICAM-1 index 0.19±0.14 0.21±0.18 0.27±0.15 0.18±0.13 0.3
Conclusion: There was no signifi cant difference among the groups (steatosis vs 
non-steatotic) regarding neutrophils infi ltration and ICAM-1 index, but severe 
steatosis group and microsteatosis (>30%) had high ICAM-1 index than others.
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Warm ischaemic reperfusion injury, in a non-transplant setting, usually 
involves an infl ammatory response. Monocytes and neutrophils are considered 
the usual effectors. TNF and interleukin cytokines are believed to mediate 
this response. However, very little attention has focused on lymphocytes and 
their role in warm ischaemic injury in a non-transplant setting. Our study 
investigated the presence of lymphocytes within a 24 hour period following 
warm ischaemic-reperfusion injury of rat livers in a non-transplant setting, and 
compared that with syngeneic and allogeneic transplants monitored at 24 hours 
post operative.
Method: Hepatic surgery was conducted on Sprague Dawley rats. A vertical 
abdominal incision was made to expose the liver, and the infra-hepatic vena 
cava, supra-hepatic vena cava and the hepatic artery were clamped for either 
15 or 30 minutes. Rats were sacrifi ced at 0, 2, 6, 12 or 24 hours post ischaemia; 
total N = 15. For transplants, Lewis rat livers were harvested, stored in UW 
solution for 1 hour or 24 hours fl ushed with saline and transplanted to DA 
rat recipients and sacrifi ced at 24 hours post transplant. Livers were fi xed, 
embedded and H&E staining was conducted. Liver sections were coded and 
assessed double blinded for injury and lymphocytic infi litration using the Banff 
scoring system. 
Results: Non-transplanted livers that had a 30 minute ischaemic event had an 
average Banff score of 6, whereas 15 min ischaemia lead to a score of zero. 
The livers that had a positive Banff score, had venulitis, bile duct infi ltrate and 
portal infi ltrate, but the profi les differed at the progressive observation points. 
Transplanted livers assessed after 24 hours showed mild rejection in livers 
stored for 1 hour and severe rejection in livers stored for 24 hours.
Discussion: These fi ndings suggest that lymphocytes may be involved 
in warm ischaemic injury in a non-transplant setting. It also suggests that 
their involvement is dependent on the severity of the ischaemic injury. The 
appearance of lymphocytes at 2 hours post ischaemia and their disappearance 
at 6 hours post ischaemia suggests that their involvement is transient in the 
absence of alloantigens. 
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COMPARISON BETWEEN ELISA-CROSSMATCH 2281 
AND THE CLASSICAL MICROLYMPHOCYTOTOXICITY 
CROSSMATCH ASSAY
J. Mytilineos, K. Pabst, H. Schrezenmeier
University Hospital of Ulm, Transplantation Immunology Laboratory
Pre-transplant crossmatches are routinely performed by the complement 
depended cytotoxicity assay (CDC). This method, however, has several 
drawbacks among which is also the fact that no differentiation between 
antibodies against HLA-class I and class II antigens is possible. In contrast, 
antibody screening can be performed by solid phase assays (SP), like ELISA 
or Luminex, and allows precise and sensitive defi nition of antibodies, 
both against class I and class II HLA molecules. SP-screening and CDC 
crossmatch may therefore lead to confl icting pre-transplant crossmatch 
result interpretation. Recently, ELISA based crossmatch techniques became 
commercially available. We compared CDC and ELISA crossmatch results 
of 20 sera from kidney transplant waiting list patients which were tested 
against T- and B-cells of 4 different donors. A total of 160 crossmatch assays 
with each method were performed. In discrepant cases additional tests with 
DTT as well as ELISA based antibody specifi city identifi cation assays were 
performed. 69 of the 80 (86.3%) crossmatch tests against HLA-class I targets 
were concordant between CDC and ELISA. 7 cases were CDC positive/
ELISA negative. Of those 3 had DTT reactive antibodies (IgM) whereas 
another 3 showed non-donor specifi c ELISA-screening detectable antibodies. 
In one case (1,25%) the discrepancy remained unresolved. In 4 cases a 
CDC negative/ELISA positive result was obtained. All four cases showed 
ELISA detectable donor specifi c antibodies. 54 of the 80 (67.5%) crossmatch 
assays against B-cells/HLA-class II targets were concordant between CDC 
and ELISA. 23 cases were CDC positive/ELISA negative. Of those 12 had 
HLA-class I antibodies which, as expected, reacted positively with B-cells 
in the CDC test. Another 9 cases (11.25%) showed donor specifi c, ELISA 
screening detectable HLA-DQ antibodies that cannot be detected in this 
particular ELISA crossmatch assay. Two cases (2.5%) remained unresolved 
(DP-antibodies?). In 3 cases a CDC negative/ELISA positive result was 
obtained. All three cases showed ELISA detectable antibodies against donor 
HLA-DRB1 antigens.
Although HLA-DQ and possibly HLA-DP antibodies – the role of which is 
currently not clarifi ed in the outcome of solid organ transplantation- could not 
be detected by the ELISA crossmatch, this test may be a helpful tool in the 
fi nal donor selection process prior to allogeneic kidney transplantation, since 
it proved to be more sensitive and more specifi c than conventional CDC. In 
addition, it allows differentiation between antibodies against HLA-class I and 
II antigens.
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REAPPRAISAL OF HLA ANTIBODY ANALYSIS AND 2282 
CROSSMATCHING IN KIDNEY TRANSPLANTATION
P-C. Lee1, C-J. Hung1, Y-J. Lin1, S-S. Chang1, T-C. Chou1, J-P. Chuang2
1Department of Surgery, National Cheng-Kung Medical College and Hospital, 
2Department of surgery, Tainan Hospital, Tainan, Taiwan
In general, a negative crossmatch is a prerequisite for renal transplantation. 
Complement-dependent lymphocytoxicity crossmatch (CDCXM) test remains 
the most commonly used crossmatch technique in pretransplant immunologic 
evaluation. The presence of preformed donor-specifi c HLA antibodies (DSA) 
is a major risk factor for early antibody-mediated rejection and graft loss. The 
antibody specifi city and crossmatch should be assessed prior to transplantation. 
Screening for such alloreactive antibodies was traditional performed using 
complement-dependent lymphocytotoxicity (CDC) assay. More recently, 
ELISA and fl ow cytometry-based techniques were introduced to overcome the 
limited sensitivity and specifi city of the CDC assay. This retrospective study 
using the LAT-M screen and identifi cation HLA class I and II specifi city and 
evaluated the accuracy of pretransplant CDC crossmatch. 
In this study, a total of 481 serum samples from patients awaiting kidney 
transplantation were tested by ELISA method: LAT-M (One Lambda). The 
results the overall prevalence of HLA antibodies positive were 24% to 17% 
according to optical density (OD) reaction strength increase. The positive 
predictive value (PPV) from PRA positive sera responsible to positive CDC 
crossmatch at the time of putative transplant was found to be 43% to 54%. 
The negative predictive value (NPV) from PRA negative sera responsible to 
negative CDC crossmatch was found to be 88%. Furthermore, PPV was 52% to 
64% from the HLA class I DSA positive sera and 46% to 58% from HLA class 
II DSA positive sera. On the other hand, NPV were 88% from the HLA class 
I DSA negative sera and 87% from HLA class II DSA negative sera.Based on 
our results, we believe HLA antibody identifi cation using ELISA still had the 
role in the negative predictive value in CDC crossmatch before transplantation. 
Further analysis of HLA antibody using fl ow cytometry technology based 
Luminex will be done to compare with present data.
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EIGHTEEN-YEAR FOLLOW-UP OF A RETROSPECTIVE 2283 
STUDY OF HLA ANTIBODY ON KIDNEY GRAFT SURVIVAL
P-C. Lee1, C-J. Hung1, Y-J. Lin1, S-S. Chang1, T-C. Chou1, J-P. Chuang2
1 Department of Surgery, National Cheng-Kung Medical College and Hospital, 
2 Department of surgery, Tainan Hospital
In general, a negative crossmatch is a prerequisite for renal transplantation. 
Complement-dependent lymphocytoxicity crossmatch (CDCXM) test remains 
the most commonly used crossmatch technique in pretransplant immunologic 
evaluation. The presence of preformed donor-specifi c HLA antibodies (DSA) 
is a major risk factor for early antibody-mediated rejection and graft loss. The 
antibody specifi city and crossmatch should be assessed prior to transplantation. 
Screening for such alloreactive antibodies was traditional performed using 
complement-dependent lymphocytotoxicity (CDC) assay. More recently, 
ELISA and fl ow cytometry-based techniques were introduced to overcome the 
limited sensitivity and specifi city of the CDC assay. This retrospective study 
using the LAT-M screen and identifi cation HLA class I and II specifi city and 
evaluated the impact of long-term graft survival. 
In this study, a total of 288 pre-transplant serum samples were tested by ELISA 
method: LAT-M (One Lambda). The results the overall prevalence of HLA antibodies 
positive before transplantation were 19%. Five years, ten years an fi fteen years after 
transplantation, functional graft survival among 234 patients not having antibodies 
was 85%, 76% and 56% compared to 65%, 53% and 28% for 54 patients with HLA 
antibodies (P=0.0021). Among patients with PRA positive before transplantation, 
twelve of them had donor-specifi c antibody (DSA) positive, six patients was HLA 
class I DSA positive and eight patients was HLA class II DSA positive. Comparison 
of the functional survival between DSA positive patients and PRA negative patients 
showed the trend of different, however, not statistically signifi cant. 
Based on our results, we believe HLA antibody identifi cation using ELISA 
still had the role to predict long term graft survival. Further analysis of HLA 
antibody using fl ow cytometry technology based Luminex will be done to 
compare with present data.
POSTER BOARD NUMBER P4 – 334
PRETRANSPLANT CROSSMATCH USING PERIPHERAL 2284 
BLOOD DERIVED LYMPHOCYTES (PBL) IS RELIABLE AND 
REDUCES CIT
A. Asderakis1, M. Ilham1, S. Lloyd2, R. Walters2, T. Rees2
1Transplant Unit, University Hospital of Wales, UK, 2Welsh Transplantation 
and Immunogenetics Laboratory
Introduction: Pre-transplant crossmatch (CXM), along with identifi cation of 
HLA specifi c antibodies is prerequisite for a successful kidney and pancreas 
transplant. Organs from donors after cardiac death (NHB) represent one of the 
attractive solutions to organ shortage, whilst pancreas transplantation (PTX), 
simultaneously or following a kidney transplant, is a successful treatment for 
selected diabetic patients. Cold Ischemic Time (CIT) is an important predictor 
of long-term kidney survival and is known to be detrimental in early and late 
pancreas survival, thus it might be even more important in those situations. 
Therefore every effort that can effectively minimise CIT should be used.
Aim: Evaluate crossmatch using donor peripheral blood derived lymphocytes 
(PBL) rather than spleen or lymph nodes once a donor has been identifi ed (in 
some cases even before the donor procedure takes place) in NHB and PTX.
Methods: In a 2-year period all NHB and PTX donors were CMX against recipient’s 
most rent serum sample available. All recipients had HLA specifi c antibodies 
previously identifi ed and actively avoided. There were 28 CMX for NHB and 10 
for PTX performed using donor PBL. Both complement dependent (CDCXM) and 
fl ow cytometry cross match (FCXM) were performed. In 12 patients the CMX was 
performed using spleen cells (as PBL were not available prior to spleen becoming 
available from the donor), and were excluded from further analysis. All 26 remaining 
CMX were repeated the following day using spleen cells and the results compared.
Results: All CDCXM using donor PBL were negative, and concurred with 
CDCXM results against spleen-derived lymphocytes (SDL). Two FCXM were 
not performed with PBL due to lack of enough cell yield while six were not 
performed with SDL for the same reason. 
One case was FCXM positive with both materials. Only one case had negative 
B-cell FCXM on PBL and was positive on SDL (linear channel shift 21 vs 51, 
cut off 41), whereas it was CDC and fl ow T-cell negative on both. There were 
no immunologic Pancreas or kidney losses among those patients. The median 
CIT for the kidney for those cases was 13 hours and compared to our unit 
overall CIT of 18 hours. There were 3 cases of NHB donors where the CIT of 
the fi rst kidney transplanted was less than 6 h.
Conclusion: Pre-transplant fi nal crossmatch using donor PBL is as reliable and 
precise as crossmatch using cells derived form donor spleen or lymph nodes. 
This method might signifi cantly reduce CIT in NHB and Pancreas transplantation 
and may also have wider implications for classic brain stem kidney donors.
POSTER BOARD NUMBER P4 – 335
ALLOCATION OF DECEASED DONOR KIDNEYS IN SÃO 2285 
PAULO, BRAZIL: EFFECT OF HUMAN LEUCOCYTE ANTIGEN 
COMPATIBILITY ON GRAFT SURVIVAL.
F. Monteiro12, S. Coria1, R. Boni1, L. Pereira1
1São Paulo Organ Allocation System, Health Secretariat of São Paulo, 
2Laboratory of Immunology, Heart Institute, Scholl of Medicine, University of 
São Paulo
Since Jan/2002, São Paulo Organ Allocation System following the Brazilian 
policy has been allocating deceased donor kidneys based on HLA-mismatches 
(MM). In this System are attributed to the HLA compatibility as follow: 6, 
3, 0pt to 0, 1, or 2 HLA-DR MM, respectively; 4, 2, 0pt to 0, 1 or 2 HLA-B 
MM, respectively; 1, 0,5 or 0pt to 0, 1, or 2 HLA-A MM, respectively (total: 
0 to 11pt). Before 2002, deceased donor kidneys were allocated to receptors 
based on wait-list timing. The aim of this study was to measure the 5-year 
kidney graft survival now transplanted under the allocation policy for HLA-
MM. Also, we investigated whether a well-matched graft is diffi cult to achieve 
in patients that are homozygous for the HLA antigens. The study involved 
3312 consecutive kidney patients transplanted in São Paulo, Brazil from 
Jan/00 to Dec/06. All transplants were ABO compatible and were performed 
with a negative XM against donor T and B cells. Endpoints for graft loss 
were recipient death or return to dialysis. The review time point was Dec/07. 
Kaplan-Meier method was used to construct graft survival curves and the 
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curves were compared with log-rank test. The results has shown better graft 
survival curves of patients (N=913) transplanted in the fi rst 2 years after jan/02 
than patients (N=715) transplanted 2 years before jan/02 (78.1% vs. 64.9% P 
< 0.001). After Jan/02 until Dec/06, a total of 2597 consecutive transplants 
were performed. From those, transplants with zero (N=121) HLA-A, -B, -DR 
MM had a signifi cantly better survival rate than those with 1-2 (N=862) or 
3-4 (N=1271) or 5-6 (N=343) HLA-A, -B, -DR MM (72.42% vs. 63.44% vs. 
58.25% vs. 56.71% P<0.050). Transplants (N=1467) with no HLA-DR MM 
had a signifi cantly better survival rate than those (N=1130) with one and two 
HLA-DR MM (62.4% vs. 59.13.0%, P<0,005). Finally, HLA homozygous 
patients (N=17) wait longer for suitable crossmatch negative organ compared 
to HLA heterozygous patients (N=2008, – 51mth vs. 35mth) and they have 
a signifi cantly reduced survival rate compared to the same group (31% vs. 
60% P<0.050). In conclusion, HLA compatibility is still a feasible criterion 
to allocate deceased donor kidneys. However, regarding to HLA homozygous 
patients, some adjustment must be done to guarantee equal distribution.
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IMPACT OF THE NON-CLASSICAL HLA-E EXPRESSION 2286 
ON KIDNEY ALLOGRAFT OUTCOME.
J.C.O. Crispim2, L.T. Saber1, R.A. Duarte3, C.P. Soares3, R.S. Costa4, 
J.S. Silva2, C.T. Mendes-Júnior5, E.A. Donadi5
1Renal Transplant Unit, Hospital Das Clinicas, University of São Paulo-
Ribeirão P, 2Department of Biochemistry and Immunology, FMRP-USP, 
Brazil, 3Department of Clinical Analysis; School of Pharmaceutical Sciences, 
UNESP, University of São Paulo State., 4Department of Pathology, FMRP-
USP, Brazil., 5Division of Clinical Immunology, FMRP-USP, Brazil
Human leukocyte antigen (HLA)-E belongs, with HLA-G and HLA-F, to the 
non-classic major histocompatibility complex (MHC) class I (Ib) molecules, 
broadly defi ned by a limited polymorphism and a restricted pattern of 
cellular expression, and may display tolerogeneic functions. In solid organ 
transplantation, the expression and function of HLA-E in physiological and 
pathologic processes remain poorly established. Since the expression of the of 
HLA-E in renal biopsies has not been performed, in this study we performed 
a cross-sectional study, systematically comparing the expression of HLA-E in 
post-transplanted renal grafts, stratifying patients according to the presence or 
not of rejection. 
Patients and Methods: Ninety-four renal specimens (12 with acute rejection 
(AR) and 19 chronic allograft nephropathy (CAN), and 63 with no signs of 
rejection were immunohistochemically evaluated for HLA-E expression. 
Results: In the group as a whole, HLA-E molecules were detected in 23 cases 
(24.5%). On the hand, among specimes that presented HLA-E expression, 
12 out of 23 (52.2%) exhibited AR and CAN, and the remaining 11 (47.8%) 
exhibited no signs of rejection. The comparison between patients with rejection 
with those without rejection, the expression of HLA-E was signifi cantly 
increased in specimens exhibiting signs of rejection (p<0.0396). 
Conclusions: Our results suggest that HLA-E expression in the kidney allograft 
is associated with susceptibility to CAN.
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LONG-RANGE LINKAGE ON CHROMOSOME 6P OF 2287 
VEGF, FKBP5, HLA AND TNF ALLELES ASSOCIATED WITH 
TRANSPLANT REJECTION
I. Hutchinson1,2, Y. Chen1,2, J. Cicciarelli1,2, V. Pravica1,2
1University of Southern California, 2National Institute of Transplantation, Los Angeles
Introduction: Polymorphisms in several genes on the short arm of chromosome 
6 (6p), among them VEGF (6p12), FKBP5 (6p21.2), HLA-DR (6p21.3) and 
TNF-α (6p21.3), have been associated with infl ammation and transplant 
outcome. Each of these genes is associated with acute rejection. Independent 
segregation of these genes is unproven, so we investigated linkage between 
distant genes on 6p and the putative existence of evolutionarily-conserved 
long-range 6p haplotypes. 
Methods: SNPs studied were VEGF-2578*C/A (rs699947), TNF-α -308*G/A 
(rs1800629) and FKBP5*C/T (rs1360780) in 206 random and 80 selected 
HLA-DR52 positive individuals. HLA-DR was typed by serology or SSP. To 
simplify the analysis, the HLA-DR genotypes were collapsed to the 5 human 
ancestral HLA-DR supertypes, namely: DR51 [DR15(2), DR16(2)], DR52 
[DR11(5), DR12(5), DR13(6), DR14(6), DR17(3), DR18(3)], DR53 [DR4, 
DR7, DR9], DR1 [DR1, DR10] and DR8. Gametic phase and linkage between 
paired genotypes were determined using ARLEQUIN 3.01 software, and 
signifi cance was determined by Chi-square and Markov chain/Fisher’s exact 
test analysis.
Results: Signifi cant allelic associations were evident across the 6p region 
examined.
 VEGF FKBP5 HLADR TNFα
VEGF * P<0.05 P<0.05
FKBP5 P<0.05 * P<0.05 P<0.05
HLADR P<0.05 P<0.05 * P<0.05
TNFα P<0.05 P<0.05 P<0.05 *
Two putative extended haplotypes were identifi ed, associated with DR52 and 
DR1.
DR52 VEGF*C FKBP*T TNF*A DR1 VEGF*A FKBP*C
Chi sq 6.79 4.19 32.54 17.14 8.76
P value <0.05 <0.05 <0.001 <0.001 <0.05
Within the HLA-DR52 supertype, TNF*A was associated with DR3, while 
FKBP5*T was associated with DR6.
Discussion: The interval between VEGF and TNF-α is 12.31Mb. Therefore, 
allelic associations are surprising considering expected recombination and 
the evolutionary time (c10MY) since divergence of DR supertypes. This 
suggests that DR1 and DR52 haplotypes have a survival advantage. Within the 
DR52 supertype, VEGF*C-DR3-TNF*A is a ‘high infl ammatory’ haplotype 
associated with acute and chronic rejection, while the FKBP5*T-DR6 haplotype 
is associated with resistance to endogenous and exogenous glucocorticoids. 
Conversely, the DR1 haplotype is a ‘low infl ammatory’ haplotype. 
Conclusion: Distant genes on chromosome 6p co-segregate. This has implications 
for transplantation and the defi nition of HLA-disease associations.
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DIFFERENT IMPACTS OF PRE-TRANSPLANT AND 2288 
POST-TRANSPLANT FLOW-PRA AND DSA ON LIVING DONOR 
RENAL GRAFTS
W. Huang, F. Zeng, P. Zhou, Z. Zhen, W. Zhang, D. Cheng
Institute of Organ Transplantation, Tongji Hospital,Tongji Medical College, 
Huaz
Background: The presence of preformed alloantibodies may pose tremendous 
risk for humoral rejection to kidney allografts. The objective of this study 
was to measure the serum creatinine levels of living donor kidney transplant 
recipients, and fi nd out what were the impacts of pre-transplant and post-
transplant panel reactive antibodies (PRA) and donor-specifi c antibodies 
(DSA) on the renal grafts.
Methods: We reviewed the data of 135 recipients of living donor kidney 
transplants from our hospital from 2001 to August 15, 2007, including 19 
positive pre-transplant HLA fl ow PRA (6 anti-HLA-IFlow PRA ;2 anti-HLA-
IIFlow PRA and 11 anti-HLA-¦ &¦ Flow PRA). All 135 patients (with 2.3±1.2 
HLA-Ι mismatches and 1.0±0.6 HLA-I mismatches¦ post-transplant 2.7±1.3ys) 
had negative pre-transplant fl ow cytometry crossmatch (FCXM). There was 
no graft lost during observation. All serum samples from the recipients were 
screened for preformed or post-transplant Flow-PRA and DSA, DSA were 
detected by the fl ow T- and B-cell crossmatch FCXM (FTXM and FBXM), 
while the creatinine levels were monitored. And, relation of humoral rejection 
with preformed or post-transplant PRA and DSA was evaluated.
Results: Approximately 30%(41/135) of tested sera were found to contain 
anti-HLA-antibody (12 anti-HLA-IFlow PRA ;5 anti-HLA-IFlow PRA 
and 20 anti-HLA-¦ &¦ Flow PRA), and 45 tested sera¦ 45/135 33.3%¦
had positive FCXM results (26 FTXM-positive and 18 FBXM-positive). 
We found that all recipients with positive pre-transplant HLA-IPRA got 
higher creatinine levels (1.80 ± 0.51mg/dl; n=17¦ than the patients with 
negative pre-transplant HLA-IPRA¦ 1.12±0.37 mg/dl; n=118¦ (p<0.05); 6 
of 8(75%) recipients with positive pre-transplant HLA-IPRA got pathology 
proved humoral rejection, but none in later group. There were no statistically 
differences between creatinine levels after transplantation of recipients 
with positive and negative pre-transplant HLA-¦ PRA. Creatinine levels 
of recipients with positive post-transplant anti-HLA-Ior¦  Flow PRA (1.17 
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± 0.33mg/dl; n =22) were not signifi cantly different from that of PRA-
negative (1.09 ± 0.30 mg/dl; n= 94) (p>0.05). Similarly, creatinine levels 
of recipients with positive FCXMs (FBXM or FTXM) (1.15 ± 0.34 mg/dl; 
n=45) were not signifi cantly different from the ones with negative FCXMs 
(1.10 ± 0.31 mg/dl; n=90) (p>0.05). 
Conclusion: The data showed serum creatinine levels of recipients with positive 
pre-transplant anti-HLA-¦ PRA were higher than that of negative ones. Anti-
HLA antibodies would be induced by transplantation, blood-transfusion or 
gestation¦ so recipients who waits for renal regraft, who got blood transfusion 
and childbearing women would be at higher risk of graft failure. This preliminary 
result would be helpful for distinguishing the recipients with higher risk of 
graft failure, and reminding the doctor to implement new therapeutic strategies, 
so as to keep the recipients from the disastrous hurts.
POSTER BOARD NUMBER P4 – 339
GRAFT SURVIVAL IN RENAL TRANSPLANT 2289 
RECIPIENTS ENHANCED BY HUMAN LEUKOCYTE 
MATCHING-SINGLE CENTER STUDY (UNIVERSITY 
HOSPITAL ZAGREB, CROATIA)
I. Humar, L. Bubic, N. Martinez, B. Palfi , V. Kerhin-Brkljacic
University Hospital Zagreb
One of the most hotly debated HLA typing topics throughout the years has 
been the signifi cance of HLA matching, including the importance of different 
match grades (if any) to transplant survival. HLA typing and the time a 
patient has spent on the waiting list are the primary criteria used to allocate 
deceased kidneys for transplantation in Croatia. Candidates with no HLA-A, 
B, and DR mismatches are given top priority, followed by candidates with the 
fewest mismatches at the HLA-B and DR loci. There has been an ongoing 
contention that new immunosuppressive drugs improve graft survival rates, 
which proscribes the need for HLA matching. 
Aim: The purpose an analysis of 572 renal transplants based on 6, 7 3, 7 
years (form 1-19 years) is to examine recent fi ndings in HLA matching 
as they are associated with organ transplant survival and to look at trends 
immunosuppressive treatments. 
Methods: We investigated the effect of HLA matching, using a Cox 
regression model for the survival rate. The results of the analyses were 
used to estimate the possible change in balance of graft survival rates that 
would result from the elimination of HLA-B matching or HLA-B and DR 
matching as a means of assigning priority. All P values are two-sided and 
considered statistically signifi cant if less than 0.05. All calculations were 
performed by STATA 7.0.
Results: The effect of increasing the number of mismatches at each locus 
is compared with the effect of one mismatch at each locus. Having one 
mismatch at the HLA-A or B locus, as compared with 5 mismatches, had 
statistically signifi cant effect after adjustment for mismatches at the other 
two loci (P values ranged from 0.012 to 0.01) relative risk from 1.63-2.1. One 
or two mismatches at the HLA-DR locus, as compared with 5 mismatches, 
did increase the risk of graft failure (relative risk with one mismatch, 1.93; 
P<0.071; two mismatches, 2.22; P<0.028). These results suggest that 
eliminating HLA-DR matching as a priority would have a greater negative 
effect on graft survival than would eliminate HLA-A or B matching. In every 
instance, notwithstanding the difference in immunosuppressive drugs used, 
the 10-year graft survival difference between 0-2 mismatch and 3-6 antigens 
mismatch is 14, 3%.
Conclusion: From the difference between zero and fi ve mismatch, it is clear 
that even one antigen mismatch was enough for the immune system to respond 
and react with an additive increase in graft survival for each mismatched 
antigen. Until we don’t have specifi c immunosuppression to eliminate the 
responding cells to the donor mismatched antigens, we will not achieve a 
tolerance state. It is important to acknowledge that immunosuppression is 
always going to put us in the predicament of too little -resulting in graft 
rejection, or too much- subjecting the recipient to infection and toxicity. 
Until we make strides in the direction of specifi c immunosuppression so that 
cells responding to mismatched donor antigens eliminated or specifi cally 
modulated them, we will need HLA matching to generate this specifi c no 
response to the donor antigens.
COMPOSITE HANDCONCURRENT ORAL SESSION 153: 
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THE BANFF 2007 WORKING CLASSIFICATION OF 2290 
SKIN-CONTAINING COMPOSITE TISSUE ALLOGRAFT 
PATHOLOGY
L.C. Cendales1, J. Kanitakis2, S. Schneeberger3, C. Burns4, P. Ruiz5, 
L. Landin6, M. Remmelink7, C.W. Hewitt8, T. Landgren9, B. Lyons10, 
C.B. Drachenberg11, K. Solez12, A.D. Kirk13, D.E. Kleiner14, L. Racusen15. 
1Emory Transplant Center, Emory University and Atlanta Veterans Affairs 
Medical Center, Atlanta, Georgia, USA, 2Department of Dermatology and 
Dermatopathology, Ed. Herriot Hospital, Lyon, France, 3Department of 
General and Transplant Surgery, Medical University Innsbrück, Innsbrück, 
Austria and Division of Plastic and Reconstructive Surgery, UPMC, Pittsburg, 
Pennsylvania, USA, 4Jewish Hospital Pathology Department, Jewish Hospital 
and St Mary’s Healthcare, Louisville, Kentucky, USA, 5Department of 
Pathology and Surgery, University of Miami, Miami, Florida, USA, 6and and 
Reconstructive Surgery Unit, Pedro Cavadas Foundation, “La Fe” University 
Hospital, Valencia, Spain, 7Department of Surgical Pathology. CUB-ULB 
Hôpital Erasme, Brussels, Belgium, 8Robert Wood Johnson Medical School, 
Camden, UMDNJ Cooper Health System, Camden, New Jersey, USA, 
9Department of Anatomical Pathology, Melbourne Health Pathology, Royal 
Melbourne Hospital, Victoria, Australia, 10Department of Histopathology, 
Derriford Hospital, Plymouth, United Kingdom, 11Department of Pathology, 
University of Maryland School of Medicine, Baltimore, Maryland, USA, 
12Department of Laboratory Medicine and Pathology, University of Alberta, 
Edmonton, Alberta, Canada, 13Emory Transplant Center, Emory University, 
Atlanta, Georgia, USA, 14Laboratory of Pathology, National Cancer Institute, 
Bethesda, Maryland, USA, and 15Department of Pathology, The Johns 
Hopkins University School of Medicine, Department of Pathology, Baltimore, 
Maryland, USA 
Composite Tissue Allotransplantation (CTA) is a recently introduced option for 
limb replacement and reconstruction of tissue defects. As with other allografts. 
CTA can undergo immune-mediated rejection; therefore standardized criteria 
are required for characterizing and reporting severity and types of rejection. 
This manuscript documents the conclusions of a symposium on CTA rejection 
held at the Ninth Banff Conference on Allograft Pathology in La-Coruňa, Spain 
on June 26,2007, and proposes a working classifi cation, the Banff CTA-07, 
for the categorization of CTA rejection. This classifi cation was derived from 
a consensus discussion session attended by the fi rst authors of three published 
classifi cation systems, pathologists and researchers from international centers 
where clinical CTA has been performed. It was open to all attendees to the 
Banff conference. To the extent possible, the format followed the established 
National Institutes of Health (NIH) guidelines on Consensus Development 
Programs. By consensus, the defi ning features to diagnose acute skin rejection 
include infl ammatory cell infi ltration with involvement of epidermis and/
or adnexal structures, epithelial apoptosis, dyskeratosis, and necrosis. Five 
grades of severity of rejection are defi ned. This classifi cation refi nes proposed 
schemas, represents international consensus on this topic, and establishes a 
working collective classifi cation system for CTA reporting of rejection in skin-
containing CTAs. 
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STEROID ELIMINATION DURING LONG TERM 2291 
FOLLOW-UP IN HAND TRANSPLANTATION
M. Marvin1,2, K. Ravindra1,2, C. Kaufman3, J. Buell1,2, R. Nagubandi1,2, 
S. Ildstad2, B. Blair3, W. Breidenbach4
1Jewish Hospital, Transplant Center, 2Department of Surgery, University of 
Louisville, 3Christine M Kleinert Institute, 4Kleinert Kutz & Associates
Background: Steroids have formed the backbone of post transplant 
immunosuppression since clinical success was attained in the 1950s. However, 
long term use is associated with untoward sequelae such as hypertension, diabetes, 
osteoporosis, weight gain etc. There has been a move towards elimination of long 
term use of steroids in solid organ transplantation. We applied the same principle 
to the fi rst 2 hand transplant recipients at our center.
Method: Two hand transplants were performed at our center in 1999 and 
2000 in men aged 37 and 38 respectively. The fi rst patient was induced with 
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Basiliximab and then maintained on Tacrolimus, Mycophenolate mofetil 
(MMF) and Prednisone. He had two episodes of rejection in the fi rst 6 months 
and none after. The Carroll test score improved from 54 to 72 over 6 years. 
The second patient was induced with Basiliximab and started on Tacrolimus, 
MMF and Prednisone. He became a diabetic in the weeks following 
transplant. In order to improve glycemic control, MMF was replaced with 
Sirolimus (to permit lower levels of Tacrolimus). This patient had multiple 
episodes of rejection during the initial 6 months (treated with intravenous 
steroids) and another episode at 6 years (treated with Thymoglobulin). He 
developed bilateral osteonecrosis of femoral head needing hip replacement. 
In early 2007 a plan was instituted to taper the Prednisone dose and stop 
the drug. 
Results: The taper of Prednisone was performed in steps of 2.5mg every 6 
weeks. Over a 5 month period this was achieved. Both the patients have been 
off steroids for the past 4 months. There has been no change in the appearance or 
function of the hand in either patient. They are both on 2 drugs only: tacrolimus 
(5-6 ng/ml) and MMF/Rapamycin.
Conclusions: This is the fi rst report of early success with steroid elimination 
in hand transplantation. Despite the patients having been on Prednisone for 8 7 
years prior to cessation, no change in the appearance or function of the grafts 
has been observed. As acute rejection is uncommon after the fi rst year of hand 
transplantation, elimination of steroids after this period should be considered 
in these patients.
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ALEMTUZUMAB INDUCTION IN HAND 2292 
TRANSPLANTATION: PROGRESS TOWARDS MINIMIZING 
IMMUNOSUPPRESSION IN COMPOSITE TISSUE 
ALLOTRANSPLANTATION (CTA)
M. Marvin1,2, K. Ravindra1,2, J. Buell1,2, C. Kaufman4, R. Nagubandi1,2, 
S. Ildstad1, B. Blair4, W. Breidenbach3
1Department of Surgery, University of Louisville, 2Jewish Hospital, Transplant 
Center, 3Kleinert Kutz & Associates, 4Christine M. Kleinert Institute
Background: Progress in CTA has been hampered by concerns related to 
complications caused by long term immunosuppression. We attempted steroid 
avoidance to lower the immunosuppression in hand transplantation.
Methods: The third hand transplant at our center was done in November 2006. 
The 54 year old man received a right proximal forearm transplant. He was 
induced with a single dose of Alemtuzumab and maintained with Tacrolimus 
and MMF. Tacrolimus levels were maintained at 10-12 ng/ml in the fi rst 6 
months and lowered to 6-9 ng/ml later. MMF was initiated at 1gm bid and 
lowered to 500 mg bid due to neutropenia. Steroids were given only peri-
operatively (3 doses) to prevent adverse reaction to Alemtuzumab. The patient 
was also started on CMV prophylaxis. 
Results: The patient tolerated the Alemtuzumab induction well and has had 
only one signifi cant episode of rejection in the fi rst year post transplant. 
As a result of low WBC (0.7), at day 54, Valcyte, CellCept and Bactrim 
were temporarily discontinued, and the patient received three doses of 
Filgrastim. He subsequently developed a CMV infection and concomitant 
rejection (Grade 2-3 skin biopsy) The concurrent CMV infection and acute 
rejection were treated with Ganciclovir and topical Tacrolimus Clobetasol 
respectively. Since the resolution of these events, the patient has remained 
incident free, and does not take oral steroids. He has returned to a productive 
life. His renal function has been stable but has needed statin therapy to 
control hyperlipidemia.
Conclusions: This is the fi rst report of success with steroid avoidance in 
hand transplantation. It has the potential to prevent long term sequel such as 
hypertension, diabetes, osteoporosis etc. Dose reduction of Tacrolimus to a 
trough of 6-9 ng/ml and MMF to 500 mg bid is a step towards the goal of 
minimizing immunosuppression in CTA. This strategy, we hope, will reduce 
the long term complications associated with systemic immunosuppression and 
lead to wider application of CTA.
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RENAL FUNCTION IN LONG TERM HAND 2293 
TRANSPLANT RECIPIENTS: IMPACT OF TACROLIMUS AND 
IMMUNOSUPPRESSION
W.C. Breidenbach1, K. Ravindra3,4, M. Marvin3,4, J. Buell3,4, B. Blair2, 
C. Kaufman2
1Kleinert Kutz & Associates, 2Christine M. Kleinert Institute, 3Department of 
Surgery, University of Louisville, 4Jewish Hospital, Transplant Center
Calcineurin based immunosuppression is nephrotoxic and is associated with 
Creatinine Creep with long term use. This has serious implications for the fi eld 
of CTA as the transplant is not a life saving venture. This data will 1) Contrast 
the management differences of monitoring kidney function in hand CTA versus 
solid organ transplantation and 2) determine if there is any deterioration in 
renal function in our three hand CTA patients.
The fi rst patient was a diabetic prior to transplantation and has received 
Tacrolimus, MMF and prednisone since the transplant. The average Creatinine 
values were 1.34 +/- 0.21 and the current GFR is 57. The patient with 7 years 
follow-up received Tacrolimus, Sirolimus and prednisone. The GFR in this 
patient has been higher and was over 100 at 5 years. The most recent patient 
showed the predictable drop in GFR attributed to use of calcineurins but has 
returned to a calculate GFR of 74 at the one year follow-up. This patient was 
induced with Alemtuzumab and has been on Tacrolimus and MMF without 
any steroids. 
An initial decrease in GFR is to be expected with use of calcineurin inhibitors 
(CNI). Pre-existing disease such as diabetes and hypertension may compound 
the effect of calcineurin nephrotoxicity (patient 1). Avoidance of steroids 
(patient 3), maintaining lower levels of CNI and the use of Sirolimus (patient 
2) have the potential of minimizing nephrotoxicity. Recent experience 
would also suggest a more aggressive approach to immunosuppression 
minimization is feasible in hand CTA. The renal toxicity incurred with the 
use of CNI for lifesaving allografts is more tenable than that incurred for a 
quality of life allograft such as a hand.. Kidney function must be carefully 
monitored so that the patient and the CTA team have the information to make 
long term decisions on the prospect of either losing the limb or needing a 
renal transplant. 
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THE ROLE OF SKIN BIOPSIES IN DIAGNOSING 2294 
CLINICAL REJECTION IN HAND COMPOSITE TISSUE 
ALLOTRANSPLANTATION (CTA)
C. Kaufman1, R. Gonzales1, K. Ravindra2,3, B. Blair1, J. Buell2,3, 
W. Breidenbach4
1Christine M. Kleinert Institute, 2Department of Surgery, University of 
Louisville, 3Jewish Hospital, Transplant Center, 4Kleinert Kutz & Associates
Aim: Traditionally allograft biopsy has dictated treatment of allograft rejection. 
We hypothesize that histological grade of the biopsy may over diagnose 
rejection in CTA Hand CTA is unique in that the organ is external and early 
signs of rejection can be viewed directly. Skin is the fi rst tissue in the CTA graft 
to show rejection. 
Methods: For this study, rejection by defi ned by requirement of treatment. 
These episodes were compared with histological grade, and hand appearance. 
We reviewed 127 skin biopsies taken during 9, 7 and 1 years of follow up. 
Results: Three observations surfaced. First, a rejection grading scale for 
CTA is still evolving. A review of the literature showed at least four different 
criteria are in use. The criteria used to grade biopsies at our center changed 
over the 9 year follow up. Bias towards calling higher grades of rejection, 
and more aggressive treatment occurred in the fi rst two patients. A re-read 
of random biopsies taken from the fi rst two patients showed a down-grade 
of rejection to grade II or I in fi ve cases. Secondly, concomitant CMV 
infection in the last patient prevented the aggressive treatment of rejection. 
Despite high grade histology, the swelling, rash and redness responded to 
topical immunosuppression. Systemic treatment was not necessary. Analysis 
indicated that swelling and/or rash, and the percentage of skin involvement 
seemed to be more informative markers of existing (or resolving) alloreactivity 
than was histology. The biopsies taken from the graft shown below showed 
a grade III histology.
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EVALUATION AND SCREENING OF POTENTIAL HAND 2295 
TRANSPLANT RECIPIENTS
C. Kaufman1, B. Blair1, K. Ravindra3,4, J. Buell3,4, W. Breidenbach2
1Christine M. Kleinert Institute, 2Kleinert Kutz & Associates, 3Department of 
Surgery, University of Louisville, 4Jewish Hospital, Transplant Center
Introduction: In the last 10 years, great interest has been generated in the 
scientifi c community and the public regarding hand transplantation. As the 
only center in the US performing the procedure many amputees contact our 
unit exploring their candidacy for the procedure. Each candidate is extensively 
assessed from the surgical, medical and psycho-social standpoint..
Aim: The goal of this study was to assess the entire evaluation process and 
determine the reasons for denial and acceptance of potential recipients.
Methods: A retrospective analysis of all enquiries from potential recipients 
was performed. The data was divided into 2 time periods based on the fi rst 
successful hand transplant pre 2000 and post 2000 era.
Results: The data in table 1 shows that nearly 25% show no further interest 
after the initial explanation of risks and benefi t. Inappropriate amputation 
and technical diffi culty account for nearly 40% of those denied. Congenital 
problems account for 14 -20% of those turned down. Medical reasons 
(advanced age, cardiac disease, cancer, infections etc.) are responsible for most 
of the remaining denials. Overall only 15 of 421 (3.5%) of enquiries led to 
complete evaluation. Of these 15, 5 (33%) were eventually listed and 3 have 
undergone transplantation. No major differences were noted between the two 
time periods. Most surprisingly, when we examined the data, there were no 
patients who could not be transplanted because of a lack of suffi cient insurance 
coverage. 
Conclusions: Hand transplantation is still in infancy and there exists a need 
for public education. As understanding increases we expect the number of 
unsuitable interested candidates to decrease. Also, as clinical experience 
increases, we will be able to broaden our inclusion criteria, (particularly the 
surgical reasons). At the present time, centers considering CTA should be 
prepared to screen a large number potential candidates.
Interested subject screening outcomes
1999 Data (N=213) Post CTA Tx Data (N=208)
Not Interested 28% 26%
Inappropriate Amputation 27% 39%
Congenital problem 14% 20%
Technical Diffi culty 6% 2.4%
Cancer 3% 0.5%
Infectious Disease 2% 0.5%
Other 16% 7%
Eligible and Interested 4% 5%
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FRAMINGHAM RISK ASSESSMENT IN COMPOSITE 2296 
TISSUE ALLOGRAFT (CTA) RECIPIENTS
M. Marvin1, R. Nagubandi1, R. Kadiyala1, C. Kaufman2, W. Briedenbach2, 
J. Buell1
1Divisions of Transplantation, Jewish Hospital, University of Louisville, 
Louisvi, 2Kleinert, Kutz and Associates, Hand Care Center, Jewish Hospital, 
Louisville, KY, United States
Background: Technical issues in hand transplantation have been overcome 
in the last decade. Despite increased interest and performance of this 
procedure, signifi cant concerns have been raised over the impact of chronic 
immunosuppression and its associated complications for a non-life saving graft. 
As cardiovascular death is a serious long-term risk to transplant recipients, 
we examined the Framingham risk of our composite tissue allograft (CTA) 
patients.
Methods: Three unilateral hand-forearm transplants have been performed at 
our institution. All three have been prospectively followed on a yearly basis. 
The length of follow-up for these patients are 9, 6 and 1 year. To address the 
issue of cardiovascular risk we calculated the pre and post transplant Coronary 
Disease Risk Prediction Score (CDRPS). 
Results: The fi rst two transplants recently underwent steroid withdrawal, while 
the third was transplanted under a steroid avoidance protocol. Both patients 
(Tx 1 and 3) who were maintained on tacrolimus and mycophenolate mofetil 
had stable CDRPS. However, a notable increase in the CDRPS was observed 
in patient #2 (Tx 2) who required the addition of sirolimus for an episode of 
late rejection.
Tx 1 Tx 1 Tx 2 Tx 2 Tx 3 Tx – 3
Date Pre-Tx 9 yrs post-Tx Pre-Tx 6.8 yrs post-Tx Pre-Tx 1yr post-Tx
Age 37 46 36 43 54 55
LDL 85 42 84 121 142 81
HDL 50 44 60 63 50 34
BP 132/82 128/70 134/80 120/80 132/78 130/88
Diabetes Y Y N Y N N
Smoker N N N N N N
CDRP score (%) 2 (4%) 2 (4%) -4 (<1%) 2 (4%) 4 (7%) 4 (7%)
No cardiac events have occurred.
Discussion: TOR inhibitors have been known to increase cholesterol and 
triglycerides. In the Coronary Risk Prediction Score, HDL and LDL contribute 
signifi cantly to the risk profi le.
Conclusion: In our experience with CTA hand allografts, we believe steroid 
elimination and immunosuppression minimization does not increase the 
cardiovascular risk for most recipients. However, we noted in our one patient 
maintained on sirolimus that there was an increase in cardiovascular risk mostly 
attributed to an altered cholesterol profi le.
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THREE CASES OF BILATERAL HAND 2297 
TRANSPLANTATION: LYON EXPERIENCE
P. Petruzzo1, L. Badet1, A. Gazarian2, M. Lanzetta3, H. Parmentier1, 
J. Kanitakis1, A. Eljafari1, E. Morelon1, X. Martin1, J.M. Dubernard1
1Department of Transplantation, Hopital Edouard Herriot, Lyon (France), 
2Chirurgie de la Main et du Membre Supérieur, Polyclinique Orthopédique de 
Lyon (France), 3Italian Institute of Hand Surgery, Monza (Italy)
In this study we reported our experience about bilateral hand 
allotransplantation.
The fi rst bilateral hand transplantation was performed in January 2000, the 
second case on April 30, 2003 and the third case on February 19, 2007. The 
fi rst recipient was a 33-year old man with bilateral amputation from four 
years, the second recipient was a 22-year old man with amputation from two 
years and the third recipient a 27-year old woman with amputation from 2 
years. The immunosuppressive protocol included tacrolimus, mycophenolate 
mofetil, prednisone and, for induction, antithymocyte globulins. 
All our patients presented two episodes of acute skin rejection (asymptomatic 
maculopapular lesions). In the fi rst two recipients they occurred in the fi rst 
three months after transplantation and were resolved by increasing oral steroid 
dose. The third patient experienced two episodes of acute rejection on day 16 
and 271 after transplantation and they were resolved by 3 bolus of steroid. 
The patients did not show other macroscopic or histological signs of acute or 
chronic rejection during the follow-up. 
The fi rst recipient presented hyperglycemia and serum sickness while the second 
recipient suffered a thrombosis of the right ulnar artery and an osteomyelitis of 
left ulna. All the complications were successfully treated.
Eight and fi ve years post-transplantation the fi rst two recipients show a relevant 
sensorimotor recovery particularly of sensibility and activity of intrinsic 
muscles and a degree of motor coordination. Although both patients present a 
limited range of motion of their joints because of fi brosis and adherences with 
a degree of impaired function and a diminished muscular power, they perform 
the majority of daily activities and live a normal social life, in fact the fi rst 
patient started to work in March 2003. One year after transplantation the third 
patient shows protective sensation and a certain degree of tactile sensation. 
Intrinsic muscle recovery is starting.
It is interesting to remark that the recovery of sensitivity and the aesthetic 
aspect of the grafted hands are very important issues for hand transplanted 
recipients, who are very satisfi ed with their grafted hands.
Poster Abstracts Thursday 14 August 2008
7 5 1
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
POSTER BOARD NUMBER P4 – 348
PROSPECTIVE ANALYSIS OF THE IMMUNOLOGIC 2298 
PROFILE OF A HAND TRANSPLANT RECIPIENT IN THE 
FIRST YEAR
M.J. Elliott, K. Ravindra1, W. Breidenbach2, J. Buell1, S. Ildstad3, M. Marvin1 
1Department of Surgery, 2Kleinert, Kutz, and Associates, 3Institute for Cellular 
Therapeutics
Introduction: A major obstacle to the wider application of hand 
transplantation is the long term complications associated with 
immunosuppression. Minimization of immunosuppression is an important 
goal in all transplant recipients. Currently there are no accurate tools to 
evaluate the immunological responsiveness which might help tailor the level 
of immunosuppression for an individual patient. The response of recipient 
lymphocytes to PHA, Candida, and alloantigen may represent laboratory tool 
towards this end. It has been reported that these 3 responses are hierarchical 
with response to alloantigen being the fi rst to be lost, followed by Candida 
and fi nally PHA.
Patient & Method: A 54 year old male received a proximal forearm 
transplant in November 2006. Immunosuppression included induction with 
a single 30 mg dose of alemtuzumab and maintenance with tacrolimus and 
mycophenolate mofetil (MMF). Six weeks post-transplant Valganciclovir, 
Bactrim and MMF were stopped due to neutropenia. The patient developed 
an episode of cytomegalovirus infection followed by acute rejection after 
reduction of his immunosuppression during the third post-operative month. 
These were successfully treated with intravenous Ganciclovir and topical 
tacrolimus & steroids respectively. Blood samples were drawn at selected 
time points and subjected to phenotyping of lymphocyte subsets and 
immune monitoring for circulating peripheral blood regulatory T cells (Treg) 
and proliferative responses to phytohemagglutinin (PHA), Candida, and 
alloantigen. 
Results: Alemtuzumab induction resulted in profound lymphopenia. At week 
2 and 1 month, the response to PHA was intact (stimulation index 110 and 24 
respectively), but response to alloantigen and Candida suppressed (SI <3). A 
similar immunologic profi le persisted up through 6 months. At 1 year, the PHA 
and Candida responses are robust (SI 69 and 38 respectively), but alloresponses 
have not returned. Current immunosuppression consists of tacrolimus (6-9 ng/ml) 
and mycophenolate mofetil (500 mg b.i.d.). There is no gross evidence of acute 
or chronic rejection. 
Conclusions: Induction with alemtuzumab alters the recovery of immune 
response: recovery to Candida was delayed beyond 6 months and to alloantigens 
beyond a year. It is interesting to note that despite severe neutropenia and a lack 
of response to alloantigen and Candida, acute rejection still occurred in the 
third month. However, the rejection was easily reversed with topical agents. 
Immune response monitoring combined with clinical fi ndings could help tailor 
immunosuppression to individual patients.
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MONITORING OF THE FIRST FACE GRAFTED PATIENT, 2299 
WITH FOXP3, PERFORIN, CCR4, CLA AND CD62E MRNAS 
IN BLOOD AND GRAFT DEMONSTRATES DIFFERENTIAL 
CHANGES IN REJECTION VERSUS VIRAL INFECTION 
EPISODES
A. Eljaafari1, B. Devauchelle2, J. Kanitakis3, J-L. Beziat4, P. Petruzzo5, L. 
Badet6, E. Morelon7, X. Martin8, P. Miossec9, J-M. Dubernard10
1Edouard Herriot Hospital, Immunogenomics Unit HCL/BioMerieux, 
Centaure Group, 2Amiens CHU, Maxillo-facial Surgery department, 3Edouard 
Herriot Hospital, Dermatology Dept, 4Croix Rousse Hospital, Maxillo-
facial Surgery department, 5Edouard Herriot Hospital, Transplantation 
Surgery Dept, Centaure group, 6Edouard Herriot Hospital,Transplantation 
Surgery Dept, Centaure group, 7Edouard Herriot Hospital,Transplantation 
dept, Centaure Group, 8 Edouard Herriot Hospital,Transplantation Surgery 
dept, Centaure Group, 9 Edouard Herriot Hospital,Immunogenomics Unit, 
10Edouard Herriot Hospital,Transplantation Surgery dept, Centaure Group
Introduction: Most regulatory T cells are known to express FoxP3, but also 
skin homing receptors such as CCR4 and CLA.
Methods: PBMCs were collected at different time-points post-transplantation. 
Biopsies were performed in the right and left oral mucosa, or in the piece of 
vascualized skin that has been grafted together with the face, as sentinel. The 
levels of FoxP3, Perforin, CCR4, CLA mRNA and CD62E, were measured by 
Q-RT-PCR.
Results: During the fi rst year post-transplantation, two rejection episodes 
were observed in our patient. The second episode occurred one month 
after a sub-clinical CMV reactivation and local herpes infection. Inside 
the graft, two weeks post-transplantation, there was no detectable levels 
of CD3epsilon mRNAs, indicating no T cell infi ltration. During rejection 
episodes, CD3, FoxP3 and Perforin mRNA levels increased inside graft and 
sentinel skin, but not in blood. While FoxP3 mRNA levels were sustained, 
those of Perforin were transient. During the viral infection episode, Perforin 
mRNA levels strongly increased in peripheral blood, right mucosa and 
sentinel skin. However, at the same period, FoxP3 mRNA levels, which 
also increased in blood, dramatically decreased in the sentinel skin and the 
right mucosa. The kinetics of CCR4 and CLA mRNA levels followed that 
of FoxP3 but not that of Perforin. CD62E, which binds to CLA, followed 
the same kinetics, as opposed with CX3CR1, which was used as a negative 
control.
Conclusion: We show here that upon rejection episodes both FoxP3 and 
Perforin mRNA levels were increased inside graft. But, during systemic viral 
infection, a dissociation was observed since FoxP3 profoundly decreased from 
graft, while Perforin mRNA levels increased. Kinetics of expression of CCR4 
and CLA mRNAs followed that of Foxp3, but not of Perforin. Our results 
suggest that the dysregulation of the effectors/Tregs balance, observed inside 
graft during the infection episode, could account for the occurrence of the 
second rejection episode. 
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TC-99M SESTAMIBI ACCURACY IN DETECTING 2300 
PARATHYROID TISSUE IS INCREASED WHEN COMBINED 
WITH PREOPERATIVE LABORATORY VALUES. A 
RETROSPECTIVE STUDY IN 453 GREEK PATIENTS 
WITH CHRONIC RENAL FAILURE WHO UNDERWENT 
PARATHYROIDECTOMY
D. Vrochides,, V. Papanikolaou, G. Imvrios, A. Papagiannis, N. Ouzounidis, 
D. Giakoustidis, I. Fouzas, N. Antoniadis, A. Ntinas, D. Takoudas
Organ Transplant Unit, Aristotle University, Thessaloniki, Hellas
Purpose: Technetium99m sestamibi (MIBI) has poor sensitivity and specifi city 
when applied to patients with secondary hyperparathyroidism. We investigate 
whether the combination of MIBI with preoperative parameters increases its 
accuracy. 
Patients and Methods: This is a prospective study of 453 consecutive patients 
with secondary hyperparathyroidism who underwent parathyroidectomy 
(bilateral neck exploration). All of them underwent preoperative MIBI 
scintigraphy. MIBI readings were compared with intraoperative and 
histopathology fi ndings and four patient groups were comprised according to 
the results: TP group for true positivity, TN group for true negativity, FP group 
for false positivity and FN group for false negativity.
Results: MIBI scintigraphy sensitivity, specifi city, positive predictive 
value and negative predictive value were 66.4%, 50%, 76.3% and 37.9% 
respectively. For the TP group, mean age and mean parathormone (PTH) 
value were 56 and 754 respectively. The binary logistic regression for the 
prediction (1) or no (2) of the true positivity was: 0.138 + (-.011) * age + 
0.001 * PTH (p =.012). For the TN group, mean age and mean phosphate 
value were 49 and 5.24 respectively. The binary logistic regression for the 
prediction (1) or no (2) of the true negativity was: -1.463 + age * (-.029) + 
phosphate * 0.233 (p =.012).
Conclusion: MIBI accuracy in patients with secondary hyperparathyroidism is 
increased when combined with other preoperative parameters. The sensitivity 
is increased as patients get older and the PTH levels get lower. The specifi city 
is increased as patients get younger and the phosphate levels get lower.
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INVESTIGATING THE ROLE OF VE-CADHERIN 2301 
MEDIATED LYMPHOCYTE TRAFFICKING IN COMPOSITE 
TISSUE ALLOTRANSPLANTATION
S. Schneeberger5, B. Pulikkottil1, T. Hautz2, B. Zelger3, G. Brandacher2, V. 
Gorantla1, 
P. Petzelbauer4, A. Lee1, R. Margreiter2
1Division of Plastic Surgery, UPMC, Pittsburgh, PA, USA, 2Dept. of General 
and Transplant Surgery, Innsbruck Medical University, Austria, 3Dept. 
of Pathology, Innsbruck Medical University, Austria, 4Department of 
Dermatology, Medical University of Vienna, Austria, 5Div. of Plastic Surgery, 
UPMC, Pittsburgh, PA, USA and Dept. of General and Transplant Surgery, 
Innsbruck Medical University, Austria
Introduction: While graft survival and good functional outcome encourage to 
continue hand transplantation in humans, skin rejection remains to be one of the 
remaining obstacles. To understand in greater depth the molecular mechanisms 
involved, molecular markers of lymphocyte traffi cking and cellular rejection 
have been investigated in human hand transplantation and targeted in an 
experimental limb transplant model. 
Methods: Skin biopsies taken from three bilateral hand transplants were assessed 
by H&E histology and graded as per previously a published classifi cation 0-IVb. 
Based on the analysis of a multitude of molecular markers lymphocyte infi ltration 
and traffi cking, VE-cadherin was selected and targeted with the fi brin derivative 
Bβ;15-42. Bβ;15-42 was investigated for its capacity to inhibit lymphocyte 
migration in a Brown Norway to Lewis rat hind-limb allotransplant model. 
Animals treated with subtherapeutic doses of Tacrolimus (0.1mg/kg) together 
with Bβ;15-42 (5mg/kg) were compared to untreated controls. 
Results: The majority of infi ltrating lymphocytes in skin rejection are positive for 
CD11a. Upon rejection, VE-cadherin was expressed exclusively on endothelial 
cells with a tendency towards higher expression prior to and during early stages 
of rejection. When tested in the animal model, treatment with Bβ;15-42 together 
with subtherapeutic doses of Tacrolimus signifi cantly prolonged limb allograft 
survival from 7 +/- 0 days to 17.25 +/-2.872 days (p=0.0056). 
Conclusion: Molecular markers involved in lymphocyte traffi cking are up-
regulated upon skin rejection after hand transplantation and represent promising 
target for prophylaxis and treatment of rejection in limb transplantation. When 
targeted in an animal model, blockade of VE-cadherin on endothelial cells 
resulted in signifi cant prolongation of limb allograft survival.
RENAL LIVING DONORCONCURRENT ORAL SESSION 154: 
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DONOR KIDNEY CHARACTERISTICS AND 2302 
RECIPIENT OUTCOME FOLLOWING LIVE DONOR KIDNEY 
TRANSPLANTATION
S. Tiwari, A. Panda, D. Bhowmik
All India Institute of Medical Sciences
Aim: To study the association between transferred donor kidney volume 
(TDKV), transferred donor glomerular fi ltration rate (TDGFR) and donor age 
(DA) to the recipient glomerular fi ltration rate (eGFRr) at different time points 
(m) after transplantation (3, 6, 9 and 12 m).
Material and methods: A prospective study was conducted in 53 living, 
related, voluntary kidney donors and their recipients. The TDKV was assessed 
using the formula V = 0.49 x L x W1 x W2 (L= length, W= width). DTPA GFR 
of the donor was used and transferred kidney GFR (TDGFR) was derived. The 
donor parameters were used to stratify recipients into two groups and they were 
compared. Factors infl uencing the eGFRr at different time points were also 
studied using linear regression analysis.
Results: The mean donor age was 41.4 ¡À 11.9 years (y) while that of recipient 
was 34 ¡À 10.6 y. The mean TDKV and TDGFR were 93 ¡À 22.2 mm3 and 
47.3 ¡À 8.6 ml/min/1.73 m2 respectively. Recipient eGFRr for those with better 
donor parameters [TDKV (¡Ý90 mm3), TDGFR (¡Ý40ml/min/1.73 m2) and 
DA (<45y)] and worse donor parameters [TDKV (<90 mm3), TDGFR (<40ml/
min/1.73 m2) and DA (¡Ý45y)] were segregated and compared. There was no 
statistical difference between the two groups. The recipient eGFRr(time) was 
84.63¡À23.4 (3m), 80.2¡À20.45 (6m), 78.82¡À21.33 (9m) and 77.80¡À17.6 
(12m) ml/min/1.73 m2. By linear regression (univariate and multivariate) DA 
had an infl uence on eGFRr at 3m and 12m. TDKV infl uenced eGFRr at 3 and 
6m. TDGFR infl uenced eGFRr at 6m.
Conclusion: TDKV, TDGFR and DA infl uence the recipient eGFRr. The 
associations vary at different points. Serial assessment can predict graft 
function during follow-up.
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BENEFICIAL EFFECTS ON THE RENAL FUNCTION OF 2303 
BOTH THE RECIPIENTS AND DONORS IN LIVING DONOR 
KIDNEY TRANSPLANTATION
S-U. Choi, C-K. Oh, S.N. Yoon, B.M. Lee, J.H. Kim, S.J. Kim, H. Kim, 
G.T. Shin
Ajou University School of Medicine
Objectives: In living donor kidney transplantation, initial function of donor¡¯s 
bilateral kidneys before donation would be split into the function of donor¡¯s 
remnant kidney and recipient¡¯s implanted kidney after transplantation. The 
questions whether the function of donor¡¯s remnant kidney would increase or 
decrease after donation and whether that of donor¡¯s donated kidney would be 
more or less than that of recipient¡¯s implanted kidney after transplantation were 
addressed. 
Methods: The functional ratio of each kidney using 99mTcDTPA as well 
as serum creatinine (Scr) and creatinine clearance (Ccr) with 24-hour urine 
from 100 donors were measured and calculated. The heights and weights of 
donors were measured and recorded. The body surface area (BSA) and the 
lean body weight (LBW) were calculated. The Ccr was also calculated using 
Cockcroft and Gault formula (Ccr-CG). After kidney donation, Scr and Ccr 
of the remnant kidney with 24-hour urine from the donors were measured and 
calculated within 7 days post-nephrectomy. The Ccr of the remnant kidney 
of the donors was also calculated using Cockcroft and Gault formula (Ccr-
CG). 
For the recipients, Scr and Ccr of the implanted kidney with 24-hour urine from 
the recipient were measured and calculated within 7 days post-transplantation. 
The BSA and LBW of recipients were also calculated. The Ccr-CG of the 
implanted kidney of the recipients was also calculated. The cases of the patients 
with an episode of rejection within 7 days post-transplantation were excluded. 
Results: The average functional ratio of donated kidney vs. remnant kidney 
before donation was 50.7:49.3. The average Scr, Ccr, and Ccr-CG of the 
donors were 0.85 ¡¾ 0.17, 110.4 ¡¾ 20.8, and 82.8 ¡¾ 17.3, respectively. 
Before donation, the average fractions of Ccr and Ccr-CG of donated kidneys 
were 55.9 ¡¾ 11.8 and 42.0 ¡¾ 9.9, respectively, compared to those of remnant 
kidneys 54.5 ¡¾ 11.4 and 40.8 ¡¾ 9.3, respectively. After donation, the Ccr 
and Ccr-CG of donor¡¯s remnant kidney increased to 68.0 ¡¾ 14.3 and 53.6 
¡¾ 11.6, respectively. On the recipient side, after implantation, the Ccr and 
Ccr-CG of donor¡¯s donated kidney also increased to 78.4 ¡¾ 18.0 and 53.3 
¡¾ 16.4, respectively. 
Conclusion: Kidney transplantation from a living donor should be encouraged 
based on the total functional benefi t of both donors and recipients after kidney 
donation and implantation.
POSTER BOARD NUMBER P4 – 354
TOWARD PATIENT SAFETY: SCREENING FOR 2304 
POTENTIAL LIVE KIDNEY DONORS
S.E-D. Al-Horani
Saad Specialist Hospital
Background: It seems that there has been an increase in patients waiting for renal 
transplantation each year. However, the major source of organs, heart beating 
cadaveric donors is declining. For that living donation is the other method of 
addressing the gulf between supply and demand for kidney transplants. However, 
few donors manage to complete the extensive work up. This study looked at 
the reasons for failure to complete the live donor renal assessment and suggests 
options, which may improve the situation as per needed.
Methods: Retrospective analysis of data collected from June 2006 till August 
2007 of all potential live donors entering the assessment program at Saad 
Specialist Hospital.
Results: Between June 2006 and August 2007, Sixty-two potential live 
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donors were seen for assessment of renal donation (37 males and 25 
females). Forty-one (66.1%) of the potential live donors seen actually went 
on to donated. Nineteen (46.3%) were brothers or sisters, nine (21.9%) 
siblings, six (14.6%) parents, four (9.7%) cousins and three (7.3%) were 
spouses. In our series there was a male preponderance. The reasons for 
non-donation classifi ed as either fi xed (absolute) or modifi able. Of the 21 
(33.9%) who did not donate, immunological problems (positive cross-
matching or blood grouping incompatibility) combined accounted for six 
(28.0%). Three potential donors were found to have inadequate glomerular 
fi ltration rate (GFR). Two potential donors (10%) were deemed unsuitable 
for a live donation after review by transplant surgeons, these individuals had 
ejection fraction (EF) less than 30% while there are eleven (52.0%) potential 
donors who did not donate because of medical reasons. There were eleven 
(52.0%) potential donors who were unable to donate for medical reasons. 
Cardiovascular disease mainly cardiac failure (36.3%) is the commonest 
reason for non-donating. Renal stone disease accounted for (18.2%), 
diabetes mellitus (18.2%), and proteinuria (18.2%). Hematuria was found 
in (9.1%) potential donors. This individual was found to have an inadequate 
glomerular fi ltration rate.
Conclusion: Promotion of donor safety is the golden rule of living donor 
program. Potential donors who did not donate because of either positive cross-
matching or blood grouping incompatibility accounted for 28.0%. These were 
taken out of the transplantation pool. If we considered them and inserted them 
in the pooled exchange it will accelerate the wheel of transplantation and 
minimize the long transplant waiting list. Donor exchange program could be 
the potential solution. 
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DO THE DONOR-SPECIFIC TRANSFUSION INFLUENCE 2305 
THE OUTCOME OF LIVING KIDNEY TRANSPLANTATION?
T Rainiene1, N. Izvolskaja2, B. Dainys1,3, G. Kucinskis1
1Vilnius University Hospital Santariskiu Klinikos, 2Vilnius University 
Antakalnio HospitalVilnius University
A pretransplant donor blood transfusion to the patients (pts) – the donor-
specific transfusion (DST) – is still being explored today. However, the 
DST benefits are controversial and its long-term effects have not been well 
discussed. We aimed at evaluating the efficacy of the DST in living kidney 
transplantation (Tx) performed between 1992 -2000. This is a report of our 
experience with 19 pts (the study group), who received the DST 1-3 times 
with a 2-week interval under CsA or AZA during the course of the DST. 
One pt (5.3%) produced a donor specific antibody after the first transfusion, 
one pt was not transplanted because of the donor’s disease, 17 – were 
grafted: 13 – from relatives and 4 – from spouses. The 17 transplanted pts 
were compared with a group of 47 living kidney transplant pts without the 
DST. The groups were comparable for the recipients’ age (29.7±15.0 vs 
30.6±9.6), the donors’ age (44.1±6.2 vs 45.6±6.1), the male/female ratio 
(0.8 vs 0.8), HLA mismatches (3.1±0.9 vs 3.1±0.5), cold ischemia time, 
time on dialysis (14.6±12.9 months vs 10.7±7.1 months), the first Tx or 
re-transplantation, the panel reactive antibody (PRA). The maintenance 
immunosuppressive therapy was the same in both groups (prednisone, 
mycophenolate mofetil or azathioprine, cyclosporine). We did not reveal 
significant differences in actuarial graft survival, calculated by Kaplan-
Meier, at 1, 5 and 10 years. In the DST group it was 100%, 93.8%, 87.1% 
and in the control group – 91.5%, 87.3%, 70.5%, respectively. Graft 
function, evaluated by the serum creatinine level, was excellent (<130 
ìmol/l) one year after Tx in 52.9% of the DST group pts and in 33.3% 
of the control group pts. The differences were not significant. The DST 
group had significantly lower acute rejection episodes during the first year 
(11.8% of pts vs 46.8%, ÷2=4.2899, p<0.05). 
Our results demonstrate that in spite of an unavoidable low risk of sensitization, 
a benefi cial effect of the DST – a signifi cantly lower incidence of acute rejection 
and tendency for better graft survival and function – was observed.
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THE IMPACT OF GRAFT VOLUME AND WEIGHT 2306 
ON EARLY LIVING DONOR KIDNEY TRANSPLANTATION 
OUTCOME
R.J. Soewardi1, R.M.R. Liquete2, M.L.S. Chua-Garcia1
1Center for Renal Diseases, St. Luke’s Medical Center, Philippines, 2The 
Transplant Service, St. Luke’s Medical Center, Philippines
Background: The impact of graft mass on living donor kidney transplantation 
outcome has not been studied extensively. Graft weight to recipient mass 
ratio represents a potentially important parameter on kidney transplantation 
outcome. Weight disproportion between donor and recipient is a risk factor for 
the development of chronic graft nephropathy. The objective of this study is to 
determine the effect of graft volume and weight, and recipient body mass on 
early living kidney transplantation outcome. 
Methods: 57 living non-related kidney transplantation, older than 18 years old, 
were included in the study. Subjects were excluded if they had simultaneous 
pancreas-kidney transplant, cadaveric donors, highly sensitized recipients 
(previous kidney transplant, positive panel reactive antibodies (PRA), multiple 
pregnancies, multiple blood transfusion prior to transplant), had systemic 
or local infection, and any complications such as urologic adverse events 
post-operatively. Immunosuppressive protocol consisted of induction with 
monoclonal antibody and maintenance with tacrolimus, mycophenolate mofetil 
and corticosteroid. Parameters of the metabolic demands of donor and recipient 
consisted of body weight, height and body mass index (BMI) were collected. 
The size of the graft was measured in-situ before retrieval, and the weight of 
the graft was measured directly before cold perfusion. Serum creatinine was 
measured on daily basis until it reached the level of less than or equal to 1.5 mg/
dL. 125I-iothalamate glomerular fi ltration rate (GFR) of the graft was obtained 
on day 7 post transplant. Independent samples t-test, chi-square test and logistic 
regression analysis were carried out to determine the signifi cant predictors of 
acute rejection or delayed graft function.
Results: Higher donor kidney weight/recipient BMI (DKW/RBMI) ratio 
was associated with better graft function (p < 0.001). Donor BMI is an 
independent predictor of kidney graft volume and weight (p < 0.001 and p < 
0.001 respectively). Graft function was signifi cantly associated with donor and 
recipient BMI, and graft volume and weight. 
Conclusions: In living donor kidney transplantation, donor and recipient BMI, 
and graft volume and weight should be considered in order to achieve better 
early graft function. Donor BMI can be used to predict kidney graft volume and 
weight for donor allocation prior to transplantation. 
Keywords: kidney transplantation, living donor, graft function, graft weight, 
graft volume, glomerular fi ltration rate
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ANALYSIS OF THE REASONS FOR APPLYING FOR 2307 
LIVING DONOR KIDNEY TRANSPLANTATION
R. Kushiyama, K. Sakai, T. Suzuki, S. Nobori, A. Yoshizawa, H. Ushigome, 
S. Sakamoto, M. Okamoto, N. Yoshimura
Kyoto Prefectural University of Medicine, Graduate School of Medicine, 
Department of Transplantation Surgery
Background: In Japan, kidney transplantation (KTx) is mainly performed from 
living donors (almost 80% of all KTx). The background of decision for living 
donor kidney transplantation (LDKTx) is more complicated than cadarveric 
donor kidney transplantation, because the will of donors as well as recipients 
should be taken into consideration. In this study, we analyze the motivation 
for LDKTx.
Method: From April 2006 till May 2007, eighty-eight patients were referred 
for LDKTx. We analyzed the background and motivation of both donors and 
recipients referred for LDKTx through several times of interviews.
Result: Sex of the recipients were 48 males, and 40 female, and the median 
age was 45 (3 – 71). Three quarters of them were under hemolytic dialysis 
(HD). The relations between recipients and donors were spouse (30%), parents 
(38.7%), child (1.1%), siblings (19.3%), cousins (1.1%), and others (5.7%). A 
quarter of them gave up LDKTx. The reasons were followed; medical reasons 
(66.7%), patients f will (14.3%), and donors f will (14.3%). The reasons for 
applying for LDKTx were followed; escape from HD (28.4%), improvement 
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of patient’s QOL (20.5%), wish for pregnancy (5.7%), improvement of family 
fs QOL (10.2%), donor fs will (12.5%), and others(22.8%). While 48.9% of 
recipients hope LDKTx for themselves, 30% of patients were referred for 
LDKTx because of the donor’s will rather than the resipent’s hope.
Conclusion: The background of reference for LDKTx is various, and nearly 
half of patients were referred for LDKTx because their family member including 
donor hopes LDKTx rather than HD or CAPD as a treatment for chronic 
renal failure. This study shows that the donors do not reluctantly propose for 
donation, but they propose for donation in expectation of improvement of their 
own and families f QOL.
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EARLY EXPERIENCE OF LIVE RELATED KIDNEY 2308 
TRANSPLANTATION IN A NEW CENTER, BANGLADESH
N. Hassan, S. Iqbal, W.M.M. Haque, M.A. Mansur, Z. Ahmed
BIRDEM Hospital
Number of patients developing ESRD from diabetes is increasing world wide 
including Bangladesh. Between November,2004 to December 2007 total 30 
cases had undergone Living Related Kidney Transplantation. Average age 
was 35 years (Range 19 – 53 years) male 23 and female 7. Cause of ESRD 
was Glomerulonephritis in 20 (66.6%), Diabetic Nephropathy in 7 (23.3%) 
and Hypertension in 3 (10%). Three cases were preemptive. All donors were 
live related. Relationship between donor and recipient were siblings 22(73%), 
mother 6(20%), spouse 1(3%), and uncle 1(3%). 
Immediate post-operative graft nephrectomy was required in 1 patient due 
to renal artery thrombosis, HD required in 1 patient due to ATN. Among 
the rest 28 recipients, renal function came to normal (1.1+0.2mg/dl) on 
discharge at 10th postoperative day in 21(70%) cases and Serum creatinine 
was elevated (2.1+0.4) in 7(23%). Blood pressure was controlled (<130/80) 
by 3 or more antihypertensive in 5 cases, 2 antihypertensive in 7 cases, only 1 
antihypertensive in 6 and without any antihypertensive in 9 patients 3 months 
after transplantation. We used Cyclosporin, Mycophenolate and Prednisolone 
as immunosupressive regimen in all recipients. Average Cyclosporin dose 
requirement was 6 mg/kg/day at 2 weeks. In last 3 years follow up 7 (23%) 
patients expired 1 due to surgical complication, 2 due to septicaemia, 1 due to 
hemorrhagic stroke, and another 3 due to chronic rejection. At one year patient 
survival was 86.6%.
Initial out come of live related renal transplantation in a new center including 
diabetic patients and with these immunosuppressive regimens is encouraging. 
Long term follow up with increased number of patients is required for further 
assessment.
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WHEN FAMILY SECRETS ARE UNCOVERED: 2309 
DISCOVERY OF MISATTRIBUTED PATERNITY 
INFORMATION AT US TRANSPLANT CENTERS
N. Schroder1, A. Haririan2, C. Welsh3, M. Cooper4
1University of Maryland Medical Center, Dept. of Social Work, 2Dept. of 
Medicine, 3Dept.of Psychiatry, 4Dept. of Surgery
Background: We sought to determine the prevalence of the discovery 
misattributed paternity (MP) in parent-child living kidney donor (LKD) 
transplants among other US transplant (Tx) centers. Established policies/
practices in treatment of such powerful and potentially explosive information 
were investigated. 
Methods: Questions regarding MP were a component of a 68-question online 
survey examining various psychosocial policies and practices among US Tx 
centers. The survey was mailed via listserv to 2 professional Tx societies.
Characteristics of the 69 participating Tx centers are summarized in Table 1.
Number/yr Overall Tx 
(% of centers)
LKD Evaluations 
(% of centers)
LKD Tx 
(% of centers)
≤ 50 21.9 43.9 63.4
51-100 37.5 22.8 22.2
101-200 23.4 19.3 11
200+ 17.7 14 3.2
Results: 70% of the centers claimed to have discovered MP upon review of 
HLA testing of parent and offspring pairs evaluated for LKD transplantation. 
Signifi cant variability was demonstrated in the manner in which Tx centers 
proceeded upon discovery. 17.6% of centers continued with evaluation and 
donation without disclosing the paternity information to either party. 2 centers 
addressed the information only if the donor and recipient were found to be a 
viable match. 3 centers disclosed the information only to the donor and 1 center 
disclosed the information only to the recipient. 44.1% discussed the results 
with a multidisciplinary team on a case-by-case basis but did not indicate a 
fi nal outcome. 
24.6% of centers include the potential for the discovery of MP information as 
part of informed consent prior to HLA testing. Although the majority of centers 
queried have encountered the discovery of MP, only 28% of centers currently 
have a policy upon discovery of this information. Transplant center volume 
showed no correlation with policy development.
Discussion: The results of this survey clearly demonstrate that discovery of MP 
is an ethical dilemma commonly experienced by many US Tx centers. There 
is, however, no consensus among transplant professionals as to the need for a 
more inclusive informed consent accounting for such discovery or the process 
in which such information should be shared and/or utilized in the decision for 
donor suitability. 
Conclusion: These results call for intense discussion and debate by the Tx 
and bioethics communities with the aim of exploring policies and standards of 
practice for this area of transplantation. 
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OUTCOME OF ASSESSMENT OF POTENTIAL LIVING 2310 
KIDNEY DONORS
S. Stacey1, J. Akoh
1Plymouth Hospitals NHS Trust, 2Plymouth Hospitals NHS Trust
Introduction: The living donor transplant programme was re-established in 
January 2003, with the appointment of a living donor transplant coordinator 
(LDTC) and meticulous assessment of all potential living donors in conjunction 
with local and national guidelines. The UK law was altered to allow altruistic 
non-directed donation and paired exchange in September 2006 and thereafter, 
these schemes were introduced. The aim of this study is to highlight the 
outcome of assessment of potential donors within a single centre.
Method: Between January 2003 and February 2008, 364 potential donors (237 
related, 120 unrelated and 7 altruistic) where referred to the stages assessment 
process for living kidney donation. By the end of February 2008, 351 of these 
had completed fi rst stage and 143 in various levels of second stage assessment. 
Records of assessment and outcomes were entered prospectively into a 
spreadsheet maintained by the LDTC. 
Results: The reasons for exclusion from stage 1 are shown in Table 1. Of the 
143 proceeding to stage 2 assessments, 25 were excluded for medical and other 
reasons and 46 currently being assessed. Sixty fi ve donor nephrectomies were 
performed with 7 awaiting surgery giving a donation rate of 21.3% (65/305) 
and a potential donation rate of 24% (72/305) if the 7 successfully donate. 
Unusual discoveries during assessment of potential donors include 1 donor 
with breast cancer, 1 with non-Hodgkin’s lymphoma identifi ed on abdominal 
CT scan and another discovered to have non-Hodgkin’s lymphoma in the 
transplanted kidney. This was possible only following the fortuitous transplant 
nephrectomy due to renal vein thrombosis on day zero.
Conclusion: The yield rate was 21.3%. There are psychological and 
economic implications of exclusion on medical grounds. The recent 
introduction of paired exchange and non-directed donation will improve 
donation rates. ABO incompatible transplantation or desensitization of 
potential recipients may also improve living donation rates.. Seventy four 
patients would have been referred for paired donation were this option 
available during the entire period.
Death while on the waiting list for transplantation still constitutes a signifi cant 
problem. Perhaps relatives and signifi cant others should be invited to consider 
the option of living donation at the time of patient entry on the transplant 
waiting list.
Table 1 Stage One (n = 351) 
Reason for exclusion Number
ABO incompatible 49
Donor/recipient withdrawal 41
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Positive crossmatch 25
Unacceptable antigens 9
More suitable live donor (multiple donors) 43
Cadaveric transplant 34
Death of prospective recipient 7
Progressed to stage two 143
Total 351
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COMPARISON OF IMMEDIATE AND SLOW GRAFT 2311 
FUNCTION IN LIVING DONOR KIDNEY TRANSPLANTATION
S.Y. Lee, H. Yoon, B. Hyoung, D.Y. Jeon, H. Hwang, B. Choi, Y. Kim, 
B. Bang, C. Yang
Division of Nephrology, Department of Medicine, The Catholic University of 
Korea Kangnam St. Mary’s Hospital, Seoul
Purpose: Slow recovery of graft function (SGF) is frequently observed in 
decreased donor transplantation. But, the defi nition and clinical outcome of 
SGF in living donor kidney transplantation are unclear. The purpose of this 
study is to evaluate the clinical characteristics and pathologic fi ndings in 
patients with SGF in living donor transplantion. 
Methods: Among, 204 adult living kidney transplants, one hundred and seventy 
four recipients were included. According to serum creatinine (SCR) level at 
day 14 after transplantation, recipients were categorized into immediate graft 
function (IGF,SCR <1.5 mg/dL) and SGF (SCR ¡Ã1.5 mg/dL) based on serum 
creatininine level at day 14 after transplantation. Of the 174 recipients, 144 
(82.8%) had IGF, 30 (17.2%) had SGF. Immunesuppressants were cyclosporine 
(n=107), FK506 (n=66) and rapamune (n=1). Clinical characteristics and 
pathologic fi ndings, and clinical course were compared between groups. 
Results: Female recipients were dominant (95.7%) in the IGF group, but male 
recipients (90%) was dominant in the SGF group (p = 0.05). In part of the 
donor characteristics, mean donor age in the IGF group was younger than the 
SGF group (37.4 years vs. 43.2 years, p = 0.009), and donor height was higher 
in the IGF than the SGF group (165.29 cm vs. 161.65 cm, p = 0.038). Donor 
creatinine clearance in the IGF group was higher than the SGF group (98.42 
mL/min/m2 vs. 85.84 mL/min/m2, p = 0.009), and donor serum albumin level 
in the IGF group was higher than the SGF group (4.37 g/dL vs. 4.25 g/dL. p 
= 0.04). Of the 141 protocol biopsy performed at day 14 after transplantation, 
114 (80.9%) was in the IGF group and 27 (19.1%) was included in the SGF. 
Of the 114 IGF, 77 (67.5%) showed normal, 12 (10.5%) borderline, 10 (8.8%) 
acute rejection, 7 (6.1%) CsA toxicity, 5 (4.4%) acute tubular necrosis, and 3 
(2.6%) obsolescence. On the other hand, near half of patients with SGF showed 
borderline change (n=13, 48.1%). And in the rest of SGF group, 7 (25.9%) 
showed normal, 5 (18.5%) CsA nephrotoxicity, and 2 (7.4%) obsolescence. (p 
< 0.05) Immunesuppressive agents also infl uenced the graft function. In the 
CsA group, 96 (89.7%) was in IGF and 11 (10.3%) was in SGF. In the FK506 
group, 47 (71.2%) was in IGF and 19 (28.8%) was in SGF. (p = 0.007). 
Conclusion: SGF in living donor transplantation is infl uenced by donor and 
receipient factors.
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LIVING KIDNEY DONORS: EVALUATION, EXCLUSION 2312 
AND ELIGIBILITY.
Y.L. Thye1, D. Lincoln2, R. Paul2, C. Jeremy
1University Malaya Medical Centre, 2Westmead Hospital, Sydney
The use of living kidney donors increased dramatically in number nowadays 
following the successful outcome of both genetically or emotionally related 
live donor kidney transplantations. The Amsterdam Forum has set forth a 
list of medical criteria including psychosocial evaluation that is now used 
internationally in the evaluation of potential kidney donors. We conduct a 
review on our living kidney donors and to examine on the centres’ practice of 
donors evaluation and exclusion criteria.
Objective: To evaluate the potential living kidney donors based on the centres’ 
practice and to compare with the Amsterdam Forum’s criteria. 
Methods: A retrospective analysis of all potential kidney donors evaluated 
from January, 2003 till December, 2006 in a single transplant centre.
Results: There were 214 potential kidney recipients with 257 potential kidney 
donors were worked up within that period. We have transplanted 107(50%) 
living kidney recipients with 18(7%) waiting to be transplanted and 20 are 
still in the middle of the work-up. In total 125(48.6%) potential living kidney 
donors were refused and excluded. Thirteen potential kidney donors did not 
proceed with the work up due to incompatible blood group. There were 30 
potential donors refusal and 5 recipients refusal. Seventy-seven donors were 
excluded based on their medical reason as below:
Medical reason: No. of donors
Glomerulonephritis 3
Renal vessels abnormalities (Bilateral double or triple renal arteries, FMD) 11
Medical unfi t (ischemic heart disease, obese (BMI>35), chronic obstructive lung 
disease, glucose intolerance, hypertension, continue to drink and smoke
27
Positive crossmatch 21
Low GFR(< 85 ml/min/1.73m2) 3
Previous h/o melanoma 1
Hepatitis C 2
Psychiatry unfi t 1
Abnormal kidney anatomy: duplex kidney, size mismatch 8
Out of the 107 living kidney donors, 99 had laproscopic donor nephrectomy 
and 8 were open nephrectomy with 4 unplanned. The living kidney donor 
transplants were mainly siblings (30%) followed by parents and spouses 
(25.5% and 24.5% respectively) with one undirected living donor. The mean 
age of the donors were 45, the youngest was 22 year old and the eldest was 
71 year old. We have 12 donors who are hypertensive and 1 well controlled 
newly diagnosed diabetic. There were 8 with previous history of malignancy in 
remission and 3 donors with history of renal calculi. Three has borderline GFR 
of 85 ml/min/1.73m2.
Conclusions: We found that our selection for donation are more restricted on 
certain medical criteria but we are now accepting older donors and even those 
with treated history of renal stones, hypertension and diabetes. Variability in 
the selection criterias among centres should be accepted provided they meet 
additional criterias as discussed elaborately at the Amsterdam Forum. The 
exclusion criteria and the eligibility criteria in our centre were comparable 
to the Amsterdam guidelines. Longer follow-up on the donors and recipients 
outcome are required. 
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EXPANDING THE POOL OF NON-TRADITIONAL LIVING 2313 
KIDNEY DONORS
W. Zuidema1, J. van de Wetering1, J. IJzermans2, W. Weimar1
1Internal Medicine; Erasmus MC, 2General Surgery; Erasmus MC
Background: In most countries the wait time for deceased donor kidney 
transplantation has increased over the last decennia. Therefore several 
approaches were undertaken to overcome the discrepancy between demand and 
supply, e.g. by the (re)introduction of living kidney donation programs.
Traditionally, living genetically related donors provided these kidneys. 
However, after it appeared that excellent results could also be obtained with 
kidneys from genetically unrelated donors, a number of non-traditional 
donation programs emerged. We here describe the shift from traditional to non-
traditional programs including donation by partners, friends, Good Samaritans, 
crossover and domino-paired donors.
Methods: We analysed all 694 living kidney donations performed in our centre 
between 1981 and 2007, and stratifi ed them in three tertiles, which took place 
from 1981-2000 (N=231), 2000-2004 (N=232), and 2005-2007 (N=231).
Results: The number of years needed to complete tertiles dramatically decreased 
from 19 years for the fi rst to 3 years for the last, refl ecting the increasing living 
donation activities. At the same time we observed in the living donor group a 
steadily growing proportion of non-traditional donors: from 12% in the fi rst, to 
35% in the second and to 57% in the last tertile. Within this unrelated donor 
group the proportion of partners decreased from 100% in the fi rst tertile to 64% 
in the second and 43% in the most recent one, refl ecting the emergence of other 
donor categories in the two last tertiles. Indeed, while the absolute number 
of partner donations remained stable in these last two tertiles, the number of 
other non-traditional donors increased 2.6-fold. In the last tertile (2005-2007), 
100 related and 131 unrelated kidney donations took place, of which 56 were 
derived from partners and 75 from others. These other non-traditional donors 
were friends (N=27), crossover donors (N=20), Good Samaritans (N=18) and 
domino-paired donors (N=10).
Thursday 14 August 2008 Poster Abstracts
7 5 6
TH
U
R
SD
AY
Supplement to Transplantation July 27, 2008, Volume 86 Number 2S
Conclusion: The number of living kidney donation is spectacular rising with 
a shift to non-traditional donors. The number of donating partners seems to 
stabilise, but the rise in other non-traditional donors still continues and further 
expands the living donor pool.
POSTER BOARD NUMBER P4 – 364
MEDICAL EXCLUSIONS TO SUCCESSFUL LIVING 2314 
KIDNEY DONATION
S. Norman, P. Song, A. Ojo, Y. Hu
University of Michigan
Background: Given the disproportionate prevalence of hypertension (HTN) 
and diabetes mellitus (DM), African American (AA) potential live kidney 
donors may be at increased risk of being medically unsuitable as donor 
candidates. We examined the barriers due to medical diagnosis and other factors 
in a large cohort of living donor candidates presenting at a large Midwestern 
kidney transplant program. 
Materials and Methods: All adult (age > 18 years) potential living kidney 
donor candidates initially evaluated between January 1, 1996 and June 30, 2006 
were studied and classifi ed according to the following primary outcomes of 
the donation process: Successful donation; medical exclusion; or non-medical 
exclusion from donation. Logistic regression was used to evaluate the effect 
of age, race, gender and other medical factors on the likelihood of successful 
donation. 
Results: Of 2,520 donor candidates in the study, 60% and 74% were female and 
Caucasian (CA), respectively. The mean age of donor candidates was 41 and 
the median body mass index (BMI) was 26.4 kg/m2. Donor BMI was higher 
in AA vs. CA candidates (1.07, p< 0.0001) and increased by 0.25% per year of 
age (p < 0.0001). Overall, 46% of donor candidates were successful. Male and 
female candidates were equally successful as donors. AA were less likely than 
CA to successfully donate (OR 0.54 p< 0.0001). Age was a signifi cant factor, 
with each advanced year of age increasing odds of donor exclusion by 2% (OR 
0.98 p < 0.0001)(fi g 1). Among donor candidates excluded for medical reasons, 
the common diagnoses leading to exclusion were HTN (23.64%), a positive 
fi nal crossmatch (11.14%) and reduced renal function or low glomerular 
fi ltration rate (GFR, 10.77%). HTN was the most frequent exclusion diagnosis 
in female candidates, but less prevalent than in males (18% vs. 33%, p < 
0.0001). HTN was equally prevalent in excluded AA and CA donors (23% and 
25% respectively, p=ns). In excluded AA donors, obesity accounted for 12.75% 
of medical exclusions. Among excluded CA donors, low GFR accounted for 
10.59% of all cases. 
Conclusion: Hypertension, increasing age and African American race are the 
leading contributors to disqualifi cation of living donor candidates. Relative to 
Caucasians, obesity accounted for a signifi cant fraction of excluded African 
American donor candidates. 
Figure 1: Plot of success rate vs. age in difference races. Red =African 
American, black = Caucasian, blue = overall effect
POSTER BOARD NUMBER P4 – 365
LIVING-UNRELATED RENAL TRANSPLANTATION 2315 
PROVIDES COMPARABLE RESULTS TO LIVING-RELATED 
RENAL TRANSPLANTATION: A 10-YEAR SINGLE-CENTER 
EXPERIENCE.
B. Aguilar1, R. Bernal, R. Mondragon
1Centro Medico ISSEMyM, 2Centro Medico ISSEMyM, 3Centro Medico 
ISSEMyM
Introduction: The increasing success of renal transplantation is paralleled by 
the increased size of the waiting list. Efforts to increase the donor pool have 
included the use of living-unrelated kidney donors. AIM: The purpose of this 
study is to compare the long-term results of kidney transplantation from living 
unrelated donors with that from living related donors. 
Patient And Methods: During a 10-year period our center performed 176 
transplants, 103 transplants came from living donors; 89 patients received 
living-related donations (LRD), and 11 patients received living non-related 
donations (LURD). During the same period 73 patients received cadaveric 
renal donor transplants. We reviewed and compared the long-term data from 
these cases. 
Results: The LURD group included 8 mens and 4 females with an overall 
mean age of 41(range 24 to 62) years with mean follow-up of 120 months. The 
LRD group included 65 males and 24 females recipients with overall mean age 
of 28 (range 14 to 50). A total of 8 (72%) of living non-raleted transplants were 
spousal transplants and three (28%) were from family friends, four cases were 0 
human leukocytes antigen–identical, 7 were identical and 0 were haploidentical 
of the patients who received LURD group, versus 0 human leukocytes antigen-
identical in four cases, identical in 78 cases and haploidentical in seven cases 
on the LRD group, the crossmatch proteins were negative in all cases. 
Results: Eigth (72%) Of 11 LURD recipients are alive, as are 81 (91%) of 89 
LRD recipients. Mean current creatinine is 1.04 mg/dl for the LURD group 
and 1.4 mg/dl for the LRD group Kaplan-Meier 1- and 5-year graft survival 
was 97% and 94% for the LRD group, 91% and 82% for the LURD group (p 
= not signifi cant), 
Conclusions: LURD patient and graft survival is comparable to LRD transplants 
despite inferior human leukocyte antigen matching. LURD transplant survival 
is superior to that of cadaveric renal donor transplants. LURDs are an excellent 
but underused source of organs for renal transplant recipients.
POSTER BOARD NUMBER P4 – 366
COMPARISON OF THE DECISION TO DONATE AND 2316 
ATTITUDES FOLLOWING DONATION IN BLACK AND WHITE 
LIVING RENAL DONORS
M.T. Nolan1,2, L.E. Boulware3, L.E. Taylor1, J.K. Melancon3, A.E. Belcher1, 
L. Rose1, K. Dane4, S. Klunk4, M. Hoffman1, R.E. Thompson5
1Johns Hopkins University School of Nursing, 2Johns Hopkins Berman 
Institute of Bioethics, 3Johns Hopkins University School of Medicine, 4The 
Johns Hopkins Hospital Department of Surgery, 5Johns Hopkins Bloomberg 
School of Public Health
Background: Blacks awaiting renal transplantation are less likely to receive 
living donor organs than Whites but few studies have prospectively explored 
racial differences in living renal donors from evaluation to the recovery period. 
Therefore, this study compared Black and White living renal donors/candidates 
in level of family stress in the year prior to donor evaluation, family income, 
family involvement in the decision to donate, and postoperative perceptions of 
the donation experience and attitude toward donation.
Methods: In interviews during donor evaluation, we measured family stress 
during the past year, family income and the donor’s relation to the recipient. Three 
months after donation, we asked about family involvement in the decision to 
donate, satisfaction with the care received while hospitalized and after discharge, 
and attitudes towards donation. Descriptive statistics, chi square analysis and 
a t-test were used. Satisfaction with care during and after hospitalization and 
attitude toward living donation were each measured on a scale ranging from 3 to 
18 with higher scores indicating a more favorable response. 
Results: Among 390 donor candidates, the mean (range) age was 44 (18-79) 
years, 61% were female, 79% were White, 80% had at least some college 
education, and 61% were married. In the 174 who went on to donate, Blacks 
had higher levels of family stress in the year before donation (323.63 vs. 
236.25, p =.01) and were more likely to report a total household annual 
income of 40,000 or less (43% vs. 16%, p =.001). Blacks were less likely 
than Whites to donate to a non-family member (12% vs. 25%, p =.02) 
and were less likely to involve a family member in the decision to donate 
(52% vs. 76%, p =.01). At three months however, there were no signifi cant 
differences in satisfaction with care during and after hospitalization (16.13 
vs 15.89, p =.71) and attitude toward living kidney donation (17.29 and 
17.15 respectively, p =.70) between Blacks and Whites respectively.
Conclusions: Transplant professionals should include family members of donor 
candidates in education about donation to the extent desired by the candidate. 
The lack of racial differences in the experience of donation and attitude toward 
donation after surgery may provide some reassurance to Black donor candidates 
who worry that they might have a more negative experience compared to White 
donors. Financial risks should be carefully explained or support considered for 
donors with limited income who might more readily suffer negative fi nancial 
consequences if recovery takes longer than anticipated.
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REASONS FOR NON PROGRESSION OF POTENTIAL 2317 
LIVE DONOR AND RECIPIENT PAIRS TO RENAL 
TRANSPLANTATION
J. Mawson, D. Verran, S. Chadban, C. Baker, R. Allen, K. Morris, K. Wyburn, 
J. Eris
Renal Transplant Programme
Introduction: Static deceased donor rates are helping increase the demand 
for live donor renal transplantation. With new initiatives in live donor renal 
transplantation such as ABO incompatible and paired exchange it is important 
to understand the reasons for potential live donor pairs not proceeding to 
transplantation. 
Methods: Retrospective review of records held from 2003-2007 of results 
of assessment of blood group compatible prospective live kidney donor and 
recipient pairings. The number declined for ABO incompatibility cannot be 
reliable determined.
Results: 151/306(49%) of potential pairs did not proceed to transplantation. 
Reasons for non progression to transplantation were donor issues in 
65/151(43%), a positive X-match in 47/151(31%), recipient issues in 
39/151(26%). In potential donors issues precluding donation were medical 
in 24/65(40%)[abnormal GFR 10; diabetes 8; cardiac 6], followed by 
psychosocial in 21/65(32%) and problems with renal anatomy on imaging 
9/65(14%). In recipients medical issues in 34/39(87%) most frequently 
precluded transplantation followed by psychosocial issues in 5/39(13%). 
Recipient medical issues predominantly included cardiac in 8/34(23%), 
malignancy in 5/34(15%), ongoing treatment of hepatitis C in 4/34(12%), 
complications of diverticular disease in 3/34(9%). Renal function stabilised in 
4/34(12%) of these recipients precluding transplantation in the short term. Two 
recipients (6%) were deemed to not be suitable for ABOI renal transplantation 
(programme commenced mid 2007), due to high Antibody titres and 2/34(6%) 
recipients deceased during the workup period.
Conclusions: In the last 5 years close to 50% of potential live donor renal 
transplant pairs did not proceed to transplantation. This has implications 
both for resourcing of the programme and future strategies that may allow 
transplantation between pairs previously turned down during workup. 
POSTER BOARD NUMBER P4 – 368
EVALUATION OF DISCARDED LIVING DONOR IN 2318 
RENAL TRANSPLANTATION. EFFECTIVENESS OF OUR 
LIVING DONOR KIDNEY TRANSPLANT PROGRAM
J. Campistol, I.R. Vicente1, R.G. del Pozo2, C. Camacho1, M.C. Sebastiá3, C. 
Nicolau3, J. Martorell4, J. Vilardell5, A.A. Asensio2, J.M.C. Plana1, F.O. Salina1
1Renal Transplant Unit. Department of Nephrology and Renal Transplant. 
University Clinic Hospital, 2Department of Urology. University Clinic 
Hospital, 3Department of Radiology and Radiodiagnosis. University 
Clinic Hospital, 4Department of Immunology. University Clinic Hospital, 
5Transplant Services Foundation. University Clinic Hospital
Introduction: Living kidney transplantation is a good option for patients with 
kidney chronic disease. An exhaustive study in potential living donors has an 
important role in order to minimize the donor risks and guarantee the success 
of the kidney transplant. Our aim is to review the main reasons of donation 
discard of different donor – recipient couples who were studied in our living 
kidney transplant program. 
Materials and methods: Retrospective, unicentre, frequency- descriptive 
study was made from January/2005 to December/2007. 155 donor- recipient 
couples were evaluated. For initial evaluation we used a basic protocol based 
on laboratory tests (general, renal function, immunological and blood group 
type), radiological techniques, and medical history. Medical guidelines from 
Amsterdam Forum were followed in order to evaluate the potential donors 
and receptors. All living kidney donor nephrectomies were made by hand – 
assistant laparoscopic technique. 
Results: 72 donor- receptor couples (46.45%) were ruled out for the donation 
versus 83 transplanted (53.55%). Donor mean age was similar in both 
groups (52.75 ± SD13.88/49.95 ± SD12.25 years). Renal patient discarded 
for transplantation were older than transplanted (46.9 ± SD13.74 vs 42.52 ± 
SD14.25). Female sex was more prevalent in discarded and transplanted donors 
meanwhile male sex in renal patients (68.1%- discarded/64.2%- transplanted)
In discarded couples, donor- receptor relationship most prevalent were married 
couple (40.3%), mother-son/daughter (25%) and brothers/sisters (18.1%). 
The most frequent reason of discard was donor pathology (45.8%) as Mellitus 
Diabetes, low glomerular fi ltration rate, previous cardiovascular pathology, 
tumoural pathology during the study, and proteinuria, followed by positive cross- 
match (16.7%), cadaveric renal transplant during the evaluation (15.3%) and 
incompatibility of blood group type (6.9%, not to fulfi l transplant criteria used in 
our center). 67.2% of discarded couples could be ruled out for transplantation with 
our basic protocol, minimizing sanitary costs. In renal transplant couples, donor 
survival was 100%, with recipient survival of 98.8%, graft survival 98.7% and 
90.1% free- acute rejection rate. Graft function has been excellent in donors (mean 
plasmatic creatinine: 1.2016 ± 0,171 mg/dl; mean creatinine cleareance: 83,69 ± 
22,23 ml/min/1,73m2; proteinuria 113,61 ± 55,513 mg/ day) and recipients (mean 
plasmatic creatinine: 1,3616 ± 0,403; mean creatinine cleareance: 80,34 ± 29.181 
ml/min/1,73m2; proteinuria 290,28 ± 405,029 mg/day).
Conclusions: The evaluation of living donor for renal transplantation is 
necessary to guarantee its health and the successful of the transplant. Two 
thirds of discarded living donors can be ruled out by a basic protocol of study, 
minimizing sanitary costs
POSTER BOARD NUMBER P4 – 369
FIRST CADAVER- THEN LIVING-RELATED Ï¿½ 2319 
WHAT IS THE APPROPRIATE SEQUENCE OF RENAL FIRST 
AND RE-TRANSPLANTATION WHEN LIVING RELATED-
TRANSPLANTATION IS AVAILABLE?
W-D. Illner, M. Rentsch, C.D. Wimmer, H. Arbogast, K-W. Jauch,
Department of Surgery
Living related (LR) kidney transplantation is associated with better graft and 
patient survival as compared to cadaver grafts. Since renal allograft survival 
is not infi nite, the necessity for renal re-transplantation becomes a clinical 
condition with increasing frequency. In children renal transplantation, therefore 
the recommended policy ‘fi rst cadaver, then live donor’ has been questioned 
in the past. However, rare information is available on the outcome of re-
transplantation in the context of living related graft donation. In this study, we 
analyzed the outcome after LR kidney transplantation and LR-re-transplantation 
in special respect to the sequence of second graft origin. 
Patients and methods: All LR kidney transplantations (n= 262 transplantations, 
233 patients), performed between 12-1982 and 03-2006, were retrospectively 
analyzed, based on a prospectively updated database. Three subgroups of graft 
recipients were distinguished: (1) recipients of fi rst living related kidney grafts 
(n=208), and (2) those receiving a second living related graft after a cadaver fi rst 
graft (n=25) or (3) any second graft after fi rst living related transplantation (n=7). 
The median follow-up was 87 months [7-329]. Analyses included measurements 
of patient and graft survival, frequency of rejections and re-operations. Survival 
rates were calculated with log-rank comparisons of Kaplan-Meier plots. Statistic 
calculations were performed with SPSS, version 15.0.
Results: Mean age of the patients was 40.5 years (women 37.8, men 41.7), with 
a median of 40 [17-68], 38 [16-66] and 35.5 [14-62] years in group 1, 2 and 3 
respectively. The median HLA-mismatch was 3 in all groups, the rejection rates 
were 15 (group 1) and 28% in both groups 2 and 3. The percentage of patients 
with a pre-emptive transplantation, indicated as remaining diuresis at the time of 
transplantation was markedly lower in group 2 (16%) compared to group 1 and 
3 (56.3 and 42%). In addition, the rate of primary graft dysfunction was 20% 
in group 2 vs. 5.7 and 0% in group 1 and 3. Twenty-four re-operations were 
indicated after transplantation for minor complications, all in group 1. One graft 
was lost due to arterial stenosis. Post transplant patient survival did not differ 
between the groups 1, 2 and 3, with rates of 91.5, 95 and 100% at 5 years, and 
90.4, 89.1 and 100% at 10 years. Evaluation of death-censored graft survival 
showed rates of 95.9, 81.3 and 100% after 5 years and 94.0, 100 and 73.9 percent 
after 10 years in group 1, 2 and 3 respectively (p=0.014, group 2 vs. 3). 
Conclusion: Our data suggests that renal allograft survival following LR re-
transplantation, following previous cadaver transplantation (group 2) is not 
necessarily reduced compared to fi rst LR transplantation. However, a lower 
percentage of preemptive transplantations and to a higher rate of primary 
dysfunction was noted in this patient- as compared the other subgroups. LR- 
re-transplantation may serve as reserve after loss of a cadaveric fi rst graft in 
adult recipients. 
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PREEMPTIVE EXPANDED CRITERIA LIVING 2320 
DONOR RENAL TRANSPLANTATION- FIRST CHOICE OF 
TREATMENT OF ESRD ON THE BALKANS? 
N. Ivanovski1, J. Masin1, S. Dohcev2, I. Rambabova-Busljetic1, V. Pusevski1, 
Z. Popov2
1Department of Nephrology, Skopje Medical Faculty, Republic of Macedonia, 
2Department of Urology, Skopje Medical Faculty, Republic of Macedonia
Background: Despite the efforts for transplants, dialysis remains the usual 
way of treatment of ESRD in the Balkans. The living renal transplantation 
(LRT) is still predominant but there is an enormous gap between the demand 
and supply of kidneys.Due to the very well known reasons, there is still no 
any cooperation in the fi eld of transplantation among the Balkan countries. 
Trying to solve the problem, we started to accept expanded criteria living 
donors (ECD) as well as preemptive transplants from ECD as a fi rst choice 
of treatment of ESRD.
Methods: 185 LRT are performed in our Department in the last 18 years. ECD 
group has 54 donors older than 65 years, 2 ABO incompatible, 21 unrelated, 10 
with mild arterial hypertension, 4 with large simple cyst, and 2 with multiple 
renal arteries, one with double ureter. 30 of ECD transplantations were 
preemptive without performing any dialysis and blood access. The quadruple 
sequential immunosuppressive protocol was used in all cases including 
induction with ATG or Il-2R antagonists, Cyclosporine A, MMF/AZA and 
Steroids. In ABO incompatible transplants a special preconditioning regimen 
for recipients was used including laparoscopic splenectomy, Rituximab, 
plasmapheresis and IvIg. The Kaplan-Meier one, three and fi ve years graft 
survival rate, rejection episodes, DGF and actual renal function were analysed.
The results were compared with the group of 80 LRT with younger donors 
(YGD) performed in the same time.
Results: One, three and fi ve years Kaplan-Meier graft survival rate for the 
ECD was 94%, 83% and 65% respectively compared with 95%, 87% et 75% 
of YGD. The group of preemptive ECD living transplantation showed superior 
graft (95, 87 and 78%) survival compared with the younger group of donors. 
The percentage of DGF was 15% in ECD group compared with 8% in YGD. 
Both differences are statistically signifi cant. The rejection episodes rate in ECD 
and YGD was 24% and 21%, respectively. The actual serum creatinin in ECD 
was 178 micromol/lit, compared with 154 in the YGD. The last two differences 
are not statistically signifi cant.
Conclusion: The results in our study fully justify the use of ECD especially in 
the regions where the LRT is predominant transplant activity. Expanded criteria 
living donors are available and their use is much more easily. The treatment 
is cheaper and more effective compared with the cadaver transplantation. As 
elsewhere, it may ameliorate the actual organ shortage in the Balkans. Bearing 
in mind the very good results, the dialysis cost and underdevelopped cadaver 
program, the preemptive living ECD transplantation is recommended as a fi rst 
choice in the treatment of ESRD on the Balkans.
POSTER BOARD NUMBER P4 – 371
THE UTILITY OF CREATININE-BASED PREDICTION 2321 
EQUATIONS AND RENAL CLEARANCE STUDIES IN 
EVALUATING THE GLOMERULAR FILTRATION RATE OF 
POTENTIAL KIDNEY DONORS
T. Jie, K. Billingham, A. Humar, H. Ibrahim, R. Kandaswamy, B. Kasiske, D. 
Sutherland, A. Matua
University of Minnesota
Introduction: The assessment of glomerular fi ltration rate (GFR) is one of 
the important steps in living kidney donor evaluation. Renal clearance studies 
are expensive and cumbersome. For healthy kidney donors, the accuracy of 
estimated GFR (eGFR) calculated from creatinine-based prediction equations 
is controversial. 
Method: Retrospective review of single center kidney donor evaluation.
Result: Among 733 potential kidney donors evaluated between January 2005 
and December 2007, 43 patients had low eGFR based on the Cockcroft-Gault 
(CG) or the modifi cation of renal disease (MDRD) formula and underwent 
either Iohexol or Tc-diethylenetriamine-pentaacetic acid renal clearance 
studies. Among them, 13 were declined for donation because of low GFR 
(10) or other medical issues (3). The 30 approved kidney donors had the 
following characteristics: 87.0% women, age 48.4±1.4 years (mean±SEM), 
body mass index (BMI) 23.1±0.6 kg/m². The GFR was 73.9, 71.0 and 98.3 
± 3.0 ml/min by CG, MDRD, and renal clearance studies respectively. The 
creatinine-based prediction equations underestimated the GFR in this group 
of patients (Pearson correlation coeffi cient r= -0.110 and 0.226 for CG and 
MDRD respectively). In comparison, patients declined for donation because 
of low GFR were older (60.2 ± 3.0, p = 0.034) and had lower GFR (68.6 ± 
2.7, p < 0.001) by renal clearance studies, but with similar BMI 23.9, and 
eGFR 63.3 and 65.5 by CG and MDRD. Of the 30 patients approved for 
kidney donation, 26 proceeded to living donor kidney transplant (average 
creatinine changed from 0.95 pre-donation to 1.29 mg/dL one month post-
donation) with no renal insuffi ciency during follow-up (1.83 ± 0.90 years), 
and 4 patients are waiting scheduling pending completion of the recipient 
workups. During the same period, 384 living donor kidney transplants 
were performed in our center. Excluding patients in this study, the average 
kidney donors were younger (41.3 ± 0.6 years) and heavier (BMI 26.6 ± 
0.2 kg/m²).
Conclusion: Cockcroft-Gault equation underestimates the GFR of potential 
kidney donors and can be safely used as a screening tool to identify patients with 
low GFR. Renal clearance studies can be selectively used in living kidney donor 
evaluation, especially in healthy middle age women with low eGFR and BMI.
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SUB-OPTIMAL GRAFT FUNCTION EARLY AFTER LIVE 2322 
DONOR KIDNEY TRANSPLANTATION
A. Natfaji1, J. Eris1,2, K. Wyburn1, D. Verran2, A. Vasilaras2, J. Boulas2, 
R.D.M. Allen2, S. Chadban1,2
1Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, 
2Transplantation Services, Royal Prince Alfred Hospital, Sydney
Background: Delayed graft function is common following deceased donor 
kidney transplantation and is usually due to acute tubular necrosis (ATN) caused 
by ischaemia-reperfusion injury (IRI). In contrast, immediate graft function is 
expected following live-donor kidney transplantation, presumably due to the 
lesser degrees of IRI. We sought to determine the incidence and causes of sub-
optimal graft function following live donor kidney transplantation. 
Methods: Retrospective study of all live donor kidney transplant recipients 
at our centre from 2004 to 2007. Data were extracted from medical records, 
including daily serum creatinine and eGFR (MDRD formula). Donor 
nephrectomy and implantation were performed sequentially and 11 of 14 
donor nephrectomies were laparoscopic. Recipients received quadruple 
immunosuppression with either basiliximab or Thymoglobulin, steroids, a 
mycophenolate and a calcineurin inhibitor CNI. Sub-optimal graft function 
was defi ned by failure to achieve a >10% decline in serum creatinine each 
day for the fi rst 5 days after transplantation, or oliguria unresponsive to fl uid 
challenge and diuretics. 
Results: Fourteen (10.6%) of 132 consecutive live-donor recipients (30 
open and 102 laparoscopic nephrectomy) experienced sub-optimal graft 
function. This was not associated with laparoscopic donor nephrectomy 
(t test P= NS). Four (28%) recipients had renovascular causes detected by 
duplex ultrasonography, 2 patients developed thrombosis, 1 kink and 1 
anastomotic stenosis, of which 3 required urgent surgical correction. Three 
(21%) had urological causes with 2 ureteric obstructions and 1 urine leak, 
all of which required surgical correction. Three (21%) recipients developed 
acute rejection confi rmed on renal biopsy. Three (21%) had ATN due to 
prolonged or complicated donor surgery, third space fl uid loss and CNI 
toxicity. One (7%) recipient experienced acute recurrence of primary disease 
and remained dialysis dependent until experiencing sudden death thirty days 
after transplant. The overall outcome in this group of patients was 1 death, 
1 graft loss from thrombosis and 12 functioning grafts, 2 of which required 
short term HD. 
Conclusion: 10% of our total live donor kidney transplantation experience was 
associated with sub-optimal graft function immediately after transplantation. In 
all cases, a cause was identifi ed and frequently (12/14) corrected thus restoring 
graft function. Implantation surgery related problems were the cause for half of 
the patients who developed sub-optimal graft function.
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POST TRANSPLANTATION LYMPHOPROLIFERATIVE 2323 
DISORDER AFTER LIVER TRANSPLANTATION: A SINGLE 
CENTER EXPERIENCE AMONG 400 PATIENT SERIES
S. Marzban, B. Geramizadeh, S-A. Malek-Hosseini, A. Bahador, H. Salahi, K. 
Bagheri-Lankarani, M-H. Imanieh
Transplant Research Center, Shiraz University of Medical Sciences
Introduction: Post transplant lymphoproliferative disorders (PTLD) are a 
heterogenous group of lymphoid proliferation occurring in the setting of solid 
organ or BM transplantation.
In this review we will consider the incidence and clinical features of this group 
of patients in our center.
Material and Methods: In this study, we present the clinical and pathologic 
features of PTLD cases after liver transplantation (LT). In the period of liver 
transplantation we had 3 pathology confi rmed cases of PTLD out of 430 liver 
transplant cases.
Results: Among 430 liver transplantation 3 cases were diagnosed as PTLD. Two 
of the patients were child (both 6 year-old) and the other was adult (45 year-old). 
One of the children was presented with diarrhea after 6 months of transplant and 
PTLD (polymorphic type) was diagnosed on duodenal biopsy, she expired despite 
of reducing the immunosuppressive therapy and starting of chemotherapy. The 
other child was present with cervical lymphadenopathy one year after transplant. 
He was also expired. The reason of liver transplantation was biliary atresia in 
both of them. The last one was an HCV positive male patient who presented 
with a very small cervical lymphnode( 1 cm) 1 year after liver transplant. He was 
diagnosed as Hodgkin’s-like type of PTLD, now after 3 years he is doing well. In 
all the three case EBV was positive in the involved tissue.
Conclusion: In conclusion, PTLD is a life treating disorder in liver transplant 
patients. According to the present data (3/430) it seems that the incidence of 
this disorder is lower than other parts of the world.
POSTER BOARD NUMBER P4 – 374
ASSESSMENT OF CAUSATIVE FACTORS FOR 2324 
LYMPHOCELE FORMATION FOLLOWING RENAL 
TRANSPLANTATION
J. Kothari, H. Talreja, A. Supariwala, R. Sirsat, A. Almeida
Pd Hinduja Hospital
Introduction: Lymphocele is a fl uid collection between the renal graft and the 
urinary bladder. It is an uncommon complication (0.6% to 18%) following renal 
transplantation. It is associated with incomplete ligation of lymphatic vessels 
of graft, extensive perivascular dissection in the recipient, acute rejection and 
use of high dose steroids.
Objective: To determine the incidence of lymphocele in post renal transplant 
patients at our center and identify potential factors responsible or associated to 
its development. 
Materials and Methods: All patients who underwent renal transplantation at 
our centre from Jan 2004 to Oct 2007 with complete medical records were 
reviewed.
Results: Out of 138 patients who had undergone renal transplantation, 48 
developed lymphocele(34.7%).28 patients (58%) required surgical drainage 
or pigtail catherization. Signifi cant variation was noted in yearly incidence of 
lymphocele which coincided with the yearly change in the surgical registrar 
preparing the ‘bed’ for the recipient. Signifi cantly, 25 out of 52 patients with 
urinary tract infection developed lymphocele as compared to 23 out of 86 
without evidence of urinary infection (p=0.016) . A total of 25 Acute rejection 
episodes was seen in total with similar incidence in the two groups, with & 
without lymphocele. Gram negative bacteria causing UTI, especially those 
resistant to beta lactam antibiotics (ESBL) were the commonest organisms 
isolated in patients with lymphocele formation.Use of IL-2R antagonists for 
induction was not associated with increased incidence of lymphocele. There is 
no association of lymphocele formation with the different immunosuppressive 
regimens used at our center. Diabetic patients had a higher incidence of 
lymphocele, but the difference was statistically insignifi cant (p=0.056).
Conclusion: More attention to careful ligation of lymphatic vessels both during 
graft bed preparation and during graft implantation can signifi cantly contribute 
to reducing the incidence of lymphocele following renal transplantation. Cases 
requiring surgical treatment cause signifi cant morbidity. Preventive methods, 
such as laparoscopic fenestration need to be done routinely to minimise 
lymphocele formation. Urinary infections post-transplant is associated with 
increased incidence of lymphocele formation. Diabetics may be more prone 
for higher lymph collection, probably due to delayed healing of the dissected 
lymphatics, but that remains to be proven conclusively.
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LAPAROTOMIC LIVE DONOR NEPHRECTOMY: IS IT 2325 
STILL JUSTIFIED?
M.A. Zargar, H. Shahrokh, M.J. Soleimani, K. Kamali, S.K. Hosseini, S.M.R. 
Rabani, A. Barzegarnejad, E. Azimi
Shaheed Hasheminejad Hospital, Iran University of Medical Sciences
Purpose: We report our experience with laparatomic Live Donor Nephretomy 
during the last 23 years.
Patents and methods: Between August 1985 and November 2007, 2260 
consecutive live donors who underwent laparatomic nephrectomy at the 
university hospital of Hasheminejad in Tehran, were included in this audit. 
All donors underwent routine preoperative assessments including renal 
angiography, to evaluate the anatomy of the renal arteries. Patients underwent 
a high midline laparatomy under general anesthesia. Principally the left kidney 
was the preferred side unless multiple left sided renal arteries were present. 
For the left kidney, in most cases, the inferior mesenteric vein was ligated and 
the retroperitoneum entered with a good access to left kidney and its pedicle. 
On the right side after duodenal kocherization, the right kidney and its pedicel 
were easily accessible. After removal of the kidney the posterior peritoneum 
defect is closed and a short term drain is placed. 
Result: 2260 live donors underwent laparatomy during a period of near 23 
years. They were 1440 male and 820 female. Left kidney was used in 95% of 
the cases. The mean donor age was 26 years (20-48 years). The mean hospital 
stay was 3 days (2-5 days). The mean incisional length was 12 cm (± 2.5 cm). 
The mean warm ischemia time was always less than 1 minute. The mean 
operation time was 55 minutes (40-70 minutes). The mean intraoperative blood 
loss was 200mls and there were no post operative transfusions. There were no 
signifi cant gastrointestinal complications. Postoperative morality occurred in 
one case with sudden death of a 31 years old male who developed abdominal 
pain 16 hours after operation. He was suspected of massive bleeding from renal 
artery stump. Incision hernia in four cases, which required operative repair. 
Signifi cant lymphocele occurred in one case, which responded well to surgical 
intervention. 
Conclusion: In our experience midline laparatomy, is a very safe and effi cacious 
approach for live donor nephrectomy. It is associated with short operative 
time and low morbidity rates and despite the rapid development of minimally 
invasive techniques, this approach will continue to have a defi nite place in high 
volume units such as ours. In our experience the only long-term disadvantage 
of laparatomic donor nephrectomy has been in the cosmetic results.
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PROTEIN TRANSDUCTION TECHNOLOGY FOR STEM 2326 
CELL REPROGRAMMING: A NOVEL STRATEGY TO OBTAIN 
INSULIN-PRODUCING CELLS
M. Ramírez-Domínguez1,2, N. Vicente-Salar2, A. Santana3, J. Domínguez-
Bendala1, L. Inverardi1, C. Ricordi1, K. Hmadcha4, B. Soria4, E. Roche2
1 Diabetes Research Institute. University of Miami, 2 Instituto de 
Bioingenieria.Universidad Miguel Hernandez de Elche, Spain, 3 Hospital 
Universitario de Las Palmas, Spain, 4 Centro Andaluz de Biologia Molecular 
y Medicina Regenerativa (CABIMER), Sevilla, Spain
Several reports have demonstrated the potential of mouse and human embryonic 
stem (ES) cells to differentiate into insulin-producing cells and revert diabetes 
in transplanted animal models. However, in vitro protocols are still ineffi cient, 
as they give rise to heterogeneous cell populations that include undifferentiated 
cells and derivatives of the three embryonic layers. Thus, there is a need for 
alternative approaches to improve the effi ciency of beta cell differentiation.
The feasibility of reprogramming strategies has already been demonstrated. 
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Collas and colleagues, for instance, showed that rat insulinoma cell extracts 
were able to reprogram fetal rat fi broblast towards a β-cell phenotype (1). 
However, the permeabilization method results in an uncontrolled loss of cell 
components that might be essential for cell function.
We hypothesized that the uptake of key beta cell transcription factors by ES 
cells might reprogram them towards a pancreatic β-cell phenotype. In a fi rst 
series of experiments, we introduced a cocktail of transcription factors from 
protein extracts of mouse embryonic pancreatic buds (donor cells) into mouse 
embryonic stem cells (target cells). We used a synthetic protein transduction 
domain (PTDs) as a vehicle for the protein cocktail inside the target cells. PTDs 
are short peptides that have been used to favor the uptake of a variety of proteins, 
including critical transcription factors involved in pancreatic development (2).
Here we report a 5% reprogramming effi ciency from the initial cell population, 
measured as the percentage of cells that express insulin. However, this 
expression was transient and the signal became diluted 11 days after the 
introduction of the proteins. 
We conclude that reprogramming ES cells by PTD-aided transduction of 
embryonic pancreatic explants is feasible, but transient. Combination of this 
strategy with other differentiation/selection methods may improve the overall 
effi ciency of the method and the stability of the reprogrammed phenotype. 
This research work was supported by the Spanish Ministry of Science and 
Technology.
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INCIDENCE OF FEMORAL NEUROPATHY AFTER 2327 
KIDNEY TRANSPLANTATION
I. Chang, T. Kim
Anesthesiology and Pain Dept, Sungkyunkwan University Hospital, Seoul, 
Korea
Purpose: Femoral neuropathy after kidney transplantation is not common and 
often reversible, but it can cause a discomfort to the patients. The incidence 
of this complication has not yet been reported in Korea. The objective of this 
study is to estimate the incidence of femoral neuropathy in our institution and 
to clarify individual risk factors including anastomosis sites, donor type, and 
etiology in kidney transplantation recipients.
Methods: From February 1995 to March 2007, a total of 869 patients who underwent 
kidney transplantation in our center were enrolled in this study. Femoral neuropathy 
was defi ned as the numbness of medial side of upper thigh or immobilization. We 
reviewed the medical records including electromyographies fi nding, replies of 
consultations, nursing records, and anesthetic records, retrospectively.
Results: For the 869 patients who were analyzed, 12 patients (1.38%) 
developed femoral neuralgia which was ipsilateral to the kidney transplantation 
site. Among these 12 patients, 11 patients (91.7%) had an anastomosis to the 
internal iliac artery and other to the common iliac artery. 12 patients (100%) 
had an anastomosis to the external iliac vein. Femoral neuropathy occurred 
in 4 living donors (33.3%) and 8 cadaver donor (66.7%), respectively. 
Electrodiagnostic studies were postoperatively performed in 11 patients. 
3 patients had lateral femoral cutaneous nerve damages, and 1 patient had 
an obturator nerve damage. All patients were fully recovered without any 
complications.
Conclusions: Femoral neuropathy is uncommon (1.38%) and a reversible 
complication of kidney transplantation often yielding good prognosis.
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VASCULAR COMPLICATIONS IN RENAL 2328 
TRANSPLANTATION: A SINGLE CENTER EXPERIENCE OF 
1.367 RENAL TRANSPLANTATIONS
P. Katsaronis, D. Dimitroulis, J. Bokos, G. Zavos, D. Oikonomopoulou, E. 
Avgerinos, E. Antoniou, N. Nikiteas, A. Kostakis
2nd Department of Propedeutic Surgery, Athens University
Introduction: Vascular complications are common after renal transplantation; 
however few reports on large scale series with a long follow up exist. We 
present a single center experience of 1367 renal transplantations with an 
average 65-month follow up.
Methods: We analyze retrospectively, the data from 1367 consecutive renal 
transplants performed during the period of September 1980 to April 2005. 
Vascular complications were recorded.
Results: Actuarial graft survival was 89%, 70%, and 52% at one, fi ve, and 
10 years, respectively. Overall there were 57 (4.2%) vascular complications, 
including 38 early ones (1-16months): 27 renal artery thromboses, 4 renal vein 
thromboses, 4 renal artery aneurysms and 3 cases of anastomotic bleeding and 
19 late ones (6-28months), all transplant renal artery stenoses (TRAS). All early 
complications led to graft loss, while PTA-managed TRAS was successful in 
16 (84%) cases. Univariate analysis showed that vascular complications 
associated with cadaveric allografts were statistically signifi cant compared to 
the living renal grafts (P<0.05).
Conclusions: Vascular complications still represent a challenge that 
increments poor graft outcome among kidney transplant recipients. Optimal 
surgical technique and close patient screening, particularly during the early 
postoperative period and in cadaveric transplants can potentially reduce early 
vascular complications and subsequent graft losses.
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THE PROTECTIVE EFFECTS OF ULINASTATIN AND 2329 
ADENOSINE TRIPHOSPHATE ON ISLET FUNCTION DURING 
ISLET ISOLATION AND AFTER ISLET TRANSPLANTATION
F-R. Li, L. Qiu, X-F. Yang, H. Qi, L-L. Ren, H-X. Zhou
Clinical Medical Research Center, The Second Clinical Medical College 
(Shenzhen Peoples Hospital) Jinan University
Background: To observe the protective effects of trypsin inhibitor-ulinastatin 
or ATP on islet function during islet isolation and islet transplantation. 
Methods: Ulinastatin or ATP were used in the entire process of collagenase 
digestion and islet isolation, while the equal amount of physiological saline 
was used in the control group. Islet yield, apoptosis and islet function 
were measured for purifi ed islets. Two hundred islets treated with ATP, 
ulinastatin and physiological saline was respectively transplanted beneath 
renal subcapsule of diabetic SCID mouse models. The blood glucose levels 
were consecutively monitored after transplantation and intraperitoneal 
glucose tolerance test (IPGTT) was performed in recipient mice 21 days after 
transplantation. 
Results: The islet cell apoptosis rates in ulinastatin and ATP group were 
signifi cantly lower than that in control group (P £¼0.01) but the insulin release 
levels in glucose stimulation test were signifi cantly higher than that in control 
group (P £¼0.01). The islet yield in ulinastatin group was signifi cantly higher 
than that in control group (P £¼0.01). Compared ATP and ulinastatin group 
with control group, there were no signifi cant differences in blood glucose 
reduction and IPGTT after islet transplantation. 
Conclusion: During islet isolation, ulinastatin can inhibit islet cell apoptosis, 
raise islet yield and protect islet viability, and ATP can inhibit islet cell apoptosis. 
Compared ATP and ulinastatin group with control group, islet function and 
ability response to glucose after transplantation were nearly equal. 
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EVALUATION OF LEISHMANIASIS DEVELOPMENT 2330 
DURING A SHORT COURSE OF FTY720
V. Bueno 1, C.T. Lopes 1, D. Paula 1, P.M. Cury 2, V. Valero 1
1 Unifesp - Federal University of Sao Paulo, 2 FAMERP - Sao Jose do Rio 
Preto Medical School
Aims: L.amazonensis (La) infects macrophage and impairs the activation 
of antigen-specifi c T cells. FTY720 (FTY) is a compound which alters T cell 
homing by trapping these cells into secondary lymphoid organs. Our aim was 
to investigate leukocytes changes due to FTY administration in leishmaniasis 
development. 
Methods and Results: BALB and C57BL female adult mice were inoculated 
with 5x105 forms of La. Lesion sizes were measured and 7½ weeks later 
mice received FTY (1mg/kg/day) orally for 10 days. Controls BALB(A) 
and C57BL(B), BALB+La(C), C57BL+La(D), BALB+La+FTY(E), 
C57BL+La+FTY(F).Nine weeks after La inoculation blood (leukocytes 
counting), spleen (counting, fl ow cytometry) and hind feet were harvested. 
Hind feet thickness (mm) increased (A=B=4.0±0.0, C=10.3±0.4, D=7.7±0.4, 
p=0.002) and was not modifi ed by FTY (E=10.1±0.2, F=6.8±1.0). Spleen 
cell numbers (x106) decreased in BALB but not in C57BL (A=42.1±3.7, 
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B=46.2±5.4, C=28.6±6.1, D=46.6±13.7, p=0.007). FTY caused a higher 
decrease in spleen cell numbers (E=11.1±0.6, F=22.4±4.9). Total lymphocytes 
(%) increased in C57BL and BALB after La inoculation (A=53.6±8.0, 
B=43.2±16.9, C=74.8±1.0, D=70.8±3.2, p=0.02) whereas FTY decreased 
this parameter (E=65.8±3.6, F=51.9±9.4). CD4 and CD8 T cells (%) 
increased (A=25.1±7.3, B=17.3±5.1, C=34.4±2.1, D= 25.8±3.4 for CD4) 
in both mice strains but while C57BL presented no change in CD4 T cells 
after FTY (F=25.7±2.8) BALB decreased signifi cantly (E=26.1±5.9). CD8 
T cells decreased both in C57BL and BALB after FTY. CD11b decreased 
(A=56.7±3.9, B=48.2±7.1, C=14.0±0.8, D=10.4±1.5, p=0.001) whereas FTY 
promoted an increase in this cell population (E=22.5±4.1, F=13.2±0.3). There 
was no increase in blood lymphocytes after La infection but FTY caused an 
important lymphopenia in parasited mice.
Conclusions: FTY did not interfere with leishmaniasis development in late 
phase probably due its preferential effects on naive cells instead of effector/
memory subpopulations. 
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UPDATE ON ORGAN SOURCING IN CHINA2331 
D. Matas
Former Canadian Minister of State David Kilgour and I wrote a report on 
organ sourcing in China, released fi rst June 2006 and, in a second version, 
January 2007 under the title "Bloody Harvest: Organ Harvesting of Falun 
Gong practitioners in China". In that report we concluded that between 2001 
and 2006 China killed Falun Gong practitioners in the tens of thousands so 
that their organs could be sold to foreign transplant tourists. Falun Gong is an 
exercise regime with a spiritual foundation based on ancient Chinese traditions 
banned in 1999.
China has no national organized organ donation system, nor a law allowing 
organ sourcing from the brain dead, cardiac alive. There is a strong cultural 
aversion against both organ donations and organ sourcing from the cardiac 
alive. Nor does China have a national organ matching and distribution system. 
Organs for transplants almost exclusively come from prisoners, whether 
prisoners sentenced to death or Falun Gong practitioners.
Since the report was released, David Kilgour and I travelled to over forty 
countries and over seventy cities to seek to end the abuse we identifi ed. 
Subsequent to our report, China changed both its death penalty and organ 
transplant laws. The combined impact was to cut down on transplant tourism 
to China. One question this presentation would address is the extent to which 
abusive sourcing of organs from Falun Gong practitioners remains in light of 
these changed laws and their application.
The initial response of the Government of China to the report David Kilgour 
and I wrote was propagandistic, without addressing the substance of the 
research. More recently, particularly in the last few months, the Government 
of China has come out with specifi c responses - by way of letter to the 
United Nations Rapporteur on Torture Manfred Nowak and also by way 
of video, interviewing some of the sources of our report. The presentation 
would evaluate these responses and re-assess our own conclusions in light 
of these responses.
Because of our travels and the publicity surrounding our report, we received 
much additional evidence relevant to the subject of our report. Some it was just 
more of the same. For instance, we continued to fi nd new examples of Falun 
Gong practitioners who in Chinese detention were systematically blood tested 
while their co-prisoners who were not practitioners were not blood tested. 
As well, categories of evidence relevant to the conclusion of our report but 
not previously considered need to be examined. One example is the presence 
or absence of holding cells for those awaiting execution after having been 
sentenced to death. 
Some of the new evidence is quite recent. For instance, a new witness, a former 
prisoner, testifying to organ sourcing from Falun Gong practitioners, has 
surfaced just a few weeks ago. A third purpose of the presentation would be to 
bring the evidentiary analysis of our report up to date by referring to the most 
recent evidence available.
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PRE- AND POST-TRANSPLANT MONITORING OF 2332 
GRANZYME B ENZYME-LINKED IMMUNOSPOT ASSAY IN 
PEDIATRIC LIVER RECIPIENTS
D.Q. Truong1, A. Cornet2, G. Wieërs3, A. Robert4, R. Reding5, D. Latinne6
1Pediatric Surgery Department, Children’s Hospital 2, Medical University 
Centre, Ho Chi Minh City, Viet Nam., 2Laboratory of Transplant Immunology, 
Saint-Luc University Clinics, Université catholique de Louvain, Brussels, 
Belgium, 3Pediatric Liver Transplant Program, Saint-Luc University Clinics, 
Université catholique de Louvain, Brussels, Belgium, 4Epidemiology and 
Biostatistics, Université catholique de Louvain, Brussels, Belgium, 5Pediatric 
Liver Transplant Program, Saint-Luc University Clinics, Université 
catholique de Louvain, Brussels, Belgium, 6Laboratory of Transplant 
Immunology, Saint-Luc University Clinics, Université catholique de Louvain, 
Brussels, Belgium
This study aims to investigate potential role of granzyme B enzyme-linked 
immunosorbent spot (GrB ELISPOT) for immunological monitoring in 
pediatric liver transplantation. Patients and methods: Peripheral blood 
mononuclear cells from 28 pediatric recipients were serially tested for GrB-
producing donor-reactive cells at day 0 pre-transplantation (baseline) and days 
7, 14, 28 post-transplantation. Results: At baseline, no difference of GrB value 
was found in acute rejection (14/28) compared to normal graft function patients 
(day 0: 4(3.9) spots versus 5(2.9) spots, respectively: p=0.65). At day 7 post-
transplantation, acute rejection patients showed frequencies of GrB ELISPOT 
higher than those with normal graft function, but the differences observed 
were not statistically signifi cant (day 7: 15(4.9) spots versus 10(4.0) spots, 
respectively: p=0.55). GrB increased signifi cantly at day 7 from baseline in 
the rejection group (15(4.9) spots versus 4(3.9), respectively p=0.04), whereas 
corresponding changes were not signifi cant in the group without rejection 
(10(4.0) versus 5(2.9), respectively: p=0.15). Conclusion: GrB ELISPOT pre-
transplantation could not predict the occurrence of early post-transplant acute 
rejection; similarly frequencies at days 7, 14 and 28 could not be correlated 
with acute rejection in pediatric liver recipients. However, a kinetic study of 
GrB ELISPOT could be helpful to predict or confi rm early rejection in the 
small group of liver allograft recipients analyzed in this study.
POSTER BOARD NUMBER P4 – 383
ACTIVE CYTOMEGALOVIRUS INFECTION IN THE 2333 
CARDIAC ALLOGRAFT PRECEDES AND CORRELATES WITH 
CARDIAC ALLOGRAFT REJECTION EPISODES
M. Dzabic, A. Rahbar, M. Grudzinska, P. Religa, C. Söderberg-Nauclér
Department of Medicine, Center for Molecular Medicine, Karolinska 
Institutet, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
Background: Cytomegalovirus (CMV) infection has been suggested to be a 
contributing factor in acute and chronic rejection via direct and indirect effects. 
Although CMV infection has been associated with acute rejection episodes and 
chronic rejection in organ transplant recipients it has been diffi cult to detect the 
virus in the affected organs. 
Methods: In this retrospective observational cohort study 35 patients receiving 
a cardiac allograft between 1998 and 2000 at the Silesian Centre for Heart 
Disease in Zabrze, Poland, were included. All patients received Ganciclovir 
during the fi rst 28 days after transplantation. Endomyocardial biopsies were 
examined for the presence of CMV proteins using a new high sensitivity 
immunohistochemistry staining (HSIS) method.
Results: In 91 examined endomyocardial biopsies, we detected CMV 
immediate early and late antigens in 98,9%, and the CMV matrix protein pp65 
in 92,3% of the biopsy samples. Linear regression analysis demonstrated a 
correlation between the level of CMV pp65 and ISHLT rejection grade (p<0.05). 
Furthermore, the presence of CMV proteins preceded rejection episodes.
Conclusions 
A vast majority of cardiac transplant patients have an active CMV infection 
in the cardiac allograft, which can be detected using the HSIS method but not 
with regular staining techniques. CMV infection in the graft precedes and is 
associated with rejection episodes. The HSIS method for CMV pp65 may be of 
clinical value in predicting cardiac allograft rejection episodes.
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EFFICACY COMPARISON BETWEEN INTRAPORTAL 2334 
AND SUBCAPSULAR ISLETS IN MURINE DIABETIC MODELS
E. Hathout, N. Sakata, J. Chrisler, A. Tan, N. Chan, P. Hayes, J. Mace, 
R. Chinnock, L. Sowers, A. Obenaus, 
Loma Linda University
Background: Islet transplantation is a useful therapeutic option for type 1 
diabetes mellitus. Intraportal transplantation is the most effective method 
at present. However, transplanted islets are very unstable partly due to 
nonspecifi c infl ammation, hypoxia, and the metabolic condition of the 
recipient. Approximately 60% of transplanted islets are lost in the fi rst couple 
of days. In clinical practice, multiple transplantations are often required for one 
recipient to maintain normoglycemia. Therefore, it is important to determine 
the effi cacy of intraportal transplantation in comparison with other transplant 
sites. In this study, we tried to determine the optimal number of islets to achieve 
normoglycemia following transplantation into the liver versus kidney using a 
mouse model.
Methods: Balb/C female mice were used as donors and recipients. 
Streptozotocin induced diabetic mice were transplanted with syngeneic islets 
via the intraportal (IP) and renal subcapsule (SC) routes. The transplanted 
islet numbers were: zero (n=4, as a control), 100 (n=5 for IP and n=4 for SC), 
200 (n=5 for IP and SC), 300 (n=4 for IP and SC), 500 (n=6 for IP and n=4 
for SC) and 800 (n=5 for IP only). Blood glucose levels of the transplanted 
mice were measured through postoperative day (POD) 28. We calculated the 
parameters indicated below, assessed the correlation between these parameters 
and islet numbers and compared the parameters in the IP versus SC groups. The 
parameters were, (1) Percentage achieving normoglycemia in each group; (2) 
Postoperative days to normoglycemia; (3) Mean blood glucose level at various 
points from pre-transplantation to end of the study (POD28). We also tested the 
correlation between mean blood glucose levels and islet number.
Results: Two hundred islets could achieve normoglycemia in renal 
subcapsular grafts, while 800 islets were the minimum required in intraportal 
transplantation. Data from both groups were approximated using the quadratic 
function, and showed that intraportal transplants required 5 times the number 
of islets as renal subcapsular transplants for an equivalent percentage of 
normoglycemia. The days to normoglycemia did not signifi cantly differ by 
the number of transplanted islets, however, they were signifi cantly different 
between intraportal and renal subcapsular islets (13.25 ± 4.38 days vs. 3.33 
± 0.70 days, p = 0.007). There was a signifi cant negative correlation between 
islet number and mean blood glucose level in both intraportal and subcapsular 
transplantation. The transplantation effi cacy of the liver was one fourth that of 
the kidney in this assessment. 
Conclusion: Effi cay of islet transplantation in murine diabetic models is 
signifi cantly higher under the kidney capsule. This may refl ect an advantage 
of maintained juxtaposition versus dispersion of islet cells. Clinical islet 
transplantation could benefi t from trials of alternative transplantation sites.
This work was supported by NIH/NIDDK Grant # 1R01-DK077541 [EH].
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LESSONS FROM PREGNANCY THAT MAY HELP IN 2335 
TRANSPLANTATION
J.E. Schjenken1, J.M. Tolosa1, 2, V. Clifton3, B. Tuch4, R. Smith1
1 Mothers and Babies Research Centre, University of Newcastle, Newcastle, 
Australia, 2 Faculty of Medical Sciences, University of Santiago of Chile, 
Santiago, Chile, 3 Department of Pediatrics and Reproductive Health, 
University of Adelaide, Adelaide, SA, Australia, 4 Diabetes Transplant Unit, 
University of NSW, Randwick, NSW, Australia
Background: During pregnancy the placenta expresses Syncytin, an 
immunosuppressive retroviral envelope protein, and secretes placental 
exosomes with immunomodulatory functions. The human placenta also secretes 
Corticotropin Releasing Hormone (CRH), an inducer of cAMP which stimulates 
the production of Fas Ligand (FasL). Syncytin also responds to cAMP stimulation. 
We hypothesised that CRH induces the expression of Syncytin and FasL which 
stimulate the production of exosomes carrying endogenous retroviruses (ERV) 
and FasL which modulate the maternal response to the fetal allograft.
Methods: BeWo cells (a human placental choriocarcinoma cell line) were 
cultured at 37oC in HAM-F12 medium in a humidifi ed atmosphere of 5% CO2 
and 95% air. Cells were subcultured and grown for 1 day to the stage of 50% 
confl uence. The medium was then changed to one containing CRH (10, 25, 50, 
100 or 200nM) or vehicle (saline, pH2.79) and incubated for 24hours. RNA 
and Protein was extracted from these cells for subsequent analysis using Real-
Time PCR (RT-PCR) and SDS-PAGE respectively. The supernatants from cell 
cultures were extracted for exosomes using differential centrifugation and 
sucrose cushion methods prior to protein analysis using silver staining and 
western blotting.
Results: Real-time PCR analysis showed an upregulation in Syncytin 1, Syncytin 
2 and FasL mRNA following 24 hour CRH treatment in a dose dependent 
fashion. There were no signifi cant differences in protein levels of Syncytin 
and FasL with increasing doses of CRH. However, there was an increase in the 
production of exosomal protein following stimulation with CRH. 
Figure 1) Real-time PCR analysis of Syncytin 1, Syncytin 2 and FasL in BeWo 
cells treated with different concentrations of CRH. Expression levels are 
normalised against the respective vehicle 
Conclusions: We show that CRH stimulation of BeWo cells results in the 
increase of the mRNA of Syncytin-1, Syncytin-2 and FasL. Both Syncytin-2 
and FasL have known immunosuppressive functions. Surprisingly, Western 
Blot analysis of the total cell proteins revealed no increase in Syncytin or FasL 
at any time points. In contrast, proteins from exosomal fractions increased 
following CRH treatment. These data suggest that CRH stimulates BeWo cell 
protein production of these immunosuppressive factors resulting in a transfer 
of the immunomodulatory proteins into an exosomal secretory pathway. This 
knowledge could be applied to transplantation strategies. 
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EFFECT OF KIDNEY TRANSPLANTATION ON 2336 
CONTROLLING ARTERY-VENOUS FISTULA SIDE EFFECTS 
IN END STAGE RENAL DISEASE
S.M.M. Ghoreishi1, S.A. Tabatabaie2, T. Ghoraishi3, A.A. Beigi4, A. 
Mirmohammadsadeghy 5, A. Khosravi6, M. Karamy7, R. Amighian 8
1Esfahan University School of Medicine, 2Esfahan University School of 
Medicine, 3Najafabad University School of Medicine,, 4Esfahan University 
School of Medicine, 5Esfahan University School of Medicine, 6 Esfahan 
University School of Medicine, 7Esfahan University School of Medicine, 8 
Najafabad University School of Medicine,
Introduction: One of the main complications of End Stage Renal Disease 
(ESRD) is pulmonary hypertension. In fact creation of temporary Artery-Venous 
Fistula (AVF) for dialysis considerably, accelerates the rise in cardiac output 
and pulmonary artery pressure in these patients. We have evaluated the effect of 
kidney transplantation on improving cardiac indices such as Pulmonary Artery 
Pressure (PAP) and Cardiac Output (CO) post transplantation.
Material and Method: 50 patients with ESRD were included in the retrospective 
clinical trial study. Echocardiography was performed to evaluate systolic PAP, 
CO and Ejection Fraction (EF) prior to creating AVF. 12 patients underwent 
kidney transplantation. None of the AV fi stulas of graft recipients were subjected 
to surgical closure post-transplantation. After a follow up interval of at least 6 
months, second echocardiography assessments and Doppler sonogram of their 
fi stula fl ow were done. Transplanted and non transplanted cases were compared. 
The two groups were matched on age, medical co-morbidities and AVF creation 
surgical technique and fl ow. P-values were obtained using the Student’s t-test.
Results: The mean systolic PAP was 20.7 mmHg prior to AVF creation in 
graft recipients (n=12); which has signifi cantly decreased to 14.8 mmHg post-
transplantation (P=0.016). Post-transplant systolic PAP increased in none of the 
recipients compared to pre-transplant values.
In non-transplanted group (n=38) a signifi cant rise in the mean systolic PAP from 
21.3 mmHg to 25.16 mmHg pre and post AVF creation was observed. There 
was no signifi cant change observed in CO post-transplant compared to pre-AVF 
creation value (6120 ml/min). Mean CO was 510 ml/min less in those who 
were not transplanted (5610 ml/min). No considerable decrease in CO may be 
explained by levels of still-existing AVF fl ow in transplanted group (P=0.32). 
The non-transplanted group has shown a 7% decrease in mean EF during the 
study period, whereas the recipients had 7.5% increase in mean EF, which was 
signifi cantly different (P=0.03).
Conclusion: The outcomes of this study are in accordance with other studies’, 
confi rming that kidney transplantation should be regarded as the best available 
method to control the end organ damage of renal failure including complications 
caused by AVF creation . Improvements in Cardiac indices after kidney 
transplantation even with open AVF can reverse clinical manifestations of 
ESRD. Moreover, surgical closure of the temporary AVF in suitable candidates 
after reassurance of graft acceptance can improve the complications; however 
more investigations are required to affi rm the accuracy.
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RENOPORTAL ANASTOMOSIS AS A RESCUE 2337 
TECHNIQUE IN POSTOPERATIVE PORTAL THROMBOSIS 
AFTER LIVER TRANSPLANTATION
I. Gonzalez-Pinto, A. Miyar, C. Garcia-Bernardo, L. Vazquez, L. Barneo, E. 
Cortes, P.Y. Diaz, N. Gutierrez, L. Fernandez
Hospital Universitario Central de Asturias
Renoportal anastomosis has been used as the primary portal revascularization 
technique in grade 4 portal thrombosis, but never after posttransplant portal 
thrombosis.
Case presentation: A 55 year-old patient with hepatocellular carcinoma on 
alcoholic and virus C cirrhosis received a liver transplant in late march/08. He 
had partial portal thrombosis.
Portal thrombosis of 2/3 of the lumen was found at surgery. The thrombus 
was removed and a good portal fl ow was obtained after reperfusion (2.8 L/
min). Severe transaminases rise took place at 9th PO day, and doppler US 
revealed complete portal thrombosis from the spleno-mesenteric confl uence. 
At emergency reoperation, newly formed and fragments of old thrombus were 
removed. Portal vein branches were fl ushed with heparin and urokinase. After 
reconstruction of the anastomosis, a fi nal fl ow of 1 L/min was achieved.
Two days later there is a new rise in transaminases and rethrombosis is 
demonstrated again on the 13th PO day by doppler US. At reoperation, 
thrombus is removed again. However, this time portal fl ow is not recovered, 
due to hepatofugal fl ow associated with both the presence of collaterals and 
pancreatic edema. Collaterals were localized in the distal retropancreatic area 
and were not accessible for ligation or shunting. The left renal vein was of larger 
diameter than the right, so we decided to perform an end-to-end renoportal 
anastomosis, by means of an interposed iliac vein graft. A catheter was placed 
in the portal vein through a recanalization of the umbilical vein of the graft.
Postoperative course was good, with progressive normalization of liver tests and 
no further thrombosis. However, some areas of bad perfusion remained in the right 
lobe, and ascites persisted, but improved with treatment. Angiography on the 41st 
PO day showed a good portal fl ow from the renal vein, with a good and uniform 
distribution within the liver. The patient was discharged on the 48th PO day.
Conclusion: Renoportal anastomosis can be useful for recovery of liver failure 
after posttransplant portal thrombosis, in the absence of portal fl ow.
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SEQUENTIALLY INCREASING 4-FOLDS GRAFT BLOOD 2338 
FLOW ACCORDING TO PHI(¥Õ) RATIO IN RIGHT LOBE 
LIVING DONOR LIVER TRANPLANTATION
Y-H. Kim1, Y.H. Roh1, G.J. Jung1, K.J. Cho2, J.H. Cho3
1Department of Surgery, College of Medicine, Dong-A University, Busan, 
Korea, 2Department of Cardiac Surgery, College of medicine, Dong-A 
University, Busan, Korea, 3Department of Diagnostic Radiology, College of 
medicine, Dong-A University, Busan, Korea
In end to side hepatic vein anatomosis, to promote smooth blood fl ow through 
infl ow and outfl ow, the construction should be slightly angulated. Insuffi cient 
stoma causes end vessel congestion, excessive opening narrows the lumen1.
To optimize outfl ow2,3, we applied the golden ratio(¥Õ, approtimately 1.618) 
to outfl ow/infl ow ratio. At the back table, septoplasty and venoplasty, great 
saphenous vein interposition graft, and then hepatic vein and inferior vena 
cava (IVC) anastomosis in the operation fi eld, sequentially the graft blood fl ow 
increased to 4 folds.(1.6 x 1.6 x 1.6)
Better saphenous vein harvest: Recently cryopreserved4, 
polyetrafl uoroethylene(PTFE)5 graft were introduced, but autologus great 
saphenous vein is more physiologic, less time consuming, familiarity for the 
small capacity transplantation program (less than 5 cases in a year) like us. to 
improve wound healing and cosmetic efforts, 2 or 3, 4cm long separate skin 
incision on the groin area were made(Fig.1).
Back table procedure: In the right hepatic vein(RHV), septum with 
intervening tissue exist, making an incision on the septum6 and peformed 
interrupted absorbable 7-0 sutures. The orifi ce were completely separates 
but not far apart, removing the undelying liver parenchym using the Cavitron 
ultrasonic surgical aspirator(CUSA, Excel, Valleylab, Inc, Boulder, Co), 
vessel edges were approximmted using contineous 7-0 sutures to make a wide 
opening7(Fig.2). With these kinds of septoplasty and venoplasty, the diameter 
could be increased to approximately x 1.6 and then the long diameter of great 
saphenous vein(GSV) was fenced along the edge of RHV using continous 7-0 
Prolene suture.(the diameter enlarged approximately x 1.6)(Fig.3).
If the diameter of drainage vein of the graft were larger than 5mm and isolated, 
remanied saphenous vein was used as venous conduit and implanted directly 
into the IVC.
Liver transplant precedure: An elliptical defect, approximately 1.6 times the 
diameter of donor RHV was created in the IVC and anchoring sutures are placed 
at the apex and base of the ellipse and then contineous 5-0 Prolene suture were 
made(Fig. 4), so far the graft blood fl ow increased sequentially about 4 folds. 
But we assumed that postoperative actual venous blood fl ow depends on the 
recepient portal infl ow, resistance of the graft, vena caval outfl ow rate.
Since 2005, 8 consecutive right lobe graft living donor liver transplantation using 
same kind of procedure were performed. All outfl ow of the graft was satisfactory.
There have been many reports reparding outfl ow tract reconsruction, some are 
too small, others are too large. We believe to achieve the appropriate smooth 
blood fl ow in end to side anastomosis, keep the outfl ow/infolw ratio to natural 
golden ratio Phi(¥Õ) 1.6 is ideal.
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INCISIONAL AND INGUINAL HERNIA AFTER RENAL 2339 
TRANSPLANTATION
R.E. Samani, S.M.M. Ghoreishi
Medical University of Isfahan
Purpose: End Stage Renal Disease (ESRD) is one of the serious problems for 
human population in the world. Renal transplantation is one of the methods 
of treatment for these patients. After operation for renal transplantation, many 
complications threaten the patient including rejection, infection, hernia and etc. 
This study is about the frequency of complications including hernia after renal 
transplantation and the results of surgical repair of hernia. 
Methods: This is descriptive-analytic study that conducted in Al-Zahra hospital 
in ISFAHAN. From 2004 to 2006, 170 patients with renal transplantation 
were studied in order to determine the frequency of complications including 
incisional and inguinal hernia .Surgical correction was established using 
propylene mesh and patient outcome was studied.
Results: Of 170 patients with renal transplantation 13 (7.6%) patients developed 
surgical site complications. 5 patients had infection, 3 patients had seroma , 2 
patients had hematoma , 1 patient had bleeding, 8 patients with urinary leakage 
and 1 patient had chronic pain. 3 patients developed hernia (2 incisional hernias 
and 1 inguinal hernia) that two of them had seroma collection. The prevalence 
of hernia was 1.8% .Incidence of hernia had no signifi cant relation with gender 
(P= 0.99), age (P= 0.86), Diabetes Mellitus (P=0.7), and Smoking (P=0.8).
Surgical repair was performed using propylene mesh. No complications and no 
relapses were noted at a mean follow up of 2 years. 
Conclusion: Lower incidence of hernia after kidney transplantation can be 
achieved by primary health care such as prevention of constipation, respiratory 
care and physical activity although surgical complications are important 
predisposing factors for hernia after renal transplantation. Surgical repair by 
propylene mesh is safe and effective in these patients. 
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Malathum K.; . . . . . . . . . . . . . . . . . . . . 2199, 2203
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Mange K.; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 684
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Marchewka Z.; . . . . . . . . . . . . . . . . . . . . 883, 1044
Marcos A.;  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
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Martinez P.; . . . . . . . . . . . . . . . . . . . . . . . . . . . 1321
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Matthew B.;  . . . . . . . . . . . . . . . . . . . . . . . . . . . 733
Matthew M.; . . . . . . . . . . . . . . . . . . . . . . . . . . . 790
Matthews D.;  . . . . . . . . . . . . . . . . . . . . . . . . . 2270
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